Date:11/03/97ISR Number: 3025593-0Report Type:Periodic Company Report #A0052454
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Discharge	Health	Wellbutrin	PS		ORAL	100MG/	TWICE PER DAY/
	Breast Tenderness	Professional						ORAL
	Galactorrhoea	Company Representative	Cetirizine Hydrochloride	C				
			Beta Carotene	C				
			Fluticasone Propionate	C				
			Aspirin	C				
			Trazodone	C				
			Clonazepam	C				
			Amlodipine	C				
			Medroxyprogesterone	C				
			Midrin	C				
			Metoclopramide	C				
			Enalapril Maleate	C				
			Estratest	C				
			Darvocet-N	C				
			Oxpentifylline	C				
			Calcium Carbonate	C				
			Parafon Forte	C				
			Hydroxychloroquine S04	C				

Date:11/03/97ISR Number: 3025599-1Report Type:Periodic Company Report #A0052699
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Health	Wellbutrin	PS		ORAL	150MG/	TWICE PER DAY/
		Professional						ORAL
		Other	Dexfenfluramine					

				Capsule	SS		ORAL

15 MG / TWICE

PER DAY /

ORAL

Date:11/03/97ISR Number: 3025602-9Report Type:Periodic Company Report #A0052754
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Wellbutrin	PS		ORAL	ORAL	

Date:11/03/97ISR Number: 3025606-6Report Type:Periodic Company Report #A0052828
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Health Professional Company Representative	Wellbutrin	PS		ORAL	150 MG / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025611-XReport Type:Periodic Company Report #A0052857
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional	Wellbutrin	PS		ORAL	150 MG/ORAL	

Date:11/03/97ISR Number: 3025615-7Report Type:Periodic Company Report #A0052904
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Discolouration	Health Professional	Wellbutrin	PS		ORAL	ORAL	

Date:11/03/97ISR Number: 3025619-4Report Type:Periodic Company Report #A0052934
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Multiforme	Health Professional	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY/ ORAL	

Date:11/03/97ISR Number: 3025622-4Report Type:Periodic Company Report #A0052935
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Multiforme	Health Professional	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY / ORAL	

Date:11/03/97ISR Number: 3025625-XReport Type:Periodic Company Report #A0052936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Multiforme	Health	Wellbutrin	PS		ORAL	150MG / PER	
		Professional					DAY / ORAL	

Date:11/03/97ISR Number: 3025631-5Report Type:Periodic Company Report #A0052941
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Wellbutrin	PS		ORAL	ORAL	
	Tremor	Professional Company Representative						

Date:11/03/97ISR Number: 3025635-2Report Type:Periodic Company Report #A0052982
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Wellbutrin	PS		ORAL	150MG / TWICE	
	Therapeutic Response						PER DAY /	
	Decreased						ORAL	
			Calcium Salt	C				
			Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025637-6Report Type:Periodic Company Report #A0052988
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Wellbutrin	PS		ORAL	150MG / TWICE	
	Feeling Abnormal						PER DAY /	
	Lethargy						ORAL	
	Paraesthesia							

Date:11/03/97ISR Number: 3025641-8Report Type:Periodic Company Report #A0053021
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Wellbutrin	PS		ORAL	300MG / PER	
	Weight Decreased	Professional					DAY/ ORAL	
			Codimal Dm	C				
			Loratadine	C				

Date:11/03/97ISR Number: 3025644-3Report Type:Periodic Company Report #A0053026
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperventilation	Health	Wellbutrin	PS		ORAL	ORAL	
	Snoring	Professional						

Date:11/03/97ISR Number: 3025650-9Report Type:Periodic Company Report #A0053069
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin	PS		ORAL	ORAL	

		Professional				

Date:11/03/97ISR Number: 3025654-6Report Type:Periodic Company Report #A0053087
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin	PS		ORAL		
		Professional	Wellbutrin	SS		ORAL	150 MG TWICE	
							PER DAY ORAL	

Date:11/03/97ISR Number: 3025656-XReport Type:Periodic Company Report #A0053150
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Wellbutrin	PS		ORAL	150 MG/ PER	
	Hyperhidrosis						DAY / ORAL	
	Insomnia		Alprazolam	C				

Date:11/03/97ISR Number: 3025660-1Report Type:Periodic Company Report #A0053152
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery	Health	Wellbutrin	PS		ORAL	150MG / PER	
	Insomnia	Professional					DAY / ORAL	
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025663-7Report Type:Periodic Company Report #A0053182
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional						
		Company						
		Representative						

Date:11/03/97ISR Number: 3025668-6Report Type:Periodic Company Report #A0053203
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health	Wellbutrin	PS		ORAL	150MG / TWICE	
		Professional					PER DAY /	
		Company					ORAL	
		Representative						

Date:11/03/97ISR Number: 3025671-6Report Type:Periodic Company Report #A0053307
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Clonic Convulsion	Health	Wellbutrin	PS		ORAL	150MG / THREE	
		Professional					TIMES PER DAY	
		Company					/ ORAL	
		Representative	Paroxetine Hydrochloride	C				
			Semisodium Valproate	C				

Date:11/03/97ISR Number: 3025674-1Report Type:Periodic Company Report #A0053396
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Wellbutrin	PS		ORAL	ORAL	

Date:11/03/97ISR Number: 3025677-7Report Type:Periodic Company Report #A0053400
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY / ORAL	

Date:11/03/97ISR Number: 3025680-7Report Type:Periodic Company Report #A0053474
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Tremor	Health Professional Company Representative	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025683-2Report Type:Periodic Company Report #A0053475
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Wellbutrin	PS		ORAL	200 MG /	
		Professional					TWICE PER DAY	
							/ ORAL	
			Thyroxine Sodium	C				
			Oral Contraceptive	C				

Date:11/03/97ISR Number: 3025686-8Report Type:Periodic Company Report #A0053520
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Wellbutrin	PS		ORAL	ORAL	
	Coordination Abnormal	Professional						
	Malaise	Company Representative						

Date:11/03/97ISR Number: 3025690-XReport Type:Periodic Company Report #A0053528
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health	Wellbutrin	PS		ORAL	ORAL	
	Tinnitus	Professional						

Date:11/03/97ISR Number: 3025694-7Report Type:Periodic Company Report #A0053589
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Wellbutrin	PS		ORAL	150MG / PER	

DAY / ORAL

Date:11/03/97ISR Number: 3025696-0Report Type:Periodic Company Report #A0053644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia	Health Professional	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY / ORAL	

Date:11/03/97ISR Number: 3025706-0Report Type:Periodic Company Report #A0053701
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY / ORAL	
	Balance Disorder							
	Dermatitis							
	Dyspnoea		Triamcinolone Acetonide	C				
	Headache		Paracetamol	C				
	Nausea		Lopoeramide Hydrochloride	C				
	Pharyngeal Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025709-6Report Type:Periodic Company Report #A0053777
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Discolouration	Consumer	Wellbutrin	PS		ORAL	75 MG / THREE TIMES PER DAY / ORAL	
			Estrogen	C				
			Atenolol	C				

Date:11/03/97ISR Number: 3025712-6Report Type:Periodic Company Report #A0053779
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Wellbutrin	PS		ORAL	ORAL	18 MON
			Medroxyprogesterone Ace.	C				
			Nizatidine	C				

Date:11/03/97ISR Number: 3025714-XReport Type:Periodic Company Report #A0053780
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin	PS		ORAL	150MG / THREE TIMES PER DAY / ORAL	

Date:11/03/97ISR Number: 3025717-5Report Type:Periodic Company Report #A0053781
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health	Wellbutrin	PS		ORAL	150MG / PER	
	Gastrointestinal	Professional					DAY / ORAL	
	Obstruction		Salbutamol Sulphate	C				
	Nausea		Famotidine	C				

Date:11/03/97ISR Number: 3025719-9Report Type:Periodic Company Report #A0053803
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Periorbital Oedema	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional Company Representative						

Date:11/03/97ISR Number: 3025721-7Report Type:Periodic Company Report #A0053804
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025723-0Report Type:Periodic Company Report #A0053873
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised	Consumer	Wellbutrin	PS		ORAL	TWICE PER DAY/ ORAL; THREE TIMES PER DAY ORAL	

Date:11/03/97ISR Number: 3025725-4Report Type:Periodic Company Report #A0054003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional	Oxazepam	C				

Date:11/03/97ISR Number: 3025727-8Report Type:Periodic Company Report #A0054026
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional Company Representative						

Date:11/03/97ISR Number: 3025730-8Report Type:Periodic Company Report #A0054027
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Clonic Convulsion	Health	Wellbutrin	PS		ORAL	150MG / PER	

Initial or Prolonged	Coordination Abnormal	Professional				
DAY / ORAL						
	Fall					
	Hyperreflexia					
	Tremor					
	Vertigo					

Date:11/03/97ISR Number: 3025733-3Report Type:Periodic Company Report #A0054028
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Health	Wellbutrin	PS		ORAL
300MG / PER						
		Professional				
DAY / ORAL						

Date:11/03/97ISR Number: 3025734-5Report Type:Periodic Company Report #A0054059
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Interaction	Health	Wellbutrin	PS		ORAL
ORAL						
	Nausea	Professional	Venlafaxine			
	Vomiting		Hydrochloride	SS		
			Lithium Salt	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025737-0Report Type:Periodic Company Report #A0054092
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Health Professional	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY / ORAL	

Date:11/03/97ISR Number: 3025740-0Report Type:Periodic Company Report #A0054112
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Wellbutrin	PS		ORAL	ORAL	
	Feeling Jittery	Professional Company Representative						

Date:11/03/97ISR Number: 3025742-4Report Type:Periodic Company Report #A0054113
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Wellbutrin	PS		ORAL	ORAL	
	Feeling Jittery	Professional Company Representative						

Date:11/03/97ISR Number: 3025745-XReport Type:Periodic Company Report #A0054153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Wellbutrin	PS		ORAL	ORAL	

Professional
Company
Representative

Date:11/03/97ISR Number: 3025748-5Report Type:Periodic Company Report #A0054157
Age:39 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Health Professional	Wellbutrin	PS		ORAL	100 MG / TWICE PER DAY / ORAL	
				..		C		

Date:11/03/97ISR Number: 3025750-3Report Type:Periodic Company Report #A0054204
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Wellbutrin	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025752-7Report Type:Periodic Company Report #A0054205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin	PS		ORAL	150MG /TWICE	
	Cough						PER DAY /	
	Headache						ORAL	
	Nervousness							

Date:11/03/97ISR Number: 3025754-0Report Type:Periodic Company Report #A0054222
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional						

Date:11/03/97ISR Number: 3025757-6Report Type:Periodic Company Report #A0054280
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional Company Representative						

Date:11/03/97ISR Number: 3025760-6Report Type:Periodic Company Report #A0054281
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional						

Company
Representative

Date:11/03/97ISR Number: 3025762-XReport Type:Periodic Company Report #A0054300
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adnexa Uteri Pain	Consumer	Wellbutrin	PS		ORAL	150 MG /	
	Pelvic Pain						TWICE PER DAY	
	Tenderness						/ ORAL	
			Wellbutrin	SS		ORAL	75 MG / AT	
							NIGHT / ORAL	
			Temazepam	C				

Date:11/03/97ISR Number: 3025764-3Report Type:Periodic Company Report #A0054302
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health	Wellbutrin	PS		ORAL	150MG / TWICE	
		Professional					PER DAY /	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025767-9Report Type:Periodic Company Report #A0054303
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Wellbutrin	PS		ORAL	150 MG. ORAL	
		Professional						

Date:11/03/97ISR Number: 3025770-9Report Type:Periodic Company Report #A0054304
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Wellbutrin	PS		ORAL	100 MG / FOUR	
	Colitis Ulcerative						TIMES PER	
	Faecal Occult Blood						DAY/ ORAL	
	Positive		Clonazepam	C				
			Mesalazine	C				

Date:11/03/97ISR Number: 3025772-2Report Type:Periodic Company Report #A0054361
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Wellbutrin	PS		ORAL	150 MG / ORAL	
	Glossodynia							

Date:11/03/97ISR Number: 3025775-8Report Type:Periodic Company Report #A0054369
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Wellbutrin	PS		ORAL	ORAL	MON
	Rash Macular	Professional						

Date:11/03/97ISR Number: 3025777-1Report Type:Periodic Company Report #A0054445
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional						
		Company						
		Representative						

Date:11/03/97ISR Number: 3025779-5Report Type:Periodic Company Report #A0054446
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Wellbutrin	PS		ORAL	150 MG /	
	Drug Ineffective						TWICE PER	
	Tobacco Abuse						DAY/ ORAL	
			Blood Pressure					
			Medication	C				

Date:11/03/97ISR Number: 3025781-3Report Type:Periodic Company Report #A0054447
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Life-Threatening	Grand Mal Convulsion	Health
		Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin	PS		
150 MG / FOUR						
TIMES PER DAY						

Date:11/03/97ISR Number: 3025783-7Report Type:Periodic Company Report #A0054450
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Agitation	Health	Wellbutrin	PS		ORAL
150 MG / PER						
	Dry Mouth	Professional				
DAY/ ORAL						
	Paraesthesia		Venlafaxine			
	Visual Disturbance		Hydrochloride	C		

Date:11/03/97ISR Number: 3025784-9Report Type:Periodic Company Report #A0054510
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Flushing	Consumer	Wellbutrin	PS		ORAL
150 MG /						
	Insomnia					
TWICE PER						
DAY/ ORAL						
			Nicotine Patch	SS		
TOPICAL						
			Prempro	C		

Date:11/03/97ISR Number: 3025785-0Report Type:Periodic Company Report #A0054528
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Constipation	Consumer	Wellbutrin	PS		ORAL
VARIABLE DOSE						
	Drug Ineffective					
/ ORAL						
	Elevated Mood		Imipramine			
	Fatigue		Hydrochloride	C		
	Sedation					

Date:11/03/97ISR Number: 3025786-2Report Type:Periodic Company Report #A0054542
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth	Consumer	Wellbutrin	PS		ORAL
150 MG /						
	Tongue Coated					
TWICE PER DAY						
	Tongue Disorder					
/ ORAL						

Date:11/03/97ISR Number: 3025789-8Report Type:Periodic Company Report #A0054544
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Health	Wellbutrin	PS		ORAL
150 MG /						
	Nausea	Professional				
TWICE PER DAY						
	Vomiting					
/ ORAL 4 MON						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025791-6Report Type:Periodic Company Report #A0054545
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional	Wellbutrin	PS		ORAL	ORAL	

Date:11/03/97ISR Number: 3025792-8Report Type:Periodic Company Report #A0054565
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Health Professional	Wellbutrin	PS		ORAL	ORAL	

Date:11/03/97ISR Number: 3025793-XReport Type:Periodic Company Report #A0054657
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Wellbutrin	PS		ORAL	ORAL	

Date:11/03/97ISR Number: 3025794-1Report Type:Periodic Company Report #A0054658
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tic	Consumer	Wellbutrin	PS		ORAL	150 MG / PER DAY/ ORAL	

Date:11/03/97ISR Number: 3025796-5Report Type:Periodic Company Report #A0054665
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Wellbutrin	PS		ORAL	150MG / TWICE	
	Hypertension						PER DAY /	
	Migraine						ORAL	
			Imitrex	SS				
			Thyroxine	C				
			Verapamil	C				
			Estratest	C				
			Prinzide	C				
			Beclomethasone Dipropion	C				
			Salmeterol Xinafoate	C				
			Fluoxetine Hydrochloride	C				

Date:11/03/97ISR Number: 3025798-9Report Type:Periodic Company Report #A0054666
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Urgency	Health	Wellbutrin	PS		ORAL	150MG / TWICE	
	Pollakiuria	Professional					PER DAY /	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025800-4Report Type:Periodic Company Report #A0054697
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional Company Representative	Wellbutrin	PS		ORAL	150 MG /TWICE PER DAY/	ORAL

Date:11/03/97ISR Number: 3025801-6Report Type:Periodic Company Report #A0054716
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin	PS		ORAL	100 MG / PER DAY / ORAL	
	Dry Mouth							
	Dysphonia		Fluvoxamine Maleate	C				
	Dyspnoea		Alesse	C				
	Hypervigilance							
	Insomnia							
	Nausea							
	Polydipsia							

Date:11/03/97ISR Number: 3025803-XReport Type:Periodic Company Report #A0054728
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Wellbutrin	PS		ORAL	150MG / THREE TIMES PER	
	Anorexia							
	Asthenia						DAY/ ORAL	4 YR
	Coordination Abnormal		Lithium Salt	C				
	Depression		Buspirone Hydrochloride	C				
	Disorientation							
	Dissociation		Carbamazepine	C				

Dizziness
Dysphemia
Fatigue
Feeling Jittery
Headache
Impaired Healing
Influenza
Muscle Spasms
Nervousness
Thinking Abnormal
Vision Blurred

Date:11/03/97ISR Number: 3025806-5Report Type:Periodic Company Report #A0054744
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Health	Wellbutrin	PS		ORAL	150MG / PER	
	Face Oedema	Professional					DAY/ ORAL	
	Pruritus	Company						
	Urticaria	Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025807-7Report Type:Periodic Company Report #A0054745
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash Pruritic	Health	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY/ ORAL
		Professional					
			Temazepam	C			
			Lorazepam	C			

Date:11/03/97ISR Number: 3025809-0Report Type:Periodic Company Report #A0054747
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urticaria	Health	Wellbutrin	PS		ORAL	ORAL
		Professional	Wellbutrin	SS		ORAL	450MG / PER DAY / ORAL

Date:11/03/97ISR Number: 3025811-9Report Type:Periodic Company Report #A0054755
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Effect Decreased	Health	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY / ORAL
		Professional					
		Company Representative					

Date:11/03/97ISR Number: 3025812-0Report Type:Periodic Company Report #A0054756
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional Company Representative	Wellbutrin	PS		ORAL	150MG / TWICE PER DAY / ORAL	

Date:11/03/97ISR Number: 3025813-2Report Type:Periodic Company Report #A0054772
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Extrapyramidal Disorder	Health Professional Company Representative	Wellbutrin	PS		ORAL	ORAL	

Date:11/03/97ISR Number: 3025814-4Report Type:Periodic Company Report #A0054794
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Wellbutrin	PS		ORAL	100MG / THREE TIMES PER DAY / ORAL	
	Rectal Haemorrhage		Doxazosin Mesylate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025815-6Report Type:Periodic Company Report #A0054796
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Wellbutrin	PS		ORAL	150MG / TWICE	
	Drug Ineffective						PER DAY/ ORAL	
	Dry Mouth							

Date:11/03/97ISR Number: 3025816-8Report Type:Periodic Company Report #A0054806
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Health	Wellbutrin	PS		ORAL	ORAL	
	Fibromyalgia	Professional						

Date:11/03/97ISR Number: 3025817-XReport Type:Periodic Company Report #A0054819
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Health	Wellbutrin	PS		ORAL	150MG / TWICE	
	Convulsion	Professional					PER DAY/ ORAL	
	Depression	Company Representative						

Date:11/03/97ISR Number: 3025818-1Report Type:Periodic Company Report #A0054822
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Grand Mal Convulsion	Health	Wellbutrin	PS		ORAL	200MG / TWICE	
		Professional					PER DAY /	

		Company				
ORAL		Representative				

Date:11/03/97ISR Number: 3025819-3Report Type:Periodic Company Report #A0054824
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Wellbutrin	PS		ORAL	100 MG /	
	Urticaria						TWICE PER DAY	
/ ORAL								
			Vanquish	C				
			Paracetamol	C				

Date:11/03/97ISR Number: 3025820-XReport Type:Periodic Company Report #A0054831
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional						
		Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025821-1Report Type:Periodic Company Report #A0054895
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Wellbutrin	PS		ORAL	ORAL	

Date:11/03/97ISR Number: 3025822-3Report Type:Periodic Company Report #A0054924
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Wellbutrin	PS		ORAL	100MG / TWICE PER DAY / ORAL	
			Oxpentifylline	C				

Date:11/03/97ISR Number: 3025823-5Report Type:Periodic Company Report #A0054925
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin	PS		ORAL	150MG / PER DAY / ORAL	
	Nausea							
	Oral Discomfort		Omeprazole	C				

Date:11/03/97ISR Number: 3025824-7Report Type:Periodic Company Report #A0054947
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Wellbutrin	PS		ORAL
150MG /TWICE						
	Vaginal Haemorrhage					
PER DAY /						
ORAL						
			Conjugated Estrogens	C		

Date:11/03/97ISR Number: 3025825-9Report Type:Periodic Company Report #A0054971
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Convulsion	Health	Wellbutrin	PS		ORAL
ORAL						
		Professional Company Representative				

Date:11/03/97ISR Number: 3025826-0Report Type:Periodic Company Report #A0055045
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Health	Wellbutrin	PS		ORAL
150MG / TWICE						
		Professional				
PER DAY /						
ORAL						
			Fluoxetine Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025827-2Report Type:Periodic Company Report #A0055056
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Wellbutrin	PS		ORAL	150MG / ORAL	
		Professional						
		Company						
		Representative						

Date:11/03/97ISR Number: 3025828-4Report Type:Periodic Company Report #A0055066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Wellbutrin	PS		ORAL	150MG / TWICE	
	Menstrual Disorder	Professional					PER DAY /	
		Company					ORAL	
		Representative						

Date:11/03/97ISR Number: 3025829-6Report Type:Periodic Company Report #A0055078
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional						
		Company						
		Representative						

Date:11/03/97ISR Number: 3025830-2Report Type:Periodic Company Report #A0055079
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Health Professional Company Representative	Wellbutrin	PS		ORAL ORAL

Date:11/03/97ISR Number: 3025831-4Report Type:Periodic Company Report #A0055092
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Abdominal Pain Anxiety Flatulence Insomnia	Consumer	Wellbutrin	PS		ORAL 150 MG / TWICE PER DAY / ORAL

Date:11/03/97ISR Number: 3025832-6Report Type:Periodic Company Report #A0055101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Amenorrhoea	Health Professional Company Representative	Wellbutrin	PS		ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025833-8Report Type:Periodic Company Report #A0055133
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Odour Abnormal	Consumer	Wellbutrin	PS		ORAL	ORAL	
			..	C				

Date:11/03/97ISR Number: 3025834-XReport Type:Periodic Company Report #A0055134
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Odour Abnormal	Consumer	Wellbutrin	PS		ORAL	ORAL	
			Hormones	C				
			Sedapap	C				
			Vitamin	C				
			Lorazepam	C				
			Diphenhydramine Hcl	C				

Date:11/03/97ISR Number: 3025835-1Report Type:Periodic Company Report #A0055135
Age:30 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Health Professional Company Representative	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:11/03/97ISR Number: 3025836-3Report Type:Periodic Company Report #A0055137
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Cough	Consumer	Wellbutrin	PS		ORAL 150 MG /
	Dyspnoea					TWICE PER DAY
	Insomnia					/ ORAL
			Zyban	SS		ORAL 150 MG / ORAL
			Fosinopril Sodium	C		
			Perphenazine	C		
			Cimetidine	C		
			Amoxapine	C		

Date:11/03/97ISR Number: 3025837-5Report Type:Periodic Company Report #A0055138
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Disorientation	Consumer	Wellbutrin	PS		ORAL 150 MG / PER
	Drug Ineffective					DAY / ORAL
	Memory Impairment		Carisoprodol	C		
	Nervousness					
	Paranoia					
	Psychomotor Hyperactivity					
	Psychotic Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025838-7Report Type:Periodic Company Report #A0055164
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Wellbutrin	PS		ORAL	150MG/TWICE	
	Epistaxis						PER DAY/ ORAL	
	Feeling Abnormal							
	Tongue Coated							

Date:11/03/97ISR Number: 3025839-9Report Type:Periodic Company Report #A0055181
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Health	Wellbutrin	PS		ORAL	150MG /TWICE	
	Dermatitis	Professional					PER DAY /	
	Drug Effect Decreased	Company					100MG TWICE	
	Hypersensitivity	Representative					PER DAY/ORAL	
	Pruritus		Wellbutrin	SS			100 MG /	
							TWICE PER DAY	
							/	
			Valproic Acid	C				

Date:11/03/97ISR Number: 3025840-5Report Type:Periodic Company Report #A0055186
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Wellbutrin	PS		ORAL	150 MG /	
	Crying						TWICE PER DAY	

	Depressed Mood					
/ ORAL						
	Insomnia		Estratest	C		
			Medroxyprogesterone Ace.	C		

Date:11/03/97ISR Number: 3025841-7Report Type:Periodic Company Report #A0055195
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Condition Aggravated	Health	Wellbutrin	PS		ORAL	150 MG /
Initial or Prolonged	Convulsion	Professional					TWICE PER DAY
	Cough	Company					/ ORAL
	Grand Mal Convulsion	Representative	Sertraline Hydrochloride	C			
	Loss Of Consciousness		Nortriptyline	C			
	Urinary Incontinence		Salmeterol Xinafoate	C			
			Flunisolide	C			
			Aspirin	C			
			Conjugated Estrogens	C			
			Clonidine	C			
			Doxepin	C			
			Prednisone	C			
			Buspirone Hydrochloride	C			
			Corticosteroid	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025843-0Report Type:Periodic Company Report #A0055252
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional						
		Company						
		Representative						

Date:11/03/97ISR Number: 3025844-2Report Type:Periodic Company Report #A0055254
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin	PS		ORAL	100MG /TWICE	
	Nausea						PER DAY /	
							ORAL	
			Nicotine Patch	SS			21MG /	
TOPICAL	1 MON							

Date:11/03/97ISR Number: 3025845-4Report Type:Periodic Company Report #A0055258
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Texture Abnormal	Health	Wellbutrin	PS		ORAL	75 MG / PER	
		Professional					DAY / ORAL	

Date:11/03/97ISR Number: 3025846-6Report Type:Periodic Company Report #A0055272
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy	Consumer	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Clonazepam	C				

Date:11/03/97ISR Number: 3025847-8Report Type:Periodic Company Report #A0055303
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Health	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY / ORAL	5 WK
	Nausea	Professional						

Date:11/03/97ISR Number: 3025848-XReport Type:Periodic Company Report #A0055320
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall	Health	Wellbutrin	PS		ORAL	150 MG / PER DAY / ORAL	
	Hyperhidrosis	Professional						
	Loss Of Consciousness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/97ISR Number: 3025849-1Report Type:Periodic Company Report #A0055431
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin	PS		ORAL	ORAL	
	Face Oedema	Professional Company Representative						

Date:11/03/97ISR Number: 3025850-8Report Type:Periodic Company Report #A0055432
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional Company Representative						

Date:11/03/97ISR Number: 3025851-XReport Type:Periodic Company Report #A0052521
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bulimia Nervosa	Health	Wellbutrin	PS		ORAL	150 MG TWICE	
	Grand Mal Convulsion	Professional					PER DAY	ORAL
			Wellbutrin	SS		ORAL	225 MF PER	
							DAY ORAL	

Date:11/05/97ISR Number: 100000187Report Type:Expedited (15-DaCompany Report #A0056490
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Convulsion	Consumer	Zyban	PS		ORAL
150 MG /PER						
Hospitalization -	Dizziness					
DAY/ ORAL/						
Initial or Prolonged	Lethargy					
TAB						
	Loss Of Consciousness		Warfarin Sodium	C		
	Viral Infection					

Date:11/05/97ISR Number: 1999981-5Report Type:Expedited (15-DaCompany Report #A0056490
Age:72 YR Gender:Male I/FU:U

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Convulsion	Consumer	Zyban	PS		ORAL
Hospitalization -	Dizziness		Warfarin Sodium	C		
Initial or Prolonged	Sedation					
	Syncope					

Date:11/05/97ISR Number: 3002688-9Report Type:Direct Company Report #
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Oedema Peripheral	Health	Zyban	PS		
150 MG BID						
	Pruritus	Professional				
	Rash Maculo-Papular					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/97ISR Number: 3005353-7Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister Rash Generalised Stevens-Johnson Syndrome		Zyban	PS	Glaxo Wellcome			

Date:11/10/97ISR Number: 100000223Report Type:Expedited (15-DaCompany Report #A0055651
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Dysarthria Speech Disorder Syncope	Consumer	Zyban Salbutamol Sulphate Prednisone Nisoldipine Beclomethasone Hydrochlorothiazide Theophyline Ipratropium Bromide	PS C C C C C C C		ORAL	150 MG /TWICE PER DAY	

Date:11/10/97ISR Number: 3005792-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban Dovonex Ultravate Claritin Hydroxyzine Triphasil	PS C C C C C			150 MG QD	1 WK

Date:11/17/97ISR Number: 3000899-XReport Type:Expedited (15-DaCompany Report #A0056815
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Body Temperature Decreased Dyspnoea Hypersensitivity Hypotension Oedema Peripheral Po2 Decreased Pruritus Urticaria	Consumer	Zyban	PS		ORAL	150 MG TWICE PER DAY/ORAL	

Date:11/17/97ISR Number: 3000902-7Report Type:Expedited (15-DaCompany Report #A0056717
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Circulatory Collapse Disorientation	Consumer	Zyban	PS		ORAL	150 MG/ TWICE PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/97ISR Number: 3001171-4Report Type:Expedited (15-DaCompany Report #A001-002-001429
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional	Aricept	PS		ORAL	5 MG BID (2 IN 1 D), PER ORAL
			Wellbutrin	SS		ORAL	75 MG BID (2 IN 1 D),PER ORAL
			Accupril	C			
			Paxil	C			
			Aspirin	C			

Date:11/17/97ISR Number: 3001223-9Report Type:Expedited (15-DaCompany Report #A0055651
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Aphasia Confusional State Dizziness	Health Professional	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
	Dysarthria		Salbutamol Sulphate	C			
	Dysphemia		Prednisone	C			
	Feeling Jittery		Nisoldipine	C			
	Headache		Beclomethasone Dipropion	C			
			Hydrochlorothiazide	C			
			Theophylline	C			
			Ipratropium Bromide	C			
			Salbutamol Sulphate	C			
			Beclomethasone Dipropion	C			
			Alprazolam	C			
			Oxygen	C			

Date:11/18/97ISR Number: 3001455-XReport Type:Expedited (15-DaCompany Report #A0055872
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agranulocytosis	Health	Wellbutrin	PS		ORAL	ORAL; TAB	
Initial or Prolonged	Leukopenia	Professional	Fluoxetine Hydrochloride	C				

Date:11/19/97ISR Number: 3001611-0Report Type:Expedited (15-DaCompany Report #MPI-97418
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression	Health	Methylphenidate	PS		ORAL	55 MG	
Initial or Prolonged	Agitation	Professional	Clonidine Hcl	SS		ORAL	0.1 MG	
	Convulsion		Bupropion	SS		ORAL	150 MG	
	Disorientation							

Date:11/19/97ISR Number: 3001886-8Report Type:Expedited (15-DaCompany Report #MPI-97418
Age:9 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression	Health	Methylphenidate	PS		ORAL	55MG PO	
Initial or Prolonged	Agitation	Professional	Clonidine Hcl	SS		ORAL	0.1MG PO	

			Bupropion	SS		ORAL
150MG PO						

Date:11/20/97ISR Number: 3002248-XReport Type:Expedited (15-DaCompany Report #A0056001
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Health Professional Company Representative	Wellbutrin	PS		ORAL

Date:11/24/97ISR Number: 3005401-4Report Type:Direct Company Report #
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Mydriasis	Health	Wellbutrin	PS		ORAL
150 MG Q AM						
		Professional				

Date:11/25/97ISR Number: 3006144-3Report Type:Direct Company Report #
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Angioneurotic Oedema		Zyban	PS		
150 MG BID						
	Arthralgia					
(THERAPY						
	Pyrexia					
DYRATION 2						
	Urticaria					
WKS) 2 WK						
			Advil Prn	SS		
PRN						

Date:11/25/97ISR Number: 3038900-XReport Type:Periodic Company Report #1977/20379
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Caverject	PS		I.CAVERN		
	Penile Pain	Company Representative	Wellbutrin	SS				
			St. John'S Wert	C				

Date:11/26/97ISR Number: 3002376-9Report Type:Expedited (15-DaCompany Report #A0054799
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Gastritis							
	Haematochezia							
	Nausea		Verapamil Hydrochloride	C				
			Indomethacin	C				
			Vitamin	C				
			Vicodin	C				

Date:11/26/97ISR Number: 3002381-2Report Type:Expedited (15-DaCompany Report #A0055872
Age:54 YR Gender:Female I/FU:F

Outcome
Hospitalization - Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agranulocytosis	Health	Wellbutrin	PS		ORAL	150MG/TWICE	
	Leukopenia	Professional					PER DAY/ORAL	
			Fluoxetine Hydrochloride	C				
			Trazodone	C				
			Minoxidil	C				
			Phenoxymethylpenicillin K	C				

Date:11/26/97ISR Number: 3002382-4Report Type:Expedited (15-DaCompany Report #A0054301
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Foreign Study Health Professional	Wellbutrin	PS		ORAL	75MG/THREE TIMES PER DAY/ ORAL	

Date:12/01/97ISR Number: 3006230-8Report Type:Direct Company Report #
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accommodation Disorder		Zyban	PS		ORAL	150 MG BID PO	
	Balance Disorder							
	Dizziness							
	Electrocardiogram Abnormal							
	Headache							
	Nausea							
	Vision Blurred							
	Vomiting							

Date:12/01/97ISR Number: 3050739-8Report Type:Periodic Company Report #A0055439
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Human Int / Long Insulin	C				

Date:12/01/97ISR Number: 3050767-2Report Type:Periodic Company Report #A0055476
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancytopenia	Health Professional Company Representative	Zyban	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/97ISR Number: 3050885-9Report Type:Periodic Company Report #A0055715
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health Professional	Zyban	PS		ORAL	150 MG TWICE PER DAY/	ORAL

Date:12/01/97ISR Number: 3050924-5Report Type:Periodic Company Report #A0055749
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour	Health Professional	Zyban	PS		ORAL	150 MG/ PER DAY/	ORAL

Date:12/01/97ISR Number: 3050931-2Report Type:Periodic Company Report #A0055753
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation	Health Professional	Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
	Anxiety							
	Derealisation							
	Drug Level Above Therapeutic		Wellbutrin	SS		ORAL	150 MG/ THREE TIMES PER DAY/	ORAL

Date:12/01/97ISR Number: 3051356-6Report Type:Periodic Company Report #A0053959
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angioneurotic Oedema	Health	Zyban	PS		ORAL	150 MG TWICE
	Urticaria	Professional					PER DAY/
							ORAL
			Oxpentifylline	C			

Date:12/01/97ISR Number: 3051424-9Report Type:Periodic Company Report #A0054056
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dizziness	Consumer	Zyban	PS		ORAL	300MG / SEE
	Feeling Abnormal						TEXT / ORAL
	Feeling Drunk		Antibiotics	C			
	Medication Error						
	Tremor						
	Vision Blurred						

Date:12/01/97ISR Number: 3051746-1Report Type:Periodic Company Report #A0054114
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Convulsion	Health	Zyban	PS		ORAL	150 MG/TWICE
Initial or Prolonged	Dizziness	Professional					PER DAY/ORAL
Other	Faecal Incontinence		Baclofen	C			
	Loss Of Consciousness		Misoprostol	C			
	Nausea		Omeprazole	C			
	Urinary Incontinence		Nabumetone	C			

			Zolpidem Tartrate	C		
			Venlafaxine Hydrochloride	C		
			Semisodium Valproate	C		
			Desamethasone	C		
			Clarithromycin	C		

Date:12/01/97ISR Number: 3051800-4Report Type:Periodic Company Report #A0054881
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Zyban	PS		ORAL	150 MG	ORAL
Other	Dyspnoea	Professional	Oestradiol	C				
	Throat Tightness	Company						
	Tongue Disorder	Representative						

Date:12/01/97ISR Number: 3052148-4Report Type:Periodic Company Report #A0053088
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort	Health	Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Costochondritis	Professional						
			Sertraline Hydrochloride	C				
			Thyroxine Sodium	C				
			Dexfenfluramine	C				
			Atorvastatin Calcium	C				

Date:12/01/97ISR Number: 3052150-2Report Type:Periodic Company Report #A0053159
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Dyspnoea	Health	Zyban	PS		ORAL
ORAL						
	Pruritus	Professional				
	Urticaria					

Date:12/01/97ISR Number: 3052152-6Report Type:Periodic Company Report #A0053181
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Disorientation	Health	Zyban	PS		ORAL
150 MG / PER						
	Disturbance In Attention	Professional				
DAY / ORAL						
	Dizziness		Lisinopril	C		
	Feeling Abnormal		Diazepam	C		
			Paracetamol	C		

Date:12/01/97ISR Number: 3052155-1Report Type:Periodic Company Report #A0053466
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder	Health	Zyban	PS		ORAL
150 MG / ORAL						
Initial or Prolonged	Chest Pain	Professional	Digoxin	C		
	Convulsion		Conjugated Estrogens Medroxyprogesterone Ace.	C		
				C		

Ipratropium Bromide	C
Salbutamol Sulphate	C
Fluticasone Prorpionate	C
Triamcinolone Acetonide	C
Diphenhydramine Hcl	C

Date:12/01/97ISR Number: 3052175-7Report Type:Periodic Company Report #A0056234
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Mania	Health Professional Company Representative	Zyban Lamotrigine Loarazepam Thiothixene Temazepam Lisinopril Ibuprofen Oestradiol	PS C C C C C C C		ORAL	150 MG / PER DAY / ORAL	

Date:12/01/97ISR Number: 3052191-5Report Type:Periodic Company Report #A0056289
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Dry Mouth Face Oedema Oral Mucosal Eruption Stevens-Johnson Syndrome Tongue Oedema	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	5 WK

Date:12/01/97ISR Number: 3053025-5Report Type:Periodic Company Report #A0053833
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Health	Zyban	PS		ORAL	150 MG TWICE	
Other	Pruritus	Professional					PER DAY/	
	Swelling	Company					ORAL	
	Urticaria	Representative						
	Vomiting							

Date:12/01/97ISR Number: 3053053-XReport Type:Periodic Company Report #A0053894
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis	Health	Zyban	PS		ORAL	150 MG	ORAL
Initial or Prolonged	Urticaria	Professional						
		Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/97ISR Number: 3053387-9Report Type:Periodic Company Report #A0056510
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypersensitivity Pruritus Rash Erythematous Swelling Urticaria	Consumer	Zyban Decongestant	PS C		ORAL	150 MG / ORAL

Date:12/01/97ISR Number: 3053388-0Report Type:Periodic Company Report #A0056511
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Consumer	Zyban	PS		ORAL	150 MG / ORAL

Date:12/01/97ISR Number: 3053553-2Report Type:Periodic Company Report #A0054981
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation Excitability Overdose	Consumer	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL

Date:12/01/97ISR Number: 3053602-1Report Type:Periodic Company Report #A0056364
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation Hypertension	Health Professional	Zyban	PS		ORAL	150 MG / TWICE PER

	Nausea	Company				
DAY/ ORAL						
	Psychomotor Hyperactivity	Representative	Multiple Medication	C		

Date:12/01/97ISR Number: 3054081-0Report Type:Periodic Company Report #A0056760
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Syncope	Health	Zyban	PS		ORAL	150 MG; ORAL
Initial or Prolonged		Professional					
Other		Company					
		Representative					

Date:12/01/97ISR Number: 3054192-XReport Type:Periodic Company Report #A0055144
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Grand Mal Convulsion	Health	Zyban	PS		ORAL	150 MG/
Initial or Prolonged		Professional					
Other		Company					TWICE PER DAY/ ORAL
		Representative					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/97ISR Number: 3054235-3Report Type:Periodic Company Report #A0055214
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Zyban	PS		ORAL	150 MG/ TWICE	
	Convulsion	Professional					PER DAY/	
	Dizziness						ORAL	2 WK
	Haematoma		Ciprofloxacin	C				
	Laceration		Loestrin	C				
	Loss Of Consciousness		Nicotine	C				
	Syncope							
	Tooth Injury							
	Urinary Tract Infection							

Date:12/01/97ISR Number: 3055015-5Report Type:Periodic Company Report #A0055397
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eyelid Oedema	Health	Zyban	PS		ORAL	150 MG TWICE	
	Hypersensitivity	Professional					PER DAY ORAL	
	Joint Swelling		Vitamin E	C				
	Rash Pruritic		Ascorbic Acid	C				
			Cyanocobalamin	C				
			Aspirin	C				

Date:12/01/97ISR Number: 3058639-4Report Type:Periodic Company Report #A0055974
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypersensitivity	Health	Zyban	PS		ORAL	150 MG ORAL	
Other	Oedema	Professional	Acyclovir	C				
	Pruritus							
	Rash Erythematous							

Date:12/02/97ISR Number: 3007014-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Zyban	PS				

Date:12/03/97ISR Number: 3006683-5Report Type:Direct Company Report #
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression Hypomania Mania Suicidal Ideation		Wellbutrin Gabapentin	PS C	Burroughs Wellcome	ORAL	150 MG QID PO	1 WK

Date:12/04/97ISR Number: 3007173-6Report Type:Direct Company Report #
Age:15 YR Gender:Female I/FU:I

Outcome
Hospitalization - Initial or Prolonged
Required Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema		Wellbutrin	PS	Glaxo Wellcome	ORAL	100 MG BID PO	
	Arthralgia		Tenex	SS		ORAL	1 MG BID PO	
	Chest Pain		Doxycycline	C			100 MG BID	
	Convulsion							
	Cyanosis							
	Diarrhoea							
	Dyspnoea							
	Face Oedema							
	Loss Of Consciousness							
	Nausea							
	Oedema Peripheral							
	Pain In Extremity							
	Rash Pruritic							
	Throat Tightness							

Date:12/04/97ISR Number: 3007606-5Report Type:Direct Company Report #
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Wellbutrin Sr	PS		ORAL	150 MG 1 TAB PO Q AM 16 DOSES (SAMPLE)	
	Dizziness							
	Dyskinesia							
	Hypoaesthesia							
	Paraesthesia							

Date:12/10/97ISR Number: 3006294-1Report Type:Expedited (15-DaCompany Report #A0057764
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	
	Dermatitis							
	Hypersensitivity		Hydrocortisone	C				
	Oedema		Warfarin Sodium	C				
	Oedema Peripheral							
	Pruritus							

Date:12/10/97ISR Number: 3006295-3Report Type:Expedited (15-DaCompany Report #A0057792
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Sodium Decreased	Consumer	Zyban	PS		ORAL	150 MG/ PER DAY/	
	Dehydration							
	Polyuria		Oxpentifylline	C				
	Vomiting		Nabumetone	C				
	Weight Decreased		Claritin-D	C				
			Lansoprazole	C				
			Conjugated Estrogens	C				
			Dyazide	C				
			Simvastatin	C				
			Alprazolam	C				
			Amitriptyline Hcl	C				
			Fluticasone Propionate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/97ISR Number: 3006296-5Report Type:Expedited (15-DaCompany Report #A0057783
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide	Foreign	Wellbutrin	PS		ORAL	150 MG/ THREE
Life-Threatening		Study					TIMES PER DAY
		Health					ORAL
		Professional	Venlafaxine Hydrechloride	C			
			Lorazepam	C			
			Temazepam	C			

Date:12/11/97ISR Number: 3007417-0Report Type:Expedited (15-DaCompany Report #A0054873
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety	Consumer	Zyban	PS		ORAL	150 MG ORAL
	Asthenia		Theophylline	C			
	Cardiac Failure		Salmeterol Xinafoate	C			
	Congestive		Salbutamol Sulphate	C			
	Dizziness		Lactulose	C			
	Dry Mouth		Frusemide	C			
	Dysgeusia		Alprazolam	C			
	Headache						
	Insomnia						
	Nausea						
	Pneumonia						

Date:12/11/97ISR Number: 3007632-6Report Type:Direct Company Report #
Age:5 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Balance Disorder		Wellbutrin Sr	PS			100 MG TID 1 DAY
	Coordination Abnormal						

Date:12/15/97ISR Number: 3006983-9Report Type:Direct Company Report #
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Iron Decreased	Other	Clozapine	PS			12.5 MG BID	
	Microcytic Anaemia		Effexor	SS				
			Wellbutrin	SS				
			Klonopin	SS				

Date:12/15/97ISR Number: 3008811-4Report Type:Expedited (15-DaCompany Report #A0057391
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Interaction	Health	Wellbutrin	PS		ORAL	UNK / TWICE	
Other	Headache	Professional					PER DAY /	
	Hypersensitivity	Company					ORAL	
		Representative	Trazodone	SS		ORAL	50 MG /	
							SINGLE DOSE /	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/97ISR Number: 3011549-0Report Type:Direct Company Report #
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Zyban	PS			AS DIRECTED	3 WK
	Erythema Multiforme							
	Urticaria							

Date:12/17/97ISR Number: 3011763-4Report Type:Direct Company Report #
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Buproprion	PS		ORAL	150MG PO BID	
Required Intervention to Prevent Permanent Impairment/Damage	Tremor							

Date:12/18/97ISR Number: 3009376-3Report Type:Expedited (15-DaCompany Report #A0057968
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gait Disturbance	Consumer	Wellbutrin	PS		ORAL	150 MG/TWICE PER DAY/ ORAL	
	Hypersensitivity							
	Joint Swelling							
	Pharyngeal Oedema							
	Urticaria							

Date:12/18/97ISR Number: 3009383-0Report Type:Expedited (15-DaCompany Report #A0057990
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Arthralgia	Health	Zyban	PS		ORAL
150 MG/ TWICE						
Initial or Prolonged	Bronchospasm	Professional				
PER DAY ORAL						
	Myalgia		Buspirone	C		
	Oedema					
	Pharyngeal Oedema					
	Serum Sickness					
	Urticaria					

Date:12/19/97ISR Number: 3008836-9Report Type:Expedited (15-DaCompany Report #A0057263
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Polyarthritis	Health	Wellbutrin	PS		ORAL
100MG / THREE						
Initial or Prolonged	Serum Sickness	Professional				
TIMES PER DAY						
	Urticaria					
ORAL						

Date:12/23/97ISR Number: 3014108-9Report Type:Expedited (15-DaCompany Report #A0056978
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Pancreatitis	Health	Zyban	PS		ORAL
150 MG /						
Hospitalization -		Professional				
TWICE PER DAY						
Initial or Prolonged		Company				
/ ORAL						
Other		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/97ISR Number: 3014415-XReport Type:Expedited (15-DaCompany Report #A0058368
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral	Consumer	Zyban	PS		ORAL	150 MG/SINGLE DOSE/ORAL
	Embolism						
	Rectal Haemorrhage		Terazosin Hydrochloride	C			
			Pravastatin Sodium	C			
			Aspirin	C			

Date:12/29/97ISR Number: 3014418-5Report Type:Expedited (15-DaCompany Report #A0054873
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Zyban	PS	Zyban	ORAL	150 MG/ UNK/ ORAL
	Asthenia	Professional					
	Cardiac Failure		Theophylline	C			
	Congestive		Salmeterol Xinafoate	C			
	Dizziness		Salbutamol Sulphate	C			
	Dry Mouth		Lactulose	C			
	Dysgeusia		Frusemide	C			
	Headache		Alprazolam	C			
	Insomnia						
	Nausea						
	Pneumonia						
	Respiratory Failure						

Date:01/07/98ISR Number: 3015994-9Report Type:Expedited (15-DaCompany Report #A0057797
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Zyban	PS		ORAL	150 MG / PER DAY/ ORAL
	Dehydration						

	Hypersomnia		Conjugated Estrogens	C			
	Malaise		Ibuprofen	C			
	Nausea						
	Vision Blurred						

Date:01/08/98ISR Number: 3015442-9Report Type:Expedited (15-DaCompany Report #97030194-1
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Nicoderm Cq	PS		TRANSDERMAL	21 MILLIGRAMS	
	Feeling Abnormal						1.0 DAILY	
	Loss Of Consciousness					TRANSDERMAL		
	Movement Disorder		Zyban	SS		ORAL	150	
	Nervousness						MILLIGRAMS	
							2.0 DAILY	
							ORAL	

Date:01/08/98ISR Number: 3016021-XReport Type:Expedited (15-DaCompany Report #8-97286-020L
Age:43 YR Gender:Female I/FU:F

Outcome
Other
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Valve Disease	Health	Pondimin	PS		ORAL	20MG THREE	
	Mitral Valve Incompetence	Professional					TIMES A DAY	
	Palpitations						ORAL	
			Fastin	SS		ORAL	30MG DAILY	
							ORAL	
			Ionamin	SS		ORAL	30MG DAILY	
							ORAL	
			Redux	SS		ORAL	30MG DAILY	
							ORAL	
			Wellbutrin	SS			100 MG BID	
			Ionamin	C				
			Ionamin	C				
			Redux	C				

Date:01/12/98ISR Number: 3016979-9Report Type:Expedited (15-DaCompany Report #A0058622
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lung Neoplasm Malignant	Consumer	Zyban	PS		ORAL	150 MG/PER	
Initial or Prolonged							DAY/ORAL	
Other			Betaxolol Hydrochloride	C				
			Lorazepam	C				
			Theophylline	C				

Date:01/13/98ISR Number: 3016394-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Wellbutrin	PS			300 MG	QD
	Shock		Zoloft	SS			75 MG	QD

Date:01/13/98ISR Number: 3016645-XReport Type:Expedited (15-DaCompany Report #A0057378
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Study	Retrovir	PS		ORAL	300 MG / TWICE PER DAY	
Other	Intentional Misuse	Health					/ ORAL	
	Suicide Attempt	Professional						
			Epivir	SS		ORAL	150 MG / TWICE PER DAY	
			Indinavir Sulfate	SS		ORAL	800 MG / THREE TIMES PER DA	
							/ ORAL	
			Placebo	SS				
			Wellbutrin	SS		ORAL	SINGLE DOSE / ORAL	
			Trazodone	C				
			Bupropion Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/15/98ISR Number: 3017125-8Report Type:Expedited (15-DaCompany Report #A0057990
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Arthralgia	Health	Zyban	PS		ORAL	150 MG /
Hospitalization -	Bronchospasm	Professional					TWICE PER DAY
Initial or Prolonged	Dyspnoea						/ ORAL
Other	Feeling Hot		Buspirone				
	Myalgia		Hydrochloride	C			
	Oedema						
	Serum Sickness						
	Throat Tightness						
	Urticaria						

Date:01/15/98ISR Number: 3017130-1Report Type:Expedited (15-DaCompany Report #A0058368
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blindness Unilateral	Consumer	Zyban	PS		ORAL	150 MG /
Initial or Prolonged	Embolism						SINGLE DOSE /
	Rectal Haemorrhage						ORAL
			Terazosin Hydrochloride	C			
			Pravastatin Sodium	C			
			Aspirin	C			
			Allopurinol	C			

Date:01/15/98ISR Number: 3017133-7Report Type:Expedited (15-DaCompany Report #A0057783
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide	Foreign	Wellbutrin	PS		ORAL	150 MG /

Life-Threatening		Study					
THREE TIMES							
		Health					
PER DAY							
		Professional	Venlafaxine				
			Hydrochloride	C			
			Lorazepam	C			
			Temazepam	C			

Date:01/15/98ISR Number: 3017147-7Report Type:Expedited (15-DaCompany Report #A0057496
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Rate Decreased	Health	Zyban	PS		ORAL	150 MG TWICE	
	Hypertension	Professional					PER DAY ORAL	
			Nadolol	C				
			Hydroxychloroquine	C				

Date:01/15/98ISR Number: 3017151-9Report Type:Expedited (15-DaCompany Report #A0058633
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Zyban	PS		ORAL	150 MG TWICE	
Initial or Prolonged	Cardiomegaly						PER DAY ORAL	
	Hypertension		Clonazepam	C				
	Palpitations		Theophylline	C				
			Hypericum	C				
			Doxazosin	C				

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Alprazolam	C				

Date:01/15/98ISR Number: 3017155-6Report Type:Expedited (15-DaCompany Report #A0058742
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Bullous	Health	Wellbutrin	PS		ORAL	ORAL	1 WK
	Petechiae	Professional	Tetracycline	C				
	Stomatitis Haemorrhagic		Phenobarbitone	C				
	Thrombocytopenia							

Date:01/15/98ISR Number: 3077789-XReport Type:Periodic Company Report #WAES 97070306
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gout	Consumer	Crixivan	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	800 MG/Q8H/PO	
	Nervousness							
	Tinnitus							
			Bupropion Hcl Unk	SS				
			Zoloft Unk	SS				
			Biaxin	C				
			Diflucan	C				
			Floxin	C				
			Indocin	C				
			Lomotil	C				
			Restoril	C				
			Sporanox	C				
			Viramune	C				
			Xanax	C				
			Zerit	C				
			Zovirax	C				
			Zyloprim	C				
			Composition Unspecified	C				
			Lamivudine	C				

Date:01/20/98ISR Number: 3017239-2Report Type:Expedited (15-DaCompany Report #A0059083
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia Tachycardia	Health Professional Company Representative	Wellbutrin	PS		ORAL	ORAL	

Date:01/20/98ISR Number: 3017242-2Report Type:Expedited (15-DaCompany Report #A0059063
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Liver Function Test	Health	Wellbutrin	PS		ORAL	75 MG/ORAL1	
Hospitalization - Initial or Prolonged	Abnormal Nausea Oedema Pancreatitis Pleural Effusion	Professional	Sertraline	C				YEARS 1 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/98ISR Number: 3017286-0Report Type:Expedited (15-DaCompany Report #A0059062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Zyban	PS		ORAL	ORAL	
	Smoker							

Date:01/20/98ISR Number: 3017288-4Report Type:Expedited (15-DaCompany Report #A0059118
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Zyban	PS		ORAL	ORAL	
	Dehydration							
	Nausea							
	Vision Blurred							

Date:01/20/98ISR Number: 3018004-2Report Type:Expedited (15-DaCompany Report #A0057927
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Consumer	Wellbutrin	PS		ORAL	150 MG/ORAL	
	Dyspnoea		Vitamin E	C				
	Oedema Peripheral		Multivitamin	C				
			Prempro	C				
			Prednisone	C				
			Ticlopidine	C				
			Metoclopramine	C				
			Nabumetone	C				
			Losartan Potassium	C				
			Terazosin Hydrochloride	C				
			Diltiazem Hydrochloride	C				
			Omeprazole	C				
			Insulin	C				

Date:01/20/98ISR Number: 3018609-9Report Type:Direct Company Report #
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia		Wiellbutrin	PS	Sr		QD X 3 D THEN	
	Hyperhidrosis						BID	
	Insomnia		Mivacor	C				
	Palpitations		Claritin	C				
			Premarin	C				
			Vasotec	C				

Date:01/20/98ISR Number: 3018611-7Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
	Arthralgia
	Asthenia
	Eyelid Oedema
	Fatigue
	Pyrexia
	Rash Generalised

	Rash Pruritic Tachycardia Urticaria	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
			Trimethoprim/Sulfamethoxazole	PS		ORAL
PO 5 DAYS						
PERIOR TO						
ADMISSION 5 DAY						
			Bupropion	SS		

Date:01/20/98ISR Number: 3083294-7Report Type:Periodic Company Report #A0053314
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Aortic Valve Stenosis	Health	Wellbutrin Tablet	PS		ORAL
ORAL						
		Professional	Sertraline Hydrochloride (Formulation Unknown)	SS		ORAL
ORAL						

Date:01/20/98ISR Number: 3083775-6Report Type:Periodic Company Report #A0053886
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL
100 MG / FOUR						
TIMES PER DAY						
ORAL 1 MON						

Date:01/20/98ISR Number: 3083799-9Report Type:Periodic Company Report #A0054330
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Wellbutrin	PS		ORAL	150 MG/TWICE PER DAY/	ORAL
	Loss Of Consciousness	Professional						
	Psychotic Disorder		Fluoxetine Hydrochloride	C				
			Olanzapine	C				

Date:01/20/98ISR Number: 3083884-1Report Type:Periodic Company Report #A0054792
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Postmenopausal	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG ORAL	
	Haemorrhage							

Date:01/20/98ISR Number: 3083924-XReport Type:Periodic Company Report #A0050599
Age:12 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Wellbutrin Tablet	PS		ORAL	75 MG TWICE PER DAY	ORAL
	Dysphagia	Professional						
	Erythema Multiforme		Clarithromycin					
	Joint Swelling		(Formulation Unknown)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/98ISR Number: 3083927-5Report Type:Periodic Company Report #A0050600
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Dermatitis Mucosal Inflammation Pyrexia Stevens-Johnson Syndrome	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	ORAL

Date:01/20/98ISR Number: 3083949-4Report Type:Periodic Company Report #A0050649
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Asthma Pneumonia	Health Professional	Wellbutrin Tablet-Controlled Release Trazodone Hydrochloride Semisodium Valproate Prednisone	 PS C C C		ORAL	150 MG / IN THE MORNING / ORAL

Date:01/20/98ISR Number: 3084003-8Report Type:Periodic Company Report #A0051411
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	450 MG / PER DAY / ORAL

Date:01/20/98ISR Number: 3084007-5Report Type:Periodic Company Report #A0051433
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Wellbutrin	PS		ORAL	75 MG/PER	
Initial or Prolonged	Hallucination						DAY/ORAL	
	Hypertension		Alprazolam	C				
	Insomnia		Unspecified					
	Paranoia		Medication	C				
			Trazodone	C				

Date:01/20/98ISR Number: 3084109-3Report Type:Periodic Company Report #A0051790
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Company	Wellbutrin Tablet	PS		ORAL	200 MG /	
		Representative					TWICE PER DAY	
							/ ORAL	

Date:01/20/98ISR Number: 3084125-1Report Type:Periodic Company Report #A0051931
Age:52 YR Gender:Female I/FU:I

Outcome	PT
Other	Abdominal Pain Upper
	Asthma

	Bronchitis Dyspepsia Flatulence	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Increased Appetite	Health	Wellbutrin Tablet	PS		ORAL 100 MG /
	Insomnia	Professional				TWICE PER DAY
	Liver Function Test					/ ORAL
	Abnormal Nausea Pruritus		Wellbutrin Tablet-Controlled Release	SS		ORAL 200 MG / PER DAY / ORAL
			Estratest	C		
			Nabumetone	C		

Date:01/20/98ISR Number: 3084132-9Report Type:Periodic Company Report #A0052026
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Convulsion	Health	Wellbutrin Tablet	PS		ORAL 200 MG /
Other	Loss Of Consciousness	Professional				THREE TIMES
						PER DAY /
						ORAL
			Nortriptyline	C		
			Alprazolam	C		
			Buspirone	C		

Date:01/20/98ISR Number: 3084157-3Report Type:Periodic Company Report #A0052320
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration

Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Wellbutrin Bupropion Hydrochloride Disulfiram	PS C C		ORAL 100 MG ORAL

Date:01/20/98ISR Number: 3084203-7Report Type:Periodic Company Report #A0052872
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vomiting	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG / THREE TIMES PER DAY /	ORAL 1 MON

Date:01/20/98ISR Number: 3084244-XReport Type:Periodic Company Report #A0052930
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia Coordination Abnormal Facial Palsy Muscle Rigidity Musculoskeletal Stiffness	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/98ISR Number: 3085328-2Report Type:Periodic Company Report #A0049086
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Wellbutrin	PS		ORAL	ORAL	

Date:01/20/98ISR Number: 3085330-0Report Type:Periodic Company Report #A0049102
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin	PS		ORAL	100MG/FOUR TIMES PER DAY/ORAL	

Date:01/20/98ISR Number: 3085350-6Report Type:Periodic Company Report #A0049148
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Overdose	Health Professional Company Representative	Wellbutrin Alprazolam	PS C		ORAL	900 MG/PER DAY/ORAL	

Date:01/20/98ISR Number: 3085390-7Report Type:Periodic Company Report #A0049329
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Agitation Convulsion	Health Professional Company Representative	Wellbutrin Caffeine	PS C			

Date:01/20/98ISR Number: 3085469-XReport Type:Periodic Company Report #A0049701
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Euphoric Mood Hallucination Overdose	Health Professional	Wellbutrin	PS		ORAL	800MG/ORAL

Date:01/20/98ISR Number: 3085643-2Report Type:Periodic Company Report #A0055690
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Aggression Agitation Disorientation Impulse-Control Disorder Memory Impairment	Health Professional Other	Wellbutrin Clonidine Methylphenidate	PS C C		ORAL	150 MG/ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/98ISR Number: 3085658-4Report Type:Periodic Company Report #A0056325
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Myocardial Infarction	Health Professional Company Representative	Wellbutrin	PS		ORAL	150 MG/TWICE PER DAY/ORAL

Date:01/20/98ISR Number: 3085733-4Report Type:Periodic Company Report #A0057417
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Confusional State Disorientation Hallucination	Health Professional Company Representative	Wellbutrin	PS		ORAL	150 MG/TWICE PER DAY/ORAL

Date:01/20/98ISR Number: 3085746-2Report Type:Periodic Company Report #A0057671
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Convulsion Overdose	Health Professional	Wellbutrin Fluoxetine Hydrochloroide (Formulation Unknwon) Ethanol (Formulation Unknown)	PS SS SS		ORAL	100 MG/ORAL

Date:01/20/98ISR Number: 3085884-4Report Type:Periodic Company Report #A0050029
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional Company Representative	Wellbutrin Diltiazem Hydrochloride Glibenclamide Ranitidine Hydrochloride	PS C C C		ORAL	ORAL	

Date:01/20/98ISR Number: 3085885-6Report Type:Periodic Company Report #A0050061
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bruxism	Health	Wellbutrin	PS		ORAL	100MG/TWICE PER DAY/ORAL	
	Pain In Jaw	Professional						

Date:01/20/98ISR Number: 3085900-XReport Type:Periodic Company Report #A0050131
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Chest Pain	Consumer	Wellbutrin	PS		ORAL	300 MG/PER DAY/ORAL	6 MON
	Convulsion		Lithium Salt Lamotrigine Thyroxine Sodium	C C C				

			Estrogen	C		
			Dalmane	C		
			Thiothixene	C		

Date:01/27/98ISR Number: 3019377-7Report Type:Expedited (15-DaCompany Report #8-98009-010H
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Valve Disease	Health	Redux	PS		ORAL	15 MG TWICE	
	Cardiomegaly	Professional					DAILY ORAL	
	Dyspnoea		Wellbutrin	SS			150 MG TWICE	
							DAILY	
			Provera	C			10 MG	
			Synthroid	C			0.125 MG	
			Wellbutrin	C			300 MG	

Date:01/27/98ISR Number: 3021414-0Report Type:Direct Company Report #
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Zyban	PS	Glaxo		1 TABLET BID	2 DAY
	Disability		Depo-Provera	C				
	Eyelid Oedema		Benadryl	C				
	Immobile							
	Joint Swelling							
	Oedema Mouth							
	Pain							
	Rash Erythematous							

Date:01/27/98ISR Number: 3030775-8Report Type:Direct Company Report #
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS			1 TABLET BID	14 DAY
	Dermatitis		Depo-Provera	C				
	Eyelid Oedema		Benadryl	C				
	Joint Swelling							
	Oedema							
	Oedema Mouth							
	Pain							

Date:01/27/98ISR Number: 3109823-2Report Type:Direct Company Report #
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased		Wellbutrin	PS		ORAL	150 G TID	

Date:01/28/98ISR Number: 3020961-5Report Type:Expedited (15-DaCompany Report #8-98016-002S
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ventricular Hypertrophy	Health	Pondimin	PS		ORAL	ORAL	6 MON
		Professional	Phentermine	SS		ORAL	ORAL	6 MON
			Wellbutrin	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/98ISR Number: 3021045-2Report Type:Expedited (15-DaCompany Report #8-98016-002S
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ventricular Hypertrophy	Health	Pondimin	PS		ORAL	ORAL	6 MON
		Professional	Wellbutrin	SS				
			Phentermine	SS				

6 MON

Date:01/28/98ISR Number: 3021583-2Report Type:Direct Company Report #
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blister		Wellbutrin	PS		ORAL	150 MG PO BID	
	Dermatitis Bullous		Tetracycline	C				
	Mucosa Vesicle							
	Mucosal Haemorrhage							
	Petechiae							
	Rosacea							

Date:01/28/98ISR Number: 3021588-1Report Type:Direct Company Report #
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Hypersensitivity		Zyban	PS	Glaxo/Wellcome		150MG PO BID	
Hospitalization - Initial or Prolonged	Pharyngeal Oedema							
	Respiratory Distress							
	Urticaria							

Date:01/28/98ISR Number: 3021674-6Report Type:Direct Company Report #
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Chest Discomfort		Zyban	PS	Glaxo	
150 MG BID 2 WK						
Initial or Prolonged	Erythema Multiforme					
	Face Oedema					
	Urticaria					
	White Blood Cell Count Increased					

Date:01/29/98ISR Number: 3112043-9Report Type:Periodic Company Report #8-97174-018L
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthenia	Health	Redux	PS		ORAL
15-30 MG						
	Fatigue	Professional				
DAILY ORAL						
			Wellbutrin	SS		ORAL
25 MG DAILY						
ORAL						

Date:01/30/98ISR Number: 3021134-2Report Type:Expedited (15-DaCompany Report #A0059505
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Euphoric Mood	Consumer	Zyban	PS		ORAL
150 MG PER						
	Feeling Abnormal					
DAY ORAL 6 DAY						
	Neoplasm Malignant		..	C		
	Psychomotor Hyperactivity					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/98ISR Number: 3021151-2Report Type:Expedited (15-DaCompany Report #A0058742
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhagic Disorder	Health	Wellbutrin	PS		ORAL	150 MG /	
Hospitalization -	Mouth Haemorrhage	Professional					TWICE PER DAY	
Initial or Prolonged	Petechiae						/ ORAL	
Other	Platelet Count Decreased		Tetracycline	C				
	Thrombocytopenia		Phenobarbitone	C				

Date:02/02/98ISR Number: 3021856-3Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Decreased Activity		Zyban	PS		ORAL	PO	
	Flashback		Lovazepam	C				
	Flushing		Pindolol	C				
	Insomnia							
	Panic Attack							
	Post-Traumatic Stress Disorder							
	Psychiatric Symptom							

Date:02/02/98ISR Number: 3022150-7Report Type:Expedited (15-DaCompany Report #A0058605
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorectal Disorder	Health	Zyban	PS		ORAL	150 MG TWICE	
Initial or Prolonged	Constipation	Professional					PER DAY	
Other	Drug Interaction		Omeprazole	SS			10 MG TWICE	
							PER DAY	

Date:02/02/98ISR Number: 3022152-0Report Type:Expedited (15-DaCompany Report #A0057797
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional	Zyban	PS		ORAL	150 MG PER DAY	
	Dehydration							
	Hypersomnia		Conjugated Estrogens	C				
	Malaise		Ibuprofen	C				
	Nausea							
	Visual Disturbance							

Date:02/02/98ISR Number: 3088615-7Report Type:Periodic Company Report #A0057121
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Drug Ineffective							
	Feeling Abnormal							
			Hyzaar	C				
			Berocca	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/98ISR Number: 3091420-9Report Type:Periodic Company Report #A0057691
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis A	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY	
		Company Representative	Simvastatin Tablet	SS		ORAL	10 MG PER DAY	

ORAL

Date:02/02/98ISR Number: 3091432-5Report Type:Periodic Company Report #A0057795
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Consumer	Wellbutrin	PS		ORAL	150 MG PER DAY	30 DAY
			Imipramine	C				
			Conjugated Estrogens	C				

Date:02/02/98ISR Number: 3107304-3Report Type:Periodic Company Report #A0058281
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Health Professional	Wellbutrin	PS		ORAL	150MG/TWICE PER DAY/ORAL	
	Blood Pressure Decreased							
	Cognitive Disorder		Diphenhydramine Hcl	SS				
	Dermatitis		Sertraline Hydrochloride	C				
	Dyspnoea							
	Hypoaesthesia Oral							
	Oedema Peripheral							
	Urticaria							

Date:02/02/98ISR Number: 3107306-7Report Type:Periodic Company Report #A0054447
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fall	Health	Wellbutrin	PS			150MG/FOUR	
	Grand Mal Convulsion	Professional					TIMES PER DAY	
	Periorbital Haematoma	Company	Wellbutrin	SS		ORAL	75 MG / SEE	
		Representative					TEXT/ ORAL	
			Desipramine	C				

Date:02/02/98ISR Number: 3114037-6Report Type:Periodic Company Report #A0055443
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine	Health	Wellbutrin	PS		ORAL	150 MG/ TWICE	
Initial or Prolonged	Phosphokinase Increased	Professional					PER DAY/ ORAL	
Other	Blood Lactate	Company	Glipizide	C				
	Dehydrogenase Increased	Representative	Metformin	C				
	Hepatic Enzyme Increased		Multivitamin	C				
	Muscle Disorder		Insulin	C				
	Rhabdomyolysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/98ISR Number: 3114038-8Report Type:Periodic Company Report #A0055506
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Coordination Abnormal	Health	Wellbutrin	PS		ORAL	75 MG/ UNK/
		Professional					ORAL
		Company Representative	Ludiomil	C			
			Lithium Salt	C			
			Thyroxine	C			

Date:02/02/98ISR Number: 3114039-XReport Type:Periodic Company Report #A0055507
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Insomnia	Health	Wellbutrin	PS		ORAL	150 MG/ TWICE
	Road Traffic Accident	Professional					PER DAY/ ORAL
	Sedation	Company Representative	Aspirin	C			
			Nicotinic Acid	C			
			Atorvastatin Calcium	C			

Date:02/02/98ISR Number: 3114040-6Report Type:Periodic Company Report #A0055603
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Face Oedema	Health	Wellbutrin	PS		ORAL	50 MG/ IN THE
	Fatigue	Professional					MORNING/ ORAL
	Malaise	Company Representative	Amitriptyline Hcl	C			
	Mucosal Inflammation		Fluticasone				
	Pruritus		Propionate	C			
	Pyrexia		Claritin-D	C			
	Rash Macular		Vitamin E	C			
	Stevens-Johnson Syndrome		Pravastatin Sodium	C			
			Zolpidem Tartrate	C			

Date:02/02/98ISR Number: 3114041-8Report Type:Periodic Company Report #A0056413
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Consumer	Wellbutrin	PS		ORAL	150 MG/	SEE TEXT/
	Chills							
	Cognitive Disorder		Venlafaxine					
	Depersonalisation		Hydrochloride	C				
	Insomnia		Caffeine	C				
	Neck Pain		Antioxidants	C				
	Overdose							
	Pain							
	Tremor							

Date:02/02/98ISR Number: 3114042-XReport Type:Periodic Company Report #A0056647
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema	Health Professional	Wellbutrin	PS		ORAL	150 MG / UNK/	
	Oedema Peripheral							
Other	Pruritus	Company Representative	Fiorinal	C				
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/98ISR Number: 3022709-7Report Type:Direct Company Report #
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS		ORAL	100 MG PO BID	

Date:02/03/98ISR Number: 3028904-5Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tachycardia	Health	Wellbutrin	PS			150MG PO QD	
		Professional	Robaxin	SS			500MG PO Q12	
			Prinivil	C			H	
			Prilosec	C				
			Cipro	C				
			Imdur	C				
			K-Dur	C				
			Ativan	C				
			Lorcet 10/650	C				

Date:02/05/98ISR Number: 3024334-0Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis		Zyban	PS		ORAL	TAKE ONE TABLET BY MOUTH EVERY MORNING FOR 3 DAYS THEN 1	
Other	Drug Hypersensitivity							
	Dyspnoea							
	Pyrexia							

Date:02/06/98ISR Number: 3026429-4Report Type:Expedited (15-DaCompany Report #A0057792
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Consumer	Zyban	PS		ORAL	150 MG/ PER	
Initial or Prolonged	Dehydration						DAY / ORAL	
	Depressed Level Of		Oxpentifylline	C				
	Consciousness		Nabumetone	C				
	Hyponatraemia		Claritin-D	C				
	Polyuria		Lansoprazole	C				
	Vomiting		Conjugated Estrogens	C				
	Weight Decreased		Dyazide	C				
			Simvastatin	C				
			Alprazolam	C				
			Amitriptyline Hcl	C				
			Fluticasone Proprionate	C				
			Aspirin	C				

Date:02/09/98ISR Number: 3027036-XReport Type:Expedited (15-DaCompany Report #A0060104
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Zyban	PS		ORAL	150 MG TWICE	
Initial or Prolonged	Cholelithiasis						PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/98ISR Number: 3027179-0Report Type:Expedited (15-DaCompany Report #A0059063
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Malaise	Health	Wellbutrin	PS		ORAL	75 MG / PER	
Hospitalization -	Pancreatic Enzymes	Professional						DAY / ORAL
Initial or Prolonged	Increased		Sertraline					
Other	Pancreatitis		Hydrochloride	C				
	Pulmonary Oedema							

Date:02/11/98ISR Number: 3029072-6Report Type:Expedited (15-DaCompany Report #1998-02-0042
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Albuterol	PS			UNKNOWN	ORAL
Other	Drug Toxicity	Professional						AER INH
			Bupropion Hydrochloride	SS				
			Hydrocodone	SS				
			Ethanol	SS				
			Phenylpropanolamine	SS				
			Chlorpheniramine	SS				

Date:02/11/98ISR Number: 3029514-6Report Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rectal Haemorrhage		Wellbutrin	PS			150 SR	BID
			Flovent	C				
			Serevent	C				
			Conbivent	C				
			Theophylline	C				

Date:02/13/98ISR Number: 3029818-7Report Type:Direct Company Report #
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haematemesis		Wellutrin	PS	Glaxo	ORAL	150MG BID PO	MONTHS MON
			Pancrease	C				
			Vit C	C				
			Vit E	C				

Date:02/17/98ISR Number: 3030644-3Report Type:Expedited (15-DaCompany Report #A0060394
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Chest Pain Disturbance In Attention Dyspnoea Palpitations Poor Peripheral Circulation Tongue Oedema Tremor	Consumer	Zyban	PS		ORAL	150 MG TWICE PER DAY (TABLET)	

Date:02/17/98ISR Number: 3030646-7Report Type:Expedited (15-DaCompany Report #A0059505
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Euphoric Mood	Consumer	Zyban	PS		ORAL	150 MG PER	
	Psychomotor Hyperactivity						DAY ORAL	
							(TABLET)	

Date:02/19/98ISR Number: 3032437-XReport Type:Expedited (15-DaCompany Report #A0059062
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Zyban	PS		ORAL	ORAL	
	Nausea		Cardovascular Medication	C				

Date:02/19/98ISR Number: 3032439-3Report Type:Expedited (15-DaCompany Report #A0060149
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Health	Wellbutrin	PS		ORAL	150 MG /	
	Dermatitis	Professional					TWICE PER	
	Heart Rate Increased	Company					DAY/	
	Oedema Peripheral	Representative						
	Tongue Oedema							

Date:02/23/98ISR Number: 3036055-9Report Type:Expedited (15-DaCompany Report #A0060690
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Dermatitis Diarrhoea Erythema Multiforme Nausea Pruritus Renal Impairment Vomiting	Health Professional	Zyban	PS	ORAL 150MG/TWICE PER DAY/ ORAL

Date:02/26/98ISR Number: 3036550-2Report Type:Expedited (15-DaCompany Report #A0060825
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcohol Interaction Asthenia Clonic Convulsion Confusional State Difficulty In Walking Encephalopathy Hallucination Syncope Urinary Incontinence	Health Professional Company Representative	Wellbutrin Ethanol	PS C		ORAL	150 MG / TWICE PER DAY / ORAL	8 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/98ISR Number: 3043863-7Report Type:Expedited (15-DaCompany Report #A0060881
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Haematuria	Health	Zyban	PS		ORAL	150MG / TWICE PER DAY / ORAL
	Subarachnoid Haemorrhage	Professional					
	Vascular Injury						

Date:02/26/98ISR Number: 3043866-2Report Type:Expedited (15-DaCompany Report #A0060760
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Zyban	PS		ORAL	150 MG / PER DAY / ORAL
	Insomnia						
	Spinal Compression		Mirtazapine	C			
	Fracture		Alprazolam	C			

Date:02/26/98ISR Number: 3116007-0Report Type:Periodic Company Report #1997-000731(0)
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Erectile Dysfunction	Consumer	Viracept (Nelfinavir				
		Health	Mesylate)	PS			750 MG TID
		Professional	Wellbutrin	SS			
			Zerit	C			
			3tc	C			

Date:02/27/98ISR Number: 3042833-2Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Rash Pruritic		Wellbutrin	PS			
150 MG BID							
	Urticaria						

Date:02/27/98ISR Number: 3043945-XReport Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis Exfoliative		Wellbutrin	PS		ORAL	
150 MG BID							
	Rash Macular						

Date:03/02/98ISR Number: 3038990-4Report Type:Expedited (15-DaCompany Report #A0011982
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anaphylactic Reaction	Study	Wellbutrin	PS		ORAL	
150 MG /							
	Cyanosis	Health					
TWICE PER							
	Diarrhoea	Professional					
DAY/ ORAL							
	Dyspnoea		Verapamil	C			
	Nausea		Chlorpheniramine	C			
	Oedema Peripheral		Diphenhydramine	C			
	Petechiae		Hydrocortisone	C			
	Pruritus		Amoxycillin + K				
	Urticaria		Clavulanat	C			
	Vomiting						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/98ISR Number: 3038994-1Report Type:Expedited (15-DaCompany Report #A0041335
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anaphylactic Reaction	Study	Bupropion				
	Cyanosis	Health	Hydrochloride	PS		ORAL	150 MG /TWICE
	Diarrhoea	Professional					PER DAY/ ORAL
	Dyspnoea		Verapamil	C			
	Nausea		Chloropheniramine	C			
	Oedema Mouth		Augmentin	C			
	Oedema Peripheral		Diphenhydramine	C			
	Periorbital Oedema		Hydrocortisone	C			
	Petechiae						
	Pruritus						
	Urticaria						
	Vomiting						

Date:03/02/98ISR Number: 3129598-0Report Type:Periodic Company Report #A0056494
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Convulsion	Health	Zyban	PS		ORAL	150 MG/TWICE
Initial or Prolonged		Professional					PER DAY/ORAL
		Company	Clarithromycin	C			
		Representative	Humibid Dm	C			
			Guaiphenesin	C			

Date:03/02/98ISR Number: 3129600-6Report Type:Periodic Company Report #A0056729
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Depersonalisation	Consumer	Zyban	PS		ORAL	ORAL
	Depression Suicidal						

Date:03/02/98ISR Number: 3129602-XReport Type:Periodic Company Report #A0056994
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dysgeusia	Consumer	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Dyspnoea						
	Tremor		Aspirin	C			
			Quinapril Hydrochloride	C			
			Diltiazem Hydrochloride	C			
			Ranitidine Hydrochloride	C			

Date:03/02/98ISR Number: 3129604-3Report Type:Periodic Company Report #A0056995
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Decreased Appetite	Consumer	Zyban	PS		ORAL	150 MG/ORAL
	Nausea		Conjugated Estrogens	C			
			Thyroxine Sodium	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/98ISR Number: 3129607-9Report Type:Periodic Company Report #A0056996
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Consumer	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
			Prempro	C			

Date:03/02/98ISR Number: 3132927-5Report Type:Periodic Company Report #9719922
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Anxiety	Health	Zoloft	PS		ORAL	
	Cardiovascular Disorder	Professional	Redux	SS		ORAL	30.00 MG TOTAL:DAILY
			Ambien	SS		ORAL	
			Wellbutrin	SS		ORAL	

Date:03/02/98ISR Number: 3133750-8Report Type:Periodic Company Report #A0058109
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dermatitis Exfoliative	Health	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Pruritus	Professional					
	Urticaria		Triamterene	C			
			Simvastatin	C			
			Potassium Chloride	C			
			Aspirin	C			

Date:03/02/98ISR Number: 3133751-XReport Type:Periodic Company Report #A0058045
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health	Zyban	PS		ORAL	150 MG/TWICE	
	Dermatitis	Professional					PER DAY	ORAL
	Hypersensitivity							
	Pruritus							
	Urticaria							

Date:03/02/98ISR Number: 3134710-3Report Type:Periodic Company Report #A0057956
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Health	Zyban	PS		ORAL	150 MG/ORAL	
Initial or Prolonged	Hypertension	Professional						
		Company						
		Representative						

Date:03/02/98ISR Number: 3138605-0Report Type:Periodic Company Report #A0055397
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Health	Zyban	PS		ORAL	150 MG /	
	Dermatitis	Professional					TWICE PER DAY	
	Eyelid Oedema						/ ORAL	
	Hypersensitivity		Vitamin E	C				
	Pruritus		Ascorbic Acid	C				

			Cyanocobalamin	C			
			Aspirin	C			
			Atenolol	C			
			Atorvastatin Calcium	C			

Date:03/02/98ISR Number: 3138607-4Report Type:Periodic Company Report #A0055439
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Zyban	PS		ORAL	150 MG/ TWICE	
Hospitalization -		Professional					PER DAY /	
Initial or Prolonged							ORAL	
Other			Human Int/Long					
			Insulin	C				

Date:03/02/98ISR Number: 3138609-8Report Type:Periodic Company Report #A0055780
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Zyban	PS		ORAL	150 MG /	
Initial or Prolonged	Hypertension	Professional					TWICE PER	
Other							DAY/ ORAL	
			Atenolol	C				
			Nifedipine	C				

Date:03/02/98ISR Number: 3138611-6Report Type:Periodic Company Report #A0055781
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Zyban	PS		ORAL	150 MG /	

	Dry Mouth	Professional				
TWICE PER DAY						
	Dysphagia					
/ ORAL						
	Mouth Ulceration					

Date:03/02/98ISR Number: 3138612-8Report Type:Periodic Company Report #A0056353
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Zyban	PS		ORAL	150 MG /	
Initial or Prolonged		Professional					TWICE PER DAY	
		Company					/ ORAL	
		Representative						

Date:03/02/98ISR Number: 3138614-1Report Type:Periodic Company Report #A0056449
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Discomfort	Consumer	Zyban	PS		ORAL	150 MG / PER	
	Vomiting						DAY / ORAL	
			Salbutamol Sulphate	C				
			Ipratropium Bromide	C				
			Zafirlukst	C				
			Conjugated Estrogens	C				
			Guaiphenesin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/98ISR Number: 3138616-5Report Type:Periodic Company Report #A0056510
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	
	Pruritus							
	Rash Erythematous							
	Swelling		Decongestant	C				
	Urticaria							

Date:03/02/98ISR Number: 3138618-9Report Type:Periodic Company Report #A0056581
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
Other	Oropharyngeal Swelling	Professional						
	Rash Erythematous	Company						
	Urticaria	Representative						

Date:03/02/98ISR Number: 3139909-8Report Type:Periodic Company Report #A0058975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mucosal Inflammation	Consumer	Zyban Tablet	PS		ORAL	150 MG/ ORAL	
	Pruritus							
	Rash Erythematous							
	Urticaria							

Date:03/02/98ISR Number: 3139913-XReport Type:Periodic Company Report #A0058600
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Flushing	Health Professional Company Representative	Zyban Tablet	PS		ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:03/02/98ISR Number: 3139916-5Report Type:Periodic Company Report #A0059506
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia Paranoia Suicide Attempt	Consumer	Zyban Tablet	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	

Date:03/02/98ISR Number: 3139917-7Report Type:Periodic Company Report #A0059708
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoaesthesia Pain In Extremity	Consumer	Zyban Tablet Metoprolol Tartrate Simvastatin Atorvastatin Calcium Losartan Potassium	PS C C C C		ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:03/02/98ISR Number: 3139919-0Report Type:Periodic Company Report #A0059766
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dyspnoea Eyelid Oedema Insomnia Oedema Peripheral Pruritus Urticaria	Consumer	Zyban Tablet Glipizide Theophylline Dyazide	PS C C C		ORAL	150 MG / TWICE PER DAY / ORAL

Date:03/02/98ISR Number: 3139921-9Report Type:Periodic Company Report #A0059794
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Bronchospasm Dyspnoea	Consumer	Zyban Tablet Salbutamol Sulphate Combivent Theophylline	PS C C C		ORAL	150 MG / SINGLE DOSE / ORAL

Date:03/02/98ISR Number: 3146677-2Report Type:Periodic Company Report #9715884
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Aortic Valve Stenosis Cardiac Failure Congestive Drug Interaction	Health Professional	Zoloft	PS		ORAL	TABLETS, 50.00 MG TOTAL:DAILY:O RAL

			Wellbutrin	SS		ORAL

100.00 MG

TOTAL:DAILY:O

RAL

Date:03/02/98ISR Number: 3147151-XReport Type:Periodic Company Report #9706189
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety	Health	Zoloft	PS		ORAL

TABLETS,

	Asthenia	Professional				

200.00 MG

	Confusional State					

TOTAL:DAILY:O

	Tremor					

RAL

	Visual Disturbance		Wellbutrin	SS		ORAL

ORAL

			Desyrel	C		

Date:03/02/98ISR Number: 3147733-5Report Type:Periodic Company Report #A0059990
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Crying	Health	Zyban	PS		ORAL

150 MG ORAL 7 DAY

	Depression	Professional	Nicotine	C		
	Psychotic Disorder	Company				
	Tremor	Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/98ISR Number: 3150053-6Report Type:Periodic Company Report #9728129
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Consumer	Zoloft	PS		ORAL	ORAL	
	Drug Ineffective		Prozac	SS				
	Erectile Dysfunction		Wellbutrin	SS		ORAL	ORAL	
			Parnate	SS		ORAL	ORAL	
			Unknown Antidepressants	C				

Date:03/02/98ISR Number: 3266458-9Report Type:Periodic Company Report #A0058677
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Insomnia							
	Speech Disorder							
	Tremor							

Date:03/02/98ISR Number: 3266463-2Report Type:Periodic Company Report #A0058688
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:03/02/98ISR Number: 3266466-8Report Type:Periodic Company Report #A0058629
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Hypersensitivity	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:03/02/98ISR Number: 3266468-1Report Type:Periodic Company Report #A0058434
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Amnesia Convulsion Loss Of Consciousness Road Traffic Accident	Health Professional	Zyban Tablet- Zyban	PS		ORAL	150 MG PER DAY ORAL	

Date:03/02/98ISR Number: 3266471-1Report Type:Periodic Company Report #A0058441
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health	Zyban Tablet- Zyban	PS		ORAL	ORAL	
	Drug Interaction Insomnia Orthostatic Hypotension	Professional	Clonidine (Formulation Unknown)	SS			.2 MG TWICE PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/98ISR Number: 3266473-5Report Type:Periodic Company Report #A0058329
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL
	Diarrhoea						
	Difficulty In Walking		Dristan	C			
	Hypersensitivity		Famotidine	C			
	Joint Swelling						
	Musculoskeletal Stiffness						
	Oedema						
	Pruritus						
	Rash Erythematous						
	Urticaria						

Date:03/02/98ISR Number: 3266477-2Report Type:Periodic Company Report #A0058318
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dizziness	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL
	Face Oedema						
	Hyperhidrosis		Diltiazem				
	Hypersensitivity		Hydrochloride	C			
	Syncope		Paroxetine				
	Tinnitus		Hydrochloride	C			
	Vomiting		Lisinopril	C			

Date:03/02/98ISR Number: 3266484-XReport Type:Periodic Company Report #A0058298
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Health	Zyban Tablet- Zyban	PS		ORAL	150 MG ORAL 2 WK
	Bronchospasm	Professional					
	Dizziness						
	Eyelid Oedema						

	Face Oedema					
	Hypersensitivity					
	Laryngeal Oedema					
	Pain					
	Periorbital Oedema					
	Swelling					
	Urticaria					

Date:03/04/98ISR Number: 3040452-5Report Type:Expedited (15-DaCompany Report #8-97307-005S
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Pondimin	PS		ORAL	20-40MG DAILY	
	Aortic Valve Incompetence	Professional				ORAL		
	Cardiac Valve Disease		Phentermine	SS		ORAL	ORAL	
	Disturbance In Attention		Phentermine	SS		ORAL	ORAL	
	Fibromyalgia		Prozac	SS				
	Herpes Simplex		Wellbutrin	SS				
	Mitral Valve Incompetence		Phentermine	C				
	Mitral Valve Prolapse		Phentermine	C				
	Oedema		Prozac	C				
	Skin Disorder		Wellbutrin	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/98ISR Number: 3147732-3Report Type:Periodic Company Report #A0059950
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Dry Mouth Nervousness Pancreatitis	Consumer	Zyban	PS		ORAL	150 MG	

Date:03/05/98ISR Number: 3050356-XReport Type:Direct Company Report #
Age:2 DY Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Complications Of Maternal Exposure To Therapeutic Drugs Irritability Screaming Tachycardia Tachypnoea		Wellbutrin	PS		ORAL	PO	

Date:03/05/98ISR Number: 3050361-3Report Type:Direct Company Report #
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema Arthropathy Urticaria		Wellbutrin	PS				

Date:03/06/98ISR Number: 3145638-7Report Type:Periodic Company Report #8-97344-007H
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Effexor	PS		ORAL	150 MG TWICE	

	Drug Withdrawal Syndrome					
DAILY TO 18+						
	Paraesthesia					
MG DAILY ORAL						
			Wellbutrin	SS		
150 MG TWICE						
DAILY						

Date:03/06/98ISR Number: 3145923-9Report Type:Periodic Company Report #8-97154-001B
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coordination Abnormal	Health Professional	Effexor	PS		ORAL	350 MG DAILY	
			Ambien	SS		ORAL	20 MG	
			Wellbutrin	SS			50-100 MG DAILY	
			Lithium	C				
			Risperidone	C				
			Thyroid	C				
			Xanax	C				
			Ambien	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/98ISR Number: 3049047-0Report Type:Expedited (15-DaCompany Report #A0061492
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion	Consumer	Zyban	PS		ORAL	150 MG/ TWICE	
	Disturbance In Attention						PER DAY/ ORAL	4 WK
	Fall		Paracetamol	C				
	Head Injury		Darvocet-N	C				
	Insomnia		Nicotine	C				

Date:03/09/98ISR Number: 3049050-0Report Type:Expedited (15-DaCompany Report #A0061472
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Medication Error	Health	Wellbutrin	PS		ORAL	ORAL	
Hospitalization - Initial or Prolonged	Status Epilepticus	Professional Company Representative						

Date:03/09/98ISR Number: 3049566-7Report Type:Expedited (15-DaCompany Report #A0061053
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Death	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional Company Representative	Beta-Blocker	C				

Date:03/10/98ISR Number: 3049124-4Report Type:Direct Company Report #
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Face Oedema		Zyban	PS	ORAL
150MG PO BID					
	Oedema Peripheral				
	Pruritus				
	Urticaria				

Date:03/10/98ISR Number: 3049152-9Report Type:Direct Company Report #
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine		Bupropion	PS		
75MG BID						
Initial or Prolonged	Increased					
7/30/96 24H						
	Blood Urea Increased		Morphine Sulfate	SS		
INTRAVENOUS 2MG IV	Q 4 HR					
	Confusional State					
PRN 2 DOSES						
	Hip Fracture		Feso4	C		
	Lethargy		Levothyroxine	C		
	Mental Impairment		Metoprolrol	C		
			Hydrocortisone	C		
			Ofloxacin	C		

Date:03/10/98ISR Number: 3056531-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT
Other	Extrapyramidal Disorder
	Paraesthesia

	Restlessness						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Bupropion	PS		ORAL	75MG PO TID
			Cyclobenzaprine	C			
			Thothixene	C			
			Lisinopril	C			
			Trazodone	C			
			Ritalin	C			
			Etodolac	C			
			Sinemet	C			

Date:03/11/98ISR Number: 3056366-0Report Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional	Zyban	PS			
	Pyrexia						
	Stevens-Johnson Syndrome						

Date:03/11/98ISR Number: 3128844-7Report Type:Expedited (15-DaCompany Report #A0069088
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Chest Pain	Health Professional	Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL
	Choking						
	Convulsion		Simvastatin	C			
	Thirst						
	Tremor						

Date:03/12/98ISR Number: 3053266-7Report Type:Expedited (15-DaCompany Report #A0060690
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization -	Anaemia	Health	Zyban	PS	ORAL
150MG/ TWICE					
Initial or Prolonged	Asthenia	Professional			
PER DAY					
Disability	Blood Creatinine				
Other	Increased				
	Blood Urea Increased				
	Dermatitis				
	Diarrhoea				
	Erythema Multiforme				
	Gastritis				
	Haematochezia				
	Hyperglycaemia				
	Nausea				
	Oedema				
	Pain				
	Pneumonia				
	Proteinuria				
	Pruritus				
	Pyrexia				
	Renal Impairment				
	Urticaria				
	Vomiting				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/98ISR Number: 3127339-4Report Type:Periodic Company Report #JAUSA-28403
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukopenia	Health Professional	Risperdal	PS				
			Clonidine (Clonidine)	SS				
			Wellbutrin (Amfebutamone)	SS				

Date:03/12/98ISR Number: 3148265-0Report Type:Periodic Company Report #JAUSA-29679
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Risperdal (Risperidone)					
			Janssen Tablet	PS	Janssen	ORAL	ORAL	
			Wellbutrin (Amfebutamone)	SS				
			Depakote	SS				

Date:03/12/98ISR Number: 3148304-7Report Type:Periodic Company Report #JAUSA-29749
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation	Consumer	Risperdal (Risperidone)					
	Chest Pain		Janssen Tablets	PS	Janssen	ORAL	3MG 2 DAILY	
	Tachycardia						ORAL, AN	
							OCASSINAL 1MG	
							IS ADDED	
							DAILY WHEN	
			Wellbutrin					

			(Amfebutamone)	SS		ORAL
75MG 2 DAILY						
ORAL,75MG 3						
DAILY	6 DAY					
			Claritin-D	C		

Date:03/16/98ISR Number: 3056168-5Report Type:Expedited (15-DaCompany Report #A0061756
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Influenza Like Illness	Health	Wellbutrin	PS		ORAL	150MG/TWICE	
		Professional					PER DAY/ORAL/	
							TAB	
			Pseudoephedrine Hcl	SS		ORAL		
			Cough Medication	C				

Date:03/16/98ISR Number: 3056172-7Report Type:Expedited (15-DaCompany Report #A0061791
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Increased
	Dizziness
	Dyspnoea
	Heart Rate Increased
	Loss Of Consciousness
	Monoparesis

	Pain In Extremity						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS		ORAL	150MG/ TWICE PER DAY/ ORAL/ TAB

Date:03/16/98ISR Number: 3056176-4Report Type:Expedited (15-DaCompany Report #A0059505
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Anxiety	Health	Zyban	PS		ORAL	150MG/PER DAY/ORAL/ TAB
	Brain Neoplasm	Professional					
	Drug Ineffective						
	Euphoric Mood						
	Psychomotor Hyperactivity						
	Small Cell Lung Cancer						
	Stage Unspecified						

Date:03/16/98ISR Number: 3057431-4Report Type:Expedited (15-DaCompany Report #A0061467
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Complications Of Maternal	Health	Wellbutrin	PS		ORAL	ORAL
	Exposure To Therapeutic Drugs	Professional Company					
	Drug Withdrawal	Representative					
	Convulsions						

Date:03/17/98ISR Number: 3055919-3Report Type:Expedited (15-DaCompany Report #COU980009
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Health	Coumadin	PS		ORAL	UNKNOWN	-2.5
Hospitalization -	Arthralgia	Professional					MG; ORAL	
Initial or Prolonged	Cardiac Failure		Wellbutrin	SS		ORAL	300 MG; ORAL	
	Congestive		Albuterol	C				
	Constipation		Atrovent	C				
	Dizziness		Axid	C				
	Drug Interaction		Beclovent	C				
	International Normalised		Colchicine	C				
	Ratio Increased		Diamox	C				
	Prothrombin Time		Digoxin	C				
	Prolonged		Isordil	C				
	Rhinorrhoea		Lisinopril	C				
			Procan	C				

Date:03/18/98ISR Number: 3056376-3Report Type:Direct Company Report #
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation		Wellbutrin Sr	PS	Glaxo-Wellcome		I BID	
	Hypoaesthesia							
	Paraesthesia							
	Skin Exfoliation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/98ISR Number: 3057789-6Report Type:Direct Company Report #
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Zyban	PS		ORAL	I PO BID	

Date:03/20/98ISR Number: 3059526-8Report Type:Expedited (15-DaCompany Report #A0058622
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	No Adverse Drug Effect	Consumer	Zyban	PS		ORAL	150 MG / PER	Initial or Prolonged
							DAY/ ORAL	
Other			Betaxolol Hydrochloride	C				
			Lorazepam	C				
			Theophylline	C				

Date:03/20/98ISR Number: 3059528-1Report Type:Expedited (15-DaCompany Report #A0062268
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Unevaluable Event	Consumer	Zyban	PS		ORAL	150 MG / UNK	Initial or Prolonged
							/ ORAL	

Date:03/20/98ISR Number: 3059530-XReport Type:Expedited (15-DaCompany Report #A0062113
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Wellbutrin	PS		ORAL	150 MG /	
Initial or Prolonged	Haemorrhage	Professional					TWICE PER DAY	

	Hypotension					
/ ORAL						
	Lethargy		Fluoxetine			
	Retching		Hydrochloride	C		
	Splenic Rupture		Oxaprozin	C		
	Vomiting		Sinemet	C		

Date:03/20/98ISR Number: 3059533-5Report Type:Expedited (15-DaCompany Report #A0062241
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Complications Of Maternal	Health	Wellbutrin	PS		ORAL	150 MG /
	Exposure To Therapeutic	Professional					TWICE PER DAY
	Drugs						/ ORAL
	Exomphalos						
	Multiple Cardiac Defects						

Date:03/20/98ISR Number: 3059534-7Report Type:Expedited (15-DaCompany Report #A0057927
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthma	Health	Wellbutrin	PS		ORAL	150 MG / UNK
Initial or Prolonged	Dyspnoea	Professional					/ ORAL
	Oedema Peripheral		Vitamin E	C			
			Multivitamin	C			
			Prempro	C			
			Prednisone	C			
			Ticlopidine	C			

Metoclopramide	C
Nabumetone	C
Losartan Potassium	C
Terazosin Hydrochloride	C
Diltiazem Hydrochloride	C
Omeprazole	C
Insulin	C

Date:03/23/98ISR Number: 3057561-7Report Type:Direct Company Report #
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Wellbutrin	PS		ORAL	150 MG POQ	
	Pruritus						DAILY	
			Prozac	C				

Date:03/23/98ISR Number: 3057611-8Report Type:Direct Company Report #
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fracture	Consumer	Wellbutrin	PS			150 MG TWICE	
Hospitalization - Initial or Prolonged	Grand Mal Convulsion						A DAY	
Disability	Joint Dislocation							
Required Intervention to Prevent Permanent Impairment/Damage	Laceration							

Date:03/24/98ISR Number: 3060328-7Report Type:Expedited (15-DaCompany Report #8-98005-018H
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Valve Disease	Consumer	Pondimin	PS		ORAL	20 MG TWICE	
	Headache						DAILY ORAL	
	Hypoaesthesia		Buspar	SS			20 MG THREE	
							TIMES DAILY,A	
							NUMBER OF	
							YEARS	
			Phentermine	SS			30MG DAILY	
			Redux	SS			THREE TIMES	
							PER DAY	1 MON
			Wellbutrin	SS			THREE TIMES A	
							DAY "A NUMBER	
							OF YEARS"	

Date:03/25/98ISR Number: 3129547-5Report Type:Periodic Company Report #8-98005-011H
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia	Consumer	Redux	PS		ORAL	THREE TIMES	
	Drug Ineffective						PER DAY ORAL	1 MON
	Headache		Buspar	SS			THREE TIMES	
	Hypoaesthesia						PER DAY "A	
	Paraesthesia Oral						NUMBER OF	

YEARS"							
				Phentermine	SS		
2 TIMES PER DAY							
				Pondimin Tablet	SS		ORAL
THREE TIMES PER DAY ORAL							
				Wellbutrin	SS		
THREE TIMES PER DAY							
"NUMBER OF YEARS"							
				Premarin	C		

Date:03/25/98ISR Number: 3130531-6Report Type:Periodic Company Report #8-97353-005B
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Consumer	Redux	PS		ORAL	15 MG TWICE DAILY ORAL	
	Amnesia							
	Condition Aggravated		Wellbutrin	SS			150 MG TWICE DAILY	
	Diarrhoea							
	Dyspnoea		Dilacor Xl	C				
	Headache		Toprol	C				
	Nervousness							
	Neurosis							
	Palpitations							
	Tinnitus							

Date:03/25/98ISR Number: 3138469-5Report Type:Periodic Company Report #8-97296-001J
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Consumer	Redux	PS		ORAL	TWO TIMES	
	Drug Withdrawal Syndrome						DAILY ORAL	6 MON
			Wellbutrin	SS				
			Depakote	C				

Date:03/25/98ISR Number: 3148868-3Report Type:Periodic Company Report #8-97305-041H
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health	Redux	PS		ORAL	15 MG DAILY	
	Drug Withdrawal Syndrome	Professional					ORAL	1 YR
	Dyspnoea		Desyrel	SS		ORAL	50 MG AT	
	Palpitations						BEDTIME ORAL	
	Vasodilatation		Neurontin	SS		ORAL	2 DAILY ORAL	
			Ultram	SS		ORAL	2 DAILY ORAL	
			Wellbutrin	SS		ORAL	400 DAILY	
							ORAL	
			Baclofen	C				
			Desyrel	C				
			Neurontin	C				
			Ultram	C				
			Vicodin	C				
			Wellbutrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/98ISR Number: 3058427-9Report Type:Expedited (15-DaCompany Report #A0061715
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Zyban	PS		ORAL	150 MG /	
Hospitalization - Initial or Prolonged	Vasospasm	Professional						
Other		Company Representative						

Date:03/30/98ISR Number: 3064847-9Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS			2 TAB	BID
	Arthralgia		Prilosecv	C				
	Blister		Librax	C				
	Chromaturia		Lopressor	C				
	Diarrhoea		Tylenol #4	C				
	Dizziness		Vallium	C				
	Dry Mouth							
	Dysuria							
	Faeces Discoloured							
	Fatigue							
	Haematuria							
	Stomatitis							

Date:03/31/98ISR Number: 3063180-9Report Type:Direct Company Report #
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS		ORAL	100MG PO	BID
			Nortriptyline	SS		ORAL	50MG PO	HS

Date:03/31/98ISR Number: 3063240-2Report Type:Direct Company Report #
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged (FOR SOME TIME)	Abdominal Pain Constipation Vomiting		Wellbutrin	PS		ORAL	PO 300 MG TID	

Date:03/31/98ISR Number: 3067119-1Report Type:Direct Company Report #
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia Oedema Peripheral Pain In Extremity Rash Erythematous Skin Exfoliation		Wellbutrin	PS	Glaxo Wellcome		2 TABLETS DAILY	3 WK

Date:04/01/98ISR Number: 3058889-7Report Type:Expedited (15-DaCompany Report #8-98009-010H
Age:18 YR Gender:Female I/FU:F

Outcome	PT
Other	Cardiac Murmur Cardiac Valve Disease

	Cardiomegaly Dyspnoea Ventricular Hypertrophy	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Redux	PS		ORAL	15 MG TWICE DAILY
		Professional	Wellbutrin	SS		ORAL	150 MG TWICE DAILY
			Provera	C			
			Synthroid	C			
			N/A	C			

Date:04/01/98ISR Number: 3063181-0Report Type:Expedited (15-DaCompany Report #8-98016-002S
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest	Health	Pondimin	PS		ORAL	20-60 MG DAILY ORAL
	Dysuria	Professional					
	Insomnia		Wellbutrin	SS		ORAL	400 MG DAILY ORAL
	Ventricular Hypertrophy						
			Ionamin	SS		ORAL	15 MG DAILY ORAL
			Loestrin 1/20	C			

Date:04/02/98ISR Number: 3059986-2Report Type:Expedited (15-DaCompany Report #A0062683
Age:25 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Facial Palsy	Health	Zyban	PS		ORAL	150

		Professional				
MG/UNK/ORAL						

Date:04/02/98ISR Number: 3059987-4Report Type:Expedited (15-DaCompany Report #A0061890
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Clonic Convulsion	Health	Wellbutrin	PS		ORAL	UNK/ORAL	
		Professional Company Representative						

Date:04/02/98ISR Number: 3071857-4Report Type:Direct Company Report #
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	150 MG ORALLY	

Date:04/02/98ISR Number: 3071950-6Report Type:Direct Company Report #
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis		Bupropion	PS		ORAL	100MG /TI TID/ORAL	
	Pruritus							
	Urticaria		Loraxepam	C				

Date:04/03/98ISR Number: 3062720-3Report Type:Expedited (15-DaCompany Report #A0061756
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Influenza Like Illness	Health Professional	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY/ ORAL/ TAB	
			Pseudoephedrine Hcl	SS		ORAL		
			Cough Medication	C				

Date:04/06/98ISR Number: 3062918-4Report Type:Expedited (15-DaCompany Report #A0062864
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Consumer	Zyban	PS		ORAL	150MG/ TWICE PER DAY/ ORAL	

Date:04/06/98ISR Number: 3062920-2Report Type:Expedited (15-DaCompany Report #A0062949
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Consumer	Zyban	PS		ORAL	150MG/TWICE PER DAY/ORAL	
Hospitalization - Initial or Prolonged	Collapse Of Lung							
	Dyspnoea		Oxygen	C				
	Epistaxis		Dilantin	C				
	Insomnia		Blood Pressure Medication	C				
	Nervousness		Nebulizer	C				

Date:04/06/98ISR Number: 3063324-9Report Type:Expedited (15-DaCompany Report #8-98005-011H
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Incompetence	Consumer	Redux	PS		ORAL	THREE TIMES PER DAY	ORAL 1 MON
	Arrhythmia							
	Feeling Abnormal		Buspar	SS			THREE TIMES PER DAY	NUMBER OF YEARS
	Headache							
	Hypoaesthesia							
	Hypoaesthesia Oral							
			Phentermine	SS		ORAL	30 MG DAILY	ORAL
			Pondimin	SS		ORAL	20 MG 2 TO 3 TIMES DAILY	ORAL
			Wellbutrin	SS			THREE TIMES PER DAY	NUMBER OF YEARS
			Buspar	C				
			Phentermine	C				
			Pondimin	C				
			Wellbutrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/98ISR Number: 3072565-6Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Bupropion	PS		ORAL	100 MG PO BID	
			Aripiprozole	SS		ORAL	30 MG PO QAM	

(NO LATER

THEN 3/28)

Date:04/09/98ISR Number: 3062490-9Report Type:Expedited (15-DaCompany Report #A0063085
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Consumer	Zyban	PS		ORAL	300 MG/TWICE	
	Vomiting						PE DAY/ORAL	
			Glibenclamide	C				
			Atorvastatin Calcium	C				
			Glucophage	C				
			Omeprazole	C				

Date:04/09/98ISR Number: 3062492-2Report Type:Expedited (15-DaCompany Report #A0063016
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban	PS		ORAL	150 MG/ORAL	
		Professional						

Date:04/10/98ISR Number: 3073150-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis		Zyban	PS				

Date:04/13/98ISR Number: 3063810-1Report Type:Expedited (15-DaCompany Report #A0063001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Health	Wellbutrin	PS		ORAL	30	
	Overdose	Professional					TABLET/SINGLE	
							DOSE/ORAL	
			Diazepam	C				

Date:04/13/98ISR Number: 3063861-7Report Type:Expedited (15-DaCompany Report #A0061492
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion	Consumer	Zyban	PS		ORAL	150 MG /	
	Cyanosis						TWICE PER DAY	
	Disability						/ ORAL	
	Disturbance In Attention		Nicotine Patch	SS			TOPICAL	21 MG/ PER
	Fall						DAY / TOPICAL	
	Head Injury		Paracetamol	C				
	Insomnia		Darvocet-N	C				
	Loss Of Consciousness							
	Tremor							

Date:04/14/98ISR Number: 3064324-5Report Type:Expedited (15-DaCompany Report #001-0991-980613
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angioneurotic Oedema	Health	Rezulin	PS		PER ORAL	
Hospitalization -	Dyspnoea	Professional	Zyban	SS		ORAL	300 MG
Initial or Prolonged	Eyelid Oedema						(DAILY) PER
	Face Oedema						ORAL
	Pharyngeal Oedema		Amaryl	C			
			Cardizem	C			
			Compazine	C			

Date:04/15/98ISR Number: 3064474-3Report Type:Expedited (15-DaCompany Report #M98-093 (2)
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anaphylactic Reaction	Health	Baycol	PS		ORAL	0.3 MG QHS
Hospitalization -	Angioneurotic Oedema	Professional					ORAL
Initial or Prolonged	Pyrexia		Zyban	SS		ORAL	150 MG BID
Required	Scrotal Oedema						ORAL
Intervention to	Urticaria		Prevacid	C			
Prevent Permanent			Wellbutrin	C			
Impairment/Damage			Xyban	C			

Date:04/15/98ISR Number: 3065424-6Report Type:Expedited (15-DaCompany Report #A0062572
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Overdose	Health	Wellbutrin	PS		ORAL	ORAL
Initial or Prolonged	Speech Disorder	Professional	Ethanol	C			
Other	Suicide Attempt						

Date:04/15/98ISR Number: 3065444-1Report Type:Expedited (15-DaCompany Report #A0057797
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Zyban	PS		ORAL	150 MG/PER	
Initial or Prolonged	Dehydration	Professional						DAY/ORAL
	Dizziness		Conjugated Estrotens	C				
	Hypersomnia		Ibuprofen	C				
	Malaise							
	Nausea							
	Sedation							
	Visual Disturbance							

Date:04/15/98ISR Number: 3065446-5Report Type:Expedited (15-DaCompany Report #A0059118
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Zyban	PS		ORAL	150 MG/PER	
Initial or Prolonged	Dehydration	Professional						DAY/ORAL
	Dizziness		Conjugated Estrogens	C				
	Hypersomnia		Ibuprofen	C				
	Malaise							
	Nausea							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/98ISR Number: 3065289-2Report Type:Expedited (15-DaCompany Report #A0063509
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blindness	Consumer	Wellbutrin	PS		ORAL	
	Dyspnoea						
	Hypersensitivity						
	Pruritus						
	Urinary Incontinence						
	Urticaria						

Date:04/20/98ISR Number: 3065925-0Report Type:Expedited (15-DaCompany Report #A0063649
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Dermatitis	Health	Zyban	PS		ORAL	150 MG
Initial or Prolonged	Stevens-Johnson Syndrome	Professional					(TABLET)
		Company Representative					

Date:04/20/98ISR Number: 3065961-4Report Type:Expedited (15-DaCompany Report #A0063323
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Agitation	Health	Wellbutrin	PS		ORAL	150 MG/PER
	Anxiety	Professional					DAY/ORAL
	Completed Suicide		Semisodium Valproate	C			
	Diarrhoea						
	Irritability						
	Paranoia						

Date:04/21/98ISR Number: 3071889-6Report Type:Direct Company Report #
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Zyban	PS		ORAL	PO BID	
	Labile Blood Pressure		Digoxin	C				
	Palpitations		Cardazen	C				
	Ventricular Tachycardia							

Date:04/21/98ISR Number: 3071930-0Report Type:Direct Company Report #
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin	PS		ORAL	150MG SR PO	QD AM

Date:04/21/98ISR Number: 3071940-3Report Type:Direct Company Report #
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Wellbutrin Sr	PS			3	WK
			Prednisone	SS				
			Vitamin B	C				
			Vitamin C					
			Supplements	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/98ISR Number: 3074808-1Report Type:Direct Company Report #
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Zyban	PS		ORAL	150 MG PO BID	
	Chest Discomfort							
	Odynophagia							
	Pruritus							
	Urticaria							

Date:04/23/98ISR Number: 3066885-9Report Type:Expedited (15-DaCompany Report #A0062993
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Fracture							
			Atenolol	C				
			Misoprostol	C				

Date:04/23/98ISR Number: 3072725-4Report Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin-Sr	PS		ORAL	150 MG PO QHS X 7 :THEN BID	
	Urticaria							

X 7 THEN RASH 7 DAY

Date:04/23/98ISR Number: 3072727-8Report Type:Direct Company Report #
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Dermatitis		Zyban	PS		ORAL
PO 5 DAY						
	Pruritus					

Date:04/24/98ISR Number: 3068779-1Report Type:Expedited (15-DaCompany Report #A0063654
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Condition Aggravated	Health	Zyban	PS		ORAL
150 MG /						
Initial or Prolonged	Drug Interaction	Professional				
TWICE PER DAY						
	International Normalised					
/ ORAL						
	Ratio Increased		Warfarin Sodium	SS		
	Phlebitis		Nabumetone	C		
	Prothrombin Time					
	Prolonged					

Date:04/24/98ISR Number: 3072261-5Report Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Grand Mal Convulsion		Bupropion	PS		
Initial or Prolonged						
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/24/98ISR Number: 3072353-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Pruritic		Zyban	PS		ORAL	150 MG PO BID	
			Diazepam	C				
			Premarin	C				

Date:04/28/98ISR Number: 3072016-1Report Type:Direct Company Report #
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Zyban	PS		ORAL	150MG PO BID	
	Dermatitis							
	Nausea							
	Oedema Peripheral							
	Pruritus							

Date:04/28/98ISR Number: 3072092-6Report Type:Direct Company Report #
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health	Wellbutrin	PS			100 MG BID	
	Pruritus	Professional						
	Rash Erythematous							
	Rash Maculo-Papular							

Date:04/28/98ISR Number: 3072573-5Report Type:Direct Company Report #
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Colitis	Consumer	Wellbutrin	PS		ORAL	2 QD	4 WK
Required	Diarrhoea		Estradiol	C				

Intervention to
Prevent Permanent
Impairment/Damage

Date:04/28/98ISR Number: 3073809-7Report Type:Direct Company Report #
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Zyban	PS		ORAL	1 PO BID	
	Burning Sensation							
	Dermatitis							
	Pyrexia							

Date:04/28/98ISR Number: 3153994-9Report Type:Periodic Company Report #A0059397
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Reaction	Health	Wellbutrin	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Dyspnoea	Professional					PER DAY/ORAL	
Other	Urticaria	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/98ISR Number: 3153996-2Report Type:Periodic Company Report #A0059398
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anaphylactic Reaction	Health	Wellbutrin	PS		ORAL	ORAL
Hospitalization - Initial or Prolonged	Urticaria	Professional Company	Lysine	C			
Other		Representative					

Date:04/28/98ISR Number: 3153997-4Report Type:Periodic Company Report #A0059419
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Confusional State	Health	Wellbutrin	PS		ORAL	100 MG/TWICE PER DAY/ORAL
	Convulsion	Professional					
	Disorientation		Pethidine Hydrochloride	C			
	Joint Stiffness						
	Tremor						

Date:04/28/98ISR Number: 3153999-8Report Type:Periodic Company Report #A0059754
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Balance Disorder	Consumer	Wellbutrin	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Dizziness						
Disability	Dysarthria		Aspirin	C			
Other	Dyspraxia		Lithium Salt	C			
	Headache						
	Nausea						
	Transient Ischaemic Attack						

Date:04/28/98ISR Number: 3154000-2Report Type:Periodic Company Report #A0060059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin	PS		ORAL	ORAL	
	Overdose	Professional						
		Company						
		Representative						

Date:04/28/98ISR Number: 3154002-6Report Type:Periodic Company Report #A0060316
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Wellbutrin	PS		ORAL	150 MG/TWICE	
Hospitalization -	Duodenitis	Professional					PER DAY/ORAL	
Initial or Prolonged	Gastritis		Ibuprofen	SS				
Other	Gastrointestinal		Pancrelipase	C				
	Haemorrhage		Vitamin E	C				
			Ascorbic Acid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/98ISR Number: 3154004-XReport Type:Periodic Company Report #A0060770
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health	Wellbutrin	PS		ORAL	150 MG/TWICE	
	Urticaria	Professional					PER DAY/ORAL	
		Company Representative						

Date:04/28/98ISR Number: 3160400-7Report Type:Periodic Company Report #A0057121
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Health	Wellbutrin					
	Antisocial Behaviour	Professional	Tablet-Controlled					
	Depression		Release	PS		ORAL	150MG TWICE	
	Disturbance In Attention						PER DAY ORAL	
	Drug Ineffective		Hyzaar	C				
	Feeling Abnormal		Berocca	C				
	Irritability		Valsartan	C				
	Mood Altered							
	Sleep Disorder							

Date:04/28/98ISR Number: 3160491-3Report Type:Periodic Company Report #A0058281
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Wellbutrin					
Hospitalization - Initial or Prolonged	Blood Pressure Decreased	Professional	Tablet-Controlled					
	Dermatitis		Release	PS		ORAL	150 MG /	
Other	Dyspnoea						TWICE PER	
	Hypoaesthesia Oral						DAY/ ORAL	
	Oedema Peripheral		Diphenhydramine Hcl					

	Urticaria			(Formaulation Unknown)	SS		
UNK/ UNK/ UNK							
				Dephenhydramine Hcl Injection	SS		
INTRAVENOUS	UNK/ UNK/						
INTRAVENOUS							
				Sertraline Hydrochloride	C		

Date:04/28/98ISR Number: 3315033-6Report Type:Periodic Company Report #A0076885
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet-Controlled Released			
	PS	ORAL	ORAL			

Date:04/28/98ISR Number: 3315035-XReport Type:Periodic Company Report #A0077287
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion	Health Professional	Wellbutrin Tablet-Controlled			
		Company	Release	PS		ORAL
150 MG/ORAL						
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/98ISR Number: 3073029-6Report Type:Expedited (15-DaCompany Report #A0064080
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension	Health	Wellbutrin	PS		ORAL	400 ORAL PER	DAY
	Dyspnoea	Professional						YR
	Dysuria		Fenfluramine Hcl	SS		ORAL	ORAL	
	Fall		Loestrin	C				
	Insomnia		Tramadol Hydrochloride	C				
	Ventricular Hypertrophy		Naproxen	C				

Date:04/30/98ISR Number: 3073820-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Paraesthesia Oral	Health	Wellbutrin Sr	PS		ORAL	1 BID PO; WAS	
	Tongue Blistering	Professional					TITRATED 1 QD	
	Tongue Oedema						X 3 DAYS,	
							THEN 1 BID	

Date:04/30/98ISR Number: 3073937-6Report Type:Direct Company Report #
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Bupropion	PS	Glaxo	ORAL	100MG PO Q8H	

Date:05/01/98ISR Number: 3072979-4Report Type:Direct Company Report #
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Wellbutrin	PS	Glaxo Welcome		1 PILL A DAY	
	Blindness							
	Depression							
	Dry Mouth							
	Hallucination							
	Headache							
	Hostility							
	Irritability							
	Memory Impairment							
	Nervousness							
	Paranoia							
	Speech Disorder							
	Suicidal Ideation							

Date:05/01/98ISR Number: 3073610-4Report Type:Expedited (15-DaCompany Report #A0064472
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypernatraemia	Health Professional	Wellbutrin	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/98ISR Number: 3073637-2Report Type:Expedited (15-DaCompany Report #A0063323
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour	Health	Wellbutrin	PS		ORAL	150 MG / PER	
	Agitation	Professional					DAY / ORAL	
	Anxiety		Semisodium Valproate	C				
	Completed Suicide		Lansoprazole	C				
	Diarrhoea		Ascorbic Acid	C				
	Irritability		Vitamin B Complex	C				
	Mood Altered		Tranylcypromine Sulphate	C				
	Paranoia							

Date:05/01/98ISR Number: 3080321-8Report Type:Direct Company Report #
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Bupropion Hcl	PS				

Date:05/01/98ISR Number: 3080564-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	150 MG OD 3	
	Decreased Appetite						DAYS	
	Depressed Mood		Atenolol	C				
	Depression		Levothyroxine	C				
	Emotional Disorder		Glucotrol	C				
	Suicidal Ideation							
	Weight Decreased							

Date:05/01/98ISR Number: 3250183-4Report Type:Periodic Company Report #JAUSA-31616
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Dizziness Dyspnoea Palpitations	Consumer	Hismanal (Astemizole), Janssen, Tablet 10 Mg	PS	Janssen	ORAL	10 MG 1 DAILY	
						ORAL		
			Wellbutrin (Amfebutamone)	SS		ORAL	150 MG DAILY	
						ORAL		

Date:05/04/98ISR Number: 3073449-XReport Type:Expedited (15-DaCompany Report #A0063965
Age:3 MON Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Complications Of Maternal Exposure To Therapeutic Drugs Jaundice	Health Professional	Wellbutrin	PS		ORAL	450 MG QD	
			Lamictal	SS		ORAL	400 MG QD	
			Buspirone Hydrochloride	C				
			Nabumetone	C				
			Thyroxine Sodium	C				
			Clonazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/98ISR Number: 3085634-1Report Type:Direct Company Report #
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Dermatitis Oedema Peripheral		Zyban	PS	Glaxo Wellcome	ORAL	ONE QD THEN INCREASE BIDI PO

Date:05/04/98ISR Number: 3090392-0Report Type:Expedited (15-DaCompany Report #A0065467
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Deep Vein Thrombosis	Health	Wellbutrin	PS		ORAL	150 MG
Life-Threatening	Grand Mal Convulsion	Professional	Venlafaxine Hydrochloride	C			
Hospitalization - Initial or Prolonged	Intentional Misuse Loss Of Consciousness Pneumonia Respiratory Failure		Alprazolam Thyroxine Sodium Nifedipine Sinemet	C C C C			

Date:05/05/98ISR Number: 3088479-1Report Type:Direct Company Report #
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Convulsion		Bupropion	PS		ORAL	75MG BID; 75 MG TID, ORAL
Hospitalization - Initial or Prolonged			Terazosin Quinapril Levothyroxine Risperidone	C C C C			

Date:05/06/98ISR Number: 3080753-8Report Type:Direct Company Report #
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion	Health	Wellbutrin Sr	PS		ORAL	150 MG BID PO	
Initial or Prolonged		Professional	Prozac	SS		ORAL	20 MG QAM	

Date:05/06/98ISR Number: 3080902-1Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Aricept	PS		ORAL	5MG PO QD	2 MON
Initial or Prolonged	Convulsion		Wellbutrin	SS		ORAL	150MG PO QD	2 MON
	Grand Mal Convulsion							
	Sleep Attacks							
	Tremor							

Date:05/12/98ISR Number: 3074854-8Report Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Prilosec	PS	Astra-Merck	ORAL	3X DAILY -	
	Pruritus	Professional					ORAL - 20MG	
			Zyban	SS	Glaxo Welcome	ORAL	2 X ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/98ISR Number: 3075607-7Report Type:Direct Company Report #
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Tremor		Zyban	PS		ORAL	150 MG PO BID	2 WK

Date:05/13/98ISR Number: 3075612-0Report Type:Direct Company Report #
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister Feeling Hot Paraesthesia Pruritus Rash Erythematous		Bupropion Sr	PS	Glaxo Wellcome	ORAL	150 MG PO BID	

Date:05/13/98ISR Number: 3079000-2Report Type:Expedited (15-DaCompany Report #A0063654
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction International Normalised Ratio Increased	Health Professional	Zyban	PS		ORAL	150 MG / TWICE PER DAY	
Disability / Other	Phlebitis Prothrombin Time Prolonged		Warfarin Sodium Nabumetone	SS C		ORAL	15 MG / PER DAY / UNK	

Date:05/13/98ISR Number: 3079004-XReport Type:Expedited (15-DaCompany Report #A0065005
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Wellbutrin	PS		ORAL	UNK / UNK /	
		Professional				ORAL		
		Company Representative						

Date:05/13/98ISR Number: 3079009-9Report Type:Expedited (15-DaCompany Report #A0064936
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Tachycardia	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY	
						/ ORAL		
			Blood Pressure Medication	C				

Date:05/14/98ISR Number: 3079126-3Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anger	Health	Zyban	PS	Glaxo	ORAL	150 MG PO BID	
	Suicidal Ideation	Professional	Voltaren-Xr	C				
			Xanax	C				
			Methotrexate	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/15/98ISR Number: 3079683-7Report Type:Expedited (15-DaCompany Report #A0060104
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health	Zyban	PS		ORAL	150 MG TWICE PER DAY	
	Cholelithiasis	Professional						
			Sertraline Hydrochloride	C				
			Metoprolol Succinate	C				

Date:05/15/98ISR Number: 3079686-2Report Type:Expedited (15-DaCompany Report #A0064987
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Zyban	PS		ORAL	150 MG ORAL TWICE PER DAY	
	Colitis							
	Condition Aggravated							
	Diarrhoea							
	Faecal Incontinence							
	Fatigue							
	Nervousness							
	Weight Decreased							
	White Blood Cell Count Increased							

Date:05/15/98ISR Number: 4456559-1Report Type:Direct Company Report #USP 51193
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Propulsid	PS				
			Restoril	SS				
			Colace	SS				
			Wellbutrin	SS				
			Pepcid	SS				

Date:05/18/98ISR Number: 3080005-6Report Type:Expedited (15-DaCompany Report #A0065101
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health Professional	Wellbutrin	PS		ORAL	100 MG/SINGLE DOSE/ORAL	

Date:05/18/98ISR Number: 3080008-1Report Type:Expedited (15-DaCompany Report #A0063649
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Conjunctivitis Dermatitis Dermatitis Exfoliative Disability Dyspnoea Erythema Multiforme Eye Irritation Mouth Ulceration Stevens-Johnson Syndrome Urticaria	Health Professional Company Representative	Zyban	PS		ORAL	150 MG/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/98ISR Number: 3080092-5Report Type:Expedited (15-DaCompany Report #A0062008
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block Left	Health	Wellbutrin	PS		ORAL	75 MG/ TWICE	
	Fatigue	Professional					PER DAY/ ORAL	
	Heart Rate Irregular	Company						
	Suicidal Ideation	Representative						
	Ventricular Extrasystoles							
	Ventricular Tachycardia							

Date:05/18/98ISR Number: 3080093-7Report Type:Expedited (15-DaCompany Report #A0061053
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Death	Health	Wellbutrin	PS		ORAL	ORAL TAB	
	Drug Interaction	Professional	Beta-Blocker	C				
		Company						
		Representative						

Date:05/19/98ISR Number: 3079928-3Report Type:Direct Company Report #
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lipase Increased	Health	Clonidine	PS		ORAL	0.1 MG BID	
		Professional	Wellbutrin	SS		ORAL	75 MG PO QD	

Date:05/22/98ISR Number: 3081788-1Report Type:Expedited (15-DaCompany Report #A0064080
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Abdominal Distension	Health	Wellbutrin	PS		ORAL
400 MG / PER						
	Dyspnoea	Professional				
DAY / ORAL YR						
	Dysuria		Fenfluramine	SS		ORAL
20 MG / PER						
	Insomnia					
DAY / ORAL						
	Ventricular Hypertrophy		Phentermine	SS		ORAL
15 MG / PER						
DAY / ORAL						
			Loestrin	C		
			Naproxen	C		

Date:05/22/98ISR Number: 3081861-8Report Type:Expedited (15-DaCompany Report #A0064577
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Creatine	Health	Zyban	PS		ORAL
150MG ORAL						
	Phosphokinase Increased	Professional	Cyclosporin	C		
	Myalgia	Company	Pyridostigmine			
	Myositis	Representative	Bromide	C		
			Doxepin	C		
			Alprazolam	C		

Date:05/26/98ISR Number: 3082953-XReport Type:Expedited (15-DaCompany Report #A0065467
Age:80 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Grand Mal Convulsion Loss Of Consciousness Overdose Pneumonia Respiratory Failure	Health Professional	Wellbutrin Venlafaxine Hydrochloride Alprazolam Thyroxine Sodium Nifedipine Sinemet	PS C C C C C		ORAL	150 MG	

Date:05/26/98ISR Number: 3082955-3Report Type:Expedited (15-DaCompany Report #20711
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased Hypertension Palpitations	Health Professional	Zyban Diltiazem Hydrochloride Losartan Potassium	PS C C		ORAL	150 MG/TWICE PER DAY	6 YR

Date:05/26/98ISR Number: 3082957-7Report Type:Expedited (15-DaCompany Report #A0063931
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Confusional State Convulsion Disorientation Fatigue Feeling Jittery Hypertension Insomnia Irritability	Consumer	Zyban Unknown	PS C		ORAL	150 MG/TWICE PER DAY ORAL	

	Motor Dysfunction
	Mouth Ulceration
	Pruritus
	Syncope
	Urticaria
	Visual Disturbance

Date:05/26/98ISR Number: 3084464-4Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tremor	Health	Zyban	PS	Glaxo Wellcome		150 MG I QD X	
		Professional					3 DAYS THEN 1	

BID;NDC#

00173-00556-0

2

Date:05/28/98ISR Number: 3161424-6Report Type:Periodic Company Report #8-97353-005B
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Amnesia

	Arrhythmia						
	Chest Pain						
	Condition Aggravated	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Depression	Consumer	Redux	PS		ORAL	15 MG TWICE
	Diarrhoea						DAILY ORAL
	Dyspnoea		Wellbutrin	SS			150 MG TWICE
	Emotional Disorder						DAILY
	Headache		Dilacor Xl	C			
	Nervousness		Toprol	C			
	Neurosis						
	Oedema Peripheral						
	Palpitations						
	Syncope						
	Tinnitus						

Date:05/28/98ISR Number: 3166234-1Report Type:Periodic Company Report #A0063808
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis	Consumer	Zyban	PS		ORAL	150 MG/ TWICE
	Pharyngeal Oedema						PER DAY/ ORAL
	Swelling		Erythromyin	C			
	Urticaria						

Date:05/29/98ISR Number: 3085227-6Report Type:Expedited (15-DaCompany Report #A0064752
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dysarthria	Health	Wellbutrin	PS		ORAL	150 MG/ TWICE
		Professional					PER DAY/ORAL

Date:05/29/98ISR Number: 3085239-2Report Type:Expedited (15-DaCompany Report #A0065468
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Clonic Convulsion Hyperreflexia Tremor	Health Professional	Zyban	PS		ORAL	150 MG ORAL	

Date:05/29/98ISR Number: 3085243-4Report Type:Expedited (15-DaCompany Report #A0065568
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Connective Tissue Disorder Dermatitis Genital Ulceration Mouth Ulceration	Health Professional	Zyban	PS		ORAL	ORAL	

Date:05/29/98ISR Number: 3085249-5Report Type:Expedited (15-DaCompany Report #A0062683
Age:25 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy	Health Professional	Zyban	PS		ORAL	150 MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3085478-0Report Type:Expedited (15-DaCompany Report #A0062175
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Zyban	PS		ORAL	150 MG TWICE	
Initial or Prolonged	Conversion Disorder	Professional					PER DAY ORAL	
	Coordination Abnormal		Digoxin	C				
	Crying		Atenolol	C				
	Depression							
	Fear							
	Pneumonia Mycoplasmal							
	Tuberculosis							

Date:05/29/98ISR Number: 3162219-XReport Type:Periodic Company Report #A0061513
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated	Consumer	Zyban	PS		ORAL	150 MG/PER	
	Tremor						DAY/ORAL	
			Conjugated Estrogens	C				
			Triamter + Hclthiazide	C				

Date:05/29/98ISR Number: 3162220-6Report Type:Periodic Company Report #A0061581
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER	
Other	Dysphagia	Professional					DAY/ORAL	3 WK
	Pain		Loracarbef	C				
	Pruritus							
	Swelling							
	Urticaria							

Date:05/29/98ISR Number: 3162221-8Report Type:Periodic Company Report #A0061585
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Consumer	Zyban	PS		ORAL	150 MG/PER	DAY/ORAL
	Cerebrovascular Accident							
	Excitability		Thyroxine Sodium	C				
	Restlessness		Hydrochlorothiazide	C				
			Nortriptyline Hcl	C				
			Alprazolam	C				

Date:05/29/98ISR Number: 3162222-XReport Type:Periodic Company Report #A0061638
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	
Other		Professional	Ipratropium Bromide	C				
			Orciprenaline Sulphate	C				
			Nebulizer	C				
			Theophylline	C				
			Beclomethasone Dipropion	C				
			Omeprazole	C				

			Doxazosin Mesylate	C		
			Oxygen	C		
			Psyllium Husk	C		
			Prednisone	C		
			Cephazolin Sodium	C		

Date:05/29/98ISR Number: 3162223-1Report Type:Periodic Company Report #A0061681
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Consumer	Zyban Tablet-Zyban	PS		ORAL		
Initial or Prolonged	Gingivitis		Diclofenac Sodium	C				
	Libido Decreased		Tramadol Hydrochloride	C				
			Multivitamin	C				

Date:05/29/98ISR Number: 3162224-3Report Type:Periodic Company Report #A0065042
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Increased Appetite						PER DAY/ORAL	
			Multiple Medication	C				
			Pravastatin Sodium	C				

Date:05/29/98ISR Number: 3162225-5Report Type:Periodic Company Report #A0065208
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	

Date:05/29/98ISR Number: 3162226-7Report Type:Periodic Company Report #A0057442
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Blood Pressure Increased	Professional					
	Chest Pain		Conjugated Estrogens	C			
	Hypoaesthesia						
	Nervousness						
	Oedema Peripheral						
	Paraesthesia						
	Tachycardia						

Date:05/29/98ISR Number: 3162227-9Report Type:Periodic Company Report #A0058434
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Amnesia	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER DAY/ORAL
Disability	Convulsion	Professional					
	Loss Of Consciousness						
	Road Traffic Accident						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3162228-0Report Type:Periodic Company Report #A0058617
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dermatitis	Health	Zyban	PS		ORAL	150 MG/TWICE
	Herpes Simplex	Professional					PER DAY/ORAL
	Urticaria		Vitamin	C			
			Ibuprofen	C			

Date:05/29/98ISR Number: 3162229-2Report Type:Periodic Company Report #A0058629
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Hypersensitivity	Professional					

Date:05/29/98ISR Number: 3162230-9Report Type:Periodic Company Report #A0058920
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Accommodation Disorder	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Dizziness						
	Dysgraphia						
	Face Oedema						
	Headache						
	Insomnia						
	Tinnitus						
	Tremor						

Date:05/29/98ISR Number: 3162231-0Report Type:Periodic Company Report #A0058975
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mucosal Inflammation	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	
	Pruritus	Professional						
	Rash Erythematous							
	Urticaria							

Date:05/29/98ISR Number: 3162232-2Report Type:Periodic Company Report #A0059110
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Fatigue	Professional					PER DAY/ORAL	
	Mental Impairment		Claritin-D	C				
	Tachycardia		Cisapride	C				
	Tremor		Triamcinolone					
	Urticaria		Acetonide	C				
			Ovral	C				

Date:05/29/98ISR Number: 3163038-0Report Type:Periodic Company Report #A0061047
Age: Gender: I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health
	Hypersensitivity	Professional
	Urticaria	Company

Representative

			Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban Tablet-Zyban	PS		ORAL
150 MG / UNK						
/ ORAL						

Date:05/29/98ISR Number: 3163206-8Report Type:Periodic Company Report #A0060935
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthralgia	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG /						
Initial or Prolonged	Urticaria					
TWICE PER DAY						
/ ORAL						

Date:05/29/98ISR Number: 3163208-1Report Type:Periodic Company Report #A0060931
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaphylactic Reaction	Health	Zyban Tablet-Zyban	PS		ORAL
150 MG /						
Initial or Prolonged	Dermatitis	Professional				
TWICE PER DAY						
Other	Dyspnoea	Company				
/ ORAL						
	Oedema	Representative	Ranitidine			
	Pruritus		Hydrochloride	C		
			Metoprolol Tartrate	C		

Date:05/29/98ISR Number: 3163209-3Report Type:Periodic Company Report #A0060908
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Zyban Tablet-Zyban	PS		ORAL 150 MG / ORAL

Date:05/29/98ISR Number: 3163211-1Report Type:Periodic Company Report #A0060907
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Company Representative	Zyban Tablet-Zyban	PS		ORAL 150 MG / ORAL

Date:05/29/98ISR Number: 3163212-3Report Type:Periodic Company Report #A0060861
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Agitation	Health	Zyban Tablets -Zyban	PS		ORAL 150 MG / TWICE PER DAY / ORAL
	Anxiety	Professional				
	Disturbance In Attention					
	Insomnia		Oral Contraceptive	C		
	Nervousness					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3164388-4Report Type:Periodic Company Report #A0057814
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation	Consumer	Zyban	PS		ORAL	150 MG TWICE	
	Bronchitis						PER DAY/ ORAL	
	Cough		Hrt	C				
	Depression		Amitriptyline Hcl	C				
	Difficulty In Walking		Decongestant	C				
	Dyspraxia							
	Hallucination							
	Headache							
	Nervousness							
	Speech Disorder							
	Tremor							

Date:05/29/98ISR Number: 3164391-4Report Type:Periodic Company Report #A0058368
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness	Health	Zyban	PS		ORAL	150 MG/SINGLE	
Initial or Prolonged	Rectal Haemorrhage	Professional					DOSE ORAL	
	Thrombosis		Terazosin Hydrochloride	C				
			Pravastatin Sodium	C				
			Aspirin	C				
			Allopurinol	C				

Date:05/29/98ISR Number: 3164458-0Report Type:Periodic Company Report #A0063074
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Consumer	Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Anger						PER DAY/ORAL	

	Disorientation		Captopril	C		
	Drug Toxicity		Isosorbide Dinitrate	C		
	Feeling Abnormal		Simvastatin	C		
	Nervousness		Thyroxine Sodium	C		
			Lansoprazole	C		
			Alprazolam	C		
			Paracetamol	C		

Date:05/29/98ISR Number: 3164461-0Report Type:Periodic Company Report #A0063111
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Reaction	Consumer	Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Anaphylactic Shock						PER DAY/ORAL	
	Arthralgia		Ibuprofen	C				
	Dermatitis							
	Hypersensitivity							
	Musculoskeletal Stiffness							
	Pneumatic Compression							
	Therapy							
	Pruritus							
	Swelling							
	Syncope							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3164464-6Report Type:Periodic Company Report #A0063297
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban	PS		ORAL	150 MG/TWICE	
	Hypersensitivity	Professional					PER DAY/ORAL	
	Oedema Peripheral	Company	Atenolol	C				
	Periorbital Oedema	Representative	Medroxyprogesterone					
	Pruritus		Ace.	C				
	Pyrexia							
	Urticaria							

Date:05/29/98ISR Number: 3164530-5Report Type:Periodic Company Report #A0063779
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Consumer	Zyban	PS		ORAL	TABLET, 150	
Initial or Prolonged	Memory Impairment						MG / TWICE	
	Tremor						PER DAY /	
							ORAL	

Date:05/29/98ISR Number: 3164533-0Report Type:Periodic Company Report #A0063660
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Zyban	PS		ORAL	TABLET, 150	
Initial or Prolonged	Pancreatitis Acute	Professional					MG / ORAL	
			Temazepam	C				

Date:05/29/98ISR Number: 3164536-6Report Type:Periodic Company Report #A0063622
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus	Health Professional	Zyban	PS		ORAL	TABLET, 150 MG / TWICE PER DAY / ORAL	

Date:05/29/98ISR Number: 3164540-8Report Type:Periodic Company Report #A0063591
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Consumer	Zyban	PS		ORAL	TABLET, 150 MG / TWICE PER DAY / ORAL	
	Dyspnoea							
	Hypersensitivity							
	Muscle Spasms							
	Muscular Weakness							
	Oesophageal Disorder							
	Swelling							

Date:05/29/98ISR Number: 3164543-3Report Type:Periodic Company Report #A0064074
Age:27 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Anaphylactic Reaction
Hospitalization - Initial or Prolonged	Chest Pain
	Dyspepsia

	Pain In Extremity					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban	PS		ORAL
TABLET, 150						
MG / TWICE						
PER DAY /						
ORAL						

Date:05/29/98ISR Number: 3164546-9Report Type:Periodic Company Report #A0064342
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Dermatitis	Consumer	Zyban	PS		ORAL
TABLET, 150						
Initial or Prolonged	Diarrhoea					
MG / TWICE						
	Dysphonia					
PER DAY /						
	Face Oedema					
ORAL						
	Nausea					
	Oedema					
	Periorbital Oedema					
	Pruritus					
	Pyrexia					
	Urticaria					

Date:05/29/98ISR Number: 3164551-2Report Type:Periodic Company Report #A0064347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Serum Sickness	Health	Zyban	PS		ORAL
TABLET, 150						
Initial or Prolonged		Professional				
MG /ORAL						
		Company	Ibuprofen	C		

Representative

Date:05/29/98ISR Number: 3164558-5Report Type:Periodic Company Report #A0062747
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Health	Zyban	PS		ORAL	TABLET, 150	
Other	Epileptic Aura	Professional					MG / TWICE	
	Feeling Abnormal	Company					PER DAY /	
	Grand Mal Convulsion	Representative					ORAL	
	Head Injury		Conjugated Estrogens	C				
	Headache		Ethanol	C				
	Laceration							

Date:05/29/98ISR Number: 3164561-5Report Type:Periodic Company Report #A0062744
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban	PS		ORAL	TABLET, 150	
	Dermatitis	Professional					MG / TWICE	
							PER DAY /	
ORAL								2 WK
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3164565-2Report Type:Periodic Company Report #A0062673
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction	Health	Zyban	PS		ORAL	TABLET, 150	
	Chills	Professional					MG / TWICE	
	Flushing						PER DAY /	
	Heart Rate Increased						ORAL	
	Hypotension							
	Pruritus							
	Swelling							
	Tongue Oedema							
	Tremor							
	Urticaria							

Date:05/29/98ISR Number: 3164568-8Report Type:Periodic Company Report #A0062647
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash Generalised	Health	Zyban	PS		ORAL	TABLET, 150	
Initial or Prolonged		Professional					MG / ORAL	
		Company Representative						

Date:05/29/98ISR Number: 3164569-XReport Type:Periodic Company Report #A0062644
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Zyban	PS		ORAL	TABLET, 150	
Initial or Prolonged		Professional					MG / ORAL	
		Company Representative						

Date:05/29/98ISR Number: 3164572-XReport Type:Periodic Company Report #A0062615
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Consumer	Zyban	PS		ORAL	TABLET, 150	
Initial or Prolonged	Choking						MG / TWICE	
	Diarrhoea						PER DAY /	
	Dizziness						ORAL	
	Dry Mouth		Librium	C				
	Insomnia		Cyclobenzaprine Hcl	C				
	Mental Impairment		Anticoagulant	C				
	Pneumonia		Diltiazem Hydrochloride	C				
	Weight Decreased		Simvastatin	C				
			Cimetidine	C				

Date:05/29/98ISR Number: 3164578-0Report Type:Periodic Company Report #A0063053
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Zyban	PS		ORAL	TABLET, 150	
Initial or Prolonged	Dyspnoea	Professional					MG / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3164580-9Report Type:Periodic Company Report #A0063042
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Dizziness Dyspnoea	Health Professional	Zyban	PS		ORAL	TABLET, 150 MG / PER DAY / ORAL	4 WK
			Nifedipine	C				

Date:05/29/98ISR Number: 3164584-6Report Type:Periodic Company Report #A0062867
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Diarrhoea Disorientation Syncope Vomiting	Consumer Company Representative	Zyban	PS		ORAL	TABLET, 150 MG / TWICE PER DAY / ORAL	

Date:05/29/98ISR Number: 3164585-8Report Type:Periodic Company Report #A0064892
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Convulsion Muscle Twitching	Health Professional	Zyban	PS		ORAL	TABLET, 150 MG / TWICE PER DAY / ORAL	

Date:05/29/98ISR Number: 3164587-1Report Type:Periodic Company Report #A0064923
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium Fall Laceration Vision Blurred	Consumer	Zyban	PS		ORAL	TABLET, 150 MG / TWICE PER DAY / ORAL	
			Vitamin	C				

Date:05/29/98ISR Number: 3164590-1Report Type:Periodic Company Report #A0064852
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease Myocardial Infarction	Consumer	Zyban	PS		ORAL	TABLET, 150 MG / ORAL	

Date:05/29/98ISR Number: 3164593-7Report Type:Periodic Company Report #A0061438
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Other	Blood Pressure Decreased Chest Discomfort Drug Interaction Ecchymosis Excoriation Fall Head Injury Malaise

Syncope

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health	Zyban	PS		ORAL
TABLET, 150						
		Professional				
MG / PER DAY						
/ ORAL						
			Aspirin	C		
			Digoxin	C		
			Diclofenac	C		
			Amlodipine	C		

Date:05/29/98ISR Number: 3165439-3Report Type:Periodic Company Report #A0063910
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Pruritus	Consumer	Zyban	PS		ORAL
150 MG; PER						
DAY; ORAL						

Date:05/29/98ISR Number: 3165442-3Report Type:Periodic Company Report #A0063911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Insomnia	Consumer	Zyban	PS		ORAL
150 MG;						
	Pruritus					
TWICE PER						
	Urticaria					
DAY; ORAL	2 WK					

Date:05/29/98ISR Number: 3165444-7Report Type:Periodic Company Report #A0063912
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Zyban	PS		ORAL	150 MG; TWICE	
	Chest Discomfort						PER DAY;	
	Dyspnoea						ORAL	

Date:05/29/98ISR Number: 3165446-0Report Type:Periodic Company Report #A0063913
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS		ORAL	150 MG;	
							ORAL	

Date:05/29/98ISR Number: 3165448-4Report Type:Periodic Company Report #A0063914
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS		ORAL	150 MG;	
	Joint Swelling						THREE TIMES	
	Oedema Peripheral						PER DAY;	
	Pruritus						ORAL	
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3165449-6Report Type:Periodic Company Report #A0063920
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS		ORAL	150 MG;	
	Pruritus						TWICE PER	
	Tenderness						DAY; ORAL	

Date:05/29/98ISR Number: 3165450-2Report Type:Periodic Company Report #A0063921
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS		ORAL	150 MG; PER	
	Dizziness						DAY; ORAL	
	Drug Ineffective							
	Emotional Disorder							
	Headache							
	Hypoaesthesia							

Date:05/29/98ISR Number: 3165451-4Report Type:Periodic Company Report #A0063922
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban	PS		ORAL	150 MG;	
	Dermatitis						TWICE PER	
	Pruritus						DAY; ORAL	
	Urticaria							

Date:05/29/98ISR Number: 3165452-6Report Type:Periodic Company Report #A0063923
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Zyban	PS		ORAL	150 MG;	
	Pruritus							
ORAL							5	DAY
	Rash Erythematous		Nicotine	C				
	Swelling							
	Urticaria							

Date:05/29/98ISR Number: 3165453-8Report Type:Periodic Company Report #A0063924
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Zyban	PS		ORAL	150 MG;	
	Dizziness							
TWICE PER								
	Dry Mouth							
DAY; ORAL								
	Nervousness		Diltiazem Hydrochloride	C				
	Rash Pruritic		Amlodipine	C				
			Nitroglycerin	C				
			Oxpentifylline	C				
			Triazolam	C				
			Aspirin	C				
			Fluoxetine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3165454-XReport Type:Periodic Company Report #A0063925
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS		ORAL	150 MG;	
	Tachycardia						TWICE PER	
							DAY; ORAL	
			Vitamin	C				

Date:05/29/98ISR Number: 3165455-1Report Type:Periodic Company Report #A0063926
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban	PS		ORAL	150 MG;	
	Disturbance In Attention						TWICE PER	
	Dry Mouth						DAY; ORAL	
	Insomnia		Oestradiol	C				
	Mood Swings							
	Nervousness							

Date:05/29/98ISR Number: 3165456-3Report Type:Periodic Company Report #A0063927
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS		ORAL	150 MG; PER	
							DAY; ORAL	

Date:05/29/98ISR Number: 3165457-5Report Type:Periodic Company Report #A0063929
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Petit Mal Epilepsy	Health	Zyban	PS		ORAL	150MG; TWICE PER DAY; ORAL	
		Professional						
			Multiple Medication	C				

Date:05/29/98ISR Number: 3165458-7Report Type:Periodic Company Report #A0063944
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain	Consumer	Zyban	PS		ORAL	150 MG; TWICE PER DAY; ORAL	
	Cough							
	Dermatitis							
	Dry Mouth		Aspirin	C				
	Parosmia		Thiamine Hydrochloride	C				
	Pruritus		Ascorbic Acid	C				
			Simvastatin	C				
			Inhaler	C				

Date:05/29/98ISR Number: 3165459-9Report Type:Periodic Company Report #A0063947
Age:67 YR Gender:Female I/FU:I

Outcome	PT
	Difficulty In Walking
	Dizziness
	Insomnia

	Tremor					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban	PS		ORAL
150 MG;						
TWICE PER						
DAY; ORAL						
			Bayer	C		
			Centrum Silver	C		
			Hyzaar	C		

Date:05/29/98ISR Number: 3165461-7Report Type:Periodic Company Report #A0063948
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Burning Sensation	Consumer	Zyban	PS		ORAL
150 MG;						
	Dermatitis					
TWICE PER						
	Pruritus					
DAY; ORAL						
	Urticaria		Hormones	C		
			Fiorinal	C		

Date:05/29/98ISR Number: 3165463-0Report Type:Periodic Company Report #A0063953
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Agitation	Consumer	Zyban	PS		ORAL
150 MG; PER						
	Anxiety					
DAY; ORAL						
	Dyspnoea					

Date:05/29/98ISR Number: 3165465-4Report Type:Periodic Company Report #A0063954
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban	PS		ORAL	150 MG;	
	Dermatitis						TWICE PER	
	Dry Skin						DAY;	ORAL

Date:05/29/98ISR Number: 3165467-8Report Type:Periodic Company Report #A0063961
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS		ORAL	150 MG;	
	Paraesthesia						TWICE PER	
	Tremor						DAY;	ORAL
			Oestradiol	C				
			Medroxyprogesterone Ace.	C				

Date:05/29/98ISR Number: 3166154-2Report Type:Periodic Company Report #A0063872
Age:32 YR Gender:Female I/FU:I

Outcome	PT
	Aggression
	Agitation
	Crying
	Depression
	Drug Ineffective

	Drug Withdrawal Syndrome Emotional Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Ibuprofen	C			
			Medroxyprogesterone Ace.	C			

Date:05/29/98ISR Number: 3166155-4Report Type:Periodic Company Report #A0063874
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Headache Vomiting	Consumer	Zyban	PS		ORAL	150 MG / PER DAY / ORAL
			Oral Contraceptive	C			

Date:05/29/98ISR Number: 3166157-8Report Type:Periodic Company Report #A0063876
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Face Oedema Influenza Like Illness Oedema Peripheral Pain Pyrexia Urticaria	Consumer	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ ORAL
			Vitamin	C			

Date:05/29/98ISR Number: 3166160-8Report Type:Periodic Company Report #A0063878
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Oral Contraceptive	C				
			Decongestant	C				

Date:05/29/98ISR Number: 3166161-XReport Type:Periodic Company Report #A0063879
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban	PS		ORAL	150 MG / ORAL	
	Dizziness		Wellbutrin	SS		ORAL	150 MG / ORAL	
	Formication							
	Hypoaesthesia							

Date:05/29/98ISR Number: 3166165-7Report Type:Periodic Company Report #A0063882
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Zyban	PS		ORAL	150 MG / ORAL	
	Panic Disorder	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3166167-0Report Type:Periodic Company Report #A0063883
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea	Health Professional Company Representative	Zyban	PS		ORAL	150 MG /	ORAL

Date:05/29/98ISR Number: 3166168-2Report Type:Periodic Company Report #A0063884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea	Health Professional Company Representative	Zyban	PS		ORAL	150 MG /	ORAL

Date:05/29/98ISR Number: 3166170-0Report Type:Periodic Company Report #A0063885
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban	PS		ORAL		ORAL

Date:05/29/98ISR Number: 3166172-4Report Type:Periodic Company Report #A0063886
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS		ORAL	150 MG /PER	
	Dysgeusia						DAY/	ORAL
			Me-Prednisolone Na Succ.	C				

			Diazepam	C		

Date:05/29/98ISR Number: 3166174-8Report Type:Periodic Company Report #A0063888
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban	PS		ORAL	150 MG/ PER	DAY / ORAL	5	DAY
			Benazepril	C						
			Alprazolam	C						

Date:05/29/98ISR Number: 3166176-1Report Type:Periodic Company Report #A0063900
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS		ORAL	150 MG /	TWICE PER	DAY/ ORAL	35	DAY
			Diphenhydramine Hcl	C						
			Diazepam	C						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3166178-5Report Type:Periodic Company Report #A0063901
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS		ORAL	150 MG /	
	Emotional Disorder							TWICE PER
	Hallucination, Auditory							DAY/ ORAL
	Insomnia		Tamoxifen	C				
	Paranoia		Diuretic	C				
	Pruritus		Potassium Salt	C				

Date:05/29/98ISR Number: 3166179-7Report Type:Periodic Company Report #A0063902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Zyban	PS		ORAL	150 MG /	
	Chills							TWICE PER DAY
	Dehydration							/ ORAL
	Night Sweats							
	Pyrexia							

Date:05/29/98ISR Number: 3166181-5Report Type:Periodic Company Report #A0063903
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Zyban	PS		ORAL	150 MG /	
	Condition Aggravated							TWICE PER
	Dizziness							DAY/ ORAL
	Feeling Cold		Paroxetine Hydrochloride	C				
	Hyperhidrosis		Clonazepam	C				
	Insomnia							

	Nausea		Warfarin Sodium	C		
	Rhinorrhoea		Prednisone	C		
	Vomiting		Methotrexate	C		
			Torasemide	C		
			Potassium Chloride	C		
			Folic Acid	C		
			Zolpidem Tartrate	C		
			Vicodin Es	C		

Date:05/29/98ISR Number: 3166183-9Report Type:Periodic Company Report #A0063904
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Zyban	PS		ORAL	150 MG / ORAL	
	Communication Disorder		Thyroxine Sodium	C				
	Constipation							
	Disturbance In Attention							
	Feeling Abnormal							
	Hyperhidrosis							
	Insomnia							

Date:05/29/98ISR Number: 3166184-0Report Type:Periodic Company Report #A0063905
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Zyban	PS		ORAL	150 MG/ TWICE	
	Insomnia						PER DAY /	

ORAL
Claritin-D C

Date:05/29/98ISR Number: 3166186-4Report Type:Periodic Company Report #A0063907
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Zyban	PS		ORAL	150 MG/ PER DAY / ORAL	

Date:05/29/98ISR Number: 3166189-XReport Type:Periodic Company Report #A0063908
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Tremor							

Date:05/29/98ISR Number: 3166191-8Report Type:Periodic Company Report #A0063909
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	2 WK

Date:05/29/98ISR Number: 3166194-3Report Type:Periodic Company Report #A0063963
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS		ORAL	150 MG;	PER DAY;
			Omeprazole	C				
			Theophylline	C				
			Antihistamine	C				

Date:05/29/98ISR Number: 3166196-7Report Type:Periodic Company Report #A0063966
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratoconjunctivitis	Consumer	Zyban	PS		ORAL	150 MG;	TWICE PER
	Sicca							DAY;
	Urticaria							
			Verapamil Hydrochloride	C				
			Conjugated Estrogens	C				

Date:05/29/98ISR Number: 3166198-0Report Type:Periodic Company Report #A0063967
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban	PS		ORAL	150 MG;	TWICE PER
	Disorientation							DAY;
	Dissociation							
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3166200-6Report Type:Periodic Company Report #A0063968
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS		ORAL	150 MG; ORAL	12 DAY
	Dry Throat							
	Insomnia							
	Tremor							

Date:05/29/98ISR Number: 3166202-XReport Type:Periodic Company Report #A0063969
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS		ORAL	150MG; TWICE	
	Pruritus						PER DAY;	
	Weight Decreased						ORAL	
			Felodipine	C				

Date:05/29/98ISR Number: 3166204-3Report Type:Periodic Company Report #A0063970
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban	PS		ORAL	150 MG;	
	Diarrhoea						TWICE PER	
	Myalgia						DAY; ORAL	
	Nausea							

Date:05/29/98ISR Number: 3166206-7Report Type:Periodic Company Report #A0063971
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Zyban	PS		ORAL	150 MG; TWICE PER DAY;	ORAL 2 WK

Date:05/29/98ISR Number: 3166208-0Report Type:Periodic Company Report #A0063972
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS		ORAL	150 MG; TWICE PER DAY;	ORAL
	Anorexia							
	Anxiety							
	Depression		Ibuprofen	C				

Date:05/29/98ISR Number: 3166210-9Report Type:Periodic Company Report #A0063988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS		ORAL	150 MG; TWICE PER DAY;	ORAL
	Insomnia							
	Pruritus							
			Conjugated Estrogens	C				
			Omeprazole	C				
			Maxzide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3166212-2Report Type:Periodic Company Report #A0063989
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS		ORAL	150MG; TWICE	
	Tinnitus						PER DAY;	
ORAL								
			Atenolol	C				
			Naproxen	C				
			Aspirin	C				

Date:05/29/98ISR Number: 3166213-4Report Type:Periodic Company Report #A0064001
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS		ORAL	150 MG; ORAL	

Date:05/29/98ISR Number: 3166215-8Report Type:Periodic Company Report #A0064002
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Immobile	Consumer	Zyban	PS		ORAL	150MG PER	
	Myalgia						DAY ORAL	
	Pain							

Date:05/29/98ISR Number: 3166217-1Report Type:Periodic Company Report #A0064004
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS		ORAL	150 MG;	

	Dizziness						
TWICE PER							
	Flushing						
DAY; ORAL							
	Headache		Diltiazem				
	Nervousness		Hydrochloride	C			
			Atenolol	C			
			Pravastatin Sodium	C			
			Omeprazole	C			
			Aspirin	C			
			Isosorbide				
			Mononitrate	C			

Date:05/29/98ISR Number: 3166218-3Report Type:Periodic Company Report #A0064005
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS		ORAL	150MG	TWICE
PER DAY;								
	Anorexia							
ORAL								
	Asthenia							
	Diarrhoea		Nifedipine	C				
			Alprazolam	C				
			Cimetidine	C				
			Lorcet	C				
			Cisapride	C				
			Clonidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3166221-3Report Type:Periodic Company Report #A0064011
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Zyban	PS		ORAL	150 MG; PER DAY;	ORAL
			Ketoprofen	C				
			Indomethacin	C				
			Morphine	C				
			Baclofen	C				

Date:05/29/98ISR Number: 3166222-5Report Type:Periodic Company Report #A0064012
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS		ORAL	150MG; TWICE PER DAY;	ORAL
	Hypoaesthesia							
	Pruritus							

Date:05/29/98ISR Number: 3166225-0Report Type:Periodic Company Report #A0064013
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban	PS		ORAL	150 MG TWICE PER DAY	ORAL
	Urticaria							

Date:05/29/98ISR Number: 3166226-2Report Type:Periodic Company Report #A0064014
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mood Altered	Consumer	Zyban	PS		ORAL	150MG TWICE PER DAY	
	Urticaria						ORAL	

Date:05/29/98ISR Number: 3166227-4Report Type:Periodic Company Report #A0064015
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS		ORAL	150MG; TWICE PER DAY;	ORAL
			Hormones	C				

Date:05/29/98ISR Number: 3166230-4Report Type:Periodic Company Report #A0064022
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban	PS		ORAL	150 MG; TWICE PER DAY;	ORAL
			Haloperidol	C				
			Paroxetine Hydrochloride	C				
			Vitamin	C				
			Gabapentin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3166232-8Report Type:Periodic Company Report #A0063803
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS		ORAL	150 MG/ TWICE	
	Disorientation						PER DAY /	
	Insomnia						ORAL	
	Tremor		Triamcinolone Acetonide	C				
			Zafirlukast	C				
			Insulin	C				
			Salbutamol Sulphate	C				
			Salmeterol Xinafoate	C				

Date:05/29/98ISR Number: 3166235-3Report Type:Periodic Company Report #A0063810
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS		ORAL	150 MG /	
	Anxiety						TWICE PER DAY	
	Dyspnoea						/ ORAL	
	Insomnia							
	Nervousness							
	Paranoia							
	Tachycardia							
	Tremor							

Date:05/29/98ISR Number: 3166236-5Report Type:Periodic Company Report #A0063815
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Benign Prostatic	Consumer	Zyban	PS		ORAL	150 MG /	

	Hyperplasia						
TWICE PER DAY							
	Confusional State						
/ ORAL							
	Dysuria			Hydrochlorothiazide	C		
	Headache			Piroxicam	C		
	Micturition Urgency			Diazepam	C		
	Pollakiuria						
	Tremor						

Date:05/29/98ISR Number: 3166237-7Report Type:Periodic Company Report #A0063827
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS		ORAL	150 MG /	
	Insomnia							
TWICE PER DAY								
/ ORAL								
			Salbutamol Sulphate	C				
			Azithromycin	C				

Date:05/29/98ISR Number: 3166238-9Report Type:Periodic Company Report #A0063828
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS		ORAL	150 MG /	
	Chest Discomfort							
TWICE PER DAY								
	Drug Ineffective							
/ ORAL								
	Flushing		Herbal Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Thyroid Medication C

Date:05/29/98ISR Number: 3166240-7Report Type:Periodic Company Report #A0063829
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS		ORAL	150 MG /	
	Irritability						TWICE PER DAY	
	Mood Altered						/ ORAL	
	Sedation							

Date:05/29/98ISR Number: 3166241-9Report Type:Periodic Company Report #A0063830
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS		ORAL	150 MG/ ORAL	

Date:05/29/98ISR Number: 3166242-0Report Type:Periodic Company Report #A0063832
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban	PS		ORAL	150 MG /	
	Vision Blurred						TWICE PER DAY	
							/ ORAL	

Date:05/29/98ISR Number: 3166244-4Report Type:Periodic Company Report #A0063833
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban	PS		ORAL	150 MG/	ORAL

Date:05/29/98ISR Number: 3166245-6Report Type:Periodic Company Report #A0063834
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban	PS		ORAL	150 MG/	ORAL
	Irritability							

Date:05/29/98ISR Number: 3166246-8Report Type:Periodic Company Report #A0063844
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akinesia	Consumer	Zyban	PS		ORAL	150 MG /	
	Chest Discomfort						ORAL	
	Depression		Diltiazem Hydrochloride	C				
	Dermatitis							
	Hypoaesthesia		Aspirin	C				
	Movement Disorder							
	Musculoskeletal Pain							
	Musculoskeletal Stiffness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3166247-XReport Type:Periodic Company Report #A0063845
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	
	Urticaria	Professional						
ORAL							4	DAY

Date:05/29/98ISR Number: 3166248-1Report Type:Periodic Company Report #A0063847
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Zyban	PS		ORAL	150 MG/ ORAL	
	Dysgeusia	Professional						

Date:05/29/98ISR Number: 3166250-XReport Type:Periodic Company Report #A0063865
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Dermatitis							
	Fatigue							
	Hypersensitivity		Omeprazole	C				
	Pharyngeal Oedema		Cortisone	C				
	Swelling							
	Urticaria							

Date:05/29/98ISR Number: 3166252-3Report Type:Periodic Company Report #A0063867
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban	PS		ORAL	150 MG/	TWICE
	Fatigue						PERDAY/	ORAL
	Feeling Drunk		Imipramine Hydrochloride	C				

Date:05/29/98ISR Number: 3166253-5Report Type:Periodic Company Report #A0063869
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS		ORAL	150 MG/	TWICE
	Pruritus						PER DAY /	
	Urticaria						ORAL	
			Conjugated Estrogens	C				
			Triamterene	C				
			Hydrochlorothiazide	C				

Date:05/29/98ISR Number: 3166254-7Report Type:Periodic Company Report #A0063870
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS		ORAL	150 MG /	
	Headache						TWICE PER DAY	
	Nausea						/ ORAL	
	Pruritus		Oxaprozin	C				
	Vomiting		Paracetamol	C				
			Cimetidine	C				

				Salbutamol Sulphate	C		
				Humibid Dm	C		
				Duratuss	C		
				Amitriptyline Hcl	C		
				Levofloxacin	C		
				Fluticasone Propionate	C		
				Salmeterol Xinafoate	C		
				Beclomethasone Dipropion.	C		
				Nicotine	C		

Date:05/29/98ISR Number: 3166255-9Report Type:Periodic Company Report #A0063871
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS		ORAL	150 MG /	
	Headache						TWICE PER DAY	
							/ ORAL	
			Cimetidine	C				
			Aspirin	C				
			Alka-Seltzer	C				

Date:05/29/98ISR Number: 3166274-2Report Type:Periodic Company Report #A0060065
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Health	Zyban	PS		ORAL	150 MG ORAL	
	Dermatitis	Professional	Ranitidine Hydrochloride	C				
	Dyspnoea		Amoxycillin	C				
	Hypersensitivity		Entex La	C				
	Pharyngeal Oedema							
	Rash Macular							
	Tachypnoea							
	Urticaria							

Date:05/29/98ISR Number: 3166275-4Report Type:Periodic Company Report #A0059950
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcohol Withdrawal Syndrome	Consumer	Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Convulsion		Estrogen	C				
	Dry Mouth		Naproxen	C				
	Nervousness		Omeprazole	C				
	Pancreatitis		Nadolol	C				

Date:05/29/98ISR Number: 3166276-6Report Type:Periodic Company Report #A0059853
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Other	Disorientation
	Dizziness
	Dysgeusia
	Headache
	Hypersensitivity
	Nausea

	Sedation					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health	Zyban	PS		ORAL
150 MG /						
		Professional				
TWICE PER DAY						
/ ORAL						
			Verapamil Hydrochloride	C		
			Conjugated Estrogens	C		
			Frusemide	C		
			Famotidine	C		
			Vitamin	C		
			Paracetamol	C		

Date:05/29/98ISR Number: 3166277-8Report Type:Periodic Company Report #A0059794
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Bronchospasm	Health	Zyban	PS		ORAL
150 MG						
Initial or Prolonged	Dyspnoea	Professional				
/SINGLE DOSE						
/ ORAL						
			Salbutamol Sulphate	C		
			Combivent	C		
			Theophyline	C		

Date:05/29/98ISR Number: 3166278-XReport Type:Periodic Company Report #A0059474
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dermatitis	Health	Zyban	PS		ORAL
150 MG /						
	Dyspnoea	Professional				
TWICE PER DAY						

	Pruritus					
/ ORAL						
	Swelling					
	Urticaria					

Date:05/29/98ISR Number: 3167109-4Report Type:Periodic Company Report #A0064432
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Zyban	PS	Zyban	ORAL	150 MG /	
	Blister	Professional					TWICE PER DAY	
	Cellulitis						/ ORAL	
	Haemorrhage		Vitamin	C				
	Hypersensitivity		Herbal Medication	C				
	Insomnia		Mineral Supplement	C				
	Irritability		Hypericum	C				
	Oedema		Garlic	C				
	Pain							
	Pruritus							
	Skin Disorder							
	Skin Lesion							
	Urticaria							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3167111-2Report Type:Periodic Company Report #A0064470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Consumer	Zyban	PS	Zyban	ORAL	150 MG ORAL	
	Convulsion		Asmacort	C				
	Sedation		Adrenaline	C				

Date:05/29/98ISR Number: 3167536-5Report Type:Periodic Company Report #A0060739
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Zyban	PS		ORAL	ORAL	

Date:05/29/98ISR Number: 3167538-9Report Type:Periodic Company Report #A0060648
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Multiforme	Health	Zyban	PS		ORAL	150 MG ORAL	17 DAY
	Pain	Professional Company Representative	Levlan	C				
	Pruritus							

Date:05/29/98ISR Number: 3167602-4Report Type:Periodic Company Report #A0062366
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ ORAL	14 DAY
	Chest Pain							
	Diarrhoea							
	Herpes Simplex							

	Nausea					
	Pyrexia					
	Swelling					
	Urticaria					
	Vomiting					
	White Blood Cell Count Increased					

Date:05/29/98ISR Number: 3167603-6Report Type:Periodic Company Report #A0062352
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ ORAL	
	Joint Swelling	Professional						
	Oedema		Oral Contraceptive	C				
	Pruritus							
	Urticaria							

Date:05/29/98ISR Number: 3167604-8Report Type:Periodic Company Report #A0062254
Age: Gender: I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Confusional State	Health
	Liver Function Test Abnormal	Professional
		Company

Representative

			Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS		ORAL
150 MG/ORAL						

Date:05/29/98ISR Number: 3167605-XReport Type:Periodic Company Report #A0062246
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Pruritus	Health	Zyban	PS		ORAL
ORAL						
		Professional				

Date:05/29/98ISR Number: 3167606-1Report Type:Periodic Company Report #A0062174
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Dermatitis	Health	Zyban	PS		ORAL
150 MG/TWICE						
Initial or Prolonged	Urticaria	Professional				
PER DAY/ ORAL						

Date:05/29/98ISR Number: 3167607-3Report Type:Periodic Company Report #A0063416
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Chest Discomfort	Health	Zyban	PS		ORAL
150 MG/TWICE						
Initial or Prolonged	Odynophagia	Professional				
PER DAY/ ORAL						
	Pruritus					
	Urticaria					

Date:05/29/98ISR Number: 3167608-5Report Type:Periodic Company Report #A0063490
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Nausea Tremor	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:05/29/98ISR Number: 3167800-XReport Type:Periodic Company Report #A0060628
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anorexia Chest Pain Drug Ineffective Dry Mouth Dyspepsia Dyspnoea Headache Insomnia	Consumer	Zyban Isosorbide Mononitrate Metoprolol Succinate Lansoprazole Simvastatin Aspirin	PS C C C C C	Zyban	ORAL	150MG TWICE PER DAY ORAL

Date:05/29/98ISR Number: 3167802-3Report Type:Periodic Company Report #A0060437
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Other	Convulsion	Health Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Zyban	ORAL	150MG TWICE PER DAY ORAL DAY

Date:05/29/98ISR Number: 3167803-5Report Type:Periodic Company Report #A0060409
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health Professional	Zyban	PS	Zyban	ORAL	150MG TWICE PER DAY ORAL
	Dysphagia		Propranolol Hydrochloride	C			
	Face Oedema		Conjugated Estrogens	C			
	Hypersensitivity						
	Oedema						
	Tongue Oedema						
	Urticaria						

Date:05/29/98ISR Number: 3167805-9Report Type:Periodic Company Report #A0062559
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Zyban	PS	Zyban	ORAL	150MG TWICE PER DAY ORAL
	Constipation						
Disability	Disturbance In Attention						
	Dyspnoea						
	Feeling Drunk						
	Hypersensitivity						
	Motor Dysfunction						
	Oedema Peripheral						
	Pruritus						
	Rash Papular						

Date:05/29/98ISR Number: 3167807-2Report Type:Periodic Company Report #A0062432
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity Oedema Peripheral Pruritus Urticaria	Health Professional	Zyban	PS	Zyban	ORAL	150MG TWICE PER DAY ORAL	

Date:05/29/98ISR Number: 3167809-6Report Type:Periodic Company Report #A0062403
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional Company Representative	Zyban	PS	Zyban	ORAL	150MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3168101-6Report Type:Periodic Company Report #A0064023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet-Zyban	PS		ORAL		
	Pruritus					ORAL		

Date:05/29/98ISR Number: 3168102-8Report Type:Periodic Company Report #A0064024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Hypersensitivity						PER DAY/ORAL	
	Pharyngeal Oedema							
	Pruritus							
	Tongue Oedema							
	Urticaria							

Date:05/29/98ISR Number: 3168105-3Report Type:Periodic Company Report #A0064026
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Rash Papular						PER DAY/ORAL	
			Atenolol	C				

Date:05/29/98ISR Number: 3168107-7Report Type:Periodic Company Report #A0064028
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	

	Urticaria		Atorvastatin Calcium	C		
			Ibuprofen	C		
			Vitamin E	C		
			Oestradiol	C		

Date:05/29/98ISR Number: 3168109-0Report Type:Periodic Company Report #A0064030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
							PER DAY/ORAL	
			Olanzapine	C				
			Antihypertensive	C				

Date:05/29/98ISR Number: 3168110-7Report Type:Periodic Company Report #A0064032
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	
	Dizziness							
	Dry Mouth							
	Feeling Abnormal							
	Nervousness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/98ISR Number: 3168154-5Report Type:Periodic Company Report #A0062106
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State	Health	Zyban	PS		ORAL	150 MG /	
	Crying	Professional					TWICE PER DAY	
	Depression						/ ORAL	
	Disorientation		Lansorprazole	C				
	Dyspnoea		Ipratropium Bromide	C				
	Emotional Disorder		Pain Medication	C				
	Furuncle							
	Hyperventilation							
	Nightmare							
	Palpitations							
	Tremor							

Date:05/29/98ISR Number: 3168156-9Report Type:Periodic Company Report #A0061979
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort	Health	Zyban	PS		ORAL	150 MG/ ORAL	
	Dermographism	Professional						
	Pruritus	Company						
	Unevaluable Event	Representative						

Date:05/29/98ISR Number: 3168158-2Report Type:Periodic Company Report #A0061938
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Health	Zyban	PS		ORAL	150 MG /	
Hospitalization -	Dyspnoea	Professional					TWICE PER DAY	
Initial or Prolonged	Eyelid Oedema						/ ORAL	
Other	Face Oedema		Glimepiride	C				

	Pharyngeal Oedema		Troglitazone	C		
	Speech Disorder		Diltiazem			
	Swelling		Hydrochloride	C		
			Compazine	C		

Date:05/29/98ISR Number: 3168160-0Report Type:Periodic Company Report #A0061929
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Consumer	Zyban	PS		ORAL	150 MG /	
	Dyspnoea						TWICE PER DAY	
	Hypersensitivity						/ ORAL	
	Pharyngeal Oedema		Diazepam	C				
	Urticaria		Ortho Cyclen	C				

Date:05/29/98ISR Number: 3188518-3Report Type:Periodic Company Report #A0063868
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS		ORAL	150 MG /	
	Dyspepsia						TWICE PER DAY	
	Oligomenorrhoea						/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/98ISR Number: 3083794-XReport Type:Periodic Company Report #A0055167
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
		Professional						

Date:06/01/98ISR Number: 3090040-XReport Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Zyban	PS		ORAL	150 MG PO BID	
Initial or Prolonged	Post-Traumatic Stress		Placebo	SS				
	Disorder		Zoloft	C				
	Suicidal Ideation		Trazodone	C				
			Buspirone	C				
			Antabuse	C				
			Albuterol	C				
			Atrovent	C				
			Cimetidine	C				

Date:06/04/98ISR Number: 3090225-2Report Type:Expedited (15-DaCompany Report #A0062175
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Conversion Disorder	Professional					PER DAY/ORAL/	
	Coordination Abnormal						TAB	
	Crying		Digoxin	C				
	Depression		Atenolol	C				
	Fear							
	Pneumonia Mycoplasmal							
	Pulmonary Tuberculosis							

Date:06/04/98ISR Number: 3090226-4Report Type:Expedited (15-DaCompany Report #A0061539
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nasal Congestion	Health	Zyban	PS		ORAL	150 MG/ PER	
	Pruritus	Professional					DAY/ ORAL/	
	Serum Sickness						TAB	

Date:06/04/98ISR Number: 3133320-1Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Disorientation		Zyban	PS		ORAL	150MG BID PO	
Other	Face Oedema							
	Heart Rate Increased							
	Urticaria							

Date:06/05/98ISR Number: 3090962-XReport Type:Expedited (15-DaCompany Report #A0065877
Age:65 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Shock	Consumer	Wellbutrin	PS		ORAL	150 MG/PER	
	Angioneurotic Oedema						DAY/ORAL	
	Drug Ineffective		Wellbutrin-Controlle					
	Face Oedema		d Release	SS		ORAL	150 MG/THREE	
	Paraesthesia						TIMES	
	Respiratory Failure						DAY/ORAL	
	Urticaria		Aspirin	C				

Date:06/05/98ISR Number: 3091334-4Report Type:Direct Company Report #
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nightmare	Health	Wellbutrin	PS			150 MG BID	
		Professional						

Date:06/08/98ISR Number: 3091260-0Report Type:Expedited (15-DaCompany Report #A0064987
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Colitis						PER DAY/ ORAL	
	Diarrhoea		Herbal Dietary					
	Faecal Incontinence		Supplement	C				
	Fatigue		Lorazepam	C				
	Nervousness							
	Tremor							
	Weight Decreased							
	White Blood Cell Count Increased							

Date:06/09/98ISR Number: 3091779-2Report Type:Direct Company Report #
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying		Wellbutrin Sr	PS			150 MG, BID	
	Depression		Zestoretic	C				
			Trental	C				
			Hytrin	C				
			Tylenol	C				
			Asa	C				

Date:06/09/98ISR Number: 3091815-3Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Zyban	PS	Glaxo	ORAL	150MG 1T PO	
	Urticaria						QD	
			Hytrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/98ISR Number: 3092899-9Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Multiforme		Zyban	PS			QD X 3 DAYS	
	Urticaria						THEN BID	
			Tylenol Sinus	C				
			St. John'S Wart	C				

Date:06/12/98ISR Number: 3093932-0Report Type:Expedited (15-DaCompany Report #A0065116
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Health	Zyban	PS		ORAL	150 MG/ORAL	
	Drug Level Above Therapeutic	Professional Company Representative						

Date:06/15/98ISR Number: 3094408-7Report Type:Expedited (15-DaCompany Report #A0065665
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Wellbutrin	PS		ORAL	75 MG/TWICE	
	Confusional State						PER DAY/ORAL	
	Convulsion		Clonazepam	C				
	Dermatitis		Carisoprodol	C				
	Dry Mouth		Botulinum Toxin	C				
	Jaundice							
	Weight Decreased							

Date:06/15/98ISR Number: 3094825-5Report Type:Expedited (15-DaCompany Report #A0066342
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Drug Interaction Hypertension Intentional Misuse Tachycardia	Health Professional Company Representative	Wellbutrin Fluvoxamine Maleate	PS SS		ORAL ORAL		

Date:06/17/98ISR Number: 3095280-1Report Type:Expedited (15-DaCompany Report #A0066297
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Depressed Level Of Consciousness	Health Professional	Wellbutrin Diphenhydramine Hcl	PS SS		ORAL ORAL	150 MG/ORAL	

Date:06/18/98ISR Number: 3095740-3Report Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Grand Mal Convulsion		Wellbutrin	PS			150 BID	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/98ISR Number: 3097062-3Report Type:Expedited (15-DaCompany Report #A0063323
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Agitation	Health	Wellbutrin	PS		ORAL	150 MG PER
Other	Anxiety	Professional					DAY ORAL
	Completed Suicide		Semisodium Valproate	C			
	Condition Aggravated		Lansoprazole	C			
	Diarrhoea		Ascorbic Acid	C			
	Irritability		Vitamin B Complex	C			
	Mood Altered		Tranylcypromine Sulphate	C			
	Paranoia						

Date:06/22/98ISR Number: 3097400-1Report Type:Direct Company Report #
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Zyban	PS	Glaxo-Wellcome		

Date:06/22/98ISR Number: 3097433-5Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150 MG 2 X'S DAILY
	Chest Discomfort						
	Chest Pain						
	Dizziness						
	Muscle Tightness						
	Vomiting						

Date:06/23/98ISR Number: 3097760-1Report Type:Expedited (15-DaCompany Report #8-98076-001K
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Incompetence	Health	Redux	PS		ORAL	15 MG TWICE	
	Basal Cell Carcinoma	Professional					DAILY ORAL	
	Blister		Wellbutrin	SS			75 TO 150 MG	
	Blood Pressure Increased						TWICE DAILY	
	Bronchitis Acute		Klonpin	C				
	Bronchospasm		Multivitamin	C				
	Cough		Vitamin C	C				
	Crying		Vitamin E	C				
	Diarrhoea		Wellbutrin	C				
	Eczema							
	Erythema Nodosum							
	Fluid Retention							
	Nausea							
	Pyrexia							
	Sedation							

Date:06/24/98ISR Number: 3098682-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Irritability		Zyban	PS		ORAL	150 MG QD X 3	
	Mental Disorder						D PO	
	Suicidal Ideation		Diabeta	C				

Asa	C
Menocor	C
Lisinopril	C

Date:06/24/98ISR Number: 3098713-XReport Type:Direct Company Report #
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis Lymphadenopathy Pain Serum Sickness		Zyban	PS	Glaxowellcome	ORAL	1T PO BID	

Date:06/29/98ISR Number: 3099734-3Report Type:Expedited (15-DaCompany Report #A0066903
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Health	Wellbutrin	PS		ORAL	SINGLE DOSE /	
Hospitalization - Initial or Prolonged Disability	Intentional Misuse Respiratory Failure	Professional Company Representative					ORAL	

Date:07/01/98ISR Number: 3100470-5Report Type:Expedited (15-DaCompany Report #A0066987
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Csf Pressure Increased Hepatic Function Abnormal Hepatitis Viral Optic Nerve Disorder Papilloedema	Consumer	Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL

	Platelet Count Decreased					
	Pyrexia					
	Visual Field Defect					
	Vomiting					

Date:07/01/98ISR Number: 3100514-0Report Type:Expedited (15-DaCompany Report #A0065877
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaphylactic Reaction	Health	Wellbutrin	PS		ORAL	150 MG/PER
Initial or Prolonged	Angioneurotic Oedema	Professional					DAY/ORAL;
Other	Face Oedema						150MG/THREE
	Hypersensitivity						TIMES PER
	Paraesthesia						DAY/ORAL
	Respiratory Failure		Aspirin	C			
	Syncope Vasovagal		Ethanol	C			
	Urticaria		Amoxycillin	C			
			Ciprofloxacin Hcl	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/98ISR Number: 3101743-2Report Type:Expedited (15-DaCompany Report #A0066676
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia	Consumer	Wellbutrin	PS		ORAL		
Other	Coordination Abnormal	Company						
	Disturbance In Attention	Representative						
	Fall							
	Joint Contracture							
	Migraine							
	Nervous System Disorder							
	Peripheral Nerve Injury							
	Petit Mal Epilepsy							
	Wrist Fracture							

Date:07/06/98ISR Number: 3102317-XReport Type:Expedited (15-DaCompany Report #A0065505
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Consumer	Wellbutrin	PS		ORAL	150 MG / PER DAY / ORAL	
	Mood Swings							
	Platelet Count Decreased		Lamictal	SS		ORAL	50 MG / TWICE PER DAY / ORAL /TABLET	
	Premenstrual Syndrome							
	Pyrexia							
	White Blood Cell Count		Quetiapine Fumarate	SS		ORAL	ORAL/TABLET	
	Decreased		Carbamazepine	SS		ORAL	ORAL/TABLET	
			Paroxetine Hydrochloride	C				
			Lorazepam	C				
			Methysergide Maleate	C				

Date:07/06/98ISR Number: 3103894-5Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Wellbutrin	PS		ORAL	150 SR PO	

Date:07/07/98ISR Number: 3103927-6Report Type:Direct Company Report #
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS			75-150 MG Q DAY	
	Tremor							
			Zoloft	C				
			Melatonin	C				

Date:07/07/98ISR Number: 3104072-6Report Type:Direct Company Report #
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Face Oedema		Olanzapine	PS			HS	
	Rash Maculo-Papular		Bupropin	SS			HS	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/98ISR Number: 3104149-5Report Type:Direct Company Report #
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blepharospasm	Health	Zyban	PS	Glaxo Wellcome	ORAL	150 MG PO	
	Palpitations	Professional					DAILY	3 DAY
			Vitamins	C				

Date:07/08/98ISR Number: 3103114-1Report Type:Expedited (15-DaCompany Report #MPI 97612
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Incompetence	Health	Ionamin	PS		ORAL	15 OR 30 MG	
	Mitral Valve Incompetence	Professional					DAILY-ORAL	
	Palpitations						VARIES	
	Tricuspid Valve		Pondimin	SS		ORAL	20 MG TID	
	Incompetence						ORAL	
			Redux	SS		ORAL	15 MG, BID	
							ORAL	
			Fastin	SS		ORAL	30 MG DAILY	
							ORAL	
			Wellbutrin	SS		ORAL	100 MG BID	
							ORAL 75 MG,	
							2, BID ORAL	

Date:07/08/98ISR Number: 3103407-8Report Type:Expedited (15-DaCompany Report #A0066944
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Chest Pain	Consumer	Wellbutrin	PS		ORAL	100 MG/TWICE PER DAY/ORAL	
			Wellbutrin	SS		ORAL	150 MG	
			Clonazepam	C				
			Aspirin	C				
			Sertraline Hydrochloride	C				

Date:07/14/98ISR Number: 3104056-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Zyban	PS		ORAL	1 PO QD X 7	
	Anxiety Disorder						DAYS THEN	
	Hostility						BID.	
	Screaming		Norvasc	C				
	Speech Disorder		Lozol	C				
	Tearfulness							
	Thinking Abnormal							

Date:07/16/98ISR Number: 3105828-6Report Type:Expedited (15-DaCompany Report #A0067512
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Indinavir Sulfate	C				
			Lamivudine	C				
			Protease Inhibitor	C				

			Sedative	C		
			Lorazepam	C		

Date:07/17/98ISR Number: 3106332-1Report Type:Expedited (15-DaCompany Report #9819711
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Consumer	Zoloft	PS		ORAL	150.00 MG	
Initial or Prolonged	Chest Discomfort						TOTAL; DAILY;	
	Chest Pain					ORAL		
	Coronary Artery Occlusion		Wellbutrin	SS		ORAL	150.00 MG	
	Drug Interaction						TOTAL; DAILY;	
	Erectile Dysfunction					ORAL		
	Eye Irritation		Clonazepam	C				
	Hyperhidrosis							
	Keratoconjunctivitis							
	Sicca							
	Libido Decreased							
	Mood Swings							
	Pollakiuria							
	Speech Disorder							

Date:07/17/98ISR Number: 3188398-6Report Type:Periodic Company Report #A0063064
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Health	Wellbutrin Tablet-					
Initial or Prolonged		Professional	Controlled Release	PS		ORAL		
ORAL								
		Company						
		Representative						

Date:07/17/98ISR Number: 3188401-3Report Type:Periodic Company Report #A0064292
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
	Dermatitis							
	Drug Interaction							
	Kidney Infection							
	Pain		Ciprofloxacin (Formulation Unknown)	SS		ORAL		
	Pyrexia							
	Urticaria							

Date:07/17/98ISR Number: 3188405-0Report Type:Periodic Company Report #A0064821
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Extrapyramidal Disorder	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
	Fall							
	Parkinson'S Disease							
			Terazodin Hydrochloride	C				
			Imipramine	C				
			Famotidine	C				
			Steroid	C				
			....	C				

			...	C		
			.....	C		

Date:07/17/98ISR Number: 3188409-8Report Type:Periodic Company Report #A0064841
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Agitation Cerebral Artery Embolism Speech Disorder	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ PER DAY/ ORAL	
			Clozapine	C				
			Semisodium Valproate	C				
			Paroxetine Hydrochloride	C				

Date:07/17/98ISR Number: 3188413-XReport Type:Periodic Company Report #A0064907
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Deafness	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ ORAL	
			Trazodone	C				

Date:07/17/98ISR Number: 3188417-7Report Type:Periodic Company Report #A0065150
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Anaphylactic Reaction Blood Pressure Decreased Dermatitis Dyspnoea	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	

	Pharyngeal Oedema		Fluoxetine Hydrochloride	C		
	Pruritus					

Date:07/17/98ISR Number: 3188421-9Report Type:Periodic Company Report #A0065505
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ PER DAY/ ORAL
	Mood Altered						
	Platelet Count Decreased						
	Pyrexia						
	White Blood Cell Count Decreased		Lamictal Tablet	SS		ORAL	50 MG/TWICE PER DAY/ ORAL
			Quetiapine Fumarate Tablet	SS		ORAL	ORAL
			Carbamazepine Tablet	SS		ORAL	ORAL
			Paroxetine Hydrochloride	C			
			Lorazepam	C			
			Methysergide Maleate	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/98ISR Number: 3188424-4Report Type:Periodic Company Report #A0065573
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aggression	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/	ORAL
	Crying							
	Delusion							
	Depression							
	Drug Ineffective		Zyban Tablet-Zyban	SS		ORAL	150 MG/	ORAL
	Hallucination		Prednisone	C				
	Mood Altered		Salbutamol Sulphate	C				
	Speech Disorder		Beclomethasone Dipropion.	C				
	Tremor		Ipratropium Bromide	C				

Date:07/17/98ISR Number: 3188428-1Report Type:Periodic Company Report #A0065668
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/	ORAL
	Confusional State							
	Insomnia							

Date:07/17/98ISR Number: 3188431-1Report Type:Periodic Company Report #A0065767
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:07/17/98ISR Number: 3188432-3Report Type:Periodic Company Report #A0065796
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis Disorientation Dizziness Haematemesis Hallucination Pyrexia Stevens-Johnson Syndrome Urticaria	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL

Date:07/17/98ISR Number: 3188434-7Report Type:Periodic Company Report #A0065820
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Asthenia Tremor	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	1 TABLET/ TWICE PER DAY/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/98ISR Number: 3188435-9Report Type:Periodic Company Report #A0065875
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin					
	Disturbance In Attention	Professional	Tablet-Controlled					
	Joint Dislocation		Release	PS		ORAL	400 MG/ PER	
							DAY/ ORAL	1 YR
			Diuretic	C				

Date:07/17/98ISR Number: 3188436-0Report Type:Periodic Company Report #A0067121
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Consumer	Wellbutrin					
	Convulsion		Tablet-Controlled					
			Release	PS		ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	
			Bromfenac Sodium	C				
			Tramadol Hydrochloride	C				
			Mirtazapine	C				

Date:07/17/98ISR Number: 3188438-4Report Type:Periodic Company Report #A0067233
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Health	Wellbutrin					
	Convulsion	Professional	Tablet-Controlled					
	Overdose	Company	Release	PS		ORAL	1500 MG/ ORAL	
		Representative						

Date:07/17/98ISR Number: 3188440-2Report Type:Periodic Company Report #A0067257
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:07/17/98ISR Number: 3188442-6Report Type:Periodic Company Report #A0067324
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
			Asthma Medication	C				
			Theophylline	C				
			Haloperidol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/98ISR Number: 3188445-1Report Type:Periodic Company Report #A0067426
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Urticaria	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL

Date:07/20/98ISR Number: 3109633-6Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain		Zyban	PS		ORAL	150 MG PO BID
	Agitation						
	Crying						
	Feeling Jittery						
	Paranoia						

Date:07/22/98ISR Number: 3108658-4Report Type:Expedited (15-DaCompany Report #MPI-981429
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Dysuria	Health Professional	Ionamin	PS		ORAL	15 MG DAILY
Life-Threatening	Fall						ORAL
	Insomnia		Pondimin	SS		ORAL	20-60 MG DAILY ORAL
	Ventricular Hypertrophy						
			Wellbutrin	SS		ORAL	400 MG DAILY ORAL MANY YEARS

			Loestrin	C	
			Naprosyn	C	
			Ultram	C	

Date:07/22/98ISR Number: 3108831-5Report Type:Direct Company Report #
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Zyban	PS			TBCR 150 MG	
Hospitalization -	Chest Discomfort						AS DIRECTED	
Initial or Prolonged	Chest Pain						ON LABEL	
	Hemiparesis							
	Sensation Of Heaviness							
	Vision Blurred							

Date:07/22/98ISR Number: 3109036-4Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia		Zyban	PS			3	WK
	Face Oedema							
	Periorbital Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/98ISR Number: 3109046-7Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Wellbutrin	PS			150 MG BID	
	Loss Of Consciousness		Effexor	C				
			Depakate	C				
			Klonopin	C				
			Zyprexa	C				

Date:07/23/98ISR Number: 3107804-6Report Type:Expedited (15-DaCompany Report #A0067257
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Auricular Swelling	Health	Wellbutrin	PS		ORAL	ORAL	
Initial or Prolonged	Blood Pressure Increased	Professional	Dexamphetamine	SS		ORAL	ORAL	
	Blood Thyroid Stimulating	Company	Olanzapine	SS		ORAL	ORAL	
	Hormone Decreased	Representative						
	Hyperglycaemia							
	Hypersensitivity							
	Leukocytosis							
	Pruritus							
	Rash Maculo-Papular							
	Tachycardia							

Date:07/27/98ISR Number: 3110819-5Report Type:Expedited (15-DaCompany Report #A0067945
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower	Health	Zyban	PS		ORAL	150 MG /	
Initial or Prolonged	Asthenia	Professional					TWICE PER DAY	
	Bronchospasm	Company					/ ORAL	

		Difficulty In Walking	Representative	Ceftriaxone	SS		
INTRAMUSCULAR	UNK /	SINGLE					
		Dizziness					
DOSE /							
		Muscle Spasms					
INTRAMUSCULAR							
		Neck Pain		Doxycycline	SS		ORAL
100 MG /							
		Pyrexia					
TWICE PER DAY							
		Serum Sickness					
/ ORAL							
		White Blood Cell Count Increased					

Date:07/27/98ISR Number: 3110822-5Report Type:Expedited (15-DaCompany Report #A0068002
Age:55 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bronchitis	Health	Zyban	PS		ORAL
150 MG /							
		Bronchospasm	Professional				
TWICE PER DAY							
		Cardiac Failure					
/ ORAL							
		Congestive		Nicotinic Acid	C		
		Cough		Aspirin	C		
		Dyspnoea					
		Haemoptysis					
		Rales					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/98ISR Number: 3157553-3Report Type:Periodic Company Report #M0157-98
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcoholic Hangover	Health	Remeron	PS			15MG/DAY PO	
	Drug Interaction	Professional	Wellbutrin Sr	SS			150MG BID	
			Claritin	C				

Date:07/28/98ISR Number: 3112923-4Report Type:Direct Company Report #
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis		Wellbutrin Sr	PS		ORAL	150 MG PO BID	
	Myalgia							
	Pyrexia							

Date:07/29/98ISR Number: 3123280-1Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Bupropion	PS		ORAL	75 MG PO Q AM	
	Chest Discomfort		Fluoxetine	SS		ORAL	20 MG PO Q AM	
	Dysphagia							
	Dyspnoea							
	Tachycardia							

Date:07/30/98ISR Number: 3111481-8Report Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Bupropion Sa	PS		ORAL	150 MG QD,	

ORAL

			Pentoxifylline	C			
			Albuterol	C			
			Aspirin	C			
			Buspirone Hcl	C			
			Zolpidem	C			
			Nifedipime (Adalat Cc)	C			
			Ferrous Sulfate	C			
			Docusate	C			
			Levothyroxine	C			
			Lovastatin	C			

Date:07/31/98ISR Number: 3111244-3Report Type:Expedited (15-DaCompany Report #A0067874
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Failure Renal Failure	Consumer	Zyban	PS		ORAL	150 MG/IN THE MORNING/ORAL	
			Paracetamol	C				
			Lorazepam	C				
			Aspirin	C				
			Cold Medication	C				
			Propanolol Hydrochloride	C				
			Methyldopa	C				
			Cimetidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/98ISR Number: 3111245-5Report Type:Expedited (15-DaCompany Report #A0068184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Zyban	PS		ORAL	150	
	Diabetic Retinopathy	Professional					MG/UNK/ORAL	
		Other	Raloxifene Hydrochloride	SS		ORAL	60 MG/PER	DAY/ORAL

Date:07/31/98ISR Number: 3111780-XReport Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Bupropion	PS		ORAL	75 MG, TWO	
	Drug Ineffective						BID, ORAL	
			Valproic Acid	C				
			Propanolol Hcl	C				

Date:07/31/98ISR Number: 3200049-0Report Type:Periodic Company Report #8-97351-028B
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Consumer	Pondimin	PS		ORAL	20 MG THREE	
	Dizziness						TIMES DAILY	
	Drug Withdrawal Syndrome						ORAL	
	Dyspnoea		Phentermine	SS			ABOUT 4 YEARS	4 YR
			Serzone	SS				
			Wellbutrin	SS				
			Premarin	C				

Date:08/03/98ISR Number: 3112548-0Report Type:Expedited (15-DaCompany Report #A0068320
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis	Consumer	Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Dyspnoea						PER DAY/ORAL	
	Feeling Abnormal							
	Laboratory Test Abnormal							
	Pyrexia							
	Urticaria							

Date:08/03/98ISR Number: 3112551-0Report Type:Expedited (15-DaCompany Report #A0066676
Age:14 YR Gender:Female I/FU:F

Outcome	PT
Disability	Amnesia
Other	Bone Disorder
	Coordination Abnormal
	Disturbance In Attention
	Eye Movement Disorder
	Fall
	Impaired Healing
	Migraine
	Movement Disorder
	Nervous System Disorder
	Pain In Extremity
	Peripheral Nerve Injury

	Petit Mal Epilepsy Photophobia Staring	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Vomiting	Health	Wellbutrin	PS		ORAL
100 MG/ TWICE						
	Wrist Deformity	Professional				
PER DAY/ORAL						
	Wrist Fracture	Company Representative	Trazodone	C		

Date:08/03/98ISR Number: 3201442-2Report Type:Periodic Company Report #8-98008-037B
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthenia	Health	Pondimin	PS		ORAL
20 MG THREE						
	Drug Withdrawal Syndrome	Professional				
TIMED DAILY						
ORAL 3 WKN						
			Ionamin	SS		
			Wellbutrin	SS		ORAL
ONE DAILY						
ORAL						
			Ionamin	C		
			Valium	C		

Date:08/04/98ISR Number: 3112697-7Report Type:Direct Company Report #
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anorexia		Wellbutrin	PS		ORAL
150MG SQ PO						
	Decreased Appetite					
BID						

Date:08/04/98ISR Number: 3113209-4Report Type:Direct Company Report #
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin	PS			150MG QD	
	Obsessive-Compulsive Disorder							

Date:08/04/98ISR Number: 3113216-1Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Mouth Ulceration		Bupropion	PS		BY MOUTH	100MG, TID,	
			Insulin Syringe	C				
			Easy Glucose Reagen Strip	C				
			Insulin Nph Human	C				
			Lisinopril	C				
			Acetaminophen	C				

Date:08/05/98ISR Number: 3113392-0Report Type:Expedited (15-DaCompany Report #8-98016-002S
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Insomnia	Health	Pondimin	PS		ORAL	20-60 MG	
	Ventricular Hypertrophy	Professional						DAILY;
			Wellbutrin	SS		ORAL	400 MG DAILY;	

ORAL						
			Ionamin	SS		ORAL
15 MG DIALY;						
ORAL						
			Naproxyn Ec	C		
			Ultram	C		
			Wellbutrin	C		
			Ionamin	C		
			Loestrin	C		

Date:08/05/98ISR Number: 3113632-8Report Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Hypotension		Zyban	PS		
150 MG BID 1 MON						
Intervention to	Orthostatic Hypotension		Hctz	C		
Prevent Permanent	Renal Impairment		Atenolol	C		
Impairment/Damage			Zestril	C		
			Zantac	C		
			Zyban	C		

Date:08/05/98ISR Number: 3202196-6Report Type:Periodic Company Report #97-12-0778
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anorexia	Health	Intron A (Interferon			
	Drug Interaction	Professional	Alfa-2b Recombinant)			
	Hypertension		Injectable	PS		
3 MU TIW						
	Hypertriglyceridaemia		Bupropion			
	Influenza Like Illness		Hydrochloride			
			Tablets	SS		ORAL
2 DAILY ORAL						

Date:08/06/98ISR Number: 3113778-4Report Type:Direct Company Report #
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Jittery		Wellbutrin Sr	PS		ORAL	150 MG PO	
	Nervousness						DAILY	
			Paxil	C				

Date:08/10/98ISR Number: 3115264-4Report Type:Expedited (15-DaCompany Report #A0068687
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Wellbutrin	PS		ORAL	ORAL	
Initial or Prolonged	Dermatitis Exfoliative	Professional						
	Pyrexia	Company						
	Urticaria	Representative						

Date:08/12/98ISR Number: 3116962-9Report Type:Direct Company Report #
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin	PS			100 MG BID	
	Chills							
	Myalgia							
	Pyrexia							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/98ISR Number: 3117261-1Report Type:Direct Company Report #
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG X 2	
	Drug Withdrawal Syndrome							

Date:08/13/98ISR Number: 3116733-3Report Type:Direct Company Report #
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall		Zyban	PS	Glaxo Wellcome			
	Grand Mal Convulsion							
	Laceration							

Date:08/14/98ISR Number: 3117355-0Report Type:Expedited (15-DaCompany Report #A0068408
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Platelet Count Decreased	Health Professional	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	
			Lithium Salt	C				
			Naproxen	C				

Date:08/14/98ISR Number: 3117417-8Report Type:Expedited (15-DaCompany Report #A0068968
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Rash Pruritic							

/ ORAL						
			Aspirin	C		
			Morphine	C		

Date:08/14/98ISR Number: 3117449-XReport Type:Expedited (15-DaCompany Report #A0065568
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban	PS		ORAL	150 MG /	
	Connective Tissue Disorder	Professional					TWICE PER DAY	
	Genital Ulceration						/ ORAL	
	Mouth Ulceration							
	Skin Disorder							

Date:08/18/98ISR Number: 3118512-XReport Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Urticaria		Welbutrin	PS				
			Lasix	C				
			Serzone	C				
			Digoxin	C				
			Ambien	C				
			Ativan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/20/98ISR Number: 3119552-7Report Type:Expedited (15-DaCompany Report #A0069321
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Wellbutrin	PS		ORAL	UNK/	UNK/
	Coordination Abnormal	Professional				ORAL		
	Movement Disorder	Company	Carisoprodol	SS		ORAL	UNK/	UNK/
		Representative				ORAL		

Date:08/20/98ISR Number: 3119555-2Report Type:Expedited (15-DaCompany Report #A0069088
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Consumer	Zyban	PS		ORAL	150 MG/TWICE	
	Choking						PER DAY/ORAL	
	Convulsion		Simvastatin	C				
	Thirst							
	Tremor							

Date:08/20/98ISR Number: 3119556-4Report Type:Expedited (15-DaCompany Report #A0067422
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cognitive Deterioration	Health	Wellbutrin	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Hallucination	Professional					PER DAY/ORAL	
Other	Muscle Rigidity		Alpraxolam	C				
	Parkinson'S Disease		Estrogen	C				
	Tremor		Famotidine	C				
			Vitamin D	C				
			Percocet	C				
			Calcium Carbonate	C				

Date:08/21/98ISR Number: 3120797-0Report Type:Expedited (15-DaCompany Report #A0069307
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Joint Swelling	Health	Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Rash Erythematous	Professional					PER DAY/ORAL	
	Serum Sickness	Company Representative						

Date:08/24/98ISR Number: 3120918-XReport Type:Expedited (15-DaCompany Report #A0069385
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Consumer	Zyban	PS		ORAL	ORAL	

Date:08/24/98ISR Number: 3121056-2Report Type:Expedited (15-DaCompany Report #A0067746
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Neoplasm	Health	Zyban	PS		ORAL	150MG; TWICE	
	Grand Mal Convulsion	Professional					PER DAY;	
		Company					ORAL	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/24/98ISR Number: 3121161-0Report Type:Direct Company Report #
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abdominal Pain		Wellbutrin Sr	PS		ORAL	150 MG PO BID
			Paxil	C			

Date:08/25/98ISR Number: 3120747-7Report Type:Expedited (15-DaCompany Report #A0066676
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Amnesia	Health Professional Company Representative	Wellbutrin	PS		ORAL	100MG / TWICE PER DAY / ORAL
Other	Bone Disorder		Trazodone	C			
	Coordination Abnormal						
	Disturbance In Attention						
	Eyelid Function Disorder						
	Fall						
	Impaired Healing						
	Migraine						
	Movement Disorder						
	Nervous System Disorder						
	Peripheral Nerve Injury						
	Petit Mal Epilepsy						
	Photophobia						
	Staring						
	Vomiting						
	Wrist Deformity						
	Wrist Fracture						

Date:08/25/98ISR Number: 3122492-0Report Type:Direct Company Report #
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Agitation		Wellbutrin	PS		ORAL	150 MG BID PO
Hospitalization -	Aspiration						

Initial or Prolonged	Blood Pressure Systolic Increased Confusional State Hallucination Hyperreflexia Overdose Respiratory Rate Increased Tachycardia					

Date:08/27/98ISR Number: 3122730-4Report Type:Expedited (15-DaCompany Report #A0068687
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Burning Sensation Dermatitis Exfoliative Malaise Pyrexia Rash Erythematous Rash Pruritic	Health Professional Company Representative	Wellbutrin	PS		ORAL	150 MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/98ISR Number: 3122733-XReport Type:Expedited (15-DaCompany Report #A0069140
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Literature	Wellbutrin	PS				
	Drug Level Above Therapeutic		Unknown Ssri (Formulation Unknown)	SS				

Date:08/27/98ISR Number: 3122735-3Report Type:Expedited (15-DaCompany Report #A0069142
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Literature	Wellbutrin	PS				
	Drug Level Above Therapeutic		Unknown Ssri (Formulation Unknown)	SS				

Date:08/27/98ISR Number: 3122737-7Report Type:Expedited (15-DaCompany Report #A0069143
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Literature	Wellbutrin	PS				
	Drug Level Above Therapeutic		Unknown Ssri (Formulation Unknown)	SS				

Date:08/27/98ISR Number: 3123040-1Report Type:Expedited (15-DaCompany Report #A0069623
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration	Consumer	Wellbutrin	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Dizziness							
	Heart Rate Increased							
	Insomnia							

Date:08/27/98ISR Number: 3123050-4Report Type:Expedited (15-DaCompany Report #A0069631
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Consumer	Zyban	PS		ORAL	TWICE PER DAY	
	Nausea							
	Pancreatitis		Lisinopril	C				
			Chlorpropamide	C				
			Fluoxetine Hydrochloride	C				

Date:08/27/98ISR Number: 3123067-XReport Type:Direct Company Report #
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine		Zyban	PS		ORAL	150 MG BID PO	1 WK
	Phosphokinase Increased							
	Pain In Extremity							
	Rhabdomyolysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/98ISR Number: 3123552-0Report Type:Expedited (15-DaCompany Report #A0068941
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Conversion Disorder		Zyban	PS		ORAL	150 MG	
Initial or Prolonged	Feeling Abnormal						/UNK/ORAL	
	Hallucination							
	Tremor							

Date:08/31/98ISR Number: 3123324-7Report Type:Expedited (15-DaCompany Report #A0069746
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Wellbutrin	PS		ORAL		
	Intentional Misuse	Professional	Diphenhydramine Hcl	SS				
		Company						
		Representative						

Date:08/31/98ISR Number: 3124018-4Report Type:Direct Company Report #
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Health	Zyban	PS		ORAL	150 BID PO	2 MON
Other		Professional	Habitrol	SS			TRANSDERMAL	14 MG
							TRANSDERMAL	2 MON

Date:09/01/98ISR Number: 3124703-4Report Type:Expedited (15-DaCompany Report #A0069000
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Apnoea	Health	Zyban	PS		ORAL	150 MG/TWICE	

	Drug Abuser	Professional				
PER DAY/ORAL						
	Grand Mal Convulsion		Cocaine	C		
			Oral Contraceptive	C		

Date:09/01/98ISR Number: 3204195-7Report Type:Periodic Company Report #A0065208
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills	Health	Zyban Tablet -					
	Flushing	Professional	Zyban	PS		ORAL	150 MG /	
	Hypersensitivity							
TWICE PER								
	Pharyngeal Oedema							
DAY/ ORAL								
	Serum Sickness							
	Urticaria							

Date:09/01/98ISR Number: 3204198-2Report Type:Periodic Company Report #A0065042
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
Initial or Prolonged	Increased Appetite							
PER DAY/ ORAL								
	Weight Increased		Pravastatin Sodium	C				
			Thyroxine Sodium	C				
			Isosorbide Mononitrate	C				
			Stool Softener	C				

			Nabumetone	C		
			Famotidine	C		
			Vicodin	C		

Date:09/01/98ISR Number: 3204199-4Report Type:Periodic Company Report #A0064923
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	
	Fall	Professional						
	Laceration		Iron Salt	C				
	Vision Blurred		Potassium Salt	C				
			Aspirin	C				
			Nephrocaps	C				

Date:09/01/98ISR Number: 3204201-XReport Type:Periodic Company Report #A0064852
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ ORAL	
	Thrombosis		Estratest	C				
			Multivitamin	C				

Date:09/01/98ISR Number: 3204203-3Report Type:Periodic Company Report #A0064613
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Choking Sensation	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	
	Hypersensitivity	Professional						
	Pruritus							
	Urticaria							

Date:09/01/98ISR Number: 3204206-9Report Type:Periodic Company Report #A0064432
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE PER DAY/	
	Blister	Professional						
	Cellulitis		Multivitamin	C				
	Haemorrhage		Herbal Medication	C				
	Hypersensitivity		Mineral Supplements	C				
	Insomnia		Hypericum	C				
	Irritability		Garlic	C				
	Oedema							
	Pain							
	Pruritus							
	Skin Disorder							
	Urticaria							
	Weight Increased							

Date:09/01/98ISR Number: 3204209-4Report Type:Periodic Company Report #A0064347
Age:39 YR Gender:Female I/FU:F

Outcome
Hospitalization - Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health	Zyban Tablets -					
	Arthralgia	Professional	Zyban	PS		ORAL	150 MG/	TWICE
	Serum Sickness	Company					PER DAY/	ORAL
	Urticaria	Representative	Ibuprofen	C				
			Cetirizine Hydrochloride	C				

Date:09/01/98ISR Number: 3204212-4Report Type:Periodic Company Report #A0064061
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus	Health	Zyban Tablets -					
		Professional	Zyban	PS		ORAL	150 MG /	
							TWICE PER	
							DAY/ ORAL	

Date:09/01/98ISR Number: 3204214-8Report Type:Periodic Company Report #A0064018
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Consumer	Zyban Tablets- Zyban	PS		ORAL	150 MG/	TWICE
Initial or Prolonged	Balance Disorder						PER DAY/	ORAL
	Confusional State							
	Dissociation							
	Dizziness							
	Ecchymosis							
	Grand Mal Convulsion							
	Haemorrhage							
	Laceration							
	Nystagmus							

Date:09/01/98ISR Number: 3204218-5Report Type:Periodic Company Report #A0063779
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Memory Impairment Tremor	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE PER DAY/	

Date:09/01/98ISR Number: 3204219-7Report Type:Periodic Company Report #A0063416
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Odynophagia Pruritus Urticaria	Health Professional	Zyban Tablets - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/98ISR Number: 3204222-7Report Type:Periodic Company Report #A0063490
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Health	Zyban Tablets- Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	
Other	Conversion Disorder	Professional						
	Joint Stiffness							
	Mental Disorder							
	Movement Disorder							
	Muscle Twitching							
	Nausea							
	Pain							
	Tremor							

Date:09/01/98ISR Number: 3204223-9Report Type:Periodic Company Report #A0063213
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER DAY/	
	Hypersensitivity	Professional						
	Insomnia		Etodolac	C				
	Pruritus		Oestradiol	C				
	Swelling		Claritin-D	C				
	Urticaria							

Date:09/01/98ISR Number: 3204226-4Report Type:Periodic Company Report #A0063157
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	
	Hypoxia	Professional	Fluticasone Propionate	C				
	Leukocytosis		Ipratropium Bromide	C				
	Pneumonitis							

Date:09/01/98ISR Number: 3204230-6Report Type:Periodic Company Report #A0062940
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG ORAL	
	Convulsion	Professional	Trazodone	C				

Date:09/01/98ISR Number: 3204232-XReport Type:Periodic Company Report #A0062673
Age:27 YR Gender:Male I/FU:F

Outcome	PT
Other	Anaphylactic Reaction
	Angioneurotic Oedema
	Chills
	Condition Aggravated
	Face Oedema
	Flushing
	Heart Rate Increased
	Hypersensitivity
	Hypotension
	Pruritus
	Rash Erythematous
	Swelling
	Tongue Oedema

	Tremor						
	Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE
		Professional					PER DAY/ ORAL

Date:09/01/98ISR Number: 3204237-9Report Type:Periodic Company Report #A0062652
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER
	Discomfort	Professional					DAY/ ORAL
	Pancreatitis						
			Ibuprofen	C			

Date:09/01/98ISR Number: 3204238-0Report Type:Periodic Company Report #A0061929
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE
	Dyspnoea	Professional					PER DAY/ ORAL
	Hypersensitivity		Diazepam	C			
	Pharyngeal Oedema		Ortho Cyclen	C			
	Urticaria						

Date:09/01/98ISR Number: 3204240-9Report Type:Periodic Company Report #A0059766
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - 150 MG/ TWICE	Dermatitis	Consumer	Zyban Tablet- Zyban	PS	ORAL
Initial or Prolonged PER DAY/ ORAL	Dysphagia				
	Dyspnoea		Glipizide	C	
	Insomnia		Theophylline	C	
	Pruritus		Dyazide	C	
	Speech Disorder		Salbutamol Sulphate	C	
	Swelling				
	Urticaria				

Date:09/01/98ISR Number: 3204242-2Report Type:Periodic Company Report #A0057814
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Disability	Agitation
	Amnesia
	Arthralgia
	Bronchitis
	Cough
	Depression
	Difficulty In Walking
	Dry Mouth
	Dyspraxia
	Grand Mal Convulsion
	Hallucination
	Headache
	Nervousness
	Neurological Symptom
	Speech Disorder

	Tremor						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY / ORAL

Date:09/01/98ISR Number: 3204248-3Report Type:Periodic Company Report #A0066526
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL

Date:09/01/98ISR Number: 3204251-3Report Type:Periodic Company Report #A0066427
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Arthralgia Chills Dyspnoea Hypersensitivity Myalgia Oedema Pain Pruritus Rash Maculo-Papular Serum Sickness Urticaria	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:09/01/98ISR Number: 3204255-0Report Type:Periodic Company Report #A0066361
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dermatitis	Professional					TWICE PER DAY	
	Pruritus						/ ORAL	
	Urticaria							

Date:09/01/98ISR Number: 3204259-8Report Type:Periodic Company Report #A0066333
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	
	Myocardial Infarction	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/98ISR Number: 3204260-4Report Type:Periodic Company Report #A0066226
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:09/01/98ISR Number: 3204263-XReport Type:Periodic Company Report #A0066137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
			Wellbutrin Tablet - Controlled Release	SS		ORAL	ORAL	

Date:09/01/98ISR Number: 3204265-3Report Type:Periodic Company Report #A0066078
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pyrexia Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	2 WK

Date:09/01/98ISR Number: 3204283-5Report Type:Periodic Company Report #A0066028
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Confusional State	Health	Zyban Tablet - Zyban	PS		ORAL 150 MG /
	Deafness	Professional				TWICE PER DAY
	Dizziness					/ ORAL
	Labyrinthitis		Hydrochlorothiazide	C		
	Meniere'S Disease		Fosinopril Sodium	C		
	Nausea					
	Vertigo					
	Vomiting					

Date:09/01/98ISR Number: 3204284-7Report Type:Periodic Company Report #A0066000
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization -	Abdominal Pain Upper	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG /
Initial or Prolonged	Asthenia					TWICE PER DAY
	Hypersensitivity					/ ORAL
	Pain In Extremity					
	Urticaria					

Date:09/01/98ISR Number: 3204287-2Report Type:Periodic Company Report #A0065873
Age:39 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Arterial Rupture
Initial or Prolonged	Face Oedema
Disability	Grand Mal Convulsion
	Hypersensitivity
	Nervous System Disorder
	Oedema Peripheral

	Urticaria Visual Field Defect						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:09/01/98ISR Number: 3204288-4Report Type:Periodic Company Report #A0065854
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion Depressed Level Of Consciousness Dyskinesia Eye Rolling	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Aspirin	C			

Date:09/01/98ISR Number: 3204290-2Report Type:Periodic Company Report #A0065816
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Aggression Agitation Amnesia Anxiety Disorientation Disturbance In Attention Excitability Fluid Retention Insomnia Paranoia Suicidal Ideation Tinnitus	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL
			Medroxyprogesterone Ace.	C			

	Tremor					

Date:09/01/98ISR Number: 3204291-4Report Type:Periodic Company Report #A0065790
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Decreased Appetite Dizziness Fall Feeling Abnormal Hip Fracture Weight Decreased	Consumer	Zyban Tablet - Zyban Blood Pressure Medication	PS C		ORAL	150 MG / TWICE PER DAY / ORAL

Date:09/01/98ISR Number: 3204294-XReport Type:Periodic Company Report #A0065789
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dermatitis	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/98ISR Number: 3204296-3Report Type:Periodic Company Report #A0065788
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG /	

Date:09/01/98ISR Number: 3204297-5Report Type:Periodic Company Report #A0065786
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG /	

Date:09/01/98ISR Number: 3204299-9Report Type:Periodic Company Report #A0065762
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Respiratory Distress Urticaria	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:09/01/98ISR Number: 3204301-4Report Type:Periodic Company Report #A0065736
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Depressed Level Of Consciousness Loss Of Consciousness	Health Professional Company Representative	Zyban Tablet - Zyban Nortriptyline	PS C		ORAL	150 MG ORAL	

Date:09/01/98ISR Number: 3204304-XReport Type:Periodic Company Report #A0065658
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Asthenia	Professional					TWICE PER DAY	
	Dermatitis						/ ORAL	
	Hypersensitivity		Centrum	C				
	Myalgia							
	Oedema							
	Pain							
	Periorbital Oedema							
	Pruritus							
	Rash Erythematous							
	Swelling							
	Urticaria							

Date:09/01/98ISR Number: 3204307-5Report Type:Periodic Company Report #A0065655
Age:69 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Balance Disorder
	Dizziness
	Fall

	Headache Hypoaesthesia Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG / PER DAY / ORAL						
			Enalapril Maleate	C		
			Alprazolam	C		
			Verapamil	C		

Date:09/01/98ISR Number: 3205205-3Report Type:Periodic Company Report #A0056995
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dysgeusia	Health	Zyban Tablet - Zyban	PS		ORAL
150 MG /UNK / ORAL	Nausea	Professional				
	Oral Intake Reduced		Conjugated Estrogens	C		
			Thyroxine Sodium	C		

Date:09/01/98ISR Number: 3205207-7Report Type:Periodic Company Report #A0068175
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebral Infarction	Health	Zyban Tablet- Zyban	PS		ORAL
150 / MG / ORAL	Cerebrovascular Accident	Professional				
		Company Representative	Simvastatin	C		

Date:09/01/98ISR Number: 3205209-0Report Type:Periodic Company Report #A0068019
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Other	Depression	Health	Zyban Tablet - Zyban	PS		ORAL
150 / MG /		Professional				
TWICE PER DAY						
/ ORAL						
			...	C		
			Diltiazem Hydrochloride	C		
			Estrogen	C		

Date:09/01/98ISR Number: 3205212-0Report Type:Periodic Company Report #A0067908
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
Initial or Prolonged	Chest Pain					
TWICE PER DAY						
	Hypoaesthesia					
/ ORAL						
	Insomnia		Progesterone	C		
			Calcium Salt	C		
			Estrogen	C		
			Multivitamin	C		
			Alendronate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/98ISR Number: 3205214-4Report Type:Periodic Company Report #A0067848
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Agitation	Professional					TWICE PER DAY	
	Anxiety						/ ORAL	
	Crying							
	Paranoia							

Date:09/01/98ISR Number: 3205217-XReport Type:Periodic Company Report #A0067448
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Chest Pain						/ ORAL	
			Conjugated Estrogens	C				
			Medroxyprogesterone Ace.	C				
			Multivitamin	C				
			Vitamin E	C				
			Ascorbic Acid	C				
			Aspirin	C				

Date:09/01/98ISR Number: 3205219-3Report Type:Periodic Company Report #A0067417
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	ORAL	

Date:09/01/98ISR Number: 3205220-XReport Type:Periodic Company Report #A0067336
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Herbal Medication	C				

Date:09/01/98ISR Number: 3205224-7Report Type:Periodic Company Report #A0067218
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Pharyngeal Oedema							
	Tongue Oedema							
	Urticaria							

Date:09/01/98ISR Number: 3205226-0Report Type:Periodic Company Report #A0067205
Age:27 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain
	Hypoaesthesia
	Joint Swelling

	Pharyngolaryngeal Pain Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:09/01/98ISR Number: 3205229-6Report Type:Periodic Company Report #A0067189
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hallucination Mania	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL
		Company Representative	Lithium Salt	C			

Date:09/01/98ISR Number: 3205231-4Report Type:Periodic Company Report #A0067126
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Agitation Amnesia Anxiety	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
	Confusional State Disorientation Nervous System Disorder Speech Disorder		Clarithromycin Cheratussin	C C			

Date:09/01/98ISR Number: 3205234-XReport Type:Periodic Company Report #A0066913
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Dyspnoea							
	Urticaria							

Date:09/01/98ISR Number: 3205236-3Report Type:Periodic Company Report #A0066889
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / THREE TIMES PER DAY / ORAL	
			Nabumetone	C				

Date:09/01/98ISR Number: 3205237-5Report Type:Periodic Company Report #A0066793
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypotension	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/98ISR Number: 3205240-5Report Type:Periodic Company Report #A0066753
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Urticaria	Professional					TWICE PER DAY	
							/ ORAL	
			Multivitamin	C				
			Estrogen	C				
			Diphenhydramine Hcl	C				

Date:09/01/98ISR Number: 3205242-9Report Type:Periodic Company Report #A0066711
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Mania	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Suicidal Ideation	Professional					TWICE PER DAY	
	Thinking Abnormal	Company					/ ORAL	
		Representative						

Date:09/01/98ISR Number: 3205243-0Report Type:Periodic Company Report #A0066646
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
Initial or Prolonged	Grand Mal Convulsion	Professional					TWICE PER DAY	
		Company					/ ORAL ;	
		Representative					WEEKS	

Date:09/01/98ISR Number: 3205245-4Report Type:Periodic Company Report #A0066587
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Hypoaesthesia Pharyngeal Oedema Tachycardia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:09/01/98ISR Number: 3205247-8Report Type:Periodic Company Report #A0066532
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Convulsion Dizziness Eye Rolling Loss Of Consciousness Tremor	Health Professional	Zyban Tablet -Zyban Tramadol Hydrochloride Cyclobenzaprine Hcl	PS C C		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:09/01/98ISR Number: 3205887-6Report Type:Periodic Company Report #A0065561
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Zyban Tablet-Zyban Alprazolam Multivitamin Orqal Contraceptive	PS C C C	Zyban	ORAL	150MG ORAL	6 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/98ISR Number: 3205888-8Report Type:Periodic Company Report #A0065495
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG TWICE PER DAY ORAL
	Dermatitis	Professional					
	Respiratory Distress	Company Representative					
	Swelling						
	Urticaria						

Date:09/01/98ISR Number: 3205889-XReport Type:Periodic Company Report #A0065339
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Bladder Disorder	Health	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG PER DAY ORAL
	Convulsion	Professional					
	Grand Mal Convulsion		Zidovudine	C			
	Hypoaesthesia Oral		Lamivudine	C			
	Loss Of Consciousness						
	Urinary Incontinence						

Date:09/01/98ISR Number: 3205890-6Report Type:Periodic Company Report #A0065334
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Convulsion	Health	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG TWICE PER DAY ORAL
Other	Syncope	Professional					
		Company Representative	Propranolol Hydrochloride	C			

Date:09/01/98ISR Number: 3205891-8Report Type:Periodic Company Report #A0065298
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG TWICE	
	Ageusia						PER DAY ORAL	
	Anorexia							
	Back Pain							
	Chills							
	Dermatitis							
	Diarrhoea							
	Dysphagia							
	Hyperhidrosis							
	Pyrexia							
	Stevens-Johnson Syndrome							
	Thermal Burn							
	Throat Tightness							
	Tongue Oedema							

Date:09/01/98ISR Number: 3205892-XReport Type:Periodic Company Report #A0065206
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG TWICE	
	Hypersensitivity						PER DAY ORAL	
	Swelling							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/98ISR Number: 3205893-1Report Type:Periodic Company Report #A0064999
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Health	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG TWICE	PER ORAL
	Bronchospasm	Professional						
	Cyanosis							
	Dermatitis							
	Dyspnoea							
	Pruritus							
	Swelling							
	Urticaria							

Date:09/01/98ISR Number: 3205894-3Report Type:Periodic Company Report #A0064880
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall	Health	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG TWICE	PER DAY ORAL
	Grand Mal Convulsion	Professional						
Other	Hip Fracture	Company Representative	Flurbiprofen	C				
			Gabapentin	C				
			Nortriptyline Hcl	C				
			Baclofen	C				

Date:09/01/98ISR Number: 3205895-5Report Type:Periodic Company Report #A0057792
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Health	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG PER DAY	ORAL
	Dehydration	Professional						
	Depressed Level Of Consciousness		Oxpentifylline	C				
			Nabumetone	C				
	Hyponatraemia		Claritin-D	C				
	Polyuria		Lansoprazole	C				

	Vomiting		Conjugated Estrogens	C		
	Weight Decreased		Dyazide	C		
			Alprazolam	C		
			Amitriptyline Hcl	C		
			Fluticasone Propionate	C		
			Aspirin	C		

Date:09/01/98ISR Number: 3205896-7Report Type:Periodic Company Report #A0061791
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG TWICE PER DAY ORAL	
	Cerebrovascular Accident	Professional						
	Dizziness		Conjugated Estrogens	C				
	Dyspnoea		Calcium Salt + Vitamin	C				
	Fear							
	Joint Stiffness							
	Loss Of Consciousness							
	Pain In Extremity							
	Tachycardia							

Date:09/02/98ISR Number: 3125110-0Report Type:Expedited (15-DaCompany Report #A0069743
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Disorientation	Consumer	Zyban	PS		ORAL	UNK/ORAL
	Dizziness		Nicotine	C			
	Palpitations						

Date:09/03/98ISR Number: 3125723-6Report Type:Expedited (15-DaCompany Report #A0065418
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angina Pectoris	Health	Zyban	PS		ORAL	150MG / PER
Hospitalization - Initial or Prolonged	Chest Discomfort	Professional					DAY / ORAL
Other	Flushing	Company	Atenolol	C			
	Myocardial Infarction	Representative	Famotidine	C			
			Amlodipine	C			
			Oxaprozin	C			

Date:09/03/98ISR Number: 3125724-8Report Type:Expedited (15-DaCompany Report #A0069407
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis	Consumer	Zyban	PS		ORAL	150MG / TWICE PER DAY / ORAL
	Eyelid Oedema						
	Face Oedema						
	Syncope						
	Urticaria						

Date:09/08/98ISR Number: 3126674-3Report Type:Expedited (15-DaCompany Report #A0070019
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Grand Mal Convulsion	Health	Zyban	PS		ORAL	150 MG ORAL	
Hospitalization - Initial or Prolonged		Professional Company Representative	Amitriptyline Hcl	SS		ORAL		

Date:09/09/98ISR Number: 3126593-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Agitation		Wellbutrin	PS			150 MG	
	Akathisia		Remeron	SS			30 MG HS	
	Muscle Rigidity		Effexor	SS			150 BID	
	Serotonin Syndrome							

Date:09/09/98ISR Number: 3126616-0Report Type:Expedited (15-DaCompany Report #M086021
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health	Serzone	PS		ORAL		
	Muscle Rigidity	Professional	Depakote	SS		ORAL		
	Rash Generalised		Wellbutrin Triamterene Timoptic Potassium	SS C C C				

			Estrogen	C
			Synthroid	C
			Calcium	C
			Ativan	C

Date:09/11/98ISR Number: 3128448-6Report Type:Expedited (15-DaCompany Report #A0069712
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Amylase Increased	Health	Wellbutrin	PS		ORAL	UNK, UNK,	
	Drug Interaction	Professional					ORAL	
	Gout							
	Liver Function Test Abnormal							
	Pancreatitis							
	Vomiting							

Date:09/14/98ISR Number: 3128407-3Report Type:Expedited (15-DaCompany Report #98090013
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Carisoprodol	PS		ORAL	DATA NA, PO	
	Coordination Abnormal		Wellbutrin	SS		ORAL	DATA NA. PO	
	Movement Disorder							

Date:09/14/98ISR Number: 3129147-7Report Type:Expedited (15-DaCompany Report #A0069197
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister	Health	Wellbutrin	PS		ORAL	ORAL TAB	
	Epidermolysis Bullosa	Professional	Paroxetine Hydrochloride	C				
	Porphyria Non-Acute							
	Pseudoporphyria		Trazodone	C				

Date:09/16/98ISR Number: 3130705-4Report Type:Direct Company Report #
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS		ORAL	150 SR BID	

Date:09/16/98ISR Number: 3131117-XReport Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mental Disorder		Famotidine	PS		ORAL	T1T PO B	
			Bupropion Hcl	SS		ORAL	T2T PO Q	
			Acetaminophen	C				
			Aspirin	C				
			Digoxin	C				

Date:09/17/98ISR Number: 3131637-8Report Type:Expedited (15-DaCompany Report #A0064074
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anaphylactic Shock	Health	Zyban	PS		ORAL	150MG/TWICE
Hospitalization -	Chest Pain	Professional					PER DAY/ORAL
Initial or Prolonged	Dyspepsia		Clove	SS			
	Dyspnoea						
	Food Interaction						
	Hypersensitivity						
	Pain In Extremity						

Date:09/18/98ISR Number: 3132553-8Report Type:Expedited (15-DaCompany Report #A0070451
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Abdominal Distension	Foreign	Wellbutrin	PS		ORAL	ORAL
	Oedema Peripheral	Consumer	Clonazepam	C			
			Estropipate	C			
			Medroxyprogesterone	C			

Date:09/21/98ISR Number: 3133432-2Report Type:Expedited (15-DaCompany Report #A0070019
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Grand Mal Convulsion	Health	Zyban	PS		ORAL	150 MG ORAL
Initial or Prolonged		Professional	Amitriptyline Hcl	SS		ORAL	ORAL
		Company Representative					

Date:09/21/98ISR Number: 3133562-5Report Type:Expedited (15-DaCompany Report #A0070795
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain	Health	Zyban	PS		ORAL	150 MG PER	
Hospitalization - Initial or Prolonged	Dizziness	Professional						
	Pulmonary Oedema	Company Representative	Fluoxetine Hydrochloride	C				
			Dalmane	C				
			Alprazolam	C				

Date:09/24/98ISR Number: 3134873-XReport Type:Expedited (15-DaCompany Report #98596.01
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Health Professional	Clonidine Hydrochloride	PS	Mylan	ORAL	0.2 MG	
Other	Crying						QHS,ORAL	
	Delirium							
	Emotional Disorder		Wellbutrin	SS	Glaxo			
	Hallucination, Auditory		Claritin-D	SS	Schering			
	Hypertonia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/25/98ISR Number: 3135134-5Report Type:Expedited (15-DaCompany Report #A0071029
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Choking	Consumer	Zyban	PS		ORAL	150 MG/ ORAL
	Foreign Body Trauma		Librax	C			
	Nausea						
	Oesophageal Obstruction						
	Pharyngolaryngeal Pain						

Date:09/25/98ISR Number: 3135138-2Report Type:Expedited (15-DaCompany Report #A0070661
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiac Arrest	Health	Wellbutrin	PS		ORAL	ORAL
Initial or Prolonged	Ventricular Fibrillation	Professional	Lamictal	SS		ORAL	ORAL
			Fluoxetine Hydrochloride	SS			
			Clonazepam	SS			
			Enflurane	SS			

Date:09/30/98ISR Number: 3136930-0Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blood Pressure Increased		Wellbutrin	PS			75MG PM 150
	Headache						MG "SR" AM
							(NDC#00173-01
							35-00)

Date:10/01/98ISR Number: 3136982-8Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Zyban	PS			150MG/X2	-4HR
Hospitalization - Initial or Prolonged	Bipolar I Disorder							
	Blast Injury							
	Burns Second Degree							
	Burns Third Degree							
	Complex Partial Seizures							
	Injury							
	Insomnia							
	Suicidal Ideation							
	Suicide Attempt							

Date:10/01/98ISR Number: 3137126-9Report Type:Expedited (15-DaCompany Report #A0069363
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Foreign	Wellbutrin	PS		ORAL	100 MG/	ORAL
Other		Health Professional	Frusemide	C				
			Omeprazole	C				
			Sinemet	C				
			Simethicone	C				
			Motilium	C				
			Olanzapine	C				
			Digoxin	C				
			Enalapril	C				

Nitroglycerin	C
Caffeine	C
Sinemet 10/100	C
Benztropine	C

Date:10/01/98ISR Number: 3137127-0Report Type:Expedited (15-DaCompany Report #A0070930
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder	Foreign Health Professional Company Representative	Wellbutrin	PS		ORAL	ORAL	

Date:10/02/98ISR Number: 3137372-4Report Type:Expedited (15-DaCompany Report #A0055625
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Literature	Wellbutrin	PS		ORAL	100 MG/THREE	TIMES PER
	Drug Interaction	Health Professional						DA/ORAL
	Grand Mal Convulsion							
	Medication Error		Guanfacine Hydrochloride Tablet	SS		ORAL	.5 MG/THREE	TIMES PER
								DAY/ORAL

Date:10/06/98ISR Number: 3138918-2Report Type:Expedited (15-DaCompany Report #A0070930
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Myocardial Infarction	Foreign	Wellbutrin	PS		ORAL
ORAL						
		Health Professional Company Representative				

Date:10/07/98ISR Number: 3139032-2Report Type:Direct Company Report #
Age:12 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Hypersensitivity		Wellbutrin Sr	PS		ORAL	150 MG QAM,
Intervention to	Urticaria						100 MG Q4 P
Prevent Permanent			Claritin	C		ORAL	10 MG TAB QD
Impairment/Damage			Cortisporin	C			4 GTTS TID

Date:10/07/98ISR Number: 3139488-5Report Type:Expedited (15-DaCompany Report #A0071135
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Convulsion	Health	Wellbutrin	PS		ORAL	60
Hospitalization -	Overdose	Professional					TABLET/SINGLE
Initial or Prolonged		Company					DOSE/ORAL
		Representative	Ethanol	C			

Date:10/07/98ISR Number: 3139498-8Report Type:Expedited (15-DaCompany Report #A0062864
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Health	Zyban	PS		ORAL	150 MG/TWICE	PER DAY/ORAL
		Professional						

Date:10/09/98ISR Number: 3142162-2Report Type:Expedited (15-DaCompany Report #A0071731
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Health	Wellbutrin	PS		ORAL	ORAL	
	Crying	Professional	Clonidine	C		ORAL	ORAL	
	Delirium	Other						
	Hallucination, Auditory							
	Muscle Disorder							

Date:10/09/98ISR Number: 3142164-6Report Type:Expedited (15-DaCompany Report #A0068282
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Wellbutrin	PS		ORAL	150 MG/TWICE	PER DAY/ORAL
	Proteinuria	Professional						
		Company Representative						

Date:10/09/98ISR Number: 3142498-5Report Type:Expedited (15-DaCompany Report #A0070674
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Constipation	Health	Wellbutrin	PS		ORAL
ORAL						
	Difficulty In Walking	Professional				
	Fatigue					
	Nausea					

Date:10/09/98ISR Number: 3142500-0Report Type:Expedited (15-DaCompany Report #A0067886
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Depression	Consumer	Wellbutrin	PS		ORAL
TWICE PER DAY						
Initial or Prolonged	Diarrhoea					
/ ORAL						
	Influenza Like Illness		Phenelaine Sulphate	C		
	Myalgia		Clonazepam	C		
	Nausea		Antihistamine	C		
	Sleep Disorder					

Date:10/09/98ISR Number: 3142502-4Report Type:Expedited (15-DaCompany Report #A0071650
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia	Health	Wellbutrin	PS		ORAL
100 MG /						
Initial or Prolonged	Ecchymosis	Professional				
ORAL 6 WK						
	Gingival Bleeding	Company				
	Neutropenia	Representative				
	Thrombocytopenia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/98ISR Number: 3141014-1Report Type:Expedited (15-DaCompany Report #A0070661
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest	Health	Wellbutrin	PS		ORAL		
Hospitalization - Initial or Prolonged	Ventricular Fibrillation	Professional	Lamictal	SS				
			Fluoxetine Hydrochloride	SS			20 MG/PER DAY	ORAL
			Clonazepam	SS				
			Enflurane	SS				
			Fentanyl	SS			50 MCG / UNK	/ INTRAVENOUS
			Propofol	SS			150 MG / UNK	/ INTRAVENOUS
			Mivacron	SS			14 MG / UNK /	INTRAVENOUS
			Glycopyrronium Bromide	SS			2 MG / UNK /	INTRAVENOUS
			Cephazolin	SS			1 G / UNK /	INTRAVENOUS
			Oxygen Gas	SS				
			Nitrous Oxide Gas	SS				

Date:10/13/98ISR Number: 3141796-9Report Type:Expedited (15-DaCompany Report #A0072020
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Vasculitis	Health Professional Company Representative	Wellbutrin	PS	ORAL

Date:10/13/98ISR Number: 3141798-2Report Type:Expedited (15-DaCompany Report #A0071991
Age:40 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Upper
	Anaemia
	Chest Discomfort
	Chest Pain
	Chills
	Cholelithiasis
	Cough
	Dehydration
	Diarrhoea
	Drug Interaction
	Eye Irritation
	Gallbladder Disorder
	Gingival Bleeding
	Hypersensitivity
	Ileus Paralytic
	Insomnia
	Loss Of Consciousness
	Muscle Twitching
	Nasal Congestion
	Pollakiuria
	Pyrexia

		Rash Erythematous					
		Red Blood Cell Sedimentation Rate	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased	Consumer	Wellbutrin	PS		ORAL
300 MG/THREE							
		Road Traffic Accident					
TIMES PER							
		Throat Irritation					
DAY/ORAL							
		Weight Decreased		Prednisone	C		
		White Blood Cell Count		Ortho-Cept	C		
		Increased		Lansoprazole	C		
				Pseudoephedrine Hcl	C		
				Semisodium Valproate	C		

Date:10/14/98ISR Number: 3141239-5Report Type:Expedited (15-DaCompany Report #A0071455
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dizziness	Foreign	Zyban	PS		ORAL
150 MG ORAL						
	Hypertension	Consumer	Blood Pressure			
	Loss Of Consciousness		Medication	C		

Date:10/19/98ISR Number: 3142501-2Report Type:Expedited (15-DaCompany Report #A0071152
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death	Foreign	Wellbutrin	PS		ORAL
ORAL						
		Health Professional Company Representative				

Date:10/19/98ISR Number: 3142870-3Report Type:Expedited (15-DaCompany Report #A0071650
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Wellbutrin	PS		ORAL	200 MG /	
Hospitalization -	Ecchymosis	Professional					TWICE PER DAY	
Initial or Prolonged	Gingival Bleeding	Company						
/ ORAL	6 WK							
	Neutropenia	Representative	Conjugated Estrogens	C				
	Thrombocytopenia		Calcium Salt	C				
			Clonazepam	C				

Date:10/19/98ISR Number: 3142871-5Report Type:Expedited (15-DaCompany Report #A0072073
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chills	Consumer	Wellbutrin	PS		ORAL	150 MG /TWICE	
Initial or Prolonged	Hyperhidrosis						PER DAY	
	Hypoaesthesia		Ranitidine					
	Memory Impairment		Hydrochloride	C				
	Pyrexia		Lisinopril	C				
	Vasculitis Cerebral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/98ISR Number: 3142873-9Report Type:Expedited (15-DaCompany Report #A0072191
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dizziness	Consumer	Zyban	PS		ORAL	150 MG /	
Hospitalization -	Haemorrhagic Stroke	Company					TWICE PER DAY	
Initial or Prolonged	Headache	Representative					/ ORAL	
	Hypertension		Nicotine	SS		TOPICAL	SEE TEXT /	
	Intracranial Aneurysm						TOPICAL	
	Loss Of Consciousness		Antibiotics	C				
	Malaise		Multivitamin	C				
	Pneumonia							
	Sinusitis							
	Tinnitus							

Date:10/19/98ISR Number: 3142874-0Report Type:Expedited (15-DaCompany Report #A0072222
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Zyban	PS		ORAL	150 MG /	
Initial or Prolonged	Increased	Professional					TWICE PER DAY	
	Disorientation	Company					/ ORAL	
	Dizziness	Representative	Calcium Salt	C				
	Dysarthria							
	Facial Palsy							
	Gait Disturbance							
	Headache							
	Hypercalcaemia							
	Hypertension							
	Nausea							
	Renal Failure Acute							
	Vomiting							

Date:10/19/98ISR Number: 3144277-1Report Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Zyban	PS		ORAL	150 MG	ORAL
Other	Chest Pain							
	Palpitations							
	Pyrexia							
	Restlessness							

Date:10/20/98ISR Number: 3143685-2Report Type:Expedited (15-DaCompany Report #A0071912
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State	Foreign	Zyban	PS	Zyban	ORAL	150 MG/PER	
	Disturbance In Attention	Health					DAY/ORAL	
	Hypercapnia	Professional						
	Malaise							

Date:10/20/98ISR Number: 3143715-8Report Type:Expedited (15-DaCompany Report #1998-10-0429
Age:15 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Behaviour
	Anxiety

	Crying Delirium Hallucination, Auditory	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertonia	Other	Clonidine	PS		ORAL	0.2 MG QHS
	Post-Traumatic Stress Disorder		Claritin-D 24 Hour	SS		ORAL	ORAL 1 TAB QD ORAL, EXTENDED RELEASE
			Wellbutrin	SS		ORAL	ORAL

Date:10/21/98ISR Number: 3144232-1Report Type:Direct Company Report #
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	International Normalised Ratio Increased Prothrombin Time Prolonged		Wellbutrin Sr Procardia Lx	PS C			COUMADIN DAW 10 MG

Date:10/21/98ISR Number: 3145350-4Report Type:Expedited (15-DaCompany Report #A0072552
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Feeling Abnormal Mydriasis Pallor Sensation Of Pressure	Consumer	Wellbutrin Atorvastatin Calcium	PS C		ORAL	150 MG/ TWICE PER DAY / ORAL

Date:10/21/98ISR Number: 3145351-6Report Type:Expedited (15-DaCompany Report #A0072624
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Hypersensitivity							
	Syncope							
	Urticaria							

Date:10/22/98ISR Number: 3145378-4Report Type:Expedited (15-DaCompany Report #A0072111
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Toxicity	Health	Wellbutrin	PS		ORAL	ORAL	
	Overdose	Professional	Lithium Salt	C				
			Valproic Acid	C				
			Risperidone	C				

Date:10/22/98ISR Number: 3145380-2Report Type:Expedited (15-DaCompany Report #A0064936
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health	Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Heart Rate Increased	Professional						
	Supraventricular Tachycardia		Lotrel	C				

Date:10/22/98ISR Number: 3145387-5Report Type:Expedited (15-DaCompany Report #A0068968
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health	Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL
	Dyspnoea	Professional					
Other	Hypersensitivity		Aspirin	C			
	Oesophagitis						
	Pruritus						
	Rash Pruritic						

Date:10/22/98ISR Number: 3145395-4Report Type:Expedited (15-DaCompany Report #A0072365
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness	Foreign	Zyban	PS		ORAL	600 MG ORAL
		Consumer					

Date:10/22/98ISR Number: 3145397-8Report Type:Expedited (15-DaCompany Report #A0072775
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign	Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL
	Dizziness	Health					
	Myalgia	Professional					
	Nausea						
	Orthostatic Hypotension						
	Pyrexia						
	Vomiting						

Date:10/22/98ISR Number: 3145399-1Report Type:Expedited (15-DaCompany Report #A0072800
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Palpitations Peripheral Coldness	Foreign Health Professional	Zyban	PS		ORAL	150 MG ORAL	

Date:10/22/98ISR Number: 3145660-0Report Type:Expedited (15-DaCompany Report #A0072801
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Convulsion Dizziness Dyspnoea Headache Tremor	Foreign Consumer	Zyban	PS		ORAL	150 MG / PER DAY / ORAL	

Date:10/26/98ISR Number: 3146418-9Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Dermatitis Toxic Epidermal Necrolysis		Atenolol Wellbutrin Pepcid Solu-Medrol	PS SS C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/98ISR Number: 3146429-3Report Type:Direct Company Report #
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Toxicity Intentional Misuse		Tegretol	PS		ORAL	200 MG BID	
	Lethargy Sinus Tachycardia		Bupropion	SS		ORAL	75 MG TID	
			Clonazepam	C		ORAL		
			Fluphenazine	C				
			Risperidone	C				

Date:10/26/98ISR Number: 3147232-0Report Type:Expedited (15-DaCompany Report #A0073034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Facial Palsy Hypoaesthesia	Foreign Consumer	Zyban	PS		ORAL	150 MG TWICE PER DAY	ORAL

Date:10/26/98ISR Number: 3147234-4Report Type:Expedited (15-DaCompany Report #A0073094
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Fall Musculoskeletal Stiffness Overdose Pyrexia	Health Professional Company Representative	Wellbutrin	PS		ORAL	150 MG ORAL	

Date:10/26/98ISR Number: 3147237-XReport Type:Expedited (15-DaCompany Report #A0072470
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypothyroidism	Health	Wellbutrin	PS		ORAL	150 MG TWICE	
	Petit Mal Epilepsy	Professional					PER DAY ORAL	
		Company Representative						

Date:10/26/98ISR Number: 3150742-3Report Type:Expedited (15-DaCompany Report #A0072311
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Zyban	PS		ORAL	150MG / SINGLE DOSE / ORAL TABLET	
	Dysarthria	Professional						
	Fall							
	Head Injury							
	Tardive Dyskinesia							

Date:10/26/98ISR Number: 3150743-5Report Type:Expedited (15-DaCompany Report #A0073099
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Decreased	Foreign	Zyban	PS		ORAL	150MG / ORAL TABLET	
	Malaise	Consumer						
	Palpitations		Glibenclamide	C				
			Metformin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/98ISR Number: 3244022-5Report Type:Periodic Company Report #9826591
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Viagra Tablets	PS		ORAL	50.00 MG	
	Hyperaesthesia							
TOTAL: PRN:								
ORAL								
			Zyban	SS			NOT SPECIFIED	
			Nefazodone	SS			NOT SPECIFIED	
			Buspirone	SS			NOT SPECIFIED	

Date:10/27/98ISR Number: 3244523-XReport Type:Periodic Company Report #9831535
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Laboratory Test Abnormal	Health	Viagra Tablets	PS		ORAL	100.00 MG	
		Professional						
TOTAL: PRN:								
ORAL								
			Zyban	SS				
			Ibuprofen	C				
			Flonase	C				
			Multi-Vitamin	C				
			Glucophage	C				

Date:10/27/98ISR Number: 3244937-8Report Type:Periodic Company Report #9825988
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Health	Viagra Tablets	PS		ORAL		
ORAL								

	Drug Interaction	Professional	Wellbutrin	SS		ORAL
ORAL						

Date:10/29/98ISR Number: 3149880-0Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Hepatocellular Damage		Wellbutrin	PS	Glaxo Wellcome		450 MG QD
			Tylenol	C			

Date:10/29/98ISR Number: 3163205-6Report Type:Periodic Company Report #A0060952
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Convulsion	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG /
Other		Professional					TWICE PER DAY
		Company					/ ORAL
		Representative					

Date:10/30/98ISR Number: 3150122-0Report Type:Expedited (15-DaCompany Report #A0069746
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide	Health	Wellbutrin	PS		ORAL	300 MG/ORAL
	Intentional Misuse	Professional	Diphenhydramine Hcl	SS			
		Company					
		Representative					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/98ISR Number: 3150123-2Report Type:Expedited (15-DaCompany Report #A0073387
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Dermatitis	Foreign	Zyban	PS		ORAL	150 MG/TWICE
	Difficulty In Walking	Consumer					PER DAY/ORAL
	Pain In Extremity						

Date:10/30/98ISR Number: 3150161-XReport Type:Expedited (15-DaCompany Report #A0087650
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	200 MG/TWICE PER PAY/ORAL
Other	Ecchymosis						
	Gingival Bleeding						
	Haemorrhage						
	Neutropenia		Conjugated Estrogens	C			
	Thrombocytopenia		Calcium Salt	C			
			Clonazepam	C			

Date:10/30/98ISR Number: 3150372-3Report Type:Expedited (15-DaCompany Report #A0073559
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dehydration	Consumer	Zyban	PS	Zyban	ORAL	150 MG/TWICE PER DAY/ORAL
	Drug Ineffective						
	Nausea		Conjugated Estrogens	C			
	Pyrexia		Propranolol Hydrochloride	C			
	Sleep Disorder						
	Weight Increased						

Date:10/30/98ISR Number: 3150373-5Report Type:Expedited (15-DaCompany Report #A0073660
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Chest Pain Tremor	Foreign Consumer	Zyban Tablet-Zyban	PS	Zyban	ORAL	150 MG/TWICE	PER DAY/ORAL

Date:11/02/98ISR Number: 3257399-1Report Type:Periodic Company Report #8-98161-046A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Premarin Tablets Wellbrutin (Buproprion Hcl) One-A-Day Vitamins	PS SS C			0.625 MG	DAILY

Date:11/02/98ISR Number: 3258317-2Report Type:Periodic Company Report #A0067845
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE	PER DAY/ORAL

				Tramadol Hydrochloride	C		

Date:11/02/98ISR Number: 3258325-1Report Type:Periodic Company Report #A0067984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Vomiting	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:11/02/98ISR Number: 3258330-5Report Type:Periodic Company Report #A0068012
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eyelid Oedema Oedema Peripheral Pain In Extremity Urticaria	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY/ ORAL	

Date:11/02/98ISR Number: 3258335-4Report Type:Periodic Company Report #A0068064
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release Sertraline Hydrochloride	PS C		ORAL	150 MG ORAL	

Date:11/02/98ISR Number: 3258339-1Report Type:Periodic Company Report #A0068180
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Hypersensitivity Throat Tightness	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
			Propranolol Hydrochloride	C				
			Ranitidine Hydrochloride	C				
			Simvastatin	C				

Date:11/02/98ISR Number: 3258346-9Report Type:Periodic Company Report #A0068242
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/98ISR Number: 3258447-5Report Type:Periodic Company Report #A0068766
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	200 MG/TWICE PER DAY/	
			Unknown Risperidone	C				

Date:11/02/98ISR Number: 3258455-4Report Type:Periodic Company Report #A0069672
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness Sleep Disorder	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/	
			Ethanol (Formulation Unknown)	SS				
			Hyoscyamine Sulphate	C				

Date:11/02/98ISR Number: 3258470-0Report Type:Periodic Company Report #A0070086
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	200 MG/TWICE PER DAY/	
			Fluoxetine Hydrochloride	C				
			Clonazepam	C				

			Olanzapine	C		
			Lithium Carbonate	C		

Date:11/02/98ISR Number: 3258479-7Report Type:Periodic Company Report #A0070432
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Suicidal Ideation	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/	
			Mesalazine	C				

Date:11/02/98ISR Number: 3258486-4Report Type:Periodic Company Report #A0070942
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/	
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/98ISR Number: 3258490-6Report Type:Periodic Company Report #A0071326
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Interaction	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/	ORAL
	Convulsion		Ethanol (Formulation Unknown)	SS		ORAL		

Date:11/02/98ISR Number: 3258494-3Report Type:Periodic Company Report #A0065796
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/	ORAL
Other	Disorientation							
	Dizziness							
	Haematemesis							
	Photopsia							
	Pyrexia							
	Stevens-Johnson Syndrome							
	Urticaria							

Date:11/02/98ISR Number: 3258499-2Report Type:Periodic Company Report #A0065951
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia	Health Professional	Wellbutrin Tablet-Controlled					
	Convulsion							

			Release	PS		ORAL

150 MG ORAL

Date:11/02/98ISR Number: 3258505-5Report Type:Periodic Company Report #A0066958
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Urticaria	Health	Wellbutrin					
Other		Professional	Tablet-Controlled Release	PS		ORAL		

150 MG/TWICE

PER DAY/

ORAL

Date:11/02/98ISR Number: 3258509-2Report Type:Periodic Company Report #A0067131
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Health	Wellbutrin					
	Depression	Professional	Tablet-Controlled					
	Suicidal Ideation		Release	PS		ORAL		

150 MG/TWICE

PER DAY/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/98ISR Number: 3258519-5Report Type:Periodic Company Report #A0067426
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Face Oedema Pruritus Urticaria	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/ ORAL

Date:11/03/98ISR Number: 3151103-3Report Type:Direct Company Report #
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Flatulence		Wellbutrin	PS		ORAL	150 MG PO BID
			Zoloft	C			

Date:11/03/98ISR Number: 3151105-7Report Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Headache		Wellbutrin	PS		ORAL	150MG PO DAILY/150MG PO BID
			Prozac	C			
			Prempro	C			

Date:11/03/98ISR Number: 3151108-2Report Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Wellbutrin	PS		ORAL	150MG PO BID	
			Prozac	C				
			Prempro	C				

Date:11/03/98ISR Number: 3151545-6Report Type:Expedited (15-DaCompany Report #A0070549
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health	Zyban	PS		ORAL	150 MG /TWICE	
	Difficulty In Walking	Professional					PER DAY /ORAL	
	Hallucination		Allopurinol	C				
			Potassium Chloride	C				
			Atenolol	C				
			Indapamide	C				
			Nadolol	C				

Date:11/03/98ISR Number: 3152649-4Report Type:Expedited (15-DaCompany Report #107134
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Systolic	Health	Klonopin	PS		ORAL	ORAL	
Initial or Prolonged	Decreased	Professional	Fluoxetine	SS		ORAL	ORAL	
	Blood Pressure Systolic	Company	Wellbutrin	SS		ORAL	ORAL	
	Increased	Representative	Lamictal	SS		ORAL	ORAL	
	Cardiac Arrest		Anesthesia	SS		ORAL	ORAL	
	Ventricular Fibrillation		Anesthesia	C				

			Epinephrine	C		

Date:11/04/98ISR Number: 3151914-4Report Type:Direct Company Report #
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Complications Of Maternal		Wellbutrin	PS		ORAL 1TAB BID PO
	Exposure To Therapeutic Drugs					
	Intra-Uterine Death					

Date:11/04/98ISR Number: 3152211-3Report Type:Expedited (15-DaCompany Report #A0071137
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Crying	Foreign	Wellbutrin	PS		ORAL 100 MG PER
Hospitalization -	Dissociation	Health				DAY ORAL
Initial or Prolonged	Suicidal Ideation	Professional	Clonazepm	C		
Disability			Indapamide	C		
Other			Metformin	C		
			Sertraline Hydrochloride	C		
			Zopiclone	C		
			Lorazepam	C		

Date:11/04/98ISR Number: 3152212-5Report Type:Expedited (15-DaCompany Report #A0073784
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Convulsion	Health	Wellbutrin	PS		ORAL 150 MG TWICE
	Feeling Abnormal	Professional				PER DAY ORAL
	Headache	Company	Venlafaxine			
	Loss Of Consciousness	Representative	Hydrochloride	C		

	Sedation					
	Speech Disorder					
	Urinary Incontinence					

Date:11/05/98ISR Number: 3152899-7Report Type:Expedited (15-DaCompany Report #A0072801
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Foreign	Zyban	PS		ORAL	150 MG	PER
	Convulsion	Consumer					DAY	ORAL
	Dizziness							
	Dyspnoea							
	Headache							
	Tremor							

Date:11/05/98ISR Number: 3152977-2Report Type:Expedited (15-DaCompany Report #A0073934
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Spasms	Foreign	Zyban	PS		ORAL	150 MG/	PER
		Consumer					DAY/	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/98ISR Number: 3153105-XReport Type:Direct Company Report #
Age:43 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysarthria		Zyban	PS		ORAL	PO BID	
Hospitalization - Initial or Prolonged	Fatigue		Tenormin	C				
	Hypercalcaemia		Cardizem	C				
	Hypertension		Lasix	C				
	Lethargy							
	Renal Failure Acute							
	Vomiting							

Date:11/06/98ISR Number: 3153443-0Report Type:Expedited (15-DaCompany Report #A0064936
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health	Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Supraventricular Tachycardia	Professional						
			Lotrel	C				

Date:11/06/98ISR Number: 3153459-4Report Type:Expedited (15-DaCompany Report #A0073938
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Asthenia							
	Convulsion							
	Dehydration		Tramadol Hydrochloride (Formulation Unknown)	SS		ORAL	ORAL	
	Hypoaesthesia							
	Nausea							
	Viral Infection							

	Vision Blurred		Amoxycillin	C		
			Fluticasone Propionate	C		
			Fexofenadine Hydrochlorid	C		
			Amitriptyline Hc1	C		
			Lorcet	C		
			Cyclobenzaprine Hc1	C		
			Multivitamin	C		

Date:11/06/98ISR Number: 3153463-6Report Type:Expedited (15-DaCompany Report #A0073662
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Other	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Paroxetine Hydrochloride (Formulation Unknown)	SS		ORAL	20 MG / PER DAY / ORAL	
			Omeprazoleq	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/98ISR Number: 3155811-XReport Type:Expedited (15-DaCompany Report #A0073917
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion Injury Injury Asphyxiation	Health Professional Company Representative	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	

Date:11/10/98ISR Number: 3155814-5Report Type:Expedited (15-DaCompany Report #A0074104
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Zyban	PS		ORAL		

Date:11/10/98ISR Number: 3155816-9Report Type:Expedited (15-DaCompany Report #A0074143
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Facial Palsy	Foreign Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:11/13/98ISR Number: 3156666-XReport Type:Expedited (15-DaCompany Report #A0074228
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Headache	Consumer	Zyban Tablet-Zyban	PS	Zyban	ORAL	150MG TWICE	

Initial or Prolonged	Hypersensitivity						
PER DAY ORAL							
	Nervousness			Inflenza Vaccine			
	Tremor			Injection	SS		
INTRAMUSCULAR	INTRAMUSCULAR						
	Weight Decreased			Presnisone	C		
	Weight Increased			Salbutamol Sulphate	C		
				Ipratropium Bromide	C		
				Salmeterol Xinafoate	C		
				Salbutamol Sulphate	C		
				Oxygen	C		

Date:11/13/98ISR Number: 3157186-9Report Type:Expedited (15-DaCompany Report #A0074224
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Wellbutrin	PS		ORAL	150 MG/ PER	
Initial or Prolonged	Blood Pressure Increased						DAY/ ORAL	
	Dizziness		Atenolol	C				
	Nausea		Prempro	C				

Date:11/13/98ISR Number: 3157189-4Report Type:Expedited (15-DaCompany Report #A0073385
Age:45 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Delirium
	Dermatitis
	Malaise
	Myalgia

		Pyrexia Serum Sickness					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Wellbutrin	PS		ORAL
150 MG/	ORAL						
			Professional				

Date:11/13/98ISR Number: 3157480-1Report Type:Expedited (15-DaCompany Report #A0071499
Age:28 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Creatine	Health	Zyban	PS		ORAL
150MG/TWICE							
		Phosphokinase Increased	Professional				
PER DAY/ORAL							
		Difficulty In Walking	Company				
		Liver Function Test	Representative				
		Abnormal					
		Monoparesis					
		Muscle Spasms					
		Rhabdomyolysis					

Date:11/13/98ISR Number: 3157491-6Report Type:Expedited (15-DaCompany Report #A0073503
Age:37 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Dyskinesia	Foreign	Zyban	PS		ORAL
150MG/TWICE							
		Dysphagia	Health				
PER DAY/ORAL							
		Dysphasia	Professional	Paracetamol	C		
		Hallucination					
		Hypoaesthesia					
		Tremor					

Date:11/13/98ISR Number: 3157495-3Report Type:Expedited (15-DaCompany Report #A0064936
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased Supraventricular Tachycardia	Health Professional	Zyban Lotrel	PS C		ORAL	150MG/TWICE PER DAY/ORAL	

Date:11/13/98ISR Number: 3157501-6Report Type:Expedited (15-DaCompany Report #A0069743
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disorientation Dizziness Palpitations	Health Professional	Zyban Nicotine	PS C		ORAL	ORAL	

Date:11/13/98ISR Number: 3157766-0Report Type:Direct Company Report #
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paraesthesia Paraesthesia Oral		Bupropion Ritalin	PS C		ORAL	100MG QD PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/98ISR Number: 3157769-6Report Type:Expedited (15-DaCompany Report #A0072801
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Foreign	Zyban	PS		ORAL	150 MG/PER	
	Convulsion	Health					DAY/ORAL	
	Dizziness	Professional						
	Dyspnoea							
	Headache							
	Panic Attack							
	Tremor							

Date:11/16/98ISR Number: 3157772-6Report Type:Expedited (15-DaCompany Report #A0072222
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine Increased	Health	Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Disorientation	Professional					PER DAY/ORAL	
	Dizziness	Company	Calcium Salt	C				
	Dysarthria	Representative	Atenolol	C				
	Facial Palsy		Diltiazem					
	Gait Disturbance		Hydrochloride	C				
	Headache		Frusemide	C				
	Hypercalcaemia							
	Nausea							
	Renal Failure Acute							
	Secondary Hypertension							
	Vomiting							

Date:11/19/98ISR Number: 3160208-2Report Type:Expedited (15-DaCompany Report #A0074896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Foreign	Zyban	PS		ORAL	150 MG/TWICE	

	Facial Palsy	Health				
PER DAY/ORAL						
		Professional				

Date:11/19/98ISR Number: 3160234-3Report Type:Expedited (15-DaCompany Report #A0073975
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Toxic Epidermal	Health	Wellbutrin	PS		ORAL	ORAL	3 WK
	Necrolysis	Professional	Lamictal	SS		ORAL	ORAL	5 MON

Date:11/19/98ISR Number: 3160235-5Report Type:Expedited (15-DaCompany Report #A0074905
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Fibrillation	Foreign	Zyban	PS		ORAL	150 MG/ TWICE	
Initial or Prolonged		Consumer					PER DAY/ ORAL	

Date:11/19/98ISR Number: 3160538-4Report Type:Expedited (15-DaCompany Report #A0068408
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombocytopenia	Health	Wellbutrin	PS		ORAL	150 MG/TWICE	
		Professional					PER DAY/ORAL	

			Lithium Salt	C		
			Naproxen	C		

Date:11/20/98ISR Number: 3160780-2Report Type:Expedited (15-DaCompany Report #A0066944
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Chest Pain	Consumer	Wellbutrin	PS		ORAL	100 MG /TWICE PER DAY / ORAL
			Wellbutrin	SS		ORAL	150 MG ORAL/CONTROLL ED RELEASE
			Clonazepam	C			
			Aspirin	C			
			Sertraline Hydrochloride	C			

Date:11/20/98ISR Number: 3160782-6Report Type:Expedited (15-DaCompany Report #A0072470
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Hypothyroidism Petit Mal Epilepsy	Health Professional	Wellbutrin	PS		ORAL	150 MG TWICE PER DAY ORAL
		Company Representative					

Date:11/20/98ISR Number: 3160930-8Report Type:Expedited (15-DaCompany Report #A0073853
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Foreign	Wellbutrin					
	Balance Disorder	Health	Tablet-Controlled					
	Decreased Appetite	Professional	Release	PS		ORAL	UNK/UNK/ORAL	
	Difficulty In Walking		Clonazepam	C				
	Migraine		Oestradiol	C				
	Myalgia		Misoprostol	C				
	Nausea							
	Speech Disorder							

Date:11/23/98ISR Number: 3161793-7Report Type:Expedited (15-DaCompany Report #A0070019
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion	Health	Zyban	PS		ORAL	150 MG ORAL	
Initial or Prolonged		Professional	Amitriptyline Hcl					
		Company	(Formulation					
		Representative	Unknown)	SS		ORAL	ORAL	

Date:11/23/98ISR Number: 3161795-0Report Type:Expedited (15-DaCompany Report #A0074755
Age:32 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Accidental Overdose
Initial or Prolonged	Aggression
	Agitation

	Delirium Electrocardiogram Qrs Complex Prolonged Electrocardiogram Qt Prolonged Feeling Jittery Grand Mal Convulsion Sinus Tachycardia Supraventricular Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Literature	Wellbutrin	PS		ORAL	9 G SINGLE DOSE ORAL

Date:11/24/98ISR Number: 3281999-6Report Type:Periodic Company Report #0175957A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Effect Decreased	Consumer	Habitrol-Nicotine Transdermal 21mg-Nvch	PS			1 PATCH/QD/TTS
			Zyban-Bupropion Hcl 150mg-Glaxo	SS	Glaxo		UNKNOWN/UNK/B ID
			Lorazepam Bid	C			

Date:11/24/98ISR Number: 3283068-8Report Type:Periodic Company Report #0182444A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abdominal Pain Dyspepsia Tremor	Consumer	Habitrol-Nicotine Transdermal 21mg-Nvch	PS	Nvch	TRANSDERMAL	1 PATCH QD TTS

			Zyban-Bupropion Hcl 150mg-Glaxo	SS	Glaxo	ORAL
BID PO						
			Insulin	C		
			Univasc	C		
			Hctz	C		
			Glyburide	C		
			Lipitor	C		
			Lanoxin	C		
			Verapamil	C		
			Quinaglute	C		
			Zantac	C		
			Catapres	C		

Date:11/25/98ISR Number: 3286987-1Report Type:Periodic Company Report #8-97286-019L
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder	Consumer	Redux	PS		ORAL	15 MG TWICE	
	Palpitations						DAILY ORAL	
			Fastin (Phentermine)	SS		ORAL	30 MG ONCE	
							DAILY ORAL	
			Ionamin (Phentermine)	SS		ORAL	15-30 MG	
							DAILY ORAL	
			Ionamin (Phentermine)	SS		ORAL	8/31/96-10/11	

/1996;

5/22/1997-

8/25/97 ORAL 5 MON

Pondimin
(Fenfluramine)
Tablet SS ORAL

INTERMITTENT:

03APR96-11OCT

96;

22MAY97-25AUG

97 ORAL

Wellbutrin
(Buproprion) SS ORAL

100-150 MG

TWICE DAILY

ORAL

Date:11/27/98ISR Number: 3163468-7Report Type:Expedited (15-DaCompany Report #A0075616
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Foreign	Zyban	PS		ORAL	150 MG/TWICE	
		Health					PER DAY/ORAL	
		Professional	Ramipril	C				

Date:11/27/98ISR Number: 3163469-9Report Type:Expedited (15-DaCompany Report #A0075934
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis	Foreign	Zyban	PS		ORAL	150 MG/TWICE	

Initial or Prolonged	Respiratory Disorder	Health					
PER DAY/ORAL							
		Professional					

Date:11/27/98ISR Number: 3163513-9Report Type:Expedited (15-DaCompany Report #A0075174
Age:59 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Psychotic Disorder	Health	Wellbutrin	PS		ORAL	150 MG /
Initial or Prolonged	Suicidal Ideation	Professional					TWICE PER DAY
		Company					/ ORAL
		Representative	Gabapentin	C			

Date:11/27/98ISR Number: 3163544-9Report Type:Expedited (15-DaCompany Report #A0072311
Age:4 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Convulsion	Health	Zyban	PS		ORAL	150 MG/
Initial or Prolonged	Dysarthria	Professional					SINGLE DOSE/
	Fall						ORAL
	Head Injury						
	Laboratory Test Abnormal						
	Medication Error						
	Tardive Dyskinesia						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/98ISR Number: 3163848-XReport Type:Expedited (15-DaCompany Report #A0075570
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Consumer	Wellbutrin	PS		ORAL	100 MG/ORAL	2 WK

Date:11/30/98ISR Number: 3164009-0Report Type:Direct Company Report #
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Wellbutrin	PS			150MG BID;	
			Lamictal	SS				

Date:12/01/98ISR Number: 3164970-4Report Type:Direct Company Report #
Age:15 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Wellbutrin	PS			150 MG SR BID	

Date:12/01/98ISR Number: 3290599-3Report Type:Periodic Company Report #A0068116
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban Tablet -					
	Hypersensitivity	Professional	Zyban	PS		ORAL	150 MG/TWICE	
	Pruritus						PER DAY/ORAL	
	Rash Erythematous							
	Swelling							
	Urticaria							

Date:12/01/98ISR Number: 3290605-6Report Type:Periodic Company Report #A0068091
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health	Zyban Tablets -					
	Arthralgia	Professional	Zyban	PS		ORAL	150 MG/TWICE	
	Dysphagia						PER DAY/ORAL	
	Oedema Peripheral		Vicodin	C				
	Rash Erythematous							
	Urticaria							

Date:12/01/98ISR Number: 3290611-1Report Type:Periodic Company Report #A0067771
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity	Health	Zyban Tablets -					
	Pruritus	Professional	Zyban	PS		ORAL	150 MG/TWICE	
	Pyrexia						PER DAY/ORAL	
	Rash Erythematous							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/98ISR Number: 3290617-2Report Type:Periodic Company Report #A0067616
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Chest Pain	Professional					PER DAY ORAL	
	Dysphagia							
	Dyspnoea							
	Urticaria							

Date:12/01/98ISR Number: 3290621-4Report Type:Periodic Company Report #A0065854
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Zyban Tablet- Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Depressed Level Of	Professional					PER DAY/ORAL	
	Consciousness		Arpirin	C				
	Dyskinesia							
	Eye Movement Disorder							

Date:12/01/98ISR Number: 3290623-8Report Type:Periodic Company Report #A0066078
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pyrexia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Urticaria	Professional					PER DAY/ORAL	2 WK
Other								

Date:12/01/98ISR Number: 3290626-3Report Type:Periodic Company Report #A0065298
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
Other	Ageusia	Professional					PER DAY/ORAL	
	Anorexia							
	Back Pain							
	Chills							
	Dermatitis							
	Diarrhoea							
	Dysphagia							
	Hyperhidrosis							
	Oedema Mouth							
	Pyrexia							
	Stevens-Johnson Syndrome							
	Throat Irritation							
	Throat Tightness							
	Tongue Oedema							

Date:12/01/98ISR Number: 3290628-7Report Type:Periodic Company Report #A0065206
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Ecchymosis	Professional					PER DAY/ORAL	
	Hypersensitivity		Nabumetone	C				
	Pruritus		Naproxen	C				
	Swelling		Multivitamin	C				
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/98ISR Number: 3290631-7Report Type:Periodic Company Report #A0074805
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	ORAL

Date:12/01/98ISR Number: 3290653-6Report Type:Periodic Company Report #A0073925
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angioneurotic Oedema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE
	Dysphagia						PER DAY/ORAL
	Hypersensitivity						
	Pruritus						
	Urticaria						

Date:12/01/98ISR Number: 3290656-1Report Type:Periodic Company Report #A0073954
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Insomnia	Consumer	Zyban Tablets - Zyban	PS		ORAL	150 MG/TWICE
	Syncope						PER DAY/ORAL
	Vomiting						
			Temazepam	C			
			Fioricet	C			

Date:12/01/98ISR Number: 3290658-5Report Type:Periodic Company Report #A0073851
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban Tablets -				

	Decreased Activity		Zyban	PS		ORAL 150 MG/TWICE DAILY PER DAY/ORAL
			Glimepiride	C		

Date:12/01/98ISR Number: 3290661-5Report Type:Periodic Company Report #A0073618
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Asthenia	Study	Zyban Tablet - Zyban	PS		ORAL ORAL
	Convulsion	Consumer				
	Ear Infection					
	Syncope					

Date:12/01/98ISR Number: 3290664-0Report Type:Periodic Company Report #A0072686
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Anorexia	Consumer	Zyban Tablet - Zyban	PS		ORAL TWICE PER DAY/ORAL
	Grand Mal Convulsion					
	Insomnia		Co-Trimoxazole	C		
			Phenazopyridine Hc1	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/98ISR Number: 3290669-XReport Type:Periodic Company Report #A0071863
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability Other	Angioneurotic Oedema Urticaria	Health Professional Company Representative	Zyban Tablet- Zyban	PS		ORAL	150 MG/ORAL

Date:12/01/98ISR Number: 3290675-5Report Type:Periodic Company Report #A0071611
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	150MG/PER DAY/ORAL

Date:12/01/98ISR Number: 3290681-0Report Type:Periodic Company Report #A0071580
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Pruritus Tongue Oedema Urticaria	Consumer	Zyban Tablet - Zyban Conjugated Estrogens	PS C		ORAL	150 MG/TWICE PER DAY/ORAL

Date:12/01/98ISR Number: 3290686-XReport Type:Periodic Company Report #A0071549
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Confusional State	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE

Initial or Prolonged	Convulsion	Company			
PER DAY/ORAL					
Other	Loss Of Consciousness	Representative	Oral Contraceptive	C	

Date:12/01/98ISR Number: 3290691-3Report Type:Periodic Company Report #A0071499
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Increased	Professional					PER DAY/ORAL	
	Aspartate	Company						
	Aminotransferase	Representative						
	Increased							
	Blood Creatine							
	Phosphokinase Increased							
	Blood Lactate							
	Dehydrogenase Increased							
	Difficulty In Walking							
	Muscle Spasms							
	Rhabdomyolysis							

Date:12/01/98ISR Number: 3290695-0Report Type:Periodic Company Report #A0071281
Age:38 YR Gender:Male I/FU:I

Outcome	PT
Other	Arthralgia
	Eye Disorder

	Face Oedema					
	Oedema Peripheral					
	Pruritus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Rash Erythematous	Consumer	Zyban Tablet- Zyban	PS		ORAL
150 MG/TWICE						
PER DAY/ORAL						
			Claritin-D	C		
			Robitussin-Dm	C		
			Clarithromycin	C		

Date:12/01/98ISR Number: 3291062-6Report Type:Periodic Company Report #A0071278
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dyspnoea	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG/ TWICE						
	Pruritus					
PER DAY/ ORAL						
	Rash Vesicular		Adrenaline	C		
	Urticaria					

Date:12/01/98ISR Number: 3291063-8Report Type:Periodic Company Report #A0070995
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Aphasia	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG/ TWICE						
	Balance Disorder					
PER DAY/ ORAL						
	Convulsion		Lorazepam	C		
	Dyspraxia		Dyazide	C		
	Hypersomnia					
	Sedation					

Date:12/01/98ISR Number: 3291064-XReport Type:Periodic Company Report #A0070995
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Balance Disorder						PER DAY/	
	Convulsion						ORAL	
	Dyspraxia		Lorazepam	C				
	Hypersomnia		Dyazide	C				
	Sedation							

Date:12/01/98ISR Number: 3291065-1Report Type:Periodic Company Report #A0070651
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG	
		Professional					ORAL	
		Company Representative						

Date:12/01/98ISR Number: 3291066-3Report Type:Periodic Company Report #A0070459
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neck Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY	
							ORAL	

			Prempro	C			

Date:12/01/98ISR Number: 3291067-5Report Type:Periodic Company Report #A0070204
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	DAY
	Pruritus							
	Tremor							

Date:12/01/98ISR Number: 3291068-7Report Type:Periodic Company Report #A0070194
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	DAY
	Convulsion							
	Drug Ineffective		Ibuprofen	C				

Date:12/01/98ISR Number: 3291069-9Report Type:Periodic Company Report #A0070089
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY	
	Drug Ineffective							
	Headache							
			Ibuprofen	C				
			Cocaine	C				
			Ethanol	C				

Date:12/01/98ISR Number: 3291070-5Report Type:Periodic Company Report #A0069988
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG	
		Professional						
			Salbutamol Sulphate	C				
			Antibiotics	C				
			Beclomethasone Dipropion	C				
			Theophylline	C				
			Benzonatate	C				

Date:12/01/98ISR Number: 3291071-7Report Type:Periodic Company Report #A0069787
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Suicidal Ideation	Professional					PER DAY	
		Company						
		Representative	Thyroxine Sodium	C				
			Metoprolol Tartrate	C				
			Oestradiol	C				
			Triamcinolone Acetonide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/98ISR Number: 3291072-9Report Type:Periodic Company Report #A0069735
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypersensitivity	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
Hospitalization -	Hypertension	Professional					PER DAY	
Initial or Prolonged							ORAL	
Other			Moexipril Hydrochloride	C				
			Omeprazole	C				

Date:12/01/98ISR Number: 3291073-0Report Type:Periodic Company Report #A0069624
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	
							THREE TIMES	
							PER DAY	
							ORAL	

Date:12/01/98ISR Number: 3291074-2Report Type:Periodic Company Report #A0069512
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dysgraphia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG	
	Eyelid Oedema	Professional					TWICE PER DAY	
	Hypersensitivity						ORAL	
	Pruritus							
	Swelling							
	Urticaria							

Date:12/01/98ISR Number: 3291075-4Report Type:Periodic Company Report #A0069465
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Claustrophobia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	PER
	Dizziness						DAY	ORAL
	Loss Of Consciousness							
	Panic Disorder Without Agoraphobia							
	Paranoia							

Date:12/01/98ISR Number: 3291076-6Report Type:Periodic Company Report #A0069451
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	TWICE PER DAY
	Dizziness						ORAL	
	Drug Effect Decreased							
	Dry Mouth							

Date:12/01/98ISR Number: 3291077-8Report Type:Periodic Company Report #A0069149
Age:63 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Chills
	Erythema Multiforme

	Pruritus						
	Rash Maculo-Papular						
		Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
		Health	Zyban Tablet - Zyban	PS		ORAL	150 MG
		Professional					
TWICE PER DAY							
ORAL							
			Methyldopa	C			
			Famotidine	C			
			Thyroxine Sodium	C			
			Diazepam	C			
			Conjugated Estrogens	C			
			Felodipine	C			
			Fluvastatin Sodium	C			
			Dextropropoxyphene	C			
			Hydrocodone	C			
			Morphine	C			
			Prednisone	C			

Date:12/02/98ISR Number: 3165485-XReport Type:Direct Company Report #
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Other	Drug Interaction		Bupropion Sr	PS			150MG BID
Required	Haemorrhage		Warfarin	SS			7.5MG QD
Intervention to Prevent Permanent Impairment/Damage	International Normalised Ratio Increased						
	Pain						
	Prothrombin Time Prolonged						

Date:12/02/98ISR Number: 3165971-2Report Type:Direct Company Report #
Age:15 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							

Other	Drug Ineffective	Health	Wellbutrin	PS		
150MG SR BID						
		Professional				

Date:12/03/98ISR Number: 3166694-6Report Type:Expedited (15-DaCompany Report #A0075267
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death	Health	Wellbutrin	PS		ORAL
ORAL						
		Professional	Fluoxetine			
		Company	Hydrochloride	C		
		Representative				

Date:12/03/98ISR Number: 3166722-8Report Type:Expedited (15-DaCompany Report #A0075941
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abortion Spontaneous	Consumer	Zyban	PS		ORAL
150 MG/TWICE						
PER DAY/ORAL						
			Propranolol	C		
			Montelukast Sodium	C		
			Omeprazole	C		
			Captopril	C		
			Cetirizine			

			Hydrochloride	C		

Date:12/04/98ISR Number: 3167501-8Report Type:Direct Company Report #
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome		3	WK
Hospitalization - Initial or Prolonged	Dermatitis							
Required Intervention to Prevent Permanent Impairment/Damage	Face Oedema							
	Oedema Mouth							
	Tongue Oedema							

Date:12/04/98ISR Number: 3167537-7Report Type:Direct Company Report #
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS			PER	
DIRECTIONS								
			Synthroid	C				
			Antihypertensives	C				

Date:12/08/98ISR Number: 3168529-4Report Type:Expedited (15-DaCompany Report #A0075616
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Foreign	Zyban	PS		ORAL	150 MG /	
		Health						
TWICE PER DAY		Professional						
/ ORAL								
			Ramipril	C				
			Lorazepam	C				

Date:12/08/98ISR Number: 3168534-8Report Type:Expedited (15-DaCompany Report #A0073901
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia	Health	Wellbutrin	PS		ORAL	150 MG ORAL	
Hospitalization - Initial or Prolonged	Decreased Appetite	Professional						
Disability	Dyspnoea Exertional							
Other	Erythema Multiforme							
	Eyelid Oedema							
	Face Oedema							
	Fatigue							
	Insomnia							
	Periorbital Oedema							
	Proteinuria							
	Pruritus							
	Stevens-Johnson Syndrome							
	Throat Tightness							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/98ISR Number: 3168536-1Report Type:Expedited (15-DaCompany Report #A0076073
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcohol Withdrawal	Health Professional Company Representative	Wellbutrin	PS		ORAL		
	Syndrome Electroencephalogram Abnormal		Ethanol (Formulation Unknown)	SS		ORAL		
			Glipizide Tablet	SS		ORAL		
	Grand Mal Convulsion Overdose Suicide Attempt		Glucophage	C		ORAL		

Date:12/08/98ISR Number: 3168578-6Report Type:Expedited (15-DaCompany Report #A0076277
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Foreign Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Conversion Disorder Diarrhoea Dizziness Nervousness Tremor Vomiting							

Date:12/08/98ISR Number: 3168731-1Report Type:Expedited (15-DaCompany Report #A0076538
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional Company Representative	Wellbutrim	PS		ORAL	ORAL	1 YR
	Drug Interaction		Diphenhydramine Hcl	SS		ORAL	ORAL	
Other	Pyrexia		Co-Trimoxazole	C				

Date:12/08/98ISR Number: 3168853-5Report Type:Expedited (15-DaCompany Report #A0076428
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cellulitis Fall Grand Mal Convulsion	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Conjugated Estrogens	C				

Date:12/10/98ISR Number: 3168834-1Report Type:Expedited (15-DaCompany Report #8-98338-012A
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Grand Mal Convulsion	Literature	Tenex	PS		ORAL	0.5 MG TWICE DAILY, ORAL	
			Bupropion	SS		ORAL	75 MG TO 300 MG DAILY, ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/98ISR Number: 3169454-5Report Type:Direct Company Report #
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Arteritis		Zyban	PS		ORAL	150MG BID PO	
	Cognitive Disorder							
	Coronary Artery Occlusion							
	Flushing							
	Hallucination, Auditory							
	Neurosis							
	Temporal Arteritis							
	Vomiting							

Date:12/11/98ISR Number: 3169752-5Report Type:Expedited (15-DaCompany Report #A0076551
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis	Foreign	Zyban	PS		ORAL	150 MG /	
	Dermatitis	Health					TWICE PER DAY	
	Pharyngolaryngeal Pain	Professional						

Date:12/11/98ISR Number: 3169755-0Report Type:Expedited (15-DaCompany Report #A0076359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health	Wellbutrin	PS		ORAL	PER DAY	
		Professional						

Date:12/11/98ISR Number: 3170074-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required	Dermatitis		Wellbutrin Sr	PS		ORAL
1 PO BID						
Intervention to			Habitol	C		
Prevent Permanent			Valium	C		
Impairment/Damage						

Date:12/11/98ISR Number: 3170075-9Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Dyspnoea		Wellbutrin Sr	PS	Glaxo/Wellcome	ORAL
1 PO BID						
Intervention to	Eyelid Oedema					
Prevent Permanent	Urticaria					
Impairment/Damage						

Date:12/14/98ISR Number: 3170787-7Report Type:Expedited (15-DaCompany Report #A0076758
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident	Consumer	Zyban	PS		ORAL
150 MG /						
Hospitalization -	Chest Pain					
SINGLE DOSE /						
Initial or Prolonged	Insomnia					
ORAL						
	Myocardial Infarction		Paracetamol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/98ISR Number: 3170791-9Report Type:Expedited (15-DaCompany Report #A0066944
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability Other	Chest Discomfort Chest Pain Coronary Artery Atherosclerosis Coronary Artery Occlusion	Health Professional	Wellbutrin	PS		ORAL	100 MG / TWICE PER DAY / ORAL
			Wellbutrin	SS		ORAL	150 MG / UNK / ORAL
			Clonazepam	C			
			Aspirin	C			
			Sertraline Hydrochloride	C			

Date:12/16/98ISR Number: 3172028-3Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Convulsion Tremor		Wellbutrin	PS			100 MG BID
			Vicodin Prn	C			

Date:12/17/98ISR Number: 3171578-3Report Type:Expedited (15-DaCompany Report #A0076725
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arrhythmia Convulsion	Consumer	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ ORAL
			Carbamazepine (Formulaton Unknown)	SS			
			Pravastatin Sodium	C			

Date:12/17/98ISR Number: 3171579-5Report Type:Expedited (15-DaCompany Report #A0077179
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Consumer	Zyban	PS		ORAL	PER DAY ORAL	

Date:12/17/98ISR Number: 3171581-3Report Type:Expedited (15-DaCompany Report #A0073598
Age:42 YR Gender:Female I/FU:I

Outcome	PT
Other	Anaphylactic Reaction
	Blood Cholesterol Increased
	Blood Pressure Increased
	Chest Discomfort
	Dermatitis
	Disturbance In Attention
	Dizziness
	Electrocardiogram Abnormal
	Feeling Jittery
	Flushing
	Movement Disorder
	Palpitations

	Psychomotor Hyperactivity Tremor						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Zyban	PS		ORAL	150 MG/TWICE
		Professional					PER DAY/ORAL
			Oestradiol	C			
			Ascorbic Acid	C			
			Vitamin E	C			

Date:12/18/98ISR Number: 3171870-2Report Type:Expedited (15-DaCompany Report #A0074822
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angina Pectoris	Foreign	Zyban	PS		ORAL	ORAL
Hospitalization - Initial or Prolonged	Chest Pain	Health					
Other	Myocardial Infarction	Professional					

Date:12/18/98ISR Number: 3171878-7Report Type:Expedited (15-DaCompany Report #A0073094
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Wellbutrin	PS		ORAL	150 MG ORAL; CONTROLLED RELEASE
	Fall	Professional					
	Musculoskeletal Stiffness	Company					
	Overdose	Representative					
	Pyrexia						

Date:12/18/98ISR Number: 3171879-9Report Type:Expedited (15-DaCompany Report #A0076551
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis	Foreign	Zyban	PS		ORAL	150 MG/TWICE	
	Dermatitis	Health					PER DAY/ORAL	
	Pharyngolaryngeal Pain	Professional						

Date:12/18/98ISR Number: 3171882-9Report Type:Expedited (15-DaCompany Report #A0073660
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Foreign	Zyban	PS		ORAL	150 MG /TWICE	
Initial or Prolonged	Chest Pain	Consumer					PER DAY/ORAL	
	Tremor		Nitroglycerin	C				
			Aspirin	C				
			Didrocal	C				
			Tamoxifen	C				
			Amlodipine	C				
			Metoprolol	C				

Date:12/18/98ISR Number: 3171886-6Report Type:Expedited (15-DaCompany Report #A0076883
Age: Gender:Unknown I/FU:I

Outcome	PT
Hospitalization -	Dehydration
Initial or Prolonged	Headache
	Nausea

	Vomiting					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban	PS		ORAL
150 MG/SEE						
TEXT/ORAL						

Date:12/18/98ISR Number: 3171888-XReport Type:Expedited (15-DaCompany Report #A0077049
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Dyspnoea	Foreign	Wellbutrin	PS		ORAL
250 MG/ORAL						
Initial or Prolonged	Hypersensitivity	Consumer	Lithium Salt	C		
Other	Lobar Pneumonia		Clomipramine Hc1	C		
			Clonazepam	C		

Date:12/21/98ISR Number: 3173160-0Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Status Epilepticus		Bupropion	PS		
Initial or Prolonged			Divalproex Sodium	C		
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

Date:12/22/98ISR Number: 3173545-2Report Type:Direct Company Report #
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Erythema Multiforme		Zyban	PS	Glaxo/Wellcome	ORAL
150 MG PO BID						
	Urticaria					

Date:12/23/98ISR Number: 3227168-7Report Type:Periodic Company Report #9816588
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams	Consumer	Zithromax Capsules	PS		ORAL	250.00 MG	
	Agitation							
TOTAL:DAILY:O								
	Anxiety							
RAL								
	Tremor		Zyban	SS		ORAL		
ORAL								
			Alprazolam	SS		ORAL		
ORAL								
			Albuterol	C				
			Atrovent	C				
			Azmacort	C				
			Indocet	C				

Date:12/24/98ISR Number: 3173587-7Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Pain		Zyban	PS		ORAL	300MG PO QD	
	Face Oedema							
DIVIDED BID	2	WK						
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/98ISR Number: 3173882-1Report Type:Expedited (15-DaCompany Report #A0077622
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Foreign	Zyban	PS		ORAL	150 MG /	
	Cyanosis	Consumer					TWICE PER DAY	
	Dermatitis						/ ORAL	
	Dyspnoea							
	Eyelid Oedema							
	Hypersensitivity							
	Joint Swelling							
	Myalgia							

Date:12/28/98ISR Number: 3175799-5Report Type:Expedited (15-DaCompany Report #A0076883
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration	Consumer	Zyban	PS		ORAL	150 MG/SEE	
Initial or Prolonged	Headache						TEXT/ORAL	
	Vomiting		Carisoprodol	C				
			Conjugated Estrogens	C				

Date:12/28/98ISR Number: 3175827-7Report Type:Expedited (15-DaCompany Report #A0070795
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Health	Zyban	PS		ORAL	150 MG / PER	
Hospitalization -	Chest Pain	Professional					DAY / ORAL	
Initial or Prolonged	Dizziness	Company	Fluoxetine					
	Pulmonary Oedema	Representative	Hydrochloride	C				
			Dalmane	C				
			Alprazolam	C				

Date:12/28/98ISR Number: 3175911-8Report Type:Expedited (15-DaCompany Report #A0077001
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Wellbutrin	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Difficulty In Walking	Company					PER DAY/ORAL	
	Face Oedema	Representative						
	Fall							
	Fatigue							
	Feeling Cold							
	Insomnia							
	Joint Stiffness							
	Migraine							
	Pain							
	Pain In Extremity							
	Pruritus							
	Rash Erythematous							
	Serum Sickness							
	Stomatitis							
	Urticaria							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/98ISR Number: 3175913-1Report Type:Expedited (15-DaCompany Report #A0077761
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Wellbutrin	PS		ORAL	150 MG /ORAL 5 DAY
	Depression	Professional	Antihypertensive	C			
	Drug Ineffective						
	Insomnia						
	Jealous Delusion						
	Paranoia						
	Rebound Effect						
	Suicidal Ideation						

Date:12/28/98ISR Number: 3175914-3Report Type:Expedited (15-DaCompany Report #A0075249
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Back Pain	Health	Wellbutrin	PS		ORAL	300 MG / PER
Other	Dysphonia	Professional					DAY / ORAL
	Fibromyalgia	Company	Lithium Salt	C			
	Pain In Extremity	Representative					
	Weight Decreased						

Date:12/28/98ISR Number: 3175915-5Report Type:Expedited (15-DaCompany Report #A0072073
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chills	Health	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG /TWICE PER DAY
	Hyperhidrosis	Professional					
	Hypoaesthesia						
	Memory Impairment						
	Pyrexia		Ranitidine Hydrochloride	C			
	Vasculitis Cerebral		Lisinopril	C			

Date:12/28/98ISR Number: 3175962-3Report Type:Expedited (15-DaCompany Report #A0077426
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health	Wellbutrin	PS		ORAL	ORAL	
		Professional	Fluoxetine Hydrochloride	SS		ORAL	ORAL	

Date:12/28/98ISR Number: 3175964-7Report Type:Expedited (15-DaCompany Report #A0077765
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Health	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY	
	Dermatitis	Professional						
	Dyspnoea							
	Hypotension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/98ISR Number: 3176034-4Report Type:Expedited (15-DaCompany Report #A0071029
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dysphagia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL
	Dyspnoea		Librax	C			
	Foreign Body Trauma						
	Nausea						
	Pharyngolaryngeal Pain						
	Retching						

Date:12/28/98ISR Number: 3176356-7Report Type:Expedited (15-DaCompany Report #A0077049
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cryptogenic Organizing Pneumonia	Foreign Consumer	Wellbutrin Tablet-Controlled				
Other	Drug Hypersensitivity		Release	PS		ORAL	250 MG/ORAL
	Dyspnoea		Lithium Salt	C			
	Lobar Pneumonia		Clomipramine Hcl	C			
			Clonazepam	C			

Date:12/28/98ISR Number: 3176532-3Report Type:Expedited (15-DaCompany Report #A0077928
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Foreign Health Professional	Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL

Date:12/28/98ISR Number: 3176533-5Report Type:Expedited (15-DaCompany Report #A0077971
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysarthria	Consumer	Zyban	PS		ORAL	150 MG TWICE	
	Dyspnoea						PER DAY ORAL	
	Erythema		Lorazepam	C				
	Hypersensitivity		Temazepam	C				
	Hypertension		Amitriptyline Hcl	C				
	Tongue Oedema							

Date:12/28/98ISR Number: 3176534-7Report Type:Expedited (15-DaCompany Report #A0077674
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Zyban	PS		ORAL	ORAL	
		Professional						

Date:12/31/98ISR Number: 3176184-2Report Type:Direct Company Report #
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression		Zyban	PS			1TABLET 2 X	
Hospitalization -	Agitation						DAY	21 DAY
Initial or Prolonged	Psychotic Disorder							
Other	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/31/98ISR Number: 3176190-8Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Pain		Zyban	PS		ORAL	300MG PO QD	
	Face Oedema						DIVIDED BID	2 WK
	Urticaria							

Date:12/31/98ISR Number: 3177016-9Report Type:Expedited (15-DaCompany Report #A0077426
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG	
							TWICE PER DAY	
							ORAL	
			Fluoxetine Hydrochloride (Formulation Unknown)	SS		ORAL	PER DAY	ORAL

Date:12/31/98ISR Number: 3177019-4Report Type:Expedited (15-DaCompany Report #A0072073
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain	Health Professional	Wellburtin Tablet - Controlled Release	PS		ORAL	150 MG TWICE	
	Chills						PER DAY ORAL	
	Hyperhidrosis							
	Hypoaesthesia		Ranitidine Hydrochloride	C				
	Pyrexia		Lisinopril	C				
	Vasculitis Cerebral							

Date:12/31/98ISR Number: 3177021-2Report Type:Expedited (15-DaCompany Report #A0076538
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	ORAL	1 YR
	Drug Interaction		Diphenhydramine Hcl Capsule	SS		ORAL		
Other	Pyrexia		Co-Trimoxazole	C				

Date:12/31/98ISR Number: 3177509-4Report Type:Expedited (15-DaCompany Report #A0078087
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Facial Bones Fracture	Foreign Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
	Fall							
	Haemorrhagic Stroke							
	Headache							

Date:01/05/99ISR Number: 3176747-4Report Type:Direct Company Report #
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin 300 Mg Bid	PS				
			Allergro D Qd	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/99ISR Number: 3177851-7Report Type:Expedited (15-DaCompany Report #A0077049
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cryptogenic Organizing	Foreign	Wellbutrin	PS		ORAL	250MG	ORAL
Other	Pneumonia	Consumer	Lithium Salt	C				
	Dyspnoea		Clomipramine Hc1	C				
	Hypersensitivity		Clonazepam	C				
	Pneumonia							

Date:01/07/99ISR Number: 3177983-3Report Type:Direct Company Report #
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Wellbutrin	PS			TWICE A DAY	
	Fall							
	Grand Mal Convulsion							

Date:01/07/99ISR Number: 3178754-4Report Type:Direct Company Report #
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Bupropion	PS		ORAL	100MG TID & PO >	
	Loss Of Consciousness							
	Muscle Twitching							
	Paraesthesia							
	Syncope							

Date:01/07/99ISR Number: 3376494-XReport Type:Periodic Company Report #SYM980001
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Convulsion	Health	Symmetrel	PS		ORAL
PO						
	Corneal Oedema	Professional	Wellbutrin	SS		

Date:01/08/99ISR Number: 3178923-3Report Type:Expedited (15-DaCompany Report #9844878
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Alcohol Poisoning	Health	Glucotrol Tablets	PS		ORAL
ORAL						
Initial or Prolonged	Alcohol Withdrawal	Professional	Bupropion	SS		ORAL
ORAL						
	Syndrome		Ethanol	SS		ORAL
ORAL						
	Grand Mal Convulsion		Glucophage	C		
	Suicide Attempt					

Date:01/11/99ISR Number: 3179377-3Report Type:Expedited (15-DaCompany Report #A0078500
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Fall	Consumer	Zyban	PS		ORAL
150 MG /						
Initial or Prolonged	Syncope					
TWICE PER DAY						
	Upper Limb Fracture					
/ ORAL						

Date:01/11/99ISR Number: 3179532-2Report Type:Expedited (15-DaCompany Report #LBID002990002
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Consumer	Lithobid	PS		ORAL	600 MG, PER DAY, PER ORAL	
	Drug Level Above Therapeutic		Zyprexa	SS		ORAL	PER ORAL	
	Feeling Drunk		Benzotropine	SS		ORAL	PER ORAL	
	Nausea		Wellbutrin	SS				
	Tremor		Neurontin	SS		ORAL	PER ORAL	
			Klonopin	SS		ORAL	PER ORAL	
			Ambien	SS		ORAL	PER ORAL	
			Zoloft	SS		ORAL	PER ORAL	
			Lithobid	SS		ORAL	600 MG, PER DAY, PER ORAL	

Date:01/11/99ISR Number: 3179695-9Report Type:Expedited (15-DaCompany Report #A0074755
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Literature	Wellbutrin Tablet	PS		ORAL	9 G/ SINGLE DOSE/ ORAL	
	Agitation							
	Delirium							
	Electrocardiogram Qrs Complex Prolonged							
	Feeling Jittery							
	Grand Mal Convulsion							
	Overdose							
	Sinus Tachycardia							
	Supraventricular Tachycardia							

Date:01/11/99ISR Number: 3192589-8Report Type:Periodic Company Report #1998006516-1
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Consumer	Nicoderm Cq 21 Mg					
			Smithkline Beecham Consumer Healthcare	PS		TRANSDERMAL	21 MILLIGRAMS	1.0 DAILY
			Zyban (Cupropion) Glaxo Wellcome	SS		ORAL	TRANSDERMAL	

Date:01/12/99ISR Number: 3370259-0Report Type:Periodic Company Report #WAES 98111411
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Propecia 1 Mg	PS		ORAL	PO	
	Anxiety		Wellbutrin	SS		ORAL	PO	
	Mental Disorder		Ativan	C				
			Seroquel	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/99ISR Number: 3382240-6Report Type:Periodic Company Report #1998015300-1
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Depression	Consumer	Nicoderm Cq 21 Mg Smithkline Beecham Consumer Healthcare	PS	Smithkline Beecham Consumer Healthcare	TRANSDERMAL	TRANSDERMAL	
			Wellbutrin (Bupropion) Glaxo Wellcome	SS	Glaxo Wellcome			
			Prozac (Fluoxetine) Dista	SS	Dista			
			Albuterol	C				
			Librium (Chlordiazepoxide)	C				
			Rhinocort (Budesonide)	C				
			Aerobid (Flunisolide)	C				

Date:01/14/99ISR Number: 3180952-0Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Medication Error	Health Professional	Wellbutrin	PS	Bw Glaxo	ORAL TABLET		
			Buspar	SS	Mead Johnson	ORAL TABLET		

Date:01/19/99ISR Number: 3181867-4Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tremor		Bupropion	PS				
			Diazepam	SS				

Date:01/19/99ISR Number: 3182139-4Report Type:Expedited (15-DaCompany Report #A0078454
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Thrombosis	Health	Zyban	PS		ORAL	ORAL	
		Professional						

Date:01/19/99ISR Number: 3182154-0Report Type:Expedited (15-DaCompany Report #A0075267
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drowning	Health	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
		Professional						
		Company						
		Representative	Fluoxetine Hydrochloridde	C				
			Perphenazine	C				
			Benztropine Mesylate	C				
			Propanolol Hydrochloride	C				
			Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/99ISR Number: 3182156-4Report Type:Expedited (15-DaCompany Report #A0077928
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Foreign Health Professional	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:01/20/99ISR Number: 3182658-0Report Type:Expedited (15-DaCompany Report #A0073559
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health Professional	Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Blood Chloride Increased		Conjugated Estrogens	C				
	Blood Sodium Increased		Propranolol Hydrochloride	C				
	Chills		Mulitvitamin	C				
	Cough							
	Dizziness							
	Drug Dependence							
	Flushing							
	Haematocrit Increased							
	Haematuria							
	Haemoglobin Increased							
	Headache							
	Mean Cell Volume Increased							
	Nausea							
	Platelet Count Decreased							
	Protein Total Increased							
	Pyrexia							
	Rash Erythematous							
	Sleep Disorder							
	Urinary Tract Infection							
	Urine Analysis Abnormal							
	Vomiting							
	Weight Increased							

Date:01/20/99ISR Number: 3182664-6Report Type:Expedited (15-DaCompany Report #A0074622
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL 5 DAY
	Serum Sickness	Professional						
	Swelling	Company						
	Tooth Abscess	Representative						

Date:01/21/99ISR Number: 3182993-6Report Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia	Health	Zyban	PS			2	WK
	Rash Pruritic	Professional	Prilosec	C				
	Throat Tightness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/99ISR Number: 3183279-6Report Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Disorientation		Zyban	PS		ORAL	150MG PO BID	
Hospitalization - Initial or Prolonged	Grand Mal Convulsion							

Date:01/21/99ISR Number: 3183993-2Report Type:Expedited (15-DaCompany Report #9821939
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Zoloft	PS		ORAL	25.00 MG	
Hospitalization -	Blood Amylase Increased	Professional					TOTAL:DAILY:O	
Initial or Prolonged	Drug Ineffective					RAL		
Required	Gastrooesophageal Reflux		Wellbutrin	SS		ORAL	75.00 MG	
Intervention to	Disease						TOTAL:DAILY:O	
Prevent Permanent	Obstruction					RAL		
Impairment/Damage	Pancreatitis Acute		Lithane	SS			900.00 MG	
							TOTAL:DAILY	
			Motrin	C				

Date:01/22/99ISR Number: 3184598-XReport Type:Expedited (15-DaCompany Report #A0079791
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm	Consumer	Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Cerebrovascular Accident						PER DAY/ORAL	
	Hemiplegia		Digoxin	C				

			Frusemide	C		
			Diclofenac Sodium	C		
			Warfarin Sodium	C		

Date:01/22/99ISR Number: 3184668-6Report Type:Expedited (15-DaCompany Report #A0077891
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Zyban	PS		ORAL	150 MG TWICE	
	Depressed Level Of Consciousness	Consumer					PER DAY ORAL	
	Fall		Clozapine	C				
	Speech Disorder		Lorazepam	C				
			Ranitidine Hydrochloride	C				

Date:01/22/99ISR Number: 3184756-4Report Type:Expedited (15-DaCompany Report #A0076551
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis	Foreign	Zyban	PS		ORAL	150 MG /	
	Dermatitis	Health					TWICE PER DAY	
	Pharyngolaryngeal Pain	Professional					/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/99ISR Number: 3184760-6Report Type:Expedited (15-DaCompany Report #A0078500
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Forearm Fracture Rib Fracture Syncope	Consumer	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:01/22/99ISR Number: 3193184-7Report Type:Periodic Company Report #980325-LX278
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coordination Abnormal	Health	Ambien	PS			20.000 MG UNK	
		Professional	Effexor	SS		ORAL	350.000 MG QD	
							PO	
			Wellbutrin	SS		ORAL	100.000 MG QD	
							PO	
			Lithium	C				
			Risperidone	C				
			Thyroid	C				
			Alprazolam	C				

Date:01/25/99ISR Number: 3185444-0Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Bupropion	PS		ORAL	150 MG BID	3 WK
		Professional	Tylenol #4	C				
			Atenolol	C				
			Lipitor (Atrovastin)	C				

			Aspirin	C		
			Cyclobenzamine	C		

Date:01/25/99ISR Number: 3185551-2Report Type:Expedited (15-DaCompany Report #A0079132
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest	Health	Wellbutrin				
Hospitalization -	Convulsion	Professional	Tablet-Controlled				
Initial or Prolonged	Intentional Misuse	Company	Release	PS		ORAL	150 MG/ SEE
	Loss Of Consciousness	Representative					TEXT/ ORAL
			Paroxetie				
			Hydrochloride	C			

Date:01/25/99ISR Number: 3185553-6Report Type:Expedited (15-DaCompany Report #A0078231
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebrovascular Accident	Foreign	Zyban	PS		ORAL	150 MG /
Initial or Prolonged	Fatigue	Health					TWICE PER DAY
	Insomnia	Professional					/ ORAL
	Tremor		Human Int/Long				
			Insulin	C			
			Atorvastatin Calcium	C			
			Fenofibrate	C			
			Enalapril Maleate	C			
			Human Short-Act.				

Insulin C

Date:01/25/99ISR Number: 3185628-1Report Type:Expedited (15-DaCompany Report #A0076146
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Agitation	Professional						
	Anger							
	Anxiety		Zyban	SS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Chromaturia							
	Confusional State							
	Disorientation							
	Emotional Disorder							
	Feeling Abnormal							
	Irritability							
	Pollakiuria							
	Urine Odour Abnormal							

Date:01/25/99ISR Number: 3185677-3Report Type:Expedited (15-DaCompany Report #A0080209
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Foreign	Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Alcohol Interaction	Health						
Other	Confusional State	Professional	Ethanol Liquid	SS		ORAL	ORAL	
	Delusion							
	Hostility							
	Insomnia							
	Paranoia							

Date:01/26/99ISR Number: 3195651-9Report Type:Periodic Company Report #9825988
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Health	Viagra Tablets	PS		ORAL	50.00MG TOTAL	
	Drug Interaction	Professional				ORAL		
			Wellbutrin	SS		ORAL		

Date:01/27/99ISR Number: 3187746-0Report Type:Expedited (15-DaCompany Report #A0080313
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban	PS		ORAL	150 MG/TWICE	
	Anxiety						PER DAY/ ORAL	
	Convulsion		Percocet	C				
	Dry Mouth		Diazepam	C				
	Haematemesis		Quinalbarbitone					
	Insomnia		Sodium	C				
	Tremor							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3189484-7Report Type:Expedited (15-DaCompany Report #A0073975
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Toxic Epidermal Necrolysis	Health Professional	Wellbutrin	PS		ORAL	100 MG/ PER DAY / ORAL
			Lamictal	SS		ORAL	200 MG / TWICE PER DAY / ORAL

Date:02/01/99ISR Number: 3189507-5Report Type:Expedited (15-DaCompany Report #A0080414
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Serum Sickness Urticaria	Foreign Consumer	Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL

Date:02/01/99ISR Number: 3189508-7Report Type:Expedited (15-DaCompany Report #A0071029
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Choking	Health	Zyban	PS		ORAL	150 MG/ORAL
	Dysphagia Dyspnoea Foreign Body Trauma Nausea Oral Intake Reduced Pharyngolaryngeal Pain Retching	Professional	Librax	C			

Date:02/01/99ISR Number: 3189705-0Report Type:Expedited (15-DaCompany Report #A0071893
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Oedema	Health	Wellbutrin	PS		ORAL	150 MG/PER	
Other	Cerebellar Infarction	Professional					DAY/ORAL	
	Cerebrovascular Accident		Loratadine	C				
	Embolism							

Date:02/01/99ISR Number: 3189884-5Report Type:Expedited (15-DaCompany Report #A0077761
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Wellbutrin					
Initial or Prolonged	Depression	Professional	Tablet-Controlled					
Other	Drug Ineffective		Release	PS		ORAL	150 MG / ORAL	5 DAY
	Insomnia		Antihypertensive	C				
	Jealous Delusion		Zestoretic	C				
	Paranoia							
	Suicidal Ideation							

Date:02/01/99ISR Number: 3196512-1Report Type:Periodic Company Report #A0067641
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
Other	Convulsion	Health
		Professional

		Company Representative	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Tablet	PS		

Date:02/01/99ISR Number: 3196513-3Report Type:Periodic Company Report #A0067421
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL
75 MG/TWICE						
	Headache	Professional				
PER DAY/ ORAL						
	Loss Of Consciousness		Salbutamol Sulphate	C		
	Mental Impairment					

Date:02/01/99ISR Number: 3196514-5Report Type:Periodic Company Report #A0066609
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL
ORAL						
		Professional				
		Company Representative				

Date:02/01/99ISR Number: 3196515-7Report Type:Periodic Company Report #A0066320
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dyspnoea	Health	Wellbutrin Tablet -			
	Rash Erythematous	Professional	Zyban	PS		ORAL
150 MG /						
	Urticaria					
TWICE PER						
DAY/ ORAL						

Date:02/01/99ISR Number: 3196516-9Report Type:Periodic Company Report #A0066185
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3196517-0Report Type:Periodic Company Report #A0065523
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Joint Swelling Pruritus Serum Sickness Skin Lesion	Health Professional	Wellbutrin Tablet - Controlled Release Desmopression	PS C		ORAL	100 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3196518-2Report Type:Periodic Company Report #A0065371
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet	PS		ORAL	100 MG/ THREE TIMES PER DAY/ ORAL

Date:02/01/99ISR Number: 3196519-4Report Type:Periodic Company Report #A0065219
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / PER DAY / ORAL
	Chest Discomfort						
	Flushing		Maxzide	C			
	Tachycardia		Multivitamin	C			
			Calcium Salt	C			
			Salbutamol Sulphate	C			
			Aspirin	C			
			Lorazepam	C			

Date:02/01/99ISR Number: 3196520-0Report Type:Periodic Company Report #A0064535
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Pruritus	Health Professional	Wellbutrin Tablet -				
	Urticaria		Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
Other		Company Representative					

Date:02/01/99ISR Number: 3196521-2Report Type:Periodic Company Report #A0063547
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
			Hyoscine (Formulation Unknown)	SS		TRANSDERMAL	TRANSDERMAL	

Date:02/01/99ISR Number: 3196522-4Report Type:Periodic Company Report #A0063059
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health Professional	Wellbutrin Tablet	PS		ORAL	100 MG / THREE TIMES PER DAY/ ORAL	
	Drug Hypersensitivity							
	Dysphoria							
	Insomnia		Lorazepam	C				
	Pruritus							
	Rash Maculo-Papular							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3196523-6Report Type:Periodic Company Report #A0063000
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Wellbutrin Tablet -					
	Face Oedema	Professional	Zyban	PS		ORAL	150 MG / PER	
	Rash Erythematous						DAY / ORAL	
	Throat Tightness		Nicotine	C				

Date:02/01/99ISR Number: 3196524-8Report Type:Periodic Company Report #A0063037
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Wellbutrin					
	Periorbital Oedema	Professional	(Formulation					
			Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3196525-XReport Type:Periodic Company Report #A0062802
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Health	Wellbutrin Tablet -					
	Difficulty In Walking	Professional	Zyban	PS		ORAL	150 MG /	
	Dyskinesia						TWICE PER DAY	
	Dysphagia						/ ORAL	
	Dyspnoea		Medroxyprogesterone					
	Fatigue		Ace.	C				
	Hyperventilation							
	Jaw Disorder							
	Muscle Rigidity							
	Nervous System Disorder							
	Speech Disorder							
	Tremor							

Date:02/01/99ISR Number: 3196527-3Report Type:Periodic Company Report #A0063358
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Auricular Swelling	Health	Wellbutrin	PS		ORAL	150 MG / TWICE PER DAY	
Other	Erythema Multiforme	Professional						
	Gastric Dilatation						/ ORAL	
	Malaise		Allergy Medication	C				
	Nausea							
	Oedema Peripheral							
	Pain							
	Pharyngeal Oedema							
	Pyrexia							
	Rash Erythematous							
	Rash Macular							
	Stevens-Johnson Syndrome							
	Urticaria							

Date:02/01/99ISR Number: 3196528-5Report Type:Periodic Company Report #A0063149
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Coordination Abnormal	Health
		Professional

Other

Product	Role	Manufacturer	Route	Dose	Duration
Wellbutrin	PS		ORAL	VARIABLE DOSE	/ ORAL
Venlafaxine Hydrochloride Tablet	SS		ORAL	350 MG / PER	DAY / ORAL
Zolpidem Tartrate (Formulation Unknown)	SS			20 MG	
Lithium Salt	C				
Risperidone	C				
Thyroid	C				
Alprazolam	C				

Date:02/01/99ISR Number: 3196529-7Report Type:Periodic Company Report #A0061149
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL

Date:02/01/99ISR Number: 3196530-3Report Type:Periodic Company Report #A0059271
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Abdominal Pain Angioneurotic Oedema	Health Professional	Wellbutrin Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Initial or Prolonged	Face Oedema	Company				
Other	Headache	Representative				
	Nausea					
	Pharyngeal Oedema					
	Urticaria					
	Vomiting					

Date:02/01/99ISR Number: 3196531-5Report Type:Periodic Company Report #A0059079
Age:6 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3196532-7Report Type:Periodic Company Report #A0072937
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conversion Disorder	Health Professional	Wellbutrin Tablet	PS		ORAL	100 MG / THREE TIMES PER DAY ORAL	
	Convulsion							
	Crying							
	Depression		Aspirin	C				
	Drug Withdrawal Syndrome							
	Headache							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3196533-9Report Type:Periodic Company Report #A0072356
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Wellbutrin Tablet	PS		ORAL	100 MG THREE	
	Clonic Convulsion	Professional					TIMES PER DAY	
	Dystonia	Company					ORAL	
	Hyperreflexia	Representative	Triamcinolone					
	Tardive Dyskinesia		Acetonide	C				
	Tremor		Melatonin	C				

Date:02/01/99ISR Number: 3196534-0Report Type:Periodic Company Report #A0071371
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus	Health	Wellbutrin Tablet	PS		ORAL	ORAL	3 WK
	Urticaria	Professional	Wellbutrin Tablet -					
		Company	Controlled Release	SS		ORAL	ORAL	
		Representative	Nitrofurantoin	C				

Date:02/01/99ISR Number: 3196535-2Report Type:Periodic Company Report #A0071498
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Wellbutrin	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3196536-4Report Type:Periodic Company Report #A0071924
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health	Wellbutrin	PS		ORAL 150 MG (TWICE PER DAY ORAL)
Other	Chest Pain	Professional				
	Urticaria	Company Representative				

Date:02/01/99ISR Number: 3196537-6Report Type:Periodic Company Report #A0070647
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL 150 MG THREE TIMES PER DAY ORAL
	Loss Of Consciousness	Professional				
			Fluoxetine Hydrochloride	C		
			Thyroxine Sodium	C		
			Nortriptyline	C		

Date:02/01/99ISR Number: 3196538-8Report Type:Periodic Company Report #A0070221
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Grand Mal Convulsion	Health	Wellbutrin Tablet	PS		ORAL 150 MG / TWICE PER DAY / ORAL
		Professional				
		Company Representative	Narcotic	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3196539-XReport Type:Periodic Company Report #A0070222
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG TWICE PER DAY / ORAL	
		Professional						
		Company						
		Representative						

Date:02/01/99ISR Number: 3196540-6Report Type:Periodic Company Report #A0070053
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
		Professional	Paroxetine Hydrochloride Tablet	SS		ORAL	ORAL	
		Other	Colchicine	C				
			Allopurinol	C				
			Temazepam	C				

Date:02/01/99ISR Number: 3196541-8Report Type:Periodic Company Report #A0070058
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL	1 WK
		Professional						
		Company						
		Representative						

Date:02/01/99ISR Number: 3196542-XReport Type:Periodic Company Report #A0069723
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG / PER	
Other		Professional					DAY / ORAL	
		Company Representative						

Date:02/01/99ISR Number: 3196543-1Report Type:Periodic Company Report #A0069889
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG ORAL	1 MON
		Professional						
		Company Representative						

Date:02/01/99ISR Number: 3196544-3Report Type:Periodic Company Report #A0069441
Age:27 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain
	Convulsion
Other	Depressed Level Of Consciousness
	Disorientation
	Overdose

	Speech Disorder Tachycardia						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Wellbutrin Tablet	PS		ORAL	100 MG ORAL

Date:02/01/99ISR Number: 3196545-5Report Type:Periodic Company Report #A0069375
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Bite Grand Mal Convulsion Pain	Consumer	Wellbutrin Tablet Sertraline Hydrochloride	PS C		ORAL	75 MG / TWICE PER DAY / ORAL

Date:02/01/99ISR Number: 3196546-7Report Type:Periodic Company Report #A0069134
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:02/01/99ISR Number: 3196547-9Report Type:Periodic Company Report #A0069196
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Grand Mal Convulsion	Consumer	Wellbutrin Tablet	PS		ORAL
PER DAY ORAL						
			Nortriptyline	C		

Date:02/01/99ISR Number: 3196548-0Report Type:Periodic Company Report #A0068887
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bundle Branch Block Right	Health	Wellbutrin Tablet	PS		ORAL
1200 MG /						
Initial or Prolonged	Convulsion	Professional				
SINGLE DOSE /						
	Electrocardiogram Qrs					
ORAL						
	Complex Prolonged					
	Sinus Tachycardia					

Date:02/01/99ISR Number: 3196549-2Report Type:Periodic Company Report #A0068803
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Convulsion	Health	Wellbutrin Tablet -			
Initial or Prolonged	Feeling Abnormal	Professional	Controlled Release	PS		ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3196550-9Report Type:Periodic Company Report #A0068334
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Wellbutrin Tablet	PS		ORAL	150 MG / THREE TIMES PER DAY / ORAL	

Date:02/01/99ISR Number: 3196551-0Report Type:Periodic Company Report #A0068155
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3197253-7Report Type:Periodic Company Report #7397306
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction	Health	Abbott-Cylert	PS	Abbott	ORAL	75.000 MG PO QD	
	Dermatitis	Professional						
	Face Oedema		Wellbutrin Sr	SS		ORAL	150.000 MG BID	

Date:02/01/99ISR Number: 3198313-7Report Type:Periodic Company Report #A0069125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	300 MG/ UNK/	
	Overdose	Professional					ORAL	
		Company Representative						

Date:02/01/99ISR Number: 3198314-9Report Type:Periodic Company Report #A0077763
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG /TWICE	
	Pharyngeal Oedema						PER DAY /ORAL	
	Urticaria		Melatonin	C				
			Buspirone Hydrochloride	C				

Date:02/01/99ISR Number: 3198315-0Report Type:Periodic Company Report #A0077656
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG /TWICE	
		Professional					PER DAY /	
		Company					ORAL	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3198316-2Report Type:Periodic Company Report #A0077409
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL /	7 DAYS

Date:02/01/99ISR Number: 3198317-4Report Type:Periodic Company Report #A0078055
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Carisoprodol	C				
			Temazepam	C				
			Carisoprodol	C				

Date:02/01/99ISR Number: 3198318-6Report Type:Periodic Company Report #A0077917
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	UNK/ UNK / ORAL	

Date:02/01/99ISR Number: 3198319-8Report Type:Periodic Company Report #A0076229
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State Grand Mal Convulsion Loss Of Consciousness	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Thyroxine Sodium	C				

Date:02/01/99ISR Number: 3198320-4Report Type:Periodic Company Report #A0067837
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3198321-6Report Type:Periodic Company Report #A0071371
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus Urticaria	Health Professional Company Representative	Wellbutrin Tablet Wellbutrin	PS		ORAL	UNK / UNK / ORAL / 3 WEEKS	

			Tablet-Controlled Release	SS			ORAL
UNK / UNK / ORAL							
			Nitrofurantoin	C			

Date:02/01/99ISR Number: 3198322-8Report Type:Periodic Company Report #A0071495
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG /
	Loss Of Consciousness	Professional					TWICE PER DAY
	Urinary Incontinence						/ ORAL
			Ortho Tri-Cyclen	C			

Date:02/01/99ISR Number: 3198323-XReport Type:Periodic Company Report #A0071644
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Electroencephalogram	Health	Wellbutrin Tablet	PS		ORAL	200 MG /
	Abnormal	Professional					TWICE PER DAY
	Grand Mal Convulsion	Company					/ ORAL
		Representative	Venlafaxine Hydrochloride	C			
			Olanzapine	C			
			Sertraline Hydrochloride	C			
			Carbamazepine	C			
			Semisodium Valproate	C			

Date:02/01/99ISR Number: 3198324-1Report Type:Periodic Company Report #A0072757
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intestinal Perforation	Health	Wellbutrin Tablet	PS		ORAL	100 MG / UNK	
		Professional					/ ORAL	
			Conjugated Estrogens	C				
			Fiorinal	C				

Date:02/01/99ISR Number: 3198325-3Report Type:Periodic Company Report #A0073013
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	UNK/ UNK /	
		Professional					ORAL	
		Company Representative						

Date:02/01/99ISR Number: 3198326-5Report Type:Periodic Company Report #A0073098
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria	Health	Wellbutrin Tablet	PS		ORAL	150 MG / UNK	
		Professional					/ ORAL	
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3198327-7Report Type:Periodic Company Report #A0073332
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG /	
	Insomnia	Professional					TWICE PER DAY	
		Company					/ ORAL	
		Representative	Amitriptyline Hcl Tablet	SS		ORAL	25 MG / UNK /	
							ORAL	

Date:02/01/99ISR Number: 3198328-9Report Type:Periodic Company Report #A0073334
Age:10 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG /	
	Staring	Professional					TWICE PER DAY	
		Company					/ ORAL	
		Representative						

Date:02/01/99ISR Number: 3198329-0Report Type:Periodic Company Report #A0073418
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bite	Health	Wellbutrin Tablet	PS		ORAL	UNK / SEE	
	Depression	Professional					TEXT / ORAL	
	Grand Mal Convulsion		Venlafaxine Hydrochloride	C				
			Olanzapine	C				

Date:02/01/99ISR Number: 3198330-7Report Type:Periodic Company Report #A0073628
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Electroencephalogram	Professional						
	Abnormal	Company						
	Fall	Representative						
	Loss Of Consciousness							
	Muscle Spasms							
	Snoring							

Date:02/01/99ISR Number: 3198331-9Report Type:Periodic Company Report #A0073629
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	150 MG / PER DAY	/ ORAL
		Professional						
		Company	Meclofenamate Sodium	C				
		Representative	Entex	C				
			Unknown	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3198332-0Report Type:Periodic Company Report #A0074135
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness Grand Mal Convulsion	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Paracetamol	C				

Date:02/01/99ISR Number: 3295673-3Report Type:Periodic Company Report #A0076853
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG ORAL	

Date:02/01/99ISR Number: 3295674-5Report Type:Periodic Company Report #A0076854
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY ORAL	
			Ascorbid Acid	C				
			Nitroglycerin	C				
			Calcium Salt	C				
			Aspirin	C				
			Vitamin E	C				
			Chromium Picolinate	C				
			Insulin	C				

Date:02/01/99ISR Number: 3295675-7Report Type:Periodic Company Report #A0076863
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Wellbutrin Tablet -Controlled Release	PS		ORAL	150 MG PER DAY	ORAL
	Dry Mouth							
	Dyspnoea							
	Fatigue		Raxar Tablet	SS		ORAL	400 MG PER DAY	ORAL
	Insomnia							
	Tension Headache		Zyban Tablet-Zyban	SS		ORAL	150 MG PER DAY	ORAL
	Urinary Incontinence							
			Wellbutrin (Formulation Unknown)	SS				
			Loratadine	C				

Date:02/01/99ISR Number: 3295676-9Report Type:Periodic Company Report #A0076957
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Tablet -Controlled Release	PS		ORAL	150 MG PER DAY	ORAL
	Insomnia							
	Tremor							
			Donnatal	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3295677-0Report Type:Periodic Company Report #A0079236
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE DAILY ORAL	
	Disturbance In Attention		Nafazodone Hydrochloride	C				
			Ginseng	C				

Date:02/01/99ISR Number: 3295678-2Report Type:Periodic Company Report #A0059262
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	
	Urticaria							

Date:02/01/99ISR Number: 3295679-4Report Type:Periodic Company Report #A0066438
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3295680-0Report Type:Periodic Company Report #A0067314
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epileptic Aura	Health Professional	Wellbutrin Tablet -Controlled Release	PS		ORAL	150 MG TWICE PER DAY ORAL	
			Paroxetine Hydrochloride	C				

Date:02/01/99ISR Number: 3295681-2Report Type:Periodic Company Report #A0067487
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Wellbutrin Tablet-Controlled Release	PS				

Date:02/01/99ISR Number: 3295682-4Report Type:Periodic Company Report #A0069807
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet -Controlled Release	PS		ORAL	1 TABLET PER DAY ORAL	
			Conjugated Estrogens	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3296011-2Report Type:Periodic Company Report #A0077712
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3296015-XReport Type:Periodic Company Report #A0077853
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	30 YR

Date:02/01/99ISR Number: 3296017-3Report Type:Periodic Company Report #A0077875
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Health Professional Company Representative	Wellbutrin Tablet - Zyban	PS		ORAL	ORAL	2 WK

Date:02/01/99ISR Number: 3296020-3Report Type:Periodic Company Report #A0077889
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hyperglycaemia	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL

ORAL

Date:02/01/99ISR Number: 3296030-6Report Type:Periodic Company Report #A0078019
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia Nausea	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL

TWICE PER DAY

/ ORAL

			Conjugated Estrogens	C		

Date:02/01/99ISR Number: 3296034-3Report Type:Periodic Company Report #A0078021
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Accommodation Disorder Lethargy	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL

150 MG / PER

DAY / ORAL

			Amitriptyline	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3296036-7Report Type:Periodic Company Report #A0078249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Memory Impairment Tinnitus	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	
			Sertraline Hydrochloride (Formulation Unknown)	SS				

Date:02/01/99ISR Number: 3296038-0Report Type:Periodic Company Report #A0078462
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Formication	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
			Lithium Salt	C				
			Insulin	C				
			Salbutamol	C				

Date:02/01/99ISR Number: 3296041-0Report Type:Periodic Company Report #A0078463
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Hallucination Vision Blurred	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Verapamil	C				

			Allopurinol	C		
			Unknown	C		
			Potassium Salt	C		
			Unknown	C		

Date:02/01/99ISR Number: 3296043-4Report Type:Periodic Company Report #A0078471
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Wellbutrin					
	Urticaria		Tablet-Controlled					
			Release	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Lithium	C				
			Zolpidem	C				
			Gabapentin	C				

Date:02/01/99ISR Number: 3296047-1Report Type:Periodic Company Report #A0078472
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching	Consumer	Wellbutrin					
			Tablet-Controlled					

			Release	PS			ORAL
150 MG / TWICE PER DAY / ORAL							
			Pirbuterol Acetate	C			

Date:02/01/99ISR Number: 3296049-5Report Type:Periodic Company Report #A0078473
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Depression	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
			Buspirone	C				
			Diazepam	C				

Date:02/01/99ISR Number: 3296052-5Report Type:Periodic Company Report #A0078474
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Claritin-D	C				
			Diphenhydramine Hcl	C				
			Birth Control	C				
			Paroxetine	C				
			Ethanol	C				

Date:02/01/99ISR Number: 3296054-9Report Type:Periodic Company Report #A0078475
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY	/ ORAL
	Insomnia							
	Irritability							

Date:02/01/99ISR Number: 3296057-4Report Type:Periodic Company Report #A0078965
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG /	TWICE PER DAY / ORAL
			Semisodium	C				
			Olanzapine	C				
			Liothyronine	C				
			Lamotrigine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3296059-8Report Type:Periodic Company Report #A0058749
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acarodermatitis	Health	Wellbutrin					
	Pruritus	Professional	Tablet-Controlled Release	PS		ORAL		

Date:02/01/99ISR Number: 3296067-7Report Type:Periodic Company Report #A0070348
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health	Wellbutrin					
	Chills	Professional	Tablet-Controlled					
	Flushing	Company	Release	PS		ORAL	100 MG /	
	Hyperhidrosis	Representative					THREE TIMES	
	Rash Erythematous						PER DAY /	
	Rash Pruritic						ORAL	
	Rhinorrhoea		Diphenhydramine	C				
	Skin Lesion							

Date:02/01/99ISR Number: 3296068-9Report Type:Periodic Company Report #A0071172
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Wellbutrin					
	Diarrhoea	Professional	Tablet-Controlled					
	Muscle Spasms		Release	PS		ORAL	150 MG / PER	
							DAY / ORAL	

Date:02/01/99ISR Number: 3296072-0Report Type:Periodic Company Report #A0071449
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Rash Erythematous	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER	DAY / ORAL
			Nicotine	C				
			Ketoconazole	C				

Date:02/01/99ISR Number: 3296076-8Report Type:Periodic Company Report #A0071646
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER	DAY / ORAL

Date:02/01/99ISR Number: 3296091-4Report Type:Periodic Company Report #A0076958
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG /	TWICE PER DAY

/ ORAL

			Methadone	C		
			Buspirone Hydrochloride	C		
			Paroxetine Hydrochloride	C		
			Hydrochlorothiazide	C		
			Oxaprozin	C		

Date:02/01/99ISR Number: 3296092-6Report Type:Periodic Company Report #A0076960
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia Insomnia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	

/ ORAL

			Dalmane	C		
			Hydrochlorothiazide	C		

Date:02/01/99ISR Number: 3296093-8Report Type:Periodic Company Report #A0076961
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Psychomotor Hyperactivity	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / ORAL	

Date:02/01/99ISR Number: 3296097-5Report Type:Periodic Company Report #A0077000
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Wellbutrin					

	Hyperhidrosis Nervousness		Tablet-Controlled Release	PS		ORAL 150 MG / PER DAY / ORAL

Date:02/01/99ISR Number: 3296098-7Report Type:Periodic Company Report #A0077069
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Confusional State Depression Disturbance In Attention Increased Appetite	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL PER DAY / ORAL

Date:02/01/99ISR Number: 3296102-6Report Type:Periodic Company Report #A0077070
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Abdominal Pain Urinary Tract Infection	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL TWICE PER DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3296103-8Report Type:Periodic Company Report #A0077080
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Paroxetine Hydrochloride	C				
			Temazepam	C				

Date:02/01/99ISR Number: 3296106-3Report Type:Periodic Company Report #A0077095
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain Eyelid Oedema Eyelid Ptosis	Health Professional	Wellbutrin Tablet - Controlled Release	PS		ORAL	100 MG / TWICE PER DAY	/ ORAL

Date:02/01/99ISR Number: 3296108-7Report Type:Periodic Company Report #A0077096
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Discomfort Flatulence	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY	/ ORAL

Date:02/01/99ISR Number: 3296110-5Report Type:Periodic Company Report #A0077101
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral Pruritus Swelling Urticaria	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3296113-0Report Type:Periodic Company Report #A0080314
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG / ORAL	

Date:02/01/99ISR Number: 3296117-8Report Type:Periodic Company Report #A0077341
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
			Lithium Salt	C				
			Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3296120-8Report Type:Periodic Company Report #A0077427
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Wellbutrin Tablet - Controlled Release	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3296123-3Report Type:Periodic Company Report #A0077452
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Headache	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Zyban Tablet - Zyban	SS		ORAL	ORAL	

Date:02/01/99ISR Number: 3296125-7Report Type:Periodic Company Report #A0077587
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder Balance Disorder Disorientation Muscle Spasms	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Combivir	C				
			Ascriptin	C				
			Dronabinol	C				
			Clonazepam	C				
			Semisodium Valproate	C				
			Amoxycillin	C				

			Vicoprofen	C		
			Venlafaxine Hydrochloride	C		

Date:02/01/99ISR Number: 3296127-0Report Type:Periodic Company Report #A0077670
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	TWICE PER DAY	/ ORAL
			Diuretic	C				
			Blood Pressure Medication	C				

Date:02/01/99ISR Number: 3296129-4Report Type:Periodic Company Report #A0077671
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations Tremor	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
			Estrogen	C				
			Progesterone	C				

				Lisinopril	C		
				Folic Acid	C		

Date:02/01/99ISR Number: 3296131-2Report Type:Periodic Company Report #A0077699
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Wellbutrin Tablet -					
	Insomnia		Controlled Release	PS		ORAL	100 MG / PER	
DAY / ORAL								4 WK
			Clonazepam	C				

Date:02/01/99ISR Number: 3296132-4Report Type:Periodic Company Report #A0077701
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin Tablet -					
	Hypotension		Controlled Release	PS		ORAL	150 MG /	
TWICE PER DAY								
/ ORAL								
			Crataegus	C				
			Clonazepam	C				

Date:02/01/99ISR Number: 3297093-4Report Type:Periodic Company Report #A0067140
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health	Lamictal Tablet	PS		ORAL	ORAL	
	Dermatitis	Professional	Wellbutrin Tablet	SS			5 WK	
	Lichen Planus							
	Periorbital Oedema							

Date:02/01/99ISR Number: 3301098-4Report Type:Periodic Company Report #A0067430
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Lamictal Tablet	PS		ORAL	ORAL	
	Headache		Wellbutrin Tablet	SS		ORAL	ORAL	
	Nausea		Olanzapine	C				
	Pruritus							
	Rash Papular							

Date:02/01/99ISR Number: 3304217-9Report Type:Periodic Company Report #A0071892
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Consumer	Lamictal Tablet	PS		ORAL	300 MG / PER	DAY / ORAL 2 MON
			Wellbutrin Tablet-Controlled Release	SS		ORAL	ORAL	3 WK
			Clomazepam	C				
			Thyroxide Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3393841-3Report Type:Periodic Company Report #A0074623
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour	Health	Wellbutrin					
	Anxiety	Professional	Tablet-Controlled					
	Crying		Release	PS		ORAL	150 MG / IN	
	Depression						THE MORNING /	
	Emotional Disorder						ORAL	
	Screaming							

Date:02/01/99ISR Number: 3393842-5Report Type:Periodic Company Report #A0074642
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Wellbutrin					
			Tablet-Controlled					
			Release	PS		ORAL	150 MG /	
							TWICE PER	
							DAY/ ORAL	
			Sertraline					
			Hydrochloride	C				
			Loratadine	C				
			Nedocromil Sodium	C				
			Budesonide	C				
			Vitamin	C				

Date:02/01/99ISR Number: 3393844-9Report Type:Periodic Company Report #A0074643
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin					
	Nausea		Tablet-Controlled					

			Release	PS		ORAL

150 MG/ THREE

TIMES PER DA

/ ORAL

			Conjugated Estrogens	C		

Date:02/01/99ISR Number: 3393846-2Report Type:Periodic Company Report #A0074644
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Sedation	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL

Dose Duration

150 MG/

TWICER PER

DAY/ ORAL

			Insulin	C		

Date:02/01/99ISR Number: 3393848-6Report Type:Periodic Company Report #A0074645
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Paraesthesia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3393849-8Report Type:Periodic Company Report #A0074646
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY/	ORAL

Date:02/01/99ISR Number: 3393851-6Report Type:Periodic Company Report #A0074660
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / ORAL	12 DAY

Date:02/01/99ISR Number: 3393853-XReport Type:Periodic Company Report #A0074720
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Agitation Dizziness	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
	Drug Interaction Hypoaesthesia Mania Syncope		Procaine Hydrochloride (Formulation Unknown) Clonazepam Nizatidine	SS C C				

Date:02/01/99ISR Number: 3393857-7Report Type:Periodic Company Report #A0074824
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3393859-0Report Type:Periodic Company Report #A0074828
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3393860-7Report Type:Periodic Company Report #A0074911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL		

Date:02/01/99ISR Number: 3393863-2Report Type:Periodic Company Report #A0074912
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Insomnia							
	Oedema							
	Rash Maculo-Papular							
	Tension							
	Urticaria		Clonazepam (Formulation Unknown)	SS			1 MG / TWICE PER DAY	
			Wellbutrin Tablet-Controlled Release	SS		ORAL		

Date:02/01/99ISR Number: 3393866-8Report Type:Periodic Company Report #A0074957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL		

Date:02/01/99ISR Number: 3393868-1Report Type:Periodic Company Report #A0074981
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Wellbutrin					
	Drug Interaction	Professional	Tablet-Controlled					
	Haematoma	Company	Release	PS		ORAL	150 MG / ORAL	
	International Normalised Ratio Increased	Representative	Warfarin Sodium (Formulation					
	Joint Swelling		Unknown)	SS			7.5 MG / ALTERNATE	DAYS
			Warfarin Sodium (Formulation					
			Unknown)	SS				

Date:02/01/99ISR Number: 3393905-4Report Type:Periodic Company Report #A0073758
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin					
	Headache		Tablet-Controlled					
			Release	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3393907-8Report Type:Periodic Company Report #A0073760
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY/	ORAL
			Insulin	C				

Date:02/01/99ISR Number: 3393908-XReport Type:Periodic Company Report #A0073779
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Texture Abnormal Nausea	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY /	ORAL
			Alprazolam	C				

Date:02/01/99ISR Number: 3393911-XReport Type:Periodic Company Report #A0073847
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	1 TABLET/ TWICE PER DAY/	ORAL

Date:02/01/99ISR Number: 3393912-1Report Type:Periodic Company Report #A0073878
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	
	Back Pain							
	Dermatitis Exfoliative							
	Diarrhoea							
	Disorientation							
	Erythema		Estropipate	C				
	Oedema Peripheral		Hydrochlorothiazide	C				
	Onycholysis		Fexofenadine Hydrochlorid	C				
	Vomiting		Alprazolam	C				
			Herbal Vitamin	C				

Date:02/01/99ISR Number: 3393913-3Report Type:Periodic Company Report #A0073879
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingivitis	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395316-4Report Type:Periodic Company Report #A0072684
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ PER	DAY/ ORAL

Date:02/01/99ISR Number: 3395317-6Report Type:Periodic Company Report #A0072698
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Mental Impairment Nervousness	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ PER	DAY/ ORAL
			Multivitamin	SS				
			Estrogen	C				

Date:02/01/99ISR Number: 3395318-8Report Type:Periodic Company Report #A0072750
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Venous Stasis	Health Professional Company	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	
		Representative	Paroxetine Hydrochloride	C				

Date:02/01/99ISR Number: 3395319-XReport Type:Periodic Company Report #A0074990
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chromaturia Dizziness Mood Altered	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	1 TABLET/ PER DAY/	ORAL
			Clonazepam	C				

Date:02/01/99ISR Number: 3395320-6Report Type:Periodic Company Report #A0075002
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction International Normalised Ratio Increased	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ ORAL	
			Warfarin Sodium (Formulation Unknown)	SS			5 MG / PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395321-8Report Type:Periodic Company Report #A0075003
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Wellbutrin					
	International Normalised	Professional	Tablet-Controlled					
	Ratio Increased	Company	Release	PS		ORAL	150 MG/	ORAL
		Representative	Warfarin Sodium (Formulation Unknown)	SS				

Date:02/01/99ISR Number: 3395322-XReport Type:Periodic Company Report #A0075004
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Wellbutrin					
	International Normalised	Professional	Tablet-Controlled					
	Ratio Increased	Company	Release	PS		ORAL	150 MG/	ORAL
		Representative	Warfarin Sodium (Formulation Unknown)	SS				

Date:02/01/99ISR Number: 3395323-1Report Type:Periodic Company Report #A0075006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Wellbutrin					
	Irritability	Professional	Tablet-Controlled					
		Company	Release	PS		ORAL	ORAL	
		Representative						

Date:02/01/99ISR Number: 3395324-3Report Type:Periodic Company Report #A0075053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	300 MG/ PER DAY / ORAL	

Date:02/01/99ISR Number: 3395325-5Report Type:Periodic Company Report #A0075054
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Insomnia Testicular Pain	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG/ THREE TIMES PER DAY/ ORAL	
			Simvastatin	C				

Date:02/01/99ISR Number: 3395326-7Report Type:Periodic Company Report #A0075057
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Malaise	Consumer	Wellbutrin Tablet-Controlled					

			Release	PS			ORAL
150 MG/ TWICE PER DAY / ORAL							
			Nicotine	C			
			Alprazolam	C			

Date:02/01/99ISR Number: 3395327-9Report Type:Periodic Company Report #A0074209
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Alprazolam	C				

Date:02/01/99ISR Number: 3395328-0Report Type:Periodic Company Report #A0074210
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Insomnia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ PER DAY/ ORAL	
			Atorvastatin Calcium	C				
			Tenoretic	C				
			Estropipate	C				

Date:02/01/99ISR Number: 3395329-2Report Type:Periodic Company Report #A0074213
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Nausea	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY/ ORAL
			Paroxetine Hydrochloride	C			
			Trazodone	C			
			Estratest	C			
			Medroxyprogesterone Ace.	C			

Date:02/01/99ISR Number: 3395330-9Report Type:Periodic Company Report #A0074379
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Dizziness Feeling Abnormal Tremor	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG/ PER DAY/ ORAL	
			Salbutamol Sulphate	C				
			Fluoxetine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395331-0Report Type:Periodic Company Report #A0074380
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	
	Hyperhidrosis		Guanethidine Monosulphate	C				
			Glipizide	C				
			Glucophage	C				
			Multivitamin	C				

Date:02/01/99ISR Number: 3395332-2Report Type:Periodic Company Report #A0074450
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Other	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY /	
	Enanthema							
	Hypersensitivity							
	Oedema Mouth							
ORAL							2	WK
			Pemoline	C				

Date:02/01/99ISR Number: 3395333-4Report Type:Periodic Company Report #A0074504
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3395334-6Report Type:Periodic Company Report #A0074576
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG/ PER DAY/ ORAL	
	Influenza Like Illness							
	Pain							
			Paroxetine Hydrochloride	SS				

Date:02/01/99ISR Number: 3395335-8Report Type:Periodic Company Report #A0074578
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	1 YR
	Drug Interaction							
			Fluvoxamine Maleate Tablet	SS			50 MG	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395336-XReport Type:Periodic Company Report #A0073880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / THREE TIMES PER DAY	
	Liver Function Test Abnormal							
	Tinnitus							
			Wellbutrin Tablet	SS				
			Gabapentin	C				

Date:02/01/99ISR Number: 3395337-1Report Type:Periodic Company Report #A0073881
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	
	Dermatitis							
	Mood Swings							
	Nightmare							
			Pseudoephedrine Hcl	C			/ ORAL	
			Paracetamol	C				

Date:02/01/99ISR Number: 3395338-3Report Type:Periodic Company Report #A0073882
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK/ PER DAY/ ORAL	

Semisodium Valproate	C
Doxepin	C
Estratest	C
Potassium Chloride	C
Atorvastatin Calcium	C
Prednisone	C
Thyroxine Sodium	C
Lansoprazole	C
Ciprofloxacin Hcl	C
Compazine	C

Date:02/01/99ISR Number: 3395339-5Report Type:Periodic Company Report #A0073883
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Headache Tachycardia Urticaria	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395340-1Report Type:Periodic Company Report #A0073884
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
			No Concurrent Medication	C				

Date:02/01/99ISR Number: 3395341-3Report Type:Periodic Company Report #A0073932
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Nausea Tremor Weight Decreased	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	200 MG / TWICE PER DAY / ORAL	
			Atenolol	C				

Date:02/01/99ISR Number: 3395342-5Report Type:Periodic Company Report #A0073933
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Simple Partial Seizures Tremor	Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Tramadol					

			Hydrochloride	C		
			Arthritis Medication	C		

Date:02/01/99ISR Number: 3395343-7Report Type:Periodic Company Report #A0073937
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention Headache Loss Of Consciousness Photophobia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Fluoxetine Hydrochloride	C				
			Zafirlukast	C				
			Sodium Cromoglycate	C				
			Omeprazole	C				
			Beclomethasone Dipropion	C				
			Salbutamol Sulphate	C				
			Fluticasone Propionate	C				
			Metronidazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395344-9Report Type:Periodic Company Report #A0073939
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3395345-0Report Type:Periodic Company Report #A0073940
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / UNK / ORAL	

Date:02/01/99ISR Number: 3395346-2Report Type:Periodic Company Report #A0073943
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Health Professional	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Trazodone	C				

Date:02/01/99ISR Number: 3395347-4Report Type:Periodic Company Report #A0073944
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Insomnia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK/ TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3395348-6Report Type:Periodic Company Report #A0073968
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pruritus Rash Papular	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / THREE TIMES PER DAY ORAL	
			Thyroxine Sodium	C				
			Ibuprofen	C				
			Lortab	C				

Date:02/01/99ISR Number: 3395349-8Report Type:Periodic Company Report #A0073977
Age:33 YR Gender:Female I/FU:I

Outcome	PT
	Anxiety Depression

	Flushing Nausea Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL
150 MG / IN THE MORNING / ORAL						
			Ranitidine Hydrochloride	C		
			Piroxicam	C		
			Dicyclomine	C		
			Nicotine	C		

Date:02/01/99ISR Number: 3395350-4Report Type:Periodic Company Report #A0074032
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dermatitis Erythema Pruritus Urticaria	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL
150 MG / PER DAY / ORAL						
			Zyban Tablet - Zyban	SS		ORAL
UNK / UNK / ORAL						

Date:02/01/99ISR Number: 3395351-6Report Type:Periodic Company Report #A0073513
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Disturbance In Attention Drug Ineffective Irritability	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL
150 MG/ TWICE						

Mood Swings

PER DAY /

ORAL 3 MON

Wellbutrin Tablet SS ORAL

UNK / UNK /

ORAL

Conjugated Estrogens C
Darvocet-N C

Date:02/01/99ISR Number: 3395352-8Report Type:Periodic Company Report #A0073518
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred Visual Disturbance	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
			No Concurrent Medication	C				

Date:02/01/99ISR Number: 3395353-XReport Type:Periodic Company Report #A0073519
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER	

DAY / ORAL

			Fluoxetine Hydrochloride	C		

Date:02/01/99ISR Number: 3395354-1Report Type:Periodic Company Report #A0073520
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nervousness Tremor	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	

/ ORAL

Date:02/01/99ISR Number: 3395356-5Report Type:Periodic Company Report #A0073538
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	

/ ORAL

			Phentermine	C		

Date:02/01/99ISR Number: 3395357-7Report Type:Periodic Company Report #A0073575
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingivitis	Consumer	Wellbutrin Tablet-Controlled					

			Release	PS		ORAL

150 MG /

TWICE PER DAY

/ ORAL

			Paroxetine Hydrochloride	C		

Date:02/01/99ISR Number: 3395375-9Report Type:Periodic Company Report #A0072208
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dermatitis	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

Date:02/01/99ISR Number: 3395376-0Report Type:Periodic Company Report #A0072223
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Insomnia Mania Tremor	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL

Dose Duration

TWICE PER DAY

/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395378-4Report Type:Periodic Company Report #A0072304
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY /	
	Drug Effect Decreased							
ORAL								1 YR

Date:02/01/99ISR Number: 3395379-6Report Type:Periodic Company Report #A0072326
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ PER DAY/ ORAL	
	Dizziness							
			Diltiazem Hydrochloride	C				
			Clonidine	C				

Date:02/01/99ISR Number: 3395381-4Report Type:Periodic Company Report #A0072327
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY/ ORAL	
	Irritability							
	Tremor							
			Paracetamol	C				

Date:02/01/99ISR Number: 3395383-8Report Type:Periodic Company Report #A0072328
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	
	Gait Disturbance		Thyroxine Sodium	C				
			Lo/Ovral	C				

Date:02/01/99ISR Number: 3395384-XReport Type:Periodic Company Report #A0072354
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3395385-1Report Type:Periodic Company Report #A0072355
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ ORAL	3 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395387-5Report Type:Periodic Company Report #A0072477
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3395388-7Report Type:Periodic Company Report #A0072497
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	10 DAY

Date:02/01/99ISR Number: 3395389-9Report Type:Periodic Company Report #A0072543
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence Headache Nervousness	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ PER DAY/ ORAL	
			Carisoprodol	C				
			Tramadol Hydrochloride	C				
			Brimonidine Tartrate	C				
			Conjugated Estrogens	C				

Date:02/01/99ISR Number: 3395390-5Report Type:Periodic Company Report #A0072544
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Wellbutrin					
	Depression		Tablet-Controlled					
	Dry Mouth		Release	PS		ORAL	TWICE PER	
							DAY/ ORAL	
			Simvastatin	C				
			Alprazolam	C				

Date:02/01/99ISR Number: 3395391-7Report Type:Periodic Company Report #A0072545
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Wellbutrin					
	Memory Impairment		Tablet-Controlled					
			Release	PS		ORAL	TWICE PER	
							DAY/ ORAL	

Date:02/01/99ISR Number: 3395393-0Report Type:Periodic Company Report #A0072603
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Wellbutrin					
	Tinnitus	Professional	Tablet-Controlled					

				Release	PS		ORAL
150MG/TWICE							
PER DAY/ ORAL							
				Fluoxetine			
				Hydrochloride	C		
				Mesalazine	C		

Date:02/01/99ISR Number: 3395394-2Report Type:Periodic Company Report #A0072604
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nightmare	Health	Wellbutrin			
		Professional	Tablet-Controlled			
		Company	Release	PS		ORAL
150 MG/ ORAL						
		Representative				

Date:02/01/99ISR Number: 3395396-6Report Type:Periodic Company Report #A0072605
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Confusional State	Health	Wellbutrin			
	Orthostatic Hypotension	Professional	Tablet-Controlled			
		Company	Release	PS		ORAL
150 MG/ ORAL						
		Representative	Blood Pressure			
			Medication	C		

Date:02/01/99ISR Number: 3395397-8Report Type:Periodic Company Report #A0072609
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Wellbutrin			
		Professional	Tablet-Controlled			
			Release	PS		ORAL
ORAL						

Date:02/01/99ISR Number: 3395399-1Report Type:Periodic Company Report #A0072610
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Other	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3395400-5Report Type:Periodic Company Report #A0072612
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY	
			Estrogen	C			/ ORAL	
			Progesterone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395402-9Report Type:Periodic Company Report #A0072619
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY	
	Pain							
	Rash Pruritic							

/ ORAL

Date:02/01/99ISR Number: 3395404-2Report Type:Periodic Company Report #A0073587
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ ORAL	
	Influenza Like Illness							
	Pyrexia		Hormones	C				

Date:02/01/99ISR Number: 3395406-6Report Type:Periodic Company Report #A0073593
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Loracarbef	C				
			Potassium Salt	C				
			Bumetanide	C				
			Carvedilol	C				
			Digoxin	C				
			Losartan Potassium	C				
			Lorazepam	C				
			Hydralazine	C				
			Prempro	C				
			Mirtazapine	C				

Date:02/01/99ISR Number: 3395408-XReport Type:Periodic Company Report #A0073394
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Apathy Attention Deficit/Hyperactivity Disorder Diarrhoea Hypersensitivity Hypomania	Health Professional	Wellbutrin Tablet - Controlled Release	PS		ORAL	300 MG/ PER DAY/ ORAL	
			Semisodium Valproate (Formulation Unknown)	SS		ORAL	750 MG/ ORAL	

Date:02/01/99ISR Number: 3395410-8Report Type:Periodic Company Report #A0073109
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Nausea	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395411-XReport Type:Periodic Company Report #A0073110
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Wellbutrin Tablet - Controlled Release	PS		ORAL	TWICE PER	DAY/ ORAL

Date:02/01/99ISR Number: 3395413-3Report Type:Periodic Company Report #A0073111
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise Mental Impairment	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG/ PER	DAY / ORAL

Date:02/01/99ISR Number: 3395415-7Report Type:Periodic Company Report #A0073112
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	TWICE PER	DAY/ ORAL
			Diazepam	C				
			Salbutamol Sulphate	C				
			Nicotine	C				

Date:02/01/99ISR Number: 3395416-9Report Type:Periodic Company Report #A0073113
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Alopecia Glossodynia Halitosis	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL 150 MG/ TWICE PER DAY / ORAL
			Wellbutrin Tablet- Controlled Release	SS		ORAL 150 MG/ TWICE PER DAY/ ORAL
			Conjugated Estrogens	C		
			Multivitamin	C		

Date:02/01/99ISR Number: 3395418-2Report Type:Periodic Company Report #A0073115
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Pruritus	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL TWICE PER DAY/ ORAL

Date:02/01/99ISR Number: 3395419-4Report Type:Periodic Company Report #A0073288
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Balance Disorder	Health Professional Company Representative	Wellbutrin Tablet - Controlled Release	PS		ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395421-2Report Type:Periodic Company Report #A0072767
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin Tablet -Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:02/01/99ISR Number: 3395422-4Report Type:Periodic Company Report #A0072768
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Wellbutrin Tablet -					
	Drug Ineffective		Controlled Release	PS		ORAL	THREE TIMES PER DAY/	ORAL
			Estrogen	C				
			Thyroxine Sodium	C				

Date:02/01/99ISR Number: 3395424-8Report Type:Periodic Company Report #A0072770
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY/	ORAL

Date:02/01/99ISR Number: 3395426-1Report Type:Periodic Company Report #A0072984
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Wellbutrin Tablet -					

	Dizziness		Controlled Release	PS		ORAL 150 MG /
	Tremor					TWICE PER DAY / ORAL
			No Concurrent Medication	C		

Date:02/01/99ISR Number: 3395427-3Report Type:Periodic Company Report #A0071750
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Tremor	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL ORAL
		Company Representative	Nefazodone Hydrochloride (Formulation Unknown)	SS		

Date:02/01/99ISR Number: 3395429-7Report Type:Periodic Company Report #A0071816
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Abnormal Behaviour Insomnia Tremor	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL 150 MG/ PER DAY/ ORAL
			Fluoxetine Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3395430-3Report Type:Periodic Company Report #A0071857
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	
			Carisoprodol	C				
			Estrogen	C				
			Omeprazole	C				
			Ibuprofen	C				

Date:02/01/99ISR Number: 3395432-7Report Type:Periodic Company Report #A0071905
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dry Mouth	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	UNK / TWICE PER DAY/ ORAL	
	Headache							
	Joint Stiffness Muscle Rigidity Tremor		Doxycycline	C				

Date:02/01/99ISR Number: 3395433-9Report Type:Periodic Company Report #A0071906
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Smoker	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3395434-0Report Type:Periodic Company Report #A0072002
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Hyperhidrosis	Consumer	Wellbutrin Tablet - Controlled Release	PS		ORAL	150 MG/ PER	DAY/ ORAL
			Oestradiol	C				

Date:02/01/99ISR Number: 3395548-5Report Type:Periodic Company Report #M082966
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Trazodone Tabs	PS		ORAL	ORAL	
			Wellbutrin	SS			1	YR

Date:02/01/99ISR Number: 3403909-0Report Type:Periodic Company Report #A0076439
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood Irritability	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / UNK	/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3403910-7Report Type:Periodic Company Report #A0076536
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Tic Weight Increased	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	450 MG / PER	DAY/ ORAL
			Paroxetine Hydrochloride (Formulation Unknown)	SS			60 MG/ PER	DAY/ UNKNOWN
			Buspirone Hydrochloride	C				

Date:02/01/99ISR Number: 3403911-9Report Type:Periodic Company Report #A0076540
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Urticaria	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER	DAY / ORAL

Date:02/01/99ISR Number: 3403912-0Report Type:Periodic Company Report #A0076581
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Feeling Abnormal Headache	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG /	

Hypoaesthesia
TWICE PER DAY

/ ORAL

Paroxetine Hydrochloride	C	
Multivitamin	C	

Date:02/01/99ISR Number: 3403913-2Report Type:Periodic Company Report #A0076759
Age:11 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG / PER	

DAY / ORAL

Date:02/01/99ISR Number: 3403914-4Report Type:Periodic Company Report #A0076787
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG /	

TWICE PER DAY

/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3403915-6Report Type:Periodic Company Report #A0076788
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
	Disorientation							
	Insomnia							
	Memory Impairment							

Date:02/01/99ISR Number: 3403916-8Report Type:Periodic Company Report #A0076789
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG / TWICE PER DAY / ORAL	YR
			Nefazodone Hydrochloride	C				
			Buspirone Hydrochloride	C				

Date:02/01/99ISR Number: 3403917-XReport Type:Periodic Company Report #A0076790
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

			Alprazolam	C		
			Omeprazole	C		
			Conjugated Estrogens	C		
			Thyroxine Sodium	C		
			Vitamin E	C		
			Paracetamol	C		
			Dycyclomine	C		

Date:02/01/99ISR Number: 3403918-1Report Type:Periodic Company Report #A0076852
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
	Nausea							
	Nervousness							
	Tremor							

Date:02/01/99ISR Number: 3404005-9Report Type:Periodic Company Report #A0061813
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK /UNK / ORAL	
			Cancer Chemotherapy	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404006-0Report Type:Periodic Company Report #A0061916
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin Tablet	PS		ORAL	UNK / UNK /	
	Dyspnoea	Professional				ORAL		
		Company Representative						

Date:02/01/99ISR Number: 3404007-2Report Type:Periodic Company Report #A0062035
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Health	Wellbutrin Tablet	PS		ORAL	UNK / UNK /	
		Professional				ORAL		

Date:02/01/99ISR Number: 3404008-4Report Type:Periodic Company Report #A0062041
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health	Wellbutrin Tablet	PS		ORAL	75 MG / TWICE	
		Professional					PER DAY /	
						ORAL		
			Diflunisal	C				

Date:02/01/99ISR Number: 3404009-6Report Type:Periodic Company Report #A0062233
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Health	Wellbutrin					

		Professional	(Formulation Unknown)	PS		ORAL

UNK / UNK /

ORAL 2 WK

Date:02/01/99ISR Number: 3404010-2Report Type:Periodic Company Report #A0062240
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Wellbutrin Tablet	PS		ORAL
75 MG / PER						
	Eye Disorder					
DAY / ORAL 1 YR						
	Muscle Spasms		Conjugated Estrogens	C		
	Pollakiuria		Loratadine	C		
	Sensation Of Pressure		Vitamin E	C		
			Multivitamin	C		
			Calcium Salt	C		

Date:02/01/99ISR Number: 3404011-4Report Type:Periodic Company Report #A0062261
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Condition Aggravated	Consumer	Wellbutrin Tablet	PS		ORAL
100 MG /						
	Drug Interaction					
TWICE PER DAY						
	Herpes Simplex					
/ ORAL						
			Famciclovir Tablet	SS		ORAL
500 MG /						
TWICE PER DAY						
/ ORAL						
			Multivitamin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404012-6Report Type:Periodic Company Report #A0062299
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK / UNK / ORAL	3 WK

Date:02/01/99ISR Number: 3404013-8Report Type:Periodic Company Report #A0062334
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Health Professional	Wellbutrin Tablet	PS		ORAL	100 MG / TWICE PER DAY / ORAL	
			Nortriptyline	C				

Date:02/01/99ISR Number: 3404014-XReport Type:Periodic Company Report #A0062375
Age:17 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Wellbutrin Tablet	PS		ORAL	75 MG / TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3404015-1Report Type:Periodic Company Report #A0062377
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK / UNK / ORAL	3 WK

Date:02/01/99ISR Number: 3404016-3Report Type:Periodic Company Report #A0062485
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / TWICE PER DAY / ORAL	
	Constipation							
	Dizziness							
	Dysphagia		Paroxetine Hydrochloride Tablet	SS		ORAL	UNK / UNK / ORAL	
			Fluvoxamine Maleate	C				
			Sertraline Hydrochloride	C				

Date:02/01/99ISR Number: 3404017-5Report Type:Periodic Company Report #A0062635
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional	Wellbutrin Tablet	PS		ORAL	UNK / UNK / ORAL	
	Dermatitis							
	Pyrexia							
	Vasculitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404018-7Report Type:Periodic Company Report #A0062734
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure	Health	Wellbutrin Tablet	PS		ORAL	150 MG / SEE	
	Fluctuation	Professional					TEXT / ORAL;	
	Dizziness						75 MG / UNK /	
							ORAL	
			Etodolac	C				

Date:02/01/99ISR Number: 3404019-9Report Type:Periodic Company Report #A0062758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG / UNK	
							/ ORAL	19 DAY

Date:02/01/99ISR Number: 3404020-5Report Type:Periodic Company Report #A0062762
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG / UNK/	
							ORAL	

Date:02/01/99ISR Number: 3404021-7Report Type:Periodic Company Report #A0062769
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Frequent Bowel Movements	Health	Wellbutrin Tablet	PS		ORAL
150 MG/ TWICE						
	Proctalgia	Professional				
PER DAY /						
		Company				
ORAL						
		Representative				

Date:02/01/99ISR Number: 3404022-9Report Type:Periodic Company Report #A0062800
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain In Jaw	Consumer	Wellbutrin			
	Pharyngolaryngeal Pain		(Formulation			
	Urticaria		Unknown)	PS		ORAL
300 MG / PER						
DAY / ORAL 2 WK						

Date:02/01/99ISR Number: 3404023-0Report Type:Periodic Company Report #A0063752
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypoaesthesia	Health	Wellbutrin Tablet	PS		ORAL
UNK/SEE TEXT/						
		Professional				
ORAL						

Date:02/01/99ISR Number: 3404024-2Report Type:Periodic Company Report #A0062861
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health	Wellbutrin			
		Professional	(Formulation			
			Unknown)	PS		ORAL
100 MG / FOUR						

TIMES PER DAY

ORAL

Gabapentin C

Date:02/01/99ISR Number: 3404025-4Report Type:Periodic Company Report #A0075563
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Rash Erythematous	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE	PER DAY /

ORAL

Levora C

Date:02/01/99ISR Number: 3404026-6Report Type:Periodic Company Report #A0075564
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Anxiety Decreased Appetite Paraesthesia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / UNK /	ORAL

Date:02/01/99ISR Number: 3404027-8Report Type:Periodic Company Report #A0075565
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Fatigue Sedation	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG /	

TWICE PER DAY

/ ORAL

				Blood Pressure Medication	C		

Date:02/01/99ISR Number: 3404028-XReport Type:Periodic Company Report #A0075592
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / IN THE MORNING / ORAL	
	Headache							
	Heart Rate Increased							
	Irritability							
	Mood Altered							
			Hydrochlorothiazide	C				
			Medroxyprogesterone	C				
			Conjugated Estrogens	C				

Date:02/01/99ISR Number: 3404029-1Report Type:Periodic Company Report #A0075593
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / IN THE MORNING /	
	Depression							
	Insomnia							

ORAL

Date:02/01/99ISR Number: 3404030-8Report Type:Periodic Company Report #A0075604
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG / TWICE PER DAY	

/ ORAL

Date:02/01/99ISR Number: 3404031-XReport Type:Periodic Company Report #A0075614
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / UNK / ORAL	

Date:02/01/99ISR Number: 3404032-1Report Type:Periodic Company Report #A0075615
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / UNK / ORAL	

Date:02/01/99ISR Number: 3404033-3Report Type:Periodic Company Report #A0075939
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Wellbutrin					
	Pain	Professional	Tablet-Controlled					
	Rash Pruritic	Company	Release	PS		ORAL	150 MG /	
	Urticaria	Representative					TWICE PER DAY	
							/ ORAL	

Date:02/01/99ISR Number: 3404034-5Report Type:Periodic Company Report #A0076011
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Wellbutrin					
			Tablet-Controlled					
			Release	PS		ORAL	100 MG /	
							TWICE PER DAY	
							/ ORAL	
			Hydroxyzine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404035-7Report Type:Periodic Company Report #A0076018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / THREE TIMES PER DAY / ORAL	

Date:02/01/99ISR Number: 3404036-9Report Type:Periodic Company Report #A0076044
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tic	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / FOUR TIMES PER DAY / ORAL	1 YR

Date:02/01/99ISR Number: 3404037-0Report Type:Periodic Company Report #A0076087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea Dry Mouth Headache	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / UNK / ORAL	3 MON

Date:02/01/99ISR Number: 3404038-2Report Type:Periodic Company Report #A0076115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Suicidal	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / UNK	/ ORAL

Date:02/01/99ISR Number: 3404039-4Report Type:Periodic Company Report #A0076196
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Diarrhoea Dry Mouth	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / THREE TIMES PER DAY /	ORAL
			Hypericum	C				

Date:02/01/99ISR Number: 3404040-0Report Type:Periodic Company Report #A0076360
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Urticaria	Health Professional

		Company Representative	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Tablet-Controlled Release	PS		ORAL
UNK / UNK /						
ORAL						

Date:02/01/99ISR Number: 3404041-2Report Type:Periodic Company Report #A0076361
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Ecchymosis	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL
UNK / UNK /						
ORAL						

Date:02/01/99ISR Number: 3404042-4Report Type:Periodic Company Report #A0076362
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Ecchymosis	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL
UNK / UNK /						
ORAL						

Date:02/01/99ISR Number: 3404043-6Report Type:Periodic Company Report #A0076363
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Urticaria	Health	Wellbutrin			

		Professional	Tablet-Controlled			
		Company	Release	PS		ORAL
UNK/ UNK/						
		Representative				
ORAL						

Date:02/01/99ISR Number: 3404044-8Report Type:Periodic Company Report #A0076390
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation	Consumer	Wellbutrin			
	Tic		Tablet-Controlled			
			Release	PS		ORAL
150 MG / PER						
DAY / ORAL 7 DAY						

Date:02/01/99ISR Number: 3404046-1Report Type:Periodic Company Report #A0075058
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Flushing	Health	Wellbutrin			
	Menopause	Professional	Tablet-Controlled			
			Release	PS		ORAL
UNK/ UNK/						
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404047-3Report Type:Periodic Company Report #A0075078
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Colic Visual Disturbance	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	/
			Lithium Salt	C				

Date:02/01/99ISR Number: 3404049-7Report Type:Periodic Company Report #A0075079
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ PER DAY	/ ORAL

Date:02/01/99ISR Number: 3404051-5Report Type:Periodic Company Report #A0075197
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Conjugated Estrogens	C				
			Quinapril Hydrochloride	C				

			Digoxin	C		
			Hydrochlorothiazide	C		

Date:02/01/99ISR Number: 3404053-9Report Type:Periodic Company Report #A0075265
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Disturbance In Attention Feeling Abnormal	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	300 MG / PER DAY / ORAL	

Date:02/01/99ISR Number: 3404058-8Report Type:Periodic Company Report #A0075266
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Dizziness	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	
			Buspirone Hydrochloride (Formulation Unknown)	SS			10 MG / UNK / UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404059-XReport Type:Periodic Company Report #A0075271
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin					
	Urticaria	Professional	Tablet-Controlled					
		Company	Release	PS		ORAL	UNK/	UNK/
		Representative						
ORAL								

Date:02/01/99ISR Number: 3404061-8Report Type:Periodic Company Report #A0075299
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose	Consumer	Wellbutrin					
	Pruritus		Tablet-Controlled					
			Release	PS		ORAL	600 MG/	PER
DAY/ ORAL								
			Venlafaxine Hydrochloride	C				
			Nefazodone Hydrochloride	C				

Date:02/01/99ISR Number: 3404063-1Report Type:Periodic Company Report #A0075302
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Wellbutrin					
	Insomnia		Tablet-Controlled					
			Release	PS		ORAL	150 MG/	IN
THE MORNING /								
ORAL								
			Nefazodone Hydrochloride	C				

Date:02/01/99ISR Number: 3404070-9Report Type:Periodic Company Report #A0075309
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	
	Dizziness							
	Flushing							
	Insomnia							
	Nausea						/ ORAL	
	Tremor		Lisinopril	C				
			Pravastatin Sodium	C				
			Thyroxine Sodium	C				
			Sulindac	C				

Date:02/01/99ISR Number: 3404080-1Report Type:Periodic Company Report #A0075311
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	
	Hair Disorder							
	Insomnia							
	Tremor							
			Lithium Salt	C				

			Alprazolam	C		
			Thyroxine Sodium	C		

Date:02/01/99ISR Number: 3404082-5Report Type:Periodic Company Report #A0075340
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Nasopharyngeal Disorder							
	Nausea							
	Panic Attack							
	Weight Decreased							
			Ascriptin	C				
			Ranitidine Hydrochloride	C				
			Multivitamin	C				

Date:02/01/99ISR Number: 3404084-9Report Type:Periodic Company Report #A0075342
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK/ UNK/ ORAL	1 WK

Date:02/01/99ISR Number: 3404085-0Report Type:Periodic Company Report #A0075391
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Wellbutrin Tablet-Controlled					
	Tinnitus							

			Release	PS		ORAL

UNK/ UNK/

ORAL

Date:02/01/99ISR Number: 3404087-4Report Type:Periodic Company Report #A0075393
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Alopecia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL
			Sumatriptan Succinate	C		
			Midrin	C		
			Beclomethasone Dipropion	C		

Dose Duration

150 MG / PER

DAY / ORAL

Date:02/01/99ISR Number: 3404092-8Report Type:Periodic Company Report #A0075394
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dysgeusia	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL

Dose Duration

150 MG/ TWICE

PER DAY /

ORAL

Date:02/01/99ISR Number: 3404094-1Report Type:Periodic Company Report #A0075395
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY /	
	Headache							
	Pollakiuria							
			Librium	C				
			Venlafaxine Hydrochloride	C				

Date:02/01/99ISR Number: 3404096-5Report Type:Periodic Company Report #A0075412
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY /	
	Oedema Peripheral							
	Rash Pruritic							
	Urticaria							

ORAL

Date:02/01/99ISR Number: 3404098-9Report Type:Periodic Company Report #A0075523
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Health Professional	Wellbutrin Tablet-Controlled					

			Company	Release	PS		ORAL
150 MG /							
			Representative				
TWICE PER							
DAY/ ORAL							

Date:02/01/99ISR Number: 3404099-0Report Type:Periodic Company Report #A0075562
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Crying	Consumer	Wellbutrin			
	Depression		Tablet-Controlled			
	Emotional Disorder		Release	PS		ORAL
150 MG/ PER						
DAY/ ORAL						
			Vicodin	C		
			Lortab	C		

Date:02/01/99ISR Number: 3404101-6Report Type:Periodic Company Report #A0060122
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysphagia	Consumer	Wellbutrin Tablet	PS		ORAL
75 MG / TWICE						
	Insomnia					
PER DAY /						
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404102-8Report Type:Periodic Company Report #A0060151
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404103-XReport Type:Periodic Company Report #A0060169
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / THREE	
	Asthenia						TIMES PER DAY	
	Chest Discomfort						ORAL	4 YR
	Dyspnoea Exertional							
	Syncope							
	Tremor							

Date:02/01/99ISR Number: 3404104-1Report Type:Periodic Company Report #A0060197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Elevated Mood	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/ PER	
	Tremor						DAY/ ORAL	

Date:02/01/99ISR Number: 3404105-3Report Type:Periodic Company Report #A0060198
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Distension	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG /
	Constipation						TWICE PER DAY
	Insomnia						/ ORAL 6 WK
			Nicotine Patch	SS			TRANSDERMAL CONTINUOUS /
							TRANSDERMAL
			Antibiotics	C			

Date:02/01/99ISR Number: 3404106-5Report Type:Periodic Company Report #A0060321
Age:17 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL

Date:02/01/99ISR Number: 3404107-7Report Type:Periodic Company Report #A0060323
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Interaction	Health Professional Other	Wellbutrin (Formulation Unknown)	PS			
			Loestrin Tablet	SS		ORAL	VARIABLE DOSE
							/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404109-0Report Type:Periodic Company Report #A0060364
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Consciousness	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG / PER	DAY / ORAL 2 MON

Date:02/01/99ISR Number: 3404110-7Report Type:Periodic Company Report #A0060379
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
			Quetiapine Fumarate	C				

Date:02/01/99ISR Number: 3404111-9Report Type:Periodic Company Report #A0060393
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness Convulsion Corneal Oedema	Health Professional Other	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
			Amantadine Hydrochloride (Formulation Unknown)	SS				

Date:02/01/99ISR Number: 3404113-2Report Type:Periodic Company Report #A0060399
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health	Wellbutrin					

	Headache	Professional	(Formulation			
	Hypoaesthesia	Other	Unknown)	PS		ORAL

THREE TIMES

PER DAY /

ORAL 1 YR

Dexfenfluramine	C
Buspirone Hydrochloride	C
Phentermine	C
Fenfluramine Hcl	C
Conjugated Estrogens	C

Date:02/01/99ISR Number: 3404114-4Report Type:Periodic Company Report #A0060406
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dizziness	Consumer	Wellbutrin			
	Drug Ineffective	Health	(Formulation			
	Tinnitus	Professional	Unknown)	PS		ORAL

Dose Duration

150 MG /

Other

TWICE PER DAY

/ ORAL

Venlafaxine Hydrochloride (Formulation Unknown)	SS		ORAL

150 MG /

TWICE PER DAY

/ ORAL

Date:02/01/99ISR Number: 3404115-6Report Type:Periodic Company Report #A0060420
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	
	Insomnia							

Date:02/01/99ISR Number: 3404117-XReport Type:Periodic Company Report #A0060458
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet	PS		ORAL	1 TABLET/	TWICE PER DAY

/ ORAL

Date:02/01/99ISR Number: 3404118-1Report Type:Periodic Company Report #A0060620
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404119-3Report Type:Periodic Company Report #A0060666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dry Mouth	Health Professional Other	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL
			Nicotine (Formulation Unknown)	SS		2 MG	

Date:02/01/99ISR Number: 3404120-XReport Type:Periodic Company Report #A0060684
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / PER
	Hypersensitivity						DAY / ORAL
	Pruritus Urticaria		Ibuprofen	C			

Date:02/01/99ISR Number: 3404121-1Report Type:Periodic Company Report #A0060765
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pollakiuria	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404123-5Report Type:Periodic Company Report #A0060783
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404124-7Report Type:Periodic Company Report #A0060789
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemolytic Anaemia Thrombocytopenia	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404126-0Report Type:Periodic Company Report #A0060791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Hypersensitivity Urticaria	Consumer	Wellbutrin Tablet	PS		ORAL	100MG ORAL	

Date:02/01/99ISR Number: 3404128-4Report Type:Periodic Company Report #A0060836
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL	ORAL	3 WK

Date:02/01/99ISR Number: 3404129-6Report Type:Periodic Company Report #A0060856
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404130-2Report Type:Periodic Company Report #A0060910
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Wellbutrin Tablet	PS		ORAL	75MG TWICE	
	Headache						PER DAY ORAL	
	Insomnia							
	Lethargy							
	Weight Increased							

Date:02/01/99ISR Number: 3404131-4Report Type:Periodic Company Report #A0060916
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin					
	Hypersensitivity		(Formulation					
	Urticaria		Unknown)	PS		ORAL	100MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404133-8Report Type:Periodic Company Report #A0060979
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS				

Date:02/01/99ISR Number: 3404135-1Report Type:Periodic Company Report #A0060980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	
	Insomnia							

Date:02/01/99ISR Number: 3404136-3Report Type:Periodic Company Report #A0061002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Wellbutrin Tablet	PS		ORAL	100MG TWICE	
	Hypersensitivity						PER DAY ORAL	
	Irritability		Wellbutrin Tablet-Controlled Release	SS		ORAL	100MG TWICE	
	Urticaria						PER DAY ORAL	

Date:02/01/99ISR Number: 3404138-7Report Type:Periodic Company Report #A0061020
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet	PS		ORAL	75MG TWICE	

PRT DAY ORAL

Potassium Salt	C
Propranolol	C
Hydrochlorothiazide	C
Clonazepam	C

Date:02/01/99ISR Number: 3404139-9Report Type:Periodic Company Report #A0061055
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Health	Wellbutrin Tablet	PS		ORAL	75MG ORAL	
		Professional	Zyban Tablet - Zyban	SS		ORAL	150MG ORAL	
			Wellbutrin Tablet-Controlled Release	SS		ORAL	100MG ORAL	

Date:02/01/99ISR Number: 3404141-7Report Type:Periodic Company Report #A0061097
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Wellbutrin Tablet	PS		ORAL	150MG IN THE	
	Insomnia						MORNING ORAL	6 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404142-9Report Type:Periodic Company Report #A0061116
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Enzymes Increased Chest Pain	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	100MG TWICE PER DAY ORAL	

Date:02/01/99ISR Number: 3404144-2Report Type:Periodic Company Report #A0061208
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional	Wellbutrin Tablet	PS		ORAL	75MG PER DAY ORAL	3 DAY
	Vomiting							

Date:02/01/99ISR Number: 3404145-4Report Type:Periodic Company Report #A0061218
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness Tinnitus	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	200MG PER DAY ORAL	

Date:02/01/99ISR Number: 3404147-8Report Type:Periodic Company Report #A0061276
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Carpal Tunnel Syndrome	Health Professional	Wellbutrin Tablets	PS		ORAL	150MG TWICE	

	Middle Insomnia	Professional				
PER DAY ORAL						
	Pain In Extremity		Cefaclor	C		
	Paraesthesia					

Date:02/01/99ISR Number: 3404148-XReport Type:Periodic Company Report #A0061333
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
		Professional						

Date:02/01/99ISR Number: 3404149-1Report Type:Periodic Company Report #A0061385
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet	PS		ORAL	100MG TWICE	
PER DAY ORAL								

Date:02/01/99ISR Number: 3404151-XReport Type:Periodic Company Report #A0061393
Age:55 YR Gender:Male I/FU:I

Outcome	PT
	Abnormal Dreams
	Burning Sensation
	Flushing
	Pruritus

	Skin Irritation Sunburn Tenderness	Report Source	Product	Role	Manufacturer	Route Dose Duration
		Consumer	Wellbutrin Tablet	PS		ORAL 100MG THREE TIMES PER DAY ORAL
			Clonidine Hydrochloride Triamcinolone Acetonide Diazepam Excedrin	C C C C		

Date:02/01/99ISR Number: 3404152-1Report Type:Periodic Company Report #A0061422
Age:6 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Abnormal Behaviour	Consumer	Wellbutrin Tablet	PS		ORAL 75MG PER DAY
	Aggression Dissociation Mania					ORAL

Date:02/01/99ISR Number: 3404154-5Report Type:Periodic Company Report #A0061437
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Agitation	Consumer	Wellbutrin Tablet	PS		ORAL 75MG THREE
	Condition Aggravated Dizziness Headache Insomnia		Wellbutrin Tablet - Controlled Release	SS		TIMES PER DAY ORAL ORAL 300MG PER DAY

	Tobacco Abuse					
ORAL						

Date:02/01/99ISR Number: 3404187-9Report Type:Periodic Company Report #A0063431
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health	Wellbutrin Tablet	PS		ORAL	100 MG/PER	
	Speech Disorder	Professional					DAY/ORAL	
			Wellbutrin Tablet-Controlled Release	SS		ORAL	150 MG/TWICE PER DAY/ORAL	
			Thyroxine Sodium	C				

Date:02/01/99ISR Number: 3404188-0Report Type:Periodic Company Report #A0063438
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/ORAL	
	Insomnia		Semisodium Valproate	C				
	Nervousness		Clonazepam	C				
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404189-2Report Type:Periodic Company Report #A0063459
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Wellbutrin					
	Amnesia	Health	(Formulation					
	Arrhythmia	Professional	Unknown)	PS		ORAL	150 MG/TWICE	
	Chest Pain	Other					PER DAY/ORAL	
	Condition Aggravated		Dexfenfluramine					
	Crying		(Formulation					
	Depression		Unknown)	SS		ORAL	15 MG/TWICE	
	Diarrhoea						PER DAY/ORAL	
	Dyspnoea		Diltiazem					
	Emotional Disorder		Hydrochloride	C				
	Headache		Metoprolol Succinate	C				
	Nervousness							
	Neurosis							
	Oedema							
	Palpitations							
	Syncope							
	Tinnitus							

Date:02/01/99ISR Number: 3404190-9Report Type:Periodic Company Report #A0063512
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antinuclear Antibody	Health	Wellbutrin Tablet	PS		ORAL	ORAL	18 MON
	Fibromyalgia	Professional						

Date:02/01/99ISR Number: 3404192-2Report Type:Periodic Company Report #A0063851
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404193-4Report Type:Periodic Company Report #A0063558
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/TWICE	
	Insomnia						PER DAY/ORAL	2 MON
	Weight Increased		Estratest	C				
			Medroxyprogesterone Ace.	C				
			Thyroxine Sodium	C				
			Simvastatin	C				

Date:02/01/99ISR Number: 3404195-8Report Type:Periodic Company Report #A0063606
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health	Wellbutrin Tablet	PS		ORAL	ORAL	2 WK
		Professional	Fluoxetine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404197-1Report Type:Periodic Company Report #A0063658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Health	Wellbutrin					
	Amnesia	Professional	(Formulation					
	Dysphagia		Unknown)	PS		ORAL	ORAL	
	Dyspraxia		Semisodium Valproate	C				

Date:02/01/99ISR Number: 3404198-3Report Type:Periodic Company Report #A0063689
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Wellbutrin Tablet	PS		ORAL	150 MG/TWICE	
	Dyspnoea	Professional					PER DAY/ORAL	
	Insomnia		Nefazodone					
	Malaise		Hydrochloride	C				
	Muscle Spasms		Multivitamin	C				
	Nightmare							
	Tremor							
	Vomiting							

Date:02/01/99ISR Number: 3404201-0Report Type:Periodic Company Report #A0064071
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antibody Test Abnormal	Health	Wellbutrin Tablet	PS		ORAL	75 MG/THREE	
	Eosinophilia	Professional					TIMES PER	
	Leukopenia						DAY/ORAL	
	Neutropenia		Wellbutrin Tablet-Controlled Release	SS		ORAL	100 MG/THREE	

TIMES PER

DAY/ORAL

Date:02/01/99ISR Number: 3404202-2Report Type:Periodic Company Report #A0069599
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased	Consumer	Wellbutrin Tablet	PS		ORAL	PER DAY/ORAL	
			Sertraline Hydrochloride	C				
			Alprazolam	C				

Date:02/01/99ISR Number: 3404203-4Report Type:Periodic Company Report #A0069621
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
		Professional	Bupropion Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404205-8Report Type:Periodic Company Report #A0069626
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404206-XReport Type:Periodic Company Report #A0069628
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
		Professional Other	Hydroxyzine Hydrochloride	C				
			Thyroxine Sodium	C				

Date:02/01/99ISR Number: 3404208-3Report Type:Periodic Company Report #A0069666
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/TWICE PER DAY/ORAL	

Date:02/01/99ISR Number: 3404209-5Report Type:Periodic Company Report #A0069703
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404211-3Report Type:Periodic Company Report #A0069978
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG/TWICE	
		Health					PER DAY/ORAL	
		Professional	Humalog	C				
		Other	Int./Long-Acting Insulin	C				

Date:02/01/99ISR Number: 3404212-5Report Type:Periodic Company Report #A0070023
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excitability	Health	Wellbutrin					
		Professional	(Formulation					
		Other	Unknown)	PS		ORAL	ORAL	
			Fluoxetine Hydrochloride	C				
			Nortriptyline Hcl	C				
			Paroxetine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404213-7Report Type:Periodic Company Report #A0070124
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health	Wellbutrin Tablet	PS		ORAL	75	
	Menorrhagia	Professional					MG/VARIABLE	
	Menstruation Irregular						DOSE/ORAL	
	Pelvic Pain		Trazodone	C				
			Glucophage	C				
			Int./Long-Acting Insulin	C				
			Enalapril Maleate	C				
			Hydrochlorothiazide	C				
			Fluvastatin Sodium	C				
			Loratadine	C				
			Ibuprofen	C				

Date:02/01/99ISR Number: 3404214-9Report Type:Periodic Company Report #A0070125
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG/THREE	
	Insomnia						TIMES PER	
	Tobacco Abuse						DAY/ORAL	
			Wellbutrin Tablet-Controlled Release	SS		ORAL	150 MG/TWICE	
							PER DAY/ORAL	
			Thyroxine Sodium	C				

Date:02/01/99ISR Number: 3404215-0Report Type:Periodic Company Report #A0070170
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Discolouration	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404216-2Report Type:Periodic Company Report #A0070258
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Headache Sexual Dysfunction	Consumer	Wellbutrin Tablet Estrogen	PS C		ORAL		

Date:02/01/99ISR Number: 3404217-4Report Type:Periodic Company Report #A0070325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Insomnia	Consumer Health Professional Other	Wellbutrin (Formulation Unknown) Nicotine (Formulation Unknown)	PS SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404218-6Report Type:Periodic Company Report #A0070327
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer Health Professional Other	Wellbutrin (Formulation Unknown)	PS		ORAL		

Date:02/01/99ISR Number: 3404220-4Report Type:Periodic Company Report #A0070428
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer Health Professional Other	Wellbutrin (Formulation Unknown)	PS		ORAL		

Date:02/01/99ISR Number: 3404221-6Report Type:Periodic Company Report #A0070467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Wellbutrin Tablet	PS		ORAL	75 MG / TWICE PER DAY	
			Mirtazapine Tablet	SS		ORAL	50 MG / TWICE PER DAY	

Date:02/01/99ISR Number: 3404222-8Report Type:Periodic Company Report #A0070468
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperbilirubinaemia	Health Professional	Wellbutrin (Formulation					

			Unknown)	PS		ORAL

Date:02/01/99ISR Number: 3404223-XReport Type:Periodic Company Report #A0070658
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Serum Sickness	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL		

Date:02/01/99ISR Number: 3404224-1Report Type:Periodic Company Report #A0070703
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose	Health Professional Company Representative	Wellbutrin Tablet	PS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404225-3Report Type:Periodic Company Report #A0070706
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Apathy	Health	Wellbutrin Tablet 75					
	Dizziness	Professional	Mg	PS		ORAL	1.5 TABLET /	
	Drug Interaction						TWICE PER DAY	
	Headache		Dye Liquid	SS		TOPICAL		
			Thyroid Medication	C				

Date:02/01/99ISR Number: 3404227-7Report Type:Periodic Company Report #A0070731
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Wellbutrin					
		Health	(Formulation					
		Professional	Unknown)	PS		ORAL		
		Other	Nicotine					
			(Formulation					
			Unknown)	SS				

Date:02/01/99ISR Number: 3404228-9Report Type:Periodic Company Report #A0070732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Wellbutrin Tablet	PS		ORAL		
		Health	Nicotine					
		Professional	(Formulation					
		Other	Unknown)	SS				

Date:02/01/99ISR Number: 3404229-0Report Type:Periodic Company Report #A0070952
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Amyotrophy	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL 150 MG / TWICE PER DAY / ORAL
	Asthenia					
	Conversion Disorder					
	Convulsion					
	Hypoaesthesia					
	Livedo Reticularis		Zyban Tablet - Zyban	SS		ORAL 150 MG/ PER DAY/ ORAL
	Malaise					
	Nausea		Paroxetine Hydrochloride	C		
	Paralysis		Ipratropium Bromide	C		
	Peripheral Coldness		Budesonide	C		
	Peripheral Vascular Disorder		Pain Medication	C		
	Pulse Absent		Beclomethasone Dipropion	C		
	Speech Disorder					
	Transient Ischaemic Attack					
	Tremor					

Date:02/01/99ISR Number: 3404231-9Report Type:Periodic Company Report #A0070973
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Wellbutrin (Formulation					

Unknown) PS ORAL
100 MG /

TWICE PER DAY

Date:02/01/99ISR Number: 3404233-2Report Type:Periodic Company Report #A0071002
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Serum Sickness	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL		

Date:02/01/99ISR Number: 3404234-4Report Type:Periodic Company Report #A0071003
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Serum Sickness	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL		

Date:02/01/99ISR Number: 3404235-6Report Type:Periodic Company Report #A0071136
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tobacco Abuse	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	3	MON

Date:02/01/99ISR Number: 3404237-XReport Type:Periodic Company Report #A0071140
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gait Disturbance	Health Professional	Wellbutrin (Formulation Unknown)	PS		

Date:02/01/99ISR Number: 3404238-1Report Type:Periodic Company Report #A0071158
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Coeliac Disease Constipation Frequent Bowel Movements	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL

Date:02/01/99ISR Number: 3404240-XReport Type:Periodic Company Report #A0071363
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia Eructation	Consumer	Wellbutrin Tablet Ibuprofen Fexofenadine Hydrochlorid Deconamine	PS C C C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404242-3Report Type:Periodic Company Report #A0065290
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/PER	DAY/ORAL
	Photosensitivity Reaction							
	Pruritus		Lithium Salt	C				
			Aloe	C				
			Warfarin Sodium	C				
			Thyroxine Sodium	C				
			Vitamin	C				

Date:02/01/99ISR Number: 3404244-7Report Type:Periodic Company Report #A0065365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mastication Disorder	Health Professional	Wellbutrin (Formulation Unknown)	PS				
	Parosmia							

Date:02/01/99ISR Number: 3404245-9Report Type:Periodic Company Report #A0065413
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	150 MG/PER	DAY/ORAL

Date:02/01/99ISR Number: 3404247-2Report Type:Periodic Company Report #A0065484
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Muscle Rigidity	Health	Wellbutrin				
	Nervous System Disorder	Professional	(Formulation				
	Tardive Dyskinesia		Unknown)	PS			

Date:02/01/99ISR Number: 3404249-6Report Type:Periodic Company Report #A0065549
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin (Formulation Unknown)	PS				

Date:02/01/99ISR Number: 3404250-2Report Type:Periodic Company Report #A0066153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404252-6Report Type:Periodic Company Report #A0066252
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	20 MG/THREE TIMES PER DAY/ORAL	
	Dizziness	Health Professional						
	Dyspnoea							
		Other	Fenfluramine Hcl (Formulation Unknown)	SS		ORAL		
			Phentermine (Formulation Unknown)	SS				
			Nefazodone Hydrochloride (Formulation Unknown)	SS				
			Conjugated Estrogens	C				
			Conjugate Estrogens	C				

Date:02/01/99ISR Number: 3404253-8Report Type:Periodic Company Report #A0066345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative	Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
	Skin Disorder							

Date:02/01/99ISR Number: 3404277-0Report Type:Periodic Company Report #A0065450
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Wellbutrin Tablet	PS	ORAL

150 MG/PER

DAY/ORAL 2 MON

Ritonavir	C
Lamivudine	C
Saquinavir	C
Co-Trimoxazole	C

Date:02/01/99ISR Number: 3404278-2Report Type:Periodic Company Report #A0065469
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Insomnia	Consumer	Wellbutrin Tablet	PS		ORAL

Dose Duration

225 MG/TWICE

Nausea

PER DAY/ORAL

Tremor	Trazodone C
	Hydroxyzine C

Date:02/01/99ISR Number: 3404281-2Report Type:Periodic Company Report #A0065582
Age:50 YR Gender:Male I/FU:I

Outcome	PT
	Agitation
	Bruxism
	Depression
	Drug Interaction

Nervousness

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Wellbutrin Tablet	PS		ORAL
150 MG/PER DAY/ORAL						
			Fluoxetine (Formulation Unknown) 10 Mg	SS		ORAL
20 MG/THREE TIMES PER DAY/ORAL	3 YR					
			Anacin	C		

Date:02/01/99ISR Number: 3404283-6Report Type:Periodic Company Report #A0065745
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Arthralgia	Health	Wellbutrin Tablet	PS		ORAL
100 MG/TWICE PER DAY/ORAL						
	Back Pain	Professional				
	Neck Pain	Company Representative	Conjugated Estrogens Tablet	SS		ORAL
.625 MG/TWICE PER DAY/ORAL						

Date:02/01/99ISR Number: 3404285-XReport Type:Periodic Company Report #A0065866
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Alopecia	Consumer	Wellbutrin Tablet	PS		ORAL
75 MG/SEE TEXT/ORAL						
			Hydroxyurea	C		

				Aspirin	C		
				Lamotrigine	C		

Date:02/01/99ISR Number: 3404287-3Report Type:Periodic Company Report #A0066012
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin Tablet	PS		ORAL	TWICE PER DAY/ORAL	
			Lorazepam	C				

Date:02/01/99ISR Number: 3404289-7Report Type:Periodic Company Report #A0066022
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG/PER DAY/ORAL	9 MON

Date:02/01/99ISR Number: 3404290-3Report Type:Periodic Company Report #A0066032
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Wellbutrin Tablet	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
	Hyponatraemia	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404291-5Report Type:Periodic Company Report #A0066039
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG/PER	
	Headache						DAY/ORAL	
	Mental Impairment		Zyban Tablet-Zyban	SS		ORAL	150 MG/TWICE	
	Palpitations						PER DAY/ORAL	
	Tinnitus		Glipizide	C				
			Amlodipine	C				
			Simvastatin	C				
			Multivitamin	C				

Date:02/01/99ISR Number: 3404293-9Report Type:Periodic Company Report #A0066231
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG/TWICE	
	Excitability						PER DAY/ORAL	
			Alprazolam	C				

Date:02/01/99ISR Number: 3404295-2Report Type:Periodic Company Report #A0066294
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/TWICE	
	Hyperaesthesia						PER DAY/ORAL	

Date:02/01/99ISR Number: 3404297-6Report Type:Periodic Company Report #A0066317
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Wellbutrin Tablet	PS		ORAL	75 MG/THREE TIMES PER DAY/ORAL	
			Ascorbic Acid	C				
			Iron Salt	C				
			Multivitamin	C				
			Ginkgo Biloba	C				
			Fluoxetine Hydrochloride	C				

Date:02/01/99ISR Number: 3404310-6Report Type:Periodic Company Report #A0061567
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK / UNK /ORAL	
	Hypersensitivity							
	Oedema Peripheral							

Date:02/01/99ISR Number: 3404313-1Report Type:Periodic Company Report #A0061568
Age: Gender:Unknown I/FU:I

Outcome	PT
	Dermatitis
	Hypersensitivity

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK/ UNK/ ORAL	

Date:02/01/99ISR Number: 3404314-3Report Type:Periodic Company Report #A0061569
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Hypersensitivity Oedema Peripheral	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK / UNK/ ORAL	

Date:02/01/99ISR Number: 3404315-5Report Type:Periodic Company Report #A0061605
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Wellbutrin Tablet	PS		ORAL	2 TABLET / PER DAY / ORAL	
			Cephalexin	C				
			Hypericum	C				
			Multivitamin	C				

Date:02/01/99ISR Number: 3404317-9Report Type:Periodic Company Report #A0061642
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	150 MG / UNK / ORAL	

Date:02/01/99ISR Number: 3404320-9Report Type:Periodic Company Report #A0061646
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK / UNK / ORAL	

Date:02/01/99ISR Number: 3404322-2Report Type:Periodic Company Report #A0061660
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional	Wellbutrin Tablet	PS		ORAL	37.5 MG / TWICE PER DAY/ ORAL	
	Leukopenia		Fluoxetine Hydrochloride (Formulation					

Unknown) SS ORAL
20 MG / PER

DAY/ ORAL

Date:02/01/99ISR Number: 3404324-6Report Type:Periodic Company Report #A0061763
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK / UNK / ORAL	

Date:02/01/99ISR Number: 3404326-XReport Type:Periodic Company Report #A0061766
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	300 MG / PER DAY / ORAL	
			Fluoxetine Hydrocholoride	C				

Date:02/01/99ISR Number: 3404328-3Report Type:Periodic Company Report #A0061809
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Wellbutrin Tablet	PS		ORAL	75 MG / PER DAY / ORAL	

Date:02/01/99ISR Number: 3404333-7Report Type:Periodic Company Report #A0063405
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea Vertigo	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	3 WK

Date:02/01/99ISR Number: 3404336-2Report Type:Periodic Company Report #A0062874
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Insomnia Mental Disorder	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	150 MG/ PER DAY / ORAL	
	Nausea							
	Nightmare		Methylphenidate Hcl	C				

Date:02/01/99ISR Number: 3404338-6Report Type:Periodic Company Report #A0062964
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404339-8Report Type:Periodic Company Report #A0062965
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatitis	Health Professional	Wellbutrin (Formulation Unknown)	PS				

Date:02/01/99ISR Number: 3404343-XReport Type:Periodic Company Report #A0062966
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Metrorrhagia	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL		ORAL

Date:02/01/99ISR Number: 3404345-3Report Type:Periodic Company Report #A0062968
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL		ORAL
			Sertraline Hydrochloride	C				

Date:02/01/99ISR Number: 3404348-9Report Type:Periodic Company Report #A0062986
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation Memory Impairment	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	100 MG/	

TWICE PER

DAY/ ORAL

Date:02/01/99ISR Number: 3404355-6Report Type:Periodic Company Report #A0062999
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health	Wellbutrin					
	Photosensitivity Reaction	Professional	(Formulation					
			Unknown)	PS		ORAL	150 MG/ PER	
							DAY/ ORAL	
			Amlodipine	C				
			Aspirin	C				

Date:02/01/99ISR Number: 3404356-8Report Type:Periodic Company Report #A0063824
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health	Wellbutrin					
		Professional	(Formulation					
			Unknown)	PS			75 MG/ TWICE	
							PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404358-1Report Type:Periodic Company Report #A0063838
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	150 MG / PER DAY / ORAL	
			Vicodin	C				
			Clonazepam	C				

Date:02/01/99ISR Number: 3404359-3Report Type:Periodic Company Report #A0063228
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Influenza Like Illness Pharyngolaryngeal Pain	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
			Sertraline Hydrochloride	C				

Date:02/01/99ISR Number: 3404362-3Report Type:Periodic Company Report #A0063229
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Hypersensitivity Insomnia Night Sweats Pain Pruritus Stevens-Johnson Syndrome Swelling	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404363-5Report Type:Periodic Company Report #A0062890
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health	Wellbutrin Tablet	PS		ORAL	PER DAY /	
	Gingival Bleeding	Professional						
ORAL							1	YR
	Platelet Count Decreased	Company Representative						

Date:02/01/99ISR Number: 3404365-9Report Type:Periodic Company Report #A0062891
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health	Wellbutrin Tablet	PS		ORAL	PER DAY/ ORAL	3 MON
	Gingival Bleeding	Professional						
	Platelet Count Decreased	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404366-0Report Type:Periodic Company Report #A0062969
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Health Professional	Wellbutrin Tablet	PS		ORAL	350 MG/ PER DAY/ ORAL	

Date:02/01/99ISR Number: 3404368-4Report Type:Periodic Company Report #A0063094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/ PER DAY/ ORAL	1 WK
			Lithium Salt	C				

Date:02/01/99ISR Number: 3404370-2Report Type:Periodic Company Report #A0063128
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional	Wellbutrin Tablet	PS		ORAL	ORAL	
	International Normalised Ratio Increased	Company Representative Other	Warfarin Sodium Tablet	SS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404372-6Report Type:Periodic Company Report #A0063269
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404373-8Report Type:Periodic Company Report #A0063321
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Motor Dysfunction	Health	Wellbutrin Tablet	PS		ORAL	100 MG/ TWICE	
		Professional					PER DAY/ ORAL	
		Company Representative						

Date:02/01/99ISR Number: 3404375-1Report Type:Periodic Company Report #A0063338
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/ TWICE	
	Dry Mouth						PER DAY/ ORAL	
	Emotional Disorder		Wellbutrin Tablet-Controlled Release	SS		ORAL	150 MG/ TWICE	
	Insomnia						PER DAY/ ORAL	
			Hyoscyamine Sulphate	C				
			Tamsulosin Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404560-9Report Type:Periodic Company Report #A0074188
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vitiligo	Consumer	Lamictal Tablet	PS		ORAL	UNK/UNK/ORAL	2 YR
			Wellbutrin Tablet-Controlled Release	SS		ORAL	450 MG/PER DAY/ORAL	3 MON
			Methylphenidate Hcl	C				
			Gabapentin	C				

Date:02/01/99ISR Number: 3404602-0Report Type:Periodic Company Report #A0073972
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
			Amlodipine	C				
			Multiple Medication	C				

Date:02/01/99ISR Number: 3404604-4Report Type:Periodic Company Report #A0060062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Wellbutrin (Formulatin Unknown)	PS		ORAL	ORAL	
	Pain							
	Urinary Tract Infection							

Date:02/01/99ISR Number: 3404606-8Report Type:Periodic Company Report #A0060069
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coordination Abnormal Hypoaesthesia Pyrexia Tachycardia Vomiting	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	200 MG/PER DYA /ORAL	

Date:02/01/99ISR Number: 3404608-1Report Type:Periodic Company Report #A0060083
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	100 MG / TWICE PER DAY / ORAL	
			Alprazolam	C				

Date:02/01/99ISR Number: 3404610-XReport Type:Periodic Company Report #A0073393
Age:45 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Wellbutrin (Formulation					

			Unknown)	PS		ORAL
ORAL						

Date:02/01/99ISR Number: 3404614-7Report Type:Periodic Company Report #A0073396
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tic	Health	Wellbutrin			
	Tremor	Professional	(Formulation			
			Unknown)	PS		ORAL
300 MG /PER						
DAY /ORAL						
			Paroxetine			
			Hydrochloride	C		

Date:02/01/99ISR Number: 3404616-0Report Type:Periodic Company Report #A0073521
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Wellbutrin			
	Dizziness		(Formulation			
	Panic Reaction		Unknown)	PS		ORAL
ORAL						
	Urticaria					

Date:02/01/99ISR Number: 3404618-4Report Type:Periodic Company Report #A0073555
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Metrorrhagia	Consumer	Wellbutrin			
			(Formulation			
			Unknown)	PS		ORAL
ORAL						

Date:02/01/99ISR Number: 3404619-6Report Type:Periodic Company Report #A0073664
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Irritability	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404621-4Report Type:Periodic Company Report #A0073738
Age:18 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Health Professional	Wellbutrin (Formulatin Unknown)	PS		ORAL	300 MG / PER DAY / ORAL	
			Multiple Medication	C				

Date:02/01/99ISR Number: 3404623-8Report Type:Periodic Company Report #A0073782
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	100 MG /TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404626-3Report Type:Periodic Company Report #A0059499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS				

Date:02/01/99ISR Number: 3404627-5Report Type:Periodic Company Report #A0059970
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcohol Interaction Convulsion	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
			Ethanol (Formulation Unknown)	SS				

Date:02/01/99ISR Number: 3404628-7Report Type:Periodic Company Report #A0059972
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Wellbutrin (Formulation Unknown)	PS			YR	

Date:02/01/99ISR Number: 3404629-9Report Type:Periodic Company Report #A0059974
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Hypoaesthesia Paraesthesia	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	300 MG /PER	

DAY / ORAL

Date:02/01/99ISR Number: 3404631-7Report Type:Periodic Company Report #A0059464
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin Tablet	PS			75 MG / PER	
	Influenza Like Illness						DAY / ORAL	5 DAY
	Tremor		Docusate	C				
	Visual Disturbance							

Date:02/01/99ISR Number: 3404632-9Report Type:Periodic Company Report #A0059980
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG /PER	
							DAY /ORAL	
			Blood Pressure Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404634-2Report Type:Periodic Company Report #A0059987
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Wellbutrin Tablet	PS		ORAL	300 MG /PER	
	Urticaria						DAY / ORAL	
			Wellbutrin Tablet-Controlled Release	SS		ORAL	300 MG /PER	DAY / ORAL
			Birth Control	C				

Date:02/01/99ISR Number: 3404636-6Report Type:Periodic Company Report #A0073945
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG /PER	
	Confusional State						DAY/ ORAL	
	Dry Mouth		Paroxetine Hydrochloride	C				
	Headache							
	Insomnia							
	Nausea							
	Nightmare							
	Visual Acuity Reduced							

Date:02/01/99ISR Number: 3404637-8Report Type:Periodic Company Report #A0073958
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance		Wellbutrin Tablet	PS		ORAL	THREE TIMES	
							PER DAY/ORAL	
			Semisodium Valproate	C				

			Fluticasone Propionate	C		
			Beclomethasone Dipropion	C		

Date:02/01/99ISR Number: 3404639-1Report Type:Periodic Company Report #A0074208
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG/	TWICE PER DAY/ ORAL
	Insomnia							
			Piroxicam	C				

Date:02/01/99ISR Number: 3404641-XReport Type:Periodic Company Report #A0074256
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional	Wellbutrin Tablet	PS		ORAL	100 MG /	TWICE PER DAY/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404643-3Report Type:Periodic Company Report #A0074390
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Wellbutrin Tablet	PS		ORAL	150 MG/ THREE	
	Primary Cerebellar Degeneration	Professional					TIMES PER DAY	ORAL
	Tremor		Lithium Salt (Formulation Unknown)	SS				

Date:02/01/99ISR Number: 3404645-7Report Type:Periodic Company Report #A0074422
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Wellbutrin Tablet	PS		ORAL	75 MG/ THREE	
	Dermatitis	Professional					TIMES PER	
	Pruritus						DAY/ ORAL	
	Rash Maculo-Papular		Clonazepam	C				
			Dexamphetamine Sulphate	C				

Date:02/01/99ISR Number: 3404646-9Report Type:Periodic Company Report #A0074827
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Health	Wellbutrin Tablet	PS		ORAL	75 MG/ THREE	
		Professional					TIMES PER DAY	
		Company					/ ORAL	
		Representative	Risperidone	C				

Date:02/01/99ISR Number: 3404648-2Report Type:Periodic Company Report #A0074909
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG/ TWICE PER DAY/	
	Paraesthesia							
			Amitriptyline Hcl	C				

Date:02/01/99ISR Number: 3404649-4Report Type:Periodic Company Report #A0074910
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG/ ORAL	
	Drug Ineffective		Methylphenidate Hcl	C				
	Tic							

Date:02/01/99ISR Number: 3404651-2Report Type:Periodic Company Report #A0075056
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Wellbutrin Tablet	PS		ORAL	100 MG/ TWICE PER DAY /	
	Fatigue	Professional						
	Rhabdomyolysis						ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404652-4Report Type:Periodic Company Report #A0075307
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fear	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG/ PER	
	Hyperhidrosis						DAY/ ORAL	
			Sertraline Hydrochloride	C				

Date:02/01/99ISR Number: 3404653-6Report Type:Periodic Company Report #A0075343
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG/ THREE	
							TIMES PER DAY	
							ORAL	
			Zyban Tablet - Zyban	SS		ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	
			Amoxycillin	C				
			Prednisone	C				
			Acyclovir	C				
			Salbutemol Sulphate	C				
			Ipratropium Bromide	C				
			Diazepam	C				

Date:02/01/99ISR Number: 3404660-3Report Type:Periodic Company Report #A0074234
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional Company	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

			Representative	Zyban Tablet - Zyban	C		ORAL
150 MG/ ORAL							

Date:02/01/99ISR Number: 3404661-5Report Type:Periodic Company Report #A0074237
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety	Health	Wellbutrin			
	Dysgeusia	Professional	(Formulation			
		Company	Unknown)	PS		ORAL
150 MG/ ORAL						
		Representative	Zyban Tablet - Zyban	SS		ORAL
150 MG/ TWICE						
PER DAY/ ORAL						

Date:02/01/99ISR Number: 3404663-9Report Type:Periodic Company Report #A0074391
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Wellbutrin			
	Tremor	Professional	(Formulation			
			Unknown)	PS		ORAL
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404664-0Report Type:Periodic Company Report #A0074393
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Hypoaesthesia Oral Miosis	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:02/01/99ISR Number: 3404665-2Report Type:Periodic Company Report #A0074512
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysmenorrhoea	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3404668-8Report Type:Periodic Company Report #A0074709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
		Other	Nicotine	C				

Date:02/01/99ISR Number: 3404669-XReport Type:Periodic Company Report #A0074823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous Urticaria	Health Professional	Wellbutrin (Formulation Unknown)	PS				

			Nicotine Patch	SS		
TOPICAL	21 MG TOPICAL					

Date:02/01/99ISR Number: 3404670-6Report Type:Periodic Company Report #A0074908
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia Areata	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL
ORAL 2 WK						
			Nicotine	C		

Date:02/01/99ISR Number: 3404671-8Report Type:Periodic Company Report #A0075085
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Lymphoproliferative Disorder	Health Professional	Wellbutrin (Formulation Unknown)	PS		
			Sertraline Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3404673-1Report Type:Periodic Company Report #A0075264
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405406-5Report Type:Periodic Company Report #A0058693
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG/	
	Apathy						SINGLE DOSE/	
	Hallucination						ORAL	
	Hypoaesthesia		Paroxetine Hydrochloride	C				
	Nausea		Alprazolam	C				
	Paranoia		Ethanol	C				
	Tremor							

Date:02/01/99ISR Number: 3405408-9Report Type:Periodic Company Report #A0058828
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/PER	
	Influenza Like Illness						DAY/ ORAL	
	Insomnia							
	Tremor							

Date:02/01/99ISR Number: 3405410-7Report Type:Periodic Company Report #A0058930
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aortic Valve Incompetence	Health	Wellbutrin Tablet	PS		ORAL	SEE TEXT/ORAL	
	Cardiac Valve Disease Mitral Valve Incompetence Palpitations	Professional Other	Phentermine (Formulation Unknown)	SS		ORAL	VARIABLE	
	Tricuspid Valve Incompetence		Fenfluramine Hcl (Formulation Unknown)	SS		ORAL	20 MG/ THREE TIMES PER DAY/ ORAL	
			Dexfenfluramine Capsule	SS		ORAL	15 MG/ TWICE PER DAY/ ORAL	
			Phentermine Hydrochloride (Formulation Unknown)	SS		ORAL	30 MG/ PER DAY/ ORAL	

Date:02/01/99ISR Number: 3405411-9Report Type:Periodic Company Report #A0058964
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia Urticaria	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3405412-0Report Type:Periodic Company Report #A0058976
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	
	Pain In Extremity		Nefazodone Hydrochloride	C				
			Loratadine	C				

Date:02/01/99ISR Number: 3405413-2Report Type:Periodic Company Report #A0058989
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG, TWICE	
	Dizziness						PER DAY, ORAL	
	Dry Mouth							
	Elevated Mood							
	Insomnia							
	Nightmare							
	Sedation							

Date:02/01/99ISR Number: 3405416-8Report Type:Periodic Company Report #A0059236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Health	Wellbutrin Tablet	PS		ORAL	75 MG, TWICE	
	Premature Ejaculation	Professional					PER DAY, ORAL	
		Company Representative						

Date:02/01/99ISR Number: 3405417-XReport Type:Periodic Company Report #A0059285
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG, THREE	
	Vomiting						TIMES PER	
							DAY, ORAL	
			Alprazolam	C				
			Zolpidem Tartrate	C				

Date:02/01/99ISR Number: 3405419-3Report Type:Periodic Company Report #A0059444
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG, PER	
							DAY, ORAL	
			Fluoxetine Hydrochloride	C				
			Clonazepam	C				

Date:02/01/99ISR Number: 3405420-XReport Type:Periodic Company Report #A0059370
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Wellbutrin					
	International Normalised Ratio Increased	Professional Other	(Formulation Unknown)	PS		ORAL	ORAL	

			Warfarin Sodium (Formulation Unknown)	SS		

Date:02/01/99ISR Number: 3405421-1Report Type:Periodic Company Report #A0059383
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405422-3Report Type:Periodic Company Report #A0059390
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405424-7Report Type:Periodic Company Report #A0059392
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405425-9Report Type:Periodic Company Report #A0059414
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Wellbutrin					
	Blood Pressure Decreased	Health	(Formulation					
	Irritability	Professional	Unknown)	PS		ORAL	150 MG, THREE	
	Personality Disorder	Other					TIMES PER	
							DAY, ORAL	5 MON
			Propranolol	C				

Date:02/01/99ISR Number: 3405427-2Report Type:Periodic Company Report #A0059440
Age:52 YR Gender:Female I/FU:I

Outcome	PT
	Anxiety
	Arthralgia
	Chest Pain
	Cough
	Dyspnoea
	Haemorrhage
	Hallucination, Auditory
	Influenza Like Illness
	Insomnia
	Joint Stiffness
	Lethargy

	Muscle Disorder Myalgia Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Palpitations Panic Disorder Pruritus	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL
100 MG, TWICE						
	Rash Generalised					
PER DAY, ORAL						
	Tremor Weight Decreased		Amitriptyline Hcl	C		
			Lorazepam	C		
			Thyroxine Sodium	C		
			Conjugated Estrogens	C		

Date:02/01/99ISR Number: 3405429-6Report Type:Periodic Company Report #A0059259
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Liver Function Test Abnormal	Health Professional Company	Wellbutrin (Formulation Unknown)	PS		ORAL
ORAL		Representative				

Date:02/01/99ISR Number: 3405431-4Report Type:Periodic Company Report #A0059280
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective Weight Increased	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL
ORAL						
			Paroxetine Hydrochloride	C		
			Sertraline Hydrochloride	C		
			Fluoxetine Hydrochloride	C		
			Buspirone Hydrochloride	C		

			Lorazepam	C		
			Dalmane	C		
			Simvastatin	C		
			Famotidine	C		
			Loratadine	C		
			Docusate Sodium	C		

Date:02/01/99ISR Number: 3405432-6Report Type:Periodic Company Report #A0059171
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
		Other	Alprazolam	C				
			Buspirone Hydrochloride	C				
			Temazepam	C				
			Lansoprazole	C				
			Frusemide	C				
			Zolpidem Tartrate	C				
			Potassium Salt	C				

Nortriptyline Hcl	C
Lortab	C
Sertraline Hydrochloride	C
Ipratropium Bromide	C
Salbutamol Sulphate	C
Acetylcysteine	C
Ibuprofen	C

Date:02/01/99ISR Number: 3405433-8Report Type:Periodic Company Report #A0058684
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
			Lithium Salt	C				

Date:02/01/99ISR Number: 3405435-1Report Type:Periodic Company Report #A0058791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405437-5Report Type:Periodic Company Report #A0057573
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excitability	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG / TWICE PER DAY / ORAL	

Omeprazole	C
Dyazide	C
Lorazepam	C

Date:02/01/99ISR Number: 3405438-7Report Type:Periodic Company Report #A0057770
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG / TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3405439-9Report Type:Periodic Company Report #A0058424
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Drug Ineffective Libido Decreased	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3405440-5Report Type:Periodic Company Report #A0058144
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405441-7Report Type:Periodic Company Report #A0058264
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405442-9Report Type:Periodic Company Report #A0058325
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Testicular Swelling	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	3 WK

Date:02/01/99ISR Number: 3405443-0Report Type:Periodic Company Report #A0058496
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405444-2Report Type:Periodic Company Report #A0058604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	18 MON
	Dry Mouth							
	Ecchymosis							
	Keratoconjunctivitis							
	Sicca							

Date:02/01/99ISR Number: 3405445-4Report Type:Periodic Company Report #A0058667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Other	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
			Warfarin Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3405446-6Report Type:Periodic Company Report #A0058578
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperproteinaemia	Health	Wellbutrin Tablet	PS		ORAL	150 MG / PER	
	Insomnia	Professional					DAY / ORAL	
	Jaundice							
	Muscle Spasms							
	Oedema Peripheral							
	Pharyngeal Oedema							
	Urticaria							

Date:02/01/99ISR Number: 3405448-XReport Type:Periodic Company Report #A0058427
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	
	Nausea		Wellbutrin Tablet-Controlled Release	SS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405449-1Report Type:Periodic Company Report #A0058326
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG / TWICE PER DAY / ORAL	
			Cimetidine	C				
			Clonidine Hydrochloride	C				

Date:02/01/99ISR Number: 3405451-XReport Type:Periodic Company Report #A0058410
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Hyperhidrosis							
	Insomnia							
	Nausea							

Date:02/01/99ISR Number: 3405452-1Report Type:Periodic Company Report #A0058418
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Wellbutrin Tablet	PS		ORAL	150 MG/ IN THE MORNING / ORAL	

Date:02/01/99ISR Number: 3405453-3Report Type:Periodic Company Report #A0057844
Age: Gender:Female I/FU:I

Outcome	PT
	Agitation
	Crying
	Depression
	Disorientation

	Dizziness					
	Dry Mouth					
	Tinnitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Urticaria	Consumer	Wellbutrin Tablet	PS		ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						
			Guaiphenesin	C		
			Ibuprofen	C		

Date:02/01/99ISR Number: 3405454-5Report Type:Periodic Company Report #A0057934
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Insomnia	Health	Wellbutrin Tablet	PS		ORAL
150 MG /						
	Tremor	Professional				
TWICE PER DAY						
	Vaginal Haemorrhage					
/ ORAL						

Date:02/01/99ISR Number: 3405455-7Report Type:Periodic Company Report #A0057991
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Erectile Dysfunction	Consumer	Wellbutrin Tablet	PS		ORAL
150 MG /						
THREE TIMES						
DA / ORAL						
			Donepezil Hcl	C		

Date:02/01/99ISR Number: 3405456-9Report Type:Periodic Company Report #A0058002
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG /	
	Anxiety						THREE TIMES	
	Arthralgia						PER DA / ORAL	
	Asthenia							
	Chest Pain							
	Dizziness							
	Faecal Incontinence							
	Insomnia							
	Malaise							
	Movement Disorder							
	Nausea							
	Tongue Ulceration							

Date:02/01/99ISR Number: 3405457-0Report Type:Periodic Company Report #A0058044
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Health	Wellbutrin Tablet	PS		ORAL	100 MG /	
	Ear Disorder	Professional					THREE TIMES	
							DA / ORAL	
			Gabapentin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3405458-2Report Type:Periodic Company Report #A0058296
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Simvastatin	C				
			M.V.I.	C				

Date:02/01/99ISR Number: 3405459-4Report Type:Periodic Company Report #A0075392
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / TWICE PER DAY / ORAL	
			Clonazepam	C				

Date:02/01/99ISR Number: 3405461-2Report Type:Periodic Company Report #A0075566
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Wellbutrin Tablet	PS		ORAL	75 MG / PER DAY / ORAL	

Date:02/01/99ISR Number: 3405462-4Report Type:Periodic Company Report #A0075605
Age:13 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Wellbutrin Tablet	PS		ORAL	75 MG / SEE	
	Chest Pain	Professional					TEXT / ORAL	

Date:02/01/99ISR Number: 3405464-8Report Type:Periodic Company Report #A0075938
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
		Professional	Wellbutrin Tablet-Controlled Release	SS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405465-XReport Type:Periodic Company Report #A0075991
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Health	Wellbutrin Tablet	PS		ORAL	75 MG/ TWICE	
	Tic	Professional					PER DAY /	
ORAL								6 MON
			Dexamphetamine Sulphate (Formulation Unknown)	SS		ORAL	2.5 MG / AT	
							NIGHT/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3405466-1Report Type:Periodic Company Report #A0076190
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG / TWICE PER DAY	/ ORAL

Date:02/01/99ISR Number: 3405467-3Report Type:Periodic Company Report #A0076523
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / PER DAY	/ ORAL
	Drug Interaction							
	Influenza Like Illness		Adderall	C				

Date:02/01/99ISR Number: 3405469-7Report Type:Periodic Company Report #A0078107
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Wellbutrin Tablet	PS		ORAL	150 MG / ORAL	

Date:02/01/99ISR Number: 3405470-3Report Type:Periodic Company Report #A0078280
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Wellbutrin Tablet	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405471-5Report Type:Periodic Company Report #A0078281
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
		Professional	Wellbutrin Tablet-Controlled Release	SS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405472-7Report Type:Periodic Company Report #A0078531
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / TWICE PER DAY/ ORAL	
	Dizziness							
	Drug Interaction		Guaiphenesin (Formulation Unknown)	SS				
			Guaiphenesin Caplet	SS		ORAL	ORAL	
			Nicotine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3405474-0Report Type:Periodic Company Report #A0078282
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405475-2Report Type:Periodic Company Report #A0078111
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405477-6Report Type:Periodic Company Report #A0077288
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405478-8Report Type:Periodic Company Report #A0076083
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mydriasis	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3405480-6Report Type:Periodic Company Report #A0076150
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin					
		Health Professional	(Formulation Unknown)	PS		ORAL	ORAL	
		Other	Nicotine	C				

Date:02/01/99ISR Number: 3405481-8Report Type:Periodic Company Report #A0075414
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Wellbutrin					
		Health Professional	(Formulation Unknown)	PS		ORAL	ORAL	
		Other	Nicotine	C				

Date:02/01/99ISR Number: 3405483-1Report Type:Periodic Company Report #A0075507
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Palpitations	Health Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL

Date:02/01/99ISR Number: 3405484-3Report Type:Periodic Company Report #A0075512
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Creatinine Renal Clearance Urinary Casts	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL
			Famotidine	C			
			Atorvastatin Calcium	C			
			Atenolol	C			
			Aspirin	C			

Date:02/01/99ISR Number: 3410842-7Report Type:Periodic Company Report #A0068113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Inappropriate Antidiuretic Hormone Secretion	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL
			Diuretic	C			

Date:02/01/99ISR Number: 3410864-6Report Type:Periodic Company Report #A0068255
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia	Consumer Health	Wellbutrin (Formulation				

		Professional	Unknown)	PS		ORAL
ORAL						
		Other	Lithium Salt (Formulation Unknown)	SS		
			Nicotine (Formulation Unknown)	SS		

Date:02/01/99ISR Number: 3410867-1Report Type:Periodic Company Report #A0068377
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Micturition Urgency	Health	Wellbutrin			
	Urinary Retention	Professional	(Formulation			
		Company	Unknown)	PS		
2 WK						
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3410870-1Report Type:Periodic Company Report #A0068401
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
	Derealisation							
	Disorientation							

Date:02/01/99ISR Number: 3410872-5Report Type:Periodic Company Report #A0068402
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/TWICE PER DAY/ORAL	
	Cough							
	Dyspnoea							
	Gastrointestinal Disorder							
	Pain In Extremity							
	Tinnitus							

Date:02/01/99ISR Number: 3410875-0Report Type:Periodic Company Report #A0068404
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Consumer	Wellbutrin Tablet	PS		ORAL	TWICE PER DAY/ORAL	
			Lorazepam	C				
			Betaxolol Hydrochloride	C				
			Clonazepam	C				

Date:02/01/99ISR Number: 3410878-6Report Type:Periodic Company Report #A0068439
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/TWICE	PER DAY/ORAL
			Isosorbide	C				
			Nitroglycerin	C				
			Loratadine	C				
			Lansoprazole	C				
			Atenolol	C				
			Amlodipine	C				
			Estropipate	C				
			Medroxyprogesterone Ace.	C				
			Clonazepam	C				

Date:02/01/99ISR Number: 3410880-4Report Type:Periodic Company Report #A0068797
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Testicular Pain	Health Professional	Wellbutrin Tablet	PS		ORAL	150 MG/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3410887-7Report Type:Periodic Company Report #A0068810
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG/THREE	
	Rash Erythematous						TIMES PER	
	Rash Vesicular						DAY/ORAL	
			Lamictal Tablet	SS		ORAL	75 MG/PER	
							DAY/ORAL	
			Nortriptyline	C				
			Thyroid Medication	C				
			Methylphenidate Hcl	C				
			M.V.I	C				
			Lansoprazole	C				
			Sucralfate	C				

Date:02/01/99ISR Number: 3410891-9Report Type:Periodic Company Report #A0068886
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
	Hypoaesthesia	Professional						

Date:02/01/99ISR Number: 3410893-2Report Type:Periodic Company Report #A0068923
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Wellbutrin Tablet	PS		ORAL	150 MG/ORAL	
		Professional						

Date:02/01/99ISR Number: 3410894-4Report Type:Periodic Company Report #A0068969
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG/PER	
	Dysphagia						DAY/ORAL	
	Hypoglycaemia							
	Insomnia							
	Muscle Rigidity							
	Swelling							

Date:02/01/99ISR Number: 3410897-XReport Type:Periodic Company Report #A0069031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	
	Tachycardia							

Date:02/01/99ISR Number: 3410899-3Report Type:Periodic Company Report #A0069238
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	1 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3410901-9Report Type:Periodic Company Report #A0069270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	6 DAY

Date:02/01/99ISR Number: 3410904-4Report Type:Periodic Company Report #A0069271
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health	Wellbutrin Tablet	PS		ORAL	1 TABLET/PER	
	Tremor	Professional					DAY/ORAL	

Date:02/01/99ISR Number: 3410905-6Report Type:Periodic Company Report #A0069302
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG/ORAL	
	Pollakiuria		Pemoline	C				

Date:02/01/99ISR Number: 3410906-8Report Type:Periodic Company Report #A0069304
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG/TWICE	
	Nausea						PER DAY/ORAL	

Date:02/01/99ISR Number: 3410909-3Report Type:Periodic Company Report #A0069317
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	150 MG/ORAL	

Date:02/01/99ISR Number: 3410910-XReport Type:Periodic Company Report #A0069408
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood	Consumer Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	150 MG/PER	
		Other					DAY/ORAL	

Date:02/01/99ISR Number: 3410915-9Report Type:Periodic Company Report #A0064376
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test Abnormal	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3410918-4Report Type:Periodic Company Report #A0064394
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
	Feeling Abnormal							
	Formication							

Date:02/01/99ISR Number: 3410919-6Report Type:Periodic Company Report #A0064538
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL		
	Muscle Twitching		Paroxetine Hydrochloride	SS				

Date:02/01/99ISR Number: 3410921-4Report Type:Periodic Company Report #A0064593
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excitability	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3410923-8Report Type:Periodic Company Report #A0064667
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / PER	

	Dizziness						
DAY / ORAL							
	Paraesthesia			Muscle Relaxant	C		
				Pain Medication	C		

Date:02/01/99ISR Number: 3410925-1Report Type:Periodic Company Report #A0064749
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Wellbutrin					
	Haemorrhage	Professional	(Formulation					
	Prothrombin Time		Unknown)	PS		ORAL		
ORAL								
	Prolonged		Warfarin Sodium	SS				

Date:02/01/99ISR Number: 3410927-5Report Type:Periodic Company Report #A0064754
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Wellbutrin					
	Aphasia	Professional	(Formulation					
	Dysphemia		Unknown)	PS		ORAL		
100 MG /								
	Irritability							
THREE TIME								
PER DAY /								
ORAL								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3410929-9Report Type:Periodic Company Report #A0064798
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL		
			Fluoxetine Hydrochloride	C				

Date:02/01/99ISR Number: 3410931-7Report Type:Periodic Company Report #A0064799
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health Professional	Wellbutrin Tablet	PS		ORAL	37.5 MG / PER	DAY / ORAL
	Hypoaesthesia Oral							
	Muscle Spasms		Verapamil Hydrochloride	C				
	Muscle Twitching		Lisinopril	C				
	Paraesthesia		Aspirin	C				
			Zolpidem Tartrate	C				
			Sulphasalazine	C				
			Vitamin E	C				

Date:02/01/99ISR Number: 3410933-0Report Type:Periodic Company Report #A0064805
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Uterine Haemorrhage	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS				

Date:02/01/99ISR Number: 3410934-2Report Type:Periodic Company Report #A0064824
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG /	
	Arthralgia						THREE TIMES	
	Bladder Pain						PER DAY /	
	Breast Engorgement						ORAL	
	Chondropathy		Multivitamin	C				
	Dyspnoea		Conjugated Estrogens	C				
	Fatigue							
	Hormone Level Abnormal							
	Hypertension							
	Joint Swelling							
	Myalgia							
	Oedema Peripheral							
	Pruritus							
	Tachycardia							
	Vaginal Pain							
	Vulvovaginal Dryness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3410938-XReport Type:Periodic Company Report #A0064866
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional	Wellbutrin Tablet	PS		ORAL	ORAL	1 MON

Date:02/01/99ISR Number: 3410939-1Report Type:Periodic Company Report #A0065000
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Tablet	PS		ORAL	TWICE PER DAY / ORAL	1 WK
	Anxiety							
	Dry Mouth		Birth Control	C				
	Excitability							
	Headache							
	Insomnia							
	Nervousness							
	Tremor							

Date:02/01/99ISR Number: 3410943-3Report Type:Periodic Company Report #A0065003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
	Syncope		Atenolol	SS				

Date:02/01/99ISR Number: 3410944-5Report Type:Periodic Company Report #A0065010
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Tooth Discolouration	Health	Wellbutrin	PS		ORAL
ORAL						
		Professional	Atorvastatin Caclium	C		
			Clarithromycin	C		
			Simvastatin	C		

Date:02/01/99ISR Number: 3410946-9Report Type:Periodic Company Report #A0065011
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Motor Dysfunction	Health	Wellbutrin	PS		ORAL
ORAL						
		Professional	Paroxetine			
		Company	Hydrochloride	C		
		Representative				

Date:02/01/99ISR Number: 3410947-0Report Type:Periodic Company Report #A0065016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fatigue	Consumer	Wellbutrin	PS		ORAL
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3410949-4Report Type:Periodic Company Report #A0065149
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health	Wellbutrin Tablet	PS		ORAL	75 MG / TWICE PER DAY / ORAL	
		Professional						
			Gabapentin	C				
			Clonazepam	C				

Date:02/01/99ISR Number: 3410951-2Report Type:Periodic Company Report #A0065252
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
		Professional						
		Company						
		Representative						

Date:02/01/99ISR Number: 3410954-8Report Type:Periodic Company Report #A0065279
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Wellbutrin Tablet	PS		ORAL	ORAL	
		Professional						
		Company						
		Representative						

Date:02/01/99ISR Number: 3410957-3Report Type:Periodic Company Report #A0071612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dry Mouth Nervous System Disorder Sleep Disorder	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL TWICE PER DAY / ORAL

Date:02/01/99ISR Number: 3410959-7Report Type:Periodic Company Report #A0071645
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Aggression	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL ORAL 6 WK

Date:02/01/99ISR Number: 3410961-5Report Type:Periodic Company Report #A0071649
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Acne Cystic	Consumer	Wellbutrin Tablet	PS		ORAL 50 MG / TWICE PER DAY / ORAL
			Loratadine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3410962-7Report Type:Periodic Company Report #A0071675
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG /	
	Irritability						TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3410965-2Report Type:Periodic Company Report #A0071678
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Wellbutrin Tablet	PS		ORAL	PER DAY / ORAL	
	Disturbance In Attention							
	Weight Increased							

Date:02/01/99ISR Number: 3410966-4Report Type:Periodic Company Report #A0071740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Wellbutrin Tablet	PS		ORAL	100 MG /	
	Mania	Professional					THREE TIMES PER DAY / ORAL	
	Psychotic Disorder							
	Tremor							
			Lithium Salt	C				
			Haloperidol	C				

Date:02/01/99ISR Number: 3410968-8Report Type:Periodic Company Report #A0071768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3410970-6Report Type:Periodic Company Report #A0071904
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression Agitation Alopecia Fatigue Hair Colour Changes	Consumer	Wellbutrin (Formulation Unknoown)	PS				

Date:02/01/99ISR Number: 3410971-8Report Type:Periodic Company Report #A0071907
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG / PER DAY / ORAL	

Date:02/01/99ISR Number: 3410972-XReport Type:Periodic Company Report #A0071981
Age: Gender:Unknown I/FU:I

Outcome	PT
	Dizziness Dyskinesia

	Feeling Abnormal					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health Professional	Wellbutrin Tablet	PS		ORAL
75 MG / TWICE PER DAY / ORAL						
			Sertraline Hydrochloride	C		

Date:02/01/99ISR Number: 3410974-3Report Type:Periodic Company Report #A0072240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Eye Movement Disorder	Health Professional Other	Wellbutrin (Formulation Unknown)	PS		ORAL
150 MG / PER DAY / ORAL						
			Risperidone Tablet	SS		ORAL
.5 MG / TWICE PER DAY / ORAL						

Date:02/01/99ISR Number: 3410976-7Report Type:Periodic Company Report #A0072299
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hyperhidrosis	Health Professional	Wellbutrin Tablet	PS		ORAL
75 MG / PER DAY / ORAL						
			Venlafaxine Hydrochloride Tablet	SS		ORAL
ORAL						

Date:02/01/99ISR Number: 3410977-9Report Type:Periodic Company Report #A0072301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3410979-2Report Type:Periodic Company Report #A0072613
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional	Wellbutrin Tablet	PS		ORAL	75 MG / TWICE PER DAY / ORAL	

Date:02/01/99ISR Number: 3410981-0Report Type:Periodic Company Report #A0072615
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG / ORAL	
		Health Professional	Conjugated Estrogens Tablet	SS		ORAL	625 MG / PER DAY / ORAL	
		Other	Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3410983-4Report Type:Periodic Company Report #A0072683
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3410984-6Report Type:Periodic Company Report #A0072769
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional	Wellbutrin Tablet	PS		ORAL	100 MG / TWICE PER DAY / ORAL	
	Dry Mouth							
	Insomnia							
	Irritability							
	Mydriasis							
	Urine Abnormality							
	Urine Odour Abnormal							

Date:02/01/99ISR Number: 3410985-8Report Type:Periodic Company Report #A0072946
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Wellbutrin	PS		ORAL	375 MG / PER DAY / ORAL	
		Company Representative						

Date:02/01/99ISR Number: 3410986-XReport Type:Periodic Company Report #A0072972
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Wellbutrin	PS		ORAL	300 MG / PER	
	Mania						DAY / ORAL	
			Conjugated Estrogens	SS				

Date:02/01/99ISR Number: 3410988-3Report Type:Periodic Company Report #A0073114
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / PER	
	Gastrointestinal Disorder						DAY / ORAL	
	Headache		Semisodium Valproate	C				
	Hypersensitivity		Clonazepam	C				
	Swelling							
	Vision Blurred							

Date:02/01/99ISR Number: 3414870-7Report Type:Periodic Company Report #A0066792
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet 75					
	Pruritus		Mg	PS		ORAL	2 TABLET /	
							TWICE PER DAY	
							/ ORAL	
			Salbutamol Sulphate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3414871-9Report Type:Periodic Company Report #A0066378
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG /	
	Fatigue						TWICE PER DAY	
	Irritability						/ ORAL	
	Libido Decreased		Gemfibrozil	C				
	Malaise		Propranolol					
	Nausea		Hydrochloride	C				
			Oestradiol	C				
			Phentermine	C				

Date:02/01/99ISR Number: 3414872-0Report Type:Periodic Company Report #A0066387
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / THREE	
	Constipation						TIMES PER	
	Flatulence						DAY/ ORAL	
	Headache		No Concurrent					
	Pain		Medication	C				

Date:02/01/99ISR Number: 3414873-2Report Type:Periodic Company Report #A0066396
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG / PER	
							/ DAY/ ORAL	
			Lorazepam	C				
			Glipizide	C				

Date:02/01/99ISR Number: 3414874-4Report Type:Periodic Company Report #A0066502
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / TWICE	
	Psychomotor Hyperactivity						PER DAY /	
							ORAL	

Date:02/01/99ISR Number: 3414876-8Report Type:Periodic Company Report #A0066559
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Wellbutrin Tablet	PS		ORAL	75 MG/ PER	
	Agitation	Professional					DAY / ORAL	
	Anxiety		No Concurrent Medication	C				

Date:02/01/99ISR Number: 3414877-XReport Type:Periodic Company Report #A0066580
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG / PER	
	Psychomotor Hyperactivity						DAY / ORAL	
			Ascorbic Acid	C				
			Ca Salt + Mg Salt	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3414878-1Report Type:Periodic Company Report #A0066634
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Wellbutrin Tablet	PS		ORAL	UNK/	UNK/
	Headache	Professional				ORAL		
		Company Representative	Wellbutrin Tablet-Controlled Release	SS		ORAL	UNK /UNK /	
						ORAL		

Date:02/01/99ISR Number: 3414879-3Report Type:Periodic Company Report #A0066718
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Wellbutrin Tablet	PS		ORAL	UNK /	UNK/
	Pain In Extremity	Professional				ORAL		
		Company Representative						

Date:02/01/99ISR Number: 3414880-XReport Type:Periodic Company Report #A0066850
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Wellbutrin Tablet	PS		ORAL	37.5 MG / PER	
	Arthralgia						DAY/ ORAL	
	Headache		Interferon	C				
	Nasal Congestion		Doxazosin Mesylate	C				
	Nausea		Dexamphetamine	C				
	Sinus Congestion		Vicoprofen	C				
	Tinnitus		Zolpidem Tartrate	C				
	Visual Disturbance		Tinnitus	C				

			Nausea	C			

Date:02/01/99ISR Number: 3414881-1Report Type:Periodic Company Report #A0066940
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fibromyalgia	Health	Wellbutrin Tablet	PS		ORAL	150 MG/ THREE	
	Myalgia	Professional					TIMES PER DA	
							ORAL	

Date:02/01/99ISR Number: 3414882-3Report Type:Periodic Company Report #A0066996
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health	Wellbutrin Tablet	PS		ORAL	100 MG /	
		Professional					THREE TIMES	
							PER DA ORAL	
			Antihistamine	C				
			Loratadine	C				
			Triamcinolone Acetonide	C				
			Budesonide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3414883-5Report Type:Periodic Company Report #A0066803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Other	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK/ UNK/ ORAL	

Date:02/01/99ISR Number: 3414884-7Report Type:Periodic Company Report #A0066826
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Libido Decreased Orgasm Abnormal	Consumer Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK/ UNK/ORAL	1 YR
	Sedation	Other	Fluoxetine Hydrochloride Tablet	SS		ORAL	UNK / UNK / ORAL	4 YR
			Trazodone Tablet	SS		ORAL	UNK/ UNK/ ORAL	

Date:02/01/99ISR Number: 3414885-9Report Type:Periodic Company Report #A0066783
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK/ UNK/ ORAL	

Date:02/01/99ISR Number: 3414886-0Report Type:Periodic Company Report #A0066635
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Acuity Reduced	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK/ ORAL	UNK/

Date:02/01/99ISR Number: 3414887-2Report Type:Periodic Company Report #A0066645
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	UNK/ ORAL	PER DAY

Date:02/01/99ISR Number: 3414888-4Report Type:Periodic Company Report #A0066541
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	100 MG/ ORAL	TWICE PER DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3414889-6Report Type:Periodic Company Report #A0066487
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3414890-2Report Type:Periodic Company Report #A0066383
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional Company Representative	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3414950-6Report Type:Periodic Company Report #A0067680
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular	Health Professional	Wellbutrin (Formulation Unknown)	PS				

Date:02/01/99ISR Number: 3414951-8Report Type:Periodic Company Report #A0067712
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3414952-XReport Type:Periodic Company Report #A0067623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Wellbutrin (Formulation Unknown)	PS				
			Zantac Tablet	SS		ORAL	ORAL	

Date:02/01/99ISR Number: 3414953-1Report Type:Periodic Company Report #A0067158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	150 MG TWICE PER DAY ORAL	
			Venlafaxine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3414954-3Report Type:Periodic Company Report #A0067091
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	
		Health Professional Other	Nicotine (Formulation Unknown)	SS				

Date:02/01/99ISR Number: 3414955-5Report Type:Periodic Company Report #A0067139
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Health	Wellbutrin Tablet	PS		ORAL	300 MG ORAL	
	Dermatitis Flushing Lichen Planus	Professional	Wellbutrin Tablet-Controlled Release	SS		ORAL	ORAL	
			Corticosteroid	C				

Date:02/01/99ISR Number: 3414956-7Report Type:Periodic Company Report #A0067225
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Wellbutrin Tablet	PS		ORAL	50 MG PER DAY	
	Sedation						ORAL	

Date:02/01/99ISR Number: 3414957-9Report Type:Periodic Company Report #A0067277
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin Tablet	PS		ORAL	ORAL	

Date:02/01/99ISR Number: 3414958-0Report Type:Periodic Company Report #A0067281
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Contractions	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG THREE	
	Involuntary						TIMES PER DAY	
	Myalgia						ORAL	
			Oestradiol	C				
			Multivitamin	C				

Date:02/01/99ISR Number: 3414959-2Report Type:Periodic Company Report #A0067326
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Wellbutrin Tablet	PS		ORAL	75 MG PER DAY	
	Vertigo	Professional					ORAL	3 DAY

Date:02/01/99ISR Number: 3414960-9Report Type:Periodic Company Report #A0067505
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG TWICE	
							PER DAY ORAL	
			Ranitidine					

			Hydrochloride	C		
			Anesthetic	C		

Date:02/01/99ISR Number: 3414961-0Report Type:Periodic Company Report #A0067533
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Wellbutrin Tablet	PS		ORAL	VARIABLE DOSE	ORAL
			Wellbutrin Tablet-Controlled Release	SS		ORAL	150 MG AT	NIGHT ORAL

Date:02/01/99ISR Number: 3414962-2Report Type:Periodic Company Report #A0067651
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG TWICE	
	Anxiety						PER DAY ORAL	
			Lithium Salt	C				
			Lamotrigine	C				
			Venlafaxine Hydrochloride	C				
			Thyroxine Sodium	C				

Date:02/01/99ISR Number: 3414963-4Report Type:Periodic Company Report #A0067653
Age:34 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Wellbutrin Tablet	PS		ORAL	150 MG TWICE	

PER DAY ORAL

Date:02/01/99ISR Number: 3414964-6Report Type:Periodic Company Report #A0067757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Wellbutrin Tablet	PS		ORAL	1TABLET PER DAY ORAL	2 DAY

Date:02/01/99ISR Number: 3414965-8Report Type:Periodic Company Report #A0067794
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health	Wellbutrin Tablet	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Menstruation Irregular	Professional						
			Amitriptyline Hcl	C				

Date:02/01/99ISR Number: 3414966-XReport Type:Periodic Company Report #A0067876
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Wellbutrin Tablet	PS		ORAL	100 MG TWICE PER DAY ORAL	
			Methylphenidate Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/99ISR Number: 3414967-1Report Type:Periodic Company Report #A0067885
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG TWICE	PER DAY ORAL
			Wellbutrin Tablet-Controlled Release	SS		ORAL	150 MG TWICE	PER DAY ORAL

Date:02/01/99ISR Number: 3414968-3Report Type:Periodic Company Report #A0067891
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG THREE	TIMES PER DAY
			Piroxicam	C		ORAL		
			Hyzaar	C				
			Quinine Sulphate	C				
			Multivitamin	C				
			Amitriptyline Hcl	C				

Date:02/01/99ISR Number: 3414969-5Report Type:Periodic Company Report #A0067960
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Wellbutrin Tablet	PS		ORAL	75 MG THREE	TIMES PER DAY

ORAL							
			Lorazepam	C			

Date:02/02/99ISR Number: 3190464-6Report Type:Direct Company Report #
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Zyban	PS				

Date:02/04/99ISR Number: 3192336-XReport Type:Expedited (15-DaCompany Report #A0065665
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State	Health	Wellbutrin	PS		ORAL	75 MG/TWICE PER DAY/	
	Convulsion	Professional						
	Dermatitis		Clonazepam	C				
	Dry Mouth		Carisoprodol	C				
	Jaundice		Botulinum Toxin	C				
	Loss Of Consciousness							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/99ISR Number: 3196585-6Report Type:Periodic Company Report #M087478
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Grand Mal Convulsion	Health	Serzone Tabs	PS		ORAL	150 MG QHR	
		Professional				ORAL		
			Wellbutrin	SS		ORAL	150 MG BID	
						ORAL		

Date:02/04/99ISR Number: 3197911-4Report Type:Periodic Company Report #A0058679
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Health	Wellbutrin	PS		ORAL	100 MG ORAL	
	Dry Skin	Professional						
	Dyspnoea							
	Eyelid Oedema							
	Face Oedema							
	Pharyngeal Oedema							
	Pruritus							
	Tongue Oedema							
	Urticaria							

Date:02/04/99ISR Number: 3197918-7Report Type:Periodic Company Report #A0058587
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intentional Misuse	Health	Wellbutrin	PS		ORAL		
Initial or Prolonged	Loss Of Consciousness	Professional	Zidovudine	C				
	Suicide Attempt		Lamivudine	C				
			Indinavir Sulfate	C				
			Trazodone	C				

Date:02/04/99ISR Number: 3197921-7Report Type:Periodic Company Report #A0057893
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Tablet	PS		ORAL	75 MG TWICE	PER DAY ORAL
		Professional						
			Donepezil Hcl	C				
			Quinapril Hydrochloride	C				
			Paroxetine Hydrochloride	C				
			Aspirin	C				

Date:02/04/99ISR Number: 3197928-XReport Type:Periodic Company Report #A0057799
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Health	Wellbutrin Tablet	PS		ORAL	150 MG THREE	
	Choking	Professional					TIMES PER DAY	
	Confusional State						ORAL	
	Convulsion		Sertraline Hydrochloride	C				
			Tamoxifen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/99ISR Number: 3296857-0Report Type:Periodic Company Report #M076943
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Serzone Tabs	PS		ORAL	300-400 MG	
	Drug Interaction	Professional				ORAL		
			Wellbutrin	SS		ORAL		

Date:02/04/99ISR Number: 3297053-3Report Type:Periodic Company Report #M089705
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia	Health	Serzone Tabs	PS		ORAL	500MG QD	ORAL 3 WK
		Professional	Wellbutrin	SS			150MG BID	

Date:02/04/99ISR Number: 3300316-6Report Type:Periodic Company Report #M078898
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Serzone Tabs	PS		ORAL	300-400 MG	
	Drug Interaction					ORAL		
			Wellbutrin	SS		ORAL		

Date:02/04/99ISR Number: 3300318-XReport Type:Periodic Company Report #M078899
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Serzone Tabs	PS		ORAL	300-400 MG	

	Drug Interaction	Professional					
ORAL							
			Wellbutrin		SS		ORAL
ORAL							

Date:02/04/99ISR Number: 3300489-5Report Type:Periodic Company Report #M083831
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Serzone Tabs	50 Mg	PS		ORAL	50 MG	QD
	Tremor								
ORAL									2 WK
			Wellbutrin		SS		ORAL		
ORAL									
			Zocor		C				
			Dayhist		C				

Date:02/04/99ISR Number: 3303157-9Report Type:Periodic Company Report #M082468
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Serzone Tabs	PS		ORAL		
ORAL							2	MON
	Pruritus	Professional	Wellbutrin	SS		ORAL		
ORAL							1	MON

Date:02/04/99ISR Number: 3303350-5Report Type:Periodic Company Report #M075277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Serzone Tabs	100 Mg	PS		ORAL	100 MG	BID
	Paraesthesia								
ORAL									
	Vasodilatation		Wellbutrin		SS		ORAL		
ORAL									

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/99ISR Number: 3303662-5Report Type:Periodic Company Report #M078897
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Serzone Tabs	PS		ORAL	300-400 MG	
	Drug Interaction	Professional				ORAL		
			Wellbutrin	SS		ORAL		

Date:02/04/99ISR Number: 3303735-7Report Type:Periodic Company Report #M077598
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea	Health	Serzone Tabs	PS		ORAL	ORAL	
		Professional	Wellbutrin	SS		ORAL	ORAL	

Date:02/04/99ISR Number: 3304353-7Report Type:Periodic Company Report #M081635
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Health	Serzone Tabs	PS		ORAL	50-100 MG BID	
	Emotional Disorder	Professional				ORAL		12 DAY
	Insomnia		Wellbutrin	SS		ORAL	300 MG HS	
	Libido Increased					ORAL		

Date:02/04/99ISR Number: 3305811-1Report Type:Periodic Company Report #M079632
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Amblyopia	Consumer	Serzone Tabs 50mg	PS		ORAL
50 MG ORAL; 1						
	Headache					
DOSES						
	Nausea		Wellbutrin	SS		ORAL
ORAL						

Date:02/04/99ISR Number: 3405202-9Report Type:Periodic Company Report #98USA11257
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination	Health	Ritalin Tablet			
	Insomnia	Professional	(Methylphenidate			
	Overdose		Hydrochloride)	PS		ORAL
DAILY, ORAL						
	Psychotic Disorder		Marijuana (Cannabis)	SS		
RESPIRATORY						
(INHALATION)	INHALATION					
			Wellbutrin Tablet			
			(Amfebutamone			
			Hydrochloride)	SS		ORAL
ORAL						

Date:02/05/99ISR Number: 3192891-XReport Type:Expedited (15-DaCompany Report #A0061783
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Ecchymosis	Health	Zyban	PS		ORAL
150 MG/TWICE						
	Thrombocytopenia	Professional				
PER DAY/ ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/99ISR Number: 3193360-3Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Rash Erythematous Rash Pruritic		Zyban 150mg	PS	Glaxo Wellcome	ORAL	150MG PO BID	

Date:02/08/99ISR Number: 3193901-6Report Type:Expedited (15-DaCompany Report #A0081197
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Kidney Infection Pneumonia	Foreign Consumer	Zyban Fluoxetine Hydrochloride	PS C		ORAL	150 MG TWICE PER DAY ORAL	

Date:02/08/99ISR Number: 3193902-8Report Type:Expedited (15-DaCompany Report #A0081366
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amblyopia Diplopia Dizziness Fall Visual Disturbance	Foreign Health Professional	Zyban Oral Contraceptive	PS C		ORAL	150 MG PER DAY ORAL	

Date:02/10/99ISR Number: 3194839-0Report Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Back Pain	Perphenazine	PS	ORAL 2 MG DAILY
	Blood Creatine Phosphokinase Increased	Bupropion	SS	ORAL 150 MG BID
	Chills			ORAL
	Dyspnoea			
	Neuroleptic Malignant Syndrome			
	Pyrexia			
	Respiratory Distress			
	Sepsis			

Date:02/10/99ISR Number: 3195526-5Report Type:Expedited (15-DaCompany Report #A0081113
Age:50 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Dysgraphia
	Dysphagia
	Facial Palsy
	Hearing Impaired
	Hemiparesis
	Hypoaesthesia
	Pruritus
	Speech Disorder
	Transient Ischaemic Attack

	Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Wellbutrin	PS		ORAL	150 MG TWICE PER DAY ORAL

Date:02/10/99ISR Number: 3195529-0Report Type:Expedited (15-DaCompany Report #A0077703
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation	Health	Wellbutrin	PS		ORAL	150 MG TWICE PER DAY ORAL
	Convulsion	Professional					
	Nausea	Company					
	Oral Intake Reduced	Representative					
	Staring						

Date:02/11/99ISR Number: 3195948-2Report Type:Expedited (15-DaCompany Report #A0081071
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Respiratory Distress	Health	Wellbutrin	PS			
	Urticaria	Professional	Aspirin	C			

Date:02/11/99ISR Number: 3196526-1Report Type:Periodic Company Report #A0063369
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Consumer	Wellbutrin (Formulation Unknown)	PS		ORAL	150 MG / PER DAY / ORAL

Date:02/12/99ISR Number: 3197976-XReport Type:Expedited (15-DaCompany Report #A0080414
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Foreign	Zyban	PS		ORAL	150MG/TWICE	
Initial or Prolonged	Oedema Peripheral	Health					PER DAY/ORAL	
Disability	Serum Sickness	Professional	Lansoprazole	C				
	Swelling		Cisapride	C				
	Urticaria							

Date:02/12/99ISR Number: 3198077-7Report Type:Expedited (15-DaCompany Report #A0081119
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
Initial or Prolonged	Difficulty In Walking	Professional					PER DAY ORAL	1 WK
Disability	Dry Skin	Company						
	Leukocytosis	Representative						
	Oedema Peripheral							
	Pruritus							
	Serum Sickness							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/99ISR Number: 3198497-0Report Type:Direct Company Report #
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health Professional	Zyban	PS		ORAL	150 MG BID PO	

Date:02/16/99ISR Number: 3198559-8Report Type:Direct Company Report #
Age:17 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Wellbutrin	PS		ORAL	200MG PO Q AM	

Date:02/16/99ISR Number: 3198585-9Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	150MG 2X'S	
Other	Arthralgia					ORAL		
	Arthritis							
	Depression							
	Joint Swelling							
	Muscle Rigidity							
	Muscle Spasms							
	Oedema Peripheral							
	Pain							

Date:02/16/99ISR Number: 3199364-9Report Type:Expedited (15-DaCompany Report #A0081946
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Abdominal Pain Upper	Consumer	Zyban Tablet - Zyban	PS		ORAL
ORAL						
Initial or Prolonged	Decreased Appetite					
	Diarrhoea					
	Dysgeusia					
	Hepatitis					
	Hypersensitivity					
	Jaundice					

Date:02/17/99ISR Number: 3200550-XReport Type:Expedited (15-DaCompany Report #9904510
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Depression	Consumer	Zoloft Tablets	PS		ORAL
50.00 MG						
Hospitalization -	Drug Ineffective					
TOTAL:DAILY						
Initial or Prolonged	Suicide Attempt		Prozac	SS		
Required			Effexor	SS		
Intervention to			Wellbutrin	SS		
Prevent Permanent			Depakote	C		
Impairment/Damage			Buspar	C		
			Unknown Medications	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/99ISR Number: 3203086-5Report Type:Expedited (15-DaCompany Report #A0062241
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY ORAL
	Exomphalos						
	Heart Disease Congenital						

Date:02/18/99ISR Number: 3203091-9Report Type:Expedited (15-DaCompany Report #A0081061
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin Tablet	PS		ORAL	SINGLE DOSE/ORAL
	Electrocardiogram Qt Prolonged	Other	Antidepressant Tablet	SS		ORAL	SINGLE DOSE/ORAL
	Intentional Misuse						
	Suicide Attempt						
			Ethanol (Formulation Unknown)	SS			

Date:02/18/99ISR Number: 3203094-4Report Type:Expedited (15-DaCompany Report #A0082079
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Balance Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/PER DAY/ORAL
	Confusional State						
	Feeling Abnormal		Vitamin E	C			
	Nausea		Calcium Salt	C			

Date:02/19/99ISR Number: 3203570-4Report Type:Expedited (15-DaCompany Report #A0074981
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health	Wellbutrin					
	Haematoma	Professional	Tablet-Controlled					
	International Normalised	Company	Release	PS		ORAL	150MG/ORAL	
	Ratio Increased	Representative	Warfarin Sodium					
	Joint Swelling		Tablet	SS		ORAL	10MG/ALTERNAT	
	Pain In Extremity						E DAYS/ORAL	
	Prothrombin Time Ratio		Warfarin Sodium					
	Increased		Tablet	SS		ORAL	7.5 MG/ALTERNATE DAYS/ORAL	

Date:02/22/99ISR Number: 3204842-XReport Type:Expedited (15-DaCompany Report #A0080063
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
	Insomnia	Professional						
	Muscle Rigidity		Multivitamin	C				
	Muscle Spasms							
	Myalgia							
	Nervousness							
	Panic Attack							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/99ISR Number: 3204849-2Report Type:Expedited (15-DaCompany Report #A0082610
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Pruritus Rash Erythematous Tongue Oedema	Foreign Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY ORAL

Date:02/22/99ISR Number: 3204908-4Report Type:Expedited (15-DaCompany Report #A0082630
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypoaesthesia	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	ORAL

Date:02/22/99ISR Number: 3204910-2Report Type:Expedited (15-DaCompany Report #A0082661
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Colitis Diarrhoea Haemorrhagic	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	ORAL

Date:02/22/99ISR Number: 3204944-8Report Type:Expedited (15-DaCompany Report #A0079791
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aneurysm	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /

Initial or Prolonged	Cerebrovascular Accident						
TWICE PER DAY							
	Hemiplegia						
/ ORAL							
			Digoxin	C			
			Frusemide	C			
			Diclofenac Sodium	C			
			Warfarin Sodium	C			

Date:02/22/99ISR Number: 3204956-4Report Type:Expedited (15-DaCompany Report #A0081197
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chills	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
Initial or Prolonged	Dehydration	Health						
TWICE PER DAY								
	Kidney Infection	Professional						
/ ORAL								
	Malaise		Fluoxetine					
	Myalgia		Hydrochloride	C				
	Oliguria							
	Pneumonia							
	Pyelonephritis							
	Pyrexia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/99ISR Number: 3205582-3Report Type:Periodic Company Report #8-98348-072A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health	Effexor Xr					
	Condition Aggravated	Professional	Capsules	PS		ORAL	300 MG;	ONCE
	Depression						DAILY;	ORAL
	Myalgia		Wellbutrin					
	Thinking Abnormal		(Bupropion)	SS		ORAL	300 MG;	
							DAILY;	ORAL

Date:02/22/99ISR Number: 3401571-4Report Type:Periodic Company Report #WAES 98030804
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Tab Zocor Unk	PS				
			Tab Zyban 150 Mg	SS		ORAL	150 MG/	
							BID/PO	

Date:02/23/99ISR Number: 3202972-XReport Type:Expedited (15-DaCompany Report #A0077674
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Zyban Tablet - Zyban	PS		ORAL	UNKNOWN	ORAL
		Professional						

Date:02/23/99ISR Number: 3204642-0Report Type:Expedited (15-DaCompany Report #MPI-97418(1)
Age:9 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Aggression Agitation Intermittent Explosive Disorder Memory Impairment Parent-Child Problem	Health Professional	Methylphenidate Tablets 10 Mg (Methylphenidate Hydrochloride 10 Mg)	PS		ORAL 55 MG, PO
			Clonidine Hydrochloride (Clonidine Hydrochloride)	SS		ORAL 0.1 MG PO
			Bupropion (Amfebutamone)	SS		ORAL 150 MG PO

Date:02/24/99ISR Number: 3206129-8Report Type:Direct Company Report #
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Angioneurotic Oedema Oedema Peripheral Pain In Extremity Pruritus Rash Erythematous Urticaria		Zyban - 150 Mg Tab (Glaxo Wellcome)	PS	Glaxo Wllome	ORAL 150MG BY MOUTH DAILY 10 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/99ISR Number: 3427033-6Report Type:Periodic Company Report #A0076399
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Insomnia						PER DAY ORAL	
			Nitroglycerin	C				

Date:02/25/99ISR Number: 3208776-6Report Type:Periodic Company Report #9835125
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Consumer	Zoloft Tablets	PS		ORAL	25 MG TOTAL	
	Erectile Dysfunction						DAILY ORAL	
	Libido Decreased		Wellbutrin	SS		ORAL	ORAL	

Date:02/25/99ISR Number: 3208806-1Report Type:Periodic Company Report #9719922
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Zoloft	PS		ORAL	ORAL	
	Cardiovascular Disorder	Professional	Redux	SS		ORAL	30.00 MG	
							TOTAL:DAILY:O	
							RAL	
			Ambien	SS		ORAL	ORAL	
			Wellbutrin	SS		ORAL	ORAL	

Date:02/25/99ISR Number: 3209582-9Report Type:Periodic Company Report #9825937
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Consumer	Zoloft Tablets	PS		ORAL	DAILY:ORAL	
	Agitation		Wellbutrin	SS		ORAL	ORAL	
	Anxiety		Remeron	SS		ORAL	ORAL	
	Arthralgia		Vitamins	C				
	Coordination Abnormal		Xanax	C				
	Dizziness							
	Drug Ineffective							
	Erectile Dysfunction							
	Increased Appetite							
	Insomnia							
	Libido Decreased							
	Listless							
	Mania							
	Nervousness							
	Oedema Peripheral							
	Paraesthesia							
	Sexual Dysfunction							
	Weight Increased							

Date:02/25/99ISR Number: 3210859-1Report Type:Periodic Company Report #9800371
Age: Gender:Male I/FU:I

Outcome	PT
Other	Abnormal Dreams
	Alopecia
	Constipation
	Depersonalisation

	Dizziness						
	Drug Ineffective						
	Insomnia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Male Sexual Dysfunction	Consumer	Zoloft Tablets	PS		ORAL	100.00 MG
	Nocturia	Health					TOTAL: DAILY:
	Weight Decreased	Professional					ORAL
			Wellbutrin	SS			87.50 MG
							TOTAL: BID

Date:02/25/99ISR Number: 3210871-2Report Type:Periodic Company Report #9800713
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dermatitis	Health	Zoloft Tablets	PS		ORAL	50.00 MG
	Hyperhidrosis	Professional					TOTAL: DAILY:
							ORAL
			Wellbutrin	SS		ORAL	ORAL

Date:02/25/99ISR Number: 3211066-9Report Type:Periodic Company Report #9801452
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Anorexia	Consumer	Zoloft Tablets	PS		ORAL	100.00 MG
	Diarrhoea	Health					TOTAL: DAILY:
	Nausea	Professional					ORAL
			Paxil	SS			
			Wellbutrin	SS			
			Hytrin	C			

			Cardizem	C		
			Dilacor Xr	C		

Date:02/25/99ISR Number: 3212165-8Report Type:Periodic Company Report #9728129
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Health	Zoloft Tablets	PS		ORAL		
	Drug Ineffective	Professional	Prozac	SS		ORAL	20.00 MG	
	Erectile Dysfunction							
			Wellbutrin	SS		ORAL		
			Parnate	SS		ORAL		

Date:02/25/99ISR Number: 3212466-3Report Type:Periodic Company Report #JAUSA-34478
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Muscle Contractions Involuntary	Health Professional	Risperdal (Risperidone)	PS	Janssen	ORAL	.5 MG DAILY	
							ORAL/ .5 MG 2	
							DAILY ORAL	
			Wellbutrin (Amfebutamone)	SS		ORAL	150 MG DAILY	
							ORAL/ 100 MG	
							1 DAILY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/99ISR Number: 3213420-8Report Type:Periodic Company Report #JAUSA-35125
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Health Professional	Risperdal (Risperidone), Janssen Tablet	PS	Janssen	ORAL	ORAL	
			Klonopin (Clonazepam) Tablet	SS		ORAL	ORAL	
			Paxil (Paroxetine)	SS		ORAL	TABLET ORAL	
			Wellbutrin (Amfebutamone)	SS			TABLET	

Date:02/25/99ISR Number: 3213792-4Report Type:Periodic Company Report #9808807
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Zoloft Tablets	PS		ORAL	50.00 MG	
	Chest Pain						TOTAL DAILY	
	Drug Ineffective						ORAL	
	Dry Mouth		Wellbutrin	SS		ORAL	150.00 MG	
	Headache						TOTAL DAILY	
							ORAL	

Date:02/25/99ISR Number: 3217332-5Report Type:Periodic Company Report #9810197
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health Professional	Zoloft Tablets	PS				
	Drug Interaction		Aricept	SS				

		Company Representative	Wellbutrin	SS		

Date:02/25/99ISR Number: 3217596-8Report Type:Periodic Company Report #9807191
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Depersonalisation	Health	Zoloft Tablets	PS		ORAL	50.00 MG
	Dizziness	Professional					TOTAL:
	Drug Ineffective						DAILY:ORAL
	Ejaculation Disorder		Wellbutrin	SS		ORAL	75.00 MG
	Insomnia						TOTAL:DAILY:O
	Thinking Abnormal						RAL
	Vertigo		Depakote	C			

Date:02/25/99ISR Number: 3217904-8Report Type:Periodic Company Report #9810841
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Anorgasmia	Consumer	Zoloft Tablets	PS		ORAL	50.00 MG
	Depression						TOTAL; DAILY;
	Drug Ineffective						ORAL
	Dyspepsia		Remeron	SS		ORAL	ORAL
	Weight Increased		Wellbutrin	SS		ORAL	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/99ISR Number: 3208619-0Report Type:Expedited (15-DaCompany Report #A0081366
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amblyopia	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Diplopia	Health					DAY / ORAL	
	Dizziness	Professional	Oral Contraceptive	C				
	Fall							
	Visual Disturbance							

Date:02/26/99ISR Number: 3213518-4Report Type:Periodic Company Report #8-98237-039A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health	Effexor	PS		ORAL	UP TO 400 MG	
	Depression	Professional					DAILY ORAL;	
	Drug Withdrawal Syndrome						TAPERED FROM	
	Hypotonia						400 MG; 275	
	Nausea						MG DAILY; 50	57 DAY
	Nervousness		Wellbutrin					
	Trismus		(Bupropion)	SS		ORAL	ORAL	
			Trazodone	C				
			Trilafon (Perphenazine)	C				

Date:02/26/99ISR Number: 3214455-1Report Type:Periodic Company Report #8-98023-015D
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia	Consumer	Effexor	PS		ORAL	37.5 MG DAILY	

	Asthenia				
ORAL					
	Confusional State		Klonopin	SS	
	Depression		Wellbutrin Sr	SS	
	Dry Mouth		Alesse	C	
	Nausea				
	Sedation				
	Yawning				

Date:02/26/99ISR Number: 3217191-0Report Type:Periodic Company Report #8-98089-039A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	White Blood Cell Disorder	Consumer	Effexor	PS		ORAL	UP TO 225 MG	
DAILY ORAL								
			Wellbutrin Tablet	SS		ORAL		
ORAL								
			Cortisone Injection					
			Epidural	C				
			Diuretic	C				
			Posicur	C				
			Welllbutrin	C				

Date:02/26/99ISR Number: 3424057-XReport Type:Periodic Company Report #001-0945-980438
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Drug Interaction	Health
	Grand Mal Convulsion	Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Neurontin (Gabapentin)	PS		ORAL	2400 MG (1200 MG, BID), PER ORAL	
Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	375 (DAILY), PER ORAL	
Prozac	C				
Klonopin	C				

Date:03/01/99ISR Number: 3208520-2Report Type:Direct Company Report #
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion	Consumer	Zyban Bupropion Hydrochloride	PS			TWO TIMES Initial or Prolonged	DAILY 1 MON
Hospitalization - Disability								

Date:03/01/99ISR Number: 3209111-XReport Type:Expedited (15-DaCompany Report #A0078454
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis Exfoliative	Foreign	Zyban - Zyban	PS		ORAL	TABLET, 150MG / TWICE PER	
Other	Retinal Vein Thrombosis	Health						

		Professional				

DAY / ORAL

Date:03/01/99ISR Number: 3209118-2Report Type:Expedited (15-DaCompany Report #A0076073
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Electroencephalogram	Health	Wellbutrin				
Hospitalization -	Abnormal	Professional	Tablet-Controlled				
Initial or Prolonged	Grand Mal Convulsion	Company	Release	PS		ORAL	TABLET, 150
Other	Medication Error	Representative					MG / TWICE
							PER DAY /
							ORAL
			Ethanol (Formulation Unknown)	SS		ORAL	ORAL
			Glucophage	C			

Date:03/01/99ISR Number: 3209132-7Report Type:Expedited (15-DaCompany Report #A0081417
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Hypoaesthesia	Foreign	Zyban Tablet - Zyban	PS		ORAL	TABLET, 150
	Myalgia	Health					MG / TWICE
	Paraesthesia	Professional					PER DAY /
							ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3209137-6Report Type:Expedited (15-DaCompany Report #A0065816
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Zyban Tablet - Zyban	PS		ORAL	TABLET, 150	
	Agitation	Professional					MG / ORAL	
	Amnesia		Medroxyprogesterone					
	Anger		Ace.	C				
	Anxiety							
	Breast Pain							
	Disorientation							
	Disturbance In Attention							
	Dizziness							
	Feeling Jittery							
	Fluid Retention							
	Galactorrhoea							
	Insomnia							
	Migraine							
	Nausea							
	Paranoia							
	Psychomotor Hyperactivity							
	Suicidal Ideation							
	Tinnitus							

Date:03/01/99ISR Number: 3209143-1Report Type:Expedited (15-DaCompany Report #A0082234
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dysphagia	Health					TWICE PER DAY	
	Dyspnoea	Professional					/ ORAL	
	Headache	Company						
	Influenza Like Illness	Representative						
	Joint Swelling							
	Pain							
	Pharyngolaryngeal Pain							
	Respiratory Distress							
	Urticaria							

Date:03/01/99ISR Number: 3209455-1Report Type:Expedited (15-DaCompany Report #A0082611
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amenorrhoea Amnesia Convulsion Head Injury	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	1 TABLET/ TWICE PER DAY/	
			Aspirin	C				

Date:03/01/99ISR Number: 3218031-6Report Type:Periodic Company Report #A0074913
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Company Representative	Zyban	PS		ORAL	150 MG; TWICE PER DAY;	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3218032-8Report Type:Periodic Company Report #A0074712
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dyspnoea Swelling Urticaria	Consumer	Zyban Tablet	PS		ORAL	150 MG; TWICE PER DAY;

Date:03/01/99ISR Number: 3218033-XReport Type:Periodic Company Report #A0074630
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban Tablet	PS		ORAL	150 MG; TWICE PER DAY;
			Tramadol Hydrochloride	C			
			Hydrocodone	C			

Date:03/01/99ISR Number: 3218034-1Report Type:Periodic Company Report #A0070651
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Company Representative	Zyban Tablet	PS		ORAL	150 MG; TWICE PER DAY;

Date:03/01/99ISR Number: 3218035-3Report Type:Periodic Company Report #A0068254
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban Tablet	PS		ORAL	150 MG;	
	Muscle Twitching	Professional					TWICE PER	
	Vision Blurred						DAY; ORAL	
			Oxybutynin	C				
			Cisapride	C				
			Carbamazepine	C				
			Gabapentin	C				
			Atorvastatin Calcium	C				
			Setraline Hydrochloride	C				
			Prempro	C				

Date:03/01/99ISR Number: 3218036-5Report Type:Periodic Company Report #A0067448
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Zyban Tablet	PS		ORAL	150 MG;	
	Chest Pain	Professional					TWICE PER	
							DAY; ORAL	
			Conjugated Estrogens	C				
			Medroxyprogesterone Ace.	C				
			Multivitamin	C				
			Vitamin E	C				
			Ascorbic Acid	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3218037-7Report Type:Periodic Company Report #A0082071
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Study	Zyban Tablet	PS		ORAL	150 MG;
		Consumer					ORAL

Date:03/01/99ISR Number: 3218038-9Report Type:Periodic Company Report #A0081611
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Consumer	Zyban Tablet	PS		ORAL	150 MG; TWICE PER
	Throat Tightness						DAY; ORAL
	Urticaria						
			Weight Loss Medication	C			

Date:03/01/99ISR Number: 3218039-0Report Type:Periodic Company Report #A0070268
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dyspnoea	Consumer	Zyban Tablet	PS		ORAL	150 MG;
	Eyelid Oedema						TWICE PER
	Face Oedema						DAY; ORAL
	Pruritus		.....	C			
	Urticaria						

Date:03/01/99ISR Number: 3218040-7Report Type:Periodic Company Report #A0080724
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Dermatitis Swelling Urticaria	Consumer	Zyban Tablet	PS		ORAL	150 MG; TWICE PER DAY;	ORAL

Date:03/01/99ISR Number: 3218041-9Report Type:Periodic Company Report #A0080138
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Zyban Tablet	PS		ORAL	ORAL	

Date:03/01/99ISR Number: 3218042-0Report Type:Periodic Company Report #A0080112
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Bronchospasm Chest Discomfort Hypersensitivity Oedema Mouth Urticaria	Health Professional Company Representative	Zyban Tablet Nicotine	PS C		ORAL	150 MG; TWICE PER DAY;	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3218043-2Report Type:Periodic Company Report #A0079702
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban Tablet	PS		ORAL	150 MG;	TWICE PER DAY;
	Syncope	Professional						
		Company						
		Representative	Cetirizine Hydrochloride	C				
			Fluoxymesterone	C				

Date:03/01/99ISR Number: 3218044-4Report Type:Periodic Company Report #A0079559
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health	Zyban Tablet	PS		ORAL	150 MG;	TWICE PER DAY;
		Professional						
		Company						
		Representative						

Date:03/01/99ISR Number: 3218045-6Report Type:Periodic Company Report #A0079375
Age:39 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health	Zyban Tablet	PS		ORAL	150 MG;	TWICE PER DAY;
	Dyspnoea	Professional						
	Hypersensitivity	Company						
	Oedema Mouth	Representative						
	Periorbital Oedema							
	Throat Tightness							
	Urticaria							

Date:03/01/99ISR Number: 3218046-8Report Type:Periodic Company Report #A0079407
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional	Zyban Tablet	PS		ORAL	150 MG; ORAL	

Date:03/01/99ISR Number: 3218047-XReport Type:Periodic Company Report #A0079414
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional	Zyban Tablet	PS		ORAL	150 MG; ORAL	

Date:03/01/99ISR Number: 3218048-1Report Type:Periodic Company Report #A0079094
Age:33 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Anaphylactic Reaction
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
	Bronchospasm
	Dyspnoea
	Erythema Multiforme
	Face Oedema
	Oedema Peripheral

	Pruritus Tongue Oedema Urticaria	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Zyban	PS		ORAL	150 MG;
		Professional					TWICE PER
							DAY; ORAL

Date:03/01/99ISR Number: 3218612-XReport Type:Periodic Company Report #A0078496
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Convulsion	Health	Zyban Tablet - Zyban	PS		ORAL	ORAL 2 MON
Initial or Prolonged		Professional	Doxepin	C			
		Company Representative	Diazepam	C			

Date:03/01/99ISR Number: 3218616-7Report Type:Periodic Company Report #A0078477
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Hypersensitivity	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE
Initial or Prolonged							PER DAY/ ORAL

Date:03/01/99ISR Number: 3218619-2Report Type:Periodic Company Report #A0078288
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE
							PER DAY/ORAL

			Co - Trimoxazole	C		

Date:03/01/99ISR Number: 3218624-6Report Type:Periodic Company Report #A0078186
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Musculoskeletal Pain	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
Other		Professional					PER DAY/ORAL	
			Nicotine	C				
			Iron Salt	C				

Date:03/01/99ISR Number: 3218626-XReport Type:Periodic Company Report #A0078110
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:03/01/99ISR Number: 3218630-1Report Type:Periodic Company Report #A0078076
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional Company

		Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban Tablet - Zyban	PS		ORAL
ORAL						

Date:03/01/99ISR Number: 3218633-7Report Type:Periodic Company Report #A0078075
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angioneurotic Oedema	Health	Zyban Tablet - Zyban	PS		ORAL
ORAL						
Initial or Prolonged		Professional				
		Company				
		Representative				

Date:03/01/99ISR Number: 3218634-9Report Type:Periodic Company Report #A0078073
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angioneurotic Oedema	Health	Zyban Tablet - Zyban	PS		ORAL
150 MG, /						
Initial or Prolonged		Professional				
ORAL						
		Company				
		Representative				

Date:03/01/99ISR Number: 3218635-0Report Type:Periodic Company Report #A0077711
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion	Health	Zyban Tablet -			
		Professional	Zyban	PS		ORAL
150 MG/TWICE						
		Company				
PER DAY/ORAL						

		Representative				

Date:03/01/99ISR Number: 3218637-4Report Type:Periodic Company Report #A0077362
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE PER DAY/ORAL	
	Convulsion							
	Nausea		Tramadol Hydrochloride	C				
	Sedation		Alprazolam	C				
	Weight Decreased		Conjugated Estrogens	C				
			Iron Salt	C				
			Multivitamin	C				

Date:03/01/99ISR Number: 3218641-6Report Type:Periodic Company Report #A0077347
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	ORAL	

Date:03/01/99ISR Number: 3218644-1Report Type:Periodic Company Report #A0077336
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Other	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Oedema Peripheral						
	Rash Erythematous		Claritin - D	C			
	Urticaria		Finasteride	C			
	Vomiting						

Date:03/01/99ISR Number: 3218648-9Report Type:Periodic Company Report #A0077155
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
			Gabapentin Capsule	SS		ORAL	

Date:03/01/99ISR Number: 3218649-0Report Type:Periodic Company Report #A0077046
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Pharyngeal Oedema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Pruritus						
	Rash Erythematous		Donnatal	C			
	Swelling						
	Throat Tightness						
	Urticaria						

Date:03/01/99ISR Number: 3218653-2Report Type:Periodic Company Report #A0076779
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Face Oedema	Professional					PER DAY/ ORAL	
	Tongue Oedema							
	Urticaria							

Date:03/01/99ISR Number: 3218657-XReport Type:Periodic Company Report #A0076534
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Overdose	Health	Zyban Tablet - Zyban	PS		ORAL	300 MG/ TWICE	
	Convulsion	Professional					PER DAY/ ORAL	
	Dermatitis							
	Urticaria							

Date:03/01/99ISR Number: 3218660-XReport Type:Periodic Company Report #A0076427
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Consumer	Zyban Tablet -Zyban	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3218663-5Report Type:Periodic Company Report #A0076211
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Consumer	Zyban Tablet -Zyban	PS		ORAL	ORAL

Date:03/01/99ISR Number: 3218666-0Report Type:Periodic Company Report #A0075090
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Zyban Tablet -Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL
	Hypoaesthesia						
	Myocardial Infarction		Atorvastatin Calcium	C			
			Aspirin	C			
			Nitroglycerin	C			

Date:03/01/99ISR Number: 3218670-2Report Type:Periodic Company Report #A0075018
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL

Date:03/01/99ISR Number: 3426816-6Report Type:Periodic Company Report #A0077030
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Flushing	Health	Bupropion				
	Insomnia	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /

Night Sweats
TWICE PER DAY

ORAL

			Ibuprofen	C		
			Zolpidem Tartrate	C		

Date:03/01/99ISR Number: 3426822-1Report Type:Periodic Company Report #A0077031
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Urticaria							

Date:03/01/99ISR Number: 3426825-7Report Type:Periodic Company Report #A0077032
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ORAL	
			Carisoprodol	C				
			Ibuprofen	C				
			Ulcer Medication	C				
			Diuretic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3426828-2Report Type:Periodic Company Report #A0077033
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	ORAL
	Disorientation							
	Pruritus							
	Urticaria							

Date:03/01/99ISR Number: 3426837-3Report Type:Periodic Company Report #A0077034
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Major Depression							
	Palpitations						DAY	ORAL
			Birth Control	C				

Date:03/01/99ISR Number: 3426840-3Report Type:Periodic Company Report #A0077066
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY	ORAL

Date:03/01/99ISR Number: 3426845-2Report Type:Periodic Company Report #A0077067
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Bupropion					

	Tremor		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE PER DAY ORAL						
			Combivent	C		
			Salbutamol Sulphate	C		
			Loratadine	C		
			Triamcinolone Acetonide	C		
			Guaphenesin	C		
			Paracetamol	C		
			Naproxen Sodium	C		

Date:03/01/99ISR Number: 3426849-XReport Type:Periodic Company Report #A0077068
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150MG PER DAY ORAL						

Date:03/01/99ISR Number: 3426854-3Report Type:Periodic Company Report #A0077071
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysgeusia Insomnia	Consumer	Zyban Tablet- Zyban	PS	Pharmacia And Upjohn Co	ORAL
150 MG TWICE PER DAY ORAL						

			Nicotine	C	Glaxo Wellcome Inc	ORAL

150 MG/TWICE

PER DAY /ORAL

Date:03/01/99ISR Number: 3426857-9Report Type:Periodic Company Report #A0077072
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation	Consumer	Bupropion			
	Dermatitis		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG /

TWICE PER DAY

ORAL

Nervousness		
Tremor		
	Mellaril	C
	Theophylline	C
	Prednisone	C
	Oxygen	C

Date:03/01/99ISR Number: 3426858-0Report Type:Periodic Company Report #A0077073
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Skin Odour Abnormal	Consumer	Bupropion			
	Sweat Gland Disorder		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG/TWICE

PER DAY/ORAL

Urine Odour Abnormal		
	Theophylline	C

Date:03/01/99ISR Number: 3426860-9Report Type:Periodic Company Report #A0077075
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Decreased Appetite	Consumer	Bupropion			

	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG TWICE

PER DAY ORAL

Date:03/01/99ISR Number: 3426864-6Report Type:Periodic Company Report #A0077076
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Abdominal Pain	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG PER

DAY ORAL

Date:03/01/99ISR Number: 3426866-XReport Type:Periodic Company Report #A0077077
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Crying	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
	Major Depression					
			Paroxetine Hydrochloride	C		
			Alprazolam	C		

Dose Duration

150 MG TWICE

PER DAY ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3426869-5Report Type:Periodic Company Report #A0077078
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hunger	Consumer	Bupropion					
	Mood Swings		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	

Date:03/01/99ISR Number: 3426874-9Report Type:Periodic Company Report #A0077079
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion					
	Mouth Ulceration		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAYORAL	

Date:03/01/99ISR Number: 3426876-2Report Type:Periodic Company Report #A0077081
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Bupropion					
	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Benazepril Hydrochloride	C				
			Thyroxine Sodium	C				
			Atorvastatin Calcium	C				

Date:03/01/99ISR Number: 3426882-8Report Type:Periodic Company Report #A0077082
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Echinacea	C				

Date:03/01/99ISR Number: 3426888-9Report Type:Periodic Company Report #A0077083
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pruritus Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Hrt	C				

Date:03/01/99ISR Number: 3426892-0Report Type:Periodic Company Report #A0077084
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3426899-3Report Type:Periodic Company Report #A0076185
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dysgeusia						PER DAY, ORAL	
	Parosmia		Pravastatin Sodium	C				
			Tamoxifen Citrate	C				
			Alprazolam	C				

Date:03/01/99ISR Number: 3426911-1Report Type:Periodic Company Report #A0076186
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Memory Impairment						PER DAY ORAL	
	Therapeutic Response		Fluoxetine					
	Unexpected		Hydrochloride	C				
			Neural Therapy	C				

Date:03/01/99ISR Number: 3426917-2Report Type:Periodic Company Report #A0076187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	

Date:03/01/99ISR Number: 3426920-2Report Type:Periodic Company Report #A0076188
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG TWICE

PER DAY ORAL

Date:03/01/99ISR Number: 3426922-6Report Type:Periodic Company Report #A0076189
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG SINGLE	
	Urticaria						DOSE ORAL	

Date:03/01/99ISR Number: 3426924-XReport Type:Periodic Company Report #A0076191
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus	Professional					PER DAY ORAL	
	Swelling		Diclofenac Sodium	C				
	Urticaria		Naproxen Sodium	C				

Date:03/01/99ISR Number: 3426926-3Report Type:Periodic Company Report #A0076192
Age:33 YR Gender:Female I/FU:I

Outcome	PT
	Insomnia
	Pruritus

	Rash Papular					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
PER DAY ORAL						
			Ibuprofen	C		

Date:03/01/99ISR Number: 3426929-9Report Type:Periodic Company Report #A0076193
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Tachycardia					
PER DAY ORAL						

Date:03/01/99ISR Number: 3426931-7Report Type:Periodic Company Report #A0076194
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Insomnia					
PER DAY ORAL						
	Pharyngolaryngeal Pain		Triphasil	C		

Date:03/01/99ISR Number: 3426934-2Report Type:Periodic Company Report #A0076195
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG PER						
	Insomnia					
DAY ORAL						
	Musculoskeletal Stiffness		Cefaclor	C		

Date:03/01/99ISR Number: 3426936-6Report Type:Periodic Company Report #A0076197
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Swelling						PER DAY ORAL	
	Urticaria							

Date:03/01/99ISR Number: 3426940-8Report Type:Periodic Company Report #A0076199
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG SINGLE	
	Feeling Abnormal						DOSE ORAL	
	Flatulence		Thyroxine Sodium	C				
	Headache							
	Mental Impairment							
	Nausea							

Date:03/01/99ISR Number: 3426943-3Report Type:Periodic Company Report #A0076200
Age:60 YR Gender:Male I/FU:I

Outcome	PT
	Constipation
	Flatulence

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Vitamin E	C				
			Aspirin	C				

Date:03/01/99ISR Number: 3426946-9Report Type:Periodic Company Report #A0076201
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Omeprazole	C				

Date:03/01/99ISR Number: 3426951-2Report Type:Periodic Company Report #A0076202
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:03/01/99ISR Number: 3426955-XReport Type:Periodic Company Report #A0076203
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dizziness	Professional						PER DAY ORAL

	Feeling Hot		Verapamil	C		
	Flatulence		Lisinopril	C		
	Haemorrhoids		Atorvastatin Calcium	C		
	Ill-Defined Disorder					
	Nausea					

Date:03/01/99ISR Number: 3426958-5Report Type:Periodic Company Report #A0076204
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dermatitis						PER DAY ORAL	
	Pruritus		Medroxyprogesterone Ace.	C				

Date:03/01/99ISR Number: 3426962-7Report Type:Periodic Company Report #A0076205
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dry Mouth						PER DAY ORAL	
	Ear Discomfort		Nifedipine	C				
	Migraine							
	Pharyngolaryngeal Pain							
	Rhinorrhoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3426966-4Report Type:Periodic Company Report #A0076206
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Insomnia						PER DAY ORAL	
	Tremor							

Date:03/01/99ISR Number: 3426967-6Report Type:Periodic Company Report #A0076207
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	
			Thyroid Medication	C				
			Magnesium Salt	C				
			Multivitamin	C				

Date:03/01/99ISR Number: 3427023-3Report Type:Periodic Company Report #A0076208
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	

Date:03/01/99ISR Number: 3427025-7Report Type:Periodic Company Report #A0076209
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	

	Pruritus					
PER DAY ORAL						
	Urticaria					

Date:03/01/99ISR Number: 3427026-9Report Type:Periodic Company Report #A0076210
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyslexia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
PER DAY ORAL								

Date:03/01/99ISR Number: 3427030-0Report Type:Periodic Company Report #A0076383
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	TWICE PER DAY	
	Dysgraphia							
ORAL								
	Feeling Drunk		Prempro	C				
	Speech Disorder							
	Vertigo							

Date:03/01/99ISR Number: 3427036-1Report Type:Periodic Company Report #A0076409
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
PER DAY ORAL								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427037-3Report Type:Periodic Company Report #A0076410
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	DAY ORAL

Date:03/01/99ISR Number: 3427041-5Report Type:Periodic Company Report #A0076412
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Rash Erythematous						PER DAY ORAL	
	Urticaria		Antibiotics	C				
			Miconazole Nitrate	C				
			Tylenol With Codeine	C				

Date:03/01/99ISR Number: 3427043-9Report Type:Periodic Company Report #A0076413
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Hyperhidrosis						DAY ORAL	
			Aspirin	C				
			Vitamin	C				

Date:03/01/99ISR Number: 3427046-4Report Type:Periodic Company Report #A0076414
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Pruritus					
PER DAY ORAL						
	Tinnitus		Simvastatin	C		

Date:03/01/99ISR Number: 3427051-8Report Type:Periodic Company Report #A0076415
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Insomnia					
PER DAY ORAL						

Date:03/01/99ISR Number: 3427055-5Report Type:Periodic Company Report #A0076416
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Vomiting					
PER DAY ORAL						
			Salbutamol Sulphate	C		

Date:03/01/99ISR Number: 3427062-2Report Type:Periodic Company Report #A0076417
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Pharyngolaryngeal Pain					
PER DAY ORAL						
			Birth Control	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427064-6Report Type:Periodic Company Report #A0076421
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:03/01/99ISR Number: 3427068-3Report Type:Periodic Company Report #A0076521
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Nausea							
			Birth Control	C				

Date:03/01/99ISR Number: 3427071-3Report Type:Periodic Company Report #A0076522
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:03/01/99ISR Number: 3427082-8Report Type:Periodic Company Report #A0076524
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Hyperhidrosis							
	Insomnia							

Memory Impairment
Nervousness
Tachycardia
Tremor

Date:03/01/99ISR Number: 3427086-5Report Type:Periodic Company Report #A0076525
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Headache						DAY ORAL	

Date:03/01/99ISR Number: 3427088-9Report Type:Periodic Company Report #A0076526
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Hypoaesthesia Oral						PER DAY ORAL	
	Pruritus							
	Urticaria							

Date:03/01/99ISR Number: 3427091-9Report Type:Periodic Company Report #A0076527
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427093-2Report Type:Periodic Company Report #A0075291
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspraxia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Movement Disorder	Professional					PER DAY ORAL	
		Company Representative	Probenecid	C				
			Clobetasol Priopionate	C				
			Atenolol	C				
			Atorvastatin Calcium	C				
			Insulin	C				
			Thyroxine Sodium	C				
			Lisinopril	C				
			Trazodone Hydrochloride	C				
			Diazepam	C				
			Aspirin	C				

Date:03/01/99ISR Number: 3427096-8Report Type:Periodic Company Report #A0075292
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	
			Oral Contraceptive	C				

Date:03/01/99ISR Number: 3427098-1Report Type:Periodic Company Report #A0075293
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	
	Pain							
	Pruritus		Clidinium Bromide	C				

	Swelling		Lansoprazole	C		
	Urticaria					

Date:03/01/99ISR Number: 3427100-7Report Type:Periodic Company Report #A0075294
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICED	
	Mouth Ulceration						PER DAY ORAL	
	Pain		Diuretic	C				
			Multivitamin	C				

Date:03/01/99ISR Number: 3427103-2Report Type:Periodic Company Report #A0075295
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Nausea						DAY ORAL	
			Azithromycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427104-4Report Type:Periodic Company Report #A0075296
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG SINGLE	
	Depression						DOSE ORAL	
	Drug Interaction		Cannabis	SS				
	Emotional Disorder							
	Mood Altered							
	Nightmare							

Date:03/01/99ISR Number: 3427107-XReport Type:Periodic Company Report #A0075297
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Insomnia						PER DAY ORAL	
	Major Depression		Hrt	C				
	Nausea		Multivitamin	C				

Date:03/01/99ISR Number: 3427112-3Report Type:Periodic Company Report #A0075298
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Nervousness							

Date:03/01/99ISR Number: 3427115-9Report Type:Periodic Company Report #A0075300
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Dizziness					
PER DAY ORAL						
	Dry Mouth		Hydrochlorothiazide	C		
	Gingival Bleeding		Microdiol	C		
	Increased Appetite					
	Insomnia					
	Toothache					

Date:03/01/99ISR Number: 3427123-8Report Type:Periodic Company Report #A0775301
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Chest Pain	Professional				
PER DAY ORAL						
	Dizziness		Atorvastatin Calcium	C		
	Insomnia					
	Palpitations					

Date:03/01/99ISR Number: 3427126-3Report Type:Periodic Company Report #A0075303
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Swelling					
PER DAY ORAL						
			Zestoretic	C		
			Atorvastatin Calcium	C		

			Ethanol	C		

Date:03/01/99ISR Number: 3427129-9Report Type:Periodic Company Report #A0075304
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	DAY ORAL
			Lisinopril	C				

Date:03/01/99ISR Number: 3427132-9Report Type:Periodic Company Report #A0075305
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Urticaria						PER DAY ORAL	

Date:03/01/99ISR Number: 3427133-0Report Type:Periodic Company Report #A0075306
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	

Date:03/01/99ISR Number: 3427136-6Report Type:Periodic Company Report #A0075308
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Fatigue					
PER DAY ORAL						
	Irritability		Multivitamin	C		
	Mood Altered					

Date:03/01/99ISR Number: 3427138-XReport Type:Periodic Company Report #A0075310
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Disturbance In Attention					
PER DAY ORAL						
	Hyperhidrosis		Buspirone Hydrochloride	C		

Date:03/01/99ISR Number: 3427142-1Report Type:Periodic Company Report #A0075312
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Nausea					
PER DAY ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427146-9Report Type:Periodic Company Report #A0075313
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Pruritus	Professional	Comtrex	C				
	Purpura		Ibuprofen	C				
	Rash Macular							
	Rash Papular							
	Urticaria							

Date:03/01/99ISR Number: 3427151-2Report Type:Periodic Company Report #A0075341
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal Clearance Decreased	Consumer	Zyban	PS	Glaxo Wellcome Inc			
	Drug Interaction		Thyroxine Sodium Tablet	SS				

Date:03/01/99ISR Number: 3427154-8Report Type:Periodic Company Report #A0075375
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	
	Dry Mouth							
	Dysgeusia							
	Epistaxis							
	Hallucination							
	Nausea							
	Palpitations							
	Pollakiuria							
	Tremor							

Date:03/01/99ISR Number: 3427167-6Report Type:Periodic Company Report #A0075038
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Nasal Congestion						DAY/ ORAL	

Date:03/01/99ISR Number: 3427171-8Report Type:Periodic Company Report #A0075039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc		10	DAY
	Irritability							

Date:03/01/99ISR Number: 3427172-XReport Type:Periodic Company Report #A0075041
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tension	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	
			Blood Pressure Medication	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427175-5Report Type:Periodic Company Report #A0075047
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:03/01/99ISR Number: 3427178-0Report Type:Periodic Company Report #A0075050
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Anxiety	Professional						PER DAY/ORAL
	Dizziness		Paroxetine Hydrochloride	C				
	Dry Mouth		Trazodone	C				
	Dry Throat		Alprazolam	C				
	Headache		Herbal Medication	C				
	Insomnia		Multivitamin	C				
	Nausea		Fluticasone Propionate	C				
	Nervousness		Salbutamol Sulphate	C				
	Tremor							

Date:03/01/99ISR Number: 3427180-9Report Type:Periodic Company Report #A0075051
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	

Date:03/01/99ISR Number: 3427182-2Report Type:Periodic Company Report #A0075052
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
			Oral Contraceptive	C				ORAL

Date:03/01/99ISR Number: 3427184-6Report Type:Periodic Company Report #A0075053
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	PER DAY/
	Tremor							ORAL
	Vomiting		Tramadol Hydrochloride	C				

Date:03/01/99ISR Number: 3427186-XReport Type:Periodic Company Report #A0075055
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Gastrooesophageal Reflux Disease							ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427188-3Report Type:Periodic Company Report #A0075074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL

Date:03/01/99ISR Number: 3427190-1Report Type:Periodic Company Report #A0075075
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Condition Aggravated						PER DAY/	ORAL
	Confusional State		Omeprazole	C				
	Dermatitis		Oral Contraceptive	C				
	Diarrhoea							
	Electric Shock							
	Feeling Abnormal							
	Hyperhidrosis							
	Smoker							
	Swelling							
	Tachycardia							
	Tremor							

Date:03/01/99ISR Number: 3427192-5Report Type:Periodic Company Report #A0075076
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
							PER DAY/	ORAL
			No Concurrent Medication	C				

Date:03/01/99ISR Number: 3427194-9Report Type:Periodic Company Report #A0075077
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Hyperhidrosis	Professional						ORAL
	Nausea		Cimetidine	C				
	Vomiting		Donnatal	C				

Date:03/01/99ISR Number: 3427217-7Report Type:Periodic Company Report #A0075109
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL

Date:03/01/99ISR Number: 3427219-0Report Type:Periodic Company Report #A0075189
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/ ORAL
			Semisodium Valproate	C				
			Paroxetine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427221-9Report Type:Periodic Company Report #A0075190
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Dissociation						DAY / ORAL	
	Disturbance In Attention							
	Insomnia							

Date:03/01/99ISR Number: 3427224-4Report Type:Periodic Company Report #A0075191
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Diarrhoea						PER DAY/ ORAL	
	Urine Abnormality		....	C				

Date:03/01/99ISR Number: 3427226-8Report Type:Periodic Company Report #A0075200
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Headache						PER DAY/ ORAL	

Date:03/01/99ISR Number: 3427229-3Report Type:Periodic Company Report #A0075289
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	

	Insomnia					
PER DAY/ ORAL						
	Sleep Talking			Birth Control	C	
	Sleep Walking					
	Tachycardia					
	Tremor					

Date:03/01/99ISR Number: 3427230-XReport Type:Periodic Company Report #A0075290
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
PER DAY/ ORAL						
			Conjugated Estrogens	C		
			Ascorbic Acid	C		

Date:03/01/99ISR Number: 3427257-8Report Type:Periodic Company Report #A0076528
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Upper	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG ORAL						
		Professional				
		Company				
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427259-1Report Type:Periodic Company Report #A0076529
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
		Professional						
		Company						
		Representative						

Date:03/01/99ISR Number: 3427261-XReport Type:Periodic Company Report #A0076557
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus	Professional					PER DAY ORAL	
	Swelling		Thyroxine Sodium	C				

Date:03/01/99ISR Number: 3427262-1Report Type:Periodic Company Report #A0076558
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
							DAY ORAL	
			Multivitamin	C				

Date:03/01/99ISR Number: 3427264-5Report Type:Periodic Company Report #A0076559
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

MONTHS MON

			Unknown Patch	SS		

Date:03/01/99ISR Number: 3427266-9Report Type:Periodic Company Report #A0076560
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Arthropathy						PER DAY ORAL	
	Fall		Amitriptyline Hcl	C				
			Famotidine	C				
			Fluticasone Propionate	C				

Date:03/01/99ISR Number: 3427269-4Report Type:Periodic Company Report #A0076561
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Insomnia						PER DAY ORAL	
			Ortho-Novum	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427271-2Report Type:Periodic Company Report #A0076562
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL
			Ibuprofen	C				

Date:03/01/99ISR Number: 3427274-8Report Type:Periodic Company Report #A0076563
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL
	Urticaria	Professional						
			Medroxyprogesterone Ace.	C				

Date:03/01/99ISR Number: 3427275-XReport Type:Periodic Company Report #A0076564
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL	4	WK
			Multivitamin	C				

Date:03/01/99ISR Number: 3427278-5Report Type:Periodic Company Report #A0076969
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Texture Abnormal	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	

PER DAY ORAL						
			Multivitamin	C		
			Mesalazine	C		

Date:03/01/99ISR Number: 3427281-5Report Type:Periodic Company Report #A0076970
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pneumonia						PER DAY ORAL	
	Upper Respiratory Tract		Thyroxine Sodium	C				
	Infection		Loestrin	C				
			Omeprazole	C				

Date:03/01/99ISR Number: 3427282-7Report Type:Periodic Company Report #A0076971
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Anxiety						PER DAY ORAL	
	Insomnia		Conjugated Estrogens	C				
	Malaise		Cimetidine	C				
	Nervousness		Oxybutynin					
	Tremor		Hydrochloride	C				
			Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427284-0Report Type:Periodic Company Report #A0076972
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Aspirin	C				
			Clopidogrel Bisulphate	C				
			Omeprazole	C				

Date:03/01/99ISR Number: 3427286-4Report Type:Periodic Company Report #A0076973
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dysgeusia							PER DAY ORAL
	Headache		Famotidine	C				
	Insomnia		Cetirizine Hydrochloride	C				
	Tremor		Alendronate Sodium	C				
			Atorvastatin Calcium	C				
			Triamcinolone Acetonide	C				
			Naproxen	C				
			Salbutamol Sulphate	C				
			Ipratropium Bromide	C				

Date:03/01/99ISR Number: 3427288-8Report Type:Periodic Company Report #A0076974
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Sensation Of Pressure							PER DAY ORAL

Date:03/01/99ISR Number: 3427289-XReport Type:Periodic Company Report #A0076975
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	TWICE
	Tremor						PER DAY	ORAL
			Ziac	C				
			Alprazolam	C				
			Bumetanide	C				
			Antibiotics	C				

Date:03/01/99ISR Number: 3427290-6Report Type:Periodic Company Report #A0076976
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Estropipate	C				
			Progesterone	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427291-8Report Type:Periodic Company Report #A0076977
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	TWICE
	Nervousness						PER DAY	ORAL
			Tamoxifen	C				

Date:03/01/99ISR Number: 3427292-XReport Type:Periodic Company Report #A0076978
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	TWICE
	Diarrhoea						PER DAY	ORAL
	Dizziness		Ranitidine					
	Nausea		Hydrochloride	C				
	Tremor		Conjugated Estrogens	C				

Date:03/01/99ISR Number: 3427294-3Report Type:Periodic Company Report #A0075390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ UKN /	
							ORAL	

Date:03/01/99ISR Number: 3427295-5Report Type:Periodic Company Report #A0075419
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc		UNK	24 DAY

Emotional Disorder
Headache
Irritability
Lethargy
Major Depression
Weight Increased

Date:03/01/99ISR Number: 3427297-9Report Type:Periodic Company Report #A0075524
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Fatigue							
	Malaise							
	Urticaria							

Date:03/01/99ISR Number: 3427298-0Report Type:Periodic Company Report #A0075525
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Sumatriptan Succinate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427300-6Report Type:Periodic Company Report #A0075526
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Hypertension						TWICE PER DAY	
	Lethargy						/ ORAL	
	Syncope							

Date:03/01/99ISR Number: 3427301-8Report Type:Periodic Company Report #A0075527
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc		150 MG /	
	Headache						TWICE PER DAY	
	Tremor						/ ORAL	

Date:03/01/99ISR Number: 3427303-1Report Type:Periodic Company Report #A0075528
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Thyroxine Sodium	C				

Date:03/01/99ISR Number: 3427308-0Report Type:Periodic Company Report #A0075529
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Headache	Professional					TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3427310-9Report Type:Periodic Company Report #A0075530
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3427311-0Report Type:Periodic Company Report #A0075531
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dry Mouth						TWICE PER DAY	
	Dysgeusia						/ ORAL	
	Headache							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427357-2Report Type:Periodic Company Report #A0076565
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Glucophage	C				
			Lisinopril	C				
			Warfarin Sodium	C				
			Glipizide	C				

Date:03/01/99ISR Number: 3427361-4Report Type:Periodic Company Report #A0076566
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Insomnia						DAY ORAL	
	Major Depression							

Date:03/01/99ISR Number: 3427363-8Report Type:Periodic Company Report #A0076567
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Eye Disorder						PER DAY ORAL	
	Eye Irritation		Nyquil	C				
	Hypersensitivity		Tylenol Sinus					
	Pruritus		Medication	C				
	Swelling							

Date:03/01/99ISR Number: 3427373-0Report Type:Periodic Company Report #A0076568
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Nervousness						DAY ORAL	
	Palpitations							

Date:03/01/99ISR Number: 3427374-2Report Type:Periodic Company Report #A0076569
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	

Date:03/01/99ISR Number: 3427376-6Report Type:Periodic Company Report #A0076570
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Insomnia						PER DAY ORAL	
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427377-8Report Type:Periodic Company Report #A0076571
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dizziness						PER DAY ORAL	
	Insomnia		Triamterene	C				
	Panic Attack		Digoxin	C				
	Syncope		Oxpentifylline	C				
			Lisinopril	C				
			Vitamin	C				
			Aspirin	C				
			Defibrillation	C				

Date:03/01/99ISR Number: 3427380-8Report Type:Periodic Company Report #A0076572
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc			
			Atorvastatin Calcium	C				
			Aspirin	C				
			Ginkgo Biloba	C				

Date:03/01/99ISR Number: 3427381-XReport Type:Periodic Company Report #A0076573
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Buspirone Hydrochloride	C				
			Hydroxyzine	C				

Date:03/01/99ISR Number: 3427383-3Report Type:Periodic Company Report #A0076574
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Confusional State						PER DAY ORAL	
	Nausea		Ibuprofen	C				
	Stomach Discomfort		Beclomethasone Dipropion.	C				

Date:03/01/99ISR Number: 3427384-5Report Type:Periodic Company Report #A0076575
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dissociation						PER DAY ORAL	
	Hyperhidrosis							
	Nausea							
	Paranoia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427386-9Report Type:Periodic Company Report #A0076610
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Arrhythmia						PER DAY ORAL	
	Dysgeusia		Amitriptyline Hcl	C				
	Dyspnoea							
	Headache							
	Tachycardia							
	Tremor							

Date:03/01/99ISR Number: 3427388-2Report Type:Periodic Company Report #A0076617
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Arrhythmia						PER DAY ORAL	
	Constipation							
	Dry Mouth							
	Dysgeusia							
	Dyspnoea							
	Headache							
	Hyperhidrosis							
	Tremor							
	Vision Blurred							

Date:03/01/99ISR Number: 3427390-0Report Type:Periodic Company Report #A0076656
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Headache						DAY ORAL	
	Nausea		Multivitamin	C				

	Vomiting					

Date:03/01/99ISR Number: 3427392-4Report Type:Periodic Company Report #A0076716
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Joint Swelling	Professional Company Representative						

Date:03/01/99ISR Number: 3427393-6Report Type:Periodic Company Report #A0076724
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Attention						PER DAY ORAL	
	Deficit/Hyperactivity Disorder							
	Depression							
	Disturbance In Attention							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427394-8Report Type:Periodic Company Report #A0076735
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Nausea						PER DAY ORAL	
	Nervousness							
	Tremor							

Date:03/01/99ISR Number: 3427396-1Report Type:Periodic Company Report #A0076739
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Company	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Nightmare	Representative						

Date:03/01/99ISR Number: 3427398-5Report Type:Periodic Company Report #A0076851
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	
	Urticaria		Entex La	C				
			Beclomethasone Dipropion.	C				

Date:03/01/99ISR Number: 3427399-7Report Type:Periodic Company Report #A0076855
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	

PER DAY ORAL

			Enalapril Maleate	C		

Date:03/01/99ISR Number: 3427400-0Report Type:Periodic Company Report #A0076884
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Major Depression						PER DAY ORAL	

Date:03/01/99ISR Number: 3427401-2Report Type:Periodic Company Report #A0076888
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dyspepsia						PER DAY ORAL	
	Nausea		Actifed	C				

Date:03/01/99ISR Number: 3427402-4Report Type:Periodic Company Report #A0076889
Age:40 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain Upper
	Face Oedema
	Fatigue

Oedema Peripheral

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
PER DAY ORAL						
			Thyroxine Sodium	C		

Date:03/01/99ISR Number: 3427403-6Report Type:Periodic Company Report #A0076890
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
PER DAY ORAL						
			Thyroxine Sodium	C		

Date:03/01/99ISR Number: 3427404-8Report Type:Periodic Company Report #A0076891
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Insomnia					
PER DAY ORAL						
	Tremor		Lovastatin	C		

Date:03/01/99ISR Number: 3427405-XReport Type:Periodic Company Report #A0076892
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Aggression	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Personality Change	Professional				
OER DAY ORAL						

Diltiazem	C
Glucophage	C
Glibenclamide	C

Date:03/01/99ISR Number: 3427406-1Report Type:Periodic Company Report #A0076893
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Tension						PER DAY ORAL	

Date:03/01/99ISR Number: 3427407-3Report Type:Periodic Company Report #A0076894
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Hypersensitivity						PER DAY ORAL	
	Urticaria							

Date:03/01/99ISR Number: 3427408-5Report Type:Periodic Company Report #A0076895
Age:43 YR Gender:Male I/FU:I

Outcome	PT
	Aggression
	Depression
	Emotional Disorder

	Paranoia						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL
			Ethanol (Formulation Unknown)	SS			
			Cyclobenzaprine Hcl	C			

Date:03/01/99ISR Number: 3427409-7Report Type:Periodic Company Report #A0076896
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Decreased Appetite	Other	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL

Date:03/01/99ISR Number: 3427410-3Report Type:Periodic Company Report #A0076897
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective	Other	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL

Date:03/01/99ISR Number: 3427411-5Report Type:Periodic Company Report #A0076898
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Erythema	Other	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL 2 WK
	Hypersensitivity						
	Pruritus						

Date:03/01/99ISR Number: 3427412-7Report Type:Periodic Company Report #A0076899
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Insomnia						PER DAY ORAL	
	Nervousness							

Date:03/01/99ISR Number: 3427413-9Report Type:Periodic Company Report #A0076900
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	

Date:03/01/99ISR Number: 3427414-0Report Type:Periodic Company Report #A0076901
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Sexual Dysfunction						PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427415-2Report Type:Periodic Company Report #A0076902
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Papular	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Vicodin	C				
			Diazepam	C				

Date:03/01/99ISR Number: 3427416-4Report Type:Periodic Company Report #A0076903
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Erythema Multiforme	Professional						
	Joint Stiffness							
	Joint Swelling							
	Oedema Peripheral							
	Urticaria							

Date:03/01/99ISR Number: 3427417-6Report Type:Periodic Company Report #A0076904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Cold Sweat						PER DAY ORAL	
	Diarrhoea							
	Malaise							
	Tachycardia							
	Vomiting							

Date:03/01/99ISR Number: 3427418-8Report Type:Periodic Company Report #A0076905
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Systolic Increased	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Headache							
	Heart Rate Increased							

Date:03/01/99ISR Number: 3427419-XReport Type:Periodic Company Report #A0076968
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Pruritus							
	Rash Generalised							
	Urticaria							

Date:03/01/99ISR Number: 3427421-8Report Type:Periodic Company Report #A0078538
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Anxiety							
	Dermatitis		Ortho-Novum	C				
	Hyperhidrosis		Ascorbic Acid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427422-XReport Type:Periodic Company Report #A0078539
Age:46 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Estrogen	C				

Date:03/01/99ISR Number: 3427423-1Report Type:Periodic Company Report #A0078566
Age:48 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3427424-3Report Type:Periodic Company Report #A0078818
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Depression							PER DAY ORAL

Date:03/01/99ISR Number: 3427425-5Report Type:Periodic Company Report #A0078819
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Hyzaar	C				
			Prempro	C				
			Etodolac	C				

Date:03/01/99ISR Number: 3427426-7Report Type:Periodic Company Report #A0059124
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc			

Date:03/01/99ISR Number: 3427427-9Report Type:Periodic Company Report #A0060052
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	
			Conjugated Estrogens	C				
			Centrum	C				
			Medroxyprogesterone Ace.	C				

Date:03/01/99ISR Number: 3427428-0Report Type:Periodic Company Report #A0064579
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	
	Malaise		Ibuprofen (Formulation					

			Unknown)	C		

Date:03/01/99ISR Number: 3427429-2Report Type:Periodic Company Report #A0066450
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Headache						PER DAY ORAL	
	Musculoskeletal Stiffness		Bupropion Hydrochloride	C				
	Paraesthesia		Vitamin E	C				
			Multivitamin	C				

Date:03/01/99ISR Number: 3427430-9Report Type:Periodic Company Report #A0070235
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Nervous System Disorder	Professional					PER DAY ORAL	
	Oral Intake Reduced							

Date:03/01/99ISR Number: 3427432-2Report Type:Periodic Company Report #A0070280
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Digoxin	C				
			Atorvastatin Calcium	C				
			Warfarin Sodium	C				
			Losartan Potassium	C				

Date:03/01/99ISR Number: 3427434-6Report Type:Periodic Company Report #A0070823
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Headache	Professional					DAY ORAL	
	Insomnia							

Date:03/01/99ISR Number: 3427436-XReport Type:Periodic Company Report #A0071074
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Dizziness	Professional						
	Hypertension							
	Joint Stiffness							
	Pain In Extremity							
	Skin Exfoliation							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427437-1Report Type:Periodic Company Report #A0071181
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Constipation	Professional					DAY ORAL	
	Disorientation		Nifedipine	C				
	Dry Mouth							
	Hyperhidrosis							
	Insomnia							
	Nausea							

Date:03/01/99ISR Number: 3427438-3Report Type:Periodic Company Report #A0071715
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Balance Disorder	Professional					PER DAY ORAL	
	Blood Pressure Increased		Conjugated Estrogens	C				
	Circulatory Collapse							
	Dizziness							
	Malaise							
	Vision Blurred							

Date:03/01/99ISR Number: 3427440-1Report Type:Periodic Company Report #A0072154
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Dizziness	Professional					DAY ORAL	
	Insomnia		Carvedilol	C				
			Simvastatin	C				
			Digoxin	C				
			Aspirin	C				

Date:03/01/99ISR Number: 3427442-5Report Type:Periodic Company Report #A0072548
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWIC	
	Insomnia	Professional					PER DAY ORAL	
	Pollakiuria		Simvastatin	C				
			Amlodipine	C				

Date:03/01/99ISR Number: 3427444-9Report Type:Periodic Company Report #A0073460
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dizziness	Professional					PER DAY ORAL	
	Fall		Ranitidine					
	Headache		Hydrochloride	C				
	Vision Blurred							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427446-2Report Type:Periodic Company Report #A0073583
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Erythema	Professional					PER DAY ORAL	
	Pruritus		Birth Control	C				

Date:03/01/99ISR Number: 3427448-6Report Type:Periodic Company Report #A0073595
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Insomnia						PER DAY ORAL	
	Pruritus							

Date:03/01/99ISR Number: 3427450-4Report Type:Periodic Company Report #A0078435
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Other	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3427452-8Report Type:Periodic Company Report #A0078436
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Nausea						PER DAY ORAL	
			Metoprolol Tartrate Diltiazem	C				

			Hydrochloride	C		
			Aspirin	C		

Date:03/01/99ISR Number: 3427455-3Report Type:Periodic Company Report #A0078437
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Amitriptyline Hcl	C				
			Glucophage	C				
			Lisinopril	C				

Date:03/01/99ISR Number: 3427456-5Report Type:Periodic Company Report #A0078438
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Decreased Appetite						PER DAY ORAL	
	Dyspepsia		Lotrel	C				
			Oxpentifylline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427457-7Report Type:Periodic Company Report #A0078439
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Headache						PER DAY ORAL	
	Nervousness							

Date:03/01/99ISR Number: 3427459-0Report Type:Periodic Company Report #A0078440
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Nicotine	C				
			Prinzide	C				

Date:03/01/99ISR Number: 3427461-9Report Type:Periodic Company Report #A0078441
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Recession	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Tooth Abscess						PER DAY ORAL	
			Multivitamins	C				

Date:03/01/99ISR Number: 3427463-2Report Type:Periodic Company Report #A0078442
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	

PER DAY ORAL

				Lansoprazole	C		
				Losartan Potassium	C		
				Prednisone	C		

Date:03/01/99ISR Number: 3427465-6Report Type:Periodic Company Report #A0078443
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Capillary Leak Syndrome	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Hypersensitivity	Professional						
	Swelling	Company Representative						

Date:03/01/99ISR Number: 3427467-XReport Type:Periodic Company Report #A0078450
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Major Depression	Professional						
		Company Representative	Conjugated Estrogens	C			PER DAY ORAL	
			Simvatatin	C				
			Ranitidine Hydrochloride	C				
			Amlodipine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427469-3Report Type:Periodic Company Report #A0078527
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dissociation						PER DAY ORAL	
	Nervousness		Warfarin Sodium	C				
			Ibuprofen	C				

Date:03/01/99ISR Number: 3427472-3Report Type:Periodic Company Report #A0078528
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dysgeusia						PER DAY ORAL	
	Insomnia		Diltiazem Hydrochloride	C				
			Simvastatin	C				
			Alprazolam	C				
			Paracetamol	C				

Date:03/01/99ISR Number: 3427474-7Report Type:Periodic Company Report #A0078529
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Orgasm Abnormal	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Sexual Dysfunction						PER DAY ORAL	
			Nortriptyline Hcl	C				

Date:03/01/99ISR Number: 3427476-0Report Type:Periodic Company Report #A0078530
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Lethargy						PER DAY ORAL	
			Simvastatin	C				
			Omeprazole	C				

Date:03/01/99ISR Number: 3427477-2Report Type:Periodic Company Report #A0078532
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pain						PER DAY ORAL	

Date:03/01/99ISR Number: 3427479-6Report Type:Periodic Company Report #A0078533
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Erythema						DAY ORAL	
	Skin Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427481-4Report Type:Periodic Company Report #A0078534
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	
	Swelling							
	Urticaria							

Date:03/01/99ISR Number: 3427483-8Report Type:Periodic Company Report #A0078535
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Drug Dependence						DAY ORAL	
	Psychomotor Hyperactivity		Alendronate Sodium	C				

Date:03/01/99ISR Number: 3427484-XReport Type:Periodic Company Report #A0078536
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dysgeusia						PER DAY ORAL	
	Insomnia		Alprazolam	C				
	Nausea							

Date:03/01/99ISR Number: 3427486-3Report Type:Periodic Company Report #A0078537
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chest Discomfort	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
TWICE PER DAY						
	Chest Pain	Professional				
ORAL						
	Excitability					
	Headache					
	Nausea					

Date:03/01/99ISR Number: 3427488-7Report Type:Periodic Company Report #A0076979
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ PER						
	Dry Mouth					
DAY/ ORAL						
	Headache		Ibuprofen	C		
	Insomnia					

Date:03/01/99ISR Number: 3427489-9Report Type:Periodic Company Report #A0076980
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Flatulence	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ PER						
	Nausea	Professional				
DAY/ ORAL						
			Antacid	C		
			Librax	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427491-7Report Type:Periodic Company Report #A0076981
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Dysgeusia							ORAL
			Prempro	C				
			Simvastatin	C				

Date:03/01/99ISR Number: 3427498-XReport Type:Periodic Company Report #A0076982
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspraxia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/ ORAL

Date:03/01/99ISR Number: 3427500-5Report Type:Periodic Company Report #A0076983
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperventilation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/ ORAL
	Panic Disorder							
	Paraesthesia		Tylenol Sinus					
	Syncope		Medication	C				
	Tachycardia		Tetracycline	C				

Date:03/01/99ISR Number: 3427502-9Report Type:Periodic Company Report #A0076984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ ORAL 17 DAY						
	Irritability					
	Mood Altered					

Date:03/01/99ISR Number: 3427504-2Report Type:Periodic Company Report #A0076985
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ PER						
	Irritability					
DAY/ ORAL						
	Nervousness					

Date:03/01/99ISR Number: 3427506-6Report Type:Periodic Company Report #A0076986
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
	Hyperhidrosis					
PER DAY/ ORAL						
	Nervousness		Nizatidine	C		
			Isosorbide Mononitrate	C		
			Enalapril Maleate	C		
			Simvastatin	C		
			Aspirin	C		
			Frusemide	C		
			Potassium Chloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427507-8Report Type:Periodic Company Report #A0076987
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Decreased Appetite						PER DAY/ ORAL	
	Disorientation							
	Faeces Discoloured							
	Gout							
	Personality Change							

Date:03/01/99ISR Number: 3427509-1Report Type:Periodic Company Report #A0076988
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Urticaria						PER DAY/ ORAL	
			Fexofenadine Hydrochlorid	C				

Date:03/01/99ISR Number: 3427511-XReport Type:Periodic Company Report #A0077002
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	
			Cefuroxime Axetil	C				

Date:03/01/99ISR Number: 3427512-1Report Type:Periodic Company Report #A0077003
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL
			Thyroxine Sodium	C				

Date:03/01/99ISR Number: 3427513-3Report Type:Periodic Company Report #A0077004
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL
	Constipation	Professional						
	Dry Mouth							
	Insomnia							
	Irritability							
	Muscle Twitching							
	Restlessness							

Date:03/01/99ISR Number: 3427514-5Report Type:Periodic Company Report #A0077005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427515-7Report Type:Periodic Company Report #A0077006
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Disorientation							
	Insomnia		Nabumetone	C				

Date:03/01/99ISR Number: 3427516-9Report Type:Periodic Company Report #A0077025
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
	Oedema Peripheral							DAILY/
	Pruritus		Conjugated Estrogen	C				
	Urticaria		Amitriptyline Hcl	C				

Date:03/01/99ISR Number: 3427517-0Report Type:Periodic Company Report #A0077026
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/

Date:03/01/99ISR Number: 3427518-2Report Type:Periodic Company Report #A0077027
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bipolar I Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE

	Suicidal Ideation					
PER DAY/ ORAL						
			Nicotine	C		
			Ketorolac No. 3	C		
			Zolpidem Tartrate	C		

Date:03/01/99ISR Number: 3427519-4Report Type:Periodic Company Report #A0077028
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Erythema						DAY/ ORAL	
	Vomiting		Nefazodone Hydrochloride	C				

Date:03/01/99ISR Number: 3427520-0Report Type:Periodic Company Report #A0077029
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Dry Mouth						PER DAY/ ORAL	
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427865-4Report Type:Periodic Company Report #A0073729
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Agitation	Professional					DAY / ORAL	

Date:03/01/99ISR Number: 3427867-8Report Type:Periodic Company Report #A0073753
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Tremor						TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3427870-8Report Type:Periodic Company Report #A0073775
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
		Professional					TIWCE PER DAY	
							/ ORAL	
			Propranolol	C				
			Medroxyprogesterone Ace.	C				
			Dicyclomine	C				
			Hypericum	C				
			Ginkgo Biloba	C				
			Stool Softener	C				
			Polycarbophil Calcium	C				
			Multivitamin	C				

Date:03/01/99ISR Number: 3427875-7Report Type:Periodic Company Report #A0073815
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Insomnia	Professional					TWICE PER DAY	
							/ ORAL	
			Oxpentifylline	C				
			Dipyridamole	C				
			Maxzide	C				
			Diltiazem Hydrochloride	C				
			Nitroglycerin	C				
			Aspirin	C				
			Glibenclamide	C				

Date:03/01/99ISR Number: 3427879-4Report Type:Periodic Company Report #A0073822
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Urticaria	Professional					TWICE PER DAY	
							/ ORAL	
			Lisinopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427882-4Report Type:Periodic Company Report #A0073823
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tic	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3427886-1Report Type:Periodic Company Report #A0073834
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	
	Urticaria							

Date:03/01/99ISR Number: 3427890-3Report Type:Periodic Company Report #A0073837
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3427893-9Report Type:Periodic Company Report #A0073850
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	

	Dysgeusia	Professional					
DAY / ORAL							
	Hypoaesthesia		Diltiazem Hydrochloride	C			
			Paroxetine Hydrochloride	C			
			Hydrochlorothiazide	C			
			Conjugated Estrogens	C			
			Vitamin	C			

Date:03/01/99ISR Number: 3427897-6Report Type:Periodic Company Report #A0074067
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Headache	Professional					DAY / ORAL	
	Hyperhidrosis							
	Insomnia							
	Nausea							
	Sedation							
	Sinus Headache							

Date:03/01/99ISR Number: 3427903-9Report Type:Periodic Company Report #A0074207
Age:65 YR Gender:Female I/FU:F

Outcome	PT
	Difficulty In Walking
	Hypersensitivity
	Insomnia

	Nail Discolouration Pain Pruritus	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Rash Erythematous	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG /
	Swelling	Professional				TWICE PER DAY
	Tachycardia					/ ORAL
			Conjugated Estrogens	C		

Date:03/01/99ISR Number: 3427907-6Report Type:Periodic Company Report #A0074222
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Agitation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ PER
	Psychomotor Hyperactivity	Professional				DAY / ORAL

Date:03/01/99ISR Number: 3427913-1Report Type:Periodic Company Report #A0074966
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Nightmare	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 / TWICE
		Professional				PER DAY /
		Company				ORAL
		Representative				

Date:03/01/99ISR Number: 3427916-7Report Type:Periodic Company Report #A0077085
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration

	Conjunctival Oedema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Urticaria					
PER DAY ORAL						

Date:03/01/99ISR Number: 3427918-0Report Type:Periodic Company Report #A0077086
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Eyelid Oedema	Professional				
PER DAY ORAL						
	Face Oedema		Nicotine	C		
	Hypersensitivity					
	Pruritus					
	Rash Erythematous					
	Rash Generalised					
	Urticaria					

Date:03/01/99ISR Number: 3427920-9Report Type:Periodic Company Report #A0077141
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG						
	Chest Pain					
TWICE PER DAY						
ORAL						
			Herbal Medication	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3427923-4Report Type:Periodic Company Report #A0077145
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL

Date:03/01/99ISR Number: 3427925-8Report Type:Periodic Company Report #A0077154
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL
			Salbutamol Sulphate	C				

Date:03/01/99ISR Number: 3427929-5Report Type:Periodic Company Report #A0077233
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	7 DAY
	Dyspnoea							
	Speech Disorder							
	Throat Tightness							

Date:03/01/99ISR Number: 3427932-5Report Type:Periodic Company Report #A0077271
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL
	Urticaria							

Date:03/01/99ISR Number: 3427936-2Report Type:Periodic Company Report #A0077337
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Other	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL

Date:03/01/99ISR Number: 3427938-6Report Type:Periodic Company Report #A0077338
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphemia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	TWICE
	Excitability						PER DAY	ORAL
	Headache							
	Insomnia							
	Tinnitus							

Date:03/01/99ISR Number: 3427940-4Report Type:Periodic Company Report #A0077339
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	PER
	Sedation						DAY	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431025-0Report Type:Periodic Company Report #A0076174
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	DAY/ ORAL
			Fosinopril Sodium	C				

Date:03/01/99ISR Number: 3431027-4Report Type:Periodic Company Report #A0076175
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:03/01/99ISR Number: 3431028-6Report Type:Periodic Company Report #A0076176
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:03/01/99ISR Number: 3431031-6Report Type:Periodic Company Report #A0076177
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Rash Generalised	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	PER DAY/ ORAL

			Nicotine Patch	SS			
TRANSDERMAL	21 MG/ AS						
REQUIRED/							
TRANSDERMAL							

Date:03/01/99ISR Number: 3431033-XReport Type:Periodic Company Report #A0076178
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
		Professional					PER DAY/ ORAL	
			Simvastatin	C				
			Estrostep 21	C				

Date:03/01/99ISR Number: 3431037-7Report Type:Periodic Company Report #A0076179
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	
			Atorvastatin Calcium	C				
			Moduretic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431042-0Report Type:Periodic Company Report #A0076180
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL
		Professional Company Representative	Wellbutrin (Formulation Unknown)	SS		ORAL	150 MG/ PER	DAY/ ORAL

Date:03/01/99ISR Number: 3431045-6Report Type:Periodic Company Report # A0076181
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Urticaria						PER DAY/ ORAL	

Date:03/01/99ISR Number: 3431064-XReport Type:Periodic Company Report #A0076182
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Insomnia						PER DAY/ ORAL	
			Polycarbophil Calcium	C				
			Multivitamin	C				

Date:03/01/99ISR Number: 3431074-2Report Type:Periodic Company Report #A0076183
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
			Thyroxine Sodium	C				
			Digoxin	C				
			Blood Pressure Medication	C				

Date:03/01/99ISR Number: 3431077-8Report Type:Periodic Company Report #A0080697
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
	Dizziness							
	Epileptic Aura		Thyroxine Sodium	C				
	Insomnia		Premphase	C				
	Pallor		Pravastatin Sodium	C				
	Paralysis		Naproxen	C				
			Montelukast Sodium	C				
			Aspirin	C				
			Fluticasone Propionate	C				
			Salmeterol Xinafoate	C				
			Salbutamol Sulphate	C				
			Methylprednisolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431081-XReport Type:Periodic Company Report #A0080698
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Insomnia						PER DAY/	ORAL
	Rash Papular		Tetracycline	C				
			Loestrin	C				

Date:03/01/99ISR Number: 3431088-2Report Type:Periodic Company Report #A0080699
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Urticaria						PER DAY/	ORAL

Date:03/01/99ISR Number: 3431117-6Report Type:Periodic Company Report #A0080700
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	PER
	Dizziness						DAY/	ORAL
	Headache							
	Vomiting							

Date:03/01/99ISR Number: 3431125-5Report Type:Periodic Company Report #A0080701
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE

PER DAY/ ORAL

Fluticasone Propionate	C
Salbutamol Sulphate	C
Ipratropium Bromide	C
Budesonide	C
Glibenclamide	C

Date:03/01/99ISR Number: 3431130-9Report Type:Periodic Company Report #A0080703
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
	Dizziness						DAY/ ORAL	
	Eye Disorder		Alprazolam	C				
	Nightmare							

Date:03/01/99ISR Number: 3431133-4Report Type:Periodic Company Report #A0080707
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
	Migraine						DAY/ ORAL	
			Estrogen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431136-XReport Type:Periodic Company Report #A0080710
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER DAY/ ORAL	TWICE

Date:03/01/99ISR Number: 3431140-1Report Type:Periodic Company Report #A0080711
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER DAY/ ORAL	TWICE
	Pollakiuria							

Date:03/01/99ISR Number: 3431143-7Report Type:Periodic Company Report #A0080713
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER DAY/ ORAL	
	Depression							
	Irritability							

Date:03/01/99ISR Number: 3431146-2Report Type:Periodic Company Report #A0080715
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	TWICE
	Insomnia							

Date:03/01/99ISR Number: 3431149-8Report Type:Periodic Company Report #A0080741
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL
	Dizziness							
	Sensation Of Pressure							
	Tremor							

Date:03/01/99ISR Number: 3431152-8Report Type:Periodic Company Report #A0080792
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL 1 MON
	Inadequate Control	Professional	Acarbose	C				
			Glipizide	C				
			Glucophage	C				

Date:03/01/99ISR Number: 3431157-7Report Type:Periodic Company Report #A0080794
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	SEE
	Overdose						TEXT	ORAL
	Tremor		Ortho Cyclen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431171-1Report Type:Periodic Company Report #A0080795
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	TWICE
	Tension						PER DAY	ORAL
			Prempro	C				

Date:03/01/99ISR Number: 3431174-7Report Type:Periodic Company Report #A0080796
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	
	Dry Mouth						TWICE PER DAY	
	Dysphagia						ORAL	
	Foreign Body Trauma		Loratadine	C				
	Throat Irritation							

Date:03/01/99ISR Number: 3431196-6Report Type:Periodic Company Report #A0080797
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	.5 TABLET	
							TWICE PER DAY	
							ORAL	
			Sertraline Hydrochloride	C				
			Diphenhydramine Hcl	C				
			Theophylline	C				
			Antihypertensive	C				

Date:03/01/99ISR Number: 3431208-XReport Type:Periodic Company Report #A0080798
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Sertaline Hydrochloride	C				
			Fexofenadine Hydrochlorid	C				

Date:03/01/99ISR Number: 3431228-5Report Type:Periodic Company Report #A0080799
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
			Wellbutrin Tablet - Controlled Release	SS		ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3431231-5Report Type:Periodic Company Report #A0080800
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Atorvastatin Calcium	C				

			Prempro	C			

Date:03/01/99ISR Number: 3431238-8Report Type:Periodic Company Report #A0080801
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	DAY ORAL
			Hydroxyzine	C				
			Theophylline	C				

Date:03/01/99ISR Number: 3431241-8Report Type:Periodic Company Report #A0080802
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Nervousness						PER DAY	ORAL

Date:03/01/99ISR Number: 3431245-5Report Type:Periodic Company Report #A0080803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3431247-9Report Type:Periodic Company Report #A0080804
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

	Face Oedema					
	Joint Swelling					
	Penile Swelling					
	Pruritus					

Date:03/01/99ISR Number: 3431254-6Report Type:Periodic Company Report #A0080805
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	PER
	Excitability							DAY ORAL
	Nervousness							

Date:03/01/99ISR Number: 3431294-7Report Type:Periodic Company Report #A0080808
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	TWICE
	Pollakiuria							PER DAY ORAL
	Tremor		Clarithromycin	C				
			Nicotine	C				
			Salbutamol Sulphate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431297-2Report Type:Periodic Company Report #A0080867
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	TWICE
	Nasal Dryness						PER DAY	ORAL
	Sleep Disorder							

Date:03/01/99ISR Number: 3431298-4Report Type:Periodic Company Report #A0080868
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	
	Hypersensitivity						TWICE PER DAY	
	Pruritus						ORAL	
			Ibuprofen	C				
			Multivitamin	C				

Date:03/01/99ISR Number: 3431299-6Report Type:Periodic Company Report #A0080870
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG; ORAL	1 YR

Date:03/01/99ISR Number: 3431301-1Report Type:Periodic Company Report #A0080871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	

	Urticaria					
DAY; ORAL 5 DAY						

Date:03/01/99ISR Number: 3431308-4Report Type:Periodic Company Report #A0080872
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
	Mental Disorder						TWICE PER
DAY; ORAL							

Date:03/01/99ISR Number: 3431329-1Report Type:Periodic Company Report #A0080873
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Back Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG; ORAL
	Hypersensitivity						
	Pain In Extremity						

Date:03/01/99ISR Number: 3431332-1Report Type:Periodic Company Report #A0080874
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER
	Nervousness						
DAY; ORAL 3 DAY							
	Tremor		Omeprazole	C			
			Hormones	C			
			Vitamin	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431335-7Report Type:Periodic Company Report #A0080875
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICER PER DAY; ORAL	3 DAY

Date:03/01/99ISR Number: 3431336-9Report Type:Periodic Company Report #A0080876
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY; ORAL	
	Constipation							
	Disturbance In Attention							
	Dizziness		Medroxyprogesterone Ace.	C				
	Headache							
	Insomnia							

Date:03/01/99ISR Number: 3431337-0Report Type:Periodic Company Report #A0080877
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY; ORAL	
	Insomnia							
	Visual Disturbance							
			Vitamin	C				

Date:03/01/99ISR Number: 3431338-2Report Type:Periodic Company Report #A0080878
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY; ORAL	

Date:03/01/99ISR Number: 3431340-0Report Type:Periodic Company Report #A0080879
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY; ORAL	
	Dizziness							
	Headache							
	Insomnia							
	Irritability							
	Major Depression							
	Mental Impairment							
	Nervousness							
	Tension							
	Tobacco Abuse							

Date:03/01/99ISR Number: 3431343-6Report Type:Periodic Company Report #A0080880
Age: Gender:Female I/FU:I

Outcome	PT
	Accommodation Disorder
	Convulsion

	Discomfort					
	Dry Mouth					
	Hypersensitivity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Muscle Rigidity	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Muscle Spasms	Professional				
TWICE PER						
	Myalgia					
DAY; ORAL						
	Panic Disorder		Magnesium Salt	C		
	Syncope					
	Tetany					
	Tremor					
	Visual Disturbance					

Date:03/01/99ISR Number: 3431348-5Report Type:Periodic Company Report #A0080881
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Pruritus					
TWICE PER						
	Swelling					
DAY; ORAL						
	Urticaria					

Date:03/01/99ISR Number: 3431350-3Report Type:Periodic Company Report #A0080882
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Acute Stress Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / PER						
	Decreased Appetite					
DAY; ORAL						
	Eczema		Salbutamol Sulphate	C		
	Tachycardia		Asmacort	C		
			Guaiphenesin	C		
			Prempro	C		

Date:03/01/99ISR Number: 3431351-5Report Type:Periodic Company Report #A0080883
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY; ORAL	
			Birth Control	C				

Date:03/01/99ISR Number: 3431356-4Report Type:Periodic Company Report #A0080884
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / SEE TEXT; ORAL	
	Disturbance In Attention							
	Insomnia		Etodolace	C				
			Atenolol	C				
			Conjugated Estrogens	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431359-XReport Type:Periodic Company Report #A0080885
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY; ORAL	
			Premphase	C				

Date:03/01/99ISR Number: 3431366-7Report Type:Periodic Company Report #A0080886
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG; ORAL	
	Myalgia	Professional Company Representative						

Date:03/01/99ISR Number: 3431369-2Report Type:Periodic Company Report #A0080887
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG; ORAL	
	Vomiting	Professional Company Representative						

Date:03/01/99ISR Number: 3431384-9Report Type:Periodic Company Report #A0080888
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Emotional Disorder	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG; ORAL

Date:03/01/99ISR Number: 3431387-4Report Type:Periodic Company Report #A0080991
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG /
	Dry Skin					TWICE PER
	Face Oedema					DAY; ORAL
	Pruritus		Tramodol Hydrochloride	C		
	Urticaria		Cyclobenzaprine Hcl	C		
			Conjugated Estrogens	C		

Date:03/01/99ISR Number: 3431396-5Report Type:Periodic Company Report #A0075532
Age:40 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Distension
	Anxiety
	Constipation
	Fluid Retention
	Insomnia

	Irritability Nervousness Skin Disorder	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/TWICE PER DAY/ORAL						
			Frusemide	C		
			Cisapride	C		
			Psyllium Husk	C		
			Omeprazole	C		
			Lisinopril	C		
			Estrogen	C		
			Progesterone	C		
			Multivitamin	C		
			Thyroxine Sodium	C		
			Atorvastatin Calcium	C		
			Insulin	C		
			Timolol Maleate	C		
			Latanoprost	C		

Date:03/01/99ISR Number: 3431400-4Report Type:Periodic Company Report #A0075533
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/TWICE PER DAY/ORAL						

Date:03/01/99ISR Number: 3431403-XReport Type:Periodic Company Report #A0075534
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG/PER						
	Blood Pressure Decreased					
DAY/ORAL						
	Dyspnoea		Verapamil			
	Headache		Hydrochloride	C		

			Beclomethasone Dipropion	C			
			Salbutamol Sulphate	C			

Date:03/01/99ISR Number: 3431406-5Report Type:Periodic Company Report #A0075535
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Peripheral Coldness						PER DAY/ORAL	
	Skin Odour Abnormal		Wellbutrin Tablet	SS		ORAL	100 MG/ORAL	
			Gabapentin	C				
			Lorazepam	C				
			Pravastatin Sodium	C				
			Lactulose	C				
			Methocarbamol	C				
			Nicotine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431417-XReport Type:Periodic Company Report #A0075537
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER	
	Hypersensitivity						DAY/ORAL	
	Syncope		Cefuroxime Axetil	C				
			Tylenol With Codeine	C				

Date:03/01/99ISR Number: 3431421-1Report Type:Periodic Company Report #A0075538
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	
	Therapeutic Response		Nicotine	C				
	Unexpected							

Date:03/01/99ISR Number: 3431427-2Report Type:Periodic Company Report #A0075539
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Insomnia						PER DAY/ORAL	
	Pruritus		Hydrochlorothiazide	C				
			Atenolol	C				

Date:03/01/99ISR Number: 3431436-3Report Type:Periodic Company Report #A0075540
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	

	Emotional Disorder					

Date:03/01/99ISR Number: 3431438-7Report Type:Periodic Company Report #A0075541
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	

Date:03/01/99ISR Number: 3431444-2Report Type:Periodic Company Report #A0075542
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Oliguria						PER DAY/ORAL	
			Atorvastatin Calcium	C				

Date:03/01/99ISR Number: 3431446-6Report Type:Periodic Company Report #A0075543
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/SINGLE	
	Dry Mouth						DOSE/ORAL	
	Nervousness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431457-0Report Type:Periodic Company Report #A0075544
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tremor	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER DAY/ORAL
			Triphasil	C			

Date:03/01/99ISR Number: 3431477-6Report Type:Periodic Company Report #A0075545
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia	Health Professional	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER DAY/ORAL
			Oral Contraceptive	C			

Date:03/01/99ISR Number: 3431480-6Report Type:Periodic Company Report #A0075546
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Insomnia						
	Nausea		Calcium Salt	C			
	Palpitations						
	Tachycardia						

Date:03/01/99ISR Number: 3431483-1Report Type:Periodic Company Report #A0075547
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Dry Mouth	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/TWICE						
	Major Depression					
PER DAY/ORAL						
	Paraesthesia					
	Tremor					

Date:03/01/99ISR Number: 3431486-7Report Type:Periodic Company Report #A0075548
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Disturbance In Attention	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/TWICE						
	Nervousness					
PER DAY/ORAL						
	Speech Disorder					
	Tremor					

Date:03/01/99ISR Number: 3431489-2Report Type:Periodic Company Report #A0075549
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Major Depression	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/TWICE						
PER DAY/ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3431492-2Report Type:Periodic Company Report #A0075550
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Decreased Appetite						PER DAY/ORAL	
	Hallucination		Antibiotics	C				
	Mood Swings		Conjugated Estrogens	C				
	Nausea							
	Paraesthesia							
	Pruritus							
	Retching							

Date:03/01/99ISR Number: 3431493-4Report Type:Periodic Company Report #A0075551
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Rash Erythematous	Professional					PER DAY/ORAL	
	Urticaria							

Date:03/01/99ISR Number: 3432699-0Report Type:Periodic Company Report #A0075552
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychotic Disorder	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
		Professional					DAY/ORAL	

Date:03/01/99ISR Number: 3432700-4Report Type:Periodic Company Report #A0075536
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/PER	DAY/ORAL

Date:03/01/99ISR Number: 3432704-1Report Type:Periodic Company Report #A0075553
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Insomnia						PER DAY/ORAL	
	Sedation		Naproxen	C				
			Theophylline	C				
			Glibenclamide	C				
			Salbutamol Sulphate	C				
			Fluticasone Propionate	C				

Date:03/01/99ISR Number: 3432706-5Report Type:Periodic Company Report #A0075554
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Urticaria						PER DAY/ORAL	
			Birth Control	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3432711-9Report Type:Periodic Company Report #A0075555
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Insomnia						PER DAY/ORAL	
	Libido Decreased		Ascorbic Acid	C				
	Lymphadenopathy							
	Weight Increased							

Date:03/01/99ISR Number: 3432714-4Report Type:Periodic Company Report #A0075556
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Disorientation	Professional					PER DAY/ORAL	
	Dizziness		Atenolol	C				
	Dry Mouth		Prednisone	C				

Date:03/01/99ISR Number: 3432718-1Report Type:Periodic Company Report #A0075557
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Insomnia						PER DAY/ORAL	

Date:03/01/99ISR Number: 3432722-3Report Type:Periodic Company Report #A0075558
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingivitis	Health	Zyban	PS	Glaxo Wellcome Inc			

Professional

Date:03/01/99ISR Number: 3432733-8Report Type:Periodic Company Report #A0075568
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Urticaria	Professional					PER DAY/ORAL	

Date:03/01/99ISR Number: 3432735-1Report Type:Periodic Company Report #A0075611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban	PS	Glaxo Wellcome Inc			
	Headache							

Date:03/01/99ISR Number: 3432741-7Report Type:Periodic Company Report #A0076043
Age:40 YR Gender:Male I/FU:I

Outcome	PT
	Face Oedema
	Headache
	Pain
	Pruritus
	Pyrexia

	Rash Generalised						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL

Date:03/01/99ISR Number: 3432757-0Report Type:Periodic Company Report #A0076113
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Conjunctival Haemorrhage	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL

Date:03/01/99ISR Number: 3432768-5Report Type:Periodic Company Report #A0076163
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL
	Vision Blurred						
			Birth Control	C			

Date:03/01/99ISR Number: 3432775-2Report Type:Periodic Company Report #A0076165
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL
	Nervousness						

Date:03/01/99ISR Number: 3432778-8Report Type:Periodic Company Report #A0076166
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Irritability						PER DAY/ORAL	
	Tobacco Abuse		Simvastatin	C				
			Augmentin	C				
			Prednisone	C				

Date:03/01/99ISR Number: 3432780-6Report Type:Periodic Company Report #A0076167
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Pruritus						PER DAY/ORAL	
			Metoprolol Succinate	C				
			Hydrochlorothiazide	C				

Date:03/01/99ISR Number: 3432784-3Report Type:Periodic Company Report #A0076169
Age:41 YR Gender:Female I/FU:I

Outcome	PT
	Abnormal Dreams
	Conjunctival Hyperaemia

	Drug Ineffective Headache Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nervousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE PER DAY/ORAL						
			Alprazolam Clorazepate Dipotassium	C C		

Date:03/01/99ISR Number: 3432786-7Report Type:Periodic Company Report #A0076170
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ORAL						
		Professional				

Date:03/01/99ISR Number: 3432790-9Report Type:Periodic Company Report #A0076171
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban Tablet	PS	Glaxo Wellcome Inc	ORAL
150 MG/PER						
	Headache					
DAY/ORAL						

Date:03/01/99ISR Number: 3432792-2Report Type:Periodic Company Report #A0076172
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mood Altered	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE						
	Neck Pain					
PER DAY/ORAL						
			Ibuprofen	C		

			Birth Control	C		

Date:03/01/99ISR Number: 3432795-8Report Type:Periodic Company Report #A0076173
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG.TWICE	
	Urticaria						PER DAY/ORAL	
			Nabumetone	C				
			Thyroxine Sodium	C				
			Potassium Chloride	C				
			Amitriptyline	C				
			Diltiazem Hydrochloride	C				

Date:03/01/99ISR Number: 3432811-3Report Type:Periodic Company Report #A0078830
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWIE	
							PER DAY /	
							ORAL	
			Paracetamol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3432815-0Report Type:Periodic Company Report #A0078831
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	
			Zestorectic	C				
			Estrogen	C				
			Tolterodine	C				
			Diphenhydramine Hcl	C				
			Potassium Salt	C				
			Arthrotec	C				

Date:03/01/99ISR Number: 3432818-6Report Type:Periodic Company Report #A0078832
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Insulin	C				

Date:03/01/99ISR Number: 3432821-6Report Type:Periodic Company Report #A0078834
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
			Conjugated Estrogens	C				
			Medroxyprogesterone Ace.	C				

			Calcium Citrate	C		
			Alprazolam	C		

Date:03/01/99ISR Number: 3432825-3Report Type:Periodic Company Report #A0078835
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL
			Aspirin	C				

Date:03/01/99ISR Number: 3432841-1Report Type:Periodic Company Report #A0078836
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL
	Hypoaesthesia							
	Vasodilatation							
			Salmeterol Xinafoate	C				
			Salbutamol Sulphate	C				
			Famotidine	C				
			Beclomethasone Dipropion	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3432845-9Report Type:Periodic Company Report #A0078837
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Menorrhagia						TWICE PER DAY	
/ ORAL								

Date:03/01/99ISR Number: 3432846-0Report Type:Periodic Company Report #A0078838
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Nausea						TWICE PER DAY	
/ ORAL								
			Sinemet	C				

Date:03/01/99ISR Number: 3432851-4Report Type:Periodic Company Report #A0078839
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Elevated Mood	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Insomnia						TWICE PERDAY	
/ ORAL								

Date:03/01/99ISR Number: 3432852-6Report Type:Periodic Company Report #A0078840
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Tremor						TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3432869-1Report Type:Periodic Company Report #A0078841
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Ibuprofen	C				

Date:03/01/99ISR Number: 3432871-XReport Type:Periodic Company Report #A0078842
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Vomiting	Professional					TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3432875-7Report Type:Periodic Company Report #A0078844
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Flushing						TWICE PER	

DAY/ ORAL

Enalapril Maleate	C
Imipramine	C
Triamterene	C
Alprazolam	C
Prempro	C

Date:03/01/99ISR Number: 3432877-0Report Type:Periodic Company Report #A0078861
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Pain						TWICE PER	

DAY/ ORAL

Thyroid	C

Date:03/01/99ISR Number: 3432880-0Report Type:Periodic Company Report #A0078880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:03/01/99ISR Number: 3432883-6Report Type:Periodic Company Report #A0078917
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Urticaria						DAY / ORAL	

Date:03/01/99ISR Number: 3432935-0Report Type:Periodic Company Report #A0078918
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	2 WK
	Nausea	Professional						

Date:03/01/99ISR Number: 3432938-6Report Type:Periodic Company Report #A0078919
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Drug Ineffective							
	Dry Mouth							
	Weight Increased		Frusemide	C				
			Colestipol Hydrochloride	C				
			Lovastatin	C				
			Oxaprozin	C				
			Librium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3432940-4Report Type:Periodic Company Report #A0078920
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:03/01/99ISR Number: 3432943-XReport Type:Periodic Company Report #A0078921
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:03/01/99ISR Number: 3432961-1Report Type:Periodic Company Report #A0078922
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dizziness						TWICE PER DAY	
	Nausea						/ ORAL	
	Palpitations							

Date:03/01/99ISR Number: 3432962-3Report Type:Periodic Company Report #A0078923
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Headache						DAY / ORAL	
	Insomnia							

Date:03/01/99ISR Number: 3432964-7Report Type:Periodic Company Report #A0078942
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Neuropathy Peripheral						TWICE PER DAY	
	Paraesthesia						/ ORAL	
			Metoprolol Tartrate	C				
			Isosorbide Mononitrate	C				
			Aspirin	C				

Date:03/01/99ISR Number: 3432966-0Report Type:Periodic Company Report #A0078943
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Aspirin	C				
			Metoprolol Tartrate	C				
			Diltiazem Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3432968-4Report Type:Periodic Company Report #A0078944
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Disturbance In Attention	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:03/01/99ISR Number: 3432970-2Report Type:Periodic Company Report #A0078945
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
	Urticaria						
			Buspirone Hydrochloride	C			

Date:03/01/99ISR Number: 3432971-4Report Type:Periodic Company Report #A0078946
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
	Anxiety						

Date:03/01/99ISR Number: 3433096-4Report Type:Periodic Company Report #1998013484-1
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching	Health Professional	Paxil	PS	Smithkline Beecham Pharmaceuticals	ORAL	ORAL	
			Buprpion Glaxo Wellcome	SS	Glaxo Wellcome			

Date:03/01/99ISR Number: 3433106-4Report Type:Periodic Company Report #A0081596
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY/	ORAL

Date:03/01/99ISR Number: 3433108-8Report Type:Periodic Company Report #A0081599
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Dysgeusia Nervousness	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY /	ORAL
			Conjugated Estrogens	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433109-XReport Type:Periodic Company Report #A0081641
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MJG / TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433111-8Report Type:Periodic Company Report #A0081642
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Raynaud'S Phenomenon	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
		Company Representative						

Date:03/01/99ISR Number: 3433113-1Report Type:Periodic Company Report #A0081643
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	

Date:03/01/99ISR Number: 3433114-3Report Type:Periodic Company Report #A0081644
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433116-7Report Type:Periodic Company Report #A0081645
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Hypoaesthesia Migraine Tremor		Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:03/01/99ISR Number: 3433117-9Report Type:Periodic Company Report #A0081646
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pruritus Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433118-0Report Type:Periodic Company Report #A0081647
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
			Salbutamol Sulphate	C				
			Prednisone	C				

Date:03/01/99ISR Number: 3433121-0Report Type:Periodic Company Report #A0081648
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nervousness Tachycardia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ORAL	
			Quinine	C				
			Blood Pressure Medication	C				
			Prednisone	C				
			Diclofenac Sodium	C				
			Hydrochlorothiazide	C				

Date:03/01/99ISR Number: 3433123-4Report Type:Periodic Company Report #A0081654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Anxiety Drug Effect Decreased Dyspnoea Nervousness	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	

	Tremor					

Date:03/01/99ISR Number: 3433126-XReport Type:Periodic Company Report #A0081655
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Nervousness		Paroxetine Hydrochloride	C				

Date:03/01/99ISR Number: 3433127-1Report Type:Periodic Company Report #A0081657
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433130-1Report Type:Periodic Company Report #A0081658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eczema	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY/	ORAL
	Tachycardia							

Date:03/01/99ISR Number: 3433131-3Report Type:Periodic Company Report #A0081659
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL	
	Dizziness							
	Nausea							

Date:03/01/99ISR Number: 3433134-9Report Type:Periodic Company Report #A0081913
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY /	ORAL
	Insomnia							

Date:03/01/99ISR Number: 3433135-0Report Type:Periodic Company Report #A0081915
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion					

	Oedema Peripheral		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Urticaria					
TWICE PER DAY						
/ ORAL						

Date:03/01/99ISR Number: 3433137-4Report Type:Periodic Company Report #A0081916
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia	Consumer	Bupropion			
	Urticaria		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						

Date:03/01/99ISR Number: 3433138-6Report Type:Periodic Company Report #A0081918
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Disorientation	Consumer	Bupropion			
	Dizziness		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG / PER						
	Nausea					
DAY/ ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433141-6Report Type:Periodic Company Report #A0081919
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Cough							
	Increased Appetite							
	Weight Increased							
			Nabumetone	C				
			Multivitamin	C				
			Estrogen	C				

Date:03/01/99ISR Number: 3433143-XReport Type:Periodic Company Report #A0078424
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ORAL	
	Groin Pain							
	Insomnia							
	Renal Colic							

Date:03/01/99ISR Number: 3433145-3Report Type:Periodic Company Report #A0078425
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation		Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433147-7Report Type:Periodic Company Report #A0078426
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
	Insomnia							
			Azithromycin	C				

Date:03/01/99ISR Number: 3433148-9Report Type:Periodic Company Report #A0078427
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Insomnia							

Date:03/01/99ISR Number: 3433150-7Report Type:Periodic Company Report #A0078428
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Condition Aggravated							
	Cough							
	Thinking Abnormal							
			Verapamil					

Hydrochloride	C
Enalapril Maleate	C
Alprazolam	C

Date:03/01/99ISR Number: 3433151-9Report Type:Periodic Company Report #A0078429
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433153-2Report Type:Periodic Company Report #A0078430
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433156-8Report Type:Periodic Company Report #A0078431
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Apathy Lethargy	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433158-1Report Type:Periodic Company Report #A0078432
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/	
	Pruritus							
	Urticaria							

Date:03/01/99ISR Number: 3433160-XReport Type:Periodic Company Report #A0078433
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ORAL	
			Etodolac	C				

Date:03/01/99ISR Number: 3433163-5Report Type:Periodic Company Report #A0078434
Age:52 YR Gender:Male I/FU:I

Outcome	PT
	Insomnia
	Paranoia

Psychotic Disorder
Sleep Disorder

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/	ORAL

Date:03/01/99ISR Number: 3433172-6Report Type:Periodic Company Report #A0077570
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:03/01/99ISR Number: 3433174-XReport Type:Periodic Company Report #A0077573
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:03/01/99ISR Number: 3433175-1Report Type:Periodic Company Report #A0077574
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL
			Ortho Tri-Cyclen	C				

Date:03/01/99ISR Number: 3433203-3Report Type:Periodic Company Report #A0077575
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Sedation						PER DAY/ ORAL	
	Skin Warm							

Date:03/01/99ISR Number: 3433206-9Report Type:Periodic Company Report #A0077577
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Diarrhoea						PER DAY/ ORAL	
			Azithromycin (Formulation Unknown)	SS				

Date:03/01/99ISR Number: 3433207-0Report Type:Periodic Company Report #A0077578
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Nausea						DAY/ ORAL	
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433210-0Report Type:Periodic Company Report #A0077580
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Hypersensitivity						DAY/ ORAL	
	Pruritus		Birth Control	C				
	Tremor		Omeprazole	C				

Date:03/01/99ISR Number: 3433212-4Report Type:Periodic Company Report #A0077581
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	
			Estratest	C				
			Medroxyprogesterone Ace.	C				
			Cimetidine	C				
			Oxybutynin Hydrochloride	C				

Date:03/01/99ISR Number: 3433213-6Report Type:Periodic Company Report #A0077583
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcoholic Hangover	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Anxiety						SINGLE DOSE/	
	Dizziness						ORAL	
	Feeling Drunk							
	Palpitations							
	Panic Reaction							
	Tachycardia							

Date:03/01/99ISR Number: 3433216-1Report Type:Periodic Company Report #A0077584
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Dry Mouth						DAY/ ORAL	
	Headache		Omeprazole	C				
	Tremor		Methocarbamol	C				
			Vicodin	C				

Date:03/01/99ISR Number: 3433218-5Report Type:Periodic Company Report #A0077585
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Face Oedema						PER DAY/ ORAL	
	Pruritus		Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433221-5Report Type:Periodic Company Report #A0077586
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Herpes Virus Infection							ORAL
	Panic Reaction							

Date:03/01/99ISR Number: 3433223-9Report Type:Periodic Company Report #A0077588
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Discomfort	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	PER DAY/
	Insomnia							ORAL
	Mental Impairment							
	Restlessness							
	Tremor							

Date:03/01/99ISR Number: 3433226-4Report Type:Periodic Company Report #A0077617
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Exertional	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Emphysema							ORAL

Date:03/01/99ISR Number: 3433228-8Report Type:Periodic Company Report #A0077659
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL

	Swelling	Professional Company Representative				
	Urticaria					

Date:03/01/99ISR Number: 3433230-6Report Type:Periodic Company Report #A0077661
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
		Professional Company Representative						

Date:03/01/99ISR Number: 3433233-1Report Type:Periodic Company Report #A0077672
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Extrapyramidal Disorder						PER DAY/ ORAL	
	Feeding Problem In Child							
	Hallucination							
	Lethargy							
	Memory Impairment							
	Petit Mal Epilepsy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433236-7Report Type:Periodic Company Report #A0077673
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL 2 WK
	Tachycardia							

Date:03/01/99ISR Number: 3433238-0Report Type:Periodic Company Report #A0077686
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL

Date:03/01/99ISR Number: 3433240-9Report Type:Periodic Company Report #A0077687
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Other	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL 11 DAY
	Insomnia							
	Pain							

Date:03/01/99ISR Number: 3433255-0Report Type:Periodic Company Report #A0082002
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/	ORAL

Date:03/01/99ISR Number: 3433256-2Report Type:Periodic Company Report #A0082003
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
			Conjugated Estrogens	C				
			Thyroxine Sodium	C				

Date:03/01/99ISR Number: 3433259-8Report Type:Periodic Company Report #A0082004
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Dry Mouth							PER DAY/ ORAL
	Headache		Lorazepam	C				

Date:03/01/99ISR Number: 3433260-4Report Type:Periodic Company Report #A0082005
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Tenderness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Headache							DAY/ ORAL
	Insomnia		Ibuprofen	C				
	Tenderness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433262-8Report Type:Periodic Company Report #A0082006
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Pollakiuria							

Date:03/01/99ISR Number: 3433263-XReport Type:Periodic Company Report #A0082022
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Hypersensitivity							
	Oedema Peripheral							

Date:03/01/99ISR Number: 3433264-1Report Type:Periodic Company Report #A0082023
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:03/01/99ISR Number: 3433265-3Report Type:Periodic Company Report #A0082087
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

PER DAY/ ORAL

Date:03/01/99ISR Number: 3433266-5Report Type:Periodic Company Report #A0082267
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	

Date:03/01/99ISR Number: 3433268-9Report Type:Periodic Company Report #A0082272
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psoriasis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE DAILY/ ORAL	

Date:03/01/99ISR Number: 3433269-0Report Type:Periodic Company Report #A0079578
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Thyroxine Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433271-9Report Type:Periodic Company Report #A0079579
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Tremor						TWICE PER	
							DAY/ ORAL	

Date:03/01/99ISR Number: 3433272-0Report Type:Periodic Company Report #A0079580
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Feeling Hot						TWICE PER	
	Insomnia						DAY/ ORAL	
	Nausea							

Date:03/01/99ISR Number: 3433274-4Report Type:Periodic Company Report #A0079581
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ THREE	
							TIMES PER	
							DAY/ ORAL	
			Cimetidine	C				
			Tetracycline	C				
			Metronidazole	C				
			Conjugated Estrogens	C				

Date:03/01/99ISR Number: 3433276-8Report Type:Periodic Company Report #A0079582
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY/ ORAL

Date:03/01/99ISR Number: 3433278-1Report Type:Periodic Company Report #A0079583
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Tachycardia						PER DAY/ ORAL	
			Hrt	C				
			Multivitamin	C				

Date:03/01/99ISR Number: 3433279-3Report Type:Periodic Company Report #A0079584
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Nausea						PER DAY/ ORAL	
			Salbutamol Sulphate	C				
			Fluticasone Propionate	C				
			Hydroxyzine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433281-1Report Type:Periodic Company Report #A0079585
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Papular	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	DAY/ ORAL
			Quinapril Hydrochloride	C				
			Glipizide	C				
			Dicloxacillin	C				

Date:03/01/99ISR Number: 3433282-3Report Type:Periodic Company Report #A0079586
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
			Diazepam	C				
			Meclozine	C				

Date:03/01/99ISR Number: 3433284-7Report Type:Periodic Company Report #A0079587
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:03/01/99ISR Number: 3433436-6Report Type:Periodic Company Report #A0074714
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Thyroid Neoplasm	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG/PER

DAY/ORAL

Date:03/01/99ISR Number: 3433437-8Report Type:Periodic Company Report #A0074885
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Dizziness					
	Headache					

Dose Duration

150 MG/TWICE

PER DAY/ORAL

Date:03/01/99ISR Number: 3433438-XReport Type:Periodic Company Report #A0074887
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Micturition Urgency					
			Multivitamin	C		
			Guaiphenesin	C		
			Combivent	C		

Dose Duration

150 MG/TWICE

PER DAY/ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433439-1Report Type:Periodic Company Report #A0074890
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	PER DAY/ORAL
			Atenolol	C				
			Hydrochlorothiazide	C				

Date:03/01/99ISR Number: 3433440-8Report Type:Periodic Company Report #A0074942
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	PER DAY/ORAL	
	Disorientation		Alprazolam	C				
	Fear							
	Paraesthesia							

Date:03/01/99ISR Number: 3433441-XReport Type:Periodic Company Report #A0074943
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	PER DAY/ORAL
			Ethanol	SS				
			Ortho Cyclen	C				

Date:03/01/99ISR Number: 3433442-1Report Type:Periodic Company Report #A0074956
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE						
	Urticaria					
PER DAY/ORAL						
			Isoniazid	C		

Date:03/01/99ISR Number: 3433443-3Report Type:Periodic Company Report #A0074978
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ORAL						
	Urticaria	Health Professional Other	Nicotine	C		

Date:03/01/99ISR Number: 3433444-5Report Type:Periodic Company Report #A0074980
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE						
PER DAY/ORAL						
			Loestrin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433445-7Report Type:Periodic Company Report #A0074982
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
	Nervousness						DAY/ORAL	
			Prednisone	C				
			Cimetidine	C				
			Acetazolamide	C				
			Doxepin	C				

Date:03/01/99ISR Number: 3433446-9Report Type:Periodic Company Report #A0074983
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Psychomotor Hyperactivity						PER DAY/ORAL	
	Sedation		Fosinopril Sodium	C				

Date:03/01/99ISR Number: 3433447-0Report Type:Periodic Company Report #A0074984
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
	Dissociation						DAY/ORAL	
	Insomnia		Clarithromycin Tablet	SS		ORAL	ORAL	
			Multivitamin	C				
			Percodan	C				
			Nitroglycerin	C				

Date:03/01/99ISR Number: 3433448-2Report Type:Periodic Company Report #A0074985
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Erythema	Professional					PER DAY/ORAL	
	Oedema Peripheral							
	Skin Irritation							

Date:03/01/99ISR Number: 3433449-4Report Type:Periodic Company Report #A0074986
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensory Disturbance	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Tinnitus						PER DAY/ORAL	
	Tremor		Sertraline Hydrochloride	C				
			Ibuprofen	C				

Date:03/01/99ISR Number: 3433450-0Report Type:Periodic Company Report #A0074987
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Level Of Consciousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Dysgeusia		Enalapril Maleate	C			PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Conjugated Estrogens C

Date:03/01/99ISR Number: 3433451-2Report Type:Periodic Company Report #A0074988
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Urticaria						PER DAY/ORAL	

Date:03/01/99ISR Number: 3433452-4Report Type:Periodic Company Report #A0074989
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Drug Ineffective							
	Headache							
	Nausea							

Date:03/01/99ISR Number: 3433453-6Report Type:Periodic Company Report #A0074991
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
							PER DAY/ORAL	

Date:03/01/99ISR Number: 3433454-8Report Type:Periodic Company Report #A0074992
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chest Pain	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/SEE
	Dizziness	Professional				TEXT/ORAL
	Nausea		Paracetamol	C		
	Visual Disturbance					
	Vomiting					

Date:03/01/99ISR Number: 3433456-1Report Type:Periodic Company Report #A0074993
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Aggression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/PER
	Irritability					DAY/ORAL
			Salbutamol Sulphate	C		
			Theophylline	C		

Date:03/01/99ISR Number: 3433457-3Report Type:Periodic Company Report #A0058433
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG ORAL 2 WK
	Ill-Defined Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433458-5Report Type:Periodic Company Report #A0059740
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
			Estrogen	C				
			Naproxen Sodium	C				

Date:03/01/99ISR Number: 3433460-3Report Type:Periodic Company Report #A0061525
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Chest Pain						PER DAY ORAL	
	Disorientation							
	Dizziness							
	Hyperhidrosis							
	Hypoaesthesia							

Date:03/01/99ISR Number: 3433461-5Report Type:Periodic Company Report #A0062656
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3433462-7Report Type:Periodic Company Report #A0062756
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG SEE	
	Nervousness						TEXT ORAL	

Tremor
Vomiting

Date:03/01/99ISR Number: 3433463-9Report Type:Periodic Company Report #A0062799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	3 WK

Date:03/01/99ISR Number: 3433464-0Report Type:Periodic Company Report #A0063424
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:03/01/99ISR Number: 3433466-4Report Type:Periodic Company Report #A0066887
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433467-6Report Type:Periodic Company Report #A0066916
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	
			Estrogen	C				
			Alprazolam	C				

Date:03/01/99ISR Number: 3433468-8Report Type:Periodic Company Report #A0069007
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	8 WK

Date:03/01/99ISR Number: 3433469-XReport Type:Periodic Company Report #A0081373
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excitability	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3433470-6Report Type:Periodic Company Report #A0081374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Dry Throat							

Date:03/01/99ISR Number: 3433471-8Report Type:Periodic Company Report #A0081387
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
			Triamterene	C				

Date:03/01/99ISR Number: 3433474-3Report Type:Periodic Company Report #A0081394
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
			Premphase	C				

Date:03/01/99ISR Number: 3433475-5Report Type:Periodic Company Report #A0081398
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	
	Diarrhoea							
	Disorientation		Fluticasone Propionate	C				
	Dyspepsia							
	Headache							
	Nausea							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433478-0Report Type:Periodic Company Report #A0081402
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:03/01/99ISR Number: 3433479-2Report Type:Periodic Company Report #A0081494
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Estrogen	C				

Date:03/01/99ISR Number: 3433480-9Report Type:Periodic Company Report #A0081516
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Insomnia							PER DAY ORAL
	Psychomotor Hyperactivity		Thyroxine Sodium	C				

Date:03/01/99ISR Number: 3433483-4Report Type:Periodic Company Report #A0081521
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:03/01/99ISR Number: 3433486-XReport Type:Periodic Company Report #A0081585
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:03/01/99ISR Number: 3433488-3Report Type:Periodic Company Report #A0074994
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	PER DAY ORAL
	Dysarthria							
	Dyspraxia		Clonazepam	C				
	Headache		Lorazepam	C				
	Insomnia		Gabapentin	C				
	Speech Disorder							

Date:03/01/99ISR Number: 3433489-5Report Type:Periodic Company Report #A0080347
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
	Hypoaesthesia Oral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433492-5Report Type:Periodic Company Report #A0080354
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Flatulence						PER DAY ORAL	3 WK
	Frequent Bowel Movements							

Date:03/01/99ISR Number: 3433494-9Report Type:Periodic Company Report #A0074995
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	
	Insomnia							
	Tobacco Abuse							

Date:03/01/99ISR Number: 3433497-4Report Type:Periodic Company Report #A0075001
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	
	Depression						DAY ORAL	
	Drug Ineffective		Ibuprofen	C				
	Emotional Disorder		Vicodin	C				
	Irritability		Multivitamin	C				
			Salbutamol Sulphate	C				
			Hypericum	C				

Date:03/01/99ISR Number: 3433499-8Report Type:Periodic Company Report #A0080355
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Crying	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Depression					
PER DAY ORAL						
	Insomnia		Hyzaar	C		
	Suicidal Ideation		Alpha-Anilinophenyl Acet.	C		
			Vitamin	C		
			Buspirone Hydrochloride	C		

Date:03/01/99ISR Number: 3433501-3Report Type:Periodic Company Report #A0075016
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Depression	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG TWICE						
	Dermatitis					
PER DAY ORAL						
	Disturbance In Attention					

Date:03/01/99ISR Number: 3433502-5Report Type:Periodic Company Report #A0080356
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Urticaria					
PER DAY ORAL						
			Dyazide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433503-7Report Type:Periodic Company Report #A0080357
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	5 DAY
	Nausea							

Date:03/01/99ISR Number: 3433506-2Report Type:Periodic Company Report #A0080358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3433508-6Report Type:Periodic Company Report #A0080359
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Disturbance In Attention							
	Dry Mouth							
	Dry Skin							
	Ear Disorder							
	Ear Haemorrhage							
	Haemorrhage							
	Keratoconjunctivitis							
	Sicca							
	Tongue Disorder							

Date:03/01/99ISR Number: 3433510-4Report Type:Periodic Company Report #A0080360
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Urticaria					
PER DAY ORAL						

Date:03/01/99ISR Number: 3433512-8Report Type:Periodic Company Report #A0080361
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysphagia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG ORAL						
	Foreign Body Trauma					

Date:03/01/99ISR Number: 3433514-1Report Type:Periodic Company Report #A0075017
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG TWICE						
	Insomnia					
PER DAY ORAL						
	Productive Cough					

Date:03/01/99ISR Number: 3433516-5Report Type:Periodic Company Report #A0080362
Age:59 YR Gender:Female I/FU:I

Outcome	PT
	Cough
	Dry Mouth

	Fatigue Insomnia Nervousness	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Pruritus	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG PER DAY ORAL
			Prempro	C		

Date:03/01/99ISR Number: 3433517-7Report Type:Periodic Company Report #A0075019
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG TWICE PER DAY ORAL
			Glucophage	C		
			Conjugated Estrogens Medroxyprogesterone Ace.	C		
			Vitamin	C		
			Hypericum	C		
			Ginkgo Biloba	C		

Date:03/01/99ISR Number: 3433519-0Report Type:Periodic Company Report #A0080363
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Constipation Diarrhoea Insomnia Mood Altered	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG TWICE PER DAY ORAL

Date:03/01/99ISR Number: 3433520-7Report Type:Periodic Company Report #A0075024
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:03/01/99ISR Number: 3433521-9Report Type:Periodic Company Report #A0080364
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mydriasis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	
			Theraflu	C				

Date:03/01/99ISR Number: 3433524-4Report Type:Periodic Company Report #A0075028
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433525-6Report Type:Periodic Company Report #A0080365
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Disturbance In Attention						DAY ORAL	
	Dizziness		Loratadine	C				
	Eating Disorder		Fluticasone					
	Eructation		Propionate	C				
	Intestinal Functional Disorder							
	Nausea							
	Sedation							
	Vertigo							

Date:03/01/99ISR Number: 3433527-XReport Type:Periodic Company Report #A0075030
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Vomiting						PER DAY ORAL	
			Frusemide	C				
			Simvastatin	C				

Date:03/01/99ISR Number: 3433528-1Report Type:Periodic Company Report #A0080366
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	

Date:03/01/99ISR Number: 3433531-1Report Type:Periodic Company Report #A0075032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	PER DAY ORAL

Date:03/01/99ISR Number: 3433532-3Report Type:Periodic Company Report #A0080367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Flatulence							

Date:03/01/99ISR Number: 3433534-7Report Type:Periodic Company Report #A0080368
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Feeling Abnormal						PER DAY ORAL	
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433535-9Report Type:Periodic Company Report #A0077340
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TOTAL	
	Headache						TWICE PER DAY	
	Sedation						ORAL	
			Birth Control	C				

Date:03/01/99ISR Number: 3433538-4Report Type:Periodic Company Report #A0077342
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Nausea						PER DAY ORAL	
	Tremor		Birth Control	C				

Date:03/01/99ISR Number: 3433539-6Report Type:Periodic Company Report #A0080369
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactoid Reaction	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Bronchospasm						PER DAY ORAL	
	Dyspnoea		Diphenhydramine Hcl	C				
	Rash Erythematous		Multivitamin	C				
	Urticaria		Allegra-D	C				

Date:03/01/99ISR Number: 3433541-4Report Type:Periodic Company Report #A0077343
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Dry Throat						PER DAY ORAL	
			Insulin	C				
			Asmacort	C				
			Ipratropium Bromide	C				
			Loratadine	C				
			Loratadine	C				
			Tramadol Hydrochloride	C				
			Amitriptyline Hcl	C				
			Orciprenaline Sulphate	C				

Date:03/01/99ISR Number: 3433542-6Report Type:Periodic Company Report #A0080370
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	

Date:03/01/99ISR Number: 3433544-XReport Type:Periodic Company Report #A0080371
Age:39 YR Gender:Female I/FU:I

Outcome	PT
	Drug Dependence
	Insomnia

	Irritability Nervousness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL

Date:03/01/99ISR Number: 3433545-1Report Type:Periodic Company Report #A0077344
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Elevated Mood Malaise Sedation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY

Date:03/01/99ISR Number: 3433548-7Report Type:Periodic Company Report #A0080372
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL

Date:03/01/99ISR Number: 3433550-5Report Type:Periodic Company Report #A0077346
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Condition Aggravated Constipation Dermatitis Ill-Defined Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL

Insomnia
Nervousness
Tobacco Abuse

Date:03/01/99ISR Number: 3433552-9Report Type:Periodic Company Report #A0077348
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	PER DAY ORAL

Date:03/01/99ISR Number: 3433556-6Report Type:Periodic Company Report #A0077439
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	DAY ORAL

Date:03/01/99ISR Number: 3433559-1Report Type:Periodic Company Report #A0077565
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Insomnia							PER DAY ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433562-1Report Type:Periodic Company Report #A0077566
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Depression						PER DAY ORAL	

Date:03/01/99ISR Number: 3433563-3Report Type:Periodic Company Report #A0077567
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Anxiety						PER DAY ORAL	
	Insomnia							
	Tremor							

Date:03/01/99ISR Number: 3433566-9Report Type:Periodic Company Report #A0079000
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
							PER DAY ORAL	

Date:03/01/99ISR Number: 3433570-0Report Type:Periodic Company Report #A0079001
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	
							DAY ORAL	

			Cetirizine Hydrocholoride	C		
			Nasonex	C		
			Duratuss	C		

Date:03/01/99ISR Number: 3433573-6Report Type:Periodic Company Report #A0079003
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 NG THREE	
							TIMES PER DAY	
							ORAL	
			Librax	C				

Date:03/01/99ISR Number: 3433574-8Report Type:Periodic Company Report #A0079006
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Insomnia						PER DAY ORAL	
	Panic Disorder							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433578-5Report Type:Periodic Company Report #A0079088
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Emotional Disorder						PER DAY ORAL	
	Motion Sickness		Lo/Ovral	C				
	Nausea		Multivitamin	C				
	Tremor							

Date:03/01/99ISR Number: 3433580-3Report Type:Periodic Company Report #A0079089
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	
	Tension						DAY ORAL	
			Conjugated Estrogens	C				

Date:03/01/99ISR Number: 3433583-9Report Type:Periodic Company Report #A0079091
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Dyspnoea						PER DAY ORAL	
	Thinking Abnormal		Medroxyprogesterone Ace.	C				
			Estrogen	C				
			Salbutamol Sulphate	C				

Date:03/01/99ISR Number: 3433584-0Report Type:Periodic Company Report #A0079099
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	3 WK
	Hypersensitivity							
	Pruritus							
	Swelling							

Date:03/01/99ISR Number: 3433585-2Report Type:Periodic Company Report #A0079100
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	
	Hypersensitivity							
	Pruritus							
	Swelling							

Date:03/01/99ISR Number: 3433587-6Report Type:Periodic Company Report #A0079135
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433588-8Report Type:Periodic Company Report #A0079181
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Urticaria						PER DAY ORAL	

Date:03/01/99ISR Number: 3433590-6Report Type:Periodic Company Report #A0079182
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3433591-8Report Type:Periodic Company Report #A0080994
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Arthralgia	Professional						
	Erythema	Company						
	Oedema Peripheral	Representative						
	Pain In Extremity							
	Pruritus							
	Urticaria							

Date:03/01/99ISR Number: 3433592-XReport Type:Periodic Company Report #A0079183
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
							PER DAY ORAL	

			Atorvastyatin			
			Calcium	C		
			Maxzide	C		
			Conjugated Estrogens	C		
			Cimetidine	C		

Date:03/01/99ISR Number: 3433593-1Report Type:Periodic Company Report #A0079184
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	
	Irritability						DAY ORAL	

Date:03/01/99ISR Number: 3433595-5Report Type:Periodic Company Report #A0081079
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Extrasystoles						DAY ORAL	
	Heart Rate Increased		Thyroxine Sodium	C				
	Insomnia		Clonazepam	C				
	Palpitations		Fluoxetine Hydrchloride	C				
	Polydipsia							
	Tachycardia		Nefazodone Hydrochloride	C				
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433596-7Report Type:Periodic Company Report #A0079185
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	DAY ORAL
			Omeprazole	C				

Date:03/01/99ISR Number: 3433598-0Report Type:Periodic Company Report #A0079186
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	PER DAY ORAL
			Atorvastatin Calcium	C				
			Ticlopidine	C				
			Metoprolol Succinate	C				

Date:03/01/99ISR Number: 3433599-2Report Type:Periodic Company Report #A0081085
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Memory Impairment							DAY ORAL
	Tremor		Glibenclamide	C				
			Quinine Sulphate	C				
			Conjugated Estrogens	C				
			Aspirin	C				

Date:03/01/99ISR Number: 3433600-6Report Type:Periodic Company Report #A0079187
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
							PER DAY ORAL	
			Gemfibrozil	C				

Date:03/01/99ISR Number: 3433601-8Report Type:Periodic Company Report #A0081090
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dry Mouth						PER DAY ORAL	
	Insomnia							
	Tremor							

Date:03/01/99ISR Number: 3433602-XReport Type:Periodic Company Report #A0079188
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Jealous Delusion						PER DAY ORAL	
	Nervousness		Ibuprofen	C				
	Paranoia		Anacin	C				
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433603-1Report Type:Periodic Company Report #A0081096
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:03/01/99ISR Number: 3433604-3Report Type:Periodic Company Report #A0081097
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	DAY ORAL
	Syncope							
	Vision Blurred							

Date:03/01/99ISR Number: 3433605-5Report Type:Periodic Company Report #A0079213
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	PER DAY ORAL
	Constipation							
	Libido Decreased		Nicotine	C				
			Trifluoperazine Hcl	C				

Date:03/01/99ISR Number: 3433606-7Report Type:Periodic Company Report #A0081099
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	

	Pruritus					
PER DAY ORAL						

Date:03/01/99ISR Number: 3433607-9Report Type:Periodic Company Report #A0079214
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Medication Error							
PER DAY ORAL								

Date:03/01/99ISR Number: 3433608-0Report Type:Periodic Company Report #A0081101
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Anxiety							
DAY ORAL								
	Tremor		Fenofibrate	C				
			Amlodipine Besylate	C				
			Alprazolam	C				
			Aspirin	C				

Date:03/01/99ISR Number: 3433610-9Report Type:Periodic Company Report #A0081115
Age:46 YR Gender:Female I/FU:I

Outcome	PT
	Eye Irritation
	Keratoconjunctivitis
	Sicca

Vision Blurred

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	DAY ORAL
			Wellbutrin Tablet	SS		ORAL	100 MG PER	DAY ORAL
			Multivitamin	C				
			Kelp	C				
			Alfalfa	C				

Date:03/01/99ISR Number: 3433611-0Report Type:Periodic Company Report #A0079252
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Vomiting						DAY / ORAL	
			Famotidine	C				

Date:03/01/99ISR Number: 3433612-2Report Type:Periodic Company Report #A0081148
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
		Professional						
		Company						
		Representative						

Date:03/01/99ISR Number: 3433614-6Report Type:Periodic Company Report #A0079253
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dizziness						TWICE PER DAY	
	Insomnia						/ ORAL	
			Montelukast Sodium	C				

Date:03/01/99ISR Number: 3433616-XReport Type:Periodic Company Report #A0079256
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Nausea						TWICE PER DAY	
	Vision Blurred						/ ORAL	

Date:03/01/99ISR Number: 3433620-1Report Type:Periodic Company Report #A0079300
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dizziness						TWICE PER DAY	
	Dry Mouth						/ ORAL	
	Dysgeusia		Darvocet-N	C				
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433626-2Report Type:Periodic Company Report #A0079301
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3433634-1Report Type:Periodic Company Report #A0079302
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hypertension						TWICE PER DAY	
	Tachycardia						/ ORAL	
			Trazodone	C				
			Amlodipine	C				
			Prempro	C				
			Fluphenazine Hcl	C				

Date:03/01/99ISR Number: 3433637-7Report Type:Periodic Company Report #A0079303
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Medroxyprogesterone Ace	C				

Date:03/01/99ISR Number: 3433641-9Report Type:Periodic Company Report #A0079304
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus						TWICE PER DAY	
							/ ORAL	
			Lisinopril	C				
			Atorvastatin Calcium	C				

Date:03/01/99ISR Number: 3433643-2Report Type:Periodic Company Report #A0079305
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
							/ ORAL	

Date:03/01/99ISR Number: 3433646-8Report Type:Periodic Company Report #A0079306
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
		Professional					/ ORAL	
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433648-1Report Type:Periodic Company Report #A0079307
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dry Mouth						TWICE PER DAY	
	Feeling Hot						/ ORAL	
	Oral Soft Tissue Disorder							

Date:03/01/99ISR Number: 3433650-XReport Type:Periodic Company Report #A0079308
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Disturbance In Attention						TWICE PER DAY	
	Dizziness						/ ORAL	
	Photosensitivity Reaction							
	Tremor							
	Vision Blurred							

Date:03/01/99ISR Number: 3433668-7Report Type:Periodic Company Report #A0079450
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Chest Pain						TWICE PER DAY	
	Dizziness						/ ORAL	
	Emotional Disorder		Maxzide	C				
	Insomnia							

Date:03/01/99ISR Number: 3433672-9Report Type:Periodic Company Report #A0079451
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Face Oedema						TWICE PER DAY	
	Oedema						/ ORAL	
	Urticaria							

Date:03/01/99ISR Number: 3433676-6Report Type:Periodic Company Report #A0081149
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dizziness						PER DAY ORAL	
	Hyperhidrosis							
	Nausea							

Date:03/01/99ISR Number: 3433677-8Report Type:Periodic Company Report #A0079452
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Other	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Nervousness						DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433681-XReport Type:Periodic Company Report #A0079572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood	Consumer	Zyban Tablet - Zyban	PS		ORAL	1450 MG /	
	Depression						UNK/ ORAL	
	Mood Altered							

Date:03/01/99ISR Number: 3433683-3Report Type:Periodic Company Report #A0079573
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
	Nervousness						/ ORAL	4 DAY
	Tremor							

Date:03/01/99ISR Number: 3433686-9Report Type:Periodic Company Report #A0079574
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fibromyalgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433689-4Report Type:Periodic Company Report #A0079576
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	

	Influenza Like Illness					
TWICE PER DAY						
	Nausea					
/ ORAL						
	Tachycardia		Fluoxetine			
	Tremor		Hydrochloride	C		
	Vomiting		Conjugated Estrogens	C		

Date:03/01/99ISR Number: 3433692-4Report Type:Periodic Company Report #A0079577
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Condition Aggravated							
TWICE PER DAY								
	Dysgeusia							
/ ORAL								
	Tobacco Abuse		Prempro	C				

Date:03/01/99ISR Number: 3433694-8Report Type:Periodic Company Report #A0081150
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Anxiety							
PER DAY ORAL								
	Headache							
	Insomnia							
	Nausea							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433697-3Report Type:Periodic Company Report #A0081151
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Nausea	Health					DAY ORAL	
		Professional Other	Nicotine Patch	SS				

Date:03/01/99ISR Number: 3433699-7Report Type:Periodic Company Report #A0081152
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	

Date:03/01/99ISR Number: 3433702-4Report Type:Periodic Company Report #A0081161
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toxicologic Test Abnormal	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3433705-XReport Type:Periodic Company Report #A0081177
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Rash Macular	Professional					DAY ORAL	
	Swelling	Company Representative						

Date:03/01/99ISR Number: 3433708-5Report Type:Periodic Company Report #A0081193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG SINGLE	
	Elevated Mood						DOSE ORAL	
	Tongue Coated							

Date:03/01/99ISR Number: 3433732-2Report Type:Periodic Company Report #A0081198
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
		Professional						
		Company						
		Representative						

Date:03/01/99ISR Number: 3433734-6Report Type:Periodic Company Report #A0081199
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
		Professional						
		Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433735-8Report Type:Periodic Company Report #A0081200
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	

Date:03/01/99ISR Number: 3433749-8Report Type:Periodic Company Report #A0081201
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	

Date:03/01/99ISR Number: 3433763-2Report Type:Periodic Company Report #A0081202
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	

Date:03/01/99ISR Number: 3433768-1Report Type:Periodic Company Report #A0081203
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional Company	Zyban	PS	Glaxo Wellcome Inc			

Date:03/01/99ISR Number: 3433771-1Report Type:Periodic Company Report #A0081319
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICER	PER DAY ORAL

Date:03/01/99ISR Number: 3433776-0Report Type:Periodic Company Report #A0081323
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
	Insomnia							
	Nervousness		Thyroxine Sodium	C				
			Cortisone	C				
			Testosterone	C				
			Hydrocodone	C				
			Calcium Salt	C				
			Nicotine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433780-2Report Type:Periodic Company Report #A0081324
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Simvastatin	C				
			Lansprazole	C				

Date:03/01/99ISR Number: 3433782-6Report Type:Periodic Company Report #A0081325
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
			Thyroxine Sodium	C				

Date:03/01/99ISR Number: 3433785-1Report Type:Periodic Company Report #A0081329
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
	Paraesthesia							
			Diltiazem Hydrochloride	C				
			Atorvastatin Calcium	C				

Date:03/01/99ISR Number: 3433789-9Report Type:Periodic Company Report #A0081330
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG PER						
	Dry Mouth					
DAY ORAL						
			Orphenadrine	C		

Date:03/01/99ISR Number: 3433790-5Report Type:Periodic Company Report #A0081331
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Accommodation Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Anxiety					
PER DAY ORAL						
	Insomnia		Pravastatin Sodium	C		
	Malaise					
	Mental Impairment					
	Tremor					

Date:03/01/99ISR Number: 3433793-0Report Type:Periodic Company Report #A0081332
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Interaction	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWIC						
	Urticaria					
PER DAY ORAL						
			Nicotine (Formulation Unknown)	SS		
TRANSDERMAL TRANSDERMAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433797-8Report Type:Periodic Company Report #A0081333
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:03/01/99ISR Number: 3433799-1Report Type:Periodic Company Report #A0081334
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Chest Discomfort							PER DAY ORAL

Date:03/01/99ISR Number: 3433801-7Report Type:Periodic Company Report #A0081335
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Urticaria							PER DAY ORAL

Date:03/01/99ISR Number: 3433818-2Report Type:Periodic Company Report #A0081336
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3433819-4Report Type:Periodic Company Report #A0081337
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	3 MON
			Glipizide	C				
			Glucophage	C				
			Fexofenadine Hydrochlorid	C				

Date:03/01/99ISR Number: 3433823-6Report Type:Periodic Company Report #A0081338
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Tremor						PER DAY ORAL	
			Birth Control	C				

Date:03/01/99ISR Number: 3433826-1Report Type:Periodic Company Report #A0081339
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433829-7Report Type:Periodic Company Report #A0081340
Age:39 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	2 MON

Date:03/01/99ISR Number: 3433837-6Report Type:Periodic Company Report #A0074417
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Photosensitivity Reaction	Professional						
	Rash Erythematous							
			Tenorectic	C				
			Sertraline Hydrochloridge	C				
			Buspirone Hydrochloride	C				
			Promethazine Hcl	C				
			Simastatin	C				

Date:03/01/99ISR Number: 3433839-XReport Type:Periodic Company Report #A0074418
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ORAL	
	Dissociation							
			No Concurrent Medication Ethanol	C				

Date:03/01/99ISR Number: 3433843-1Report Type:Periodic Company Report #A0074419
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ORAL 2 WK
		Professional						

Date:03/01/99ISR Number: 3433847-9Report Type:Periodic Company Report #A0074420
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ORAL
	Muscular Weakness	Professional						
			Simvastatin	C				
			Multivitamin	C				
			Enalapril Maleste	C				

Date:03/01/99ISR Number: 3433850-9Report Type:Periodic Company Report #A0074421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Headache	Consumer
		Health
		Professional

Other

			Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / UNK						
/ORAL	1 DAY					
			Nicotine	C		

Date:03/01/99ISR Number: 3433853-4Report Type:Periodic Company Report #A0074423
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Insomnia					
TWICE PER DAY						
/ ORAL						

Date:03/01/99ISR Number: 3433855-8Report Type:Periodic Company Report #A0074424
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Erectile Dysfunction	Consumer	Zyban	PS	Glaxo Wellcome Inc	
150 MG /						
TWICE PER DAY						
/ ORAL						
			Ranitidine Hydrochloride	C		

Date:03/01/99ISR Number: 3433857-1Report Type:Periodic Company Report #A0074425
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL						
			Metoprolol Succinate	C		
			Nicotinic Acid	C		

Date:03/01/99ISR Number: 3433859-5Report Type:Periodic Company Report #A0074426
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433863-7Report Type:Periodic Company Report #A0074427
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Vitiligo							
			Diazepam	C				
			Co-Trimoxazole	C				
			Zyban	C	Glaxo Wellcome Inc			
			Bethanidine	C				
			Triamcinolone Acetonide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433867-4Report Type:Periodic Company Report #A0074428
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	
	Dysgeusia						/ ORAL	
	Insomnia							
	Vision Blurred							

Date:03/01/99ISR Number: 3433871-6Report Type:Periodic Company Report #A0074429
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	
	Hypersensitivity						/ ORAL	

Date:03/01/99ISR Number: 3433874-1Report Type:Periodic Company Report #A0074430
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Vision Blurred	Professional					PER DAY /ORAL	
			Hydroxyzine Hydrochloride	C				
			Digoxic	C				
			Omeprazole	C				
			Trimethoprim	C				

Date:03/01/99ISR Number: 3433877-7Report Type:Periodic Company Report #A0074431
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433880-7Report Type:Periodic Company Report #A0074432
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY /ORAL	

Date:03/01/99ISR Number: 3433882-0Report Type:Periodic Company Report #A0074481
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG / TWICE PER DAY / ORAL	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3433883-2Report Type:Periodic Company Report #A0074482
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	2 WK

Date:03/01/99ISR Number: 3433886-8Report Type:Periodic Company Report #A0074547
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK / ORAL	

Date:03/01/99ISR Number: 3433889-3Report Type:Periodic Company Report #A0074641
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dermatitis Gastritis Hypersensitivity Pain Pruritus Rash Erythematous Swelling	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG / TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3433951-5Report Type:Periodic Company Report #A0074713
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Haematochezia						TWICE PER DAY	
	Headache						/ ORAL	
	Insomnia							
	Nausea							
	Tremor							

Date:03/01/99ISR Number: 3434001-7Report Type:Periodic Company Report #A0077688
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG/ ORAL	

Date:03/01/99ISR Number: 3434003-0Report Type:Periodic Company Report #A0077689
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434006-6Report Type:Periodic Company Report #A0077690
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	DAY/ ORAL
			Thyroxine Sodium	C				

Date:03/01/99ISR Number: 3434009-1Report Type:Periodic Company Report #A0077691
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Oedema Peripheral						PER DAY/ ORAL	
	Urticaria							

Date:03/01/99ISR Number: 3434012-1Report Type:Periodic Company Report #A0077692
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Pruritus						PER DAY/ ORAL	

Date:03/01/99ISR Number: 3434016-9Report Type:Periodic Company Report #A0077693
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	

			Atorvastatin Calcium	C			
			Calcium Carbonate	C			
			Centrum	C			
			Loratadine	C			

Date:03/01/99ISR Number: 3434018-2Report Type:Periodic Company Report #A0077694
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	75 MG / SEE	
	Pain						TEXT/ ORAL	
	Pruritus		Darvocet-N	C				
			Estrogen	C				
			Nortriptyline	C				
			Zolpidem Tartrate	C				
			Amlodipine	C				
			Cisapride	C				
			Metolazone	C				
			Multivitamin	C				
			Calcium Salt	C				
			Mirtazapine	C				
			Clonazepam	C				
			Simvastatin	C				
			Aspirin	C				
			Diltiazem Hydrochloride	C				
			Cyproheptadine	C				
			Desocort	C				
			Decongestant	C				

			Lansoprazole	C		

Date:03/01/99ISR Number: 3434021-2Report Type:Periodic Company Report #A0077695
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Dizziness	Professional					DAY/ ORAL	
	Hypoaesthesia		Oxaprozin	C				
	Nausea							
	Sedation							

Date:03/01/99ISR Number: 3434025-XReport Type:Periodic Company Report #A0077696
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE	
	Urticaria						PER DAY/ ORAL	

Date:03/01/99ISR Number: 3434027-3Report Type:Periodic Company Report #A0077697
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE	
	Vomiting						PER DAY/ ORAL	

Date:03/01/99ISR Number: 3434030-3Report Type:Periodic Company Report #A0077698
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE PER DAY/	ORAL

Date:03/01/99ISR Number: 3434033-9Report Type:Periodic Company Report #A0077709
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	ORAL	

Date:03/01/99ISR Number: 3434036-4Report Type:Periodic Company Report #A0077837
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	/ SEE TEXT/	
	Ventricular Extrasystoles						ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434040-6Report Type:Periodic Company Report #A0077847
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	ORAL	3 WK
	Head Injury							

Date:03/01/99ISR Number: 3434041-8Report Type:Periodic Company Report #A0077869
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / DAY / ORAL	PER
	Dry Mouth							
	Insomnia		Multivitamin	C				
	Tachycardia		Chromium Picolinate	C				

Date:03/01/99ISR Number: 3434044-3Report Type:Periodic Company Report #A0077871
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ DAY / ORAL	PER
	Chest Pain							
	Confusional State		Nicotine	C				
	Disorientation							
	Dizziness							
	Eye Disorder							
	Headache							
	Nausea							

Date:03/01/99ISR Number: 3434047-9Report Type:Periodic Company Report #A0077952
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hyperhidrosis						TWICE PER DAY	
	Insomnia						/ ORAL	
	Tachycardia		Hydroxyzine	C				

Date:03/01/99ISR Number: 3434049-2Report Type:Periodic Company Report #A0077953
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Major Depression						TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3434051-0Report Type:Periodic Company Report #A0077954
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Urinary Retention	Professional					TWICE PER	
							DAY/ ORAL	
			Fluoxetine Hydrochloride	C				
			Cyanocobalamin	C				
			Salbutamol Sulphate	C				

			Salbutamol Sulphate	C		
			Salmeterol Xinafoate	C		
			Multivitamin	C		

Date:03/01/99ISR Number: 3434055-8Report Type:Periodic Company Report #A0077955
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Myalgia							
			Tri-Levlen	C				

Date:03/01/99ISR Number: 3434063-7Report Type:Periodic Company Report #A0081370
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3434064-9Report Type:Periodic Company Report #A0077956
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	
	Insomnia							
	Nervousness							
			Nafarelin Acetate	C				

Date:03/01/99ISR Number: 3434065-0Report Type:Periodic Company Report #A0077957
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
			Estrogen	C				
			Medroxyprogesterone	C				

Date:03/01/99ISR Number: 3434066-2Report Type:Periodic Company Report #A0077958
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Urticaria							PER DAY/ ORAL
			Nicotine	C				

Date:03/01/99ISR Number: 3434067-4Report Type:Periodic Company Report #A0077959
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434068-6Report Type:Periodic Company Report #A0077960
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
	Irritability						PER DAY /
							ORAL

Date:03/01/99ISR Number: 3434069-8Report Type:Periodic Company Report #A0077961
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER
	Tremor						DAY/ ORAL
			Amitriptyline	C			
			Aspirin	C			
			Multivitamin	C			

Date:03/01/99ISR Number: 3434070-4Report Type:Periodic Company Report #A0077962
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Aggression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
	Disorientation						PER DAY/ORAL
	Personality Change		Sertraline Hydrochloride	C			
			Olanzapine	C			
			Propranolol Hydrochloride	C			

Date:03/01/99ISR Number: 3434071-6Report Type:Periodic Company Report #A0077963
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
	Indifference						DAILY/	ORAL
	Insomnia							

Date:03/01/99ISR Number: 3434072-8Report Type:Periodic Company Report #A0077974
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
							DAILY/	ORAL

Date:03/01/99ISR Number: 3434073-XReport Type:Periodic Company Report #A0078008
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
	Dizziness						PER DAY/	ORAL
	Hallucination							
	Tremor							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434074-1Report Type:Periodic Company Report #A0078014
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ YWICE	
	Drug Ineffective						PER DAY/ ORAL	
	Joint Swelling							
	Lymphocytosis							
	Nausea							
	Pain							
	Paraesthesia							
	Rash Pruritic							
	Red Blood Cell Sedimentation Rate Increased							
	White Blood Cell Count Increased							

Date:03/01/99ISR Number: 3434075-3Report Type:Periodic Company Report #A0078054
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Urticaria	Professional					PER DAY /	
							ORAL	

Date:03/01/99ISR Number: 3434076-5Report Type:Periodic Company Report #A0078056
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	
		Professional Company Representative						

Date:03/01/99ISR Number: 3434077-7Report Type:Periodic Company Report #A0078182
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Abdominal Pain						PER DAY/ ORAL	
	Abdominal Pain Upper							

Date:03/01/99ISR Number: 3434078-9Report Type:Periodic Company Report #A0078183
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
							PER DAY /	
							ORAL	

Date:03/01/99ISR Number: 3434079-0Report Type:Periodic Company Report #A0078184
Age:32 YR Gender:Female I/FU:I

Outcome	PT
	Constipation
	Dizziness

Headache Tachycardia Vision Blurred	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL

Date:03/01/99ISR Number: 3434080-7Report Type:Periodic Company Report #A0078185
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL
	Insomnia						
	Therapeutic Response		Percodan	C			
	Unexpected						

Date:03/01/99ISR Number: 3434081-9Report Type:Periodic Company Report #A0078187
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Conversion Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE DAILY/ ORAL
	Crying						
	Dysgeusia		Paracetamol	C			
	Fear		Ibuprofen	C			

Date:03/01/99ISR Number: 3434082-0Report Type:Periodic Company Report #A0078188
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE

	Psoriasis					
PER DAY /						
ORAL						
			Estrogen	C		

Date:03/01/99ISR Number: 3434083-2Report Type:Periodic Company Report #A0078189
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Choking	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Retching							

Date:03/01/99ISR Number: 3434084-4Report Type:Periodic Company Report #A0078190
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Dizziness						PER DAY/ORAL	
	Fatigue							
	Feeling Abnormal							
	Nausea							
	Vertigo							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434085-6Report Type:Periodic Company Report #A0078191
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	PER DAY/ORAL
			Semisodium Valproate	C				
			Clonazepam	C				
			Zolpidem Tartrate	C				

Date:03/01/99ISR Number: 3434086-8Report Type:Periodic Company Report #A0078192
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG / TWICE	
	Feeling Abnormal							PER DAY/ORAL
	Palpitations							
	Syncope							
	Tachycardia							

Date:03/01/99ISR Number: 3434087-XReport Type:Periodic Company Report #A0078193
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150	
	Vomiting						N=MG/TWICE	
								PER DAY/ORAL
			Amlodipine	C				
			Atorvastatin Calcium	C				
			Nicotinic Acid	C				

Date:03/01/99ISR Number: 3434088-1Report Type:Periodic Company Report #A0078194
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Dermatitis Exfoliative	Professional					PER DAY/ ORAL	
	Face Oedema		Waarfarin Sodium	C				
			Salbutamol Sulphate	C				
			Beclomethasone Dipropion	C				
			Ipratropium Bromide	C				
			Oxygen	C				

Date:03/01/99ISR Number: 3434089-3Report Type:Periodic Company Report #A0078195
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Eczema						TWICE PER DAY	
	Insomnia						/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434090-XReport Type:Periodic Company Report #A0078196
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	3 WK

Date:03/01/99ISR Number: 3434091-1Report Type:Periodic Company Report #A0078270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:03/01/99ISR Number: 3434092-3Report Type:Periodic Company Report #A0078413
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3434093-5Report Type:Periodic Company Report #A0078414
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ ORAL	

Date:03/01/99ISR Number: 3434094-7Report Type:Periodic Company Report #A0078415
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dizziness						DAY / ORAL	
	Dry Mouth							
	Hyperacusis							
	Mental Disorder							
	Sedation							
	Tachycardia							
	Tremor							

Date:03/01/99ISR Number: 3434095-9Report Type:Periodic Company Report #A0078416
Age:47 YR Gender:Female I/FU:I

Outcome	PT
	Arthralgia
	Cough
	Dermatitis
	Difficulty In Walking
	Dry Mouth
	Headache
	Hypoaesthesia
	Logorrhoea
	Nausea
	Oedema Peripheral
	Paraesthesia

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	

Date:03/01/99ISR Number: 3434096-0Report Type:Periodic Company Report #A0078417
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	
	Headache							
	Nervousness							
	Smoker		Fexofenadine Hydrochlorid	C				
			Multivitamin	C				

Date:03/01/99ISR Number: 3434097-2Report Type:Periodic Company Report #A0078418
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
	Eyelid Oedema							
	Urticaria		Birth Control	C				

Date:03/01/99ISR Number: 3434098-4Report Type:Periodic Company Report #A0078419
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER	DAY / ORAL
			Maxzide	C				
			Lisinopril	C				

Date:03/01/99ISR Number: 3434099-6Report Type:Periodic Company Report #A0078420
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL

Date:03/01/99ISR Number: 3434100-XReport Type:Periodic Company Report #A0078421
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL
	Confusional State							
	Disturbance In Attention							
	Influenza Like Illness							
	Irritability							
	Myalgia							
	Pain							
	Skin Irritation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434101-1Report Type:Periodic Company Report #A0078422
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dysphagia	Professional					TWICE PER DAY	
		Other					/ ORAL	

Date:03/01/99ISR Number: 3434102-3Report Type:Periodic Company Report #A0078423
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Emotional Disorder						PER DAY /	
	Panic Reaction						ORAL	

Date:03/01/99ISR Number: 3434399-XReport Type:Periodic Company Report #A0078948
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus						TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3434405-2Report Type:Periodic Company Report #A0078951
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Nausea					
TWICE PER DAY						
	Tinnitus					
/ ORAL						

Date:03/01/99ISR Number: 3434407-6Report Type:Periodic Company Report #A0078952
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL
1 TABLET /						
ORAL						
			Diphenhydramine Hcl	C		
			Esgic-Plus	C		

Date:03/01/99ISR Number: 3434408-8Report Type:Periodic Company Report #A0078953
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Excitability	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Insomnia					
TWICE PER DAY						
	Mood Swings					
/ ORAL						
			Birth Control	C		
			Multivitamin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434411-8Report Type:Periodic Company Report #A0078954
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3434413-1Report Type:Periodic Company Report #A0078955
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:03/01/99ISR Number: 3434414-3Report Type:Periodic Company Report #A0078956
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:03/01/99ISR Number: 3434418-0Report Type:Periodic Company Report #A0078957
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychomotor Hyperactivity	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Clarithromycin	C				
			Vitamin E	C				

				Librium	C		
				Doxylamine Succinate	C		
				Pyridoxine Hydrochloride	C		

Date:03/01/99ISR Number: 3434421-0Report Type:Periodic Company Report #A0078958
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Chest Discomfort						TWICE PER	
	Dyspepsia						DAY/ ORAL	
			Doxylamine Succinate	C				

Date:03/01/99ISR Number: 3434422-2Report Type:Periodic Company Report #A0078960
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434425-8Report Type:Periodic Company Report #A0078963
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	PER DAY/ORAL
			Verapamil	C				
			Atenolol	C				
			Medrol	C				
			Potassium Salt	C				
			Conjugates Estrogens	C				
			Triamter. +Hclthiazide	C				
			Pravastatin Sodium	C				

Date:03/01/99ISR Number: 3434427-1Report Type:Periodic Company Report #A0078967
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet-Zyban	PS		ORAL	150MG/ THREE	TIMES PER DAY/ORAL
	Insomnia							
	Nausea							
	Overdose							
	Tremor							

Date:03/01/99ISR Number: 3434429-5Report Type:Periodic Company Report #A0078968
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	PER DAY/ORAL
	Tremor							
			Oestradiol	C				
			Simvastatin	C				

Date:03/01/99ISR Number: 3434430-1Report Type:Periodic Company Report #A0079588
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban	PS		ORAL	150 MG /TWICE	
	Drug Ineffective						PER DAY /	
	Insomnia						ORAL	
			Pravastatin Sodium	C				

Date:03/01/99ISR Number: 3434432-5Report Type:Periodic Company Report #A0079589
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS		ORAL	150 MG /	
	Feeling Abnormal						TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3434434-9Report Type:Periodic Company Report #A0079590
Age:67 YR Gender:Male I/FU:I

Outcome	PT
	Constipation
	Dizziness

	Insomnia					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban	PS		ORAL
150 MG TWICE						
PER DAY /						
ORAL						
			Ibuprofen	C		

Date:03/01/99ISR Number: 3434436-2Report Type:Periodic Company Report #A0079591
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Nausea	Consumer	Zyban	PS		ORAL
150 MG /						
	Retching					
TWICE PER DAY						
/ ORAL	14 DAY					
			Allopurinol	C		
			Terazosin Hydrochloride	C		
			Chlorthalidone	C		

Date:03/01/99ISR Number: 3434438-6Report Type:Periodic Company Report #A0079592
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Pollakiuria	Consumer	Zyban	PS		ORAL
150 MG / ORAL	7 DAY					
			Amoxycillin	C		

Date:03/01/99ISR Number: 3434439-8Report Type:Periodic Company Report #A0079617
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Zyban	PS		ORAL	150 MG / PER	
	Dizziness						DAY / ORAL	
	Dyspnoea		Birth Control	C				
	Feeling Abnormal							
	Hyperventilation							
	Nausea							
	Pruritus							
	Syncope							
	Tachycardia							
	Tremor							
	Urticaria							

Date:03/01/99ISR Number: 3434440-4Report Type:Periodic Company Report #A0079764
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Zyban Tablet - Zyban	PS		ORAL	ORAL	3 DAY
	Pruritus	Professional	Wellbutrin Tablet-Controlled Release	SS		ORAL	150 MG / ORAL	3 WK
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434441-6Report Type:Periodic Company Report #A0079951
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE	
	Anxiety						PER DAY /	
	Headache						ORAL	
	Nausea		Cortisone	C				
	Nervousness		Prednisone	C				

Date:03/01/99ISR Number: 3434442-8Report Type:Periodic Company Report #A0079953
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE	
	Insomnia						PER DAY /	
							ORAL	
			Tylenol W/ Codeine No. 4	C				
			Cyclobenzaprine Hcl	C				
			Clorazepic Acid	C				

Date:03/01/99ISR Number: 3434443-XReport Type:Periodic Company Report #A0079954
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3434444-1Report Type:Periodic Company Report #A0079955
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Hypertension						PER DAY /	
	Pruritus						ORAL	
	Vomiting							

Date:03/01/99ISR Number: 3434445-3Report Type:Periodic Company Report #A0079956
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	1 WK
	Crying							
	Dermatitis							

Date:03/01/99ISR Number: 3434447-7Report Type:Periodic Company Report #A0079957
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dyspraxia						TWICE PER DAY	
	Nervousness						/ ORAL	
	Sedation		Nortripgyline Hcl	C				
			Diazepam	C				
			Carisoprodol	C				

			Oxycodone Hydrochloride	C		

Date:03/01/99ISR Number: 3434448-9Report Type:Periodic Company Report #A0079958
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Fatigue		Dilantin	C				
	Feeling Abnormal							

Date:03/01/99ISR Number: 3434454-4Report Type:Periodic Company Report #A0080013
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Convulsion	Professional					DAY /ORAL	
	Influenza Like Illness							
	Lacrimation Increased							
	Pyrexia							
	Rhinorrhoea							
	Sneezing							
	Tremor							

Date:03/01/99ISR Number: 3434457-XReport Type:Periodic Company Report #A0080099
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	
		Professional					PER DAY/ ORAL	

Date:03/01/99ISR Number: 3434461-1Report Type:Periodic Company Report #A0080050
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Paraesthesia						DAY / ORAL	
			Prempro	C				

Date:03/01/99ISR Number: 3434464-7Report Type:Periodic Company Report #A0080051
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	
			Isosorbide Mononitrate	C				
			Conjugated Estrogens	C				
			Atorvastatin Calcium	C				
			Ranitidine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434466-0Report Type:Periodic Company Report #A0080052
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Tachycardia							

Date:03/01/99ISR Number: 3434467-2Report Type:Periodic Company Report #A0080053
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Dizziness							
	Nausea		Amlodipine	C				
			Diazepam	C				
			Insulin	C				
			Guanfacine Hydrochloride	C				
			Glipizide	C				

Date:03/01/99ISR Number: 3434470-2Report Type:Periodic Company Report #A0080054
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ORAL	
			Glipizide	C				

Date:03/01/99ISR Number: 3434472-6Report Type:Periodic Company Report #A0080055
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Zyban Tablet-Zyban	PS		ORAL	150M MG/PER	
	Hypoglycaemia						DAY/ORAL	
			Insulin	C				
			Captopril	C				
			Frusemide	C				
			Digoxin	C				
			Isotretinoin	C				
			Warfarin Sodium	C				
			Amlodipine	C				
			Isosorbide	C				

Date:03/01/99ISR Number: 3434474-XReport Type:Periodic Company Report #A0080056
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TIWCE	
							PER DAY/	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434476-3Report Type:Periodic Company Report #A0080057
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG /TWICE	
	Pruritus						PER DAY/ ORAL	
	Urticaria							

Date:03/01/99ISR Number: 3434478-7Report Type:Periodic Company Report #A0080058
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ PER	
	Agitation						DAY/ ORAL	
	Disorientation							
	Headache							
	Hyperhidrosis							

Date:03/01/99ISR Number: 3434479-9Report Type:Periodic Company Report #A0080059
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG/ ORAL	
			Famotidine	I				

Date:03/01/99ISR Number: 3434482-9Report Type:Periodic Company Report #A0080060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ ORAL	
	Pruritus							

Date:03/01/99ISR Number: 3434485-4Report Type:Periodic Company Report #A0080061
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	
	Anorexia							
	Blood Pressure Increased							
	Chest Pain							
	Depression							
	Disturbance In Attention							
	Heart Rate Increased							
	Insomnia							
	Mental Disorder							
	Paranoia							
	Tremor							

Date:03/01/99ISR Number: 3434490-8Report Type:Periodic Company Report #A0080062
Age:26 YR Gender:Female I/FU:I

Outcome	PT
	Dry Mouth
	Dry Skin
	Hypersensitivity
	Insomnia
	Lichen Planus

	Milia Pharyngolaryngeal Pain Pruritus	Report Source	Product	Role	Manufacturer	Route Dose Duration
		Consumer	Zyban Tablet-Zyban	PS		ORAL 150 MG / TWICE PER DAY/ ORAL
			Multivitamin	C		

Date:03/01/99ISR Number: 3434492-1Report Type:Periodic Company Report #A0080064
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Arthralgia Dry Mouth Insomnia	Consumer	Zyban Tablet-Zyban	PS		ORAL 150 MG/ TWICE PER DAY/ORAL

Date:03/01/99ISR Number: 3434494-5Report Type:Periodic Company Report #A0080065
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Drug Ineffective	Consumer	Zyban Tablet-Zyban	PS		ORAL 150 MG/ TWICE PER DAY/ORAL
			Natural Medication	C		

Date:03/01/99ISR Number: 3434497-0Report Type:Periodic Company Report #A0080066
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Abnormal Dreams	Consumer	Zyban Tablet-Zyban	PS		ORAL 150 MG/ TWICE

	Dermatitis					

PER DAY/ ORAL

Date:03/01/99ISR Number: 3434499-4Report Type:Periodic Company Report #A0080079
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG /	

TIWCE PER

DAY/ ORAL

Date:03/01/99ISR Number: 3434502-1Report Type:Periodic Company Report #A0080093
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ ORAL	
			Thiothixene	C				
			Benztropine Mesylate	C				
			Clonidine Hydrochloride	C				

Date:03/01/99ISR Number: 3434505-7Report Type:Periodic Company Report #A0080094
Age:31 YR Gender:Female I/FU:I

Outcome	PT
	Burning Sensation
	Pruritus

	Rash Erythematous					
		Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/ TWICE PER DAY/ORAL						
			Naproxen Sodium	C		

Date:03/01/99ISR Number: 3434507-0Report Type:Periodic Company Report #A0080095
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/ TWICE PER DAY/ORAL						

Date:03/01/99ISR Number: 3434509-4Report Type:Periodic Company Report #A0080096
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urticaria	Health Professional	Zyban Tablet-Zyban	PS		ORAL
150 MG/ ORAL 2 WK						

Date:03/01/99ISR Number: 3434512-4Report Type:Periodic Company Report #A0080097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Suicidal Ideation	Health Professional	Zyban Tablet-Zyban	PS		ORAL
150 MG/ ORAL						

Date:03/01/99ISR Number: 3434514-8Report Type:Periodic Company Report #A0080098
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	
	Bruxism						PER DAY/ORAL	
	Dermatitis		Birth Control	C				
	Headache							
	Pruritus							
	Toothache							
	Urticaria							

Date:03/01/99ISR Number: 3434521-5Report Type:Periodic Company Report #A0080106
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Blood Pressure Increased						TWICE PER DAY	
	Cold Sweat						/ ORAL	
	Dermatitis							
	Dizziness							
	Headache							
	Insomnia							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434523-9Report Type:Periodic Company Report #A0080108
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						VARIABLE DOSE	
	Ulcer						/ ORAL	
			Ranitidine Hydrochloride	C				

Date:03/01/99ISR Number: 3434524-0Report Type:Periodic Company Report #A0080171
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Atenolol	C				
			Thyroxine Sodium	C				
			Aspirin	C				
			Conjugated Estrogens	C				
			Medroxyprogesterone Ace.	C				
			Trazodone	C				

Date:03/01/99ISR Number: 3434528-8Report Type:Periodic Company Report #A0080172
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	

/ ORAL

Date:03/01/99ISR Number: 3434530-6Report Type:Periodic Company Report #A0080173
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Nausea						TWICE PER DAY	
/ ORAL								
			Fexofenadine Hydrochlorid	C				
			Desogen	C				

Date:03/01/99ISR Number: 3434532-XReport Type:Periodic Company Report #A0080174
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eating Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 /TWICE	
	Hyperhidrosis						PER DAY /	
	Nausea						ORAL	
	Throat Tightness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434535-5Report Type:Periodic Company Report #A0080175
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Drug Ineffective		Aspirin	C				
			Cetirizine Hydrochloride	C				
			Lisinopril	C				
			Diltiazem Hydrochloride	C				
			Pravastatin Sodium	C				

Date:03/01/99ISR Number: 3434539-2Report Type:Periodic Company Report #A0080326
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:03/01/99ISR Number: 3434551-3Report Type:Periodic Company Report #A0080329
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
	Pollakiuria						/ ORAL	
			Conjugated Estrogens	C				
			Gemfibrozil	C				
			Famotidine	C				

Date:03/01/99ISR Number: 3434559-8Report Type:Periodic Company Report #A0080346
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Rash Pruritic						TWICE PER DAY	
							/ ORAL	

Date:03/01/99ISR Number: 3434562-8Report Type:Periodic Company Report #A0081341
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Vicodin	C				
			Ciprofloxacin Hcl	C				
			Prempro	C				
			Hydrochlorothiazide	C				

Date:03/01/99ISR Number: 3434568-9Report Type:Periodic Company Report #A0081342
Age: Gender:Female I/FU:I

Outcome	PT
	Dysphagia
	Glossitis

Tongue Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	ORAL 13 DAY

Date:03/01/99ISR Number: 3434573-2Report Type:Periodic Company Report #A0081343
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Dry Mouth							
	Excitability							
	Flushing		Tramadol Hydrochloride	C				

Date:03/01/99ISR Number: 3434575-6Report Type:Periodic Company Report #A0081344
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY /	ORAL
	Dermatitis							
	Diarrhoea							
	Dizziness							
	Dysarthria							
	Insomnia							
	Nausea							
	Tremor							

Date:03/01/99ISR Number: 3434579-3Report Type:Periodic Company Report #A0081345
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Monarthritis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Levlen	C				

Date:03/01/99ISR Number: 3434581-1Report Type:Periodic Company Report #A0081346
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Urticaria							
			Enalapril Maleate	C				
			Atorvastatin Calcium	C				

Date:03/01/99ISR Number: 3434584-7Report Type:Periodic Company Report #A0081347
Age: Gender: I/FU:I

Outcome	PT
	Abnormal Dreams
	Confusional State
	Constipation
	Dry Mouth
	Eye Disorder

	Hallucination, Auditory Ill-Defined Disorder Palpitations	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
150 MG / ORAL 8 DAY	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL

Date:03/01/99ISR Number: 3434589-6Report Type:Periodic Company Report #A0081348
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
150 MG /	Anxiety		Zyban Tablet - Zyban	PS		ORAL
TWICE PER DAY	Insomnia					
/ ORAL			Thyroxine Sodium	C		

Date:03/01/99ISR Number: 3434590-2Report Type:Periodic Company Report #A0081349
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
150 MG /	Hallucination	Consumer	Zyban Tablet - Zyban	PS		ORAL
TWICE PER DAY						
/ ORAL			Propranolol Hydrochloride	C		

Date:03/01/99ISR Number: 3434592-6Report Type:Periodic Company Report #A0081369
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
150 MG / ORAL	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL

Date:03/01/99ISR Number: 3434602-6Report Type:Periodic Company Report #A0080531
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Chest Pain						PER DAY/ ORAL	
			Moexipril Hydrochloride	C				
			Clonidine	C				
			Percocet	C				

Date:03/01/99ISR Number: 3434605-1Report Type:Periodic Company Report #A0080532
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Flatulence						PER DAY/ ORAL	
	Insomnia		Glibenclamide	C				
			Verapamil Hydrochloride	C				
			Conjugated Estrogens	C				
			Triamterene	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3434606-3Report Type:Periodic Company Report #A0080667
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	PER DAY/ORAL
			Conjugated Estrogens	C				

Date:03/01/99ISR Number: 3434607-5Report Type:Periodic Company Report #A0080690
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Oral Mucosal Blistering							PER DAY/ORAL
			Simvastatin	C				

Date:03/01/99ISR Number: 3434608-7Report Type:Periodic Company Report #A0080691
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	
	Eating Disorder							PER DAY/ORAL
			Quinapril Hydrochloride	C				

Date:03/01/99ISR Number: 3434611-7Report Type:Periodic Company Report #A0080693
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/UNKNOWN	

Professional
/ ORAL

Date:03/01/99ISR Number: 3435069-4Report Type:Periodic Company Report #A0080025
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban Tablet -Zyban	PS		ORAL	150 MG /TWICE	
	Urticaria						PER DAY /	
							ORAL	

Date:03/01/99ISR Number: 3436404-3Report Type:Periodic Company Report #A0080694
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	
	Mania						PER DAY/ ORAL	

Date:03/01/99ISR Number: 3436406-7Report Type:Periodic Company Report #A0080695
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	
	Dry Mouth						PER DAY/ ORAL	
	Insomnia		Alprazolam	C				
	Tobacco Abuse							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3436408-0Report Type:Periodic Company Report #A0080696
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	PER DAY/ ORAL

Date:03/01/99ISR Number: 3436411-0Report Type:Periodic Company Report #A0078820
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	PER DAY/ ORAL
	Nausea							
			Frusemide	C				
			Warfarin Sodium	C				
			Human Insulin	C				
			Nitroglycerin	C				
			Diazepam	C				
			Fluoxetine Hydrochloride	C				
			Thyroxine Sodium	C				
			Meclozine Hydrochloride	C				
			Metoprolol Tartrate	C				
			Isosorbide Mononitrate	C				
			Tolterodine	C				

Date:03/01/99ISR Number: 3436415-8Report Type:Periodic Company Report #A0078821
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	PER DAY/ ORAL

Date:03/01/99ISR Number: 3436418-3Report Type:Periodic Company Report #A0078822
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE PER DAY/	ORAL

Date:03/01/99ISR Number: 3436421-3Report Type:Periodic Company Report #A0078823
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE PER DAY/	ORAL
	Nausea							
			Birth Control	C				

Date:03/01/99ISR Number: 3436425-0Report Type:Periodic Company Report #A0078824
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE PER DAY/	ORAL
	Headache							
			No Concurrent					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Medication C

Date:03/01/99ISR Number: 3436427-4Report Type:Periodic Company Report #A0078825
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	PER DAY/ ORAL

Date:03/01/99ISR Number: 3436430-4Report Type:Periodic Company Report #A0078826
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	PER DAY/ ORAL
	Disturbance In Attention							
	Insomnia							

Date:03/01/99ISR Number: 3436433-XReport Type:Periodic Company Report #A0078827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	PER DAY/ ORAL

Date:03/01/99ISR Number: 3436437-7Report Type:Periodic Company Report #A0078828
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	

	Joint Swelling					
PER DAY/ ORAL						

Date:03/01/99ISR Number: 3436440-7Report Type:Periodic Company Report #A078829
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE	
	Disorientation						PER DAY/ ORAL	
	Dyspnoea		Medroxyprogesterone					
	Hyperhidrosis		Ace	C				
	Insomnia							

Date:03/01/99ISR Number: 3436444-4Report Type:Periodic Company Report #A0080373
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	
	Irritability						DAY ORAL	

Date:03/01/99ISR Number: 3436447-XReport Type:Periodic Company Report #A0080374
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150MG TWICE	
	Malaise						PER DAY ORAL	
	Tremor		Enalapril Maleate	C				

				Diltiazem Hydrochloride	C		
				Amoxycillin Trihydrate	C		
				Sildenafil Citrate	C		

Date:03/01/99ISR Number: 3436451-1Report Type:Periodic Company Report #A0080375
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	PER DAY ORAL
			Omeprazole	C				

Date:03/01/99ISR Number: 3436456-0Report Type:Periodic Company Report #A0080376
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	PER DAY ORAL

Date:03/01/99ISR Number: 3436458-4Report Type:Periodic Company Report #A0080377
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	PER DAY ORAL
			Amoxycillin	C				
			Atenolol	C				

Date:03/01/99ISR Number: 3436463-8Report Type:Periodic Company Report #A0080378
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	

Date:03/01/99ISR Number: 3436469-9Report Type:Periodic Company Report #A0080379
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Bone Pain						PER DAY ORAL	
	Dyspraxia		Diltiazem Hydrochloride	C				
	Feeling Abnormal		Pravastatin Sodium	C				
	Hyperhidrosis		Aspirin	C				
	Insomnia							

Date:03/01/99ISR Number: 3436471-7Report Type:Periodic Company Report #A0080405
Age:49 YR Gender:Female I/FU:I

Outcome	PT
	Diplopia
	Disorientation
	Dizziness

	Headache						
	Hypoaesthesia						
	Vision Blurred	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban Tablet - Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL
			Thyroxine Sodium	C			

Date:03/01/99ISR Number: 3436474-2Report Type:Periodic Company Report #A0080406
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL

Date:03/01/99ISR Number: 3436480-8Report Type:Periodic Company Report #A0080411
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL

Date:03/01/99ISR Number: 3436483-3Report Type:Periodic Company Report #A0080413
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Decreased Appetite	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL
	Disturbance In Attention						
	Dysgeusia						
	Hallucination						
	Headache						

Insomnia

Date:03/01/99ISR Number: 3436485-7Report Type:Periodic Company Report #A0080417
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Insomnia						PER DAY ORAL	
	Restlessness		Hydroxyzine					
	Suicidal Ideation		Hydrochloride	C				

Date:03/01/99ISR Number: 3436487-0Report Type:Periodic Company Report #A0080422
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Fatigue						PER DAY ORAL	
			Aspirin	C				

Date:03/01/99ISR Number: 3436492-4Report Type:Periodic Company Report #A0080423
Age:55 YR Gender:Female I/FU:I

Outcome	PT
	Anxiety
	Disturbance In Attention

Nausea

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	3 DAY

Date:03/01/99ISR Number: 3436495-XReport Type:Periodic Company Report #A0080424
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:03/01/99ISR Number: 3436498-5Report Type:Periodic Company Report #A0080442
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER DAY ORAL	
	Photopsia							
			Ibuprofen	C				

Date:03/01/99ISR Number: 3436502-4Report Type:Periodic Company Report #A0080444
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ill-Defined Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Nausea							
			Nifedipine	C				
			Thyroxine Sodium	C				

Date:03/01/99ISR Number: 3436504-8Report Type:Periodic Company Report #A0080446
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ill-Defined Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	
	Nausea							

Date:03/01/99ISR Number: 3436509-7Report Type:Periodic Company Report #A0080529
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG ORAL	

Date:03/01/99ISR Number: 3436513-9Report Type:Periodic Company Report #A0080530
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/99ISR Number: 3443034-6Report Type:Periodic Company Report #A0065843
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Imitrex Injection	PS		SUBCUTANEOUS	AS REQUIRED/SUBCUTANEOUS	4 YR
	Drug Interaction		Wellbutrin Tablet-Controlled Release	SS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:03/02/99ISR Number: 3210328-9Report Type:Expedited (15-DaCompany Report #A0079255
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	
Other	Pain In Extremity	Professional						
			Buspirone Hydrochloride	C				
			Ibuprofen	C				

Date:03/02/99ISR Number: 3210330-7Report Type:Expedited (15-DaCompany Report #A0082565
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Faecaloma	Consumer						
			Antibiotics	C				

Date:03/02/99ISR Number: 3210332-0Report Type:Expedited (15-DaCompany Report #A0082079
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Balance Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG PER DAY ORAL
	Confusional State						
	Feeling Abnormal		Vitamin E	C			
	Nausea		Calcium Salt	C			
	Vision Blurred						

Date:03/02/99ISR Number: 3433775-9Report Type:Periodic Company Report #A0081320
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL
			Diphenhydramine Hcl	C			

Date:03/04/99ISR Number: 3212945-9Report Type:Expedited (15-DaCompany Report #A0082408
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Joint Dislocation	Health Professional	Aspirin	C			
			Olanzapine	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/99ISR Number: 3214713-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angioneurotic Oedema Urticaria		Zyban Sustained Release Tablet	PS	Glaxo Wellcome	ORAL	ORAL DOSE	

Date:03/05/99ISR Number: 3214470-8Report Type:Expedited (15-DaCompany Report #A0082673
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Health Professional Other	Wellbutrin Tablet	PS		ORAL	ORAL	
	Drug Level Above Therapeutic		Lithium Carbonate Tablet	SS		ORAL	ORAL	
	Feeling Drunk		Olanzapine Tablet	SS		ORAL	ORAL	
	Nausea		Benzatropine Tablet	SS		ORAL	ORAL	
	Tremor		Gabapentin Tablet	SS		ORAL	ORAL	
			Clonazepam Tablet	SS		ORAL	ORAL	
			Zolpidem Tartrate Tablet	SS		ORAL	ORAL	
			Sertraline Hydrochloride Tablet	SS		ORAL	ORAL	

Date:03/05/99ISR Number: 3214640-9Report Type:Expedited (15-DaCompany Report #A0074224
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Wellbutrin	PS		ORAL	150 MG / PER	

Initial or Prolonged	Blood Pressure Increased	Professional					
DAY							
	Dizziness		Atenolol	C			
	Nausea		Prempro	C			

Date:03/08/99ISR Number: 3214861-5Report Type:Expedited (15-DaCompany Report #A0084548
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG TWICE	
Initial or Prolonged	Dyspnoea						PER DAY ORAL	
	Hypersensitivity							
	Insomnia							
	Nausea							
	Oedema							
	Pharyngeal Oedema							
	Pruritus							
	Skin Discolouration							
	Urticaria							

Date:03/08/99ISR Number: 3214862-7Report Type:Expedited (15-DaCompany Report #A0080441
Age:27 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Confusional State
Initial or Prolonged	Disorientation
Other	Dizziness
	Dizziness Postural
	Headache

	Stupor Syncope						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional Company Representative	Wellbutrin Tablets -Controlled Release	PS		ORAL	150 MG PER DAY ORAL

Date:03/08/99ISR Number: 3214863-9Report Type:Expedited (15-DaCompany Report #A0078251
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Bipolar I Disorder Condition Aggravated Convulsion Hallucination	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY ORAL

Date:03/08/99ISR Number: 3215088-3Report Type:Expedited (15-DaCompany Report #A0076758
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged	Anaemia Cardiac Failure Cerebrovascular Accident Chest Pain Coronary Artery Disease Gastric Ulcer Gastrointestinal Haemorrhage Haematemesis Insomnia Myocardial Infarction Pneumonia Respiratory Failure	Health Professional	Zyban Paracetamol	PS C		ORAL	150 MG SINGLE DOSE ORAL

	Sepsis					
	Vomiting					

Date:03/08/99ISR Number: 3215565-5Report Type:Expedited (15-DaCompany Report #A0084700
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Toxicity	Consumer	Wellbutrin					
	Overdose		(Formulation					
			Unknown)	PS		ORAL	100 MG / UNK	
							/ ORAL	

Date:03/11/99ISR Number: 3217771-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Bupropion	PS		ORAL	150 MG BID PO	
	Hallucination, Auditory							
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/99ISR Number: 3219018-XReport Type:Expedited (15-DaCompany Report #A0078500
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Rib Fracture Syncope Upper Limb Fracture	Health Professional	Zyban	PS		ORAL	15 MG / TWICE PER DAY / ORAL	

Date:03/12/99ISR Number: 3431285-6Report Type:Periodic Company Report #A0080806
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excitability	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	10 DAY

Date:03/12/99ISR Number: 3431290-XReport Type:Periodic Company Report #A0080807
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Rash Erythematous Rash Papular	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:03/12/99ISR Number: 3434609-9Report Type:Periodic Company Report #A0080692
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/TWICE PER DAY/ ORAL	

	Pruritus					

Date:03/12/99ISR Number: 3443038-3Report Type:Periodic Company Report #1998001360-1
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Nicorette Otc 2 Mg Smithkline Beecham Consumer Healthcare	PS	Smithkline Beecham Consumer Healthcare	BUCCAL	BUCCAL	
			Nicorette Otc 4 Mg Smithkline Beecham Consumer Healthcare	SS	Smithkline Beecham Consumer Healthcare	BUCCAL	BUCCAL	44 DAY
			Wellbutrin (Bupropion) Glaxo Wellcome	SS		ORAL	ORAL	

Date:03/15/99ISR Number: 3220366-8Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal	Health	Zyban	PS	Glaxo/Wellcome	ORAL	150 MG QD X	
	Nervous System Disorder	Professional					3D PO 150 MG	
	Nightmare						BID PO	11 DAY
	Panic Attack		Effexor Xr	C				
	Thinking Abnormal		Haloperidol	C				
	Vomiting		Clonazepam	C				

				Estradiol	C		
				Tums/Rolaids	C		

Date:03/17/99ISR Number: 3222051-5Report Type:Expedited (15-DaCompany Report #A0085087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Injury	Health	Wellbutrin Tablet	PS		ORAL	UNK/ UNK/
	Overdose	Professional					ORAL

Date:03/17/99ISR Number: 3222058-8Report Type:Expedited (15-DaCompany Report #A0080126
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Diabetes Mellitus	Health	Wellbutrin				
Hospitalization -	Inadequate Control	Professional	Tablet-Controlled				
Initial or Prolonged	Grand Mal Convulsion	Company	Release	PS		ORAL	150 MG / SEE
Other	Insomnia	Representative					TEXT/ ORAL
			Insulin	C			

Date:03/17/99ISR Number: 3222323-4Report Type:Expedited (15-DaCompany Report #A0085804
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Myocardial Infarction	Health	Wellbutrin				
		Professional	Tablet-Controlled				
		Company	Release	PS		ORAL	150 MG/TWICE
		Representative					PER DAY/ORAL
			Sildenafil Citrate	C			

Date:03/17/99ISR Number: 3222325-8Report Type:Expedited (15-DaCompany Report #A0085805
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/ORAL	1 MON
			Tamoxifen	C				

Date:03/19/99ISR Number: 3225172-6Report Type:Periodic Company Report #8-97286-019L
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder	Consumer	Redux	PS		ORAL	15 MG TWICE DAILY ORAL	
	Palpitations							
	Pulmonary Hypertension		Fastin (Phentermine)	SS		ORAL	30 MG ONCE DAILY ORAL	
			Ionamin (Phentermine)	SS		ORAL	15-30 MG DAILY ORAL	18 WK
			Pondimin (Fenfluramine) Tablet	SS		ORAL	20 MG THREE TIMES DAILY ORAL	

			Wellbutrin (Buproprion)	SS		ORAL	100-150 MG TWICE DAILY ORAL

Date:03/22/99ISR Number: 3224264-5Report Type:Expedited (15-DaCompany Report #A0086553
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angina Pectoris	Foreign	Zyban Tablet	PS		ORAL	150 MG/TWICE
	Myocardial Infarction	Health					PER DAY/ORAL
		Professional					

Date:03/22/99ISR Number: 3224298-0Report Type:Expedited (15-DaCompany Report #A0086052
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Diabetes Mellitus	Foreign	Zyban Tablet (Zyban)	PS		ORAL	150 MG TWICE
Initial or Prolonged	Polyuria	Health					DAILY ORAL
Other	Vision Blurred	Professional					

Date:03/22/99ISR Number: 3224381-XReport Type:Expedited (15-DaCompany Report #A0077049
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Bronchiolitis	Foreign	Wellbutrin	PS		ORAL	250 MG/ORAL
Hospitalization -	Dyspnoea Exacerbated	Health	Lithium Salt	C			
Initial or Prolonged	Hypoxia	Professional	Clomipramine Hc1	C			
Other	Lung Infiltration		Clonazepam	C			
	Pyrexia		Lithium Carbonate	C			

			Clonazepam	C		

Date:03/22/99ISR Number: 3224382-1Report Type:Expedited (15-DaCompany Report #A0086318
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Zyban	PS		ORAL	150 MG/TWICE	
	Dysphagia						PER DAY/ORAL	
	Eyelid Oedema		Zyban	SS		ORAL	150 MG/SINGLE	
	Face Oedema						DOSE/ORAL	
	Pharyngeal Oedema		Lansoprazole	C				
			Lorcet	C				

Date:03/22/99ISR Number: 3224414-0Report Type:Expedited (15-DaCompany Report #A0086224
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Medication Error	Foreign	Zyban	PS		ORAL	150 MG/TWICE	
	Myocardial Infarction	Literature					PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/99ISR Number: 3224451-6Report Type:Expedited (15-DaCompany Report #A0081012
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complex Partial Seizures Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	2 WK

Date:03/22/99ISR Number: 3225548-7Report Type:Direct Company Report #
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Malaise Pyrexia Serum Sickness Urticaria White Blood Cell Count Increased		Zyban	PS		ORAL	ORAL DAILY	

Date:03/23/99ISR Number: 3225607-9Report Type:Direct Company Report #
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angioneurotic Oedema Arthralgia Dyspnoea Eyelid Oedema Hypoaesthesia Insomnia Joint Swelling Pain Pharyngolaryngeal Pain Swelling		Wellbutrin 150 Sr	PS		ORAL	ONE TAB AT 8:30 AM AND 12:00 PM	

Date:03/23/99ISR Number: 3420370-0Report Type:Periodic Company Report #5686/20536
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery Paranoia	Consumer Company	Nicotrol	PS	Pharmacia And Upjohn Co	TRANSDERMAL	15 MG - 1Q1DY; T.DERM	
		Representative	Wellbutrin	SS				
			Lithium	C				

Date:03/24/99ISR Number: 3226001-7Report Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tremor		Bupropion 100mg Sr Tab	PS		ORAL	100MG SR BID PO	
			Aspirin	C				
			Temazepam	C				
			Buspar	C				
			Ranitidine	C				
			Tamslosin	C				

Multivitamin.Mineral C

Date:03/25/99ISR Number: 3226398-8Report Type:Expedited (15-DaCompany Report #A0085728
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema Arthralgia Dyspnoea Insomnia Joint Swelling Pain	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	TWICE PER DAY/ ORAL	

Date:03/25/99ISR Number: 3226401-5Report Type:Expedited (15-DaCompany Report #A0086604
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release Aspartame (Formulation Unknown)	PS SS		ORAL ORAL		

Date:03/25/99ISR Number: 3226406-4Report Type:Expedited (15-DaCompany Report #A0086619
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release Aspartame (Formulation Unknown)	PS SS		ORAL ORAL		

Date:03/26/99ISR Number: 3227632-0Report Type:Expedited (15-DaCompany Report #A0085426
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aspiration Convulsion Intentional Misuse Vomiting	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	3 G / DOSE/	SINGLE ORAL

Date:03/26/99ISR Number: 3227814-8Report Type:Expedited (15-DaCompany Report #A0085560
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Intentional Misuse Medication Error Nausea Vomiting	Consumer	Wellbutrin Tablet -Controlled Release	PS		ORAL	3 G/SINGLE DOSE/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/99ISR Number: 3227845-8Report Type:Expedited (15-DaCompany Report #A0086438
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Bipolar I Disorder Glaucoma Intraocular Pressure Increased Visual Acuity Reduced	Consumer	Wellbutrin Venlafaxine Hydrochloride Lithium Salt	PS C C		ORAL	150 MG	ORAL

Date:03/28/99ISR Number: 3332514-XReport Type:Periodic Company Report #A0087342
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Balance Disorder Burning Sensation Dermatitis Hypersensitivity Pain In Extremity Pruritus Swelling	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL

Date:03/29/99ISR Number: 3229434-8Report Type:Expedited (15-DaCompany Report #A0086620
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Interaction Completed Suicide Drug Toxicity Head Injury	Health Professional	Wellbutrin Tablet - Controlled Release Ethanol (Formulation Unknown)	PS SS		ORAL ORAL	150 MG TWICE PER DAY	ORAL

			Dextropropoxyphene Hcl Tablet	SS		ORAL
			Buspirone Hydrochloride	C		

Date:03/29/99ISR Number: 3229438-5Report Type:Expedited (15-DaCompany Report #A0077426
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	100 MG TWICE PER DAY	
			Fluoxetine Hydrochloride (Formulation Unknown)	SS		ORAL	20 MG PER DAY	
			Metoprolol Tartrate	SS		ORAL		
			Paracetamol	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/99ISR Number: 3229443-9Report Type:Expedited (15-DaCompany Report #A0086553
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Angina Pectoris	Foreign	Zyban Tablet	PS		ORAL	150 MG TWICE
Other	Myocardial Infarction	Health					PER DAY ORAL
		Professional	Glucophage	C			
			Conjugated Estrogens	C			
			Atorvastatin Calcium	C			
			Glibenclamide	C			

Date:03/30/99ISR Number: 3230085-XReport Type:Expedited (15-DaCompany Report #9911866
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Abdominal Pain Upper	Consumer	Zoloft Tablets	PS		ORAL	ORAL
Intervention to	Drug Interaction		Wellbutrin	SS			
Prevent Permanent	Flatulence		Marijuana	SS			
Impairment/Damage			Beer	SS			

Date:03/31/99ISR Number: 3230925-4Report Type:Expedited (15-DaCompany Report #A0065816
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Aggression	Health	Zyban Tablet- Zyban	PS		ORAL	150 MG ORAL
	Agitation	Professional	Medroxyprogesterone				
	Amnesia		Ace	C			
	Anger						
	Anxiety						
	Breast Pain						
	Condition Aggravated						
	Disorientation						
	Disturbance In Attention						
	Dizziness						
	Feeling Abnormal						
	Feeling Jittery						

	Fluid Retention					
	Galactorrhoea					
	Insomnia					
	Migraine					
	Paranoia					
	Serotonin Syndrome					
	Suicidal Ideation					
	Tinnitus					

Date:03/31/99ISR Number: 3230927-8Report Type:Expedited (15-DaCompany Report #A0082610
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactoid Reaction	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG PER	
Initial or Prolonged	Angioneurotic Oedema	Health					DAY ORAL	
	Pruritus	Professional	Thyroxine Sodium	C				
	Rash Erythematous		Hrt	C				
	Rash Morbilliform							
	Tongue Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/99ISR Number: 3230929-1Report Type:Expedited (15-DaCompany Report #A0086505
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Grand Mal Convulsion Hallucination Illusion Memory Impairment Sedation	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release Olanzapine (Formulation Unknown) Fluvoxamine Maleate Lithium Salt Propranolol Hydrochloride Lorazepam Thyroxine Sodium	PS SS C C C C C		ORAL	150 MG THREE TIMES PER DAY ORAL 10 MG PER DAY	

Date:04/01/99ISR Number: 3231319-8Report Type:Expedited (15-DaCompany Report #A0087673
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Zyban	PS			150 MG/SINGLE DOSE	

Date:04/01/99ISR Number: 3231322-8Report Type:Expedited (15-DaCompany Report #A0087656
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock	Study	Zyban	PS		ORAL	1	

Dizziness Consumer
TABLET/TWICE
Dysphagia
PER DAY/ORAL
Dyspnoea Pseudoephedrine Hcl C
Fall
Gingival Hypertrophy
Hypersensitivity
Hypoventilation
Influenza
Insomnia
Joint Swelling
Myalgia
Nasal Oedema
Oedema Peripheral
Pain In Extremity
Swelling
Tongue Oedema
Urticaria
Weight Decreased

Date:04/01/99ISR Number: 3231458-1Report Type:Expedited (15-DaCompany Report #9911957
Age: Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia	Health	Zoloft Tablets	PS		ORAL		
	Drug Interaction	Professional	Zyban	SS		ORAL		
	Lethargy							
	Syncope							

Date:04/02/99ISR Number: 3235621-5Report Type:Periodic Company Report #9809438
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Disturbance	Health	Cardura	PS		ORAL		
		Professional	Wellbutrin	SS		ORAL		
			Cyclosporine	C				
			Zestril	C				

Date:04/05/99ISR Number: 3233013-6Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Wellbutrin Sr	PS		ORAL	300 MG PO QD	
Initial or Prolonged	Convulsion							
	Psychotic Disorder							

Date:04/05/99ISR Number: 3233084-7Report Type:Expedited (15-DaCompany Report #A0087951
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Decreased	Foreign	Zyban	PS		ORAL	150 MG/TWICE	

	Condition Aggravated	Consumer				
PER DAY/ORAL						
	Convulsion					
	Fall					

Date:04/06/99ISR Number: 3234412-9Report Type:Direct Company Report #
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS		ORAL	100 MG PO	
Initial or Prolonged	Vomiting						TID	
			Allegra	C				
			Azithromycin	C				
			Proventil Inhaler	C				
			Azmacort Inhaler	C				
			Prednix	C				

Date:04/07/99ISR Number: 3234550-0Report Type:Expedited (15-DaCompany Report #A0087443
Age: Gender:Male I/FU:I

Outcome	PT
Congenital Anomaly	Atrial Septal Defect
	Cardiac Malposition
	Complications Of Maternal
	Exposure To Therapeutic
	Drugs
	Hypoplastic Left Heart

	Syndrome Multiple Congenital Abnormalities Pulmonary Artery Atresia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Transposition Of The Great Vessels	Study Health	Wellbutrin	PS			100MG /PER DAY/
	Ventricular Septal Defect Acquired	Professional					

Date:04/07/99ISR Number: 3234562-7Report Type:Expedited (15-DaCompany Report #A0087794
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Epistaxis	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE
	Haematochezia	Health					PER DAY/ORAL
	Lacrimation Increased Reading Disorder Vaginal Haemorrhage	Professional					

Date:04/09/99ISR Number: 3237680-2Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dermatitis	Health	Zyban 150 Mg	PS	Glaxo Welcome	ORAL	150 MG BID
	Periorbital Oedema	Professional					ORALLY 19 DAY
	Pruritus		Alesse Mvi	C C			

Date:04/12/99ISR Number: 3237586-9Report Type:Direct Company Report #
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Required	Metrorrhagia		Zyban	PS	Glaxowellcome	ORAL
300MG BID						
Intervention to						
ORAL						
Prevent Permanent			Depo Provera	SS	Upjohn	
Impairment/Damage						

Date:04/12/99ISR Number: 3237985-5Report Type:Expedited (15-DaCompany Report #A0088107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Foreign	Wellbutrin			
	Fall	Health	Tablet-Controlled			
	Upper Limb Fracture	Professional	Release	PS		ORAL
ORAL WEEKS						
			Carbamazepine	C		

Date:04/12/99ISR Number: 3237987-9Report Type:Expedited (15-DaCompany Report #A0088588
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris	Foreign	Zyban Tablet-Zyban	PS		ORAL
150 MG/TWICE						
Initial or Prolonged	Cardiac Disorder	Consumer				
PER DAY/ORAL						
	Dyspnoea		Nicotine	C		
	Hypertension					
	Swelling					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/99ISR Number: 3238231-9Report Type:Expedited (15-DaCompany Report #A0081071
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Respiratory Distress	Health	Wellbutrin				
Hospitalization - Initial or Prolonged	Urticaria	Professional	Tablet-Controlled Release	PS		ORAL	150 MG/PER Other DAY/ORAL
			Aspirin	C			

Date:04/12/99ISR Number: 3238232-0Report Type:Expedited (15-DaCompany Report #A0088466
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dysphonia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY ORAL
	Feeling Jittery						
	Tremor		Ranitidine Hydrochloride	C			
			Thyroxine Sodium	C			
			Hydrochlorothiazide	C			
			Digoxin	C			
			Paracetamol	C			
			Potassium Salt	C			

Date:04/13/99ISR Number: 3239039-0Report Type:Expedited (15-DaCompany Report #A0079587
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Burning Sensation	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY
	Dermatitis	Professional					
	Dry Skin						
	Eczema						
	Pruritus						
	Rash Erythematous						

	Rash Macular					
	Rash Vesicular					
	Skin Ulcer					
	Urticaria					

Date:04/13/99ISR Number: 3239041-9Report Type:Expedited (15-DaCompany Report #A0080356
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Consumer	Zyban Tablets -				
	Blood Pressure Increased		Zyban	PS		ORAL	150 MG /
	Cardiac Disorder						TWICE PER DAY
	Cardiac Murmur		Dyazide	C			
	Coronary Artery Occlusion						
	Dermatitis						
	Oedema Peripheral						
	Urticaria						

Date:04/13/99ISR Number: 3239043-2Report Type:Expedited (15-DaCompany Report #A0084557
Age:49 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Disorder
	Disorientation

Psychotic Disorder
Tremor

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	

Date:04/14/99ISR Number: 3239702-1Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Zyban	PS				
	Hypoaesthesia							
	Joint Stiffness							
	Lacrimation Increased							

Date:04/14/99ISR Number: 3239860-9Report Type:Expedited (15-DaCompany Report #A0086275
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hemiparesis	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Hypoaesthesia	Health Professional					/ ORAL	

Date:04/14/99ISR Number: 3239896-8Report Type:Direct Company Report #
Age:6 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS		ORAL	50MG PO TID	6 WK
	Depressed Level Of							

	Consciousness					
	Gaze Palsy					
	Movement Disorder					
	Pharyngitis					
	Pyrexia					
	Speech Disorder					
	Urinary Incontinence					

Date:04/14/99ISR Number: 3239910-XReport Type:Direct Company Report #
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Zyban	PS				
SMOKING								
	Dyspnoea							
CESSATION								
	Eyelid Oedema		Xanax	C				
	Face Oedema		Indenal	C				
	Pruritus							
	Urticaria							

Date:04/14/99ISR Number: 3239943-3Report Type:Direct Company Report #
Age:63 YR Gender:Female I/FU:I

Outcome
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health	Wellbutrin	PS			1 BID	15 DAY
		Professional	Wellbutrin Sr 100mg	SS			1 QD	3 WK
			Atenolol	C				
			Medroxyprogesterone	C				
			Hctz	C				
			Lisinopril	C				
			Cometidine	C				
			Zoloft	C				
			Premarin	C				

Date:04/15/99ISR Number: 3239857-9Report Type:Expedited (15-DaCompany Report #A0081012
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breath Odour	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Complex Partial Seizures	Professional					PER DAY /	
	Convulsion	Company					ORAL	
	Drug Eruption	Representative	Allopurinol	C				
	Grand Mal Convulsion		Simvastatin	C				
	Lower Respiratory Tract		Aspirin	C				
	Infection		Frusemide	C				
	Rash Pruritic		Atenolol	C				
	Rhinitis		Omeprazole	C				
	Sinusitis		Nitroglycerin	C				
	Skin Exfoliation		Glucophage	C				
	Staphylococcal Infection		Isosorbide					
	Streptococcal Infection		Mononitrate	C				
	Urticaria		Potassium Chloride	C				
			Nsaid	C				

Date:04/16/99ISR Number: 3241403-0Report Type:Expedited (15-DaCompany Report #WAES 99040593
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain Grand Mal Convulsion Intentional Misuse Medication Error	Literature Other	Tab Mevacor Unk Wellbutrin Unk	PS SS				

Date:04/16/99ISR Number: 3241604-1Report Type:Expedited (15-DaCompany Report #A0087945
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Convulsion	Consumer	Zyban Tablet - Zyban 150 MG / PER DAY / ORAL	PS		ORAL		
Disability	Epistaxis Haematemesis Loss Of Consciousness Nasal Congestion		Claritin-D Nicotine	C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/99ISR Number: 3242407-4Report Type:Expedited (15-DaCompany Report #A0080313
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Zyban	PS		ORAL	150 MG TWICE	
	Anxiety	Professional					PER DAY ORAL	
	Convulsion		Percocet	C				
	Dry Mouth		Diazepam	C				
	Haematemesis		Quinalbarbitone					
	Head Injury		Sodium	C				
	Insomnia							
	Photopsia							
	Pneumonia							
	Tremor							
	Vision Blurred							

Date:04/19/99ISR Number: 3242408-6Report Type:Expedited (15-DaCompany Report #A0086318
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG TWICE	
	Dysphagia						PER DAY; 150	
	Eyelid Oedema						MG SINGLE	
	Face Oedema						DOSE ORAL	
	Hypersensitivity		Lansoprazole	C				
	Pharyngeal Oedema		Lorcet	C				

Date:04/19/99ISR Number: 3242447-5Report Type:Expedited (15-DaCompany Report #A0087807
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking	Health	Wellbutrin					
Other	Diplopia	Professional	Tablet-Controlled					

	Dyspnoea		Release	PS		ORAL
150 MG /						
	Myasthenia Gravis					
TWICE PER DAY						
	Sensation Of Heaviness					
/ ORAL						
			Pyridostigmine Bromide	C		
			Prostigmine	C		
			Beclomethasone Dipropion	C		
			Bromfed-Pd	C		
			Sumatriptan Succinate	C		
			Tylenol No. 3	C		

Date:04/19/99ISR Number: 3242554-7Report Type:Expedited (15-DaCompany Report #A0082447
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Wellbutrin	PS		ORAL	150 MG /	
	Dermatitis	Professional					TWICE PER DAY	
	Dry Throat						/ ORAL	
	Oedema		Amoxycillin	C				
	Petechiae							
	Pharyngolaryngeal Pain							
	Pruritus							
	Throat Tightness							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/99ISR Number: 3242555-9Report Type:Expedited (15-DaCompany Report #A0085728
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health	Wellbutrin	PS		ORAL	TWICE PER DAY	
	Arthralgia	Professional					/ ORAL	
	Depression							
	Dermographism							
	Dyspnoea							
	Emotional Distress							
	Insomnia							
	Joint Swelling							
	Myalgia							
	Pain							
	Pharyngeal Oedema							
	Pruritus							
	Serum Sickness							
	Urticaria							

Date:04/19/99ISR Number: 3242557-2Report Type:Expedited (15-DaCompany Report #A0086620
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	
	Head Injury	Professional					/ ORAL	
			Ethanol (Formulation Unknown)	SS		ORAL	ORAL	
			Dextropropoxyphene Hcl Tablet	SS		ORAL	ORAL	
			Buspirone Hydrochloride	C				

Date:04/19/99ISR Number: 3242666-8Report Type:Expedited (15-DaCompany Report #1154856A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Unk Acetaminophen					
	Intentional Misuse	Professional	Product	PS				
			Wellbutrin Tablet-Controlled Release	SS		ORAL	100 MG, BID, PO	
			Fluoxetine Hydrochloride (Formulation Unknown)	SS		ORAL	20 MG/DAY PO	
			Metoprolol Tartrate	SS				

Date:04/20/99ISR Number: 3320135-4Report Type:Periodic Company Report #1999SUS0049
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health	Sustiva	PS				
	Drug Interaction	Professional	Wellbutrin	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/99ISR Number: 3322188-6Report Type:Periodic Company Report #99USA10029
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional	Diovan Capsule 80 Mg (Valsartan)	PS		ORAL	80 MG QD	ORAL
	Dizziness							
	Erectile Dysfunction		Wellbutrin Tablets (Amfebutamone Hydrochloride)	SS		ORAL	ORAL	

Date:04/22/99ISR Number: 3244821-XReport Type:Expedited (15-DaCompany Report #A0089661
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Olanzapine	C				
			Quetiapine Fumarate	C				
			Temazepam	C				
			Prempro	C				
			Dyazide	C				
			Ibuprofen	C				

Date:04/22/99ISR Number: 3244824-5Report Type:Expedited (15-DaCompany Report #A0083661
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Interaction	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER	
	Blood Glucose Decreased	Health						

	Convulsion	Professional				
DAY/ ORAL						
	Eye Rolling		Human Short-Act,			
	Hypoglycaemia		Insulin	C		
	Medication Error		Human Int/Long			
			Insulin	C		

Date:04/22/99ISR Number: 3244835-XReport Type:Expedited (15-DaCompany Report #A0089381
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Foreign	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/PER	
		Consumer					ORAL/ORAL	

Date:04/26/99ISR Number: 3246876-5Report Type:Expedited (15-DaCompany Report #A0089898
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Communication Disorder	Foreign	Zyban Tablet - Zyban	PS		ORAL	150MG/PER	
	Disturbance In Attention	Consumer					DAY/ORAL	
	Feeling Abnormal							
	Feeling Drunk							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/99ISR Number: 3246877-7Report Type:Expedited (15-DaCompany Report #A0089735
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Zyban Tablet - Zyban	PS				
	Drug Interaction		Alprazolam (Formulation Unknown)	SS				

Date:04/26/99ISR Number: 3246879-0Report Type:Expedited (15-DaCompany Report #A0089717
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Angiopathy	Consumer					PER DAY/ORAL	

Date:04/26/99ISR Number: 3246898-4Report Type:Expedited (15-DaCompany Report #A0088445
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Foreign	Zyban Tablets	PS		ORAL	150 MG TWICE	
	Constipation	Health Professional					PER DAY ORAL	2 WK
	Fluid Retention		Oral Contraceptive	C				
	Irritability							
	Oliguria							

Date:04/26/99ISR Number: 3246900-XReport Type:Expedited (15-DaCompany Report #A0089140
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG ORAL	
	Intentional Misuse							

Other (SEE TEXT)	Suicide Attempt					

Date:04/26/99ISR Number: 3246901-1Report Type:Expedited (15-DaCompany Report #B0065751
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue	Health	Wellbutrin	PS		ORAL		
	Liver Function Test	Professional	Troglitazone Tablet	SS		ORAL	300 MG TWICE	
	Abnormal						PER DAY ORAL	
	Weight Increased		Atorvastatin	C				
			Estrogen	C				
			Metformin	C				
			Lansoprazole	C				
			Clonazepam	C				
			Insulin	C				
			Thioridazine	C				
			Pyridoxine	C				

Date:04/26/99ISR Number: 3247143-6Report Type:Expedited (15-DaCompany Report #A0089368
Age:42 YR Gender:Male I/FU:I

Outcome
Death
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcohol Poisoning	Health	Wellbutrin					
	Cardiac Arrest	Professional	Tablet-Controlled					
	Convulsion		Release	PS		ORAL	150 MG	
	Loss Of Consciousness		Ethanol	SS				
	Overdose							

Date:04/26/99ISR Number: 3250090-7Report Type:Periodic Company Report #A0088435
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Health	Wellbutrin					
Initial or Prolonged	Convulsion	Professional	Tablet-Controlled					
Other	Psychotic Disorder		Release	PS		ORAL	TWICE PER DAY	
						ORAL		

Date:04/26/99ISR Number: 3250091-9Report Type:Periodic Company Report #A0088100
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion	Health	Wellbutrin					
Initial or Prolonged	Loss Of Consciousness	Professional	Tablet-Controlled					
			Release	PS		ORAL	150 MG TWICE	
						PER DAY ORAL	11	DAY

Date:04/26/99ISR Number: 3250092-0Report Type:Periodic Company Report #A0087970
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin					

		Professional	Tablet-Controlled			
		Company	Release	PS		ORAL
150 MG ORAL						
		Representative				

Date:04/26/99ISR Number: 3250093-2Report Type:Periodic Company Report #A0087647
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Wellbutrin			
		Professional	Tablet-Controlled			
		Company	Release	PS		
		Representative				

Date:04/26/99ISR Number: 3250094-4Report Type:Periodic Company Report #A0087481
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Wellbutrin			
		Professional	Tablet-Controlled			
		Company	Release	PS		ORAL
150 MG TWICE						
		Representative				
PER DAY ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/99ISR Number: 3250095-6Report Type:Periodic Company Report #A0087281
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:04/26/99ISR Number: 3250096-8Report Type:Periodic Company Report #A0086240
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG ORAL	
			Tricyclin Antidepresant	C				

Date:04/26/99ISR Number: 3250097-XReport Type:Periodic Company Report #A0085964
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash Generalised	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY ORAL	
			Alprazolam	C				

Date:04/26/99ISR Number: 3250098-1Report Type:Periodic Company Report #A0084704
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Dyspnoea Headache	Consumer	Wellbutrin Tablet-Controlled Release	PS			ORAL 150 MG TWICE PER DAY ORAL

Date:04/26/99ISR Number: 3250099-3Report Type:Periodic Company Report #A0084373
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Dysgeusia	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL ORAL
			Thyroxine Sodium	C		

Date:04/26/99ISR Number: 3250100-7Report Type:Periodic Company Report #A0084031
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL 150 MG TWICE PER DAY ORAL
			Fluoxetine	C		
			Clonazepam	C		

				Quetiapine Fumarate	C		

Date:04/26/99ISR Number: 3250101-9Report Type:Periodic Company Report #A0083747
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	3 WK
			Olanzapine (Formulation Unknown)	SS				

Date:04/26/99ISR Number: 3250102-0Report Type:Periodic Company Report #A0082995
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Overdose	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	

Date:04/26/99ISR Number: 3250103-2Report Type:Periodic Company Report #A0082989
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Mastication Disorder Tooth Injury	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY	ORAL
			Paroxetine Hydrochloride	C				

Date:04/26/99ISR Number: 3250104-4Report Type:Periodic Company Report #A0082594
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY	ORAL

Date:04/26/99ISR Number: 3250105-6Report Type:Periodic Company Report #A0082573
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Hypersensitivity Pruritus Rash Generalised	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/99ISR Number: 3250106-8Report Type:Periodic Company Report #A0080712
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health	Wellbutrin					
	Hypoaesthesia	Professional	Tablet-Controlled					
		Company	Release	PS		ORAL	150 MG PER	
		Representative					DAY	ORAL
			Atorvastatin Calcium	C				
			Conjugated Estrogens	C				
			Amitriptyline	C				

Date:04/26/99ISR Number: 3250107-XReport Type:Periodic Company Report #A0080556
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Health	Wellbutrin					
		Professional	Tablet-Controlled					
			Release	PS		ORAL	ORAL	

Date:04/26/99ISR Number: 3250108-1Report Type:Periodic Company Report #A0080551
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin					
		Professional	Tablet-Controlled					
			Release	PS		ORAL	150 MG PER	
							DAY	ORAL
			Methylphenidate Hcl	C				
			Diphenhydramine Hcl	C				

Date:04/26/99ISR Number: 3250109-3Report Type:Periodic Company Report #A0080543
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electroencephalogram Abnormal Grand Mal Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY	ORAL
			Risperidone	C				
			Lithium Carbonate	C				
			Thyroxine Sodium	C				

Date:04/26/99ISR Number: 3250110-XReport Type:Periodic Company Report #A0080518
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY	ORAL
			Antihistamine Cetirizine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/99ISR Number: 3250111-1Report Type:Periodic Company Report #A0080224
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin					
	Overdose	Professional	Tablet-Controlled					
		Company	Release	PS		ORAL	150 MG THREE	
		Representative					TIMES PER DAY	
						ORAL		
			Amitriptyline Hcl	C				

Date:04/26/99ISR Number: 3250112-3Report Type:Periodic Company Report #A0080213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paranoia	Health	Wellbutrin					
		Professional	Tablet-Controlled					
			Release	PS		ORAL	150 MG TWICE	
							PER DAY	ORAL
			Nefazodne Hcl	C				
			Olanzapine	C				
			Pyridostigimine Bromide	C				

Date:04/26/99ISR Number: 3250113-5Report Type:Periodic Company Report #A0080125
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Wellbutrin					
		Professional	Tablet-Controlled					
		Company	Release	PS		ORAL	150 MG TWICE	
		Representative					PER DAY	ORAL
			Methytlphenidate Hcl	C				

Date:04/26/99ISR Number: 3250114-7Report Type:Periodic Company Report #A0079398
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health	Wellbutrin					
	Drug Toxicity	Professional	Tablet-Controlled					
	Eyelid Oedema	Company	Release	PS		ORAL	ORAL	
	Face Oedema	Representative						
	Oedema Peripheral							
	Pruritus							
	Rash Erythematous							
	Rash Generalised							
	Urticaria							

Date:04/29/99ISR Number: 3250150-0Report Type:Expedited (15-DaCompany Report #A0090004
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Zyban Tablet- Zyban	PS		ORAL	150 MG ORAL	
	Chest Discomfort		Lorazepam	C				
	Dyspnoea		Cefurozime Axetil	C				
	Pulmonary Embolism		Combivent	C				
			Budesonide	C				
			Tetracycline	C				

			Theophylline	C			

Date:04/29/99ISR Number: 3250159-7Report Type:Expedited (15-DaCompany Report #A0081071
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Dermatitis	Health	Wellbutrin Tablets-				
Hospitalization -	Oedema Mouth	Professional	Controlled Release	PS		ORAL	150 MG PER
Initial or Prolonged	Pharyngeal Oedema						DAY ORAL
Other	Pruritus		Aspirin	C			
	Respiratory Distress						
	Tongue Oedema						
	Urticaria						

Date:04/29/99ISR Number: 3250162-7Report Type:Expedited (15-DaCompany Report #A0088100
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cyanosis	Health	Wellbutrin Tablet-				
Other	Fatigue	Professional	Controlled Release	PS		ORAL	150 MG TWICE
	Grand Mal Convulsion						PER DAY ORAL
	Loss Of Consciousness		Pethidine				
	Muscle Contractions		Hydrochloride	C			
	Involuntary		Ibuprofen	C			
	Myalgia		Darvocet-N	C			

Date:04/29/99ISR Number: 3251132-5Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Arterial Occlusive		Zyban	PS	Glaxo Wellcome	ORAL	150MG PO
Hospitalization -	Disease						QD/BID

Initial or Prolonged	Finger Amputation		Prednisone	C	
Other	Gangrene				
	Necrosis Ischaemic				
	Pain				
	Pain In Extremity				
	Petechiae				
	Pyrexia				
	Skin Discolouration				

Date:04/30/99ISR Number: 3251007-1Report Type:Expedited (15-DaCompany Report #A0089788
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Headache	Consumer						
	Hypertension							
	Loss Of Consciousness							
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/99ISR Number: 3251348-8Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Bupropion Sr 100mg	PS		ORAL	100MG QD PO; 100MG BID PO	
	Rash Pruritic							
	Urticaria		Genkgo Biloba	C				
			Nizatidine	C				
			Estropippate	C				
			Vitamin E	C				
			Mult E	C				
			Multi=Vit	C				

Date:05/03/99ISR Number: 3252406-4Report Type:Expedited (15-DaCompany Report #A0090134
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Foreign	Zyban Tablet - Zban	PS		ORAL	150 MG/ TWICE PER DAY / ORAL	
	Dizziness	Consumer						
	Feeling Abnormal							
	Listless							
	Loss Of Consciousness							

Date:05/03/99ISR Number: 3252413-1Report Type:Expedited (15-DaCompany Report #A0089368
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Wellbutrin					
Hospitalization - Initial or Prolonged	Convulsion	Professional	Tablet-Controlled Release	PS		ORAL	200 TABLET / SINGLE DOSE/ ORAL	
	Drug Toxicity							
Other	Intentional Misuse							
	Loss Of Consciousness							

	Suicide Attempt		Ethanol (Formulation Unknown)	SS		

Date:05/03/99ISR Number: 3252782-2Report Type:Expedited (15-DaCompany Report #A0089575
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Medication Error	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	600 MG / UNK	/ ORAL
			Mirtazapine	C				
			Mytussin Ac	C				

Date:05/03/99ISR Number: 3252784-6Report Type:Expedited (15-DaCompany Report #A0089899
Age:69 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Coordination Abnormal Demyelinating Polyneuropathy Disturbance In Attention Dysarthria Educational Problem Headache Hypoaesthesia

	Memory Impairment Oedema Peripheral Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Paraesthesia	Foreign Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL

Date:05/03/99ISR Number: 3252785-8Report Type:Expedited (15-DaCompany Report #A0090630
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Coma Convulsion Overdose	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / UNK / ORAL
			Ethanol Liquid	SS		ORAL	UNK / UNK / ORAL

Date:05/03/99ISR Number: 3252786-XReport Type:Expedited (15-DaCompany Report #A0075655
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Status Epilepticus	Foreign Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:05/03/99ISR Number: 3253378-9Report Type:Expedited (15-DaCompany Report #A0090016
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hypertension	Consumer					TWICE PER DAY	
	Tremor		Acebutolol Hydrochloride	C				
			Thyroxine Sodium	C				
			Desipramine	C				
			Clonazepam	C				
			Clonazepam	C				
			Blood Pressure Medication	C				

Date:05/03/99ISR Number: 3253381-9Report Type:Expedited (15-DaCompany Report #A0090299
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG	
	Chest Pain							
	Pericarditis							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/99ISR Number: 3252788-3Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Bupropion 100 Mgm					
	Urticaria	Professional	Bid	PS			100MG BID	
			Clotriazole	C				
			Furosemide	C				
			Hemorroidal Rectal Supp	C				
			Lisinopril	C				
			Naproxen	C				
			Nifidepril	C				
			Nystaten	C				
			Kcl	C				
			Povodine - Iodine	C				
			Simvastatin	C				

Date:05/05/99ISR Number: 3254911-3Report Type:Direct Company Report #
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Zyban	PS		ORAL	150MG BID	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage			Lorazepam	C				
			Glipizide	C				
			Diltiazem (Tiazac)	C				
			Trazodone Hcl	C				
			Pentoxifylline	C				

Date:05/06/99ISR Number: 3255610-4Report Type:Expedited (15-DaCompany Report #A0075934
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis	Foreign	Zyban Tablet- Zyban	PS		ORAL	150 MG /	

Initial or Prolonged	Dizziness	Health					
TWICE PER							
	Lung Disorder	Professional					
DAY / ORAL							
	Pruritus						

Date:05/10/99ISR Number: 3257946-XReport Type:Expedited (15-DaCompany Report #A0090921
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Foreign	Zyban Tablet-Zyban	PS		ORAL		
150 MG/ PER								
Initial or Prolonged	Chest Pain	Consumer						
DAY/ ORAL								
	Dyspnoea		Multiple Medication	C				
	Hypotension							
	Pneumonia							

Date:05/10/99ISR Number: 3257966-5Report Type:Expedited (15-DaCompany Report #A0090688
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia	Consumer	Wellbutrin Tablet -					
	Cerebrovascular Accident		Controlled Release	PS		ORAL		
150 MG								
	Choking							
TWICE PER DAY								
	Hemiplegia							
ORAL								
	Hypoaesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/99ISR Number: 3259696-2Report Type:Direct Company Report #
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyskinesia		Wellbutrin 100mg					
	Dystonia		Glaxo Wellcome	PS	Glaxo Wellcome		100MG 2X 1ST DAY THEN 100MG 3X PER DAY	
			Zyban 150mg Glaxo Wellcome	SS	Glaxo Wellcome			

Date:05/12/99ISR Number: 3260096-XReport Type:Expedited (15-DaCompany Report #A0080356
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
Other	Angiopathy							
	Blood Pressure Increased		Dyazide	C				
	Cardiac Disorder							
	Cardiac Murmur							
	Dermatitis							
	Oedema Peripheral							
	Urticaria							

Date:05/13/99ISR Number: 3261006-1Report Type:Direct Company Report #
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS		ORAL	200MG BID ORAL	

Date:05/13/99ISR Number: 3261242-4Report Type:Expedited (15-DaCompany Report #A0075934
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
Hospitalization -	Dizziness	Health					TWICE PER DAY	
Initial or Prolonged	Pruritus	Professional					/ ORAL	
	Respiratory Disorder							
	Urticaria							

Date:05/13/99ISR Number: 3261243-6Report Type:Expedited (15-DaCompany Report #A0087951
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Decreased	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Convulsion	Health					PER DAY/ ORAL	
	Fall	Professional	Humalog	C				
			Human Int/Long Insulin	C				
			Short-Acting Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/99ISR Number: 3261245-XReport Type:Expedited (15-DaCompany Report #A0090953
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Overdose	Health Professional	Wellbutrin Tablet - Controlled Release	PS		ORAL	15 GRAMS/ SINGLE DOSE/ ORAL

Date:05/13/99ISR Number: 3261328-4Report Type:Expedited (15-DaCompany Report #A0090907
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis Dyspnoea Eating Disorder Face Oedema Tongue Oedema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ ORAL

Date:05/13/99ISR Number: 3261329-6Report Type:Expedited (15-DaCompany Report #A0091460
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dyspnoea Oedema	Foreign Health Professional	Zyban Tablet- Zyban Amitriptyline Hcl	PS C		ORAL	150 MG/ TWICE PER DAY/ ORAL

Date:05/13/99ISR Number: 3262492-3Report Type:Direct Company Report #
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Chest Pain Pruritus Rash Generalised Urticaria		Zyban	PS		ORAL	150 MG PO BID	

Date:05/14/99ISR Number: 3262528-XReport Type:Direct Company Report #
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Zyban 150mg	PS			ONE TABLET TWICE A DAY	

Date:05/14/99ISR Number: 3262553-9Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Crying Panic Disorder Tremor		Wellbutrin Sr 150mg	PS		ORAL	1 TAB PO BID	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/99ISR Number: 3262569-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS		ORAL	100MG BID PO	
	Ventricular Tachycardia						* STARTED BID	
							DOSING	
			Betapace	C				

Date:05/14/99ISR Number: 3262717-4Report Type:Expedited (15-DaCompany Report #A0089203
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Chest Discomfort	Professional					PER DAY/ ORAL	
	Disturbance In Attention							
	Memory Impairment							

Date:05/14/99ISR Number: 3262720-4Report Type:Expedited (15-DaCompany Report #A0091511
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Dizziness	Consumer					PER DAY/ ORAL	
	Mental Impairment							

Date:05/14/99ISR Number: 3262724-1Report Type:Expedited (15-DaCompany Report #A0087656
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Anaphylactic Shock	Study	Zyban Tablet - Zyban	PS	ORAL
1					
	Dizziness	Health			
TABLET/TWICE					
	Dysphagia	Professional			
PER DAY/ORAL					
	Dyspnoea		Pseudoephedrine Hcl	C	
	Face Oedema				
	Gingivitis				
	Hypersensitivity				
	Hypoventilation				
	Influenza				
	Insomnia				
	Joint Swelling				
	Myalgia				
	Oedema Peripheral				
	Oral Intake Reduced				
	Pain In Extremity				
	Swelling				
	Tongue Oedema				
	Urticaria				
	Weight Decreased				

Date:05/14/99ISR Number: 3262742-3Report Type:Expedited (15-DaCompany Report #A0055443
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization -	Hepatic Enzyme Increased	Literature
Initial or Prolonged	Muscle Injury	Health
Other	Nasopharyngitis	Professional
	Rhabdomyolysis	Company

Representative

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin Tablet-Controlled Release	PS		ORAL	150MG/TWICE PER DAY/ORAL	
			Glipizide	C				
			Metformin	C				
			Multivitamin	C				
			Insulin	C				
			Stool Softener	C				

Date:05/14/99ISR Number: 3262769-1Report Type:Expedited (15-DaCompany Report #A0086505
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Central Nervous System Stimulation Confusional State Grand Mal Convulsion Illusion Memory Impairment Sedation	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/THREE TIMES PER DA ORAL	
			Olanzapine (Formulation Unnown)	SS			10 MG/PER DAY	
			Fluvoxamine Maleate	C				
			Lithium Salt	C				
			Propranolol Hydrochloride	C				
			Lorazepam	C				
			Thyroxine Sodium	C				

Date:05/14/99ISR Number: 3262782-4Report Type:Expedited (15-DaCompany Report #A0092017
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Foreign	Zyban Tablet-Zyban	PS		ORAL	ORAL	
	Atrial Fibrillation	Health						
	Bronchospasm	Professional						
	Tachycardia							

Date:05/14/99ISR Number: 3262784-8Report Type:Expedited (15-DaCompany Report #A0092018
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Foreign	Zyban Tablet - Zyban	PS		ORAL	ORAL	
	Atrial Fibrillation	Health						
	Bronchospasm	Professional						
	Tachycardia							

Date:05/14/99ISR Number: 3262785-XReport Type:Expedited (15-DaCompany Report #A0091961
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/PER	
	Pruritus						DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/99ISR Number: 3262787-3Report Type:Expedited (15-DaCompany Report #A0091658
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL
	Atrial Fibrillation	Health					
	Bronchospasm	Professional					
	Tachycardia						

Date:05/14/99ISR Number: 3262789-7Report Type:Expedited (15-DaCompany Report #A0089238
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Arthralgia	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
	Bronchospasm	Health					
	Conjunctival Disorder	Professional					
	Conjunctivitis						
	Eyelid Oedema						
	Face Oedema						
	Myalgia						
	Oedema Peripheral						
	Serum Sickness						
	Throat Tightness						
	Urticaria						

Date:05/14/99ISR Number: 3264632-9Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoaesthesia		Bupropion	PS			150MG BID
			Warfarin	C			
			Fosinopril	C			
			Simvoslatin	C			
			Caco3	C			

Date:05/17/99ISR Number: 3263494-3Report Type:Expedited (15-DaCompany Report #A0091793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Foreign	Wellbutrin					
	Physical Assault	Health	Tablet-Controlled					
	Psychotic Disorder	Professional	Release	PS		ORAL		

Date:05/17/99ISR Number: 3263495-5Report Type:Expedited (15-DaCompany Report #A0088811
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Foreign	Zyban Tablet -					
Other		Health	Zyban	PS		ORAL	150 MG/TWICE	
		Professional					PER DAY/ORAL	
			Ramipril	C				
			Isosorbide	C				
			Metoprolol	C				
			Nicotinic Acid	C				
			Lorazepam	C				
			Nitroglycerin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/99ISR Number: 3263802-3Report Type:Expedited (15-DaCompany Report #A0092189
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign	Zyban	PS		ORAL	150 MG/TWICE PER DAY/	ORAL
	Burning Sensation	Consumer						
	Eyelid Oedema							
	Facial Palsy							
	Hypersensitivity							
	Pruritus							

Date:05/17/99ISR Number: 3263803-5Report Type:Expedited (15-DaCompany Report #A0092480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gait Disturbance	Foreign	Zyban	PS		ORAL		ORAL
	Speech Disorder	Consumer						

Date:05/17/99ISR Number: 3263841-2Report Type:Expedited (15-DaCompany Report #A0092016
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Foreign	Zyban Tablet - Zyban	PS		ORAL		ORAL
	Atrial Fibrillation	Health Professional						
	Bronchospasm							
	Tachycardia							

Date:05/18/99ISR Number: 3264987-5Report Type:Periodic Company Report #S99-USA-00106-01
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Celexa	PS		ORAL	880 MG ONCE	

Initial or Prolonged	Electrocardiogram Qt	Professional				
PO						
	Prolonged		Wellbutrin	SS		ORAL
600 MG ONCE						
	Intentional Misuse					
PO						
	Suicide Attempt		Ethanol	SS		

Date:05/19/99ISR Number: 3264878-XReport Type:Direct Company Report #
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anxiety	Consumer	Zyban 150mg			
	Apathy		Glaxowellcome	PS	Glaxowellcome	
150MG 2 A DAY						
	Conversion Disorder					
	Crying					
	Depression					
	Malaise					

Date:05/19/99ISR Number: 3264906-1Report Type:Direct Company Report #
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dizziness		Wellbutrin Sr 150mg			
	Headache		Bid	PS		
150MG BID						
	Influenza Like Illness					
	Malaise					
	Pyrexia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/99ISR Number: 3267142-8Report Type:Periodic Company Report #8-99054-165A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health	Effexor Xr Capsules	PS		ORAL	37.5 MG ONCE	
	Tachycardia	Professional					DAILY ORAL;	
							75 MG ONCE	
							DAILY; 150 MG	
							ONCE DAILY	1 WK
			Wellbutrin (Bupropion)	SS		ORAL	450 MG DAILY	
							DECREASED TO	
							300 MG DAILY	
							ORAL	

Date:05/19/99ISR Number: 3299510-2Report Type:Periodic Company Report #S99-USA-00764-01
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia	Health	Celexa	PS		ORAL	20 MG QD PO ;	
	Nausea	Professional					10 MG QD PO	
	Sedation		Wellbutrin	SS		ORAL	150 MG QD PO	

Date:05/20/99ISR Number: 3265559-9Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness		Wellbutrin	PS		ORAL
100MG BID PO;						
	Ventricular Tachycardia					
* STARTED BID						
DOSING						
			Betapace	C		

Date:05/21/99ISR Number: 3267464-0Report Type:Expedited (15-DaCompany Report #A0085560
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Health	Wellbutrin Tablet -					
Hospitalization -	Nausea	Professional	Controlled Release	PS		ORAL	3 GRAMS/	
Initial or Prolonged	Vomiting						SINGLE DOSE/	
Disability							ORAL	
Other								

Date:05/21/99ISR Number: 3267728-0Report Type:Expedited (15-DaCompany Report #A0092017
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Foreign	Zyban Tablet-Zyban	PS		ORAL	ORAL	
	Atrial Fibrillation	Health						
	Bronchospasm	Professional						
	Tachycardia							

Date:05/21/99ISR Number: 3267819-4Report Type:Expedited (15-DaCompany Report #A0091712
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neuroleptic Malignant	Health	Wellbutrin					
	Syndrome	Professional	(Formulation					

			Unknown)	PS			ORAL
ORAL							

Date:05/21/99ISR Number: 3267823-6Report Type:Expedited (15-DaCompany Report #A0092506
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Spontaneous Metrorrhagia	Study Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/ORAL

Date:05/24/99ISR Number: 3283646-6Report Type:Periodic Company Report #JAUSA-36367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dyskinesia	Health Professional	Propulsid (Cisapride), Janssen, Tablet 10 Mg	PS	Janssen	ORAL	10 MG 4 DAILY ORAL
			Bupropion (Amfebutamone) Tablet 75 Mg	SS		ORAL	75 MG 3 DAILY ORAL

Date:05/25/99ISR Number: 3269450-3Report Type:Expedited (15-DaCompany Report #A0085426
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization -	Aspiration Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	3 GRAMS

Initial or Prolonged	Intentional Misuse					
SINGLE DOSE						
Other	Nausea					
ORAL						
	Vomiting					

Date:05/25/99ISR Number: 3269451-5Report Type:Expedited (15-DaCompany Report #A0092674
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue	Foreign	Zyban	PS		ORAL	150 MG TWICE	
	Hypersomnia	Consumer					PER DAY ORAL	
	Insomnia							
	Sleep Disorder							
	Tachycardia							

Date:05/25/99ISR Number: 3269452-7Report Type:Expedited (15-DaCompany Report #A0092867
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Foreign	Zyban	PS		ORAL	ORAL	
		Consumer						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/99ISR Number: 3269453-9Report Type:Expedited (15-DaCompany Report #A0089735
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban	PS		ORAL	150 MG TWICE	
	Drug Interaction	Professional					PER DAY ORAL	
			Alprazolam (Formulation Unknown)	SS		ORAL	1 MG AS	
							REQUIRED ORAL	
			Ranitidine Hydrochloride	C				

Date:05/25/99ISR Number: 3354072-6Report Type:Periodic Company Report #A0082509
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Major Depression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Nicotine	C				

Date:05/26/99ISR Number: 3270466-1Report Type:Expedited (15-DaCompany Report #A0092868
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hypoaesthesia	Consumer					TWICE PER DAY	
	Paraesthesia						/ ORAL	
	Sensation Of Heaviness							

Tremor

Date:05/26/99ISR Number: 3270469-7Report Type:Expedited (15-DaCompany Report #A0090923
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alcohol Withdrawal	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
Hospitalization -	Syndrome	Health					TWICE PER DAY	
Initial or Prolonged	Coma	Professional					/ ORAL	
	Convulsion	Company						
	Hypoxia	Representative						
	Liver Function Test Abnormal							
	Pneumonia Aspiration							

Date:05/26/99ISR Number: 3270879-8Report Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coma	Health	Wellbutrin Sr 150 Mg					
	Grand Mal Convulsion	Professional	Bid	PS		ORAL	150 MG BID PO	3 MON
	Urinary Incontinence		Ultram 50 Mg Bid	SS		ORAL	50 MG BID PO	3 MON
			Seroquel	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/99ISR Number: 3272704-8Report Type:Periodic Company Report #8-98271-019A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder	Consumer	Redux	PS		ORAL		
			Fastin (Phentermine)	SS		ORAL		
			Pondimin (Fenfluramine)					
			Tablet	SS		ORAL		
			Pro-Fast (Phentermine)	SS		ORAL		
			Welbutrin (Bupropion)	SS		ORAL	150 MG TWICE	DAILY ORAL

Date:05/27/99ISR Number: 3271216-5Report Type:Direct Company Report #
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Zyban 150 Mg Po Bid	PS		ORAL	150 MG PO BID	1 MON
	Dyskinesia	Professional	Amtriptyline	C				
	Saliva Altered		Effexer	C				
			Remeron	C				

Date:05/28/99ISR Number: 3272922-9Report Type:Expedited (15-DaCompany Report #A0091510
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Foreign	Zyban Tablet- Zyban	PS		ORAL	150 MG/TWICE	PER DAY/ORAL
Disability	Dermatitis	Health						
	Leukocytosis	Professional						

	Obstructive Airways Disorder Respiratory Disorder Serum Sickness Swelling Urticaria					

Date:05/28/99ISR Number: 3272927-8Report Type:Expedited (15-DaCompany Report #A0092789
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Dyspnoea Pruritus Speech Disorder Urticaria	Foreign Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:05/28/99ISR Number: 3272929-1Report Type:Expedited (15-DaCompany Report #A0089661
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3273170-9Report Type:Expedited (15-DaCompany Report #A0093370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Consumer	Zyban Tablet - Zyban	PS				

Date:05/28/99ISR Number: 3282842-1Report Type:Periodic Company Report #A0087404
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Consumer	Zyban	PS		ORAL	150 MG /	
	Face Oedema						TWICE PER	
	Hypersensitivity						DAY/ ORAL	
	Urticaria							

Date:05/28/99ISR Number: 3282845-7Report Type:Periodic Company Report #A0088006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban	PS		ORAL	150 MG / UNK/	
		Professional					ORAL	
		Company Representative						

Date:05/28/99ISR Number: 3282847-0Report Type:Periodic Company Report #A0088853
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema	Consumer	Zyban	PS		ORAL	UNK/ TWICE	
	Pruritus						PER DAY/ ORAL	

	Urticaria		Triphasil	C		

Date:05/28/99ISR Number: 3282849-4Report Type:Periodic Company Report #A0088991
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Zyban	PS		ORAL	150 MG/ UNK/	
Hospitalization - Initial or Prolonged	Eyelid Oedema	Professional				ORAL		
	Face Oedema							
	Pharyngeal Oedema							

Date:05/28/99ISR Number: 3282852-4Report Type:Periodic Company Report #A0089382
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Consumer	Zyban	PS		ORAL	150 MG/ TWICE	
	Ecchymosis	Company					PER DAY/ ORAL	
	Urticaria	Representative						

Date:05/28/99ISR Number: 3282854-8Report Type:Periodic Company Report #A0089444
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban	PS		ORAL	300 MG / SEE	
	Overdose	Professional					TEXT/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3282857-3Report Type:Periodic Company Report #A0089660
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Zyban	PS		ORAL	150 MG / PER DAY/ ORAL	

Date:05/28/99ISR Number: 3282860-3Report Type:Periodic Company Report #A0090183
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eyelid Oedema	Health	Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Face Oedema	Professional						
		Company Representative	Tamoxifen	C				
			Alendronate Sodium	C				
			Lisinopril	C				

Date:05/28/99ISR Number: 3282861-5Report Type:Periodic Company Report #A0090576
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health	Zyban	PS		ORAL	150 MG/ UNK/ ORAL	
		Professional						
		Company Representative						

Date:05/28/99ISR Number: 3282863-9Report Type:Periodic Company Report #A0059506
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Anorexia	Health	Zyban	PS		ORAL
150 MG /						
	Paranoia	Professional				
TWICE PER						
	Suicide Attempt					
DAY/ ORAL						

Date:05/28/99ISR Number: 3282864-0Report Type:Periodic Company Report #A0070204
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Fatigue	Consumer	Zyban	PS		ORAL
150 MG / PER						
	Headache					
DAY/ ORAL						
	Loss Of Consciousness					
	Nervousness					
	Pruritus					
	Pyrexia					
	Sedation					
	Tremor					

Date:05/28/99ISR Number: 3282865-2Report Type:Periodic Company Report #A0073851
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Zyban	PS		ORAL
150 MG/ TWICE						
	Fall	Professional				
PER DAY/ ORAL						
	Hypoglycaemia		Glimepiride	C		
	Injury		Multivitamin	C		
	Tremor		Vitamin E	C		
			Ester-C	C		

			Ampicillin	C			

Date:05/28/99ISR Number: 3282871-8Report Type:Periodic Company Report #A0076211
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypersensitivity Urticaria	Health Professional	Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:05/28/99ISR Number: 3282873-1Report Type:Periodic Company Report #A0077336
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypersensitivity Oedema Peripheral Rash Erythematous Urticaria Vomiting	Health Professional	Zyban Claritin - D Finasteride	PS C C		ORAL	150 MG / TWICE PER DAY/ ORAL

Date:05/28/99ISR Number: 3282876-7Report Type:Periodic Company Report #A0077347
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Convulsion Syncope	Health Professional Company	Zyban	PS		ORAL	150 MG / TWICE PER DAY/ ORAL
		Representative	Oestradiol Salbutamol Sulphate	C C			

				Theophylline	C		
				Allopurinol	C		
				Alendronate Sodium	C		

Date:05/28/99ISR Number: 3282880-9Report Type:Periodic Company Report #A0078443
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Capillary Leak Syndrome	Health	Zyban	PS		ORAL	150 MG/ UNK/	
	Hypersensitivity	Professional				ORAL		
	Swelling	Company Representative	Omeprazole	C				

Date:05/28/99ISR Number: 3282885-8Report Type:Periodic Company Report #A0078477
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Bone Pain
Other	Chills
	Diarrhoea
	Dizziness
	Dyspepsia
	Face Oedema
	Headache
	Hypersensitivity
	Pruritus

	Pyrexia					
	Rash Maculo-Papular					
	Swelling	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urticaria	Health	Zyban	PS		ORAL
150 MG /						
	Vomiting	Professional				
TWICE PER						
DAY/ ORAL						
			Ibuprofen	C		

Date:05/28/99ISR Number: 3282888-3Report Type:Periodic Company Report #A0079702
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Zyban	PS		ORAL
150 MG / WICE						
	Syncope	Professional				
PER DAY/ ORAL						
		Company	Cetirizine			
		Representative	Hydrochloride	C		
			Fluoxymesterone	C		

Date:05/28/99ISR Number: 3282890-1Report Type:Periodic Company Report #A0080413
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Decreased Appetite	Health	Zyban	PS		ORAL
150 MG /						
Initial or Prolonged	Disturbance In Attention	Professional				
TWICE PER						
Other	Dysgeusia					
DAY/ ORAL						
	Hallucination		Naproxen Sodium	C		
	Headache					
	Insomnia					

Date:05/28/99ISR Number: 3282892-5Report Type:Periodic Company Report #A0080693
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperglycaemia	Health Professional	Zyban	PS		ORAL	150 MG / UNK/ORAL	
			Choline Theophyllinate	C				
			Gemfibrozil	C				
			Atenolol	C				
			Human Int / Long Insulin	C				
			Human Short-Act. Insulin	C				
			Frusemide	C				
			Lansoprazole	C				

Date:05/28/99ISR Number: 3282900-1Report Type:Periodic Company Report #A0080807
Age:20 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Burning Sensation
	Dry Skin
	Dyspnoea
	Hypersensitivity
	Pruritus
	Rash Erythematous
	Rash Papular

	Skin Irritation Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Zyban	PS		ORAL	150 MG / TWICE PER DAY/ ORAL

Date:05/28/99ISR Number: 3282903-7Report Type:Periodic Company Report #A0081611
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dyspnoea Throat Tightness Urticaria	Health Professional	Zyban	PS		ORAL	150 MG / TWICE PER DAY/ ORAL
			Weight Loss Medication	C			

Date:05/28/99ISR Number: 3282909-8Report Type:Periodic Company Report #A0081603
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Pharyngeal Oedema Tongue Oedema Urticaria	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY
			Cyclobenzaprin Hcl Tablet	SS		ORAL	10 MG / THREE TIMES PER DA
			Armour Thyroid	C			
			Naproxen	C			

Date:05/28/99ISR Number: 3282912-8Report Type:Periodic Company Report #A0082017
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Tremor						DAY	

Date:05/28/99ISR Number: 3282914-1Report Type:Periodic Company Report #A0082065
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Mydriasis						TWICE PER DAY	
	Nervousness							
	Oedema							
	Oedema Peripheral							
	Pruritus							
	Urticaria							

Date:05/28/99ISR Number: 3282917-7Report Type:Periodic Company Report #A0082357
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
Hospitalization -	Grand Mal Convulsion	Professional					TWICE PER DAY	
Initial or Prolonged	Loss Of Consciousness	Company	Simvastatin	C				
	Mood Swings	Representative	Nicotine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3282920-7Report Type:Periodic Company Report #A0082921
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /
	Pruritus	Professional					TWICE PER DAY
	Swelling						

Date:05/28/99ISR Number: 3282921-9Report Type:Periodic Company Report #A0083363
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	150 MG

Date:05/28/99ISR Number: 3282923-2Report Type:Periodic Company Report #A0083631
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /
	Urticaria						TWICE PER DAY
			Birth Control	C			

Date:05/28/99ISR Number: 3282925-6Report Type:Periodic Company Report #A0083648
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis Dyspnoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150MG ORAL

	Hypersensitivity					

Date:05/28/99ISR Number: 3282927-XReport Type:Periodic Company Report #A0083649
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis Dyspnoea Hypersensitivity	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG

Date:05/28/99ISR Number: 3282929-3Report Type:Periodic Company Report #A0084374
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY

Date:05/28/99ISR Number: 3282930-XReport Type:Periodic Company Report #A0084412
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY

			Vicodin	C			

Date:05/28/99ISR Number: 3282932-3Report Type:Periodic Company Report #A0084629
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
		Company Representative	Colestipol	C				
			Pravastatin Sodium	C				

Date:05/28/99ISR Number: 3282934-7Report Type:Periodic Company Report #A0084862
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Study	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Hyperhidrosis	Consumer						
	Nasopharyngitis							
	Pallor							
	Tremor							

Date:05/28/99ISR Number: 3282936-0Report Type:Periodic Company Report #A0085003
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Convulsion							
	Insomnia							
	Myalgia							
	Nervousness							
	Tremor							

Date:05/28/99ISR Number: 3282938-4Report Type:Periodic Company Report #A0085850
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	

Date:05/28/99ISR Number: 3282941-4Report Type:Periodic Company Report #A0086000
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	TWICE PER DAY	

Date:05/28/99ISR Number: 3282943-8Report Type:Periodic Company Report #A0086021
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Dermatitis Dyspnoea Face Oedema Oedema Tongue Oedema

	Urticaria					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
TWICE PER DAY						
			Claritin-D	C		
			Conjugated Estrogens	C		
			Medroxyprogesterone Ace.	C		

Date:05/28/99ISR Number: 3282945-1Report Type:Periodic Company Report #A0086086
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
Initial or Prolonged	Dermatitis					
TWICE PER DAY						
	Pruritus					

Date:05/28/99ISR Number: 3282947-5Report Type:Periodic Company Report #A0086828
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG / SEE						
	Influenza Like Illness					
TEXT						
	Pharyngeal Oedema		Nocotine	C		
	Urticaria					

Date:05/28/99ISR Number: 3282950-5Report Type:Periodic Company Report #A0087268
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - Initial or Prolonged	Myocardial Infarction Sinus Congestion	Consumer	Zyban Tablet - Zyban	PS		ORAL 1500 MG / TWICE PER DAY
			Simvastatin	C		
			Lisinopril	C		
			Metoprolol	C		
			Nitroglycerin	C		

Date:05/28/99ISR Number: 3332413-3Report Type:Periodic Company Report #A0086568
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Accommodation Disorder Dizziness Hypertension Muscle Contractions Involuntary Nausea Sensation Of Pressure	Consumer	Zyban Tablet - Zyban Ranitidine Hydrochloride	PS C		ORAL 150 MG/ TWICE PER DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332414-5Report Type:Periodic Company Report #A0086587
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
	Pruritus						DAY / ORAL	
			Thyroid Medication	C				
			Prempro	C				
			Erythromycin	C				

Date:05/28/99ISR Number: 3332415-7Report Type:Periodic Company Report #A0086696
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG/ TWICE	
	Insomnia						PER DAY/ ORAL	
	Nausea		Excedrin	C				

Date:05/28/99ISR Number: 3332416-9Report Type:Periodic Company Report #A0086698
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	

Date:05/28/99ISR Number: 3332417-0Report Type:Periodic Company Report #A0086700
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	

DAY / ORAL

			Glibenclamide	C		
			Acarbose	C		
			Lisinopril	C		

Date:05/28/99ISR Number: 3332418-2Report Type:Periodic Company Report #A0086701
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Flatulence						PER DAY/	ORAL
	Insomnia		Prempro	C				
	Tachycardia		Pravastatin Sodium	C				
			Multivitamin	C				

Date:05/28/99ISR Number: 3332419-4Report Type:Periodic Company Report #A0086702
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Tachycardia						TWICE PER	
	Tremor						DAY/ ORAL	
			Cyclobenzaprine Hc1	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332420-0Report Type:Periodic Company Report #A0086703
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	DAY / ORAL
			Ibuprofen	C				

Date:05/28/99ISR Number: 3332421-2Report Type:Periodic Company Report #A0086704
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	DAY/ ORAL
			Multivitamin	C				

Date:05/28/99ISR Number: 3332422-4Report Type:Periodic Company Report #A0086705
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dry Mouth						TWICE PER	
	Dyspnoea						DAY/ ORAL	
	Insomnia							
	Tachycardia							

Date:05/28/99ISR Number: 3332423-6Report Type:Periodic Company Report #A0086706
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Weight Decreased	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG/ PER DAY/ ORAL
			Blood Pressure Medication	C		
			Nifedipine	C		

Date:05/28/99ISR Number: 3332424-8Report Type:Periodic Company Report #A0086708
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Epistaxis	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG/ TWICE PER DAY/ ORAL
	Headache					
	Irritability					

Date:05/28/99ISR Number: 3332425-XReport Type:Periodic Company Report #A0086709
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Diarrhoea	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG/ TWICE PER DAY/ ORAL
			Ibuprofen	C		
			Baclofen	C		
			Diazepam	C		
			Alendronate Sodium	C		
			Multivitamin	C		
			Iron Salt	C		
			Calcium Salt	C		

			Folic Acid	C			

Date:05/28/99ISR Number: 3332426-1Report Type:Periodic Company Report #A0086710
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY / ORAL
			Acyclovir	C			

Date:05/28/99ISR Number: 3332427-3Report Type:Periodic Company Report #A0086711
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Peripheral	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL
	Urticaria						

Date:05/28/99ISR Number: 3332428-5Report Type:Periodic Company Report #A0086712
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / VARIABLE DOSE / ORAL
	Headache						
	Hepatitis C						
	Muscle Twitching		Trazodone	C			
	Nausea		Clonazepam	C			
			Ranitidine Hydrochloride	C			
			Naltrexone				

			Hydrochloride	C		

Date:05/28/99ISR Number: 3332429-7Report Type:Periodic Company Report #A0086713
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL

Date:05/28/99ISR Number: 3332430-3Report Type:Periodic Company Report #A0086714
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:05/28/99ISR Number: 3332431-5Report Type:Periodic Company Report #A0086715
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Agitation	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
	Amnesia						
	Drug Ineffective						
	Smoker		Multivitamin	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332432-7Report Type:Periodic Company Report #A0086716
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Dry Mouth	Professional					DAY / ORAL	
	Eye Movement Disorder							

Date:05/28/99ISR Number: 3332433-9Report Type:Periodic Company Report #A0087215
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Haematemesis	Professional					TWICE PER DAY	
	Mood Swings						/ ORAL	

Date:05/28/99ISR Number: 3332435-2Report Type:Periodic Company Report #A0087216
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Mydriasis						TWICE PER DAY	
							/ ORAL	
			Levofloxacin	C				
			Prednisone	C				
			Salbutamol Sulphate	C				

Date:05/28/99ISR Number: 3332436-4Report Type:Periodic Company Report #A0087246
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS			150 MG / AT	
	Drug Hypersensitivity	Professional					NIGHT/	
	Pruritus							
	Urticaria							

Date:05/28/99ISR Number: 3332438-8Report Type:Periodic Company Report #A0087256
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Flatulence						TWICE PER	
	Gastrointestinal Disorder						DAY/ ORAL	

Date:05/28/99ISR Number: 3332439-XReport Type:Periodic Company Report #A0087282
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Drug Hypersensitivity	Professional					TWICE PER	
	Hypoaesthesia						DAY/ ORAL	
	Joint Stiffness							
	Lacrimation Increased							
	Neurological Symptom							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332440-6Report Type:Periodic Company Report #A0087313
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER	
							DAY/ ORAL	
			Amlodipine	C				

Date:05/28/99ISR Number: 3332442-XReport Type:Periodic Company Report #A0087314
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER	
							DAY/ ORAL	

Date:05/28/99ISR Number: 3332443-1Report Type:Periodic Company Report #A0087315
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toxicologic Test Abnormal	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER	
							DAY/ ORAL	

Date:05/28/99ISR Number: 3332444-3Report Type:Periodic Company Report #A0087316
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Headache						TWICE PER	
	Irritability						DAY/ ORAL	
	Malaise							

Date:05/28/99ISR Number: 3332446-7Report Type:Periodic Company Report #A0087317
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ill-Defined Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Influenza Like Illness							

Date:05/28/99ISR Number: 3332447-9Report Type:Periodic Company Report #A0087318
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER	
							DAY/ ORAL	

Date:05/28/99ISR Number: 3332448-0Report Type:Periodic Company Report #A0087319
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER	
							DAY/ ORAL	

			Blood Pressure Medication	C		

Date:05/28/99ISR Number: 3332449-2Report Type:Periodic Company Report #A0087320
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Rash Generalised							
			Cannabis	C				

Date:05/28/99ISR Number: 3332451-0Report Type:Periodic Company Report #A0087321
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Dermatitis	Professional						
	Dizziness		Thyroxine Sodium	C				
	Irritability		Multivitamin	C				
	Memory Impairment		Vitamin E	C				
	Nervousness		Hypericum	C				
	Pruritus							
	Rash Erythematous							
	Rash Papular							
	Syncope							
	Urticaria							

Date:05/28/99ISR Number: 3332452-2Report Type:Periodic Company Report #A0087322
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Urticaria					
TWICE PER DAY						
/ ORAL						

Date:05/28/99ISR Number: 3332453-4Report Type:Periodic Company Report #A0087323
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						
			Prempro	C		
			Ziac	C		

Date:05/28/99ISR Number: 3332455-8Report Type:Periodic Company Report #A0087324
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Condition Aggravated	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Diarrhoea					
TWICE PER						
	Sedation					
DAY/ ORAL						
			Ascorbic Acid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332456-XReport Type:Periodic Company Report #A0087325
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL
	Dizziness	Professional						
	Gait Disturbance	Company Representative						

Date:05/28/99ISR Number: 3332458-3Report Type:Periodic Company Report #A0087326
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
	Pruritus	Professional						
	Urticaria							

Date:05/28/99ISR Number: 3332459-5Report Type:Periodic Company Report #A0087327
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY /	ORAL
			Amitriptyline	C				

Date:05/28/99ISR Number: 3332461-3Report Type:Periodic Company Report #A0087727
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Confusional State	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG / ORAL						
	Dizziness					
	Headache					
	Insomnia					
	Nausea					

Date:05/28/99ISR Number: 3332462-5Report Type:Periodic Company Report #A0087728
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Constipation					
TWICE PER DAY						
	Hyperhidrosis					
/ ORAL						
	Insomnia					

Date:05/28/99ISR Number: 3332463-7Report Type:Periodic Company Report #A0087729
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
TWICE PER DAY						
/ ORAL 7 DAY						
			Diltiazem Hydrochloride	C		
			Digoxin	C		
			Gemfibrozil	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332465-0Report Type:Periodic Company Report #A0087753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Insomnia	Professional					DAY / ORAL	

Date:05/28/99ISR Number: 3332466-2Report Type:Periodic Company Report #A0087754
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Depression						TWICE PER DAY	
	Disturbance In Attention						/ ORAL	
	Drug Ineffective							
	Emotional Disorder							
	Fear							
	Nervousness							

Date:05/28/99ISR Number: 3332468-6Report Type:Periodic Company Report #A0087755
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER	
							DAY/ ORAL	
			Fluvastatin Sodium	C				
			Ketoprofen	C				

Date:05/28/99ISR Number: 3332470-4Report Type:Periodic Company Report #A0087756
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Back Pain						TWICE PER	
	Dry Skin						DAY/ ORAL	
	Fatigue		Pravastatin Sodium	C				
	Myalgia		Allopurinol	C				
	Neck Pain		Aspirin	C				
	Nightmare		Calcium Salt	C				
			Multivitamin	C				

Date:05/28/99ISR Number: 3332471-6Report Type:Periodic Company Report #A0087757
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Diarrhoea						TWICE PER DAY	
							/ ORAL	
			Amlodipine	C				
			Spironolactone	C				
			Hydrazaline Hydrochloride	C				
			Nifedipine	C				
			Dilantin	C				
			Potassium Chloride	C				
			Aspirin	C				
			Finasteride	C				

			Frusemide	C		
			Prednisone	C		

Date:05/28/99ISR Number: 3332472-8Report Type:Periodic Company Report #A0087758
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dry Mouth						TWICE PER	
	Dyspnoea						DAY/ ORAL	5 DAY

Date:05/28/99ISR Number: 3332473-XReport Type:Periodic Company Report #A0087759
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER	
							DAY/ ORAL	
			Nifedipine	C				
			Thyroxine Sodium	C				
			Atorvastatin Calcium	C				
			Hormones	C				
			Aspirin	C				

Date:05/28/99ISR Number: 3332474-1Report Type:Periodic Company Report #A0087760
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
							DAY / ORAL	

Date:05/28/99ISR Number: 3332475-3Report Type:Periodic Company Report #A0087761
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Dissociation						DAY/ ORAL	
	Dizziness							
	Malaise							

Date:05/28/99ISR Number: 3332476-5Report Type:Periodic Company Report #A0087762
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER	
							DAY/ ORAL	

Date:05/28/99ISR Number: 3332478-9Report Type:Periodic Company Report #A0087763
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332479-0Report Type:Periodic Company Report #A0087764
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dermatitis	Professional					TWICE PER	
	Disturbance In Attention						DAY/ ORAL	
	Dizziness		Nordette	C				
	Folliculitis							
	Pruritus							
	Rash Erythematous							
	Weight Decreased							

Date:05/28/99ISR Number: 3332481-9Report Type:Periodic Company Report #A0087765
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Smoker	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Valsartan	C				
			Sulphasalazine	C				

Date:05/28/99ISR Number: 3332482-0Report Type:Periodic Company Report #A0087766
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Headache						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3332483-2Report Type:Periodic Company Report #A0087329
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	DAY/ ORAL
	Vision Blurred							
			Ortho Tri-Cyclen	C				

Date:05/28/99ISR Number: 3332484-4Report Type:Periodic Company Report #A0087767
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Drug Ineffective	Professional						
	Smoker							

Date:05/28/99ISR Number: 3332486-8Report Type:Periodic Company Report #A0087768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban	PS		ORAL	150 MG / ORAL	
	Dermatitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332487-XReport Type:Periodic Company Report #A0087328
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Tylenol No. 3	C				
			Carisoprodol	C				

Date:05/28/99ISR Number: 3332489-3Report Type:Periodic Company Report #A0087330
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3332490-XReport Type:Periodic Company Report #A0087331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Symptom	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Sensation Of Pressure	Professional						

Date:05/28/99ISR Number: 3332491-1Report Type:Periodic Company Report #A0087332
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL

150 MG /

TWICE PER DAY

/ ORAL

Date:05/28/99ISR Number: 3332493-5Report Type:Periodic Company Report #A0087333
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Abdominal Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL
	Pain					
			Diazepam	C		

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

Date:05/28/99ISR Number: 3332495-9Report Type:Periodic Company Report #A0087334
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Hypertonia	Consumer	Zyban Tablet - Zyban	PS		ORAL
	Insomnia					
	Tremor					
			Diazepam	C		
			Clonidine	C		
			Dicyclomine	C		

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332496-0Report Type:Periodic Company Report #A0087335
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Lichenification	Professional					TWICE PER DAY	
	Pruritus						/ ORAL	
	Rash Erythematous		Triamcinolone Acetonide	C				
	Rash Papular		Oxymetazoline Hcl	C				
			Clindamycin Phosphate	C				

Date:05/28/99ISR Number: 3332497-2Report Type:Periodic Company Report #A0087336
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Dry Mouth						DAY / ORAL	
	Insomnia							
	Myalgia							
	Oedema Peripheral							
	Pallor							

Date:05/28/99ISR Number: 3332500-XReport Type:Periodic Company Report #A0087337
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Irritability						TWICE PER DAY	
							/ ORAL	
			Estrogen	C				

			Multivitamin	C			

Date:05/28/99ISR Number: 3332501-1Report Type:Periodic Company Report #A0087338
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Anxiety						TWICE PER DAY	
	Crying						/ ORAL	
	Depression		Alendronate Sodium	C				
	Disturbance In Attention		Atorvastatin Calcium	C				
	Insomnia							
	Nervousness							
	Phobia							
	Tremor							
	Weight Decreased							

Date:05/28/99ISR Number: 3332504-7Report Type:Periodic Company Report #A0087339
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
							DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332505-9Report Type:Periodic Company Report #A0087340
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Micturition Urgency						TWICE PER DAY	
	Nervousness						/ ORAL	
	Tinnitus		Alprazolam	C				
			Inhaler	C				
			Omeprazole	C				

Date:05/28/99ISR Number: 3332512-6Report Type:Periodic Company Report #A0087341
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus						TWICE PER DAY	
							/ ORAL	
			Alprazolam	C				
			Aspirin	C				

Date:05/28/99ISR Number: 3332515-1Report Type:Periodic Company Report #A0087343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	4 DAY

Date:05/28/99ISR Number: 3332517-5Report Type:Periodic Company Report #A0087344
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
	Pruritus						/ ORAL	
	Urticaria		Clonazepam	C				

Date:05/28/99ISR Number: 3332518-7Report Type:Periodic Company Report #A0087345
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Sleep Disorder	Professional	Multivitamin	C				

Date:05/28/99ISR Number: 3332519-9Report Type:Periodic Company Report #A0087346
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Headache							
	Myalgia							
	Neck Pain							
	Paraesthesia							
	Sinus Headache							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332520-5Report Type:Periodic Company Report #A0087347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Depression							

Date:05/28/99ISR Number: 3332522-9Report Type:Periodic Company Report #A0087348
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/	
		Professional					ORAL	

Date:05/28/99ISR Number: 3332524-2Report Type:Periodic Company Report #A0087349
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Decreased Appetite						TWICE PER DAY	
	Feeling Drunk						/ ORAL	
	Insomnia							
	Judgement Impaired							

Date:05/28/99ISR Number: 3332526-6Report Type:Periodic Company Report #A0087350
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
							DAY / ORAL	

			Estrogen	C		

Date:05/28/99ISR Number: 3332527-8Report Type:Periodic Company Report #A0087351
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dizziness	Professional					TWICE PER DAY	
	Dry Mouth						/ ORAL	
	Sleep Disorder							
	Syncope							
	Tremor							

Date:05/28/99ISR Number: 3332529-1Report Type:Periodic Company Report #A0087352
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
	Dry Mouth						/ ORAL	
	Dyspnoea							
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332530-8Report Type:Periodic Company Report #A0087353
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Condition Aggravated						TWICE PER DAY	
	Dry Mouth						/ ORAL	
	Dysgeusia		Diazepam	C				
	Dysphagia		Unknown	C				
	Oesophageal Spasm		Diltiazem Hydrochloride	C				

Date:05/28/99ISR Number: 3332531-XReport Type:Periodic Company Report #A0087411
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Excitability						TWICE PER DAY	
	Insomnia						/ ORAL	

Date:05/28/99ISR Number: 3332532-1Report Type:Periodic Company Report #A0087412
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3332533-3Report Type:Periodic Company Report #A0087461
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS			UNK / UNK /	
	Night Sweats						UNK	
	Throat Tightness		Amoxycillin	C				

Date:05/28/99ISR Number: 3332535-7Report Type:Periodic Company Report #A0087466
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Depression						DAY / ORAL	
	Suicidal Ideation		Ranitidine Hydrochloride	C				

Date:05/28/99ISR Number: 3332536-9Report Type:Periodic Company Report #A0087597
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
	Dizziness	Professional					/ ORAL	
	Gait Disturbance	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332537-0Report Type:Periodic Company Report #A0087666
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Flatulence						TWICE PER DAY	
							/ ORAL	
			Pravastatin Sodium	C				

Date:05/28/99ISR Number: 3332540-0Report Type:Periodic Company Report #A0087669
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Gastrointestinal Disorder						TWICE PER DAY	
							/ ORAL	
			Atenolol	C				
			Simvastatin	C				

Date:05/28/99ISR Number: 3332542-4Report Type:Periodic Company Report #A0087719
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Hormones	C				

Date:05/28/99ISR Number: 3332544-8Report Type:Periodic Company Report #A0087720
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3332546-1Report Type:Periodic Company Report #A0087721
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK / ORAL	
	Urticaria							
			Ortho-Cept	C				
			Multivitamin	C				

Date:05/28/99ISR Number: 3332548-5Report Type:Periodic Company Report #A0087722
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK / ORAL	8 WK
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332550-3Report Type:Periodic Company Report #A0087723
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	
			Thyroid	C				

Date:05/28/99ISR Number: 3332552-7Report Type:Periodic Company Report #A0087724
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Swelling						TWICE PER DAY	
	Urticaria						/ ORAL	

Date:05/28/99ISR Number: 3332555-2Report Type:Periodic Company Report #A0087725
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Difficulty In Walking						TWICE PER DAY	
	Disturbance In Attention						ORAL	
	Malaise							
	Speech Disorder							
	Tremor							

Date:05/28/99ISR Number: 3332556-4Report Type:Periodic Company Report #A0087726
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
		Health					/ ORAL	
		Professional						
		Other						

Date:05/28/99ISR Number: 3332560-6Report Type:Periodic Company Report #A0086410
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	
	Fluid Retention						TWICE PER DAY	
	Hypersensitivity						ORAL	
	Lacrimation Increased		Zinc Salt	C				
	Nasopharyngitis		Vitamin B Complex	C				
	Pulmonary Congestion		Ascorbic Acid	C				
	Sneezing		Vitamin E	C				
			Thyroxine Sodium	C				
			Estrogen	C				

Date:05/28/99ISR Number: 3332561-8Report Type:Periodic Company Report #A0086411
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	
							TWICE PER DAY	

ORAL

Oral Contraceptive C

Date:05/28/99ISR Number: 3332563-1Report Type:Periodic Company Report #A0086412
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	
	Insomnia						PER DAY	
	Major Depression						ORAL	
	Tremor							

Date:05/28/99ISR Number: 3332565-5Report Type:Periodic Company Report #A0086413
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	
							TWICE PER DAY	
							ORAL	
			Oral Contraceptive	C				

Date:05/28/99ISR Number: 3332567-9Report Type:Periodic Company Report #A0086414
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	
	Insomnia						TWICE PER DAY	
							ORAL	
			Estrogen	C				

			Calcium Salt	C		

Date:05/28/99ISR Number: 3332568-0Report Type:Periodic Company Report #A0086415
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	TWICE PER DAY
ORAL								
			Thyroxine Sodium	C				

Date:05/28/99ISR Number: 3332570-9Report Type:Periodic Company Report #A0086416
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	
	Nausea							TWICE PER DAY
ORAL								

Date:05/28/99ISR Number: 3332583-7Report Type:Periodic Company Report #A0086417
Age:56 YR Gender:Male I/FU:I

Outcome	PT
	Dermatitis
	Dysphagia
	Dysuria
	Ecchymosis

	Pharyngeal Oedema Pruritus Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route Dose Duration
		Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG TWICE PER DAY ORAL
			Ibuprofen	C		

Date:05/28/99ISR Number: 3332585-0Report Type:Periodic Company Report #A0086418
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dry Mouth Insomnia Personality Change	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG TWICE PER DAY ORAL

Date:05/28/99ISR Number: 3332586-2Report Type:Periodic Company Report #A0086419
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Tinnitus	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG TWICE PER DAY ORAL

Date:05/28/99ISR Number: 3332589-8Report Type:Periodic Company Report #A0086420
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration

	Abdominal Distension	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG						
	Anorexia					
TWICE PER DAY						
	Gastric Dilatation					
ORAL						
	Oedema Peripheral					
	Weight Increased					

Date:05/28/99ISR Number: 3332591-6Report Type:Periodic Company Report #A0086421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG						
		Company				
ORAL						
		Representative				

Date:05/28/99ISR Number: 3332593-XReport Type:Periodic Company Report #A0086422
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Health	Zyban Tablet - Zyban	PS		ORAL
150 MG						
		Professional				
ORAL						

Date:05/28/99ISR Number: 3332597-7Report Type:Periodic Company Report #A0086423
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Tremor	Health
		Professional

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban Tablet - Zyban	PS		ORAL
150 MG						
TWICE PER DAY						
ORAL						

Date:05/28/99ISR Number: 3332599-0Report Type:Periodic Company Report #A0086424
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG						
	Local Swelling					
ORAL						

Date:05/28/99ISR Number: 3332600-4Report Type:Periodic Company Report #A0086425
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG						
TWICE PER DAY						
ORAL						

Date:05/28/99ISR Number: 3332603-XReport Type:Periodic Company Report #A0086426
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG						

TWICE PER DAY

ORAL

Date:05/28/99ISR Number: 3332606-5Report Type:Periodic Company Report #A0086427
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG	
	Diarrhoea	Professional				ORAL		
	Headache		Nicotine Patch	SS		TRANSDERMAL	TRANSDERMAL	
	Therapeutic Response		Nicotine Gum	SS		ORAL	2 MG	AS
	Unexpected					REQUIRED		
						ORAL		
			Inhaler	C				
			Estropipate	C				

Date:05/28/99ISR Number: 3332607-7Report Type:Periodic Company Report #A0086428
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	PER
						DAY	ORAL	
			Methyldopa	C				
			Diltiazem Hydrochloride	C				
			M.V.I.	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332610-7Report Type:Periodic Company Report #A0086541
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Consumer	Zyban Tablet - Zyban	PS		ORAL	1 TABLET	
	Dizziness						PER DAY	
							ORAL	
			Multivitamin	C				

Date:05/28/99ISR Number: 3332614-4Report Type:Periodic Company Report #A0084833
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
							DAY/ ORAL	

Date:05/28/99ISR Number: 3332616-8Report Type:Periodic Company Report #A0084834
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Pain						PER DAY/ ORAL	

Date:05/28/99ISR Number: 3332617-XReport Type:Periodic Company Report #A0084835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperphagia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ ORAL	
	Weight Increased		Purified Water	C				

Date:05/28/99ISR Number: 3332620-XReport Type:Periodic Company Report #A0084836
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/	
		Professional	Prednisone					
		Other	(Formulation Unknown)	SS				
			Nicotine Patch	SS				
			Pseudoephedrine (Formulation Unknown)	SS				

Date:05/28/99ISR Number: 3332624-7Report Type:Periodic Company Report #A0084837
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
	Influenza						DAY/	
			Theraflu	C				
			Diazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332625-9Report Type:Periodic Company Report #A0084838
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopause	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Oligomenorrhoea						PER DAY/ ORAL	
			Birth Control	C				

Date:05/28/99ISR Number: 3332629-6Report Type:Periodic Company Report #A0084841
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Condition Aggravated						PER DAY/ ORAL	
	Crying		Conj.					
	Decreased Activity		Estrogen+Medroxyprog	C				
	Depression		Multivitamin	C				
	Insomnia							
	Lethargy							
	Nervous System Disorder							
	Tremor							

Date:05/28/99ISR Number: 3332631-4Report Type:Periodic Company Report #A0084842
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Nasopharyngitis						PER DAY/ ORAL	
	Nausea							
	Productive Cough							

Date:05/28/99ISR Number: 3332634-XReport Type:Periodic Company Report #A0084843
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Texture Abnormal		Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Muscle Spasms						PER DAY/ORAL	
	Tongue Ulceration		Lotrel	C				
			Omeprazole	C				
			Vitamin E	C				
			Calcium Salt	C				
			Garlic	C				
			Hypericum	C				
			Kava	C				
			Hyoscyamine Sulphate	C				
			Metronidazole	C				
			Estrogen	C				
			Allergy Medication	C				
			Trimethoprim	C				

Date:05/28/99ISR Number: 3332637-5Report Type:Periodic Company Report #A0084844
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Cough						PER DAY/ORAL	
	Dyspnoea		Naproxen Sodium	C				
	Fatigue		Cyanocobalamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332640-5Report Type:Periodic Company Report #A0084845
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Fatigue						PER DAY/ORAL	
	Increased Appetite							

Date:05/28/99ISR Number: 3332642-9Report Type:Periodic Company Report #A0084846
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinusitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
							PER DAY/ORAL	

Date:05/28/99ISR Number: 3332645-4Report Type:Periodic Company Report #A0084847
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/PER	
	Pruritus						DAY/ORAL	
	Tremor		Multivitamin	C				
			Zinc Salt	C				

Date:05/28/99ISR Number: 3332648-XReport Type:Periodic Company Report #A0084848
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	

PER DAY/ORAL

Date:05/28/99ISR Number: 3332649-1Report Type:Periodic Company Report #A0084849
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Drug Withdrawal Syndrome						PER DAY/ORAL	
	Irritability							
	Nervousness							

Date:05/28/99ISR Number: 3332654-5Report Type:Periodic Company Report #A0084850
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
							PER DAY/ORAL	
			Cholestyramine	C				
			Diazepam	C				
			Trifluoperazine	C				

Date:05/28/99ISR Number: 3332656-9Report Type:Periodic Company Report #A0084851
Age:47 YR Gender:Male I/FU:I

Outcome	PT
	Anxiety
	Disturbance In Attention

	Insomnia					
	Stress					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG/TWICE						
PER DAY/ORAL						
			Etodolac	C		
			Allegra-D	C		
			Tramadol Hydrochloride	C		

Date:05/28/99ISR Number: 3332657-0Report Type:Periodic Company Report #A0084852
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Diarrhoea	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG/TWICE						
	Escherichia Infection					
PER DAY/ORAL						
			Prempro	C		
			Ranitidine Hydrochloride	C		
			Thyroxine Sodium	C		

Date:05/28/99ISR Number: 3332660-0Report Type:Periodic Company Report #A0084853
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG/ ORAL						
	Pruritus					

Date:05/28/99ISR Number: 3332681-8Report Type:Periodic Company Report #A0084854
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Dermatitis	Health Professional	Zyban Tablet - Zyban	PS		ORAL

150 MG/TWICE

PER DAY/ ORAL

Date:05/28/99ISR Number: 3332685-5Report Type:Periodic Company Report #A0084855
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL

Dose Duration

150 MG/TWICE

PER DAY/ORAL

Date:05/28/99ISR Number: 3332686-7Report Type:Periodic Company Report #A0084856
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Pruritus	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL

Dose Duration

150 MG/TWICE

PER DAY/ORAL 3 WK

Date:05/28/99ISR Number: 3332688-0Report Type:Periodic Company Report #A0084857
Age:55 YR Gender:Male I/FU:I

Outcome	PT
	Insomnia
	Pruritus

	Rash Pruritic Swelling Urticaria	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG/TWICE PER DAY/ORAL						

Date:05/28/99ISR Number: 3332690-9Report Type:Periodic Company Report #A0084858
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG/TWICE PER DAY/ORAL						
			Nicotine	C		

Date:05/28/99ISR Number: 3332691-0Report Type:Periodic Company Report #A0085002
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG/TWICE						
	Tachycardia					
PER DAY/ORAL						
			Ostradiol	C		

Date:05/28/99ISR Number: 3332694-6Report Type:Periodic Company Report #A0085004
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG/TWICE						
	Dry Mouth					
PER DAY/ORAL						
	Insomnia					

	Nausea					

Date:05/28/99ISR Number: 3332696-XReport Type:Periodic Company Report #A0085005
Age:32 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Disorder	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/TWICE PER DAY/ORAL	

Date:05/28/99ISR Number: 3332698-3Report Type:Periodic Company Report #A0085006
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/TWICE PER DAY/ORAL	
	Drug Effect Decreased							
	Insomnia		Verapamil	C				

Date:05/28/99ISR Number: 3332700-9Report Type:Periodic Company Report #A0085007
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/TWICE PER DAY/ORAL	
	Rash Generalised							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332703-4Report Type:Periodic Company Report #A0085008
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/PER	
	Pruritus						DAY/ORAL	

Date:05/28/99ISR Number: 3332706-XReport Type:Periodic Company Report #A0085009
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/TWICE	
	Nausea						PER DAY/ORAL	

Date:05/28/99ISR Number: 3332707-1Report Type:Periodic Company Report #A0085010
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcoholic Hangover	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/TWICE	
	Confusional State						PER DAY/ORAL	
	Disorientation		Thyroid	C				
	Dizziness		Hormones	C				

Date:05/28/99ISR Number: 3332709-5Report Type:Periodic Company Report #A0085011
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/TWICE	
	Fungal Infection						PER DAY/ORAL	

	Pruritus		Hrt	C		

Date:05/28/99ISR Number: 3332711-3Report Type:Periodic Company Report #A0085012
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/PER
	Feeling Abnormal						DAY/ORAL
	Nausea		Prempro	C			
	Tremor		Salmetrol Xinafoate	C			

Date:05/28/99ISR Number: 3332713-7Report Type:Periodic Company Report #A0085013
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Alopecia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/TWICE PER DAY/ORAL

Date:05/28/99ISR Number: 3332714-9Report Type:Periodic Company Report #A0085014
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Neck Pain	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/PER DAY/ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3332716-2Report Type:Periodic Company Report #A0085015
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/PER	
	Overdose	Professional					DAY/ORAL	
	Pruritus		Nicotine Patch	SS		TRANSDERMAL	21 MG/PER	
	Rash Erythematous						DAY/TRANSDERM	
	Rash Papular						AL	
	Urticaria							

Date:05/28/99ISR Number: 3332721-6Report Type:Periodic Company Report #A0085016
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/TWICE	
	Pruritus	Professional					PER DAY/ORAL	
	Urticaria							

Date:05/28/99ISR Number: 3332723-XReport Type:Periodic Company Report #A0085017
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/TWICE	
							PER DAY/ORAL	

Date:05/28/99ISR Number: 3332724-1Report Type:Periodic Company Report #A0085018
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Urticaria						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333422-0Report Type:Periodic Company Report #A0082282
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Crying						TWICE PER DAY	
	Depression						/ ORAL	
	Emotional Disorder		Thyroxine Sodium	C				
	Nervousness		Nicotine	C				

Date:05/28/99ISR Number: 3333423-2Report Type:Periodic Company Report #A0082283
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333424-4Report Type:Periodic Company Report #A0082284
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Initial Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Insomnia		Omeprazole	C				
			Atorvastatin Calcium	C				
			Aspirin	C				

Date:05/28/99ISR Number: 3333425-6Report Type:Periodic Company Report #A0082285
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Nausea							
			Omeprazole	C				

Date:05/28/99ISR Number: 3333426-8Report Type:Periodic Company Report #A0082287
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Nightmare							
	Tachycardia							
	Tremor							

Date:05/28/99ISR Number: 3333427-XReport Type:Periodic Company Report #A0082288
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Muscle Spasms							
	Muscle Twitching							

Date:05/28/99ISR Number: 3333428-1Report Type:Periodic Company Report #A0082289
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chorea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Tremor							
							TWICE PER DAY	
							/ ORAL	
			Atorvastatin Calcium	C				
			Ramipril	C				
			Maxzide	C				

Date:05/28/99ISR Number: 3333429-3Report Type:Periodic Company Report #A0082290
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pain							
							TWICE PER DAY	
	Pruritus						/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333430-XReport Type:Periodic Company Report #A0082291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Priapism							
	Sexual Dysfunction							

Date:05/28/99ISR Number: 3333431-1Report Type:Periodic Company Report #A0082292
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Frusemide	C				
			Potassium Salt	C				
			Multivitamin	C				

Date:05/28/99ISR Number: 3333432-3Report Type:Periodic Company Report #A0082354
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER DAY / ORAL	
			Birth Control	C				

Date:05/28/99ISR Number: 3333433-5Report Type:Periodic Company Report #A0082368
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3333434-7Report Type:Periodic Company Report #A0082380
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	

Date:05/28/99ISR Number: 3333435-9Report Type:Periodic Company Report #A0082381
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Odour Abnormal	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Verapamil	C				
			Frusemide	C				
			Potassium Salt	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333436-0Report Type:Periodic Company Report #A0082382
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Headache						TWICE PER DAY	
	Hypersensitivity						/ ORAL	
	Pruritus							
	Rash Maculo-Papular							
	Swelling							

Date:05/28/99ISR Number: 3333437-2Report Type:Periodic Company Report #A0082383
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333438-4Report Type:Periodic Company Report #A0082384
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dyspnoea						TWICE PER DAY	
	Headache						/ ORAL	
	Insomnia							
	Night Sweats							
	Pruritus							
	Urticaria							

Date:05/28/99ISR Number: 3333439-6Report Type:Periodic Company Report #A0082385
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Pancreatic Enzyme	C				

Date:05/28/99ISR Number: 3333440-2Report Type:Periodic Company Report #A0082386
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Fatigue	Professional						
	Hypertension		Desogen	C				
	Nausea							
	Orthostatic Hypotension							
	Vision Blurred							

Date:05/28/99ISR Number: 3333441-4Report Type:Periodic Company Report #A0082387
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Tongue Disorder							

/ ORAL 10 DAY

Doxazosin Mesylate C

Date:05/28/99ISR Number: 3333442-6Report Type:Periodic Company Report #A0088471
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ UNK /	ORAL 1 WK

Date:05/28/99ISR Number: 3333443-8Report Type:Periodic Company Report #A0088496
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY / ORAL	
	Rash Erythematous							
	Skin Disorder							
	Swelling		Conjugated Estrogens	C				
	Urticaria		Alprazolam	C				

Date:05/28/99ISR Number: 3333444-XReport Type:Periodic Company Report #A0088516
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY / ORAL	
	Nausea							
	Pain							
	Palpitations		Conjugated Estrogens	C				
	Tremor		Alprazolam	C				
	Visual Disturbance		Hydroxyzine	C				

			Simvastatin	C		
			Aspirin	C		

Date:05/28/99ISR Number: 3333445-1Report Type:Periodic Company Report #A0088517
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Hyperaesthesia						PER DAY /	
	Thinking Abnormal						ORAL	

Date:05/28/99ISR Number: 3333446-3Report Type:Periodic Company Report #A0088520
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Flushing						PER DAY /	
	Insomnia						ORAL	
			Pentetrazol	C				
			Estrogen	C				
			Nabumetone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333447-5Report Type:Periodic Company Report #A0088521
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Decreased Appetite						PER DAY /	
	Dissociation						ORAL	
	Dry Mouth		Conjugated Estrogens	C				
	Dysgraphia		Folic Acid	C				
	Insomnia		Extra Strength					
	Tremor		Tylenol Pm	C				
			Cyanocobalamin	C				

Date:05/28/99ISR Number: 3333448-7Report Type:Periodic Company Report #A0088522
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Salivary Hypersecretion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY /	
							ORAL	
			Premphase	C				

Date:05/28/99ISR Number: 3333449-9Report Type:Periodic Company Report #A0088523
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Sedation						PER DAY /	
							ORAL	

Date:05/28/99ISR Number: 3333450-5Report Type:Periodic Company Report #A0088524
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Headache						PER DAY /	
							ORAL	
			Amitriptyline	C				

Date:05/28/99ISR Number: 3333451-7Report Type:Periodic Company Report #A0088525
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Disturbance In Attention						PER DAY /	
	Tremor						ORAL	
			Librium	C				
			Conjugated Estrogens	C				
			Vitamin	C				

Date:05/28/99ISR Number: 3333452-9Report Type:Periodic Company Report #A0088544
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY /	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333453-0Report Type:Periodic Company Report #A0088628
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / SEE	
	Irritability						TEXT / ORAL	

Date:05/28/99ISR Number: 3333454-2Report Type:Periodic Company Report #A0088676
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ UNK/	
	Insomnia						ORAL	

Date:05/28/99ISR Number: 3333455-4Report Type:Periodic Company Report #A0088699
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Paraesthesia						PER DAY /	
	Pruritus						ORAL	
	Urticaria		Fosinopril Sodium	C				
			Amlodipine	C				
			Simvastatin	C				

Date:05/28/99ISR Number: 3333456-6Report Type:Periodic Company Report #A0088707
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Zyban Tablet - Zyban	PS			ORAL 150 MG/ PER
	Abdominal Pain Upper						DAY / ORAL
	Anxiety						
	Disorientation						
	Nervousness						
	Tremor						

Date:05/28/99ISR Number: 3333457-8Report Type:Periodic Company Report #A0088708
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Drug Effect Decreased	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG/ TWICE
	Dry Mouth					PER DAY /
	Insomnia					ORAL
			Multivitamin	C		
			Mineral Supplements	C		
			Omega - 3 Marine Triglyceri	C		

Date:05/28/99ISR Number: 3333458-XReport Type:Periodic Company Report #A0088709
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG/ PER DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333459-1Report Type:Periodic Company Report #A0088710
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Urticaria						PER DAY /	
							ORAL	

Date:05/28/99ISR Number: 3333460-8Report Type:Periodic Company Report #A0088712
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY /	
							ORAL	
			Prempro	C				
			Aspirin	C				
			Calcium Salt	C				
			Verapamil	C				

Date:05/28/99ISR Number: 3333461-XReport Type:Periodic Company Report #A0088860
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Insomnia						PER DAY /	
							ORAL	
			Irbesartan	C				
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3333462-1Report Type:Periodic Company Report #A0089908
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Tachycardia						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333463-3Report Type:Periodic Company Report #A0089909
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Cardiovascular Disorder						DAY / ORAL	
	Dermatitis		Lisinopril	C				
	Dry Mouth							
	Hypoaesthesia							
	Insomnia							
	Keratoconjunctivitis							
	Sicca							
	Palpitations							
	Paraesthesia							
	Peripheral Coldness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333464-5Report Type:Periodic Company Report #A0089910
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Nicotine Gum	SS		ORAL		

Date:05/28/99ISR Number: 3333465-7Report Type:Periodic Company Report #A0089911
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Pruritus							
			Frusemide	C				
			Clopidogrel Bisulphate	C				
			Multivitamin	C				

Date:05/28/99ISR Number: 3333466-9Report Type:Periodic Company Report #A0089912
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Fluid Retention							
			Mefenidramium Metilsulfat	C				

Date:05/28/99ISR Number: 3333467-0Report Type:Periodic Company Report #A0089913
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333468-2Report Type:Periodic Company Report #A0089914
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
							PER DAY/ORAL	
			Verapamil Hydrochloride	C				
			Conjugated Estrogens	C				
			Pravastatin Sodium	C				

Date:05/28/99ISR Number: 3333469-4Report Type:Periodic Company Report #A0089915
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
							PER DAY/ORAL	
			Nifedipine	C				

			Oestradiol	C		
			Mefenidramium Metilsulfat	C		
			Calcium Salt	C		

Date:05/28/99ISR Number: 3333470-0Report Type:Periodic Company Report #A0089916
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ ORAL	
	Hypersensitivity							
	Pruritus		Estrogen	C				

Date:05/28/99ISR Number: 3333471-2Report Type:Periodic Company Report #A0089917
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
	Dry Mouth							
	Mental Impairment		Omeprazole	C				
	Nausea		Trazodone Hydrochloride	C				
	Tremor							

Date:05/28/99ISR Number: 3333472-4Report Type:Periodic Company Report #A0089918
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
	Pruritus							

Date:05/28/99ISR Number: 3333473-6Report Type:Periodic Company Report #A0089919
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Blood Pressure Abnormal						PER DAY/ORAL	
	Dysarthria		Atenolol	C				
	Tremor		Digoxin	C				

Date:05/28/99ISR Number: 3333474-8Report Type:Periodic Company Report #A0090065
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Face Oedema						PER DAY/ORAL	
	Tongue Oedema		Oestradiol	C				

Date:05/28/99ISR Number: 3333475-XReport Type:Periodic Company Report #A0090176
Age:53 YR Gender:Female I/FU:I

Outcome	PT
	Cough
	Dizziness
	Influenza Like Illness
	Insomnia

	Pain Personality Change Rhinorrhoea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sneezing	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
			Imipramine Hydrochloride	C			
			Nadolol	C			
			Clonazepam	C			
			Naproxen Sodium	C			
			Estrogen	C			

Date:05/28/99ISR Number: 3333476-1Report Type:Periodic Company Report #A0090177
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness Syncope	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Combivent	C			
			Triamcinolone Acetonide	C			

Date:05/28/99ISR Number: 3333477-3Report Type:Periodic Company Report #A0090178
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Metoprolol	C			
			Lisinopril	C			

				Pravastatin Sodium	C		
				Aspirin	C		
				Clopidogrel Bisulphate	C		
				Magnesium Salt	C		
				Hypericum	C		

Date:05/28/99ISR Number: 3333478-5Report Type:Periodic Company Report #A0090179
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Excitability							TWICE PER DAY
	Hyperhidrosis						/ ORAL	
			Aspirin	C				

Date:05/28/99ISR Number: 3333479-7Report Type:Periodic Company Report #A0090180
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Urgency	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pollakiuria							TWICE PER DAY
	Polyuria						/ ORAL	
	Urine Abnormality		Bcg Vaccine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333480-3Report Type:Periodic Company Report #A0090181
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet -					
	Drug Tolerance Decreased		Zyban	PS		ORAL	150 MG/	PER
	Malaise							DAY / ORAL
	Nausea							

Date:05/28/99ISR Number: 3333481-5Report Type:Periodic Company Report #A0090182
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Headache							TWICE PER DAY
								/ ORAL
			Ibuprofen	C				

Date:05/28/99ISR Number: 3333482-7Report Type:Periodic Company Report #A0090719
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Irritability							TWICE PER DAY
	Nausea							/ ORAL
	Vomiting							

Date:05/28/99ISR Number: 3333483-9Report Type:Periodic Company Report #A0090720
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/ TWICE	
	Nausea						PER DAY /	
							ORAL	
			Atorvastatin Calcium	C				

Date:05/28/99ISR Number: 3333484-0Report Type:Periodic Company Report #A0090721
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Feeling Abnormal						TWICE PER DAY	
	Hyperaesthesia						/ ORAL	
	Hypoaesthesia		Nelfinavir Mesylate	C				
			Combivir	C				

Date:05/28/99ISR Number: 3333485-2Report Type:Periodic Company Report #A0090722
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / PER	
	Dyspnoea						DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333486-4Report Type:Periodic Company Report #A0090723
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER DAY / ORAL	
			Atenolol	C				
			Atorvastatin Calcium	C				
			Vitamin E	C				
			Folic Acid	C				
			Aspirin	C				

Date:05/28/99ISR Number: 3333487-6Report Type:Periodic Company Report #A0090724
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER DAY / ORAL	
	Major Depression							
			Atenolol	C				
			Amlodipine	C				
			Pravastatin Sodium	C				
			Aspirin	C				

Date:05/28/99ISR Number: 3333488-8Report Type:Periodic Company Report #A0090725
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER	
	Dermatitis							

	Nervousness					
DAY/ ORAL						

Date:05/28/99ISR Number: 3333489-XReport Type:Periodic Company Report #A0090726
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Sleep Disorder	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG/ TWICE						
PER DAY /						
ORAL						
			Multivitamin	C		
			Cetirizine Hydrochloride	C		

Date:05/28/99ISR Number: 3333490-6Report Type:Periodic Company Report #A0090727
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG/ TIWCE						
	Headache					
PER DAY/ ORAL						
	Insomnia		Cephalexin	C		
	Neck Pain					
	Paraesthesia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333491-8Report Type:Periodic Company Report #A0090769
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/	ORAL
		Professional	Cimetidine	C				
		Company Representative						

Date:05/28/99ISR Number: 3333492-XReport Type:Periodic Company Report #A0090823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/ PER	DAY / ORAL

Date:05/28/99ISR Number: 3333493-1Report Type:Periodic Company Report #A0090824
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Headache						TWICE PER DAY	
	Nausea						/ ORAL	
	Neck Pain		Nicotine	C				
			Glibenclamide	C				

Date:05/28/99ISR Number: 3333494-3Report Type:Periodic Company Report #A0090825
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG / PER
	Headache					DAY / ORAL
			Clonazepam	C		

Date:05/28/99ISR Number: 3333495-5Report Type:Periodic Company Report #A0090826
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Flatulence	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL 150 MG /
	Insomnia					TWICE PER DAY
	Mouth Ulceration					/ ORAL

Date:05/28/99ISR Number: 3333496-7Report Type:Periodic Company Report #A0090827
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Amnesia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL 150 MG/ TWICE
	Muscle Twitching					PER DAY /
	Weight Decreased					ORAL
			Paracetamol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333497-9Report Type:Periodic Company Report #A0090828
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/ ORAL	WK
	Arthralgia	Professional						
	Insomnia							
	Lymphadenopathy							
	Myalgia							

Date:05/28/99ISR Number: 3333498-0Report Type:Periodic Company Report #A0090829
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/ TWICE	
	Insomnia						PER DAY /	
	Pruritus						ORAL	
	Rash Erythematous							
	Urticaria							

Date:05/28/99ISR Number: 3333499-2Report Type:Periodic Company Report #A0090830
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Dysgeusia						TWICE PER DAY	
	Insomnia						/ ORAL	
	Nausea							
	Paranoia							

Date:05/28/99ISR Number: 3333500-6Report Type:Periodic Company Report #A0090831
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Nausea						TWICE PER DAY	
/ ORAL								
			Glipizide	C				
			Atenolol	C				
			Diltiazem Hydrochloride	C				
			Clopidogrel Bisulphate	C				

Date:05/28/99ISR Number: 3333501-8Report Type:Periodic Company Report #A0090967
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
DAY/ ORAL								
			Nsaid	C				
			Cetirizine Hydrochloride	C				
			Claritin-D	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333502-XReport Type:Periodic Company Report #A0082388
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE PER DAY/
	Cough							
	Emotional Disorder		Multivitamin	C				
	Salivary Hypersecretion		Naproxen Sodium	C				
			Ibuprofen	C				

Date:05/28/99ISR Number: 3333503-1Report Type:Periodic Company Report #A0082389
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL

Date:05/28/99ISR Number: 3333504-3Report Type:Periodic Company Report #A0082390
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL
	Rash Erythematous						2.5	WEEKS
	Skin Exfoliation							

Date:05/28/99ISR Number: 3333505-5Report Type:Periodic Company Report #A0082391
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE PER DAY/
	Sedation							
							ORAL	

Frusemide	C	
Guanfacine Hydrochloride	C	
Imipramine Hydrochloride	C	

Date:05/28/99ISR Number: 3333506-7Report Type:Periodic Company Report #A0082392
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE PER DAY/
	Rash Generalised	Professional						
	Urticaria							

Date:05/28/99ISR Number: 3333507-9Report Type:Periodic Company Report #A0082393
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE PER DAY/

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333508-0Report Type:Periodic Company Report #A0082466
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Zyban Tablet - Zyban	PS		ORAL	150 MG/	
	Dyspnoea						SINGLE DOSE /	
	Heart Rate Increased						ORAL	
	Vision Blurred							

Date:05/28/99ISR Number: 3333509-2Report Type:Periodic Company Report #A0082469
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban Tablet -Zyban	PS	Zyban	ORAL	150 MG/ TWICE	
	Nervousness						PER DAY/ ORAL	
			Nicotine	C				

Date:05/28/99ISR Number: 3333510-9Report Type:Periodic Company Report #A0082470
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/ TWICE	
	Chest Pain						PER DAY/ ORAL	6 DAY
	Dry Mouth							
	Headache							
	Malaise							
	Nervousness							
	Sedation							

Date:05/28/99ISR Number: 3333511-0Report Type:Periodic Company Report #A0082496
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	1 WK

Date:05/28/99ISR Number: 3333512-2Report Type:Periodic Company Report #A0082497
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Chest Pain	Professional					PER DAY/	ORAL
	Headache							
	Nausea							

Date:05/28/99ISR Number: 3333513-4Report Type:Periodic Company Report #A0082498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL

Date:05/28/99ISR Number: 3333514-6Report Type:Periodic Company Report #A0082499
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL 2 DAY
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333515-8Report Type:Periodic Company Report #A0082500
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Face Oedema						PER DAY/ ORAL	
			Clonidine	C				
			Spironolactone	C				
			Multivitamin	C				
			Aspirin	C				

Date:05/28/99ISR Number: 3333516-XReport Type:Periodic Company Report #A0082501
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	
	Dizziness						SINGLE DOSE/	
	Dry Mouth						ORAL	
	Headache							
	Insomnia							
	Vision Blurred							

Date:05/28/99ISR Number: 3333517-1Report Type:Periodic Company Report #A0082502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150MG/ORAL	3 WK
		Professional						

Date:05/28/99ISR Number: 3333518-3Report Type:Periodic Company Report #A0082503
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	PER DAY/ORAL
			Doxepin Hydrochloride	C				
			Zestorectic	C				
			Nicotine	C				

Date:05/28/99ISR Number: 3333519-5Report Type:Periodic Company Report #A0082504
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	PER DAY/ORAL

Date:05/28/99ISR Number: 3333520-1Report Type:Periodic Company Report #A0082505
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	PER DAY/ORAL
	Oedema							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333521-3Report Type:Periodic Company Report #A0082506
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:05/28/99ISR Number: 3333522-5Report Type:Periodic Company Report #A0081652
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Disturbance In Attention Fatigue Irritability	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / ORAL	5 DAY

Date:05/28/99ISR Number: 3333523-7Report Type:Periodic Company Report #A0081653
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3333524-9Report Type:Periodic Company Report #A0081660
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	

	Eructation	Professional				
TWICE PER DAY						
	Nausea					
/ ORAL						
			Loratadine	C		
			Oxaprozin	C		

Date:05/28/99ISR Number: 3333525-0Report Type:Periodic Company Report #A0081661
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
TWICE PER DAY								
/ ORAL								

Date:05/28/99ISR Number: 3333526-2Report Type:Periodic Company Report #A0081865
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Insomnia							
TWICE PER DAY								
	Tremor							
/ ORAL								
			Wellbutrin Tablet - Controlled Release	SS		ORAL		
ORAL								
			Trazodone Hydrochloride	C				
			Thyroid Medication	C				
			Antibiotics	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333527-4Report Type:Periodic Company Report #A0081880
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / PER	
	Cough						DAY / ORAL	
	Depression		Wellbutrin Tablet -					
	Dry Mouth		Controlled Release	SS		ORAL	150 MG /	
	Flushing						TWICE PER DAY	
	Mouth Ulceration						/ ORAL	
	Nervousness		Conjugated Estrogens	C				
	Pain		Flunisolide	C				
	Pain In Extremity		Ipratropium Bromide	C				
			Ipratropium Bromide	C				
			Alendronate Sodium	C				

Date:05/28/99ISR Number: 3333528-6Report Type:Periodic Company Report #A0081921
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Hypertension	Professional					TWICE PER DAY	
	Insomnia						/ ORAL	
			Nicotine Patch	SS				
			Omeprazole	C				
			Thyroxine Sodium	C				

Date:05/28/99ISR Number: 3333529-8Report Type:Periodic Company Report #A0082007
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Diabetes Mellitus	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG / PER						
	Hypoglycaemia	Professional				
DAY / ORAL						
			Trandolapril	C		
			Insulin	C		
			Salbutamol Sulphate	C		
			Beclomethasone Dipropion	C		

Date:05/28/99ISR Number: 3333530-4Report Type:Periodic Company Report #A0082008
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						
			Birth Control	C		

Date:05/28/99ISR Number: 3333531-6Report Type:Periodic Company Report #A0082009
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Glossodynia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						
			Clarithromycin	C		
			Combivent	C		
			Omeprazole	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333532-8Report Type:Periodic Company Report #A0082010
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3333553-5Report Type:Periodic Company Report #A0082011
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3333554-7Report Type:Periodic Company Report #A0082012
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / ORAL	2 WK
	Food Allergy Urticaria	Professional Company Representative						

Date:05/28/99ISR Number: 3333555-9Report Type:Periodic Company Report #A0082013
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	

Muscle Spasms
TWICE PER DAY

/ ORAL

Clonidine C
Hydrochlorothiazide C

Date:05/28/99ISR Number: 3333556-0Report Type:Periodic Company Report #A0082014
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Nervousness							

TWICE PER DAY

/ ORAL

Conjugated Estrogens C
Omeprazole C

Date:05/28/99ISR Number: 3333557-2Report Type:Periodic Company Report #A0082015
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / PER	
	Nervousness							

DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333559-6Report Type:Periodic Company Report #A0082016
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / PER	
	Keratoconjunctivitis						DAY / ORAL	
	Sicca							
	Nervousness							
	Tachycardia							
	Tremor							

Date:05/28/99ISR Number: 3333560-2Report Type:Periodic Company Report #A0082018
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Hypertriglyceridaemia						TWICE PER DAY	
	Liver Function Test						/ ORAL	
	Abnormal							

Date:05/28/99ISR Number: 3333562-6Report Type:Periodic Company Report #A0082019
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333563-8Report Type:Periodic Company Report #A0082020
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:05/28/99ISR Number: 3333564-XReport Type:Periodic Company Report #A0070207
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
	Gastrooesophageal Reflux Disease							
	Insomnia							
	Pruritus							

Date:05/28/99ISR Number: 3333566-3Report Type:Periodic Company Report #A0077455
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Bronchospasm							
	Dermatitis		Wellbutrin Tablet - Controlled Release	SS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Face Oedema							
	Pyrexia							
	Urticaria							
			Paracetamol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333567-5Report Type:Periodic Company Report #A0080328
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Syncope						TWICE PER DAY	
							/ ORAL	
			Amisulpride	C				
			Fluticasone Propionate	C				
			Birth Control	C				

Date:05/28/99ISR Number: 3333568-7Report Type:Periodic Company Report #A0080869
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
	Drug Ineffective						/ ORAL	
	Major Depression							
	Suicidal Ideation							
	Weight Increased							

Date:05/28/99ISR Number: 3333570-5Report Type:Periodic Company Report #A0081514
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Tinnitus	Professional					TWICE PER DAY	
	Tympanic Membrane Disorder						/ ORAL	
			Minocycline	C				
			Ciprofloxacin Hcl	C				
			Antibiotics	C				

Date:05/28/99ISR Number: 3333571-7Report Type:Periodic Company Report #A0081515
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Metrorrhagia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
			Birth Control	C				

Date:05/28/99ISR Number: 3333573-0Report Type:Periodic Company Report #A0081517
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
	Depressed Mood							
	Emotional Disorder							
	Feeling Abnormal		Birth Control	C				
	Major Depression							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333574-2Report Type:Periodic Company Report #A0081518
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Agitation						TWICE PER DAY	
	Drug Ineffective						/ ORAL	
	Insomnia		Prempro	C				
	Irritability							

Date:05/28/99ISR Number: 3333576-6Report Type:Periodic Company Report #A0081519
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Metrorrhagia						TWICE PER DAY	
	Night Sweats						/ ORAL	1 WK
	Panic Disorder		Prempro	C				
			Diazepam	C				

Date:05/28/99ISR Number: 3333577-8Report Type:Periodic Company Report #A0081520
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dermatitis						TWICE PER DAY	
	Insomnia						/ ORAL	

Date:05/28/99ISR Number: 3333579-1Report Type:Periodic Company Report #A0081595
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
	Depression						/ ORAL	9 DAY
	Insomnia							
	Nausea							

Date:05/28/99ISR Number: 3333581-XReport Type:Periodic Company Report #A0081635
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Tolazamide	C				
			Cimetidine	C				
			Potassium Salt	C				

Date:05/28/99ISR Number: 3333583-3Report Type:Periodic Company Report #A0081637
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Psychomotor Hyperactivity							
			Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333584-5Report Type:Periodic Company Report #A0081638
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Headache						TWICE PER DAY	
	Oedema Peripheral						/ ORAL	
	Pruritus		Hormones	C				
	Skin Test Positive		Claritin-D	C				
	Tongue Oedema							
	Urticaria							

Date:05/28/99ISR Number: 3333586-9Report Type:Periodic Company Report #A0081639
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333588-2Report Type:Periodic Company Report #A0081640
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
							/ ORAL	6 WK

Date:05/28/99ISR Number: 3333589-4Report Type:Periodic Company Report #A0081648
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dizziness	Professional					TWICE PER DAY	
	Nervousness						/ ORAL	
	Tachycardia		Quinine	C				
			Blood Pressure Medication	C				
			Prednisone	C				
			Diclofenac Sodium	C				
			Hydrochlorothiazide	C				

Date:05/28/99ISR Number: 3333591-2Report Type:Periodic Company Report #A0081649
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
							/ ORAL	3 WK

Date:05/28/99ISR Number: 3333593-6Report Type:Periodic Company Report #A0081650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
	Nightmare						/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333594-8Report Type:Periodic Company Report #A0081651
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Discomfort						TWICE PER DAY	
	Ill-Defined Disorder						/ ORAL	
	Insomnia							
	Vomiting							

Date:05/28/99ISR Number: 3333596-1Report Type:Periodic Company Report #A0082101
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Chest Pain						TWICE PER DAY	
	Dyspnoea						/ ORAL	
	Tachycardia							
	Tremor							

Date:05/28/99ISR Number: 3333597-3Report Type:Periodic Company Report #A0082103
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet -					
	Dysphagia		Zyban	PS		ORAL	150 MG /	
	Face Oedema						TWICE PER DAY	
	Tachycardia						/ ORAL	
	Throat Tightness							
	Urticaria							

Date:05/28/99ISR Number: 3333599-7Report Type:Periodic Company Report #A0082108
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Oxaprozin	C				
			Centrum	C				

Date:05/28/99ISR Number: 3333601-2Report Type:Periodic Company Report #A0082158
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Food Allergy Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Atorvastatin Calcium	C				
			M.V. I	C				
			Torasemide	C				
			Metoprolol Succinate	C				
			Irbesartan	C				
			...	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333602-4Report Type:Periodic Company Report #A0082264
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Apathy	Consumer	Zyban Tablet	-				
	Depression		Zyban	PS		ORAL	150 MG /	
	Nausea						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333603-6Report Type:Periodic Company Report #A0082265
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excitability	Health	Zyban Tablet	-				
	Insomnia	Professional	Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Ibuprofen	C				

Date:05/28/99ISR Number: 3333604-8Report Type:Periodic Company Report #A0082266
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban Tablet	-				
			Zyban	PS		ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3333606-1Report Type:Periodic Company Report #A0082268
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL

150 MG /

TWICE PER DAY

/ ORAL

Atenolol	C
Lisinopril	C
Salbutamol Sulphate	C

Date:05/28/99ISR Number: 3333607-3Report Type:Periodic Company Report #A0082269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Rash Generalised Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Thyroxine Sodium	C

Date:05/28/99ISR Number: 3333608-5Report Type:Periodic Company Report #A0082270
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333610-3Report Type:Periodic Company Report #A0082271
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Disorder	Consumer	Zyban Tablet -					
	Muscle Twitching		Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Nutritional Supplement	C				

Date:05/28/99ISR Number: 3333611-5Report Type:Periodic Company Report #A0082273
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet -					
	Anxiety		Zyban	PS		ORAL	150 MG /	
	Cystitis						TWICE PER DAY	
	Dizziness						/ ORAL	
			Atenolol	C				
			Quinapril Hydrochloride	C				
			Prempro	C				
			Thyroxine Sodium	C				
			Clopidogrel Bisulphate	C				
			Fluvastatin Sodium	C				
			Aspirin	C				

Date:05/28/99ISR Number: 3333613-9Report Type:Periodic Company Report #A0082274
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban Tablet -					

	Pruritus		Zyban	PS		ORAL
150 MG /						
	Urticaria					
TWICE PER DAY						
/ ORAL						

Date:05/28/99ISR Number: 3333615-2Report Type:Periodic Company Report #A0082275
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chills	Health	Zyban Tablet -			
	Sensation Of Heaviness	Professional	Zyban	PS		ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						

Date:05/28/99ISR Number: 3333616-4Report Type:Periodic Company Report #A0082276
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cold Sweat	Consumer	Zyban Tablet -			
	Nightmare		Zyban	PS		ORAL
1.5 TABLET /						
THREE TIMES						
PE ORAL						
			Diclofenac	C		
			Codeine	C		
			Nicotine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333617-6Report Type:Periodic Company Report #A0082277
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet -					
	Fatigue		Zyban	PS		ORAL	150 MG /	
	Irritability						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333619-XReport Type:Periodic Company Report #A0082278
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet -					
	Anxiety		Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333620-6Report Type:Periodic Company Report #A0082279
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet -					
	Anxiety		Zyban	PS		ORAL	150 MG /	
	Condition Aggravated						TWICE PER DAY	
	Confusional State						/ ORAL	
	Disorientation		Ibuprofen	C				
	Migraine		Paracetamol	C				
	Smoker							

Date:05/28/99ISR Number: 3333622-XReport Type:Periodic Company Report #A0082280
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL

Date:05/28/99ISR Number: 3333623-1Report Type:Periodic Company Report #A0082281
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Insomnia							
	Pruritus							

Date:05/28/99ISR Number: 3333689-9Report Type:Periodic Company Report #A0083898
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333692-9Report Type:Periodic Company Report #A0083919
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Disorientation						TWICE PER DAY	
	Dyspnoea						/ ORAL	
	Euphoric Mood							
	Hypoaesthesia							
	Panic Disorder							

Date:05/28/99ISR Number: 3333693-0Report Type:Periodic Company Report #A0083922
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Pruritus	Professional					DAY / ORAL	

Date:05/28/99ISR Number: 3333694-2Report Type:Periodic Company Report #A0083923
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Back Pain						DAY / ORAL	
	Headache		Percocet	C				
			Ranitidine Hydrochloride	C				

Date:05/28/99ISR Number: 3333697-8Report Type:Periodic Company Report #A0083925
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
/ ORAL								

Date:05/28/99ISR Number: 3333699-1Report Type:Periodic Company Report #A0083927
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Zyban Tablet -Zyban	PS		ORAL	150 MG /	
	Cough						TWICE PER DAY	
	Drug Dependence							
/ ORAL							4	WK
	Dry Mouth		Metoprolol Tartate	C				
	Headache		Clorazepate					
	Insomnia		Dipotassium	C				
	Nervousness		Indapamide	C				

Date:05/28/99ISR Number: 3333700-5Report Type:Periodic Company Report #A0083977
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Palpitations						TWICE PER DAY	
/ ORAL								
			Glipizide	C				
			Loratadine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333701-7Report Type:Periodic Company Report #A0083980
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
		Professional	Omeprazole	C				
			Multivitamin	C				
			Aspirin	C				

Date:05/28/99ISR Number: 3333703-0Report Type:Periodic Company Report #A0084028
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban Tablet - Zyban	PS		ORAL	3 TABLETS / UNK / ORAL	
	Dyspnoea	Professional						
	Urticaria							

Date:05/28/99ISR Number: 3333704-2Report Type:Periodic Company Report #A0084043
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Formication	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	

Date:05/28/99ISR Number: 3333705-4Report Type:Periodic Company Report #A0084044
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Irritability	Consumer	Zyban Tablet - Zyban	PS		ORAL

150 MG / PER

DAY / ORAL

Date:05/28/99ISR Number: 3333707-8Report Type:Periodic Company Report #A0084418
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Chest Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL
	Dyspnoea					
	Feeling Drunk					
	Flushing					

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

Date:05/28/99ISR Number: 3333710-8Report Type:Periodic Company Report #A0084632
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	White Blood Cell Count	Health	Zyban Tablet - Zyban	PS		ORAL
	Decreased	Professional				
		Company Representative	Fluvastatin Sodium	C		

Dose Duration

UNK / UNK /

ORAL 9 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333712-1Report Type:Periodic Company Report #A0084702
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dyspnoea						TWICE PER DAY	
	Face Oedema						/ ORAL	
	Hypersensitivity		Ibuprofen	C				
	Tremor							
	Urticaria							

Date:05/28/99ISR Number: 3333715-7Report Type:Periodic Company Report #A0084800
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Cimetidine	C				

Date:05/28/99ISR Number: 3333716-9Report Type:Periodic Company Report #A0084823
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dermatitis						TWICE PER DAY	
	Dyspnoea						/ ORAL	
	Pruritus		Valaciclovir	C				
	Urticaria							

Date:05/28/99ISR Number: 3333718-2Report Type:Periodic Company Report #A0084825
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Tenderness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Dry Mouth						DAY / ORAL	

Date:05/28/99ISR Number: 3333745-5Report Type:Periodic Company Report #A0084828
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Oedema Peripheral						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333746-7Report Type:Periodic Company Report #A0084829
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hypersensitivity						TWICE PER DAY	
							/ ORAL	
			Birth Control	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333748-0Report Type:Periodic Company Report #A0084831
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / UNK	
	Erythema	Health					/ ORAL	
	Pain	Professional	Nicotine Patch	SS			UNK / UNK /	
	Pruritus	Other					UNK	
	Swelling							

Date:05/28/99ISR Number: 3333753-4Report Type:Periodic Company Report #A0085267
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	ORAL	

Date:05/28/99ISR Number: 3333755-8Report Type:Periodic Company Report #A0085328
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
							DAY / ORAL	

Date:05/28/99ISR Number: 3333759-5Report Type:Periodic Company Report #A0085329
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Dyspnoea							

	Insomnia					
	Pharyngeal Oedema					
	Pruritus					

Date:05/28/99ISR Number: 3333762-5Report Type:Periodic Company Report #A0085330
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Halitosis						TWICE PER DAY	
							/ ORAL	
			Atorvastatin Calcium	C				

Date:05/28/99ISR Number: 3333765-0Report Type:Periodic Company Report #A0085331
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Naproxen	C				
			Glipizide	C				
			Hydrocodone + Paracetamol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333767-4Report Type:Periodic Company Report #A0085332
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Nausea						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3333769-8Report Type:Periodic Company Report #A0085333
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Swelling						TWICE PER DAY	
	Urticaria						/ ORAL	

Date:05/28/99ISR Number: 3333771-6Report Type:Periodic Company Report #A0085335
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bipolar I Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Psychotic Disorder							

Date:05/28/99ISR Number: 3333775-3Report Type:Periodic Company Report #A0085336
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	

	Herpes Simplex	Professional				
TWICE PER DAY						
	Pruritus					
/ ORAL						
	Urticaria					

Date:05/28/99ISR Number: 3333777-7Report Type:Periodic Company Report #A0085337
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Influenza Like Illness					
TWICE PER DAY						
	Insomnia					
/ ORAL						
	Lethargy		Cold Medication	C		
	Pruritus		M.V.I	C		

Date:05/28/99ISR Number: 3333779-0Report Type:Periodic Company Report #A0085338
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Convulsion	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Dizziness					
TWICE PER DAY						
	Syncope					
/ ORAL						
			Insulin	C		
			Thyroxine Sodium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333781-9Report Type:Periodic Company Report #A0085339
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Paraesthesia						TWICE PER DAY	
							/ ORAL	
			Coffee (Formulation Unknown)	SS		ORAL	ORAL	
			Buspirone Hydrochloride	C				

Date:05/28/99ISR Number: 3333783-2Report Type:Periodic Company Report #A0085340
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Estrogen	C				
			Thyroxine Sodium	C				
			Esgic	C				

Date:05/28/99ISR Number: 3333785-6Report Type:Periodic Company Report #A0085341
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
			Fluoxetine Hydrochloride	C				

Date:05/28/99ISR Number: 3333788-1Report Type:Periodic Company Report #A0085342
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	DAY / ORAL
			Glucophage	C				
			Simvastatin	C				
			Famotidine	C				
			Conjugated Estrogens	C				
			Fluticasone Propionate	C				
			Salbutamol Sulphate	C				
			Ipratropium Bromide	C				

Date:05/28/99ISR Number: 3333790-XReport Type:Periodic Company Report #A0085343
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia	Professional					TWICE PER DAY	
							/ ORAL	
			Alendronate Sodium	C				
			Conjugated Estrogens	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333794-7Report Type:Periodic Company Report #A0085344
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL; DURATION: ?? WEEKS	

Date:05/28/99ISR Number: 3333797-2Report Type:Periodic Company Report #A0085345
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Difficulty In Walking							
	Hypersensitivity							
	Inflammation							
	Oedema Peripheral							
	Pain							
	Pruritus							
	Rash Erythematous							
	Urticaria							

Date:05/28/99ISR Number: 3333800-XReport Type:Periodic Company Report #A0085373
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Discomfort							
	Feeling Hot	Company Representative	Amlodipine	C				
	Oedema Peripheral		Hydrochlorothiazide	C				

	Pain		Metoprolol Tartrate	C		
	Paraesthesia					
	Rash Erythematous					

Date:05/28/99ISR Number: 3333801-1Report Type:Periodic Company Report #A0085554
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	ORAL

Date:05/28/99ISR Number: 3333803-5Report Type:Periodic Company Report #A0085657
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER	DAY/ORAL

Date:05/28/99ISR Number: 3333806-0Report Type:Periodic Company Report #A0085658
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER	DAY/ORAL
			Estrogen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333808-4Report Type:Periodic Company Report #A0085659
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER
	Chest Pain						DAY/ORAL

Date:05/28/99ISR Number: 3333811-4Report Type:Periodic Company Report #A0085660
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Headache	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER
	Nausea						DAY/ORAL
			Prempro	C			

Date:05/28/99ISR Number: 3333813-8Report Type:Periodic Company Report #A0085661
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gingival Bleeding	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE
							PER DAY/ORAL
			Nicotine	C			

Date:05/28/99ISR Number: 3333815-1Report Type:Periodic Company Report #A0085662
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gingival Bleeding	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE
							PER DAY/ORAL

Date:05/28/99ISR Number: 3333817-5Report Type:Periodic Company Report #A0085663
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:05/28/99ISR Number: 3333818-7Report Type:Periodic Company Report #A0085664
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
	Emotional Disorder							

Date:05/28/99ISR Number: 3333824-2Report Type:Periodic Company Report #A0085665
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
	Lip Dry	Professional						
	Urticaria		Librax	C				
			Herbal Medication	C				
			Famciclovir	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333826-6Report Type:Periodic Company Report #A0085666
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Hypersensitivity	Professional					PER DAY/ORAL	
	Rash Generalised		Vitamin	C				

Date:05/28/99ISR Number: 3333827-8Report Type:Periodic Company Report #A0085667
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG/PER	
	Muscle Twitching	Professional					DAY/ORAL	
			Prempro	C				
			Atorvastatin Calcium	C				
			Verapamil Hydrochloride	C				

Date:05/28/99ISR Number: 3333832-1Report Type:Periodic Company Report #A0085668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	
			Guaiphenesin (Formulation Unknown)	SS				
			Guaifenesin Dm (Formulation Unknown)	SS				

Date:05/28/99ISR Number: 3333834-5Report Type:Periodic Company Report #A0085669
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	
	Dizziness							
	Malaise							
	Nausea							
	Vomiting							

Date:05/28/99ISR Number: 3333837-0Report Type:Periodic Company Report #A0085670
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ORAL	

Date:05/28/99ISR Number: 3333839-4Report Type:Periodic Company Report #A0085671
Age:51 YR Gender:Female I/FU:I

Outcome	PT
	Arthralgia
	Dermatitis
	Dysgeusia
	Face Oedema
	Myalgia
	Oral Candidiasis

	Swelling					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/TWICE PER DAY/ORAL						
			Thyroxine Sodium	C		

Date:05/28/99ISR Number: 3333842-4Report Type:Periodic Company Report #A0085672
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Feeling Abnormal	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/ORAL						
	Hypoaesthesia		Birth Control	C		
	Paranoia					

Date:05/28/99ISR Number: 3333843-6Report Type:Periodic Company Report #A0085674
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Disorientation	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/PER DAY/ORAL						
	Dizziness					
	Dry Mouth					
	Headache					
	Paraesthesia					
	Tremor					
	Vomiting					

Date:05/28/99ISR Number: 3333846-1Report Type:Periodic Company Report #A0085675
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Abdominal Pain	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/TWICE						
	Headache					
PER DAY/ORAL						
			Ascorbic Acid	C		

Date:05/28/99ISR Number: 3333848-5Report Type:Periodic Company Report #A0085676
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/TWICE						
PER DAY/ORAL						
			Lorazepam	C		
			Mirtazapine	C		
			Montelukast Sodium	C		
			Glibenclamide	C		
			Simvastatin	C		
			Verapamil Hydrochloride	C		
			Prednisone	C		
			Salbutamol Sulphate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333851-5Report Type:Periodic Company Report #A0085677
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
	Parosmia						PER DAY/ORAL	
			Antibiotics	C				

Date:05/28/99ISR Number: 3333962-4Report Type:Periodic Company Report #A0087976
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	
	Constipation						PER DAY/ ORAL	
	Crying		Alendronate Sodium	C				
	Headache		Alprazolam	C				
	Therapeutic Response		Prednisone	C				
	Unexpected		Unknown	C				

Date:05/28/99ISR Number: 3333978-8Report Type:Periodic Company Report #A0087977
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG/ TWICE	
	Fatigue						PER DAY/ ORAL	
	Insomnia							
	Nausea							
	Tachycardia							

Date:05/28/99ISR Number: 3333980-6Report Type:Periodic Company Report #A0087978
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	
	Insomnia						PER DAY/ ORAL	
	Micturition Urgency		Loratadine	C				
	Pollakiuria		Fluticasone Propionate	C				
			Ipratropium Bromide	C				

Date:05/28/99ISR Number: 3333983-1Report Type:Periodic Company Report #A0087979
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	

Date:05/28/99ISR Number: 3333985-5Report Type:Periodic Company Report #A0087980
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	
	Dry Mouth						PER DAY/ ORAL	
	Insomnia		Conj. Estrogen + Medroxyprog	C				
	Nausea		Paracetamol	C				
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3333987-9Report Type:Periodic Company Report #A0087981
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Health Professional	Zyban Tablet-Zyban	PS		ORAL	150 MG/ PER DAY/	ORAL
			Temazepam	C				

Date:05/28/99ISR Number: 3333991-0Report Type:Periodic Company Report #A0087982
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
	Hypoaesthesia Oral							

Date:05/28/99ISR Number: 3334043-6Report Type:Periodic Company Report #A0087983
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Zyban Tablet- Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
	Dysarthria							
	Hypotension		Atenolol	C				
	Sedation		Digoxin	C				
	Tremor							

Date:05/28/99ISR Number: 3334046-1Report Type:Periodic Company Report #A0087984
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	

PER DAY/ ORAL

Date:05/28/99ISR Number: 3334048-5Report Type:Periodic Company Report #A0087985
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	
	Glossodynia						PER DAY/ ORAL	
	Mouth Ulceration		Conjugated Estrogens	C				
			Ibuprofen	C				
			Nicotine Polacrilex	C				

Date:05/28/99ISR Number: 3334051-5Report Type:Periodic Company Report #A0087986
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	
	Pruritus						PER DAY/ ORAL	

Date:05/28/99ISR Number: 3334053-9Report Type:Periodic Company Report #A0087987
Age:40 YR Gender:Female I/FU:I

Outcome	PT
	Dermatitis
	Face Oedema
	Pain

	Pruritus					
	Rash Erythematous					
	Urticaria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/ PER						
DAY/ ORAL						
			Atenolol	C		
			Tyleno No. 3	C		
			Opium	C		

Date:05/28/99ISR Number: 3334070-9Report Type:Periodic Company Report #A0087988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Affective Disorder	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/ ORAL						

Date:05/28/99ISR Number: 3334073-4Report Type:Periodic Company Report #A0087989
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Depression	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/ TWICE						
PER DAY/ ORAL						

Date:05/28/99ISR Number: 3334076-XReport Type:Periodic Company Report #A0087990
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Confusional State	Consumer	Zyban Tablet-Zyban	PS		ORAL
150 MG/ TWICE						
	Dizziness					
PER DAY/ ORAL						
			Thyroxine Sodium	C		
			Ranitidine			

			Hydrochloride	C		
			Prempro	C		
			Esgic-Plus	C		

Date:05/28/99ISR Number: 3334077-1Report Type:Periodic Company Report #A0087991
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ TWICE	
	Crying						PER DAY/ ORAL	
	Headache		Wellbutrin					
	Malaise		Tablet-Controlled					
	Nausea		Release	SS		ORAL	150 MG/ TWICE	
	Nervousness						PER DAY/ ORAL	
	Sedation		Demulen	C				

Date:05/28/99ISR Number: 3334080-1Report Type:Periodic Company Report #A0087992
Age:41 YR Gender:Male I/FU:I

Outcome	PT
	Abnormal Dreams
	Aggression
	Depression
	Diarrhoea
	Dysgeusia
	Fatigue

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Libido Decreased Parosmia	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/ PER DAY/	ORAL

Date:05/28/99ISR Number: 3334084-9Report Type:Periodic Company Report #A0087993
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphemia Dyspnoea Hypoglycaemia Muscle Twitching Vision Blurred	Consumer	Zyban Tablet- Zyban Tylenol No. 3 Loratadine Temazepam Famotidine Diphenoxylate Ranitidine Hydrochloride	PS C C C C C C		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:05/28/99ISR Number: 3334087-4Report Type:Periodic Company Report #A0087994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Nervousness Stomach Discomfort	Consumer	Zyban Tablet-Zyban Salbutamol Sulphate	PS C		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:05/28/99ISR Number: 3334088-6Report Type:Periodic Company Report #A0087995
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Furuncle	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG/ TWICE	
	Pain						PER DAY/ ORAL	7 DAY
	Swelling							
	Urticaria							

Date:05/28/99ISR Number: 3334133-8Report Type:Periodic Company Report #A0090968
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus						TWICE PER DAY	
	Urticaria						/ ORAL	
			Nicotine	C				
			Isoniazid	C				

Date:05/28/99ISR Number: 3334137-5Report Type:Periodic Company Report #A0090974
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Dermatitis							
	Dizziness							
	Headache							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334139-9Report Type:Periodic Company Report #A0090976
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	1 MON
	Tobacco Abuse	Professional						
	Weight Increased							

Date:05/28/99ISR Number: 3334141-7Report Type:Periodic Company Report #A0090977
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Amlodipine	C				

Date:05/28/99ISR Number: 3334143-0Report Type:Periodic Company Report #A0090978
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Pruritus							
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3334145-4Report Type:Periodic Company Report #A0090979
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Amnesia	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG / PER
	Disturbance In Attention					DAY / ORAL
	Tremor					

Date:05/28/99ISR Number: 3334147-8Report Type:Periodic Company Report #A0090980
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG /
	Nausea					TWICE PER DAY
	Tachycardia					/ ORAL

Date:05/28/99ISR Number: 3334152-1Report Type:Periodic Company Report #A0091163
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Rash Generalised	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG /
	Urticaria					TWICE PER DAY
						/ ORAL

Date:05/28/99ISR Number: 3334153-3Report Type:Periodic Company Report #A0091167
Age:68 YR Gender:Female I/FU:I

Outcome	PT
	Dermatitis Bullous
	Oedema Peripheral

	Pruritus					
	Rash Erythematous					
	Rash Macular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Skin Nodule	Health	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Urticaria	Professional				
TWICE PER DAY						
/ ORAL						
			Prempro	C		
			Amlodipine	C		

Date:05/28/99ISR Number: 3334156-9Report Type:Periodic Company Report #A0091168
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Decreased Appetite					
TWICE PER DAY						
	Dry Mouth					
/ ORAL						
	Insomnia		Naproxen Sodium	C		
	Therapeutic Response					
	Unexpected					

Date:05/28/99ISR Number: 3334157-0Report Type:Periodic Company Report #A0091169
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Flatulence					
TWICE PER DAY						

/ ORAL;

DURATION :

WEEKS

Date:05/28/99ISR Number: 3334158-2Report Type:Periodic Company Report #A0091170
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Lower	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Back Pain						TWICE PER DAY	
	Pollakiuria						/ ORAL	
			Antibiotics	C				

Date:05/28/99ISR Number: 3334160-0Report Type:Periodic Company Report #A0091171
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Birth Control	C				

Date:05/28/99ISR Number: 3334163-6Report Type:Periodic Company Report #A0091172
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pain In Extremity						TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334164-8Report Type:Periodic Company Report #A0091173
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Diarrhoea						DAY / ORAL	
	Headache							
	Pain							
	Pain In Extremity							

Date:05/28/99ISR Number: 3334307-6Report Type:Periodic Company Report #A0091176
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Eye Irritation						TWICE PER DAY	
	Insomnia						/ ORAL	
	Urticaria		Prempro	C				

Date:05/28/99ISR Number: 3334308-8Report Type:Periodic Company Report #A0091178
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Balance Disorder						DAY / ORAL	
	Dry Mouth		Alprazolam	C				
	Nausea		Zovia	C				
	Tremor							
	Visual Disturbance							

Date:05/28/99ISR Number: 3334309-XReport Type:Periodic Company Report #A0091180
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3334310-6Report Type:Periodic Company Report #A0091181
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Malaise						DAY / ORAL	
			Birth Control	C				

Date:05/28/99ISR Number: 3334311-8Report Type:Periodic Company Report #A0091182
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Arthritis	Professional						
	Myalgia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334790-6Report Type:Periodic Company Report #A0090409
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Urticaria						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3334791-8Report Type:Periodic Company Report #A0090577
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
		Professional						
		Company						
		Representative						

Date:05/28/99ISR Number: 3334792-XReport Type:Periodic Company Report #A0090683
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Coordination Abnormal						TWICE PER DAY	
	Disorientation						/ ORAL	
	Dizziness							
	Headache							
	Speech Disorder							

Date:05/28/99ISR Number: 3334794-3Report Type:Periodic Company Report #A0090701
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Headache							

Date:05/28/99ISR Number: 3334795-5Report Type:Periodic Company Report #A0090702
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
			Iron Supplements	C				

Date:05/28/99ISR Number: 3334797-9Report Type:Periodic Company Report #A0090703
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Atenolol	C				
			Propafenone Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334798-0Report Type:Periodic Company Report #A0090704
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dermatitis						TWICE PER DAY	
	Hypersensitivity						/ ORAL	
	Oedema Peripheral		Quinapril Hydrochloride	C				
	Pain		Amlodipine	C				
	Urticaria		Loratadine	C				
			Metoprolol Succinate	C				

Date:05/28/99ISR Number: 3334799-2Report Type:Periodic Company Report #A0090705
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Apathy	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Decreased Appetite						TWICE PER DAY	
	Dizziness						/ ORAL	
	Hyperhidrosis		Prednisone	C				
	Nervousness		Simvastatin	C				
	Throat Tightness		Salbutamol Sulphate	C				

Date:05/28/99ISR Number: 3334801-8Report Type:Periodic Company Report #A0090706
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dry Mouth						TWICE PER DAY	
	Oedema Peripheral						/ ORAL	

	Pruritus		Diazepam	C		
			Conjugated Estrogens	C		
			Simvastatin	C		
			Amitriptyline Hcl	C		

Date:05/28/99ISR Number: 3334803-1Report Type:Periodic Company Report #A0090707
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3334804-3Report Type:Periodic Company Report #A0090708
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Omeprazole	C				
			Diltiazem Hydrochloride	C				
			Enalapril Maleate	C				
			Amlodipine	C				
			Metoprolol	C				
			Glipizide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334806-7Report Type:Periodic Company Report #A0090710
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
			Multivitamin	C				
			Calcium Salt	C				
			Ascorbic Acid	C				
			Vitamin E	C				

Date:05/28/99ISR Number: 3334807-9Report Type:Periodic Company Report #A0090711
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
	Dry Mouth							
	Dysgeusia							
	Headache							
	Night Sweats							
	Paraesthesia							
	Weight Decreased							

Date:05/28/99ISR Number: 3334809-2Report Type:Periodic Company Report #A0090712
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL

			Atorvastatin Calcium	C			
			Isosorbide Mononitrate	C			
			Amlodipine	C			
			Metoprolol	C			

Date:05/28/99ISR Number: 3334810-9Report Type:Periodic Company Report #A0090713
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Zafirlukast	C				
			Estrogen	C				

Date:05/28/99ISR Number: 3334812-2Report Type:Periodic Company Report #A0090714
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Ortho-Novum	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334814-6Report Type:Periodic Company Report #A0090715
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hallucination						TWICE PER DAY	
	Psychomotor Hyperactivity						/ ORAL	
	Syncope							

Date:05/28/99ISR Number: 3334815-8Report Type:Periodic Company Report #A0090716
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Tremor						DAY / ORAL	
			Terbinafine	C				

Date:05/28/99ISR Number: 3334816-XReport Type:Periodic Company Report #A0090717
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Drug Dependence							
	Insomnia							

Date:05/28/99ISR Number: 3334817-1Report Type:Periodic Company Report #A0090718
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	

Insomnia
TWICE PER

DAY/ ORAL

Date:05/28/99ISR Number: 3334818-3Report Type:Periodic Company Report #A0077079
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Mouth Ulceration	Professional						

TWICE PER DAY

/ ORAL

Date:05/28/99ISR Number: 3334819-5Report Type:Periodic Company Report #A0077145
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	

TWICE PER DAY

/ ORAL

Date:05/28/99ISR Number: 3334820-1Report Type:Periodic Company Report #A0077952
Age:38 YR Gender:Female I/FU:F

Outcome	PT
	Dysphagia
	Hyperhidrosis
	Insomnia

	Tachycardia					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
		Professional				
TWICE PER DAY						
/ ORAL						
			Hydroxyzine	C		

Date:05/28/99ISR Number: 3334821-3Report Type:Periodic Company Report #A0077953
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Crying	Health	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Depression	Professional				
TWICE PER DAY						
	Headache					
/ ORAL						

Date:05/28/99ISR Number: 3334822-5Report Type:Periodic Company Report #A0078431
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Apathy	Health	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Asthenia	Professional				
TWICE PER DAY						
	Hypoaesthesia					
/ ORAL						
	Lethargy		Ascorbic Acid	C		
	Nausea					
	Vertigo					

Date:05/28/99ISR Number: 3334824-9Report Type:Periodic Company Report #A0078434
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Paranoia	Professional					TWICE PER DAY	
	Psychotic Disorder						/ ORAL	
	Sleep Disorder		Lovastatin	C				

Date:05/28/99ISR Number: 3334826-2Report Type:Periodic Company Report #A0078822
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
		Professional					TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3334828-6Report Type:Periodic Company Report #A0078836
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Feeling Abnormal	Professional					TWICE PER DAY	
	Headache						/ ORAL	
	Hypoaesthesia		Salmeterol Xinafoate	C				
			Salbutamol Sulphate	C				
			Famotidine	C				
			Beclomethasone Dipropion	C				

.. C

Date:05/28/99ISR Number: 3334830-4Report Type:Periodic Company Report #A0079576
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hyperhidrosis	Professional					TWICE PER DAY	
	Influenza Like Illness						/ ORAL	
	Nausea		Fluoxetine					
	Serotonin Syndrome		Hydrochloride Tablet	SS		ORAL	20 MG / ORAL	
	Tachycardia		Conjugated Estrogens	C				
	Tremor							
	Vomiting							

Date:05/28/99ISR Number: 3334831-6Report Type:Periodic Company Report #A0079617
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Dizziness	Professional					DAY / ORAL	
	Dyspnoea		Birth Control	C				
	Feeling Abnormal							
	Hyperventilation							
	Nausea							
	Pruritus							
	Syncope							
	Tachycardia							
	Tremor							
	Urticaria							

Date:05/28/99ISR Number: 3334833-XReport Type:Periodic Company Report #A0080055
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Hypoglycaemia	Professional						
			Human Insulin (Formulation Unknown)	SS		SUBCUTANEOUS	AS DIRECTED /	SUBCUTANEOUS
			Captopril	C				
			Frusemide	C				
			Digoxin	C				
			Isotretinoin	C				
			Warfarin Sodium	C				
			Amlodipine	C				
			Isosorbide	C				
			Int./Long-Acting Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334834-1Report Type:Periodic Company Report #A0080060
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Pruritus	Professional						

Date:05/28/99ISR Number: 3334835-3Report Type:Periodic Company Report #A0080096
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	2 WK
		Professional						

Date:05/28/99ISR Number: 3334837-7Report Type:Periodic Company Report #A0080372
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	

Date:05/28/99ISR Number: 3334839-0Report Type:Periodic Company Report #A0080700
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Dizziness	Professional						
	Headache							
	Vomiting							

Date:05/28/99ISR Number: 3334840-7Report Type:Periodic Company Report #A0080878
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgraphia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Tremor	Professional					TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3334843-2Report Type:Periodic Company Report #A0081148
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Nightmare	Professional Company Representative						

Date:05/28/99ISR Number: 3334845-6Report Type:Periodic Company Report #A0081198
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334848-1Report Type:Periodic Company Report #A0081199
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
		Professional						
		Company						
		Representative						

Date:05/28/99ISR Number: 3334851-1Report Type:Periodic Company Report #A0081332
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus	Professional					TWICE PER DAY	
	Rash Erythematous						/ ORAL	
	Urticaria		Nicotine (Formulation Unknown)	SS		TRANSDERMAL	TRANSDERMAL	

Date:05/28/99ISR Number: 3334853-5Report Type:Periodic Company Report #A0090184
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3334856-0Report Type:Periodic Company Report #A0090185
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Nervousness						TWICE PER DAY	
							/ ORAL	
			Lovastatin	C				
			Atenolol	C				

Date:05/28/99ISR Number: 3334857-2Report Type:Periodic Company Report #A0090186
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Swelling	Professional					TWICE PER DAY	
	Urticaria						/ ORAL	

Date:05/28/99ISR Number: 3334860-2Report Type:Periodic Company Report #A0090188
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334861-4Report Type:Periodic Company Report #A0090189
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hypoaesthesia						TWICE PER DAY	
							/ ORAL	
			Desogen	C				

Date:05/28/99ISR Number: 3334862-6Report Type:Periodic Company Report #A0090190
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Dizziness							

Date:05/28/99ISR Number: 3334863-8Report Type:Periodic Company Report #A0090191
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3334865-1Report Type:Periodic Company Report #A0090192
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3334867-5Report Type:Periodic Company Report #A0090193
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Psychomotor Hyperactivity						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3334869-9Report Type:Periodic Company Report #A0090194
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Famotidine	C				
			Theophylline	C				
			Conjugated Estrogens	C				
			Potassium Salt	C				
			Ramipril	C				
			Diltiazem Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334871-7Report Type:Periodic Company Report #A0090195
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Musculoskeletal Stiffness						TWICE PER DAY	
	Tremor						/ ORAL	
			Sinemet	C				
			Conjugated Estrogens	C				
			Medroxyprogesterone Ace.	C				

Date:05/28/99ISR Number: 3334874-2Report Type:Periodic Company Report #A0090196
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Alopecia						TWICE PER DAY	
							/ ORAL	
			Conjugated Estrogens	C				
			Diazepam	C				
			Entex	C				
			Fexofenadine Hydrochlorid	C				
			Acyclovir	C				

Date:05/28/99ISR Number: 3334878-XReport Type:Periodic Company Report #A0090197
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dry Mouth						TWICE PER DAY	

	Epistaxis					
/ ORAL						
	Nervousness					

Date:05/28/99ISR Number: 3334882-1Report Type:Periodic Company Report #A0090245
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Chest Pain							TWICE PER DAY
	Nervousness							/ ORAL
	Pulmonary Congestion		Terazosin Hydrochloride	C				

Date:05/28/99ISR Number: 3334884-5Report Type:Periodic Company Report #A0090329
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Asthenia							TWICE PER DAY
	Dry Mouth							/ ORAL
	Insomnia		Birth Control	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3334886-9Report Type:Periodic Company Report #A0090404
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3334887-0Report Type:Periodic Company Report #A0090405
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Dry Skin							
			Thyroxine Sodium	C				

Date:05/28/99ISR Number: 3334891-2Report Type:Periodic Company Report #A0090406
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	5 DAY
	Dry Mouth							
	Insomnia							
	Tremor							

Date:05/28/99ISR Number: 3334892-4Report Type:Periodic Company Report #A0090407
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dizziness						TWICE PER DAY	
	Insomnia						/ ORAL	
			Aspirin	C				
			Tramadol Hydrochloride	C				
			Calcium Salt	C				
			Nitroglycerin	C				
			Salsalate	C				

Date:05/28/99ISR Number: 3334895-XReport Type:Periodic Company Report #A0090408
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Abnormal	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Hyperhidrosis	Professional	Insulin	C				

Date:05/28/99ISR Number: 3335283-2Report Type:Periodic Company Report #A0089570
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Insomnia						DAY / ORAL	
	Tachycardia							
	Trismus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3335284-4Report Type:Periodic Company Report #A0089571
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3335285-6Report Type:Periodic Company Report #A0089572
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3335286-8Report Type:Periodic Company Report #A0089604
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Sleep Disorder						/ ORAL	
			Atenolol	C				
			Nabumentone	C				
			Inhaler	C				

Date:05/28/99ISR Number: 3335287-XReport Type:Periodic Company Report #A0089605
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Rash Erythematous							
			Conjugated Estrogens	C				

			Atenolol	C			

Date:05/28/99ISR Number: 3335288-1Report Type:Periodic Company Report #A0089606
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus		Estrogen	C				
	Urticaria		Armour Thyroid	C				
			Actifed	C				
			Multivitimin	C				

Date:05/28/99ISR Number: 3335289-3Report Type:Periodic Company Report #A0089607
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Flushing						TWICE PER DAY	
	Insomnia						/ ORAL	

Date:05/28/99ISR Number: 3335290-XReport Type:Periodic Company Report #A0089608
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Urticaria						TWICE PER DAY	

/ ORAL 4 WK

Hormones C

Date:05/28/99ISR Number: 3335291-1Report Type:Periodic Company Report #A0089609
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Mental Impairment						TWICE PER DAY	

/ ORAL

Date:05/28/99ISR Number: 3335292-3Report Type:Periodic Company Report #A0089610
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Sedation						DAY / ORAL	

Date:05/28/99ISR Number: 3335293-5Report Type:Periodic Company Report #A0089611
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus						TWICE PER DAY	

/ ORAL

Diltiazem Hydrochloride C
Estrogen C

Date:05/28/99ISR Number: 3335294-7Report Type:Periodic Company Report #A0089612
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL 1 MON
	Pruritus							
			Blood Pressure Medication	C				

Date:05/28/99ISR Number: 3335295-9Report Type:Periodic Company Report #A0089613
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Amitriptyline Hcl	C				
			Tylenol No. 3	C				
			Human Insulin	C				
			Naproxen	C				
			Ticlopidine	C				
			Oestradiol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3335296-0Report Type:Periodic Company Report #A0089614
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3335297-2Report Type:Periodic Company Report #A0089615
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Oedema Peripheral						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3335298-4Report Type:Periodic Company Report #A0089616
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Agitation						DAY / ORAL	
	Feeling Abnormal							
	Nausea							
	Paraesthesia							
	Sensation Of Heaviness							

Date:05/28/99ISR Number: 3335299-6Report Type:Periodic Company Report #A0089617
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Oestradiol	C				

Date:05/28/99ISR Number: 3335300-XReport Type:Periodic Company Report #A0089618
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	2 WK
	Dyspepsia							
	Flatulence							
	Gastrointestinal Disorder							

Date:05/28/99ISR Number: 3335301-1Report Type:Periodic Company Report #A0089619
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
			Ascorbic Acid	C				
			Ginseng	C				
			Hypericum	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3335302-3Report Type:Periodic Company Report #A0089620
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dyspnoea						TWICE PER DAY	
	Heart Rate Increased						/ ORAL	
	Paraesthesia		Thyroxine Sodium	C				
			Nordette	C				
			Cerivastatin	C				

Date:05/28/99ISR Number: 3335303-5Report Type:Periodic Company Report #A0089621
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dry Skin						TWICE PER DAY	
	Insomnia						/ ORAL	
	Irritability							
	Nausea							
	Palpitations							
	Tremor							

Date:05/28/99ISR Number: 3335304-7Report Type:Periodic Company Report #A0089622
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	
			Amlodipine	C				

			Hydrochlorothiazide	C		
			Potassium Chloride	C		

Date:05/28/99ISR Number: 3335305-9Report Type:Periodic Company Report #A0089623
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Bone Pain						TWICE PER DAY	
							/ ORAL	
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3335306-0Report Type:Periodic Company Report #A0089624
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Urticaria						TWICE PER DAY	
							/ ORAL	
			Digoxin	C				
			Atenolol	C				
			Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3335307-2Report Type:Periodic Company Report #A0089635
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Erectile Dysfunction						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3335308-4Report Type:Periodic Company Report #A0089636
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Aspirin	C				

Date:05/28/99ISR Number: 3335309-6Report Type:Periodic Company Report #A0089637
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Anorexia						TWICE PER DAY	
	Cold Sweat						/ ORAL	
	Headache		Diavan	C				
	Muscle Twitching		Omeprazole	C				
	Nightmare		Oxycodone Hydrochloride	C				

Date:05/28/99ISR Number: 3335310-2Report Type:Periodic Company Report #A0089638
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3335311-4Report Type:Periodic Company Report #A0089639
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	6 DAY
			Thyroid Blood Pressure Medication	C				

Date:05/28/99ISR Number: 3335313-8Report Type:Periodic Company Report #A0089640
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3335315-1Report Type:Periodic Company Report #A0089641
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3335317-5Report Type:Periodic Company Report #A0089642
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	10 DAY

Date:05/28/99ISR Number: 3335322-9Report Type:Periodic Company Report #A0089643
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Ejaculation Disorder	Professional						
	Erectile Dysfunction							
	Insomnia		Minoxidil	C				
	Urticaria		Clarithromycin	C				
			Entex	C				

Date:05/28/99ISR Number: 3335323-0Report Type:Periodic Company Report #A0089901
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Urticaria					
TWICE PER DAY						
/ ORAL						

Date:05/28/99ISR Number: 3335325-4Report Type:Periodic Company Report #A0089902
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG / ORAL						
	Nausea	Health	Nicotine Patch	SS		
INTRADERMAL INTRADERMAL						
	Nervousness	Professional				
	Rash Erythematous	Other				

Date:05/28/99ISR Number: 3335326-6Report Type:Periodic Company Report #A0089903
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Dry Mouth					
TWICE PER DAY						
	Insomnia					
/ ORAL						
	Lip Disorder		Ciprofloxacin Hcl	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3335327-8Report Type:Periodic Company Report #A0089904
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dry Mouth						TWICE PER DAY	
	Insomnia						/ ORAL	
			Terbutaline Sulphate	C				
			Theophylline	C				
			Salbutamol Sulphate	C				
			Ipratropium Bromide	C				
			Zinc Oxide	C				

Date:05/28/99ISR Number: 3335331-XReport Type:Periodic Company Report #A0089905
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Diazepam	C				
			Percocet	C				

Date:05/28/99ISR Number: 3335332-1Report Type:Periodic Company Report #A0089906
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Major Depression						DAY / ORAL	

Date:05/28/99ISR Number: 3335333-3Report Type:Periodic Company Report #A0089907
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
			Nicotine	C				
			Clorazepate Dipotassium	C				
			Metolazone	C				

Date:05/28/99ISR Number: 3335335-7Report Type:Periodic Company Report #A0091739
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
			Birth Control	C				

Date:05/28/99ISR Number: 3335336-9Report Type:Periodic Company Report #A0091746
Age:52 YR Gender:Male I/FU:I

Outcome	PT
	Chest Pain
	Increased Appetite

Muscle Spasms
Nausea
Sedation Report Source Product Role Manufacturer Route Dose Duration
Consumer Zyban Tablet - Zyban PS ORAL 150 MG /

TWICE PER DAY

/ ORAL

Date:05/28/99ISR Number: 3335338-2Report Type:Periodic Company Report #A0092020
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration
Insomnia Consumer Zyban Tablet - Zyban PS ORAL 150 MG /

TWICE PER DAY

/ ORAL

Date:05/28/99ISR Number: 3335340-0Report Type:Periodic Company Report #A0092114
Age:45 YR Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration
Urticaria Consumer Zyban Tablet - Zyban PS ORAL 150 MG/ TWICE

PER DAY /

ORAL

Date:05/28/99ISR Number: 3335342-4Report Type:Periodic Company Report #A0092115
Age:50 YR Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration

	Chills	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Dyspnoea					
TWICE PER DAY						
	Tremor					
/ ORAL						

Date:05/28/99ISR Number: 3335343-6Report Type:Periodic Company Report #A0092116
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Flushing					
TWICE PER DAY						
	Hyperhidrosis					
/ ORAL 25 DAY						
	Nausea		Cetirizine Hydrochloride	C		
			Fluticasone Propionate	C		

Date:05/28/99ISR Number: 3335344-8Report Type:Periodic Company Report #A0092144
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						
			Betaxolol Hydrochloride	C		
			Ipratropium Bromide	C		
			Digoxin	C		
			Diltiazem	C		
			Warfarin Sodium	C		

			Lorazepam	C		
			Salbutamol Sulphate	C		

Date:05/28/99ISR Number: 3335346-1Report Type:Periodic Company Report #A0065235
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Disorder	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Chest Wall Pain	Professional					TWICE PER DAY	
	Condition Aggravated						/ ORAL	
	Depression		Atorvastatin Calcium	C				
	Insomnia		Ascorbic Acid	C				
	Pruritus		Chromium Salt	C				
	Psychomotor Hyperactivity		Aspirin	C				
	Weight Increased		Back Problems	C				
			Tenderness: Chest Region	C				

Date:05/28/99ISR Number: 3335348-5Report Type:Periodic Company Report #A0066257
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctival Hyperaemia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Discomfort	Professional					SINGLE DOSE /	
	Eye Disorder						ORAL	
	Eye Irritation		Amlodipine	C				
	Paraesthesia							
	Rash Erythematous							
	Retinal Vascular Disorder							
	Transient Ischaemic Attack							
	Visual Acuity Reduced							
	Visual Disturbance							

Date:05/28/99ISR Number: 3335350-3Report Type:Periodic Company Report #A0070971
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Constipation	Professional					TWICE PER DAY	
	Depression						/ ORAL	
	Dizziness		Amlodipine					
	Hypercholesterolaemia		(Formulation					
	Insomnia		Unknown)	SS			5 MG	
	Nausea		Aspirin	C				
	Orthostatic Hypotension		Famotidine	C				
	Palpitations		Estropipate	C				
	Syncope		Metoclopramide Hcl	C				
	Weight Decreased		Thyroxine Sodium	C				
			Amitriptyline	C				
			Timolol Maleate	C				
			Brimonidine Tartrate	C				
			Rimexolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3335351-5Report Type:Periodic Company Report #A0073811
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hallucination	Professional					TWICE PER DAY	
	Insomnia						/ ORAL	
	Nausea							

Date:05/28/99ISR Number: 3335353-9Report Type:Periodic Company Report #A0073830
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
	Dermatitis	Professional					DAY/ ORAL	
	Pruritus							
	Rales							
	Rash Erythematous							
	Throat Tightness							
	Urticaria							

Date:05/28/99ISR Number: 3335354-0Report Type:Periodic Company Report #A0074641
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Chest Pain						TWICE PER DAY	
	Dermatitis						/ ORAL	
	Dyspepsia							
	Gastritis							
	Hypersensitivity							
	Pain							

	Pruritus
	Rash Erythematous
	Skin Irritation
	Swelling

Date:05/28/99ISR Number: 3335359-XReport Type:Periodic Company Report #A0075297
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Depression	Professional					TWICE PER DAY	
	Insomnia						/ ORAL	
	Nausea		Hrt	C				
			Multivitamin	C				

Date:05/28/99ISR Number: 3335370-9Report Type:Periodic Company Report #A0076043
Age:40 YR Gender:Male I/FU:F

Outcome	PT
	Dermatitis
	Dizziness
	Face Oedema
	Headache
	Hunger
	Hypersensitivity
	Nausea

	Pain Pruritus Pyrexia	Report Source	Product	Role	Manufacturer	Route
Dose Duration	Sedation	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG / TWICE PER DAY / ORAL						
			Imitrex Tablet	SS		ORAL
50 MG / AS REQUIRED / ORAL						

Date:05/28/99ISR Number: 3335372-2Report Type:Periodic Company Report #A0076416
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration	Dizziness	Health	Zyban Tablet - Zyban	PS		ORAL
150 MG / TWICE PER DAY / ORAL	Nausea Vomiting	Professional				
			Salbutamol Sulphate	C		

Date:05/28/99ISR Number: 3335374-6Report Type:Periodic Company Report #A0076427
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration	Hypersensitivity	Health	Zyban Tablet - Zyban	PS		ORAL
150 MG / TWICE PER DAY / ORAL		Professional				

Date:05/28/99ISR Number: 3335376-XReport Type:Periodic Company Report #A0076894
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hypersensitivity	Professional					TWICE PER DAY	
	Urticaria						/ ORAL	

Date:05/28/99ISR Number: 3335380-1Report Type:Periodic Company Report #A0076971
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Agitation	Professional					TWICE PER DAY	
	Anxiety						/ ORAL	
	Dyspnoea Exertional		Cojugated Estrogens	C				
	Insomnia		Cimetidine	C				
	Malaise		Oxybutynin					
	Nervousness		Hydrochloride	C				
	Stress		Multivitamin	C				
	Tremor		Beclomethasone					
			Dipropion.	C				
			...	C				
			...	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3335381-3Report Type:Periodic Company Report #A0076978
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Diarrhoea	Professional					TWICE PER DAY	
	Dizziness						/ ORAL	
	Nausea		Ranitidine					
	Tremor		Hydrochloride	C				
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3352572-6Report Type:Periodic Company Report #A0091183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ ORAL	
		Professional						
		Company						
		Representative						

Date:05/28/99ISR Number: 3352574-XReport Type:Periodic Company Report #A0091184
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
	Hyperventilation						DAY/ ORAL	
	Nervousness							
	Palpitations							
	Tachycardia							

Date:05/28/99ISR Number: 3352575-1Report Type:Periodic Company Report #A0091186
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hearing Impaired	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Insomnia						PER DAY/ ORAL	

Date:05/28/99ISR Number: 3352576-3Report Type:Periodic Company Report #A0091187
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	17 DAY
			Nicotine	C				

Date:05/28/99ISR Number: 3352578-7Report Type:Periodic Company Report #A0091188
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Elevated Mood	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Insomnia						PER DAY/ ORAL	
	Tremor		Cetirizine Hydrochloride	C				
			Zafirlukast	C				
			Salbutamol Sulphate	C				
			Fluticasone Propionate	C				

			Nicotine	C		

Date:05/28/99ISR Number: 3352580-5Report Type:Periodic Company Report #A0091189
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:05/28/99ISR Number: 3352581-7Report Type:Periodic Company Report #A0091190
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
	Psychotic Disorder							

Date:05/28/99ISR Number: 3352582-9Report Type:Periodic Company Report #A0091191
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
	Headache							
	Neck Pain		Ascorbic Acid	C				

Date:05/28/99ISR Number: 3352584-2Report Type:Periodic Company Report #A0091192
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Feeling Abnormal	Consumer	Zyban Tablet - Zyban	PS			ORAL
150 MG/ TWICE							
	Nausea						
PER DAY/ ORAL							
	Night Sweats		Simvastatin	C			
	Tremor						

Date:05/28/99ISR Number: 3352586-6Report Type:Periodic Company Report #A0091194
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
	Insomnia							
DAY/ ORAL								
	Malaise							

Date:05/28/99ISR Number: 3352588-XReport Type:Periodic Company Report #A0091229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	2 WK
	Face Oedema							
	Oedema							
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3352589-1Report Type:Periodic Company Report #A0091529
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL 3 MON
	Weight Increased		Nicotine Polacrilex	C				

Date:05/28/99ISR Number: 3352590-8Report Type:Periodic Company Report #A0091530
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL

Date:05/28/99ISR Number: 3352592-1Report Type:Periodic Company Report #A0091531
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Major Depression						PER DAY/	ORAL
	Tobacco Abuse							

Date:05/28/99ISR Number: 3352594-5Report Type:Periodic Company Report #A0091532
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Anxiety	Professional					PER DAY /	
	Brief Psychotic Disorder	Company					ORAL	
	Without Marked Stressors Psychotic Disorder	Representative						

Date:05/28/99ISR Number: 3352595-7Report Type:Periodic Company Report #A0091734
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Drug Dependence						PER DAY/ ORAL	
			Glucophage	C				
			Simvastatin	C				
			Famotidine	C				
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3352597-0Report Type:Periodic Company Report #A0091735
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Nausea						PER DAY/ ORAL	
			Methimazole	C				

Date:05/28/99ISR Number: 3352599-4Report Type:Periodic Company Report #A0091736
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Urticaria						PER DAY/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3352601-XReport Type:Periodic Company Report #A0091737
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Diltiazem Hydrochloride	C				
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3352603-3Report Type:Periodic Company Report #A0091738
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Verapamil	C				
			Amlodipine	C				
			Warfarin Sodium	C				
			Clonidine Hydrochloride	C				

Date:05/28/99ISR Number: 3352604-5Report Type:Periodic Company Report #A0089123
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3352605-7Report Type:Periodic Company Report #A0089125
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL

Date:05/28/99ISR Number: 3352606-9Report Type:Periodic Company Report #A0089126
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL

Date:05/28/99ISR Number: 3352609-4Report Type:Periodic Company Report #A0089127
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3352610-0Report Type:Periodic Company Report #A0089128
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER DAY / ORAL	

Date:05/28/99ISR Number: 3352611-2Report Type:Periodic Company Report #A0089179
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY / ORAL	
			Lansoprazole	C				

Date:05/28/99ISR Number: 3352612-4Report Type:Periodic Company Report #A0089184
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/ TWICE PER DAY / ORAL	
	Gait Disturbance							
			Diazepam	C				
			Aspirin	C				
			Lisinopril	C				
			Imipramine Hydrochloride	C				
			Trifluoperazine Hc1	C				

Date:05/28/99ISR Number: 3352613-6Report Type:Periodic Company Report #A0089190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	2 YR
	Drug Dependence							
	Major Depression							

Date:05/28/99ISR Number: 3352616-1Report Type:Periodic Company Report #A0089191
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Diarrhoea						DAY / ORAL	

Date:05/28/99ISR Number: 3352618-5Report Type:Periodic Company Report #A0089192
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	
			Atenolol	C				
			Amlodipine	C				
			Multivitamin	C				
			Estrogen	C				
			Sulphasalazine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3352620-3Report Type:Periodic Company Report #A0089193
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY /	
	Dysgeusia							
						ORAL		
			Thyroid Medication	C				

Date:05/28/99ISR Number: 3352622-7Report Type:Periodic Company Report #A0089194
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
							PER DAY /	
						ORAL		
			Birth Control	C				

Date:05/28/99ISR Number: 3352630-6Report Type:Periodic Company Report #A0089196
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Dysgeusia						PER DAY /	
						ORAL		
			Paroxetine Hydrochloride	C				
			Doxycycline	C				

Date:05/28/99ISR Number: 3352631-8Report Type:Periodic Company Report #A0089197
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
	Dizziness						DAY/ ORAL	
			Venlafaxine Hydrochloride	C				
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3352632-XReport Type:Periodic Company Report #A0089204
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Drug Ineffective						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3352637-9Report Type:Periodic Company Report #A0089205
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Myalgia						TWICE PER DAY	
							/ ORAL	
			Claritin- D	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3352640-9Report Type:Periodic Company Report #A0089255
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / PER	
		Professional					DAY / ORAL	

Date:05/28/99ISR Number: 3352641-0Report Type:Periodic Company Report #A0089256
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Cephalexin	C				
			Histussin	C				

Date:05/28/99ISR Number: 3352642-2Report Type:Periodic Company Report #A0089257
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / PER	
	Excitability						DAY / ORAL	
			Diazepam	C				

Date:05/28/99ISR Number: 3352643-4Report Type:Periodic Company Report #A0089258
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral	Consumer	Zyban Tablet -Zyban	PS		ORAL 150 MG/ TWICE
	Rash Erythematous					PER DAY / ORAL
			Paracetamol	C		

Date:05/28/99ISR Number: 3352653-7Report Type:Periodic Company Report #A0088861
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER DAY/ ORAL	
	Eyelid Oedema	Professional						
	Pruritus							
	Rash Erythematous							
	Rash Papular							
	Rubella							
	Scar							

Date:05/28/99ISR Number: 3352655-0Report Type:Periodic Company Report #A0088864
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER DAY/ ORAL	
	Diarrhoea							
	Influenza Like Illness							
	Pruritus							
	Swelling							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3352657-4Report Type:Periodic Company Report #A0088994
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL
		Health Professional Other	Nicotine (Formulation Unknown)	SS			21 MG	

Date:05/28/99ISR Number: 3352658-6Report Type:Periodic Company Report #A0088995
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
							PER DAY/	ORAL
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3352660-4Report Type:Periodic Company Report #A0088996
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Vision Blurred						PER DAY /	
							ORAL	

Date:05/28/99ISR Number: 3352661-6Report Type:Periodic Company Report #A0088997
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Confusional State	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG/ TWICE
	Dry Mouth					PER DAY/ ORAL

Date:05/28/99ISR Number: 3352664-1Report Type:Periodic Company Report #A0088998
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL 150 MG/ TWICE
	Pruritus	Professional				PER DAY /
	Urticaria					ORAL
			Triamcinolone Acetonide	C		

Date:05/28/99ISR Number: 3352666-5Report Type:Periodic Company Report #A0088999
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG/ PER
	Asthenia					DAY/ ORAL
	Insomnia		Arthritis Medication	C		
	Tremor		Amoxycillin Trihydrate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3352669-0Report Type:Periodic Company Report #A0089027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL
	Menstruation Irregular	Professional	Medroxyprogesterone					
	Metrorrhagia		Ace.	C				

Date:05/28/99ISR Number: 3352671-9Report Type:Periodic Company Report #A0089088
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ PER	
	Insomnia						DAY / ORAL	
	Nausea		Loestrin	C				
	Neck Pain							

Date:05/28/99ISR Number: 3352674-4Report Type:Periodic Company Report #A0089089
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delusion	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Insomnia						PER DAY/ ORAL	
	Paranoia		Alprazolam	C				
			Ibuprofen	C				

Date:05/28/99ISR Number: 3352677-XReport Type:Periodic Company Report #A0089090
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	

Insomnia
PER DAY /
Irritability
ORAL
Birth Control C

Date:05/28/99ISR Number: 3352712-9Report Type:Periodic Company Report #A0089091
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Migraine						DAY/ ORAL	
	Sedation		Cetirizine					
	Tremor		Hydrochloride	C				

Date:05/28/99ISR Number: 3352715-4Report Type:Periodic Company Report #A0089092
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Urticaria	Health	Nicotine Patch	SS			INTRADERMAL	INTRADERMAL
		Professional						
		Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3352717-8Report Type:Periodic Company Report #A0089093
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL
	Urticaria	Health Professional Other						

Date:05/28/99ISR Number: 3352719-1Report Type:Periodic Company Report #A0089094
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS			150 MG / PER	DAY/ ORAL
			Lisinopril	C				
			Doxazosin Mesylate	C				

Date:05/28/99ISR Number: 3352722-1Report Type:Periodic Company Report #A0089119
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/	TWICE
	Muscle Spasms						PER DAY/	ORAL
			Fluoxetine Hydrochloride	C				

Date:05/28/99ISR Number: 3352724-5Report Type:Periodic Company Report #A0089120
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL

150 MG/ TWICE

PER DAY/ ORAL

Date:05/28/99ISR Number: 3352726-9Report Type:Periodic Company Report #A0089121
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL

150 MG/ TWICE

	Hypotension					

PER DAY /

ORAL

			Isosorbide	C		
			Frusemide	C		
			Fluvastatin Sodium	C		

Date:05/28/99ISR Number: 3352727-0Report Type:Periodic Company Report #A0089122
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Stomatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL

150 MG/ TWICE

PER DAY /

ORAL

			Conjugated Estrogens	C		
			Glucosamine			
			Chondroitin C	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3353692-2Report Type:Periodic Company Report #A0085853
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Nausea						TWICE PER DAY	
							/ ORAL	
			Ramipril	C				
			Diltiazem Hydrochloride	C				
			Atenolol	C				

Date:05/28/99ISR Number: 3353693-4Report Type:Periodic Company Report #A0085854
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Agitation						DAY / ORAL	
	Anxiety		Conjugated Estrogens	C				
	Hallucination		Ibuprofen	C				
	Insomnia		Beclomethasone Dipropion	C				
	Nausea		Ipratropium Bromide	C				
	Nervousness							
	Panic Reaction							

Date:05/28/99ISR Number: 3353694-6Report Type:Periodic Company Report #A0085855
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Nausea						DAY / ORAL	

Date:05/28/99ISR Number: 3353695-8Report Type:Periodic Company Report #A0085856
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Pruritus							

Date:05/28/99ISR Number: 3353696-XReport Type:Periodic Company Report #A0086067
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Catatonia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Decreased Appetite							
	Feeling Of Relaxation							
	Paraesthesia		Conjugated Estrogens	C				
	Paralysis		Multivitamin	C				
			Hypericum	C				

Date:05/28/99ISR Number: 3353697-1Report Type:Periodic Company Report #A0086105
Age:68 YR Gender:Male I/FU:I

Outcome	PT
	Dysgeusia
	Dysphonia

	Headache Insomnia					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
150 MG/ TWICE		Consumer	Zyban Tablet - Zyban	PS		ORAL
PER DAY/ ORAL						
			Bromfenex	C		
			Vitamin E	C		
			Amlodipine	C		
			Atrovastatin Calcium	C		

Date:05/28/99ISR Number: 3353698-3Report Type:Periodic Company Report #A0086106
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Oedema Peripheral					
TWICE PER DAY						
/ ORAL						
			Paracetamol	C		

Date:05/28/99ISR Number: 3353699-5Report Type:Periodic Company Report #A0086107
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Disturbance In Attention	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Feeling Abnormal					
TWICE PER DAY						
/ ORAL						
			Fexofenadine Hydrochoride	C		

Date:05/28/99ISR Number: 3353700-9Report Type:Periodic Company Report #A0086108
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dermatitis						TWICE PER DAY	
	Insomnia						/ ORAL	
	Pruritus							
	Systemic Lupus Erythematosus							

Date:05/28/99ISR Number: 3353701-0Report Type:Periodic Company Report #A0086109
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Neck Pain	Professional					TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3353702-2Report Type:Periodic Company Report #A0086110
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3353703-4Report Type:Periodic Company Report #A0086111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
		Health Professional						
		Other	Nicotine (Formulation Unknown)	SS				

Date:05/28/99ISR Number: 3353704-6Report Type:Periodic Company Report #A0086112
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Co-Trimoxazole	C				

Date:05/28/99ISR Number: 3353705-8Report Type:Periodic Company Report #A0086113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	WK
	Drug Effect Decreased							
	Pain							
	Pruritus							

Date:05/28/99ISR Number: 3353706-XReport Type:Periodic Company Report #A0086114
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	DAY / ORAL

Date:05/28/99ISR Number: 3353707-1Report Type:Periodic Company Report #A0086115
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	DAY / ORAL

Date:05/28/99ISR Number: 3353708-3Report Type:Periodic Company Report #A0086116
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis Influenza Like Illness Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3353710-1Report Type:Periodic Company Report #A0086117
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Constipation	Professional					TWICE PER DAY	
							/ ORAL	
			Oestradiol	C				
			Multivitamin	C				

Date:05/28/99ISR Number: 3353712-5Report Type:Periodic Company Report #A0086118
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Fatigue						TWICE PER DAY	
	Headache						/ ORAL	
	Urticaria							

Date:05/28/99ISR Number: 3353713-7Report Type:Periodic Company Report #A0086198
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health	Zyban Tablet - Zyban	PS		ORAL	ORAL	2 WK
	Urticaria	Professional						
		Company Representative						

Date:05/28/99ISR Number: 3353913-6Report Type:Periodic Company Report #A0083642
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Dry Mouth						DAY / ORAL	
	Insomnia		Sleeping Medication	C				

Date:05/28/99ISR Number: 3353914-8Report Type:Periodic Company Report #A0083643
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Mood Altered						TWICE PER DAY	
	Paraesthesia						/ ORAL	

Date:05/28/99ISR Number: 3353916-1Report Type:Periodic Company Report #A0083644
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Pruritus						PER DAY /	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3353918-5Report Type:Periodic Company Report #A0083645
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Early Morning Awakening						TWICE PER DAY	
	Feeling Abnormal						/ ORAL	
	Insomnia							
	Sleep Disorder							

Date:05/28/99ISR Number: 3353920-3Report Type:Periodic Company Report #A0083646
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Anxiety						TWICE PER DAY	
	Disturbance In Attention						/ ORAL	
	Insomnia							

Date:05/28/99ISR Number: 3353922-7Report Type:Periodic Company Report #A0083647
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
	Hypersensitivity							

Date:05/28/99ISR Number: 3353923-9Report Type:Periodic Company Report #A0083858
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Aggression	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG/ TWICE
	Agitation					PER DAY /
	Anxiety					ORAL
	Disturbance In Attention					
	Irritability					

Date:05/28/99ISR Number: 3353924-0Report Type:Periodic Company Report #A0083864
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Chest Discomfort	Consumer	Zyban Tablet - Zyban	PS		ORAL 150 MG /
	Headache					TWICE PER DAY
	Nausea					/ ORAL

Date:05/28/99ISR Number: 3353926-4Report Type:Periodic Company Report #A0083867
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Nausea	Health	Zyban Tablet - Zyban	PS		ORAL 150 MG / PER
	Vision Blurred	Professional				DAY / ORAL
			Desogen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3353951-3Report Type:Periodic Company Report #A0083874
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Rash Erythematous	Professional					TWICE PER DAY	
	Urticaria						/ ORAL	
			Digoxin	C				
			Propranolol Hydrochloride	C				
			Omeprazole	C				
			Hydrochlorothiazide	C				
			Losartan Potassium	C				
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3353984-7Report Type:Periodic Company Report #A0083870
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Insomnia						DAY / ORAL	
			Conjugated Estrogens	C				
			Carisoprodol	C				

Date:05/28/99ISR Number: 3353986-0Report Type:Periodic Company Report #A0083875
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3353989-6Report Type:Periodic Company Report #A0083879
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Skin Odour Abnormal						TWICE PER DAY	
							/ ORAL	

Date:05/28/99ISR Number: 3353991-4Report Type:Periodic Company Report #A0083885
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER	
							DAY/ ORAL	

Date:05/28/99ISR Number: 3353992-6Report Type:Periodic Company Report #A0083888
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Influenza Like Illness						TWICE PER DAY	
	Insomnia						/ ORAL	
			Tetracycline	C				
			Oestradiol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3353995-1Report Type:Periodic Company Report #A0083893
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	3 WK
	Dyspnoea							
			Cefprozil (Formulation Unknown)	SS				

Date:05/28/99ISR Number: 3353997-5Report Type:Periodic Company Report #A0083894
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Stomatitis							
			Naproxen	C				
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3353998-7Report Type:Periodic Company Report #A0083895
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Nausea							
			Atenolol	C				
			Enalapril Maleate	C				

Date:05/28/99ISR Number: 3354002-7Report Type:Periodic Company Report #A0083896
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Discomfort	Professional					SINGLE DOSE /	
	Dyspnoea						ORAL	
	Nervousness		Salbutamol Sulphate	C				
	Pharyngeal Oedema		Alprazolam	C				
	Vision Blurred		Zafirlukast	C				
			Progesterone	C				
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3354004-0Report Type:Periodic Company Report #A0083897
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Asthenia	Professional					TWICE PER DAY	
	Tremor	Company					/ ORAL	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354010-6Report Type:Periodic Company Report #A0082955
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Headache						TWICE PER DAY	
	Nervousness						/ ORAL	
			Birth Control	C				

Date:05/28/99ISR Number: 3354012-XReport Type:Periodic Company Report #A0082956
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3354014-3Report Type:Periodic Company Report #A0082958
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Disturbance In Attention						TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3354016-7Report Type:Periodic Company Report #A0082960
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3354022-2Report Type:Periodic Company Report #A0082962
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Pruritus						TWICE PER DAY	
							/ ORAL	
			Ciprofloxacin Hc1	C				

Date:05/28/99ISR Number: 3354023-4Report Type:Periodic Company Report #A0082964
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Pruritus	Professional					TWICE PER DAY	
	Urticaria						/ ORAL	

Date:05/28/99ISR Number: 3354026-XReport Type:Periodic Company Report #A0083090
Age:67 YR Gender:Male I/FU:I

Outcome	PT
	Amnesia
	Confusional State
	Encephalopathy
	Mental Disorder

Speech Disorder

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health Professional	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG / PER DAY / ORAL	3 DAY					
		Company Representative	Diphenhydramine Hc1 (Formulation Unknown0	SS		
			Lorazepam (Formulation Unknown)	SS		
			Lisinopril	C		
			Simvastatin	C		

Date:05/28/99ISR Number: 3354029-5Report Type:Periodic Company Report #A0083178
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Flatulence	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG / ORAL						
	Skin Odour Abnormal		Nicotine	C		

Date:05/28/99ISR Number: 3354031-3Report Type:Periodic Company Report #A0083561
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Cough	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG / ORAL						
	Postnasal Drip					

Date:05/28/99ISR Number: 3354036-2Report Type:Periodic Company Report #A0083630
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL
150 MG/ ORAL						
		Health Professional Other	Nicotine	C		

Date:05/28/99ISR Number: 3354038-6Report Type:Periodic Company Report #A0083632
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Zyban Tablet- Zyban	PS	Zyban	ORAL
150 MG /						
	Chest Discomfort					
TWICE PER DAY						
	Diarrhoea					
/ ORAL						
	Dizziness		Gabapentin	C		
	Headache					
	Heart Rate Increased					
	Muscle Spasms					

Date:05/28/99ISR Number: 3354041-6Report Type:Periodic Company Report #A0083633
Age:33 YR Gender:Female I/FU:I

Outcome	PT
	Confusional State
	Drug Effect Decreased
	Hangover

	Headache Hyperphagia Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / PER DAY / ORAL

Date:05/28/99ISR Number: 3354043-XReport Type:Periodic Company Report #A0083634
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Alopecia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER DAY / ORAL
	Insomnia						
	Pruritus						
	Swelling						

Date:05/28/99ISR Number: 3354047-7Report Type:Periodic Company Report #A0083635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash Generalised	Health Professional Company Representative	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / ORAL

Date:05/28/99ISR Number: 3354051-9Report Type:Periodic Company Report #A0083636
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pruritus	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /

	Urticaria	Professional				
TWICE PER DAY / ORAL						
			Ibuprofen	C		

Date:05/28/99ISR Number: 3354052-0Report Type:Periodic Company Report #A0083637
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER DAY / ORAL	
	Headache							
	Pruritus							
			Birth Control	C				
			Ibuprofen	C				

Date:05/28/99ISR Number: 3354055-6Report Type:Periodic Company Report #A0083638
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/ TWICE PER DAY / ORAL	
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354057-XReport Type:Periodic Company Report #A0083639
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Dyspnoea						TWICE PER DAY	
	Palpitations						/ ORAL	
	Tremor							

Date:05/28/99ISR Number: 3354060-XReport Type:Periodic Company Report #A0083640
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Excitability						TIWCE PER DAY	
	Nervousness						/ ORAL	
			Thyroxine Sodium	C				
			Hydroxyzine Hydrochloride	C				
			Clonazepam	C				

Date:05/28/99ISR Number: 3354062-3Report Type:Periodic Company Report #A0083641
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
	Pruritus						TWICE PER	
							DAY/ ORAL	
			Thyroxine Sodium	C				

Date:05/28/99ISR Number: 3354065-9Report Type:Periodic Company Report #A0082507
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Pruritus						PER DAY/ ORAL	
	Urticaria							

Date:05/28/99ISR Number: 3354068-4Report Type:Periodic Company Report #A0082508
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Dizziness						PER DAY/ ORAL	
	Dry Mouth							
	Tachycardia							

Date:05/28/99ISR Number: 3354074-XReport Type:Periodic Company Report #A0082510
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE	
	Drug Hypersensitivity	Professional					PER DAY/ ORAL	
	Joint Swelling		Hyzaar	C				
	Myalgia							
	Pruritus							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354077-5Report Type:Periodic Company Report #A0082553
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colour Blindness	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG/	ORAL
		Professional						

Date:05/28/99ISR Number: 3354079-9Report Type:Periodic Company Report #A0082761
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban Tablet - Zyban	PS		ORAL	ORAL	
	Flushing	Professional	Buspirone					
	Malaise		Hydrochloride	C				
	Pyrexia							

Date:05/28/99ISR Number: 3354082-9Report Type:Periodic Company Report #A0082762
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban Tablet- Zyban	PS		ORAL	ORAL	
	Flushing	Professional						
	Malaise							
	Pyrexia							

Date:05/28/99ISR Number: 3354085-4Report Type:Periodic Company Report #A0082763
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban Tablet - Zyban	PS		ORAL	ORAL	
	Flushing	Professional						
	Malaise							
	Pyrexia							

Date:05/28/99ISR Number: 3354088-XReport Type:Periodic Company Report #A0082903
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	ORAL	1 WK

Date:05/28/99ISR Number: 3354091-XReport Type:Periodic Company Report #A0082918
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Tongue Ulceration							

Date:05/28/99ISR Number: 3354094-5Report Type:Periodic Company Report #A0082923
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Naproxen Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354096-9Report Type:Periodic Company Report #A0082926
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Zyban Tablet - Zyban Lotrel	PS C		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3354098-2Report Type:Periodic Company Report #A0082929
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Zyban Tablet - Zyban Multivitamin Metoprolol Succinate Aspirin Atorvastatin Calcium Lisinopril Thyroxine Sodium Nabumetone Isosorbide Mononitrate	PS C C C C C C C C		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3354100-8Report Type:Periodic Company Report #A0082938
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3354103-3Report Type:Periodic Company Report #A0082940
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3354105-7Report Type:Periodic Company Report #A0082942
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Insomnia							

Date:05/28/99ISR Number: 3354108-2Report Type:Periodic Company Report #A0082946
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ ORAL	
	Stomach Discomfort							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354110-0Report Type:Periodic Company Report #A0082949
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperbilirubinaemia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3354112-4Report Type:Periodic Company Report #A0082951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Migraine							
			Salbutamol Sulphate	C				

Date:05/28/99ISR Number: 3354115-XReport Type:Periodic Company Report #A0082953
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Propranolol Hydrochloride	C				
			Cimetidine	C				
			Maxzide	C				
			Thyroxine Sodium	C				
			Griseofulvin	C				
			Triazolam	C				

Date:05/28/99ISR Number: 3354357-3Report Type:Periodic Company Report #A0087769
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	ORAL

Date:05/28/99ISR Number: 3354362-7Report Type:Periodic Company Report #A0087770
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Fluticasone Propionate	C				

Date:05/28/99ISR Number: 3354364-0Report Type:Periodic Company Report #A0087771
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Dysgeusia							
	Nausea							
			Fluvastatin Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354366-4Report Type:Periodic Company Report #A0087772
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL

Date:05/28/99ISR Number: 3354368-8Report Type:Periodic Company Report #A0087773
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
			Dristan	C				
			Multivitamin	C				

Date:05/28/99ISR Number: 3354372-XReport Type:Periodic Company Report #A0087774
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY / ORAL
	Nervousness							
	Paraesthesia							
			Fluticasone Propionate	C				
			Salmeterol Xinafoate	C				
			Ipratropium Bromide	C				

Date:05/28/99ISR Number: 3354374-3Report Type:Periodic Company Report #A0087775
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Hypersensitivity	Professional					TWICE PER DAY	
	Pruritus						/ ORAL	
	Rash Erythematous		Cyclobenzaprine	C				
	Skin Nodule		Gentamicin	C				
	Swelling		Ibuprofen	C				
			Nizatidine	C				
			Misoprostol	C				
			Terbinafine	C				
			Methotrexate	C				

Date:05/28/99ISR Number: 3354376-7Report Type:Periodic Company Report #A0087777
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcoholic Hangover	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Feeling Abnormal						TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354377-9Report Type:Periodic Company Report #A0087778
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Flushing	Professional					TWICE PER DAY	
	Insomnia						/ ORAL	

Date:05/28/99ISR Number: 3354379-2Report Type:Periodic Company Report #A0087779
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgraphia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Headache						TWICE PER DAY	
	Insomnia						/ ORAL	
	Tremor		Simvastatin	C				
			Aspirin	C				

Date:05/28/99ISR Number: 3354381-0Report Type:Periodic Company Report #A0087780
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Headache						DAY / ORAL	
	Nausea		Glucophage	C				
			Glipizide	C				
			Clonazepam	C				

Date:05/28/99ISR Number: 3354385-8Report Type:Periodic Company Report #A0087781
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Face Oedema						DAY / ORAL	
			Diavan	C				

Date:05/28/99ISR Number: 3354387-1Report Type:Periodic Company Report #A0087782
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia	Professional					TWICE PER DAY	
	Tremor						/ ORAL	
			Ibuprofen	C				

Date:05/28/99ISR Number: 3354390-1Report Type:Periodic Company Report #A0087898
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / SEE	
	Pruritus						TEXT / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354392-5Report Type:Periodic Company Report #A0087902
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Nervousness Tremor	Consumer	Zyban Tablet - Zyban	PS				

Date:05/28/99ISR Number: 3354396-2Report Type:Periodic Company Report #A0087971
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	2 DAY
			Conjugated Estrogens	C				

Date:05/28/99ISR Number: 3354398-6Report Type:Periodic Company Report #A0087972
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Paroxetine Hydrochloride	C				

Date:05/28/99ISR Number: 3354401-3Report Type:Periodic Company Report #A0087973
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	

	Oligomenorrhoea					
TWICE PER DAY						
/ ORAL						

Date:05/28/99ISR Number: 3354404-9Report Type:Periodic Company Report #A0087974
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG /	
TWICE PER DAY								
/ ORAL								
			Quinapril Hydrochloride	C				
			Salbutamol Sulphate	C				

Date:05/28/99ISR Number: 3354406-2Report Type:Periodic Company Report #A0087975
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
TWICE PER DAY								
/ ORAL								
			Hydrocodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354512-2Report Type:Periodic Company Report #A0088232
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Disturbance In Attention						TWICE PER DAY	
	Nervousness						/ ORAL	
			Alprazolam	C				

Date:05/28/99ISR Number: 3354514-6Report Type:Periodic Company Report #A0088233
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Dermatitis						DAY / ORAL	
	Dyspepsia							
	Pruritus							

Date:05/28/99ISR Number: 3354520-1Report Type:Periodic Company Report #A0088234
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	
			Fluoxetine Hydrochloride	C				
			Naproxen	C				
			Omeprazole	C				
			Loratadine	C				

Date:05/28/99ISR Number: 3354521-3Report Type:Periodic Company Report #A0088235
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
			Thyroxine Sodium	C				
			Birth Control	C				

Date:05/28/99ISR Number: 3354523-7Report Type:Periodic Company Report #A0088236
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Atorvastatin Calcium	C				
			Zestoretic	C				
			Multivitamin	C				

Date:05/28/99ISR Number: 3354526-2Report Type:Periodic Company Report #A0088237
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Drug Ineffective							

/ ORAL

Date:05/28/99ISR Number: 3354530-4Report Type:Periodic Company Report #A0088238
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dissociation						TWICE PER DAY	
	Hypokinesia						/ ORAL	
	Vomiting							

Date:05/28/99ISR Number: 3354531-6Report Type:Periodic Company Report #A0088239
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	
			Nasal (Unspecified)	C				

Date:05/28/99ISR Number: 3354534-1Report Type:Periodic Company Report #A0088240
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Headache						TWICE PER DAY	
	Heart Rate Increased						/ ORAL	
	Nausea		Sertraline Hydrochloride	C				

			Birth Control	C		

Date:05/28/99ISR Number: 3354548-1Report Type:Periodic Company Report #A0088241
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	1 WK

Date:05/28/99ISR Number: 3354550-XReport Type:Periodic Company Report #A0088242
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Testosterone Decreased	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Erectile Dysfunction							

Date:05/28/99ISR Number: 3354552-3Report Type:Periodic Company Report #A0088243
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY / ORAL	
	Disturbance In Attention							
	Emotional Disorder							
	Sedation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354556-0Report Type:Periodic Company Report #A0088244
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3354557-2Report Type:Periodic Company Report #A0088274
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Dizziness							
	Drug Effect Decreased							
	Headache		Multivitamin	C				
	Insomnia							
	Middle Insomnia							
	Nausea							
	Tremor							

Date:05/28/99ISR Number: 3354559-6Report Type:Periodic Company Report #A0088416
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Pruritus							
	Urticaria							

Date:05/28/99ISR Number: 3354561-4Report Type:Periodic Company Report #A0088419
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Oestradiol	C				

Date:05/28/99ISR Number: 3354563-8Report Type:Periodic Company Report #A0088420
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Nausea							

Date:05/28/99ISR Number: 3354566-3Report Type:Periodic Company Report #A0088421
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY	/ ORAL
			Birth Control	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354568-7Report Type:Periodic Company Report #A0088422
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
			Prednisone	C				
			Thyroxine Sodium	C				
			Lorazepam	C				

Date:05/28/99ISR Number: 3354575-4Report Type:Periodic Company Report #A0088423
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3354580-8Report Type:Periodic Company Report #A0087996
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY	
	Insomnia							
			Atorvastatin Calcium	C				
			Digoxin	C				
			Orciprenaline Sulphate	C				

Date:05/28/99ISR Number: 3354582-1Report Type:Periodic Company Report #A0087997
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Libido Decreased						TWICE PER DAY	

Date:05/28/99ISR Number: 3354584-5Report Type:Periodic Company Report #A0087998
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Vomiting						TWICE PER DAY	
			Diltiazem Hydrochloride	C				
			Atenolol	C				
			Doxazosin Mesylate	C				
			Omeprazole	C				
			Nitroglycerin	C				

Date:05/28/99ISR Number: 3354613-9Report Type:Periodic Company Report #A0087999
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
			Terazosin Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354615-2Report Type:Periodic Company Report #A0088000
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Anxiety						TWICE PER DAY	
			Enalapril Maleate	C				
			Lovstatin	C				

Date:05/28/99ISR Number: 3354616-4Report Type:Periodic Company Report #A0088001
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	
	Rectal Haemorrhage							

Date:05/28/99ISR Number: 3354619-XReport Type:Periodic Company Report #A0088002
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	

Date:05/28/99ISR Number: 3354621-8Report Type:Periodic Company Report #A0088003
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
							TWICE PER DAY	
			Verapamil					

				Hydrochloride	C		
				Hydrochlorothiazide	C		
				Omeprazole	C		

Date:05/28/99ISR Number: 3354623-1Report Type:Periodic Company Report #A0088004
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY
	Rash Erythematous							

Date:05/28/99ISR Number: 3354626-7Report Type:Periodic Company Report #A0088027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	TWICE PER DAY
	Hyperaesthesia	Professional						
	Hyperkeratosis		Nicotine	C				
	Myalgia		Vitamin	C				
	Rash Maculo-Papular		Calcium Salt	C				
	Skin Discolouration		Aspirin	C				
	Therapeutic Response		Nicotine Polacrilex	C				
	Unexpected							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354630-9Report Type:Periodic Company Report #A0088044
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Consumer	Zyban Tablet - Zyban	PS		ORAL	TWICE PER DAY	
			Minocycline Hydrochloride	C				

Date:05/28/99ISR Number: 3354632-2Report Type:Periodic Company Report #A0088118
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Dizziness							
	Headache							
	Insomnia							

Date:05/28/99ISR Number: 3354633-4Report Type:Periodic Company Report #A0088119
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	

Date:05/28/99ISR Number: 3354635-8Report Type:Periodic Company Report #A0088120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	

Date:05/28/99ISR Number: 3354636-XReport Type:Periodic Company Report #A0088121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG	1 WK

Date:05/28/99ISR Number: 3354640-1Report Type:Periodic Company Report #A0088122
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Urticaria							
			Birth Control	C				

Date:05/28/99ISR Number: 3354664-4Report Type:Periodic Company Report #A0088123
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Psoriasis	Professional						
			Baclofen	C				
			Oxycodone Hydrochloride	C				
			Clonazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354669-3Report Type:Periodic Company Report #A0088124
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Urticaria						TWICE PER DAY	

Date:05/28/99ISR Number: 3354672-3Report Type:Periodic Company Report #A0088144
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	

Date:05/28/99ISR Number: 3354675-9Report Type:Periodic Company Report #A0088169
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER DAY	
	Liver Function Test Abnormal							
	Urinary Tract Infection							

Date:05/28/99ISR Number: 3354682-6Report Type:Periodic Company Report #A0089259
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY	
	Irritability							

	Tremor						
/ ORAL							
				Aspirin	C		

Date:05/28/99ISR Number: 3354686-3Report Type:Periodic Company Report #A0089260
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Headache							
TWICE PER DAY								
/ ORAL								
			Prednisone	C				
			Salbutamol Sulphate	C				
			Theophylline	C				
			Diazepam	C				

Date:05/28/99ISR Number: 3354689-9Report Type:Periodic Company Report #A0089261
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
	Confusional State							
DAY / ORAL								
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354692-9Report Type:Periodic Company Report #A0089262
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
	Oliguria						/ ORAL	
	Skin Odour Abnormal		Metoprolol	C				

Date:05/28/99ISR Number: 3354695-4Report Type:Periodic Company Report #A0089263
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dry Mouth						TWICE PER DAY	
	Fatigue						/ ORAL	
	Hyperglycaemia		Human Int/Long Insulin	C				
			Vicodin	C				

Date:05/28/99ISR Number: 3354697-8Report Type:Periodic Company Report #A0089264
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	
			Warfarin Sodium	C				

Date:05/28/99ISR Number: 3354700-5Report Type:Periodic Company Report #A0089276
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Discharge	Health Professional Company Representative	Zyban Tablet - Zyban	PS		ORAL	ORAL	

Date:05/28/99ISR Number: 3354701-7Report Type:Periodic Company Report #A0089369
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction Sexual Dysfunction	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/28/99ISR Number: 3354702-9Report Type:Periodic Company Report #A0089375
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Atrovastatin Calcium	C				
			Metoprolol	C				
			Ipratropium Bromide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354706-6Report Type:Periodic Company Report #A0089486
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Disturbance In Attention						TWICE PER DAY	
	Headache						/ ORAL	5 DAY
	Pain In Extremity							

Date:05/28/99ISR Number: 3354707-8Report Type:Periodic Company Report #A0089487
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG / ORAL	

Date:05/28/99ISR Number: 3354709-1Report Type:Periodic Company Report #A0089488
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	
			Dirithromycin	C				
			Nasonex	C				

Date:05/28/99ISR Number: 3354711-XReport Type:Periodic Company Report #A0089489
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG /						
	Drug Withdrawal Syndrome					
TWICE PER DAY						
/ ORAL						
			Cardiovascular Medication	C		

Date:05/28/99ISR Number: 3354712-1Report Type:Periodic Company Report #A0089490
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG / PER						
DAY / ORAL						
			Salbutamol Sulphate	C		
			Steroid	C		

Date:05/28/99ISR Number: 3354713-3Report Type:Periodic Company Report #A0089491
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Zyban Tablet - Zyban	PS		ORAL
150 MG / ORAL						
	Pruritus		Multivitamins	C		
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/99ISR Number: 3354714-5Report Type:Periodic Company Report #A0089492
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Psychomotor Hyperactivity						TWICE PER DAY	
/ ORAL								

Date:05/28/99ISR Number: 3354716-9Report Type:Periodic Company Report #A0089493
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Pruritus	Professional					TWICE PER DAY	
	Urticaria							
/ ORAL								

Date:05/28/99ISR Number: 3354717-0Report Type:Periodic Company Report #A0089494
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Choking	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
/ ORAL								
			Thyroid Medication	C				

Date:05/28/99ISR Number: 3354718-2Report Type:Periodic Company Report #A0089495
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
							/ ORAL	
			Fluoxetine Hydrochloride	C				

Date:05/28/99ISR Number: 3354720-0Report Type:Periodic Company Report #A0089569
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / PER	
							DAY / ORAL	
			Salbutamol Sulphate	C				
			Steroid	C				

Date:06/01/99ISR Number: 3274163-8Report Type:Expedited (15-DaCompany Report #A0075934
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Foreign	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE	
Hospitalization -	Dizziness	Health					PER DAY/ORAL	
Initial or Prolonged	Dyspnoea	Professional						
	Pruritus							
	Respiratory Disorder							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/01/99ISR Number: 3274165-1Report Type:Expedited (15-DaCompany Report #A0092791
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dyspnoea Laryngitis	Foreign Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG /TWICE PER DAY/ ORAL

Date:06/01/99ISR Number: 3275117-8Report Type:Expedited (15-DaCompany Report #A0075655
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Amnesia Dyspnoea Emotional Disorder Grand Mal Convulsion Status Epilepticus	Foreign Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:06/01/99ISR Number: 3275405-5Report Type:Expedited (15-DaCompany Report #A0093420
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain Dermatitis Dyspnoea Hypoaesthesia Pain In Jaw Pharyngeal Oedema Proctalgia Pruritus Urethral Pain Urticaria White Blood Cell Count Increased	Consumer	Zyban Tablet- Zyban	PS		ORAL	150 MG / TWICE PER DAY

Date:06/01/99ISR Number: 3275421-3Report Type:Expedited (15-DaCompany Report #A0093419
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Insomnia	Foreign Consumer	Zyban Tablets - Zyban	PS		ORAL	150 MG / TWICE PER DAY	

Date:06/03/99ISR Number: 3275549-8Report Type:Expedited (15-DaCompany Report #A0093694
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Grand Mal Convulsion Spinal Fracture	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/PER DAY/ ORAL	1 MON

Date:06/03/99ISR Number: 3275550-4Report Type:Expedited (15-DaCompany Report #A0090630
Age:30 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcohol Poisoning Coma	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	ORAL	
	Disorientation	Company	Ethanol Liquid	SS		ORAL	ORAL	
	Dizziness Intentional Misuse Metabolic Encephalopathy Nystagmus Status Epilepticus	Representative						

Date:06/03/99ISR Number: 3355153-3Report Type:Periodic Company Report #1998UW48296
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Paraesthesia	Health Professional	Tenormin Zyban	PS SS		ORAL	150 MG BID PO	
			Quinapril Hydrochloride	C				
			Metronidazole	C				
			Dipyridamole	C				
			Allopurinol	C				

Date:06/05/99ISR Number: 3277700-2Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Oedema Peripheral		Welbutrin 150mg Sr Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	150MG 2 X DAY ORAL	
			Ritalin	C				

Date:06/07/99ISR Number: 3277398-3Report Type:Expedited (15-DaCompany Report #A0089648
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Valve Replacement International Normalised Ratio Decreased	Health Professional Other	Wellbutrin (Formulation Unknown)	PS		ORAL	100 MG/PER DAY	/ORAL
			Mirtazapine	SS		ORAL	60 MG/PER DAY	/ORAL
			Warfarin Sodium	C				
			Atenolol	C				
			Beclomethasone Dipropion	C				
			Clonazepam	C				
			Docusate Sodium	C				
			Terazosin Hydrochloride	C				
			Lisinopril	C				
			Nitrofurantoin	C				
			Metronidazole	C				
			Simvastatin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/99ISR Number: 3277400-9Report Type:Expedited (15-DaCompany Report #A0086682
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Level Above	Health	Lamictal Tablet	PS		ORAL	25 MG/ AT	
	Therapeutic	Professional					NIGHT ORAL	
	Tremor	Other	Wellbutrin (Formulation Unknown)	SS			150 MG	
			Valproic Acid (Formulation Unknown)	SS		ORAL	2000 MG/AT	NIGHT/ORAL
			Olanzapine	C				
			Paroxetine Hydrochloride	C				
			Clonazepam	C				
			Liothyronine Sodium	C				
			Thyroxine Sodium	C				

Date:06/07/99ISR Number: 3277401-0Report Type:Expedited (15-DaCompany Report #A0093717
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE	
	Difficulty In Walking	Consumer					PER DAY ORAL	
	Myalgia							
	Pain							

Date:06/09/99ISR Number: 3278626-0Report Type:Direct Company Report #
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Completed Suicide Disturbance In Attention Judgement Impaired Memory Impairment		Wellbutrin - Dose And Type Unknown	PS	

Date:06/10/99ISR Number: 3280027-6Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Joint Swelling Rash Pruritic Urticaria	Health Professional	Zyban Prednisone Allegra Hydroxyzine Doxycycline	PS C C C C		

Date:06/10/99ISR Number: 3280754-0Report Type:Expedited (15-DaCompany Report #A0094450
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Aortic Injury Road Traffic Accident	Consumer	Zyban Tablet - Zyban	PS		ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/99ISR Number: 3280771-0Report Type:Expedited (15-DaCompany Report #A0093619
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Anomaly Of External Ear Congenital Cleft Lip And Palate	Study Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	ORAL	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Congenital Diaphragmatic Hernia							
	Foetal Growth Retardation							
	Hemivertebra							
	Hypoplastic Left Heart Syndrome							
	Limb Malformation							
	Microcephaly							
	Premature Baby							

Date:06/10/99ISR Number: 3280791-6Report Type:Expedited (15-DaCompany Report #A0093970
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm	Foreign Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:06/10/99ISR Number: 3281160-5Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tongue Oedema		Glaxo Wellcome - Wellbutrin	PS	Glaxo Wellcome	ORAL	300 MG PO	
			Prinivil	C				
			Hctz	C				
			Premarin	C				

Date:06/11/99ISR Number: 3281087-9Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Hypersensitivity Pruritus Rash Erythematous		Zyban (Bupropion) Septra	PS SS		ORAL	150 MG PO BID	

Date:06/11/99ISR Number: 3281245-3Report Type:Direct Company Report #
Age:16 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening
Hospitalization -
Initial or Prolonged
Disability
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia		Wellbutrin					
	Coma		Controlled Release					
	Convulsion		150 Mg (Glaxo					
	Overdose		Wellcome)	PS	Glaxo Wellcome		150 MG BID	3 MON
	Pulse Absent							
	Ventricular Tachycardia							

Date:06/11/99ISR Number: 3281273-8Report Type:Direct Company Report #
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hypoaesthesia	Health	Bupropion	PS		ORAL	150 MG BID PO	5 WK
Intervention to Prevent Permanent Impairment/Damage	Hypoaesthesia Oral	Professional						
	Oedema Peripheral							
	Urticaria							

Date:06/11/99ISR Number: 3281312-4Report Type:Direct Company Report #
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Sr 150 Mg	PS			BID	
	Nausea							
	Rash Generalised							
	Red Blood Cell Sedimentation Rate Increased							
	Urticaria							

Date:06/11/99ISR Number: 3281896-6Report Type:Expedited (15-DaCompany Report #A0092789
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Auricular Swelling	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dermatitis	Health					TWICE PER DAY	
	Dyspnoea	Professional					/ ORAL	
	Eyelid Oedema							
	Oedema							
	Oedema Peripheral							
	Pruritus							
	Pyrexia							
	Rash Papular							
	Speech Disorder							
	Urticaria							

Date:06/14/99ISR Number: 3282754-3Report Type:Expedited (15-DaCompany Report #A0090688
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Disability	Amnesia
	Aphasia
	Cerebrovascular Accident
	Choking
	Cognitive Deterioration
	Condition Aggravated

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hemiplegia Hypoaesthesia Medication Error	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Poverty Of Speech	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:06/14/99ISR Number: 3336395-XReport Type:Periodic Company Report #WAES 98060990
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia Chest Pain	Consumer	Tab Losartan Potassium Unk	PS		ORAL	PO	
	Drug Interaction		Zyban 150 Mg	SS		ORAL	150 MG/DAILY/PO	
	Palpitations							
			Composition Unspecified	C				
			Nitroglycerin	C				

Date:06/15/99ISR Number: 3284190-2Report Type:Direct Company Report #
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Fall		Buproprion Glaxo Wellcome	PS	Glaxo Wellcome		100MG BID	
	Head Injury		Chloral Hydrate	C				
			Divalproex	C				
			Ibuprofen	C				

Date:06/16/99ISR Number: 3284272-5Report Type:Expedited (15-DaCompany Report #A0079132
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Wellbutrin					
Life-Threatening	Completed Suicide	Professional	Tablet-Controlled					
Hospitalization - Initial or Prolonged	Convulsion	Company	Release	PS		ORAL	150 MG / SEE TEXT / ORAL	
	Loss Of Consciousness	Representative						
Other	Overdose		Paroxetine Hydrochloride	C				

Date:06/16/99ISR Number: 3284303-2Report Type:Expedited (15-DaCompany Report #A0094003
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dry Mouth	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Feeling Of Despair	Health						
	Headache	Professional						
	Myopia							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/16/99ISR Number: 3284304-4Report Type:Expedited (15-DaCompany Report #A0090360
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Amylase Increased	Health	Wellbutrin					
Hospitalization -	Lipase Increased	Professional	Tablet-Controlled					
Initial or Prolonged	Pancreatitis	Company	Release	PS		ORAL	150 MG / PER	
Other		Representative					DAY / ORAL	
			Prempro (Formulation					
			Unknown)	SS		ORAL	PER DAY /	
							ORAL	

Date:06/16/99ISR Number: 3284305-6Report Type:Expedited (15-DaCompany Report #A0089648
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable	Health	Wellbutrin					
Initial or Prolonged	Coronary Artery Disease	Professional	(Formulation					
	Coronary Artery Surgery	Other	Unknown)	PS		ORAL	100 MG / PER	
	International Normalised						DAY / ORAL	
	Ratio Decreased		Mirtazapine Tablet	SS		ORAL	60 MG / PER	
	Mitral Valve Incompetence						DAY / ORAL	
	Mitral Valve Replacement		Warfarin Sodium	C				
			Atenolol	C				
			Beclomethasone Dipropion	C				
			Clonazepam	C				
			Docusate Sodium	C				
			Terazosin Hydrochloride	C				
			Lisinopril	C				
			Nitrofurantoin	C				
			Metronidazole	C				
			Simvastatin	C				

Date:06/16/99ISR Number: 3284791-1Report Type:Expedited (15-DaCompany Report #A0087945
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Zyban Tablet-Zyban	PS		ORAL	150 MG / PER	
Initial or Prolonged	Convulsion	Professional					DAY / ORAL	
Disability	Epistaxis		Claritin-D	C				
	Loss Of Consciousness		Nicotine	C				
	Mouth Haemorrhage							
	Nasal Congestion							

Date:06/17/99ISR Number: 3286264-9Report Type:Expedited (15-DaCompany Report #A0094827
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dyspnoea	Consumer					TWICE PER DAY	
	Oedema						/	
	Serum Sickness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/99ISR Number: 3286403-XReport Type:Expedited (15-DaCompany Report #A0091793
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Aggression	Foreign	Wellbutrin				
Hospitalization - Initial or Prolonged	Depression	Health	Tablet-Controlled				
	Paranoia	Professional	Release	PS		ORAL	100 MG / PER
Other	Physical Assault						DAY / ORAL
	Psychotic Disorder		Clavulin	C			
	Suicidal Ideation						

Date:06/21/99ISR Number: 3288383-XReport Type:Expedited (15-DaCompany Report #A0092189
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign	Zyban Tablet- Zyban	PS		ORAL	150 MG / TWICE PER DAY
	Burning Sensation	Health					
	Drug Hypersensitivity	Professional					/ ORAL
	Eyelid Oedema						
	Facial Palsy						
	Pruritus						
	Urticaria						

Date:06/21/99ISR Number: 3288502-5Report Type:Expedited (15-DaCompany Report #1999-06-0585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Interaction	Study	Wellbutrin Tablets	PS		ORAL	ORAL
	Grand Mal Convulsion	Consumer	Intron A (Interferon				
		Other	Alfa-2b Recombina Injectable)	SS			5 MU TIW
			Rebetol (Ribavirin)				

			Capsules	SS		ORAL
1200 MG DAILY						
ORAL						

Date:06/21/99ISR Number: 3288509-8Report Type:Expedited (15-DaCompany Report #A0093320
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Agitation	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL
150 MG/TWICE PER DAY/ORAL	Cerebrovascular Accident Crying Emotional Distress					
	Facial Palsy		Azithromycin	C		
	Hypoaesthesia		Ranitidine Hydrochloride	C		
	Irritability		Nasonex	C		
	Medication Error Mental Disorder Transient Ischaemic Attack					

Date:06/23/99ISR Number: 3289562-8Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin 75 Mg (Glaxo- Wellcome)	PS	Glaxo-Wellcome	ORAL
37.5MG PO TID						
			Prilosec	C		

Cardizem Cd	C
Lasix	C
Kcl	C
Acetaminophen	C
Darvocet	C
Buspar	C
Oxistat	C
Zostrix	C
Mentax	C

Date:06/23/99ISR Number: 3289788-3Report Type:Expedited (15-DaCompany Report #A0095039
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /	
	Dysphonia	Consumer					TWICE PER DAY	
	Fall						/ ORAL	
	Head Injury							
	Muscle Rigidity							
	Nausea							
	Nervousness							

Date:06/24/99ISR Number: 3293878-9Report Type:Periodic Company Report #A001-002-003251
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Aricept (Donepezil)	PS		ORAL	5MG (1 IN 1D), PER ORAL	
	Hypertension	Health Professional	Wellbutrin (Bupropion Hcl) (Amfebutamone Hydrochloride)	SS			NA	
			Aspirin (Acetylsalicylic Acid)	C				

			Atenolol (Atenolol)	C		
			Diltiazem (Diltiazem)	C		
			Timoptic (Timolol Maleate)	C		
			Digoxin (Digoxin)	C		

Date:06/25/99ISR Number: 3291868-3Report Type:Expedited (15-DaCompany Report #A0094919
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Metastases To Lung	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/ORAL	5 DAY
			Omeprazole	C				
			Alprazolam	C				
			Dilantin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/99ISR Number: 3291906-8Report Type:Expedited (15-DaCompany Report #A0094798
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Paranoia	Foreign Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG / TWICE PER DAY

Date:06/25/99ISR Number: 3291926-3Report Type:Expedited (15-DaCompany Report #A0079132
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Brain Damage	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / SEE TEXT
Life-Threatening	Cardiac Arrest						
Hospitalization - Initial or Prolonged	Convulsion						
	Loss Of Consciousness						
Disability	Overdose		Paroxetine Hydrochloride	C			
Other	Tachycardia						

Date:06/25/99ISR Number: 3291929-9Report Type:Expedited (15-DaCompany Report #B0067691
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Medication Error	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG/ UNK/ ORAL
	Road Traffic Accident	Health Professional					

Date:06/28/99ISR Number: 3292685-0Report Type:Expedited (15-DaCompany Report #A0085805
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death	Health	Wellbutrin				

		Professional	Tablet-Controlled			
		Company	Release	PS		ORAL
150 MG TWICE						
		Representative				
PER DAY ORAL	1 MON					
			Tamoxifen	C		

Date:06/28/99ISR Number: 3292762-4Report Type:Expedited (15-DaCompany Report #A0094985
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Alkaline	Foreign	Wellbutrin			
	Phosphatase Increased	Health	Tablet-Controlled			
	Blood Bilirubin Increased	Professional	Release	PS		ORAL
150 MG / PER						
	Blood Creatinine					
DAY / ORAL						
	Increased		Cyclosporin	C		
	Blood Lactate					
	Dehydrogenase Increased					
	Gamma-Glutamyltransferase					
	Increased					

Date:06/29/99ISR Number: 3294540-9Report Type:Expedited (15-DaCompany Report #A0095026
Age:51 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Anaphylactic Shock
Initial or Prolonged	Asthenia
	Heart Rate Increased

	Hypersensitivity Hypotension Palpitations	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Skin Disorder Swelling	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY

Date:06/29/99ISR Number: 3294543-4Report Type:Expedited (15-DaCompany Report #A0094393
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Hallucination Psychotic Disorder	Health Professional Company Representative	Zyban Tablet - Zyban Haloperidol	PS C			3 WK

Date:06/30/99ISR Number: 3294734-2Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain Dermatitis Gastrooesophageal Reflux Disease Muscle Disorder Rash Pruritic Urticaria		Bupropion Sr 100 Mg Ginkgo Biloba Nizatidine Estropipate Vitamin E Multi-Vit	PS C C C C C		ORAL	100 MG OD PO

Date:06/30/99ISR Number: 3295013-XReport Type:Expedited (15-DaCompany Report #A0084631
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health	Wellbutrin Tablet -				

	Depressed Level Of Consciousness	Professional	Controlled Release	PS	ORAL 150 MG / TWICE PER DAY
			Oral Contraceptive	C	
			Fluoxetine Hydrochloride	C	
			Amitriptyline	C	
			Sumatriptan Succinate	C	
			Fiorinal	C	
			Fexofenadine Hydrochlorid	C	
			Fluticasone Propionate	C	

Date:06/30/99ISR Number: 3295035-9Report Type:Expedited (15-DaCompany Report #A0089368
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Death	Agitation
Hospitalization - Initial or Prolonged	Alcohol Interaction
Other	Atrioventricular Block
	Blood Alcohol Increased
	Cardiac Arrest
	Completed Suicide
	Convulsion

		Intentional Misuse Loss Of Consciousness Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL
200 TABLET/ SINGLE DOSE/ ORAL							
				Ethanol (Formulation Unknown)	SS		

Date:06/30/99ISR Number: 3295039-6Report Type:Expedited (15-DaCompany Report #A0085804
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL
150 MG/ TWICE PER DAY/ ORAL							
				Sildenafil Citrate	C		

Date:06/30/99ISR Number: 3295040-2Report Type:Expedited (15-DaCompany Report #A0093402
Age:47 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Liver Disorder Metastases To Liver	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL
150 MG/ PER DAY/ ORAL							
				Tamoxifen	C		
				Paroxetine Hydrochloride	C		

Date:06/30/99ISR Number: 3295341-8Report Type:Expedited (15-DaCompany Report #A0095803
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health Professional Company Representative	Zyban Tablet - Zyban	PS	Zyban			

Date:06/30/99ISR Number: 3295342-XReport Type:Expedited (15-DaCompany Report #A0095677
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Insomnia	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG	

Date:07/01/99ISR Number: 3294898-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT
Death	Anomaly Of External Ear Congenital Cleft Lip And Palate

	Complications Of Maternal Exposure To Therapeutic Drugs	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Congenital Diaphragmatic Hernia Congenital Hand Malformation Congenital Osteodystrophy Congenital Spinal Cord Anomaly Foetal Growth Retardation Hypoplastic Left Heart Syndrome Microcephaly Multiple Congenital Abnormalities Premature Baby		Wellbutrin	PS			

Date:07/01/99ISR Number: 3297085-5Report Type:Expedited (15-DaCompany Report #A0094919
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion Metastases To Central Nervous System	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL 5 YR
			Omeprazole	C			

Date:07/01/99ISR Number: 3341444-9Report Type:Periodic Company Report #USA008973
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Agitation Confusional State	Health Professional	Meridia	PS		ORAL	10 MG OD PO

	Gait Disturbance	Other	Zyban	SS		ORAL
150 MG						
	Restlessness					
UNK PO						

Date:07/01/99ISR Number: 3346622-0Report Type:Periodic Company Report #USA008215
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abnormal Dreams	Consumer	Meridia	PS		ORAL
10 MG OD PO						
	Central Nervous System Stimulation	Other	Wellbutrin	SS		
			Lithium	C		
	Feeling Of Relaxation		Serzone	C		
	Therapeutic Response		Synthroid	C		
	Unexpected					

Date:07/06/99ISR Number: 3297829-2Report Type:Expedited (15-DaCompany Report #A0095664
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bronchospasm	Health	Zyban Tablet - Zyban	PS		ORAL
150 MG/TWICE						
Initial or Prolonged	Dermatitis	Professional				
PER DAY ORAL						
	Loss Of Consciousness	Company Representative	Nitrofurantoin (Formulation			

			Unknown)	SS			
			Clonazepam	C			
			Hydroxyzine Hydrochloride	C			
			Oxybutynin Hydrochloride	C			
			Thyroxine Sodium	C			
			Phenazopyridine Hcl	C			

Date:07/06/99ISR Number: 3297832-2Report Type:Expedited (15-DaCompany Report #A0095671
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion Drug Level Below Therapeutic Fall	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL	100 MG/TWICE PER DAY ORAL
	Head Injury		Chloral Hydrate	C			
			Semisodium Valproate	C			
			Ibuprofen	C			

Date:07/06/99ISR Number: 3297998-4Report Type:Expedited (15-DaCompany Report #A0095916
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Constipation	Literature	Wellbutrin Tablet	PS		ORAL	150 MG/DAY / UNK / ORAL 3 WK
	Faecaloma		Lithium Salt	C			
	Ileus Paralytic		Diltiazem	C			
	Vomiting		Ranitidine Hydrochloride	C			
			Aspirin	C			
			Calcium Salt	C			

Date:07/06/99ISR Number: 3298001-2Report Type:Expedited (15-DaCompany Report #A0095916
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Literature	Wellbutrin Tablet	PS		ORAL	150 MG/DAY / UNK /	ORAL 3 WK
	Constipation							
	Faecaloma		Lithium Salt	C				
	Ileus Paralytic		Diltiazem	C				
	Vomiting		Ranitidine Hydrochloride	C				
			Aspirin	C				
			Calcium Salt	C				

Date:07/06/99ISR Number: 3298373-9Report Type:Expedited (15-DaCompany Report #A0095889
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER DAY / ORAL	
	Fatigue	Consumer						
	Hypoglycaemia							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/99ISR Number: 3300658-4Report Type:Periodic Company Report #107251
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder	Consumer	Klonopin	PS		ORAL	1 MG 4 PER	DAY ORAL
	Hypoaesthesia							
	Motion Sickness		Zyban (Bupropion Hydrochloride)	SS		ORAL	ORAL	
			Premarin	C				

Date:07/08/99ISR Number: 3299256-0Report Type:Expedited (15-DaCompany Report #A0095816
Age:6 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Consumer	Wellbutrin Tablet	PS		ORAL	37.5 MG ALTERNATE	DAYS ORAL
	Candidiasis							
	Dysphemia							
	Kidney Infection							
	Pharyngitis Streptococcal							
	Tongue Disorder							

Date:07/12/99ISR Number: 3301398-8Report Type:Direct Company Report #
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis		Bupropion 100mg Sr Tab	PS		ORAL	100MG SR BID	PO
	Pruritus							
			Gabapentin	C				
			Multivitamin/Minerals	C				

Date:07/12/99ISR Number: 3301440-4Report Type:Expedited (15-DaCompany Report #A0095928
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased	Health Professional	Wellbutrin (Formulation Unknown)	PS		ORAL		
Other	Leukopenia							
ORAL								
	Neuroleptic Malignant Syndrome		Dexamphetamine Sulphate (Formulation Unknown)	SS				
	Pyrexia							
	Sepsis							
	Serotonin Syndrome							
	Urinary Tract Infection							

Date:07/12/99ISR Number: 3302470-9Report Type:Expedited (15-DaCompany Report #A0096258
Age:42 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Brain Oedema
	Chest Pain
	Coma
	Diabetes Mellitus
	Inadequate Control
	Difficulty In Walking
	Loss Of Consciousness
	Oedema Peripheral

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS		ORAL	150 MG / PER DAY / ORAL
			Gabapentin	C			
			Troglitazone	C			
			Amlodipine	C			
			Int./Long-Acting Insulin	C			

Date:07/14/99ISR Number: 3303994-0Report Type:Expedited (15-DaCompany Report #A0095916
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Blood Creatinine Increased Blood Urea Increased Constipation Drug Interaction Faecaloma Ileus Paralytic Vomiting	Literature	Wellbutrin Tablet	PS		ORAL	150MG DAY ORAL 3 WK
			Lithium Salt	C			
			Diltiazem	C			
			Ranitidine Hydrochloride	C			
			Aspirin	C			
			Calcium Salt	C			

Date:07/14/99ISR Number: 3304022-3Report Type:Expedited (15-DaCompany Report #A0077001
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Arthralgia Dermatitis Difficulty In Walking Dyspnoea Exertional Erythema Multiforme	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/TWICE PER DAY/ ORAL

Eyelid Oedema
Face Oedema
Fall
Fatigue
Joint Stiffness
Migraine
Pain
Pain In Extremity
Proteinuria
Pruritus
Serum Sickness
Stevens-Johnson Syndrome
Throat Tightness
Urticaria
Vomiting

Date:07/14/99ISR Number: 3304023-5Report Type:Expedited (15-DaCompany Report #A0073901
Age:29 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Wellbutrin					
	Decreased Appetite	Professional	Tablet-Controlled					
	Dyspnoea Exertional	Company	Release	PS		ORAL	150 MG/ TWICE	
	Erythema Multiforme	Representative					PER DAY/ ORAL	
	Face Oedema							
	Fall							
	Insomnia							
	Joint Stiffness							
	Migraine							
	Oral Pain							
	Orbital Oedema							
	Pain In Extremity							
	Proteinuria							
	Rash Erythematous							
	Serum Sickness							
	Stevens-Johnson Syndrome							
	Throat Tightness							
	Urticaria							
	Vomiting							
	White Blood Cell Count Increased							

Date:07/15/99ISR Number: 3305168-6Report Type:Expedited (15-DaCompany Report #A0093619
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acrochordon	Study	Wellbutrin					
Life-Threatening	Bone Development Abnormal	Health	(Formulation					
Hospitalization -	Cleft Lip	Professional	Unknown)	PS		ORAL		
ORAL								
Initial or Prolonged	Cleft Palate							
Congenital Anomaly	Complications Of Maternal							
	Exposure To Therapeutic							
	Drugs							
	Diaphragmatic Hernia							
	Foetal Growth Retardation							
	Hemivertebra							
	Hypoplastic Left Heart							

	Syndrome
	Limb Malformation
	Microcephaly
	Premature Baby

Date:07/15/99ISR Number: 3305172-8Report Type:Expedited (15-DaCompany Report #A0095664
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaphylactic Reaction
	Blood Creatine Increased
	Bronchospasm
	Circulatory Collapse
	Depressed Level Of Consciousness
	Dizziness
	Dysuria
	Faeces Discoloured
	Hallucination

	Hypotension						
	Personality Change						
	Rash Maculo-Papular	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	White Blood Cell Count	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG /
	Increased	Professional					TWICE PER DAY
	White Blood Cells Urine	Company					/ ORAL
	Positive	Representative	Nitrofurantoin	SS			
			Clonazepam	C			
			Hydroxyzine Hydrochloride	C			
			Oxybutynin Hydrochloride	C			
			Thyroxine Sodium	C			
			Phenazopyridine Hcl	C			

Date:07/15/99ISR Number: 3305177-7Report Type:Expedited (15-DaCompany Report #A0093422
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Arthralgia	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG /
	Joint Swelling	Health					TWICE PER DAY
	Rash Erythematous	Professional					/ ORAL
	Rash Generalised	Company	Nicotine	C			
	Rash Papular	Representative					
	Red Blood Cell Sedimentation Rate Increased						
	Rheumatoid Arthritis						
	Rheumatoid Factor Positive						
	Serum Sickness						
	Urticaria						
	White Blood Cell Count Increased						

Date:07/16/99ISR Number: 3305591-XReport Type:Expedited (15-DaCompany Report #A0096492
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysphagia Dyspnoea Embolism Oedema Peripheral Swelling	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG/ TWICE PER DAY / ORAL	
			Paracetamol	C				

Date:07/16/99ISR Number: 3305593-3Report Type:Expedited (15-DaCompany Report #A0096292
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG /PER DAY / ORAL	2 DAY
			Nefazodone Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/99ISR Number: 3305577-5Report Type:Direct Company Report #
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blood Pressure Increased		Zyban 150mg Glaxo	PS	Glaxo	ORAL	150MG QD PO
	Drug Withdrawal Syndrome						
	Headache						
	Insomnia						

Date:07/20/99ISR Number: 3307410-4Report Type:Expedited (15-DaCompany Report #A0093420
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cardiomegaly	Health	Zyban Tablet - Zyban	PS		ORAL	150 MG / TWICE PER DAY
	Chest Discomfort	Professional					
	Chest Pain						/ ORAL
	Dyspnoea						
	Hyperhidrosis						
	Pain In Jaw						
	Proctalgia						
	Pruritus						
	Rash Macular						
	Throat Tightness						
	Urethral Pain						
	Urticaria						
	White Blood Cell Count Increased						

Date:07/20/99ISR Number: 3307424-4Report Type:Expedited (15-DaCompany Report #A0095964
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Apnoea	Consumer	Zyban Tablet-Zyban	PS		ORAL	150 MG/TWICE PER DAY/ORAL
	Dysarthria						

	Feeling Hot		Ethanol Liquid	SS		ORAL
ORAL						
	Headache		Fluoxetine			
	Movement Disorder		Hydrochloride	C		
	Nausea		Aspirin	C		
	Syncope					
	Tremor					
	Urinary Incontinence					

Date:07/21/99ISR Number: 3308227-7Report Type:Expedited (15-DaCompany Report #A0090688
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Amnesia	Consumer	Wellbutrin			
	Aphasia		Tablet-Controlled			
	Cerebral Artery Occlusion		Release	PS		ORAL
150 MG /						
	Cerebrovascular Accident					
TWICE PER DAY						
	Choking					
/ ORAL						
	Craniotomy					
	Hemiplegia					
	Hypoaesthesia					
	Mental Impairment					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/99ISR Number: 3308995-4Report Type:Expedited (15-DaCompany Report #A0094985
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Bilirubin Increased	Foreign	Wellbutrin					
	Blood Creatinine Increased	Health Professional	Tablet-Controlled Release	PS		ORAL	150 MCG PER DAY	
	Liver Function Test Abnormal Thrombocythaemia		Cyclosporin	C				
			Clonidine	C				
			Dapsone	C				
			Metoclopramide	C				
			Acyclovir	C				
			Mycophanolate Mofetil	C				
			Omeprazole	C				
			Sodium Bicarbonate	C				
			Salbutamol Sulphate	C				
			Fluticasone Propionate	C				
			Prednisone	C				
			Insulin	C				

Date:07/22/99ISR Number: 3308996-6Report Type:Expedited (15-DaCompany Report #A0096983
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Wellbutrin					
	Headache	Consumer	Tablet-Controlled Release	PS		ORAL	ORAL	
	Petit Mal Epilepsy		Dilantin	C				
			Semisodium Valproate	C				
			Ibuprofen	C				

Date:07/22/99ISR Number: 3309971-8Report Type:Direct Company Report #
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Bupropion (Zyban)	PS		ORAL	150 MG PO BID	

Date:07/22/99ISR Number: 3309972-XReport Type:Direct Company Report #
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Bupropion (Zyban)	PS		ORAL	150 MG PO BID	
	Urticaria							

Date:07/23/99ISR Number: 3310515-5Report Type:Direct Company Report #
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Wellbutrin 100mg Tab	PS	Glaxo Wellcome		100MG BID	
	Convulsion		Aspirin	C				
	Monoparesis		Cycrohaptachine	C				
			Thiothiarie	C				
			Licarb	C				
			Dovusate	C				
			Calcium Carbonate	C				

			Multivitamin	C		

Date:07/27/99ISR Number: 3311855-6Report Type:Expedited (15-DaCompany Report #A0097480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Zyban Tablet - Zyban	PS	Zyban	ORAL		
ORAL								
	Complications Of Maternal Exposure To Therapeutic Drugs	Health Professional						

Date:07/27/99ISR Number: 3311863-5Report Type:Expedited (15-DaCompany Report #A0090907
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL		
150 MG /								
Initial or Prolonged	Dysphagia	Professional						
TWICE PER DAY								
	Dyspnoea							
/ ORAL								
	Face Oedema							
	Tongue Oedema							

Date:07/27/99ISR Number: 3311864-7Report Type:Expedited (15-DaCompany Report #A0094393
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination	Health	Zyban Tablet - Zyban	PS	Zyban	ORAL		
ORAL							3	WK
Initial or Prolonged	Schizophrenia	Professional	Amantadine	C				
	Suicidal Ideation	Company Representative	Haloperidol	C				

Date:07/27/99ISR Number: 3311865-9Report Type:Expedited (15-DaCompany Report #A0097494
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Confusional State Depression Eating Disorder Insomnia Mental Impairment Paranoia Personality Change Psychiatric Symptom	Consumer	Zyban Tablet - Zyban	PS	Zyban	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:07/27/99ISR Number: 3311866-0Report Type:Expedited (15-DaCompany Report #A0097409
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Health Professional Company Representative	Zyban Tablet - Zyban	PS	Zyban	ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/99ISR Number: 3311867-2Report Type:Expedited (15-DaCompany Report #A0097410
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional Company Representative	Zyban Tablet - Zyban	PS	Zyban	ORAL	ORAL	

Date:07/27/99ISR Number: 3313893-6Report Type:Direct Company Report #
Age:15.6 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Prolactin Increased Galactorrhoea	Health Professional	Risperadol 1.5mg Bid, Decreased 1mg Bid, Decreased 0.5mg Bid	PS			1.5MG BID, DECREASES 1MG BID, DECREASED 0.5MG BID	
			Wellbutrin 75mg Q Am	SS		ORAL	75MG PO Q AM	

Date:07/28/99ISR Number: 3312826-6Report Type:Expedited (15-DaCompany Report #A0097643
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease	Foreign	Zyban Tablet - Zyban	PS		ORAL	ORAL	
	Myocardial Infarction	Health Professional						

Date:07/28/99ISR Number: 3312853-9Report Type:Expedited (15-DaCompany Report #A0097619
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Foreign	Zyban Tablet- Zyban	PS		ORAL	150 MG TWICE	
Initial or Prolonged	Arthralgia	Health					PER DAY ORAL	
	Dermatitis	Professional	Ibuprofen	C				
	Difficulty In Walking							
	Ecchymosis							
	Heart Rate Increased							
	Malaise							
	Oedema Peripheral							
	Pain In Extremity							
	Pruritus							
	Serum Sickness							
	Skin Discolouration							
	Urticaria							

Date:07/28/99ISR Number: 3313807-9Report Type:Direct Company Report #
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dissociation		Zyban 150 Mg	PS		ORAL	150MG PO X 1T	
Required	Dysphoria							
Intervention to	Self Mutilation							
Prevent Permanent	Suicidal Ideation							
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/99ISR Number: 3313992-9Report Type:Direct Company Report #
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema Heart Rate Increased Rash Pruritic		Wellbutrin /150 Mg /Glaxo Wellcome	PS	Glaxco Wellcome		150MG	

Date:07/29/99ISR Number: 3314836-1Report Type:Periodic Company Report #A0091454
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet -Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:07/29/99ISR Number: 3314841-5Report Type:Periodic Company Report #A0091249
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bite Convulsion Lethargy Lip Disorder Myalgia Petit Mal Epilepsy Sedation Syncope Tremor	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release Cyclobenzaprine Hcl Fexofenadine Hydrochlorid Oral Contraceptive	PS C C C		ORAL	150 MG / TWICE PER DAY / ORAL	14 DAY

Date:07/29/99ISR Number: 3314849-XReport Type:Periodic Company Report #A0090423
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG/ TWICE PER DAY / ORAL	
			Gabapentin	C				

Date:07/29/99ISR Number: 3314853-1Report Type:Periodic Company Report #A0090175
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Suicidal Ideation	Health Professional Company Representative	Wellbutrin Tablet -Controlled Release	PS		ORAL	UNK / THREE TIMES PER DAY / ORAL	
			Lithium Salt	C				
			Risperidone	C				
			Propranolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/99ISR Number: 3314857-9Report Type:Periodic Company Report #A0090056
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Convulsion							
	Obsessive-Compulsive Disorder							
			Citalopram	C				

Date:07/29/99ISR Number: 3314860-9Report Type:Periodic Company Report #A0089931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Zolpidem Tartrate	C				

Date:07/29/99ISR Number: 3314863-4Report Type:Periodic Company Report #A0089310
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Malaise Pallor Tinnitus	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK/ TWICE PER DAY / ORAL	
			Quinapril					

			Hydrochloride	C		
			Omeprazole	C		
			Guaiphenesin	C		

Date:07/29/99ISR Number: 3314866-XReport Type:Periodic Company Report #A0088986
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination Psychotic Disorder	Health Professional Company Representative	Wellbutrin Tablet -Controlled Release	PS		ORAL	150 MG / Other TWICE PER DAY / ORAL	
			Bupropion Hydrochloride	C				

Date:07/29/99ISR Number: 3314870-1Report Type:Periodic Company Report #A0088918
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet -Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Fluoxetine Hydrochloride	C				
			Risperidone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/99ISR Number: 3314874-9Report Type:Periodic Company Report #A0088578
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / UNK / ORAL	
		Company Representative						

Date:07/29/99ISR Number: 3315404-8Report Type:Periodic Company Report #A0087647
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Road Traffic Accident	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	8 WK
			Dexamphetamine	C				

Date:07/29/99ISR Number: 3315411-5Report Type:Periodic Company Report #A0085964
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Burning Sensation Dehydration Dermatitis Exfoliative Dry Skin Erythema Multiforme Fatigue Fungal Skin Infection Infection	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Alprazolam	C				

	Pruritus					
	Psoriasis					
	Rash Generalised					

Date:07/29/99ISR Number: 3315418-8Report Type:Periodic Company Report #A0084031
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
			Fluoxetine Hydrochloride	C				
			Clonazepam	C				
			Quetiapine Fumarate	C				

Date:07/29/99ISR Number: 3315424-3Report Type:Periodic Company Report #A0077917
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	

/ ORAL

Lortab	C
Salbutamol Sulphate	C
Triamcinolone Acetonide	C
Testosterone	C

Date:07/29/99ISR Number: 3315431-0Report Type:Periodic Company Report #A0079654
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Accidental Overdose Alcohol Interaction Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / THREE TIMES PER DAY ORAL	
			Ethanol (Formulation Unknown)	SS		ORAL	UNK / UNK / ORAL	

Date:07/29/99ISR Number: 3315435-8Report Type:Periodic Company Report #A0096490
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / UNK / ORAL	

Date:07/29/99ISR Number: 3315438-3Report Type:Periodic Company Report #A0096029
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	1 YR

Date:07/29/99ISR Number: 3315442-5Report Type:Periodic Company Report #A0095870
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	3 DAY

Date:07/29/99ISR Number: 3315446-2Report Type:Periodic Company Report #A0095616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / UNK / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/99ISR Number: 3315450-4Report Type:Periodic Company Report #A0095478
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma Suicide Attempt	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
			Citalopram	SS		ORAL	40 MG / PER DAY / ORAL	
			Trazodone	C				

Date:07/29/99ISR Number: 3315453-XReport Type:Periodic Company Report #A0094080
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Paclitaxel	C				

Date:07/29/99ISR Number: 3315457-7Report Type:Periodic Company Report #A0093073
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Dermatitis Pruritus	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	

/ ORAL

Date:07/29/99ISR Number: 3315459-0Report Type:Periodic Company Report #A0092987
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion Loss Of Consciousness	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / PER DAY / ORAL	
			Moexipril Hydrochloride	C				
			Sertraline Hydrochloride	C				

Date:07/29/99ISR Number: 3315461-9Report Type:Periodic Company Report #A0092653
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion Overdose	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / THREE TIMES PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/99ISR Number: 3315463-2Report Type:Periodic Company Report #A0092326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / ORAL	UNK /

Date:07/29/99ISR Number: 3315464-4Report Type:Periodic Company Report #A0092331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / ORAL	UNK /

Date:07/29/99ISR Number: 3315466-8Report Type:Periodic Company Report #A0092357
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Micturition Urgency Urinary Retention	Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / DAY	PER
			Mirtazepine	C				
			Thyroxine Sodium	C				
			Phentermine Hydrochloride	C				
			Valaciclovir	C				

Date:07/29/99ISR Number: 3315468-1Report Type:Periodic Company Report #A0092192
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Overdose Respiratory Failure	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	UNK / SEE TEXT /	ORAL

Date:07/29/99ISR Number: 3315470-XReport Type:Periodic Company Report #A0091964
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Feeling Abnormal	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY /	ORAL
			Medroxyprogesterone Ace. (Formulation Unknown)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/99ISR Number: 3315476-0Report Type:Periodic Company Report #A0091692
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:07/30/99ISR Number: 3315130-5Report Type:Expedited (15-DaCompany Report #A0073099
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Foreign	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY / ORAL	
	Chest Pain	Health Professional						
	Hypoglycaemia							
	Malaise		Glibenclamide	C				
	Palpitations		Metformin	C				

Date:07/30/99ISR Number: 3315131-7Report Type:Expedited (15-DaCompany Report #A0094919
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	5 DAY
Other	Metastases To Central Nervous System							
	Metastases To Lung							
			Omeprazole	C				

Date:07/30/99ISR Number: 3315153-6Report Type:Expedited (15-DaCompany Report #A0088466
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Feeling Jittery Tremor	Health Professional	Zyban Tablet - Zyban	PS		ORAL	150 MG;	TWICE PER DAY;
			Unknown	C				
			Ranitidine Hydrochloride	C				
			Thyroxine Sodium	C				
			Hydrochlorothiazide	C				
			Digoxin	C				
			Paracetamol	C				
			Potassium Salt	C				

Date:07/30/99ISR Number: 3315159-7Report Type:Expedited (15-DaCompany Report #A0083735
Age:23 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Anaphylactoid Reaction
	Arthralgia
	Dyspnoea
	Face Oedema
	Oedema Peripheral
	Pruritus

	Rash Pruritic Serum Sickness Urticaria	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Study Health Professional	Wellbutrin Tablet-Controlled Release	PS		ORAL
150 MG; TWICE PER DAY; ORAL						
			Medroxyprogesterone Ace.	C		

Date:07/30/99ISR Number: 3315160-3Report Type:Expedited (15-DaCompany Report #A0097852
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Antidiuretic Hormone Increased	Health Professional	Wellbutrin Tablet - Controlled Release	PS		ORAL
ORAL						
	Hyponatraemia	Company	Methocarbamol	C		
	Pituitary Tumour	Representative	Carisoprodol	C		

Date:07/30/99ISR Number: 3315163-9Report Type:Expedited (15-DaCompany Report #A0091712
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Neuroleptic Malignant Syndrome	Health Professional	Wellbutrin (Formultion Unknown)	PS		ORAL
ORAL						

Date:07/30/99ISR Number: 3315165-2Report Type:Expedited (15-DaCompany Report #A0095184
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health	Wellbutrin Tablet	PS	ORAL
	Cerebrovascular Accident	Professional	Donepezil Hcl Tablet	SS	ORAL
		Other			
			Aspirin	C	
			Diltiazem	C	
			Timolol Maleate	C	
			Digoxin	C	

Date:07/30/99ISR Number: 3317738-XReport Type:Direct Company Report #
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin	PS		ORAL	150 ORAL	21 DAY
	Nausea							
	Swelling							

Date:08/02/99ISR Number: 3316269-0Report Type:Expedited (15-DaCompany Report #A0097619
Age:28 YR Gender:Female I/FU:F

Outcome	PT
	Arthralgia
	Dermatitis
	Ecchymosis
	Heart Rate Increased
	Malaise

	Oedema Peripheral Pain In Extremity Pruritus	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Serum Sickness	Foreign	Zyban Tablet - Zyban	PS		ORAL 150 MG /
	Skin Discolouration	Health				TWICE PER DAY
	Urticaria	Professional				/ ORAL
			Ibuprofen	C		

Date:08/02/99ISR Number: 3316525-6Report Type:Expedited (15-DaCompany Report #A0092192
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Grand Mal Convulsion Intentional Misuse Respiratory Failure	Health Professional Company	Wellbutrin Tablet-Controlled Release	PS		ORAL UNK/ SEE TEXT
	Suicide Attempt	Representative				/ ORAL

Date:08/02/99ISR Number: 3318345-5Report Type:Periodic Company Report #8-97286-020L
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Cardiovascular Disorder	Consumer	Pondimin	PS		ORAL 20 MG THREE
	Palpitations					TIMES A DAY
	Pulmonary Hypertension					ORAL
			Phentermine	SS		ORAL 15-30 MG
						DAILY ORAL
			Redux	SS		ORAL 30 MG DAILY
						ORAL

			Wellbutrin	SS		ORAL
10-150 MG						
TWICE DAILY						
ORAL						

Date:08/02/99ISR Number: 3318696-4Report Type:Periodic Company Report #8-97318-014L
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiovascular Disorder	Consumer	Pondimin	PS		ORAL
60-120 MG						
Initial or Prolonged	Pulmonary Hypertension					
DAILY ORAL 86 MON						
Required			Effexor			
Intervention to			(Venlafaxine)	SS		
75-225 MG						
Prevent Permanent						
DAILY						
Impairment/Damage			Prozac (Fluoxetine)	SS		
20-60 MG						
DAILY						
			Wellbutrin			
			(Bupropion)	SS		
150-300 MG						
DAILY						
			Zoloft (Sertraline)	SS		
50 MG DAILY						
			Ritalin	C		
			Cylert	C		
			Cytomel	C		
			Estraderm	C		
			Amitriptyline	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/99ISR Number: 3321789-9Report Type:Expedited (15-DaCompany Report #A0098119A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cardiac Valve Disease Dizziness	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG / TWICE PER DAY/ ORAL	

Date:08/09/99ISR Number: 3321791-7Report Type:Expedited (15-DaCompany Report #A0096005A
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination Insomnia Muscle Spasms Muscle Twitching Neck Pain	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	3 YR
			Cyclobenzapine Hcl (Formulation Unknown) (Cyclobenzaprine Hcl)	SS		ORAL	10 MG / TWICE TIMES PER DAY / ORAL	

Date:08/09/99ISR Number: 3321892-3Report Type:Expedited (15-DaCompany Report #A0097683A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged Other	Delirium Muscle Rigidity Muscle Rupture Neuroleptic Malignant Syndrome Pyrexia	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL

Date:08/09/99ISR Number: 3321896-0Report Type:Expedited (15-DaCompany Report #A0095217A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adrenergic Syndrome Chills Dizziness Hyperhidrosis	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY	
	Hypotension Muscle Spasms Nausea Tremor		Temazepam Buspirone Hydrochloride Venlafaxine Hydrochloride	C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/99ISR Number: 3326617-3Report Type:Expedited (15-DaCompany Report #A0082611A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amenorrhoea Convulsion Head Injury Memory Impairment	Health Professional	Wellbutrin Tablet-Controlled Release(Bupropion Hydrochloride)	PS		ORAL	1 TABLET	TWICE DAILY

Date:08/17/99ISR Number: 3327979-3Report Type:Expedited (15-DaCompany Report #A0098621A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chromaturia Convulsion Difficulty In Walking Dysphagia Feeling Abnormal Insomnia Lethargy Nausea Sedation	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /	TWICE PER DAY / ORAL

Date:08/17/99ISR Number: 3327985-9Report Type:Expedited (15-DaCompany Report #A0098738A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation Blood Pressure Increased Dizziness Fatigue Headache	Consumer	Wellbutrin Tablet - Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG /	TWICE PER DAY

	Insomnia					
/ ORAL						
	Palpitations		Verapamil	C		
			Hyzaar	C		
			Librium	C		

Date:08/17/99ISR Number: 3327992-6Report Type:Expedited (15-DaCompany Report #A0098933A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fatigue	Foreign	Wellbutrin Tablet -					
Hospitalization -	Hepatic Failure	Health	Controlled Release					
Initial or Prolonged	Nausea	Professional	(Bupropion					
			Hydrochloride)	PS		ORAL	150 MG /	
TWICE PER DAY								
/ ORAL								

Date:08/17/99ISR Number: 3331448-4Report Type:Periodic Company Report #S99-USA-01116-01
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma	Health	Celexa	PS			20 MG	
Initial or Prolonged	Overdose	Professional	Wellbutrin	SS			150 MG	
		Company Representative	Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/24/99ISR Number: 3333249-XReport Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Haemoglobin Decreased White Blood Cell Count Decreased		Bupropion	PS				

Date:08/26/99ISR Number: 3334282-4Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Anorexia Chromaturia Jaundice Pyrexia		Buproprion 75mg Bid 6/7 Increased To 75mg Tid 7/9	PS			75MG BID 6/7 INCREASED TO 75MG TID 7/9	
			Sertraline 100mg Qam Increased To 200mg Qam 6/7	SS			100MG QAM INCREASED TO 200MG QAM 6/7	

Date:08/27/99ISR Number: 3336302-XReport Type:Expedited (15-DaCompany Report #A0098621A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chromaturia Convulsion Difficulty In Walking Dysphagia	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY	

	Feeling Abnormal					
/ ORAL						
	Hypersomnia					
	Insomnia					
	Lethargy					
	Nausea					

Date:08/27/99ISR Number: 3336332-8Report Type:Expedited (15-DaCompany Report #A0052441A
Age:13 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Apallic Syndrome	Consumer	Bupropion					
Hospitalization -	Brain Hypoxia		Hydrochloride Tablet					
Initial or Prolonged	Cardio-Respiratory Arrest		(Bupropion					
	Condition Aggravated		Hydrochloride)	PS		ORAL	3600 MG /	
	Convulsion						SINGLE DOSE	
	Iatrogenic Injury		Semisodium Valproate	C				
	Intentional Misuse							
	Mydriasis							
	Suicidal Ideation							

Date:08/30/99ISR Number: 3337368-3Report Type:Expedited (15-DaCompany Report #A0092653A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Wellbutrin					
		Professional	Tablet-Controlled					

				Release (Bupropion Hydrochloride)	PS		ORAL
150 MG / THREE TIMES PER DA / ORAL							
				Methylphenidate Hcl	C		

Date:08/31/99ISR Number: 3338187-4Report Type:Expedited (15-DaCompany Report #A0095803A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health Professional Company Representative	Bupropion Hydrochloride Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150MG TWICE PER DAY	ORAL

Date:08/31/99ISR Number: 3338188-6Report Type:Expedited (15-DaCompany Report #A0095916A
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Literature	Bupropion Hydrochloride Tablet					
Disability	Blood Creatinine Increased	Health Professional	(Bupropion					
Required	Blood Urea Increased		Hydrochloride)	PS		ORAL	75MG DAY	
Intervention to Prevent Permanent Impairment/Damage	Constipation						TWICE PER DAY	
	Drug Interaction						ORAL	3 WK
	Faecaloma		Lithium Salt	C				
	Ileus Paralytic		Diltiazem	C				
	Nausea		Ranitidine Hydrochloride	C				
	Vomiting		Aspirin	C				
			Calcium Salt	C				

Date:08/31/99ISR Number: 3338254-5Report Type:Expedited (15-DaCompany Report #CDN/99/00705/SIM03
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other Required	Anaemia Drug Interaction	Foreign Health Professional	Sandimmune Neoral (Cyclosporine)	PS		ORAL	100 MG, TWICE A DAY, ORAL;	
Intervention to Prevent Permanent Impairment/Damage	Haemoglobin Decreased Thrombocytopenia		Adalat (Nifedipine)	SS		ORAL	UNSPECIFIED, UNKNOWN, ORAL;	
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	UNSPECIFIED, UNKNOWN, ORAL;	
			Paxil (Paroxetine Hydrochloride)	C				
			Norvasc (Amlodipine Besilate)	C				
			Flomax (Morniflumate)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/99ISR Number: 3339102-XReport Type:Expedited (15-DaCompany Report #A0098119A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Foreign	Wellbutrin					
	Cardiac Murmur	Health	Tablet-Controlled					
	Cardiac Valve Disease	Professional	Release (Bupropion					
	Condition Aggravated		Hydrochloride)	PS		ORAL	100 MG TWICE	
	Dizziness						PER DAY ORAL	

Date:09/01/99ISR Number: 3339162-6Report Type:Expedited (15-DaCompany Report #A0099506A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Wellbutrin					
Initial or Prolonged	Feeling Abnormal	Professional	Tablet-Controlled					
	Overdose	Company	Release (Bupropion					
	Vaginal Candidiasis	Representative	Hydrochloride)	PS		ORAL	150 MG / SEE	
							TEXT/ ORAL	
			Oral Contraceptive	C				

Date:09/01/99ISR Number: 3339166-3Report Type:Expedited (15-DaCompany Report #A0077179A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Consumer	Zyban Tablet - Zyban					
Initial or Prolonged	Influenza Like Illness		(Bupropion					
	Rift Valley Fever		Hydrochloride)	PS		ORAL	PER DAY /	
							ORAL	

Date:09/01/99ISR Number: 3341480-2Report Type:Periodic Company Report #A0086021A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis Dyspnoea Face Oedema Oral Mucosal Eruption Tongue Oedema Urticaria	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Claritin-D Conjugated Estrogens Medroxyprogesterone Ace	PS C C C		ORAL ORAL	150 MG TWICE PER DAY	

Date:09/01/99ISR Number: 3341484-XReport Type:Periodic Company Report #A0086000A
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Anaphylactic Reaction Bronchospasm Dermatitis Dyspnoea Eye Disorder Face Oedema Pharyngeal Oedema Pruritus Respiratory Distress Swelling

		Tongue Oedema Urticaria					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Bupropion Hydrochloride Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG TWICE PER DAY ORAL							

Date:09/01/99ISR Number: 3341491-7Report Type:Periodic Company Report #A0081646A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Insomnia Pruritus Urticaria	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG TWIC PER DAY ORAL						

Date:09/01/99ISR Number: 3341495-4Report Type:Periodic Company Report #A0098261A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		

Date:09/01/99ISR Number: 3341499-1Report Type:Periodic Company Report #A0098165A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Blood Pressure Increased Cerebrovascular Accident Headache	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY	
ORAL							6	WK
			Amlodipine	C				
			Metoprolol Succinate	C				
			Valsartan	C				

Date:09/01/99ISR Number: 3341502-9Report Type:Periodic Company Report #A0097853A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/99ISR Number: 3341505-4Report Type:Periodic Company Report #A0097223A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG	TWICE PER DAY
			Maalox	C				
			Aspirin	C				
			Atenolol	C				
			Felodipine	C				
			Ranitidine Hydrochloride	C				
			Losartan Potassium	C				

Date:09/01/99ISR Number: 3341508-XReport Type:Periodic Company Report #A0096229A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective Photosensitivity Reaction	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG	TWICE PER DAY
			Amitriptyline Hc1	C				

Date:09/01/99ISR Number: 3341511-XReport Type:Periodic Company Report #A0082332A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Fall	Foreign Consumer	Zyban Tablet - Zyban (Bupropion					

	Head Injury		Hydrochloride)	PS			ORAL
150 MG							
	Laceration						
TWICE PER DAY							
	Loss Of Consciousness						
ORAL							
			Percocet	C			
			Alprazolam	C			
			Diamorphine Hydrochloride	C			

Date:09/01/99ISR Number: 3341522-4Report Type:Periodic Company Report #A0095875A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Hallucination Psychotic Disorder	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:09/01/99ISR Number: 3341530-3Report Type:Periodic Company Report #A0095819A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Drug Ineffective	Consumer	Zyban Tablet - Zyban (Bupropion					

Hydrochloride) PS ORAL
1 TABLET

TWICE PER DAY

ORAL

Date:09/01/99ISR Number: 3341536-4Report Type:Periodic Company Report #A0095428A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Bite Convulsion Feeling Cold Haemorrhage Loss Of Consciousness Tongue Disorder Tongue Haematoma	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:09/01/99ISR Number: 3341541-8Report Type:Periodic Company Report #A0094675A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:09/01/99ISR Number: 3341545-5Report Type:Periodic Company Report #A0093712A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Arthralgia Chest Pain Drug Hypersensitivity Joint Swelling Rash Pruritic Swelling Urticaria	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL

Date:09/01/99ISR Number: 3341550-9Report Type:Periodic Company Report #A0093374A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion Malaise	Consumer	Bupropion Hydrochloride Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL

Date:09/01/99ISR Number: 3341551-0Report Type:Periodic Company Report #A0093077A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride) Fluticasone	PS		ORAL	150 MG TWICE PER DAY ORAL

				Propionate	C		
				Combivent	C		
				Lorazepam	C		

Date:09/01/99ISR Number: 3341552-2Report Type:Periodic Company Report #A0092866A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Hyperhidrosis Nausea Nervousness Tremor	Consumer	Bupropion Hydrochloride Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG	PER DAY
						ORAL		

Date:09/01/99ISR Number: 3341558-3Report Type:Periodic Company Report #A0092517A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Dermatitis Headache Myalgia Pain	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG	TWICE PER DAY
						ORAL		
			Diclofenac Sodium	C				

Date:09/01/99ISR Number: 3341564-9Report Type:Periodic Company Report #A0092396A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Bupropion Hydrochloride Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	1 TABLET	

TWICE PER DAY

ORAL

			Multivitamin	C		

Date:09/02/99ISR Number: 3339597-1Report Type:Expedited (15-DaCompany Report #A0098933A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fatigue	Foreign	Wellbutrin					
Hospitalization -	Hepatic Failure	Health	Tablet-Controlled					
Initial or Prolonged	Jaundice	Professional	Release (Bupropion					
	Nausea		Hydrochloride)	PS		ORAL	150 MG /	

TWICE PER DAY

/ ORAL

			Salbutamol Sulphate	C		
			Beclomethasone Dipropion	C		
			Venlafaxine Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/99ISR Number: 3342133-7Report Type:Expedited (15-DaCompany Report #A0100405A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lymphoedema Oedema Peripheral Weight Increased	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS	Zyban	ORAL	ORAL	

Date:09/07/99ISR Number: 3342135-0Report Type:Expedited (15-DaCompany Report #A0100230A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs Congenital Anomaly	Study Health Professional Company Representative	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:09/08/99ISR Number: 3343029-7Report Type:Direct Company Report #
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dry Mouth Dysgeusia Headache Nausea		Bupropion (Zyban)	PS			150MG BID	

Date:09/08/99ISR Number: 3343719-6Report Type:Direct Company Report #
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Bullous Hypoaesthesia		Bupropion 150 Mg (Zyban) - Glaxo					

	Rash Maculo-Papular		Wellcome	PS	Glaxo Wellcome	ORAL
150MG PO QD X						
3D THEN 150MG						
BID						

Date:09/09/99ISR Number: 3343508-2Report Type:Direct Company Report #
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Depression	Health	Bupropion	PS		ORAL
150MG BID						
	Drug Ineffective	Professional				
ORAL 2 MON						
			Carbamazepine (Tegretol)	C		
			Oxycodone/Acetaminophen	C		

Date:09/09/99ISR Number: 3343536-7Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Medication Residue		Bupropoin Sr	PS		
100MG TID						
			Zolpidem	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/09/99ISR Number: 3344246-2Report Type:Expedited (15-DaCompany Report #A0100352A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Jaundice Liver Function Test Abnormal	Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	75 MG/SEE TEXT/ORAL	

Date:09/11/99ISR Number: 3345423-7Report Type:Direct Company Report #
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Insomnia Irritability Mania Thinking Abnormal		Bupropion	PS			150 MG SR BID	

Date:09/13/99ISR Number: 3345500-0Report Type:Expedited (15-DaCompany Report #A0100543A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS				

Date:09/16/99ISR Number: 3347915-3Report Type:Direct Company Report #
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion		Zyban	PS		ORAL	150 MG BID PO	14 DAY

Initial or Prolonged Other			B.C. Pill	C		

Date:09/16/99ISR Number: 3349491-8Report Type:Expedited (15-DaCompany Report #A0097683A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other Required Intervention to Prevent Permanent Impairment/Damage	Confusional State Delirium Muscle Atrophy Muscle Rigidity Neuroleptic Malignant Syndrome Pyrexia	Health Professional Company Representative	Welbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Semisodium Valproate Librium Buspirone Hydrochloride Diltiazem Hydrochloride Conjugated Estrogens Thyroxine Sodium Hydrochlorothiazide Omeprazole	PS C C C C C C C C		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/99ISR Number: 3352405-8Report Type:Expedited (15-DaCompany Report #A0099452A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State	Consumer	Zyban Tablet - Zyban					
	Feeling Abnormal		(Bupropion					
	Pancreatic Carcinoma		Hydrochloride)	PS		ORAL	150 MG /	
	Suicidal Ideation						TWICE PER DAY	
	Tremor						/ ORAL	

Date:09/20/99ISR Number: 3352406-XReport Type:Expedited (15-DaCompany Report #A0099702A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Foreign	Zyban Tablet - Zyban					
Hospitalization -	Dyspnoea	Health	(Bupropion					
Initial or Prolonged	Fatigue	Professional	Hydrochloride)	PS		ORAL	150 MG /	
Disability	Hypophosphataemia						TWICE PER DAY	
	Mutism						/ ORAL	
	Paraesthesia		Phenoxymethylpenicil					
			lin	C				
			Nicotine	C				

Date:09/22/99ISR Number: 3354160-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Wellbutrin Sr-B/W	PS		ORAL	150MG PO BID	
	Crying		Premarin	C				
	Depression		Fosamax	C				
			Beconase	C				
			Allegra	C				
			Cycrin	C				

Date:09/22/99ISR Number: 3354173-2Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Wellbutrin Sr	PS		ORAL	150 BID	ORAL
	Cardiomyopathy		Tamoxifen	SS				
	Sudden Death							

Date:09/22/99ISR Number: 3354177-XReport Type:Direct Company Report #
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Welbutrin Sr 100bid	PS		ORAL	150 BID	ORAL
	Ventricle Rupture		Viagra -Prn Last Dose 2-4d Prior To Event	SS		ORAL	ORAL	

Date:09/22/99ISR Number: 3355502-6Report Type:Direct Company Report #
Age:26 YR Gender:Male I/FU:I

Outcome	PT
Other	Asthenia
	Creatine Phosphokinase

		Decreased Myalgia					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Zyban Glaxo Wellcome	PS	Glaxo Wellcome	
150MG Q AM X 3 DAYS THE 150MG BID							

Date:09/23/99ISR Number: 3355813-4Report Type:Direct Company Report #
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Asthenia		Zyban Glaxo Wellcome	PS	Glaxo Wellcome	
150MG Q AM X						
	Creatine Phosphokinase					
3 DAYS THEN						
	Decreased					
150 MG BID						
	Myalgia					

Date:09/23/99ISR Number: 3356835-XReport Type:Expedited (15-DaCompany Report #A0096492A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Disorder	Health	Zyban Tablet-Zyban			
Hospitalization -	Dysphagia	Professional	(Bupropion			
Initial or Prolonged	Dyspnoea		Hydrochloride)	PS		ORAL
150 MG/ TWICE						
Disability	Embolism					
PER DAY/ ORAL						
Required	Eye Disorder		Paracetamol	C		
Intervention to	Oedema Peripheral					
Prevent Permanent	Pulmonary Embolism					
Impairment/Damage	Swelling					
	Thrombosis					

Date:09/23/99ISR Number: 3356837-3Report Type:Expedited (15-DaCompany Report #A0101029A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Psychotic Disorder Suicidal Ideation	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochlordie)	PS				

Date:09/24/99ISR Number: 3356978-0Report Type:Direct Company Report #
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Influenza Like Illness Syncope		Zyban	PS				

Date:09/27/99ISR Number: 3357338-9Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation Glossodynia	Health Professional	Wellbutrin 100mg Glaxo/Wellcome	PS	Glaxo/Wellcome	ORAL	100MG PO UP TO TID	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/99ISR Number: 3358988-6Report Type:Expedited (15-DaCompany Report #A0078462A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Fear Feeling Abnormal Hallucination Paraesthesia	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	300 MG / PER DAY / ORAL	
			Pain Medication (Formulation Unknown) (Pain Medication)	SS				
			Muscle Relaxant (Formulation Unknown) (Muscle Relaxant)	C				
			Ventolin (Formulation Unknown) (Albuterol Sulfate)	C				
			Lithium Salt	C				
			Insulin	C				

Date:09/27/99ISR Number: 3361311-4Report Type:Periodic Company Report #A001-002-003251
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hypertension	Consumer Health Professional	Aricept (Donepezil)	PS		ORAL	SEE IMAGE	
			Wellbutrin (Bupropion Hcl) (Amfebutamone Hydrochloride)	SS				
			Aspirin	C				
			Atenolol	C				
			Timoptic	C				
			Digoxin	C				
			Diltiazem	C				

Date:09/28/99ISR Number: 3358827-3Report Type:Direct Company Report #
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness		Bupropion Sr	PS		ORAL	150MG PO Q	DAY
	Hypertension		Solumedrol	C				
	Hypertensive Encephalopathy		Theodur	C				
	Speech Disorder							

Date:09/28/99ISR Number: 3366643-1Report Type:Periodic Company Report #USA009619
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Meridia	PS		ORAL	10 MG OD	
	Nausea		Wellbutrin	SS		ORAL	100 MG BID	
	Vision Blurred		Toprol Xl	SS		ORAL	100 MG OD	
			Ogen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/99ISR Number: 3359705-6Report Type:Direct Company Report #
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health	Wellbutrin	PS				4 MON
	Urticaria	Professional						

Date:09/29/99ISR Number: 3361004-3Report Type:Expedited (15-DaCompany Report #A0096492A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Health	Zyban Tablet - Zyban					
Hospitalization -	Dysphagia	Professional	(Bupropion					
Initial or Prolonged	Dyspnoea		Hydrochloride)	PS		ORAL	150 MG /	
Disability	Embolism						TWICE PER DAY	
Required	Eye Disorder						/ ORAL	
Intervention to	Oedema Peripheral		Paracetamol	C				
Prevent Permanent	Pulmonary Embolism							
Impairment/Damage	Swelling							

Date:09/30/99ISR Number: 3360922-XReport Type:Direct Company Report #
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Health	Zyban 150mg	PS			ONE BID	
	Face Oedema	Professional	Desowen Lotion	C				
	Oedema Peripheral							
	Periorbital Oedema							
	Scrotal Swelling							
	Urticaria							

Date:10/01/99ISR Number: 3361364-3Report Type:Direct Company Report #
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Bupropion Sr 150mg	PS		ORAL	150MG PO QD ; 150MG PO BID	
	Post Procedural Complication		Imdur	C				
	Wound Infection		Lopressor	C				
	Wound Secretion		Lipitor	C				
			Bupropion	C				
			Eco Asa	C				

Date:10/01/99ISR Number: 3363020-4Report Type:Expedited (15-DaCompany Report #A0072356A
Age:45 YR Gender:Female I/FU:I

Outcome	PT
Other	Akathisia
	Clonic Convulsion
	Diaphragmatic Paralysis
	Diarrhoea
	Dyskinesia
	Dyspnoea
	Dystonia
	Fatigue
	Nervous System Disorder
	Respiratory Alkalosis
	Tardive Dyskinesia

		Tremor					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL
100 MG / THREE TIMES PER DAY; ORAL							
				Triamcinolone Acetonide	C		
				Melatonin	C		

Date:10/01/99ISR Number: 3363022-8Report Type:Expedited (15-DaCompany Report #A0102044A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs	Foreign Study Health Professional	Zyban Tablet -Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG / UNK / ORAL						
	Congenital Anomaly	Company Representative				

Date:10/01/99ISR Number: 3363025-3Report Type:Expedited (15-DaCompany Report #A0101960A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Arrest	Foreign Health Professional	Zyban Tablet -Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG / PER DAY / ORAL	Required					
Intervention to Prevent Permanent			Metoprolol	C		
			Glibenclamide	C		

Impairment/Damage			Metformin	C		
			Aspirin	C		

Date:10/04/99ISR Number: 3364083-2Report Type:Expedited (15-DaCompany Report #A0095928A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Blood Creatine Phosphokinase Increased Hyperpyrexia Leukopenia Neuroleptic Malignant Syndrome Sepsis Serotonin Syndrome Urinary Tract Infection	Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride) Dexamphentamine Sulphate (Formulation Unknown) (Dextroamphetamine	PS SS		ORAL ORAL		

Date:10/04/99ISR Number: 3364087-XReport Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:I

Outcome	PT
Disability	Autonomic Nervous System Imbalance Blood Glucose Increased

	Blood Triglycerides Increased Bradycardia Dizziness Haematuria Headache Hyperhidrosis Hypertension Hypoaesthesia Hypomania Labile Blood Pressure Mental Impairment Mitral Valve Incompetence Muscle Twitching Musculoskeletal Stiffness Panic Attack Paraesthesia Renal Disorder Tachycardia	Report Source Consumer	Product Zyban Tablet - Zyban (Bupropion Hydrochloride) Conjugated Estrogens Vitamin Asspirin Melatonin	Role PS C C C C	Manufacturer	Route ORAL	Dose Duration 150MG PER DAY ORAL

Date:10/04/99ISR Number: 3364114-XReport Type:Expedited (15-DaCompany Report #A0099553A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dizziness Feeling Abnormal Tachycardia	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride) Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS SS		ORAL ORAL	150MG ORAL ORAL

Date:10/04/99ISR Number: 3364118-7Report Type:Expedited (15-DaCompany Report #A0101583A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Grand Mal Convulsion Hypokalaemia Loss Of Consciousness Overdose Sinus Tachycardia Vomiting	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150MG SEE TEXT	

Date:10/04/99ISR Number: 3364122-9Report Type:Expedited (15-DaCompany Report #A0101990A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dry Mouth Oesophageal Disorder Sensation Of Foreign Body Speech Disorder Stomatitis Throat Irritation Tongue Oedema	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150MG TWICE PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/05/99ISR Number: 3364637-3Report Type:Expedited (15-DaCompany Report #A0101636A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Chills Difficulty In Walking Fatigue Leukocytosis Movement Disorder Myalgia Oedema Peripheral Pyrexia Serum Sickness Tenderness Urticaria	Literature Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	300 MG/DAY/ORAL	3 WK

Date:10/05/99ISR Number: 3364748-2Report Type:Expedited (15-DaCompany Report #A0102079A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypothyroidism Oedema Peripheral Tinnitus Weight Increased	Foreign Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:10/05/99ISR Number: 3364980-8Report Type:Expedited (15-DaCompany Report #A0102184A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Clonic Convulsion Decreased Appetite Depression	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG /	

	Grand Mal Convulsion						
TWICE PER DAY							
	Headache						
/ ORAL							
	Respiratory Failure		Fluoxetine				
	Suicidal Ideation		Hydrochloride	C			
	Weight Decreased		Ferrous Sulfate	C			
			Demulen	C			

Date:10/06/99ISR Number: 3366190-7Report Type:Expedited (15-DaCompany Report #A0073385A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arthralgia	Literature	Wellbutrin				
Initial or Prolonged	Delirium	Health	Tablet-Controlled				
	Dermatitis	Professional	Release (Bupropion				
	Malaise		Phydrochloride)	PS		ORAL	
150MG ORAL							
	Myalgia						
	Pyrexia						
	Serum Sickness						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/99ISR Number: 3366218-4Report Type:Expedited (15-DaCompany Report #A0102058A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Study	Zyban Tablet - Zyban					
	Depressed Level Of Consciousness	Health Professional	(Bupropion Hydrochloride)	PS		ORAL	150MG PER DAY	
	Hypertension					ORAL		
	Hypertensive Encephalopathy		Me-Prednisolone Na Succ	C				
	Speech Disorder		Theophylline	C				
	Vision Blurred		Diltiazem	C				
			Lisionpril	C				
			Salbutamol Sulphate	C				
			Ipratropium Bromide	C				
			Procainamide Hcl	C				
			Aspirin	C				
			Isosorbide Dinitrate	C				
			Metoprolol Tartrate	C				
			Vitamin E	C				
			Clopidogrel Bisulphate	C				

Date:10/06/99ISR Number: 3366220-2Report Type:Expedited (15-DaCompany Report #A0102413A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign	Zyban Tablet - Zyban					
	Transient Ischaemic Attack	Consumer	(Bupropion Hydrochloride)	PS		ORAL	150MG TWICE PER DAY ORAL	

Date:10/06/99ISR Number: 3369484-4Report Type:Periodic Company Report #99USA10317
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Overdose	Health Professional Other	Lopressor Tablet (Metoprolol Tartrate)	PS		ORAL
DAILY, ORAL						
			Acetaminophen Tablet (Paracetamol)	SS		ORAL
ORAL						
			Fluoxetine Capsule 20 Mg (Fluoxetine)	SS		ORAL
20 MG, DAILY,						
ORAL						
			Wellbutrin Slow Release Tablet 100 Mg (Amfebutamone Hydrochloride)	SS		ORAL
200 MG,						
DAILY, ORAL						

Date:10/07/99ISR Number: 3366394-3Report Type:Direct Company Report #
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Bupropion Sr 150mg	PS		ORAL
150MG PO BID						
Initial or Prolonged	Post Procedural Complication		Imdur	C		
	Wound Infection		Lopressor	C		
	Wound Secretion		Lipitor	C		
			Eloasa	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/99ISR Number: 3366399-2Report Type:Direct Company Report #
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive		Bupropion Sr	PS		ORAL	150 PO Q DAY	
	Encephalopathy		Solumedrol	C				
			Theodur	C				

Date:10/07/99ISR Number: 3366423-7Report Type:Direct Company Report #
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Clonic Convulsion	Health	Wellbutrin Sr 150 Mg	PS		ORAL	1 BID ORAL	10 DAY
	Confusional State	Professional						
	Convulsion							
	Fall							
	Head Injury							
	Loss Of Consciousness							
	Syncope							

Date:10/08/99ISR Number: 3368492-7Report Type:Expedited (15-DaCompany Report #A0073385A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Literature	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL	
	Agitation	Health						
	Arthralgia	Professional						
	Chest Pain							
	Confusional State							
	Delirium		Thiothixene	C				
	Disorientation		Lithium Salt	C				
	Drug Hypersensitivity		Venlafaxine Hydrochloride	C				
	Malaise		Thyroxine Sodium	C				
	Myalgia		Haloperidol	C				
	Pyrexia		Lorazepam	C				
	Rash Morbilliform							

Red Blood Cell Sedimentation Rate Increased		Trazodone	C	
Restlessness		Olanazapine	C	
Serum Sickness				

Date:10/08/99ISR Number: 3369009-3Report Type:Expedited (15-DaCompany Report #PRIUSA1999006684
Age:35 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Self-Injury	Literature Health	Haldol (Unspecified) (Haloperidol)	PS		ORAL	ORAL	
		Professional	Aspirin (Acetylsalicylic Acid)	SS		ORAL	ORAL	
			Bupropion (Amfebutamone)	SS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/99ISR Number: 3369040-8Report Type:Expedited (15-DaCompany Report #A0102079A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Deafness Face Oedema Hypothyroidism Oedema Peripheral Tinnitus Weight Increased	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ ORAL

Date:10/08/99ISR Number: 3369041-XReport Type:Expedited (15-DaCompany Report #A0102535A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower Aphonia Decreased Appetite	Foreign Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL

Date:10/08/99ISR Number: 3369051-2Report Type:Expedited (15-DaCompany Report #A0102360A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anuria Back Pain Bladder Disorder Oedema Renal Disorder Renal Hypertrophy	Consumer	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride) Fluoxetine Hydrochloride (Formulation Unknown) (Fluoxetine Hydrochloride)	PS SS		ORAL	150 MG/ORAL

Date:10/09/99ISR Number: 3367993-5Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Palsy		Zyban 150mg	PS			BID	

Date:10/12/99ISR Number: 3371405-5Report Type:Expedited (15-DaCompany Report #9942002
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Activated Partial	Health	Zoloft Tablets	PS		ORAL	100.00 MG	
Intervention to	Thromboplastin Time	Professional					TOTAL;DAILY;O	
Prevent Permanent	Prolonged						RAL	
Impairment/Damage	Anxiety		Bupropion	SS		ORAL	ORAL	
	Drug Ineffective		Nitropatch	C				
	Drug Interaction		Nitrex	C				
	Feeling Abnormal		Levothyroxine	C				
	Haemorrhage		Lansoprazole	C				
	Suicidal Ideation		Alprazolam	C				
			Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/99ISR Number: 3371607-8Report Type:Expedited (15-DaCompany Report #A0102566A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Aggression Coma Grand Mal Convulsion Intentional Misuse Lethargy Suicide Attempt	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Gabapentin (Formulation Unknown) (Gabapentin)	PS SS		ORAL ORAL	150 MG/SEE TEXT/ORAL SEE TEXT/ORAL	

Date:10/13/99ISR Number: 3371770-9Report Type:Expedited (15-DaCompany Report #A0097643A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Enalapril Maleate Nicotine	PS C C		ORAL	ORAL	

Date:10/14/99ISR Number: 3371013-6Report Type:Direct Company Report #
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Bupropion Sr Bupropion Sr Colace Ec Asa Lipitor Plavix	PS SS C C C C		ORAL ORAL	150 MG QD PO 150 MG BID PO	3 DAY

			Lopressor	C		
			Ntg Sl	C		

Date:10/15/99ISR Number: 3373503-9Report Type:Expedited (15-DaCompany Report #A0102803A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Drug Hypersensitivity Dyspnoea Laryngeal Oedema	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/ ORAL	TWICE

Date:10/15/99ISR Number: 3373873-1Report Type:Expedited (15-DaCompany Report #A0100352A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Jaundice Liver Function Test Abnormal	Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	75 MG SEE TEXT ORAL	
			Sertraline Tablet (Sertraline)	SS		ORAL	200 MG IN THE	

MORNING

ORAL

Date:10/18/99ISR Number: 3375713-3Report Type:Expedited (15-DaCompany Report #1999UW03215
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Seroquel "Zeneca"	PS	Zeneca			
	Drug Toxicity	Professional	Bupropion	SS				
	Intentional Misuse		Olanzapine	SS				
			Carbamazepine	SS				
			Pramoxine	SS				

Date:10/19/99ISR Number: 3375675-9Report Type:Expedited (15-DaCompany Report #A0086318A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Zyban Tablet- Zyban					
	Drug Hypersensitivity	Professional	(Bupropion					
	Dysphagia		Hydrochloride)	PS		ORAL	150 MG/	TWICE PER DAY/
	Eyelid Oedema							
	Face Oedema		Zyban Tablet - Zyban					
	Pharyngeal Oedema		(Bupropion					
			Hydrochloride)	SS		ORAL	150 MG/	SINGLE DOSE/
								ORAL
			Lansoprazole	C				
			Lorcet	C				

Date:10/19/99ISR Number: 3375678-4Report Type:Expedited (15-DaCompany Report #A0102868A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/	
			Trovafloxacin Mesylate	C				
			Morphine	C				

Date:10/19/99ISR Number: 3375747-9Report Type:Expedited (15-DaCompany Report #A0101186A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Pain Rash Generalised Skin Exfoliation	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY /	

Date:10/19/99ISR Number: 3375749-2Report Type:Expedited (15-DaCompany Report #A0102884A
Age:45 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blister Blood Glucose Increased

	Dyspnoea Eyelid Oedema Nail Discolouration	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash Pruritic Skin Discolouration Stevens-Johnson Syndrome	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG / TWICE PER DAY / ORAL	Weight Increased					

Date:10/19/99ISR Number: 3375982-XReport Type:Expedited (15-DaCompany Report #A0095816A
Age:6 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Candidiasis Dysphemia Kidney Infection	Consumer	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL
37.5 MG / ALTERNATE DAYS / ORAL	Migraine Pharyngitis Streptococcal Tongue Spasm					

Date:10/19/99ISR Number: 3375984-3Report Type:Expedited (15-DaCompany Report #A0102783A
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Bronchospasm Dermatitis Dyspnoea Oedema Pyrexia Stevens-Johnson Syndrome Urticaria Vomiting	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		

Date:10/19/99ISR Number: 3375986-7Report Type:Expedited (15-DaCompany Report #A0102623A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrchloride)	PS		ORAL	150 MG /TWICE PER DAY/	
			Fluoxetine Hydrochloride Capsule (Fluoxetine Hydrochloride)	SS		ORAL	40 MG/	ORAL

Date:10/19/99ISR Number: 3375992-2Report Type:Expedited (15-DaCompany Report #A0080880A
Age: Gender:Female I/FU:I

Outcome	PT
Disability	Discomfort
	Dizziness
	Drug Hypersensitivity
	Dry Mouth
	Feeling Abnormal
	Feeling Jittery

	Illogical Thinking Insomnia Muscle Rigidity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Muscle Spasms Myalgia Nervousness	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY / ORAL
	Panic Disorder Without Agoraphobia						
	Tetany Vision Blurred Visual Disturbance		Magnesium Salt	C			

Date:10/19/99ISR Number: 3375994-6Report Type:Expedited (15-DaCompany Report #A0080063A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Discomfort Dizziness Drug Hypersensitivity Dry Mouth Fatigue	Health Professional	Bupropion Hydrochloride Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL
	Feeling Jittery						
	Illogical Thinking Insomnia Muscle Rigidity Muscle Spasms Myalgia Nervousness Panic Reaction Tetany Vision Blurred Visual Disturbance		Multivitamin	C			

Date:10/19/99ISR Number: 3376106-5Report Type:Expedited (15-DaCompany Report #A0103180A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Arrest Dyspnoea Tongue Oedema Tracheal Oedema Tracheostomy	Consumer	Wellbutrin Tablet (Bupropion Hydrochloride)	PS			100 MG / THREE TIMES PER DAY	
			Blood Pressure Medication	C				

Date:10/19/99ISR Number: 3376114-4Report Type:Expedited (15-DaCompany Report #A0095964A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysarthria Feeling Hot Headache Monoparesis Nausea Respiratory Arrest Syncope Tremor Urinary Incontinence	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Ethanol Liquid (Alcohol)	SS		ORAL	ORAL	
			Fluoxetine Hydrochloride	C				

			Aspirin	C			

Date:10/20/99ISR Number: 3376492-6Report Type:Expedited (15-DaCompany Report #A0103160A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Disorder	Foreign	Wellbutrin					
	Pneumonia	Health	Tablet-Controlled					
		Professional	Release (Bupropion					
			Hydrochloride)	PS		ORAL	150 MG	
							TWICE PER DAY	
							ORAL	
			Nifedipine	C				

Date:10/20/99ISR Number: 3376495-1Report Type:Expedited (15-DaCompany Report #A0097683A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Health	Wellbutrin					
Initial or Prolonged	Delirium	Professional	Tablet-Controlled					
Other	Muscle Disorder	Company	Release (Bupropion					
Required	Muscle Rigidity	Representative	Hydrochloride)	PS		ORAL	150 MG	
Intervention to	Neuroleptic Malignant						TWICE PER DAY	
Prevent Permanent	Syndrome						ORAL	
Impairment/Damage	Pyrexia		Semisodium Valproate	C				
			Librium	C				
			Buspirone Hydrochloride	C				
			Diltiazem Hydrochloride	C				
			Conjugated Estrogens	C				
			Thyroxine Sodium	C				
			Hydrochlorothiazide	C				
			Omeprazole	C				
			Lisinopril	C				

Date:10/22/99ISR Number: 3377668-4Report Type:Periodic Company Report #990083.01
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Muscle Spasms Paraesthesia	Consumer	Furosemide Tablets 20 Mg Mylan	PS	Mylan	ORAL	20 MG QD, ORAL	
			Wellbutrin 75 Mg Glaxo Wellcome	SS	Glaxo Wellcome	ORAL	75 MG QD, ORAL	1 MON

Date:10/22/99ISR Number: 3378767-3Report Type:Direct Company Report #
Age:49 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Health	Bupropion	PS			150MG BID	
	Muscle Rigidity	Professional					APPROXIMATELY	
	Nausea						2 DAYS	2 DAY
	Pyrexia							
	Sedation							

Date:10/25/99ISR Number: 3381320-9Report Type:Expedited (15-DaCompany Report #A0093402A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Cancer Recurrent	Health	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL	
	Metastases To Liver	Professional	Tamoxifen	C				
			Paroxetine Hydrochloride	C				

Date:10/25/99ISR Number: 3381565-8Report Type:Expedited (15-DaCompany Report #A0101636A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Literature	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	300 MG/DAY / ORAL	
	Chills	Health						
	Difficulty In Walking	Professional						
	Fatigue							
	Leukocytosis							
	Myalgia							
	Oedema Peripheral							

	Pyrexia					
	Serum Sickness					
	Tenderness					
	Urticaria					

Date:10/25/99ISR Number: 3381679-2Report Type:Expedited (15-DaCompany Report #A0086318A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Health	Bupropion					
Hospitalization -	Drug Hypersensitivity	Professional	Hydrochloride Tablet					
Initial or Prolonged	Dysphagia		-Zyban (Bupropion					
Other	Eyelid Oedema		Hydrochloride)	PS		ORAL	150 MG /	
Required	Face Oedema						TWICE PER DAY	
Intervention to	Pharyngeal Oedema						/ ORAL	
Prevent Permanent			Bupropion					
Impairment/Damage			Hydrochloride Tablet					
			-Zyban (Bupropion					
			Hydrochloride)	SS		ORAL	150 MG /	
							SINGLE DOSE /	
							ORAL	
			Lansoprazole	C				
			Lorcet	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/99ISR Number: 3382299-6Report Type:Expedited (15-DaCompany Report #A0068941A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Conversion Disorder Feeling Abnormal Hallucination Tremor	Consumer	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL

Date:10/25/99ISR Number: 3382918-4Report Type:Expedited (15-DaCompany Report #A0077179A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Influenza Lung Neoplasm Malignant Pyrexia	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL

Date:10/26/99ISR Number: 3381635-4Report Type:Direct Company Report #
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain Arthralgia Bronchospasm Forced Expiratory Volume Abnormal Hypersensitivity Influenza Like Illness Malaise Pruritus Urticaria		Zyban (Bupropion)	PS		ORAL	150 MG BID P.O.

Date:10/27/99ISR Number: 3382458-2Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder	Health	Wellbutrin 75mg	PS		ORAL	75MG PO BID	
	Feeling Jittery	Professional	Cardizem Cd	C				
			Erythromycin	C				
			Hydroxyzine	C				
			Zocor	C				

Date:10/27/99ISR Number: 3383444-9Report Type:Expedited (15-DaCompany Report #A0103571A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Health	Wellbutrin	PS		ORAL	100 MG FOUR TIMES PER DAY	
	Dizziness	Professional						
	Nausea							

Date:10/28/99ISR Number: 3384829-7Report Type:Expedited (15-DaCompany Report #A0103729A
Age:31 YR Gender:Female I/FU:I

Outcome	PT
Other	Convulsion
	Tachycardia

Tremor

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign	Ceftin (Cefuroxime					
		Consumer	Axetil)	PS				
		Other	Zyban	SS		ORAL	150 MG / UNK	
							/ ORAL	
			Ibuprofen	SS				
			Amoxycillin Trihydrate	SS				

Date:10/29/99ISR Number: 3384931-XReport Type:Direct Company Report #
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin-Glaxo	PS	Glaxo	ORAL	150MG ORAL	
			Luvox	C				

Date:10/29/99ISR Number: 3386131-6Report Type:Periodic Company Report #A0102154A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Wellbutrin					
	Overdose		Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	300 MG/TWICE PER DAY/ ORAL	

Date:10/29/99ISR Number: 3386132-8Report Type:Periodic Company Report #A0102376A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS			ORAL

ORAL

Date:10/29/99ISR Number: 3386133-XReport Type:Periodic Company Report #A0087281A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL

Date:10/29/99ISR Number: 3386135-3Report Type:Periodic Company Report #A0089931A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL

			Cancer Chemotherapy (Formulation Unknown) (Cancer Chemotherapy)	SS		
			Zolpidem Tartrate	C		

Date:10/29/99ISR Number: 3386138-9Report Type:Periodic Company Report #A0095478A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/	
	Suicide Attempt		Citalopram (Formulation Unknown) (Citalopram)	SS			20 MG/ PER DAY/	
			Trazodone	C				

Date:10/29/99ISR Number: 3386140-7Report Type:Periodic Company Report #A0096029A
Age:11 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/ ORAL	1 YR

Date:10/29/99ISR Number: 3386144-4Report Type:Periodic Company Report #A0095490A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Head Injury	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Cyclobenzaprine Hcl	C				
			Dilantin	C				

Date:10/29/99ISR Number: 3386145-6Report Type:Periodic Company Report #A0096293A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Syncope	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	250 MG / TWICE PER DAY / ORAL	
			Cisapride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/99ISR Number: 3386149-3Report Type:Periodic Company Report #A0096370A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	Required
			Tramadol Hydrochloride (Formulation Unknown) (Tramadol Hydrochloride)	SS		ORAL	Intervention to Prevent Permanent Impairment/Damage	
			Venlafaxine Hydrochloride	C				

Date:10/29/99ISR Number: 3386152-3Report Type:Periodic Company Report #A0096390A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Paroxetine Hydrochloride	C				
			Darvocet-N	C				
			Zolpidem Tartrate	C				

Date:10/29/99ISR Number: 3386155-9Report Type:Periodic Company Report #A0096971A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Convulsion Migraine	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY	ORAL 4 YR
			Sertraline Hydrochloride	C				

Date:10/29/99ISR Number: 3386159-6Report Type:Periodic Company Report #A0097592A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Ineffective Laceration	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / SEE TEXT	ORAL 4 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/99ISR Number: 3386161-4Report Type:Periodic Company Report #A0097691A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Depression Fatigue	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	200 MG / TWICE PER DAY / ORAL	

Date:10/29/99ISR Number: 3386164-XReport Type:Periodic Company Report #A0098230A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Pruritus Rash Papular Stevens-Johnson Syndrome Urticaria	Health Professional	Wellbutrin Tablet-Controlled Release 150 Mg (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:10/29/99ISR Number: 3386169-9Report Type:Periodic Company Report #A0098258A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS				

Date:10/29/99ISR Number: 3386172-9Report Type:Periodic Company Report #A0098464A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Health	Wellbutin Tablet					
	Grand Mal Convulsion	Professional	(Bupropion Hydrochloride)	PS		ORAL	400 MG	
			Citalopram Hydrobromide	C				

Date:10/29/99ISR Number: 3386180-8Report Type:Periodic Company Report #A0098531A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin					
	Dysgeusia	Professional	Tablet-Controlled					
	Eye Rolling	Company	Release (Bupropion					
	Movement Disorder	Representative	Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY	
	Muscle Twitching							
	Posturing						/ ORAL	10 DAY
	Sedation		Lorazepam	C				
	Speech Disorder		Semisodium Valproate	C				
	Vision Blurred		Diphenhydramine Hcl	C				
			Cyclobenzaprine Hcl	C				
			Excedrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/99ISR Number: 3386185-7Report Type:Periodic Company Report #A0099382A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY	/ ORAL
			Azithromycin	C				
			Doxycycline	C				
			Oral Contraceptive	C				

Date:10/29/99ISR Number: 3386191-2Report Type:Periodic Company Report #A0099922A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema	Consumer	Wellbutrin Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL
	Oedema Peripheral							
	Periorbital Oedema							
	Pruritus							
	Skin Disorder							
	Swelling		Multivitamin	C				
	Urticaria							

Date:10/29/99ISR Number: 3386197-3Report Type:Periodic Company Report #A0100210A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Bydrochloride)	PS		ORAL	150 MG /	
	Angioneurotic Oedema							
	Arthralgia							
	Dermatitis							

Dyspnoea
TWICE PER DAY
Pain
/ ORAL

Date:10/29/99ISR Number: 3386201-2Report Type:Periodic Company Report #A0100421A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Disorientation Sedation	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Semisodium Valproate	PS C				

Date:10/29/99ISR Number: 3386206-1Report Type:Periodic Company Report #A0100585A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/99ISR Number: 3386210-3Report Type:Periodic Company Report #A0101446A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		
			Citalopram Hydrobromide	C				

Date:10/29/99ISR Number: 3386213-9Report Type:Periodic Company Report #A0101495A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	10 DAY

Date:10/29/99ISR Number: 3386215-2Report Type:Periodic Company Report #A0101936A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Control Release (Bupropion Hydrochloride)	PS				

Date:11/01/99ISR Number: 3386411-4Report Type:Direct Company Report #
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin 150 Sr	PS		ORAL	150 PO QD ->	
	Extrapyramidal Disorder	Professional					BID	30 DAY
	Muscle Twitching		Zyprexa 10mg	SS			10MG	30 DAY
	Neuroleptic Malignant Syndrome		Clonazepam	C				
			Prolixin	C				
			Cogentin	C				
			Celexa	C				

Date:11/01/99ISR Number: 3386412-6Report Type:Direct Company Report #
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error	Health	Wellbutrin Sr 150mg	PS			150AM 75PM	30 DAY
		Professional	Tramadol 50mg Po	SS		ORAL	50 Q ? PO	2 DAY
			Zyprexa	C				

Date:11/01/99ISR Number: 3387206-8Report Type:Expedited (15-DaCompany Report #A0103746A
Age:24 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Chills

	Difficulty In Walking Dyspepsia Face Oedema Lymphadenitis Myalgia Oedema Oesophageal Disorder Pruritus Pyrexia Rash Erythematous Serum Sickness Synovitis Urticaria White Blood Cell Count Increased	Report Source Foreign Literature Health Professional	Product Zyban Tablet - Zyban (Bupropion Hydrochloride)	Role PS	Manufacturer	Route ORAL	Dose Duration 150 MG/ TWICE PER DAY/ ORAL 16 DAY

Date:11/01/99ISR Number: 3387287-1Report Type:Expedited (15-DaCompany Report #A0103905A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / ORAL 7 WK

Date:11/01/99ISR Number: 3387291-3Report Type:Expedited (15-DaCompany Report #A0103615A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abnormal Dreams Angioneurotic Oedema Dermatitis Dyspnoea	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /TWICE PER DAY/ORAL
	Eyelid Oedema Face Oedema Hypertension		Nabumetone	C			

	Nausea					
	Oral Intake Reduced					
	Pain					
	Pruritus					
	Psychotic Disorder					
	Urticaria					

Date:11/01/99ISR Number: 3387292-5Report Type:Expedited (15-DaCompany Report #A0102535A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Lower	Foreign Health Professional	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
	Aphonia							
	Blood Sodium Decreased							
	Decreased Appetite							
	Influenza		Metformin	C				
	Pyrexia		Aspirin	C				
	Vomiting		Diltiazem Hydrochloride	C				
			Cerivastatin	C				
			Ramipril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/99ISR Number: 3388598-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme Lymphadenopathy Stevens-Johnson Syndrome		Zyban 150mg	PS			150MG QD X3 THEN BID	

Date:11/03/99ISR Number: 3389230-8Report Type:Expedited (15-DaCompany Report #A0102044A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs Foetal Disorder Gastroschisis	Foreign Study Health Professional Company Representative	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:11/03/99ISR Number: 3389236-9Report Type:Expedited (15-DaCompany Report #A0104285A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Burning Sensation Decreased Activity Dehydration Muscle Spasms Rash Generalised Rash Pruritic	Foreign Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:11/04/99ISR Number: 3388895-4Report Type:Expedited (15-DaCompany Report #A0104362A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Interaction Urinary Tract Infection	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	SEE TEXT/	
			Bactrim (Formulation Unknown) (Sulfamethoxazole/Trimetho)	SS		ORAL		
			Fluoxetine Hydrochloride	C				

Date:11/04/99ISR Number: 3388898-XReport Type:Expedited (15-DaCompany Report #A0104365A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Headache Tinnitus	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
			Atenolol	C				
			Pravastatin Sodium	C				
			Nitroglycerin	C				
			Salbutamol Sulphate	C				

			Lorazepam	C			

Date:11/05/99ISR Number: 3390175-8Report Type:Expedited (15-DaCompany Report #A0098418A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Abnormal Behaviour Belligerence Convulsion Fall Haemorrhage Head Injury Upper Respiratory Tract Infection	Health Professional Company Representative	Wellbutrin Tablet -Controlled Release (Bupropion Hydrochlride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL
			Pseudoephedrine (Formulation Unknown) (Pseudoephedrine)	SS		ORAL	ORAL
			Dextromethorphan (Formulation Unknown) (Dextromethorphan)	SS		ORAL	ORAL

Date:11/05/99ISR Number: 3390176-XReport Type:Expedited (15-DaCompany Report #A0102803A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Arthralgia Dermatitis Drug Hypersensitivity Dyspnoea Laryngeal Oedema	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ ORAL

Date:11/08/99ISR Number: 3390236-3Report Type:Direct Company Report #
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Clonic Convulsion Coma Overdose Tachycardia	Health Professional	Bupropion Citalopram	PS C		ORAL	6GM PO X 1 DOSE	

Date:11/08/99ISR Number: 3390751-2Report Type:Expedited (15-DaCompany Report #9942002
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Activated Partial Thromboplastin Time Prolonged Anxiety Bleeding Time Prolonged Depressed Mood Drug Ineffective Ear Haemorrhage Fatigue Feeling Abnormal Sleep Disorder Suicidal Ideation	Health Professional	Zoloft Tablets Bupropion Nitropatch Nitrex Levothyroxine Lansoprazole Alprazolam Coumadin Vitamin B12 Vitamin E Vitamin C	PS SS C C C C C C C C C		ORAL	100 MG TOTAL DAILY ORAL ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/99ISR Number: 3391243-7Report Type:Expedited (15-DaCompany Report #A0104721A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150MG ORAL	
			Spironolactone (Formulation Unknown) (Spironolactone)	SS			25MG TWICE PER DAY	
			Frusemide	C				

Date:11/08/99ISR Number: 3391335-2Report Type:Expedited (15-DaCompany Report #A0098556A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dysphagia Dyspnoea Oesophagitis	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150MG ORAL	
			Omeprazole	C				
			Ranitidine Hydrochloride	C				

Date:11/09/99ISR Number: 3391436-9Report Type:Direct Company Report #
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma Confusional State		Welbutrin (Buproprion)	PS		ORAL	150MG BID PO	
Required Intervention to Prevent Permanent	Convulsion Muscle Rigidity Paranoia		Antihistamin	C				

Impairment/Damage	Sensory Loss
	Speech Disorder
	Vomiting

Date:11/10/99ISR Number: 3391808-2Report Type:Direct Company Report #
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr 150mg	PS			150MG 2X	
	Urticaria						DAILY	

Date:11/12/99ISR Number: 3396181-1Report Type:Expedited (15-DaCompany Report #A0104815A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block	Health	Wellbutrin					
	Complete	Professional	Tablet-Controlled					
	Dyspnoea		Release (Bupropion Hydrochloride)	PS		ORAL	1 TABLET / PER DAY /	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/99ISR Number: 3396185-9Report Type:Expedited (15-DaCompany Report #B0072373A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Alopecia Dermatitis Atopic Dermatitis Exfoliative Dry Mouth Extrasystoles Face Oedema Flushing Gastrooesophageal Reflux Disease Hypertension Muscle Rigidity Muscle Spasms Palpitations Paraesthesia Photosensitivity Reaction Pruritus Tachycardia Tremor Urinary Retention Urticaria	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS				

Date:11/12/99ISR Number: 3396816-3Report Type:Expedited (15-DaCompany Report #A0098933A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Ascites Blood Bilirubin Increased Coagulopathy Depression Epididymitis Fatigue Hepatic Cirrhosis Hepatic Enzyme Increased Hepatic Failure Hepatic Fibrosis Hepatic Necrosis	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Salbutamol Sulphate Beclomethasone Dipropion. Venlafaxine Hydrochloride Fluticasone	PS C C C		ORAL	150 MG/TWICE PER DAY/	ORAL

	Hepatitis	Propionate	C
	International Normalised		
	Ratio Increased		
	Jaundice		
	Nausea		
	Petechiae		
	Pleural Effusion		
	Prothrombin Time		
	Prolonged		
	Pulmonary Congestion		
	Renal Failure		
	Splenomegaly		

Date:11/12/99ISR Number: 3396937-5Report Type:Expedited (15-DaCompany Report #A0104511A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Other	Complex Partial Seizures	Health
	Drug Interaction	Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Ritonavir (Formulation Unknown) (Ritonavir)	SS			
			Anti-Viral Medication	C			

Date:11/12/99ISR Number: 3397224-1Report Type:Expedited (15-DaCompany Report #A0102868A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Overdose	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL
			Trovafloxacin Mesylate	C			
			Morphine	C			

Date:11/12/99ISR Number: 3397374-XReport Type:Expedited (15-DaCompany Report #A0103746A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia Asthma Chills	Foreign Literature Health	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /

Dyspepsia Professional
TWICE PER DAY
Face Oedema
/ ORAL 16 DAY
Lymphadenopathy
Movement Disorder
Myalgia
Odynophagia
Oedema Peripheral
Pain In Extremity
Periorbital Oedema
Pruritus
Pyrexia
Rash Erythematous
Serum Sickness
Synovitis
Urticaria
White Blood Cell Count
Increased

Date:11/15/99ISR Number: 3397214-9Report Type:Expedited (15-DaCompany Report #A0102889A
Age:23 YR Gender:Male I/FU:I

Outcome PT
Other Abdominal Pain
Anaphylactic Reaction

	Arthralgia Bronchospasm Dyspnoea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Malaise Peak Expiratory Flow Rate Decreased	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL
	Pharyngolaryngeal Pain Pruritus Pulmonary Function Test Abnormal Throat Tightness Urticaria						

Date:11/15/99ISR Number: 3397218-6Report Type:Expedited (15-DaCompany Report #A0105273A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness Renal Failure	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			7 DAY
	Rhabdomyolysis		Ethanol (Formulation Unknown) (Alcohol)	SS			

Date:11/15/99ISR Number: 3397912-7Report Type:Expedited (15-DaCompany Report #A0104240A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent	Aggression Mania Suicidal Ideation	Study Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	400 MG PER DAY ORAL

Impairment/Damage			Paracetamol	C		

Date:11/16/99ISR Number: 3397464-1Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Bupropion Sr	PS			100MG TID	
			Ranitidine	C				
			Naproxene	C				
			Darvocet	C				
			Zolpidem	C				

Date:11/17/99ISR Number: 3399752-1Report Type:Expedited (15-DaCompany Report #A0105253A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Convulsion Loss Of Consciousness Respiratory Arrest	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Aspirin	C				
			Sertraline Hydrochloride	C				
			Atorvastatin Calcium	C				

			Cetirizine Hydrochloride	C		

Date:11/18/99ISR Number: 3402656-9Report Type:Expedited (15-DaCompany Report #A0062864A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Pregnancy	Health Professional	Bupropion Hydrochloride Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:11/18/99ISR Number: 3402657-0Report Type:Expedited (15-DaCompany Report #A0062610A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abortion Spontaneous Pregnancy	Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:11/19/99ISR Number: 3403049-0Report Type:Expedited (15-DaCompany Report #A0105423A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Hypoaesthesia Multiple Sclerosis	Foreign Health Professional	Bupropion Hydrochloride Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ ORAL	

Date:11/19/99ISR Number: 3403933-8Report Type:Expedited (15-DaCompany Report #A0104285A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Decreased Activity Dehydration Dermatitis Muscle Spasms Pruritus Urticaria Vomiting	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY	

Date:11/22/99ISR Number: 3403652-8Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia Drug Interaction Loss Of Consciousness Tonic Convulsion		Wellbutrin Sr	PS			TITRATED FROM 6/2-6/25 150MG Q AM , NOON & PM	
			Clozapine 150mg	SS			150MG Q HS	
			Effexor Xr	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/99ISR Number: 3408491-XReport Type:Periodic Company Report #S99-USA-01718-01
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Celexa	PS		ORAL	40 MG QD PO	
	Pruritus	Professional	Wellbutrin	SS				
	Urticaria		Oral Contraceptives	C				

Date:11/23/99ISR Number: 3409304-2Report Type:Expedited (15-DaCompany Report #A0105636A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abdominal Pain Blood Creatine Phosphokinase Increased Grand Mal Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	SEE TEXT	
	Hallucination, Visual						ORAL	
	Intentional Misuse Mental Impairment Sedation Sinus Tachycardia Suicide Attempt							

Date:11/23/99ISR Number: 3409306-6Report Type:Expedited (15-DaCompany Report #A0105554A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Agranulocytosis Fatigue Influenza	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	THREE TIMES PER DAY	
	Libido Decreased							
	Lung Disorder						ORAL	
	Malaise							

	Pneumonia					
	Pyrexia					
	Suicidal Ideation					
	Vomiting					
	White Blood Cell Count Decreased					

Date:11/24/99ISR Number: 3406829-0Report Type:Direct Company Report #
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bite		Wellbutrin Sr 150mg	PS			150MG SR BID	
	Convulsion		Ortho-Tricyclen	C				
	Cyanosis							
	Salivary Hypersecretion							
	Tremor							

Date:11/24/99ISR Number: 3410232-7Report Type:Expedited (15-DaCompany Report #A0102413A
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Other	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain

		Dysarthria Headache Hemiparesis Hyperhidrosis Transient Ischaemic Attack Vertigo	Report Source Foreign Health Professional	Product Zyban Tablet - Zyban (Bupropion Hydrochloride) Sinemet	Role PS C	Manufacturer	Route ORAL

Dose: 150 MG / TWICE PER DAY / ORAL

Duration:

Date:11/26/99ISR Number: 3408907-9Report Type:Expedited (15-DaCompany Report #A0105636A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Other	Abdominal Pain Blood Creatine Phosphokinase Increased Grand Mal Convulsion Hallucination, Visual Intentional Misuse Mental Impairment Sedation Sinus Tachycardia Suicide Attempt	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL

Dose: SEE TEXT / ORAL

Duration:

Date:11/26/99ISR Number: 3408919-5Report Type:Expedited (15-DaCompany Report #A0105877A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Confusional State Cyanosis Dyspnoea Eye Rolling	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL

Dose: 150 MG / TWICE PER DAY

Duration:

	Movement Disorder						
/ ORAL							
	Sedation		Sumatriptan Succinate	C			
			Propranolol Hydrochloride	C			
			Salbutamol Sulphate	C			
			Triquilar	C			

Date:11/26/99ISR Number: 3408922-5Report Type:Expedited (15-DaCompany Report #A0105879A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis		Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY	
	Diarrhoea							
	Dizziness							
	Erythema Multiforme							
	Leukocytosis							
/ ORAL								15 DAY
	Nausea							
	Neutrophilia							
	Oedema							
	Pruritus							
	Serum Sickness							
	Tachycardia							
	Tongue Disorder							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/99ISR Number: 3411023-3Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Zyban (Glaxo)	PS		ORAL	150MG BID PO	
	Urticaria	Professional	Synthroid	C				

Date:11/30/99ISR Number: 3411804-6Report Type:Expedited (15-DaCompany Report #A0098738A
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aneurysm	Consumer	Wellbutrin					
Hospitalization -	Arterial Rupture		Tablet-Controlled					
Initial or Prolonged	Atrial Fibrillation		Release (Bupropion					
Other	Dizziness		Hydrochloride)	PS		ORAL	150 MG	
	Fatigue						TWICE PER DAY	
	Headache							
	Hypertension						ORAL	
	Insomnia		Verapamil	C				
	Metastases To Liver		Hyzaar	C				
	Nephrolithiasis		Librium	C				
	Palpitations							
	Pneumonia							

Date:11/30/99ISR Number: 3411839-3Report Type:Expedited (15-DaCompany Report #A0104511A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complex Partial Seizures	Health	Wellbutrin					
	Drug Interaction	Professional	Tablet-Controlled					
		Company	Release (Bupropion					
		Representative	Hydrochloride)	PS		ORAL	150 MG	
		Other					TWICE PER DAY	

ORAL						
			Ritonavir Solution (Ritonavir)	SS		ORAL
ORAL						
			Anti-Viral Medication	C		

Date:11/30/99ISR Number: 3411840-XReport Type:Expedited (15-DaCompany Report #A0105888A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS	Zyban	ORAL	150 MG PER DAY	ORAL 2 DAY
Other								

Date:11/30/99ISR Number: 3411841-1Report Type:Expedited (15-DaCompany Report #A0105871A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration	Foreign	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS				
	Overdose		Nortriptyline					

			(Nortriptyline)				
			(Formulation Unkown)	SS			
			Cocaine (Cocaine)				
			(Formulation				
			Unknown)	SS			

Date:11/30/99ISR Number: 3411842-3Report Type:Expedited (15-DaCompany Report #A0105850A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin					
	Overdose	Professional	Tablet-Controlled					
		Company	Release (Bupropion					
		Representative	Hydrochloride)	PS		ORAL	ORAL	

Date:11/30/99ISR Number: 3414970-1Report Type:Periodic Company Report #A0089382A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort	Consumer	Zyban Tablet - Zyban					
	Chest Pain		(Bupropion					
	Ecchymosis		Hydrochloride)	PS		ORAL	150 MG/ TWICE	
	Hypersensitivity						PER DAY/ ORAL	
	Rash Erythematous							
	Rash Maculo-Papular							
	Urticaria							

Date:11/30/99ISR Number: 3414971-3Report Type:Periodic Company Report #A0082332A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Zyban Tablet - Zyban					
	Fall	Consumer	(Bupropion					
	Head Injury		Hydrochloride)	PS		ORAL	150 MG/ TWICE	

	Laceration						
PER DAY/ ORAL							
	Loss Of Consciousness		Percocet	C			
			Alprazolam	C			
			Diamorphine Hydrochloride	C			

Date:11/30/99ISR Number: 3414972-5Report Type:Periodic Company Report #A0070364A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angioneurotic Oedema	Health	Zyban Tablet - Zyban			
	Dermatitis	Professional	(Bupropion			
	Hypersensitivity		Hydrochloride)	PS		ORAL
150 MG/ TWICE						
	Pruritus					
PER DAY/ ORAL						
	Swelling					
	Urticaria					

Date:11/30/99ISR Number: 3414973-7Report Type:Periodic Company Report #A0101092A
Age: Gender:Female I/FU:I

Outcome	PT
Other	Bladder Disorder
	Convulsion

	Faecal Incontinence Feeling Abnormal Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscle Spasms Musculoskeletal Disorder Tremor	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/ ORAL						
			Fluoxetine Hydrochloride	C		

Date:11/30/99ISR Number: 3414974-9Report Type:Periodic Company Report #A0094675A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Rash Generalised Stevens-Johnson Syndrome	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/ TWICE PER DAY/ ORAL						
			Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL
ORAL						
			Thyroxine Sodium	C		

Date:11/30/99ISR Number: 3414975-0Report Type:Periodic Company Report #A0102353A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Fatigue Flushing Malaise Myocardial Infarction Nausea	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/ PER DAY/ ORAL						

Date:11/30/99ISR Number: 3414976-2Report Type:Periodic Company Report #A0101445A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL	

Date:11/30/99ISR Number: 3414977-4Report Type:Periodic Company Report #A0101335A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	1 TABLET/ TWICE PER DAY/ ORAL	11 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/99ISR Number: 3414978-6Report Type:Periodic Company Report #A0101180A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	300 MG/ PER DAY/ ORAL
			Oral Contraceptive	C			

Date:11/30/99ISR Number: 3414979-8Report Type:Periodic Company Report #A0100132A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion Insomnia	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL
			Ortho-Novum	C			

Date:11/30/99ISR Number: 3414980-4Report Type:Periodic Company Report #A0100142A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Agitation Delusion Dry Mouth Insomnia Mania Mood Altered Paranoia	Consumer	Zyban Tablet - Zyban	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL

Date:11/30/99ISR Number: 3414981-6Report Type:Periodic Company Report #A0099050A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Memory Impairment	Consumer	Zyban Tablet -Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/	
			Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS		ORAL	150 MG/ PER	DAY/

Date:11/30/99ISR Number: 3414982-8Report Type:Periodic Company Report #A0096097A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia Circulatory Collapse Convulsion Disturbance In Attention Hypoaesthesia	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/99ISR Number: 3412862-5Report Type:Expedited (15-DaCompany Report #A0090299A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Chest Pain Pericarditis Vomiting	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	100 MG / PER DAY	7 DAY

Date:12/02/99ISR Number: 3412864-9Report Type:Expedited (15-DaCompany Report #A0090004A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest Chest Discomfort Dyspnoea	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG	
	Pulmonary Embolism		Lorazepam	C				
			Cefuroxime Axetil	C				
			Combivent	C				
			Budesonide	C				
			Tetracycline	C				
			Theophylline	C				

Date:12/02/99ISR Number: 3412921-7Report Type:Expedited (15-DaCompany Report #A0103729A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Sinus Tachycardia Suicide Attempt Tremor	Foreign	Ceftin (Formulation Unknown) (Cefuroxime Axetil)	PS				
			Zyban Tablet - Zyban (Bupropion Hydrochloride)	SS			150 MG	ORAL
			Ibuprofen (Formulation Unknown) (Ibuprofen)	SS				

				Amoxycillin Trihydrate (Formulation Unknown) (Amoxycillin	SS		

Date:12/06/99ISR Number: 3414110-9Report Type:Expedited (15-DaCompany Report #A0105850A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Intentional Misuse Suicidal Ideation Suicide Attempt	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupriopn Hydrochloride)	PS		ORAL	SEE TEXT	

Date:12/06/99ISR Number: 3414153-5Report Type:Expedited (15-DaCompany Report #A0105840A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged Other	Cerebrovascular Accident	Health Professional Company

Representative

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Sertraline Hydrochloride	C				
			Mirtazapine	C				

Date:12/06/99ISR Number: 3414174-2Report Type:Expedited (15-DaCompany Report #A0105839A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional Company Representative	Wellbutrin (Bupropion Hydrochloride) (Formulation Unknown)	PS		ORAL	ORAL	1 WK
			Fluoxetine Hydrochloride	C				

Date:12/06/99ISR Number: 3414176-6Report Type:Expedited (15-DaCompany Report #A0093402A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Cancer Recurrent Metastases To Liver	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG PER DAY	ORAL
			Tamoxifen	C				
			Paroxetine					

			Hydrochloride	C		

Date:12/06/99ISR Number: 3414177-8Report Type:Expedited (15-DaCompany Report #A0106235A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Dreams Anaphylactic Shock Blood Pressure Decreased Dermatitis Face Oedema Flushing Loss Of Consciousness Peripheral Coldness Rash Erythematous Skin Exfoliation Tongue Oedema	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride) Clarithromycin	PS C		ORAL ORAL	150 MG PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/99ISR Number: 3414178-XReport Type:Expedited (15-DaCompany Report #A0106475A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy Discomfort Swelling Urticaria	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:12/06/99ISR Number: 3414181-XReport Type:Expedited (15-DaCompany Report #A0106383A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation Confusional State Disorientation Disturbance In Attention Flight Of Ideas	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Headache Memory Impairment Mood Swings Nausea Priapism Rash Pruritic Tenderness		Salbutamol Sulphate	C				

Date:12/07/99ISR Number: 3415134-8Report Type:Expedited (15-DaCompany Report #A0106452A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoglycaemia Loss Of Consciousness	Foreign Consumer	Zyban Tablet - Zyban (Bupropion					

	Road Traffic Accident		Hydrochloride)	PS		ORAL

150 MG /

TWICE PER DAY

/ ORAL

Date:12/07/99ISR Number: 3415135-XReport Type:Expedited (15-DaCompany Report #A0093420A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiomegaly	Health	Zyban Tablet - Zyban			
Initial or Prolonged	Chest Discomfort	Professional	(Bupropion			
	Chest Pain		Hydrochloride)	PS		ORAL

150 MG /

	Drug Hypersensitivity					

TWICE PER DAY

	Dyspnoea					

/ ORAL

	Hyperhidrosis					
	Hypoaesthesia					
	Pain In Jaw					
	Photosensitivity Reaction					
	Proctalgia					
	Pruritus					
	Rash Erythematous					
	Throat Tightness					
	Urethral Pain					
	Urticaria					
	White Blood Cell Count Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/99ISR Number: 3416792-4Report Type:Expedited (15-DaCompany Report #B0072373A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Alopecia Chills Dermatitis Atopic Dermatitis Exfoliative Extrasystoles Face Oedema Flushing Gastrooesophageal Reflux Disease Hypersensitivity Hypertension Muscle Spasms Palpitations Paraesthesia Photosensitivity Reaction Rash Erythematous Tachycardia Tremor Urinary Retention Urticaria	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Thyroxine Sodium	PS C				

Date:12/08/99ISR Number: 3416795-XReport Type:Expedited (15-DaCompany Report #A0106237A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills Dermatitis Hypersensitivity Localised Oedema Oedema Peripheral Pruritus Urticaria	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:12/10/99ISR Number: 3418592-8Report Type:Expedited (15-DaCompany Report #7399530
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Health	Abbott - Norvir Soft Gelatin Capsules	PS	Abbott	ORAL	400.000 MG PO	BID
	Complex Partial Seizures	Professional						
	Drug Interaction	Other						
			Wellbutrin	SS		ORAL	150.000 MG PO	BID
			Fortovase	C				
			Zerit	C				
			Epivir	C				

Date:12/10/99ISR Number: 3418605-3Report Type:Expedited (15-DaCompany Report #PRIUSA1999006684
Age:35 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization - Initial or Prolonged
Required

Intervention to Prevent Permanent Impairment/Damage

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Agitation Cardiac Arrest Completed Suicide Convulsion	Literature Health Professional	Haldol(Tablet) (Haloperidol)	PS		ORAL	1 TABLE, 30 IN 1 TIME(S),	ORAL
Intentional Misuse Tachycardia Toxicologic Test Abnormal Ventricular Fibrillation Vomiting		Aspirin(Acetylsalicylic Acid)	SS		ORAL	1 TABLE, 500 IN 1 TIME(S),	ORAL
		Bupropion(Amfebutamone)	SS		ORAL	100 MG, 30 IN 1TIME(S),	ORAL

Date:12/10/99ISR Number: 3419037-4Report Type:Expedited (15-DaCompany Report #A0104885A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Burning Sensation Erythema Erythema Multiforme Lymphadenopathy Malaise Pain Pruritus Pyrexia Serum Sickness	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:12/13/99ISR Number: 3420202-0Report Type:Expedited (15-DaCompany Report #A0106978A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	100 MG/ THREE TIMES PER DAY/	
			Carbamazepine Tablet (Carbamazepaine)	SS		ORAL	200 MG/ THREE TIMES PER DAY/	
			Oestradiol	C				

Date:12/13/99ISR Number: 3420204-4Report Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Disability	Asthenia
	Blood Glucose Increased
	Chills
	Dizziness
	Drug Hypersensitivity
	Headache
	Hyperhidrosis
	Hypertension

		Hypoaesthesia					
		Mania					
		Mental Impairment	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence	Health	Zyban Tablet-Zyban			
		Muscle Twitching	Professional	(Bupropion			
		Musculoskeletal Stiffness		Hydrochloride)	PS		ORAL
150 MG/ PER							
		Nervousness					
DAY/ ORAL							
		Paraesthesia		Conjugated Estrogens	C		
		Renal Impairment		Vitamin	C		
		Tongue Oedema		Aspirin	C		
		Tremor		Melatonin	C		
		Urinary Incontinence					

Date:12/13/99ISR Number: 3420692-3Report Type:Expedited (15-DaCompany Report #A0106200A
Age:54 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Chest Pain	Consumer	Wellbutrin Tablets -			
Initial or Prolonged		Dysgeusia		Controlled Release			
		Dyspepsia		(Bupropion			
		Sinusitis		Hydrochloride)	PS		ORAL
150 MG /							
TWICE PER							
DAY/ ORAL	2 WK						
				Gabapentin	C		
				Oxybutynin	C		
				Baclofen	C		
				Frusemide	C		
				Rofecoxib	C		

Date:12/13/99ISR Number: 3421072-7Report Type:Expedited (15-DaCompany Report #A0073385A
Age:45 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abnormal Behaviour	Literature	Wellbutrin			
Initial or Prolonged		Agitation	Health	Tablet-Controlled			

	Arthralgia	Professional	Release (Bupropion		
	Chest Pain		Hydrochloride)	PS	ORAL 150 MG / PER DAY / ORAL
	Confusional State				
	Delirium		Thiothixene	C	
	Disorientation		Lithium Salt	C	
	Drug Hypersensitivity		Venlafaxine Hydrochloride	C	
	Malaise		Thyroxine Sodium	C	
	Myalgia		Haloperidol	C	
	Pyrexia		Lorazepam	C	
	Rash Morbilliform		Trazodone	C	
	Rash Pruritic		Olanzapine	C	
	Red Blood Cell Sedimentation Rate Increased				
	Restlessness				
	Serum Sickness				

Date:12/14/99ISR Number: 3420932-0Report Type:Direct Company Report #
Age:24 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Diarrhoea

	Hallucination						
	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
			Bupropion	PS			

Date:12/14/99ISR Number: 3421148-4Report Type:Expedited (15-DaCompany Report #
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Hospitalization -	Anxiety		Bupropion Sr	PS		ORAL	
150 MG PO QD;							
Initial or Prolonged	Chest Pain						
150 MG PO BID							
	Dizziness		Ecotrin	C			
	Dyspnoea		Plavix	C			
	Hyperhidrosis		Atenolol	C			
	Hypotension		Imdur	C			
			Lipitor	C			
			Folate	C			
			Vitamin C	C			
			Vitamin E	C			

Date:12/14/99ISR Number: 3421152-6Report Type:Expedited (15-DaCompany Report #
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Hospitalization -	Cardiac Failure		Bupropion Sr	PS		ORAL	
150MG PO QD							
Initial or Prolonged	Congestive		Bupropion Sr	SS		ORAL	
300MG PO QD							
	Dyspnoea Exertional		Flagyl	C			
	Myocardial Infarction		Catapril	C			
	Orthopnoea		Prilosec	C			
	Oxygen Saturation		Atenolol	C			
	Decreased		Zocor	C			
			Asa	C			
			Ntg	C			

Date:12/15/99ISR Number: 3422453-8Report Type:Expedited (15-DaCompany Report #USA011874
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour	Health	Meridia	PS		ORAL	15 MG UNK PO	
Life-Threatening	Bradycardia	Professional	Wellbutrin Sr	SS		ORAL	150 MG UNK PO	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Coma		Klonopin	SS				
	Completed Suicide		Potassium	SS				
	Grand Mal Convulsion		Lasix	SS				
	Hypoglycaemia		Alcohol	SS				
	Lung Disorder							
	Sinus Tachycardia							

Date:12/16/99ISR Number: 3422749-XReport Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Zyban 150 Glaxo Wellcome	PS	Glaxo Wellcome		1 T BID	
	Medication Error		Celexa Forest	SS	Forest			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/99ISR Number: 3423545-XReport Type:Expedited (15-DaCompany Report #A0106621A
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration	Health	Wellbutrin					
	Choking	Professional	Tablet-Controlled					
	Muscle Rigidity		Release (Bupropion					
	Rhinorrhoea		Hydrochloride)	PS		ORAL	100 MG / PER	
	Sepsis						DAY / ORAL	
	Vomiting		Donepezil Hcl	C				
			Doxazosin Mesylate	C				
			Vitamin E	C				
			Glucosamine	C				

Date:12/16/99ISR Number: 3423550-3Report Type:Expedited (15-DaCompany Report #A0104511A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Complex Partial Seizures	Health	Wellbutrin					
Other	Drug Interaction	Professional	Tablet-Controlled					
Required		Company	Release (Bupropoin					
Intervention to		Representative	Hydrochloride)	PS		ORAL	150 MG /	
Prevent Permanent		Other					TWICE PER DAY	
Impairment/Damage							/ ORAL	
			Ritonavir Solution					
			(Ritonavir)	SS		ORAL	400 MG /	
							TWICE PLER	
							DAY / ORAL	
			Saquinavir	C				
			Stavudine	C				
			Lamivudine	C				
			Atovaquone	C				
			Loperamide Hydrochloride	C				

Date:12/16/99ISR Number: 3423555-2Report Type:Expedited (15-DaCompany Report #A0107071A
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrophy Confusional State Convulsion Delusion Disorientation Drug Interaction Miosis Muscle Rigidity Urinary Tract Infection Visual Disturbance	Health Professional	Zyban Tablet -Zyban (Bupropion Hydrochloride) Hormones Multivitamin Citalopram Hydrobromide (Formulation Unknown) (Citalopram Hydrobromide)	PS C C I		ORAL	150 MG / PER DAY / ORAL 20 MG / UNK / UNKNOWN	

Date:12/16/99ISR Number: 3423560-6Report Type:Expedited (15-DaCompany Report #A0068941A
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Other	Agitation Conversion Disorder Dizziness

	Feeling Abnormal Hallucination Hallucination, Auditory	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea Nephrolithiasis Pain	Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / UNK
	Tremor						/ ORAL
	Urinary Tract Infection						

Date:12/17/99ISR Number: 3425009-6Report Type:Expedited (15-DaCompany Report #A0107117A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion Insomnia Nausea	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE
	Tremor						PER DAY/ORAL
	Visual Acuity Reduced						

Date:12/20/99ISR Number: 3425894-8Report Type:Expedited (15-DaCompany Report #A0100230A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs Congenital Anomaly	Study Health Professional Company	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL	UNK / UNK /
	Heart Disease Congenital	Representative					ORAL

Date:12/20/99ISR Number: 3425935-8Report Type:Expedited (15-DaCompany Report #A0104240A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required	Aggression Child Abuse Mania Suicidal Ideation	Study Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	400 MG / PER Intervention to DAY/	
Prevent Permanent Impairment/Damage			Paracetamol	C				

Date:12/20/99ISR Number: 3426738-0Report Type:Expedited (15-DaCompany Report #A0080414A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arthralgia Joint Swelling Oedema Serum Sickness Urticaria	Foreign Health Professional	Bupropion Hydrochloride Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/	
			Lansoprazole	C				
			Cisapride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/99ISR Number: 3426699-4Report Type:Direct Company Report #
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pruritus Urticaria		Zyban 150mg Glaxo	PS	Glaxo		2 DAILY	

Date:12/21/99ISR Number: 3426765-3Report Type:Expedited (15-DaCompany Report #A0105273A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Anaemia Blood Creatine Phosphokinase Increased Blood Creatinine Increased Candidiasis Confusional State Crush Injury Delirium Depressed Level Of Consciousness Disorientation Herpes Zoster Hyperphosphataemia Hypoaesthesia Hypocalcaemia Hypovolaemia Liver Function Test Abnormal Myocarditis Neuropathy Peripheral Paraesthesia Renal Failure Acute Rhabdomyolysis	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Ethanol (Formulation Unknown) (Alcohol)	PS SS			7 DAY	

Date:12/23/99ISR Number: 3430073-4Report Type:Expedited (15-DaCompany Report #990809-LX254
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Dysphonia	Health	Ambien	PS		ORAL	QHS PO	
Intervention to	Stereotypy	Professional	Lithium Carbonate	SS		ORAL	900.000 MG QD	
Prevent Permanent		Company					PO	
Impairment/Damage		Representative	Wellbutrin	SS		ORAL	150.000 MG	
							TID PO	
			Other Cns Drugs	C				
			Celecoxib	C				

Date:12/23/99ISR Number: 3430277-0Report Type:Periodic Company Report #A0092326A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	SEE TEXT/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/99ISR Number: 3430279-4Report Type:Periodic Company Report #A0092331A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	SEE TEXT/ ORAL

Date:12/23/99ISR Number: 3430281-2Report Type:Periodic Company Report #A0069375A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	75 MG/ TWICE PER DAY/ ORAL
Other	Pain						
	Soft Tissue Injury						
	Tongue Disorder						
			Sertraline Hydrochloride	C			

Date:12/23/99ISR Number: 3430283-6Report Type:Periodic Company Report #A0099384A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion Overdose	Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL

Date:12/23/99ISR Number: 3430285-XReport Type:Periodic Company Report #A0097837A
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS				

Date:12/23/99ISR Number: 3430286-1Report Type:Periodic Company Report #A0097641A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	75 MG/	
Other	Grand Mal Convulsion							
Required Intervention to Prevent Permanent Impairment/Damage	Lacrimation Increased							
	Productive Cough		Paroxetine Hydrochloride Tablet (Paroxetine Hydrochloride)	SS		ORAL	30 MG/	
			Perphenazine	C				

Date:12/23/99ISR Number: 3430288-5Report Type:Periodic Company Report #A0096336A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
Other	Convulsion	Health Professional
	Overdose	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

		Company Representative	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin (Formulatioin Unknown) (Bupropion Hydrochloride)	PS		

Date:12/23/99ISR Number: 3430290-3Report Type:Periodic Company Report #A0096393A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		
Other			Glibenclamide	C		
			Doxepin	C		
			Benazepril Hydrochloride	C		
			Diltiazem Hydrochloride	C		

Date:12/23/99ISR Number: 3430292-7Report Type:Periodic Company Report #A0095678A
Age:6 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion	Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL
Required Intervention to Prevent Permanent Impairment/Damage		Company Representative				
112.5 MG/ THREE TIMES PER ORAL						
			Salbutamol Sulphate	C		
			Prednisone	C		
			Clonidine	C		

Date:12/23/99ISR Number: 3430295-2Report Type:Periodic Company Report #A0094046A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Overdose	Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:12/23/99ISR Number: 3430298-8Report Type:Periodic Company Report #A0093758A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional Other	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Omeprazole	C				
			Loratadine	C				
			Lorazepam	C				
			Conjugated Estrogens	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/99ISR Number: 3430301-5Report Type:Periodic Company Report #A0091695A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abnormal Behaviour Delusion Hallucination Suicide Attempt	Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	SINGLE DOSE/ORAL	
			Phentermine Tablet (Phentermine)	SS		ORAL	37.5 MG/ORAL	
			Doxylamine Succinate	C				
			Ketoprofen	C				
			Erythromycin	C				

Date:12/23/99ISR Number: 3430303-9Report Type:Periodic Company Report #A0091099A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	100 MG/ THREE TIMES PER DA ORAL	
			Methylphenidate Hcl	C				
			Guanfacine Hydrochloride	C				
			Methylphenidate Hcl	C				

Date:12/23/99ISR Number: 3430306-4Report Type:Periodic Company Report #A0090199A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Health Professional	Wellbutrin (Formulation					

		Company Representative	Unknown) (Bupropion Hydrochloride)	PS		ORAL

ORAL

Date:12/23/99ISR Number: 3430308-8Report Type:Periodic Company Report #A0087645A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Grand Mal Convulsion	Health Professional	Wellbutrin (Formulation Unknown)	PS		
			Lithium Salt	C		

Date:12/23/99ISR Number: 3430311-8Report Type:Periodic Company Report #A0086778A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion Medication Error	Health Professional Company Representative	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL

100 MG/ PER

DAY/ ORAL

			Wellbutrin Tablet-Controlled Release (Bupropion			

			Hydrochloride)	SS		ORAL

100 MG/

SINGLE DOSE/

ORAL

Date:12/23/99ISR Number: 3430315-5Report Type:Periodic Company Report #A0084030A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Tongue Oedema	Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL		
Other Required Intervention to Prevent Permanent Impairment/Damage			Conjugated Estrogens	C		ORAL		

Date:12/23/99ISR Number: 3430318-0Report Type:Periodic Company Report #A0083663A
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Methylphenidate Hcl	C				
			Erythromycin	C				
			Tretinoin	C				
			Melatonin	C				

Date:12/23/99ISR Number: 3430321-0Report Type:Periodic Company Report #A0083479A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional	Wellbutrin (Formulation Unknown) (Bupropion					

			Hydrochloride)	PS			ORAL
ORAL							
			Neuroleptic	C			

Date:12/23/99ISR Number: 3430324-6Report Type:Periodic Company Report #A0082070A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Chills Delusion Hearing Impaired	Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL	ORAL	3 WK
	Insomnia Pyrexia Tremor Weight Decreased							

Date:12/27/99ISR Number: 3430560-9Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia Coma Confusional State

	Convulsion Muscle Rigidity Tremor	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Bupropion	PS		ORAL	150MG QD OR BID? PO

Date:12/27/99ISR Number: 3433476-7Report Type:Expedited (15-DaCompany Report #A0107781A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion Drug Interaction	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Citalopram Hydrobromide (Citalopram Hydrobromide)	SS			

Date:12/27/99ISR Number: 3433482-2Report Type:Expedited (15-DaCompany Report #A0104499A
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Asthenia Balance Disorder Cerebral Ischaemia Cerebrovascular Accident Confusional State Convulsion Dizziness Fall	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Aspirin	C			
			Atorvastatin Calcium	C			

	Headache					
	Hemiplegia					
	Paralysis					
	Tremor					

Date:12/28/99ISR Number: 3432984-2Report Type:Expedited (15-DaCompany Report #A0104783A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Antibody Test Positive Blindness Brain Oedema Chest Pain Dermatitis Difficulty In Walking Discomfort Optic Neuropathy Pruritus Serum Sickness Syncope Urticaria	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Ranitidine Hydrochloride Metronidazole Temazepam	PS C C C		ORAL	150 MG/TWICE PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/99ISR Number: 3435167-5Report Type:Expedited (15-DaCompany Report #001-0945-991279
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Intentional Misuse Lethargy Loss Of Consciousness Suicide Attempt	Health Professional	Neurontin (Gabapentin)	PS		ORAL	1)PER ORAL;2) PER ORAL; 3) PER ORAL	3000 MG (AS ONE DOSE),
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	1) PER ORAL; 2) 4500 MG (AS ONE DOSE), PER ORAL; 3) PER	

Date:01/03/00ISR Number: 3435491-6Report Type:Direct Company Report #
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin 75mg	PS			75MG BID X 1 WEEK	1 WK
			Wellbutrin Sr 150mg	SS			150MG BID X 2 DAYS	

Date:01/03/00ISR Number: 3435514-4Report Type:Expedited (15-DaCompany Report #A0108167A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blindness Brain Oedema Chest Pain Difficulty In Walking Optic Nerve Disorder Pruritus Serum Sickness Skin Disorder Syncope Urticaria	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Ranitidine Hydrochloride Metronidazole Temazepam	PS C C C		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:01/07/00ISR Number: 3440573-9Report Type:Periodic Company Report #0218638A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Application Site Reaction	Consumer	Habitrol-Nicotine Transdermal 21mg-Nvch Zyban-Bupropion Hcl 150mg-Glaxo Antihypertensive	PS SS C	Nvch Glaxo	TRANSDERMAL TTD QD	1 PATCH/ QD/ 150 MG/ BID/	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/00ISR Number: 3441735-7Report Type:Expedited (15-DaCompany Report #A0108484A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Anxiety Decreased Activity Dermatitis Exfoliative Dysgeusia Dysphagia Face Oedema Fatigue Gingival Ulceration Halitosis Insomnia Lip Disorder Nail Avulsion Oedema Oral Intake Reduced Oral Pain Pain Pruritus Rash Erythematous Salivary Hypersecretion	Foreign Consumer	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG ORAL	

Date:01/10/00ISR Number: 3442243-XReport Type:Expedited (15-DaCompany Report #B0074965A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Laryngospasm Rash Pruritic	Foreign Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	1 TABLET/TWICE PER DAY/ORAL	

Date:01/12/00ISR Number: 3443168-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Zyban (Bupropion Sr)					
	Eye Pain		150 Mg	PS		ORAL	150MG PO QD	
	Headache							
	Neck Pain							
	Tremor							

Date:01/12/00ISR Number: 3443574-XReport Type:Expedited (15-DaCompany Report #224296
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Bactrim					
	Drug Interaction	Professional	(Sulfamethoxazole /					
	Loss Of Consciousness	Other	Trimethoprim)	PS		ORAL	1 DOSE FORM 2	
	Medication Error						PER DAY ORAL	
			Wellbutrin (Bupropion Hydrochloride) 200					
			Mg	SS		ORAL	150 MG 2 PER	
							DAY ORAL	
			Prozac (Fluoxetine					

			Hydrochloride)	C			

Date:01/12/00ISR Number: 3443588-XReport Type:Expedited (15-DaCompany Report #A0104783A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Autoimmune Disorder	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL
	Brain Oedema						
	Chest Pain						
	Difficulty In Walking						
	Optic Nerve Disorder		Ranitidine Hydrochloride	C			
	Pruritus						
	Serum Sickness		Metronidazole	C			
	Syncope		Temazepam	C			
	Urticaria						
	Visual Acuity Reduced						

Date:01/12/00ISR Number: 3443591-XReport Type:Expedited (15-DaCompany Report #A0108167A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Blindness	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL
	Brain Oedema						
	Chest Pain						
	Difficulty In Walking						
	Discomfort		Ranitidine Hydrochloride	C			
	Optic Nerve Disorder						
	Pruritus		Metronidazole	C			
	Serum Sickness		Temazepam	C			
	Syncope						
	Urticaria						

Date:01/12/00ISR Number: 3443593-3Report Type:Expedited (15-DaCompany Report #A0108666A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Dermatitis Exfoliative Hyperglycaemia Oral Mucosal Exfoliation Stevens-Johnson Syndrome	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
			Glibenclamide	C				
			Diltiazem Hydrochloride	C				
			Loxapine	C				
			Aspirin	C				
			Losartan Potassium	C				
			Conjugated Estrogens	C				
			Thyroxine Sodium	C				

Date:01/12/00ISR Number: 3443761-0Report Type:Expedited (15-DaCompany Report #A0108441A
Age:10 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Laboratory Test Abnormal Overdose	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/00ISR Number: 3443467-8Report Type:Direct Company Report #USP 52773
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr	PS	Catalytica Pharmaceuticals/Glaxo Wellcome, Inc.			
			Wellbutrin	SS	Catalytica Pharmaceuticals/Glaxo Wellcome, Inc.			

Date:01/14/00ISR Number: 3443753-1Report Type:Direct Company Report #
Age:6 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Multiforme	Health	Wellbutrin 75mg Glx	PS	Glx		37.5MG TO START THEN 75MG BID	AM/NOON
	Oedema Peripheral	Professional						
	Synovitis							

Date:01/14/00ISR Number: 3444512-6Report Type:Expedited (15-DaCompany Report #A0102623A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS			OPHTHALMIC	150MG SEE TEXT
	Intentional Misuse	Company Representative						
		Other	Fluoxetine Hydrochloride Capsule (Fluoxetine Hydochloride)	SS		ORAL	20MG SEE TEXT	

ORAL

			Venlafaxine Hydochloride Tablet (Venlafaxine Hydrochloride)	SS		ORAL

37.5MG SEE

TEXT ORAL

Date:01/18/00ISR Number: 3444741-1Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspepsia		Zyban 150mg Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	1T PO QD X 3	
	Erythema							
	Erythema Multiforme						DAYS THEN 1T	
	Flatulence						PO BID	
	Mucosal Inflammation		Lipitor	C				
	Rash Pruritic		Premarin	C				
	Urticaria		Vitamin E	C				
	Vaginal Infection		Multivitamins	C				
			Stool Softener	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/00ISR Number: 3444770-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Colitis Ischaemic Rectal Haemorrhage Syncope		Zyban Sustained Release/150 Mg/Tablet /Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	150MG TWICE DAILY ORAL	
			Birth Control Pills	C				

Date:01/18/00ISR Number: 3445321-4Report Type:Expedited (15-DaCompany Report #A0107579A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Dehydration Dermatitis Dermatitis Exfoliative Erythema Multiforme Hyperglycaemia Stevens-Johnson Syndrome	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
			Glibenclamide	C				
			Metformin	C				
			Losartan Potassium	C				
			Thyroxine Sodium	C				
			Diltiazem	C				
			Loxapine	C				
			Aspirin	C				
			Conjugated Estrogens	C				

Date:01/18/00ISR Number: 3445322-6Report Type:Expedited (15-DaCompany Report #A0108666A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Dehydration Dermatitis Dermatitis Exfoliative	Foreign Health Professional	Bupropion Hydrochloride Tablet - Zyban (Bupropion					

	Erythema Multiforme		Hydrochloride)	PS		ORAL
150 MG/TWICE						
	Hyperglycaemia					
PER DAY/ORAL						
	Stevens-Johnson Syndrome		Glibenclamide	C		
			Diltiazem			
			Hydrochloride	C		
			Loxapine	C		
			Aspirin	C		
			Losartan Potassium	C		
			Conjugated Estrogens	C		
			Thyroxine Sodium	C		
			Metformin	C		

Date:01/18/00ISR Number: 3445757-1Report Type:Expedited (15-DaCompany Report #A0109272A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthma	Foreign	Zyban Tablet - Zyban			
Initial or Prolonged	Pruritus	Health	(Bupropion			
	Urticaria	Professional	Hydrochloride)	PS		ORAL
150 MG /						
UNKNOWN /						
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/00ISR Number: 3445319-6Report Type:Expedited (15-DaCompany Report #A0108878A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharyngeal Oedema	Health	Wellbutrin					
	Tongue Oedema	Professional	Tablet-Controlled					
		Company	Release (Bupropion					
		Representative	Hydrochloride)	PS		ORAL	150 MG/TWICE	PER DAY/ORAL

Date:01/20/00ISR Number: 3445588-2Report Type:Expedited (15-DaCompany Report #A0109223A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Health	Zyban	PS		ORAL	150 MG/ TWICE	
	Immobile	Professional					PER DAY /	
	Urticaria						ORAL	

Date:01/24/00ISR Number: 3446533-6Report Type:Expedited (15-DaCompany Report #A0108853A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Foreign	Bupropion					
Hospitalization -	Dysphagia	Health	Hydrochloride Tablet					
Initial or Prolonged	Face Oedema	Professional	- Zyban (Bupropion					
	Pruritus		Hydrochloride)	PS		ORAL	150 MG /	
	Shock						TWICE PER DAY	
	Swelling						/ ORAL	
	Urticaria		Fosinopril Sodium	C				
			Hydrochlorothiazide	C				
			Medroxyprogesterone Ace.	C				

			Amlodipine	C			

Date:01/24/00ISR Number: 3446625-1Report Type:Expedited (15-DaCompany Report #B0075853A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperventilation Malaise Nausea	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS				

Date:01/24/00ISR Number: 3446789-XReport Type:Expedited (15-DaCompany Report #A0108087A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Convulsion Dysphemia	Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
	Electroencephalogram Abnormal		Blood Pressure					
	Sedation		Medication	C				
	Tremor		Hormones	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/00ISR Number: 3446792-XReport Type:Expedited (15-DaCompany Report #A0109400A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Zyban Tablet - Zyban					
	Cognitive Disorder		(Bupropion					
	Convulsion		Hydrochloride)	PS		ORAL	150 MG/TWICE	
	Dizziness						DAILY/ORAL	
	Fall							
	Head Injury							
	Tremor							

Date:01/24/00ISR Number: 3446794-3Report Type:Expedited (15-DaCompany Report #A0109220A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased	Literature	Wellbutrin					
Initial or Prolonged	Bundle Branch Block Left	Health	(Formulation					
	Drug Level Above	Professional	Unknown) (Bupropion					
	Therapeutic		Hydrochloride)	PS		ORAL	4.5 G/ SINGLE	
	Drug Toxicity						DOSE/ORAL	
	Electrocardiogram Qrs		Paroxetine	C				
	Complex Prolonged		Paracetamol	C				
	Electrocardiogram Qt							
	Prolonged							
	Heart Rate Increased							
	Overdose							
	Tachycardia							

Date:01/24/00ISR Number: 3446801-8Report Type:Expedited (15-DaCompany Report #A0109367A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diabetes Mellitus	Health	Wellbutrin					
	Non-Insulin-Dependent	Professional	(Formulation					
		Other	Unknown) (Bupropion					

			Hydrochloride)	PS		ORAL
ORAL						
			Risperidone (Formulation Unknown)			
			(Risperidone)	SS		ORAL
ORAL						

Date:01/24/00ISR Number: 3447110-3Report Type:Expedited (15-DaCompany Report #A0109619A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abnormal Behaviour	Health	Zyban Tablet - Zyban			
	Burns Third Degree	Professional	(Bupropion			
	Mania	Company	Hydrochloride)	PS		ORAL
ORAL						
		Representative				

Date:01/24/00ISR Number: 3447480-6Report Type:Expedited (15-DaCompany Report #A0106235A
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaphylactic Shock
	Face Oedema
	Flushing

		Hypotension Loss Of Consciousness Peripheral Coldness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Rash Erythematous Skin Exfoliation Tongue Oedema	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL
				Clarithromycin	C			

Date:01/27/00ISR Number: 3447358-8Report Type:Expedited (15-DaCompany Report #2000001499-1
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Amnesia Cerebrovascular Accident Myocardial Infarction Sinusitis	Consumer	Nicoderm Cq 21 Mg	PS	Smithkline Beecham Consumer Healthcare	TRANSDERMAL	21 MILLIGRAMS 2.0 DAILY TRANSDERMAL
			Zyban (Bupropion Hcl) Glaxo Wellcome, Inc.	SS	Glaxo Wellcome, Inc.	ORAL	150 MILLIGRAMS 2.0 DAILY ORAL

Date:01/27/00ISR Number: 3448419-XReport Type:Periodic Company Report #9944261
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Effect Decreased	Consumer	Viagra Tablets	PS		ORAL	50.00 MG

	Drug Ineffective						
TOTAL:PRN:ORA							
	Drug Interaction						
L							
			Wellbutrin	SS		ORAL	
300.00 MG							
TOTAL:BID:ORA							
L							
			Norvasc	C			
			Accupril	C			
			Zantac	C			

Date:01/28/00ISR Number: 3448015-4Report Type:Expedited (15-DaCompany Report #A0103586A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Foreign	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL		
Other	Confusional State							
ORAL	Convulsion							
	Grand Mal Convulsion							
	Loss Of Consciousness							
	Sedation							

Date:01/28/00ISR Number: 3448016-6Report Type:Expedited (15-DaCompany Report #A0109909A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /	TWICE PER DAY
	Headache	Consumer						
	Visual Acuity Reduced							

/ ORAL

Date:01/28/00ISR Number: 3448280-3Report Type:Expedited (15-DaCompany Report #S99-USA-02273-01
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Scan Abnormal Coma	Health Professional	Celexa (Citalopram Hydrochloride)	PS		ORAL	20 MG QD PO	
	Confusional State Convulsion		Celexa (Citalopram Hydrobromide)	SS		ORAL	40 MG QD PO	
	Decreased Interest Dermatitis Atopic		Zyban (Amfebutamone Hydrochloride)	SS		ORAL	150 MG BID PO	
	Disorientation		B Complex	C				
	Insomnia		Synthroid	C				
	Lethargy		Folic Acid	C				
	Memory Impairment							
	Miosis							
	Muscle Rigidity							
	Urinary Tract Infection							
	Visual Disturbance							

Date:01/31/00ISR Number: 3447850-6Report Type:Direct Company Report #
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Clonic Convulsion Gait Disturbance Parkinson'S Disease Speech Disorder		Buproprion (Wellbutrin) 100mg Trazodone	PS C				

Date:01/31/00ISR Number: 3448785-5Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required	Tremor	Health	Welbutrin 150 Mg	PS		ORAL
PO BID						
Intervention to		Professional	Rocalcetrol	C		
Prevent Permanent			Lotensin	C		
Impairment/Damage			Erythropoietin	C		
			Iron	C		
			Allopurinol	C		
			Renigel	C		
			Lipitor	C		
			Pepcid	C		

Date:02/02/00ISR Number: 3450944-2Report Type:Expedited (15-DaCompany Report #A0103729A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Foreign	Zyban Tablet -Zyban					
Initial or Prolonged	Intentional Misuse		(Bupropion					
Other	Sinus Tachycardia		Hydrohcloride)	PS		ORAL	150 MG/	ORAL
	Suicide Attempt		Ceftin (Formualation					
	Tremor		Unknown) (Cefuroxime					
	Vomiting		Axetil)	SS				
			Ibuprofen					
			(Formulation					
			Unknown) (Ibuprofen)	SS				
			Amoxycillin					

			Trihydrate (Formulation Unknown) (Amoxycillin	SS			

Date:02/02/00ISR Number: 3451155-7Report Type:Expedited (15-DaCompany Report #A0109223A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy Arthralgia Arthritis Immobile Inflammation Rheumatoid Arthritis Urticaria	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/02/00ISR Number: 3451869-9Report Type:Periodic Company Report #A0101377A
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	75 SEE TEXT / TWICE PER DAY / ORAL	6 MON
			Desipramine	C				
			Methylphenidate Hcl	C				

Date:02/02/00ISR Number: 3451871-7Report Type:Periodic Company Report #A0102784A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Interaction	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	1 TABLET / TWICE PER DAY/ ORAL	
			Desipramine Hydrochloride (Formulation Unknown) (Desipramine	SS			UNK/ UNK/ UNKNOWN	

Date:02/02/00ISR Number: 3451874-2Report Type:Periodic Company Report #A0102910A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Electroencephalogram Abnormal Weight Increased	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/00ISR Number: 3451876-6Report Type:Periodic Company Report #A0103516A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY	/ ORAL

Date:02/02/00ISR Number: 3451878-XReport Type:Periodic Company Report #A0103526A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER	DAY/ ORAL

Date:02/02/00ISR Number: 3451880-8Report Type:Periodic Company Report #A0104375A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Asthenia Back Pain Chest Pain	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER	
	Difficulty In Walking						DAY/ ORAL	
	Dysphagia		Ziac	C				

Fatigue
Hypersensitivity
Joint Swelling
Nausea
Oedema Peripheral
Oral Intake Reduced
Urticaria

Date:02/02/00ISR Number: 3451882-1Report Type:Periodic Company Report #A0104843A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY	/ ORAL

Date:02/02/00ISR Number: 3451885-7Report Type:Periodic Company Report #A0105026A
Age:18 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Other
Required

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Intervention to Prevent Permanent Impairment/Damage	Grand Mal Convulsion Intentional Misuse Suicide Attempt	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	1500 MG/ SINGLE DOSE / ORAL	
			Ibuprofen Tablet (Ibuprefen)	SS		ORAL	50 TABLET / SINGLE DOSE / ORAL	

Date:02/02/00ISR Number: 3451887-0Report Type:Periodic Company Report #A0105971A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:02/02/00ISR Number: 3451889-4Report Type:Periodic Company Report #A0108085A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional Company	Wellbutrin Tablet-Controlled Release (Bupropion					

			Representative	Hydrochloride)	PS		ORAL

450 MG/ PER

DAY / ORAL

Date:02/02/00ISR Number: 3451891-2Report Type:Periodic Company Report #A0081121A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other Required Intervention to Prevent Permanent Impairment/Damage	Conjunctival Hyperaemia Depression Dermatitis Dermatitis Exfoliative Hypersensitivity Oral Intake Reduced Periorbital Oedema Sedation Suicidal Ideation Suicide Attempt	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Wellbutrin Tablet (Bupropion Hydrochloride)	SS		ORAL	UNK/ UNK/ ORAL
			Fluoxetine Hydrochloride	C			

Date:02/02/00ISR Number: 3451893-6Report Type:Periodic Company Report #A0100421A
Age: Gender: I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Convulsion Disorientation

	Sedation						
Dose	Duration	Report Source	Product	Role	Manufacturer	Route	
UNK/ UNK/ UNKNOWN		Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS			
			Nutritional Supplement (Formulation Unknown) (Nutritional	SS			
UNK/ UNK/ UNKNOWN			Semidodium Valproate	C			

Date:02/02/00ISR Number: 3451895-XReport Type:Periodic Company Report #A0101936A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Other Required Intervention to Prevent Permanent Impairment/Damage	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	
150 MG/ TWICE PER DAY/ ORAL							
			Hydrochlorothiazide	C			
			Phentermine Hydrochloride	C			
			Fluoxetine Hydrochloride	C			

Date:02/02/00ISR Number: 3451898-5Report Type:Periodic Company Report #A0102154A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Overdose	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	300 MG / TWICE PER DAY/ ORAL	

Date:02/03/00ISR Number: 3451165-XReport Type:Expedited (15-DaCompany Report #A0103727A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Agitation Alcohol Interaction Alcohol Withdrawal Syndrome Amnesia Blood Alcohol Increased Convulsion Delirium Irritability Overdose Suicide Attempt Tachycardia	Foreign	Zyban Tablet -Zyban (Bupropion Hydrochloride) Ethanol (Formulation Unknown) (Alcohol) Lorazepam (Formulation Unknown) (Lorazepam)	PS SS SS		ORAL	150 MG, ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/00ISR Number: 3451184-3Report Type:Expedited (15-DaCompany Report #A0096983A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Headache Petit Mal Epilepsy	Foreign	Wellbutrin Tablet - Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Dilantin	C				
			Semisodium Valproate	C				
			Ibuprofen	C				

Date:02/04/00ISR Number: 3452543-5Report Type:Direct Company Report #
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Amnesia Anger Drug Dependence Fatigue Influenza Like Illness Irritability Libido Increased		Wellbutrin 100mg Glaxowellcome?	PS	Glaxowellcome		100 3X A DAY	

Date:02/04/00ISR Number: 3452825-7Report Type:Expedited (15-DaCompany Report #A0107356A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills Chromaturia Drug Interaction Ear Haemorrhage Haematuria Haemorrhage International Normalised Ratio Increased Prothrombin Time	Consumer	Zyban Tablets - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL	
			Warfarin Sodium (Formulation Unknow) (Warfarin Sodium)	SS				

	Prolonged					
	Pyrexia					
	Renal Colic					
	Tremor					

Date:02/04/00ISR Number: 3452827-0Report Type:Expedited (15-DaCompany Report #A0106892A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Coordination Abnormal Depression Disturbance In Attention Drug Interaction	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Drug Level Above Therapeutic Dysphoria Increased Appetite Sedation		Imipramine Tablet (Imipramine)	SS		ORAL	300 MG/ AT NIGHT/ ORAL / YEARS	
			Inhaler	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/00ISR Number: 3452837-3Report Type:Expedited (15-DaCompany Report #A0110172A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dry Mouth Feeling Abnormal Hiatus Hernia Tremor	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:02/04/00ISR Number: 3452839-7Report Type:Expedited (15-DaCompany Report #B0076434A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Chest Pain	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/	ORAL
			Aspirin	C				
			Doxycycline	C				
			Hyzaar	C				
			Beclomethasone+Salbutamol	C				

Date:02/04/00ISR Number: 3452979-2Report Type:Expedited (15-DaCompany Report #A0105554A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agranulocytosis Asthenia Bone Marrow Depression Corynebacterium Infection Dizziness Postural Ecchymosis Fatigue	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	UNK/SEE TEXT/ORAL	
			Fluticasone Propionate	C				

	Gram Stain Positive		Fexofenadine	
	Influenza Like Illness		Hydrochlorid	C
	Libido Decreased		Budesonide	C
	Lung Infiltration		Oral Contraceptive	C
	Neutropenia			
	Pain			
	Pharyngolaryngeal Pain			
	Pleuritic Pain			
	Pneumonia			
	Pyrexia			
	Sedation			
	Staphylococcal Infection			
	Suicidal Ideation			

Date:02/08/00ISR Number: 3454305-1Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Congenital Anomaly	Calcinosis		Klonopin	PS		
	Congenital Anomaly		Paxil	SS		
	Nervous System Disorder		Depakote	SS		
			Gabapentin	SS		
			Wellbutrin	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/00ISR Number: 3455517-3Report Type:Expedited (15-DaCompany Report #A0110103A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Colitis Ischaemic Rectal Haemorrhage Syncope	Study Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Birth Control	C				

Date:02/09/00ISR Number: 3455518-5Report Type:Expedited (15-DaCompany Report #A0110688A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Pneumonia Renal Failure Wegener'S Granulomatosis	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / THREE TIMES PER DAY ORAL	
			Olanzapine	C				
			Alprazolam	C				

Date:02/09/00ISR Number: 3456962-2Report Type:Direct Company Report #
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Difficulty In Walking Erythema Multiforme Pruritus		Wellbutrin	PS				

Date:02/11/00ISR Number: 3456737-4Report Type:Direct Company Report #
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin Sr 150mg	PS			1 TAB 2X/DAY,	
	Anger						MID-MORNING	
	Drug Dependence						AND 4 PM	
	Emotional Disorder		Vitamins	C				
	Euphoric Mood		Tylenol	C				
	Marital Problem							
	Nightmare							
	Personality Change							
	Psychotic Disorder							

Date:02/11/00ISR Number: 3456934-8Report Type:Expedited (15-DaCompany Report #A0110477A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Zyban	PS		ORAL	150 MG/TWICE	
Initial or Prolonged	Faecaloma						PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/00ISR Number: 3456936-1Report Type:Expedited (15-DaCompany Report #A0110910A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Foreign	Zyban	PS		ORAL	150MG/TWICE	
Life-Threatening	Blood Disorder	Health					PER DAY/ORAL	
Disability	Cardiac Arrest Influenza	Professional	Pain Medication	C				

Date:02/11/00ISR Number: 3456982-8Report Type:Expedited (15-DaCompany Report #A0110682A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Cerebrovascular Accident	Consumer Other	Zyban Tablet - Zyban (Bupropion					
Required Intervention to Prevent Permanent Impairment/Damage	Loss Of Consciousness Myocardial Infarction Sinusitis		Hydrochloride) Nicotine Patch (Nicotine)	PS SS		ORAL	150MG - TWICE PER DAY	ORAL
TOPICAL	42MG PER DAY							
TOPICAL								

Date:02/11/00ISR Number: 3456984-1Report Type:Expedited (15-DaCompany Report #A0110609A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme Hyperlipidaemia Hypersensitivity Leukocytosis Pain Prostatic Specific Antigen Increased Purpura Pyrexia	Consumer Other	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS				

		Rash Pruritic					
		Sinusitis					
		Urticaria					

Date:02/14/00ISR Number: 3457280-9Report Type:Direct Company Report #
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Wellbutrin 150 Mg					
	Confusional State		Glaxxo Wellcome	PS				
	Headache							
	Memory Impairment							

Date:02/14/00ISR Number: 3457648-0Report Type:Expedited (15-DaCompany Report #A0110940A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS				

Date:02/14/00ISR Number: 3457649-2Report Type:Expedited (15-DaCompany Report #A0102044A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs Gastroschisis Systemic Candida Ultrasound Antenatal Screen Abnormal	Foreign Study Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/14/00ISR Number: 3457651-0Report Type:Expedited (15-DaCompany Report #A0102884A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Blister Blood Glucose Increased Dyspnoea Eyelid Oedema Nail Discolouration Oedema Peripheral Rash Pruritic Stevens-Johnson Syndrome Weight Increased	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/14/00ISR Number: 3457655-8Report Type:Expedited (15-DaCompany Report #A0106621A
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Aspiration Choking Malaise	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion					

	Muscle Rigidity		Hydrochloride)	PS		ORAL
100 MG / PER						
	Rhinorrhoea					
DAY / ORAL						
	Sepsis		Donepezil Hcl	C		
	Vomiting		Doxazosin Mesylate	C		
			Vitamin E	C		
			Glucosamine	C		

Date:02/14/00ISR Number: 3457855-7Report Type:Expedited (15-DaCompany Report #A0110613A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Foreign	Zyban Tablet - Zyban					
Initial or Prolonged	Cold Sweat	Consumer	(Bupropion					
	Hyperhidrosis		Hydrochloride)	PS		ORAL		
150 MG/ TWICE								
	Nausea							
PER DAY /								
ORAL								
			Nitroglycerin	C				
			Isosorbide Dinitrate	C				

Date:02/14/00ISR Number: 3459567-2Report Type:Periodic Company Report #001-0945-980906
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Stevens-Johnson Syndrome	Health	Neurontin					
Initial or Prolonged		Professional	(Gabapentin)	PS		ORAL		
PER ORAL								

			Zyban (Amfebutamone)	SS		ORAL 300 MG (150 MG,BID), PER ORAL

Date:02/14/00ISR Number: 3459611-2Report Type:Periodic Company Report #001-0945-990106
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Agitation Drug Level Above Therapeutic Feeling Drunk Nausea	Consumer	Neurontin (Gabapentin)	PS		ORAL 600 MG (DAILY), PER ORAL
			Lithobid (Lithium Carbonate)	SS		ORAL PER ORAL
			Zyprexa (Olanzapine)	SS		ORAL PER ORAL
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL PER ORAL
			Ambien (Zolpidem Tartrate)	SS		ORAL PER ORAL
			Zoloft (Sertraline Hydrochloride)	SS		ORAL PER ORAL
			Klonopin (Clonazepam)	SS		ORAL PER ORAL
			Benzotropine (Benzatropine Mesilate)	SS		ORAL PER ORAL
			Inderal (Propranolol Hydrochloride)	C		

Date:02/15/00ISR Number: 3457366-9Report Type:Expedited (15-DaCompany Report #A0110939A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety Depression Feeling Abnormal Mental Disorder Mood Swings	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL
			Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:02/15/00ISR Number: 3458422-1Report Type:Expedited (15-DaCompany Report #A0111455A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Chest Pain Myocarditis	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	UNK / UNK / ORAL
			Cannabis	C			
			Mushrooms	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/00ISR Number: 3458451-8Report Type:Expedited (15-DaCompany Report #A0102623A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Health Professional Company Representative Other	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / SEE TEXT	/ ORAL
			Fluoxetine Hydrochloride Capsule (Fluoxetine Hydrochloride)	SS		ORAL	20 MG / SEE TEXT	/ ORAL
			Venflaxine Hydrochloride Tablet (Venlafaxine Hydrochloride)	SS		ORAL	37.5 MG / SEE TEXT	/ ORAL

Date:02/15/00ISR Number: 3458516-0Report Type:Periodic Company Report #M094176
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lethargy	Health Professional	Serzone Tabs (Nefazodone Hcl)	PS		ORAL	ORAL	
			Wellbutrin (Bupropion Hcl)	SS		ORAL	ORAL	
			Risperidone	SS		ORAL	ORAL	

Date:02/17/00ISR Number: 3459083-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Colitis Ischaemic Mucous Membrane Disorder Rectal Haemorrhage Syncope		Zyban Sustained Release 150 Mg Tablet Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	150MG TWICE DAILY ORAL	
			Birth Control Pills	C				
			Acupril	C				

Date:02/18/00ISR Number: 3460142-4Report Type:Periodic Company Report #HQ9426222DEC1999
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health Professional	Effexor	PS		ORAL	600 MG OVERDOSE	AMOUNT, ORAL
			Prozac	SS		ORAL	440 MG OVERDOSE	AMOUNT, ORAL
			Wellbutrin	SS		ORAL	APPROX. 12000 MG OVERDOSE	AMOUNT, ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/00ISR Number: 3460213-2Report Type:Expedited (15-DaCompany Report #HQ1070415FEB2000
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cervix Disorder	Consumer	Effexor Xr	PS			UNKNOWN TO 75	
	Depression						MG DAILY	3 YR
	Headache		Wellbutrin	SS				
	Menstruation Irregular		Anaprox	C				
	Soft Tissue Disorder							

Date:02/22/00ISR Number: 3461030-XReport Type:Expedited (15-DaCompany Report #A0096492A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysphagia	Health	Zyban Tablet-Zyban					
Hospitalization -	Dyspnoea	Professional	(Bupropion					
Initial or Prolonged	Embolism		Hydrochloride)	PS		ORAL	150 MG /	
Disability	Eye Disorder						TWICE PER DAY	
Required	Oedema Peripheral						/ ORAL	
Intervention to	Swelling		Paracetamol	C				
Prevent Permanent								
Impairment/Damage								

Date:02/22/00ISR Number: 3461213-9Report Type:Expedited (15-DaCompany Report #A0112060A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Pain	Consumer	Wellbutrin					
	Intraocular Pressure		Tablet-Controlled					
	Increased		Release (Bupropion					
	Open Angle Glaucoma		Hydrochloride)	PS		ORAL	150 MG /	
	Optic Nerve Disorder						TWICE PER DAY	

/ ORAL

Date:02/22/00ISR Number: 3461315-7Report Type:Expedited (15-DaCompany Report #A0111797A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Study	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG PER DAY	
	Confusional State	Health Professional						
	Dehydration							
	Depressed Level Of Consciousness		Placebo Tablet	SS		ORAL	1 TABLET PER DAY	
	Dizziness							
	Dysarthria		Clopidogrel Bisulphate	C				
	Hypotension		Atenolol	C				
	Ventricular Tachycardia		Lisinopril	C				
			Omeprazole	C				
			Aspirin	C				
			Atorvastatin Calcium	C				
			Nitroglycerin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/00ISR Number: 3461318-2Report Type:Expedited (15-DaCompany Report #A0110611A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective Drug Interaction Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	350 MG, PER DAY, ORAL	
			Venlafaxine Hydrochloride (Formulation Unknown) (Venlafaxine	SS		ORAL	37.5 MG PER DAY ORAL	
			Hormones	C				

Date:02/23/00ISR Number: 3461662-9Report Type:Expedited (15-DaCompany Report #A0110172A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Disorientation Dry Mouth Hiatus Hernia Malaise Myocardial Infarction Nausea Tremor	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS	Zyban	ORAL	150 MG TWICE PER DAY ORAL	

Date:02/23/00ISR Number: 3461725-8Report Type:Expedited (15-DaCompany Report #A0111148A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Amnesia	Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS	ORAL 100 MG / UNK / ORAL
	Clonic Convulsion				
	Dysgraphia				
	Gait Disturbance				
	Muscle Rigidity				
	Parkinson'S Disease				
	Skin Disorder				
	Speech Disorder				
			Trazodone	C	
			Estratest	C	
			Thyroxine Sodium	C	
			Lisinopril	C	
			Flunisolide	C	
			Salbutamol Sulphate	C	
			Clorazepate Dipotassium	C	
			Salmeterol Xinafoate	C	
			Depression	C	
			Asthma	C	

Date:02/23/00ISR Number: 3462465-1Report Type:Periodic Company Report #9937752
Age: Gender:Female I/FU:I

Outcome	PT
Other	Dizziness
	Headache
	Influenza
	Personality Disorder

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zoloft Tablets	PS		ORAL	100.00 MG
		Health					TOTAL: BID:
		Professional					ORAL
			Wellbutrin	SS		ORAL	300.00 MG
							TOTAL: BID:
							ORAL

Date:02/23/00ISR Number: 3462954-XReport Type:Periodic Company Report #9933726
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Depression	Health	Zoloft Tablets	PS		ORAL	ORAL
	Hyperhidrosis	Professional	Wellbutrin	SS		ORAL	ORAL
	Nausea		Xanax	C			
	Pain		Prempro	C			
	Sedation		Multivitamins	C			
	Stupor						
	Thinking Abnormal						
	Yawning						

Date:02/23/00ISR Number: 3465744-7Report Type:Periodic Company Report #9910420
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dizziness	Consumer	Zoloft Tablets	PS		ORAL	50.00 MG
	Drug Ineffective	Health					TOTAL:DAILY:O

	Tremor	Professional				
RAL						
	Vertigo		Wellbutrin	SS		ORAL
ORAL						
			Advil	C		

Date:02/23/00ISR Number: 3466594-8Report Type:Periodic Company Report #9951766
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Alopecia	Health	Zoloft Tablets	PS		ORAL
100.00 MG						
		Professional				
TOTAL DAILY						
ORAL						
			Wellbutrin	SS		
			Birth Control	SS		

Date:02/23/00ISR Number: 3467331-3Report Type:Periodic Company Report #9919213
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Depression	Health	Zoloft Tablets	PS		
50.00 MG						
		Professional				
TOTAL:DAILY						
			Zyban	SS		
			Nizoral Shampoo	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/00ISR Number: 3467779-7Report Type:Periodic Company Report #9937968
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Zoloft Tablets	PS		ORAL	100.00 MG	TOTAL DAILY
Required Intervention to Prevent Permanent Impairment/Damage	Anorexia							
	Depression							
	Jaundice		Bupropion	SS		ORAL	150.00 MG	TOTAL BID
	Nausea							
	Pyrexia							
	Vomiting							

Date:02/23/00ISR Number: 3468259-5Report Type:Periodic Company Report #9904353
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Zoloft Tablets	PS		ORAL	100MG TOTAL;	DAILY; ORAL
	Tremor							
			Wellbutrin	SS				
			Xanax	C				

Date:02/23/00ISR Number: 3469832-0Report Type:Periodic Company Report #9944600
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Zoloft Tablets	PS		ORAL	100.00 MG	TOTAL:DAILY:O
	Dizziness							
	Drug Withdrawal Syndrome							RAL

	Thinking Abnormal		Wellbutrin	SS		ORAL
ORAL						
	Weight Increased		Ambien	C		

Date:02/23/00ISR Number: 3470125-6Report Type:Periodic Company Report #9948895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety	Health	Zoloft Tablets	PS		ORAL
100.00 MG						
	Attention	Professional				
TOTAL:DAILY:O						
	Deficit/Hyperactivity					
RAL						
	Disorder		Effexor	SS		
	Drug Ineffective		Wellbutrin	SS		
	Hostility					
	Hyperhidrosis					

Date:02/23/00ISR Number: 3470470-4Report Type:Periodic Company Report #9943253
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Prolactin Increased	Health	Zoloft Tablets	PS		ORAL
150.00 MG						
	Depression	Professional				
TOTAL: ORAL						
	Female Sexual Dysfunction		Wellbutrin	SS		ORAL
150.00 MG						
	Galactorrhoea					
TOTAL: DAILY:						
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/00ISR Number: 3565792-2Report Type:Periodic Company Report #A0113107A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Therapeutic Response						TWICE PER DAY	
	Decreased						/ ORAL	
			Metronidazole	C				
			Cephalexin	C				

Date:02/24/00ISR Number: 3463088-0Report Type:Expedited (15-DaCompany Report #A0110613A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Cold Sweat Hyperhidrosis Nausea Panic Attack	Foreign Consumer	Bupropion Hydrochloride Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	
			Nitroglycerin	C				
			Isosorbide Dinitrate	C				

Date:02/24/00ISR Number: 3463203-9Report Type:Direct Company Report #
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aggression Cognitive Disorder Coma Confusional State Drug Level Below Therapeutic		Bupropion Sr Tetracycline Divalpro Ex	PS SS SS				

Ecchymosis
Fatigue
Folliculitis
Headache
Hypotension
Influenza Like Illness
Movement Disorder
Muscle Rigidity
Nausea
Oxygen Saturation
Decreased
Pupillary Reflex Impaired
Respiratory Rate
Decreased
Skin Discolouration
Speech Disorder
Tachycardia
Tremor

Date:02/25/00ISR Number: 3463091-0Report Type:Expedited (15-DaCompany Report #A0112179A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Cardiomyopathy	Health Professional
	Overdose	

		Company Representative	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL
			Mirtazapine (Formulation Unknown) (Mirtazapine)	SS			

Date:02/25/00ISR Number: 3463974-1Report Type:Expedited (15-DaCompany Report #A0112549A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cellulitis Oedema Peripheral Rash Erythematous Vasculitic Rash	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ORAL 2 WK

Date:02/25/00ISR Number: 3464045-0Report Type:Expedited (15-DaCompany Report #A0112039A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Bite Memory Impairment Pain Syncope Tongue Disorder	Health Professional Company Representative	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL

Date:02/28/00ISR Number: 3464397-1Report Type:Expedited (15-DaCompany Report #A0112382A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Cyanosis Drug Interaction Respiratory Arrest	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	TWICE PER DAY	/ ORAL
			Venlafaxine Hydrochloride Tablet (Venlafaxine Hydrochloride)	SS		ORAL	25 MG / SEE	TEXT/ ORAL

Date:02/28/00ISR Number: 3464843-3Report Type:Expedited (15-DaCompany Report #A0102623A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Health Professional Company Representative Other	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / SEE	TEXT / ORAL
			Fluoxetine Hydrochloride					

			Capsule (Fluoxetine Hydrochloride)	SS		ORAL 20 MG / SEE TEXT / ORAL
			Venlafaxine Hydrochloride Tablet (Venlafaxine Hydrochloride)	SS		ORAL 37.5 MG / SEE TEXT / ORAL

Date:02/28/00ISR Number: 3464858-5Report Type:Expedited (15-DaCompany Report #A0112392A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Burning Sensation Complement Factor Increased Decreased Activity Difficulty In Walking	Foreign Health Professional	Bupropion Hydrochloride Tablet - Zyban (Buproipion Hydrochloride)	PS		ORAL 150 MG / TWICE PER DAY / ORAL
	Drug Hypersensitivity Dysphagia Erythema Multiforme Eyelid Oedema Face Oedema Fatigue Feeling Cold Insomnia Oedema Peripheral Pain Peripheral Coldness Pharyngolaryngeal Pain Rash Pruritic Sensation Of Heaviness Skin Discolouration Type Iv Hypersensitivity Reaction Urticaria Vasculitis		Mometasone Furoate	C		

Date:02/28/00ISR Number: 3464859-7Report Type:Expedited (15-DaCompany Report #A0112549A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cellulitis Gingivitis Influenza Like Illness Lymphangiopathy Pruritus Pyrexia Swelling Vasculitic Rash	Foreign Health Professional	Bupropion Hydrochloride Tablet - Zyban (Bupropion Hydrochloride) Aspirin	PS C		ORAL	150 MG / ORAL	

Date:02/28/00ISR Number: 3464860-3Report Type:Expedited (15-DaCompany Report #A0112179A
Age:35 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Disorder Cardiomyopathy Chest Pain

		Dyspnoea Electrocardiogram Qt Prolonged	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intentional Misuse Myocardial Ischaemia Syncope Toxicologic Test Abnormal	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
100 MG / SEE TEXT / ORAL							
		Tricuspid Valve Incompetence		Mirtazapine Tablet (Mirtazapine)	SS		ORAL
20 MG / SEE TEXT / ORAL							
				Librium (Formulation Unknown) (Librium)	SS		
SINGLE DOSE							

Date:02/28/00ISR Number: 3465209-2Report Type:Expedited (15-DaCompany Report #M0091-2000
Age:53 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Cholesterol	Health	Remeron	PS		ORAL
7.5 - 22.5 MG/DAY PO		Increased	Professional				
		Blood Triglycerides Increased Liver Function Test Abnormal Oedema Peripheral		Wellbutrin Desoxyn Synthroid	SS C C		

Date:03/01/00ISR Number: 3466568-7Report Type:Expedited (15-DaCompany Report #A005730
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Required Intervention to Prevent Permanent		Abdominal Distension Dissociative Identity Disorder	Health Professional	Zoloft Tablets Bupropion	PS SS		

Impairment/Damage	Hysterectomy
	Ill-Defined Disorder
	Nausea
	Tremor

Date:03/01/00ISR Number: 3469426-7Report Type:Periodic Company Report #A0108483A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Palpitations	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS				

Date:03/01/00ISR Number: 3469429-2Report Type:Periodic Company Report #A0104885A
Age:19 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Burning Sensation
	Erythema Multiforme
	Lymphadenopathy
	Malaise
	Pain

	Pruritus						
	Pyrexia						
	Serum Sickness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:03/01/00ISR Number: 3469431-0Report Type:Periodic Company Report #A0105122A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Tachycardia	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY/ ORAL
			Conjugated Estrogens	C			
			Aspirin	C			

Date:03/01/00ISR Number: 3469434-6Report Type:Periodic Company Report #A0082834A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:03/01/00ISR Number: 3469436-XReport Type:Periodic Company Report #A0083096A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3469440-1Report Type:Periodic Company Report #A0081611A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Throat Tightness Urticaria	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Weight Loss Medication	C				

Date:03/01/00ISR Number: 3469442-5Report Type:Periodic Company Report #A0086000A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain Anaphylactic Reaction Bronchospasm Conjunctivitis Dermatitis Dyspnoea Eyelid Oedema Face Oedema Headache Nausea Pharyngeal Oedema Pruritus Respiratory Distress Tongue Oedema Urticaria	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3469452-8Report Type:Periodic Company Report #A0110912A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Hypersensitivity	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS				

Date:03/01/00ISR Number: 3469455-3Report Type:Periodic Company Report #A0110651A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Interaction	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride) Septra (Formulation	PS		ORAL	ORAL	

			Unknown) (Sulfamethoxazole Trimetho)	SS		

Date:03/01/00ISR Number: 3469458-9Report Type:Periodic Company Report #A0109719A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Akinesia Dystonia	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:03/01/00ISR Number: 3469461-9Report Type:Periodic Company Report #A0107904A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY/	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3469464-4Report Type:Periodic Company Report #A0107591A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Birth Control	C				

Date:03/01/00ISR Number: 3469466-8Report Type:Periodic Company Report #A0107632A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Dry Mouth	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / ORAL	

Date:03/01/00ISR Number: 3469469-3Report Type:Periodic Company Report #A0107283A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other Required Intervention to Prevent Permanent Impairment/Damage	Convulsion	Health Professional	Zyban Tablet - Zyban (Bupriopion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Ortho Cyclen	C				

Date:03/01/00ISR Number: 3547102-XReport Type:Periodic Company Report #A0109325A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Nervousness					
TWICE PER DAY						
	Psychomotor Hyperactivity					
/ ORAL						

Date:03/01/00ISR Number: 3547108-0Report Type:Periodic Company Report #A0109434A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Dysphonia					
TWICE PER DAY						
	Rash Erythematous					
/ ORAL						
	Rash Pruritic					
	Throat Tightness					

Date:03/01/00ISR Number: 3547109-2Report Type:Periodic Company Report #A0109437A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash Erythematous	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Rash Pruritic					
TWICE PER						
DAY/ ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547112-2Report Type:Periodic Company Report #A0109438A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	1 MON
	Ill-Defined Disorder							

Date:03/01/00ISR Number: 3547114-6Report Type:Periodic Company Report #A0109496A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Apathy						TWICE PER	
	Tremor						DAY/ ORAL	

Date:03/01/00ISR Number: 3547115-8Report Type:Periodic Company Report #A0109497A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Throat Tightness						TWICE PER	
							DAY/ ORAL	

Date:03/01/00ISR Number: 3547117-1Report Type:Periodic Company Report #A0109498A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

Dysarthria
PER DAY/ ORAL
Insomnia
Speech Disorder

Date:03/01/00ISR Number: 3547120-1Report Type:Periodic Company Report #A0109499A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3547122-5Report Type:Periodic Company Report #A0109500A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Atopic	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Drug Hypersensitivity							
	Face Oedema							
	Pruritus							
	Urticaria							

Date:03/01/00ISR Number: 3547169-9Report Type:Periodic Company Report #A0107721A
Age: Gender:Female I/FU:I

Outcome	PT
	Bruxism
	Feeling Abnormal

	Insomnia Neck Pain Psychomotor Hyperactivity	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Tachycardia Tension Tremor Vertigo	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ ORAL

Date:03/01/00ISR Number: 3547171-7Report Type:Periodic Company Report #A0107722A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Agitation Vaginal Infection	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG/ UNKNOWN / ORAL

Date:03/01/00ISR Number: 3547173-0Report Type:Periodic Company Report #A0107819A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / TWICE PER DAY / ORAL

Date:03/01/00ISR Number: 3547175-4Report Type:Periodic Company Report #A0107821A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration

	Dizziness Postural	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG/ PER

DAY/ ORAL

Date:03/01/00ISR Number: 3547176-6Report Type:Periodic Company Report #A0107834A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Insomnia					
	Psychomotor Hyperactivity					
	Pyrexia					

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3547177-8Report Type:Periodic Company Report #A0107835A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Breast Tenderness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Menorrhagia					

Dose Duration

150 MG /

TWICE PER

DAY/ ORAL

Date:03/01/00ISR Number: 3547178-XReport Type:Periodic Company Report #A0107839A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Mydriasis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG/ TWICE

PER DAY/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547179-1Report Type:Periodic Company Report #A0107871A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3547181-XReport Type:Periodic Company Report #A0107873A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	3 MON
			Lansoprazole	C				
			Methylphenidate Hcl	C				

Date:03/01/00ISR Number: 3547183-3Report Type:Periodic Company Report #A0107929A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ ORAL	
	Urticaria							

Date:03/01/00ISR Number: 3547185-7Report Type:Periodic Company Report #A0107931A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:03/01/00ISR Number: 3547187-0Report Type:Periodic Company Report #A0107937A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3547190-0Report Type:Periodic Company Report #A0108071A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngeal Oedema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	2 WK

Date:03/01/00ISR Number: 3547192-4Report Type:Periodic Company Report #A0108072A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547195-XReport Type:Periodic Company Report #A0108073A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY/ ORAL	

Date:03/01/00ISR Number: 3547198-5Report Type:Periodic Company Report #A0108074A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3547201-2Report Type:Periodic Company Report #A0108075A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY/ ORAL	
	Myalgia							
	Nausea							

Date:03/01/00ISR Number: 3547203-6Report Type:Periodic Company Report #A0108076A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

TWICE PER

DAY/ ORAL

Date:03/01/00ISR Number: 3547205-XReport Type:Periodic Company Report #A0108077A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
	Feelings Of Worthlessness						PER DAY/ ORAL

Date:03/01/00ISR Number: 3547209-7Report Type:Periodic Company Report #A0108079A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
	Feelings Of Worthlessness						TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3547216-4Report Type:Periodic Company Report #A0107030A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dysgeusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /

TWICE PER DAY

/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547218-8Report Type:Periodic Company Report #A0107031A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dizziness						DAY/ ORAL	
	Nausea							
	Tremor							

Date:03/01/00ISR Number: 3547220-6Report Type:Periodic Company Report #A0107032A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
		Professional					DAY/ ORAL	

Date:03/01/00ISR Number: 3547221-8Report Type:Periodic Company Report #A0107037A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Consciousness	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Speech Disorder	Professional					TWICE PER	
							DAY/ ORAL	
			Ethanol	C				

Date:03/01/00ISR Number: 3547222-XReport Type:Periodic Company Report #A0107039A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG /

TWICE PER

DAY/ ORAL

Date:03/01/00ISR Number: 3547223-1Report Type:Periodic Company Report #A0107040A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Hyperhidrosis					
	Insomnia					
	Pollakiuria		Atorvastatin	C		
	Vomiting		Multivitamin	C		

Dose Duration

150 MG /

TWICE PER

DAY/ ORAL

Date:03/01/00ISR Number: 3547225-5Report Type:Periodic Company Report #A0107043A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Burning Sensation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Pruritus					
	Urticaria					

Dose Duration

ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547226-7Report Type:Periodic Company Report #A0107065A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Irritability						TWICE PER	
	Weight Increased						DAY/ ORAL	2 WK

Date:03/01/00ISR Number: 3547228-0Report Type:Periodic Company Report #A0107067A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dysgeusia						TWICE PER	
	Tremor						DAY/ ORAL	

Date:03/01/00ISR Number: 3547229-2Report Type:Periodic Company Report #A0107068A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:03/01/00ISR Number: 3547230-9Report Type:Periodic Company Report #A0107069A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
		Other					ORAL	

			Nicotine (Formulation Unknown)	SS		

7 MG

Date:03/01/00ISR Number: 3547233-4Report Type:Periodic Company Report #A0107093A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Tremor						PER DAY/ ORAL	

Date:03/01/00ISR Number: 3547234-6Report Type:Periodic Company Report #A0107112A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	6 WK
	Emotional Disorder		Nitrous Oxide Gas (Nitrous Oxide)	SS				
	Panic Reaction							

Date:03/01/00ISR Number: 3547235-8Report Type:Periodic Company Report #A0107159A
Age:41 YR Gender:Male I/FU:I

Outcome	PT
	Agitation
	Blood Pressure Increased
	Discomfort
	Dizziness
	Excitability

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Nervousness Tachycardia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3547236-XReport Type:Periodic Company Report #A0107188A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder Dry Mouth Tachycardia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3547237-1Report Type:Periodic Company Report #A0107200A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Feeling Abnormal	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3547239-5Report Type:Periodic Company Report #A0107202A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Dysgeusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	

	Insomnia					
/ ORAL						
	Vision Blurred					

Date:03/01/00ISR Number: 3547243-7Report Type:Periodic Company Report #A0107203A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dyspnoea						TWICE PER DAY	
	Pruritus						/ ORAL	
	Urticaria							

Date:03/01/00ISR Number: 3547246-2Report Type:Periodic Company Report #A0107204A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:03/01/00ISR Number: 3547249-8Report Type:Periodic Company Report #A0107205A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Texture Abnormal	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	1 YR
	Nail Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547291-7Report Type:Periodic Company Report #A0109501A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Fatigue							ORAL
	Insomnia							
	Lethargy							

Date:03/01/00ISR Number: 3547294-2Report Type:Periodic Company Report #A0109508A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Dizziness							ORAL
	Dry Mouth							
	Dysgeusia							

Date:03/01/00ISR Number: 3547296-6Report Type:Periodic Company Report #A0109560A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Syncope	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	PER DAY/ ORAL
	Tachycardia							
			Coffee Liquid (Coffee)	SS		ORAL		

Date:03/01/00ISR Number: 3547298-XReport Type:Periodic Company Report #A0109600A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
	Nausea	Professional				
PER DAY/ ORAL						

Date:03/01/00ISR Number: 3547300-5Report Type:Periodic Company Report #A0109601A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ PER						
DAY/ ORAL						

Date:03/01/00ISR Number: 3547303-0Report Type:Periodic Company Report #A0109604A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Flushing	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
PER DAY/ ORAL						

Date:03/01/00ISR Number: 3547308-XReport Type:Periodic Company Report #A0109611A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
	Dry Mouth					
PER DAY/ ORAL						
	Insomnia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547310-8Report Type:Periodic Company Report #A0110307A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Bupropion					
	Personality Change	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Psychiatric Symptom	Company					UNK/ORAL	
		Representative						

Date:03/01/00ISR Number: 3547312-1Report Type:Periodic Company Report #A0110328A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Bupropion					
	Dyspnoea		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG, /	
	Insomnia						TWICE PER	
	Tachycardia						DAY/ ORAL	

Date:03/01/00ISR Number: 3547313-3Report Type:Periodic Company Report #A0109633A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Nausea						UNK/ORAL	

Date:03/01/00ISR Number: 3547315-7Report Type:Periodic Company Report #A0110329A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion					

	Urticaria		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG / UNK

/ ORAL

Date:03/01/00ISR Number: 3547316-9Report Type:Periodic Company Report #A0110331A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
	Irritability					

Dose Duration

150 MG /UNK /

ORAL

Date:03/01/00ISR Number: 3547317-0Report Type:Periodic Company Report #A0110332A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
	Irritability					

Dose Duration

150 MG / UNK

/ ORAL

Date:03/01/00ISR Number: 3547319-4Report Type:Periodic Company Report #A0110354A
Age:55 YR Gender:Female I/FU:U

Outcome	PT
	Dysphagia
	Dyspnoea
	Pharyngeal Oedema

	Rash Erythematous Rash Pruritic						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL

Date:03/01/00ISR Number: 3547321-2Report Type:Periodic Company Report #A0110371A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain	Consumer	Zyban Tablet	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Feeling Abnormal Flushing Gastrointestinal Disorder Pyrexia Urticaria						

Date:03/01/00ISR Number: 3547323-6Report Type:Periodic Company Report #A0110377A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL

Date:03/01/00ISR Number: 3547326-1Report Type:Periodic Company Report #A0110378A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dermatitis						TWICE PER DAY	
							/ORAL	

Date:03/01/00ISR Number: 3547328-5Report Type:Periodic Company Report #A0110379A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	
	Feeling Abnormal						/ ORAL	3 DAY
	Nausea							

Date:03/01/00ISR Number: 3547330-3Report Type:Periodic Company Report #A0110399A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	
							/ ORAL	7 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547331-5Report Type:Periodic Company Report #A0110419A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Visual Disturbance	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3547333-9Report Type:Periodic Company Report #A0110562A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3547335-2Report Type:Periodic Company Report #A0110563A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Irritability	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3547336-4Report Type:Periodic Company Report #A0110564A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3547338-8Report Type:Periodic Company Report #A0110565A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder Agitation Disturbance In Attention Dizziness Mental Impairment Nausea Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3547340-6Report Type:Periodic Company Report #A0110566A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547343-1Report Type:Periodic Company Report #A0110567A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Bupropion					
	Pruritus		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							UKNOWN /	ORAL

Date:03/01/00ISR Number: 3547345-5Report Type:Periodic Company Report #A0110568A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Bupropion					
	Memory Impairment		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							UNKNOWN /	
ORAL								5 MON

Date:03/01/00ISR Number: 3547346-7Report Type:Periodic Company Report #A0110569A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Bupropion					
	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK/	
	Urticaria							
ORAL								

Date:03/01/00ISR Number: 3547362-5Report Type:Periodic Company Report #A0109634A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
	Drug Dependence					
PER DAY/ ORAL						

Date:03/01/00ISR Number: 3547366-2Report Type:Periodic Company Report #A0109635A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
	Micturition Urgency					
PER DAY/ ORAL 1 WK						
	Pollakiuria					

Date:03/01/00ISR Number: 3547368-6Report Type:Periodic Company Report #A0109636A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Apathy	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
	Insomnia					
PER DAY/ ORAL						

Date:03/01/00ISR Number: 3547371-6Report Type:Periodic Company Report #A0109637A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
UNK/ SEE						
	Nausea	Professional				
TEXT/ ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547373-XReport Type:Periodic Company Report #A0109640A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:03/01/00ISR Number: 3547376-5Report Type:Periodic Company Report #A0109641A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ UNK/	
	Rash Pruritic	Professional					ORAL	
		Company Representative						

Date:03/01/00ISR Number: 3547379-0Report Type:Periodic Company Report #A0109690A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Mouth Ulceration						DAY/ ORAL	
	Oedema Peripheral							
	Urticaria							

Date:03/01/00ISR Number: 3547383-2Report Type:Periodic Company Report #A0109721A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

	Hypertrophy Breast	Professional				

PER DAY/ ORAL

Date:03/01/00ISR Number: 3547386-8Report Type:Periodic Company Report #A0109722A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

PER DAY/ ORAL

Date:03/01/00ISR Number: 3547392-3Report Type:Periodic Company Report #A0109723A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/ UNK/	

ORAL

Date:03/01/00ISR Number: 3547402-3Report Type:Periodic Company Report #A0109725A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Paraesthesia							

PER DAY/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547406-0Report Type:Periodic Company Report #A0109767A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Insomnia						PER DAY/ ORAL	
	Thinking Abnormal							

Date:03/01/00ISR Number: 3547420-5Report Type:Periodic Company Report #A0108269A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blepharospasm	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dizziness						TWICE PER DAY	
							/ ORAL	

Date:03/01/00ISR Number: 3547422-9Report Type:Periodic Company Report #A0108270A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Flushing						TWICE PER DAY	
	Nausea						/ ORAL	
	Sedation		Decongestant	C				

Date:03/01/00ISR Number: 3547424-2Report Type:Periodic Company Report #A0108271A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG /

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3547431-XReport Type:Periodic Company Report #A0108276A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Burning Sensation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG /

Chills

TWICE PER DAY

Dizziness

/ ORAL

Dysphagia
Headache
Sensation Of Pressure
Tremor
Vision Blurred

Date:03/01/00ISR Number: 3547433-3Report Type:Periodic Company Report #A0108290A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Depressed Mood	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547435-7Report Type:Periodic Company Report #A0108293A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

Date:03/01/00ISR Number: 3547437-0Report Type:Periodic Company Report #A0108303A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3547438-2Report Type:Periodic Company Report #A0108485A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY/ ORAL	
	Sedation							
			Sertraline Hydrochloride	C				
			Diazepam	C				

Date:03/01/00ISR Number: 3547439-4Report Type:Periodic Company Report #A0108622A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pollakiuria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG /

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3547442-4Report Type:Periodic Company Report #A0108623A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Depressed Mood					
	Nervousness					

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3547445-XReport Type:Periodic Company Report #A0108624A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Nervousness					

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3547447-3Report Type:Periodic Company Report #A0108625A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Headache					
	Insomnia					

Dose Duration

150 MG / PER

DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547461-8Report Type:Periodic Company Report #A0108626A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:03/01/00ISR Number: 3547466-7Report Type:Periodic Company Report #A0108627A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Tremor						TWICE PER DAY	/ ORAL

Date:03/01/00ISR Number: 3547469-2Report Type:Periodic Company Report #A0108628A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Tachycardia						TWICE PER DAY	/ ORAL

Date:03/01/00ISR Number: 3547472-2Report Type:Periodic Company Report #A0108629A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	

/ ORAL

Date:03/01/00ISR Number: 3547475-8Report Type:Periodic Company Report #A0108630A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Nausea						TWICE PER DAY	
	Urticaria						/ ORAL	

Date:03/01/00ISR Number: 3547477-1Report Type:Periodic Company Report #A0108631A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
	Nervousness						/ ORAL	
	Tremor							

Date:03/01/00ISR Number: 3547483-7Report Type:Periodic Company Report #A0108632A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3547486-2Report Type:Periodic Company Report #A0108633A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	WK

Date:03/01/00ISR Number: 3548822-3Report Type:Periodic Company Report #A0102578A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Drug Withdrawal Syndrome							
	Tremor		Thyroxine Sodium	C				

Date:03/01/00ISR Number: 3548823-5Report Type:Periodic Company Report #A0102897A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Disorientation	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG UNK ORAL	
	Dizziness							
	Erythema Multiforme							
	Fatigue							
	Pharyngolaryngeal Pain							
	Pyrexia							

Date:03/01/00ISR Number: 3548825-9Report Type:Periodic Company Report #A0103098A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG TWICE	

	Pruritus	Professional				
PER DAY ORAL						
	Urticaria		Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS		ORAL
150 MG TWICE PER DAY ORAL						
			Lisinopril	C		
			Hydrochlorothiazide	C		

Date:03/01/00ISR Number: 3548826-0Report Type:Periodic Company Report #A0103106A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Nausea	Professional						
	Tremor							

Date:03/01/00ISR Number: 3548831-4Report Type:Periodic Company Report #A0103108A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG TWICE PER DAY ORAL	
	Pain In Extremity	Professional						
	Paraesthesia							
	Peripheral Coldness							
	Pulse Pressure Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3548832-6Report Type:Periodic Company Report #A0103165A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Paraesthesia	Professional					PER DAY ORAL	1 MON

Date:03/01/00ISR Number: 3548833-8Report Type:Periodic Company Report #A0103325A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Oedema	Professional					DAY ORAL	
	Pruritus							

Date:03/01/00ISR Number: 3548834-XReport Type:Periodic Company Report #A0103421A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affective Disorder	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Depression	Professional					PER DAY ORAL	
	Dry Mouth							
	Dysarthria							
	Lip Dry							
	Mental Impairment							
	Nervousness							
	Tremor							

Date:03/01/00ISR Number: 3548835-1Report Type:Periodic Company Report #A0103653A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	African Trypanosomiasis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Aggression	Professional					PER DAY ORAL	
	Depression							
	Lethargy							
	Mood Altered							
	Pain							
	Sedation							
	Weight Increased							

Date:03/01/00ISR Number: 3548837-5Report Type:Periodic Company Report #A0104078A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Dissociation	Professional					DAY ORAL	
	Irritability							
	Major Depression							
	Nausea							
	Pain							
	Pyrexia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3548854-5Report Type:Periodic Company Report #A0104325A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG TWICE PER DAY	ORAL
			Insulin	C				

Date:03/01/00ISR Number: 3548855-7Report Type:Periodic Company Report #A0104459A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG TWICE A DAY	ORAL
	Dry Mouth							
	Urticaria		Esterified Estrogens Medroxyprogesterone Ace.	C C				

Date:03/01/00ISR Number: 3548856-9Report Type:Periodic Company Report #A0104485A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG TWICE PER DAY	ORAL
	Nausea							

Date:03/01/00ISR Number: 3548858-2Report Type:Periodic Company Report #A0104493A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conversion Disorder	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG PER DAY	

	Crying	Professional				
ORAL						
	Delusion		Medroxyprogesterone			
	Major Depression		Ace	C		
	Mental Impairment					
	Panic Disorder Without Agoraphobia					

Date:03/01/00ISR Number: 3548861-2Report Type:Periodic Company Report #A0104588A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Dry Skin	Professional					DAY ORAL	
	Erythema							
	Immune System Disorder							
	Pruritus							
	Upper Respiratory Tract Infection							
	Urticaria							

Date:03/01/00ISR Number: 3548864-8Report Type:Periodic Company Report #A0081321A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Insomnia	Other	Nicotine Patch	SS			TRANSDERMAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3548887-9Report Type:Periodic Company Report #A0085269A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
Intervention to	Erythema						PER DAY	
Prevent Permanent	Hypersensitivity		Aspirin	C				
Impairment/Damage	Lacrimation Increased		Digoxin	C				
	Throat Tightness		Semisodium Valproate	C				
			Vitamin	C				
			Frusemide	C				
			Loracarbef	C				

Date:03/01/00ISR Number: 3548890-9Report Type:Periodic Company Report #A0096361A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG PER DAY	
	Flatulence						ORAL	
	Headache		Lisinopril	C				
	Irritable Bowel Syndrome		Int/Long-Acting					
	Pyrexia		Insulin	C				
			Insulin Lispro	C				

Date:03/01/00ISR Number: 3548891-0Report Type:Periodic Company Report #A0096591A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Drug Withdrawal Syndrome						PER DAY ORAL	

Date:03/01/00ISR Number: 3548893-4Report Type:Periodic Company Report #A0096594A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Pruritus						DAY ORAL	

Date:03/01/00ISR Number: 3548918-6Report Type:Periodic Company Report #A0105084A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL	

Date:03/01/00ISR Number: 3548923-XReport Type:Periodic Company Report #A0105085A
Age:44 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain
	Back Pain
	Chest Pain
	Condition Aggravated
	Depression
	Diarrhoea

	Dry Mouth Increased Appetite Insomnia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
	Pyrexia						TWICE PER DAY
	Sinus Headache						/ ORAL
	Therapeutic Response Unexpected						

Date:03/01/00ISR Number: 3548926-5Report Type:Periodic Company Report #A0105123A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
		Other					TWICE PER DAY
							/ ORAL
			Nicotine Patch (Nicotine)	SS			
TRANSDERMAL	21 MG/						
							TRANSDERMAL

Date:03/01/00ISR Number: 3548929-0Report Type:Periodic Company Report #A0105124A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
	Anxiety						TWICE PER DAY
	Disturbance In Attention						/ ORAL
	Tachycardia						

Date:03/01/00ISR Number: 3548931-9Report Type:Periodic Company Report #A0105307A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Decreased Appetite						TWICE PER DAY	
	Diarrhoea						/ ORAL	
	Hyperhidrosis		Hyoscyamine Sulphate	C				
	Nausea		Mesalazine	C				
	Pollakiuria							
	Tremor							
	Viral Infection							

Date:03/01/00ISR Number: 3548933-2Report Type:Periodic Company Report #A0105374A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Nervousness						TWICE PER	
	Tension						DAY/ ORAL	
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3548935-6Report Type:Periodic Company Report #A0105375A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Sedation	Professional					DAY / ORAL	
		Company Representative	Tamoxifen	C				

Date:03/01/00ISR Number: 3548938-1Report Type:Periodic Company Report #A0105377A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dyspepsia						DAY / ORAL	
	Headache							
	Insomnia							
	Nausea							

Date:03/01/00ISR Number: 3548941-1Report Type:Periodic Company Report #A0105390A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Face Oedema						TWICE PER DAY	
	Flushing						/ORAL	
	Hyperhidrosis							
	Hypersensitivity							
	Oedema							
	Oedema Peripheral							
	Pruritus							
	Urticaria							
	Weight Increased							

Date:03/01/00ISR Number: 3548944-7Report Type:Periodic Company Report #A0105392A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Headache							

Date:03/01/00ISR Number: 3548946-0Report Type:Periodic Company Report #A0105393A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 GM / TWICE PER DAY / ORAL	8 DAY
	Decreased Activity							
	Diarrhoea							
	Headache							

Date:03/01/00ISR Number: 3548950-2Report Type:Periodic Company Report #A0105394A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	
	Pruritus							
	Swelling							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3548953-8Report Type:Periodic Company Report #A0105396A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Nausea						TWICE PER	DAY/ ORAL

Date:03/01/00ISR Number: 3548955-1Report Type:Periodic Company Report #A0105397A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Malaise							

Date:03/01/00ISR Number: 3548957-5Report Type:Periodic Company Report #A0105404A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER	DAY/ ORAL

Date:03/01/00ISR Number: 3548960-5Report Type:Periodic Company Report #A0105405A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	

	Insomnia					
DAY / ORAL						

Date:03/01/00ISR Number: 3548963-0Report Type:Periodic Company Report #A0105506A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mood Altered	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:03/01/00ISR Number: 3548965-4Report Type:Periodic Company Report #A0105507A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hunger	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	40 DAY
	Weight Increased	Other	Nicotine Polacrilex	C				

Date:03/01/00ISR Number: 3548969-1Report Type:Periodic Company Report #A0105510A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:03/01/00ISR Number: 3548972-1Report Type:Periodic Company Report #A0105511A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3548975-7Report Type:Periodic Company Report #A0110730A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Syncope Visual Disturbance	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ AS DIRECTED/	ORAL 4 DAY

Date:03/01/00ISR Number: 3548979-4Report Type:Periodic Company Report #A0110842A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3548982-4Report Type:Periodic Company Report #A0110850A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Abnormal Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	

Date:03/01/00ISR Number: 3548985-XReport Type:Periodic Company Report #A0110991A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Bupropion					

	Drug Interaction	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG ORAL						
	Dysphonia	Company	Thyroxine Sodium			
	Tremor	Representative	(Levothyroxine Sodium)	SS		
15 MG						
			Pravastatin Sodium (Pravastatin Sodium)	SS		
10 MG						

Date:03/01/00ISR Number: 3548989-7Report Type:Periodic Company Report #A0111092A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE						
PER DAY /ORAL						

Date:03/01/00ISR Number: 3548992-7Report Type:Periodic Company Report #A0055184A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
	Feeling Abnormal					
150 MG/PER						
	Insomnia					
DAY/ORAL						
	Tremor		Cisapride	C		
			Loratadine	C		
			Herbal Medication	C		
			Glucophage	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3548994-0Report Type:Periodic Company Report #A0058731A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	2 MON
	Nervousness							
	Tremor							

Date:03/01/00ISR Number: 3548997-6Report Type:Periodic Company Report #A0066125A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	2 WK
	Drug Ineffective							
	Headache							
	Nervousness		Zyban Tablet-Zyban (Bupropion Hydrochloride)	SS		ORAL	150 MG/TWICE PER DAY/ORAL	2 WK
			Etodolac	C				
			Cardiovascular Medication	C				
			Pain Medication	C				
			Sleeping Medication	C				

Date:03/01/00ISR Number: 3549000-4Report Type:Periodic Company Report #A0080417A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ ORAL	
	Insomnia							
	Restlessness							

	Suicidal Ideation		Hydroxyzine Hydrochloride	C		

Date:03/01/00ISR Number: 3549002-8Report Type:Periodic Company Report #A0087975A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Papular	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL
			Hydrocodone	C				

Date:03/01/00ISR Number: 3549004-1Report Type:Periodic Company Report #A0096164A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Irritability Mood Altered Nightmare	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549007-7Report Type:Periodic Company Report #A0099338A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Health	Bupropion					
	Derealisation	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL
	Emotional Disorder							
	Feeling Abnormal							
	Hyperhidrosis							
	Insomnia							
	Nausea							
	Paranoia							
	Psychotic Disorder							
	Tremor							

Date:03/01/00ISR Number: 3549010-7Report Type:Periodic Company Report #A0099558A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Health	Bupropion					
	Dysgeusia	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Insomnia						PER DAY/ ORAL	
	Irritability							
	Parosmia							

Date:03/01/00ISR Number: 3549011-9Report Type:Periodic Company Report #A0100148A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Bupropion					
	Pruritus	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Swelling						PER DAY/ORAL	
	Urticaria							

Date:03/01/00ISR Number: 3549013-2Report Type:Periodic Company Report #A0100882A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health	Bupropion					
	Hair Disorder	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Insomnia						PER DAY/ORAL	
			Nicotine	C				
			Benazepril Hydrochloride	C				
			Nifedipine	C				
			Thyroid Medication	C				

Date:03/01/00ISR Number: 3549014-4Report Type:Periodic Company Report #A0101306A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion					
	Feeling Abnormal		Hydrochloride	PS	Glaxo Wellcome Inc		OPHTHALMIC	150 MG/ TWICE
	Ill-Defined Disorder						PER DAY/ORAL	
	Insomnia							
	Malaise							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549016-8Report Type:Periodic Company Report #A0101851A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Bupropion					
	Disturbance In Attention	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
	Hyperhidrosis						DAY/ORAL	
	Insomnia							
	Nervousness							

Date:03/01/00ISR Number: 3549017-XReport Type:Periodic Company Report #A0102168A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health	Bupropion					
	Hyperhidrosis	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
							PER DAY/ORAL	

Date:03/01/00ISR Number: 3549019-3Report Type:Periodic Company Report #A0102172A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Bupropion					
	Emotional Disorder	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	
	Flushing							
	Nausea							
	Personality Change							
	Psychomotor Hyperactivity							

Date:03/01/00ISR Number: 3549021-1Report Type:Periodic Company Report #A0102506A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Bupropion					
	Neck Pain	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	DAY/ORAL
			Theophylline	C				
			Salbutamol Sulphate	C				

Date:03/01/00ISR Number: 3549120-4Report Type:Periodic Company Report #A0109768A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Bupropion					
	Tremor		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	DAY/ ORAL

Date:03/01/00ISR Number: 3549121-6Report Type:Periodic Company Report #A0109910A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Bupropion					
	Insomnia	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG, ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549122-8Report Type:Periodic Company Report #A0109913A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Benign Prostatic Hyperplasia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:03/01/00ISR Number: 3549123-XReport Type:Periodic Company Report #A0109919A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY	ORAL

Date:03/01/00ISR Number: 3549124-1Report Type:Periodic Company Report #A0109921A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Hypersensitivity	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY	
	Urticaria							

Date:03/01/00ISR Number: 3549125-3Report Type:Periodic Company Report #A0109922A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

TWICE PER DAY

ORAL

Date:03/01/00ISR Number: 3549126-5Report Type:Periodic Company Report #A0109924A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction Premature Ejaculation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL

Date:03/01/00ISR Number: 3549127-7Report Type:Periodic Company Report #A0110045A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL

Date:03/01/00ISR Number: 3549129-0Report Type:Periodic Company Report #A0110048A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549130-7Report Type:Periodic Company Report #A0110051A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:03/01/00ISR Number: 3549131-9Report Type:Periodic Company Report #A0110057A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:03/01/00ISR Number: 3549132-0Report Type:Periodic Company Report #A0110059A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Tinnitus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/	ORAL

Date:03/01/00ISR Number: 3549133-2Report Type:Periodic Company Report #A0110061A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	

	Malaise					
	Tremor					

Date:03/01/00ISR Number: 3549135-6Report Type:Periodic Company Report #A0110113A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:03/01/00ISR Number: 3549136-8Report Type:Periodic Company Report #A0110114A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/	ORAL
	Rash Generalised							
	Vasculitis							

Date:03/01/00ISR Number: 3549137-XReport Type:Periodic Company Report #A0110116A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	ORAL
		Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549139-3Report Type:Periodic Company Report #A0110117A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY	ORAL
	Dyspnoea							
	Hyperhidrosis							
	Insomnia							
	Lethargy							
	Psychomotor Hyperactivity							
	Tachycardia							

Date:03/01/00ISR Number: 3549140-XReport Type:Periodic Company Report #A0110118A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/	ORAL

Date:03/01/00ISR Number: 3549141-1Report Type:Periodic Company Report #A0110119A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ORAL	
	Cough							
	Dyspnoea							
	Nausea							

Date:03/01/00ISR Number: 3549142-3Report Type:Periodic Company Report #A0110120A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Suicidal Ideation	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
		Company Representative						

Date:03/01/00ISR Number: 3549297-0Report Type:Periodic Company Report #A0109065A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability Palpitations	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:03/01/00ISR Number: 3549298-2Report Type:Periodic Company Report #A0109066A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549299-4Report Type:Periodic Company Report #A0109067A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:03/01/00ISR Number: 3549302-1Report Type:Periodic Company Report #A0109068A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:03/01/00ISR Number: 3549304-5Report Type:Periodic Company Report #A0109110A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Attack	Consumer Other	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	

Date:03/01/00ISR Number: 3549306-9Report Type:Periodic Company Report #A0109131A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:03/01/00ISR Number: 3549309-4Report Type:Periodic Company Report #A0109200A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:03/01/00ISR Number: 3549311-2Report Type:Periodic Company Report #A0109201A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/	ORAL

Date:03/01/00ISR Number: 3549313-6Report Type:Periodic Company Report #A0109202A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Rash Pruritic	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL 2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549314-8Report Type:Periodic Company Report #A0109203A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Insomnia						PER DAY/ ORAL	
	Nausea							
	Tremor							

Date:03/01/00ISR Number: 3549316-1Report Type:Periodic Company Report #A0109204A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Headache						PER DAY/ ORAL	
	Insomnia							

Date:03/01/00ISR Number: 3549319-7Report Type:Periodic Company Report #A0109205A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Muscle Spasms						PER DAY/ ORAL	
	Nausea							

Date:03/01/00ISR Number: 3549323-9Report Type:Periodic Company Report #A0109216A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Bupropion					

	Headache		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
	Nausea					
PER DAY/ ORAL						
	Neck Pain					

Date:03/01/00ISR Number: 3549325-2Report Type:Periodic Company Report #A0109292A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Bupropion			
	Feeling Abnormal		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
	Vertigo					
PER DAY/ ORAL						

Date:03/01/00ISR Number: 3549327-6Report Type:Periodic Company Report #A0109319A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Depression	Consumer	Bupropion			
			Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
PER DAY/ORAL						
			Sertraline			
			Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549329-XReport Type:Periodic Company Report #A0109320A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Urticaria						PER DAY/ ORAL	

Date:03/01/00ISR Number: 3549331-8Report Type:Periodic Company Report #A0109321A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysarthria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Psychomotor Hyperactivity						DAY/ ORAL	
	Tachycardia							

Date:03/01/00ISR Number: 3549334-3Report Type:Periodic Company Report #A0109322A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Pruritus						PER DAY/ ORAL	
	Vision Blurred							

Date:03/01/00ISR Number: 3549337-9Report Type:Periodic Company Report #A0109323A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Hallucination, Auditory							

	Nausea					
PER DAY/ ORAL						
	Tremor					

Date:03/01/00ISR Number: 3549340-9Report Type:Periodic Company Report #A0109324A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Dyspnoea							
	Fatigue							
PER DAY/ ORAL								
	Feeling Abnormal							
	Insomnia							

Date:03/01/00ISR Number: 3549362-8Report Type:Periodic Company Report #A0110570A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
PER DAY/ ORAL								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549365-3Report Type:Periodic Company Report #A0110571A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/	ORAL
	Insomnia							
	Tremor							

Date:03/01/00ISR Number: 3549369-0Report Type:Periodic Company Report #A0110572A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL
	Dry Mouth							
	Dyspepsia							
	Mood Altered		Diazepam	C				
	Psychomotor Hyperactivity		Nabumetone	C				
	Tachycardia		Darvocet-N	C				

Date:03/01/00ISR Number: 3549370-7Report Type:Periodic Company Report #A0110573A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/	ORAL

Date:03/01/00ISR Number: 3549372-0Report Type:Periodic Company Report #A0110577A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cataract Subcapsular	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	MON

Date:03/01/00ISR Number: 3549374-4Report Type:Periodic Company Report #A0110654A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Restlessness Tachycardia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	

Date:03/01/00ISR Number: 3549376-8Report Type:Periodic Company Report #A0110656A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pruritus Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549378-1Report Type:Periodic Company Report #A0110658A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention Flat Affect Memory Impairment Sedation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:03/01/00ISR Number: 3549380-XReport Type:Periodic Company Report #A0110675A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dry Mouth Irritability Lethargy	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/	ORAL

Date:03/01/00ISR Number: 3549381-1Report Type:Periodic Company Report #A0110692A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Hypersensitivity Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL

Date:03/01/00ISR Number: 3549383-5Report Type:Periodic Company Report #A0110697A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion					

	Constipation		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ ORAL						
	Dry Mouth					

Date:03/01/00ISR Number: 3549385-9Report Type:Periodic Company Report #A0110700A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Bupropion			
	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
PER DAY/ ORAL						
			Nicotine Patch			
			(Nicotine)	SS		
TRANSDERMAL TRANSDERMAL						

Date:03/01/00ISR Number: 3549387-2Report Type:Periodic Company Report #A0110701A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Formication	Health	Bupropion			
	Insomnia	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ PER						
DAY/ ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549389-6Report Type:Periodic Company Report #A0110704A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL
	Chest Pain							
	Dizziness							
	Dry Mouth							
	Dry Throat							
	Dysphagia							

Date:03/01/00ISR Number: 3549391-4Report Type:Periodic Company Report #A0110707A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperventilation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	
	Paraesthesia							

Date:03/01/00ISR Number: 3549392-6Report Type:Periodic Company Report #A0110710A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL
	Insomnia							

Date:03/01/00ISR Number: 3549393-8Report Type:Periodic Company Report #A0110711A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Bupropion					

	Urticaria		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG/ TWICE

PER DAY/ ORAL

Date:03/01/00ISR Number: 3549395-1Report Type:Periodic Company Report #A0110712A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Depression	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG/ PER

DAY/ ORAL

Date:03/01/00ISR Number: 3549396-3Report Type:Periodic Company Report #A0110718A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Crying	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
	Depression					

Dose Duration

150 MG/ ORAL

Date:03/01/00ISR Number: 3549398-7Report Type:Periodic Company Report #A0110719A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dyspnoea	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG/ TWICE

PER DAY/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549477-4Report Type:Periodic Company Report #A0106915A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY),	ORAL

Date:03/01/00ISR Number: 3549480-4Report Type:Periodic Company Report #A0106957A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL

Date:03/01/00ISR Number: 3549482-8Report Type:Periodic Company Report #A0106958A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL

Date:03/01/00ISR Number: 3549485-3Report Type:Periodic Company Report #A0106959A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Bupropion					

	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG (TWICE						
	Nightmare					
PER DAY) ORAL						

Date:03/01/00ISR Number: 3549488-9Report Type:Periodic Company Report #A0106960A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Feeling Abnormal	Consumer	Bupropion			
	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG (TWICE						
PER DAY) ORAL						

Date:03/01/00ISR Number: 3549493-2Report Type:Periodic Company Report #A0106961A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Excitability	Consumer	Bupropion			
	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG (TWICE						
PER DAY) ORAL						
			Theraflu	C		

Date:03/01/00ISR Number: 3549494-4Report Type:Periodic Company Report #A0106962A
Age:49 YR Gender:Male I/FU:I

Outcome	PT
	Dermatitis
	Hypertension

	Tachycardia					
	Tension					
	Tremor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG (TWICE PER DAY) ORAL						
			Nicotine	C		

Date:03/01/00ISR Number: 3549495-6Report Type:Periodic Company Report #A0106963A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blister	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG (PER DAY) ORAL	Dermatitis Exfoliative					
	Oedema					
	Pain		Methotrexate	C		
	Photosensitivity Reaction		Verapamil	C		
	Urinary Retention					

Date:03/01/00ISR Number: 3549497-XReport Type:Periodic Company Report #A0106964A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dry Mouth	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
	Insomnia					
150 MG (PER DAY) ORAL						

Date:03/01/00ISR Number: 3549502-0Report Type:Periodic Company Report #A0106965A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Alopecia	Consumer	Bupropion			
	Dermatitis		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG (TWICE
	Pruritus					
PER DAY) ORAL						

Date:03/01/00ISR Number: 3549505-6Report Type:Periodic Company Report #A0106966A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Anxiety	Health	Bupropion			
	Cognitive Disorder	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG ORAL
	Emotional Disorder					
	Fatigue					
	Poverty Of Speech					

Date:03/01/00ISR Number: 3549516-0Report Type:Periodic Company Report #A0106967A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Agitation	Consumer	Bupropion			
	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG ORAL
	Skin Odour Abnormal					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549519-6Report Type:Periodic Company Report #A0106968A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Mental Disorder	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL

Date:03/01/00ISR Number: 3549520-2Report Type:Periodic Company Report #A0106969A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY),	ORAL

Date:03/01/00ISR Number: 3549522-6Report Type:Periodic Company Report #A0106970A
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY),	ORAL

Date:03/01/00ISR Number: 3549523-8Report Type:Periodic Company Report #A0106971A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Bupropion					

	Nausea		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG (TWICE

PER DAY) ORAL

Date:03/01/00ISR Number: 3549525-1Report Type:Periodic Company Report #A0106972A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chest Discomfort	Consumer	Bupropion			
	Dizziness		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG (PER

	Panic Disorder					

DAY) ORAL

Date:03/01/00ISR Number: 3549530-5Report Type:Periodic Company Report #A0106973A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anger	Health	Bupropion			
	Communication Disorder	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG (TWICE

	Confusional State					

PER DAY) ORAL

	Crying					
	Emotional Disorder					
	Fear					
	Hyperhidrosis					
	Musculoskeletal Stiffness					
	Nausea					
	Palpitations					
	Restlessness					
	Thinking Abnormal					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3549532-9Report Type:Periodic Company Report #A0106974A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
		Other	Nicotine Patch (Nicotine)	SS			14 MG PATCH	

Date:03/01/00ISR Number: 3549535-4Report Type:Periodic Company Report #A0106984A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
			Claritin-D	C				

Date:03/01/00ISR Number: 3553421-3Report Type:Periodic Company Report #A0106396A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated Drug Dependence Increased Appetite Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Augmentin	C				

Date:03/01/00ISR Number: 3553424-9Report Type:Periodic Company Report #A0106397A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Chills							
	Flushing							
	Tinnitus							
	Tremor							
			Triamcinolone Acetonide	C				
			Azelastine Hydrochloride	C				
			Salbutamol Sulphate	C				
			Adrenaline	C				

Date:03/01/00ISR Number: 3553427-4Report Type:Periodic Company Report #A0106398A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553429-8Report Type:Periodic Company Report #A0106399A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL

Date:03/01/00ISR Number: 3553433-XReport Type:Periodic Company Report #A0106400A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness Pain In Extremity Pyrexia Swelling	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL

Date:03/01/00ISR Number: 3553435-3Report Type:Periodic Company Report #A0106401A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL

Date:03/01/00ISR Number: 3553437-7Report Type:Periodic Company Report #A0106402A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Erythema							
	Feeling Hot						DAY / ORAL	3 DAY
	Hyperaesthesia							
	Paraesthesia							

Date:03/01/00ISR Number: 3553441-9Report Type:Periodic Company Report #A0106453A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	5 WK

Date:03/01/00ISR Number: 3553445-6Report Type:Periodic Company Report #A0106455A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Major Depression	Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553448-1Report Type:Periodic Company Report #A0106463A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3553450-XReport Type:Periodic Company Report #A0106466A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Discomfort	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL
	Feeling Abnormal							
	Muscle Twitching							

Date:03/01/00ISR Number: 3553453-5Report Type:Periodic Company Report #A0106495A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL

Date:03/01/00ISR Number: 3553460-2Report Type:Periodic Company Report #A0106504A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL

Date:03/01/00ISR Number: 3553463-8Report Type:Periodic Company Report #A0106505A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL

Date:03/01/00ISR Number: 3553468-7Report Type:Periodic Company Report #A0106887A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Nervousness Tachycardia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL

Date:03/01/00ISR Number: 3553473-0Report Type:Periodic Company Report #A0106888A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553477-8Report Type:Periodic Company Report #A0106889A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Bupropion					
	Irritability	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG	1 WK

Date:03/01/00ISR Number: 3553481-XReport Type:Periodic Company Report #A0106890A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Bupropion					
	Skin Exfoliation		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL 3 WK

Date:03/01/00ISR Number: 3553485-7Report Type:Periodic Company Report #A0106891A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health	Bupropion					
		Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL

Date:03/01/00ISR Number: 3553489-4Report Type:Periodic Company Report #A0106893A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare	Consumer	Bupropion					
			Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL
			Lisinopril	C				
			Oral Contraceptive	C				

			One-A-Day Vitamins	C		

Date:03/01/00ISR Number: 3553498-5Report Type:Periodic Company Report #A0105913A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

Date:03/01/00ISR Number: 3553502-4Report Type:Periodic Company Report #A0105914A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	
	Disturbance In Attention	Professional						
	Dry Mouth							
	Insomnia		Nicotine	C				

Date:03/01/00ISR Number: 3553505-XReport Type:Periodic Company Report #A0105915A
Age:68 YR Gender:Female I/FU:I

Outcome	PT
	Decreased Appetite
	Headache
	Insomnia

	Nausea					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL						

Date:03/01/00ISR Number: 3553509-7Report Type:Periodic Company Report #A0105916A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Swelling	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL	Toothache					

Date:03/01/00ISR Number: 3553513-9Report Type:Periodic Company Report #A0105917A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL						

Date:03/01/00ISR Number: 3553516-4Report Type:Periodic Company Report #A0106201A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Excitability	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / ORAL						
	Feeling Abnormal					

Date:03/01/00ISR Number: 3553520-6Report Type:Periodic Company Report #A0106204A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Anxiety	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
Intervention to	Depression	Professional				
TWICE PER DAY						
Prevent Permanent	Drug Withdrawal Syndrome					
/ ORAL						
Impairment/Damage	Insomnia		Extra Strength			
	Nervousness		Tylenol Pm	C		
	Palpitations		Kava	C		
	Tremor					

Date:03/01/00ISR Number: 3553524-3Report Type:Periodic Company Report #A0106206A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Headache					
TWICE PER DAY						
/ ORAL						
			Paracetamol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553527-9Report Type:Periodic Company Report #A0106209A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Cystocele						TWICE PER DAY	
	Depressed Mood						/ ORAL	
	Drug Ineffective		Nicotine	C				
	Dry Mouth							
	Flushing							
	Increased Appetite							
	Insomnia							
	Keratoconjunctivitis							
	Sicca							
	Nervousness							
	Night Sweats							
	Pollakiuria							
	Rectocele							
	Thyroid Disorder							

Date:03/01/00ISR Number: 3553529-2Report Type:Periodic Company Report #A0106216A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Fatigue						TWICE PER DAY	
	Nausea						/ ORAL	
	Sedation							

Date:03/01/00ISR Number: 3553533-4Report Type:Periodic Company Report #A0106222A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / PER
	Excitability					DAY / ORAL
	Flushing		Caffeine			
	Headache		(Formulation			
	Tachycardia		Unknown) (Caffeine)	SS		ORAL ORAL

Date:03/01/00ISR Number: 3553536-XReport Type:Periodic Company Report #A0106228A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Headache	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / PER
	Nausea	Professional				DAY/ ORAL

Date:03/01/00ISR Number: 3553539-5Report Type:Periodic Company Report #A0106230A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dermatitis	Consumer	Bupropion			
	Pruritus		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG /
	Urticaria					TWICE PER DAY
						/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553542-5Report Type:Periodic Company Report #A0106232A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Middle Insomnia						PER DAY/ORAL	
	Tremor							

Date:03/01/00ISR Number: 3553545-0Report Type:Periodic Company Report #A0106276A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Haematochezia						TWICE PER DAY	
	Hyperhidrosis						/ ORAL	
	Tremor							

Date:03/01/00ISR Number: 3553547-4Report Type:Periodic Company Report #A0106390A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
							DAY / ORAL	
			Multivitamin	C				
			Calcium Salt	C				

Date:03/01/00ISR Number: 3553548-6Report Type:Periodic Company Report #A0106392A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL
			Guaifen	C				
			Co-Trimoxazole	C				

Date:03/01/00ISR Number: 3553553-XReport Type:Periodic Company Report #A0106393A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:03/01/00ISR Number: 3553555-3Report Type:Periodic Company Report #A0106394A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553557-7Report Type:Periodic Company Report #A0106395A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Erythema						TWICE PER DAY	
	Pruritus						/ ORAL	2 MON

Date:03/01/00ISR Number: 3553563-2Report Type:Periodic Company Report #A0104673A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Bupropion					
	Tremor		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Urticaria						PER DAY/ ORAL	

Date:03/01/00ISR Number: 3553565-6Report Type:Periodic Company Report #A0104674A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Bupropion					
	Dizziness		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Drug Ineffective						PER DAY/ ORAL	3 WK
	Nervousness							

Date:03/01/00ISR Number: 3553570-XReport Type:Periodic Company Report #A0104702A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Bupropion					

	Lethargy		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG/ PER

DAY/ORAL

Date:03/01/00ISR Number: 3553574-7Report Type:Periodic Company Report #A0104703A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Abdominal Pain	Consumer	Bupropion			
	Nausea		Hydrochloride	PS	Glaxo Wellcome Inc	
	Pain In Extremity					

Dose Duration

Date:03/01/00ISR Number: 3553577-2Report Type:Periodic Company Report #A0104704A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Headache	Consumer	Bupropion			
	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
	Nausea					
	Neck Pain					
	Tinnitus					
	Weight Decreased					

Dose Duration

150 MG/TWICE

PER DAY/ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553580-2Report Type:Periodic Company Report #A0104705A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL	
	Nausea							

Date:03/01/00ISR Number: 3553585-1Report Type:Periodic Company Report #A0104742A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ORAL	

Date:03/01/00ISR Number: 3553589-9Report Type:Periodic Company Report #A0104778A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3553594-2Report Type:Periodic Company Report #A0104861A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Bupropion					

	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG /

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3553598-XReport Type:Periodic Company Report #A0104862A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Insomnia	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL WEEKS

Date:03/01/00ISR Number: 3553601-7Report Type:Periodic Company Report #A0104863A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dermatitis Swelling	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG / PER

DAY /ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553605-4Report Type:Periodic Company Report #A0104864A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Bupropion					
	Mood Altered		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Personality Change						PER DAY /ORAL	

Date:03/01/00ISR Number: 3553608-XReport Type:Periodic Company Report #A0104865A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion					
	Nausea		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:03/01/00ISR Number: 3553610-8Report Type:Periodic Company Report #A0104884A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Bupropion					
	Pruritus		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:03/01/00ISR Number: 3553614-5Report Type:Periodic Company Report #A0105053A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Bupropion					
	Depressed Mood	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dermatitis						DAY / ORAL	
	Insomnia							
	Pruritus							
	Urticaria							

Date:03/01/00ISR Number: 3553615-7Report Type:Periodic Company Report #A0105054A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose	Consumer	Bupropion					
	Palpitations		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:03/01/00ISR Number: 3553618-2Report Type:Periodic Company Report #A0105055A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Bupropion					
			Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553621-2Report Type:Periodic Company Report #A0105057A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Consumer	Bupropion					
	Pain		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL
			Asthma Medication	C				

Date:03/01/00ISR Number: 3553623-6Report Type:Periodic Company Report #A0105058A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Bupropion					
	Nausea		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Paraesthesia Oral						TWICE PER	DAY/ ORAL

Date:03/01/00ISR Number: 3553625-XReport Type:Periodic Company Report #A0105083A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Bupropion					
	Malaise		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	/ ORAL

Date:03/01/00ISR Number: 3553630-3Report Type:Periodic Company Report #A0108634A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dizziness						DAY / ORAL	
	Early Morning Awakening							
	Insomnia							
	Nausea							
	Nightmare							

Date:03/01/00ISR Number: 3553631-5Report Type:Periodic Company Report #A0108785A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Insomnia						DAY / ORAL	
	Vision Blurred							

Date:03/01/00ISR Number: 3553635-2Report Type:Periodic Company Report #A0108786A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Tobacco Abuse						DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553637-6Report Type:Periodic Company Report #A0108787A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3553640-6Report Type:Periodic Company Report #A0108790A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Dyspnoea	Professional						

Date:03/01/00ISR Number: 3553643-1Report Type:Periodic Company Report #A0108880A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3553645-5Report Type:Periodic Company Report #A0108881A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Headache Consumer Zyban PS Glaxo Wellcome Inc ORAL
150 MG /
Nausea
TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3553647-9Report Type:Periodic Company Report #A0108882A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	5 DAY

Date:03/01/00ISR Number: 3553649-2Report Type:Periodic Company Report #A0108883A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	8 DAY

Date:03/01/00ISR Number: 3553655-8Report Type:Periodic Company Report #A0108884A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553659-5Report Type:Periodic Company Report #A0108885A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:03/01/00ISR Number: 3553666-2Report Type:Periodic Company Report #A0108886A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Nightmare	Professional						

Date:03/01/00ISR Number: 3553670-4Report Type:Periodic Company Report #A0108887A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3553674-1Report Type:Periodic Company Report #A0108888A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	
	Pollakiuria							

/ ORAL

Date:03/01/00ISR Number: 3553675-3Report Type:Periodic Company Report #A0108889A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Drug Ineffective						TWICE PER DAY	
	Nervousness						/ ORAL	
	Tremor							

Date:03/01/00ISR Number: 3553677-7Report Type:Periodic Company Report #A0109060A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Oral	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Tongue Oedema						DAY / ORAL	
			Herbal Medication	C				

Date:03/01/00ISR Number: 3553678-9Report Type:Periodic Company Report #A0109061A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3553680-7Report Type:Periodic Company Report #A0109062A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Vision Blurred						TWICE PER DAY	
							/ ORAL	

Date:03/01/00ISR Number: 3553682-0Report Type:Periodic Company Report #A0109063A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:03/01/00ISR Number: 3553685-6Report Type:Periodic Company Report #A0109064A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Tinnitus						PER DAY/ORAL	

Date:03/01/00ISR Number: 3554700-6Report Type:Periodic Company Report #A0108118A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3554701-8Report Type:Periodic Company Report #A0108120A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Nervousness						TWICE PER DAY	
							/ ORAL	

Date:03/01/00ISR Number: 3554702-XReport Type:Periodic Company Report #A0108233A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Deterioration	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Depressed Level Of Consciousness						TWICE PER DAY	
	Dizziness						/ ORAL	
	Dry Mouth							
	Headache							
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3554703-1Report Type:Periodic Company Report #A0108249A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Nausea						TWICE PER DAY	

/ ORAL

Date:03/01/00ISR Number: 3554704-3Report Type:Periodic Company Report #A0108253A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Tremor						DAY / ORAL	

Date:03/01/00ISR Number: 3554705-5Report Type:Periodic Company Report #A0108254A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Palpitations						TWICE PER DAY	

/ ORAL

Date:03/01/00ISR Number: 3554706-7Report Type:Periodic Company Report #A0108255A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3554707-9Report Type:Periodic Company Report #A0108256A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

PER DAY /

ORAL

Date:03/01/00ISR Number: 3554708-0Report Type:Periodic Company Report #A0108257A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3554709-2Report Type:Periodic Company Report #A0108258A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

TWICE PER DAY

/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3554710-9Report Type:Periodic Company Report #A0108259A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:03/01/00ISR Number: 3554711-0Report Type:Periodic Company Report #A0108260A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:03/01/00ISR Number: 3554712-2Report Type:Periodic Company Report #A0108261A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	PER DAY / ORAL

Date:03/01/00ISR Number: 3554713-4Report Type:Periodic Company Report #A0108262A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Flushing	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Nausea					
TWICE PER						
DAY/ ORAL						

Date:03/01/00ISR Number: 3554714-6Report Type:Periodic Company Report #A0108263A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						

Date:03/01/00ISR Number: 3554715-8Report Type:Periodic Company Report #A0108264A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Euphoric Mood					
TWICE PER DAY						
/ ORAL						

Date:03/01/00ISR Number: 3554716-XReport Type:Periodic Company Report #A0108265A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Insomnia					
TWICE PER DAY						
	Pruritus					
/ ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3554717-1Report Type:Periodic Company Report #A0108266A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
/ ORAL								

Date:03/01/00ISR Number: 3554718-3Report Type:Periodic Company Report #A0108267A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Psychomotor Hyperactivity						TWICE PER DAY	
/ ORAL								

Date:03/01/00ISR Number: 3554719-5Report Type:Periodic Company Report #A0108268A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Burning Sensation						TWICE PER DAY	
	Dysgeusia							
/ ORAL								

Date:03/01/00ISR Number: 3554720-1Report Type:Periodic Company Report #A0107206A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Oligomenorrhoea Consumer Zyban PS Glaxo Wellcome Inc ORAL
150 MG

/UNK/ORAL 1 MON

Date:03/01/00ISR Number: 3554721-3Report Type:Periodic Company Report #A0107208A
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Nervousness Consumer Zyban PS Glaxo Wellcome Inc ORAL
150 MG /
Nightmare
TWICE PER DAY

/ ORAL
Caffeine C

Date:03/01/00ISR Number: 3554722-5Report Type:Periodic Company Report #A0107211A
Age:51 YR Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Headache Consumer Zyban PS Glaxo Wellcome Inc ORAL
150 MG /

TWICE PER DAY

/ ORAL

Date:03/01/00ISR Number: 3554723-7Report Type:Periodic Company Report #A0107213A
Age:33 YR Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Urticaria Consumer Zyban PS Glaxo Wellcome Inc ORAL
150 MG /

TWICE PER DAY

/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3554724-9Report Type:Periodic Company Report #A0107223A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dry Mouth						TWICE PER DAY	
	Insomnia						/ ORAL	

Date:03/01/00ISR Number: 3554725-0Report Type:Periodic Company Report #A0107224A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							ORA L	
			Ibuprofen	C				
			Birth Control	C				

Date:03/01/00ISR Number: 3554726-2Report Type:Periodic Company Report #A0107234A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Chest Pain						TWICE PER DAY	
	Discomfort						/ OROAL	
	Flushing							
	Insomnia							
	Nausea							
	Sensation Of Pressure							
	Vision Blurred							

Date:03/01/00ISR Number: 3554727-4Report Type:Periodic Company Report #A0107249A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3554728-6Report Type:Periodic Company Report #A0107293A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Dissociation							
	Disturbance In Attention							
	Dizziness							
	Feeling Abnormal							
	Hyperhidrosis							
	Urinary Incontinence							

Date:03/01/00ISR Number: 3554729-8Report Type:Periodic Company Report #A0107393A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TGWICE PER	
	Excitability							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

DAY / ORAL

Date:03/01/00ISR Number: 3554730-4Report Type:Periodic Company Report #A0107483A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Health	Zyban	PS	Glaxo Wellcome Inc			
	Dermatitis	Professional						
	Dermatitis Exfoliative							
	Rash Generalised							

Date:03/01/00ISR Number: 3554731-6Report Type:Periodic Company Report #A0107494A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3554732-8Report Type:Periodic Company Report #A0107495A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/01/00ISR Number: 3554733-XReport Type:Periodic Company Report #A0107496A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Tremor						PER DAY /	
							ORAL	

Date:03/01/00ISR Number: 3554734-1Report Type:Periodic Company Report #A0107586A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Chills						TWICE PER DAY	
	Diarrhoea						/ ORAL	
	Pyrexia		Nicotine Patch	SS		TRANSDERMAL	21 MG / UNK /	
	Rash Erythematous						TRANSDERMAL	
	Sleep Disorder							
	Vomiting Projectile							

Date:03/01/00ISR Number: 3554735-3Report Type:Periodic Company Report #A0107640A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Tremor						DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3554736-5Report Type:Periodic Company Report #A0107649A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK/	ORAL

Date:03/01/00ISR Number: 3554737-7Report Type:Periodic Company Report #A0107717A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Urticaria						TWICE PER DAY	/ ORAL

Date:03/01/00ISR Number: 3554738-9Report Type:Periodic Company Report #A0107719A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc			
	Irritability							

Date:03/01/00ISR Number: 3554739-0Report Type:Periodic Company Report #A0107720A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctival Hyperaemia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dermatitis						TWICE PER DAY	
	Eyelid Oedema						/ ORAL	

			Flonase Aqueous Spray (Fluticasone Propionate)	SS		

1 SPRAY / PER

DY /

INTRANASAL

Date:03/01/00ISR Number: 3554740-7Report Type:Periodic Company Report #A0105647A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Disturbance In Attention							
	Hyperphagia						PER DAY/ORAL	
	Speech Disorder		Estrogen	C				
	Urticaria		Amitriptyline Hcl	C				

Date:03/01/00ISR Number: 3554741-9Report Type:Periodic Company Report #A0105714A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Irritability							

PER DAY /ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3554742-0Report Type:Periodic Company Report #A0105720A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation	Health	Bupropion					
	Feeling Abnormal	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Major Depression						PER DAY/ORAL	

Date:03/01/00ISR Number: 3554743-2Report Type:Periodic Company Report #A0105722A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL	

Date:03/01/00ISR Number: 3554744-4Report Type:Periodic Company Report #A0105723A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Bupropion					
	Dry Mouth		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Dysgeusia						PER DAY/ORAL	
	Insomnia							
	Nausea							

Date:03/01/00ISR Number: 3554745-6Report Type:Periodic Company Report #A0105724A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Bupropion					

	Constipation	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG/SEE
	Drug Ineffective					TEXT/ORAL
	Dry Mouth					
	Insomnia					
	Libido Increased					
	Nausea					
	Tremor					

Date:03/01/00ISR Number: 3554746-8Report Type:Periodic Company Report #A0105725A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Constipation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG/PER DAY /ORAL
	Dyspepsia					
	Migraine					
	Pruritus					
	Rash Erythematous					

Date:03/01/00ISR Number: 3554747-XReport Type:Periodic Company Report #A0105726A
Age:36 YR Gender:Female I/FU:I

Outcome	PT
	Face Oedema
	Feeling Abnormal
	Feeling Hot
	Headache

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Psychomotor Hyperactivity	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY	/ORAL

Date:03/01/00 ISR Number: 3554748-1 Report Type:Periodic Company Report #A0105759A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY	/ORAL

Date:03/01/00 ISR Number: 3554749-3 Report Type:Periodic Company Report #A0105762A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Pruritus Swelling Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY./	ORAL

Date:03/01/00 ISR Number: 3554750-X Report Type:Periodic Company Report #A0105763A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG./TWICE	

PER DAY/ORAL

Date:03/01/00ISR Number: 3554751-1Report Type:Periodic Company Report #A0105765A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	20 DAY

Date:03/01/00ISR Number: 3554752-3Report Type:Periodic Company Report #A0105854A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Apathy Dysgeusia Insomnia Sedation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/	

Date:03/01/00ISR Number: 3554753-5Report Type:Periodic Company Report #A0105856A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3554754-7Report Type:Periodic Company Report #A0105859A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
	Tachycardia							

Date:03/01/00ISR Number: 3554755-9Report Type:Periodic Company Report #A0105862A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	DAY/ ORAL
	Pruritus							
			Alesse	C				

Date:03/01/00ISR Number: 3554756-0Report Type:Periodic Company Report #A0105863A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ORAL
			Nicotine	C				

Date:03/01/00ISR Number: 3554757-2Report Type:Periodic Company Report #A0105865A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Bupropion					

	Bone Pain		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE						
	Dizziness					
PER DAY/ORAL						
	Nausea					

Date:03/01/00ISR Number: 3554758-4Report Type:Periodic Company Report #A0105911A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash Erythematous	Consumer	Bupropion			
	Swelling		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE						
	Urticaria					
PER DAY/ORAL						
			Lovastatin	C		
			Lithium Salt	C		
			Multivitamin	C		

Date:03/01/00ISR Number: 3554759-6Report Type:Periodic Company Report #A0105912A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Health	Bupropion			
	Herpes Simplex	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE						
	Lip Ulceration					
PER DAY/ORAL						
	Swelling					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/00ISR Number: 3468081-XReport Type:Expedited (15-DaCompany Report #A0112057A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Joint Swelling Pruritus Urticaria	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/02/00ISR Number: 3468093-6Report Type:Expedited (15-DaCompany Report #A0112807A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Sudden Death	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride) Fentanyl Celecoxib	PS C C		ORAL	150 MG / ORAL	4 DAY

Date:03/02/00ISR Number: 3468094-8Report Type:Expedited (15-DaCompany Report #A0112851A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation Dermatitis Pain Rash Erythematous	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE DAY / ORAL	

Date:03/06/00ISR Number: 3470357-7Report Type:Expedited (15-DaCompany Report #A0113407A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ecchymosis Epistaxis Skin Disorder Thrombocytopenia	Health Professional Company Representative	Wellbutrin Tablet -Controlled Release (Bupropion Hydrochloride)	PS		ORAL	UNK / SEE TEXT / ORAL	

Date:03/07/00ISR Number: 3471269-5Report Type:Expedited (15-DaCompany Report #A0113660A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Drug Interaction Feeling Hot Joint Swelling Rash Erythematous	Foreign Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Pseudoephedrine Hcl (Formulation Unknown) (Non-Us Product)	SS				
			Chlorpheniramine Maleate (Formulation Unknown) (Chlorpheniramine Maleate)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/00ISR Number: 3471367-6Report Type:Expedited (15-DaCompany Report #A0112576A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Failure Rash Vesicular Renal Failure	Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:03/07/00ISR Number: 3471517-1Report Type:Expedited (15-DaCompany Report #B0075853A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Chest Discomfort Dizziness Dry Mouth Herpes Simplex Hypertension Hyperventilation Insomnia Nausea Oral Intake Reduced Palpitations Tachycardia Tremor	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG / SEE TEXT / UNKNOWN	

Date:03/08/00ISR Number: 3471158-6Report Type:Direct Company Report #
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Dysphagia Dyspnoea Finger Deformity	Health Professional	Wellbutrin Sr 100 Mg	PS		ORAL	100MG PO QD	

	Influenza Like Illness Motor Dysfunction Nausea Paraesthesia					

Date:03/08/00ISR Number: 3472130-2Report Type:Expedited (15-DaCompany Report #A0110370A
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Speech Disorder	Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:03/08/00ISR Number: 3472139-9Report Type:Expedited (15-DaCompany Report #A0107781A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Drug Interaction	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Citalopram Hydrobromide					

			(Formulation Unknown) (Citalopram Hydrobromide)	SS			

Date:03/08/00ISR Number: 3472140-5Report Type:Expedited (15-DaCompany Report #A0107071A
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrophy Confusional State Convulsion	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER	DAY/ ORAL
	Delusion Disorientation Drug Interaction Hypersensitivity Joint Stiffness Miosis		Citalopram Hydrobromide (Formulation Unknown) (Citalopram Hydrobromide)	SS			20 MG/	UNKNOWN
	Nervous System Disorder Pupil Fixed Pupillary Reflex Impaired Sedation Sleep Disorder Urinary Tract Infection Visual Disturbance		Hormones Multivitamin	C C				

Date:03/09/00ISR Number: 3472617-2Report Type:Expedited (15-DaCompany Report #B0078241A
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypotension	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /	SINGLE DOSE /
			Captopril	C			ORAL	

Alprazolam C

Date:03/09/00ISR Number: 3472619-6Report Type:Expedited (15-DaCompany Report #A0114129A
Age:49 YR Gender:Female I/FU:I

Outcome	PT
Other	Arthralgia
	Asthenia
	Chest Pain
	Coordination Abnormal
	Cough
	Cyanosis
	Disorientation
	Dizziness
	Dyspepsia
	Fatigue
	Feeling Abnormal
	Feeling Cold
	Feeling Hot
	Feeling Jittery
	Headache
	Hearing Impaired
	Insomnia
	Neck Pain

	Oedema						
	Pallor						
	Paraesthesia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Parkinsonian Gait	Foreign	Zyban Tablet - Zyban				
	Pollakiuria	Health	(Bupropion				
	Sneezing	Professional	Hydrochloride)	PS		ORAL	150 MG/ TWICE
	Tinnitus						PER DAY /
	Tremor						ORAL
	Vertigo		Diuretic	C			
	Visual Acuity Reduced						

Date:03/09/00ISR Number: 3473462-4Report Type:Expedited (15-DaCompany Report #A0110477A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain	Consumer	Zyban	PS		ORAL	150 MG/ TWICE
Initial or Prolonged	Faecaloma						PER DAY/ ORAL

Date:03/09/00ISR Number: 3473464-8Report Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alopecia
Initial or Prolonged	Anuria
Disability	Anxiety
	Arrhythmia
	Supraventricular
	Asthenia
	Autonomic Nervous System
	Imbalance
	Bipolar Ii Disorder
	Blood Triglycerides
	Increased
	Bradycardia
	Chills
	Condition Aggravated

Convulsion
Depression
Disorientation
Dizziness
Drug Hypersensitivity
Dysarthria
Dyspnoea
Fatigue
Haematuria
Headache
Hyperglycaemia
Hyperhidrosis
Hypertension
Hyperventilation
Hypoaesthesia
Hypomania
Labile Blood Pressure
Localised Oedema
Memory Impairment
Mental Impairment
Micturition Urgency
Mitral Valve Incompetence
Muscle Rigidity

		Muscle Twitching					
		Musculoskeletal Stiffness					
		Nervousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Obsessive-Compulsive	Health	Zyban	PS		ORAL
150 MG/ PER							
		Disorder	Professional				
DAY/ ORAL							
		Oedema		Conjugated Estrogens	C		
		Palpitations		Vitamin	C		
		Panic Disorder Without		Aspirin	C		
		Agoraphobia		Melatonin	C		
		Paraesthesia					
		Renal Disorder					
		Renal Impairment					
		Sensation Of Pressure					
		Tachycardia					
		Tinnitus					
		Tongue Oedema					
		Transient Ischaemic					
		Attack					
		Tremor					
		Urethral Stricture					
		Urinary Incontinence					
		Ventricular Extrasystoles					
		Weight Increased					

Date:03/10/00ISR Number: 3474118-4Report Type:Periodic Company Report #8-99137-155A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Alopecia	Consumer	Lo/Ovral Tablet	PS		ORAL
1 TABLET 1X						
PER DAY, ORAL						
			Lithium	SS		ORAL
ORAL						
			Wellbutrin	SS		ORAL
ORAL						
			Lithium	C		
			Ritalin (Methylphenidate)	C		
			Wellbutrin (Bupropion)	C		

Date:03/10/00ISR Number: 3474219-0Report Type:Expedited (15-DaCompany Report #A007269
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angioneurotic Oedema Anorgasmia Face Oedema Libido Decreased Oedema Peripheral Pruritus Tongue Oedema Urticaria	Consumer	Zoloft Tablets Wellbutrin Ortho Tri-Cyclen	PS SS C	50.00 Mg Total:Daily:Oral	ORAL		

Date:03/10/00ISR Number: 3474517-0Report Type:Expedited (15-DaCompany Report #A007267
Age:18 YR Gender:Female I/FU:I

Outcome
Hospitalization - Initial or Prolonged Required

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Intervention to Prevent Permanent Impairment/Damage	Bone Marrow Depression Drug Interaction Infection In An Immunocompromised Host Leukopenia Varicella Vomiting	Health Professional Company Representative	Glucotrol Xl Extended Release Tablets Wellbutin Ritalin	PS SS SS		ORAL ORAL	5.00 MG TOTAL; DAILY;	

Date:03/13/00ISR Number: 3474992-1Report Type:Expedited (15-DaCompany Report #A0107071A
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Atrophy Coma Confusional State Convulsion Delusion Disorientation Drug Interaction Hypersensitivity Joint Stiffness Miosis Nervous System Disorder Pupil Fixed Sedation Urinary Tract Infection Visual Disturbance	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride) Citalopram Hydrobromide (Formulation Unknown) (Citalopram Hydrobromide) Hormones Multivitamin	PS SS C C		ORAL ORAL	150 MG/ PER DAY/ 20 MG	

Date:03/13/00ISR Number: 3474994-5Report Type:Expedited (15-DaCompany Report #A0068941A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation Conversion Disorder Dizziness Feeling Abnormal Hallucination, Auditory Nephrolithiasis Renal Colic Tremor Urinary Tract Infection Vomiting	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG ORAL	

Date:03/13/00ISR Number: 3475026-5Report Type:Expedited (15-DaCompany Report #A0109223A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Inflammation Pain In Extremity Pruritus Urticaria Vasculitis	Health Professional	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:03/14/00ISR Number: 3475615-8Report Type:Expedited (15-DaCompany Report #B0078436A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Tachycardia	Foreign	Zyban Tablet - Zyban					
	Stress	Health	(Bupropion					
		Professional	Hydrochloride)	PS		ORAL		
ORAL								
			Nicotine	C				

Date:03/14/00ISR Number: 3475623-7Report Type:Expedited (15-DaCompany Report #D0006860A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Surgery	Foreign	Zyban Tablet - Zyban					
	Influenza	Health	(Bupropion					
	Respiratory Disorder	Professional	Hydrochloride)	PS		ORAL		
ORAL								

Date:03/14/00ISR Number: 3475624-9Report Type:Expedited (15-DaCompany Report #A0114289A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glaucoma	Foreign	Zyban Tablet - Zyban					
		Consumer	(Bupropion					
			Hydrochloride)	PS		ORAL		
ORAL								

Date:03/14/00ISR Number: 3475628-6Report Type:Expedited (15-DaCompany Report #A0110705A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion	Foreign	Wellbutrin					
Initial or Prolonged	Sleep Disorder	Health	Tablet-Controlled					
Other		Professional	Release (Bupropion					
			Hydrochloride)	PS		ORAL		
150 MG /								

TWICE PER DAY

/ ORAL

Doxepin Hydrochloride	C
Herbal Medication	C
Thanol	C

Date:03/14/00ISR Number: 3475629-8Report Type:Expedited (15-DaCompany Report #A0107356A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chromaturia	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL	
	Drug Interaction							
	Haematuria							
	Haemorrhage		Warfarin Sodium (Formulation Unknoen) (Warfarin Sodium)	SS				
	International Normalised Ratio Increased							
	Prothrombin Time Prolonged							
	Pyrexia							
	Renal Colic							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/00ISR Number: 3476290-9Report Type:Direct Company Report #
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Zyban 150mg	PS			1T QD	

Date:03/15/00ISR Number: 3476417-9Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chills Erythema Joint Stiffness Joint Swelling Skin Disorder	Health Professional	Zyban Sr 150 Mg Tablet	PS				

Date:03/15/00ISR Number: 3476990-0Report Type:Periodic Company Report #19990600691
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue	Consumer	Toprol-Xl	PS		ORAL	100 MG QD PO	
	Nausea		Meridia	SS		ORAL	10 MG QD PO	
	Vision Blurred		Wellbutrin	SS		ORAL	100 MG BID PO	
			Ogen	C				

Date:03/16/00ISR Number: 3476537-9Report Type:Expedited (15-DaCompany Report #A0112851A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Required Intervention to	Arthralgia Burning Sensation Dyspnoea	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE	

Prevent Permanent Impairment/Damage	Face Oedema Pain Rash Erythematous Rash Macular					

Date:03/16/00ISR Number: 3477052-9Report Type:Expedited (15-DaCompany Report #A0111797A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arrhythmia Confusional State Dehydration	Study Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/ ORAL
	Depressed Level Of Consciousness Dizziness Dysarthria		Placebo Tablet (Placebo)	SS		ORAL	1 TABLET/ PER DAY/ ORAL
	Hypotension Myocardial Ischaemia Ventricular Tachycardia		Clopidogrel Bisulphate Atenolol Lisinopril Omeprazole Aspirin Atorvastatin Calcium Nitroglycerin	C C C C C C C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/00ISR Number: 3477054-2Report Type:Expedited (15-DaCompany Report #A0111148A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Required Intervention to Prevent Permanent Impairment/Damage	Amnesia Dysgraphia Gait Disturbance Muscle Rigidity Parkinson'S Disease Skin Disorder Speech Disorder	Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride) Trazodone Estratest Thyroxine Sodium Lisinopril Flunisolide Salbutamol Sulphate Clorazepate Dipotassium Salmeterol Xinafoate Nabumetone Ibuprofen	PS C C C C C C C C C C		ORAL	100 MG/	

Date:03/17/00ISR Number: 3477421-7Report Type:Expedited (15-DaCompany Report #A0114528A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Chest Discomfort Communication Disorder Jaw Disorder Nausea Respiratory Distress Tongue Disorder Tongue Oedema Tremor	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride) Ethanol (Formulation Unknown) (Alcohol)	PS SS		ORAL	150 MG / PER DAY / ORAL	

Date:03/20/00ISR Number: 3477570-3Report Type:Expedited (15-DaCompany Report #A0107356A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills Chromaturia Drug Interaction Ear Haemorrhage Haematuria Haemorrhage International Normalised Ratio Increased Prothrombin Time Prolonged Pyrexia Renal Colic	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Warfarin Sodium (Formulation Unknown)(Warfarin Sodium)	PS SS		ORAL ORAL	150 MG / UNK 10 MG / UNK /	

Date:03/21/00ISR Number: 3477185-7Report Type:Direct Company Report #
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder Difficulty In Walking Diplopia Sleep Disorder		Zyban Sr 150mg Glaxo Wellcome	PS	Glaxowellcome	ORAL	150MG ONE A DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/00ISR Number: 3477736-2Report Type:Direct Company Report #
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS			150MG/D	
			Zyban	SS			150 MG/D.	

Date:03/22/00ISR Number: 3478723-0Report Type:Expedited (15-DaCompany Report #A0114289A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Glaucoma	Foreign Consumer	Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:03/22/00ISR Number: 3478777-1Report Type:Expedited (15-DaCompany Report #A0115400A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ecchymosis Eyelid Oedema Joint Swelling Pharyngeal Oedema Rash Generalised Swelling Urticaria Vaginal Haemorrhage	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:03/23/00ISR Number: 3479269-6Report Type:Expedited (15-DaCompany Report #A0115630A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Dermatitis Bullous Eczema Nervousness Rash Erythematous Rash Generalised Rash Macular Rash Papular Toxic Epidermal Necrolysis	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Lisinopril Hydrochlorothiazide	PS C C		ORAL	150 MG/ TWICE PER DAY/	

Date:03/24/00ISR Number: 3479745-6Report Type:Expedited (15-DaCompany Report #044-0991-980010
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angioneurotic Oedema Dyspnoea Face Oedema Pharyngeal Oedema Speech Disorder Tachycardia	Foreign Health Professional	Rezulin (Troglitazone) Zyban (Bupropion Hydrochloride) Amaryl (Glimepiride) Cardizem (Diltiazem Hydrochloride) Compazine (Prochlorperazine Edisylate)	PS SS C C C		ORAL ORAL	PER ORAL 300 MG, DAILY, PER ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3480099-XReport Type:Expedited (15-DaCompany Report #A0109179A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Pain Drug Interaction	Health Professional Company Representative	Bupropion Hydrochloride Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG/VARIABLE DOSE/ORAL
			Pemoline Unspecified Tablet (Pemoline)	SS		ORAL	ORAL
			Methylphenidate Hc1 Tablet	SS		ORAL	5 MG TWICE PER DAY ORAL

Date:03/24/00ISR Number: 3480102-7Report Type:Expedited (15-DaCompany Report #A0114679A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Convulsion Drug Interaction Feeling Jittery Fungal Infection Pain Pneumonia Tremor	Foreign	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL
			Venlafaxine Hydrochloride (Venlafaxine Hydrochloride)	SS		ORAL	300 MG/FOUR TIMES PER DAY ORAL

	Fluconazole (Fluconazole)	SS	ORAL

300 MG/PER

DAY/ORAL

	Cyclophosphamide	C
	Fluorouracil	C
	Methotrexate	C

Date:03/27/00ISR Number: 3480380-4Report Type:Expedited (15-DaCompany Report #A0114129A
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Disability	Arthralgia
Other	Asthenia
	Chest Pain
	Coordination Abnormal
	Cough
	Disorientation
	Dizziness
	Dyspepsia
	Fatigue
	Feeling Abnormal
	Feeling Cold
	Feeling Hot
	Feeling Jittery
	Headache
	Hearing Impaired
	Insomnia
	Oedema

	Pallor Palpitations Paraesthesia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Parkinsonian Gait Pollakiuria Skin Discolouration	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL
	Sneezing Tinnitus Visual Acuity Reduced		Diuretic	C			

Date:03/28/00ISR Number: 3480292-6Report Type:Direct Company Report #
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hepatitis Hepatitis Cholestatic Hepatocellular Damage Liver Function Test Abnormal	Health Professional	Wellbutrin 75mg Bid Ritalin 20mg Allergy Injection Alburteral Vancenase Ibuprofen 600mg	PS C C C C C			ONE TWICE DAILY

Date:03/28/00ISR Number: 3481187-4Report Type:Expedited (15-DaCompany Report #A0115676A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dizziness Dysphagia Dyspnoea Finger Deformity Influenza Like Illness Nausea Paraesthesia Retching	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Nefazodone Hydrochloride	PS C		ORAL	100 MG/ PER DAY/ ORAL

Date:03/28/00ISR Number: 3481191-6Report Type:Expedited (15-DaCompany Report #A0109223A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Akinesia Angiopathy Arthralgia Inflammation Leukocytoclastic Vasculitis Pharyngolaryngeal Pain Pruritus Purpura Rheumatoid Arthritis Sneezing Urticaria	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/00ISR Number: 3481311-3Report Type:Direct Company Report #
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Zyban 150 Mg	PS			150 BID	
	Urticaria		Caladryl	C				

Date:03/30/00ISR Number: 3482141-9Report Type:Expedited (15-DaCompany Report #A0112392A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Foreign	Zyban Tablet - Zyban					
Required	Burning Sensation	Health	(Bupropion					
Intervention to	Complement Factor	Professional	Hydrochloride)	PS		ORAL	150 MG/ TWICE	
Prevent Permanent	Increased						PER DAY/ ORAL	
Impairment/Damage	Decreased Activity		Mometasone Furoate	C				
	Dermatitis							
	Difficulty In Walking							
	Discomfort							
	Dysphagia							
	Erythema							
	Eyelid Oedema							
	Face Oedema							
	Fatigue							
	Feeling Cold							
	Insomnia							
	Obstruction							
	Oedema							
	Pain							
	Peripheral Coldness							
	Pharyngolaryngeal Pain							
	Rash Pruritic							
	Skin Discolouration							
	Type Iv Hypersensitivity							
	Reaction							
	Urticaria							
	Vasculitis							

Date:03/30/00ISR Number: 3482223-1Report Type:Expedited (15-DaCompany Report #A0115400A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ecchymosis Eyelid Oedema Joint Swelling Pharyngeal Oedema Rash Generalised Urticaria Vaginal Haemorrhage	Foreign Health Professional	Zyban Tablet -Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:03/31/00ISR Number: 3482200-0Report Type:Direct Company Report #
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Welbutrin Sr 150mg	PS		ORAL	ONE TABLET 2 TIMES ORAL	
			Dilantin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/00ISR Number: 3482801-XReport Type:Expedited (15-DaCompany Report #A0115944A
Age:8 MON Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Medication Error Toxicologic Test Abnormal	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/	ORAL

Date:03/31/00ISR Number: 3483217-2Report Type:Periodic Company Report #A002002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diabetes Mellitus	Consumer	Cardura	PS		ORAL	ORAL	
			Pravachol	SS				
			Lamisil	SS		ORAL	ORAL	
			Wellbutrin	SS				

Date:04/03/00ISR Number: 3483994-0Report Type:Expedited (15-DaCompany Report #B0079458A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Drug Interaction	Foreign Health Professional Other	Zyban (Bupropion Hydrochloride)	PS			150 MG/	ORAL
			Thyroxine (Levothyroxine Sodium)	SS				

Date:04/03/00ISR Number: 3483997-6Report Type:Expedited (15-DaCompany Report #A0115984A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiopathy Blood Potassium Decreased	Consumer	Zyban Tablet - Zyban (Bupropion					

	Dermatitis		Hydrochloride)	PS		ORAL 150 MG TWICE
	Diarrhoea					PER DAY ORAL
	Drug Interaction		Cisapride			
	Dyspnoea		(Formulation			
	Eyelid Oedema		Unknown) (Cisapride)	SS		
	Headache					
	Oedema					
	Pharyngeal Oedema					
	Pyrexia					

Date:04/03/00ISR Number: 3484034-XReport Type:Expedited (15-DaCompany Report #A0116641A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Circulatory Collapse	Foreign	Zyban	PS		ORAL	150 MG /
	Myocardial Infarction	Consumer					TWICE PER DAY / ORAL

Date:04/05/00ISR Number: 3484446-4Report Type:Expedited (15-DaCompany Report #00P-163-0087711-00(0)
Age:29 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Aggression
	Coma

	Confusional State Depression Drug Interaction	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Drug Level Below Therapeutic	Health Professional	Depakote (Depakote) (Divalproex Sodium)	PS		ORAL 1000 MG, 1 IN
	Dyspnoea					1 D, PER ORAL
	Ecchymosis Fatigue		Amfebutamone (Amfebutamone)	SS		ORAL 150 MG, 1 IN
	Folliculitis					1 D, PER ORAL
	Headache Hypotension Influenza Like Illness		Amantadine (Amantadine) (Amantadine)	SS		ORAL PER ORAL
	Movement Disorder Muscle Rigidity Nausea Oxygen Saturation Decreased Pallor Pupillary Reflex Impaired Respiratory Rate Decreased Speech Disorder Tachycardia Tremor		Tetracycline Hydrochloride (Tetracycline Hydrochloride) Skin Discoloration Pupillary Reflex Impaired Ecchymosis Lab Test Abnormality Hostility Confusion Headache Personality Disorder	C C C C C C C C		

Date:04/06/00ISR Number: 3485009-7Report Type:Expedited (15-DaCompany Report #A0111455A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Chest Pain	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL ORAL
	Myocarditis		Cannabis Mushrooms	C C		

Date:04/07/00ISR Number: 3485172-8Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Bupropion	PS		ORAL	ORAL	

Date:04/07/00ISR Number: 3485505-2Report Type:Expedited (15-DaCompany Report #A0116863A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health Professional Company Representative	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/07/00ISR Number: 3485508-8Report Type:Expedited (15-DaCompany Report #A0116939A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased Dermatitis Urticaria	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:04/07/00ISR Number: 3485511-8Report Type:Expedited (15-DaCompany Report #A0116472A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated Dizziness Meniere'S Disease Nausea Syncope Vomiting	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:04/07/00ISR Number: 3485815-9Report Type:Expedited (15-DaCompany Report #A0116999A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Change Of Bowel Habit Condition Aggravated Muscle Spasms	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:04/10/00ISR Number: 3486408-XReport Type:Expedited (15-DaCompany Report #A0116641A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Zyban Tablet - Zyban					
	Coronary Ostial Stenosis	Health	(Bupropion					
	Myocardial Infarction	Professional	Hydrochloride)	PS		ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	

Date:04/11/00ISR Number: 3486449-2Report Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis		Buproprion	PS				
9 DAYS PRIOR								
Initial or Prolonged	Hypersensitivity							
TO EVENT								
Required	Pruritus							
Intervention to	Throat Tightness							
Prevent Permanent								
Impairment/Damage								

Date:04/11/00ISR Number: 3487016-7Report Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT
Agitation
Anaphylactic Shock
Anxiety
Autonomic Nervous System Imbalance
Back Pain
Bipolar Disorder
Blood Pressure Fluctuation
Bradycardia
Chills
Condition Aggravated
Convulsion
Delusion
Depersonalisation
Disorientation
Disturbance In Attention
Dizziness
Drug Hypersensitivity
Dysarthria
Dyspnoea
Fatigue
Haematuria
Hallucination, Auditory
Hallucination, Olfactory
Hyperglycaemia
Hyperhidrosis
Hypertension
Hyperventilation
Hypoaesthesia
Localised Oedema
Logorrhoea
Mania
Mental Impairment
Mitral Valve Incompetence
Mood Swings
Muscle Twitching
Muscular Weakness
Musculoskeletal Stiffness
Nervous System Disorder
Nervousness
Palpitations
Panic Disorder
Paraesthesia

Paranoia
Psychomotor Hyperactivity
Renal Disorder
Renal Impairment
Schizophrenia
Supraventricular
Extrasystoles
Tachycardia
Throat Tightness
Tinnitus
Tongue Disorder
Tongue Oedema
Transient Ischaemic
Attack

		Urethral Stricture Urinary Incontinence Ventricular Extrasystoles	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Increased	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/ PER DAY/ ORAL							
				Conjugated Estrogens	C		
				Vitamin	C		
				Aspirin	C		
				Melatonin	C		

Date:04/12/00ISR Number: 3487652-8Report Type:Expedited (15-DaCompany Report #A0102058A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Blood Pressure	Study	Zyban	PS		ORAL
150 MG/ PER DAY/ ORAL						
Hospitalization - Initial or Prolonged	Fluctuation	Health				
	Blood Pressure Increased	Professional	Me-Prednisolone Na Succ.	C		
Required Intervention to Prevent Permanent Impairment/Damage	Chest Pain		Theophylline	C		
	Condition Aggravated		Diltiazem	C		
	Confusional State		Lisinopril	C		
	Depressed Level Of Consciousness		Salbutamol Sulphate	C		
	Hypertensive Encephalopathy		Ipratropium Bromide	C		
	Speech Disorder		Procainamide Hcl	C		
	Vision Blurred		Aspirin	C		
			Isosorbide Dinitrate	C		
			Metoprolol Tartrate	C		
			Vitamin E	C		
			Clopidogrel Bisulphate	C		

Date:04/13/00ISR Number: 3488063-1Report Type:Expedited (15-DaCompany Report #A0073901A
Age:29 YR Gender:Female I/FU:F

Outcome	PT

Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Arthralgia
Disability	Decreased Activity
Other	Decreased Appetite
Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis
	Difficulty In Walking
	Dyspnoea Exertional
	Erythema
	Erythema Multiforme
	Eyelid Oedema
	Face Oedema
	Fall
	Fatigue
	Feeling Cold
	Fibromyalgia
	Food Intolerance
	Insomnia
	Joint Stiffness
	Leukocytosis
	Migraine
	Mouth Ulceration
	Pain

		Periorbital Oedema Proteinuria Pruritus Serum Sickness Stevens-Johnson Syndrome Throat Tightness Urticaria Vomiting	Report Source Health Professional Company Representative	Product Wellbutrin Tablet - Controlled Release (Bupropion Hydrochloride)	Role PS	Manufacturer	Route ORAL
Dose 150 MG / TWICE PER DAY / ORAL	Duration						

Date:04/14/00ISR Number: 3488692-5Report Type:Expedited (15-DaCompany Report #10349645
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Pancreatitis Sedation	Health Professional	Serzone Tabs (Nefazodone Hcl)	PS		ORAL
Dose 300 MILLIGRAM, ORAL	Duration					
			Wellbutrin (Bupropion Hcl)	SS		
75 MILLIGRAM						

Date:04/17/00ISR Number: 3488881-XReport Type:Expedited (15-DaCompany Report #A0112807A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Death	Myocardial Infarction Sudden Death	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
Dose 150 MG / UNK / ORAL	Duration 4 WK					
			Fentanyl	C		
			Celecoxib	C		

Date:04/17/00ISR Number: 3488942-5Report Type:Expedited (15-DaCompany Report #A0117477A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Macular Degeneration Retinal Haemorrhage	Health Professional	Bupropion Hydrochloride Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	SEE TEXT/ORAL	YR

Date:04/17/00ISR Number: 3488945-0Report Type:Expedited (15-DaCompany Report #A0116737A
Age:29 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Aggression Coma Confusional State Depression Ecchymosis Fall Fatigue Folliculitis Grand Mal Convulsion Head Injury Headache

		Heart Rate Increased Influenza Like Illness Movement Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscle Rigidity Nausea Oxygen Saturation Decreased Pallor	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
150 MG /SEE TEXT/	ORAL						
		Pupillary Reflex Impaired Respiratory Rate Decreased Speech Disorder		Amantadine (Formulation Unknown) (Amantadine)	SS		
TWICE PER DAY							
		Tremor		Semisodium Valproate	C		

Date:04/17/00ISR Number: 3489012-2Report Type:Expedited (15-DaCompany Report #A0115993A
Age:69 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Amblyopia	Foreign	Zyban Tablet	PS		ORAL
ORAL							
		Brain Neoplasm	Health Professional				

Date:04/17/00ISR Number: 3489024-9Report Type:Expedited (15-DaCompany Report #A0112392A
Age:39 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Required Intervention to Prevent Permanent Impairment/Damage		Abdominal Pain Arthralgia Burning Sensation Decreased Activity Dermatitis Difficulty In Walking Dysphagia Eyelid Oedema	Foreign Health Professional	Zyban Mometasone Furoate	PS C		ORAL
150 MG/ TWICE PER DAY/	ORAL						

Face Oedema
Fatigue
Feeling Cold
Insomnia
Oedema Peripheral
Pain
Pharyngolaryngeal Pain
Pruritus
Rash Erythematous
Rash Pruritic
Raynaud'S Phenomenon
Sensation Of Heaviness
Skin Discolouration
Type Iv Hypersensitivity
Reaction
Urticaria
Vasculitic Rash
Vasculitis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/17/00ISR Number: 3489029-8Report Type:Expedited (15-DaCompany Report #A0110688A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pneumonia	Health	Wellbutrin					
Hospitalization - Initial or Prolonged	Renal Failure	Professional	Tablet-Controlled					
	Wegener'S Granulomatosis	Company	Release (Bupropion					
		Representative	Hydrochloride)	PS		ORAL	150 MG/ THREE	
							TIMES PER	
							DAY/ ORAL	
			Olanzapine	C				
			Alprazolam	C				

Date:04/18/00ISR Number: 3489624-6Report Type:Direct Company Report #
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delusion	Health	Wellbutrin	PS		ORAL	150 PO BID	
	Dizziness	Professional	Premarin	C				
	Dyspnoea							
	Hyperventilation							
	Hypoaesthesia							
	Nausea							
	Paraesthesia							

Date:04/18/00ISR Number: 3489728-8Report Type:Expedited (15-DaCompany Report #A0113640A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Collapse Of Lung	Consumer	Wellbutrin					
	Emphysema		(Bupropion					
	Lung Injury		Hydrochloride)	PS		ORAL	150 MG/ PER	
	Tobacco Abuse						DAY/ ORAL	
	Weight Increased		Sumatriptan					

			Succinate	C		

Date:04/18/00ISR Number: 3489729-XReport Type:Expedited (15-DaCompany Report #A0110912A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Hypersensitivity Hypotension Pruritus Respiratory Arrest Swelling Syncope Urticaria	Consumer	Zyban	PS		ORAL		

Date:04/18/00ISR Number: 3489734-3Report Type:Expedited (15-DaCompany Report #A0106978A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Health	Wellbutrin	PS		ORAL	100 MG/ THREE	
	Oedema	Professional					TIMES PER	
							DAY/ ORAL	
			Carbamazepine Tablet (Carbamazepine)	SS		ORAL	200 MG/ THREE	

TIMES PER DAY/ ORAL			Oestradiol	C			

Date:04/18/00ISR Number: 3489897-XReport Type:Expedited (15-DaCompany Report #A0117782A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Creatinine Renal Clearance Decreased Multiple Sclerosis Renal Failure Acute	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG / TWICE PER DAY / ORAL
			Olanzapine	C			
			Semisodium Valproate	C			

Date:04/19/00ISR Number: 3490241-2Report Type:Expedited (15-DaCompany Report #A0116939A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Dermatitis Dysphagia Dyspnoea Face Oedema Liver Function Test Abnormal Mean Cell Haemoglobin Concentration Increased Tongue Oedema Urticaria	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:04/19/00ISR Number: 3490242-4Report Type:Expedited (15-DaCompany Report #A0108087A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Asthenia Decreased Appetite Dizziness Postural Dysphemia Electroencephalogram Abnormal Feeling Jittery Grand Mal Convulsion Hypersomnia Irritability Loss Of Consciousness Memory Impairment Sedation Tremor Vomiting	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/00ISR Number: 3490257-6Report Type:Expedited (15-DaCompany Report #A0117821A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adrenal Disorder Amnesia Anaphylactic Shock Gastrointestinal Disorder Panic Attack Tremor	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL	

Date:04/19/00ISR Number: 3490272-2Report Type:Direct Company Report #
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Balance Disorder Medication Error Vision Blurred		Wellbutrin Sr 150 Mg	PS		ORAL	300 MG BID PO, APPROX. 2 WEEKS	

Date:04/19/00ISR Number: 3490919-0Report Type:Expedited (15-DaCompany Report #JRFUSA2000000083
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Accidental Overdose Alcohol Poisoning Cardiomegaly Coma Drug Level Above Therapeutic	Consumer Health Professional	Duragesic (Patch) (Fentanyl) Nortriptyline	PS		TRANSDERMAL	50 MCH/H, 1 IN 72 HOUR(S), TRANSD	

	Medication Error	(Nortriptyline)	SS	ORAL
ORAL				
		Alprazolam (Alprazolam)	SS	ORAL
ORAL				
		Hydrocodone (Hydrocodone)	SS	ORAL
PRN, ORAL				
		Wellbutrin (Amfebutamone Hydrochloride)	SS	ORAL
ORAL				
		Alcohol (Ethanol)	SS	ORAL
ORAL				
		Stimulants (Psychostimulants And Nootropics)	SS	
		Diazepam (Diazepam)	SS	
		Chlordiazepoxide (Chlordiazepoxide)	SS	

Date:04/20/00ISR Number: 3490806-8Report Type:Expedited (15-DaCompany Report #A0112668A
Age:26 YR Gender:Female I/FU:I

Outcome	PT
Required	Complex Partial Seizures
Intervention to	Confusional State
Prevent Permanent	Convulsion
Impairment/Damage	Disorientation
	Dizziness
	Grand Mal Convulsion
	Headache
	Hyperhidrosis
	Hypoglycaemia

	Hypokalaemia Migraine Nausea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nervousness Panic Attack Visual Acuity Reduced Transiently	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Tri-Levlen	C			

Date:04/21/00ISR Number: 3491038-XReport Type:Expedited (15-DaCompany Report #B0080118A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arrhythmia Atrial Flutter Cardiogenic Shock Cardiovascular Disorder Respiratory Failure	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	1 TABLET / TWICE PER DAY/ ORAL

Date:04/21/00ISR Number: 3491041-XReport Type:Expedited (15-DaCompany Report #A0117940A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia Bronchospasm Burning Sensation Chest Pain Dizziness	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY/ ORAL
	Dyspnoea Eyelid Oedema		Carisoprodol Diazepam	C C			

	Hypersensitivity					
	Irritability					
	Palpitations					
	Pruritus					
	Swelling					
	Toxic Shock Syndrome					
	Urticaria					

Date:04/21/00ISR Number: 3491920-3Report Type:Expedited (15-DaCompany Report #A0118416A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ageusia Anosmia Face Oedema Hypoaesthesia Pharyngeal Oedema Pyrexia Rash Erythematous Rash Pruritic	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/24/00ISR Number: 3491515-1Report Type:Expedited (15-DaCompany Report #JRFUSA2000000083
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Consumer	Duragesic (Patch)					
Hospitalization -	Alcohol Poisoning	Health	(Fentanyl)	PS		TRANSDERMAL	50 MCG/H, 1	
Initial or Prolonged	Coma	Professional						IN 72
	Drug Level Above							HOUR(S),
	Therapeutic							TRANSD/200
	Medication Error							MCG/H
			Nortriptyline (Nortriptyline)	SS		ORAL		ORAL
			Alprazolam (Alprazolam)	SS		ORAL		ORAL
			Hydrocodone (Hydrocodone)	SS		ORAL		PRN, ORAL
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL		ORAL
			Alcohol (Alcohol)	SS		ORAL		ORAL
			Diazepam (Diazepam)	SS				
			Chlordiazepoxide (Chlordiazepoxide)	SS				
			Phenylpropanolamine (Phenylpropanolamine)	SS				
			Ephedrine (Ephedrine)	SS				
			Pseudoephedrine (Pseudoephedrine)	SS				

Date:04/24/00ISR Number: 3491575-8Report Type:Expedited (15-DaCompany Report #A0118209A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemolysis Hyperkalaemia	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / ORAL	
			Nicotine	C				

Date:04/24/00ISR Number: 3491924-0Report Type:Expedited (15-DaCompany Report #B0079430A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Drug Interaction International Normalised Ratio Decreased Prothrombin Time Prolonged	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG SEE TEXT ORAL	
			Warfarin Sodium	C				
			Moduretic	C				
			Simvastatin	C				
			Paroxetine	C				
			Zolpidem	C				
			Alprazolam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/00ISR Number: 3493637-8Report Type:Direct Company Report #
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aplastic Anaemia		Paxil 40mg 4yrs	PS		ORAL	40 MG 4 YRS	4 YR
	Chills		Wellbutrin	SS		ORAL	UNKNOWN	2 DAY
	Dermatitis		Anthrax Vaccine	C				
	Fatigue							
	Malaise							
	Menorrhagia							
	Petechiae							
	Pyrexia							

Date:04/27/00ISR Number: 3493939-5Report Type:Expedited (15-DaCompany Report #HQ4412325APR2000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health	Effexor	PS		ORAL	37.5 MG 1X	
	Grand Mal Convulsion	Professional					PER 1 DAY,	
							ORAL	
			Wellbutrin	SS		ORAL	350 MG 1X PER	
							1 DAY, ORAL	

Date:04/28/00ISR Number: 3494455-7Report Type:Expedited (15-DaCompany Report #A0117771A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Literature	Bupropion Hydrochloride Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
	Confusional State	Health Professional						
	Coordination Abnormal							
	Dizziness							
	Drug Interaction							

	Gait Disturbance		Amantadine				
	Neurotoxicity		(Formulation				
	Restlessness		Unknown)				
	Tremor		(Amantadine)	SS			
	Vertigo						

Date:04/28/00ISR Number: 3494456-9Report Type:Expedited (15-DaCompany Report #A0117770A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Literature	Bupropion					
	Confusional State	Health	Hydrochloride					
	Coordination Abnormal	Professional	Unspecified Tablet					
	Dizziness		(Bupropion					
	Drug Interaction		Hydrochloride)	PS		ORAL	ORAL	
	Gait Disturbance		Amantadine					
	Neurotoxicity		(Formulation					
	Restlessness		Unknown)					
	Tremor		(Amantadine)	SS				
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/00ISR Number: 3494992-5Report Type:Expedited (15-DaCompany Report #B0079458A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Palpitations	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150	MG/UNK/ORAL
			Thyroxine Sodium Tablet (Levothyroxine Sodium)	SS		ORAL	.1	MG/UNKNOWN/OR AL

Date:05/01/00ISR Number: 3495043-9Report Type:Expedited (15-DaCompany Report #A0110705A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Grand Mal Convulsion Insomnia	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	1509 MG/	TWICE PER DAY / ORAL
			Doxepin Hydrochloride	C				
			Herbal Medication	C				
			Ethanol	C				

Date:05/01/00ISR Number: 3495117-2Report Type:Expedited (15-DaCompany Report #A0110103A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Colitis Ischaemic Rectal Haemorrhage Syncope	Study Health Professional	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /TWICE PER DAY/ ORAL
			Oral Contraceptive Tablet (Oral Contraceptive)	SS		ORAL	150 MF /TWICE PER DAY/ ORAL
			Quinapril Hydrochloride	SS		ORAL	ORAL

Date:05/01/00ISR Number: 3495119-6Report Type:Expedited (15-DaCompany Report #A0104240A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Aggression Child Abuse Mania Suicidal Ideation	Study Health Professional	Wellbutrin	PS		ORAL	400 MG /PER DAY/ ORAL
			Paracetamol	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/00ISR Number: 3495122-6Report Type:Expedited (15-DaCompany Report #A0113640A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Collapse Of Lung Condition Aggravated Emphysema Lung Injury Smoker Weight Increased	Consumer	Wellbutrin Tablet-Controlled Release Sumatriptan Succinate Vicodin Cortisone Procaine Hydrochloride	PS C C C C		ORAL	150 MG /PER DAY/	

Date:05/01/00ISR Number: 3495142-1Report Type:Expedited (15-DaCompany Report #A0117127A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Arthralgia Escherichia Infection Joint Swelling Livedo Reticularis Myalgia Pruritus Pyrexia Serum Sickness Urinary Tract Infection Urticaria White Blood Cell Count Increased	Foreign Literature Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Oral Contraceptive	PS C		ORAL	150 MG SEE TEXT	ORAL 13 DAY

Date:05/01/00ISR Number: 3495164-0Report Type:Expedited (15-DaCompany Report #B0079430A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Drug Interaction International Normalised Ratio Decreased Prothrombin Time Prolonged	Foreign Health Professional	Bupropion Hydrochloride Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG	SEE TEXT
			Warfarin Sodium (Formulation Unknown) (Warfarin Sodium)	SS		ORAL	6.25 MG	PER DAY
			Moduretic	C				
			Simvastatin	C				
			Paroxetine	C				
			Zolpidem	C				
			Alprazolam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/00ISR Number: 3496404-4Report Type:Periodic Company Report #PRIUSA1999006408
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Grand Mal Convulsion	Health Professional	Ultram (50 Mg Tablet) (Tramadol Hydrochloride)	PS		ORAL	150 MG, 2 IN	1 DAILY, ORAL
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL		
			Venlafaxine Hydrochloride (Venlafaxine Hydrochloride)	C				

Date:05/02/00ISR Number: 3495398-5Report Type:Direct Company Report #
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Arthropathy Conjunctivitis Dermatitis Erythema Multiforme Myalgia Serum Sickness Urticaria		Bupropion-Wellbutrin 100mg	PS		ORAL	100MG BID	ORAL
			Adderall	C				
			Dexedrine	C				

Date:05/03/00ISR Number: 3495646-1Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Arthritis		Wellbutrin	PS				
			Adderall	C				

	Dyspnoea		Ritalin	C		
	Erythema Multiforme					
	Laryngeal Oedema					
	Swelling					
	Urticaria					

Date:05/03/00ISR Number: 3495834-4Report Type:Direct Company Report #
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Convulsion	Health	Bupropion			
	Dyskinesia	Professional	(Wellbutrin Sr)	PS		ORAL
150 MG BID PO						
	Hypoglycaemia		Human Insulin			
			(Humalog)	SS		
SUBCUTANEOUS HUMALOG 75U						
SQ						
			Human Insulin			
			(Humulin U)	SS		
SUBCUTANEOUS HUMALIN U 40						
U SQ						
			Prevacid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/00ISR Number: 3496212-4Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Health	Wellbutrin	PS			150 MG BID	1 WK
	Eye Rolling	Professional	Levaquin	C				
	Grand Mal Convulsion		Colace	C				
	Lethargy		Xanax	C				
			Toradol	C				
			Demerol	C				
			Zoloft	C				
			Bellergal	C				
			Depakote	C				
			Serzone	C				

Date:05/03/00ISR Number: 3496527-XReport Type:Expedited (15-DaCompany Report #A0116863A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Required Intervention to Prevent Permanent Impairment/Damage	Completed Suicide	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY/	ORAL
			Ethanol (Formulation Unknown) (Alcohol)	SS				
			Aspirin (Formulation Unknown) (Aspirin)	SS				

Date:05/05/00ISR Number: 3497095-9Report Type:Expedited (15-DaCompany Report #A0114122A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Health	Wellbutrin					
	Blepharospasm	Professional	Tablet-Controlled					

Disability Required Intervention to Prevent Permanent Impairment/Damage	Dystonia Oculogyration Trismus		Release (Bupropion Hydrochloride)	PS		ORAL 150 MG / TWICE PER DAY / ORAL
			Semisodium Valproate	C		

Date:05/05/00ISR Number: 3497096-0Report Type:Expedited (15-DaCompany Report #A0119185A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Decreased Activity Multiple Sclerosis	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL 150 MG / UNK / ORAL
			Prednisone	C		

Date:05/05/00ISR Number: 3497302-2Report Type:Expedited (15-DaCompany Report #A0110940A
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Death	Alcohol Poisoning Completed Suicide

		Injury					
		Toxicologic Test Abnormal					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/ORAL							

Date:05/05/00ISR Number: 3497883-9Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Rash Papular	Health	Zyban	PS		ORAL
PO 1 QD X 3						
	Rash Pruritic	Professional				
THEN 2 QD						

Date:05/08/00ISR Number: 3497771-8Report Type:Expedited (15-DaCompany Report #WAES 00032541
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Dizziness	Health				
MG/DAILY/PO						
	Dysphagia	Professional	Wellbutrin Sr 150 Mg	SS		ORAL
150 MG/BID/PO						
	Pharyngeal Oedema					
	Pharyngitis					
	Pyrexia					
	Urticaria					

Date:05/08/00ISR Number: 3498215-2Report Type:Expedited (15-DaCompany Report #9915007
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Required	Anxiety	Consumer	Marax Tablets	PS	ORAL
ORAL					
Intervention to	Depression	Health	Wellbutin	SS	
Prevent Permanent	Depression Suicidal	Professional	Azmacort	C	
Impairment/Damage	Drug Ineffective		Ventolin	C	
	Gastric Disorder		Vancenase	C	
	Hypertension		Potassium	C	
	Irritable Bowel Syndrome		Prilosec	C	
	Suicidal Ideation		Tagamet Hb	C	
	Weight Decreased				

Date:05/08/00ISR Number: 3498277-2Report Type:Expedited (15-DaCompany Report #A0117940A
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Blister
	Bronchospasm
	Burning Sensation
	Chest Pain
	Dizziness
	Drug Hypersensitivity
	Dyspnoea
	Eye Irritation
	Eyelid Oedema
	Haemorrhage
	Irritability
	Palpitations

	Pruritus Sunburn Swelling	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Toxic Shock Syndrome Urticaria	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Carisoprodol	C			
			Diazepam	C			

Date:05/08/00ISR Number: 3498279-6Report Type:Expedited (15-DaCompany Report #A0119044A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Congenital Anomaly	Abortion Induced Anal Atresia Calcinosis Cleft Palate	Study Health Professional	Bupropion Hydrochloride Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL
	Complications Of Maternal Exposure To Therapeutic Drugs Mesomelia Multiple Congenital Abnormalities Pierre Robin Syndrome		Influenza Vaccine	C			

Date:05/09/00ISR Number: 3497779-2Report Type:Direct Company Report #
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome		Wellbuterin 300mg	PS		ORAL	300MG TWICE DAY ORAL
			Vitamin B				

			Supplements	C			

Date:05/10/00ISR Number: 3498196-1Report Type:Direct Company Report #
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia Pharyngeal Oedema Urticaria	Health Professional	Bupropion Sr (Zyban)	PS		ORAL	150 MG PO BID

Date:05/10/00ISR Number: 3504424-6Report Type:Periodic Company Report #990926.01
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cough	Health Professional	Indapamide	PS	Mylan Pharmaceuticals Inc	ORAL	2.5MG QD, ORAL
			Allopurinol 300mg	SS			
			Beconase Glaxo Wellcome	SS		ORAL	2 PUFFS UD, ORAL
			Cozaar 50mg Merck	SS	Merck	ORAL	50MG QD, ORAL
			Glucophage Bristol				

	Myers Squibb	SS	Bristol Myers Squibb	ORAL	1 GRAM TID, ORAL
	Lipitor 10mg Parke-Davis	SS	Parke-Davis	ORAL	10MG QD, ORAL
	Rezulin Parke-Davis	SS	Parke-Davis	ORAL	200MG BID, ORAL
	Trental 400mg Hoechst Marion Roussel	SS	Hoechst Marion Roussel	ORAL	400MG TID, ORAL
	Wellbutrin 150mg Glaxo Wellcome	SS	Glaxo Wellcome	ORAL	150MG QD, ORAL
	Glipizide 10mg	SS		ORAL	10MG BID, ORAL
	Quinine 325mg	SS		ORAL	325MG TID, ORAL

Date:05/12/00ISR Number: 3499875-2Report Type:Expedited (15-DaCompany Report #A0117940A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia Bronchospasm Burning Sensation	Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL
	Chest Pain Dermatitis Dizziness Dyspnoea		Carisoprodol Diazepam	C C			

	Dyspnoea Exertional					
	Erythema					
	Eye Irritation					
	Eyelid Oedema					
	Hypersensitivity					
	Irritability					
	Palpitations					
	Periorbital Oedema					
	Photosensitivity Reaction					
	Pruritus					
	Swelling					
	Toxic Shock Syndrome					
	Urticaria					

Date:05/12/00ISR Number: 3499878-8Report Type:Expedited (15-DaCompany Report #A0112039A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Loss Of Consciousness Memory Impairment Pain Syncope Tongue Disorder	Health Professional Company Representative	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/00ISR Number: 3499897-1Report Type:Expedited (15-DaCompany Report #D0006860A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angina Pectoris	Foreign	Bupropion				
Hospitalization -	Cardiac Disorder	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL
Initial or Prolonged	Coronary Artery Surgery	Professional					
Disability	Influenza						

Date:05/12/00ISR Number: 3499898-3Report Type:Expedited (15-DaCompany Report #A0119608A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Bronchospasm	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE
Initial or Prolonged	Dehydration						PER DAY/ORAL
	Difficulty In Walking						
	Dyspnoea						
	Oedema						
	Pharyngolaryngeal Pain						
	Pruritus						
	Urticaria						

Date:05/15/00ISR Number: 3500475-6Report Type:Expedited (15-DaCompany Report #A0115993A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Amblyopia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Brain Neoplasm	Health Professional					

Date:05/15/00ISR Number: 3500484-7Report Type:Expedited (15-DaCompany Report #A0069088A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Choking	Professional					TWICE PER DAY	
	Convulsion	Other					/ ORAL	
	Feeling Jittery		Simvastatin	C				
	Thirst		Aspirin	C				
	Tremor							

Date:05/15/00ISR Number: 3501204-2Report Type:Expedited (15-DaCompany Report #00P-163-0089665-00(0)
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Pain Drug Interaction	Health Professional	Cylert	PS	Abbott Laboratories Pharmaceutical Products Div	ORAL	PER ORAL	
			Amfebutamone Hydrochloride (Amfebutamone Hydrochloride)	SS		ORAL	400 MG, 1 IN	1 D, PER ORAL
			Methylphenidate Hydrochloride (Methylphenidate Hydrochloride)	SS		ORAL	5 MG, 2 IN 1	D, PER ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/15/00ISR Number: 3501216-9Report Type:Expedited (15-DaCompany Report #A0120078A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bipolar Disorder	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
Initial or Prolonged	Bipolar I Disorder	Consumer					DAY / ORAL	
Other	Convulsion		Clonazepam	C				
	Disorientation		Paroxetine Hydrochloride	C				
	Disturbance In Attention		Perphenazine	C				
	Mood Swings							
	Visual Disturbance							

Date:05/16/00ISR Number: 3501192-9Report Type:Expedited (15-DaCompany Report #200011497HMRI
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Lasix	PS	Aventis Pharmaceuticals Inc			
			Amfebutamone Hydrochloride (Wellbutrin - Slow Release)	SS				

Date:05/16/00ISR Number: 3501780-XReport Type:Periodic Company Report #HQ0846901FEB2000
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health Professional	Effexor Xr	PS	Wyeth Ayerst Laboratories Inc	ORAL	37.5 MG 1X	
							PER 1 DAY,	
							ORAL	
			Prozac	SS		ORAL	20 MG 2X PER	
							1 DAY ORAL	

	Effexor Xr	SS	ORAL

14 CAPSULES

OVERDOSE

AMOUNT, ORAL

	Prozac	SS	ORAL

OVERDOSE

AMOUNT

UNKNOWN, ORAL

	Wellbutrin	SS	ORAL

150 MG 1X PER

1 DAY, ORAL

	Wellbutrin	SS	ORAL

OVERDOSE

AMOUNT

UNKNOWN, ONE

TIME, ORAL

Date:05/17/00ISR Number: 3561205-5Report Type:Periodic Company Report #S00-USA-00214-01
Age:46 YR Gender:Male I/FU:I

Outcome

PT
Anxiety
Ejaculation Disorder
Emotional Disorder
Headache
Hyperhidrosis
Libido Decreased
Nervousness
Paraesthesia
Sedation

	Tooth Disorder Vasodilatation					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Celexa	PS	Forest Laboratories Inc	ORAL
15 MG QD PO						
			Celexa	SS		ORAL
10 MB BID PO						
			Celexa	SS		ORAL
10 MG QD PO						
			Celexa	SS		ORAL
5 MG QD PO						
			Wellbutrin	SS		ORAL
75 MG TID PO						
			Wellbutrin	SS		ORAL
75 MG QD PO						

Date:05/17/00ISR Number: 3561232-8Report Type:Periodic Company Report #S00-USA-00234-01
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Accident	Health Professional	Celexa	PS	Forest Laboratories Inc	
			Wellbutrin	SS		

Date:05/18/00ISR Number: 3501390-4Report Type:Direct Company Report #USP 53031
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Medication Error		Wellbutrin	PS	Glaxo Wellcome	
			Wellbutrin (Bupropion Hydrochloride)	SS	Glaxo Wellcome	

Date:05/18/00ISR Number: 3501462-4Report Type:Direct Company Report #
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Cerebrovascular Accident Convulsion	Consumer	Zyban / 150mg / Glaxo	PS	Glaxo	ORAL	300MG DAILY	ORAL

Date:05/18/00ISR Number: 3501483-1Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling Urticaria	Health Professional	Zyban 150mg Bid	PS		ORAL	150 MG BID PO	

Date:05/18/00ISR Number: 3502211-6Report Type:Expedited (15-DaCompany Report #M0316-2000
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to								

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour	Health	Remeron	PS	Organon Inc Sub			
	Angina Pectoris	Professional			Akzona Inc	ORAL	560 MG PO	
	Aspartate	Other	Wellbutrin	SS		ORAL	900 MG PO	
	Aminotransferase		Librium	SS				
	Increased		Benzonatatc	C				
	Blood Creatine		Cefuroxime	C				
	Phosphokinase Increased		Docusate	C				
	Cardiac Disorder		Doxycycline	C				
	Cardiomyopathy		Kcl	C				
	Chest Pain		Levaquin	C				
	Dyspnoea		Methadone	C				
	Electrocardiogram Qt		Robitussin	C				
	Corrected Interval		Tylenol	C				
	Prolonged							
	Electrocardiogram Qt							
	Prolonged							
	Electrocardiogram T Wave							
	Inversion							
	Hypokalaemia							
	Mitral Valve Incompetence							
	Myocardial Ischaemia							
	Overdose							
	Pneumonia							
	Toxicologic Test Abnormal							
	Tricuspid Valve							
	Incompetence							

Date:05/19/00ISR Number: 3501934-2Report Type:Expedited (15-DaCompany Report #A0110912A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Zyban Tablet	PS	Glaxo Wellcome Inc	ORAL		
Hospitalization -	Arthralgia	Professional						
Initial or Prolonged	Dyspnoea							
Required	Hypersensitivity							
Intervention to	Hypotension							
Prevent Permanent	Pruritus							

Impairment/Damage	Respiratory Arrest
	Swelling
	Syncope
	Urticaria

Date:05/19/00ISR Number: 3501935-4Report Type:Expedited (15-DaCompany Report #A0116737A
Age:29 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Aggression
Hospitalization -	Amnesia
Initial or Prolonged	Coma
	Confusional State
	Depression
	Drug Level Below
	Therapeutic
	Ecchymosis
	Fatigue
	Folliculitis

	Grand Mal Convulsion Head Injury Headache	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Heart Rate Increased	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL 150 MG / SEE
	Influenza Like Illness	Professional				TEXT / ORAL
	Movement Disorder Muscle Rigidity Nausea Oxygen Saturation		Amantadine (Formulation Unknown) (Amantadine)	SS		TWICE PER DAY
	Decreased Pallor Pupillary Reflex Impaired Respiratory Rate Decreased Speech Disorder		Semisodium Valproate	C		

Date:05/19/00ISR Number: 3502241-4Report Type:Expedited (15-DaCompany Report #A0113561A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization -	Ageusia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG /
Initial or Prolonged	Angioneurotic Oedema	Health				TWICE PER DAY
	Anosmia	Professional				/ ORAL
	Face Oedema Paraesthesia Pharyngeal Oedema Pyrexia Rash Pruritic Tongue Oedema	Company Representative	Salbutamol Sulphate	C		

Date:05/19/00ISR Number: 3502244-XReport Type:Expedited (15-DaCompany Report #A0118416A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration

Hospitalization - 150 MG / Initial or Prolonged TWICE PER DAY / ORAL	Ageusia Anosmia Dermatitis Face Oedema Paraesthesia Pharyngeal Oedema Pruritus Pyrexia	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

Date:05/23/00ISR Number: 3503758-9Report Type:Direct Company Report #
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other 150MG QD X 3 THEN BID	Rash Pruritic Urticaria	Health Professional	Zyban 150 Mg (Glaxo-Wellcome) Biaxin Ibuprofen Robitussin	PS C C C	Glaxo-Wellcome	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/00ISR Number: 3503844-3Report Type:Expedited (15-DaCompany Report #A0119823A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
Initial or Prolonged	Dyspnoea						DAY/ORAL	
	Hypoxia		Metoprolol Succinate	C				
	Palpitations		Amlodipine	C				
	Ventricular Extrasystoles		Isosorbide Mononitrate	C				

Date:05/24/00ISR Number: 3504498-2Report Type:Direct Company Report #
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Partial Seizures		Bupropion	PS			100MG BID	
			Prednisone	C				
			Flovent	C				
			Lanoxin	C				
			Lasix	C				
			Kcl	C				
			Singulair	C				
			Atrovent	C				
			Albuterol	C				

Date:05/24/00ISR Number: 3504499-4Report Type:Direct Company Report #
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Wellbutrin-Sr					
	Rash Papular		(Glaxo-Wellcome)	PS	Glaxo -Wellcome		150MG BID	
			Deconamine	C				
			Allegra	C				

Date:05/24/00ISR Number: 3504501-XReport Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Urticaria		Zyban 150mg (Glaxo-Wellcome)	PS	Glaxo-Wellcome	ORAL	150MG PO QD X 3 THEN BID	
			Ambien	C				
			Aspirin	C				
			Nicoderm Patch	C				

Date:05/24/00ISR Number: 3504531-8Report Type:Expedited (15-DaCompany Report #A0117763A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Decreased Appetite	Professional						
	Headache	Company Representative	Aspirin	C				
			Armour Thyroid	C				
			Terbinafine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/00ISR Number: 3505018-9Report Type:Expedited (15-DaCompany Report #A0117940A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	
	Blister							
	Bronchospasm							
	Burning Sensation		Carisoprodol	C				
	Chest Pain		Diazepam	C				
	Dizziness							
	Dyspnoea							
	Dyspnoea Exertional							
	Ear Haemorrhage							
	Erythema							
	Eye Disorder							
	Eye Irritation							
	Eyelid Oedema							
	Haemorrhage							
	Hypersensitivity							
	Irritability							
	Oedema							
	Pain							
	Palpitations							
	Periorbital Oedema							
	Pruritus							
	Rash Erythematous							
	Toxic Shock Syndrome							
	Urticaria							

Date:05/26/00ISR Number: 3505483-7Report Type:Expedited (15-DaCompany Report #A016814
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Cholesterol Increased	Consumer	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL	50.00 MG TOTAL DAILY	
	Drug Ineffective							
	Exophthalmos							

	Infection		Flagyl	SS	ORAL
ORAL					
	Lymphocyte Count		Wellbutrin	SS	ORAL
300.00 MG					
	Increased				
TOTAL DIALY					
	Malaise				
ORAL					
	Oral Candidiasis		Azidothymidine	C	
	Tongue Discolouration		Viracept	C	
			Combivir	C	
			Methamphetamine	C	
			Prevacid	C	
			Zyrtec	C	

Date:05/26/00ISR Number: 3566696-1Report Type:Periodic Company Report #10868-AR
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Bupropion Hcl	PS	Teva Pharmaceuticals	
	Hostility				Usa Inc	
280 MG						
	Hyperhidrosis					
DECREASED TO						
	Vasodilatation					
75 MG BID						
			Acyclovir	C		
			Allopurinol	C		
			Celexa	C		
			Remeron	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/00ISR Number: 3566702-4Report Type:Periodic Company Report #10872-AR
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention	Health Professional	Bupropion Hcl	PS	Teva Pharmaceuticals Usa Inc		75 MG BID	

Date:05/26/00ISR Number: 3566704-8Report Type:Periodic Company Report #10878-AR
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Headache Hostility	Consumer	Bupropion Hcl	PS	Teva Pharmaceuticals Usa Inc		150 MG AM, 75 MG NOON AND HS	
			Bupropion Hydrochloride Tablets, 75 Mg	SS			150 MG AM, NOON AND HS	

Date:05/30/00ISR Number: 3505698-8Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Eye Rolling Hallucination Muscle Rigidity Tremor		Zyban 150mg Lipitor Prevacid Hytrin Zoloft Asa Clonidine	PS C C C C C C		ORAL ORAL	150MG BID	

Date:05/30/00ISR Number: 3506782-5Report Type:Expedited (15-DaCompany Report #A0120940A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Neck Pain	Consumer						
	Night Sweats							
	Pain							
	Paraesthesia							
	Visual Acuity Reduced							

Date:05/30/00ISR Number: 3506783-7Report Type:Expedited (15-DaCompany Report #A0120791A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / THREE TIMES PER DAY ORAL	6 MON
	Delusion							
	Psychotic Disorder							
	Self Mutilation		Baclofen	C				
			Oxycodone Hydrochloride	C				

Date:05/30/00ISR Number: 3506784-9Report Type:Expedited (15-DaCompany Report #A0120487A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Disorder	Literature	Bupropion					
	Skin Degenerative Disorder	Health Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNKNOWN / ORAL	
	Stevens-Johnson Syndrome							
	Toxic Epidermal Necrolysis							

Date:05/30/00ISR Number: 3506834-XReport Type:Periodic Company Report #3654/11757
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia	Consumer	Depo-Medrol	PS	Pharmacia And Upjohn Co	INTRAMUSCULAR	20 MG-1 DOSE;IM	
	Dizziness	Company						
	Dyspnoea	Representative						
	Feeling Jittery		Wellbutrin	SS			300 MG/DAY	
	Headache		Celexa	SS				
	Mood Swings		Risperdol	C				
	Nervousness							
	Pain In Extremity							
	Photophobia							
	Restlessness							
	Sedation							
	Vomiting							

Date:05/31/00ISR Number: 3507206-4Report Type:Periodic Company Report #A0109497A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

	Hypersensitivity					
PER DAY/ ORAL						
	Joint Swelling					
	Oedema Peripheral					
	Pharyngeal Oedema					
	Rash Generalised					
	Throat Tightness					
	Urticaria					

Date:05/31/00ISR Number: 3507207-6Report Type:Periodic Company Report #A0107904A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Grand Mal Convulsion	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
Hospitalization -	Pyrexia	Professional					PER DAY/ ORAL
Initial or Prolonged			Conjugated Estrogens	C			
Required			Medroxyprogesterone				
Intervention to			Ace.	C			
Prevent Permanent							
Impairment/Damage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3507208-8Report Type:Periodic Company Report #A0060628A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Back Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE
Initial or Prolonged	Chest Pain						PER DAY/ORAL
	Decreased Appetite		Isosorbide				
	Dizziness		Mononitrate	C			
	Drug Ineffective		Metoprolol Succinate	C			
	Dry Mouth		Lansoprazole	C			
	Dysgeusia		Aspirin	C			
	Dyspepsia						
	Dyspnoea						
	Headache						
	Insomnia						

Date:05/31/00ISR Number: 3507209-XReport Type:Periodic Company Report #A0118622A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL
			Triamcinolone Acetonide	C			

Date:05/31/00ISR Number: 3507210-6Report Type:Periodic Company Report #A0116791A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Dizziness	Health	Zyban	PS	Glaxo Wellcome Inc		150 MG/TWICE
Initial or Prolonged		Professional					PER DAY/
			Atorvastatin Calcium	C			

Date:05/31/00ISR Number: 3507211-8Report Type:Periodic Company Report #A0116361A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Dermatitis Hypersensitivity	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:05/31/00ISR Number: 3507212-XReport Type:Periodic Company Report #A0115677A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Urticaria	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc			

Date:05/31/00ISR Number: 3507213-1Report Type:Periodic Company Report #A0114547A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3507214-3Report Type:Periodic Company Report #A0114398A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Tremor	Professional					SINGLE DOSE/	
		Company					ORAL	
		Representative						

Date:05/31/00ISR Number: 3507215-5Report Type:Periodic Company Report #A0114203A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Dry Mouth						PER DAY/ ORAL	
	Insomnia							

Date:05/31/00ISR Number: 3507216-7Report Type:Periodic Company Report #A0113908A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc			

Date:05/31/00ISR Number: 3507217-9Report Type:Periodic Company Report #A0111695A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Eyelid Oedema						PER DAY/ ORAL	
	Face Oedema		Oral Contraceptive	C				

	Hypersensitivity					
	Oedema Peripheral					
	Pain					
	Pharyngeal Oedema					
	Urticaria					

Date:05/31/00ISR Number: 3507218-0Report Type:Periodic Company Report #A0113182A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Drug Toxicity	Professional						

Date:05/31/00ISR Number: 3563220-4Report Type:Periodic Company Report #A0115654A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
			Nicotine (Nicotine)	C				

Date:05/31/00ISR Number: 3563225-3Report Type:Periodic Company Report #A0115703A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Bupropion					
	Suicidal Ideation		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

TWICE PER

DAY/ ORAL

Hypericum C

Date:05/31/00ISR Number: 3563227-7Report Type:Periodic Company Report #A0115704A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Irritability						PER DAY/ ORAL	

Date:05/31/00ISR Number: 3563229-0Report Type:Periodic Company Report #A0115772A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Euphoric Mood						TWICE PER DAY	
	Feeling Abnormal						/ ORAL	
	Feeling Drunk							
	Nervousness							

Date:05/31/00ISR Number: 3563233-2Report Type:Periodic Company Report #A0115784A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Joint Swelling						PER DAY /	
	Pruritus						ORAL	

Date:05/31/00ISR Number: 3563235-6Report Type:Periodic Company Report #A0115837A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	3 WK
	Rash Generalised							

Date:05/31/00ISR Number: 3563236-8Report Type:Periodic Company Report #A0115873A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:05/31/00ISR Number: 3563237-XReport Type:Periodic Company Report #A0115879A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	1 DAY

Date:05/31/00ISR Number: 3563240-XReport Type:Periodic Company Report #A0115882A
Age:73 YR Gender:Female I/FU:I

Outcome	PT
	Dissociation
	Dizziness
	Headache

	Nausea Vertigo						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / SINGLE DOSE/ ORAL

Date:05/31/00ISR Number: 3563242-3Report Type:Periodic Company Report #A0115926A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash Generalised	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL

Date:05/31/00ISR Number: 3563244-7Report Type:Periodic Company Report #A0115927A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Arthralgia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Difficulty In Walking Dyspnoea Dyspraxia Eyelid Oedema Joint Swelling Pain Pruritus Rheumatoid Arthritis Serum Sickness Swelling Urticaria						

Date:05/31/00ISR Number: 3563245-9Report Type:Periodic Company Report #A0115928A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Insomnia						TWICE PER	
	Lymphadenopathy						DAY/ ORAL	
	Tinnitus							
	Urticaria							

Date:05/31/00ISR Number: 3563248-4Report Type:Periodic Company Report #A0115929A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
			Nicotine Patch (Nicotine)	SS		TRANSDERMAL	21 MG /	
							TRANSDERMAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3563250-2Report Type:Periodic Company Report #A0115932A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/	ORAL
	Nervousness	Professional						

Date:05/31/00ISR Number: 3563251-4Report Type:Periodic Company Report #A0115949A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	ORAL

Date:05/31/00ISR Number: 3563252-6Report Type:Periodic Company Report #A0115953A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL
	Dizziness							
	Eating Disorder							
	Feeling Abnormal							
	Headache							
	Insomnia							
	Malaise							
	Nausea							
	Psychomotor Hyperactivity							
	Tremor							

Date:05/31/00ISR Number: 3563253-8Report Type:Periodic Company Report #A0115955A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Rash Pruritic						TWICE PER	
							DAY/ ORAL	

Date:05/31/00ISR Number: 3563254-XReport Type:Periodic Company Report #A0115958A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL	
	Dry Skin		Simvastatin	C				
	Dysphagia		Nadolol	C				
	Mucosal Dryness		Aspirin	C				

Date:05/31/00ISR Number: 3563255-1Report Type:Periodic Company Report #A0115960A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3563256-3Report Type:Periodic Company Report #A0116037A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Chest Pain						TWICE PER	
	Conjunctival Irritation						DAY/ ORAL	
	Hallucination, Visual		Conjugated Estrogens	C				
	Mental Impairment							
	Paraesthesia							
	Sensation Of Heaviness							

Date:05/31/00ISR Number: 3563257-5Report Type:Periodic Company Report #A0116067A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Bupropion					
	Disturbance In Attention		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER	
	Malaise						DAY) ORAL	
	Tobacco Abuse							

Date:05/31/00ISR Number: 3563258-7Report Type:Periodic Company Report #A0116070A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion					
	Drug Ineffective		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
	Erythema						PER DAY) ORAL	
	Irritability		Glucophage	C				
	Scar							

Date:05/31/00ISR Number: 3563260-5Report Type:Periodic Company Report #A0116090A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL
	Oedema Peripheral							
	Pain In Extremity							
	Pruritus							
	Rash Erythematous							
	Urticaria							

Date:05/31/00ISR Number: 3563265-4Report Type:Periodic Company Report #A0116091A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	1 WK
	Neoplasm Skin							
	Rash Pruritic							

Date:05/31/00ISR Number: 3563268-XReport Type:Periodic Company Report #A0116092A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER	
	Parosmia							

DAY) ORAL

Date:05/31/00ISR Number: 3563272-1Report Type:Periodic Company Report #A0116094A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	

PER DAY) ORAL

Date:05/31/00ISR Number: 3563274-5Report Type:Periodic Company Report #A0116133A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
	Dysgeusia							
	Oral Intake Reduced							

PER DAY) ORAL

Date:05/31/00ISR Number: 3563279-4Report Type:Periodic Company Report #A0116136A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
	Insomnia							

PER DAY) ORAL

Date:05/31/00ISR Number: 3563282-4Report Type:Periodic Company Report #A0116148A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
	Neck Pain							

Date:05/31/00ISR Number: 3563284-8Report Type:Periodic Company Report #A0116154A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	8 MON
	Sleep Disorder							
			Multivitamin	C				
			Ibuprofen	C				
			Nicotine	C				

Date:05/31/00ISR Number: 3563285-XReport Type:Periodic Company Report #A0116180A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
	Flatulence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3563286-1Report Type:Periodic Company Report #A0116182A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	

Date:05/31/00ISR Number: 3563287-3Report Type:Periodic Company Report #A0116185A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation Dermatitis Disorientation Hypoaesthesia Nervousness Pruritus Tachycardia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	

Date:05/31/00ISR Number: 3563288-5Report Type:Periodic Company Report #A0116197A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia Confusional State Disturbance In Attention Dizziness Learning Disorder Thinking Abnormal Vision Blurred	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	15-0 MG (TWICE PER DAY) ORAL	

Date:05/31/00ISR Number: 3563289-7Report Type:Periodic Company Report #A0116198A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:05/31/00ISR Number: 3563290-3Report Type:Periodic Company Report #A0116200A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
	Disturbance In Attention							
	Headache							
	Major Depression							
	Tremor							
	Visual Disturbance							

Date:05/31/00ISR Number: 3563291-5Report Type:Periodic Company Report #A0116201A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3563292-7Report Type:Periodic Company Report #A0116202A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY) ORAL	
	Nausea							
	Oral Intake Reduced							
	Vomiting		Glucophage	C				

Date:05/31/00ISR Number: 3563296-4Report Type:Periodic Company Report #A0116204A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
	Insomnia							
	Sedation							

Date:05/31/00ISR Number: 3563301-5Report Type:Periodic Company Report #A0116205A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	1 WK

Date:05/31/00ISR Number: 3563806-7Report Type:Periodic Company Report #A0115305A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Discomfort	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

	Tinnitus					

TWICE PER

DAY/ ORAL 4 WK

Date:05/31/00ISR Number: 3563808-0Report Type:Periodic Company Report #A0115306A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Diplopia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE
	Hypertension						PER DAY/ ORAL
	Muscle Spasms		Amlodipine	C			
	Muscle Twitching		Lisinopril	C			
	Tremor		Latanoprost	C			

Date:05/31/00ISR Number: 3563810-9Report Type:Periodic Company Report #A0115317A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE

PER DAY /ORAL

Date:05/31/00ISR Number: 3563812-2Report Type:Periodic Company Report #A0115319A
Age:34 YR Gender:Female I/FU:I

Outcome	PT
	Chest Discomfort
	Confusional State

	Depersonalisation Dyspnoea Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY/ ORAL						

Date:05/31/00ISR Number: 3563813-4Report Type:Periodic Company Report #A0115339A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrooesophageal Reflux Disease	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY/ ORAL	Nausea					

Date:05/31/00ISR Number: 3563815-8Report Type:Periodic Company Report #A0115352A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / ORAL 2 DAY						

Date:05/31/00ISR Number: 3563816-XReport Type:Periodic Company Report #A0115367A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
250 MG / PER DAY / ORAL						

Date:05/31/00ISR Number: 3563817-1Report Type:Periodic Company Report #A0115375A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Feeling Abnormal						DAY / ORAL	
	Hyperhidrosis							
	Syncope							
	Visual Disturbance							

Date:05/31/00ISR Number: 3563818-3Report Type:Periodic Company Report #A0115413A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Depression						PER DAY/ ORAL	
	Dizziness		Wellbutrin					
	Drug Ineffective		Tablet-Controlled					
	Feeling Abnormal		Release (Bupropion					
	Nausea		Hydrochloride)	SS		ORAL	ORAL	2 WK
	Syncope		Multiple Medication	C				

Date:05/31/00ISR Number: 3563819-5Report Type:Periodic Company Report #A0115415A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Throat Irritation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:05/31/00ISR Number: 3563820-1Report Type:Periodic Company Report #A0115419A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	3 WK
	Constipation							
	Dysgeusia							
	Nausea							

Date:05/31/00ISR Number: 3563821-3Report Type:Periodic Company Report #A0115420A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	
	Arthralgia							
	Eyelid Oedema							
	Face Oedema							
	Insomnia							
	Joint Swelling							
	Oedema Peripheral							
	Pruritus							
	Urticaria							

Date:05/31/00ISR Number: 3563822-5Report Type:Periodic Company Report #A0115492A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY /ORAL	
	Sensation Of Heaviness							

Date:05/31/00ISR Number: 3563823-7Report Type:Periodic Company Report #A0115493A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	3 WK
	Abnormal							

Date:05/31/00ISR Number: 3563824-9Report Type:Periodic Company Report #A0115509A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3563825-0Report Type:Periodic Company Report #A0115511A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	2 MON

Date:05/31/00ISR Number: 3563826-2Report Type:Periodic Company Report #A0115521A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	1 WK
	Insomnia							

Date:05/31/00ISR Number: 3563827-4Report Type:Periodic Company Report #A0115530A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Headache							
	Insomnia							

Date:05/31/00ISR Number: 3563828-6Report Type:Periodic Company Report #A0115544A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG /
Headache
TWICE PER

DAY/ ORAL

Date:05/31/00ISR Number: 3563830-4Report Type:Periodic Company Report #A0115642A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

Dose Duration
150 MG /TWICE

PER DAY/ ORAL

Date:05/31/00ISR Number: 3564384-9Report Type:Periodic Company Report #A0118239A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Hypersensitivity Rash Generalised	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration
150 MG/ TWICE

PER DAY/ ORAL

Date:05/31/00ISR Number: 3564397-7Report Type:Periodic Company Report #A0118665A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Insomnia Mouth Ulceration	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration
150MG / TWICE
Pharyngolaryngeal Pain
PER DAY/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564412-0Report Type:Periodic Company Report #A0118666A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	OPHTHALMIC	150 MG/ TWICE PER DAY /	
	Burning Sensation							
	Confusional State							
	Elevated Mood					ORAL	3	WK
	Erythema							
	Pruritus							

Date:05/31/00ISR Number: 3564428-4Report Type:Periodic Company Report #A0117914A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Syncope							
	Therapeutic Response							
	Unexpected		Bupropion Hydrochloride					
			Unspecified Tablet (Bupropion Hydrochloride)	SS		ORAL	UNK / UNK / ORAL	

Date:05/31/00ISR Number: 3564438-7Report Type:Periodic Company Report #A0117916A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

TWICE PER DAY

/ ORAL

Date:05/31/00ISR Number: 3564442-9Report Type:Periodic Company Report #A0118240A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150MG / PER DAY / ORAL	

Date:05/31/00ISR Number: 3564443-0Report Type:Periodic Company Report #A0117917A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Dry Mouth							
	Eructation							
	Flatulence							
	Gastrointestinal Disorder							
	Hyperchlorhydria							
	Insomnia							
	Nausea							
	Throat Irritation							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564448-XReport Type:Periodic Company Report #A0117919A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3564452-1Report Type:Periodic Company Report #A0117924A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Disturbance In Attention							
	Sedation		Omeprazole	C				

Date:05/31/00ISR Number: 3564455-7Report Type:Periodic Company Report #A0117938A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Chest Pain							
	Derealisation							
	Dizziness							
	Dyspnoea							
	Fatigue							
	Malaise							
	Memory Impairment							
	Palpitations							
	Speech Disorder							
	Syncope							
	Tachycardia							

	Yawning					

Date:05/31/00ISR Number: 3564457-0Report Type:Periodic Company Report #A0118283A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK/	ORAL
			Nicotine	C				
			Nicotine	C				

Date:05/31/00ISR Number: 3564463-6Report Type:Periodic Company Report #A0117945A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fixed Eruption	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Pruritus	Professional					TWICE PER DAY	
	Rash Erythematous						/ ORAL	
	Rash Generalised		Prempro	C				
	Rash Macular							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564464-8Report Type:Periodic Company Report #A0118310A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Rash Papular							
	Urticaria							

Date:05/31/00ISR Number: 3564466-1Report Type:Periodic Company Report #A0118051A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Health Professional Company Representative	Bupropion Hydrochloride Unspecified Tablet	PS	Glaxo Wellcome Inc	ORAL	75 MG / UNK / ORAL	
	Hypersensitivity							
	Hypoaesthesia Oral							

Date:05/31/00ISR Number: 3564467-3Report Type:Periodic Company Report #A0118371A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Drug Ineffective							
	Irritability							
	Laryngitis							
	Lymphadenopathy							
	Pain							
	Pharyngolaryngeal Pain							

Date:05/31/00ISR Number: 3564468-5Report Type:Periodic Company Report #A0118052A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3564469-7Report Type:Periodic Company Report #A0118056A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	1 WK
	Anxiety							
	Feeling Abnormal							
	Hyperhidrosis							

Date:05/31/00ISR Number: 3564470-3Report Type:Periodic Company Report #A0118393A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564471-5Report Type:Periodic Company Report #A0118059A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dysgeusia						DAY / ORAL	
	Insomnia							

Date:05/31/00ISR Number: 3564472-7Report Type:Periodic Company Report #A0118435A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3564474-0Report Type:Periodic Company Report #A0118060A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Insomnia						TWICE PER DAY	
	Tremor						/ ORAL	

Date:05/31/00ISR Number: 3564476-4Report Type:Periodic Company Report #A0118062A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Dependence	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG /

TWICE PER DAY

/ ORAL

Date:05/31/00ISR Number: 3564477-6Report Type:Periodic Company Report #A0118438A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dermatitis	Consumer	Bupropion			
	Dyspnoea		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG /

Oedema

TWICE PER DAY

Vomiting

/ ORAL

Date:05/31/00ISR Number: 3564479-XReport Type:Periodic Company Report #A0118128A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL 14 DAY

Date:05/31/00ISR Number: 3564482-XReport Type:Periodic Company Report #A0118133A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL 3 WK

Date:05/31/00ISR Number: 3564484-3Report Type:Periodic Company Report #A0118439A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion					
	Dysgeusia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3564486-7Report Type:Periodic Company Report #A0118135A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	
	Dyspepsia							
							/ ORAL	2 WK
	Pollakiuria							

Date:05/31/00ISR Number: 3564488-0Report Type:Periodic Company Report #A0118457A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Bupropion					
	Insomnia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Irritability							
							DAY / ORAL	

Date:05/31/00ISR Number: 3564490-9Report Type:Periodic Company Report #A0118140A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dysgeusia						TWICE PER DAY	
	Headache						/ ORAL	
	Insomnia							
	Parosmia							
	Tinnitus							

Date:05/31/00ISR Number: 3564493-4Report Type:Periodic Company Report #A0118152A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Pruritus	Professional					TWICE PER DAY	
	Rash Erythematous						/ ORAL	

Date:05/31/00ISR Number: 3564500-9Report Type:Periodic Company Report #A0118463A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Urticaria						TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564501-0Report Type:Periodic Company Report #A0118162A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Pruritus	Professional					TWICE PER DAY	
							/ ORAL	
			Hrt	C				

Date:05/31/00ISR Number: 3564504-6Report Type:Periodic Company Report #A0118220A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Irritability						DAY / ORAL	
	Nervousness							
	Sleep Disorder							

Date:05/31/00ISR Number: 3564505-8Report Type:Periodic Company Report #A0118476A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	
							/ ORAL	

Date:05/31/00ISR Number: 3564508-3Report Type:Periodic Company Report #A0118487A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Rash Erythematous	Consumer	Bupropion			
	Rash Papular		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG /

TWICE PER DAY

/ ORAL

Date:05/31/00ISR Number: 3564510-1Report Type:Periodic Company Report #A0118488A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abnormal Behaviour	Health	Bupropion			
	Crying	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG / PER

	Depression

DAY / ORAL

Date:05/31/00ISR Number: 3564512-5Report Type:Periodic Company Report #A0118489A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Bupropion			
	Eyelid Oedema		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG /

	Oedema

TWICE PER DAY

	Pruritus

/ ORAL

	Pyrexia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564515-0Report Type:Periodic Company Report #A0118579A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Renal Colic							

Date:05/31/00ISR Number: 3564518-6Report Type:Periodic Company Report #A0118596A
Age:40 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Constipation							
	Headache							
	Sinus Congestion							
	Sinusitis							

Date:05/31/00ISR Number: 3564519-8Report Type:Periodic Company Report #A0117473A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Central Nervous System	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Function Test Abnormal							
	Condition Aggravated							
	Disturbance In Attention							
	Irritability							
	Restlessness							

Date:05/31/00ISR Number: 3564521-6Report Type:Periodic Company Report #A0118612A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	/ ORAL 4 DAY

Date:05/31/00ISR Number: 3564524-1Report Type:Periodic Company Report #A0117475A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Nightmare							

Date:05/31/00ISR Number: 3564526-5Report Type:Periodic Company Report #A0117485A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Cough							
	Dry Mouth							
	Ejaculation Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564530-7Report Type:Periodic Company Report #A0117603A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	3 DAY
	Dermatitis		Wellbutrin					
	Excoriation		Tablet-Controlled					
	Pruritus		Release (Bupropion Hydrochloride)	SS		ORAL	ORAL	1 WK

Date:05/31/00ISR Number: 3564533-2Report Type:Periodic Company Report #A0117654A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Night Sweats							
			Conjugated Estrogens	C				

Date:05/31/00ISR Number: 3564536-8Report Type:Periodic Company Report #A0117659A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	3 WK
			Nicotine Patch (Nicotine)	SS			TRANSDERMAL	21 MG
							TRANSDERMAL	

Date:05/31/00ISR Number: 3564545-9Report Type:Periodic Company Report #A0117660A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
			Nicotine Patch (Nicotine)	SS		TRANSDERMAL	21 MG	
						TRANSDERMAL		

Date:05/31/00ISR Number: 3564548-4Report Type:Periodic Company Report #A0117686A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	

Date:05/31/00ISR Number: 3564552-6Report Type:Periodic Company Report #A0117687A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Dysgeusia							

Date:05/31/00ISR Number: 3564553-8Report Type:Periodic Company Report #A0117688A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Skin Discolouration							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564556-3Report Type:Periodic Company Report #A0117694A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:05/31/00ISR Number: 3564563-0Report Type:Periodic Company Report #A0117719A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngolaryngeal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:05/31/00ISR Number: 3564570-8Report Type:Periodic Company Report #A0117725A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:05/31/00ISR Number: 3564573-3Report Type:Periodic Company Report #A0117779A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
	Pruritus							
	Rash Erythematous		Nicotine Patch					
	Therapeutic Response		(Nicotine)	SS		TRANSDERMAL	TRANSDERMAL	
	Unexpected		Fluticasone					

			Propionate	C		

Date:05/31/00ISR Number: 3564577-0Report Type:Periodic Company Report #A0117785A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Back Pain						DAY ORAL	
	Dermatitis							
	Disturbance In Attention							
	Neck Pain							
	Pain In Jaw							

Date:05/31/00ISR Number: 3564580-0Report Type:Periodic Company Report #A0117793A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dysgeusia						PER DAY ORAL	
	Tobacco Abuse							

Date:05/31/00ISR Number: 3564583-6Report Type:Periodic Company Report #A0117879A
Age:42 YR Gender:Female I/FU:I

Outcome	PT
	Apathy
	Balance Disorder

	Dermatitis					
	Difficulty In Walking					
	Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dysarthria	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Excitability	Professional				
PER DAY ORAL						
	Fatigue		Atenolol	C		
	Headache		Isosorbide Dinitrate	C		
	Hypoaesthesia Oral		Atorvastatin Calcium	C		
	Sensation Of Foreign Body		Clopidogrel			
	Speech Disorder		Bisulphate	C		
	Tremor		Aspirin	C		
			Vitamin B Complex	C		
			Vitamin E	C		
			Estrogen	C		

Date:05/31/00ISR Number: 3564592-7Report Type:Periodic Company Report #A0117903A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG ORAL						
			Caffeine	C		

Date:05/31/00ISR Number: 3564594-0Report Type:Periodic Company Report #A0117907A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
PER DAY ORAL						

Date:05/31/00ISR Number: 3564597-6Report Type:Periodic Company Report #A0117913A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Urticaria						DAY ORAL	

Date:05/31/00ISR Number: 3564715-XReport Type:Periodic Company Report #A0118667A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Feeling Abnormal						TWICE PER DAY	
	Pain						/ ORAL	2 WK
	Pruritus							
	Rash Papular							
	Speech Disorder							
	Tremor							

Date:05/31/00ISR Number: 3564716-1Report Type:Periodic Company Report #A0118668A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564717-3Report Type:Periodic Company Report #A0118669A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Lisinopril	C				

Date:05/31/00ISR Number: 3564718-5Report Type:Periodic Company Report #A0118675A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased Lethargy Sedation	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3564719-7Report Type:Periodic Company Report #A0118676A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3564720-3Report Type:Periodic Company Report #A0118682A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL 3 DAY

Date:05/31/00ISR Number: 3564728-8Report Type:Periodic Company Report #A0118684A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL

Date:05/31/00ISR Number: 3564730-6Report Type:Periodic Company Report #A0118686A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased Weight Increased	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564733-1Report Type:Periodic Company Report #A0118696A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Vomiting							

Date:05/31/00ISR Number: 3564735-5Report Type:Periodic Company Report #A0118729A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	2 WK
	Arthritis							
	Dermatitis							
	Muscle Disorder							
	Muscle Spasms							
	Muscular Weakness							
	Pyrexia							
	Tic							
	Urticaria							

Date:05/31/00ISR Number: 3564737-9Report Type:Periodic Company Report #A0118733A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Irritability							
	Mood Swings							
	Nervousness							

Date:05/31/00ISR Number: 3564739-2Report Type:Periodic Company Report #A0118734A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Erythema							
	Flushing							
	Pain In Extremity							

Date:05/31/00ISR Number: 3564741-0Report Type:Periodic Company Report #A0118753A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY / ORAL	
	Bruxism							
	Depression							
	Disorientation							
	Disturbance In Attention							
	Dysgeusia							
	Feeling Abnormal							
	Insomnia							
	Irritability							
	Malaise							
	Movement Disorder							
	Sensation Of Heaviness							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564743-4Report Type:Periodic Company Report #A0118754A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	/ ORAL 7 DAY

Date:05/31/00ISR Number: 3564744-6Report Type:Periodic Company Report #A0118755A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Insomnia Therapeutic Response Unexpected Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150MG / PER DAY	/ ORAL

Date:05/31/00ISR Number: 3564747-1Report Type:Periodic Company Report #A0118757A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Central Nervous System Stimulation Insomnia Mental Disorder Vision Blurred	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL

Date:05/31/00ISR Number: 3564749-5Report Type:Periodic Company Report #A0118758A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK/	ORAL

Date:05/31/00ISR Number: 3564751-3Report Type:Periodic Company Report #A0118759A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG UNK /	ORAL
			Nicotine Patch (Nicotine)	SS		TRANSDERMAL	UNK /UNK/	TRTANSDERMAL

Date:05/31/00ISR Number: 3564753-7Report Type:Periodic Company Report #A0118784A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Rash Erythematous	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564754-9Report Type:Periodic Company Report #A0111412A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:05/31/00ISR Number: 3564755-0Report Type:Periodic Company Report #A0118793A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:05/31/00ISR Number: 3564756-2Report Type:Periodic Company Report #A0111413A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL
	Haemorrhage Subcutaneous							
	Testicular Swelling							

Date:05/31/00ISR Number: 3564757-4Report Type:Periodic Company Report #A0111417A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Chest Pain	Professional					TWICE PER DAY	
	Constipation						/ ORAL	
	Dermatitis							
	Dyspnoea							
	Emotional Disorder							
	Hypersensitivity							
	Panic Attack							
	Pruritus							
	Swelling							
	Urticaria							

Date:05/31/00ISR Number: 3564758-6Report Type:Periodic Company Report #A0111419A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Tremor						DAY / ORAL	

Date:05/31/00ISR Number: 3564759-8Report Type:Periodic Company Report #A0111421A
Age:57 YR Gender:Male I/FU:I

Outcome	PT
	Agitation
	Disturbance In Attention
	Dry Mouth
	Feeling Abnormal
	Gait Disturbance

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability Sleep Disorder	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3564760-4Report Type:Periodic Company Report #A0111424A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3564761-6Report Type:Periodic Company Report #A0111541A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Cardiovascular Disorder Dry Mouth Feeling Abnormal Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3564762-8Report Type:Periodic Company Report #A0111542A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Asthenia						TWICE PER DAY	
	Dizziness						/ ORAL	
	Sensation Of Heaviness							

Date:05/31/00ISR Number: 3564763-XReport Type:Periodic Company Report #A0111595A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3564764-1Report Type:Periodic Company Report #A0111604A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	
	Crying						/ ORAL	
	Depression							
	Dry Mouth							
	Feeling Hot And Cold							
	Insomnia							
	Tachycardia							
	Tinnitus							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564765-3Report Type:Periodic Company Report #A0111605A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Chromaturia						TWICE PER DAY	
	Dermatitis						/ ORAL	
	Dry Skin							
	Dysgeusia							
	Fatigue							
	Urine Odour Abnormal							

Date:05/31/00ISR Number: 3564766-5Report Type:Periodic Company Report #A0111606A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Insomnia	Professional					TWICE PER DAY	
	Tremor						/ ORAL	

Date:05/31/00ISR Number: 3564767-7Report Type:Periodic Company Report #A0111607A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	
							/ ORAL	3 WK

Date:05/31/00ISR Number: 3564768-9Report Type:Periodic Company Report #A0111636A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	/ ORAL

Date:05/31/00ISR Number: 3564769-0Report Type:Periodic Company Report #A0111637A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL
	Drug Ineffective							
	Dry Mouth							
	Pruritus		Imipramine Hydrochloride	C				
	Rash Erythematous		Lansoprazole	C				
	Tremor		Prempro	C				
	Urinary Retention		Glucophage	C				
	Visual Disturbance		Acarbose	C				
			Hyzaar	C				
			Nicotine	C				

Date:05/31/00ISR Number: 3564770-7Report Type:Periodic Company Report #A0111648A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG, ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564771-9Report Type:Periodic Company Report #A0111743A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG, TWICE	
	Urticaria						PER DAY, ORAL	2 WK

Date:05/31/00ISR Number: 3564772-0Report Type:Periodic Company Report #A0111744A
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG, TWICE	
							PER DAY, ORAL	

Date:05/31/00ISR Number: 3564774-4Report Type:Periodic Company Report #A0111745A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG, TWICE	
							PER DAY, ORAL	

Date:05/31/00ISR Number: 3564775-6Report Type:Periodic Company Report #A0111746A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG, TWICE	
	Eyelid Oedema	Professional					PER DAY, ORAL	
	Joint Swelling							
	Oedema Peripheral							

	Swelling					

Date:05/31/00ISR Number: 3564862-2Report Type:Periodic Company Report #A0112744A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Bupropion					
	Rash Generalised		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3564863-4Report Type:Periodic Company Report #A0112745A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Bupropion					
	Weight Decreased		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Weight Increased						TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3564864-6Report Type:Periodic Company Report #A0112765A
Age:41 YR Gender:Female I/FU:I

Outcome	PT
	Dysgeusia
	Feeling Of Relaxation
	Insomnia

	Nausea						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:05/31/00ISR Number: 3564866-XReport Type:Periodic Company Report #A0112766A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL
	Dizziness						
	Dysgeusia						
	Headache						
	Nausea						

Date:05/31/00ISR Number: 3564868-3Report Type:Periodic Company Report #A0112803A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
	Agitation						
	Difficulty In Walking						
	Dry Mouth						
	Insomnia						
	Oedema Peripheral						
	Pain						
	Tinnitus						
	Tremor						
	Urticaria						

Date:05/31/00ISR Number: 3564870-1Report Type:Periodic Company Report #A0112922A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Lethargy						TWICE PER DAY	
	Syncope						/ ORAL	
	Tremor							

Date:05/31/00ISR Number: 3564871-3Report Type:Periodic Company Report #A0112939A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3564874-9Report Type:Periodic Company Report #A0112970A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							UNKNOWN /	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3564877-4Report Type:Periodic Company Report #A0112971A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	/ ORAL

Date:05/31/00ISR Number: 3564879-8Report Type:Periodic Company Report #A0112993A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL

Date:05/31/00ISR Number: 3564880-4Report Type:Periodic Company Report #A0112994A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / SINGLE DOSE /	ORAL 1 DAY
	Urticaria	Professional Company Representative						

Date:05/31/00ISR Number: 3564882-8Report Type:Periodic Company Report #A0112995A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG /

TWICE PER DAY

/ ORAL

Date:05/31/00ISR Number: 3564885-3Report Type:Periodic Company Report #A0112996A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Pruritus					

Dose Duration

150 MG /

UNKNOWN /

ORAL

Date:05/31/00ISR Number: 3564888-9Report Type:Periodic Company Report #A0113010A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Anxiety	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Irritability	Professional				
	Nervousness					

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

Date:05/31/00ISR Number: 3564890-7Report Type:Periodic Company Report #A0113012A
Age:71 YR Gender:Female I/FU:I

Outcome	PT
	Dizziness
	Ill-Defined Disorder
	Pyrexia

	Vomiting					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
150 MG / TWICE PER DAY / ORAL		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

Date:05/31/00ISR Number: 3564891-9Report Type:Periodic Company Report #A0113017A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Agraphia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL	Anxiety Tremor	Professional				

Date:05/31/00ISR Number: 3564892-0Report Type:Periodic Company Report #A0113019A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL						

Date:05/31/00ISR Number: 3564895-6Report Type:Periodic Company Report #A0113029A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Hyperhidrosis					
TWICE PER DAY						
	Insomnia					
/ ORAL						
	Tremor					

Date:05/31/00ISR Number: 3564896-8Report Type:Periodic Company Report #A0113074A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cough	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Drug Ineffective					
TWICE PER DAY						
/ ORAL						

Date:05/31/00ISR Number: 3564897-XReport Type:Periodic Company Report #A0113081A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Disturbance In Attention					
TWICE PER DAY						
	Lethargy					
/ ORAL						
	Sedation					

Date:05/31/00ISR Number: 3564984-6Report Type:Periodic Company Report #A0111005A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
TWICE PER DAY						

/ ORAL

Date:05/31/00ISR Number: 3564988-3Report Type:Periodic Company Report #A0111006A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Nausea						TWICE PER	
							DAY/ ORAL	
			Protuss	C				
			Pilocarpine Hydrochloride	C				
			Trazodone	C				

Date:05/31/00ISR Number: 3564993-7Report Type:Periodic Company Report #A0111007A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER	
							DAY/ ORAL	3 WK

Date:05/31/00ISR Number: 3564997-4Report Type:Periodic Company Report #A0111009A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Headache						TWICE PER DAY	
	Nausea						/ ORAL	

Tremor

Date:05/31/00ISR Number: 3565003-8Report Type:Periodic Company Report #A0111010A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Activity	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Pruritus	Professional					DAY/ ORAL	
	Rash Papular							
	Urticaria							

Date:05/31/00ISR Number: 3565008-7Report Type:Periodic Company Report #A0111011A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Insomnia						TWICE PER	
							DAY/ ORAL	

Date:05/31/00ISR Number: 3565011-7Report Type:Periodic Company Report #A0111012A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
							PER DAY /	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565013-0Report Type:Periodic Company Report #A0111013A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL

Date:05/31/00ISR Number: 3565017-8Report Type:Periodic Company Report #A0111014A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dysphagia						DAY/	ORAL
	Headache							
	Nausea							
	Nervousness							
	Paranoia							
	Vomiting							

Date:05/31/00ISR Number: 3565020-8Report Type:Periodic Company Report #A0111015A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
	Malaise						PER DAY /	
	Tinnitus						ORAL	
	Tremor							

Date:05/31/00ISR Number: 3565023-3Report Type:Periodic Company Report #A0111065A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL

150 MG /

TWICE PER

DAY/ORAL

Date:05/31/00ISR Number: 3565025-7Report Type:Expedited (15-DaCompany Report #A0111095A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG/ PO

Date:05/31/00ISR Number: 3565028-2Report Type:Periodic Company Report #A0111152A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Decreased Appetite	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
	Dysgeusia					
	Headache					
	Nausea					
	Psychomotor Hyperactivity					
	Thirst					

Dose Duration

150 MG /

TWICE PER DAY

/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565033-6Report Type:Periodic Company Report #A0111155A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:05/31/00ISR Number: 3565036-1Report Type:Periodic Company Report #A0111292A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY / ORAL

Date:05/31/00ISR Number: 3565039-7Report Type:Periodic Company Report #A0111293A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Pruritus							PER DAY/ ORAL

Date:05/31/00ISR Number: 3565044-0Report Type:Periodic Company Report #A0111294A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:05/31/00ISR Number: 3565048-8Report Type:Periodic Company Report #A0111295A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Disturbance In Attention						TWICE PER	
	Dizziness						DAY/ ORAL	
	Headache							
	Tinnitus							

Date:05/31/00ISR Number: 3565051-8Report Type:Periodic Company Report #A0111302A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Bupropion					
	Nervousness		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Obstructive Airways						TWICE PER	
	Disorder						DAY/ ORAL	
	Pruritus							
	Swelling							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565055-5Report Type:Periodic Company Report #A0111379A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Bronchospasm						TWICE PER	
	Dyspnoea						DAY/ ORAL	
	Fatigue							
	Pruritus							
	Tachycardia							
	Urticaria							

Date:05/31/00ISR Number: 3565111-1Report Type:Periodic Company Report #A0104884A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Pruritus	Professional					TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3565112-3Report Type:Periodic Company Report #A0106495A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Erythema	Professional						
	Pain							
	Pruritus							
	Urticaria							

Date:05/31/00ISR Number: 3565113-5Report Type:Periodic Company Report #A0118984A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	4 DAY
	Irritability							
	Nausea							

Date:05/31/00ISR Number: 3565114-7Report Type:Periodic Company Report #A0118989A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Bupropion					
	Subcutaneous Nodule		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Tendonitis						DAY ORAL	

Date:05/31/00ISR Number: 3565115-9Report Type:Periodic Company Report #A0119010A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Bupropion					
		Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG./	
							TWICE PER	
							DAY/ ORAL	12 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565116-0Report Type:Periodic Company Report #A0119014A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/	

Date:05/31/00ISR Number: 3565117-2Report Type:Periodic Company Report #A0119015A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Pruritus							
	Rash Erythematous							
	Urticaria							

Date:05/31/00ISR Number: 3565118-4Report Type:Periodic Company Report #A0106504A
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	16 DAY
	Pain	Professional						
	Pruritus							
	Rash Erythematous							
	Urticaria							

Date:05/31/00ISR Number: 3565119-6Report Type:Periodic Company Report #A0119016A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE

Disorientation
PER DAY/ ORAL
Emotional Disorder
Hypoaesthesia
Thinking Abnormal

Date:05/31/00ISR Number: 3565120-2Report Type:Periodic Company Report #A0119017A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	

Date:05/31/00ISR Number: 3565121-4Report Type:Periodic Company Report #A0119020A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY./ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565122-6Report Type:Periodic Company Report #A0107720A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctival Hyperaemia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dermatitis	Professional					TWICE PER DAY	
	Eyelid Oedema						/ ORAL	
	Pruritus		Flonase Aqueous					
	Urticaria		Spray (Fluticasone Propionate)	SS		NASAL	1 SPRAY / PER	
							DAY /	
							INTRANASAL	

Date:05/31/00ISR Number: 3565123-8Report Type:Periodic Company Report #A0119021A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Middle Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	

Date:05/31/00ISR Number: 3565124-XReport Type:Periodic Company Report #A0108626A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
		Professional	Desogen	C				

Date:05/31/00ISR Number: 3565125-1Report Type:Periodic Company Report #A0119022A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL
	Headache		Nicotine Patch					
	Ill-Defined Disorder		(Nicotine)	SS				
INTRADERMAL							21 MG	
	Nervousness							
INTRADERMAL							15	DAY

Date:05/31/00ISR Number: 3565126-3Report Type:Periodic Company Report #A0119027A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL
	Insomnia							

Date:05/31/00ISR Number: 3565127-5Report Type:Periodic Company Report #A0108628A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Tachycardia	Professional						
TWICE PER DAY								
							/ ORAL	
			Oral Contraceptive	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565128-7Report Type:Periodic Company Report #A0119050A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Motion Sickness						PER DAY/	
	Nausea						ORAL	6 DAY

Date:05/31/00ISR Number: 3565129-9Report Type:Periodic Company Report #A0108630A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dermatitis						TWICE PER DAY	
	Dizziness						/ ORAL	
	Hypersensitivity							
	Nausea							
	Oedema Peripheral							
	Pruritus							
	Rash Generalised							
	Urticaria							

Date:05/31/00ISR Number: 3565130-5Report Type:Periodic Company Report #A0109155A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3565131-7Report Type:Periodic Company Report #A0119056A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Insomnia	Professional Other	Nicotine Patch (Nicotine)	SS		TRANSDERMAL	21 MG/	TRANSDERMAL
			Nasonex	C				
			Cetirizine Hydrochloride	C				
			Medroxyprogesterone Ace	C				

Date:05/31/00ISR Number: 3565132-9Report Type:Periodic Company Report #A0109319A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
		Professional					TWICE PER DAY	
			Sertraline Hydrochloride	C			/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565133-0Report Type:Periodic Company Report #A0119058A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Paraesthesia Pruritus		Nicotine Patch (Nicotine)	SS		TRANSDERMAL	21 MG/ PER DAY/	
	Swelling Weight Increased					TRANSDERMAL		

Date:05/31/00ISR Number: 3565134-2Report Type:Periodic Company Report #A0119064A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Unexpected	Professional						
			Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL	VARIABLE DOSE/ ORAL	

Date:05/31/00ISR Number: 3565135-4Report Type:Periodic Company Report #A0109322A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Vision Blurred	Professional						

Date:05/31/00ISR Number: 3565136-6Report Type:Periodic Company Report #A0119083A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	12 WK

Date:05/31/00ISR Number: 3565137-8Report Type:Periodic Company Report #A0109324A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Dyspnoea Fatigue Feeling Abnormal Insomnia Negativism	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3565138-XReport Type:Periodic Company Report #A0119189A
Age:49 YR Gender:Male I/FU:I

Outcome	PT
	Dermatitis Hyperaesthesia Myalgia Pyrexia Serum Sickness

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL 10 DAY

Company Representative

Date:05/31/00ISR Number: 3565139-1Report Type:Periodic Company Report #A0109434A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dizziness Dysphonia Erythema Rash Pruritic Throat Tightness	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY /	ORAL

Date:05/31/00ISR Number: 3565140-8Report Type:Periodic Company Report #A0109500A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema Hypersensitivity Pruritus Urticaria	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY /	ORAL

Date:05/31/00ISR Number: 3565141-XReport Type:Periodic Company Report #A0119194A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	4 MON

Date:05/31/00ISR Number: 3565142-1Report Type:Periodic Company Report #A0109600A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Nausea	Professional						
	Rash Erythematous							
	Skin Disorder		Isoniazid	C				
			Cyanocobalamin	C				
			Pyridoxine Hydrochloride	C				
			Mylanta	C				
			Oral Contraceptive	C				

Date:05/31/00ISR Number: 3565143-3Report Type:Periodic Company Report #A0109723A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565144-5Report Type:Periodic Company Report #A0110048A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Pruritus							
	Skin Lesion							
	Speech Disorder							
	Urticaria							

Date:05/31/00ISR Number: 3565145-7Report Type:Periodic Company Report #A0110057A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Feeling Abnormal						TWICE PER DAY	
	Insomnia						/ ORAL	
	Psychomotor Hyperactivity							
	Tachycardia							
	Tremor							

Date:05/31/00ISR Number: 3565146-9Report Type:Periodic Company Report #A0119196A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Depression						PER DAY/ ORAL	
	Fatigue							
	Feeling Abnormal							
	Irritability							
	Nausea							

Date:05/31/00ISR Number: 3565147-0Report Type:Periodic Company Report #A0110061A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Depressed Mood						TWICE PER DAY	
	Dry Mouth						/ ORAL	
	Dysgeusia							
	Fatigue							
	Insomnia							
	Malaise							
	Tremor							

Date:05/31/00ISR Number: 3565148-2Report Type:Periodic Company Report #A0119201A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Gastrointestinal Pain						PER DAY/ ORAL	
	Pain							
	Pyrexia							
	Rash Pruritic							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565149-4Report Type:Periodic Company Report #A0110114A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Leukocytoclastic	Professional					DAY / ORAL	
	Vasculitis							
	Petechiae							
	Purpura							
	Rash Erythematous							
	Rash Generalised							
	Urticaria							

Date:05/31/00ISR Number: 3565150-0Report Type:Periodic Company Report #A0110329A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Urticaria	Professional					TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3565153-6Report Type:Periodic Company Report #A0118800A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toxicologic Test Abnormal	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG UNK	
		Professional					ORAL	

Date:05/31/00ISR Number: 3565155-XReport Type:Periodic Company Report #A0111747A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Dizziness						DAY/ ORAL	
	Headache							
	Nausea							
	Tremor							

Date:05/31/00ISR Number: 3565157-3Report Type:Periodic Company Report #A0118801A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Yawning						PER DAY ORAL	

Date:05/31/00ISR Number: 3565161-5Report Type:Periodic Company Report #A0118844A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Alanine Aminotransferase Increased		Simvastatin (Formulation Unknown)				PER DAY ORAL	1 MON
	Condition Aggravated		(Simvastatin)	SS		ORAL	UNK ORAL	
	Hepatitis C		Loratadine	C				
			Lansoprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565162-7Report Type:Periodic Company Report #A0111748A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:05/31/00ISR Number: 3565164-0Report Type:Periodic Company Report #A0118847A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	1 TABLET	TWICE PER DAY

ORAL

Date:05/31/00ISR Number: 3565165-2Report Type:Periodic Company Report #A0111749A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL

Date:05/31/00ISR Number: 3565167-6Report Type:Periodic Company Report #A0118867A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:05/31/00ISR Number: 3565168-8Report Type:Periodic Company Report #A0111750A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Level Of Consciousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/	ORAL
	Dizziness		Tylenol Cold Medication (Formulation Unknown) (Tylenol And Cold Medication)	SS				

Date:05/31/00ISR Number: 3565169-XReport Type:Periodic Company Report #A0118881A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG UNKNOWN	ORAL

Date:05/31/00ISR Number: 3565170-6Report Type:Periodic Company Report #A0111814A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG/ TWICE PER DAY/	ORAL 2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565172-XReport Type:Periodic Company Report #A0118886A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Tremor						PER DAY	ORAL

Date:05/31/00ISR Number: 3565174-3Report Type:Periodic Company Report #A0118906A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Metrorrhagia	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY	ORAL 10 DAY
			Ortho-Tri-Cyclen	C				

Date:05/31/00ISR Number: 3565176-7Report Type:Periodic Company Report #A0118912A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Headache						PER DAY	ORAL
	Insomnia							

Date:05/31/00ISR Number: 3565178-0Report Type:Periodic Company Report #A0111815A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG/ TWICE	
							PER DAY/	ORAL

Date:05/31/00ISR Number: 3565179-2Report Type:Periodic Company Report #A0118913A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 TWICE PER	
	Pruritus						DAY ORAL	
			Tetracycline (Formulation Unknown) (Tetracycline)	SS				
UNKNOWN							UNKNOWN	

Date:05/31/00ISR Number: 3565180-9Report Type:Periodic Company Report #A0111870A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Throat Tightness						SINGLE DOSE/	
							ORAL	

Date:05/31/00ISR Number: 3565182-2Report Type:Periodic Company Report #A0118925A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	4 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565183-4Report Type:Periodic Company Report #A0112117A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Urticaria							ORAL

Date:05/31/00ISR Number: 3565185-8Report Type:Periodic Company Report #A0112119A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Dizziness							ORAL
	Flushing							

Date:05/31/00ISR Number: 3565186-XReport Type:Periodic Company Report #A0118926A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ill-Defined Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	DAY ORAL
	Nausea							
	Vomiting							

Date:05/31/00ISR Number: 3565187-1Report Type:Periodic Company Report #A0112120A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Rash Erythematous							ORAL

	Urticaria					

Date:05/31/00ISR Number: 3565188-3Report Type:Periodic Company Report #A0118949A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	
	Urticaria							

Date:05/31/00ISR Number: 3565190-1Report Type:Periodic Company Report #A0112121A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Dry Mouth						DAY/ ORAL	
	Fatigue							

Date:05/31/00ISR Number: 3565191-3Report Type:Periodic Company Report #A0118959A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	
							UNKNOWN ORAL	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565192-5Report Type:Periodic Company Report #A0112122A
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER	DAY/ ORAL

Date:05/31/00ISR Number: 3565194-9Report Type:Periodic Company Report #A0118972A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL
	Dry Mouth							
	Hallucination							
	Nausea							
	Visual Field Defect							

Date:05/31/00ISR Number: 3565195-0Report Type:Periodic Company Report #A0112123A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	DAY/ ORAL
	Fatigue							
	Headache							
	Insomnia							
	Mental Impairment							
	Nausea							

Date:05/31/00ISR Number: 3565196-2Report Type:Periodic Company Report #A0118976A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	

Date:05/31/00ISR Number: 3565197-4Report Type:Periodic Company Report #A0112124A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Hyperhidrosis							

Date:05/31/00ISR Number: 3565198-6Report Type:Periodic Company Report #A0118977A
Age:46 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Chest Discomfort							
	Dyspnoea							
	Hypersensitivity							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565199-8Report Type:Periodic Company Report #A0112125A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Urticaria	Professional					PER DAY/ ORAL	
			Glucophage	C				
			Quinapril Hydrochloride	C				
			Glibenclamide	C				

Date:05/31/00ISR Number: 3565200-1Report Type:Periodic Company Report #A0112126A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcoholic Hangover	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Dizziness	Professional					DAY/ ORAL	
	Fatigue							
	Insomnia							
	Malaise							
	Nausea							
	Retching							

Date:05/31/00ISR Number: 3565201-3Report Type:Periodic Company Report #A0118978A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:05/31/00ISR Number: 3565202-5Report Type:Periodic Company Report #A0112127A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	
			Alprazolam	C				

Date:05/31/00ISR Number: 3565203-7Report Type:Periodic Company Report #A0118980A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:05/31/00ISR Number: 3565204-9Report Type:Periodic Company Report #A0112128A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Night Sweats							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565206-2Report Type:Periodic Company Report #A0112187A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Myalgia						PER DAY/ ORAL	

Date:05/31/00ISR Number: 3565207-4Report Type:Periodic Company Report #A0118981A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Crying	Professional					PER DAY ORAL	
	Irritability							

Date:05/31/00ISR Number: 3565208-6Report Type:Periodic Company Report #A0112312A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Diarrhoea						PER DAY/ ORAL	

Date:05/31/00ISR Number: 3565210-4Report Type:Periodic Company Report #A0110653A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion					
	Mental Disorder		Hydrochloride	PS		ORAL	150 MG/PER	
							DAY/ORAL	

Date:05/31/00ISR Number: 3565212-8Report Type:Periodic Company Report #A0110713A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL
			Thyroxine Sodium	C				

Date:05/31/00ISR Number: 3565214-1Report Type:Periodic Company Report #A0110714A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Eye Irritation Pharyngolaryngeal Pain	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL 2 WK
	Rash Pruritic		Nortriptyline	C				
			Prempro	C				

Date:05/31/00ISR Number: 3565215-3Report Type:Periodic Company Report #A0110716A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea Retching	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL

			Radiotherapy	C		

Date:05/31/00ISR Number: 3565218-9Report Type:Periodic Company Report #A0110727A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Bupropion					
	Nausea		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Retching						PER DAY ORAL	

Date:05/31/00ISR Number: 3565221-9Report Type:Periodic Company Report #A0110728A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion					
	Tachycardia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
							DAY ORAL	

Date:05/31/00ISR Number: 3565223-2Report Type:Periodic Company Report #A0110849A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Consumer	Bupropion					
	Movement Disorder		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150MG TWICE	
	Tremor						PER DAY ORAL	
			Inhaler	C				

Date:05/31/00ISR Number: 3565226-8Report Type:Periodic Company Report #A0110942A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:05/31/00ISR Number: 3565227-XReport Type:Periodic Company Report #A0116543A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Feeling Cold Penis Disorder	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	6 WK

Date:05/31/00ISR Number: 3565228-1Report Type:Periodic Company Report #A0110993A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abdominal Pain Upper	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565230-XReport Type:Periodic Company Report #A0116544A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dizziness Headache Hypertension	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	5 DAY

Date:05/31/00ISR Number: 3565232-3Report Type:Periodic Company Report #A0116579A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Gingival Bleeding Gingivitis Sleep Disorder	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3565235-9Report Type:Periodic Company Report #A0116767A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Discomfort Insomnia Nervousness Nightmare	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY / ORAL	

Date:05/31/00ISR Number: 3565237-2Report Type:Periodic Company Report #A0116768A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Nausea							
	Paraesthesia						TWICE PER DAY	
	Psychomotor Hyperactivity						/ ORAL	
	Tremor							

Date:05/31/00ISR Number: 3565239-6Report Type:Periodic Company Report #A0116769A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Urticaria							
							TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3565242-6Report Type:Periodic Company Report #A0116770A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
							DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565246-3Report Type:Periodic Company Report #A0116771A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3565248-7Report Type:Periodic Company Report #A0116773A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ UNK / ORAL	
			Nicotine Patch	SS		TRANSDERMAL	21 MG / UNK/ TRANSDERMAL	
			Thyroxine Sodium	C				

Date:05/31/00ISR Number: 3565250-5Report Type:Periodic Company Report #A0116777A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depersonalisation Depression Disorientation Dry Mouth Feeling Abnormal Hypersomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Psychiatric Symptom

Date:05/31/00ISR Number: 3565253-0Report Type:Periodic Company Report #A0116779A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	8 DAY

Date:05/31/00ISR Number: 3565258-XReport Type:Periodic Company Report #A0110994A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood Sedation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:05/31/00ISR Number: 3565259-1Report Type:Periodic Company Report #A0110995A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Emotional Disorder Feeling Abnormal Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565260-8Report Type:Periodic Company Report #A0110996A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Nodosum	Health	Bupropion					
	Hypersensitivity	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Pruritus						PER DAY ORAL	
	Rash Erythematous		Ascorbic Acid	C				

Date:05/31/00ISR Number: 3565261-XReport Type:Periodic Company Report #A0110997A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Bupropion					
	Panic Reaction		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
							PER DAY/ORAL	

Date:05/31/00ISR Number: 3565262-1Report Type:Periodic Company Report #A0110998A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Bupropion					
			Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
							PER DAY /	
							ORAL	

Date:05/31/00ISR Number: 3565263-3Report Type:Periodic Company Report #A0110999A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Insomnia	Consumer	Bupropion			
	Tinnitus		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG /

	Tremor

TWICE PER DAY

/ ORAL

Date:05/31/00ISR Number: 3565264-5Report Type:Periodic Company Report #A0111000A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Anxiety	Consumer	Bupropion			
	Depression		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG /

	Nervousness

TWICE PER

DAY/ ORAL

Date:05/31/00ISR Number: 3565266-9Report Type:Periodic Company Report #A0111001A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dermatitis	Health	Bupropion			
	Hypersensitivity	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

Dose Duration

150 MG/ TWICE

PER DAY /ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565267-0Report Type:Periodic Company Report #A0111002A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	
	Ecchymosis							
	Headache							
	Pruritus							
	Swelling							
	Urticaria							

Date:05/31/00ISR Number: 3565268-2Report Type:Periodic Company Report #A0116792A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Diarrhoea							

Date:05/31/00ISR Number: 3565269-4Report Type:Periodic Company Report #A0111003A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Irritability							

Date:05/31/00ISR Number: 3565270-0Report Type:Periodic Company Report #A0111004A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL	
	Insomnia							
	Nausea							
	Tinnitus							
	Tremor							

Date:05/31/00ISR Number: 3565271-2Report Type:Periodic Company Report #A0116795A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	
	Insomnia							

Date:05/31/00ISR Number: 3565272-4Report Type:Periodic Company Report #A0116796A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565273-6Report Type:Periodic Company Report #A0116797A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression Agitation Feeling Abnormal Irritability	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3565275-XReport Type:Periodic Company Report #A0116803A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Feeling Cold	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3565277-3Report Type:Periodic Company Report #A0116806A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Weight Increased	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3565279-7Report Type:Periodic Company Report #A0116808A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Dry Mouth							

Date:05/31/00ISR Number: 3565280-3Report Type:Periodic Company Report #A0116894A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Anxiety							
	Headache							

Date:05/31/00ISR Number: 3565282-7Report Type:Periodic Company Report #A0116898A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Pruritus	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150 MG / TWICE PER DAY / ORAL	
	Rash Erythematous							
	Urticaria							

Date:05/31/00ISR Number: 3565701-6Report Type:Periodic Company Report #A0116207A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Agitation	Professional					PER DAY ORAL	
	Anxiety		Nicotine	C				
	Depression							
	Irritability							
	Mood Altered							
	Nervousness							

Date:05/31/00ISR Number: 3565704-1Report Type:Periodic Company Report #A0116208A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
							PER DAY ORAL	

Date:05/31/00ISR Number: 3565707-7Report Type:Periodic Company Report #A0116209A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Dyspnoea						PER DAY ORAL	
	Face Oedema							
	Hypersensitivity							
	Pruritus							
	Urticaria							

Date:05/31/00ISR Number: 3565709-0Report Type:Periodic Company Report #A0116269A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Urticaria						PER DAY ORAL	

Date:05/31/00ISR Number: 3565711-9Report Type:Periodic Company Report #A0116281A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	3 WK
	Constipation							
	Flatulence							

Date:05/31/00ISR Number: 3565715-6Report Type:Periodic Company Report #A0116440A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Swelling						PER DAY ORAL	
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565716-8Report Type:Periodic Company Report #A0116459A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:05/31/00ISR Number: 3565717-XReport Type:Periodic Company Report #A0116462A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Drug Ineffective							PER DAY ORAL

Date:05/31/00ISR Number: 3565718-1Report Type:Periodic Company Report #A0116468A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Depression							PER DAY ORAL
	Dermatitis							
	Dissociation							
	Elevated Mood							
	Euphoric Mood							
	Hypersensitivity							
	Irritability							
	Lichen Planus							
	Oedema Genital							
	Pruritus							
	Urticaria							

Date:05/31/00ISR Number: 3565719-3Report Type:Periodic Company Report #A0116473A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:05/31/00ISR Number: 3565722-3Report Type:Periodic Company Report #A0116475A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Urticaria	Professional Company Representative						

Date:05/31/00ISR Number: 3565732-6Report Type:Periodic Company Report #A0116480A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Depression							
	Neoplasm							
	Swelling							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565741-7Report Type:Periodic Company Report #A0116490A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	3 WK

Date:05/31/00ISR Number: 3565742-9Report Type:Periodic Company Report #A0116493A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:05/31/00ISR Number: 3565743-0Report Type:Periodic Company Report #A0116494A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:05/31/00ISR Number: 3565744-2Report Type:Periodic Company Report #A0116529A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	7 DAY
	Urticaria							

Date:05/31/00ISR Number: 3565745-4Report Type:Periodic Company Report #A0116530A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:05/31/00ISR Number: 3565746-6Report Type:Periodic Company Report #A0116540A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	PER DAY ORAL

Date:05/31/00ISR Number: 3565747-8Report Type:Periodic Company Report #A0113683A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Face Oedema							

Date:05/31/00ISR Number: 3565748-XReport Type:Periodic Company Report #A0113690A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperuricaemia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565750-8Report Type:Periodic Company Report #A0113693A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eructation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Flatulence						PER DAY/ ORAL	

Date:05/31/00ISR Number: 3565751-XReport Type:Periodic Company Report #A0113744A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Hyperhidrosis						TWICE PER	
	Tremor						DAY/ ORAL	3 WK

Date:05/31/00ISR Number: 3565753-3Report Type:Periodic Company Report #A0113745A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dermatitis						TWICE PER	
	Pruritus						DAY/ ORAL	
	Rash Erythematous							

Date:05/31/00ISR Number: 3565757-0Report Type:Periodic Company Report #A0113746A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ PER
	Communication Disorder					DAY / ORAL
	Feeling Abnormal					

Date:05/31/00ISR Number: 3565760-0Report Type:Periodic Company Report #A0113747A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Asthenia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG /
	Fatigue					TWICE PER
	Insomnia					DAY/ ORAL 3 WK
			Nicotine	C		

Date:05/31/00ISR Number: 3565761-2Report Type:Periodic Company Report #A0113748A
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dissociation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ TWICE
	Dry Mouth					PER DAY /
	Tremor					ORAL

Date:05/31/00ISR Number: 3565765-XReport Type:Periodic Company Report #A0113749A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG /

TWICE PER

DAY/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565771-5Report Type:Periodic Company Report #A0113750A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/	ORAL

Date:05/31/00ISR Number: 3565773-9Report Type:Periodic Company Report #A0113751A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/	ORAL
	Glossodynia							
	Tongue Disorder							

Date:05/31/00ISR Number: 3565776-4Report Type:Periodic Company Report #A0113752A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/	ORAL

Date:05/31/00ISR Number: 3565782-XReport Type:Periodic Company Report #A0113753A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Middle Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	ORAL

Date:05/31/00ISR Number: 3565783-1Report Type:Periodic Company Report #A0113754A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	9 DAY

Date:05/31/00ISR Number: 3565784-3Report Type:Periodic Company Report #A0113755A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:05/31/00ISR Number: 3565785-5Report Type:Periodic Company Report #A0113756A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565786-7Report Type:Periodic Company Report #A0113758A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	ORAL

Date:05/31/00ISR Number: 3565787-9Report Type:Periodic Company Report #A0113765A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dizziness						DAY/	ORAL
	Feeling Abnormal		Nicotine	C				
	Nausea							
	Vomiting							

Date:05/31/00ISR Number: 3565788-0Report Type:Periodic Company Report #A0113768A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER	DAY/ ORAL

Date:05/31/00ISR Number: 3565789-2Report Type:Periodic Company Report #A0113900A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

TWICE PER

DAY/ ORAL

Date:05/31/00ISR Number: 3565790-9Report Type:Periodic Company Report #A0113099A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	

PER DAY/ORAL

Date:05/31/00ISR Number: 3565791-0Report Type:Periodic Company Report #A0113102A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Flatulence						TWICE PER DAY	

/ ORAL

Date:05/31/00ISR Number: 3565793-4Report Type:Periodic Company Report #A0113109A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerumen Impaction	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Feeling Abnormal							
	Gingival Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565794-6Report Type:Periodic Company Report #A0113125A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3565795-8Report Type:Periodic Company Report #A0113130A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:05/31/00ISR Number: 3565796-XReport Type:Periodic Company Report #A0113368A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

Date:05/31/00ISR Number: 3565797-1Report Type:Periodic Company Report #A0113369A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ORAL	MON
	Aggression							
	Crying							
	Drug Dependence							

Drug Ineffective
Insomnia
Psychiatric Symptom

Date:05/31/00ISR Number: 3565798-3Report Type:Periodic Company Report #A0113370A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3565799-5Report Type:Periodic Company Report #A0113379A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
			Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565800-9Report Type:Periodic Company Report #A0113408A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Agitation						PER DAY /	
	Dizziness						ORAL	
	Insomnia		Lisinopril	C				
			Verapamil Hydrochloride	C				
			Estropipate	C				
			Medroxyprogesterone Ace.	C				

Date:05/31/00ISR Number: 3565801-0Report Type:Periodic Company Report #A0113559A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3565802-2Report Type:Periodic Company Report #A0113573A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Insomnia						DAY / ORAL	

Date:05/31/00ISR Number: 3565803-4Report Type:Periodic Company Report #A0113575A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWCE	
	Crying						PER DAY /	
	Emotional Disorder						ORAL	9 DAY

Date:05/31/00ISR Number: 3565804-6Report Type:Periodic Company Report #A0113576A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3565806-XReport Type:Periodic Company Report #A0113625A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Hypersensitivity	Professional						
	Pruritus							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565807-1Report Type:Periodic Company Report #A0113632A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Feeling Hot And Cold						PER DAY /	
	Insomnia						ORAL	
	Menstruation Irregular							
	Tinnitus							
	Tremor							

Date:05/31/00ISR Number: 3565808-3Report Type:Periodic Company Report #A0113645A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Dizziness						PER DAY /	
	Fatigue						ORAL	
	Feeling Abnormal							
	Irritability							
	Vision Blurred							

Date:05/31/00ISR Number: 3565809-5Report Type:Periodic Company Report #A0113661A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
		Professional					TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3565810-1Report Type:Periodic Company Report #A0113680A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL

Date:05/31/00ISR Number: 3565922-2Report Type:Periodic Company Report #A0112333A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL
	Pruritus							

Date:05/31/00ISR Number: 3565925-8Report Type:Periodic Company Report #A0112334A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL
	Miosis							
	Mydriasis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565928-3Report Type:Periodic Company Report #A0112354A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Sleep Talking						TWICE PER DAY	
/ ORAL								

Date:05/31/00ISR Number: 3565930-1Report Type:Periodic Company Report #A112357A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Eye Movement Disorder						UNKNOWN	
/ORAL								

Date:05/31/00ISR Number: 3565932-5Report Type:Periodic Company Report #A0112358A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Decreased Appetite						TWICE PER DAY	
	Feeling Abnormal						/ ORAL	
	Insomnia							
	Irritability							
	Muscle Rigidity							

Date:05/31/00ISR Number: 3565933-7Report Type:Periodic Company Report #A0112359A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Confusional State	Professional					TWICE PER DAY	
	Drug Interaction						/ ORAL	
	Dysgeusia		Desipramine Tablet	SS		ORAL	50 MG / EIGHT	
	Flatulence						TIMES PER DAY	
	Nausea						ORAL	
	Tremor		Lansoprazole	C				
	Ulcer		Theophylline	C				
			Salbutamol Sulphate	C				
			Beclomethasone Dipropion	C				
			Diclofenac Sodium	C				
			Clopidogrel Bisulphate	C				
			Conjugated Estrogens	C				
			Buspirone Hydrochloride	C				
			Iodinated Glycerol	C				
			Thyroxine Sodium	C				
			Ticlopidine	C				

Date:05/31/00ISR Number: 3565935-0Report Type:Periodic Company Report #A0112360A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Libido Decreased						TWICE PER DAY	

/ ORAL

Date:05/31/00ISR Number: 3565939-8Report Type:Periodic Company Report #A0112361A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Irritability						TWICE PER DAY	

/ ORAL

Date:05/31/00ISR Number: 3565941-6Report Type:Periodic Company Report #A0112362A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	

/ ORAL

Date:05/31/00ISR Number: 3565945-3Report Type:Periodic Company Report #A0112363A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	

/ ORAL

Date:05/31/00ISR Number: 3565948-9Report Type:Periodic Company Report #A0112364A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Pharyngolaryngeal Pain						TWICE PER DAY	
							/ ORAL	
			Tenoric	C				
			Alendronate Sodium	C				

Date:05/31/00ISR Number: 3565953-2Report Type:Periodic Company Report #A0112365A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Chest Discomfort						TWICE PER DAY	
	Dermatitis						/ ORAL	
	Diarrhoea		Ibuprofen	C				
	Oedema							
	Pruritus							
	Urticaria							

Date:05/31/00ISR Number: 3565955-6Report Type:Periodic Company Report #A0112366A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Urticaria						TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3565958-1Report Type:Periodic Company Report #A0112367A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous		Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Rash Pruritic						TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3565961-1Report Type:Periodic Company Report #A0112368A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dyspnoea						TWICE PER DAY	
	Eructation						/ ORAL	

Date:05/31/00ISR Number: 3565966-0Report Type:Periodic Company Report #A0112369A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Tongue Disorder						TWICE PER DAY	
	Tongue Oedema						/ ORAL	

Date:05/31/00ISR Number: 3565972-6Report Type:Periodic Company Report #A0112394A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Arthralgia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Oedema Peripheral					
TWICE PER DAY						
/ ORAL						

Date:05/31/00ISR Number: 3565975-1Report Type:Periodic Company Report #A0112398A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Depression	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /		Professional				
TWICE PER DAY						
/ ORAL						

Date:05/31/00ISR Number: 3565980-5Report Type:Periodic Company Report #A0112399A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Night Sweats					
TWICE PER DAY						
	Tremor					
/ ORAL						

Date:05/31/00ISR Number: 3565981-7Report Type:Periodic Company Report #A0112400A
Age:75 YR Gender:Female I/FU:I

Outcome	PT
	Agitation
	Asthenia
	Dyspnoea Exacerbated
	Excitability

	Tremor					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						

Date:05/31/00ISR Number: 3565987-8Report Type:Periodic Company Report #A0114978A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Confusional State	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Dermatitis					
TWICE PER DAY						
	Pruritus					
/ ORAL						
			Arthritis Medication	C		

Date:05/31/00ISR Number: 3565988-XReport Type:Periodic Company Report #A0114981A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / ORAL						

Date:05/31/00ISR Number: 3565990-8Report Type:Periodic Company Report #A0115063A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Constipation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Insomnia	Professional				
TWICE PER DAY						

	Rash Pruritic					
/ ORAL						

Date:05/31/00ISR Number: 3565991-XReport Type:Periodic Company Report #A0115070A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Face Oedema						TWICE PER DAY	
	Rash Generalised						/ ORAL	
	Urticaria							

Date:05/31/00ISR Number: 3565996-9Report Type:Periodic Company Report #A0115078A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
		Professional						
		Company						
		Representative						

Date:05/31/00ISR Number: 3565998-2Report Type:Periodic Company Report #A0115079A
Age:51 YR Gender:Female I/FU:I

Outcome	PT
	Anxiety
	Feeling Abnormal
	Insomnia

Irritability Nightmare						
Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / PER DAY / ORAL	2 DAY					

Date:05/31/00ISR Number: 3566000-9Report Type:Periodic Company Report #A0115081A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Chest Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL						

Date:05/31/00ISR Number: 3566001-0Report Type:Periodic Company Report #A0115111A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dizziness Hangover	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL	8 DAY					

Date:05/31/00ISR Number: 3566004-6Report Type:Periodic Company Report #A0115147A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Crying	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / PER						

DAY / ORAL

Date:05/31/00ISR Number: 3566007-1Report Type:Periodic Company Report #A0115180A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

Date:05/31/00ISR Number: 3566010-1Report Type:Periodic Company Report #A0115207A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cluster Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Headache							
	Nausea							

Date:05/31/00ISR Number: 3566014-9Report Type:Periodic Company Report #A0115212A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Personality Change		Oral Contraceptive	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566021-6Report Type:Periodic Company Report #A0115214A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:05/31/00ISR Number: 3566024-1Report Type:Periodic Company Report #A0115217A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dysgeusia						DAY / ORAL	
	Insomnia		Augmentin	C				
	Nervousness							
	Night Sweats							
	Nightmare							
	Tension							

Date:05/31/00ISR Number: 3566026-5Report Type:Periodic Company Report #A0115250A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	4 WK

Date:05/31/00ISR Number: 3566029-0Report Type:Periodic Company Report #A0115267A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Pruritus						TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3566032-0Report Type:Periodic Company Report #A0115268A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Agitation Drug Interaction Mood Swings	Professional	Oral Contraceptive (Formulation Unknown) (Oral Contraceptive)	SS		ORAL	ORAL	

Date:05/31/00ISR Number: 3566033-2Report Type:Periodic Company Report #A0115300A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566034-4Report Type:Periodic Company Report #A0115303A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Blood Pressure Increased	Professional					DAY / ORAL	
	Feeling Abnormal		Lotensin Hct (Formulation Unknown) (Lotensin Hct)	SS				

Date:05/31/00ISR Number: 3566035-6Report Type:Periodic Company Report #A0115304A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:05/31/00ISR Number: 3566039-3Report Type:Periodic Company Report #A0112405A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	3 WK

Date:05/31/00ISR Number: 3566041-1Report Type:Periodic Company Report #A0112407A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Headache							
	Weight Increased							

Date:05/31/00ISR Number: 3566043-5Report Type:Periodic Company Report #A0112412A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/THREE	
	Anxiety	Professional					TIMES PER	
	Dizziness						DAY/ORAL	
	Insomnia							
	Nausea							

Date:05/31/00ISR Number: 3566046-0Report Type:Periodic Company Report #A0112415A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
							DAY/ORAL	

Date:05/31/00ISR Number: 3566047-2Report Type:Periodic Company Report #A0112416A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
							PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566061-7Report Type:Periodic Company Report #A0112417A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	1 WK

Date:05/31/00ISR Number: 3566063-0Report Type:Periodic Company Report #A0112421A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
	Insomnia							

Date:05/31/00ISR Number: 3566065-4Report Type:Periodic Company Report #A0112589A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	2 WK
	Influenza		Irbesartan	C				
	Nausea		Chlorpheniramine Maleate	C				

Date:05/31/00ISR Number: 3566066-6Report Type:Periodic Company Report #A0112592A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
			Nicotine	SS				

Date:05/31/00ISR Number: 3566068-XReport Type:Periodic Company Report #A0112602A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Consciousness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Pruritus							
	Urticaria							

Date:05/31/00ISR Number: 3566069-1Report Type:Periodic Company Report #A0112604A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Hypersensitivity						PER DAY/ORAL	
	Rash Papular							
	Rash Pruritic							

Date:05/31/00ISR Number: 3566072-1Report Type:Periodic Company Report #A0112612A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
							PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566074-5Report Type:Periodic Company Report #A0112613A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Pain In Extremity						PER DAY/ORAL	

Date:05/31/00ISR Number: 3566077-0Report Type:Periodic Company Report #A0112614A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Palpitations							

Date:05/31/00ISR Number: 3566079-4Report Type:Periodic Company Report #A0112617A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
							PER DAY/ORAL	
			Muscle Relaxant	C				

Date:05/31/00ISR Number: 3566081-2Report Type:Periodic Company Report #A0112736A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	

Date:05/31/00ISR Number: 3566083-6Report Type:Periodic Company Report #A0112737A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Dysarthria						PER DAY/ORAL	
	Speech Disorder		Ethanol	SS		ORAL	ORAL	

Date:05/31/00ISR Number: 3566084-8Report Type:Periodic Company Report #A0114964A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Vision Blurred						PER DAY /	
ORAL								5 DAY

Date:05/31/00ISR Number: 3566087-3Report Type:Periodic Company Report #A0114965A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Dysphagia						PER DAY /	
	Sleep Disorder						ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566088-5Report Type:Periodic Company Report #A0112738A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Erythema						PER DAY/ORAL	
	Pruritus							
	Urticaria							

Date:05/31/00ISR Number: 3566091-5Report Type:Periodic Company Report #A0112739A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	

Date:05/31/00ISR Number: 3566092-7Report Type:Periodic Company Report #A0114968A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL	
	Pruritus							
	Urticaria							

Date:05/31/00ISR Number: 3566093-9Report Type:Periodic Company Report #A0112743A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
	Insomnia						DAY/ORAL	

Date:05/31/00ISR Number: 3566094-0Report Type:Periodic Company Report #A0114975A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	
	Decreased Appetite							
	Diarrhoea							
	Flatulence							

Date:05/31/00ISR Number: 3566097-6Report Type:Periodic Company Report #A0114541A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Haematuria							
	Insomnia							

Date:05/31/00ISR Number: 3566100-3Report Type:Periodic Company Report #A0114543A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	1 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566101-5Report Type:Periodic Company Report #A0114545A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER DAY / ORAL	

Date:05/31/00ISR Number: 3566103-9Report Type:Periodic Company Report #A0114549A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	7 DAY
	Depressed Level Of Consciousness							
	Feeling Abnormal							
	Nervousness							
	Tremor							

Date:05/31/00ISR Number: 3566106-4Report Type:Periodic Company Report #A0114557A
Age:50 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL	
	Insomnia							

Date:05/31/00ISR Number: 3566108-8Report Type:Periodic Company Report #A114559A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

	Dizziness					
TWICE PER DAY						
	Paraesthesia					
/ ORAL						
	Sensation Of Pressure					
	Syncope					

Date:05/31/00ISR Number: 3566109-XReport Type:Periodic Company Report #A0114682A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgraphia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER	
	Feeling Abnormal							
DAY / ORAL								
	Feeling Drunk							
	Insomnia							
	Irritability							
	Tremor							

Date:05/31/00ISR Number: 3566111-8Report Type:Periodic Company Report #A0114683A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dry Mouth							
TWICE PER								
	Feeling Abnormal							
DAY/ORAL								
	Insomnia							
	Major Depression							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566113-1Report Type:Periodic Company Report #A0114684A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Dry Mouth						DAY/ ORAL	
	Insomnia							
	Irritability							
	Psychomotor Hyperactivity							

Date:05/31/00ISR Number: 3566115-5Report Type:Periodic Company Report #A0114746A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	No Adverse Drug Effect	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER	
							DAY / ORAL	

Date:05/31/00ISR Number: 3566117-9Report Type:Periodic Company Report #A0114838A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	

Date:05/31/00ISR Number: 3566119-2Report Type:Periodic Company Report #A0114866A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:05/31/00ISR Number: 3566123-4Report Type:Periodic Company Report #A0114869A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Derealisation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Flight Of Ideas						PER DAY /	
	Gastric Disorder						ORAL	
	Insomnia							
	Nightmare							

Date:05/31/00ISR Number: 3566125-8Report Type:Periodic Company Report #A0114870A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspraxia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	
	Tremor						/VARIABLE	
							DOSE/ ORAL	

Date:05/31/00ISR Number: 3566127-1Report Type:Periodic Company Report #A0114962A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566128-3Report Type:Periodic Company Report #A0114963A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY /	
	Dissociation							
	Disturbance In Attention							
ORAL								1 WK
	Feeling Abnormal							
	Staring							

Date:05/31/00ISR Number: 3566136-2Report Type:Periodic Company Report #A0111596A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
	Insomnia							

Date:05/31/00ISR Number: 3566144-1Report Type:Periodic Company Report #A0110331A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Fatigue							
	Irritability							

Date:05/31/00ISR Number: 3566146-5Report Type:Periodic Company Report #A0110332A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chest Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Drug Ineffective					
TWICE PER						
	Irritability					
DAY / ORAL						

Date:05/31/00ISR Number: 3566147-7Report Type:Periodic Company Report #A0110371A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Dizziness	Professional				
TWICE PER DAY						
	Flushing					
/ ORAL						
	Gastrointestinal Disorder					
	Ill-Defined Disorder					
	Influenza Like Illness					
	Pyrexia					
	Urticaria					

Date:05/31/00ISR Number: 3566150-7Report Type:Periodic Company Report #A0110563A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Dry Mouth	Professional				
TWICE PER DAY						
	Insomnia					
/ ORAL						
	Irritability					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566152-0Report Type:Periodic Company Report #A0110565A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Agitation						DAY / ORAL	
	Disturbance In Attention							
	Dizziness							
	Mental Impairment							
	Nausea							
	Tremor							

Date:05/31/00ISR Number: 3566154-4Report Type:Periodic Company Report #A0110570A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Parosmia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3566159-3Report Type:Periodic Company Report #A0110701A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Formication	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Insomnia	Professional					DAY / ORAL	

Date:05/31/00ISR Number: 3566162-3Report Type:Periodic Company Report #A0110704A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Chest Pain	Professional					TWICE PER DAY	
	Dizziness						/ ORAL	
	Dry Mouth		Loratadine	C				
	Dry Throat		Gemfibrozil	C				
	Dysphagia		Cimetidine	C				
	Feeling Abnormal		Conjugated Estrogens	C				
			Salbutamol Sulphate	C				
			Vitamin E	C				
			Selenium	C				
			Vitamin B	C				
			Ascorbic Acid	C				

Date:05/31/00ISR Number: 3566164-7Report Type:Periodic Company Report #A0110707A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperventilation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Hypoaesthesia						TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566167-2Report Type:Periodic Company Report #A0110850A
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Drug Ineffective	Professional					TWICE PER DAY	
							/ ORAL	
			Vicodin	C				
			Cyclobenzaprine Hcl	C				

Date:05/31/00ISR Number: 3566173-8Report Type:Periodic Company Report #A0110991A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG / ORAL	
	Drug Interaction	Professional	Thyroxine Sodium					
	Dysphonia	Company	(Formulation					
	Irritability	Representative	Unknown)					
	Nervousness		(Levothyroxine					
	Tremor		Sodium)	SS			15 MG /	
			Pravastatin Sodium					
			(Formulation Uknown)					
			(Pravastatin Sodium)	SS			20 MG /	

Date:05/31/00ISR Number: 3566175-1Report Type:Periodic Company Report #A0055869A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Hypersensitivity							
	Pruritus							

Date:05/31/00ISR Number: 3566176-3Report Type:Periodic Company Report #A0062919A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL
			Alprazolam	C				

Date:05/31/00ISR Number: 3566178-7Report Type:Periodic Company Report #A0062920A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL

Date:05/31/00ISR Number: 3566214-8Report Type:Periodic Company Report #A0113901A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Insomnia Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566218-5Report Type:Periodic Company Report #A0113902A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY /	
ORAL								8 WK

Date:05/31/00ISR Number: 3566220-3Report Type:Periodic Company Report #A0113903A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Irritability							
PER DAY/ ORAL								

Date:05/31/00ISR Number: 3566225-2Report Type:Periodic Company Report #A0113925A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Urticaria							
PER DAY/ ORAL								

Date:05/31/00ISR Number: 3566227-6Report Type:Periodic Company Report #A0113936A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

Constipation
PER DAY/
Dry Mouth
ORAL
Tremor

Date:05/31/00ISR Number: 3566228-8Report Type:Periodic Company Report #A0113937A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 ,G/	TWICE
	Urticaria						PER DAY /	
	Vision Blurred						ORAL	

Date:05/31/00ISR Number: 3566231-8Report Type:Periodic Company Report #A0113938A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
	Rash Erythematous						PER DAY/ ORAL	

Date:05/31/00ISR Number: 3566234-3Report Type:Periodic Company Report #A0113941A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
							PER DAY /	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566236-7Report Type:Periodic Company Report #A0113964A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	

Date:05/31/00ISR Number: 3566239-2Report Type:Periodic Company Report #A0114126A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

Date:05/31/00ISR Number: 3566242-2Report Type:Periodic Company Report #A0114127A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Discomfort	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Nasopharyngitis	Professional					TWICE PER DAY	
	Tinnitus						/ ORAL	1 WK

Date:05/31/00ISR Number: 3566247-1Report Type:Periodic Company Report #A0114347A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

Date:05/31/00ISR Number: 3566255-0Report Type:Periodic Company Report #A0114348A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
	Depression						PER DAY/ ORAL	
	Dry Mouth							
	Emotional Disorder							

Date:05/31/00ISR Number: 3566258-6Report Type:Periodic Company Report #A0114381A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Insomnia						DAY /ORAL	

Date:05/31/00ISR Number: 3566262-8Report Type:Periodic Company Report #A0114390A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Multiforme	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
		Professional						
		Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3566264-1Report Type:Periodic Company Report #A0114397A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Rash Pruritic						TWICE PER DAY	
/ ORAL								

Date:05/31/00ISR Number: 3566266-5Report Type:Periodic Company Report #A0114476A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dysgeusia						TWICE PER DAY	
/ ORAL								

Date:05/31/00ISR Number: 3566270-7Report Type:Periodic Company Report #A0114526A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Throat Tightness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Vomiting						TWICE PER	
DAY/ ORAL								

Date:05/31/00ISR Number: 3566273-2Report Type:Periodic Company Report #A0114530A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chest Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG /
	Dermatitis					TWICE PER
	Dyspnoea					DAY / ORAL
	Hypoaesthesia					
	Swelling					

Date:05/31/00ISR Number: 3566275-6Report Type:Periodic Company Report #A0114538A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG /TWICE
	Sedation					PER ORAL/ORAL
	Tremor					
	Vision Blurred					

Date:05/31/00ISR Number: 3588334-4Report Type:Periodic Company Report #A0116900A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG /TWICE PER DAY / ORAL

Date:05/31/00ISR Number: 3588335-6Report Type:Periodic Company Report #A0116936A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	3 WK

Date:05/31/00ISR Number: 3588336-8Report Type:Periodic Company Report #A0116940A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Dizziness Postural							
	Euphoric Mood							
	Feeling Abnormal							
	Hypokinesia							
	Nausea							

Date:05/31/00ISR Number: 3588337-XReport Type:Periodic Company Report #A0117055A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delusion	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / SEE TEXT / ORAL	
	Irritability							
	Suicide Attempt							

Date:05/31/00ISR Number: 3588338-1Report Type:Periodic Company Report #A0117149A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:05/31/00ISR Number: 3588339-3Report Type:Periodic Company Report #A0117178A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	TWICE PER DAY / ORAL

Date:05/31/00ISR Number: 3588340-XReport Type:Periodic Company Report #A0117179A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG /	TWICE PER DAY/ ORAL
	Overdose							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3588341-1Report Type:Periodic Company Report #A0117200A
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Benign Prostatic Hyperplasia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	5 DAY
	Condition Aggravated							
	Dysuria							

Date:05/31/00ISR Number: 3588342-3Report Type:Periodic Company Report #A0117206A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Costochondritis							
	Dysgeusia							
	Insomnia							
	Nausea							

Date:05/31/00ISR Number: 3588343-5Report Type:Periodic Company Report #A0117209A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3588344-7Report Type:Periodic Company Report #A0117220A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Tinnitus	Professional					TWICE PER DAY	
							/ ORAL	5 WK

Date:05/31/00ISR Number: 3588345-9Report Type:Periodic Company Report #A0117226A
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
		Professional					TWICE PER DAY	
							/ ORAL	
			Felodipine	C				
			Hydrochlorothiazide	C				

Date:05/31/00ISR Number: 3588346-0Report Type:Periodic Company Report #A0117230A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
							TWICE PER DAY	
							/ ORAL	3 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3588347-2Report Type:Periodic Company Report #A0117232A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Body Temperature						DAY / ORAL	
	Decreased							
	Feeling Abnormal							
	Feeling Cold							
	Insomnia							
	Irritability							

Date:05/31/00ISR Number: 3588348-4Report Type:Periodic Company Report #A0117233A
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Rash Pruritic						TWICE PER DAY	
							/ ORAL	1 WK
			Nicotine	C				

Date:05/31/00ISR Number: 3588349-6Report Type:Periodic Company Report #A0117283A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Drug Dependence						TWICE PER DAY	
							/ ORAL	

Date:05/31/00ISR Number: 3588350-2Report Type:Periodic Company Report #A0117286A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Ibuprofen	C				

Date:05/31/00ISR Number: 3588351-4Report Type:Periodic Company Report #A0117299A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Drug Ineffective							
	Headache							
	Insomnia							
	Nausea							

Date:05/31/00ISR Number: 3588352-6Report Type:Periodic Company Report #A0117320A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	2 WK
	Confusional State							
	Drug Ineffective							
	Insomnia							
	Mental Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3588353-8Report Type:Periodic Company Report #A0117337A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	12 DAY

Date:05/31/00ISR Number: 3588377-0Report Type:Periodic Company Report #A0119212A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:05/31/00ISR Number: 3588379-4Report Type:Periodic Company Report #A0119215A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Irritability Tremor	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

Date:05/31/00ISR Number: 3588380-0Report Type:Periodic Company Report #A0119342A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:05/31/00ISR Number: 3588383-6Report Type:Periodic Company Report #A0119347A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Apathy	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY/ ORAL	
	Dyspnoea Exacerbated							
	Feeling Abnormal							
	Therapeutic Response							
	Unexpected							

Date:05/31/00ISR Number: 3588385-XReport Type:Periodic Company Report #A0119400A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	1 TABLET / TWICE PER DAY/ ORAL	
	Pruritus							
	Rash Generalised							

Date:05/31/00ISR Number: 3588387-3Report Type:Periodic Company Report #A0119413A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Dry Mouth							
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3588390-3Report Type:Periodic Company Report #A0119420A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Irritability							
	Mood Altered							

Date:05/31/00ISR Number: 3588393-9Report Type:Periodic Company Report #A0119423A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Hypersensitivity							

Date:05/31/00ISR Number: 3588395-2Report Type:Periodic Company Report #A0119426A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	
	Nausea							
	Oral Intake Reduced							
	Vomiting							

Date:05/31/00ISR Number: 3588397-6Report Type:Periodic Company Report #A0119432A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Bupropion					

	Dry Mouth		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Insomnia					
TWICE PER DAY						
/ ORAL						
			Levofloxacin Tablet	SS		ORAL
500 MG / PER						
DAY / ORAL						

Date:05/31/00ISR Number: 3588399-XReport Type:Periodic Company Report #A0119438A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urticaria	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG / ORAL						

Date:05/31/00ISR Number: 3588402-7Report Type:Periodic Company Report #A0119439A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
TWICE PER DAY						
/ ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3588403-9Report Type:Periodic Company Report #A0119441A
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking Dizziness Gait Disturbance Sensation Of Heaviness	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3588404-0Report Type:Periodic Company Report #A0119495A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour Drug Ineffective	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	1 WK

Date:05/31/00ISR Number: 3588405-2Report Type:Periodic Company Report #A0119576A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Depressed Mood Depression Drug Level Changed Exercise Electrocardiogram Abnormal Flushing Headache Heart Rate Abnormal Hypertension Hypothyroidism Insomnia Panic Disorder Pyrexia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

	Tachycardia					
	Tremor					

Date:05/31/00ISR Number: 3588406-4Report Type:Periodic Company Report #A0119758A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:05/31/00ISR Number: 3588407-6Report Type:Periodic Company Report #A0119849A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Other	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Dizziness							
	Nausea		Nicotine Patch	SS		TRANSDERMAL	14 MG/	TRANSDERMAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3588408-8Report Type:Periodic Company Report #A0120199A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:05/31/00ISR Number: 3588409-XReport Type:Periodic Company Report #A0070637A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / SINGLE DOSE / ORAL	
	Agitation							
	Anxiety							
	Confusional State							
	Headache							
	Hyperaesthesia							
	Nervousness							
	Paraesthesia							
	Psychotic Disorder							
	Tension							
	Tinnitus							

Date:05/31/00ISR Number: 3588411-8Report Type:Periodic Company Report #A0103803A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	
	Constipation							
	Insomnia							

/ ORAL

Date:06/02/00ISR Number: 3507890-5Report Type:Expedited (15-DaCompany Report #A005730
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Distension Dissociative Identity Disorder Nausea Nervousness Tremor	Health Professional	Zoloft Bupropion	PS SS	Pfizer Pharmaceuticals Inc			

Date:06/02/00ISR Number: 3507892-9Report Type:Expedited (15-DaCompany Report #A0088169A
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain Face Oedema Fatigue Hyperchlorhydria Hypothyroidism Liver Function Test Abnormal Palpitations Paraesthesia

		Pericardial Effusion Swelling Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ PER							
DAY/ ORAL							

Date:06/05/00ISR Number: 3508735-XReport Type:Expedited (15-DaCompany Report #A0117763A
Age:64 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Ageusia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE							
		Decreased Appetite	Professional				
PER DAY ORAL							
		Headache	Company Representative Other	Terbinafine (Formulation Unknown) (Terbinafine)	SS		ORAL
250 MG PER							
DAY ORAL							
				Aspirin	C		
				Armour Thyroid	C		

Date:06/05/00ISR Number: 3508739-7Report Type:Expedited (15-DaCompany Report #A0119802A
Age:8 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Required		Arthralgia	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
100 MG TWICE							
Intervention to		Conjunctivitis	Professional				
PER DAY ORAL							
Prevent Permanent		Erythema Multiforme		Methylphenidate Hcl	C		
Impairment/Damage		Joint Swelling		Adderall	C		
		Myalgia					
		Serum Sickness					
		Urticaria					

Date:06/05/00ISR Number: 3509248-1Report Type:Expedited (15-DaCompany Report #A0118008A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL		
	Hallucination	Professional Other	Zolpidem Tartrate (Formulation Unknown) (Zolpidem Tartrate)	SS				
			Alprazolam (Formulation Unknown) (Alprazolam)	SS				
			Temazepam (Formulation Unknown) (Temazepam)	SS				

Date:06/05/00ISR Number: 3509249-3Report Type:Expedited (15-DaCompany Report #A0121104A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL
	Myocardial Infarction		Sildefanil Citrate Tablet (Sildenafil Citrate)	SS		ORAL	SINGLE DOSE.	

ORAL
Co-Trimoxazole C

Date:06/05/00ISR Number: 3509251-1Report Type:Expedited (15-DaCompany Report #A0119185A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Multiple Sclerosis	Foreign Health Professional	Zyban Prednisone	PS C	Glaxo Wellcome Inc	ORAL	150 MG / ORAL

Date:06/07/00ISR Number: 3508637-9Report Type:Direct Company Report #USP 081288
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Medication Error		Wellbutrin 100mg Wellbutrin Sr 100 (Bupirion 100 Sr)	PS SS	Glaxo Pharm Glaxo Pharm		

Date:06/08/00ISR Number: 3510563-6Report Type:Expedited (15-DaCompany Report #A007267
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Bone Marrow Depression Diabetes Mellitus	Health Professional	Glucotrol Xl	PS	Pfizer Inc	ORAL	10.00 MG TOTAL; DAILY;
Required Intervention to Prevent Permanent Impairment/Damage	Inadequate Control Drug Interaction Fatigue Herpes Zoster Leukopenia		Wellbutrin Ritalin	SS SS		ORAL	200.00 MG TOTAL; BID 100.00 MG TOTAL; QID

	Urine Glucose False Positive Vomiting					

Date:06/08/00ISR Number: 3510643-5Report Type:Expedited (15-DaCompany Report #A0120487A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Biopsy Skin Abnormal	Literature	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL
	Eye Disorder Scar Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Visual Disturbance	Health Professional					

Date:06/08/00ISR Number: 3510667-8Report Type:Expedited (15-DaCompany Report #USA/00/01444/LAS
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Ageusia Drug Interaction	Health Professional	Lamisil	PS	Novartis Pharmaceuticals Corp	ORAL	250 MG, ONCE A DAY, ORAL
			Wellbutrin	SS		ORAL	150 MG, ONCE A DAY, ORAL;
			Aspirin (Acetylsalicylic				

Acid)	C
Thyroid	C
Prempo (Provella-14)	C

Date:06/09/00ISR Number: 3511199-3Report Type:Expedited (15-DaCompany Report #A0117940A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Bronchospasm Burning Sensation Chest Pain Dizziness Drug Hypersensitivity Dyspnoea Eye Irritation Eyelid Oedema Haemorrhage Irritability Oedema Pain Palpitations Pruritus Rash Erythematous Rash Vesicular Toxic Shock Syndrome Urticaria	Consumer	Bupropion Hydrochloride Carisoprodol Diazepam	PS C C	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/	ORAL

Date:06/09/00ISR Number: 3511496-1Report Type:Expedited (15-DaCompany Report #A0121649A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased Arthralgia Bronchospasm Dermatitis Eyelid Oedema Rash Generalised	Foreign Health Professional	Bupropion Hydrochloride Echinacea Ginseng Lignocaine Fusidate Sodium	PS C C C C	Glaxo Wellcome Inc	ORAL	ORAL	

	Urticaria					

Date:06/09/00ISR Number: 3516348-9Report Type:Periodic Company Report #209927
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Accutane	PS	Hlr Technology	ORAL	2 PER DAY	
	Condition Aggravated					ORAL		
	Confusional State		Serzone (Nefazodone					
	Depression		Hydrochloride)	SS		ORAL	2 PER DAY	
	Dry Skin					ORAL		
	Headache		Wellbutrin					
	Lip Dry		(Bupropion					
	Musculoskeletal Stiffness		Hydrochloride)	SS		ORAL	ORAL	
	Nausea							
	Schizophrenia							
	Suicidal Ideation							
	Thinking Abnormal							
	Vomiting							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/00ISR Number: 3511675-3Report Type:Expedited (15-DaCompany Report #A0070194A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia	Consumer	Bupropion					
Other	Cognitive Disorder		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
	Convulsion						DAY/ORAL	
	Drug Ineffective		Ibuprofen	C				
	Encephalopathy		General Anesthetic	C				
	Feeling Abnormal		Surgery	C				

Date:06/14/00ISR Number: 3513457-5Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Morphine Pca	PS			PCA 1MG Q 8	
	Coma						MIN	
			Bupropine 25mg	SS			75MG QD	
			Diffenlyderm	C				
			Dartax	C				
			Dubansetere					
			Hydarcharde	C				
			Trarodore	C				
			Tigas	C				
			Cefraolin	C				
			Bethameehol	C				
			Proxyrine	C				
			Polycreboph	C				
			Cromolyin	C				
			Primarin	C				
			Ketorolac	C				
			Tums	C				
			Bashosc	C				
			Hydrocodone/Apap	C				
			Fentanyl	C				
			Versied	C				
			Propofool	C				

Date:06/14/00ISR Number: 3514915-XReport Type:Expedited (15-DaCompany Report #A0121644A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Artery Embolism	Health Professional Company Representative	Wellbutrin Warfarin Sodium	PS C	Glaxo Wellcome Inc			

Date:06/14/00ISR Number: 3514916-1Report Type:Expedited (15-DaCompany Report #A0121923A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	DAY
	Fear	Health						
	Feeling Abnormal Hiccups	Professional Company Representative	Amitriptyline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/14/00ISR Number: 3514918-5Report Type:Expedited (15-DaCompany Report #A0121921A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL
	Dyspnoea							
	Hypersensitivity		Blood Pressure Medication	C				
	Leukocytosis		Allegra-D	C				
	Localised Oedema		Budesonide	C				
	Pharyngolaryngeal Pain							
	Pyrexia							
	Urticaria							

Date:06/15/00ISR Number: 3513785-3Report Type:Direct Company Report #
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Effect Decreased		Teva Usa Bupropion	PS	Teva Usa	ORAL	100MG QID	
ORAL								90 DAY
			Zyprexa	C				
			..	C				

Date:06/15/00ISR Number: 3514777-0Report Type:Expedited (15-DaCompany Report #A0122022A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Degeneration	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:06/15/00ISR Number: 3514778-2Report Type:Expedited (15-DaCompany Report #A0122021A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Degeneration	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
		Professional						

Date:06/15/00ISR Number: 3514780-0Report Type:Expedited (15-DaCompany Report #B0082488A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Retinal Detachment Retinal Exudates Retinal Oedema Retinitis Vasculitis Visual Disturbance	Foreign Study Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:06/19/00ISR Number: 3515684-XReport Type:Expedited (15-DaCompany Report #A0117734A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis Ulcerative Diarrhoea	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
			Mesalazine	C				
			Cyclobenzaprine Hc1	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/00ISR Number: 3515685-1Report Type:Expedited (15-DaCompany Report #A0121698A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Level Of	Literature	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG	ORAL
	Consciousness	Health						
	Grand Mal Convulsion	Professional						
	Intentional Misuse							
	Intentional Self-Injury							
	Lethargy							
	Status Epilepticus							

Date:06/19/00ISR Number: 3515686-3Report Type:Expedited (15-DaCompany Report #A0122018A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Fluctuation	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY	ORAL
	Coma		Wellbutrin Tablet-Controlled Released (Bupropion Hydrochloride)	SS		ORAL	150 MG/TWICE PER DAY	ORAL
	Condition Aggravated							
	Emphysema							
	Oxygen Saturation Decreased							
	Pneumonia		Levofloxacin	C				
			Alendronate Sodium	C				
			Frusemide	C				
			Metoprolol Succinate	C				
			Oestradiol	C				
			Verapamil	C				
			Fenofibrate	C				
			Potassium Chloride	C				
			Tylenol No. 3	C				

Date:06/20/00ISR Number: 3515908-9Report Type:Direct Company Report #
Age:5 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Complications Of Maternal Exposure To Therapeutic Drugs Convulsion Fear Tremor		Wellbutrin Burroughs Well	PS	Burroughs Well	ORAL	SR 150 MG BID PO	
			Diflucan Nystatin Cream Neb Tx	C C C				

Date:06/20/00ISR Number: 3516367-2Report Type:Expedited (15-DaCompany Report #203784
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia Arthritis Dermatitis Pyrexia	Study Health Professional	Ticlid	PS	Syntex (Usa) Inc	ORAL	250 MG 1 PER 12 HOUR ORAL	
			Sibrafiban (Sibrafiban)	SS		ORAL	4.5 MG 1 PER 12 HOUR ORAL	
			Wellbutrin (Ibupropion Hydrochloride)	SS			150 MG DAILY	
			Placebo (Placebo)	SS		ORAL	1 PER 12 HOUR ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3517395-3Report Type:Direct Company Report #
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nausea Pruritus Pyrexia Rash Erythematous Rash Papular Urticaria		Wellbutrin	PS			2	WK

Date:06/22/00ISR Number: 3518369-9Report Type:Expedited (15-DaCompany Report #D0008602A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amaurosis Fugax Condition Aggravated	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL ORAL		

Date:06/23/00ISR Number: 3518642-4Report Type:Expedited (15-DaCompany Report #A0122304A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Magnesium Decreased Grand Mal Convulsion	Health Professional Other	Wellbutrin Sr Tarka Hydrochlorothiazide	PS C C	Glaxo Wellcome Inc	ORAL ORAL	6	MON

Date:06/23/00ISR Number: 3518645-XReport Type:Expedited (15-DaCompany Report #A0122473A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Stem Infarction Dysarthria	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL PER DAY /	150 MG/	TWICE

		Dysphagia	Company					
ORAL	4 MON							
		Hypoaesthesia Oral	Representative	Glipizide	C			
		Nervous System Disorder		Rosiglitazone	C			
		Tongue Paralysis		Antihypertensive	C			

Date:06/23/00ISR Number: 3518649-7Report Type:Expedited (15-DaCompany Report #A0122591A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
		Health Professional						

Date:06/23/00ISR Number: 3518653-9Report Type:Expedited (15-DaCompany Report #A0122595A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicide Attempt	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/00ISR Number: 3518706-5Report Type:Expedited (15-DaCompany Report #A0120940A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Foreign	Bupropion					
	Neck Pain	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Night Sweats	Professional					PER DAY/ORAL	
	Pain							
	Paraesthesia							
	Visual Disturbance							

Date:06/26/00ISR Number: 3519482-2Report Type:Expedited (15-DaCompany Report #A0122595A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	8 DAY
	Suicide Attempt	Professional						
		Company						
		Representative						

Date:06/26/00ISR Number: 3519486-XReport Type:Expedited (15-DaCompany Report #A0122538A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
Initial or Prolonged	Coma	Professional					PER DAY/ ORAL	
	Lethargy		Opiate (Opiate)	SS				
	Neuroleptic Malignant		Benzodiazepines	SS				
	Syndrome							
	Overdose							
	Pupil Fixed							
	Rhabdomyolysis							
	Stupor							
	Toxicologic Test Abnormal							

Date:06/26/00ISR Number: 3519488-3Report Type:Expedited (15-DaCompany Report #A0122740A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Cholelithiasis Dyspnoea Pruritus Urticaria	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ORAL	

Date:06/26/00ISR Number: 3519745-0Report Type:Expedited (15-DaCompany Report #B0082531A
Age:59 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased Atrioventricular Block Complete Blood Creatine Phosphokinase Increased Blood Creatine Phosphokinase Mb

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Bradycardia Cardiac Disorder Hypokinesia							
	Myocardial Infarction Supraventricular Tachycardia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/	

Date:06/29/00ISR Number: 3521889-4Report Type:Direct Company Report #
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Anxiety Dizziness Fatigue Insomnia Joint Swelling Lymphocyte Count Decreased Memory Impairment Musculoskeletal Stiffness Myalgia Vision Blurred Visual Disturbance		Zyban / Wellbutrin Glaxo/ Wellcome	PS	Glaxco / Wellcome	ORAL	1 OR 2 A ORAL	

Date:06/29/00ISR Number: 3522237-6Report Type:Expedited (15-DaCompany Report #A0066944A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Required Intervention to	Agitation Bone Pain Chest Discomfort Chest Pain Coronary Artery Occlusion	Health Professional	Wellbutrin Sr Wellbutrin Tablet (Bupropion Hydrochloride)	PS SS	Glaxo Wellcome Inc	ORAL ORAL	100 MG/ TWICE PER DAY/ 100 MG /	

Prevent Permanent Impairment/Damage	Dermatitis Disorientation Dyspnoea Fatigue Flatulence Increased Appetite Pharyngolaryngeal Pain Pruritus Weight Increased	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Clonazepam Aspirin Sertraline Hydrochloride Semisodium Valproate	SS C C C C	TWICE PER DAY/ ORAL ORAL 150 MG/ ORAL

Date:06/29/00ISR Number: 3522338-2Report Type:Expedited (15-DaCompany Report #A0066944A
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation Chest Discomfort
Disability	Chest Pain
Required Intervention to Prevent Permanent Impairment/Damage	Coronary Artery Atherosclerosis Coronary Artery Occlusion Dermatitis Disorientation Dyspnoea

	Fatigue Increased Appetite Pain	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Pharyngolaryngeal Pain	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL 100 MG/ TWICE
	Pruritus	Professional				PER DAY/ ORAL
	Weight Increased		Wellbutrin Tablet (Bupropion Hydrochloride)	SS		ORAL 100 MG/ TWICE PER DAY/ ORAL
			Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL 150 MG/ ORAL
			Clonazepam	C		
			Aspirin	C		
			Sertraline Hydrochloride	C		
			Semisodium Valproate	C		

Date:06/30/00ISR Number: 3522972-XReport Type:Expedited (15-DaCompany Report #A0120078A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Bipolar I Disorder Condition Aggravated	Foreign Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG TWICE
	Convulsion	Professional				PER DAY ORAL
	Disorientation Disturbance In Attention Grand Mal Convulsion Mood Swings Visual Acuity Reduced		Clonazepam Paroxetine Hydrochloride Perphenazine	C C C		

Date:06/30/00ISR Number: 3522983-4Report Type:Expedited (15-DaCompany Report #A0122805A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Multiple Sclerosis Neurological Symptom	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	

Date:07/03/00ISR Number: 3524436-6Report Type:Expedited (15-DaCompany Report #PRIUSA2000006683
Age:32 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Completed Suicide	Literature Health Professional	Haldol	PS	Rw Johnson Pharmaceutical Research Institute Div Ortho Pharm	ORAL
ORAL						
			Amitriptyline (Amitriptyline)	SS		ORAL
ORAL						
			Bupropion (Amfebutamone)	SS		ORAL
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/03/00ISR Number: 3524825-XReport Type:Expedited (15-DaCompany Report #B0083476A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache Malignant Hypertension	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:07/03/00ISR Number: 3524829-7Report Type:Expedited (15-DaCompany Report #A0123050A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs	Foreign Study Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:07/03/00ISR Number: 3524831-5Report Type:Expedited (15-DaCompany Report #A0122980A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest Grand Mal Convulsion Myocardial Infarction Pulse Absent	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Diazepam	C				
			Ranitidine Hydrochloride	C				
			Rosiglitazone	C				
			Glibenclamide	C				
			Metoprolol Tartrate	C				
			Enalapril Maleate	C				
			Atorvastatin Calcium	C				

			Allopurinol	C		
			Fenofibrate	C		
			Nicotinic Acid	C		

Date:07/05/00ISR Number: 3524824-8Report Type:Expedited (15-DaCompany Report #A0123011A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Hallucination Hyperventilation Paranoia	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Oxycodone Hydrochloride	C				

Date:07/06/00ISR Number: 3525179-5Report Type:Direct Company Report #
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin Alcohol	PS C			?	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/00ISR Number: 3525629-4Report Type:Expedited (15-DaCompany Report #HQ8104303JUL2000
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Cyanosis	Health Professional	Effexor	PS	Wyeth Ayerst Laboratories Inc	ORAL	25 MG ORAL	
	Drug Interaction Respiratory Arrest		Wellbutrin - Slow Release	SS		ORAL	300 MG IN THE AM AND 150 MG IN THE PM (DOSE WAS INCREASED)	

Date:07/11/00ISR Number: 3527248-2Report Type:Direct Company Report #
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Pain Tachycardia		Zyban 150 Mg Glaxo-Wellcome	PS	Glaxo-Wellcome	ORAL	2 TABLE DAILY ORAL	

Date:07/11/00ISR Number: 3527791-6Report Type:Expedited (15-DaCompany Report #JRFUSA2000004633
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Duragesic	PS	Alza Corp	TRANSDERMAL	TRANSD	
			Sertraline (Sertraline)	SS				
			Olanzapine (Olanzapine)	SS				
			Bupropion					

			(Amfebutamone)	SS		
			Codeine (Codeine)	SS		

Date:07/13/00ISR Number: 3528993-5Report Type:Expedited (15-DaCompany Report #A0083735A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactoid Reaction	Study	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE PER DAY/
	Arthralgia	Health						
	Dyspnoea	Professional	Medroxyprogesterone Ace.	C				
	Face Oedema							
	Joint Stiffness							
	Oedema Peripheral							
	Pruritus							
	Serum Sickness							
	Urticaria							

Date:07/13/00ISR Number: 3528995-9Report Type:Expedited (15-DaCompany Report #A0117940A
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Blister
	Bronchospasm
	Burning Sensation
	Chest Pain
	Cyst

	Dizziness						
	Dyspnoea						
	Ear Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Erythema	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE
	Eye Disorder	Professional					PER DAY/ORAL
	Eye Irritation		Carisoprodol	C			
	Eyelid Oedema		Diazepam	C			
	Folliculitis						
	Haemorrhage						
	Hypersensitivity						
	Irritability						
	Localised Infection						
	Pain						
	Palpitations						
	Pruritus						
	Rash Pustular						
	Swelling						
	Toxic Shock Syndrome						
	Urticaria						

Date:07/13/00ISR Number: 3529023-1Report Type:Expedited (15-DaCompany Report #A0116641A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Arrhythmia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE
	Circulatory Collapse	Health					PER DAY ORAL
	Coronary Artery Disease	Professional					
	Myocardial Infarction						
	Ventricular Fibrillation						

Date:07/13/00ISR Number: 3529026-7Report Type:Expedited (15-DaCompany Report #A0122980A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE

	Grand Mal Convulsion	Professional		
PER DAY ORAL				
	Myocardial Infarction	Company	Diazepam	C
	Palpitations	Representative	Ranitidine Hydrochloride	C
	Pulse Absent		Rosiglitazone	C
	Syncope		Glibenclamide	C
			Metoprolol Tartrate	C
			Enalapril Maleate	C
			Atorvastatin Calcium	C
			Allopurinol	C
			Fenofibrate	C
			Nicotinic Acid	C

Date:07/14/00ISR Number: 3529926-8Report Type:Expedited (15-DaCompany Report #B0083707A
Age:29 YR Gender:Male I/FU:I

Outcome	PT
Required	Arthralgia
Intervention to	Blood Creatine
Prevent Permanent	Phosphokinase Increased
Impairment/Damage	Blood Lactate
	Dehydrogenase Increased
	Mouth Ulceration

		Myalgia Urticaria White Blood Cell Count	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Increased	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	/THREE TIMES PER DAY/ ORAL

Date:07/14/00ISR Number: 3529929-3Report Type:Expedited (15-DaCompany Report #B0082488A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Retinal Disorder Retinal Exudates Retinal Oedema Retinal Vasculitis Retinitis Visual Disturbance	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ ORAL

Date:07/17/00ISR Number: 3530293-4Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angioneurotic Oedema		Zyban	PS			

Date:07/17/00ISR Number: 3530321-6Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Platelet Count Decreased		Zyban 150 Mg	PS		ORAL	1T PO BID

Date:07/17/00ISR Number: 3530640-3Report Type:Expedited (15-DaCompany Report #B0083961A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	40 RABLET	
	Crying	Health					/SINGLE DOSE/	
	Depressed Level Of	Professional					ORAL	
	Consciousness		Zyban Tablet- Zyban					
	Erectile Dysfunction		(Bupropion					
	Fall		Hydrochloride)	SS		ORAL	ORAL	
	Intentional Misuse		Digoxin	C				
	Nervousness		Captopril	C				
	Suicidal Ideation		Frusemide	C				
	Visual Disturbance							

Date:07/17/00ISR Number: 3530721-4Report Type:Expedited (15-DaCompany Report #A0122805A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyskinesia	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Fatigue	Professional					PER DAY/ORAL	
	Multiple Sclerosis	Company	Oral Contraceptive	C				
	Muscle Disorder	Representative						
	Neurological Symptom							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/00ISR Number: 3530744-5Report Type:Expedited (15-DaCompany Report #A0123857A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Above Therapeutic Drug Toxicity	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL

Date:07/17/00ISR Number: 3583408-6Report Type:Periodic Company Report #2000SUS0406
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Interaction	Health Professional	Sustiva	PS	Dupont Pharmaceuticals Co	ORAL	PO	
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	PO	
			Combivir (Zidovudine/Lamivudine)	C				
			Paxil (Paroxetine Hydrochloride)	C				
			Depakote (Valproate Semisodium)	C				
			Lipitor (Atorvastatin Calcium)	C				

Date:07/18/00ISR Number: 3531310-8Report Type:Expedited (15-DaCompany Report #B0084242A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Depression Dizziness	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		1 TABLET / TWICE PER DAY	

	Headache					
/ UNKNOWN						
	Insomnia					
	Neck Pain					
	Tachycardia					
	Tremor					
	Visual Disturbance					
	Vomiting					

Date:07/19/00ISR Number: 3534897-4Report Type:Expedited (15-DaCompany Report #A0123997A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Complications Of Maternal	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	UNK	ORAL
Congenital Anomaly	Exposure To Therapeutic Drugs	Professional						
	Hydrocephalus							
	Induced Labour							
	Stillbirth							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/00ISR Number: 3533529-9Report Type:Expedited (15-DaCompany Report #A0122740A
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Cholelithiasis Dyspnoea Pruritus Urticaria	Foreign Health Professional	Zyban Cephzolin Sodium	PS SS	Glaxo Wellcome Inc	ORAL INTRAVENOUS	150 MG/TWICE PER DAY ORAL INTRAVENOUS	24 HR

Date:07/21/00ISR Number: 3533530-5Report Type:Expedited (15-DaCompany Report #D0009000A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Retinal Artery Thrombosis	Foreign Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL ORAL		

Date:07/21/00ISR Number: 3533534-2Report Type:Expedited (15-DaCompany Report #A0122304A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Magnesium Decreased Grand Mal Convulsion	Health Professional Other	Wellbutrin Sr Tarka Hydrochlorothiazide	PS C C	Glaxo Wellcome Inc	ORAL ORAL	6	MON

Date:07/24/00ISR Number: 3534226-6Report Type:Expedited (15-DaCompany Report #A0123751A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Chest X-Ray Abnormal	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL 150 MG TWICE PER DAY ORAL
	Dermatitis					
	Dysphagia	Company Representative	Omeprazole	C		
	Face Oedema					
	Headache					
	Hypersensitivity					
	Mucous Membrane Disorder					
	Nausea					
	Proteinuria					
	Pruritus					
	Pyrexia					
	Rash Maculo-Papular					
	Tachycardia					

Date:07/24/00ISR Number: 3534227-8Report Type:Expedited (15-DaCompany Report #A0123746A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	225 MG PER DAY ORAL	1 YR
		Company Representative	Adderall (Formulation Unknown) (Adderall)	SS			20 MG IN THE MORNING	4 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/00ISR Number: 3534232-1Report Type:Expedited (15-DaCompany Report #A0105636A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT	
Initial or Prolonged	Blood Creatine	Professional						
ORAL								
Other	Phosphokinase Increased							
	Grand Mal Convulsion							
	Hallucination							
	Intentional Misuse							
	Mental Impairment							
	Sedation							
	Sinus Tachycardia							
	Suicide Attempt							

Date:07/24/00ISR Number: 3534249-7Report Type:Expedited (15-DaCompany Report #A0120791A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG	THREE
Initial or Prolonged	Agitation	Professional					TIMES PER DAY	
	Confusional State							
ORAL	6 MON							
	Delusion		Baclofen	C				
	Drug Level Above		Oxycodone					
	Therapeutic		Hydrochloride	C				
	Hallucination							
	Paranoia							
	Psychotic Disorder							

Date:07/24/00ISR Number: 3534892-5Report Type:Expedited (15-DaCompany Report #D0009020A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	UNKNOWN	ORAL

Hospitalization - Initial or Prolonged	Blood Glucose Increased Dehydration Fatigue Ketoacidosis Pollakiuria Thirst Weight Decreased		Hydrochlorothiazide Thyroxine Sodium Sitosterol Triamterene	C C C C		

Date:07/24/00ISR Number: 3534894-9Report Type:Expedited (15-DaCompany Report #A0120136A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Ovarian Cyst Vomiting	Health Professional	Wellbutrin Sr Citalopram Hydrobromide	PS C	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:07/24/00ISR Number: 3536131-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Hypertonia Tremor		Wellbutrin Sr 150mg Tablet Flexeril	PS C		ORAL	1T PO BID	

			Motrin	C			

Date:07/25/00ISR Number: 3534553-2Report Type:Direct Company Report #
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Amnesia		Welbutrin	PS			300 MG
	Cognitive Disorder		Claritin	SS			1 SR
	Speech Disorder						

Date:07/25/00ISR Number: 3535059-7Report Type:Expedited (15-DaCompany Report #240967
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety	Health Professional	Klonopin	PS	Hoffmann La Roche Inc	ORAL	ORAL
	Chest Pain						
	Convulsion	Other	Wellbutrin Sr (Bupropion Hydrochloride)	SS		ORAL	100 MG 1 PER DAY ORAL
	Drug Withdrawal Convulsions						
	Drug Withdrawal Syndrome						
	Electroencephalogram Abnormal		Zolepidem (Zolpidem Tartrate)	SS		ORAL	10 MG 1 PER DAY ORAL
	Grand Mal Convulsion						
	Headache		Thyroxine Sodium (Levothyroxine Sodium)	C			
	Spinal Fracture		Loestrin (Ethinyl Estradiol/Norethindrone Acetate)	C			
			Quinapril Hydrochloride (Quinapril Hydrochloride)	C			

Date:07/25/00ISR Number: 3535160-8Report Type:Expedited (15-DaCompany Report #A0070194A
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Disability	Amnesia
	Anxiety
	Apathy
	Asthenia
	Breast Fibrosis
	Breast Hyperplasia
	Breast Mass
	Cognitive Disorder
	Convulsion
	Decreased Appetite
	Depression
	Disturbance In Attention
	Drug Ineffective
	Encephalopathy
	Fatigue
	Feeling Abnormal
	Fibrocystic Breast
	Disease
	Hodgkin'S Disease Nodular
	Sclerosis Stage

	Unspecified						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL
			General Anesthetic (General Anesthetic)	SS			
			Ibuprofen	C			
			Surgery	C			
			Loperamide Hydrochloride	C			

Date:07/27/00ISR Number: 3536092-1Report Type:Direct Company Report #
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Chest Pain		Zyban 150mg	PS		ORAL	1 QD F3 THEN
	Dizziness						1 PO BID
	Dyspnoea		Motrin	C			
	Electrocardiogram Abnormal						
	Orthostatic Hypotension						

Date:07/27/00ISR Number: 3536508-0Report Type:Expedited (15-DaCompany Report #A0103180A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	100 MG/THREE TIMES PER DAY/ORAL
	Cardiac Arrest						
	Cough						
	Dysphagia		Ace Inhibitor				
	Dyspnoea		(Formulation				

	Laryngeal Oedema		Unknown)	SS	
	Lymphocytosis		Pravastatin	C	
	Post Procedural		Lorazepam	C	
	Complication		Aspirin	C	
	Throat Tightness		Ibuprofen	C	
	Tongue Oedema				
	Tracheal Oedema				

Date:07/27/00ISR Number: 3536511-0Report Type:Expedited (15-DaCompany Report #A0124404A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Decreased Activity							
	Difficulty In Walking							
	Pain							
	Pruritus							
	Swelling							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/00ISR Number: 3537865-1Report Type:Expedited (15-DaCompany Report #A0124525A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT/	ORAL
	Complications Of Maternal Exposure To Therapeutic Drugs	Study Health Professional						
	Neonatal Apnoeic Attack							
	Oxygen Saturation Decreased							
	Pregnancy							

Date:07/28/00ISR Number: 3537932-2Report Type:Expedited (15-DaCompany Report #A0120776A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar Ii Disorder	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc		UNKNOWN	200 MG TWICE PER DAY
	Condition Aggravated	Professional						
	Headache							UNKNOWN
	Muscle Twitching		Lamictal Tablet					
	Petit Mal Epilepsy		(Lamotrigine)	SS		ORAL	100 MG	
	Rash Pruritic							UNKNOWN ORAL
	Sinusitis		Clonazepam	C				
	Stevens-Johnson Syndrome		Omeprazole	C				
	Toxic Epidermal		Dalmane	C				
	Necrolysis		Citalopram					
	Tremor		Hydrobromide	C				
	Urinary Incontinence		Trazodone	C				
			Compazine	C				
			Sucralfate	C				
			Multivitamin	C				
			Olanzapine	C				

Date:07/28/00ISR Number: 3537936-XReport Type:Expedited (15-DaCompany Report #A0124641A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	UNKNOWN	ORAL
	Dehydration	Health	Ethanol (Formulation					
	Heat Stroke	Professional	Unknown) (Alcohol)	SS			UNKNOWN	UNKNOWN

Date:07/28/00ISR Number: 3538047-XReport Type:Periodic Company Report #8-98295-013A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Consumer	Pondimin	PS	Ah Robins Co	ORAL		
	Cardiac Valve Disease		Phentermine	SS			INTERMITTENTL	
Other	Chest Pain						Y	
			Prozac	SS			20 TO 40 MG	DAILY
			Wellbutrin	SS			50 MG TWICE	DAILY
			Zoloft	SS			100 MG DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/00ISR Number: 3541035-0Report Type:Periodic Company Report #8-97286-020L
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Valve Disease	Consumer	Ponderex	PS	Ah Robins Co	ORAL	20 MG THREE TIMES A DAY, ORAL	
	Palpitations							
	Pulmonary Hypertension							
			Phentermine	SS		ORAL	15-30 MG DAILY, ORAL	
			Redux	SS		ORAL	30 MG DAILY, ORAL	
			Wellbutrin	SS		ORAL	100-150 MG TWICE DAILY, ORAL	

Date:07/28/00ISR Number: 3541089-1Report Type:Periodic Company Report #8-97318-014L
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cardiac Valve Disease	Consumer	Ponderex	PS	Ah Robins Co	ORAL	60-120 MG DAILY, ORAL	
	Pulmonary Hypertension							
			Effexor	SS			75-225 MG DAILY	
			Prozac	SS			20-60 MG DAILY	
			Wellbutrin	SS			150-300 MG	

DAILY						
			Zoloft	SS		
50 MG DAILY						
			Amitriptyline	C		
			Cylert	C		
			Cytomel	C		
			Estraderm	C		
			Ritalin	C		

Date:07/31/00ISR Number: 3538605-2Report Type:Expedited (15-DaCompany Report #A0122099A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ SEE
Initial or Prolonged	Amnesia	Health					TEXT/ ORAL
	Overdose	Professional	Hydromorphone Hcl				
	Suicide Attempt		(Formulation Unknown)				
			(Hydromorphone Hcl)	SS		ORAL	4 MG/ SEE
							TEXT/ ORAL
			Cocaine	C			

Date:07/31/00ISR Number: 3538912-3Report Type:Expedited (15-DaCompany Report #B0084888A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Sudden Death	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	AS
		Health					DIRECTED/ORAL
		Professional	Pravastatin	C			
			Frusemide	C			
			Aspirin	C			
			Omeprazole	C			
			Ramipril	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/00ISR Number: 3540219-5Report Type:Expedited (15-DaCompany Report #000403-LX957
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Discomfort	Health Professional	Ambien	PS	Lorex Pharmaceuticals	ORAL	PO
	Drug Interaction						
	Hallucination		Alprazolam	SS			
			Temazepam	SS			
			Wellbutrin	SS		ORAL	PO

Date:08/07/00ISR Number: 3544684-9Report Type:Expedited (15-DaCompany Report #B0085017A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Epilepsy	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL
	Fatigue	Other					
Required Intervention to Prevent Permanent Impairment/Damage	Memory Impairment						
	Nervous System Disorder						
	Status Epilepticus						

Date:08/07/00ISR Number: 3544832-0Report Type:Expedited (15-DaCompany Report #D0009329A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hemiparesis		Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL 9 DAY
	Tinnitus						

Date:08/07/00ISR Number: 3544833-2Report Type:Expedited (15-DaCompany Report #B0085154A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization -	Cardiac Arrest	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ORAL						
Initial or Prolonged	Cardiac Enzymes Increased		Phenytoin	C		
	Circulatory Collapse		Carbamazepine	C		
	Ventricular Fibrillation					

Date:08/14/00ISR Number: 3550028-9Report Type:Expedited (15-DaCompany Report #A0125473A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
	Bite	Professional				
PER DAY ORAL						
	Blood Potassium Decreased		Diltiazem			
	Blood Sodium Decreased		Hydrochloride	C		
	Ecchymosis		Thyroxine Sodium	C		
	Fall		Prempro	C		
	Grand Mal Convulsion		Maxzide	C		
	Head Injury		Ranitidine			
	Headache		Hydrochloride	C		
	Memory Impairment					
	Mouth Haemorrhage					
	Musculoskeletal Stiffness					
	Myalgia					
	Tongue Disorder					
	Tongue Oedema					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550031-9Report Type:Expedited (15-DaCompany Report #B0085539A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Motion Sickness	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Vertigo	Health						
	Visual Acuity Reduced	Professional						
		Company						
		Representative						

Date:08/14/00ISR Number: 3550057-5Report Type:Expedited (15-DaCompany Report #A0122473A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Stem Infarction	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
Initial or Prolonged	Dysarthria	Professional						
PER DAY) ORAL	4 MON							
	Dysphagia	Company	Glipizide	C				
	Hypoaesthesia	Representative	Rosiglitazone	C				
	Neurological Symptom		Antihypertensive	C				
	Tongue Disorder							
	Tongue Paralysis							

Date:08/14/00ISR Number: 3550060-5Report Type:Expedited (15-DaCompany Report #A0121921A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Shock	Health	Bupropion					
Initial or Prolonged	Angioneurotic Oedema	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
	Dermatitis							
PER DAY) ORAL								
	Dyspnoea		Blood Pressure					
	Hypersensitivity		Medication	C				
	Localised Oedema		Allegra-D	C				
	Pharyngolaryngeal Pain		Budesonide	C				
	Pruritus							
	Pyrexia							

	Urticaria					
	White Blood Cell Count Increased					

Date:08/14/00ISR Number: 3550113-1Report Type:Expedited (15-DaCompany Report #A0125213A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Balance Disorder	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	200 MG / TWICE PER DAY/ ORAL
	Difficulty In Walking						
	Fall						
	Gait Disturbance		Valproic Acid	C			
	Tremor		Lithium Salt	C			
			Venlafaxine Hydrochloride	C			
			Clonazepam	C			
			Glipizide	C			
			Medroxyprogesterone Ace.	C			
			Oestradiol	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550171-4Report Type:Expedited (15-DaCompany Report #A0119646A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	Required
	Asthenia	Professional						
	Chest Pain							
Intervention to Prevent Permanent Impairment/Damage	Confusional State		Fenofibrate	C				
	Depression		Nicotine	C				
	Fatigue							
	Flushing							
	Headache							
	Hypertension							
	Insomnia							
	Panic Disorder Without Agoraphobia							
	Pruritus							
	Psychotic Disorder							
	Tinnitus							

Date:08/15/00ISR Number: 3551188-6Report Type:Expedited (15-DaCompany Report #AMANTADI2000-00169
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Literature	Symmetrel	PS	Endo Pharmaceuticals Inc	ORAL	100 MG QOTHRD PO	
	Agitation	Health						
	Confusional State	Professional						
	Dizziness		Buproprion	SS		ORAL	75 MG BID PO	
	Insomnia		Lasix	C				
	Memory Impairment		Kci	C				
	Neurological Symptom		Quinaglute	C				
	Neurotoxicity		Vitamin B12	C				
	Orthostatic Hypotension		Feosol	C				
	Pain In Extremity		Multivitamin	C				
	Peripheral Coldness							
	Peripheral Embolism							
	Restlessness							

	Syncope					
	Tremor					

Date:08/16/00ISR Number: 3551544-6Report Type:Expedited (15-DaCompany Report #A0125519A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc			
Disability	Asthenia							
	Gait Disturbance							
	Ill-Defined Disorder							
	Injury							
	Pain							

Date:08/16/00ISR Number: 3551560-4Report Type:Expedited (15-DaCompany Report #A0122805A
Age:42 YR Gender:Female I/FU:F

Outcome
Other
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coordination Abnormal	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
	Fatigue	Professional					PER DAY/	ORAL
	Gait Disturbance Multiple Sclerosis Muscle Spasms Neurological Symptom Tremor	Company Representative	Oral Contraceptive	C				

Date:08/18/00ISR Number: 3553758-8Report Type:Expedited (15-DaCompany Report #240967
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Anxiety Body Temperature	Health Professional	Clonopin	PS	Hoffmann La Roche Inc	ORAL		
ORAL Initial or Prolonged Disability	Increased Chest Pain Drug Withdrawal	Other	Wellbutrin Sr (Bupropion Hydrochloride)	SS		ORAL	300 MG DAILY,	
	Convulsions						1 PER DAY;	
	Drug Withdrawal Syndrome						ORAL	
	Electroencephalogram Abnormal		Zolepidem (Zolpidem Tartrate)	SS		ORAL	10 MG 1 PER	
	Grand Mal Convulsion						DAY; ORAL	
	Headache Medication Error Personality Disorder Spinal Compression Fracture Spinal Fracture White Blood Cell Count Increased		Synthroid (Levothyroxine Sodium) Loestrin (Ethinyl Estradiol/Norethindrone Acette) Accupril (Quinapril Hydrochloride) Bcp (Oral Contraceptive Nos)	C C C C				

			Ambien (Zolpidem Tartrate)	C		
			Celexa (Citalopram)	C		

Date:08/18/00ISR Number: 3588957-2Report Type:Periodic Company Report #S00-USA-00534-01
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Malaise	Consumer	Celexa	PS	Forest Laboratories Inc	ORAL	20 MG PO	
			Wellbutrin(Amfebutamone Hydrochloride)	SS			200 MG QD PO	
			Desyrel (Trazodone Hydrochloride)	C				
			Klonopin (Clonazepam)	C				
			Neurontin (Gabapentin)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/00ISR Number: 3591383-3Report Type:Periodic Company Report #S00-USA-00489-01
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Celexa	PS	Forest Laboratories Inc	ORAL	40 MG QD PO	
			Atenolol	SS				
			Verapamil	SS				
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	300 MG QD PO	
			Ritalin (Methylphenidate Hydrochloride)	C				

Date:08/21/00ISR Number: 3554654-2Report Type:Expedited (15-DaCompany Report #A0125734A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bradycardia Cardiac Disorder Depressed Level Of Consciousness Hypotension Overdose	Health Professional Company Representative	Wellbutrin Olanzapine (Formulation Unknown) (Olanzapine)	PS SS	Glaxo Wellcome Inc			

Date:08/21/00ISR Number: 3554655-4Report Type:Expedited (15-DaCompany Report #A0125460A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Hospitalization - Initial or Prolonged	Fall Wrist Fracture		Clozapine Lisinopril Docusate Sodium Amlodipine	C C C C				

Date:08/22/00ISR Number: 3554813-9Report Type:Direct Company Report #
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatitis	Health	Wellbutrin 75	PS		ORAL	1 PO BID	
Required Intervention to Prevent Permanent Impairment/Damage	Liver Function Test Abnormal	Professional	Ambien	C				
			Fiortal/Codeine	C				
			Morphine	C				
			...	C				
			Cimetidine	C				
			Ventolin	C				

Date:08/22/00ISR Number: 3555915-3Report Type:Expedited (15-DaCompany Report #B0085873A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
Hospitalization - Initial or Prolonged			Phenytoin Tablet (Phenytoin)	SS		ORAL	PER DAY/ORAL	
			Carbamazepine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/00ISR Number: 3555918-9Report Type:Expedited (15-DaCompany Report #B0085514A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TTWICE	PER DAY/ORAL
	Inflammatory Bowel Disease		Ciprofloxacin	C				
	Mucosal Erosion		Amoxycillin	C				
	Rectal Haemorrhage		Augmentin	C				
			Prednisolone	C				

Date:08/22/00ISR Number: 3555919-0Report Type:Expedited (15-DaCompany Report #B0084724A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	AS	DIRECTED/ORAL
	Blood Pressure Fluctuation	Consumer	Allopurinol	C				
	Dermatitis Exfoliative							
	Erythema							
	Hypothermia							
	Malaise							
	Pigmentation Disorder							
	Skin Inflammation							

Date:08/22/00ISR Number: 3555932-3Report Type:Expedited (15-DaCompany Report #9947976
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiopathy	Consumer	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL	50.00 MG	Required
	Arthralgia						TOTAL: DAILY:	
	Condition Aggravated							
Intervention to	Delirium						ORAL	

Prevent Permanent Impairment/Damage	Diarrhoea		Aricept	SS		ORAL 10.00 MG TOTAL: DAILY: ORAL
	Drooling					
	Fall					
	Hallucination		Wellbutrin	SS		
	Hip Fracture		Iron	C		
	Insomnia		Lanoxin	C		
	Pneumonia		Vitamin E	C		
			Baby Aspirin	C		
			Centrum Silver	C		
			Unknown Laxative/Stool Softener	C		
			Sinemet Cr	C		
			Glucosamine	C		
			Vitamin B12	C		

Date:08/23/00ISR Number: 3556113-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Decreased Appetite		Wellbutrin 150mg Sr	PS		ORAL 150MG PO BID
	Dizziness					
	Fall					
	Head Injury					
	Lethargy					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/24/00ISR Number: 3557611-5Report Type:Expedited (15-DaCompany Report #044-0073-M0000016
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction	Foreign Health Professional	Dilantin	PS	Parke Davis Div Warner Lambert Co	ORAL	1 TABLET(S) (DAILY), PER ORAL	
			Zyban (Amfebutamone Hydrochloride)	SS		ORAL	150 MG (DAILY), PER ORAL	
			(Carbamazepine)	C				

Date:08/24/00ISR Number: 3557660-7Report Type:Expedited (15-DaCompany Report #PRIUSA2000006683
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Completed Suicide Electrocardiogram Qrs Complex Prolonged Grand Mal Convulsion	Literature Health Professional	Haldol	PS	Rw Johnson Pharmaceutical Research Institute Div Ortho Pharm	ORAL	ORAL	
	Intentional Misuse		Amitriptyline	SS		ORAL	ORAL	
	Intentional Self-Injury		Bupropion (Amfebutamone)	SS		ORAL	ORAL	

Date:08/24/00ISR Number: 3557738-8Report Type:Expedited (15-DaCompany Report #A0124755A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Amnesia	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
200 MG TWICE						
Hospitalization -	Convulsion	Professional				
PER DAY ORAL						
Initial or Prolonged	Insomnia		Venlafaxine			
	Intentional Misuse		Hydrochloride			
	Loss Of Consciousness		(Formulation			
	Suicide Attempt		Unknown)			
	Tympanic Membrane		(Venlafaxine	SS		
AT NIGHT						
	Perforation		Olanzapine			
	Weight Increased		(Formulation			
			Unknown)			
			(Olanzapine)	SS		
			Ibuprofen			
			(Formulation			
			Unknown) (Ibuprofen)	SS		
			Percocet	C		

Date:08/24/00ISR Number: 3557817-5Report Type:Expedited (15-DaCompany Report #A0125417A
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
UNKNOWN ORAL						
		Professional	Tramadol			
		Company	Hydrochloride	SS		
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/25/00ISR Number: 3558980-2Report Type:Expedited (15-DaCompany Report #A021954
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Decreased Appetite	Consumer Health	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL	ORAL
	Difficulty In Walking						
	Emotional Disorder	Professional	Wellbutrin	SS		ORAL	
	Gait Disturbance		Tnp-470 (Experimental Drug)	C			
	Halo Vision		Taxol	C			
	Hypoaesthesia		Flecainide	C			
	Insomnia		Ritalin	C			
	Neuropathy Peripheral		Restoril	C			
	Paraesthesia						
	Tearfulness						
	Tunnel Vision						
	Vision Blurred						
	Vomiting						
	Weight Decreased						

Date:08/28/00ISR Number: 3560528-3Report Type:Expedited (15-DaCompany Report #B0086215A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Circulatory Collapse	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Myalgia	Consumer					
	Myocardial Infarction						

Date:08/28/00ISR Number: 3560530-1Report Type:Expedited (15-DaCompany Report #B0086401A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Crepitations	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL
	Cyanosis						
	Depressed Level Of Consciousness		Paroxetine	C			
			Temazepam	C			

	Dyspnoea		Aldactide	C		
	Left Ventricular Failure		Combivent	C		
	Respiratory Failure		Movicol	C		

Date:08/28/00ISR Number: 3560537-4Report Type:Expedited (15-DaCompany Report #A0126045A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Epilepsy	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/AT	
	Sudden Death	Professional					NIGHT/ORAL	
			Carbamazepine	C				
			Sertraline Hydrochloride	C				
			Methylphenidate Hcl	C				

Date:08/28/00ISR Number: 3560740-3Report Type:Expedited (15-DaCompany Report #B0086031A
Age:43 YR Gender:Female I/FU:I

Outcome	PT
Other	Depression
	Headache
	Oedema Peripheral
	Physical Assault

Suicide Attempt

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	1 TABLET/TWICE PER DAY/ ORAL	

Date:08/29/00ISR Number: 3561543-6Report Type:Expedited (15-DaCompany Report #A0113937A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Serum Sickness Urticaria Vision Blurred	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	

Date:08/29/00ISR Number: 3561657-0Report Type:Expedited (15-DaCompany Report #A0104240A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Abnormal Behaviour Aggression Mania Physical Assault Suicidal Ideation	Study Health Professional	Wellbutrin Sr Paracetamol	PS C	Glaxo Wellcome Inc	ORAL	400 MG/ PER DAY/ ORAL	

Date:08/30/00ISR Number: 3562025-8Report Type:Expedited (15-DaCompany Report #D0009801A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cheyne-Stokes Respiration	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	TWICE PER DAY	
Hospitalization -	Dysarthria	Health					/ ORAL	
Initial or Prolonged	Respiratory Depression	Professional	Allopurinol	C				
	Sedation		Digitoxin	C				
			Torasemide	C				
			Molsidomine	C				
			Dipyridamole	C				
			Potassium Chloride	C				
			Phenprocoumon	C				
			Heparin Sodium	C				

Date:08/30/00ISR Number: 3562120-3Report Type:Expedited (15-DaCompany Report #US0013200
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Wellbutrin	PS	Shire Richwood Inc		225 MG DAILY	1 YR
		Professional	Adderall	SS			20 MG IN THE MORNING	4 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/00ISR Number: 3565698-9Report Type:Periodic Company Report #A0116206A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL
			Triamcinoline	C				

Date:08/31/00ISR Number: 3565708-9Report Type:Periodic Company Report #A0116210A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heat Rash Pruritus	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY	ORAL
			Etodolac	C				
			Doxazosin Mesylate	C				
			Aspirin	C				

Date:09/01/00ISR Number: 3562866-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Circulatory Collapse Pulse Absent		Remeron	PS		ORAL	60MG PO Q HS	
			Wellbutrin Sr	SS		ORAL	150MG PO TID	
			Neurontin	SS		ORAL	600MG 1 PO QAM AMD 2 PO Q HS	
			Lamictal	SS		ORAL	200MG PO BID	
			Cytomel	SS			25MCG PO QD	

Date:09/01/00ISR Number: 3564170-XReport Type:Periodic Company Report #A0116991A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Study	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
Initial or Prolonged		Health					DAY / ORAL	
Required		Professional	Conjugated Estrogens	C				
Intervention to			Antioxidants	C				
Prevent Permanent								
Impairment/Damage								

Date:09/01/00ISR Number: 3564171-1Report Type:Periodic Company Report #A0121024A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Health	Bupropion					
	Dizziness	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Eyelid Oedema		Dicyclomine					
	Face Oedema		Hydrochloride	C				
	Hypersensitivity		Ethanol	C				
	Intentional Misuse							
	Nausea							
	Oedema Peripheral							
	Pharyngeal Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/00ISR Number: 3564172-3Report Type:Periodic Company Report #A0121050A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	2 WK

Date:09/01/00ISR Number: 3564173-5Report Type:Periodic Company Report #A0121379A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Hypertension	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	

Date:09/01/00ISR Number: 3564175-9Report Type:Periodic Company Report #A0122019A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyskinesia	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	1 YR

Date:09/01/00ISR Number: 3564177-2Report Type:Periodic Company Report #A0123999A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

Initial or Prolonged	Constipation						
TWICE PER							
	Dizziness						
DAY/ ORAL							
	Hypoaesthesia			Vitamin		C	
	Insomnia						
	Paraesthesia						
	Pollakiuria						

Date:09/01/00ISR Number: 3564178-4Report Type:Periodic Company Report #A0124881A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Oedema Peripheral							
TWICE PER DAY								
	Rash Pruritic							
/ORAL							3	WK
	Urticaria							

Date:09/01/00ISR Number: 3564180-2Report Type:Periodic Company Report #A0124945A
Age:26 YR Gender:Female I/FU:I

Outcome	PT
Other	Arthralgia
	Candidiasis
	Decreased Activity
	Dermatitis
	Difficulty In Walking
	Erythema
	Face Oedema
	Insomnia
	Oedema Peripheral

	Pruritus Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL
			Medroxyprogesterone Ace.	C			

Date:09/01/00ISR Number: 3564181-4Report Type:Periodic Company Report #A0124983A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc		

Date:09/01/00ISR Number: 3564184-XReport Type:Periodic Company Report #A0109719A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability Other Required Intervention to Prevent Permanent Impairment/Damage	Akinesia Dystonia	Health Professional	Zyban Venlafaxine Hydrochloride	PS C	Glaxo Wellcome Inc	ORAL	

Date:09/01/00ISR Number: 3564186-3Report Type:Periodic Company Report #A0116361A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaphylactic Shock	Health	Zyban	PS	Glaxo Wellcome Inc		

Initial or Prolonged	Dermatitis	Professional					
	Face Oedema						
	Hypersensitivity						
	Oedema Peripheral						
	Urticaria						
	Vomiting						

Date:09/01/00ISR Number: 3564189-9Report Type:Periodic Company Report #A0104586A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Arthralgia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
	Convulsion						TWICE PER DAY
	Weight Decreased						/ ORAL

Date:09/01/00ISR Number: 3564190-5Report Type:Periodic Company Report #A0109688A
Age:22 YR Gender:Female I/FU:I

Outcome	PT
Other	Back Pain
	Depression
	Fatigue
	Hypoaesthesia

	Migraine						
	Nausea						
	Vision Blurred	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:09/01/00ISR Number: 3564192-9Report Type:Periodic Company Report #A0109834A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthritis	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL
	Joint Stiffness						

Date:09/01/00ISR Number: 3564193-0Report Type:Periodic Company Report #A0112059A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Bronchospasm	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis	Professional					
	Dyspnoea	Company					
	Face Oedema	Representative					
	Hyperhidrosis						
	Hypersensitivity						
	Pruritus						
	Rash Papular						
	Throat Tightness						
	Tongue Oedema						
	Urticaria						

Date:09/01/00ISR Number: 3564196-6Report Type:Periodic Company Report #A0115264A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain Dyspnoea Pruritus Rash Pruritic	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL

Date:09/01/00ISR Number: 3564198-XReport Type:Periodic Company Report #A0116901A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc		

Date:09/01/00ISR Number: 3577814-3Report Type:Periodic Company Report #A0121399A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Agitation	Consumer	Lotronex	PS	Glaxo Wellcome Inc	ORAL	1 MG / TWICE PER DAY / ORAL
	Frequent Bowel Movements						
	Muscle Spasms						
			Citalopram Hydrobromide (Formulation Unknown) (Citalopram				

			Hydrobromide)	SS		
			Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL
ORAL						

Date:09/05/00ISR Number: 3565455-3Report Type:Expedited (15-DaCompany Report #A0126869A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Dizziness	Consumer	Lamictal	PS	Glaxo Wellcome Inc		100 MG/ TWICE
Initial or Prolonged	Headache						PER DAY/
	Orthostatic Hypotension		Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL	150 MG/ TWICE
PER DAY/ PO							
			Amitriptyline Hcl (Formulation Unknown) (Amitriptyline Hcl)	SS			300 MG / PER
DAY/							
			Clonazepam	C			
			Thyroxine Sodium	C			
			Mirtazapine	C			
			Zolpidem Tartrate	C			

Date:09/08/00ISR Number: 3568263-2Report Type:Direct Company Report #
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to	Abnormal Behaviour Convulsion	Health Professional	Wellbutrin 150mg + 75mg Glaxo Wellcome	PS	Glaxo Wellcome		SEE IMAGE
Prevent Permanent	Hyperhidrosis		Acetaminophen	C			

Impairment/Damage	Lethargy	Milk Of Magnesia	C	
	Loose Associations	Maalox Suspension	C	
	Loss Of Consciousness	Hydroxyzine Pamoate	C	
	Nervousness	Hydroxyzine	C	
		Lithobid	C	
		Eskalith	C	
		Depakote	C	

Date:09/11/00ISR Number: 3569205-6Report Type:Expedited (15-DaCompany Report #A0126585A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Hypertension	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	TWICE PER	
		Professional					DAY/ ORAL	
			Nefazodone Hydrochloride	C				

Date:09/11/00ISR Number: 3569344-XReport Type:Expedited (15-DaCompany Report #B0086888A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /SEE	
							TEXT/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/11/00ISR Number: 3569345-1Report Type:Expedited (15-DaCompany Report #B0086885A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / AS	
	Bronchospasm						DIRECTED/	
	Drug Interaction						ORAL	
	Dyspnoea		Ramipril (Formulation Unknown) (Ramipril)	SS		ORAL	50 MG /PER	DAY / ORAL

Date:09/11/00ISR Number: 3569346-3Report Type:Expedited (15-DaCompany Report #B0086215A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Myalgia	Consumer						
	Myocardial Infarction							

Date:09/11/00ISR Number: 3569347-5Report Type:Expedited (15-DaCompany Report #B0086827A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Ischaemia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL
			Omeprazole	C				
			Diclofenac	C				

Date:09/11/00ISR Number: 3569348-7Report Type:Expedited (15-DaCompany Report #B0083476A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	
	Hemianopia	Health Professional						
	Malignant Hypertension							
	Vision Blurred		Diane-35	C				

Date:09/11/00ISR Number: 3569349-9Report Type:Expedited (15-DaCompany Report #B0085154A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	
Hospitalization - Initial or Prolonged	Cardiac Enzymes Increased	Consumer						
	Circulatory Collapse							
	Drug Interaction		Phenytoin					
	Myalgia		(Phenytoin)	SS		ORAL		
	Ventricular Fibrillation		Carbamazepine	C				

Date:09/11/00ISR Number: 3569350-5Report Type:Expedited (15-DaCompany Report #B0085873A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL	
Hospitalization - Initial or Prolonged								
			Phenytoin Tablet					

			(Phenytoin)	SS			ORAL
PER DAY/							
ORAL							
			Carbamazepine	C			

Date:09/12/00ISR Number: 3570356-0Report Type:Expedited (15-DaCompany Report #A0127152A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Drug Level Above Therapeutic Overdose	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	
			Sertraline Hydrochloride (Sertraline Hudrochloride)	SS		

Date:09/12/00ISR Number: 3570586-8Report Type:Expedited (15-DaCompany Report #B0086864A
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Respiratory	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
ORAL						
Hospitalization - Initial or Prolonged	Distress Syndrome Bronchospasm Dyspnoea Hyperhidrosis Inspiratory Capacity Decreased	Health Professional	Prednisolone	C		
			Beclomethasone Dipropion	C		
			Salmeterol Xinafoate	C		
			Gallopamil Hydrochloride	C		
			Nitroglycerin	C		
			Dipyridamole	C		

Date:09/12/00ISR Number: 3570587-XReport Type:Expedited (15-DaCompany Report #D0009801A
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
Hospitalization -	Cerebral Ischaemia	Health				
TWICE PER DAY						

Initial or Prolonged / ORAL		Cheyne-Stokes Respiration	Professional				
		Dysarthria		Dipyridamole			
		Nervous System Disorder		Injection 45 Mg			
		Respiratory Depression		(Dipyridamole)	SS		
INTRAVENOUS	SINGLE	DOSE /					
		Sedation					
INTRAVENOUS							
				Allopurinol	C		
				Digitoxin	C		
				Torasemide	C		
				Molsidomine	C		
				Potassium Chloride	C		
				Phenprocoumon	C		
				Heparin Sodium	C		

Date:09/12/00ISR Number: 3570588-1Report Type:Expedited (15-DaCompany Report #B0086711A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Respiratory Alkalosis	Foreign	Bupropion					
	Tetany	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/12/00ISR Number: 3571006-XReport Type:Expedited (15-DaCompany Report #A0125417A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
Other		Professional					PER DAY) ORAL	
Required		Company	Tramadol					
Intervention to		Representative	Hydrochloride	C				
Prevent Permanent			Atorvastatin Calcium	C				
Impairment/Damage								

Date:09/13/00ISR Number: 3570377-8Report Type:Direct Company Report #
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis		Zyban 150mg Glaxo					
Initial or Prolonged	Erythema Multiforme		Wellcome	PS	Glaxo Wellcome	ORAL	150MG BID	
	Eyelid Oedema						ORAL	
	Myalgia		Nicotine Patch	C				
	Oedema							
	Rash Generalised							
	Tongue Oedema							

Date:09/13/00ISR Number: 3570903-9Report Type:Direct Company Report #
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Zyban	PS		ORAL	BID PO	3 WK

Date:09/14/00ISR Number: 3570904-0Report Type:Direct Company Report #
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Blood Creatinine Increased Chromaturia Coma Dialysis Grand Mal Convulsion Intentional Misuse Rhabdomyolysis		Wellbutrin	PS		

Date:09/14/00ISR Number: 3571728-0Report Type:Expedited (15-DaCompany Report #10519379
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Balance Disorder Dizziness Drug Interaction	Foreign Health Professional	Serzone	PS	Bristol Myers Squibb Co Pharmaceutical Research Institute	ORAL
100 MILLIGRAMS, 2/1 DAY ORAL						
			Zyban (Bupropion Hcl)	SS		ORAL
150 MILLIGRAMS, 2/1 DAY ORAL						
			Cipramil (Citalopram			

Hydrochloride)	C	
Predsol (Prednisolone)	C	

Date:09/14/00ISR Number: 3571752-8Report Type:Expedited (15-DaCompany Report #A0127330A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose Toxicologic Test Abnormal	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	1 TABLET/ SEE TEXT/ ORAL	

Date:09/15/00ISR Number: 3572872-4Report Type:Expedited (15-DaCompany Report #B0087305A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Alcohol Increased Completed Suicide Drug Abuser	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc			

Date:09/15/00ISR Number: 3572873-6Report Type:Expedited (15-DaCompany Report #B0087742A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphonia Dysphonia Squamous Cell Carcinoma Vocal Cord Disorder	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /AS DIRECTED/ ORAL	

Date:09/15/00ISR Number: 3572874-8Report Type:Expedited (15-DaCompany Report #B0087339A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dyspnoea Exacerbated Left Ventricular Failure Myocardial Infarction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL

Date:09/15/00ISR Number: 3572875-XReport Type:Expedited (15-DaCompany Report #B0087727A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Bradycardia Electrocardiogram St Segment Elevation Nodal Arrhythmia Pericardial Effusion Pericarditis Sick Sinus Syndrome	Foreign	Zyban Bendroflurazide	PS C	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL

Date:09/18/00ISR Number: 3574699-6Report Type:Expedited (15-DaCompany Report #A0125270A
Age:48 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged

Drug Level Above Therapeutic Grand Mal Convulsion International Normalised Ratio Increased Pneumonia Sepsis Therapeutic Agent Toxicity	Report Source Foreign Health Professional	Product	Role	Manufacturer	Route	Dose Duration
		Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
		Paroxetine Hydrochloride (Paroxetine Hydrochloride)	SS		ORAL	60 MG / PER DAY / ORAL
		Lanoxin (Digoxin)	SS			.125 MG / PER DAY /
		Warfarin Sodium (Warfarin Sodium)	SS		ORAL	2.5 MG / PER DAY / ORAL
		Zafirlukast	C			
		Prednisone	C			
		Salmeterol + Fluticasone	C			
		Beclomethasone Dipropion.	C			
		Prochlorperazine	C			
		Alprazolam	C			
		Codeine Phosphate	C			
		Enalapril Maleate	C			
		Lorazepam	C			
		Nitroglycerin	C			
		Salbutamol Sulphate	C			
		Temazepam	C			
		Hycodan	C			
		Amitriptyline	C			
		Ipratropium Bromide	C			
		Salbutamol Sulphate	C			

Date:09/18/00ISR Number: 3574701-1Report Type:Expedited (15-DaCompany Report #A0127464A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Foreign	Bupropion					
	Depression	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Dysgeusia						DAY / ORAL	
	Self Mutilation		Multivitamin	C				
	Suicidal Ideation		Hypericum	C				
			Ethanol	C				

Date:09/18/00ISR Number: 3574703-5Report Type:Expedited (15-DaCompany Report #B0084724A
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
Disability	Dermatitis Exfoliative
Required Intervention to Prevent Permanent Impairment/Damage	Eosinophilia
	Hypersensitivity
	Hypothermia
	Malaise
	Pigmentation Disorder
	Rash Erythematous
	Skin Inflammation

Skin Lesion
Viral Infection

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Allopurinol	C				

Date:09/19/00ISR Number: 3573345-5Report Type:Direct Company Report #
Age:40 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Grand Mal Convulsion		Zyban 150 Mgs Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	1 TAB TWICE DAILY ORAL	

Date:09/21/00ISR Number: 3576886-XReport Type:Expedited (15-DaCompany Report #A0122712A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Condition Aggravated Pyoderma Gangrenosum	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Azathioprine	C				
			Metoprolol	C				
			Prednisone	C				
			Nortriptyline Hc1	C				
			Acyclovir	C				
			Fluoxetine Hydrochloride	C				

Date:09/21/00ISR Number: 3576891-3Report Type:Expedited (15-DaCompany Report #A0127813A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Potassium Decreased	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Convulsion						DAY/ORAL	
	Fall		Potassium Chloride	C				
	Fatigue		Multivitamin	C				
	Grand Mal Convulsion							
	Headache							
	Muscle Rigidity							
	Pain							
	Skin Discolouration							

Date:09/21/00ISR Number: 3576925-6Report Type:Expedited (15-DaCompany Report #B0087347A
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fall	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Femoral Neck Fracture	Other	Paracetamol Dihydrocodeine Tartrate	C				
			Indomethacin	C				
			Iron Sulfate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/00ISR Number: 3578342-1Report Type:Expedited (15-DaCompany Report #B0087889A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Depression	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT /
	Suicide Attempt						ORAL
			Dihydrocodeine+Paracetam.	C			
			Cimetidine	C			
			Diazepam	C			

Date:09/22/00ISR Number: 3578343-3Report Type:Expedited (15-DaCompany Report #B0087719A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Angiodysplasia Haemorrhagic	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL
	Haemoglobin Decreased		Aspirin	C			
			Ramipril	C			

Date:09/22/00ISR Number: 3578344-5Report Type:Expedited (15-DaCompany Report #B0087304A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Optic Nerve Disorder Vision Blurred Visual Acuity Reduced	Foreign Study Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
	Visual Disturbance	Professional	Citalopram Hydrobromide	C			

Date:09/25/00ISR Number: 3579498-7Report Type:Expedited (15-DaCompany Report #2000AP04229
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Drug Interaction	Foreign Health Professional Other	Tenormin Bupropion Hydrochloride	PS SS	Astrazeneca Pharmaceuticals Lp	ORAL ORAL	50 MG DAILY 150 MG BID PO	PO

Date:09/25/00ISR Number: 3579650-0Report Type:Expedited (15-DaCompany Report #2000030151GB
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Artery Thrombosis	Foreign Health Professional Other	Cyklokapron Bupropion (Amfebutamone) Fluoxetine (Fluoxetine)	PS SS C	Pharmacia And Upjohn Co	ORAL ORAL	500 MG , TID, 150 MG, QD,	ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/26/00ISR Number: 3580490-7Report Type:Expedited (15-DaCompany Report #A0127997A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Drug Level Above	Health					PER DAY/ORAL	
	Therapeutic	Professional	Olanzapine	SS				
	Intentional Misuse	Other	Fluoxetine	SS				
	Toxicologic Test Abnormal		Lorazepam	C				
			Haloperidol	C				

Date:09/26/00ISR Number: 3580558-5Report Type:Expedited (15-DaCompany Report #A0127864A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Initial or Prolonged	Hypotension						TWICE DAY /	
	Pneumonia						ORAL	
	Sedation		Nifedipine (Formulation Unknown) (Nifedipine)	SS				
	Speech Disorder							
	Urine Analysis Abnormal							
			Atenolol (Formulation Unknown) (Atenolol)	SS				
			Gabapentin (Formulation Unknown) (Gabapentin)	SS				
2 YR								

Date:09/28/00ISR Number: 3581577-5Report Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Swelling		Zyban 150mg Glaxo	PS	Glaxo	
OROPHARINGEAL 150MG 3	Urticaria					
300MGF OR 16						
OROPHARINGEAL						
			Prilosec	C		
			Diovan	C		
			Pulmicort	C		
			Rhinocort	C		

Date:09/28/00ISR Number: 3582972-0Report Type:Expedited (15-DaCompany Report #A0114445A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cognitive Disorder	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Depersonalisation		Lamotrigine	C				
	Electroencephalogram Abnormal							
	Emotional Disorder							
	Feeling Abnormal							
	Feeling Hot							
	Headache							
	Nervous System Disorder							
	Pyrexia							
	Vomiting							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/28/00ISR Number: 3583029-5Report Type:Expedited (15-DaCompany Report #A0128110A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adrenal Neoplasm	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	
	Blood Catecholamines Increased	Professional						
	Epinephrine Increased		Antidepressant	C				
	Hypertension		Blood Pressure Medication	C				

Date:09/28/00ISR Number: 3583031-3Report Type:Expedited (15-DaCompany Report #A0128188A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ORAL	
	Amnesia							
	Atrial Fibrillation		Warfarin Sodium	C				
	Constipation		Lorazepam	C				
	Coordination Abnormal		Zolpidem Tartrate	C				
	Depression		Temazepam	C				
	Difficulty In Walking		Liothyronine Sodium	C				
	Disorientation		Gabapentin	C				
	Dysarthria							
	Fatigue							
	Insomnia							
	Libido Decreased							
	Loss Of Consciousness							
	Malaise							
	Restlessness							
	Sexual Dysfunction							
	Sinus Congestion							
	Speech Disorder							
	Thyroid Disorder							
	Urinary Tract Infection							

Date:09/28/00ISR Number: 3583221-XReport Type:Expedited (15-DaCompany Report #B0088230A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Bupropion					
	Metabolic Acidosis	Health	Hydrochloride	PS	Glaxo Wellcome Inc		50 TABLET	
	Overdose	Professional						

Date:09/29/00ISR Number: 3583129-XReport Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Zyban 150mg Glaxo					
	Dyspnoea		Wellcome Inc	PS	Glaxo Wellcome Inc	ORAL	WEEK 1 1	
	Urticaria						TABLET WEEK 2	
							2 TABLET	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/00ISR Number: 3584460-4Report Type:Expedited (15-DaCompany Report #A0070194A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Anger	Professional					DAY/ ORAL	
	Anxiety		General Anesthetic					
	Anxiety Disorder		(Formulation					
	Asthenia		Unknown) (General					
	Brain Hypoxia		Anesthetic)	SS				
	Breast Fibrosis		Ibuprofen	C				
	Breast Hyperplasia		Loperamide					
	Breast Mass		Hydrochloride	C				
	Cognitive Disorder							
	Confusional State							
	Convulsion							
	Decreased Activity							
	Decreased Appetite							
	Depressed Mood							
	Depression							
	Disturbance In Attention							
	Drug Ineffective							
	Dysphoria							
	Early Morning Awakening							
	Encephalopathy							
	Fatigue							
	Fear							
	Feeling Abnormal							
	Fibrocystic Breast Disease							
	Headache							
	Hodgkin'S Disease Nodular Sclerosis Stage Unspecified							
	Hypochondriasis							
	Initial Insomnia							
	Loss Of Libido							
	Mental Impairment							
	Mood Swings							
	Nausea							
	Needle Biopsy Site							
	Unspecified Abnormal							
	Suicidal Ideation							
	Thinking Abnormal							

	Vomiting					

Date:09/29/00ISR Number: 3584462-8Report Type:Expedited (15-DaCompany Report #A0128346A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erectile Dysfunction	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	2 MON
	Semen Abnormal		Olanzapine					
	Spermatozoa Abnormal		(Formulation Unknown)					
			(Olanzapine)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/00ISR Number: 3584468-9Report Type:Expedited (15-DaCompany Report #A0128376A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ SEE	
Hospitalization -	Brain Herniation	Professional					TEXT/ ORAL	
Initial or Prolonged	Convulsion	Company						
	Dyspnoea	Representative						
	Overdose							
	Pupils Unequal							
	Suicide Attempt							
	Vaginal Haemorrhage							
	Vasospasm							

Date:10/02/00ISR Number: 3585611-8Report Type:Expedited (15-DaCompany Report #B0088136A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
Initial or Prolonged	Circulatory Collapse	Health					PER DAY/ORAL	
	Confusional State	Professional						
	Eye Rolling							
	Headache							
	Loss Of Consciousness							
	Pallor							
	Salivary Hypersecretion							

Date:10/02/00ISR Number: 3585757-4Report Type:Expedited (15-DaCompany Report #A0125460A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	PO	
Hospitalization -	Fall	Professional	Clozapine	C				
Initial or Prolonged	Wrist Fracture	Company	Lisinopril	C				
		Representative	Docusate Sodium	C				

			Amlodipine	C		

Date:10/02/00ISR Number: 3585759-8Report Type:Expedited (15-DaCompany Report #A0054084A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Neurosensory	Health	Bupropion					
	Dermatitis	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Dizziness						PER DAY/ PO	
	Ear Discomfort							
	Ear Disorder							
	Hypersensitivity							
	Labyrinthitis							
	Nausea							
	Nystagmus							
	Pruritus							
	Tympanic Membrane Disorder							
	Urticaria							
	Vertigo							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/00ISR Number: 3585828-2Report Type:Expedited (15-DaCompany Report #B0086864A
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Respiratory	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Hospitalization - Initial or Prolonged	Distress Syndrome	Health Professional	Prednisolone	C				
	Bronchospasm		Beclomethasone Dipropion	C				
	Dyspnoea		Salmeterol Xinafoate	C				
	Hyperhidrosis		Gallopamil Hydrochloride	C				
	Hypersensitivity		Nitroglycerin	C				
	Pulmonary Function Test Decreased		Dipyridamole	C				

Date:10/02/00ISR Number: 3585829-4Report Type:Expedited (15-DaCompany Report #B0086888A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /SEE TEXT/ORAL	

Date:10/02/00ISR Number: 3585830-0Report Type:Expedited (15-DaCompany Report #B0088163A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT/ORAL	
	Encephalitis		Allopurinol	C				
			Amoxycillin	C				

Date:10/02/00ISR Number: 3585848-8Report Type:Expedited (15-DaCompany Report #B0087304A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Multiple Sclerosis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /TWICE						
Initial or Prolonged	Optic Nerve Disorder	Study				
PER DAY/ ORAL						
	Vision Blurred	Health	Citalopram			
	Visual Acuity Reduced	Professional	Hydrobromide	C		
	Visual Disturbance					

Date:10/02/00ISR Number: 3585863-4Report Type:Expedited (15-DaCompany Report #A0128480A
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hip Fracture	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
100 MG/TWICE						
Initial or Prolonged	Leukocytosis	Professional				
PER DAY/ORAL						
	Liver Function Test		Alprazolam	C		
	Abnormal		Pulmocare	C		
	Respiratory Failure		Vicodin	C		
			Digoxin	C		
			Megestrol Acetate	C		
			Heparin	C		
			Promod Supplement	C		
			Ranitidine Hydrochloride	C		
			Frusemide	C		
			Potassium Chloride	C		
			Ferrous Sulfate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/00ISR Number: 3585938-XReport Type:Expedited (15-DaCompany Report #B0088136A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG, TWICE PER DAY, ORAL	
	Circulatory Collapse	Health						
	Confusional State	Professional						
	Dystonia							
	Eye Rolling							
	Headache							
	Loss Of Consciousness							
	Pallor							
	Salivary Hypersecretion							

Date:10/02/00ISR Number: 3585939-1Report Type:Expedited (15-DaCompany Report #B0088158A
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block Left	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Supraventricular		Ipratropium Bromide	C				
	Tachycardia		Fluticasone Propionate	C				
	Tachycardia		Terbutaline	C				
			Losartan Potassium	C				
			Aspirin	C				

Date:10/02/00ISR Number: 3586124-XReport Type:Expedited (15-DaCompany Report #WAES 00091109
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Health	Flexeril	PS	Merck And Co Inc			
	Back Pain	Professional	Betaseron Unk	SS			SUBCUTANEOUS	SC
Other	Coma		Wellbutrin Unk	SS				
	Confusional State		Depakote Unk	SS				
	Depression		Ativan	C				

	Diplopia		Potassium Chloride	C		
	Drug Interaction					
	Drug Level Below Therapeutic					
	Epilepsy					
	Grand Mal Convulsion					
	Hypokalaemia					
	Multiple Sclerosis					
	Peptic Ulcer					
	Pyrexia					
	Respiratory Failure					
	Scoliosis					
	Urinary Tract Infection					

Date:10/03/00ISR Number: 3586823-XReport Type:Expedited (15-DaCompany Report #B0088627A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Psoriasis		Calcipotriene	C				
			Fluticasone Propionate	C				
			Allopurinol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/00ISR Number: 3586824-1Report Type:Expedited (15-DaCompany Report #B0088634A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	DAY/ORAL
			Gaviscon	C				
			Nizatidine	C				
			Aspirin	C				
			Nifedipine	C				

Date:10/03/00ISR Number: 3586825-3Report Type:Expedited (15-DaCompany Report #B0088630A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Neutropenia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/SEE	TEXT/ORAL
	Tonsillitis							
			Birth Control	C				

Date:10/03/00ISR Number: 3586917-9Report Type:Expedited (15-DaCompany Report #A0128274A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Feeling Abnormal							TWICE PER DAY
	Feeling Hot							/ ORAL
	Hyperaesthesia		Nicotine	C				
	Irritability							
	Nervousness							
	Nightmare							
	Oedema							
	Pruritus							
	Skin Discolouration							

	Urticaria					

Date:10/04/00ISR Number: 3586657-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression		Wellbutrin Sr	PS	Glaxo Welcome			

Date:10/05/00ISR Number: 3589083-9Report Type:Expedited (15-DaCompany Report #A0125213A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	200 MG / TWICE PER DAY / ORAL	
	Difficulty In Walking	Professional						
	Fall							
	Parkinsonian Gait		Valproic Acid	C				
	Tremor		Lithium Salt	C				
			Venlafaxine Hydrochloride	C				
			Clonazepam	C				
			Glipizide	C				
			Medroxyprogesterone Ace.	C				
			Oestradiol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/00ISR Number: 3590708-2Report Type:Expedited (15-DaCompany Report #A0127152A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc			
			Sertraline Hydrochloride (Sertraline Hydrochloride)	SS				

Date:10/06/00ISR Number: 3590803-8Report Type:Expedited (15-DaCompany Report #D0010641A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL		
	Headache	Health Professional						
	Tachycardia							

Date:10/06/00ISR Number: 3590804-XReport Type:Expedited (15-DaCompany Report #B0086470A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE	
Disability	Hyperhidrosis	Health Professional					PER DAY/ ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Nausea		Combivent	C				
			Beclomethasone Dipropion	C				

Date:10/06/00ISR Number: 3598782-4Report Type:Periodic Company Report #USA015005
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Meridia	PS	Knoll Pharmaceutical			

	Central Nervous System	Other			Co Sub Basf Corp	ORAL 10 MG OD PO
	Stimulation		Meridia	SS		ORAL 10 MG OD PO
	Migraine		Wellbutrin	SS		ORAL 150 MG OD PO
	Nausea Therapeutic Response Unexpected					

Date:10/10/00ISR Number: 3591925-8Report Type:Expedited (15-DaCompany Report #A0128493A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Cardiac Arrest	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL ORAL

Date:10/10/00ISR Number: 3592070-8Report Type:Expedited (15-DaCompany Report #D0010662A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Epilepsy	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/00ISR Number: 3592695-XReport Type:Expedited (15-DaCompany Report #A0128801A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	200 MG/TWICE	
	Tremor	Professional					PER DAY/ ORAL	
	Tunnel Vision		Citalopram Hydrobromide (Citalopram Hydrobromide)	SS			60 MG/PER DAY	
			Lithium Salt	C				
			Perphenazine	C				

Date:10/11/00ISR Number: 3592416-0Report Type:Direct Company Report #
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Accutane 40 Mg Roche	PS	Roche		40 MG 1 A DAY	
	Constipation		Zyban 150 Mg Catalytica For Glaxo Wellcome	SS	Catalytica For Glaxo Wellcome		150MG 2 A DAY	
	Crying							
	Headache							
	Hypoaesthesia							
	Major Depression							
	Musculoskeletal Stiffness							
	Neck Pain							
	Panic Attack							
	Speech Disorder							
	Suicidal Ideation							
	Trismus							

Date:10/13/00ISR Number: 3605050-0Report Type:Expedited (15-DaCompany Report #A0130183A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc			

			Atropine (Formulation Unknown) (Atropine)	SS		
			Chloral Hydrate (Formulation Unknown) (Chloral Hydrate)	SS		
			Daizepam (Formulation Unknown) (Diazepam)	SS		

Date:10/13/00ISR Number: 3605051-2Report Type:Expedited (15-DaCompany Report #B0088745A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Chest Pain Electrocardiogram T Wave Inversion Myocardial Infarction	Foreign Health Professional	Zyban Ipratropium Bromide Salbutamol Sulphate Aspirin Bendrofluazide Prednisolone Beclomethasone Dipropion	PS C C C C C C	Glaxo Wellcome Inc	ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/00ISR Number: 3595759-XReport Type:Expedited (15-DaCompany Report #A0128376A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Herniation	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/	SEE
Hospitalization -	Convulsion	Professional					TEXT/	ORAL
Initial or Prolonged	Intubation	Company						
	Overdose	Representative						
	Pupils Unequal							
	Respiratory Failure							
	Suicide Attempt							
	Vasospasm							

Date:10/16/00ISR Number: 3595760-6Report Type:Expedited (15-DaCompany Report #A0070194A
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Disability	Affective Disorder
	Amnesia
	Anger
	Anxiety
	Apathy
	Asthenia
	Biopsy Breast Abnormal
	Breast Hyperplasia
	Breast Mass
	Cognitive Disorder
	Confusional State
	Convulsion
	Decreased Appetite
	Depressed Mood
	Depression
	Disturbance In Attention
	Drug Ineffective
	Early Morning Awakening
	Encephalopathy
	Fatigue
	Fear
	Feeling Abnormal
	Fibroadenoma Of Breast
	Fibrocystic Breast
	Disease

Headache
Hodgkin'S Disease Nodular
Sclerosis Stage
Unspecified
Hypochondriasis
Hypoxia
Initial Insomnia
Loss Of Libido
Memory Impairment
Mental Disorder
Mental Impairment
Mood Swings
Nausea
Nervous System Disorder
Petit Mal Epilepsy
Post Procedural
Complication
Suicidal Ideation
Sweat Gland Disorder

	Thinking Abnormal Vomiting						
Dose	Duration	Report Source	Product	Role	Manufacturer	Route	
		Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	
150 MG/ PER DAY/ ORAL							
			General Anesthetic (Formulation Unknown) (General Anesthetic)	SS			
			Ibuprofen	C			
			Surgery	C			
			Loperamide Hydrochloride	C			
			Dextrose + Lactated Ringers	C			
			Tylenol No. 3	C			
			Hyoscyamine Sulphate	C			
			Bupivacaine Hdyrochloride	C			
			Hydrocodone + Paracetamol	C			
			Propofol	C			
			Lignocaine	C			
			Fentanyl	C			
			Midazolam	C			
			Suxamethonium Chloride	C			
			Oxygen	C			
			Droperidol	C			
			Nitrous Oxide	C			

Date:10/16/00ISR Number: 3595783-7Report Type:Expedited (15-DaCompany Report #A0121698A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Hospitalization - Initial or Prolonged Other	Convulsion Depressed Level Of Consciousness Grand Mal Convulsion Intentional Misuse	Literature Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	
150 MG/ ORAL							

	Lethargy
	Status Epilepticus
	Suicide Attempt

Date:10/16/00ISR Number: 3595784-9Report Type:Expedited (15-DaCompany Report #A0122538A
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Cardiovascular Disorder
Hospitalization -	Coma
Initial or Prolonged	Hypoxic Encephalopathy
Disability	Lethargy
Required	Neuroleptic Malignant
Intervention to	Syndrome
Prevent Permanent	Overdose
Impairment/Damage	Renal Failure Acute
	Rhabdomyolysis
	Staring
	Stupor

Urine Analysis Abnormal

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Opiate (Formulation Unknown) (Opiate)	SS				
			Benzodiazepines (Formulation Unknown) (Benzodiazepines)	SS				

Date:10/16/00ISR Number: 3595785-0Report Type:Expedited (15-DaCompany Report #A0093694A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Decreased Activity Depression Grand Mal Convulsion Pain Spinal Fracture	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	1 MON

Date:10/16/00ISR Number: 3595788-6Report Type:Expedited (15-DaCompany Report #A0129437A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG/ PER DAY/ ORAL	10 DAY

Date:10/16/00ISR Number: 3595926-5Report Type:Expedited (15-DaCompany Report #B0089470A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
			Ibuprofen	C				
			Dextroprop. + Paracetamol	C				
			Dihydrocodeine+Paracetam.	C				

Date:10/16/00ISR Number: 3595929-0Report Type:Expedited (15-DaCompany Report #B0089165A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
	Pregnancy	Health Professional						

Date:10/16/00ISR Number: 3595944-7Report Type:Expedited (15-DaCompany Report #B0089357A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
	Athetosis	Health Professional						
	Fear		Mefenamic Acid	C				

				Macrodex	C		

Date:10/16/00ISR Number: 3595946-0Report Type:Expedited (15-DaCompany Report #B0089436A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL		
	Feeling Abnormal	Health Professional Company Representative						

Date:10/16/00ISR Number: 3595948-4Report Type:Expedited (15-DaCompany Report #B0089550A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block	Foreign	Zyban	PS	Glaxo Wellcome Inc		2	MON
	Second Degree	Health Professional	Diazepam	C				
			Beclomethasone Dipropion	C				

Date:10/16/00ISR Number: 3595952-6Report Type:Expedited (15-DaCompany Report #B0088136A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY	
	Circulatory Collapse	Health Professional						
	Confusional State						/ ORAL	
	Eye Rolling							
	Headache							
	Loss Of Consciousness							
	Pallor							
	Salivary Hypersecretion							

	Tonic Convulsion

Date:10/16/00ISR Number: 3595954-XReport Type:Expedited (15-DaCompany Report #B0088627A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Psoriasis		Calcipotriene	C				
			Fluticasone Propionate	C				
			Allopurinol	C				

Date:10/16/00ISR Number: 3595956-3Report Type:Expedited (15-DaCompany Report #B0084724A
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Blood Pressure Fluctuation
Disability Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis Exfoliative
	Eosinophilia
	Erythema
	Hypersensitivity

	Hypothermia						
	Malaise						
	Rash Erythematous	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Skin Inflammation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
	Skin Lesion	Health					PER DAY/ ORAL
	Viral Infection	Professional	Allopurinol	C			

Date:10/16/00ISR Number: 3595958-7Report Type:Expedited (15-DaCompany Report #B0089466A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Asthma	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL
			Salbutamol Sulphate	C			
			Beclomethasone Dipropion.	C			
			Ipratropium Bromide	C			
			Fluoxetine	C			

Date:10/16/00ISR Number: 3595961-7Report Type:Expedited (15-DaCompany Report #B0082531A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Aspartate	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL
Hospitalization - Initial or Prolonged	Aminotransferase Increased	Literature Health					
	Atrioventricular Block Complete	Professional					
	Blood Creatine Phosphokinase Increased						
	Blood Creatine Phosphokinase Mb Increased						
	Bradycardia						
	Hypokinesia						
	Myocardial Infarction						
	Supraventricular						

	Tachycardia					

Date:10/16/00ISR Number: 3595963-0Report Type:Expedited (15-DaCompany Report #B0088823A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Constipation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
Initial or Prolonged	Intestinal Obstruction	Consumer					PER DAY/	ORAL

Date:10/16/00ISR Number: 3595965-4Report Type:Expedited (15-DaCompany Report #B0089068A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Headache	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Ruptured Cerebral Aneurysm							
	Subarachnoid Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/00ISR Number: 3595966-6Report Type:Expedited (15-DaCompany Report #B0089121A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Haematuria Rash Maculo-Papular	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	DAY/ ORAL

Date:10/16/00ISR Number: 3595967-8Report Type:Expedited (15-DaCompany Report #B0089166A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Emotional Disorder Fatigue Hallucination Nightmare Sleep Walking Stress	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:10/16/00ISR Number: 3595968-XReport Type:Expedited (15-DaCompany Report #D0010841A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Amnesia Cardiac Arrest Electroencephalogram Abnormal Epilepsy	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	DAY/ ORAL

Date:10/16/00ISR Number: 3595970-8Report Type:Expedited (15-DaCompany Report #D0010722A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Multiple Sclerosis	Foreign Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:10/16/00ISR Number: 3595974-5Report Type:Expedited (15-DaCompany Report #B0089112A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Circulatory Collapse Hyperhidrosis Syncope Vasovagal	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:10/16/00ISR Number: 3595976-9Report Type:Expedited (15-DaCompany Report #B0089069A
Age:62 YR Gender:Male I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Brain Stem Infarction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Circulatory Collapse		Diclofenac	C				
			Allopurinol	C				

Date:10/16/00ISR Number: 3596416-6Report Type:Expedited (15-DaCompany Report #A0128949A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	1 WK
		Study						
		Health						
		Professional						

Date:10/17/00ISR Number: 3595457-2Report Type:Expedited (15-DaCompany Report #A0129577A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erectile Dysfunction		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	
	Hypoaesthesia							
	Triple Vessel Bypass Graft		Cardiac Medication	SS				

Date:10/17/00ISR Number: 3595454-7Report Type:Expedited (15-DaCompany Report #A0129318A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG PER DAY	
	Dyspnoea		Wellbutrin	C	Glaxo Wellcome	ORAL		
	Eyelid Oedema		No Concurrent					

	Malaise		Medications	C		
	Medication Error					
	Pruritus					

Date:10/17/00ISR Number: 3595459-6Report Type:Expedited (15-DaCompany Report #B0089482A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Left Ventricular Failure		Bupropion					
	Oedema		Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE	PER DAY 20 DAY
			No Concurrent Medication	C				

Date:10/18/00ISR Number: 3597615-XReport Type:Expedited (15-DaCompany Report #A0129318A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG/PER	
Initial or Prolonged	Eyelid Oedema	Professional					DAY/ORAL	
	Malaise		Bupropion					
	Medication Error		Hydrochloride	C				
	Pruritus							
	Respiratory Disorder							

Date:10/18/00ISR Number: 3598141-4Report Type:Expedited (15-DaCompany Report #A0129577A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erectile Dysfunction Hypoaesthesia Sexual Dysfunction Triple Vessel Bypass Graft	Foreign Consumer	Bupropion Hydrochloride Cardiac Medication (Formulation Unknown) (Cardiac Medication)	PS SS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	

Date:10/18/00ISR Number: 3598158-XReport Type:Expedited (15-DaCompany Report #B0089482A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Left Ventricular Failure Oedema	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	

Date:10/20/00ISR Number: 3598180-3Report Type:Expedited (15-DaCompany Report #A0128376A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Agitation Blood Gases Abnormal Brain Herniation Brain Oedema Bundle Branch Block Left Cerebrovascular Accident Coma Confusional State Convulsion		Wellbutrin Zyban Tylenol Pm	PS SS C	Glaxo Wellcome Glaxo Wellcome	ORAL ORAL	150MG SEE TEXT	1 DAY

Dyspnoea
Extensor Plantar Response
Hemiparesis
Hypokalaemia
Lung Infiltration
Muscle Twitching
Mydriasis
Overdose
Pulmonary Oedema
Pupillary Reflex Impaired
Pupils Unequal
Respiratory Disorder
Respiratory Failure
Sinus Tachycardia
Suicide Attempt

Date:10/20/00ISR Number: 3598887-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Zyban	PS		ORAL	150 MG PO BID	2 MON
	Diarrhoea		Evista	C				
	Dyspepsia							
	Medication Error							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/00ISR Number: 3598928-8Report Type:Direct Company Report #
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Discomfort		Zyban 150mg Dicyclomine	PS C			BID	

Date:10/20/00ISR Number: 3598182-7Report Type:Expedited (15-DaCompany Report #A0129538A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electrocardiogram Qt Corrected Interval		Wellbutrin Concurrent Medications	PS C	Glaxo Wellcome			

Date:10/20/00ISR Number: 3598188-8Report Type:Expedited (15-DaCompany Report #B0088713A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia Blood Creatine Phosphokinase Increased Myositis Oedema Peripheral Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	2 WK

Date:10/20/00ISR Number: 3598191-8Report Type:Expedited (15-DaCompany Report #B0089511A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Arrest Diabetes Mellitus		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE	

		Ventricular Tachycardia				
PER DAY	32 DAY					
			Aspirin	C		ORAL
75MG PER DAY						
			Atenolol	C		ORAL
50MG PER DAY						
			Frusemide	C		ORAL
40MG PER DAY						
			Lisinopril	C		ORAL
10MG PER DAY						
			Spironolactone	C		ORAL
25MG PER DAY						
			Gemfibrozil	C		ORAL
600MG TWICE						
PER DAY						

Date:10/23/00ISR Number: 3599909-0Report Type:Expedited (15-DaCompany Report #A0129538A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electrocardiogram Qt Corrected Interval Prolonged	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc			

Date:10/23/00ISR Number: 3599911-9Report Type:Expedited (15-DaCompany Report #A0128376A
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Death	Abnormal Behaviour
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome

	Agitation					
	Blood Gases Abnormal					
	Brain Herniation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Bundle Branch Block Left	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
150 MG / SEE						
	Cerebrovascular Accident	Professional				
TEXT / ORAL						
	Coma	Company	Bupropion			
	Convulsion	Representative	Hydrochloride Tablet			
	Dry Throat		- Zyban (Bupropion			
	Dyspnoea		Hydrochloride)	SS		ORAL
SEE TEXT /						
	Extensor Plantar Response					
ORAL						
	Hemiparesis		Extra Strength			
	Hypertension		Tylenol Pm	C		
	Lip Dry					
	Lung Infiltration					
	Miosis					
	Muscle Twitching					
	Mydriasis					
	Overdose					
	Pulmonary Oedema					
	Pupillary Reflex Impaired					
	Pupils Unequal					
	Respiratory Disorder					
	Respiratory Failure					
	Sinus Tachycardia					
	Suicide Attempt					
	Vaginal Haemorrhage					
	Vasospasm					

Date:10/23/00ISR Number: 3600401-5Report Type:Expedited (15-DaCompany Report #B0089511A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiac Arrest	Foreign	Bupropion			
Initial or Prolonged	Diabetes Mellitus	Other	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Ventricular Tachycardia					
TWICE PER DAY						
/ ORAL						

Aspirin	C
Atenolol	C
Frusemide	C
Lisinopril	C
Spironolactone	C
Gemfibrozil	C

Date:10/23/00ISR Number: 3600402-7Report Type:Expedited (15-DaCompany Report #B0088713A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Foreign	Bupropion					
	Blood Creatine Phosphokinase Increased	Health Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL 2 WK
	Myositis	Other						
	Oedema Peripheral							
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/00ISR Number: 3599071-4Report Type:Expedited (15-DaCompany Report #A0129781A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Laryngeal Oedema		Lamictal	SS	Glaxo Wellcome	ORAL		
	Mania							

Date:10/24/00ISR Number: 3599704-2Report Type:Expedited (15-DaCompany Report #B0089739A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL		
	Chronic Obstructive Airways Disease Exacerbated		Combivent	C				
	Electrocardiogram T Wave Inversion							

Date:10/24/00ISR Number: 3600705-6Report Type:Expedited (15-DaCompany Report #JRFUSA2000004633
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Literature	Duragesic	PS	Alza Corp	TRANSDERMAL	TRANSD	
	Drug Toxicity	Health Professional	Codeine (Codeine)	SS				
			Sertraline (Sertraline)	SS				
			Olanzapine (Olanzapine)	SS				
			Bupropion (Amfebutamone)	SS				

Date:10/24/00ISR Number: 3601103-1Report Type:Expedited (15-DaCompany Report #A0129781A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Laryngeal Oedema	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
ORAL						
	Mania	Professional	Lamictal Unspecified			
		Company	Tablet (Lamotrigine)	SS		ORAL
ORAL						
		Representative				

Date:10/24/00ISR Number: 3601897-5Report Type:Expedited (15-DaCompany Report #B0089987A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Circulatory Collapse	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE
Initial or Prolonged	Hypoglycaemia						PER DAY/ORAL
	Hypoglycaemic Coma		Perindopril	C			
			Human Insulin	C			

Date:10/24/00ISR Number: 3599698-XReport Type:Expedited (15-DaCompany Report #A0129782A
Age:22 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Bite
Initial or Prolonged	Convulsion
	Electroencephalogram

	Abnormal						
	Intentional Misuse						
	Suicide Attempt						
	Toxicologic Test Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	2250MG SINGLE
							DOSE 1 DAY
			Zyban	SS	Glaxo Wellcome	ORAL	150MG PER DAY 2 WK
			Prenatal Vitamins	C			
			Marijuana	C			1 DAY

Date:10/24/00ISR Number: 3599708-XReport Type:Expedited (15-DaCompany Report #B0089987A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Bupropion	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY
	Hypoglycaemic Coma						
			Perindopril	C		ORAL	2MG PER DAY
			Human Insulin	C			

Date:10/24/00ISR Number: 3599709-1Report Type:Expedited (15-DaCompany Report #B0090105A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Respiratory Distress		Zyban	PS	Glaxo Wellcome		

Date:10/25/00ISR Number: 3601561-2Report Type:Expedited (15-DaCompany Report #A0129782A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Bite	Health	Bupropion				

Initial or Prolonged	Complications Of Maternal	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
2250						
	Exposure To Therapeutic					
MG/SINGLE						
	Drugs					
DOSE/ORAL						
	Convulsion		Zyban Tablet - Zyban			
	Electroencephalogram		(Bupropion			
	Abnormal		Hydrochloride)	SS		ORAL
150 MG/PER						
	Intentional Misuse					
DAY/ORAL						
	Maternal Use Of Illicit		Prenatal	C		
	Drugs		Cannabis	C		
	Suicide Attempt					
	Tongue Disorder					
	Toxicologic Test Abnormal					

Date:10/25/00ISR Number: 3601934-8Report Type:Expedited (15-DaCompany Report #B0090105A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Respiratory Distress	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	

Date:10/25/00ISR Number: 3601936-1Report Type:Expedited (15-DaCompany Report #B0089739A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Initial or Prolonged	Cardiac Disorder	Health	Combivent	C				
	Chest Pain	Professional						
	Condition Aggravated							
	Electrocardiogram T Wave Inversion							
	Respiratory Disorder							

Date:10/25/00ISR Number: 3600343-5Report Type:Expedited (15-DaCompany Report #A0129656A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE	
	Erythema						PER DAY	
	Infection							
	Pruritus							
	Pyrexia							
	Rash Maculo-Papular							
	Skin Discolouration							
	Skin Exfoliation							
	Tremor							

Date:10/25/00ISR Number: 3600349-6Report Type:Expedited (15-DaCompany Report #B0089929A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Zyban	PS	Glaxo Wellcome		150MG TWICE	
	Eye Irritation						PER DAY	7 WK
	Insomnia		Cimetidine	C				
	Keratoconjunctivitis		Temazepam	C				
	Sicca							

Micturition Disorder

Date:10/25/00ISR Number: 3600350-2Report Type:Expedited (15-DaCompany Report #B0089984A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Bupropion	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	5 DAY
			Atenolol + Chlorthalidone	C		ORAL		
			Doxazosin	C		ORAL	2MG PER DAY	

Date:10/25/00ISR Number: 3600351-4Report Type:Expedited (15-DaCompany Report #B0089998A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oculogyration		Bupropion	PS	Glaxo Wellcome	ORAL	150MG PER DAY	2 DAY
			Fluoxetine	C		ORAL	20MG PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/00ISR Number: 3601007-4Report Type:Expedited (15-DaCompany Report #A0123011A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hallucination		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	7 DAY
	Hyperventilation							
	Overdose		Oxycontin	SS		ORAL	20MG TWICE PER DAY	
	Paranoia							
			Amantadine	C		ORAL	100MG THREE TIMES PER DAY	

Date:10/26/00ISR Number: 3601021-9Report Type:Expedited (15-DaCompany Report #B0089784A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	5 DAY
	Grand Mal Convulsion							
	Hypersensitivity		Losartan	C		ORAL	1TAB PER DAY	
	Thrombocythaemia		Bromazepam	C		ORAL	1TAB PER DAY	

Date:10/30/00ISR Number: 3602848-XReport Type:Expedited (15-DaCompany Report #A0130183A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Toxicity		Bupropion	PS	Glaxo Wellcome			
			Chloral Hydrate	SS			UNKNOWN	
			Atropine	SS			UNKNOWN	

			Diazepam	SS		
UNKNOWN						

Date:10/30/00ISR Number: 3602854-5Report Type:Expedited (15-DaCompany Report #A0130633A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Bupropion	PS	Glaxo Wellcome	ORAL	150MG PER DAY	
	Arrhythmia		Venlafaxine	SS				
UNKNOWN							375MG PER DAY	

Date:10/30/00ISR Number: 3602856-9Report Type:Expedited (15-DaCompany Report #A0130638A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Bupropion	PS	Glaxo Wellcome	ORAL		
	Arrhythmia		Venlafaxine	SS				
UNKNOWN								

Date:10/30/00ISR Number: 3602865-XReport Type:Expedited (15-DaCompany Report #B0088745A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL		
	Electrocardiogram T Wave		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		
Disability	Inversion							
	Myocardial Infarction		Aspirin	C		ORAL		
			Bendrofluazide	C	Glaxo Wellcome	ORAL		
			Prednisolone	C		ORAL		
			Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		
			Ipratropium	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/00ISR Number: 3603787-0Report Type:Expedited (15-DaCompany Report #A0125519A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
Disability	Arrhythmia	Professional						
	Atherosclerosis							
	Coronary Artery Disease							
	Fibrosis							
	Hepatic Steatosis							
	Ill-Defined Disorder							
	Injury							
	Oedema							
	Pain							
	Pancreatic Disorder							
	Pulmonary Congestion							
	Pulmonary Oedema							

Date:10/30/00ISR Number: 3603788-2Report Type:Expedited (15-DaCompany Report #A0123011A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hallucination	Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Hyperventilation	Professional						
	Overdose							
	Paranoia							
			Oxycodone Hydrochloride (Formulation Unknown) (Oxycodone Hydrochloride)	SS		ORAL	20 MG / TWICE PER DAY / ORAL	
			Amantadine	C				

Date:10/30/00ISR Number: 3604167-4Report Type:Expedited (15-DaCompany Report #HQ2762525OCT2000
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Disorientation	Consumer	Effexor Xr	PS	Wyeth Ayerst Laboratories	ORAL	SEE IMAGE	
	Hallucination Hyperhidrosis Lethargy		Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	ORAL	
	Syncope Thinking Abnormal		Synthroid (Levothyroxien Sodium)	C				

Date:10/30/00ISR Number: 3604397-1Report Type:Expedited (15-DaCompany Report #B0089998A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Oculogyration	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ DAY/ ORAL	
			Fluoxetine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/00ISR Number: 3604400-9Report Type:Expedited (15-DaCompany Report #B0089984A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Angina Pectoris	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
Intervention to	Condition Aggravated						PER DAY/ ORAL
Prevent Permanent	Coronary Artery Occlusion		Atenolol +				
Impairment/Damage			Chlorthalidone	C			
			Doxazosin	C			

Date:10/30/00ISR Number: 3604401-0Report Type:Expedited (15-DaCompany Report #B0089929A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Eye Irritation	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG/ TWICE
	Insomnia	Health					PER DAY/ 7 WK
	Keratoconjunctivitis	Professional	Cimetidine	C			
	Sicca		Temazepam	C			
	Micturition Disorder						

Date:10/30/00ISR Number: 3604408-3Report Type:Expedited (15-DaCompany Report #B0089784A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Amnesia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
Initial or Prolonged	Drug Hypersensitivity	Health					PER DAY/ ORAL
	Grand Mal Convulsion	Professional	Losartan Potassium	C			
	Thrombocythaemia		Bromazepam	C			

Date:10/30/00ISR Number: 3602873-9Report Type:Expedited (15-DaCompany Report #B0090537A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Femur Fracture		Zyban	PS	Glaxo Wellcome	ORAL	300MG PER DAY	5 WK

Date:10/31/00ISR Number: 3603414-2Report Type:Expedited (15-DaCompany Report #A0120776A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar Disorder		Lamictal	PS	Glaxo Wellcome	ORAL	7 DAY	
	Condition Aggravated		Wellbutrin	SS	Glaxo Wellcome		200MG TWICE PER DAY	
	Dermatitis							
	Headache		Klonopin	C			1MG AS REQUIRED	
	Muscle Twitching							
	Petit Mal Epilepsy		Prilosec	C				
	Pruritus		Dalmane	C				
	Sinusitis		Celexa	C				
	Stevens-Johnson Syndrome		Trazodone	C				
	Toxic Epidermal Necrolysis		Compazine	C				
			Carafate	C				
	Tremor		Vitamins	C				
	Urinary Incontinence		Zyprexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/00ISR Number: 3603596-2Report Type:Direct Company Report #
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS			BID	
			Tetracycline	C				
			Ery Solution	C				
			Ritalin	C				

Date:10/31/00ISR Number: 3604492-7Report Type:Direct Company Report #
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Akathisia		Zyban (Bupropion					
Other	Amnesia		Hcl) Sustained-					
	Anxiety		Released Tablets 150					
	Confusional State		Mg	PS		ORAL	150 MG ORALLY	
	Disturbance In Attention						PER DAY	
	Epistaxis							
	Movement Disorder							
	Speech Disorder							
	Tardive Dyskinesia							
	Tinnitus							
	Vision Blurred							

Date:10/31/00ISR Number: 3605053-6Report Type:Expedited (15-DaCompany Report #B0090537A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fall	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	5 WK
Initial or Prolonged	Feeling Abnormal	Consumer						
	Femur Fracture							

Date:10/31/00ISR Number: 3605054-8Report Type:Expedited (15-DaCompany Report #A0130633A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER	DAY/ORAL
	Arrhythmia		Venlafaxine Hydrochloride (Formulation Unknown) (Venlafaxine	SS			375 MG/PER	DAY

Date:10/31/00ISR Number: 3605055-XReport Type:Expedited (15-DaCompany Report #A0130638A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Arrhythmia		Venlafaxine Hydrochloride (Formulation Unknown) (Venlafaxine	SS				

Date:10/31/00ISR Number: 3606776-5Report Type:Periodic Company Report #AMANTADI2000-00258
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression	Distributor	Symmetrel	PS	Endo Pharmaceuticals Inc	ORAL	BID PO	
Hospitalization - Initial or Prolonged	Coma							
	Confusional State		Wellbutrin Sr Glaxo Wellcome	SS	Glaxo Wellco	ORAL	150 MG DLY PO	
	Convulsion							
	Drug Interaction		Semisodium Valproate	C				
	Drug Level Below Therapeutic							
	Ecchymosis							
	Fall							
	Fatigue							
	Headache							
	Heart Rate Increased							
	Memory Impairment							
	Movement Disorder							
	Muscle Rigidity							
	Nausea							
	Oxygen Saturation Decreased							
	Pallor							
	Respiratory Rate Decreased							
	Speech Disorder							

Date:10/31/00ISR Number: 3603416-6Report Type:Expedited (15-DaCompany Report #A0130226A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Tenderness		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG PER DAY	90 DAY
	Albuminuria		Methadone	SS	Glaxo Wellcome			
	Blood Creatine Phosphokinase Increased							
	Chest Wall Pain							
	Chromaturia							
	Haematocrit Decreased							
	Haemoglobinuria							
	Hepatic Enzyme Increased							

	Hepatitis C
	Hypercalcaemia
	Hypokalaemia
	Leukopenia
	Rhabdomyolysis
	White Blood Cells Urine
	Positive

Date:10/31/00ISR Number: 3603417-8Report Type:Expedited (15-DaCompany Report #A0130639A
Age:22 YR Gender:Female I/FU:I

Outcome	PT
Other	Angioneurotic Oedema
	Arthralgia
	Joint Swelling
	Leukocytosis
	Myalgia
	Pyrexia
	Skin Discolouration
	Urinary Tract Infection

Urticaria

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	
			Oral Contraceptive	C				

Date:11/01/00ISR Number: 3604014-0Report Type:Expedited (15-DaCompany Report #A0070194A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Activities Of Daily		Zyban	PS	Glaxo Wellcome	ORAL	150MG PER DAY	24 DAY
	Living Impaired		Lidocaine	C			1	DAY
	Amnesia		General Anesthesia	C			1	DAY
	Anger		Surgery	C				
	Anorexia		D5 L.R	C			INTRAVENOUS	1 DAY
	Anxiety Disorder		Levsin	C				
	Apathy		Demerol	C			INTRAVENOUS	1 DAY
	Asthenia		Diprivan	C			1	DAY
	Cognitive Disorder		Midazolam	C			1	DAY
	Confusional State		Nitrous Oxide	C			1	DAY
	Convulsion		Droperidol	C			1	DAY
	Depression		Zofran	C	Glaxo Wellcome		1	DAY
	Diarrhoea		Desflurane	C			1	DAY
	Disturbance In Attention		Succinylcholine	C	Glaxo Wellcome		1	DAY
	Drug Ineffective		Fentanyl	C			1	DAY
	Early Morning Awakening		Hydrocodone + Acetaminophen	C				
	Encephalopathy							

	Fatigue	Marcaine	C	
1 DAY				
	Fear	Tylenol #3	C	ORAL
	Feeling Abnormal	Imodium	C	
	Feeling Guilty	Motrin	C	
	Fibroadenoma Of Breast	Oxygen	C	
1 DAY				
	Headache			
	Hypochondriasis			
	Initial Insomnia			
	Loss Of Libido			
	Mood Swings			
	Nausea			
	Suicidal Ideation			
	Thinking Abnormal			
	Vomiting			

Date:11/01/00ISR Number: 3604036-XReport Type:Expedited (15-DaCompany Report #B0090510A
Age:45 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Bupropion	PS	Glaxo Wellcome	ORAL	150MG PER DAY	5 DAY
			Diclofenac	C		ORAL	100MG PER DAY	
			Amoxycillin	C		ORAL	250MG PER DAY	6 DAY

Date:11/01/00ISR Number: 3604025-5Report Type:Expedited (15-DaCompany Report #B0090063A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Artery Embolism		Zyban	PS	Glaxo Wellcome	ORAL	2TAB PER DAY	14 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/00ISR Number: 3604032-2Report Type:Expedited (15-DaCompany Report #B0090433A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Ischaemia		Zyban	PS	Glaxo Wellcome	ORAL	150MG AS	
	Sudden Death						DIRECTED	

Date:11/01/00ISR Number: 3604035-8Report Type:Expedited (15-DaCompany Report #B0090507A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis Exfoliative		Bupropion	PS	Glaxo Wellcome	ORAL	150MG TWICE	
	Vasculitis						PER DAY	
			Dextropropoxyphene + Paracetamol	C		ORAL		
			Flucloxacillin	C		ORAL	250MG FOUR	
							TIMES PER DAY	8 DAY
			Betamethasone Valerate + Salicylic Acid	C				
							TOPICAL	

Date:11/02/00ISR Number: 3605180-3Report Type:Expedited (15-DaCompany Report #A0127926A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ageusia	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE	
Initial or Prolonged	Anxiety	Professional					PER DAY	8 DAY
	Condition Aggravated		Paxil	C		ORAL		
	Depression		Enteric Coated Asa	C		ORAL	325MG PER DAY	
	Dyspnoea		Unspecified					

	Feeling Abnormal	Immunosuppressants	C		
	Hypertension	Cyclosporin	C		
125MG TWICE					
	Panic Attack				
PER DAY					
	Tearfulness	Ramipril	C		ORAL
12.5MG PER					
	Tobacco Abuse				
DAY					
	Tremor	Pravachol	C		
40MG PER DAY					
		Losec	C		ORAL
20MG PER DAY					
		Oxazepam	C		ORAL
15MG AS					
REQUIRED					
		Oxazepam	C		ORAL
30MG AT NIGHT					
		Hytrin	C		ORAL
1MG PER DAY					
		Lasix	C		ORAL
60MG PER DAY					
		Atrovent	C	Glaxo Wellcome	
RESPIRATORY					
(INHALATION)	2PUFF FOUR				
TIMES PER DAY					
		Prednisone	C		ORAL
5MG PER DAY					
		Septra	C	Glaxo Wellcome	ORAL
1TAB PER DAY					
		Cozaar	C		ORAL
25MG PER DAY					

Date:11/02/00ISR Number: 3605987-2Report Type:Expedited (15-DaCompany Report #A0120776A
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Headache
Initial or Prolonged	Muscle Twitching
	Petit Mal Epilepsy
	Rash Pruritic
	Sinusitis
	Stevens-Johnson Syndrome

	Toxic Epidermal Necrolysis Tremor	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Urinary Incontinence	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	UNKNOWN 200 MG / TWICE PER DAY/ UNKNOWN
			Lamictal Tablet (Lamotrigine)	SS		ORAL 100 MG / ORAL
			Clonazepam	C		
			Omeprazole	C		
			Dalmane	C		
			Citalopram Hydrobromide	C		
			Trazadone	C		
			Prochlorperazine	C		
			Sucralfate	C		
			Multivitamin	C		
			Olanzapine	C		

Date:11/02/00ISR Number: 3605989-6Report Type:Expedited (15-DaCompany Report #A0130226A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Albuminuria Blood Creatine Phosphokinase Increased Chest Wall Pain Chromaturia Haematocrit Decreased Haemoglobinuria Hepatic Enzyme Increased Hepatic Function Abnormal Hepatitis C Hypocalcaemia Hypokalaemia Leukopenia	Health Professional	Wellbutrin Methadone Hydrochloride (Formulation Unknown) (Methadone Hydrochloride)	PS SS	Glaxo Wellcome Inc	ORAL 100 MG / PER DAY / ORAL

	Rhabdomyolysis					
	White Blood Cells Urine Positive					

Date:11/02/00ISR Number: 3606471-2Report Type:Expedited (15-DaCompany Report #A0130639A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/	
	Arthralgia							
	Joint Swelling							
	Leukocytosis		Oral Contraceptive	C				
	Myalgia							
	Pruritus							
	Pyrexia							
	Skin Discolouration							
	Urinary Tract Infection							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/00ISR Number: 3605188-8Report Type:Expedited (15-DaCompany Report #B0089839A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	C-Reactive Protein		Zyban	PS	Glaxo Wellcome	ORAL		13 DAY
Initial or Prolonged	Increased							
Other	Dermatitis							
	Myopathy							
	Polyarthritis							

Date:11/03/00ISR Number: 3606861-8Report Type:Expedited (15-DaCompany Report #A0070194A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Anaesthetic Complication	Professional						DAY / ORAL
	Anger		General Anesthetic					
	Anxiety		(Formulation					
	Anxiety Disorder		Unknown) (General					
	Apathy		Anesthetic)	SS				
	Asthenia		Ibuprofen	C				
	Brain Contusion		Loperamide					
	Cognitive Disorder		Hydrochloride	C				
	Confusional State		Dextrose + Lactated					
	Convulsion		Ringers	C				
	Crying		Tylenol No. 3	C				
	Decreased Activity		Hyoscyamine Sulphate	C				
	Decreased Appetite		Bupivacaine					
	Depressed Mood		Hydrochloride	C				
	Depression		Pethidine					
	Disturbance In Attention		Hydrochloride	C				
	Drug Ineffective		Hydrocodone +					
	Dysphoria		Paracetamol	C				
	Encephalopathy		Propofol	C				
	Fatigue		Lignocaine	C				
	Fear		Fentanyl	C				
	Feeling Abnormal		Midazolam	C				
	Headache		Suxamethonium					
	Hypochondriasis		Chloride	C				
	Hypoxia		Desflurane	C				

	Insomnia		Ondansetron		
	Loss Of Libido		Hydrochloride	C	
	Memory Impairment		Oxygen	C	
	Mood Swings		Droperidol	C	
	Nausea		Nitrous Oxide	C	
	Suicidal Ideation				
	Thinking Abnormal				

Date:11/03/00ISR Number: 3607169-7Report Type:Expedited (15-DaCompany Report #B0090507A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis Exfoliative	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Vasculitis		Dextroprop. + Paracetamol	C				
			Flucloxacillin	C				
			Betamet.Val.+Salicyl					

			ic Acid	C		

Date:11/03/00ISR Number: 3607171-5Report Type:Expedited (15-DaCompany Report #B0090510A
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angina Unstable	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL
			Diclofenac	C			
			Amoxycillin	C			

Date:11/03/00ISR Number: 3607172-7Report Type:Expedited (15-DaCompany Report #B0090433A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Myocardial Ischaemia Sudden Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / AS DIRECTED / ORAL

Date:11/03/00ISR Number: 3605721-6Report Type:Expedited (15-DaCompany Report #D0011443A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Difficulty In Walking Pain In Extremity		Zyban	PS	Glaxo Wellcome	ORAL	

Date:11/06/00ISR Number: 3606520-1Report Type:Expedited (15-DaCompany Report #A0128801A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG TWICE	
	Drug Interaction						PER DAY	YR
	Tremor		Celexa	SS			60MG PER DAY	
	Tunnel Vision		Lithium	C				
			Trilafon	C	Glaxo Wellcome			

Date:11/06/00ISR Number: 3607154-5Report Type:Expedited (15-DaCompany Report #B0090063A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Artery Embolism	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	14 DAY

Date:11/06/00ISR Number: 3607766-9Report Type:Expedited (15-DaCompany Report #B0089839A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis Myopathy Polyarthritis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/00ISR Number: 3607768-2Report Type:Expedited (15-DaCompany Report #A0127926A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL
	Condition Aggravated	Health Professional						
	Depression							
	Dysgeusia		Immunosuppressive	C				
	Dyspnoea		Paroxetine Hydrochloride	C				
	Feeling Abnormal		Prednisone	C				
	Hypertension		Cyclosporin	C				
	Panic Attack		Ipratropium Bromide	C				
	Tearfulness		Ramipril	C				
	Tremor		Frusemide	C				
			Co-Trimoxazole	C				
			Aspirin	C				
			Pravastatin Sodium	C				
			Terazosin Hydrochloride	C				
			Omeprazole	C				
			Oxazepam	C				
			Losartan Potassium	C				

Date:11/06/00ISR Number: 3607833-XReport Type:Expedited (15-DaCompany Report #D0011443A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG, ORAL	
	Pain In Extremity	Health Professional						

Date:11/06/00ISR Number: 3606525-0Report Type:Expedited (15-DaCompany Report #B0086032A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL
1TAB PER DAY 2 DAY						
Initial or Prolonged	Atrial Fibrillation					
	Cardiomegaly					
	Dyspnoea					
	Echocardiogram Abnormal					
	Hypertension					
	Pulmonary Oedema					

Date:11/06/00ISR Number: 3606533-XReport Type:Expedited (15-DaCompany Report #B0090441A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Multiple Sclerosis		Bupropion			
	Nervous System Disorder		Hydrochloride	PS	Glaxo Wellcome	ORAL
150MG TWICE						
PER DAY						
			Loratadine	C		ORAL
10MG PER DAY						
			Flucloxacillin	C		ORAL
250MG FOUR						
TIMES PER DAY 6 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/00ISR Number: 3607293-9Report Type:Expedited (15-DaCompany Report #A0066944A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG TWICE	
Initial or Prolonged	Chest Discomfort						PER DAY	
Disability	Chest Pain		Wellbutrin	SS	Glaxo Wellcome	ORAL		
Other	Coronary Artery		Klonopin	C				
	Atherosclerosis		Aspirin	C				
	Coronary Artery Occlusion		Zoloft	C				
							2	YR
	Dermatitis		Depakote	C				
	Disorientation							
	Drug Ineffective							
	Dyspnoea							
	Fatigue							
	Headache							
	Hyperhidrosis							
	Increased Appetite							
	Myalgia							
	Pharyngolaryngeal Pain							
	Pruritus							
	Weight Increased							

Date:11/07/00ISR Number: 3608290-XReport Type:Direct Company Report #
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS			BID	
			Tetracycline	C				
			Ery Solution	C				
			Ritalin	C				

Date:11/07/00ISR Number: 3608310-2Report Type:Expedited (15-DaCompany Report #A0128801A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
200 MG /						
	Drug Interaction	Professional				
TWICE PER						
	Tremor					
DAY/ ORAL 1 YR						
	Tunnel Vision		Citalopram Hydrobromide (Formulation Unknown) (Citalopram Hydrobromide)	SS		
UNKNOWN 60 MG / PER						
DAY/ UNKNOWN						
			Lithium Salt	C		
			Perphenazine	C		

Date:11/07/00ISR Number: 3608445-4Report Type:Expedited (15-DaCompany Report #B0086032A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arrhythmia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
1 TABLET/ PER						
Initial or Prolonged	Atrial Fibrillation	Health				
DAY/ ORAL						
	Cardiomegaly	Professional				
	Dyspnoea					
	Echocardiogram Abnormal					
	Hypertension					
	Pulmonary Oedema					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/00ISR Number: 3608446-6Report Type:Expedited (15-DaCompany Report #B0090441A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Multiple Sclerosis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL
			Loratadine	C			
			Flucloxacillin	C			

Date:11/08/00ISR Number: 3608263-7Report Type:Expedited (15-DaCompany Report #A0130681A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Drug Abuser		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG PER DAY 2 MON
	Fall		Alcohol	C			
	Grand Mal Convulsion		No Concurrent Medications	C			
	Humerus Fracture		Marijuana	C			
	Intentional Misuse						
	Stress						
	Suicide Attempt						

Date:11/08/00ISR Number: 3608273-XReport Type:Expedited (15-DaCompany Report #B0090959A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome		

Date:11/08/00ISR Number: 3608274-1Report Type:Expedited (15-DaCompany Report #B0091014A
Age:63 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Extrasystoles		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE
	Palpitations						

PER DAY						
			Thyroxine	C	Glaxo Wellcome	ORAL
75UG PER DAY						

Date:11/09/00ISR Number: 3608768-9Report Type:Expedited (15-DaCompany Report #B0091004A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Condition Aggravated		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG PER DAY	
	Hemiparesis		Aspirin	C		ORAL	75MG PER DAY	
	Transient Ischaemic Attack		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	100UG PER DAY	
			Ipratropium	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	20UG PER DAY	
			Salmeterol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	25UG PER DAY	

Date:11/09/00ISR Number: 3608770-7Report Type:Expedited (15-DaCompany Report #B0091092A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vision Blurred Visual Field Defect		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	29 DAY

			Ascorbic Acid	C		ORAL 500MG PER DAY
			Multivitamins	C		ORAL 1CAP PER DAY YR

Date:11/09/00ISR Number: 3609604-7Report Type:Direct Company Report #
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Grand Mal Convulsion		Concerta 18mg	PS		ORAL 1 QD ORAL
	Insomnia		Wellbutrin Sr 100mg	SS		ORAL 2 BID ORAL
	Medication Error					

Date:11/09/00ISR Number: 3610188-8Report Type:Expedited (15-DaCompany Report #A0066944A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Agitation	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL ORAL
	Chest Discomfort		Wellbutrin Tablet (Bupropion Hydrochloride)	SS		ORAL 100 MG / TWICE PER DAY / ORAL
	Chest Pain					
	Coronary Artery Atherosclerosis					
	Coronary Artery Occlusion					
	Dermatitis		Clonazepam	C		
	Disorientation		Aspirin	C		
	Drug Ineffective		Sertraline Hydrochloride	C		
	Dyspnoea		Semisodium Valproate	C		
	Fatigue					
	Headache					
	Hyperhidrosis					
	Increased Appetite					
	Pharyngolaryngeal Pain					
	Pruritus					
	Weight Increased					

Date:11/09/00ISR Number: 3608758-6Report Type:Expedited (15-DaCompany Report #A0131125A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Caesarean Section		Bupropion	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	5 WK
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Congenital Aortic Valve Incompetence							
	Congenital Aortic Valve Stenosis							

Date:11/09/00ISR Number: 3608767-7Report Type:Expedited (15-DaCompany Report #B0090989A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Migraine With Aura		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG PER DAY	41 DAY
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/00ISR Number: 3608769-0Report Type:Expedited (15-DaCompany Report #B0091015A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Hypokalaemia Tachycardia		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	3 DAY
			Aspirin	C		ORAL	150MG PER DAY	
			Enalapril	C		ORAL	10MG PER DAY	
			Zopiclone	C		ORAL	7.5MG PER DAY	
			Calcium Carbonate + Disodium Etidronate	C		ORAL		
			Atenolol	C		ORAL	100MG PER DAY	
			Mebeverine	C		ORAL	135MG THREE TIMES PER DAY	
			Ranitidine	C	Glaxo Wellcome	ORAL	150MG PER DAY	

Date:11/13/00ISR Number: 3609968-4Report Type:Expedited (15-DaCompany Report #B0091033A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Stem Infarction Cerebellar Infarction Drug Interaction Headache Hypertension		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	15 DAY
			Catecholamine Reuptake Inhibitor	SS				
			Atenolol	SS		ORAL	50MG PER DAY	

Date:11/13/00ISR Number: 3609992-1Report Type:Expedited (15-DaCompany Report #B0086470A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE	
Disability	Hyperhidrosis						PER DAY	11 DAY
Other	Malaise		Combivent	C			RESPIRATORY (INHALATION)	2PUFF FOUR TIMES PER DAY
	Night Sweats		Beclomethasone	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	2PUFF TWICE PER DAY

Date:11/13/00ISR Number: 3609993-3Report Type:Expedited (15-DaCompany Report #B0086888A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxo Wellcome	ORAL	150MG SEE TEXT	
	Feeling Abnormal							
	Personality Change							

Date:11/13/00ISR Number: 3609995-7Report Type:Expedited (15-DaCompany Report #B0089436A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	
	Feeling Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/13/00ISR Number: 3610000-7Report Type:Expedited (15-DaCompany Report #B0091168A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis		Bupropion	PS	Glaxo Wellcome	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Hyperhidrosis		Paracetamol	SS				
	Hypotension		Alcohol	SS				
Other	Intentional Misuse							
	Pyrexia							
	Tachycardia							

Date:11/13/00ISR Number: 3610826-XReport Type:Expedited (15-DaCompany Report #2000UW04157
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Consumer	Tenormin	PS	Astrazeneca Pharmaceuticals Lp			
	Confusional State							
	Hypotension		Zyban	SS		ORAL	150	MG BID PO
	Pneumonia		Nifedipine	SS				
	Sedation		Gabapentin	SS				
	Speech Disorder							
	Toxicologic Test Abnormal							

Date:11/13/00ISR Number: 3609948-9Report Type:Expedited (15-DaCompany Report #A0128539A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	3	WK
	Blood Creatine Phosphokinase Increased		No Concurrent Medications	C				
	Dermatomyositis							
	Face Oedema							
	Myalgia							
	Oedema							

Date:11/14/00ISR Number: 3611401-3Report Type:Expedited (15-DaCompany Report #A0128539A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Arthralgia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	3 WK
Intervention to Prevent Permanent Impairment/Damage	Blood Creatine Phosphokinase Increased Dermatomyositis Face Oedema Myalgia	Professional						

Date:11/14/00ISR Number: 3611431-1Report Type:Expedited (15-DaCompany Report #A0131125A
Age: Gender:Male I/FU:I

Outcome	PT
Congenital Anomaly	Aortic Valve Disease Caesarean Section Complications Of Maternal Exposure To Therapeutic Drugs Congenital Aortic Valve Incompetence Heart Disease Congenital

Twin Pregnancy

		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE
		Health					PER DAY/ORAL
		Professional					

Date:11/14/00ISR Number: 3611630-9Report Type:Expedited (15-DaCompany Report #B0091014A
Age:63 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Extrasystoles Palpitations	Foreign Other	Zyban	PS	Pharmacia And Upjohn Co	ORAL	150MG (TWICE PER DAY) ORAL
			Thyroxine Sodium	C			

Date:11/14/00ISR Number: 3611631-0Report Type:Expedited (15-DaCompany Report #B0090959A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Spontaneous	Foreign Health Professional Other	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		

Date:11/14/00ISR Number: 3611644-9Report Type:Expedited (15-DaCompany Report #B0086470A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Disability	Atrial Fibrillation Hyperhidrosis	Foreign Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER

Required	Nausea	Professional				
DAY/ ORAL						
Intervention to Prevent Permanent Impairment/Damage	Night Sweats		Combivent	C		
			Beclomethasone Dipropion	C		

Date:11/14/00ISR Number: 3611826-6Report Type:Expedited (15-DaCompany Report #B0089436A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	TWICE
		Health						
PER DAY ORAL		Professional Company Representative						

Date:11/14/00ISR Number: 3611827-8Report Type:Expedited (15-DaCompany Report #B0086888A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG	SEE
	Feeling Abnormal	Health						
TEXT ORAL		Professional						

Date:11/14/00ISR Number: 3611921-1Report Type:Expedited (15-DaCompany Report #B0091168A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Blood Ph Decreased							
	Coma		Paracetamol (Acetaminophen)	SS				
	Convulsion							
	Hyperhidrosis		Ethanol (Alcohol)	SS				
	Hypotension							
	Irritability							
	Medication Error							
	Overdose							
	Pyrexia							
	Tachycardia							

Date:11/14/00ISR Number: 3611940-5Report Type:Expedited (15-DaCompany Report #B0091033A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Stem Infarction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ ORAL	
	Cerebellar Infarction							
	Drug Interaction							
	Headache		Atenolol (Formulation Unknown) (Atenolol)	SS		ORAL	ORAL	
	Hypertension							
			Catecholamine Reuptake Inhibitor (Formulation	SS				

Date:11/14/00ISR Number: 3611946-6Report Type:Expedited (15-DaCompany Report #B0091004A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Foreign	Bupropion					

Initial or Prolonged	Hemiparesis		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG/PER
	Transient Ischaemic					DAY/ ORAL
	Attack		Aspirin	C		
			Salbutamol Sulphate	C		
			Ipratropium Bromide	C		
			Salmeterol Xinafoate	C		

Date:11/14/00ISR Number: 3611948-XReport Type:Expedited (15-DaCompany Report #B0091015A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization -	Chest Pain	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ TWICE
Initial or Prolonged	Hypokalaemia					PER DAY/ ORAL
	Tachycardia		Aspirin	C		
			Enalapril	C		
			Zopiclone	C		
			Ca Carbonate+Na Etidronat	C		
			Atenolol	C		
			Mebeverine	C		
			Ranitidine Hydrochloride	C		

Date:11/14/00ISR Number: 3611949-1Report Type:Expedited (15-DaCompany Report #B0091092A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vision Blurred	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Visual Field Defect						PER DAY/ ORAL	
			Ascorbic Acid	C				
			Multivitamin	C				

Date:11/14/00ISR Number: 3611950-8Report Type:Expedited (15-DaCompany Report #B0090989A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Migraine With Aura	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Visual Disturbance							

Date:11/14/00ISR Number: 3612383-0Report Type:Expedited (15-DaCompany Report #A0125460A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Hospitalization - Initial or Prolonged	Ecchymosis	Professional	Clozapine	C				
	Excoriation	Company	Lisinopril	C				
	Fall	Representative	Docusate Sodium	C				
	Gastrointestinal Disorder		Amlodipine	C				
	Hepatic Congestion							
	Hepatic Failure							
	Hepatic Steatosis							
	Intestinal Ischaemia							
	Laceration							
	Liver Disorder							
	Mucosal Haemorrhage							
	Pancreatic Disorder							
	Pulmonary Congestion							

	Pulmonary Oedema						
	Rib Fracture						
	Splenic Injury						
	Wrist Fracture						

Date:11/14/00ISR Number: 3612564-6Report Type:Expedited (15-DaCompany Report #A130601A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Blindness Unilateral	Literature Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Disability	Brain Damage Brain Hypoxia Cardiac Arrest Cerebrovascular Accident Coma Convulsion Dyspnoea Haemorrhage Headache Hemiplegia Rash Generalised	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/00ISR Number: 3612648-2Report Type:Expedited (15-DaCompany Report #A0130681A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fall	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
Initial or Prolonged	Grand Mal Convulsion	Professional					DAY/ ORAL	
Other	Humerus Fracture	Company	Ethanol	C				
	Intentional Misuse	Representative	Cannabis	C				
	Suicide Attempt							

Date:11/15/00ISR Number: 3611257-9Report Type:Expedited (15-DaCompany Report #B0091314A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Left Ventricular Failure		Zyban	PS	Glaxo Wellcome	ORAL	150MG PER DAY	1 DAY
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY	
							(INHALATION)	
			Salbutamol	C	Glaxo Wellcome		RESPIRATORY	
							(INHALATION)	

Date:11/15/00ISR Number: 3611261-0Report Type:Expedited (15-DaCompany Report #A0070194A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adjustment Disorder		General Anesthesia	PS			1 DAY	
	Amnesia		Zyban	SS	Glaxo Wellcome	ORAL	150MG PER DAY	24 DAY
	Anger		Motrin	C				
	Anxiety		Surgery	C				
	Anxiety Disorder		Imodium	C				
	Asthenia		D5 L.R	C				
INTRAVENOUS	1 DAY							

	Cognitive Disorder	Tylenol #3	C		ORAL
	Confusional State	Levsin	C		
	Convulsion	Marcaine	C		
1 DAY					
	Crying	Demerol	C		
INTRAVENOUS	1 DAY				
	Decreased Activity	Hydrocodone +			
	Depressed Mood	Acetaminophen	C		
	Depression	Diprivan	C		
1 DAY					
	Diarrhoea	Lidocaine	C		
1 DAY					
	Disturbance In Attention	Fentanyl	C		
1 DAY					
	Drug Ineffective	Midazolam	C		
1 DAY					
	Early Morning Awakening	Succinylcholine	C	Glaxo Wellcome	
1 DAY					
	Encephalopathy	Desflurane	C		
1 DAY					
	Fatigue	Zofran	C	Glaxo Wellcome	
1 DAY					
	Fear	Oxygen	C		
1 DAY					
	Feeling Abnormal	Droperidol	C		
1 DAY					
	Headache	Nitrous Oxide	C		
1 DAY					
	Hypoxia				
	Injury				
	Insomnia				
	Mental Impairment				
	Mood Swings				
	Nausea				
	Nervous System Disorder				
	Thinking Abnormal				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/00ISR Number: 3611267-1Report Type:Expedited (15-DaCompany Report #B0089784A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	4 DAY
	Hypersensitivity							
	Loss Of Consciousness		Losartan	C		ORAL	1TAB PER DAY	
	Thrombocythaemia		Bromazepam	C		ORAL	1TAB PER DAY	

Date:11/15/00ISR Number: 3611766-2Report Type:Direct Company Report #
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bipolar I Disorder		Wellbutrin 75mg					
Hospitalization - Initial or Prolonged	Condition Aggravated		Burroughs Wellcome	PS	Burroughs Wellcome		3X DAILY, 75MG EACH	1 YR
Required Intervention to Prevent Permanent Impairment/Damage	Suicide Attempt							

Date:11/15/00ISR Number: 3611241-5Report Type:Expedited (15-DaCompany Report #A0131385A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Confusional State		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	
Hospitalization - Initial or Prolonged	Dermatitis							
	Liver Function Test Abnormal							
Other	Multi-Organ Failure							
	Pyrexia							
	Stevens-Johnson Syndrome							

	Toxic Epidermal Necrolysis					

Date:11/15/00ISR Number: 3611247-6Report Type:Expedited (15-DaCompany Report #B0089979A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Erythema Multiforme		Zyban	PS	Glaxo Wellcome	ORAL	2	WK
Initial or Prolonged	Hyperkeratosis		Coproxamol	C				
	Rash Pustular							
	Skin Disorder							

Date:11/15/00ISR Number: 3611248-8Report Type:Expedited (15-DaCompany Report #B0090811A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crohn'S Disease		Zyban	PS	Glaxo Wellcome	ORAL	5	DAY
			Mesalazine	C				

Date:11/16/00ISR Number: 3611880-1Report Type:Expedited (15-DaCompany Report #A0131900A
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Blood Creatine
Initial or Prolonged	Phosphokinase Increased

	Blood Creatine Phosphokinase Mb Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Chest Pain		Bupropion	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY 65 DAY
	Myocardial Infarction						
			Placebo	SS		ORAL	1TAB TWICE PER DAY 65 DAY

Date:11/16/00ISR Number: 3611883-7Report Type:Expedited (15-DaCompany Report #B0085539A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Motion Sickness		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY 15 DAY
	Vertigo						
	Visual Acuity Reduced		Insulin	C		SUBCUTANEOUS	
			Flixotide	C	Glaxo Wellcome	RESPIRATORY	(INHALATION)

Date:11/16/00ISR Number: 3611886-2Report Type:Expedited (15-DaCompany Report #B0089069A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Brain Stem Infarction		Bupropion	PS	Glaxo Wellcome	ORAL	300MG PER DAY 11 DAY
Hospitalization - Initial or Prolonged	Circulatory Collapse		Diclofenac	C		ORAL	5MG THREE TIMES PER DAY
			Allopurinol	C	Glaxo Wellcome	ORAL	300MG PER DAY 185 DAY

Date:11/16/00ISR Number: 3611887-4Report Type:Expedited (15-DaCompany Report #B0089166A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE	
Initial or Prolonged	Agitation						PER DAY	2 MON
Other	Emotional Disorder							
	Emotional Distress							
	Fatigue							
	Hallucination							
	Nightmare							
	Paranoia							
	Sleep Walking							

Date:11/16/00ISR Number: 3611890-4Report Type:Expedited (15-DaCompany Report #B0089994A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebellar Ataxia		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE	
	Cerebral Ischaemia							
PER DAY	11 DAY							
	Viral Infection		Atenolol + Chlorthalidone	C		ORAL		
			Lisinopril	C		ORAL	2.5MG PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/00ISR Number: 3611894-1Report Type:Expedited (15-DaCompany Report #B0090960A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glaucoma		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	10 DAY

Date:11/16/00ISR Number: 3611899-0Report Type:Expedited (15-DaCompany Report #B0091448A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG SINGLE DOSE	1 DAY
	Cardiovascular Disorder							
	Decreased Activity							
	Dyspnoea		Corticosteroids	C			UNKNOWN	
	Muscular Weakness		Antibiotics	C			UNKNOWN	
			Unspecified Medication	C			UNKNOWN	

Date:11/16/00ISR Number: 3611901-6Report Type:Expedited (15-DaCompany Report #B0091583A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG PER DAY	

Date:11/17/00ISR Number: 3613270-4Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills Malaise Oral Pain Pyrexia Rash Erythematous Serum Sickness Vomiting		Zyban (Bupropion)	PS		ORAL	150MG PO	

Date:11/17/00ISR Number: 3613388-6Report Type:Expedited (15-DaCompany Report #A0131385A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Confusional State Dermatitis Liver Function Test Abnormal Multi-Organ Failure Pyrexia Rash Generalised Stevens-Johnson Syndrome	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:11/17/00ISR Number: 3613411-9Report Type:Expedited (15-DaCompany Report #B0091314A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Left Ventricular Failure	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

			Beclomethasone Dipropion	C			
			Salbutamol Sulphate	C			

Date:11/17/00ISR Number: 3613414-4Report Type:Expedited (15-DaCompany Report #B0089979A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	UNK / UNK / ORAL	2 WK
	Hyperkeratosis	Health						
	Psoriasis	Professional	Co-Proxamol	C				
	Rash Pustular	Company Representative						

Date:11/17/00ISR Number: 3613415-6Report Type:Expedited (15-DaCompany Report #B0090811A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Crohn'S Disease	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	UNK / UNK / ORAL	5 DAY
		Health						
		Professional	Mesalazine	C				

Date:11/17/00ISR Number: 3613533-2Report Type:Expedited (15-DaCompany Report #1458727A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Foreign	Tylenol	PS	Mcneil Consumer			
Hospitalization - Initial or Prolonged	Convulsion	Other			Products Co Div Mcneilab Inc			
Other	Hyperhidrosis							
Required Intervention to Prevent Permanent	Hypotension		Zyban (R) Prolonged Release Tablets 150 Mg	SS				
	Irritability							
	Metabolic Acidosis							
	Nervousness							

Impairment/Damage	Oral Intake Reduced
	Overdose
	Pyrexia
	Tachycardia

Date:11/17/00ISR Number: 3612413-6Report Type:Expedited (15-DaCompany Report #A0131854A
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Fall Intracranial Aneurysm		Zyban	PS	Glaxo Wellcome	ORAL	150MG PER DAY	

Date:11/17/00ISR Number: 3612414-8Report Type:Expedited (15-DaCompany Report #B0091238A
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Cardiac Failure
	Congestive
	Cardiomegaly
	Chest X-Ray Abnormal
	Dyspnoea

		Face Oedema Fatigue Fluid Retention	Report Source	Product	Role	Manufacturer	Route	Dose
Duration		Hyponatraemia Oedema Peripheral		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY
40	DAY	Urine Osmolarity Decreased		Lisinopril	C		ORAL	20MG PER DAY
				Atorvastatin	C		ORAL	10MG PER DAY
62	DAY			Atorvastatin	C		ORAL	10MG PER DAY
62	DAY			Atorvastatin	C		ORAL	90MG PER DAY
				Aspirin	C		ORAL	150MG PER DAY

Date:11/17/00ISR Number: 3612415-XReport Type:Expedited (15-DaCompany Report #B0091443A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Asthma		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	10MG PER DAY	
			Cetirizine	C	Glaxo Wellcome	ORAL	UNKNOWN	
			Flixonase	C	Glaxo Wellcome		UNKNOWN	
			Beclomethasone	C	Glaxo Wellcome		UNKNOWN	
			Salbutamol	C	Glaxo Wellcome		UNKNOWN	

Date:11/17/00ISR Number: 3612416-1Report Type:Expedited (15-DaCompany Report #B0091452A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Bupropion					

	Pruritus		Hydrochloride	PS	Glaxo Wellcome	ORAL
150MG PER DAY 9 DAY						
	Rash Macular					
	Upper Respiratory Tract Infection					

Date:11/17/00ISR Number: 3612417-3Report Type:Expedited (15-DaCompany Report #B0091581A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dermatitis Exfoliative		Bupropion			
Initial or Prolonged	Electrocardiogram T Wave		Hydrochloride	PS	Glaxo Wellcome	ORAL
150MG TWICE						
	Amplitude Decreased					
PER DAY 19 DAY						
	Face Oedema		Gaviscon	C		
	Oesophageal Disorder					
	Urticaria					

Date:11/20/00ISR Number: 3613233-9Report Type:Expedited (15-DaCompany Report #A0127813A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Potassium Decreased		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG PER DAY						
	Epilepsy		K-Dur	C		
	Fall		Vitamins	C		
	Fatigue		Alcohol	C		
	Headache					
	Muscle Rigidity					
	Myalgia					
	Pallor					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/00ISR Number: 3613236-4Report Type:Expedited (15-DaCompany Report #A0129577A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE	
	Erectile Dysfunction						PER DAY	
	Fatigue		Cardiac Medication	SS				
	Hypoaesthesia		Metoprolol	C		ORAL	25MG TWICE	
	Paraesthesia						PER DAY	
	Sexual Dysfunction		Ramipril	C		ORAL	5MG PER DAY	
	Triple Vessel Bypass		Metformin	C		ORAL	1000MG TWICE	
	Graft						PER DAY	
			Glyburide	C		ORAL	10MG TWICE	
							PER DAY	
			Losec	C		ORAL	20MG PER DAY	
			Gemfibrozil	C		ORAL	600MG TWICE	
							PER DAY	

Date:11/20/00ISR Number: 3614432-2Report Type:Expedited (15-DaCompany Report #B0085539A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Motion Sickness	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Vertigo	Health					PER DAY/ ORAL	
	Visual Acuity Reduced	Professional	Insulin	C				
		Company	Fluticasone					
		Representative	Propionate	C				

Date:11/20/00ISR Number: 3614435-8Report Type:Expedited (15-DaCompany Report #B0089069A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Brain Stem Infarction	Foreign	Bupropion				
Hospitalization - Initial or Prolonged	Circulatory Collapse		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	
			Diclofenac	C			
			Allopurinol	C			

Date:11/20/00ISR Number: 3614436-XReport Type:Expedited (15-DaCompany Report #B0091448A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Bronchospasm	Foreign	Bupropion				
	Cardiovascular Disorder	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ SINGLE DOSE/ ORAL
	Decreased Activity	Professional					
	Dyspnoea						
	Muscular Weakness		Corticosteroid	C			
			Antibiotics	C			
			Unknown	C			

Date:11/20/00ISR Number: 3614437-1Report Type:Expedited (15-DaCompany Report #B0090960A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Glaucoma	Foreign	Bupropion				
		Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL
		Professional					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/00ISR Number: 3614439-5Report Type:Expedited (15-DaCompany Report #B0089994A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Cerebellar Ataxia Cerebral Ischaemia	Foreign	Bupropion Hydrochloride Atenolol + Chlorthalidone Lisinopril	PS C C	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:11/20/00ISR Number: 3614444-9Report Type:Expedited (15-DaCompany Report #B0091583A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

Date:11/20/00ISR Number: 3614490-5Report Type:Expedited (15-DaCompany Report #A0070194A
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Disability	Amnesia
	Anger
	Anhedonia
	Anxiety
	Anxiety Disorder
	Asthenia
	Brain Contusion
	Breast Hyperplasia
	Breast Neoplasm
	Cognitive Disorder
	Condition Aggravated
	Confusional State
	Convulsion
	Decreased Appetite

Depressed Mood
Depression
Diarrhoea
Disturbance In Attention
Drug Ineffective
Dysphoria
Early Morning Awakening
Encephalopathy
Fatigue
Feeling Abnormal
Fibroadenoma Of Breast
Fibrocystic Breast
Disease
Headache
Hodgkin'S Disease Nodular
Sclerosis Stage
Unspecified
Hypochondriasis
Hypoxia
Initial Insomnia
Loss Of Libido
Memory Impairment
Mood Swings

	Nausea Petit Mal Epilepsy Suicidal Ideation	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Thinking Abnormal	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER
	Vomiting	Professional					DAY / ORAL
			General Anesthetic (Formulation Unknown) (General Anesthetic)	SS			
			Ibuprofen	C			
			Surgery	C			
			Loperamide Hydrochloride	C			
			Dextrose + Lactated Ringers	C			
			Tylenol No. 3	C			
			Hyoscyamine Sulphate	C			
			Bupivacaine Hydrochloride	C			
			Pethidine Hydrochloride	C			
			Hydrocodone + Paracetamol	C			
			Propofol	C			
			Lignocaine	C			
			Fentanyl	C			
			Midazolam	C			
			Suxmethonium Chloride	C			
			Desflurane	C			
			Ondansetron Hydrochloride	C			
			Oxygen	C			
			Droperidol	C			
			Nitrous Oxide	C			

Date:11/20/00ISR Number: 3614600-XReport Type:Expedited (15-DaCompany Report #B0091238A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Life-Threatening	Cardiac Failure	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ TWICE PER DAY/ ORAL
	Congestive	Health				
	Cardiomegaly	Professional	Aspirin	C		
	Chest X-Ray Abnormal		Lisinopril	C		
	Dyspnoea		Atorvastatin Calcium	C		
	Face Oedema					
	Fatigue					
	Fluid Retention					
	Hyponatraemia					
	Oedema Peripheral					
	Urine Osmolarity Decreased					

Date:11/20/00ISR Number: 3614602-3Report Type:Expedited (15-DaCompany Report #B0091452A
Age:35 YR Gender:Female I/FU:I

Outcome
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Pruritus							
	Rash Macular							
	Upper Respiratory Tract Infection							

Date:11/20/00ISR Number: 3614604-7Report Type:Expedited (15-DaCompany Report #B0091443A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
Hospitalization - Initial or Prolonged			Cetirizine Hydrochloride	C				
			Fluticasone Propionate	C				
			Beclomethasone Dipropion.	C				
			Salbutamol Sulphate	C				

Date:11/20/00ISR Number: 3614606-0Report Type:Expedited (15-DaCompany Report #B0091581A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	
	Dermatitis Exfoliative							
	Electrocardiogram T Wave Amplitude Decreased		Gaviscon	C				
	Face Oedema							
	Oesophageal Disorder							
	Urticaria							

Date:11/20/00ISR Number: 3614634-5Report Type:Expedited (15-DaCompany Report #B0089166A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	Required
Intervention to Prevent Permanent Impairment/Damage	Emotional Disorder	Health						
	Emotional Distress	Professional						
	Fatigue							
	Hallucination							
	Nightmare							
	Paranoia							
	Sleep Disorder							

Date:11/20/00ISR Number: 3614655-2Report Type:Expedited (15-DaCompany Report #B0089784A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE DAILY/ ORAL	
	Hypersensitivity	Health						
	Loss Of Consciousness	Professional	Losartan Potassium	C				
	Thrombocythaemia		Bromazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/00ISR Number: 3614849-6Report Type:Expedited (15-DaCompany Report #A0131854A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Fall Intracranial Aneurysm	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL

Date:11/20/00ISR Number: 3615282-3Report Type:Expedited (15-DaCompany Report #A0131900A
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cardiac Enzymes Increased Chest Pain Myocardial Infarction	Study Health Professional	Zyban Placebo	PS SS	Glaxo Wellcome Inc	ORAL ORAL	150 MG/TWICE PER DAY/ORAL 1 TABLET/TWICE PER DAY/ORAL

Date:11/20/00ISR Number: 3618538-3Report Type:Periodic Company Report #HQ9690310AUG2000
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Spontaneous Pregnancy	Health Professional	Effexor Xr	PS	Wyeth Ayerst Laboratories	ORAL	75 MG 1 X PER 1 DAY, ORAL
			Tegretol (Carbamazepine)	SS		ORAL	ORAL
			Wellbutrin (Amfebutamone				

			Hydrochloride)	SS		ORAL
ORAL						
			Zyrtec (Cetirizine Hydrochloride)	SS		ORAL
ORAL						

Date:11/20/00ISR Number: 3613246-7Report Type:Expedited (15-DaCompany Report #B0091703A
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperventilation		Bupropion					
Initial or Prolonged	Pyrexia		Hydrochloride	PS	Glaxo Wellcome	ORAL		

Date:11/20/00ISR Number: 3613248-0Report Type:Expedited (15-DaCompany Report #D0010443A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome	ORAL	1TAB PER DAY	
Initial or Prolonged	Arthralgia		Thyronajod	C		ORAL	1TAB PER DAY	YR
	C-Reactive Protein		Orgametril	C		ORAL	1TAB TWICE PER DAY	
	Increased							
	Diarrhoea							
	Joint Swelling							
	Lymphocytosis							
	Pruritus							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/00ISR Number: 3614109-3Report Type:Expedited (15-DaCompany Report #A0109223A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy		Zyban	PS	Glaxo Wellcome	ORAL	39	DAY
	Arthralgia		Ibuprofen	C				
	Bone Density Decreased							
	Immobile							
	Inflammation							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Disorder							
	Leukocytoclastic Vasculitis							
	Osteoporosis							
	Pain In Extremity							
	Polyarthritis							
	Pruritus							
	Purpura							
	Rash Erythematous							
	Sneezing							
	Throat Irritation							
	Urticaria							
	White Blood Cell Count Increased							

Date:11/21/00ISR Number: 3614111-1Report Type:Expedited (15-DaCompany Report #A0128188A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adrenal Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	1 YR
	Aggression							
	Atrial Fibrillation		Neurontin	C				
	Blood Disorder		Coumadin	C	Glaxo Wellcome			
	Constipation		Ativan	C				
	Coordination Abnormal		Ambien	C				
	Depressed Mood		Restoril	C				
	Difficulty In Walking		T3	C	Glaxo Wellcome			
UNKNOWN								

Disorientation
Fatigue
Hyperthyroidism
Libido Decreased
Loss Of Consciousness
Malaise
Restlessness
Sexual Dysfunction
Sinus Congestion
Sleep Disorder
Speech Disorder
Urinary Tract Infection

Date:11/21/00ISR Number: 3614124-XReport Type:Expedited (15-DaCompany Report #B0090537A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Femoral Neck Fracture Loss Of Consciousness		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	

Date:11/21/00ISR Number: 3615555-4Report Type:Expedited (15-DaCompany Report #B0091703A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hyperventilation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Pyrexia	Health Professional					

Date:11/21/00ISR Number: 3615559-1Report Type:Expedited (15-DaCompany Report #D0010443A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	1 TABLET / PER DAY/ ORAL
	Arthralgia	Health Professional					
	C-Reactive Protein Increased		Thyronajod	C			
	Diarrhoea		Lynoestrenol	C			
	Joint Swelling						
	Lymphocytosis						
	Pruritus						
	Urticaria						

Date:11/21/00ISR Number: 3615591-8Report Type:Expedited (15-DaCompany Report #A0129577A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Asthenia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL
	Erectile Dysfunction	Health Professional					
	Fatigue		Cardiac Medication (Formulation Unknown) (Cardiac Medication)	SS			
	Hypoaesthesia						
	Paraesthesia						
			Metoprolol	C			
			Ramipril	C			
			Metformin	C			

			Glibenclamide	C		
			Omeprazole	C		
			Gemfibrozil	C		

Date:11/21/00ISR Number: 3615657-2Report Type:Expedited (15-DaCompany Report #A0127813A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Potassium Decreased	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG, PER	
	Condition Aggravated	Professional					DAY, ORAL	
	Convulsive Threshold		Potassium Chloride	C				
	Lowered		Multivitamin	C				
	Fall		Ethanol	C				
	Fatigue							
	Grand Mal Convulsion							
	Headache							
	Muscle Rigidity							
	Pain							
	Skin Discolouration							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/00ISR Number: 3617568-5Report Type:Periodic Company Report #S00-USA-01104-01
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Asthenia Depersonalisation Dizziness Drug Withdrawal Syndrome Hypertension Palpitations Tachycardia Thinking Abnormal	Health Professional	Celexa Wellbutrin (Amfebutamone Hydrochloride)	PS SS	Forest Laboratories Inc	ORAL	150 MG QD PO	

Date:11/21/00ISR Number: 3631290-0Report Type:Periodic Company Report #S00-USA-01152-01
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional	Celexa	PS	Forest Laboratories Inc	ORAL	20 MG QD PO	
		Company Representative	Wellbutrin (Amfebumatone Hydrochloride)	SS		ORAL	100 MG QD PO	
			Wellbutrin (Amfebumatone Hydrochloride)	SS		ORAL	200 MG QD PO	

Date:11/21/00ISR Number: 3614117-2Report Type:Expedited (15-DaCompany Report #A0131760A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Wellbutrin	PS	Glaxo Wellcome	ORAL	350MG PER DAY	8 MON
	Increased		Zoloft	C			UNKNOWN	100MG PER DAY 1 YR
	Blood Amylase Increased							

	Blood Glucose Increased					
	Chromaturia					
	Hepatitis					

Date:11/22/00ISR Number: 3615123-4Report Type:Expedited (15-DaCompany Report #A0132245A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Transient		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE	
Initial or Prolonged	Communication Disorder						PER DAY	1 MON
	Convulsion		Zyban	SS	Glaxo Wellcome	ORAL	150MG TWICE	
	Dizziness						PER DAY	3 MON
	Feeling Hot		Vitamin E	C				
	Hearing Impaired		Aspirin	C				
	Hyperglycaemia		Vitamin C	C				
	Hyperhidrosis		Multivitamin	C				
	Hypoglycaemia							
	Nervous System Disorder							
	Tinnitus							
	Tremor							
	Tunnel Vision							

Date:11/22/00ISR Number: 3615125-8Report Type:Expedited (15-DaCompany Report #B0082488A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Irritation Maculopathy		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	31 DAY
Other	Post Procedural Complication Retinal Disorder Retinal Oedema Retinal Vasculitis Retinitis Visual Disturbance							

Date:11/22/00ISR Number: 3615139-8Report Type:Expedited (15-DaCompany Report #B0091958A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	1 DAY
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	250MCG TWICE PER DAY
			Ipratropium	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	40MG THREE TIMES PER DAY
			Aminophylline	C		ORAL		
			Salbutamol	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	
			Prednisolone	C		ORAL	40MG PER DAY	

			Eformoterol	C		

RESPIRATORY

(INHALATION) 12MCG TWICE

PER DAY

Date:11/22/00ISR Number: 3615140-4Report Type:Expedited (15-DaCompany Report #B0091959A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Bupropion	PS	Glaxo Wellcome	ORAL	150MG TWICE	
Initial or Prolonged	Constipation						PER DAY	WK
Other	Diarrhoea		Lisinopril	SS		ORAL	10MG PER DAY	5 DAY
	Dysphagia		Betahistine	C		ORAL	16MG THREE	
	Rectal Haemorrhage						TIMES PER DAY	
	Urticaria		Prochlorperazine	C		ORAL	10MG THREE	
							TIMES PER DAY	
			Clomipramine	C		ORAL	10MG PER DAY	
			Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG PER DAY	

Date:11/22/00ISR Number: 3615366-XReport Type:Direct Company Report #
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperhidrosis		Zyban Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	150MG SR FOR	
	Sleep Disorder						3DY THEN BID	
	Tremor						ORAL	
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/00ISR Number: 3615407-XReport Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Wellbutrin 150mg	PS		ORAL	150MG PO ONE	
	Movement Disorder						DOSE	
	Urinary Incontinence							

Date:11/22/00ISR Number: 3616584-7Report Type:Expedited (15-DaCompany Report #B0091959A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
Required	Constipation						PER DAY) ORAL	
Intervention to Prevent Permanent Impairment/Damage	Diarrhoea		Lisinopril (Lisinopril)	C		ORAL	10 MG (PER	
	Dysphagia						DAY) ORAL	
	Rectal Haemorrhage							
	Urticaria							
			Betahistine	C				
			Prochlorperazine	C				
			Clomipramine Hcl	C				
			Bendrofluazide	C				

Date:11/22/00ISR Number: 3616585-9Report Type:Expedited (15-DaCompany Report #B0091958A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Airways Disease	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
	Exacerbated						PER DAY) ORAL	
			Beclomethasone Dipropion	C				

Ipratropium Bromide	C
Aminophylline	C
Salbutamol Sulphate	C
Prednisolone	C
Eformoterol	C

Date:11/22/00ISR Number: 3616586-0Report Type:Expedited (15-DaCompany Report #B0091876A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Metrorrhagia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
			Norimin	C				

Date:11/22/00ISR Number: 3616587-2Report Type:Expedited (15-DaCompany Report #B0091876A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Metrorrhagia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
			Norimin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/00ISR Number: 3616588-4Report Type:Expedited (15-DaCompany Report #B0091290A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Rheumatic Fever	Foreign Study	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL
	Systemic Lupus Erythematosus	Health Professional	Prednisone	C			
			Azathioprine	C			
			Flupirtine Maleate	C			
			Atorvastatin Calcium	C			
			Magnerot N	C			
			Dorzolamide Hcl	C			

Date:11/22/00ISR Number: 3616815-3Report Type:Expedited (15-DaCompany Report #B0082488A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Required / ORAL Intervention to Prevent Permanent Impairment/Damage	Maculopathy Retinal Deposits Retinal Disorder Retinal Oedema Retinitis Vasculitis Visual Disturbance	Foreign Study Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY

Date:11/22/00ISR Number: 3617771-4Report Type:Expedited (15-DaCompany Report #A036897
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Amnesia Confusional State	Health Professional	Procardia Xl	PS	Pfizer Laboratories Div Pfizer Inc	ORAL	ORAL
	Hypotension		Bupropion	SS		ORAL	300.00 MG

	Pneumonia					
TOTAL:BID:ORA						
	Sedation					
L						
	Speech Disorder		Gabapentin	SS		
	Toxicologic Test Abnormal		Atenolol	SS		

Date:11/22/00ISR Number: 3617824-0Report Type:Expedited (15-DaCompany Report #A0132245A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blindness Transient	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
Initial or Prolonged	Convulsion						TWICE PER DAY
	Deafness						/ ORAL
	Dizziness		Zyban Tablet - Zyban				
	Feeling Hot		(Bupropion				
	Hyperglycaemia		Hydrochloride)	SS		ORAL	150 MG /
	Hyperhidrosis						TWICE PER DAY
	Hypoglycaemia						/ ORAL
	Nervous System Disorder		Multivitamin	C			
	Speech Disorder		Vitamin E	C			
	Tinnitus		Ascorbic Acid	C			
	Tremor		Aspirin	C			
	Tunnel Vision						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/00ISR Number: 3615129-5Report Type:Expedited (15-DaCompany Report #B0091290A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Rheumatic Fever Systemic Lupus Erythematosus		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	
			Decortin	C			5MG PER DAY	
			Katadolon	C			100MG PER DAY	
			Sortis	C			10MG PER DAY	
			Trusopt	C			20MG TWICE PER DAY	
			Magnerot N	C			48.6MG TWICE PER DAY	
			Imurek	C	Glaxo Wellcome		50MG PER DAY	

Date:11/22/00ISR Number: 3615138-6Report Type:Expedited (15-DaCompany Report #B0091876A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Metrorrhagia		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	
			Norimin	C		ORAL		

Date:11/24/00ISR Number: 3616420-9Report Type:Expedited (15-DaCompany Report #A0128188A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 150 MG/ TWICE	Adrenal Disorder	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
Initial or Prolonged PER DAY/ ORAL	Aggression					
	Atrial Fibrillation		Warfarin Sodium	C		
	Blood Disorder		Lorazepam	C		
	Constipation		Zolpidem Tartrate	C		
	Coordination Abnormal		Temazepam	C		
	Difficulty In Walking					
	Disorientation					
	Dysarthria					
	Fatigue					
	Hyperthyroidism					
	Insomnia					
	Libido Decreased					
	Loss Of Consciousness					
	Malaise					
	Restlessness					
	Sexual Dysfunction					
	Sinus Congestion					
	Speech Disorder					
	Urinary Tract Infection					

Date:11/24/00ISR Number: 3616450-7Report Type:Expedited (15-DaCompany Report #A0109223A
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Other	Arthralgia
	Arthritis
	Back Pain
	Bone Density Decreased
	Condition Aggravated
	Decreased Activity

	Dysphonia Intervertebral Disc Degeneration	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Leukocytoclastic Vasculitis	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG ORAL						
	Osteoporosis Pain In Extremity Polyarthritis Pruritus Purpura Rash Erythematous Rheumatoid Arthritis Sneezing Urticaria Vasculitis White Blood Cell Count Increased		Ibuprofen	C		

Date:11/24/00ISR Number: 3616474-XReport Type:Expedited (15-DaCompany Report #A0131760A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Alanine Aminotransferase Increased	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
350 MG PER DAY; ORAL 8 MON						
	Blood Amylase Increased Blood Glucose Increased Chromaturia Hepatitis		Sertraline Hydrochloride	C		

Date:11/24/00ISR Number: 3616888-8Report Type:Expedited (15-DaCompany Report #B0090537A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Fall Feeling Abnormal	Foreign Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG (TWICE						

	Femoral Neck Fracture	Professional				
PER DAY) ORAL						
	Loss Of Consciousness					

Date:11/27/00ISR Number: 3616080-7Report Type:Expedited (15-DaCompany Report #A0131639A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hyperkalaemia		Zantac	PS	Glaxo Wellcome	ORAL
150MG PER DAY 2 YR						
Initial or Prolonged	Intestinal Ischaemia		Zyban	SS	Glaxo Wellcome	ORAL
150MG PER DAY						
	Rectal Haemorrhage		Theophylline	C		
			Multivitamin	C		

Date:11/27/00ISR Number: 3616091-1Report Type:Expedited (15-DaCompany Report #B0086711A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia		Bupropion	PS	Glaxo Wellcome	ORAL
6 DAY						
Hospitalization -	Fatigue		Atenolol	C		
Initial or Prolonged	Muscle Spasms		Benzodiazepines	C		ORAL
	Paraesthesia					
	Respiratory Alkalosis					
	Tetany					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/00ISR Number: 3616092-3Report Type:Expedited (15-DaCompany Report #B0088230A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coma		Zyban	PS	Glaxo Wellcome			
	Convulsion							
	Hypotension							
	Metabolic Acidosis							
	Overdose							

Date:11/27/00ISR Number: 3616094-7Report Type:Expedited (15-DaCompany Report #B0089068A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Oedema		Bupropion	PS	Glaxo Wellcome	ORAL	150MG PER DAY	57 DAY
	Coma							
	Haematoma							
	Haemorrhagic Stroke							
	Headache							
	Hemiparesis							
	Ruptured Cerebral Aneurysm							
	Sedation							
	Subarachnoid Haemorrhage							

Date:11/27/00ISR Number: 3616097-2Report Type:Expedited (15-DaCompany Report #B0090063A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Zyban	PS	Glaxo Wellcome	ORAL	2TAB PER DAY	14 DAY
Other	Cerebral Artery Embolism							
	Cerebral Infarction							
	Hemiplegia							

Date:11/27/00ISR Number: 3616109-6Report Type:Expedited (15-DaCompany Report #B0092034A
Age:52 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Joint Swelling		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG TWICE PER DAY	9 DAY
			Sulphasalazine	SS		ORAL	3UNIT PER DAY	
			Metronidazole	C		ORAL	200UG THREE TIMES PER DAY	6 DAY
			Indomethacin	C		ORAL	150MG PER DAY	
			Prednisolone	C		ORAL	10MG PER DAY	

Date:11/27/00ISR Number: 3616667-1Report Type:Expedited (15-DaCompany Report #D0010841A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	9 DAY
Hospitalization - Initial or Prolonged	Cardiac Arrest	Professional						
Other	Electroencephalogram Abnormal							
	Epilepsy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/00ISR Number: 3617031-1Report Type:Expedited (15-DaCompany Report #A0131639A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Colitis Ischaemic Hyperkalaemia Rectal Haemorrhage	Health Professional	Zantac 150 Zyban Tablet - Zyban (Bupropion Hydrochloride) Theophylline Multivitamin	PS SS C C	Glaxo Wellcome Inc	ORAL ORAL	150 MG / PER DAY 150 MG / PER DAY

Date:11/27/00ISR Number: 3617253-XReport Type:Expedited (15-DaCompany Report #B0091999A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Aspiration Cardio-Respiratory Arrest Depressed Level Of Consciousness Salivary Hypersecretion Skin Discolouration Ventricular Fibrillation	Foreign	Bupropion Hydrochloride Aspirin Ranitidine Hydrochloride Co-Dydramol Nitrazepam	PS C C C C	Glaxo Wellcome Inc	ORAL	150 MG ORAL

Date:11/27/00ISR Number: 3617316-9Report Type:Expedited (15-DaCompany Report #2000035041GB
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Rheumatoid Arthritis Skin Nodule	Foreign Health Professional Other	Azulfidine Zyban(Amfebutamone Hydrochloride)	PS SS	Pharmacia And Upjohn Co	ORAL ORAL	TID, ORAL 150

MG,BID,ORAL						
			Metronidazole	C		
			Indocid(Indometacin)	C		
			Delta-Cortril	C		

Date:11/27/00ISR Number: 3617400-XReport Type:Expedited (15-DaCompany Report #B0092002A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Foreign	Bupropion					
	Difficulty In Walking	Other	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Erythema		Thyroxine Sodium	C				
	Oedema		Evening Primrose Oil	C				
	Pruritus							
	Synovitis							
	Viral Infection							

Date:11/27/00ISR Number: 3617401-1Report Type:Expedited (15-DaCompany Report #B0092034A
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Arthropathy	Foreign	Bupropion					
Intervention to	Rheumatoid Arthritis	Other	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
Prevent Permanent							PER DAY) ORAL	
Impairment/Damage			Sulphasalazine					

			(Sulfasalazine)	SS			ORAL
ORAL							
			Metronidazole	C			
			Indomethacin	C			
			Prednisolone	C			

Date:11/27/00ISR Number: 3617403-5Report Type:Expedited (15-DaCompany Report #B0092029A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL
			Kapake	C			

Date:11/27/00ISR Number: 3617404-7Report Type:Expedited (15-DaCompany Report #D0011104A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	1 TABLET (PER DAY) ORAL
	Dyspnoea	Health					
	Face Oedema	Professional					
	Myalgia						
	Pharyngolaryngeal Pain						
	Pruritus						
	Urine Analysis Abnormal						
	Urticaria						

Date:11/27/00ISR Number: 3617406-0Report Type:Expedited (15-DaCompany Report #B0088740A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Diabetes Mellitus	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY
	Inadequate Control	Health					
	Vision Blurred	Professional					

/ ORAL

Insulin Lispro	C
Human Insulin	C

Date:11/27/00ISR Number: 3617571-5Report Type:Expedited (15-DaCompany Report #B0086711A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
Hospitalization - Initial or Prolonged	Fatigue	Health Professional	Atenolol	C				
	Muscle Spasms		Benzodiazepines	C				
	Paraesthesia							
	Respiratory Alkalosis							
	Tetany							

Date:11/27/00ISR Number: 3617573-9Report Type:Expedited (15-DaCompany Report #B0088230A
Age: Gender:Male I/FU:F

Outcome	PT
Other	Acidosis
	Coma
	Convulsion
	Hypotension
	Metabolic Acidosis

	Overdose						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Zyban	PS	Glaxo Wellcome Inc		50 TABLET
		Health Professional					

Date:11/27/00ISR Number: 3617574-0Report Type:Expedited (15-DaCompany Report #B0089068A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Brain Oedema	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Cerebral Infarction						
	Coma						
	Haematoma						
	Headache						
	Hemiparesis						
	Ruptured Cerebral Aneurysm						
	Sedation						
	Subarachnoid Haemorrhage						

Date:11/27/00ISR Number: 3617575-2Report Type:Expedited (15-DaCompany Report #B0090063A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Aphasia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL
Other	Cerebral Artery Embolism	Health Professional					
	Cerebral Infarction						
	Hemiplegia						

Date:11/27/00ISR Number: 3616093-5Report Type:Expedited (15-DaCompany Report #B0088740A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vision Blurred		Zyban	PS	Glaxo Wellcome	ORAL	150MG TWICE	PER DAY 9 DAY
			Humalog	C				
			Humulin	C				

Date:11/27/00ISR Number: 3616106-0Report Type:Expedited (15-DaCompany Report #B0091999A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardio-Respiratory Arrest		Zyban	PS	Glaxo Wellcome	ORAL	39 DAY	
	Cyanosis		Aspirin	C		ORAL		
	Depressed Level Of Consciousness		Ranitidine	C	Glaxo Wellcome	ORAL		
			Co-Dydramol	C	Glaxo Wellcome	ORAL		
	Ventricular Fibrillation		Nitrazepam	C		ORAL		

Date:11/27/00ISR Number: 3616107-2Report Type:Expedited (15-DaCompany Report #B0092002A
Age:28 YR Gender:Female I/FU:I

Outcome	PT
Disability	Arthralgia
	Autoimmune Disorder

	Difficulty In Walking					
	Erythema					
	Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Pruritus		Bupropion			
	Synovitis		Hydrochloride	PS	Glaxo Wellcome	ORAL
150MG PER DAY	14 DAY					
			Thyroxine	C	Glaxo Wellcome	ORAL
150MG PER DAY						
			Evening Primrose Oil	C		ORAL

Date:11/27/00ISR Number: 3616108-4Report Type:Expedited (15-DaCompany Report #B0092029A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrial Fibrillation		Bupropion			
Initial or Prolonged			Hydrochloride	PS	Glaxo Wellcome	ORAL
150MG PER DAY	9 DAY					
			Kapake	C		ORAL
2TAB PER DAY						

Date:11/27/00ISR Number: 3616113-8Report Type:Expedited (15-DaCompany Report #D0011104A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL
1TAB PER DAY						
Initial or Prolonged	Dyspnoea					
	Face Oedema					
	Haematuria					
	Myalgia					
	Pharyngolaryngeal Pain					
	Pruritus					
	Urticaria					
	White Blood Cells Urine					
	Positive					

Date:11/28/00ISR Number: 3617660-5Report Type:Expedited (15-DaCompany Report #A0130408A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Dyspnoea Malaise Nervousness Vision Blurred		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	5 DAY

Date:11/28/00ISR Number: 3617667-8Report Type:Expedited (15-DaCompany Report #B0088745A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	20	DAY
Hospitalization - Initial or Prolonged	Electrocardiogram T Wave Inversion Myocardial Infarction		Ipratropium Bromide	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	500MCG Six times per day
Disability			Salbutamol	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	5MG Six times per day
			Aspirin	C		ORAL	75MG Per day	
			Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG Per day	
			Prednisolone	C		ORAL	30MG Per day	
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	2PUFF Twice

per day

Date:11/28/00ISR Number: 3617672-1Report Type:Expedited (15-DaCompany Report #B0091225A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coordination Abnormal		Zyban	PS	Glaxo Wellcome	ORAL	1200MG	
	Delusion						cumulative	
	Diarrhoea						dose	6 DAY
	Dry Mouth							
	Dysarthria							
	Extrapyramidal Disorder							
	Hypotension							
	Insomnia							
	Muscle Rigidity							
	Pneumonia Aspiration							
	Sedation							

Date:11/28/00ISR Number: 3617676-9Report Type:Expedited (15-DaCompany Report #B0092066A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperhidrosis		Zyban	PS	Glaxo Wellcome		150MG As directed	
	Hypertension							
	Ventricular Hypertrophy							
	Visual Disturbance							

Date:11/28/00ISR Number: 3617681-2Report Type:Expedited (15-DaCompany Report #B0092404A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Zyban	PS	Glaxo Wellcome	ORAL		

	Peak Expiratory Flow Rate		Prednisolone	C		ORAL
10MG Per day						
	Decreased		Fluticasone	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION)	1000MCG Twice					
per day						
			Salmeterol	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION)	50MCG Twice					
per day						
			Salbutamol	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION)	200MCG As					
required						
			Quinine	C		
			Nasonex	C		

Date:11/28/00ISR Number: 3617684-8Report Type:Expedited (15-DaCompany Report #B0092571A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Suicide Attempt		Zyban	PS	Glaxo Wellcome	

Date:11/28/00ISR Number: 3617686-1Report Type:Expedited (15-DaCompany Report #D0010583A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Visual Disturbance		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
Initial or Prolonged	Vitreous Disorder					
per day	7 DAY					

			Bactrim	C	Glaxo Wellcome	ORAL	1TAB Twice
per day	4 DAY						

Date:11/29/00ISR Number: 3618203-2Report Type:Expedited (15-DaCompany Report #A0117940A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acne Cystic		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Arthropod Bite						per day	3 DAY
	Asthenia		Soma	C				
	Bronchospasm		Valium	C				
	Burning Sensation							
	Chest Pain							
	Dermatitis							
	Dizziness							
	Drug Hypersensitivity							
	Dyspnoea Exertional							
	Ear Haemorrhage							
	Eye Disorder							
	Eye Irritation							
	Eyelid Oedema							
	Folliculitis							
	Haemorrhage							
	Hypoventilation							
	Infection							
	Irritability							
	Oedema							
	Pain							
	Palpitations							
	Pruritus							
	Rash Erythematous							
	Rash Papular							
	Rash Pustular							
	Respiratory Disorder							
	Scratch							
	Skin Lesion							
	Sunburn							
	Toxic Shock Syndrome							
	Urticaria							

Date:11/29/00ISR Number: 3618215-9Report Type:Expedited (15-DaCompany Report #A0132668A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Vaginal Haemorrhage							

Date:11/29/00ISR Number: 3618224-XReport Type:Expedited (15-DaCompany Report #B0091997A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	18 DAY
	Bronchial Obstruction							
	Eyelid Oedema							
	Pruritus							
	Rash Generalised							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/00ISR Number: 3618230-5Report Type:Expedited (15-DaCompany Report #B0092355A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis		Zyban Statines	PS C	Glaxo Wellcome	ORAL		

Date:11/29/00ISR Number: 3618231-7Report Type:Expedited (15-DaCompany Report #B0092499A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Blister Rash Pruritic		Zyban	PS	Glaxo Wellcome			

Date:11/29/00ISR Number: 3619214-3Report Type:Expedited (15-DaCompany Report #2000AP05073
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Constipation	Foreign Health	Zestril	PS	Astrazeneca Pharmaceuticals Lp	ORAL	10 MG DAILY	
Required	Diarrhoea	Professional					PO	
Intervention to Prevent Permanent Impairment/Damage	Dysphagia Rectal Haemorrhage Urticaria	Other	Bupropion Betahistine Prochlorperazine Anafranil Bendrofluazide	SS C C C C		ORAL	150 MG BID PO	

Date:11/30/00ISR Number: 3618945-9Report Type:Expedited (15-DaCompany Report #A0131760A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Wellbutrin	PS	Glaxo Wellcome	ORAL	350MG Per day	8 MON

	Increased		Zoloft	C			
UNKNOWN	100MG Per day 1 YR						
	Blood Amylase Increased						
	Blood Glucose Increased						
	Chromaturia						
	Hepatitis C						

Date:11/30/00ISR Number: 3618950-2Report Type:Expedited (15-DaCompany Report #A0132722A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocarditis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
							per day	
			Depoprovera	SS				
INTRAMUSCULAR	150MG See							
	text							
			Alfalfa	C				
			Calcium	C				
			Activated Charcoal	C				
			Kelp	C				
			Potassium	C				
			Rose Hips	C				
			Vitamin C	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3625779-8Report Type:Periodic Company Report #A0114567A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL

Date:11/30/00ISR Number: 3625785-3Report Type:Periodic Company Report #A0114618A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion Hypoglycaemia	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL

Date:11/30/00ISR Number: 3625793-2Report Type:Periodic Company Report #A0114245A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion Drug Interaction Medication Error	Health Professional Company Representative	Wellbutrin Sr	PS	Pharmacia And Upjohn Co	ORAL	150 MG /THREE TIMES PER DA /ORAL
			Nortriptyline (Nortriptyline)	SS		ORAL	150 MG/ ORAL

Date:11/30/00ISR Number: 3625795-6Report Type:Periodic Company Report #A0114247A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc			
		Company	Furosemide Tablet(Furosemide)	SS		ORAL	ORAL	
		Representative						

Date:11/30/00ISR Number: 3625800-7Report Type:Periodic Company Report #A0114119A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
	Head Injury	Professional					VARIABLE	
		Company					DOSE/ ORAL	
		Representative	Paroxetine Hydrochloride	C				

Date:11/30/00ISR Number: 3625804-4Report Type:Periodic Company Report #A0113009A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	4500 MG / SINGLE DOSE/	
	Overdose	Professional						
Other		Company						
ORAL		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3625807-XReport Type:Periodic Company Report #A0112414A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	200 MG /TWICE PER DAY /	
			Sertraline Hydrochloride (Sertraline Hydrochloride)	SS		ORAL	50 MG / PER DAY/ ORAL	6 MON 3 DAY

Date:11/30/00ISR Number: 3625808-1Report Type:Periodic Company Report #A0112470A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	200 MG /TWICE PER DAY/ ORAL	
		Company Representative	Quetiapine Fumarate	C				

Date:11/30/00ISR Number: 3625810-XReport Type:Periodic Company Report #A0112385A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ ORAL	DAY

Date:11/30/00ISR Number: 3625812-3Report Type:Periodic Company Report #A0112386A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	DAY

Date:11/30/00ISR Number: 3625815-9Report Type:Periodic Company Report #A0111400A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG / PER DAY / ORAL	
			Carbamazepine	C				

Date:11/30/00ISR Number: 3625819-6Report Type:Periodic Company Report #A0111423A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3625822-6Report Type:Periodic Company Report #A0111466A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 M G / THREE TIMES PER DAY / ORAL

Date:11/30/00ISR Number: 3625823-8Report Type:Periodic Company Report #A0110050A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain Difficulty In Walking Erythema Multiforme Face Oedema Oedema Pain In Extremity Pharyngeal Oedema Tenderness Urinary Tract Infection Urticaria	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:11/30/00ISR Number: 3625824-XReport Type:Periodic Company Report #A0109827A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY

			Company			
/ ORAL			Representative			

Date:11/30/00ISR Number: 3625825-1Report Type:Periodic Company Report #A0109828A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
		Professional						
TWICE PER DAY		Company						
/ ORAL		Representative					2	MON

Date:11/30/00ISR Number: 3625826-3Report Type:Periodic Company Report #A0109899A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyskinesia	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG /	
	Epilepsy	Professional						
SINGLE DOSE /								
ORAL			Cannabis	C				
			Echinacea	C				
			Semisodium Valproate	C				
			Fluoxetine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3625828-7Report Type:Periodic Company Report #A0103570A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Required		Professional					TWICE PER DAY	
Intervention to		Company					/ ORAL	
Prevent Permanent		Representative	Alprazolam	C				
Impairment/Damage			Fluoxetine Hydrochloride	C				
			Zolpidem Tartrate	C				

Date:11/30/00ISR Number: 3625829-9Report Type:Periodic Company Report #A0105852A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Epileptic Aura	Professional					TWICE PER DAY	
	Syncope						/ ORAL	
	Urinary Incontinence		Nortriptyline	C				
			Citalopram Hydrobromide	C				
			Lithium Salt	C				

Date:11/30/00ISR Number: 3625831-7Report Type:Periodic Company Report #A0108726A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Other		Professional					TWICE PER DAY	
Required		Company					/ ORAL	

Intervention to Prevent Permanent Impairment/Damage		Representative	Prednisone	C	
			Hydrochloroquine	C	

Date:11/30/00ISR Number: 3627138-0Report Type:Periodic Company Report #A0121035A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG / TWICE PER DAY	/ ORAL 3 MON

Date:11/30/00ISR Number: 3627139-2Report Type:Periodic Company Report #A0120808A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	
Other	Delirium						/ ORAL	
	Intentional Misuse							
	Suicide Attempt							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3627142-2Report Type:Periodic Company Report #A0120790A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Confusional State	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	VARIABLE DOSE
Initial or Prolonged	Convulsion	Professional					/ ORAL
	Delirium		Baclofen	C			
			Oxycodone Hydrochloride	C			

Date:11/30/00ISR Number: 3627144-6Report Type:Periodic Company Report #A0120622A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Alanine Aminotransferase	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL
Initial or Prolonged	Increased Blood Alkaline Phosphatase Increased	Professional Company Representative					
	Grand Mal Convulsion						
	Intentional Misuse						

Date:11/30/00ISR Number: 3627146-XReport Type:Periodic Company Report #A0119914A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc		
	Hallucination	Professional Company Representative	Venlafaxine Hydrochloride	C			

Date:11/30/00ISR Number: 3627147-1Report Type:Periodic Company Report #A0118761A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Abnormal Faeces	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL 150 MG / SEE
	Defaecation Urgency	Professional				TEXT / ORAL 5 DAY
	Feeling Hot	Company	Levofloxacin Tablet	SS		ORAL ORAL
	Grand Mal Convulsion	Representative	Oral Contraceptive	C		
	Hyperhidrosis					
	Nausea					
	Tremor					
	Urinary Tract Infection					

Date:11/30/00ISR Number: 3627149-5Report Type:Periodic Company Report #A0118454A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization -	Anxiety	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL 150 MG / PER
Initial or Prolonged	Asthenia					DAY / ORAL 4 WK
	Blood Pressure Increased		Citalopram			
	Dissociation		Hydrobromide			
	Disturbance In Attention		(Formulation			
	Dizziness		Unknown)	SS		
	Drug Withdrawal Syndrome					
	Palpitations					
	Simple Partial Seizures					
	Syncope					
	Tachycardia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3627152-5Report Type:Periodic Company Report #A0117091A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Effect Decreased	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Hospitalization -	Grand Mal Convulsion	Professional					TWICE PER DAY	
Initial or Prolonged	Pyrexia						/ ORAL	3 YR
Required			Cetirizine					
Intervention to			Hydrochloride	C				
Prevent Permanent			Salbutamol Sulphate	C				
Impairment/Damage			Fluticasone					
			Propionate	C				

Date:11/30/00ISR Number: 3627153-7Report Type:Periodic Company Report #A0116851A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Initial or Prolonged		Professional						
		Company						
		Representative						

Date:11/30/00ISR Number: 3627155-0Report Type:Periodic Company Report #A0116644A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tic	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	400 MG / PER	
	Tremor	Professional					DAY / ORAL	6 WK
			Lithium Salt	SS				
			Methadone Hydrochloride	SS		ORAL	250 MG / FOUR	

TIMES PER DAY

ORAL

			Tamsulosin Hcl	C		
			Psychiatric Consultation	C		

Date:11/30/00ISR Number: 3627161-6Report Type:Periodic Company Report #A0116263A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
		Professional Company Representative	Antidepressant	C				

Date:11/30/00ISR Number: 3627162-8Report Type:Periodic Company Report #A0116264A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
		Professional Company Representative	Antidepressant	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3627163-XReport Type:Periodic Company Report #A0116265A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL
		Professional Company Representative	Antidepressant	C			

Date:11/30/00ISR Number: 3627164-1Report Type:Periodic Company Report #A0116266A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL
		Professional Company Representative	Antidepressant	C			

Date:11/30/00ISR Number: 3627167-7Report Type:Periodic Company Report #A0116329A
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL

Date:11/30/00ISR Number: 3627170-7Report Type:Periodic Company Report #A0116346A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL
		Professional Company Representative					

Date:11/30/00ISR Number: 3627173-2Report Type:Periodic Company Report #A0116040A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Injury Convulsion Drug Level Changed Vomiting	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL, 225 MG / PER DAY/ORAL	2 WK
			Carbamazepine	C				
			Primidone	C				
			Topiramate	C				

Date:11/30/00ISR Number: 3627176-8Report Type:Periodic Company Report #A0114700A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression Drug Effect Decreased Weight Increased	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
			Semisodium Valproate	C				
			Citalopram Hydrobromide	C				

Date:11/30/00ISR Number: 3627178-1Report Type:Periodic Company Report #A0114779A
Age:7 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / DAY / ORAL	PER

Date:11/30/00ISR Number: 3627181-1Report Type:Periodic Company Report #A0114780A
Age:6 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Required Intervention to Prevent Permanent Impairment/Damage	Drug Ineffective Dyskinesia Grunting Tic	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG / TWICE PER DAY/ ORAL	6 MON

Date:11/30/00ISR Number: 3627373-1Report Type:Periodic Company Report #A0103624A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Nuclear Magnetic Resonance Imaging Abnormal	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:11/30/00ISR Number: 3627377-9Report Type:Periodic Company Report #A0105553A
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	6 MON
	Convulsion	Professional						
	Epileptic Aura							
	Syncope							

Date:11/30/00ISR Number: 3627379-2Report Type:Periodic Company Report #A0105559A
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Inappropriate Antidiuretic Hormone Secretion	Professional Company Representative						

Date:11/30/00ISR Number: 3627381-0Report Type:Periodic Company Report #A0107151A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG / ORAL	
	Choking	Professional	Methylphenidate Chl	C				
	Dizziness	Company						
	Dyspnoea	Representative						
	Food Allergy							
	Hypersensitivity							
	Retching							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3627383-4Report Type:Periodic Company Report #A0107580A
Age:12 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	75 MG / TWICE PER DAY / ORAL
	Maternal Drugs Affecting Foetus						
			Prenatal	C			

Date:11/30/00ISR Number: 3627385-8Report Type:Periodic Company Report #A0124973A
Age:17 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
		Company Representative	Wellbutrin Tablet (Bupropion Hyrochloride)	SS		ORAL	75 MG / TWICE PER DAY / ORAL

Date:11/30/00ISR Number: 3627389-5Report Type:Periodic Company Report #A0108085A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Grand Mal Convulsion	Health Professional Company	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	450 MG / PER DAY / ORAL
			Quetiapine Fumarate	C			

Required Intervention to Prevent Permanent Impairment/Damage		Representative	Temazepam	C		

Date:11/30/00ISR Number: 3627393-7Report Type:Periodic Company Report #A0105971A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	
Other	Cyanosis							
	Drooling							
	Tremor		Ortho Tri-Cyclen	C				

Date:11/30/00ISR Number: 3627396-2Report Type:Periodic Company Report #A0104843A
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3627399-8Report Type:Periodic Company Report #A0101377A
Age:13 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	75 SEE TEXT /	
	Memory Impairment	Professional					TWICE PER DAY	
	Tongue Disorder	Company					/ ORAL	
		Representative	Desipramine	C				
			Methylphenidate Hcl	C				

Date:11/30/00ISR Number: 3627472-4Report Type:Periodic Company Report #PRIUSA2000008297
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Defaecation Urgency	Health	Levaquin	PS	Rw Johnson Pharmaceutical Research Institute			
	Grand Mal Convulsion	Professional						
	Hyperhidrosis							
	Nausea				Div Ortho Pharm	ORAL	ORAL	
	Paraesthesia		Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	150 MG,	
	Tremor						DIALY, ORAL	5 DAY
			Oral Contraceptive (Oral Contraceptive Nos)	C				

Date:11/30/00ISR Number: 3627524-9Report Type:Periodic Company Report #A0123848A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
		Professional Company	Methylphenidate Hc1	C				

Representative

Date:11/30/00ISR Number: 3627528-6Report Type:Periodic Company Report #A0123716A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis Urticaria	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL

Date:11/30/00ISR Number: 3627532-8Report Type:Periodic Company Report #A0123213A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL
			Golden Seal (Formulation Unknown) (Golden Seal)	SS		ORAL	ORAL
			Cannabis	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3627536-5Report Type:Periodic Company Report #A0123216A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL		
	Drug Interaction	Professional Company Representative	Cannabis (Formulation Unknown) (Cannabis)	SS		ORAL		

Date:11/30/00ISR Number: 3627538-9Report Type:Periodic Company Report #A0123110A
Age:7 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	200 MG / PER	
Hospitalization -		Professional					DAY/ ORAL	
Initial or Prolonged		Company						
Required		Representative						
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:11/30/00ISR Number: 3627541-9Report Type:Periodic Company Report #A0123131A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
		Professional					TWICE PER DAY	
		Company					/ ORAL	
		Representative	Venlafaxine Hydrochloride	C				

Date:11/30/00ISR Number: 3627543-2Report Type:Periodic Company Report #A0122533A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Anxiety Confusional State Disturbance In Attention Insomnia Irritability Memory Impairment Paranoia Thinking Abnormal	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/	ORAL

Date:11/30/00ISR Number: 3627545-6Report Type:Periodic Company Report #A0122205A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Insomnia Tooth Disorder	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3627548-1Report Type:Periodic Company Report #A0121951A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Overdose	Health Professional Company Representative	Wellbutrin	PS	Glaxo Wellcome Inc			

Date:11/30/00ISR Number: 3627552-3Report Type:Periodic Company Report #A0121920A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL		
Hospitalization - Initial or Prolonged	Back Pain	Professional	Clonazepam (Formulation					
Required	Chest Pain	Company	Unknown)					
Intervention to	Convulsion	Representative	(Clonazepam)	SS				
Prevent Permanent	Electroencephalogram		Zolpidem Tartrate					
Impairment/Damage	Abnormal		(Formulation					
	Headache		Unknown) (Zolpidem					
			Tartrate)	SS		ORAL	10 MG / AT	
							NIGHT / ORAL	
			Thyroxine Sodium	C				
			Loestrin	C				
			Quinapril					
			Hydrochloride	C				

Date:11/30/00ISR Number: 3627737-6Report Type:Periodic Company Report #A0102154A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	300 MG/ TWICE	
	Overdose	Professional					PER DAY/ ORAL	

Date:11/30/00ISR Number: 3627739-XReport Type:Periodic Company Report #A0128927A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:11/30/00ISR Number: 3627740-6Report Type:Periodic Company Report #A0128474A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	1 TABLET/ TWICE PER DAY/	ORAL 1 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3627743-1Report Type:Periodic Company Report #A0128492A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL
		Professional					

Date:11/30/00ISR Number: 3627746-7Report Type:Periodic Company Report #A0128275A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Anaphylactic Reaction	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER
Required	Dermatitis	Professional					DAY/ ORAL
Intervention to Prevent Permanent Impairment/Damage	Urticaria		Oral Contraceptive	C			

Date:11/30/00ISR Number: 3627748-0Report Type:Periodic Company Report #A0128201A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL
		Professional	Ssri	C			
		Company Representative	Cannabis	C			

Date:11/30/00ISR Number: 3627749-2Report Type:Periodic Company Report #A0127739A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Fall	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE

	Grand Mal Convulsion	Professional					
PER DAY/ ORAL							
	Headache		Amoxycillin	C			
	Memory Impairment		Carisoprodol	C			
	Motor Dysfunction		Cyclobenzaprine Hcl	C			
	Movement Disorder						
	Pain In Extremity						
	Tremor						

Date:11/30/00ISR Number: 3627752-2Report Type:Periodic Company Report #A0127242A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Fatigue						PER DAY/ ORAL	
	Pruritus		Prednisone (Formulation Unknown)	SS				
	Tenderness							
	Urticaria							
			Progesterone	C				

Date:11/30/00ISR Number: 3627753-4Report Type:Periodic Company Report #A0127247A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional Company

Representative

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL		

Date:11/30/00ISR Number: 3627777-7Report Type:Periodic Company Report #A0126856A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL		
		Professional Company Representative	Fluoxetine Hydrochloride (Formulation Unknown) (Fluoxetine Hydrochloride)	SS				

Date:11/30/00ISR Number: 3627780-7Report Type:Periodic Company Report #A0126468A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/	ORAL 3 WK
		Professional	Beta-Blocker	C				

Date:11/30/00ISR Number: 3627782-0Report Type:Periodic Company Report #A0126488A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER	

DAY/ ORAL

			Metoprolol Succinate	C		

Date:11/30/00ISR Number: 3627785-6Report Type:Periodic Company Report #A0125786A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL		
ORAL								
	Productive Cough	Professional Company Representative	Olanzapine (Formulation Unknown) (Olanzapine)	SS			5 MG	
			Theophylline	C				
			Inhaler	C				
			Oral Contraceptive	C				

Date:11/30/00ISR Number: 3627787-XReport Type:Periodic Company Report #A0125239A
Age:43 YR Gender:Female I/FU:I

Outcome	PT
Other	Convulsion
	Electroencephalogram Abnormal
	Epilepsy
	Hypertension
	Intentional Misuse

	Loss Of Consciousness Memory Impairment Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE PER DAY/ ORAL						
		Professional				
			Glatiramer Acetate Injection (Glatiramer Acetate)	SS		
SUBCUTANEOUS 20 MG / PER DAY / SUBCUTANEOUS						
			Oxcarbazepine (Formulation Unknown) (Oxcarbazepine)	SS		ORAL
150 MG/ SEE TEXT/ ORAL						
			Rantidine Hydrochloride	C		
			Amantadine Hydrochloride	C		
			Estroven	C		
			Chromium Picolinate	C		

Date:11/30/00ISR Number: 3627789-3Report Type:Periodic Company Report #A0124316A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
150 MG / ORAL 3 MON						
		Professional Company Representative	Alprazolam (Formulation Unknown) (Alprazolam)	SS		

Date:11/30/00ISR Number: 3627790-XReport Type:Periodic Company Report #A0124317A
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	3000 MG / SEE TEXT/ ORAL	
	Overdose	Professional						
		Company Representative						

Date:11/30/00ISR Number: 3627792-3Report Type:Periodic Company Report #A0124152A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Burning Sensation	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	6 DAY
	Condition Aggravated		Atenolol	C				
	Gastrooesophageal Reflux Disease		Lisinopril	C				
	Insomnia		Atorvastatin Calcium	C				

Date:11/30/00ISR Number: 3627794-7Report Type:Periodic Company Report #A0124006A
Age:18 YR Gender:Female I/FU:I

Outcome
Other
Required

Intervention to
Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
	Dermatitis	Professional					PER DAY/	ORAL
	Dizziness		Fiorinal	C				
	Hypersensitivity							
	Oedema Peripheral							
	Orthostatic Hypotension							
	Pruritus							
	Rash Erythematous							
	Urticaria							

Date:11/30/00ISR Number: 3627797-2Report Type:Periodic Company Report #A0123987A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL		
Initial or Prolonged	Chest Pain	Professional	Propanolol					
	Myocardial Infarction	Company	Hydrochloride	C				
		Representative	Hydroxyzine	C				

Date:11/30/00ISR Number: 3627799-6Report Type:Periodic Company Report #A0123847A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL		
		Professional	Methylphenidate Hcl	C				
		Company	Imipramine	C				
		Representative						

Date:12/01/00ISR Number: 3619959-5Report Type:Expedited (15-DaCompany Report #A0132705A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Cellulitis							
	Dyspnoea							
	Erythema							
	Feeling Hot							
	Hypersensitivity							
	Pain In Extremity							
	Swelling							
	Urticaria							

Date:12/01/00ISR Number: 3619961-3Report Type:Expedited (15-DaCompany Report #B0086031A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Zyban	PS	Glaxo Wellcome	ORAL	1TAB Twice per day	12 DAY
	Headache							
	Oedema Peripheral							
	Physical Assault							
	Suicide Attempt							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/00ISR Number: 3619964-9Report Type:Expedited (15-DaCompany Report #B0092315A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	48 DAY
	Headache							
	Nausea							

Date:12/01/00ISR Number: 3619967-4Report Type:Expedited (15-DaCompany Report #B0092451A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperreflexia		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	5 DAY
	Paraesthesia							
	Tachycardia							
	Tremor		Aciclovir	C	Glaxo Wellcome			

Date:12/01/00ISR Number: 3619970-4Report Type:Expedited (15-DaCompany Report #B0092811A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amenorrhoea		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	46 DAY
	Dysgeusia							
			Loestrin	C		ORAL	30MCG Per day	

Date:12/01/00ISR Number: 3619971-6Report Type:Expedited (15-DaCompany Report #B0092839A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Dermatitis		Zyban	PS	Glaxo Wellcome	ORAL 150MG Twice per day 17 DAY
	Psoriasis					
			Calcipotriol	C		TOPICAL
			Betamethasone	C	Glaxo Wellcome	TOPICAL
			Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)
			Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION)
			Meloxicam	C		ORAL 15MG Per day

Date:12/01/00ISR Number: 3619972-8Report Type:Expedited (15-DaCompany Report #B0092845A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization -	Periorbital Oedema		Zyban	PS	Glaxo Wellcome	ORAL 300MG Per day 6 DAY
Initial or Prolonged	Urticaria		Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION) 100MCG Per day
			Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)

Date:12/01/00ISR Number: 3619974-1Report Type:Expedited (15-DaCompany Report #D0011022A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization -	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL 4 WK
Initial or Prolonged	Hypertension		Oral Contraceptives	C		1 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/00ISR Number: 3620886-8Report Type:Expedited (15-DaCompany Report #A0130408A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis Dyspnoea Malaise Nervousness Vision Blurred	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL

Date:12/01/00ISR Number: 3621136-9Report Type:Expedited (15-DaCompany Report #B0091225A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Coordination Abnormal Delusion Diarrhoea Dry Mouth Dysarthria Extrapyramidal Disorder Feeling Abnormal Hypotension Insomnia Muscle Rigidity Pneumonia Aspiration Sedation	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL

Date:12/01/00ISR Number: 3621137-0Report Type:Expedited (15-DaCompany Report #B0092404A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Asthma Peak Expiratory Flow Rate Decreased	Foreign Health Professional	Bupropion Hydrochloride Prednisolone Fluticasone Propionate	PS C C	Glaxo Wellcome Inc	ORAL	ORAL

Salmeterol Xinafoate	C
Salbutamol Sulphate	C
Quinine	C
Nasonex	C

Date:12/01/00ISR Number: 3621138-2Report Type:Expedited (15-DaCompany Report #B0092066A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperhidrosis Hypertension Ventricular Hypertrophy Visual Disturbance	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG/AS	DIRECTED

Date:12/01/00ISR Number: 3621139-4Report Type:Expedited (15-DaCompany Report #B0092571A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicide Attempt	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/00ISR Number: 3621140-0Report Type:Expedited (15-DaCompany Report #B0088745A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Chest Pain	Foreign	Bupropion				
Hospitalization -	Electrocardiogram T Wave	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT /
Initial or Prolonged	Inversion	Professional					ORAL
Disability	Myocardial Infarction		Ipratropium Bromide	C			
			Salbutamol Sulphate	C			
			Aspirin	C			
			Bendrofluazide	C			
			Prednisolone	C			
			Beclomethasone Dipropion	C			

Date:12/01/00ISR Number: 3621277-6Report Type:Expedited (15-DaCompany Report #D0010841A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Amnesia	Foreign	Bupropion				
Hospitalization -	Cardiac Arrest	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL
Initial or Prolonged	Electroencephalogram	Professional					
Required	Abnormal						
Intervention to	Grand Mal Convulsion						
Prevent Permanent							
Impairment/Damage							

Date:12/01/00ISR Number: 3621279-XReport Type:Expedited (15-DaCompany Report #D0010583A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Photopsia	Foreign	Bupropion				
Initial or Prolonged	Visual Disturbance	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE
	Vitreous Opacities	Professional					PER DAY/ORAL
			Co-Trimoxazole	C			

Date:12/04/00ISR Number: 3620761-9Report Type:Expedited (15-DaCompany Report #B0093052A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Allergy		Zyban	PS	Glaxo Wellcome	ORAL		
	Rash Pruritic		Fluoxetine	C				
			Chlorhexidine	C				

Date:12/04/00ISR Number: 3620762-0Report Type:Expedited (15-DaCompany Report #B0093061A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diplopia		Zyban	PS	Glaxo Wellcome			
	Insomnia							
	Tinnitus							
	Tongue Disorder							
	Vision Blurred							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/00ISR Number: 3620763-2Report Type:Expedited (15-DaCompany Report #B0093064A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vision Blurred		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	9 DAY
			Humalog	C				
			Humulin I	C				

Date:12/04/00ISR Number: 3620764-4Report Type:Expedited (15-DaCompany Report #B0093067A
Age:67 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rectal Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 DAY
			Co-Codamol	C		ORAL	2U Four times per day	
			Ibuprofen	C		ORAL	400MG Per day	

Date:12/04/00ISR Number: 3620810-8Report Type:Expedited (15-DaCompany Report #B0092443A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chemical Poisoning Drug Interaction Intentional Self-Injury	Health Professional	Zyban Fluoxetine	PS I	Glaxo Wellcome			

Date:12/04/00ISR Number: 3621668-3Report Type:Expedited (15-DaCompany Report #A0131760A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Alanine Aminotransferase Increased	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL

350 MG / PER DAY / ORAL 8 MON

Blood Amylase Increased
Blood Glucose Increased
Chromaturia
Hepatitis C

Sertraline Hydrochloride C

Date:12/04/00ISR Number: 3621683-XReport Type:Expedited (15-DaCompany Report #A0117940A
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acne Cystic
	Asthenia
	Bronchospasm
	Burning Sensation
	Chest Pain
	Dermatitis
	Dizziness
	Dyspnoea Exertional
	Ear Haemorrhage
	Erythema
	Eyelid Oedema
	Folliculitis
	Haemorrhage
	Hypersensitivity
	Hypoventilation
	Irritability
	Oedema

	Pain					
	Palpitations					
	Pruritus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Purulence	Health	Bupropion			
	Rash Erythematous	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Rash Papular					
TWICE PER DAY						
	Respiratory Disorder					
/ ORAL						
	Scratch		Carisoprodol	C		
	Shock		Diazepam	C		
	Skin Infection					
	Skin Lesion					
	Urticaria					
	Visual Disturbance					

Date:12/04/00ISR Number: 3621705-6Report Type:Expedited (15-DaCompany Report #A0132668A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Haemorrhage	Health				
TWICE PER DAY						
		Professional				
/ ORAL						

Date:12/04/00ISR Number: 3622221-8Report Type:Expedited (15-DaCompany Report #A0132722A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocarditis	Foreign	Bupropion			
			Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
TWICE ER DAY						
/ ORAL						
			Medroxyprogesterone			

			Ace. Injection	SS		

INTRAMUSCULAR 150 MG / SEE

TEXT /

INTRAMUSCULAR

Alfalfa	C
Calcium Salt	C
Activated Charcoal	C
Kelp	C
Potassium Salt	C
Rose Hips	C
Ascorbic Acid	C

Date:12/04/00ISR Number: 3622293-0Report Type:Expedited (15-DaCompany Report #B0092499A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister Eye Disorder Rash Pruritic Visual Acuity Reduced	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:12/04/00ISR Number: 3622294-2Report Type:Expedited (15-DaCompany Report #B0092355A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis	Foreign Health

Professional
Company
Representative

Product	Role	Manufacturer	Route	Dose	Duration
Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL		
Statines	C				

Date:12/04/00ISR Number: 3622295-4Report Type:Expedited (15-DaCompany Report #B0091997A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Bronchial Obstruction Dermatitis Eyelid Oedema Pruritus Rash Generalised Urticaria	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL

Date:12/04/00ISR Number: 3622389-3Report Type:Expedited (15-DaCompany Report #WAES 00111289
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abdominal Pain Constipation Diarrhoea Dysphagia Rectal Haemorrhage Urticaria	Foreign Other	Prinivil	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	10 MG	1832 DAY
			Zyban (Bupropion Hcl)	SS		ORAL	150 MG	
			Anafranil	C				
			Bendroflumethiazide	C				
			Betahistine	C				
			Prochlorperazine	C				

Date:12/05/00ISR Number: 3621719-6Report Type:Expedited (15-DaCompany Report #A0086224A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			No Concurrent Medications	C				

Date:12/05/00ISR Number: 3621720-2Report Type:Expedited (15-DaCompany Report #A0105888A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Per day	2 DAY

Date:12/05/00ISR Number: 3621725-1Report Type:Expedited (15-DaCompany Report #A0131022A
Age:30 YR Gender:Female I/FU:F

Outcome	PT
Other	Bleeding Time Prolonged
	Cholelithiasis
	Platelet Count Decreased

	Post Procedural Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Three times per day
			Lamictal	SS	Glaxo Wellcome	ORAL	25MG As directed
			Risperdal	C			
			Paxil	C			
			Ambien	C			
			Celexa	C			
			Sonata	C			

Date:12/05/00ISR Number: 3622806-9Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Eye Pain		Zyban (Bupropion Sr)				
	Headache		(150 Mg)	PS		ORAL	150 MG PO QD
	Mental Impairment						
	Neck Pain						
	Tremor						

Date:12/06/00ISR Number: 3622603-4Report Type:Expedited (15-DaCompany Report #A0133264A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Deafness		Wellbutrin	PS	Glaxo Wellcome		
	Tinnitus		Wellbutrin Sr	SS	Glaxo Wellcome	ORAL	

Date:12/06/00ISR Number: 3622626-5Report Type:Expedited (15-DaCompany Report #B0093039A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Sudden Death							
			Aspirin	C		ORAL	75MG Per day	
			Ranitidine	C	Glaxo Wellcome	ORAL	150MG Per day	

Date:12/06/00ISR Number: 3622627-7Report Type:Expedited (15-DaCompany Report #B0093101A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	7 DAY
			Clopidogrel	C		ORAL		
			Amitriptyline	C		ORAL		
			Ipratropium	C	Glaxo Wellcome	ORAL		

Date:12/06/00ISR Number: 3622628-9Report Type:Expedited (15-DaCompany Report #B0093206A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL		

Date:12/06/00ISR Number: 3623572-3Report Type:Expedited (15-DaCompany Report #D0011022A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Hypertension	Foreign Health Professional	Bupropion Hydrochloride Oral Contraceptive	PS C	Glaxo Wellcome Inc	ORAL ORAL	

Date:12/06/00ISR Number: 3623574-7Report Type:Expedited (15-DaCompany Report #B0092845A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Periorbital Oedema Urticaria	Foreign	Bupropion Hydrochloride Beclomethasone Dipropion Salbutamol Sulphate	PS C C	Glaxo Wellcome Inc	ORAL	300 MG/ PER DAY/ ORAL

Date:12/06/00ISR Number: 3623576-0Report Type:Expedited (15-DaCompany Report #B0092811A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Amenorrhoea Dysgeusia	Foreign	Bupropion Hydrochloride Loestrin	PS C	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL

Date:12/06/00ISR Number: 3623606-6Report Type:Expedited (15-DaCompany Report #B0086031A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Depression	Foreign	Bupropion			
	Headache	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 1 TABLET
	Oedema Peripheral	Professional				(TWICE PER
	Physical Assault					DAY) ORAL
	Suicide Attempt					

Date:12/06/00ISR Number: 3623680-7Report Type:Expedited (15-DaCompany Report #A0132705A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Arthralgia	Foreign	Bupropion			
	Cellulitis	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG (TWICE
	Dyspnoea					PER DAY) ORAL
	Erythema					
	Feeling Hot					
	Hypersensitivity					
	Joint Swelling					
	Oedema Peripheral					
	Pain In Extremity					
	Swelling					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/00ISR Number: 3623682-0Report Type:Expedited (15-DaCompany Report #B0092315A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke	Foreign	Bupropion					
	Headache	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
	Nausea	Professional					PER DAY) ORAL	

Date:12/06/00ISR Number: 3623715-1Report Type:Expedited (15-DaCompany Report #B0092839A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Psoriasis	Foreign	Bupropion					
Intervention to		Other	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
Prevent Permanent							PER DAY) ORAL	
Impairment/Damage			Calcipotriene	C				
			Betamethasone	C				
			Salbutamol Sulphate	C				
			Beclomethasone Dipropion	C				
			Meloxicam	C				

Date:12/06/00ISR Number: 3623716-3Report Type:Expedited (15-DaCompany Report #B0092451A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperreflexia	Foreign	Bupropion					
Initial or Prolonged	Paraesthesia	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
	Tachycardia	Professional					PER DAY) ORAL	
	Tremor		Acyclovir	C				

Date:12/07/00ISR Number: 3623427-4Report Type:Expedited (15-DaCompany Report #B0093033A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	International Normalised Ratio Increased		Warfarin	I	Glaxo Wellcome	ORAL	5MG Per day	

Date:12/08/00ISR Number: 3624513-5Report Type:Direct Company Report #
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin Sr	PS		ORAL	100 MG BID PO	
	Anger		Tenex	SS		ORAL	0.5 MG Q AM	
	Epilepsy						PO	
	Headache		Risperdal	SS		ORAL	1 MG Q HS PO	
	Loss Of Consciousness		Risperdal	SS		ORAL	1 MG BID PO	
	Memory Impairment		Adderal	C				
	Vision Blurred		Flonase	C				
			Haldol Im	C				
			Haldol	C				
			Tylenol	C				
			Vistaril Im	C				
			Vistaril	C				
			Maalox	C				
			Mom	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/00ISR Number: 3624600-1Report Type:Expedited (15-DaCompany Report #A0111797A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Dizziness		Placebo	SS		ORAL	1TAB Per day	
	Dysarthria		Plavix	C		ORAL	75MG Per day	
	Hypotension		Atenolol	C		ORAL	25MG Per day	
	Syncope		Zestril	C		ORAL	2.5MG Per day	
	Ventricular Tachycardia		Prilosec	C		ORAL	20MG Twice per day	
			Enteric-Coated Aspirin	C		ORAL		
			Lipitor	C		ORAL		
			Nitroglycerin 1/150 SUBLINGUAL	C	Glaxo Wellcome			

Date:12/08/00ISR Number: 3624618-9Report Type:Expedited (15-DaCompany Report #B0089165A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Health Professional	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	9 DAY
	Pregnancy							

Date:12/08/00ISR Number: 3624620-7Report Type:Expedited (15-DaCompany Report #B0090959A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Health Professional	Zyban	PS	Glaxo Wellcome			

Date:12/08/00ISR Number: 3624621-9Report Type:Expedited (15-DaCompany Report #B0092066A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG As	
Hospitalization - directed	Hyperhidrosis							7 DAY
Initial or Prolonged	Malignant Hypertension							
	Ventricular Hypertrophy							
	Visual Disturbance							

Date:12/08/00ISR Number: 3624629-3Report Type:Expedited (15-DaCompany Report #B0093404A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoptysis		Zyban	PS	Glaxo Wellcome			
Initial or Prolonged	International Normalised							
	Ratio Increased							

Date:12/08/00ISR Number: 3625343-0Report Type:Expedited (15-DaCompany Report #HQ2762525OCT2000
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Agitation
Initial or Prolonged	Asthenia
	Disorientation
	Hallucination
	Headache

		Hyperhidrosis Hypoaesthesia Lethargy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Paraesthesia Thinking Abnormal	Consumer	Effexor Xr	PS	Wyeth Ayerst Laboratories	ORAL
175 MG, 450 MG, 75 MG, DAILY, ORAL							
				Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL
ORAL							
				Synthroid (Levothyroxine Sodium)	C		

Date:12/08/00ISR Number: 3625451-4Report Type:Expedited (15-DaCompany Report #A0131022A
Age:30 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Bleeding Time Prolonged	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
150 MG / THREE TIMES PER DAY / ORAL		Cholelithiasis	Professional				
		Platelet Count Decreased					
		Post Procedural Haemorrhage					
				Lamictal Tablet (Lamotrigine)	SS		ORAL
25 MG / ORAL/ AS DIRECTED							
				Risperidone	C		
				Paroxetine Hydrochloride	C		
				Zolpidem Tartrate	C		
				Citalopram Hydrobromide	C		
				Zaleplon	C		

Date:12/08/00ISR Number: 3625616-1Report Type:Expedited (15-DaCompany Report #A0086224A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Overdose	Literature					PER DAY/ ORAL	
		Health Professional						

Date:12/08/00ISR Number: 3625617-3Report Type:Expedited (15-DaCompany Report #A0105888A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
							DAY/ ORAL	2 DAY

Date:12/08/00ISR Number: 3625620-3Report Type:Expedited (15-DaCompany Report #B0093064A
Age:24 YR Gender:Female I/FU:I

Outcome
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
			Insulin Lispro	C				
			Human Int/Long Insulin	C				

Date:12/08/00ISR Number: 3625621-5Report Type:Expedited (15-DaCompany Report #B0093067A
Age:67 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Rectal Haemorrhage	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	
			Co-Codamol	C				
			Ibuprofen	C				

Date:12/08/00ISR Number: 3625622-7Report Type:Expedited (15-DaCompany Report #B0093052A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK,	ORAL
		Other	Fluoxetine	C				
			Chlorhexidine	C				

Date:12/08/00ISR Number: 3625623-9Report Type:Expedited (15-DaCompany Report #B0093061A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Diplopia	Foreign	Bupropion			
	Dry Mouth	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	
UNKNOWN	150 MG/ UNK/					
	Insomnia					
UNKNOWN						
	Tinnitus					
	Vision Blurred					
	Visual Disturbance					

Date:12/08/00ISR Number: 3625624-0Report Type:Expedited (15-DaCompany Report #B0092443A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abnormal Behaviour	Foreign	Zyban	PS	Glaxo Wellcome Inc	
UNKNOWN	UNK/UNK/					
Initial or Prolonged	Disinhibition	Health				
UNKNOWN						
	Drug Interaction	Professional	Fluoxetine			
	Intentional Self-Injury	Other	(Formulation Unknown)			
			(Fluoxetine)	SS		
UNKNOWN	UNK/ UNK/					
UNKNOWN						

Date:12/11/00ISR Number: 3625422-8Report Type:Expedited (15-DaCompany Report #B0093505A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatine		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Other	Phosphokinase Increased						per day	63 DAY
	Chest Pain		Cetirizine	C	Glaxo Wellcome		150MG Per day	
	Convulsion		Omeprazole	C			200MG Twice	
	Gamma-Glutamyltransferase Increased		Fluticasone	C	Glaxo Wellcome	NASAL	per day	
	Insomnia		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		
	Lethargy							
	Muscle Spasms		Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		

Date:12/11/00ISR Number: 3625423-XReport Type:Expedited (15-DaCompany Report #B0093507A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Variable dose	12 DAY

Date:12/11/00ISR Number: 3625424-1Report Type:Expedited (15-DaCompany Report #B0093510A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Periorbital Oedema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	17 DAY
	Stridor							

	Urticaria					

Date:12/11/00ISR Number: 3626713-7Report Type:Expedited (15-DaCompany Report #A0133264A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc			
	Tinnitus		Wellbutrin	SS		ORAL	ORAL	

Date:12/11/00ISR Number: 3627087-8Report Type:Expedited (15-DaCompany Report #B0093206A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:12/11/00ISR Number: 3627089-1Report Type:Expedited (15-DaCompany Report #B0093033A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY, ORAL	
	International Normalised Ratio Increased		Warfarin Sodium	SS		ORAL	5 MG (PER DAY) ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/00ISR Number: 3627108-2Report Type:Expedited (15-DaCompany Report #B0093101A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL	
			Clopidogrel	C				
			Amitriptyline	C				
			Ipratropium Bromide	C				

Date:12/11/00ISR Number: 3627343-3Report Type:Expedited (15-DaCompany Report #B0093039A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
		Other	Aspirin	C				
			Ranitidine Hydrochloride	C				

Date:12/12/00ISR Number: 3626592-8Report Type:Expedited (15-DaCompany Report #A0109223A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban	PS	Glaxo Wellcome	ORAL	39	DAY
	Back Pain	Professional	Ibuprofen	C				
	Bone Density Decreased							
	Intervertebral Disc Degeneration							
	Leukocytoclastic Vasculitis							

Osteoporosis
Pain
Pain In Extremity
Pruritus
Purpura
Rash Erythematous
Rheumatoid Arthritis
Sneezing
Throat Irritation
Urticaria
White Blood Cell Count
Increased

Date:12/12/00ISR Number: 3627261-0Report Type:Direct Company Report #
Age:7 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Bupropion	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/00ISR Number: 3627615-2Report Type:Expedited (15-DaCompany Report #A0111797A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY)	ORAL
	Myocardial Ischaemia	Health						
	Syncope	Professional						
	Ventricular Tachycardia		Placebo Tablet (Placebo)	SS		ORAL	1 TABLET (PER DAY)	ORAL
			Clopidogrel Bisulphate	C				
			Atenolol	C				
			Lisinopril	C				
			Omeprazole	C				
			Aspirin	C				
			Atorvastatin Calcium	C				
			Nitroglycerin	C				

Date:12/12/00ISR Number: 3627687-5Report Type:Expedited (15-DaCompany Report #B0093404A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoptysis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
	International Normalised Ratio Increased	Health						
		Professional						

Date:12/12/00ISR Number: 3627806-0Report Type:Expedited (15-DaCompany Report #B0092066A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Malignant Hypertension	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ AS	
Hospitalization -	Ventricular Hypertrophy	Health						

Initial or Prolonged Professional
DIRECTED/

ORAL

Date:12/12/00ISR Number: 3627808-4Report Type:Expedited (15-DaCompany Report #B0090959A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:12/12/00ISR Number: 3627809-6Report Type:Expedited (15-DaCompany Report #B0089165A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/00ISR Number: 3627847-3Report Type:Expedited (15-DaCompany Report #B0091833A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angioneurotic Oedema	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	16 DAY
	Asthma	Professional						
	Urticaria							

Date:12/13/00ISR Number: 3627861-8Report Type:Expedited (15-DaCompany Report #D0010662A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Zyban	PS	Glaxo Wellcome	ORAL	450MG per day	10 DAY
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Professional						
	Pulse Absent							

Date:12/13/00ISR Number: 3627862-XReport Type:Expedited (15-DaCompany Report #D0011022A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health	Zyban	PS	Glaxo Wellcome	ORAL	4	WK
	Catecholamines Urine	Professional	Oral Contraceptives	C			1	YR
	Increased							
	Epistaxis							
	Headache							
	Hypertension							

Date:12/13/00ISR Number: 3628961-9Report Type:Expedited (15-DaCompany Report #B0093510A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Periorbital Oedema	Foreign	Bupropion					

	Stridor	Other	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG /PER
	Urticaria					DAY/ORAL

Date:12/13/00ISR Number: 3628962-0Report Type:Expedited (15-DaCompany Report #B0093507A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Psoriasis	Foreign Health Professional Other	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG/ VARIABLE DOSE/ORAL

Date:12/13/00ISR Number: 3628986-3Report Type:Expedited (15-DaCompany Report #B0093505A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Disability Required Intervention to Prevent Permanent Impairment/Damage	Blood Creatine Phosphokinase Increased	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG/ TWICE PER DAY/ ORAL
	Chest Pain					
	Convulsion					
	Gamma-Glutamyltransferase Increased		Cetirizine Hydrochloride	C		
	Insomnia		Omeprazole	C		
	Lethargy		Fluticasone Propionate	C		
	Muscle Spasms					

			Salbutamol Sulphate	C		
			Beclomethasone Dipropion	C		

Date:12/14/00ISR Number: 3628923-1Report Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria		Bupropion 150mg Sa	PS		ORAL	150 MG BID	ORAL
			Asa	C				
			Atenolol	C				
			Ipratropium	C				
			Isdn	C				
			Niacin	C				
			Nicotine Patch	C				
			Simvastatin	C				

Date:12/14/00ISR Number: 3628924-3Report Type:Expedited (15-DaCompany Report #A0133478A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma		Wellbutrin	PS	Glaxo Wellcome	ORAL	38TAB Single	
	Dialysis						dose	
	Ileus Paralytic		Tegretol	SS		ORAL	54TAB Single	
	Overdose						dose	
	Oxygen Saturation Decreased		Trazodone	SS		ORAL	12TAB Single	
							dose	
			Seroquel	SS		ORAL	38TAB Single	
							dose	

			Advil	SS		ORAL
1600MG Single						
dose						

Date:12/14/00ISR Number: 3628931-0Report Type:Expedited (15-DaCompany Report #B0089929A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Circulatory Collapse	Health	Zyban	PS	Glaxo Wellcome	
150MG Twice						
	Depressed Level Of	Professional				
per day 51 DAY						
	Consciousness		Cimetidine	C		ORAL
400MG Twice						
	Dyspepsia					
per day 6 DAY						
	Dyspnoea		Temazepam	C		ORAL
	Dysuria					
	Eye Irritation					
	Grand Mal Convulsion					
	Keratoconjunctivitis					
	Sicca					
	Myocardial Infarction					

Date:12/14/00ISR Number: 3628977-2Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Diarrhoea		Bupropion	PS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/00ISR Number: 3630326-0Report Type:Expedited (15-DaCompany Report #A0134365A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia		Zyban	PS	Glaxo Wellcome	ORAL	1	MON
	Cystitis		No Concurrent					
	Dysarthria		Medication	C				

Date:12/15/00ISR Number: 3630335-1Report Type:Expedited (15-DaCompany Report #B0092251A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eyelid Disorder		Zyban	PS	Glaxo Wellcome	ORAL	30	DAY
	Nausea		Oestradiol	C				
	Pain							
	Retinal Disorder							
	Retinal Vascular Disorder							
	Vision Blurred							
	Visual Acuity Reduced							

Date:12/15/00ISR Number: 3630342-9Report Type:Expedited (15-DaCompany Report #B0093973A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy		Zyban	PS	Glaxo Wellcome			
Other	Stevens-Johnson Syndrome							

Date:12/15/00ISR Number: 3630343-0Report Type:Expedited (15-DaCompany Report #B0093986A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation		Zyban	PS	Glaxo Wellcome		150MG	
	Pruritus							
Variable dose							6	DAY

Date:12/18/00ISR Number: 3631624-7Report Type:Expedited (15-DaCompany Report #A0132705A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Other	Cellulitis						per day	24 DAY
	Dyspnoea							
	Feeling Hot							
	Hypersensitivity							
	Pain In Extremity							
	Rash Erythematous							
	Stevens-Johnson Syndrome							
	Swelling							
	Urticaria							

Date:12/18/00ISR Number: 3631633-8Report Type:Expedited (15-DaCompany Report #B0093969A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Zyban	PS	Glaxo Wellcome	ORAL		
Other	Erythema Multiforme		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	2PUFF As required	
	Urticaria							

			Antihistamine	C		

Date:12/18/00ISR Number: 3631634-XReport Type:Expedited (15-DaCompany Report #B0093975A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Vaginal Haemorrhage						per day	23 DAY
			Microgynon	C		ORAL	1TAB Per day	
			Sultrin	C		VAGINAL		

Date:12/18/00ISR Number: 3631635-1Report Type:Expedited (15-DaCompany Report #B0093979A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Akinesia		Zyban	PS	Glaxo Wellcome	ORAL	6	DAY
Hospitalization - Initial or Prolonged	Dyspnoea		Atenolol + Chlorthalidone	C		ORAL		

Date:12/18/00ISR Number: 3633253-8Report Type:Expedited (15-DaCompany Report #B0089929A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Bupropion					
	Dyspepsia	Health	Hydrochloride	PS	Glaxo Wellcome Inc		150 MG /TWICE	
	Dyspnoea	Professional					PER DAY	
	Grand Mal Convulsion		Cimetidine	C				
	Keratoconjunctivitis Sicca		Temazepam	C				
	Loss Of Consciousness							
	Myocardial Infarction							

	Urinary Tract Disorder					

Date:12/18/00ISR Number: 3633257-5Report Type:Expedited (15-DaCompany Report #B0091833A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Angioneurotic Oedema	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL
	Asthma	Health					
	Urticaria	Professional					

Date:12/18/00ISR Number: 3633289-7Report Type:Expedited (15-DaCompany Report #A0133478A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Coma	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	38 TABLET/ SINGLE DOSE/ ORAL
	Dialysis	Professional					
	Ileus Paralytic						
	Overdose		Carbamazepine Tablet (Carbamazepine)	SS		ORAL	54 TABLET/ SINGLE DOSE/ ORAL
	Oxygen Saturation Decreased						
	Sedation						
			Trazodone Tablet (Trazodone)	SS		ORAL	12 TABLET/ SINGLE DOSE/ ORAL

			Quetiapine Fumarate Tablet (Quetiapine Fumarate)	SS		ORAL	38 TABLET/SINGLE DOSE/ ORAL
			Ibuprofen Tablet (Ibuprofen)	SS		ORAL	1600 MG/ SINGLE DOSE/ ORAL

Date:12/18/00ISR Number: 3633358-1Report Type:Expedited (15-DaCompany Report #D0011022A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Blood Catecholamines	Foreign Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Abnormal Epistaxis Headache Pulmonary Arterial Wedge Pressure Increased	Professional	Oral Contraceptive	C				

Date:12/18/00ISR Number: 3633359-3Report Type:Expedited (15-DaCompany Report #D0010662A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Convulsion Dyspnoea Pulse Absent	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	10 DAY

Date:12/18/00ISR Number: 3633571-3Report Type:Direct Company Report #
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tremor		Wellbutrin Sr 150mg	PS		ORAL	150MG ONCE A DAY ORAL	

Date:12/19/00ISR Number: 3632879-5Report Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accelerated Hypertension
Disability	Alopecia
	Anaphylactic Shock
	Anuria
	Anxiety
	Asthenia
	Autonomic Nervous System Imbalance
	Back Pain
	Bipolar Disorder
	Bradycardia
	Chills
	Cognitive Disorder
	Convulsion
	Cystocele
	Depersonalisation

Depression
Disorientation
Dizziness
Drug Hypersensitivity
Dysarthria
Dyspepsia
Dyspnoea
Dysthymic Disorder
Fatigue
Fear
Feeling Abnormal
Haematuria
Headache
Heart Rate Abnormal
Hyperglycaemia
Hyperhidrosis
Hypertension
Hyperventilation
Hypoaesthesia
Hypomania
Intervertebral Disc
Degeneration
Labile Blood Pressure
Memory Impairment
Mental Impairment
Micturition Urgency
Mitral Valve Incompetence
Movement Disorder
Muscle Disorder
Muscle Rigidity
Muscle Spasms
Muscle Twitching
Muscular Weakness
Musculoskeletal Stiffness
Neck Pain
Nervousness
Neurosis
Obsessive-Compulsive
Disorder
Oedema
Palpitations
Panic Disorder
Paraesthesia
Renal Disorder
Renal Failure Chronic
Respiratory Disorder
Schizophrenia

Sciatica
Stupor
Swelling
Tachycardia
Tangentiality
Throat Tightness
Tinnitus
Tongue Oedema
Transient Ischaemic
Attack
Tremor
Urethral Stricture
Urinary Incontinence
Ventricular Extrasystoles

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	12 DAY
			Premarin	C			1.25MG Per day	
			Vitamin	C				
			Asa	C				
			Melatonin	C				

Date:12/19/00ISR Number: 3632904-1Report Type:Expedited (15-DaCompany Report #B0082488A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Macular Degeneration		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice	
Other	Retinal Exudates						per day	31 DAY
	Retinal Oedema							
	Retinal Vasculitis							
	Retinitis							

Date:12/19/00ISR Number: 3632907-7Report Type:Expedited (15-DaCompany Report #B0092236A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Astigmatism		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Eye Movement Disorder						per day	18 DAY
	Hypermetropia		Salbutamol	C	Glaxo Wellcome		4PUFF Twice	
	Hypertension						per day	
	Vision Blurred		Beclomethasone Dipropionate	C	Glaxo Wellcome		4PUFF Twice	
	Visual Disturbance							

per day						
			Frusemide	C		
30MG Per day						
			Spironolactone	C		
100MG Per day						
			Digoxin	C	Glaxo Wellcome	
.25MG Per day						

Date:12/19/00ISR Number: 3632909-0Report Type:Expedited (15-DaCompany Report #B0092251A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eye Pain	Health	Zyban	PS	Glaxo Wellcome	ORAL	30	DAY
Other	Nausea	Professional	Oestradiol	C				
	Retinoschisis							

Date:12/19/00ISR Number: 3632911-9Report Type:Expedited (15-DaCompany Report #B0093187A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY
	Delirium Tremens		Salmeterol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		
	Hallucination							
	Suicidal Ideation		Alprazolam	C		ORAL		
	Trismus							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/00ISR Number: 3632925-9Report Type:Expedited (15-DaCompany Report #B0093977A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	16 DAY
Other	Dyspnoea		Salbutamol	C	Glaxo Wellcome		1PUFF Three times per day	
			Eformoterol	C			1PUFF Three times per day	
			Steroids	C				

Date:12/19/00ISR Number: 3632926-0Report Type:Expedited (15-DaCompany Report #B0094080A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	14 DAY
	Gait Disturbance							
	Hypoaesthesia Oral		Atenolol	C		ORAL	50MG per day	
			Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG per day	
			Nicotine	C				

Date:12/19/00ISR Number: 3632927-2Report Type:Expedited (15-DaCompany Report #B0094092A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
Hospitalization - Initial or Prolonged			Co-Dydramol	C	Glaxo Wellcome	ORAL		51 DAY

Date:12/19/00ISR Number: 3632929-6Report Type:Expedited (15-DaCompany Report #D0011104A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Zyban	PS	Glaxo Wellcome	ORAL	1TAB Twice	
Initial or Prolonged	Dyspnoea	Professional					per day	2 WK
	Haematuria							
	Hypersensitivity							
	Myalgia							
	Urticaria							
	White Blood Cells Urine Positive							

Date:12/19/00ISR Number: 3633679-2Report Type:Expedited (15-DaCompany Report #A0134365A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Foreign	Bupropion					
	Cystitis	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Dysarthria	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/00ISR Number: 3633681-0Report Type:Expedited (15-DaCompany Report #B0093973A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy	Foreign	Bupropion					
Required	Stevens-Johnson Syndrome		Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:12/19/00ISR Number: 3633688-3Report Type:Expedited (15-DaCompany Report #B0092251A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Eye Pain	Foreign	Bupropion					
Intervention to	Nausea	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
Prevent Permanent	Retinal Disorder	Professional	Oestradiol	C				
Impairment/Damage	Visual Disturbance							

Date:12/19/00ISR Number: 3633690-1Report Type:Expedited (15-DaCompany Report #B0093986A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Burning Sensation	Foreign	Bupropion					
Intervention to	Pruritus		Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
Prevent Permanent							VARIABLE DOSE	
Impairment/Damage								

Date:12/19/00ISR Number: 3633960-7Report Type:Periodic Company Report #0323283A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Effect Decreased	Consumer	Habitrol	PS	Novartis Consumer			

					Health Inc	
1						
PATCH/QD/TTS						
			Wellbutrin-Bupropion Hcl	SS	Glaxo Wellcome	
1						
PATCH/QD/TTS						

Date:12/19/00ISR Number: 3633996-6Report Type:Expedited (15-DaCompany Report #HQ2762525OCT2000
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Asthenia Disorientation Hallucination Headache Hyperhidrosis Hypoaesthesia Lethargy Panic Attack Paraesthesia Syncope Thinking Abnormal	Health Professional	Effexor Xr Wellbutrin (Amfebutamone Hydrochloride, Capsule, Extended Release) Synthroid (Levothyroxine Sodium)	PS SS C	Wyeth Ayerst Laboratories	ORAL ORAL	175 MG DAILY, ORAL ORAL; SEE IMAGE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/00ISR Number: 3634102-4Report Type:Periodic Company Report #0303996A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Application Site Reaction Pruritus Sedation	Consumer	Habitrol	PS	Novartis Consumer Health Inc	PATCH/QD/TTS		1
			Zyban - Bupropion Hcl 150mg - Glaxo	SS	Glaxo	ORAL	150 MG/PO	

Date:12/19/00ISR Number: 3634166-8Report Type:Periodic Company Report #0269684A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams Insomnia	Health Professional	Habitrol	PS	Novartis Consumer Health Inc	TRANSDERMAL	PATCH/QD/TTS	1
			Zyban-Bupropion Hcl 150 Mg-Glaxo	SS		ORAL	PO QD	
			Nasonex	C				
			Zyrtec	C				
			Depo Provera	C				

Date:12/19/00ISR Number: 3634175-9Report Type:Periodic Company Report #0272578A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea Dizziness	Consumer	Habitrol	PS	Novartis Consumer Health Inc	1 PATCH /TTS		
	Nausea		Zyban-Bupropion Hcl-Glaxo	SS		ORAL	PO	
			Zestoretic	C				

Date:12/19/00ISR Number: 3634235-2Report Type:Periodic Company Report #0272281A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus Rash Erythematous Urticaria	Consumer	Habitrol	PS	Novartis Consumer Health Inc	PATCH/QD/TTS	1	
			Wellbutrin-Bupropion Hcl Tab-Glaxo Wellcome	SS	Glaxo Wellcome	ORAL	PO	

Date:12/19/00ISR Number: 3634266-2Report Type:Periodic Company Report #0309310A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Pruritus	Consumer	Habitrol	PS	Novartis Consumer Health Inc	TRANSDERMAL	2	PATCHES/QD/TTS
			Zyban-Bupropion-Hcl 150 Mg	SS	Glaxo	ORAL	150 MG OD PO,	THEN 300
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/00ISR Number: 3634309-6Report Type:Periodic Company Report #0315170A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State	Consumer	Habitrol	PS	Novartis Consumer Health Inc	TRANSDERMAL	1 PATCH/ QD/TTS	
			Wellbutrin - Bupropion Hcl - Glaxo Wellcome	SS	Glaxo Wellcome			

Date:12/19/00ISR Number: 3634744-6Report Type:Periodic Company Report #0266794A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Mouth Pharyngeal Oedema Urticaria	Consumer	Habitrol	PS	Novartis Consumer Health Inc	TRANSDERMAL	1 PATCH/ QD/ TTS	
			Zyban (Glaxo Wellcome)	SS	Glaxo Wellcome	ORAL	QD PO	
			Zyban	C				
			Synthroid	C				

Date:12/19/00ISR Number: 3634804-XReport Type:Periodic Company Report #0268640A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Nervousness	Consumer	Habitrol	PS	Novartis Consumer Health Inc	TRANSDERMAL	TTS	15 DAY
			Zyban - Bupropion Hcl 150 Mg - Glaxo	SS	Glaxo	ORAL	PO	

Date:12/19/00ISR Number: 3634812-9Report Type:Periodic Company Report #0268835A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Application Site Reaction Oedema Paraesthesia Weight Increased	Consumer	Habitrol Zyban-Bupropion Hcl 150 Mg-Glaxo	PS SS	Novartis Consumer Health Inc Glaxo	ORAL	1 PATCH/QD/TTS PO	

Date:12/19/00ISR Number: 3634886-5Report Type:Periodic Company Report #0296321A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia Headache Hyperhidrosis	Consumer	Habitrol Zyban-Bupropion Hcl 150 Mg - Glaxo	PS SS	Novartis Consumer Health Inc Glaxo	ORAL	1 PATCH/QD/TTS 150 MG BID PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/00ISR Number: 3633819-5Report Type:Direct Company Report #
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria		Wellbutrin Sr 150 Mg	PS		ORAL	1 TAB	
			Paxil	C				
			Lithium	C				
			Zyprexa	C				

Date:12/20/00ISR Number: 3633822-5Report Type:Expedited (15-DaCompany Report #A0121104A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL	1	WK
			Bactrim	C	Glaxo Wellcome			
			Viagra	I		ORAL	1	DAY

Date:12/20/00ISR Number: 3633824-9Report Type:Expedited (15-DaCompany Report #A0128274A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	18 DAY
	Feeling Abnormal							
	Feeling Hot		Nicoderm	C			11	DAY
	Hyperaesthesia							
	Irritability							
	Nervousness							
	Nightmare							
	Oedema							
	Pruritus							
	Skin Discolouration							
	Urticaria							

Date:12/20/00ISR Number: 3633839-0Report Type:Expedited (15-DaCompany Report #B0093439A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm		Zyban	PS	Glaxo Wellcome			7 DAY
Initial or Prolonged	Dizziness		Ipratropium	C	Glaxo Wellcome			
	Dyspnoea							
	Tremor							

Date:12/20/00ISR Number: 3633845-6Report Type:Expedited (15-DaCompany Report #B0094062A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Decreased Activity		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	20 DAY
	Urticaria							

Date:12/20/00ISR Number: 3633846-8Report Type:Expedited (15-DaCompany Report #B0094077A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged							per day	
			Aspirin	C		ORAL	75MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/00ISR Number: 3633847-XReport Type:Expedited (15-DaCompany Report #B0094079A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Other	Dry Mouth						per day	14 DAY
	Malaise		Propanolol	C				
	Migraine							
	Nausea							
	Pain							

Date:12/20/00ISR Number: 3633849-3Report Type:Expedited (15-DaCompany Report #B0094291A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	3	WK

Date:12/20/00ISR Number: 3635022-1Report Type:Expedited (15-DaCompany Report #B0093187A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation	Foreign	Bupropion					
	Delirium Tremens	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
	Hallucination	Professional					DAY/ORAL	
	Suicidal Ideation	Company	Salmeterol	C				
	Trismus	Representative	Alprazolam	C				
	Visual Disturbance							

Date:12/20/00ISR Number: 3635023-3Report Type:Expedited (15-DaCompany Report #B0094080A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Atrial Fibrillation Gait Disturbance Hypoaesthesia Oral	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/' ORAL	
			Atenolol	C				
			Bendrofluazide	C				
			Nicotine	C				

Date:12/20/00ISR Number: 3635024-5Report Type:Expedited (15-DaCompany Report #B0093977A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Required Intervention to Prevent Permanent Impairment/Damage	Asthma	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ ORAL	
			Salbutamol Sulphate	C				
			Eformoterol	C				
			Steroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/00ISR Number: 3635025-7Report Type:Expedited (15-DaCompany Report #B0094092A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coronary Artery Disease	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL
Hospitalization - Initial or Prolonged			Co-Dydramol	C			

Date:12/20/00ISR Number: 3635026-9Report Type:Expedited (15-DaCompany Report #B0092236A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Astigmatism	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL
	Eye Movement Disorder	Health					
	Hypermetropia	Professional					
	Hypertension		Salbutamol Sulphate	C			
	Vision Blurred		Beclomethasone Dipropion	C			
			Frusemide	C			
			Spironolactone	C			
			Digoxin	C			

Date:12/20/00ISR Number: 3635033-6Report Type:Expedited (15-DaCompany Report #B0092251A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Nausea	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL
Required Intervention to Prevent Permanent Impairment/Damage	Retinal Detachment	Health					
		Professional	Oestradiol	C			

Date:12/20/00ISR Number: 3635034-8Report Type:Expedited (15-DaCompany Report #D0011104A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Haematuria Hypersensitivity Myalgia White Blood Cells Urine Positive	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	1 TABLET/TWICE PER DAY/ORAL	

Date:12/20/00ISR Number: 3635035-XReport Type:Expedited (15-DaCompany Report #B0082488A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Eye Irritation Maculopathy Retinal Oedema Retinal Tear Retinitis	Foreign Study Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/00ISR Number: 3635126-3Report Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL
Disability	Anxiety							
	Blood Glucose Increased							
	Blood Triglycerides		Conjugated Estrogens	C				
	Increased		Vitamin	C				
	Bradycardia		Aspirin	C				
	Cognitive Disorder		Melatonin	C				
	Confusional State							
	Cystocele							
	Diplopia							
	Dizziness							
	Drug Hypersensitivity							
	Dry Mouth							
	Dry Throat							
	Dysarthria							
	Dyspepsia							
	Dysthymic Disorder							
	Dysuria							
	Enuresis							
	Faeces Pale							
	Feeling Abnormal							
	Feeling Hot And Cold							
	Fluid Retention							
	Headache							
	Hypertension							
	Hypoaesthesia							
	Insomnia							
	Intervertebral Disc Protrusion							
	Memory Impairment							
	Mental Impairment							
	Movement Disorder							
	Muscle Spasms							
	Muscular Weakness							
	Musculoskeletal Stiffness							
	Nausea							
	Nervousness							
	Oedema							
	Palpitations							
	Panic Disorder							

Paraesthesia
Sciatica
Spinal Osteoarthritis
Syncope
Throat Tightness
Tinnitus
Tremor

Date:12/21/00ISR Number: 3634583-6Report Type:Expedited (15-DaCompany Report #A0134853A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cervix Carcinoma		Wellbutrin	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Drug Toxicity Overdose							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/00ISR Number: 3634599-XReport Type:Expedited (15-DaCompany Report #B0092443A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amputation		Zyban	PS	Glaxo Wellcome		150MG Twice per day	47 DAY
	Disinhibition							
	Intentional Self-Injury		Aspirin	C		ORAL	75MG Per day	
			Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG Per day	
			Fosinopril	C		ORAL	10MG Per day	
			Fluoxetine	I				

Date:12/21/00ISR Number: 3634623-4Report Type:Expedited (15-DaCompany Report #B0094547A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:12/21/00ISR Number: 3634624-6Report Type:Expedited (15-DaCompany Report #B0094550A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Decreased Appetite		Zyban	PS	Glaxo Wellcome	ORAL	150MG Single dose	1 DAY
	Panic Attack							
	Psychomotor Hyperactivity		Cilest	C		ORAL	1U Per day	
	Thirst							
	Vision Blurred							

Date:12/21/00ISR Number: 3634625-8Report Type:Expedited (15-DaCompany Report #B0094552A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG	
	Dry Mouth						Variable dose	3 DAY
	Insomnia							
	Vision Blurred							

Date:12/21/00ISR Number: 3634626-XReport Type:Expedited (15-DaCompany Report #B0094555A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bipolar Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG As	
	Mania						directed	
			Lithium	C		ORAL	600MG Per day	
			Paracetamol	C		ORAL		

Date:12/21/00ISR Number: 3634627-1Report Type:Expedited (15-DaCompany Report #B0094565A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Disorientation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Fear						per day	3 DAY
Initial or Prolonged	Feeling Abnormal		Salbutamol	C	Glaxo Wellcome		RESPIRATORY	
Other	Malaise						(INHALATION)	
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY	
							(INHALATION)	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/00ISR Number: 3634628-3Report Type:Expedited (15-DaCompany Report #B0094566A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL		
			Amlodipine	C		ORAL		
			Atenolol	C		ORAL	50MG Twice per day	
			Aspirin	C		ORAL	75MG Per day	
			Meloxicam	C		ORAL	7.5MG Per day	

Date:12/21/00ISR Number: 3634630-1Report Type:Expedited (15-DaCompany Report #B0094567A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	28	DAY

Date:12/21/00ISR Number: 3634631-3Report Type:Expedited (15-DaCompany Report #B0094571A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	36 DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction		Aspirin	C			75MG Twice per day	
			Atenolol	C			50MG Per day	
			Nitroglycerin	C	Glaxo Wellcome		1PUFF As required	
			Fucibet	C			TOPICAL	

			Finasteride	C		
5MG Per day						
			Lisinopril	C		
10MG Per day						
			Betamethasone	C	Glaxo Wellcome	
TOPICAL						
			Quinine	C		
300MG Per day						

Date:12/21/00ISR Number: 3635694-1Report Type:Expedited (15-DaCompany Report #B0093969A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthma	Foreign	Bupropion			
Required	Erythema Multiforme		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ORAL						
Intervention to	Urticaria		Salbutamol Sulphate	C		
Prevent Permanent			Antihistamine	C		
Impairment/Damage						

Date:12/21/00ISR Number: 3635696-5Report Type:Expedited (15-DaCompany Report #B0093979A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dyspnoea	Foreign	Bupropion			
Hospitalization -	Paralysis		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ORAL						
Initial or Prolonged			Atenolol +			
			Chlorothalidone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/00ISR Number: 3635697-7Report Type:Expedited (15-DaCompany Report #B0093975A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Abortion Spontaneous Menstruation Irregular Vaginal Haemorrhage	Foreign	Bupropion Hydrochloride Microgynon Sultrin	PS C C	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:12/21/00ISR Number: 3635700-4Report Type:Expedited (15-DaCompany Report #A0132705A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other Required Intervention to Prevent Permanent Impairment/Damage	Cellulitis Hypersensitivity Stevens-Johnson Syndrome	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:12/22/00ISR Number: 3635299-2Report Type:Expedited (15-DaCompany Report #A0135070A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity		Zyban	PS	Glaxo Wellcome			

Date:12/22/00ISR Number: 3635320-1Report Type:Expedited (15-DaCompany Report #B0089482A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Left Ventricular Failure	Consumer	Bupropion					

	Oedema		Hydrochloride	PS	Glaxo Wellcome	ORAL 150MG Twice
	Oedema Peripheral					per day 20 DAY
			Beclomethasone	C	Glaxo Wellcome	NASAL 2PUFF At night

Date:12/22/00ISR Number: 3635322-5Report Type:Expedited (15-DaCompany Report #B0091290A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Rheumatic Fever	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL 150MG Twice per day
	Systemic Lupus Erythematosus		Decortin	C		5MG Per day
			Azathioprine	C	Glaxo Wellcome	50MG Per day
			Katadolon	C		100MG Per day
			Sortis	C		10MG Per day
			Magnerot N	C		48.6MG Twice per day
			Trusopt	C		20MG Twice per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/00ISR Number: 3635324-9Report Type:Expedited (15-DaCompany Report #B0092236A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Astigmatism	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Blood Pressure Increased	Professional					per day	18 DAY
	Eye Movement Disorder		Salbutamol	C	Glaxo Wellcome		4PUFF Twice	
	Hypermetropia						per day	
	Ophthalmoplegia		Beclomethasone Dipropionate	C	Glaxo Wellcome		4PUFF Twice	
							per day	
			Frusemide	C			30MG Per day	
			Spironolactone	C			100MG Per day	
			Digoxin	C	Glaxo Wellcome		.25MG Per day	

Date:12/22/00ISR Number: 3635354-7Report Type:Expedited (15-DaCompany Report #B0094589A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL		
	Arthralgia		Losec	C		ORAL		
	Chest Pain		Vioxx	C		ORAL		
	Cold Sweat							
	Condition Aggravated							
	Dizziness							
	Dry Mouth							
	Dry Throat							
	Feeling Hot							
	Hypertension							
	Ill-Defined Disorder							
	Myalgia							
	Ulcer							
	Vision Blurred							

Date:12/22/00ISR Number: 3635361-4Report Type:Expedited (15-DaCompany Report #B0094740A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Claustrophobia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	7 DAY
	Depressed Mood							
	Suicidal Ideation		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	10PUFF per day	
			Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	500MCG Twice per day	

Date:12/22/00ISR Number: 3635362-6Report Type:Expedited (15-DaCompany Report #B0094743A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	15 DAY
	Oedema Peripheral							
	Periorbital Oedema		Hrt	C		ORAL		
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/00ISR Number: 3635363-8Report Type:Expedited (15-DaCompany Report #B0094744A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	1	DAY
Hospitalization -	Convulsion		Anadin	SS		ORAL	1	DAY
Initial or Prolonged	Hypotension							
Other	Intentional Misuse							
	Tachycardia							

Date:12/22/00ISR Number: 3635364-XReport Type:Expedited (15-DaCompany Report #B0094745A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	11 DAY
	Confusional State		Etidronic Acid	C		ORAL	400MG per day	
	Fatigue		Sulphasalazine	C		ORAL		

Date:12/22/00ISR Number: 3635365-1Report Type:Expedited (15-DaCompany Report #B0094748A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Erythema		Zyban	PS	Glaxo Wellcome	ORAL	32	DAY
			Co-Codamol	C				

Date:12/22/00ISR Number: 3636019-8Report Type:Expedited (15-DaCompany Report #A0134853A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cervix Carcinoma	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT /	

Hospitalization - Initial or Prolonged	Drug Toxicity Overdose						ORAL

Date:12/22/00ISR Number: 3636319-1Report Type:Expedited (15-DaCompany Report #B0094552A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Pain Dry Mouth Insomnia Vision Blurred	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / VARIABLE DOSE / ORAL

Date:12/22/00ISR Number: 3636325-7Report Type:Expedited (15-DaCompany Report #B0094565A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Required	Disorientation Malaise	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
Intervention to Prevent Permanent Impairment/Damage			Salbutamol Sulphate Beclomethasone Dipropion	C C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/00ISR Number: 3636328-2Report Type:Expedited (15-DaCompany Report #B0093439A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchospasm	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
	Dizziness	Consumer						
	Dyspnoea		Ipratropium Bromide	C				
	Tremor							

Date:12/22/00ISR Number: 3636355-5Report Type:Expedited (15-DaCompany Report #B0094571A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER	Initial or Prolonged
Hospitalization - Initial or Prolonged	Myocardial Infarction						DAY/ ORAL	
			Aspirin	C				
			Atenolol	C				
			Nitroglycerin	C				
			Fucibet	C				
			Finasteride	C				
			Lisinopril	C				
			Betamethasone	C				
			Quinine	C				

Date:12/22/00ISR Number: 3636357-9Report Type:Expedited (15-DaCompany Report #B0094567A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Psoriasis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:12/22/00ISR Number: 3636359-2Report Type:Expedited (15-DaCompany Report #B0094566A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angina Pectoris	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL
			Amlodipine	C				
			Atenolol	C				
			Aspirin	C				
			Meloxicam	C				

Date:12/22/00ISR Number: 3639382-7Report Type:Expedited (15-DaCompany Report #B0094744A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Acidosis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	7.5G/	ORAL
	Convulsion							
	Hypotension		Anadin (Formulation Unknown) (Anadin)	SS		ORAL	7.5G/	ORAL
	Intentional Misuse							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3636409-3Report Type:Expedited (15-DaCompany Report #B0092443A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disinhibition Medication Error	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG / TWICE PER DAY	
			Fluoxetine (Formulation Unknown) (Fluoxetine)	SS				
			Aspirin	C				
			Bendrofluazide	C				
			Fosinopril	C				

Date:12/26/00ISR Number: 3638607-1Report Type:Expedited (15-DaCompany Report #A0135070A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:12/26/00ISR Number: 3638608-3Report Type:Expedited (15-DaCompany Report #A0135193A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin	PS	Glaxo Wellcome Inc		3	MON
	Euphoric Mood Murder	Health Professional Company Representative	Pain Medication (Formulation Unknown) (Pain Medication)	SS				

Date:12/26/00ISR Number: 3638775-1Report Type:Expedited (15-DaCompany Report #A0128274A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anxiety Feeling Abnormal Feeling Hot Hyperaesthesia Irritability Nervousness Nightmare Pallor Pruritus Swelling Urticaria	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
			Nicotine	C				

Date:12/26/00ISR Number: 3638777-5Report Type:Expedited (15-DaCompany Report #A0121104A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction Myocardial Infarction	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
			Sildenafil Citrate Tablet (Sildenafil Citrate)	SS				

			Co-Trimoxazole	C		

Date:12/26/00ISR Number: 3639159-2Report Type:Expedited (15-DaCompany Report #B0092236A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Disability	Astigmatism	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG / TWICE PER DAY / ORAL
	Blood Pressure Increased	Health Professional				
	Hypermetropia					
	Ophthalmoplegia					
	Visual Disturbance		Salbutamol Sulphate	C		
			Beclomethasone Dipropion	C		
			Frusemide	C		
			Spironolactone	C		
			Digoxin	C		

Date:12/26/00ISR Number: 3639160-9Report Type:Expedited (15-DaCompany Report #B0091290A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Rheumatic Fever	Foreign Study	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG / TWICE PER DAY / ORAL
	Systemic Lupus Erythematosus	Health Professional				
			Prednisone	C		
			Azathioprine	C		
			Flupirtine Maleate	C		
			Atorvastatin Calcium	C		
			Magnerot N	C		
			Dorzolamide Hcl	C		

Date:12/26/00ISR Number: 3639161-0Report Type:Expedited (15-DaCompany Report #B0089482A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage / ORAL	Left Ventricular Failure Oedema Oedema Peripheral	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY
			Beclomethasone Dipropion	C			

Date:12/26/00ISR Number: 3639375-XReport Type:Expedited (15-DaCompany Report #B0094740A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Claustrophobia Depressed Mood Suicidal Ideation	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL
			Salbutamol Sulphate	C			
			Beclomethasone Dipropion	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3639377-3Report Type:Expedited (15-DaCompany Report #B0094589A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Arthralgia Blood Pressure Increased Chest Pain Cold Sweat Condition Aggravated Dizziness Dry Mouth Dry Throat Feeling Hot Heart Rate Increased Malaise Myalgia Ulcer Vision Blurred	Foreign Consumer	Bupropion Hydrochloride Omeprazole Rofecoxib	PS C C	Glaxo Wellcome Inc	ORAL ORAL		

Date:12/26/00ISR Number: 3639378-5Report Type:Expedited (15-DaCompany Report #B0094748A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Rash Erythematous	Foreign	Bupropion Hydrochloride Co-Codamol	PS C	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	

Date:12/26/00ISR Number: 3639380-3Report Type:Expedited (15-DaCompany Report #B0094745A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Confusional State Fatigue	Foreign	Bupropion Hydrochloride Etidronic Acid	PS C	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL	

			Sulphasalazine	C			

Date:12/26/00ISR Number: 3639381-5Report Type:Expedited (15-DaCompany Report #B0094743A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative Oedema Peripheral Periorbital Oedema Urticaria	Foreign	Bupropion Hydrochloride Hrt	PS C	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	

Date:12/26/00ISR Number: 3639965-4Report Type:Expedited (15-DaCompany Report #B0094291A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	3 WK

Date:12/26/00ISR Number: 3639966-6Report Type:Expedited (15-DaCompany Report #B0094077A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
			Aspirin	C			

Date:12/26/00ISR Number: 3639967-8Report Type:Expedited (15-DaCompany Report #B0094062A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Urticaria	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER DAY / ORAL

Date:12/26/00ISR Number: 3639969-1Report Type:Expedited (15-DaCompany Report #B0094079A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Dry Mouth	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
Required Intervention to Prevent Permanent Impairment/Damage	Feeling Abnormal Headache Malaise Pain Parosmia Syncope		Propanolol Hydrochloride	C			

Date:12/28/00ISR Number: 3637903-1Report Type:Expedited (15-DaCompany Report #A0135312A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Wellbutrin 150MG Twice per day	PS	Glaxo Wellcome	ORAL		3 YR
			Lithium 900MG Per day	C				
			Largactil 10MG As required	C				

Date:12/28/00ISR Number: 3638077-3Report Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin Sr Glaxo/Welcome 150 AM + HS	PS	Glaxo/Welcome	ORAL		
			Olanzapine PO	C				

Date:12/29/00ISR Number: 3638853-7Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Dermatitis
	Dysphagia
	Face Oedema
	Oedema Peripheral
	Pruritus
	Skin Lesion

	Urticaria					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS		
			Nicotine Inhaler	C		

Date:12/29/00ISR Number: 3640478-4Report Type:Periodic Company Report #A001253
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Eructation	Health	Vistaril	PS	Pfizer Laboratories	
	Nausea	Professional			Div Pfizer Inc	
	Sedation		Wellbutrin	SS		
			Diphenhydramine/Pseudoephedrine	SS		
			Tagamet Hb	SS		
			Hydrocotone Valerate Cream	C		

Date:01/02/01ISR Number: 3640473-5Report Type:Expedited (15-DaCompany Report #2000AU03968
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Potassium Decreased	Health	Prilosec	PS	Astrazeneca Lp	ORAL
20 MG QD PO						
Initial or Prolonged	Drug Interaction	Professional	Lithium	SS		
	Drug Toxicity		Trazodone	SS		
	Heart Rate Increased		Wellbutrin	SS		

Date:01/02/01ISR Number: 3640862-9Report Type:Expedited (15-DaCompany Report #A0135312A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrioventricular Block	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE						
Initial or Prolonged		Health				
PER DAY/ORAL						

		Professional	Lithium Salt	C		
			Largactil	C		

Date:01/02/01ISR Number: 3640920-9Report Type:Expedited (15-DaCompany Report #HQ5327428DEC2000
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Craniopharyngioma	Health	Effexor Xr	PS	Wyeth Ayerst			
	Mouth Ulceration	Professional			Laboratories	ORAL	112.5 MG	
	Oral Pain						DAILY, ORAL	
	Tardive Dyskinesia		Wellbutrin (Amfebutamone Hydrochloride,)	SS		ORAL	ORAL	

Date:01/03/01ISR Number: 3640294-3Report Type:Expedited (15-DaCompany Report #B0094866A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Zyban	PS	Glaxo Wellcome		UNKNOWN	
Initial or Prolonged	Blood Potassium Decreased		Unspecified					
	Blood Sodium Decreased		Medications	C				
	Malaise							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/01ISR Number: 3640767-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin Sr 100 Mg	PS		ORAL	100 MG BID	
	Vomiting							

Date:01/04/01ISR Number: 3641036-8Report Type:Expedited (15-DaCompany Report #B0093061A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diplopia	Consumer	Zyban	PS	Glaxo Wellcome			
	Insomnia							
	Tinnitus							
	Tongue Disorder							
	Vision Blurred							

Date:01/04/01ISR Number: 3641045-9Report Type:Expedited (15-DaCompany Report #B0094941A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Zyban	PS	Glaxo Wellcome		1 MON	
	Rectal Haemorrhage							

Date:01/04/01ISR Number: 3641891-1Report Type:Direct Company Report #
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin Sr (Glaxo Wellcome)	PS	Glaxo Wellcome		100MG 2 TABS AM /PM	
Hospitalization - Initial or Prolonged	Diabetes Mellitus							
	Drug Interaction							
	Ecchymosis		Clozaril (Novartis					

	Fall		Pharmaceutical)	SS	Novartis
	Haemorrhage				Pharmaceutical
100MG 3 BID					
	Head Injury		Norvasc	C	
	Hepatic Failure		Zestril	C	
	Hypertension		Colace	C	
	Intestinal Ischaemia				
	Loss Of Consciousness				
	Medication Error				
	Mental Retardation				
	Severity Unspecified				
	Obesity				
	Schizoaffective Disorder				
	Sudden Death				

Date:01/05/01ISR Number: 3641975-8Report Type:Direct Company Report #
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tinnitus		Zyban 150 Mg	PS		ORAL	1 TABLET PER	

DAY=ROUTE=

ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/01ISR Number: 3642326-5Report Type:Expedited (15-DaCompany Report #B0091930A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis		Zyban	PS	Glaxo Wellcome	ORAL	50TAB	Single
Hospitalization -	Coma							
dose							1	DAY
Initial or Prolonged	Hypotension		Anadin Extra	SS		ORAL	24TAB	Single
	Intentional Misuse							
dose							1	DAY
	Vomiting							

Date:01/05/01ISR Number: 3642335-6Report Type:Expedited (15-DaCompany Report #B0095016A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	150MG	See
Hospitalization -	Cardiac Arrest							
text								
Initial or Prolonged	Coma							
Other	Convulsion							
	Intentional Misuse							
	Suicide Attempt							

Date:01/05/01ISR Number: 3642336-8Report Type:Expedited (15-DaCompany Report #B0095023A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Colic		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Twice
Initial or Prolonged								
per day								
			Analgesics	C				

Date:01/05/01ISR Number: 3642337-XReport Type:Expedited (15-DaCompany Report #B0095024A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Petechiae Vasculitis		Zyban	PS	Glaxo Wellcome			

Date:01/05/01ISR Number: 3642341-1Report Type:Expedited (15-DaCompany Report #B0095172A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Urinary Tract Infection		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:01/05/01ISR Number: 3642343-5Report Type:Expedited (15-DaCompany Report #D0013022A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lenticular Opacities Vision Blurred		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	13 DAY

Date:01/05/01ISR Number: 3642344-7Report Type:Expedited (15-DaCompany Report #D0013064A
Age:35 YR Gender:Male I/FU:I

Outcome	PT
Other	Dermatitis Atopic Skin Disorder

	Skin Exfoliation						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome		1TAB cumulative dose 1 DAY

Date:01/08/01ISR Number: 3642639-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Fatigue		Sporanox 100 Mg	PS		ORAL	2 TABLETS
Intervention to	Myalgia						TWICE A DAY
Prevent Permanent	Pyrexia						ORAL
Impairment/Damage	Rash Erythematous		Wellbutrin	SS			
	Rash Pruritic						

Date:01/08/01ISR Number: 3643524-7Report Type:Expedited (15-DaCompany Report #B0095016A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Arrhythmia	Foreign	Bupropion				
Hospitalization -	Cardiac Arrest	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ SEE
Initial or Prolonged	Coma	Professional					TEXT/ ORAL
Required	Convulsion						
Intervention to	Overdose						
Prevent Permanent	Suicide Attempt						
Impairment/Damage							

Date:01/08/01ISR Number: 3643532-6Report Type:Expedited (15-DaCompany Report #B0091930A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Foreign	Bupropion					
Hospitalization -	Coma	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	50 TABLET/	
Initial or Prolonged	Hypotension	Professional					SINGLE	
	Intentional Misuse						DOSE/ORAL	
	Vomiting		Anadin Extra Tablet (Anadin Extra)	SS		ORAL	24	

TABLET/SINGLE

DOSE/ORAL

Date:01/08/01ISR Number: 3643552-1Report Type:Expedited (15-DaCompany Report #D0013064A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity	Foreign	Bupropion					
	Rash Generalised		Hydrochloride	PS	Glaxo Wellcome Inc			
	Skin Disorder							

Date:01/08/01ISR Number: 3643555-7Report Type:Expedited (15-DaCompany Report #B0095172A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization -	Cerebrovascular Accident	Foreign
Initial or Prolonged	Urinary Tract Infection	Health

Professional

			Product	Role	Manufacturer	Route	Dose	Duration
			Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL

Date:01/08/01ISR Number: 3643556-9Report Type:Expedited (15-DaCompany Report #D0013022A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lenticular Opacities Vision Blurred Visual Disturbance	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL

Date:01/08/01ISR Number: 3643558-2Report Type:Expedited (15-DaCompany Report #B0095024A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Petechiae Vasculitis	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	

Date:01/08/01ISR Number: 3643559-4Report Type:Expedited (15-DaCompany Report #B0095023A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Colic	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL

			Analgesic	C		

Date:01/08/01ISR Number: 3643693-9Report Type:Expedited (15-DaCompany Report #B0094941A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Haematemesis Rectal Haemorrhage Vomiting	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		1	MON

Date:01/08/01ISR Number: 3643694-0Report Type:Expedited (15-DaCompany Report #B0093061A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diplopia Insomnia Tinnitus Tongue Disorder Vision Blurred Visual Disturbance	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150	MG

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/08/01ISR Number: 3644405-5Report Type:Expedited (15-DaCompany Report #B0094866A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Blood Potassium Decreased Blood Sodium Decreased Malaise	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:01/08/01ISR Number: 3653655-3Report Type:Periodic Company Report #2000029474US
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Detrol	PS	Glaxo Wellcome Inc	ORAL	2 DF	QD
	Movement Disorder		Cefalexin (Cefalexin)	SS				
			Estraderm	C				
			Hydrodiuril	C				
			Slow-K	C				
			Elavil (Amitriptyline Hydrochloride)	C				
			Synthroid (Levothyroxine Sodium)	C				
			Urised (Metylionium Chloride, Benzoic Acid, Methenamine, Hyoscyamine, Phenylsalycate,	C				
			Entex La	C				

Date:01/08/01ISR Number: 3653875-8Report Type:Periodic Company Report #2000026940US
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Detrol	PS	Pharmacia & Upjohn	ORAL	2 MG	BID
	Dry Skin		Plendil	C				

	Skin Exfoliation		Premarin (Estrogens Conjugated)	C		

Date:01/08/01ISR Number: 3655507-1Report Type:Periodic Company Report #2000033755US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Detrol	PS	Pharmacia And Upjohn Co	ORAL		
	Dry Mouth							
			Zyban/Amfebutamone	SS				

Date:01/09/01ISR Number: 3643529-6Report Type:Expedited (15-DaCompany Report #A0136085A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG Per day	
	Gastrointestinal Disorder		Adalat	C				
	Pain In Extremity		Synthroid	C	Glaxo Wellcome			
			Lipitor	C				
			Hytrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/01ISR Number: 3643533-8Report Type:Expedited (15-DaCompany Report #B0092403A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Atrial Fibrillation							
per day							7	WK
Initial or Prolonged								

Date:01/09/01ISR Number: 3643537-5Report Type:Expedited (15-DaCompany Report #B0095014A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Zyban	PS	Glaxo Wellcome		3	WK
Initial or Prolonged	Diabetes Mellitus							
	Disturbance In Attention							
	Haemorrhage							
	Menstruation Irregular							
	Paraesthesia							
	Polydipsia							
	Visual Disturbance							

Date:01/09/01ISR Number: 3643538-7Report Type:Expedited (15-DaCompany Report #B0095288A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization -	Dyspnoea		Amiodarone	C		ORAL		
Initial or Prolonged			Glycerol Trinitrate	C	Glaxo Wellcome			
			Isosorbide	C		ORAL	60MG Per day	
			Paracetamol	C		ORAL		
			Tramadol	C		ORAL	50MG As required	
			Simvastatin	C		ORAL	20MG Per day	

				Bisoprolol	C		ORAL
				Pantoprazole	C		ORAL
				Clopidogrel	C		ORAL
				Rofecoxib	C		ORAL
12.5MG Per day							
				Nicorandil	C		ORAL
10MG Twice per day							

Date:01/09/01ISR Number: 3643540-5Report Type:Expedited (15-DaCompany Report #B0095293A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	International Normalised Ratio Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	8 DAY
			Warfarin	C	Glaxo Wellcome			
			Methotrexate	C		ORAL	10MG Weekly	
			Folic Acid	C		ORAL	5MG Two times per week	
			Co-Amilofruse	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/01ISR Number: 3643541-7Report Type:Expedited (15-DaCompany Report #B0095307A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	29 DAY
			Pravastatin	C		ORAL	20MG Per day	
			Lisinopril	C		ORAL	10MG Per day	
			Gliclazide	C		ORAL	80MG Twice per day	

Date:01/09/01ISR Number: 3643542-9Report Type:Expedited (15-DaCompany Report #B0095308A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY
	Dyspnoea		Gliclazide	C		ORAL	80MG Per day	
			Diltiazem	C		ORAL	300MG Per day	
			Nizatidine	C		ORAL	100MG Per day	
			Isosorbide Mononitrate	C		ORAL		

Date:01/10/01ISR Number: 3644729-1Report Type:Expedited (15-DaCompany Report #A0130183A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Toxicologic Test Abnormal	Consumer	Bupropion	PS	Glaxo Wellcome		UNKNOWN	
			Atropine	SS				
			Chloral Hydrate	SS			UNKNOWN	

			Diazepam	SS		
UNKNOWN						
			Venlafaxine	SS		
			Methadone	SS	Glaxo Wellcome	
			Sertraline	SS		
			Lidocaine	SS		

Date:01/10/01ISR Number: 3644731-XReport Type:Expedited (15-DaCompany Report #A0131760A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	350MG Per day	8 MON
	Hepatitis C	Professional	Zoloft	C				
UNKNOWN							100MG Per day	1 YR
	Hepatitis Infectious							

Date:01/11/01ISR Number: 3645633-5Report Type:Expedited (15-DaCompany Report #B0095597A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Hemiparesis							
per day							5	DAY
Initial or Prolonged	Hemiplegia							

Date:01/12/01ISR Number: 3647307-3Report Type:Expedited (15-DaCompany Report #B0095288A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Foreign	Bupropion					
Hospitalization -		Other	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
Initial or Prolonged			Amiodarone	C				

			Nitroglycerin	C		
			Isosorbide	C		
			Paracetamol	C		
			Tramadol Hydrochloride	C		
			Simvastatin	C		
			Bisoprolol	C		
			Pantoprazole	C		
			Clopidogrel	C		
			Rofecoxib	C		
			Nicorandil	C		

Date:01/12/01ISR Number: 3647308-5Report Type:Expedited (15-DaCompany Report #B0095307A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Atrial Fibrillation	Foreign Other	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY) ORAL	
			Pravastatin	C				
			Lisinopril	C				
			Gliclazide	C				

Date:01/12/01ISR Number: 3647311-5Report Type:Expedited (15-DaCompany Report #B0095293A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	International Normalised Ratio Increased	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Warfarin	C				
			Methotrexate	C				
			Folic Acid	C				
			C0-Amilofruse	C				

Date:01/12/01ISR Number: 3647317-6Report Type:Expedited (15-DaCompany Report #B0092403A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Foreign	Bupropion					
Hospitalization -	Atrial Fibrillation	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
Initial or Prolonged	Chest Pain	Professional					PER DAY/ ORAL	

Date:01/12/01ISR Number: 3647319-XReport Type:Expedited (15-DaCompany Report #B0095308A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Angina Pectoris	Foreign	Bupropion					
Intervention to	Dyspnoea		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
Prevent Permanent							DAY/ ORAL	
Impairment/Damage			Gliclazide	C				
			Diltiazem	C				
			Nizatidine	C				
			Isosorbide Mononitrate	C				

Date:01/12/01ISR Number: 3647320-6Report Type:Expedited (15-DaCompany Report #B0095014A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Blindness Diabetes Mellitus Disturbance In Attention Haemorrhage Menstruation Irregular Mood Altered Paraesthesia Visual Disturbance	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:01/12/01ISR Number: 3647321-8Report Type:Expedited (15-DaCompany Report #A0136085A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	300 MG/ PER	DAY / ORAL
	Gastrointestinal Disorder	Health						
	Pain In Extremity	Professional	Nifedipine	C				
			Thyroxine Sodium	C				
			Atorvastatin Calcium	C				
			Terazosin Hydrochloride	C				

Date:01/15/01ISR Number: 3646711-7Report Type:Expedited (15-DaCompany Report #A0135962A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Dyspnoea Haemorrhage Lung Infiltration Nervous System Disorder Respiratory Arrest		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	2 WK

	Sarcoidosis

Date:01/15/01ISR Number: 3646713-0Report Type:Expedited (15-DaCompany Report #A0136308A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome		400MG per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Congenital Anomaly							
	Pregnancy							

Date:01/15/01ISR Number: 3646718-XReport Type:Expedited (15-DaCompany Report #B0093439A
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Bronchospasm
	Chest Discomfort
Disability	Disorientation
Other	Dizziness
	Dyspnoea

Tremor

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Zyban	PS	Glaxo Wellcome			7 DAY
			Combivent	C				RESPIRATORY (INHALATION)
							120MCG per day	

Date:01/15/01ISR Number: 3646719-1Report Type:Expedited (15-DaCompany Report #B0094653A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	4 DAY
	Difficulty In Walking		Oestrogen	C		ORAL	625MCG per day	
			Fluvastatin	C		ORAL	40MG per day	
			Aspirin	C		ORAL	250MG per day	

Date:01/15/01ISR Number: 3646722-1Report Type:Expedited (15-DaCompany Report #B0095614A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	11 DAY
			Aspirin	C		ORAL		
			Alcohol	C				

Date:01/16/01ISR Number: 3647439-XReport Type:Expedited (15-DaCompany Report #A0131854A
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Amnesia Cerebrovascular Accident Fall		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY

Date:01/16/01ISR Number: 3647443-1Report Type:Expedited (15-DaCompany Report #A0136085A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Arthritis							
	Gastrointestinal Disorder		Adalat Xl	C		ORAL	60MG Per day	
			Synthroid	C	Glaxo Wellcome	ORAL	300MG Per day	
			Lipitor	C		ORAL	40MG Per day	
			Hytrin	C				

Date:01/16/01ISR Number: 3647458-3Report Type:Expedited (15-DaCompany Report #B0095936A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchospasm Lower Respiratory Tract Infection Respiratory Depression		Zyban	PS	Glaxo Wellcome		2 WK	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/01ISR Number: 3648779-0Report Type:Expedited (15-DaCompany Report #A0131760A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis C	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	350 MG / PER	
	Hepatitis Infectious	Professional					DAY / ORAL	8 MON
			Sertraline Hydrochloride	C				

Date:01/16/01ISR Number: 3648799-6Report Type:Expedited (15-DaCompany Report #A0130183A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Toxicologic Test Abnormal	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc			
			Atropine	SS				
			Chloral Hydrate	SS				
			Diazepam	SS				
			Venlafaxine Hydrochloride	SS				
			Methadone Hydrochloride	SS				
			Sertraline	SS				
			Lignocaine	SS				

Date:01/16/01ISR Number: 3648872-2Report Type:Expedited (15-DaCompany Report #B0095597A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Foreign	Bupropion					
Hospitalization - Initial or Prolonged	Hemiplegia	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
		Professional						

Date:01/17/01ISR Number: 3648118-5Report Type:Direct Company Report #
Age:6.5 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin					
	Dysuria		-Bupropion	PS			50 MG QOD X 2	
	Erythema Multiforme						WKS THEN 50	
	Joint Swelling						MG QD	
	Pharyngolaryngeal Pain							
	Pyrexia							

Date:01/17/01ISR Number: 3648137-9Report Type:Expedited (15-DaCompany Report #A0131639A
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ischaemic		Zantac	PS	Glaxo Wellcome	ORAL	150MG Per day	2 YR
Initial or Prolonged	Hyperkalaemia		Zyban	SS	Glaxo Wellcome	ORAL	150MG Per day	
	Megaloblasts Increased		Theophylline	C				
	Rectal Haemorrhage		Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/17/01ISR Number: 3648144-6Report Type:Expedited (15-DaCompany Report #A0136900A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	300MG per day	46 DAY
	Haemorrhage							

Date:01/17/01ISR Number: 3648147-1Report Type:Expedited (15-DaCompany Report #B0088136A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Headache							
	Loss Of Consciousness							
	Pallor		Contraceptive	C		ORAL		
	Post-Traumatic Amnestic Disorder							
	Tonic Convulsion							

Date:01/17/01ISR Number: 3648154-9Report Type:Expedited (15-DaCompany Report #B0095172A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	7 DAY
	Cerebrovascular Accident							
Other	Trismus		Beclomethasone (INHALATION)	C	Glaxo Wellcome	RESPIRATORY		
	Urinary Tract Infection							
			Beconase Nasal	C	Glaxo Wellcome	NASAL	1PUFF Twice per day	
			Aspirin	C		ORAL	75MG per day	

			Theophylline	C		ORAL
60MG Twice per day						
			Amlodipine Besylate	C		ORAL
5G per day						

Date:01/17/01ISR Number: 3648160-4Report Type:Expedited (15-DaCompany Report #B0095928A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hydrocephalus		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	39 DAY

Date:01/18/01ISR Number: 3649141-7Report Type:Direct Company Report #
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin 150 Sr INCREASED TO BID X 1 1/2 WK	PS		ORAL	P.O. 1 TAB EACH AM	
			Prozac	C				
			Oral Contraceptive	C				
			Proventil	C				
			Entex	C				
			Flonase	C				
			Allegra	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/01ISR Number: 3649162-4Report Type:Direct Company Report #
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bacterial Infection		Zyban (Buproprion 300mg) Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	150 MG BID PO	
			Hydrochlorthiazide	C				
			Ultram	C				

Date:01/18/01ISR Number: 3649205-8Report Type:Expedited (15-DaCompany Report #A0126045A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG At night	
			Tegretol	C				
			Zoloft	C				
			Ritalin	C				

Date:01/18/01ISR Number: 3649206-XReport Type:Expedited (15-DaCompany Report #A0134853A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Adhesions		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Three	
Hospitalization - Initial or Prolonged	Anaemia						times per day	6 DAY
	Anorexia		Triphasil	C		ORAL	1TAB Per day	
	Chest Pain		St. John'S Wort	C				
	Fistula		Vitamins	C				
	Hypoaesthesia							
	Lung Disorder							
	Metastases To Lymph Nodes							
	Neutropenia							
	Night Sweats							

Orthostatic Hypotension
Paraesthesia
Post Coital Bleeding
Pyrexia
Rhinitis
Sinus Tachycardia
Squamous Cell Carcinoma
Of The Cervix
Thyroid Function Test
Abnormal
Vaginal Haemorrhage

Date:01/18/01ISR Number: 3649212-5Report Type:Expedited (15-DaCompany Report #A0137061A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	4500MG per day	
	Sinus Tachycardia							
	Suicide Attempt		Celexa	SS		ORAL	400MG per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/01ISR Number: 3649214-9Report Type:Expedited (15-DaCompany Report #A0137073A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL		

Date:01/18/01ISR Number: 3649215-0Report Type:Expedited (15-DaCompany Report #B0093922A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intervertebral Disc Protrusion Sciatica		Zyban	PS	Glaxo Wellcome	ORAL		

Date:01/18/01ISR Number: 3649217-4Report Type:Expedited (15-DaCompany Report #B0095016A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Arrhythmia Brain Oedema Cardiac Arrest Coma Convulsion Intentional Misuse Suicide Attempt		Zyban	PS	Glaxo Wellcome	ORAL	150MG See text	

Date:01/18/01ISR Number: 3649232-0Report Type:Expedited (15-DaCompany Report #B0096058A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	24 DAY

Date:01/18/01ISR Number: 3649233-2Report Type:Expedited (15-DaCompany Report #B0096062A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Zyban	PS	Glaxo Wellcome	ORAL	15	DAY
	Dermatitis Exfoliative		Nifedipine	C		ORAL	10MG Twice	
	Pruritus						per day	
			Bendrofluazide	C	Glaxo Wellcome		2.5MG In the	
							morning	
			Nitrazepam	C			5MG At night	
			Co-Codamol	C				

Date:01/18/01ISR Number: 3649234-4Report Type:Expedited (15-DaCompany Report #B0096063A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -							per day	
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/01ISR Number: 3649235-6Report Type:Expedited (15-DaCompany Report #D0012242A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hemiparesis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	2 WK
			Iodid 200	C		ORAL		YR
			Bikalm	C		ORAL		4 WK
			Diclofenac	C				UNKNOWN
			Contraceptives	C				UNKNOWN

Date:01/19/01ISR Number: 3650387-2Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin Sr	PS			SR 150MG / DAY	
			Coumadin	C				
			Paxil	C				
			Bumex	C				
			Tegretol	C				
			Prinivil	C				
			Premarin	C				
			Synthroid	C				
			Verapamil	C				
			Ativan	C				

Date:01/19/01ISR Number: 3651566-0Report Type:Expedited (15-DaCompany Report #A0136085A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Osteoarthritis	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

		Health				
PER DAY /						
		Professional				
ORAL						
			Nifedipine	C		
			Thyroxine Sodium	C		
			Atorvastatin Calcium	C		
			Terazosin Hydrochloride	C		

Date:01/19/01ISR Number: 3651567-2Report Type:Expedited (15-DaCompany Report #A0131854A
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY /	
Disability	Aneurysm	Health						
	Cerebrovascular Accident	Professional						
	Fall							
	Paraesthesia							

Date:01/19/01ISR Number: 3651568-4Report Type:Expedited (15-DaCompany Report #B0095936A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lower Respiratory Tract Infection	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		2	WK
		Health						
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/01ISR Number: 3651594-5Report Type:Expedited (15-DaCompany Report #B0093439A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Bronchospasm Chest Discomfort Disorientation Dizziness Dyspnoea Tremor	Foreign Health Professional	Zyban Combivent	PS C	Glaxo Wellcome Inc		150 MG	

Date:01/19/01ISR Number: 3651600-8Report Type:Expedited (15-DaCompany Report #A0136308A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Foetal Disorder Pregnancy	Foreign Study Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc			

Date:01/19/01ISR Number: 3651601-XReport Type:Expedited (15-DaCompany Report #B0095614A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Coronary Artery Disease	Foreign	Zyban Aspirin Ethanol	PS C C	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	

Date:01/19/01ISR Number: 3651602-1Report Type:Expedited (15-DaCompany Report #B0094653A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Chest Pain	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ PER
	Myalgia	Health				DAY/ ORAL
		Professional	Estrogen	C		
			Fluvastatin Sodium	C		
			Aspirin	C		

Date:01/19/01ISR Number: 3652486-8Report Type:Expedited (15-DaCompany Report #A0135962A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ TWICE
	Dyspnoea	Professional				PER DAY/ ORAL
	Haemorrhage					
	Lung Infiltration					
	Nervous System Disorder					
	Respiratory Disorder					
	Sarcoidosis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/01ISR Number: 3651242-4Report Type:Expedited (15-DaCompany Report #A0133472A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Asthma							
	Convulsion		Advair	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	500MCG Twice per day	
	Decreased Appetite							
	Disturbance In Attention							
	Ecchymosis		Ventolin	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		
	Fatigue							
	Fear							
	Feeling Abnormal							
	Insomnia							
	Nausea							
	Nervousness							
	Oedema Peripheral							
	Speech Disorder							
	Tremor							

Date:01/22/01ISR Number: 3651243-6Report Type:Expedited (15-DaCompany Report #A0136520A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Zyban	PS	Glaxo Wellcome		60TABS cumulative dose	
	Intentional Misuse							
	Suicide Attempt							
	Thyroid Gland Cancer		Quinidine	SS				
			Benadryl	SS				
			Alcohol	SS				

Date:01/22/01ISR Number: 3651259-XReport Type:Expedited (15-DaCompany Report #B0095557A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermographism		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	18 DAY
	Urticaria Papular							

Date:01/22/01ISR Number: 3651262-XReport Type:Expedited (15-DaCompany Report #B0096064A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	20 DAY
	Anxiety							
	Chest Pain		Alcohol	C				
	Confusional State		Imovane	C				
	Depression		Sobril	C				
	Dermatitis		Naproxen	C				
	Disturbance In Attention							
	Dysuria							
	Hallucination							
	Hyperhidrosis							
	Insomnia							
	Malaise							
	Nausea							
	Pyrexia							
	Tremor							
	Vertigo							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/01ISR Number: 3651263-1Report Type:Expedited (15-DaCompany Report #B0096199A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	23	DAY
	Bronchospasm		Simvastatin	C		ORAL	20MG per day	
			Isosorbide	C		ORAL	25MG per day	
			Atenolol	C		ORAL	50MG per day	
			Aspirin	C		ORAL	75MG per day	

Date:01/22/01ISR Number: 3651264-3Report Type:Expedited (15-DaCompany Report #B0096202A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	1 DAY
	Difficulty In Walking							

Date:01/22/01ISR Number: 3651265-5Report Type:Expedited (15-DaCompany Report #B0096210A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Glossodynia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	61 DAY
	Pharyngitis		Allopurinol	C	Glaxo Wellcome	ORAL	100MG per day	

Date:01/22/01ISR Number: 3651266-7Report Type:Expedited (15-DaCompany Report #B0096213A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL		

Hospitalization -	Fall		Paroxetine	C		ORAL
20MG per day						
Initial or Prolonged	Gamma-Glutamyltransferase		Thioridazine	C		ORAL
50MG per day						
Disability	Increased		Oestrone	C		ORAL
1.25MG per						
	Macrocytosis					
day						
	Spinal Fracture					

Date:01/22/01ISR Number: 3651469-1Report Type:Expedited (15-DaCompany Report #B0094941A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastritis		Zyban	PS	Glaxo Wellcome	
UNKNOWN	1 MON					
Initial or Prolonged	Haematemesis					
	Rectal Haemorrhage					

Date:01/22/01ISR Number: 3651476-9Report Type:Expedited (15-DaCompany Report #D0013322A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dry Mouth		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
Initial or Prolonged	Obstructive Airways					
per day 1 DAY						
Other	Disorder					
	Panic Disorder					
	Tachycardia					
	Tongue Oedema					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/01ISR Number: 3652089-5Report Type:Direct Company Report #
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatitis Toxic Epidermal Necrolysis		Wellbutrin Sr 150mg Glaxowellcome	PS	Glaxowellcome	ORAL	150MG B.I.D.	ORAL

Date:01/22/01ISR Number: 3652380-2Report Type:Expedited (15-DaCompany Report #A0137073A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	

Date:01/22/01ISR Number: 3652383-8Report Type:Expedited (15-DaCompany Report #B0093922A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intervertebral Disc Protrusion Sciatica	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG/ORAL	

Date:01/22/01ISR Number: 3652385-1Report Type:Expedited (15-DaCompany Report #B0096058A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

PER DAY/ ORAL

Date:01/22/01ISR Number: 3652387-5Report Type:Expedited (15-DaCompany Report #B0095016A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Foreign	Bupropion					
Hospitalization -	Brain Oedema	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ SEE	
Initial or Prolonged	Cardiac Arrest	Professional					TEXT/ ORAL	
Required	Coma							
Intervention to	Convulsion							
Prevent Permanent	Intentional Misuse							
Impairment/Damage	Suicide Attempt							

Date:01/22/01ISR Number: 3652411-XReport Type:Expedited (15-DaCompany Report #B0095928A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hydrocephalus	Foreign	Bupropion					
Required			Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG (PER	
Intervention to							DAY) ORAL	
Prevent Permanent								
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/01ISR Number: 3652413-3Report Type:Expedited (15-DaCompany Report #A0136900A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Occupational Exposure To Toxic Agent	Study Health Professional						

Date:01/22/01ISR Number: 3652417-0Report Type:Expedited (15-DaCompany Report #B0095172A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Cerebral Infarction Cerebrovascular Accident Urinary Tract Infection	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY), ORAL	
			Beclomethasone Dipropion	C				
			Beclomethasone Dipropion	C				
			Aspirin	C				
			Theophylline	C				
			Amlodipine Besylate	C				

Date:01/22/01ISR Number: 3652419-4Report Type:Expedited (15-DaCompany Report #B0088136A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Asthenia Circulatory Collapse Eye Rolling Headache	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
			Birth Control	C				

Loss Of Consciousness
Pallor
Salivary Hypersecretion
Tonic Convulsion

Date:01/22/01ISR Number: 3652746-0Report Type:Expedited (15-DaCompany Report #B0096062A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Constipation Dermatitis Dermatitis Exfoliative Pruritus	Foreign	Bupropion Hydrochloride Nifedipine Bendrofluazide Nitrazepam Co-Codamol	PS C C C C	Glaxo Wellcome Inc	ORAL	150 MG ORAL

Date:01/22/01ISR Number: 3652747-2Report Type:Expedited (15-DaCompany Report #B0096063A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/01ISR Number: 3652748-4Report Type:Expedited (15-DaCompany Report #D0012242A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hemiparesis	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY)	ORAL
			Iodide Salt	C				
			Zolpidem Tartrate	C				
			Diclofenac	C				
			Birth Control	C				

Date:01/22/01ISR Number: 3652749-6Report Type:Expedited (15-DaCompany Report #A0137061A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT,	ORAL
	Sinus Tachycardia							
	Suicide Attempt		Citalopram Hydrobromide Tablet (Citalopram Hydrobromide)	SS		ORAL	SEE TEXT,	ORAL
	Tremor							

Date:01/22/01ISR Number: 3652889-1Report Type:Expedited (15-DaCompany Report #A0126045A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Epilepsy	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / AT NIGHT / ORAL	
	Sudden Death							
			Carbamazepine	C				
			Sertraline					

Hydrochloride	C
Methylphenidate Hcl	C

Date:01/22/01ISR Number: 3652891-XReport Type:Expedited (15-DaCompany Report #A0134853A
Age:27 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Adhesions
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain
	Anaemia
	Anorexia
	Anxiety
	Back Pain
	Chest Discomfort
	Chest Pain
	Cough
	Crying
	Cystitis
	Diarrhoea
	Drug Toxicity
	Dyspnoea
	Fatigue
	Feeling Jittery
	Fistula
	Flatulence
	Headache

	Hypoaesthesia Hysterectomy Insomnia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Malaise	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /
	Metastases To Lymph Nodes	Professional					THREE TIMES
	Nervousness						PER DAY /
	Neutropenia						ORAL
	Night Sweats		Triphasil	C			
	Orthostatic Hypotension		Hypericum	C			
	Overdose		Multivitamin	C			
	Palpitations						
	Paraesthesia						
	Post Coital Bleeding						
	Pyrexia						
	Rhinitis						
	Sinus Tachycardia						
	Squamous Cell Carcinoma Of The Cervix						
	Thyroxine Increased						
	Upper Respiratory Tract Infection						
	Vaginal Haemorrhage						
	Vomiting						
	Weight Decreased						

Date:01/22/01ISR Number: 3652981-1Report Type:Expedited (15-DaCompany Report #A0131639A
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Hyperkalaemia	Health	Zantac 150	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER
Initial or Prolonged	Intestinal Ischaemia	Professional					DAY/ORAL
	Megaloblasts Increased		Zyban Tablet - Zyban (Bupropion Hydrochloride)	SS		ORAL	150 MG/PER
	Rectal Haemorrhage						DAY/ORAL

			Theophylline	C		
			Multivitamin	C		

Date:01/23/01ISR Number: 3652286-9Report Type:Expedited (15-DaCompany Report #A0137018A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Health Professional	Wellbutrin	PS	Glaxo Wellcome		
			Ephedra	SS			

Date:01/24/01ISR Number: 3653401-3Report Type:Expedited (15-DaCompany Report #A0137270A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	

Date:01/24/01ISR Number: 3653418-9Report Type:Expedited (15-DaCompany Report #B0095925A
Age:38 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Fluctuation						per day	16 DAY
	Chest Pain							
	Condition Aggravated							
	Dyspnoea							
	Oedema							
	Rash Maculo-Papular							

Date:01/24/01ISR Number: 3653423-2Report Type:Expedited (15-DaCompany Report #D0013329A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression		Zyban	PS	Glaxo Wellcome	ORAL	300MG per day	17 DAY
Hospitalization - Initial or Prolonged	Suicide Attempt							

Date:01/25/01ISR Number: 3654005-9Report Type:Expedited (15-DaCompany Report #B0096116A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	4 DAY
Other	Ear Pain		Ovysmen	C		ORAL		
	Headache							
	Panic Attack							
	Photophobia							

Date:01/25/01ISR Number: 3654007-2Report Type:Expedited (15-DaCompany Report #B0096573A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Epistaxis International Normalised Ratio Increased		Zyban	PS	Glaxo Wellcome	ORAL
			Bezafibrate	C		
			Indapamide	C		
			Aspirin	C		
			Bisoprolol	C		
			Lisinopril	C		
			Digoxin	C	Glaxo Wellcome	
			Allopurinol	C	Glaxo Wellcome	
			Warfarin	C	Glaxo Wellcome	

Date:01/25/01ISR Number: 3654009-6Report Type:Expedited (15-DaCompany Report #B0096574A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	5 DAY
	Dizziness		Evening Primrose Oil	C				
	Sedation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/01ISR Number: 3655712-4Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Atrial Fibrillation Blood Magnesium Decreased Hypocalcaemia Hypovolaemia Inappropriate Antidiuretic Hormone Secretion		Bupropion (Wellbutrin) 150mg Po Q Day	PS		ORAL	150MG DAILY PO 2 WEEKS PRIOR TO ADMISSION

Date:01/25/01ISR Number: 3655720-3Report Type:Expedited (15-DaCompany Report #A036897
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Amnesia Blood Pressure Decreased	Consumer Health	Procardia Xl	PS	Pfizer Laboratories Div Pfizer Inc	ORAL	ORAL
	Pneumonia Sedation Speech Disorder Toxicologic Test Abnormal	Professional	Bupropion Gabapentin Atenolol	SS SS SS		ORAL	300.00 MG TOTAL:BID:ORAL

Date:01/25/01ISR Number: 3655726-4Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Agitation Disturbance In Attention Feeling Jittery		Prozac 20mg Eli Lilly Wellbutrin Sr 100mg	PS	Eli Lilly	ORAL	40MG DAY ORAL

	Hypoaesthesia		Glaxo-Wellcome	SS	Glaxo-Wellcome	ORAL 100MG DAY
	Intervertebral Disc Disorder		Xanax	C		ORAL
	Muscle Rigidity		Minocycline	C		
	Muscle Spasms					
	Sensory Disturbance					

Date:01/25/01ISR Number: 3655735-5Report Type:Direct Company Report #
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Depression Intentional Misuse		Wellbutrin / Glaxowelcome	PS	Glaxowelcome	ORAL EVERYDAY ORAL

Date:01/25/01ISR Number: 3655782-3Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Pruritus Urticaria	Consumer	Wellbutrin	PS		ORAL 75 MG DAILY ORAL
			Yellow #5/#6	SS		ORAL 75 MG TWICE DAILY ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/01ISR Number: 3656344-4Report Type:Expedited (15-DaCompany Report #B0095557A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dermographism Urticaria Papular	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:01/25/01ISR Number: 3656356-0Report Type:Expedited (15-DaCompany Report #A0133472A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Asthma Convulsion Decreased Appetite Ecchymosis Fall Fatigue Fear Feeling Abnormal Flashback Injury Insomnia Nausea Nervousness Oedema Peripheral Speech Disorder Tremor	Foreign Consumer	Bupropion Hydrochloride Salmeterol + Fluticasone Salbutamol Sulphate	PS C C	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	

Date:01/25/01ISR Number: 3656357-2Report Type:Expedited (15-DaCompany Report #B0096064A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Agitation	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	
	Anxiety							
	Chest Pain							
	Confusional State							
	Depression		Ethanol	C				
	Disturbance In Attention		Zopiclone	C				
	Dysuria		Oxazepam	C				
	Hallucination		Naproxen	C				
	Hyperhidrosis							
	Insomnia							
	Nausea							
	Pyrexia							
	Rash Psoriaform							
	Tremor							
	Vertigo							
	Visual Disturbance							

Date:01/25/01ISR Number: 3656358-4Report Type:Expedited (15-DaCompany Report #B0096213A
Age:62 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Dizziness							
	Fall		Paroxetine	C				
	Feeling Abnormal		Thioridazine	C				
	Gamma-Glutamyltransferase Increased		Oestrone	C				
	Loss Of Consciousness							
	Macrocytosis							
	Spinal Compression Fracture							

Date:01/25/01ISR Number: 3656359-6Report Type:Expedited (15-DaCompany Report #B0096199A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angina Pectoris	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	
	Bronchospasm							
	Dyspnoea		Simvastatin	C				
			Isosorbide	C				
			Atenolol	C				
			Aspirin	C				

Date:01/25/01ISR Number: 3656360-2Report Type:Expedited (15-DaCompany Report #B0096202A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Confusional State	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY / ORAL	
	Convulsion							
	Difficulty In Walking							
	Dizziness							
	Speech Disorder							

Date:01/25/01ISR Number: 3656362-6Report Type:Expedited (15-DaCompany Report #B0096210A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Glossodynia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Oral Intake Reduced							
	Pharyngitis							
			Allopurinol	C				

Date:01/25/01ISR Number: 3656401-2Report Type:Expedited (15-DaCompany Report #D0013322A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dry Mouth	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Obstructive Airways Disorder							
	Panic Reaction							
	Tachycardia							
	Tongue Oedema							

Date:01/25/01ISR Number: 3656622-9Report Type:Expedited (15-DaCompany Report #B0094941A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Rectal Haemorrhage Vomiting	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc		1	MON

Date:01/26/01ISR Number: 3655075-4Report Type:Expedited (15-DaCompany Report #B0095016A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged Other	Brain Oedema Cardiac Arrest Convulsion Encephalopathy Hallucination Hepatic Failure Overdose Suicide Attempt	Health Professional	Zyban	PS	Glaxo Wellcome	ORAL	10.5G per day	18 DAY

Date:01/26/01ISR Number: 3655081-XReport Type:Expedited (15-DaCompany Report #B0096570A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatine Phosphokinase Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG	
	Dizziness Dyspnoea Myalgia		Rabeprazole Salbutamol	C C	Glaxo Wellcome	ORAL	Variable dose	16 DAY

Date:01/26/01ISR Number: 3655082-1Report Type:Expedited (15-DaCompany Report #B0096577A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Depression							
							per day	57 DAY
	Hypothyroidism		Dydrogesterone	C		ORAL		
	Lethargy							
	Mood Swings							
	Skin Nodule							
	Weight Increased							

Date:01/26/01ISR Number: 3655084-5Report Type:Expedited (15-DaCompany Report #B0096694A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Consumer	Zyban	PS	Glaxo Wellcome		150MG As	
Initial or Prolonged	Blood Pressure Decreased						directed	
	Drug Interaction		Deptran	I				
	Face Oedema							
	Paralysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/01ISR Number: 3655122-XReport Type:Expedited (15-DaCompany Report #A0136520A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			
	Haemorrhage	Professional	Quinidine	SS				
	Intentional Misuse	Company	Diphenhydramine Hcl	SS				
	Ovarian Cyst	Representative	Ethanol	SS				

Date:01/26/01ISR Number: 3655785-9Report Type:Direct Company Report #
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Skin Discolouration		Wellbutrin (150mg)	PS		ORAL	150MG QD PO	

Date:01/29/01ISR Number: 3655880-4Report Type:Expedited (15-DaCompany Report #B0096583A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Vision Blurred		Timolol	C		OPHTHALMIC		
			Diltiazem	C		ORAL		
			Dorzolamide Hydrochloride	C		OPHTHALMIC		
			Warfarin	C	Glaxo Wellcome	ORAL		
			Gtn	C	Glaxo Wellcome			

Date:01/29/01ISR Number: 3655881-6Report Type:Expedited (15-DaCompany Report #B0096688A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Blister						per day	12 DAY
	Ecchymosis							
	Pruritus							

Date:01/29/01ISR Number: 3656432-2Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Poisoning		Wellbutrin 300 Mg	PS			QD	
	Grand Mal Convulsion							

Date:01/29/01ISR Number: 3656433-4Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin 75 Mg	PS			1-AM	
	Loss Of Consciousness		Prozac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/01ISR Number: 3656533-9Report Type:Expedited (15-DaCompany Report #A0137018A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Health Professional	Wellbutrin Ma-Huang	PS SS	Glaxo Wellcome Inc		

Date:01/29/01ISR Number: 3656726-0Report Type:Expedited (15-DaCompany Report #HQ6358124JAN2001
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Agitation Confusional State Convulsion Coordination Abnormal	Health Professional Other	Advil	PS	Whitehall Laboratories Inc Div American Home Products Corp	ORAL	ORAL
	Hallucination Intentional Misuse Tremor		Zyban (Amfebutamone Hydrochloride)	SS		ORAL	9 GRAMS, ORAL 1 DAY

Date:01/29/01ISR Number: 3656764-8Report Type:Expedited (15-DaCompany Report #B0095016A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Arrhythmia Brain Oedema Cardiac Arrest Coma Completed Suicide Convulsion Encephalopathy Hallucination Hepatic Failure Intracranial Pressure Increased Overdose	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK / ORAL

Date:01/29/01ISR Number: 3656771-5Report Type:Expedited (15-DaCompany Report #B0096694A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Blood Pressure Decreased Drug Interaction Face Oedema Paralysis	Foreign Consumer	Bupropion Hydrochloride Deptran Tablet (Deptran)	PS SS	Glaxo Wellcome Inc		150 MG / AS DIRECTED / UNKNOWN UNK / AS REQUIRED / UNKNOWN	

Date:01/29/01ISR Number: 3656772-7Report Type:Expedited (15-DaCompany Report #B0096577A
Age:39 YR Gender:Female I/FU:I

Outcome	PT
Required Intervention to Prevent Permanent Impairment/Damage	Constipation Depression Hypothyroidism Lethargy Mean Cell Volume

	Increased Mood Swings Skin Nodule Tearfulness	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Weight Increased	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL						
			Dydrogesterone	C		

Date:01/29/01ISR Number: 3656774-0Report Type:Expedited (15-DaCompany Report #B0096570A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Creatine Phosphokinase Increased	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG / VARIABLE DOSE / ORAL	Dizziness Dyspnoea Myalgia		Sodium Rabeprazole Salbutamol Sulphate	C C		

Date:01/30/01ISR Number: 3656821-6Report Type:Expedited (15-DaCompany Report #B0094589A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Upper		Zyban	PS	Glaxo Wellcome	ORAL
2TAB Per day 5 DAY						
	Arthralgia		Losec	C		ORAL
10MG Per day						
	Chest Pain		Vioxx	C		ORAL
12.5MG Twice per day	Cold Sweat					
	Dizziness		Clarityn	C		ORAL
10MG Per day						

	Dry Mouth		Paracetamol	C		ORAL
	Dry Throat					
	Gastrointestinal Ulcer					
	Heart Rate Increased					
	Hyperhidrosis					
	Myalgia					
	Nausea					
	Vision Blurred					

Date:01/30/01ISR Number: 3656832-0Report Type:Expedited (15-DaCompany Report #B0096539A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Eyelid Oedema		Bupropion			
	Nausea		Hydrochloride	PS	Glaxo Wellcome	ORAL
150MG Per day 2 DAY						
	Throat Irritation					

Date:01/30/01ISR Number: 3656842-3Report Type:Expedited (15-DaCompany Report #B0096982A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Nail Disorder		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
Other	Rash Generalised					
per day						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/01ISR Number: 3656843-5Report Type:Expedited (15-DaCompany Report #B0096984A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	14	DAY
			Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	100MCG Per day	

Date:01/30/01ISR Number: 3657360-9Report Type:Direct Company Report #
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin	PS		ORAL	100 MG PO BID	
			Haloperidol	C				
			Ddavp	C				

Date:01/30/01ISR Number: 3657931-XReport Type:Expedited (15-DaCompany Report #2001041398GB
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Foreign	Motrin	PS	Mcneil Consumer Healthcare	ORAL	9 G.	
	Confusional State	Health				ORAL		
	Convulsion	Professional	Bupropion(Amfebutamone)	SS				
	Coordination Abnormal	Other						
	Hallucination							
	Intentional Misuse							
	Tremor							

Date:01/30/01ISR Number: 3658639-7Report Type:Expedited (15-DaCompany Report #B0096116A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Foreign	Bupropion					
Required	Ear Pain	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
Intervention to	Headache	Professional					DAY/ORAL	
Prevent Permanent	Panic Attack		Ovysmen	C				
Impairment/Damage	Photophobia							

Date:01/30/01ISR Number: 3658641-5Report Type:Expedited (15-DaCompany Report #B0096573A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Epistaxis	Foreign	Bupropion					
Initial or Prolonged	International Normalised		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Ratio Increased		Bezafibrate	C				
			Indapamide	C				
			Aspirin	C				
			Bisoprolol	C				
			Lisinopril	C				
			Digoxin	C				
			Allopurinol	C				
			Warfarin Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/01ISR Number: 3658649-XReport Type:Expedited (15-DaCompany Report #B0096574A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY,ORAL	
	Dizziness							
	Sedation							
			Evening Primrose Oil	C				

Date:01/30/01ISR Number: 3659181-XReport Type:Expedited (15-DaCompany Report #A0137270A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
		Health Professional						

Date:01/30/01ISR Number: 3659824-0Report Type:Expedited (15-DaCompany Report #D0013329A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Depression Suicide Attempt	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	UNK / UNK / ORAL	

Date:01/30/01ISR Number: 3659825-2Report Type:Expedited (15-DaCompany Report #B0095925A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Blood Pressure Abnormal Chest Pain	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

Initial or Prolonged	Dyspnoea					
TWICE PER DAY						
	Oedema					
/ ORAL						
	Rash Maculo-Papular					

Date:01/31/01ISR Number: 3657619-5Report Type:Expedited (15-DaCompany Report #A0137597A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gingivitis		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Jaw Disorder							

Date:01/31/01ISR Number: 3657623-7Report Type:Expedited (15-DaCompany Report #A0138130A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Anger							
per day							4	DAY
	Angina Pectoris		Nefazodone	C				
	Blood Pressure Increased							
	Cyanosis							
	Skin Discolouration							
	Speech Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/01ISR Number: 3657624-9Report Type:Expedited (15-DaCompany Report #A0138288A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disturbance In Attention		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Headache						per day	12 WK
	Irritability							
	Malaise							
	Mood Swings							
	Sleep Disorder							
	Thyroid Function Test Abnormal							

Date:01/31/01ISR Number: 3657650-XReport Type:Expedited (15-DaCompany Report #B0097007A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased		Zyban	PS	Glaxo Wellcome			
	Erysipelas							
	Hypersensitivity							
	Streptococcal Infection							

Date:01/31/01ISR Number: 3657651-1Report Type:Expedited (15-DaCompany Report #B0097054A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression		Zyban	PS	Glaxo Wellcome		14 DAY	
	Insomnia		Singulair	C		ORAL	10MG Per day	
	Sensory Loss		Theophylline	C		ORAL	600MG per day	
	Subarachnoid Haemorrhage		Salmeterol	C	Glaxo Wellcome		INTRA-ARTICULAR	50NG per day
			Flutide	C	Glaxo Wellcome		RESPIRATORY	

(INHALATION) 1MG per day

			Atrovent	C	Glaxo Wellcome
			Ventolin	C	Glaxo Wellcome

Date:01/31/01ISR Number: 3657652-3Report Type:Expedited (15-DaCompany Report #B0097265A
Age:50 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome		UNKNOWN	
Hospitalization - Initial or Prolonged	Chest Pain							

Date:01/31/01ISR Number: 3658029-7Report Type:Periodic Company Report #C2000-0781.01
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Consumer	Metoprolol Tartrate	PS	Mylan Pharmaceuticals Inc	ORAL	12.5 MG BID	
	Haematuria							
	Oliguria						ORAL	
	Pollakiuria		Wellbutrin Glaxo Wellcome	SS	Glaxo Wellcome	ORAL	100 MG QD	
	Prostatitis						ORAL	
			Triameterene/Hctz	C				
			Atorvastatin	C				
			Enalapril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/01ISR Number: 3658131-XReport Type:Periodic Company Report #A0122448A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism	Health Professional Other	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
			Clozapine (Formulation Unknown) (Clozapine)	SS				
			Oral Contraceptive	C				
			Lithium Salt	C				
			Clonazepam	C				
			Thyroxine Sodium	C				

Date:01/31/01ISR Number: 3658132-1Report Type:Periodic Company Report #A0117336A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cognitive Disorder Depersonalisation Depressed Level Of Consciousness	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:01/31/01ISR Number: 3658133-3Report Type:Periodic Company Report #A0113556A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:01/31/01ISR Number: 3658134-5Report Type:Periodic Company Report #A0111402A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
ORAL						
		Professional				
		Company				
		Representative				

Date:01/31/01ISR Number: 3658135-7Report Type:Periodic Company Report #A0111156A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Loss Of Consciousness	Professional				
TWICE PER DAY						
		Company				
/ ORAL						
		Representative	Oral Contraceptive	C		
			Vitamin	C		

Date:01/31/01ISR Number: 3658136-9Report Type:Periodic Company Report #A0110920A
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Grand Mal Convulsion	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
ORAL						
Initial or Prolonged		Professional	Venlafaxine			
		Other	Hydrochloride			
			(Venlafaxine			
			Hydrochloride)	SS		ORAL
150 MG /						

TWICE PER DAY

/ ORAL

Date:01/31/01ISR Number: 3658137-0Report Type:Periodic Company Report #A0129999A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health Professional Other	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Bipolar Disorder		Risperidone (Risperidone)	SS		ORAL	ORAL	
	Crying		Human Insulin	C				
	Delusion		Alendronate Sodium	C				
	Depression		Aspirin	C				
	Disturbance In Attention		Multivitamin	C				
	Elevated Mood		Paracetamol	C				
	Fatigue		Ibuprofen	C				
	Ideas Of Reference		Carmellose Sodium	C				
	Insomnia							
	Logorrhoea							
	Mania							
	Pressure Of Speech							
	Psychomotor Hyperactivity							
	Psychotic Disorder							
	Suicidal Ideation							
	Thinking Abnormal							

Date:01/31/01ISR Number: 3658138-2Report Type:Periodic Company Report #A0128383A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	1 TABLET /	
	Convulsion						THREE TIMES	
	Drug Interaction						PER ORAL	
	Electroencephalogram Abnormal		Amitriptyline Hcl Tablet					

	Hypoglycaemia		(Amitriptyline Hcl)	SS		ORAL
ORAL						
	Loss Of Consciousness					

Date:01/31/01ISR Number: 3658139-4Report Type:Periodic Company Report #A0127311A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Convulsion	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
ORAL						
Initial or Prolonged		Professional Company Representative	Tramadol Hydrochloride	C		

Date:01/31/01ISR Number: 3658140-0Report Type:Periodic Company Report #A0127100A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dermatitis	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
ORAL						
Initial or Prolonged	Face Oedema	Professional				
	Pruritus					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/01ISR Number: 3658141-2Report Type:Periodic Company Report #A0109620A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Overdose Suicide Attempt	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc			

Date:01/31/01ISR Number: 3658142-4Report Type:Periodic Company Report #A0108729A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension Abdominal Pain Convulsion Crying Decreased Appetite Depression Dermatitis Dyspnoea Fatigue Headache Insomnia Mental Disorder Nausea Palpitations Photosensitivity Reaction Pruritus Tremor Urinary Retention Urticaria Weight Decreased	Consumer	Wellbutrin Leuprorelin Acetate Injection (Leuprolide Acetate) Loratadine	PS SS C	Glaxo Wellcome Inc	ORAL	100 MG/ TWICE PER DAY/ 3.75 MG	

Date:01/31/01ISR Number: 3658143-6Report Type:Periodic Company Report #A0106624A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Amnesia	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc
	Convulsion				
	Loss Of Consciousness				

Date:01/31/01ISR Number: 3658519-7Report Type:Periodic Company Report #A0126047A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	75 MG/ TWICE	
	Confusional State	Professional					PER DAY/ ORAL	
	Convulsion							
	Dizziness							
	Fall							
	Muscle Rigidity							
	Tongue Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/01ISR Number: 3658521-5Report Type:Periodic Company Report #A0126044A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Injury	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	75 MG/ SEE TEXT/	ORAL
	Convulsion							
	Deja Vu		Clonazepam (Formulation Unknown)					
	Difficulty In Walking							
	Hallucination, Olfactory							
	Injury		(Clonazepam)	SS			.5 MG/ AS	
	Insomnia						REQUIRED	
	Loss Of Consciousness		Lithium Salt	C				
	Pain							
	Road Traffic Accident							

Date:01/31/01ISR Number: 3658523-9Report Type:Periodic Company Report #A0125633A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	100 MG/ THREE TIMES PER	
		Company					DAY/ ORAL	
		Representative	Ethanol (Formulation Unknown) (Alcohol)	SS				
			Combivent	C				

Date:01/31/01ISR Number: 3658525-2Report Type:Periodic Company Report #A0124191A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
			Sertraline					

Hydrochloride	C
Carbamazepine	C

Date:01/31/01ISR Number: 3658527-6Report Type:Periodic Company Report #A0123986A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	250 MG/ PER DAY/ ORAL	2 MON

Date:01/31/01ISR Number: 3658529-XReport Type:Periodic Company Report #A0108252A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Grand Mal Convulsion	Professional						
	Loss Of Consciousness	Company						
	Mouth Haemorrhage	Representative						
	Muscle Twitching							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/01ISR Number: 3658530-6Report Type:Periodic Company Report #A0102483A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	450 MG/ PER	
Other	Epileptic Aura	Professional					DAY/ ORAL	
	Loss Of Consciousness	Company	Aurothioglucose	C				
	Road Traffic Accident	Representative	Oxaprozin	C				
			Prednisone	C				
			Famotidine	C				

Date:02/01/01ISR Number: 3660626-XReport Type:Expedited (15-DaCompany Report #B0096688A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Asthenia	Foreign	Bupropion					
Intervention to	Blister		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
Prevent Permanent	Ecchymosis						PER DAY/ORAL	
Impairment/Damage	Pruritus							

Date:02/01/01ISR Number: 3660741-0Report Type:Expedited (15-DaCompany Report #B0096583A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Eye Pain	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Intervention to	Vision Blurred						TWICE PER DAY	
Prevent Permanent							/ ORAL	
Impairment/Damage			Timolol	C				
			Diltiazem	C				
			Dorzolamide Hcl	C				
			Warfarin Sodium	C				
			Nitroglycerin	C				

Date:02/02/01ISR Number: 3658981-XReport Type:Expedited (15-DaCompany Report #A0130601A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arthralgia Blindness Unilateral Brain Hypoxia Cardiac Arrest Cerebrovascular Accident Coma Convulsion Dermatitis Dyspnoea Haemorrhage Lymphadenopathy Medication Error Sarcoidosis		Zyban No Concurrent Medications	PS C	Glaxo Wellcome	ORAL	150MG Twice per day	2 WK

Date:02/02/01ISR Number: 3658983-3Report Type:Expedited (15-DaCompany Report #A0132722A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocarditis		Zyban Depoprovera	PS SS	Glaxo Wellcome	ORAL INTRAMUSCULAR	150MG Twice per day 150MG See	

text

Alfalfa	C		ORAL
Calcium	C		ORAL
Activated Charcoal	C		
Kelp	C		ORAL
Potassium	C		ORAL
Vitamin C With Rose Hips	C		

MON

Antacid	C		ORAL
Herbal Multivitamin	C		ORAL

Date:02/02/01ISR Number: 3658984-5Report Type:Expedited (15-DaCompany Report #A0135962A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Nervous System Disorder Sarcoidosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	2 WK

Date:02/02/01ISR Number: 3658986-9Report Type:Expedited (15-DaCompany Report #A0136852A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Keratitis Keratoconjunctivitis Sicca Peripheral Nerve Injury		Zyban	PS	Glaxo Wellcome	ORAL	1	MON

Date:02/02/01ISR Number: 3658989-4Report Type:Expedited (15-DaCompany Report #A0138368A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Twice	

Initial or Prolonged per day 6 MON	Condition Aggravated					
	Drug Abuser		Marijuana	SS		
	Drug Interaction		No Concurrent Medications	C		
	Glycosuria					
	Syncope					

Date:02/02/01ISR Number: 3659028-1Report Type:Expedited (15-DaCompany Report #A0129782A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	2250MG Single	
Initial or Prolonged	Intentional Misuse							
dose								1 DAY
			Zyban	SS	Glaxo Wellcome	ORAL	150MG Per day	2 WK
			Prenatal Vitamins	C				
			Marijuana	C				1 DAY

Date:02/02/01ISR Number: 3659035-9Report Type:Expedited (15-DaCompany Report #A0138561A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dementia		Wellbutrin Sr	PS	Glaxo Wellcome			
	Memory Impairment		Celexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/01ISR Number: 3659037-2Report Type:Expedited (15-DaCompany Report #B0084724A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	3 WK
Disability	Blood Pressure Fluctuation		Allopurinol	C	Glaxo Wellcome		300MG Per day	8 YR
Other	Dermatitis Exfoliative Drug Hypersensitivity Eosinophilia Erythema Pigmentation Disorder Psoriasis Rash Erythematous Skin Inflammation Viral Infection							

Date:02/02/01ISR Number: 3659042-6Report Type:Expedited (15-DaCompany Report #B0096692A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pyrexia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Vasculitis		Magnyl	C				

Date:02/02/01ISR Number: 3659046-3Report Type:Expedited (15-DaCompany Report #B0097051A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	International Normalised Ratio Increased		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Memory Impairment		Frusemide	C		ORAL	40MG per day	
			Warfarin	I	Glaxo Wellcome	ORAL	5MG per day	

Date:02/02/01ISR Number: 3659047-5Report Type:Expedited (15-DaCompany Report #B0097436A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	12 DAY
	Dysphagia							

Date:02/02/01ISR Number: 3659048-7Report Type:Expedited (15-DaCompany Report #B0097575A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	17 DAY
Initial or Prolonged	Constipation		Isosorbide	C		ORAL	40MG per day	
			Atenolol	C		ORAL	50MG per day	
			Nifedipine	C		ORAL	30MG per day	
			Simvastatin	C		ORAL	10MG per day	
			Lansoprazole	C		ORAL	15MG per day	
			Aspirin	C		ORAL	75MG per day	
			Gaviscon	C		ORAL		
			Glyceryl Trinitrate	C	Glaxo Wellcome			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/01ISR Number: 3659049-9Report Type:Expedited (15-DaCompany Report #B0097832A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lower Respiratory Tract Infection		Zyban	PS	Glaxo Wellcome			

Date:02/02/01ISR Number: 3660218-2Report Type:Expedited (15-DaCompany Report #B0096984A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Psoriasis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
			Beclomethasone Dipropion.	C				

Date:02/02/01ISR Number: 3660219-4Report Type:Expedited (15-DaCompany Report #B0096539A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Eyelid Oedema Nausea	Foreign Study Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

Date:02/02/01ISR Number: 3660249-2Report Type:Expedited (15-DaCompany Report #B0096982A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nail Disorder	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Required	Rash Generalised						TWICE PER DAY	

Intervention to
/ ORAL
Prevent Permanent
Impairment/Damage

Date:02/02/01ISR Number: 3660258-3Report Type:Direct Company Report #
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Wellbutrin	PS				
	Arthralgia							
	Dermatitis Bullous							
	Malaise							
	Pruritus							
	Urticaria							

Date:02/02/01ISR Number: 3660261-3Report Type:Direct Company Report #
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS		ORAL	PO	
	Paraesthesia							
	Periorbital Oedema							
	Pharyngeal Oedema							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/01ISR Number: 3660399-0Report Type:Expedited (15-DaCompany Report #B0094589A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	2 TABLET /	
	Arthralgia	Health					PER DAY /	
	Blood Pressure Increased	Professional					ORAL	
	Chest Pain		Omeprazole	C				
	Cold Sweat		Rofecoxib	C				
	Dizziness		Loratadine	C				
	Dry Mouth		Paracetamol	C				
	Dry Throat							
	Feeling Hot And Cold							
	Heart Rate Increased							
	Myalgia							
	Nausea							
	Ulcer							
	Vision Blurred							

Date:02/05/01ISR Number: 3659239-5Report Type:Expedited (15-DaCompany Report #B0097367A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	18 DAY
	Panic Attack							
	Tremor							

Date:02/05/01ISR Number: 3659240-1Report Type:Expedited (15-DaCompany Report #B0097417A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Pruritus							
per day	42 DAY							

	Skin Disorder	Fluconazole	C		ORAL
50MG Per day					
	Sleep Disorder	Nystatin	C		
	Sleep Talking	Prednisolone	C		
1TAB As					
required					
		Nitrazepam	C		
10MG At night					
		Beclomethasone	C	Glaxo Wellcome	
800MCG Twice					
per day					
		Co-Trimoxazole	C	Glaxo Wellcome	
480MG Twice					
per day					
		Combivent	C		
RESPIRATORY					
(INHALATION)	200MCG Four				
times per day					
		Salbutamol	C	Glaxo Wellcome	
1NEB As					
required					
		Amitriptyline Hydrochloride	C	Glaxo Wellcome	
25MG Three					
times per day					
		Ranitidine	C	Glaxo Wellcome	
150MG Twice					
per day					
		Co-Proxamol	C		
		Ointment	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/01ISR Number: 3659241-3Report Type:Expedited (15-DaCompany Report #B0097573A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Influenza Like Illness		Zyban	PS	Glaxo Wellcome	ORAL	19	DAY
	Mouth Ulceration		Atenolol	C		ORAL	100MG	Per day
	Oedema Peripheral		Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG	Per day
	Rash Generalised		Aspirin	C		ORAL	75MG	Per day

Date:02/05/01ISR Number: 3661253-0Report Type:Expedited (15-DaCompany Report #A0135962A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nervous System Disorder Post Procedural Haemorrhage Respiratory Disorder Sarcoidosis	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/05/01ISR Number: 3661257-8Report Type:Expedited (15-DaCompany Report #A0130601A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arthralgia Blindness Unilateral Brain Damage Cardiac Arrest Cerebrovascular Accident Chest Pain Chest X-Ray Abnormal	Literature Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

	Coma					
	Convulsion					
	Dermatitis					
	Dyspnoea					
	Haemorrhage					
	Headache					
	Hemiplegia					
	Lung Infiltration					
	Lymphadenopathy					
	Nervous System Disorder					
	Respiratory Arrest					

Date:02/05/01ISR Number: 3661276-1Report Type:Expedited (15-DaCompany Report #A0136852A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Disorder	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Eye Pain							
	Keratitis							
	Keratoconjunctivitis							
	Sicca							
	Sensory Loss							
	Viral Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/01ISR Number: 3661279-7Report Type:Expedited (15-DaCompany Report #A0138368A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG / TWICER PER DAY / ORAL	
	Disturbance In Social Behaviour	Professional						
	Drug Interaction		Cannabis	SS				
	Movement Disorder							
	Syncope							

Date:02/05/01ISR Number: 3661524-8Report Type:Expedited (15-DaCompany Report #A0138130A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	4 DAY
	Anger	Professional						
	Angina Pectoris		Nefazodone Hydrochloride	C				
	Blood Pressure Increased							
	Cyanosis							
	Speech Disorder							

Date:02/05/01ISR Number: 3661525-XReport Type:Expedited (15-DaCompany Report #A0137597A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Disorder	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Gingivitis							

Date:02/05/01ISR Number: 3662664-XReport Type:Expedited (15-DaCompany Report #B0097265A
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:02/05/01ISR Number: 3662688-2Report Type:Expedited (15-DaCompany Report #B0097054A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Headache Insomnia Motor Dysfunction Nausea Subarachnoid Haemorrhage	Foreign	Zyban Montelukast Sodium Theophylline Salmeterol Xinafoate Fluticasone Propionate Ipratropium Bromide Salbutamol Sulphate	PS C C C C C C	Glaxo Wellcome Inc		150 MG	14 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/01ISR Number: 3662690-0Report Type:Expedited (15-DaCompany Report #B0097007A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased Erysipelas Hypersensitivity Joint Swelling Pharyngitis Streptococcal Pyrexia Rash Pruritic	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	

Date:02/05/01ISR Number: 3662693-6Report Type:Expedited (15-DaCompany Report #A0138288A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypothyroidism	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY /	ORAL 12 WK

Date:02/05/01ISR Number: 3663077-7Report Type:Expedited (15-DaCompany Report #A0132722A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocarditis	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL
			Medroxyprogesterone (Medroxyprogesterone Ace.)	SS		INTRAMUSCULAR	150 MG/ SEE TEXT/	

INTRAMUSCULAR

Alfalfa	C
Calcium Salt	C
Activated Charcoal	C
Kelp	C
Potassium Salt	C
Ascorbic Acid + Rose Hips	C
Antacid	C
Herbal Vitamins	C

Date:02/06/01ISR Number: 3660025-0Report Type:Expedited (15-DaCompany Report #A0128480A
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hip Fracture		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Twice per day	490 DAY
	Liver Function Test Abnormal		Xanax	C		ORAL	.125MG Three times per day	
	Respiratory Failure							
	White Blood Cell Count		Pulmocare	C		OTHER		162 DAY
	Increased		Vicodin	C		ORAL		136 DAY
			Digoxin	C	Glaxo Wellcome	ORAL		181 DAY
			Megace	C		ORAL	40MG Four times per day	161 DAY
			Heparin	C		SUBCUTANEOUS	5000IU Twice per day	185 DAY
			Promod Supplement	C		ORAL		192 DAY

				Zantac	C	Glaxo Wellcome	ORAL 150MG At night
190 DAY							
				Lasix	C		ORAL 20MG Twice per day
102 DAY							
				Kcl	C		ORAL 20MEQ Twice per day
102 DAY							
				Feso4	C		ORAL 107 DAY

Date:02/06/01ISR Number: 3660035-3Report Type:Expedited (15-DaCompany Report #A0138183A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	200MG per day	98 DAY
			Prozac	SS		ORAL		
			Klonopin	SS		ORAL		

Date:02/06/01ISR Number: 3660037-7Report Type:Expedited (15-DaCompany Report #A0138183B
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	200MG per day	98 DAY
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs		Prozac	SS		ORAL		
	Skull Malformation		Klonopin	SS		ORAL		

Date:02/06/01ISR Number: 3660051-1Report Type:Expedited (15-DaCompany Report #B0092315A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aneurysm		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	48 DAY
	Haemorrhagic Stroke							
	Headache							
	Nausea							

Date:02/06/01ISR Number: 3660063-8Report Type:Expedited (15-DaCompany Report #B0097298A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Polydipsia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:02/06/01ISR Number: 3660069-9Report Type:Expedited (15-DaCompany Report #B0097835A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Crohn'S Disease		Zyban	PS	Glaxo Wellcome		UNKNOWN	7 DAY

Date:02/06/01ISR Number: 3660070-5Report Type:Expedited (15-DaCompany Report #B0097960A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/06/01ISR Number: 3660394-1Report Type:Direct Company Report #
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Libido Increased		Bupropion	PS	Teva	ORAL	100MH/BID/ORA	
L								
			Paxil	C				

Date:02/07/01ISR Number: 3660812-9Report Type:Expedited (15-DaCompany Report #A0138544A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	450MG Per day	1 YR
Initial or Prolonged	Drug Interaction		Doxycycline	C				
			Acne Medication	C			TOPICAL	
			Methylphenidate	I			18MG Per day	

Date:02/07/01ISR Number: 3661187-1Report Type:Expedited (15-DaCompany Report #B0098045A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Zyban	PS	Glaxo Wellcome	ORAL		
Initial or Prolonged	Cerebral Ischaemia		Atenolol	C			25MG per day	
	Cerebrovascular Accident		Valsartan	C			160MG per day	
	Condition Aggravated		Pravastatin	C				
	Coordination Abnormal							
	Dysarthria							
	Heart Rate Decreased							
	Hypertension							
	Palpitations							

Date:02/07/01ISR Number: 3662336-1Report Type:Expedited (15-DaCompany Report #HQ6802405FEB2001
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Health Professional Company Representative	Effexor Xr	PS	Wyeth Ayerst Laboratories	ORAL	300 MG DAILY, ORAL	
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride)	SS		ORAL	200 MG DAILY, ORAL	

Date:02/08/01ISR Number: 3661880-0Report Type:Expedited (15-DaCompany Report #A0138421A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY
	Clonic Convulsion							
	Hyperreflexia							
	Hypoaesthesia							
	Muscle Spasms							
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/01ISR Number: 3661882-4Report Type:Expedited (15-DaCompany Report #A0138874A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Disorder		Wellbutrin Sr	PS	Glaxo Wellcome			
			Concurrent Medications	C				

Date:02/08/01ISR Number: 3661892-7Report Type:Expedited (15-DaCompany Report #B0091312A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Per day	4 DAY
	Hypersensitivity							
	Lower Respiratory Tract Infection							
	Respiratory Distress							
	Urticaria							

Date:02/08/01ISR Number: 3662246-XReport Type:Direct Company Report #
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Wellbutrin Sr 150	PS		ORAL	150MG BID PO	
	Dermatitis							

Date:02/08/01ISR Number: 3662312-9Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Purpura		Wellbutrin 100 Mg	PS			100MG -> 150 MG BID	
	Rash Papular							
	Skin Lesion		Colace	C				

	Vasculitis		Remeron	C		
			Synthroid	C		
			Hctz	C		
			Senekot	C		
			Levaquin	C		

Date:02/08/01ISR Number: 3662603-1Report Type:Expedited (15-DaCompany Report #B0092315A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke	Foreign	Bupropion					
	Headache	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Intracranial Aneurysm	Professional					PER DAY/ORAL	
	Nausea							

Date:02/08/01ISR Number: 3662610-9Report Type:Expedited (15-DaCompany Report #B0097960A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign	Bupropion					
		Literature	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/01ISR Number: 3662613-4Report Type:Expedited (15-DaCompany Report #B0097835A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Crohn'S Disease	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		7 DAY

Date:02/08/01ISR Number: 3662636-5Report Type:Expedited (15-DaCompany Report #B0097573A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Influenza Like Illness Mouth Ulceration Oedema Peripheral Rash Generalised	Foreign	Bupropion Hydrochloride Atenolol Bendrofluazide Aspirin	PS C C C	Glaxo Wellcome Inc	ORAL	150 MG ORAL

Date:02/08/01ISR Number: 3662640-7Report Type:Expedited (15-DaCompany Report #B0097417A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hallucination Pruritus Skin Disorder Sleep Disorder Sleep Talking	Foreign Health Professional Other	Zyban Fluconazole Nystatin Prednisolone Nitrazepam Beclomethasone Dipropion Co-Trimoxazole Combivent Salbutamol Sulphate Amitriptyline Hcl Ranitidine Hydrochloride	PS C C C C C C C C C C	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL

			Co-Proxamol	C		
			Ointment	C		

Date:02/08/01ISR Number: 3662641-9Report Type:Expedited (15-DaCompany Report #B0097367A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Headache	Foreign	Bupropion				
	Panic Attack	Study	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER
	Tremor	Health					DAY/ ORAL
		Professional					

Date:02/08/01ISR Number: 3662859-5Report Type:Expedited (15-DaCompany Report #A0128480A
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Hip Fracture	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	100 MG /
Initial or Prolonged	Respiratory Failure	Professional					TWICE PER DAY
	White Blood Cell Count						/ ORAL
	Increased		Alprazolam	C			
			Pulmocare	C			
			Vicodin	C			

			Digoxin	C		
			Megestrol Acetate	C		
			Heparin	C		
			Promod	C		
			Ranitidine	C		
			Frusemide	C		
			Postassium Chloride	C		
			Ferrous Sulfate	C		

Date:02/08/01ISR Number: 3662872-8Report Type:Expedited (15-DaCompany Report #A0138544A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Drug Interaction	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	450 MG/PER DAY/ORAL	1 YR
			Methylphenidate (Formulation Unknown)	SS			18 MG/PER DAY	
			Doxycyline	C				
			Acne Medication	C				

Date:02/08/01ISR Number: 3662874-1Report Type:Expedited (15-DaCompany Report #A0138183A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL SEE TEXT	
		Professional	Fluoxetine Hydrochloride Capsule	SS		ORAL	ORAL	
			Clonazepam	SS		ORAL	ORAL	

Date:02/08/01ISR Number: 3662878-9Report Type:Expedited (15-DaCompany Report #A0138183B
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL SEE TEXT	
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs	Health Professional	Fluoxetine Hydrochloride Capsule	SS		ORAL	ORAL	
	Skull Malformation		Clonazepam Tablet	SS		ORAL	ORAL	

Date:02/09/01ISR Number: 3662612-2Report Type:Expedited (15-DaCompany Report #B0097298A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Polydipsia	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	

Date:02/09/01ISR Number: 3663043-1Report Type:Expedited (15-DaCompany Report #A0130601A
Age:36 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Blindness Unilateral						per day	2 WK
	Brain Damage		No Concurrent					
	Cardiac Arrest		Medications	C				
	Cerebrovascular Accident							
	Chest Pain							
	Coma							
	Convulsion							
	Dermatitis							
	Dyspnoea							
	Haemorrhage							
	Headache							
	Hypoxia							
	Inflammation							
	Lung Infiltration							
	Lymphadenopathy							
	Nervous System Disorder							
	Paralysis							
	Respiratory Arrest							
	Sarcoidosis							

Date:02/09/01ISR Number: 3663049-2Report Type:Expedited (15-DaCompany Report #A0139224A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Per day	26 DAY

Date:02/09/01ISR Number: 3663072-8Report Type:Expedited (15-DaCompany Report #B0098183A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ventricular Fibrillation		Quomem	PS	Glaxo Wellcome	ORAL		

Date:02/09/01ISR Number: 3663073-XReport Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	16 DAY

Date:02/09/01ISR Number: 3663074-1Report Type:Expedited (15-DaCompany Report #B0098198A
Age:55 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	55 DAY
			Perindopril	C		ORAL	2MG Per day	286 DAY
			Metformin	C			500MG Twice per day	258 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/01ISR Number: 3663687-7Report Type:Expedited (15-DaCompany Report #B0084724A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Alopecia Blood Pressure Fluctuation Body Temperature Decreased Dermatitis Exfoliative Drug Hypersensitivity Eosinophilia Rash Erythematous Skin Inflammation Viral Infection	Foreign Health Professional	Zyban Allopurinol	PS C	Glaxo Wellcome Inc	ORAL ORAL	150 MG / TWICE PER DAY	

Date:02/09/01ISR Number: 3663700-7Report Type:Expedited (15-DaCompany Report #B0097051A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	International Normalised Ratio Increased Memory Impairment	Foreign	Wellbutrin Sr Warfarin Sodium (Formulation Unknown) (Warfarin Sodium) Frusemide	PS SS C	Glaxo Wellcome Inc	ORAL ORAL ORAL	150 MG/TWICE PER DAY/ORAL	

Date:02/09/01ISR Number: 3663702-0Report Type:Expedited (15-DaCompany Report #B0096692A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pyrexia	Foreign	Bupropion					

Initial or Prolonged	Vasculitis		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/PER						
DAY/ORAL						
			Magnyl	C		

Date:02/09/01ISR Number: 3663703-2Report Type:Expedited (15-DaCompany Report #B0097832A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bronchospasm	Foreign	Bupropion			
Initial or Prolonged	Dyspnoea		Hydrochloride	PS	Glaxo Wellcome Inc	
150 MG						
	Lower Respiratory Tract Infection					
	Respiratory Depression					

Date:02/09/01ISR Number: 3663719-6Report Type:Expedited (15-DaCompany Report #B0097436A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Asthma	Foreign	Bupropion			
	Dysphagia		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/PER						
DAY/ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/01ISR Number: 3663720-2Report Type:Expedited (15-DaCompany Report #B0097575A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Constipation	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG /PER DAY/ORAL
			Isosorbide	C			
			Atenolol	C			
			Nifedipine	C			
			Simvastatin	C			
			Lansoprazole	C			
			Aspirin	C			
			Gaviscon	C			
			Nitroglycerin	C			

Date:02/09/01ISR Number: 3663841-4Report Type:Expedited (15-DaCompany Report #B0098045A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Brain Stem Ischaemia Condition Aggravated	Foreign Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Heart Rate Decreased Hypertension Palpitations	Professional	Atenolol Valsartan Pravastatin	C C C			

Date:02/09/01ISR Number: 3664410-2Report Type:Expedited (15-DaCompany Report #A0138561A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cognitive Disorder Dementia Disturbance In Attention Memory Impairment	Health Professional Company Representative	Wellbutrin Sr Citalopram Hydrobromide	PS C	Glaxo Wellcome Inc		

Date:02/09/01ISR Number: 3664411-4Report Type:Expedited (15-DaCompany Report #A0129782A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amphetamines Positive Convulsion Electrocardiogram Abnormal Intentional Misuse Suicide Attempt	Health Professional	Bupropion Hydrochloride Prenatal Cannabis	PS C C	Glaxo Wellcome Inc	ORAL ORAL	2250 MG / SINGLE DOSE / ORAL, 150 MG / PER DAY/	

Date:02/12/01ISR Number: 3663328-9Report Type:Expedited (15-DaCompany Report #B0089984A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Condition Aggravated Coronary Artery Occlusion		Bupropion Atenolol + Chlorthalidone Doxazosin	PS C C	Glaxo Wellcome	ORAL ORAL ORAL	150MG Twice per day 2MG per day	5 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/12/01ISR Number: 3663331-9Report Type:Expedited (15-DaCompany Report #B0097894A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenopia		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Per day	15 DAY
	Condition Aggravated							
	Gastrointestinal Candidiasis							
	Insomnia							
	Oral Candidiasis							
	Pharyngolaryngeal Pain							

Date:02/12/01ISR Number: 3664055-4Report Type:Periodic Company Report #HQ9426222DEC1999
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health Professional	Effexor	PS	Wyeth Ayerst Laboratories	ORAL	600 MG	
							OVERDOSE	
							AMOUNT, ORAL	
			Prozac (Fluoxetine Hydrochloride)	SS		ORAL	440 MG	
							OVERDOSE	
							AMOUNT, ORAL	
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	12000 MG	
							OVERDOSE	
							AMOUNT, ORAL	

Date:02/12/01ISR Number: 3664151-1Report Type:Expedited (15-DaCompany Report #A0138874A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Disorder	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc			

Date:02/12/01ISR Number: 3664514-4Report Type:Expedited (15-DaCompany Report #B0091312A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma Hypersensitivity Lower Respiratory Tract Infection Respiratory Distress Urticaria	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY	ORAL

Date:02/12/01ISR Number: 3664516-8Report Type:Expedited (15-DaCompany Report #A0138421A
Age:38 YR Gender:Female I/FU:I

Outcome	PT
Disability	Asthenia Clonic Convulsion Hyperreflexia Hypoaesthesia

	Muscle Spasms						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL

Date:02/13/01ISR Number: 3664546-6Report Type:Expedited (15-DaCompany Report #B0093437A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia Confusional State Depression Dizziness Eating Disorder Hyperhidrosis Tremor Visual Disturbance Vomiting		Zyban	PS	Glaxo Wellcome		3 WK

Date:02/13/01ISR Number: 3664564-8Report Type:Expedited (15-DaCompany Report #B0098045A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome	ORAL	
	Condition Aggravated		Atenolol	C			25MG per day
	Coordination Abnormal		Valsartan	C			160MG per day
	Dysarthria		Pravastatin	C			
	Heart Rate Decreased						
	Palpitations						

Date:02/13/01ISR Number: 3664566-1Report Type:Expedited (15-DaCompany Report #B0098443A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Tremor						per day	
	Visual Disturbance		Eformoterol	C				
			Salbutamol	C	Glaxo Wellcome			
RESPIRATORY								
(INHALATION)								
			Beclomethasone	C	Glaxo Wellcome			
RESPIRATORY								
(INHALATION)								
			Prempak-C	C				
.625MCG Per								
day								

Date:02/13/01ISR Number: 3664567-3Report Type:Expedited (15-DaCompany Report #B0098449A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Left Ventricular Failure						per day	17 DAY
	Tachycardia		Simvastatin	C			20MG per day	
			Pantoprazole	C			40MG per day	
			Digoxin	C	Glaxo Wellcome		125MCG per	
							day	
			Warfarin	C	Glaxo Wellcome		6MG per day	

			Losartan	C			
50MG per day							
			Bumetanide	C			
3MG per day							
			Gtn	C	Glaxo Wellcome		
			Spironolactone	C			
25MG per day							

Date:02/13/01ISR Number: 3664568-5Report Type:Expedited (15-DaCompany Report #D0013784A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Torsade De Pointes		Zyban	PS	Glaxo Wellcome	ORAL	150MG per day	
Life-Threatening	Ventricular Fibrillation		Dynacil	C		ORAL		
			Digimerck	C		ORAL	.1MG per day	

Date:02/13/01ISR Number: 3664569-7Report Type:Expedited (15-DaCompany Report #D0013944A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Convulsion Dizziness Paralysis		Zyban	PS	Glaxo Wellcome	ORAL	5	DAY

Date:02/13/01ISR Number: 3664641-1Report Type:Expedited (15-DaCompany Report #A0139224A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL	

Date:02/13/01ISR Number: 3664730-1Report Type:Direct Company Report #
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Bupropion	PS				

Date:02/13/01ISR Number: 3665171-3Report Type:Expedited (15-DaCompany Report #A0130601A
Age:36 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
Disability	Blindness Unilateral
Required Intervention to Prevent Permanent Impairment/Damage	Cardiac Arrest
	Cerebrovascular Accident
	Chest Pain
	Coma
	Convulsion
	Dermatitis
	Dyspnoea
	Haemorrhage
	Headache
	Hemiplegia
	Hypoxia
	Inflammation
	Lung Infiltration

	Lymphadenopathy Nervous System Disorder Respiratory Arrest	Report Source	Product	Role	Manufacturer	Route Dose Duration
		Literature Health Professional Company Representative	Zyban (Bupropion Hydrochloride)	PS		ORAL 150 MG TWICE PER DAY ORAL

Date:02/13/01ISR Number: 3665225-1Report Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Death	Sudden Death	Foreign	Bupropion Hydrochloride	PS		ORAL 150 MG PER DAY ORAL

Date:02/13/01ISR Number: 3665226-3Report Type:Expedited (15-DaCompany Report #B0098198A
Age:55 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Death	Sudden Death	Foreign	Bupropion Hydrochloride	PS		ORAL 150 MG PER DAY ORAL
			Perindopril	C		
			Metformin	C		

Date:02/13/01ISR Number: 3665233-0Report Type:Expedited (15-DaCompany Report #B0098183A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration

Hospitalization - Initial or Prolonged	Ventricular Fibrillation	Foreign Health Professional	Bupropion Hydrochloride	PS		ORAL 150 MG ORAL

Date:02/14/01ISR Number: 3664783-0Report Type:Expedited (15-DaCompany Report #B0098813A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cutaneous Vasculitis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Pruritus							
	Rash Erythematous							
	Urticaria							

Date:02/14/01ISR Number: 3664784-2Report Type:Expedited (15-DaCompany Report #D0013945A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	16 DAY
	Erythema Multiforme							
	Haemoglobin Decreased		Orelox	C			UNKNOWN	
	Pruritus		Contraceptives	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/01ISR Number: 3666053-3Report Type:Expedited (15-DaCompany Report #HQ7096312FEB2001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional	Effexor	PS		ORAL	75 MG (FREQUENCY UNKNOWN), ORAL	
	Drug Interaction		Wellbutrin - Slow Release (Amfebutamone)	SS		ORAL	100 MG 1X PER 1 DAY, ORAL	
			Thyroxine Sodium (Levothyroxine Sodium)	C				
			Amitriptyline (Amitriptyline)	C				
			Atorvastatin Calcium (Atorvastatin Calcium)	C				
			Lansoprazole (Lansoprazole)	C				
			Aspirin (Acetylsalicylic Acid)	C				
			Oxygen (Oxygen)	C				

Date:02/15/01ISR Number: 3665588-7Report Type:Expedited (15-DaCompany Report #A0138400A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Combivir	PS	Glaxo Wellcome	ORAL	1TAB Twice	

Initial or Prolonged	Chest Pain	Professional				
per day						
	Clostridium Colitis		Wellbutrin	SS	Glaxo Wellcome	ORAL
100MG Twice						
	Condition Aggravated					
per day						
	Gallbladder Disorder		Viramune	SS		ORAL
200MG Twice						
	Leukocytoclastic					
per day						
	Vasculitis		Azithromycin	C		

Date:02/15/01ISR Number: 3665594-2Report Type:Expedited (15-DaCompany Report #A0139732A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cyanosis		Zyban	PS	Glaxo Wellcome	ORAL		
150MG Twice								
Initial or Prolonged	Dermatitis							
per day							7	DAY
	Pharyngeal Oedema							
	Urticaria							

Date:02/15/01ISR Number: 3665595-4Report Type:Expedited (15-DaCompany Report #A0139738A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Optic Neuritis		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL		
2	YR							
	Visual Acuity Reduced		Serzone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/01ISR Number: 3665601-7Report Type:Expedited (15-DaCompany Report #B0088230A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	50TAB Single	
Hospitalization -	Coma	Health						
dose							1	DAY
Initial or Prolonged	Hypotension	Professional	Anadin Extra	SS		ORAL	24TAB Single	
	Intentional Misuse							
dose							1	DAY
	Vomiting							

Date:02/15/01ISR Number: 3665603-0Report Type:Expedited (15-DaCompany Report #B0091526A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Bupropion					
Initial or Prolonged			Hydrochloride	PS	Glaxo Wellcome	ORAL		

Date:02/15/01ISR Number: 3665604-2Report Type:Expedited (15-DaCompany Report #B0091930A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Unevaluable Event		Zyban	PS	Glaxo Wellcome			
Initial or Prolonged								

Date:02/15/01ISR Number: 3665610-8Report Type:Expedited (15-DaCompany Report #B0098808A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Schizophreniform Disorder		Zyban	PS	Glaxo Wellcome			
			Quetiapine	C				

Date:02/15/01ISR Number: 3665611-XReport Type:Expedited (15-DaCompany Report #B0098815A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Tongue Oedema		Aspirin	C		ORAL		
			Metformin	C		ORAL	1G Twice per day	
			Gliclazide	C		ORAL	160MG Per day	

Date:02/15/01ISR Number: 3665612-1Report Type:Expedited (15-DaCompany Report #B0098877A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	12 DAY
	Haematemesis							

Date:02/15/01ISR Number: 3665980-0Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Bupropion	PS				
	Hypoglycaemia							
	Mental Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/01ISR Number: 3665996-4Report Type:Direct Company Report #
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Laboratory Test Abnormal		Wellbutrin Xr (150mg)	PS		ORAL	3750 MG ONCE	
Other	Overdose						PO	
	Road Traffic Accident							

Date:02/15/01ISR Number: 3666446-4Report Type:Expedited (15-DaCompany Report #B0097894A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenopia Gastrointestinal Candidiasis Insomnia Oral Candidiasis Pharyngolaryngeal Pain	Foreign Study Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG (PER DAY), ORAL	

Date:02/15/01ISR Number: 3666451-8Report Type:Expedited (15-DaCompany Report #B0089984A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angina Pectoris	Foreign Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL	150 MG (TWICE PER DAY) ORAL	
			Atenolol + Chlorthalidone	C				
			Doxazosin	C				

Date:02/16/01ISR Number: 3667536-2Report Type:Expedited (15-DaCompany Report #B0098443A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY	/ORAL
	Tremor							
	Visual Disturbance							
			Eformoterolc	C				
			Salbutamol Sulphate	C				
			Baclomethasone Dipropion	C				
			Prempak-C	C				

Date:02/16/01ISR Number: 3667988-8Report Type:Expedited (15-DaCompany Report #B0098045A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Cerebral Ischaemia	Health						
	Cerebrovascular Accident	Professional						
	Coordination Abnormal		Atenolol	C				
	Dysarthria		Valsartan	C				
			Pravastatin	C				

Date:02/16/01ISR Number: 3668002-0Report Type:Expedited (15-DaCompany Report #B0098449A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Left Ventricular Failure Tachycardia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Simvastatin	C				
			Pantoprazole	C				
			Digoxin	C				
			Warfarin Sodium	C				
			Losartan Potassium	C				
			Bumetanide	C				
			Nitroglycerin	C				
			Spironolactone	C				

Date:02/16/01ISR Number: 3668008-1Report Type:Expedited (15-DaCompany Report #D0013784A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Torsade De Pointes	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Life-Threatening	Ventricular Fibrillation		Fosinopril Sodium	C				
			Digitoxin	C				

Date:02/16/01ISR Number: 3668010-XReport Type:Expedited (15-DaCompany Report #B0093437A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Confusional State Depression Dizziness Headache Hyperhidrosis Oral Intake Reduced	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc		150 MG	3 WK

	Tremor					
	Visual Disturbance					
	Vomiting					

Date:02/16/01ISR Number: 3668013-5Report Type:Expedited (15-DaCompany Report #D0013944A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Convulsion Dizziness Paralysis	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	ORAL 5 DAY

Date:02/16/01ISR Number: 3668073-1Report Type:Expedited (15-DaCompany Report #B0098813A
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Disability	Arthralgia
	Cutaneous Vasculitis
	Discomfort
	Pruritus
	Rash Erythematous
	Rash Macular

	Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY / ORAL

Date:02/16/01ISR Number: 3668323-1Report Type:Expedited (15-DaCompany Report #D0013945A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
	C-Reactive Protein Increased						
	Difficulty In Walking		Cefpodoxime Proxetil	C			
	Erythema Multiforme		Birth Control	C			
	Haemoglobin Decreased						
	Joint Swelling						
	Pruritus						

Date:02/19/01ISR Number: 3666538-XReport Type:Expedited (15-DaCompany Report #A0139794A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	
	Completed Suicide						

Date:02/19/01ISR Number: 3666547-0Report Type:Expedited (15-DaCompany Report #B0098962A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholelithiasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:02/19/01ISR Number: 3666548-2Report Type:Expedited (15-DaCompany Report #B0098974A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	11 DAY
	Angina Pectoris		Nicorandil	C		ORAL	10MG Twice per day	
	Palpitations		Isosorbide	C		ORAL	60MG per day	
			Moduretic	C		ORAL		
			Diltiazem	C		ORAL	120MG Three times per day	
			Aspirin	C		ORAL	75MG per day	

Date:02/19/01ISR Number: 3666549-4Report Type:Expedited (15-DaCompany Report #B0098976A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG	
	Nausea						Variable dose	
	Sleep Disorder		Aspirin	C		ORAL	75MG Per day	

			Atenolol	C		ORAL	25MG Per day
			Gtn	C	Glaxo Wellcome	ORAL	400MCG per day
			Pravastatin	C		ORAL	40MG per day

Date:02/20/01ISR Number: 3666802-4Report Type:Expedited (15-DaCompany Report #A0123999A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	13 DAY
	Anxiety Constipation Dizziness Hypoaesthesia Insomnia Paraesthesia Pollakiuria		Vitamin	C				

Date:02/20/01ISR Number: 3666805-XReport Type:Expedited (15-DaCompany Report #A0139668A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour Dyskinesia		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Twice per day	25 DAY
	Feeling Jittery Headache Memory Impairment Neck Pain Thinking Abnormal							

Date:02/20/01ISR Number: 3666806-1Report Type:Expedited (15-DaCompany Report #A0139749A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Astrocytoma		Wellbutrin Sr	SS	Glaxo Wellcome	ORAL		
	Body Temperature Increased		Klonopin	SS				6 MON
	Brain Neoplasm Malignant		Luvox	SS				6 MON
	Coma		Triphasil	C				
	Convulsion		Aspirin	C				
	Eye Movement Disorder		Biotin	C				
	Grand Mal Convulsion		Vitamin C	C				
	Loss Of Consciousness		Zinc	C				
	Medication Error		Mvi	C				
	Ocular Hyperaemia							

Date:02/20/01ISR Number: 3666813-9Report Type:Expedited (15-DaCompany Report #B0093945A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	9 DAY
	Dizziness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/01ISR Number: 3666818-8Report Type:Expedited (15-DaCompany Report #D0010841A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL	150MG per day	9 DAY
Hospitalization - Initial or Prolonged	Cardiac Arrest							
Other	Epilepsy							

Date:02/20/01ISR Number: 3667605-7Report Type:Periodic Company Report #S00-USA-02047-01
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Celexa (Citalopram)	PS	Forest Laboratories Inc	ORAL	40 MG QD PO	
	Paraesthesia		Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	150 MG BID PO	
			Hydroxyzine	C				
			Alprazolam	C				

Date:02/20/01ISR Number: 3667669-0Report Type:Periodic Company Report #S00-USA-01104-01
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Health Professional	Celexa	PS	Forest Laboratories Inc			
	Anxiety							
	Asthenia		Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	150 MG QD PO	
	Depersonalisation							
	Dizziness							
	Drug Withdrawal Syndrome							
	Hypertension							
	Palpitations							
	Sexual Dysfunction							
	Tachycardia							
	Thinking Abnormal							

Date:02/21/01ISR Number: 3667492-7Report Type:Expedited (15-DaCompany Report #A0139670A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Wellbutrin	PS	Glaxo Wellcome	ORAL		2 MON
Initial or Prolonged	Congestive		Rocephin	C				
INTRAVENOUS							1G Per day	
	Convulsion		Pepcid	C				
	Loss Of Consciousness		Kcl	C				
			Captopril	C	Glaxo Wellcome			
			Depakote	C				
			Buspar	C				
			Nicoderm Patch	C				
			Seroquel	C				
							75MG Per day	
			Lasix	C				
			Lanoxin	C	Glaxo Wellcome			
			Albuterol	C	Glaxo Wellcome			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/21/01ISR Number: 3667497-6Report Type:Expedited (15-DaCompany Report #B0091711A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative		Zyban	PS	Glaxo Wellcome			
	Eye Allergy		Prozac	C				
	Pharyngitis		Corsodyl (Mouthwash)	C				
	Rash Erythematous							
	Rash Pruritic							

Date:02/21/01ISR Number: 3667498-8Report Type:Expedited (15-DaCompany Report #B0093052A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Allergy		Zyban	PS	Glaxo Wellcome	ORAL		
	Rash Pruritic		Fluoxetine	C				
			Chlorhexidine	C				

Date:02/21/01ISR Number: 3667499-XReport Type:Expedited (15-DaCompany Report #B0097367A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache		Bupropion					
	Panic Attack		Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Per day	18 DAY
	Sedation							
	Tremor							

Date:02/21/01ISR Number: 3667500-3Report Type:Expedited (15-DaCompany Report #B0097894A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenopia		Bupropion					
	Candidiasis		Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Per day	15 DAY
	Dizziness							
	Insomnia							

Throat Tightness

Date:02/21/01ISR Number: 3668101-3Report Type:Expedited (15-DaCompany Report #2000030406-1
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aggression Dizziness		Paxil	PS	Smithkline Beecham Pharmaceuticals	ORAL	10 MILLIGRAMS 1.0 DAILY	
	Drug Ineffective Drug Withdrawal Syndrome						ORAL	2 WK
	Emotional Disorder Feeling Abnormal		Wellbutrin (Bupropion Hcl)	SS		ORAL	100 MILLIGRAMS 2.0 DAILY	
	Hyperacusis Irritability Malaise						ORAL	
	Mood Swings Muscle Spasms		Paxil Smithkline Beecham	SS				2 YR
	Nausea Photophobia		Paxil Smithkline Beecham	SS		ORAL	40 MILLIGRAMS 1.0 DAILY	
	Sexual Dysfunction Temperature Intolerance						ORAL	2 YR
			Paxil Smithkline Beecham	SS				

				Paxil Smithkline Beecham	SS		ORAL
20 MILLIGRAMS							
1.0 DAILY							
ORAL	1	MON					
				Paxil Smithkline Beecham	SS		
				Paxil Smithkline Beecham	SS		ORAL
30 MILLIGRAMS							
1.0 DAILY							
ORAL							
				Paxil Smithkline Beecham	SS		

Date:02/21/01ISR Number: 3668441-8Report Type:Direct Company Report #
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Biaxin 500 Mg	PS		ORAL	1 TAB BID	
	Feeling Drunk					ORAL		
	Pain		Wellbutrin Sr	SS		ORAL	1 TAB BID	
	Paraesthesia					ORAL		

Date:02/21/01ISR Number: 3668516-3Report Type:Expedited (15-DaCompany Report #A0139738A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Optic Neuritis	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL		
	Visual Acuity Reduced	Consumer	Nefazodone Hydrochloride	C				

Date:02/21/01ISR Number: 3668518-7Report Type:Expedited (15-DaCompany Report #A0139732A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pharyngeal Oedema Rash Generalised Skin Discolouration Urticaria	Foreign Consumer	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/21/01ISR Number: 3668520-5Report Type:Expedited (15-DaCompany Report #B0098808A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Schizophrenia	Foreign Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride) Quetiapine	PS C	Glaxo Wellcome Inc		150 MG	

Date:02/21/01ISR Number: 3668522-9Report Type:Expedited (15-DaCompany Report #B0098815A
Age:62 YR Gender:Male I/FU:I

Outcome	PT
Death	Lethargy Malaise Myocardial Infarction

Tongue Oedema

		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER DAY/ ORAL
			Aspirin	C			
			Metformin	C			
			Gliclazide	C			

Date:02/21/01ISR Number: 3668524-2Report Type:Expedited (15-DaCompany Report #B0091526A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Confusional State	Foreign Health Professional	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	ORAL

Date:02/21/01ISR Number: 3668527-8Report Type:Expedited (15-DaCompany Report #B0098877A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastritis Haematemesis	Foreign	Zyban Tablet -Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY / ORAL

Date:02/21/01ISR Number: 3668535-7Report Type:Expedited (15-DaCompany Report #B0091930A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - Initial or Prolonged	Unevaluable Event	Foreign Health Professional	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	

Date:02/21/01ISR Number: 3668536-9Report Type:Expedited (15-DaCompany Report #B0088230A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	50 TABLET	/SINGLE
Hospitalization - Initial or Prolonged	Coma							
	Hypotension							
	Intentional Misuse							
	Vomiting						DOSE/ORAL	
			Anadin Extra Tablet (Anadin Extra)	SS		ORAL	24 TABLET	/SINGLE

DOSE/ORAL

Date:02/21/01ISR Number: 3668862-3Report Type:Expedited (15-DaCompany Report #A0138400A
Age:31 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Aspartate

	Aminotransferase Increased Blood Amylase Decreased Chest Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gallbladder Disorder	Health	Combivir	PS	Glaxo Wellcome Inc	ORAL	1 TABLET /
	Leukocytoclastic Vasculitis	Professional Other					TWICE PER DAY / ORAL
	Lipase Increased Rash Pruritic		Wellbutrin Tablet (Bupropion Hydrochloride)	SS		ORAL	100 MG / TWICE PER DAY / ORAL
			Nevirapine Tablet (Nevirapine)	SS		ORAL	200 MG / TWICE PER DAY / ORAL
			Azithromycin	C			

Date:02/21/01ISR Number: 3669009-XReport Type:Periodic Company Report #JRFUSA2000001990
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - SEE IMAGE	Depression	Consumer	Risperdal	PS	Janssen Research Fdn	ORAL	
Initial or Prolonged	Mania	Health	Risperdal	SS			
	Sedation	Professional	Risperdal Wellbutrin (Amfebutamone Hydrochloride)	SS SS		ORAL	ORAL
			Humulin Insulin 70/30 (Humulin 70/30)	C			
			Fosamax (Alendronate Sodium)	C			

Aspirin (Acetylsalicylic Acid)	C	
Multivitamin (Multiple Vitamins)	C	
Acetaminophen (Paracetamol)	C	
Motrin (Ibuprofen)	C	
Celluvisc (Celluvisc)	C	

Date:02/21/01ISR Number: 3701984-7Report Type:Periodic Company Report #GBR001652
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite Nonspecific Reaction	Consumer Other	Meridia	PS	Knoll Pharmaceutical Co Sub Basf Corp		15 MG OD	
			Meridia	SS			15 MG OD	
			Wellbutrin	SS				
			Loestrin	C				
			Cipro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/01ISR Number: 3668146-3Report Type:Expedited (15-DaCompany Report #A0123857A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	MON	
	Drug Toxicity							
	Emphysema							
	Hepatic Steatosis							
	Overdose							
	Vomiting							

Date:02/22/01ISR Number: 3668149-9Report Type:Expedited (15-DaCompany Report #A0139732A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pharyngeal Oedema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Rash Generalised						per day	8 DAY
Disability	Skin Discolouration		Zantac	C	Glaxo Wellcome	ORAL	150MG Twice	
Other	Urticaria						per day	

Date:02/22/01ISR Number: 3668152-9Report Type:Expedited (15-DaCompany Report #A0140093A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	400MG per day	348 DAY
			Ambien	C			UNKNOWN	

Date:02/22/01ISR Number: 3668153-0Report Type:Expedited (15-DaCompany Report #A0140271A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emphysema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Fatigue						per day	
			Singulair	C			10MG Per day	
			Advair	C	Glaxo Wellcome		RESPIRATORY	
							(INHALATION)	
			Combivent	C			RESPIRATORY	
							(INHALATION)	

Date:02/22/01ISR Number: 3668155-4Report Type:Expedited (15-DaCompany Report #A0140316A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL		

Date:02/22/01ISR Number: 3668170-0Report Type:Expedited (15-DaCompany Report #B0097835A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Crohn'S Disease		Zyban	PS	Glaxo Wellcome	ORAL	1TAB Twice	
Initial or Prolonged							per day	18 DAY
Disability			Omeprazole	C		ORAL	20MG per day	
Other			Diltiazem	C		ORAL	120MG Per day	
			Simvastatin	C		ORAL	10MG per day	
			Kliofem	C		ORAL		
			Motival	C		ORAL		
			Folic Acid	C			5MG Per day	

			Dipyridamole	C			
			Prednisolone	C			
5MG per day							

Date:02/22/01ISR Number: 3668171-2Report Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	16 DAY

Date:02/22/01ISR Number: 3668180-3Report Type:Expedited (15-DaCompany Report #B0099236A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Suicide Attempt		Zyban	PS	Glaxo Wellcome			

Date:02/22/01ISR Number: 3668181-5Report Type:Expedited (15-DaCompany Report #B0099239A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome		150MG Twice per day	
	Clumsiness							
	Dysgraphia		Cipramil	C				
	Paralysis		Eformoterol	C				
			Hypertension Med	C				

Date:02/22/01ISR Number: 3669958-2Report Type:Expedited (15-DaCompany Report #A0139794A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / ORAL
	Completed Suicide	Consumer				

Date:02/22/01ISR Number: 3669960-0Report Type:Expedited (15-DaCompany Report #B0098974A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / PER DAY / ORAL
	Angina Pectoris					
	Palpitations		Nicorandil	C		
			Isosorbide	C		
			Moduretic	C		
			Diltiazem	C		
			Aspirin	C		

Date:02/22/01ISR Number: 3669975-2Report Type:Expedited (15-DaCompany Report #B0098976A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Disability	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG
	Nausea					VARIABLE DOSE
	Sleep Disorder					ORAL
			Aspirin	C		
			Atenolol	C		
			Nitroglycerin	C		

			Pravastatin	C		

Date:02/22/01ISR Number: 3669984-3Report Type:Expedited (15-DaCompany Report #B0098962A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cholelithiasis	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL

Date:02/23/01ISR Number: 3668794-0Report Type:Expedited (15-DaCompany Report #B0091583A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Circulatory Collapse		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Per day
			Alcohol	C			

Date:02/23/01ISR Number: 3668800-3Report Type:Expedited (15-DaCompany Report #B0098567A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Depression Dermatitis Eyelid Oedema Face Oedema Pruritus Psoriasis Tongue Oedema		Zyban	PS	Glaxo Wellcome	ORAL	15 DAY

Date:02/23/01ISR Number: 3668805-2Report Type:Expedited (15-DaCompany Report #B0099220A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	50 DAY
	Confusional State							
	Convulsion		Aspirin	C				
	Electroencephalogram Abnormal		Alcohol	C				
	Grand Mal Convulsion							
	Hyperglycaemia							
	Lactic Acidosis							
	Nervousness							
	Salivary Hypersecretion							
	Thrombocythaemia							
	Urinary Incontinence							

Date:02/23/01ISR Number: 3668806-4Report Type:Expedited (15-DaCompany Report #B0099224A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 DAY
	Hallucination							
	Headache							
	Subarachnoid Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/01ISR Number: 3668808-8Report Type:Expedited (15-DaCompany Report #B0099526A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Astrocytoma		Zyban	PS	Glaxo Wellcome			
UNKNOWN								
Hospitalization - Initial or Prolonged	Body Temperature Increased		Prozac	C				
	Coma							
	Dysphagia							
	Infection							
	Memory Impairment							
	Urinary Incontinence							
	Vomiting							

Date:02/23/01ISR Number: 3669200-2Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angioneurotic Oedema		Zyban	PS	Glaxo	ORAL		
	Erythema Multiforme		Plendil	C				
	Urticaria		Centrum	C				
			Nsaid	C				

Date:02/23/01ISR Number: 3669870-9Report Type:Expedited (15-DaCompany Report #A0139749A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL		
	Anaplastic Astrocytoma							
	Convulsion		Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL	150 MG/	TWICE PER DAY/
	Eye Movement Disorder							
	Hyperpyrexia							
	Loss Of Consciousness							
	Medication Error							
	Ocular Hyperaemia		Clonazepam					

(Formulation Unknown)	
(Clonazepam)	SS
Fluvoxamine Maleate (Formulation Unknown)	
(Fluvoxamine Maleate)	SS
Triphasil	C
Aspirin	C
Biotin	C
Ascorbic Acid	C
Zinc Salt	C
M.V.I.	C

Date:02/23/01ISR Number: 3669911-9Report Type:Expedited (15-DaCompany Report #D0010841A
Age:24 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Arrest	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL		
	Convulsion	Health						
	Electroencephalogram Abnormal	Professional						

Date:02/23/01ISR Number: 3669948-XReport Type:Expedited (15-DaCompany Report #A0123999A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	
	Anxiety		Vitamin	C				
	Constipation							
	Dizziness							
	Hypoaesthesia							
	Insomnia							
	Paraesthesia							
	Pollakiuria							

Date:02/23/01ISR Number: 3669950-8Report Type:Expedited (15-DaCompany Report #A0139668A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	
	Feeling Jittery							
	Headache							
	Movement Disorder							
	Neck Pain							
	Thinking Abnormal							

Date:02/23/01ISR Number: 3670092-6Report Type:Expedited (15-DaCompany Report #B0093945A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Dizziness	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:02/26/01ISR Number: 3669369-XReport Type:Expedited (15-DaCompany Report #A0133472A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Asthma Convulsion Decreased Appetite Ecchymosis Fall Insomnia Oedema Peripheral Panic Disorder Tremor		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Advair	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	500MCG Twice per day	
			Ventolin	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3669373-1Report Type:Expedited (15-DaCompany Report #A0140573A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Decreased		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Caesarean Section							
per day							21	DAY
Initial or Prolonged	Cardiovascular Disorder		Prenatal Vitamins	C				
	Hepatic Failure		Proventil	C	Glaxo Wellcome			
	Hepatic Steatosis							
	Premature Baby							

Date:02/26/01ISR Number: 3669376-7Report Type:Expedited (15-DaCompany Report #B0098045A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome	ORAL		
Initial or Prolonged	Coordination Abnormal		Atenolol	C			25MG per day	
	Dysarthria		Valsartan	C			160MG per day	
	Hypercholesterolaemia		Pravastatin	C				
	Hypertension							
	Palpitations							

Date:02/26/01ISR Number: 3669381-0Report Type:Expedited (15-DaCompany Report #B0099487A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alopecia Areata		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Costochondritis							
per day							15	DAY
	Dyspnoea							
	Hyperventilation							
	Palpitations							

Date:02/26/01ISR Number: 3669382-2Report Type:Expedited (15-DaCompany Report #B0099502A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Ruptured Cerebral Aneurysm		Estracombi	C		TRANSDERMAL	per day	

Date:02/26/01ISR Number: 3669383-4Report Type:Expedited (15-DaCompany Report #B0099512A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	5 DAY
	Cerebral Cyst		Omeprazole	C			20MG per day	
Other	Congenital Central Nervous System Anomaly		Bisoprolol	C		ORAL	2.5MG per day	
			Enalapril	C		ORAL	10MG Three times per day	
	Diplopia							
	Gait Disturbance		Clopidogrel	C		ORAL	75MG per day	
	Headache		Citalopram	C		ORAL	20MG per day	
	Pain							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3669384-6Report Type:Expedited (15-DaCompany Report #B0099514A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Feeling Abnormal		Zyban	PS	Glaxo Wellcome	ORAL	300MG Three	
	Palpitations							
times per day							5	DAY
	Tearfulness		Prempak C	C		ORAL		
	Visual Disturbance							

Date:02/26/01ISR Number: 3669385-8Report Type:Expedited (15-DaCompany Report #B0099522A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	13 DAY
Initial or Prolonged	Attention							
	Deficit/Hyperactivity							
	Disorder							
	Meningitis							

Date:02/26/01ISR Number: 3669386-XReport Type:Expedited (15-DaCompany Report #B0099529A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Candidiasis		Zyban	PS	Glaxo Wellcome		26	DAY
Initial or Prolonged	Dermatitis							
	Malaise							
	Mouth Ulceration							
	Paraesthesia							

Date:02/26/01ISR Number: 3670467-5Report Type:Expedited (15-DaCompany Report #A0139670A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cardiac Failure	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
150 MG / UNK						
Initial or Prolonged	Congestive					
/ ORAL 2 MON						
	Convulsion		Ceftriaxone Sodium	C		
	Loss Of Consciousness		Famotidine	C		
			Potassium Chloride	C		
			Captopril	C		
			Semisodium Valproate	C		
			Buspirone Hydrochloride	C		
			Nicotine	C		
			Quetiapine Fumarate	C		
			Frusemide	C		
			Digoxin	C		
			Salbutamol Sulphate	C		

Date:02/26/01ISR Number: 3670475-4Report Type:Expedited (15-DaCompany Report #A0123857A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	
	Drug Toxicity						(DURATION:	
	Emphysema						MONTHS)	
	Hepatic Steatosis							
	Overdose							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3670480-8Report Type:Expedited (15-DaCompany Report #A0140093A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Spontaneous	Study	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT/
	Complications Of Maternal	Health					ORAL
	Exposure To Therapeutic Drugs	Professional	Zolipdem Tartrate	C			

Date:02/26/01ISR Number: 3670499-7Report Type:Expedited (15-DaCompany Report #A103444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Drug Ineffective	Consumer	Zoloft	PS	Pfizer Pharmaceuticals Inc		100.00 MG TOTAL: DAILY 900.00 TOTAL
	Ecchymosis						
	Epistaxis						
	Haemorrhagic Stroke		Wellbutrin	SS			
	Syncope		Coumadin	SS			
			Toprol	C			
			Zebeta	C			

Date:02/26/01ISR Number: 3670639-XReport Type:Expedited (15-DaCompany Report #B0091583A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Circulatory Collapse	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY) ORAL
	Sudden Death	Literature					
			Ethanol	C			

Date:02/26/01ISR Number: 3670836-3Report Type:Periodic Company Report #A0116124A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Agitation Arthralgia Dermatitis Erythema Multiforme Headache Hypersensitivity Influenza Like Illness Nausea Pruritus Stevens-Johnson Syndrome Weight Increased	Health Professional Company Representative	Lamictal Wellbutrin Unspecified Tablet (Bupropion Hydrochloride) S-Adenosyl-L-Methionine	PS SS C	Glaxo Wellcome Inc	ORAL ORAL ORAL	25 MG / SEE TEXT / ORAL 10 WK

Date:02/26/01ISR Number: 3670907-1Report Type:Expedited (15-DaCompany Report #B0091711A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis Dermatitis Exfoliative Hypersensitivity Pharyngitis Rash Pruritic	Foreign Health Professional	Zyban Fluoxetine Hydrochloride Chlorhexidine Gluconate	PS C C	Glaxo Wellcome Inc		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3671309-4Report Type:Expedited (15-DaCompany Report #B0093052A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eye Allergy	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	
Initial or Prolonged	Rash Pruritic		Fluoxetine	C				
			Chlorhexidine	C				

Date:02/26/01ISR Number: 3671394-XReport Type:Expedited (15-DaCompany Report #A0140316A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Bupropion					
		Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:02/26/01ISR Number: 3671396-3Report Type:Expedited (15-DaCompany Report #A0140271A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emphysema	Foreign	Bupropion					
	Fatigue	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
							PER DAY /	
							ORAL	
			Montelukast Sodium	C				
			Salmeterol +Fluaticasone Combivent	C				

Date:02/26/01ISR Number: 3671397-5Report Type:Expedited (15-DaCompany Report #B0099239A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required Intervention to Prevent Permanent Impairment/Damage	Cerebrovascular Accident Clumsiness Dysgraphia Facial Palsy	Foreign Health Professional Company Representative	Bupropion Hydrochloride Citalopram Hydrobromide Eformoterol Antihypertensive	PS C C C	Glaxo Wellcome Inc	150 MG /TWICE PER DAY

Date:02/26/01ISR Number: 3671399-9Report Type:Expedited (15-DaCompany Report #B0099236A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Suicide Attempt	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG

Date:02/26/01ISR Number: 3671428-2Report Type:Expedited (15-DaCompany Report #B0099220A
Age:41 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation Confusional State Grand Mal Convulsion

	Hyperglycaemia						
	Lactic Acidosis						
	Leukocytosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nervousness	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
	Salivary Hypersecretion	Health					PER DAY/ ORAL
	Thrombocythaemia	Professional	Aspirin	C			
	Urinary Incontinence		Ethanol	C			

Date:02/26/01ISR Number: 3671430-0Report Type:Expedited (15-DaCompany Report #B0099224A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Depression	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER
Initial or Prolonged	Hallucination						DAY/ ORAL
	Headache						
	Subarachnoid Haemorrhage						

Date:02/26/01ISR Number: 3671433-6Report Type:Expedited (15-DaCompany Report #B0099526A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Astrocytoma	Foreign	Zyban	PS	Glaxo Wellcome Inc		
Hospitalization -	Coma	Consumer	Fluoxetne				
Initial or Prolonged	Dysphagia		Hydrochloride	C			
	Eating Disorder						
	Infection						
	Memory Impairment						
	Urinary Incontinence						
	Vomiting						

Date:02/26/01ISR Number: 3671443-9Report Type:Expedited (15-DaCompany Report #A0139732A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Pharyngeal Oedema	Foreign Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
Disability	Skin Discolouration	Professional						
Required Intervention to Prevent Permanent Impairment/Damage	Urticaria		Ranitidine Hydrochloride	C				

Date:02/26/01ISR Number: 3671453-1Report Type:Expedited (15-DaCompany Report #B0097835A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Crohn'S Disease Intestinal Dilatation	Foreign Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	1 TABLET (TWICE PER DAY) ORAL	
Disability		Professional						
Required Intervention to Prevent Permanent Impairment/Damage			Omeprazole	C				
			Diltiazem	C				
			Simvastatin	C				
			Kliofem	C				
			Motival	C				
			Folic Acid	C				
			Dipyridamole	C				

			Prednisolone	C			

Date:02/26/01ISR Number: 3671454-3Report Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY) ORAL	

Date:02/26/01ISR Number: 3671494-4Report Type:Expedited (15-DaCompany Report #B0097367A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache Panic Attack Sedation Tremor	Foreign Study Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY) ORAL	

Date:02/26/01ISR Number: 3671495-6Report Type:Expedited (15-DaCompany Report #B0097894A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenopia Candidiasis Condition Aggravated Discomfort Dizziness Gastrointestinal Disorder Insomnia Oral Candidiasis Throat Tightness	Foreign Study Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY) ORAL	

Date:02/26/01ISR Number: 3671600-1Report Type:Expedited (15-DaCompany Report #A0140463A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Euphoric Mood	Foreign	Bupropion					
	Feeling Abnormal	Literature	Hydrochloride	PS	Glaxo Wellcome Inc			

Date:02/26/01ISR Number: 3671610-4Report Type:Expedited (15-DaCompany Report #B0098567A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression	Foreign	Bupropion					
	Dermatitis	Consumer	Hydrochloride	PS		ORAL	ORAL	
	Difficulty In Walking							
	Eyelid Oedema							
	Face Oedema							
	Pruritus							
	Psoriasis							
	Tongue Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/27/01ISR Number: 3670396-7Report Type:Expedited (15-DaCompany Report #B0099508A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	13 DAY
	Ear Discomfort		Influenza Vaccine	C		INTRAMUSCULAR		1 DAY
	Headache							
	Malaise							
	Palpitations							

Date:02/27/01ISR Number: 3670397-9Report Type:Expedited (15-DaCompany Report #B0099518A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	12 DAY	
Initial or Prolonged	Dizziness							
	Dyskinesia							
	Hypertension							
	Nausea							
	Tremor							

Date:02/27/01ISR Number: 3670399-2Report Type:Expedited (15-DaCompany Report #B0099524A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Zyban	PS	Glaxo Wellcome		150MG Twice	
Initial or Prolonged	Chest Pain							
per day	4 DAY							

Date:02/27/01ISR Number: 3670418-3Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blood Pressure Decreased	Health	Zyban	PS		ORAL
PO						
Hospitalization -	Chest Discomfort	Professional				
Initial or Prolonged	Urticaria					
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

Date:02/28/01ISR Number: 3671094-6Report Type:Expedited (15-DaCompany Report #B0099500A
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation	Foreign	Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 3 DAY						
Initial or Prolonged	Chest Pain	Consumer	Finasteride	C		ORAL
5MG Per day						
Other	Dyspnoea		Omeprazole	C		ORAL
20MG Per day 8 DAY						
	Left Ventricular Failure					

Date:02/28/01ISR Number: 3671096-XReport Type:Expedited (15-DaCompany Report #B0099525A
Age:60 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Benign Respiratory Tract
Initial or Prolonged	Neoplasm
	Convulsion
	Grand Mal Convulsion

	Muscle Spasms						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day 1 WK
		Consumer					

Date:02/28/01ISR Number: 3671097-1Report Type:Expedited (15-DaCompany Report #B0099531A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Arthritis	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Erythema Marginatum	Consumer					per day 26 DAY

Date:02/28/01ISR Number: 3671099-5Report Type:Expedited (15-DaCompany Report #B0099756A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Alcohol Interaction	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	
	Drowning	Consumer	Alcohol	SS			

Date:02/28/01ISR Number: 3671100-9Report Type:Expedited (15-DaCompany Report #B0099804A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day 18 DAY
Initial or Prolonged	Chest Pain	Consumer	Arthrotec	C		ORAL	
	Dyspnoea		Zopiclone	C		ORAL	7.5MG As required
			Oestrone	C		ORAL	
			Antibiotics	C			8 DAY

Date:02/28/01ISR Number: 3671101-0Report Type:Expedited (15-DaCompany Report #B0099815A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
		Consumer	Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	2PUFF As required	
			Thyroxine	C	Glaxo Wellcome	ORAL	100MCG per day	
			Glyceryl Trinitrate	C	Glaxo Wellcome	ORAL		
			Candesartan	C			4G Per day	
			Fluoxetine	C			20MG Per day	
			Omeprazole	C			20MG Per day	
			Frusemide	C			40MG Per day	
			Didronel	C		ORAL	1TAB Per day	

Date:02/28/01ISR Number: 3671102-2Report Type:Expedited (15-DaCompany Report #B0099834A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	2 DAY
			Dihydrocodeine	C		ORAL		
			Enalapril	C			2.5MG Per day	
			Bendrofluazide	C	Glaxo Wellcome		2.5MG Per day	

			Cimetidine	C			
200MG Twice							
per day							

Date:02/28/01ISR Number: 3671103-4Report Type:Expedited (15-DaCompany Report #B0099836A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Radiculitis Brachial		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	14 DAY
Initial or Prolonged	Turner'S Syndrome							

Date:02/28/01ISR Number: 3671104-6Report Type:Expedited (15-DaCompany Report #B0099837A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 DAY
	Anxiety		Simvastatin	C		ORAL		
	Tachycardia		Indomethacin	C		ORAL		
			Gtn	C	Glaxo Wellcome			
			Gaviscon	C		ORAL		
			Enalapril	C		ORAL		
			Aspirin	C		ORAL		

Date:02/28/01ISR Number: 3671849-8Report Type:Periodic Company Report #001-0945-M0001223
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Consumer	Neurontin	PS	Parke Davis			
Initial or Prolonged	Blood Pressure Decreased				Pharmaceuticals Ltd			
	Laboratory Test Abnormal		Zyban (Amfebutamone					
	Pneumonia		Hydrochloride)	SS		ORAL	300 MG (150	
	Sedation							
MG, BID), PER								

	Speech Disorder					
ORAL						
			(Nifedipine)	SS		
			(Atenolol)	SS		

Date:02/28/01ISR Number: 3675771-2Report Type:Periodic Company Report #A005685
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Health	Zoloft	PS	Pfizer			
	Dermatitis	Professional			Pharmaceuticals Inc			
25MG TOTAL								
	Drug Ineffective							
DAILY								
			Wellbutrin Sr	SS				
100 MG TOTAL								
DAILY								

Date:02/28/01ISR Number: 3676137-1Report Type:Periodic Company Report #A012674
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Zoloft	PS	Pfizer			
	Cough				Pharmaceuticals Inc	ORAL		
ORAL								
	Drug Ineffective		Bupropion	SS		ORAL		
150.00 MG								
	Dyspnoea							
TOTAL:BID:ORA								
	Malaise							
L								
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/01ISR Number: 3676281-9Report Type:Periodic Company Report #A028832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test Abnormal	Health Professional	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL		
			Neurontin	SS				
			Wellbutrin	SS				

Date:02/28/01ISR Number: 3677286-4Report Type:Periodic Company Report #A025527
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coordination Abnormal	Health Professional	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL	50.00 MG	TOTAL:DAILY:O
	Dizziness							
	Drug Ineffective							
	Increased Appetite							
	Libido Decreased		Wellbutrin Sustained Release	SS		ORAL	100.00 MG	TOTAL:DAILY:O
	Weight Increased							

Date:02/28/01ISR Number: 3677394-8Report Type:Periodic Company Report #A004071
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health Professional	Zoloft	PS	Pfizer Pharmaceuticals Inc			
	Hypertension		Wellbutrin	SS				

Date:02/28/01ISR Number: 3677626-6Report Type:Periodic Company Report #A025366
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Consumer	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL	50.00 MG	TOTAL DAILY
						ORAL		3 DAY
			Wellbutrin Sr	SS		ORAL	200.00 MG	TOTAL BID
						ORAL		6 MON

Date:02/28/01ISR Number: 3677830-7Report Type:Periodic Company Report #9800371
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Other	Abnormal Dreams
	Alopecia
	Constipation
	Depersonalisation
	Dizziness
	Drug Ineffective
	Drug Withdrawal Syndrome
	Haematuria
	Insomnia
	Neurosis
	Nocturia
	Sexual Dysfunction

	Weight Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL	100.00 MG TOTAL:DAILY:ORAL
		Professional					
			Wellbutrin	SS			87.50 MG TOTAL:BID
			Aspirin	C			
			Buspar	C			
			Valium	C			

Date:02/28/01ISR Number: 3678092-7Report Type:Periodic Company Report #A040753
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Apathy	Consumer	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL	250.00 MG TOTAL:DAILY:ORAL
	Asthenia						
	Drug Ineffective						
	Intentional Misuse						
	Medication Error		Wellbutrin	SS		ORAL	600.00 MG TOTAL:BID:ORAL
	Nervousness						

Date:02/28/01ISR Number: 3683295-1Report Type:Periodic Company Report #A016975
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Anxiety	Consumer	Zoloft	PS	Pfizer	
	Asthenia				Pharmaceuticals Inc	ORAL
50.00 MG						
	Attention					
TOTAL:DAILY:O						
	Deficit/Hyperactivity					
RAL						
	Disorder		Zidovudine	SS		
	Depression		Sustiva	SS		
	Drug Ineffective		Wellbutrin	SS		
	Drug Level Below		Paxil	C		
	Therapeutic		Serzone	C		
	Headache		Effexor	C		
	Hostility		Norpramin	C		
	Hypercholesterolaemia		Prevacid	C		
	Insomnia					
	Laboratory Test Abnormal					
	Leukopenia					
	Libido Decreased					
	Myalgia					
	Nausea					
	Sedation					
	Testicular Disorder					
	Thinking Abnormal					

Date:03/01/01ISR Number: 3671689-XReport Type:Expedited (15-DaCompany Report #A0138368A
Age:15 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Condition Aggravated
Initial or Prolonged	Disturbance In Social
Other	Behaviour

	Drug Interaction Glycosuria Movement Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Syncope	Health Professional	Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Twice per day 6 MON
			Marijuana	SS			
			Benadryl	C		ORAL	25MG As required

Date:03/01/01ISR Number: 3671691-8Report Type:Expedited (15-DaCompany Report #A0140271A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Emphysema	Foreign Health Professional	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day
			Singulair	C			10MG Per day
			Advair	C	Glaxo Wellcome		RESPIRATORY (INHALATION)
			Combivent	C			RESPIRATORY (INHALATION)

Date:03/01/01ISR Number: 3671692-XReport Type:Expedited (15-DaCompany Report #A0141153A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 7 DAY

Date:03/01/01ISR Number: 3671700-6Report Type:Expedited (15-DaCompany Report #B0098813A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Cutaneous Vasculitis	Health					per day	16 DAY
	Rash Macular	Professional	Lisinopril	C			20MG per day	
	Urticaria		Dytenzide	C			1TAB per day	

Date:03/01/01ISR Number: 3671706-7Report Type:Expedited (15-DaCompany Report #B0099637A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Obstruction		Zyban	PS	Glaxo Wellcome	ORAL		

Date:03/01/01ISR Number: 3672077-2Report Type:Expedited (15-DaCompany Report #A0140573A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Decreased	Study	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Hospitalization - Initial or Prolonged	Caesarean Section	Health					TWICE PER DAY / ORAL	
	Complications Of Maternal	Professional						
	Exposure To Therapeutic		Prenatal	C				
	Drugs		Salbutamol Sulphate	C				
	Hepatic Failure							
	Hepatic Steatosis							
	Premature Labour							
	Shock							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/01ISR Number: 3672411-3Report Type:Expedited (15-DaCompany Report #B0098045A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Cerebrovascular Accident	Health					
	Condition Aggravated	Professional	Atenolol	C			
	Heart Rate Decreased		Valsartan	C			
	Hypertension		Pravastatin	C			
	Palpitations						

Date:03/01/01ISR Number: 3672412-5Report Type:Expedited (15-DaCompany Report #A0133472A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL
	Asthma	Consumer					
	Convulsion						
	Decreased Appetite		Salmeterol + Fluticasone	C			
	Disturbance In Attention		Salbutamol Sulphate	C			
	Dizziness						
	Ecchymosis						
	Fatigue						
	Feeling Abnormal						
	Flashback						
	Insomnia						
	Nausea						
	Nervousness						
	Oedema Peripheral						
	Panic Reaction						
	Tremor						

Date:03/01/01ISR Number: 3672414-9Report Type:Expedited (15-DaCompany Report #B0099487A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Alopecia Areata	Foreign	Bupropion				

	Costochondritis		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG (TWICE						
	Dyspnoea					
PER DAY) ORAL						
	Hyperventilation					
	Palpitations					

Date:03/01/01ISR Number: 3672415-0Report Type:Expedited (15-DaCompany Report #B0099502A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemorrhagic Stroke	Foreign	Bupropion			
	Ruptured Cerebral		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG (TWICE						
	Aneurysm					
PER DAY)						
ORAL						
			Estracombi	C		

Date:03/01/01ISR Number: 3672416-2Report Type:Expedited (15-DaCompany Report #B0099514A
Age:51 YR Gender:Female I/FU:I

Outcome	PT
Disability	Feeling Abnormal
	Palpitations

	Sedation Tearfulness Visual Disturbance	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
300 MG/THREE						
TIMES PER DAY						
ORAL						
			Prempak-C	C		

Date:03/01/01ISR Number: 3672417-4Report Type:Expedited (15-DaCompany Report #B0099512A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased	Foreign	Bupropion			
Initial or Prolonged	Cough		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/PER						
Required	Diplopia					
DAY/ORAL						
Intervention to	Gait Disturbance		Omeprazole	C		
Prevent Permanent	Headache		Bisoprolol	C		
Impairment/Damage	Vomiting		Enalapril	C		
			Clopidogrel	C		
			Citalopram	C		

Date:03/01/01ISR Number: 3672418-6Report Type:Expedited (15-DaCompany Report #B0099522A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Aggression	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
300 MG/PER						
Initial or Prolonged	Attention					
DAY/ORAL						
	Deficit/Hyperactivity					
	Disorder					
	Meningitis					

Date:03/01/01ISR Number: 3672419-8Report Type:Expedited (15-DaCompany Report #B0099529A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ageusia Dehydration Dermatitis Dry Mouth Mouth Ulceration Nausea Oral Candidiasis Oral Pain	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	

Date:03/02/01ISR Number: 3672194-7Report Type:Expedited (15-DaCompany Report #B0099829A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Blood Pressure Increased Heart Rate Increased Hypersensitivity Inflammation Syncope		Zyban	PS	Glaxo Wellcome		150MG As directed	13 DAY

Date:03/02/01ISR Number: 3672200-XReport Type:Expedited (15-DaCompany Report #D0014384A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL	4	WK
	Sedation							

Date:03/02/01ISR Number: 3673056-1Report Type:Expedited (15-DaCompany Report #B0099518A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK	/ ORAL
	Dizziness							
	Dyskinesia							
	Hypertension							
	Nausea							
	Tremor							

Date:03/02/01ISR Number: 3673061-5Report Type:Expedited (15-DaCompany Report #B0099524A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG/ TWICE PER DAY /	
	Chest Pain	Consumer						

UNKNOWN

Date:03/02/01ISR Number: 3673064-0Report Type:Expedited (15-DaCompany Report #B0099508A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Dizziness	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / PER
	Ear Discomfort					DAY / ORAL
	Headache		Influenza Vaccine	C		
	Malaise					
	Palpitations					

Date:03/05/01ISR Number: 3673112-8Report Type:Expedited (15-DaCompany Report #A0141089A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Suicide Attempt		Zyban	PS	Glaxo Wellcome	ORAL 150MG Per day
			Alcohol	SS		
			Flovent	C	Glaxo Wellcome	
			Serevent	C	Glaxo Wellcome	
			Atrovent	C	Glaxo Wellcome	
			Proventil	C	Glaxo Wellcome	

Date:03/05/01ISR Number: 3673118-9Report Type:Expedited (15-DaCompany Report #B0095116A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome	ORAL
	Lipids Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/01ISR Number: 3674046-5Report Type:Expedited (15-DaCompany Report #A0138368A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG /TWICE PER DAY /ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Drug Dependence							
	Drug Interaction		Cannabis (Cannabis)	SS				
	Glycosuria		Diphenhydramine Hcl	C				
	Movement Disorder							
	Syncope							

Date:03/05/01ISR Number: 3674449-9Report Type:Expedited (15-DaCompany Report #B0099531A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Arthritis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Erythema Marginatum							

Date:03/05/01ISR Number: 3674450-5Report Type:Expedited (15-DaCompany Report #B0099837A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Anxiety							
	Tachycardia		Simvastatin	C				
			Indomethacin	C				
			Nitroglycerin	C				
			Gaviscon	C				
			Enalapril	C				
			Aspirin	C				

Date:03/05/01ISR Number: 3674451-7Report Type:Expedited (15-DaCompany Report #B0099836A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Radiculitis Brachial	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER DAY / ORAL	

Date:03/05/01ISR Number: 3674508-0Report Type:Expedited (15-DaCompany Report #B0099500A
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Chest Pain							
Required Intervention to Prevent Permanent Impairment/Damage	Dyspnoea		Finasteride	C				
	Left Ventricular Failure		Omeprazole	C				

Date:03/05/01ISR Number: 3674510-9Report Type:Expedited (15-DaCompany Report #B0099834A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Foreign	Zyban Tablet - Zyban (Bupropion					

			Hydrochloride)	PS			ORAL
150 MG /							
PER DAY /							
ORAL							
			Dihydrocodeine	C			
			Enalapril	C			
			Bendrofluazide	C			
			Cimetidine	C			

Date:03/05/01ISR Number: 3674512-2Report Type:Expedited (15-DaCompany Report #B0099815A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Sudden Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL
			Salbutamol Sulphate	C			
			Thyroxine Sodium	C			
			Nitroglycerin	C			
			Candesartan Cilexetil	C			
			Fluoxetine	C			
			Omeprazole	C			
			Frusemide	C			
			Disodium Etidronate	C			

Date:03/05/01ISR Number: 3674514-6Report Type:Expedited (15-DaCompany Report #B0099804A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Dyspnoea	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER DAY /

ORAL

Arthrotec	C	
Zopiclone	C	
Oestrone	C	
Antibiotics	C	

Date:03/05/01ISR Number: 3674520-1Report Type:Expedited (15-DaCompany Report #B0099525A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Lung Disorder Neoplasm	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER DAY /	ORAL 1 WK

Date:03/05/01ISR Number: 3674524-9Report Type:Expedited (15-DaCompany Report #B0099756A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Interaction Drowning	Foreign Literature	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	UNK / UNK	/ ORAL
			Ethanol (Formulation Unknown) (Alcohol)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/01ISR Number: 3674586-9Report Type:Expedited (15-DaCompany Report #A0140271A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Chronic Obstructive Airways Disease Exacerbated	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
	Cough		Montelukast Sodium	C			
	Dyspnoea Exacerbated		Salmeterol + Fluticasone Combivent	C			
	Emphysema			C			
	Fatigue			C			

Date:03/05/01ISR Number: 3674588-2Report Type:Expedited (15-DaCompany Report #B0098813A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Arthralgia Cutaneous Vasculitis Pruritus	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
	Rash Erythematous		Lisinopril	C			
	Rash Macular		Dytenzide	C			
	Urticaria						

Date:03/05/01ISR Number: 3674590-0Report Type:Expedited (15-DaCompany Report #A0141153A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angina Pectoris	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL

Date:03/05/01ISR Number: 3674592-4Report Type:Expedited (15-DaCompany Report #B0099637A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Obstruction	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:03/06/01ISR Number: 3673996-3Report Type:Expedited (15-DaCompany Report #A0141087A
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coordination Abnormal		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Twice per day	
	Fall							
	Gait Disturbance		Eskalith	C	Glaxo Wellcome			
			Coumadin	C	Glaxo Wellcome			
			Procardia	C				
			Zestril	C				

Date:03/06/01ISR Number: 3674002-7Report Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Headache		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	16 DAY
	Loss Of Consciousness		Chloroquine	C				
	Sudden Death		Diphenhydramine	C				
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/01ISR Number: 3674004-0Report Type:Expedited (15-DaCompany Report #B0099532A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Intermittent Claudication Retinal Detachment		Zyban	PS	Glaxo Wellcome			

Date:03/06/01ISR Number: 3674005-2Report Type:Expedited (15-DaCompany Report #B0099946A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hearing Impaired Influenza Like Illness Upper Respiratory Tract Infection		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL		

Date:03/06/01ISR Number: 3674006-4Report Type:Expedited (15-DaCompany Report #B0100055A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Blood Pressure Decreased Dermatitis Heart Rate Decreased Palpitations Vomiting		Zyban	PS	Glaxo Wellcome	ORAL		

Date:03/06/01ISR Number: 3674007-6Report Type:Expedited (15-DaCompany Report #B0100063A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accident Head Injury Suicide Attempt		Zyban	PS	Glaxo Wellcome			

Date:03/06/01ISR Number: 3674008-8Report Type:Expedited (15-DaCompany Report #B0100066A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Influenza Like Illness		Zyban	PS	Glaxo Wellcome		150MG Per day	7 DAY
	Pulmonary Embolism							

Date:03/06/01ISR Number: 3674009-XReport Type:Expedited (15-DaCompany Report #B0100069A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Zyban	PS	Glaxo Wellcome		5	DAY
Initial or Prolonged	Gastrooesophageal Reflux		Sertraline	C				
	Disease							
	Hyperventilation							
	Malaise							
	Nausea							
	Tremor							
	Vomiting							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/01ISR Number: 3674010-6Report Type:Expedited (15-DaCompany Report #B0100194A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Insomnia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	9 DAY
	Irritability		Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG per day	
	Panic Reaction							

Date:03/06/01ISR Number: 3674011-8Report Type:Expedited (15-DaCompany Report #B0100196A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration		Zyban	PS	Glaxo Wellcome			
	Hypersensitivity							
	Pharyngolaryngeal Pain							

Date:03/06/01ISR Number: 3674012-XReport Type:Expedited (15-DaCompany Report #B0100202A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis		Zyban	PS	Glaxo Wellcome			

Date:03/06/01ISR Number: 3674013-1Report Type:Expedited (15-DaCompany Report #B0100203A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome			
	Chest Discomfort							
	Circulatory Collapse							
	Dyspnoea							
	Panic Attack							

Date:03/06/01ISR Number: 3674633-4Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Zyban	PS			2 QD	
	Increased Aspartate Aminotransferase Increased Blood Creatine Phosphokinase Increased Gamma-Glutamyltransferase Increased Monocytosis Oedema Peripheral Serum Ferritin Increased							

Date:03/06/01ISR Number: 3674675-9Report Type:Direct Company Report #
Age:32 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaphylactoid Reaction Chest Discomfort Dyspnoea

	Pruritus Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Bupropion (Wellbutrin)	PS	Wellbutrin	ORAL	PO
			Clonazepam	C			
			Paroxetine	C			

Date:03/06/01ISR Number: 3675238-1Report Type:Direct Company Report #
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Convulsion		Wellbutrin Sr Glaxco-Welcome	PS	Glaxco-Welcome		

Date:03/06/01ISR Number: 3675388-XReport Type:Expedited (15-DaCompany Report #D0014384A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide Sedation	Foreign Health Professional Other	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / UNK / ORAL

Date:03/06/01ISR Number: 3675394-5Report Type:Expedited (15-DaCompany Report #B0099829A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia Blood Pressure Increased Dizziness Ear Infection	Foreign Consumer Other	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG / AS DIRECTED /

	Heart Rate Increased					
	Hypersensitivity					

Date:03/07/01ISR Number: 3674830-8Report Type:Expedited (15-DaCompany Report #A0136085A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Gastrointestinal Disorder						per day	
	Joint Stiffness		Adalat Xl	C		ORAL	60MG Per day	
	Pain In Extremity		Synthroid	C	Glaxo Wellcome	ORAL	300MG Per day	
			Lipitor	C		ORAL	40MG Per day	
			Hytrin	C				

Date:03/07/01ISR Number: 3674832-1Report Type:Expedited (15-DaCompany Report #A0136852A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Pain		Zyban	PS	Glaxo Wellcome	ORAL	1	MON
	Keratitis							
	Keratoconjunctivitis							
	Sicca							
	Nervous System Disorder							
	Sensory Loss							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/01ISR Number: 3674839-4Report Type:Expedited (15-DaCompany Report #A0141476A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Twice per day	4 WK
	Fall							
	Haemoglobin Decreased		Birth Control Pills	C				
	Hypokalaemia							
	Syncope							
	Tremor							

Date:03/07/01ISR Number: 3674841-2Report Type:Expedited (15-DaCompany Report #A0141486A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL		
	Cardiac Failure							
	Congestive							

Date:03/07/01ISR Number: 3674842-4Report Type:Expedited (15-DaCompany Report #B0082488A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Retinal Tear		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	31 DAY
	Retinitis							
Other	Vasculitis							

Date:03/07/01ISR Number: 3674845-XReport Type:Expedited (15-DaCompany Report #B0091526A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL		

Date:03/07/01ISR Number: 3674870-9Report Type:Expedited (15-DaCompany Report #B0100045A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Myocarditis		Zyban	PS	Glaxo Wellcome			

Date:03/07/01ISR Number: 3674871-0Report Type:Expedited (15-DaCompany Report #B0100365A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute		Zyban	PS	Glaxo Wellcome		UNKNOWN	

Date:03/07/01ISR Number: 3675547-6Report Type:Expedited (15-DaCompany Report #A0141089A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Toxicity Suicide Attempt	Health Professional	Bupropion Hydrochloride Ethanol (Formulation	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	

Unknown) (Alcohol)	C
Fluticasone Propionate	C
Salmeterol Xinafoate	C
Ipratropium Bromide	C
Salbutamol Sulphate	C

Date:03/07/01ISR Number: 3675724-4Report Type:Expedited (15-DaCompany Report #B0095116A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Lipids Increased	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL ORAL		

Date:03/08/01ISR Number: 3675836-5Report Type:Expedited (15-DaCompany Report #B0098815A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Discomfort		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	1 WK
	Chest Pain		Aspirin	C		ORAL		
	Decreased Appetite		Metformin	C		ORAL	1G Twice per day	
	Dehydration							
	Dermatitis		Gliclazide	C		ORAL	160MG Per day	
	Dizziness							
	Dry Mouth							
	Dry Skin							
	Dyspnoea							
	Fatigue							
	Headache							
	Insomnia							
	Lethargy							
	Malaise							
	Myocardial Infarction							
	Swelling							

Date:03/08/01ISR Number: 3675838-9Report Type:Expedited (15-DaCompany Report #B0099525A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Convulsion Grand Mal Convulsion Neoplasm		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	8 DAY

Date:03/08/01ISR Number: 3675845-6Report Type:Expedited (15-DaCompany Report #B0099781A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Malaise		Zyban No Concurrent Medication	PS C	Glaxo Wellcome		UNKNOWN	4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/01ISR Number: 3675847-XReport Type:Expedited (15-DaCompany Report #B0100349A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	5	DAY
	Haemoptysis		Beclomethasone	C	Glaxo Wellcome	RESPIRATORY	(INHALATION)	250MCG per day
			Gaviscon	C		ORAL		
			Loratadine	C			10MG Per day	
			Salmeterol	C	Glaxo Wellcome	RESPIRATORY	(INHALATION)	2PUFF Twice per day

Date:03/08/01ISR Number: 3675849-3Report Type:Expedited (15-DaCompany Report #B0100357A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	22 DAY
	Vasculitis							
			Mefenamic Acid	C		ORAL	500MG Three times per day	

Date:03/08/01ISR Number: 3675850-XReport Type:Expedited (15-DaCompany Report #B0100358A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Depression		Zyban	PS	Glaxo Wellcome			

	Haemorrhagic Stroke					

Date:03/08/01ISR Number: 3675852-3Report Type:Expedited (15-DaCompany Report #B0100501A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Zyban	PS	Glaxo Wellcome		150MG Twice	
Initial or Prolonged	Dizziness						per day	8 DAY
	Dry Mouth							
	Nausea							

Date:03/08/01ISR Number: 3675854-7Report Type:Expedited (15-DaCompany Report #B0100520A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Circulatory Collapse		Zyban	PS	Glaxo Wellcome			
Initial or Prolonged	Dizziness							
	Hypoaesthesia							
	Musculoskeletal Stiffness							
	Nausea							
	Photophobia							
	Retching							

Date:03/08/01ISR Number: 3675855-9Report Type:Expedited (15-DaCompany Report #B0100605A
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Convulsion
Initial or Prolonged	Overdose

	Sedation						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	22TAB Per day

Date:03/08/01ISR Number: 3675856-0Report Type:Expedited (15-DaCompany Report #D0014564A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	7TAB
	Gamma-Glutamyltransferase Increased						cumulative dose
	Liver Function Test Abnormal		Amoxycillin	C			
	Respiratory Arrest						

Date:03/08/01ISR Number: 3676575-7Report Type:Expedited (15-DaCompany Report #B0100069A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG
	Gastrooesophageal Reflux Disease	Literature Health Professional	Sertraline	C			
	Hyperventilation						
	Pallor						
	Tremor						
	Vomiting						
	Weight Decreased						

Date:03/08/01ISR Number: 3676579-4Report Type:Expedited (15-DaCompany Report #B0100196A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Dehydration Dermatitis Hypersensitivity Oedema Peripheral	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc		150 MG	

Date:03/08/01ISR Number: 3676581-2Report Type:Expedited (15-DaCompany Report #B0100194A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Insomnia Irritability Panic Reaction	Foreign Health Professional	Zyban Bendrofluazide	PS C	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

Date:03/08/01ISR Number: 3676583-6Report Type:Expedited (15-DaCompany Report #B0100203A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Circulatory Collapse Panic Attack Respiratory Disorder	Foreign Literature Consumer	Zyban	PS	Glaxo Wellcome Inc		150 MG	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/01ISR Number: 3676587-3Report Type:Expedited (15-DaCompany Report #B0100202A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis	Foreign Health Professional Other	Zyban	PS	Glaxo Wellcome Inc		150 MG	

Date:03/08/01ISR Number: 3676599-XReport Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Headache	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	DAY/ ORAL
	Loss Of Consciousness	Literature						
	Sudden Death	Health						
	Vision Blurred	Professional	Chloroquine	C				
			Diphenhydramine	C				

Date:03/08/01ISR Number: 3676623-4Report Type:Expedited (15-DaCompany Report #B0100066A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Influenza Like Illness	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG (PER DAY)	
	Pulmonary Embolism							

Date:03/08/01ISR Number: 3676628-3Report Type:Expedited (15-DaCompany Report #B0100055A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Foreign	Bupropion					

Initial or Prolonged	Blood Pressure Decreased	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG ORAL						
	Dermatitis					
	Heart Rate Decreased					
	Palpitations					
	Vomiting					

Date:03/08/01ISR Number: 3676629-5Report Type:Expedited (15-DaCompany Report #B0100063A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Suicide Attempt	Foreign	Bupropion			
Initial or Prolonged		Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	
150 MG						

Date:03/08/01ISR Number: 3676630-1Report Type:Expedited (15-DaCompany Report #B0099532A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Intermittent Claudication	Foreign	Bupropion			
	Retinal Detachment	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/01ISR Number: 3676632-5Report Type:Expedited (15-DaCompany Report #B0099946A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hearing Impaired	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL		
	Influenza Like Illness	Health Professional						

Date:03/08/01ISR Number: 3676686-6Report Type:Expedited (15-DaCompany Report #A0141087A
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG /	
	Coordination Abnormal						TWICE PER DAY	
	Difficulty In Walking						/ ORAL	
	Fall		Lithium Carbonate	C				
	Gait Disturbance		Warfarin Sodium	C				
			Nifedipine	C				
			Lisinopril	C				

Date:03/09/01ISR Number: 3676495-8Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia		Bupropion	PS		ORAL	75 MG BID	
							ORAL	
			Amitriptyline Hcl	C				
			Insulin Nph Human	C				
			Insulin Reg Human	C				
			Metformin Hcl	C				
			Zolpidem	C				

Date:03/09/01ISR Number: 3676855-5Report Type:Expedited (15-DaCompany Report #A0141757A
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Increased		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	200MG Twice per day	18 MON
	Blood Urea Increased							
	Dehydration							
	Electrocardiogram Qt Prolonged							
	Nausea							
	Vomiting							

Date:03/09/01ISR Number: 3676856-7Report Type:Expedited (15-DaCompany Report #B0096694A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxo Wellcome		150MG Twice per day	
	Blood Pressure Decreased							
	Drug Interaction		Seretide	C	Glaxo Wellcome		2UNIT per day	
	Face Oedema		Aspirin	C				
	Paraesthesia		Deptran	I			10MG Three times per day	
	Paralysis							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/01ISR Number: 3676872-5Report Type:Expedited (15-DaCompany Report #B0100339A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Conversion Disorder		Zyban	PS	Glaxo Wellcome			
	Fall		Atorvastatin	C			10MG per day	
	Feeling Abnormal		Enalapril	C			2.5MG per day	
	Headache							
	Lethargy							
	Loss Of Consciousness							
	Malaise							
	Movement Disorder							
	Syncope							
	Tremor							

Date:03/09/01ISR Number: 3676873-7Report Type:Expedited (15-DaCompany Report #B0100353A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	33 DAY
Hospitalization - Initial or Prolonged	Overdose		Paracetamol	SS				

Date:03/09/01ISR Number: 3676878-6Report Type:Expedited (15-DaCompany Report #B0100670A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	17 DAY
	Mouth Ulceration		Diclofenac	C		ORAL	50MG per day	12 DAY
	Vulval Ulceration		Co-Codamol	C		ORAL		

Date:03/09/01ISR Number: 3676879-8Report Type:Expedited (15-DaCompany Report #B0100671A
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Left Ventricular Failure		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	65 DAY
Hospitalization -			Amitriptyline	C		ORAL	75MG per day	
Initial or Prolonged			Temazepam	C		ORAL	20MG per day	
			Human Insulin	C		SUBCUTANEOUS		

Date:03/09/01ISR Number: 3676880-4Report Type:Expedited (15-DaCompany Report #B0100677A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Back Pain						per day	
	Insomnia							

Date:03/09/01ISR Number: 3676882-8Report Type:Expedited (15-DaCompany Report #B0100678A
Age:45 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Acute Psychosis
Hospitalization -	Bite
Initial or Prolonged	Convulsion
	Muscle Contractions Involuntary

		Oxygen Saturation Decreased Respiratory Depression	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Tongue Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day 18 DAY
		Urinary Incontinence						
				Lithium	C		ORAL	800MG per day 130 DAY
				Clomipramine	C		ORAL	150MG per day 170 DAY
				Folic Acid	C		ORAL	1TAB per day

Date:03/09/01ISR Number: 3676883-XReport Type:Expedited (15-DaCompany Report #B0100682A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Glucose Decreased		Zyban	PS	Glaxo Wellcome		150MG Twice per day
	Circulatory Collapse Dizziness Hypoaesthesia Visual Disturbance		Coffee	C		ORAL	

Date:03/09/01ISR Number: 3676884-1Report Type:Expedited (15-DaCompany Report #B0100684A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death		Zyban	PS	Glaxo Wellcome		
			Lovan	C			
			Alcohol	C			

Date:03/12/01ISR Number: 3678075-7Report Type:Expedited (15-DaCompany Report #A0141841A
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	2	WK

Date:03/12/01ISR Number: 3678079-4Report Type:Expedited (15-DaCompany Report #B0100043A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	
	Myocardial Infarction		Carbimazole	C		ORAL	5MG Per day	
			Enalapril	C		ORAL	2.5MG Per day	
			Clarithromycin	C		ORAL	1000MG Per day	8 DAY
			Doxycycline	C		ORAL	100MG Per day	8 DAY

Date:03/12/01ISR Number: 3678083-6Report Type:Expedited (15-DaCompany Report #B0100749A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Fibrinogen Increased Haematoma Mean Cell Volume Abnormal Red Blood Cell Count Decreased		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	14 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/01ISR Number: 3678085-XReport Type:Expedited (15-DaCompany Report #B0100755A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome		

Date:03/12/01ISR Number: 3678086-1Report Type:Expedited (15-DaCompany Report #B0100763A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anaphylactic Reaction		Zyban	PS	Glaxo Wellcome		
Hospitalization - Initial or Prolonged	Aphasia						
	Circulatory Collapse						
	Dermatitis						
	Respiratory Arrest						
	Tremor						

Date:03/12/01ISR Number: 3680290-3Report Type:Expedited (15-DaCompany Report #A0141476A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaemia	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL 4 WK
	Convulsion	Professional					
	Fall		Oral Contraceptive	C			
	Hypokalaemia						
	Syncope						

Date:03/12/01ISR Number: 3680291-5Report Type:Expedited (15-DaCompany Report #A0136852A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Eye Infection Viral	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL
	Keratitis	Professional					
	Keratoconjunctivitis						

Sicca

Date:03/12/01ISR Number: 3680666-4Report Type:Expedited (15-DaCompany Report #A0136085A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Arthritis	Health					PER DAY ORAL	
	Gastrointestinal Disorder	Professional	Nifedipine	C				
	Joint Stiffness		Thyroxine Sodium	C				
			Atorvastatin Calcium	C				
			Terazosin Hydrochloride	C				

Date:03/12/01ISR Number: 3680670-6Report Type:Expedited (15-DaCompany Report #B0091526A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL		
		Health Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/01ISR Number: 3680689-5Report Type:Expedited (15-DaCompany Report #B0100365A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Foreign Health Professional Other	Zyban	PS	Glaxo Wellcome Inc			

Date:03/12/01ISR Number: 3680693-7Report Type:Expedited (15-DaCompany Report #A0141486A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cardiac Failure Congestive	Foreign Health Professional Other	Zyban	PS	Glaxo Wellcome Inc	ORAL ORAL		

Date:03/12/01ISR Number: 3680695-0Report Type:Expedited (15-DaCompany Report #B0100045A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocarditis	Foreign Health Professional Other	Zyban	PS	Glaxo Wellcome Inc		150 MG	

Date:03/12/01ISR Number: 3680834-1Report Type:Expedited (15-DaCompany Report #B0082488A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Maculopathy Retinal Exudates	Foreign Study	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ ORAL	

Required Intervention to Prevent Permanent Impairment/Damage	Retinal Oedema Retinal Tear Retinal Vasculitis Retinitis Visual Disturbance	Health Professional

Date:03/12/01ISR Number: 3680843-2Report Type:Expedited (15-DaCompany Report #A0140463A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia Cardiac Arrest Euphoric Mood Feeling Abnormal Heart Rate Increased Palpitations Psychomotor Hyperactivity	Foreign Literature	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	10 DAY

Date:03/13/01ISR Number: 3679122-9Report Type:Expedited (15-DaCompany Report #A0134853A
Age:27 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Distension		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Three	
Abdominal Pain						times per day	6 DAY
Abscess		Triphasil	C		ORAL	1TAB Per day	
Anaemia		St. John'S Wort	C				
Anorexia		Vitamins	C				
Anxiety							
Back Pain							
Cellulitis							
Cervix Carcinoma							
Chest Pain							
Constipation							
Crepitations							
Cystitis							
Depression							
Drug Toxicity							
Dyspnoea							
Embolism							
Fistula							
Hypoaesthesia							
Hypokalaemia							
Hyponatraemia							
Hypovolaemia							
Insomnia							
Malaise							
Menorrhagia							
Muscle Spasms							
Nervousness							
Neutropenia							
Night Sweats							
Oedema							
Oral Candidiasis							
Orthostatic Hypotension							
Palpitations							
Paraesthesia							
Pollakiuria							
Post Coital Bleeding							
Postoperative Adhesion							
Proteinuria							
Pyrexia							
Rectal Haemorrhage							

Respiratory Disorder
Rhinitis
Sepsis
Small Intestinal
Obstruction
Squamous Cell Carcinoma
Tachycardia
Urinary Tract Infection
Urine Analysis Abnormal
Weight Decreased

Date:03/13/01ISR Number: 3679125-4Report Type:Expedited (15-DaCompany Report #A0138336A
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Blood Creatine

		Phosphokinase Increased					
		Dyspnoea					
		Rhabdomyolysis					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Twice							
per day							
				Benazepril	C		ORAL
				Vioxx	C		ORAL
25MG Per day							

Date:03/13/01ISR Number: 3679126-6Report Type:Expedited (15-DaCompany Report #A0141472A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Eye Disorder		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
per day						

Date:03/13/01ISR Number: 3679127-8Report Type:Expedited (15-DaCompany Report #A0141548A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Dyspnoea					
per day						
	Fatigue		Accupril	C		
UNKNOWN	10MG Twice					
	Haemoptysis					
per day						
	Lower Respiratory Tract Infection					

Date:03/13/01ISR Number: 3679133-3Report Type:Expedited (15-DaCompany Report #B0098808A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome		150MG Twice	
	Depression						per day	
			Quetiapine	C				

Date:03/13/01ISR Number: 3679138-2Report Type:Expedited (15-DaCompany Report #B0100348A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	C-Reactive Protein		Zyban	PS	Glaxo Wellcome	ORAL	150MG Three	
	Increased						times per day	9 DAY
	Confusional State		Catapressan	C				
	Drug Dependence		Penicillin	C	Glaxo Wellcome			
	Drug Withdrawal Syndrome		Netromycin					
	Dysphonia		(Netilmicin)	C				
	Hallucination, Visual		Haloperidol	C				
	Psychotic Disorder		Morphine Chloride	C				
	Restlessness							
	Sepsis							

Date:03/13/01ISR Number: 3679148-5Report Type:Expedited (15-DaCompany Report #B0100733A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Akinesia		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	12 DAY
	Dysarthria		Danazol	C		ORAL	100MG per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/13/01ISR Number: 3679149-7Report Type:Expedited (15-DaCompany Report #B0100762A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Zyban	PS	Glaxo Wellcome			
	Intentional Misuse		Ibuprofen	SS				
	Suicide Attempt		Alcohol	SS				

Date:03/13/01ISR Number: 3679151-5Report Type:Expedited (15-DaCompany Report #B0100897A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Zyban	PS	Glaxo Wellcome		150MG As directed	
	Headache							

Date:03/13/01ISR Number: 3679152-7Report Type:Expedited (15-DaCompany Report #B0101145A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	9 DAY
	Dizziness							

Date:03/13/01ISR Number: 3679860-8Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Movement Disorder		Wellbutrin Sr (150mg)	PS			1T BID	17 DAY
	Oedema Mouth							
	Oedema Peripheral		Motrin	C				
	Rash Maculo-Papular		Adalat	C				
	Tenderness		Prinivil	C				
	Tremor							

Date:03/13/01ISR Number: 3680170-3Report Type:Expedited (15-DaCompany Report #B0100677A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
	Back Pain							
	Sleep Disorder							
	Sudden Death							

Date:03/13/01ISR Number: 3680172-7Report Type:Expedited (15-DaCompany Report #B0100684A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
			Fluoxetine Hydrochloride	C				
			Ethanol	C				

Date:03/13/01ISR Number: 3680173-9Report Type:Expedited (15-DaCompany Report #B0100682A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Transient Blood Glucose Decreased Circulatory Collapse Dizziness Hypoaesthesia	Foreign Consumer	Bupropion Hydrochloride Coffee	PS C	Glaxo Wellcome Inc			

Date:03/13/01ISR Number: 3680175-2Report Type:Expedited (15-DaCompany Report #B0100678A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Dyskinesia Oxygen Saturation Abnormal Respiratory Depression Urinary Incontinence	Foreign	Bupropion Hydrochloride Lithium Salt Clomipramine Hcl Folic Acid	PS C C C	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ORAL	

Date:03/13/01ISR Number: 3680176-4Report Type:Expedited (15-DaCompany Report #B0100339A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Conversion Disorder Fall Headache Lethargy Loss Of Consciousness Malaise Movement Disorder Syncope Tremor	Foreign Consumer	Bupropion Hydrochloride Atorvastatin Calcium Enalapril	PS C C	Glaxo Wellcome Inc			

Date:03/13/01ISR Number: 3680179-XReport Type:Expedited (15-DaCompany Report #B0100670A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Mouth Ulceration Vulval Ulceration	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG/PER DAY/ORAL	
			Diclofenac	C				
			Co-Codamol	C				

Date:03/13/01ISR Number: 3680181-8Report Type:Expedited (15-DaCompany Report #B0100353A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Depression Intentional Misuse	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG /PER DAY/ ORAL	
			Paracetamol (Acetaminophen)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/13/01ISR Number: 3680182-XReport Type:Expedited (15-DaCompany Report #B0100671A
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Foreign	Bupropion					
Hospitalization -	Electrocardiogram		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
Initial or Prolonged	Abnormal						DAY/ ORAL	
	Left Ventricular Failure		Amitriptyline	C				
	Myocardial Ischaemia		Temazepam	C				
	Pulmonary Oedema		Human Insulin	C				

Date:03/13/01ISR Number: 3680418-5Report Type:Expedited (15-DaCompany Report #B0099781A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis	Foreign	Zyban	PS	Glaxo Wellcome Inc		4	DAY
Initial or Prolonged	Malaise	Health Professional						

Date:03/13/01ISR Number: 3680419-7Report Type:Expedited (15-DaCompany Report #B0100501A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG /	
Initial or Prolonged	Dizziness						TWICE PER DAY	
	Dry Mouth							
	Nausea							
	Tachycardia							

Date:03/13/01ISR Number: 3680421-5Report Type:Expedited (15-DaCompany Report #B0100349A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Chest Discomfort Chest Pain Haemoptysis	Foreign	Zyban Beclomethasone Dipropion Gaviscon Loratadine Salmeterol Xinafoate	PS C C C C	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:03/13/01ISR Number: 3680423-9Report Type:Expedited (15-DaCompany Report #D0014564A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion Gamma-Glutamyltransferase Increased Liver Function Test Abnormal Respiratory Arrest	Foreign Health Professional Company Representative Other	Zyban Amoxycillin	PS C	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:03/13/01ISR Number: 3680425-2Report Type:Expedited (15-DaCompany Report #B0100520A
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Circulatory Collapse Dizziness

		Hypoaesthesia Musculoskeletal Stiffness Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Photophobia	Foreign	Zyban	PS	Glaxo Wellcome Inc	
150 MG							
		Retching	Health Professional Other				

Date:03/13/01ISR Number: 3680427-6Report Type:Expedited (15-DaCompany Report #B0100605A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Convulsion	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
22 TABLET						
Initial or Prolonged	Sedation	Health				
/PER DAY/ORAL						
		Professional				

Date:03/13/01ISR Number: 3680428-8Report Type:Expedited (15-DaCompany Report #B0100358A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Angiopathy	Foreign	Zyban	PS	Glaxo Wellcome Inc	
150 MG						
	Emotional Distress Haemorrhagic Stroke	Literature Consumer Other				

Date:03/13/01ISR Number: 3680430-6Report Type:Expedited (15-DaCompany Report #B0100357A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Required	Urticaria	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
Intervention to	Vasculitis	Other				
TWICE PER DAY						

Prevent Permanent
/ ORAL
Impairment/Damage | | | Mefenamic Acid | C

Date:03/13/01ISR Number: 3680936-XReport Type:Expedited (15-DaCompany Report #B0096694A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG / TWICE PER DAY	
	Blood Pressure Decreased	Health						
	Drug Interaction	Professional						
	Face Oedema		Deptran Tablet	SS			10 MG / THREE TIMES PER DAY	
	Transient Ischaemic Attack		Salmeterol + Fluticasone	C				
			Aspirin	C				

Date:03/13/01ISR Number: 3680988-7Report Type:Expedited (15-DaCompany Report #B0099525A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG PER DAY ORAL	
	Respiratory Tract Neoplasm							

Date:03/13/01ISR Number: 3680995-4Report Type:Expedited (15-DaCompany Report #B0098815A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Discomfort	Foreign	Bupropion					
	Chest Pain	Literature	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
	Decreased Appetite	Consumer					DAY ORAL	
	Dehydration		Aspirin	C				
	Dermatitis		Metformin	C				
	Dizziness		Gliclazide	C				
	Dry Mouth							
	Dry Skin							
	Dyspnoea							
	Fatigue							
	Headache							
	Insomnia							
	Lethargy							
	Myocardial Infarction							
	Oedema							
	Pain							
	Tongue Oedema							

Date:03/13/01ISR Number: 3681042-0Report Type:Expedited (15-DaCompany Report #A0116641A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation	Foreign	Bupropion					
	Arrhythmia	Literature	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Coronary Artery Disease	Health					PER DAY ORAL	
	Dizziness	Professional						
	Feeling Abnormal							
	Myocardial Infarction							
	Sudden Death							
	Ventricular Fibrillation							

Date:03/13/01ISR Number: 3682633-3Report Type:Expedited (15-DaCompany Report #A0141757A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Blood Urea Increased Dehydration Electrocardiogram Qt Prolonged Vomiting	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	200 MG / TWICE PER DAY / ORAL	18 MON

Date:03/14/01ISR Number: 3680050-3Report Type:Expedited (15-DaCompany Report #A0139116A
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Other	Asthenia Dyspnoea Erythema Multiforme Hypoaesthesia Leukocytoclastic Vasculitis Neck Pain Paraesthesia

		Skin Exfoliation					
		Urticaria					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice							
per day	3 WK						
				Sorbitol	C		
				Centrum Vitamin	C		
				Plendil	C		

Date:03/14/01ISR Number: 3680052-7Report Type:Expedited (15-DaCompany Report #A0140680A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Constipation		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Dizziness					
per day 19 DAY						
	Dyspnoea					
	Feeling Jittery					
	Headache					
	Hypertension					
	Visual Disturbance					

Date:03/14/01ISR Number: 3680053-9Report Type:Expedited (15-DaCompany Report #A0141508A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amnesia		Wellbutrin	PS	Glaxo Wellcome	ORAL
22 DAY						
Initial or Prolonged	Anorexia		Alcohol	SS		
	Burning Sensation		Paxil	C		
	Confusional State		Remeron	C		
	Crying		Depakote	C		
	Dry Mouth		Klonopin	C		
	Dyspnoea		Premarin	C		
	Feeling Abnormal					
	Feeling Jittery					
	Heart Rate Increased					

	Insomnia					
	Loss Of Consciousness					
	Road Traffic Accident					
	Suicide Attempt					
	Thirst					

Date:03/14/01ISR Number: 3680057-6Report Type:Expedited (15-DaCompany Report #A0141931A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	1TAB Twice per day	
	Electroencephalogram							
	Abnormal							
	Grand Mal Convulsion							
	Injury							
	Memory Impairment							
	Skin Injury							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/01ISR Number: 3681038-9Report Type:Expedited (15-DaCompany Report #A0141841A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	2 WK
		Professional						
		Company						
		Representative						

Date:03/14/01ISR Number: 3682730-2Report Type:Expedited (15-DaCompany Report #B0100043A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Occlusion	Foreign	Bupropion					
	Ear Infection	Literature	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER	
	Myocardial Infarction						DAY / ORAL	
			Carbimazole	C				
			Enalapril	C				
			Clarithromycin	C				
			Doxycycline	C				

Date:03/14/01ISR Number: 3682733-8Report Type:Expedited (15-DaCompany Report #B0100763A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Bupropion					
Hospitalization - Initial or Prolonged	Aphasia	Literature	Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
	Circulatory Collapse							
	Dermatitis							
	Paralysis							
	Throat Tightness							
	Tremor							
	Vomiting							

Date:03/14/01ISR Number: 3682736-3Report Type:Expedited (15-DaCompany Report #B0100749A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Fibrinogen Increased Haematoma Mean Cell Volume Abnormal Red Blood Cell Count Decreased	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER DAY / ORAL	

Date:03/14/01ISR Number: 3682740-5Report Type:Expedited (15-DaCompany Report #B0100755A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/01ISR Number: 3680997-8Report Type:Expedited (15-DaCompany Report #A0141153A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	7 DAY
	Condition Aggravated		Zyban	SS	Glaxo Wellcome	ORAL		
	Constipation							
	Pain In Extremity							

Date:03/15/01ISR Number: 3680998-XReport Type:Expedited (15-DaCompany Report #A0141870A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Grand Mal Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Ischaemic Stroke		Celexa	C				
			Multiple Medications	C				

Date:03/15/01ISR Number: 3681004-3Report Type:Expedited (15-DaCompany Report #B0092315A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Headache		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	48 DAY
	Nausea							
	Ruptured Cerebral Aneurysm							
	Subarachnoid Haemorrhage							

Date:03/15/01ISR Number: 3681005-5Report Type:Expedited (15-DaCompany Report #B0096809A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	

Initial or Prolonged	Dyspnoea		
per day			
	Nausea	Estracombi	C
TRANSDERMAL			

Date:03/15/01ISR Number: 3681006-7Report Type:Expedited (15-DaCompany Report #B0097263A
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Amnesia
	Constipation
	Depression
	Diarrhoea
	Dysgeusia
	Dysphonia
	Feeling Abnormal
	Headache
	Insomnia
	Lethargy
	Malaise
	Mouth Ulceration
	Pain
	Panic Attack
	Personality Change
	Psychiatric Symptom
	Sedation
	Social Avoidant Behaviour
	Tongue Oedema

	Vision Blurred						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	

Date:03/15/01ISR Number: 3681011-0Report Type:Expedited (15-DaCompany Report #B0099529A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Ageusia Dehydration Dizziness Face Oedema Hypersensitivity Mouth Ulceration Oral Candidiasis Oral Pain Stevens-Johnson Syndrome		Zyban	PS	Glaxo Wellcome		150MG Twice per day 29 DAY

Date:03/15/01ISR Number: 3681015-8Report Type:Expedited (15-DaCompany Report #B0100994A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Diarrhoea Psychotic Disorder Rectal Haemorrhage		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	4 WK

Date:03/15/01ISR Number: 3681016-XReport Type:Expedited (15-DaCompany Report #B0101024A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 8 DAY

Dry Mouth
Fatigue
Hordeolum
Insomnia
Migraine
Mood Swings
Thirst

Date:03/15/01ISR Number: 3681017-1Report Type:Expedited (15-DaCompany Report #B0101026A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	18 DAY
			Bisoprolol	C				
			Diclofenac	C				
			Ranitidine	C	Glaxo Wellcome			
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/01ISR Number: 3681018-3Report Type:Expedited (15-DaCompany Report #B0101033A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL	42	DAY

Date:03/15/01ISR Number: 3681019-5Report Type:Expedited (15-DaCompany Report #B0101048A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY
Hospitalization -			Maxsoten	C			1TAB per day	
Initial or Prolonged			Ciprofibrate	C			100MG per day	
			Allopurinol	C	Glaxo Wellcome		150MG per day	
			Salmeterol	C	Glaxo Wellcome		50UG Twice	
							per day	
			Fluticasone	C	Glaxo Wellcome		500UG Twice	
							per day	
			Duovent	C			2PUFF Three	
							times per day	
			Methylprednisolone	C				

Date:03/15/01ISR Number: 3681607-6Report Type:Direct Company Report #
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Grand Mal Convulsion		Bupropion Hcl					
Intervention to			Tablets 75mg Geneva	PS	Geneva	ORAL	150MG BID	

Prevent Permanent Impairment/Damage			Dexedrine	C		
			Celexa	C		
			Risperdal	C		

Date:03/15/01ISR Number: 3682063-4Report Type:Expedited (15-DaCompany Report #B0100348A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anxiety	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/THREE TIMES PER DAY/ORAL
	C-Reactive Protein Increased						
	Confusional State						
	Drug Withdrawal Syndrome		Clonidine Hydrochloride	C			
	Dysphonia		Benzylpenicillin	C			
	Hallucination, Visual		Netilmicin Sulphate	C			
	Psychotic Disorder		Haloperidol	C			
	Restlessness		Morphine Hydrochloride	C			
	Sepsis						

Date:03/15/01ISR Number: 3682064-6Report Type:Expedited (15-DaCompany Report #A0141548A
Age:64 YR Gender:Female I/FU:I

Outcome	PT
Other	Chest Pain
	Condition Aggravated
	Dyspnoea
	Fatigue
	Lower Respiratory Tract

	Infection						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL
			Quinapril Hydrochloride	C			

Date:03/15/01ISR Number: 3682066-XReport Type:Expedited (15-DaCompany Report #B0100897A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Haemorrhagic Stroke	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG/AS DIRECTED
	Headache	Health Professional					

Date:03/15/01ISR Number: 3682067-1Report Type:Expedited (15-DaCompany Report #B0101145A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER DAY / ORAL
	Dizziness						

Date:03/15/01ISR Number: 3682068-3Report Type:Expedited (15-DaCompany Report #B0100762A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Overdose	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG
	Suicide Attempt	Literature	Ibuprofen	SS			

			Ethanol (Alcohol)	SS		

Date:03/15/01ISR Number: 3682072-5Report Type:Expedited (15-DaCompany Report #B0100733A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Asthenia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER
	Dysarthria						DAY / ORAL
	Haemorrhagic Stroke		Danazol	C			
	Transient Ischaemic Attack						

Date:03/15/01ISR Number: 3682074-9Report Type:Expedited (15-DaCompany Report #B0098808A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG / TWICE PER DAY
	Depression	Health Professional					
	Schizophrenia		Quetiapine	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/01ISR Number: 3682412-7Report Type:Expedited (15-DaCompany Report #A0134853A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Hospitalization -	Aggression	Professional						
THREE TIMES								
Initial or Prolonged	Anaemia							
PER DAY/ ORAL								
	Anxiety		Triphasil	C				
	Ascites		Hypericum	C				
	Back Pain		Multivitamin	C				
	Bacteriuria							
	Candidiasis							
	Cellulitis							
	Cervix Carcinoma Stage I							
	Chest Discomfort							
	Chest Pain							
	Constipation							
	Cough							
	Crepitations							
	Crying							
	Cystitis							
	Decreased Appetite							
	Depression							
	Drug Level Below							
	Therapeutic							
	Dyspnoea							
	Feeling Jittery							
	Flatulence							
	Gastro-Intestinal Fistula							
	Headache							
	Hypokalaemia							
	Hyponatraemia							
	Hypoxia							
	Implant Site Infection							
	Insomnia							
	Micturition Urgency							
	Muscle Spasms							
	Nervousness							
	Night Sweats							
	Oedema							
	Oral Candidiasis							
	Orthostatic Hypotension							
	Overdose							

Palpitations
Paraesthesia
Pneumonia
Pollakiuria
Post Coital Bleeding
Postoperative Adhesion
Rectal Haemorrhage
Rhinitis
Sinus Tachycardia
Small Intestinal
Obstruction
Thyroxine Increased
Urinary Tract Infection
Vaginal Haemorrhage
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/01ISR Number: 3682428-0Report Type:Expedited (15-DaCompany Report #A0138336A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL
	Dyspnoea	Professional						
	Rhabdomyolysis	Company Representative	Benezepril	C				
			Rofecoxib	C				

Date:03/15/01ISR Number: 3682432-2Report Type:Expedited (15-DaCompany Report #A0141472A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Disorder	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL
	Visual Disturbance							

Date:03/16/01ISR Number: 3681942-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Wellbutrin Sr 150mg	PS		ORAL	1 TAB EVERY DAY	ORAL
	Nausea							

Date:03/16/01ISR Number: 3682004-XReport Type:Expedited (15-DaCompany Report #A0142204A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intracranial Aneurysm		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	14	MON

Date:03/16/01ISR Number: 3682014-2Report Type:Expedited (15-DaCompany Report #B0087305A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Alcohol Increased		Zyban	PS	Glaxo Wellcome	ORAL		
	Completed Suicide		Alcohol	I				
	Drowning							
	Drug Abuser							
	Drug Interaction							
	Toxicologic Test Abnormal							

Date:03/16/01ISR Number: 3682015-4Report Type:Expedited (15-DaCompany Report #B0089264A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal		Bupropion					
	Exposure To Therapeutic		Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Drugs							
							per day	43 DAY
	Premature Baby							
	Stillbirth							
	Twin Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/01ISR Number: 3682030-0Report Type:Expedited (15-DaCompany Report #B0101035A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Movement Disorder Paraesthesia Tongue Oedema		Zyban Salbutamol Beclomethasone	PS C C	Glaxo Wellcome Glaxo Wellcome Glaxo Wellcome	ORAL RESPIRATORY (INHALATION) RESPIRATORY (INHALATION)	150MG Twice per day 2UNIT Twice per day	10 DAY

Date:03/16/01ISR Number: 3683189-1Report Type:Expedited (15-DaCompany Report #A0140680A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Constipation Dyspnoea Headache Tremor Visual Disturbance	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:03/16/01ISR Number: 3683664-XReport Type:Expedited (15-DaCompany Report #A0141508A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia Burning Sensation	Consumer	Wellbutrin Sr Ethanol (Alcohol)	PS SS	Glaxo Wellcome Inc	ORAL UNKNOWN		

	Confusional State	Paroxetine	
	Crying	Hydrochloride	C
	Dry Mouth	Mirtazapine	C
	Dyspnoea	Semisodium Valproate	C
	Feeling Abnormal	Clonazepam	C
	Feeling Jittery	Conjugated Estrogens	C
	Heart Rate Increased		
	Insomnia		
	Loss Of Consciousness		
	Mental Impairment		
	Road Traffic Accident		
	Suicide Attempt		
	Thirst		

Date:03/16/01ISR Number: 3683665-1Report Type:Expedited (15-DaCompany Report #A0139116A
Age:48 YR Gender:Male I/FU:I

Outcome	PT
Required	Angioneurotic Oedema
Intervention to	Asthenia
Prevent Permanent	Dyspnoea
Impairment/Damage	Erythema
	Erythema Multiforme
	Hypoaesthesia
	Leukocytoclastic
	Vasculitis
	Nausea
	Neck Pain
	Paraesthesia
	Periorbital Oedema

	Skin Exfoliation					
	Throat Irritation					
	Urticaria	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Xerosis	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /TWICE PER DAY/ORAL						
			Sorbitol	C		
			Centrum	C		
			Felodipine	C		

Date:03/16/01ISR Number: 3683667-5Report Type:Expedited (15-DaCompany Report #A0141931A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angiopathy	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
1 TABLET /TWICE PER DAY/ORAL						
	Cerebral Ischaemia					
	Electroencephalogram Abnormal					
	Grand Mal Convulsion					
	Injury					
	Memory Impairment					

Date:03/19/01ISR Number: 3683049-6Report Type:Expedited (15-DaCompany Report #B0100993A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthma		Zyban	PS	Glaxo Wellcome	ORAL
150MG See text	Chronic Obstructive Airways Disease Exacerbated		Salmeterol	C	Glaxo Wellcome	
50MCG Twice per day						

			Salbutamol	C	Glaxo Wellcome	
4U As required						
			Becotide	C	Glaxo Wellcome	
200MCG Twice per day						

Date:03/19/01ISR Number: 3683971-0Report Type:Expedited (15-DaCompany Report #PHBS2001BE02687
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Neoral	PS	Novartis			
	Drug Level Below	Health			Pharmaceuticals Corp	ORAL	ORAL	
	Therapeutic	Professional	Zyban (Amfebutamone)	SS		ORAL	ORAL	

Date:03/20/01ISR Number: 3684148-5Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Wellbutrin (Generic)	PS			100 MG BID	
	Headache		Bupropion	C				
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/20/01ISR Number: 3684572-0Report Type:Expedited (15-DaCompany Report #B0095941A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Malaise Neutrophil Count Decreased Tonsillitis Weight Decreased White Blood Cell Count Decreased		Zyban	PS	Glaxo Wellcome	ORAL		4 WK

Date:03/20/01ISR Number: 3684579-3Report Type:Expedited (15-DaCompany Report #B0101536A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Overdose Cerebrovascular Accident Dizziness		Zyban No Concurrent Medication	PS C	Glaxo Wellcome		1200MG per day	

Date:03/20/01ISR Number: 3685076-1Report Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Medication Error		Bupropion Risperidone Clonazepam Venlafaxine	PS SS SS SS				

Date:03/20/01ISR Number: 3685079-7Report Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Confusional State	Bupropion 150mg Q Am	PS	
	Delirium	Effexor 150mg Bid	SS	
	Fall	Risperidone	C	
	Overdose	Clonazepam	C	
	Urinary Incontinence			

Date:03/20/01ISR Number: 3685228-0Report Type:Direct Company Report #
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Dermatitis		Zyban (150mg) (Catalytica Pharmaceuticals)	PS	Catalytica Pharmaceuticals	ORAL

Dose Duration
150MG PO BID

Date:03/20/01ISR Number: 3685235-8Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Rash Pruritic		Zyban (150mg) (Catalytica Pharmaceuticals)	PS	Catalytica Pharmaceuticals	ORAL

Dose Duration
150MG PO BID

			Nicoderm	C			

Date:03/20/01ISR Number: 3685613-7Report Type:Expedited (15-DaCompany Report #A0141870A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coma	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Professional	Citalopram Hydrobromide	C			
	Ischaemic Stroke	Company	Multiple Medication	C			
		Representative					

Date:03/20/01ISR Number: 3685655-1Report Type:Expedited (15-DaCompany Report #10405
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Concerta	PS	Alza Corp	ORAL	18 MG 1X/1 DAY, ORAL
	Drug Interaction	Professional					
		Other	Wellbutrin	SS		ORAL	450 MG 1X/1 DAY, PO
			Doxycycline	C			
			Acne Cream	C			

Date:03/20/01ISR Number: 3686287-1Report Type:Expedited (15-DaCompany Report #B0097263A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Amnesia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Constipation	Health					
	Depression	Professional					
	Diarrhoea						
	Disturbance In Attention						
	Dysphonia						

	Feeling Abnormal
	Headache
	Insomnia
	Lethargy
	Malaise
	Mouth Haemorrhage
	Mouth Ulceration
	Palpitations
	Panic Attack
	Personality Change
	Psychiatric Symptom
	Rectal Tenesmus
	Sedation
	Social Avoidant Behaviour
	Tongue Oedema
	Vision Blurred
	Weight Increased

Date:03/20/01ISR Number: 3686288-3Report Type:Expedited (15-DaCompany Report #B0101024A
Age:29 YR Gender:Female I/FU:I

Outcome	PT
Disability	Dizziness
	Dry Mouth
	Fatigue

	Hordeolum Insomnia Migraine	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Mood Swings	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER
	Thirst						DAY/ORAL

Date:03/20/01ISR Number: 3686289-5Report Type:Expedited (15-DaCompany Report #B0101033A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Sudden Death	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL

Date:03/20/01ISR Number: 3686290-1Report Type:Expedited (15-DaCompany Report #B0101026A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Sudden Death	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE
							PER DAY/ORAL
			Bisoprolol	C			
			Diclofenac	C			
			Ranitidine Hydrochloride	C			
			Aspirin	C			

Date:03/20/01ISR Number: 3686291-3Report Type:Expedited (15-DaCompany Report #B0096809A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain Condition Aggravated	Foreign Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL

	Dyspnoea	Professional	Estracombi	C		
	Hiatus Hernia					
	Malaise					

Date:03/20/01ISR Number: 3686292-5Report Type:Expedited (15-DaCompany Report #B0101048A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
Hospitalization -	Malaise	Health						DAY/ORAL
Initial or Prolonged		Professional	Maxsoten	C				
			Ciprofibrate	C				
			Allopurinol	C				
			Salmeterol Xinafoate Fluticasone	C				
			Propionate	C				
			Duovent	C				
			Methylprednisolone	C				

Date:03/20/01ISR Number: 3686293-7Report Type:Expedited (15-DaCompany Report #B0100994A
Age:36 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Circulatory Collapse
Initial or Prolonged	Diarrhoea
	Psychotic Disorder

Rectal Haemorrhage

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Zyban	PS	Glaxo Wellcome Inc	ORAL
ORAL	4	WK					

Date:03/20/01ISR Number: 3686297-4Report Type:Expedited (15-DaCompany Report #B0092315A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Haemorrhagic Stroke	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
	Headache	Health				
PER DAY/ ORAL						
	Intraventricular Haemorrhage	Professional				
	Nausea					
	Nervous System Disorder					
	Ruptured Cerebral Aneurysm					
	Subarachnoid Haemorrhage					

Date:03/20/01ISR Number: 3686298-6Report Type:Expedited (15-DaCompany Report #B0099529A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Dizziness	Foreign	Zyban	PS	Glaxo Wellcome Inc	
UNKNOWN	150 MG/ TWICE					
Initial or Prolonged	Dry Mouth	Health				
PER DAY/						
	Face Oedema	Professional				
UNKNOWN						
	Hypersensitivity					
	Mouth Ulceration					
	Oral Candidiasis					
	Sensory Loss					
	Stevens-Johnson Syndrome					

Date:03/20/01ISR Number: 3686299-8Report Type:Expedited (15-DaCompany Report #A0141153A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Chest Pain	Health					DAY/ ORAL	
	Constipation	Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	SS		ORAL	150 MG/ UNK/	
							ORAL	

Date:03/20/01ISR Number: 3686519-XReport Type:Expedited (15-DaCompany Report #B0089264A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic	Foreign Study	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Drugs	Health					PER DAY/ ORAL	
	Premature Baby	Professional						
	Stillbirth							
	Twin Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/20/01ISR Number: 3686542-5Report Type:Expedited (15-DaCompany Report #B0101035A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Paraesthesia Tongue Oedema	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/	ORAL
			Salbutamol Sulphate	C				
			Beclomethasone Dipropion	C				

Date:03/20/01ISR Number: 3686543-7Report Type:Expedited (15-DaCompany Report #A0142204A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intracranial Aneurysm	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	14 MON
		Consumer						

Date:03/20/01ISR Number: 3686615-7Report Type:Expedited (15-DaCompany Report #B0087305A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Alcohol Increased	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Completed Suicide Drowning Drug Abuser Drug Interaction Drug Level Above Therapeutic	Health Professional	Ethanol (Formulation Unknown) (Alcohol)	SS				

Date:03/21/01ISR Number: 3685954-3Report Type:Expedited (15-DaCompany Report #A0131385A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Pain	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Confusional State	Professional					per day	
Initial or Prolonged	Eosinophilia		Xanax	C				
Other	Headache							
	Hepatitis Viral							
	Liver Function Test							
	Abnormal							
	Multi-Organ Failure							
	Neutrophilia							
	Petechiae							
	Pyrexia							
	Stevens-Johnson Syndrome							
	Thrombocytopenia							
	Toxic Epidermal							
	Necrolysis							
	Viral Infection							

Date:03/21/01ISR Number: 3685956-7Report Type:Expedited (15-DaCompany Report #A0136852A
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Corneal Erosion
Initial or Prolonged	Hypoaesthesia Eye
	Keratitis

Peripheral Nerve Injury

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Zyban	PS	Glaxo Wellcome	ORAL
1	MON						
			Professional	Ventolin	C	Glaxo Wellcome	
				Singulair	C		
				Ecotrin	C		
				Paxil	C		

Date:03/21/01ISR Number: 3685961-0Report Type:Expedited (15-DaCompany Report #A0141624A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Brain Damage		Wellbutrin	PS	Glaxo Wellcome	ORAL
	Convulsion					
	Mental Impairment					

Date:03/21/01ISR Number: 3685972-5Report Type:Expedited (15-DaCompany Report #B0088230A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acidosis	Health	Zyban	PS	Glaxo Wellcome	ORAL
50TAB Single						
Hospitalization -	Coma	Professional				
dose 1 DAY						
Initial or Prolonged	Convulsion		Anadin Extra	SS		ORAL
24TAB Single						
	Hyperhidrosis					
dose 1 DAY						
	Hypotension		Alcohol	SS		
	Intentional Misuse					
	Irritability					
	Pyrexia					
	Tachycardia					
	Vomiting					

Date:03/21/01ISR Number: 3685973-7Report Type:Expedited (15-DaCompany Report #B0088388A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accident		Zyban	PS	Glaxo Wellcome	ORAL	3	WK
	Circulatory Collapse		Lithium	C				
	Ecchymosis							
	Petit Mal Epilepsy							

Date:03/21/01ISR Number: 3685974-9Report Type:Expedited (15-DaCompany Report #B0091168A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Consumer	Bupropion	PS	Glaxo Wellcome	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Hyperhidrosis		Paracetamol	SS				
	Hypotension		Alcohol	SS				
Other	Overdose							
	Pyrexia							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/01ISR Number: 3685975-0Report Type:Expedited (15-DaCompany Report #B0094744A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	1	DAY
Hospitalization -	Convulsion		Anadin	SS		ORAL	1	DAY
Initial or Prolonged	Hypotension							
Other	Overdose							
	Tachycardia							

Date:03/21/01ISR Number: 3685979-8Report Type:Expedited (15-DaCompany Report #B0099522A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Attention	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	100MG Twice	
Initial or Prolonged	Deficit/Hyperactivity							
per day	13 DAY							
Disability	Disorder							
	Encephalitis							
	Meningitis Aseptic							
	Pleocytosis							

Date:03/21/01ISR Number: 3685980-4Report Type:Expedited (15-DaCompany Report #B0099526A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Astrocytoma	Consumer	Zyban	PS	Glaxo Wellcome		UNKNOWN	
Hospitalization -	Coma		Prozac	C				
Initial or Prolonged	Dysphagia							
	Infection							
	Nervous System Disorder							
	Sedation							
	Urinary Incontinence							
	Vomiting							

Date:03/21/01ISR Number: 3685981-6Report Type:Expedited (15-DaCompany Report #B0099532A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intermittent Claudication		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Vitreous Haemorrhage		Isib	C		ORAL	60MG In the morning	
			Co-Codamol	C				
			Cerivastatin	C			400MCG At night	
			Clopidogrel	C			75MG Per day	
			Frusemide	C			40MG In the morning	
			Lacidipine	C	Glaxo Wellcome		4MG In the morning	
			Fluoxetine	C			20MG In the morning	
			Aspirin	C			75MG Per day	
			Gtn	C	Glaxo Wellcome			
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	2PUFF Twice per day
			Ranitidine	C	Glaxo Wellcome		150MG Twice per day	
			Amitriptyline	C			20MG At night	

			Senna	C			
7.5G At night							

Date:03/21/01ISR Number: 3685983-XReport Type:Expedited (15-DaCompany Report #B0100785A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	7	DAY
	Crying							
	Depression							
	Diarrhoea							
	Diplopia							
	Disturbance In Attention							
	Dizziness							
	Eye Pain							
	Fatigue							
	Headache							
	Nausea							
	Suicidal Ideation							
	Vomiting							

Date:03/21/01ISR Number: 3685984-1Report Type:Expedited (15-DaCompany Report #B0100789A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Bupropion					
	Arthralgia		Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Hyperhidrosis						per day	
	Nausea							
	Peripheral Coldness							
	Tremor							

Date:03/21/01ISR Number: 3685987-7Report Type:Expedited (15-DaCompany Report #B0101027A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Gamolenic Acid	SS		ORAL	120MG Twice per day	
			Diclofenac	C		ORAL	50MG Three times per day	
			Co-Codamol	C		ORAL		

Date:03/21/01ISR Number: 3685993-2Report Type:Expedited (15-DaCompany Report #B0101331A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Myocardial Infarction							

Date:03/21/01ISR Number: 3685994-4Report Type:Expedited (15-DaCompany Report #B0101340A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL	150MG As directed	
	Drug Interaction							
	Thyroxine Increased		Thyroxine	SS	Glaxo Wellcome	ORAL	200MCG per	

day

Date:03/21/01ISR Number: 3685995-6Report Type:Expedited (15-DaCompany Report #B0101341A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	5 DAY
Hospitalization - RESPIRATORY	Cardiac Failure		Salbutamol	C	Glaxo Wellcome			
Initial or Prolonged (INHALATION)	Congestive Dizziness		Beclomethasone	C	Glaxo Wellcome			
RESPIRATORY (INHALATION)	Headache						10	DAY

Date:03/21/01ISR Number: 3685996-8Report Type:Expedited (15-DaCompany Report #B0101342A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	7 DAY
	Circulatory Collapse							
	Dyspnoea		Ramipril	C		ORAL	125MG per day	
	Lower Respiratory Tract Infection		Amlodipine	C		ORAL	10MG per day	
			Isosorbide	C		ORAL	20MG Twice per day	
			Simvastatin	C		ORAL	10MG per day	
RESPIRATORY (INHALATION)			Combivent	C				

Date:03/21/01ISR Number: 3685997-XReport Type:Expedited (15-DaCompany Report #B0101343A
Age:68 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	40 DAY
			Diclofenac	C		ORAL	50MG Twice per day	

Date:03/21/01ISR Number: 3685998-1Report Type:Expedited (15-DaCompany Report #B0101345A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Respiratory Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
			Combivent	C		RESPIRATORY (INHALATION)		

Date:03/21/01ISR Number: 3686000-8Report Type:Expedited (15-DaCompany Report #B0101349A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Zyban	PS	Glaxo Wellcome	ORAL	29	DAY
			Warfarin	I	Glaxo Wellcome	ORAL	173	DAY

Date:03/21/01ISR Number: 3686001-XReport Type:Expedited (15-DaCompany Report #B0101353A
Age:67 YR Gender:Female I/FU:I

Outcome	PT
Death	Cerebrovascular Accident
	Dyspnoea

	Oedema					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice per day						
			Aspirin	C		
UNKNOWN	75MG per day					
			Salbutamol	C	Glaxo Wellcome	
UNKNOWN	2PUFF Four times per day					
			Fluticasone	C	Glaxo Wellcome	
UNKNOWN	250MCG Twice per day					
			Diclofenac	C		
UNKNOWN	75MG Twice per day					
			Salmeterol	C	Glaxo Wellcome	
UNKNOWN	50MCG Twice per day					
			Oxitropium	C		
UNKNOWN	200MCG Twice per day					
			Imipramine	C		
UNKNOWN	10MG Per day					
			Frusemide	C		
UNKNOWN	40MG Per day					

Date:03/21/01ISR Number: 3686003-3Report Type:Expedited (15-DaCompany Report #B0101358A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Hypertension		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice per day						
	Myocardial Ischaemia					

			Valsartan	C		ORAL 80MG Per day
			Bendrofluazide	C	Glaxo Wellcome	ORAL 5MG Per day

Date:03/21/01ISR Number: 3686004-5Report Type:Expedited (15-DaCompany Report #B0101365A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Blood Viscosity Increased Embolism Facial Palsy		Zyban	PS	Glaxo Wellcome			10 DAY

Date:03/21/01ISR Number: 3686005-7Report Type:Expedited (15-DaCompany Report #B0101366A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Blood Pressure Increased Chills Heart Rate Increased Urticaria	Consumer	Zyban Amoxicillin Budesonide Xylometazoline	PS SS C C	Glaxo Wellcome	ORAL	150MG As directed 500MG Three times per day .05ML Four times per day	

Date:03/21/01ISR Number: 3686006-9Report Type:Expedited (15-DaCompany Report #B0101413A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alcoholism Grand Mal Convulsion Status Epilepticus		Zyban Tramadol Alcohol	PS C C	Glaxo Wellcome	ORAL	150MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/01ISR Number: 3686007-0Report Type:Expedited (15-DaCompany Report #B0101420A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:03/21/01ISR Number: 3686008-2Report Type:Expedited (15-DaCompany Report #B0101422A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Therapeutic Response		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	92 DAY
	Unexpected		Amitriptyline	C		ORAL	20MG per day	
	Vitreous Haemorrhage		Isosorbide	C		ORAL	30MG per day	
			Co-Codamol	C		ORAL	8U per day	
			Cerivastatin	C		ORAL	400MCG per day	
			Clopidogrel	C		ORAL	75MG per day	
			Frusemide	C		ORAL	40MG per day	
			Lacidipine	C	Glaxo Wellcome	ORAL	40MG per day	
			Fluoxetine	C		ORAL	20MG per day	
			Aspirin	C		ORAL	75MG per day	
			Ranitidine	C	Glaxo Wellcome	ORAL	300MG per day	
			Senna	C		ORAL	7.5MG per day	
			Salbutamol	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	

			Naproxen	C		ORAL 1000MG per day
			Trimethoprim	C	Glaxo Wellcome	ORAL 400MG per day
			Nicorandil	C		ORAL

Date:03/21/01ISR Number: 3686013-6Report Type:Expedited (15-DaCompany Report #D0014384A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Zyban	PS	Glaxo Wellcome	ORAL	300MG per day	6 WK
	Sedation	Professional						

Date:03/21/01ISR Number: 3687101-0Report Type:Expedited (15-DaCompany Report #A038609
Age:18 YR Gender:Male I/FU:F

Outcome	PT
Required Intervention to Prevent Permanent Impairment/Damage	Confusional State
	Crying
	Depression
	Disorientation
	Dizziness
	Drug Interaction
	Emotional Disorder
	Feeling Jittery
	Hallucination, Visual
	Hyperhidrosis
	Inappropriate Affect
	Mood Swings
	Nasopharyngitis
	Psychomotor Hyperactivity
	Serotonin Syndrome
	Thinking Abnormal
	Tremor

Vision Blurred

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL
75.00 MG							
TOTAL:DAILY:O							
RAL							
				Wellbutrin	SS		
150.00 MG							
TOTAL:BID							
				Nyquil	SS		
UNKNOWN							

Date:03/21/01ISR Number: 3687618-9Report Type:Expedited (15-DaCompany Report #B0100993A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Asthma	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 ORAL						
Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated	Health Professional	Salmeterol Xinafoate	C		
			Salbutamol Sulphate	C		
			Beclomethasone Dipropion	C		

Date:03/22/01ISR Number: 3687226-XReport Type:Expedited (15-DaCompany Report #A0142820A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Insomnia		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Lung Neoplasm Malignant					
per day						
	Pruritus					

Date:03/22/01ISR Number: 3687231-3Report Type:Expedited (15-DaCompany Report #B0100196A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Zyban	PS	Glaxo Wellcome		150MG Twice per day	20 DAY
	Cough							
	Dehydration							
	Dyspnoea							
	Fatigue							
	Hypersensitivity							
	Oedema Peripheral							
	Pharyngolaryngeal Pain							
	Pyrexia							
	Rash Pruritic							
	Urticaria							

Date:03/22/01ISR Number: 3687232-5Report Type:Expedited (15-DaCompany Report #B0100198A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Zyban	PS	Glaxo Wellcome			
	Hyperventilation		Medroxyprogesterone Acetate	C				
			Amitriptyline Hydrochloride	C	Glaxo Wellcome	ORAL		
			Fluoxetine Hydrochloride	C		ORAL		
			Pizotifen Malate	C				

			Orlistat	C		

Date:03/22/01ISR Number: 3687236-2Report Type:Expedited (15-DaCompany Report #B0101350A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
							per day	
			Isosorbide	C			60MG Twice	
							per day	
			Nifedipine	C			20MG Twice	
							per day	
			Alverine	C				
			Aspirin	C				

Date:03/22/01ISR Number: 3687238-6Report Type:Expedited (15-DaCompany Report #B0101552A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Sudden Death		Zyban	PS	Glaxo Wellcome	ORAL		

Date:03/22/01ISR Number: 3687239-8Report Type:Expedited (15-DaCompany Report #B0101558A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome	ORAL	14	DAY
			Lormetazepam	C		ORAL	1MG At night	
			Thyroxine	C	Glaxo Wellcome	ORAL	100MCG per	

day

			Gliclazide	C			ORAL
80MG per day							

Date:03/22/01ISR Number: 3687240-4Report Type:Expedited (15-DaCompany Report #B0101569A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	150MG	
	Asthma						Variable dose	9 DAY
	Dyspnoea		Fluticasone	C	Glaxo Wellcome		RESPIRATORY	
	Hallucination						(INHALATION)	500MCG
	Insomnia						Twice per day	
	Panic Attack		Salbutamol	C	Glaxo Wellcome		RESPIRATORY	
							(INHALATION)	
			Trinordiol	C		ORAL	1TAB per day	

Date:03/22/01ISR Number: 3687242-8Report Type:Expedited (15-DaCompany Report #B0101671A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Zyban	PS	Glaxo Wellcome			
	Nephritis							
	Renal Disorder							
	Swelling							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3688206-0Report Type:Expedited (15-DaCompany Report #A0142629A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Akathisia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	7 DAY
	Depersonalisation		Multivitamin	C				
	Mental Disorder		Calcium	C				
	Tremor							

Date:03/23/01ISR Number: 3688212-6Report Type:Expedited (15-DaCompany Report #B0099781A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhoids		Zyban	PS	Glaxo Wellcome		UNKNOWN	4 DAY
Initial or Prolonged	Malaise		No Concurrent Medication	C				

Date:03/23/01ISR Number: 3688982-7Report Type:Expedited (15-DaCompany Report #B0099532A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intermittent Claudication	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER DAY/ORAL	
	Periorbital Haematoma	Health						
	Retinal Detachment	Professional						
	Vitreous Haemorrhage		Isosorbide Monitrate	C				
			Co-Codamol	C				
			Cerivastatin	C				
			Clopidogrel	C				
			Frusemide	C				
			Lacidipine	C				
			Fluoxetine	C				
			Aspirin	C				
			Nitroglycerin	C				
			Beclomethasone Dipropion	C				
			Ranitidine					

			Hydrochloride	C		
			Amitriptyline	C		
			Sennosides	C		

Date:03/23/01ISR Number: 3688984-0Report Type:Expedited (15-DaCompany Report #B0088230A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Acidosis	Foreign	Bupropion				
Hospitalization -	Blood Pressure Decreased	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	50
Initial or Prolonged	Coma	Professional					TABLET/SINGLE
	Hyperhidrosis						DOSE/ORAL
	Hypotension		Anadin Extra Tablet				
	Intentional Misuse		(Anadin Extra)	SS		ORAL	24 TABLET
	Irritability						/SINGLE DOSE/
	Pyrexia						ORAL
	Tachycardia		Ethanol L(Alcohol)	SS			UNKNOWN
	Vomiting						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3688986-4Report Type:Expedited (15-DaCompany Report #B0094744A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	7.5 G /ORAL	
Hospitalization - Initial or Prolonged	Convulsion							
Required Intervention to Prevent Permanent Impairment/Damage	Hypotension		Anadin((Anadin)	SS		ORAL	7.5 G /ORAL	
	Intentional Misuse							
	Tachycardia							

Date:03/23/01ISR Number: 3688988-8Report Type:Expedited (15-DaCompany Report #B0091168A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
Hospitalization - Initial or Prolonged	Convulsion							
Required Intervention to Prevent Permanent Impairment/Damage	Hyperhidrosis		Paracetamol (Acetaminophen)	SS			UNKNOWN	
	Hypotension							
	Irritability		Ethanol (Alcohol)	SS			UNKNOWN	
	Overdose							
	Pyrexia							
	Tachycardia							

Date:03/23/01ISR Number: 3689074-3Report Type:Expedited (15-DaCompany Report #B0101536A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			
	Medication Error	Health Professional						

Date:03/23/01ISR Number: 3689077-9Report Type:Expedited (15-DaCompany Report #B0095941A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Malaise Tonsillitis Weight Decreased White Blood Cell Count Decreased	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	4 WK

Date:03/23/01ISR Number: 3689470-4Report Type:Expedited (15-DaCompany Report #A0141624A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Damage Convulsion Thinking Abnormal	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:03/23/01ISR Number: 3689485-6Report Type:Expedited (15-DaCompany Report #A0136852A
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Corneal Erosion Eye Pain

	Keratitis					
	Keratoconjunctivitis Sicca	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Sensory Loss	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / ORAL						
		Professional	Salbutamol Sulphate	C		
			Montelukast Sodium	C		
			Aspirin	C		
			Paroxetine Hydrochloride	C		

Date:03/23/01ISR Number: 3689486-8Report Type:Expedited (15-DaCompany Report #A0131385A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Back Pain	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
Hospitalization -	Confusional State	Professional				
TWICE PER DAY						
Initial or Prolonged	Dermatitis					
/ ORAL						
Required	Eosinophilia		Alprazolam	C		
Intervention to	Headache					
Prevent Permanent	Liver Function Test					
Impairment/Damage	Abnormal					
	Multi-Organ Failure					
	Neutrophilia					
	Petechiae					
	Pyrexia					
	Stevens-Johnson Syndrome					
	Thrombocytopenia					
	Toxic Epidermal Necrolysis					
	Viral Infection					

Date:03/23/01ISR Number: 3689989-6Report Type:Expedited (15-DaCompany Report #B0100785A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Aggression	Foreign	Bupropion			

	Crying	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
ORAL 7 DAY						
	Depression	Professional				
	Diarrhoea					
	Diplopia					
	Disturbance In Attention					
	Dizziness					
	Eye Pain					
	Fatigue					
	Headache					
	Nausea					
	Suicidal Ideation					
	Vomiting					

Date:03/23/01ISR Number: 3689990-2Report Type:Expedited (15-DaCompany Report #B0101027A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Drug Interaction	Foreign	Bupropion			
Hospitalization -	Grand Mal Convulsion		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG (PER						
Initial or Prolonged						
DAY) ORAL						
			Gamolenic Acid			
			(Gamolenic Acid)	SS		ORAL
120 MG (TWICE						

PER DAY) ORAL

			Diclofenac	C		
			Co-Comadol	C		

Date:03/23/01ISR Number: 3689992-6Report Type:Expedited (15-DaCompany Report #B0100789A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Foreign	Bupropion					
	Arthralgia	Study	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
	Hyperhidrosis	Health					PER DAY) ORAL	
	Nausea	Professional						
	Peripheral Coldness							
	Tremor							

Date:03/23/01ISR Number: 3689993-8Report Type:Expedited (15-DaCompany Report #B0088388A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Circulatory Collapse	Foreign	Bupropion					
Intervention to	Ecchymosis	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	3 WK
Prevent Permanent	Petit Mal Epilepsy	Professional	Lithium Salt	C				
Impairment/Damage								

Date:03/23/01ISR Number: 3689997-5Report Type:Expedited (15-DaCompany Report #B0101343A
Age:68 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
							PER DAY/ ORAL	
			Diclofenac	C				

Date:03/23/01ISR Number: 3689998-7Report Type:Expedited (15-DaCompany Report #B0101342A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	
	Dyspnoea							
	Lower Respiratory Tract Infection		Ramipril	C				
			Amlodipine	C				
			Isosorbide	C				
			Simvastatin	C				
			Combivent	C				

Date:03/23/01ISR Number: 3690000-1Report Type:Expedited (15-DaCompany Report #B0101422A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Therapeutic Response	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/	
	Unexpected							
	Vitreous Haemorrhage		Amitriptyline	C				
			Isosorbide	C				
			Co-Codamol	C				
			Cerivastatin	C				
			Clopidogrel	C				
			Frusemide	C				
			Lacidipine	C				

			Fluoxetine	C		
			Aspirin	C		
			Ranitidine Hydrochloride	C		
			Sennosides	C		
			Salbutamol Sulphate	C		
			Naproxen	C		
			Trimethoprim	C		
			Nicorandil	C		

Date:03/23/01ISR Number: 3690001-3Report Type:Expedited (15-DaCompany Report #B0101366A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Blood Pressure Increased Chills Heart Rate Increased Pruritus Urticaria	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ AS DIRECTED/ ORAL
			Amoxycillin Capsule (Amoxicillin)	SS			500 MG/ THREE TIMES PER DAY
			Budesonide	C			
			Xylometazoline	C			

Date:03/23/01ISR Number: 3690002-5Report Type:Expedited (15-DaCompany Report #B0101365A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Embolism Facial Palsy Haemoconcentration	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc		150 MG

Date:03/23/01ISR Number: 3690003-7Report Type:Expedited (15-DaCompany Report #B0101341A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
Hospitalization -	Cardiac Failure						DAY/ ORAL	
Initial or Prolonged	Congestive		Salbutamol Sulphate	C				
	Dizziness		Beclomethasone					
	Headache		Dipropion.	C				

Date:03/23/01ISR Number: 3690004-9Report Type:Expedited (15-DaCompany Report #B0101340A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ AS	
Initial or Prolonged	Drug Interaction						DIRECTED/	
							ORAL	
			Thyroxine Sodium (Formulation Unknown) (Levothyroxine Sodium)	SS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3690006-2Report Type:Expedited (15-DaCompany Report #B0101331A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease Myocardial Infarction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL

Date:03/23/01ISR Number: 3690007-4Report Type:Expedited (15-DaCompany Report #B0101420A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL

Date:03/23/01ISR Number: 3690008-6Report Type:Expedited (15-DaCompany Report #B0101413A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion Status Epilepticus	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL
			Tramadol Hydrochloride	C				
			Ethanol	C				

Date:03/23/01ISR Number: 3690009-8Report Type:Expedited (15-DaCompany Report #B0101358A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypertension Myocardial Ischaemia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG (TWICE PER DAY)	
			Valsartan	C				
			Bendrofluazide	C				

Date:03/23/01ISR Number: 3690010-4Report Type:Expedited (15-DaCompany Report #B0101353A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL
			Aspirin	C				
			Salbutamol Sulphate	C				
			Fluticasone Propionate	C				
			Diclofenac	C				
			Salmeterol Xinafoate	C				
			Oxitropium Bromide	C				
			Imipramine	C				
			Frusemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3690011-6Report Type:Expedited (15-DaCompany Report #B0101349A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage (AS DIRECT)	Drug Interaction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
			Warfarin Sodium (Warfarin Sodium)	SS		ORAL		

Date:03/23/01ISR Number: 3690012-8Report Type:Expedited (15-DaCompany Report #B0101345A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Respiratory Disorder Sudden Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY)	ORAL
			Combivent	C				

Date:03/23/01ISR Number: 3690013-XReport Type:Expedited (15-DaCompany Report #B0099526A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Astrocytoma Body Temperature Increased Coma Dysphagia Ganglioneuroma Infection Memory Impairment Urinary Incontinence Vomiting	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			
			Fluoxetine Hydrochloride	C				

Date:03/23/01ISR Number: 3690014-1Report Type:Expedited (15-DaCompany Report #D0014384A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Sedation	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:03/23/01ISR Number: 3690015-3Report Type:Expedited (15-DaCompany Report #B0099522A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Aggression Attention Deficit/Hyperactivity Disorder Encephalitis Meningitis Aseptic	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	100 MG (TWICE PER DAY) ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/01ISR Number: 3688834-2Report Type:Expedited (15-DaCompany Report #A0140463A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	10	DAY
	Euphoric Mood							
	Feeling Abnormal							
	Hypersensitivity							
	Myocardial Infarction							
	Palpitations							
	Psychomotor Hyperactivity							

Date:03/26/01ISR Number: 3689555-2Report Type:Direct Company Report #
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Zyban	PS				
	Pruritus							
	Urticaria							

Date:03/26/01ISR Number: 3689561-8Report Type:Direct Company Report #
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Gammahydroxybutyrate (Ghb)	PS	Wellbutrin		3	PER DAY
	Coma		Wellbutrin	SS				

Date:03/26/01ISR Number: 3689879-9Report Type:Expedited (15-DaCompany Report #B0100198A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150	MG
	Hyperventilation	Health						

		Professional	Medroxyprogresterone Ace.	C		
			Amitriptyline Hcl	C		
			Fluoxetine Hdyrochloride	C		
			Pizotifen Malate	C		
			Orlistat	C		

Date:03/26/01ISR Number: 3689881-7Report Type:Expedited (15-DaCompany Report #B0101350A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL
			Isosorbide	C				
			Nifedipine	C				
			Alverine Citrate	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/01ISR Number: 3689884-2Report Type:Expedited (15-DaCompany Report #B0101558A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
			Lormetazepam	C				
			Thyroxine Sodium	C				
			Gliclazide	C				

Date:03/26/01ISR Number: 3689886-6Report Type:Expedited (15-DaCompany Report #B0101569A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anxiety	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG VARIABLE DOSE ORAL	
	Asthma							
	Hallucination							
	Insomnia							
	Panic Attack		Fluticasone Propionate	C				
			Salbutamol Sulphate	C				
			Trinordiol	C				

Date:03/26/01ISR Number: 3689888-XReport Type:Expedited (15-DaCompany Report #B0100196A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG TWICE PER DAY	
	Cough							
	Dehydration							
	Dyspnoea							
	Fatigue							
	Hypersensitivity							
	Oedema Peripheral							

	Pharyngolaryngeal Pain					
	Pyrexia					
	Rash Pruritic					
	Urticaria					

Date:03/26/01ISR Number: 3690157-2Report Type:Expedited (15-DaCompany Report #A0142820A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Insomnia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Lung Neoplasm Malignant	Consumer					PER DAY /	
	Pruritus						ORAL	

Date:03/26/01ISR Number: 3690158-4Report Type:Expedited (15-DaCompany Report #A0101552A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Sudden Death							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/01ISR Number: 3690159-6Report Type:Expedited (15-DaCompany Report #B0101671A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG /	
	Nephritis	Health						
	Renal Disorder	Professional						
	Swelling							

Date:03/27/01ISR Number: 3689661-2Report Type:Expedited (15-DaCompany Report #B0100993A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG See text	4 DAY
Other	Chronic Obstructive Airways Disease Exacerbated		Salmeterol	C	Glaxo Wellcome		50MCG Twice per day	
			Salbutamol	C	Glaxo Wellcome		4U As required	
			Becotide	C	Glaxo Wellcome		200MCG Twice per day	

Date:03/27/01ISR Number: 3689665-XReport Type:Expedited (15-DaCompany Report #B0101861A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression		Zyban	PS	Glaxo Wellcome		150MG Twice per day	19 DAY
	Drug Hypersensitivity							
	Dysphagia							

Eyelid Oedema
Face Oedema
Gastritis
Insomnia
Muscle Spasms
Pharyngeal Oedema
Pruritus
Urticaria

Date:03/27/01ISR Number: 3689666-1Report Type:Expedited (15-DaCompany Report #B0101874A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	11 DAY
			Salmeterol RESPIRATORY (INHALATION)	C	Glaxo Wellcome		2PUFF Twice per day	
			Combivent RESPIRATORY (INHALATION)	C			2PUFF Four times per day	
			Frusemide	C		ORAL	20MG per day	
			Theophylline	C		ORAL	400MG Twice per day	
			Didronel Pmo	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/01ISR Number: 3689667-3Report Type:Expedited (15-DaCompany Report #B0101875A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Delirium		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	2 DAY
	Dizziness		Lansoprazole	C		ORAL	15MG per day	
	Hyperaesthesia		Diazepam	C		ORAL	5MG per day	
	Nausea		Metoclopramide	C		ORAL	10MG per day	
	Tongue Oedema		Dicyclomine	C		ORAL	20MG per day	
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	200MCG per day
			Salmeterol	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	25MCG per day
			Montelukast	C		ORAL	10MG per day	
			Combivent	C			RESPIRATORY (INHALATION)	

Date:03/27/01ISR Number: 3689668-5Report Type:Expedited (15-DaCompany Report #B0101979A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	7 DAY
Other	Feeling Drunk							
	Insomnia							
	Vision Blurred							

Date:03/27/01ISR Number: 3689669-7Report Type:Expedited (15-DaCompany Report #B0101980A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Multiple Sclerosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	24 DAY
			Irbesartan	C		ORAL	150MG Per day	

Date:03/27/01ISR Number: 3689670-3Report Type:Expedited (15-DaCompany Report #B0101992A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	75MG per day	
			Venlafaxine	C		ORAL	12.5MG per day	
			Captopril	C	Glaxo Wellcome	ORAL		
			Co-Proxamol	C		ORAL		
			Senna	C		ORAL		

Date:03/27/01ISR Number: 3689678-8Report Type:Expedited (15-DaCompany Report #B0100993A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG See text	4 DAY
Other	Chronic Obstructive Airways Disease Exacerbated		Salmeterol	C	Glaxo Wellcome		50MCG Twice per day	
			Salbutamol	C	Glaxo Wellcome		4U As required	
			Becotide	C	Glaxo Wellcome		200MCG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/01ISR Number: 3689682-XReport Type:Expedited (15-DaCompany Report #B0101861A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression Gastritis Hypersensitivity Insomnia Muscle Spasms		Zyban	PS	Glaxo Wellcome		150MG Twice per day	19 DAY

Date:03/27/01ISR Number: 3689683-1Report Type:Expedited (15-DaCompany Report #B0101874A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	11 DAY
			Salmeterol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	2PUFF Twice per day	
			Combivent	C		RESPIRATORY (INHALATION)	2PUFF Four times per day	
			Frusemide	C		ORAL	20MG per day	
			Theophylline	C		ORAL	400MG Twice per day	
			Didronel Pmo	C		ORAL		

Date:03/27/01ISR Number: 3689684-3Report Type:Expedited (15-DaCompany Report #B0101875A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Delirium		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	2 DAY
	Dizziness		Lansoprazole	C		ORAL	15MG per day	
	Hyperaesthesia		Diazepam	C		ORAL	5MG per day	
	Nausea		Metoclopramide	C		ORAL	10MG per day	
	Tongue Oedema		Dicyclomine	C		ORAL	20MG per day	
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	200MCG per day
			Salmeterol	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	25MCG per day
			Montelukast	C		ORAL	10MG per day	
			Combivent	C			RESPIRATORY (INHALATION)	

Date:03/27/01ISR Number: 3689685-5Report Type:Expedited (15-DaCompany Report #B0101979A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	7 DAY
Other	Feeling Drunk							
	Insomnia							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/01ISR Number: 3689686-7Report Type:Expedited (15-DaCompany Report #B0101980A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Joint Stiffness						per day	24 DAY
	Multiple Sclerosis		Irbesartan	C		ORAL	150MG Per day	

Date:03/27/01ISR Number: 3689687-9Report Type:Expedited (15-DaCompany Report #B0101992A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	75MG per day	
			Venlafaxine	C		ORAL		
			Captopril	C	Glaxo Wellcome	ORAL	12.5MG per day	
			Co-Proxamol	C		ORAL		
			Senna	C		ORAL		

Date:03/27/01ISR Number: 3690482-5Report Type:Expedited (15-DaCompany Report #A0142629A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Akathisia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Depressed Level Of Consciousness	Professional	Multivieamin	C			DAY ORAL	
	Dissociative Disorder		Calcium Salt	C				
	Restlessness							
	Tremor							

Date:03/27/01ISR Number: 3690667-8Report Type:Direct Company Report #
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Convulsion Intentional Misuse Vomiting		Wellbutrin 150mg Glaxo-Wellcome X 46 TABS ORAL Neurontin 300mg Parke-Davis X 50 TABS ORAL Celexa	PS SS C	Glaxo-Wellcome Parke-Davis	ORAL ORAL		

Date:03/27/01ISR Number: 3691039-2Report Type:Expedited (15-DaCompany Report #B0099781A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhoids Malaise	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc		4	DAY

Date:03/27/01ISR Number: 3691770-9Report Type:Expedited (15-DaCompany Report #A0142629A
Age: Gender:Female I/FU:I

Outcome	PT
Other	Akathisia Feeling Abnormal Mental Impairment

		Tremor					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ PER DAY/ ORAL							
				Multivitamin	C		
				Calcium Salt	C		

Date:03/28/01ISR Number: 3692427-0Report Type:Expedited (15-DaCompany Report #A0140463A
Age:27 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Arrhythmia	Foreign	Bupropion			
		Cardiac Arrest	Literature	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
ORAL	10 DAY						
		Euphoric Mood	Consumer				
		Feeling Abnormal					
		Hypersensitivity					
		Myocardial Infarction					
		Palpitations					
		Psychomotor Hyperactivity					

Date:03/29/01ISR Number: 3691244-5Report Type:Expedited (15-DaCompany Report #B0101602A
Age:40 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Amnesia		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice							
Hospitalization -		Apnoea					
per day	9 DAY						
Initial or Prolonged		Cardio-Respiratory Arrest		Vitamin C	C		ORAL
1G per day							
Other		Cyanosis		Multivitamins	C		ORAL
		Eye Movement Disorder					
		Grand Mal Convulsion					
		Hypoaesthesia					

Date:03/29/01ISR Number: 3691583-8Report Type:Expedited (15-DaCompany Report #A0142204A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intracranial Aneurysm	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	14	MON

Date:03/29/01ISR Number: 3691593-0Report Type:Expedited (15-DaCompany Report #A0143409A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaesthesia Insomnia Sleep Apnoea Syndrome Weight Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:03/29/01ISR Number: 3691605-4Report Type:Expedited (15-DaCompany Report #B0099220A
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation Confusional State

	Grand Mal Convulsion						
	Hyperglycaemia						
	Lactic Acidosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Leukocytosis	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 50 DAY
	Thrombocythaemia	Health	Aspirin	C			
		Professional	Alcohol	C			

Date:03/29/01ISR Number: 3691606-6Report Type:Expedited (15-DaCompany Report #B0099526A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Astrocytoma	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	
Hospitalization -	Coma	Health	Prozac	C			
Initial or Prolonged	Dysphagia	Professional					
	Glioma						
	Infection						
	Nervous System Disorder						
	Urinary Incontinence						
	Vomiting						

Date:03/29/01ISR Number: 3691615-7Report Type:Expedited (15-DaCompany Report #B0101048A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthma	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 3 DAY
Initial or Prolonged	Cyanosis	Health	Maxsoten	C			1TAB per day
Disability	Malaise	Professional	Ciprofibrate	C			100MG per day
Other			Allopurinol	C	Glaxo Wellcome		150UG per day
			Salmeterol	C	Glaxo Wellcome		50UG Twice per day
			Fluticasone	C	Glaxo Wellcome		500UG Twice

per day

	Duovent	C

2PUFF Three

times per day

	Methylprednisolone	C

16MG Per day

Date:03/29/01ISR Number: 3691617-0Report Type:Expedited (15-DaCompany Report #B0101365A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Disorder Blood Pressure Increased Embolism Facial Palsy	Foreign Health Professional	Zyban	PS	Glaxo Wellcome		10	DAY

Date:03/29/01ISR Number: 3691635-2Report Type:Expedited (15-DaCompany Report #B0102032A
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Depression Dermatitis Dysgeusia Fatigue Feeling Hot And Cold Headache Injection Site Haemorrhage

	Nocturia						
	Pruritus						
	Skin Warm	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urticaria		Zyban	PS	Glaxo Wellcome		9 DAY

Date:03/29/01ISR Number: 3691636-4Report Type:Expedited (15-DaCompany Report #B0102048A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Chest Discomfort						per day 34 DAY
			Bendrofluazide	C	Glaxo Wellcome	ORAL	5MG per day

Date:03/29/01ISR Number: 3691637-6Report Type:Expedited (15-DaCompany Report #B0102049A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blood Viscosity Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Dermatitis						per day
	Joint Swelling						
	Muscular Weakness						
	Night Sweats						
	Serum Sickness						

Date:03/29/01ISR Number: 3691638-8Report Type:Expedited (15-DaCompany Report #B0102062A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatine		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 17 DAY
Initial or Prolonged	Phosphokinase Increased						

Dyspnoea

Date:03/29/01ISR Number: 3691639-XReport Type:Expedited (15-DaCompany Report #B0102063A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Subarachnoid Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	37	DAY

Date:03/29/01ISR Number: 3691640-6Report Type:Expedited (15-DaCompany Report #B0102228A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Erythema Multiforme		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	29 DAY
Other	Psoriasis							

Date:03/29/01ISR Number: 3691641-8Report Type:Expedited (15-DaCompany Report #B0102229A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	5 DAY
			Terbutaline	C				

RESPIRATORY

(INHALATION)

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/01ISR Number: 3691642-XReport Type:Expedited (15-DaCompany Report #B0102251A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse		Zyban	PS	Glaxo Wellcome		150MG As directed	
	Malaise							
	Ventricular Fibrillation		Homeopathic Drug	C				

Date:03/30/01ISR Number: 3692352-5Report Type:Expedited (15-DaCompany Report #254325
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Accutane Capsules	PS	Roche		108	DAY
			Wellbutrin	SS			123	DAY
			Prozac	C				

Date:03/30/01ISR Number: 3692576-7Report Type:Expedited (15-DaCompany Report #B0087305A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Interaction		Zyban	PS	Glaxo Wellcome	ORAL		
	Completed Suicide		Alcohol	I				
	Drowning							
	Medication Error							

Date:03/30/01ISR Number: 3692580-9Report Type:Expedited (15-DaCompany Report #B0099756A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Interaction		Zyban	PS	Glaxo Wellcome	ORAL		
	Drowning		Alcohol	SS				
	Medication Error							

Date:03/30/01ISR Number: 3693047-4Report Type:Direct Company Report #
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia		Comtrex Maximum					
	Dizziness		Bristol-Myers Squibb	PS	Bristol-Myers Squibb	ORAL	2 TABS	Q
	Nausea						12HR	PO
	Vision Blurred		Wellbutrin Sr 150mg					
			Glaxo	SS	Glaxo	ORAL	150MG	QAM
							PO	

Date:03/31/01ISR Number: 3693549-0Report Type:Expedited (15-DaCompany Report #B0101979A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Foreign	Bupropion					
Required	Feeling Drunk		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER	
Intervention to	Insomnia						DAY/ORAL	
Prevent Permanent Impairment/Damage	Vision Blurred							

Date:03/31/01ISR Number: 3693550-7Report Type:Expedited (15-DaCompany Report #B0101992A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL	
			Venlafaxine Hydrochloride	C				
			Captopril	C				
			Co-Proxamol	C				
			Sennosides	C				

Date:03/31/01ISR Number: 3693551-9Report Type:Expedited (15-DaCompany Report #B0101861A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			
	Dysphagia	Consumer					UNKNOWN	150 MG/TWICE PER DAY
	Eyelid Oedema							
	Face Oedema							
	Gastritis							
	Hypersensitivity							
	Insomnia							
	Muscle Spasms							
	Pharyngeal Oedema							
	Pruritus							
	Urticaria							

Date:03/31/01ISR Number: 3693552-0Report Type:Expedited (15-DaCompany Report #B0101875A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent	Angioneurotic Oedema	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL	
	Delirium							
	Dizziness							

Impairment/Damage	Hyperaesthesia		Lansoprazole	C		
	Tongue Oedema		Diazepam	C		
			Metoclopramide	C		
			Dicyclomine	C		
			Beclomethasone Dipropion	C		
			Salmeterol Xinafoate	C		
			Montelukast Sodium	C		
			Combivent	C		

Date:03/31/01ISR Number: 3693553-2Report Type:Expedited (15-DaCompany Report #B0101980A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Difficulty In Walking Joint Stiffness Multiple Sclerosis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ORAL
			Irbesartan	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/01ISR Number: 3693554-4Report Type:Expedited (15-DaCompany Report #B0100993A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma Chronic Obstructive Airways Disease Exacerbated	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/SEE TEXT/ORAL	Required
Intervention to Prevent Permanent Impairment/Damage			Salmeterol Xinafoate Salbutamol Sulphate Beclomethasone Dipropion	C C C				

Date:03/31/01ISR Number: 3693561-1Report Type:Expedited (15-DaCompany Report #B0101874A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	150 MG, TWICE PER DAY, ORAL	
			Salmeterol Xinafoate Combivent Frusemide Theophylline Disodium Etidronate	C C C C C				

Date:04/02/01ISR Number: 3693386-7Report Type:Expedited (15-DaCompany Report #A0141624A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Damage Convulsion Thinking Abnormal		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:04/02/01ISR Number: 3693395-8Report Type:Expedited (15-DaCompany Report #B0095016A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	10.5G per day	18 DAY
Hospitalization -	Blood Alcohol Increased		Dafalgan	C			10TAB Per day	
Initial or Prolonged	Brain Oedema		Alcohol	C				
Other	Cardiac Arrest							
	Coagulation Factor V Level Decreased							
	Coma							
	Condition Aggravated							
	Convulsion							
	Electroencephalogram Abnormal							
	Encephalopathy							
	Hallucination							
	Hepatic Failure							
	Intentional Misuse							
	Prothrombin Level Decreased							
	Suicide Attempt							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/01ISR Number: 3693398-3Report Type:Expedited (15-DaCompany Report #B0100368A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Dermatitis Difficulty In Walking Dyspnoea Lip Disorder Swelling		Zyban	PS	Glaxo Wellcome			

Date:04/02/01ISR Number: 3693402-2Report Type:Expedited (15-DaCompany Report #B0102234A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bronchospasm		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	22 DAY
Other	Insomnia							
			Warfarin	C	Glaxo Wellcome	ORAL	3MG per day	
			Frusemide	C		ORAL	40MG per day	
			Lisinopril	C		ORAL	5MG per day	
			Simvastatin	C		ORAL	10MG per day	

Date:04/02/01ISR Number: 3694389-9Report Type:Expedited (15-DaCompany Report #254325
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Accutane	PS	Hlr Technology	ORAL	40 MG 2 PER DAY; ORAL	
	Loss Of Consciousness	Professional						
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	25 MG 2 PER	

DAY; ORAL

			Prozac (Fluoxetine Hydrochloride)	C		

Date:04/02/01ISR Number: 3694567-9Report Type:Expedited (15-DaCompany Report #B0102048A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angina Pectoris	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ ORAL
			Bendrofluazide	C			

Date:04/02/01ISR Number: 3694568-0Report Type:Expedited (15-DaCompany Report #A0143409A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypoaesthesia Insomnia	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ORAL
	Sleep Apnoea Syndrome Weight Increased						

Date:04/02/01ISR Number: 3694569-2Report Type:Expedited (15-DaCompany Report #B0102228A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Required	Erythema Multiforme Psoriasis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150MG /TWICE PER DAY/ORAL	Intervention to Prevent Permanent Impairment/Damage

Date:04/02/01ISR Number: 3694570-9Report Type:Expedited (15-DaCompany Report #B0102229A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
			Terbutaline	C				

Date:04/02/01ISR Number: 3694571-0Report Type:Expedited (15-DaCompany Report #B0102251A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse Condition Aggravated Ventricular Fibrillation	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		UNKNOWN DIRECTRED	150 MG / AS
			Homeopathic Medication	C				

Date:04/02/01ISR Number: 3694572-2Report Type:Expedited (15-DaCompany Report #B0102063A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache Subarachnoid Haemorrhage	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL	

Date:04/02/01ISR Number: 3694573-4Report Type:Expedited (15-DaCompany Report #B0102049A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Viscosity Increased Dermatitis Joint Swelling Muscular Weakness Night Sweats Serum Sickness	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:04/02/01ISR Number: 3694574-6Report Type:Expedited (15-DaCompany Report #B0102062A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Dyspnoea	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER DAY/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/01ISR Number: 3694575-8Report Type:Expedited (15-DaCompany Report #B0102032A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		UNKNOWN	150 MG 9 DAY
	Dysgeusia	Consumer						
	Fatigue							
	Feeling Hot And Cold							
	Headache							
	Injection Site Haemorrhage							
	Rash Pruritic							
	Urticaria							

Date:04/02/01ISR Number: 3694755-1Report Type:Expedited (15-DaCompany Report #A0142204A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intracranial Aneurysm	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
		Health Professional						

Date:04/02/01ISR Number: 3694757-5Report Type:Expedited (15-DaCompany Report #B0101048A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	
	Bronchospasm	Health Professional						
Disability	Cyanosis		Maxsoten	C				
Required Intervention to Prevent Permanent Impairment/Damage	Dyspnoea		Ciprofibrate	C				
	Malaise		Allopurinol	C				
			Salmeterol Xinafoate Fluticasone Propionate	C				
			Duovent	C				
			Methylprednisolone	C				

Date:04/02/01ISR Number: 3694758-7Report Type:Expedited (15-DaCompany Report #B0101365A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Coagulopathy Embolism Facial Palsy	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc		150 MG	

Date:04/02/01ISR Number: 3694759-9Report Type:Expedited (15-DaCompany Report #B0099526A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	AS DIRECTED /	
Hospitalization - Initial or Prolonged	Dysphagia Eating Disorder Gliosis Infection Memory Impairment Urinary Incontinence Vomiting	Health Professional	Fluoxetine Hydrochloride	C			ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/01ISR Number: 3694761-7Report Type:Expedited (15-DaCompany Report #B0099220A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
Initial or Prolonged	Confusional State	Health					DAY / ORAL	
	Grand Mal Convulsion	Professional	Aspirin	C				
	Hyperglycaemia		Ethanol	C				
	Lactic Acidosis							
	Leukocytosis							
	Nervousness							
	Salivary Hypersecretion							
	Thrombocythaemia							
	Urinary Incontinence							

Date:04/02/01ISR Number: 3694825-8Report Type:Expedited (15-DaCompany Report #B0101602A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
Hospitalization -	Balance Disorder						PER DAY/ORAL	
Initial or Prolonged	Cardio-Respiratory Arrest		Ascorbic Acid	C				
Required	Cyanosis		Multivitamin	C				
Intervention to	Dizziness							
Prevent Permanent	Eye Rolling							
Impairment/Damage	Fall							
	Grand Mal Convulsion							
	Hypoaesthesia							
	Screaming							

Date:04/03/01ISR Number: 3694452-2Report Type:Expedited (15-DaCompany Report #A0143055A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Per day	YR

	Dizziness		Wellbutrin Sr	SS	Glaxo Wellcome	ORAL 150MG In the
	Ear Discomfort					
morning YR						
	Hearing Impaired		Hormones	C		
	Hyperhidrosis					
	Hypersensitivity					
	Pharyngeal Oedema					
	Tinnitus					

Date:04/03/01ISR Number: 3694459-5Report Type:Expedited (15-DaCompany Report #B0100069A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization -	Anxiety	Foreign	Zyban	PS	Glaxo Wellcome	
5 DAY						
Initial or Prolonged	Chest Pain	Health	Sertraline	C		
	Gastrooesophageal Reflux	Professional				
	Disease					
	Hyperventilation					
	Malaise					
	Nausea					
	Pallor					
	Tremor					
	Vomiting					
	Weight Decreased					

Date:04/03/01ISR Number: 3694461-3Report Type:Expedited (15-DaCompany Report #B0100785A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	8	DAY
	Crying	Health						
	Depression	Professional						
	Diarrhoea							
	Diplopia							
	Disturbance In Attention							
	Dizziness							
	Eye Pain							
	Fatigue							
	Headache							
	Retching							
	Suicidal Ideation							
	Vomiting							

Date:04/03/01ISR Number: 3694465-0Report Type:Expedited (15-DaCompany Report #B0102365A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Convulsion							
per day							18	DAY
Initial or Prolonged	Loss Of Consciousness		Salbutamol	C	Glaxo Wellcome			
RESPIRATORY								
	Metabolic Acidosis							
(INHALATION)								
	Respiratory Acidosis		Medroxyprogesterone	C		ORAL	5MG Per day	
			Oestrone	C		ORAL	.625MG Per	
							day	

Date:04/03/01ISR Number: 3694468-6Report Type:Expedited (15-DaCompany Report #B0102451A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tremor		Zyban	PS	Glaxo Wellcome			
	Vision Blurred							

Date:04/03/01ISR Number: 3694469-8Report Type:Expedited (15-DaCompany Report #B0102453A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Zyban	PS	Glaxo Wellcome			6 WK
	Haemorrhage							
	Salivary Hypersecretion							
	Sudden Death							

Date:04/03/01ISR Number: 3694470-4Report Type:Expedited (15-DaCompany Report #B0102456A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Peripheral Ischaemia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged			Quinine	C		ORAL	300MG Per day	
			Latanoprost	C				TOPICAL
			Carteolol	C			TOPICAL	2UNIT per day
			Calcium Carbonate	C		ORAL		
			Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG per day	
			Sunerven	C		ORAL	1MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/01ISR Number: 3694471-6Report Type:Expedited (15-DaCompany Report #B0102461A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Dyspnoea Heart Rate Irregular Pallor		Zyban Diltiazem	PS C	Glaxo Wellcome	ORAL ORAL	150MG Twice per day 200MG Per day	8 DAY

Date:04/03/01ISR Number: 3694472-8Report Type:Expedited (15-DaCompany Report #B0102462A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm Face Oedema Pruritus Urticaria		Zyban Allopurinol	PS C	Glaxo Wellcome Glaxo Wellcome	ORAL ORAL	150MG Twice per day 300MG Per day	20 DAY

Date:04/03/01ISR Number: 3696703-7Report Type:Expedited (15-DaCompany Report #B0087305A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Interaction Blood Alcohol Increased Completed Suicide Drowning Drug Abuser Drug Level Above Therapeutic	Foreign Literature Health Professional	Zyban Ethanol (Formulation Unknown) (Alcohol)	PS SS	Glaxo Wellcome Inc	ORAL ORAL		

Date:04/03/01ISR Number: 3696706-2Report Type:Expedited (15-DaCompany Report #B0099756A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Interaction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Drowning	Literature	Ethanol (Formulation Unknown) (Alcohol)	SS				

Date:04/04/01ISR Number: 3695150-1Report Type:Expedited (15-DaCompany Report #A0143570A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
Hospitalization - Initial or Prolonged	Overdose							9 DAY
			Celexa	C		ORAL	40MG Per day	
			Buspar	C		ORAL	15MG Twice per day	
			Lamisil	C		ORAL	250MG Per day	
			Zyrtec	C	Glaxo Wellcome	ORAL	10MG Per day	
			Prevacid	C		ORAL	30MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/01ISR Number: 3695152-5Report Type:Expedited (15-DaCompany Report #A0143899A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:04/04/01ISR Number: 3695161-6Report Type:Expedited (15-DaCompany Report #B0102052A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY
	Eye Pain							
	Headache							
	Joint Stiffness							
	Paraesthesia							
	Tinnitus							
	Tremor							

Date:04/04/01ISR Number: 3695165-3Report Type:Expedited (15-DaCompany Report #B0102458A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	41 DAY
	Lower Respiratory Tract Infection							
	Sudden Death							

Date:04/05/01ISR Number: 3698516-9Report Type:Direct Company Report #
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache		Saint Johns Wort / 300mg	PS				
	Vomiting		Wellbutrin 150mg	SS				

Date:04/05/01ISR Number: 3698808-3Report Type:Direct Company Report #USP 53877
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Zyban	PS	Catalytica Pharmaceuticals/Glaxo-Wellcome			

Date:04/05/01ISR Number: 3698868-XReport Type:Expedited (15-DaCompany Report #B0102234A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bronchospasm	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	
Required Intervention to Prevent Permanent Impairment/Damage	Insomnia							
			Warfarin Sodium	C				
			Frusemide	C				
			Lisinopril	C				
			Simvastatin	C				

Date:04/05/01ISR Number: 3698872-1Report Type:Expedited (15-DaCompany Report #B0100368A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Asthenia Difficulty In Walking Dyspnoea Lip Disorder Oxygen Saturation Decreased Rash Generalised Swelling	Foreign Literature Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	

Date:04/05/01ISR Number: 3699658-4Report Type:Expedited (15-DaCompany Report #A0141624A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Damage Convulsion Decreased Activity Thinking Abnormal	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:04/05/01ISR Number: 3699746-2Report Type:Expedited (15-DaCompany Report #B0095016A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Brain Oedema Cardiac Arrest Coagulation Factor V Level Decreased Coma Convulsion Electroencephalogram Abnormal Encephalopathy	Health Professional	Paracetamol Ethanol	C C				

	Hallucination					
	Hepatic Failure					
	Intentional Misuse					
	Prothrombin Level Decreased					
	Suicide Attempt					

Date:04/06/01ISR Number: 3700116-9Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Appetite Disorder Dizziness Dyspepsia Fatigue Headache Insomnia Malaise Nausea Palpitations Restlessness		Wellbutrin Sr / 150mg	PS		ORAL	1 FOR 1 BID	THEN ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/01ISR Number: 3700201-1Report Type:Expedited (15-DaCompany Report #A0143055A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	100 MG / PER	
	Deafness						DAY / ORAL	
	Dizziness		Wellbutrin Tablet - Controlled Release (Bupropion Hydrochloride)	SS		ORAL	150 MG / IN	
	Hyperhidrosis						THE MORNING /	
	Pain In Extremity						ORAL	
	Pharyngeal Oedema							
	Tinnitus							
			Hormones	C				

Date:04/06/01ISR Number: 3700334-XReport Type:Expedited (15-DaCompany Report #B0102451A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tremor	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
	Vision Blurred	Health Professional						

Date:04/06/01ISR Number: 3700370-3Report Type:Expedited (15-DaCompany Report #B0102453A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	6 WK
	Haemorrhage	Consumer						
	Salivary Hypersecretion							
	Sudden Death							

Date:04/06/01ISR Number: 3700418-6Report Type:Expedited (15-DaCompany Report #B0102456A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Peripheral Ischaemia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL
			Quinine	C			
			Latanoprost	C			
			Carteolol	C			
			Calcium Carbonate	C			
			Bendrofluazide	C			
			Sunerven	C			

Date:04/06/01ISR Number: 3700419-8Report Type:Expedited (15-DaCompany Report #B0102461A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL
	Dyspnoea						
	Heart Rate Irregular						
	Pallor		Diltiazem	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/01ISR Number: 3700420-4Report Type:Expedited (15-DaCompany Report #B0102462A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Bronchospasm Face Oedema Pruritus Urticaria	Foreign Health Professional	Bupropion Hydrochloride Allopurinol	PS C	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY ORAL

Date:04/06/01ISR Number: 3700496-4Report Type:Expedited (15-DaCompany Report #B0102365A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Circulatory Collapse Convulsion Loss Of Consciousness Metabolic Acidosis Respiratory Acidosis	Foreign	Zyban Salbutamol Sulphate Medroxyprogesterone Oestrone	PS C C C	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:04/06/01ISR Number: 3700499-XReport Type:Expedited (15-DaCompany Report #B0100785A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Aggression Crying Depression Depression Suicidal Diarrhoea Diplopia Disturbance In Attention Dizziness Eye Pain Fatigue	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL

	Headache					
	Nausea					
	Retching					
	Vomiting					

Date:04/06/01ISR Number: 3700500-3Report Type:Expedited (15-DaCompany Report #B0100069A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Chest Pain Gastrooesophageal Reflux Disease Hyperventilation Malaise Tremor Vomiting	Foreign Literature Health Professional	Bupropion Hydrochloride Sertraline	PS C	Glaxo Wellcome Inc		150 MG	

Date:04/06/01ISR Number: 3700868-8Report Type:Periodic Company Report #990926.01
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough	Health Professional	Indapamide	PS	Mylan Pharmaceuticals Inc	ORAL	2.5 MG QD,	

ORAL

Allopurinol SS
Beconase SS

OCCLUSIVE

DRESSING 2 PUFFS UD,

ORAL

Cozaar SS ORAL

50 MG QD.

ORAL

Glucophage SS ORAL

1GRAM

TID,ORAL

Lipitor SS ORAL

10 MG, QD,

ORAL

Rezulin SS ORAL

200MG, TID,

ORAL

Trental SS ORAL

400MG TID,

ORAL

Welbutrin SS ORAL

150MG, QD,

ORAL

Glipizide SS ORAL

10MG,BID,

OROAL

Quinine SS ORAL

325MG,TID,

ORAL

Date:04/09/01ISR Number: 3699939-4Report Type:Expedited (15-DaCompany Report #A0141931A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Crushing		Wellbutrin	PS	Glaxo Wellcome	ORAL	1TAB Twice	
Hospitalization -	Grand Mal Convulsion						per day	
Initial or Prolonged	Memory Impairment		Antabuse	C		ORAL	250MG Per day	
Other	Peripheral Ischaemia		Prozac	C		ORAL	20MG Per day	
	Skin Disorder							

Date:04/09/01ISR Number: 3699940-0Report Type:Expedited (15-DaCompany Report #A0143021A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Confusional State		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG See	
Hospitalization -	Drug Toxicity						text	
Initial or Prolonged	Fall		Amantadine	SS		ORAL	100MG Three	
	Limb Injury						times per day	8 MON
	Schizophrenia		Prozac	C				
	Tremor		Loxapine	C				
			Seroquel	C				
			Risperdal	C				

Date:04/09/01ISR Number: 3699941-2Report Type:Expedited (15-DaCompany Report #A0143253A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatic Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	DAY
Initial or Prolonged								

Date:04/09/01ISR Number: 3699996-5Report Type:Expedited (15-DaCompany Report #B0102580A
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Chest Pain
Initial or Prolonged	Dyspnoea

		Triple Vessel Bypass Graft					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice per day	6 WK						

Date:04/09/01ISR Number: 3699998-9Report Type:Expedited (15-DaCompany Report #B0102924A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Agitation		Zyban	PS	Glaxo Wellcome	
150MG As Initial or Prolonged directed 11 DAY	Anxiety					
	Blood Pressure Increased		Steroids	C		
RESPIRATORY (INHALATION)	Convulsion					
	Depressed Level Of Consciousness		Cyproterone Acetate	C		
	Diplopia					
	Feeling Abnormal					
	Haemorrhagic Stroke					
	Headache					
	Hemianopia					
	Memory Impairment					
	Respiratory Disorder					
	Urinary Incontinence					
	Visual Acuity Reduced					

Date:04/09/01ISR Number: 3700304-1Report Type:Expedited (15-DaCompany Report #B0091784A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abnormal Dreams		Zyban	PS	Glaxo Wellcome	
150MG Twice per day	Chronic Obstructive					
Initial or Prolonged						

	Airways Disease		Erythromycin	SS	Glaxo Wellcome	
250MG Four						
	Exacerbated					
times per day 10 DAY						
	Drug Interaction					
	Emphysema					
	Hallucination					
	Lower Respiratory Tract Infection					
	Lymphadenopathy					

Date:04/09/01ISR Number: 3700305-3Report Type:Expedited (15-DaCompany Report #B0094748A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Erythema		Zyban	PS	Glaxo Wellcome	ORAL
32 DAY						
			Ipratropium	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION) 40MCG Three						
times per day						
			Fluticasone	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION) 500MCG Twice						
per day						
			Norethisterone Acetate + Oestradiol + Oestriol	C		ORAL
			Dextropropoxyphene + Paracetamol	C		ORAL
2TAB As						
required						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/01ISR Number: 3700311-9Report Type:Expedited (15-DaCompany Report #B0100686A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bone Disorder		Zyban	PS	Glaxo Wellcome	ORAL	5G Twice per day	
	Delirium		Ssri	C				
	Post Procedural Complication		Zaleplon	C				
			Diazepam	C				
			Sevoflurane	C				
			Propofol	C				
			Fentanyl	C				
			Rocuronium	C				
			Atropine	C				
			Bupivacaine	C				

Date:04/09/01ISR Number: 3700315-6Report Type:Expedited (15-DaCompany Report #B0102788A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
Other	Rash Pustular							

Date:04/09/01ISR Number: 3700316-8Report Type:Expedited (15-DaCompany Report #B0102951A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	4 DAY
	Depression							
	Palpitations		Perindopril	C		ORAL	4MG Per day	
			Nicorandil	C		ORAL	20MG Twice	

per day

15MG Per day

30MG Per day

UNKNOWN 10MG Per day

UNKNOWN 30MG Per day

UNKNOWN

UNKNOWN 75MG Per day

RESPIRATORY

(INHALATION) 50MCG Twice

per day

RESPIRATORY

(INHALATION)

Lansoprazole	C		ORAL
Isosorbide	C		ORAL
Felodipine	C		
Atorvastatin	C		
Gaviscon	C		
Aspirin	C		
Beclomethasone	C	Glaxo Wellcome	
Salbutamol	C	Glaxo Wellcome	

Date:04/09/01ISR Number: 3700318-1Report Type:Expedited (15-DaCompany Report #B0103067A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Quomem	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY

Date:04/09/01ISR Number: 3700954-2Report Type:Expedited (15-DaCompany Report #A0143570A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG, TWICE PER DAY, ORAL	9 DAY
Hospitalization - Initial or Prolonged	Overdose	Professional	Citalopram					

				Hydrobromide	C		
				Buspiurone Hydrochloride	C		
				Terbinafine	C		
				Cetirizine Hydrochloride	C		
				Lansoprazole	C		

Date:04/09/01ISR Number: 3700968-2Report Type:Expedited (15-DaCompany Report #A0143253A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatic Disorder	Health Professional	Bupropion Hydrochloride - Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG, PER DAY, ORAL	

Date:04/09/01ISR Number: 3700972-4Report Type:Expedited (15-DaCompany Report #A0143021A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Confusional State	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	150 MG, SEE TEXT, ORAL	
Hospitalization - Initial or Prolonged	Drug Toxicity							
	Fall							
	Hallucination, Auditory							
	Injury							
	Schizophrenia		Amantadine Tablet (Amantadine Hydrochloride)	SS		ORAL	100 MG, THREE TIMES PER DAY, ORAL	8 MON
	Surgical Procedure Repeated							
	Tremor							
			Fluoxetine Hydrochloride	C				
			Loxapine	C				
			Quetiapine Fumarate	C				

			Risperidone	C		

Date:04/09/01ISR Number: 3701006-8Report Type:Expedited (15-DaCompany Report #A0143899A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:04/09/01ISR Number: 3701201-8Report Type:Expedited (15-DaCompany Report #A0141931A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angiopathy	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	1 TABLET /	
Hospitalization -	Electroencephalogram	Professional					TWICE PER DAY	
Initial or Prolonged	Abnormal						/ ORAL	
Required	Grand Mal Convulsion		Disulfiram	C				
Intervention to	Memory Impairment		Fluoxetine					
Prevent Permanent	Skin Injury		Hydrochloride	C				
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/01ISR Number: 3701485-6Report Type:Expedited (15-DaCompany Report #B0102052A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Diastolic Increased Dizziness Eye Pain Headache Joint Stiffness Paraesthesia Tinnitus Tremor	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY/ ORAL	

Date:04/09/01ISR Number: 3701486-8Report Type:Expedited (15-DaCompany Report #B0102458A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthma Lower Respiratory Tract Infection Sudden Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ORAL	

Date:04/09/01ISR Number: 3701489-3Report Type:Expedited (15-DaCompany Report #B0102580A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Dyspnoea Triple Vessel Bypass Graft	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG/TWICE PER DAY/ORAL	

Date:04/09/01ISR Number: 3701495-9Report Type:Expedited (15-DaCompany Report #B0102924A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	UNKNOWN	150 MG/AS DIRECTED/	
	Anxiety	Health						
	Blood Pressure Increased	Professional						
	Convulsion		Steroid	C				
	Diplopia		Cyproterone Acetate	C				
	Dyspnoea							
	Feeling Abnormal							
	Haemorrhagic Stroke							
	Headache							
	Hemianopia							
	Hypertension							
	Memory Impairment							
	Urinary Incontinence							
	Visual Acuity Reduced							

Date:04/10/01ISR Number: 3701093-7Report Type:Expedited (15-DaCompany Report #A0144245A
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Other	Choroidal Detachment
	Conjunctival Hyperaemia
	Eye Disorder

	Eye Pain Intraocular Pressure Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Malaise		Zyban Cozaar	PS C	Glaxo Wellcome	ORAL	

Date:04/10/01ISR Number: 3701094-9Report Type:Expedited (15-DaCompany Report #A0144419A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion Neuropathy Peripheral		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	

Date:04/10/01ISR Number: 3701105-0Report Type:Expedited (15-DaCompany Report #B0101861A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Depression Drug Hypersensitivity Dysphagia Dyspnoea Eyelid Oedema Face Oedema Gastritis Insomnia Laryngeal Oedema Muscle Spasms Pharyngeal Oedema Pruritus Urticaria	Health Professional	Zyban	PS	Glaxo Wellcome		150MG Twice per day 19 DAY

Date:04/10/01ISR Number: 3701106-2Report Type:Expedited (15-DaCompany Report #B0102451A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Health	Zyban	PS	Glaxo Wellcome		300MG Twice per day	
	Disturbance In Attention	Professional						
	Dry Mouth							
	Overdose							
	Paraesthesia							
	Tremor							
	Vision Blurred							

Date:04/10/01ISR Number: 3703146-6Report Type:Direct Company Report #
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Zyban(R), Buproprion	PS		ORAL	1 BID PO	
	Depression		Demulin 1/35	C				
	Hallucination							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/01ISR Number: 3702378-0Report Type:Expedited (15-DaCompany Report #A0139749A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Overdose		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Astrocytoma		Wellbutrin Sr	SS	Glaxo Wellcome	ORAL		
	Body Temperature Increased		Klonopin	SS				6 MON
	Grand Mal Convulsion		Luvox	SS				6 MON
	Loss Of Consciousness		Triphasil	C				
	Ocular Hyperaemia		Aspirin	C				
			Biotin	C				
			Vitamin C	C				
			Zinc	C				
			Mvi	C				

Date:04/11/01ISR Number: 3702388-3Report Type:Expedited (15-DaCompany Report #A0144603A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Asthma							
	Bronchospasm							
	Chest Pain							
	Dermatitis							
	Face Oedema							
	Insomnia							
	Myocardial Infarction							
	Pruritus							
	Urticaria							

Date:04/11/01ISR Number: 3702391-3Report Type:Expedited (15-DaCompany Report #A0144702A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	8 DAY
	Feeling Jittery							
	Lethargy		Ortho Novum 777	C				
	Oedema Peripheral							
	Rash Erythematous							
	Throat Tightness							

Date:04/11/01ISR Number: 3702397-4Report Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchopneumonia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	16 DAY
	Ecchymosis		Chloroquine	C				
	Gastritis Erosive		Diphenhydramine	C				
	Hepatic Congestion							
	Hypotension							
	Intracranial Pressure Increased							
	Loss Of Consciousness							
	Pleural Haemorrhage							
	Pulmonary Congestion							
	Respiratory Distress							
	Syncope							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/01ISR Number: 3702413-XReport Type:Expedited (15-DaCompany Report #B0103161A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	25 DAY
	Dermatitis							
	Psoriasis		Doxepin	C		ORAL	10MG Per day	
			Norimin	C		ORAL		
			Acitretin	C			25MG Two times per week	
			Trandolapril	C		ORAL	2MG Per day	
			Panadeine Forte	C				

Date:04/11/01ISR Number: 3702415-3Report Type:Expedited (15-DaCompany Report #B0103201A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Lichen Planus		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	13 DAY

Date:04/11/01ISR Number: 3702416-5Report Type:Expedited (15-DaCompany Report #B0103209A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	2 DAY
	Influenza Like Illness							
	Myalgia		Mebeverine	C		ORAL	135MG Per day	

Date:04/11/01ISR Number: 3702417-7Report Type:Expedited (15-DaCompany Report #B0103210A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	30 DAY
	Joint Swelling		Co-Dydramol	C	Glaxo Wellcome	ORAL		
	Medication Error		Omeprazole	C		ORAL	20MG Per day	
	Serum Sickness							
	Urticaria							

Date:04/11/01ISR Number: 3702419-0Report Type:Expedited (15-DaCompany Report #B0103211A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antinuclear Antibody		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Positive						per day	32 DAY
	Arthralgia							
	Autoimmune Disorder							
	Mouth Ulceration							
	Rash Pruritic							

Date:04/11/01ISR Number: 3702422-0Report Type:Expedited (15-DaCompany Report #B0103453A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Optic Disc Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Other	Retinopathy						per day	29 DAY
			Premique	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/01ISR Number: 3702423-2Report Type:Expedited (15-DaCompany Report #B0103470A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hemiplegia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Single	
	Nausea							
dose							1	DAY
	Palpitations							

Date:04/11/01ISR Number: 3702424-4Report Type:Expedited (15-DaCompany Report #B0103473A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Purpura							
per day							45	DAY

Date:04/11/01ISR Number: 3702426-8Report Type:Expedited (15-DaCompany Report #B0103477A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Headache		Zyban	PS	Glaxo Wellcome	ORAL		
Initial or Prolonged	Hemiparesis		Gaviscon	C		ORAL	10ML Twice	
	Nystagmus							
per day								
			Omeprazole	C				

Date:04/11/01ISR Number: 3702427-XReport Type:Expedited (15-DaCompany Report #B0103481A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	

per day	56 DAY		Atenolol	C		ORAL	50MG Per day
			Aspirin	C		ORAL	75MG Per day
			Glyceryl Trinitrate	C	Glaxo Wellcome		SUBLINGUAL
			Ranitidine	C	Glaxo Wellcome	ORAL	150MG Twice per day

Date:04/11/01ISR Number: 3702428-1Report Type:Expedited (15-DaCompany Report #B0103576A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Atrial Fibrillation Sleep Disorder		Zyban	PS	Glaxo Wellcome			

Date:04/11/01ISR Number: 3702429-3Report Type:Expedited (15-DaCompany Report #B0103584A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhagic Stroke		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	2 WK
Initial or Prolonged	Hemiparesis		Carvedilol	C	Glaxo Wellcome	ORAL	25MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/01ISR Number: 3702430-XReport Type:Expedited (15-DaCompany Report #D0013784A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Life-Threatening	Bundle Branch Block Right		Dynacil	C		ORAL		
Hospitalization -	Cardiac Failure		Digimerck	C		ORAL	.1MG per day	
Initial or Prolonged	Nervous System Disorder		Allopurinol	C	Glaxo Wellcome	ORAL		
Other	Pleural Effusion							
	Pyrexia							
	Torsade De Pointes							
	Ventricular Fibrillation							

Date:04/12/01ISR Number: 3703312-XReport Type:Expedited (15-DaCompany Report #A0139738A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	2 YR	
	Optic Nerve Disorder		Serzone	C				

Date:04/12/01ISR Number: 3703322-2Report Type:Expedited (15-DaCompany Report #A0144832A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brief Psychotic Disorder		Zyban	PS	Glaxo Wellcome	ORAL		
Initial or Prolonged	Without Marked Stressors		Alcohol	SS				
	Complex Partial Seizures							
	Confusional State							
	Hallucination, Visual							
	Memory Impairment							
	Persecutory Delusion							

Date:04/12/01ISR Number: 3703326-XReport Type:Expedited (15-DaCompany Report #B0100605A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	22TAB Single	
Hospitalization -	Convulsion						dose	
Initial or Prolonged	Drug Interaction		Dothiepin	SS		ORAL	14TAB Single	
	Intentional Misuse						dose	
	Sedation							

Date:04/12/01ISR Number: 3703333-7Report Type:Expedited (15-DaCompany Report #B0103253A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Zyban	PS	Glaxo Wellcome		10 DAY	
Initial or Prolonged	Dry Throat							
	Dysgeusia							
	Eye Disorder							

Date:04/12/01ISR Number: 3703334-9Report Type:Expedited (15-DaCompany Report #B0103454A
Age:51 YR Gender:Female I/FU:I

Outcome	PT
Other	Anaphylactic Shock
	Irritable Bowel Syndrome

	Proctitis						
	Rash Pruritic						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day 26 DAY
			Premique Cycle	C			

Date:04/12/01ISR Number: 3703335-0Report Type:Expedited (15-DaCompany Report #B0103456A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Serotonin Syndrome		Zyban	PS	Glaxo Wellcome		
	Tremor		Sertraline	C			

Date:04/12/01ISR Number: 3703336-2Report Type:Expedited (15-DaCompany Report #B0103457A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hallucination		Zyban	PS	Glaxo Wellcome		150MG Twice per day 13 DAY
	Tachycardia						

Date:04/12/01ISR Number: 3703340-4Report Type:Expedited (15-DaCompany Report #B0103553A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day
Other	Feeling Abnormal		Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG per day
	Hypertension		Atenolol	C		ORAL	100MG per day
			Ethynodiol	C		ORAL	

Date:04/12/01ISR Number: 3703342-8Report Type:Expedited (15-DaCompany Report #B0103580A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Arrhythmia						per day	18 DAY
			Irbesartan	C		ORAL		
			Alprazolam	C		ORAL		

Date:04/12/01ISR Number: 3703343-XReport Type:Expedited (15-DaCompany Report #B0103725A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome			

Date:04/12/01ISR Number: 3703344-1Report Type:Expedited (15-DaCompany Report #B0103731A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	19 DAY
Initial or Prolonged	Difficulty In Walking							
	Joint Stiffness							
	Oedema Peripheral							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/01ISR Number: 3703345-3Report Type:Expedited (15-DaCompany Report #B0103735A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Vaginal Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day

Date:04/12/01ISR Number: 3704094-8Report Type:Expedited (15-DaCompany Report #A0144419A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Neuropathy Peripheral	Professional Company Representative					

Date:04/12/01ISR Number: 3704295-9Report Type:Expedited (15-DaCompany Report #A0144245A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Choroidal Detachment	Foreign	Bupropion				
	Eye Pain	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL
	Intraocular Pressure Increased	Professional	Losartan Potassium	C			
	Malaise						

Date:04/12/01ISR Number: 3704308-4Report Type:Expedited (15-DaCompany Report #B0101861A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Depression	Foreign	Bupropion				
	Dysphagia	Health	Hydrochloride	PS	Glaxo Wellcome Inc		150 MG/TWICE
	Dyspnoea	Professional					PER DAY

	Eyelid Oedema					
	Face Oedema					
	Gastritis					
	Hypersensitivity					
	Insomnia					
	Muscle Spasms					
	Oral Intake Reduced					
	Pharyngeal Oedema					
	Pruritus					
	Urticaria					

Date:04/12/01ISR Number: 3704309-6Report Type:Expedited (15-DaCompany Report #B0102451A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Foreign	Bupropion					
	Disturbance In Attention	Health	Hydrochloride	PS	Glaxo Wellcome Inc		300 MG/TWICE	
	Dry Mouth	Professional					PER DAY	
	Overdose							
	Paraesthesia							
	Tremor							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/01ISR Number: 3704311-4Report Type:Expedited (15-DaCompany Report #B0103067A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER/ORAL	

Date:04/12/01ISR Number: 3704312-6Report Type:Expedited (15-DaCompany Report #B0102788A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Required Intervention to Prevent Permanent Impairment/Damage	Psoriasis	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	

Date:04/12/01ISR Number: 3704313-8Report Type:Expedited (15-DaCompany Report #B0100686A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	
	Post Procedural Complication	Health Professional	Ssri	C				
			Zaleplon	C				
			Diazepam	C				
			Sevoflurane	C				
			Propofol	C				
			Fentanyl	C				
			Rocuronium Bromide	C				
			Atropine	C				
			Bupivacaine	C				

Date:04/12/01ISR Number: 3704314-XReport Type:Expedited (15-DaCompany Report #B0102951A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
Intervention to	Depression						PER DAY/ORAL	
Prevent Permanent	Palpitations		Perindopril	C				
Impairment/Damage			Nicorandil	C				
			Lansoprazole	C				
			Isosorbide	C				
			Felodipine	C				
			Atorvastatn Calcium	C				
			Gaviscon	C				
			Aspirin	C				
			Beclomethasone Dipropion.	C				
			Salbutamol Sulphate	C				

Date:04/12/01ISR Number: 3704317-5Report Type:Expedited (15-DaCompany Report #B0091784A
Age:65 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Abnormal Dreams
Initial or Prolonged	Bronchospasm
	Chronic Obstructive

Airways Disease Exacerbated Drug Interaction Dyspnoea Emphysema Hallucination Insomnia Lower Respiratory Tract Infection Lymphadenopathy Productive Cough	Report Source Foreign Health Professional	Product Zyban Erythromycin (Formulation Unknown) (Erythromycin)	Role PS SS	Manufacturer Glaxo Wellcome Inc	Route ORAL	Dose 150 MG/TWICE PER DAY/ORAL 250 MG/FOUR TIMES PER DAY	Duration 10 DAY

Date:04/12/01ISR Number: 3704321-7Report Type:Expedited (15-DaCompany Report #B0094748A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Erythema	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
			Ipratropium Bromide	C				
			Fluticasone Propionate	C				
			Norethi.+Oestradiol+ Oestr	C				
			Dextroprop. + Paracetamol	C				

Date:04/12/01ISR Number: 3714095-1Report Type:Periodic Company Report #2001SUS0121
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Dyspepsia Dysphonia Pharyngitis	Consumer	Sustiva Wellbutrin (Bupropion Hcl) Prilosec	PS SS	Dupont Pharmaceuticals Co	ORAL ORAL	PO 1 TAB BID PO	

			(Omeprazole)	C			

Date:04/13/01ISR Number: 3704016-XReport Type:Expedited (15-DaCompany Report #B0103385A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lower Respiratory Tract Infection		Zyban	PS	Glaxo Wellcome	ORAL	2	WK

Date:04/13/01ISR Number: 3704380-1Report Type:Direct Company Report #
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Wellbutrin Sr (150mg)	PS		ORAL	1 PO BID	
	Disorientation							
	Hallucination		Detrol 2mg	SS		ORAL	1 PO BID	
	Paranoia		Sinemet	C				
			Metamucil	C				
			Prilosec	C				
			Asa	C				
			Plavix	C				
			Trazodone	C				
			Fibercon	C				
			Pericolace	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/01ISR Number: 3704422-3Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Oedema Pain In Extremity Pruritus Urticaria		Wellbutrin Darvocet Vioxx	PS C C		ORAL	1 TAB TWICE A DAY	ORAL

Date:04/16/01ISR Number: 3705852-6Report Type:Expedited (15-DaCompany Report #A0139749A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Astrocytoma Body Temperature Increased Brain Neoplasm Malignant Coma Convulsion Eye Movement Disorder Grand Mal Convulsion Loss Of Consciousness Medication Error Ocular Hyperaemia	Consumer	Bupropion Hydrochloride Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Clonazepam (Formulation Unknown) Fluvoxamine Maleate (Formulation Unknown) (Fluvoxamine Maleate) Triphasil Aspirin Biotin Ascorbic Acid Zinc Salt M.V.I.	PS SS SS SS C C C C C C	Glaxo Wellcome Inc	ORAL ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:04/16/01ISR Number: 3705982-9Report Type:Expedited (15-DaCompany Report #A0144702A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Dermatitis Dry Mouth Dyspnoea Erythema Feeling Jittery Lethargy Oedema Peripheral Throat Tightness	Consumer	Bupropion Hydrochloride Ortho-Novum	PS C	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY	ORAL

Date:04/16/01ISR Number: 3705992-1Report Type:Expedited (15-DaCompany Report #PHBS2001US03455
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Drug Level Below Therapeutic	Literature Health Professional	Tegretol Bupropion (Amfebutamone) Lithium	PS SS C	Novartis Pharmaceuticals Corp		800 MG/DAY 450 MG/DAY	

			Trifluoperazine (Trifluoperazine)	C		

Date:04/16/01ISR Number: 3706039-3Report Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Distress Syndrome	Foreign Literature	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	
	Blood Pressure Decreased	Health Professional	Chloroquine	C				
	Bronchopneumonia		Diphenhydramine	C				
	Conjunctival Hyperaemia							
	Deep Vein Thrombosis							
	Ecchymosis							
	Feeling Abnormal							
	Gastritis Erosive							
	Headache							
	Hepatic Congestion							
	Intracranial Pressure Increased							
	Loss Of Consciousness							
	Mucous Membrane Disorder							
	Pleural Haemorrhage							
	Pulmonary Congestion							
	Purulence							
	Sudden Death							
	Swelling							
	Vision Blurred							

Date:04/16/01ISR Number: 3706057-5Report Type:Expedited (15-DaCompany Report #B0100605A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aggression Convulsion Drug Interaction	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	22 TABLET / SINGLE DOSE /	

	Intentional Misuse					
ORAL						
	Sedation		Dothiepin Tablet (Dothiepin)	SS		ORAL

14 TABLET /

SINGLE DOSE /

ORAL

Date:04/16/01ISR Number: 3706069-1Report Type:Expedited (15-DaCompany Report #A0139738A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	2 YR
	Optic Neuritis	Health Professional	Nefazodone Hydrochloride	C				
	Photopsia							
	Scotoma							

Date:04/16/01ISR Number: 3706088-5Report Type:Expedited (15-DaCompany Report #D0013784A
Age:67 YR Gender:Male I/FU:F

Outcome
Death
Life-Threatening

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Arrhythmia Bundle Branch Block Right Cardiac Failure Cardiomegaly Pleural Effusion Torsade De Pointes Ventricular Fibrillation	Foreign	Zyban Fosinopril Sodium Digitoxin Allopurinol	PS C C C	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	

Date:04/16/01ISR Number: 3706093-9Report Type:Expedited (15-DaCompany Report #B0103731A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Joint Stiffness Oedema Urticaria	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG /PER DAY/ORAL	

Date:04/16/01ISR Number: 3706095-2Report Type:Expedited (15-DaCompany Report #B0103735A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Vaginal Haemorrhage	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORA	

Date:04/16/01ISR Number: 3706099-XReport Type:Expedited (15-DaCompany Report #B0103253A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anxiety Dry Throat	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	
UNKNOWN 150 MG						
	Dysgeusia Feeling Abnormal Photophobia					

Date:04/16/01ISR Number: 3706100-3Report Type:Expedited (15-DaCompany Report #B0103456A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Serotonin Syndrome	Foreign Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	
UNKNOWN 150 MG						
		Professional Company Representative	Sertraline	C		

Date:04/16/01ISR Number: 3706101-5Report Type:Expedited (15-DaCompany Report #B0103209A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dizziness Influenza Like Illness	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /TWICE						
	Myalgia					
PER DAY/ORAL						

			Mebeverine	C		

Date:04/16/01ISR Number: 3706102-7Report Type:Expedited (15-DaCompany Report #B0103453A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability Required	Papilloedema Retinopathy	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ORAL
Intervention to Prevent Permanent Impairment/Damage			Premique	C			

Date:04/16/01ISR Number: 3706103-9Report Type:Expedited (15-DaCompany Report #B0103470A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Gait Disturbance Hemiplegia Nausea Palpitations	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /SINGLE DOSE/ORAL

Date:04/16/01ISR Number: 3706104-0Report Type:Expedited (15-DaCompany Report #B0103473A
Age:26 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral Purpura	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ORAL

Date:04/16/01ISR Number: 3706105-2Report Type:Expedited (15-DaCompany Report #B0103477A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Hemiparesis							
	Nystagmus		Gaviscon	C				
			Omeprazole	C				

Date:04/16/01ISR Number: 3706106-4Report Type:Expedited (15-DaCompany Report #B0103481A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angina Pectoris		Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY/ORAL	
			Atenolol	C				
			Aspirin	C				
			Nitroglycerin	C				
			Ranitidine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/01ISR Number: 3706107-6Report Type:Expedited (15-DaCompany Report #B0103576A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Foreign	Bupropion					
	Atrial Fibrillation	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc			
UNKNOWN							150 MG	
	Insomnia							

Date:04/16/01ISR Number: 3706109-XReport Type:Expedited (15-DaCompany Report #B0103584A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhagic Stroke	Foreign	Bupropion					
Initial or Prolonged	Hemiparesis		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG /PER	
DAY/ ORAL							2	WK
			Carvedilol	C				

Date:04/16/01ISR Number: 3706119-2Report Type:Expedited (15-DaCompany Report #B0103201A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Lichen Planus	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
DAY ORAL								

Date:04/16/01ISR Number: 3706121-0Report Type:Expedited (15-DaCompany Report #B0103161A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Psoriasis	Foreign	Bupropion					
Initial or Prolonged	Rash Generalised	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	

		Professional				
PER DAY ORAL						
			Doxepin	C		
			Normin	C		
			Acitretin	C		
			Trandolapril	C		
			Panadeine Forte	C		

Date:04/16/01ISR Number: 3706122-2Report Type:Expedited (15-DaCompany Report #A0144603A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Asthma	Health					PER DAY ORAL	
	Bronchospasm	Professional						
	Burning Sensation							
	Chest Pain							
	Dermatitis							
	Dyspnoea							
	Face Oedema							
	Insomnia							
	Joint Stiffness							
	Oedema Peripheral							
	Pruritus							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/01ISR Number: 3706239-2Report Type:Expedited (15-DaCompany Report #B0103725A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG UNK	
		Health Professional						

Date:04/16/01ISR Number: 3706241-0Report Type:Expedited (15-DaCompany Report #B0103553A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Feeling Abnormal	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	
Required	Hypertension						DAY ORAL	
Intervention to			Bendrofluazide	C				
Prevent Permanent			Atenolol	C				
Impairment/Damage			Ethynodiol	C				

Date:04/16/01ISR Number: 3706242-2Report Type:Expedited (15-DaCompany Report #B0103454A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Proctitis	Foreign	Bupropion					
Intervention to	Pruritus	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
Prevent Permanent	Urticaria	Professional					PER DAY ORAL	
Impairment/Damage		Other	Premique Cycle	C				

Date:04/16/01ISR Number: 3706243-4Report Type:Expedited (15-DaCompany Report #B0103580A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG TWICE
	Arrhythmia					PER DAY ORAL
			Irbesartan	C		
			Alprazolam	C		

Date:04/16/01ISR Number: 3706262-8Report Type:Expedited (15-DaCompany Report #A0144832A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Brief Psychotic Disorder Without Marked Stressors	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL SINGLE DOSE/ORAL
	Cognitive Disorder					
	Complex Partial Seizures		Ethanol (Alcohol)	SS		
	Confusional State					
	Hallucination, Visual					
	Memory Impairment					
	Persecutory Delusion					

Date:04/16/01ISR Number: 3706263-XReport Type:Expedited (15-DaCompany Report #B0103457A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	150 MG/TWICE PER DAY
	Drug Toxicity	Consumer				
	Hallucination					
	Tachycardia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/01ISR Number: 3709305-0Report Type:Expedited (15-DaCompany Report #B0103210A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Feeling Hot Joint Swelling Serum Sickness Urticaria	Foreign	Bupropion Hydrochloride Co-Dydramol Omeprazole	PS C C	Glaxo Wellcome Inc	ORAL	300 MG /PER DAY/ORAL

Date:04/16/01ISR Number: 3710210-4Report Type:Expedited (15-DaCompany Report #B0103211A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Antinuclear Antibody Positive Arthralgia Autoimmune Disorder Mouth Ulceration Rash Pruritic	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:04/17/01ISR Number: 3705492-9Report Type:Expedited (15-DaCompany Report #A0144855A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Papilloedema Photosensitivity Reaction Retinal Disorder Vision Blurred Visual Field Defect Vitreous Floaters		Wellbutrin Sr Pepcid Nasalide Covera Calan Tylenol With Codeine Estrace Librium Benadryl	PS C C C C C C C C	Glaxo Wellcome	ORAL	2TAB Per day

Date:04/17/01ISR Number: 3707000-5Report Type:Expedited (15-DaCompany Report #B0103385A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Lower Respiratory Tract Infection Nausea	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	2 WK

Date:04/17/01ISR Number: 3707225-9Report Type:Expedited (15-DaCompany Report #S01-USA-00683-01
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs Intra-Uterine Death Stillbirth	Health Professional	Celexa	PS	Forest Laboratories Inc	ORAL	60 MG QD PO	
			Wellbutrin - Slow Release (Bupropion Hydrochloride)	SS		ORAL	200 MG BID PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/01ISR Number: 3706392-0Report Type:Expedited (15-DaCompany Report #A0145045A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal		Wellbutrin	PS	Glaxo Wellcome	ORAL	400MG Per day	
	Exposure To Therapeutic		Celexa	SS			UNKNOWN	60MG Per day
	Drugs							
	Stillbirth							

Date:04/19/01ISR Number: 3707389-7Report Type:Expedited (15-DaCompany Report #B0097263A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL		
	Constipation							
	Depression							
	Diarrhoea							
	Disturbance In Attention							
	Dysphonia							
	Headache							
	Insomnia							
	Joint Stiffness							
	Lethargy							
	Mouth Haemorrhage							
	Mouth Ulceration							
	Pain							
	Palpitations							
	Panic Attack							
	Personality Change							
	Psychiatric Symptom							
	Rectal Tenesmus							
	Sedation							
	Social Avoidant Behaviour							
	Tongue Oedema							
	Vision Blurred							
	Weight Increased							

Date:04/19/01ISR Number: 3707406-4Report Type:Expedited (15-DaCompany Report #B0103442A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Nitrazepam	C		ORAL	5MG Per day	

Date:04/19/01ISR Number: 3713272-3Report Type:Periodic Company Report #US007954
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Provigil	PS	Cephalon Inc	ORAL	200 MG QAM	
	Heart Rate Increased							
			Provigil	SS		ORAL	100 MG QD	
			Zyban	SS			150 MG BID	
			Zyban	SS				
			Avonex "Biogen"	C				
			Micronor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708056-6Report Type:Expedited (15-DaCompany Report #A0131125A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Aortic Valve Disease		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Aortic Valve Incompetence						per day	5 WK
	Caesarean Section		Multivitamins	C				
	Cardiac Valve Disease		Septra	C	Glaxo Wellcome	UNKNOWN		
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Neonatal Disorder							
	Twin Pregnancy							

Date:04/20/01ISR Number: 3708065-7Report Type:Expedited (15-DaCompany Report #A0145057A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Completed Suicide		Unisom	SS		UNKNOWN		
	Epistaxis							
	Face Oedema							
	Mouth Haemorrhage							
	Pulse Absent							

Date:04/20/01ISR Number: 3708069-4Report Type:Expedited (15-DaCompany Report #B0091583A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Respiratory Disorder							
	Sudden Death		Alcohol	C				

Date:04/20/01ISR Number: 3708071-2Report Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchopneumonia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	16 DAY
	Convulsion		Medroxy Progesterone Acetate	C				
	Drug Hypersensitivity		Chloroquine	C				
	Ecchymosis		Diphenhydramine	C				
	Epistaxis							
	Gastritis Erosive							
	Head Injury							
	Hearing Impaired							
	Hepatic Congestion							
	Hepatitis							
	Intracranial Pressure Increased							
	Pleural Haemorrhage							
	Pulmonary Congestion							
	Pulse Absent							
	Respiratory Arrest							
	Syncope							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708072-4Report Type:Expedited (15-DaCompany Report #B0100488A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction		Zyban	PS	Glaxo Wellcome		150MG Single	
	Dermatitis						dose	1 DAY
	Drug Interaction		Tinidazole	SS			1	DAY
	Myocardial Infarction							
	Pyrexia							
	Swelling							

Date:04/20/01ISR Number: 3708079-7Report Type:Expedited (15-DaCompany Report #B0104098A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Zyban	PS	Glaxo Wellcome			
	Hallucination							

Date:04/20/01ISR Number: 3708692-7Report Type:Expedited (15-DaCompany Report #A0144855A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Papilloedema	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	2 TABLET /	
	Photosensitivity Reaction						PER DAY /	
	Retinal Disorder						ORAL	
	Vision Blurred		Famotidine	C				
	Visual Field Defect		Flunisolide	C				
	Vitreous Floaters		Verapamil Hydrochloride	C				
			Tylenol With Codeine	C				
			Oestradiol	C				
			Librium	C				
			Diphenhydramine Hcl	C				

Date:04/23/01ISR Number: 3708623-XReport Type:Expedited (15-DaCompany Report #A0145297A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Nodosum		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Oedema Peripheral							

Date:04/23/01ISR Number: 3708624-1Report Type:Expedited (15-DaCompany Report #A0145351A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Pregnancy							

Date:04/23/01ISR Number: 3708627-7Report Type:Expedited (15-DaCompany Report #B0102453A
Age:37 YR Gender:Male I/FU:F

Outcome	PT
Death	Convulsion
	Hypoglycaemia
	Mouth Haemorrhage
	Respiratory Arrest
	Salivary Hypersecretion

Sudden Death

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Zyban	PS	Glaxo Wellcome		150MG Twice per day	6 WK

Date:04/23/01ISR Number: 3709034-3Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Covera 180mg	PS				
Hospitalization - Initial or Prolonged	Medication Error		Wellbutrin 100mg	SS				
Required Intervention to Prevent Permanent Impairment/Damage	Nervousness							
	Paranoia							
	Sleep Disorder							

Date:04/23/01ISR Number: 3709035-5Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Wellbutrin 75mg					
	Fatigue		Glaxo	PS	Glaxo	ORAL	1 BID	ORAL
Required Intervention to Prevent Permanent Impairment/Damage	Gastrooesophageal Reflux		Quinapril	C				
	Disease		Naicin	C				
	Head Injury							

Date:04/23/01ISR Number: 3709107-5Report Type:Expedited (15-DaCompany Report #2001009504-1
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Consumer	Paxil	PS	Smithkline Beecham			

Initial or Prolonged	Condition Aggravated				Pharmaceuticals	ORAL
20 MILLIGRAMS						
	Lethargy					
1.0 DAILY						
ORAL						
			Wellbutrin Sr (Bupropion)	SS		ORAL
100						
MILLIGRAMS						
1.0 DAILY						
ORAL 9 DAY						
			Wellbutrin Sr (Bupropion)	SS		ORAL
200						
MILLIGRAMS						
ORAL						

Date:04/23/01ISR Number: 3709146-4Report Type:Expedited (15-DaCompany Report #A0145045A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Arrest	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL
400 MG/PER						
	Complications Of Maternal	Health				
DAY/ORAL						
	Exposure To Therapeutic Drugs	Professional	Citalopram Hydrobromide			
	Foetal Disorder		(Citalopram			
	Stillbirth		Hydrobromide)	SS		
60 MG/PER DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/01ISR Number: 3709700-XReport Type:Periodic Company Report #PHEH2000US03164
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination	Health Professional	Restoril	PS	Novartis Pharmaceuticals Corp			
			Bupropion (Amfebutamone)	SS				
			Alprazolam "Nm Pharma" (Alprazolam)	SS				
			Zolpidem Tartrate (Zolpidem Tartrate)	SS				

Date:04/24/01ISR Number: 3709074-4Report Type:Expedited (15-DaCompany Report #B0093206A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL		

Date:04/24/01ISR Number: 3709076-8Report Type:Expedited (15-DaCompany Report #B0104336A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome			

Date:04/24/01ISR Number: 3709077-XReport Type:Expedited (15-DaCompany Report #B0104339A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Infection In An Immunocompromised Host							
	Stevens-Johnson Syndrome							

Date:04/24/01ISR Number: 3709078-1Report Type:Expedited (15-DaCompany Report #B0104342A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Alcohol	C				
			Triazolam	C			1TAB Per day	

Date:04/24/01ISR Number: 3710170-6Report Type:Expedited (15-DaCompany Report #A0131125A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Aortic Valve Disease	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ORAL	
	Aortic Valve Incompetence	Health						
	Caesarean Section	Professional	Multivitamin	C				
	Complications Of Maternal Exposure To Therapeutic Drugs		Co-Trimoxazole	C				
	Twin Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/24/01ISR Number: 3710197-4Report Type:Expedited (15-DaCompany Report #A0145057A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	UNK / UNK /	
	Completed Suicide						ORAL	
	Cyanosis		Doxylamine Succinate					
	Epistaxis		(Formulation					
	Face Oedema		Unknown) (Doxylamine					
	Mouth Haemorrhage		Succinate)	SS				
	Pulse Absent							

Date:04/24/01ISR Number: 3710613-8Report Type:Expedited (15-DaCompany Report #B0091583A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Sudden Death	Literature					DAY / ORAL	
			Ethanol	C				

Date:04/24/01ISR Number: 3710614-XReport Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT
Death	Bronchopneumonia
	Convulsion
	Cyanosis
	Dizziness
	Ecchymosis
	Encephalitis
	Epistaxis
	Fall
	Fatigue
	Feeling Abnormal
	Gastritis Erosive
	Head Injury
	Headache

Hearing Impaired
Hepatic Congestion
Hepatitis
Intracranial Pressure
Increased
Livedo Reticularis
Loss Of Consciousness
Lymphadenopathy
Meningitis
Nasal Congestion
Ocular Hyperaemia
Pallor
Pleural Haemorrhage
Pulmonary Congestion
Pulmonary Oedema
Pulse Absent
Respiratory Arrest
Respiratory Distress
Rhinitis
Sedation
Sudden Death
Syncope
Trismus

		Vision Blurred Vomiting					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / PER							
			Literature				
DAY / ORAL							
			Health	Medroxyprogesterobne			
			Professional	Ace.	C		
				Chloroquine	C		
				Diphenhydramine	C		

Date:04/24/01ISR Number: 3710778-8Report Type:Expedited (15-DaCompany Report #B0104098A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Depression	Foreign	Zyban	PS	Glaxo Wellcome Inc	
150 MG						
	Hallucination	Consumer				
	Nervousness					

Date:04/24/01ISR Number: 3710780-6Report Type:Expedited (15-DaCompany Report #B0100488A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaphylactic Reaction	Foreign	Zyban	PS	Glaxo Wellcome Inc	
150 MG /						
Initial or Prolonged	Chest Pain	Health				
SINGLE DOSE /						
	Dermatitis	Professional	Tinidazole			
	Myocardial Infarction		(Formulation			
	Pyrexia		Unknown)			
	Swelling		(Tinidazole)	SS		
SINGLE DOSE						

Date:04/24/01ISR Number: 3710787-9Report Type:Expedited (15-DaCompany Report #A107917
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anger Depression Drug Interaction Irritability Suicidal Ideation Thinking Abnormal	Foreign Health Professional Other	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL	100.00 MG TOTAL:DAILY:ORAL
			Bupropion	SS		ORAL	300.00 MG TOTAL:BID:ORAL
			Atorvastatin	C			

Date:04/24/01ISR Number: 3710830-7Report Type:Expedited (15-DaCompany Report #B0097263A
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Amnesia Constipation Depressed Mood Diarrhoea Disturbance In Attention Dysphonia Headache Insomnia Joint Stiffness Lethargy Mouth Haemorrhage

	Mouth Ulceration						
	Pain						
	Palpitations	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Panic Attack	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Personality Change	Health					
	Psychiatric Symptom	Professional					
	Rectal Tenesmus						
	Sedation						
	Social Avoidant Behaviour						
	Tongue Oedema						
	Vision Blurred						
	Weight Increased						

Date:04/25/01ISR Number: 3710049-XReport Type:Expedited (15-DaCompany Report #A0143021A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Confusional State	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG per day
Hospitalization -	Drug Toxicity	Professional	Amantadine	SS		ORAL	100MG Three
Initial or Prolonged	Extrapyramidal Disorder						times per day YR
	Fall		Prozac	C			
	Hallucination, Auditory		Loxapine	C			
	Insomnia		Seroquel	C			
	Limb Injury		Risperdal	C			
	Memory Impairment						
	Paranoia						
	Schizophrenia						
	Tremor						

Date:04/25/01ISR Number: 3710054-3Report Type:Expedited (15-DaCompany Report #A0145483A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Growth Retardation		Wellbutrin	PS	Glaxo Wellcome	ORAL	400MG per day 2 YR
	Hand Fracture		No Concurrent				

	Insomnia		Medications	C			
	Irritability						

Date:04/25/01ISR Number: 3710056-7Report Type:Expedited (15-DaCompany Report #A0145632A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Surgery		Zyban	PS	Glaxo Wellcome	ORAL	
	Tooth Disorder						

Date:04/25/01ISR Number: 3710063-4Report Type:Expedited (15-DaCompany Report #B0103456A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Foreign	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day
	Serotonin Syndrome	Health Professional	Effexor Xr	SS		ORAL	75MG Per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/01ISR Number: 3710072-5Report Type:Expedited (15-DaCompany Report #B0104340A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholelithiasis		Zyban	PS	Glaxo Wellcome		300MG Per day	
	Pancreatitis Acute		Combivir	C	Glaxo Wellcome		2U Per day	
			Nevirapine	C			400MG Per day	
			Co-Trimoxazole	C	Glaxo Wellcome		1TAB Per day	
			Carbasalate	C				
			Alcohol	C			3U Per day	

Date:04/25/01ISR Number: 3710076-2Report Type:Expedited (15-DaCompany Report #B0104482A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Erythema							
	Flushing		Cyanocobalamin	C	Glaxo Wellcome			
	Oedema Peripheral		Kliogest	C				
	Pruritus							
	Psoriasis							
	Rash Erythematous							
	Rash Generalised							
	Rash Pruritic							
	Skin Exfoliation							

Date:04/25/01ISR Number: 3710077-4Report Type:Expedited (15-DaCompany Report #B0104484A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome		300MG Per day	

	Shock		Amiodarone	C			
200MG per day							
	Ventricular Fibrillation		Captopril	C	Glaxo Wellcome		
50MG per day							
	Ventricular Tachycardia		Warfarin	C	Glaxo Wellcome		
			Lanoxin	C	Glaxo Wellcome		
250MG per day							
			Influenza Vaccination	C			
INTRAVENOUS							

Date:04/25/01ISR Number: 3710078-6Report Type:Expedited (15-DaCompany Report #B0104493A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthma		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 4 DAY						
Initial or Prolonged	Bronchospasm		Salbutamol	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION)						
			Beclomethasone	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION)						

Date:04/25/01ISR Number: 3710079-8Report Type:Expedited (15-DaCompany Report #B0104495A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Dermatitis Bullous		Zyban	PS	Glaxo Wellcome	ORAL
300MG Per day 22 DAY						
	Myocardial Infarction		Cefaclor	C		ORAL

Date:04/25/01ISR Number: 3710080-4Report Type:Expedited (15-DaCompany Report #B0104497A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Blood Pressure Increased						per day	36 DAY
Initial or Prolonged	Chest Pain		Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG per day	54 MON
Disability								

Date:04/25/01ISR Number: 3711364-6Report Type:Expedited (15-DaCompany Report #B0103442A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dermatitis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Sudden Death						PER DAY/ ORAL	
			Nitrazepam	C				

Date:04/26/01ISR Number: 3710947-7Report Type:Expedited (15-DaCompany Report #A0133478A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma		Wellbutrin	PS	Glaxo Wellcome	ORAL	38TAB Single	
Hospitalization -	Dialysis						dose	
Initial or Prolonged	Drug Level Above		Tegretol	SS		ORAL	54TAB Single	
Other	Therapeutic						dose	
	Ileus Paralytic		Trazodone	SS		ORAL	12TAB Single	
	Overdose						dose	
	Oxygen Saturation		Seroquel	SS		ORAL	38TAB Single	

	Decreased					
dose						
	Sedation		Advil	SS		ORAL
1600MG Single						
dose						

Date:04/26/01ISR Number: 3710953-2Report Type:Expedited (15-DaCompany Report #B0102510A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased		Zyban	PS	Glaxo Wellcome	
	Convulsion		Celecoxib	C		
	Dizziness					
	Dry Mouth					
	Dysgeusia					
	Fatigue					
	Weight Decreased					

Date:04/26/01ISR Number: 3710957-XReport Type:Expedited (15-DaCompany Report #B0104518A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - UNKNOWN	Angina Pectoris		Zyban	PS	Glaxo Wellcome	
Initial or Prolonged 25MG Per day	Dizziness		Atenolol	C		
	Lower Respiratory Tract Infection		Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/01ISR Number: 3711532-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Wellbutrn-Sr 100 Mg	PS			100 MG	
			Zovirax 200 Mg	SS		ORAL	200 MG Q4H	
ORAL								

Date:04/26/01ISR Number: 3711895-9Report Type:Expedited (15-DaCompany Report #A0145351A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Complications Of Maternal Exposure To Therapeutic Drugs Pregnancy	Health Professional					DAY / ORAL	

Date:04/26/01ISR Number: 3712047-9Report Type:Expedited (15-DaCompany Report #A0145297A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Nodosum	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Joint Swelling	Consumer					TWICE PER DAY	
/ ORAL								

Date:04/26/01ISR Number: 3712092-3Report Type:Expedited (15-DaCompany Report #B0102453A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG/TWICE	
	Diabetes Mellitus	Health					PER DAY	6 WK
	Hypoglycaemia	Professional						
	Respiratory Arrest							
	Sudden Death							

Date:04/27/01ISR Number: 3711700-0Report Type:Expedited (15-DaCompany Report #A0138130A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Anger						per day	4 DAY
	Angina Pectoris		Nefazodone	C		ORAL	100MG At	
	Blood Pressure Increased						night	
	Cyanosis		Risperidone	C		ORAL	1TAB At night	
	Speech Disorder							

Date:04/27/01ISR Number: 3711702-4Report Type:Expedited (15-DaCompany Report #A0142161A
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Activated Partial
	Thromboplastin Time
	Shortened
	Blood Potassium Decreased
	Culture Urine Positive
	Decreased Activity

		Ecchymosis Epistaxis Gram Stain Negative	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematocrit Decreased		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice							
		Haemoglobin Decreased					
per day							
		Idiopathic		Rivotril	C		ORAL
.5MG Twice							
		Thrombocytopenic Purpura					
per day							
		Lymphocyte Count Increased Monocyte Count Increased Musculoskeletal Stiffness Neutrophil Count Increased Purpura Rectal Haemorrhage Red Blood Cell Count Decreased Specific Gravity Urine Abnormal White Blood Cell Count Increased		Asa	C		

Date:04/27/01ISR Number: 3711707-3Report Type:Expedited (15-DaCompany Report #A0144646A
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Dermatitis		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice							
		Dizziness					
per day	6 DAY						
		Hyperhidrosis		Hydrochlorothiazide	C		ORAL
25MG Per day							
		Middle Insomnia		Zestril	C		ORAL
10MG Per day							
		Nausea		Vioxx	C		ORAL
25MG Per day							
		Tremor		Premarin	C		ORAL
.625MG Per							

day

Date:04/27/01ISR Number: 3711709-7Report Type:Expedited (15-DaCompany Report #A0145297A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Nodosum		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	88 DAY
			Synthroid	C	Glaxo Wellcome	ORAL		YR
			Pravachol	C		ORAL		

Date:04/27/01ISR Number: 3713522-3Report Type:Expedited (15-DaCompany Report #A0145483A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Growth Retardation	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT	
	Hand Fracture	Professional					/ORAL	
	Insomnia							
	Irritability							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/01ISR Number: 3713528-4Report Type:Expedited (15-DaCompany Report #A0143021A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Hospitalization - Initial or Prolonged	Confusional State Drug Toxicity Extrapyramidal Disorder	Professional	Amantadine Tablet (Amantadine Hydrochloride)	SS		ORAL	SEE TEXT/ORAL	
	Fall Hallucination, Auditory Insomnia Limb Injury Memory Impairment Paranoia Schizophrenia Tremor		Fluoxetine Hydrochloride Loxapine Quetiapine Fumarate Risperidone	C C C C				

Date:04/27/01ISR Number: 3713600-9Report Type:Expedited (15-DaCompany Report #B0103456A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Drug Interaction Dyskinesia	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL
	Flushing Heart Rate Increased Movement Disorder Serotonin Syndrome Tremor	Company Representative	Velafaxine Hydrochloride (Venlafaxine Hydrochloride)	SS		ORAL	75 MG (PER DAY)	ORAL

Date:04/27/01ISR Number: 3713603-4Report Type:Expedited (15-DaCompany Report #B0093206A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Completed Suicide	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL ORAL

Date:04/27/01ISR Number: 3713608-3Report Type:Expedited (15-DaCompany Report #B0104336A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Death	Completed Suicide	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	150 MG

Date:04/27/01ISR Number: 3713609-5Report Type:Expedited (15-DaCompany Report #B0104339A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme Immunosuppression Stevens-Johnson Syndrome	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG (TWICE PER DAY) ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/01ISR Number: 3713610-1Report Type:Expedited (15-DaCompany Report #B0104342A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Circulatory Collapse	Foreign	Bupropion				
	Convulsion	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE
	Nasopharyngitis	Professional					PER DAY) ORAL
			Ethanol	C			
			Triazolam	C			

Date:04/27/01ISR Number: 3713612-5Report Type:Expedited (15-DaCompany Report #B0104482A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Alopecia	Foreign	Zyban Tablet - Zyban				
Intervention to	Oedema Peripheral	Health	(Bupropion				
Prevent Permanent	Pruritus	Professional	Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	150 MG, TWICE
Impairment/Damage	Psoriasis						PER DAY, ORAL
	Rash Generalised		Cyanocobalamin	C			
			Kliogest	C			

Date:04/27/01ISR Number: 3713614-9Report Type:Expedited (15-DaCompany Report #B0104495A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Blister	Foreign	Zyban Tablet - Zyban				
	Dermatitis		(Bupropion				
	Lower Respiratory Tract		Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	300 MG, PER
	Infection						DAY, ORAL
	Myocardial Infarction		Cefaclor	C			

Date:04/27/01ISR Number: 3713622-8Report Type:Expedited (15-DaCompany Report #A0145632A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Tooth Repair	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Date:04/27/01ISR Number: 3713670-8Report Type:Expedited (15-DaCompany Report #B0104340A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		300 MG/PER DAY	
	Blood Pressure Increased							
	Cholelithiasis							
	Pallor		Combivir	C				
	Pancreatitis Acute		Nevirapine	C				
	Vomiting		Co-Trimoxazole	C				
			Carbaspirin Calcium	C				
			Ethanol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/01ISR Number: 3713672-1Report Type:Expedited (15-DaCompany Report #B0104497A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angina Pectoris	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE
Hospitalization - Initial or Prolonged	Blood Pressure Increased						PER DAY/ORAL
	Chest Pain						
Disability			Bendrofluazide	C			

Date:04/27/01ISR Number: 3713673-3Report Type:Expedited (15-DaCompany Report #B0104493A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL
			Salbutamol Sulphate	C			
			Beclomethasone Dipropion	C			

Date:04/27/01ISR Number: 3713674-5Report Type:Expedited (15-DaCompany Report #B0104484A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		300 MG/PER DAY
	Shock						
	Ventricular Fibrillation						
	Ventricular Tachycardia		Amiodarone	C			
			Captopril	C			
			Warfarin Sodium	C			
			Digoxin	C			
			Influenza Vaccine	C			

Date:04/30/01ISR Number: 3713068-2Report Type:Expedited (15-DaCompany Report #B0100732A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Zyban	PS	Glaxo Wellcome			
	Palpitations							
	Sleep Disorder Due To General Medical Condition, Insomnia Type							
	Tremor							
	Vein Pain							

Date:04/30/01ISR Number: 3713865-3Report Type:Expedited (15-DaCompany Report #A0133478A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dialysis	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	38 TABLET, SINGLE DOSE, ORAL	
Hospitalization - Initial or Prolonged	Overdose	Professional						
Required Intervention to Prevent Permanent Impairment/Damage			Carbamazepine Tablet (Carbamazepine)	SS		ORAL	54 TABLET/SINGLE DOSE/ORAL	
			Trazodone Tablet	SS		ORAL	12 TABLET/SINGLE	

DOSE/ORAL							
			Quetiapine Fumarate Tablet (Quetiapine Fumarate)	SS			ORAL
38							
TABLET/SINGLE							
DOSE/ORAL							
			Ibuprofen Tablet (Ibuprofen)	SS			ORAL
1600							
MG/SINGLE							
DOSE/ORAL							

Date:04/30/01ISR Number: 3715077-6Report Type:Expedited (15-DaCompany Report #B0104518A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc			
	Asthenia	Consumer	Atenolol	C				
	Chest Pain		Aspirin	C				
	Cough							
	Dizziness							
	Nausea							
	Neck Pain							

Date:04/30/01ISR Number: 3715080-6Report Type:Expedited (15-DaCompany Report #B0102510A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	
	Convulsion	Health Professional	Celecoxib	C				
	Dizziness							
	Dry Mouth							
	Dysgeusia							
	Fatigue							
	Weight Decreased							

Date:05/01/01ISR Number: 3713767-2Report Type:Expedited (15-DaCompany Report #A0145759A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	100MG Per day	2 YR
	Lethargy							
	Myocardial Ischaemia							
	Sedation							
	Ventricular Hypertrophy							

Date:05/01/01ISR Number: 3713772-6Report Type:Expedited (15-DaCompany Report #B0104997A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diabetes Mellitus		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/01ISR Number: 3713773-8Report Type:Expedited (15-DaCompany Report #B0105005A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG	
Hospitalization -	Soft Tissue Injury						Variable dose	8 DAY
Initial or Prolonged	Urinary Tract Infection		Dianette	C		ORAL		
Other			Salbutamol	C	Glaxo Wellcome	RESPIRATORY		
						(INHALATION)		

Date:05/01/01ISR Number: 3713775-1Report Type:Expedited (15-DaCompany Report #B0105091A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Inflammation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	17 DAY
	Swelling		Beclomethasone	C	Glaxo Wellcome	RESPIRATORY		
						(INHALATION)	200MCG Twice	
							per day	
			Salbutamol	C	Glaxo Wellcome	RESPIRATORY		
						(INHALATION)		

Date:05/01/01ISR Number: 3713776-3Report Type:Expedited (15-DaCompany Report #B0105093A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Gastroenteritis						per day	31 DAY

	Helicobacter		Dipyridamole	C		ORAL 200MG Twice per day
			Aspirin	C		ORAL 75MG per day
			Amlodipine	C		ORAL 10MG per day
			Omeprazole	C		ORAL

Date:05/01/01ISR Number: 3714642-XReport Type:Expedited (15-DaCompany Report #A0138130A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Agitation Anger Angina Pectoris Blood Pressure Increased Cyanosis Speech Disorder	Health Professional	Bupropion Hydrochloride Nefazodone Hydrochloride Risperidone	PS C C	Glaxo Wellcome Inc	ORAL 150 MG/ TWICE PER DAY / ORAL 4 DAY

Date:05/01/01ISR Number: 3715176-9Report Type:Expedited (15-DaCompany Report #A0145297A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Erythema Nodosum Pain In Extremity	Foreign Health Professional	Bupropion Hydrochloride Thyroxine Sodium Pravastatin Sodium	PS C C	Glaxo Wellcome Inc	ORAL 150 MG (TWICE PER DAY) ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/01ISR Number: 3715194-0Report Type:Expedited (15-DaCompany Report #A0142161A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activated Partial Thromboplastin Time Shortened	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Bacterial Infection							
	Blood Potassium Decreased		Clonazepam	C				
	Ecchymosis		Aspirin	C				
	Epistaxis							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Idiopathic Thrombocytopenic Purpura							
	Lymphocyte Count Increased							
	Monocyte Count Increased							
	Musculoskeletal Stiffness							
	Neutrophil Count Increased							
	Rectal Haemorrhage							
	Red Blood Cell Count Decreased							
	Specific Gravity Urine Abnormal							
	White Blood Cell Count Increased							

Date:05/01/01ISR Number: 3715202-7Report Type:Expedited (15-DaCompany Report #A0144646A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis Dizziness Hyperhidrosis Middle Insomnia	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Nausea	Hydrochlorothiazide	C	
Tremor	Lisinopril	C	
	Rofecoxib	C	
	Conjugated Estrogens	C	

Date:05/02/01ISR Number: 3714664-9Report Type:Expedited (15-DaCompany Report #A0139332A
Age:7 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Teeth Brittle		Wellbutrin	PS	Glaxo Wellcome	ORAL	6	MON
			No Concurrent Medications	C				

Date:05/02/01ISR Number: 3714671-6Report Type:Expedited (15-DaCompany Report #B0099812A
Age: Gender:Female I/FU:F

Outcome	PT
Other	Anaphylactic Shock
	Blood Pressure Increased
	Dizziness
	Dry Mouth
	Dry Skin

	Food Allergy						
	Headache						
	Malaise	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
	Nausea		Zyban	PS	Glaxo Wellcome		
	Pallor		Quinapril	C			
	Palpitations		Trisequens	C			
	Paraesthesia		Ketoconazole	C			
	Pharyngeal Oedema						
	Sneezing						
	Tongue Oedema						
	Vertigo						
	Vision Blurred						

Date:05/02/01ISR Number: 3714677-7Report Type:Expedited (15-DaCompany Report #B0102612A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Metrorrhagia		Zyban	PS	Glaxo Wellcome	
WK						
			Levonorgestrel	C		
INTRA-UTERINE	4 YR					
			Diazepam	C		ORAL
10MG Per day						

Date:05/02/01ISR Number: 3714679-0Report Type:Expedited (15-DaCompany Report #B0104340A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cholelithiasis		Zyban	PS	Glaxo Wellcome	
300MG Per day						
Initial or Prolonged	Pancreatitis Acute		Nevirapine	SS		
400MG Per day						
			Combivir	SS	Glaxo Wellcome	
750MG per day						
			Co-Trimoxazole	C	Glaxo Wellcome	
			Carbasalate	C		
			Alcohol	C		
3U Per day						

Date:05/02/01ISR Number: 3714684-4Report Type:Expedited (15-DaCompany Report #B0105086A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dry Mouth Dyspnoea Laryngeal Oedema Throat Irritation		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG As directed	

Date:05/02/01ISR Number: 3714685-6Report Type:Expedited (15-DaCompany Report #B0105236A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Arrhythmia Myocardial Infarction		Zyban	PS	Glaxo Wellcome		150MG As directed	7 DAY

Date:05/02/01ISR Number: 3714687-XReport Type:Expedited (15-DaCompany Report #D0013944A
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Bronchospasm Chest Pain

	Convulsion						
	Dizziness						
	Dyspnoea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Paralysis		Zyban	PS	Glaxo Wellcome	ORAL	150MG See
	Tachycardia						text 6 DAY

Date:05/03/01ISR Number: 3716074-7Report Type:Expedited (15-DaCompany Report #A0130681A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day 2 MON
Initial or Prolonged	Fall		Alcohol	C			
Other	Grand Mal Convulsion		No Concurrent				
	Humerus Fracture		Medications	C			
	Intentional Misuse		Marijuana	C			

Date:05/03/01ISR Number: 3716083-8Report Type:Expedited (15-DaCompany Report #B0099476A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Constipation		Zyban	PS	Glaxo Wellcome	ORAL	5 WK
Initial or Prolonged	Decreased Appetite		Temazepam	C			10G per day
	Diverticulum						
	Erythema						
	Hallucination						
	Insomnia						

Date:05/03/01ISR Number: 3716084-XReport Type:Expedited (15-DaCompany Report #B0101144A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Circulatory Collapse		Zyban	PS	Glaxo Wellcome		

	Dyskinesia		Dothiepin	C			
50MG At night							
	Formication		Temazepam	C			
10MG At night							
	Heart Rate Increased		Oestradiol	C			
	Hyperhidrosis						
	Muscle Contractions Involuntary						
	Nausea						
	Night Sweats						
	Palpitations						
	Panic Attack						
	Tremor						

Date:05/03/01ISR Number: 3716094-2Report Type:Expedited (15-DaCompany Report #B0105094A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epilepsy		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Loss Of Consciousness							
	Overdose							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/01ISR Number: 3716098-XReport Type:Expedited (15-DaCompany Report #B0105940A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia Monoplegia Tunnel Vision		Zyban	PS	Glaxo Wellcome			

Date:05/03/01ISR Number: 3717044-5Report Type:Expedited (15-DaCompany Report #B0100732A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	
	Palpitations	Health						
	Tremor	Professional						
	Vein Pain							

Date:05/04/01ISR Number: 3716877-9Report Type:Expedited (15-DaCompany Report #A0146512A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Wellbutrin	PS	Glaxo Wellcome	OTHER	150MG Twice per day	
	Circulatory Collapse							
	Drug Level Above Therapeutic		Paxil	SS				
			Depakote	SS				
	Parkinson'S Disease		Celexa	SS				
	Tremor							

Date:05/04/01ISR Number: 3716885-8Report Type:Expedited (15-DaCompany Report #B0105221A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactoid Reaction Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome	ORAL		

Anxiety
Circulatory Collapse
Flushing
Irritability
Irritable Bowel Syndrome
Rash Erythematous
Swelling
Urticaria

Date:05/04/01ISR Number: 3717519-9Report Type:Direct Company Report #
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other Required Intervention to Prevent Permanent Impairment/Damage	Cerebrovascular Accident Embolism Hemiplegia		Wellbutrin Sr 150mg Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	1 TABLET TWICE DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/01ISR Number: 3718211-7Report Type:Expedited (15-DaCompany Report #B0104997A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diabetes Mellitus	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG/PER	Required
							DAY/ORAL	
Intervention to Prevent Permanent Impairment/Damage								

Date:05/04/01ISR Number: 3718213-0Report Type:Expedited (15-DaCompany Report #B0105091A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Inflammation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
Intervention to	Swelling						DAY/ORAL	
Prevent Permanent			Beclomethasone					
Impairment/Damage			Dipropion	C				
			Salbutamol Sulphate	C				

Date:05/04/01ISR Number: 3718216-6Report Type:Expedited (15-DaCompany Report #B0105093A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Atrial Fibrillation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
Intervention to	Gastroenteritis						PER DAY/ORAL	
Prevent Permanent	Helicobacter		Dipyridamole	C				
Impairment/Damage			Aspirin	C				
			Amlodipine	C				
			Omeprazole	C				

Date:05/04/01ISR Number: 3718217-8Report Type:Expedited (15-DaCompany Report #B0105005A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150MG/VARIABL	
Hospitalization -	Head Injury						E DOSE/ORAL	
Initial or Prolonged	Urinary Tract Infection		Dianette	C				
Required			Salbutamol Sulphate	C				
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:05/04/01ISR Number: 3718413-XReport Type:Expedited (15-DaCompany Report #A0145759A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG / PER	
	Lethargy						DAY / ORAL	
	Peripheral Ischaemia							
	Sedation							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/01ISR Number: 3719166-1Report Type:Periodic Company Report #PRIUSA2000008733
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company	Ultram	PS	Rw Johnson Pharmaceutical Research Institute	ORAL	ORAL	
		Representative	Bupropion Hydrochloride (Amfebutamone Hydrochloride)	SS				

Date:05/04/01ISR Number: 3720085-5Report Type:Expedited (15-DaCompany Report #NSADSS2001012819
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Foreign Study Health Professional	Remicade (Infliximab, Recombinant)	PS		INTRAVENOUS	5 MG/KG, 1 IN	1 TIME(S), IV
			Wellbutrin (Amfebutamone Hydrochloride)	SS				
			Pentasa	C				
			Losec	C				
			Buscopan	C				
			Demerol	C				
			Maxeran	C				
			Vitamin B12	C				
			Entocort	C				
			Imuran	C				

Date:05/07/01ISR Number: 3717303-6Report Type:Expedited (15-DaCompany Report #B0096539A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Discomfort		Bupropion					

Eyelid Oedema Hydrochloride PS Glaxo Wellcome ORAL
150MG Per day 2 DAY
Nausea

Date:05/07/01ISR Number: 3717304-8Report Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT
Death	Benign Lung Neoplasm
	Dizziness
	Drug Hypersensitivity
	Ecchymosis
	Encephalitis
	Epilepsy
	Epistaxis
	Fall
	Fatigue
	Feeling Abnormal
	Gastritis Erosive
	Head Injury
	Headache
	Hearing Impaired
	Hepatic Congestion

	Hepatitis						
	Intracranial Pressure Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Livedo Reticularis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 16 DAY
	Loss Of Consciousness		Chloroquine	SS			
	Lymphadenopathy		Diphenhydramine	SS			
	Meningitis		Medroxy Progesterone				
	Ocular Hyperaemia		Acetate	C			
	Pallor						
	Pleural Haemorrhage						
	Pulmonary Congestion						
	Pulmonary Oedema						
	Pulse Absent						
	Respiratory Arrest						
	Rhinitis						
	Sudden Death						
	Viral Infection						
	Vision Blurred						
	Vomiting						

Date:05/07/01ISR Number: 3717305-XReport Type:Expedited (15-DaCompany Report #B0100897A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Arrhythmia		Zyban	PS	Glaxo Wellcome		150MG As
	Cardiac Arrest						directed 17 DAY
	Coma		Paracetamol	C			
	Hypertension						
	Hypotension						
	Respiratory Failure						
	Subarachnoid Haemorrhage						

Date:05/07/01ISR Number: 3717306-1Report Type:Expedited (15-DaCompany Report #B0105726A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Anger		Zyban	PS	Glaxo Wellcome		

	Completed Suicide					
	Irritability					
	Psychomotor Hyperactivity					

Date:05/07/01ISR Number: 3718428-1Report Type:Expedited (15-DaCompany Report #B0099476A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Constipation	Health Professional	Temazepam	C				
	Decreased Appetite							
	Diverticulum							
	Erythema							
	Hallucination							
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/01ISR Number: 3718431-1Report Type:Expedited (15-DaCompany Report #B0101144A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	
	Formication	Health	Dothiepin	C				
	Heart Rate Increased	Professional	Temazepam	C				
	Hyperhidrosis		Oestradiol	C				
	Muscle Contractions Involuntary							
	Night Sweats							
	Palpitations							
	Panic Attack							
	Tremor							

Date:05/07/01ISR Number: 3719009-6Report Type:Expedited (15-DaCompany Report #B0105094A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epilepsy	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
Hospitalization - Initial or Prolonged	Loss Of Consciousness	Health Professional						
Required Intervention to Prevent Permanent Impairment/Damage	Overdose							

Date:05/07/01ISR Number: 3719010-2Report Type:Expedited (15-DaCompany Report #B0105940A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Foreign	Zyban	PS	Glaxo Wellcome Inc			
	Movement Disorder	Consumer						
	Tunnel Vision							

Date:05/07/01ISR Number: 3719021-7Report Type:Expedited (15-DaCompany Report #A0139332A
Age:7 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Teeth Brittle Tooth Disorder	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	

Date:05/07/01ISR Number: 3719175-2Report Type:Expedited (15-DaCompany Report #B0105086A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accident Dry Mouth Dyspnoea Laryngeal Oedema Throat Irritation	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / AS DIRECTED /ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/01ISR Number: 3719177-6Report Type:Expedited (15-DaCompany Report #B0105236A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG/AS	
Hospitalization - DIRECTED/ Initial or Prolonged	Myocardial Infarction							

Date:05/07/01ISR Number: 3719180-6Report Type:Expedited (15-DaCompany Report #B0102612A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Metrorrhagia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			
		Health Professional	Levonorgestrel	C				
			Diazepam	C				

Date:05/07/01ISR Number: 3719183-1Report Type:Expedited (15-DaCompany Report #B0099812A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	
	Dehydration	Health Professional	Quinapril	C				
	Dizziness		Trisequens	C				
	Dry Mouth		Ketoconazole	C				
	Dry Skin							
	Feeling Abnormal							
	Food Allergy							
	Headache							
	Hypersensitivity							
	Hypertension							
	Malaise							
	Nausea							
	Pallor							
	Palpitations							
	Paraesthesia							
	Pharyngeal Oedema							

	Tongue Oedema					
	Vertigo					
	Vision Blurred					

Date:05/07/01ISR Number: 3719214-9Report Type:Expedited (15-DaCompany Report #B0104340A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		300 MG/ PER DAY/	
	Abdominal Tenderness							
	Blood Amylase Increased							
	Cholelithiasis		Nevirapine (Formulation Unknown)	SS			400 MG/ PER DAY	
	Pallor							
	Pancreatitis Acute							
	Vomiting							
			Combivir (Formulation Unknown) (Combivir)	SS				
			Co-Trimoxazole	C				
			Carbaspirin Calcium	C				
			Ethanol	C				

Date:05/07/01ISR Number: 3719217-4Report Type:Expedited (15-DaCompany Report #D0013944A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Bronchospasm Chest Pain Convulsion Dizziness Dyspnoea Paralysis	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ SEE TEXT/ ORAL	

Date:05/07/01ISR Number: 3719244-7Report Type:Expedited (15-DaCompany Report #A0130681A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Fall Grand Mal Convulsion Humerus Fracture Intentional Misuse Suicide Attempt	Health Professional Company Representative	Wellbutrin Sr Ethanol No Concurrent Medication Cannabis	PS C C C	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	

Date:05/08/01ISR Number: 3718282-8Report Type:Expedited (15-DaCompany Report #A0145045A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs Stillbirth		Wellbutrin Celexa	PS SS	Glaxo Wellcome	ORAL	200MG Twice per day 60MG Per day	

Date:05/08/01ISR Number: 3718287-7Report Type:Expedited (15-DaCompany Report #A0146305A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Per day	10 DAY
			Synthroid	C	Glaxo Wellcome			

Date:05/08/01ISR Number: 3718884-9Report Type:Direct Company Report #
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Zyban	PS				
			Fosinopril Na	C				
			Simvastatin	C				
			Ibuprofen	C				
			Diphenhydramine Hcl	C				
			Triamcinolone Acetonide	C				
			Nicotine	C				
			Quit Smart Bupropion Sr	C				
			Hydrocortisone	C				
			Furosemide	C				
			Potassium Chloride	C				
			Beclomethasone	C				

Date:05/08/01ISR Number: 3719692-5Report Type:Expedited (15-DaCompany Report #A0146512A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc		150 MG / TWICE PER DAY
	Circulatory Collapse						
	Difficulty In Walking						/ PERIPHERAL LINE
	Parkinson'S Disease						
	Tremor		Paroxetine Hydrochloride (Formulation Unknown)	SS			

Date:05/08/01ISR Number: 3719867-5Report Type:Expedited (15-DaCompany Report #B0105221A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Bupropion				
	Anaphylactic Reaction	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Angioneurotic Oedema	Professional					
	Anxiety						
	Circulatory Collapse						
	Diarrhoea						
	Flushing						
	Irritability						
	Irritable Bowel Syndrome						
	Rash Erythematous						
	Urticaria						

Date:05/10/01ISR Number: 3720063-6Report Type:Expedited (15-DaCompany Report #B0093206A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice

Coronary Artery Disease
per day 47 DAY

Pantoprazole C ORAL
20MG per day

Chlormethiazole C ORAL
1TAB At night

Lofepramine C
UNKNOWN 70MG At night

Gaviscon C ORAL
10ML Four

times per day

Lactulose C
409ML per day

Desipramine C
Tramadol C
Ecstasy C

Date:05/10/01ISR Number: 3720071-5Report Type:Expedited (15-DaCompany Report #B0106124A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hearing Impaired		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	5 DAY
	Photopsia							

Date:05/10/01ISR Number: 3720072-7Report Type:Expedited (15-DaCompany Report #B0106152A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nail Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	29 DAY
	Skin Exfoliation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/01ISR Number: 3720073-9Report Type:Expedited (15-DaCompany Report #B0106347A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Furuncle		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:05/10/01ISR Number: 3720074-0Report Type:Expedited (15-DaCompany Report #B0106364A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Pain		Zyban	PS	Glaxo Wellcome		4	DAY
	Eyelid Oedema		Levonorgestrel	C		ORAL	1TAB Per day	
	Headache							

Date:05/10/01ISR Number: 3720075-2Report Type:Expedited (15-DaCompany Report #B0106366A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	7 DAY
	Chest Discomfort		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	8PUFF As required	
	Hypoventilation							
			Budesonide	C		RESPIRATORY (INHALATION)	400MCG Twice per day	
			Ipratropium	C	Glaxo Wellcome	RESPIRATORY		

(INHALATION) 2PUFF Twice

per day

			Migraleve Pink	C		ORAL

Date:05/10/01ISR Number: 3720076-4Report Type:Expedited (15-DaCompany Report #B0106367A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Dermatitis							
per day								21 DAY
Initial or Prolonged	Dyspnoea		Microgynon	C		ORAL	1TAB Per day	
Disability	Visual Disturbance							

Date:05/10/01ISR Number: 3721582-9Report Type:Expedited (15-DaCompany Report #B0105726A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	
	Completed Suicide	Consumer						
	Irritability							
	Psychomotor Hyperactivity							

Date:05/10/01ISR Number: 3721612-4Report Type:Expedited (15-DaCompany Report #B0096539A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Discomfort	Foreign	Bupropion					
	Eyelid Oedema	Study	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
	Nausea	Health					DAY/ORAL	
	Oesophageal Disorder	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/01ISR Number: 3721614-8Report Type:Expedited (15-DaCompany Report #B0100897A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Foreign	Bupropion					
	Atrioventricular Block	Health	Hydrochloride	PS	Glaxo Wellcome Inc		150 MG/AS	
	Coma	Professional					DIRECTED	
	Headache		Paracetamol	C				
	Hypertension							
	Hypotension							
	Musculoskeletal Stiffness							
	Myalgia							
	Respiratory Failure							
	Subarachnoid Haemorrhage							

Date:05/10/01ISR Number: 3721616-1Report Type:Expedited (15-DaCompany Report #B0098194A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Benign Lung Neoplasm	Foreign	Bupropion					
	Convulsion	Literature	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
	Cyanosis	Health					DAY/ORAL	
	Dizziness	Professional	Chloroquine					
	Dysgeusia		(Chloroquine)	SS				
	Ecchymosis		Diphenhydramine					
	Embolism		(Diphenhydramine)	SS				
	Encephalitis		Medroxyprogesterone					
	Epilepsy		Ace	C				
	Epistaxis							
	Fall							
	Fatigue							
	Feeling Abnormal							
	Gastritis Erosive							
	Headache							
	Hearing Impaired							
	Hepatic Congestion							
	Hepatitis							
	Inflammation							
	Injury							

Intracranial Pressure
Increased
Loss Of Consciousness
Lung Disorder
Lymphadenopathy
Nasal Congestion
Ocular Hyperaemia
Pallor
Petechiae
Pleural Haemorrhage
Pulmonary Congestion
Pulmonary Oedema
Pulse Absent
Respiratory Arrest
Respiratory Distress
Skin Discolouration
Sudden Death
Syncope
Vision Blurred
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/01ISR Number: 3720855-3Report Type:Expedited (15-DaCompany Report #A0144832A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cognitive Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Single	
	Complex Partial Seizures						dose	7 DAY
	Confusional State		Alcohol	SS				
	Hallucination, Visual							
	Psychotic Disorder							

Date:05/11/01ISR Number: 3720862-0Report Type:Expedited (15-DaCompany Report #B0101512A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diabetes Mellitus		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 WK
Other			Hypoglycaemic Medication	C		ORAL		
			Viagra	C		ORAL		
			Lipostat	C				
			Tritace	C				
			Aspirin	C				
			Gliclazide	C		ORAL	80MG per day	

Date:05/11/01ISR Number: 3720866-8Report Type:Expedited (15-DaCompany Report #B0105221A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Amnesia							
	Anaphylactic Reaction							
Other	Angioneurotic Oedema							
	Anxiety							
	Circulatory Collapse							
	Diarrhoea							
	Disturbance In Attention							
	Dry Skin							

	Flushing
	Irritability
	Rash Erythematous
	Rash Pruritic
	Swelling
	Urticaria

Date:05/11/01ISR Number: 3720871-1Report Type:Expedited (15-DaCompany Report #B0106121A
Age:42 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Agitation
Initial or Prolonged	Anxiety
Other	Asthenia
	Bronchospasm
	Chest Discomfort
	Depression
	Dermatitis
	Disturbance In Attention
	Dry Mouth
	Headache
	Hyperhidrosis
	Insomnia

	Tinnitus						
	Tremor						
	Visual Disturbance	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day

Date:05/11/01ISR Number: 3720872-3Report Type:Expedited (15-DaCompany Report #B0106128A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blister		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Joint Stiffness						per day 15 DAY
	Oedema						
	Pain In Extremity						
	Proteinuria						
	Rash Erythematous						

Date:05/11/01ISR Number: 3720873-5Report Type:Expedited (15-DaCompany Report #B0106260A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Depression						per day 15 DAY
	Insomnia						
	Paranoia						
	Suicidal Ideation						

Date:05/11/01ISR Number: 3720874-7Report Type:Expedited (15-DaCompany Report #B0106345A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Facial Palsy		Zyban	PS	Glaxo Wellcome	ORAL	150MG

	Hypertension					
Variable dose 41 DAY						

Date:05/11/01ISR Number: 3720875-9Report Type:Expedited (15-DaCompany Report #B0106348A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Brain Hypoxia		Zyban	PS	Glaxo Wellcome		15 DAY
Hospitalization - Initial or Prolonged	Circulatory Collapse Loss Of Consciousness Myocardial Infarction Ventricular Fibrillation						

Date:05/11/01ISR Number: 3721857-3Report Type:Expedited (15-DaCompany Report #A0145045A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs Intra-Uterine Death Stillbirth	Study Health Professional Other	Wellbutrin Sr Citalopram Hydrobromide Tablet (Citalopram Hydrobromide)	PS SS	Glaxo Wellcome Inc	ORAL OROPHARINGEAL	200 MG / TWICE PER DAY / ORAL 60 MG / PER DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/01ISR Number: 3721864-0Report Type:Expedited (15-DaCompany Report #A0146305A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Complications Of Maternal	Consumer					DAY/ ORAL	
	Exposure To Therapeutic Drugs Pregnancy		Thyroxine Sodium	C				

Date:05/11/01ISR Number: 3721948-7Report Type:Expedited (15-DaCompany Report #10819928
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional	Paraplatin	PS	Bristol Myers Squibb Co Pharmaceutical Research Institute			
Other	Dyspnoea					INTRAVENOUS	640	
	Feeling Abnormal						MILLIGRAM,	
	Flushing						1/1 CYCLE IV	
	Hypersensitivity							
	Petit Mal Epilepsy		Wellbutrin (Bupropion Hcl)	SS				

Date:05/14/01ISR Number: 3721874-3Report Type:Expedited (15-DaCompany Report #B0104334A
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysuria		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	23 DAY
	Myocardial Infarction							
Other	Oedema Peripheral		Adrenaline	SS				
	Urticaria		Citalopram	C				

Date:05/14/01ISR Number: 3721876-7Report Type:Expedited (15-DaCompany Report #B0106581A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome	ORAL		
	Completed Suicide							
	Road Traffic Accident							

Date:05/14/01ISR Number: 3721878-0Report Type:Expedited (15-DaCompany Report #B0106828A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Oedema		Zyban	PS	Glaxo Wellcome			
Hospitalization -	Cerebral Infarction		Contraceptive	C		ORAL		
Initial or Prolonged	Dysphagia							
	Hemiparesis							

Date:05/14/01ISR Number: 3721879-2Report Type:Expedited (15-DaCompany Report #B0106830A
Age:65 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Diarrhoea
	Inflammation
	Nausea
	Nephritis

	Vomiting						
		Report Source	Product	Role	Manufacturer		Route
Dose	Duration						
			Zyban	PS	Glaxo Wellcome		
1	WK						

Date:05/14/01ISR Number: 3721883-4Report Type:Expedited (15-DaCompany Report #B0107035A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL
2	MON					
	Depression		Chloroquine	C		
	Dissociation					
	Disturbance In Attention					
	Feeling Abnormal					
	Headache					
	Palpitations					

Date:05/14/01ISR Number: 3721884-6Report Type:Expedited (15-DaCompany Report #B0107040A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Choking		Zyban	PS	Glaxo Wellcome	ORAL
	Cyanosis		Nitrazepam	C		ORAL
	Loss Of Consciousness					

Date:05/14/01ISR Number: 3723935-1Report Type:Expedited (15-DaCompany Report #S01-USA-00846-01
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Circulatory Collapse	Consumer	Celexa	PS	Forest Laboratories Inc	
	Parkinson'S Disease					
	Tremor		Wellbutrin(Amfebutamone Hydrochloride)	SS		
			Depakote(Valproate Semidsodium)	SS		

			Paxil(Paroxetine Hydrochloride)	SS		

Date:05/14/01ISR Number: 3724057-6Report Type:Expedited (15-DaCompany Report #B0106367A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	
Hospitalization - Initial or Prolonged Disability	Dermatitis							
	Dizziness							
	Dyspnoea							
	Visual Disturbance		Microgynon	C				

Date:05/14/01ISR Number: 3724065-5Report Type:Expedited (15-DaCompany Report #B0106152A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis Exfoliative	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	
	Nail Disorder							

Date:05/14/01ISR Number: 3724066-7Report Type:Expedited (15-DaCompany Report #B0106347A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Furuncle	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
Intervention to		Consumer					PER DAY/ ORAL	
Prevent Permanent								
Impairment/Damage								

Date:05/14/01ISR Number: 3724067-9Report Type:Expedited (15-DaCompany Report #B0106364A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Eye Pain	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG/ UNK	
Intervention to	Eyelid Oedema		Levonorgestrel	C				
Prevent Permanent	Headache							
Impairment/Damage								

Date:05/14/01ISR Number: 3724069-2Report Type:Expedited (15-DaCompany Report #B0106124A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hearing Impaired	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
Intervention to	Migraine						DAY/ ORAL	
Prevent Permanent	Photopsia							
Impairment/Damage								

Date:05/14/01ISR Number: 3724070-9Report Type:Expedited (15-DaCompany Report #B0106366A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Asthma	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/PER DAY/ ORAL
			Salbutamol Sulphate	C		
			Budesonide	C		
			Ipratropium Bromide	C		
			Migraleve (Pink Tablets)	C		

Date:05/14/01ISR Number: 3724079-5Report Type:Expedited (15-DaCompany Report #B0093206A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Death	Arrhythmia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ TWICE PER DAY/ ORAL
	Coronary Artery Disease	Health Professional Company Representative	Pantoprazole	C		
			Chlormethiazole	C		
			Lofepramine	C		
			Gaviscon	C		
			Lactulose	C		
			Desipramine	C		
			Tramadol Hydrochloride	C		
			Methylenedioxymetham phet.	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/01ISR Number: 3726066-XReport Type:Periodic Company Report #RS001648-USA
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased	Consumer	Aciphex	PS	Eisai Inc	ORAL	20 MG, PER	
	Libido Decreased						ORAL	
	Muscle Rigidity		Zyban (Amfetbutamone					
	Pollakiuria		Hydrochloride)	SS		ORAL	PER ORAL	
			Tagamet (Cimetidine)	C				
			Pepcid (Famotidine)	C				
			Maalox (Maalox)	C				
			Tums (Tums)	C				
			Other Medications (Unspecified)	C				
			Cephalexin (Cefalexin)	C				

Date:05/15/01ISR Number: 3722915-XReport Type:Expedited (15-DaCompany Report #A0142161A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Activated Partial						per day	
Initial or Prolonged	Thromboplastin Time		Rivotril	C		ORAL	.5MG Twice	
Disability	Shortened						per day	
	Asthenia		Asa	C				
	Bacillus Infection							
	Bacterial Infection							
	Blister							
	Blood Cholesterol Increased							
	Blood Potassium Decreased							
	Decreased Activity							
	Ecchymosis							
	Fatigue							
	Haematocrit Decreased							

Haemoglobin Decreased
Idiopathic
Thrombocytopenic Purpura
Infection
Lymphocyte Count
Increased
Monocyte Count Increased
Musculoskeletal Stiffness
Nervous System Disorder
Neutrophil Count
Increased
Oedema Peripheral
Pain
Platelet Count Decreased
Rectal Haemorrhage
Red Blood Cell Count
Decreased
Specific Gravity Urine
Abnormal
Spleen Disorder
Thrombocytopenia
Visual Disturbance
Weight Increased
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/15/01ISR Number: 3722930-6Report Type:Expedited (15-DaCompany Report #B0106346A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged	Back Pain		Cilest	C		ORAL		
	Depression		Senna	C		ORAL		
	Disturbance In Attention							
	Dizziness							
	Headache							
	Indifference							
	Nausea							
	Neck Pain							
	Optic Discs Blurred							
	Sedation							
	Staring							

Date:05/15/01ISR Number: 3724222-8Report Type:Direct Company Report #
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Erythema		Zyban 150 Mg Skb	PS	Skb		TOBACCO	
Intervention to	Urticaria						CESSATION	
Prevent Permanent			Nicoderm	C				
Impairment/Damage								

Date:05/15/01ISR Number: 3724223-XReport Type:Direct Company Report #
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Rash Pruritic		Zyban 150mg Skb	PS	Skb	ORAL	150 MG BID	
Intervention to							ORAL	
Prevent Permanent			Nicoderm	C				
Impairment/Damage			Colace	C				
			Loovral	C				

Date:05/16/01ISR Number: 3723631-0Report Type:Expedited (15-DaCompany Report #A0138535A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum Oesophageal		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Dry Mouth							
							per day	124 DAY
Disability	Gastric Polyps		Effexor Xr	SS		ORAL	75MG Twice	
Other	Gingival Pain							
							per day	3 YR
	Hypokalaemia		Nicotine	SS				
	Hyponatraemia		Trazodone	C		ORAL	50MG At night	
	Pituitary Tumour		Klonopin	C		ORAL	.5MG As	
	Post Procedural						required	
	Complication		Dextrostat	C		ORAL	10MG Twice	
	Salivary Hypersecretion							
							per day	700 DAY
	Speech Disorder		Synthroid	C	Glaxo Wellcome	ORAL		
	Stress							
	Tardive Dyskinesia							
	Visual Field Defect							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/01ISR Number: 3723640-1Report Type:Expedited (15-DaCompany Report #B0099812A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxo Wellcome		150MG Twice	
	Accident						per day	
	Asthenia		Quinapril	C				
	Blood Pressure Increased		Trisequens	C				
	Dehydration		Ketoconazole	C				
	Diplopia		Alcohol	C				
	Dizziness							
	Dry Mouth							
	Dry Skin							
	Feeling Abnormal							
	Food Allergy							
	Fungal Infection							
	Headache							
	Hypersensitivity							
	Malaise							
	Nausea							
	Pallor							
	Palpitations							
	Paraesthesia							
	Pharyngeal Oedema							
	Sneezing							
	Tongue Oedema							
	Vertigo							
	Vision Blurred							

Date:05/16/01ISR Number: 3723641-3Report Type:Expedited (15-DaCompany Report #B0104518A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Per day
Hospitalization -	Chest Pain		Atenolol	C		ORAL	50MG Per day	
Initial or Prolonged	Cough		Aspirin	C		ORAL	75MG In the	
Disability	Dizziness						morning	

	Lower Respiratory Tract		Dipyridamole	C	ORAL 200MG Twice
	Infection				per day
	Nausea		Atorvastatin	C	ORAL 10MG Per day
	Neck Pain		Premarin	C	ORAL 1.25MG Per day

Date:05/16/01ISR Number: 3723644-9Report Type:Expedited (15-DaCompany Report #B0107247A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia		Zyban	PS	Glaxo Wellcome			
	Paralysis							

Date:05/16/01ISR Number: 3723645-0Report Type:Expedited (15-DaCompany Report #B0107381A
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Death	Amnesia
	Balance Disorder
	Confusional State
	Ecchymosis
	Excoriation

		Fall					
		Head Injury					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Overdose		Zyban	PS	Glaxo Wellcome	
UNKNOWN							
		Periorbital Haematoma		Fluoxetine	C		
		Speech Disorder		Alcohol	C		
		Subdural Haematoma					
		Toxicologic Test Abnormal					

Date:05/16/01ISR Number: 3724981-4Report Type:Expedited (15-DaCompany Report #2001-BP-01469
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardio-Respiratory Arrest	Health	Flomax	PS	Boehringer Ingelheim	
Hospitalization -	Convulsion	Professional			Pharmaceuticals Inc	ORAL
0.4MG/1						
Initial or Prolonged	Tachycardia					
CAPSULE / QD/						
PO						
			Wellbutrin	SS		ORAL
350 MG / PO	7 YR					
			Lipitor	C		
			Lorazepam	C		
			Viagra	C		
			Baby Aspirin	C		
			Msm	C		
			Co Q10	C		
			Multivitamins	C		
			Fish Oil	C		
			Pentatanic Acid	C		

Date:05/17/01ISR Number: 3724257-5Report Type:Expedited (15-DaCompany Report #B0107423A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abdominal Distension		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						

	Depression					
per day						
	Drug Withdrawal Syndrome					

Date:05/17/01ISR Number: 3724393-3Report Type:Direct Company Report #
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Polyarthritis		Zyban	PS		ORAL	1 BID PO	
			Nicoderm Patches	C				

Date:05/17/01ISR Number: 3725080-8Report Type:Expedited (15-DaCompany Report #B0107035A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Bupropion					
	Disturbance In Attention	Literature	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Feeling Abnormal		Chloroquine	C				
	Headache							
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/01ISR Number: 3725082-1Report Type:Expedited (15-DaCompany Report #B0104334A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
Required	Dysuria	Health					PER DAY ORAL	
Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction	Professional						
	Swelling	Company Representative	Adrenaline (Epinephrine)	SS		INTRAVENOUS	INTRAVENOUS	
	Urticaria		Citalopram	C				

Date:05/17/01ISR Number: 3725084-5Report Type:Expedited (15-DaCompany Report #B0106830A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		UNKNOWN	
	C-Reactive Protein Increased	Health						
	Chromaturia	Professional						
	Diarrhoea							
	Inflammation							
	Nausea							
	Nephritis							
	Vomiting							
	White Blood Cell Count Increased							

Date:05/17/01ISR Number: 3725086-9Report Type:Expedited (15-DaCompany Report #B0106581A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Road Traffic Accident	Health						
		Professional						

Date:05/17/01ISR Number: 3725088-2Report Type:Expedited (15-DaCompany Report #B0106828A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Oedema	Foreign	Bupropion					
Hospitalization -	Cerebral Infarction		Hydrochloride	PS	Glaxo Wellcome Inc			
UNKNOWN							150 MG	
Initial or Prolonged	Dysphagia							
UNKNOWN								
	Hemiparesis		Bith Controlpills	C				

Date:05/17/01ISR Number: 3725090-0Report Type:Expedited (15-DaCompany Report #B0107040A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Choking	Foreign	Bupropion					
	Loss Of Consciousness	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL		
ORAL								
	Skin Discolouration		Nitrazpam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/01ISR Number: 3724928-0Report Type:Expedited (15-DaCompany Report #B0092571A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Overdose		Zyban	PS	Glaxo Wellcome	ORAL	1TAB As	
Hospitalization - directed	Stress							34 DAY
Initial or Prolonged	Suicide Attempt		Paracetamol	SS				
Other			Alcohol	SS				

Date:05/18/01ISR Number: 3724932-2Report Type:Expedited (15-DaCompany Report #B0099532A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Poor Peripheral		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 MON
	Circulation		Isib	C		ORAL	60MG In the morning	
	Retinal Detachment							
	Vitreous Haemorrhage		Co-Codamol	C				
			Cerivastatin	C			400MCG At night	
			Clopidogrel	C			75MG Per day	
			Frusemide	C			40MG In the morning	
			Lacidipine	C	Glaxo Wellcome		4MG In the morning	
			Fluoxetine	C			20MG In the morning	
			Aspirin	C			75MG Per day	
			Gtn	C	Glaxo Wellcome			

			Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	2PUFF Twice per day
			Ranitidine	C	Glaxo Wellcome		150MG Twice per day
			Amitriptyline	C			20MG At night
			Senna	C			7.5G At night
			Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	
			Naproxen	C		ORAL	1000MG per day
			Trimethoprim	C	Glaxo Wellcome	ORAL	400MG per day
			Nicorandil	C		ORAL	
			Cephradine	C	Glaxo Wellcome		
			Metronidazole	C			

Date:05/18/01ISR Number: 3724934-6Report Type:Expedited (15-DaCompany Report #B0101422A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eye Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	92 DAY
	Therapeutic Response		Amitriptyline	C		ORAL	20MG per day	
	Unexpected		Isosorbide	C		ORAL	30MG per day	
	Vitreous Disorder		Co-Codamol	C		ORAL	8U per day	
			Cerivastatin	C		ORAL	400MCG per day	
			Clopidogrel	C		ORAL	75MG per day	
			Frusemide	C		ORAL	40MG per day	
			Lacidipine	C	Glaxo Wellcome	ORAL	40MG per day	

Fluoxetine	C		ORAL
Aspirin	C		ORAL
Ranitidine	C	Glaxo Wellcome	ORAL

20MG per day

75MG per day

300MG per day

			Senna	C		ORAL 7.5MG per day
			Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)
			Naproxen	C		ORAL 1000MG per day
			Trimethoprim	C	Glaxo Wellcome	ORAL 400MG per day
			Nicorandil	C		ORAL

Date:05/18/01ISR Number: 3725865-8Report Type:Expedited (15-DaCompany Report #A0142161A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Activated Partial Thromboplastin Time Shortened	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / TWICE PER DAY / ORAL
Hospitalization - Initial or Prolonged						
Disability	Bacteriuria		Clonazepam	C		
	Blister		Aspirin	C		
	Blood Cholesterol Increased					
	Blood Potassium Decreased					
	Ecchymosis					
	Epistaxis					
	Eye Disorder					
	Fatigue					
	Haematocrit Decreased					
	Haemoglobin Decreased					
	Idiopathic Thrombocytopenic Purpura					
	Laboratory Test Abnormal					
	Lymphocyte Count Increased					
	Mental Disorder					
	Monocyte Count Increased					
	Musculoskeletal Stiffness					
	Nervous System Disorder					

	Neutrophil Count Increased
	Oedema Peripheral
	Pain
	Purpura
	Rectal Haemorrhage
	Red Blood Cell Count Decreased
	Specific Gravity Urine Abnormal
	Spleen Disorder
	Thrombocytopenia
	Weight Increased
	White Blood Cell Count Increased

Date:05/18/01ISR Number: 3725897-XReport Type:Expedited (15-DaCompany Report #B0106346A
Age:27 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Back Pain
	Coordination Abnormal
	Depression

		Disturbance In Attention					
		Dizziness					
		Electroencephalogram	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal	Foreign	Bupropion			
		Feeling Abnormal		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG / PER							
		Headache					
DAY / ORAL							
		Nausea		Cileste	C		
		Neck Pain		Sennosides	C		
		Papilloedema					
		Sedation					

Date:05/18/01ISR Number: 3726330-4Report Type:Expedited (15-DaCompany Report #A0123857A
Age:46 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Aortic Atherosclerosis	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
150 MG ORAL	MON						
		Cardiomegaly	Professional				
		Cardiovascular Disorder					
		Coma					
		Convulsion					
		Coronary Artery Disease					
		Drug Level Above					
		Therapeutic					
		Ecchymosis					
		Emphysema					
		Excoriation					
		Hepatic Congestion					
		Hepatic Fibrosis					
		Hepatic Steatosis					
		Histology Normal					
		Hypertension					
		Overdose					
		Pulmonary Congestion					
		Pulmonary Fibrosis					
		Pulmonary Oedema					
		Ventricular Hypertrophy					
		Vomiting					

Date:05/18/01ISR Number: 3726355-9Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Akinesia	Consumer	Zoloft	PS	Pfizer Pharmaceuticals Inc		50.00 MG TOTAL:DAILY:	
	Blood Pressure Increased							
	Drug Ineffective							
	Dysphonia		Wellbutrin	SS		ORAL	300.00 MG TOTAL:BID:ORAL	
	Ecchymosis							
	Epistaxis							
	Haemorrhagic Stroke		Coumadin	SS				
	Headache		Effexor Sr	SS		ORAL	300.00 MG TOTAL:BID:ORAL	
	Heart Rate Decreased							
	Mood Swings							
	Overdose		Toprol	C				
	Parkinson'S Disease		Zebeta	C				
	Staring		Lanoxin	C				
	Syncope		Lasix	C				
	Thyroid Function Test Abnormal		Synthroid	C				
			Vitamin E	C				
			Estrogen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/01ISR Number: 3725777-XReport Type:Expedited (15-DaCompany Report #A0139670A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	2 MON
	Congestive		Rocephin	C		INTRAVENOUS	1G Per day	
	Convulsion		Pepcid	C			20MG Per day	
	Loss Of Consciousness		Kcl	C				
			Captopril	C	Glaxo Wellcome		12.5MG Twice per day	
			Depakote	C			500MG Per day	
			Buspar	C			10MG Twice per day	
			Nicoderm Patch	C			7MG At night	
			Seroquel	C			75MG Per day	
			Lasix	C				
			Lanoxin	C	Glaxo Wellcome			
			Albuterol	C	Glaxo Wellcome			
			Spironolactone	C			12.5MG Per day	
			Aspirin	C			325MG Per day	
			Antivert	C			12.5MG Three times per day	
			Artificial Tears	C				
			Proventil	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	
			Atrovent	C	Glaxo Wellcome		RESPIRATORY	

(INHALATION)

Date:05/21/01ISR Number: 3725781-1Report Type:Expedited (15-DaCompany Report #B0100682A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Zyban	PS	Glaxo Wellcome		150MG Twice per day	
	Blindness							
	Blood Glucose Decreased		Coffee	C		ORAL		
	Circulatory Collapse		Naprosyn	C		ORAL	50MG Twice per day	
	Dizziness							
	Headache							
	Hypoaesthesia							
	Photophobia							
	Vision Blurred							

Date:05/21/01ISR Number: 3725784-7Report Type:Expedited (15-DaCompany Report #B0107510A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	16 DAY
			Aminophylline	C		ORAL		
			Prednisolone	C		ORAL	50MG As required	
			Diclofenac	C		ORAL	50MG As required	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/01ISR Number: 3725785-9Report Type:Expedited (15-DaCompany Report #B0107658A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Disturbance In Attention						per day	7 DAY
	Feeling Abnormal							
	Speech Disorder							
	Tinnitus							
	Visual Disturbance							

Date:05/21/01ISR Number: 3725787-2Report Type:Expedited (15-DaCompany Report #B0107823A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Decreased Appetite		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	1 WK
Initial or Prolonged	Depression							
	Overdose							

Date:05/21/01ISR Number: 3725789-6Report Type:Expedited (15-DaCompany Report #B0107842A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	2 DAY
			Kliofem	C		ORAL		

Date:05/21/01ISR Number: 3726400-0Report Type:Expedited (15-DaCompany Report #A0138535A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum Oesophageal	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

Initial or Prolonged	Dry Mouth	Professional				
TWICE PER DAY						
Disability	Dyskinesia	Company				
/ ORAL						
Required	Gastric Polyps	Representative	Venlafaxine			
Intervention to	Gingival Pain		Hydrochloride			
Prevent Permanent	Hypokalaemia		(Formulation			
Impairment/Damage	Hyponatraemia		Unknown)	SS		ORAL
75 MG / TWICE						
	Pituitary Tumour Benign					
PER DAY /						
	Salivary Hypersecretion					
ORAL						
	Speech Disorder		Nicotine Gum	SS		
	Tardive Dyskinesia		Trazodone	C		
			Clonazepam	C		
			Dexamphetamine			
			Sulphate	C		
			Thyroxine Sodium	C		

Date:05/21/01ISR Number: 3726417-6Report Type:Expedited (15-DaCompany Report #2001SUS0407
Age:0 DY Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Complications Of Maternal	Health	Sustiva	PS	Dupont	
	Exposure To Therapeutic	Professional			Pharmaceuticals Co	
TRANSPLACENTAL TR						
	Drugs		Combivir			
	Cystic Fibrosis		(Lamivudine/Zidovudi			
	Meconium Ileus		ne)	SS		
TRANSPLACENTAL TR						
			Norvir (Ritonavir)	SS		
TRANSPLACENTAL TR						
			Crixivan (Indinavir)	SS		
TRANSPLACENTAL TR						
			Bupropion			

				(Amfebutamone)	SS		
TR							
				Viramune (Nevirapine)	SS		
TRANSPLACENTAL	TR						
				Epivir (Lamivudine)	SS		
TRANSPLACENTAL	TR						
				Zerit (Stavudine)	SS		
TRANSPLACENTAL	TR						
				Viracept (Nelfinavir)	SS		
TRANSPLACENTAL	TR						

Date:05/21/01ISR Number: 3726825-3Report Type:Expedited (15-DaCompany Report #B0104518A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG/ PER	
Hospitalization -	Cough	Health					DAY/	
Initial or Prolonged	Dizziness	Professional	Atenolol	C				
Disability	Infection		Aspirin	C				
	Nausea		Dipyridamole	C				
	Neck Pain		Atorvastatin Calcium	C				
	Pain		Conjugated Estrogens	C				

Date:05/21/01ISR Number: 3726827-7Report Type:Expedited (15-DaCompany Report #B0099812A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG/ TWICE	
	Blood Pressure Increased	Health					PER DAY/	
	Dehydration	Professional	Quinapril	C				
	Diplopia		Trisequens	C				
	Dizziness		Ketoconazole	C				
	Dry Mouth		Ethanol	C				
	Dry Skin							
	Feeling Abnormal							
	Food Allergy							

Headache
Hypersensitivity
Malaise
Nasopharyngitis
Nausea
Pallor
Palpitations
Paraesthesia
Pharyngeal Oedema
Sneezing
Tongue Disorder
Tongue Oedema
Vertigo
Vision Blurred

Date:05/21/01ISR Number: 3726978-7Report Type:Expedited (15-DaCompany Report #B0092571A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Overdose	Foreign	Bupropion					
Hospitalization - Initial or Prolonged	Stress	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	1 TABLET / AS DIRECTED /	
Required Intervention to Prevent Permanent Impairment/Damage	Suicide Attempt	Professional	Paracetamol (Formulation Unknown)			ORAL		

			(Acetaminophen)	SS		
			Ethanol (Formulation Unknown) (Alcohol)	SS		

Date:05/21/01ISR Number: 3726979-9Report Type:Expedited (15-DaCompany Report #B0101422A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Therapeutic Response	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL
	Unexpected							
	Vitreous Haemorrhage							
			Amitriptyline	C				
			Isosorbide	C				
			Co-Codamol	C				
			Cerivastatin	C				
			Clopidogrel	C				
			Frusemide	C				
			Lacidipine	C				
			Fluoxetine	C				
			Aspirin	C				
			Ranitidine Hydrochloride	C				
			Sennosides	C				
			Salbutamol Sulphate	C				
			Naproxen	C				
			Trimethoprim	C				
			Nicorandil	C				

Date:05/21/01ISR Number: 3726980-5Report Type:Expedited (15-DaCompany Report #B0099532A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Interaction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL
	Intermittent Claudication	Health						
	Therapeutic Response	Professional						
	Unexpected		Isosorbide Mononitrate	C				
	Vitreous Haemorrhage		Co-Codamol	C				

Cerivastatin	C
Clopidogrel	C
Frusemide	C
Lacidipine	C
Fluoxetine	C
Aspirin	C
Nitroglycerin	C
Beclomethasone Dipropion.	C
Ranitidine Hydrochloride	C
Amitriptyline	C
Sennosides	C
Salbutamol Sulphate	C
Naproxen	C
Trimethoprim	C
Nicorandil	C
Cephradine	C
Metronidazole	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/01ISR Number: 3726988-XReport Type:Expedited (15-DaCompany Report #B0107423A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage / ORAL	Abdominal Distension Depression Drug Withdrawal Syndrome	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	

Date:05/22/01ISR Number: 3726477-2Report Type:Expedited (15-DaCompany Report #A0148065A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Amnesia Asthenia Bite Convulsion Decreased Activity Difficulty In Walking Eyelid Disorder Grand Mal Convulsion Haematuria Hypoaesthesia Insomnia Loss Of Consciousness Mouth Haemorrhage Muscle Twitching Tongue Disorder Tremor Vision Blurred		Wellbutrin Birth Control Pills	PS C	Glaxo Wellcome	ORAL	150MG Twice per day	9 DAY

Date:05/22/01ISR Number: 3726481-4Report Type:Expedited (15-DaCompany Report #B0100055A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Increased							
	Arthralgia							
	Blood Pressure Decreased							
	Dermatitis							
	Heart Rate Decreased							
	Hypersensitivity							
	Infection							
	Joint Swelling							
	Malaise							
	Palpitations							
	Vomiting							

Date:05/22/01ISR Number: 3726482-6Report Type:Expedited (15-DaCompany Report #B0100789A
Age:29 YR Gender:Female I/FU:F

Outcome	PT
	Anxiety
	Arthralgia
	Cyanosis
	Hyperhidrosis
	Musculoskeletal Stiffness
	Nausea

Peripheral Coldness
Tremor

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:05/22/01ISR Number: 3726485-1Report Type:Expedited (15-DaCompany Report #B0107427A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumothorax		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	55 DAY
			Salmeterol	C	Glaxo Wellcome		2PUFF Twice per day	
			Ipratropium	C	Glaxo Wellcome		2PUFF Twice per day	
			Terbutaline	C			2PUFF Twice per day	

Date:05/22/01ISR Number: 3726488-7Report Type:Expedited (15-DaCompany Report #B0108509A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diabetes Mellitus		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	62 DAY
	Non-Insulin-Dependent		Ranitidine	C	Glaxo Wellcome		UNKNOWN	150MG Unknown
	Malaise							

Date:05/22/01ISR Number: 3726489-9Report Type:Expedited (15-DaCompany Report #B0108517A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome			

Date:05/22/01ISR Number: 3726865-4Report Type:Expedited (15-DaCompany Report #B0107381A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ecchymosis	Foreign	Bupropion					
	Excoriation	Health	Hydrochloride	PS	Glaxo Wellcome Inc			
	Fall	Professional	Fluoxetine	C				
	Overdose		Ethanol	C				
	Periorbital Haematoma							
	Subdural Haematoma							

Date:05/22/01ISR Number: 3726866-6Report Type:Expedited (15-DaCompany Report #B0107247A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hemiplegia	Foreign	Bupropion					
	Paraesthesia	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/01ISR Number: 3727624-9Report Type:Direct Company Report #
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Arrest		Metabolife	PS			6 CAPS PER	
Initial or Prolonged	Grand Mal Convulsion						DAY	3 WK
	Metabolic Acidosis		Wellbutrin	SS			BID	3 WK
	Respiratory Arrest							
	Ventricular Fibrillation							
	Vomiting							

Date:05/23/01ISR Number: 3727296-3Report Type:Expedited (15-DaCompany Report #A0147746A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL	75MG Per day	1 WK
	Feeling Abnormal							
	Petit Mal Epilepsy							

Date:05/23/01ISR Number: 3727318-XReport Type:Expedited (15-DaCompany Report #B0108029A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome			
	Dyspnoea							

Date:05/23/01ISR Number: 3727319-1Report Type:Expedited (15-DaCompany Report #B0108034A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Postmenopausal		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	

	Haemorrhage		Ranitidine	C	Glaxo Wellcome	ORAL
150MG						
Variable dose						
			Trisequens	C		

Date:05/23/01ISR Number: 3727320-8Report Type:Expedited (15-DaCompany Report #B0108210A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Fatigue		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Headache					
per day 18 DAY						
	Insomnia					
	Keratitis					

Date:05/23/01ISR Number: 3727321-XReport Type:Expedited (15-DaCompany Report #B0108213A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Diarrhoea Haemorrhagic		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
per day 9 DAY						
			Levonorgestrel	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/01ISR Number: 3727322-1Report Type:Expedited (15-DaCompany Report #B0108220A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema		Zyban	PS	Glaxo Wellcome			

Date:05/23/01ISR Number: 3727323-3Report Type:Expedited (15-DaCompany Report #B0108504A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	5 DAY
			Nifedipine	C		ORAL	10MG Three times per day	
			Frusemide	C		ORAL	40MG Per day	
			Potassium Chloride	C		ORAL	1U Four times per day	
			Glyceryl Trinitrate	C	Glaxo Wellcome	SUBLINGUAL		

Date:05/23/01ISR Number: 3727324-5Report Type:Expedited (15-DaCompany Report #B0108505A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Exertional Left Ventricular Failure		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	53 DAY
			Lisinopril	C		ORAL		
			Diltiazem	C		ORAL		
			Aspirin	C		ORAL		

			Cerivastatin	C		
UNKNOWN						
			Isosorbide	C		
UNKNOWN	20MG Twice					
per day						

Date:05/23/01ISR Number: 3727325-7Report Type:Expedited (15-DaCompany Report #B0108747A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	
UNKNOWN	300MG per day 3 WK					
	Pregnancy					

Date:05/23/01ISR Number: 3727868-6Report Type:Expedited (15-DaCompany Report #B0100682A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	
150 MG /						
Initial or Prolonged	Blood Glucose Decreased	Health				
TWICE PER DAY						
	Circulatory Collapse	Professional				
/						
	Dizziness		Coffee	C		
	Headache		Naproxen	C		
	Hypoaesthesia					
	Photophobia					
	Vision Blurred					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/01ISR Number: 3727912-6Report Type:Expedited (15-DaCompany Report #B0107842A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Deep Vein Thrombosis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG (PER DAY) ORAL
			Kliofem	C			

Date:05/23/01ISR Number: 3727915-1Report Type:Expedited (15-DaCompany Report #B0107510A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthma Back Pain	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY) ORAL
			Aminophylline	C			
			Prednisolone	C			
			Diclofenac	C			

Date:05/23/01ISR Number: 3727918-7Report Type:Expedited (15-DaCompany Report #B0107658A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Agitation Disturbance In Attention Feeling Abnormal Speech Disorder Tinnitus Visual Disturbance	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL

Date:05/23/01ISR Number: 3727924-2Report Type:Expedited (15-DaCompany Report #B0107823A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Decreased Appetite Depression Flat Affect Overdose	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	1 WK

Date:05/23/01ISR Number: 3728001-7Report Type:Expedited (15-DaCompany Report #A0139670A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Convulsion Loss Of Consciousness	Consumer	Wellbutrin Sr Ceftriaxone Sodium Famotidine Potassium Chloride Captopril Semisodium Valproate Buspirone Hydrochloride Nicotine Quetiapine Fumarate Frusemide Digoxin Salbutamol Sulphate	PS C C C C C C C C C C C	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY) ORAL	2 MON

			Spironolactone	C		
			Aspirin	C		
			Meclozine Hydrochloride	C		
			Hypremellose	C		
			Ipratropium Bromide	C		

Date:05/24/01ISR Number: 3727940-0Report Type:Expedited (15-DaCompany Report #A0093694A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Convulsion Decreased Activity Depression Grand Mal Convulsion Pain Spinal Fracture		Wellbutrin Concurrent Medications	PS C	Glaxo Wellcome	ORAL	150MG Per day	4 MON

Date:05/24/01ISR Number: 3727951-5Report Type:Expedited (15-DaCompany Report #B0100520A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Circulatory Collapse Dizziness Hypoaesthesia Musculoskeletal Stiffness Nausea Photophobia Retching		Zyban	PS	Glaxo Wellcome			

Date:05/24/01ISR Number: 3728480-5Report Type:Expedited (15-DaCompany Report #A0148065A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

Amnesia
TWICE PER DAY
Difficulty In Walking
/ ORAL
Grand Mal Convulsion Oral Contraceptive C
Haematuria
Hypoaesthesia
Insomnia
Loss Of Consciousness
Mouth Haemorrhage
Muscle Twitching
Tremor
Vision Blurred

Date:05/24/01ISR Number: 3728699-3Report Type:Expedited (15-DaCompany Report #B0100055A
Age:27 YR Gender:Male I/FU:F

Outcome PT
Arthralgia
Aspartate
Aminotransferase
Increased
Blood Pressure Decreased
Dermatitis

	Heart Rate Decreased						
	Hypersensitivity						
	Infection	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Joint Swelling	Foreign	Bupropion				
	Malaise	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
	Palpitations	Professional					PER DAY /
	Vomiting						ORAL

Date:05/24/01ISR Number: 3728700-7Report Type:Expedited (15-DaCompany Report #B0100789A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Anxiety	Foreign	Bupropion				
	Arthralgia	Study	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /
	Hyperhidrosis	Health					TWICE PER DAY
	Musculoskeletal Stiffness	Professional					/ ORAL
	Nausea						
	Peripheral Coldness						
	Skin Discolouration						
	Tremor						

Date:05/24/01ISR Number: 3728738-XReport Type:Expedited (15-DaCompany Report #B0108517A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Sudden Death	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG

Date:05/24/01ISR Number: 3728739-1Report Type:Expedited (15-DaCompany Report #B0108509A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diabetes Mellitus	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Non-Insulin-Dependent						DAY / ORAL	
	Malaise		Ranitidine Hydrochloride	C				

Date:05/24/01ISR Number: 3728740-8Report Type:Expedited (15-DaCompany Report #B0107427A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumothorax	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	
							/ ORAL	
			Salmeterol Xinafoate	C				
			Ipratropium Bromide	C				
			Terbutaline	C				

Date:05/25/01ISR Number: 3728381-2Report Type:Expedited (15-DaCompany Report #B0107824A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypothermia		Zyban	PS	Glaxo Wellcome	ORAL	10 DAY	
	Mood Altered		Aspirin	SS			UNKNOWN	
	Overdose							
	Social Avoidant Behaviour							
	Stress							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/01ISR Number: 3728819-0Report Type:Expedited (15-DaCompany Report #A0147746A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	75 MG (PER
	Feeling Abnormal						DAY) ORAL

Date:05/25/01ISR Number: 3729339-XReport Type:Expedited (15-DaCompany Report #B0108220A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG

Date:05/25/01ISR Number: 3729340-6Report Type:Expedited (15-DaCompany Report #B0108213A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Diarrhoea Haemorrhagic	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL
			Levonorgestrel	C			

Date:05/25/01ISR Number: 3729341-8Report Type:Expedited (15-DaCompany Report #B0108210A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Fatigue	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
	Headache						

	Insomnia					
PER DAY/ ORAL						
	Keratitis					

Date:05/25/01ISR Number: 3729390-XReport Type:Expedited (15-DaCompany Report #B0108034A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Postmenopausal	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG PER
Intervention to	Haemorrhage						DAY ORAL
Prevent Permanent			Ranitidine				
Impairment/Damage			Hydrochloride	C			
			Trisequens	C			

Date:05/25/01ISR Number: 3729398-4Report Type:Expedited (15-DaCompany Report #B0108504A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE
Intervention to							PER DAY ORAL
Prevent Permanent			Nifedipine	C			
Impairment/Damage			Frusemide	C			
			Potassium Chloride	C			
			Nitroglycerin	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/01ISR Number: 3729399-6Report Type:Expedited (15-DaCompany Report #B0108029A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Foreign	Zyban	PS	Glaxo Wellcome Inc			
UNKNOWN							150 MG	
	Dyspnoea	Consumer						
UNKNOWN								

Date:05/25/01ISR Number: 3729400-XReport Type:Expedited (15-DaCompany Report #B0108747A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Foreign	Zyban	PS	Glaxo Wellcome Inc			
UNKNOWN								3 WK
	Complications Of Maternal Exposure To Therapeutic Drugs Pregnancy	Health Professional						

Date:05/25/01ISR Number: 3729401-1Report Type:Expedited (15-DaCompany Report #B0108505A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Left Ventricular Failure	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
			Lisinopril	C				
			Diltiazem	C				
			Aspirin	C				
			Cerivastatin	C				
			Isosorbide	C				

Date:05/25/01ISR Number: 3733469-6Report Type:Periodic Company Report #HQ8388514MAR2001
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Protonix	PS		ORAL	40 MG 1 X PER	
	Dizziness						1 DAY, ORAL	
	Drug Interaction		Estratest (Estorgens Esterified/Methyltes tosterone)	SS		ORAL	1 TABLET 1X PER 1 DAY, ORAL	
			Univasc (Moexipril Hydrochloride)	SS		ORAL	15 MG 1X PER 1 DAY, ORAL	
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	150 MG 2X PER 1 DAY, ORAL	

Date:05/29/01ISR Number: 3729842-2Report Type:Expedited (15-DaCompany Report #S01-USA-00846-01
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Consumer	Celexa	PS	Forest Laboratories Inc			
	Circulatory Collapse							
	Drug Level Above Therapeutic		Wellbutrin (Amfebutamone Hydrochloride)	SS				
	Parkinson'S Disease							
INTRAVENOUS	BID IV						150 MG	
			Depakote (Valproate					

			Semisodium)	SS		
			Paxil (Paroxetine Hydrochloride)	SS		

Date:05/29/01ISR Number: 3730019-5Report Type:Expedited (15-DaCompany Report #A0093694A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Convulsion Depression Grand Mal Convulsion Pain Spinal Compression Fracture	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL	

Date:05/29/01ISR Number: 3730364-3Report Type:Expedited (15-DaCompany Report #B0100520A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Circulatory Collapse Dizziness Hypoaesthesia Musculoskeletal Stiffness Nausea Photophobia Retching	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	

Date:05/30/01ISR Number: 3729804-5Report Type:Expedited (15-DaCompany Report #A0148248A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Amnesia Cardio-Respiratory Arrest		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	11 DAY

Initial or Prolonged	Coma		Flomax	SS		ORAL
.4MG Per day 1 DAY						
	Convulsion		Viagra	SS		
2 YR						
	Drug Interaction		Lipitor	C		
YR						
	Fall		Lorazepam	C		
YR						
	Head Injury		Baby Aspirin	C		
YR						
			Msm	C		
8 DAY						
			Co Q10	C		
			Multivitamins	C		
			Fish Oil	C		
			Pentatanic Acid	C		

Date:05/30/01ISR Number: 3729814-8Report Type:Expedited (15-DaCompany Report #B0103784A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Alcohol Intolerance		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Haematuria					
per day 21 DAY						
	Rhabdomyolysis		Alcohol	C		

Date:05/30/01ISR Number: 3729819-7Report Type:Expedited (15-DaCompany Report #B0106830A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort Diarrhoea Lung Consolidation Nephritis Red Blood Cell Sedimentation Rate Increased Vomiting White Blood Cell Count Increased		Zyban	PS	Glaxo Wellcome			8 DAY

Date:05/30/01ISR Number: 3729822-7Report Type:Expedited (15-DaCompany Report #B0108202A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL		

Date:05/30/01ISR Number: 3729825-2Report Type:Expedited (15-DaCompany Report #B0108364A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Arthralgia Blister Chest Discomfort Constipation Cough Dizziness Dyspnoea Face Oedema Feeling Cold Haemoptysis Hypoventilation Oliguria Pharyngeal Oedema		Zyban	PS	Glaxo Wellcome			

	Urticaria					

Date:05/30/01ISR Number: 3729826-4Report Type:Expedited (15-DaCompany Report #B0108503A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Proctitis Ulcerative						per day	55 DAY
	Purulence		Mefanamic Acid	C		ORAL	15	WK

Date:05/30/01ISR Number: 3730651-9Report Type:Expedited (15-DaCompany Report #B0107824A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypothermia	Foreign	Bupropion					
Initial or Prolonged	Mood Altered	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL		
ORAL							10	DAY
	Overdose	Professional	Aspirin (Aspirin)	SS				
	Stress							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/30/01ISR Number: 3730929-9Report Type:Direct Company Report #
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Wellbutrin	PS				1 MON
	Back Pain							
	Cardio-Respiratory Arrest							
	Electrocardiogram Qt Prolonged							
	Sinus Tachycardia							
	Vomiting							

Date:05/30/01ISR Number: 3730931-7Report Type:Expedited (15-DaCompany Report #A0148393A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE TEXT / Initial or Prolonged	Asthenia	Literature	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	1 MON
	Heart Rate Increased	Health						
	Pyrexia	Professional	Valproic Acid	C				
	Supraventricular Tachycardia		Mirtazapine	C				

Date:05/31/01ISR Number: 3731139-1Report Type:Expedited (15-DaCompany Report #A0097619A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	23 DAY
	Arthralgia							
	Heart Rate Increased		Ibuprofen	C		ORAL	200MG As required	3 DAY
	Malaise							
	Oedema Peripheral							
	Pruritus							
	Serum Sickness							

Skin Discolouration
Urticaria

Date:05/31/01ISR Number: 3731140-8Report Type:Expedited (15-DaCompany Report #A0103746A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Analgesic Drug Level		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Angioneurotic Oedema						per day	16 DAY
	Arthralgia							
	Asthma							
	Chills							
	Dyspepsia							
	Face Oedema							
	Lymphadenopathy							
	Myalgia							
	Odynophagia							
	Oedema							
	Oedema Peripheral							
	Periorbital Oedema							
	Pruritus							
	Pyrexia							
	Rash Erythematous							
	Serum Sickness							
	Synovitis							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/01/01ISR Number: 3731735-1Report Type:Expedited (15-DaCompany Report #B0108772A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction		Bupropion Hcl	PS	Glaxo Wellcome	ORAL	150MG Per day	
			Aspirin	C		ORAL	1UNIT Per day	
			Atenolol	C		ORAL	RESPIRATORY (INHALATION)	200MCG Twice per day
			Beclomethasone	C	Glaxo Wellcome			
			Co-Amilofruse	C		ORAL	1UNIT Per day	
			Imdur	C		ORAL	60MG Per day	
			Lactulose	C		ORAL	15ML Twice per day	
			Lisinopril	C		ORAL	20MG Twice per day	
			Zydol	C		ORAL	100MG Twice per day	
			Fluoxetine	C		ORAL	20MG Per day	
			Cetirizine	C	Glaxo Wellcome	ORAL	10MG Per day	
			Betnovate	C	Glaxo Wellcome		TOPICAL	.1PCT Twice per day

Date:06/01/01ISR Number: 3731736-3Report Type:Expedited (15-DaCompany Report #B0108775A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Bupropion Hcl	PS	Glaxo Wellcome	ORAL		
Hospitalization -	Hallucination		Nifedipine	C		ORAL	5MG Three	
Initial or Prolonged	Overdose						times per day	
	Tremor							

Date:06/01/01ISR Number: 3731738-7Report Type:Expedited (15-DaCompany Report #B0109122A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY
	Increased							
	Alpha 1 Foetoprotein							
	Increased							
	Aspartate							
	Aminotransferase							
	Increased							
	Asthenia							
	Blood Bilirubin Increased							
	Gamma-Glutamyltransferase							
	Increased							
	Laboratory Test Abnormal							
	Malaise							

Date:06/01/01ISR Number: 3731739-9Report Type:Expedited (15-DaCompany Report #B0109126A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL		
			Indoramin	C	Glaxo Wellcome			
			Beclomethasone Dipropionate	C	Glaxo Wellcome			
			Diazepam	C				

			Salbutamol	C	Glaxo Wellcome	

Date:06/01/01ISR Number: 3731741-7Report Type:Expedited (15-DaCompany Report #B0109574A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	11	DAY
	Asthenia		Prempak-C	C		ORAL	1.25MG Per	
	Dizziness						day	
	Flight Of Ideas		Thyroxine	C	Glaxo Wellcome	ORAL	300MCG Weekly	
	Insomnia							
	Memory Impairment							
	Palpitations							
	Speech Disorder							
	Tremor							
	Vertigo							

Date:06/01/01ISR Number: 3731742-9Report Type:Expedited (15-DaCompany Report #B0109579A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis Ulcerative		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Diarrhoea Haemorrhagic						per day	62 DAY

Date:06/01/01ISR Number: 3731743-0Report Type:Expedited (15-DaCompany Report #B0109588A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Supraventricular		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Tachycardia						per day	

Initial or Prolonged			Aspirin	C		
Other			Ketoprofen	C		

Date:06/01/01ISR Number: 3731744-2Report Type:Expedited (15-DaCompany Report #B0109706A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke Status Epilepticus		Zyban	PS	Glaxo Wellcome			

Date:06/01/01ISR Number: 3732214-8Report Type:Expedited (15-DaCompany Report #B0103784A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alcohol Intolerance	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Haematuria	Health					PER DAY/ ORAL	
	Rhabdomyolysis	Professional	Ethanol	C				

Date:06/01/01ISR Number: 3732215-XReport Type:Expedited (15-DaCompany Report #B0108503A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Proctitis Haemorrhagic Proctitis Ulcerative	Foreign	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	

PER DAY/ ORAL

Mefenamic Acid C

Date:06/01/01ISR Number: 3732222-7Report Type:Expedited (15-DaCompany Report #B0108364A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Arthralgia Blister Chest Discomfort Constipation Cough Dizziness Dyspnoea Face Oedema Feeling Cold Haemoptysis Hypoventilation Oliguria Pharyngeal Oedema Urticaria	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc			

Date:06/01/01ISR Number: 3732228-8Report Type:Expedited (15-DaCompany Report #B0106830A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort Blood Test Abnormal Chromaturia Diarrhoea Ill-Defined Disorder Inflammation Lung Consolidation Malaise Nephritis Vomiting White Blood Cell Count Increased	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:06/01/01ISR Number: 3732276-8Report Type:Expedited (15-DaCompany Report #B0108202A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
		Health Professional						

Date:06/01/01ISR Number: 3732277-XReport Type:Expedited (15-DaCompany Report #A0148248A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Hospitalization -	Convulsion						TWICE PER DAY	
Initial or Prolonged	Drug Interaction						/ ORAL	
	Fall		Tamsulosin Hcl					
	Head Injury		Capsule	SS		ORAL	.4 MG / PER	
	Tachycardia						DAY / ORAL	

Sildenafil Citrate (Formulation Unknown)	SS
Atorvastatin Calcium	C
Lorazepam	C
Aspirin	C
Dimethyl Sulfone	C
Ubidecarenone	C
Multivitamin	C
Fish Oil	C
Pentatanic Acid	C

Date:06/01/01ISR Number: 3738398-XReport Type:Expedited (15-DaCompany Report #A0149544A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Amnesia Brain Damage Concussion Convulsion Fall Head Injury Loss Of Consciousness Spinal Fracture	Consumer	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	PER DAY/ORAL

Date:06/04/01ISR Number: 3732293-8Report Type:Expedited (15-DaCompany Report #B0100818A
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Nausea Vomiting		Zyban Magnesium Trisilicate	PS C	Glaxo Wellcome	ORAL ORAL	150MG Per day 10ML Three times per day

Date:06/04/01ISR Number: 3732296-3Report Type:Expedited (15-DaCompany Report #B0103185A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Zyban	PS	Glaxo Wellcome	ORAL		
	Abdominal Tenderness		Anti-Inflammatory					
	Chest Pain		Agents	C				
	Dry Mouth							
	Fatigue							
	Lethargy							
	Malaise							
	Red Blood Cell Count Decreased							
	Tinnitus							
	White Blood Cell Count Decreased							

Date:06/04/01ISR Number: 3732297-5Report Type:Expedited (15-DaCompany Report #B0103385A
Age:69 YR Gender:Female I/FU:F

Outcome	PT
	Anorexia
	Cough

	Dizziness Lower Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Nausea		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Vomiting						per day
12 DAY							
			Aspirin	C		ORAL	75MG Unknown
			Simvastatin	C		ORAL	20MG Unknown

Date:06/04/01ISR Number: 3732298-7Report Type:Expedited (15-DaCompany Report #B0108028A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Hospitalization - Initial or Prolonged	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Headache						per day
13 DAY							
	Palpitations		Monoplus	C			
	Tremor						

Date:06/04/01ISR Number: 3732302-6Report Type:Expedited (15-DaCompany Report #B0109127A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Complications Of Maternal Exposure To Therapeutic Drugs Pregnancy						per day
15 DAY							

Date:06/04/01ISR Number: 3732303-8Report Type:Expedited (15-DaCompany Report #B0109589A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Zyban	PS	Glaxo Wellcome		150MG Per day	
	Clonic Convulsion		Lorazepam	C				
	Convulsion		Irbesartan	C				
	Dizziness							
	Feeling Abnormal							
	Loss Of Consciousness							
	Malaise							
	Tremor							

Date:06/04/01ISR Number: 3732304-XReport Type:Expedited (15-DaCompany Report #B0109704A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	36 DAY
Hospitalization - Initial or Prolonged	Cerebral Ischaemia							
	Epilepsy							
	Lipase Increased							
	Liver Function Test Abnormal							
	Red Blood Cell Sedimentation Rate Increased							
	Thrombocytopenia							
	White Blood Cell Count Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/01ISR Number: 3732306-3Report Type:Expedited (15-DaCompany Report #D0017224A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intracranial Haemangioma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Movement Disorder							
	Nervous System Disorder		Ass	C			UNKNOWN	
			Amaryl	C			UNKNOWN	

Date:06/04/01ISR Number: 3733442-8Report Type:Periodic Company Report #A108581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health Professional	Geodon	PS	Pfizer Central Research	ORAL	150.00 MG	TOTAL:BID:ORAL
	Drug Interaction							
			Wellbutrin	SS		ORAL	250.00 MG	TOTAL:BID:ORAL

Date:06/05/01ISR Number: 3733204-1Report Type:Expedited (15-DaCompany Report #B0107381A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Poisoning		Zyban	PS	Glaxo Wellcome		UNKNOWN	
	Balance Disorder		Fluoxetine	C				
	Drug Level Above Therapeutic		Alcohol	C				

	Ecchymosis					
	Excoriation					
	Fall					
	Head Injury					
	Hypoaesthesia					
	Overdose					
	Periorbital Haematoma					
	Subdural Haematoma					

Date:06/05/01ISR Number: 3733213-2Report Type:Expedited (15-DaCompany Report #B0109966A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	3	DAY
	Hyperventilation							

Date:06/05/01ISR Number: 3733214-4Report Type:Expedited (15-DaCompany Report #B0109968A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cough		Zyban	PS	Glaxo Wellcome	ORAL		
	Heart Rate Increased							
	Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/01ISR Number: 3733953-5Report Type:Expedited (15-DaCompany Report #B0109579A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Colitis Ulcerative	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	

Date:06/05/01ISR Number: 3733956-0Report Type:Expedited (15-DaCompany Report #B0108775A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
Hospitalization - Initial or Prolonged	Hallucination		Nifedipine	C				
	Tremor							

Date:06/05/01ISR Number: 3733960-2Report Type:Expedited (15-DaCompany Report #B0109126A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
			Indoramin	C				
			Beclomethasone Dipropion	C				
			Diazepam	C				
			Salbutamol Sulphate	C				

Date:06/05/01ISR Number: 3733964-XReport Type:Expedited (15-DaCompany Report #B0109574A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL 150MG ORAL
	Asthenia		Prempak-C	C		
	Insomnia		Thyroxine Sodium	C		
	Memory Impairment					
	Palpitations					
	Speech Disorder					
	Syncope					
	Thinking Abnormal					
	Tremor					
	Vertigo					
	Visual Disturbance					

Date:06/05/01ISR Number: 3733966-3Report Type:Expedited (15-DaCompany Report #B0109122A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Alanine Aminotransferase Increased	Foreign Health	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG PER DAY ORAL
	Aspartate Aminotransferase Increased	Professional				
	Asthenia					
	Blood Bilirubin Increased					
	Gamma-Glutamyltransferase Increased					
	Malaise					

Date:06/05/01ISR Number: 3733967-5Report Type:Expedited (15-DaCompany Report #B0109588A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
Hospitalization -	Supraventricular	Health					PER DAY ORAL	
Initial or Prolonged	Tachycardia	Professional	Aspirin	C				
Required			Ketoprofen	C				
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:06/05/01ISR Number: 3734139-0Report Type:Expedited (15-DaCompany Report #2012743
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion	Foreign	Dhc Plus	PS	Purdue Frederick			
Initial or Prolonged	Impaired Work Ability	Health			Cp.			
		Professional	Zyban (Bupropion					
		Company	Hydrochloride)	SS		ORAL	150 MG	
		Representative					1-2/DAY PO	
			Co-Amoxiclav (Amoxycillin/Clavula nic Acid	C				
			Salbutamol Sulphate, Budesonide	C				

Date:06/05/01ISR Number: 3734565-XReport Type:Expedited (15-DaCompany Report #A0097619A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking	Foreign	Bupropion					
	Heart Rate Increased	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	
	Malaise	Professional					PER DAY) ORAL	

	Oedema Peripheral	Ibuprofen	C
	Pain In Extremity		
	Serum Sickness		
	Skin Discolouration		

Date:06/05/01ISR Number: 3734567-3Report Type:Expedited (15-DaCompany Report #A0103746A
Age:24 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
	Arthralgia
	Asthma
	Chills
	Dyspepsia
	Erythema
	Face Oedema
	Lymphadenopathy
	Movement Disorder
	Myalgia
	Odynophagia
	Oedema Peripheral
	Periorbital Oedema
	Pruritus
	Pyrexia
	Serum Sickness

	Synovitis Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Literature Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL 16 DAY

Date:06/05/01ISR Number: 3734657-5Report Type:Expedited (15-DaCompany Report #B0109706A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke Status Epilepticus	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG

Date:06/05/01ISR Number: 3734829-XReport Type:Expedited (15-DaCompany Report #10819928
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Hypersensitivity Loss Of Consciousness Petit Mal Epilepsy	Health Professional	Paraplatin	PS	Bristol Myers Squibb Co Pharmaceutical Research Institute		INTRAVENOUS 640 MILLIGRAM, 1/1 CYCLE IV
			Wellbutrin (Bupropion Hcl)	SS			
			Decadron	C			
			Anzemet	C			
			Gemzar	C			

Date:06/05/01ISR Number: 3735064-1Report Type:Expedited (15-DaCompany Report #B0108772A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
			Aspirin	C				
			Atenolol	C				
			Beclomethasone Dipropion.	C				
			Co-Amilofruse	C				
			Isosorbide Mononitrate	C				
			Lactulose	C				
			Lisinopril	C				
			Tramadol Hydrochloride	C				
			Fluoxetine	C				
			Cetirizine Hydrochloride	C				
			Betamethasone Valerate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/01ISR Number: 3735639-XReport Type:Expedited (15-DaCompany Report #2012618
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Atherosclerosis	Health	Oxycontin	PS	Purdue Pharma Lp	ORAL	MG PO
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased	Professional Other	Bupropion	SS			
	Blood Glucose Increased		Carisoprodol	SS			
	Bronchopneumonia		Amitriptyline	SS			
	Cardiomegaly		Benzodiazepine	SS			
	Drug Abuser		Ibuprofen	SS			
	Haemodialysis		Thorazine (Chlorpromazine Hcl)	C			
	Hepatitis C		Plendil	C			
	Hypotension		Risperdal	C			
	Hypothermia						
	Overdose						
	Peritonitis						
	Renal Failure						

Date:06/06/01ISR Number: 3734042-6Report Type:Expedited (15-DaCompany Report #A0149363A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day
	Disturbance In Attention						
	Drug Ineffective		Wellbutrin	SS	Glaxo Wellcome		
	Electroencephalogram		Tylenol	SS			
	Abnormal		Imodium	SS			
	Grand Mal Convulsion		Paxil	C	Glaxo Wellcome	ORAL	10MG Per day
	Hallucination		Tetracycline	C			
	Intentional Misuse		Retin-A	C			TOPICAL
	Irritability						
	Memory Impairment						
	Sedation						
	Tachycardia						

Date:06/06/01ISR Number: 3734045-1Report Type:Expedited (15-DaCompany Report #A0149803A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	7.5G See text	
	Catatonia		Amphetamine	C				
	Convulsion		Cannabis	C				
	Intentional Misuse							
	Sedation							
	Tachycardia							

Date:06/06/01ISR Number: 3734046-3Report Type:Expedited (15-DaCompany Report #A0149863A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dry Mouth		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Dry Throat							
	Emphysema							
	Laryngitis							
	Speech Disorder							

Date:06/06/01ISR Number: 3734050-5Report Type:Expedited (15-DaCompany Report #A0150080A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Decreased Activity		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Feeling Cold							
	Hypoaesthesia							

Date:06/06/01ISR Number: 3734059-1Report Type:Expedited (15-DaCompany Report #B0109581A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxo Wellcome		150MG Twice per day	
	Convulsion							
	Drug Effect Decreased		Lithium Carbonate	C	Glaxo Wellcome		150MG Twice per day	
	Dysgeusia							
	Joint Dislocation		Thyroxine	C	Glaxo Wellcome		50MCG Twice per day	
			Nortriptyline Hydrochloride	C			10MG Twice per day	

Date:06/06/01ISR Number: 3734062-1Report Type:Expedited (15-DaCompany Report #B0110167A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Decreased Activity		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	21 DAY
	Staphylococcal Scalded Skin Syndrome							

	Swelling						

Date:06/06/01ISR Number: 3734063-3Report Type:Expedited (15-DaCompany Report #B0110168A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	

Date:06/06/01ISR Number: 3734064-5Report Type:Expedited (15-DaCompany Report #B0110170A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Retroperitoneal		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Haemorrhage							
per day							48	DAY

Date:06/06/01ISR Number: 3734065-7Report Type:Expedited (15-DaCompany Report #B0110171A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension		Zyban	PS	Glaxo Wellcome	ORAL	8	DAY
	Oedema							

Date:06/06/01ISR Number: 3735445-6Report Type:Expedited (15-DaCompany Report #B0109704A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged	Anaemia Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Blood Creatine Phosphokinase Increased Cerebral Ischaemia Epilepsy Lipase Increased Liver Function Test Abnormal Red Blood Cell Sedimentation Rate Increased Thrombocytopenia White Blood Cell Count Increased	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL

Date:06/06/01ISR Number: 3735446-8Report Type:Expedited (15-DaCompany Report #B0109127A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Pregnancy	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL

Date:06/06/01ISR Number: 3735447-XReport Type:Expedited (15-DaCompany Report #B0103185A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Foreign	Bupropion					
	Chest Pain	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Dry Mouth	Professional	Anti-Inflammatory	C				
	Fatigue	Company						
	Lethargy	Representative						
	Malaise							
	Red Blood Cell Count Decreased							
	Tinnitus							
	White Blood Cell Count Decreased							

Date:06/06/01ISR Number: 3735448-1Report Type:Expedited (15-DaCompany Report #B0108028A
Age:62 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Balance Disorder
	Dizziness
	Headache
	Palpitations

	Tremor						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL
			Monoplus	C			

Date:06/06/01ISR Number: 3735449-3Report Type:Expedited (15-DaCompany Report #B0100818A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Lung Neoplasm Malignant	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL
	Metastasis						
	Nausea						
	Vomiting		Magnesium Trisilicate	C			

Date:06/06/01ISR Number: 3735450-XReport Type:Expedited (15-DaCompany Report #B0109589A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Amnesia	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG/PER DAY
	Clonic Convulsion						
	Convulsion						
	Dizziness		Lorazepam	C			
	Loss Of Consciousness		Irbesartan	C			
	Malaise						
	Tremor						

Date:06/06/01ISR Number: 3735451-1Report Type:Expedited (15-DaCompany Report #B0109585A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc		3.75 G/SINGLE DOSE	
	Convulsion	Literature						
	Hallucinations, Mixed	Health Professional						
	Hyperreflexia							
	Hypertonia							
	Mental Disorder							
	Overdose							
	Tachycardia							

Date:06/06/01ISR Number: 3735452-3Report Type:Expedited (15-DaCompany Report #D0017224A
Age:69 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Movement Disorder	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY / ORAL	
		Health Professional						
			Aspirin	C				
			Glimepiride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/01ISR Number: 3735456-0Report Type:Expedited (15-DaCompany Report #B0103385A
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Foreign	Bupropion					
	Cough	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Dizziness	Professional					TWICE PER DAY	
	Lower Respiratory Tract						/ ORAL	
	Infection		Aspirin	C				
	Nausea		Simvastatin	C				
	Vomiting							

Date:06/07/01ISR Number: 3734968-3Report Type:Expedited (15-DaCompany Report #B0109628A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome	ORAL	1	DAY
	Confusional State							
	Dysarthria							
	Hallucination							
	Overdose							
	Tremor							
	Vomiting							

Date:06/07/01ISR Number: 3735561-9Report Type:Direct Company Report #
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Medication Error		Wellbutrin Sr 100	PS		ORAL	2/2/ORAL	

Date:06/07/01ISR Number: 3735967-8Report Type:Expedited (15-DaCompany Report #2001058760US
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache Pruritus	Health Professional	Solu-Medrol	PS	Pharmacia And Upjohn Co	INTRAVENOUS	125 MG, QID,	
Other	Urticaria					IV		
			Hydroxyzine (Hydroxyzine)	SS		ORAL		
			Prednisone (Prednisone)	SS		ORAL		
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	150 MG, BID,	
			Ortho Tri-Cyclen	C		ORAL		

Date:06/08/01ISR Number: 3735597-8Report Type:Expedited (15-DaCompany Report #A0138183A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	200MG per day	98 DAY
	Convulsion		Prozac	SS		ORAL		
			Klonopin	SS		ORAL		
			Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/01ISR Number: 3735598-XReport Type:Expedited (15-DaCompany Report #A0138183B
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	200MG per day	98 DAY
Congenital Anomaly	Complications Of Maternal		Prozac	SS		ORAL		
	Exposure To Therapeutic Drugs		Klonopin	SS		ORAL		
			Multivitamins	C				
	Convulsion							
	Skull Malformation							

Date:06/08/01ISR Number: 3735602-9Report Type:Expedited (15-DaCompany Report #A0149544A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Brain Damage							
	Concussion							
	Convulsion							
	Fall							
	Head Injury							
	Loss Of Consciousness							
	Spinal Fracture							

Date:06/08/01ISR Number: 3735607-8Report Type:Expedited (15-DaCompany Report #A0150205A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Exposure To Therapeutic Drugs		Ferrous Sulfate	C		ORAL	300MG Per day	
	Intra-Uterine Death		Folic Acid	C		ORAL	500MG Per day	
	Pregnancy							

Date:06/08/01ISR Number: 3735613-3Report Type:Expedited (15-DaCompany Report #B0104336A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome			
			Salbutamol	C	Glaxo Wellcome			

Date:06/08/01ISR Number: 3735618-2Report Type:Expedited (15-DaCompany Report #B0109566A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Vision Blurred							
							per day	29 DAY

Date:06/08/01ISR Number: 3736781-XReport Type:Expedited (15-DaCompany Report #B0107381A
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Death	Ecchymosis
	Excoriation
	Fall
	Head Injury
	Overdose

	Subdural Haematoma						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Zyban	PS	Glaxo Wellcome Inc		
		Health	Fluoxetine	C			
		Professional	Ethanol	C			

Date:06/08/01ISR Number: 3736839-5Report Type:Expedited (15-DaCompany Report #B0109966A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anxiety	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL
	Hyperventilation						

Date:06/08/01ISR Number: 3736904-2Report Type:Expedited (15-DaCompany Report #B0109968A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cough	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL
	Palpitations	Health					
	Paraesthesia	Professional					

Date:06/11/01ISR Number: 3736396-3Report Type:Expedited (15-DaCompany Report #A0150427A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Diabetes Mellitus		Wellbutrin	PS	Glaxo Wellcome	ORAL	1TAB Per day 6 WK
			No Concurrent Medication	C			

Date:06/11/01ISR Number: 3736398-7Report Type:Expedited (15-DaCompany Report #B0098184A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Hyperhidrosis Hypoaesthesia Monoparesis Paraesthesia Skin Discolouration		Zyban	PS	Glaxo Wellcome		150MG As directed	4 DAY

Date:06/11/01ISR Number: 3736404-XReport Type:Expedited (15-DaCompany Report #B0110444A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/01ISR Number: 3736405-1Report Type:Expedited (15-DaCompany Report #B0110446A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Palpitations		Zyban	PS	Glaxo Wellcome	ORAL		

Date:06/11/01ISR Number: 3736406-3Report Type:Expedited (15-DaCompany Report #B0110451A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	29 DAY
	Syncope							
	Ventricular Tachycardia		Omeprazole	C			UNKNOWN	
			Atorvastatin	C			UNKNOWN	1UNIT At night
			Amiodarone	C			UNKNOWN	
			Isosorbide	C			UNKNOWN	

Date:06/11/01ISR Number: 3736407-5Report Type:Expedited (15-DaCompany Report #B0110587A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Photopsia		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG As directed	
	Retinal Detachment							
			Atenolol	C			25MG per day	

Date:06/11/01ISR Number: 3736408-7Report Type:Expedited (15-DaCompany Report #B0110591A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG As directed	10 DAY
			Salmeterol + Fluticasone	SS	Glaxo Wellcome	RESPIRATORY (INHALATION)	2U Twice per day	27 DAY

Date:06/11/01ISR Number: 3736800-0Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Wellbutrin	PS			150 MG, ONCE DAILY	
	Convulsion							
	Diarrhoea		Ambien	C				
	Insomnia							

Date:06/11/01ISR Number: 3737369-7Report Type:Expedited (15-DaCompany Report #B0109628A
Age:38 YR Gender:Male I/FU:I

Outcome	PT
Death	Cardiac Arrest
	Confusional State
	Dysarthria
	Hallucination, Visual
	Overdose
	Tremor

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL

Date:06/11/01ISR Number: 3737802-0Report Type:Expedited (15-DaCompany Report #B0110168A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Psoriasis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL

Date:06/11/01ISR Number: 3737810-XReport Type:Expedited (15-DaCompany Report #A0149803A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	7.5 MG/ SEE TEXT/ ORAL
	Catatonia						
	Convulsion		Amphetamine	C			
	Sedation		Cannabis	C			
	Tachycardia						

Date:06/11/01ISR Number: 3737820-2Report Type:Expedited (15-DaCompany Report #B0109581A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Foreign	Zyban	PS	Glaxo Wellcome Inc	UNKNOWN	150 MG/TWICE PER DAY/
	Dysgeusia	Health					
	Electroencephalogram	Professional					UNKNOWN

Abnormal		Lithium Carbonate	C
Hyperventilation		Thyroxine Sodium	C
Joint Dislocation		Notriptyline Hcl	C
Salivary Hypersecretion			

Date:06/11/01ISR Number: 3737821-4Report Type:Expedited (15-DaCompany Report #A0150080A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Cold	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Hypoaesthesia	Consumer					DAY/ ORAL	

Date:06/11/01ISR Number: 3737823-8Report Type:Expedited (15-DaCompany Report #A0149863A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dry Mouth	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
	Dry Throat	Health					PER DAY/ORAL	
	Emphysema	Professional						
	Laryngitis							
	Speech Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/01ISR Number: 3737824-XReport Type:Expedited (15-DaCompany Report #B0110170A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Retroperitoneal Haemorrhage	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ORAL

Date:06/11/01ISR Number: 3737826-3Report Type:Expedited (15-DaCompany Report #B0110171A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Abdominal Distension Oedema Peripheral	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/UNK/ORAL

Date:06/11/01ISR Number: 3737827-5Report Type:Expedited (15-DaCompany Report #B0110167A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Staphylococcal Scalded Skin Syndrome	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL

Date:06/11/01ISR Number: 3737869-XReport Type:Expedited (15-DaCompany Report #A0149363A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Disturbance In Attention Drug Ineffective	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE PER DAY / ORAL

	Grand Mal Convulsion		Wellbutrin Tablet (Bupropion Hydrochloride)	SS		
	Hallucination, Visual		Paracetamol (Formulation Unknown) (Acetaminophen)	SS		
	Intentional Misuse		Loperamide Hydrochloride Tablet (Loperamide Hydrochloride)	SS		
	Irritability		Paroxetine Hydrochloride	C		
	Memory Impairment		Tetracycline	C		
	Sedation		Tretinoin	C		
	Tachycardia					

Date:06/11/01ISR Number: 3738380-2Report Type:Periodic Company Report #252815
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Induced	Consumer	Accutane	PS	Hlr Technology	ORAL	40 MG DAILY	
			Wellbutrin	SS		ORAL		
			Effexor	C				
			Spermacide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/01ISR Number: 3737249-7Report Type:Expedited (15-DaCompany Report #B0100125A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Ecchymosis Headache		Zyban Inhalers	PS C	Glaxo Wellcome		150MG Twice per day	8 DAY

Date:06/12/01ISR Number: 3737253-9Report Type:Expedited (15-DaCompany Report #B0108029A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Flutter Cardiac Failure Dyspnoea		Zyban Metoprolol Tartrate Diltiazem Hydrochloride	PS C C	Glaxo Wellcome	 ORAL ORAL	50MG Twice per day	

Date:06/12/01ISR Number: 3737263-1Report Type:Expedited (15-DaCompany Report #B0109965A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Formication Headache Nausea Pruritus Sleep Disorder		Zyban	PS	Glaxo Wellcome	ORAL	15 DAY	

Date:06/12/01ISR Number: 3737265-5Report Type:Expedited (15-DaCompany Report #B0110766A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Chest Discomfort		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 4 DAY						
	Chest Pain		Enalapril	C		ORAL
20MG Per day						
			Beclomethasone	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION) 50MCG Twice						
per day						
			Nifedipine	C		ORAL
60MG Per day						
			Bendrofluazide	C	Glaxo Wellcome	ORAL
2.5MG Per day						
			Salbutamol	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION) 100MCG Twice						
per day						
			Insulin Lispro	C		
SUBCUTANEOUS						
			Aspirin	C		ORAL
75MG Per day						

Date:06/12/01ISR Number: 3737266-7Report Type:Expedited (15-DaCompany Report #B0110768A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	International Normalised		Zyban	PS	Glaxo Wellcome	ORAL
	Ratio Increased		Warfarin	C	Glaxo Wellcome	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/01ISR Number: 3737267-9Report Type:Expedited (15-DaCompany Report #B0110774A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Confusional State							
per day							17	DAY
Initial or Prolonged	Depression		Captopril	C	Glaxo Wellcome	ORAL	100MG per day	
	Disturbance In Attention		Zafirlukast	C		ORAL	20MG Twice	
	Haemophilus Infection							
per day								
	Hypercapnia		Theophylline	C		ORAL	600MG per day	
	Lung Disorder		Salmeterol	C	Glaxo Wellcome			
RESPIRATORY								
	Respiratory Distress							
(INHALATION)							50UG Twice	
	Thinking Abnormal							
per day								
			Fluticasone	C	Glaxo Wellcome			
RESPIRATORY								
(INHALATION)							500UG Twice	
per day								
			Duovent	C				

Date:06/12/01ISR Number: 3738140-2Report Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pancytopenia		Wellbutrin / 150mg /					
Required			Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	150 MG TID	
Intervention to								
ORAL								
Prevent Permanent			Celexa	SS	Forest	ORAL	20 MG QD ORAL	
Impairment/Damage			Lithium	C				

Date:06/12/01ISR Number: 3738768-XReport Type:Expedited (15-DaCompany Report #B0091930A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose	Foreign Literature Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:06/12/01ISR Number: 3738770-8Report Type:Expedited (15-DaCompany Report #B0088230A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Foreign Literature Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	50 TABLET/SINGLE	
Hospitalization - Initial or Prolonged	Agitation						DOSE/ORAL	
	Coma							
	Grand Mal Convulsion							
	Hypotension		Anadin Extra Tablet (Anadin Extra)	SS			24 TABLET/SINGLE	
	Intentional Misuse							
	Pyrexia							
	Sinus Tachycardia						DOSE/24	
	Suicide Attempt		Ethanol (Formulation Unknown) (Alcohol)	SS				
	Vomiting							

Date:06/12/01ISR Number: 3738773-3Report Type:Expedited (15-DaCompany Report #B0104336A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source
Death	Completed Suicide	Foreign Health

Professional

			Product	Role	Manufacturer	Route
Dose	Duration					
			Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	
150 MG						
			Salbutarol Sulphate	C		

Date:06/12/01ISR Number: 3738782-4Report Type:Expedited (15-DaCompany Report #A0150205A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Complications Of Maternal	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG /						
	Exposure To Therapeutic	Study				
TWICE PER DAY						
	Drugs	Health				
/ ORAL						
	Intra-Uterine Death	Professional	Ferrous Sulfate	C		
	Pregnancy		Folic Acid	C		
	Uterine Dilation And Curettage					

Date:06/12/01ISR Number: 3738919-7Report Type:Expedited (15-DaCompany Report #MPI-2001-05634(0)
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign	Semprex-D	PS	Celltech Pharmaceuticals Inc	ORAL
9 TABLETS,	Chest Pain	Literature				
Required	Myocardial Infarction	Health				
TAKEN OVER 72						
Intervention to		Professional				
HOURS, PO						
Prevent Permanent			Bupropion	SS		
TAKEN OVER 72						
Impairment/Damage						
HOURS						
			Erythromycin (Erythromycin)	C		

Date:06/12/01ISR Number: 3738946-XReport Type:Expedited (15-DaCompany Report #B0109566A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL
	Vision Blurred							

Date:06/12/01ISR Number: 3738981-1Report Type:Expedited (15-DaCompany Report #A0138183B
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	TRANSPLACENTAL	SEE TEXT/	
Congenital Anomaly	Complications Of Maternal	Health				ORAL		
	Exposure To Therapeutic Drugs	Professional	Fluoxetine Hydrochloride					
	Convulsion		Capsule (Fluoxetine					
	Skull Malformation		Hydrochloride)	SS		TRANSPLACENTAL	ORAL	
			Clonazepam Tablet (Clonazepam)	SS		TRANSPLACENTAL	ORAL	
			Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/01ISR Number: 3738982-3Report Type:Expedited (15-DaCompany Report #A0138183A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT/ORAL	
	Complications Of Maternal Exposure To Therapeutic Drugs	Health Professional	Fluoxetine Hydrochloride Capsule (Fluoxetine Hydrochloride)	SS		ORAL	ORAL	
	Convulsion		Clonazepam Tablet (Clonazepam)	SS		ORAL	ORAL	
			Multivitamin	C				

Date:06/13/01ISR Number: 3738076-7Report Type:Expedited (15-DaCompany Report #A0107343A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	100MG Twice per day	
	Drug Interaction							
	Hypertension		Paxil	SS	Glaxo Wellcome	ORAL		
	Insomnia							
	Sinus Tachycardia							

Date:06/13/01ISR Number: 3738077-9Report Type:Expedited (15-DaCompany Report #A0108484A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression		Zyban	PS	Glaxo Wellcome	ORAL		
	Anxiety							
	Dysgeusia							
	Dysphagia							
	Erythema							
	Face Oedema							
	Fatigue							
	Halitosis							

Insomnia
Nail Disorder
Oedema Peripheral
Oral Pain
Oral Soft Tissue Disorder
Pain In Extremity
Pruritus
Salivary Hypersecretion
Stomatitis

Date:06/13/01ISR Number: 3738078-0Report Type:Expedited (15-DaCompany Report #A0120078A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar I Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	1 MON
	Condition Aggravated							
	Convulsion		Clonazepam	C		ORAL	.5MG Twice per day	
	Mood Swings							
	Psychotic Disorder		Paxil	C	Glaxo Wellcome	ORAL	20MG Per day	
	Visual Disturbance		Perphenazine	C	Glaxo Wellcome	ORAL	2MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/01ISR Number: 3738079-2Report Type:Expedited (15-DaCompany Report #A0124641A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dehydration		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Heat Stroke						per day	6 MON
	Sudden Death		Alcohol	SS				

Date:06/13/01ISR Number: 3738080-9Report Type:Expedited (15-DaCompany Report #A0130642A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Thyroid Stimulating		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Hormone Increased						per day	15 DAY
	Dermatitis							
	Malaise							
	Pyrexia							
	Red Blood Cell Sedimentation Rate Increased							

Date:06/13/01ISR Number: 3738084-6Report Type:Expedited (15-DaCompany Report #A0147746A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL	75MG Per day	1 WK
	Crying		Klonopin	C				
	Feeling Abnormal							
	Nervousness							
	Petit Mal Epilepsy							

Date:06/13/01ISR Number: 3738087-1Report Type:Expedited (15-DaCompany Report #A0150616A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	19 DAY
			Ginseng	C				
			Vitamins	C		ORAL		

Date:06/13/01ISR Number: 3738089-5Report Type:Expedited (15-DaCompany Report #A0150720A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Pancreatitis							
			Aspirin	C		ORAL	325MG Per day	
			Colace	C			100MG Twice per day	
			Habitrol	C			14MG Per day	
			Oxazepam	C			15MG Per day	
			Parafon Forte	C				
			Zocor	C			10MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/01ISR Number: 3738090-1Report Type:Expedited (15-DaCompany Report #A0150723A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Petechiae		Zyban	PS	Glaxo Wellcome	ORAL	150TAB Twice	
	Rash Pruritic						per day	

Date:06/13/01ISR Number: 3738091-3Report Type:Expedited (15-DaCompany Report #A0150739A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Physical Assault		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:06/13/01ISR Number: 3738092-5Report Type:Expedited (15-DaCompany Report #A0150823A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Increased						per day	17 DAY
	Angioneurotic Oedema							
	Arthralgia							
	Aspartate							
	Aminotransferase							
	Increased							
	Asthenia							
	Dizziness							
	Dysphagia							
	Dyspnoea							
	Hypoaesthesia							
	Osteoarthritis							
	Paraesthesia							
	Pruritus							
	Urticaria							

Date:06/13/01ISR Number: 3738093-7Report Type:Expedited (15-DaCompany Report #A0150828A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Airomir	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		

Date:06/13/01ISR Number: 3738094-9Report Type:Expedited (15-DaCompany Report #A0150884A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retroperitoneal Fibrosis		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Twice per day	3 MON

Date:06/13/01ISR Number: 3738095-0Report Type:Expedited (15-DaCompany Report #A0150891A
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Other	Agitation
	Confusional State
	Epileptic Aura

		Flushing					
		Paraesthesia					
		Psychotic Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Bupropion	PS	Glaxo Wellcome	ORAL
150MG Twice							
per day							

Date:06/13/01ISR Number: 3738096-2Report Type:Expedited (15-DaCompany Report #A0150908A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety		Bupropion	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Crying					
per day 5 DAY						
	Dizziness		Triphasil	C		
	Fear					
	Feeling Jittery					
	Hyperventilation					
	Panic Reaction					

Date:06/13/01ISR Number: 3738098-6Report Type:Expedited (15-DaCompany Report #A0150917A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety		Bupropion	PS	Glaxo Wellcome	ORAL
75MG Twice						
	Hallucination, Auditory					
per day						
	Panic Reaction		Clonazepam	C		ORAL
.5MG Twice						
per day						
			Epival	C		ORAL
500MG Twice						
per day						

Date:06/13/01ISR Number: 3738101-3Report Type:Expedited (15-DaCompany Report #B0098815A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY
	Arrhythmia		Bisoprolol	C			5MG Per day	
	Chest Discomfort		Aspirin	C		ORAL	75MG Per day	
	Decreased Appetite		Metformin	C		ORAL	1G Twice per day	
	Dehydration							
	Dry Skin		Gliclazide	C		ORAL	160MG Per day	
	Feeling Abnormal							
	Insomnia							
	Lethargy							
	Malaise							
	Myocardial Infarction							
	Oedema							
	Pain							

Date:06/13/01ISR Number: 3738110-4Report Type:Expedited (15-DaCompany Report #B0110962A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Small Cell Lung Cancer		Zyban	PS	Glaxo Wellcome	ORAL		
	Stage Unspecified		Orciprenaline	C		ORAL	10ML Three times per day	
	Tonsillitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/01ISR Number: 3738111-6Report Type:Expedited (15-DaCompany Report #B0110963A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Depression						per day	32 DAY
	Insomnia		Alcohol	C				
	Self Mutilation							

Date:06/13/01ISR Number: 3739226-9Report Type:Expedited (15-DaCompany Report #HQ5327428DEC2000
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Craniopharyngioma	Health	Effexor Xr	PS	Wyeth Ayerst			
	Diverticulum Oesophageal	Professional			Laboratories	ORAL	112.5 MG	
Other	Gastric Polyps						DAILY, ORAL	
	Hypokalaemia		Nicotine (Nicotine)	SS				
	Hyponatraemia		Wellbutrin					
	Pituitary Tumour Benign		(Amfebutamone					
	Salivary Hypersecretion		Hydrochloride)	SS		ORAL	150 MG 2X PER	
	Speech Disorder						1 DAY, ORAL	
	Tardive Dyskinesia		Trazodone					
	Visual Field Defect		(Trazodone)	C				
			Clonazepam(Clonazepa					
			m0	C				
			Dexamfetamine					
			(Dexamfetamine)	C				
			Thyroxine Sodium					
			(Levothyroxine					
			Sodium)	C				

Date:06/13/01ISR Number: 3739464-5Report Type:Expedited (15-DaCompany Report #B0110587A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Retinal Detachment	Foreign Consumer	Zyban Atenolol	PS C	Glaxo Wellcome Inc	ORAL	150 MG / AS DIRECTED / ORAL	

Date:06/13/01ISR Number: 3739468-2Report Type:Expedited (15-DaCompany Report #B0110444A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Arrhythmia Syncope	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

Date:06/13/01ISR Number: 3739469-4Report Type:Expedited (15-DaCompany Report #B0110446A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Irregular	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/01ISR Number: 3739470-0Report Type:Expedited (15-DaCompany Report #B0110591A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (AS DIRECTED) ORAL	
			Salmeterol + Fluticasone (Salmeterol + Fluticasone)	SS			RESPIRATORY (INHALATION)	2 UNKNOWN (TWICE PER DAY) INHALED

Date:06/13/01ISR Number: 3739473-6Report Type:Expedited (15-DaCompany Report #B0110451A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Syncope Ventricular Tachycardia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
			Omeprazole	C				
			Atorvastatin Calcium	C				
			Amiodarone	C				
			Isosorbide	C				

Date:06/13/01ISR Number: 3739499-2Report Type:Expedited (15-DaCompany Report #B0098184A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Hyperhidrosis Hypoaesthesia Monoparesis Paraesthesia Skin Discolouration	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG (AS DIRECTED)	

Date:06/13/01ISR Number: 3739625-5Report Type:Expedited (15-DaCompany Report #A0150427A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Chloride Decreased Blood Sodium Decreased Blood Urea Increased Diabetes Mellitus	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	1 TABLET / PER DAY / ORAL	

Date:06/15/01ISR Number: 3740147-6Report Type:Expedited (15-DaCompany Report #A0106360A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy Hypoaesthesia Urticaria		Zyban Premarin	PS C	Glaxo Wellcome	ORAL	150MG Twice per day .625MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/01ISR Number: 3740148-8Report Type:Expedited (15-DaCompany Report #A0128949A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	1 WK
	Complications Of Maternal							
	Exposure To Therapeutic Drugs							

Date:06/15/01ISR Number: 3740149-XReport Type:Expedited (15-DaCompany Report #A0141486A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL		
	Atrial Flutter							
	Cardiac Failure Congestive							

Date:06/15/01ISR Number: 3740150-6Report Type:Expedited (15-DaCompany Report #A0144603A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Bronchospasm							
	Burning Sensation							
	Chest Pain							
	Dermatitis							
	Dyspnoea							
	Face Oedema							
	Insomnia							
	Joint Stiffness							
	Myocardial Infarction							
	Oedema Peripheral							
	Pruritus							
	Urticaria							

Date:06/15/01ISR Number: 3740153-1Report Type:Expedited (15-DaCompany Report #A0149803A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	7.5G	See text
	Catatonia		Amphetamine	C				
	Convulsion		Cannabis	C				
	Intentional Misuse							
	Sedation							
	Tachycardia							

Date:06/15/01ISR Number: 3740156-7Report Type:Expedited (15-DaCompany Report #A0150913A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Zyban	PS	Glaxo Wellcome	ORAL	1	WK
	Asthenia		Alprazolam	C			.5MG	As required
	Chest Discomfort							
	Dyspnoea		Aspirin	C		ORAL	80MG	Per day
	Heart Rate Increased		Atenolol	C		ORAL	50MG	Per day
	Hypertension		Baycol	C		ORAL	.2MG	Per day
	Hypoaesthesia		Dalteparin	C		SUBCUTANEOUS	10000IU	Twice

per day	4 DAY			Prinzide	C		ORAL

Date:06/15/01ISR Number: 3740157-9Report Type:Expedited (15-DaCompany Report #A0150949A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Arthralgia						per day	
	Chest Pain		Nefazodone	SS				
	Diarrhoea		Aspirin	C				
	Drug Interaction		Atenolol	C				
	Intestinal Obstruction		Lipitor	C		ORAL		
	Malaise							
	Neck Pain							

Date:06/15/01ISR Number: 3740158-0Report Type:Expedited (15-DaCompany Report #B0104342A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Circulatory Collapse		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Convulsion						per day	13 DAY
			Alcohol	SS				
			Triazolam	SS			.25MG Per day	
			Mercilon	SS		ORAL		

Date:06/15/01ISR Number: 3740159-2Report Type:Expedited (15-DaCompany Report #B0109704A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bone Marrow Depression		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	36 DAY
Hospitalization -	Cerebral Ischaemia		Sulpiride	C				

Initial or Prolonged	Coma	Migril	C	Glaxo Wellcome
	Convulsion			
	Haemolytic Anaemia			
	Hepatitis			
	Hypertonia			
	Lipase Increased			
	Metabolic Acidosis			
	Pancytopenia			
	Paralysis Flaccid			
	Peripheral Ischaemia			
	Petechiae			
	Respiratory Failure			
	Shock			
	Tachycardia			
	Thrombotic			
	Thrombocytopenic Purpura			
	Trismus			
	Urinary Incontinence			

Date:06/15/01ISR Number: 3740163-4Report Type:Expedited (15-DaCompany Report #B0110588A
Age:42 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Convulsion
	Fall
	Headache

	Insomnia						
	Muscle Spasms						
	Salivary Hypersecretion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sensation Of Pressure		Zyban	PS	Glaxo Wellcome		13 DAY

Date:06/15/01ISR Number: 3740198-1Report Type:Expedited (15-DaCompany Report #A0075655A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
Initial or Prolonged	Dyspnoea						per day 5 DAY
	Emotional Disorder		Calcium	C			500MG Per day
	Grand Mal Convulsion		Ces	C		ORAL	1.25MG Per
	Status Epilepticus						day
	Suicidal Ideation		St. Johns Wort	C			
			Vitamin C	C			

Date:06/15/01ISR Number: 3740199-3Report Type:Expedited (15-DaCompany Report #A0082610A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaphylactoid Reaction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 6 DAY
Initial or Prolonged	Angioneurotic Oedema		Synthroid	C	Glaxo Wellcome		4 YR
			Hormone Replacement Therapy	C			

Date:06/15/01ISR Number: 3740200-7Report Type:Expedited (15-DaCompany Report #A0086553A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Other	Myocardial Infarction						per day	11 DAY
			Glucophage	C				
			Premarin	C				
			Lipitor	C				
			Diabeta	C				

Date:06/15/01ISR Number: 3740201-9Report Type:Expedited (15-DaCompany Report #A0090004A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome	ORAL	150MG Single	
	Chest Discomfort						dose	1 DAY
	Dyspnoea		Ativan	C		ORAL	.5MG Twice	
	Pulmonary Embolism						per day	
			Ceftin	C	Glaxo Wellcome	ORAL	500MG Twice	
							per day	
			Combivent	C			RESPIRATORY	
							(INHALATION)	2UNIT Twice
							per day	
			Pulmicort	C			RESPIRATORY	
							(INHALATION)	.5MG Four
							times per day	
			Tetracycline	C		ORAL	250MG Four	
							times per day	
			Uniphyl	C		ORAL	400MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/01ISR Number: 3740202-0Report Type:Expedited (15-DaCompany Report #A0090299A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	100MG Per day	7 DAY
	Chest Pain							
	Pericarditis							
	Vomiting							

Date:06/15/01ISR Number: 3740203-2Report Type:Expedited (15-DaCompany Report #A0096983A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG per day	33 DAY
Initial or Prolonged	Generalised		Ibuprofen	C			600MG per day	
Other	Non-Convulsive Epilepsy		Epival	C		ORAL	1000MG per	
	Headache						day	

Date:06/15/01ISR Number: 3740204-4Report Type:Expedited (15-DaCompany Report #A0104189A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	MON
	Arthralgia		Triphasil	C		ORAL		
	Back Pain							
	Chest Pain							
	Dyspepsia							
	Eye Irritation							
	Hypersensitivity							
	Urticaria							

Date:06/15/01ISR Number: 3740205-6Report Type:Expedited (15-DaCompany Report #A0105423A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Multiple Sclerosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	9 DAY
Disability			No Concurrent Medications	C				

Date:06/15/01ISR Number: 3740206-8Report Type:Expedited (15-DaCompany Report #A0105871A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation		Wellbutrin	PS	Glaxo Wellcome			
	Overdose		Nortriptyline	SS				
			Cocaine	SS				

Date:06/15/01ISR Number: 3740207-XReport Type:Expedited (15-DaCompany Report #A0105877A
Age:26 YR Gender:Female I/FU:F

Outcome	PT
Other	Confusional State
	Cyanosis
	Dyspnoea
	Eye Rolling
	Movement Disorder

Sedation

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Imitrex	C	Glaxo Wellcome		100MG As required	
	Propanolol	C			40MG Twice per day	
	Salbutamol	C	Glaxo Wellcome		2U Twice per day	
	Triquilar	C			21 DAY	

Date:06/15/01ISR Number: 3740208-1Report Type:Expedited (15-DaCompany Report #A0106433A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	20 DAY
	Dyspepsia							
	Ecchymosis		Penicillin	SS	Glaxo Wellcome		600MG Twice per day	11 DAY
	Face Oedema							
	Fatigue							
	Lip Dry							
	Myalgia							
	Pruritus							
	Throat Tightness							
	Urticaria							

Date:06/15/01ISR Number: 3740209-3Report Type:Expedited (15-DaCompany Report #A0129592A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	20 DAY
	Dyspnoea		No Concurrent Medications	C				
	Erythema Multiforme							
	Face Oedema							
	Leukocytoclastic Vasculitis							
	Serum Sickness							

Date:06/15/01ISR Number: 3740214-7Report Type:Expedited (15-DaCompany Report #A0150827A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block Left		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Per day	
	Chest Pain		Vioxx	C			25MG Per day	
	Dizziness		Thiamine	C			100MG Per day	
	Headache		Ritalin Sr	C		ORAL	20MG Per day	
	Hypertension		Effexor Xr	C		ORAL	150MG Per day	
	Vomiting		Conjugated Estrogens	C			.625MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/01ISR Number: 3740215-9Report Type:Expedited (15-DaCompany Report #A0150905A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Anxiety						per day	19 DAY
	Coordination Abnormal							
	Depression							
	Dizziness							
	Fatigue							
	Headache							
	Intentional Self-Injury							
	Lethargy							
	Panic Disorder							
	Paranoia							
	Phobia							

Date:06/15/01ISR Number: 3740217-2Report Type:Expedited (15-DaCompany Report #A0151169A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Hypoaesthesia						per day	8 DAY
	Sensory Disturbance		Estraderm	C			TRANSDERMAL	50MCG Two times per week
			Calcium + Vitamin D	C		ORAL		
			Avalide	C		ORAL		

Date:06/15/01ISR Number: 3740218-4Report Type:Expedited (15-DaCompany Report #A0151174A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Anaemia		Wellbutrin	PS	Glaxo Wellcome	ORAL
250MG Per day						
	Bronchiolitis		Anafranil	SS		
125MG Per day YR						
	Cough		Lithium	C		
1050MG Per						
	Drug Interaction					
day						
	Hyperhidrosis		Rivotril	C		
.25MG Per day						
	Hypoxia					
	Pyrexia					

Date:06/15/01ISR Number: 3740224-XReport Type:Expedited (15-DaCompany Report #B0110444A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL
7 DAY						
Hospitalization -	Coma		Fluticasone	C	Glaxo Wellcome	
RESPIRATORY						
Initial or Prolonged	Malaise					
(INHALATION)						
	Nausea		Salmeterol	C	Glaxo Wellcome	
RESPIRATORY						
	Pulmonary Embolism					
(INHALATION)						
	Syncope					

Date:06/15/01ISR Number: 3740225-1Report Type:Expedited (15-DaCompany Report #B0110521A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome	
3 DAY						
Initial or Prolonged	Suicide Attempt		Clonazepam	C		

			Sodium Valproate	C			
			Anxiolytic	C			

Date:06/15/01ISR Number: 3740226-3Report Type:Expedited (15-DaCompany Report #B0110727A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Myocardial Infarction							

Date:06/15/01ISR Number: 3740227-5Report Type:Expedited (15-DaCompany Report #B0110883A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomyopathy		Zyban	PS	Glaxo Wellcome	ORAL	10	DAY
	Left Ventricular Failure		Amitriptyline	C		ORAL	50MG Unknown	
	Pulmonary Oedema		Nitrazepam	C		ORAL	5MG Unknown	
	Sudden Death		Loperamide	C		ORAL	2MG Unknown	
			Co-Codamol	C		ORAL		

Date:06/15/01ISR Number: 3740229-9Report Type:Expedited (15-DaCompany Report #B0111230A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	31 DAY
Other	Hepatic Steatosis							
	Hepatomegaly							

Date:06/15/01ISR Number: 3740230-5Report Type:Expedited (15-DaCompany Report #D0016065A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Formication		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Gastrointestinal Disorder						per day	10 DAY
	Headache							
	Paraesthesia							
	Sensation Of Pressure							

Date:06/15/01ISR Number: 3740751-5Report Type:Expedited (15-DaCompany Report #B0108029A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
	Atrial Flutter	Health						
	Cardiac Failure	Professional	Metoprolol Tartrate	C				
			Diltiazem Hydrochloride	C				

Date:06/15/01ISR Number: 3741098-3Report Type:Expedited (15-DaCompany Report #B0110774A
Age:67 YR Gender:Male I/FU:I

Outcome	PT
Death	Asthenia
Hospitalization - Initial or Prolonged	Confusional State
	Depression

	Disturbance In Attention Haemophilus Infection Hypercapnia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Lung Disorder Respiratory Distress	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
			Captopril	C			
			Zafirlukast	C			
			Theophylline	C			
			Salmeterol Xinafoate	C			
			Fluticasone Propionate	C			
			Duovent	C			

Date:06/15/01ISR Number: 3741110-1Report Type:Expedited (15-DaCompany Report #B0110768A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	International Normalised Ratio Increased	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL
			Warfarin Sodium	C			

Date:06/15/01ISR Number: 3741111-3Report Type:Expedited (15-DaCompany Report #B0110766A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angina Pectoris Chest Discomfort Chest Pain	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL
			Enalapril	C			
			Beclomethasone Dipropion.	C			

Nifedipine	C
Bendrofluazide	C
Salbutamol Sulphate	C
Insulin Lispro	C
Aspirin	C

Date:06/15/01ISR Number: 3741112-5Report Type:Expedited (15-DaCompany Report #B0109965A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Formication Headache Nausea Pruritus Sleep Disorder	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

Date:06/15/01ISR Number: 3741113-7Report Type:Expedited (15-DaCompany Report #B0100125A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Ecchymosis Headache	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG / TWICE PER DAY	

/

			Inhaler	C		

Date:06/18/01ISR Number: 3740564-4Report Type:Expedited (15-DaCompany Report #A0075616A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Hypertensive Crisis						per day	5 DAY
			Ramipril	C		ORAL	2.5MG Per day	
			Lorazepam	C		ORAL	1MG As	
							required	

Date:06/18/01ISR Number: 3740566-8Report Type:Expedited (15-DaCompany Report #A0083661A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Hypoglycaemia						per day	16 DAY
	Medication Error		Humulin R	SS				
			Humulin N	C				
			Alcohol	C				

Date:06/18/01ISR Number: 3740567-XReport Type:Expedited (15-DaCompany Report #A0087951A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Decreased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Convulsion						per day	

			Humalog	C		ORAL
			Humulin N	C		
			Regular Insulin	C		

Date:06/18/01ISR Number: 3740568-1Report Type:Expedited (15-DaCompany Report #A0090158A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukopenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Neutropenia						per day	13 DAY
			Acetaminophen	C				
			Chlorpheniramine	C				
			Cytosar	C				
			Etoposide	C				
						INTRAVENOUS	240MG Per day	5 DAY
			Idarubicin	C				
			Novantrone	C				
							24MG Per day	5 DAY
			Salbutamol	C	Glaxo Wellcome			
						RESPIRATORY		
						(INHALATION)		

Date:06/18/01ISR Number: 3740569-3Report Type:Expedited (15-DaCompany Report #A0090923A
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Alcohol Withdrawal
Hospitalization - Initial or Prolonged	Syndrome
	Aspartate Aminotransferase Increased

		Blood Alkaline Phosphatase Increased					
		Coma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Convulsion		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice per day	20 DAY	Gamma-Glutamyltransferase Increased		Ethanol	SS		
		Hypoxia					
		Pneumonia Aspiration					

Date:06/18/01ISR Number: 3740570-XReport Type:Expedited (15-DaCompany Report #A0103160A
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Lung Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Twice per day	10 DAY	Pneumonia					
				Adalat	C		
				Unspecified Medications	C		

Date:06/18/01ISR Number: 3740571-1Report Type:Expedited (15-DaCompany Report #A0103586A
Age:34 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged	300MG Per day 24 DAY	Coma		Wellbutrin	PS	Glaxo Wellcome	ORAL
		Confusional State					
		Grand Mal Convulsion					
		Sedation					

Date:06/18/01ISR Number: 3740572-3Report Type:Expedited (15-DaCompany Report #A0104181A
Age:29 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Other	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Tendon Disorder					
per day 16 DAY						
	Urticaria		Ortho 1/35	C		

Date:06/18/01ISR Number: 3740573-5Report Type:Expedited (15-DaCompany Report #A0105879A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthritis		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Diarrhoea					
per day 15 DAY						
	Dizziness					
	Erythema Multiforme					
	Leukocytosis					
	Serum Sickness					
	Tachycardia					
	Tongue Disorder					

Date:06/18/01ISR Number: 3740574-7Report Type:Expedited (15-DaCompany Report #A0106203A
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Other	Abdominal Pain
	Proctitis
	Rectal Haemorrhage

	Rectal Tenesmus Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	100MG Per day 1 MON
			Betnesol	C	Glaxo Wellcome	RECTAL	
			Desyrel	C		ORAL	250MG Per day
			Imuran	C	Glaxo Wellcome	ORAL	100MG Per day
			Voltaren Sr	C		ORAL	75MG As required

Date:06/18/01ISR Number: 3740575-9Report Type:Expedited (15-DaCompany Report #A0106475A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthropathy Crepitations Oedema Urticaria		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day 17 DAY

Date:06/18/01ISR Number: 3740576-0Report Type:Expedited (15-DaCompany Report #A0137061A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion Suicide Attempt		Wellbutrin	PS	Glaxo Wellcome	ORAL	4500MG per day
			Celexa	SS		ORAL	400MG per day

Date:06/18/01ISR Number: 3740578-4Report Type:Expedited (15-DaCompany Report #A0143251A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	60 DAY
	Fall							
	Loss Of Consciousness		Naproxen	C			500MG Twice per day	
	Malaise							
			Losec	C			20MG Per day	
			Aspirin	C			300MG Per day	
			Norvasc	C			5MG Per day	
			Trazodone	C			50MG At night	
			Provera	C			10MG Every two weeks	
			Lectopam	C			3MG Three times per day	
			Zoloft	C			200MG Per day	
			Fiorinal	C				
			Percocet	C				

Date:06/18/01ISR Number: 3740582-6Report Type:Expedited (15-DaCompany Report #A0150726A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Coma		Cardizem Cd	SS		ORAL		
	Oliguria		Clonazepam	SS		ORAL		
	Suicide Attempt		Demerol	SS		ORAL		
			Desipramine	SS		ORAL		
			Loxapine	SS		ORAL		

			Ms Contin	SS	Glaxo Wellcome	ORAL
			Trazodone	SS		ORAL
			Zopiclone	SS		ORAL

Date:06/18/01ISR Number: 3740584-XReport Type:Expedited (15-DaCompany Report #A0150947A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Body Temperature		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Increased						per day	18 DAY
	Chest Pain		Lipitor	C		ORAL	40MG Per day	
	Face Oedema							
	Periorbital Oedema							
	Pharyngolaryngeal Pain							
	Pruritus							
	Urticaria							

Date:06/18/01ISR Number: 3740587-5Report Type:Expedited (15-DaCompany Report #A0151323A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL		
	Angina Pectoris		Lipidil Micro	SS		ORAL		
	Drug Interaction							

Date:06/18/01ISR Number: 3740588-7Report Type:Expedited (15-DaCompany Report #A0151352A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electrocardiogram Qrs		Zyban	PS	Glaxo Wellcome	ORAL	15G Single	
	Complex Prolonged						dose	
			Ativan	C				

Date:06/18/01ISR Number: 3740589-9Report Type:Expedited (15-DaCompany Report #A0151353A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agranulocytosis		Bupropion	PS	Glaxo Wellcome	ORAL		
	Infection		Rivotril	SS		ORAL		

Date:06/18/01ISR Number: 3740592-9Report Type:Expedited (15-DaCompany Report #B0099946A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conductive Deafness		Bupropion					
	Influenza Like Illness		Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Middle Ear Disorder		Paracetamol	C		ORAL	500MG As required	

Date:06/18/01ISR Number: 3740597-8Report Type:Expedited (15-DaCompany Report #B0110591A
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyntabac	PS	Glaxo Wellcome	ORAL	300MG Per day	10 DAY
			Salmeterol +					

			Fluticasone	SS	Glaxo Wellcome		

RESPIRATORY

(INHALATION) 2U Twice per

day

Date:06/18/01ISR Number: 3740601-7Report Type:Expedited (15-DaCompany Report #B0111327A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomyopathy		Zyban	PS	Glaxo Wellcome	ORAL		

Date:06/18/01ISR Number: 3740603-0Report Type:Expedited (15-DaCompany Report #B0111329A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyntabac	PS	Glaxo Wellcome	ORAL		

Date:06/18/01ISR Number: 3741394-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Luvox	PS				
	Anger		Effexor	SS				
	Muscle Spasms		Trazodone	SS				
			Wellbutrin	SS				
			Tegretol	SS				
			Paxil	SS				

Date:06/18/01ISR Number: 3741492-0Report Type:Expedited (15-DaCompany Report #A0150917A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required	Anxiety	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
75 MG TWICE						
Intervention to	Hallucination, Auditory					
PER DAY ORAL						
Prevent Permanent	Panic Reaction		Clonazepam	C		
Impairment/Damage			Semisodium Valproate	C		

Date:06/18/01ISR Number: 3741493-2Report Type:Expedited (15-DaCompany Report #B0110962A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Small Cell Lung Cancer	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG ORAL						
	Stage Unspecified		Orciprenaline	C		
	Tonsillitis					

Date:06/18/01ISR Number: 3741494-4Report Type:Expedited (15-DaCompany Report #B0110963A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Anger	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
Intervention to	Depression					
PER DAY ORAL						
Prevent Permanent	Insomnia		Ethanol	C		
Impairment/Damage	Self Mutilation					

Date:06/18/01ISR Number: 3741514-7Report Type:Expedited (15-DaCompany Report #A0130642A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Thyroid Stimulating Hormone Increased Dermatitis Malaise Pyrexia Red Blood Cell Sedimentation Rate Increased	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL 15 DAY

Date:06/18/01ISR Number: 3741516-0Report Type:Expedited (15-DaCompany Report #A0150891A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Agitation Confusional State Epileptic Aura Flushing Paraesthesia Psychotic Disorder	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:06/18/01ISR Number: 3741554-8Report Type:Expedited (15-DaCompany Report #A0147746A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	75 MG / PER DAY / ORAL
	Crying						
	Feeling Abnormal Nervousness		Clonazepam	C			

Date:06/18/01ISR Number: 3741567-6Report Type:Expedited (15-DaCompany Report #A0150739A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Convulsion	Professional						
	Psychotic Disorder							
	Sexual Offence							

Date:06/18/01ISR Number: 3741887-5Report Type:Expedited (15-DaCompany Report #A0108484A
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aggression
	Anxiety
	Breath Odour
	Dermatitis Exfoliative
	Dysgeusia
	Dysphagia
	Erythema
	Face Oedema
	Fatigue
	Insomnia
	Lip Dry
	Nail Disorder

	Oedema						
	Oral Intake Reduced						
	Oral Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain	Foreign	Bupropion				
	Pruritus	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL
	Salivary Hypersecretion						
	Skin Lesion						
	Stomatitis						

Date:06/18/01ISR Number: 3741888-7Report Type:Expedited (15-DaCompany Report #A0124641A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Alcohol Poisoning	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE
	Arrhythmia	Health					PER DAY ORAL
	Dehydration	Professional	Ethanol (Formulation				
	Heat Stroke		Unknown) (Alcohol)	SS			
	Sudden Death						

Date:06/18/01ISR Number: 3741889-9Report Type:Expedited (15-DaCompany Report #B0098815A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Anaphylactic Reaction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER
	Arrhythmia	Literature					DAY ORAL
	Chest Discomfort	Health	Bisoprolol	C			
	Chest Pain	Professional	Aspirin	C			
	Decreased Appetite		Metformin				
	Dehydration		Hydrochloride	C			
	Dermatitis		Glicazide	C			
	Dizziness						
	Dry Mouth						
	Dyspnoea						
	Fatigue						
	Headache						

Insomnia
Lethargy
Malaise
Myocardial Infarction
Pain
Swelling
Tongue Oedema

Date:06/18/01ISR Number: 3741892-9Report Type:Expedited (15-DaCompany Report #A0150884A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Retroperitoneal Fibrosis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	3 MON
Intervention to Prevent Permanent Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/01ISR Number: 3741903-0Report Type:Expedited (15-DaCompany Report #A0120078A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar Disorder	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY)	ORAL
	Bipolar I Disorder	Health						
	Disorientation	Professional						
	Disturbance In Attention		Clonazepam	C				
	Grand Mal Convulsion		Paroxetine Hydrochloride	C				
	Mood Swings							
	Psychotic Disorder		Perphenazine	C				
	Visual Disturbance							

Date:06/18/01ISR Number: 3741919-4Report Type:Expedited (15-DaCompany Report #A0150723A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 TABLET/ TWICE PER DAY/	ORAL
	Petechiae							
	Pruritus							

Date:06/18/01ISR Number: 3741920-0Report Type:Expedited (15-DaCompany Report #A0150616A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Drug Hypersensitivity	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/	ORAL 19 DAY
			Ginseng	C				
			Multivitamin	C				

Date:06/18/01ISR Number: 3741921-2Report Type:Expedited (15-DaCompany Report #A0150823A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Alanine Aminotransferase Increased Angioneurotic Oedema Aspartate Aminotransferase Increased Asthenia Dizziness Dysphagia Dyspnoea Hypoaesthesia Osteoarthritis Paraesthesia Urticaria	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	17 DAY

Date:06/18/01ISR Number: 3741922-4Report Type:Expedited (15-DaCompany Report #A0150828A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

			Salbutamol Sulphate	C		

Date:06/18/01ISR Number: 3741923-6Report Type:Expedited (15-DaCompany Report #A0150720A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis	Foreign	Bupropion					
	Pancreatitis		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY/ ORAL	
			Aspirin	C				
			Docusate Sodium	C				
			Nicotine	C				
			Oxazepam	C				
			Parafon Forte	C				
			Simvastatin	C				

Date:06/18/01ISR Number: 3741924-8Report Type:Expedited (15-DaCompany Report #A0150908A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anxiety	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY/ ORAL	5 DAY
	Crying							
	Dizziness							
	Fear		Triphasil	C				
	Feeling Jittery							
	Hyperventilation							
	Panic Disorder							

Date:06/18/01ISR Number: 3741925-XReport Type:Expedited (15-DaCompany Report #A0107343A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required	Chest Pain	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
100 MG/ TWICE						
Intervention to	Drug Interaction					
PER DAY/ ORAL						
Prevent Permanent	Hypertension		Paroxetine			
Impairment/Damage	Insomnia		Hydrochloride			
	Sinus Tachycardia		(Formulation			
			Unknown) (Paroxetine			
			Hydrochloride)	SS		ORAL
SEE TEXT/						
ORAL						

Date:06/18/01ISR Number: 3743005-6Report Type:Expedited (15-DaCompany Report #A0105871A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Aspiration	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	
UNKNOWN						
	Overdose		Nortriptyline			
			(Nortriptyline)	SS		
UNKNOWN						
			Cocaine (Cocaine)	SS		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/01ISR Number: 3743550-3Report Type:Periodic Company Report #LBID00201001555
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coordination Abnormal Paranoia Speech Disorder	Health Professional	Lithobid	PS	Solvay Pharmaceuticals	ORAL	900 MG DAILY PO	
			Seroquel (Seroquel)	SS		ORAL	600 MG DAILY PO	
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride)	SS		ORAL	150 MG DAILY PO	
			Klonopin (Clonazepam)	SS		ORAL	2 MG DAILY PO	
			Celebrex (Celecoxib)	SS		ORAL	UNK DAILY PO	

Date:06/19/01ISR Number: 3741347-1Report Type:Expedited (15-DaCompany Report #A0086224A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Medication Error Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	2 DAY
			No Concurrent Medications	C				

Date:06/19/01ISR Number: 3741348-3Report Type:Expedited (15-DaCompany Report #A0114129A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Other	Asthenia						per day	8 DAY
	Chest Pain		Diuretic	C				
	Coordination Abnormal							
	Cyanosis							
	Depressed Level Of Consciousness							
	Disorientation							
	Dizziness							
	Dyspepsia							
	Fatigue							
	Feeling Abnormal							
	Feeling Hot							
	Feeling Jittery							
	Headache							
	Hearing Impaired							
	Insomnia							
	Neck Pain							
	Oedema Peripheral							
	Pallor							
	Paraesthesia							
	Parkinsonian Gait							
	Pollakiuria							
	Tinnitus							
	Tremor							
	Vertigo							
	Visual Disturbance							

Date:06/19/01ISR Number: 3741349-5Report Type:Expedited (15-DaCompany Report #A0130455A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Asthenia		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Unknown
	Dysarthria		Fluvoxamine	SS		ORAL	100MG Per day
	Gait Disturbance						
	Hypothermia						

Date:06/19/01ISR Number: 3742565-9Report Type:Expedited (15-DaCompany Report #B0110883A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiomyopathy	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	SEE TEXT /
	Left Ventricular Failure						ORAL
	Pulmonary Oedema		Amitriptyline	C			
	Sudden Death		Nitrazepam	C			
			Loperamide Hydrochloride	C			
			Co-Codamol	C			

Date:06/19/01ISR Number: 3742566-0Report Type:Expedited (15-DaCompany Report #A0104189A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Distension	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL (DURATION: MONTHS)
	Arthralgia						
	Back Pain						
	Chest Pain						
	Dyspepsia		Triphasil	C			
	Eye Irritation						
	Hypersensitivity						

	Urticaria					

Date:06/19/01ISR Number: 3742567-2Report Type:Expedited (15-DaCompany Report #B0111230A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain Hepatic Steatosis Hepatomegaly	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:06/19/01ISR Number: 3742568-4Report Type:Expedited (15-DaCompany Report #A0150827A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Bundle Branch Block Left Chest Pain Dizziness Headache Hypertension Vomiting	Foreign	Wellbutrin Sr Rofecoxib Thiamine Methylphenidate Hcl Venlafaxine Hydrochloride Conjugated Estrogens	PS C C C C C	Glaxo Wellcome Inc	ORAL	100 MG/ PER DAY/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/01ISR Number: 3742570-2Report Type:Expedited (15-DaCompany Report #A0150905A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Aggression	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
Intervention to	Anxiety						PER DAY/ ORAL	19 DAY
Prevent Permanent	Coordination Abnormal							
Impairment/Damage	Depression							
	Dizziness							
	Fatigue							
	Headache							
	Lethargy							
	Panic Reaction							
	Paranoia							
	Phobia							
	Suicidal Ideation							

Date:06/19/01ISR Number: 3742571-4Report Type:Expedited (15-DaCompany Report #D0016065A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Formication	Health					PER DAY/ ORAL	
	Headache	Professional						
	Paraesthesia							

Date:06/19/01ISR Number: 3742572-6Report Type:Expedited (15-DaCompany Report #A0106433A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Dermatitis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
Intervention to	Dyspepsia						PER DAY/ ORAL	20 DAY
Prevent Permanent	Ecchymosis		Phenoxymethylpenicil					
Impairment/Damage	Face Oedema		lin K (Formulation					

	Fatigue		Unknown) (Penicillin			
	Lip Dry		V Potassium)	SS		
600 MG/ TWICE						
	Myalgia					
PER DAY/ 11 DAY						
	Pruritus					
	Throat Tightness					
	Urticaria					

Date:06/19/01ISR Number: 3742577-5Report Type:Expedited (15-DaCompany Report #A0106360A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Facial Palsy	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
Intervention to	Hypoaesthesia						PER DAY/ ORAL
Prevent Permanent	Urticaria		Conjugated Estrogens	C			
Impairment/Damage							

Date:06/19/01ISR Number: 3742589-1Report Type:Expedited (15-DaCompany Report #A0129592A
Age:31 YR Gender:Female I/FU:I

Outcome	PT
Disability	Agitation
	Arthralgia
	Dyspnoea
	Erythema Multiforme

	Leukocytoclastic Vasculitis Serum Sickness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL
		Health Professional					

Date:06/19/01ISR Number: 3742590-8Report Type:Expedited (15-DaCompany Report #A0151174A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anaemia Bronchiolitis Cough Drug Interaction Hyperhidrosis Hypoxia Pyrexia	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	250 MG/ PER DAY/ ORAL
			Clomipramine Hcl (Formulation Unknown) (Clomipramine Hcl)	SS			125 MG/ PER DAY (DURATION: YEARS)
			Lithium Salt	C			
			Clonazepam	C			

Date:06/19/01ISR Number: 3742593-3Report Type:Expedited (15-DaCompany Report #A0151169A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent	Facial Palsy Hypoaesthesia Sensory Disturbance	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL 8 DAY
			Oestradiol	C			

Impairment/Damage	Calcium With Vitamin D	C
	Avalide	C

Date:06/19/01ISR Number: 3742601-XReport Type:Expedited (15-DaCompany Report #B0110588A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Sensation In Eye Convulsion Fall Headache Insomnia Muscle Spasms Salivary Hypersecretion	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:06/19/01ISR Number: 3742606-9Report Type:Expedited (15-DaCompany Report #A0150949A
Age:52 YR Gender:Male I/FU:I

Outcome	PT
Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain Arthralgia Chest Pain Diarrhoea Drug Interaction Intestinal Obstruction Malaise

Neck Pain

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY	/ORAL
			Nefazodone Hydrochloride	SS				
			Aspirin	C				
			Atenolol	C				
			Atorvastatin Calcium	C				

Date:06/19/01ISR Number: 3742607-0Report Type:Expedited (15-DaCompany Report #A0150913A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angina Unstable Asthenia Dyspnoea Heart Rate Increased Hypoaesthesia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	TWICE PER DAY/ORAL	1 WK
			Alprazolam	C				
			Aspirin	C				
			Atenolol	C				
			Cerivastatin	C				
			Dalteparin Sodium	C				
			Prinzide	C				

Date:06/19/01ISR Number: 3742610-0Report Type:Expedited (15-DaCompany Report #B0110727A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease Myocardial Infarction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/	ORAL

Date:06/19/01ISR Number: 3742613-6Report Type:Expedited (15-DaCompany Report #B0109704A
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Death	Aspartate
Hospitalization -	Aminotransferase
Initial or Prolonged	Increased
	Blood Alkaline
	Phosphatase Increased
	Blood Bilirubin Increased
	Blood Creatine
	Phosphokinase Increased
	Blood Lactate
	Dehydrogenase Increased
	Cerebral Ischaemia
	Coma
	Haemolytic Anaemia
	Hypertonia
	Lipase Increased
	Metabolic Acidosis
	Pancytopenia
	Respiratory Failure
	Shock
	Sinus Tachycardia

	Thrombotic Thrombocytopenic Purpura Urinary Incontinence	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ PER DAY/ ORAL						
			Sulpiride	C		
			Migril	C		

Date:06/19/01ISR Number: 3742619-7Report Type:Expedited (15-DaCompany Report #B0104342A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE PER DAY/ ORAL						
			Ethanol (Formulation Unknown) (Alcohol)	SS		
			Triazolam Tablet (Triazolam)	SS		
.25 MG/ PER DAY/						
			Mercilon (Formulation Unknown) (Mercilon)	SS		ORAL
ORAL						

Date:06/19/01ISR Number: 3742623-9Report Type:Expedited (15-DaCompany Report #A0128949A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abortion Spontaneous Complications Of Maternal	Foreign Study	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						

		Exposure To Therapeutic	Health				
PER DAY/ORAL	1 WK						
		Drugs	Professional				

Date:06/19/01ISR Number: 3742629-XReport Type:Expedited (15-DaCompany Report #A0141486A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Atrial Flutter	Foreign Health	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Cardiac Failure Congestive	Professional						

Date:06/19/01ISR Number: 3742630-6Report Type:Expedited (15-DaCompany Report #A0144603A
Age: Gender:Male I/FU:F

Outcome	PT
Other	Arthralgia
	Bronchospasm
	Burning Sensation
	Chest Pain
	Dermatitis
	Dyspnoea
	Face Oedema
	Insomnia
	Joint Stiffness
	Myocardial Infarction

	Oedema					
	Pruritus					
	Urticaria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Foreign	Bupropion			
		Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/	TWICE					
		Professional				
PER DAY/	ORAL					

Date:06/19/01ISR Number: 3742632-XReport Type:Expedited (15-DaCompany Report #A0149803A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Catatonia	Foreign	Bupropion			
	Convulsion		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
7.5 G/	SEE					
	Intentional Misuse					
TEXT/	ORAL					
	Sedation		Amphetamine	C		
	Tachycardia		Cannabis	C		

Date:06/19/01ISR Number: 3742655-0Report Type:Expedited (15-DaCompany Report #B0110521A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abnormal Behaviour	Foreign	Bupropion			
Initial or Prolonged	Suicide Attempt	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	
150 MG	3 DAY					
			Clonazepam	C		
			Valproate Sodium	C		
			Anxiolytic	C		

Date:06/19/01ISR Number: 3742814-7Report Type:Expedited (15-DaCompany Report #A0090004A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Arrest	Foreign	Bupropion			

	Pulmonary Embolism		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG /

SINGLE DOSE /

ORAL 1 DAY

Lorazepam	C
Cefuroxime Axetil	C
Combivent	C
Budesonide	C
Tetracycline	C
Theophylline	C

Date:06/19/01ISR Number: 3742816-0Report Type:Expedited (15-DaCompany Report #A0086553A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Angina Pectoris	Foreign	Bupropion			
Other	Myocardial Infarction	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150 MG /

Professional

TWICE PER DAY

/ ORAL

Metformin Hydrochloride	C
Conjugated Estrogens	C
Atorvastatin Calcium	C
Glibenclamide	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/01ISR Number: 3742818-4Report Type:Expedited (15-DaCompany Report #A0090299A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	100 MG / PER DAY / ORAL	7 DAY
	Chest Pain							
	Pericarditis							
	Vomiting							

Date:06/19/01ISR Number: 3742819-6Report Type:Expedited (15-DaCompany Report #A0105877A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Cyanosis							
	Dyspnoea							
	Eye Rolling							
	Movement Disorder		Sumatriptan Succinate	C				
	Sedation		Propranolol Hydrochloride	C				
			Salbutamol Sulphate	C				
			Triquilar	C				

Date:06/19/01ISR Number: 3742988-8Report Type:Expedited (15-DaCompany Report #A0105423A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Multiple Sclerosis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Sensory Loss	Health Professional						
Disability								

Date:06/19/01ISR Number: 3743006-8Report Type:Expedited (15-DaCompany Report #A0075655A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL	
	Convulsion	Consumer						
	Dyspnoea		Calcium Salt	C				
	Grand Mal Convulsion		Conjugated Estrogens	C				
	Status Epilepticus		Hypericum	C				
	Suicidal Ideation		Ascorbic Acid	C				

Date:06/19/01ISR Number: 3743007-XReport Type:Expedited (15-DaCompany Report #A0082610A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactoid Reaction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER DAY ORAL	
	Angioneurotic Oedema	Health						
	Dermatitis	Professional	Thyroxine Sodium	C				
	Pruritus		Hrt	C				
	Rash Erythematous							
	Tongue Oedema							

Date:06/19/01ISR Number: 3743009-3Report Type:Expedited (15-DaCompany Report #A0096983A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	100 MG ORAL	
	Headache		Ibuprofen	C				
Other			Semisodium Valproate	C				

Date:06/19/01ISR Number: 3743234-1Report Type:Expedited (15-DaCompany Report #2001SUS0407
Age:0 DY Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Complications Of Maternal Exposure To Therapeutic Drugs Cystic Fibrosis Meconium Ileus	Health Professional	Sustiva	PS	Dupont Pharmaceuticals Co	TRANSPLACENTAL	TR	
			Combivir (Lamivudine/Zidovudine)	SS		TRANSPLACENTAL	TR	
			Norvir (Ritonavir)	SS		TRANSPLACENTAL	TR	
			Crixivan (Indinavir)	SS		TRANSPLACENTAL	TR	
			Bupropion (Amfebutamone)	SS		TRANSPLACENTAL	TR	
			Viramune (Nevirapine)	SS		TRANSPLACENTAL	TR	
			Epivir (Lamivudine)	SS		TRANSPLACENTAL	TR	
			Zerit (Stavudine)	SS		TRANSPLACENTAL	TR	
			Viracept (Nelfinavir)	SS		TRANSPLACENTAL	TR	

Date:06/19/01ISR Number: 3743704-6Report Type:Expedited (15-DaCompany Report #B0110444A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Foreign	Bupropion					
Hospitalization - Initial or Prolonged	Coma Malaise Nausea Pulmonary Embolism	Health Professional	Hydrochloride Fluticasone Propionate Salmeterol Xinafoate	PS C C	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	7 DAY

Date:06/20/01ISR Number: 3742240-0Report Type:Expedited (15-DaCompany Report #A0150739A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bipolar Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Convulsion		Zyban	SS	Glaxo Wellcome	ORAL	2	MON
	Psychotic Disorder							
	Sexual Offence							
	Therapeutic Response							
	Unexpected							

Date:06/20/01ISR Number: 3742247-3Report Type:Expedited (15-DaCompany Report #B0108775A
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Death	Cardiac Arrest
Hospitalization - Initial or Prolonged	Confusional State
	Dysarthria
	Hallucination, Visual
	Overdose

	Tremor						
	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Bupropion Hcl	PS	Glaxo Wellcome	ORAL	
			Nifedipine	C		ORAL	5MG Three times per day

Date:06/20/01ISR Number: 3742248-5Report Type:Expedited (15-DaCompany Report #B0109628A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome	ORAL	1 DAY
	Confusional State						
	Dysarthria						
	Hallucination, Visual						
	Overdose						
	Tremor						
	Vomiting						

Date:06/20/01ISR Number: 3743639-9Report Type:Expedited (15-DaCompany Report #A0083661A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL
	Eye Rolling	Health					
	Hypoglycaemia	Professional					
			Human Short-Act. Insulin (Formulation Unknown) (Human Short-Act. Insulin)	SS			
			Human Int/Long Insulin	C			
			Ethanol	C			

Date:06/20/01ISR Number: 3743641-7Report Type:Expedited (15-DaCompany Report #B0110591A
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER	DAY / ORAL
			Fluticasone+Salmeterol (Formulation Unknown) (Fluticasone+Salmeterol)	SS				RESPIRATORY
						(INHALATION)	2 / TWICE PER	DAY / INHALED

Date:06/20/01ISR Number: 3743642-9Report Type:Expedited (15-DaCompany Report #B0099946A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conductive Deafness	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	DAY / ORAL
	Conjunctivitis	Health Professional						SEE TEXT
	Ear Disorder							
	Influenza Like Illness		Paracetamol	C				
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/01ISR Number: 3743643-0Report Type:Expedited (15-DaCompany Report #A0106475A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:06/20/01ISR Number: 3743644-2Report Type:Expedited (15-DaCompany Report #A0090923A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase Increased	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
Hospitalization - Initial or Prolonged	Alcohol Withdrawal Syndrome	Health Professional						
	Aspartate Aminotransferase Increased	Company Representative	Ethanol (Formulation Unknown) (Alcohol)	SS				
	Blood Alkaline Phosphatase Increased							
	Coma							
	Convulsion							
	Gamma-Glutamyltransferase Increased							
	Hypoxia							
	Pneumonia Aspiration							

Date:06/20/01ISR Number: 3743645-4Report Type:Expedited (15-DaCompany Report #A0087951A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Glucose Decreased	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

Intervention to	Convulsion	Health					
TWICE PER DAY							
Prevent Permanent	Fall	Professional					
/ ORAL							
Impairment/Damage			Insulin Lispro	C			
			Human Int/Long				
			Insulin	C			
			Short-Acting Insulin	C			

Date:06/20/01ISR Number: 3743646-6Report Type:Expedited (15-DaCompany Report #A0075616A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
		Health						
TWICE PER DAY								
		Professional						
/ ORAL								
			Ramipril	C				
			Lorazepam	C				

Date:06/20/01ISR Number: 3743648-XReport Type:Expedited (15-DaCompany Report #A0103586A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	300 MG/ PER	
Initial or Prolonged	Grand Mal Convulsion							
DAY/ ORAL								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/01ISR Number: 3743655-7Report Type:Expedited (15-DaCompany Report #A0150726A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Bradycardia	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
Intervention to Prevent Permanent Impairment/Damage	Coma Oliguria Suicide Attempt		Diltiazem Hydrochloride Capsule (Diltiazem Hydrochloride)	SS		ORAL	300 MG/ ORAL	
			Clonazepam Tablet (Cloazepam)	SS		ORAL	.5 MG / ORAL	
			Pethidine Hydrochloride (Meperidine Hydrochloride)	SS		ORAL	50 MG / ORAL	
			Desipramine Tablet (Desipramine)	SS		ORAL	750 MG / ORAL	
			Loxapine (Formulation Unknown) (Loxapine)	SS		ORAL	10 MG / ORAL	
			Morphine Sulphate (Formulation Unknown) (Morphine Sulfate)	SS		ORAL	30 MG / ORAL	
			Trazodone Tablet (Trazodone)	SS		ORAL	50 MG / ORAL	
			Zopiclone (Formulation Unknown) (Zopiclone)	SS		ORAL	7.5 MG / ORAL	

Date:06/20/01ISR Number: 3743656-9Report Type:Expedited (15-DaCompany Report #A0104181A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required	Arthralgia	Foreign	Bupropion			
Intervention to	Tendon Disorder		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 150 MG /
Prevent Permanent	Urticaria					TWICE PER DAY
Impairment/Damage						/ ORAL 16 DAY
			Ortho 1/35	C		

Date:06/20/01ISR Number: 3743657-0Report Type:Expedited (15-DaCompany Report #A0151352A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Required	Electrocardiogram Qrs	Foreign	Bupropion			
Intervention to	Complex Prolonged		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL 15 G/ SINGLE
Prevent Permanent	Overdose					DOSE / ORAL
Impairment/Damage			Lorazepam	C		

Date:06/20/01ISR Number: 3743658-2Report Type:Expedited (15-DaCompany Report #A0151323A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Required	Abdominal Pain	Foreign	Bupropion			
Intervention to	Angina Pectoris		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL ORAL
Prevent Permanent	Drug Interaction		Fenofibrate Capsule			
Impairment/Damage			(Fenofibrate)	SS		ORAL 200 MG / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/01ISR Number: 3743659-4Report Type:Expedited (15-DaCompany Report #A0090158A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Leukopenia Neutropenia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	13 DAY
			Paracetamol	C				
			Chlorpheniramine	C				
			Cytarabine	C				
			Etoposide	C				
			Idarubicin	C				
			Mitozantrone Hcl	C				
			Salbutamol Sulphate	C				

Date:06/20/01ISR Number: 3743739-3Report Type:Expedited (15-DaCompany Report #A0105879A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Diarrhoea Dizziness Erythema Multiforme Leukocytosis Nausea Neutrophilia Oedema Serum Sickness Tachycardia Tongue Disorder	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	15 DAY

Date:06/20/01ISR Number: 3743747-2Report Type:Expedited (15-DaCompany Report #A0137061A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
SEE TEXT/ORAL						
	Sinus Tachycardia		Citalopram			
	Suicide Attempt		Hydrobromide Tablet	SS		ORAL
SEE TEXT/ORAL						
	Tremor					

Date:06/20/01ISR Number: 3743758-7Report Type:Expedited (15-DaCompany Report #B0111327A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiomyopathy	Foreign	Bupropion			
Initial or Prolonged			Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ORAL						

Date:06/20/01ISR Number: 3743760-5Report Type:Expedited (15-DaCompany Report #A0106203A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Abdominal Pain	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
100 MG/PER						
Intervention to	Proctitis					
DAY/ORAL 1 MON						
Prevent Permanent	Rectal Haemorrhage		Betamehtasone Na Po4	C		
Impairment/Damage	Rectal Tenesmus		Trazodone			
	Vomiting		Hydrochloride	C		
			Azathioprine	C		
			Diclofenac Sodium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/01ISR Number: 3743818-0Report Type:Expedited (15-DaCompany Report #A0103160A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pneumonia	Foreign Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Nifedipine	C				

Date:06/20/01ISR Number: 3743832-5Report Type:Expedited (15-DaCompany Report #B0111329A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Stress	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	

Date:06/20/01ISR Number: 3743833-7Report Type:Expedited (15-DaCompany Report #A0150947A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Body Temperature Increased Chest Pain Face Oedema Periorbital Oedema Pharyngolaryngeal Pain Urticaria White Blood Cell Disorder	Foreign	Bupropion Hydrochloride Atoravastin Calcium	PS C	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ ORAL	18 DAY

Date:06/20/01ISR Number: 3743834-9Report Type:Expedited (15-DaCompany Report #A0143251A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Loss Of Consciousness	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	
			Naproxen	C				
			Omeprazole	C				
			Aspirin	C				
			Amlodipine	C				
			Trazodone	C				
			Medroxyprogesterone Ace.	C				
			Bromazepam	C				
			Sertraline Hydrochloride	C				
			Fiorinal	C				
			Percocet	C				

Date:06/20/01ISR Number: 3743835-0Report Type:Expedited (15-DaCompany Report #A0151353A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Agranulocytosis Infection	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
			Clonazepam (Formulation Unknown)	SS		ORAL	2 MG/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/01ISR Number: 3743451-0Report Type:Expedited (15-DaCompany Report #A0110910A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
Life-Threatening	Cardiac Arrest							15 DAY
Disability	Idiopathic Thrombocytopenic Purpura		Pain Medication (Unspecified)	C				

Date:06/21/01ISR Number: 3743465-0Report Type:Expedited (15-DaCompany Report #A0151572A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Cardiovascular Medication	SS				

Date:06/21/01ISR Number: 3743469-8Report Type:Expedited (15-DaCompany Report #A0151751A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ectopic Pregnancy		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:06/21/01ISR Number: 3744003-9Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Pressure Increased	Consumer	Zoloft	PS	Pfizer			

Intervention to	Drug Ineffective			Pharmaceuticals Inc	
50.00 MG					
Prevent Permanent	Ecchymosis				
TOTAL:DAILY					
Impairment/Damage	Haemorrhagic Stroke	Wellbutrin	SS		ORAL
300.000					
	Head Injury				
TOTAL:BID:ORA					
	Headache				
L					
	Heart Rate Decreased	Coumadin	SS		
	Heart Rate Increased	Effexor Sr	SS		ORAL
300.00 MG					
	Hyperhidrosis				
TOTAL:BID:ORA					
	Laboratory Test Abnormal				
L					
	Medication Error	Toprol	C		
	Overdose	Zebeta	C		
	Syncope	Lanoxin	C		
		Lasix	C		
		Synthroid	C		
		Vitamin E	C		
		Estrogen	C		

Date:06/22/01ISR Number: 3744090-8Report Type:Expedited (15-DaCompany Report #A0149803A
Age:29 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Agitation
Initial or Prolonged	Alcoholism
Other	Catatonia
	Coma
	Convulsion
	Depression
	Hallucination

	Intentional Misuse						
	Tachycardia						
	Toxicologic Test Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vomiting	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	7.5G See text
			Amphetamine	C			
			Cannabis	C			

Date:06/22/01ISR Number: 3744094-5Report Type:Expedited (15-DaCompany Report #A0152007A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Coronary Artery Disease		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	450MG Per day YR
			Statins	C			

Date:06/22/01ISR Number: 3745460-4Report Type:Expedited (15-DaCompany Report #A0130455A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Asthenia	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL
	Dysarthria		Fluvoxamine Tablet				
	Gait Disturbance		(Fluvoxamine)	SS		ORAL	100 MG / PER
	Hypothermia						DAY / ORAL

Date:06/22/01ISR Number: 3745462-8Report Type:Expedited (15-DaCompany Report #A0114129A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Asthenia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /TWICE
Other	Chest Pain	Health					PER DAY /

	Coordination Abnormal	Professional		
ORAL				
	Cough		Diuretic	C
	Cyanosis			
	Disorientation			
	Dizziness			
	Fatigue			
	Feeling Cold			
	Feeling Hot			
	Feeling Jittery			
	Headache			
	Hearing Impaired			
	Insomnia			
	Neck Pain			
	Pallor			
	Paraesthesia			
	Pollakiuria			
	Poverty Of Thought			
	Content			
	Sneezing			
	Tinnitus			
	Visual Disturbance			

Date:06/22/01ISR Number: 3745463-XReport Type:Expedited (15-DaCompany Report #A0086224A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source
Death	Myocardial Infarction	Foreign
		Literature

Health Professional

Product	Role	Manufacturer	Route	Dose	Duration
Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	2 DAY

Date:06/22/01ISR Number: 3745495-1Report Type:Expedited (15-DaCompany Report #A114068
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Foreign	Viagra	PS	Pfizer Agricultural Div			
Hospitalization - Initial or Prolonged	Cardio-Respiratory Arrest Coma Convulsion Drug Interaction Fall Head Injury Tachycardia	Consumer	Bupropion	SS		ORAL	300.00 MG TOTAL:BID:ORAL	
			Tamsulosin	SS		ORAL	0.40 MG TOTAL:DAILY:ORAL	
			Atorvastatin	C				
			Lorazepam	C				
			Aspirin	C				
			Dimethyl Sulfone	C				
			Ubidecarenone	C				
			Multivitamin	C				
			Fish Oil	C				
			Pentanic Acid	C				

Date:06/22/01ISR Number: 3749762-7Report Type:Periodic Company Report #A0124951A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/UNK/	
	Convulsion					ORAL		
	Epileptic Aura							
	Fatigue							
	Loss Of Consciousness							
	Malaise							
	Muscle Tightness							
	Neck Pain							
	Overdose							
	Speech Disorder							
	Syncope							

Date:06/22/01ISR Number: 3749763-9Report Type:Periodic Company Report #A0124945A
Age:26 YR Gender:Female I/FU:F

Outcome	PT
Other	Arthralgia
	Candidiasis
	Decreased Activity
	Difficulty In Walking
	Erythema
	Face Oedema
	Insomnia
	Muscle Spasms
	Oedema Peripheral
	Pruritus

	Urticaria					
		Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE PER DAY/ORAL		Professional				
			Medroxyprogesterone Ace.	C		

Date:06/22/01ISR Number: 3749764-0Report Type:Periodic Company Report #A0123486A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Back Pain	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE PER DAY/ ORAL	Convulsion					
	Dysphagia		One-A-Day Vitamins	C		
	Dyspnoea					
	Nausea					
	Speech Disorder					
	Throat Tightness					
	Tremor					

Date:06/22/01ISR Number: 3749765-2Report Type:Periodic Company Report #A0057814A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Agitation	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE PER DAY/ ORAL	Amnesia	Professional				
	Arthralgia		Diazepam (Formulation Uknown)			
	Bronchitis		(Diazepam)	SS		
	Confusional State		Ethanol (Formulation Unknown) (Alcohol)	SS		
	Cough		Conjugated Estrogens	C		
	Decreased Activity		Amitriptyline Hcl	C		
	Depression					
	Difficulty In Walking					

	Dry Mouth		Decongestant	C	
	Dyspraxia		Medroxypregesterone		
	Grand Mal Convulsion		Ace.	C	
	Hallucination		Nabumetone	C	
	Headache		Aspirin	C	
	Nervousness				
	Speech Disorder				
	Tremor				

Date:06/22/01ISR Number: 3749766-4Report Type:Periodic Company Report #A0145488A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
	Blood Pressure Increased						PER DAY/	ORAL
	Erythema							
	Flushing							
	Hypersensitivity							
	Hyperventilation							
	Paraesthesia							
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749767-6Report Type:Periodic Company Report #A0145142A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Face Oedema Hypersensitivity Pain Throat Tightness Urticaria	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	9 DAY

Date:06/22/01ISR Number: 3749768-8Report Type:Periodic Company Report #A0145079A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ORAL	

Date:06/22/01ISR Number: 3749769-XReport Type:Periodic Company Report #A0144963A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Hypersensitivity Pruritus Vomiting	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:06/22/01ISR Number: 3749770-6Report Type:Periodic Company Report #A0142980A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Circulatory Collapse	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/TWICE
	Convulsion					PER DAY/ ORAL
	Disorientation					
	Memory Impairment					
	Tongue Disorder					

Date:06/22/01ISR Number: 3749771-8Report Type:Periodic Company Report #A0142186A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Arthralgia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG/ TWICE
	Burning Sensation	Professional				PER DAY/ ORAL
	Dry Skin					
	Dyspnoea					
	Fatigue					
	Myalgia					
	Pain					
	Pruritus					
	Rash Scaly					
	Serum Sickness					
	Swelling					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749772-XReport Type:Periodic Company Report #A0130468A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock Dermatitis Dyspnoea	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	1 TABLET/ TWICE PER DAY/ORAL	

Date:06/22/01ISR Number: 3749773-1Report Type:Periodic Company Report #A0130291A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysgeusia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL	

Date:06/22/01ISR Number: 3749774-3Report Type:Periodic Company Report #A0129542A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bite Dizziness Grand Mal Convulsion Head Injury Loss Of Consciousness Tremor	Health Professional	Zyban Pravastatin Sodium Nicotine	PS C C	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:06/22/01ISR Number: 3749786-XReport Type:Periodic Company Report #A0139615A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / TWICE PER DAY / ORAL

Date:06/22/01ISR Number: 3749787-1Report Type:Periodic Company Report #A0138575A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Convulsion Feeling Abnormal Muscle Twitching	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / TWICE PER DAY / ORAL

Date:06/22/01ISR Number: 3749788-3Report Type:Periodic Company Report #A0137592A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Convulsion Road Traffic Accident	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL 150 MG / TWICE PER DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749789-5Report Type:Periodic Company Report #A0137115A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blood Pressure Increased	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
	Confusional State						TWICE PER DAY
	Convulsion						/ ORAL
	Disorientation						
	Muscle Rigidity						
	Pain						
	Panic Reaction						
	Rhinorrhoea						
	Salivary Hypersecretion						
	Tremor						
	Urinary Incontinence						
	Visual Acuity Reduced						

Date:06/22/01ISR Number: 3749790-1Report Type:Periodic Company Report #A0135779A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc		

Date:06/22/01ISR Number: 3749791-3Report Type:Periodic Company Report #A0134397A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Amnesia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	600 MG /
	Grand Mal Convulsion	Professional					SINGLE DOSE /
	Overdose	Company					ORAL
		Representative	Semisodium Valproate	C			
			Clonazepam	C			

			Olanzapine	C		

Date:06/22/01ISR Number: 3749792-5Report Type:Periodic Company Report #A0132271A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Convulsion		Oxygen	C				
	Difficulty In Walking		Salbutamol Sulphate	C				
	Dizziness		Ipratropium Bromide	C				
	Dyskinesia		Nebulizer	C				
	Tremor		Diazepam	C				
			Primidone	C				

Date:06/22/01ISR Number: 3749793-7Report Type:Periodic Company Report #A0131564A
Age:42 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Dermatitis
	Dyspepsia
	Dyspnoea
	Face Oedema
	Hypersensitivity
	Nausea

	Oedema Peripheral Pruritus Urticaria	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:06/22/01ISR Number: 3749794-9Report Type:Periodic Company Report #A0131413A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agranulocytosis Neutropenia	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:06/22/01ISR Number: 3749795-0Report Type:Periodic Company Report #A0131272A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:06/22/01ISR Number: 3749796-2Report Type:Periodic Company Report #A0128124A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Life-Threatening	Cardiac Failure	Health	Bupropion			
Hospitalization -	Congestive	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG/ TWICE						
Initial or Prolonged	Chest Pain					
PER DAY/ ORAL						
Disability	Convulsion		Nicotine	C		
Other	Myocardial Infarction					
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

Date:06/22/01ISR Number: 3749797-4Report Type:Periodic Company Report #A0127489A
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dermatitis	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ ORAL						
Required	Hypersensitivity	Professional				
Intervention to	Pruritus					
Prevent Permanent	Rash Macular					
Impairment/Damage	Skin Hypopigmentation					
	Urticaria					

Date:06/22/01ISR Number: 3749798-6Report Type:Periodic Company Report #A0127208A
Age:55 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Chest Pain
Initial or Prolonged	Depressed Level Of
	Consciousness

	Gastrooesophageal Reflux Disease						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL
			Multivitamin	C			

Date:06/22/01ISR Number: 3749799-8Report Type:Periodic Company Report #A0127038A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional Company Representative	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL

Date:06/22/01ISR Number: 3749800-1Report Type:Periodic Company Report #A0126954A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL

Date:06/22/01ISR Number: 3749801-3Report Type:Periodic Company Report #A0126757A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Amnesia	Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL 5 WK
	Grand Mal Convulsion						
	Petit Mal Epilepsy		Prednisone	SS			
			Diazepam	SS			

Date:06/22/01ISR Number: 3749802-5Report Type:Periodic Company Report #A0126289A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Zyban	PS	Glaxo Wellcome Inc			

Date:06/22/01ISR Number: 3749803-7Report Type:Periodic Company Report #A0126220A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State	Health	Zyban	PS	Glaxo Wellcome Inc			
Hospitalization - Initial or Prolonged	Ecchymosis	Professional	Conjugated Estrogens	C				
	Excoriation							
	Grand Mal Convulsion							
	Loss Of Consciousness							
	Weight Increased							

Date:06/22/01ISR Number: 3749804-9Report Type:Periodic Company Report #A0126219A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
			Phenobarbitone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749805-0Report Type:Periodic Company Report #A0125898A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Difficulty In Walking	Professional					PER DAY/ ORAL	
	Eyelid Oedema		Thyroxine Sodium	C				
	Joint Stiffness							
	Pruritus							
	Rash Erythematous							
	Swelling							
	Urticaria							

Date:06/22/01ISR Number: 3749806-2Report Type:Periodic Company Report #A0125812A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bite	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
Initial or Prolonged	Convulsion						PER DAY/ ORAL	
	Fall		Lisinopril	C				
	Head Injury		Atorvastatin Calcium	C				
	Loss Of Consciousness							
	Movement Disorder							
	Tongue Disorder							

Date:06/22/01ISR Number: 3749807-4Report Type:Periodic Company Report #A0125320A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depersonalisation	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
Initial or Prolonged	Dyspnoea						PER DAY/ ORAL	1 WK
	Hyperhidrosis							
	Malaise							
	Nervousness							

	Pallor					
	Syncope					
	Tachycardia					

Date:06/25/01ISR Number: 3745249-6Report Type:Expedited (15-DaCompany Report #A0137061A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	
Initial or Prolonged	Sinus Tachycardia		Celexa	SS		ORAL	400MG per day
Other	Suicide Attempt						
	Tremor						

Date:06/25/01ISR Number: 3745252-6Report Type:Expedited (15-DaCompany Report #A0149863A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dry Mouth	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Dry Throat						per day
	Emphysema						
	Speech Disorder						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/01ISR Number: 3745254-XReport Type:Expedited (15-DaCompany Report #A0151556A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Valtrex	PS	Glaxo Wellcome	ORAL		
	Drug Interaction		Wellbutrin	SS	Glaxo Wellcome	ORAL		

Date:06/25/01ISR Number: 3746187-5Report Type:Expedited (15-DaCompany Report #A0150739A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bipolar Disorder	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Sexual Offence	Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	SS		ORAL	ORAL	2 MON

Date:06/25/01ISR Number: 3746425-9Report Type:Expedited (15-DaCompany Report #A0151751A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ectopic Pregnancy	Foreign Study Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG, TWICE PER DAY, ORAL	

Date:06/25/01ISR Number: 3746430-2Report Type:Expedited (15-DaCompany Report #B0109628A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
	Confusional State							
	Dysarthria							

	Hallucination					
	Overdose					
	Tremor					
	Vomiting					

Date:06/25/01ISR Number: 3746431-4Report Type:Expedited (15-DaCompany Report #B0108775A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Bupropion					
Hospitalization -	Confusional State		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG, ORAL	
Initial or Prolonged	Dysarthria		Nifedipine	C				
	Hallucination							
	Overdose							
	Tremor							
	Vomiting							

Date:06/25/01ISR Number: 3746458-2Report Type:Expedited (15-DaCompany Report #A0110910A
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Life-Threatening	Blood Disorder
Disability	Cardiac Arrest
	Idiopathic

	Thrombocytopenic Purpura Influenza						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
		Health					TWICE PER DAY
		Professional					/ ORAL
			Pain Medication	C			

Date:06/25/01ISR Number: 3747190-1Report Type:Expedited (15-DaCompany Report #A0151572A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cardiovascular Disorder	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
		Professional					PER DAY/ ORAL
		Company Representative					

Date:06/26/01ISR Number: 3746299-6Report Type:Expedited (15-DaCompany Report #A0145968A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day 3 DAY
Initial or Prolonged	Decreased Appetite		Unknown				
	Difficulty In Walking		Anti-Depressant	C			
	Dysphagia						
	Hypersensitivity						

Date:06/26/01ISR Number: 3746305-9Report Type:Expedited (15-DaCompany Report #B0100202A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization -	Hypertensive Crisis	Health	Zyban	PS	Glaxo Wellcome	150MG Twice
Initial or Prolonged	Paraesthesia	Professional				per day 8 DAY
	Transient Ischaemic		Aspirin	C		150MG In the
	Attack					morning
			Hrt	C		

Date:06/26/01ISR Number: 3746307-2Report Type:Expedited (15-DaCompany Report #B0109587A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	10.5G	
Initial or Prolonged	Hypothermia						cumulative	
	Intentional Misuse						dose	
	Nausea							
	Pyrexia							
	Tachycardia							
	Vomiting							

Date:06/26/01ISR Number: 3746311-4Report Type:Expedited (15-DaCompany Report #B0111705A
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Depressed Level Of
Initial or Prolonged	Consciousness
	Muscular Weakness

	Nystagmus						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	WK
			Proton Pump Inhibitor	C			

Date:06/26/01ISR Number: 3746313-8Report Type:Expedited (15-DaCompany Report #B0111849A
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest Circulatory Collapse		Zyban	PS	Glaxo Wellcome		

Date:06/26/01ISR Number: 3746314-XReport Type:Expedited (15-DaCompany Report #B0111850A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome		

Date:06/26/01ISR Number: 3746315-1Report Type:Expedited (15-DaCompany Report #B0111851A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Fall		Zyban	PS	Glaxo Wellcome		
			Sildenafil	C			
			Alcohol	C			

Date:06/26/01ISR Number: 3746316-3Report Type:Expedited (15-DaCompany Report #B0111855A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angiopathy		Zyban	PS	Glaxo Wellcome		

	Myocardial Infarction
	Tachycardia
	Vith Nerve Paralysis

Date:06/26/01ISR Number: 3746318-7Report Type:Expedited (15-DaCompany Report #B0111862A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Artery Occlusion		Zyban	PS	Glaxo Wellcome	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Cerebral Artery Thrombosis Ischaemic Stroke Oedema							

Date:06/26/01ISR Number: 3746320-5Report Type:Expedited (15-DaCompany Report #B0111882A
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Convulsion Hypoglycaemia Intentional Misuse Renal Failure Acute

Rhabdomyolysis

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Zyban	PS	Glaxo Wellcome	ORAL	6G cumulative dose	
			Co-Dydramol	SS	Glaxo Wellcome		UNKNOWN	20TAB cumulative dose
			Bezafibrate	SS			UNKNOWN	15TAB cumulative dose
			Gliclazide	SS			UNKNOWN	15TAB cumulative dose
			Salbutamol	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	
			Alcohol	C				

Date:06/26/01ISR Number: 3746321-7Report Type:Expedited (15-DaCompany Report #B0111884A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Joint Effusion		Zyban	PS	Glaxo Wellcome			

Date:06/26/01ISR Number: 3746322-9Report Type:Expedited (15-DaCompany Report #B0111886A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Hyponatraemia						per day	7 DAY
			Atenolol	C		ORAL		

Date:06/26/01ISR Number: 3746323-0Report Type:Expedited (15-DaCompany Report #B0111947A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Right		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Chest Pain						per day	7 DAY
	Dyspnoea		Zopiclone	C				
	Palpitations		Propiomazine	C				
	Pulmonary Embolism		Somadril	C				

Date:06/26/01ISR Number: 3746324-2Report Type:Expedited (15-DaCompany Report #B0111954A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Zyban	PS	Glaxo Wellcome		150MG Per day	
Hospitalization -	Haemorrhagic Stroke		Salbutamol	C	Glaxo Wellcome			
Initial or Prolonged			Diclofenac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/01ISR Number: 3748136-2Report Type:Expedited (15-DaCompany Report #A0149803A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	7.5 G/SEE	
Other	Coma						TEXT/ORAL	
	Confusional State		Amphetamine	C				
	Convulsion		Cannabis	C				
	Depression							
	Gait Disturbance							
	Hallucination							
	Intentional Misuse							
	Sedation							
	Tachycardia							
	Vomiting							

Date:06/26/01ISR Number: 3748210-0Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS				

Date:06/26/01ISR Number: 3748455-XReport Type:Expedited (15-DaCompany Report #A0152007A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	450 MG / PER DAY	YR
			Statins	C				

Date:06/27/01ISR Number: 3747617-5Report Type:Expedited (15-DaCompany Report #B0109706A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Health	Zyban	PS	Glaxo Wellcome	ORAL	6	WK
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Professional						
Disability	Ruptured Cerebral Aneurysm							
Other	Status Epilepticus							

Date:06/27/01ISR Number: 3747619-9Report Type:Expedited (15-DaCompany Report #B0111860A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Effect Decreased	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	11 DAY
	Drug Interaction							
	Pregnancy On Oral Contraceptive		Micronor	SS		ORAL	350MCG Per day	412 DAY
			Cabergoline	C		ORAL	500MCG Weekly	

Date:06/27/01ISR Number: 3747620-5Report Type:Expedited (15-DaCompany Report #B0111950A
Age:35 YR Gender:Male I/FU:I

Outcome
Hospitalization - Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Attack		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	

Date:06/27/01ISR Number: 3747624-2Report Type:Expedited (15-DaCompany Report #B0112183A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Facial Palsy						per day	
			Atorvastatin	C		ORAL	20MG At night	
			Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG Per day	

Date:06/27/01ISR Number: 3747625-4Report Type:Expedited (15-DaCompany Report #B0112188A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	12 DAY
	Chest Pain							
	Hyperhidrosis							
	Suicide Attempt							
	Visual Disturbance							

Date:06/27/01ISR Number: 3747626-6Report Type:Expedited (15-DaCompany Report #B0112285A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Zyban	PS	Glaxo Wellcome		150MG Per day	4 DAY
	Cerebellar Infarction							

Cerebrovascular Disorder
Coordination Abnormal
Dizziness

Date:06/27/01ISR Number: 3747627-8Report Type:Expedited (15-DaCompany Report #B0112291A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	2 DAY
Hospitalization -	Renal Failure		Loperamide	C		ORAL	2MG Per day	
Initial or Prolonged			Allopurinol	C	Glaxo Wellcome	ORAL	300MG Per day	
			Meloxicam	C		ORAL	7.5MG Per day	
			Salbutamol	C	Glaxo Wellcome			
RESPIRATORY								
(INHALATION)	100MCG As							
required								
			Temazepam	C		ORAL	10MG Per day	

Date:06/27/01ISR Number: 3747628-XReport Type:Expedited (15-DaCompany Report #B0112293A
Age:45 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Balance Disorder
Initial or Prolonged	Hypoaesthesia
Other	Malaise
	Monoparesis
	Tearfulness

	Transient Ischaemic Attack						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 2 DAY

Date:06/27/01ISR Number: 3749369-1Report Type:Expedited (15-DaCompany Report #A0145968A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL
	Burning Sensation						
	Difficulty In Walking		Antidepressant	C			
	Dysphagia						
	Dyspnoea						
	Hypersensitivity						
	Oral Intake Reduced						

Date:06/27/01ISR Number: 3749726-3Report Type:Expedited (15-DaCompany Report #B0100202A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG/TWICE PER DAY/UNKNOWN
	Transient Ischaemic Attack	Health Professional					
			Aspirin	C			
			Hrt	C			

Date:06/27/01ISR Number: 3749732-9Report Type:Expedited (15-DaCompany Report #B0111851A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Fall	Foreign	Zyban	PS	Glaxo Wellcome Inc	150 MG
		Health Professional	Sildenafil Citrate Ethanol	C C		

Date:06/27/01ISR Number: 3749733-0Report Type:Expedited (15-DaCompany Report #B0111947A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block Chest Pain Dyspnoea Palpitations Pulmonary Embolism	Foreign	Zyban Zopiclone Propiomazine Carisoprodol	PS C C C	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:06/27/01ISR Number: 3749734-2Report Type:Expedited (15-DaCompany Report #B0111886A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Chest Pain Hyponatraemia	Foreign	Zyban Atenolol	PS C	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/01ISR Number: 3749735-4Report Type:Expedited (15-DaCompany Report #B0111882A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Hypoglycaemia		Co-Dydramol Tablet (Co-Dydramol)	SS				
	Intentional Misuse							
	Renal Failure Acute		Bezafibrate Tablet (Bezafibrate)	SS				
	Rhabdomyolysis		Gliclazide Tablet (Gliclazide)	SS				
			Salbutamol Sulphate	C				
			Ethanol	C				

Date:06/27/01ISR Number: 3749736-6Report Type:Expedited (15-DaCompany Report #B0111855A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cranial Nerve Disorder	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	
	Diplopia							
	Myocardial Infarction							
	Tachycardia							

Date:06/27/01ISR Number: 3749737-8Report Type:Expedited (15-DaCompany Report #B0111705A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Neurological Symptom	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
		Health Professional	Proton Pump Inhibitors	C				

Date:06/27/01ISR Number: 3749738-XReport Type:Expedited (15-DaCompany Report #B0109587A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Hypothermia Intentional Misuse Nausea Pyrexia Tachycardia Vomiting	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	

Date:06/27/01ISR Number: 3749899-2Report Type:Expedited (15-DaCompany Report #B0111954A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Coma Haemorrhagic Stroke Headache	Foreign	Zyban Salbutamol Sulphate Diclofenac	PS C C	Glaxo Wellcome Inc		150 MG/ PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/01ISR Number: 3749900-6Report Type:Expedited (15-DaCompany Report #B0111884A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Emphysema	Foreign	Bupropion					
Hospitalization - Initial or Prolonged	Joint Effusion	Consumer	Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	

Date:06/27/01ISR Number: 3749901-8Report Type:Expedited (15-DaCompany Report #B0111862A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Artery Thrombosis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	
Hospitalization - Initial or Prolonged	Ischaemic Stroke							
	Pulmonary Oedema							

Date:06/27/01ISR Number: 3749902-XReport Type:Expedited (15-DaCompany Report #B0111849A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	
	Circulatory Collapse							

Date:06/27/01ISR Number: 3749903-1Report Type:Expedited (15-DaCompany Report #B0111850A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	
		Health Professional						

Date:06/28/01ISR Number: 3748535-9Report Type:Expedited (15-DaCompany Report #A0152031A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiopathy		Wellbutrin	PS	Glaxo Wellcome	ORAL	400MG per day	4 MON
Initial or Prolonged	Convulsion		Beclovent	C	Glaxo Wellcome			
	Excessive Masturbation		Celexa	C				
	Loss Of Consciousness		Synthroid	C	Glaxo Wellcome			
	Sedation		Tetracycline	C				
	Speech Disorder		Neurontin	C				

Date:06/28/01ISR Number: 3748542-6Report Type:Expedited (15-DaCompany Report #B0110855A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abortion Induced		Zyban	PS	Glaxo Wellcome	ORAL	150MG	
Initial or Prolonged	Pregnancy						Variable dose	
	Venous Thrombosis Limb							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/01ISR Number: 3748545-1Report Type:Expedited (15-DaCompany Report #B0111869A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Variable dose	36	DAY

Date:06/28/01ISR Number: 3748546-3Report Type:Expedited (15-DaCompany Report #B0111956A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Intestinal Gangrene		Zyban	PS	Glaxo Wellcome		150MG Per day	4	DAY

Date:06/28/01ISR Number: 3748549-9Report Type:Expedited (15-DaCompany Report #B0112406A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Zyntabac	PS	Glaxo Wellcome			

Date:06/28/01ISR Number: 3748550-5Report Type:Expedited (15-DaCompany Report #B0112411A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	4	DAY
			Amlodipine	C		ORAL	10MG per day		

Date:06/29/01ISR Number: 3749418-0Report Type:Expedited (15-DaCompany Report #A0141089A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Hospitalization - Initial or Prolonged	Fall		Alcohol	SS				
	Fracture		Flovent	C	Glaxo Wellcome			
	Stupor		Serevent	C	Glaxo Wellcome			
	Suicide Attempt		Atrovent	C	Glaxo Wellcome			
	Therapeutic Agent Toxicity		Proventil	C	Glaxo Wellcome			

Date:06/29/01ISR Number: 3749424-6Report Type:Expedited (15-DaCompany Report #A0151751A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ectopic Pregnancy		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	56 DAY
	Post Procedural Complication							

Date:07/02/01ISR Number: 3750354-4Report Type:Expedited (15-DaCompany Report #B0097894A
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Disability	Asthenopia
	Condition Aggravated
	Dizziness
	Gastrointestinal

	Candidiasis						
	Insomnia						
	Pharyngolaryngeal Pain						
	Throat Tightness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Per day 15 DAY

Date:07/02/01ISR Number: 3750355-6Report Type:Expedited (15-DaCompany Report #B0100339A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxo Wellcome		3 DAY
	Headache		Atorvastatin	C			10MG per day
	Hypoaesthesia		Enalapril	C			2.5MG per day
	Lethargy						
	Loss Of Consciousness						

Date:07/02/01ISR Number: 3750362-3Report Type:Expedited (15-DaCompany Report #B0112544A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Migraine		Zyban	PS	Glaxo Wellcome		
	Subarachnoid Haemorrhage						

Date:07/02/01ISR Number: 3750364-7Report Type:Expedited (15-DaCompany Report #D0017705A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Chemical Poisoning		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Completed Suicide						per day 82 DAY
	Depression Suicidal		L-Thyroxin 125	C	Glaxo Wellcome	ORAL	125MG Per day YR

			Baymycard	C		ORAL
10MG Per day YR						

Date:07/02/01ISR Number: 3750773-6Report Type:Direct Company Report #
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest		Wellbutrin	PS		
PT TOOK						
Other						
OVERDOSE ONCE 1 DAY						
			Benadryl	C		

Date:07/02/01ISR Number: 3750997-8Report Type:Expedited (15-DaCompany Report #A0141089A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arthralgia	Health	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / PER						
Hospitalization -	Fall	Professional				
DAY / ORAL						
Initial or Prolonged	Fracture		Fluticasone			
	Intentional Misuse		Propionate	C		
	Restlessness		Salmeterol Xinafoate	C		
	Stupor		Ipratropium Bromide	C		
	Suicide Attempt		Salbutamol Sulphate	C		

Date:07/02/01ISR Number: 3751047-XReport Type:Expedited (15-DaCompany Report #B0110855A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Induced Complications Of Maternal Health Exposure To Therapeutic Drugs Venous Thrombosis Limb	Foreign Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/VARIABLE DOSE/ ORAL	

Date:07/02/01ISR Number: 3751048-1Report Type:Expedited (15-DaCompany Report #B0111956A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Gait Disturbance Intestinal Ischaemia	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		UNKNOWN	150 MG/ PER DAY

Date:07/02/01ISR Number: 3751049-3Report Type:Expedited (15-DaCompany Report #B0112406A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		UNKNOWN	150 MG

Date:07/02/01ISR Number: 3751269-8Report Type:Expedited (15-DaCompany Report #A0152031A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Angiopathy Convulsion Loss Of Consciousness Psychosexual Disorder Speech Disorder	Consumer	Wellbutrin Sr Beclomethasone Dipropion Citalopram Hydrobromide Thyroxine Sodium Tetracycline Gabapentin	PS C C C C C	Glaxo Wellcome Inc	ORAL ORAL

Date:07/02/01ISR Number: 3751398-9Report Type:Expedited (15-DaCompany Report #A0151556A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Valtrex	PS	Glaxo Wellcome Inc	ORAL
ORAL						
	Drug Interaction	Professional Company Representative	Bupropion Hydrochloride Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL
ORAL						

Date:07/02/01ISR Number: 3751432-6Report Type:Expedited (15-DaCompany Report #A0151751A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Ectopic Pregnancy Post Procedural Complication	Foreign Study Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/01ISR Number: 3751635-0Report Type:Expedited (15-DaCompany Report #B0112188A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG/PER	DAY/ORAL
	Chest Pain							
	Hyperhidrosis							
	Suicide Attempt							
	Visual Disturbance							

Date:07/02/01ISR Number: 3751639-8Report Type:Expedited (15-DaCompany Report #B0112291A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	DAY/ORAL
Hospitalization - Initial or Prolonged	Malaise							
	Renal Failure							
			Loperamide Hydrochloride	C				
			Allopurinol	C				
			Meloxicam	C				
			Salbutamol Sulphate	C				
			Temazepam	C				

Date:07/02/01ISR Number: 3751646-5Report Type:Expedited (15-DaCompany Report #B0112293A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	DAY/ORAL
	Hypoaesthesia							
Required Intervention to Prevent Permanent Impairment/Damage	Malaise							
	Tearfulness							
	Transient Ischaemic Attack							

Date:07/02/01ISR Number: 3751650-7Report Type:Expedited (15-DaCompany Report #B0112285A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Cerebellar Infarction	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG/PER DAY	

Date:07/02/01ISR Number: 3751654-4Report Type:Expedited (15-DaCompany Report #B0111950A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Panic Attack	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL	

Date:07/02/01ISR Number: 3751703-3Report Type:Expedited (15-DaCompany Report #B0109706A
Age:31 YR Gender:Female I/FU:F

Outcome
Life-Threatening Hospitalization -

Initial or Prolonged Disability Required Intervention to	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Prevent Permanent Impairment/Damage	Haemorrhagic Stroke Ruptured Cerebral Aneurysm Status Epilepticus	Foreign Health Professional Company Representative	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	6 WK

Date:07/02/01ISR Number: 3751741-0Report Type:Expedited (15-DaCompany Report #A0137061A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Sinus Tachycardia Suicide Attempt Tremor	Foreign	Wellbutrin Sr Citalopram Hydrobromide Tablet (Citalopram Hydrobromide)	PS SS	Glaxo Wellcome Inc	ORAL ORAL	ORAL	

Date:07/02/01ISR Number: 3751743-4Report Type:Expedited (15-DaCompany Report #A0149863A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dry Mouth Dry Throat Emphysema Speech Disorder	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:07/02/01ISR Number: 3751771-9Report Type:Expedited (15-DaCompany Report #B0111860A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Drug Effect Decreased Drug Interaction Pregnancy	Foreign Other	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Norethisterone (Formulation Unknown) (Norethindrone)	SS		ORAL	350 MCG / PER DAY / ORAL	
			Cabergoline	C				

Date:07/02/01ISR Number: 3751772-0Report Type:Expedited (15-DaCompany Report #B0112183A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Atorvastatin Calcium	C				
			Bendrofluazide	C				

Date:07/02/01ISR Number: 3751804-XReport Type:Expedited (15-DaCompany Report #B0112411A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Pain	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (PER DAY) ORAL
			Amlodipine	C			

Date:07/02/01ISR Number: 3751805-1Report Type:Expedited (15-DaCompany Report #B0111869A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Deep Vein Thrombosis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG (VARIABLE DOSE) ORAL

Date:07/03/01ISR Number: 3750964-4Report Type:Expedited (15-DaCompany Report #A0151572A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Phlebitis	Health Professional	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day
Other	Pulmonary Embolism		Ibuprofen	C		ORAL	800MG As required

Date:07/03/01ISR Number: 3750965-6Report Type:Expedited (15-DaCompany Report #A0152843A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Missed		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							

Date:07/03/01ISR Number: 3750975-9Report Type:Expedited (15-DaCompany Report #B0112964A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Ventricular Tachycardia		Zyban	PS	Glaxo Wellcome			

Date:07/03/01ISR Number: 3750976-0Report Type:Expedited (15-DaCompany Report #B0112965A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased Blood Bilirubin Increased Liver Function Test Abnormal Malaise Red Blood Cell Sedimentation Rate Increased		Zyban	PS	Glaxo Wellcome			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/01ISR Number: 3751488-0Report Type:Expedited (15-DaCompany Report #A0153272A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block		Wellbutrin	PS	Glaxo Wellcome	ORAL	75MG Twice	
	Complete						per day	
	Bundle Branch Block Right		Relafen	SS	Glaxo Wellcome	ORAL	500MG Twice	
	Drug Interaction						per day	14 DAY
	Heart Rate Irregular							
	Medication Error							
	Ventricular Extrasystoles							

Date:07/05/01ISR Number: 3751514-9Report Type:Expedited (15-DaCompany Report #B0113104A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Condition Aggravated						per day	42 DAY
	Headache		Tylex	C		ORAL		
	Palpitations		Hydroxyzine	C		ORAL	100MG per day	

Date:07/05/01ISR Number: 3751515-0Report Type:Expedited (15-DaCompany Report #B0113105A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	7 DAY
	Insomnia		Diclofenac	C		ORAL	75MG Per day	
			Kliofem	C		ORAL		
			Omeprazole	C		ORAL	20MG Per day	

Date:07/05/01ISR Number: 3752859-9Report Type:Expedited (15-DaCompany Report #A0151572A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150MG (TWICE PER DAY) ORAL	
Other	Phlebitis							
	Pulmonary Embolism	Company Representative	Ibuprofen	C				

Date:07/05/01ISR Number: 3753414-7Report Type:Periodic Company Report #254104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Alkaline Phosphatase Increased	Consumer	Clonopin	PS	Hoffmann La Roche Inc	ORAL	1 MG 3 PER DAY ORAL	3653 DAY
	Gamma-Glutamyltransferase Increased		Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	1MG 3PER DAY ORAL	

Date:07/05/01ISR Number: 3753490-1Report Type:Expedited (15-DaCompany Report #EMADSS2001003946
Age:33 YR Gender:Female I/FU:I

Outcome	PT
Other	Drug Interaction
	Pregnancy On Oral

Contraceptive

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Micronor	PS	Rw Johnson Pharmaceutical Research Institute Div Ortho Pharm	ORAL
350 MCG, DAILY, ORAL							
				Zyban (Amfebutamone Hydrochloride)	SS		ORAL
150 MG, 2 IN 1 DAILY, ORAL							
				Dostinex	C		

Date:07/05/01ISR Number: 3753534-7Report Type:Expedited (15-DaCompany Report #A0152843A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Missed Blighted Ovum Complications Of Maternal Exposure To Therapeutic Drugs	Foreign Study Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY / ORAL						

Date:07/05/01ISR Number: 3753629-8Report Type:Expedited (15-DaCompany Report #B0112964A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Ventricular Tachycardia	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	
150 MG						

Date:07/05/01ISR Number: 3753630-4Report Type:Expedited (15-DaCompany Report #B0112965A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
	Blood Bilirubin Increased							
	Malaise							
	Red Blood Cell Sedimentation Rate Increased							

Date:07/06/01ISR Number: 3753122-2Report Type:Expedited (15-DaCompany Report #A0149363A
Age:14 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Attention Deficit/Hyperactivity Disorder
Other	Blood Pressure Increased
	Condition Aggravated
	Drug Ineffective
	Electroencephalogram Abnormal
	Grand Mal Convulsion
	Hallucination

		Intentional Misuse Irritability Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Memory Impairment	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Twice							
		Sedation	Professional				
per day							
		Tachycardia		Wellbutrin	SS	Glaxo Wellcome	
				Tylenol	SS		
				Imodium	SS		
				Paxil	C	Glaxo Wellcome	ORAL
10MG Per day							
				Tetracycline	C		
				Retin-A	C		
TOPICAL							

Date:07/06/01ISR Number: 3753129-5Report Type:Expedited (15-DaCompany Report #B0107040A
Age:48 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Choking	Health	Zyban	PS	Glaxo Wellcome	ORAL
		Coronary Artery Disease	Professional	Nitrazepam	C		ORAL
5MG At night							
		Cyanosis		Meptazinol	C		ORAL
200MG As							
		Loss Of Consciousness					
required							
		Myocardial Infarction		Salbutamol	C	Glaxo Wellcome	
RESPIRATORY							
(INHALATION)	200MCG As						
required							

Date:07/06/01ISR Number: 3753935-7Report Type:Expedited (15-DaCompany Report #2001011567-1
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Atrioventricular Block	Health	Relafen	PS	Smithkline Beecham	

	Complete	Professional			Pharmaceuticals	ORAL

500

Ventricular Arrhythmia

MILLIGRAMS

1.0 AS NEEDED

ORAL 14 DAY

	Wellbutrin (Amfebutamone Hydrochloride)	SS	ORAL

75 MILLIGRAMS

2.0 DAILY

ORAL

Date:07/06/01ISR Number: 3754397-6Report Type:Expedited (15-DaCompany Report #D0017705A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Foreign	Bupropion			
	Depression Suicidal	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
150 MG /		Professional				
TWICE PER DAY						
/ ORAL						
			Thyroxine Sodium	C		
			Nisoldipine	C		

Date:07/06/01ISR Number: 3754398-8Report Type:Expedited (15-DaCompany Report #B0112544A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Migraine	Foreign	Bupropion			
	Subarachnoid Haemorrhage	Health	Hydrochloride	PS	Glaxo Wellcome Inc	
		Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/01ISR Number: 3754400-3Report Type:Expedited (15-DaCompany Report #B0097894A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenopia	Foreign	Bupropion					
	Discomfort	Study	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Dizziness	Health					DAY / ORAL	
	Gastrointestinal	Professional						
	Candidiasis							
	Insomnia							
	Oral Candidiasis							
	Throat Tightness							

Date:07/06/01ISR Number: 3754401-5Report Type:Expedited (15-DaCompany Report #B0100339A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Foreign	Bupropion					
Initial or Prolonged	Asthenia	Health	Hydrochloride	PS	Glaxo Wellcome Inc		AS DIRECTED	
	Fall	Professional	Atorvastatin Calcium	C				
	Headache		Enalapril	C				
	Hyperventilation							
	Lethargy							
	Loss Of Consciousness							
	Malaise							
	Movement Disorder							
	Paraesthesia							
	Syncope							
	Tremor							
	Vision Blurred							

Date:07/09/01ISR Number: 3753829-7Report Type:Expedited (15-DaCompany Report #A0153280A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alcoholism		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	

Initial or Prolonged	Amnesia						
per day 1 YR							
	Drug Abuser		Ethanol	SS			
	Grand Mal Convulsion		No Concurrent				
	Medication Error		Medication	C			
	Toxicologic Test Abnormal						

Date:07/09/01ISR Number: 3753830-3Report Type:Expedited (15-DaCompany Report #B0099253A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	C-Reactive Protein		Zyban	PS	Glaxo Wellcome	ORAL		
							11	DAY
Hospitalization -	Increased		Oral Contraceptive	C		ORAL		
Initial or Prolonged	Cerebrovascular Accident							
Disability	Precerebral Artery							
	Occlusion							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/01ISR Number: 3753834-0Report Type:Expedited (15-DaCompany Report #B0113284A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome			
	Overdose							
	Sudden Death							

Date:07/09/01ISR Number: 3753835-2Report Type:Expedited (15-DaCompany Report #B0113566A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	35 DAY
			Aspirin	C		ORAL	150MG Per day	
			Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG Per day	
			Amlodipine	C		ORAL	10MG Per day	
			Simvastatin	C		ORAL	10MG At night	
			Enalapril	C		ORAL	10MG At night	

Date:07/09/01ISR Number: 3753836-4Report Type:Expedited (15-DaCompany Report #B0113572A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	28 DAY
			Simvastatin	C		ORAL	10MG Per day	
			Amlodipine	C		ORAL	5MG per day	
			Indomethacin	C		ORAL	50MG per day	

Date:07/09/01ISR Number: 3753837-6Report Type:Expedited (15-DaCompany Report #D0018145A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Zyban	PS	Glaxo Wellcome	ORAL		
	Hypertension		Diclofenac	C				
							UNKNOWN	

Date:07/09/01ISR Number: 3754727-5Report Type:Expedited (15-DaCompany Report #A0149363A
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Initial or Prolonged	Disturbance In Attention	Professional					TWICE PER	
Required	Drug Ineffective						DAY/ ORAL	
Intervention to	Electroencephalogram		Wellbutrin Tablet					
Prevent Permanent	Abnormal		(Bupropion					
Impairment/Damage	Grand Mal Convulsion		Hydrochloride)	SS				
	Hallucination		Paracetamol					
	Intentional Misuse		(Formulation					
	Irritability		Unknown)					
	Memory Impairment		(Acetaminophen)	SS				
	Sedation		Loperamide					
	Tachycardia		Hydrochloride Tablet	SS				
			Paroxetine					
			Hydrochloride	C				
			Tetracycline	C				
			Tretinoin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/01ISR Number: 3754815-3Report Type:Expedited (15-DaCompany Report #A0153272A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	75 MG/TWICE	
	Complete	Professional					PER DAY/ORAL	
	Bundle Branch Block		Nabumetone (					
	Bilateral		Nabumetone)	SS		ORAL	500 MG/TWICE	
	Drug Interaction						PER DAY/ORAL	
	Ventricular Extrasystoles							

Date:07/09/01ISR Number: 3754868-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour		Zoloft 100 Mgs					
Disability	Alcoholism		Roerig, J.B.	PS	Roerig, J.B.	ORAL	2 PER DAY	
	Delinquency						ORAL	
	Drug Abuser		Wellbutrin 150 Mgs					
	Imprisonment		Glaxo Well	SS	Glaxo Well	ORAL	1 PER DAY	
	Obsessive-Compulsive						ORAL	
	Disorder							
	Paraphilia							
	Suicide Attempt							
	Theft							
	Thinking Abnormal							

Date:07/09/01ISR Number: 3754914-6Report Type:Expedited (15-DaCompany Report #2001058760US
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Headache	Health	Solu-Medrol	PS	Pharmacia And Upjohn			

Initial or Prolonged	Pruritus	Professional			Co	
INTRAVENOUS 125 MG, QID,						
Other	Urticaria					
IV						
			Hydroxyzine	SS		ORAL
ORAL						
			Prednisone	SS		ORAL
ORAL						
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL
150 MG, BID						
ORAL						
			Ortho Tri-Cyclen	C		
			Propranolol	C		

Date:07/09/01ISR Number: 3755450-3Report Type:Expedited (15-DaCompany Report #B0107040A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Choking	Foreign	Bupropion			
	Coronary Artery Disease	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
ORAL						
	Cyanosis	Professional	Nitrazepam	C		
	Loss Of Consciousness		Meptazinol	C		
	Myocardial Infarction		Salbutamol Sulphate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/01ISR Number: 3755531-4Report Type:Expedited (15-DaCompany Report #B0113104A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL
	Condition Aggravated						
	Headache		Tylex	C			
	Palpitations		Hydroxyzine	C			

Date:07/09/01ISR Number: 3755533-8Report Type:Expedited (15-DaCompany Report #B0113105A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Arthritis	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	300 MG/ PER DAY/ ORAL
	Insomnia						
			Diclofenac	C			
			Kliofem	C			
			Omeprazole	C			

Date:07/10/01ISR Number: 3754634-8Report Type:Expedited (15-DaCompany Report #A0152291A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Twice per day 265 DAY
	Increased						
	Cholelithiasis		Orthotricyclen	C		ORAL	1TAB Per day
	Weight Decreased						

Date:07/10/01ISR Number: 3754642-7Report Type:Expedited (15-DaCompany Report #B0111329A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyntabac	PS	Glaxo Wellcome	ORAL		

Date:07/10/01ISR Number: 3754645-2Report Type:Expedited (15-DaCompany Report #B0112964A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Ventricular Tachycardia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	19 DAY

Date:07/10/01ISR Number: 3754649-XReport Type:Expedited (15-DaCompany Report #B0113567A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety Dizziness Panic Attack		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	5 DAY

Date:07/10/01ISR Number: 3754651-8Report Type:Expedited (15-DaCompany Report #D0018424A
Age:60 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged Other	Atrophy Convulsion Delirium

	Malaise					
	Nervous System Disorder					
		Report Source	Product	Role	Manufacturer	Route
Dose Duration						
			Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 1 DAY						
			Hormone-Plaster	SS		
UNKNOWN						

Date:07/10/01ISR Number: 3756647-9Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Blood Pressure Increased	Consumer	Zoloft Tablets	PS	Pfizer	
Intervention to	Drug Ineffective				Pharmaceuticals Inc	
50.00 MG						
Prevent Permanent	Ecchymosis					
TOTAL:DAILY						
Impairment/Damage	Fall		Wellbutrin	SS		ORAL
300.00 MG						
	Haemorrhagic Stroke					
TOTAL:BID:ORA						
	Head Injury					
L						
	Headache		Coumadin	SS		
	Heart Rate Decreased		Effexor Sr	SS		ORAL
300.00 MG						
	Heart Rate Increased					
TOTAL:BID:ORA						
	Hyperhidrosis					
L						
	Medication Error		Toprol	C		
	Overdose		Zebeta	C		
	Syncope		Lanoxin	C		
			Lasix	C		
			Synthroid	C		
			Vitamin E	C		
			Estrogen	C		

Date:07/11/01ISR Number: 3755614-9Report Type:Expedited (15-DaCompany Report #263690
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Xenical	PS	Roche			
	Bone Disorder		Didronel	C			WITH MEALS	181 DAY
	Bone Pain		Estrace	C				
	Condition Aggravated		Zestril	C				
	Drug Ineffective		Naprosyn Ec	I	Roche			
	Drug Interaction		Keflex	I				
	Food Craving		Ceftin	I				
	Haemophilus Infection		Augmentin	I				
	Hypoaesthesia		Wellbutrin	I				
	Neuralgia							
	Osteomyelitis							
	Osteonecrosis							
	Pain In Jaw							
	Poor Peripheral Circulation							

Date:07/11/01ISR Number: 3755628-9Report Type:Expedited (15-DaCompany Report #A0153345A
Age:31 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Complications Of Maternal Exposure To Therapeutic Drugs
	Premature Baby
	Premature Labour
	Premature Rupture Of

Membranes

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Bupropion	PS	Glaxo Wellcome	ORAL	250MG per day	139 DAY

Date:07/11/01ISR Number: 3755633-2Report Type:Expedited (15-DaCompany Report #B0110444A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	7	DAY
Hospitalization - RESPIRATORY	Coma		Fluticasone	C	Glaxo Wellcome			
Initial or Prolonged	Malaise							
(INHALATION)	Nausea		Salmeterol	C	Glaxo Wellcome			
RESPIRATORY	Pulmonary Embolism							
(INHALATION)	Syncope		Beclomethasone	C	Glaxo Wellcome			
RESPIRATORY								
(INHALATION)							6PUFF per day	
			Salbutamol	C	Glaxo Wellcome			
RESPIRATORY								
(INHALATION)							100UG Six	
times per day								
			Spironolactone	C		ORAL		
			Losartan	C		ORAL	75MG Twice	
per day								
			Frusemide	C		ORAL		

Date:07/11/01ISR Number: 3755643-5Report Type:Expedited (15-DaCompany Report #B0113169A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Decreased Appetite		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Dry Throat						per day	
Initial or Prolonged	Dyspnoea							
	Oedema Peripheral							
	Retching							

Date:07/11/01ISR Number: 3755644-7Report Type:Expedited (15-DaCompany Report #B0113282A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Malaise		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY
	Myocardial Infarction							

Date:07/11/01ISR Number: 3756507-3Report Type:Expedited (15-DaCompany Report #TEST00201002994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Androgel	PS	Unimed			
	Dermatitis	Professional			Pharmaceuticals Inc		5 G QD TD	
	Serum Sickness	Company	Wellbutrin					
	Urticaria	Representative	(Amfebutamone					
			Hydrochloride)	SS		ORAL	DAILY PO	
			Growth Hormone					
			(Human Growth					
			Hormone,					
			Recombinant)	C				
			Steroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/01ISR Number: 3756349-9Report Type:Expedited (15-DaCompany Report #B0100762A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL	22	DAY
Hospitalization -	Coma		Brufen	SS		ORAL	9.6G	Single
Initial or Prolonged	Confusional State							
dose								
Other	Coordination Abnormal		Alcohol	SS		ORAL		
	Disorientation		Alcohol	C				
	Grand Mal Convulsion		Cannabis	C				
	Headache							
	Loss Of Consciousness							
	Overdose							
	Suicide Attempt							

Date:07/12/01ISR Number: 3756351-7Report Type:Expedited (15-DaCompany Report #B0104336A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Per day
			Salbutamol	C	Glaxo Wellcome			
RESPIRATORY								
(INHALATION)								

Date:07/12/01ISR Number: 3756353-0Report Type:Expedited (15-DaCompany Report #B0109122A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase	Health	Zyntabac	PS	Glaxo Wellcome	ORAL	150MG	Per day 3 DAY
	Increased	Professional						
	Alpha 1 Foetoprotein							
	Increased							
	Aspartate							
	Aminotransferase							

	Increased					
	Carcinoembryonic Antigen Increased					
	Gamma-Glutamyltransferase Increased					

Date:07/12/01ISR Number: 3756355-4Report Type:Expedited (15-DaCompany Report #B0111855A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Lactate Dehydrogenase Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	7 WK
Other	Cardiac Disorder		Citalopram	C			20MG Per day	
	Cranial Nerve Disorder		Thiamine	C			300MG Per day	
	Diplopia		Alprazolam	C			.25MG Twice per day	
	Hypercholesterolaemia							
	Myocardial Infarction		Fluticasone	C	Glaxo Wellcome		2U Per day	
	Nystagmus		Salmeterol	C	Glaxo Wellcome		2U Per day	
	Pulmonary Function Test Decreased							
	Supraventricular Extrasystoles							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/01ISR Number: 3756363-3Report Type:Expedited (15-DaCompany Report #B0113725A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	5 DAY
	Pericardial Effusion							

Date:07/12/01ISR Number: 3756364-5Report Type:Expedited (15-DaCompany Report #B0114026A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fracture		Zyban	PS	Glaxo Wellcome		150MG As directed	
	Insomnia							
	Palpitations							
	Tremor							

Date:07/12/01ISR Number: 3757002-8Report Type:Expedited (15-DaCompany Report #A0152291A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased	Study Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE PER DAY) ORAL	
	Cholelithiasis	Professional	Ortho Tri-Cyclen	C				
	Weight Decreased							

Date:07/12/01ISR Number: 3757004-1Report Type:Expedited (15-DaCompany Report #A0153280A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG (TWICE	

Initial or Prolonged | Grand Mal Convulsion | Professional
PER DAY) ORAL

	Intentional Misuse	Company	Ethanol (Alcohol)	SS
	Suicide Attempt	Representative		
	Toxicologic Test Abnormal			

Date:07/12/01ISR Number: 3757029-6Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hearing Impaired		Zyban (150mg)	PS		
150MG BID 1 MON						
	Hypoaesthesia					

Date:07/12/01ISR Number: 3757179-4Report Type:Expedited (15-DaCompany Report #B0113572A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Atrial Fibrillation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG TWICE						
PER DAY ORAL						
			Simvastatin	C		
			Amlodipine	C		
			Indomethacin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/01ISR Number: 3757180-0Report Type:Expedited (15-DaCompany Report #B0113566A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG PER	DAY ORAL
			Aspirin	C				
			Bendrofluazide	C				
			Amlodipine	C				
			Simvastatin	C				
			Enalapril	C				

Date:07/12/01ISR Number: 3757181-2Report Type:Expedited (15-DaCompany Report #D0018145A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Hypertension		Diclofenac	C				

Date:07/12/01ISR Number: 3757182-4Report Type:Expedited (15-DaCompany Report #B0099253A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	C-Reactive Protein	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
Hospitalization - Initial or Prolonged	Increased	Health Professional	Oral Contraceptive	C				
Disability	Carotid Artery Stenosis							
	Cerebrovascular Accident							
	Precerebral Artery Occlusion							
	Urticaria							

Date:07/12/01ISR Number: 3757189-7Report Type:Expedited (15-DaCompany Report #B0113284A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease Overdose Sudden Death	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc			

Date:07/12/01ISR Number: 3757190-3Report Type:Expedited (15-DaCompany Report #B0113567A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety Dizziness Panic Attack	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:07/12/01ISR Number: 3757192-7Report Type:Expedited (15-DaCompany Report #D0018424A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cerebral Atrophy Convulsion Delirium Malaise	Foreign Health Professional	Zyban Hormones (Formulation Unknown)	PS SS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL	1 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/01ISR Number: 3757224-6Report Type:Expedited (15-DaCompany Report #B0111329A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Myocardial Infarction	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL

Date:07/12/01ISR Number: 3757225-8Report Type:Expedited (15-DaCompany Report #B0112964A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Ventricular Tachycardia	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL

Date:07/12/01ISR Number: 3757414-2Report Type:Expedited (15-DaCompany Report #A0152528A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Angina Pectoris Hypokalaemia Myocardial Infarction Myocardial Ischaemia Respiratory Alkalosis Tachypnoea	Foreign Literature Health Professional	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL 3 DAY
			Pseudoephedrine (Formulation Unknown) (Pseudoephedrine)	SS			
			Erythromycin (Formulation Unknown) (Erythromycin)	SS			
			Nicotine (Formulation Unknown) (Nicotine)	SS			

Date:07/13/01ISR Number: 3757131-9Report Type:Direct Company Report #
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Zyban 150mg					
			Catalytica/Glaxo Wellcome	PS	Catalytica/Glaxo Wellcome	ORAL	150MG BID	
			Glucophage	C			ORAL	
			Isordil	C				
			Nicoderm	C				
			Micronase	C				

Date:07/13/01ISR Number: 3757330-6Report Type:Expedited (15-DaCompany Report #A0138561A
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alcoholism
	Cognitive Disorder
Disability	Dementia
Other	Disturbance In Attention
	Injury
	Memory Impairment

	Road Traffic Accident						
	Sleep Apnoea Syndrome						
	Social Avoidant Behaviour	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day
			Alcohol	SS			
			Celexa	C		ORAL	20MG Per day

Date:07/13/01ISR Number: 3757331-8Report Type:Expedited (15-DaCompany Report #A0149272A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Haemoptysis		Zyban	PS	Glaxo Wellcome	ORAL	71 DAY
	Lung Disorder		Prevacid	C			
	Neoplasm		Estrogel	C		TOPICAL	

Date:07/13/01ISR Number: 3758668-9Report Type:Expedited (15-DaCompany Report #B0113282A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Malaise	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER
	Myocardial Infarction	Literature					DAY/ ORAL

Date:07/13/01ISR Number: 3758671-9Report Type:Expedited (15-DaCompany Report #B0113169A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Decreased Appetite	Foreign	Bupropion				
Hospitalization -	Dry Throat	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE

Initial or Prolonged	Dyspnoea	Professional				
PER DAY/ ORAL						
	Oedema Peripheral					
	Retching					

Date:07/13/01ISR Number: 3758753-1Report Type:Expedited (15-DaCompany Report #263690
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abnormal Dreams	Consumer	Xenical	PS	Hlr Technology	ORAL	120 MG 3 PER
	Angiopathy						DAY ORAL
	Bone Pain		Naprosyn Ec				
	Condition Aggravated		(Naproxen)	SS		ORAL	1 PER PRN
	Drug Ineffective						ORAL
	Drug Interaction		Keflex (Cephalexin)	SS		ORAL	4 GRAM DAILY
	Food Craving						ORAL
	Haemophilus Infection		Ceftin (Cefuroxime				
	Hypoaesthesia		Axetil)	SS		ORAL	ORAL
	Osteomyelitis		Augmentin				
	Osteonecrosis		(*Amoxicillin/*Amoxi				
	Pain In Jaw		cillin				
			Sodium/*Clavulanate				
			Potassium)	SS		ORAL	375MG 3 PER
							DAY ORAL
			Wellbutrin				
			(Bupropion				
			Hydrochloride)	SS		ORAL	ORAL
			Zestril (Lisinopril)	C			
			Didronel (Etidronate				

				Disodium)	C		
				Estrace (Estradiol)	C		

Date:07/13/01ISR Number: 3758804-4Report Type:Expedited (15-DaCompany Report #HQ3100411JUL2001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Complications Of Maternal Exposure To Therapeutic Drugs Convulsion Neonatal	Health Professional	Effexor	PS	Wyeth Ayerst Laboratories	ORAL	ORAL
			Remeron (Mirtazapine)	SS		ORAL	
			Wellbutrin	SS		ORAL	

Date:07/13/01ISR Number: 3758905-0Report Type:Expedited (15-DaCompany Report #B0110444A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged	Arrhythmia Coma Malaise Nausea Pulmonary Embolism Syncope	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL
			Fluticasone Propionate	C			
			Salmeterol Xinafoate	C			
			Beclomethasone Dipropion	C			
			Salbutamol Sulphate	C			
			Spironolactone	C			
			Losartan Potassium	C			
			Frusemide	C			

Date:07/13/01ISR Number: 3758940-2Report Type:Expedited (15-DaCompany Report #A0153345A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Complications Of Maternal	Foreign	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	TWICE PER

Initial or Prolonged	Exposure To Therapeutic	Study					
DAY/ ORAL							
	Drugs	Health					
	Pregnancy	Professional					
	Premature Baby						
	Premature Rupture Of Membranes						

Date:07/16/01ISR Number: 3758460-5Report Type:Expedited (15-DaCompany Report #B0111853A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Thrombosis		Zyban	PS	Glaxo Wellcome		150MG Twice	
Initial or Prolonged	Cerebrovascular Accident							
per day							16	WK
Disability	Supraventricular		Alprazolam	C		ORAL		
	Extrasystoles		Sertraline	C				
	Ventricular Extrasystoles		Premelle	C		ORAL		
	Ventricular Hypertrophy		Alcohol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/01ISR Number: 3758465-4Report Type:Expedited (15-DaCompany Report #B0114027A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
Other	Benign Breast Neoplasm						per day
	Emotional Disorder		Mebeverine	C		ORAL	

Date:07/16/01ISR Number: 3758466-6Report Type:Expedited (15-DaCompany Report #B0114185A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome		
	Dementia						
	Mental Disorder						

Date:07/16/01ISR Number: 3759442-XReport Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased	Consumer	Zoloft	PS	Pfizer Pharmaceuticals Inc		50.00 MG TOTAL:DAILY
	Blood Thyroid Stimulating Hormone Decreased						
	Drug Ineffective		Wellbutrin	SS		ORAL	300.000 MG TOTAL:BID:ORA
	Ecchymosis						
	Epistaxis						L
	Fall		Coumadin	SS			
	Haemorrhagic Stroke		Effexor Sr	SS		ORAL	300.00
	Head Injury						TOTAL:BID:ORA
	Headache						L

	Heart Rate Decreased		Toprol	C
	Heart Rate Increased		Zebeta	C
	Hyperhidrosis		Lanoxin	C
	Medication Error		Lasix	C
	Mood Swings		Synthroid	C
	Movement Disorder		Vitamin E	C
	Overdose		Estrogen	C
	Parkinson'S Disease			
	Staring			
	Syncope			
	Thyroid Function Test Abnormal			

Date:07/16/01ISR Number: 3759478-9Report Type:Expedited (15-DaCompany Report #A0149272A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemoptysis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Lung Disorder	Health						
	Neoplasm	Professional	Lansoprazole	C				
			Oestradiol	C				

Date:07/16/01ISR Number: 3759788-5Report Type:Direct Company Report #
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Pruritic		Zyban 150mg Catalytica/Glaxowell					

			come	PS	Catalytica/Glaxowell come	ORAL
150 MG / BID/						
ORAL						
			Nicoderm	C		

Date:07/16/01ISR Number: 3759829-5Report Type:Expedited (15-DaCompany Report #A0138561A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Alcoholism Dementia Memory Impairment Personality Change Road Traffic Accident Sleep Apnoea Syndrome Social Avoidant Behaviour Spinal Cord Injury	Health Professional Company Representative	Wellbutrin Sr Ethanol (Formulation Unknown) (Alcohol) Citalopram Hydrobromide	PS SS C	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY ORAL

Date:07/16/01ISR Number: 3760012-8Report Type:Expedited (15-DaCompany Report #B0113725A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Hepatitis Pericardial Effusion	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY / ORAL

Date:07/16/01ISR Number: 3760028-1Report Type:Expedited (15-DaCompany Report #B0100762A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Amnesia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL
Hospitalization -	Confusional State	Literature	Ibuprofen Otc Tablet	SS		ORAL	9.6 G/SINGLE

Initial or Prolonged	Coordination Abnormal	Health			
DOSE/ORAL					
Required	Disorientation	Professional	Ethanol(Formulation		
Intervention to	Grand Mal Convulsion		Unknown) (Alcohol)	SS	ORAL
ORAL					
Prevent Permanent	Headache		Cannabis	C	
Impairment/Damage	Intentional Misuse		Ethanol	C	
	Loss Of Consciousness				
	Suicide Attempt				

Date:07/16/01ISR Number: 3760032-3Report Type:Expedited (15-DaCompany Report #B0111855A
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angiopathy
Initial or Prolonged	Arterial Stenosis
Required	Blood Lactate
Intervention to	Dehydrogenase Increased
Prevent Permanent	Cardiomyopathy
Impairment/Damage	Diplopia
	Echography Abnormal
	Electrocardiogram
	Ambulatory Abnormal
	Electrocardiogram Q Waves
	Electrocardiogram St
	Segment Elevation
	Eye Disorder
	Hypercholesterolaemia
	Hypokinesia

		Myocardial Infarction					
		Myocardial Ischaemia					
		Nystagmus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Function Test	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/TWICE							
		Abnormal	Health				
PER DAY/ORAL							
		Supraventricular	Professional	Citalopram	C		
		Extrasystoles		Thiamine	C		
		Tachycardia		Alprazolam	C		
		Vith Nerve Paralysis		Fluticasone			
				Propionate	C		
				Salmeterol Xinafoate	C		

Date:07/16/01ISR Number: 3760034-7Report Type:Expedited (15-DaCompany Report #B0109122A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Alanine Aminotransferase	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/PER						
	Increased	Health				
DAY/ORAL						
	Alpha 1 Foetoprotein	Professional				
	Increased					
	Aspartate					
	Aminotransferase					
	Increased					
	Gamma-Glutamyltransferase					
	Increased					
	Hepatitis A					
	Liver Function Test					
	Abnormal					

Date:07/16/01ISR Number: 3760077-3Report Type:Expedited (15-DaCompany Report #B0104336A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Completed Suicide	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / PER						

		Health				
DAY / ORAL						
		Professional	Salbutamol Sulphate	C		

Date:07/16/01ISR Number: 3760625-3Report Type:Expedited (15-DaCompany Report #B0114026A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Fracture	Foreign	Zyban	PS	Glaxo Wellcome Inc	
150 MG / AS						
Initial or Prolonged	Insomnia	Health				
DIRECTED						
	Palpitations	Professional				
	Surgery					
	Tremor					

Date:07/17/01ISR Number: 3759265-1Report Type:Expedited (15-DaCompany Report #A0154036A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Wellbutrin	PS	Glaxo Wellcome	ORAL
			Paxil	SS	Glaxo Wellcome	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/01ISR Number: 3759267-5Report Type:Expedited (15-DaCompany Report #A0154344A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	300MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							

Date:07/17/01ISR Number: 3759803-9Report Type:Direct Company Report #
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blepharospasm		Burproprion (75mg)	PS		ORAL	75MG Q AM PO	
	Muscle Spasms							

Date:07/17/01ISR Number: 3760205-XReport Type:Periodic Company Report #HQ2500719OCT2000
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria	Consumer	Advil	PS	Whitehall Laboratories Inc Div American Home Products Corp	ORAL	THREE TO SIX TABLETS ONCE	DAILY, ORAL
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	150 MG 1X PER	1 DAY, ORAL
			Unspecified Estrogen Replacement Therapy (Unspecified					

			Estrogen Replacement Therapy)	C		
			Atarax (Hydroxyzine Hydrochloride)	C		

Date:07/18/01ISR Number: 3760399-6Report Type:Expedited (15-DaCompany Report #A0154486A
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 3 MON	Brain Neoplasm Benign		Wellbutrin	PS	Glaxo Wellcome	ORAL	
Initial or Prolonged	Depression Psychotic Disorder		Procardia	C			

Date:07/19/01ISR Number: 3761213-5Report Type:Expedited (15-DaCompany Report #B0094547A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/01ISR Number: 3761705-9Report Type:Expedited (15-DaCompany Report #A0154344A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER	
	Complications Of Maternal	Health					DAY / ORAL	
	Exposure To Therapeutic Drugs	Professional						

Date:07/19/01ISR Number: 3761852-1Report Type:Expedited (15-DaCompany Report #A0154036A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
		Consumer	Paroxetine Hydrochloried (Paroxetiene Hydrochloride)	SS		ORAL	ORAL	

Date:07/20/01ISR Number: 3762278-7Report Type:Direct Company Report #
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Relafin 200mg	PS		ORAL	2, 2 ORAL	
	Anxiety		Wellbutrin Sr 150 Mg					
	Cough		Catalytica	SS		ORAL	1 /2/ ORAL	
	Diarrhoea							
	Dry Skin							
	Flushing							
	Insomnia							
	Movement Disorder							
	Oedema Peripheral							
	Saliva Altered							

Date:07/20/01ISR Number: 3762405-1Report Type:Expedited (15-DaCompany Report #A0154486A
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Brain Neoplasm Benign Depression Psychotic Disorder	Consumer	Wellbutrin Nifedipine	PS C	Glaxo Wellcome Inc	ORAL ORAL		

Date:07/23/01ISR Number: 3762477-4Report Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Agitation Agoraphobia Alopecia Anaphylactic Shock Anuria Autonomic Nervous System Imbalance Back Pain Balance Disorder Bipolar Disorder Blood Cholesterol

Increased Blood Glucose Increased Blood Pressure Fluctuation		Report Source	Product	Role	Manufacturer	Route	Dose Duration
Blood Pressure Increased			Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 12 DAY
Bradycardia			Premarin	C			1.25MG Per day
Cognitive Disorder							
Convulsion			Vitamin	C			
Cystocele			Asa	C			
Delusion			Melatonin	C			
Depersonalisation							
Disorientation							
Disturbance In Attention							
Drug Hypersensitivity							
Dyspepsia							
Dyspnoea							
Dysthymic Disorder							
Dysuria							
Fatigue							
Haematuria							
Hallucination, Auditory							
Hallucination, Olfactory							
Hyperventilation							
Hypomania							
Intervertebral Disc Degeneration							
Labile Blood Pressure							
Mania							
Memory Impairment							
Mental Impairment							
Micturition Urgency							
Mitral Valve Incompetence							
Mood Swings							
Obsessive-Compulsive Disorder							
Oedema							
Palpitations							
Paranoia							
Psychomotor Hyperactivity							
Renal Disorder							
Renal Impairment							
Sciatica							
Speech Disorder							
Spinal Osteoarthritis							

Tachycardia
Tinnitus
Transient Ischaemic
Attack
Urethral Stricture
Urinary Incontinence
Ventricular Extrasystoles
Weight Increased

Date:07/23/01ISR Number: 3762479-8Report Type:Expedited (15-DaCompany Report #A0144968A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Ulcer		Aspirin	SS				
			Coumadin	C	Glaxo Wellcome			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/01ISR Number: 3762480-4Report Type:Expedited (15-DaCompany Report #A0150198A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	2 DAY
			Clonidine	C				
			Estradiol	C				
			Aspirin	C				

Date:07/23/01ISR Number: 3762490-7Report Type:Expedited (15-DaCompany Report #B0112965A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased		Zyban	PS	Glaxo Wellcome			
	Arthralgia							
	Blood Bilirubin Increased							
	Jaundice							
	Lethargy							
	Malaise							
	Myalgia							
	Red Blood Cell Sedimentation Rate Increased							

Date:07/23/01ISR Number: 3762493-2Report Type:Expedited (15-DaCompany Report #B0113971A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Per day	
			Dihydrocodeine	C		ORAL		
			Prothiaden	C				UNKNOWN
			Imipramine	C				UNKNOWN

Date:07/23/01ISR Number: 3762498-1Report Type:Expedited (15-DaCompany Report #B0114445A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking		Zyban	PS	Glaxo Wellcome		64	DAY
	Dyspnoea							
	Fatigue							
	Feeling Abnormal							
	Headache							
	Insomnia							
	Pain In Extremity							
	Paralysis							
	Polymyalgia Rheumatica							
	Sedation							
	Tremor							

Date:07/23/01ISR Number: 3762499-3Report Type:Expedited (15-DaCompany Report #B0114486A
Age:66 YR Gender:Female I/FU:I

Outcome	PT
Disability	Abdominal Pain Upper
Other	Blister
	Feeling Hot
	Headache

	Hyperhidrosis						
	Nausea						
	Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tremor		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 13 DAY
			Thyroxine	C	Glaxo Wellcome	ORAL	
			Mebeverine	C		ORAL	135MG Three times per day

Date:07/23/01ISR Number: 3762500-7Report Type:Expedited (15-DaCompany Report #B0114491A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Duodenal Ulcer		Zyban	PS	Glaxo Wellcome	ORAL	
	Perforation		Trimipramine	C			UNKNOWN
			Theophylline	C			UNKNOWN
			Aspirin	C		ORAL	

Date:07/23/01ISR Number: 3762502-0Report Type:Expedited (15-DaCompany Report #B0114651A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Myocardial Ischaemia		Zyban	PS	Glaxo Wellcome	ORAL	
	Sudden Death						

Date:07/23/01ISR Number: 3762503-2Report Type:Expedited (15-DaCompany Report #B0114664A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Anorexia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Diplopia						per day 11 DAY

	Hyperhidrosis		Paludrine	SS		ORAL
100MG Per day 6 DAY						
	Nausea					
	Palpitations					
	Vision Blurred					

Date:07/23/01ISR Number: 3763712-9Report Type:Expedited (15-DaCompany Report #EMADSS2001003946
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Interaction	Foreign	Micronor	PS	Rw Johnson	
	Unintended Pregnancy	Health			Pharmaceutical	
		Professional			Research Institute	
					Div Ortho Pharm	ORAL
350 MCG,						
DAILY, ORAL						
			Zyban (Amfebutamone Hydrochloride)	SS		ORAL
150 MG, 2 IN						
1 DAILY, ORAL						
			Dostinex (Cabergoline)	C		

Date:07/23/01ISR Number: 3763772-5Report Type:Expedited (15-DaCompany Report #B0094547A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source
Death	Completed Suicide	Foreign
		Health

		Professional Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG / TWICE PER DAY/ ORAL						

Date:07/24/01ISR Number: 3763660-4Report Type:Expedited (15-DaCompany Report #A0154610A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL
300MG Per day						
	Complications Of Maternal Exposure To Therapeutic Drugs					

Date:07/24/01ISR Number: 3763662-8Report Type:Expedited (15-DaCompany Report #A0154846A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Per day						
	Complications Of Maternal Exposure To Therapeutic Drugs					

Date:07/24/01ISR Number: 3763666-5Report Type:Expedited (15-DaCompany Report #B0110446A
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrial Flutter	Health	Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						

Initial or Prolonged	Dyspnoea	Professional				
per day 47 DAY						

Date:07/24/01ISR Number: 3763667-7Report Type:Expedited (15-DaCompany Report #B0110883A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomyopathy	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG See	
	Left Ventricular Failure							
text								10 DAY
	Pulmonary Oedema		Amitriptyline	C		ORAL	50MG Unknown	
			Nitrazepam	C		ORAL	5MG Unknown	
			Loperamide	C		ORAL	2MG Unknown	
			Co-Codamol	C		ORAL		

Date:07/24/01ISR Number: 3763674-4Report Type:Expedited (15-DaCompany Report #B0114448A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Congestion	Consumer	Zyntabac	PS	Glaxo Wellcome	ORAL	55 DAY	
	Hepatomegaly							
	Myocardial Infarction							
	Pulmonary Haemorrhage							
	Pulmonary Oedema							
	Thyroid Neoplasm							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/01ISR Number: 3763676-8Report Type:Expedited (15-DaCompany Report #B0114827A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nystagmus		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	13 DAY
	Vertigo							
			Fluticasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		
			Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		
			Tramadol	C				
			Lansoprazole	C		ORAL	80MG Per day	
			Frusemide	C		ORAL	20MG Per day	

Date:07/24/01ISR Number: 3763677-XReport Type:Expedited (15-DaCompany Report #B0114829A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hypothyroidism		Zyban	PS	Glaxo Wellcome	ORAL		
			Hepatitis A Immunization	C			1	DAY
			Salmonella Typhi Vaccine	C			1	DAY
			Salbutamol	C	Glaxo Wellcome			

Date:07/24/01ISR Number: 3763678-1Report Type:Expedited (15-DaCompany Report #B0114982A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Abdominal Hernia	Health	Zyntabac	PS	Glaxo Wellcome	ORAL
150MG						
Initial or Prolonged		Professional				
Variable dose						

Date:07/24/01ISR Number: 3763679-3Report Type:Expedited (15-DaCompany Report #B0115003A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypertensive Crisis		Zyban	PS	Glaxo Wellcome	
Initial or Prolonged			Irbesartan	C		
150MG Per day						
			Diltiazem	C		
360MG Per day						
			Calcium Carbonate	C		
			Hydrochlorothiazide	C		
			Vitamins	C		
			Frusemide	C		

Date:07/24/01ISR Number: 3763680-XReport Type:Expedited (15-DaCompany Report #B0115005A
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthenia		Zyban	PS	Glaxo Wellcome	
38 DAY						
	Blood Pressure Increased					
	Convulsion					
	Dysgeusia					
	Fatigue					
	Loss Of Consciousness					
	Weight Decreased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/01ISR Number: 3763681-1Report Type:Expedited (15-DaCompany Report #B0115008A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Physical Assault		Zyban	PS	Glaxo Wellcome			

Date:07/25/01ISR Number: 3764352-8Report Type:Expedited (15-DaCompany Report #A0124641A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Health	Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Dehydration	Professional					per day	6 MON
	Heat Stroke		Alcohol	SS				
	Sudden Death							

Date:07/25/01ISR Number: 3764356-5Report Type:Expedited (15-DaCompany Report #A0152007A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease	Health	Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	450MG Per day	YR
		Professional	Statins	C				

Date:07/25/01ISR Number: 3764365-6Report Type:Expedited (15-DaCompany Report #B0094547A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Alcohol Increased	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Completed Suicide	Professional					per day	
			Alcohol	SS				

Date:07/25/01ISR Number: 3764366-8Report Type:Expedited (15-DaCompany Report #B0094689A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Other	Insomnia						per day	12 DAY
	Restlessness							
	Weight Decreased							

Date:07/25/01ISR Number: 3764367-XReport Type:Expedited (15-DaCompany Report #B0103442A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Dermatitis						per day	
	Myocardial Infarction		Prednisolone	C		ORAL	40MG Per day	6 DAY
			Nitrazepam	C		ORAL	5MG Per day	

Date:07/25/01ISR Number: 3764375-9Report Type:Expedited (15-DaCompany Report #B0114925A
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Deformity Of Orbit
	Diplopia
Other	Ecchymosis
	Electroencephalogram

	Abnormal Facial Bones Fracture Sedation Wrist Fracture	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	

Date:07/25/01ISR Number: 3764389-9Report Type:Direct Company Report #
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aggression Hyperthyroidism Impulsive Behaviour Psychotic Disorder		Zyban	PS		ORAL	BID ORAL

Date:07/26/01ISR Number: 3765377-9Report Type:Expedited (15-DaCompany Report #A0125519A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Disability	Anxiety Arrhythmia	Health Professional	Wellbutrin Acular	PS C	Glaxo Wellcome	ORAL	INTRAOCULAR
	Coronary Artery Disease Fibrosis Hepatic Steatosis Ill-Defined Disorder Injury Pain Pancreatic Disorder Pulmonary Congestion Pulmonary Oedema		Vancenase Aq	C	Glaxo Wellcome	NASAL	

Date:07/26/01ISR Number: 3765379-2Report Type:Expedited (15-DaCompany Report #A0149272A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Haemoptysis	Health	Zyban	PS	Glaxo Wellcome	ORAL 150MG Twice
	Lung Disorder	Professional				per day 81 DAY
	Neoplasm		Prevacid	C		30MG Per day
			Estrogel	C		TOPICAL

Date:07/26/01ISR Number: 3765392-5Report Type:Expedited (15-DaCompany Report #B0099502A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Death	Haemorrhagic Stroke	Consumer	Zyban	PS	Glaxo Wellcome	ORAL 150MG Twice
	Ruptured Cerebral					per day
	Aneurysm		Estracombi	C		TRANSDERMAL

Date:07/26/01ISR Number: 3765393-7Report Type:Expedited (15-DaCompany Report #B0101345A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Death	Coronary Artery Disease	Consumer	Zyban	PS	Glaxo Wellcome	ORAL 150MG Per day
	Respiratory Disorder		Combivent	C		RESPIRATORY (INHALATION)

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/01ISR Number: 3765394-9Report Type:Expedited (15-DaCompany Report #B0101353A
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Diabetes Mellitus						per day	
			Aspirin	C				
UNKNOWN							75MG per day	
			Salbutamol	C	Glaxo Wellcome			
UNKNOWN							2PUFF Four	
							times per day	
			Fluticasone	C	Glaxo Wellcome			
UNKNOWN							250MCG Twice	
							per day	
			Diclofenac	C				
UNKNOWN							75MG Twice	
							per day	
			Salmeterol	C	Glaxo Wellcome			
UNKNOWN							50MCG Twice	
							per day	
			Oxitropium	C				
UNKNOWN							200MCG Twice	
							per day	
			Imipramine	C				
UNKNOWN							10MG Per day	
			Frusemide	C				
UNKNOWN							40MG Per day	

Date:07/26/01ISR Number: 3765395-0Report Type:Expedited (15-DaCompany Report #B0101420A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Myocardial Infarction						per day	

			Metformin	C		
850MG Three						
times per day						
			Human Insulin	C		
			Simvastatin	C		
20MG Per day						

Date:07/26/01ISR Number: 3765396-2Report Type:Expedited (15-DaCompany Report #B0104495A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blister		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	22 DAY
	Dermatitis		Cefaclor	C		ORAL		
	Myocardial Infarction							

Date:07/26/01ISR Number: 3765398-6Report Type:Expedited (15-DaCompany Report #B0107823A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Decreased Appetite	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	1 WK
Initial or Prolonged	Depression	Professional						
	Flat Affect							
	Intentional Misuse							

Date:07/26/01ISR Number: 3765399-8Report Type:Expedited (15-DaCompany Report #B0107824A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypothermia	Health	Zyban	PS	Glaxo Wellcome	ORAL	10 DAY	
Initial or Prolonged	Mood Altered	Professional	Aspirin	SS			UNKNOWN	
	Social Avoidant Behaviour							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/01ISR Number: 3765400-1Report Type:Expedited (15-DaCompany Report #B0111133A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lower Respiratory Tract		Zyban	PS	Glaxo Wellcome		150MG Single	
Hospitalization -	Infection							
dose							1	DAY
Initial or Prolonged	Malaise		Loperamide	C				
	Renal Failure		Allopurinol	C	Glaxo Wellcome	ORAL	300MG per day	
	Urinary Tract Infection		Co-Proxamol	C		ORAL		
	Vomiting		Meloxicam	C		ORAL		
			Salbutamol	C	Glaxo Wellcome			

RESPIRATORY

(INHALATION) 200MCG Twice

per day

Date:07/26/01ISR Number: 3765401-3Report Type:Expedited (15-DaCompany Report #B0111862A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Zyban	PS	Glaxo Wellcome	ORAL	7	DAY
Hospitalization -	Cerebral Artery Occlusion							
Initial or Prolonged	Cheyne-Stokes Respiration							
	Crepitations							
	Hemiparesis							
	Ischaemic Stroke							
	Pulmonary Oedema							
	Ventricular Hypertrophy							

Date:07/26/01ISR Number: 3765423-2Report Type:Expedited (15-DaCompany Report #B0115263A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG	

Initial or Prolonged	Dyspepsia					
Variable dose 6 DAY						
	Hypocalcaemia		Bendrofluazide	SS	Glaxo Wellcome	
UNKNOWN 2.5MG Per day						
			Tamoxifen	C		ORAL
20MG Per day						
			Aspirin	C		ORAL
75MG Twice						
per day						
			Amitriptyline	C		ORAL
10MG At night						
			Simvastatin	C		ORAL
20MG At night						
			Diltiazem	C		ORAL
90MG Twice						
per day						
			Glyceryl Trinitrate	C	Glaxo Wellcome	
UNKNOWN						
			Atenolol	C		ORAL
25MG Per day						
			Enalapril	C		ORAL
20MG Per day						
			Bendrofluazide	C	Glaxo Wellcome	ORAL
2.5MG Per day						

Date:07/26/01ISR Number: 3766258-7Report Type:Expedited (15-DaCompany Report #B0114651A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease	Foreign	Bupropion					
	Sudden Death		Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/01ISR Number: 3766317-9Report Type:Expedited (15-DaCompany Report #B0115005A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Foreign	Bupropion					
	Blood Pressure Increased		Hydrochloride	PS	Glaxo Wellcome Inc			
UNKNOWN							150 MG	
	Convulsion							
	Dysgeusia							
	Fatigue							
	Syncope							
	Weight Decreased							

Date:07/26/01ISR Number: 3766318-0Report Type:Expedited (15-DaCompany Report #B0114448A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
	Pulmonary Haemorrhage							
	Pulmonary Oedema							
	Stress							

Date:07/26/01ISR Number: 3766319-2Report Type:Expedited (15-DaCompany Report #B0115008A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Foreign	Bupropion					
	Physical Assault	Literature	Hydrochloride	PS	Glaxo Wellcome Inc			
UNKNOWN							150 MG	
		Consumer						

Date:07/26/01ISR Number: 3766320-9Report Type:Expedited (15-DaCompany Report #B0114982A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Health	Bupropion					

Initial or Prolonged	Hernia	Professional	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL

150

MG/VARIABLE

DOSE/ORAL

Date:07/26/01ISR Number: 3766321-0Report Type:Expedited (15-DaCompany Report #B0114829A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Hypothyroidism	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL
			Hepatitis A Vaccine	C		
			Typhoid Vaccine	C		
			Salbutamol Sulphate	C		

150 MG/ORAL

Date:07/26/01ISR Number: 3766348-9Report Type:Expedited (15-DaCompany Report #B0114445A
Age: Gender:Female I/FU:I

Outcome	PT
Other	Arthralgia
	Decreased Activity
	Difficulty In Walking
	Dyspnoea
	Fatigue

		Headache					
		Insomnia					
		Malaise	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea	Foreign	Zyban	PS	Glaxo Wellcome Inc	
150 MG							
		Pain In Extremity	Consumer				
		Polymyalgia Rheumatica					
		Red Blood Cell					
		Sedimentation Rate					
		Increased					
		Sedation					
		Tremor					

Date:07/26/01ISR Number: 3766361-1Report Type:Expedited (15-DaCompany Report #B0112965A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Alanine Aminotransferase	Foreign	Bupropion			
	Increased	Health	Hydrochloride	PS	Glaxo Wellcome Inc	
150 MG						
	Arthralgia	Professional				
	Jaundice					
	Lethargy					
	Liver Function Test					
	Abnormal					
	Malaise					
	Myalgia					
	Red Blood Cell					
	Sedimentation Rate					
	Increased					

Date:07/26/01ISR Number: 3766420-3Report Type:Expedited (15-DaCompany Report #HQ3592224JUL2001
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Effexor	PS	Wyeth Ayerst	
	Drug Interaction	Professional			Laboratories	ORAL
150 MG 1 X						
		Other				
PER 1 DAY						

ORAL

Bupropion (Amfebutamone)	SS		ORAL

300 MG 1 X

PER 1 DAY

ORAL

Alprazolam (Alprazolam)	C		

Date:07/26/01ISR Number: 3766427-6Report Type:Expedited (15-DaCompany Report #HQ3605224JUL2001
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Drug Interaction Serotonin Syndrome	Health Professional	Effexor Xr	PS	Wyeth Ayerst Laboratories	ORAL

Dose Duration

420 MG 1X PER

1 DAY ORAL

Zyban (Amfebutamone Hydrochloride)	SS		ORAL

150 MG 1X PER

1 DAY ORAL 6 DAY

Epilim (Valproate Sodium)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/01ISR Number: 3766445-8Report Type:Expedited (15-DaCompany Report #B0114827A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Nervous System Disorder Nystagmus Vertigo	Foreign	Zyban Fluticasone Propionate Salbutamol Sulphate Tramadol Hydrochloride Lansoprazole Frusemide Tamoxifen	PS C C C C C C	Glaxo Wellcome Inc	ORAL	150 MG/TWICE PER DAY/ORAL	

Date:07/26/01ISR Number: 3766452-5Report Type:Expedited (15-DaCompany Report #B0110883A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomyopathy Left Ventricular Failure Pulmonary Oedema Sudden Death	Foreign	Zyban Amitriptyline Nitrazepam Loperamide-Hydrochloride Co-Codamol	PS C C C C	Glaxo Wellcome Inc	ORAL	150 MG/ORAL	

Date:07/26/01ISR Number: 3766465-3Report Type:Expedited (15-DaCompany Report #B0110446A
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Flutter Dyspnoea	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:07/26/01ISR Number: 3766467-7Report Type:Expedited (15-DaCompany Report #B0115003A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
			Irbesartan	C				
			Diltiazem	C				
			Calcium Carbonate	C				
			Hydrochlorothiazide	C				
			Multivitamin	C				
			Frusemide	C				

Date:07/26/01ISR Number: 3766468-9Report Type:Expedited (15-DaCompany Report #A0144968A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Ulcer	Foreign Health Professional	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
			Aspirin (Aspirin)	SS				
			Warfarin Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/01ISR Number: 3766470-7Report Type:Expedited (15-DaCompany Report #B0114486A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
Required Intervention to Prevent Permanent Impairment/Damage	Blister						DAY / ORAL	
	Feeling Hot		Thyroxine Sodium	C				
	Headache		Mebeverine	C				
	Nausea							
	Night Sweats							
	Pain							
	Tremor							

Date:07/26/01ISR Number: 3766471-9Report Type:Expedited (15-DaCompany Report #B0114664A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anorexia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Diplopia	Health					TWICE PER DAY	
	Hyperhidrosis	Professional					/ ORAL	
	Nausea		Proguanil Hydrochloride (Formulation Unknown)	SS		ORAL	100 MG / PER	
	Palpitations						DAY / ORAL	
	Vision Blurred							

Date:07/26/01ISR Number: 3766472-0Report Type:Expedited (15-DaCompany Report #B0113971A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	

DAY / ORAL

			Dihydrocodeine	C		
			Dothiepin Hydrochloride	C		
			Imipramine	C		

Date:07/26/01ISR Number: 3766473-2Report Type:Expedited (15-DaCompany Report #B0114491A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Duodenal Ulcer	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
Intervention to Prevent Permanent Impairment/Damage	Perforation		Trimipramine	C				
			Theophylline	C				
			Aspirin	C				

Date:07/26/01ISR Number: 3766530-0Report Type:Expedited (15-DaCompany Report #A0154610A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	300 MG / PER	
	Complications Of Maternal Health						DAY / ORAL	
	Exposure To Therapeutic Drugs	Professional						
	Pregnancy							

Date:07/26/01ISR Number: 3766586-5Report Type:Expedited (15-DaCompany Report #A0154846A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER	
	Complications Of Maternal	Health					DAY/ORAL	
	Exposure To Therapeutic Drugs	Professional						

Date:07/26/01ISR Number: 3766595-6Report Type:Expedited (15-DaCompany Report #A0150198A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Facial Palsy	Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY/	
			Clonidine	C				
			Oestradiol	C				
			Aspirin	C				

Date:07/26/01ISR Number: 3766602-0Report Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Agoraphobia
Disability	Alopecia
	Anxiety
	Asthenia
	Autonomic Nervous System Imbalance
	Blood Glucose Increased
	Blood Pressure Increased
	Blood Triglycerides Increased
	Bradycardia
	Chills

Cognitive Disorder
Confusional State
Convulsion
Cystocele
Decreased Activity
Diplopia
Dizziness
Dry Mouth
Dysarthria
Dyspepsia
Dysthymic Disorder
Enuresis
Euphoric Mood
Faeces Discoloured
Fatigue
Fear
Feeling Abnormal
Feeling Hot And Cold
Fluid Retention
Headache
Hyperhidrosis
Hypoaesthesia
Insomnia

	Intervertebral Disc Protrusion						
	Muscle Rigidity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Muscle Spasms	Health	Bupropion				
	Muscle Twitching	Professional	Hydrochloride	PS	Eisai Inc	ORAL	150 MG/ PER DAY / ORAL
	Musculoskeletal Stiffness						
	Neck Pain		Conjugated Estrogens	C			
	Nervousness		Vitamin	C			
	Panic Attack		Aspirin	C			
	Paraesthesia		Melatonin	C			
	Sciatica						
	Spinal X-Ray Abnormal						
	Stress						
	Throat Tightness						
	Tinnitus						
	Tongue Oedema						
	Transient Ischaemic Attack						
	Tremor						

Date:07/27/01ISR Number: 3766111-9Report Type:Expedited (15-DaCompany Report #B0100684A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome		
			Lovan	C			
			Alcohol	C			

Date:07/27/01ISR Number: 3766112-0Report Type:Expedited (15-DaCompany Report #B0100755A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome		

Date:07/27/01ISR Number: 3766113-2Report Type:Expedited (15-DaCompany Report #B0101552A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchopneumonia		Zyban	PS	Glaxo Wellcome	ORAL		
	Cardiac Arrest							
	Coronary Artery Disease							
	Myocardial Infarction							
	Myocardial Ischaemia							

Date:07/27/01ISR Number: 3766685-8Report Type:Expedited (15-DaCompany Report #B0094689A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Required	Insomnia	Health					TWICE PER DAY	
Intervention to	Restlessness	Professional					/ ORAL	12 DAY
Prevent Permanent	Weight Decreased							
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/01ISR Number: 3766725-6Report Type:Expedited (15-DaCompany Report #A0124641A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcoholism	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
	Arrhythmia	Health					PER DAY ORAL	
	Dehydration	Professional						
	Heat Stroke							
	Sudden Death							

Date:07/27/01ISR Number: 3766727-XReport Type:Expedited (15-DaCompany Report #B0094547A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Alcohol Increased	Foreign	Bupropion					
	Completed Suicide	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE	
		Professional					PER DAY ORAL	
		Company						
		Representative						

Date:07/27/01ISR Number: 3766738-4Report Type:Expedited (15-DaCompany Report #B0103442A
Age:5 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis	Foreign	Bupropion					
	Dermatitis		Hydrochloride (Zyban					
	Myocardial Infarction		Tablet - Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	
							PER DAY/ORAL	
			Prednisolone	C				
			Nitrazepam	C				

Date:07/27/01ISR Number: 3766747-5Report Type:Expedited (15-DaCompany Report #B0114925A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ecchymosis	Foreign	Bupropion Hydrochloride (Zyban					
Other	Electroencephalogram	Health						
ORAL	Abnormal	Professional	Tablet-Zyban)	PS	Glaxo Wellcome Inc	ORAL		
	Facial Bones Fracture	Company						
	Sedation	Representative						
	Wrist Fracture							

Date:07/27/01ISR Number: 3767111-5Report Type:Expedited (15-DaCompany Report #A0152007A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bu7propion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	450 MG/PER DAY	1 YR
			Statins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/01ISR Number: 3767234-0Report Type:Expedited (15-DaCompany Report #HQ3535223JUL2001
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Concussion	Health Professional	Effexor Xr	PS	Wyeth Ayerst Laboratories	ORAL	150 MG 1 X	
Other	Drug Interaction							PER 1 DAY
	Grand Mal Convulsion	Other						
			Zyban (Amfebutamone Hydrochloride,)	SS				
			Unspecified Antianxiety Agent	C				
			Valium (Diazepam)	C				

Date:07/27/01ISR Number: 3767283-2Report Type:Expedited (15-DaCompany Report #HQ3601124JUL2001
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health Professional	Effexor Xr	PS	Wyeth Ayerst Laboratories	ORAL	75 MG 1 X PER	
	Feeling Hot							1 DAY ORAL
	Insomnia	Other						
	Malaise		Zyban (Amfebutamone Hydrochloride)	SS		ORAL	150 MG 1 X	
	Serotonin Syndrome							PER 1 DAY,
	Tachycardia							300 MG 1 X
								PER 1 DAY
								ORAL

Date:07/27/01ISR Number: 3767435-1Report Type:Periodic Company Report #A112580
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Libido Decreased	Consumer	Tikosyn	PS	Pfizer Pharmaceuticals Production Corp Ltd	ORAL

1000.00 MCG

TOTAL BID

ORAL

			Wellbutrin	SS		ORAL

300.00 MG

TOTAL BID

ORAL

			Lopressor	SS		ORAL

100.00 MG

TOTAL BID

ORAL

			Vitamins	C		

Date:07/30/01ISR Number: 3766791-8Report Type:Expedited (15-DaCompany Report #A0150739A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Psychotic Disorder		Zyban	SS	Glaxo Wellcome	ORAL	2	MON
	Sexual Offence		Prevacid	C		ORAL		

Date:07/30/01ISR Number: 3766798-0Report Type:Expedited (15-DaCompany Report #B0089068A
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Death	Brain Oedema
	Cerebral Infarction

	Haematoma						
	Headache						
	Hemiparesis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ruptured Cerebral		Bupropion	PS	Glaxo Wellcome	ORAL	150MG per day 57 DAY
	Aneurysm						
	Sedation						
	Subarachnoid Haemorrhage						

Date:07/30/01ISR Number: 3766799-2Report Type:Expedited (15-DaCompany Report #B0089069A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Brain Stem Infarction		Bupropion	PS	Glaxo Wellcome	ORAL	300MG per day 11 DAY
Hospitalization - Initial or Prolonged	Circulatory Collapse		Diclofenac	C		ORAL	50MG Three times per day
			Allopurinol	C	Glaxo Wellcome	ORAL	300MG Per day 185 DAY

Date:07/30/01ISR Number: 3766800-6Report Type:Expedited (15-DaCompany Report #B0090433A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL	150MG As directed
	Myocardial Ischaemia						
	Sudden Death						

Date:07/30/01ISR Number: 3766801-8Report Type:Expedited (15-DaCompany Report #B0099815A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL 150MG Per day
	Mitral Valve Disease		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION) 2PUFF As required
	Myocardial Infarction					
	Ventricular Hypertrophy					
			Thyroxine	C	Glaxo Wellcome	ORAL 100MCG per day
			Glyceryl Trinitrate	C	Glaxo Wellcome	ORAL
			Candesartan	C		4G Per day
			Fluoxetine	C		20MG Per day
			Omeprazole	C		20MG Per day
			Frusemide	C		40MG Per day
			Didronel	C		ORAL 1TAB Per day

Date:07/30/01ISR Number: 3766804-3Report Type:Expedited (15-DaCompany Report #B0115085A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - 3 DAY	Amblyopia		Zyban	PS	Glaxo Wellcome	
Initial or Prolonged	Burning Sensation					
	Fatigue					
	Myelitis					
	Paraesthesia					
	Peripheral Coldness					
	Weight Decreased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/01ISR Number: 3767824-5Report Type:Expedited (15-DaCompany Report #B0111133A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Lower Respiratory Tract	Foreign	Zyban	PS	Glaxo Wellcome Inc	
150 MG /						
Hospitalization -	Infection	Health				
SINGLE DOSE						
Initial or Prolonged	Malaise	Professional	Loperamide			
	Renal Failure		Hydrochloride	C		
	Vomiting		Allopurinol	C		
			Co-Proxamol	C		
			Meloxicam	C		
			Salbutamol Sulphate	C		

Date:07/30/01ISR Number: 3767834-8Report Type:Expedited (15-DaCompany Report #B0100684A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest	Foreign	Zyban	PS	Glaxo Wellcome Inc	
150 MG						
			Fluoxetine			
			Hydrochloride	C		
			Ethanol	C		

Date:07/30/01ISR Number: 3767835-XReport Type:Expedited (15-DaCompany Report #B0101552A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Bronchopneumonia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/ ORAL						
	Cardiac Arrest					
	Coronary Artery Disease					
	Myocardial Infarction					
	Myocardial Ischaemia					

Date:07/30/01ISR Number: 3767854-3Report Type:Expedited (15-DaCompany Report #A0149272A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	
	Haemoptysis	Health					PER DAY/ ORAL	
	Respiratory Tract Neoplasm	Professional	Lansoprazole Oestradiol	C C				

Date:07/30/01ISR Number: 3767859-2Report Type:Expedited (15-DaCompany Report #B0107824A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypothermia	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	PER DAY/ ORAL	10 DAY
	Mood Altered Overdose Social Avoidant Behaviour Stress	Health Professional	Aspirin (Formulation Unknown) (Aspirin)	SS				

Date:07/30/01ISR Number: 3767860-9Report Type:Expedited (15-DaCompany Report #B0107823A
Age:20 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Decreased Appetite Depression

	Overdose						
		Report Source	Product	Role	Manufacturer		Route
Dose	Duration						
		Foreign	Zyban	PS	Glaxo Wellcome Inc		ORAL
150 MG/	1 WK						
		Health Professional					

Date:07/30/01ISR Number: 3767861-0Report Type:Expedited (15-DaCompany Report #B0104495A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Blister	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
300 MG/ PER						
	Dermatitis					
DAY/ ORAL						
	Myocardial Infarction		Cefaclor	C		

Date:07/30/01ISR Number: 3767864-6Report Type:Expedited (15-DaCompany Report #B0115263A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/						
Initial or Prolonged	Dyspepsia					
VARIABLE						
	Hypocalcaemia					
DOSE/ ORAL						
			Bendrofluazide (Formulation Unknown)	SS		
2.5 MG/ PER						
DAY/						
			Tamoxifen	C		
			Aspirin	C		
			Amitriptyline	C		
			Simvastatin	C		
			Diltiazem	C		
			Nitroglycerin	C		

			Atenolol	C		
			Enalapril	C		
			Bendrofluazide	C		

Date:07/30/01ISR Number: 3767866-XReport Type:Expedited (15-DaCompany Report #B0111862A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cerebral Artery Occlusion	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/ORAL
Hospitalization - Initial or Prolonged	Cerebral Artery Thrombosis Cheyne-Stokes Respiration Crepitations Hemiparesis Ischaemic Stroke Left Ventricular Failure Pulmonary Oedema Ventricular Hypertrophy						

Date:07/30/01ISR Number: 3767867-1Report Type:Expedited (15-DaCompany Report #B0101345A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coronary Artery Disease Sudden Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /PER

DAY/ORAL

			Combivent	C		

Date:07/30/01ISR Number: 3767868-3Report Type:Expedited (15-DaCompany Report #B0101420A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TWICE	PER DAY/ORAL
	Myocardial Infarction		Metformin Hydrochloride	C				
			Human Insulin	C				
			Simvastatin	C				

Date:07/30/01ISR Number: 3767888-9Report Type:Expedited (15-DaCompany Report #B0101353A
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE	PER DAY/ ORAL
	Diabetes Mellitus		Aspirin	C				
			Salbutamol Sulphate	C				
			Fluticasone Propionate	C				
			Diclofenac	C				
			Salmeterol Xinafoate	C				
			Oxitropium Bromide	C				
			Imipramine	C				
			Frusemide	C				

Date:07/30/01ISR Number: 3767889-0Report Type:Expedited (15-DaCompany Report #B0099502A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/	TWICE
	Ruptured Cerebral						PER DAY/	ORAL
	Aneurysm		Estracombi	C				

Date:07/30/01ISR Number: 3767901-9Report Type:Expedited (15-DaCompany Report #B0100755A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Bupropion					
		Health	Hydrochloride	PS	Glaxo Wellcome Inc		150 MG	
		Professional						
		Company						
		Representative						

Date:07/30/01ISR Number: 3768319-5Report Type:Expedited (15-DaCompany Report #A0125519A
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Death	Anxiety
Disability	Arrhythmia
	Cardiac Disorder
	Coronary Artery

	Atherosclerosis						
	Fibrosis						
	Hepatic Fibrosis						
	Hepatic Steatosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Injury	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ ORAL
	Oedema	Professional	Ketorolac Trometamol	C			
	Pain		Beclomethasone				
	Pancreatic Disorder		Dipropion	C			
	Pulmonary Congestion						
	Pulmonary Oedema						

Date:07/31/01ISR Number: 3767766-5Report Type:Expedited (15-DaCompany Report #A0144419A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Per day
	Movement Disorder						
	Neuropathy Peripheral						

Date:07/31/01ISR Number: 3767767-7Report Type:Expedited (15-DaCompany Report #A0153280A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abnormal Behaviour		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice
Initial or Prolonged	Amnesia						per day 1 YR
	Grand Mal Convulsion		Ethanol	SS			
	Toxicologic Test Abnormal		No Concurrent Medication	C			

Date:07/31/01ISR Number: 3767769-0Report Type:Expedited (15-DaCompany Report #A0155843A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization -	Arthralgia		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Twice						
Initial or Prolonged	Dermatitis					
per day 19 DAY						
	Hypogammaglobulinaemia					
	Joint Swelling					
	Liver Function Test					
	Abnormal					
	Red Blood Cell					
	Sedimentation Rate					
	Increased					
	Serum Sickness					
	Urticaria					

Date:07/31/01ISR Number: 3767772-0Report Type:Expedited (15-DaCompany Report #B0097298A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypokalaemia		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
Initial or Prolonged	Hyponatraemia					
per day 1 WK						
	Mental Disorder		No Concurrent			
	Polydipsia		Medications	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/01ISR Number: 3767777-XReport Type:Expedited (15-DaCompany Report #B0115262A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	1 DAY
			Amoxycillin	SS		ORAL		
			Thyroxine	C	Glaxo Wellcome	ORAL	200MG Per day	
			Enalapril	C		ORAL	50MG Per day	
			Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG Per day	

Date:07/31/01ISR Number: 3767779-3Report Type:Expedited (15-DaCompany Report #B0115681A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoaesthesia		Zyban	PS	Glaxo Wellcome		150MG As directed	
	Hypoaesthesia Oral							
	Motor Dysfunction							
	Nervous System Disorder							
	Pulse Abnormal							

Date:07/31/01ISR Number: 3768626-6Report Type:Expedited (15-DaCompany Report #2013032
Age:41 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Adhesions	Health Professional Other	Morphine Sulfate (Similar To Andas 74-769 And 74-862)	PS				
	Hepatic Steatosis							
	Malaise							
	Oedema Peripheral		Morphine Sulfate (Similar To Nda 19-516)	SS				
	Overdose							
	Postoperative Adhesion							
	Pulmonary Congestion		Oxycontin Cr Tablets, 40 Mg (Oxycodone					
	Pulmonary Oedema							
	Renal Cell Carcinoma							

	Stage Unspecified	Hydrochloride)	SS	ORAL PO
	Spinal Osteoarthritis	Oxycontin Cr		
	Toxicologic Test Abnormal	Tablets, 20 Mg (Oxycodone Hydrochloride)	SS	ORAL PO
		Bupropion	SS	
		Promethazine Hcl	SS	
		Acetaminophen	SS	
		Doxylamine	SS	
		Metoprolol	SS	
		Oxazepam	SS	
		Salicylic Acid	SS	
		Ephedrine	SS	
		Pseudophedrine Hcl	SS	
		Carbamazepine	SS	
		Trazodone Hcl	C	
		Prevacid (Lansoprazole)	C	
		Diovan (Valsartan)	C	
		Baclofen (Lioresal)	C	
		Levoxyl	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/01ISR Number: 3777716-3Report Type:Periodic Company Report #2001056168US
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coordination Abnormal	Health	Celebrex	PS	Gd Searle And Co	ORAL		
	Paranoia Speech Disorder	Professional	Lithobid (Lithium Carbonate)	SS		ORAL	900 MG, QD,	ORAL
			Seroquel (Quetiapine)	SS		ORAL	600 MG, QD,	ORAL
			Klonopin (Clonazepam)	SS		ORAL	2 MG, QD,	ORAL
			Wellbutrin-Slow Release (Amfebutamone Hydrochloride)	SS		ORAL	150 MG, QD,	ORAL

Date:08/01/01ISR Number: 3768424-3Report Type:Expedited (15-DaCompany Report #A0155404A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:08/01/01ISR Number: 3768425-5Report Type:Expedited (15-DaCompany Report #A0155706A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Systemic Lupus Erythematosus		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Premarin	C				
			Tenormin	C				
			Norvasc	C				
			Cozaar	C				
			Aspirin	C				

Date:08/01/01ISR Number: 3768440-1Report Type:Expedited (15-DaCompany Report #B0115683A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister Pruritus		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	25 DAY

Date:08/01/01ISR Number: 3769202-1Report Type:Expedited (15-DaCompany Report #A0150739A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bipolar Disorder	Health	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Convulsion Incest Psychotic Disorder	Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	SS		ORAL	ORAL	
			Lansoprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/01ISR Number: 3769593-1Report Type:Expedited (15-DaCompany Report #B0115085A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Influenza Like Illness Myelitis	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc			

Date:08/01/01ISR Number: 3769603-1Report Type:Expedited (15-DaCompany Report #B0089069A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Brain Stem Infarction Circulatory Collapse	Foreign	Bupropion Hydrochloride Diclofenac Allopurinol	PS C C	Glaxo Wellcome Inc	ORAL ORAL		

Date:08/01/01ISR Number: 3769604-3Report Type:Expedited (15-DaCompany Report #B0090433A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease Myocardial Ischaemia Sudden Death	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / AS DIRECTED / ORAL	

Date:08/01/01ISR Number: 3769605-5Report Type:Expedited (15-DaCompany Report #B0089068A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Infarction Ruptured Cerebral	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	ORAL	

Aneurysm
Subarachnoid Haemorrhage

Date:08/01/01ISR Number: 3769606-7Report Type:Expedited (15-DaCompany Report #B0099815A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Mitral Valve Disease	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER DAY /	ORAL
	Myocardial Infarction							
	Nausea							
			Salbutamol Sulphate	C				
			Thyroxine Sodium	C				
			Nitroglycerin	C				
			Candesartan Cilexetil	C				
			Fluoxetine	C				
			Omeprazole	C				
			Frusemide	C				
			Disodium Etidronate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/01ISR Number: 3769152-0Report Type:Expedited (15-DaCompany Report #A0155912A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG	Unknown
	Injury		Celexa	SS		ORAL		
	Overdose		Alcohol	SS		ORAL		
			Benadryl	SS		ORAL		

Date:08/02/01ISR Number: 3769155-6Report Type:Expedited (15-DaCompany Report #B0084888A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL		
Disability	Myocardial Infarction		Pravastatin	C		ORAL	40MG	At night
Other	Pulmonary Infarction		Frusemide	C		ORAL	40MG	per day
			Aspirin	C		ORAL	150MG	per day
			Omeprazole	C		ORAL	20MG	Per day
			Ramipril	C		ORAL	5MG	per day

Date:08/02/01ISR Number: 3769161-1Report Type:Expedited (15-DaCompany Report #B0115845A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthma		Zyban	PS	Glaxo Wellcome		21	DAY
			Celecoxib	C				

Date:08/02/01ISR Number: 3769162-3Report Type:Expedited (15-DaCompany Report #B0115848A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hyperventilation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 DAY
	Panic Attack							
	Tachycardia							

Date:08/02/01ISR Number: 3769163-5Report Type:Expedited (15-DaCompany Report #B0115850A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Subarachnoid Haemorrhage		Zyban	PS	Glaxo Wellcome		13	DAY

Date:08/02/01ISR Number: 3770225-7Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Wellbutrin 100 Mg					
	Fatigue		Generic	PS			1 BID	
	Irritability							

Date:08/03/01ISR Number: 3770119-7Report Type:Expedited (15-DaCompany Report #A0155486A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	450MG Per day	
Initial or Prolonged	Hypothyroidism		Alcohol	SS				
	Weight Decreased		Unspecified					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Medications C

Date:08/03/01ISR Number: 3770127-6Report Type:Expedited (15-DaCompany Report #B0114485A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea		Zyban	PS	Glaxo Wellcome		150MG Per day	5 DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction							

Date:08/03/01ISR Number: 3770843-6Report Type:Direct Company Report #
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Benztropine	PS			UNKNOWN	
	Heat Stroke		Bupropion	SS			UNKNOWN	

Date:08/03/01ISR Number: 3770900-4Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coordination Abnormal	Health Professional Company Representative	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ORAL	
	Drug Interaction							
	Feeling Abnormal							
	Gait Disturbance							
	Speech Disorder		Anafranil	SS				
	Vision Blurred		Lamictal	SS				
			Dipentum	SS				
			Zoloft	SS				
			Premarin	SS				
			Wellbutrin	SS				
			Klonopin	C				
			Motrin	C				

Date:08/03/01ISR Number: 3771020-5Report Type:Expedited (15-DaCompany Report #A0155404A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Complications Of Maternal Exposure To Therapeutic Drugs	Health Professional						

Date:08/03/01ISR Number: 3771022-9Report Type:Expedited (15-DaCompany Report #A0155706A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Impairment	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE PER DAY/ORAL	
	Systemic Lupus Erythematosus	Professional Company Representative	Conjugated Estrogens	C				
			Atenolol	C				
			Amlodipine	C				
			Losartan Potassium	C				
			Aspirin	C				

Date:08/03/01ISR Number: 3771058-8Report Type:Expedited (15-DaCompany Report #B0115683A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blister Pruritus	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG PER DAY/ORAL	

Date:08/03/01ISR Number: 3771073-4Report Type:Expedited (15-DaCompany Report #S01-USA-01399-01
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health Professional	Celexa	PS	Forest Laboratories Inc	ORAL	20 MG QD PO	
		Other	Wellbutrin (Amfebutamone Hydrochloride)	SS			150 MG QD	
			Lithium	C				

Date:08/03/01ISR Number: 3771172-7Report Type:Expedited (15-DaCompany Report #B0097298A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypokalaemia Hyponatraemia Polydipsia	Foreign Health Professional	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	/ ORAL 1 WK

Date:08/03/01ISR Number: 3771179-XReport Type:Expedited (15-DaCompany Report #A0155843A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Hypogammaglobulinaemia Liver Function Test Abnormal Red Blood Cell Sedimentation Rate Increased Serum Sickness	Foreign Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:08/03/01ISR Number: 3771181-8Report Type:Expedited (15-DaCompany Report #B0115262A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Foreign	Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc	ORAL	300 MG/ PER DAY/ ORAL	
			Amoxycillin (Amoxicillin)	SS		ORAL	50 MG/ ORAL	
			Thyroxine Sodium	C				
			Enalapril	C				
			Bendrofluazide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/01ISR Number: 3771186-7Report Type:Expedited (15-DaCompany Report #B0115681A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Damage Hypoaesthesia Hypoaesthesia Oral Motor Dysfunction	Foreign Consumer	Zyban (Bupropion Hydrochloride)	PS	Glaxo Wellcome Inc		150 MG/ AS DIRECTED/ UNKNOWN	

Date:08/03/01ISR Number: 3771344-1Report Type:Expedited (15-DaCompany Report #HQ3535223JUL2001
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Drug Interaction Grand Mal Convulsion Head Injury	Foreign Health Professional Other	Effexor Xr	PS	Wyeth Ayerst Laboratories	ORAL	150 MG 1 X PER 1 DAY ORAL	
			Zyban (Amfebutamone Hydrochloride)	SS				
			Unspecified Antianxiety Agent (Unspecified Antianxiety Agent)	C				
			Valium (Diazepam)	C				

Date:08/03/01ISR Number: 3771553-1Report Type:Expedited (15-DaCompany Report #A0153280A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Grand Mal Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY	

	Medication Error	Company				
/ ORAL						
	Overdose	Representative	Ethanol (Formulation Unknown) (Alcohol)	SS		

Date:08/03/01ISR Number: 3771554-3Report Type:Expedited (15-DaCompany Report #A0144419A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG / PER	
	Neuropathy Peripheral	Professional					DAY ORAL	
		Company Representative						

Date:08/06/01ISR Number: 3770867-9Report Type:Expedited (15-DaCompany Report #A0139670A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	10 MON
Initial or Prolonged	Cardiac Failure		Rocephin	C				
INTRAVENOUS							1G Per day	8 DAY
	Congestive		Pepcid	C			20MG Per day	
	Condition Aggravated		Kcl	C				
	Convulsion		Captopril	C	Glaxo Wellcome		12.5MG Twice	
	Depressed Level Of Consciousness		Depakote	C			per day	
	Dyskinesia		Buspar	C			500MG Per day	2 YR
	Loss Of Consciousness						10MG Twice	
			Nicoderm Patch	C			per day	2 YR
							7MG At night	1 DAY

					Seroquel	C		
75MG Per day	5	YR						
					Lasix	C		
					Lanoxin	C	Glaxo Wellcome	
					Albuterol	C	Glaxo Wellcome	
					Spironolactone	C		
12.5MG Per								
day								
					Aspirin	C		
325MG Per day	5	YR						
					Antivert	C		
12.5MG As								
required								
					Artificial Tears	C		
					Proventil	C	Glaxo Wellcome	
RESPIRATORY								
(INHALATION)			YR					
					Atrovent	C	Glaxo Wellcome	
RESPIRATORY								
(INHALATION)			YR					
					Fluoroquinolone	C		
INTRAVENOUS								

Date:08/06/01ISR Number: 3770871-0Report Type:Expedited (15-DaCompany Report #A0154004A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Blister		Zyban	PS	Glaxo Wellcome	ORAL
150MG See						
	Burning Sensation					
text	3 DAY					
	Erythema		No Concurrent			
	Insomnia		Medication	C		
	Pain					
	Pruritus					
	Scab					
	Scar					
	Sensory Loss					
	Skin Discolouration					
	Swelling					

Date:08/06/01ISR Number: 3771519-1Report Type:Expedited (15-DaCompany Report #2013643
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis	Health	Oxycontin	PS	Purdue Pharma Lp	ORAL	MG PO	
	Bronchopneumonia	Professional	Amitriptyline	SS			MG	
	Cardiac Arrest	Other	Cyclobenzaprine Hcl	SS			MG	
	Cardiomegaly		Wellbutrin					
	Cerebral Ischaemia		(Bupropion)	SS			MG	
	Foreign Body Aspiration		Diazepam	SS			MG	
	Hepatic Steatosis		Lidocaine Hcl	SS			MG	
	Hepatomegaly							
	Obstructive Airways Disorder							
	Splenomegaly							
	Toxicologic Test Abnormal							

Date:08/06/01ISR Number: 3771653-6Report Type:Expedited (15-DaCompany Report #B0115845A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthma	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	21 DAY
			Celecoxib	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/01ISR Number: 3771654-8Report Type:Expedited (15-DaCompany Report #B0115850A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Subarachnoid Haemorrhage	Foreign	Zyban	PS	Glaxo Wellcome Inc		150 MG	

Date:08/06/01ISR Number: 3771657-3Report Type:Expedited (15-DaCompany Report #B0115848A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hyperventilation	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER	
	Panic Attack						DAY/ ORAL	
	Tachycardia							

Date:08/06/01ISR Number: 3771661-5Report Type:Expedited (15-DaCompany Report #B0084888A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	AS DIRECTED/	
Disability	Coronary Artery Occlusion	Health					ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction	Professional	Pravastatin	C				
	Pulmonary Infarction		Frusemide	C				
			Aspirin	C				
			Omeprazole	C				
			Ramipril	C				

Date:08/06/01ISR Number: 3772038-9Report Type:Expedited (15-DaCompany Report #B0114485A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea	Foreign	Bupropion					

Hospitalization - 150 MG/PER Initial or Prolonged DAY	Myocardial Infarction	Health Professional	Hydrochloride	PS	Glaxo Wellcome Inc	

Date:08/06/01ISR Number: 3772198-XReport Type:Expedited (15-DaCompany Report #A0155486A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 450 MG / PER Initial or Prolonged DAY / ORAL	Convulsion	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	
	Hypothyroidism						
	Weight Decreased	Company Representative	Ethanol (Formulation Unknown) Alcohol	SS			

Date:08/06/01ISR Number: 3772342-4Report Type:Expedited (15-DaCompany Report #2000022913-1
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Human Chorionic Gonadotropin Negative	Consumer Health	Famvir 500 MILLIGRAMS 3.0 DAILY	PS	Novartis Pharmaceuticals Corp	ORAL	37 DAY
	Laboratory Test Abnormal	Professional					
	Medication Error						
	Ovarian Cyst						
	Vomiting		Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	4 YR
			Claritin (Loratadine)	C			

Date:08/06/01ISR Number: 3772343-6Report Type:Expedited (15-DaCompany Report #A0155912A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG ORAL	
	Injury Intentional Misuse Toxicologic Test Abnormal	Professional	Citalopram Hydrobromide Tablet (Citalopram Hydrobromide)	SS		ORAL	ORAL	
			Ethanol Liquid (Alcohol)	SS		ORAL	ORAL	
			Diphenhydramine Hcl (Formulation Unknown) (Diphenhydramine Hcl)	SS		ORAL	ORAL	

Date:08/07/01ISR Number: 3771426-4Report Type:Expedited (15-DaCompany Report #A0150080A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Cold		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Hypoaesthesia							

Date:08/07/01ISR Number: 3771428-8Report Type:Expedited (15-DaCompany Report #A0153069A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG In the	
	Anxiety						morning	36 DAY
	Aphasia Coordination Abnormal Depression		No Concurrent Medications	C				

	Insomnia					
	Nervousness					
	Neuromyopathy					
	Speech Disorder					
	Weight Increased					

Date:08/07/01ISR Number: 3771432-XReport Type:Expedited (15-DaCompany Report #A0156108A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Coagulopathy		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	300MG per day
Initial or Prolonged	Condition Aggravated		Herbs	C			
	Ecchymosis		Homeopathy	C			
	Endometriosis						
	Menorrhagia						
	Stress						

Date:08/07/01ISR Number: 3771437-9Report Type:Expedited (15-DaCompany Report #B0111329A
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Death	Hepatic Congestion
	Hepatomegaly
	Hyperplasia
	Myocardial Infarction

	Pulmonary Haemorrhage						
	Pulmonary Oedema						
	Thyroid Neoplasm	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyntabac	PS	Glaxo Wellcome	ORAL	55 DAY

Date:08/07/01ISR Number: 3771440-9Report Type:Expedited (15-DaCompany Report #B0114448A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Hepatic Congestion		Zyntabac	PS	Glaxo Wellcome	ORAL	55 DAY
	Hepatomegaly						
	Hyperplasia						
	Myocardial Infarction						
	Pulmonary Haemorrhage						
	Pulmonary Oedema						
	Stress						
	Thyroid Neoplasm						

Date:08/07/01ISR Number: 3771448-3Report Type:Expedited (15-DaCompany Report #B0115843A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Back Pain		Zyban	PS	Glaxo Wellcome	ORAL	
Hospitalization -	Urinary Tract Infection		Dihydrocodeine	SS		ORAL	1 DAY
Initial or Prolonged	Vomiting		Estracombi	C		TRANSDERMAL	

Date:08/07/01ISR Number: 3771449-5Report Type:Expedited (15-DaCompany Report #B0116004A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL	
	Depression						
	Mental Disorder						

	Stress					

Date:08/07/01ISR Number: 3771450-1Report Type:Expedited (15-DaCompany Report #B0116186A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Aggression						per day	
	Disinhibition		Thyroxine	C	Glaxo Wellcome	ORAL	200MCG per	
							day	
			Co-Codamol	C		ORAL		

Date:08/08/01ISR Number: 3771889-4Report Type:Expedited (15-DaCompany Report #B0116466A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxo Wellcome		150MG	
	Headache						Variable dose	
	Insomnia		Bromazepam	C		ORAL	3MG Three	
	Petit Mal Epilepsy						times per day	
	Syncope		Gtn	C	Glaxo Wellcome	ORAL	100MG Twice	
	Tremor						per day	
			Atenolol	C		ORAL	100MG Per day	

			Conjugated Oestrogens	C			ORAL 625MCG Three times per week

Date:08/08/01ISR Number: 3772814-2Report Type:Expedited (15-DaCompany Report #A0154004A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blister Burning Sensation Erythema Hypoaesthesia Oedema Peripheral Pain Pruritus Scab Scar Skin Discolouration Ulcer	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/SEE TEXT/ORAL

Date:08/08/01ISR Number: 3772858-0Report Type:Expedited (15-DaCompany Report #A0139670A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anorexia Cardiac Failure Convulsion Depressed Level Of Consciousness	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ PER DAY/ ORAL
			Ceftriaxone Sodium	C			
			Famotidine	C			
			Potassium Chloride	C			
			Captopril	C			
			Semisodium Valproate	C			
			Buspirone Hydrochloride	C			

Nicotine	C
Quetiapine Fumarate	C
Frusemide	C
Digoxin	C
Salbutamol Sulphate	C
Spironolactone	C
Aspirin	C
Meclozine Hydrochloride	C
Hypromellose	C
Salbutamol Sulphate	C
Ipratropium Bromide	C
Fluoroquinolone	C

Date:08/08/01ISR Number: 3773455-3Report Type:Expedited (15-DaCompany Report #PHBS2001US07798
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Literature	Sandimmune	PS	Novartis Pharmaceuticals Corp	ORAL	420 MG/D,	
	Drug Level Above Therapeutic	Health Professional						
ORAL								22 DAY
	Drug Level Below Therapeutic		Bupropion (Amfebutamone)	SS				
			Methylphenidate				75 MG, BID	22 DAY

				(Methylphenidate Hydrochloride)	SS		
5 MG, BID	22	DAY					
				Azathioprine (Azathioprine)	C		
				Prednisone	C		
				Dipyridamole (Dipyridamole)	C		
				Nifedipine	C		
				Sulfamethoxazole W/Trimethoprim (Sulfamethoxazole)	C		
				Calcium Carbonate	C		
				Aluminium Hyrdoxide W/Magnesium Hydroxide	C		

Date:08/08/01ISR Number: 3773483-8Report Type:Expedited (15-DaCompany Report #A0155184A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Literature	Wellbutrin	PS	Glaxo Wellcome Inc	ORAL	75 MG / TWICE PER DAY / ORAL	
	Drug Level Below Therapeutic	Health Professional						
			Cyclosporin (Formulation Unknown) (Cyclosporine)	SS			420 MG/DAY/	
			Azathioprine	C				
			Prednisone	C				
			Dipyridamole	C				
			Nifedipine	C				
			Co-Trimoxazole	C				
			Calcium Carbonate	C				
			Aluminium Salt+ Mg(Oh)2	C				

Date:08/09/01ISR Number: 3772945-7Report Type:Expedited (15-DaCompany Report #A0152291A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Twice per day	265 DAY
	Cholelithiasis		Orthotricyclen	C		ORAL	1TAB Per day	
	Gallbladder Disorder Weight Decreased							

Date:08/09/01ISR Number: 3772948-2Report Type:Expedited (15-DaCompany Report #A0156426A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Twice per day	3 YR
	Congestive		Amantadine	SS			1 MON	
			Selegiline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/01ISR Number: 3772952-4Report Type:Expedited (15-DaCompany Report #A0156690A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Dermatitis							
	Hypersensitivity							
	Loss Of Consciousness							
	Pruritus							
	Urticaria							
	Viral Infection							

Date:08/09/01ISR Number: 3773983-0Report Type:Expedited (15-DaCompany Report #B0116004A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	ORAL	
	Depression	Literature						
	Mental Disorder							
	Stress							

Date:08/09/01ISR Number: 3773986-6Report Type:Expedited (15-DaCompany Report #B0116186A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	
	Aggression							
	Disinhibition							
			Thyroxine Sodium	C				
			Co-Codamol	C				

Date:08/09/01ISR Number: 3774090-3Report Type:Expedited (15-DaCompany Report #B0115843A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Urinary Tract Infection	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / ORAL	
Hospitalization - Initial or Prolonged	Vomiting		Dihydrocodeine Tablet (Dihydrocodeine)	SS		ORAL	2 TABLET / ORAL	
			Estracombi	C				

Date:08/09/01ISR Number: 3774208-2Report Type:Expedited (15-DaCompany Report #A0150080A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia Peripheral Coldness	Foreign Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/PER DAY/ORAL	

Date:08/09/01ISR Number: 3774220-3Report Type:Expedited (15-DaCompany Report #B0111329A
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Stress Disorder Hepatomegaly Myocardial Infarction

		Pulmonary Haemorrhage Pulmonary Oedema Thyroid Neoplasm	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/	ORAL						
			Health Professional				

Date:08/09/01ISR Number: 3774221-5Report Type:Expedited (15-DaCompany Report #B0114448A
Age:44 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Hepatomegaly	Foreign	Zyban	PS	Glaxo Wellcome Inc	ORAL
150 MG/	ORAL						
		Hyperplasia Myocardial Infarction Pulmonary Haemorrhage Pulmonary Oedema Thyroid Neoplasm					

Date:08/09/01ISR Number: 3774242-2Report Type:Expedited (15-DaCompany Report #A0153069A
Age:43 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Amnesia	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL
150 MG/	IN						
		Anxiety					
THE MORNING/							
		Depression					
ORAL							
		Insomnia Neuromyopathy Weight Increased					

Date:08/09/01ISR Number: 3774246-XReport Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Health	Vioxx	PS	Merck Research			
	Coordination Abnormal	Professional			Laboratories Div			
	Difficulty In Walking	Company			Merck Co Inc	ORAL	25	
	Disorientation	Representative					MG/DAILY	ORAL
	Drug Interaction		Anafranil	SS				
	Speech Disorder		Klonopin	SS				
	Vision Blurred		Lamictal	SS				
			Wellbutrin	SS				
			Dipentum	SS				
			Premarin	SS				
			Zoloft	SS				
			Coumadin	C				
			Motrin	C				
			Lithium Carbonate	C				

Date:08/09/01ISR Number: 3774459-7Report Type:Expedited (15-DaCompany Report #WAES 01072531
Age:37 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Vioxx	PS	Merck Research			
	Spinal Disorder	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	
							MG/DAILY	PO
			Wellbutrin	SS				
							UNKNOWN	

			Delestrogen	C		
			Flexeril	C		
			Lipitor	C		
			Clonazepam	C		

Date:08/09/01ISR Number: 3774530-XReport Type:Expedited (15-DaCompany Report #A0156108A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Stress Disorder Condition Aggravated Endometrial Disorder Increased Tendency To Bruise Menstrual Disorder	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL	
			Herbal Medication Homeopathic Medication	C C				

Date:08/09/01ISR Number: 3774582-7Report Type:Expedited (15-DaCompany Report #WAES 01072531
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Spinal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Wellbutrin	SS			PO	
			Delestrogen	C			UNKNOWN	
			Flexeril	C				
			Lipitor	C				
			Clonazepam	C				

Date:08/09/01ISR Number: 3774888-1Report Type:Expedited (15-DaCompany Report #A114068
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Arrhythmia	Consumer	Viagra	PS	Pfizer Agricultural	
Hospitalization - Initial or Prolonged	Cardio-Respiratory Arrest Coma	Health Professional	Bupropion	SS	Div	ORAL 300.00 MG TOTAL:BID ORAL
	Convulsion Drug Interaction					
	Fall		Tamsulosin	SS		ORAL 0.40 MG TOTAL:DAILY:ORAL
	Head Injury Tachycardia					
			Atorvastatin	C		
			Lorazepam	C		
			Aspirin	C		
			Dimethyl Sulfone	C		
			Ubidecarenone	C		
			Multivitamin	C		
			Fish Oil	C		
			Pentatanic Acid	C		

Date:08/09/01ISR Number: 3775286-7Report Type:Expedited (15-DaCompany Report #B0116466A
Age:49 YR Gender:Female I/FU:I

Outcome	PT
Other	Dizziness
	Headache

		Insomnia					
		Syncope					
		Tremor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign	Bupropion			
			Consumer	Hydrochloride	PS	Glaxo Wellcome Inc	
150 MG							
VARIABLE							
DOSE;							
				Bromazepam	C		
				Nitroglycerin	C		
				Atenolol	C		
				Conjugated Estrogens	C		

Date:08/10/01ISR Number: 3773873-3Report Type:Expedited (15-DaCompany Report #A0127152A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Drug Level Above		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Per day						
	Therapeutic		Zoloft	SS		ORAL
100MG Twice						
	Overdose					
per day						
			Unspecified			
			Medication	C		

Date:08/10/01ISR Number: 3773874-5Report Type:Expedited (15-DaCompany Report #A0154589A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Vision Blurred		Wellbutrin	PS	Glaxo Wellcome	ORAL
14 DAY						

Date:08/11/01ISR Number: 3779413-7Report Type:Expedited (15-DaCompany Report #NSADSS2001012819
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Grand Mal Convulsion	Foreign Study Health Professional	Remicade (5 Mg/Ml Lyophilized Powder) (Infliximab, Recombinant)	PS		
INTRAVENOUS 5 MG/KG, 1 IN 1 TIME(S), IV						
			Wellbutrin (Amfebutamone Hydrochloride)	SS		
			Pentasa (Mesalazine)	C		
			Losec (Omeprazole)	C		
			Buscopan (Hyoscine Butylbromide)	C		
			Demerol (Pethidine Hydrochloride)	C		
			Maxeran (Metoclopramide Hydrochloride)	C		
			Vitamin B12 (Cyanocobalamin)	C		
			Entocort (Budesonide)	C		
			Imuran (Azathioprine)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/01ISR Number: 3774994-1Report Type:Expedited (15-DaCompany Report #A0157043A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	50MG Per day	
			Flomax	C				

Date:08/13/01ISR Number: 3774998-9Report Type:Expedited (15-DaCompany Report #B0109588A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization - Initial or Prolonged	Asthenia						per day	
	Blood Pressure Decreased		Aspirin	C			150MG per day	
Other	Dizziness		Ketoprofen	C				
	Dyspnoea		Alcohol	C				
	Feeling Abnormal							
	Insomnia							
	Pallor							
	Palpitations							
	Pulse Absent							
	Supraventricular Tachycardia							
	Syncope							

Date:08/13/01ISR Number: 3775001-7Report Type:Expedited (15-DaCompany Report #B0114323A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Three	
	Fall							
times per day							2	YR
	Tooth Loss							

Date:08/13/01ISR Number: 3775002-9Report Type:Expedited (15-DaCompany Report #B0116763A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	6 DAY

Date:08/13/01ISR Number: 3775003-0Report Type:Expedited (15-DaCompany Report #B0116765A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	34 DAY
	Hypomania		Amoxycillin	C		ORAL	500MG Per day	13 DAY
	Mania		Alcohol	C		ORAL		

Date:08/13/01ISR Number: 3776009-8Report Type:Expedited (15-DaCompany Report #PHBS2001US07876
Age:4 MON Gender:Female I/FU:I

Outcome	PT
Other	Abdominal Pain Upper
	Complications Of Maternal Exposure To Therapeutic Drugs
	Oesophageal Disorder

	Vomiting						
Dose	Duration	Report Source	Product	Role	Manufacturer	Route	
TRANSPLACENTAL	TRANSPLACENTAL	Health Professional	Famvir	PS	Novartis Pharmaceuticals Corp		
			Wellbutrin (Amfebutamone Hydrochloride)	SS			
			Claritin (Loratadine)	C			

Date:08/13/01ISR Number: 3776036-0Report Type:Expedited (15-DaCompany Report #A0156690A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Dermatitis Hypersensitivity Loss Of Consciousness Pruritus Urticaria Viral Infection	Foreign Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG / TWICE PER DAY / ORAL	

Date:08/13/01ISR Number: 3776258-9Report Type:Expedited (15-DaCompany Report #A0127152A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Above Therapeutic	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	250 MG / PER DAY / ORAL	

	Overdose		Sertraline Hydrochloride (Formulation Unknown) (Sertraline Hydrochloride)	SS		ORAL

100 MG /

TWICE PER DAY

/ ORAL

Date:08/13/01ISR Number: 3776316-9Report Type:Expedited (15-DaCompany Report #A0156426A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
	Congestive	Professional					TWICE PER DAY	
							/ ORAL	3 YR
			Amantadine (Amantadine Hydrochloride)	SS			1 MON	
			Selegiline	C				

Date:08/13/01ISR Number: 3776415-1Report Type:Expedited (15-DaCompany Report #A0152291A
Age:35 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased

	Cholecystectomy Cholelithiasis Gallbladder Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain	Study	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG/ TWICE
	Weight Decreased	Health					PER DAY/ORAL
		Professional	Ortho Tri-Cyclen	C			

Date:08/13/01ISR Number: 3776417-5Report Type:Expedited (15-DaCompany Report #A0154589A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Vision Blurred	Health Professional Company Representative	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	150 MG /ORAL

Date:08/14/01ISR Number: 3776187-0Report Type:Expedited (15-DaCompany Report #A0156593A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion Convulsive Threshold Lowered		Wellbutrin Narcotics	PS SS	Glaxo Wellcome	ORAL	

Date:08/14/01ISR Number: 3776188-2Report Type:Expedited (15-DaCompany Report #A0156711A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day
	Complications Of Maternal Exposure To Therapeutic Drugs		Prozac	C			

Date:08/14/01ISR Number: 3776189-4Report Type:Expedited (15-DaCompany Report #A0157266A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Atrial Fibrillation Nervousness		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	7 DAY

Date:08/14/01ISR Number: 3776196-1Report Type:Expedited (15-DaCompany Report #B0116926A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation Neoplasm Malignant		Zyban	PS	Glaxo Wellcome			

Date:08/15/01ISR Number: 3777433-XReport Type:Expedited (15-DaCompany Report #A0157251A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Laboratory Test Abnormal Multiple Sclerosis		Zyban Premarin	PS C	Glaxo Wellcome	ORAL	150MG Twice per day	2 WK

Vitamin E	C
Vitamin C	C
Vitamin A	C
Multivitamin	C

Date:08/15/01ISR Number: 3777434-1Report Type:Expedited (15-DaCompany Report #B0113169A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Valve Stenosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Cardiac Failure						per day	
Initial or Prolonged	Coronary Artery Disease							
	Decreased Appetite							
	Dry Throat							
	Dyspnoea							
	Oedema Peripheral							
	Retching							

Date:08/15/01ISR Number: 3779307-7Report Type:Periodic Company Report #2001011456-1
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Palpitations	Health	Paxil	PS	Smithkline Beecham	ORAL	60 MILLIGRAMS	
		Professional					1.0 DAILY	
ORAL								112 DAY
			Wellbutrin Sr (Bupropion Hcl)	SS		ORAL	200 MILLIGRAMS	
							2.0 DAILAY	
ORAL								87 DAY

Date:08/15/01ISR Number: 3779338-7Report Type:Periodic Company Report #US CDC 0426000002
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Cardiomyopathy	Health Professional	Librium	PS	Icn Pharmaceuticals Inc	ORAL	PO	
	Chest Pain Dyspnoea Electrocardiogram Qt Prolonged		Wellbutrin Tablet-Controlled Release	SS		ORAL	100 MG SEE TEXT	PO
	Intentional Misuse Laboratory Test Abnormal Peripheral Ischaemia		Mirtazapin Tablet (Mirtazapine)	SS		ORAL	20 MG SEE TEXT	PO
	Syncope Tricuspid Valve Incompetence							

Date:08/16/01ISR Number: 3778359-8Report Type:Expedited (15-DaCompany Report #A0156690A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypersensitivity		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	18 DAY
Hospitalization - Initial or Prolonged	Hypotension Loss Of Consciousness Viral Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/01ISR Number: 3778453-1Report Type:Direct Company Report #
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis		Wellburtin 150 Sr	PS		ORAL	150 PO BID	
	Prostration		Atenolol 25	C				
	Serum Sickness							
	Urticaria							

Date:08/16/01ISR Number: 3778665-7Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Stress Disorder	Health	Vioxx	PS	Merck Research			
	Aphasia	Professional			Laboratories Div			
	Coordination Abnormal	Company			Merck Co Inc	ORAL	25	
	Difficulty In Walking	Representative					MG/DAILY/ORAL	
	Disorientation		Anafranil	SS				
	Drug Interaction		Klonopin	SS				
	Transient Ischaemic		Lamictal	SS				
	Attack		Wellbutrin	SS				
	Vision Blurred		Dipentum	SS				
			Premarin	SS				
			Zoloft	SS				
			Coumadin	C				
			Motrin	C				
			Lithium Carbonate	C				

Date:08/16/01ISR Number: 3779412-5Report Type:Periodic Company Report #US CDC 0426000002
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiopathy	Health	Librium	PS	Icn Pharmaceuticals Inc	ORAL	PO	
	Cardiac Disorder	Professional						
	Cardiomyopathy		Wellbutrin Tablet-Controlled					
	Chest Pain							

	Dyspnoea	Release	SS	ORAL
100 MG SEE				
	Electrocardiogram Qt			
TEXT PO				
	Prolonged			
	Intentional Misuse			
	Laboratory Test Abnormal			
	Syncope			
	Tricuspid Valve			
	Incompetence			

Date:08/16/01ISR Number: 3781852-5Report Type:Periodic Company Report #US CDC 0426000003*
Age:35 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Cardiac Disorder
Initial or Prolonged	Cardiomyopathy
	Chest Pain
	Dyspnoea
	Electrocardiogram Qt
	Prolonged
	Intentional Misuse
	Laboratory Test Abnormal
	Syncope
	Tricuspid Valve

	Incompetence						
Dose	Duration	Report Source	Product	Role	Manufacturer	Route	
		Health Professional	Librium (Chlorodiazepoxide Hcl)	PS		ORAL	PO
			Wellbutrin Tablet-Controlled Release	SS		ORAL	100 MG SEE TEXT PO
			Mirtazapin Tablet (Mirtazepine)	SS		ORAL	20 MG SEE TEXT PO

Date:08/17/01ISR Number: 3778759-6Report Type:Expedited (15-DaCompany Report #A0156108A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	300MG per day	
	Endometriosis		Herbs	C				
	Haemorrhage		Homeopathy	C				
	Haemorrhagic Disorder							
	Increased Tendency To Bruise							
	Menstrual Disorder							
	Stress							

Date:08/17/01ISR Number: 3778767-5Report Type:Expedited (15-DaCompany Report #B0115303A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Zyban	PS	Glaxo Wellcome		UNKNOWN	
	Convulsion							

	Fatigue						

Date:08/17/01ISR Number: 3778773-0Report Type:Expedited (15-DaCompany Report #B0117311A
Age:55 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Herpes Zoster		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day
Other			Thyroxine	C	Glaxo Wellcome	ORAL	100MCG Per day

Date:08/17/01ISR Number: 3778774-2Report Type:Expedited (15-DaCompany Report #B0117315A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Chronic Lymphocytic Leukaemia Skin Lesion		Zyban	PS	Glaxo Wellcome	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/01ISR Number: 3779653-7Report Type:Expedited (15-DaCompany Report #A0156711A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Spontaneous	Study	Wellbutrin	PS	Glaxosmithkline	ORAL	150 MG/PER
	Complications Of Maternal	Health					DAY/ORAL
	Exposure To Therapeutic Drugs	Professional	Fluoxetine Hydrochloride	C			
	Pregnancy						

Date:08/17/01ISR Number: 3779654-9Report Type:Expedited (15-DaCompany Report #A0156593A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	ORAL
	Convulsive Threshold	Professional	Narcotic (Narcotic)	SS			UNKNOWN
	Lowered	Company Representative					

Date:08/17/01ISR Number: 3779656-2Report Type:Expedited (15-DaCompany Report #A0157251A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Headache	Consumer	Zyban	PS	Glaxo Wellcome Inc	ORAL	150 MG /
	Joint Stiffness						TWICE PER DAY
	Multiple Sclerosis						/ ORAL
	Neck Pain		Conjugated Estrogens	C			
	Pyrexia		Vitamin E	C			
	Tinnitus		Ascorbic Acid	C			
			Retinol	C			
			Multivitamin	C			

Date:08/17/01ISR Number: 3779710-5Report Type:Expedited (15-DaCompany Report #A0157266A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Atrial Fibrillation Nervousness Palpitations	Consumer	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	300 MG PER DAY/ORAL	

Date:08/17/01ISR Number: 3779818-4Report Type:Expedited (15-DaCompany Report #A114068
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Amnesia Cardio-Respiratory Arrest Coma Convulsion Drug Interaction Fall Head Injury Tachycardia	Consumer Health Professional	Viagra	PS	Pfizer Agricultural Div	ORAL	50.00 MG TOTAL:PRN:ORAL	
			Bupropion	SS		ORAL	300.00 MG TOTAL:BID:ORAL	
			Tamsulosin	SS		ORAL	40 MG TOTAL:DAILY:ORAL	
			Atorvastatin	C				
			Lorazepam	C				
			Aspirin	C				

Dimethyl Sulfone	C
Ubidecarenone	C
Multivitamin	C
Fish Oil	C
Pentatanic Acid	C

Date:08/17/01ISR Number: 3780297-1Report Type:Expedited (15-DaCompany Report #B0113169A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Aortic Valve Stenosis	Foreign	Bupropion				
Hospitalization -	Cardiac Failure	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG TWICE
Initial or Prolonged	Coronary Artery Disease	Professional					PER DAY ORAL
	Decreased Appetite						
	Dry Throat						
	Retching						

Date:08/17/01ISR Number: 3785650-8Report Type:Expedited (15-DaCompany Report #B0116926A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Constipation	Foreign	Zyban Tablet - Zyban				
	Neoplasm Malignant	Consumer	(Bupropion Hydrochloride)	PS			150 MG

Date:08/20/01ISR Number: 3779611-2Report Type:Expedited (15-DaCompany Report #A0155325A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angioneurotic Oedema		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Twice
Initial or Prolonged	Arthralgia						per day 18 DAY
	Dermatitis						
	Eyelid Oedema						

Face Oedema
Herpes Zoster
Joint Swelling
Oedema Peripheral
Serum Sickness
Urticaria

Date:08/20/01ISR Number: 3779613-6Report Type:Expedited (15-DaCompany Report #A0155843A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Dermatitis Joint Swelling Serum Sickness Urticaria		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	19 DAY

Date:08/20/01ISR Number: 3779780-4Report Type:Direct Company Report #
Age:38 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Heart Rate Increased Hyperhidrosis

	Palpitations					
	Panic Attack					
	Tremor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS		ORAL
1 DAILY ORAL						
			Coumadin	C		
			Factor V	C		

Date:08/20/01ISR Number: 3780396-4Report Type:Expedited (15-DaCompany Report #B0114323A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Balance Disorder	Foreign	Wellbutrin	PS		ORAL
100 MG /						
	Fall	Consumer				
THREE TIMES						
	Tooth Loss					
PER DAY /						
ORAL	2 YR					

Date:08/20/01ISR Number: 3780397-6Report Type:Expedited (15-DaCompany Report #B0116765A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Mania	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG / PER						
DAY/ ORAL						
			Amoxycillin	C		
			Ethanol	C		

Date:08/20/01ISR Number: 3780402-7Report Type:Expedited (15-DaCompany Report #B0109588A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Foreign	Zyban Tablet - Zyban					
Hospitalization -	Asthenia	Health	(Bupropion					
Initial or Prolonged	Blood Pressure Decreased	Professional	Hydrochloride)	PS		ORAL	150 MG /	
Required	Dizziness						TWICE PER DAY	
Intervention to	Dyspnoea						/ ORAL	
Prevent Permanent	Feeling Abnormal		Aspirin	C				
Impairment/Damage	Pallor		Ketoprofen	C				
	Palpitations		Ethanol	C				
	Supraventricular							
	Tachycardia							
	Syncope							

Date:08/20/01ISR Number: 3780521-5Report Type:Expedited (15-DaCompany Report #A0156690A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypersensitivity	Foreign	Bupropion					
Hospitalization -	Viral Infection	Health	Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG /	
Initial or Prolonged		Professional					TWICE PER DAY	
							/ ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/20/01ISR Number: 3780808-6Report Type:Expedited (15-DaCompany Report #B0116763A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Foreign	Bupropion Hydrochloride	PS	Glaxo Wellcome Inc	ORAL	150 MG/TTWICE	PER DAY, ORAL

Date:08/20/01ISR Number: 3780809-8Report Type:Expedited (15-DaCompany Report #A0157043A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign	Wellbutrin Sr	PS	Glaxo Wellcome Inc	ORAL	50 MG/PER DAY/ORAL	
		Consumer	Tamsulosin Hcl	C				

Date:08/21/01ISR Number: 3780539-2Report Type:Expedited (15-DaCompany Report #A0157983A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged								

Date:08/21/01ISR Number: 3780540-9Report Type:Expedited (15-DaCompany Report #B0107247A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Zyban	PS	Glaxo Wellcome			
	Paraesthesia		Seretide	C	Glaxo Wellcome			
			Ceclor	C		ORAL	375MG Twice	

per day

			Solone	C		

Date:08/21/01ISR Number: 3780541-0Report Type:Expedited (15-DaCompany Report #B0113284A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease Sudden Death		Zyban	PS	Glaxo Wellcome			

Date:08/21/01ISR Number: 3780545-8Report Type:Expedited (15-DaCompany Report #B0116842A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome			

Date:08/21/01ISR Number: 3780547-1Report Type:Expedited (15-DaCompany Report #B0117368A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome		150MG As directed	

Date:08/21/01ISR Number: 3780548-3Report Type:Expedited (15-DaCompany Report #B0117371A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:08/21/01ISR Number: 3780549-5Report Type:Expedited (15-DaCompany Report #B0117516A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thermal Burn		Zyban	PS	Glaxo Wellcome			

Date:08/21/01ISR Number: 3780550-1Report Type:Expedited (15-DaCompany Report #D0019085A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	7 DAY
	Constipation		Carbimazol	C		ORAL	5MG Per day	
	Dysuria		Bisomerck	C		ORAL		
	Erythema		Omeprazol	C		ORAL	20MG Per day	
	Feeling Hot		Other Herbal Medications	C		ORAL		
	Genital Pruritus Female							
	Gingivitis							
	Headache							
	Hyperaemia							
	Mastitis							
	Pruritus							

Date:08/22/01ISR Number: 3781489-8Report Type:Expedited (15-DaCompany Report #A0155912A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG	Unknown
	Head Injury		Celexa	SS		ORAL		
	Overdose		Alcohol	SS		ORAL		
	Toxicologic Test Abnormal		Benadryl	SS		ORAL		

Date:08/22/01ISR Number: 3781490-4Report Type:Expedited (15-DaCompany Report #A0157654A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Decreased		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	4 MON
	Blood Sodium Decreased		Zyprexa	C				
	Convulsion		Prozac	C				

Date:08/22/01ISR Number: 3781500-4Report Type:Expedited (15-DaCompany Report #B0117515A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Chest Discomfort		Nicotine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/01ISR Number: 3781618-6Report Type:Direct Company Report #
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Bupropion	PS				
UNKNOWN								
Initial or Prolonged	Dyspnoea		Excedrin	C				
Required	Electrocardiogram							
Intervention to	Abnormal							
Prevent Permanent	Electrocardiogram St							
Impairment/Damage	Segment Abnormal							
	Stevens-Johnson Syndrome							

Date:08/22/01ISR Number: 3782160-9Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Aphasia	Professional					MG/DAILY/ORAL	
	Asthenia	Company	Anafranil	SS			25 MG/BID	
	Balance Disorder	Representative	Klonopin	SS			0.5 MG/BID	
	Blood Pressure Increased		Lamictal	SS			100 MG/BID	
	Confusional State		Wellbutrin	SS			150 MG/BID	
	Coordination Abnormal		Dipentum	SS			250 MG	
	Difficulty In Walking		Premarin	SS			1.25 MG/DAILY	
	Disorientation		Zoloft	SS			100 MG/DAILY	
	Dizziness		Coumadin	C				
	Drug Interaction		Motrin	C				
	Dry Skin		Lithium Carbonate	C				
	Dysarthria							
	Dysphagia							
	Dyspnoea							
	Emotional Distress							
	Feeling Abnormal							

Gait Disturbance
Headache
Mental Disorder
Mental Impairment
Motor Dysfunction
Respiratory Rate
Increased
Restlessness
Skin Warm
Speech Disorder
Transient Ischaemic
Attack
Vision Blurred

Date:08/23/01ISR Number: 3781909-9Report Type:Expedited (15-DaCompany Report #A0145968A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY
			Unknown					
			Anti-Depressant	C				
			Oxycontin	C				
			Percocet	C				

Date:08/23/01ISR Number: 3781918-XReport Type:Expedited (15-DaCompany Report #B0100202A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis		Zyban	PS	Glaxo Wellcome		150MG Twice per day	8 DAY
	Transient Ischaemic Attack		Grapefruit Juice	C			UNKNOWN	
			Aspirin	C			150MG In the morning	
			Hrt	C				

Date:08/23/01ISR Number: 3781922-1Report Type:Expedited (15-DaCompany Report #B0117830A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	

Date:08/23/01ISR Number: 3782583-8Report Type:Expedited (15-DaCompany Report #A0156108A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Ecchymosis Haemorrhagic Disorder Menstrual Disorder	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	
	Stress		Herbal Medication	C				
			Homeopathic Medication	C				

Date:08/23/01ISR Number: 3782735-7Report Type:Expedited (15-DaCompany Report #B0117516A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thermal Burn	Foreign Health Professional Company Representative	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS			150 MG	

Date:08/23/01ISR Number: 3782737-0Report Type:Expedited (15-DaCompany Report #B0117368A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS			150 MG / AS DIRECTED	

Date:08/23/01ISR Number: 3782738-2Report Type:Expedited (15-DaCompany Report #B0117371A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Chest Pain	Foreign Health Professional Company Representative	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/23/01ISR Number: 3782741-2Report Type:Expedited (15-DaCompany Report #B0116842A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Myocardial Infarction	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS			150 MG

Date:08/23/01ISR Number: 3782742-4Report Type:Expedited (15-DaCompany Report #A0157983A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged	Anaphylactic Reaction Hypersensitivity	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL

Date:08/23/01ISR Number: 3782756-4Report Type:Expedited (15-DaCompany Report #B0117315A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Chronic Lymphocytic Leukaemia Lymphocytosis Skin Disorder	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / ORAL

Date:08/23/01ISR Number: 3782758-8Report Type:Expedited (15-DaCompany Report #B0115303A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Confusional State Convulsion Fatigue	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG

Date:08/23/01ISR Number: 3782759-XReport Type:Expedited (15-DaCompany Report #B0117311A
Age:55 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Herpes Zoster	Foreign	Zyban Tablet - Zybam (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL	
Required Intervention to Prevent Permanent Impairment/Damage			Thyroxine Sodium	C				

Date:08/23/01ISR Number: 3782767-9Report Type:Expedited (15-DaCompany Report #B0107247A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Paraesthesia	Foreign Health Professional	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS			150 MG	
			Fluticasone+Salmeterol	C				
			Cefaclor	C				
			Solone	C				

Date:08/23/01ISR Number: 3782770-9Report Type:Expedited (15-DaCompany Report #A0155325A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Arthralgia Dermatitis Difficulty In Walking Hepatic Function Abnormal Herpes Zoster Hypogammaglobulinaemia Joint Swelling Red Blood Cell Sedimentation Rate Increased Serum Sickness Urticaria	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL

Date:08/23/01ISR Number: 3782790-4Report Type:Expedited (15-DaCompany Report #D0019085A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Pain Constipation Dysuria Erythema Feeling Hot Gingivitis Headache Hyperaemia Mastitis Pruritus	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Carbimazole Bisoprolol Omeprazole Herbal Medication	PS C C C C		ORAL	150 MG/ PER DAY/ ORAL

Date:08/23/01ISR Number: 3783287-8Report Type:Expedited (15-DaCompany Report #B0113284A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease Overdose Sudden Death	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS				

Date:08/23/01ISR Number: 3783293-3Report Type:Expedited (15-DaCompany Report #A0155843A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Serum Sickness	Foreign Health Professional	Wellbutrin Tablet-Controlled Release (Buproprion Hydrochloride)	PS		ORAL	150 MG /TWICE PER DAY/ORAL	

Date:08/24/01ISR Number: 3782396-7Report Type:Expedited (15-DaCompany Report #A0158445A
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Other	Attention Deficit/Hyperactivity Disorder

	Bronchitis Upper Respiratory Tract Infection					
	Urticaria		Wellbutrin	PS	Glaxo Wellcome	ORAL
1 MON						
			Ceftin	SS	Glaxo Wellcome	ORAL
			Penicillin	SS	Glaxo Wellcome	ORAL

Date:08/24/01ISR Number: 3782945-9Report Type:Expedited (15-DaCompany Report #B0117515A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Chest Discomfort	Foreign Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/PER DAY/ORAL						
			Nicotine	C		

Date:08/24/01ISR Number: 3783160-5Report Type:Expedited (15-DaCompany Report #A0157654A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Potassium Decreased Blood Sodium Decreased Convulsion	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
150 MG / PER DAY / ORAL						
			Olanzapine	C		
			Fluoxetine Hydrochloride	C		

Date:08/24/01ISR Number: 3783166-6Report Type:Expedited (15-DaCompany Report #A0155912A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Injury Intentional Misuse	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/	ORAL
			Citalopram Hydrobromide Tablet (Citalopram Hydrobromide)	SS		ORAL		ORAL
			Ethanol Liquid (Alcohol)	SS		ORAL		ORAL
			Diphenhydramine Hcl (Formulation Unknown) (Diphenhydramine Hcl)	SS		ORAL		ORAL

Date:08/27/01ISR Number: 3782699-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT
Other	Arthralgia Joint Stiffness Myalgia

	Pyrexia						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban 150 Mgm/Day X 3 D (Began 17 July 01) Than Bid	PS			150 MGM WEEKLY X3 D - THEN BID
			Nicoderm Patch	SS			1 DAILY

Date:08/27/01ISR Number: 3782987-3Report Type:Expedited (15-DaCompany Report #A0155443A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day
	Convulsion		Vioxx	SS			
	Fall		Celebrex	SS			
	Head Injury		Neurontin	C			
	Headache						
	Inflammation						
	Migraine						
	Mucous Membrane Disorder						
	Pruritus						
	Sinus Headache						
	Swelling						

Date:08/27/01ISR Number: 3783020-XReport Type:Expedited (15-DaCompany Report #B0116466A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dizziness		Zyban	PS	Glaxo Wellcome		150MG As directed 8 DAY
	Feeling Abnormal						

	Headache		Bromazepam	C		ORAL
3MG Three						
	Insomnia					
times per day						
	Syncope		Gtn	C	Glaxo Wellcome	ORAL
100MG Twice						
	Tremor					
per day						
			Atenolol	C		ORAL
100MG Per day						
			Conjugated Oestrogens	C		ORAL
625MCG Three						
times per						
week						

Date:08/27/01ISR Number: 3783022-3Report Type:Expedited (15-DaCompany Report #B0118184A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	17 DAY
			Aspirin	C		ORAL	28 DAY	
			Ramipril	C		ORAL	2.5MG Per day	
			Oestradiol	C		ORAL	2MG Per day	
			Levonorgestrel	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/01ISR Number: 3783314-8Report Type:Expedited (15-DaCompany Report #GBR004231
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lethargy	Health Professional	Meridia	PS				
	Overdose		Wellbutrin	SS				
	Vomiting	Other	Prozac	SS				
			Serzone	SS				
			Lorazepam	SS				
			Duract	SS				

Date:08/27/01ISR Number: 3783435-XReport Type:Expedited (15-DaCompany Report #A0145968A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Wellbutrin Tablet - Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG, PER DAY, ORAL	
	Decreased Appetite							
	Dysphagia							
	Hypersensitivity							
			Antidepressant	C				
			Oxycodone Hydrochloride	C				
			Percocet	C				

Date:08/27/01ISR Number: 3783445-2Report Type:Expedited (15-DaCompany Report #A0158445A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Attention Deficit/Hyperactivity Disorder	Health Professional Company	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
	Bronchitis	Representative	Ceftin Tablet (Cefuroxime Axetil)	SS		ORAL	ORAL	
	Infection		Phenoxymethylpenicil lin K (Formulation					
	Urticaria							

	Unknown) (Penicillin V Potassium)	SS	ORAL
ORAL			

Date:08/27/01ISR Number: 3783523-8Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Required	Aggression
Intervention to	Blood Pressure Increased
Prevent Permanent	Blood Thyroid Stimulating
Impairment/Damage	Hormone Decreased
	Drug Ineffective
	Ecchymosis
	Epistaxis
	Fall
	Haemorrhagic Stroke
	Head Injury
	Headache
	Heart Rate Decreased
	Heart Rate Increased
	Hostility
	Hyperhidrosis
	Overdose

	Palpitations Parkinson'S Disease Syncope	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Thinking Abnormal	Consumer	Zoloft Tablets	PS		
50.00 MG						
	Transient Ischaemic					
TOTAL: DAILY						
	Attack		Wellbutrin	SS		ORAL
300.00 MG						
TOTAL: BID:						
ORAL						
			Coumadin	SS		
			Effexor Sr	SS		ORAL
300.00 MG						
TOTAL: BID:						
ORAL						
			Toprol	C		
			Zebeta	C		
			Lanoxin	C		
			Lasix	C		
			Synthroid	C		
			Vitamin E	C		
			Estrogen	C		

Date:08/27/01ISR Number: 3783809-7Report Type:Expedited (15-DaCompany Report #B0117830A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Chest Pain	Foreign	Zyban Tablet - Zyban			
Intervention to	Hypoaesthesia		(Bupropion			
Prevent Permanent			Hydrochloride)	PS	Glaxosmithkline	ORAL
150 MG / PER						
Impairment/Damage						
DAY / ORAL						

Date:08/27/01ISR Number: 3783811-5Report Type:Expedited (15-DaCompany Report #B0100202A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis Transient Ischaemic Attack	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS	Glaxosmithkline		150 MG / TWICE PER DAY	
			Grapefruit Juice	C				
			Aspirin	C				
			Hrt	C				

Date:08/28/01ISR Number: 3783328-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Wellbutrin Sr/ 150 Mg	PS		ORAL	1 PER/ ORAL	

Date:08/28/01ISR Number: 3783481-6Report Type:Expedited (15-DaCompany Report #B0117307A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	14 DAY
	Mental Impairment Pupillary Disorder		Femodene	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/01ISR Number: 3783484-1Report Type:Expedited (15-DaCompany Report #B0118326A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cold Sweat		Zyban	PS	Glaxo Wellcome	ORAL	6	DAY
	Pain In Extremity							
	Pallor							
	Palpitations							

Date:08/28/01ISR Number: 3783904-2Report Type:Direct Company Report #
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Zyban	PS			150 MG SR BID	

Date:08/29/01ISR Number: 3784006-1Report Type:Expedited (15-DaCompany Report #B0117827A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Zyban	PS	Glaxo Wellcome		UNKNOWN	33 DAY
	Depression							
	Difficulty In Walking							
	Dizziness							
	Dystonia							
	Headache							
	Malaise							
	Pain In Extremity							

Date:08/29/01ISR Number: 3785299-7Report Type:Expedited (15-DaCompany Report #A0155443A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin Tablet-Controlled					
	Fall							

	Head Injury		Release (Bupropion			
	Headache		Hydrochloride)	PS	Glaxosmithkline	ORAL
150 MG/ PER						
	Increased Viscosity Of					
DAY / ORAL						
	Bronchial Secretion		Rofecoxib			
	Migraine		(Formulation			
	Pruritus		Unknown) (Rofecoxib)	SS		
	Sinus Headache		Celecoxib			
	Swelling		(Formulation			
			Unknown) (Celecoxib)	C		
			Gabapentin	C		

Date:08/29/01ISR Number: 3785604-1Report Type:Expedited (15-DaCompany Report #B0118184A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Dyspepsia	Foreign	Zyban Tablet - Zyban			
Intervention to	Gastritis		(Bupropion			
Prevent Permanent			Hydrochloride)	PS		ORAL
150 MG /						
Impairment/Damage						
TWICE PER DAY						
/ ORAL						
			Aspirin	C		
			Ramipril	C		
			Oestradiol	C		
			Levonorgestrel	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/29/01ISR Number: 3785620-XReport Type:Expedited (15-DaCompany Report #B0116466A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Foreign	Zyban Tablet - Zyban					
	Headache	Consumer	(Bupropion					
	Insomnia		Hydrochloride)	PS			150 MG/AS	
	Petit Mal Epilepsy						DIRECTED	
	Syncope		Bromazepam	C				
	Tremor		Nitroglycerin	C				
			Atenolol	C				
			Conjugated Estrogens	C				

Date:08/30/01ISR Number: 3785121-9Report Type:Expedited (15-DaCompany Report #A0155912A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Head Injury	Professional					per day	
	Overdose		Celexa	SS		ORAL		
	Toxicologic Test Abnormal		Alcohol	SS		ORAL		
			Benadryl	SS		ORAL		

Date:08/30/01ISR Number: 3785124-4Report Type:Expedited (15-DaCompany Report #A0159165A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	200MG Twice	
	Bone Graft						per day	6 MON
	Drug Interaction		Toprol Xl	SS		ORAL	50MG Per day	
	Liver Function Test		Nitrodur	C	Glaxo Wellcome			
	Abnormal		Ranitidine	C	Glaxo Wellcome			
	Scleral Discolouration		Hydroxyzine	C				

Tinnitus
Tooth Disorder

Date:08/30/01ISR Number: 3785131-1Report Type:Expedited (15-DaCompany Report #B0118186A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	9 DAY
	Hemiparesis							
	Hypoaesthesia							
	Hyporeflexia							
	Nervousness							
	Sensory Disturbance							

Date:08/30/01ISR Number: 3785132-3Report Type:Expedited (15-DaCompany Report #B0118455A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Zyban	PS	Glaxo Wellcome		150MG As directed	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/01ISR Number: 3785916-1Report Type:Direct Company Report #
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin /					
	Coordination Abnormal		Bupropion Sr 100mg	PS			100MG SR Q AM	
	Hyperhidrosis		Clonazepam	C				
	Mydriasis		Zoloft	C				
	Tachycardia		Mertazapine	C				
	Tremor							

Date:08/31/01ISR Number: 3785967-7Report Type:Expedited (15-DaCompany Report #A0141089A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged	Fall		Alcohol	SS				
	Intentional Misuse		Flovent	C	Glaxo Wellcome			
	Multiple Fractures		Serevent	C	Glaxo Wellcome			
	Stupor		Atrovent	C	Glaxo Wellcome			
	Suicide Attempt		Proventil	C	Glaxo Wellcome			

Date:08/31/01ISR Number: 3785982-3Report Type:Expedited (15-DaCompany Report #A0159004A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Surgery		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Heart Rate Decreased						per day	
	Syncope		Aspirin	C		ORAL	81MG Per day	
			Glucophage	C				
			Nitroglycerin	C	Glaxo Wellcome			
			Altace	C				
			Zocor	C				
			Niaspan	C				

Date:08/31/01ISR Number: 3785985-9Report Type:Expedited (15-DaCompany Report #B0089512A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme Psoriasis Rash Pustular Skin Disorder		Bupropion Hydrochloride Co-Proxamol Dothiepin	PS C C	Glaxo Wellcome	ORAL ORAL ORAL	150MG Twice per day	21 DAY

Date:08/31/01ISR Number: 3785986-0Report Type:Expedited (15-DaCompany Report #B0089979A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme Psoriasis Skin Disorder		Zyban Coproxamol	PS C	Glaxo Wellcome	ORAL	2	WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/01ISR Number: 3785994-XReport Type:Expedited (15-DaCompany Report #B0118584A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome		150MG Single	dose

Date:08/31/01ISR Number: 3787093-XReport Type:Periodic Company Report #A115200
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Ziprasidone Po	PS			25.00 MG	
	Glossitis	Professional						TOTAL:DAILY
		Company Representative	Wellbutrin (Ibupropion)	SS				

Date:08/31/01ISR Number: 3787140-5Report Type:Periodic Company Report #A117193
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Akathisia	Health	Ziprasidone Po	PS		ORAL	160.00 MG	
	Mania	Professional						TOTAL:BID:ORA
								L
			Wellbutrin	SS				
			Klonopin	C				
			Luvox	C				

Date:08/31/01ISR Number: 3787319-2Report Type:Expedited (15-DaCompany Report #B0117827A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia	Foreign	Zyban Tablet - Zyban					
	Depression	Consumer	(Bupropion					
	Difficulty In Walking		Hydrochloride)	PS				
	Dizziness							
	Dystonia							
	Malaise							
	Pain							

Date:08/31/01ISR Number: 3787767-0Report Type:Periodic Company Report #A118566
Age:27 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Ziprasidone Po	PS		ORAL		
NOT SPECIFIED								
Initial or Prolonged	Electrocardiogram Qt	Professional	Wellbutrin	SS				
Required	Prolonged	Company	Prozac	SS				
Intervention to	Intentional Misuse	Representative	Depakote	SS				
Prevent Permanent	Tachycardia							
Impairment/Damage								

Date:08/31/01ISR Number: 3788846-4Report Type:Periodic Company Report #A108581
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Ziprasidone Po	PS		ORAL	150.00 MG	
	Drug Interaction	Professional						

TOTAL:BID:ORA

L

			Wellbutrin	SS		ORAL
250.00 MG						
TOTAL:BID:ORA						
L						

Date:09/04/01ISR Number: 3786883-7Report Type:Expedited (15-DaCompany Report #B0115303A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anxiety		Zyban	PS	Glaxo Wellcome	
UNKNOWN	20 DAY					
Hospitalization -	Bite		Dianette	C		ORAL
1TAB Per day						
Initial or Prolonged	Confusional State					
Other	Grand Mal Convulsion					
	Loss Of Consciousness					
	Tongue Disorder					

Date:09/04/01ISR Number: 3786885-0Report Type:Expedited (15-DaCompany Report #B0116842A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
Hospitalization -						
per day						
Initial or Prolonged						

Date:09/04/01ISR Number: 3788024-9Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Aggression		Zoloft 100 Mg Pfizer	PS	Pfizer	ORAL
3 TABS/ EVERY						
Other	Agitation					
MORNIN/ORAL						

	Anger		Wellbutrin Sr 100 Mg			
	Bipolar I Disorder		Glaxo	SS	Glaxo	ORAL
2 TABS / 2						
	Crying					
TIMES/ ORAL						
	Dizziness					
	Euphoric Mood					
	Fear					
	Feeling Abnormal					
	Irritability					
	Nausea					
	Premenstrual Syndrome					
	Suicidal Ideation					
	Tinnitus					

Date:09/05/01ISR Number: 3787337-4Report Type:Expedited (15-DaCompany Report #A0158740A
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Parkinson'S Disease		Wellbutrin	PS	Glaxo Wellcome	ORAL

Date:09/05/01ISR Number: 3787350-7Report Type:Expedited (15-DaCompany Report #B0118929A
Age:28 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Blood Pressure Abnormal
Initial or Prolonged	Dysphagia
	Erythema
	Eyelid Oedema

	Face Oedema						
	Heart Rate Increased						
	Jaundice	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Skin Discolouration		Zyban	PS	Glaxo Wellcome	ORAL	

Date:09/05/01ISR Number: 3788288-1Report Type:Expedited (15-DaCompany Report #A0141089A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health Professional	Zyban Tablets - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/ ORAL
	Blood Pressure Increased						
	Condition Aggravated						
	Fracture						
	Liver Function Test Abnormal		Ethanol (Formulation Unknown) (Alcohol)	SS			
	Renal Impairment		Fluticasone Propionate	C			
	Suicide Attempt		Salmeterol Xinafoate	C			
			Ipratropium Bromide	C			
			Salbutamol Sulphate	C			

Date:09/05/01ISR Number: 3788369-2Report Type:Expedited (15-DaCompany Report #B0118186A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Aggression	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY/ ORAL
	Fluid Overload						
	Hemiparesis						
	Hypoaesthesia						
	Hyporeflexia						
	Nervousness						

Date:09/05/01ISR Number: 3788370-9Report Type:Expedited (15-DaCompany Report #B0118455A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Thrombosis	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG / AS DIRECTED /	

Date:09/05/01ISR Number: 3788381-3Report Type:Expedited (15-DaCompany Report #A0155912A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Injury Intentional Misuse	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
			Citalopram Hydrobromide Tablet (Citalopram Hydrobromide)	SS		ORAL	ORAL	
			Ethanol Liquid (Alcohol)	SS		ORAL	ORAL	
			Diphenhydramine Hcl					

			(Formulation Unknown) (Diphenhydramine Hcl)	SS		ORAL	ORAL

Date:09/05/01ISR Number: 3788382-5Report Type:Expedited (15-DaCompany Report #A0159165A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Amnesia Drug Interaction Loss Of Consciousness Scleral Discolouration Tinnitus Tooth Disorder	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	200 MG TWICE PER DAY ORAL
			Metoprolol Succinate (Formulation Unknown) (Metoprolol Succinate)	SS		ORAL	50 MG PER DAY ORAL
			Nitrogylcerin	C			
			Ranitidine Hydrochloride	C			
			Hydroxyzine	C			

Date:09/05/01ISR Number: 3788391-6Report Type:Expedited (15-DaCompany Report #A0159004A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Heart Rate Decreased Quadruple Vessel Bypass Graft	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL
			Aspirin	C			
			Metformin				

			Hydrochloride	C		
			Nitrogylcerin	C		
			Ramipril	C		
			Simvastatin	C		
			Nicotinic Acid	C		

Date:09/05/01ISR Number: 3788401-6Report Type:Expedited (15-DaCompany Report #B0089979A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme Psoriasis	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	2 WK
		Company Representative	Co-Proxamol	C				

Date:09/05/01ISR Number: 3788412-0Report Type:Expedited (15-DaCompany Report #B0089512A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme Psoriasis	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /	

TWICE PER DAY

/ ORAL

		Co-Proxamol	C
		Dothiepin	C

Date:09/05/01ISR Number: 3788677-5Report Type:Expedited (15-DaCompany Report #B0118584A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG/ SINGLE DOSE	

Date:09/06/01ISR Number: 3787894-8Report Type:Expedited (15-DaCompany Report #A0158740A
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Parkinson'S Disease		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:09/06/01ISR Number: 3787907-3Report Type:Expedited (15-DaCompany Report #B0118929A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal Dysphagia Erythema Eyelid Oedema Face Oedema Heart Rate Increased Jaundice Skin Discolouration		Zyban	PS	Glaxo Wellcome	ORAL		

Date:09/06/01ISR Number: 3788044-4Report Type:Expedited (15-DaCompany Report #A0159343A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Back Pain							
							per day	6 WK
	Difficulty In Walking		Vitamins	C				
	Fatigue							
	Feeling Jittery							
	Muscle Spasms							
	Myalgia							
	Pain							

Date:09/06/01ISR Number: 3788060-2Report Type:Expedited (15-DaCompany Report #B0119110A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Zyban	PS	Glaxo Wellcome			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/06/01ISR Number: 3788948-2Report Type:Expedited (15-DaCompany Report #2010427
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diverticulum Drug Level Above Therapeutic Overdose	Study Health Professional Other	Oxycontin Cr Tablets, 40 Mg (Oxycodone Hydrochloride)	PS		ORAL	40 MG TID PO	
	Pulmonary Congestion Pulmonary Oedema		Oxycontin Cr Tablets, 20 Mg (Oxycodone Hydrochloride)	SS		ORAL	20 MG TID PO	
			Bupropion Hydrochloride	SS				
			Promethazine Hydrochloride	SS				
			Diazepam	SS				
			Acetaminophen	SS				
			Tetrahydrocannabinol	SS				
			Premarin (Conjugated Estrogens)	C				
			Wellbutrin (Bupropion)	C				
			Lortab (Hydrocodone/Acetaminophen)	C				
			Diazepam	C				

Date:09/07/01ISR Number: 3789066-XReport Type:Expedited (15-DaCompany Report #A0159874A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Difficulty In Walking Drug Hypersensitivity Dry Mouth Insomnia Muscle Spasms Oedema Peripheral		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	26 DAY

	Pyrexia					
	Urticaria					

Date:09/07/01ISR Number: 3789080-4Report Type:Expedited (15-DaCompany Report #B0118244A
Age:63 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Tenderness Chest Pain Circulatory Collapse Dyspepsia Dyspnoea Heart Rate Increased Pain Pharyngolaryngeal Pain Vertigo		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	11 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/01ISR Number: 3789085-3Report Type:Expedited (15-DaCompany Report #B0119109A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome			

Date:09/07/01ISR Number: 3789087-7Report Type:Expedited (15-DaCompany Report #B0119241A
Age:57 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome			

Date:09/07/01ISR Number: 3789088-9Report Type:Expedited (15-DaCompany Report #B0119242A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Zyban	PS	Glaxo Wellcome			

Date:09/07/01ISR Number: 3789584-4Report Type:Expedited (15-DaCompany Report #HQ3100411JUL2001
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Complications Of Maternal Exposure To Therapeutic Drugs	Health Professional	Effexor	PS		ORAL	ORAL	
	Convulsion Neonatal		Remeron (Mirtazapine)	SS		ORAL	ORAL	
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	ORAL	

Date:09/07/01ISR Number: 3789585-6Report Type:Expedited (15-DaCompany Report #B0115303A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Confusional State Grand Mal Convulsion Loss Of Consciousness	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG	
Other Required Intervention to Prevent Permanent Impairment/Damage			Dianette	C				

Date:09/07/01ISR Number: 3789587-XReport Type:Expedited (15-DaCompany Report #B0116842A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cardiac Arrest	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/10/01ISR Number: 3789554-6Report Type:Expedited (15-DaCompany Report #A0159171A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Per day	2 MON
	Chest Pain		Phenergan	SS		INTRAVENOUS		
	Circulatory Collapse		Atenolol	C				
	Convulsion		Lipitor	C				
	Dizziness		Methotrexate	C				
	Drug Interaction		Folic Acid	C				
	Ecchymosis		Ambien	C				
	Face Oedema		Ativan	C				
	Fall		Zantac	C	Glaxo Wellcome			
	Headache							
	Muscle Spasms							
	Nausea							
	Paralysis							
	Sedation							
	Tremor							

Date:09/10/01ISR Number: 3789556-XReport Type:Expedited (15-DaCompany Report #B0105578A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Cerebrovascular Accident						per day	
	Liver Function Test		Eltroxin	C	Glaxo Wellcome	ORAL	100UG Twice	
	Abnormal						per day	
			Vascace	C		ORAL	5MG Per day	
			Mirtazapine	C				
			Pravastatin	C				
			Aspirin	C				
			Omeprazole	C				
			Atenolol	C				
			Isosorbide	C				
			Ramipril	C				

			Gemfibrozil	C		

Date:09/10/01ISR Number: 3790054-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin Sr 150 Mg (Glaxowellcome)	PS	Glaxowellcome	ORAL	150MG PO QD X 3 DAYS THEN 150MG BID	
			Ultram	C				
			Paxil	C				
			Tylenol #4	C				

Date:09/11/01ISR Number: 3790241-9Report Type:Expedited (15-DaCompany Report #B0119467A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Purpura		Zyban	PS	Glaxo Wellcome	ORAL	8	DAY
Other RESPIRATORY (INHALATION)			Combivent	C				
			Salmeterol	C	Glaxo Wellcome			
RESPIRATORY (INHALATION)								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/11/01ISR Number: 3790242-0Report Type:Expedited (15-DaCompany Report #B0119683A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Poisoning		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Drug Toxicity						per day	
			Prothiaden	SS		ORAL	275MG At	
							night	
			Alcohol	SS				
			Olanzapine	C		ORAL	5MG Twice per	
							day	
			Lithium	C		ORAL		
			Nitrazepam	C		ORAL	5MG At night	
			Oxybutynin	C		ORAL		

Date:09/11/01ISR Number: 3791424-4Report Type:Expedited (15-DaCompany Report #B0117307A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Emotional Disorder Eye Disorder Mental Disorder	Foreign	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	300 MG/PER DAY/ORAL	
			Femodene	C				

Date:09/11/01ISR Number: 3791444-XReport Type:Expedited (15-DaCompany Report #A0158740A
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Parkinson'S Disease	Health Professional	Wellbutrin Unspecified Tablet					

			(Bupropion Hydrochloride)	PS		ORAL	ORAL

Date:09/11/01ISR Number: 3791505-5Report Type:Expedited (15-DaCompany Report #B0118326A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Cold Sweat Pain In Extremity Pallor Palpitations	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL

Date:09/11/01ISR Number: 3791518-3Report Type:Expedited (15-DaCompany Report #B0118929A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal Dysphagia Eyelid Oedema Face Oedema Heart Rate Increased Jaundice Skin Discolouration	Foreign Consumer	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/12/01ISR Number: 3792211-3Report Type:Expedited (15-DaCompany Report #B0105578A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia	Foreign	Zyban Tablet - Zyban					
	Cerebrovascular Accident	Health	(Bupropion					
	Liver Function Test	Professional	Hydrochloride)	PS		ORAL	150 MG /	
	Abnormal						TWICE PER DAY	
							/ ORAL	
			Thyroxine Sodium	C				
			Cilazapril	C				
			Mirtazapine	C				
			Pravastatin	C				
			Aspirin	C				
			Omeprazole	C				
			Atenolol	C				
			Isosorbide	C				
			Ramipril	C				
			Gemfibrozil	C				

Date:09/12/01ISR Number: 3792243-5Report Type:Expedited (15-DaCompany Report #A0159874A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy	Foreign	Zyban	PS		ORAL	150 MG /	
Initial or Prolonged	Difficulty In Walking	Consumer					TWICE PER DAY	
	Drug Hypersensitivity						/ ORAL	

Date:09/12/01ISR Number: 3792267-8Report Type:Expedited (15-DaCompany Report #B0118244A
Age:63 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Tenderness	Foreign	Zyban Tablet - Zyban					
Initial or Prolonged	Angina Unstable	Study	(Bupropion					

	Chest Pain	Health	Hydrochloride)	PS		ORAL
150 MG /						
	Dyspepsia	Professional				
TWICE PER DAY						
	Dyspnoea					
/ ORAL						
	Heart Rate Increased					
	Pharyngolaryngeal Pain					

Date:09/12/01ISR Number: 3792269-1Report Type:Expedited (15-DaCompany Report #B0119242A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemorrhagic Stroke	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		
150 MG						

Date:09/12/01ISR Number: 3792413-6Report Type:Expedited (15-DaCompany Report #A0159171A
Age:48 YR Gender:Female I/FU:I

Outcome	PT
Other	Chest Pain
	Circulatory Collapse
	Convulsion
	Dizziness
	Drug Interaction
	Ecchymosis

		Face Oedema					
		Fall					
		Gait Disturbance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Head Injury	Consumer	Wellbutrin			
		Muscle Spasms		Tablet-Controlled			
		Nausea		Release (Bupropion			
		Paralysis		Hydrochloride)	PS		ORAL
100 MG/ PER							
		Refusal Of Treatment By					
DAY/ORAL							
		Patient		Promethazine Hcl			
		Sedation		Injection			
				(Promethazine Hcl)	SS		
INTRAVENOUS	SINGLE						
DOSE/INTRAVEN							
OUS							
				Atenolol	C		
				Atorvasatin Calcium	C		
				Methotrexate	C		
				Folic Acid	C		
				Zolpidem Tartrate	C		
				Lorazepam	C		
				Ranitidine			
				Hydrochloride	C		

Date:09/12/01ISR Number: 3792885-7Report Type:Expedited (15-DaCompany Report #A0159343A
Age:30 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Asthenia	Health	Zyban Tablet - Zyban			
		Difficulty In Walking	Professional	(Bupropion			
		Fatigue		Hydrochloride)	PS		ORAL
150 MG /							
		Feeling Jittery					
TWICE PER DAY							
		Muscle Spasms					
/ ORAL	6 WK						
		Pain		Multivitamin	C		

Date:09/12/01ISR Number: 3792926-7Report Type:Expedited (15-DaCompany Report #B0119241A
Age:57 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		UNKNOWN		

Date:09/12/01ISR Number: 3792929-2Report Type:Expedited (15-DaCompany Report #B0119109A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Zyban Tablet - Zyban(Bupropion Hydrochloride)	PS		UNKNOWN	150 MG	

Date:09/13/01ISR Number: 3792103-XReport Type:Expedited (15-DaCompany Report #B0119682A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anger Depression Overdose		Zyban Paracetamol Panadeine	PS SS SS	Glaxo Wellcome		10TABS Per day 10TABS Per	

day						
			Mersyndol Forte	SS		
10TABS Per day						

Date:09/14/01ISR Number: 3792818-3Report Type:Expedited (15-DaCompany Report #A0155912A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Head Injury							
	Overdose		Celexa	SS		ORAL		
	Toxicologic Test Abnormal		Alcohol	SS		ORAL		
			Benadryl	SS		ORAL		

Date:09/14/01ISR Number: 3792819-5Report Type:Expedited (15-DaCompany Report #A0159903A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL		

Date:09/14/01ISR Number: 3792829-8Report Type:Expedited (15-DaCompany Report #B0120029A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome			
	Overdose		Slow K	SS				
			Temazepam	C				
			Hydrochlorothiazide	C				
			Salbutamol	C	Glaxo Wellcome			
			Fluticasone	C	Glaxo Wellcome			

Date:09/17/01ISR Number: 3793471-5Report Type:Expedited (15-DaCompany Report #B0120031A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome			8 DAY
	Circulatory Collapse							

Date:09/17/01ISR Number: 3793863-4Report Type:Direct Company Report #
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Zyban 150mg					
			Catalytica	PS	Catalytica	ORAL	150MG BID	
							ORAL	
			Nicoderm Patch	C				

Date:09/17/01ISR Number: 3793864-6Report Type:Direct Company Report #
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Zyban 150mg					
	Vomiting		Catalytica	PS	Catalytica	ORAL	150MG BID	
							ORAL	
			Ortho-Novum 777	C				

			Nicoderm	C		

Date:09/17/01ISR Number: 3793868-3Report Type:Direct Company Report #
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Generalised		Zyban	PS	Catalytica	ORAL	150 MG/	BID/
	Rash Pruritic						ORAL	
			Nicoderm	C				

Date:09/17/01ISR Number: 3793874-9Report Type:Direct Company Report #
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Zyban	PS	Catalytica	ORAL	150 MG/	QD TO
	Pruritus						BID/ ORAL	
			Nicoderm	C				
			Verapamil	C				

Date:09/17/01ISR Number: 3794365-1Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Aphasia	Professional					MG/DAILY/ORAL	
	Asthenia	Company	Anafranil Unk	SS			25 MG/BID	
	Balance Disorder	Representative	Klonopin Unk	SS			0.5 MG/BID	
	Blood Pressure Increased		Lamictal Unk	SS			100 MG/BID	

	Confusional State	Wellbutrin Sr Unk	SS
150 MG/BID			
	Coordination Abnormal	Dipentum Unk	SS
250 MG			
	Difficulty In Walking	Premarin Unk	SS
1.25 MG/DAILY			
	Disorientation	Zoloft Unk	SS
100 MG/DAILY			
	Dizziness	Coumadin	C
	Drug Interaction	Motrin	C
	Dry Skin	Lithium Carbonate	C
	Dysarthria		
	Dysphagia		
	Dyspnoea		
	Emotional Distress		
	Headache		
	Mental Disorder		
	Motor Dysfunction		
	Respiratory Rate Increased		
	Restlessness		
	Skin Warm		
	Speech Disorder		
	Transient Ischaemic Attack		
	Vision Blurred		

Date:09/17/01ISR Number: 3794470-XReport Type:Expedited (15-DaCompany Report #B0119682A
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anger
	Depression

Overdose

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
150 MG		Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		
10 TABLETS PER DAY			Paracetamol (Formulation Unknown) (Acetaminophen)	SS		
10 TABLETS PER DAY			Panadeine (Formulation Unknown) (Panadeine)	SS		
10 TABLETS PER DAY			Mersyndol (Formulation Unknown) (Mersyndol)	SS		

Date:09/17/01ISR Number: 3794485-1Report Type:Expedited (15-DaCompany Report #B0119683A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Alcohol Poisoning Drug Toxicity	Foreign Health Professional	Zyban Tablet -Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG / TWICE PER DAY / ORAL						
			Dothiepin Hydrochloride (Dothiepin			

			Hydrochloride)	SS		ORAL
275 MG / AT						
NIGHT / ORAL						
			Ethanol (Alcohol)	SS		
			Olanzapine	C		
			Lithium Salt	C		
			Nitrazepam	C		
			Oxybutynin	C		

Date:09/17/01ISR Number: 3794506-6Report Type:Expedited (15-DaCompany Report #B0119467A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Purpura	Foreign	Zyban Tablet - Zyban			
Required			(Bupropion			
Intervention to			Hydrochloride)	PS		ORAL
150 MG/ORAL						
Prevent Permanent			Combivent	C		
Impairment/Damage			Salmeterol Xinafoate	C		

Date:09/19/01ISR Number: 3795450-0Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Effect Decreased		Wellbutrin Sr 100mg	PS		
2 AM 1 PM						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/01ISR Number: 3795895-9Report Type:Expedited (15-DaCompany Report #B0114598A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	62 DAY
	Accident							
	Aggression							
	Amnesia							
	Angioneurotic Oedema							
	Balance Disorder							
	Blood Bilirubin Increased							
	Blood Pressure Increased							
	Chest Pain							
	Circulatory Collapse							
	Complement Factor C3 Increased							
	Confusional State							
	Convulsion							
	Dermatitis							
	Diarrhoea							
	Disorientation							
	Disturbance In Attention							
	Dizziness							
	Dry Skin							
	Dysphagia							
	Dyspnoea							
	Eyelid Oedema							
	Face Oedema							
	Feeling Hot							
	Flatulence							
	Flushing							
	Hyperhidrosis							
	Illusion							
	Immunology Test Abnormal							
	Irritability							
	Irritable Bowel Syndrome							
	Loss Of Consciousness							
	Malaise							
	Nausea							
	Ocular Hyperaemia							
	Oedema Peripheral							
	Pharyngeal Oedema							
	Pruritus							
	Rhinitis							

	Speech Disorder
	Tinnitus
	Tongue Oedema
	Urine Abnormality
	Urticaria

Date:09/20/01ISR Number: 3795904-7Report Type:Expedited (15-DaCompany Report #B0119910A
Age:42 YR Gender:Unknown I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Bacterial Infection
	C-Reactive Protein Increased
	Cd4 Lymphocytes Decreased
	Dermatitis
	Neutrophil Count Increased

	White Blood Cell Count Increased						
		Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
			Zyban	PS	Glaxo Wellcome	ORAL	

Date:09/20/01ISR Number: 3795910-2Report Type:Expedited (15-DaCompany Report #B0120302A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Convulsion		Zyban	PS	Glaxo Wellcome	
UNKNOWN	1TAB Single					
Initial or Prolonged dose	Loss Of Consciousness					
	Metabolic Acidosis		Ibuprofen	C		
	Tachycardia					

Date:09/20/01ISR Number: 3795911-4Report Type:Expedited (15-DaCompany Report #D0014305A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome	ORAL
20 DAY						
Initial or Prolonged	Arthritis Gonococcal		Plastulen N	C		ORAL
Disability	Pain In Extremity		Cyclo Ostrogynal	C		ORAL
3 YR						
	Red Blood Cell Sedimentation Rate Increased					
	Serum Sickness					
	Vasculitis					

Date:09/20/01ISR Number: 3795929-1Report Type:Expedited (15-DaCompany Report #B0108747A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	
UNKNOWN	300MG per day 3 WK					

	Complications Of Maternal Exposure To Therapeutic Drugs					

Date:09/20/01ISR Number: 3795931-XReport Type:Expedited (15-DaCompany Report #B0111884A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypoxia		Zyban	PS	Glaxo Wellcome			
Hospitalization - Initial or Prolonged	Joint Effusion							
	Respiratory Failure							

Date:09/20/01ISR Number: 3795941-2Report Type:Expedited (15-DaCompany Report #B0120405A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Joint Dislocation		Alcohol	SS				
	Spinal Fracture		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	2PUFF Twice per day	
			Seretide	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	2PUFF Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/01ISR Number: 3795942-4Report Type:Expedited (15-DaCompany Report #B0120407A
Age:49 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG As directed	

Date:09/20/01ISR Number: 3795943-6Report Type:Expedited (15-DaCompany Report #B0120468A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain	Health	Zyntabac	PS	Glaxo Wellcome		150MG Per day	20 DAY
	Oesophageal Disorder	Professional	Unspecified					
	Urticaria		Medication	C				
			Gliclazide	C				

Date:09/20/01ISR Number: 3795944-8Report Type:Expedited (15-DaCompany Report #B0120523A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	42 DAY	
	Myocardial Fibrosis		Sotalol	C			UNKNOWN	
	Sudden Death		Warfarin	C	Glaxo Wellcome		UNKNOWN	

Date:09/21/01ISR Number: 3796366-6Report Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Agoraphobia
	Alopecia
Disability	Anaphylactic Shock
	Anxiety

Bipolar Disorder
Blood Triglycerides
Increased
Bradycardia
Chills
Condition Aggravated
Convulsion
Cystocele
Dizziness
Drug Dependence
Drug Hypersensitivity
Dysarthria
Dyspepsia
Dyspnoea
Dysuria
Fatigue
Haematuria
Headache
Hyperglycaemia
Hypertension
Hyperventilation
Hypoaesthesia
Labile Blood Pressure
Mania
Memory Impairment
Micturition Urgency
Mitral Valve Incompetence

	Muscle Twitching						
	Muscular Weakness						
	Musculoskeletal Stiffness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Neck Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 12 DAY
	Nervousness		Premarin	C			1.25MG Per day
	Obsessive-Compulsive Disorder		Vitamin	C			
	Oedema		Asa	C			
	Oesophageal Disorder		Melatonin	C			
	Panic Disorder Without Agoraphobia						
	Paraesthesia						
	Renal Disorder						
	Renal Impairment						
	Schizophrenia						
	Sciatica						
	Sensation Of Heaviness						
	Stupor						
	Tachycardia						
	Tinnitus						
	Tobacco Abuse						
	Transient Ischaemic Attack						
	Tremor						
	Urethral Stricture						
	Urinary Incontinence						
	Urinary Retention						
	Ventricular Extrasystoles						
	Weight Increased						

Date:09/21/01ISR Number: 3796371-XReport Type:Expedited (15-DaCompany Report #A0160261A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Crying		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day 2 WK
	Depression		Meridia	SS		ORAL	6 WK
	Diabetes Mellitus		Toprol	C			
	Memory Impairment		Hctz	C			

Mood Swings
Palpitations
Serotonin Syndrome
Suicidal Ideation

Date:09/21/01ISR Number: 3796381-2Report Type:Expedited (15-DaCompany Report #B0120525A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Congestive Cardiomyopathy						per day	
	Drug Interaction		Aspirin	C		ORAL	150MG per day	
			Atenolol	C		ORAL	50MG per day	
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY	
							(INHALATION)	200MG per day
			Co-Amilofruse	C		ORAL	1UNIT per day	
			Isosorbide	C		ORAL	60MG per day	
			Lactulose	C		ORAL	15ML Twice	
							per day	
			Lisinopril	C		ORAL	20MG Twice	
							per day	

			Tramadol	C		ORAL
100MG Twice per day						
			Fluoxetine	C		ORAL
20MG Per day						
			Cetirizine	C	Glaxo Wellcome	ORAL
10MG Per day						
			Betamethasone	C	Glaxo Wellcome	
TOPICAL						

Date:09/21/01ISR Number: 3796382-4Report Type:Expedited (15-DaCompany Report #B0120692A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	41 DAY
	Bronchitis Chronic Lower Respiratory Tract Infection							

Date:09/21/01ISR Number: 3796993-6Report Type:Direct Company Report #
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia Dysphagia Emotional Disorder Hemiparesis Hyperacusis Hyperaesthesia Photosensitivity Reaction Visual Disturbance		Wellbutrin Sr	PS				

Date:09/21/01ISR Number: 3797707-6Report Type:Expedited (15-DaCompany Report #B0120031A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardiac Arrest Circulatory Collapse	Foreign	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		
150 MG						

Date:09/24/01ISR Number: 3797833-1Report Type:Expedited (15-DaCompany Report #HQ5310429AUG2001
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Other	Dysphoria Libido Decreased Malaise Nausea	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule,	PS		ORAL
SEE IMAGE	Suicidal Ideation		Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL
150 MG 1 X PER 1 DAY, ORAL						

Date:09/24/01ISR Number: 3797853-7Report Type:Expedited (15-DaCompany Report #A118566
Age:27 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Required Intervention to Prevent Permanent Impairment/Damage	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Health	Ziprasidone Po	PS		ORAL	BID	
	Convulsion	Professional	Wellbutrin	SS				
	Electrocardiogram	Company	Prozac	SS			BID	
	Abnormal Electrocardiogram Qt Prolonged Myocardial Infarction Overdose Sinus Tachycardia	Representative	Depakote	SS				

Date:09/24/01ISR Number: 3798115-4Report Type:Expedited (15-DaCompany Report #B0108747A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS				

Date:09/24/01ISR Number: 3798116-6Report Type:Expedited (15-DaCompany Report #B0120405A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion Joint Dislocation Spinal Fracture	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER	DAY/ ORAL
			Ethanol (Formulation Unknown) (Alcohol)	SS				
			Salbutamol Sulphate	C				
			Fluticasone+Salmeterol	C				

Date:09/24/01ISR Number: 3798473-0Report Type:Expedited (15-DaCompany Report #B0114598A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Angioneurotic Oedema Balance Disorder Blood Pressure Increased Circulatory Collapse Convulsion Disorientation Dizziness Dry Skin Irritable Bowel Syndrome Rhinitis Stress Urticaria	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798563-2Report Type:Expedited (15-DaCompany Report #B0120407A
Age:49 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG AS DIRECTED / ORAL	

Date:09/24/01ISR Number: 3798565-6Report Type:Expedited (15-DaCompany Report #B0120302A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Loss Of Consciousness Metabolic Acidosis Tachycardia	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			1 TABLET SINGLE DOSE	
			Ibuprofen	C				

Date:09/24/01ISR Number: 3798637-6Report Type:Expedited (15-DaCompany Report #B0111884A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Hypoxia Joint Effusion Respiratory Failure	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG	

Date:09/24/01ISR Number: 3798686-8Report Type:Expedited (15-DaCompany Report #D0020665A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign Literature Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:09/24/01ISR Number: 3798687-XReport Type:Expedited (15-DaCompany Report #B0120523A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Myocardial Fibrosis Sudden Death	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / ORAL	
			Sotalol	C				
			Warfarin Sodium	C				

Date:09/24/01ISR Number: 3798688-1Report Type:Expedited (15-DaCompany Report #B0120468A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain Oesophageal Disorder Urticaria	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG / PER DAY	20 DAY
			Gliclazide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3802045-9Report Type:Expedited (15-DaCompany Report #D0014305A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angioneurotic Oedema Antinuclear Antibody Positive Pain In Extremity Serum Sickness Urticaria Vasculitis	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Plastulen N Cycloostrogynal	PS C C		ORAL	150 MG/	ORAL

Date:09/24/01ISR Number: 3802048-4Report Type:Expedited (15-DaCompany Report #B0119910A
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bacterial Infection C-Reactive Protein Increased Dermatitis Lymphocyte Count Decreased Neutrophil Count Increased White Blood Cell Count Increased	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:09/25/01ISR Number: 3797887-2Report Type:Expedited (15-DaCompany Report #A0161283A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	10 DAY

Date:09/25/01ISR Number: 3797888-4Report Type:Expedited (15-DaCompany Report #A0161303A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Pregnancy							

Date:09/25/01ISR Number: 3797890-2Report Type:Expedited (15-DaCompany Report #B0097007A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Zyban	PS	Glaxo Wellcome			
	Drug Hypersensitivity							
	Erysipelas							
	Streptococcal Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/25/01ISR Number: 3797891-4Report Type:Expedited (15-DaCompany Report #B0110588A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Fall Headache Insomnia Muscle Spasms Salivary Hypersecretion Sensation Of Pressure		Zyban	PS	Glaxo Wellcome			13 DAY

Date:09/25/01ISR Number: 3797896-3Report Type:Expedited (15-DaCompany Report #B0118244A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Abdominal Tenderness Angina Unstable Blood Pressure Increased Cardiac Failure Congestive Chest Pain Dyspnoea Heart Rate Increased Pharyngolaryngeal Pain		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	11 DAY

Date:09/25/01ISR Number: 3797897-5Report Type:Expedited (15-DaCompany Report #B0119920A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Discomfort Face Oedema Inflammation Loss Of Consciousness		Zyban Stimulant	PS C	Glaxo Wellcome	ORAL	150MG Twice per day	15 DAY

Rash Erythematous
Rash Papular
Rash Pruritic
Respiratory Disorder
Urticaria

Date:09/25/01ISR Number: 3799243-XReport Type:Direct Company Report #
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lacrimation Increased		Zyban (150 Mg) (Gsk)	PS	Gsk	ORAL	150 MG BID PO	
	Pruritus							
	Urticaria							

Date:09/25/01ISR Number: 3799988-1Report Type:Direct Company Report #
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Bupropion (150mg Sa) (Gsk)	PS	Gsk	ORAL	150MG SA 1 PO BID	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/25/01ISR Number: 3800753-7Report Type:Expedited (15-DaCompany Report #A0160261A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Diabetes Mellitus Serotonin Syndrome	Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY /ORAL	2 WK
			Sibutramine Hydrochloride Tablet (Sibutramine Hydrochloride)	SS		ORAL	ORAL	6 WK
			Metoprolol Succinate	C				
			Hydrochlorothiazide	C				

Date:09/25/01ISR Number: 3801259-1Report Type:Expedited (15-DaCompany Report #B0120525A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive Cardiomyopathy	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY/ ORAL	
			Aspirin	C				
			Atenolol	C				
			Beclomethasone Dipropion.	C				
			Co-Amilofruse	C				
			Isosorbide	C				
			Lactulose	C				
			Lisinopril	C				
			Tramadol Hydrochloride	C				
			Fluoxetine	C				
			Cetirizine					

			Hydrochloride	C			
			Betamethasone	C			

Date:09/25/01ISR Number: 3801262-1Report Type:Expedited (15-DaCompany Report #B0120692A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchitis Chronic	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /PER DAY	/ ORAL

Date:09/25/01ISR Number: 3806051-XReport Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Alopecia
Disability	Anxiety
	Autonomic Nervous System Imbalance
	Blood Glucose Increased

		Blood Pressure Increased Blood Triglycerides Increased Bradycardia Condition Aggravated Convulsion Drug Hypersensitivity Dysarthria Dyspepsia Dyspnoea Dysthymic Disorder Enuresis Euphoric Mood Faeces Pale Feeling Hot And Cold Fluid Retention Haematuria Hyperventilation Hypoaesthesia Hypomania Insomnia Intervertebral Disc Protrusion Labile Blood Pressure Memory Impairment Mental Impairment Mitral Valve Incompetence Musculoskeletal Stiffness Oedema Palpitations Panic Disorder Paraesthesia Renal Disorder Renal Impairment Sensation Of Pressure Syncope Vasovagal Tachycardia Tinnitus Tongue Disorder Transient Ischaemic Attack Tremor Urethral Stricture Urinary Incontinence	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Conjugated Estrogens Vitamin Aspirin Melatonin	PS C C C C		ORAL	150 MG/PER DAY/ORAL

Weight Increased

Date:09/26/01ISR Number: 3798439-0Report Type:Expedited (15-DaCompany Report #A0157251A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Scan Abnormal		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	2 WK
	Headache							
	Multiple Sclerosis		Premarin	C				
	Musculoskeletal Stiffness		Vitamin E	C				
	Neck Pain		Vitamin C	C				
	Pyrexia		Vitamin A	C				
	Tinnitus		Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/26/01ISR Number: 3798443-2Report Type:Expedited (15-DaCompany Report #B0118455A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Zyban	PS	Glaxo Wellcome		150MG As directed	
	Thrombosis							
			Coumarin	SS		ORAL		

Date:09/26/01ISR Number: 3798446-8Report Type:Expedited (15-DaCompany Report #B0120825A
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	25 DAY
			Aspirin	C		ORAL		
			Levothyroxine	C	Glaxo Wellcome			

Date:09/26/01ISR Number: 3798447-XReport Type:Expedited (15-DaCompany Report #B0120882A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspepsia		Quomem	PS	Glaxo Wellcome	ORAL	150MG As directed	34 DAY
	Haematemesis							

Date:09/26/01ISR Number: 3798449-3Report Type:Expedited (15-DaCompany Report #D0018145A
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Zyban	PS	Glaxo Wellcome	ORAL		
	Hypertensive Crisis		Diclofenac	C			UNKNOWN	

Date:09/26/01ISR Number: 3798866-1Report Type:Direct Company Report #
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required	Dermatitis Erythema Multiforme Pruritus		Keflex (Cephalexin) Bupropion	PS SS		ORAL ORAL	250 MG QID PO 100SR 1 PO Q AM X 2 THEN BID	Intervention to Prevent Permanent Impairment/Damage

Date:09/27/01ISR Number: 3798981-2Report Type:Expedited (15-DaCompany Report #A0141870A
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Death	Balance Disorder
Life-Threatening	Blood Creatinine Increased
Hospitalization - Initial or Prolonged	Blood Urea Increased
Other	Cerebral Ischaemia
	Cerebrovascular Accident
	Coma
	Depressed Level Of Consciousness
	Fall
	Grand Mal Convulsion
	Head Injury

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Lethargy Oral Intake Reduced							
	Rib Fracture		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Twice per day	9 DAY
			Celexa	C		ORAL		
			Cyclosporin	C		ORAL	100MG Twice per day	
			Prednisone	C		ORAL	10MG Per day	
			Metoprolol	C		ORAL	25MG Twice per day	
			Transderm Nitro	C	Glaxo Wellcome	TOPICAL	.2MG Per day	
			Zocor	C		ORAL	10MG At night	
			Lasix	C		ORAL	40MG Per day	
			Enteric Coated Aspirin	C		ORAL	1TAB Per day	
			Tums	C		ORAL	1TAB Twice per day	

Date:09/27/01ISR Number: 3798991-5Report Type:Expedited (15-DaCompany Report #A0161553A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis Cerebral		Zyban	PS	Glaxo Wellcome	ORAL		

Date:09/27/01ISR Number: 3798994-0Report Type:Expedited (15-DaCompany Report #B0111884A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Emphysema		Zyban	PS	Glaxo Wellcome			
Hospitalization - Initial or Prolonged	Joint Effusion							
	Respiratory Failure							

Date:09/27/01ISR Number: 3798995-2Report Type:Expedited (15-DaCompany Report #B0119050A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Zyntabac	PS	Glaxo Wellcome	ORAL	18 DAY	
Hospitalization - Initial or Prolonged	Dermatitis							
	Dysphagia							
	Dyspnoea							
	Pyrexia							
	Rash Generalised							

Date:09/27/01ISR Number: 3798999-XReport Type:Expedited (15-DaCompany Report #B0120884A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blister		Zyban	PS	Glaxo Wellcome		150MG As directed	
	Dizziness							
	Sleep Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/01ISR Number: 3799000-4Report Type:Expedited (15-DaCompany Report #B0120885A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Idiopathic		Zyban	PS	Glaxo Wellcome		150MG Per day	4 DAY
	Thrombocytopenic Purpura							

Date:09/27/01ISR Number: 3799001-6Report Type:Expedited (15-DaCompany Report #B0121084A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol Increased		Zyban	PS	Glaxo Wellcome			
	Myocardial Infarction							

Date:09/27/01ISR Number: 3799002-8Report Type:Expedited (15-DaCompany Report #B0121088A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsive Threshold Lowered		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY
			Trimipramine	SS		ORAL	350MG Per day	
	Drug Interaction		Fluctine	SS		ORAL	40MG Per day	
	Epilepsy							

Date:09/27/01ISR Number: 3799003-XReport Type:Expedited (15-DaCompany Report #B0121093A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Clumsiness		Zyban	PS	Glaxo Wellcome	ORAL		
Other	Dizziness		Microgynon	C		ORAL		
	Fluid Retention							
	Flushing							
	Hypertension							

	Insomnia						
	Weight Increased						

Date:09/27/01ISR Number: 3800235-2Report Type:Direct Company Report #
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Bupropion Gsk	PS				
	Urticaria							

Date:09/28/01ISR Number: 3800386-2Report Type:Expedited (15-DaCompany Report #A0161559A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL		
	Drug Interaction		Ultram	SS				

Date:09/28/01ISR Number: 3800403-XReport Type:Expedited (15-DaCompany Report #B0120883A
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Dysgeusia
	Nervous System Disorder

	Nervousness						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome		150MG Per day 39 DAY
			Amoxycillin	C			750MG Twice per day 8 DAY
			Hydroquinine Hydrobromide	C			100MG Per day

Date:09/28/01ISR Number: 3800405-3Report Type:Expedited (15-DaCompany Report #B0121198A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Sudden Death						per day 63 DAY
			Aspirin	C		ORAL	75MG per day
			Lisinopril	C		ORAL	20MG per day
			Simvastatin	C		ORAL	40MG per day

Date:09/28/01ISR Number: 3801921-0Report Type:Expedited (15-DaCompany Report #A122280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Agitation	Consumer	Zoloft Tablets	PS			
	Cognitive Disorder		Bupropion	SS		ORAL	225.00 MG TOTAL:DAILY:ORAL
	Depression						
	Disturbance In Attention						
	Hallucination						

Memory Impairment
Mood Swings
Personality Change

Date:09/28/01ISR Number: 3802134-9Report Type:Expedited (15-DaCompany Report #A0161283A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs	Study Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	10 DAY

Date:09/28/01ISR Number: 3802135-0Report Type:Expedited (15-DaCompany Report #A0161303A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Pregnancy	Study Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL	

Date:09/28/01ISR Number: 3802410-XReport Type:Expedited (15-DaCompany Report #B0110588A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Headache Insomnia Intraocular Pressure Increased	Foreign	Zyban Tablet- (Bupropion Hydochloride)	PS				

Date:09/28/01ISR Number: 3802453-6Report Type:Expedited (15-DaCompany Report #B0097007A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erysipelas Hypersensitivity Streptococcal Infection	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG	

Date:09/28/01ISR Number: 3802456-1Report Type:Expedited (15-DaCompany Report #B0118244A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Tenderness Angina Unstable Cardiac Failure Congestive Chest Pain Condition Aggravated Dyspepsia Dyspnoea Exacerbated Heart Rate Increased Pharyngolaryngeal Pain	Foreign Study Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:09/28/01ISR Number: 3802457-3Report Type:Expedited (15-DaCompany Report #B0119920A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Immunoglobulin E Increased	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	
	Face Oedema							
	Inflammation							
	Loss Of Consciousness		Stimulnt	C				
	Rash Erythematous							
	Rash Papular							
	Rash Pruritic							
	Respiratory Disorder							
	Urticaria							

Date:09/28/01ISR Number: 3802660-2Report Type:Periodic Company Report #2000UW03177
Age:47 YR Gender:Female I/FU:I

Outcome	PT
Other	Confusional State
	Drug Interaction
	Face Oedema
	Hyperhidrosis
	Hypoaesthesia
	Influenza Like Illness

	Oedema Peripheral						
	Pain						
	Toothache	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Seroquel "Zeneca"	PS	Zeneca	ORAL	100 MG PO	
			Celebrex	SS		ORAL	100 MG PO	
			Oxycodone	SS				
			Wellbutrin	SS			300 MG	
			Valium	SS			10 MG PRN	
			Valium	SS				
			Ambien	SS				
			Ambien	SS				

Date:10/01/01ISR Number: 3801625-4Report Type:Expedited (15-DaCompany Report #A0159343A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Jittery		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Myopathy						per day	6 WK
			Vitamins	C				

Date:10/01/01ISR Number: 3801630-8Report Type:Expedited (15-DaCompany Report #A0161900A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pain		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Tardive Dyskinesia							

Date:10/01/01ISR Number: 3801642-4Report Type:Expedited (15-DaCompany Report #B0121348A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 7 WK	Angina Pectoris		Zyban	PS	Glaxo Wellcome	
Initial or Prolonged	Dyspepsia					
	Dyspnoea					

Date:10/01/01ISR Number: 3801643-6Report Type:Expedited (15-DaCompany Report #B0121383A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Respiratory Failure		Desipramine	SS				
			Dihydrocodeine	SS		ORAL		
			Imipramine	SS				
			Dothiepin	C				

Date:10/01/01ISR Number: 3802965-5Report Type:Direct Company Report #
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blepharospasm		Bupropion	PS		ORAL	75 MG Q AM PO	
	Eye Movement Disorder		Olanzapine	C				
	Eyelid Ptosis		Miratazapine	C				
	Movement Disorder		Thiamine	C				
	Muscle Spasms		Lorazepam	C				
	Strabismus		Gosereline Acetate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/01ISR Number: 3803192-8Report Type:Expedited (15-DaCompany Report #B0120884A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blister	Foreign	Zyban Tablet - Zyban					
	Dizziness	Health	(Bupropion					
	Sleep Disorder	Professional	Hydrochloride)	PS			150 MG / AS	
							DIRECTED	

Date:10/01/01ISR Number: 3803324-1Report Type:Expedited (15-DaCompany Report #2001UW11959
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Lidocaine	PS				
		Other	Atropine	SS				
			Chloral Hydrate	SS				
			Diazepam	SS				
			Methadone	SS				
			Sertraline	SS				
			Bupropion	SS				
			Venlafaxine	SS				

Date:10/01/01ISR Number: 3803801-3Report Type:Expedited (15-DaCompany Report #B0111884A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypoxia	Foreign	Bupropion					
Hospitalization -	Joint Effusion	Health	Hydrochloride Tablet					
Initial or Prolonged	Respiratory Failure	Professional	- Zyban (Bupropion					
			Hydrochloride)	PS			150MG	

Date:10/01/01ISR Number: 3804109-2Report Type:Expedited (15-DaCompany Report #A0161553A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hemiparesis Stress Vasculitis Cerebral	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:10/01/01ISR Number: 3804110-9Report Type:Expedited (15-DaCompany Report #B0119050A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angioneurotic Oedema Dysphagia Oedema Photosensitivity Reaction Pyrexia Rash Erythematous Rash Generalised Respiratory Disorder	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	300 MG/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/01ISR Number: 3804111-0Report Type:Expedited (15-DaCompany Report #B0120885A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Idiopathic Thrombocytopenic Purpura	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG/PER	DAY

Date:10/01/01ISR Number: 3804112-2Report Type:Expedited (15-DaCompany Report #B0121084A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol Increased Myocardial Infarction	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS			150 MG	

Date:10/01/01ISR Number: 3804113-4Report Type:Expedited (15-DaCompany Report #B0121088A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Epilepsy	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER	DAY/ORAL
			Surmonatil (Formulation Unknown)	SS		ORAL	350 MG/PER	DAY/ORAL
			Fluctine (Formulation Unknown) (Fluctine)	SS		ORAL	40 MG/PER	

DAY/ORAL

Date:10/01/01ISR Number: 3804114-6Report Type:Expedited (15-DaCompany Report #B0121093A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Clumsiness	Foreign	Zyban Tablet - Zyban					
Required	Dizziness		(Bupropion					
Intervention to	Feeling Hot And Cold		Hydrochloride)	PS		ORAL	150 MG	
Prevent Permanent	Fluid Retention		Microgynon	C				
Impairment/Damage	Flushing							
	Hypertension							
	Insomnia							
	Weight Increased							

Date:10/01/01ISR Number: 3804176-6Report Type:Expedited (15-DaCompany Report #A0141870A
Age:68 YR Gender:Male I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Health	Wellbutrin					
	Bite	Professional	Tablet-Controlled					
	Blood Creatine	Company	Release (Bupropion					
	Phosphokinase Increased	Representative	Hydrochloride)	PS		ORAL	100 MG /	
	Blood Urea Increased						TWICE PER DAY	
	Coma						/ ORAL	
	Ecchymosis		Citalompram					
	Fall		Hydrobromide	C				
	Grand Mal Convulsion		Cyclosporin	C				
	Head Injury		Prednisone	C				
	Insomnia		Metoprolol	C				
	Ischaemic Stroke		Nitroglycerin	C				
	Nervous System Disorder		Simvasatin	C				
	Oral Intake Reduced		Frusemide	C				
	Pain		Aspirin	C				
	Platelet Count Decreased		Calcium Carbonate	C				
	Rib Fracture							
	Tongue Disorder							

Date:10/02/01ISR Number: 3803547-1Report Type:Expedited (15-DaCompany Report #B0120882A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Foreign	Zyban Tablet -Zyban					
Initial or Prolonged	Haematemesis	Health	(Bupropion					
		Professional	Hydrochlorde)	PS		ORAL	150 MG / AS	
							DIRECTED /	
							ORAL	

Date:10/02/01ISR Number: 3803641-5Report Type:Direct Company Report #
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsive Threshold Lowered		Bupropion 150mg Wellcome	PS	Wellcome	ORAL	150MG QAM	
			Bupropion	SS	Wellcome	ORAL	75 MG / 1PM /	
			Olanzapine	C				
			Nortriptyline	C				
			Divalproex	C				
			Mercaptopurine	C				

Date:10/02/01ISR Number: 3803643-9Report Type:Direct Company Report #
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia Pain In Extremity Tendon Injury Urticaria		Wellbutrin Sr 150 Mgs. Twice Daily Glaxo	PS	Glaxo	ORAL	150 MGS. / TWICE DAILY /	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/01ISR Number: 3803909-2Report Type:Expedited (15-DaCompany Report #A0161559A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Interaction	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	UNK/UNK/ORAL	
			Tramadol Hydrochloride (Formulation Unknown) (Tramadol Hydrochloride)	SS				

Date:10/02/01ISR Number: 3804076-1Report Type:Expedited (15-DaCompany Report #D0018145A
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke Hypertensive Crisis	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG ORAL	
			Diclofenac	C				

Date:10/02/01ISR Number: 3804077-3Report Type:Expedited (15-DaCompany Report #B0118455A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Drug Interaction Thrombosis	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG AS DIRECTED	
			Coumarin (Formulation Unknown) (Coumarin)	SS		ORAL	ORAL	

Date:10/02/01ISR Number: 3804217-6Report Type:Expedited (15-DaCompany Report #A0157251A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Health	Zyban Tablet - Zyban					
	Musculoskeletal Stiffness	Professional	(Bupropion					
	Neck Pain		Hydrochloride)	PS		ORAL	150 MG/TWICE	
	Nervous System Disorder						PER DAY/ORAL	
	Nuclear Magnetic		Conjugated Estrogens	C				
	Resonance Imaging		Vitamin E	C				
	Abnormal		Ascorbic Acid	C				
	Pyrexia		Retinol	C				
	Tinnitus		Multivitamin	C				

Date:10/02/01ISR Number: 3805552-8Report Type:Expedited (15-DaCompany Report #B0120883A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysgeusia	Foreign	Zyban Tablet - Zyban					
Initial or Prolonged	Nervous System Disorder		(Bupropion					
	Nervousness		Hydrochloride)	PS			150 MG / PER	
							DAY /	
			Amoxycillin	C				

			Hydroquinine Hydrobromide	C			

Date:10/02/01ISR Number: 3805553-XReport Type:Expedited (15-DaCompany Report #B0121198A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Arrhythmia Sudden Death Syncope	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL
			Aspirin	C			
			Lisinopril	C			
			Simvastatin	C			

Date:10/02/01ISR Number: 3805564-4Report Type:Expedited (15-DaCompany Report #B0120825A
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Drug Hypersensitivity	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL
			Aspirin	C			
			Thyroxine Sodium	C			

Date:10/03/01ISR Number: 3803375-7Report Type:Expedited (15-DaCompany Report #B0121689A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Chronic Obstructive		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice

	Pulmonary Disease					
per day						
	Respiratory Failure		Isosorbide	C		
120MG per day						
	Sudden Death		Nifedipine	C		
40MG per day						
			Alverine	C		
			Aspirin	C		

Date:10/03/01ISR Number: 3803377-0Report Type:Expedited (15-DaCompany Report #D0021164A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Zyban	PS	Glaxo Wellcome	ORAL
150MG Unknown						
Initial or Prolonged	Myeloproliferative					
	Disorder					
	Thrombocythaemia					

Date:10/04/01ISR Number: 3803916-XReport Type:Expedited (15-DaCompany Report #A0161749A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Murmur		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Per day 4 YR						
	Mitral Valve Incompetence		Pepcid	C		
	Mitral Valve Prolapse		Prevacid	C		
			Multivitamin	C		

Date:10/04/01ISR Number: 3803918-3Report Type:Expedited (15-DaCompany Report #A0162004A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Wellbutrin	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Medication Error		Zyban	SS	Glaxo Wellcome	ORAL		

Date:10/05/01ISR Number: 3804372-8Report Type:Expedited (15-DaCompany Report #A0161755A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Corneal Oedema		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Fluphenazine	C				
			Unspecified Medication	C				
			Amantadine	C				
			Depakote	C				

Date:10/05/01ISR Number: 3804376-5Report Type:Expedited (15-DaCompany Report #A0162391A
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchospasm		Zyban	PS	Glaxo Wellcome	ORAL		
	Cardiovascular Disorder		Vitamin B	C				
	Eyelid Oedema		Vitamin C	C				
	Rash Erythematous		Mvi	C				
	Rash Generalised							
	Respiratory Distress							

Date:10/05/01ISR Number: 3804385-6Report Type:Expedited (15-DaCompany Report #B0121094A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 15TAB Per day 1 DAY	Confusional State		Zyban	PS	Glaxo Wellcome	ORAL	
Initial or Prolonged 1 DAY	Convulsion		Alcohol	C		ORAL	
	Hallucination						
	Hypokalaemia						
	Overdose						

Date:10/05/01ISR Number: 3806715-8Report Type:Expedited (15-DaCompany Report #A01161900A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Pain	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL
	Tardive Dyskinesia						

Date:10/05/01ISR Number: 3806720-1Report Type:Expedited (15-DaCompany Report #A0159343A
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Other	Asthenia
	Back Pain
	Difficulty In Walking

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery Muscle Spasms Myopathy	Health Professional	Zyban Tablet	PS		ORAL	150 MG / TWICE PER DAY / ORAL	6 WK
			Multivitamin	C				

Date:10/05/01ISR Number: 3808950-1Report Type:Expedited (15-DaCompany Report #B0121383A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose Renal Disorder Respiratory Failure Toxicologic Test Abnormal	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG PER DAY ORAL	
			Desipramine (Formulation Unknown) (Desipramine)	SS				
			Dihydrocodeine (Formulation Unknown) (Dihydrocodeine)	SS		ORAL	VARIABLE DOSE ORAL	
			Imipramine (Formulation Unknown) (Imipramine)	SS				
			Dothiepin	C				

Date:10/05/01ISR Number: 3808956-2Report Type:Expedited (15-DaCompany Report #B0121348A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Dyspepsia Dyspnoea	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS				

Date:10/08/01ISR Number: 3805036-7Report Type:Expedited (15-DaCompany Report #B0118584A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse Myocardial Infarction		Zyban	PS	Glaxo Wellcome		150MG Single dose	

Date:10/08/01ISR Number: 3805041-0Report Type:Expedited (15-DaCompany Report #B0122029A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Gases Abnormal		Zyban	PS	Glaxo Wellcome	ORAL	1	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/09/01ISR Number: 3805419-5Report Type:Expedited (15-DaCompany Report #A0159874A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	27 DAY
	Blister							
	Dry Mouth							
	Insomnia							
	Muscle Spasms							
	Oedema Peripheral							
	Pyrexia							
	Serum Sickness							
	Urticaria							

Date:10/09/01ISR Number: 3805422-5Report Type:Expedited (15-DaCompany Report #A0162388A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Depakote	C				9 DAY
			Dexamethasone	C				

Date:10/09/01ISR Number: 3805423-7Report Type:Expedited (15-DaCompany Report #A0162626A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL	900MG Per day	5 YR
	Blood Potassium Abnormal		Eskalith Cr	SS	Glaxo Wellcome	ORAL	UNKNOWN	
	Blood Sodium Abnormal		Zyprexa	SS			UNKNOWN	
	Condition Aggravated		Prilosec	SS				
	Diplopia							

	Disorientation
	Electrolyte Imbalance
	Fall
	Tremor

Date:10/09/01ISR Number: 3805427-4Report Type:Expedited (15-DaCompany Report #A0162932A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased		Zyban	PS	Glaxo Wellcome	ORAL		
	Cardiac Disorder							
	Loss Of Consciousness							

Date:10/09/01ISR Number: 3805432-8Report Type:Expedited (15-DaCompany Report #B0120704A
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Other	Agitation
	Breast Pain
	Condition Aggravated
	Confusional State
	Depression
	Disturbance In Attention
	Dizziness
	Feeling Abnormal
	Hallucinations, Mixed

	Insomnia						
	Irritability						
	Mood Altered	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
	Nausea		Zyban	PS	Glaxo Wellcome		
150MG Twice							
	Pollakiuria						
per day	21 DAY						
	Psoriasis		Zopiclone	C			
	Seborrhoea		Oxazepam	C			
	Tremor		Naproxen	C			
	Visual Disturbance						

Date:10/09/01ISR Number: 3805433-XReport Type:Expedited (15-DaCompany Report #B0121882A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Headache		Zyban	PS	Glaxo Wellcome	ORAL
	Therapeutic Agent		Olanzapine	SS		ORAL
20MG per day						
	Toxicity		Methadone	SS	Glaxo Wellcome	
UNKNOWN						
			Lithium Carbonate	C	Glaxo Wellcome	
UNKNOWN						
			Carbimazole	C		
UNKNOWN						

Date:10/09/01ISR Number: 3805434-1Report Type:Expedited (15-DaCompany Report #B0122089A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Coronary Artery		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Atherosclerosis					
per day	18 DAY					
	Coronary Artery Occlusion		Bisoprolol	C		ORAL
10MG Per day						
			Diclofenac	C		
75MG Twice						
per day						

			Ranitidine	C	Glaxo Wellcome		
			Aspirin	C			
75MG per day							

Date:10/10/01ISR Number: 3806165-4Report Type:Expedited (15-DaCompany Report #A0143570A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Bundle Branch Block		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice
Hospitalization -	Completed Suicide						per day
Initial or Prolonged	Intentional Misuse		Celexa	C		ORAL	40MG Per day
	Loss Of Employment		Buspar	C		ORAL	15MG Twice
	Suicide Attempt						per day
			Lamisil	C		ORAL	250MG Per day
			Zyrtec	C	Glaxo Wellcome	ORAL	10MG Per day
			Prevacid	C		ORAL	30MG Twice
							per day

Date:10/10/01ISR Number: 3806173-3Report Type:Expedited (15-DaCompany Report #B0122442A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Dermatitis Bullous		Zyban	PS	Glaxo Wellcome	ORAL	12 DAY
Initial or Prolonged	Erythema Multiforme		Propofan	SS		ORAL	1 DAY
	Oral Soft Tissue Disorder		Lysanxia	SS			
	Rash Pustular		Stilnox	SS			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3808086-XReport Type:Expedited (15-DaCompany Report #D0021164A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Myeloproliferative Disorder Thrombocythaemia	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / ORAL	

Date:10/10/01ISR Number: 3808153-0Report Type:Expedited (15-DaCompany Report #A0161749A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Murmur Mitral Valve Incompetence Mitral Valve Prolapse	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloried)	PS		ORAL	150 MG/ PER DAY/ORAL	
			Famotidine	C				
			Lansoprazole	C				
			Multivitamin	C				

Date:10/10/01ISR Number: 3808154-2Report Type:Expedited (15-DaCompany Report #A0162004A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cardiac Failure	Consumer	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Zyban Tablet- Zyban (Bupropion Hydrochloride)	SS		ORAL	ORAL	

Date:10/10/01ISR Number: 3808182-7Report Type:Expedited (15-DaCompany Report #A0161755A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Corneal Oedema	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Fluphenazine	C				
			Amantadine	C				
			Semisodium Valproate	C				

Date:10/10/01ISR Number: 3808201-8Report Type:Expedited (15-DaCompany Report #2001074931US
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Detrol(Tolterodine) Tablet	PS		ORAL	ORAL	2 DAY
	Fall							
	Haematoma		Wellbutrin(Amfebutamone Hydrochloride)	SS			3285 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3809150-1Report Type:Expedited (15-DaCompany Report #2001023091-1
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Balance Disorder	Consumer	Eskalith	PS	Smith Beecham	ORAL		5 YR
Initial or Prolonged	Condition Aggravated		Wellbutrin (Bupropion)	SS	Glaxowellcome			
	Diplopia		Zyprexa	SS	Lilly			
	Disorientation		Prilosec (Omeprazole)	SS	Astrazeneca			
	Electrolyte Imbalance							
	Fall							
	Tremor							

Date:10/10/01ISR Number: 3809257-9Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
Hospitalization -	Anxiety	Professional						
Initial or Prolonged	Aphasia	Company	Anafranil	SS			25 MG/BID	
Other	Asthenia	Representative	Klonopin	SS			0.5 MG/BID	
	Balance Disorder		Lamictal	SS			100 MG/BID	
	Blood Pressure Systolic		Wellbutrin Sr	SS			150 MG/BID	
	Increased		Dipentum	SS			250 MG	
	Confusional State		Premarin	SS			1.25 MG/DAILY	
	Coordination Abnormal		Zoloft	SS			100 MG/DAILY	
	Difficulty In Walking		Coumadin	C				
	Disorientation		Motrin	C				
	Dizziness		Lithium Carbonate	C				
	Drug Interaction							
	Dysphagia							
	Dyspnoea							
	Emotional Distress							
	Fear							

Gait Disturbance
Headache
Nausea
Palpitations
Restlessness
Speech Disorder
Transient Ischaemic
Attack
Vision Blurred

Date:10/10/01ISR Number: 3809500-6Report Type:Expedited (15-DaCompany Report #2001023368-1
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Haemorrhage	Health	Paxil					
	Conjunctival Hyperaemia	Professional	Glaxosmithkline	PS	Glaxosmithkline	ORAL	30 MILLIGRAMS	
	Constipation						1.0 DAILY	
	Ecchymosis						ORAL	99 DAY
	Orgasm Abnormal		Wellbutrin Sr					
			Glaxosmithkline	SS	Glaxosmithkline	ORAL	150	
							MILLIGRAMS	
							2.0 DAILY	
							ORAL	44 DAY
			Wellbutrin Sr					
			Glaxosmithkline	SS	Glaxosmithkline	ORAL	150	
							MILLIGRAMS	
							1.0 DAILY	

ORAL 3 DAY

Date:10/10/01ISR Number: 3809549-3Report Type:Expedited (15-DaCompany Report #B0121094A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Confusional State Convulsion Hallucination Hypokalaemia	Foreign Health Professional	Zyban (Bupropion Hydrochloride) Ethanol	PS C		ORAL	15 TABLET/PER DAY/ORAL

Date:10/10/01ISR Number: 3809569-9Report Type:Expedited (15-DaCompany Report #A0162391A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Bronchospasm Dermatitis Eyelid Oedema Peripheral Circulatory Failure Rash Generalised Respiratory Distress	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Vitamin B Ascorbic Acid M.V.I.	PS C C C		ORAL	ORAL

Date:10/10/01ISR Number: 3809666-8Report Type:Expedited (15-DaCompany Report #B0121689A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Angina Pectoris Chronic Obstructive Pulmonary Disease Mesenteric Artery Stenosis	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL

	Respiratory Failure		Isosorbide	C		
	Sudden Death		Nifedipine	C		
			Alverine Citrate	C		
			Aspirin	C		

Date:10/12/01ISR Number: 3807770-1Report Type:Expedited (15-DaCompany Report #A0067430A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Asthenia						per day	3 YR
	Blood Iron Increased		Lamictal	SS	Glaxo Wellcome	ORAL		
	Confusional State		Paxil	SS	Glaxo Wellcome	ORAL	10MG Per day	
	Dizziness		Celexa	SS			UNKNOWN	
	Dyspnoea		Blood Transfusion	SS			INTRAVENOUS	
	Fatigue		Zyprexa	C				
	Haematocrit Decreased		Glucophage	C				
	Headache		Allegra	C				
	Memory Impairment		Ativan	C				
	Myelofibrosis							
	Nausea							
	Nervousness							
	Palpitations							
	Pruritus							
	Rash Papular							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/01ISR Number: 3807777-4Report Type:Expedited (15-DaCompany Report #A0143021A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG per day	
Hospitalization - Initial or Prolonged	Confusional State		Amantadine	SS		ORAL	100MG Three times per day	YR
	Delirium							
	Drug Toxicity		Prozac	C				
	Extrapyramidal Disorder		Loxapine	C				
	Fall		Seroquel	C				
	Feeling Abnormal		Risperdal	C				
	Hallucination, Auditory							
	Injury							
	Insomnia							
	Memory Impairment							
	Paranoia							
	Schizophrenia							
	Tremor							

Date:10/12/01ISR Number: 3807782-8Report Type:Expedited (15-DaCompany Report #A0157251A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Stem Auditory		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Evoked Response Abnormal							
per day	2	WK						
	Deafness Neurosensory		Premarin	C				
	Headache		Vitamin E	C				
	Multiple Sclerosis		Vitamin C	C				
	Musculoskeletal Stiffness		Vitamin A	C				
	Neck Pain		Multivitamin	C				
	Nervous System Disorder							
	Pyrexia							
	Tinnitus							

Date:10/12/01ISR Number: 3807786-5Report Type:Expedited (15-DaCompany Report #A0162941A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Neoplasm		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL		

Date:10/12/01ISR Number: 3807787-7Report Type:Expedited (15-DaCompany Report #A0162942A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Neoplasm		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL		

Date:10/12/01ISR Number: 3807793-2Report Type:Expedited (15-DaCompany Report #B0111329A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Congestion		Zyntabac	PS	Glaxo Wellcome	ORAL	55 DAY	
	Hepatomegaly							
	Myocardial Infarction							
	Pulmonary Haemorrhage							
	Pulmonary Oedema							
	Thyroid Disorder							
	Thyroid Neoplasm							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/01ISR Number: 3807794-4Report Type:Expedited (15-DaCompany Report #B0112406A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyntabac	PS	Glaxo Wellcome			

Date:10/12/01ISR Number: 3807797-XReport Type:Expedited (15-DaCompany Report #B0114445A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxo Wellcome		150MG Twice per day	61 DAY
	Difficulty In Walking							
	Dyspnoea							
	Headache							
	Malaise							
	Nausea							
	Pain In Extremity							
	Polymyalgia Rheumatica							
	Red Blood Cell Sedimentation Rate Increased							
	Sedation							
	Tremor							

Date:10/12/01ISR Number: 3807810-XReport Type:Expedited (15-DaCompany Report #B0121704A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	9 DAY
			Aspirin	C		ORAL		

Date:10/12/01ISR Number: 3808484-4Report Type:Expedited (15-DaCompany Report #B0122029A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Gases Abnormal	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	300 MG/ORAL	

Date:10/12/01ISR Number: 3808886-6Report Type:Expedited (15-DaCompany Report #B0118584A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse Myocardial Infarction Pulse Absent	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG SINGLE DOSE	

Date:10/15/01ISR Number: 3808163-3Report Type:Expedited (15-DaCompany Report #D0018145A
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Death Hospitalization - Initial or Prolonged	Bradycardia Brain Oedema Cerebral Ischaemia Depressed Level Of

	Consciousness Dyspnoea Haemorrhagic Stroke Hemiplegia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertension		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day
	Hypotension		Diclofenac	C			UNKNOWN 100MG As
	Loss Of Consciousness						required
			Anti-Hyperlipidaemic (Unspecified)	C			UNKNOWN
			Trental	C			UNKNOWN

Date:10/16/01ISR Number: 3808985-9Report Type:Expedited (15-DaCompany Report #B0122683A
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Chronic Obstructive		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 4 DAY
	Airways Disease		Ranitidine	C	Glaxo Wellcome		UNKNOWN 150MG Twice
	Exacerbated						per day
	Respiratory Failure		Alendronate Sodium	C			UNKNOWN 10MG Per day
			Gaviscon Advance	C			UNKNOWN 8ML Three
							times per day
			Alfuzosin	C			UNKNOWN 5MG Twice per
							day
			Combivent	C			RESPIRATORY
							(INHALATION) 2.5ML Four
							times per day
			Aminophylline	C			UNKNOWN 225MG As

required

			Salmeterol	C	Glaxo Wellcome	

RESPIRATORY

(INHALATION)

			Fluticasone	C	Glaxo Wellcome	

UNKNOWN 250MCG Per

day

Date:10/16/01ISR Number: 3809424-4Report Type:Direct Company Report #
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin Sr (150)	PS		ORAL	150; 1 PO	TID
	Grand Mal Convulsion							
	Medication Error							

Date:10/16/01ISR Number: 3809425-6Report Type:Direct Company Report #
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Sr (150 1 Bid)	PS		ORAL	150 BID PO	

Date:10/16/01ISR Number: 3810151-8Report Type:Expedited (15-DaCompany Report #B0122089A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /	
	Coronary Artery Occlusion							

TWICE PER DAY

/ ORAL

			Bisoprolol	C		

			Diclofenac	C			
			Ranitidine Hydrochloride	C			
			Aspirin	C			

Date:10/16/01ISR Number: 3810152-XReport Type:Expedited (15-DaCompany Report #B0121882A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Toxicity Headache	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG	ORAL
			Olanzapine (Formulation Unknown) (Olanzapine)	SS		ORAL	ORAL	
			Methadone Hydrochloride (Formulation Unknown) (Methadone Hydrochloride)	SS				
			Lithium Carbonate	C				
			Carbimazole	C				

Date:10/16/01ISR Number: 3810153-1Report Type:Expedited (15-DaCompany Report #A0162932A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased Cardiac Disorder Loss Of Consciousness	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG /	ORAL

Date:10/16/01ISR Number: 3810154-3Report Type:Expedited (15-DaCompany Report #B0120704A
Age:46 YR Gender:Male I/FU:I

Outcome	PT

Other	Agitation
	Anxiety
	Breast Pain
	Confusional State
	Depression
	Dermatitis
	Disturbance In Attention
	Dizziness
	Fatigue
	Feeling Abnormal
	Hallucinations, Mixed
	Insomnia
	Irritability
	Mental Disorder
	Mood Altered
	Nausea
	Pain
	Pollakiuria
	Pruritus
	Psoriasis
	Seborrhoea
	Sleep Disorder

	Tremor						
	Visual Disturbance						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG / TWICE PER DAY
			Zopiclone	C			
			Oxazepam	C			
			Naproxen	C			

Date:10/16/01ISR Number: 3810156-7Report Type:Expedited (15-DaCompany Report #A0159874A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL
	Blister						
	Drug Hypersensitivity						
	Dry Mouth						
	Insomnia						
	Oedema Peripheral						
	Serum Sickness						

Date:10/16/01ISR Number: 3810209-3Report Type:Expedited (15-DaCompany Report #B0122442A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dermatitis Bullous	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ORAL
	Erythema Multiforme						
	Mouth Ulceration						
			Propofan (Formulation Unknown) (Propofan)	SS		ORAL	ORAL
			Prazepam				

(Formulation
Unknown) (Prasepam) SS
UNKNOWN

Zolpidem
(Formulation
Unknown)(Zolpidem) SS
UNKNOWN

Date:10/16/01ISR Number: 3810447-XReport Type:Expedited (15-DaCompany Report #A118566
Age:27 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Decreased
Required Intervention to Prevent Permanent Impairment/Damage	Bundle Branch Block Left
	Convulsion
	Electrocardiogram Abnormal
	Electrocardiogram Qrs Complex Prolonged
	Electrocardiogram Qt Corrected Interval Prolonged
	Electrocardiogram St Segment Abnormal
	Infarction

		Overdose Sinus Tachycardia					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Ziprasidone Po	PS		
BID							
			Professional	Wellbutrin			
			Company	(Bupropion)	SS		
			Representative	Prozac (Fluoxetine)	SS		
BID							
				Depakote (Divalproex Sodium)	SS		

Date:10/16/01ISR Number: 3810504-8Report Type:Expedited (15-DaCompany Report #A0143570A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Bundle Branch Block	Health	Wellbutrin			
Hospitalization -	Completed Suicide	Professional	Tablet-Controlled			
Initial or Prolonged	Intentional Misuse		Release (Bupropion			
	Suicide Attempt		Hydrochloride)	PS		ORAL
150 MG /						
	Toxicologic Test Abnormal					
TWICE PER DAY						
/ ORAL						
			Citalopram Hydrobromide	C		
			Buspirone Hydrochloride	C		
			Terbinafine	C		
			Cetirizine Hydrochloride	C		
			Lansoprazole	C		

Date:10/16/01ISR Number: 3810515-2Report Type:Expedited (15-DaCompany Report #A0162626A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Balance Disorder	Consumer	Wellbutrin			
Initial or Prolonged	Condition Aggravated		Unspecified Tablet			

	Diplopia Disorientation	(Bupropion Hydrochloride)	PS	ORAL
ORAL				
	Electrolyte Imbalance Fall Tremor	Lithium Carbonate (Formulation Unknown) (Lithium Carbonate)	SS	ORAL
900 MG / PER				
DAY / ORAL				
		Olanzapine (Formulation Unknown) (Olanzapine)	SS	
		Omeprazole (Formulation Unknown) (Omeprazole)	SS	

Date:10/16/01ISR Number: 3810517-6Report Type:Expedited (15-DaCompany Report #A0162388A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Death	Completed Suicide	Health Professional
	Injury Asphyxiation	Company

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
Semisodium Valproate	C				
Dexamethasone	C				

Date:10/17/01ISR Number: 3809799-6Report Type:Expedited (15-DaCompany Report #A0153715A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG Twice per day	1 YR
	Malabsorption							
	Medication Residue							

Date:10/17/01ISR Number: 3809810-2Report Type:Expedited (15-DaCompany Report #A0163486A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Atrial Septal Defect		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs Pregnancy							
	Pulmonary Valve Stenosis Congenital							

Date:10/17/01ISR Number: 3809812-6Report Type:Expedited (15-DaCompany Report #A0163666A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Three times per day	
	Drug Level Above Therapeutic		Lamictal	C	Glaxo Wellcome	ORAL	225MG Twice per day	
			Zyprexa	C		ORAL	35MG per day	
			Luvox	C		ORAL		

Date:10/18/01ISR Number: 3810573-5Report Type:Expedited (15-DaCompany Report #B0106367A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
Hospitalization - Initial or Prolonged	Dizziness							21 DAY
	Dyspnoea		Microgynon	C		ORAL	1TAB Per day	
Disability	Rash Generalised							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/01ISR Number: 3810574-7Report Type:Expedited (15-DaCompany Report #B0110958A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Dizziness							
per day							21	DAY
Initial or Prolonged	Dyspnoea		Microgynon	C		ORAL	1TAB Per day	
Disability	Rash Generalised							
	Visual Disturbance							

Date:10/18/01ISR Number: 3810577-2Report Type:Expedited (15-DaCompany Report #B0123297A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Zyban	PS	Glaxo Wellcome			
Initial or Prolonged	Circulatory Collapse							

Date:10/18/01ISR Number: 3810578-4Report Type:Expedited (15-DaCompany Report #D0021744A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erythema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	4 DAY
	Fatigue		Nitrendipin	C		ORAL		
	Oedema Peripheral		Bisoprolol	C		ORAL		

Date:10/18/01ISR Number: 3811102-2Report Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Wellbutrin Sr	PS		ORAL	150 MG PO QD	
			Zoloft	C				

Date:10/18/01ISR Number: 3811478-6Report Type:Expedited (15-DaCompany Report #B0112406A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG	

Date:10/18/01ISR Number: 3811504-4Report Type:Expedited (15-DaCompany Report #A0143021A
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Death	Confusional State
Hospitalization - Initial or Prolonged	Delirium
	Extrapyramidal Disorder
	Fall
	Feeling Abnormal
	Hallucination, Auditory
	Insomnia
	Limb Injury
	Medication Error
	Memory Impairment
	Paranoia
	Schizophrenia
	Toxicologic Test Abnormal

	Tremor						
Dose	Duration	Report Source	Product	Role	Manufacturer	Route	
		Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	
SEE TEXT / ORAL							
			Amantadine Tablet (Amantadine Hydrochloride)	SS		ORAL	
100 MG/ THREE TIMES PER DAY/ ORAL							
			Fluoxetine Hydrochloride	C			
			Loxapine	C			
			Quetiapine Fumarate	C			
			Risperidone	C			

Date:10/18/01ISR Number: 3811510-XReport Type:Expedited (15-DaCompany Report #A0157251A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Deafness Neurosensory	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
	Headache					
	Multiple Sclerosis					
150 MG/ TWICE PER DAY/ ORAL	Musculoskeletal Stiffness					
	Neck Pain		Conjugated Estrogens	C		
	Pyrexia		Vitamin E	C		
	Tinnitus		Ascorbic Acid	C		
			Retinol	C		
			Multivitamin	C		

Date:10/18/01ISR Number: 3811519-6Report Type:Expedited (15-DaCompany Report #B0111329A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Congestion	Foreign	Zyban Tablet - Zyban					
	Hepatomegaly	Health	(Bupropion					
	Hyperplasia	Professional	Hydrochloride)	PS		ORAL	150 MG/ORAL	
	Myocardial Infarction							
	Pulmonary Haemorrhage							
	Pulmonary Oedema							
	Thyroid Neoplasm							

Date:10/18/01ISR Number: 3811578-0Report Type:Expedited (15-DaCompany Report #B0121704A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Asthma	Foreign	Zyban Tablet-Zyban					
Intervention to			(Bupropion					
Prevent Permanent			Hydrochloride)	PS		ORAL	300 MG/PER	
Impairment/Damage							DAY/ORAL	
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/01ISR Number: 3811774-2Report Type:Expedited (15-DaCompany Report #A0162942A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Neoplasm	Health Professional	Wellbutrin Tablet - Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:10/18/01ISR Number: 3811776-6Report Type:Expedited (15-DaCompany Report #A0162941A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Neoplasm	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:10/18/01ISR Number: 3811828-0Report Type:Expedited (15-DaCompany Report #A0067430A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia Anxiety Asthenia Biopsy Bone Marrow Abnormal Blood Iron Increased Confusional State Depression Dizziness Dyspnoea Fatigue Headache	Consumer	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride) Lamictal Tablet (Lamotrigine) Paroxetine Hydrochloride (Formulation Unknown) (Paroxetine	PS SS		ORAL ORAL	150 MG / TWICE PER DAY / ORAL	

	Memory Impairment	Hydrochloride)	SS	ORAL
10 MG / PER				
	Myelofibrosis			
DAY / ORAL				
	Nausea	Citalopram		
	Nervousness	Hydrobromide		
	Palpitations	(Formulation		
	Pruritus	Unknown) (Citalopram		
	Rash Papular	Hydrobromide)	SS	
		Blood (Formulation		
		Uknown) (Blood)	SS	
INTRAVENOUS	EVERY TWO			
WEEKS /				
INTRAVENOUS				
		Olanzapine	C	
		Metformin		
		Hydrochloride	C	
		Fexofenadine		
		Hydrochlorid	C	
		Lorazepam	C	

Date:10/18/01ISR Number: 3812060-7Report Type:Expedited (15-DaCompany Report #B0114445A
Age: Gender:Female I/FU:F

Outcome	PT
Other	Arthralgia
	Asthenia
	Decreased Activity

	Difficulty In Walking						
	Dyspnoea						
	Fatigue	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Feeling Abnormal	Foreign	Zyban Tablet - Zyban				
	Headache	Consumer	(Bupropion				
	Ill-Defined Disorder		Hydrochloride)	PS			150 MG /
	Insomnia						TWICE PER DAY
	Malaise						
	Pain In Extremity						
	Polymyalgia Rheumatica						
	Red Blood Cell						
	Sedimentation Rate						
	Increased						
	Sedation						
	Tremor						

Date:10/19/01ISR Number: 3811174-5Report Type:Expedited (15-DaCompany Report #A0163484A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abnormal Behaviour		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice
Initial or Prolonged	Hostility						per day 3 WK
	Social Avoidant Behaviour						
	Social Phobia						

Date:10/19/01ISR Number: 3811181-2Report Type:Expedited (15-DaCompany Report #B0121084A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome		150MG Twice
	Myocardial Infarction						
	Myocardial Ischaemia						per day 20 DAY

Date:10/19/01ISR Number: 3811188-5Report Type:Expedited (15-DaCompany Report #B0123296A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Decreased Appetite Malaise		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	10 DAY
	Psoriasis		Cyclosporin	C		ORAL	225MG Per day	
	Skin Infection Vomiting							

Date:10/19/01ISR Number: 3812553-2Report Type:Expedited (15-DaCompany Report #B0122683A
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chronic Obstructive Airways Disease Exacerbated Respiratory Failure	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY	ORAL
			Ranitidine Hydrochloride	C				
			Alendronate Sodium	C				
			Gaviscon Advance	C				
			Alfuzosin	C				
			Combivent	C				

				Aminophylline	C		
				Salmeterol Xinafoate	C		
				Fluticasone Propionate	C		

Date:10/22/01ISR Number: 3813327-9Report Type:Direct Company Report #
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin 150 Mg Sr	PS	Sr	ORAL	150 MG ONCE	PO QD

Date:10/22/01ISR Number: 3813341-3Report Type:Direct Company Report #
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia		Zyban	PS			150MG QD X 3	THEN BID
			Nicorette	C				

Date:10/22/01ISR Number: 3813800-3Report Type:Expedited (15-DaCompany Report #A0055937A
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation
Disability	Agoraphobia
	Anaphylactic Shock
	Anxiety
	Arrhythmia Supraventricular
	Autonomic Nervous System Imbalance
	Blood Glucose Increased
	Blood Triglycerides Increased

Bradycardia
Cognitive Disorder
Condition Aggravated
Convulsion
Delusion
Depersonalisation
Depression
Drug Hypersensitivity
Dyspnoea
Dysthymic Disorder
Haematuria
Hallucination
Hyperhidrosis
Hypertension
Hypomania
Intervertebral Disc
Degeneration
Labile Blood Pressure
Memory Impairment
Mental Impairment
Mitral Valve Incompetence
Mood Swings
Muscle Spasms

	Neurosis						
	Obsessive-Compulsive Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Palpitations		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 12 DAY
	Panic Attack		Premarin	C			1.25MG Per day
	Paranoia						
	Psychomotor Hyperactivity		Vitamin	C			
	Renal Disorder		Asa	C			
	Renal Impairment		Melatonin	C			
	Schizophrenia						
	Sciatica						
	Speech Disorder						
	Stress						
	Stupor						
	Tachycardia						
	Tinnitus						
	Tobacco Abuse						
	Transient Ischaemic Attack						
	Urethral Stricture						
	Urinary Incontinence						
	Ventricular Extrasystoles						
	Weight Increased						

Date:10/22/01ISR Number: 3813810-6Report Type:Expedited (15-DaCompany Report #B0121094A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 3 WK
Other	Confusional State		Zyban	SS	Glaxo Wellcome	ORAL	2250MG Single dose 1 DAY
	Delirium						
	Grand Mal Convulsion		Alcohol	SS		ORAL	1 DAY
	Hallucination						
	Hypokalaemia						
	Leukocytosis						
	Overdose						

Date:10/22/01ISR Number: 3813817-9Report Type:Expedited (15-DaCompany Report #B0123589A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 DAY
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness							
	Ecchymosis							
	Panic Reaction							

Date:10/22/01ISR Number: 3813818-0Report Type:Expedited (15-DaCompany Report #B0123591A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bronchospasm		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	15 DAY
			Salbutamol	C	Glaxo Wellcome		RESPIRATORY (INHALATION)	
			Dihydrocodeine	C		ORAL		
			Eformoterol	C			RESPIRATORY (INHALATION)	

			Indoramin	C	Glaxo Wellcome	ORAL	60MG per day
			Ipratropium	C	Glaxo Wellcome		RESPIRATORY (INHALATION)
			Ipratropium	C	Glaxo Wellcome		RESPIRATORY (INHALATION) 8PUFF per day

Date:10/22/01ISR Number: 3813820-9Report Type:Expedited (15-DaCompany Report #B0123592A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperaesthesia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	31 DAY
	Micturition Urgency							
	Penis Disorder							
	Pollakiuria							
	Premature Ejaculation							

Date:10/22/01ISR Number: 3813821-0Report Type:Expedited (15-DaCompany Report #B0123594A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis		Wellbutrin	PS	Glaxo Wellcome		1UNIT Per day	15 DAY
	Hypokalaemia		Microval	SS		ORAL		
			Cholstat	SS		ORAL		

Date:10/23/01ISR Number: 3811928-5Report Type:Expedited (15-DaCompany Report #A0155443A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	

Initial or Prolonged	Convulsion		Vioxx	SS		
Other	Fall		Celebrex	SS		
14 DAY						
	Head Injury		Neurontin	C		ORAL
300MG Four						
	Headache					
times per day YR						
	Inflammation					
	Migraine					
	Mucous Membrane Disorder					
	Paralysis					
	Pruritus					
	Sinus Headache					
	Sinus Polyp					
	Swelling					

Date:10/23/01ISR Number: 3811944-3Report Type:Expedited (15-DaCompany Report #D0021964A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 33 DAY						
	Loss Of Consciousness					
	Palpitations					
	Pulse Absent					
	Tachycardia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/01ISR Number: 3812699-9Report Type:Expedited (15-DaCompany Report #B0106367A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Arthralgia	Foreign	Zyban Tablet - Zyban				
Hospitalization -	Dizziness		(Bupropion				
Initial or Prolonged	Dyspnoea		Hydrochloride)	PS		ORAL	150 MG/TWICE
Disability	Rash Generalised						PER DAY/ORAL
	Visual Disturbance		Microgynon	C			

Date:10/23/01ISR Number: 3812884-6Report Type:Expedited (15-DaCompany Report #A0163666A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health	Wellbutrin-Tablet-Co				
	Drug Level Above	Professional	ntrolled Release				
	Therapeutic	Company	(Bupropion				
	Drug Level Below	Representative	Hydrochloride)	PS		ORAL	150 MG /
	Therapeutic						THREE TIMES
							PER DAY /
							ORAL
			Lamotrigine	C			
			Olanzapine	C			
			Fluvoxamine Maleate	C			

Date:10/23/01ISR Number: 3812886-XReport Type:Expedited (15-DaCompany Report #A0163486A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Atrial Septal Defect	Study	Wellbutrin				
	Complications Of Maternal	Health	Unspecified Tablet				
	Exposure To Therapeutic	Professional	(Bupropion				
	Drugs		Hydrochloride)	PS		ORAL	300 MG / PER

	Pregnancy					
DAY / ORAL						
	Pulmonary Valve Stenosis					
	Congenital					

Date:10/23/01ISR Number: 3813572-2Report Type:Expedited (15-DaCompany Report #D0018145A
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bradycardia	Foreign	Zyban Tablet - Zyban					
Hospitalization -	Brain Oedema	Health	(Bupropion					
Initial or Prolonged	Cerebral Ischaemia	Professional	Hydrochloride)	PS		ORAL	150 MG PER	
	Depressed Level Of							
DAY ORAL								
	Consciousness		Diclofenac	C				
	Dyspnoea		Anti-Hyperlipidemic	C				
	Haemorrhagic Stroke		Oxpentifylline	C				
	Hypertension							
	Loss Of Consciousness							
	Muscle Spasms							
	Pupils Unequal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/01ISR Number: 3813664-8Report Type:Expedited (15-DaCompany Report #B0110958A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy	Foreign	Zyban Tablet - Zyban					
Hospitalization -	Dizziness		(Bupropion					
Initial or Prolonged	Dyspnoea		Hydrochloride)	PS		ORAL	150 MG TWICE	
Disability	Rash Generalised						PER DAY/ ORAL	
	Tenderness		Mycrogynon	C				
	Visual Disturbance							

Date:10/23/01ISR Number: 3813724-1Report Type:Expedited (15-DaCompany Report #B0123297A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Foreign	Zyban Tablet - Zyban					
Initial or Prolonged	Circulatory Collapse	Health	(Bupropion					
		Professional	Hydrochloride)	PS			150 MG	

Date:10/23/01ISR Number: 3813732-0Report Type:Expedited (15-DaCompany Report #D0021744A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erythema	Foreign	Zyban Tablet - Zyban					
	Fatigue	Health	(Bupropion					
	Oedema Peripheral	Professional	Hydrochloride)	PS		ORAL	150 MG / ORAL	
			Nitrendipine	C				
			Bisoprolol	C				

Date:10/23/01ISR Number: 3814284-1Report Type:Expedited (15-DaCompany Report #A0153715A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required Intervention to Prevent Permanent Impairment/Damage	Depression Malabsorption Medication Residue	Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL

200/MG/TWICE

PER DAY/ORAL

Date:10/24/01ISR Number: 3812620-3Report Type:Expedited (15-DaCompany Report #A0121035A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Pancreatitis		Wellbutrin	PS	Glaxo Wellcome	ORAL
Other			Adderall	C		ORAL
Other			Effexor	C		ORAL

Dose Duration
100MG Twice per day
10MG Per day 104 DAY
37.5MG Per day

Date:10/24/01ISR Number: 3812629-XReport Type:Expedited (15-DaCompany Report #B0122925A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL
	Dyskinesia		Co-Proxamol	C		ORAL
			Diazepam	C		ORAL

Dose Duration
4 DAY
8UNIT per day
2MG As required

		Diclofenac	C		ORAL
		Paraffin	C		
		Erythromycin	C	Glaxo Wellcome	ORAL
250MG Four					
times per day					
		Fluticasone	C	Glaxo Wellcome	
RESPIRATORY					
(INHALATION)	125MCG Twice				
per day					
		Gtn	C	Glaxo Wellcome	
		Hydrocortisone	C	Glaxo Wellcome	
TOPICAL					
		Isosorbide	C		ORAL
120MG per day					
		Ipratropium	C	Glaxo Wellcome	
RESPIRATORY					
(INHALATION)					
		Mucogel	C		ORAL
		Oilatum Plus	C		
TOPICAL					
		Otomize	C		
AURICULAR					
(OTIC)					
		Quinine Sulphate	C		ORAL
300MG per day					
		Ranitidine	C	Glaxo Wellcome	ORAL
150MG per day					
		Salbutamol	C	Glaxo Wellcome	
RESPIRATORY					
(INHALATION)					
		Salmeterol	C	Glaxo Wellcome	
RESPIRATORY					
(INHALATION)	50MCG Twice				
per day					
		Sodium Cromoglycate	C		
OPHTHALMIC	1DROP Four				
times per day					

			Tramadol	C		ORAL 100MG Three times per day
			Diltiazem	C	Glaxo Wellcome	ORAL 300MG Per day
			Aqueous Cream	C		TOPICAL
			Aspirin	C		ORAL 75MG per day
			Gtn	C	Glaxo Wellcome	TRANSDERMAL
			Ipratropium	C	Glaxo Wellcome	RESPIRATORY (INHALATION) 250MCG Four times per day
			Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION) 2.5MG As required
			Locorten Vioform	C		AURICULAR (OTIC) 2DROP Twice per day

Date:10/24/01ISR Number: 3814906-5Report Type:Expedited (15-DaCompany Report #B0123296A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Decreased Appetite Malaise Pain Psoriasis Skin Infection Vomiting	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL 150 MG/TWICE PER DAY/ORAL
			Cyclosporin	C		

Date:10/24/01ISR Number: 3815064-3Report Type:Expedited (15-DaCompany Report #A0163484A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hostility Phobia Social Avoidant Behaviour	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion					

			Hydrochloride)	PS		ORAL

150 MG/ TWICE

PER DAY/ ORAL 3 WK

Date:10/24/01ISR Number: 3815090-4Report Type:Expedited (15-DaCompany Report #A0143021A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Health	Bupropion					
Hospitalization - Initial or Prolonged	Confusional State	Professional	Hydrochloride Tablet - Controlled Release (Bupropion					
	Delirium							
	Drug Toxicity							
	Fall		Hydrochloride)	PS		ORAL	SEE TEXT	ORAL
	Memory Impairment		Amantadine Tablet (Amantadine					
	Paranoia							
	Schizophrenia		Hydrochloride)	SS		ORAL	SEE TEXT	ORAL
	Tremor		Fluoxetine Hydrochloride	C				
			Loxapine	C				
			Quetiapine Fumarate	C				
			Risperidone	C				
			Lorazepam	C				

Date:10/24/01ISR Number: 3815293-9Report Type:Expedited (15-DaCompany Report #B0121084A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease	Foreign	Zyban Tablet-					
	Myocardial Infarction	Health	(Bupropion					
	Myocardial Ischaemia	Professional	Hydrochloride)	PS			150 MG	

TWICE PER DAY

Date:10/25/01ISR Number: 3814631-0Report Type:Direct Company Report #
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Respiratory		Zyban	PS		ORAL	150 MG PO	
	Distress Syndrome		Serevent	C				
	Laryngeal Oedema		Azmacort	C				
	Medication Error							
	Obstructive Airways Disorder							

Date:10/25/01ISR Number: 3819398-8Report Type:Periodic Company Report #HQ4496309AUG2001
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose	Health Professional	Ativan (Lorazepam, Tablet)	PS		ORAL	OVERDOSE,	
							ORAL	
			Duract (Bromfenac, Capsule)	SS		ORAL	OVERDOSE,	
							ORAL	
			Meridia (Sibutramine Hydrochloride,)	SS		ORAL	OVERDOSE,	
							ORAL	
			Prozac (Fluoxetine Hydrochloride)	SS		ORAL	OVERDOSE,	
							ORAL	

				Serzone (Mefazodone Hydrochloride,)	SS		ORAL
OVERDOSE,							
ORAL							
				Wellbutrin (Amfebutamone Hydrochloride,)	SS		ORAL
OVERDOSE,							
ORAL							

Date:10/26/01ISR Number: 3814734-0Report Type:Expedited (15-DaCompany Report #A0093320A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	307 DAY
	Asthenia							
	Crying		Azithromycin	C				
	Eye Disorder		Zantac	C	Glaxo Wellcome			
	Facial Palsy		Nasonex	C				
	Hypoaesthesia							
	Irritability							
	Mental Disorder							
	Transient Ischaemic Attack							

Date:10/26/01ISR Number: 3814738-8Report Type:Expedited (15-DaCompany Report #A0164646A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs		Zyban	PS	Glaxo Wellcome	ORAL		
			No Concurrent Medications	C				
	Intra-Uterine Death							
	Umbilical Cord Abnormality							

Date:10/26/01ISR Number: 3814744-3Report Type:Expedited (15-DaCompany Report #B0105568A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome	ORAL	10MCG Twice per day	
	Dizziness		Levothyroxine	C	Glaxo Wellcome	ORAL		
			Cilazapril	C			5MG Per day	

Date:10/26/01ISR Number: 3814745-5Report Type:Expedited (15-DaCompany Report #B0105578A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	32 DAY
	Liver Function Test							
	Abnormal		Mirtazapine	C			30MG Per day	
	Nausea		Pravastatin	C			20MG Per day	
			Aspirin	C			75MG Per day	
			Omeprazole	C			20MG Per day	
			Atenolol	C		ORAL	25MG Per day	
			Isosorbide Mononitrate	C			60MG Per day	
			Ramipril	C		ORAL	2MG Per day	

			Gemfibrozil	C			
20MG Per day							

Date:10/26/01ISR Number: 3814746-7Report Type:Expedited (15-DaCompany Report #B0114323A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Balance Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Three	
Hospitalization -	Deafness						times per day	
Initial or Prolonged	Depression		Citalopram	C				
	Fall		Sodium Valproate	C			300MG Twice	
	Feeling Jittery						per day	
	Loss Of Consciousness		Fluoxetine	C			40MG per day	
	Multiple Sclerosis		Zopiclone	C		ORAL	1	DAY
	Orthostatic Hypotension							
	Photopsia							
	Road Traffic Accident							
	Syncope							
	Tooth Injury							
	Visual Acuity Reduced							

Date:10/26/01ISR Number: 3814747-9Report Type:Expedited (15-DaCompany Report #B0114925A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL	24	DAY
Initial or Prolonged	Diplopia							
Disability	Ecchymosis							
Other	Eye Pain							
	Facial Bones Fracture							
	Sedation							
	Sleep Disorder							
	Wrist Fracture							

Date:10/26/01ISR Number: 3814754-6Report Type:Expedited (15-DaCompany Report #B0123953A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	5 DAY

Date:10/26/01ISR Number: 3814755-8Report Type:Expedited (15-DaCompany Report #B0123954A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Eruption		Zyban	PS	Glaxo Wellcome	ORAL	11 DAY	
	Psoriasis		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	2PUFF Four times per day	
			Ipratropium	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	2PUFF Three times per day	
			Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/01ISR Number: 3816065-1Report Type:Expedited (15-DaCompany Report #A123115
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Lethargy Overdose	Health Professional	Ziprasidone Po	PS		ORAL	160.00 MG	TOTAL;BID;ORAL
			Buproprion	SS		ORAL	100.00 MG	TOTAL;DAILY;ORAL
			Trazodone	SS		ORAL		
			Alprazolam	SS				

Date:10/30/01ISR Number: 3816532-0Report Type:Expedited (15-DaCompany Report #A0156108A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Ecchymosis Haemorrhage Hysterectomy Menorrhagia Stress		Wellbutrin Sr Herbs Homeopathy	PS C C	Glaxo Wellcome	ORAL	300MG per day	

Date:10/30/01ISR Number: 3816543-5Report Type:Expedited (15-DaCompany Report #B0123957A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Laryngeal Oedema Mouth Ulceration		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG Twice per day	22 DAY

Date:10/30/01ISR Number: 3816545-9Report Type:Expedited (15-DaCompany Report #B0124107A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Zyban	PS	Glaxo Wellcome		150MG Twice	
Hospitalization -	Feeling Hot						per day	
Initial or Prolonged								
Other								

Date:10/31/01ISR Number: 3817276-1Report Type:Expedited (15-DaCompany Report #A0155864A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Infectious Mononucleosis		Wellbutrin	PS	Glaxo Wellcome	ORAL		
Initial or Prolonged	Neutropenia		No Concurrent Medications	C				

Date:10/31/01ISR Number: 3817278-5Report Type:Expedited (15-DaCompany Report #A0162401A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Effect Decreased		Zyban	PS	Glaxo Wellcome	ORAL		
Initial or Prolonged	Mood Swings		Topamax	SS			UNKNOWN	
	Suicidal Ideation		Zyprexa	SS			UNKNOWN	
			Klonopin	SS			UNKNOWN	
			Ziprasidone	SS			UNKNOWN	

			Depakote	SS		
UNKNOWN						

Date:10/31/01ISR Number: 3817284-0Report Type:Expedited (15-DaCompany Report #B0107035A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	2	WK
	Decreased Appetite		Chloroquine	C				
	Depression							
	Disturbance In Attention							
	Irritability							
	Mood Swings							
	Vision Blurred							

Date:10/31/01ISR Number: 3817291-8Report Type:Expedited (15-DaCompany Report #B0124387A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Albuminuria							
per day							13	DAY
Other	Condition Aggravated		Glyceryl Trinitrate	C	Glaxo Wellcome	SUBLINGUAL		
	Haematuria							
	Malignant Hypertension							
	Pancreatitis							
	Retinopathy Hypertensive							

Date:10/31/01ISR Number: 3817292-XReport Type:Expedited (15-DaCompany Report #B0124405A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock		Zyban	PS	Glaxo Wellcome	ORAL		
	Angina Pectoris							

Date:10/31/01ISR Number: 3818554-2Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Balance Disorder	Consumer	Zoloft Tablets	PS			50.00 MG	
Intervention to	Cerebrovascular Accident						TOTAL:DAILY	
Prevent Permanent	Convulsion		Wellbutrin	SS		ORAL	300.00 MG	
Impairment/Damage	Drug Ineffective						TOTAL:BID:ORA	
	Fall							
L								
	Heart Rate Increased		Coumadin	SS				
	Hostility		Effexor Sr	SS		ORAL	300.00 MG	
	Hyperhidrosis						TOTAL:BID:ORA	
	Laceration							
L								
	Mental Impairment		Toprol	C				
	Prothrombin Time		Zebeta	C				
	Prolonged		Lanoxin	C				
	Vaginal Haemorrhage		Lasix	C				
			Synthroid	C				
			Vitamin E	C				
			Estrogen	C				
			Amantadine	C				
			Zocor	C				
			Estradiol Vaginal Ring	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/01ISR Number: 3817868-XReport Type:Expedited (15-DaCompany Report #A0159004A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia Syncope		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Aspirin	C		ORAL	81MG Per day	
			Glucophage	C				
			Nitroglycerin	C	Glaxo Wellcome			
			Altace	C				
			Zocor	C				
			Niaspan	C				

Date:11/01/01ISR Number: 3817869-1Report Type:Expedited (15-DaCompany Report #A0163666A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Three times per day	
Other	Depression		Lamictal	C	Glaxo Wellcome	ORAL	300MG Twice per day	
	Drug Level Above Therapeutic		Zyprexa	C		ORAL	35MG per day	
	Grand Mal Convulsion		Luvox	C		ORAL		
			Remeron	C				
			Lithium	C				

Date:11/01/01ISR Number: 3817875-7Report Type:Expedited (15-DaCompany Report #A0165315A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	

	Tinnitus					
per day 10 DAY						
			Paxil	C	Glaxo Wellcome	
			Klonopin	C		

Date:11/01/01ISR Number: 3817884-8Report Type:Expedited (15-DaCompany Report #B0120884A
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm		Zyban	PS	Glaxo Wellcome		150MG As	
	Blister						directed	
	Dizziness							
	Insomnia							
	Tremor							

Date:11/02/01ISR Number: 3818796-6Report Type:Expedited (15-DaCompany Report #A0165224A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Complications Of Maternal		Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG Twice	
	Exposure To Therapeutic						per day	
	Drugs		Buspar	C				
	Oesophageal Atresia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/01ISR Number: 3818801-7Report Type:Expedited (15-DaCompany Report #B0101026A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Sudden Death						per day	18 DAY
			Bisoprolol	C			10MG At night	
			Voltarol Sr	C	Glaxo Wellcome		UNKNOWN	75MG Twice
								per day
			Ranitidine	C	Glaxo Wellcome			
			Aspirin Ec	C			UNKNOWN	

Date:11/02/01ISR Number: 3818803-0Report Type:Expedited (15-DaCompany Report #B0114323A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Balance Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Three	
Hospitalization -	Deafness						times per day	
Initial or Prolonged	Depression		Citalopram	C				
	Fall		Sodium Valproate	C			300MG Twice	
	Feeling Jittery						per day	
	Loss Of Consciousness		Fluoxetine	C			40MG per day	
	Nervous System Disorder		Zopiclone	C		ORAL	1	DAY
	Orthostatic Hypotension							
	Overdose							
	Photopsia							
	Road Traffic Accident							
	Syncope							
	Tooth Loss							
	Tremor							
	Visual Disturbance							

Date:11/02/01ISR Number: 3818804-2Report Type:Expedited (15-DaCompany Report #B0115008A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Toxicity Physical Assault		Zyban	PS	Glaxo Wellcome			

Date:11/02/01ISR Number: 3818805-4Report Type:Expedited (15-DaCompany Report #B0118455A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis Drug Interaction		Zyban	PS	Glaxo Wellcome		150MG As directed	
			Coumarin	SS		ORAL		

Date:11/02/01ISR Number: 3818807-8Report Type:Expedited (15-DaCompany Report #B0122089A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease Coronary Artery Occlusion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	18 DAY
			Bisoprolol	C		ORAL	10MG Per day	
			Diclofenac	C			75MG Twice per day	
			Ranitidine	C	Glaxo Wellcome			
			Aspirin	C			75MG per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/01ISR Number: 3818808-XReport Type:Expedited (15-DaCompany Report #B0123963A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Disorder		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG Per day	23 DAY
	Hypertension		Enalapril	C			20MG Per day	
	Monoparesis Transient Ischaemic Attack							

Date:11/02/01ISR Number: 3819944-4Report Type:Expedited (15-DaCompany Report #200110-1486 (0)
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Bite Grand Mal Convulsion	Health Professional	Sudafed - Dosage Form Unspecified (Pseudoephedrine)	PS		ORAL	PER ORAL	
	Tongue Disorder		Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	150 MG BID,	
							PER ORAL	
			Paroxetine Hydrochloride (Paroxetine Hydrochloride)	C				
			Oral Contraceptive	C				
			Quetiapine Fumarate (Quetiapine Fumarate)	C				

Date:11/05/01ISR Number: 3820684-6Report Type:Expedited (15-DaCompany Report #02720
Age:46 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Literature	Naproxen	PS				

			Bupropine Sr	SS		

Date:11/05/01ISR Number: 3820703-7Report Type:Expedited (15-DaCompany Report #02597
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Carbamazepine	PS		
	Intentional Misuse		Bupropion	SS		

Date:11/05/01ISR Number: 3820704-9Report Type:Expedited (15-DaCompany Report #02611
Age:37 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Carbamazepine	PS		
	Intentional Misuse		Bupropion	SS		
			Olanzepine	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/01ISR Number: 3820725-6Report Type:Expedited (15-DaCompany Report #02612
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Clonazepam	PS				
	Intentional Misuse		Trazodone	SS				
			Bupropion	SS				

Date:11/05/01ISR Number: 3820727-XReport Type:Expedited (15-DaCompany Report #02608
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Clonidine	PS				
	Intentional Misuse	Health	Amtriptyline	SS				
		Professional	Bupropion	SS				

Date:11/05/01ISR Number: 3820746-3Report Type:Expedited (15-DaCompany Report #02613
Age:21 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Clonazepam	PS				
	Intentional Misuse		Bupropion	SS				
			Olanzepine	SS				

Date:11/05/01ISR Number: 3820763-3Report Type:Expedited (15-DaCompany Report #02663
Age:46 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Alprazolam	PS				
	Intentional Misuse		Bupropion	SS				
			Olanzapine	SS				

Date:11/06/01ISR Number: 3820310-6Report Type:Expedited (15-DaCompany Report #A0165053A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bacterial Infection Crying Derealisation Drug Withdrawal Syndrome Pregnancy		Wellbutrin	PS	Glaxo Wellcome	ORAL		12 YR

Date:11/06/01ISR Number: 3820314-3Report Type:Expedited (15-DaCompany Report #B0123589A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angioneurotic Oedema Convulsion Depressed Level Of Consciousness Ecchymosis Panic Reaction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/01ISR Number: 3820317-9Report Type:Expedited (15-DaCompany Report #B0124304A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Irritability		Zyban	PS	Glaxo Wellcome	ORAL	150MG Variable dose	
	Logorrhoea							
	Nausea		Zyban	SS	Glaxo Wellcome	ORAL	2700MG Single dose	1 DAY
	Overdose							
	Suicide Attempt		Alcohol	C				
	Tearfulness							

Date:11/07/01ISR Number: 3820835-3Report Type:Expedited (15-DaCompany Report #A0164667A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pain In Extremity		Zyban	PS	Glaxo Wellcome	ORAL	4	MON
	Tremor							

Date:11/07/01ISR Number: 3820836-5Report Type:Expedited (15-DaCompany Report #A0164944A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG See dosage text	
	Blood Potassium Decreased							
	Dizziness		Prozac	C		ORAL	60MG Per day	
	Grand Mal Convulsion							
	Stress							

Date:11/07/01ISR Number: 3820839-0Report Type:Expedited (15-DaCompany Report #B0108772A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Bupropion Hcl	PS	Glaxo Wellcome	ORAL	150MG Per day	
			Aspirin	C		ORAL	1UNIT Per day	
			Atenolol	C		ORAL	RESPIRATORY (INHALATION)	200MCG Twice per day
			Beclomethasone	C	Glaxo Wellcome		1UNIT Per day	
			Co-Amilofruse	C		ORAL	60MG Per day	
			Imdur	C		ORAL	15ML Twice per day	
			Lactulose	C		ORAL	20MG Twice per day	
			Lisinopril	C		ORAL	100MG Twice per day	
			Zydol	C		ORAL	20MG Per day	
			Fluoxetine	C		ORAL	10MG Per day	
			Cetirizine	C	Glaxo Wellcome	ORAL	TOPICAL .1PCT Twice per day	
			Betnovate	C	Glaxo Wellcome			

Date:11/07/01ISR Number: 3820842-0Report Type:Expedited (15-DaCompany Report #B0120525A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Congestive Cardiomyopathy							
	Drug Interaction		Aspirin	C		ORAL	150MG per day	

			Atenolol	C		ORAL 50MG per day
			Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION) 200MG per day
			Co-Amilofruse	C		ORAL 1UNIT per day
			Isosorbide	C		ORAL 60MG per day
			Lactulose	C		ORAL 15ML Twice per day
			Lisinopril	C		ORAL 20MG Twice per day
			Tramadol	C		ORAL 100MG Twice per day
			Fluoxetine	C		ORAL 20MG Per day
			Cetirizine	C	Glaxo Wellcome	ORAL 10MG Per day
			Betamethasone	C	Glaxo Wellcome	TOPICAL

Date:11/07/01ISR Number: 3823287-2Report Type:Expedited (15-DaCompany Report #M0697-2001
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Asthenia	Literature	Remeron	PS		ORAL 22.5 MGS PO L.I.D.
	Body Temperature Increased		Valproic Acid	SS		ORAL 500 MGS PO QHS
	Electrocardiogram Abnormal		Bupropion	SS		ORAL 150 MG PO BID

	Respiratory Rate		Bupropion	SS		ORAL
7.5 MG PO AT						
	Increased					
NOON						
	Supraventricular Tachycardia					

Date:11/08/01ISR Number: 3821680-5Report Type:Expedited (15-DaCompany Report #B0124639A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Erythema Psoriasis		Zyban	PS	Glaxo Wellcome	

Date:11/08/01ISR Number: 3821682-9Report Type:Expedited (15-DaCompany Report #B0125311A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dyspepsia		Zyban	PS	Glaxo Wellcome	ORAL
4 WK						
	Glomerulonephritis Nephrotic Syndrome Weight Increased					

Date:11/08/01ISR Number: 3821683-0Report Type:Expedited (15-DaCompany Report #D0020665A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/01ISR Number: 3822367-5Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Tongue Oedema		Wellbutrin 150mg Tid	PS		ORAL	150MG PO TID	
Required Intervention to Prevent Permanent Impairment/Damage			Zocor	C				
			Diltiazem	C				
			Aspirin	C				
			Atenol	C				
			Glucotrol	C				

Date:11/08/01ISR Number: 3822847-2Report Type:Expedited (15-DaCompany Report #A0159165A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	SEE DOSAGE TEXT / ORAL	
	Amnesia							
	Conjunctival Discolouration							
	Deafness							
	Depression		Metoprolol Succinate (Formulation Unknown) (Metoprolol Succinate)	SS		ORAL	50 MG PER DAY	
	Drug Interaction							
	Liver Function Test Abnormal							
	Tinnitus						ORAL	
	Tooth Disorder		Nitroglycerin	C				
			Ranitidine Hydrochloride	C				
			Hydroxyzine	C				

Date:11/08/01ISR Number: 3823862-5Report Type:Expedited (15-DaCompany Report #B0125004A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression	Foreign	Zyban Tablet - Zyban					

Initial or Prolonged	Depression Fatigue Loss Of Consciousness Weight Decreased	Consumer	(Bupropion Hydrochloride)	PS		
150 MG						

Date:11/08/01ISR Number: 3823893-5Report Type:Expedited (15-DaCompany Report #B0123286A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged 150 MG/ PER Required DAY	Angioneurotic Oedema Convulsion Depressed Level Of Consciousness	Foreign Health Professional Company Representative	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		
Intervention to Prevent Permanent Impairment/Damage	Head Injury Hyperventilation Obstructive Airways Disorder Panic Reaction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/01ISR Number: 3823907-2Report Type:Expedited (15-DaCompany Report #B0124852A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Aggression Dyskinesia Fall Head Injury Loss Of Consciousness	Foreign	Zyban Tablet- Zyban (Bupropion Hydrochloride) Bendrofluazide	PS C		ORAL	150 MG/TWICE PER DAY/ORAL

Date:11/08/01ISR Number: 3823918-7Report Type:Expedited (15-DaCompany Report #B0115303A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Other Required Intervention to Prevent Permanent Impairment/Damage	Bite Confusional State Decreased Activity Dyspnoea Fatigue Grand Mal Convulsion Loss Of Consciousness Tongue Disorder	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Dianette	PS C			150 MG

Date:11/08/01ISR Number: 3823920-5Report Type:Expedited (15-DaCompany Report #B0119682A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Acute Psychosis Anger Depression Overdose Suicidal Ideation	Foreign Health Professional	Zyban Tablet -Zyban (Bupropion Hydrochloride) Paracetamol (Formulation Unknown) (Acetaminophen)	PS SS		ORAL	150 MG/ ORAL 10 TABLETS

PER DAY

Paracetamol + Codeine Po4 (Formulation Unknown) (Acetaminophen + SS

10 TABLETS

PER DAY

Mersyndol (Formulation Unknown) (Mersyndol) SS

Date:11/08/01ISR Number: 3823945-XReport Type:Expedited (15-DaCompany Report #B0122882A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia Rash Erythematous	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ AS	DIRECTED/

ORAL 2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/13/01ISR Number: 3823065-4Report Type:Expedited (15-DaCompany Report #A0157251A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Deafness Neurosensory							
per day								2 WK
	Headache		Premarin	C				
	Joint Stiffness		Vitamin E	C				
	Neck Pain		Vitamin C	C				
	Pyrexia		Vitamin A	C				
	Tinnitus		Multivitamin	C				

Date:11/13/01ISR Number: 3823066-6Report Type:Expedited (15-DaCompany Report #A0160261A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	2 WK
	Crying		Meridia	SS		ORAL	6	WK
	Diabetes Mellitus		Toprol	C				
	Feeling Abnormal		Hctz	C				
	Mood Swings							
	Palpitations							
	Psychomotor Hyperactivity							
	Serotonin Syndrome							
	Suicidal Ideation							

Date:11/13/01ISR Number: 3823067-8Report Type:Expedited (15-DaCompany Report #A0163660A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Peyronie'S Disease		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Priapism							
per day								14 DAY
Disability	Scar		Catapres Tts	C				
22 DAY								

Other			Desyrel	C			

Date:11/13/01ISR Number: 3823068-XReport Type:Expedited (15-DaCompany Report #A0165555A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome			
	Vomiting		Alcohol	SS				
			Hydrocodone	C				

Date:11/13/01ISR Number: 3823069-1Report Type:Expedited (15-DaCompany Report #A0166622A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	3	WK
	Cholelithiasis							
	Convulsion							
	Muscle Twitching							
	Nightmare							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/13/01ISR Number: 3823071-XReport Type:Expedited (15-DaCompany Report #A0166978A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							

Date:11/13/01ISR Number: 3823073-3Report Type:Expedited (15-DaCompany Report #B0111855A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	7 WK
Other	Diplopia							
	Echocardiogram Abnormal		Citalopram	C			20MG Per day	
	Hypercholesterolaemia		Thiamine	C			300MG Per day	
	Myocardial Infarction		Alprazolam	C			.25MG Twice per day	
	Nystagmus							
	Respiratory Failure		Fluticasone	C	Glaxo Wellcome		2U Per day	
	Supraventricular Extrasystoles		Salmeterol	C	Glaxo Wellcome		2U Per day	
	Tachycardia							
	Ventricular Extrasystoles							
	Vith Nerve Paralysis							

Date:11/13/01ISR Number: 3823079-4Report Type:Expedited (15-DaCompany Report #B0124304A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome	ORAL 150MG As
Hospitalization -	Anger					
directed 9 DAY						
Initial or Prolonged	Dry Mouth		Zyban	SS	Glaxo Wellcome	ORAL 2700MG Single
	Dry Skin					
dose 1 DAY						
	Dysuria		Alcohol	C		
	Excitability					
	Heart Rate Increased					
	Impulsive Behaviour					
	Insomnia					
	Irritability					
	Logorrhoea					
	Mydriasis					
	Nervousness					
	Overdose					
	Sedation					
	Suicide Attempt					
	Tearfulness					
	Vomiting					

Date:11/13/01ISR Number: 3823086-1Report Type:Expedited (15-DaCompany Report #B0125839A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Circulatory Collapse		Zyban	PS	Glaxo Wellcome	2 DAY
	Face Oedema					
	Shock					
	Urticaria					

Date:11/14/01ISR Number: 3823315-4Report Type:Expedited (15-DaCompany Report #B0120884A
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm		Zyban	PS	Glaxo Wellcome		150MG As directed	9 DAY
	Blister							
	Dizziness							
	Insomnia							
	Tremor							

Date:11/14/01ISR Number: 3823325-7Report Type:Expedited (15-DaCompany Report #B0125993A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness		Alcohol	C				
Other	Headache							
	Neck Pain							
	Subarachnoid Haemorrhage							

Date:11/14/01ISR Number: 3823326-9Report Type:Expedited (15-DaCompany Report #B0125995A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Dissection		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Blood Pressure Increased		Hydrocortisone	C	Glaxo Wellcome			
INTRAMUSCULAR	1 DAY							
	Cardiomegaly							
	Pericardial Haemorrhage							

Date:11/14/01ISR Number: 3823327-0Report Type:Expedited (15-DaCompany Report #B0125999A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	9	DAY
			Fluticasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	1G Twice per day	
			Montelukast	C		ORAL		
			Combivent	C		RESPIRATORY (INHALATION)		

Date:11/14/01ISR Number: 3823328-2Report Type:Expedited (15-DaCompany Report #B0126006A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome			

Date:11/14/01ISR Number: 3825082-7Report Type:Expedited (15-DaCompany Report #2001UW14424
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder	Other	Prilosec	PS				
	Condition Aggravated		Zyprexa	SS				
	Disorientation		Eskalith	SS				
	Fall		Wellbutrin	SS				

Date:11/15/01ISR Number: 3824478-7Report Type:Expedited (15-DaCompany Report #A0160255A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Asthenia							
per day								14 DAY
Initial or Prolonged	Atrioventricular Block		Thioridazine	C		ORAL	10MG Twice	
	Blood Creatine							
per day								5 YR
	Phosphokinase Increased							
	Bradycardia							
	Face Oedema							
	Hypotension							
	Loss Of Consciousness							
	Pruritus							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							
	Scrotal Oedema							
	Serum Sickness							
	Sinoatrial Block							
	Urticaria							
	White Blood Cell Count							
	Increased							

Date:11/15/01ISR Number: 3824490-8Report Type:Expedited (15-DaCompany Report #B0126090A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypoaesthesia		Zyban	PS	Glaxo Wellcome	ORAL	15 DAY	
Initial or Prolonged	Monoparesis							

Date:11/19/01ISR Number: 3825687-3Report Type:Expedited (15-DaCompany Report #A0132245A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blindness Unilateral		Zyban	PS	Glaxo Wellcome	ORAL 150MG Twice per day 1 MON
	Deafness					
	Dizziness		Zyban	SS	Glaxo Wellcome	ORAL 150MG Twice per day
	Hyperglycaemia					
	Hypoglycaemia		Multivitamin	C		
	Nervous System Disorder		Vitamin E	C		
	Tinnitus		Vitamin C	C		
			Aspirin	C		

Date:11/19/01ISR Number: 3825689-7Report Type:Expedited (15-DaCompany Report #A0162932A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged Other	Angiopathy		Zyban	PS	Glaxo Wellcome	ORAL
	Blood Pressure Decreased					
	Cardiac Disorder					
	Loss Of Consciousness					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/01ISR Number: 3825693-9Report Type:Expedited (15-DaCompany Report #A0166999A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Complications Of Maternal						per day	
	Exposure To Therapeutic Drugs		Synthroid	C	Glaxo Wellcome			

Date:11/19/01ISR Number: 3825694-0Report Type:Expedited (15-DaCompany Report #A0167029A
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm		Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG Twice	
	Dizziness						per day	4 MON
	Drug Withdrawal Syndrome							

Date:11/19/01ISR Number: 3825708-8Report Type:Expedited (15-DaCompany Report #B0126404A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	27 DAY
Initial or Prolonged			Lansoprazole	C		ORAL		

Date:11/19/01ISR Number: 3825709-XReport Type:Expedited (15-DaCompany Report #B0126406A
Age:43 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gingival Bleeding		Zyban	PS	Glaxo Wellcome	ORAL		
Initial or Prolonged	Neutropenia		Lansoprazole	C		ORAL		
	Thrombocytopenia							

Date:11/19/01ISR Number: 3826725-4Report Type:Periodic Company Report #263963
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Drug Interaction	Health Professional	Xenical (Orlistat) 120 Mg	PS		ORAL	120 MG 3 PER DAY	ORAL
			Wellbutrin Sr (Bupropion Hydrochloride)	SS				
			Synthroid (Levothyroxine Sodium)	C				
			Dexedrine (Dextroamphetamine Sulfate)	C				
			Effexor Xr (Venlafaxine Hydrochloride)	C				
			Pindolol (Pindolol)	C				
			Norvasc (Amlodipine Besylate)	C				
			Ambien (Zolpidem Tartrate)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/01ISR Number: 3827356-2Report Type:Direct Company Report #
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Mental Impairment		Ms Contin (60)	PS			3 TABS BID	1 MON
Initial or Prolonged	Respiratory Failure		Wellbutrin Sr	SS			1 TAB BID	1 MON
Other			Serzone	C				
			Neurontin	C				
			Synthroid	C				

Date:11/20/01ISR Number: 3826280-9Report Type:Expedited (15-DaCompany Report #A0154004A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Zyban	PS	Glaxo Wellcome	ORAL	150MG See	
	Burning Sensation						dosage text	3 DAY
	Burns Third Degree		No Concurrent					
	Feeling Abnormal		Medication	C				
	Flat Affect							
	Insomnia							
	Oedema Peripheral							
	Pain							
	Pain In Extremity							
	Penis Disorder							
	Pruritus							
	Rash Erythematous							
	Scab							
	Scar							
	Skin Discolouration							
	Vascular Injury							

Date:11/20/01ISR Number: 3826283-4Report Type:Expedited (15-DaCompany Report #A0159171A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other		Chest Pain	Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Twice
		Circulatory Collapse					
per day	2 MON						
		Convulsion	Phenothiazine	SS			INTRAVENOUS
		Dizziness	Atenolol	C			
		Drug Interaction	Lipitor	C			
		Ecchymosis	Methotrexate	C			
		Face Oedema	Folic Acid	C			
		Fall	Ambien	C			
		Head Injury	Ativan	C			
		Muscle Spasms	Zantac	C	Glaxo Wellcome		
		Nausea					
		Paralysis					
		Sedation					
		Tremor					

Date:11/20/01ISR Number: 3826288-3Report Type:Expedited (15-DaCompany Report #B0114598A
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Aggression
	Amnesia
	Anaphylactic Shock
	Angioneurotic Oedema

	Balance Disorder						
	Blister						
	Blood Pressure Increased	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Circulatory Collapse						
per day	62 DAY						
	Confusional State						
	Convulsion						
	Diarrhoea						
	Disorientation						
	Dizziness						
	Dry Skin						
	Dysphagia						
	Dyspnoea						
	Feeling Drunk						
	Feeling Hot						
	Flatulence						
	Gastroenteritis						
	Hyperhidrosis						
	Irritability						
	Irritable Bowel Syndrome						
	Loss Of Consciousness						
	Mental Impairment						
	Nausea						
	Oedema Peripheral						
	Pharyngeal Oedema						
	Pruritus						
	Rash Generalised						
	Rhinitis						
	Speech Disorder						
	Tinnitus						
	Tongue Oedema						
	Urticaria						

Date:11/20/01ISR Number: 3827397-5Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Other	Dyspnoea		Ziprasidone(Geodon)	PS			40MG BID
	Throat Tightness		Bupropion Sr				

			(Wellbutrin Sr)	SS			
100MG BID							
			Clozapine	C			
			Ddavp	C			
			Lamotrigine	C			
			Oxcarbezeprine	C			

Date:11/20/01ISR Number: 3827400-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysphagia		Ziprasidone(Geodon)	PS		ORAL	40MG PO BID	
Other	Dyspnoea		Bupropion Sr(Wellbutrin Sr)	SS		ORAL	150MG PO BID	
			Lithium Carbonate	C				
			Clozapine	C				
			Guanfacine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/01ISR Number: 3827086-7Report Type:Expedited (15-DaCompany Report #A0157983A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Cardiac Arrest							
per day								27 DAY
Initial or Prolonged	Cardiac Failure		Hctz	C		ORAL	5MG Per day	
	Cardiomegaly		Vasotec	C		ORAL	10MG Per day	
	Coronary Artery Disease							
	Hypersensitivity							
	Loss Of Consciousness							
	Ventricular Fibrillation							
	Vomiting							

Date:11/21/01ISR Number: 3827110-1Report Type:Expedited (15-DaCompany Report #B0126786A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fall		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Head Injury		Nevirapine	C		ORAL	200MG per day	
	Headache		Stavudine	C		ORAL	40MG per day	
	Insomnia		Famciclovir	C	Glaxo Wellcome		500MG per day	
			Lamivudine	C	Glaxo Wellcome	ORAL	150MG per day	
			Testosterone	C	Glaxo Wellcome		INTRAMUSCULAR	

Date:11/21/01ISR Number: 3827111-3Report Type:Expedited (15-DaCompany Report #B0126795A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Atrial Flutter		Zyban	PS	Glaxo Wellcome	
150MG Per day 15 DAY						
Initial or Prolonged						

Date:11/21/01ISR Number: 3827119-8Report Type:Expedited (15-DaCompany Report #D0022804A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bowel Sounds Abnormal		Zyban	PS	Glaxo Wellcome	ORAL
Initial or Prolonged	Coma		Amphetamine Sulphate	SS		ORAL
800MG per day						
	Drug Toxicity		Ritalin	SS		ORAL
60MG per day						
	Fatigue		Wine	SS		ORAL
3BT per day						
	Suicide Attempt					
	Tachycardia					

Date:11/21/01ISR Number: 3829553-9Report Type:Direct Company Report #
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia		Zyban	PS		ORAL
150 MG TAB PO						
BID						
			Habitrol 21mg	C		

Date:11/26/01ISR Number: 3828457-5Report Type:Expedited (15-DaCompany Report #A0167897A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3828463-0Report Type:Expedited (15-DaCompany Report #B0126564A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Asthma		Zyban	PS	Glaxo Wellcome		UNKNOWN	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Eczema							
	Neonatal Disorder							
	Pregnancy							
	Ventricular Septal Defect							

Date:11/26/01ISR Number: 3828465-4Report Type:Expedited (15-DaCompany Report #B0126796A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Zyban	PS	Glaxo Wellcome		150MG Twice per day	5 DAY
	Feeling Of Despair							
	Heart Rate Increased							
	Oxygen Saturation Decreased							

Date:11/26/01ISR Number: 3828466-6Report Type:Expedited (15-DaCompany Report #B0126849A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Multiple Sclerosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
			Interferon Beta	SS			UNKNOWN	
			Lioresal	SS			UNKNOWN	

Date:11/26/01ISR Number: 3828471-XReport Type:Expedited (15-DaCompany Report #A0167897A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:11/26/01ISR Number: 3828477-0Report Type:Expedited (15-DaCompany Report #B0126564A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Asthma		Zyban	PS	Glaxo Wellcome	UNKNOWN		
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Eczema							
	Neonatal Disorder							
	Pregnancy							
	Ventricular Septal Defect							

Date:11/26/01ISR Number: 3828479-4Report Type:Expedited (15-DaCompany Report #B0126796A
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Confusional State
	Feeling Of Despair
	Heart Rate Increased

	Oxygen Saturation Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome		150MG Twice per day 5 DAY

Date:11/26/01ISR Number: 3828480-0Report Type:Expedited (15-DaCompany Report #B0126849A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Multiple Sclerosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day UNKNOWN
			Interferon Beta	SS			
			Lioresal	SS			UNKNOWN

Date:11/26/01ISR Number: 3828485-XReport Type:Expedited (15-DaCompany Report #A0167897A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL	

Date:11/26/01ISR Number: 3828491-5Report Type:Expedited (15-DaCompany Report #B0126564A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Asthma		Zyban	PS	Glaxo Wellcome		UNKNOWN
	Complications Of Maternal Exposure To Therapeutic Drugs						
	Eczema						
	Neonatal Disorder						
	Pregnancy						

	Ventricular Septal Defect					

Date:11/26/01ISR Number: 3828493-9Report Type:Expedited (15-DaCompany Report #B0126796A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Zyban	PS	Glaxo Wellcome		150MG Twice per day	5 DAY
	Dyspnoea							
	Feeling Of Despair							
	Heart Rate Increased							

Date:11/26/01ISR Number: 3828494-0Report Type:Expedited (15-DaCompany Report #B0126849A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Multiple Sclerosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
			Interferon Beta	SS			UNKNOWN	
			Lioresal	SS			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3828499-XReport Type:Expedited (15-DaCompany Report #A0167897A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:11/26/01ISR Number: 3828505-2Report Type:Expedited (15-DaCompany Report #B0126564A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Asthma		Zyban	PS	Glaxo Wellcome	UNKNOWN		
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Congenital Anomaly							
	Eczema							
	Neonatal Disorder							
	Pregnancy							
	Ventricular Septal Defect							

Date:11/26/01ISR Number: 3828507-6Report Type:Expedited (15-DaCompany Report #B0126796A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Zyban	PS	Glaxo Wellcome	150MG Twice per day	5	DAY
	Feeling Of Despair							
	Heart Rate Increased							
	Oxygen Saturation Decreased							

Date:11/26/01ISR Number: 3828508-8Report Type:Expedited (15-DaCompany Report #B0126849A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Multiple Sclerosis		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day						
Initial or Prolonged			Interferon Beta	SS		
UNKNOWN						
			Lioresal	SS		
UNKNOWN						

Date:11/26/01ISR Number: 3828513-1Report Type:Expedited (15-DaCompany Report #A0167897A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL

Date:11/26/01ISR Number: 3828519-2Report Type:Expedited (15-DaCompany Report #B0126564A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Congenital Anomaly	Asthma		Zyban	PS	Glaxo Wellcome	
UNKNOWN						
	Complications Of Maternal					
	Exposure To Therapeutic					
	Drugs					
	Eczema					
	Neonatal Disorder					
	Pregnancy					
	Ventricular Septal Defect					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3828521-0Report Type:Expedited (15-DaCompany Report #B0126796A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Feeling Of Despair Heart Rate Increased Oxygen Saturation Decreased		Zyban	PS	Glaxo Wellcome		150MG Twice per day	5 DAY

Date:11/26/01ISR Number: 3828522-2Report Type:Expedited (15-DaCompany Report #B0126849A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Multiple Sclerosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
			Interferon Beta	SS			UNKNOWN	
			Lioresal	SS			UNKNOWN	

Date:11/26/01ISR Number: 3828606-9Report Type:Expedited (15-DaCompany Report #301831
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Mood Swings Tobacco Abuse		Klonopin Zyban Topamax Zyprexa Geodon Divalproex	PS I I I I I	Roche			

Date:11/27/01ISR Number: 3829634-XReport Type:Expedited (15-DaCompany Report #A0155904A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myeloid Metaplasia		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Twice	
Other	Pancytopenia						per day	2 YR
			Depakote	C		ORAL	500MG Twice	
							per day	

Date:11/27/01ISR Number: 3829640-5Report Type:Expedited (15-DaCompany Report #B0101350A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chronic Obstructive		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Pulmonary Disease						per day	
	Respiratory Failure		Isosorbide	C			60MG Twice	
	Sudden Death						per day	
			Nifedipine	C	Glaxo Wellcome		20MG Twice	
							per day	
			Alverine	C				
			Aspirin	C				

Date:11/27/01ISR Number: 3829642-9Report Type:Expedited (15-DaCompany Report #B0121383A
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Death	Drug Level Above Therapeutic

	Overdose Pulmonary Congestion Renal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Respiratory Failure		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day						
			Desipramine	SS		
			Dihydrocodeine	SS		ORAL
			Imipramine	SS		
UNKNOWN						
			Dothiepin	C		
UNKNOWN						

Date:11/27/01ISR Number: 3829643-0Report Type:Expedited (15-DaCompany Report #B0121689A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Chronic Obstructive		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Pulmonary Disease					
per day						
	Respiratory Failure		Isosorbide	C		
120MG per day						
	Sudden Death		Nifedipine	C	Glaxo Wellcome	
40MG per day						
			Alverine	C		
			Aspirin	C		

Date:11/27/01ISR Number: 3829646-6Report Type:Expedited (15-DaCompany Report #B0126090A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypoaesthesia		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 12 DAY						
Initial or Prolonged	Metastases To Central Nervous System Monoparesis					

Date:11/27/01ISR Number: 3829655-7Report Type:Expedited (15-DaCompany Report #B0127002A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Facial Palsy		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	4 DAY
			Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	100MCG As required	
			Indomethacin	C		ORAL	25MG Three times per day	

Date:11/27/01ISR Number: 3829656-9Report Type:Expedited (15-DaCompany Report #B0127123A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Feeling Abnormal		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
Hospitalization - Initial or Prolonged	Suicidal Ideation							101 DAY
	Suicide Attempt		Herbicide	SS				

Date:11/27/01ISR Number: 3830476-XReport Type:Direct Company Report #
Age:46 YR Gender:Male I/FU:I

Outcome	PT
Other	Depression
	Hearing Impaired
	Panic Attack
	Paranoia

	Sensory Disturbance Suicidal Ideation Visual Disturbance	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban 150mg				
			Glaxosmithkline	PS	Glaxosmithkline	ORAL	1 TABLE TWICE DAILY ORAL

Date:11/27/01ISR Number: 3830973-7Report Type:Expedited (15-DaCompany Report #HQ8752026NOV2001
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule,	PS		ORAL	ORAL
			Remeron (Mirtazapine,)	SS			
			Wellbutrin (Amfebutamone Hydrochloride)	SS			

Date:11/28/01ISR Number: 3830608-3Report Type:Expedited (15-DaCompany Report #B0113971A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Overdose		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Per day
	Pulmonary Congestion		Dihydrocodeine	SS		ORAL	
	Renal Disorder		Imipramine	SS			UNKNOWN
	Respiratory Failure		Desipramine	SS			UNKNOWN
			Prothiaden	C			UNKNOWN

Date:11/28/01ISR Number: 3831358-XReport Type:Expedited (15-DaCompany Report #301831
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Drug Interaction Mood Swings Tobacco Abuse	Consumer Other	Klonopin (Clonazepam) Zyban (Bupropion Hydrochloride) Topamax (Topiramate) Zyprexa (Olanzapine) Geodon (Ziprasidone Hydrochloride) Divalproex (Divalproex Sodium)	PS SS SS SS SS		ORAL ORAL		

Date:11/28/01ISR Number: 3831812-0Report Type:Expedited (15-DaCompany Report #NSADSS2001034911
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mood Swings Suicidal Ideation	Consumer	Topamax (Unspecified) (Topiramate) Zyban (Amfebutamone Hydrochloride) Olanzapine (Olanzapine)	PS SS SS		ORAL		

			Clonazepam (Clonazepam)	SS		

Date:11/28/01ISR Number: 3842958-5Report Type:Periodic Company Report #A0129608A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Required Intervention to Prevent Permanent Impairment/Damage	Condition Aggravated Eye Disorder Migraine	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release	PS		ORAL	100 MG / DAY / ORAL	PER

Date:11/28/01ISR Number: 3842959-7Report Type:Periodic Company Report #A0129610A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased Urticaria	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release	PS		ORAL	75 MG / ORAL	
			Sertraline Hydrochloride	C				

Date:11/28/01ISR Number: 3842960-3Report Type:Periodic Company Report #A0129338A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dystonia Muscle Tightness	Consumer	Wellbutrin Sr Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:11/28/01ISR Number: 3842961-5Report Type:Periodic Company Report #A0129391A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Date:11/28/01ISR Number: 3842962-7Report Type:Periodic Company Report #A0129304A
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Overdose	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release	PS		ORAL	150 MG / SEE DOSAGE TEXT / ORAL	WK
			Digoxin	C				
			Frusemide	C				
			Warfarin Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3842963-9Report Type:Periodic Company Report #A0130333A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Health	Wellbutrin Sr					
Other	Loss Of Consciousness	Professional	Tablet-Controlled					
	Petit Mal Epilepsy	Company	Release	PS		ORAL	ORAL	
		Representative	Fluoxetine Hydrochloride (Formation Unknown) (Fluoxetine Hydrochloride)	SS				

Date:11/28/01ISR Number: 3842964-0Report Type:Periodic Company Report #A0131024A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Wellbutrin Sr Tablet-Controlled	PS		ORAL	150 MG / FOUR TIMES PER DAY / ORAL	1 MON
	Constipation							
	Headache							
	Medication Error							
	Overdose							
	Paranoia							
	Sleep Disorder							

Date:11/28/01ISR Number: 3842965-2Report Type:Periodic Company Report #A0131053A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Enzymes Increased	Consumer	Wellbutrin Sr Tablet-Controlled Release	PS		ORAL	150 MG / TWICE PER DAY	
	Chest Pain							
	Leukocytosis							
	Pruritus							

Pyrexia
/ ORAL
Rash
Sensation Of Foreign Body
Toothache
Urticaria
Urticaria Papular

Date:11/28/01ISR Number: 3842966-4Report Type:Periodic Company Report #A0135817A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Wellbutrin Sr Tablet-Controlled Release	PS		ORAL	200MG / TWICE PER DAY/ ORAL	1 YR

Date:11/28/01ISR Number: 3842967-6Report Type:Periodic Company Report #A0134688A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose Somnolence	Health Professional	Wellbutrin Sr Tablet-Controlled Arelease (Bupropion Hydrochloride)	PS		ORAL	89 TABLET / SINGLE DOSE /	

ORAL

			Trazodone (Formulation Unknown) (Trazodone)	SS		

Date:11/28/01ISR Number: 3843813-7Report Type:Periodic Company Report #A0134384A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/	
Hospitalization - Initial or Prolonged	Road Traffic Accident	Company Representative						
Other							Required	6 MON
			Omeprazole	C				
Intervention to Prevent Permanent Impairment/Damage			Iron Salt	C				

Date:11/28/01ISR Number: 3843814-9Report Type:Periodic Company Report #A0137064A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	300 MG/ TWICE PER DAY/	
			Venlafaxine Hydrochloride	C				
			Citalopram Hydrobromide	C				
			Clonazepam	C				
			Quetiapine Fumarate	C				

Date:11/28/01ISR Number: 3843816-2Report Type:Periodic Company Report #A0137857A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Convulsion Headache Overdose	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	20	TABLET/ORAL

Date:11/28/01ISR Number: 3843820-4Report Type:Periodic Company Report #A0137635A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Libido Decreased	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER	DAY/ORAL
			Orlistat	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3843822-8Report Type:Periodic Company Report #A0139117A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Arthralgia Blood Pressure Abnormal Dizziness Pruritus Urticaria Vomiting	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ ORAL

Date:11/28/01ISR Number: 3843825-3Report Type:Periodic Company Report #A0138783A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Accommodation Disorder Amnesia Asthenia Constipation Depression Disturbance In Attention Pain In Extremity Tremor	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Topiramate Venlafaxine Hydrochloride Claritin-D Zaleplon	PS C C C		ORAL	150 MG/TWICE PER DAY/ORAL

Date:11/28/01ISR Number: 3843827-7Report Type:Periodic Company Report #A0138545A
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Electroencephalogram Abnormal Epilepsy Fall	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG/PER

		Hemiplegia					
DAY/ORAL	4 YR						
		Hypoaesthesia		Methylphenidate	C		
		Movement Disorder					
		Simple Partial Seizures					
		Tremor					

Date:11/28/01ISR Number: 3843828-9Report Type:Periodic Company Report #A0138336A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety	Health	Wellbutrin Sr			
Initial or Prolonged	Blood Creatine	Professional	Tablet-Controlled			
	Phosphokinase Increased	Company	Release (Bupropion			
	Dyspnoea	Representative	Hydrochloride)	PS		ORAL
150 MG/TWICE						
PER DAY/ORAL						
			Benazepril	C		
			Rofecoxib	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3843831-9Report Type:Periodic Company Report #A0138131A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Arrest Convulsion Overdose	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	1000 MG/SINGLE DOSE/ORAL	

Date:11/28/01ISR Number: 3843833-2Report Type:Periodic Company Report #A0138069A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability Required Intervention to Prevent Permanent Impairment/Damage	Bradykinesia Convulsion Crying Depression Drug Toxicity Electroencephalogram Abnormal Emotional Disorder Loss Of Consciousness Memory Impairment Mental Impairment	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Phenytoin (Formulation Unknown) (Phenytoin) Nitroglycerin Thyroxine Sodium Famotidine Conjugated Estrogens Fluvastatin Sodium Metoprolol Tartrate Spironolactone Verapamil Perdnisone	PS SS C C C C C C C C		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:11/28/01ISR Number: 3844209-4Report Type:Periodic Company Report #A0152863A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular Urticaria	Health Professional	Wellbutrin Sr Tablet-Controlled Released (Bupropoin Hydrochloride)	PS		ORAL		

Date:11/28/01ISR Number: 3844210-0Report Type:Periodic Company Report #A0152864A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular Urticaria	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3844211-2Report Type:Periodic Company Report #A0152865A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular Urticaria	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		

Date:11/28/01ISR Number: 3844212-4Report Type:Periodic Company Report #A0152866A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular Urticaria	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		

Date:11/28/01ISR Number: 3844213-6Report Type:Periodic Company Report #A0152867A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		

	Urticaria						

Date:11/28/01ISR Number: 3844214-8Report Type:Periodic Company Report #A0152868A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular Urticaria	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		

Date:11/28/01ISR Number: 3844215-XReport Type:Periodic Company Report #A0152869A
Age: Gender:Male I/FU:I

Outcome
Hospitalization - Initial or Prolonged

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular Urticaria	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:11/28/01ISR Number: 3844216-1Report Type:Periodic Company Report #A0152870A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular Urticaria	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:11/28/01ISR Number: 3844217-3Report Type:Periodic Company Report #A0152871A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular Urticaria	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:11/28/01ISR Number: 3844218-5Report Type:Periodic Company Report #A0154808A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Coordination Abnormal Dyskinesia Fatigue Feeling Hot Headache Nervousness Tardive Dyskinesia	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Vitamin E Conjugated Estrogens Thyroid Ascorbic Acid	PS C C C C		ORAL	150 MG PER DAY ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3844219-7Report Type:Periodic Company Report #A0155864A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Infectious Mononucleosis Neutropenia Pyrexia	Health Professional Company Representative	Wellbutrin	PS		ORAL		

Date:11/28/01ISR Number: 3844220-3Report Type:Periodic Company Report #A0155718A
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Convulsion	Health Professional Company Representative	Wellbutrin Fluoxetine Hydrochloride Metoprolol Succinate Atorvastatin Calcium Isosorbide Dinitrate Ranitidine Hydrochloride Aspirin Theophylline Fluticasone Propionate Combivent Ascorbic Acid Vitamin E	PS C C C C C C C C C C		ORAL	100 MG / PER DAY / ORAL	

Date:11/28/01ISR Number: 3844221-5Report Type:Periodic Company Report #A0155624A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Health	Wellbutrin	PS		ORAL	150 MG /	

Initial or Prolonged	Convulsion	Professional					
TWICE PER DAY							
	Fall	Company					
/ ORAL							
	Grand Mal Convulsion	Representative	Levofloxacin	C			
	Irritability						

Date:11/28/01ISR Number: 3844222-7Report Type:Periodic Company Report #A0156488A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Wellbutrin	PS		ORAL	300 MG / ORAL	
Initial or Prolonged		Professional	Citalopram					
		Company	Hydrobromide	C				
		Representative						

Date:11/28/01ISR Number: 3844223-9Report Type:Periodic Company Report #A0157244A
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Health	Wellbutrin Sr					
Initial or Prolonged	Aphasia	Professional	Tablet-Controlled					
	Pyrexia		Release (Bupropion					
			Hydrochloride)	PS		ORAL	ORAL	
			Venlafaxine					

			Hydrochloride (Formulation Unknown) (Venlafaxine	SS		

Date:11/28/01ISR Number: 3844224-0Report Type:Periodic Company Report #A0157023A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Health	Wellbutrin	PS			150 MG / PER	DAY /
Hospitalization - Initial or Prolonged		Professional Company Representative						

Date:11/28/01ISR Number: 3844225-2Report Type:Periodic Company Report #A0156900A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination, Auditory Hallucination, Visual Infection	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	200 MG / PER	DAY / ORAL
			Lithium Salt	C				
			Haloperidol	C				
			Nortriptyline Hcl	C				

Date:11/28/01ISR Number: 3844226-4Report Type:Periodic Company Report #A0157660A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required	Arthralgia Red Blood Cell Sedimentation Rate	Company Representative	Wellbutrin	PS		ORAL		ORAL
			Atorvastatin Calcium	C				

Intervention to Prevent Permanent Impairment/Damage	Increased Serum Sickness Urticaria					

Date:11/28/01ISR Number: 3844227-6Report Type:Periodic Company Report #A0159578A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin	PS		ORAL	TWICE PER DAY	/ ORAL
		Company Representative	Claritin-D	C				
			Hydroxyzine	C				
			Inhaler	C				
			Oral Contraceptive	C				

Date:11/28/01ISR Number: 3844228-8Report Type:Periodic Company Report #A0159581A
Age:3 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Exposure Hypoglycaemia Vomiting	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG	/ ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3844332-4Report Type:Periodic Company Report #A0159463A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agoraphobia Amnesia Back Pain Compression Fracture Convulsion Night Sweats Photosensitivity Reaction Vomiting	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Lovastatin Actifed Aspirin	PS C C C		ORAL	200 MG / TWICE PER DAY/ ORAL	2 YR

Date:11/28/01ISR Number: 3844333-6Report Type:Periodic Company Report #A0160489A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Deafness Dizziness Ear Disorder Nausea Tinnitus Vomiting	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Pravastatin Sodium Aspirin Fexofenadine Hydrochlorid Metoprolol	PS C C C C		ORAL	150 MG / PER DAY / ORAL	

Date:11/28/01ISR Number: 3844334-8Report Type:Periodic Company Report #A0160503A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Crying Depression	Consumer	Wellbutrin Sr Tablet-Controlled					

	Feeling Abnormal Hypoaesthesia Hypoaesthesia Oral Sedation Suicide Attempt	Release (Bupropion Hydrochloride)	PS	ORAL 150 MG / TWICE PER DAY / ORAL
		Paracetamol (Formulation Unknown) (Acetaminophen)	SS	
		Sertraline Hydrochloride (Formulation Unknown) (Sertraline Hydrochloride)	SS	100 MG / PER DAY
		Methylphenidate Hc1 (Formulation Unknown) (Methylphenidate Hcl)	SS	20 MG
		Disulfiram (Formulation Unknown) (Disulfiram)	SS	250 MG / PER DAY
		Lorazepam		

			(Formulation Unknown) (Lorazepam)	SS		ORAL	5 MG / AS REQUIRED / ORAL

Date:11/28/01ISR Number: 3844335-XReport Type:Periodic Company Report #A0161251A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block Bradycardia	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL
			Venlafaxine Hydrochloride	C			

Date:11/28/01ISR Number: 3844336-1Report Type:Periodic Company Report #A0161748A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL

Date:11/28/01ISR Number: 3844337-3Report Type:Periodic Company Report #A0118454A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Asthenia Blood Pressure Increased Depersonalisation Dissociation Disturbance In Attention Dizziness Drug Withdrawal Syndrome Palpitations Panic Attack Simple Partial Seizures Tachycardia	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Citalopram Hydrobromide (Formulation Unknown) (Citalopram Hydrobromide) Buspirone Hydrochloride	PS SS C		ORAL	150 MG / PER DAY / ORAL	4 WK

Date:11/28/01ISR Number: 3844338-5Report Type:Periodic Company Report #A0124798A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis Pyrexia Serum Sickness Urticaria	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3844339-7Report Type:Periodic Company Report #A0139382A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort Abdominal Pain Confusional State Convulsion Fall Nausea Overdose		Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/SEE DOSAGE TEXT/ORAL	

Date:11/28/01ISR Number: 3844340-3Report Type:Periodic Company Report #A0139566A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other Required Intervention to Prevent Permanent Impairment/Damage	Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:11/28/01ISR Number: 3844342-7Report Type:Periodic Company Report #A0141090A
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Overdose	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	SINGLE DOSE / ORAL	

Date:11/28/01ISR Number: 3844350-6Report Type:Periodic Company Report #A0140813A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State	Health	Wellbutrin Sr					
Other	Dizziness	Professional	Tablet-Controlled					
	Fall	Company	Release (Bupropion					
	Grand Mal Convulsion	Representative	Hydrochloride)	PS		ORAL	150 MG/ TWICE	
	Headache						PER DAY/ ORAL	
	Hyperhidrosis		Biaxin	C				
	Laceration		Terbinafine	C				
	Loss Of Consciousness							
	Pallor							
	Postictal State							
	Vision Blurred							
	Vomiting							
	Weight Increased							

Date:11/28/01ISR Number: 3844352-XReport Type:Periodic Company Report #A0140570A
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Dizziness
	Hypoglycaemia
	Loss Of Consciousness

	Syncope						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG/TWICE PER DAY/ORAL
			Insulin	C			

Date:11/28/01ISR Number: 3844353-1Report Type:Periodic Company Report #A0139845A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Urinary Retention	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ ORAL

Date:11/28/01ISR Number: 3844354-3Report Type:Periodic Company Report #A0141485A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia Burning Sensation Dyspnoea Face Oedema Fear Hypersensitivity Oedema Peripheral Pain Pain In Extremity Pharyngeal Oedema	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG/TWICE PER DAY/ORAL

	Pruritus					
	Rash					
	Swelling					
	Tenderness					
	Unemployment					
	Urticaria					

Date:11/28/01ISR Number: 3844355-5Report Type:Periodic Company Report #A0141554A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Loss Of Consciousness Mouth Haemorrhage Tongue Biting	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
			Centrum Silver	C				
			Iron Salt	C				
			Ibuprofen	C				
			Lansoprazole	C				
			Alprazolam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3844356-7Report Type:Periodic Company Report #A0141899A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Petit Mal Epilepsy Tremor Yawning	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
			Vicodin	C				
			Prednisone	C				
			Co-Trimoxazole	C				
			Fluconazole	C				
			Nystatin	C				
			Medroxyprogesterone Ace.	C				

Date:11/28/01ISR Number: 3844357-9Report Type:Periodic Company Report #A0142036A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Required Intervention to Prevent Permanent Impairment/Damage	Tremor	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY/ORAL	

Date:11/28/01ISR Number: 3844358-0Report Type:Periodic Company Report #A0142590A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Tremor	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG / ORAL	

Wellbutrin Tablet (Bupropion Hydrochloride)	SS	ORAL
		ORAL
Citalopram Hydrobromide	C	
Olanzapine	C	
Paroxetine Hydrochloride	C	
Venlafaxine Hydrochloride	C	
Verapamil Hydrochloride	C	
Metoprolol Tartrate	C	
Warfarin Sodium	C	
Atorvastatin Calcium	C	
Tylenol No. 3	C	
Oxycodone Hydrochloride	C	
Fiorinal	C	
Tylenol W/ Codeine No. 4	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3844359-2Report Type:Periodic Company Report #A0143252A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Arrest Myocardial Infarction	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		

ORAL

Date:11/28/01ISR Number: 3844360-9Report Type:Periodic Company Report #A0143904A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		

ORAL

Date:11/28/01ISR Number: 3844361-0Report Type:Periodic Company Report #A0144030A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY	/

ORAL

Date:11/28/01ISR Number: 3844362-2Report Type:Periodic Company Report #A0143948A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Electroencephalogram Abnormal	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	DAY

Date:11/28/01ISR Number: 3844363-4Report Type:Periodic Company Report #A0145187A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Accommodation Disorder Amnesia Confusional State Headache	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:11/28/01ISR Number: 3844364-6Report Type:Periodic Company Report #A0144973A
Age:35 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Cold Sweat Coordination Abnormal Drug Ineffective Screaming Speech Disorder

Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG / TWICE PER DAY / ORAL	
	Lamictal Tablet (Lamotrigine)	SS		ORAL	12.5 MG / PER DAY / ORAL	
	Fluoxetine Hydrochloride (Formulation Unknown) (Fluoxetine Hydrochloride)	SS			20 MG / PER DAY	
	Gabapentin	C				
	Quetiapine Fumarate	C				

Date:11/28/01ISR Number: 3844365-8Report Type:Periodic Company Report #A0144927A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Feeling Abnormal Lethargy	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG / PER DAY / ORAL	
			Paroxetine Hydrochloride (Formulation Unknown) (Paroxetine					

			Hydrochloride)	SS		

20 MG

Date:11/28/01ISR Number: 3844366-XReport Type:Periodic Company Report #A0144931A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:11/28/01ISR Number: 3844367-1Report Type:Periodic Company Report #A0144731A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Erythema Pruritus Rash Respiratory Distress Urticaria	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3844368-3Report Type:Periodic Company Report #A0145663A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse Lethargy Nausea	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	SEE DOSAGE TEXT	/ ORAL

Date:11/28/01ISR Number: 3844369-5Report Type:Periodic Company Report #A0146394A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Euphoric Mood Fall Fatigue Grand Mal Convulsion Libido Decreased Tooth Loss	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL
			Paroxetine Hydrochloride Tablet (Paroxetine Hydrochloride)	SS		ORAL	20 MG/ PER DAY/	ORAL
			Clonazepam Tablet (Clonazepam)	SS		ORAL	ORAL	

Date:11/28/01ISR Number: 3844370-1Report Type:Periodic Company Report #A0145969A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Effect Decreased Stress	Health Professional	Wellbutrin Sr Tablet-Controlled					

Required Intervention to Prevent Permanent Impairment/Damage	Urticaria		Release (Bupropion Hydrochloride)	PS		ORAL 150 MG/ TWICE PER DAY/ ORAL
			Methylprednisolone (Formulation Unknown) (Methylprednisolone)	SS		ORAL ORAL

Date:11/28/01ISR Number: 3844371-3Report Type:Periodic Company Report #A0145970A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Headache Pruritus Stress Urticaria	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Methylprednisolone (Formulation Unknown) (Methylprednisolone)	SS		ORAL ORAL		
			Me-Prednisolone Na Succ. (Formulation Unknown) (Me-Prednisolone Na Succ.)	SS		INTRAVENOUS	125 MG/ FOUR	

TIMES PER DAY/ INTRAV							
			Prednisone (Formulation Unknown) (Prednisone)	SS			ORAL
ORAL							
			Ortho Tri-Cyclen	C			

Date:11/28/01ISR Number: 3844372-5Report Type:Periodic Company Report #A0147190A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Gastrointestinal Infection Haematochezia Stomach Discomfort	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	400 MG/ THREE TIMES PER DAY/ ORAL	

Date:11/28/01ISR Number: 3844373-7Report Type:Periodic Company Report #A0147579A
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia Inappropriate Antidiuretic Hormone Secretion Urinary Tract Infection	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:11/28/01ISR Number: 3844374-9Report Type:Periodic Company Report #A0150071A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation Drug Eruption Dry Skin Hypersensitivity Pain Pruritus Rash Maculo-Papular Skin Ulcer Urticaria	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		

Date:11/28/01ISR Number: 3844375-0Report Type:Periodic Company Report #A0150103A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL 4 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3844376-2Report Type:Periodic Company Report #A0152014A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		

Date:11/28/01ISR Number: 3844377-4Report Type:Periodic Company Report #A0153398A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Psychotic Disorder	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	2 YR
			Paroxetine Hydrochloride	C				

Date:11/29/01ISR Number: 3831200-7Report Type:Expedited (15-DaCompany Report #A0159004A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia Dehydration Syncope		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Aspirin	C		ORAL	81MG Per day	
			Glucophage	C				
			Nitroglycerin	C	Glaxo Wellcome			
			Altace	C				
			Zocor	C				
			Niaspan	C				

Date:11/29/01ISR Number: 3831203-2Report Type:Expedited (15-DaCompany Report #A0168050A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Effect Decreased		Wellbutrin	PS	Glaxo Wellcome	ORAL	400MG per day	3 YR
	Insomnia		Pepcid Ac	C				
	Medication Residue		Albuterol	C	Glaxo Wellcome			
			Combivent	C				
			Flovent	C	Glaxo Wellcome			

Date:11/29/01ISR Number: 3831210-XReport Type:Expedited (15-DaCompany Report #B0127463A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	42 DAY
	Drug Effect Decreased		Climaston	C				
	Malaise							
	Stress							
	Syncope Vasovagal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/01ISR Number: 3831211-1Report Type:Expedited (15-DaCompany Report #B0127467A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	300MG Twice per day	26 DAY
	Depression							
	Mood Swings		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		
			Beclomethasone	C	Glaxo Wellcome	UNKNOWN		

Date:11/29/01ISR Number: 3832493-2Report Type:Expedited (15-DaCompany Report #HQ8542216NOV2001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Consumer	Effexor (Venlafaxine Hydrochloride, Tablet)	PS				
	Injury		Ativan (Lorazepam)	SS				
			Buspar (Buspirone Hydrochloride)	SS				
			Inderal (Propranolol Hydrochloride)	SS				
			Paxil (Paroxetine Hydrochloride)	SS				
			Prozac (Fluoxetine Hydrochloride)	SS				
			Wellbutrin (Amfebutamone Hydrochloride)	SS				

Date:11/30/01ISR Number: 3831960-5Report Type:Expedited (15-DaCompany Report #B0102458A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchitis Chronic		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	41 DAY

Date:11/30/01ISR Number: 3831961-7Report Type:Expedited (15-DaCompany Report #B0117985A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bronchospasm		Zyban	PS	Glaxo Wellcome		8	WK
	Dizziness							
	Dyspnoea							
	Pain							

Date:11/30/01ISR Number: 3831962-9Report Type:Expedited (15-DaCompany Report #B0120692A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchitis Chronic		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	41 DAY
	Circulatory Collapse							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/01ISR Number: 3831963-0Report Type:Expedited (15-DaCompany Report #B0120884A
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm		Zyban	PS	Glaxo Wellcome		150MG As directed	9 DAY
	Blister							
	Dizziness							
	Insomnia							
	Tremor							

Date:11/30/01ISR Number: 3831970-8Report Type:Expedited (15-DaCompany Report #B0127466A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	20 DAY
	Joint Swelling							
	Lung Disorder							
	Oedema Peripheral							
	Urticaria							

Date:11/30/01ISR Number: 3833720-8Report Type:Direct Company Report #
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Wellbutrin Sr 1150 Mg	PS			ONCE QD	
	Rash							
	Urticaria		Vitamins	C				

Date:11/30/01ISR Number: 3833847-0Report Type:Direct Company Report #
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hypoaesthesia		Wellbutrin Sr 150mg					

Intervention to 1 BID	Rash	Initially	PS	
Prevent Permanent Impairment/Damage 2 BID	Urticaria	Wellbutrin Sr 100mg (Dose Increased)	SS	
		Celexa	C	

Date:12/03/01ISR Number: 3832651-7Report Type:Expedited (15-DaCompany Report #A0093320A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	307 DAY
	Asthenia							
	Carpal Tunnel Syndrome		Azithromycin	C				
	Crying		Zantac	C	Glaxo Wellcome			
	Drug Ineffective		Nasonex	C				
	Emotional Distress							
	Eye Disorder							
	Facial Palsy							
	Hypoaesthesia							
	Insomnia							
	Irritability							
	Nervousness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/01ISR Number: 3832653-0Report Type:Expedited (15-DaCompany Report #A0154004A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy		Zyban	PS	Glaxo Wellcome	ORAL	150MG See	
	Blister						dosage text	3 DAY
	Burning Sensation		No Concurrent					
	Dermatitis Bullous		Medication	C				
	Erythema							
	Hypersensitivity							
	Insomnia							
	Pain In Extremity							
	Penile Pain							
	Penis Disorder							
	Pruritus							
	Scab							
	Scar							
	Skin Discolouration							
	Swelling							
	Ulcer							

Date:12/03/01ISR Number: 3832654-2Report Type:Expedited (15-DaCompany Report #A0161553A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	2 DAY
	Hemiparesis							
	Migraine							

Date:12/03/01ISR Number: 3832658-XReport Type:Expedited (15-DaCompany Report #B0100684A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome			
			Lovan	C				
			Alcohol	C				

Date:12/03/01ISR Number: 3832669-4Report Type:Expedited (15-DaCompany Report #D0023165A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psychotic Disorder		Zyban	PS	Glaxo Wellcome	ORAL		

Date:12/03/01ISR Number: 3833744-0Report Type:Direct Company Report #
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion Loss Of Consciousness		Wellbutrin Sr 150 Mg Glaxo Smith Kline	PS	Glaxo Smith Kline	ORAL	150 MG TWICE	DAILY ORAL
			Bupropion 150mg Lemmon	SS	Lemmon	ORAL	150MG TWICE	DAILY ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3833080-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin Sr 150 Mg	PS			150 MG BID	
	Dyspnoea		Ziprasidone (Geodon)	SS			150 MG BID	
			Bupropion	SS			SEE IMAGE	
			Albuterol Inhaler	C				
			Guanfacine	C				

Date:12/04/01ISR Number: 3834052-4Report Type:Direct Company Report #
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Wellbutrin Sr (100mg)	PS			100MG ONE IN ADAY	
	Dermatitis							
	Difficulty In Walking							
	Oedema							

Date:12/05/01ISR Number: 3834165-7Report Type:Expedited (15-DaCompany Report #A0167282A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY
Hospitalization - Initial or Prolonged	Conjunctival Hyperaemia		No Concurrent Medications	C				
Disability	Dry Mouth							
	Dyspnoea							
	Neck Pain							
	Palpitations							
	Pharyngolaryngeal Pain							
	Pulmonary Embolism							
	Rash Erythematous							

Date:12/05/01ISR Number: 3834178-5Report Type:Expedited (15-DaCompany Report #B0127547A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased		Zyban	PS	Glaxo Wellcome		150MG Twice per day	
	Pain							
	Phlebitis							
	Thrombophlebitis							
	Superficial							
	Varicose Vein							

Date:12/05/01ISR Number: 3834183-9Report Type:Expedited (15-DaCompany Report #B0127963A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Zyban	PS	Glaxo Wellcome			
	Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/05/01ISR Number: 3834184-0Report Type:Expedited (15-DaCompany Report #B0127964A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Agitation Confusional State Fatigue Hyperhidrosis Lymphadenopathy Pyrexia		Zyban	PS	Glaxo Wellcome	ORAL		

Date:12/05/01ISR Number: 3834185-2Report Type:Expedited (15-DaCompany Report #B0127965A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome		150MG Per day	6 DAY
	Cardiomyopathy		Enalapril	C			20MG per day	
			Omeprazole	C			40MG per day	
			Acenocoumarol	C				
			Simvastatin	C			20MG per day	
			Carvedilol	C	Glaxo Wellcome		25MG per day	

Date:12/05/01ISR Number: 3834186-4Report Type:Expedited (15-DaCompany Report #B0128139A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Renal Impairment						per day	71 DAY
			Atenolol	C		ORAL	50MG per day	
			Felodipine	C		ORAL	10MG per day	

			Bendrofluazide	C	Glaxo Wellcome	ORAL	2.5MG per day
			Tibolone	C		ORAL	2.5MG per day

Date:12/05/01ISR Number: 3834188-8Report Type:Expedited (15-DaCompany Report #B0128148A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	4	DAY
			Salmeterol	C	Glaxo Wellcome			

RESPIRATORY

(INHALATION) 1PUFF Twice

per day

Date:12/05/01ISR Number: 3834189-XReport Type:Expedited (15-DaCompany Report #B0128149A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Localised Infection							
per day	Oedema						78	DAY
	Proteinuria							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/05/01ISR Number: 3834190-6Report Type:Expedited (15-DaCompany Report #B0128151A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG Per day	
Hospitalization - Initial or Prolonged	Renal Failure		Sertraline	C				
Disability	Respiratory Failure		Alprazolam	C				
Other								

Date:12/05/01ISR Number: 3834191-8Report Type:Expedited (15-DaCompany Report #B0128157A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Zyban	PS	Glaxo Wellcome		150MG Twice per day	18 DAY
	Enzyme Abnormality							
	Obsessive-Compulsive Disorder		Clomipramide	C				
			Alprazolam	C				
	Suicidal Ideation							

Date:12/05/01ISR Number: 3834193-1Report Type:Expedited (15-DaCompany Report #B0128228A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Csf Protein Increased		Zyban	PS	Glaxo Wellcome	ORAL	10 DAY	
	Loss Of Consciousness							
	Muscle Twitching							
	Toxicologic Test Abnormal							

Date:12/05/01ISR Number: 3834195-5Report Type:Expedited (15-DaCompany Report #D0023445A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 150MG In the Initial or Prolonged morning 2 WK	Blood Creatine Phosphokinase Increased		Zyban	PS	Glaxo Wellcome	ORAL
	Psychotic Disorder		Pantozol 40MG Per day	C		ORAL
			Leponex 50MG Twice per day	C		ORAL
			Tenormin 25MG Twice per day	C		ORAL
			Rivotril 500MCG As required	C		ORAL

Date:12/05/01ISR Number: 3836267-8Report Type:Direct Company Report #
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin (100mg)	PS		ORAL	100MG 1 BID	ORAL
			Ortho-Cyclen	C				

Date:12/06/01ISR Number: 3834767-8Report Type:Expedited (15-DaCompany Report #A0168510A
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Other	Depression
	Dysphonia

		Mood Swings Psychiatric Symptom Psychomotor Hyperactivity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Suicidal Ideation		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL
150MG Twice							
		Thinking Abnormal					
per day	56 DAY						
		Tremor		Neurontin	C		
				Anti-Hypertensive	C		
				Unspecified			
				Medications	C		

Date:12/06/01ISR Number: 3834776-9Report Type:Expedited (15-DaCompany Report #B0098813A
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Antimitochondrial		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice							
		Antibody Positive					
per day	16 DAY						
		Cutaneous Vasculitis		Lisinopril	C		
20MG per day							
		Dermatitis Exfoliative		Dytenzide	C	Glaxo Wellcome	
1TAB per day							
		Leukocytosis					
		Rash Erythematous					
		Rash Maculo-Papular					
		Rash Pruritic					

Date:12/06/01ISR Number: 3834787-3Report Type:Expedited (15-DaCompany Report #B0128344A
Age:69 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Haemorrhagic Stroke		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice							
Hospitalization -							
per day							
Initial or Prolonged				Bendrofluazide	C	Glaxo Wellcome	ORAL
2.5MG Per day							

Disability			Nifedipine	C	Glaxo Wellcome	ORAL	20MG Twice per day
			Atenolol	C		ORAL	10MG Per day
			Nicorandil	C		ORAL	20MG Twice per day
			Becotide	C	Glaxo Wellcome		RESPIRATORY (INHALATION)
			Ventolin	C	Glaxo Wellcome		RESPIRATORY (INHALATION)

Date:12/07/01ISR Number: 3835595-XReport Type:Expedited (15-DaCompany Report #A0169154A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis Retinal Detachment		Zyban	PS	Glaxo Wellcome	ORAL		

Date:12/07/01ISR Number: 3835608-5Report Type:Expedited (15-DaCompany Report #B0128267A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Mydriasis Suicide Attempt Tachycardia Tremor		Zyban	PS	Glaxo Wellcome	ORAL	6000MG Per day	1 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/01ISR Number: 3836551-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Zyban (150 Mg)					
	Crying		Catalytica					
	Dysphemia		Pharmaceuticals 1 1x					
	Fear		Oral	PS	Catalytica			
	Feeling Abnormal				Pharmaceuticals	ORAL	150 MG 1X	
	Hallucination						ORAL	
	Headache							
	Hyperacusis							
	Nausea							
	Paranoia							
	Suicidal Ideation							
	Tinnitus							
	Vision Blurred							

Date:12/07/01ISR Number: 3837149-8Report Type:Expedited (15-DaCompany Report #2001082086US
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased	Health	Linezolid(Linezolid)					
	Delirium	Professional	Solution, Sterile	PS				
INTRAVENOUS							600 MG, BID,	
	Delusion						IV	
	Drug Interaction		Flagyl					
	Dry Mouth		(Metronidazole)					
	Haematocrit Decreased		Tablet	SS		ORAL	500 MG, QID,	
	Haemoglobin Decreased						ORAL	
	Hallucination, Visual		Sertraline(Sertralin					
	Mydriasis		e)	SS			200 MG, QD,	
	Respiratory Rate		Risperidone(Risperid					
	Increased		one)	SS			1 MG, BID,	
	Serotonin Syndrome		Bupropion					

	Vomiting		(Amfebutamone)	SS			
75 MG, BID							
	White Blood Cell Count Increased		Trazodone	C			
			Litiumkarbonat (Lithium Carbonate)	C			
			Baclofen	C			
			Promethazine(Promethazine)	C			
			Docusate Sodium(Docusate Sodium)	C			
			Bisacodyl(Bisacodyl)	C			
			Megestrol(Megestrol)	C			
			Lansoprazole	C			

Date:12/10/01ISR Number: 3838049-XReport Type:Direct Company Report #
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Zyban 150mg Sr	PS		ORAL	150MG 1 TAB	

PO QD X3 D

THEN BID

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/01ISR Number: 3836830-4Report Type:Expedited (15-DaCompany Report #A0163666A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Three times per day	
	Grand Mal Convulsion							
Other			Lamictal	C	Glaxo Wellcome	ORAL	225MG Twice per day	
			Zyprexa	C		ORAL	35MG per day	
			Luvox	C		ORAL		
			Remeron	C				
			Lithium	C			300MG Twice per day	
			Risperdal	C		ORAL	8MG Per day	
			Antabuse	C		ORAL		

Date:12/11/01ISR Number: 3836835-3Report Type:Expedited (15-DaCompany Report #B0123297A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Zyban	PS	Glaxo Wellcome		150MG As directed	
	Circulatory Collapse							

Date:12/11/01ISR Number: 3836842-0Report Type:Expedited (15-DaCompany Report #B0128343A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Zyban	PS	Glaxo Wellcome	ORAL	7	DAY

			Salbutamol	C	Glaxo Wellcome		
RESPIRATORY							
(INHALATION)							
			Salmeterol	C	Glaxo Wellcome		
RESPIRATORY							
(INHALATION)							
			Beclomethasone	C	Glaxo Wellcome		
RESPIRATORY							
(INHALATION)							
			Co-Proxamol	C			ORAL
			Arthrotec	C			

Date:12/11/01ISR Number: 3836843-2Report Type:Expedited (15-DaCompany Report #B0128345A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	4	DAY
	Dysarthria		Mometasone	C		NASAL	1UNIT Twice	
per day								

Date:12/11/01ISR Number: 3836844-4Report Type:Expedited (15-DaCompany Report #B0128468A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	13 DAY
Initial or Prolonged	Attention Deficit/Hyperactivity Disorder							
	Meningitis							

Date:12/11/01ISR Number: 3836845-6Report Type:Expedited (15-DaCompany Report #B0128545A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Haemolytic Anaemia							
	Jaundice							
	Psoriasis							
	Pyrexia							
	Renal Impairment							
	Sepsis							
	Thrombotic							
	Thrombocytopenic Purpura							

Date:12/11/01ISR Number: 3836846-8Report Type:Expedited (15-DaCompany Report #B0128645A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetes Mellitus		Zyban	PS	Glaxo Wellcome		150MG Per day	
			Albyl-E	SS		ORAL	160MG Per day	
			Selozok	SS		ORAL	100MG Per day	

Date:12/11/01ISR Number: 3836847-XReport Type:Expedited (15-DaCompany Report #B0128651A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Valve Stenosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY
	Brain Oedema		Adepal	C		ORAL		
	Cardiac Failure		Lisinopril	C		ORAL	8	DAY
	Haemorrhagic Stroke							
	Headache							
	Hypertensive Crisis							
	Intracranial Aneurysm							
	Mydriasis							
	Neck Pain							

Otitis Externa
Palpitations
Ventricular Extrasystoles

Date:12/12/01ISR Number: 3837381-3Report Type:Expedited (15-DaCompany Report #A0169561A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:12/12/01ISR Number: 3837382-5Report Type:Expedited (15-DaCompany Report #A0169565A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Induced		Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Trisomy 21							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/01ISR Number: 3837383-7Report Type:Expedited (15-DaCompany Report #B0114598A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Aggression							
per day							62	DAY
Initial or Prolonged	Amnesia							
Other	Anaphylactic Shock							
	Anxiety							
	Balance Disorder							
	Blister							
	Blood Bilirubin Increased							
	Blood Pressure Increased							
	Bone Density Decreased							
	Chest Pain							
	Confusional State							
	Convulsion							
	Dermatitis							
	Diarrhoea							
	Disorientation							
	Disturbance In Attention							
	Dizziness							
	Dry Skin							
	Dysphagia							
	Dyspnoea							
	Eyelid Oedema							
	Face Oedema							
	Feeling Abnormal							
	Feeling Drunk							
	Feeling Hot							
	Flatulence							
	Gastroenteritis							
	Hyperhidrosis							
	Irritability							
	Irritable Bowel Syndrome							
	Loss Of Consciousness							
	Malaise							
	Memory Impairment							
	Nausea							
	Ocular Hyperaemia							
	Oedema Peripheral							
	Pain							
	Pharyngeal Oedema							
	Pruritus							

	Rhinitis					
	Speech Disorder					
	Tinnitus					
	Tongue Oedema					
	Urticaria					

Date:12/12/01ISR Number: 3837395-3Report Type:Expedited (15-DaCompany Report #B0128808A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation		Bupropion					
	Dermatitis Exfoliative		Hydrochloride	PS	Glaxo Wellcome			
UNKNOWN							1	WK
	Erythema							
	Psoriasis							
	Rash Generalised							
	Throat Irritation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/01ISR Number: 3839141-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Intolerance		Buproprion	PS		ORAL	100MG 1 BID	
	Tongue Oedema						PO	

Date:12/12/01ISR Number: 3839772-3Report Type:Expedited (15-DaCompany Report #PHBS2001US12331
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest Neonatal	Literature	Ritaline					
	Coma	Health	(Methylphenidate					
	Cyanosis Neonatal	Professional	Hydrocloride)	PS		TRANSPLACENTAL	TRANSPLACENTA	
	Hyporeflexia						L	
	Hypotonia Neonatal		Wellbutrin					
	Maternal Drugs Affecting		(Amfebutamone					
	Foetus		Hydrochloride)	SS		TRANSPLACENTAL	TRANSPLACENTA	
	Neonatal Apnoeic Attack						L	
	Oliguria		Benadryl					
	Tremor Neonatal		(Diphenhydramine					
			Hydrochloride)	SS		TRANSPLACENTAL	TRANSPLACENTA	
							L	

Date:12/13/01ISR Number: 3838221-9Report Type:Expedited (15-DaCompany Report #B0105221A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization -	Amnesia							
Initial or Prolonged	Anaphylactic Shock							
Other	Anxiety							

	Diarrhoea						
	Disturbance In Attention						
	Irritability						
	Pruritus						
	Rash Erythematous						

Date:12/13/01ISR Number: 3838227-XReport Type:Expedited (15-DaCompany Report #B0128151A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG Per day	
Hospitalization - Initial or Prolonged	Malaise		Sertraline	C				
	Renal Failure		Alprazolam	C				
Disability	Respiratory Failure							
Other								

Date:12/13/01ISR Number: 3838233-5Report Type:Expedited (15-DaCompany Report #B0128893A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	52 DAY
	Cerebrovascular Accident							
Disability	Diabetes Mellitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/01ISR Number: 3839172-6Report Type:Expedited (15-DaCompany Report #A0169154A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis		Zyban	PS	Glaxo Wellcome	ORAL		
	Retinal Detachment							
	Tension Headache							

Date:12/14/01ISR Number: 3839177-5Report Type:Expedited (15-DaCompany Report #B0096692A
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pyrexia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged	Vasculitis		Magnyl	C				

Date:12/14/01ISR Number: 3839181-7Report Type:Expedited (15-DaCompany Report #B0126564A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Asthma		Zyban	PS	Glaxo Wellcome		UNKNOWN	300MG per day
	Caesarean Section							
	Complications Of Maternal							
	Exposure To Therapeutic							
	Drugs							
	Congenital Anomaly							
	Dermatitis Atopic							
	Neonatal Disorder							
	Pregnancy							
	Ventricular Septal Defect							
	Acquired							

Date:12/14/01ISR Number: 3839182-9Report Type:Expedited (15-DaCompany Report #B0128084A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Dizziness		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL
	Nausea					
150MG Per day	6 DAY					
	Vision Blurred					

Date:12/17/01ISR Number: 3839283-5Report Type:Expedited (15-DaCompany Report #A0165224A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Congenital Anomaly	Acquired		Wellbutrin	PS	Glaxo Wellcome	ORAL
200MG Twice						
	Tracheo-Oesophageal					
per day 316 DAY						
	Fistula		Buspar	C		ORAL
15MG Three						
	Drug Exposure During					
times per day 424 DAY						
	Pregnancy					
	Neonatal Disorder					
	Oesophageal Atresia					

Date:12/17/01ISR Number: 3839290-2Report Type:Expedited (15-DaCompany Report #B0126849A
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Difficulty In Walking
	Faecal Incontinence

	Multiple Sclerosis Urinary Incontinence						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day
			Interferon Beta	SS		SUBCUTANEOUS	
			Lioresal	SS		ORAL	3UNIT per day
			Paracetamol	C	Glaxo Wellcome	ORAL	1000MG Twice per day

Date:12/17/01ISR Number: 3839295-1Report Type:Expedited (15-DaCompany Report #B0128930A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Aphasia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day
	Carotid Artery Thrombosis						
	Cerebrovascular Accident		Ketoprofen	C			
	Erythema		Alcohol	C			
	Hemiplegia						
	Hypercholesterolaemia						
	Thrombosis						

Date:12/18/01ISR Number: 3840066-0Report Type:Expedited (15-DaCompany Report #A0162932A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Bradycardia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day
	Cardiac Disorder						
	Hypotension		Tylenol #1	C	Glaxo Wellcome	ORAL	
	Loss Of Consciousness						
	Syncope						
	Syncope Vasovagal						

Date:12/18/01ISR Number: 3840075-1Report Type:Expedited (15-DaCompany Report #A0169635A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG Twice per day	
	Coma							
	Fall							
	Feeling Jittery							
	Medication Error							
	Urinary Incontinence							

Date:12/18/01ISR Number: 3840081-7Report Type:Expedited (15-DaCompany Report #B0126850A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Hospitalization - Initial or Prolonged			Bisoprolol	C				
			Potassium	C				
			Pravastatin	C				
			Glipizide	C				
			Lysine	C				
			Frusemide	C	Glaxo Wellcome			
			Omeprazole	C				
			Nitroglycerin	C	Glaxo Wellcome			
			Repaglinide	C				

			Clopidogrel	C			
			Ramipril	C			

Date:12/18/01ISR Number: 3840088-XReport Type:Expedited (15-DaCompany Report #B0128862A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Chest Pain							
	Cholelithiasis							
	Hepatitis							
	Oesophagitis							

Date:12/18/01ISR Number: 3841902-4Report Type:Expedited (15-DaCompany Report #2015123
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly	Health	Morphine Sulfate					
	Coma	Professional	(Similar To Andas					
	Pulmonary Congestion	Other	74-769 And 74-862)	PS				
	Pulmonary Oedema		Oxycodone					
	Therapeutic Agent		Hydrochloride					
	Toxicity		(Similar To Nda					
	Toxicologic Test Abnormal		20-553)	SS				
			Codeine	SS		ORAL	PO	
			Olanzapine	SS		ORAL	PO	
			Acetaminophen	SS		ORAL	PO	
			Paroxetine	SS		ORAL	PO	
			Bupropion	SS		ORAL	PO	
			Nicotine	SS		ORAL	PO	

Date:12/19/01ISR Number: 3840969-7Report Type:Expedited (15-DaCompany Report #A0135919A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Burning Sensation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Dysgeusia						per day	11 DAY
	Dyskinesia		Amitriptyline	C			UNKNOWN	200MG Per day
	Hypoaesthesia		Unknown Medication	C				
	Insomnia							
	Muscle Injury							
	Neuralgia							
	Neuropathy Peripheral							
	Oral Pain							
	Panic Attack							
	Rash							

Date:12/19/01ISR Number: 3840973-9Report Type:Expedited (15-DaCompany Report #A0169154A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Corneal Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	62 DAY
	Epistaxis							
	Retinal Detachment							
	Tension Headache							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/01ISR Number: 3840976-4Report Type:Expedited (15-DaCompany Report #A0170133A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Petit Mal Epilepsy		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Status Epilepticus						per day	
			Anti-Epileptic Drug	C				

Date:12/19/01ISR Number: 3840977-6Report Type:Expedited (15-DaCompany Report #A0170310A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged	Congestive							
	Coronary Artery Disease							
	Dystonia							

Date:12/19/01ISR Number: 3840978-8Report Type:Expedited (15-DaCompany Report #A0170371A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged	Speech Disorder							
	Weight Decreased							

Date:12/19/01ISR Number: 3840990-9Report Type:Expedited (15-DaCompany Report #B0125004A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression		Zyban	PS	Glaxo Wellcome			
Initial or Prolonged	Depression		Mefanamic Acid	C		ORAL	100UNIT	

	Emotional Distress					
Unknown						
	Fatigue		Gamolenic Acid	C		ORAL
40UNIT Twice						
	Loss Of Consciousness					
per day						
	Memory Impairment					
	Weight Decreased					

Date:12/19/01ISR Number: 3840994-6Report Type:Expedited (15-DaCompany Report #B0129161A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure		Zyban	PS	Glaxo Wellcome	ORAL
Initial or Prolonged	Pneumonia					
	Pulmonary Oedema					
	Ventricular Hypokinesia					

Date:12/20/01ISR Number: 3841759-1Report Type:Expedited (15-DaCompany Report #A0107071A
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Coma
	Confusional State
	Convulsion
	Delusion
	Dementia Alzheimer'S Type
	Depressed Level Of

	Consciousness						
	Disorientation						
	Drug Interaction						
	Hypersensitivity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Joint Stiffness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 2 DAY
	Middle Insomnia		Celexa	SS			
	Miosis		Hormones	C			
	Pupillary Reflex Impaired		Vitamins	C			
	Urinary Tract Infection						
	Visual Disturbance						

Date:12/20/01ISR Number: 3841762-1Report Type:Expedited (15-DaCompany Report #A0162004A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
Hospitalization -	Aortic Valve Sclerosis						per day 9 DAY
Initial or Prolonged	Asthenia		Wellbutrin	SS	Glaxo Wellcome	ORAL	150MG Twice
	Atrioventricular Block						per day
	Cardiac Failure		Hyoscyamine	SS			.188MG Twice
	Cardiac Failure						per day
	Congestive		Relafen	C	Glaxo Wellcome		
	Cardiomegaly		Nitroglycerine	C	Glaxo Wellcome	TOPICAL	1IN Twice per
	Cerebral Infarction						day
	Cerebrovascular Accident		Synthroid	C	Glaxo Wellcome		
	Confusional State		Lasix	C	Glaxo Wellcome		
	Dysarthria		Risperdal	C			4MG Per day
	Dyspnoea		Depakote	C			250MG Twice
	Ejection Fraction						per day
	Decreased		Sinemet Cr	C			
	Electrocardiogram Qrs		Benztropine	C			2MG Twice per

	Complex Prolonged						
day							
	Electrocardiogram T Wave		Zestril	C			
	Abnormal		Azmacort	C			
2PUFF Twice							
	Facial Palsy						
per day							
	Headache		Atrovent	C	Glaxo Wellcome		
2PUFF Twice							
	Hemiparesis						
per day							
	Hypoaesthesia		Peri-Colace	C			
100MG Per day							
	Mitral Valve Incompetence		Cipro	C			ORAL
500MG Twice							
	Tongue Dry						
per day							
	Ventricular Extrasystoles						
	Ventricular Hypertrophy						
	Ventricular Hypokinesia						
	Vision Blurred						
	Vomiting						

Date:12/20/01ISR Number: 3841765-7Report Type:Expedited (15-DaCompany Report #A0169595A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apathy		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Hallucination, Auditory		Synthroid	C	Glaxo Wellcome	ORAL	.075MCG Per	
	Memory Impairment						day	
	Paranoia		Ritalin	C		ORAL	25MG Twice	
	Rash						per day	
	Scar		Vitamin	C		ORAL		
	Suicidal Ideation		Depakote	C		ORAL	15 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/01ISR Number: 3841780-3Report Type:Expedited (15-DaCompany Report #B0127463A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Malaise Syncope Vasovagal		Zyban Climaston	PS C	Glaxo Wellcome	ORAL	300MG Per day	11 DAY

Date:12/20/01ISR Number: 3841784-0Report Type:Expedited (15-DaCompany Report #B0129486A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Dysarthria Feeling Drunk Vomiting		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	3 DAY

Date:12/20/01ISR Number: 3841785-2Report Type:Expedited (15-DaCompany Report #B0129668A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypothyroidism Urticaria		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	

Date:12/20/01ISR Number: 3846396-0Report Type:Periodic Company Report #HQ9690310AUG2000
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Headache Pregnancy Vision Blurred	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended					

			Release)	PS		ORAL
1) 75 MG 1X PER 1 DAY, ORAL; 2) ORAL						
			Tegretol (Carbamazepine,)	SS		ORAL
ORAL						
			Wellbutrin (Amfebutamone Hydrochloride,)	SS		ORAL
ORAL						
			Zyrtec (Cetirizine Hydrochloride,)	SS		ORAL
ORAL						

Date:12/20/01ISR Number: 3848232-5Report Type:Periodic Company Report #HQ4476109AUG2001
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia Pyrexia	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule,	PS		ORAL	150 MG 1X PER 1 DAY, ORAL	
			Wellbutrin (Amfebutamone Hydrochloride,)	SS		ORAL	150 MG 2X PER 1 DAY, ORAL	

Date:12/21/01ISR Number: 3842767-7Report Type:Expedited (15-DaCompany Report #A0170813A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Intentional Misuse		Unspecified					
	Suicide Attempt		Medications	SS				
UNKNOWN								

Date:12/21/01ISR Number: 3842788-4Report Type:Expedited (15-DaCompany Report #B0126402A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Zyban	PS	Glaxo Wellcome	ORAL	23	DAY
Hospitalization -	Second Degree							
Initial or Prolonged	Bradycardia							
Disability	Coronary Artery Surgery							
Other	Electrocardiogram							
	Repolarisation							
	Abnormality							
	Feeling Cold							
	Flushing							
	Headache							
	Myocardial Infarction							
	Pallor							

Date:12/21/01ISR Number: 3842804-XReport Type:Expedited (15-DaCompany Report #B0128266A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Blood Pressure Decreased							
per day	13	DAY						
	Electrocardiogram St		Fexofenadine	SS				
UNKNOWN	180MG per day	7 DAY						
	Segment Depression							
	Syncope							
	Urticaria							

Date:12/21/01ISR Number: 3842813-0Report Type:Expedited (15-DaCompany Report #B0129422A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastric Haemorrhage Haematocrit Decreased Malaise		Zyntabac Pantoprazole	PS C	Glaxo Wellcome			

Date:12/21/01ISR Number: 3842818-XReport Type:Expedited (15-DaCompany Report #B0129835A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose Somnolence Suicide Attempt		Zyban Zolpidem Antidepressant	PS SS SS	Glaxo Wellcome	ORAL ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/01ISR Number: 3842827-0Report Type:Expedited (15-DaCompany Report #B0130322A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall		Zyban	PS	Glaxo Wellcome	ORAL		
	Food Craving		Aspirin	C				
	Hypoglycaemia		Nicotine	C	Glaxo Wellcome			
	Loss Of Consciousness							
	Muscle Rigidity							
	Scratch							
	Trismus							

Date:12/21/01ISR Number: 3842830-0Report Type:Expedited (15-DaCompany Report #B0130344A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
			Dothiepin	SS		ORAL	50MG At night	
			Prempak-C	C		ORAL	.625MG	
							Unknown	
			Salbutamol	C	Glaxo Wellcome		RESPIRATORY	
							(INHALATION)	100MCG As required
			Diazepam	C			UNKNOWN	5MG As required
			Fluoxetine	C			UNKNOWN	40MG Per day
			Zopiclone	C			UNKNOWN	7.5MG At night
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY	

(INHALATION) 100U Unknown

Date:12/21/01ISR Number: 3842836-1Report Type:Expedited (15-DaCompany Report #B0130602A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	63 DAY
			Ranitidine	C	Glaxo Wellcome		UNKNOWN	1U Twice per day
			Beclomethasone Dipropionate	C	Glaxo Wellcome	RESPIRATORY	(INHALATION)	2PUFF As required
			Aspirin	C			UNKNOWN	1U As directed
			Simvastatin	C			UNKNOWN	1U Per day
			Lansoprazole	C			UNKNOWN	1U Per day

Date:12/26/01ISR Number: 3844395-6Report Type:Expedited (15-DaCompany Report #2001027085-1
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective	Health Professional	Paxil					
	Fracture		Glaxosmithkline	PS	Glaxosmithkline	ORAL	30 MILLIGRAMS	
Disability	Grand Mal Convulsion						1.0 DAILY	
Required	Joint Dislocation						ORAL	
Intervention to Prevent Permanent Impairment/Damage	Sedation		Wellbutrin Sr (Bupropion) Glaxowellcome	SS	Glaxowellcome	ORAL	SEE IMAGE	3 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/01ISR Number: 3844757-7Report Type:Expedited (15-DaCompany Report #001-0945-M0101302
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Accommodation Disorder Astigmatism	Health Professional	Neurontin (Gabapentin)	PS		ORAL	1200 MG
Other	Dyspepsia						(TID), PER
	Hypoaesthesia						ORAL
	Malaise Memory Impairment Mental Disorder		Wellbutrin (Amfebutamone Hydrochloride)	SS			
			Methadone (Methadone)	SS		ORAL	40 MG (QID),
							PER ORAL
			(Paracetamol, Hydrocodone Bitartrate)	C			

Date:12/26/01ISR Number: 3844848-0Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Medication Error		Wellbutrin Sr 100mg Glaxo-Wellcome	PS	Glaxo-Wellcome	ORAL	200MG Q12
							ORAL

Date:12/26/01ISR Number: 3844893-5Report Type:Direct Company Report #
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Heart Rate Increased		Wellbutrin Sr 100 Mg	PS		ORAL	100 MG DAILY

	Palpitations						
ORAL							
	Tremor		Zoloft	C			
			Synthroid	C			
			Prevacid	C			

Date:12/26/01ISR Number: 3850322-8Report Type:Periodic Company Report #A0136960A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Eosinophilia Leukopenia	Health Professional Company Representative	Wellbutrin Tablet (Bupropionhydrochloride)	PS		ORAL	SEE DOSAGE TEXT/ ORAL
			Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL	SEE DOSAGE TEXT / ORAL
			Valproic Acid	C			

Date:12/27/01ISR Number: 3844300-2Report Type:Expedited (15-DaCompany Report #A0162401A
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Condition Aggravated Drug Effect Decreased Loss Of Employment

	Mania Mood Swings Suicidal Ideation	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tobacco Abuse		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 1 WK						
			Topamax	SS		
UNKNOWN						
			Zyprexa	SS		
UNKNOWN						
			Klonopin	SS		
UNKNOWN 1MG Unknown						

Date:12/27/01ISR Number: 3844301-4Report Type:Expedited (15-DaCompany Report #A0165315A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Deafness		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Tinnitus					
per day 10 DAY						
			Paxil	C	Glaxo Wellcome	
			Klonopin	C		

Date:12/27/01ISR Number: 3844303-8Report Type:Expedited (15-DaCompany Report #A0170847A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Depressed Level Of		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL
Initial or Prolonged	Consciousness		Uniphyl	C		
400MG Per day						
	Inappropriate		Lipidil	C		
	Antidiuretic Hormone		Novasen	C		
325MG Per day						
	Secretion		Rivotril	C		
.5MG Three						
	Polydipsia					
times per day						
			Norvasc	C		
2.5MG Per day						

			Risperdal	C		
.5MG At night						
			Zoloft	C		
			Kemadrin	C	Glaxo Wellcome	
			Norvasen	C		

Date:12/27/01ISR Number: 3855970-7Report Type:Periodic Company Report #WAES 01091620
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Asthenia						MG/DAILY/PO	
	Fatigue		Meridia	SS		ORAL	15	
	Nervousness						MG/DAILY/PO	
			Synthroid	SS		ORAL	50	
							MICROGM/DAILY	
							/PO	
			Lorazepam	SS		ORAL	1 MG/BID/PO	
			Wellbutrin	SS		ORAL	150	
							MG/DAILY/PO	

Date:01/02/02ISR Number: 3846136-5Report Type:Expedited (15-DaCompany Report #B0128152A
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Fall
	Fatigue
	Gamma-Glutamyltransferase Increased
	Grand Mal Convulsion

	Hyperhidrosis Loss Of Consciousness Malaise	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Orthostatic Hypotension		Zyban	PS	Glaxo Wellcome	ORAL	40 DAY
	Pallor		Valsartan	SS		ORAL	160MG per day
	Syncope Vasovagal		Celiprolol	SS		ORAL	200MG per day
	Tooth Injury		Frusemide	SS	Glaxo Wellcome	ORAL	40MG per day 8 DAY
			Atorvastatin	C		ORAL	

Date:01/02/02ISR Number: 3846140-7Report Type:Expedited (15-DaCompany Report #B0130243A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Antinuclear Antibody Positive Asthenia Bilirubin Conjugated Increased Hepatic Enzyme Increased Hepatitis Cholestatic Hepatocellular Damage Jaundice Nausea		Bupropion	PS	Glaxo Wellcome		

Date:01/02/02ISR Number: 3846146-8Report Type:Expedited (15-DaCompany Report #B0130748A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Circulatory Collapse		Zyban	PS	Glaxo Wellcome		UNKNOWN 150MG Twice
Initial or Prolonged	Ventricular Tachycardia						per day 10 DAY
			Diuretic	C			

Date:01/02/02ISR Number: 3847519-XReport Type:Direct Company Report #CTU 158144
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Generalised		Bupropian 100 Mg					
	Rash Pruritic		Kaiser Permanente	PS	Kaiser Permanente	ORAL	100 MIG	
	Skin Tightness						TWICE PER	
							ORAL	

Date:01/02/02ISR Number: 3847957-5Report Type:Direct Company Report #CTU 158146
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State		Paxil 40mg					
	Crying		Smithklinebeecham	PS	Smithklinebeecham	ORAL	40 MG ORAL	
	Depression		Wellbutrin 50-150 Mg	SS		ORAL	50-15 MG ORAL	
	Drug Withdrawal Syndrome						0 MG	
	Feeling Abnormal							
	Feeling Hot							
	Irritability							
	Nervousness							
	Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/02ISR Number: 3848973-XReport Type:Expedited (15-DaCompany Report #2014816
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchopneumonia	Health	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS				
	Drug Toxicity	Professional	Fluoxetine Hydrochloride	SS				
	Toxicologic Test Abnormal	Other	Chlordiazepoxide	SS				
			Bupropion Hydrochloride	SS				
			Cocaine	SS				
			Trazodone Hcl	SS				
			Insulin	C				
			Lithium	C				
			Risperdal (Risperidone)	C				

Date:01/07/02ISR Number: 3848657-8Report Type:Expedited (15-DaCompany Report #B0130993A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Zyban	PS	Glaxo Wellcome			15 DAY
Initial or Prolonged	Balance Disorder		Amlodipine Besylate	C		ORAL	1UD per day	87 DAY
	Flatulence		Lithium Carbonate	C	Glaxo Wellcome	ORAL		
	Gastrointestinal Disorder							
	Neoplasm Skin							

Date:01/07/02ISR Number: 3849470-8Report Type:Expedited (15-DaCompany Report #2014857
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis	Health	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS				
	Drug Toxicity	Professional						
	Toxicologic Test Abnormal	Other						

			Carbamazepine	SS		
			Propoxyphene Hcl	SS		
			Bupropion Hydrochloride	SS		
			Citalopram	SS		

Date:01/07/02ISR Number: 3850142-4Report Type:Direct Company Report #CTU 158536
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 2 WEEKS PTA	Angioneurotic Oedema		Wellbutrin	PS			2	WK
Initial or Prolonged	Dyspnoea							
	Face Oedema							
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/08/02ISR Number: 3849090-5Report Type:Expedited (15-DaCompany Report #A0167755A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Twice	
	Dysphonia						per day	24 DAY
	Urticaria							
	Wheezing							

Date:01/08/02ISR Number: 3849093-0Report Type:Expedited (15-DaCompany Report #A0171241A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG Per day	
	Maternal Drugs Affecting Foetus							

Date:01/08/02ISR Number: 3849095-4Report Type:Expedited (15-DaCompany Report #B0116763A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Overdose						per day	6 DAY
			Alcohol	C		ORAL		

Date:01/08/02ISR Number: 3849104-2Report Type:Expedited (15-DaCompany Report #B0131087A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Overdose		Zyban	PS	Glaxo Wellcome		UNKNOWN	12000MG

Initial or Prolonged cumulative dose	Suicide Attempt					

Date:01/08/02ISR Number: 3849873-1Report Type:Expedited (15-DaCompany Report #A130158
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Pain In Extremity	Health Professional	Procardia Capsules	PS		SUBCUTANEOUS	8.00	TOTAL:EVERY OTHER DAY:
	Peripheral Coldness		Amlodipine	SS				
	Peripheral Vascular		Betaseron	SS				
	Disorder							
	Pulse Abnormal							
	Skin Discolouration							
			Wellburtrin	SS		SUBCUTANEOUS		
			Vivelle	C				
			Neurontin	C				
			Prozac	C				
			Zanaflex	C				
			Darvocet	C				
			Xanax	C				

Date:01/08/02ISR Number: 3850083-2Report Type:Direct Company Report #CTU 158601
Age:27 YR Gender:Female I/FU:I

Outcome	PT
	Grand Mal Convulsion
	Vertigo

Visual Disturbance

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
			Septra (Co-Trimaxazole)	PS		ORAL
PO 80-160MG BID	2 DAY					
			Zyban	SS		ORAL
150MG (PO) BID	9 MON					
			Norplant	C		
			Prozac	C		
			Loratadine	C		
			Trimeth	C		
			Benzamide 250mg	C		
			Loperamide	C		

Date:01/08/02ISR Number: 3850518-5Report Type:Direct Company Report #CTU 158619
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Asthma		Buproprion			
Other	Cardiomyopathy		(Welbutrin Sr)	PS		ORAL
150MG BID PO	2 YR					

Date:01/09/02ISR Number: 3849503-9Report Type:Expedited (15-DaCompany Report #B0128084A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Asthenia		Bupropion			
	Dizziness		Hydrochloride	PS	Glaxo Wellcome	ORAL
150MG Per day	6 DAY					
	Nausea					
	Vision Blurred					

Date:01/09/02ISR Number: 3850947-XReport Type:Direct Company Report #CTU 158777
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Wellbutrin Sr					
	Palpitations		150mg. Glax	PS	Glax			

1 FOR THEN 2

A

Date:01/10/02ISR Number: 3850005-4Report Type:Expedited (15-DaCompany Report #A0164944A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG See	
	Blood Potassium Decreased						dosage text	
	Dizziness		Prozac	C		ORAL	60MG Per day	
	Grand Mal Convulsion							
	Stress							

Date:01/10/02ISR Number: 3850018-2Report Type:Expedited (15-DaCompany Report #A0171493A
Age:32 YR Gender:Female I/FU:F

Outcome	PT
Other	Abortion Spontaneous
	Complications Of Maternal
	Exposure To Therapeutic

	Drugs Maternal Drugs Affecting Foetus Placental Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pregnancy		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day

Date:01/10/02ISR Number: 3850020-0Report Type:Expedited (15-DaCompany Report #A0171611A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Vaginal Haemorrhage		Wellbutrin	PS	Glaxo Wellcome	ORAL	
			Zyban	SS	Glaxo Wellcome	ORAL	

Date:01/10/02ISR Number: 3850026-1Report Type:Expedited (15-DaCompany Report #B0131129A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Zyban	PS	Glaxo Wellcome		UNKNOWN
	Renal Failure						

Date:01/10/02ISR Number: 3850974-2Report Type:Expedited (15-DaCompany Report #2014808
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coma	Health	Oxycontin Cr				
	Drug Toxicity	Professional	Tablets, 40 Mg				
	Ecchymosis	Other	(Oxycodone				
	Laceration		Hydrochloride)	PS		ORAL	40 MG PO
	Toxicologic Test Abnormal		Doxepin Hcl	SS			
			Bupropion Hydrochloride	SS			

Date:01/10/02ISR Number: 3851098-0Report Type:Direct Company Report #CTU 158835
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abnormal Behaviour		Wellbutrin Sr	PS			150 MG 3X/DAY	
	Aggression		Lipitor	C				
	Agitation		Thorazine	C				
	Delusion							
	Gender Identity Disorder							
	Insomnia							
	Mania							
	Mental Impairment							
	Paranoia							
	Pressure Of Speech							
	Psychomotor Hyperactivity							
	Thinking Abnormal							
	Tinnitus							
	Transvestism							

Date:01/10/02ISR Number: 3851473-4Report Type:Expedited (15-DaCompany Report #LBID00202000039
Age:45 YR Gender:Male I/FU:I

Outcome	PT
Other	Anxiety
	Confusional State

		Convulsion Depression Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Somnolence	Literature	Lithium (Lithium)	PS		ORAL
300 MG BID							
			Health				
PO, 900 MG							
			Professional				
DAILY PO,							
1200 MG DAILY							
PO	1 DAY						
				Venlafaxine (Venlafaxine)	SS		ORAL
150 MG BID PO							
				Bupropion (Bupropion)	SS		ORAL
100 MG BID							
PO, 300 MG							
DAILY PO, 200							
MG DAILY PO							
				Gabapentin (Gabapentin)	C		
				Clonazepam (Clonazepam)	C		
				Glycopyrrolate (Glycophyrrolate)	C		
				Methotexital (Methohexital)	C		
				Succinylcholine (Succinylcholine Chloride)	C		
				Oxygen (Oxygen)	C		

Date:01/11/02ISR Number: 3850913-4Report Type:Expedited (15-DaCompany Report #A0170847A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - Initial or Prolonged	Coma		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	100MG Per day 9 DAY
	Convulsion		Zoloft	SS		ORAL	100MG Per day YR
	Inappropriate		Risperdal	SS		ORAL	1MG Per day
	Antidiuretic Hormone		Uniphyl	C			400MG Per day
	Secretion		Lipidil	C			
	Loss Of Consciousness		Novasen	C			325MG Per day
	Polydipsia		Rivotril	C		ORAL	.5MG Twice
	Respiratory Tract Infection		Norvasc	C			per day 2.5MG Per day
			Kemadrin	C	Glaxo Wellcome		

Date:01/14/02ISR Number: 3852218-4Report Type:Expedited (15-DaCompany Report #B0130243A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Asthenia	Foreign	Bupropion				
	Hepatitis Cholestatic	Literature	Hydrochloride				
	Jaundice	Health	(Bupropion				
	Nausea	Professional	Hydrochloride)	PS			

Date:01/17/02ISR Number: 3854205-9Report Type:Expedited (15-DaCompany Report #B0125399A
Age:42 YR Gender:Female I/FU:I

Outcome
Hospitalization - Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Balance Disorder	Foreign	Zyban Tablet - Zyban					
Cerebellar Syndrome	Health	(Bupropion					
Cerebrovascular Accident	Professional	Hydrochloride)	PS		ORAL	150 MG PER	
Confusional State						DAY ORAL	
Coordination Abnormal		Ferrous Sulfate	C				
Difficulty In Walking		Promethazine	C				
Dizziness		Propiomazine	C				
Dysarthria							
Fall							
Fear							
Fumbling							
Hallucination							
Hallucination, Visual							
Hypoaesthesia							
Lung Consolidation							
Paresis							
Pharyngolaryngeal Pain							
Swelling							
Tenderness							
Tongue Paralysis							
Vision Blurred							

Date:01/17/02ISR Number: 3854978-5Report Type:Expedited (15-DaCompany Report #A0155826A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Wellbutrin Sr					
Initial or Prolonged	Diarrhoea Haemorrhagic	Professional	Tablet-Controlled					
	Gastritis		Release (Bupropion					
	Gastrointestinal Disorder		Hydrochloride)	PS		ORAL	150 MG /	
	Haemorrhoids						TWICE PER DAY	
	Hyperplasia						/ ORAL	
	Hypersensitivity		Famotidine	C				
	Rectal Haemorrhage		Hrt	C				

Date:01/17/02ISR Number: 3854989-XReport Type:Expedited (15-DaCompany Report #A0171730A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Anxiety Contusion Convulsion Depression Homicidal Ideation Injury Memory Impairment Mental Disorder Premenstrual Syndrome Suicidal Ideation Swelling	Consumer	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS			VARIALE DOSE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/17/02ISR Number: 3855045-7Report Type:Expedited (15-DaCompany Report #A0165315A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Neurosensory Tinnitus	Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	
			Paroxetine Hydrochloride	C				
			Vitamin E	C				
			Ascorbic Acid	C				
			Clonazepam	C				
			Calcium Carbonate	C				
			Multivitamins + Iron	C				
			Hydrochlorothiazide	C				

Date:01/17/02ISR Number: 3855861-1Report Type:Expedited (15-DaCompany Report #B0126090A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoaesthesia Metastases To Central Nervous System Monoparesis Neurological Symptom	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG PER DAY ORAL	

Date:01/18/02ISR Number: 3854120-0Report Type:Expedited (15-DaCompany Report #B0120704A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation Anxiety		Zyban	PS	Glaxo Wellcome		150MG Twice per day	21 DAY

Breast Pain	Zopiclone	C
Confusional State	Oxazepam	C
Depression	Naproxen	C
Disturbance In Attention		
Dizziness		
Exanthem		
Feeling Abnormal		
Hallucinations, Mixed		
Insomnia		
Irritability		
Malaise		
Mental Disorder		
Mood Altered		
Nausea		
Pain		
Pollakiuria		
Pruritus		
Psoriasis		
Seborrhoea		
Tremor		
Visual Disturbance		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/02ISR Number: 3854130-3Report Type:Expedited (15-DaCompany Report #B0132126A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome		150MG Twice per day	10 DAY
	Automatism							
	Complex Partial Seizures		Carbamazepine	C			2TAB Twice per day	
	Confusional State							
	Deja Vu		Lithium	C			1.5TAB Twice per day	
	Echopraxia							
	Epilepsy		Phenytoin	C			1TAB Twice per day	
	Hallucination, Auditory							
	Thinking Abnormal		Amitriptyline	C			1TAB Per day	
			Amoxycillin	C			1TAB Three times per day	10 DAY

Date:01/18/02ISR Number: 3855669-7Report Type:Expedited (15-DaCompany Report #HQ9911115JAN2002
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Consumer	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	ORAL	
	Drug Withdrawal Syndrome							
	Hepatitis							
	Nausea							
	Vomiting							
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	ORAL	

Date:01/18/02ISR Number: 3856814-XReport Type:Expedited (15-DaCompany Report #B0131464A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Purpura	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ORAL	
			Methylenedioxymethamphet (Formulation Unknown) (Methylenedioxymethamphet)	SS				

Date:01/21/02ISR Number: 3854442-3Report Type:Expedited (15-DaCompany Report #A0172430A
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Asthenia Blood Pressure Increased Constipation Depression Dizziness Excitability Immobile Insomnia Irritability Nervousness Oral Intake Reduced Rash Pruritic

	Tremor						
	Vision Blurred						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Lamictal	PS	Glaxo Wellcome	ORAL	150MG Twice per day
			Wellbutrin	SS	Glaxo Wellcome	ORAL	
			Paxil	SS	Glaxo Wellcome	ORAL	
			Nardil	SS			UNKNOWN
			Zoloft	SS			UNKNOWN
			Ativan	C			20 YR
			Norvasc	C			
			Avapro	C			
			Klonopin	C			

Date:01/21/02ISR Number: 3854449-6Report Type:Expedited (15-DaCompany Report #B0131906A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastrointestinal Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day 12 DAY
	Intestinal Dilatation						
	Intestinal Obstruction						

Date:01/22/02ISR Number: 3858046-8Report Type:Expedited (15-DaCompany Report #B0131893A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign	Zyban Tablet (Bupropion Hydrochloride)	PS		ORAL	150MG/ORAL
	Cerebral Infarction						
	Dysphasia						
	Memory Impairment						
	Nausea						
	Personality Disorder						

	Ventricular Extrasystoles Visual Disturbance					

Date:01/22/02ISR Number: 3858052-3Report Type:Expedited (15-DaCompany Report #B0131129A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Dizziness Dyspepsia Heart Rate Increased Myocardial Infarction Renal Failure Ventricular Extrasystoles	Foreign Consumer	Bupropion Hydrochloride Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG	

Date:01/22/02ISR Number: 3858057-2Report Type:Expedited (15-DaCompany Report #B0132111A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Testis Cancer	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	
			Salbutamol Sulphate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/02ISR Number: 3858183-8Report Type:Expedited (15-DaCompany Report #A0169635A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other Required Intervention to Prevent Permanent Impairment/Damage	Anxiety Coma Fall Feeling Jittery Medication Error Overdose Urinary Incontinence	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	200 MG/ PER DAY/	TWICE
			Conjugated Estrogens Valaciclovir Hydrochlorid Gabapentin	C C C				

Date:01/23/02ISR Number: 3856112-4Report Type:Expedited (15-DaCompany Report #A0169561A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vision Blurred Visual Acuity Reduced		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	22 DAY

Date:01/23/02ISR Number: 3856115-XReport Type:Expedited (15-DaCompany Report #A0173197A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse Myocardial Infarction		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Nausea Urinary Incontinence Vomiting		Entex Pse	C		ORAL		

Date:01/23/02ISR Number: 3856127-6Report Type:Expedited (15-DaCompany Report #B0132864A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antinuclear Antibody		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	6 DAY
	Positive							
	Erythema							
	Oedema Peripheral							
	Swelling							
	Tenderness							

Date:01/23/02ISR Number: 3856157-4Report Type:Expedited (15-DaCompany Report #301407
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disturbance In Attention		Lariam	PS	Roche		36	DAY
	Dry Mouth		Zyban	SS			7	DAY
	Energy Increased		Trinordiol	C				
	Hyperhidrosis							
	Insomnia							
	Tremor							
	Vertigo							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/02ISR Number: 3859513-3Report Type:Expedited (15-DaCompany Report #A130158
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Chest Pain	Health	Procardia Capsules	PS				
Intervention to	Pain In Extremity	Professional	Amlodipine	SS				
Prevent Permanent	Peripheral Coldness		Betaseron	SS				
SUBCUTANEOUS								8.00
Impairment/Damage	Peripheral Vascular							
TOTAL:EVERY								
	Disorder							
OTHER DAY:								
SUBCUTANEOUS								
			Wellbutrin	SS				
			Vivelle	C				
			Neurontin	C				
			Prozac	C				
			Zanaflex	C				
			Xanax	C				
			Darvocet	C				

Date:01/23/02ISR Number: 3859628-XReport Type:Direct Company Report #CTU 159951
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Wellbutrin	100 Mg				
Hospitalization -	Asthenia		B.I.D.	PS				
100 MG								
Initial or Prolonged	Blood Pressure Decreased							
B.I.D.								
Disability	Catatonia							
Required	Cognitive Disorder							
Intervention to	Confusional State							
Prevent Permanent	Decreased Activity							
Impairment/Damage	Depression							
	Disorientation							
	Hallucination							
	Hypoaesthesia							
	Malaise							
	Palpitations							
	Speech Disorder							
	Suicidal Ideation							

Date:01/23/02ISR Number: 3859836-8Report Type:Periodic Company Report #NSADSS2001014108
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tardive Dyskinesia	Consumer	Risperdal (2 Mg Tablet) (Risperidone)	PS		ORAL	2 MG, 1 IN 1	DAY(S), ORAL
			Prozac (Fluoxetine Hydrochloride)	SS		ORAL	ORAL	
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	ORAL	

Date:01/23/02ISR Number: 3859988-XReport Type:Direct Company Report #CTU 159889
Age:33 YR Gender:Female I/FU:I

Outcome	PT
Other	Agitation
	Dizziness
	Headache

	Tremor Vision Blurred						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin Sr 150mg				
			Glaxo	PS	Glaxo	ORAL	150 MG 2X/DAY
							ORAL

Date:01/23/02ISR Number: 3860089-5Report Type:Direct Company Report #CTU 160078
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Confusional State		Zyban Catalytica	PS	Catalytica	ORAL	1 TAB 150 MG
Hospitalization -	Depression						2X DAY ORAL
Initial or Prolonged	Insomnia		Paxil	C			
Disability	Suicidal Ideation						
Required	Syncope						
Intervention to	Tremor						
Prevent Permanent							
Impairment/Damage							

Date:01/24/02ISR Number: 3856839-4Report Type:Expedited (15-DaCompany Report #B0120523A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Failure Acute		Zyban	PS	Glaxo Wellcome	ORAL	42 DAY
	Myocardial Fibrosis		Sotalol	C			UNKNOWN
	Sudden Death		Warfarin	C	Glaxo Wellcome		UNKNOWN

Date:01/24/02ISR Number: 3856844-8Report Type:Expedited (15-DaCompany Report #B0132587A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Rupture Depressed Level Of Consciousness Haemorrhage Headache Hypertension Meningeal Disorder Musculoskeletal Stiffness Vomiting		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY

Date:01/24/02ISR Number: 3856845-XReport Type:Expedited (15-DaCompany Report #B0133010A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haematemesis Haematocrit Decreased Middle Insomnia Nausea Oesophagitis Ulcerative Sleep Disorder Vomiting		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	24 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/02ISR Number: 3857846-8Report Type:Expedited (15-DaCompany Report #A0164667A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Twitching		Zyban	PS	Glaxo Wellcome	ORAL	4	MON
	Nerve Injury							
	Nervous System Disorder							
	Pain In Extremity							
	Tremor							

Date:01/25/02ISR Number: 3857850-XReport Type:Expedited (15-DaCompany Report #A0169595A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxo Wellcome	ORAL	.075MCG Per	
	Blister		Synthroid	C	Glaxo Wellcome	ORAL	day	
	Depression							
	Erythema		Ritalin	C		ORAL	25MG Twice	
	Hallucination, Auditory						per day	
	Memory Impairment		Vitamin	C		ORAL		
	Nervousness		Depakote	C		ORAL	15	DAY
	Paranoia							
	Pruritus							
	Rash Generalised							
	Scratch							
	Suicidal Ideation							

Date:01/25/02ISR Number: 3857851-1Report Type:Expedited (15-DaCompany Report #A0170813A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	YR	

Initial or Prolonged	Euphoric Mood		Soma	SS		
UNKNOWN						
	Overdose		Neurontin	SS		
UNKNOWN						
	Suicide Attempt		Effexor	C		

Date:01/25/02ISR Number: 3857856-0Report Type:Expedited (15-DaCompany Report #A0173850A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Alopecia		Wellbutrin	PS	Glaxo Wellcome	ORAL
100MG Per day						
	Cyst		Ssri	C		

Date:01/25/02ISR Number: 3860071-8Report Type:Expedited (15-DaCompany Report #301407
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Disturbance In Attention	Foreign	Lariam			
	Dry Mouth	Health	(Mefloquine			
	Energy Increased	Professional	Hydrochloride)	PS		ORAL
1 DOSE FORM 1						
	Hyperhidrosis					
PER WEEK ORAL						
	Insomnia		Zyban (Bupropion			
	Tremor		Hydrochloride)	SS		ORAL
1 DOSE FORM						
	Vertigo					
DAILY ORAL						
	Vision Blurred		Trinordiol (Ethinyl			
			Estradiol/Levonorges			
			trel)	C		

Date:01/25/02ISR Number: 3860273-0Report Type:Expedited (15-DaCompany Report #B0130243A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive Asthenia Cholestasis Chromaturia Faeces Discoloured Hepatitis Acute Hepatitis Cholestatic Hepatomegaly Hepatotoxicity Jaundice Liver Tenderness Nausea Prothrombin Time Prolonged	Foreign Literature Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride) Nebivolol Hcl Ethanol	PS C C			150 MG / TWICE PER DAY /	

Date:01/28/02ISR Number: 3858975-5Report Type:Expedited (15-DaCompany Report #B0131464A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Drug Abuser Ecchymosis Myocardial Infarction Toxicologic Test Abnormal		Zyban Methylenedioxymetham phetamine	PS SS	Glaxo Wellcome	ORAL	150MG	Unknown / UNKNOWN

Date:01/28/02ISR Number: 3858991-3Report Type:Expedited (15-DaCompany Report #A0166999A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL 150MG Twice per day
	Maternal Drugs Affecting Foetus		Synthroid	C	Glaxo Wellcome	ORAL .75MG Per day

Date:01/28/02ISR Number: 3858998-6Report Type:Expedited (15-DaCompany Report #B0131129A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Flutter Condition Aggravated Dehydration Dizziness Dyspepsia Electrolyte Imbalance Myocardial Infarction Palpitations Renal Failure Ventricular Tachycardia		Zyban	PS	Glaxo Wellcome	UNKNOWN	150MG Unknown	7 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/02ISR Number: 3859009-9Report Type:Expedited (15-DaCompany Report #B0133231A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	9 DAY
	Chest X-Ray Abnormal		Candesartan Cilexetil	SS		ORAL	8MG	Unknown
	Dyspnoea		Hydrochlorothiazide	SS		ORAL	12.5MG	Unknown
	Hypoxia		Thyroxine Sodium	SS	Glaxo Wellcome	ORAL	UNKNOWN	
	Infection		Oestradiol	SS			UNKNOWN	
	Spirometry Abnormal		Progesterone	SS			UNKNOWN	
			Fluoxetine Hydrochloride	SS		ORAL	20MG	Unknown
			Dirithromycin	C			UNKNOWN	
			Toplexil	C			UNKNOWN	
			Erdosteine	C			UNKNOWN	

Date:01/28/02ISR Number: 3859010-5Report Type:Expedited (15-DaCompany Report #B0133703A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown
	Condition Aggravated Coronary Artery Disease		Simvastatin	SS		ORAL		

Date:01/28/02ISR Number: 3859011-7Report Type:Expedited (15-DaCompany Report #B0133707A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Thrombotic		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown
Hospitalization - Initial or Prolonged	Thrombocytopenic Purpura							

Date:01/28/02ISR Number: 3859012-9Report Type:Expedited (15-DaCompany Report #B0133710A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Per day
	Arthralgia		Corticosteroid	SS			UNKNOWN	
	Tendon Disorder							
	Urticaria							

Date:01/28/02ISR Number: 3860397-8Report Type:Direct Company Report #CTU 160229
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Zyban 150mg Tbsr	PS	Tbsr	ORAL	150MG 1 TAB	
	Pruritus						PO BID	
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/02ISR Number: 3862202-2Report Type:Expedited (15-DaCompany Report #A0172394A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Literature	Wellbutrin Tablet					
	Confusional State	Health	(Bupropion					
	Convulsion	Professional	Hydrochloride)	PS		ORAL	ORAL	
	Depression		Lithium Salt					
	Drug Ineffective		(Lithium Salt)	SS				
	Insomnia		Venlafaxine					
	Somnolence		Hydrochloride					
			(Venalfaxine					
			Hydrochloride)	SS			150 MG/TWICE	
							PER DAY	
			Electroconvulsive					
			Therapy					
			(Electroconvulsive					
			Therapy)	SS			SEE DOSAGE	
							TEXT	
			Gabapentin	C				
			Clonazepam	C				
			Glycopyrronium					
			Bromide	C				
			Methohexitone	C				
			Suxamethonium	C				
			Oxygen	C				
			Citalopram	C				

Date:01/29/02ISR Number: 3860867-2Report Type:Expedited (15-DaCompany Report #B0101033A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute		Zyban	PS	Glaxo Wellcome	ORAL	42	DAY
	Myocardial Fibrosis		Sotalol	C				
	Sudden Cardiac Death		Warfarin	C	Glaxo Wellcome		UNKNOWN	

Date:01/29/02ISR Number: 3860882-9Report Type:Expedited (15-DaCompany Report #B0134007A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache Hypertension Meningism Mental Disorder Musculoskeletal Stiffness Pain Vomiting Projectile		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	2 MON

Date:01/29/02ISR Number: 3860883-0Report Type:Expedited (15-DaCompany Report #B0134016A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxo Wellcome	UNKNOWN	150MG Unknown	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/02ISR Number: 3861794-7Report Type:Direct Company Report #CTU 160321
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chills		Wellbutrin 150 Mg Sr Tab Glaxo	PS	Glaxo	ORAL	150 MG SR TABLET BY MOUTH 2 X DAILY	1
	Coordination Abnormal							
	Depression							
	Insomnia							
	Mania							
	Memory Impairment							
	Suicidal Ideation							
	Tremor							

Date:01/29/02ISR Number: 3862106-5Report Type:Direct Company Report #CTU 160282
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Zyban (Bupropion) 150 Mg	PS		ORAL	150 MG BID PO	
	Dyspnoea							
	Headache		Albuterol Inhaler	C				
	Medication Error		Afrin Nasal Spray	C				
	Nausea		Motrin	C				
	Palpitations		Multivitamin	C				

Date:01/29/02ISR Number: 3903414-9Report Type:Periodic Company Report #A127209
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Tikosyn Capsules	PS		ORAL	250.00 MCG TOTAL:BID:ORA	
	Depression							
	Diarrhoea							

	Rash		Wellbutrin	SS			
225.00 MG							
	Tremor						
TOTAL:TID							
			Levoxyl	C			
			Valium	C			

Date:01/29/02ISR Number: 3903459-9Report Type:Periodic Company Report #A128334
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Depression	Consumer	Tikosyn Capsules	PS		ORAL	250.00 MCG
	Rash						
TOTAL:BID							
:ORAL							
			Wellbutrin	SS		ORAL	75:00 MG
TOTAL:DAILY:O							
RAL							
			Thyroid	C			

Date:01/30/02ISR Number: 3862121-1Report Type:Expedited (15-DaCompany Report #HQ0174226JAN2002
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Arthralgia Leukocytoclastic Vasculitis Myalgia	Health Professional	Efexor (Venlafaxine Hydrochloride, Tablet) Zyban (Amfebutamone Hydrochloride,) Unspecified	PS SS		ORAL	

			Contraceptive (Unspecified Contraceptive)	C		

Date:01/30/02ISR Number: 3863609-XReport Type:Periodic Company Report #PHEH2001US01007
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Fall Loss Of Consciousness	Health Professional	Ritalin(Methylphenidate Hydrochloride) Tablet, 10mg	PS		ORAL	5 0MG QD,	ORAL 2190 DAY
			Wellbutrin-Slow Release (Amfebutamone Hydrochloride) 150mg	SS		ORAL	150 MG, BID,	ORAL 30 DAY

Date:01/31/02ISR Number: 3861042-8Report Type:Expedited (15-DaCompany Report #A0174691A
Age:8 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	450MG per day	
	Infection		Depakote	C		ORAL	100MG Twice per day	
	Personality Change							
	Respiratory Arrest		Celexa	C		ORAL	10MG Per day	6 MON
	Status Epilepticus		Risperdal	C		ORAL	2MG Twice per day	

Date:01/31/02ISR Number: 3861043-XReport Type:Expedited (15-DaCompany Report #B0101363A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Zyban	PS	Glaxo Wellcome	ORAL	150MG See dosage text	31 DAY
	Blood Immunoglobulin G Increased							
Disability	Brain Scan Abnormal							
	Coordination Abnormal							
	Demyelination							
	Diplopia							
	Dysaesthesia							
	Dysarthria							
	Monoparesis							
	Multiple Sclerosis							
	Paraesthesia							

Date:01/31/02ISR Number: 3861044-1Report Type:Expedited (15-DaCompany Report #B0124304A
Age:31 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abnormal Behaviour
Hospitalization - Initial or Prolonged	Aggression
	Dry Mouth
	Dry Skin
	Dysuria
	Excitability
	Heart Rate Increased
	Insomnia

	Irritability Logorrhoea Mydriasis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea		Zyban	PS	Glaxo Wellcome	ORAL	150MG As
directed 9 DAY	Nervousness						
	Overdose		Zyban	SS	Glaxo Wellcome	ORAL	2700MG Single
dose 1 DAY	Somnolence						
	Suicide Attempt Tearfulness Vomiting		Alcohol	C			

Date:01/31/02ISR Number: 3861049-0Report Type:Expedited (15-DaCompany Report #B0133422A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - UNKNOWN	Chest Pain		Zyban	PS	Glaxo Wellcome		
Initial or Prolonged	Coordination Abnormal Dizziness Malaise Trigeminal Neuralgia						

Date:01/31/02ISR Number: 3861056-8Report Type:Expedited (15-DaCompany Report #B0134019A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Mouth Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	150MG As directed
			Fluoxetine	SS		ORAL	20MG Per day
			Olanzapine	SS		ORAL	7.5MG Unknown
			Loxapine	SS		ORAL	50MG Per day

			Mepronizine	SS		ORAL
2UNIT Per day						

Date:01/31/02ISR Number: 3861579-1Report Type:Direct Company Report #CTU 160479
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alcoholism		Wellbutrin 150mg	PS		ORAL	150 MG QD	
	Flushing					ORAL		
	Paraesthesia Oral Swelling							

Date:01/31/02ISR Number: 3863242-XReport Type:Expedited (15-DaCompany Report #2020164
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Oedema Contusion Depressed Level Of Consciousness Overdose Pulmonary Oedema Toxicologic Test Abnormal	Health Professional Other	Morphine Sulfate (Similar To Andas 74-769 And 74-862)	PS		ORAL	MG UNKNOWN PO	
			Oxycodone Hydrochloride (Similar To Nda 20-553)	SS		ORAL	MG UNKNOWN PO	
			Bupropion Hydrochloride	SS		ORAL	MG UNKNOWN PO	
			Methadone	SS		ORAL	MG UNKNOWN PO	
			Diazepam	SS		ORAL	MG UNKNOWN PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/02ISR Number: 3861658-9Report Type:Expedited (15-DaCompany Report #A0173831A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Ageusia Anosmia	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	

Date:02/01/02ISR Number: 3861659-0Report Type:Expedited (15-DaCompany Report #A0173931A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cholelithiasis Grand Mal Convulsion	Health Professional	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day
			Singulair	C			
			Levoxyl	C	Glaxo Wellcome		
			Prevacid	C			
			Luvox	C			

Date:02/01/02ISR Number: 3861672-3Report Type:Expedited (15-DaCompany Report #B0131127A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day
	Chest Pain						
	Decreased Appetite		Acetylcysteine	C	Glaxo Wellcome		UNKNOWN
	Depression		Flunisolide	C			UNKNOWN
	Disturbance In Attention		Salbutamol	C	Glaxo Wellcome		UNKNOWN
	Dizziness		Dexchlorpheniramine				
	Dry Mouth		Maleate	C			UNKNOWN
	Dyspnoea		Salmeterol +				
	Headache		Fluticasone	C	Glaxo Wellcome		UNKNOWN

	Influenza Like Illness		Tenoxicam	C	
UNKNOWN					
	Nausea		Piroxicam	C	
UNKNOWN					
	Oedema Peripheral				
	Palpitations				
	Sleep Disorder				

Date:02/01/02ISR Number: 3861679-6Report Type:Expedited (15-DaCompany Report #B0133944A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Infarction		Zyban	PS	Glaxo Wellcome		150MG	Unknown

Date:02/01/02ISR Number: 3861683-8Report Type:Expedited (15-DaCompany Report #B0134202A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	33 DAY
Initial or Prolonged	Flatulence							
	Intestinal Obstruction							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/02ISR Number: 3861685-1Report Type:Expedited (15-DaCompany Report #B0134232A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown
			Oxygen Therapy	C				

Date:02/01/02ISR Number: 3861686-3Report Type:Expedited (15-DaCompany Report #B0134348A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown

Date:02/01/02ISR Number: 3863259-5Report Type:Direct Company Report #CTU 160600
Age:47 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Zyban 150mg Tbsr	PS		ORAL	1T TAB PO	BID
			Habitrol	C				

Date:02/04/02ISR Number: 3862298-8Report Type:Expedited (15-DaCompany Report #B0134351A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown 31 DAY
	Gastric Ulcer		Alcohol	C				
	Gastrointestinal Haemorrhage							
	Haematemesis							
	Hiatus Hernia							
	Oesophagitis Haemorrhagic							

Date:02/04/02ISR Number: 3862302-7Report Type:Expedited (15-DaCompany Report #B0134762A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown

Date:02/05/02ISR Number: 3863191-7Report Type:Expedited (15-DaCompany Report #A0175184A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	2 DAY
			Celexa	C				
			Ziac	C				
			Spironolactone	C				
			Reglan	C	Glaxo Wellcome			
			Zyrtec	C	Glaxo Wellcome			

Date:02/05/02ISR Number: 3863198-XReport Type:Expedited (15-DaCompany Report #B0096692A
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Exanthem
	Hepatic Steatosis
	Hepatomegaly

	Lung Infiltration					
	Petechiae					
	Red Blood Cell	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Sedimentation Rate		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day						
	Increased					
	Vasculitis					

Date:02/05/02ISR Number: 3863199-1Report Type:Expedited (15-DaCompany Report #B0102171A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Alanine Aminotransferase		Zyban	PS	Glaxo Wellcome	
UNKNOWN	DAY					
	Increased					
	Burning Sensation					
	Dermatitis Exfoliative					
	Fatigue					
	Neutrophilia					
	Oedema Peripheral					
	Rash Generalised					
	Rash Maculo-Papular					
	Rash Pruritic					
	Vision Blurred					

Date:02/05/02ISR Number: 3863208-XReport Type:Expedited (15-DaCompany Report #B0126564A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Congenital Anomaly	Asthma		Zyban	PS	Glaxo Wellcome	
UNKNOWN	300MG per day					
	Caesarean Section					
	Complications Of Maternal					
	Exposure To Therapeutic					
	Drugs					
	Dermatitis Atopic					
	Maternal Drugs Affecting					
	Foetus					
	Neonatal Disorder					
	Pregnancy					

	Ventricular Septal Defect
	Acquired

Date:02/05/02ISR Number: 3863221-2Report Type:Expedited (15-DaCompany Report #B0135045A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Head Injury		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown

Date:02/05/02ISR Number: 3863225-XReport Type:Expedited (15-DaCompany Report #B0135166A
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
	Arthralgia
	Aspartate Aminotransferase Increased
	Blood Bilirubin Increased

		Leukocytosis Neutrophil Count Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pyrexia		Zyban	PS	Glaxo Wellcome	ORAL
150MG	Unknown						
		Urticaria					

Date:02/05/02ISR Number: 3865355-5Report Type:Expedited (15-DaCompany Report #A0174500A
Age:29 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Facial Palsy Lagophthalmos	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG / PER							
DAY / ORAL							

Date:02/05/02ISR Number: 3865911-4Report Type:Expedited (15-DaCompany Report #A0159165A
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Deafness Depression Drug Interaction Liver Function Test	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
SEE DOSAGE							
TEXT/ORAL		Abnormal					
		Loss Of Consciousness Memory Impairment Scleral Discolouration		Metoprolol Succinate (Metoprolol Succinate)	SS		ORAL
50 MG PER							
DAY/ORAL		Tinnitus					
		Tooth Disorder Tooth Loss		Nitroglycerin	C		
				Ranitidine Hydrochloride	C		
				Hydroxyzine	C		

Date:02/05/02ISR Number: 3866408-8Report Type:Expedited (15-DaCompany Report #A0140463A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Foreign	Zyban Tablet - Zyban					
	Cardiac Arrest	Literature	(Bupropion					
	Confusional State	Health	Hydrochloride)	PS		ORAL	ORAL	10 DAY
	Euphoric Mood	Professional						
	Feeling Abnormal							
	Hypersensitivity							
	Memory Impairment							
	Myocardial Infarction							
	Palpitations							
	Psychomotor Hyperactivity							
	Pyrexia							
	Speech Disorder							

Date:02/05/02ISR Number: 3866618-XReport Type:Expedited (15-DaCompany Report #B0111327A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomyopathy	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/02ISR Number: 3866620-8Report Type:Expedited (15-DaCompany Report #A0170371A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills Convulsion Mental Disorder Pyrexia Speech Disorder Weight Decreased	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Varicella Virus Vaccine (Formulation Ukn) (Varicella Virus Vaccine)	PS SS		ORAL	150 MG/ PER DAY / ORAL	

Date:02/05/02ISR Number: 3866622-1Report Type:Expedited (15-DaCompany Report #B0134015A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG	

Date:02/05/02ISR Number: 3866682-8Report Type:Expedited (15-DaCompany Report #B0131464A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Blood Creatine Increased Blood Pressure Decreased Cardiac Failure Cutaneous Vasculitis Ecchymosis Hyperpyrexia Malaise Myocardial Infarction Toxicologic Test Abnormal	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Methylenedioxymethamphet (Methylenedioxymethamphet.) Ethanol Cannabis	PS SS C C		ORAL	150 MG ORAL	

Date:02/07/02ISR Number: 3866464-7Report Type:Direct Company Report #CTU 161205
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Wellbutrin	PS		ORAL	150 MG 2	
	Stress						TABLET TWICE	
							A DAY ORAL	

Date:02/07/02ISR Number: 3866949-3Report Type:Expedited (15-DaCompany Report #001-0945-M0200153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Health Professional	Neurontin (Gabapentin)	PS		ORAL	1500 MG (QID)	
Other	Blood Glucose Fluctuation						PER ORAL	
	Hypoglycaemia		(Bupropion)	SS		ORAL	450 MG (TID)	
	Incontinence						PER ORAL	
			(Advair)	C				
			(Prednisone)	C				
			(Diazepam)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/12/02ISR Number: 3866922-5Report Type:Expedited (15-DaCompany Report #A0175186A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dehydration		Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG Twice	
	Grand Mal Convulsion						per day	
	Stress		Zoloft	C			UNKNOWN	

Date:02/13/02ISR Number: 3867728-3Report Type:Expedited (15-DaCompany Report #B0100348A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	150MG Three	
	Confusional State						times per day	9 DAY
	Hallucination		Catapressan	C				
	Hallucination, Visual		Penicillin	C	Glaxo Wellcome			
	Psychotic Disorder		Netromycin					
	Restlessness		(Netilmicin)	C				
			Haloperidol	C				
			Morphine Chloride	C				

Date:02/13/02ISR Number: 3867733-7Report Type:Expedited (15-DaCompany Report #B0134349A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	

Date:02/13/02ISR Number: 3867734-9Report Type:Expedited (15-DaCompany Report #B0134350A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Zyban	PS	Glaxo Wellcome	
UNKNOWN	150MG Unknown					

Date:02/13/02ISR Number: 3869419-1Report Type:Periodic Company Report #2013325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Intentional Misuse	Health Professional Other	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS		
			Bupropion Hydrochloride	SS		
			Effexor (Venlafaxine)	SS		
			Diazepam	SS		
			Acetaminophen	SS		
			Ethanol (Alcohol, Anhydrous)	SS		

Date:02/13/02ISR Number: 3869517-2Report Type:Periodic Company Report #2013220
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Accidental Overdose	Health Professional Other	Oxycodone Hydrochloride (Similar To Nda			

			20-553)	PS		
			Alprazolam	SS		
			Diazepam	SS		
			Bupropion Hydrochloride	SS		

Date:02/13/02ISR Number: 3869518-4Report Type:Periodic Company Report #2013221
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse	Health Professional Other	Oxycontin Cr Tablets, 10 Mg (Oxycodone Hydrochloride)	PS		ORAL	PO	
			Alprazolam	SS				
			Bupropion Hydrochloride	SS				
			Cyclobenzaprine Hcl	SS				
			Paroxetine Hcl	SS				

Date:02/13/02ISR Number: 3869590-1Report Type:Periodic Company Report #2012330
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health Professional Other	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS				
			Hydrocodone Bitartrate	SS				
			Diazepam	SS				
			Bupropion	SS				
			Propoxyphene	SS				
			Diclofenac Sodium	SS				
			Caffeine	SS				
			Nicotine	SS				

Date:02/13/02ISR Number: 3870599-2Report Type:Periodic Company Report #2013430
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health Professional Other	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS				
			Hydrocodone Bitartrate	SS				
			Chlorpheniramine	SS				
			Cyclobenzaprine	SS				
			Bupropion	SS				
			Propoxyphene	SS				
			Lidocaine	SS				
			Caffeine	SS				
			Nicotine	SS				
			Diazepam	SS				
			Oxazepam	SS				
			Temazepam	SS				
			Lorazepam	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/02ISR Number: 3871103-5Report Type:Periodic Company Report #2015056
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health Professional Other	Oxycodone Hydrochloride	PS				
			Morphine Sulfate (Similar To Nda 19-516)	SS				
			Codeine	SS				
			Olanzapine	SS				
			Acetaminophen	SS				
			Paroxetine	SS				
			Bupropion	SS				
			Nicotine	SS				

Date:02/13/02ISR Number: 3872392-3Report Type:Periodic Company Report #2014089
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health Professional Other	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS				
			Ethyl Alcohol	SS				
			Bupropion	SS				
			Diazepam	SS				
			Acetaminophen	SS				
			Ibuprofen	SS				

Date:02/13/02ISR Number: 3875457-5Report Type:Periodic Company Report #2012980
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health Professional Other	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS				
			Bupropion Hydrochloride	SS				

			Nicotine	SS		

Date:02/13/02ISR Number: 3875463-0Report Type:Periodic Company Report #2012972
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Intentional Misuse	Health Professional Other	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS		
			Propoxyphene	SS		
			Acetaminophen	SS		
			Bupropion	SS		
			Diazepam	SS		
			Trazodone	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/02ISR Number: 3876144-XReport Type:Periodic Company Report #2014807
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Dependence	Health	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS				
Other	Intentional Misuse	Professional	Bupropion Hydrochloride	SS				
		Other						

Date:02/13/02ISR Number: 3876166-9Report Type:Periodic Company Report #2013012
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS				
		Professional	Ethanol (Alcohol, Anhydrous)	SS				
		Other	Temazepam	SS				
			Acetaminophen	SS				
			Propoxyphene Hcl	SS				
			Bupropion Hydrochloride	SS				
			Nicotine	SS				
			Caffeine Anhydride	SS				

Date:02/13/02ISR Number: 3876676-4Report Type:Periodic Company Report #2012177
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health Professional	Oxycodone Hydrochloride	PS		ORAL	MG PO	
		Other	Hydrocodone Bitartrate	SS				
			Bupropion	SS		ORAL	MG PO	

			Meprobamate	SS		ORAL
MG PO						
			Diazepam	SS		ORAL
MG PO						
			Oxazepam	SS		ORAL
MG PO						
			Lorazepam	SS		ORAL
MG PO						
			Trazodone	SS		ORAL
MG PO						

Date:02/13/02ISR Number: 3876797-6Report Type:Periodic Company Report #2012673
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Intentional Misuse	Health Professional Other	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS		
			Bupropion	SS		
			Doxepin	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/02ISR Number: 3877723-6Report Type:Periodic Company Report #2013135
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health	Oxycodone Hydrochloride (Similar To Nda 20-553)	PS		ORAL	MG, PO	
		Professional	Amitriptyline	SS				
		Other	Bupropion Hydrochloride	SS				
			Acetazolamide	C				
			Seroquel	C				
			Clonazepam	C				
			Nefazodone	C				
			Naprozen	C				
			Claritin (Loratadine)	C				
			Biaxin	C				

Date:02/13/02ISR Number: 3877736-4Report Type:Periodic Company Report #2013040
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health	Oxycontin Cr Tablets	PS			MG	
		Professional	Diazepam	SS				
		Other	Bupropion	SS				
			Fluconazole	SS				
			Oxazepam	SS				
			Temazepam	SS				

Date:02/13/02ISR Number: 3877738-8Report Type:Periodic Company Report #2013023
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse	Health	Oxycodone Hydrochloride	PS				
		Professional	Bupropion	SS				
		Other						

			Meperidine	SS		
			Acetaminophen	SS		
			Ketamine Hydrochloride	SS		
			Ritalin (Methylphenidate)	SS		

Date:02/13/02ISR Number: 3878322-2Report Type:Periodic Company Report #2013076
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health Professional Other	Oxycodone Hydrochloride	PS				
			Welbutrin (Bupropion)	SS				
			Dalmane (Flurazepam)	SS				
			Ethyl Alcohol	SS				
			Salicylates	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/02ISR Number: 3878382-9Report Type:Periodic Company Report #2013697
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health Professional Other	Oxycontin Cr Tablets, 40 Mg (Oxycodone Hydrochloride)	PS		ORAL	40 MG, PO	
			Wellbutrin (Bupropion)	SS			MG	
			Amitriptyline	SS			MG	
			Alprazolam	SS			MG	
			Alcohol	SS				

Date:02/14/02ISR Number: 3868750-3Report Type:Expedited (15-DaCompany Report #A0359101A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Respiratory Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:02/14/02ISR Number: 3868759-XReport Type:Expedited (15-DaCompany Report #B0132587A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aneurysm Ruptured Brain Scan Abnormal Headache Hydrocephalus Hypertension Loss Of Consciousness Meningorrhagia Musculoskeletal Stiffness Nervous System Disorder Osteoma		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY

	Vomiting					

Date:02/14/02ISR Number: 3868761-8Report Type:Expedited (15-DaCompany Report #B0135181A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardioactive Drug Level		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown
Initial or Prolonged	Increased		Human Insulin	SS				
INTRAVENOUS	1000IU per							
	Clonic Convulsion							
day	1 DAY							
	Dyskinesia		Zopiclone	SS		ORAL	22.5MG Per	
	Feeling Abnormal							
day	1 DAY							
	Hypoglycaemic Coma		Digoxin	SS	Glaxo Wellcome	ORAL	1	DAY
	Overdose							
	Tremor							

Date:02/14/02ISR Number: 3869747-XReport Type:Direct Company Report #CTU 161637
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Apnoea		Wellbutrin Sr					
	Grand Mal Convulsion		(Bupropion) 150 Mg					
			Tab	PS		ORAL	150 MG PO BID	
			Prozac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/02ISR Number: 3870033-2Report Type:Direct Company Report #CTU 161647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying		Paxil 60mg					
	Depression		Glaxosmithkline	PS	Glaxosmithkline	ORAL	30MG TWICE	
	Diarrhoea						DAILY ORAL	
	Dizziness		Welbutrin 125mg					
	Drug Withdrawal Syndrome		Glaxowellcome	SS	Glaxowellcome	ORAL	125MG TWICE	
	Ear Disorder						DAILY ORAL	
	Feeling Abnormal							
	Headache							
	Influenza Like Illness							
	Nausea							
	Night Sweats							
	Nightmare							
	Paraesthesia							
	Suicidal Ideation							

Date:02/14/02ISR Number: 3870459-7Report Type:Expedited (15-DaCompany Report #A202614
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Testosterone	Health Professional	Zoloft Tablets	PS				
	Decreased		Neurontin	SS				
	Hyponatraemia		Paxil	SS				
			Wellbutrin	SS				
			Ambien	C				
			Albuterol Inhaler	C				
			Atenolol	C				
			Folic Acid	C				
			Zocor	C				
			Hydrochlorothiazide	C				

Date:02/14/02ISR Number: 3870486-XReport Type:Expedited (15-DaCompany Report #001-0945-M0200061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Testosterone Decreased Hyponatraemia	Health Professional	Neurontin (Gabapentin)	PS				
			Sertraline Hydrochloride	SS				
			Bupropion	SS				
			Paroxetine Hydrochloride	SS				
			Zolpidem Tartrate	C				
			Salbutamol	C				
			Atenolol	C				
			Folic Acid	C				
			Simvastatin	C				
			Hydrochlorothiazide	C				

Date:02/15/02ISR Number: 3869246-5Report Type:Expedited (15-DaCompany Report #B0117368A
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Death	Bronchial Carcinoma
	Cardiac Failure Acute
	Coronary Artery

	Atherosclerosis						
	Metastases To Lymph Nodes						
	Myocardial Ischaemia						
	Sudden Death	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG As directed
			Captopril	C	Glaxo Wellcome		25MG per day
			Furosemide	C	Glaxo Wellcome		40MG per day
			Salbutamol	C	Glaxo Wellcome		RESPIRATORY (INHALATION)
			Fluticasone	C	Glaxo Wellcome		

Date:02/15/02ISR Number: 3869254-4Report Type:Expedited (15-DaCompany Report #B0135382A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dehydration		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 2 WK
Disability	Dysuria		Nomegestrol	SS		ORAL	
	Eosinophil Count Increased						
	Exanthem						
	Mucosal Erosion						
	Oedema Peripheral						
	Pruritus						
	Pyrexia						
	Skin Exfoliation						
	Toxic Skin Eruption						

Date:02/15/02ISR Number: 3869257-XReport Type:Expedited (15-DaCompany Report #B0259229A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Overdose		Zyban	PS	Glaxo Wellcome	ORAL	15000MG

Single dose

Date:02/15/02ISR Number: 3870837-6Report Type:Direct Company Report #CTU 161754
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Wellbutrin	PS		ORAL	200MG PO BID	
			Lithium Carbonate	C				

Date:02/18/02ISR Number: 3869787-0Report Type:Expedited (15-DaCompany Report #A0173850A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Per day	
	Cyst		Celexa	C		ORAL		

Date:02/18/02ISR Number: 3869788-2Report Type:Expedited (15-DaCompany Report #A0175712A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complex Partial Seizures		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Unknown	
	Convulsion		Fastin	SS	Glaxo Wellcome		30MG Per day	
	Drug Interaction		Vistaril	C			50MG Twice	

per day

			Ambien	C			
10MG At night							
			Talwin	C			
			Imitrex	C	Glaxo Wellcome		
			Phenergan	C	Glaxo Wellcome		

Date:02/18/02ISR Number: 3869803-6Report Type:Expedited (15-DaCompany Report #B0259361A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	21 DAY

Date:02/18/02ISR Number: 3869804-8Report Type:Expedited (15-DaCompany Report #B0259370A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	7 DAY
			Naproxen	C		ORAL	250MG Three times per day	
			Lorazepam	C		ORAL	1MG At night	
			Dihydrocodeine	C		ORAL	60MG As required	
			Hydroxyzine	C		ORAL	25MG As required	

Date:02/18/02ISR Number: 3869805-XReport Type:Expedited (15-DaCompany Report #B0259495A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Urticaria							
per day	31 DAY							
	Wheezing		Zovirax	SS	Glaxo Wellcome	TOPICAL		
			Aspirin	C		ORAL	75MG Per day	

Date:02/20/02ISR Number: 3870925-4Report Type:Expedited (15-DaCompany Report #A0359237A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG per day	
Other	Convulsion		Depakote	C				
	Medication Error							
	Overdose							

Date:02/20/02ISR Number: 3870927-8Report Type:Expedited (15-DaCompany Report #A0359335A
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blindness
	Coma
	Depression
	Disturbance In Attention
	Epileptic Aura
	Generalised
	Non-Convulsive Epilepsy
	Memory Impairment
	Optic Nerve Disorder

Visual Acuity Reduced

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	YR
			Oxycontin	C				
			Flexeril	C				
			Acyclovir	C	Glaxo Wellcome		200MG As required	

Date:02/20/02ISR Number: 3870928-XReport Type:Expedited (15-DaCompany Report #A0359405A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Fall							
	Gait Disturbance							
	Hip Fracture							

Date:02/20/02ISR Number: 3870935-7Report Type:Expedited (15-DaCompany Report #B0259584A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	1 WK
	Blood Lactate Dehydrogenase Increased		Pancrelipase	SS		ORAL		
	Condition Aggravated							
	Hypertension							
	Pancreatitis							
	Tachycardia							
	White Blood Cell Count Increased							

Date:02/20/02ISR Number: 3870936-9Report Type:Expedited (15-DaCompany Report #B0259585A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Confusional State		Proguanil	SS		ORAL		
	Disturbance In Attention		Chloroquine	SS		ORAL		
	Drug Interaction							
	Muscle Spasms							
	Tachycardia							

Date:02/20/02ISR Number: 3870937-0Report Type:Expedited (15-DaCompany Report #B0259831A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG See dosage text	9 DAY
	Electrocardiogram							
	Repolarisation Abnormality							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/02ISR Number: 3872606-XReport Type:Direct Company Report #CTU 161881
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Wellbutrin Sr	PS			150MG	
	Blood Pressure Increased		Zyban	SS				
	Chronic Fatigue Syndrome							
	Disturbance In Attention							
	Fibromyalgia							
	Insomnia							
	Nervousness							

Date:02/20/02ISR Number: 3873029-XReport Type:Expedited (15-DaCompany Report #A202713
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Dry Skin	Consumer	Zoloft Tablets	PS		ORAL	100.00 MG	
Intervention to	Energy Increased						TOTAL:DAILY:O	
Prevent Permanent	Fatigue						RAL	
Impairment/Damage	Hernia		Amitriptyline	SS		ORAL	50.00 MG	
	Hunger						TOTAL:DAILY:O	
	Nausea						RAL	
	Night Sweats		Welbutrin	SS				
	Paranoia		Tricor	C				
	Pollakiuria		Lipitor	C				
	Productive Cough		Vitamin Unspecified	C				
	Sleep Disorder		Thioridazine	C				
	Tooth Abscess							
	Tremor							
	Viral Infection							
	Weight Decreased							

Date:02/21/02ISR Number: 3871529-XReport Type:Expedited (15-DaCompany Report #B0259698A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Amnesia		Alcohol	C				
	Confusional State							
	Disturbance In Attention							
	Dizziness							
	Loss Of Consciousness							
	Malaise							
	Postictal State							
	Road Traffic Accident							

Date:02/21/02ISR Number: 3871530-6Report Type:Expedited (15-DaCompany Report #B0259830A
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Asthenia
	Cyanosis
	Diabetes Mellitus
	Dyspnoea
	Hyperhidrosis
	Hypoglycaemic Coma
	Oxygen Saturation Decreased
	Pallor

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachypnoea							
			Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 DAY
			Metformin	SS		ORAL		3 YR
			Glimepiride	SS		ORAL		3 YR
			Tramadol	C				
			Bisoprolol	C		ORAL	5MG per day	
			Paracetamol	C	Glaxo Wellcome			
			Meprobamate	C				
			Buflomedil	C				
			Lysine Aspirin	C		ORAL		3 YR
			Lansoprazole	C				
			Frusemide	C	Glaxo Wellcome			
			Ciprofibrate	C				
			Pepsane	C				
			Clorazepate	C				
			Ramipril	C		ORAL	1.25MG Per day	
			Vit B1 B6	C				

Date:02/21/02ISR Number: 3871531-8Report Type:Expedited (15-DaCompany Report #B0260146A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysgeusia		Zyban	PS	Glaxo Wellcome	ORAL	2TAB Twice per day	10 DAY
	Medication Error							
	Sputum Abnormal							

Date:02/21/02ISR Number: 3872709-XReport Type:Direct Company Report #CTU 161965
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Convulsion Grand Mal Convulsion		Wellbutrin Sr Blue Pill	PS		ORAL	1 PILL DAILY ORAL	

Date:02/21/02ISR Number: 3872747-7Report Type:Direct Company Report #CTU 162017
Age:35 YR Gender:Female I/FU:I

Outcome	PT
Other	Agitation Balance Disorder Dizziness Dyspnoea Feeling Hot And Cold Flushing Influenza Insomnia Lower Respiratory Tract Infection Mood Swings Muscle Spasms

	Nausea					
	Paraesthesia					
	Rash Pruritic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Throat Tightness		Wellbutrin Sr 150 Mg			
	Tinnitus		X 2 Day = 300mg	PS		
150MG X 2/DAY						
	Urticaria					
	Vision Blurred					

Date:02/21/02ISR Number: 3873305-0Report Type:Expedited (15-DaCompany Report #B0259331A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anxiety	Foreign	Nicoderm Cq Patch 14			
Initial or Prolonged	Convulsion	Health	Mg (Nicotine)	PS		
TRANSDERMAL	14 MG/PER					
	Loss Of Consciousness	Professional				
DAY/						
	Tongue Biting					
TRANSDERMAL						
	Urinary Incontinence		Zyban Tablet-Zyban (Bupropion Hydrochloride)	SS		ORAL
150 MG/ORAL						

Date:02/22/02ISR Number: 3871912-2Report Type:Expedited (15-DaCompany Report #A0132245A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blindness Transient	Health	Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
Initial or Prolonged	Convulsion	Professional				
per day	1 MON					
	Deafness		Zyban	SS	Glaxo Wellcome	ORAL
150MG Twice						
	Dizziness					
per day						
	Hyperglycaemia		Multivitamin	C		
	Hypoglycaemia		Vitamin E	C		
	Nervous System Disorder		Vitamin C	C		

	Tinnitus		Aspirin	C		

Date:02/22/02ISR Number: 3871915-8Report Type:Expedited (15-DaCompany Report #A0359236A
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Optic Nerve Disorder Vision Blurred	Consumer	Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Twice per day 41 DAY
			No Concurrent Medications	C			

Date:02/22/02ISR Number: 3871916-XReport Type:Expedited (15-DaCompany Report #A0359405A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Condition Aggravated Fall Gait Disturbance	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	

Date:02/22/02ISR Number: 3871921-3Report Type:Expedited (15-DaCompany Report #B0124405A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock Angina Pectoris	Health Professional	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day 17 DAY

			Hepatyrix	C	Glaxo Wellcome	INTRAMUSCULAR
			Ciprofloxacin	C		ORAL
			Norethisterone	C		ORAL
350UG Per day						

Date:02/22/02ISR Number: 3871923-7Report Type:Expedited (15-DaCompany Report #B0134062A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Artery Occlusion	Health	Quomem	PS	Glaxo Wellcome	ORAL	150MG As	
	Convulsion	Professional					directed	29 DAY
	Nuclear Magnetic		Diazepam	SS			UNKNOWN	2MG per day
	Resonance Imaging Brain		Alcohol	C				
	Abnormal							
	Photopsia							

Date:02/22/02ISR Number: 3871928-6Report Type:Expedited (15-DaCompany Report #B0259603A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acne	Health	Zyban	PS	Glaxo Wellcome		150MG Per day	6 DAY
	Dysgeusia	Professional						
	Facial Pain							
	Facial Palsy							
	Pain							
	Sleep Disorder							
	Tongue Ulceration							

Date:02/22/02ISR Number: 3871929-8Report Type:Expedited (15-DaCompany Report #B0259722A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Hallucination, Auditory	Consumer	Zyban	PS	Glaxo Wellcome	ORAL
300MG Unknown 10 DAY						
	Suicidal Ideation		Paracetamol	C	Glaxo Wellcome	ORAL
1000MG As						
required						

Date:02/22/02ISR Number: 3871931-6Report Type:Expedited (15-DaCompany Report #B0259958A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypothyroidism		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 73 DAY						
	Oedema		Salbutamol	C	Glaxo Wellcome	
RESPIRATORY						
	Weight Increased					
(INHALATION)						

Date:02/22/02ISR Number: 3871932-8Report Type:Expedited (15-DaCompany Report #B0260109A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Urticaria		Zyban	PS	Glaxo Wellcome	ORAL
150MG Unknown 2 WK						
	Wheezing					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/02ISR Number: 3871933-XReport Type:Expedited (15-DaCompany Report #B0260117A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Panic Attack		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown
	Rash							

Date:02/22/02ISR Number: 3871934-1Report Type:Expedited (15-DaCompany Report #B0260178A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Auditory		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown 22 DAY

Date:02/22/02ISR Number: 3875272-2Report Type:Expedited (15-DaCompany Report #200211202GDDC
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Indapamide					
		Health	(Dapa-Tabs) Tablets	PS		ORAL	2.5 MG PO	1 YR
		Professional	Amfebutamone					
		Other	Hydrochloride					
			(Zyban)	SS			8	DAY
			Quinapril					
			Hydrochloride					
			(Accupril)	C				
			Acetylsalicylate					
			Calcium (Solprin)	C				

Date:02/22/02ISR Number: 3879462-4Report Type:Periodic Company Report #HQ2442222JUN2001
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Effexor (Venlafaxine					

			Hydrochloride, Unspec)	PS		ORAL	ORAL
			Haldol (Haloperidol,)	SS			
			Remeron (Mirtazapine,)	SS			
			Wellbutrin (Amfebutamone Hydrochloride,)	SS			

Date:02/25/02ISR Number: 3873437-7Report Type:Direct Company Report #CTU 162124
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Zyban (150mg) Tbsr	PS		ORAL	150MG 1T PO QD X 3 D THEN BID	

Date:02/25/02ISR Number: 3874220-9Report Type:Expedited (15-DaCompany Report #B0130905A
Age:47 YR Gender:Male I/FU:I

Outcome	PT
Disability	Ageusia
	Dermatitis Bullous

	Difficulty In Walking					
	Erythema					
	Glossitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Oropharyngeal Swelling	Foreign	Zyban Tablet -			
	Pruritus	Health	Zyban(Bupropion			
	Rash Vesicular	Professional	Hydrochloride)	PS		ORAL
150 MG/ TWICE						
	Skin Exfoliation					
PER DAY/ORAL						
			Ketoprofen	C		

Date:02/25/02ISR Number: 3874230-1Report Type:Expedited (15-DaCompany Report #B0259252A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	C-Reactive Protein	Foreign	Zyban Tablet - Zyban			
Initial or Prolonged	Increased		(Bupropion			
	Cheilitis		Hydrochloride)	PS		ORAL
150 MG/ PER						
	Dermatitis Bullous					
DAY/ ORAL						
	Hypopyon		Propofan			
	Neutrophilia		(Formulation			
	Pyrexia		Unknown) (Propofan)	SS		ORAL
ORAL						
	Rash Erythematous		Prazepam	C		
	Rash Pustular		Zolpidem	C		
			Alprazolam	C		

Date:02/25/02ISR Number: 3874252-0Report Type:Expedited (15-DaCompany Report #B0259334A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dyspnoea	Foreign	Zyban Tablet - Zyban			
	Hyperventilation	Consumer	(Bupropion			
	Muscle Spasms		Hydrochloride)	PS	Zyban	ORAL
150MG / TWICE						
PER DAY /						

ORAL

Date:02/25/02ISR Number: 3874253-2Report Type:Expedited (15-DaCompany Report #B0133422A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Coordination Abnormal Dizziness Hypoaesthesia Malaise Trigeminal Neuralgia Wheezing	Foreign Health Professional	Zyban Tablet - Zyban (Buproprion Hydrochloride) Oral Contraceptive	PS C	Zyban	ORAL	150 MG / PER DAY / ORAL	

Date:02/25/02ISR Number: 3874313-6Report Type:Expedited (15-DaCompany Report #B0129422A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastric Haemorrhage Haematocrit Decreased Irritability Malaise Mood Altered	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			150 MG	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/02ISR Number: 3873670-4Report Type:Expedited (15-DaCompany Report #A0167897A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Treatment Noncompliance							

Date:02/26/02ISR Number: 3873675-3Report Type:Expedited (15-DaCompany Report #A0359984A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:02/26/02ISR Number: 3873687-XReport Type:Expedited (15-DaCompany Report #D0037982A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deafness Neurosensory		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Intentional Misuse							
	Suicide Attempt							
Other	Tinnitus							
	Vestibular Disorder							

Date:02/26/02ISR Number: 3873688-1Report Type:Expedited (15-DaCompany Report #D0038006A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Cardiac Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown

Date:02/27/02ISR Number: 3874199-XReport Type:Expedited (15-DaCompany Report #A0359318A
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	9 MON
Hospitalization - Initial or Prolonged	Medication Error Overdose						

Date:02/27/02ISR Number: 3876517-5Report Type:Expedited (15-DaCompany Report #EMADSS2002001073
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Arrest Cerebral Ischaemia Overdose	Foreign Health Professional	Zydol (Tablet) (Tramadol Hydrochloride)	PS		ORAL	1.3 G, 1IN 1
Disability	Status Epilepticus						TIME (S), Required
Intervention to Prevent Permanent Impairment/Damage			Zyban (Amfebutamone Hydrochloride)	SS		ORAL	9 G, 1IN 1 TIME (S),

ORAL

Date:02/28/02ISR Number: 3875251-5Report Type:Expedited (15-DaCompany Report #A0174691A
Age:8 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Level Above	Health	Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	450MG per day	19 MON
Hospitalization - Initial or Prolonged	Therapeutic	Professional	Depakote	C		ORAL	1000MG Twice per day	
	Drug Level Increased							
Other	Grand Mal Convulsion		Celexa	C		ORAL	10MG Per day	6 MON
	Infection		Risperdal	C		ORAL	2MG Twice per day	
	Personality Change							
	Pyrexia							
	Respiratory Arrest							
	Status Epilepticus							

Date:02/28/02ISR Number: 3875252-7Report Type:Expedited (15-DaCompany Report #A0175021A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	86 DAY
		Professional						
			Effexor	C				

Date:02/28/02ISR Number: 3875254-0Report Type:Expedited (15-DaCompany Report #A0175712A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complex Partial Seizures	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Unknown	
	Convulsion	Professional	Fastin	SS	Glaxo Wellcome		30MG Per day	
	Drug Interaction		Vistaril	C			50MG Twice	

per day

	Ambien	C		
10MG At night				
	Talwin	C		
	Imitrex	C	Glaxo Wellcome	
	Phenergan	C	Glaxo Wellcome	
	Prozac	C		ORAL

Date:02/28/02ISR Number: 3875256-4Report Type:Expedited (15-DaCompany Report #A0360169A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Overdose	Health Professional	Wellbutrin	PS	Glaxo Wellcome	ORAL

Date:02/28/02ISR Number: 3875258-8Report Type:Expedited (15-DaCompany Report #B0126006A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction	Health Professional	Zyban	PS	Glaxo Wellcome	

Date:02/28/02ISR Number: 3875264-3Report Type:Expedited (15-DaCompany Report #B0260668A
Age:31 YR Gender:Female I/FU:I

Outcome	PT
Other	Drug Interaction
	Headache
	Ill-Defined Disorder

	Malaise						
	Nausea						
	Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyntabac	PS	Glaxo Wellcome	ORAL	300MG Per day 9 DAY
			Flu Medication	SS		ORAL	4 DAY
			Ethinyloestradiol	SS		ORAL	

Date:02/28/02ISR Number: 3875265-5Report Type:Expedited (15-DaCompany Report #D0038028A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Fear	Health	Zyban	PS	Glaxo Wellcome	ORAL	7.5G per day 1 DAY
Other	Intentional Misuse	Professional					
	Suicide Attempt						
	Tachycardia						
	Tremor						
	Visual Disturbance						
	Vomiting						

Date:02/28/02ISR Number: 3877113-6Report Type:Direct Company Report #CTU 162543
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abdominal Pain		Zyban 1 A Day	PS		ORAL	1 A DAY PO
	Alanine Aminotransferase Increased		Prednisone	C			
			Solumedrol	C			
	Arthralgia		Hydroxyzine	C			
	Aspartate Aminotransferase Increased						
	Red Blood Cell Sedimentation Rate Increased						
	Subarachnoid Haemorrhage						
	Urticaria						

Date:02/28/02ISR Number: 3877332-9Report Type:Expedited (15-DaCompany Report #B0259427A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Aspiration Blood Pressure Increased Clonic Convulsion Coma Convulsion Disorientation Dystonia Extrapyramidal Disorder Hyperreflexia Hypertonia Hypotension Overdose Tachycardia Tremor	Foreign Literature Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Ethanol	PS C		ORAL	150 MG / ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/02ISR Number: 3875966-9Report Type:Expedited (15-DaCompany Report #A0360184A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coma		Zyban	PS	Glaxo Wellcome	ORAL	
Hospitalization - Initial or Prolonged	Convulsion						

Date:03/01/02ISR Number: 3875973-6Report Type:Expedited (15-DaCompany Report #B0259906A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 2 DAY
	Fall		Atacand	C		ORAL	1%DS Per day
	Malaise						
	Meningioma						

Date:03/01/02ISR Number: 3875974-8Report Type:Expedited (15-DaCompany Report #B0260007A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Bronchospasm		Zyban	PS	Glaxo Wellcome	ORAL	
	Pharyngolaryngeal Pain						
	Respiratory Disorder						

Date:03/01/02ISR Number: 3875977-3Report Type:Expedited (15-DaCompany Report #B0260166A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Delirium		Zyban	PS	Glaxo Wellcome	ORAL	
	Loss Of Consciousness		Illicit Drug(S)	C			RESPIRATORY
	Medication Error						(INHALATION)
	Memory Impairment						

Date:03/01/02ISR Number: 3878242-3Report Type:Direct Company Report #CTU 162612
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Wellbutrin (Generic					
Other	Diarrhoea		Form)	PS			75 MG	BID
	Pharmaceutical Product Complaint							

Date:03/01/02ISR Number: 3878249-6Report Type:Direct Company Report #CTU 162615
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Zyban (150 Mg) Tbsr	PS	150 Mg 1 Tab Qd X 3 Then Bid			
			Nicorette	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/02ISR Number: 3878807-9Report Type:Expedited (15-DaCompany Report #A204048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Anxiety	Health Professional Company Representative	Zoloft Tablets	PS		ORAL	50.00 MG TOTAL:DAILY:ORAL	
	Depression							
	Diabetes Mellitus							
	Drug Effect Decreased		Wellbutrin	SS		ORAL	300.00 MG TOTAL:BID:ORAL	
	Fatigue							
	Fear							
	Gait Disturbance		Zyprexa	SS		ORAL	10.00 TOTAL:DAILY:ORAL	
	Hallucination, Visual							
	Hemianopia							
	Insomnia							

Date:03/05/02ISR Number: 3877376-7Report Type:Expedited (15-DaCompany Report #A0171269A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pneumonitis	Health Professional	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	3 YR
	Pulmonary Fibrosis		Celexa	C		UNKNOWN	20MG Per day	

Date:03/05/02ISR Number: 3877379-2Report Type:Expedited (15-DaCompany Report #A0359960A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 2 WK	Coronary Artery Disease		Zyban	PS	Glaxo Wellcome	ORAL
Initial or Prolonged	Disorientation		No Concurrent Medication	C		
	Dyspnoea					
	Hallucination, Visual					
	Nervousness					

Date:03/05/02ISR Number: 3877383-4Report Type:Expedited (15-DaCompany Report #A0360114A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL
4500MG						
	Confusional State					
Unknown						
	Convulsion					
	Heart Rate Decreased					
	Overdose					
	Somnolence					
	Tachycardia					

Date:03/05/02ISR Number: 3877384-6Report Type:Expedited (15-DaCompany Report #A0360115A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Consumer	Bupropion	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Drug Interaction					
per day						
	Drug Level Increased		Surmontil	SS		ORAL
100MG Per day						
	Loss Of Consciousness		Electroconvulsive Therapy	C		
			Liothyronine	C	Glaxo Wellcome	ORAL
25MG Per day						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/02ISR Number: 3877388-3Report Type:Expedited (15-DaCompany Report #A0360367A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Disorder	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Pain	Professional	Ssri	C				
	Swelling							

Date:03/05/02ISR Number: 3877412-8Report Type:Expedited (15-DaCompany Report #B0134019A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Mouth Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	150MG As	
	Overdose						directed	
			Fluoxetine	SS		ORAL	20MG Per day	
			Olanzapine	SS		ORAL	7.5MG Twice	
							per day	
			Aceprometazine + Meprobamate	SS		ORAL	1UNIT per day	
			Anethole	SS		ORAL	6UNIT per day	
			Zolpidem	SS		ORAL	1UNIT per day	
			Loxapine	SS		ORAL	50MG Per day	
			Cyamemazine	C		ORAL	25MG Three	
							times per day	
			Pristinamycin	C		ORAL		

Date:03/05/02ISR Number: 3877415-3Report Type:Expedited (15-DaCompany Report #B0259607A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Erythema		Zyban	PS	Glaxo Wellcome			
UNKNOWN							150MG Per day	39 DAY
	Hypersensitivity		Fluvastatin	C		ORAL	80MG Per day	
	Infarction		Nateglinide	C		ORAL	120MG Per day	
	Malaise							

Date:03/05/02ISR Number: 3877417-7Report Type:Expedited (15-DaCompany Report #B0260160A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome	ORAL	1UD Per day	
Initial or Prolonged	Confusional State		Ciblor	SS	Glaxo Wellcome	ORAL	2UD Unknown	
	Disorientation		Aspegic	SS		ORAL	1G Three	
	Headache						times per day	
	Muscular Weakness		Solupred	SS		ORAL	1UD Twice per	
	Musculoskeletal Stiffness						day	
	Nausea		Exomuc	SS	Glaxo Wellcome	ORAL	1UD Three	
	Photophobia						times per day	

Date:03/05/02ISR Number: 3877418-9Report Type:Expedited (15-DaCompany Report #B0260324A
Age:49 YR Gender:Male I/FU:I

Outcome	PT
Death	Brain Oedema
Hospitalization -	C-Reactive Protein
Initial or Prolonged	Increased
	Cardiac Arrest
	Cardio-Respiratory Arrest
	Cyanosis

	Fall						
	Hepatic Failure						
	Injury	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Laryngeal Oedema		Zyban	PS	Glaxo Wellcome	ORAL	75MG per day
	Leukocytosis		Kardegic	SS		ORAL	2TAB per day 1 DAY
	Malaise		Surgam	SS		ORAL	1 DAY
	Mydriasis		Rulid	SS	Glaxo Wellcome	ORAL	UNKNOWN
	Pyrexia		Elisor	C			
	Renal Failure		Discotrine	C	Glaxo Wellcome	ORAL	UNKNOWN
	Renal Impairment		Sectral	C			
	Syncope		Artotec	C		ORAL	
	Ventricular Fibrillation						

Date:03/05/02ISR Number: 3877421-9Report Type:Expedited (15-DaCompany Report #B0260698A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Quomem	PS	Glaxo Wellcome		UNKNOWN 7 DAY
Initial or Prolonged	Body Temperature		Levothyroxine	SS	Glaxo Wellcome		UNKNOWN 150MG per day
Disability	Decreased						
Other	Bowel Sounds Abnormal						
	Cardiac Murmur						
	Chest Pain						
	Chills						
	Diarrhoea						
	Echocardiogram Abnormal						
	Electrocardiogram St Segment Depression						
	Fungal Infection						
	Insomnia						
	Malaise						
	Palpitations						
	Pco2 Decreased						
	Red Blood Cells Urine						
	Respiratory Rate Increased						

	Thirst
	Vomiting

Date:03/05/02ISR Number: 3877426-8Report Type:Expedited (15-DaCompany Report #B0260870A
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown 6 DAY
Disability	Congestive		Salmeterol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		
Other	Chest Pain							
	Dyspnoea Exacerbated		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)		

Date:03/05/02ISR Number: 3879324-2Report Type:Expedited (15-DaCompany Report #A204303
Age: Gender:Male I/FU:I

Outcome	PT
Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased
	Burns Third Degree
	Euphoric Mood
	Nausea
	Pruritus

		Skin Disorder Somnolence Urine Analysis Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Increased	Consumer	Zoloft Tablets	PS		ORAL
100.00 MG							
TOTAL DAILY							
ORAL							
				Benadryl (Diphenhydramine)	SS		
TOPICAL	TOPICAL						
				Wellbutrin (Bupropion)	SS		ORAL
ORAL							
				Oxycodone	SS		ORAL
ORAL							
				Acetaminophen/Diphenhydramine	C		
				Darvon (Propoxyphene)	C		
				Vitamin C (Ascorbic Acid)	C		

Date:03/05/02ISR Number: 3879326-6Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Anger	Consumer	Zoloft Tablets	PS		
50.00 MG						
Intervention to	Autoimmune Thyroiditis					
TOTAL DAILY						
Prevent Permanent	Balance Disorder		Wellbutrin	SS		ORAL
300.00 MG						
Impairment/Damage	Blood Oestrogen Decreased					
TOTAL BID						
	Cerebral Haemorrhage					
ORAL						
	Cerebrovascular Accident		Coumadin	SS		
	Contusion		Effexor Sr	SS		ORAL
300.00 MG						
	Convulsion					
TOTAL BID						

	Drug Ineffective		
ORAL			
	Epistaxis	Toprol	C
	Fall	Zebeta	C
	Head Injury	Lanoxin	C
	Heart Rate Decreased	Lasix	C
	Heart Rate Increased	Synthroid	C
	Hostility	Vitamin E	C
	Hyperhidrosis	Estrogen	C
	Illogical Thinking	Amantadine	C
	Laceration	Zocor	C
	Medication Error	Estradiol Vaginal	
	Meningioma	Ring	C
	Nuclear Magnetic		
	Resonance Imaging Brain		
	Abnormal		
	Palpitations		
	Parkinsonism		
	Prothrombin Time		
	Prolonged		
	Syncope		
	Vaginal Haemorrhage		

Date:03/05/02ISR Number: 3880013-9Report Type:Expedited (15-DaCompany Report #A203837
Age:24 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Dysphonia
	Face Oedema
	Laryngeal Disorder

	Oedema Peripheral Urticaria					
		Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Foreign	Zyrtec Tablets	PS		
		Health	Hydroxyzine	SS		ORAL
25.00 MG						
		Professional				
TOTAL:DAILY:O						
RAL						
			Prazepam	SS		
			Zyban	SS		ORAL
150.00 MG						
TOTAL:						
DAILY:ORAL						
			.....	C		

Date:03/07/02ISR Number: 3879227-3Report Type:Expedited (15-DaCompany Report #A0360688A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Congenital Anomaly	Dacryostenosis Congenital		Wellbutrin	PS	Glaxo Wellcome	ORAL
	Drug Exposure Via Breast Milk		Vitamins	C		ORAL
	Lethargy					
	Maternal Drugs Affecting Foetus					
	Neonatal Disorder					

Date:03/07/02ISR Number: 3879242-XReport Type:Expedited (15-DaCompany Report #B0261298A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Conversion Disorder		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 5 DAY						
Initial or Prolonged	Dyspnoea		Sertraline	C		ORAL
100MG Per day						
			Nitrazepam	C		ORAL

		Propranolol	C	Glaxo Wellcome	ORAL
		Ethinyloestradiol + Levonorgestrel	C		ORAL

Date:03/07/02ISR Number: 3880501-5Report Type:Direct Company Report #CTU 163005
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tinnitus		Wellbutrin Sr	PS		ORAL	150 MG BID PO	

Date:03/07/02ISR Number: 3881197-9Report Type:Expedited (15-DaCompany Report #A0359597A
Age:14 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Aggression
	Agitation
	Confusional State
	Coordination Abnormal
	Difficulty In Walking
	Disorientation
	Dysarthria
	Grand Mal Convulsion
	Hallucination, Visual
	Intentional Misuse
	Nervous System Disorder

		Neurological Examination Abnormal Somnolence Suicide Attempt Tachycardia Toxicologic Test Abnormal Vomiting	Report Source Literature Health Professional	Product Wellbutrin Unspecified Tablet (Bupropion Hydrochloride) Cannabis	Role PS C	Manufacturer	Route ORAL
Dose SEE DOSAGE TEXT/ORAL	Duration						

Date:03/07/02ISR Number: 3881362-0Report Type:Expedited (15-DaCompany Report #A0359376A
Age:16 YR Gender:Female I/FU:I

Outcome Hospitalization - Initial or Prolonged	PT Aggression Agitation Cardiotoxicity Conduction Disorder Dysarthria Electrocardiogram Qt Prolonged Grand Mal Convulsion Neurotoxicity Overdose Sinus Tachycardia Ventricular Tachycardia	Report Source Literature Health Professional	Product Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Cannabis	Role PS C	Manufacturer	Route ORAL	
Dose 1500 MG/ SEE DOSAGE TEXT/ORAL	Duration						

Date:03/08/02ISR Number: 3879868-3Report Type:Expedited (15-DaCompany Report #B0114598A
Age:56 YR Gender:Male I/FU:F

Outcome Life-Threatening Hospitalization - Initial or Prolonged Other	PT Abdominal Pain Aggression Alcohol Poisoning Amnesia Anaphylactic Shock						

Angioneurotic Oedema
Balance Disorder
Blister
Blood Bilirubin Increased
Blood Pressure Increased
Chest Pain
Circulatory Collapse
Confusional State
Convulsion
Diarrhoea
Disorientation
Disturbance In Attention
Dizziness
Dry Skin
Dysphagia
Dyspnoea
Feeling Hot
Flatulence
Gastroenteritis
Irritability
Loss Of Consciousness
Malaise
Nausea

	Ocular Hyperaemia						
	Oedema Peripheral						
	Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pruritus	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
	Rash Erythematous	Professional					per day 62 DAY
	Rhinitis						
	Sensation Of Foreign Body						
	Speech Disorder						
	Tinnitus						
	Urticaria						

Date:03/08/02ISR Number: 3879875-0Report Type:Expedited (15-DaCompany Report #B0260318A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Unstable		Zyban	PS	Glaxo Wellcome	ORAL	3 DAY
Initial or Prolonged	Anxiety						
	Chest Pain						
	Diabetes Mellitus						
	Rash Erythematous						
	Rash Pruritic						

Date:03/11/02ISR Number: 3880684-7Report Type:Expedited (15-DaCompany Report #A0159874A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
Initial or Prolonged	Arthropathy						per day 27 DAY
	Blister						
	Difficulty In Walking						
	Drug Hypersensitivity						
	Dry Mouth						
	Insomnia						
	Malaise						
	Muscle Spasms						

	Oedema Peripheral						
	Pain						
	Pain In Extremity						
	Pyrexia						
	Serum Sickness						
	Urticaria						

Date:03/11/02ISR Number: 3880685-9Report Type:Expedited (15-DaCompany Report #A0360876A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG	Per day
	Maternal Drugs Affecting		Depakote	C			UNKNOWN	
	Foetus		Prozac	C		ORAL		

Date:03/11/02ISR Number: 3880692-6Report Type:Expedited (15-DaCompany Report #B0261434A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown
Initial or Prolonged	Dyspnoea							
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/02ISR Number: 3880693-8Report Type:Expedited (15-DaCompany Report #B0261457A
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Volvulus Of Bowel		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 43 DAY
Initial or Prolonged			Co-Proxamol	C		ORAL	
			Vitamin D + Calcium	C		ORAL	

Date:03/11/02ISR Number: 3880695-1Report Type:Expedited (15-DaCompany Report #D0038006A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Sudden Cardiac Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown

Date:03/12/02ISR Number: 3882670-XReport Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Anger	Consumer	Zoloft Tablets	PS			50.00 MG
Intervention to	Autoimmune Thyroiditis						TOTAL:DAILY
Prevent Permanent	Balance Disorder		Wellbutrin	SS		ORAL	300.00 MG
Impairment/Damage	Blood Oestrogen Decreased						TOTAL:BID:ORA
	Blood Pressure Increased						L
	Blood Thyroid Stimulating		Coumadin	SS			
	Hormone Decreased		Effexor Sr	SS		ORAL	300.00 MG
	Contusion						TOTAL:BID:ORA
	Convulsion						L
	Drug Ineffective		Toprol	C			
	Epistaxis		Zebeta	C			
	Essential Tremor		Lanoxin	C			

Fall	
Haemorrhagic Stroke	
Head Injury	
Headache	
Heart Rate Decreased	
Heart Rate Increased	
Hostility	
Hyperhidrosis	
Laceration	
Nuclear Magnetic Resonance Imaging Brain Abnormal	
Palpitations	
Parkinson'S Disease	
Prothrombin Time Prolonged	
Syncope	
Thinking Abnormal	
Thyroid Function Test Abnormal	
Transient Ischaemic Attack	
Treatment Noncompliance	
Vaginal Haemorrhage	
Lasix	C
Synthroid	C
Vitamin E	C
Estrogen	C
Amantadine	C
Zocor	C
Estradiol Vaginal Ring	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/13/02ISR Number: 3881848-9Report Type:Expedited (15-DaCompany Report #B0083476A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hemianopia Ventricular Hypertrophy Vision Blurred		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	7 DAY
			Ethinylestradiol + Cyproterone	C		ORAL		

Date:03/13/02ISR Number: 3881849-0Report Type:Expedited (15-DaCompany Report #B0092066A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL	150MG As directed	7 DAY
Hospitalization - Initial or Prolonged	Hyperhidrosis Malignant Hypertension Ventricular Hypertrophy Visual Disturbance		No Concurrent Medication	C				

Date:03/13/02ISR Number: 3881853-2Report Type:Expedited (15-DaCompany Report #B0259427A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	
	Aspiration Blood Pressure Increased Clonic Convulsion Coma Convulsion Disorientation Dystonia Extrapyramidal Disorder Hyperreflexia Hypertonia		Alcohol	C				

Hypotension
Overdose
Tachycardia
Tremor
Ventricular Tachycardia

Date:03/13/02ISR Number: 3881856-8Report Type:Expedited (15-DaCompany Report #B0260146A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysgeusia Medication Error		Zyban	PS	Glaxo Wellcome	ORAL	2TAB Twice per day	10 DAY
Other	Sputum Abnormal							

Date:03/13/02ISR Number: 3881863-5Report Type:Expedited (15-DaCompany Report #B0261713A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	21 DAY

Date:03/13/02ISR Number: 3881864-7Report Type:Expedited (15-DaCompany Report #B0261714A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown WK
	Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							
	Stillbirth							

Date:03/13/02ISR Number: 3881865-9Report Type:Expedited (15-DaCompany Report #B0261801A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Anxiety							
	Myocardial Infarction							

Date:03/14/02ISR Number: 3882514-6Report Type:Expedited (15-DaCompany Report #A0162401A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar Disorder	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	1 WK
	Drug Ineffective	Professional	Topamax	SS			UNKNOWN	
	Psychotic Disorder		Zyprexa	SS			UNKNOWN	
			Klonopin	SS			UNKNOWN	1MG Unknown

Date:03/14/02ISR Number: 3882515-8Report Type:Expedited (15-DaCompany Report #A0172391A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gamma-Glutamyltransferase Increased	Health Professional	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG See dosage text	
	Lipase Increased		Trazodone	SS			UNKNOWN	
	Overdose							

Date:03/14/02ISR Number: 3882517-1Report Type:Expedited (15-DaCompany Report #A0175186A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration	Health Professional	Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG Twice per day	
	Grand Mal Convulsion							
	Stress		Zoloft	C		ORAL		

Date:03/14/02ISR Number: 3882518-3Report Type:Expedited (15-DaCompany Report #A0359318A
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	9	MON
Hospitalization - Initial or Prolonged	Medication Error	Professional						
	Overdose							
	Poisoning							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/02ISR Number: 3882519-5Report Type:Expedited (15-DaCompany Report #A0360364A
Age:12 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Influenza Like Illness		Wellbutrin No Concurrent Medications	PS C	Glaxo Wellcome	ORAL	300MG Per day	6 MON

Date:03/14/02ISR Number: 3882521-3Report Type:Expedited (15-DaCompany Report #A0361722A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Grand Mal Convulsion	Health Professional	Wellbutrin Zoloft	PS SS	Glaxo Wellcome	ORAL	50MG Per day	

Date:03/14/02ISR Number: 3882537-7Report Type:Expedited (15-DaCompany Report #B0262044A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Hallucination Ileus Paralytic Overdose		Zyban Alcohol	PS C	Glaxo Wellcome		UNKNOWN	150MG Unknown

Date:03/14/02ISR Number: 3882539-0Report Type:Expedited (15-DaCompany Report #B0262046A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Dizziness Electrocardiogram Qt Prolonged		Zyban	PS	Glaxo Wellcome		UNKNOWN dosage text	150MG See

Flushing
Grand Mal Convulsion
Hallucination
Heart Rate Increased
Hypothermia
Overdose
Respiratory Rate
Increased
Tachycardia
Vomiting

Date:03/14/02ISR Number: 3882540-7Report Type:Expedited (15-DaCompany Report #B0262054A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose Suicide Attempt		Zyban Paracetamol	PS SS	Glaxo Wellcome Glaxo Wellcome	ORAL	150MG Per day UNKNOWN	10TAB cumulative dose
			Panadeine Forte	SS	Glaxo Wellcome		10TAB	cumulative dose
			Mersyndol Forte	SS			UNKNOWN	10TAB cumulative dose

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/02ISR Number: 3883871-7Report Type:Expedited (15-DaCompany Report #A0361528A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apnoea		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Convulsion		Zofran	SS	Glaxo Wellcome	INTRAVENOUS		
	Depressed Level Of Consciousness		Versed	SS		INTRAVENOUS		
			Fentanyl	SS		INTRAVENOUS		
	Drug Interaction		Toradol	SS		INTRAVENOUS		
	Heart Rate Increased							
	Hyperventilation							

Date:03/18/02ISR Number: 3883872-9Report Type:Expedited (15-DaCompany Report #A0361723A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour		Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG Twice per day	6 MON
	Condition Aggravated							
	Convulsion							

Date:03/18/02ISR Number: 3883873-0Report Type:Expedited (15-DaCompany Report #A0361761A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	5 DAY
	Bipolar Disorder							
	Convulsion		Inhalers	C		RESPIRATORY (INHALATION)		
	Loss Of Consciousness							
			Imipramine	C		ORAL		
			Lodine	C		ORAL		

Vicodin Es	C	ORAL
Unspecified Medication	C	ORAL

Date:03/19/02ISR Number: 3885899-XReport Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Required	Anger
Intervention to	Balance Disorder
Prevent Permanent	Blood Oestrogen Decreased
Impairment/Damage	Blood Pressure Increased
	Blood Thyroid Stimulating Hormone Decreased
	Cerebral Haemorrhage
	Cerebrovascular Accident
	Contusion
	Convulsion
	Drug Ineffective
	Epistaxis
	Fall
	Head Injury
	Headache
	Heart Rate Decreased
	Heart Rate Increased
	Hostility
	Hyperhidrosis
	Illogical Thinking
	Laceration

	Meningioma Nuclear Magnetic Resonance Imaging Brain	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Abnormal	Consumer	Zoloft Tablets	PS		 50.00 MG
	Overdose					 TOTAL:DAILY
	Palpitations		Wellbutrin	SS		ORAL 300.00 MG
	Parkinsonism					 TOTAL:BID:ORA
	Prothrombin Time L					
	Prolonged		Coumadin	SS		
	Syncope		Effexor Sr	SS		ORAL 300.00 MG
	Treatment Noncompliance					 TOTAL:BID:ORA
	Tremor L					
	Vaginal Haemorrhage		Toprol	C		
			Zebeta	C		
			Lanoxin	C		
			Lasix	C		
			Synthroid	C		
			Vitamin E	C		
			Estrogen	C		
			Amantadine	C		
			Zocor	C		
			Estradiol Vaginal Ring	C		

Date:03/19/02ISR Number: 3886238-0Report Type:Direct Company Report #CTU 163739
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Urticaria		Zyban	PS		ORAL 2 DAY ORAL

Date:03/20/02ISR Number: 3885010-5Report Type:Expedited (15-DaCompany Report #B0262696A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Dependence		Quomem	PS	Glaxo Wellcome	ORAL	150MG Twice per day	7 DAY
	Insomnia							
	Muscle Spasms		Loratadine + Pseudoephedrine	C			UNKNOWN	1TAB Twice per day
	Syncope							
			Unspecified Nasal Spray	C		NASAL		

Date:03/20/02ISR Number: 3885013-0Report Type:Expedited (15-DaCompany Report #D0037982A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deafness		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Intentional Misuse							
	Suicide Attempt							
Other	Therapeutic Agent Toxicity							
	Tinnitus							
	Vestibular Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/20/02ISR Number: 3885680-1Report Type:Direct Company Report #CTU 163802
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pruritus Rash Erythematous		Zyban	PS				

Date:03/20/02ISR Number: 3892700-7Report Type:Direct Company Report #CTU 164583
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Myalgia		Zyban	PS			150MG BID	

Date:03/21/02ISR Number: 3885584-4Report Type:Expedited (15-DaCompany Report #B0262336A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG As directed 42 DAY
	Asthenia							
	Cerebral Haemorrhage		Venlafaxine	SS			UNKNOWN	150MG Per day
	Cerebrovascular Accident		Pantoprazole	C			40MG Variable dose	
	Condition Aggravated							
	Confusional State		Rofecoxib	C			25MG Per day	
	Disturbance In Attention		Temazepam	C			10MG As required	
	Fall							
	Hypertension							
	Malaise							
	Snoring							
	Subdural Haematoma							
	Tremor							

	Weight Decreased						

Date:03/21/02ISR Number: 3885586-8Report Type:Expedited (15-DaCompany Report #B0262560A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ectopic Pregnancy		Zyban	PS	Glaxo Wellcome	ORAL		

Date:03/21/02ISR Number: 3885588-1Report Type:Expedited (15-DaCompany Report #B0262674A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL		
	Aortic Aneurysm Rupture							
	Malaise							
	Nervousness							
	Sudden Death							

Date:03/21/02ISR Number: 3885589-3Report Type:Expedited (15-DaCompany Report #B0262805A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/02ISR Number: 3887372-1Report Type:Expedited (15-DaCompany Report #A204303
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Pressure Increased	Consumer	Zoloft Tablets	PS		ORAL	100.00 MG	
Intervention to	Burns Third Degree	Health					TOTAL:DAILY:O	
Prevent Permanent	Euphoric Mood	Professional					RAL	
Impairment/Damage	Nausea		Benadryl (Diphenhydramine)	SS		TOPICAL	TOPICAL	
	Pruritus							
	Somnolence		Wellbutrin(Bupropion)	SS		ORAL	ORAL	
	Weight Increased							
			Oxycodone	SS		ORAL	ORAL	
			Acetaminophen/Diphen hydramine	C				
			Darvon (Propoxyphene)	C				
			Vitamin C (Ascorbic Acid)	C				

Date:03/21/02ISR Number: 3888014-1Report Type:Direct Company Report #CTU 163962
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin Sr 150 Mg	PS			BID	
	Gait Disturbance		Effexor Xr 150 Mg	SS			ONE DAILY	
			Claritin	C				
			Zyrtec	C				

Date:03/22/02ISR Number: 3886683-3Report Type:Expedited (15-DaCompany Report #A0362556A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Apnoea		Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG Twice
Initial or Prolonged	Coma						per day
	Hypotonia		Elavil	C	Glaxo Wellcome		25MG In the
	Mydriasis						morning

Date:03/22/02ISR Number: 3886691-2Report Type:Expedited (15-DaCompany Report #B0261810A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abnormal Behaviour		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown
Initial or Prolonged	Anxiety		Benzodiazepines	C			
	Condition Aggravated		Nicotine	C	Glaxo Wellcome		
	Confusional State						
	Depression						
	Hallucination, Auditory						
	Head Injury						
	Injury						
	Insomnia						
	Loss Of Consciousness						
	Mental Disorder						
	Paranoia						
	Schizoaffective Disorder						
	Suicide Attempt						
	Thinking Abnormal						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/02ISR Number: 3887103-5Report Type:Expedited (15-DaCompany Report #HQ2442222JUN2001
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Drug Ineffective Murder	Literature	Effexor (Venlafaxine Hydrochloride, Unspec)	PS		ORAL	ORAL	
			Haldol (Haloperidol)	SS				
			Remeron (Mirtazapine)	SS				
			Wellbutrin (Amfebutamone Hydrochloride)	SS				

Date:03/25/02ISR Number: 3887336-8Report Type:Expedited (15-DaCompany Report #B0262751A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Respiratory Depression		Zyban	PS	Glaxo Wellcome	ORAL		

Date:03/25/02ISR Number: 3888085-2Report Type:Direct Company Report #CTU 164102
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcoholism Grand Mal Convulsion		Clonazepam 1mg Tablet Generic	PS		ORAL	4 DAY ORAL	
	Muscle Twitching		Wellbutrin 150mg Tablet Glaxo Wellcome	SS	Glaxo Wellcome	ORAL	2 DAY ORAL	
			Azmacort	C				
			Serevent	C				
			Albuteral	C				
			Zoloft	C				

Date:03/26/02ISR Number: 3888170-5Report Type:Expedited (15-DaCompany Report #A0363291A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Carbon Monoxide Poisoning		Bupropion	PS	Glaxo Wellcome			
UNKNOWN								

Date:03/26/02ISR Number: 3888171-7Report Type:Expedited (15-DaCompany Report #A0363292A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Bupropion	PS	Glaxo Wellcome			
UNKNOWN								

Date:03/26/02ISR Number: 3889776-XReport Type:Direct Company Report #CTU 164235
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Pruritus		Bupropion	PS				
Intervention to	Rash		Aspirin	C				
Prevent Permanent	Urticaria		Glipizide	C				
Impairment/Damage			Lisinopril	C				
			Metformin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/02ISR Number: 3890887-3Report Type:Expedited (15-DaCompany Report #EMADSS2002001073
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest	Foreign	Zydol (Tablet)					
Hospitalization -	Cerebral Ischaemia	Health	(Tramadol					
Initial or Prolonged	Medication Error	Professional	Hydrochlorde)	PS		ORAL	1.3 G, 1 IN 1	
Disability	Overdose						TIME(S), ORAL	
Required	Status Epilepticus		Zyban (Amfebutamone					
Intervention to			Hydrochloride)	SS		ORAL	9 G, 1 IN 1	
Prevent Permanent							TIMES(S),	
Impairment/Damage							ORAL	

Date:03/28/02ISR Number: 3890150-0Report Type:Expedited (15-DaCompany Report #A0363470A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Interaction		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Anaphylactic Reaction		Ethanol	SS				
			Ortho Tri-Cyclen	C				
			Neoral	C				

Date:03/28/02ISR Number: 3890167-6Report Type:Expedited (15-DaCompany Report #B0262849A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Zyntabac	PS	Glaxo Wellcome			
UNKNOWN	Exanthem						150MG As	
directed	Headache							21 DAY
	Insomnia							
	Nasopharyngeal Disorder							
	Nervousness							

Date:03/28/02ISR Number: 3891873-XReport Type:Expedited (15-DaCompany Report #B0262338A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Haematuria	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / DAY / ORAL	

Date:03/28/02ISR Number: 3891892-3Report Type:Expedited (15-DaCompany Report #B0262209A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Convulsion	Foreign Literature	Zyban (Bupropion Hydrochloride)	PS			UNKNOWN	150 MG/ SEE DOSAGE TEXT/UNKNOWN
	Drug Toxicity	Health Professional						
	Loss Of Consciousness							
	Overdose Respiratory Depression Tachycardia		Ethanol (Formulation Unknown) (Alcohol)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3892047-9Report Type:Expedited (15-DaCompany Report #B0122442A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Cheilitis Dermatitis Bullous Leukocytosis	Foreign Health Professional	Zyban Tablet -(Bupropion Hydrochloride)	PS		ORAL	150 MG / UNK / ORAL
	Oral Soft Tissue Disorder Pyrexia Rash Rash Pustular Skin Lesion		Propofan (Formulation Unknown) (Propofan)	SS		ORAL	ORAL
			Prazepam (Formulation Unknown) (Prazepam)	SS			UNKNOWN
			Zolpidem (Formulation Unknown) (Zolpidem)	SS			UNKNOWN
			Alprazolam (Formulation Unknown)	SS		ORAL	ORAL

Date:03/28/02ISR Number: 3892048-0Report Type:Expedited (15-DaCompany Report #B0262369A
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Choreoathetosis	Foreign	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG, ORAL
			Naproxen	C			
			Atorvastatin Calcium	C			
			Clopidogrel	C			

Date:03/28/02ISR Number: 3892071-6Report Type:Expedited (15-DaCompany Report #B0262088A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Condition Aggravated Impaired Driving Ability Nystagmus Tremor	Foreign Health Professional	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL	

Date:03/28/02ISR Number: 3892073-XReport Type:Expedited (15-DaCompany Report #B0262087A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia Lymphocyte Count Increased Pain Paralysis Pruritus Generalised Rash Generalised	Foreign Health Professional	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ AS DIRECTED / ORAL	

Date:03/28/02ISR Number: 3892074-1Report Type:Expedited (15-DaCompany Report #B0261810A
Age:32 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Behaviour Aggression

	Anxiety					
	Confusional State					
	Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Emotional Distress	Foreign	Zyban (Bupropion			
	Energy Increased	Consumer	Hydrochloride)	PS		ORAL
150 MG / ORAL						
	Hallucination, Auditory		Benzodiazepines	C		
	Head Injury		Nicotine	C		
	Injury					
	Insomnia					
	Loss Of Consciousness					
	Mental Disorder					
	Paranoia					
	Speech Disorder					
	Suicide Attempt					
	Tendon Injury					
	Toxicologic Test Abnormal					

Date:03/28/02ISR Number: 3892075-3Report Type:Expedited (15-DaCompany Report #B0261797A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Diplopia	Foreign	Zyban (Bupropion			
Initial or Prolonged	Drug Ineffective		Hydrochloride)	PS		ORAL
150 MG /						
	Grand Mal Convulsion					
TWICE PER DAY						
	Status Epilepticus					
/ ORAL						
			Multivitamin	C		

Date:03/28/02ISR Number: 3892077-7Report Type:Expedited (15-DaCompany Report #B0261782A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Suicide Attempt	Foreign	Zyban (Bupropion			
			Hydrochloride)	PS		ORAL
150 MG / PER						
DAY/ ORAL						

Date:03/28/02ISR Number: 3892085-6Report Type:Expedited (15-DaCompany Report #B0262370A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alcohol Problem Anxiety Decreased Activity Stress	Foreign	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / ORAL	

Date:03/28/02ISR Number: 3892125-4Report Type:Expedited (15-DaCompany Report #B0262329A
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation Anxiety Arthralgia Constipation Disturbance In Attention Dizziness Dry Mouth Dysgeusia Dyspnoea

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Fatigue Flushing	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Headache	Foreign Consumer	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / ORAL	
	Hostility Insomnia Irritability Mood Altered Nausea Oedema Mouth Pyrexia Tinnitus Tremor Urticaria Visual Acuity Reduced Wheezing							

Date:03/28/02ISR Number: 3892126-6Report Type:Expedited (15-DaCompany Report #B0262184A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse Somnolence Suicide Attempt	Foreign Health Professional	Zyban (Bupropion Hydrochloride)	PS		ORAL	3000 MG SINGLE DOSE ORAL	
			Benzodiazepines (Formulation Unknown) (Benzodiazepines)	SS		ORAL	SINGLE DOSE ORAL	

Date:03/29/02ISR Number: 3891154-4Report Type:Expedited (15-DaCompany Report #A0170371A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Chills Convulsion Mental Disorder Pyrexia Speech Disorder Weight Decreased		Zyban Varivax	PS SS	Glaxo Wellcome Glaxo Wellcome	ORAL	150MG Per day	

Date:03/29/02ISR Number: 3891160-XReport Type:Expedited (15-DaCompany Report #A0363028A
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis Rash Red Blood Cell Sedimentation Rate Increased		Wellbutrin	PS	Glaxo Wellcome	ORAL	1	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/02ISR Number: 3891164-7Report Type:Expedited (15-DaCompany Report #A0364009A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lung Neoplasm Malignant		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Therapeutic Response						per day	61 DAY
	Unexpected							

Date:03/29/02ISR Number: 3891165-9Report Type:Expedited (15-DaCompany Report #B0259229A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Above	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG As	
	Therapeutic	Professional					directed	
	Overdose		Alcohol	C				
	Toxicologic Test Abnormal		Salicylate	C				

Date:03/29/02ISR Number: 3891167-2Report Type:Expedited (15-DaCompany Report #B0259698A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	5 DAY
	Amnesia	Professional	Bromazepam	SS		ORAL	6MG Unknown	
	Confusional State		Alcohol	SS				
	Disturbance In Attention							
	Dizziness							
	Excitability							
	Loss Of Consciousness							
	Malaise							
	Road Traffic Accident							
	Sleep Attacks							

Date:03/29/02ISR Number: 3891172-6Report Type:Expedited (15-DaCompany Report #B0263091A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Zyban	PS	Glaxo Wellcome	ORAL	15	DAY
Initial or Prolonged	Intentional Misuse	Professional	Trizivir	SS	Glaxo Wellcome	ORAL		
	Somnolence		Myolastan	SS		ORAL	500MG per day	
	Suicide Attempt							

Date:03/29/02ISR Number: 3891173-8Report Type:Expedited (15-DaCompany Report #B0263361A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Depression		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Unknown
Other	Suicidal Ideation		No Concurrent Medications	C				

Date:03/29/02ISR Number: 3891178-7Report Type:Expedited (15-DaCompany Report #D0038006A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Cardiac Death	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/02ISR Number: 3891179-9Report Type:Expedited (15-DaCompany Report #D0038185A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown WK
	Haemorrhagic Stroke							
	Myocardial Infarction							
	Renal Embolism							

Date:03/30/02ISR Number: 3892695-6Report Type:Direct Company Report #CTU 164579
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Bupropion (Wellbutrin)	PS		ORAL	150MG PO BID	

Date:03/30/02ISR Number: 3892696-8Report Type:Direct Company Report #CTU 164580
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria		Bupoprion (Zyban)	PS		ORAL	150MG PO BID	
			Celexa	C				

Date:03/30/02ISR Number: 3892713-5Report Type:Direct Company Report #CTU 164588
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angle Closure Glaucoma		Zyban	PS				
Other Required Intervention to Prevent Permanent Impairment/Damage	Cataract							

Date:04/01/02ISR Number: 3892060-1Report Type:Expedited (15-DaCompany Report #B0095597A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Hemiplegia							
per day							5	DAY
Initial or Prolonged								

Date:04/01/02ISR Number: 3892063-7Report Type:Expedited (15-DaCompany Report #B0263173A
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Areflexia
Initial or Prolonged	Arterial Disorder
	Blood Pressure
	Fluctuation
	Cerebral Perfusion
	Pressure Decreased
	Dysphasia
	Electroencephalogram
	Abnormal
	Hemiparesis
	Hemiplegia

	Nervous System Disorder						
	Single Photon Emission Computerised Tomogram	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abnormal		Zyban	PS	Glaxo Wellcome		UNKNOWN 150MG Twice per day 5 DAY
	Ultrasound Scan Abnormal						

Date:04/01/02ISR Number: 3892773-1Report Type:Direct Company Report #CTU 164682
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion		Zyban, Glaxowellcome	PS	Glaxowellcome		150 MG BID, 047
			Nicotine Patch	C			

Date:04/02/02ISR Number: 3892792-5Report Type:Expedited (15-DaCompany Report #A0135919A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Burning Sensation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day 12 DAY
	Dysgeusia						
	Dyskinesia		Amitriptyline	C			UNKNOWN 200MG Per day
	Hypoaesthesia		Unknown Medication	C			
	Insomnia						
	Muscle Strain						
	Neuralgia						
	Neuropathy Peripheral						
	Oral Pain						
	Pain						
	Panic Attack						
	Paraesthesia						
	Rash						

Date:04/02/02ISR Number: 3892796-2Report Type:Expedited (15-DaCompany Report #A0359984A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Increased		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Overdose							

Date:04/02/02ISR Number: 3892799-8Report Type:Expedited (15-DaCompany Report #A0363247A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	5 DAY
	Cyanosis		Plavix	C				
	Depression		Altace	C				
	Grand Mal Convulsion		Prozac	C				
	Pneumonia		Flexeril	C				
			Lipitor	C				
			Toprol Xl	C				
			Advair	C	Glaxo Wellcome			
			Albuterol	C	Glaxo Wellcome			
			Duragesic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/02ISR Number: 3892801-3Report Type:Expedited (15-DaCompany Report #A0363417A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Wellbutrin	PS	Glaxo Wellcome	ORAL	200MG Twice	
Initial or Prolonged	Chest Pain						per day	MON
	Gallbladder Disorder		Topamax	SS				
	Liver Function Test Abnormal		Lipitor	C				

Date:04/02/02ISR Number: 3893886-0Report Type:Direct Company Report #CTU 164757
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Wellbutrin Sr 150 Mg					
	Gastroenteritis Viral		Glaxo	PS	Glaxo	ORAL	1 PILL 3	
	Nausea						TIMES ORAL	
	Pharmaceutical Product Complaint							

Date:04/02/02ISR Number: 3894237-8Report Type:Direct Company Report #CTU 164810
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Zyban 150mg					
			Glaxo-Wellcome	PS	Glaxo-Wellcome	ORAL	150MG BID	
							ORAL	
			Nicoderm	C				

Date:04/03/02ISR Number: 3894510-3Report Type:Expedited (15-DaCompany Report #A0356146A 2001029370-1
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Female Orgasmic Disorder Libido Decreased	Consumer	Paxil Tablet (Paroxetine Hydrochloride)	PS		ORAL	40 MG/ORAL	
	Pregnancy		Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS				
			Clonazepam	C				

Date:04/03/02ISR Number: 3896444-7Report Type:Direct Company Report #CTU 164881
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Zyban 150mg Tbsr	PS	Tbsr	ORAL	1 PO QD X 3D	
	Lethargy						THEN BID	
	Paraesthesia Sinusitis Tremor		Nicorette 2mg	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/02ISR Number: 3894062-8Report Type:Expedited (15-DaCompany Report #B0262329A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown
	Anxiety							
	Constipation							
	Disturbance In Attention							
	Dizziness							
	Dry Mouth							
	Dysgeusia							
	Dyspepsia							
	Fatigue							
	Flushing							
	Hallucination							
	Headache							
	Hostility							
	Insomnia							
	Irritability							
	Mood Altered							
	Nausea							
	Serum Sickness							
	Tinnitus							
	Tremor							
	Visual Acuity Reduced							

Date:04/04/02ISR Number: 3894068-9Report Type:Expedited (15-DaCompany Report #B0263835A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Discomfort		Zyban	PS	Glaxo Wellcome	ORAL	14	DAY
	Dysphagia							
	Oedema							
	Peak Expiratory Flow Rate Decreased							
	Respiratory Disorder							
	Urticaria Generalised							

Date:04/04/02ISR Number: 3894069-0Report Type:Expedited (15-DaCompany Report #B0264143A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Detachment		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG	Unknown

Date:04/05/02ISR Number: 3894837-5Report Type:Expedited (15-DaCompany Report #A0364473A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG	Per day
	Constipation		Paxil	C	Glaxo Wellcome	ORAL	20MG	Per day 1 YR
	Dyspnoea		Unspecified					
	Haemorrhoids		Medication	C				
	Libido Decreased							
	Night Sweats							
	Tremor							
	Vision Blurred							

Date:04/05/02ISR Number: 3894838-7Report Type:Expedited (15-DaCompany Report #B0111133A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Zyban	PS	Glaxo Wellcome		150MG Single	
Hospitalization -	Lower Respiratory Tract							
dose							1	DAY
Initial or Prolonged	Infection		Temazepam	C		ORAL	10MG Per day	
	Malaise		Loperamide	C		ORAL	2MG Per day	
	Renal Failure		Allopurinol	C	Glaxo Wellcome	ORAL	300MG per day	
	Urinary Tract Infection		Co-Proxamol	C		ORAL		
	Vomiting		Meloxicam	C		ORAL	7.5MG per day	
			Salbutamol	C	Glaxo Wellcome			

RESPIRATORY

(INHALATION) 200MCG Twice

per day

Date:04/05/02ISR Number: 3894839-9Report Type:Expedited (15-DaCompany Report #B0112291A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	2 DAY
Hospitalization -	Renal Failure		Loperamide	C		ORAL	2MG Per day	
Initial or Prolonged			Allopurinol	C	Glaxo Wellcome	ORAL	300MG Per day	
			Meloxicam	C		ORAL	7.5MG Per day	
			Salbutamol	C	Glaxo Wellcome			

RESPIRATORY

(INHALATION) 100MCG As

required

			Temazepam	C		ORAL
10MG Per day						

Date:04/08/02ISR Number: 3898185-9Report Type:Direct Company Report #CTU 165150
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypersensitivity		Zyban 150 Mg Tbsr	PS		
ONCE PO QD X						
	Rash					
3D, THEN BID						
			Habitrol 21 Mg Patch	SS		
TOPICAL ONCE PATCH						
TOP QD						

Date:04/09/02ISR Number: 3896308-9Report Type:Expedited (15-DaCompany Report #B0131342A
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Creatinine		Zyban	PS	Glaxo Wellcome	ORAL
13 DAY						
	Increased		Piribedil	SS		
UNKNOWN						
	Hyperkalaemia		Gemfibrozil	SS		
UNKNOWN						
			Zopiclone	SS		
UNKNOWN						
			Buflomedil Hydrochloride	SS		
UNKNOWN						
			Metformin Hydrochloride	SS		
UNKNOWN						
			Clonazepam	C		

Date:04/09/02ISR Number: 3896311-9Report Type:Expedited (15-DaCompany Report #B0263833A
Age:65 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Dysphagia
	Hypersensitivity

	Myalgia					
	Rash					
	Rash Psoriaform	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Weight Decreased		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 8 DAY						

Date:04/09/02ISR Number: 3896313-2Report Type:Expedited (15-DaCompany Report #B0264067A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL
300MG per day						

Date:04/09/02ISR Number: 3896314-4Report Type:Expedited (15-DaCompany Report #B0264074A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 1 MON						
Initial or Prolonged			Antihypertensive (Unspecified)	C		
			Statines	C		

Date:04/09/02ISR Number: 3899602-0Report Type:Direct Company Report #CTU 165372
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaphylactic Reaction		Bupropion 75 Mg			
Initial or Prolonged	Joint Swelling		Generic	PS		ORAL
75MG 2 TIMES						
	Oedema Peripheral					
ORAL						
	Pain		Serax-Oxezapam	C		
	Pruritus					
	Throat Tightness					
	Urticaria					

Date:04/10/02ISR Number: 3896976-1Report Type:Expedited (15-DaCompany Report #A0364404A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Visual Field Defect						per day	
			Zoloft	C				
			Trazodone	C				
			Atenolol	C				
			Micardis	C	Glaxo Wellcome			
			Hydrochlorothiazide	C				
			Estrace	C				
			Lipitor	C				
			Plavix	C				

Date:04/10/02ISR Number: 3898377-9Report Type:Expedited (15-DaCompany Report #2002099876FR
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall	Foreign	Aldactazine					
	Inappropriate Antidiuretic Hormone Secretion	Health Professional	(Spironolactone, Althiazide) Tablet	PS		ORAL	ORAL	
	Weight Increased		Zyban (Amfebutamone Hydrochloride)	SS		ORAL	150 MG, BID,	

ORAL

Date:04/10/02ISR Number: 3899394-5Report Type:Direct Company Report #CTU 165452
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Erythema Multiforme		Wellbutrin Sr 150mg	PS		ORAL	150 MG QD	ORAL

Date:04/10/02ISR Number: 3899460-4Report Type:Expedited (15-DaCompany Report #001-0945-M0200269
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Overdose	Health Professional	Neurontin (Gabapentin)	PS		ORAL	PER ORAL	
			Amfebutamone Hydrochloride	SS		ORAL	PER ORAL	
			Carisoprodol	SS		ORAL	PER ORAL	
			Venlafaxine Hydrochloride	C				

Date:04/10/02ISR Number: 3899545-2Report Type:Direct Company Report #CTU 165455
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia Ear Disorder		Wellbutrin Sr 100mg Qd	PS		ORAL	100MG PO /QD	

Date:04/11/02ISR Number: 3897617-XReport Type:Expedited (15-DaCompany Report #A0359237A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG per day	
			Depakote	C				

Date:04/11/02ISR Number: 3897618-1Report Type:Expedited (15-DaCompany Report #A0359335A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aura		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	YR
	Blindness							
	Coma		Oxycontin	C				
	Depression		Flexeril	C				
	Disturbance In Attention		Acyclovir	C	Glaxo Wellcome		200MG As required	
	Memory Impairment							
	Optic Nerve Disorder							
	Petit Mal Epilepsy							
	Sleep Attacks							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/02ISR Number: 3897620-XReport Type:Expedited (15-DaCompany Report #A0361528A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Apnoea		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Clonic Convulsion		Zofran	SS	Glaxo Wellcome	INTRAVENOUS		1 DAY
	Coma		Versed	C		INTRAVENOUS		
	Drug Interaction		Fentanyl	C		INTRAVENOUS		
	Heart Rate Increased		Toradol	C		INTRAVENOUS		
	Hyperventilation		Sevoflurane	C		RESPIRATORY (INHALATION)		
	Memory Impairment							
	Muscle Rigidity		Propofol	C		INTRAVENOUS		
	Respiratory Rate Increased							

Date:04/11/02ISR Number: 3897621-1Report Type:Expedited (15-DaCompany Report #A0361722A
Age:13 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	9 MON
	Drug Interaction							
	Electroencephalogram		Zoloft	SS			50MG Per day	
	Abnormal		Trazodone	C			50MG At night	
	Grand Mal Convulsion							

Date:04/11/02ISR Number: 3897622-3Report Type:Expedited (15-DaCompany Report #A0361723A
Age:10 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Convulsion Wellbutrin PS Glaxo Wellcome ORAL
200MG Twice

per day 6 MON

Date:04/11/02ISR Number: 3897627-2Report Type:Expedited (15-DaCompany Report #A0365391A
Age: Gender:Unknown I/FU:F

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Pulmonary Hypertension Zyban PS Glaxo Wellcome ORAL
150MG See

dosage text 8 DAY

Date:04/11/02ISR Number: 3897642-9Report Type:Expedited (15-DaCompany Report #B0264055A
Age:34 YR Gender:Female I/FU:F

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Hospitalization - Grand Mal Convulsion Zyban PS Glaxo Wellcome ORAL
Initial or Prolonged Respiratory Arrest Antidepressant C

Date:04/11/02ISR Number: 3897646-6Report Type:Expedited (15-DaCompany Report #B0264147A
Age:45 YR Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Leukocytoclastic Zyban PS Glaxo Wellcome
UNKNOWN 150MG As
Vasculitis
directed 19 DAY
Conjugated
Oestrogens C
UNKNOWN
Lormetazepam C
UNKNOWN .5UNIT As

required

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/02ISR Number: 3897647-8Report Type:Expedited (15-DaCompany Report #B0264148A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Formication		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Twice
Initial or Prolonged	Peripheral Coldness							per day
Other			Diltiazem Hydrochloride	C	Glaxo Wellcome		UNKNOWN	120MG Per day
			Isoflavone	C				
			Levothyroxine	C	Glaxo Wellcome		UNKNOWN	50MG Per day

Date:04/11/02ISR Number: 3897649-1Report Type:Expedited (15-DaCompany Report #B0264529A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diabetes Mellitus		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Per day 61 DAY
Initial or Prolonged	Insulin-Dependent							
Disability	Headache							
	Pruritus							

Date:04/11/02ISR Number: 3897650-8Report Type:Expedited (15-DaCompany Report #B0264531A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Phlebothrombosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	
Initial or Prolonged								

Date:04/11/02ISR Number: 3897652-1Report Type:Expedited (15-DaCompany Report #B0264661A
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Acute Myocardial		Zyban	PS	Glaxo Wellcome	
UNKNOWN 150MG Per day 5 DAY						
	Infarction		Tramadol			
	Malaise		Hydrochloride	C		
UNKNOWN						
	Nausea					

Date:04/12/02ISR Number: 3898872-2Report Type:Expedited (15-DaCompany Report #A0364303A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angina Pectoris		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL
	Hypertension					

Date:04/12/02ISR Number: 3898883-7Report Type:Expedited (15-DaCompany Report #B0262849A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Difficulty In Walking	Health	Zyntabac	PS	Glaxo Wellcome	ORAL
150MG						
	Dyspepsia	Professional				
Variable dose 21 DAY						
	Exanthem					
	Headache					
	Insomnia					
	Nasopharyngeal Disorder					
	Nervousness					
	Pruritus					
	Rash					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/02ISR Number: 3898886-2Report Type:Expedited (15-DaCompany Report #B0264401A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Overdose	Consumer	Zyban	PS	Glaxo Wellcome	ORAL		17 DAY
Initial or Prolonged	Suicide Attempt		Bromazepam	SS			200MG per day	
	Therapeutic Agent		Kardegic	C		ORAL	160MG Per day	
	Toxicity		Amarel	C		ORAL	2MG Per day	
			Monicor	C		ORAL	40MG Per day	

Date:04/15/02ISR Number: 3901257-3Report Type:Expedited (15-DaCompany Report #A0364109A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Application Site Pruritus	Health	Nicotine Patch					
	Convulsion	Professional	(Nicotine)	PS			TOPICAL	TOPICAL
			Bupropion Hydrochloride Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL	150 MG//ORAL	

Date:04/16/02ISR Number: 3899837-7Report Type:Expedited (15-DaCompany Report #WAES 0204ESP00009
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Noroxin	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged			Bupropion Hydrochloride	SS		ORAL		37 DAY

Date:04/16/02ISR Number: 3900670-8Report Type:Direct Company Report #CTU 165767
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dysgraphia		Wellbutrin	PS				
CANT RECALL I								
	Nervous System Disorder							
CUT IT IN								
	Tremor							
HALF								

Date:04/16/02ISR Number: 3901964-2Report Type:Expedited (15-DaCompany Report #200211202GDDC
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Indapamide					
		Health	(Dapa-Tabs) Tablets	PS		ORAL		
2.5 MG PO							436	DAY
		Professional	Amfebutamone					
		Other	Hydrochloride					
			(Zyban)	SS				
8 DAY								
			Quinapril					
			Hydrochloride					
			(Accupril)	C				
			Acetylsalicylate					
			Calcium (Solprin)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/02ISR Number: 3901476-6Report Type:Expedited (15-DaCompany Report #A0364730A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Crying						per day	15 DAY
	Hallucination, Visual		Norplant	C				
	Memory Impairment		Synthroid	C	Glaxo Wellcome			
	Panic Attack		Xanax	C				
	Schizoaffective Disorder							

Date:04/18/02ISR Number: 3901484-5Report Type:Expedited (15-DaCompany Report #B0259229A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Toxicity		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Excoriation		Alcohol	C				
	Mucous Membrane Disorder		Salicylate	C				
	Overdose							
	Pulmonary Haemorrhage							
	Pulmonary Oedema							

Date:04/18/02ISR Number: 3902435-XReport Type:Direct Company Report #CTU 166101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mallory-Weiss Syndrome		Bupropion 100 Mg Bid Plus 75 Mg Hs	PS			100 MG BID PLUS 75 MG HS	YR
	Nausea							
	Pharmaceutical Product							
	Complaint							
	Vomiting							

Date:04/19/02ISR Number: 3902287-8Report Type:Expedited (15-DaCompany Report #A0365819A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea Haemorrhagic		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	13 DAY
	Pain							
			Aspirin	C			1 DAY	
			Fexofenadine	C			2 DAY	
			Atorvastatin	C				
			Levothyroxine	C	Glaxo Wellcome			

Date:04/19/02ISR Number: 3902295-7Report Type:Expedited (15-DaCompany Report #B0134349A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown

Date:04/19/02ISR Number: 3902296-9Report Type:Expedited (15-DaCompany Report #B0134350A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Unknown

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/02ISR Number: 3902300-8Report Type:Expedited (15-DaCompany Report #B0265475A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pericarditis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	4 DAY

Date:04/22/02ISR Number: 3903730-0Report Type:Expedited (15-DaCompany Report #B0134348A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	

Date:04/22/02ISR Number: 3903736-1Report Type:Expedited (15-DaCompany Report #B0265190A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Depression Dizziness Mouth Ulceration Muscle Rigidity Nausea Vision Blurred		Zyban	PS	Glaxo Wellcome	ORAL		

Date:04/22/02ISR Number: 3903738-5Report Type:Expedited (15-DaCompany Report #B0265412A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Agitation		Zyban	PS	Glaxo Wellcome		UNKNOWN	

Date:04/22/02ISR Number: 3903739-7Report Type:Expedited (15-DaCompany Report #B0265413A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Emotional Disorder		Zyban	PS	Glaxo Wellcome		UNKNOWN	

Date:04/22/02ISR Number: 3904707-1Report Type:Expedited (15-DaCompany Report #A0141408A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anger Delusion Depression	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE	
	Dizziness						PER DAY ORAL	
	Feeling Jittery		Semisodium Valproate	C				
	Impulsive Behaviour		Gabapentin	C				
	Mania		Venlafaxine Hydrochloride	C				
	Nervousness		Glipizide	C				
	Psychomotor Hyperactivity		Vicodin	C				
	Suicidal Ideation							
	Tremor							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/02ISR Number: 3904734-4Report Type:Expedited (15-DaCompany Report #A204048
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Zoloft Tablets	PS		ORAL	50.00 MG	TOTAL:DAILY:O
Required Intervention to Prevent Permanent Impairment/Damage	Depression	Professional						
	Diabetes Mellitus							
	Drug Ineffective		Wellbutrin	SS		ORAL	300.00 MG	TOTAL:BID:ORA
	Fatigue							
	Fear							
	Gait Disturbance		Zyprexa	SS		ORAL	10.00	TOTAL:DAILY:O
	Hallucination, Visual							
	Hemianopia							
	Insomnia							

Date:04/22/02ISR Number: 3904736-8Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Required Intervention to Prevent Permanent Impairment/Damage	Akinesia
	Anger
	Autoimmune Thyroiditis
	Balance Disorder
	Blood Oestrogen Decreased
	Blood Pressure Increased
	Blood Thyroid Stimulating Hormone Decreased
	Cerebral Haemorrhage
	Contusion
	Convulsion
	Dementia
	Drug Ineffective
	Dysphonia
	Epistaxis
	Fall

Head Injury
Headache
Heart Rate Decreased
Heart Rate Increased
Hostility
Hyperhidrosis
Laceration
Medication Error
Meningioma
Mood Swings
Nervous System Disorder
Nuclear Magnetic
Resonance Imaging
Abnormal
Overdose
Palpitations
Parkinson'S Disease
Prothrombin Time
Prolonged
Staring
Syncope
Thinking Abnormal
Thyroid Function Test
Abnormal
Transient Ischaemic
Attack

Vaginal Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Zoloft Tablets	PS			50.00 MG	TOTAL:DAILY
	Wellbutrin	SS		ORAL	300.00 MG	TOTAL:BID:ORAL
	Coumadin	SS				
	Effexor Xr	SS		ORAL	300.00 MG	TOTAL:BID:ORAL
	Toprol	C				
	Zebeta	C				
	Lanoxin	C				
	Lasix	C				
	Synthroid	C				
	Vitamin E	C				
	Estrogen	C				
	Amantadine	C				
	Zocor	C				
	Estradiol Vaginal Ring	C				

Date:04/22/02ISR Number: 3904888-XReport Type:Expedited (15-DaCompany Report #WAES 0204ESP00009
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Other	Tab Noroxin (Norfloxacin)	PS		ORAL	400 MG/BID PO	10 DAY
			Tab Bupropion Hcl	SS		ORAL	150 MG/DAILY PO	37 DAY

Date:04/22/02ISR Number: 3904902-1Report Type:Expedited (15-DaCompany Report #B0264913A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	1 TABLET/ TWICE PER DAY/ ORAL	
			Omeprazole	C				
			Betahistine	C				

Date:04/22/02ISR Number: 3904906-9Report Type:Expedited (15-DaCompany Report #B0264464A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY/ORAL	
			Bromazepam Tablet (Bromazepam)	SS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/02ISR Number: 3904907-0Report Type:Expedited (15-DaCompany Report #B0264307A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Clonic Convulsion Intentional Misuse Muscle Contractions Involuntary Suicide Attempt	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	3000 MG/SINGLE DOSE/ORAL	
			Bromazepam Tablet (Bromazepam)	SS		ORAL	ORAL	
			Oxazepam	SS				

Date:04/22/02ISR Number: 3905066-0Report Type:Expedited (15-DaCompany Report #B0265019A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Anhedonia Convulsion Decreased Activity Dizziness Dyspnoea Fatigue Fear Gastrointestinal Disorder Joint Stiffness Loss Of Consciousness Pancreatitis Panic Attack Peritonitis Purulence Sexual Dysfunction Sleep Disorder	Foreign Health Professional	Zyban Tablt - Zyban (Bupropion Hydrochloride)	PS			150 MG/AS DIRECTED/ UNKNOWN	
			Simvastatin	C				
			Seloken	C				
			Renitec	C				
			Frusemide	C				
			Aspirin	C				

Date:04/22/02ISR Number: 3905146-XReport Type:Expedited (15-DaCompany Report #B0264762A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/	ORAL
			Norfloxacin (Formulation Unknown) (Norfloxacin)	SS		ORAL	800 MG / TWICE PER DAY/	ORAL

Date:04/22/02ISR Number: 3905188-4Report Type:Expedited (15-DaCompany Report #B0264124A
Age: Gender: I/FU:I

Outcome
Death
Congenital Anomaly
Required Intervention to Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Congenital Diaphragmatic Hernia Maternal Drugs Affecting Foetus Pregnancy Pulmonary Malformation	Foreign	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	1 TABLET / ORAL	
			Folic Acid	C				
			Amoxicillin Trihydrate	C				

Date:04/22/02ISR Number: 3905190-2Report Type:Expedited (15-DaCompany Report #B0264762A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Foreign	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL	
			Norfloxacin (Norfloxacin) (Formulation Unknown)	SS		ORAL	800 MG / TWICE PER DAY / ORAL	

Date:04/22/02ISR Number: 3905407-4Report Type:Direct Company Report #CTU 166383
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Bipolar I Disorder Suicide Attempt		Wellbutrin 75mg Burroughs Wellcome	PS	Burroughs Wellcome	ORAL	3X DAILY	

Initial or Prolonged
ORALLY 75MG
Required
EACH APPROX 1
Intervention to
YEAR 1 YR
Prevent Permanent
Impairment/Damage

Date:04/23/02ISR Number: 3904636-3Report Type:Expedited (15-DaCompany Report #A0359318A
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	9	MON
Hospitalization - Initial or Prolonged	Drug Level Increased Medication Error Overdose Therapeutic Agent Toxicity							

Date:04/23/02ISR Number: 3904641-7Report Type:Expedited (15-DaCompany Report #A0366482A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Unevaluable Event		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/02ISR Number: 3904642-9Report Type:Expedited (15-DaCompany Report #B0101413A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Status Epilepticus						per day	22 DAY
			Diazepam	C			UNKNOWN	
			Tramadol	C		ORAL		
			Alcohol	C				

Date:04/23/02ISR Number: 3904644-2Report Type:Expedited (15-DaCompany Report #B0264307A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Clonic Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	3000MG Single	
Initial or Prolonged	Completed Suicide						dose	1 DAY
	Intentional Misuse		Lexomil	SS		ORAL	1 DAY	
	Muscle Contractions		Seresta	SS		ORAL	1 DAY	
	Involuntary		Alcohol	C				
	Somnolence							

Date:04/23/02ISR Number: 3904645-4Report Type:Expedited (15-DaCompany Report #B0264464A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	9 DAY
	Insomnia		Lexomil	SS		ORAL	9 DAY	
	Nervousness							

Date:04/23/02ISR Number: 3904647-8Report Type:Expedited (15-DaCompany Report #B0264957A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Ventricular Fibrillation						per day	40 DAY
			Digoxin	C	Glaxo Wellcome	ORAL		
			Lisinopril	C		ORAL	5MG Unknown	
			Aspirin	C		ORAL	75MG Unknown	
			Thyroxine	C	Glaxo Wellcome	ORAL	100MG Unknown	

Date:04/23/02ISR Number: 3904649-1Report Type:Expedited (15-DaCompany Report #B0265519A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholestasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged	Focal Nodular Hyperplasia							
	Liver Disorder							
	Systemic Lupus							
	Erythematosus Rash							

Date:04/24/02ISR Number: 3905736-4Report Type:Expedited (15-DaCompany Report #A0062462A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Eye Disorder	Professional					per day	
	Vision Blurred		Zestril	C				

				Triamterene	C	Glaxo Wellcome	
				Prinivil	C		

Date:04/24/02ISR Number: 3905741-8Report Type:Expedited (15-DaCompany Report #A0366054A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome	ORAL	39	DAY
	Drug Ineffective		Effexor	C		ORAL	25MG Per day	
	Libido Decreased		Neurontin	C		ORAL	400MG Twice per day	
	Overdose							
	Pulmonary Congestion							
	Sexual Dysfunction							
	Toxicologic Test Abnormal							
	Urinary Retention							

Date:04/24/02ISR Number: 3905742-XReport Type:Expedited (15-DaCompany Report #A0366092A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	42	DAY
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							

Date:04/24/02ISR Number: 3905743-1Report Type:Expedited (15-DaCompany Report #A0366462A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Neutropenia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	

Initial or Prolonged	Pneumonia Necrotising					
per day 6 MON						
	White Blood Cell Count Abnormal		Levothyroxine	C	Glaxo Wellcome	ORAL

Date:04/24/02ISR Number: 3905744-3Report Type:Expedited (15-DaCompany Report #A0366463A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Dystonia		Haldol	SS		ORAL	1	DAY
	Fatigue		Zoloft	C				
UNKNOWN	100MG Per day	1	YR					
	Gaze Palsy		Oral Contraceptives	C		ORAL	2	WK
	Headache							
	Muscle Spasms							
	Musculoskeletal Stiffness							
	Oculogyration							
	Pruritus							
	Rash							
	Viral Infection							
	Vision Blurred							

Date:04/25/02ISR Number: 3906203-4Report Type:Expedited (15-DaCompany Report #A0364704A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Hair Disorder							
per day								47 DAY
	Hair Growth Abnormal							
	Thyroid Disorder							

Date:04/25/02ISR Number: 3906212-5Report Type:Expedited (15-DaCompany Report #B0133710A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	17 DAY
Hospitalization -	Arthralgia							
Initial or Prolonged	Tendon Disorder							
Disability	Urticaria							
Other								

Date:04/25/02ISR Number: 3906213-7Report Type:Expedited (15-DaCompany Report #B0134007A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Csf Protein Increased		Zyban	PS	Glaxo Wellcome	ORAL	92 DAY	
Initial or Prolonged	Headache							
Disability	Hypertension							
	Meningeal Disorder							
	Mental Disorder							
	Musculoskeletal Stiffness							
	Pain							
	Vomiting Projectile							

Date:04/25/02ISR Number: 3906215-0Report Type:Expedited (15-DaCompany Report #B0265714A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	150MG See dosage text	8 DAY
	Blood Creatine Phosphokinase Increased							
	Chest Pain							
	Dry Mouth							
	Tachycardia							
	Tremor							

Date:04/25/02ISR Number: 3907615-5Report Type:Direct Company Report #CTU 166660
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin 100					
	Anxiety		Generic	PS			1 AM 1 NOON	
	Cerebrovascular Accident		Wellbutrin 75mg					
	Depression		Generic	SS			1 5 PM	
	Fear		Cardiac Medications	C				
	Hallucination, Visual							
	Psychotic Disorder							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/02ISR Number: 3906912-7Report Type:Expedited (15-DaCompany Report #B0099525A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Lung Neoplasm		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	8 DAY

Date:04/26/02ISR Number: 3906915-2Report Type:Expedited (15-DaCompany Report #B0262805A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL		

Date:04/26/02ISR Number: 3908559-5Report Type:Expedited (15-DaCompany Report #B0261797A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Diplopia Epilepsy Status Epilepticus	Foreign Other	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
			Multivitamin Capsule (Multivitamin)	SS		ORAL	ORAL	
			Ephedrine (Formulation Unknown) (Ephedrine)	SS				
			Guarana (Formulation Unknown) (Guarana)	SS		ORAL	ORAL	
			Neuroleptic	C				
			Antidepressant	C				
			Benzodiazepines	C				

Date:04/26/02ISR Number: 3908731-4Report Type:Expedited (15-DaCompany Report #A0361279A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness Dysarthria Medication Error Vision Blurred	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS	Wellbutrin	ORAL	150 MG / SEE DOSAGE TEXT / ORAL	
			Thyroxine Sodium	C				
			Metformin Hydrochloride	C				
			Irbesartan	C				

Date:04/26/02ISR Number: 3908947-7Report Type:Expedited (15-DaCompany Report #B0264954A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent RESPIRATORY Impairment/Damage	Asthma Hypoaesthesia Hypoaesthesia Oral	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS			(INHALATION) 150 MG/INHALED	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/02ISR Number: 3910106-9Report Type:Periodic Company Report #01P-163-0106856-00
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Circulatory Collapse Drug Level Increased Parkinson'S Disease	Other	Depakote (Divalproex Sodium) (Divalproex Sodium)	PS		ORAL	1000 MG, PER ORAL	
			Bupropion Hydrochloride	SS			150 MG, 2 IN 1 D	
			Paroxetine Hydrochloride	SS		ORAL	20 MG, 1 IN 1 D, PER ORAL	
			Citalopram	SS		ORAL	20 MG, 1 IN 1 D, PER ORAL	
			Paroxetine Hydrochloride	C				

Date:04/26/02ISR Number: 3923573-1Report Type:Periodic Company Report #A127209
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Depression Diarrhoea Rash Tremor	Consumer Health Professional	Tikosyn Capsules	PS		ORAL	250.00 MCG TOTAL BID	
			Wellbutrin	SS			75.00 MG TOTAL DAILY	
			Levoxyl	C				
			Valium	C				

Date:04/29/02ISR Number: 3907744-6Report Type:Expedited (15-DaCompany Report #A0366602A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block Left		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Chest Pain		Celexa	C				
	Dyspnoea		Tricor	C				
	Electrocardiogram St		Ranitidine	C	Glaxo Wellcome			
	Segment Abnormal		Disopyramide	C				25 YR
			Aspirin	C		ORAL	81MG Per day	

Date:04/29/02ISR Number: 3907746-XReport Type:Expedited (15-DaCompany Report #A0366645A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Olfactory		Zyban	PS	Glaxo Wellcome			
	Temporal Lobe Epilepsy							

Date:04/29/02ISR Number: 3907749-5Report Type:Expedited (15-DaCompany Report #B0259252A
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cheilitis
	Dermatitis Bullous
	Hypopyon
	Neutrophilia
	Pyrexia

	Rash Erythematous						
	Rash Pustular						
	Skin Inflammation	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 12 DAY
			Propofan	SS		ORAL	1UNIT per day 1 DAY
			Prazepam	C		ORAL	40MG per day 277 DAY
			Zolpidem	C		ORAL	1UNIT per day 277 DAY
			Alprazolam	C		ORAL	.25MG As required 277 DAY

Date:04/29/02ISR Number: 3907751-3Report Type:Expedited (15-DaCompany Report #B0262674A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	
	Aortic Aneurysm Rupture						
	Chest Pain						
	Dyspnoea						
	Malaise						
	Nervousness						
	Sudden Death						

Date:04/29/02ISR Number: 3907752-5Report Type:Expedited (15-DaCompany Report #B0263361A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome		
UNKNOWN	Unknown						150MG
Other	Depression		No Concurrent				
	Overdose		Medications	C			

Date:04/29/02ISR Number: 3907754-9Report Type:Expedited (15-DaCompany Report #B0265665A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	4 DAY
Hospitalization - Initial or Prolonged	Coronary Artery Dissection Ventricular Fibrillation		Ethinyloestradiol + Norgestimate	C		ORAL		

Date:04/29/02ISR Number: 3907755-0Report Type:Expedited (15-DaCompany Report #B0265912A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Epilepsy Intracranial Aneurysm Loss Of Consciousness		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	30 DAY

Date:04/29/02ISR Number: 3910761-3Report Type:Periodic Company Report #NSADSS2001031860
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Ultram	PS		ORAL ORAL		
	Drug Interaction	Professional	Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/02ISR Number: 3908288-8Report Type:Expedited (15-DaCompany Report #B0262751A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pharyngolaryngeal Pain Respiratory Disorder Respiratory Failure		Zyban	PS	Glaxo Wellcome	ORAL	12	DAY

Date:04/30/02ISR Number: 3908289-XReport Type:Expedited (15-DaCompany Report #B0263835A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Discomfort Dysphagia Hypovolaemia Lymphocyte Count Decreased Neutrophil Count Decreased Oedema Peripheral Pain Red Blood Cell Sedimentation Rate Increased Respiratory Disorder Skin Lesion Urticaria Generalised White Blood Cell Count Increased		Zyban	PS	Glaxo Wellcome	ORAL	14	DAY

Date:04/30/02ISR Number: 3908292-XReport Type:Expedited (15-DaCompany Report #B0264397A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased		Zyban Lipanthyl	PS SS	Glaxo Wellcome	ORAL ORAL	200MG	Per day

	Blood Cholesterol Increased Diabetes Mellitus Non-Insulin-Dependent Drug Interaction Gamma-Glutamyltransferase Increased					

Date:04/30/02ISR Number: 3908296-7Report Type:Expedited (15-DaCompany Report #B0266376A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome			
Initial or Prolonged	Fatigue Malaise Sleep Disorder		Proton Pump Inhibitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/02ISR Number: 3909116-7Report Type:Direct Company Report #CTU 166884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Crying		Bupropion 150mg 1					
	Depression		Bid , Glaxo	PS	Glaxo	ORAL	1 BID, 150MG	
	Emotional Disorder						SR ORAL	
	Mood Altered		Vioxx	C				
	Suicidal Ideation		Aleve	C				

Date:05/01/02ISR Number: 3909189-1Report Type:Expedited (15-DaCompany Report #A0170371A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged	Chills	Professional	Influenza Vaccine	SS	Glaxo Wellcome			
	Convulsion							
	Pyrexia							
	Speech Disorder							
	Weight Decreased							

Date:05/01/02ISR Number: 3909192-1Report Type:Expedited (15-DaCompany Report #A0366635A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Flutter		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG per day	
	Blindness Transient							
	Dyspnoea							

Date:05/01/02ISR Number: 3909194-5Report Type:Expedited (15-DaCompany Report #A0367027A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myasthenia Gravis		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Twice per day 10 DAY						
			No Concurrent Medication	C		

Date:05/01/02ISR Number: 3909195-7Report Type:Expedited (15-DaCompany Report #A0367126A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL
	Intentional Misuse		Ritalin	C		ORAL
	Suicide Attempt					
	Vomiting					

Date:05/01/02ISR Number: 3909200-8Report Type:Expedited (15-DaCompany Report #B0266132A
Age: Gender:Female I/FU:I

Outcome	PT
Disability	Abdominal Pain
	Abdominal Pain Upper
	Chest Wall Pain
	Dizziness
	Drug Interaction
	Fall

	Fatigue Headache Nausea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain In Extremity	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day
	Rib Fracture	Professional	Tranxene	SS		ORAL	
	Road Traffic Accident Syncope Tendonitis		Unknown Selective Serotonin Reuptake Inhibitor	SS		ORAL	

Date:05/01/02ISR Number: 3909203-3Report Type:Expedited (15-DaCompany Report #B0266558A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL	1TAB Per day 3 DAY
			Fenoterol	C			UNKNOWN
			Formoterol	C			UNKNOWN
			Fluticasone	C	Glaxo Wellcome		UNKNOWN

Date:05/01/02ISR Number: 3911535-XReport Type:Direct Company Report #CTU 167177
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation		Wellbutrin Sr 100mg	PS		ORAL	100MG BID
							ORAL
			Depakote	C			
			Augmentin	C			
			Paxil	C			

Date:05/02/02ISR Number: 3909769-3Report Type:Expedited (15-DaCompany Report #A0367102A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Cholelithiasis		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG See dosage text	
	Constipation		Birth Control Pill	C		ORAL		
			Valtrex	C	Glaxo Wellcome	ORAL	500MG As required	

Date:05/02/02ISR Number: 3909780-2Report Type:Expedited (15-DaCompany Report #B0260822A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	International Normalised Ratio Increased		Zyban	PS	Glaxo Wellcome		UNKNOWN	75 DAY
			Warfarin	SS	Glaxo Wellcome		UNKNOWN	
			Spironolactone	C		ORAL	25MG Per day	
			Enalapril	C		ORAL	5MG Per day	
			Unspecified Medication	C			UNKNOWN	
			Furosemide	C	Glaxo Wellcome	ORAL	40MG Per day	

Date:05/02/02ISR Number: 3911428-8Report Type:Direct Company Report #CTU 167198
Age:38 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Required Intervention to Prevent Permanent Impairment/Damage	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Fall		Wellbutrin Sr 150mg (Glaxo Wellcome)	PS	Glaxo Wellcome	ORAL	150MG	PO QD
	Gaze Palsy Grand Mal Convulsion		Seroquel 25mg (Astra Zeneca)	SS	Astra Zeneca	ORAL	50MG	PO Q 1HR
	Lethargy						PRN	
			Birth Control Pills (Necon 0.5/35)	C				
			Lorazepam	C				

Date:05/03/02ISR Number: 3910249-XReport Type:Expedited (15-DaCompany Report #B0102171A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Alanine Aminotransferase Increased	Health	Zyban	PS	Glaxo Wellcome		2	DAY
Initial or Prolonged	Burning Sensation Decreased Appetite Dermatitis Exfoliative Dry Skin Fatigue Hyperhidrosis Neutrophilia Pain Pain Of Skin Pruritus Rash Maculo-Papular Skin Discolouration Vision Blurred Weight Decreased	Professional	No Concurrent Medications	C				

Date:05/03/02ISR Number: 3910256-7Report Type:Expedited (15-DaCompany Report #B0265412A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression	Consumer	Zyban	PS	Glaxo Wellcome			
UNKNOWN							300MG per day	6 DAY
Initial or Prolonged	Agitation							

Date:05/03/02ISR Number: 3910257-9Report Type:Expedited (15-DaCompany Report #B0265413A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression	Consumer	Zyban	PS	Glaxo Wellcome			
UNKNOWN							2TABS per day	8 DAY
Initial or Prolonged	Agitation		Celecoxib	C				
UNKNOWN							200MG per day	
	Emotional Disorder							
	Headache							
	Mood Swings							

Date:05/03/02ISR Number: 3910259-2Report Type:Expedited (15-DaCompany Report #B0266443A
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Abnormal Behaviour
Initial or Prolonged	Atrial Fibrillation
	Brain Neoplasm

		Irritability					
		Speech Disorder					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Zyban	PS	Glaxo Wellcome	ORAL
5	WK						

Date:05/03/02ISR Number: 3910262-2Report Type:Expedited (15-DaCompany Report #B0266566A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Bundle Branch Block Left		Zyntabac	PS	Glaxo Wellcome	
UNKNOWN						
	Myalgia		Contraceptives	C		
UNKNOWN						

Date:05/03/02ISR Number: 3910274-9Report Type:Expedited (15-DaCompany Report #NSADSS2002014533
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Ph Decreased		Risperidone	PS		ORAL
Initial or Prolonged	Confusional State		Divalproex	SS		ORAL
Other	Depressed Level Of		Bupropion	SS		
UNKNOWN						
	Consciousness					
	Drug Level Increased					
	Haemodialysis					
	Intentional Misuse					
	Respiratory Depression					
	Restlessness					

Date:05/03/02ISR Number: 3912130-9Report Type:Direct Company Report #CTU 167331
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Psychotic Disorder		Wellbutrin	PS		

Date:05/06/02ISR Number: 3912309-6Report Type:Expedited (15-DaCompany Report #NSADSS2002014533
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required	Blood Ph Decreased Confusional State Depressed Level Of Consciousness Drug Level Above Therapeutic Haemodialysis	Literature Health Professional	Risperidone (Unspecified) (Risperidone)	PS		ORAL		
Intervention to Prevent Permanent Impairment/Damage			Divalproex (Valproate Semisodium)	SS		ORAL	180 TABLE, TOTAL, ORAL	
	Overdose Respiratory Depression Restlessness		Bupropion (Amfebutamone)	SS				

Date:05/07/02ISR Number: 3911816-XReport Type:Expedited (15-DaCompany Report #A0364730A
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Other	Convulsion Crying Delusion Hallucinations, Mixed Headache

	Memory Impairment Mood Swings Panic Attack	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Paranoia		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Schizoaffective Disorder					
per day 14 DAY						
			Norplant	C		
			Synthroid	C	Glaxo Wellcome	
			Xanax	C		

Date:05/07/02ISR Number: 3911817-1Report Type:Expedited (15-DaCompany Report #A0365391A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dysphagia		Zyban	PS	Glaxo Wellcome	ORAL
150MG See						
	Pulmonary Hypertension					
dosage text 11 DAY						
	Throat Tightness					

Date:05/07/02ISR Number: 3911837-7Report Type:Expedited (15-DaCompany Report #B0266864A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Zyntabac	PS	Glaxo Wellcome	
UNKNOWN	32 DAY					
Initial or Prolonged	Blood Creatinine		Furosemide	C	Glaxo Wellcome	
UNKNOWN						
	Increased		Doxazosine	C		
UNKNOWN						
	Blood Urea Increased		Eprosartan	C	Glaxo Wellcome	
UNKNOWN						
	Hyperhidrosis Pyrexia					

Date:05/07/02ISR Number: 3911838-9Report Type:Expedited (15-DaCompany Report #B0266914A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Convulsion Dry Mouth Dry Throat Hyperhidrosis Insomnia Palpitations		Bupropion Hcl	PS	Glaxo Wellcome	ORAL	150MG Twice per day	7 DAY

Date:05/07/02ISR Number: 3911839-0Report Type:Expedited (15-DaCompany Report #B0266928A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Intentional Misuse Suicide Attempt		Zyban	PS	Glaxo Wellcome	UNKNOWN	150MG See dosage text	

Date:05/07/02ISR Number: 3911840-7Report Type:Expedited (15-DaCompany Report #B0266930A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxo Wellcome	UNKNOWN		

Date:05/07/02ISR Number: 3911841-9Report Type:Expedited (15-DaCompany Report #D0038216A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown 27 DAY
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							
	Pregnancy							

Date:05/07/02ISR Number: 3912989-5Report Type:Direct Company Report #CTU 167418
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome		Wellbutrin	PS				2 WK

Date:05/07/02ISR Number: 3913646-1Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Required Intervention to Prevent Permanent Impairment/Damage	Anger
	Apathy
	Autoimmune Thyroiditis
	Balance Disorder
	Blood Oestrogen Decreased
	Blood Pressure Increased
	Blood Thyroid Stimulating Hormone Decreased
	Cerebral Haemorrhage
	Contusion
	Convulsion
	Dementia
	Drug Ineffective
	Dysphonia
	Emotional Disorder
	Epistaxis

Fall
Head Injury
Headache
Heart Rate Decreased
Heart Rate Increased
Hostility
Hyperhidrosis
Laceration
Meningioma
Nervous System Disorder
Nuclear Magnetic
Resonance Imaging
Abnormal
Overdose
Palpitations
Parkinson'S Disease
Personality Disorder
Prothrombin Time
Prolonged
Syncope
Thinking Abnormal

	Thyroid Function Test Abnormal Transient Ischaemic Attack	Report Source Consumer	Product Zoloft Tablets	Role PS	Manufacturer	Route Dose Duration 50.00 MG TOTAL:DAILY
	Treatment Noncompliance Tremor		Wellbutrin	SS		ORAL 300.00 MG TOTAL:BID:ORA L
	Vaginal Haemorrhage		Coumadin	SS		
			Effexor Xr	SS		ORAL 300.00 MG TOTAL:BID:ORA L
			Toprol	C		
			Zebeta	C		
			Lanoxin	C		
			Lasix	C		
			Synthroid	C		
			Vitamin E	C		
			Estrogen	C		
			Amantadine	C		
			Zocor	C		
			Estradiol Vaginal Ring	C		

Date:05/07/02ISR Number: 3913906-4Report Type:Expedited (15-DaCompany Report #A0367423A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Burning Sensation Stevens-Johnson Syndrome Stress Vision Blurred	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL 300 MG/PER DAY/ORAL

Date:05/08/02ISR Number: 3913130-5Report Type:Direct Company Report #CTU 167539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Delusion		Zyban 150mg					
Other	Disturbance In Attention		Glaxowellcome	PS	Glaxowellcome	ORAL	ONE TABLE	
	Hallucinations, Mixed						FIRST 3 DAYS	
	Memory Impairment						ORAL	
	Mood Swings							
	Panic Attack							
	Tinnitus							

Date:05/09/02ISR Number: 3913387-0Report Type:Expedited (15-DaCompany Report #A0367475A
Age:47 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Anxiety
	Blindness
	Cardiac Murmur
	Cardiac Valve Disease
	Chest Pain
	Dizziness
	Dyspnoea

	Hypoaesthesia Myocardial Infarction Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
			Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 1 DAY						

Date:05/09/02ISR Number: 3913400-0Report Type:Expedited (15-DaCompany Report #A0368187A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hepatitis C		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL
150MG Twice per day						

Date:05/09/02ISR Number: 3913409-7Report Type:Expedited (15-DaCompany Report #B0267211A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Depression		Zyban	PS	Glaxo Wellcome	ORAL
300MG per day 17 DAY						
	Emotional Disorder		Norgestrel +			
	Psychotic Disorder		Oestrone	C		ORAL
			Paracetamol	C	Glaxo Wellcome	ORAL
2TAB As required						

Date:05/09/02ISR Number: 3913429-2Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11850310
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Health Professional	Sustiva Caps 600 Mg	PS	Bristol-Myers Squibb Company	ORAL
			Stavudine	SS	Bristol-Myers Squibb Company	
			Didanosine	SS	Bristol-Myers Squibb	

					Company	
			Wellbutrin	SS		

Date:05/10/02ISR Number: 3913824-1Report Type:Expedited (15-DaCompany Report #A0360688A
Age:9 DY Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Dacryostenosis Congenital	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	9 MON
	Drug Exposure Via Breast Milk	Professional	Vitamins	C		ORAL	
	Lethargy						
	Maternal Drugs Affecting Foetus						
	Somnolence						

Date:05/10/02ISR Number: 3913841-1Report Type:Expedited (15-DaCompany Report #B0264074A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angina Unstable	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 1 MON
Hospitalization - Initial or Prolonged	Electrocardiogram St Segment Abnormal	Professional	Hyperium	C		ORAL	1MG Per day
			Fenofibrate	C		ORAL	200MG Per day
	Myocardial Infarction		Piascledine	C		ORAL	300MG Per day
			Stilnox	C		ORAL	10MG Per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/02ISR Number: 3913843-5Report Type:Expedited (15-DaCompany Report #B0266376A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Zyban	PS	Glaxo Wellcome			
UNKNOWN							150MG Per day	14 DAY
Initial or Prolonged	Condition Aggravated	Professional	Proton Pump					
Other	Fatigue		Inhibitor	C				
	Malaise							
	Sleep Disorder							

Date:05/10/02ISR Number: 3913844-7Report Type:Expedited (15-DaCompany Report #B0266756A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxo Wellcome	ORAL	60TAB Single	
	Completed Suicide						dose	
	Epilepsy							
	Intentional Misuse							
	Urinary Incontinence							

Date:05/10/02ISR Number: 3913850-2Report Type:Expedited (15-DaCompany Report #D0038493A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intentional Misuse	Health	Zyban	PS	Glaxo Wellcome	ORAL	60TAB Single	
	Suicide Attempt	Professional					dose	1 DAY
			Diclofenac	SS		ORAL	40TAB Single	
							dose	1 DAY
			Diphenhydramine Hydrochloride	SS	Glaxo Wellcome	ORAL	10TAB Single	
							dose	1 DAY

Date:05/13/02ISR Number: 3914784-XReport Type:Expedited (15-DaCompany Report #A0366092A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	42	DAY
	Complications Of Maternal Exposure To Therapeutic Drugs	Professional						
	Maternal Drugs Affecting Foetus							

Date:05/13/02ISR Number: 3914793-0Report Type:Expedited (15-DaCompany Report #B0130322A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall	Health	Zyban	PS	Glaxo Wellcome	ORAL	11	DAY
	Food Craving	Professional	Aspirin	C			500MG	Per day
	Hypoglycaemia		Nicotine	C	Glaxo Wellcome			
	Loss Of Consciousness							
	Malaise							
	Muscle Rigidity							
	Scratch							
	Trismus							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/02ISR Number: 3914795-4Report Type:Expedited (15-DaCompany Report #B0259252A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	12 DAY
	Increased		Prazepam	SS		ORAL	40MG per day	276 DAY
	Cheilitis		Propofan	C		ORAL	1UNIT per day	1 DAY
	Corneal Epithelium		Zolpidem	C		ORAL	1UNIT per day	276 DAY
	Disorder		Alprazolam	C		ORAL	.25MG As required	276 DAY
	Dermatitis Bullous							
	Hypopyon							
	Inflammation							
	Intertrigo							
	Leukocytosis							
	Oedema							
	Pyrexia							
	Rash Pustular							
	Skin Necrosis							

Date:05/14/02ISR Number: 3915446-5Report Type:Expedited (15-DaCompany Report #A0366642A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Pulmonary Disease		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	MON
	Drug Ineffective		Nitroquick	C	Glaxo Wellcome			
	Pneumonia							

Date:05/14/02ISR Number: 3915453-2Report Type:Expedited (15-DaCompany Report #A0368437A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus		Wellbutrin	PS	Glaxo Wellcome	ORAL

Date:05/14/02ISR Number: 3915458-1Report Type:Expedited (15-DaCompany Report #B0267248A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetes Mellitus Insulin-Dependent		Zyban	PS	Glaxo Wellcome	ORAL	7	WK

Date:05/14/02ISR Number: 3915459-3Report Type:Expedited (15-DaCompany Report #B0267249A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetes Mellitus Insulin-Dependent		Zyban	PS	Glaxo Wellcome	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/02ISR Number: 3916520-XReport Type:Direct Company Report #CTU 168054
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion					
	Dizziness		(Wellbutrin Sr)	PS		ORAL	150MG BID PO	
	Fall		Diphenhyramine	C				
	Limb Injury		Hydrocodone	C				
	Loss Of Consciousness		Acetaminophen	C				
			Warfarin	C				
			Salsalate	C				
			Ranitidine	C				

Date:05/14/02ISR Number: 3917098-7Report Type:Expedited (15-DaCompany Report #200205-0247 (0)
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health	Halls Cough Drops					
	Medication Error	Professional	(Menthol)	PS		ORAL	ORAL TOPICAL	
	Memory Impairment		Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	100 MG BID, PER ORAL	
			Alcohol (Nos)	SS				
			Neurontin (Gabapentin)	C				
			Trileptal (Oxcarbazepine)	C				

Date:05/15/02ISR Number: 3916035-9Report Type:Expedited (15-DaCompany Report #B0102510A
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health	Zyban	PS	Glaxo Wellcome		38 DAY	
	Convulsion	Professional	Celecoxib	C				

Dizziness
Dry Mouth
Dysgeusia
Fatigue
Thought Blocking
Thyroid Disorder
Weight Decreased

Date:05/15/02ISR Number: 3916036-0Report Type:Expedited (15-DaCompany Report #B0115005A
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Zyban	PS	Glaxo Wellcome			38 DAY
	Blood Pressure Increased							
	Convulsion							
	Dysgeusia							
	Fatigue							
	Loss Of Consciousness							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/15/02ISR Number: 3916042-6Report Type:Expedited (15-DaCompany Report #B0266928A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Hallucination Intentional Misuse Suicide Attempt	Health Professional	Zyban Benzodiazepine	PS SS	Glaxo Wellcome	UNKNOWN	150MG See dosage text UNKNOWN	

Date:05/15/02ISR Number: 3916043-8Report Type:Expedited (15-DaCompany Report #B0266929A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aphasia Clonic Convulsion Fall Head Injury Hyperglycaemia Hypotension Salivary Hypersecretion Syncope Tremor		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	21 DAY

Date:05/15/02ISR Number: 3916046-3Report Type:Expedited (15-DaCompany Report #B0267268A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Withdrawal Syndrome Exophthalmos Somnolence Swelling		Quomem	PS	Glaxo Wellcome	ORAL	150MG Variable dose	15 DAY

Date:05/16/02ISR Number: 3916659-9Report Type:Expedited (15-DaCompany Report #A0368118A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Road Traffic Accident							

Date:05/16/02ISR Number: 3916664-2Report Type:Expedited (15-DaCompany Report #A0368606A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Wellbutrin	PS	Glaxo Wellcome		150MG Twice per day	
	Blindness							
	Chromatopsia		Prozac	C			20MG Per day	
	Headache		Ambien	C				
	Intestinal Obstruction		Xanax	C			2MG As required	YR
	Retinal Artery Thrombosis							
			Aspirin	C			325MG Per day	
			Estradiol	C				
			Flomax	C				
			Percocet	C				
			Flexeril	C				
			Proventil	C	Glaxo Wellcome			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/02ISR Number: 3916669-1Report Type:Expedited (15-DaCompany Report #B0264464A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY
	Insomnia	Professional	Lexomil	C		ORAL	1.5MG Per day	8 DAY

Date:05/16/02ISR Number: 3916673-3Report Type:Expedited (15-DaCompany Report #B0267386A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Depressed Mood						per day	32 DAY
	Somnolence							

Date:05/16/02ISR Number: 3916675-7Report Type:Expedited (15-DaCompany Report #B0267494A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypomania		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Unknown
	Psychotic Disorder		Blood Pressure Medication	C				

Date:05/16/02ISR Number: 3916676-9Report Type:Expedited (15-DaCompany Report #B0267624A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome		UNKNOWN	

Date:05/17/02ISR Number: 3917161-0Report Type:Expedited (15-DaCompany Report #B0266930A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersensitivity		Zyban	PS	Glaxo Wellcome			
UNKNOWN								DAY
Initial or Prolonged	Malaise							
	Psoriasis							
	Rash							

Date:05/17/02ISR Number: 3917165-8Report Type:Expedited (15-DaCompany Report #B0268075A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Level Increased		Zyban	PS	Glaxo Wellcome	ORAL	1	DAY
Initial or Prolonged	Intentional Misuse		Prozac	SS		ORAL	1	DAY
	Logorrhoea		Previscan	SS		ORAL	1	DAY

Date:05/20/02ISR Number: 3918595-0Report Type:Expedited (15-DaCompany Report #B0265714A
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety
	Blood Creatine
	Phosphokinase Increased
	Chest Pain
	Dry Mouth
	Flushing

	Tachycardia						
	Tremor						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG See dosage text 10 DAY

Date:05/21/02ISR Number: 3919044-9Report Type:Expedited (15-DaCompany Report #A0149265B
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Accidental Exposure	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	
	Breech Presentation	Professional	Buspar	C		ORAL	7.5MG Twice per day
	Caesarean Section						
	Congenital Eyelid		Zoloft	C		ORAL	100MG Per day
	Malformation						
	Finger Deformity						
	Plagiocephaly						
	Pregnancy						
	Premature Labour						
	Transmission Of Drug Via Semen						

Date:05/21/02ISR Number: 3920491-XReport Type:Direct Company Report #CTU 168514
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Arthritis		Zyban	PS			2 WK
	Pain						
	Urticaria						

Date:05/22/02ISR Number: 3919534-9Report Type:Expedited (15-DaCompany Report #A0175184A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	3 DAY
	Muscle Contractions		Celexa	C		ORAL	40MG Per day	
	Involuntary		Ziac	C		ORAL	2.5MG Per day	
	Paraesthesia		Spironolactone	C				
			Reglan	C	Glaxo Wellcome		5MG As required	
			Zyrtec	C	Glaxo Wellcome	ORAL	10MG Per day	

Date:05/22/02ISR Number: 3919537-4Report Type:Expedited (15-DaCompany Report #A0364704A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Hair Disorder						per day	47 DAY
	Hair Growth Abnormal							
	Thyroid Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/02ISR Number: 3919542-8Report Type:Expedited (15-DaCompany Report #A0369185A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							

Date:05/22/02ISR Number: 3919870-6Report Type:Direct Company Report #CTU 168634
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Wellbutrin 150 Sr					
	Nasopharyngeal Disorder		Glaxo	PS	Glaxo	ORAL	1 BID ORAL	
	Pharmaceutical Product Complaint		Prozac	C				

Date:05/22/02ISR Number: 3921343-1Report Type:Expedited (15-DaCompany Report #MK200205-0227-1
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident		Pamelor 25mg					
	Communication Disorder		Capsules	PS				
	Drug Interaction		Wellbutrin-Slow Release	SS			100 MG BID	
			Celexa (Citalopram)	SS				

Date:05/22/02ISR Number: 3922173-7Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required	Blood Pressure Increased	Consumer	Zoloft Tablets	PS	
50.00 MG					
Intervention to	Cerebral Haemorrhage				
TOTAL: DAILY					
Prevent Permanent	Contusion		Wellbutrin	SS	ORAL
300.00 MG					
Impairment/Damage	Dementia				
TOTAL: BID:					
	Drug Ineffective				
ORAL					
	Epistaxis		Coumadin	SS	
	Fall		Effexor Xr	SS	ORAL
300.00 MG					
	Head Injury				
TOTAL:					
	Headache				
BID:ORAL					
	Heart Rate Decreased		Toprol	C	
	Heart Rate Increased		Zebeta	C	
	Hyperhidrosis		Lanoxin	C	
	Overdose		Lasix	C	
	Parkinson'S Disease		Synthroid	C	
	Syncope		Vitamin E	C	
			Estrogen	C	
			Amantadine	C	
			Zocor	C	
			Estradiol Vaginal Ring	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/02ISR Number: 3922257-3Report Type:Expedited (15-DaCompany Report #A210802
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Depression	Consumer	Zoloft Tablets	PS			50.000 MG	
Intervention to	Grand Mal Convulsion							TOTAL
Prevent Permanent			Wellbutrin Sr	SS		ORAL	150.00 MG	
Impairment/Damage								
TOTAL:BID:ORA								
L								

Date:05/22/02ISR Number: 3922545-0Report Type:Expedited (15-DaCompany Report #B0267143A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acidosis	Foreign	Bupropion					
Initial or Prolonged	Agitation	Literature	Hydrochloride Tablet					
	Confusional State	Health	- Zyban (Bupropion					
	Delusion Of Grandeur	Professional	Hydrochloride)	PS				
	Grand Mal Convulsion							
	Hallucination, Visual							
	Overdose							
	Respiratory Rate Increased							
	Sinus Tachycardia							
	Vomiting							

Date:05/23/02ISR Number: 3920481-7Report Type:Expedited (15-DaCompany Report #B0266864A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Zyntabac	PS	Glaxo Wellcome		UNKNOWN	32 DAY
Initial or Prolonged	Blood Creatinine		Furosemide	C	Glaxo Wellcome		UNKNOWN	

	Increased		Doxazosine	C		
UNKNOWN						
	Blood Urea Increased		Eprosartan	C	Glaxo Wellcome	
UNKNOWN						
	Hyperhidrosis					
	Pyrexia					

Date:05/23/02ISR Number: 3920964-XReport Type:Direct Company Report #CTU 168735
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abnormal Behaviour		Wellbutrin	PS		
200 MG 200 MG						
	Anger					
	Depression					
	Divorced					
	Drug Dependence					
	Feeling Abnormal					
	Job Dissatisfaction					
	Paranoia					
	Parent-Child Problem					
	Sleep Disorder					
	Weight Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/02ISR Number: 3921498-9Report Type:Expedited (15-DaCompany Report #A0368754A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:05/24/02ISR Number: 3921506-5Report Type:Expedited (15-DaCompany Report #B0268007A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension		Zyban	PS	Glaxo Wellcome	ORAL		
	Blood Glucose Abnormal							
	Chest Pain							

Date:05/24/02ISR Number: 3921507-7Report Type:Expedited (15-DaCompany Report #B0268089A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Zyban	PS	Glaxo Wellcome		UNKNOWN	

Date:05/24/02ISR Number: 3921511-9Report Type:Expedited (15-DaCompany Report #B0268467A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Mood		Zyban	PS	Glaxo Wellcome	ORAL	150MG	
	Feeling Drunk							
Variable dose	Suicidal Ideation						9	DAY

Date:05/28/02ISR Number: 3923289-1Report Type:Expedited (15-DaCompany Report #A0369795A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Hyperaemia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Vision Blurred							

Date:05/28/02ISR Number: 3923292-1Report Type:Expedited (15-DaCompany Report #B0260822A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health	Zyban	PS	Glaxo Wellcome		UNKNOWN	75 DAY
	International Normalised Ratio Increased	Professional	Warfarin	SS	Glaxo Wellcome		UNKNOWN	
			Spironolactone	C		ORAL	25MG Per day	
			Enalapril	C		ORAL	5MG Per day	
			Unspecified Medication	C			UNKNOWN	
			Furosemide	C	Glaxo Wellcome	ORAL	40MG Per day	
			Ethanol	C			UNKNOWN	

Date:05/29/02ISR Number: 3924107-8Report Type:Expedited (15-DaCompany Report #B0263173A
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Areflexia
	Depressed Level Of Consciousness
	Dysphasia

	Epilepsy Hemiparesis Hemiplegia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Paraesthesia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day 5 DAY

Date:05/29/02ISR Number: 3924108-XReport Type:Expedited (15-DaCompany Report #B0263835A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Dysphagia Hypovolaemia Lymphocyte Percentage Decreased Neutrophil Percentage Decreased Oedema Peripheral Pain Painful Respiration Paralysis Peak Expiratory Flow Rate Decreased Urticaria Generalised White Blood Cell Count Increased		Zyban	PS	Glaxo Wellcome	ORAL	14 DAY

Date:05/29/02ISR Number: 3924111-XReport Type:Expedited (15-DaCompany Report #B0268361A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Confusional State		Zyban	PS	Glaxo Wellcome	UNKNOWN	150MG Twice per day
	Dizziness						
	Insomnia		Alprazolam	C			.25MG per day

Sensory Disturbance

Date:05/29/02ISR Number: 3925257-2Report Type:Direct Company Report #CTU 169081
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Pruritic		Zyban 150 Mg Catalytica	PS	Catalytica	ORAL	150 MG QD	ORAL
			Albuterol	C				
			Glucophage	C				
			Cetaphil	C				
			Calcium	C				
			Xanax	C				
			Nicoderm	C				

Date:05/29/02ISR Number: 3925280-8Report Type:Direct Company Report #CTU 169088
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Generalised Rash Pruritic		Zyban 150 Mg Catalytica	PS	Catalytica	ORAL	150 MG BID	ORAL

			Synthroid	C		

Date:05/29/02ISR Number: 3925893-3Report Type:Direct Company Report #CTU 169143
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharmaceutical Product		Wellbutrin Sr 100 Mg	PS			2 TABS BID	
	Complaint							
	Rash							

Date:05/30/02ISR Number: 3925597-7Report Type:Expedited (15-DaCompany Report #B0267897A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	49	DAY
	Panic Attack		Nicorette	C	Glaxo Wellcome		SUBLINGUAL	2MG Five
	Suicidal Ideation						times per day	
			Ethanol	C		ORAL	4UNIT per day	

Date:05/30/02ISR Number: 3925600-4Report Type:Expedited (15-DaCompany Report #B0268687A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Fall						per day	
	Malaise		Contraceptive (Unspecified)	C				

Date:05/30/02ISR Number: 3926262-2Report Type:Direct Company Report #CTU 169234
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Zyban (Bupropion)	PS			600MG/DAY	
	Agitation		Wellbutran	SS				
	Confusional State		Bupropion	SS				
	Convulsion							
	Gastroenteritis Viral							
	Medication Error							
	Vomiting							

Date:05/30/02ISR Number: 3927773-6Report Type:Expedited (15-DaCompany Report #2002107579GB
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Depo-Medrone					
	Drug Interaction	Health	(Methylprednisolone)					
	Lumbar Vertebral Fracture	Professional	Suspension, Sterile	PS			INTRAVENOUS	30 MG,
		Other					SINGLE, IV	
			Bupropion (Amfebutamone)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/02ISR Number: 3926325-1Report Type:Expedited (15-DaCompany Report #A0370078A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Drug Interaction Drug Level Decreased Suicide Attempt		Wellbutrin Protease Inhibitor	PS SS	Glaxo Wellcome	ORAL	

Date:05/31/02ISR Number: 3926421-9Report Type:Direct Company Report #CTU 169263
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Rash		Buproprion 75 Mg Mylan Lot 1k1074	PS	Mylan	ORAL	150 MG BID PO

Date:05/31/02ISR Number: 3927112-0Report Type:Expedited (15-DaCompany Report #A0366054A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coma Completed Suicide Drug Ineffective Drug Toxicity Libido Decreased Overdose Pulmonary Congestion Toxicologic Test Abnormal Urinary Retention	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Venlafaxine Hydrochloride Gabapentin Ethanol Fexofenadine Hydrochlorid Alprazolam Hyoscyamine	PS C C C C C C		ORAL	SEE IMAGE/ORAL

Date:06/03/02ISR Number: 3926797-2Report Type:Expedited (15-DaCompany Report #B0266443A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Aggression Aphasia Ganglioneuroma Heart Rate Irregular Irritability Sleep Disorder Speech Disorder		Zyban	PS	Glaxo Wellcome	ORAL	6	WK

Date:06/03/02ISR Number: 3926808-4Report Type:Expedited (15-DaCompany Report #B0269491A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Zyban	PS	Glaxo Wellcome		150MG Twice per day	
			Atorvastatin	C			UNKNOWN	
			Amlodipine	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/02ISR Number: 3926811-4Report Type:Expedited (15-DaCompany Report #D0038591A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bowel Sounds Abnormal		Zyban	PS	Glaxo Wellcome	ORAL	16TAB Single	
	Coma						dose	1 DAY
	Intentional Misuse		Atosil	SS	Glaxo Wellcome	ORAL	10TAB Single	
	Suicide Attempt						dose	1 DAY
	Toxicologic Test Abnormal		Normoc	SS		ORAL	10TAB Single	
							dose	1 DAY
			Extr. Rad. Valerianae	SS		ORAL	10TAB Single	
							dose	1 DAY
			Hop Extract	SS		ORAL	10TAB Single	
							dose	1 DAY
			Alcohol	SS		ORAL	1 DAY	

Date:06/03/02ISR Number: 3928596-4Report Type:Expedited (15-DaCompany Report #A211508
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Electroencephalogram	Consumer	Zoloft Tablets	PS				
Intervention to	Abnormal		Wellbutrin Sr	SS		ORAL	150.00 MG	
Prevent Permanent	Grand Mal Convulsion						TOTAL: BID:	
Impairment/Damage							ORAL	

Date:06/04/02ISR Number: 3927256-3Report Type:Expedited (15-DaCompany Report #A0370262A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Dreams		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Anorexia							
	Back Injury							
	Crying							
	Epistaxis							
	Insomnia							
	Mood Altered							
	Nasal Odour							
	Rhinorrhoea							

Date:06/05/02ISR Number: 3927994-2Report Type:Expedited (15-DaCompany Report #A0369011A
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysphagia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Single dose	
	Foreign Body Trauma							
	Oesophageal Spasm		Elavil	C	Glaxo Wellcome			
	Retching							

Date:06/05/02ISR Number: 3932576-2Report Type:Periodic Company Report #A0160250A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Swelling	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
	Pruritus							
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/02ISR Number: 3932578-6Report Type:Periodic Company Report #A0161127A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Anger Anxiety Asthenia Coma Depression Fear Grand Mal Convulsion Impatience Limb Injury Loss Of Consciousness Marital Problem Memory Impairment Mood Altered Movement Disorder Pain In Extremity Personality Change Salivary Hypersecretion Snoring Somnolence Staring Tremor Vomiting	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride) Amitriptyline	PS C		ORAL	100 MG / TWICE PER DAY / ORAL	

Date:06/05/02ISR Number: 3932579-8Report Type:Periodic Company Report #A0161473A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Swelling Joint Swelling Nasopharyngitis Oedema Peripheral Urticaria	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Tylenol Cold Medication (Tylenol	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

			Cold Medication)	SS		ORAL
ORAL						
			Neocon	C		

Date:06/05/02ISR Number: 3932580-4Report Type:Periodic Company Report #A0164564A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Consumer	Zyban Tablet - Zyban			
	Fall		(Bupropion			
	Loss Of Consciousness		Hydrochloride)	PS		ORAL
150 MG/ TWICE						
PER DAY/ORAL						

Date:06/05/02ISR Number: 3932582-8Report Type:Periodic Company Report #A0168570A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Zyban Tablet - Zyban			
		Professional	(Bupropion			
			Hydrochloride)	PS		ORAL
150 MG/ PER						
DAY/ ORAL 1 WK						
			Thyroxine Sodium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/02ISR Number: 3932584-1Report Type:Periodic Company Report #A0168990A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	1 MON

Date:06/05/02ISR Number: 3932586-5Report Type:Periodic Company Report #A0169235A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	1 MON

Date:06/05/02ISR Number: 3932587-7Report Type:Periodic Company Report #A0169236A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ORAL	1 MON

Date:06/05/02ISR Number: 3932588-9Report Type:Periodic Company Report #A0170001A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ORAL	

Date:06/05/02ISR Number: 3932589-0Report Type:Periodic Company Report #A0170679A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angioneurotic Oedema Arthralgia Asthenia Eyelid Oedema Face Oedema Insomnia Joint Stiffness Lip Pain Musculoskeletal Stiffness Pain Rash Erythematous Skin Lesion Swelling Tenderness Throat Irritation Urticaria	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Esterified Estrogens Medroxyprogestrone Ace.	PS C C		ORAL	150 MG/TWICE PER DAY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/02ISR Number: 3932591-9Report Type:Periodic Company Report #A0106207A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Discomfort Dyspnoea	Foreign	Zyban Tablet - Zylan (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL 5 DAY
			Diltiazem Hydrochloride	C				
			Conjugated Estrogens	C				
			Hydrochlorothiazide	C				
			Atorvastatin Calcium	C				
			Nitroglycerine	C				
			Lorazepam	C				
			Pantoprazole	C				
			Lorazepam	C				

Date:06/05/02ISR Number: 3932592-0Report Type:Periodic Company Report #A0106346A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Liver Function Test Abnormal Musculoskeletal Disorder Vomiting	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	300 MG/ PER DAY;	ORAL 2 WK

Date:06/05/02ISR Number: 3932593-2Report Type:Periodic Company Report #A0106354A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent	Chest Pain Extrasystoles	Foreign	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	300 MG / PER	

Impairment/Damage
DAY / ORAL 10 DAY

Date:06/05/02ISR Number: 3932594-4Report Type:Periodic Company Report #A0143678A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anxiety Hypersensitivity Pruritus Rash Throat Tightness Urticaria	Health Professional Company Representative	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL

Date:06/05/02ISR Number: 3932595-6Report Type:Periodic Company Report #A0148626A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Disability Other	Convulsion Laceration	Health Professional Company Representative	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL 2 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/02ISR Number: 3932596-8Report Type:Periodic Company Report #A0149866A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Level Changed Hallucination, Auditory Loss Of Consciousness Photopsia Road Traffic Accident Tremor	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride) Meclozine (Formulation Unknown) (Meclozine)	PS SS		ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:06/05/02ISR Number: 3932597-XReport Type:Periodic Company Report #A0151283A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Face Oedema Joint Swelling Malaise Pain Pruritus Pyrexia Rash Maculo-Papular Serum Sickness	Foreign	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	19 DAY

Date:06/05/02ISR Number: 3932598-1Report Type:Periodic Company Report #A0151863A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Hypersensitivity Oropharyngeal Swelling Urticaria	Health Professional	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	

Date:06/05/02ISR Number: 3932599-3Report Type:Periodic Company Report #A0156006A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain Chest Discomfort Chest Pain Pain In Extremity	Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/ ORAL	

Date:06/05/02ISR Number: 3932600-7Report Type:Periodic Company Report #A0159085A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction Dyspnoea Fatigue Laryngeal Dyspnoea Rash Urticaria	Health Professional Company Representative	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/ ORAL	3 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/02ISR Number: 3944093-4Report Type:Periodic Company Report #A0172431A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Consumer	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL		

Date:06/05/02ISR Number: 3944096-XReport Type:Periodic Company Report #A0173889A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Difficulty In Walking Eye Swelling Joint Swelling Rash Urticaria	Foreign Consumer	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:06/05/02ISR Number: 3944097-1Report Type:Periodic Company Report #A0359127A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema Face Oedema Rash Urticaria	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:06/05/02ISR Number: 3944098-3Report Type:Periodic Company Report #A0360041A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Angioneurotic Oedema	Health	Zyban Tablet - Zyban			
Required	Asthenia	Professional	(Bupropion			
Intervention to	Dizziness		Hydrochloride)	PS		ORAL
150 MG/THREE						
Prevent Permanent	Eye Swelling					
TIMES PER						
Impairment/Damage	Face Oedema					
DAY/ORAL						
	Hypotension		Ziac	C		
	Oedema Mouth		Gemfibrozil	C		
	Palpitations					
	Pruritus					
	Rash					
	Rash Vesicular					
	Tremor					
	Urticaria					
	Urticaria Generalised					

Date:06/05/02ISR Number: 3944099-5Report Type:Periodic Company Report #A0361077A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Pressure	Health	Zyban Tablet - Zyban			
	Fluctuation	Professional	(Bupropion			
	Blood Pressure Increased		Hydrochloride)	PS		ORAL
150 MG/						
SINGLE DOSE/						
ORAL						
			Atorvastatin Calcium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/02ISR Number: 3944100-9Report Type:Periodic Company Report #A0137115A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Confusional State Convulsion Disorientation Muscle Rigidity Pain Panic Reaction Rhinorrhoea Salivary Hypersecretion Tremor Urinary Incontinence Visual Acuity Reduced	Health Professional	Zyban Tablet - Zyban (Bupropion Hydrchloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:06/05/02ISR Number: 3944101-0Report Type:Periodic Company Report #A0144963A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Dyspnoea Hypersensitivity Pruritus Rash Urticaria Vomiting	Consumer	Zyban Tablet - Zyban (Bupropion Hydrchloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:06/05/02ISR Number: 3944102-2Report Type:Periodic Company Report #A0145155A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness	Consumer	Zyban Tablet - Zyban (Bupropion					

	Hydrchloride)	PS	ORAL
ORAL			
	Ethanol (Alcohol)	SS	

Date:06/06/02ISR Number: 3930360-7Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Required	Abnormal Behaviour
Intervention to	Anger
Prevent Permanent	Balance Disorder
Impairment/Damage	Blood Oestrogen Decreased
	Blood Pressure Increased
	Blood Thyroid Stimulating
	Hormone Decreased
	Cerebral Haemorrhage
	Cognitive Disorder
	Contusion
	Convulsion
	Drug Ineffective
	Dysphonia
	Ear Disorder
	Epistaxis
	Fall
	Head Injury

	Headache					
	Heart Rate Decreased					
	Heart Rate Increased	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hostility	Consumer	Zoloft Tablets	PS		
50.00 MG						
	Hyperhidrosis					
TOTAL:DAILY						
	Injury		Wellbutrin	SS		ORAL
300.00 MG						
	Masked Facies					
TOTAL:BID:ORA						
	Medication Error					
L						
	Meningioma		Coumadin	SS		
	Mood Swings		Effexor Xr	SS		ORAL
300.00 MG						
	Nuclear Magnetic					
TOTAL:BID:ORA						
	Resonance Imaging					
L						
	Abnormal		Toprol	C		
	Palpitations		Zebeta	C		
	Parkinson'S Disease		Lanoxin	C		
	Prothrombin Time		Lasix	C		
	Prolonged		Synthroid	C		
	Sluggishness		Vitamin E	C		
	Syncope		Estrogen	C		
	Thyroxine Abnormal		Amantadine	C		
	Transient Ischaemic		Zocor	C		
	Attack		Estradiol Vaginal			
	Treatment Noncompliance		Ring	C		
	Tremor					
	Vaginal Haemorrhage					

Date:06/06/02ISR Number: 3933557-5Report Type:Expedited (15-DaCompany Report #B0264771A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Anxiety	Foreign	Paxil (Paroxetine			
Intervention to	Depression	Health	Hydrochloride)	PS		ORAL
ORAL						
Prevent Permanent	Malaise	Professional	Zyban Tablet			
Impairment/Damage	Nausea		(Bupropion			

			Hydrochloride)	SS		ORAL

1 TABLET/

TWICE PER

DAY/ ORAL

			Nicotine	C		

Date:06/07/02ISR Number: 3929339-0Report Type:Expedited (15-DaCompany Report #B0268848A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Zyban	PS	Glaxo Wellcome	ORAL
Initial or Prolonged	Blood Creatine		Becotide	C	Glaxo Wellcome	

RESPIRATORY

	Phosphokinase Increased					

(INHALATION)

	Chest Discomfort		Serevent	C	Glaxo Wellcome	

RESPIRATORY

	Chest Pain					

(INHALATION)

	Dyspnoea		Ventoline	C	Glaxo Wellcome	

UNKNOWN

	Electrocardiogram St Segment Abnormal					

Date:06/07/02ISR Number: 3929340-7Report Type:Expedited (15-DaCompany Report #B0269619A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Impaired Driving Ability		Zyban	PS	Glaxo Wellcome	
UNKNOWN 150MG Per day 1 MON						
	Labyrinthitis		Atenolol	C		

.25MG per day

			Alprazolam	C		
.5MG per day						

Date:06/07/02ISR Number: 3929341-9Report Type:Expedited (15-DaCompany Report #B0269621A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	ORAL	150MG per day	

Date:06/10/02ISR Number: 3930009-3Report Type:Expedited (15-DaCompany Report #A0169595A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antisocial Behaviour	Consumer	Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Apathy		Synthroid	C	Glaxo Wellcome	ORAL	.075MCG Per day	
	Hallucination, Auditory							
	Memory Impairment		Ritalin	C		ORAL	25MG Twice per day	
	Nervousness							
	Paranoia		Vitamin	C		ORAL		
	Pruritus		Depakote	C		ORAL	15 DAY	
	Rash Erythematous							
	Rash Vesicular							
	Scar							
	Suicidal Ideation							

Date:06/10/02ISR Number: 3930012-3Report Type:Expedited (15-DaCompany Report #A0367475A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	1 DAY
	Anxiety							

	Blindness					
	Cardiac Murmur					
	Cardiac Valve Disease					
	Chest Pain					
	Dyspnoea					
	Hypoaesthesia					
	Myocardial Infarction					
	Thrombosis					

Date:06/10/02ISR Number: 3930013-5Report Type:Expedited (15-DaCompany Report #A0370078A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Drug Ineffective	Consumer	Wellbutrin	PS	Glaxo Wellcome	ORAL	YR
Initial or Prolonged	Drug Interaction		Protease Inhibitor	SS			
	Drug Level Decreased		Ethanol	SS		ORAL	
	Intentional Misuse		Ambien	SS		ORAL	
	Suicide Attempt						

Date:06/10/02ISR Number: 3930014-7Report Type:Expedited (15-DaCompany Report #A0370671A
Age:36 YR Gender:Female I/FU:F

Outcome	PT
Other	Fatigue
	Grand Mal Convulsion
	Hypercalcaemia

Loss Of Consciousness

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	3 MON
			Lipitor	C		ORAL	20MG Per day	
			Amitriptyline	C		ORAL	25MG Per day	

Date:06/11/02ISR Number: 3933127-9Report Type:Expedited (15-DaCompany Report #A210802
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Drug Interaction	Consumer	Zoloft Tablets	PS			50.00 MG TOTAL	
	Grand Mal Convulsion	Health Professional	Wellbutrin Sr	SS			300.00 MG TOTAL: BID	
			Trazodone	C				

Date:06/11/02ISR Number: 3933217-0Report Type:Expedited (15-DaCompany Report #A0368764A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypertension	Health Professional Company Representative	Augmentin (Amox. Trihyd+Pot.Clavulan)	PS				
			Zyban Tablet - Zyban (Bupropion Hydrochloride)	SS		ORAL	150 MG / TWICE PER DAY	/ ORAL

				Expectorant (Expectorant)	SS	

Date:06/11/02ISR Number: 3934027-0Report Type:Expedited (15-DaCompany Report #B0269609A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Complex Partial Seizures Malaise	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		
UNKNOWN 3 WK						

Date:06/11/02ISR Number: 3934217-7Report Type:Expedited (15-DaCompany Report #B0269682A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus Pregnancy	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/ PER DAY/ ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/02ISR Number: 3934219-0Report Type:Expedited (15-DaCompany Report #D0038599A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Zyban Tablet - Zyban					
Life-Threatening	Loss Of Consciousness	Health Professional	(Bupropion Hydrochloride)	PS		ORAL	300 MG/ PER DAY/ ORAL	
			Antihypertensive	C				

Date:06/12/02ISR Number: 3931860-6Report Type:Expedited (15-DaCompany Report #A0364976A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	5 MON
	Diarrhoea							
	Epistaxis							
	Gastrointestinal Disorder							
	Vomiting							

Date:06/12/02ISR Number: 3931863-1Report Type:Expedited (15-DaCompany Report #A0368754A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Completed Suicide							
	Convulsion							
	Drug Level Increased							
	Intentional Misuse							
	Pulmonary Congestion							
	Pulmonary Oedema							
	Somnolence							
	Urinary Incontinence							

Date:06/12/02ISR Number: 3931870-9Report Type:Expedited (15-DaCompany Report #B0107035A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anorexia		Zyban	PS	Glaxo Wellcome	ORAL	2	WK
	Anxiety		Chloroquine	C				
	Completed Suicide							
	Depression							
	Dissociation							
	Disturbance In Attention							
	Feeling Abnormal							
	Headache							
	Injury Asphyxiation							
	Irritability							
	Mood Swings							
	Palpitations							
	Vision Blurred							

Date:06/12/02ISR Number: 3931875-8Report Type:Expedited (15-DaCompany Report #B0269481A
Age:56 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Tachycardia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	32 DAY

Date:06/12/02ISR Number: 3931879-5Report Type:Expedited (15-DaCompany Report #B0270232A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Major Depression		Zyban	PS	Glaxo Wellcome	ORAL	15 DAY	

Date:06/13/02ISR Number: 3932412-4Report Type:Expedited (15-DaCompany Report #A0173931A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholelithiasis		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Grand Mal Convulsion		Singulair	C				
			Levoxyl	C	Glaxo Wellcome			
			Prevacid	C				
			Luvox	C				

Date:06/13/02ISR Number: 3932418-5Report Type:Expedited (15-DaCompany Report #A0370680A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Brain Oedema							

	Glaucoma	Lipitor	C
	Haematemesis	Estrace	C
	Headache	Timoptic	C
	Intracranial Pressure	Carbachol	C
	Increased	Vagifem	C
	Intraocular Pressure	Baby Aspirin	C
	Increased	Protonix	C

Date:06/13/02ISR Number: 3932423-9Report Type:Expedited (15-DaCompany Report #A0371413A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrooesophageal Reflux		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	38	DAY
	Disease		Prozac	C		ORAL		
	Retching		Nicoderm	C	Glaxo Wellcome	TOPICAL		
	Thyroid Neoplasm		Levoxyl	C	Glaxo Wellcome	ORAL	.075MG	

Unknown

Date:06/13/02ISR Number: 3932449-5Report Type:Expedited (15-DaCompany Report #B0270183A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Colitis Ulcerative		Zyntabac	PS	Glaxo Wellcome	ORAL	300MG per day	41 DAY
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/02ISR Number: 3932452-5Report Type:Expedited (15-DaCompany Report #B0270350A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Foetal Distress Syndrome		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	35 DAY
	Jaundice							

Date:06/14/02ISR Number: 3933152-8Report Type:Expedited (15-DaCompany Report #B0269764A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchial Obstruction		Zyban	PS	Glaxo Wellcome	ORAL	20TAB Single dose	1 DAY
	Clonic Convulsion							
	Convulsion		Deroxat	SS	Glaxo Wellcome	ORAL	14TAB Single dose	1 DAY
	Depressed Level Of Consciousness		Arestal	C		ORAL	16TAB Single dose	1 DAY
	Intentional Misuse							
	Somnolence		Nifuroxazide	C	Glaxo Wellcome	ORAL	1 DAY	
	Suicide Attempt		Lexomil	C		ORAL	30TAB Single dose	1 DAY
	Tracheal Obstruction							

Date:06/14/02ISR Number: 3933157-7Report Type:Expedited (15-DaCompany Report #B0269840A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Increased		Ecstasy	SS		ORAL	1 DAY	
	Blood Ph Decreased							

Cardiac Arrest
Diarrhoea
Disseminated
Intravascular Coagulation
Drug Interaction
General Physical Health
Deterioration
Hyperhidrosis
Hyperpyrexia
Hypotension
Metabolic Acidosis
Mydriasis
Renal Failure
Rhabdomyolysis
Serotonin Syndrome
Shock

Date:06/18/02ISR Number: 3934255-4Report Type:Expedited (15-DaCompany Report #A0371095A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cystitis	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Drug Interaction		Atenolol	SS		ORAL	50MG Per day	
	Hypotension		Cardizem Cd	SS	Glaxo Wellcome	ORAL	360MG Unknown	
	Medication Error							
	Pharmaceutical Product Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/02ISR Number: 3934256-6Report Type:Expedited (15-DaCompany Report #A0371180A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Clonic Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Marijuana	C				
			Naprosyn	C				
			Flexeril	C				

Date:06/18/02ISR Number: 3934265-7Report Type:Expedited (15-DaCompany Report #B0270362A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Zyban	PS	Glaxo Wellcome	ORAL		
	Dyspnoea		Amarel	C				
	Headache							
	Hypertension							
	Pulmonary Oedema							

Date:06/18/02ISR Number: 3934267-0Report Type:Expedited (15-DaCompany Report #B0270415A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Unknown
Other	Overdose							
	Psychotic Disorder							

Date:06/18/02ISR Number: 3934269-4Report Type:Expedited (15-DaCompany Report #B0270422A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Thrombosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	23 DAY

Hospitalization - Initial or Prolonged	Cerebrovascular Accident Transient Ischaemic Attack		Oestrone Salmeterol	C C	 Glaxo Wellcome	ORAL RESPIRATORY (INHALATION) 50MCG Twice per day
			Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION) 2PUFF Four times per day
			Beclomethasone	C	Glaxo Wellcome	RESPIRATORY (INHALATION) 500MCG Four times per day
			Ipratropium	C	Glaxo Wellcome	RESPIRATORY (INHALATION) 40MCG Four times per day

Date:06/18/02ISR Number: 3934270-0Report Type:Expedited (15-DaCompany Report #B0270659A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain Hypothermia Urticaria		Zyntabac Alendronate Sodium	PS C	Glaxo Wellcome	UNKNOWN UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/02ISR Number: 3934271-2Report Type:Expedited (15-DaCompany Report #D0038028A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Diplopia Fear Hallucination Headache Intentional Misuse Suicide Attempt Tachycardia Tremor Vomiting	Health Professional	Zyban	PS	Glaxo Wellcome	ORAL	7.5G per day	1 DAY

Date:06/18/02ISR Number: 3935704-8Report Type:Expedited (15-DaCompany Report #A0371291A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State Convulsion Crying Dysgeusia Emotional Disorder Thinking Abnormal Vaginal Infection	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Lamictal Tablet (Lamotrigine) Wellbutrin Unspecified Tablet (Bupropion Hydrochloride) Clonazepam Lorazepam Ortho-Tri-Cyclen	PS SS SS C C C		ORAL ORAL ORAL	SEE DOSAGE TEXT 25 MG ORAL	ORAL 2 YEARS ORAL ORAL

Date:06/18/02ISR Number: 3935774-7Report Type:Expedited (15-DaCompany Report #A0370880A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Eye Pain Thrombosis	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	1	TABLET/TWICE
			Cetirizine Hydrochloride	C				DALY/ORAL

Date:06/19/02ISR Number: 3935138-6Report Type:Expedited (15-DaCompany Report #D0038714A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Epilepsy Respiratory Arrest		Zyban	PS	Glaxo Wellcome	ORAL		
			Miranova	C		ORAL		

Date:06/20/02ISR Number: 3935966-7Report Type:Expedited (15-DaCompany Report #A0170310A
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive Coronary Artery Disease Dystonia	Health Professional	Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	150MG Per day	

Date:06/20/02ISR Number: 3935970-9Report Type:Expedited (15-DaCompany Report #A0371430A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Withdrawal Convulsions		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:06/20/02ISR Number: 3935973-4Report Type:Expedited (15-DaCompany Report #A0372010A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction International Normalised Ratio Decreased	Health Professional	Wellbutrin Trazodone Warfarin Lovenox Zyprexa Clonazepam Colace Zoloft Tylenol Motrin Diphenhydramine Reglan	PS SS SS C C C C C C C C C	Glaxo Wellcome Glaxo Wellcome Glaxo Wellcome Glaxo Wellcome Glaxo Wellcome	ORAL	75MG Per day	12 DAY

Date:06/20/02ISR Number: 3935978-3Report Type:Expedited (15-DaCompany Report #B0122442A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	C-Reactive Protein	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	12 DAY
Initial or Prolonged	Increased	Professional	Propofan	SS		ORAL	1UNIT per day	1 DAY
Disability	Cheilitis		Prazepam	SS		ORAL	40MG per day	277 DAY
	Dermatitis Bullous		Alprazolam	C		ORAL	.25MG per day	277 DAY
	Erythema Multiforme		Zolpidem	C		ORAL	1UNIT per day	277 DAY
	Gamma-Glutamyltransferase Increased							
	Hypopyon							
	Intertrigo							
	Leukocytosis							
	Oedema							
	Oral Soft Tissue Disorder							
	Pyrexia							
	Rash Pustular							
	Skin Exfoliation							
	Skin Necrosis							
	White Blood Cell Count Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/02ISR Number: 3935979-5Report Type:Expedited (15-DaCompany Report #B0259252A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	C-Reactive Protein	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	12 DAY
Initial or Prolonged	Increased		Prazepam	SS		ORAL	40MG per day	276 DAY
	Cheilitis		Propofan	C		ORAL	1UNIT per day	1 DAY
	Dermatitis Bullous		Zolpidem	C		ORAL	1UNIT per day	276 DAY
	Hypopyon		Alprazolam	C		ORAL	.25MG As	
	Inflammation						required	276 DAY
	Intertrigo							
	Leukocytosis							
	Oedema							
	Pyrexia							
	Rash Pustular							
	Skin Exfoliation							
	Skin Necrosis							

Date:06/20/02ISR Number: 3935984-9Report Type:Expedited (15-DaCompany Report #B0270679A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Overdose		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Unknown
	Serotonin Syndrome							

Date:06/20/02ISR Number: 3935986-2Report Type:Expedited (15-DaCompany Report #B0270906A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Psychotic Disorder		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG As
							directed	52 DAY

			Paracetamol + Codeine	C		UNKNOWN
			Fenoterol + Ipratropium	C		RESPIRATORY (INHALATION)
			Cocaine	C		UNKNOWN

Date:06/20/02ISR Number: 3936777-9Report Type:Direct Company Report #CTU 170637
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin	PS		ORAL	MINIMUM DAILY	
	Hostility					ORAL		

Date:06/21/02ISR Number: 3936682-8Report Type:Expedited (15-DaCompany Report #A0372195A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Metabolic Acidosis	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Overdose	Professional	Topamax	SS		ORAL		
			Amaryl	SS				
			Prozac	SS				
			Vasotec	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/02ISR Number: 3936684-1Report Type:Expedited (15-DaCompany Report #B0122944A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	41 DAY
	Drug Withdrawal Syndrome							

Date:06/21/02ISR Number: 3936688-9Report Type:Expedited (15-DaCompany Report #B0269955A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alpha 2 Globulin		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	3 WK
	Increased							
	Arthralgia							
	C-Reactive Protein							
	Increased							
	Myalgia							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							

Date:06/21/02ISR Number: 3936696-8Report Type:Expedited (15-DaCompany Report #B0271139A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Enterocolitis		Zyban	PS	Glaxo Wellcome	ORAL		
	Haemorrhagic							

Date:06/21/02ISR Number: 3937138-9Report Type:Direct Company Report #CTU 170729
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Aggression		Bupropion	PS		ORAL	75MG BID ORAL	
Intervention to	Agitation		Diltiazem Sa	C				

Prevent Permanent Impairment/Damage	Anxiety Homicidal Ideation		Hctz 25mg/Triamterene Potassium Chloride Oxycodone Hcl Baclofen Pseudoephedrine Promethazine	 C C C C C C

Date:06/21/02ISR Number: 3937144-4Report Type:Direct Company Report #CTU 170717
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Zyban 150mg	PS		ORAL	1T TAB PO QD	X 3 D THEN PO
							BID , NOW QD	
			Habitrol Patch	C				

Date:06/24/02ISR Number: 3937901-4Report Type:Direct Company Report #CTU 170796
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Buproprion-Wellbutrin- 100mg Tabs					

				Glaxosmithkline	PS	Glaxosmithkline	ORAL
100MG 2X							
DAILY ORAL							
				Prozac	C		
				Atarax	C		

Date:06/24/02ISR Number: 3939099-5Report Type:Expedited (15-DaCompany Report #2002-BP-02683AU (0)
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Overdose	Health	Atrovent			
Other		Professional	(Ipratropium			
		Other	Bromide) (Nr)			
			(Ipratropium-Br)	PS		
			Zyban Sr (Nr)	SS		
			Temazepam			
			(Temazepam) (Nr)	SS		
			Antenex (Diazepam)			
			(Nr)	SS		
			Dichlotride			
			(Hydrochlorothiazide			
			) (Nr)	SS		
			Epilim (Valproate			
			Sodium) (Nr)	SS		
			Ventolin			
			(Salbutamol) (Nr)	SS		
			Flixotide			
			(Fluticasone			
			Propionate) (Nr)	C		

Date:06/27/02ISR Number: 3940684-5Report Type:Direct Company Report #CTU 171129
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea		Wellbutrin Sr 150mg	PS		ORAL
150MG SR PO						
Initial or Prolonged	Face Oedema					
BID 11 DAY						
	Medication Error		Prenatal Vitamin	C		
	Pruritus		Acetaminophen	C		
			Ibuprofen	C		

			Mahuana	C		

Date:06/27/02ISR Number: 3940929-1Report Type:Expedited (15-DaCompany Report #A0372287A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Foetal Growth Retardation Maternal Drugs Affecting Foetus	Study Health Professional	Bupropion Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		

ORAL

Date:06/27/02ISR Number: 3940963-1Report Type:Expedited (15-DaCompany Report #A0372286A
Age: Gender: I/FU:I

Outcome	PT
Other	Angiopathy Complications Of Maternal Exposure To Therapeutic Drugs Drug Exposure During

	Pregnancy Placental Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Study Health Professional	Bupropion Unspecifed (Bupropion Hydrochloride)	PS			
TRANSPLACENTAL	ORAL						

Date:06/27/02ISR Number: 3941582-3Report Type:Expedited (15-DaCompany Report #B0271009A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Anxiety Nausea Panic Attack Tremor	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG PER DAY ORAL

Date:06/28/02ISR Number: 3942017-7Report Type:Expedited (15-DaCompany Report #B0261044A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Asthenia Blindness Transient Conjunctival Hyperaemia	Foreign Health Professional	Amoxil (Formulation Unknown) (Amoxicillin)	PS		ORAL	ORAL
	Depressed Level Of Consciousness Diarrhoea		Zyban Tablet - Zyban (Bupropion Hydrochloride)	SS		ORAL	ORAL
	Dysstasia Hypertension Syncope Urticaria		Acetaminophen + Codeine	C			

Date:07/01/02ISR Number: 3942081-5Report Type:Direct Company Report #CTU 171325
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban 150mg Glaxco	PS	Glaxco	ORAL	1 PILL 2	
	Feeling Abnormal						TIMES ORAL	
	Hypoaesthesia							
	Hypoaesthesia Oral							
	Nervousness							
	Panic Attack							
	Paraesthesia							

Date:07/01/02ISR Number: 3942537-5Report Type:Expedited (15-DaCompany Report #A0364730A
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Other	Convulsion
	Crying
	Delusion
	Hallucination, Auditory
	Hallucination, Visual
	Headache
	Memory Impairment
	Mood Swings
	Panic Attack

		Paranoia Schizoaffective Disorder					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/TWICE PER DAY/ORAL							
				Levonorgestrel	C		
				Thyroxine Sodium	C		
				Alprazolam	C		

Date:07/01/02ISR Number: 3942987-7Report Type:Expedited (15-DaCompany Report #B0271436A
Age:36 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus	Foreign Health Professional Company Representative	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL
SEE DOSAGE TEXT / ORAL							

Date:07/01/02ISR Number: 3942996-8Report Type:Expedited (15-DaCompany Report #D0038746A
Age:55 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Acidosis Circulatory Collapse Convulsion Overdose	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
ORAL							
				Metformin Hydrochloride	C		

Date:07/01/02ISR Number: 3943434-1Report Type:Expedited (15-DaCompany Report #B0271581A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Tongue Ulceration	Foreign Health Professional	Nicoderm Cq Patch (Nicotine)	PS		TRANSDERMAL	TRANSDERMAL	
			Zyban Tablet - Zyban (Bupropion Hydrochloride)	SS			150 MG/TWICE PER DAY	
			Ranitidine Hydrochloride	C				
			Labetalol Hydrochloride	C				
			Napratec	C				

Date:07/01/02ISR Number: 3943450-XReport Type:Expedited (15-DaCompany Report #B0266566A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block Left Chest Discomfort Myalgia	Foreign Health Professional	Zyban Tablet- Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL	
	Myocardial Ischaemia	Company Representative	Birth Control	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/02ISR Number: 3942578-8Report Type:Direct Company Report #CTU 171445
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block Bundle Branch Block Right Dizziness Fall		Bupropion 150mg Verapamil Lisinopril Glipizide Hctz	PS C C C C		ORAL	150MG BID ORAL	

Date:07/02/02ISR Number: 3943700-XReport Type:Expedited (15-DaCompany Report #A0372639A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Blighted Ovum Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus Pregnancy	Study Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	300 MG PER DAY ORAL	

Date:07/02/02ISR Number: 3944131-9Report Type:Periodic Company Report #260829
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Euphoric Mood Fall Fatigue Grand Mal Convulsion Libido Decreased	Consumer Health Professional Other	Klonopin Tablets (Clonazepam) 0.5 Mg Wellbutrin (Ibupropion	PS		ORAL	1 PER PRN ORAL	

	Memory Impairment		Hydrochloride)	SS		ORAL	150 MG 2 PER
	Tooth Injury						DAY ORAL 7 DAY
			Paxil (Paroxetine)	SS		ORAL	20 MG DAILY
							ORAL

Date:07/03/02ISR Number: 3944208-8Report Type:Expedited (15-DaCompany Report #B0125399A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Confusional State Coordination Abnormal	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG ORAL
	Dizziness		Ferrour Sulfate	C			
	Drug Toxicity		Promethazine	C			
	Dysarthria		Propiomazine	C			
	Fall						
	Feeling Abnormal						
	Hallucination, Visual						
	Metabolic Disorder						
	Motion Sickness						
	Swelling						
	Vision Blurred						

Date:07/03/02ISR Number: 3944209-XReport Type:Expedited (15-DaCompany Report #B0130344A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Alcohol Poisoning Atherosclerosis Cardiac Arrest Drug Toxicity Overdose Pulmonary Congestion Pulmonary Oedema Toxicologic Test Abnormal Ventricular Hypertrophy	Foreign Health Professional	Zyban Tablet -Zyban (Bupropion Hydrochloride) Dothiepin (Formulation Unknown) (Dothiepin) Ethanol Liquid (Alcohol) Prempak-C Salbutamol Sulphate Diazepam Fluoxetine Zopiclone Beclomethasone Dipropion	PS SS SS C C C C C C		ORAL ORAL ORAL	150 MG/ PER DAY/ORAL 50 MG SEE DOSAGE TEXT / ORAL ORAL

Date:07/03/02ISR Number: 3944302-1Report Type:Expedited (15-DaCompany Report #B0270659A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain Hypothermia Urticaria	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Alendronate Sodium	PS C		ORAL	150 MG / ORAL

Date:07/03/02ISR Number: 3944304-5Report Type:Expedited (15-DaCompany Report #B0270415A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Zyban Tablet - Zyban					
Required	Overdose	Health	(Bupropion					
Intervention to	Psychotic Disorder	Professional	Hydrochloride)	PS			150 MG/ AS	
Prevent Permanent								
DIRECTED								
Impairment/Damage								
			Oxazepam	C				
			Mirtazapine	C				

Date:07/03/02ISR Number: 3944909-1Report Type:Expedited (15-DaCompany Report #US008746
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atelectasis	Health	Provigil	PS		ORAL	200 MG QD	
Initial or Prolonged	Bipolar Disorder	Professional						
ORAL								
	Coma		Provigil	SS				
	Delusion		Wellbutrin	SS		ORAL	6 TAB ONCE	
	Depression							
ORAL								
	Electrocardiogram T Wave		Wellbutrin	SS		ORAL	200 MG QD	
	Abnormal							
ORAL								
	Hypomania		Zyprexa	SS				
	Mania		Lithium	C				
	Overdose							
	Psychotic Disorder							
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/02ISR Number: 3944959-5Report Type:Expedited (15-DaCompany Report #B0271767A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Literature	Paxil (Paroxetine Hydrochloride)	PS				
	Drug Interaction	Health	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS			1	YR
	Hypomania	Professional	Carbamazepine	C				

Date:07/05/02ISR Number: 3945789-0Report Type:Expedited (15-DaCompany Report #B0272251A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / VARIABLE DOSE / ORAL	
	Fall	Health	Propranolol Hydrochloride	C				
	Hyperthyroidism	Professional	Ethanol	C				
			Silymarin	C				

Date:07/05/02ISR Number: 3945968-2Report Type:Expedited (15-DaCompany Report #A0372635A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness	Foreign	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER	
	Feeling Abnormal	Consumer						
	Heart Rate Decreased							

DAY / ORAL

Date:07/05/02ISR Number: 3945981-5Report Type:Expedited (15-DaCompany Report #B0271148A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pruritus Tenosynovitis	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER	DAY / ORAL

Date:07/05/02ISR Number: 3945992-XReport Type:Expedited (15-DaCompany Report #B0114445A
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety Arthralgia Depression Difficulty In Walking Fatigue Headache Hypersomnia Insomnia Malaise

		Movement Disorder Myalgia Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity Polymyalgia Rheumatica Red Blood Cell	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		
150 MG/ TWICE							
		Sedimentation Rate					
PER DAY/							
		Increased Somnolence Tremor					

Date:07/05/02ISR Number: 3945999-2Report Type:Expedited (15-DaCompany Report #B0269491A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Facial Palsy	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/						
VARIABLE						
DOSE/ ORAL						
			Atorvastatin Calcium Amlodipine Enalapril	C C C		

Date:07/05/02ISR Number: 3946022-6Report Type:Expedited (15-DaCompany Report #B0271161A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Mean Cell Volume Abnormal Neuropathy Peripheral	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG/PER						
DAY/ORAL						
			Miniphase Tablet			

			(Miniphase)	SS		ORAL	1 TABLET/PER DAY/ORAL
			Bromazepam Tablet (Bromazepam)	SS		ORAL	.5 TABLET/TWICE PER DAY/ORAL
			Di-Antalvic (Di-Antalvic)	SS		ORAL	2 UNIT/MONTHLY/ ORAL

Date:07/05/02ISR Number: 3946044-5Report Type:Expedited (15-DaCompany Report #B0271860A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation Anxiety Depressed Mood Depression Dry Mouth Insomnia Malaise Medication Error Panic Attack Suicidal Ideation	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride) Temazepam	PS C		ORAL	SEE DOSAGE TEXT/ORAL	

Date:07/05/02ISR Number: 3946237-7Report Type:Expedited (15-DaCompany Report #A0367126A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Convulsion Intentional Misuse Intentional Self-Injury Vomiting	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Methylphenidate Hci	PS C		ORAL	1500 MG	ORAL

Date:07/05/02ISR Number: 3946287-0Report Type:Expedited (15-DaCompany Report #B0271672A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pneumothorax	Foreign Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:07/05/02ISR Number: 3946325-5Report Type:Expedited (15-DaCompany Report #B0272116A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disinhibition Elevated Mood Hallucination, Auditory Mania Psychomotor Hyperactivity	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	

Date:07/05/02ISR Number: 3946593-XReport Type:Expedited (15-DaCompany Report #A0373043A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Interaction Potentiation	Health Professional Company Representative	Wellburtin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Cetirizine Hydrochloride (Formulation Unknown) (Cetirizine Hydrochloride)	SS		ORAL	ORAL	
			Antibiotics (Formulation Unknown) (Antibiotics)	SS		ORAL	ORAL	
			Montelukast Sodium (Formulation Unknown) (Montelukast Sodium)	SS		ORAL	ORAL	
			Allergy Medication (Formulation Unknown) (Allergy Medication)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/02ISR Number: 3946610-7Report Type:Expedited (15-DaCompany Report #B0270679A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Overdose	Foreign	Zyban Tablet - Zyban					
	Serotonin Syndrome	Health	(Bupropion					
		Professional	Hydrochloride)	PS			150 MG	
			Quetiapine	C				
			Clonazepam	C				

Date:07/08/02ISR Number: 3944409-9Report Type:Expedited (15-DaCompany Report #B0269955A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alpha 2 Globulin		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	3 WK
	Increased							
	Arthralgia							
	C-Reactive Protein							
	Increased							
	Myalgia							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							

Date:07/08/02ISR Number: 3944418-XReport Type:Expedited (15-DaCompany Report #D0038493A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Apathy		Zyban	PS	Glaxo Wellcome	ORAL	60TAB Single	
Initial or Prolonged	Disorientation							
dose							1	DAY
	Disturbance In Attention		Diclofenac	SS		ORAL	40TAB Single	
	Hypertension							
dose							1	DAY
	Intentional Misuse		Diphenhydramine					

	Suicide Attempt		Hydrochloride	SS	Glaxo Wellcome	ORAL
10TAB Single						
	Tachycardia					
dose 1 DAY						
			Amphetamine	SS		
UNKNOWN						

Date:07/09/02ISR Number: 3945042-5Report Type:Expedited (15-DaCompany Report #A0360169A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Anxiety		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Twice						
	Depressed Mood					
per day 8 MON						
	Fatigue		Paxil	C	Glaxo Wellcome	ORAL
20MG Per day						
	Intentional Misuse		Epival	C		
750MG At						
night						
			Lipitor	C		ORAL
40MG Per day						
			Remeron	C		
45MG At night						

Date:07/09/02ISR Number: 3945151-0Report Type:Direct Company Report #CTU 171795
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Alopecia		Sulfasalazine 500mg			
			Watson Laboratories	PS	Watson Laboratories	ORAL
500MG TWICE						
DAILY ORAL						
			Wellbutrin 150mg	SS		ORAL
150MG ONCE						
DAILY ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/02ISR Number: 3945742-7Report Type:Direct Company Report #CTU 171802
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity		Wellbutrin Sr Tab 100 Mg Glaxo Smithkline	PS	Glaxo Smithkline	ORAL	100MG SR QAM	ORAL
			Dilantin	C				
			Norvasc	C				
			Cipro	C				
			Nicoderm Patch	C				
			Ativan	C				
			Ambien	C				
			Tylenol	C				

Date:07/09/02ISR Number: 3945771-3Report Type:Direct Company Report #CTU 171815
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Serum Sickness		Wellbutrin Sr 150mg	PS			BID	
			Lescol Xl	C				
			Adallat Cc	C				

Date:07/09/02ISR Number: 3946846-5Report Type:Expedited (15-DaCompany Report #A0373063A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion Drug Abuser Fall Laceration Road Traffic Accident	Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	100 MG / THREE TIMES PER DAY /	

ORAL						
			Wellbutrin Sr Tablet-Controlled Release	SS		ORAL
ORAL						
			Methadone Hydrochloride	C		

Date:07/09/02ISR Number: 3946987-2Report Type:Expedited (15-DaCompany Report #USA-2002-0001076
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Atherosclerosis	Consumer	Oxycontin Tablets					
Other	Coronary Artery Atherosclerosis	Health Professional	(Oxycodone Hydrochloride) Cr Tablet	PS				
	Drug Abuser	Other	Methadone (Methadone)	Unknown	SS			
	Drug Dependence		Hydrocodone Bitartrate (Similar To Ind 59,175) (Hydrocodone Bitartrate)	Unknown	SS			
	Drug Toxicity							
	Fibrosis							
	Mitral Valve Disease							
	Pericardial Effusion							
	Pleural Effusion							
	Pneumonia Bacterial							
MG								
	Respiratory Tract Infection		Dihydrocodeine / Caffeine / Acetaminophen					

				(Similar To Anda 88-584)	SS			MG
				Bupropion (Amfebutamone) Unknown	SS			MG
				Ibuprofen (Ibuprofen) Tablet	SS			MG
				Dextromethorphan (Dextromethorphan)	SS			MG
				Ephedrine (Ephedrine) Unknown	SS			MG
				Pseudoephedrine (Pseudoephedrine) Unknown	SS			MG
				Doxylamine (Doxylamine) Unknown	SS			MG
				Levorphanol (Levorphanol) Unknown	SS			MG
				Alprazolam (Alprazolam) Unknown	SS			MG
				Codeine (Codeine) Unknown	SS			MG
				Heroin (Diamorphine) Unknown	SS			MG

Date:07/09/02ISR Number: 3947122-7Report Type:Expedited (15-DaCompany Report #A0371095A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Cystitis	Consumer	Zyban (Bupropion Hyrochloride)	PS		ORAL	150 MG/PER	

	Drug Interaction					
DAY/ORAL						
	Myocardial Infarction		Atenolol (Formulation Unknown) (Generic) (Atenolol)	SS		ORAL
50 MG/PER DAY/ORAL						
			Diltiazem Hydrochloride	SS		ORAL
360 MG/ORAL						

Date:07/09/02ISR Number: 3947135-5Report Type:Expedited (15-DaCompany Report #A0362556A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Conversion Disorder	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
200 MG/TWICE PER DAY/ORAL						
			Amitriptyline Hcl	C		

Date:07/09/02ISR Number: 3947185-9Report Type:Expedited (15-DaCompany Report #A0359984A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Ecchymosis Overdose Pulmonary Congestion	Foreign Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion			

			Hydrochloride)	PS			ORAL 150 MG PER DAY/ORAL
			Citalopram Hydrobromide	C			
			Clonazepam	C			

Date:07/09/02ISR Number: 3947262-2Report Type:Expedited (15-DaCompany Report #B0272342A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Foreign	Zyban Tablet - Zyban					
	Insomnia	Health	(Bupropion					
	Joint Effusion	Professional	Hydrchoride)	PS		ORAL	ORAL	
	Nephrolithiasis							
	Renal Colic							
	Tremor							

Date:07/09/02ISR Number: 3947273-7Report Type:Expedited (15-DaCompany Report #B0272177A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Sudden Death	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Zestoretic	C				

Date:07/10/02ISR Number: 3945938-4Report Type:Expedited (15-DaCompany Report #A0370262A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	61 DAY
	Anorexia							
	Back Injury							

	Crying
	Epistaxis
	Insomnia
	Mood Altered
	Nasal Odour
	Rhinorrhoea
	Stress

Date:07/10/02ISR Number: 3945944-XReport Type:Expedited (15-DaCompany Report #B0260007A
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Death	Aphasia
	Brain Oedema
	Bronchospasm
	C-Reactive Protein
	Increased
	Cardio-Respiratory Arrest
	Chest X-Ray Abnormal
	Coma
	Computerised Tomogram
	Abnormal
	Cyanosis
	Hepatic Failure
	Injury

	Laryngeal Oedema						
	Leukocytosis						
	Malaise	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Mydriasis		Zyban	PS	Glaxo Wellcome	ORAL	
	Painful Respiration		Kardegic	SS		ORAL	75MG Per day
	Pharyngolaryngeal Pain		Rulid	SS	Glaxo Wellcome	ORAL	1 DAY
	Pyrexia		Surgam	C		ORAL	400MG per day 1 DAY
	Renal Failure		Elisor	C		ORAL	
	Syncope		Discotrine	C	Glaxo Wellcome	TRANSDERMAL	
	Ventricular Fibrillation		Sectral	C		ORAL	
			Artotec	C		ORAL	

Date:07/11/02ISR Number: 3948193-4Report Type:Expedited (15-DaCompany Report #0714201A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Tongue Ulceration	Foreign	Habitrol-Nicotine				
		Health	Transdermal				
		Professional	21mg-Hvch	PS	Nvch		1
		Other					PATCH/QD/TTS
			Zyban (Bupropion)	SS		ORAL	150 MG/BD/PO
			Ranitidine	C			
			Labetalol	C			
			Naparatec (Naproxen, Misoprostol)	C			

Date:07/12/02ISR Number: 3948285-XReport Type:Expedited (15-DaCompany Report #2002114146GB
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Tongue Ulceration	Foreign	Nicoderm (Nicotine)				
		Health	Patch	PS		TRANSDERMAL	SEE IMAGE

	Professional Other	Zyban (Amfebutamone Hydrochloride)	SS	ORAL 150 MG, BID, ORAL
		Ranitidine Hydrochloride	C	
		Labetalol Hydrochloride (Labetalol Hydrochloride)	C	

Date:07/12/02ISR Number: 3948713-XReport Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Required	Anger
Intervention to	Balance Disorder
Prevent Permanent	Blood Oestrogen Decreased
Impairment/Damage	Blood Pressure Increased
	Blood Thyroid Stimulating Hormone Decreased
	Cerebral Haemorrhage
	Contusion
	Convulsion
	Drug Ineffective
	Epistaxis
	Fall

	Head Injury					
	Headache					
	Heart Rate Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Heart Rate Increased	Consumer	Zoloft Tablets	PS		ORAL
50.00 MG						
	Hostility					
TOTAL : DAILY						
	Hyperhidrosis					
: ORAL						
	Laceration		Wellbutrin Sr	SS		ORAL
300.00 MG						
	Medication Error					
TOTAL: BID:						
	Meningioma					
ORAL						
	Nuclear Magnetic		Coumadin	SS		
	Resonance Imaging Brain		Effexor Xr	SS		ORAL
300.00 MG						
	Abnormal					
TOTAL : BID :						
	Overdose					
ORAL						
	Palpitations		Toprol	C		
	Parkinsonism		Zebeta	C		
	Prothrombin Time		Lanoxin	C		
	Prolonged		Lasix	C		
	Syncope		Synthroid	C		
	Transient Ischaemic		Vitamin E	C		
	Attack		Estrogen	C		
	Tremor		Zocor	C		
	Vaginal Haemorrhage		Estradiol With			
			Vaginal Ring	C		
			Inderal	C		
			Monopril	C		
			Cardizem	C		
			Folic Acid	C		
			Amantadine (Subject)	C		

Date:07/15/02ISR Number: 3948156-9Report Type:Expedited (15-DaCompany Report #A0373618A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dyspnoea	Health	Zantac	PS	Glaxo Wellcome	

	Urticaria	Professional	Wellbutrin	SS	Glaxo Wellcome	
			Paxil	SS	Glaxo Wellcome	
			Celebrex	SS		
			Neurontin	SS		
			Topamax	SS		
			Klonopin	SS		
			Progesterone	C		
			Salbutamol	C	Glaxo Wellcome	
			Pentosane Polysulfate	C		
			Hydroxyzine	C		
			Amitriptyline	C		
			Oxycodone Hydrochloride	C		

Date:07/15/02ISR Number: 3948158-2Report Type:Expedited (15-DaCompany Report #A0373917A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	2 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/02ISR Number: 3948168-5Report Type:Expedited (15-DaCompany Report #B0271008A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Zyban	PS	Glaxo Wellcome	ORAL	10	DAY
	Erythema	Professional	Nicorette	C	Glaxo Wellcome	ORAL		
	Joint Swelling							
	Malaise							
	Myalgia							
	Oedema Peripheral							
	Pyrexia							
	Serum Sickness							
	Urticaria							

Date:07/15/02ISR Number: 3948439-2Report Type:Direct Company Report #CTU 172287
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Bupropion 150 Mg Glaxo-Wellcome	PS	Glaxo-Wellcome	ORAL	150 MG.	BID
	Hallucination							
	Hypoglycaemia							
ORAL								
			Amaryl	C				
			Actos	C				
			Glucophage	C				

Date:07/15/02ISR Number: 3948605-6Report Type:Direct Company Report #CTU 172300
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chills		Zyban 150mg					
Hospitalization - Initial or Prolonged	Confusional State		Glaxo-Wellcome	PS	Glaxo-Wellcome		ONE IN AM	
Disability	Dizziness		Premarin 1.25mg	C				
	Dysarthria		Aspirin	C				
	Euphoric Mood		Centr	C				
	Eye Rolling		Silver Vitiman	C				
	Fear							

	Hyperhidrosis						
	Movement Disorder						
	Oedema						
	Sensation Of Heaviness						

Date:07/16/02ISR Number: 3948684-6Report Type:Expedited (15-DaCompany Report #A0369795A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Hyperaemia	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Eye Irritation	Professional					per day	21 DAY
	Vision Blurred							
	Visual Disturbance							

Date:07/16/02ISR Number: 3948687-1Report Type:Expedited (15-DaCompany Report #A0373866A
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Dyspepsia
	Fall
	Lower Limb Fracture
	Tinnitus

Upper Limb Fracture

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Twice per day							
				Diltiazem	C	Glaxo Wellcome	
240MG per day							
				Prinivil	C		
5MG per day							
				Clonazepam	C		
1.5MG per day							
				Ticlid	C		
250MG Twice per day							
				Neurontin	C		
600MG per day							
				Insulin	C		
40UNIT Twice per day							
				Vitamin B12	C	Glaxo Wellcome	
				Tylenol	C	Glaxo Wellcome	

Date:07/16/02ISR Number: 3948707-4Report Type:Expedited (15-DaCompany Report #B0271860A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Agitation	Health	Zyban	PS	Glaxo Wellcome	ORAL
18 DAY						
	Anxiety	Professional	Temazepam	C		
UNKNOWN						
	Depressed Mood					
	Depression					
	Drug Ineffective					
	Dry Mouth					
	Insomnia					
	Malaise					
	Medication Error					
	Panic Attack					
	Suicidal Ideation					

Date:07/16/02ISR Number: 3949386-2Report Type:Direct Company Report #CTU 172424
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Grand Mal Convulsion		Wellbutrin Sr	PS			150 MGM BID	
Required Intervention to Prevent Permanent Impairment/Damage			Ritalin	C				
			Ambien	C				

Date:07/16/02ISR Number: 3949721-5Report Type:Expedited (15-DaCompany Report #B0272924A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Foreign	Zyban Tablet - Zyban	PS		ORAL	ORAL	
	Pyromania	Health Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/02ISR Number: 3950017-6Report Type:Expedited (15-DaCompany Report #B0270415A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Zyban Tablet-Zyban					
Required	Injury	Health	(Bupropion					
Intervention to	Overdose	Professional	Hydrochloride)	PS			150 MG/AS	
Prevent Permanent	Psychotic Disorder						DIRECTED	
Impairment/Damage	Skin Injury		Oxazepam	C				
	Tendon Injury		Mirtazapine	C				

Date:07/16/02ISR Number: 3950020-6Report Type:Expedited (15-DaCompany Report #D0038838A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aggression	Foreign	Zyban Tablet-Zyban					
	Anxiety	Consumer	(Bupropion					
	Bipolar Disorder		Hydrochloride)	PS		ORAL	150 MG/ ORAL	
	Depression		Paxil (Formulation					
	Diarrhoea		Unknown) (Paroxetine					
	Disturbance In Attention		Hydrochloride)	SS				
	Hyperhidrosis							
	Hypomania							
	Migraine							
	Nausea							
	Nervousness							
	Sleep Disorder							
	Tachycardia							
	Vertigo							
	Weight Decreased							

Date:07/16/02ISR Number: 3950278-3Report Type:Expedited (15-DaCompany Report #A0072356A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Akathisia	Health	Wellbutrin Tablet					
Required	Clonic Convulsion	Professional	(Bupropion					

Intervention to	Depersonalisation	Company	Hydrochloride)	PS		ORAL
100 MG/THREE						
Prevent Permanent	Dystonia	Representative				
TIMES PER						
Impairment/Damage	Nervous System Disorder					
DAY/ORAL						
	Respiratory Alkalosis		Triamcinolone			
	Tardive Dyskinesia		Acetonide	C		
	Tremor		Melatonin	C		

Date:07/16/02ISR Number: 3950292-8Report Type:Expedited (15-DaCompany Report #A0366635A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Flutter	Health	Wellbutrin Sr					
Initial or Prolonged	Blindness Transient	Professional	Tablet-Controlled					
Required	Dyspnoea		Release (Bupropion					
Intervention to	Heart Rate Increased		Hydrochloride)	PS		ORAL		
SEE DOSAGE								
Prevent Permanent								
TEXT/ORAL								
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/02ISR Number: 3949441-7Report Type:Expedited (15-DaCompany Report #A0373933A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	
		Professional	Tegretol	C				

Date:07/17/02ISR Number: 3949442-9Report Type:Expedited (15-DaCompany Report #A0374100A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Consumer	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	4 DAY
	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus							

Date:07/17/02ISR Number: 3949555-1Report Type:Expedited (15-DaCompany Report #316974
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Health	Klonopin	PS	Roche			
	Urticaria	Professional	Celebrex	SS				
			Neurontin	SS				
			Topamax	SS				
			Paxil	SS				
			Zantac	SS				
			Wellbutrin	SS				
			Progesterone	C				
			Salbutamol	C				
			Pentosane					
			Polysulphate	C				
			Hydroxyzine	C				
			Amitriptyline	C				

Date:07/17/02ISR Number: 3950439-3Report Type:Expedited (15-DaCompany Report #B0273130A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eczema	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL	

Date:07/17/02ISR Number: 3950473-3Report Type:Expedited (15-DaCompany Report #A0373400A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Feeling Hot Haemoglobin Decreased Headache Malaise	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/ ORAL	
	Oral Intake Reduced		Nitrazepam	C				
			Glibenclamide	C				
			Fluoxetine Hydrochloride	C				

Date:07/17/02ISR Number: 3950886-XReport Type:Expedited (15-DaCompany Report #A0373158A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Spasms	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	200 MG/ TWICE PER DAY/ORAL	
			Citalopram Hydrobrome	C				

Date:07/18/02ISR Number: 3950201-1Report Type:Expedited (15-DaCompany Report #A0374178B
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Developmental Delay		Wellbutrin	PS	Glaxo Wellcome		150MG	Unknown
	Maternal Drugs Affecting Foetus							
	Premature Baby							

Date:07/19/02ISR Number: 3950827-5Report Type:Expedited (15-DaCompany Report #A0373936A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	450MG	Unknown
			Unknown	C				

Date:07/19/02ISR Number: 3950830-5Report Type:Expedited (15-DaCompany Report #B0120942A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis		Bupropion					

Initial or Prolonged	Arthritis Reactive	Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice
	Asthma					
per day 26 DAY						
	Dyspnoea	Decortin	C			
	Heart Rate Increased					
	Hypersensitivity					
	Osteoarthritis					
	Pyrexia					
	Rash					
	Tobacco Abuse					
	Urticaria					
	Yersinia Infection					

Date:07/19/02ISR Number: 3950834-2Report Type:Expedited (15-DaCompany Report #B0273496A
Age:23 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	C-Reactive Protein Increased
	Coagulation Factor V Level Decreased
	Coagulation Factor Vii Level Decreased
	Fibrin D Dimer Increased
	Proteinuria

	Prothrombin Level Decreased Urticaria Generalised	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS	Glaxo Wellcome	ORAL
21	DAY					
			Adepal	C		
UNKNOWN						

Date:07/19/02ISR Number: 3950837-8Report Type:Expedited (15-DaCompany Report #B0273786A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Depression		Zyban	PS	Glaxo Wellcome	
UNKNOWN	150MG					
	Mania					
Variable dose	11 DAY					

Date:07/19/02ISR Number: 3950842-1Report Type:Expedited (15-DaCompany Report #D0038746A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acidosis		Zyban	PS	Glaxo Wellcome	ORAL
1800MG per						
Initial or Prolonged	Blood Lactic Acid					
day	2 DAY					
Other	Increased		Metformin	C		ORAL
850MG Per day						
	Circulatory Collapse					
	Convulsion					
	Overdose					
	White Blood Cell Count Increased					

Date:07/22/02ISR Number: 3951379-6Report Type:Direct Company Report #CTU 172642
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Condition Aggravated		Wellbutrin Sr	PS		ORAL
150 MG PO BID						
	Cough		Aspirin	C		
	Extrasystoles		Vitamins	C		
	Sinus Bradycardia					
	Supraventricular Extrasystoles					
	Ventricular Arrhythmia					
	Ventricular Extrasystoles					

Date:07/22/02ISR Number: 3951863-5Report Type:Direct Company Report #CTU 172700
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety		Bupropion	PS		ORAL
100MG PO						
	Crying					
	Decreased Appetite					
	Dyspnoea					
	Fatigue					

Date:07/23/02ISR Number: 3951888-XReport Type:Expedited (15-DaCompany Report #A0374687A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Ventricular Tachycardia		Bupropion	PS	Glaxo Wellcome	ORAL
200MG Per day 3 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/02ISR Number: 3951892-1Report Type:Expedited (15-DaCompany Report #B0131464A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown 29 DAY
	Angina Pectoris		Methylenedioxymethamphetamine	SS		ORAL	2	DAY
	Blood Creatine Increased		Alcohol	C				
	Blood Creatine Phosphokinase Increased		Cannabis	C				
	Cardiac Disorder							
	Cardiac Failure							
	Chest Pain							
	Cutaneous Vasculitis							
	Cytomegalovirus Infection							
	Diarrhoea							
	Ecchymosis							
	Ejection Fraction Decreased							
	Electrocardiogram St Segment Elevation							
	Gangrene							
	Hepatomegaly							
	Hyperpyrexia							
	Hypotension							
	Leukocytoclastic Vasculitis							
	Malaise							
	Myocardial Infarction							
	Skin Necrosis							
	Somnolence							
	Splenomegaly							
	Troponin I Increased							
	Vomiting							

Date:07/23/02ISR Number: 3951896-9Report Type:Expedited (15-DaCompany Report #B0267249A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetes Mellitus	Health	Zyban	PS	Glaxo Wellcome	ORAL	3	WK
	Insulin-Dependent	Professional						

Weight Decreased

Date:07/24/02ISR Number: 3952669-3Report Type:Expedited (15-DaCompany Report #A0372286A
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Maternal Drugs Affecting Foetus Placental Disorder Placental Insufficiency Stillbirth		Bupropion	PS	Glaxo Wellcome	ORAL		

Date:07/24/02ISR Number: 3952690-5Report Type:Expedited (15-DaCompany Report #B0272783A
Age:32 YR Gender:Female I/FU:F

Outcome	PT
Other	Alanine Aminotransferase Increased Aspartate

	Aminotransferase Increased Blood Creatine Phosphokinase Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Lactate		Zyban	PS	Glaxo Wellcome	ORAL
16 DAY						
	Dehydrogenase Increased		Nicotine Patch	SS	Glaxo Wellcome	
TRANSDERMAL						
	Insomnia		Ikaran	C		
YR						
	Muscle Spasms		Adepal	C		
YR						

Date:07/24/02ISR Number: 3952692-9Report Type:Expedited (15-DaCompany Report #B0273874A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Aspartate		Zyban	PS	Glaxo Wellcome	ORAL
300MG per day	31 DAY					
Life-Threatening	Aminotransferase		Lectil	SS		ORAL
26 DAY						
Hospitalization -	Increased		Tanganil	SS		ORAL
10 DAY						
Initial or Prolonged	Blood Creatine		Stilnox	SS		ORAL
10MG Per day	30 DAY					
Other	Phosphokinase Increased					
	Blood Creatinine Increased					
	Brain Oedema					
	Cardio-Respiratory Arrest					
	Cervical Vertebral Fracture					
	Coma					
	Corneal Reflex Decreased					
	Electrocardiogram T Wave Amplitude Increased					
	Fall					
	Hyperkalaemia					
	Laboratory Test Abnormal					
	Malaise					
	Mydriasis					
	Pallor					
	Sinus Tachycardia					
	Ventricular Fibrillation					

Date:07/24/02ISR Number: 3952698-XReport Type:Expedited (15-DaCompany Report #B0274253A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome		Zyban	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Mb Increased		Tahor	C		ORAL	40MG Per day	
Disability	Chest Pain		Discotrine	C	Glaxo Wellcome	TRANSDERMAL	10MGD Per day	
	Troponin I Increased		Kardegic	C		ORAL	160MG Per day	
			Monotildiem	C	Glaxo Wellcome	ORAL	200MG Per day	

Date:07/24/02ISR Number: 3952699-1Report Type:Expedited (15-DaCompany Report #B0274315A
Age:35 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
Disability	Dyspnoea
	Face Oedema
	Gamma-Glutamyltransferase Increased
	Hepatic Enzyme Increased
	Myalgia

	Oedema Peripheral					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day	1 WK					

Date:07/24/02ISR Number: 3952836-9Report Type:Direct Company Report #CTU 172860
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Anorexia		Wellbutrin Sr 150mg			
	Anxiety		Glaxo/Smit	PS	Glaxo/Smit	ORAL
150MG BID						
	Confusional State					
ORAL						
	Mydriasis		Fluoxetine 10mg			
	Tachycardia		Generic	SS		ORAL
10MG QD ORAL						
	Tremor					
	Vomiting					

Date:07/25/02ISR Number: 3953122-3Report Type:Expedited (15-DaCompany Report #A0374100A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Per day	4 DAY					
	Complications Of Maternal					
	Exposure To Therapeutic					
	Drugs					
	Maternal Drugs Affecting					
	Foetus					

Date:07/25/02ISR Number: 3954978-0Report Type:Expedited (15-DaCompany Report #B0274041A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Psoriasis	Foreign Literature Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL 150 MG / TWICE PER DAY / ORAL

Date:07/25/02ISR Number: 3954981-0Report Type:Expedited (15-DaCompany Report #B0274017A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Dehydration Dermatitis Exfoliative Ectropion Malaise Mean Cell Volume Increased Staphylococcal Infection	Foreign Literature Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL 150 MG/ TWICE PER DAY / ORAL
			Emollient	C		

Date:07/25/02ISR Number: 3954983-4Report Type:Expedited (15-DaCompany Report #B0093634A
Age:43 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Face Oedema Malaise

		Neutrophil Count Increased Psoriasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Red Blood Cell Sedimentation Rate Increased	Foreign Literature Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Cyclosporin	PS C		ORAL
ORAL							

Date:07/26/02ISR Number: 3953754-2Report Type:Expedited (15-DaCompany Report #B0273542A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Ill-Defined Disorder		Zyban	PS	Glaxo Wellcome	ORAL
150MG Unknown 1 DAY						
	Oligomenorrhoea		Beclomethasone	C	Glaxo Wellcome	
RESPIRATORY						
	Staring					
(INHALATION) 200MCG	Twice					
	Tremor					
per day						
			Salbutamol	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION) 2PUFF	Unknown					

Date:07/26/02ISR Number: 3956680-8Report Type:Expedited (15-DaCompany Report #B0089512A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Erythema Multiforme Leukocytosis Psoriasis	Foreign Literature Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG /						
TWICE PER DAY		Company				
/ ORAL		Representative	Co-Proxamol Dothiepin	C C		

Coal Tar	C
Corticosteroid	C
Dithranol	C

Date:07/29/02ISR Number: 3954537-XReport Type:Expedited (15-DaCompany Report #B0274449A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxo Wellcome	ORAL		

Date:07/29/02ISR Number: 3954541-1Report Type:Expedited (15-DaCompany Report #B0274763A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Keratitis		Zyban	PS	Glaxo Wellcome	ORAL	7	WK
	Sjogren'S Syndrome							

Date:07/29/02ISR Number: 3954542-3Report Type:Expedited (15-DaCompany Report #B0275022A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	ORAL	1TAB Per day	8 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/02ISR Number: 3954606-4Report Type:Direct Company Report #CTU 173068
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour		Bupropion 100mg					
Hospitalization -	Crying		Teva	PS		ORAL	100 MG TWICE	
Initial or Prolonged	Eye Disorder						DAILY ORAL	
	Feeling Cold		Concerta	C				
	Hypersomnia							
	Incoherent							
	Insomnia							
	Malaise							
	Medication Error							
	Mental Disorder							
	Mood Altered							
	Overdose							
	Speech Disorder							
	Suicide Attempt							
	Thinking Abnormal							
	Trance							

Date:07/29/02ISR Number: 3954989-5Report Type:Direct Company Report #CTU 173122
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Zyban 150mg Tbsr	PS	Tbsr	ORAL	1TAB PO QD X	
							3 D , THEN	
							BID	
			Seroquel	C				
			Serzone	C				
			Prozac	C				
			Imipramine	C				
			Buspar	C				

Date:07/30/02ISR Number: 3955018-XReport Type:Expedited (15-DaCompany Report #B0271436A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Health	Zyban	PS	Glaxo Wellcome	ORAL	1	MON
	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus	Professional						

Date:07/30/02ISR Number: 3955033-6Report Type:Expedited (15-DaCompany Report #B0275127A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	17	DAY
	Depression Dissociative Disorder Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/02ISR Number: 3955607-2Report Type:Direct Company Report #CTU 173219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Anotia		Bupropion Sr	PS			100MG QD	
	Maternal Drugs Affecting						STARTED	
	Foetus						BEFORE	
	Microtia						PREGNANCY	
			Desonide Ointment	SS			PRN VERY	
							SPARINGLY	
							EARLY	
							PREGNANCY	
			Metronidazole Lotion	C				

Date:07/30/02ISR Number: 3955958-1Report Type:Expedited (15-DaCompany Report #A0072356A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acquired Porphyria	Health	Wellbutrin Tablet					
Required	Acute Stress Disorder	Professional	(Bupropion					
Intervention to	Alopecia	Company	Hydrochloride)	PS		ORAL	100 MG / SEE	
Prevent Permanent	Anxiety	Representative					DOSAGE TEXT /	
Impairment/Damage	Clonic Convulsion						ORAL	
	Convulsion		Diazepam					
	Cytomegalovirus Antibody		(Formulation					
	Positive		Unknown) (Diazepam)	SS		ORAL	VARIABLE DOSE	
	Depersonalisation						/ ORAL	
	Depressed Level Of		Bismuth					
	Consciousness		Subsalicylate					
	Dissociation		(Formulation					

	Drug Toxicity		Unknown) (Bismuth				
	Dystonia		Subsalicylate)	SS			
	Encephalopathy		Triamcinolone				
	Epstein-Barr Virus		Acetonide	C			
	Antibody Positive		Melatonin	C			
	Joint Stiffness		Herbal Medication	C			
	Mood Altered						
	Muscle Contracture						
	Nail Discolouration						
	Nail Disorder						
	Pressure Of Speech						
	Rash Erythematous						
	Skin Discolouration						
	Staring						
	Tardive Dyskinesia						
	Thyroid Neoplasm						
	Tremor						
	Visual Disturbance						
	Weight Decreased						

Date:07/31/02ISR Number: 3955787-9Report Type:Direct Company Report #CTU 173243
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin 150 Mg-Sr					
	Decreased Appetite		1 Po Bid	PS		ORAL	1 PO BID	
	Dehydration							
	Emotional Distress							
	Insomnia							
	Sunburn							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/02ISR Number: 3956280-XReport Type:Direct Company Report #CTU 173337
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS				
	Gun Shot Wound							

Date:08/01/02ISR Number: 3956384-1Report Type:Expedited (15-DaCompany Report #A0374178B
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Heart Disease Congenital		Wellbutrin	PS	Glaxo Wellcome		150MG	Unknown
	Premature Baby		Celexa	C				

Date:08/01/02ISR Number: 3956393-2Report Type:Expedited (15-DaCompany Report #B0271008A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	10	DAY
Initial or Prolonged	Discomfort		Nicorette	C	Glaxo Wellcome	ORAL		
Other	Erythema							
	Joint Swelling							
	Malaise							
	Myalgia							
	Oedema							
	Oedema Peripheral							
	Pyrexia							
	Serum Sickness							
	Urticaria							

Date:08/01/02ISR Number: 3956394-4Report Type:Expedited (15-DaCompany Report #B0272783A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Alanine Aminotransferase	Zyban	PS	Glaxo Wellcome	ORAL
16 DAY					
	Increased	Nicotine Patch	C	Glaxo Wellcome	
TRANSDERMAL					
	Aspartate	Ikaran	C		
10MG per day					
	Aminotransferase	Adepal	C		
YR					
	Increased				
	Blood Creatine				
	Phosphokinase Increased				
	Blood Lactate				
	Dehydrogenase Increased				
	Insomnia				
	Muscle Spasms				
	Myalgia				

Date:08/01/02ISR Number: 3956398-1Report Type:Expedited (15-DaCompany Report #B0274315A
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
	Arthralgia
Disability	C-Reactive Protein Increased
	Dyspnoea
	Face Oedema
	Liver Function Test

	Abnormal					
	Myalgia					
	Oedema Peripheral					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day	8 DAY					

Date:08/01/02ISR Number: 3956413-5Report Type:Expedited (15-DaCompany Report #B0275303A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Physical Abuse		Zyban	PS	Glaxo Wellcome	
UNKNOWN						

Date:08/01/02ISR Number: 3958181-XReport Type:Expedited (15-DaCompany Report #A202614
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Required	Blood Sodium Abnormal	Health	Zoloft Tablets	PS		
Intervention to	Blood Testosterone	Professional	Neurontin	SS		
Prevent Permanent	Decreased		Paxil	SS		
Impairment/Damage			Wellbutrin	SS		
			Ambien	C		
			Albuterol Inhaler	C		
			Atenolol	C		
			Folic Acid	C		
			Zocor	C		
			Hydrochlorothiazide	C		

Date:08/01/02ISR Number: 3958565-XReport Type:Expedited (15-DaCompany Report #B0274494A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Anorexia	Literature	Eskalith			
	Bradycardia	Health	(Formulation			
	Bradyphrenia	Professional	Unknown) (Lithium			
	Depression		Carbonate)	PS		
1500 MG / PER						

	Disturbance In Attention		
DAY			
	Drug Ineffective	Topiramate	
	Drug Interaction	(Formulation	
	Drug Level Increased	Unknown)	
	Fatigue	(Topiramate)	SS
	Lethargy	Wellbutrin	
	Medication Error	(Formulation	
	Memory Impairment	Unknown) (Bupropion	
	Nausea	Hydrochloride)	SS
	Neurotoxicity	Semisodium Valproate	
	Nystagmus	(Formulation	
	Tremor	Unknown) (Divalproex	
	Weight Increased	Sodium)	SS
		Citalopram	C

Date:08/02/02ISR Number: 3956954-0Report Type:Expedited (15-DaCompany Report #A0372798A
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness
	Grand Mal Convulsion
	Intentional Misuse

	Nystagmus						
	Respiratory Depression						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	9000MG cumulative dose
			Ethanol	C		ORAL	
			Metabolite Herbal Supplement	C			
			Enbrel	C		ORAL	

Date:08/02/02ISR Number: 3956957-6Report Type:Expedited (15-DaCompany Report #A0376136A
Age: YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Anotia		Wellbutrin	PS	Glaxo Wellcome		100MG Unknown 2 YR
	Maternal Drugs Affecting		Metronidazole	C	Glaxo Wellcome	TOPICAL	
	Foetus		Desonide	C		TOPICAL	
	Microtia						

Date:08/02/02ISR Number: 3957744-5Report Type:Direct Company Report #CTU 173451
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin	PS			600MG/24HOURS 1 DAY
	Blindness Transient						
	Productive Cough						
	Tremor						

Date:08/02/02ISR Number: 3960456-5Report Type:Periodic Company Report #2001AP05222
Age:48 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Amitriptylline	PS				
		Health Professional	Bupropion	SS				

Date:08/05/02ISR Number: 3957571-9Report Type:Expedited (15-DaCompany Report #A0062462A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Diplopia						per day	
	Eye Disorder		Xanax	C			1.5MG per day	
	Vision Blurred		Triamterene	C	Glaxo Wellcome		12.5MG per	
							day	
			Prinivil	C			40MG per day	

Date:08/05/02ISR Number: 3957575-6Report Type:Expedited (15-DaCompany Report #B0120942A
Age:20 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis Reactive
	Asthma
	Fungal Infection
	Heart Rate Increased

	Hypersensitivity					
	Osteoarthritis					
	Tobacco Abuse	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Yersinia Infection		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL
150MG Twice per day	26 DAY					
			Decortin	C		

Date:08/05/02ISR Number: 3957576-8Report Type:Expedited (15-DaCompany Report #B0275736A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aggression		Zyban	PS	Glaxo Wellcome	
UNKNOWN	2TAB per day					
Initial or Prolonged	Agitation					
	Depression					
	Palpitations					
	Panic Attack					

Date:08/05/02ISR Number: 3957804-9Report Type:Direct Company Report #CTU 173480
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Chest Discomfort		Wellbutrin	PS		ORAL
150 MG PO TD	1 DAY					
	Diarrhoea		Glucophage	C		
	Heart Rate Increased		Avandia	C		
			Precose	C		
			Atarax	C		
			Ginko	C		

Date:08/07/02ISR Number: 3958753-2Report Type:Expedited (15-DaCompany Report #A0375990A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - Initial or Prolonged	Back Injury		Wellbutrin	PS	Glaxo Wellcome	ORAL 150MG Twice per day
	Convulsion					
	Headache		Zyban	SS	Glaxo Wellcome	ORAL 150MG See dosage text
			Zocor	C		
			Stool Softener	C		

Date:08/07/02ISR Number: 3958754-4Report Type:Expedited (15-DaCompany Report #A0376093A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL 150MG Twice per day 19 DAY
	Arthralgia					
	Cyanosis		No Concurrent Medication	C		
	Difficulty In Walking					
	Insomnia					
	Oedema Peripheral					
	Rash					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/07/02ISR Number: 3958755-6Report Type:Expedited (15-DaCompany Report #A0376196A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyponatraemia Inappropriate Antidiuretic Hormone Secretion		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:08/07/02ISR Number: 3958756-8Report Type:Expedited (15-DaCompany Report #A0376485A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Thrombosis		Zyban	PS	Glaxo Wellcome	ORAL		

Date:08/07/02ISR Number: 3960398-5Report Type:Expedited (15-DaCompany Report #B0274494A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia	Literature	Eskalith (Lithium Carbonate)	PS			1500 MG / PER	DAY
	Bradycardia	Health						
	Bradyphrenia	Professional						
	Depression		Topiramate (Topiramate)	SS				
	Disturbance In Attention							
	Drug Interaction		Wellbutrin (Bupropion Hydrochloride)	SS				
	Drug Level Increased							
	Fatigue		Semisodium Valproate (Divalproex Sodium)	SS				
	Lethargy							
	Medication Error		Citalopram	C				
	Memory Impairment							
	Nausea							
	Neurotoxicity							
	Nystagmus							
	Tremor							
	Weight Decreased							
	Weight Increased							

Date:08/08/02ISR Number: 3959455-9Report Type:Expedited (15-DaCompany Report #A0370671A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Calcium Increased		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Fatigue						per day	3 MON
	Grand Mal Convulsion		Lipitor	C		ORAL	20MG Per day	
	Loss Of Consciousness		Amitriptyline	C		ORAL	25MG Per day	

Date:08/08/02ISR Number: 3959461-4Report Type:Expedited (15-DaCompany Report #B0275697A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness		Zyban	PS	Glaxo Wellcome	ORAL	150MG As	
	Tinnitus						directed	
			Dihydrocodeine	C		ORAL		
			Hormone Replacement Therapy	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/02ISR Number: 3959687-XReport Type:Direct Company Report #CTU 173780
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Buprion-Wellbutrin-	PS		ORAL	ORAL	

Date:08/08/02ISR Number: 3959912-5Report Type:Direct Company Report #CTU 173781
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Sr	PS		ORAL	150MG BID PO	
			Alesse	C				
			Flovent	C				
			Ambien	C				
			Xanax	C				
			Effexor Xr	C				
			Imitrex	C				

Date:08/09/02ISR Number: 3960002-6Report Type:Expedited (15-DaCompany Report #A0376700A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma Incoherent Intentional Misuse Suicide Attempt		Wellbutrin No Concurrent Medication	PS C	Glaxo Wellcome	ORAL		

Date:08/09/02ISR Number: 3960005-1Report Type:Expedited (15-DaCompany Report #B0264307A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchial Obstruction Clonic Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	3000MG Single dose	1 DAY

	Depressed Level Of		Deroxat	SS	Glaxo Wellcome	ORAL	280MG Single
	Consciousness						dose 1 DAY
	Intentional Misuse		Seresta	SS		ORAL	1 DAY
	Muscle Contractions		Lexomil	SS		ORAL	180MG Single
	Involuntary						dose 1 DAY
	Somnolence		Alcohol	C			
	Suicide Attempt		Nifuroxazide	C	Glaxo Wellcome	ORAL	1 DAY
	Tracheal Obstruction		Arestal	C		ORAL	16MG Single
							dose 1 DAY

Date:08/09/02ISR Number: 3960088-9Report Type:Direct Company Report #CTU 173829
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Abuser		Wellbutrin Sr	PS	Glaxcosmithkline	NASAL	150MG DAILY
	Medication Error						NASAL

Date:08/09/02ISR Number: 3962187-4Report Type:Expedited (15-DaCompany Report #USA-2002-0000807
Age:28 YR Gender:Female I/FU:F

Outcome	PT
Death	Accidental Overdose
	Drug Toxicity
	Ecchymosis

	Pulmonary Congestion Pulmonary Oedema	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer Health Professional Other	Morphine Sulfate (Similar To Nda 19-516)(Morphine Sulfate)Unknown	PS			
			Hydromorphone Hcl (Similar To Ind 38,424)(Hydromorphone Hydrochloride)Unknow	SS			
			Fluoxetine (Fluoxetine) Tablet	SS		ORAL	ORAL
			Diazepam (Diazepam) Injectable	SS			
			Bupropion (Amfebutamone) Unknown	SS			
			Promethazine (Promethazine) Unknown	SS			
			Propranolol (Propranolol) Tablet	SS			
			Oxepam(Oxazepam) Unknown	SS			
			Caffeine (Caffeine) Unknown	SS			
			Nicotine(Nicotine)Unknown	SS			

Date:08/12/02ISR Number: 3960666-7Report Type:Expedited (15-DaCompany Report #B0270679A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Confusional State		Zyban	PS	Glaxo Wellcome		
UNKNOWN	150MG Unknown						
	Hyperhidrosis		Quetiapine	C			1000MG per
	Hypertension						day

	Loss Of Consciousness		Clonazepam	C		
5MG per day						
	Overdose		Alcohol	C		
	Serotonin Syndrome					
	Somnolence					
	Tachycardia					

Date:08/12/02ISR Number: 3961388-9Report Type:Periodic Company Report #11850310
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Health Professional	Sustiva Caps 600 Mg (Efavirenz)	PS		ORAL	600 MILLIGRAM, DAY, ORAL	
		Company Representative						
			Stavudine	SS				
			Didanosine	SS				
			Wellbutrin(Bupropion Hcl)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/02ISR Number: 3961228-8Report Type:Expedited (15-DaCompany Report #A0163498A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	57 DAY
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Insomnia							
	Maternal Drugs Affecting Foetus							
	Pruritus							

Date:08/13/02ISR Number: 3961229-XReport Type:Expedited (15-DaCompany Report #A0376142A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Unknown	5 MON
	Chest Pain		Synthroid	C	Glaxo Wellcome			
	Gastrointestinal Disorder		Tenormin	C				
	Hostility		Premarin	C				
	Memory Impairment							
	Mood Swings							

Date:08/13/02ISR Number: 3961230-6Report Type:Expedited (15-DaCompany Report #A0376485A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Thrombosis		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:08/13/02ISR Number: 3961232-XReport Type:Expedited (15-DaCompany Report #A0377262A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Anxiety	Wellbutrin	PS	Glaxo Wellcome	ORAL
300MG Per day 2 YR					
	Aphasia	Estrogen Replacement	C		ORAL
3MG Per day					
	Balance Disorder	Advil	C	Glaxo Wellcome	ORAL
	Constipation	Calcium	C		ORAL
	Dry Mouth	Fish Oil	C		ORAL
	Dysgeusia				
	Insomnia				
	Libido Increased				
	Memory Impairment				
	Nausea				
	Pharyngolaryngeal Pain				
	Tinnitus				

Date:08/13/02ISR Number: 3961248-3Report Type:Expedited (15-DaCompany Report #B0276351A
Age:35 YR Gender:Male I/FU:I

Outcome	PT
Other	Anxiety
	Choking Sensation
	Confusional State
	Histrionic Personality
	Disorder
	Panic Attack
	Paranoia

	Sensation Of Foreign Body Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG Variable dose 8 DAY

Date:08/15/02ISR Number: 3963976-2Report Type:Expedited (15-DaCompany Report #WAES 01072531
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Amnesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 Initial or Prolonged
	Asthenia	Health					MG/DAILY/PO
Disability	Back Pain	Professional	Wellbutrin 150 Mg	SS			150 MG/BID
	Cervical Spinal Stenosis		Astelin	C			
	Depression		Delestrogen	C			
	Electrocardiogram St		Flexeril	C			
	Segment Depression		Lipitor	C			
	Faecal Incontinence		Nasonex	C			
	Gait Spastic		Profen Ii	C			
	Grand Mal Convulsion		Ultram	C			
	Hypoaesthesia		Clonazepam	C			
	Impaired Driving Ability						
	Intervertebral Disc Protrusion						
	Loss Of Consciousness						
	Loss Of Employment						
	Myelopathy						
	Pain						
	Petit Mal Epilepsy						
	Quadriparesis						
	Spinal Cord Injury						
	Syncope						
	Urinary Incontinence						

Date:08/16/02ISR Number: 3962920-1Report Type:Expedited (15-DaCompany Report #A0377435A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL		

Date:08/16/02ISR Number: 3962928-6Report Type:Expedited (15-DaCompany Report #B0276132A
Age:45 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased
	Blood Albumin Decreased
	Blood Potassium Decreased
	Blood Sodium Decreased
	Blood Urea Decreased
	C-Reactive Protein Increased
	Diabetes Mellitus
	Erythema Multiforme
	Gamma-Glutamyltransferase Increased

	Heart Rate Increased Lymphocyte Count Decreased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Neutrophil Count		Zyban	PS	Glaxo Wellcome	ORAL	11 DAY
	Increased		Mediator	SS		ORAL	150MG Twice per day
	Prurigo Pyrexia Rosacea White Blood Cell Count Increased						

Date:08/16/02ISR Number: 3962996-1Report Type:Direct Company Report #CTU 174352
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide Decreased Appetite Gun Shot Wound Medication Error		Zyban 150mg Sr Catalytica Pharmaceuticals	PS	Catalytica Pharmaceuticals	ORAL	1 TABLET 3 DAYS ORAL
			Zyban	SS	Catalytica Pharmaceuticals	ORAL	1 TAB TWICE DAILY ORAL

Date:08/19/02ISR Number: 3963401-1Report Type:Expedited (15-DaCompany Report #A0371180A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Clonic Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day
			Marijuana	C			

			Naprosyn	C		
			Flexeril	C		

Date:08/19/02ISR Number: 3963410-2Report Type:Expedited (15-DaCompany Report #B0276134A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Clonic Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	14UNIT	Single
Initial or Prolonged	Intentional Misuse						dose	1 DAY
	Suicide Attempt		Cimicifuga	C		ORAL	1	DAY
	Toxicologic Test Abnormal		Alcohol	C				

Date:08/19/02ISR Number: 3963419-9Report Type:Direct Company Report #CTU 174419
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intentional Misuse		Topomax	PS			25MG BID	
Initial or Prolonged	Suicide Attempt		Wellbutrin	SS			100MG BID	

Date:08/19/02ISR Number: 3964158-0Report Type:Direct Company Report #CTU 174530
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Welbutrin-	PS				
Initial or Prolonged			Venlafaxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/02ISR Number: 3964175-0Report Type:Direct Company Report #CTU 174511
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Bruxism Dizziness Dyskinesia Erythema Headache Hyperacusis Insomnia Joint Stiffness Nausea Pyrexia		Wellbutrin Sr 150mg Wellbutrinsr	PS		ORAL	150MG 1X FOR 3 ORAL, 150MG 2X PER	

Date:08/19/02ISR Number: 3964735-7Report Type:Expedited (15-DaCompany Report #2002119339GB
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Interaction Lumbar Vertebral Fracture	Foreign Other	Depo-Medrone (Methylprednisolone) Suspension, Sterile Zyban Prolonged Realeased Tablets	PS SS		ORAL		ORAL

Date:08/20/02ISR Number: 3964009-4Report Type:Expedited (15-DaCompany Report #A0377456A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Respiratory Depression		Bupropion Hydrochloride Cocaine Morphine Heroin Codeine	PS SS C C C	Glaxo Wellcome			

Date:08/20/02ISR Number: 3964081-1Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11850310
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Health Professional	Sustiva Caps 600 Mg	PS	Bristol-Myers Squibb Company	ORAL		
			Stavudine	SS	Bristol-Myers Squibb Company	ORAL	unknown start date-prior to 06-Dec-00	
			Videx Ec Caps	SS	Bristol-Myers Squibb Company	ORAL	at hour of sleep	
			Wellbutrin	SS		ORAL	AM + 1600 x 30 days	

Date:08/20/02ISR Number: 3964535-8Report Type:Direct Company Report #CTU 174626
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Zyban 150 Mg Tbsr	PS			ONE DOSE PO	QD X 3D OTHER

BID

Date:08/20/02ISR Number: 3964561-9Report Type:Direct Company Report #CTU 174643
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Wellbutrin Sr 100mg	PS		ORAL	100MG	6 DAY
	Rash Papular		Calcium	C				
			Depakote	C				
			Multivitamin	C				

Date:08/21/02ISR Number: 3964459-6Report Type:Expedited (15-DaCompany Report #A0378334A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Serum Sickness		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	18 DAY
			Concerta	C			1	YR

Date:08/21/02ISR Number: 3964460-2Report Type:Expedited (15-DaCompany Report #B0130344A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Adhesions	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	
	Blood Ethanol Increased	Professional	Dothiepin	SS		ORAL	50MG See dosage text	47 DAY
	Cardiac Arrest							
	Coronary Artery Atherosclerosis		Alcohol	SS		ORAL		
			Prempak-C	C		ORAL	.625MG	
	Intentional Misuse						Unknown	

Pulmonary Congestion Salbutamol C Glaxo Wellcome
RESPIRATORY
Pulmonary Oedema
(INHALATION) 100MCG As
Ventricular Hypertrophy
required
Diazepam C
UNKNOWN 5MG As
required
Fluoxetine C
UNKNOWN 40MG Per day
Zopiclone C
UNKNOWN 7.5MG At
night
Beclomethasone C Glaxo Wellcome
RESPIRATORY
(INHALATION) 100U Unknown

Date:08/21/02ISR Number: 3964467-5Report Type:Expedited (15-DaCompany Report #B0276547A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intentional Misuse	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	14	DAY
Initial or Prolonged	Suicide Attempt		Zoloft	SS		ORAL	50MG	per day
			Lexomil	C		ORAL	4MG	per day

Date:08/21/02ISR Number: 3964473-0Report Type:Expedited (15-DaCompany Report #B0277109A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Monoplegia		Zyban	PS	Glaxo Wellcome			
UNKNOWN	150MG Twice							
Hospitalization -	Respiratory Failure							
per day	6	DAY						
Initial or Prolonged								
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/21/02ISR Number: 3965979-0Report Type:Expedited (15-DaCompany Report #A0361723A
Age:10 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abnormal Behaviour Condition Aggravated Grand Mal Convulsion Orchidectomy	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	200 MG/TWICE PER DAY/ORAL	

Date:08/21/02ISR Number: 3965982-0Report Type:Expedited (15-DaCompany Report #A0377696A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia Strabismus	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	450 MG / IN THE MORNING/ ORAL	

Date:08/23/02ISR Number: 3965386-0Report Type:Expedited (15-DaCompany Report #B0264661A
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death UNKNOWN	Acute Myocardial Infarction Bronchopneumonia Hypoxia Malaise Nausea		Zyban Tramadol Hydrochloride	PS C	Glaxo Wellcome	 UNKNOWN	150MG Per day	5 DAY

Date:08/23/02ISR Number: 3965387-2Report Type:Expedited (15-DaCompany Report #B0265519A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholestasis Hepatic Neoplasm Hyperplasia Systemic Lupus Erythematosus Rash		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	

Date:08/23/02ISR Number: 3965388-4Report Type:Expedited (15-DaCompany Report #B0271436A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus		Zyban	PS	Glaxo Wellcome	ORAL	1	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/23/02ISR Number: 3965915-7Report Type:Direct Company Report #CTU 174894
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Cold		Wellbutrin Sr 150mg					
	Pain In Extremity		Glaxo-Wellcome	PS	Glaxo-Wellcome	PARENTERAL	150MG SR QD	
	Tremor					PARENTERAL		

Date:08/23/02ISR Number: 3967053-6Report Type:Expedited (15-DaCompany Report #A0377881A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Consumer	Nicorette Otc Gum					
	Chronic Obstructive Pulmonary Disease		(Nicotine Polacrilex)	PS		ORAL		
	Drug Dependence		Wellbutrin					
	Emphysema		(Bupropion					
	Hyperphagia		Hydrochloride)	SS		ORAL		

Date:08/26/02ISR Number: 3966012-7Report Type:Expedited (15-DaCompany Report #B0264067A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Discomfort		Zyban	PS	Glaxo Wellcome	ORAL	300MG per day	62 DAY
	Malaise							
	Sudden Death							

Date:08/26/02ISR Number: 3966013-9Report Type:Expedited (15-DaCompany Report #B0271008A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 15 DAY	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL
Initial or Prolonged	Erythema		Nicorette	C	Glaxo Wellcome	ORAL
Other	Hepatic Steatosis					
	Joint Swelling					
	Malaise					
	Myalgia					
	Oedema Peripheral					
	Pyrexia					
	Serum Sickness					
	Urticaria					

Date:08/26/02ISR Number: 3966020-6Report Type:Expedited (15-DaCompany Report #B0277513A
Age:61 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL
150MG Unknown 26 DAY						
Other	Myalgia					
	Oedema Peripheral					
	Red Blood Cell Sedimentation Rate Increased					
	Urticaria					
	White Blood Cell Count Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/02ISR Number: 3966329-6Report Type:Expedited (15-DaCompany Report #A0376142A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Unknown	5 MON
	Alopecia		Synthroid	C	Glaxo Wellcome			
	Chest Pain		Tenormin	C				
	Gastrointestinal Disorder		Premarin	C				
	Hostility							
	Memory Impairment							
	Mood Swings							

Date:08/27/02ISR Number: 3966330-2Report Type:Expedited (15-DaCompany Report #A0378086A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Disturbance In Attention							
	Fear		Paxil	SS	Glaxo Wellcome	ORAL	19	DAY
	Hallucination, Visual		Ambien	C				
	Irritability		Trazodone	C				
	Sleep Walking		Depakote	C			500MG Twice per day	
	Suicide Attempt							
			Ritalin	C			YR	

Date:08/27/02ISR Number: 3966336-3Report Type:Expedited (15-DaCompany Report #A0378902A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Coarctation Of The Aorta		Wellbutrin	PS	Glaxo Wellcome		200MG Per day	
	Maternal Drugs Affecting Foetus		Depakote	C				

	Pregnancy					
	Ventricular Septal Defect					

Date:08/27/02ISR Number: 3968149-5Report Type:Expedited (15-DaCompany Report #B0276683A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Motor Dysfunction	Foreign	Zyban Tablet - Zyban					
Hospitalization -	Respiratory Disorder	Health	(Bupropion					
Initial or Prolonged	Suicide Attempt	Professional	Hydrochloride)	PS		ORAL	150 MG/TWICE	
Disability		Company					PER DAY/ORAL	
Required		Representative	Mineral Oil					
Intervention to			Injection (Mineral					
Prevent Permanent			Oil)	SS		INTRAVENOUS	INTRAVENOUS	
Impairment/Damage			Citalopram	C				
			Sertraline	C				

Date:08/27/02ISR Number: 3968171-9Report Type:Expedited (15-DaCompany Report #A0363292A
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Death	Atherosclerosis
	Cardiac Disorder
	Cardiac Failure Acute
	Cardio-Respiratory Arrest
	Ischaemia

		Myocardial Infarction Ventricular Arrhythmia					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL
ORAL							
				Salbutamol Sulphate	C		
				Salmeterol Xinafoate	C		
				Irbesartan	C		

Date:08/27/02ISR Number: 3969095-3Report Type:Expedited (15-DaCompany Report #A0377076A
Age:47 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Antidepressant Drug Level Above Therapeutic Coma Grand Mal Convulsion	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
4200 MG/SEE DOSAGE TEXT/ORAL	1 HR	Intentional Misuse Metabolic Acidosis					

Date:08/27/02ISR Number: 3969109-0Report Type:Expedited (15-DaCompany Report #A0378058A
Age:37 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Loss Of Consciousness Overdose	Health Professional	Wellbutrin Sr Tablet-Controlled Release	PS		ORAL
27 GRAM (S)/ SINGLE DOSE/ ORAL							

Date:08/27/02ISR Number: 3969363-5Report Type:Expedited (15-DaCompany Report #DSA_21894_2002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Cystitis Drug Interaction Medication Error Myocardial Infarction	Consumer	Cardizem Cd	PS		ORAL	360 MG DAILY	
			Zyban Tablet (Bupropion Hcl)	SS		ORAL	150 MG DAILY	
			Atenolol	SS		ORAL	50 MG DAILY	

Date:08/28/02ISR Number: 3967022-6Report Type:Expedited (15-DaCompany Report #B0277431A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Accident Dyspnoea Echocardiogram Abnormal Hypernatraemia Hypocapnia Hypotonia Hypoxia Loss Of Consciousness		Zyban	PS	Glaxo Wellcome	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/02ISR Number: 3968133-1Report Type:Expedited (15-DaCompany Report #D0039102A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Psychosis Disturbance In Attention Insomnia Schizophreniform Disorder Suicidal Ideation Vision Blurred	Foreign Literature Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	5 DAY

Date:08/29/02ISR Number: 3967700-9Report Type:Expedited (15-DaCompany Report #B0118244A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable Aortic Valve Stenosis Cardiac Disorder Cardiac Failure Congestive Chest Pain Chronic Obstructive Pulmonary Disease Dyspepsia Dyspnoea Dyspnoea Exertional Heart Rate Increased Hypokinesia Left Ventricular Failure Pharyngolaryngeal Pain Ventricular Hypertrophy		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	11 DAY

Date:08/29/02ISR Number: 3967709-5Report Type:Expedited (15-DaCompany Report #D0038838A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Aggression		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 6 WK						
Other	Bipolar Disorder		Seroxat	SS	Glaxo Wellcome	
UNKNOWN	92 DAY					
	Crying					
	Diarrhoea					
	Gastrointestinal Disorder					
	Hyperhidrosis					
	Hypomania					
	Migraine					
	Nausea					
	Sleep Disorder					
	Tachycardia					
	Vertigo					
	Weight Decreased					

Date:08/29/02ISR Number: 3968415-3Report Type:Expedited (15-DaCompany Report #C2002-2710.01
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cystitis	Consumer	Zyban Tablets 150 Mg			
Initial or Prolonged	Hypotension	Other	Glaxosmithkline	PS	Glaxosmithkline	ORAL
150MG DAY						
Other	Medication Error					
ORAL						
			Atenolol Tablets			
			50mg Mylan	SS	Mylan	ORAL
50MG DAY ORAL						

			Cardizem Cd Aventis	SS	Aventis	ORAL	360MG DAY
							ORAL

Date:08/30/02ISR Number: 3968361-5Report Type:Expedited (15-DaCompany Report #B0274152A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Electric Shock		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Twice
	Tremor						per day	26 DAY

Date:08/30/02ISR Number: 3970052-1Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Anger	Consumer	Zoloft (Sertraline)	PS		ORAL	50 MG DAILY,	
Intervention to	Autoimmune Thyroiditis					ORAL		
Prevent Permanent	Balance Disorder		Wellbutrin Sr					
Impairment/Damage	Blood Pressure Increased		(Bupropion					
	Blood Thyroid Stimulating		Hydrochloride)	SS		ORAL	300 MG	
	Hormone Decreased						(BID), ORAL	
	Cerebral Haemorrhage		Coumadin (Warfarin)	SS				
	Contusion		Effexor Xr					
	Convulsion		(Venlafaxine					
	Cough		Hydrochloride)	SS		ORAL	300 MG BID,	
	Drug Ineffective					ORAL		
	Dysphonia		Amantadine	SS				
	Epistaxis		Monopril (Fosinopril					
	Fall		Sodium)	SS				
	Feeling Cold		Toprol Xl					
	Head Injury		(Metoprolol					
	Heart Rate Decreased		Succinate)	C				

Heart Rate Increased	Zebeta (Bisoprolol Fumarate)	C
Hostility	Lanoxin (Digoxin)	C
Hyperhidrosis	Lasix (Furosemide)	C
Laceration	Synthroid (Levothyroxine Sodium)	C
Medication Error	Vitamin E (Tocopherol)	C
Meningioma	Estrogen (Estrogen Nos)	C
Mood Swings	Zocor (Simvastatin)	C
Overdose	Estradiol Vaginal Ring (Estradiol)	C
Pain	Inderal (Propranolol Hydrochloride)	C
Palpitations	Cardizem (Diltiazem Hydrochloride)	C
Parkinson'S Disease	Folic Acid	C
Prothrombin Time Prolonged	Sinemet (Carbidopa / Levodopa)	C
Pulmonary Oedema	Carzon	C
Rib Fracture		
Syncope		
Transient Ischaemic Attack		
Vaginal Haemorrhage		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/30/02ISR Number: 3970174-5Report Type:Expedited (15-DaCompany Report #A0151352A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Agitation	Foreign	Zyban Tablet - Zyban	PS		ORAL	15 GRAM9S)
Intervention to	Cardiotoxicity	Literature					SINGLE DOSE /
Prevent Permanent	Cardiovascular Disorder	Health					ORAL
Impairment/Damage	Electrocardiogram Qrs Complex Prolonged	Professional	Lorazepam	C			
	Hallucination						
	Intentional Misuse						
	Sinus Tachycardia						
	Suicide Attempt						
	Tremor						

Date:09/03/02ISR Number: 3970070-3Report Type:Direct Company Report #CTU 175458
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Grand Mal Convulsion		Wellbutrin Sr 100 Mg	PS		ORAL	100 MG TID
Initial or Prolonged							ORAL
			Zoloft	C			

Date:09/04/02ISR Number: 3969848-1Report Type:Expedited (15-DaCompany Report #B0114598A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abdominal Pain	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice
Hospitalization -	Abnormal Behaviour	Professional					per day 62 DAY
Initial or Prolonged	Amnesia						
Other	Anaphylactic Shock						
	Angioneurotic Oedema						
	Blister						

	Blood Bilirubin Increased
	Blood Pressure Increased
	Chest Pain
	Convulsion
	Diarrhoea
	Dry Skin
	Eczema
	Feeling Drunk
	Hypersensitivity
	Rhinitis
	Tinnitus

Date:09/04/02ISR Number: 3969850-XReport Type:Expedited (15-DaCompany Report #B0259361A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	21 DAY

Date:09/04/02ISR Number: 3969853-5Report Type:Expedited (15-DaCompany Report #B0270906A
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Death	Agitation
	Delusional Disorder,

	Persecutory Type Injury						
		Report Source	Product	Role	Manufacturer		Route
Dose	Duration						
			Zyban	PS	Glaxo Wellcome		
UNKNOWN	150MG As directed 52 DAY						
			Paracetamol + Codeine	C			
UNKNOWN							
			Fenoterol + Ipratropium	C			
RESPIRATORY (INHALATION)							
			Cocaine	C			
UNKNOWN							

Date:09/04/02ISR Number: 3971338-7Report Type:Expedited (15-DaCompany Report #B0102029A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Drug Hypersensitivity	Foreign	Zyban	PS		
150 MG/PER DAY/	14 DAY					
	Haematuria	Literature				
	Proteinuria	Health Professional				

Date:09/05/02ISR Number: 3970620-7Report Type:Expedited (15-DaCompany Report #A0370880A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Retinal Artery Thrombosis	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL
1TAB Twice per day	3 WK					
	Retinal Exudates	Professional				
	Visual Acuity Reduced		Zyrtec	C	Glaxo Wellcome	

Date:09/05/02ISR Number: 3970626-8Report Type:Expedited (15-DaCompany Report #B0134204A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Haemochromatosis						per day	4 WK
Initial or Prolonged	Impaired Driving Ability		Lormetazepam					
	Myalgia		(Noctamide)	C		ORAL	1MG per day	
	Myocardial Infarction		Fluoxetine					
	Myocardial Ischaemia		Hydrochloride	C			UNKNOWN	20MG per day
			Alprazolam	C		ORAL	.25MG per day	

Date:09/05/02ISR Number: 3970630-XReport Type:Expedited (15-DaCompany Report #B0271161A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	24 DAY
	Mean Cell Volume		Miniphase	SS		ORAL	1TAB Per day	YR
	Increased		Lexomil	SS		ORAL	.5TAB Twice	
	Peripheral Sensory						per day	YR
	Neuropathy		Di-Antalvic	SS		ORAL	2UNIT Monthly	YR
	Spinal Osteoarthritis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/02ISR Number: 3970631-1Report Type:Expedited (15-DaCompany Report #B0274419A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxo Wellcome	ORAL	31	DAY
	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus Pregnancy		Emergency Contraception	C				

Date:09/05/02ISR Number: 3970643-8Report Type:Expedited (15-DaCompany Report #B0278335A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Visual Disturbance		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Variable dose 2 DAY
			Aspirin	C		ORAL	75MG	Unknown
			Omeprazole	C		ORAL	10MG	Unknown
			Beclomethasone	C	Glaxo Wellcome		RESPIRATORY	(INHALATION) 100MCG Twice per day
			Salbutamol	C	Glaxo Wellcome		RESPIRATORY	(INHALATION)
			Simvastatin	C		ORAL	20MG	Per day
			Diltiazem	C	Glaxo Wellcome	ORAL		

Date:09/06/02ISR Number: 3972586-2Report Type:Expedited (15-DaCompany Report #A0379437A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Detachment Vitreous Floaters	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ORAL	
			Adderall	C				

Date:09/06/02ISR Number: 3972817-9Report Type:Expedited (15-DaCompany Report #A0072356A
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Disability Required Intervention to Prevent Permanent Impairment/Damage	Acquired Porphyria Akathisia Alopecia Anxiety Apathy Asthenia Autoimmune Thyroiditis Cardiolipin Antibody Positive Cerebellar Syndrome Chronic Fatigue Syndrome Circulatory Collapse Clonic Convulsion Cogwheel Rigidity Computerised Tomogram Abnormal

		Cytomegalovirus Antibody Positive					
		Depersonalisation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diaphragmatic Paralysis	Health	Wellbutrin Tablet			
		Diarrhoea	Professional	(Bupropion			
		Disturbance In Attention	Company	Hydrochloride)	PS		ORAL
100 MG ORAL							
		Drug Withdrawal Syndrome	Representative	Diazepam (Diazepam)	SS		ORAL
VARIABLE							
		Dysarthria					
DOSE/ ORAL							
		Dyspnoea		Bismuth			
		Dysstasia		Subsalicylate			
		Dystonia		(Bismuth			
		Encephalopathy		Subsalicylate)	SS		
		Epstein-Barr Virus		Triamcinolone			
		Antibody Positive		Acetonide	C		
		Erythema		Melatonin	C		
		Facial Palsy		Herbal Medication	C		
		Fall					
		Fatigue					
		Fibromyalgia					
		Hemiparesis					
		Loss Of Consciousness					
		Malaise					
		Nail Disorder					
		Nervous System Disorder					
		Nuclear Magnetic					
		Resonance Imaging					
		Abnormal					
		Optic Nerve Disorder					
		Optic Neuritis					
		Porphyria					
		Rash Macular					
		Red Blood Cell					
		Sedimentation Rate					
		Increased					
		Respiratory Alkalosis					
		Tardive Dyskinesia					
		Visual Acuity Reduced					
		Weight Decreased					

Date:09/06/02ISR Number: 3972835-0Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Balance Disorder Cough Drug Ineffective Fall Irritability Pulmonary Oedema Rib Fracture	Consumer	Zoloft (Sertraline) Wellbutrin Sr (Bupropion Hydrochloride) Coumadin (Warfarin) Effexor Xr (Venlafaxine Hydrochloride) Amantadine Monopril(Fosinopril Sodium) Toprol Xl (Metoprolol Succinate)	PS SS SS SS SS SS C		ORAL ORAL ORAL ORAL	50 MG 300 MG (BID), 300 MG (BID),	(DAILY), ORAL ORAL ORAL

			Zebeta (Bisoprolol Fumarate)	C			
			Lanoxin (Digoxin)	C			
			Synthroid (Levothyroxine Sodium)	C			
			Vitamin E (Tocopherol)	C			
			Estrogen (Estrogen Nos)	C			
			Zocor(Simvastatin)	C			
			Estradiol Vaginal Ring (Estradiol)	C			
			Inderal (Propranolol Hydrochloride)	C			
			Cardizem (Diltiazem Hydrochloride)	C			
			Folic Acid	C			
			Stinemet (Carbidopa/Levodopa)	C			
			"Carzon"	C			
			Lasix (Furosemide)	C			

Date:09/06/02ISR Number: 3972863-5Report Type:Expedited (15-DaCompany Report #B0270362A
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort Headache Hypertension	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY	
	Obstructive Airways Disorder Orthopnoea Pulmonary Oedema	Company Representative	Labetalol Hydrochloride Tablet (Non-Us Product)	SS		ORAL	200 MG / PER DAY	
			Glimepiride	C				
			Allopurinol	C				
			Buflomedil Hydrochloride	C				
			Quinapril					

			Hydrochloride	C		
			Atorvastatin Calcium	C		
			Clopidogrel Bisulphate	C		
			Theophylline	C		
			Formoterol	C		

Date:09/06/02ISR Number: 3973171-9Report Type:Expedited (15-DaCompany Report #B0278040A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Disorder Grand Mal Convulsion	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ORAL	
			Captopril	C				
			Etodolac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/09/02ISR Number: 3974158-2Report Type:Direct Company Report #CTU 175983
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rhabdomyolysis		Wellbutrin Sr 150 Mg	PS		ORAL	150 MG PO BID	

Date:09/10/02ISR Number: 3972720-4Report Type:Expedited (15-DaCompany Report #B0274763A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Keratitis	Health	Zyban	PS	Glaxo Wellcome	ORAL	7	WK
Other	Sjogren'S Syndrome	Professional						

Date:09/10/02ISR Number: 3972739-3Report Type:Expedited (15-DaCompany Report #D0039257A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Bicarbonate		Zyban	PS	Glaxo Wellcome	ORAL	4TAB per day	2 DAY
	Decreased Blood Ph Abnormal							
	Convulsion							
	Disturbance In Attention							
	Lactic Acidosis							

Date:09/11/02ISR Number: 3973364-0Report Type:Expedited (15-DaCompany Report #B0135382A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	2 WK
Disability	Dehydration	Professional	Nomegestrol	SS		ORAL		
	Dysuria							
	Eosinophil Count							

	Increased
	Headache
	Mucosal Erosion
	Oedema Peripheral
	Pruritus
	Pyrexia
	Rash Generalised
	Skin Exfoliation
	Sleep Disorder
	Stevens-Johnson Syndrome

Date:09/12/02ISR Number: 3974391-XReport Type:Expedited (15-DaCompany Report #B0265019A
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Claustrophobia
	Confusional State
	Convulsion
	Dyspnoea
	Fatigue
	Fear
	Gastrointestinal Disorder
	General Physical Health Deterioration

	Initial Insomnia						
	Joint Stiffness						
	Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Malaise		Zyban	PS	Glaxo Wellcome	UNKNOWN	150MG Twice per day 30 DAY
	Memory Impairment						
	Pancreatitis		Simvastatin	C			
	Panic Reaction		Seloken	C			200MG per day
	Peritonitis		Renitec	C			10MG per day
	Purulence		Frusemide	C	Glaxo Wellcome		40MG per day
	Sexual Dysfunction		Aspirin	C			75MG per day
	Sleep Disorder						

Date:09/13/02ISR Number: 3974845-6Report Type:Expedited (15-DaCompany Report #B0271683A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Ageusia		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day 4 DAY
	Anosmia		Diclofenac	C		ORAL	50MG Unknown
	Anxiety		Codrydamol	C	Glaxo Wellcome	ORAL	2TABS Unknown
	Dyspnoea Exertional		Prempak C	C		ORAL	
	Tachycardia						

Date:09/16/02ISR Number: 3975499-5Report Type:Expedited (15-DaCompany Report #B0134762A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Mydriasis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown
	Sudden Death						

Date:09/16/02ISR Number: 3975501-0Report Type:Expedited (15-DaCompany Report #B0276132A
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased
	Blood Albumin Decreased
	Blood Potassium Decreased
	Blood Sodium Decreased
	Blood Urea Decreased
	C-Reactive Protein Increased
	Eosinophilia
	Gamma-Glutamyltransferase Increased
	Heart Rate Increased
	Hyperglycaemia
	Lymphocyte Count Decreased
	Neutrophil Count Increased
	Proteinuria
	Pyrexia
	Rash Generalised
	Rash Maculo-Papular
	Rash Pruritic
	Rosacea
	Toxic Skin Eruption

	White Blood Cell Count Increased						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	11 DAY
			Mediator	SS		ORAL	150MG Twice per day

Date:09/16/02ISR Number: 3975502-2Report Type:Expedited (15-DaCompany Report #B0276547A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Intentional Misuse		Zyban	PS	Glaxo Wellcome	ORAL	14 DAY
	Suicide Attempt		Zoloft	SS		ORAL	50MG per day
			Lexomil	C		ORAL	4MG per day

Date:09/16/02ISR Number: 3975504-6Report Type:Expedited (15-DaCompany Report #B0277431A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Accident		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day
Hospitalization - Initial or Prolonged	Dyspnoea						
	Hypernatraemia						
	Hypoxia						
	Loss Of Consciousness						

Date:09/16/02ISR Number: 3975505-8Report Type:Expedited (15-DaCompany Report #B0278802A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization -	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 26 DAY						
Initial or Prolonged	Arrhythmia		Kardegic	C		ORAL
	Blood Creatine		Lasilix	C	Glaxo Wellcome	ORAL
	Phosphokinase Increased		Triatec	C		ORAL
	Blood Lactate					
	Dehydrogenase Increased					
	Disorientation					
	Hallucination					
	Hepatic Enzyme Increased					
	Hyponatraemia					
	Malaise					

Date:09/16/02ISR Number: 3975510-1Report Type:Expedited (15-DaCompany Report #B0279427A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Discomfort		Zyban	PS	Glaxo Wellcome	ORAL
150MG As						
Initial or Prolonged	Dizziness					
directed 10 DAY						
Other	Fatigue					
	Panic Reaction					

Date:09/16/02ISR Number: 3976290-6Report Type:Direct Company Report #CTU 176549
Age:37 YR Gender:Female I/FU:I

Outcome	PT
	Abnormal Dreams
	Dry Mouth

	Headache Insomnia Tremor	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban 150mg	PS		ORAL	150 MG ONE PO QD X 3 D, THEN BID
			Habitrol	C			

Date:09/17/02ISR Number: 3976078-6Report Type:Expedited (15-DaCompany Report #A0371353A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Twice per day 4 DAY
	Anxiety Depression Euphoric Mood Feeling Abnormal Insomnia Malaise Panic Reaction Performance Status Decreased		Ethanol	C		ORAL	

Date:09/17/02ISR Number: 3976079-8Report Type:Expedited (15-DaCompany Report #A0378334A
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Serum Sickness		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice Initial or Prolonged per day 18 DAY
Other			Concerta	C			1 YR

Date:09/17/02ISR Number: 3976087-7Report Type:Expedited (15-DaCompany Report #B0118244A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Angina Unstable Cardiac Failure Congestive Chest Discomfort Chest Pain Chronic Obstructive Pulmonary Disease Circulatory Collapse Dyspepsia Dyspnoea Dyspnoea Exertional Heart Rate Increased Pharyngolaryngeal Pain		Bupropion Hydrochloride	PS	Glaxo Wellcome	ORAL	150MG Twice per day	11 DAY

Date:09/17/02ISR Number: 3976088-9Report Type:Expedited (15-DaCompany Report #B0134124A
Age:34 YR Gender:Male I/FU:F

Outcome	PT
Disability	Angioneurotic Oedema Arthralgia Erythema Nodosum

	Oedema						
	Proteinuria						
	Pruritus	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	9 DAY

Date:09/17/02ISR Number: 3976089-0Report Type:Expedited (15-DaCompany Report #B0260806A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Lichen Planus		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 6 DAY

Date:09/18/02ISR Number: 3976840-XReport Type:Expedited (15-DaCompany Report #B0267494A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Hypomania		Zyban	PS	Glaxo Wellcome		UNKNOWN 150MG Unknown
	Psychotic Disorder		Blood Pressure Medication	C			

Date:09/18/02ISR Number: 3976841-1Report Type:Expedited (15-DaCompany Report #B0272342A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arthralgia	Health	Zyban	PS	Glaxo Wellcome	ORAL	3 WK
Initial or Prolonged	Hypokalaemia	Professional					
	Hyponatraemia						
	Insomnia						
	Joint Effusion						
	Renal Colic						
	Tremor						

Date:09/18/02ISR Number: 3976842-3Report Type:Expedited (15-DaCompany Report #B0272924A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression	Health	Zyban	PS	Glaxo Wellcome	ORAL	9	DAY
Hospitalization - Initial or Prolonged	Agitation	Professional	Apranax	C		ORAL	1TAB As required	
	Condition Aggravated							
	Impulsive Behaviour		Magnesium Pidolate	C		ORAL	1.5G Twice per day	9 DAY
	Orthostatic Hypotension							
	Pyromania		Tiapride	C		ORAL	200MG per day	9 DAY
			Xanax	C		ORAL	1MG per day	9 DAY

Date:09/18/02ISR Number: 3976846-0Report Type:Expedited (15-DaCompany Report #B0278546A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Conjunctival Hyperaemia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	13 DAY
			Simvastatin	C		ORAL	20MG per day	
			Telmisartan	C	Glaxo Wellcome	ORAL	40MG per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/18/02ISR Number: 3976847-2Report Type:Expedited (15-DaCompany Report #B0278942A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Zyban	PS	Glaxo Wellcome	ORAL	10	DAY
	Convulsion		Oral Contraceptive					
	Cyanosis		Pill	C		ORAL		
	Dyspnoea							
	Excitability							
	Sudden Death							

Date:09/18/02ISR Number: 3977437-8Report Type:Direct Company Report #CTU 176745
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Zyban 150mg Tbsr	PS		ORAL	1T PO QD X 3D	
	Dry Mouth						, THEN BID	
	Face Oedema		Nicorette 2mg Gum	SS			1T Q H UP TO	
	Pharmaceutical Product						8 PIECES/D	
	Complaint							

Date:09/19/02ISR Number: 3977493-7Report Type:Expedited (15-DaCompany Report #A0373936A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Sr	PS	Glaxo Wellcome	ORAL	450MG	Unknown
			Unknown	C				

Date:09/19/02ISR Number: 3978188-6Report Type:Expedited (15-DaCompany Report #A0380102A
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Increased Intentional Misuse Suicide Attempt	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Carbamazepine (Carbamazepine)	SS				
			Ethanol (Alcohol)	SS				

Date:09/19/02ISR Number: 3978191-6Report Type:Expedited (15-DaCompany Report #A0380101A
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Increased Intentional Misuse Suicide Attempt	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:09/19/02ISR Number: 3978293-4Report Type:Expedited (15-DaCompany Report #A0379982A
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	

			Clonazepam (Clonazepam)	SS			
			Trazodone (Trazodone)	SS			

Date:09/19/02ISR Number: 3978294-6Report Type:Expedited (15-DaCompany Report #A0379981A
Age:37 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Carbamazepine (Carbamazepine)	SS		ORAL		
			Olanzapine (Olanzapine)	SS				

Date:09/19/02ISR Number: 3978296-XReport Type:Expedited (15-DaCompany Report #A0379980A
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		
			Hydrocodone + Paracetamol (Hydrocodone + Acetaminoph)	SS		ORAL		
			Carisoprodol (Carisoprodol)	SS				

Date:09/19/02ISR Number: 3978297-1Report Type:Expedited (15-DaCompany Report #A0379979A
Age:41 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:09/19/02ISR Number: 3978298-3Report Type:Expedited (15-DaCompany Report #A0379918A
Age:17 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/19/02ISR Number: 3978454-4Report Type:Expedited (15-DaCompany Report #A0379990A
Age:46 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Alprazolam (Alprazolam)	SS				
			Olanzapine (Olanzapine)	SS				

Date:09/19/02ISR Number: 3978455-6Report Type:Expedited (15-DaCompany Report #A0379989A
Age:16 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL		
			Quetiapine (Quetiapine)	SS				
			Valproic Acid (Valproic Acid)	SS				

Date:09/19/02ISR Number: 3978458-1Report Type:Expedited (15-DaCompany Report #A0379988A
Age:44 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Fluoxetine (Fluoxetine)	SS				
			Hydrocodone +					

				Paracetamol (Formulation Unknown) (Hydrocodone +	SS		

Date:09/19/02ISR Number: 3978460-XReport Type:Expedited (15-DaCompany Report #A0379987A
Age:35 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Venlafaxine Hydrochloride (Formulation Unknown) (Venlafaxine	SS				
			Methylphenidate (Formulation Unknown) (Methylphenidate)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/19/02ISR Number: 3978463-5Report Type:Expedited (15-DaCompany Report #A0379986A
Age:21 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Olanzapine (Formulation Unknown) (Olanzapine)	SS				
			Clonazepam (Formulation Unknown) (Clonazepam)	SS				

Date:09/19/02ISR Number: 3978465-9Report Type:Expedited (15-DaCompany Report #A0379985A
Age:46 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Abuser Intentional Misuse	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Naproxen (Formulation Unknown) (Naproxen)	SS		ORAL	ORAL	
			Cocaine (Formulation Unknown) (Cocaine)	SS				

Date:09/19/02ISR Number: 3978466-0Report Type:Expedited (15-DaCompany Report #A0379984A
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health	Wellbutrin Unspecified Tablet					

			Professional	(Bupropion Hydrochloride)	PS		ORAL
ORAL							
				Ethylene Glycol (Formulation Unknown) (Ethylene Glycol)	SS		ORAL
ORAL							
				Hypericum (Formulation Unknown) (Hypericum)	SS		ORAL
ORAL							

Date:09/19/02ISR Number: 3978469-6Report Type:Expedited (15-DaCompany Report #A0379983A
Age:51 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Ethanol (Formulation Unknown) (Alcohol)	SS		ORAL
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/19/02ISR Number: 4008125-XReport Type:Periodic Company Report #S02-USA-00997-01
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stupor	Health Professional	Celexa (Citalopram Hydrobromide)	PS		ORAL	40 MG QD PO	
			Celexa (Citalopram Hydrobromide)	SS		ORAL	40 MG QD PO	
			Wellbutrin (Amfebutamone Hydrochloride)	SS			100 MG BID	
			Pamelor (Nortriptyline Hydrochloride)	C				

Date:09/20/02ISR Number: 3977925-4Report Type:Expedited (15-DaCompany Report #A0380991A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Diarrhoea Headache Hyperhidrosis Impaired Work Ability Vomiting Weight Decreased		Zyban	PS	Glaxo Wellcome	ORAL		

Date:09/20/02ISR Number: 3977926-6Report Type:Expedited (15-DaCompany Report #A0381096A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus		Wellbutrin	PS	Glaxo Wellcome			

Date:09/20/02ISR Number: 3977939-4Report Type:Expedited (15-DaCompany Report #B0279967A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hemiparesis		Zyban	PS	Glaxo Wellcome			UNKNOWN

Date:09/24/02ISR Number: 3980442-9Report Type:Expedited (15-DaCompany Report #DSA_21894_2002
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased	Consumer	Cardizem Cd	PS		ORAL	360 MG DAILY	
	Blood Pressure Decreased						PO	
	Blood Pressure Increased		Zyban Tablet (Bupropion Hcl)	SS		ORAL	150 MG DAILY	
	Cystitis						PO	
	Drug Interaction		Atenolol	SS		ORAL	50 MG DAILY	
							PO	
			Glucophage Xr (Metformin)	C				
			Altace	C				

				Lantus	C		

Date:09/25/02ISR Number: 3981329-8Report Type:Direct Company Report #CTU 177114
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Dizziness		Bupropion	PS		ORAL	150MG 1 PO BID ORAL	

Date:09/25/02ISR Number: 3982560-8Report Type:Expedited (15-DaCompany Report #NSADSS2002032610
Age:33 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Literature Health	Risperdal (Risperidone)	PS		ORAL	ORAL	
		Professional	Bupropion (Amfebutamone)	SS				

Date:09/26/02ISR Number: 3981983-0Report Type:Direct Company Report #CTU 177337
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Bupropion 150mg	PS		ORAL	150MG QD ORAL	

Date:09/27/02ISR Number: 3982877-7Report Type:Expedited (15-DaCompany Report #NSADSS2002032843
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Completed Suicide Toxicologic Test Abnormal	Literature Health Professional	Concerta (Sustained Release Tablet) (Methylpehenidate Hydrochloride) Bupropion(Amfebutamone)	PS SS		

Date:09/27/02ISR Number: 3982889-3Report Type:Expedited (15-DaCompany Report #NSADSS2002032842
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death	Literature Health Professional	Concerta (Sustained Release Tablet) (Methylphenidate Hydrochloride) Bupropion	PS SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/02ISR Number: 3982959-XReport Type:Direct Company Report #CTU 177501
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Neuroleptic Malignant Syndrome		Haloperidol	PS		INTRAVENOUS BOLUS	1MG Q4H PRN	
			Bupropion Sr 100 Mg	SS		ORAL	100 MG QD	
			Seroquel	C				

Date:09/27/02ISR Number: 3983538-0Report Type:Expedited (15-DaCompany Report #B0129833A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia C-Reactive Protein Increased Eyelid Oedema Face Oedema Pyrexia Sigmoiditis White Blood Cell Count White Blood Cell Count Increased	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY/ORAL	
			Amisulpride	C				

Date:09/27/02ISR Number: 3983543-4Report Type:Expedited (15-DaCompany Report #B0280402A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Latent Tetany	Foreign	Zyban Tablet - Zyban					

Initial or Prolonged			Health Professional	(Bupropion Hydrochloride)	PS		ORAL
ORAL							
			Company Representative				

Date:09/27/02ISR Number: 3983544-6Report Type:Expedited (15-DaCompany Report #B0280371A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Depression Haematoma Irritability Tremor Vomiting	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY/ ORAL	

Date:09/27/02ISR Number: 3983587-2Report Type:Expedited (15-DaCompany Report #B0280370A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Intestinal Hypomotility	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/02ISR Number: 3983652-XReport Type:Expedited (15-DaCompany Report #A0380888A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Abnormal Blood Sodium Abnormal Drug Withdrawal Syndrome Hyperglycaemia Hypoglycaemia	Foreign Consumer	Zyban Tablet - Zyban (Bupropion Hydrochloride) Paxil (Paroxetine Hydrochloride)	PS SS		ORAL ORAL	30 MG PER DAY	

Date:09/27/02ISR Number: 3984179-1Report Type:Expedited (15-DaCompany Report #B0259361A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis	Foreign Health Professional	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY	

Date:09/27/02ISR Number: 3984181-XReport Type:Expedited (15-DaCompany Report #B0270415A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Required Intervention to Prevent Permanent Impairment/Damage	Injury Intentional Misuse Psychotic Disorder Self Mutilation Wound	Foreign Health Professional	Zyban (Bupropion Hydrochloride) Oxazepam Mitrazapine	PS C C			150 MG/AS DIRECTED	

Date:09/27/02ISR Number: 3984182-1Report Type:Expedited (15-DaCompany Report #B0271008A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Blood Immunoglobulin G Decreased Hepatic Steatosis Serum Sickness Tooth Infection	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride) Nicotine Polacrilex	PS C		ORAL TEXT / ORAL	SEE DOSAGE	

Date:09/27/02ISR Number: 3984828-8Report Type:Expedited (15-DaCompany Report #A0377288A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Required Intervention to Prevent Permanent Impairment/Damage	Anxiety Chest Discomfort Drug Abuser Medication Error Nasal Discomfort Tremor	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		NASAL	150 MG/SEE DOSAGE TEXT/ INTRANASA	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/02ISR Number: 3984837-9Report Type:Expedited (15-DaCompany Report #A0380744A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Cholelithiasis Hypoaesthesia	Consumer	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	150 MG / THREE TIMES PER DAY /	
ORAL								14 YR
			Thyroxine Sodium	C				
			Fioricet	C				
			Castor Oil	C				
			Somatropin	C				

Date:09/27/02ISR Number: 3985313-XReport Type:Expedited (15-DaCompany Report #A0173197A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse Myocardial Infarction Nausea Urinary Incontinence Vomiting	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG TWICE PER DAY ORAL	
			Entex Pse	C				
			Hydrocodone + Paracetamol	C				
			Amox. Trihyd+Pot.Clavulan	C				
			Prednisone	C				

Date:09/27/02ISR Number: 3985801-6Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT

Required Intervention to Prevent Permanent Impairment/Damage	Affective Disorder
	Anger
	Arrhythmia
	Autoimmune Thyroiditis
	Balance Disorder
	Blood Oestrogen Decreased
	Blood Pressure Diastolic Decreased
	Blood Pressure Increased
	Blood Thyroid Stimulating Hormone Decreased
	Contusion
	Cough
	Dementia
	Depression
	Drug Ineffective
	Dyssomnia
	Epistaxis
	Excoriation
	Fall
	Haemorrhagic Stroke
	Hallucination
	Heart Rate Increased
	Hostility
	Meningioma

Nuclear Magnetic Resonance Imaging Abnormal	Report Source	Product	Role	Manufacturer	Route
Overdose	Consumer	Zoloft (Sertraline)	PS		ORAL
Pain					
Palpitations		Wellbutrin Sr			
Parkinson'S Disease		(Bupropion			
Prothrombin Time		Hydrochloride)	SS		ORAL
Prolonged					
Rib Fracture		Coumadin (Warfarin)	SS		
Syncope		Effexor Xr			
Thinking Abnormal		(Venlafaxine			
Thyroid Disorder		Hydrochloride)	SS		ORAL
Transient Ischaemic					
Attack		Amantadine	SS		
Treatment Noncompliance		Monopril (Fosinopril			
Vaginal Haemorrhage		Sodium)	SS		
		Donepezil Hydrochloride	C		
		Zebeta (Bisoprolol Fumarate)	C		
		Lanoxin (Digoxin)	C		
		Lasix (Furosemide)	C		
		Synthroid (Levothyroxine Sodium)	C		
		Vitamin E (Tocopherol)	C		
		Estrogen (Estrogen Nos)	C		
		Zocor (Simvvastatin)	C		
		Estradiol Vaginal Ring (Estradiol)	C		
		Inderal (Propranolol Hydrochloride)	C		
		Cardizem (Diltiazem Hydrochloride)	C		
		Folic Acid	C		
		Sinemet (Carbidopa / Levodopa)	C		

Dose	Duration
50 MG	
(DAILY), ORAL	
300 MG (BID),	
ORAL	
300 MG (BID),	
ORAL	

			"Carzon"	C		
			Metoprolol Succinate	C		

Date:09/30/02ISR Number: 3983757-3Report Type:Direct Company Report #CTU 177601
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin	PS			200 MG SR BID	X 3 MO PTA
	Pneumonia Aspiration							

Date:10/01/02ISR Number: 4008711-7Report Type:Periodic Company Report #2001AP05211
Age:16 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Quetiapine	PS				
		Health Professional	Valproic Acid	SS				
			Bupropion	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3986583-4Report Type:Expedited (15-DaCompany Report #B0280644A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Neoplasm Cerebellar Syndrome Concomitant Disease Progression Langerhans' Cell Granulomatosis Vertigo	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:10/02/02ISR Number: 3987190-XReport Type:Expedited (15-DaCompany Report #A0381384A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion Intentional Misuse Medication Error	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		RESPIRATORY	(INHALATION)	900 MG/ SINGLE DOSE/ INHALED
			Ethanol	C				
			Cannabis	C				

Date:10/02/02ISR Number: 3987193-5Report Type:Expedited (15-DaCompany Report #A0381535A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour Hallucination, Auditory Impulsive Behaviour Mania	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ORAL	

	Paranoia					
	Personality Change					
	Psychotic Disorder					
	Self Injurious Behaviour					
	Thinking Abnormal					
	Tinnitus					

Date:10/02/02ISR Number: 3987466-6Report Type:Expedited (15-DaCompany Report #A0377706A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Sr					
	Encephalopathy	Professional	Tablet-Controlled					
	Hypothyroidism	Company	Release (Bupropion					
	Metabolic Disorder	Representative	Hydrochloride)	PS		ORAL	150 MG TWICE	
							PER DAY ORAL	
			Oral Contraceptive	C				
			Zolpidem Tartrate	C				
			Quetiapine Fumarate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3987469-1Report Type:Expedited (15-DaCompany Report #A0379580A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis Hypotension Pneumonia Haemophilus	Health Professional Company	Zyban (Bupropion Hydrochloride)	PS		ORAL		
	Renal Failure Stevens-Johnson Syndrome	Representative	Semisodium Valproate Lithium Carbonate Zolmitriptan Vicodin	C C C C				

Date:10/02/02ISR Number: 3987471-XReport Type:Expedited (15-DaCompany Report #A0380824A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Hypersensitivity Dysphagia Oesophageal Stenosis	Consumer	Wellbutrin Sr Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG PER DAY	ORAL
			Oral Contraceptive Vitamin	C C				

Date:10/02/02ISR Number: 3987982-7Report Type:Expedited (15-DaCompany Report #B0276132A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased	Foreign	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	SEE DOSAGE TEXT / ORAL	
	Blood Albumin Decreased Blood Glucose Increased Blood Potassium Decreased Blood Sodium Decreased		Benfluorex Hydrochloride Tablet (Benfluorex					

	Blood Sodium Increased	Hydrochloride)	SS		ORAL
150 MG /					
	Blood Urea Increased				
TWICE PER DAY					
	C-Reactive Protein				
/ ORAL					
	Increased				
	Dermatitis Exfoliative				
	Dyskinesia				
	Eosinophilia				
	Exanthem				
	Gamma-Glutamyltransferase				
	Increased				
	Lymphocyte Count				
	Decreased				
	Neutrophil Count				
	Increased				
	Proteinuria				
	Rash				
	Rash Maculo-Papular				
	Rosacea				
	Toxic Skin Eruption				
	White Blood Cell Count				
	Increased				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/02ISR Number: 3985628-5Report Type:Direct Company Report #CTU 177878
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Wellbutrin	PS			150 MGM BID	
	Blood Pressure Systolic		Erythromycin	SS			333 MGM TID	
	Increased		Ibuprofen	C				
	Headache		Trilevelon	C				
	Tachycardia							
	Tremor							

Date:10/03/02ISR Number: 3989056-8Report Type:Expedited (15-DaCompany Report #A103444
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anger	Consumer	Zoloft (Sertraline)	PS		ORAL	50 MG (DAILY), ORAL	
	Arrhythmia							
	Balance Disorder		Wellbutrin Sr (Bupropion Hydrochloride)	SS		ORAL	300 MG (BID), ORAL	
	Blood Oestrogen Decreased							
	Blood Pressure Increased							
	Blood Thyroid Stimulating Hormone Decreased		Coumadin (Warfarin)	SS				
	Cerebral Haemorrhage		Effexor Xr (Venlafaxine Hydrochloride)	SS		ORAL	300 MG (BID), ORAL	
	Cognitive Disorder							
	Contusion							
	Cough							
	Depression		Amantadine	SS				
	Drooling		Monopril (Fosinopril Sodium)	SS				
	Drug Ineffective							
	Epistaxis		Donepezil Hydrochloride	C				
	Fall							
	Hallucination		Zebeta (Bisoprolol Fumarate)	C				
	Head Injury							
	Heart Rate Decreased		Lanoxin (Digoxin)	C				
	Heart Rate Increased		Lasix (Furosemide)	C				

Hostility	Synthroid	
Hyperhidrosis	(Levothyroxine	
Medication Error	Sodium)	C
Memory Impairment	Vitamin E	
Meningioma	(Tocopherol)	C
Overdose	Estrogen (Estrogen	
Pain	Nos)	C
Prothrombin Time Abnormal	Zocor (Simvastatin)	C
Pulmonary Oedema	Estradiol Vaginal	
Rib Fracture	Ring (Estradiol)	C
Sedation	Inderal (Propranolol	
Sleep Talking	Hydrochloride)	C
Syncope	Cardizem (Diltiazem	
Transient Ischaemic	Hydrochloride)	C
Attack	Folic Acid	C
Treatment Noncompliance	Sinemet (Carbidopa /	
Tremor	Levodopa)	C
Vaginal Haemorrhage	"Carzon"	C
	Metoprolol Succinate	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/02ISR Number: 3988045-7Report Type:Expedited (15-DaCompany Report #B0133703A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angina Unstable Chest Pain Coronary Artery Stenosis	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY/ORAL
			Omega-3 Marine Triglyceri	C			
			Simvastatin	C			

Date:10/04/02ISR Number: 3988287-0Report Type:Expedited (15-DaCompany Report #A0377881A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Alopecia Chronic Obstructive Pulmonary Disease Emphysema Hyperphagia Medication Error Weight Increased	Consumer	Nicorette Otc Gum (Nicotine Polacrilex)	PS		ORAL	4 MG/ TWELVE TIMES PER DAY / ORAL
			Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS		ORAL	ORAL

Date:10/04/02ISR Number: 3988345-0Report Type:Expedited (15-DaCompany Report #A0345310A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Blood Creatinine Increased Bradyphrenia	Foreign Health Professional	Paxil Tablet (Paroxetine Hydrochloride)	PS		ORAL	ORAL

Required Intervention to Prevent Permanent Impairment/Damage	Confusional State Depression Disorientation Drug Interaction Fall Grand Mal Convulsion Hallucination Memory Impairment Movement Disorder Rhabdomyolysis Speech Disorder Thinking Abnormal	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Fluoxetine (Fluoxetine)	SS SS	ORAL 250 MG / PER DAY / ORAL ORAL 20 MG / PER DAY / ORAL
		Clonazepam Oxazepam	C C	

Date:10/07/02ISR Number: 3984417-5Report Type:Expedited (15-DaCompany Report #B0131464A
Age:25 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arteriospasm Coronary Blood Pressure Decreased Cardiac Failure Chest Pain Cutaneous Vasculitis Cytomegalovirus Infection Diarrhoea Disseminated Intravascular Coagulation

	Drug Dependence Ecchymosis Ejection Fraction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Decreased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown 29 DAY
	Gangrene Hyperhidrosis		Methylenedioxymetham phetamine	SS		ORAL	2 DAY
	Hyperpyrexia		Alcohol	C		ORAL	
	Influenza Like Illness Malaise Myocardial Infarction Purpura Skin Necrosis Ventricular Dysfunction Vomiting		Cannabis	C			

Date:10/07/02ISR Number: 3984419-9Report Type:Expedited (15-DaCompany Report #B0264055A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Epilepsy Grand Mal Convulsion Respiratory Arrest		Zyban	PS	Glaxo Wellcome	ORAL	
			Antidepressant	C			

Date:10/07/02ISR Number: 3984421-7Report Type:Expedited (15-DaCompany Report #B0280402A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Latent Tetany Suffocation Feeling Trismus		Zyban	PS	Glaxo Wellcome	ORAL	

Date:10/07/02ISR Number: 3984427-8Report Type:Expedited (15-DaCompany Report #B0281217A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Depression	Consumer	Zyban	PS	Glaxo Wellcome	
UNKNOWN						
	Sudden Death					

Date:10/07/02ISR Number: 3984770-2Report Type:Expedited (15-DaCompany Report #B0268687A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL		
	Fall		Contraceptive					
	Loss Of Consciousness		(Unspecified)	C				
	Malaise							

Date:10/07/02ISR Number: 3987115-7Report Type:Expedited (15-DaCompany Report #2002054675
Age:35 YR Gender:Male I/FU:F

Outcome	PT
Other	Convulsion
	Drug Level Decreased
	Hemiplegia
	Migraine
	Muscle Twitching

Paranoia

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Neurontin			
		Health	(Gabapentin)	PS		ORAL
300 MG (TID),						
		Professional				
ORAL						
			Bupropion			
			Hydrochloride	SS		
			Citalopram			
			Hydrobromide	C		

Date:10/07/02ISR Number: 3987131-5Report Type:Direct Company Report #CTU 178139
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Rash Erythematous		Wellbutrin - 150mg			
	Rash Pruritic		Bid	PS		ORAL
PO						
			Lipitor -10mg	SS		ORAL
PO						

Date:10/07/02ISR Number: 3987300-4Report Type:Expedited (15-DaCompany Report #200219747US
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Agitation	Consumer	Fexofenadine			
	Condition Aggravated		Hydrochloride			
	Convulsion		(Allegra) Tablets	PS		ORAL
180 MG; PO	20 DAY					
	Difficulty In Walking		Amfebutamone			
	Insomnia		Hydrochloride			
	Rash		(Wellbutrin Sr)	SS		ORAL
300 MG QD; PO						
	Speech Disorder		Amfebutamone			
	Tongue Spasm		Hydrochloride			
	Tremor		(Wellbutrin Sr)	SS		ORAL
200 MG BID;						

PO

			Cefuroxime Axetil (Ceftin)	C		
			Gabapentin (Neurontin)	C		

Date:10/07/02ISR Number: 3990440-7Report Type:Direct Company Report #CTU 178101
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Grand Mal Convulsion		Wellbutrin Sr 100mg	PS		ORAL	200MG BID PO	
Intervention to Prevent Permanent Impairment/Damage			Celexa	C				
			Zyprexa	C				

Date:10/08/02ISR Number: 3987206-0Report Type:Expedited (15-DaCompany Report #02P-163-0201368-00
Age:16 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Valproic Acid (Depakene) (Valproic Acid) (Valproic Acid)	PS				
	Completed Suicide	Health Professional	Quetiapine	SS				
			Bupropion	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/02ISR Number: 3987364-8Report Type:Expedited (15-DaCompany Report #A0372870A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other Required Intervention to Prevent Permanent Impairment/Damage	Drug Interaction Grand Mal Convulsion	Health Professional	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG / THREE TIMES PER DAY / ORAL	
			Ludiomil (Formulation Unknown) (Ludiomil)	SS			150 MG / PER DAY	
			Acarbose	C				
			Metformin Hydrochloride	C				
			Thyroid	C				
			Celecoxib	C				
			Omeprazole	C				
			Risperidone	C				
			Doxepin	C				
			Alprazolam	C				
			Vitamin D	C				
			Calcium Salt	C				
			Glucosamine Chondroitin C	C				

Date:10/08/02ISR Number: 3987378-8Report Type:Expedited (15-DaCompany Report #A0382184A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Benign Intracranial Hypertension	Health Professional	Wellbutrin Sr (Bupropion					

				Hydrochloride)	PS		ORAL

400 MG / PER

DAY / ORAL

Date:10/08/02ISR Number: 3989761-3Report Type:Expedited (15-DaCompany Report #02P-163-0201358-00
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Hydrocodone/Acetamin					
		Health	ophen					
		Professional	(Vicodin)(Hydrocodon					
			e/Acetaminophen)	PS				
			Bupropion	SS				
			Carisoprodol	SS				

Date:10/08/02ISR Number: 3990027-6Report Type:Expedited (15-DaCompany Report #B0281102A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Zyban Tablet-Zyban					
		Health	(Bupropion					
		Professional	Hydrochloride)	PS		ORAL		
								ORAL
			Nicotine Substitute	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/02ISR Number: 3990048-3Report Type:Expedited (15-DaCompany Report #B0118244A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Aortic Valve Stenosis Blood Pressure Systolic Increased Cardiac Failure Congestive Chronic Obstructive Pulmonary Disease Dilatation Ventricular Dyspepsia Pharyngolaryngeal Pain Ventricular Hypokinesia	Foreign Study Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/ ORAL

Date:10/08/02ISR Number: 3990062-8Report Type:Expedited (15-DaCompany Report #B0274449A
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged	Insomnia Respiratory Failure	Foreign Health Professional Company Representative	Zyban Tablet - Zyban (Bupropion Hydrochloride) Ace Inhibitor	PS C		ORAL	SEE DOSAGE TEXT / ORAL

Date:10/08/02ISR Number: 3990073-2Report Type:Expedited (15-DaCompany Report #B0274795A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Required	Convulsion Rheumatoid Arthritis	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/

Intervention to VARIABLE Prevent Permanent DOSE/ORAL Impairment/Damage			Nimesulide	C			

Date:10/08/02ISR Number: 3990074-4Report Type:Expedited (15-DaCompany Report #B0269955A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Myalgia Polyarthritis	Foreign Health Professional	Zyban Tablet - Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL

Date:10/08/02ISR Number: 3990087-2Report Type:Expedited (15-DaCompany Report #B0264074A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angina Unstable Myocardial Infarction	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY/ ORAL
		Company Representative	Rilmenidine	C			
			Fenofibrate	C			
			Piascledine	C			

			Zolpidem	C			

Date:10/08/02ISR Number: 3990090-2Report Type:Expedited (15-DaCompany Report #B0134232A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/	
			Paroxetine Hydrochloride	C				
			Diltiazem Hydrochloride	C				
			Oxygen	C				

Date:10/09/02ISR Number: 3986359-8Report Type:Expedited (15-DaCompany Report #A0380744A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Three times per day	14 YR
	Cholelithiasis							
	Hypoaesthesia		Levothroid	C	Glaxo Wellcome			
			Fioricet	C				
			Castor Oil	C				
			Human Growth Hormone	C				

Date:10/09/02ISR Number: 3986363-XReport Type:Expedited (15-DaCompany Report #A0382619A
Age:9 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Serum Sickness		Wellbutrin	PS	Glaxo Wellcome	ORAL	100MG Per day	22 DAY
	Stevens-Johnson Syndrome							

Date:10/09/02ISR Number: 3986366-5Report Type:Expedited (15-DaCompany Report #B0261797A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diplopia		Zyban	PS	Glaxo Wellcome	ORAL	150MG See	
Hospitalization -	Epilepsy						dosage text	
Initial or Prolonged	Loss Of Consciousness		Vitamins	SS		ORAL		
	Status Epilepticus		Ephedrine	SS			UNKNOWN	
			Guarana	SS		ORAL		
			Neuroleptic	C			UNKNOWN	
			Antidepressant (Unspecified)	C			UNKNOWN	
			Benzodiazepines	C			UNKNOWN	

Date:10/09/02ISR Number: 3986371-9Report Type:Expedited (15-DaCompany Report #B0281345A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxo Wellcome	ORAL	150MG Unknown	8 DAY
	Panic Reaction							
	Paranoia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/09/02ISR Number: 3986372-0Report Type:Expedited (15-DaCompany Report #B0281421A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Strain		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	7 DAY

Date:10/09/02ISR Number: 3986373-2Report Type:Expedited (15-DaCompany Report #B0281501A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Bone Pain Inflammation Pyrexia		Zyban	PS	Glaxo Wellcome	ORAL	150MG per day	27 DAY

Date:10/09/02ISR Number: 3986418-XReport Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-11018074
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Buspar Tabs	PS	Bristol-Myers Squibb Company	ORAL		
			Wellbutrin	SS				

Date:10/09/02ISR Number: 3990863-6Report Type:Expedited (15-DaCompany Report #A0379437A
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Detachment Vitreous Floaters	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY	

/ ORAL

			Adderall	C		

Date:10/10/02ISR Number: 3987292-8Report Type:Expedited (15-DaCompany Report #A0382701A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus		Bupropion	PS	Glaxo Wellcome	ORAL		

Date:10/10/02ISR Number: 3987293-XReport Type:Expedited (15-DaCompany Report #A0382751A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cardiac Arrest Ventricular Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/02ISR Number: 3987294-1Report Type:Expedited (15-DaCompany Report #B0269609A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complex Partial Seizures	Health	Zyban	PS	Glaxo Wellcome			
UNKNOWN							3	WK
	Malaise	Professional						

Date:10/10/02ISR Number: 3991105-8Report Type:Direct Company Report #CTU 178512
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flat Affect		Zyban 150	PS				
BID								

Date:10/10/02ISR Number: 3991108-3Report Type:Direct Company Report #CTU 178515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin 150mg	PS				
BID								
	Tremor							

Date:10/10/02ISR Number: 3991109-5Report Type:Direct Company Report #CTU 178516
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare		Wellbutrin 150mg	PS				
BID								

Date:10/10/02ISR Number: 3991110-1Report Type:Direct Company Report #CTU 178517
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Rash		Wellbutrin 150	PS		
BID						

Date:10/10/02ISR Number: 3991111-3Report Type:Direct Company Report #CTU 178518
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Palpitations		Wellbutrin 150mg	PS		
BID						

Date:10/10/02ISR Number: 3991113-7Report Type:Direct Company Report #CTU 178520
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Urticaria		Wellbutrin	PS		

Date:10/11/02ISR Number: 3988128-1Report Type:Expedited (15-DaCompany Report #A0382851A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Abuser		Wellbutrin	PS	Glaxo Wellcome	
INTRAVENOUS						
Initial or Prolonged	Medication Error					

Date:10/14/02ISR Number: 3989442-6Report Type:Expedited (15-DaCompany Report #B0281921A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cyanosis		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Discomfort							
per day	18 DAY							
	Influenza Like Illness		Salatel	C				
	Oedema							
	Physical Disability							
	Urticaria							

Date:10/14/02ISR Number: 3989444-XReport Type:Expedited (15-DaCompany Report #B0282033A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Zyntabac	PS	Glaxo Wellcome	ORAL		
	Hyperthyroidism							
	Insomnia							
	Nervousness							
	Palpitations							
	Tremor							

Date:10/15/02ISR Number: 3989827-8Report Type:Expedited (15-DaCompany Report #A0382885A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity		Wellbutrin	PS	Glaxo Wellcome	ORAL		
	Oxygen Saturation Decreased							
	Rash Pustular							

Date:10/15/02ISR Number: 3993747-2Report Type:Expedited (15-DaCompany Report #NSADSS2002032582
Age:42 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death Hospitalization - Initial or Prolonged SEE IMAGE Required Intervention to Prevent Permanent 60 TABLE, Impairment/Damage ORAL	Acute Respiratory Distress Syndrome Aspiration Coma Completed Suicide Convulsion Depressed Level Of Consciousness Hypotension Intentional Misuse	Literature Health Professional	Topamax (Unspecified) (Topiramate) Wellbutrin Sr (Amfebutamone Hydrochloride) Acetaminophen/Propoxyphene (Aporex)	PS SS SS		ORAL ORAL ORAL

Date:10/15/02ISR Number: 4027522-XReport Type:Periodic Company Report #2001-09-1438
Age: Gender: I/FU:I

Outcome Dose Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Claritin-D 24 Hour (Loratadine 10mg/Pseudoephedrin Extended Release Tablet Wellbutrin Sr (Bupropion)	PS SS		ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/02ISR Number: 4027579-6Report Type:Periodic Company Report #HQ2565804JUN2002
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Drug Withdrawal Syndrome Grand Mal Convulsion		Ativan (Lorazepam, Tablet)	PS		ORAL	0.5 MG 1X PER	1 DAY, ORAL
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride)	SS		ORAL	200 MG 2X PER	1 DAY, ORAL
			Nortriptyline (Nortriptyline)	C				

Date:10/16/02ISR Number: 3990616-9Report Type:Expedited (15-DaCompany Report #A0382751A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	1 WK
Hospitalization - Initial or Prolonged Other	Ventricular Fibrillation	Professional	Micardis	C	Glaxo Wellcome	ORAL	80MG Per day	
			Hydrochlorothiazide	C		ORAL	25MG Per day	

Date:10/16/02ISR Number: 3990617-0Report Type:Expedited (15-DaCompany Report #A0383055A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Cancer		Zyban	PS	Glaxo Wellcome	ORAL		

Date:10/16/02ISR Number: 3990618-2Report Type:Expedited (15-DaCompany Report #B0133707A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown 2 DAY
Hospitalization - Initial or Prolonged	Aggression Agitation Anxiety Autonomic Nervous System Imbalance Blood Bilirubin Increased Blood Lactate Dehydrogenase Increased C-Reactive Protein Decreased Haptoglobin Decreased Headache Jaundice Loss Of Consciousness Malaise Normochromic Normocytic Anaemia Pallor Thrombotic Thrombocytopenic Purpura Treatment Noncompliance	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/02ISR Number: 3990626-1Report Type:Expedited (15-DaCompany Report #B0282017A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Missed	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	10	DAY
	Complications Of Maternal		Triflucan	SS		ORAL	50MG Per day	8 DAY
	Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							
	Pregnancy							

Date:10/16/02ISR Number: 3993626-0Report Type:Direct Company Report #CTU 178854
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme		Wellbutrin Sr	PS		ORAL	150MG PO QD	
	Stevens-Johnson Syndrome							

Date:10/17/02ISR Number: 3991181-2Report Type:Expedited (15-DaCompany Report #B0282085A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Health	Zyban	PS	Glaxo Wellcome		3	WK
Hospitalization - Initial or Prolonged	Heart Injury	Professional	Previscan	SS		ORAL		
	International Normalised Ratio Increased		Aspirine	SS		ORAL		
			Lasilix	C	Glaxo Wellcome	ORAL		
	Intracardiac Thrombus		Diffu K	C		ORAL		
	Pericardial Haemorrhage		Beta-Blocker(Unspecified)	C		ORAL		
	Procedural Complication		Triatec	C		ORAL		
			Vasten	C		ORAL		
			Discotrine	C	Glaxo Wellcome	TRANSDERMAL		

Date:10/17/02ISR Number: 3991182-4Report Type:Expedited (15-DaCompany Report #B0282206A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Hospitalization -	Nausea							
per day							29	DAY
Initial or Prolonged	Oedema		Aspirin	C		ORAL	75MG Per day	
	Urticaria		Perindopril	C		ORAL	2MG Unknown	
			Salbutamol	C	Glaxo Wellcome		RESPIRATORY	
(INHALATION)							2UNIT	Four
times per day								
			Ipratropium	C	Glaxo Wellcome		RESPIRATORY	
(INHALATION)							2UNIT	Three
times per day								

Date:10/17/02ISR Number: 3995778-5Report Type:Expedited (15-DaCompany Report #NSADSS2002032610
Age:33 YR Gender: I/FU:F

Outcome	PT
Death	Abdominal Pain
Required	Abnormal Faeces
Intervention to	Blood Sodium Increased
Prevent Permanent	Cardiac Arrest
Impairment/Damage	Catatonia

		Circulatory Collapse Disseminated Intravascular Coagulation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematocrit Decreased Heart Rate Increased	Literature Health	Risperdal (Risperidone)	PS		ORAL
ORAL							
		Hypertension Medication Error	Professional	Bupropion (Amfebutamone)	SS		ORAL
ORAL							
		Mental Status Changes Pyrexia		Diphenhydramine (Diphenhydramine)	SS		ORAL
ORAL							
		Tremor					

Date:10/18/02ISR Number: 3992011-5Report Type:Expedited (15-DaCompany Report #B0134232A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Fatigue	Health	Zyban	PS	Glaxo Wellcome	ORAL
150MG Unknown						
		Professional	Ventoline	SS	Glaxo Wellcome	
RESPIRATORY						
(INHALATION)	4UNIT Twice					
per day						
			Seretide	SS	Glaxo Wellcome	
RESPIRATORY						
(INHALATION)						
			Paroxetine Hydrochloride	SS	Glaxo Wellcome	ORAL
			Nicotine Polacrilex	SS	Glaxo Wellcome	
UNKNOWN						
			Theophylline	SS		ORAL
300MG Three						
times per day						
			Diltiazem Hydrochloride	C	Glaxo Wellcome	ORAL
			Wine	C		ORAL
.75L per day						
			Oxygen Therapy	C		

Date:10/18/02ISR Number: 3992012-7Report Type:Expedited (15-DaCompany Report #B0279967A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hemiparesis	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	1TAB	Variable
	Sensory Loss							
dose	5	WK						

Date:10/18/02ISR Number: 3992015-2Report Type:Expedited (15-DaCompany Report #B0282033A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Health Professional	Zyntabac	PS	Glaxo Wellcome	ORAL		
	Atrial Fibrillation							
	Hyperthyroidism							
	Insomnia							
	Nervousness							
	Palpitations							
	Tremor							

Date:10/18/02ISR Number: 3992016-4Report Type:Expedited (15-DaCompany Report #B0282196A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Panic Attack		Zyban	PS	Glaxo Wellcome		UNKNOWN	
	Suicidal Ideation							

Date:10/18/02ISR Number: 3992019-XReport Type:Expedited (15-DaCompany Report #B0282592A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Influenza Like Illness		Zyban	PS	Glaxo Wellcome	ORAL	1TAB	Unknown 29 DAY
	Pain In Extremity							
	Paraesthesia							

Date:10/21/02ISR Number: 3992742-7Report Type:Expedited (15-DaCompany Report #A0383421A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction		Zyban	PS	Glaxo Wellcome	ORAL		
	Malaise		Effexor	SS		ORAL		
			Ativan	C				
			Elavil	C	Glaxo Wellcome			
			Salbutamol	C	Glaxo Wellcome			
			Tylenol	C	Glaxo Wellcome			

Date:10/21/02ISR Number: 3992743-9Report Type:Expedited (15-DaCompany Report #A0383562A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aneurysm		Wellbutrin	PS	Glaxo Wellcome	ORAL	8	MON
	Convulsion							
Other	Libido Increased							

Date:10/21/02ISR Number: 3992998-0Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12075131
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Trazodone Hcl Tabs	PS	Apothecon	ORAL	"As required"	
	International Normalised Ratio Decreased		Enoxaparin	C				
			Olanzapine	C				

	Clonazepam	C		
	Sertraline Hcl	C		
	Ibuprofen	C		
	Metoclopramide Hcl	C		
	Diphenhydramine	C		
	Paracetamol Elixir	C		
	Docusate Sodium	C		
	Warfarin Sodium	I	Bristol-Myers Squibb Company	
	Wellbutrin	I		ORAL

Date:10/21/02ISR Number: 3995534-8Report Type:Direct Company Report #CTU 179097
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Zyban 150mg	PS		ORAL	150 MG ORAL	
	Crying							
	Depression							
	Dyspnoea							
	Feeling Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/02ISR Number: 3995774-8Report Type:Direct Company Report #CTU 179088
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Sr 150 Mg	PS		ORAL	150 MG BID	
	Feeling Jittery						ORAL	
	Hypersensitivity							
	Insomnia							

Date:10/21/02ISR Number: 3998273-2Report Type:Expedited (15-DaCompany Report #S02-USA-02227-01
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Lexapro (Escitalopram)	PS		ORAL	10 MG QD PO	
		Company Representative	Wellbutrin (Bupropion Hydrochloride)	SS				
			Prozac (Fluoxetine Hydrochloride)	SS			80 MG QD	
			Prozac (Fluoxetine Hydrochloride)	SS			40 MG QD	

Date:10/21/02ISR Number: 3998619-5Report Type:Expedited (15-DaCompany Report #2002061185
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Spontaneous	Foreign Health Professional	Fluconazole (Fluconazole)	PS		ORAL	50 MG	
	Complications Of Maternal Exposure To Therapeutic Drugs						(DAILY), ORAL	
			Bupropion	SS		ORAL	(DAILY), ORAL	
	Intra-Uterine Death							

		Maternal Drugs Affecting Foetus					

Date:10/22/02ISR Number: 3996071-7Report Type:Direct Company Report #CTU 179183
Age: Gender:Female I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other			Disturbance In Attention		Wellbutrin	PS		
BUCCAL	100	SR	BUCCAL					
			Drug Ineffective		Tricyclic	SS		
			Hallucination		Zoloft	SS		
			Pharmaceutical Product Complaint					

Date:10/22/02ISR Number: 3997826-5Report Type:Expedited (15-DaCompany Report #NSADSS2002032843
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Death	Brain Herniation
Hospitalization - Initial or Prolonged	Brain Oedema
Required Intervention to Prevent Permanent Impairment/Damage	Cardiomegaly
	Cerebral Artery Occlusion
	Coma
	Completed Suicide
	Cyanosis
	Hepatosplenomegaly
	Loss Of Consciousness

	Moaning					
	Pulmonary Congestion					
	Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Respiratory Failure	Literature	Concerta (Sustained			
	Retroperitoneal	Health	Release Tablet)			
	Haemorrhage	Professional	(Methylphenidate			
	Shock		Hydrochloride)	PS		ORAL
ORAL						
	Ventricular Hypertrophy		Bupropion			
			(Amfebutamone)	SS		

Date:10/23/02ISR Number: 3994909-0Report Type:Expedited (15-DaCompany Report #B0280070A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL
13 DAY						
Initial or Prolonged	C-Reactive Protein					
	Increased					
	Fibrin Increased					
	Hilar Lymphadenopathy					
	Metastases To Lung					
	Neoplasm					
	Oedema Peripheral					
	Paraesthesia					
	Pyrexia					
	Red Blood Cell					
	Sedimentation Rate					
	Increased					

Date:10/23/02ISR Number: 3998905-9Report Type:Expedited (15-DaCompany Report #1662554A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Convulsion	Literature	Regular Strength			
Hospitalization -	Disseminated	Health	Tylenol 325 Mg	PS		ORAL
ORALLY						
Initial or Prolonged	Intravascular Coagulation	Professional	Extra Strength			
	Hepatic Failure		Tylenol Pm Product	SS		ORAL
ORALLY						

Hyperpyrexia		Effexor	SS	
Posturing		Wellbutrin Sr	SS	
Pupil Fixed		Librium	SS	
Renal Failure		Ambien	SS	
Rhabdomyolysis		Skelaxin	SS	
Tachycardia		Midol	SS	
		Pyridium	SS	
		Aleve	SS	
		Relafen	SS	

Date:10/23/02ISR Number: 3999404-0Report Type:Expedited (15-DaCompany Report #A0383144A
Age:49 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
	Intentional Misuse	Health Professional	Warfarin Sodium (Formulation Unknown) (Warfarin Sodium)	SS		ORAL		

				Carbamazepine (Formulation Unknown) (Carbamazepine)	SS		

Date:10/23/02ISR Number: 3999406-4Report Type:Expedited (15-DaCompany Report #A0383146A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Olanzapine (Formulation Unknown) (Olanzapine)	SS				

Date:10/23/02ISR Number: 3999408-8Report Type:Expedited (15-DaCompany Report #A0383148A
Age:43 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Quetiapine (Formulation Unknown) (Quetiapine)	SS				

Date:10/23/02ISR Number: 3999410-6Report Type:Expedited (15-DaCompany Report #A0383149A
Age:33 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Literature	Wellbutrin					

			Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL							
				Risperidone (Formulation Unknown) (Risperidone)	SS		
				Diphenhydramine (Formulation Unknown) (Diphenhydramine)	SS		

Date:10/23/02ISR Number: 3999566-5Report Type:Expedited (15-DaCompany Report #A0383151A
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Completed Suicide	Literature	Wellbutrin			
	Intentional Misuse	Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Coreg (Formulation			

				Unknown) (Cavedilol)	SS		
				Amlodipine + Benazepril (Formulation Unknown) (Amlodipine + Benazepril)	SS		

Date:10/23/02ISR Number: 3999568-9Report Type:Expedited (15-DaCompany Report #A0383128A
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Fluvoxamine (Formulation Unkown) (Fluvoxamine)	SS				
			Ethanol (Formulation Unknown) (Alcohol)	SS				

Date:10/23/02ISR Number: 3999571-9Report Type:Expedited (15-DaCompany Report #A0383129A
Age:34 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecfied Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Isotretinoin (Formulation Unknown) (Isotretinoin)	SS				
			Diphenhydramine (Formulation Unknown) (Diphenhydramine)	SS				

Date:10/23/02ISR Number: 3999575-6Report Type:Expedited (15-DaCompany Report #A0383132A
Age:67 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin					
	Intentional Misuse	Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Sertraline (Formulation Unknown) (Sertraline)	SS		ORAL		

Date:10/23/02ISR Number: 3999578-1Report Type:Expedited (15-DaCompany Report #A0383133A
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin					
	Intentional Misuse	Health Professional	Unspecified Tablet (Bupropion					

			Hydrochloride)	PS		ORAL
ORAL						
			Topiramate (Formulation Unknown) (Topiramate)	SS		
			Dextroprop. + Paracetamol (Formulation Unknown) (Propoxyphene +	SS		

Date:10/23/02ISR Number: 3999588-4Report Type:Expedited (15-DaCompany Report #A0383134A
Age:19 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Wellbutrin			
	Intentional Misuse	Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Valproic Acid (Valproic Acid)	SS		
			Olanzapine (Olanzapine)	SS		

Date:10/23/02ISR Number: 3999590-2Report Type:Expedited (15-DaCompany Report #A0383135A
Age:31 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Wellbutrin			
	Intentional Misuse	Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Citalopram (Formulation Unknown) (Citalopram)	SS		
			Amphetamine (Formulation Unknown)			

			(Amphetamine)	SS			
			Dexedrine (Formulation Unknown) (Dextroamphetamine Sulfate)	SS			

Date:10/23/02ISR Number: 3999592-6Report Type:Expedited (15-DaCompany Report #A0383136A
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Doxepin (Doxepin)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/02ISR Number: 3999594-XReport Type:Expedited (15-DaCompany Report #A0383137A
Age:28 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Trazodone (Formulation Unknown) (Trazodone)	SS				
			Venlafaxine Hydrochloride (Formulation Unknown) (Venlafaxine	SS				

Date:10/23/02ISR Number: 3999596-3Report Type:Expedited (15-DaCompany Report #A0383140A
Age:30 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Diphenhydramine + Paraceta. (Formulation Unknown) (Acetaminophen +	SS				
			Venlafaxine Hydrochloride (Formulation Unknown) (Venlafaxine	SS				

Date:10/23/02ISR Number: 3999598-7Report Type:Expedited (15-DaCompany Report #A0383141A
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Hydrocodone + Paracetamol (Formulation Unknown) (Hydrocodone + Dextropropoxyphene (Formulation Unknown) (Dextropropoxyphene)	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/02ISR Number: 3999600-2Report Type:Expedited (15-DaCompany Report #A0383142A
Age:37 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Aspirin (Formulation Unknown) (Aspirin)	SS				
			Olanzapine (Formulation Unknown) (Olanzapine)	SS				

Date:10/23/02ISR Number: 3999602-6Report Type:Expedited (15-DaCompany Report #A0383143A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Tramadol Hydrochloride (Formulation Unknown) (Tramadol Hydrochloride)	SS				
			Metoclopramide (Formulation Unknown) (Metoclopramide)	SS				

Date:10/23/02ISR Number: 3999606-3Report Type:Expedited (15-DaCompany Report #A0383124A
Age:15 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin					

	Intentional Misuse	Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL						

Date:10/23/02ISR Number: 3999609-9Report Type:Expedited (15-DaCompany Report #A0383127A
Age:17 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Wellbutrin			
	Intentional Misuse	Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Fluvoxamine (Formulation Unknown) (Fluvoxamine)	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/02ISR Number: 3999612-9Report Type:Expedited (15-DaCompany Report #A0383147A
Age:33 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Quetiapine (Formulation Unknown) (Quetiapine)	SS		ORAL		

Date:10/23/02ISR Number: 3999617-8Report Type:Expedited (15-DaCompany Report #A0383130A
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Methylphenidate (Formulation Unknown) (Methylphenidate)	SS		ORAL		

Date:10/23/02ISR Number: 3999628-2Report Type:Expedited (15-DaCompany Report #A0383131A
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL		
			Methylphenidate (Formulation Unknown)					

			(Methylphenidate)	SS		

Date:10/23/02ISR Number: 4027648-0Report Type:Periodic Company Report #NSADSS2002015369
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain	Health	Remicade (5 Mg/Ml			
Hospitalization -	Headache	Professional	Lyophilized Powder)			
Initial or Prolonged	Hypersensitivity		(Infliximab,			
Other	Hypertension		Recombinant)	PS		
INTRAVENOUS 500MG , 1 IN	Pain					
1 TIMES, IV						
	Sexual Dysfunction		Wellbutrin			
	Vertigo		(Amfebutamone			
			Hydrochloride)	SS		
			Vioxx (Rofecoxib)	SS		
			Prednisone	C		
			Methotrexate	C		
			Celebrex (Celecoxib)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/02ISR Number: 3996314-XReport Type:Expedited (15-DaCompany Report #A0383992A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL		

Date:10/28/02ISR Number: 3997563-7Report Type:Expedited (15-DaCompany Report #A0383140A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Bupropion	PS	Glaxo Wellcome	ORAL		
Hospitalization - Initial or Prolonged	Convulsion	Professional	Relafen	SS	Glaxo Wellcome	ORAL		
	Disseminated Intravascular Coagulation		Acetaminophen + Diphenhydramine	SS				UNKNOWN
	Hepatic Failure		Venlafaxine	SS				UNKNOWN
	Intentional Misuse		Tylenol	SS	Glaxo Wellcome			UNKNOWN
	Nystagmus		Librium	SS				UNKNOWN
	Posturing		Ambien	SS				UNKNOWN
	Pupil Fixed		Skelaxin	SS				UNKNOWN
	Pyrexia		Midol	SS				UNKNOWN
	Renal Failure		Pyridium	SS				UNKNOWN
	Rhabdomyolysis		Aleve	SS				UNKNOWN
	Tachycardia							

Date:10/28/02ISR Number: 3997567-4Report Type:Expedited (15-DaCompany Report #B0135045A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	No Adverse Drug Effect	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown
		Professional						

Date:10/28/02ISR Number: 3997580-7Report Type:Expedited (15-DaCompany Report #B0282937A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Tolerance Decreased Malaise Muscle Spasms Visual Disturbance		Zyban	PS	Glaxo Wellcome	ORAL		

Date:10/28/02ISR Number: 3997586-8Report Type:Expedited (15-DaCompany Report #B0283367A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Papilloedema Visual Acuity Reduced		Zyban	PS	Glaxo Wellcome	ORAL	15	DAY

Date:10/28/02ISR Number: 3997587-XReport Type:Expedited (15-DaCompany Report #B0283519A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral Urticaria Wheezing		Zyban	PS	Glaxo Wellcome	ORAL	300MG Per day	10 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/02ISR Number: 3998526-8Report Type:Expedited (15-DaCompany Report #A0384610A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Stenosis Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:10/29/02ISR Number: 3998534-7Report Type:Expedited (15-DaCompany Report #B0283267A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening UNKNOWN Hospitalization - Initial or Prolonged	Conversion Disorder Dysphonia Urticaria		Zyban	PS	Glaxo Wellcome			56 DAY

Date:10/29/02ISR Number: 3998535-9Report Type:Expedited (15-DaCompany Report #B0283291A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety Meniere'S Disease Nausea Palpitations Rash Visual Disturbance		Zyban	PS	Glaxo Wellcome	ORAL	3	DAY

Date:10/29/02ISR Number: 3998536-0Report Type:Expedited (15-DaCompany Report #B0283322A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Nephritis		Zyban	PS	Glaxo Wellcome	ORAL	10	DAY

Date:10/29/02ISR Number: 3998543-8Report Type:Expedited (15-DaCompany Report #B0283515A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL		
	Headache		Thyroid Medication	C				
	Inner Ear Disorder							
	Psychosomatic Disease							

Date:10/29/02ISR Number: 4000461-6Report Type:Direct Company Report #CTU 179774
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Pruritic		Gabatril 2 Mg	PS		ORAL	2 MG QHS ORAL	
	Rash Scaly		Tenormin	C				
			Valium	C				
			Zoloft	C				
			Lomotil	C				
			Synthroid	I				
			Kcl	I				
			Wellbutrin	I				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/02ISR Number: 3999548-3Report Type:Expedited (15-DaCompany Report #D0039368A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aortic Valve Stenosis		Zyban	PS	Glaxo Wellcome	ORAL	
Initial or Prolonged	Disturbance In Attention		Diclofenac	C		ORAL	
	Drug Dependence						
	Memory Impairment						
	Restlessness						
	Visual Disturbance						

Date:10/31/02ISR Number: 4000512-9Report Type:Expedited (15-DaCompany Report #A0382619A
Age:9 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Hypersensitivity	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	
100MG Per day 22 DAY							
Initial or Prolonged	Serum Sickness	Professional					
Other	Stevens-Johnson Syndrome						

Date:10/31/02ISR Number: 4000517-8Report Type:Expedited (15-DaCompany Report #B0282735A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Alanine Aminotransferase		Zyban	PS	Glaxo Wellcome	ORAL	
150MG Twice							
	Increased						
per day 3 WK							
	Arthralgia						
	Blood Creatine						
	Phosphokinase Increased						
	Difficulty In Walking						
	Myositis						

Date:10/31/02ISR Number: 4003925-4Report Type:Expedited (15-DaCompany Report #HQ4742622OCT2002
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Completed Suicide Convulsion Disseminated Intravascular Coagulation Electroencephalogram Abnormal Hepatic Failure Mydriasis Nystagmus Posturing Pupil Fixed Pyrexia Renal Failure Rhabdomyolysis Tachycardia	Literature	Effexor (Venlafaxine Hydrochloride, Tablet) Aleve (Naproxen Sodium,) Ambien (Zolpidem Tartrate,) Librium (Chlordiazepoxide Hydrochloride,) Metaxalone (Metaxalone,) Midol (Acetylsalicylic	PS SS SS SS SS		ORAL ORAL ORAL ORAL ORAL	OVERDOSE OVERDOSE OVERDOSE OVERDOSE OVERDOSE	AMOUNT AMOUNT AMOUNT AMOUNT AMOUNT	UNKNOWN, ORAL UNKNOWN, ORAL UNKNOWN, ORAL UNKNOWN, ORAL UNKNOWN, ORAL

				Acid/Caffeine/Cinnamedrine/Phenacetin,)	SS		
				Pyridium (Phenazopyridine Hydrochloride,)	SS		ORAL
OVERDOSE							
AMOUNT							
UNKNOWN, ORAL							
				Relafen (Nabumetone,)	SS		ORAL
OVERDOSE							
AMOUNT							
UNKNOWN, ORAL							
				Tylenol (Paracetamol,)	SS		ORAL
OVERDOSE							
AMOUNT							
UNKNOWN, ORAL							
				Tylenol Pm (Diphenhydramine/Paracetamol,)	SS		ORAL
OVERDOSE							
AMOUNT							
UNKNOWN, ORAL							
				Wellbutrin (Amfebutamone Hydrochloride,)	SS		ORAL
OVERDOSE							
AMOUNT							
UNKNOWN, ORAL							

Date:10/31/02ISR Number: 4004475-1Report Type:Expedited (15-DaCompany Report #HQ4898628OCT2002
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Drug Interaction	Health Professional	Effexor Xr (Venlafaxine Hydrochloride,Capsule, Extended Release)	PS	ORAL

75 MG 1 X PER

1 DAY, ORAL

Zyban (Amfebutamone Hydrochloride)	SS
Tylenol (Paracetamol)	C
Salbutamol (Salbutamol)	C
Ativan (Lorazepam)	C
Elavil (Amitriptyline Hydrochloride)	C

Date:10/31/02ISR Number: 4004514-8Report Type:Expedited (15-DaCompany Report #200213918BCC
Age:30 YR Gender:Male I/FU:I

Outcome	PT
Death	Cardiac Arrest
Hospitalization - Initial or Prolonged	Completed Suicide
	Convulsion
	Disseminated Intravascular Coagulation
	Hepatic Failure
	Nystagmus
	Posturing
	Pupil Fixed
	Pyrexia

		Renal Failure Rhabdomyolysis Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Literature Health	Aleve (Naproxen Sodium)	PS		ORAL
ORAL							
			Professional Other	Midol Tylenol Pm	SS SS		
				Effexor (Venlafaxine Hydrochloride)	SS		
				Wellbutrin Sr (Amfebutamone Hydrochloride)	SS		
				Librium	SS		
				Ambien (Zolpidem Tartrate)	SS		
				Skelaxin (Metalone)	SS		
				Pyridium (Phenazopyridine Hydrochloride)	SS		
				Tylenol (Paracetamol)	SS		
				Relafen (Nabumetone)	SS		

Date:10/31/02ISR Number: 4004888-8Report Type:Expedited (15-DaCompany Report #2002AP03609
Age:43 YR Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardio-Respiratory Arrest Completed Suicide Intentional Misuse	Literature Health Professional	Quetiapine Bupropion	PS SS		

Date:10/31/02ISR Number: 4004924-9Report Type:Expedited (15-DaCompany Report #2002AP03602
Age:33 YR Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardio-Respiratory Arrest Completed Suicide Intentional Misuse	Literature Health Professional	Quetiapine Bupropion	PS SS		

Date:11/01/02ISR Number: 4001455-7Report Type:Expedited (15-DaCompany Report #B0283370A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL	60TABS Single	
Initial or Prolonged	Confusional State						dose	1 DAY
	Delirium		Equanil	C		ORAL	1 DAY	
	Intentional Misuse							
	Somnolence							
	Suicide Attempt							

Date:11/01/02ISR Number: 4001460-0Report Type:Expedited (15-DaCompany Report #D0039698A
Age:28 YR Gender:Male I/FU:I

Outcome	PT
Other	Dry Mouth
	Intentional Misuse
	Overdose

	Suicide Attempt Tremor						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Zyban	PS	Glaxo Wellcome	ORAL	12TABS Single dose 1 DAY
			Alcohol	SS		ORAL	1 DAY

Date:11/01/02ISR Number: 4005534-XReport Type:Expedited (15-DaCompany Report #HQ4742622OCT2002
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide Disseminated Intravascular Coagulation Hepatic Failure Hyperpyrexia Mydriasis Nervous System Disorder Pupil Fixed Renal Failure Rhabdomyolysis	Literature	Effexor (Venlafaxine Hydrochloride, Tablet)	PS		ORAL	OVERDOSE AMOUNT UNKNOWN, ORAL
			Aleve (Naproxen Sodium,)	SS		ORAL	OVERDOSE AMOUNT UNKNOWN, ORAL
			Ambien (Zolpidem Tartrate)	SS		ORAL	OVERDOSE AMOUNT UNKNOWN, ORAL
			Librium (Chlordiazepoxide Hydrochloride)	SS		ORAL	OVERDOSE AMOUNT

UNKNOWN, ORAL			
	Metaxalone (Metaxalone)	SS	ORAL
OVERDOSE			
AMOUNT			
UNKNOWN, ORAL			
	Midol (Acetylsalicylic Acid/Caffeine/Cinnamedrine/Phenacetin,)	SS	
	Pyridium (Phenazopyridine Hydrochloride,)	SS	ORAL
OVERDOSE			
AMOUNT			
UNKNOWN, ORAL			
	Relafen (Nabumetone)	SS	ORAL
OVERDOSE			
AMOUNT			
UNKNOWN, ORAL			
	Tylenol (Paracetamol)	SS	ORAL
OVERDOSE			
AMOUNT			
UNKNOWN, ORAL			
	Tylenol Pm (Diphenhydramine/Paracetamol)	SS	ORAL
OVERDOSE			
AMOUNT			
UNKNOWN, ORAL			
	Wellbutrin (Amfebutamone Hydrochloride)	SS	ORAL
OVERDOSE			
AMOUNT			
UNKNOWN, ORAL			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/02ISR Number: 4006263-9Report Type:Expedited (15-DaCompany Report #HQ4984731OCT2002
Age:34 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature	Diphenhydramine Hcl (Diphenhydramine Hydrochloride, Injection)	PS		ORAL	ORAL	
			Bupropion (Amfebutamone,)	SS		ORAL	ORAL	
			Isotretinoin (Isotretinoin,)	SS		ORAL	ORAL	

Date:11/05/02ISR Number: 4006764-3Report Type:Expedited (15-DaCompany Report #HQ4986031OCT2002
Age:33 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse	Literature	Diphenhydramine Hcl (Diphenhydramine Hydrochloride, Injection)	PS			OVERDOSE	AMOUNT UNKNOWN
			Bupropion (Amfebutamone,)	SS			OVERDOSE	AMOUNT UNKNOWN
			Risperidone (Risperidone,)	SS			OVERDOSE	AMOUNT UNKNOWN

Date:11/05/02ISR Number: 4006923-XReport Type:Expedited (15-DaCompany Report #HQ4926530OCT2002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Overdose	Literature	Metoclopramide (Metoclopramide Hydrochloride,	PS		ORAL	OVEDOSE AMOUNT UNKNOWN, ORAL	
			Bupropion (Amfebutamone,)	SS		ORAL	OVERDOSE AMOUNT UNKNOWN, ORAL	
			Tramadol (Tramadol,)	SS		ORAL	OVERDOSE AMOUNT UNKNOWN, ORAL	

Date:11/06/02ISR Number: 4004617-8Report Type:Expedited (15-DaCompany Report #A0375799A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	4 WK
	Dysgeusia Dyspepsia Feeling Jittery		Triamterene/Hctz 37.5mg/25mg	C	Glaxo Wellcome	ORAL	1UNIT Per day	
	Pain In Extremity		Xanax	C		ORAL	.5MG Per day	YR

			Premarin	C		ORAL	1.25MG Per day	YR

Date:11/06/02ISR Number: 4004618-XReport Type:Expedited (15-DaCompany Report #A0376093A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	19 DAY
	Arthralgia							
	Cyanosis		No Concurrent Medication	C				
	Difficulty In Walking							
	Insomnia							
	Oedema Peripheral							
	Rash							
	Urticaria							

Date:11/06/02ISR Number: 4004620-8Report Type:Expedited (15-DaCompany Report #A0383335A
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyponatraemia		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG Per day	
	Inappropriate		Micardis	C	Glaxo Wellcome	ORAL	40MG Per day	2 MON
	Antidiuretic Hormone		Pravachol	C		ORAL	40MG Per day	10 YR
	Secretion		Aspirin	C		ORAL	81MG Per day	10 YR
			Neurontin	C		ORAL	300MG As required	YR
			Niaspan	C				
UNKNOWN	500MG Per day							

Date:11/06/02ISR Number: 4004623-3Report Type:Expedited (15-DaCompany Report #A0385250A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastroenteritis		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	6 MON
			Remeron	C			UNKNOWN	
			Xanax	C			UNKNOWN	
			Gas-X	C			UNKNOWN	

Date:11/06/02ISR Number: 4004645-2Report Type:Expedited (15-DaCompany Report #B0283868A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Fibrinogen Increased		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	8 DAY
	C-Reactive Protein Increased		Urbanyl	C		ORAL		
	Csf Protein Increased		Alcohol	C		ORAL		
	Grand Mal Convulsion							
	Pyrexia							
	Red Blood Cell Count Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/02ISR Number: 4004648-8Report Type:Expedited (15-DaCompany Report #B0283974A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphonia		Zyban	PS	Glaxo Wellcome	ORAL	24	DAY
	Dysphonia							
	Laryngitis							

Date:11/06/02ISR Number: 4004649-XReport Type:Expedited (15-DaCompany Report #B0283976A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emotional Distress		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown 12 DAY
	Fear							

Date:11/06/02ISR Number: 4004650-6Report Type:Expedited (15-DaCompany Report #B0283979A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Withdrawal Syndrome		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Twice
Other	Panic Attack						per day	54 DAY

Date:11/06/02ISR Number: 4007804-8Report Type:Expedited (15-DaCompany Report #2002AP03419
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Increased	Consumer	Atenolol	PS		ORAL	50 MG	DAILY
Initial or Prolonged	Cardiac Disorder						PO	
	Cystitis		Cardizem	SS		ORAL	360 MG	DAILY

	Hypertension					
PO						
	Hypotension		Zyban	SS		ORAL
150 MG DAILY						
	Medication Error					
PO						
	Myocardial Infarction		Glucophage "Abic"	C		
			Altace	C		
			Lantus	C		

Date:11/06/02ISR Number: 4023761-2Report Type:Periodic Company Report #A0161304A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Grand Mal Convulsion Loss Of Consciousness	Health Professional Company Representative	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG / THREE TIMES PER DAY / ORAL
			Dexamphetamine Sulphate	C			

Date:11/06/02ISR Number: 4023764-8Report Type:Periodic Company Report #A0160041A
Age:36 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Oedema Peripheral Pruritus Rash	Health Professional Company Representative	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG / DAY / ORAL	

Date:11/06/02ISR Number: 4023765-XReport Type:Periodic Company Report #A0152014A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Hypersensitivity Urticaria Visual Acuity Reduced	Consumer	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	1 TABLET / PER DAY / ORAL	
			Blood Pressure Medication	C				

Date:11/06/02ISR Number: 4023767-3Report Type:Periodic Company Report #A0141485A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Asthenia Burning Sensation Dyspnoea Face Oedema Fear Hypersensitivity Mobility Decreased	Consumer	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	

Oedema Peripheral
Oropharyngeal Swelling
Pain
Pain In Extremity
Pruritus
Rash
Swelling
Tenderness
Urticaria

Date:11/06/02ISR Number: 4028909-1Report Type:Periodic Company Report #A0380851A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS			200 MG/ PER DAY/	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/02ISR Number: 4028910-8Report Type:Periodic Company Report #A0380199A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Migraine Pulmonary Embolism	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	250 MG/ TWICE PER DAY/	ORAL 2 YR

Date:11/06/02ISR Number: 4028911-XReport Type:Periodic Company Report #A0372787A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL

Date:11/06/02ISR Number: 4028912-1Report Type:Periodic Company Report #A0370877A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue Rhabdomyolysis	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY/	ORAL 4 YR
			Alprazolam	C				
			Zolpidem Tartrate	C				

Date:11/06/02ISR Number: 4028913-3Report Type:Periodic Company Report #A0370550A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Health	Wellbutrin Sr					
Hospitalization - Initial or Prolonged	Food Intolerance	Professional	Tablet-Controlled					
	Hypersensitivity		Release (Bupropion					
Required	Psychomotor Hyperactivity		Hydrochloride)	PS		ORAL	150 MG/	TWICE
Intervention to	Throat Tightness						PER DAY/	ORAL
Prevent Permanent	Urticaria		Diphenhydramine					
Impairment/Damage			Hydrochloride					
			(Formulation					
			Unknown)					
			(Diphenhydramine	SS				
			Alprazolam	C				
			Diuretic	C				

Date:11/06/02ISR Number: 4028914-5Report Type:Periodic Company Report #A0370004A
Age:20 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER DAY/ ORAL	6 MON

Date:11/06/02ISR Number: 4028915-7Report Type:Periodic Company Report #A0369151A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other Required Intervention to Prevent Permanent Impairment/Damage	Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	SEE DOSAGE TEXT/ ORAL	

Date:11/06/02ISR Number: 4028916-9Report Type:Periodic Company Report #A0368833A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	200 MG/ TWICE PER DAY/ ORAL	(THERAPY DATES: SEE

TEXT)

			Lorazepam (Formulation Unknown) (Lorazepam)	SS		ORAL

5 MG/ IN THE

MORNING/ ORAL

(THERAPY

DATES: YEARS)

			Nortriptyline	C		

Date:11/06/02ISR Number: 4028917-0Report Type:Periodic Company Report #A0368730A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Lamivudine	C		
			Efavirenz	C		
			Didanosine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/02ISR Number: 4028918-2Report Type:Periodic Company Report #A0368647A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG/ TWICE PER DAY/	ORAL
			Fluvoxamine Maleate	C				
			Olanzapine	C				

Date:11/06/02ISR Number: 4028919-4Report Type:Periodic Company Report #A0366264A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Hypoglycaemia	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	UNK / UNK /	ORAL
			Sulfonylurea Agent	C				
			Insulin	C				

Date:11/06/02ISR Number: 4028920-0Report Type:Periodic Company Report #A0366204A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	UNK / UNKNOWN	/ ORAL

Date:11/06/02ISR Number: 4028921-2Report Type:Periodic Company Report #A0365838A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Grand Mal Convulsion Joint Dislocation	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ TWICE PER DAY / ORAL	Required Intervention to Prevent Permanent Impairment/Damage

Date:11/06/02ISR Number: 4028922-4Report Type:Periodic Company Report #A0365478A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Drug Interaction	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride) Nortriptyline Hcl	PS		ORAL	100 MG/ TWICE PER DAY / ORAL	

			Capsule (Nortriptyline Hcl)	SS		ORAL	UNK / UNK / ORAL
			Citaloram Hydrobromide (Formulation Unknown) (Citalopram Hydrobromide)	SS		ORAL	UNK / UNK / ORAL

Date:11/06/02ISR Number: 4028923-6Report Type:Periodic Company Report #A0171156A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Delusion Hallucination Medication Error Paranoia Psychotic Disorder	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	50 MG / TWICE PER DAY / ORAL
			Thiothixene	C			
			Methysergide Maleate	C			
			Benztropine Mesylate	C			

Date:11/06/02ISR Number: 4028924-8Report Type:Periodic Company Report #A0169144A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abasia Arthralgia Oedema Peripheral Pain In Extremity Rash	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	100 MG / PER DAY / ORAL

Serum Sickness

Date:11/06/02ISR Number: 4028925-XReport Type:Periodic Company Report #A0168576A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required	Coma Convulsion Overdose	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	UNK / SEE DOSAGE TEXT / ORAL	
Intervention to Prevent Permanent Impairment/Damage			Fluoxetine Hydrochloride Tablet (Fluoxetine Hydrochloride)	SS		ORAL	UNK/ SEE DOSAGE TEXT / ORAL	
			Ethanol (Formulation Unknown) (Alcohol)	SS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/02ISR Number: 4028926-1Report Type:Periodic Company Report #A0168351A
Age:8 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Amnesia Complex Partial Seizures Confusional State Coordination Abnormal Dyskinesia Grand Mal Convulsion	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	UNK / SEE DOSAGE TEXT / ORAL
	Tardive Dyskinesia		Clonidine	C			

Date:11/06/02ISR Number: 4028927-3Report Type:Periodic Company Report #A0167595A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain Rhabdomyolysis	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL
			Semisodium Valproate	C			
			Risperidone	C			

Date:11/06/02ISR Number: 4028928-5Report Type:Periodic Company Report #A0167591A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Chest Discomfort Chest Pain Diarrhoea Ear Pruritus	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY

	Erythema					
/ ORAL						
	Flushing					

Date:11/06/02ISR Number: 4028929-7Report Type:Periodic Company Report #A0171410A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction	Health Professional Company Representative	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY/ORAL	
	Cerebrovascular Accident							
	Difficulty In Walking							
	Dysarthria							
	Dysgraphia		Quinapril Hydrochloride	C				
	Hemiparesis		Carbamazepine	C				
	Nausea		Darvocet-N	C				
	Speech Disorder		Glipizide	C				
	Vomiting		Metformin Hydrochloride	C				

Date:11/06/02ISR Number: 4028930-3Report Type:Periodic Company Report #A0166131A
Age: Gender: I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional

			Company Representative	Product	Role	Manufacturer	Route
Dose	Duration						
				Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL
ORAL							

Date:11/06/02ISR Number: 4028931-5Report Type:Periodic Company Report #A0166132A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
ORAL						

Date:11/06/02ISR Number: 4028932-7Report Type:Periodic Company Report #A0166133A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
ORAL						

Date:11/06/02ISR Number: 4028933-9Report Type:Periodic Company Report #A0164485A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged Disability	Grand Mal Convulsion Joint Dislocation Upper Limb Fracture	Health Professional Company Representative	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL
150 MG/ ORAL Required						

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Anorexia Convulsion Diarrhoea	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY / ORAL	
			Olanzapine	C				

Date:11/06/02ISR Number: 4028934-0Report Type:Periodic Company Report #A0164455A
Age:43 YR Gender:Female I/FU:I

Date:11/06/02ISR Number: 4028935-2Report Type:Periodic Company Report #A0162501A
Age:13 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased Grand Mal Convulsion Hypoacusis

	Intentional Misuse Irritability Suicide Attempt	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Tachycardia Tremor	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL 150 MG/ORAL

Date:11/06/02ISR Number: 4028936-4Report Type:Periodic Company Report #A0162571A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Accidental Overdose Syncope Tremor	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL ORAL
			Thyroxine Sodium	C		
			Valsartan	C		

Date:11/06/02ISR Number: 4028937-6Report Type:Periodic Company Report #A0162687A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health Professional Company Representative	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL 150 MG / TWICE PER DAY / ORAL 4 WK

Date:11/06/02ISR Number: 4028938-8Report Type:Periodic Company Report #A0162688A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral	Consumer Health Professional Company Representative	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL,	MONTHS

Date:11/06/02ISR Number: 4028939-XReport Type:Periodic Company Report #A0360567A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash	Health Professional	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
			Etanercept	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/02ISR Number: 4028940-6Report Type:Periodic Company Report #A0360368A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:11/06/02ISR Number: 4028941-8Report Type:Periodic Company Report #A0359697A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Required Intervention to Prevent Permanent Impairment/Damage	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	200 MG/TWICE PER DAY/ORAL	6 MON
			Desipramine (Desipramine)	SS		ORAL	200 MG/PER DAY/ORAL	
			Carbamazepine	C				

Date:11/06/02ISR Number: 4028942-XReport Type:Periodic Company Report #A0175740A
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Asthenia Blood Pressure Fluctuation Decreased Appetite Difficulty In Walking Dysstasia	Consumer	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY/ORAL	
			Citalopram					

Feeding Disorder	Hydrobromide	C	
Heart Rate Irregular	Megestrol Acetate	C	
Tremor	Atenolol	C	

Date:11/06/02ISR Number: 4028943-1Report Type:Periodic Company Report #A0175691A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin Sr					
		Company Representative	(Bupropion Hydrochloride)	PS		ORAL	150 MG/PER	DAY/ORAL

Date:11/06/02ISR Number: 4028944-3Report Type:Periodic Company Report #A0175373A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion	Health Professional	Wellbutrin Sr					
Hospitalization - Initial or Prolonged			(Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE	
Required Intervention to Prevent Permanent Impairment/Damage			Theophylline (Theophylline)	SS		ORAL	PER DAY/ORAL	
			Prednisone					

			(Prednisone)	SS		ORAL
VARIABLE						
DOSE/ORAL						
			Gatifloxacin (Gatifloxacin)	SS		ORAL
400 MG/PER						
DAY/ORAL						

Date:11/06/02ISR Number: 4028945-5Report Type:Periodic Company Report #A0174702A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Health Professional Company Representative	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	
			Adderall	C				

Date:11/06/02ISR Number: 4028946-7Report Type:Periodic Company Report #A0174492A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Flushing Insomnia Shock	Consumer	Wellbutrin Sr (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:11/06/02ISR Number: 4028947-9Report Type:Periodic Company Report #A0173914A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Wellbutrin Sr					

Initial or Prolonged Disability		Professional Company Representative	Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
150 MG/ORAL	1 WK					

Date:11/06/02ISR Number: 4028948-0Report Type:Periodic Company Report #A0173089A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Convulsion	Health Professional	Wellbutrin Sr			
Hospitalization - Initial or Prolonged		Company Representative	(Bupropion Hydrochloride)	PS		ORAL
Required						
SEE DOSAGE						
Intervention to						
TEXT/ORAL						
Prevent Permanent			Adderall	C		
Impairment/Damage			Cannabis	C		

Date:11/06/02ISR Number: 4028949-2Report Type:Periodic Company Report #A0171989A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Convulsion	Health Professional	Wellbutrin Sr			
Required	Postictal State					
Intervention to			(Bupropion			
Prevent Permanent			Hydrochloride)	PS		ORAL
150 MG/TWICE						
Impairment/Damage						
PER DAY/ORAL						
			Liotrix	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/02ISR Number: 4028950-9Report Type:Periodic Company Report #A0379128A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	200 MG/ TWICE PER DAY/	ORAL

Date:11/06/02ISR Number: 4028951-0Report Type:Periodic Company Report #A0377112A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	300 MG/ PER DAY/	ORAL

Date:11/06/02ISR Number: 4028952-2Report Type:Periodic Company Report #A0376857A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Enzymes Increased Overdose	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	SEE DOSAGE	TEXT / ORAL

Date:11/06/02ISR Number: 4028953-4Report Type:Periodic Company Report #A0376579A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Convulsion	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:11/06/02ISR Number: 4028954-6Report Type:Periodic Company Report #A0375560A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache Migraine	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:11/06/02ISR Number: 4028955-8Report Type:Periodic Company Report #A0374621A
Age:53 YR Gender:Female I/FU:I

Outcome
Life-Threatening Required

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Intervention to Prevent Permanent Impairment/Damage	Decreased Appetite Depression Drug Ineffective Suicidal Ideation	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	300 MG/ PER/ DAY/ ORAL	

Date:11/06/02ISR Number: 4028956-XReport Type:Periodic Company Report #A0363301A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Intentional Misuse Suicide Attempt	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS				
			Fluoxetine Hydrochloride (Formulation Unknown (Fluoxetine Hydrochloride)	SS				
			Ibuprofen (Formulation Unknown) (Ibuprofen)	SS				

Date:11/06/02ISR Number: 4028957-1Report Type:Periodic Company Report #A0362683A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent	Convulsion	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ THREE TIMES PER	

Impairment/Damage						
DAY/ ORAL						
			Clonazepam	C		
			Adderall	C		

Date:11/06/02ISR Number: 4028958-3Report Type:Periodic Company Report #A0362388A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion	Health	Wellbutrin Sr					
Hospitalization -		Professional	Tablet-Controlled					
Initial or Prolonged		Company	Release (Bupropion					
Required		Representative	Hydrochloride)	PS		ORAL	200 MG/ TWICE	
Intervention to							PER DAY/ ORAL	
Prevent Permanent			Fluvoxamine Maleate	C				
Impairment/Damage			Fluoxetine					
			Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/02ISR Number: 4028959-5Report Type:Periodic Company Report #A0361668B
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Convulsion Nausea Tremor	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ SINGLE DOSE/	ORAL 1 DAY

Date:11/07/02ISR Number: 4005272-3Report Type:Expedited (15-DaCompany Report #A0377262A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	2 YR	
	Balance Disorder	Professional	Estrace	C		ORAL	3MG Per day	
	Constipation		Advil	C	Glaxo Wellcome	ORAL		
	Dry Mouth		Calcium/Vitamin D	C		ORAL	1000MG Per day	
	Dysgeusia							
	Insomnia		Fish Oil	C		ORAL		
	Libido Increased		Aspirin	C				
	Memory Impairment							
	Mental Disorder							
	Nausea							
	Pharyngolaryngeal Pain							
	Tinnitus							

Date:11/07/02ISR Number: 4005281-4Report Type:Expedited (15-DaCompany Report #A0385418A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Per day						
			Claritin	C		
			Monopril	C		
20MG Per day						
			Iud	C		

Date:11/07/02ISR Number: 4005283-8Report Type:Expedited (15-DaCompany Report #A0385531A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Discomfort		Wellbutrin	PS	Glaxo Wellcome	ORAL
400MG Per day						
Initial or Prolonged	Hyperhidrosis		Effexor Xr	C		
	Palpitations		Xanax	C		
	Ventricular Tachycardia		Atarax	C		

Date:11/07/02ISR Number: 4005292-9Report Type:Expedited (15-DaCompany Report #A0385736A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Wellbutrin	PS	Glaxo Wellcome	ORAL
	Congestive					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/02ISR Number: 4005297-8Report Type:Expedited (15-DaCompany Report #B0280070A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia C-Reactive Protein Increased Fibrin Increased Hilar Lymphadenopathy Metastases To Lung Neoplasm Oedema Peripheral Paraesthesia Pyrexia Red Blood Cell Sedimentation Rate Increased	Health Professional	Zyban	PS	Glaxo Wellcome	ORAL		13 DAY

Date:11/07/02ISR Number: 4005302-9Report Type:Expedited (15-DaCompany Report #B0284138A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Balance Disorder Contusion Difficulty In Walking Discomfort Dyspnoea Emotional Distress Face Oedema Fatigue Malaise Memory Impairment Oedema Peripheral Rash Generalised Rash Papular Tinnitus Urticaria		Zyban	PS	Glaxo Wellcome			UNKNOWN

Date:11/07/02ISR Number: 4005303-0Report Type:Expedited (15-DaCompany Report #B0284170A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Zyban	PS	Glaxo Wellcome	ORAL	14	DAY
	Haemoptysis							

Date:11/07/02ISR Number: 4005555-7Report Type:Direct Company Report #CTU 180550
Age:41 YR Gender:Female I/FU:I

Outcome	PT
Other	Anxiety
	Breathing-Related Sleep Disorder
	Crying
	Depersonalisation
	Dyspnoea
	Muscle Twitching
	Pain
	Pruritus

	Sensation Of Pressure Tinnitus Vertigo	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin Sr 150 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	150 MG 1X
			Claritind	C			ORAL
			Vitamins	C			
			Minerals	C			

Date:11/08/02ISR Number: 4006092-6Report Type:Expedited (15-DaCompany Report #B0281421A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Muscle Rupture	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 6 DAY
Other		Professional					

Date:11/08/02ISR Number: 4006097-5Report Type:Expedited (15-DaCompany Report #B0283515A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dizziness Headache	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day 64 DAY
	Hypomania		Thyroid Medication	C		ORAL	150MCG per day
	Inner Ear Disorder						

Date:11/08/02ISR Number: 4006100-2Report Type:Expedited (15-DaCompany Report #D0039689A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL
150MG Unknown 3 DAY						
	Dizziness		Trimipramine	C		ORAL
25MG Per day						
	Dyspnoea					
	Exanthem					
	Gastrointestinal Disorder					

Date:11/08/02ISR Number: 4007486-5Report Type:Direct Company Report #CTU 180626
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Wellbutrin 150 Mg.	PS		ORAL
150 MG 2X						
Initial or Prolonged	Chest Pain					
DAILY ORAL						
	Dyspnoea		Nicoderm Patch Step			
	Heart Rate Increased		1	SS		
TRANSDERMAL 1 PATCH EVERY						
	Hypoaesthesia					
24						
	Panic Disorder					
TRANSDERMAL						

Date:11/11/02ISR Number: 4006927-7Report Type:Expedited (15-DaCompany Report #A0075655A
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Depression
	Dyspnoea
	Emotional Disorder
	Grand Mal Convulsion

	Status Epilepticus Suicidal Ideation						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day 5 DAY
			Calcium	C			500MG Per day
			Ces	C		ORAL	1.25MG Per day
			Vitamin C	C			

Date:11/12/02ISR Number: 4008406-XReport Type:Direct Company Report #CTU 180799
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dizziness		Bupropion	PS			

Date:11/13/02ISR Number: 4008407-1Report Type:Expedited (15-DaCompany Report #A0380824A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Dysphagia Hypersensitivity Oesophageal Stenosis Pain		Wellbutrin Birth Control Pill Vitamin	PS C C	Glaxo Wellcome	ORAL	150MG Per day 1TAB Per day

Date:11/13/02ISR Number: 4008409-5Report Type:Expedited (15-DaCompany Report #A0386005A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blood Glucose Increased		Wellbutrin	PS	Glaxo Wellcome	ORAL	300MG Per day 1 YR

	Conversion Disorder		Prozac	C		ORAL
60MG Per day						
	Hypertension		Remeron	C		ORAL
45MG Per day						
	Lipids Increased		Synthroid	C	Glaxo Wellcome	ORAL
			Hypertension Med	C		
			Hypertension Med	C		
			Anti-Hyperlipidaemic (Unspecified)	C		

Date:11/13/02ISR Number: 4008411-3Report Type:Expedited (15-DaCompany Report #A0386169A
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Autoimmune Thyroiditis		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	9 MON
	Dysmenorrhoea							
	Headache							

Date:11/14/02ISR Number: 4009026-3Report Type:Expedited (15-DaCompany Report #A0385936A
Age:4 DY Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Bradycardia
	Drug Withdrawal Syndrome
Other	Neonatal
	Feeling Jittery
	Maternal Drugs Affecting Foetus
	Neonatal Apnoeic Attack

		Neonatal Disorder Sepsis Neonatal					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Wellbutrin	PS	Glaxo Wellcome	
3	WK						
				Ampicillin	C	Glaxo Wellcome	
UNKNOWN							
				Kanamycin	C		
UNKNOWN							
				Prenatal Vitamin	C		
				Iron	C		

Date:11/14/02ISR Number: 4009028-7Report Type:Expedited (15-DaCompany Report #A0386329A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxo Wellcome	ORAL
150MG Twice	Tic					
per day						

Date:11/14/02ISR Number: 4009031-7Report Type:Expedited (15-DaCompany Report #B0275736A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aggression		Zyban	PS	Glaxo Wellcome	
UNKNOWN	2TAB per day 9 DAY					
Initial or Prolonged	Agitation					
	Depression					
	Palpitations					
	Panic Attack					

Date:11/14/02ISR Number: 4009032-9Report Type:Expedited (15-DaCompany Report #B0282085A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Life-Threatening	Cardiac Disorder		Zyban	PS	Glaxo Wellcome	
90 DAY						
Hospitalization -	Drug Interaction		Previscan	SS		ORAL
25MG Per day						
Initial or Prolonged	Haematoma		Aspegic 100	SS		ORAL
	Iatrogenic Injury		Lasilix	C	Glaxo Wellcome	ORAL
	International Normalised		Diffu K	C		ORAL
	Ratio Increased		Sectral	C		ORAL
300MG per day						
	Intracardiac Thrombus		Triatec	C		ORAL
2.5MG Twice						
	Pericardial Haemorrhage					
per day						
	Post Procedural		Vasten	C		ORAL
20MG Twice						
	Complication					
per day						
			Discotrine	C	Glaxo Wellcome	
TRANSDERMAL						

Date:11/14/02ISR Number: 4009039-1Report Type:Expedited (15-DaCompany Report #B0284793A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 18 DAY						
Initial or Prolonged	Depression					
	Supraventricular Extrasystoles					
	Tachyarrhythmia					
	Tachycardia					
	Ventricular Extrasystoles					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/02ISR Number: 4009975-6Report Type:Direct Company Report #CTU 180969
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Migraine		Wellbutrin Sr 100 Mg	PS		ORAL	100 MG BID	
	Nausea						ORAL	
	Pyrexia							
	Vomiting							

Date:11/14/02ISR Number: 4012907-8Report Type:Expedited (15-DaCompany Report #2002133101US
Age:34 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Dramamine(Dimenhydrinate) Tablet	PS		ORAL	ORAL	
		Health Professional	Isotretinoin(Isotretinoin)					
			Acetaminophen(Paracetamol)	SS				
			Bupropion(Amfebutamone)	SS				

Date:11/15/02ISR Number: 4010024-4Report Type:Expedited (15-DaCompany Report #A0382851A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Abuser		Wellbutrin	PS	Glaxo Wellcome		INTRAVENOUS	
Initial or Prolonged	Medication Error		Seroquel	C		ORAL	100MG Per day	
	Phlebitis		Wellbutrin	C	Glaxo Wellcome	ORAL	200MG Per day	
			Lithium	C	Glaxo Wellcome	ORAL	150MG Per day	

Date:11/15/02ISR Number: 4010029-3Report Type:Expedited (15-DaCompany Report #A0386403A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome		150MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							

Date:11/15/02ISR Number: 4010030-XReport Type:Expedited (15-DaCompany Report #A0386477A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxo Wellcome	ORAL	1	WK

Date:11/18/02ISR Number: 4010894-XReport Type:Expedited (15-DaCompany Report #B0284567A
Age:53 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Fibrinogen Increased
	C-Reactive Protein Increased
	Csf Glucose Abnormal

	Csf Protein Abnormal Csf White Blood Cell Count Positive	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Grand Mal Convulsion		Zyban	PS	Glaxo Wellcome	ORAL
150MG Per day 8 DAY						
	Pyrexia Red Blood Cells Csf Positive					

Date:11/18/02ISR Number: 4013271-0Report Type:Expedited (15-DaCompany Report #2002065752
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Confusional State	Consumer	Zoloft (Sertraline)	PS		ORAL
ORAL						
Initial or Prolonged	Diarrhoea		Aricept (Donepezil)	SS		
	Drooling		Bupropion			
	Fall		Hydrochloride	SS		
	Hip Fracture					
	Pelvic Fracture					
	Weight Decreased					

Date:11/18/02ISR Number: 4014589-8Report Type:Expedited (15-DaCompany Report #B0284705A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthralgia	Foreign	Zyban Tablet - Zyban			
Initial or Prolonged	Blood Alkaline	Health	(Bupropion			
	Phosphatase Increased	Professional	Hydrochloride)	PS		
	Blood Bilirubin Increased					
	Cardiac Murmur					
	Dyspnoea					
	Gamma-Glutamyltransferase Increased					
	Haematuria					
	Hypersensitivity					
	Pericardial Effusion					
	Urinary Casts					
	White Blood Cells Urine Positive					

Date:11/19/02ISR Number: 4011453-5Report Type:Expedited (15-DaCompany Report #B0280687A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Zyban	PS	Glaxo Wellcome	ORAL	7	WK
Initial or Prolonged	Phlebitis		Allopurinol	C	Glaxo Wellcome	ORAL	200MG Per day	
	Pulmonary Embolism		Fenofibrate	C		ORAL	300MG Per day	

Date:11/19/02ISR Number: 4011708-4Report Type:Direct Company Report #CTU 181223
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Impaired Gastric Emptying		Zyban 150 Bid	PS		ORAL	150MG BID PO	
Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/02ISR Number: 4014600-4Report Type:Expedited (15-DaCompany Report #B0276683A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Aggression	Foreign	Zyban Tablet - Zyban				
Hospitalization -	Agitation	Health	(Bupropion				
Initial or Prolonged	Anxiety	Professional	Hydrochloride)	PS		ORAL	150 MG / PER
Disability	Coma	Company					DAY / ORAL
Required	Conjunctival Hyperaemia	Representative	Mineral Oil				
Intervention to	Disturbance In Attention		Injection (Mineral				
Prevent Permanent	Hyperhidrosis		Oil)	SS		INTRAVENOUS	INTRAVENOUS
Impairment/Damage	Indifference		Sertraline	C			
	Lung Disorder						
	Motor Dysfunction						
	Multi-Organ Failure						
	Suicide Attempt						
	Tachycardia						
	Tremor						

Date:11/20/02ISR Number: 4012165-4Report Type:Expedited (15-DaCompany Report #A0386665A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Asthenia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice
	Blindness Unilateral						per day
	Hypoaesthesia		Metadate Cd	C			
			Effexor Xr	C			
			Geodon	C			

Date:11/20/02ISR Number: 4028995-9Report Type:Periodic Company Report #001-0981-M0108765
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Eosinophilia	Health	Atorvastatin				

Initial or Prolonged	Rash	Professional	(Atorvastatin)	PS		ORAL
10 MG						
(DAILY), ORAL						
			(Bupropion)	SS		ORAL
ORAL						
			Timolol Maleate	C		
			Sulindac	C		
			Ibuprofen	C		

Date:11/21/02ISR Number: 4012726-2Report Type:Expedited (15-DaCompany Report #A0386663A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Libido Decreased		Paxil	PS	Glaxo Wellcome	ORAL
60MG Per day						
	Retinal Disorder		Wellbutrin	SS	Glaxo Wellcome	ORAL
100MG Per day						

Date:11/21/02ISR Number: 4012737-7Report Type:Expedited (15-DaCompany Report #B0285200A
Age: Gender:Female I/FU:I

Outcome	PT
Other	Emotional Disorder
	Feeling Hot
	Insomnia
	Lethargy
	Pain
	Tinnitus

	Tremor						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxo Wellcome	ORAL	150MG
							Variable dose
			Esomeprazole	C		ORAL	20MG Unknown
			Ethinylestradiol + Levonorgestrel	C		ORAL	1TAB per day

Date:11/21/02ISR Number: 4013304-1Report Type:Direct Company Report #CTU 181490
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Crying		Bupropion Hcl - 100				
Other	Depression		Mg	PS			1 TAB
	Drug Effect Decreased						EVERYDAY; 1
	Feeling Abnormal						TAB TWICE A
	Libido Decreased						DAY

Date:11/22/02ISR Number: 4013823-8Report Type:Expedited (15-DaCompany Report #A0386899A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Optic Neuritis		Wellbutrin	PS	Glaxo Wellcome	ORAL	
			Celexa	SS		ORAL	

Date:11/25/02ISR Number: 4014171-2Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-11850310
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Health Professional	Sustiva Caps 600 Mg	PS	Bristol-Myers Squibb Company	ORAL	unknown start date-prior to 06-Dec-00	
			Stavudine	SS	Bristol-Myers Squibb Company	ORAL	at hour of sleep	
			Videx Ec Caps	SS	Bristol-Myers Squibb Company	ORAL	AM + 1600 x 30 days	
			Wellbutrin	SS		ORAL		

Date:11/25/02ISR Number: 4014390-5Report Type:Expedited (15-DaCompany Report #B0285487A
Age:23 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Anxiety
	Blood Creatine Phosphokinase Increased
	Confusional State
	Convulsion
	Dermabrasion
	Disorientation
	Ecchymosis
	Haematoma
	Incoherent

	Intentional Misuse Irritability Mydriasis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Suicidal Ideation		Zyban	PS	Glaxo Wellcome	ORAL	1 WK
	Suicide Attempt Urine Amphetamine Positive						

Date:11/25/02ISR Number: 4014438-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA01406
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Drug Interaction		Cogentin	PS	Merck & Co., Inc		
	Heat Stroke		Wellbutrin	SS			
			Neurontin	SS			

Date:11/25/02ISR Number: 4017279-0Report Type:Expedited (15-DaCompany Report #CEL-2002-01391-ROC(0)
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Foreign Literature Health Professional	Methylphenidate Tablets (Unspecified) (Methylphenidate Hydrochloride)	PS			60 MG (UNK, DAILY)
			Bupropion (Bupropion)	SS			SEE IMAGE 4 WK

Date:11/26/02ISR Number: 4015319-6Report Type:Expedited (15-DaCompany Report #A0378902A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Congenital Anomaly	Bronchitis	Health	Wellbutrin	PS	Glaxo Wellcome	300MG Per day
	Coarctation Of The Aorta	Professional	Albuterol Inhaler	SS	Glaxo Wellcome	
	Complications Of Maternal		Depakote	SS		500MG Per day
	Exposure To Therapeutic		Synthroid	SS	Glaxo Wellcome	.175MG Per
	Drugs					day
	Maternal Drugs Affecting		Effexor Xr	SS		150MG Per day
	Foetus		Trimox	SS	Glaxo Wellcome	
	Pregnancy		Niferex	SS		1TAB Per day
	Premature Baby		Zithromax	SS		250MG Per day 5 DAY
	Ventricular Septal Defect		Phenergan Vc With			
	Acquired		Codeine	SS		2TSP As
						required 8 DAY

Date:11/26/02ISR Number: 4015329-9Report Type:Expedited (15-DaCompany Report #A0387263A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Dose Duration
Other	Hypersensitivity		Wellbutrin	PS	Glaxo Wellcome	ORAL 150MG Per day 3 DAY
	Multiple Sclerosis		Betaseron	C		
	Oral Mucosal Blistering		Ditropan	C		
	Swelling		Baclofen	C		
	Throat Tightness					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/02ISR Number: 4015340-8Report Type:Expedited (15-DaCompany Report #B0285464A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Retinal Artery Thrombosis Visual Disturbance		Zyban	PS	Glaxo Wellcome	UNKNOWN	150MG Twice per day	6 DAY

Date:11/26/02ISR Number: 4015341-XReport Type:Expedited (15-DaCompany Report #B0285584A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness Dysstasia Malaise Muscular Weakness Paraplegia Sensory Loss		Zyban Humalog Insulin Stagid Nicotine Patch Alcohol	PS C C C C	Glaxo Wellcome Glaxo Wellcome	ORAL UNKNOWN ORAL TRANSDERMAL ORAL	150MG Per day	31 DAY 1 DAY

Date:11/26/02ISR Number: 4017903-2Report Type:Expedited (15-DaCompany Report #US010405
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma Road Traffic Accident Status Epilepticus Tonic Clonic Movements	Health Professional	Gabitril Wellbutrin	PS SS				

Date:11/26/02ISR Number: 4017971-8Report Type:Expedited (15-DaCompany Report #12110755
Age:49 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Warfarin (Warfarin Sodium)	PS				
Other	Drug Level Above Therapeutic	Health Professional	Carbamazepine	SS				
	Overdose		Bupropion (Bupropion Hcl)	SS				

Date:11/26/02ISR Number: 4018186-XReport Type:Expedited (15-DaCompany Report #2002066467
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Neurosensory	Health	Zoloft (Sertraline)	PS		ORAL	175 MG (DAILY), ORAL	
	Tinnitus	Professional	Bupropion	SS		ORAL	300 MG (TID), ORAL	
			Fexofenadine Hydrochloride	C				
			Fluticasone Propionate	C				
			All Other Therapeutic Products	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/02ISR Number: 4019168-4Report Type:Expedited (15-DaCompany Report #SKEL000128
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health Professional	Skelaxin (Metaxalone)	PS		ORAL		
Hospitalization - Initial or Prolonged	Convulsion							
	Disseminated Intravascular Coagulation	Distributor	Tylenol (Acetaminophen)	SS		ORAL		
	Hepatic Failure		Tylenol Pm, Extra Strength (Acetaminophen D	SS		ORAL		
	Mydriasis							
	Nystagmus							
	Posturing		Effexor (Venlafaxine)	SS		ORAL		
	Pupil Fixed							
	Pyrexia		Wellbutrin Sr (Bupropion)	SS		ORAL		
	Renal Failure							
	Rhabdomyolysis		Librium (Chlordiazepoxide)	SS		ORAL		
	Tachycardia							
			Ambien (Zolpidem)	SS		ORAL		
			Midol (Apap/Pyrilamine/Caffeine)	SS		ORAL		
			Pyridium (Phenazopyridine)	SS		ORAL		
			Aleve (Naproxen)	SS		ORAL		
			Relafen (Nabumetone)	SS				

Date:11/29/02ISR Number: 4018288-8Report Type:Expedited (15-DaCompany Report #2002003791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ulcerative	Consumer	Zoloft (Sertraline)	PS				
	Depression		Mirtazapine	SS				
Other	Flashback		Bupropion					

	Gallbladder Disorder	Hydrochloride	SS
	Gastric Ulcer	All Other	
	Gastritis Erosive	Therapeutic Products	SS
	Loss Of Consciousness	Anti-Parkinson	
	Pain	Agents	SS
	Panic Attack		
	Restless Legs Syndrome		
	Serotonin Syndrome		
	Suicidal Ideation		
	Weight Decreased		

Date:11/29/02ISR Number: 4019863-7Report Type:Expedited (15-DaCompany Report #200213918BCC
Age:30 YR Gender:Male I/FU:F

Outcome	PT
Death	Body Temperature
Hospitalization -	Increased
Initial or Prolonged	Cardio-Respiratory Arrest
	Completed Suicide
	Convulsion
	Disseminated
	Intravascular Coagulation
	Hepatic Failure
	Nystagmus
	Posturing
	Pupil Fixed
	Renal Failure

	Rhabdomyolysis Tachycardia						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Literature	Aleve (Naproxen Sodium)	PS		ORAL	ORAL
		Health					
		Professional	Tylenol Pm	SS			
		Other	Effexor (Venlafaxine Hydrochloride)	SS			
			Wellbutrin Sr (Amfebutamone Hydrochloride)	SS			
			Librium	SS			
			Ambien (Zolpidem Tartrate)	SS			
			Skelaxin (Metaxalone)	SS			
			Pyridium (Phenazopyridine Hydrochloride)	SS			
			Tylenol (Paracetamol)	SS			
			Relafen (Nabumetone)	SS			
			Midol	SS			

Date:12/02/02ISR Number: 4017532-0Report Type:Expedited (15-DaCompany Report #A0387586A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Intentional Misuse Suicide Attempt		Wellbutrin	PS	Glaxo Wellcome	ORAL	

Date:12/02/02ISR Number: 4018349-3Report Type:Direct Company Report #CTU 181873
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation Heart Rate Increased Hypoaesthesia		Wellbutrin Sr 150mg (Bupropion Hydrochloride)	PS			1 TWICE A DAY

	Oedema Peripheral					
	Pain					
	Pruritus					
	Rash					

Date:12/03/02ISR Number: 4018226-8Report Type:Expedited (15-DaCompany Report #A0387654B
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Congenital Anomaly	Maternal Drugs Affecting Foetus Necrotising Colitis Pregnancy Premature Baby Pulmonary Valve Stenosis Congenital Vacuum Extractor Delivery		Bupropion	PS	Glaxo Wellcome			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/02ISR Number: 4018236-0Report Type:Expedited (15-DaCompany Report #B0134604A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Zyban	PS	Glaxo Wellcome	ORAL		
	Insomnia		Mercilon	C		ORAL		
	Oesophageal Spasm							
	Urticaria							

Date:12/03/02ISR Number: 4018237-2Report Type:Expedited (15-DaCompany Report #B0259750A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Zyban	PS	Glaxo Wellcome	ORAL	150MG See dosage text	32 DAY
	Bronchitis Chronic							
	C-Reactive Protein Increased							
	Hodgkin'S Disease							
	Neutrophil Count Increased							
	Red Blood Cell Sedimentation Rate Increased							

Date:12/03/02ISR Number: 4021391-XReport Type:Expedited (15-DaCompany Report #2002107579GB
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Depo-Medrone(Methylprednisolone) Suspension, Sterile	PS			INTRA-ARTICULAR 30 MG, SINGLE, INTRA-ARTICULAR	
	Drug Interaction	Literature						
	Lumbar Vertebral Fracture	Health Professional						
		Other						

			Zyban(Amfebutamone Hydrochloride) 150 Mg	SS		ORAL	ORAL

Date:12/03/02ISR Number: 4025895-5Report Type:Periodic Company Report #2002061599
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block	Health Professional	Geodon (Ziprasidone)	PS		ORAL	160 MG (BID),	ORAL
			Bupropion Hydrochloride	SS		ORAL	200 MG (BID),	ORAL
			Lorazepam	C				

Date:12/04/02ISR Number: 4018742-9Report Type:Expedited (15-DaCompany Report #A0385736A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive	Health Professional	Wellbutrin	PS	Glaxo Wellcome	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/02ISR Number: 4018748-XReport Type:Expedited (15-DaCompany Report #A0387850A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL		
	Drug Ineffective							

Date:12/04/02ISR Number: 4019467-6Report Type:Direct Company Report #CTU 182169
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Bupropion	PS		ORAL	150MG PO BID	
Initial or Prolonged			Metoprolol	SS		ORAL	75MG PO BID	

[GREATER THAN

1 YR]

Date:12/04/02ISR Number: 4019473-1Report Type:Direct Company Report #CTU 182171
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Wellbutrin	PS				
			St John'S Wart	SS				
			Colostrum	SS				

Date:12/06/02ISR Number: 4022598-8Report Type:Expedited (15-DaCompany Report #B0285143A
Age:34 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse	Literature	Diphenhydramine					
		Health Professional	Hydrochloride (Formulation Unknown)					

			(Diphenhydramine	PS		ORAL	ORAL
			Isotretinoin (Formulation Unknown) (Isotretinoin)	SS		ORAL	ORAL
			Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS			

Date:12/06/02ISR Number: 4022600-3Report Type:Expedited (15-DaCompany Report #B0285160A
Age:33 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Literature Health Professional	Diphenhydramine Hydrochloride (Formulation Unknown) (Diphenhydramine	PS		ORAL	ORAL	
			Risperidone (Formulation Unknown) (Risperidone)	SS		ORAL	ORAL	
			Wellbutrin (Formulation Unknown) (Bupropion					

			Hydrochloride)	SS		ORAL
ORAL						

Date:12/09/02ISR Number: 4020258-0Report Type:Expedited (15-DaCompany Report #B0265019A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	30 DAY
	Confusional State	Professional						
	Convulsion		Simvastatin	C			20MG per day	
	Dizziness		Seloken	C			200MG per day	
	Fatigue		Renitec	C			10MG per day	
	Fear		Frusemide	C	Glaxo Wellcome		40MG per day	
	Gastrointestinal Disorder		Aspirin	C			75MG per day	
	General Physical Health Deterioration							
	Loss Of Consciousness							
	Malaise							
	Memory Impairment							
	Pancreatitis							
	Panic Attack							
	Peritonitis							
	Purulence							
	Sexual Dysfunction							
	Sleep Disorder							
	Swelling							

Date:12/09/02ISR Number: 4020263-4Report Type:Expedited (15-DaCompany Report #B0283974A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphonia	Health	Zyban	PS	Glaxo Wellcome	ORAL	29 DAY	
	Dysphonia	Professional	Tahor	C		ORAL	20MG Per day	

	Laryngitis					

Date:12/09/02ISR Number: 4020264-6Report Type:Expedited (15-DaCompany Report #B0284170A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lung Neoplasm Malignant	Health Professional	Zyban	PS	Glaxo Wellcome	ORAL	14	DAY

Date:12/09/02ISR Number: 4020278-6Report Type:Expedited (15-DaCompany Report #B0287228A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emotional Distress		Zyban	PS	Glaxo Wellcome	ORAL	150MG	Unknown 21 DAY
	Nausea		Mirena	C		INTRA-UTERINE		
	Throat Tightness							
	Urticaria							
	Vomiting							
	Wheezing							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/02ISR Number: 4020872-2Report Type:Direct Company Report #CTU 182333
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Welbutrin 100mg Sr					
Hospitalization -			Glaxo	PS	Glaxo	ORAL	1 PILL A.M.	
Initial or Prolonged								
ORAL								
			Wellbutrin 150mg Sr					
			Glaxo	SS	Glaxo	ORAL	1 PILL A.M.	
ORAL								

Date:12/09/02ISR Number: 4020922-3Report Type:Direct Company Report #182415
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Zyban	PS				
	Blood Pressure Systolic Increased							
	Excoriation							
	Heart Rate Increased							
	Hypersensitivity							
	Oedema Peripheral							
	Respiratory Disorder							
	Respiratory Rate Increased							
	Serum Sickness							
	Throat Tightness							

Date:12/10/02ISR Number: 4020896-5Report Type:Expedited (15-DaCompany Report #B0273556A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Supraventricular		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	12 DAY
Initial or Prolonged	Tachycardia		Rivotril	C		ORAL	800UG Per day	

Date:12/10/02ISR Number: 4020905-3Report Type:Expedited (15-DaCompany Report #B0286752A
Age:34 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetes Mellitus		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Inadequate Control						per day	
			Frusemide	C	Glaxo Wellcome		40MG per day	
			Porcine Insuline	C				
			Warfarin	C	Glaxo Wellcome			
			Insulin	C				
			Ramipril	C			5MG per day	

Date:12/10/02ISR Number: 4020907-7Report Type:Expedited (15-DaCompany Report #B0286803A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depersonalisation		Zyban	PS	Glaxo Wellcome	ORAL	10	DAY
	Feeling Abnormal		Deroxat	C	Glaxo Wellcome	ORAL	MON	
	Insomnia							
	Nausea							
	Tearfulness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/02ISR Number: 4021777-3Report Type:Direct Company Report #CTU 182455
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Dyspnoea Erythema Feeling Abnormal Flushing Hypersensitivity Hypoaesthesia Palpitations Paraesthesia Tongue Oedema		Wellbutrin 150mg Tablets Glaxo	PS	Glaxo	ORAL	150MG 2X PER ORAL	

Date:12/10/02ISR Number: 4024748-6Report Type:Expedited (15-DaCompany Report #HYDROCOD2002-00427
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Pulmonary Oedema	Literature	Hydrocodone/Apap	PS		ORAL	PO	
	Completed Suicide	Health	Propoxyphene	SS		ORAL	PO	
	Drug Screen Positive	Professional	Bupropion	SS		ORAL	PO	
	Overdose		Doxepin	SS		ORAL	PO	
	Pulmonary Congestion		Fluoxetine	SS		ORAL	PO	
			Zolpidem	SS		ORAL	PO	

Date:12/10/02ISR Number: 4024802-9Report Type:Expedited (15-DaCompany Report #02P-163-0205266-00
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Hydrocodone/Acetamin					
	Completed Suicide	Health	ophen (Vicodin)					

		Professional	(Hydrocodone/Acetaminophen)			
			(Hydrocodone/Acetami	PS		
			Dextropropoxyphene	SS		
			Bupropion	SS		

Date:12/11/02ISR Number: 4021400-8Report Type:Expedited (15-DaCompany Report #A0388692A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Burning Sensation		Wellbutrin	PS	Glaxo Wellcome			5 DAY
Initial or Prolonged	Photosensitivity Reaction							

Date:12/11/02ISR Number: 4021401-XReport Type:Expedited (15-DaCompany Report #B0111947A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged	Bundle Branch Block						per day	7 DAY
	Chest Pain		Zopiclone	C				
	Dizziness		Propiomazine	C				
	Palpitations		Somadril	C				
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/02ISR Number: 4021402-1Report Type:Expedited (15-DaCompany Report #B0286866A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Zyban	PS	Glaxo Wellcome		150MG	Unknown
	Fear		Aspirin	C		ORAL	75MG	Unknown
	Hyperventilation		Glyceryl Trinitrate	C	Glaxo Wellcome	SUBLINGUAL		
	Malaise		Salbutamol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)	2PUFF	Unknown

Date:12/12/02ISR Number: 4021689-5Report Type:Expedited (15-DaCompany Report #A0388553A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction		Wellbutrin	PS	Glaxo Wellcome		150MG	Twice per day
	Pneumonia							
			Biaxin	C		ORAL	500MG	Twice per day
			Prednisone	C		ORAL		
			Avandia	C	Glaxo Wellcome	ORAL	4MG	Per day
			Humulin R	C		SUBCUTANEOUS		
			Humulin N	C		SUBCUTANEOUS		
			Lorcet 10	C		ORAL		
			Xanax	C		ORAL		
			Diflucan	C		ORAL	200MG	Per day
			Lithium	C	Glaxo Wellcome	ORAL	900MG	Per day
			Paxil	C	Glaxo Wellcome	ORAL	40MG	Per day

			Neurontin	C		ORAL 600MG Per day
			Prevacid	C		ORAL 30MG Per day
			Albuterol	C	Glaxo Wellcome	RESPIRATORY (INHALATION)
			Atrovent	C		RESPIRATORY (INHALATION)
			Flovent	C	Glaxo Wellcome	RESPIRATORY (INHALATION)

Date:12/12/02ISR Number: 4021701-3Report Type:Expedited (15-DaCompany Report #B0287227A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Arterial Spasm	Consumer	Zyban	PS	Glaxo Wellcome	ORAL 150MG Per day
Other	Drug Interaction		Iopamidol	SS		UNKNOWN 30ML per day 1 DAY
	Electrocardiogram St		Aspirin	C		ORAL 75MG per day
	Segment Elevation		Felodipine	C		ORAL 10MG per day
	Nausea		Atorvastatin	C		ORAL 20MG per day
	Vomiting		Rabeprazole	C		ORAL 20MG per day

Date:12/12/02ISR Number: 4021702-5Report Type:Expedited (15-DaCompany Report #B0287325A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL 1 MON
	Anxiety					
	Confusional State					
	Depression					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/02ISR Number: 4021724-4Report Type:Expedited (15-DaCompany Report #B0260318A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable Chest Pain Coronary Artery Occlusion Coronary Artery Stenosis Diabetes Mellitus Rash Erythematous Rash Pruritic	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	2TABS per day	3 DAY

Date:12/12/02ISR Number: 4021725-6Report Type:Expedited (15-DaCompany Report #B0281421A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dysstasia	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 DAY
Other	Muscle Rupture Myalgia	Professional						

Date:12/12/02ISR Number: 4021730-XReport Type:Expedited (15-DaCompany Report #B0287403A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Galactorrhoea		Zyntabac	PS	Glaxo Wellcome	ORAL	300MG per day	

Date:12/12/02ISR Number: 4021731-1Report Type:Expedited (15-DaCompany Report #D0039257A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Bicarbonate	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	4TAB per day	2 DAY
Hospitalization - Initial or Prolonged	Decreased Blood Glucose Increased		Metformin	SS		ORAL		

Other	Blood Ph Decreased
	Blood Pressure Increased
	Circulatory Collapse
	Communication Disorder
	Convulsion
	Disturbance In Attention
	General Physical Health Deterioration
	Lactic Acidosis
	Overdose
	Refusal Of Treatment By Patient
	Sinus Tachycardia
	White Blood Cell Count Increased

Date:12/12/02ISR Number: 4025484-2Report Type:Expedited (15-DaCompany Report #02P-163-0205719-00
Age:38 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Difficulty In Walking
	Lymphadenopathy
	Myalgia
	Oral Intake Reduced

Weight Decreased

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Kaletra Soft Gelatin Capsules (Kaletra) (Lopinavir/ Ritonavir)(Lopinavir / Ritonavir)	PS		ORAL	6 TABLET, 1 IN 1 D, PER ORAL	
			Bupropion Hydrochloride	SS		ORAL	150 MG , 2 IN 1 D, PER ORAL	
			Tenofovir	C				
			Lamivudine	C				
			Lexapro	C				

Date:12/13/02ISR Number: 4022654-4Report Type:Expedited (15-DaCompany Report #A0388881A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Choreoathetosis Coordination Abnormal		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	5 DAY

Date:12/13/02ISR Number: 4022655-6Report Type:Expedited (15-DaCompany Report #A0388982A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Hepatic Neoplasm		Wellbutrin	PS	Glaxo Wellcome	ORAL	400MG Per day	YR
			Effexor	C				
			Birth Control	C				
			Atenolol	C				

			Unknown Medication	C		

Date:12/13/02ISR Number: 4022657-XReport Type:Expedited (15-DaCompany Report #A0389005A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Cancer Female		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:12/13/02ISR Number: 4027164-6Report Type:Expedited (15-DaCompany Report #02P-163-0205470-00
Age:19 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Completed Suicide	Literature Health Professional	Valproic Acid (Depakene) (Valproic Acid) (Valproic Acid)	PS		ORAL	PER ORAL	
			Bupropion	SS		ORAL	PER ORAL	
			Olanzapine	SS		ORAL	PER ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/02ISR Number: 4027237-8Report Type:Expedited (15-DaCompany Report #S02-USA-03225-01
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Optic Neuritis	Health Professional	Celexa (Citalopram Hydrobromide)	PS				
			Wellbutrin Sr (Bupropion Hydrochloride)	SS				

Date:12/17/02ISR Number: 4026091-8Report Type:Direct Company Report #CTU 182820
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conversion Disorder		Wellbutrin 200mg	PS		ORAL	200MG TWICE A	
	Crying						DAY ORAL	
	Memory Impairment							

Date:12/18/02ISR Number: 4025589-6Report Type:Direct Company Report #CTU 182981
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness		Buproprion	PS			300MG QD	CHRONIC
	Petit Mal Epilepsy							
	Road Traffic Accident		Amitriptyline	SS		ORAL	75MG PO QHS	CHRONIC
			Labetolol	C				
			Altace	C				
			Levoxyl	C				
			Norvasc	C				
			Wellbutrin	C				

Date:12/18/02ISR Number: 4029418-6Report Type:Expedited (15-DaCompany Report #A0387790A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State Drug Interaction Grand Mal Convulsion Somnolence	Foreign Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	PER DAY/ORAL	
			Methylphenidate (Formulation Unknown) (Methylphenidate)	SS			60 MG/PER DAY	

Date:12/18/02ISR Number: 4029817-2Report Type:Expedited (15-DaCompany Report #B0287094A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Drug Dependence Myocardial Infarction Tobacco Abuse	Foreign Literature Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/02ISR Number: 4025667-1Report Type:Expedited (15-DaCompany Report #A0386329A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Grand Mal Convulsion	Professional					per day	
	Tic		Klonopin	C		ORAL	1MG Three	
							times per day	
			Lorcet	C				

Date:12/19/02ISR Number: 4025708-1Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12135786
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Health	Aripiprazole	PS	Otsuka Pharmaceutical Company, Ltd.	ORAL		
	Schizoaffective Disorder	Professional						
			Wellbutrin	SS				
			Prozac	SS				
			Topamax	C				
			Klonopin	C				

Date:12/19/02ISR Number: 4026267-XReport Type:Direct Company Report #CTU 183081
Age:28 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Zyban 180mg Tbsr	PS		ORAL	1T PO QD X3D	
	Insomnia						THEN 1T PO	
							BID	
			Nicorette	C				

Date:12/20/02ISR Number: 4028619-0Report Type:Direct Company Report #CTU 183173
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills Coma		Tramadol 50mg Qid Started 12/9	PS		ORAL	50MG PO QID	
Other	Confusional State		Imitrex 6mg Sq X 1	SS		SUBCUTANEOUS	6 MG X	SQ X
	Delirium		Paxil 20mg	SS		ORAL	20 MG PO QD	
	Hypotension		Zyban 150 Mg	SS		ORAL	150 MG PO BID	
	Labile Blood Pressure		Nicotine Patch 21	SS		TOPICAL	21G TOP QD	
	Muscle Spasms							
	Pyrexia							
	Restlessness							
	Tremor							

Date:12/20/02ISR Number: 4030873-6Report Type:Expedited (15-DaCompany Report #2002070646
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Respiratory Failure	Health Professional Company Representative	Geodon (Ziprasidone)	PS				
			Zoloft (Sertraline)	SS				
			Wellbutrin (Bupropion Hydrochloride)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/02ISR Number: 4027471-7Report Type:Expedited (15-DaCompany Report #A0375990A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Health Professional	Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Back Injury							
	Confusional State		Zyban	SS	Glaxo Wellcome	ORAL	150MG See dosage text	3 MON
	Convulsion							
	Embolism		Zocor	C				
	Fracture		Stool Softener	C				
	Headache							

Date:12/23/02ISR Number: 4027475-4Report Type:Expedited (15-DaCompany Report #A0389501A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemothorax		Wellbutrin	PS	Glaxo Wellcome	ORAL	5	MON

Date:12/23/02ISR Number: 4027476-6Report Type:Expedited (15-DaCompany Report #A0389718A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure		Wellbutrin	PS	Glaxo Wellcome	ORAL		
			Trilafon	C	Glaxo Wellcome			
			Zoloft	C				
			Unknown	C				

Date:12/23/02ISR Number: 4027488-2Report Type:Expedited (15-DaCompany Report #B0288015A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Dizziness		Zyban	PS	Glaxo Wellcome	ORAL
150MG Twice per day 7 DAY	Exophthalmos Face Oedema Malaise Migraine Visual Disturbance		Ethinyloestradiol + Levonorgestrel	C		ORAL

Date:12/24/02ISR Number: 4033557-3Report Type:Expedited (15-DaCompany Report #B0287475A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Influenza Like Illness Myalgia	Foreign	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL

Date:12/24/02ISR Number: 4033559-7Report Type:Expedited (15-DaCompany Report #B0287549A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Suicidal Ideation Suicide Attempt	Foreign	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL
			Paroxetine Hydrochloride	C			
			Alprazolam	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/02ISR Number: 4033566-4Report Type:Expedited (15-DaCompany Report #B0126002A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Toxic Skin Eruption	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/AS	DIRECTED/ORAL

Date:12/24/02ISR Number: 4033568-8Report Type:Expedited (15-DaCompany Report #B0134062A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Stenosis Convulsion	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/AS	DIRECTED/ORAL
			Diazepam (Diazepam)	SS				
			Ethanol	C				

Date:12/24/02ISR Number: 4033757-2Report Type:Expedited (15-DaCompany Report #S02-USA-03223-01
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Health Professional Company Representative	Celexa (Citalopram Hydrobromide)	PS				
			Celexa (Citalopram Hyrobromide)	SS				
			Lamictal (Lamotrigine)	SS				
			Wellbutrin (Bupropion Hydrochloride)	SS				

Date:12/24/02ISR Number: 4034046-2Report Type:Expedited (15-DaCompany Report #B0287207A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Myalgia Pruritus Purpura Rash Pruritic	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL

Date:12/24/02ISR Number: 4034295-3Report Type:Expedited (15-DaCompany Report #A0388161A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Intentional Misuse	Health Professional	Lamictal Unspecified Tablet (Lamotrigine)	PS		ORAL	ORAL
		Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	SS		ORAL	ORAL
			Citalopram Hydrobromide (Citalopram Hydrobromide)	SS			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/02ISR Number: 4034575-1Report Type:Expedited (15-DaCompany Report #B0287627A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperhidrosis Insomnia Irritability Nephrolithiasis Renal Colic	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / SEE DOSAGE TEXT / ORAL	

Date:12/24/02ISR Number: 4036242-7Report Type:Periodic Company Report #A0100574A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other Required Intervention to Prevent Permanent Impairment/Damage	Dyskinesia Tardive Dyskinesia	Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	100 MG / TWICE PER DAY / ORAL	

Date:12/24/02ISR Number: 4036247-6Report Type:Periodic Company Report #A0383258A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion	Health Professional Other	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Lexapro (Formulation Unknown) (Lexapro)	SS		ORAL	10 MG / PER	

DAY / ORAL							
			Fluoxetine Hydrochloride (Formulation Unknown) (Fluoxetine Hydrochloride)	SS			ORAL
80 MG / PER							
DAY / ORAL							
			Fluoxetine Hydrochloride (Formulation Unknown) (Fluoxetine Hydrochloride)	SS			ORAL
40 MG / PER							
DAY / ORAL							

Date:12/24/02ISR Number: 4036254-3Report Type:Periodic Company Report #A0379765A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/02ISR Number: 4036259-2Report Type:Periodic Company Report #A0376644A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Grand Mal Convulsion	Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:12/24/02ISR Number: 4036277-4Report Type:Periodic Company Report #A0372838A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:12/24/02ISR Number: 4036278-6Report Type:Periodic Company Report #A0369927A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Health Professional	Wellbutrin	PS		ORAL	100 MG / TWICE PER DAY / ORAL	
		Other	Ethanol	SS		ORAL	ORAL	
			Halls	SS		ORAL	SEE DOSAGE TEXT / ORAL	
			Gabapentin	C				
			Oxcarbazepine	C				

Date:12/24/02ISR Number: 4036279-8Report Type:Periodic Company Report #A0174498A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Grand Mal Convulsion	Health Professional Company Representative	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	100 MG / TWICE PER DAY / ORAL	
			Simvastatin	C				
			Doxazosin Mesylate	C				
			Aspirin	C				
			Meclozine Hydrochloride	C				

Date:12/24/02ISR Number: 4036280-4Report Type:Periodic Company Report #A0169662A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Overdose Suicide Attempt	Health Professional Company Representative	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / SEE DOSAGE TEXT / ORAL	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/02ISR Number: 4034649-5Report Type:Expedited (15-DaCompany Report #A0389722A
Age:5 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Study	Wellbutrin Sr					
	Drug Exposure Via Breast Milk	Health Professional	Tablet-Controlled Release (Bupropion Hydrochloride)	PS				
TRANSMAMMARY	TRANSMAMMARY							
	Foetus		Fluvoxamine Meleate (Fluvoxamine Maleate)	SS				
TRANSMAMMARY	TRANSMAMMARY							

Date:12/27/02ISR Number: 4035526-6Report Type:Expedited (15-DaCompany Report #B0287652A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Systolic Increased	Foreign	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL		
ORAL								
	Flushing							
	Malaise							
	Nausea							
	Tremor							

Date:12/30/02ISR Number: 4032147-6Report Type:Expedited (15-DaCompany Report #A0389949A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxo Wellcome	ORAL	450MG per day	2 WK
	Loss Of Consciousness		Birth Control Pill	C				
	Tremor		Flexeril	C			10MG per day	
			Losec	C		ORAL	20MG per day	

Date:12/30/02ISR Number: 4032148-8Report Type:Expedited (15-DaCompany Report #A0390002A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
	Difficulty In Walking							
	Dysarthria							
	Vision Blurred							

Date:12/30/02ISR Number: 4032161-0Report Type:Expedited (15-DaCompany Report #B0288380A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	6 DAY
	Haematuria		Bisoprolol	C				
	Leukocyturia		Hydrochlorothiazide	C				
	Malaise		Amlodipine	C				
	Proteinuria		Atorvastatin	C				
	Renal Failure Acute							

Date:12/30/02ISR Number: 4032162-2Report Type:Expedited (15-DaCompany Report #B0288386A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Headache		Quomem	PS	Glaxo Wellcome	ORAL	9TAB per day	
Initial or Prolonged	Hyperhidrosis		Alprazolam	C			UNKNOWN	
	Nausea		Amitriptyline	C			UNKNOWN	
	Overdose		Clonidine	C			UNKNOWN	
	Palpitations							
	Vomiting							

Date:12/30/02ISR Number: 4036494-3Report Type:Expedited (15-DaCompany Report #2002070646
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fall	Health	Geodon (Ziprasidone)	PS		ORAL	160 MG, ORAL	
	Respiratory Failure	Professional	Zoloft (Sertraline)	SS		ORAL	ORAL	
	Toxicologic Test Abnormal	Company Representative	Wellbutrin (Bupropion Hydrochloride)	SS				
			Obetrol	C				
			Risperidone	C				

Date:12/30/02ISR Number: 4036588-2Report Type:Expedited (15-DaCompany Report #B0286165A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coordination Abnormal	Foreign	Zyban Tablet-Zyban					
	Dizziness	Health	(Bupropion					
	Eye Movement Disorder	Professional	Hydrochloride)	PS		ORAL	SEE DOSAGE	
	Impaired Driving Ability						TEXT/ORAL	
	Insomnia							

	Speech Disorder					
	Vertigo					

Date:12/31/02ISR Number: 4036699-1Report Type:Expedited (15-DaCompany Report #A0390002A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Foreign	Zyban Tablet-Zyban					
	Difficulty In Walking	Consumer	(Bupropion					
	Dysarthria		Hydrochloride)	PS		ORAL	150 MG TWICE	
	Vision Blurred						PER DAY ORAL	

Date:12/31/02ISR Number: 4036700-5Report Type:Expedited (15-DaCompany Report #A0389949A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Zyban Tablet- Zyban					
	Loss Of Consciousness		(Bupropion					
	Tremor		Hydrochloride)	PS		ORAL	ORAL	2 WK
			Oral Contraceptive	C				
			Cyclobenzaprine Hcl	C				
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/31/02ISR Number: 4036743-1Report Type:Expedited (15-DaCompany Report #B0288380A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Asthenia Renal Failure Acute	Foreign Health Professional Company Representative	Zyban Tablet-Zyban (Bupropion Hydrochloride) Bisoprolol Hydrochlorothiazide Amlodipine Atorvastatin Calcium	PS C C C C	Zyban	ORAL	150 MG / PER DAY / ORAL	

Date:12/31/02ISR Number: 4036744-3Report Type:Expedited (15-DaCompany Report #B0288386A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache Hyperhidrosis Nausea Overdose Palpitations Vomiting	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride) Alprazolam Amitriptyline Clonidine	PS C C C	Zyban	ORAL	ORAL	

Date:01/01/03ISR Number: 4033979-0Report Type:Direct Company Report #CTU 183686
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Erythematous Rash Macular		Wellbutrin Sr 150 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	150 MG DAILY ORAL	

Date:01/02/03ISR Number: 4033703-1Report Type:Expedited (15-DaCompany Report #A0390229A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cognitive Disorder		Zyban	PS	Glaxo Wellcome	ORAL		
	Drug Dependence							

Date:01/02/03ISR Number: 4033708-0Report Type:Expedited (15-DaCompany Report #B0267268A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Exophthalmos		Quomem	PS	Glaxo Wellcome	ORAL	150MG	
	Eye Pain							
	Ocular Vascular Disorder						Variable dose	15 DAY
	Somnolence							
	Swelling							
	Vision Blurred							

Date:01/03/03ISR Number: 4034662-8Report Type:Expedited (15-DaCompany Report #A0390178A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome		UNKNOWN	
	Intentional Misuse		Lamictal	SS	Glaxo Wellcome		UNKNOWN	
			Celexa	SS			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/03ISR Number: 4034681-1Report Type:Expedited (15-DaCompany Report #B0288569A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Coordination Abnormal		Zyban	PS	Glaxo Wellcome	ORAL	19 DAY
Initial or Prolonged	Dizziness		Levothyrox	C	Glaxo Wellcome		
	Motor Dysfunction						
	Muscular Weakness						
	Pallor						

Date:01/06/03ISR Number: 4039508-XReport Type:Expedited (15-DaCompany Report #US010405
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Coma	Health	Gabitril	PS			
Initial or Prolonged	Complex Partial Seizures	Professional	Wellbutrin	SS			
	Epileptic Aura						
	Grand Mal Convulsion						
	Parosmia						
	Road Traffic Accident						
	Status Epilepticus						

Date:01/07/03ISR Number: 4037697-4Report Type:Expedited (15-DaCompany Report #A0386665A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Asthenia		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice
	Blindness Unilateral						per day
	Drug Interaction		Metadate Cd	C		ORAL	60MG Per day
	Hypoaesthesia		Effexor Xr	C		ORAL	150MG Per day
	Vision Blurred		Geodon	C		ORAL	20MG Per day

Date:01/08/03ISR Number: 4038453-3Report Type:Expedited (15-DaCompany Report #A0390432A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health	Wellbutrin	PS	Glaxo Wellcome			
	Intentional Misuse	Professional	Alcohol	SS				

Date:01/09/03ISR Number: 4039389-4Report Type:Expedited (15-DaCompany Report #B0267268A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Exophthalmos		Quomem	PS	Glaxo Wellcome	ORAL	150MG	
	Eye Pain							
	Ocular Vascular Disorder						Variable dose	15 DAY
	Somnolence							
	Swelling							
	Vasodilatation							
	Vision Blurred							

Date:01/10/03ISR Number: 4040007-XReport Type:Expedited (15-DaCompany Report #A0391302A
Age:18 YR Gender:Male I/FU:I

Outcome	PT
Other	Aggression
	Libido Increased

	Sexual Abuse					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin	PS	Glaxo Wellcome	
150MG Twice						
per day						

Date:01/10/03ISR Number: 4040008-1Report Type:Expedited (15-DaCompany Report #A0391477A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxo Wellcome	ORAL
2 YR						
	Complications Of Maternal Exposure To Therapeutic Drugs					
	Maternal Drugs Affecting Foetus					

Date:01/10/03ISR Number: 4040012-3Report Type:Expedited (15-DaCompany Report #A0391683A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome	ORAL
225MG Per day						
	Complications Of Maternal Exposure To Therapeutic Drugs					
	Maternal Drugs Affecting Foetus					
	Pregnancy					

Date:01/10/03ISR Number: 4040013-5Report Type:Expedited (15-DaCompany Report #A0391700A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Death	Completed Suicide Intentional Misuse Photosensitivity Reaction Somnolence Sunburn		Wellbutrin Benadryl	PS SS	Glaxo Wellcome Glaxo Wellcome

Date:01/10/03ISR Number: 4041455-4Report Type:Expedited (15-DaCompany Report #200212-1919 (0)
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Somnolence Sunburn	Consumer	Benadryl - Formulation Unspecified (Diphenhydramine)	PS		ORAL	PER ORAL	
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	PER ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/03ISR Number: 4040999-9Report Type:Direct Company Report #CTU 184264
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated		6-Mercaptopurine	PS		ORAL	125 MG PO QHS	
	Hypotension		Methotrexate	SS		ORAL	30 MG PO QWK	
	Pyrexia		Wellbutrin	SS		ORAL	200 MG PO BID	
	Sepsis		Depakote	SS		ORAL	250 MG PO BID	
	Sinusitis		Clonidine	SS			0.6 MG QHS	
			Primaxin	SS			INTRAVENOUS	1 GM IV EVERY 8 HOURS

Date:01/13/03ISR Number: 4041054-4Report Type:Expedited (15-DaCompany Report #A0391727A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Disorder		Bupropion	PS	Glaxo Wellcome		75MG Twice per day	
	Arthropathy							
	Attention Deficit/Hyperactivity Disorder		Paxil	C	Glaxo Wellcome		5MG Per day	
	Autism Spectrum Disorder							
	Breech Presentation							
	Congenital Anomaly							
	Expressive Language Disorder							
	Maternal Drugs Affecting Foetus							

Date:01/13/03ISR Number: 4041055-6Report Type:Expedited (15-DaCompany Report #A0391739A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Communication Disorder		Wellbutrin	PS	Glaxo Wellcome	ORAL	400MG Per day	
Initial or Prolonged	Convulsion		Topomax	C				
Other	Difficulty In Walking		Prozac	C				
	Loss Of Consciousness		Desyrel	C				

Date:01/13/03ISR Number: 4041060-XReport Type:Expedited (15-DaCompany Report #B0287627A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperhidrosis	Health	Zyban	PS	Glaxo Wellcome	ORAL	150MG See	
Initial or Prolonged	Insomnia	Professional					dosage text	
	Irritability							
	Nephrolithiasis							
	Renal Colic							

Date:01/13/03ISR Number: 4042347-7Report Type:Periodic Company Report #2002-05-2190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional Company Representative	Claritin-D 12 Hour (Loratadine 5mg / Pseudoephedrine Extended Release Tablet	PS		ORAL	ORAL	
			Paxil	SS				

			Wellbutrin (Bupropion)	SS		

Date:01/13/03ISR Number: 4042370-2Report Type:Periodic Company Report #2002063780
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Diflucan Tablets (Fluconazole)	PS		ORAL	ORAL	
			Bupropion Hydrochloride	SS		ORAL	250 MG	(DAILY), ORAL

Date:01/15/03ISR Number: 4042096-5Report Type:Direct Company Report #CTU 184528
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Tinnitus		Wellbutrin Sr 150mg	PS		ORAL	1 TWICE DAILY ORAL	

Date:01/15/03ISR Number: 4042128-4Report Type:Direct Company Report #CTU 184548
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Welbutrin Sr 150 Mg	PS		ORAL	150 MG BID ORAL	
			Nasonex	C				

Date:01/15/03ISR Number: 4042195-8Report Type:Expedited (15-DaCompany Report #B0289056A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Zyban	PS	Glaxo Wellcome	ORAL		
	Anaemia		Ercefuryl	SS	Glaxo Wellcome	ORAL		3 DAY
	Haemolytic Uraemic		Visceralgine	SS		ORAL		3 DAY
	Syndrome		Vogalene	SS		ORAL		3 DAY
	Haptoglobin Decreased		Mushrooms	C		ORAL		1 DAY
	Hyperbilirubinaemia							
	Influenza Like Illness							
	Jaundice							
	Purpura							
	Renal Failure							
	Scan Abdomen Abnormal							
	Thrombocytopenia							
	Thrombotic Microangiopathy							
	Vomiting							

Date:01/15/03ISR Number: 4042196-XReport Type:Expedited (15-DaCompany Report #B0289066A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Zyntabac	PS	Glaxo Wellcome	ORAL	150MG Twice per day	27 DAY
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/15/03ISR Number: 4042303-9Report Type:Direct Company Report #CTU 184544
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Wellbutrin 150mg	PS		ORAL	150MG PO BID	
	Urticaria		Premarin	C				
			Synthroid	C				
			Aciphex	C				
			Celebrex	C				

Date:01/16/03ISR Number: 4042655-XReport Type:Expedited (15-DaCompany Report #A0388161A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Lamictal	PS	Glaxo Wellcome	ORAL		
	Intentional Misuse		Wellbutrin	SS	Glaxo Wellcome	ORAL		
			Celexa	SS				

Date:01/16/03ISR Number: 4042657-3Report Type:Expedited (15-DaCompany Report #A0390178A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxo Wellcome		UNKNOWN	
	Intentional Misuse		Lamictal	SS	Glaxo Wellcome		UNKNOWN	
			Celexa	SS			UNKNOWN	

Date:01/16/03ISR Number: 4042670-6Report Type:Expedited (15-DaCompany Report #D0010841A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	9 DAY
Hospitalization -	Cardiac Arrest							

Initial or Prolonged	Electroencephalogram
Other	Abnormal
	Grand Mal Convulsion

Date:01/17/03ISR Number: 4043214-5Report Type:Expedited (15-DaCompany Report #A0392519A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Twice per day	
			Adipex-P	C	Glaxo Wellcome			

Date:01/17/03ISR Number: 4043215-7Report Type:Expedited (15-DaCompany Report #A0392586A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Phaeochromocytoma		Wellbutrin	PS	Glaxo Wellcome	ORAL		

Date:01/17/03ISR Number: 4043226-1Report Type:Expedited (15-DaCompany Report #B0289128A
Age:31 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased

		Dizziness Dysarthria Intentional Misuse	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Oxygen Saturation Decreased	Consumer	Zyban	PS	Glaxo Wellcome	ORAL	40TABS Single
		Sinus Tachycardia		Zopiclone	SS		ORAL	dose 1 DAY
		Somnolence Vomiting		Valium	SS		ORAL	1PACK Single dose 1 DAY

Date:01/20/03ISR Number: 4043555-1Report Type:Expedited (15-DaCompany Report #A0380824A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Dysphagia Hypersensitivity Oesophageal Stenosis		Wellbutrin Birth Control Pill Vitamin	PS C C	Glaxo Wellcome	ORAL	150MG Per day 1TAB Per day

Date:01/20/03ISR Number: 4043558-7Report Type:Expedited (15-DaCompany Report #A0392609A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Ileus Paralytic Urinary Retention		Wellbutrin	PS	Glaxo Wellcome		150MG Twice per day 5 MON
			Paxil	C	Glaxo Wellcome	ORAL	40MG Per day
			Klonopin	C		ORAL	.5MG As required

Date:01/20/03ISR Number: 4043561-7Report Type:Expedited (15-DaCompany Report #B0260713A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Zyban	PS	Glaxo Wellcome	ORAL	14	DAY
	Excitability							
	Insomnia							
	Lymphocytic Lymphoma							
	Pruritus Generalised							
	Rash Erythematous							
	Vertigo							

Date:01/20/03ISR Number: 4043562-9Report Type:Expedited (15-DaCompany Report #B0271161A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Mean Cell Volume		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	24 DAY
	Increased		Miniphase	SS		ORAL	1TAB Per day	YR
	Pain In Extremity		Lexomil	SS		ORAL	.5TAB Twice	
	Peripheral Sensory						per day	YR
	Neuropathy		Di-Antalvic	SS		ORAL	2UNIT Monthly	YR
	Spinal Osteoarthritis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/03ISR Number: 4043563-0Report Type:Expedited (15-DaCompany Report #B0273874A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspartate		Zyban	PS	Glaxo Wellcome	ORAL	300MG per day	31 DAY
Life-Threatening	Aminotransferase		Lectil	SS		ORAL	26 DAY	
Hospitalization -	Increased		Tanganil	SS		ORAL	10 DAY	
Initial or Prolonged	Blood Creatine		Stilnox	SS		ORAL	10MG Per day	7 DAY
Other	Phosphokinase Increased							
	Blood Creatinine							
	Increased							
	Brain Oedema							
	Cardiac Enzymes Increased							
	Cardio-Respiratory Arrest							
	Cervical Vertebral							
	Fracture							
	Coma							
	Corneal Reflex Decreased							
	Electrocardiogram T Wave							
	Amplitude Increased							
	Fall							
	Hyperkalaemia							
	Malaise							
	Mydriasis							
	Pallor							
	Sinus Tachycardia							
	Ventricular Fibrillation							

Date:01/20/03ISR Number: 4043568-XReport Type:Expedited (15-DaCompany Report #B0289266A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly		Zyban	PS	Glaxo Wellcome		UNKNOWN	150MG Per day
	Coronary Artery							
	Atherosclerosis							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Fatigue							

Haemorrhage

Date:01/20/03ISR Number: 4043570-8Report Type:Expedited (15-DaCompany Report #B0289510A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Oedema		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	4 DAY

Date:01/21/03ISR Number: 4045566-9Report Type:Expedited (15-DaCompany Report #L02-USA-03743-04
Age:31 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Citalopram					
		Health	(Citalopram					
		Professional	Hydrobromide)	PS				
			Bupropion	SS				
			Amphetamine/Dextroph					
			etamine	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/03ISR Number: 4044515-7Report Type:Expedited (15-DaCompany Report #B0289403A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypothyroidism		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
	Urticaria						per day	21 DAY
			Dextropropoxyphene + Paracetamol	C		ORAL		

Date:01/22/03ISR Number: 4044549-2Report Type:Direct Company Report #CTU 184990
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depressed Level Of		Zyprexa	PS		ORAL	10MG BID ORAL	
Hospitalization - Initial or Prolonged	Consciousness		Wellbutrin	SS		ORAL	150MG BID ORAL	
	Neuroleptic Malignant Syndrome							

Date:01/23/03ISR Number: 4044995-7Report Type:Expedited (15-DaCompany Report #A0381384A
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Abuser	Health	Wellbutrin	PS	Glaxo Wellcome	RESPIRATORY (INHALATION)	900MG Single dose	
	Euphoric Mood	Professional						
	Grand Mal Convulsion							
	Intentional Misuse		Ethanol	C				
	Medication Error		Cannabis	C				

Date:01/23/03ISR Number: 4047156-0Report Type:Expedited (15-DaCompany Report #A0393335A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest	Literature	Wellbutrin			
	Coma	Health	(Unspecified Tablet			
	Completed Suicide	Professional	(Bupropion			
	Convulsion		Hydrochloride)	PS		
	Overdose					
	Tachycardia					

Date:01/23/03ISR Number: 4047161-4Report Type:Expedited (15-DaCompany Report #A0393333A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Electrolytes	Literature	Wellbutrin Sr			
	Abnormal	Health	Tablet-Controlled			
	Cardiac Arrest	Professional	Release (Bupropion			
	Coma		Hydrochloride)	PS		
	Completed Suicide					
	Convulsion					
	Hyperpyrexia					
	Liver Function Test					
	Abnormal					
	Overdose					
	Renal Failure					
	Respiratory Arrest					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/03ISR Number: 4047223-1Report Type:Expedited (15-DaCompany Report #L03-USA-00135-08
Age:49 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Carbamazepine	PS				
	Intentional Misuse	Health	Warfarin	SS				
		Professional	Bupropion	SS				

Date:01/24/03ISR Number: 4045780-2Report Type:Expedited (15-DaCompany Report #A0393342A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration	Health	Bupropion	PS	Glaxo Wellcome	ORAL	100MG Twice per day	9 DAY
	Dysarthria	Professional						
	Emotional Distress		Ambien	SS		ORAL	10MG At night	
	Insomnia		Oxycodone	SS		ORAL	5MG As required	
	Oral Intake Reduced							
			Oxycontin	SS		ORAL	30MG Three times per day	
			Blinded Trial Medication	C	Glaxo Wellcome			65 DAY
			Neurontin	C				
			Tenormin	C				
			Paxil	C	Glaxo Wellcome			
			Pamelor	C				

Date:01/24/03ISR Number: 4045781-4Report Type:Expedited (15-DaCompany Report #A0393594A
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia		Wellbutrin	PS	Glaxo Wellcome	ORAL	4	YR

	Growth Retardation		Depakote	C		
	Malnutrition		Lithium	C	Glaxo Wellcome	
			Synthroid	C	Glaxo Wellcome	

Date:01/24/03ISR Number: 4045782-6Report Type:Expedited (15-DaCompany Report #B0100993A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthma	Health	Zyban	PS	Glaxo Wellcome	ORAL
150MG See						
Hospitalization -	Chronic Obstructive	Professional				
dosage text 4 DAY						
Initial or Prolonged	Airways Disease		Salmeterol	C	Glaxo Wellcome	
RESPIRATORY						
Other	Exacerbated					
(INHALATION) 50MCG Twice						
per day						
			Salbutamol	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION) 2PUFF Four						
times per day						
			Becotide	C	Glaxo Wellcome	
RESPIRATORY						
(INHALATION) 2PUFF Twice						
per day						

Date:01/24/03ISR Number: 4045783-8Report Type:Expedited (15-DaCompany Report #B0107035A
Age:18 YR Gender:Male I/FU:F

Outcome	PT
Death	Aggression
	Alcohol Poisoning
	Anorexia

Anxiety Completed Suicide Depression	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disturbance In Attention	Health	Zyban	PS	Glaxo Wellcome	ORAL	3 WK
Drug Abuser Feeling Abnormal Head Injury Headache Hypochondriasis Indifference Injury Asphyxiation Irritability Loss Of Consciousness Mania Mood Swings Palpitations Personality Change Vision Blurred	Professional	Chloroquine	C			

Date:01/24/03ISR Number: 4048253-6Report Type:Periodic Company Report #A001-002-005407
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Confusional State	Consumer	Aricept (Donepezil)	PS		ORAL	1 IN 1 D, PER
Initial or Prolonged	Fall						ORAL
	Injury Salivary Hypersecretion		Zoloft (Sertraline Hydrochloride)	SS		ORAL	25 MG, 1 IN 1
	Weight Decreased						D, PER ORAL
			Wellbutrin (Bupropion)	SS		ORAL	ORAL

Date:01/27/03ISR Number: 4046864-5Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12093845
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Trazodone Hcl Tabs	PS	Apothecon	ORAL	50 mg at	
	Feeling Abnormal						night	
	Sedation		Wellbutrin Sr	I		ORAL		

Date:01/27/03ISR Number: 4047032-3Report Type:Expedited (15-DaCompany Report #A0393180A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice	
Initial or Prolonged							per day	

Date:01/27/03ISR Number: 4047033-5Report Type:Expedited (15-DaCompany Report #A0393978A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxo Wellcome		200MG per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							
	Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/03ISR Number: 4047034-7Report Type:Expedited (15-DaCompany Report #B0087348A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Bupropion	PS	Glaxo Wellcome	ORAL	150MG Twice per day	8 DAY
	Depressed Level Of Consciousness		Premique	SS				
	Grand Mal Convulsion		Nicotine	C	Glaxo Wellcome	TRANSDERMAL	1 DAY	
	Malaise		Omeprazole	C				
	Parosmia		Paracetamol	C	Glaxo Wellcome	2UNIT Four times per day		
	Periorbital Oedema							
	Vision Blurred							

Date:01/27/03ISR Number: 4047036-0Report Type:Expedited (15-DaCompany Report #B0285584A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Zyban	PS	Glaxo Wellcome	ORAL	150MG Per day	29 DAY
	Blood Alcohol Increased		Humalog Insulin	C			UNKNOWN	
	Blood Cholesterol Increased		Stagid	C		ORAL		
			Nicotine Patch	C	Glaxo Wellcome	TRANSDERMAL	46 DAY	
	Chest Pain		Alcohol	C		ORAL	1 DAY	
	Confusional State							
	Depressed Level Of Consciousness							
	Fall							
	Hypertension							
	Hypertriglyceridaemia							
	Lipids Abnormal							
	Malaise							
	Muscular Weakness							
	Paresis							
	Sensory Loss							
	Transient Ischaemic							

Attack

Date:01/27/03ISR Number: 4047042-6Report Type:Expedited (15-DaCompany Report #B0290194A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Exanthem		Zyban	PS	Glaxo Wellcome			
UNKNOWN							150MG Twice per day	16 DAY
			Fluticasone Propionate	C	Glaxo Wellcome			
RESPIRATORY								
(INHALATION)							.5MG Twice per day	

Date:01/27/03ISR Number: 4047946-4Report Type:Expedited (15-DaCompany Report #325095
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Literature	Accutane					
Life-Threatening	Coagulopathy	Health	(Isotretinoin)	PS				
	Completed Suicide	Professional	Bupropion (Bupropion Hydrochloride)	SS				
	Haemorrhage		Diphenhydramine (Diphenhydramine Hydrochloride)	SS				
	Multi-Organ Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/03ISR Number: 4048687-XReport Type:Expedited (15-DaCompany Report #S02-USA-03223-01
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Celexa (Citalopram					
	Overdose	Professional	Hydrobromide)	PS				
		Company	Celexa (Citalopram					
		Representative	Hydrobromide)	SS		ORAL	60 MG QD PO	
			Lamictal (Lamotrigine)	SS				
			Wellbutrin (Bupropion Hydrochloride)	SS			300 MG QD	

Date:01/28/03ISR Number: 4047979-8Report Type:Expedited (15-DaCompany Report #A0388161A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Lamictal	PS	Glaxo Wellcome	ORAL		
	Intentional Misuse		Wellbutrin	SS	Glaxo Wellcome	ORAL		
			Celexa	SS				

Date:01/28/03ISR Number: 4047982-8Report Type:Expedited (15-DaCompany Report #A0392609A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ileus Paralytic		Wellbutrin	PS	Glaxo Wellcome		150MG Twice	
Initial or Prolonged	Urinary Retention							
per day								5 MON
			Paxil	C	Glaxo Wellcome	ORAL	40MG Per day	
			Klonopin	C		ORAL	.5MG As	
							required	

Date:01/28/03ISR Number: 4047983-XReport Type:Expedited (15-DaCompany Report #A0393413A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Drug Interaction		Zyban Unspecified Medications	PS SS	Glaxo Wellcome	ORAL	150MG Per day	

Date:01/28/03ISR Number: 4048549-8Report Type:Direct Company Report #CTU 185460
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Erythematous Rash Macular		Wellbutrin Sr 150mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	150MG DAILY ORAL	

Date:01/28/03ISR Number: 4048845-4Report Type:Expedited (15-DaCompany Report #A03200300069
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Potassium Abnormal Cerebral Ischaemia Dehydration Dysarthria Electrocardiogram Qrs

	Complex Prolonged Electrocardiogram T Wave Abnormal Electroencephalogram Abnormal Emotional Distress Insomnia Oligodipsia Oral Intake Reduced	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Ambien - Zolpidem Tartrate - Tablet - 10 Mg	PS		ORAL	10 MG HS -
			Investigational Drug - Not Provided - Unknown - Unit Dose: Unknown	SS			NI UNK - UNKNOWN
			Oxycontin - Oxycodone Hydrochloride - Unknown - Unit Dose: Unknown	SS		ORAL	30 MG TID - ORAL
			Oxycodone - Unknown - Unit Dose: Unknown	SS		ORAL	5 MG PRN - ORAL
			Wellbutrin - Bupropion Hydrochloride - Unknown - Unit Dose: Unknown	SS		ORAL	100 MG BID - ORAL
			Gabapentin	C			
			Atenolol	C			
			Paroxetine Hydrochloride	C			
			Nortriptyliine Hydrochlorde	C			

Date:01/28/03ISR Number: 4049367-7Report Type:Expedited (15-DaCompany Report #A0392905A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest Completed Suicide Overdose Respiratory Arrest	Literature Health Professional	Wellbutrin Tablet (Bupropion Hydrochloride)	PS				

Date:01/29/03ISR Number: 4048725-4Report Type:Expedited (15-DaCompany Report #B0290356A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper Dyspepsia Joint Swelling Urticaria		Zyban	PS	Glaxo Wellcome	ORAL	150MG Twice per day	20 DAY

Date:01/31/03ISR Number: 4049592-5Report Type:Expedited (15-DaCompany Report #A0393425A
Age:17 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Complex Partial Seizures Epileptic Aura

	Road Traffic Accident						
	Status Epilepticus						
	Tonic Clonic Movements	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
		Health	Wellbutrin	PS	Glaxo Wellcome	ORAL	
		Professional	Gabitril	SS			

Date:01/31/03ISR Number: 4049980-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA01406
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Circulatory Collapse		Cogentin	PS	Merck & Co., Inc	
	Drug Interaction		Wellbutrin	SS		
	Drug Level Increased		Neurontin	SS		
	Heat Stroke					

Date:01/31/03ISR Number: 4050970-9Report Type:Expedited (15-DaCompany Report #USA-2002-0002070
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Anoxic Encephalopathy	Consumer	Oxycontin			
Hospitalization -	Apallic Syndrome	Health	Tablets(Oxycodone			
Initial or Prolonged	Circulatory Collapse	Professional	Hydrochloride) Cr			
Other	Depression	Other	Tablet	PS		
INTRAVENOUS	INTRAVENOUS					
	Drug Toxicity		Trazodone(Trazodone)	SS		
	Loss Of Consciousness		Propoxyphene(Dextrop			
	Multi-Organ Failure		ropoxyphene) Unknown	SS		
	Overdose		Acetaminophen(Parace			
	Polysubstance Abuse		tamol) Unknown	SS		
	Respiratory Arrest		Bupropion(Amfebutamo			
	Skin Disorder		ne)	SS		

Date:02/03/03ISR Number: 4050409-3Report Type:Direct Company Report #CTU 185772
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Chest Pain		Zyban 150 Mg Began			

	Erythema Multiforme		1/9	PS		
ZYBAN 150 MG BID						
			Nicotine Patch Began 1/9/03	SS		
NICOTINE PATCH						

Date:02/03/03ISR Number: 4050686-9Report Type:Direct Company Report #CTU 183825
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Bupropion Sr 150mg	PS		ORAL	150MG BID	
	Purpura							
ORAL								

Date:02/03/03ISR Number: 4051499-4Report Type:Expedited (15-DaCompany Report #2003002684
Age:84 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Doxazosin					
		Health	(Doxazosin)	PS				
		Professional	Digoxin (Digoxin)	SS				

				Bupropion (Bupropion)	SS		

Date:02/04/03ISR Number: 4052245-0Report Type:Expedited (15-DaCompany Report #B0290660A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:02/04/03ISR Number: 4052642-3Report Type:Expedited (15-DaCompany Report #HQWYE070029JAN03
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electroencephalogram Abnormal Grand Mal Convulsion Headache Malaise Parosmia	Health Professional Other	Premique (Conjugated Estrogens/Medroxyprogesterone Acetate, Tablet, 5 Mg)	PS		ORAL	150MG DAILY	8 DAY
			Zyban (Amfebutaome Hydrochloride)	SS				
	Periorbital Oedema Vision Blurred		Nicotine (Nicotine)	C				
			Omeprazole (Omeprazole)	C				
			Paracetamol (Paracetamol)	C				

Date:02/04/03ISR Number: 4052662-9Report Type:Expedited (15-DaCompany Report #B0290662A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Suicide Attempt	Foreign Consumer	Bupropion Hydrochloride Tablet-Zyban (Bupropion					

			Hydrochloride)	PS		ORAL

ORAL

Date:02/05/03ISR Number: 4051209-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0263321A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	19	DAY
	Agitation		Zithromax	C		ORAL	250MG Twice	
	Bipolar Disorder						per day	3 DAY
	Crying		Surgam	C		ORAL	200MG Twice	
	Insomnia						per day	3 DAY
	Micturition Urgency		Doliprane	C	Glaxosmithkline	ORAL	3	DAY
	Obsessive-Compulsive Disorder							
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/03ISR Number: 4051210-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0282944A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Anxiety Delirium Delusional Disorder, Persecutory Type Depression Suicide Attempt		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	32 DAY

Date:02/05/03ISR Number: 4051211-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0283322A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Nephritis		Zyban	PS	Glaxosmithkline	ORAL		10 DAY

Date:02/05/03ISR Number: 4051217-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0290894A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Neoplasm Convulsion		Zyban	PS	Glaxosmithkline	ORAL		81 DAY

Date:02/05/03ISR Number: 4051769-XReport Type:Direct Company Report #CTU 186083
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Insomnia		Wellbutrin Sr	PS		ORAL	150 MG PO 1 BID	

			Buspar	C		

Date:02/06/03ISR Number: 4051792-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395439A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Congenital Anomaly		Wellbutrin	PS	Glaxosmithkline			
	Maternal Drugs Affecting Foetus		Unknown Medication	C				

Date:02/06/03ISR Number: 4051793-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395460A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/06/03ISR Number: 4051794-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395488A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
	Drug Interaction							
			Phenergan With Codeine	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/03ISR Number: 4053840-5Report Type:Periodic Company Report #2002107546US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dyspnoea Urticaria	Health Professional	Celebrex(Celecoxib)Capsule	PS				
			Neurontin(Gabapentin)	SS				
			Topamax(Topiramate)	SS				
			Zantac(Ranitidine Hydrochaloride)	SS				
			Wellbutrin(Amfebutamone Hydrochloride)	SS				
			Paxil(Paroxetine Hydrochloride)	SS				
			Klonopin(Clonazepam)	SS				
			Oxycodone Hydrochloride (Oxycodone Hydrochloride)	C				
			Progesterone	C				
			Salbutamol(Salbutamol)	C				
			Pentosan Polysulfate(Pentosan Polysulfate)	C				
			Hydroxyzine(Hydroxyzine)	C				
			Amitriptyline	C				

Date:02/07/03ISR Number: 4055166-2Report Type:Expedited (15-DaCompany Report #B0290194A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Aggression Dizziness Exanthem Hyperhidrosis Nausea Skin Exfoliation	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / TWICE PER DAY / ORAL	
			Fluticasone					

	Sleep Disorder		Propionate	C		
	Vomiting		Nicotine	C		

Date:02/10/03ISR Number: 4053176-2Report Type:Expedited (15-DaCompany Report #NZ-GLAXOSMITHKLINE-B0289919A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Intolerance		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 41 DAY
	Hypertension							

Date:02/10/03ISR Number: 4055356-9Report Type:Expedited (15-DaCompany Report #B0290662A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Suicide Attempt	Foreign Consumer	Bupropion Hydrochloride Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/03ISR Number: 4055467-8Report Type:Expedited (15-DaCompany Report #A0394895A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Neuroleptic Malignant Syndrome	Health Professional Company Representative	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		
			Aripiprazole (Formulation Unknown) (Aripiprazole)	SS		

Date:02/11/03ISR Number: 4053975-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0388881A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 5 DAY						
Initial or Prolonged	Choreoathetosis		Prograf	C		
Other	Coordination Abnormal		Neurontin	C		
			Synthroid	C	Glaxosmithkline	
			Fosamax	C		
			Vasotec	C		
			Florinef	C		
			Hydrocortisone	C	Glaxosmithkline	

Date:02/11/03ISR Number: 4053983-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0288380A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day 6 DAY						
	Haematuria		Bisoprolol	C		
	Laboratory Test		Hydrochlorothiazide	C		
	Interference		Amlodipine	C		
	Leukocyturia		Atorvastatin	C		
	Malaise					
	Proteinuria					

Date:02/11/03ISR Number: 4053985-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0290826A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Dermatitis Exfoliative Ectropion Malaise Mean Cell Volume Increased Psoriasis Rash Papular Skin Hypertrophy Staphylococcal Infection		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/03ISR Number: 4053991-5Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0040415A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma Intentional Misuse		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	1 DAY
	Suicide Attempt		Paracetamol	SS	Glaxosmithkline	ORAL	500MG See dosage text	1 DAY

Date:02/11/03ISR Number: 4056013-5Report Type:Direct Company Report #CTU 186548
Age:22 WK Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Exposure Via Breast Milk		Luvox (Taken By Mother) (Fluovoxamine Maleate)	PS			TRANSMAMMARY	DAILY BF
			Wellbutrin (Taken By Mother)(Amfebutamone Hydrochloride	SS			TRANSMAMMARY	300MG DAILY BF

Date:02/11/03ISR Number: 4059250-9Report Type:Direct Company Report #CTU 187041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Bupropion 150mg Sr	PS				

Date:02/12/03ISR Number: 4054733-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0392917A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Supraventricular Tachycardia		Wellbutrin Trazodone	PS SS	Glaxosmithkline	ORAL	50MG Per day	

Date:02/12/03ISR Number: 4054736-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395212A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Grand Mal Convulsion Impaired Work Ability		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/12/03ISR Number: 4057640-1Report Type:Periodic Company Report #A0385046A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chromatopsia Hallucination	Consumer Other	Paxil (Formulation Unknown) (Paroxetine Hydrochloride) Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride) Esomeprazole Diphenhydramine Hcl Citalopram	PS SS C C		ORAL	ORAL	

Hydrobromide	C
Metaxalone	C
Biaxin	C
Ziac	C
Tenoretic	C
Excedrin Migraine	C
Arthrotec	C
Perphenazine	C
Famotidine	C
Benztropine Mesylate	C
Decongestant	C
Ziprasidone Hci	C
Oxcarbazepine	C
Paracetamol	C
Hydrocodone	C
Alka-Seltzer	C
Cold Medication	C

Date:02/13/03ISR Number: 4055486-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0396170A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse Suicide Attempt		Wellbutrin	PS	Glaxosmithkline		9900MG Single dose	

Date:02/13/03ISR Number: 4055489-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0396270A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Overdose	Health Professional	Wellbutrin Amitriptyline	PS SS	Glaxosmithkline	ORAL		

Date:02/14/03ISR Number: 4056052-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0380141A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	14 DAY
	Face Oedema	Professional						
	Mouth Ulceration		Equate Nicotine Patch	SS	Glaxosmithkline	INTRADERMAL		
	Pharyngeal Oedema							
	Pyrexia		Clarinex	C				
	Sinus Congestion							
	Tongue Oedema							
	Tongue Ulceration							
	Urticaria							
	Viral Infection							

Date:02/14/03ISR Number: 4056053-6Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0390002A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Difficulty In Walking							
	Dysarthria							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/03ISR Number: 4056061-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0396296B
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coarctation Of The Aorta Maternal Drugs Affecting Foetus		Bupropion	PS	Glaxosmithkline		150MG Per day	

Date:02/14/03ISR Number: 4056063-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0396676A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Interaction		Wellbutrin Provigil Ambien Seroquel	PS SS SS SS	Glaxosmithkline	ORAL		

Date:02/14/03ISR Number: 4056072-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0291519A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Wheezing		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	5 DAY
			Oestradiol	C			UNKNOWN	2MG per day
			Salmeterol	C	Glaxosmithkline		UNKNOWN	50UG Twice per day
			Salbutamol	C	Glaxosmithkline		UNKNOWN	100UG As required
			Beclomethasone	C	Glaxosmithkline		RESPIRATORY (INHALATION)	100UG Twice per day

Date:02/14/03ISR Number: 4056075-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0291822A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Withdrawal	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Syndrome		Disulfiram	SS		ORAL	200MG Per day	5 DAY
	Coccydynia		Atorvastatin	C		ORAL	40MG Per day	
			Alcohol	C			UNKNOWN	

Date:02/14/03ISR Number: 4056077-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0291848A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Multiple Sclerosis		Zyban	PS	Glaxosmithkline	ORAL	150MG Variable dose	36 DAY
			Thyroxine	C	Glaxosmithkline		3UNIT per day	
			Simvastatin	C			1UNIT per day	
			Nortriptyline	C				
			Lactulose	C				
			Frusemide	C	Glaxosmithkline		1UNIT per day	
			Aspirin	C			1UNIT per day	
			Diltiazem	C	Glaxosmithkline		3UNIT per day	
			Cephalexin	C	Glaxosmithkline		2UNIT per day	
			Tolterodine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/03ISR Number: 4056079-2Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0291940A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Bupropion Hydrochloride	PS	Glaxosmithkline	UNKNOWN	150MG	Unknown 2 MON

Date:02/14/03ISR Number: 4056674-0Report Type:Direct Company Report #CTU 186681
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Libido		Zoloft 200mg	PS		ORAL	200MG/DAY	
	Sexual Dysfunction					ORAL		
			Wellbutrin Sr 100mg	SS		ORAL	100MG/DAY	
						ORAL		

Date:02/18/03ISR Number: 4056391-7Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0290894A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	81	DAY
Initial or Prolonged	Blood Glucose Abnormal		Aspirin	C				
UNKNOWN	1TAB per day							
	Brain Neoplasm		Antibiotics	C				
UNKNOWN								
	Convulsion		Alcohol	C				
	Nausea							
	Somnolence							
	Ventricular Tachycardia							
	Vomiting							

Date:02/18/03ISR Number: 4056396-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0291987A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pleuritic Pain		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	6 DAY

Date:02/18/03ISR Number: 4056397-8Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-B0292143A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	22 DAY
	Generalised Oedema							
Disability	Immobile							
Other	Pain							
	Pyrexia							
	Rash							
	Weight Decreased							

Date:02/19/03ISR Number: 4056867-2Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0039257A
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Glucose Abnormal
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased
Other	Circulatory Collapse
	Communication Disorder
	Convulsion

		Disturbance In Attention General Physical Health Deterioration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lactic Acidosis		Zyban	PS	Glaxosmithkline	ORAL
4TAB per day	2 DAY						
		Overdose		Metformin	SS		ORAL
		Sinus Tachycardia White Blood Cell Count Increased					

Date:02/19/03ISR Number: 4057591-2Report Type:Direct Company Report #CTU 186846
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Anxiety		Wellbutrin 150 Mg	PS		
	Discomfort Dizziness Extrasystoles Heart Rate Increased Insomnia Ventricular Extrasystoles					

Date:02/19/03ISR Number: 4059931-7Report Type:Periodic Company Report #A03200201075
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Ambien	PS		
	Hypotension	Professional	Wellbutrin - Slow			
	Loss Of Consciousness		Release	SS		ORAL
400 MG DAILY						
ORAL 2 YR						
			Ethanol	SS		
			Venlafaxine Hydrochloride	C		
			Adderall	C		

Date:02/19/03ISR Number: 4060460-5Report Type:Expedited (15-DaCompany Report #US010627
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Consumer	Provigil	PS		ORAL	50 MG QD	ORAL
	Headache		Celexa	SS		ORAL	40 MG QD	ORAL
			Wellbutrin	SS		ORAL	100 MG QD	ORAL
			Synthroid	C				

Date:02/20/03ISR Number: 4058056-4Report Type:Direct Company Report #CTU 186990
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Decreased		Amoxicillin 500mg	PS		ORAL	500MG PO TID	
	Dyspnoea		Zyban 150mg	SS		ORAL	150MG PO BID	
	Rash		Metformin	C				
			Actos	C				
			Xenical	C				
			Zocor	C				
			Lisinopril	C				
			Hctz	C				
			Oxybutin	C				

			Mvi	C		
			Percocet	C		
			Darvocet	C		
			Fish Oil	C		
			Calcium	C		

Date:02/20/03ISR Number: 4058166-1Report Type:Direct Company Report #CTU 187006
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tremor		Wellbutrin (Buproprion) 150 Mg Sr Tablet	PS		ORAL	300 MG/DAY	ORAL
			Valproic Acid	C				
			Hydroxyzine	C				
			Trazodone	C				
			Paxil	C				

Date:02/20/03ISR Number: 4058315-5Report Type:Direct Company Report #CTU 186926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Sertraline 100mg	PS		ORAL	200MG DAILY	ORAL
			Bupropion 75mg	SS		ORAL	75MG BID ORAL	
			Carbamazepine	C				
			Fentanyl	C				
			Furosemide	C				
			Insulin	C				
			Metolazone	C				
			Propoxyphene/Apap	C				
			Simvastatin	C				
			Trazosone	C				
			Valsartan	C				
			Warfarin	C				

Date:02/21/03ISR Number: 4058516-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0397012A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blighted Ovum		Bupropion	PS	Glaxosmithkline	ORAL	300MG per day	
	Maternal Drugs Affecting Foetus							
	Pregnancy							
	Vaginal Haemorrhage							

Date:02/21/03ISR Number: 4058518-XReport Type:Expedited (15-DaCompany Report #NZ-GLAXOSMITHKLINE-B0284138A
Age:28 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Balance Disorder
	Derealisation
	Difficulty In Walking
	Discomfort
	Dyspnoea
	Emotional Distress

	Erythema Multiforme						
	Face Oedema						
	Fatigue	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Feeling Abnormal		Zyban	PS	Glaxosmithkline	ORAL	150MGD per
	Memory Impairment						day 16 DAY
	Oedema Peripheral						
	Panic Reaction						
	Rash Papular						
	Rash Pruritic						
	Tenderness						
	Tinnitus						

Date:02/21/03ISR Number: 4058519-1Report Type:Expedited (15-DaCompany Report #NZ-GLAXOSMITHKLINE-B0284417A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaphylactic Reaction		Zyban	PS	Glaxosmithkline	ORAL	150MG per day 9 DAY
Initial or Prolonged	Neutrophilia						

Date:02/21/03ISR Number: 4058525-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0292446A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Chills		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice
Initial or Prolonged	Diplopia						per day
	Dizziness		Oestradiol	C			TRANSDERMAL
	Headache						
	Musculoskeletal Stiffness						
	Tremor						

Date:02/21/03ISR Number: 4059246-7Report Type:Direct Company Report #CTU 187072
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria Papular		Bupropion 150mg Sr	PS				

Date:02/21/03ISR Number: 4059247-9Report Type:Direct Company Report #CTU 187074
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations		Bupropion 150mg Sr	PS				

Date:02/24/03ISR Number: 4059456-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0396990A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fall		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Motor Dysfunction							
	Paralysis							
	Psychomotor Skills Impaired							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/03ISR Number: 4059899-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0397019A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Damage	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	24G Single	
Initial or Prolonged	Convulsion	Professional					dose	
	Electrocardiogram Qt Prolonged		Alcohol	SS		ORAL		
	Hypoxia							
	Overdose							

Date:02/25/03ISR Number: 4059901-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0397394A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline	ORAL	150MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							

Date:02/25/03ISR Number: 4059902-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0397823A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Damage		Wellbutrin	PS	Glaxosmithkline			
	Convulsion							

Date:02/25/03ISR Number: 4059905-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0292325A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Anxiety		Zyban	PS	Glaxosmithkline	
150MG See						
Initial or Prolonged	Depression					
dosage text						
	Neuralgia					
	Paraesthesia					
	Pyrexia					
	Sense Of Oppression					

Date:02/25/03ISR Number: 4059909-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0292690A
Age:33 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Increased						per day	9 DAY
	Drug Interaction		Tacrolimus	SS			UNKNOWN	
	Drug Level Decreased		Insulin	C			UNKNOWN	

Date:02/25/03ISR Number: 4059916-0Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0038746A
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Pressure Systolic
Hospitalization -	Increased
Initial or Prolonged	Circulatory Collapse
Other	Communication Disorder

	Convulsion Diabetes Mellitus Disturbance In Attention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	General Physical Health	Health	Zyban	PS	Glaxosmithkline	ORAL
2 DAY						
	Deterioration	Professional	Metformin	SS		ORAL
850MG Per day						
	Lactic Acidosis Po2 Decreased Prescribed Overdose Refusal Of Treatment By Patient Sinus Tachycardia White Blood Cell Count Increased					

Date:02/26/03ISR Number: 4060635-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0292855A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Agitation		Zyban	PS	Glaxosmithkline	ORAL
150MG						
	Hyperventilation					
Variable dose	12 DAY					
	Syncope		Medroxyprogesterone	C		
INTRAMUSCULAR	150MG See					
	Tremor					
dosage text						

Date:02/26/03ISR Number: 4060636-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0292859A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Asthma		Zyban	PS	Glaxosmithkline	ORAL
150MG per day	12 DAY					
			Salmeterol + Fluticasone	C	Glaxosmithkline	
RESPIRATORY						
(INHALATION)	50UG Unknown					

				Salbutamol	C	Glaxosmithkline	

RESPIRATORY

(INHALATION) 100UG Unknown

Date:02/26/03ISR Number: 4060668-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0397636A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline			
UNKNOWN	12 YR							
	Difficulty In Walking							
	Disorientation							
	Dizziness							
	Drug Withdrawal Syndrome							
	Dysstasia							
	Migraine							
	Musculoskeletal Stiffness							
	Tinnitus							

Date:02/26/03ISR Number: 4060674-4Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0397797B
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Withdrawal Syndrome		Bupropion	PS	Glaxosmithkline		150MG Twice	
Initial or Prolonged	Neonatal						per day	
	Maternal Drugs Affecting							
	Foetus							
	Tachypnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/27/03ISR Number: 4061861-1Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0397804A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Interaction						per day	
	Ear Pain		Anesthetic	SS				
	Hearing Impaired		Tylenol #3	SS				
	Hypoacusis							
	Tinnitus							

Date:02/27/03ISR Number: 4061865-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0107035A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression		Zyban	PS	Glaxosmithkline	ORAL	3	WK
	Agitation		Chloroquine	C				
	Alcoholism							
	Anorexia							
	Anxiety							
	Completed Suicide							
	Depression							
	Disturbance In Attention							
	Drug Abuser							
	Feeling Abnormal							
	Head Injury							
	Headache							
	Hypochondriasis							
	Irritability							
	Loss Of Consciousness							
	Mania							
	Mood Swings							
	Obsessive-Compulsive							
	Personality Disorder							
	Palpitations							
	Personality Change							
	Restlessness							
	Vision Blurred							

Date:02/27/03ISR Number: 4068402-3Report Type:Expedited (15-DaCompany Report #200310607BCC
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Difficulty In Walking Pruritus	Consumer Other	Aleve (Naproxen Sodium)	PS		ORAL	440 MG, ONCE, ORAL	
			Wellbutrin (Amfebutamone Hydrochloride)	SS				

Date:02/27/03ISR Number: 4068453-9Report Type:Expedited (15-DaCompany Report #HQWYE535320FEB03
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Confabulation Confusional State Convulsion Delirium Disorientation

	Drug Interaction Hallucination, Visual Memory Impairment	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	37.5 MG OR 75 MG DAILY, ORAL; 375 MG 1X PER 1 DAY, ORAL
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride,)	SS		ORAL	200 MG 2X PER 1 DAY, ORAL
			Zyprexa (Olanzapine)	C			

Date:02/28/03ISR Number: 4062501-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0393969B
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Caesarean Section		Bupropion	PS	Glaxosmithkline		300MG Per day
	Maternal Drugs Affecting Foetus Neonatal Respiratory Distress Syndrome Premature Baby		Terbutaline Zofran Ambien Tylenol Tylenol Pm	C C C C C	 Glaxosmithkline Glaxosmithkline 		

Date:02/28/03ISR Number: 4062503-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395488A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
			Phenergan With Codeine	SS			UNKNOWN	

Date:02/28/03ISR Number: 4062511-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0397981A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Other	Wellbutrin	PS	Glaxosmithkline	ORAL	11 DAY	
Hospitalization - Initial or Prolonged	Drug Toxicity Lobar Pneumonia		Prozac Ultram	SS SS			11 DAY 11 DAY	
			Phenergan	SS	Glaxosmithkline		11 DAY	

Date:02/28/03ISR Number: 4062515-8Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0398318A
Age:40 YR Gender: I/FU:I

Outcome	PT
Other	Convulsion Depressed Level Of Consciousness Electrocardiogram Qrs Complex Prolonged

	Hypoxia						
	Opisthotonus						
	Overdose	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tachycardia	Consumer	Bupropion	PS	Glaxosmithkline	ORAL	7000MG Single dose
			Plaquenil	SS			

Date:02/28/03ISR Number: 4062516-XReport Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0398320A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Electrocardiogram Qt Prolonged	Consumer	Bupropion	PS	Glaxosmithkline		
	Grand Mal Convulsion		Citalopram	SS			
	Intentional Misuse		Methotrimeprazine	SS			

Date:02/28/03ISR Number: 4062517-1Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0398322A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blood Potassium Decreased	Consumer	Bupropion	PS	Glaxosmithkline		
	Convulsion		Celexa	SS			
	Electrocardiogram Qrs Complex Prolonged		Clonazepam	SS			
	Hallucination						
	Pyrexia						
	Serotonin Syndrome						

Date:02/28/03ISR Number: 4062518-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0282937A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Zyban	PS	Glaxosmithkline	ORAL	
	Fall		Flixotide	C	Glaxosmithkline		
RESPIRATORY							

Flushing
(INHALATION) 2PUFF Twice
Malaise
per day
Paraesthesia Serevent C Glaxosmithkline
RESPIRATORY
Syncope
(INHALATION) 2PUFF Twice
Tetany
per day
Trismus
Visual Disturbance

Date:02/28/03ISR Number: 4062522-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0292806A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	31	DAY
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Drug Exposure During Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/03ISR Number: 4062523-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0292808A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	32 DAY
	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus							

Date:02/28/03ISR Number: 4067181-3Report Type:Expedited (15-DaCompany Report #02P-163-0204399-00
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Convulsion	Health Professional Other	Semisodium Valproate (Depakote)(Divalproex Sodium) (Divalproex Sodium)	PS		ORAL		
ORAL								
			Bupropion Hydrochloride	SS		ORAL		
ORAL								

Date:03/03/03ISR Number: 4064786-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0398359A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Complications Of Maternal Exposure To Therapeutic Drugs Drug Exposure During Pregnancy		Seroquel	C				

Date:03/03/03ISR Number: 4069171-3Report Type:Expedited (15-DaCompany Report #2003002619
Age:36 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Sinequan (Cap)					
Other	Completed Suicide	Health	(Doxepin)	PS				
	Intentional Misuse	Professional	Bupropion	SS				

Date:03/04/03ISR Number: 4066053-8Report Type:Direct Company Report #CTU 187869
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Growth Retardation		Wellbutrin 100 Mg Sr	PS		ORAL	100 MG SR QD	
	Weight Gain Poor						ORAL	
			Wellbutrin	SS		ORAL	100 MG SR BID	
							ORAL	
			Depakote	C				
			Synthroid	C				
			Remeron	C				
			Lithium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/03ISR Number: 4066218-5Report Type:Direct Company Report #USP 55553
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr	PS	Glaxosmithkline			
			Wellbutrin Sr	SS	Glaxosmithkline			

Date:03/04/03ISR Number: 4070209-8Report Type:Expedited (15-DaCompany Report #2003EU005404
Age:33 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased Drug Interaction Drug Level Decreased	Foreign Health Professional Other	Prograf (Tacrolimus) Formulation Unknown Zyban(Amfebutamone Hydrochloride)	PS SS		ORAL	150 MG, BID,	ORAL

Date:03/05/03ISR Number: 4066228-8Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0393180A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Drug Ineffective Dyspnoea		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 DAY

Date:03/05/03ISR Number: 4066230-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0398610A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline		300MG per day	
	Drug Exposure During Pregnancy		Seroquel	C				

Maternal Drugs Affecting
Foetus

Date:03/05/03ISR Number: 4066242-2Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0010662A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	9 DAY
Hospitalization - Initial or Prolonged	Cardiac Arrest							
	Grand Mal Convulsion							
Other								

Date:03/05/03ISR Number: 4066243-4Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0010841A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	9 DAY
Hospitalization - Initial or Prolonged	Cardiac Arrest							
	Grand Mal Convulsion							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/03ISR Number: 4068206-1Report Type:Direct Company Report #CTU 187921
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysarthria		Bupropion Sr 300mg Daily					
	Grand Mal Convulsion							
	Mental Impairment		(Glaxosmithkline)	PS	Glaxosmithkline		300MG DAILY	
			Sertraline	C				
			Lamictal	C				
			Eskalith Cr	C				
			Seroquel	C				

Date:03/05/03ISR Number: 4071300-2Report Type:Expedited (15-DaCompany Report #US010627
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Interaction	Health	Provigil	PS		ORAL	50 MG QD ORAL	
	Headache	Professional	Celexa	SS		ORAL	40 MG QD ORAL	
	Migraine		Wellbutrin	SS		ORAL	100 MG QD	
							ORAL	
			Synthroid	C				

Date:03/05/03ISR Number: 4072173-4Report Type:Periodic Company Report #2003005856
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health	Geodon (Ziprasidone)	PS		ORAL		
Other		Professional	Bupropion Hydrochloride	SS				
		Company Representative	Olanzapine	SS				
			All Other Non-Therapeutic Products	SS				

Date:03/06/03ISR Number: 4066862-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0398921A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Somnolence	Professional	Heroin	SS				
	Tachycardia							

Date:03/06/03ISR Number: 4066866-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0292305A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Alcohol Increased		Zyban	PS	Glaxosmithkline	ORAL	3000MG per day	
	Blood Pressure Systolic Increased							
	Chills							
	Confusional State							
	Drug Screen Positive							
	Intentional Misuse							
	Mydriasis							
	Respiratory Acidosis							
	Somnolence							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/03ISR Number: 4068853-7Report Type:Direct Company Report #CTU 188030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Buproprion Sr 300 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	300MG DAILY	
			Sertraline	C			ORAL	
			Lamictal	C				
			Eskalith	C				
			Seroquel	C				

Date:03/07/03ISR Number: 4069513-9Report Type:Direct Company Report #CTU 188184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Grand Mal Convulsion		Wellbutrin 150 Mg	PS		ORAL	150 MG DAILY	
			Synthroid	C			ORAL	
			Lipitor	C				
			Norvasc	C				
			Phoslo	C				
			Reglan	C				
			Ibuprofen/Tylenol	C				

Date:03/07/03ISR Number: 4069585-1Report Type:Direct Company Report #CTU 188131
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Vertigo		Wellbutrin	PS			300 MG MORNING 200 MG 1:PM	

Date:03/07/03ISR Number: 4069592-9Report Type:Direct Company Report #CTU 188136
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bipolar Ii Disorder		Wellbutrin	PS			WELLBUTRIN 4	
Hospitalization -								DAYS
Initial or Prolonged			Paxil	SS			PAXIL 2 WEEKS	
Required			Zyprexa	C				
Intervention to			Depakote	C				
Prevent Permanent			Effexor	C				
Impairment/Damage								

Date:03/10/03ISR Number: 4068763-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0294006A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine		Zyban	PS	Glaxosmithkline	ORAL	150MG	
Hospitalization -	Phosphokinase Increased							
Variable dose								10 DAY
Initial or Prolonged	Left Ventricular Failure		Aspirin	C	Glaxosmithkline	ORAL	75MG	Unknown
			Simvastatin	C		ORAL	40MG	Unknown
			Cinchocaine + Hydrocortisone	C			TOPICAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/03ISR Number: 4069959-9Report Type:Direct Company Report #CTU 188304
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin 150 Mg					
	Nausea		Catalytica Pharmaceuticals	PS	Catalytica Pharmaceuticals	AURICULAR	(OTIC)	1 TWICE DAILY
						AURICULAR	(OTIC)	

Date:03/10/03ISR Number: 4070131-7Report Type:Direct Company Report #CTU 188263
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Bupropion	PS			BUPROPION 150 MG BID	
	Formication							
	Hallucination, Tactile		Ambien	C				
	Restlessness		Metoprolol	C				
			Hctz	C				
			Losartan	C				
			Nexium	C				
			Asa	C				
			Simvastatin	C				

Date:03/10/03ISR Number: 4070273-6Report Type:Direct Company Report #CTU 188305
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ear Infection		Wellbutrin S.R. 150					
Required	Gastrooesophageal Reflux		Mg Glaxo Wellcome	PS	Glaxo Wellcome	ORAL	150 MG TWICE	

Intervention to Disease
DAILY ORAL
Prevent Permanent Hiccups
Impairment/Damage Pharyngitis
Vomiting

Date:03/10/03ISR Number: 4070349-3Report Type:Direct Company Report #CTU 188354
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Zyban 150 Tbsr	PS	Tbsr		ONCE PO QD X	3 D THEN BID

Date:03/10/03ISR Number: 4070358-4Report Type:Direct Company Report #CTU 188359
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Zyban 150 Mg Tbsr	PS	Tbsr	ORAL	ONCE PO QDSX	3D THEN BID

Date:03/11/03ISR Number: 4069296-2Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12135786
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Condition Aggravated
	Insomnia

Schizoaffective Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aripiprazole	PS	Otsuka Pharmaceutical Company, Ltd.	ORAL		
	Wellbutrin	SS				
	Prozac	SS				
	Topamax	C				
	Klonopin	C				

Date:03/11/03ISR Number: 4069473-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395534A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
Other	Blood Pressure Systolic Increased		Sam E	C				
	Convulsion		Zoloft	C				
	Disturbance In Attention							
	Dizziness							
	Drug Screen Positive							
	Fatigue							
	Hallucination							
	Headache							
	Lethargy							
	Malaise							
	Medication Error							
	Pyrexia							
	Status Epilepticus							
	Tachycardia							
	Tongue Biting							
	Urinary Incontinence							
	Vision Blurred							

Date:03/11/03ISR Number: 4069476-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0398543A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Risperdal	C				

Date:03/11/03ISR Number: 4069477-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0398716A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
		Professional					per day	
			Celexa	SS			UNKNOWN	
			Risperdal	C				
			Buspar	C				
			Synthroid	C	Glaxosmithkline			
			Ferrous Sulfate	C				
			Kdur	C	Glaxosmithkline			
			Lasix	C	Glaxosmithkline			
			Folic Acid	C				
			Mvi	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/03ISR Number: 4069479-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0399473A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Intentional Misuse							
	Thermal Burn							

Date:03/11/03ISR Number: 4069480-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0399478A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine		Wellbutrin	PS	Glaxosmithkline	ORAL	250MG Per day	1 YR
	Phosphokinase Increased		Kaletra	C				
			Sustiva	C				
			Valcyte	C				
			Diflucan	C				
			Bactrim	C	Glaxosmithkline			
			Epivir	C	Glaxosmithkline			
			Ziagen	C	Glaxosmithkline			
			Elavil	C	Glaxosmithkline			
			Trazodone	C				
			Ativan	C				
			Percocet	C				
			Allegra	C				
			Neurontin	C				
			Albuterol	C	Glaxosmithkline			

Date:03/11/03ISR Number: 4069489-4Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0293848A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Poisoning	Consumer	Zyban	PS	Glaxosmithkline	UNKNOWN	150MG Twice per day	
	Drug Interaction							

			Ethanol	SS			

UNKNOWN

Date:03/11/03ISR Number: 4070395-XReport Type:Direct Company Report #CTU 188428
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin Sr 150mg	PS		ORAL	2 DAY ORAL	
	Dermatitis Atopic							
	Irritability							
	Obsessive Thoughts							
	Pharmaceutical Product Complaint							
	Psychiatric Symptom							
	Rash Pruritic							
	Reaction To Medical Agent							
	Preservatives							
	Suicidal Ideation							

Date:03/11/03ISR Number: 4072830-XReport Type:Direct Company Report #CTU 188491
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharmaceutical Product Complaint		Generic Wellbutrin 75mg	PS			75MG TWO BID	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/03ISR Number: 4070155-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0386663A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Disorder		Paxil	PS	Glaxosmithkline	ORAL	60MG Per day	
	Libido Decreased		Wellbutrin	SS	Glaxosmithkline	ORAL	100MG Per day	

Date:03/12/03ISR Number: 4070159-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0399790A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR

Date:03/12/03ISR Number: 4070165-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0294437A
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Congestive		Digoxin	C	Glaxosmithkline		UNKNOWN	250MCG Per day
	Myocardial Infarction							
			Aspirin	C	Glaxosmithkline		UNKNOWN	75MG Per day

Date:03/12/03ISR Number: 4070168-8Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0294671A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aphasia		Zyban	PS	Glaxosmithkline		43 DAY	

Other	Brain Scan Abnormal					
	Cerebral Arteritis					
	Grand Mal Convulsion					
	Headache					
	Mental Status Changes					

Date:03/13/03ISR Number: 4071164-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0294329A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	13 DAY
	Convulsion							
	Eye Disorder		Tea	SS		ORAL		
	Hypokalaemia		Stablon	C		ORAL	2TAB per day	
	Malaise							

Date:03/13/03ISR Number: 4076436-8Report Type:Expedited (15-DaCompany Report #HQWYE808303MAR03
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Consumer	Phenergan (Promethazine Hydrochloride, Unspec)	PS				
	Drug Interaction		Prozac (Fluoxetine Hydrochloride,)	SS				
	Drug Toxicity		Ultram (Tramadol Hydrochloride,)	SS				
	Lobar Pneumonia		Wellbutrin					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Amfebutamone Hydrochloride,) SS

Date:03/14/03ISR Number: 4072141-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0294420A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Periorbital Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Aspirin	C	Glaxosmithkline	ORAL	75MG Per day	
			Simvastatin	C		ORAL	20MG Per day	
			Atenolol	C		ORAL	50MG Per day	
			Ramipril	C		ORAL	1.25MG Per day	
			Nicotine	C	Glaxosmithkline	UNKNOWN	4MG Four times per day	

Date:03/14/03ISR Number: 4072142-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0294422A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Homicidal Ideation		Zyban	PS	Glaxosmithkline	ORAL	150MG	
	Paranoia						Variable dose	14 DAY

Date:03/14/03ISR Number: 4072144-8Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0294464A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression	Consumer	Zyban	PS	Glaxosmithkline	UNKNOWN	150MG Twice	

Hospitalization - per day	80 DAY	Disease Recurrence					
Initial or Prolonged		Suicide Attempt		Temazepam	SS		
UNKNOWN	20MG Unknown 1 DAY	Suspiciousness					

Date:03/14/03ISR Number: 4072244-2Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0399254A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anaphylactic Shock		Paxil	PS	Glaxosmithkline	ORAL
			Wellbutrin	SS	Glaxosmithkline	

Date:03/14/03ISR Number: 4074353-0Report Type:Direct Company Report #CTU 188768
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Agitation		Buproprion	PS		
150MG BID 3 WK						
Initial or Prolonged	Hallucination, Tactile		Ambien	C		
	Restlessness		Metoprolol	C		
			Hctz	C		
			Losartin	C		
			Nexium	C		
			Asa	C		
			Simvastatin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/03ISR Number: 4072846-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0398921A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Somnolence	Professional	Heroin	SS				
	Tachycardia							

Date:03/17/03ISR Number: 4072850-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0400040A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antepartum Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Caesarean Section							
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Gestational Diabetes							
	Maternal Drugs Affecting Foetus							
	Pregnancy							
	Premature Separation Of Placenta							

Date:03/17/03ISR Number: 4072867-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0294481A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG per day	19 DAY
	Aggression		Alcohol	SS		ORAL		
	Anger							
	Drug Interaction							
	Judgement Impaired							
	Laceration							
	Mood Swings							
	Thinking Abnormal							

Date:03/17/03ISR Number: 4072871-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0294655A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Eye Pain						per day	
	Tremor		Medroxyprogesterone	C		INTRAMUSCULAR		
	Vomiting							

Date:03/17/03ISR Number: 4072872-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0294665A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eczema		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash						per day	20 DAY
			Sildenafil	C		ORAL	100MG As	
							required	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/03ISR Number: 4074720-5Report Type:Direct Company Report #CTU 188835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS		ORAL	200-400 MG	
							PILL ORAL	
			Lithium	C				
			Zyprexa	C				

Date:03/17/03ISR Number: 4074728-XReport Type:Direct Company Report #CTU 188866
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion Sr 400 Mg					
	Dysphonia		Gsk	PS	Gsk		200 MG BID	
	Memory Impairment		Sudal	C				
	Syncope							

Date:03/17/03ISR Number: 4074818-1Report Type:Direct Company Report #CTU 188853
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Amantadine	PS		ORAL	100 MG PO BID	
Initial or Prolonged	Balance Disorder		Bupropion	SS	100 Mg Po Bid	ORAL		
	Fall		Olanzapine	C				
	Hallucinations, Mixed							
	Serotonin Syndrome							

Date:03/17/03ISR Number: 4077295-XReport Type:Expedited (15-DaCompany Report #2003009863
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Congenital Anomaly	Complications Of Maternal	Health	Geodon (Ziprasidone)	PS			
120 MG (BID)							
	Exposure To Therapeutic	Professional	Bupropion				
	Drugs	Company	Hydrochloride	SS			
	Congenital Anomaly	Representative					
	Maternal Drugs Affecting						
	Foetus						
	Pregnancy						

Date:03/19/03ISR Number: 4074224-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0398921A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Intentional Misuse	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
Hospitalization -	Somnolence	Professional	Heroin	SS		
Initial or Prolonged	Tachycardia		Cocaine	SS		
			Valium	SS		

Date:03/19/03ISR Number: 4074229-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0092202A
Age:32 YR Gender:Female I/FU:F

Outcome	PT
Other	Aggression
	Anger
	Anhedonia
	Anorexia

	Crying Depression Diarrhoea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Disturbance In Attention		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice
	Fatigue						per day
	Feeling Abnormal Feeling Hot Headache Homicidal Ideation Irritability Lethargy Mood Altered Night Sweats Personality Change Screaming Suicidal Ideation Tinnitus Tremor						

Date:03/19/03ISR Number: 4076591-XReport Type:Direct Company Report #CTU 189083
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoaesthesia Pruritus Rash		Wellbutrin (Bupropion) 150 Mg Sr	PS			150 MG BID./ 4-5 DAYS
			Citalopram (Celexa) 40 Mg	SS			40 MG DAILY

Date:03/19/03ISR Number: 4078378-0Report Type:Expedited (15-DaCompany Report #2003006006
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Cardiomegaly	Health	Geodon (Ziprasidone)	PS		ORAL 40 MG
	Coronary Artery	Professional				
	Atherosclerosis	Company	Bupropion			(DAILY), ORAL
	Mitral Valve Incompetence	Representative	Hydrochlordie	SS		ORAL 450 MG (TID),
	Pulmonary Valve					ORAL
	Incompetence		Mirtazapine	C		
			Lithium Carbonate	C		
			Methadone	C		
			Desloratadine	C		
			Pseudoephedrine Hydrochloride	C		
			Chlorphenamine	C		

Date:03/20/03ISR Number: 4074886-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0400724A
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchial Obstruction		Wellbutrin	PS	Glaxosmithkline	ORAL	1	DAY
	Convulsion							
	Dyspnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/20/03ISR Number: 4074887-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0400777A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Swelling		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	15 DAY
	Face Oedema							
	Oedema Peripheral		Yasmin	C				
	Pruritus							
	Skin Discolouration							
	Urticaria							

Date:03/20/03ISR Number: 4074889-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0107035A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour	Health	Zyban	PS	Glaxosmithkline	ORAL	3	WK
	Aggression	Professional	Chloroquine	C			37.5MG per day	
	Agitation							
	Alcoholism							
	Anxiety							
	Completed Suicide							
	Decreased Appetite							
	Depression							
	Dissociation							
	Disturbance In Attention							
	Drug Abuser							
	Fear							
	Feeling Abnormal							
	Head Injury							
	Headache							
	Hypochondriasis							
	Irritability							
	Loss Of Consciousness							
	Mania							
	Mood Swings							
	Obsessive-Compulsive							
	Personality Disorder							
	Palpitations							

	Personality Change					
	Restlessness					
	Vision Blurred					

Date:03/20/03ISR Number: 4074898-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0294557A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Bulimia Nervosa						dosage text	15 DAY
	Crying		Nicopatch	C	Glaxosmithkline	TRANSDERMAL		32 DAY
	Depression							
	Fatigue							
	Hyperphagia							
	Insomnia							
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/20/03ISR Number: 4074900-9Report Type:Expedited (15-DaCompany Report #CZ-GLAXOSMITHKLINE-B0294593A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	166 DAY	
	Drug Toxicity		Antidepressants	C			UNKNOWN	
	Hypothermia		Carbamazepine	C			UNKNOWN	
			Citalopram	C			UNKNOWN	
			Methotrimeprazine	C			UNKNOWN	25MG per day
			Piracetam	C			UNKNOWN	1600MG per day
			Promethazine	C			UNKNOWN	404 DAY
			Norethisterone Acetate + Oestradiol	C	Glaxosmithkline		UNKNOWN	42 DAY

Date:03/20/03ISR Number: 4074901-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0295005A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psychotic Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	10 DAY

Date:03/20/03ISR Number: 4074902-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0295110A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG See	

	Erythema					
dosage text 18 DAY						
	Gastroenteritis		Ercefuryl	C	Glaxosmithkline	
3 DAY						
	Pruritus		Debridat	C		
3 DAY						
	Urticaria		Ultra Levure	C		
3 DAY						

Date:03/20/03ISR Number: 4080630-XReport Type:Expedited (15-DaCompany Report #L02-USA-03743-04
Age:31 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration	Literature	Citalopram					
	Cardiac Arrest	Health	(Citalopram					
	Completed Suicide	Professional	Hydrobromide)	PS		ORAL	900 MG ONCE	
	Convulsion						PO	
	Intentional Misuse		Bupropion	SS		ORAL	3000 MG ONCE	
	Somnolence						PO	
			Amphetamine / Dextroamphetamine 30 Mg	SS		ORAL	10 UNITS ONCE	
							PO	
			Lisinopril	SS				
			Trazodone	SS				

Date:03/21/03ISR Number: 4075751-1Report Type:Expedited (15-DaCompany Report #IE-GLAXOSMITHKLINE-B0293852A
Age:30 YR Gender:Male I/FU:F

Outcome	PT
Other	Abnormal Behaviour
	Agitation
	Confusional State
	Drug Interaction
	Memory Impairment

Paranoia

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS	Glaxosmithkline	ORAL
150MG						
Variable dose	8 DAY					
			Alcohol	SS		
UNKNOWN	2UNIT Unknown					

Date:03/24/03ISR Number: 4076732-4Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0040676A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Convulsion		Zyban	PS	Glaxosmithkline	ORAL
18G per day						
Initial or Prolonged	Intentional Misuse					
	Suicide Attempt					

Date:03/24/03ISR Number: 4082407-8Report Type:Expedited (15-DaCompany Report #US010627
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Migraine	Health	Provigil	PS		ORAL
50 MG QD ORAL						
		Professional	Celexa	SS		ORAL
40 MG QD ORAL						
			Welbutrin	SS		ORAL
100 MG QD						
ORAL						
			Synthroid	C		

Date:03/25/03ISR Number: 4077698-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0107035A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Death	Abnormal Behaviour	Health	Zyban	PS	Glaxosmithkline	ORAL
3 WK						
	Aggression	Professional	Chloroquine	C		
37.5MG per						
	Agitation					
day						
	Alcoholism					
	Anxiety					
	Apathy					
	Cardiac Disorder					
	Completed Suicide					
	Decreased Appetite					
	Depression					
	Dissociation					
	Drug Abuser					
	Fear					
	Head Injury					
	Headache					
	Hypochondriasis					
	Irritability					
	Loss Of Consciousness					
	Mania					
	Mood Swings					
	Obsessive-Compulsive					
	Personality Disorder					
	Palpitations					
	Personality Change					
	Restlessness					
	Treatment Noncompliance					
	Vision Blurred					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/03ISR Number: 4080663-3Report Type:Direct Company Report #CTU 189456
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression		Bupropion Sr	PS				
	Agitation		Trazodone	SS				
	Blood Creatine Phosphokinase Increased		Olanzapine	SS				
	Depression		Ziprasidone	C				
	Drug Ineffective		Lithium	C				
	Electrocardiogram Qt Prolonged		Beclomethasone	C				
	Medication Error		Fexofenadine	C				
	Mental Status Changes		Folic Acid	C				
	White Blood Cell Count Increased		Naproxen	C				
			Propranold	C				
			Rabeprazole	C				
			Simvastatin	C				
			Thiamine	C				
			Trazodone	C				
			Ziprasidone	C				
			Lithium	C				
			Olanzapine	C				
			Bupropion	C				

Date:03/26/03ISR Number: 4083442-6Report Type:Expedited (15-DaCompany Report #200310607BCC
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Aleve (Naproxen Sodium)	PS		ORAL	440 MG, ONCE,	ORAL
	Difficulty In Walking	Other						
	Pain In Extremity							
	Pruritus Generalised		Wellbutrin (Amfebutamone Hydrochloride)	SS				
	Tendonitis							

Date:03/27/03ISR Number: 4079588-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0401597A
Age:5 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Oedema						per day	3 WK
	Oliguria							
	Rash							

Date:03/27/03ISR Number: 4079589-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0401801A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Overdose		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Suicide Attempt		Paxil	SS	Glaxosmithkline		UNKNOWN	
			Xanax	SS			UNKNOWN	

Date:03/27/03ISR Number: 4082800-3Report Type:Direct Company Report #USP 55741
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Wellbutrin Sr 100mg (Bupropion) Wellbutrin Sr 150mg	PS	Glaxo Wellcome			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Bupropion) SS Glaxo Wellcome

Date:03/28/03ISR Number: 4080292-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395460A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Phosphokinase Increased						per day	
	Renal Disorder		Vioxx	C		ORAL		

Date:03/28/03ISR Number: 4083683-8Report Type:Direct Company Report #CTU 189714
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin Sr 150mg					
Required	Chest Discomfort		Glaxo Smith Kline	PS	Glaxo Smith Kline	ORAL	SEE IMAGE	
Intervention to	Myalgia							
Prevent Permanent	Rash							
Impairment/Damage	Urticaria							

Date:03/31/03ISR Number: 4080832-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0264861A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adrenal Adenoma		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Headache		Alcohol	C		ORAL		
	Hypertension							
	Malaise							
	Vision Blurred							

Date:03/31/03ISR Number: 4080836-XReport Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0294464A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression	Consumer	Zyban	PS	Glaxosmithkline	UNKNOWN	150MG Twice	
Hospitalization -	Somnolence							
per day							80	DAY
Initial or Prolonged	Suicide Attempt		Temazepam	SS				
UNKNOWN							20MG	Unknown
	Suspiciousness							

Date:03/31/03ISR Number: 4080847-4Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0040676A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aspiration	Health	Zyban	PS	Glaxosmithkline	ORAL	18G per day	
Hospitalization -	Coma	Professional						
Initial or Prolonged	Epilepsy							
	Intentional Misuse							
	Suicide Attempt							

Date:04/02/03ISR Number: 4083494-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0292587A
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Disability	Diarrhoea
	Dissociation
	Hallucination

	Poisoning Tremor Vomiting	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxosmithkline	ORAL	1UNIT Twice per day 8 DAY

Date:04/02/03ISR Number: 4083502-XReport Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0295743A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Interaction		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day 19 DAY
	Epilepsy		Trimipramine	SS		ORAL	25MG per day
			Methotrimeprazine	SS		ORAL	5MG Per day
			Moclobemide	SS		ORAL	300MG Per day
			Alprazolam	C		ORAL	2MG per day

Date:04/02/03ISR Number: 4083504-3Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0295748A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Agitation		Zyntabac	PS	Glaxosmithkline	ORAL	40TAB cumulative dose 1 DAY
	Clonic Convulsion						
	Overdose						
	Suicide Attempt						

Date:04/02/03ISR Number: 4083505-5Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0295775A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia		Zyban	PS	Glaxosmithkline	ORAL	43	DAY
	Cerebral Arteritis							
	Cerebral Haemorrhage							
	Convulsion							
	Nausea							
	Personality Change							
	Vomiting							

Date:04/02/03ISR Number: 4086302-XReport Type:Expedited (15-DaCompany Report #B0294984A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coagulopathy	Foreign	Zyban Tablet-Zyban					
	Hepatic Failure	Literature	(Bupropion					
	Renal Impairment	Health	Hydrochloride)	PS			10	DAY
	Sepsis	Professional	Carbimazole					
			(Formulation					
			Unknown)					
			(Carbimazole)	SS				
			Propranolol					
			Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/03ISR Number: 4087906-0Report Type:Expedited (15-DaCompany Report #B0294985A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Foreign	Zyban Tablet-Zyban					
	Aspartate	Literature	(Bupropion					
	Aminotransferase	Health	Hydrochloride)	PS		ORAL	ORAL	
	Increased	Professional						
	Asthenia							
	Blood Lactate							
	Dehydrogenase Increased							
	Haematuria							
	Haemolytic Uraemic							
	Syndrome							
	Headache							
	Jaundice							
	Menometrorrhagia							
	Petechiae							
	Red Blood Cell							
	Schistocytes Present							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							
	Thrombotic							
	Thrombocytopenic Purpura							
	Uterine Leiomyoma							

Date:04/03/03ISR Number: 4084091-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0391256A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour	Health	Wellbutrin	PS	Glaxosmithkline	NASAL		
	Conversion Disorder	Professional	Zoloft	SS		NASAL		
	Convulsion							
	Drug Abuser							
	Feeling Abnormal							
	Mania							
	Medication Error							

Date:04/03/03ISR Number: 4084093-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402194A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams	Consumer	Bupropion	PS	Glaxosmithkline	ORAL		
	Convulsion		Tegretol	SS		ORAL		
	Drug Interaction		Nicoderm	C	Glaxosmithkline	OTHER		
	Dyskinesia							
	Epistaxis							
	Head Injury							
	Laceration							
	Local Swelling							

Date:04/03/03ISR Number: 4084095-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402428A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Paxil	SS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/03ISR Number: 4087135-0Report Type:Direct Company Report #CTU 190119
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Diabetes Mellitus		Wellbutrin Sr 150 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL 150 MG BID ORAL		
			Insulin Pump	C				

Date:04/04/03ISR Number: 4085023-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0393425A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Complex Partial Seizures		Wellbutrin	PS	Glaxosmithkline	ORAL	20	DAY
	Epileptic Aura		Gabitril	SS		ORAL	20	DAY
	Road Traffic Accident							
	Status Epilepticus							
	Tonic Clonic Movements							

Date:04/04/03ISR Number: 4085025-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402014A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	150MG Twice per day		
	Drug Exposure During Pregnancy							
	Maternal Drugs Affecting Foetus							

Date:04/04/03ISR Number: 4085027-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402277A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Drug Interaction Headache Migraine		Wellbutrin Provigil Celexa Synthroid	PS SS SS C	Glaxosmithkline Glaxosmithkline	ORAL ORAL ORAL	100MG Per day 50MG Per day 40MG Per day	15 YR

Date:04/04/03ISR Number: 4085028-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402520A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Cirrhosis Hepatitis C		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:04/04/03ISR Number: 4085030-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402594A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Above Therapeutic		Wellbutrin Paxil Benadryl Doxylamine	PS SS C C	Glaxosmithkline Glaxosmithkline Glaxosmithkline	ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/03ISR Number: 4085032-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402679A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Choreoathetosis Drug Interaction Therapeutic Agent Toxicity		Wellbutrin Effexor Xr Pepcid Synthroid Klonopin Lorcet 10/650 Vioxx Hctz	PS SS C C C C C C	Glaxosmithkline Glaxosmithkline 	ORAL 	200MG Twice per day 75MG Twice per day 40MG Per day 150MCG Per day 1.5MG At night 2TAB Three times per day 25MG Per day 25MG Per day	MON

Date:04/04/03ISR Number: 4085035-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402911A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Encephalopathy Intentional Misuse Suicide Attempt Tachycardia		Wellbutrin	PS	Glaxosmithkline			

Date:04/04/03ISR Number: 4085132-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402860A
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Digoxin	PS	Glaxosmithkline	ORAL		
	Cardiac Failure		Bupropion Hydrochloride	SS	Glaxosmithkline	ORAL		
	Congestive Drug Toxicity		Insulin	C				
	Pulmonary Oedema		Levothyroxine Sodium	C	Glaxosmithkline			
	Ventricular Extrasystoles		Linezolid	C				
			Metoclopramide Hcl	C	Glaxosmithkline			
			Zolpidem Tartrate	C				

Date:04/04/03ISR Number: 4088056-XReport Type:Direct Company Report #CTU 190286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Wellbutrin Er	PS			100MG BID	
			Ibuprofen	C				

Date:04/07/03ISR Number: 4085773-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0403090A
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Other	Complications Of Maternal Exposure To Therapeutic Drugs
	Maternal Drugs Affecting Foetus
	Pregnancy

	Stillbirth						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline		
			Paxil	SS	Glaxosmithkline	ORAL	

Date:04/07/03ISR Number: 4085775-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0403504A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dysphemia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day
	Energy Increased		Zoloft	C			
	Speech Disorder						

Date:04/07/03ISR Number: 4085776-8Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0099812A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Alopecia		Zyban	PS	Glaxosmithkline		150MG Twice
Other	Arthralgia						per day
	Asthenia		Quinapril	C			
	Balance Disorder		Trisequens	C	Glaxosmithkline		
	Blood Pressure Increased		Ketoconazole	C			
	Circulatory Collapse		Alcohol	C			
	Dehydration						
	Difficulty In Walking						
	Disturbance In Attention						
	Dizziness						
	Drug Withdrawal Syndrome						
	Dry Skin						
	Feeling Abnormal						
	Food Allergy						
	Headache						
	Hypersensitivity						
	Loss Of Libido						
	Malaise						
	Memory Impairment						

Pain In Extremity
Pain Of Skin
Pallor
Palpitations
Paraesthesia
Pharyngeal Oedema
Sneezing
Tongue Dry
Tongue Oedema

Date:04/07/03ISR Number: 4085780-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0295862A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	34 DAY
	Psoriasis							
			Elisor	C				
			Questran	C				
			Puva	C				
			Daivonex	C				
			Diprosone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/07/03ISR Number: 4085781-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0296281A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	16 DAY
			Sildenafil	C		ORAL	100MG per day	

Date:04/08/03ISR Number: 4086290-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0296280A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	15 DAY
	Phosphokinase Increased							
	Capillary Disorder							
	Dermatomyositis							
	Erythema							
	Myalgia							

Date:04/08/03ISR Number: 4086294-3Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0038185A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	WK
	Renal Embolism							

Date:04/08/03ISR Number: 4090982-2Report Type:Direct Company Report #CTU 190441
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS			100 MG (2) Initial or Prolonged	DAILY 6 MON

Date:04/09/03ISR Number: 4091030-0Report Type:Direct Company Report #CTU 190498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Tramadol 50 Mg	PS		ORAL	100 MG TID	
Hospitalization - Initial or Prolonged			Bupropion 100 Mg	SS		ORAL	100 MG TID ORAL	

Date:04/10/03ISR Number: 4088144-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0404175A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Lotronex	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Abdominal Pain Upper		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Bladder Cancer							
	Flatulence		Tenormin	C				
	Irritable Bowel Syndrome		Klonopin	C				
	Tinnitus		Claritin	C				
			Serzone	C				
			Estratest	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/10/03ISR Number: 4088150-3Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0296475A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose		Zyban	PS	Glaxosmithkline	ORAL	7500MG Single	
	Supraventricular dose							
	Extrasystoles		Alcohol	C			UNKNOWN	
	Ventricular Extrasystoles							

Date:04/10/03ISR Number: 4088153-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0296761A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Obstruction		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	15 DAY
			Hivid	C				
			Retrovir	C	Glaxosmithkline			

Date:04/10/03ISR Number: 4093521-5Report Type:Expedited (15-DaCompany Report #B0294984A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Activated Partial Thromboplastin Time	Foreign Literature	Zyban Tablet-Zyban (Bupropion					
Hospitalization - Initial or Prolonged	Prolonged	Health Professional	Hydrochloride)	PS			10 DAY	
	Cholestasis		Carbimazole(Carbimazole)	SS			5 YR	
	Coagulopathy							
	Dialysis		Propranolol Hydrochloride	C				
	Disseminated Intravascular Coagulation		Paracetamol	C				
	Encephalopathy		Ethanol	C				
	Haemoglobin Decreased							
	Hepatic Failure							
	Hepatic Necrosis							
	Hepatorenal Syndrome							

Hypokalaemia
Hyponatraemia
Hypotension
Intra-Abdominal
Haemorrhage
Metabolic Acidosis
Mouth Haemorrhage
Oliguria
Prothrombin Time
Prolonged
Pulmonary Haemorrhage
Pulmonary Oedema
Rectal Haemorrhage
Renal Impairment
Sepsis

Date:04/10/03ISR Number: 4093835-9Report Type:Expedited (15-DaCompany Report #A208038
Age:17 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acidosis	Literature	Ziprasidone					
	Coma	Health	(Ziprasidone)	PS		ORAL	2400 MG, ORAL	
	Electrocardiogram Qrs Complex Prolonged	Professional	Wellbutrin (Bupropion)					
	Electrocardiogram Qt Corrected Interval		(Bupropion Hydrohloride)	SS		ORAL	ORAL	
	Prolonged Electrocardiogram Qt		Klonopin (Clonazepam0	SS		ORAL	7.5 MG, ORAL	
	Prolonged Hyperventilation		Ativan (Lorazepam) (Lorazepam)	SS		ORAL	2 MG, ORAL	
	Intentional Misuse							
	Lethargy							
	Somnolence							

Date:04/11/03ISR Number: 4088863-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0404161A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carcinoid Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Phaeochromocytoma							

Date:04/11/03ISR Number: 4088871-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0295110A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG See	
Other	Arthralgia	Professional					dosage text	18 DAY
	Blood Immunoglobulin E		Ercefuryl	C	Glaxosmithkline	ORAL	3TAB per day	4 DAY
	Increased		Debridat	C		ORAL	4	DAY

	C-Reactive Protein		Ultra Levure	C	
3 DAY					
	Increased				
	Diarrhoea				
	Erythema				
	Gastroenteritis				
	Pruritus				
	Urticaria				
	Vomiting				
	White Blood Cell Count Increased				

Date:04/11/03ISR Number: 4088878-5Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0296637A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Aptyalism		Zyban	PS	Glaxosmithkline	ORAL
	Electrocardiogram Qt Prolonged		Norethisterone + Ethinyloestradiol	C		ORAL
	Intentional Misuse					
	Somnolence					
	Speech Disorder					
	Tachycardia					
	Therapeutic Agent Toxicity					
	Tremor					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/03ISR Number: 4088880-3Report Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0296745A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Depression	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 8 DAY
	Disease Recurrence		Citalopram	SS		ORAL	40MG per day
	Drug Interaction		Flupentixol + Melitracen Hydrochloride	SS		ORAL	.5MG Twenty times per day
			Thyroxine Sodium	C	Glaxosmithkline	ORAL	.1MG per day

Date:04/11/03ISR Number: 4088885-2Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0040836A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Ageusia Anosmia Myalgia		Zyban	PS	Glaxosmithkline	ORAL	

Date:04/11/03ISR Number: 4091130-5Report Type:Direct Company Report #CTU 190714
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Deafness Unilateral		Wellburtin 100mg Glaxosmithkline	PS	Glaxosmithkline		1Q AM
			Alprzolam	C			

Date:04/11/03ISR Number: 4091756-9Report Type:Direct Company Report #CTU 190755
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Cardio-Respiratory Arrest Grand Mal Convulsion		Wellbutrin 100mg Po 7am 150mg Po 830hs	PS		ORAL	150MG PO 7PM ; 150MG PO 830PM	

Date:04/14/03ISR Number: 4092094-0Report Type:Direct Company Report #CTU 190836
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Sr 150 Mg Glaxo Smith Kline	PS	Glaxo Smith Kline	ORAL	150 MG BID ORAL	

Date:04/14/03ISR Number: 4092097-6Report Type:Direct Company Report #CTU 190838
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity		Wellbutrin Sr 150 Mg Glaxo Smith Kline	PS	Glaxo Smith Kline	ORAL	150 MG BID ORAL	
			Zoloft	C				
			Seroquel	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/03ISR Number: 4092136-2Report Type:Direct Company Report #CTU 190772
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin 150mg Glaxo Smith Kline	PS	Glaxo Smith Kline	ORAL	150MG BID	ORAL

Date:04/14/03ISR Number: 4092138-6Report Type:Direct Company Report #CTU 190775
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Hypersensitivity Urticaria		Wellbutrin Sr 160mg Glaxo Smith Kline	PS	Glaxo Smith Kline	ORAL	150MG BID	ORAL

Date:04/14/03ISR Number: 4092327-0Report Type:Direct Company Report #CTU 190805
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Arthralgia Face Oedema Joint Swelling Oedema Peripheral Pruritus Tremor		Wellbutrin	PS				

Date:04/14/03ISR Number: 4095197-XReport Type:Expedited (15-DaCompany Report #A0403475A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acidosis Arrhythmia	Literature Health	Wellbutrin Sr Tablet-Controlled					

	Drug Toxicity	Professional	Release (Bupropion		
	Electrocardiogram Qrs		Hydrochloride)	PS	ORAL
SEE DOSAGE					
	Complex Prolonged				
TEXT/ORAL					
	Electrocardiogram Qt		Ziprasidone Hcl		
	Prolonged		(Formulation		
	Lethargy		Unknown)(Ziprasidone		
	Overdose		Hcl)	SS	ORAL
2400 MG/					
	Somnolence				
SINGLE DOSE/					
ORAL					
			Clonazepam		
			(Formulation		
			Unknown)	SS	ORAL
7.5 MG /					
SINGLE DOSE /					
ORAL					
			Lorazepam		
			(Formulation		
			Unknown) (Lorazepam)	SS	
2 MG / SINGLE					
DOSE /					

Date:04/15/03ISR Number: 4090707-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0385531A
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Chest Discomfort
Initial or Prolonged	Heart Rate Increased

	Hyperhidrosis Ventricular Tachycardia					
		Report Source	Product	Role	Manufacturer	Route
Dose Duration						
			Wellbutrin	PS	Glaxosmithkline	ORAL
400MG Per day						
			Effexor Xr	C		
			Xanax	C		ORAL
.5MG At night						
			Atarax	C		ORAL
75MG As						
required						

Date:04/15/03ISR Number: 4090711-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0392586A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Laboratory Test Interference Phaeochromocytoma		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:04/15/03ISR Number: 4090713-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0400724A
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Bronchial Obstruction	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
1 DAY						
	Convulsion Dyspnoea Mucous Membrane Disorder	Professional				

Date:04/15/03ISR Number: 4090714-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0404165A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day						

	Drug Exposure During					
	Pregnancy					
	Maternal Drugs Affecting					
	Foetus					

Date:04/15/03ISR Number: 4090715-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0404554A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
	Pregnancy							
	Pregnancy							
	Pregnancy Induced							
	Hypertension							
	Proteinuria							

Date:04/15/03ISR Number: 4090742-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0403696A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Consumer	Wellbutrin Sr	PS	Glaxosmithkline			
	Dysphonia		Paxil	SS	Glaxosmithkline	ORAL		
	Speech Disorder		Remeron	SS				
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/03ISR Number: 4093145-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0380858A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dacryostenosis Acquired		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Single	
	Energy Increased						dose	2 DAY
	Face Oedema		Sudafed	C	Glaxosmithkline			
	Flushing							
	Headache							
	Pain In Jaw							
	Pruritus							
	Rash Erythematous							

Date:04/18/03ISR Number: 4093147-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0397981A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Other	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Distress Syndrome						per day	
	Bronchospasm		Prozac	SS		ORAL	40MG Per day	
	Cardiac Arrest		Ultram	SS		ORAL	50MG As	
	Cardiac Disorder						required	13 DAY
	Cardiomegaly		Phenergan With					
	Drug Toxicity		Codeine	SS		ORAL	1TSP As	
	Fall						required	12 DAY
	Lobar Pneumonia		Chlorpheniramine	SS				
	Lung Consolidation		Ultracet	SS				
	Lung Disorder		Vioxx	C				
	Musculoskeletal Pain		Reglan	C	Glaxosmithkline			
	Neck Pain		Theodur	C			300MG Twice	
	Pernicious Anaemia						per day	
	Pleural Disorder		Prednisone	C				

	Pneumonia	Flovent	C	Glaxosmithkline
	Renal Disorder	Singulair	C	
	Thyroiditis	Premarin	C	
		Prevacid	C	
		Rhinocort	C	
		Klonopin	C	
		Vioxx	C	
		Combivent	C	

RESPIRATORY

(INHALATION) 2PUFF Three

times per day

Neurontin	C	
Baclofen	C	
Vitamin B12	C	Glaxosmithkline
Darvocet	C	

1TAB Three

times per day

Levaquin	C	

Date:04/18/03ISR Number: 4093158-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0297338A
Age:40 YR Gender:Female I/FU:I

Outcome	PT
Other	Ageusia
	Confusional State
	Depression
	Excitability
	Hyposmia
	Insomnia
	Mood Altered

	Muscle Twitching Somnolence						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text 29 DAY

Date:04/18/03ISR Number: 4093159-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0297365A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abdominal Pain Upper		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown 4 DAY
	Anorexia		Eugynon	C		ORAL	1Z Per day
	Depression Disturbance In Attention Fatigue Headache Irritability Nausea						

Date:04/18/03ISR Number: 4093161-8Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0038838A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 6 WK
Other	Bipolar Disorder 92 DAY		Seroxat	SS	Glaxosmithkline		UNKNOWN
	Crying Diarrhoea Disturbance In Attention Gastrointestinal Disorder Hyperhidrosis Hypomania Illusion Migraine Nausea						

	Nervousness					
	Sleep Disorder					
	Suicidal Ideation					
	Tachycardia					
	Vertigo					
	Weight Decreased					

Date:04/22/03ISR Number: 4094756-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0405398A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lethargy		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Three times per day	
	Prescribed Overdose							
	Sensation Of Heaviness		Trazodone	C				
	Tremor		Zyprexa	C				
	Visual Disturbance		Zolpidem	C				
			Colace	C				
			Iron	C				
			Vicodin	C				
			Motrin	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/03ISR Number: 4094792-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0405398A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lethargy	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Three times per day	
	Prescribed Overdose	Professional						
	Sensation Of Heaviness		Trazodone	C				
	Tremor		Zyprexa	C				
	Visual Disturbance		Zolpidem	C				
			Colace	C				
			Iron	C				
			Vicodin	C				
			Motrin	C	Glaxosmithkline			

Date:04/23/03ISR Number: 4095787-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0145759A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Postural		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	2 YR
	Hypertension		Norvasc	C				
	Lethargy		Premarin	C				
	Myocardial Ischaemia		Prevacid	C				
	Somnolence		Multivitamin	C				
	Ventricular Hypertrophy							

Date:04/23/03ISR Number: 4095791-6Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0405380A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Myalgia							
	Rhabdomyolysis							

Date:04/23/03ISR Number: 4102151-8Report Type:Expedited (15-DaCompany Report #2003016733
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Murder	Consumer	Zoloft (Sertraline) Bupropion Hydrochloride (Bupropion Hydrochloride)	PS SS				

Date:04/24/03ISR Number: 4100490-8Report Type:Direct Company Report #CTU 191554
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Aggression Agitation Depression Irritability Mood Altered Sexual Dysfunction		Zoloft 50 Mg Pfizer Wellbutrin 150 Mg Glaxo	PS SS	Pfizer Glaxo	ORAL OTHER	50 MG DAY 150 MG DAY	ORAL OTHER

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/03ISR Number: 4097721-XReport Type:Direct Company Report #USP 51576
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Wellbutrin Sr(Bupropion)	PS	Wellcome			

Date:04/25/03ISR Number: 4101237-1Report Type:Direct Company Report #USP 55812
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr 150	PS	Glaxo			

Date:04/25/03ISR Number: 4117226-7Report Type:Periodic Company Report #NSADSS2002032542
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Literature	Ultram (50 Mg Tablet) (Tramadol Hydrochloride)	PS		ORAL		
	Respiratory Depression	Health Professional						
	Therapeutic Response							
	Increased		Metoclopramide(Metoclopramide)	SS		ORAL		
			Bupropion (Amfebutamone)	SS		ORAL		

Date:04/28/03ISR Number: 4101197-3Report Type:Direct Company Report #CTU 191710
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Paxil 20 Mg 1x A Day ?	PS				
	Bedridden							
Other	Decreased Activity		Wellbutrin Sr 100 Mg 1x A Day	SS				
	Difficulty In Walking							
	Eye Movement Disorder							

	Headache
	Medication Error
	Migraine
	Movement Disorder
	Nausea
	Pharmaceutical Product Complaint
	Photophobia
	Suicidal Ideation
	Vertigo
	Vomiting

Date:04/28/03ISR Number: 4101671-XReport Type:Direct Company Report #CTU 191740
Age: Gender:Female I/FU:I

Outcome	PT
Other	Aggression
	Confusional State
	Disorientation
	Dizziness
	Nightmare
	Sexual Dysfunction
	Social Avoidant Behaviour
	Weight Increased

Weight Loss Poor

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Zoloft 25 Mg	PS		ORAL	ZOLOFT 1 X PER ORAL	
	Wellbutrin 100 Mg	SS		ORAL	WELLBUTRIN 1 X PER ORAL	

Date:04/29/03ISR Number: 4099833-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406259A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Convulsion Facial Bones Fracture		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:04/29/03ISR Number: 4099835-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406391A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Asthenia Convulsion Dizziness Dyspnoea Hyperaesthesia Hypersensitivity Hypoxia Immune System Disorder Muscle Spasms Myalgia Nightmare		Bupropion	PS	Glaxosmithkline	ORAL		

	Throat Tightness						
	Tremor						
	Vestibular Disorder						

Date:04/29/03ISR Number: 4099845-XReport Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0297272A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomyopathy		Zyntabac	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Erythema Multiforme							
	Hypertension							

Date:04/30/03ISR Number: 4100926-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406365A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Wellbutrin	PS	Glaxosmithkline		150MG Twice per day	
	Chest Pain							
	Hypotension		Vicodin	C				
	Lung Disorder							
	Myocardial Infarction							
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/03ISR Number: 4103722-5Report Type:Direct Company Report #CTU 191975
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Celexa 40mg 40mg	PS		ORAL	1	1 ORAL
	Drug Ineffective		Wellbutrin Sr 150 Mg	SS		ORAL	150	2 ORAL
	Feeling Abnormal							
	Loss Of Libido							
	Neurological Symptom							
	Oral Intake Reduced							
	Weight Increased							

Date:04/30/03ISR Number: 4105818-0Report Type:Expedited (15-DaCompany Report #A0372195A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Blood Carbon Monoxide Blood Chloride Blood Creatinine Blood Glucose	Literature Health Professional Other	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	4500 MG/ SINGLE DOSE/ORAL	
	Blood Potassium Blood Sodium Blood Urea Depressed Level Of Consciousness Hypertension		Topiramate Tablet (Topiramate)	SS		ORAL	3000 MG/SINGLE DOSE/ORAL	
	Metabolic Acidosis Overdose Tachycardia		Glimepiride (Formulation Unknown) (Glimepiride)	SS			20 MG/SINGLE DOSE	
			Fluoxetine Hydrochloride					

			(Formulation Unknown), (Fluoxetine	SS			
600 MG/SINGLE DOSE							
			Enalapril Maleate (Formulation Unknown) (Enalapril Maleate)	SS			
200 MG/SINGLE DOSE							

Date:05/01/03ISR Number: 4105194-3Report Type:Direct Company Report #CTU 192111
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hyperreflexia		Wellbutrin Sr 150mg	PS		ORAL	150MG BID PO	
Other Required Intervention to Prevent Permanent Impairment/Damage	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/03ISR Number: 4107055-2Report Type:Expedited (15-DaCompany Report #2003017811
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign Health Professional	Atorvastatin (Atorvastatin)	PS		ORAL	20 MG	(DAILY), ORAL
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS		ORAL	300 MG	(DAILY), ORAL

Date:05/05/03ISR Number: 4103016-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0397981A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Distress Syndrome	Other	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Asthma		Prozac	SS		ORAL	40MG Per day	
	Cardiac Arrest		Ultram	SS		ORAL	50MG As required	13 DAY
	Cyanosis							
	Drug Toxicity		Phenergan With Codeine	SS		ORAL	1TSP As required	12 DAY
	Fall							
	Lobar Pneumonia							
	Lung Consolidation		Chlorpheniramine	SS				
			Ultracet	SS				
			Vioxx	C				
			Reglan	C	Glaxosmithkline			
			Theodur	C			300MG Twice	

per day

Prednisone	C	
Flovent	C	Glaxosmithkline
Singulair	C	
Premarin	C	
Prevacid	C	
Rhinocort	C	
Klonopin	C	
Vioxx	C	
Combivent	C	

RESPIRATORY

(INHALATION) 2PUFF Three

times per day

Neurontin	C	
Baclofen	C	
Vitamin B12	C	Glaxosmithkline
Darvocet	C	

1TAB Three

times per day

Levaquin	C	

Date:05/05/03ISR Number: 4103022-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406924A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis		Wellbutrin	PS	Glaxosmithkline	ORAL	4	MON
	Diarrhoea		Klonopin	C				
	Intestinal Obstruction		Trileptal	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/03ISR Number: 4105686-7Report Type:Direct Company Report #CTU 192292
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Condition Aggravated		Buproprion	PS		ORAL	150 MG BID PO
Intervention to Prevent Permanent Impairment/Damage	Tremor						

Date:05/05/03ISR Number: 4107962-0Report Type:Expedited (15-DaCompany Report #HQWYE808303MAR03
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Accidental Exposure	Health	Phenergan				
Other	Accidental Overdose	Professional	(Promethazine Hydrochloride, Unspec)	PS			
	Cardiac Arrest		Prozac (Fluoxetine Hydrochloride,)	SS			
	Cardiomegaly		Ultram (Tramadol Hydrochloride,)	SS			
	Drug Interaction		Wellbutrin (Amfebutamone Hydrochloride,)	SS			
	Drug Toxicity						
	Lobar Pneumonia						
	Lung Disorder						
	Medication Error						
	Oedema						
	Renal Disorder						
	Toxicologic Test Abnormal						

Date:05/06/03ISR Number: 4103911-XReport Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0298177A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Zyntabac	PS	Glaxosmithkline	ORAL	150MG Per day 12 DAY
Initial or Prolonged	Extrasystoles		Verapamil	C		ORAL	
	Ventricular Extrasystoles						

Date:05/06/03ISR Number: 4103913-3Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0298247A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Dependence		Bupropion					
	Euphoric Mood		Hydrochloride	PS	Glaxosmithkline			
UNKNOWN							150MG As directed	
	Libido Increased							
	Personality Change		Cannabis	C				
UNKNOWN								

Date:05/07/03ISR Number: 4104935-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0407308A
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
Initial or Prolonged	Status Epilepticus							

Date:05/07/03ISR Number: 4104938-4Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0293561A
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Drug Reaction
Initial or Prolonged	Arthralgia
	Chest Discomfort

	Chest Pain						
	Dizziness						
	Dyspnoea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoaesthesia		Zyban	PS	Glaxosmithkline	ORAL	150MG
	Mediastinal Disorder						Variable dose 7 DAY
	Pallor		Diclofenac +				
	Palpitations		Misoprostol	C			UNKNOWN
	Paraesthesia						

Date:05/07/03ISR Number: 4104940-2Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0298038A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Pressure Decreased	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown 3 WK
Initial or Prolonged	Burning Sensation		Anesthetic	SS			UNKNOWN 1 DAY
	Face Oedema						
	Flushing						
	Rash						
	Urticaria						

Date:05/07/03ISR Number: 4104942-6Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0298053A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Aggression		Zyban	PS	Glaxosmithkline		UNKNOWN 150MG Unknown
	Arrhythmia						
	Cardiac Disorder						
	Insomnia						
	Nausea						
	Sensation Of Foreign Body						

Date:05/07/03ISR Number: 4104946-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0298454A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Zyban	PS	Glaxosmithkline		UNKNOWN	
Hospitalization - Initial or Prolonged	Mental Impairment Neoplasm Personality Change							

Date:05/07/03ISR Number: 4107641-XReport Type:Direct Company Report #CTU 192460
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity		Wellbutrin Sr 150 Mg Gsk	PS	Gsk	ORAL	150 MG QD ORAL	

Date:05/07/03ISR Number: 4109692-8Report Type:Expedited (15-DaCompany Report #HQWYE808303MAR03
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Death	Accidental Exposure Cardiac Arrest Cardiomegaly Drug Interaction

		Drug Screen Positive Drug Toxicity Lobar Pneumonia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lung Disorder Medication Error Renal Disorder Respiratory Arrest	Consumer	Phenergan (Promethazine Hydrochloride, Unspec)	PS		
				Prozac (Fluoxetine Hydrochloride,)	SS		
				Ultram (Tramadol Hydrochloride,)	SS		
				Wellbutrin (Amfebutamone Hydrochloride,)	SS		

Date:05/08/03ISR Number: 4110115-3Report Type:Expedited (15-DaCompany Report #2003UW05734
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Required	Retinal Haemorrhage	Health	Seroquel	PS		ORAL
25 MG DAILY						
Intervention to		Professional				
PO						
Prevent Permanent			Eskalith	SS		
300 MG						
Impairment/Damage			Xanax	SS		
0.25 MG PRN						
			Wellbutrin	SS		
150 MG BID						

Date:05/08/03ISR Number: 4110196-7Report Type:Expedited (15-DaCompany Report #200310607BCC
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Arthralgia	Consumer	Aleve (Naproxen			
	Difficulty In Walking	Health	Sodium)	PS		ORAL
440 MG, ONCE,						
	Pain In Extremity	Professional				
ORAL						
	Pruritus Generalised	Other	Wellbutrin			

	Tendonitis		(Amfebutamone Hydrochloride)	SS		

Date:05/09/03ISR Number: 4106574-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0298813A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diplopia Ophthalmoplegia Visual Disturbance		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	

Date:05/12/03ISR Number: 4110853-2Report Type:Direct Company Report #CTU 192718
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Wellbutrin Sr 150mg Glaxo Smith Kline	PS	Glaxo Smith Kline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/03ISR Number: 4111111-2Report Type:Direct Company Report #USP 51755
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Welbutrin 75mg	PS	Glaxo Wellcome		75 MG	
			Welbutrin Sr 150	SS	Glaxowellcome			

Date:05/12/03ISR Number: 4111153-7Report Type:Direct Company Report #USP 51611
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Zyban	PS	Glaxo Wellcome			
			Buspar	SS	Bristol-Myers Squibb			

Date:05/13/03ISR Number: 4108378-3Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0408081A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased		Bupropion	PS	Glaxosmithkline	ORAL		

Date:05/13/03ISR Number: 4108380-1Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0291940A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage Nicotine Dependence Restlessness	Consumer	Bupropion Hydrochloride	PS	Glaxosmithkline	UNKNOWN	150MG Unknown	2 MON

Date:05/13/03ISR Number: 4111365-2Report Type:Expedited (15-DaCompany Report #8002289
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Hydrocodone					
	Intentional Misuse	Health	W/Acetaminophen	PS		ORAL	PO	
		Professional	Bupropion (Long-Acting)	SS		ORAL	PO	
			Carisoprodol	SS		ORAL	PO	

Date:05/13/03ISR Number: 4111367-6Report Type:Expedited (15-DaCompany Report #8002291
Age:44 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Hydrocodone					
	Overdose	Health	W/Acetaminophen	PS		ORAL	PO	
		Professional	Fluoxetine	SS		ORAL	PO	
			Bupropion	SS		ORAL	PO	

Date:05/13/03ISR Number: 4111793-5Report Type:Expedited (15-DaCompany Report #HQWYE446302APR03
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Behaviour
	Accidental Overdose
Other	Choreoathetosis
	Confusional State

Drug Interaction Euphoric Mood Gait Disturbance Hallucination Medication Error Mental Status Changes Movement Disorder Nausea Poisoning Self-Medication Systemic Lupus Erythematosus	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	SEE IMAGE	
		Ditropan (Oxybutynin,)	SS		ORAL	5 MG 1X PER 1 DAY, ORAL	
		Klonopin (Clonazepam,)	SS			1.5 MG 1X PER 1 DAY	
		Levothyroxine (Levothyroxine,)	SS		ORAL	150 MCG, ORAL	
		Synthroid (Levothyroxine Sodium,)	SS		ORAL	150 MCG, ORAL; 0.1 MG 1X PER 1 DAY, ORAL	
		Wellbutrin (Amfebutamone Hydrochloride,)	SS			200 MG 2X PER 1 DAY	3 MON
		Pepcid (Famotidine)	C				
		Hydrochlorothiazide	C				
		Elavil (Amitriptyline Hydrochloride)	C				
		Vioxx (Rofecoxib)	C				
		Lortab (Hydrocodone Bitartrate/Paracetam					

ol)	C
Valdecoxib	C
Flexeril (Cyclobenzaprine Hydrochloride)	C
Enalapril	C
Tylenol (Paracetamol)	C

Date:05/14/03ISR Number: 4109214-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0298537A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperhidrosis Urinary Tract Infection		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/14/03ISR Number: 4109300-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0298799A
Age:55 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Gamma-Glutamyltransferase Increased Lipase Increased

		Pancreatitis Acute Pancreatolithiasis					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Zyban	PS	Glaxosmithkline	ORAL
				Acid Acetylsalicylique	SS	Glaxosmithkline	ORAL
				Maalox	SS		ORAL
				Carbocisteine	SS	Glaxosmithkline	ORAL
1UNIT per day	3 DAY						
				Augmentin	SS	Glaxosmithkline	ORAL
2UNIT per day	5 DAY						
				Myolastan	C		ORAL
3UNIT per day	8 DAY						

Date:05/15/03ISR Number: 4109955-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0377262A
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other	2 YR	Aphasia		Wellbutrin	PS	Glaxosmithkline	ORAL
		Balance Disorder		Estrace	C		ORAL
3MG Per day							
		Constipation		Advil	C	Glaxosmithkline	ORAL
		Dry Mouth		Calcium/Vitamin D	C		ORAL
1000MG Per day		Dysgeusia					
		Insomnia		Fish Oil	C		ORAL
		Libido Increased		Aspirin	C	Glaxosmithkline	
		Memory Impairment					
		Nausea					
		Pharyngolaryngeal Pain					
		Therapeutic Response					
		Unexpected					
		Tinnitus					

Date:05/15/03ISR Number: 4109957-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395424A
Age:38 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anger						per day	
	Bipolar Disorder							
	Paranoia							
	Rash							

Date:05/15/03ISR Number: 4109958-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402679A
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Urea Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	MON
	Choreoathetosis							
	Confusional State		Effexor Xr	SS			75MG Twice per day	
	Drug Interaction							
	Hallucination, Visual		Pepcid	C			40MG Per day	
	Medication Error		Synthroid	C	Glaxosmithkline		150MCG Per day	
	Poisoning							
	White Blood Cell Count Increased		Klonopin	C			1.5MG At night	
			Lorcet 10/650	C			2TAB Three times per day	
			Vioxx	C			25MG Per day	
			Hctz	C			25MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/15/03ISR Number: 4109978-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0299369A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Eyelid Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	15 DAY
Hospitalization - Initial or Prolonged	Hypersensitivity							
	Local Swelling							
Other	Obstructive Airways Disorder							

Date:05/15/03ISR Number: 4109979-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0299399A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	8 DAY
			Gliclazide	C		ORAL	160MG per day	
			Metformin	C		ORAL	500MG Twice per day	

Date:05/15/03ISR Number: 4112818-3Report Type:Expedited (15-DaCompany Report #B0298148A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Literature	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS				
	Alanine Aminotransferase Increased	Health Professional						
	Aspartate Aminotransferase Increased							
	Cardiolipin Antibody Positive							
	Fibrosis							
	Hypersensitivity							
	Red Blood Cell Sedimentation Rate							

Increased
Subarachnoid Haemorrhage

Date:05/15/03ISR Number: 4113339-4Report Type:Periodic Company Report #327494
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tinnitus	Health Professional	Pegasys (Peg-Interferon Alfa 2a)	PS		SUBCUTANEOUS	1 PER WEEK;	
			Lexapro (Escitalopram)	SS		ORAL	10 MG DAILY;	
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	2 PER DAY;	
			Ambien (Zolpidem Tartrate)	SS		ORAL	1 PER DAY;	
			Phenergan (Promethazine Hydrochloride)	SS			1 PER; PRN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/03ISR Number: 4114135-4Report Type:Direct Company Report #CTU 193195
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mental Status Changes		Duragesic	PS				
			Vicodin	SS				
			Cardura	SS				
			Wellbutrin	SS				
			Neurontin	SS				
			Tequin	SS				

Date:05/20/03ISR Number: 4112078-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0408639A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Function Test		Bupropion	PS	Glaxosmithkline	ORAL	1	YR
	Abnormal							
	Viral Infection							

Date:05/20/03ISR Number: 4112089-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0299690A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/21/03ISR Number: 4113005-5Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0293848A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Poisoning		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG Twice per day
	Drug Interaction							
	Loss Of Consciousness		Ethanol	SS			UNKNOWN	
	Memory Impairment							

Date:05/21/03ISR Number: 4113006-7Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0295743A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Interaction						per day	19 DAY
	Epilepsy		Trimipramine	SS		ORAL	25MG per day	
	Headache		Methotrimeprazine	SS		ORAL	5MG Per day	
	Loss Of Consciousness		Moclobemide	SS		ORAL	300MG Per day	
	Muscle Spasms		Alprazolam	C		ORAL	2MG per day	
	Salivary Hypersecretion							
	Tongue Biting							

Date:05/21/03ISR Number: 4115507-4Report Type:Expedited (15-DaCompany Report #B0299573A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypokalaemia	Foreign	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS				
	Muscular Weakness		Irbesartan	C				
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/03ISR Number: 4115551-7Report Type:Expedited (15-DaCompany Report #B0299299A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Foreign	Zyban Tablet-Zyban					
	Chest Pain	Consumer	(Bupropion					
	Dilatation Ventricular		Hydrochloride)	PS		ORAL	ORAL	4 DAY

Date:05/21/03ISR Number: 4115553-0Report Type:Expedited (15-DaCompany Report #B0299244A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Depression	Foreign	Zyban Tablet-Zyban					
Intervention to	Malaise		(Bupropion					
Prevent Permanent	Suicide Attempt		Hydrochloride)	PS		ORAL	ORAL	
Impairment/Damage			Pravastatin Sodium	C				

Date:05/21/03ISR Number: 4115578-5Report Type:Expedited (15-DaCompany Report #B0289510A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Retinal Oedema	Foreign	Zyban Tablet-Zyban					
Intervention to	Visual Field Defect	Health	(Bupropion					
Prevent Permanent		Professional	Hydrochloride)	PS		ORAL	150 MG/PER	
Impairment/Damage							DAY/ORAL	

Date:05/21/03ISR Number: 4115582-7Report Type:Expedited (15-DaCompany Report #B0288569A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Coordination Abnormal	Foreign	Wellbutrin					
Intervention to	Dizziness	Health	Tablet-Zyban					
Prevent Permanent	Motor Dysfunction	Professional	(Bupropion					

Impairment/Damage	Muscular Weakness		Hydrochloride)	PS		ORAL
SEE DOSAGE TEXT / ORAL	Pallor		Thyroxine Sodium	C		

Date:05/21/03ISR Number: 4115598-0Report Type:Expedited (15-DaCompany Report #A0402277A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Interaction Headache Migraine	Health Professional Other	Wellbutrin (Bupropion Hydrochloride) (Formulation Unknown)	PS		ORAL
100 MG/ PER DAY/ ORAL						
			Modafinil (Modafinil) (Formulation Unknown)	SS		ORAL
50 MG/ PER DAY/ ORAL						
			Citalopram Hydrobromide (Citalopram Hydrobromide) (Formulation	SS		ORAL
40 MG/ PER DAY/ ORAL						

			Thyroxine Sodium	C			

Date:05/21/03ISR Number: 4115785-1Report Type:Expedited (15-DaCompany Report #B0287207A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Myalgia Purpura Serum Sickness Urticaria	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL

Date:05/22/03ISR Number: 4113844-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0409059A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Interaction	Consumer	Bupropion	PS	Glaxosmithkline	ORAL	150MG Per day 9 DAY
	Grand Mal Convulsion		Alcohol	SS			
			Nexium	C			

Date:05/22/03ISR Number: 4113849-XReport Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0295775A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Aphasia	Consumer	Zyban	PS	Glaxosmithkline	ORAL	43 DAY
	Cerebral Arteritis						
	Cerebral Haemorrhage						
	Convulsion						
	Headache						
	Nausea						
	Personality Change						
	Vomiting						

Date:05/22/03ISR Number: 4113850-6Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0296637A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aptyalism	Consumer	Zyban	PS	Glaxosmithkline	ORAL		
	Electrocardiogram Qt Prolonged		Norethisterone + Ethinyloestradiol	C		ORAL		
	Intentional Misuse							
	Poisoning							
	Somnolence							
	Speech Disorder							
	Tachycardia							
	Tremor							

Date:05/22/03ISR Number: 4117383-2Report Type:Direct Company Report #USP 51006
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Buspar	PS	Bristol Myers Squibb		TABLET	
			Wellbutrin	SS			TABLET	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/03ISR Number: 4160216-9Report Type:Periodic Company Report #SU-2003-000485
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Benicar	PS		ORAL	20 MG QD PO	
	Rash		Wellbutrin	SS				
	Skin Odour Abnormal		Prevacid	C				
			Claritin	C				
			Effexor - Slow Release	C				
			Nabumetone	C				

Date:05/23/03ISR Number: 4114683-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0300222A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Crohn'S Disease		Lansoprazole	C		ORAL	30MG Per day	
			Azathioprine	C	Glaxosmithkline	ORAL	50MG Three times per day	
			Hydroxocobalamin	C	Glaxosmithkline	INTRAMUSCULAR	3MG Monthly	
			Codeine	C		ORAL	30MG As required	

Date:05/23/03ISR Number: 4118608-XReport Type:Direct Company Report #USP 55845
Age:12 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Voltaren	PS			TABLET	
			Wellbutrin	SS			TABLET	

Date:05/28/03ISR Number: 4117117-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0392586A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Laboratory Test	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Interference	Professional					per day	
			Levothyroxine	C	Glaxosmithkline		.05MG Per day	

Date:05/28/03ISR Number: 4117118-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0407308A
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
Initial or Prolonged	Overdose	Professional						
	Status Epilepticus							

Date:05/28/03ISR Number: 4117120-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0409371A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Bupropion	PS	Glaxosmithkline	ORAL		
Initial or Prolonged	Nausea		Strattera	SS				
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/03ISR Number: 4117121-3Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0038838A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aggression	Other	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
Other	Anxiety		Seroxat	SS	Glaxosmithkline		UNKNOWN	92 DAY
	Bipolar Disorder		Sortis	C		ORAL		
	Crying		Diclo	C	Glaxosmithkline		INTRAMUSCULAR	
	Depression		Dexa-Phlogont	C			INTRAMUSCULAR	
	Diarrhoea		Perenterol	C		ORAL		
	Disturbance In Attention		Mutaflor	C		ORAL		
	Gastrointestinal Disorder							
	Hyperhidrosis							
	Hypomania							
	Illusion							
	Migraine							
	Nausea							
	Nervousness							
	Sleep Disorder							
	Suicidal Ideation							
	Tachycardia							
	Vertigo							
	Weight Decreased							

Date:05/29/03ISR Number: 4118197-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0409518A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Bupropion	PS	Glaxosmithkline	ORAL		
			Ibuprofen	SS	Glaxosmithkline			
	Intentional Misuse							

Date:05/29/03ISR Number: 4118198-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0409537A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Congenital Anomaly	Cleft Lip		Bupropion	PS	Glaxosmithkline	
	Maternal Drugs Affecting		Neurontin	C		
	Foetus		Maxalt	C		

Date:05/29/03ISR Number: 4118204-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0297338A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ageusia	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG See	
Other	Aggression	Professional					dosage text	36 DAY
	Agitation		Oligosol(S)	C		ORAL		
	Akathisia							
	Asthenia							
	Confusional State							
	Depression							
	Hyposmia							
	Insomnia							
	Mood Altered							
	Muscle Twitching							
	Somnolence							
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/03ISR Number: 4119394-XReport Type:Direct Company Report #CTU 194258
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Grand Mal Convulsion		Bupropion Sr	PS			100 MG SR	
	Loss Of Consciousness						BID	
			Sertraline	C				
			Zolpidem	C				
			Alcohol	C				

Date:05/29/03ISR Number: 4119395-1Report Type:Direct Company Report #CTU 194260
Age:5 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Bupropion Sr	PS			100 MG SR Q	
							AM	
			Guanfacine	C				

Date:05/29/03ISR Number: 4119454-3Report Type:Direct Company Report #CTU 194224
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tremor		Wellbutrin 150 Mg X R	PS		ORAL	300 MG PO QD	

Date:05/29/03ISR Number: 4121166-7Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12252938
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia		Abilify Tabs 15 Mg	PS	Otsuka			
	Anxiety				Pharmaceutical			

	Headache			Company, Ltd.	ORAL
10 mg/day					
	Hypomania				
from					
	Panic Disorder				
18-Mar-2003					
until					
07-Apr-2003,					
		Abilify Tabs 15 Mg	SS	Otsuka Pharmaceutical Company, Ltd.	ORAL
10 mg/day					
from					
18-Mar-2003					
until					
07-Apr-2003,					
		Wellbutrin Sr	SS		
		Vitamin E	C		
		Lamictal	C		
		Trazodone Hcl	C	Apothecon	
		Inderal La	C		
		Premarin	C		
		Vitamin C	C		
		Valtrex	C		

Date:05/30/03ISR Number: 4119376-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0397636A
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Distension
	Difficulty In Walking

	Disorientation					
	Dizziness					
	Drug Withdrawal Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dysstasia		Wellbutrin	PS	Glaxosmithkline	
UNKNOWN	12 YR					
	Migraine		Maxalt	C		
	Musculoskeletal Stiffness		Botox	C		
	Tinnitus		Luvox	C		
			Eskalith	C	Glaxosmithkline	
			Premarin	C		

Date:05/30/03ISR Number: 4119380-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0410077A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death		Bupropion	PS	Glaxosmithkline	
8 MON						

Date:05/30/03ISR Number: 4119390-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0300655A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Agitation		Zyban	PS	Glaxosmithkline	ORAL
3.7G per day	1 DAY					
Initial or Prolonged	Balance Disorder		Xanax	C		ORAL
6.25MG per						
	Chorea					
day	1 DAY					
	Coordination Abnormal					
	Dysarthria					
	Hallucinations, Mixed					
	Suicide Attempt					
	Tremor					

Date:05/30/03ISR Number: 4119391-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0300707A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	16 DAY
Hospitalization - Initial or Prolonged	Blood Fibrinogen Decreased		Esberiven	C		ORAL		
			Orthosiphon	C		ORAL		
	C-Reactive Protein Increased		Lithium Oligosol	C			UNKNOWN	
	Dermographism							
	Dyspnoea							
	Generalised Oedema							
	Leukocytosis							
	Lung Consolidation							
	Macroglossia							
	Pharyngolaryngeal Pain							
	Pruritus							
	Pyrexia							
	Respiratory Disorder							

Date:05/30/03ISR Number: 4119515-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0399254A
Age:31 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Distension
Other	Anaphylactic Shock
	Erythema
	Hallucination, Auditory

	Hallucination, Visual Oedema Peripheral Pruritus	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash		Paxil	PS	Glaxosmithkline	ORAL
30MG Per day						
	Swelling Face		Wellbutrin	SS	Glaxosmithkline	ORAL
300MG Twice						
	Swollen Tongue					
per day 79 DAY						
			Epival	C		ORAL
750MG Per day						
			Eltroxin	C	Glaxosmithkline	ORAL
500MG Per day						
			Clonazepam	C		ORAL

Date:05/30/03ISR Number: 4119689-XReport Type:Direct Company Report #CTU 194373
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Tremor		Bupropion	PS		ORAL
150 MG PO BID						
Intervention to Prevent Permanent Impairment/Damage						

Date:05/30/03ISR Number: 4121322-8Report Type:Expedited (15-DaCompany Report #B029989A
Age:16 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature Health Professional	Paxil (Formulation Unknown) (Paroxetine Hydrochloride)	PS		ORAL
ORAL						
			Wellbutrin (Formulation Unknown)(Bupropion Hydrochloride)	SS		ORAL
ORAL						

Date:06/02/03ISR Number: 4120339-7Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0410089A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion		Bupropion	PS	Glaxosmithkline	ORAL	2	MON
Other	Disability							
	Fall							
	Head Injury							

Date:06/02/03ISR Number: 4120684-5Report Type:Direct Company Report #CTU 194444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS		ORAL	300 MG BID	
						ORAL		

Date:06/02/03ISR Number: 4122361-3Report Type:Expedited (15-DaCompany Report #USA-2003-0005834
Age:46 YR Gender:Male I/FU:I

Outcome	PT
Death	Coma
	Coronary Artery Disease
	Cryptogenic Organizing
	Pneumonia
	Hepatic Haemorrhage

		Hepatic Necrosis Hilar Lymphadenopathy Hypertensive Cardiomegaly	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia Aspiration Prescribed Overdose Pulmonary Haemorrhage	Health Professional Other	Oxycontin Tablets(Oxycodone Hydrochloride) Cr Tablet	PS		
80 MG, Q8H							
				Hydrocodone Bitartrate (Similar To Ind 59,175)(Hydrocodone Bitartrate) Unknown	SS		
				Trazodone(Trazodone)	SS		
				Acetaminophen(Parace tamol)	SS		
				Diazepam(Diazepam)	SS		
				Wellbutrin(Amfebutam one Hydrochloride)	SS		

Date:06/02/03ISR Number: 4140932-5Report Type:Periodic Company Report #2003005856
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion	Health	Geodon (Ziprasidone)	PS		ORAL
80 MG, BID,						
		Professional				
ORAL						
		Company Representative	Bupropion Hydrochloride	SS		
300 MG BID						
			Non-Therapeutic Products	SS		
			Alprazolam	C		
			Zolpidem Tartrate	C		

Date:06/03/03ISR Number: 4122045-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0410328A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Antepartum Haemorrhage		Bupropion	PS	Glaxosmithkline	ORAL
150MG Per day						
	Complications Of Maternal Exposure To Therapeutic Drugs Drug Exposure During Pregnancy Pregnancy					

Date:06/03/03ISR Number: 4122046-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0410340A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Enterocolitis		Bupropion	PS	Glaxosmithkline	ORAL
100MG Per day 2 WK						
Hospitalization -	Haemorrhagic		Flagyl	SS	Glaxosmithkline	
Initial or Prolonged	Rash		Cipro	SS		
Disability						
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/03ISR Number: 4122048-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0410361A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline	ORAL	300MG per day	374 DAY
	Drug Exposure During Pregnancy							
	Pregnancy							

Date:06/04/03ISR Number: 4122389-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0301009A
Age:24 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	34 DAY
Other								

Date:06/04/03ISR Number: 4124276-3Report Type:Expedited (15-DaCompany Report #B0300463A
Age:47 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Wellbutrin (Formulation Unknown) (Buproppion Hydrochloride)	PS				
	Completed Suicide	Health Professional	Dextropropoxyphene (Formulation Unknown) (Dextropropoxyphene)	SS		ORAL		
	Toxicologic Test Abnormal		Alprazolam (Formulation Unknown) (Alparzolam)	SS				

Date:06/04/03ISR Number: 4124278-7Report Type:Expedited (15-DaCompany Report #B0300448A
Age:22 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin					
	Overdose	Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Imipramine (Formulation Unknown) (Imipramine)	SS				
			Secobarbital Sodium (Formulation Unknown) (Secobarbital Sodium)	SS				

Date:06/04/03ISR Number: 4124280-5Report Type:Expedited (15-DaCompany Report #B0300446A
Age:77 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature Health Professional	Wellbutrin (Formulation Unknown) (Bupropion					

			Hydrochloride)	PS			ORAL
ORAL							
			Nifedipine (Formulation Unknown) (Nifedipine)	SS			ORAL
ORAL							
			Tolcapone (Formulation Unknown) (Tolcapone)	SS			

Date:06/04/03ISR Number: 4124281-7Report Type:Expedited (15-DaCompany Report #B0300447A
Age:47 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest	Literature Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		
			Theophylline (Formulation Unknown) (Theophylline)	SS		ORAL
ORAL						
			Vancomycin (Formulation Unknown) (Vancomycin)	SS		

Date:06/04/03ISR Number: 4124284-2Report Type:Expedited (15-DaCompany Report #B0300507A
Age:29 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Ethanol (Formulation Unknown) (Alcohol)	SS		
			Sibutramine Hydrochloride			

			(Formulation Unknown) (Sibutramine	SS			

Date:06/04/03ISR Number: 4124285-4Report Type:Expedited (15-DaCompany Report #B0300503A
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Overdose	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Olanzapine (Formulation Unknown) (Olanzapine)	SS				
			Fluoxetine (Formulation Unknonw) (Fluoxetine)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/03ISR Number: 4124288-XReport Type:Expedited (15-DaCompany Report #B0300502A
Age:57 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin					
		Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Olanzapine (Formulation Unknown) (Olanzapine)	SS				
			Gabapentin (Formulation Unknown) (Gabapentin)	SS				

Date:06/04/03ISR Number: 4124290-8Report Type:Expedited (15-DaCompany Report #B0300506A
Age:35 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin					
		Health Professional	(Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Fluvoxamine (Formulation Unknown) (Fluvoxamine)	SS				
			Olanzapine (Formulation Unknown) (Olanzapine)	SS				

Date:06/04/03ISR Number: 4124294-5Report Type:Expedited (15-DaCompany Report #B0300510A
Age:41 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardio-Respiratory Arrest Completed Suicide	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS	ORAL	ORAL

Date:06/04/03ISR Number: 4124295-7Report Type:Expedited (15-DaCompany Report #B0300511A
Age:24 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Completed Suicide	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:06/04/03ISR Number: 4124296-9Report Type:Expedited (15-DaCompany Report #B0300509A
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source
Death	Completed Suicide	Literature Health

Professional

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	

Date:06/04/03ISR Number: 4124297-0Report Type:Expedited (15-DaCompany Report #B0300504A
Age:40 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Olanzapine (Formulation Unknown) (Olanzapine)	SS				

Date:06/04/03ISR Number: 4124298-2Report Type:Expedited (15-DaCompany Report #B0300505A
Age:41 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature Health Professional	Wellbutrin (Bupropion Hydorchloride)	PS		ORAL	ORAL	
			Imipramine (Imipramine)	SS				
			Despiramine (Desipramine)	SS				

Date:06/04/03ISR Number: 4124414-2Report Type:Expedited (15-DaCompany Report #2003022495
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar I Disorder Condition Aggravated Dizziness Drug Ineffective Drug Interaction Fall Mania Nausea	Consumer	Antivert (Meclizine)(Meclizine)	PS		ORAL	25 MG (DAILY), ORAL	
			Metaxalone (Metaxalone)	SS				
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS				
			Olanzapine (Olanzapine)	C				
			Rabeprazole Sodium (Rabeprazole Sodium)	C				
			Trazodone (Trazodone)	C				
			Thyroid (Thyroid)	C				
			All Other Non-Therapeutic Products	C				
			Montelukast Sodium (Montelukast Sodium)	C				

Clopidogrel Sulfate (Clopidogrel Sulfate)	C
Potassium Chloride (Potassium Chloride)	C
Aporex (Paracetamol, Dextropropoxyphene Hydrochloride)	C
Allegra-D - Slow Release (Pseudoephedrine Hydrochloride, Fexofenadine	C
Lomotil (Atropine Sulfate Diphenoxylate Hydrochloride)	C
Doxazosin (Doxazosin)	C
Valdecoxib (Valdecoxib)	C
Estradiol (Estradiol)	C
Sertraline Hydrochloride (Sertraline Hydrochloride)	C
Ginkgo Biloba (Ginkgo Biloba)	C
Lamotrigine (Lamotrigine)	C
Deloratadine (Desloratadine)	C
Ubidecarenone (Ubidecarenone)	C
Furosemide (Furosemide)	C
Estradiol (Estradiol)	C
Budesonide (Budesonide)	C
Baclofen (Baclofen)	C
Tramdol Hydrochloride (Tramadol Hydrochloride)	C
Librax	

				(Chlordiazepoxide Hydrochloride, Clidinium Bromide)	C			
				All Other Therapeutic Products	C			

Date:06/04/03ISR Number: 4124509-3Report Type:Expedited (15-DaCompany Report #B0300450A
Age:22 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Completed Suicide	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion					

				Hydrochloride)	PS		ORAL
ORAL							
				Fluoxetine (Formulation Unknown) (Fluoxetine)	SS		

Date:06/04/03ISR Number: 4124511-1Report Type:Expedited (15-DaCompany Report #B0300451A
Age:71 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Wellbutrin			
		Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL						

Date:06/04/03ISR Number: 4124512-3Report Type:Expedited (15-DaCompany Report #B0300452A
Age:28 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Wellbutrin			
		Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL						

Date:06/04/03ISR Number: 4124514-7Report Type:Expedited (15-DaCompany Report #B0300508A
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Wellbutrin			
		Health Professional	Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Ethanol (Formulation Unknown) (Alcohol)	SS		

Date:06/04/03ISR Number: 4124720-1Report Type:Expedited (15-DaCompany Report #B0300294A
Age:32 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin					
		Health	(Bupropion					
		Professional	Hydrochloride)	PS				
			Amitriptyline					
			(Amitriptyline)	SS				
			Haloperidol					
			(Formulation					
			Unknown)					
			(Haloperidol)	SS				

Date:06/05/03ISR Number: 4122959-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0407071A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Health	Wellbutrin	PS	Glaxosmithkline	INTRAVENOUS	150MG Twice	
Other	Hypotension	Professional					per day	
			Blood Transfusion	SS				

				Coreg	C	Glaxosmithkline	
UNKNOWN	6.25MG Twice per day						

Date:06/05/03ISR Number: 4124772-9Report Type:Expedited (15-DaCompany Report #2003023103
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cleft Lip Maternal Drugs Affecting Foetus Pregnancy	Health Professional	Neurontin (Gabapentin)	PS		ORAL	UNKNOWN	(UNKNOWN), ORAL
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS			UNKNOWN	UNKNOWN
			Rizatriptan Benzoate (Rizatriptan Benzoate)	SS			UNKNOWN	UNKNOWN

Date:06/05/03ISR Number: 4125359-4Report Type:Expedited (15-DaCompany Report #B0300490A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Ethanol Increased Bradycardia Brain Death	Literature Health Professional	Wellbutrin (Formulation Unknown) (Bupropion					

	Cardiac Arrest		Hydrochloride)	PS		ORAL
9 GRAM(S)/						
	Coma					
SINGLE DOSE/						
	Completed Suicide					
ORAL						
	Gastritis Haemorrhagic		Ethanol (Formulation			
	Grand Mal Convulsion		Unknown)(Alcohol)	SS		
	Hypotension					
	Intentional Misuse					
	Intestinal Ischaemia					
	Pneumonia Aspiration					
	Vomiting					

Date:06/05/03ISR Number: 4125459-9Report Type:Expedited (15-DaCompany Report #03-414-968-01
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Grand Mal Convulsion	Health	Fluvoxamine Maleate			
Intervention to		Professional	Tablets 50 Mg	PS		ORAL
1 TAB DAILY						
Prevent Permanent						
PO						
Impairment/Damage			Wellbutrin 100 Mg	SS		ORAL
1 TAB 3 TIMES						
A DAY PO						
			Vivactil 5 Mg	SS		ORAL
1 TAB 2 TIMES						
A DAY PO						
			Wellbutrin	C		
			Vivactil	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/03ISR Number: 4123709-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0398921A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse		Wellbutrin	PS	Glaxosmithkline	ORAL	45000MG See	
Hospitalization -	Somnolence						dosage text	
Initial or Prolonged	Tachycardia		Heroin	SS				
			Cocaine	SS				
			Valium	SS				

Date:06/09/03ISR Number: 4124549-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0411195A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Bupropion	PS	Glaxosmithkline	ORAL	1000MG Per	
Initial or Prolonged	Confusional State						day	
	Mania							
	Panic Attack							
	Prescribed Overdose							
	Tremor							

Date:06/09/03ISR Number: 4124550-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0411263A
Age:18 MON Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accidental Exposure		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Single	
Initial or Prolonged							dose	

Date:06/09/03ISR Number: 4124551-2Report Type:Expedited (15-DaCompany Report #SK-GLAXOSMITHKLINE-B0118186A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	9 DAY
	Areflexia							
	Feeling Abnormal							
	Hemiparesis							
	Hypoaesthesia							
	Nervousness							

Date:06/09/03ISR Number: 4124556-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0301370A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	27 DAY
Initial or Prolonged	Psoriasis		Kardegic	C		ORAL		
	Rash Pustular		Praxilene	C		ORAL		
			Colchimax	C		ORAL		

Date:06/09/03ISR Number: 4125431-9Report Type:Direct Company Report #CTU 195299
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Buproprion Sr 150mg	PS		ORAL	150MG QD ORAL	
	Drug Exposure Via Breast Milk							
	Postictal State							
	Restlessness							

Date:06/09/03ISR Number: 4126148-7Report Type:Expedited (15-DaCompany Report #B0300536A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination, Auditory	Study	Wellbutrin(Formulation Unknown)(Bupropion Hydrochloride)	PS				
Required Intervention to Prevent Permanent Impairment/Damage	Psychiatric Evaluation	Literature	Valproate Sodium	C				
	Abnormal	Health Professional	Risperidone	C				
			Perphenazine	C				

Date:06/10/03ISR Number: 4127715-7Report Type:Expedited (15-DaCompany Report #S03-USA-02425-01
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health Professional	Lexapro (Escitalopram)	PS		ORAL	10 MG QAM PO	
	Grand Mal Convulsion							
	Injury	Company Representative	Wellbutrin - Slow Release (Bupropion Hydrochloride)	SS			150 MG BID	
	Libido Decreased							
			Wellbutrin (Bupropion Hydrochloride)	SS			100 MG QD	

Date:06/11/03ISR Number: 4126384-XReport Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0372234B
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Drug Exposure During Pregnancy		Bupropion	PS	Glaxosmithkline			
	Finger Deformity							

Date:06/11/03ISR Number: 4126392-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0411383A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Drug Exposure During Pregnancy Maternal Drugs Affecting Foetus		Bupropion	PS	Glaxosmithkline	ORAL	300MG per day	

Date:06/11/03ISR Number: 4126396-6Report Type:Expedited (15-DaCompany Report #SG-GLAXOSMITHKLINE-B0294984A
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization - Initial or Prolonged	Accident Activated Partial Thromboplastin Time Prolonged Alanine Aminotransferase Increased Apoptosis Ascites Aspartate Aminotransferase

		Increased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Creatinine Increased		Bupropion Hydrochloride	PS	Glaxosmithkline	
UNKNOWN	150MG per day 10 DAY						
		Cholestasis		Carbimazole	SS		
UNKNOWN	15MG per day 5 YR						
		Coagulopathy		Propranolol	C		
UNKNOWN	10MG per day 5 YR						
		Condition Aggravated		Paracetamol	C	Glaxosmithkline	
UNKNOWN	2 DAY						
		Dialysis Disseminated Intravascular Coagulation Dyspepsia Encephalopathy Epigastric Discomfort Granuloma Haemoglobin Decreased Hepatic Failure Hepatic Trauma Hepatorenal Syndrome Hypertrophy Hypokalaemia Hyponatraemia Hypotension Insomnia Intra-Abdominal Haemorrhage Jaundice Lethargy Metabolic Acidosis Mouth Haemorrhage Nausea Necrosis Prothrombin Time Prolonged Pulmonary Haemorrhage Pulmonary Oedema Rash Rectal Haemorrhage Refusal Of Treatment By Patient Renal Impairment Sepsis		Alcohol	C		ORAL

Urine Output Decreased

Date:06/11/03ISR Number: 4126399-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0299299A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	4 DAY
	Dilatation Ventricular							
	Hypertension							

Date:06/11/03ISR Number: 4126464-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0403696A
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Other	Deafness Neurosensory
	Dysphonia
	Speech Disorder

Tremor

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Wellbutrin Sr	PS	Glaxosmithkline			
			Paxil	SS	Glaxosmithkline	ORAL		
			Remeron	SS				
			Lopressor	C		ORAL	12.5MG Per	day
			Lorazepam	C		ORAL	.5MG As	required

Date:06/12/03ISR Number: 4127889-8Report Type:Expedited (15-DaCompany Report #FLUV00203001421
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health	Luvox (Fluvoxamine					
	Grand Mal Convulsion	Professional	Maleate)	PS		ORAL	50 MG DAILY	PO
			Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL	100 MG TID PO	
			Vivactil (Protriptyline Hydrochloride)	SS		ORAL	5 MG BID PO	

Date:06/12/03ISR Number: 4127898-9Report Type:Expedited (15-DaCompany Report #B0300447A US
Age:47 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Bupropion					
	Drug Level Above		Hydrochloride	PS				

	Therapeutic		Theophylline	SS		ORAL
ORAL						
			Vancomycin	SS		

Date:06/12/03ISR Number: 4129143-7Report Type:Expedited (15-DaCompany Report #B0300536A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Hallucination, Auditory	Study Literature Health Professional	Bupropion Hydrochloride	PS		
			Valproate Sodium	C		
			Risperidone	C		
			Perphenazine	C		

Date:06/13/03ISR Number: 4127904-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0412053A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice Other per day 2 DAY						
			Xanax	C		ORAL
			Klonopin	C		ORAL
			Zoloft	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/03ISR Number: 4127905-3Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0295743A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	19 DAY
	Drug Interaction							
	Epilepsy		Trimipramine	SS		ORAL	25MG per day	
	Headache		Methotrimeprazine	SS		ORAL	5MG Per day	
	Loss Of Consciousness		Moclobemide	SS		ORAL	150MG Twice per day	
	Muscle Spasms							
	Salivary Hypersecretion		Alprazolam	C		ORAL	2MG per day	
	Tongue Biting							

Date:06/13/03ISR Number: 4127915-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0301595A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	10 DAY
	Complications Of Maternal		Noroxine	SS	Glaxosmithkline	ORAL		11 DAY
	Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							
	Pregnancy							

Date:06/13/03ISR Number: 4127918-1Report Type:Expedited (15-DaCompany Report #NZ-GLAXOSMITHKLINE-B0301669A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	

	Complications Of Maternal Exposure To Therapeutic Drugs
	Maternal Drugs Affecting Foetus
	Pregnancy

Date:06/13/03ISR Number: 4127920-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0301731A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour	Health	Zyban	PS	Glaxosmithkline	ORAL	2TABS per day	4 WK
Hospitalization - Initial or Prolonged	Amnesia	Professional	Alcohol	SS				
	Head Banging		Temazepam	SS				
	Overdose							
	Suicide Attempt							

Date:06/13/03ISR Number: 4127923-5Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0038838A
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Disability	Aggression
Other	Anxiety
	Bipolar Disorder
	Crying
	Depression
	Diarrhoea
	Disturbance In Attention

Emotional Disorder						
Fatigue						
Gastrointestinal Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hyperhidrosis	Other	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 6 WK
Hypomania		Seroxat	SS	Glaxosmithkline		UNKNOWN 92 DAY
Illusion		Sortis	C		ORAL	
Migraine		Diclo	C	Glaxosmithkline		INTRAMUSCULAR
Nausea		Dexa-Phlogont	C			INTRAMUSCULAR
Nervousness		Perenterol	C		ORAL	
Pain In Extremity		Mutaflor	C		ORAL	
Palpitations						
Panic Reaction						
Restlessness						
Retching						
Sleep Disorder						
Suicidal Ideation						
Tachycardia						
Tongue Disorder						
Vertigo						
Weight Decreased						

Date:06/13/03ISR Number: 4138044-XReport Type:Periodic Company Report #A0364417A
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypersensitivity	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ ORAL
			Ethanol	C			

Date:06/13/03ISR Number: 4138045-1Report Type:Periodic Company Report #A0173731A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypersensitivity	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ ORAL	

Date:06/13/03ISR Number: 4138046-3Report Type:Periodic Company Report #A0402681A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	/PER DAY/ ORAL	

Date:06/13/03ISR Number: 4138047-5Report Type:Periodic Company Report #A0375316A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to								

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/	ORAL

Date:06/13/03ISR Number: 4138048-7Report Type:Periodic Company Report #A0371219A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Pain Pruritus Rash Swelling	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/	ORAL

Date:06/13/03ISR Number: 4138049-9Report Type:Periodic Company Report #A0370912A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Discomfort Chest Pain	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/	ORAL

Date:06/13/03ISR Number: 4138050-5Report Type:Periodic Company Report #A0370366A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Reaction	Health	Zyban Tablet-Zyban					

Initial or Prolonged		Professional	(Bupropion Hydrochloride)	PS		ORAL

150 MG/TWICE

PER DAY/ ORAL

Date:06/13/03ISR Number: 4138051-7Report Type:Periodic Company Report #A0369803A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Enzymes Increased Chest Pain	Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL

ORAL

Date:06/13/03ISR Number: 4138052-9Report Type:Periodic Company Report #A0367670A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required Intervention to Prevent Permanent Impairment/Damage	Serum Sickness	Health Professional Company Representative	Zyban Tablet-Zyban (Bupropion Hydrochloride) Ibuprofen	PS C		ORAL

150 MG/ ORAL WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/03ISR Number: 4138053-0Report Type:Periodic Company Report #A0364417A
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypersensitivity	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/	
			Ethanol	C				

Date:06/13/03ISR Number: 4138054-2Report Type:Periodic Company Report #A0173731A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypersensitivity	Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/	

Date:06/16/03ISR Number: 4128942-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0412212A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 MON
	Drug Abuser		Ultram	SS		ORAL	50MG See dosage text	YR
	Overdose							

Date:06/16/03ISR Number: 4128948-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0300655A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Balance Disorder Chorea Coordination Abnormal Dysarthria Hallucinations, Mixed Overdose Suicide Attempt Tremor	Consumer	Zyban Xanax	PS C	Glaxosmithkline	ORAL	3.7G per day 6.25MG per day	1 DAY 1 DAY

Date:06/16/03ISR Number: 4128951-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0301940A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brief Psychotic Disorder With Marked Stressors		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY

Date:06/16/03ISR Number: 4128952-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0301984A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Cerebral Haemorrhage Coma Ruptured Cerebral Aneurysm		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/16/03ISR Number: 4128953-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0302002A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative Epidermal Necrosis Inflammation Leukocytosis Pyrexia Rash Papular Rash Psoriaform Rash Pustular Toxic Skin Eruption		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	22 DAY

Date:06/16/03ISR Number: 4130322-3Report Type:Expedited (15-DaCompany Report #200318842BWH
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Diarrhoea Enterocolitis Haemorrhagic Rash	Health Professional Other	Cipro (Ciprofloxacin Hydrochloride)	PS				
			Wellbutrin Sr (Amfebutamone Hydrochloride)	SS		ORAL	100 MG, TOTAL	
							DAILY, ORAL	
			Metronidazole	SS				

Date:06/17/03ISR Number: 4129951-2Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0296637A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aptyalism Electrocardiogram Qt Prolonged Intentional Misuse Poisoning Somnolence	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	
			Norethisterone + Ethinyloestradiol	C		ORAL		

	Speech Disorder
	Tachycardia
	Tremor

Date:06/17/03ISR Number: 4130575-1Report Type:Direct Company Report #CTU 196033
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Stevens-Johnson Syndrome		Zyban (150 Mg)	PS			SEE IMAGE	3 MON
Hospitalization - Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:06/17/03ISR Number: 4131180-3Report Type:Expedited (15-DaCompany Report #03P-163-0221247-00
Age:41 YR Gender: I/FU:I

Outcome	PT	Report Source
Death	Completed Suicide	Literature
	Multiple Drug Overdose	Health

Professional

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Imipramine (Janimine) (Imipramine Hcl)					
			(Imipramine Hcl)	PS				
			Bupropion	SS				
			Desipramine	SS				

Date:06/17/03ISR Number: 4131528-XReport Type:Expedited (15-DaCompany Report #2003009863
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Complications Of Maternal	Health	Geodon (Ziprasidone)	PS			120 MG (BID)	
Other	Exposure To Therapeutic Drugs	Professional Company	Bupropion Hydrochloride					
	Congenital Central Nervous System Anomaly	Representative	(Bupropion Hydrochloride)	SS			UNKNOWN	UNKNOWN
	Congenital Oesophageal Anomaly							
	Maternal Drugs Affecting Foetus							
	Pregnancy							

Date:06/18/03ISR Number: 4131092-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0399473A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
	Intentional Misuse	Professional						
	Thermal Burn							

Date:06/18/03ISR Number: 4131093-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0403504A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Dysphemia	Professional	Zoloft	SS				
	Energy Increased							
	Feeling Jittery							
	Speech Disorder							

Date:06/18/03ISR Number: 4131208-0Report Type:Direct Company Report #CTU 196062
Age:32 YR Gender:Female I/FU:I

Outcome	PT
Other	Activities Of Daily Living Impaired
	Amnesia
	Attention Deficit/Hyperactivity Disorder
	Brain Damage
	Drug Ineffective
	Dyslexia
	Fear

	Judgement Impaired					
	Memory Impairment					
	Speech Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Sr	PS		OTHER
150 MG 2 X						
DAY OTHER						

Date:06/19/03ISR Number: 4131494-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402911A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
200MG Unknown						
Initial or Prolonged	Encephalopathy		Antiepileptic Agent	C		
Other	Intentional Misuse					
	Suicide Attempt					
	Tachycardia					

Date:06/20/03ISR Number: 4132301-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0371291A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Confusional State	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL
600MG per day	2 YR					
	Convulsion		Lamictal	SS	Glaxosmithkline	ORAL
	Crying		Wellbutrin	SS	Glaxosmithkline	ORAL
	Dysgeusia		Pain Medication	SS		ORAL
	Emotional Disorder		Klonopin	C		ORAL
	Gastric Disorder		Lorazepam	C		
	Head Injury		Ortho Tri-Cyclen	C		ORAL
	Insomnia					
	Mental Impairment					
	Nausea					
	Prescribed Overdose					
	Rash					
	Rash Psoriaform					
	Road Traffic Accident					
	Temporal Lobe Epilepsy					
	Vaginal Infection					

Vaginal Mycosis
Vomiting
Weight Decreased

Date:06/20/03ISR Number: 4132302-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0393612A
Age:4 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	112MG Twice per day	1 MON
			Benadryl	SS	Glaxosmithkline			1 DAY
			Salbutamol	SS	Glaxosmithkline			

Date:06/20/03ISR Number: 4132304-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402428A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Paxil	SS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/03ISR Number: 4132414-1Report Type:Expedited (15-DaCompany Report #US-ROCHE-339787
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acidosis		Klonopin	PS	Roche	ORAL	15 TABLETS.	
Initial or Prolonged	Arrhythmia		Wellbutrin Sr	SS		ORAL	15-20	
	Drug Screen Positive						TABLETS.	
	Electrocardiogram Qrs		Geodon	SS		ORAL	120 TABLETS.	
	Complex Prolonged		Ativan	SS		ORAL	4 TABLETS.	
	Electrocardiogram Qt Prolonged							
	Hyperventilation							
	Lethargy							
	Multiple Drug Overdose							
	Somnolence							

Date:06/23/03ISR Number: 4132926-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0402594A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Level Increased		Paxil	SS	Glaxosmithkline	ORAL		
	Intentional Misuse		Benadryl	C	Glaxosmithkline			
			Doxylamine	C				
			Celexa	C				

Date:06/23/03ISR Number: 4132927-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0410340A
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Bupropion	PS	Glaxosmithkline	ORAL	100MG Per day	27 DAY
Hospitalization -	Diarrhoea		Flagyl	SS	Glaxosmithkline	ORAL	4	DAY

Initial or Prolonged	Enterocolitis		Cipro	SS		ORAL
3 DAY						
Other	Haemorrhagic					
	Giardiasis					
	Rash					
	Rectal Haemorrhage					

Date:06/23/03ISR Number: 4132935-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0302412A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Parapsoriasis		Bupropion	PS	Glaxosmithkline	ORAL
150MG Twice						
per day 32 DAY						
			Cipramil	C		ORAL
20MG per day						
			Terbutaline	C		
RESPIRATORY						
(INHALATION) 500MCG per						
day						

Date:06/23/03ISR Number: 4134315-1Report Type:Direct Company Report #CTU 196325
Age:36 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Aggression
Initial or Prolonged	Anger
Other	Anxiety
	Depression
	Dizziness

	Feeling Abnormal Mental Disorder Personality Change	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Restlessness		Wellbutrin Sr 150 Mg Tablets Glaxo Wellcome	PS	Glaxowellcome	
1 TABLE						
TWICE DAILY						

Date:06/24/03ISR Number: 4133949-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0302485A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Bradycardia	Health	Zyban	PS	Glaxosmithkline	ORAL
12G Single						
Hospitalization -	Coma	Professional				
dose 1 DAY						
Initial or Prolonged	Convulsion		Zyprexa	SS		ORAL
80TAB Single						
	Intentional Misuse					
dose						
	Pyrexia		Imovane	SS		ORAL
	Suicide Attempt					
	Tachycardia					

Date:06/24/03ISR Number: 4134113-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0300451A
Age:71 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide		Zyban	PS	Glaxosmithkline	ORAL

Date:06/24/03ISR Number: 4134114-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0300452A
Age:28 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide		Zyban	PS	Glaxosmithkline	ORAL

Date:06/24/03ISR Number: 4134115-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0300509A
Age:45 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline	ORAL		

Date:06/24/03ISR Number: 4134116-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0300510A
Age:41 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Completed Suicide		Bupropion	PS	Glaxosmithkline	ORAL		

Date:06/24/03ISR Number: 4134117-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0300511A
Age:24 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Completed Suicide		Bupropion	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/03ISR Number: 4134118-8Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0302490A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Leukopenia Neutropenia		Zyban	PS	Glaxosmithkline			

Date:06/25/03ISR Number: 4135074-9Report Type:Direct Company Report #CTU 196594
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other Required Intervention to Prevent Permanent Impairment/Damage	Aggression Alcoholic Dependence Drug Abuser Intermittent Explosive Disorder Legal Problem Physical Assault Suicidal Ideation Verbal Abuse		Paxil 5mg Wellbutrin 150mg	PS SS				

Date:06/25/03ISR Number: 4135182-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0302713A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Confusional State Head Banging Overdose Suicidal Ideation		Zyban No Concurrent Medication	PS C	Glaxosmithkline	ORAL	150MG Twice per day	31 DAY

Date:06/27/03ISR Number: 4136509-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0107035A
Age:18 YR Gender:Male I/FU:F

Outcome	PT

Death	Aggression
	Agitation
	Alcohol Poisoning
	Alcoholism
	Anorexia
	Anxiety
	Asthenia
	Chest Pain
	Completed Suicide
	Depersonalisation
	Depression
	Derealisation
	Dissociation
	Disturbance In Attention
	Dizziness
	Drug Abuser
	Dry Mouth
	Fear
	Feeling Abnormal
	Feeling Of Despair
	Head Injury
	Headache
	Hypochondriasis

	Irritability						
	Loss Of Consciousness						
	Mania	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Mental Disorder	Health	Zyban	PS	Glaxosmithkline	ORAL	3 WK
	Mood Swings	Professional	Chloroquine	C			37.5MG per day
	Obsessive-Compulsive						
	Personality Disorder						
	Palpitations						
	Personality Change						
	Psychiatric Symptom						
	Restlessness						
	Social Avoidant Behaviour						
	Treatment Noncompliance						
	Vision Blurred						

Date:06/27/03ISR Number: 4136526-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0302778A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Acute Respiratory		Zyban	PS	Glaxosmithkline		150MG Twice per day 3 WK
	Distress Syndrome						
	Convulsion		Methotrexate	C			
	Dermatomyositis		Corticosteroids	C			
	Renal Failure		Cyclophosphamide	C			

Date:06/27/03ISR Number: 4139048-3Report Type:Expedited (15-DaCompany Report #200301196
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blood Creatinine Abnormal	Consumer	Extra Strength				
	Blood Urea Abnormal	Other	Tylenol Product	PS		ORAL	500 MG BID PO
	Hypokalaemia		Wellbutrin	SS		ORAL	100 MG TID PO
	Renal Injury		Tylenol Arthritis				

				Pain Er Caplet 650 Mg/Caplet	SS		ORAL

1300 MG BID

PO

Date:06/30/03ISR Number: 4147697-1Report Type:Periodic Company Report #A211395
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Serotonin Syndrome	Health Professional	Zoloft (Sertraline) (Sertraline Hydrochloride)	PS		ORAL	125 MG (DAILY), ORAL
			Wellbutrin (Bupropion) (Bupropion Hydrochloride)	SS		ORAL	150 MG (DAILY), ORAL

Date:06/30/03ISR Number: 4148626-7Report Type:Periodic Company Report #2002066465
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion	Health Professional	Sertraline (Sertraline)	PS		ORAL	200 MG (BID),

ORAL						
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS		ORAL
300 MG (BID),						
ORAL						
			Olanzapine (Olanzapine)	SS		ORAL
5 MG (BID),						
ORAL						
			Allegra-D (Pseudoephedrine Hydrochloride, Fexofenadine)	SS		ORAL
(BID), ORAL						
			Minocycline (Minocycline)	SS		
200 MG (BID						

Date:07/01/03ISR Number: 4138565-XReport Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0414180A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Irritable Bowel Syndrome Nausea Vomiting		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:07/01/03ISR Number: 4138566-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0296280A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased	Health Professional	Zyban Soprol	PS C	Glaxosmithkline	ORAL ORAL	150MG Unknown .5TAB Per day	23 DAY

Other	Capillary Disorder		Microval	C	ORAL
	Dermatomyositis				
	Erythema				
	Myalgia				
	Skin Ulcer				

Date:07/01/03ISR Number: 4138873-2Report Type:Direct Company Report #CTU 196958
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Convulsion		Bupropion 100mg Tab	PS		ORAL	300MG PO QAM
Intervention to	Fall		Oxycodone	C			
Prevent Permanent	Head Injury		Mvi	C			
Impairment/Damage	Loss Of Consciousness		Trazodone	C			
	Memory Impairment		Lorazepam	C			
	Tremor		Daypro	C			
			Nicotine Patch	C			
			Hctz	C			
			Felodipine	C			

Date:07/01/03ISR Number: 4140406-1Report Type:Expedited (15-DaCompany Report #2003165781US
Age:74 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability	PT	Report Source	Product	Role	Manufacturer	Route
Required Intervention to Prevent Permanent Impairment/Damage	Condition Aggravated Diarrhoea Enterocolitis Haemorrhagic Rash	Health Professional	Flagyl(Metronidazole) Tablet Wellbutrin - Slow Release(Amfebutamone Hydrochloride) Ciprofloxacin Hydrochloride(Ciprofloxacin Hydrochloride)	PS SS SS		ORAL

Dose: 100 MG, QD, ORAL

Date:07/02/03ISR Number: 4139571-1Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0414404A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus		Bupropion	PS	Glaxosmithkline	

Date:07/02/03ISR Number: 4139572-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0414610A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Fall Mental Status Changes Psychotic Disorder		Wellbutrin Mellaril	PS C	Glaxosmithkline	ORAL

Dose: 150MG Twice per day Duration: 2 WK

Date:07/02/03ISR Number: 4139573-5Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0414773A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		300MG per day	
	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus		Dexedrine	C	Glaxosmithkline			

Date:07/03/03ISR Number: 4141767-XReport Type:Direct Company Report #CTU 197234
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin 100mg Bid	PS		ORAL	100MG BID PO	

Date:07/07/03ISR Number: 4142114-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0405398A
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Lethargy Medication Error

	Prescribed Overdose Sensation Of Heaviness Tremor	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Visual Disturbance	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Three times per day
			Trazodone	C			
			Zyprexa	C			
			Zolpidem	C			
			Colace	C			
			Iron	C			
			Vicodin	C			
			Motrin	C	Glaxosmithkline		

Date:07/07/03ISR Number: 4142115-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0410077A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day 8 MON
			Cocaine	SS			UNKNOWN

Date:07/07/03ISR Number: 4142140-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0302485A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization -	Atrioventricular Block Bradycardia	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	12G Single dose 1 DAY
Initial or Prolonged	Coma		Zyprexa	SS		ORAL	80TAB Single dose
	Convulsion Drug Ineffective Intentional Misuse		Imovane	SS		ORAL	

	Pyrexia
	Suicide Attempt
	Supraventricular
	Tachycardia

Date:07/07/03ISR Number: 4142145-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0303164A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline			
UNKNOWN							150MG per day	29 DAY
	Depression		Modecate	C				
INTRAMUSCULAR							25MG per day	
	Drug Ineffective		Kliofem	C				
UNKNOWN								
	Drug Withdrawal Syndrome		Diazepam	C		ORAL		
10MG Three times per day								
			Procyclidine	C	Glaxosmithkline	ORAL		
5MG Three times per day								

Date:07/07/03ISR Number: 4142149-7Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0041169A
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Diabetes Mellitus
	Fatigue
	Hepatitis B
	Jaundice

Ocular Icterus

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Zyban	PS	Glaxosmithkline	ORAL
1TAB Per day						

Date:07/07/03ISR Number: 4144601-7Report Type:Expedited (15-DaCompany Report #HQWYE509309JUN03
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Arrhythmia	Literature	Ativan (Lorazepam, Tablet)	PS		ORAL
4 TABLETS OF 0.5 MG (2MG) OVERDOSE	Cardiotoxicity					
	Depressed Level Of Consciousness					
AMOUNT, ORAL 1 DAY	Drug Screen Positive					
	Electrocardiogram Qrs Complex Prolonged		Clonazepam (Clonazepam)	SS		ORAL
15 TABLETS OF 0.5 MG (7.5 MG) OVERDOSE	Electrocardiogram Qt Corrected Interval Prolonged					
AMOUNT, ORAL 1 DAY	Intentional Misuse		Geodon (Ziprasidone)	SS		ORAL
120 TABLETS OF 20 MG (2400 MG) OVERDOSE	Lethargy					
	Somnolence					
AMOUNT, ORAL 1 DAY						
			Wellbutrin-Slow Release (Amfebutamone Hydrochloride)	SS		ORAL
15-20 TABLETS						

OF 150 MG,

OVERDOSE

AMOUNT, ORAL 1 DAY

Date:07/08/03ISR Number: 4142995-XReport Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0302778A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome	Health Professional	Zyban	PS	Glaxosmithkline		150MG Twice per day	3 WK
	Convulsion		Methotrexate	C				
	Dermatomyositis		Corticosteroids	C				
	Renal Failure		Cyclophosphamide	C				
			Pain Killers	C				

Date:07/08/03ISR Number: 4143272-3Report Type:Direct Company Report #CTU 197451
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Wellbutrin Sr 150mg	PS		ORAL	150MG 2 TIMES	

ORAL

Date:07/08/03ISR Number: 4155402-8Report Type:Direct Company Report #CTU 198780
Age:46 YR Gender:Male I/FU:I

Outcome	PT
Other	Carpal Tunnel Syndrome
	Muscle Spasms
	Pharmaceutical Product

	Complaint Pharyngolaryngeal Pain						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Bupropion 100mg Teva	PS	Teva	ORAL	100 MG 3 TIMES/ ORAL

Date:07/09/03ISR Number: 4143780-5Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0415583A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dementia Hepatomegaly		Zyban	PS	Glaxosmithkline	ORAL	

Date:07/10/03ISR Number: 4144474-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0297338A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Ageusia	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG See
Other	Aggression Agitation Akathisia Asthenia Confusional State Depression Excitability Hyposmia Insomnia Mood Altered Muscle Twitching Somnolence Suicidal Ideation	Professional	Oligosol(S)	C		ORAL	dosage text 36 DAY

Date:07/10/03ISR Number: 4146700-2Report Type:Expedited (15-DaCompany Report #2003-04-4611
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Lotrisone (Clotrimazole/Betamethasone Dipropionate) Cream	PS		TRANSDERMAL	TOP-DERM	
	Difficulty In Walking							
	Drug Toxicity							
	Feeling Abnormal							
	Hyperhidrosis		Zoloft	SS				
	Hypoaesthesia		Wellbutrin (Bupropion)	SS				
	Loss Of Consciousness		Valium	C				
	Mania							
	Middle Insomnia							
	Nervous System Disorder							
	Pain							
	Rash							
	Tinnitus							
	Weight Increased							

Date:07/14/03ISR Number: 4146088-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0415814A
Age:58 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation
	Anxiety

		Back Pain					
		Crying					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective		Paxil	PS	Glaxosmithkline	ORAL
		Drug Withdrawal Syndrome		Wellbutrin Sr	SS	Glaxosmithkline	
		Fatigue					
		Feeling Abnormal					
		Feeling Hot And Cold					
		Headache					
		Hyperhidrosis					
		Insomnia					
		Irritability					
		Mental Disorder					
		Muscle Spasms					
		Nausea					
		Nightmare					
		Tremor					
		Vertigo					

Date:07/14/03ISR Number: 4146176-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0411832A
Age:37 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Three							
		Grand Mal Convulsion					
times per day	3 MON						
				Luvox	SS		ORAL
50MG Per day	26 DAY						
				Vivactil	SS		ORAL
5MG Twice per							
day							

Date:07/14/03ISR Number: 4146178-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0414404A
Age:33 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL
		Complications Of Maternal					

	Exposure To Therapeutic
	Drugs
	Maternal Drugs Affecting
	Foetus
	Premature Menopause

Date:07/15/03ISR Number: 4147153-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0380991A
Age:30 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anxiety
Disability	Asthenia
	Cold Sweat
	Crying
	Depression
	Diarrhoea
	Disability
	Disturbance In Attention
	Dizziness
	Drug Ineffective
	Energy Increased
	Faeces Discoloured

	Feeling Abnormal					
	Headache					
	Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Insomnia		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day						
	Mood Swings		Xanax	C		
	Muscle Spasms		Pepcid	C		
	Panic Attack		Nexium	C		
	Paranoia		Ativan	C		
	Pyrexia		Zyprexa	C		
	Tremor		Serzone	C		
	Vomiting		Gabitril	C		
	Weight Decreased					

Date:07/15/03ISR Number: 4147154-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395212A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Amnesia	Other	Wellbutrin	PS	Glaxosmithkline	ORAL
50MG Twice						
	Convulsion					
per day						
	Disability					
	Fall					
	Grand Mal Convulsion					

Date:07/15/03ISR Number: 4147155-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0404161A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Carcinoid Syndrome	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
	Phaeochromocytoma	Professional				

Date:07/15/03ISR Number: 4147161-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0290894A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Life-Threatening	Asthenia	Health	Zyban	PS	Glaxosmithkline	ORAL
81 DAY						
Hospitalization -	Blood Glucose	Professional	Aspirin	C	Glaxosmithkline	
UNKNOWN 1TAB per day						
Initial or Prolonged	Central Nervous System		Antibiotics	C		
UNKNOWN						
Other	Mass		Alcohol	C		
	Convulsion					
	Dizziness					
	Gliosarcoma					
	Glycosuria					
	Haematuria					
	Headache					
	Nausea					
	Somnolence					
	Ventricular Tachycardia					
	Vomiting					

Date:07/15/03ISR Number: 4147165-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0303269A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Difficulty In Walking		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
	Gout					
per day						
			Allopurinol + Benzbromarone	C		ORAL
30MG per day YR						

			Felodipine	C		ORAL
5MG per day	YR					
			Indapamide	C		ORAL
2.5MG per day	YR					
			Prazosin	C		ORAL
1MG per day	YR					
			Simvastatin	C		
UNKNOWN						
			Lipitor	C		ORAL
20MG per day	YR					

Date:07/17/03ISR Number: 4150924-8Report Type:Expedited (15-DaCompany Report #2003-04-4611
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Consumer	Lotrisone (Clotrimazole/Betamethasone Dipropionate) Cream	PS		
	Hyperhidrosis					
	Loss Of Consciousness					
	Mania					
TOPICAL TOP-DERM						
	Nervous System Disorder		Zoloft	SS		
	Weight Increased		Wellbutrin (Bupropion)	SS		
			Valium	C		

Date:07/17/03ISR Number: 4194548-5Report Type:Periodic Company Report #HQ4699818OCT2002
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dermatitis	Consumer	Advil (Ibuprofen, Capsule, Soft Gelatin)	PS		ORAL
	Urticaria					
ORAL						
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride,)	SS		ORAL
150 MG 2X PER						
1 DAY, ORAL						

Date:07/18/03ISR Number: 4149414-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0416863A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antinuclear Antibody		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
	Positive							
	Arthralgia							
	Systemic Lupus Erythematosus							

Date:07/18/03ISR Number: 4149415-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0416890A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline	ORAL	150MG Per day	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Maternal Drugs Affecting Foetus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/03ISR Number: 4149419-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0301731A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Hospitalization -	Amnesia	Professional						
per day							31	DAY
Initial or Prolonged	Confusional State		Alcohol	SS				
Other	Overdose		Temazepam	SS				
	Suicide Attempt		No Concurrent Medication	C				

Date:07/18/03ISR Number: 4149420-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0302713A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Confusional State							
per day							31	DAY
	Head Banging		No Concurrent Medication	C				
	Overdose							
	Suicidal Ideation							

Date:07/18/03ISR Number: 4149424-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0304114A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Follicle		Zyban	PS	Glaxosmithkline	ORAL	21	DAY
	Stimulating Hormone		Microgynon	C		ORAL		
	Decreased		Asthma Medication	C				
	Fatigue							
	Menstruation Irregular							
	Thyroxine Decreased							

Date:07/21/03ISR Number: 4150364-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395212A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	50MG Twice	
	Convulsion						per day	
	Disability		Vicodin	C				
	Fall		Allegra	C				
	Grand Mal Convulsion		Septra Ds	C	Glaxosmithkline			
	Postictal State		Sudafed	C	Glaxosmithkline			
			Nasacort	C				
			Cortisone	C				

Date:07/21/03ISR Number: 4150383-5Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417269A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline	ORAL		
Other			Alcohol	SS				
			Ms Contin	SS	Glaxosmithkline			
			Diphenhydramine	SS				
			Amitriptyline	SS				
			Pamelor	SS				
			Oxazepam	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4150384-7Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417270A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Bupropion	PS	Glaxosmithkline	ORAL		
	Completed Suicide		Ethanol	SS				
	Fall		Zyprexa	SS				
	Intentional Misuse		Nortriptyline	SS				
			Xanax	SS				
			Acetaminophen	SS	Glaxosmithkline			
			Nexium	C				
			Nicorette	C	Glaxosmithkline			

Date:07/21/03ISR Number: 4150385-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417271A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline			
Other	Intentional Misuse		Benadryl	SS	Glaxosmithkline			
	Oedema		Ritalin	SS				
	Pulmonary Congestion		Codeine	SS				
			Acetaminophen	SS	Glaxosmithkline			

Date:07/21/03ISR Number: 4150386-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417272A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline			
Other	Intentional Misuse		Carbon Monoxide	SS				
	Poisoning		Desipramine	SS				

Date:07/21/03ISR Number: 4150403-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0304144A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urinary Retention		Zyban	PS	Glaxosmithkline		150MG Twice	

per day

			Tamsulosin	C		

Date:07/21/03ISR Number: 4152987-2Report Type:Expedited (15-DaCompany Report #200301196
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Abnormal	Consumer	Extra Strength					
	Blood Urea Abnormal	Other	Tylenol Product	PS		ORAL	500 MG BID PO	
	Dysphagia		Wellbutrin	SS		ORAL	100 MG TID PO	
	Gastric Haemorrhage		Tylenol Arthritis					
	Hypokalaemia		Pain Er Caplet					
	Renal Injury		650mg/Caplet	SS		ORAL	1300 MG BID	
							PO	

Date:07/22/03ISR Number: 4151338-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0404175A
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Distension
	Abdominal Pain Upper

	Bladder Cancer					
	Flatulence					
	Tinnitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Lotronex	PS	Glaxosmithkline	ORAL
			Wellbutrin	SS	Glaxosmithkline	ORAL
150MG Twice						
per day						
			Tenormin	C		
			Klonopin	C		
			Claritin	C		
			Serzone	C		
			Estratest	C		

Date:07/22/03ISR Number: 4151341-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0409520A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Jaundice		Wellbutrin	PS	Glaxosmithkline	ORAL
200MG Per day						
	Metastases To Liver		Celexa	C		
	Pancreatic Carcinoma					

Date:07/22/03ISR Number: 4151364-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0304588A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Headache		Zyban	PS	Glaxosmithkline	ORAL
1050MG per						
Initial or Prolonged	Intentional Misuse					
day	1 DAY					
	Suicide Attempt					
	Tremor					
	Vertigo					

Date:07/22/03ISR Number: 4151366-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0304615A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Dyspnoea		No Concurrent Medication	C				

Date:07/22/03ISR Number: 4154581-6Report Type:Expedited (15-DaCompany Report #S03-USA-02189-01
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dry Mouth	Consumer	Celexa (Citalopram Hydrobromide)	PS		ORAL	20 MG QD PO	
	Hepatitis A							
	Pancreatic Carcinoma		Wellbutrin (Buprpion Hydrochloride)	SS			200 MG QD	

Date:07/22/03ISR Number: 4154704-9Report Type:Expedited (15-DaCompany Report #2003029776
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Helicobacter Infection	Health Professional	Zoloft (Sertraline)	PS				
Other	Mental Status Changes		Venlafaxine Hydrochloride (Venlafaxine Hydrochloride)	SS				

			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS		
			Clarithromycin (Clarithromycin)	SS		
			Atorvastatin (Atorvastatin)	C		
			Amoxicillin (Amoxicillin)	C		

Date:07/23/03ISR Number: 4152091-3Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417273A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Bupropion	PS	Glaxosmithkline			
	Coronary Artery Stenosis		Lorazepam	SS				
	Pulmonary Oedema		Cocaine	SS				

Date:07/23/03ISR Number: 4152093-7Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417274A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline			
	Polytraumatism		Flurazepam	SS				
	Road Traffic Accident		Dimenhydrinate	SS				

Date:07/23/03ISR Number: 4152094-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417275A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline			
	Drug Toxicity		Cocaine	SS				
			Hydrodiuril	C				
			Adalat	C	Glaxosmithkline			
			Catapres	C				
			Losec	C				

Date:07/23/03ISR Number: 4152095-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417276A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline			
	Injury Asphyxiation		Alcohol	SS				

Date:07/23/03ISR Number: 4152096-2Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417277A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline			
	Injury Asphyxiation		Alcohol	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/03ISR Number: 4152097-4Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417278A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Drug Level Above Therapeutic		Bupropion	PS	Glaxosmithkline			

Date:07/23/03ISR Number: 4152151-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0417468A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abnormal Behaviour Fatigue Mania		Paxil Wellbutrin Lithium Zyprexa	PS SS SS C	Glaxosmithkline Glaxosmithkline Glaxosmithkline	ORAL ORAL ORAL	40MG Per day 200MG Per day 1200MG Per day	

Date:07/23/03ISR Number: 4154876-6Report Type:Expedited (15-DaCompany Report #USA-2003-0008657
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia Blood Creatinine Blood Potassium Cerebral Ischaemia Dehydration Dysarthria Electrocardiogram Qrs Complex Prolonged Electrocardiogram T Wave Peaked	Study Health Professional Other	Oxycontin Tablets (Oxycodone Hydrochloride) Cr Tablet Oxycodone Hydrochloride (Oxycodone Hydrochloride) Other	PS SS		ORAL ORAL	30 MG, TID, 5 MG, PRN,	

	Electroencephalogram Abnormal Emotional Distress Insomnia		Ambien (Zolpidem Tartrate) Wellbutrin (Amfebutamone Hydrochloride) Investigational Oncology Drug () Neurontin (Gabapentin) Tenormin (Atenolol) Paxil (Paroxetine Hydrochloride) Pamelor (Nortriptyline Hydrochloride)	SS SS SS C C C C		ORAL 10 MG, NOCTE PRN, ORAL ORAL 100 MG, BID, ORAL 361 DAY

Date:07/23/03ISR Number: 4158491-XReport Type:Expedited (15-DaCompany Report #2003-07-1190
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ischaemic Stroke	Foreign Health Professional Other	Viraferonpeg (Peg Interferon Alfa-2b Recombinant) Injectable Solution Rebetol (Ribavirin)	PS		SUBCUTANEOUS	SUBCUTANEOUS	

			Capsules	SS		ORAL	1000 MG QD
							ORAL
			Zyban (Bupropion Hcl)	SS		ORAL	ORAL

Date:07/24/03ISR Number: 4153165-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0386261A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ageusia		Wellbutrin	PS	Glaxosmithkline	ORAL	25	DAY
	Hyperaesthesia		Prozac	C			20MG Per day	
	Weight Decreased							

Date:07/24/03ISR Number: 4153168-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0415390A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abasia		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	DAY
	Arthralgia							
	Bronchospasm							
	Dysphagia							
	Dyspnoea							
	Hypersensitivity							
	Musculoskeletal Stiffness							
	Myalgia							
	Pain							
	Pharyngitis							
	Pharyngolaryngeal Pain							
	Pruritus							
	Rash Generalised							
	Rheumatoid Arthritis							
	Swelling							

Date:07/24/03ISR Number: 4153173-2Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0417279A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline			
	Heart Injury							
	Lung Injury							

Date:07/24/03ISR Number: 4153187-2Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0041169A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	
Initial or Prolonged	Diabetes Mellitus							
	Fatigue							
	Hepatic Cirrhosis							
	Jaundice							
	Ocular Icterus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/03ISR Number: 4153189-6Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0041333A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Zyban	PS	Glaxosmithkline	ORAL	1TABS See	
Initial or Prolonged	Narcolepsy							
dosage text							21	DAY
Disability	Road Traffic Accident		Agopton	C		ORAL	15MG Per day	
	Sleep Attacks							
	Suicidal Ideation							

Date:07/25/03ISR Number: 4154017-5Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0305031A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea Haemorrhagic		Bupropion	PS	Glaxosmithkline		150MG Per day	4 DAY
	Dyspepsia		Serevent	C	Glaxosmithkline		100MCG per	
	Nausea						day	
	Palpitations		Becotide	C	Glaxosmithkline		1200MCG per	
							day	
			Omeprazole	C			40MG per day	

Date:07/28/03ISR Number: 4155157-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0417842A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melanocytic Naevus		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
							per day	1 YR
			Concurrent Medications	C				

Date:07/28/03ISR Number: 4155363-1Report Type:Direct Company Report #CTU 198741
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Memory Impairment		Wellbutrin Sr 150 Mg	PS		ORAL	150 MG 1/DAY	

ORAL

Date:07/28/03ISR Number: 4155366-7Report Type:Direct Company Report #CTU 198743
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Wellbutrin 150 Mg	PS		ORAL	150 DAY ORAL	

Date:07/29/03ISR Number: 4156167-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0418387A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Drug Exposure During Pregnancy		Bupropion	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/03ISR Number: 4156171-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0304591A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	
Initial or Prolonged	Humerus Fracture		Atepadene	C		ORAL		
			Duspatalin	C		ORAL		
			Pentasa	C	Glaxosmithkline	ORAL		

Date:07/29/03ISR Number: 4156180-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0305011A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Zyban	PS	Glaxosmithkline		150MG Twice	
	Joint Dislocation							
per day							30	DAY

Date:07/29/03ISR Number: 4157475-5Report Type:Direct Company Report #CTU 198898
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis		Wellbutrin 100mg Sr	PS		ORAL	ONE PO BID	
	Hypertensive Crisis							

Date:07/29/03ISR Number: 4157491-3Report Type:Direct Company Report #CTU 198887
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban 150mg	PS		ORAL	150MG QD PO	
			Nicotine 4g Gum	SS		ORAL	4MG , INCR TO	
							8 PIECES PER	

DAY PO

Date:07/29/03ISR Number: 4157539-6Report Type:Direct Company Report #CTU 198884
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban 150mg	PS		ORAL	150MG, QD, PO	
			Nicotine 4mg Gum	SS		ORAL	4MG, INCREASED TO 8 PIECES/DAY PO	

Date:07/30/03ISR Number: 4157444-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0405379A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Intentional Self-Injury							
	Obsessive Thoughts							
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/03ISR Number: 4157449-4Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0418052A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Body Temperature Decreased		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	13 DAY
	Chest Pain							
	Dissociation							
	Drug Toxicity							
	Ear Congestion							
	Erythema							
	Hypersensitivity							
	Hypotension							
	Oedema Peripheral							
	Oropharyngeal Swelling							
	Pharyngolaryngeal Pain							
	Pruritus							

Date:07/30/03ISR Number: 4157450-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0418605A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:07/30/03ISR Number: 4157805-4Report Type:Direct Company Report #CTU 198945
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Welbutrin Sr	PS		ORAL	ORAL	

Date:07/30/03ISR Number: 4161035-XReport Type:Expedited (15-DaCompany Report #S03-USA-03156-01
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Aggression	Celexa (Citalopram Hydrobromide)	PS
	Akathisia		
	Depression	Wellbutrin (Bupropion Hydrochloride)	SS
	Euphoric Mood		
	Psychiatric Symptom	Paxil (Paroxetine Hydrochloride)	SS
	Sedation		
	Sexual Abuse		
	Suicidal Ideation		
	Tension		

Date:07/30/03ISR Number: 4161181-0Report Type:Expedited (15-DaCompany Report #A03200300069
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia
	Blood Creatinine
	Blood Potassium
	Cerebral Ischaemia
	Dehydration
	Dysarthria
	Electrocardiogram Qrs Complex Prolonged
	Electrocardiogram T Wave Peaked

	Electroencephalogram Abnormal Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Family Stress Insomnia	Health Professional	Ambien-Zolpidem Tartrate-Tablet-10 Mg	PS		ORAL
10 MG HS-ORAL						
			Investigational Drug	SS		
			Oxycontin-Oxycodone Hydrochloride	SS		ORAL
30 MG TID-ORAL						
			Oxycodone	SS		ORAL
5 MG PRN-ORAL						
			Wellbutrin-Bupropion Hydrochloride	SS		ORAL
100 MG BID-ORAL						
			Gabapentin	C		
			Atenolol	C		
			Paroxetine Hydrochloride	C		
			Nortriptyline Hydrochloride	C		

Date:07/31/03ISR Number: 4158460-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0417863A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebral Ischaemia Dehydration		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice per day 9 DAY						
	Dysarthria Electrocardiogram Qrs		Blinded Trial Medication	SS	Glaxosmithkline	
UNKNOWN						
	Complex Prolonged		Oxycontin	SS		ORAL
30MG Three times per day	Electrocardiogram T Wave					

	Peaked		Oxycodone	SS		ORAL 5MG As
	Electroencephalogram					required
	Abnormal		Ambien	SS		ORAL 10MG At night
	Emotional Distress		Neurontin	C		ORAL 600MG Twice
	Family Stress					per day
	Ill-Defined Disorder		Tenormin	C		ORAL 50MG Per day
	Insomnia		Paxil	C	Glaxosmithkline	ORAL 20MG As
						required
			Pamelor	C		ORAL 50MG At night

Date:08/01/03ISR Number: 4160237-6Report Type:Direct Company Report #CTU 199059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Death	Drug Toxicity		Wellbutrin Sr 100 Mg	PS		ORAL ONE QAM ORAL
			Risperdal 2 Mg Janssen	SS	Janssen	ORAL ONE BID ORAL
			Benadryl	C		

Date:08/04/03ISR Number: 4160143-7Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12075131
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Warfarin Sodium	PS	Bristol-Myers Squibb Company	
	International Normalised Ratio Decreased		Trazodone Hcl Tabs	SS		ORAL "As required"
			Wellbutrin	SS		ORAL

Enoxaparin	C
Olanzapine	C
Clonazepam	C
Docusate Sodium	C
Sertraline Hcl	C
Acetaminophen Elixir	C
Ibuprofen	C
Diphenhydramine	C
Metoclopramide Hcl	C

Date:08/04/03ISR Number: 4160709-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395212A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	50MG Twice
	Convulsion						per day
	Disability		Vicodin	C			
	Fall		Allegra	C			
	Grand Mal Convulsion		Septra Ds	C	Glaxosmithkline		
	Postictal State		Sudafed	C	Glaxosmithkline		
			Nasacort	C			
			Cortisone	C			
			Celexa	C			

Date:08/04/03ISR Number: 4160712-4Report Type:Expedited (15-DaCompany Report #SG-GLAXOSMITHKLINE-B0294984A
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
	Alanine Aminotransferase Increased
	Ascites
	Aspartate Aminotransferase Increased
	Blood Alkaline Phosphatase Increased

Blood Bilirubin Increased
Blood Creatinine
Increased
Cholestasis
Coagulopathy
Disseminated
Intravascular Coagulation
Dyspepsia
Encephalopathy
Epigastric Discomfort
Granuloma
Haemoglobin Decreased
Hepatic Failure
Hepatic Trauma
Hepatorenal Syndrome
Hypertrophy
Hypotension
Insomnia
Intra-Abdominal

		PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Haemorrhage							
		Jaundice							
		Lethargy							
		Metabolic Acidosis							
		Mouth Haemorrhage		Bupropion					
		Nausea		Hydrochloride	PS	Glaxosmithkline			
UNKNOWN								150MG per day	10 DAY
		Necrosis		Carbimazole	SS				
UNKNOWN								15MG per day	5 YR
		Prothrombin Time		Propranolol	C				
UNKNOWN								10MG per day	5 YR
		Prolonged		Paracetamol	C	Glaxosmithkline			
UNKNOWN									2 DAY
		Pulmonary Haemorrhage		Alcohol	C		ORAL		
		Pulmonary Oedema							
		Rash							
		Rectal Haemorrhage							
		Renal Impairment							
		Sepsis							
		Urine Output Decreased							

Date:08/04/03ISR Number: 4160718-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0295110A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Zyban	PS	Glaxosmithkline	ORAL		
150MG See								
Other	Arthralgia							
dosage text								18 DAY
	Diarrhoea		Ercefuryl	C	Glaxosmithkline	ORAL		
3TAB per day								4 DAY
	Erythema		Debridat	C		ORAL		
4 DAY								
	Gastroenteritis		Ultra Levure	C				
3 DAY								
	Pruritus							
	Urticaria							
	Vomiting							

Date:08/04/03ISR Number: 4160720-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0305473A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Sleep Apnoea Syndrome		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	85 DAY
			Warfarin	C	Glaxosmithkline	ORAL		

Date:08/04/03ISR Number: 4161258-XReport Type:Direct Company Report #USP 50185
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxo Wellcome			
			Zyban	SS	Glaxo Wellcome			

Date:08/04/03ISR Number: 4161477-2Report Type:Direct Company Report #USP 50459
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Diovan	PS	Ciba Geigy		CAPSULE	
			Zyban	SS	Glaxo Wellcome		TABLET	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/03ISR Number: 4161651-5Report Type:Direct Company Report #CTU 199303
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dystonia		Wellbutrin Sr 150mg Glaxo	PS	Glaxo	ORAL	150MG DAILY	ORAL

Date:08/05/03ISR Number: 4165548-6Report Type:Expedited (15-DaCompany Report #HQWYE200125JUL03
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coordination Abnormal	Study	Effexor (Venlafaxine Hydrochloride, Tablet)	PS		ORAL		
Other	Drug Interaction							
	Dysarthria							
	Feeling Drunk		Clarithromycin (Clarithromycin)	SS		ORAL		
	Mental Status Changes							
	Nuclear Magnetic Resonance Imaging Brain Abnormal		Wellbutrin (Amfebutamone Hydrochloride)	SS		ORAL		
			Zoloft (Sertraline Hydrochloride)	SS		ORAL		
			Atorvastatin (Atorvastatin)	C				
			Amoxicillin (Amoxicillin)	C				
			Atenolol (Atenolol)	C				
			Clonazepam (Clonazepam)	C				
			Aspirin (Acetylsalicylic Acid)	C				
			Omeprazole (Omeprazole)	C				

Date:08/05/03ISR Number: 4165675-3Report Type:Expedited (15-DaCompany Report #03P-163-0225962-00
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coordination Abnormal Drug Interaction Dysarthria	Health Professional Other	Clarithromycin (Clarithromycin) (Clarithromycin)	PS		ORAL	PER ORAL	
	Lung Infiltration Mental Status Changes		Effexor (Venlafaxine Hydrochloride)	SS		ORAL	PER ORAL	
	Nuclear Magnetic Resonance Imaging		Zoloft (Sertraline Hydrochloride)	SS		ORAL	PER ORAL	
	Abnormal		Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	PER ORAL	
			Atorvastatin (Atorvastatin)	SS			SEE IMAGE	
			Atenolol	C				
			Clonazepam	C				
			Acetylsalicylic Acid	C				
			Omeprazole	C				
			Fosinopril Sodium	C				
			Ranitidine Hydrochloride	C				
			Tetracycline	C				
			Bismuth					

			Subsalicylate	C		
			Metronidazole	C		

Date:08/06/03ISR Number: 4162492-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379918A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL
	Completed Suicide		Valproic Acid	SS		
	Grand Mal Convulsion					
	Intentional Misuse					
	Pupil Fixed					
	Tachycardia					

Date:08/06/03ISR Number: 4162493-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379979A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Apnoea		Bupropion	PS	Glaxosmithkline	ORAL
	Cardio-Respiratory Arrest					
	Completed Suicide					
	Convulsion					
	Cyanosis					
	Intentional Misuse					
	Pupil Fixed					
	Ventricular Fibrillation					

Date:08/06/03ISR Number: 4162494-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379980A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline	ORAL
	Convulsion		Acetaminophen +			
	Intentional Misuse		Hydrocodone	SS		ORAL
	Liver Function Test		Carisoprodol	SS		
UNKNOWN						
	Abnormal		Opiates	C		
	Loss Of Consciousness					
	Oxygen Saturation					

	Decreased
	Respiratory Rate
	Decreased
	Tachycardia

Date:08/06/03ISR Number: 4162495-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383124A
Age:15 YR Gender:Male I/FU:F

Outcome	PT
Death	Aggression
Hospitalization -	Agitation
Initial or Prolonged	Blood Creatine Increased
	Brain Oedema
	Cardiac Arrest
	Coma
	Completed Suicide
	Grand Mal Convulsion
	Hallucination
	Hypotension
	Intentional Misuse

		Labile Blood Pressure					
		Paralysis					
		Pupillary Reflex Impaired	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL
2	WK						
		Status Epilepticus					
		Tachycardia					

Date:08/06/03ISR Number: 4162496-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383131A
Age:42 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebral Infarction		Bupropion	PS	Glaxosmithkline	ORAL
		Completed Suicide		Methylphenidate	SS		
UNKNOWN							
		Cyanosis					
		Drug Level Increased					
		Intentional Misuse					
		Loss Of Consciousness					
		Nervous System Disorder					
		Renal Failure					
		Respiratory Failure					
		Shock					

Date:08/06/03ISR Number: 4162500-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0411832A
Age:37 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Three							
		Grand Mal Convulsion					
times per day	3 MON						
				Luvox	SS		ORAL
50MG Per day	26 DAY						
				Vivactil	SS		ORAL
5MG Twice per							
day							

Date:08/06/03ISR Number: 4162501-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0414552A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	5 YR
			Levothyroxine	C	Glaxosmithkline			
			Estradiol	C				
			Mvi	C				

Date:08/06/03ISR Number: 4162506-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0419143A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Vitamin A Deficiency		Effexor	C				
			Neurontin	C				

Date:08/06/03ISR Number: 4162508-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0419179A
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation
	Anxiety
	Delusion

	Hallucination Mental Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day 17 DAY

Date:08/06/03ISR Number: 4162509-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0419316A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Caesarean Section		Bupropion	PS	Glaxosmithkline		400MG per day
	Cardiac Disorder Cardiac Murmur Cardiac Septal Defect Drug Exposure During Pregnancy Gastrointestinal Disorder Insomnia Malabsorption Pregnancy						

Date:08/06/03ISR Number: 4162566-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0305578A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Deep Vein Thrombosis		Zyban	PS	Glaxosmithkline	ORAL	150MG per day 18 DAY

Date:08/06/03ISR Number: 4166233-7Report Type:Expedited (15-DaCompany Report #DSA_23038_2003
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiotoxicity	Literature	Ativan	PS		ORAL	2 MG ONE PO
Initial or Prolonged	Drug Screen Positive	Health	Ziprasidone	SS		ORAL	2400 MG ONCE

	Electrocardiogram Qrs Complex Prolonged	Professional	Klonopin	SS	ORAL	7.5 MG ONCE
	Electrocardiogram Qt Corrected Interval Prolonged		Wellbutrin - Slow Release	SS	PO	3000 MG ONCE
	Intentional Misuse Lethargy Po2 Decreased Pulmonary Function Test Abnormal Somnolence				PO	

Date:08/06/03ISR Number: 4166271-4Report Type:Expedited (15-DaCompany Report #USA-2003-0006512
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose Coma Drug Toxicity Hepatomegaly Portal Triaditis Postoperative Infection Pulmonary Congestion Pulmonary Oedema	Consumer Health Professional Other	Oxycontin Tablets (Oxycodone Hydrochloride) Cr Tablet Celexa (Citalopram Hydrobromide) Carisoprodol (Carisoprodol) Meprobamate	PS SS SS				

	(Meprobamate)	SS
	Bupriopion (Amfebutamone)	SS

Date:08/07/03ISR Number: 4163287-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0419536A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Increased Aspartate Aminotransferase							
	Increased Chromaturia							
	Viral Infection							

Date:08/07/03ISR Number: 4163340-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0302485A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Zyban	PS	Glaxosmithkline	ORAL	12G Single	
Hospitalization -	Blood Creatine							
dose	1 DAY							
Initial or Prolonged	Phosphokinase Increased		Imovane	SS		ORAL		
	Bradycardia		Zyprexa	C		ORAL		
	Bundle Branch Block Right		Loxapac	C				
	Cardiogenic Shock							
	Coma							
	Diarrhoea							
	Electrocardiogram Qrs Complex Prolonged							
	Hepatitis							
	Hyperthermia Malignant							
	Hypotension							
	Intentional Misuse							
	Lactic Acidosis							
	Lung Disorder							
	Mydriasis							
	Nodal Rhythm							
	Respiratory Failure							

	Septic Shock						
	Sinusitis						
	Status Epilepticus						
	Suicide Attempt						
	Supraventricular Tachycardia						
	Tachycardia						

Date:08/07/03ISR Number: 4165239-1Report Type:Expedited (15-DaCompany Report #2003106276
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypokalaemia Leukocytosis Myocardial Ischaemia Prinzmetal Angina Respiratory Alkalosis	Foreign Literature Health Professional	Paracetamol/Pseudoephedrine (Paracetamol, Pseudoephedrine)	PS		ORAL	9 TABLETS	WITHIN 72 HOURS, ORAL
			Bupropion (Bupropion)	SS		ORAL		ORAL

19-Aug-2005 12:44 PM
Page: 2066

			Erythromycin (Erythromycin)	SS		ORAL	ORAL

Date:08/08/03ISR Number: 4164023-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0410328A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Induced		Bupropion	PS	Glaxosmithkline	ORAL	150MG Per day
	Complications Of Maternal Exposure To Therapeutic Drugs						
	Drug Exposure During Pregnancy						
	Haemorrhage						
	Maternal Drugs Affecting Foetus						

Date:08/09/03ISR Number: 4167362-4Report Type:Expedited (15-DaCompany Report #HQWYE525831JUL03
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Gun Shot Wound Murder	Consumer Company Representative	Effexor (Venlafaxine Hydrochloride, Tablet)	PS		ORAL	ORAL
			Ambien (Zolpidem Tartrate)	SS			
			Clonazepam (Clonazepam)	SS			
			Methylphenidate (Methylphenidate)	SS			
			Wellbutrin (Amfebutamone Hydrochloride)	SS			

Date:08/11/03ISR Number: 4203734-7Report Type:Periodic Company Report #A0399789A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypersensitivity	Health Professional	Paxil (Formulation Unknown) (Paroxetine Hydrochloride)	PS		ORAL		
			Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS		ORAL		

Date:08/12/03ISR Number: 4165966-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0420287A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Supraventricular Extrasystoles		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Vioxx	C				
			Lopressor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/03ISR Number: 4165980-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0306189A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hereditary Angioedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	62 DAY
Hospitalization - Initial or Prolonged								

Date:08/12/03ISR Number: 4166486-5Report Type:Direct Company Report #CTU 199790
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour		Wellbutrin 100 Mg					
Hospitalization -	Anger		Glaxowellcome	PS	Glaxowellcome	ORAL	100 MG BID	
Initial or Prolonged	Feeling Of Despair						ORAL	
Required	Irritability		Wellbutrin 150 Mg					
Intervention to	Mania		Glaxowellcome	SS	Glaxowellcome	ORAL	150 MG SID	
Prevent Permanent	Mood Swings						AND ORAL	
Impairment/Damage	Self Mutilation							
	Suicidal Ideation							
	Suicide Attempt							
	Thinking Abnormal							

Date:08/14/03ISR Number: 4167942-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0301940A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brief Psychotic Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
Initial or Prolonged	With Marked Stressors							

Date:08/14/03ISR Number: 4167951-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0306220A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Withdrawal Syndrome		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	2 MON
Other	Rheumatoid Arthritis							

Date:08/14/03ISR Number: 4167953-0Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0039998A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Zyban	PS	Glaxosmithkline	ORAL		
	Angiopathy							
	Anxiety							
	Sleep Disorder							
	Tinnitus							

Date:08/15/03ISR Number: 4168645-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0420979A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cellulitis		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice per day	2 MON
	Oedema							
	Pruritus		Lithium	SS	Glaxosmithkline			
	Rash		Diovan	C				
			Armour Thyroid	C				
			Glucophage	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/03ISR Number: 4168650-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0305867A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Blood Creatine Phosphokinase Mb Increased Chest Pain		Zyban	PS	Glaxosmithkline		150MG Twice per day	21 DAY

Date:08/15/03ISR Number: 4168658-2Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0041169A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Diabetes Mellitus Fatigue Hepatic Cirrhosis Jaundice Ocular Icterus		Zyban Diclofenac	PS C	Glaxosmithkline	ORAL UNKNOWN	1TAB Per day 75MG Twice per day	21 DAY 1 WK

Date:08/15/03ISR Number: 4171256-8Report Type:Direct Company Report #USP 56019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Zovirax	PS	Glaxo Wellcome	TABLET		
			Wellbutrin Sr	SS	Galxosmithkline	TABLET		

Date:08/18/03ISR Number: 4171929-7Report Type:Expedited (15-DaCompany Report #2003-BP-05715RO
Age:64 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Digoxin Elixir Usp, 0.05 Mg/Ml (Digoxin)	PS		ORAL	PO	
			Bupropion (Amfebutamone)	SS		ORAL	PO	
			Doxazosin (Doxazosin)	C		ORAL	PO	

Date:08/18/03ISR Number: 4172179-0Report Type:Expedited (15-DaCompany Report #HQ2220008MAY2002
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Human Chorionic Gonadotropin Positive Caesarean Section Complications Of Maternal Exposure To Therapeutic Drugs Drug Ineffective Pre-Eclampsia Pregnancy Pregnancy Test Urine Positive Premature Baby	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	SEE IMAGE	
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride,)	SS		ORAL	150 MG 2X PER 1 DAY,	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/03ISR Number: 4172311-9Report Type:Expedited (15-DaCompany Report #HQWYE065613AUG03
Age:1 DY Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apgar Score Low Caesarean Section Feeding Problem In Newborn Maternal Drugs Affecting Foetus Neonatal Apnoeic Attack Premature Baby	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule Extended Release)	PS		TRANSPLACENTAL	150 MG 3X PER	1 DAY,
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride)	SS		TRANSPLACENTAL	150 MG 2X PER	1 DAY,

Date:08/19/03ISR Number: 4170021-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0422196A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Back Pain Eye Irritation Eye Pain Headache Thinking Abnormal Visual Acuity Reduced		Clonazepam	C				

Date:08/19/03ISR Number: 4170022-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0422216A
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	8 MON
Hospitalization - Initial or Prolonged								

Date:08/19/03ISR Number: 4170028-8Report Type:Expedited (15-DaCompany Report #SK-GLAXOSMITHKLINE-B0118186A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	9 DAY
	Areflexia							
	Feeling Abnormal							
	Hemiparesis							
	Hypoaesthesia							
	Nervousness							

Date:08/21/03ISR Number: 4171553-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0422294A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	34 DAY
	Faecaloma							
			Effexor Xr	C				

Birth Control Pills C

Date:08/21/03ISR Number: 4171559-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0422754A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	6 YR
	Aggression							
	Insomnia		Trazodone	SS			50MG As required	10 YR
	Negativism							
	Self Mutilation							
	Suicide Attempt							

Date:08/21/03ISR Number: 4171574-3Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0041696A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	61 DAY

Date:08/22/03ISR Number: 4172145-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0395212A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	50MG Twice per day	
	Convulsion							
	Disability		Vicodin	C				
	Fall		Allegra	C				
	Grand Mal Convulsion		Septra Ds	C	Glaxosmithkline			
	Treatment Noncompliance		Sudafed	C	Glaxosmithkline			
			Nasacort	C				
			Cortisone	C				

			Celexa	C		
			Oral Contraceptive	C		

Date:08/22/03ISR Number: 4172156-XReport Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0422610A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Self-Injury		Wellbutrin	PS	Glaxosmithkline	ORAL	30TAB Per day	
	Laceration		Venlafaxine	SS		ORAL	10TAB Per day	
	Overdose		Estazolam	SS		ORAL	10TAB Per day	
	Suicide Attempt							

Date:08/22/03ISR Number: 4172162-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0422842A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Prescribed Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	3 WK
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/03ISR Number: 4172173-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0307137A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disinhibition		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Mania							
per day								30 DAY
	Mood Swings		No Concurrent Medication	C				

Date:08/22/03ISR Number: 4173059-7Report Type:Direct Company Report #CTU 200472
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bruxism		Zoloft 50-100mg					
	Tooth Injury		Pfizer	PS	Pfizer	ORAL	100MG Q.D.	
	Trismus							
ORAL								
			Wellbutrin 150mg					
			Glaxowellcome	SS	Glaxo Wellcome	ORAL	150MG B.I.D.	
ORAL								

Date:08/25/03ISR Number: 4172883-4Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0294671A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aphasia		Zyban	PS	Glaxosmithkline	ORAL	43 DAY	
Other	Cerebral Arteritis							
	Electroencephalogram Abnormal							
	Grand Mal Convulsion							
	Headache							
	Mental Status Changes							

Date:08/25/03ISR Number: 4172884-6Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0295775A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aphasia		Zyban	PS	Glaxosmithkline	ORAL	43	DAY
Other	Cerebral Arteritis							
	Cerebral Haemorrhage							
	Computerised Tomogram Abnormal							
	Electroencephalogram Abnormal							
	Grand Mal Convulsion							
	Headache							
	Nausea							
	Personality Change							
	Vomiting							

Date:08/25/03ISR Number: 4172887-1Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-B0305654A
Age:24 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
	Cough
Other	Drug Rash With Eosinophilia And Systemic Symptoms

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia							
	Dyspnoea							
	Electrocardiogram St Segment Elevation		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice per day	21 DAY
	Eosinophils Urine							
	Hepatitis Acute							
	Hypersensitivity							
	Hypoxia							
	Liver Function Test Abnormal							
	Muscle Necrosis							
	Myalgia							
	Myocarditis							
	Myositis							
	Obstructive Airways Disorder							
	Pruritus							
	Pyrexia							
	Renal Disorder							

Date:08/25/03ISR Number: 4173751-4Report Type:Direct Company Report #CTU 200588
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Lexapro 20 Mg Threw Away	PS		ORAL	20 DAILY ORAL	
	Depression							
	Dizziness		Wellbutrin 100 Glaxosmithkline	SS	Glaxosmithkline	ORAL	300 DAILY ORAL	
	Dyspepsia							
	Fatigue							
	Hypoaesthesia		Nasonex	C				
	Insomnia		Motrin	C				
	Malaise							
	Paraesthesia							
	Somnolence							
	Weight Increased							
	White Blood Cell Count Increased							

Date:08/25/03ISR Number: 4174323-8Report Type:Direct Company Report #CTU 200622
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin 150 Mg	PS		ORAL	150 MG PO QHS	
	Nausea							

Date:08/25/03ISR Number: 4174358-5Report Type:Direct Company Report #CTU 200649
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Maculo-Papular		Wellbutrin Sr 200	PS		ORAL	PO QD	7 DAY
			Pravachol	C				
			Tenoratic	C				
			Synthroid	C				

Date:08/25/03ISR Number: 4177879-4Report Type:Expedited (15-DaCompany Report #2003023103
Age:1 DY Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Caesarean Section Cleft Lip Maternal Drugs Affecting Foetus	Health Professional	Neurontin (Gabapentin)	PS		ORAL	600 MG (300, BID), ORAL	
			Bupropion Hydrochloride(Bupropion Hydrochloride)	SS		ORAL	300 MG (150, BID), ORAL	
			Rizatriptan Benzoate (Rizatriptan Benzoate)	SS				

Date:08/25/03ISR Number: 4177883-6Report Type:Expedited (15-DaCompany Report #2003034365
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Caesarean Section Complications Of Maternal Exposure To Therapeutic Drugs Pregnancy Test Positive Uterine Dilation And Curettage	Health Professional	Neurontin (Gabapentin)	PS		ORAL	600 MG (300, BID), ORAL	
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS		ORAL	300 MG (150, BID), ORAL	
			Rizatriptan Benzoate (Rizatriptan Benzoate)	SS				

Date:08/26/03ISR Number: 4173455-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0295862A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral Psoriasis		Zyban Elisor Questran Puva Daivonex Diprosone	PS C C C C C	Glaxosmithkline	ORAL	150MG See dosage text	34 DAY

Date:08/26/03ISR Number: 4173460-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0307344A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphemia Suicidal Ideation		Zyban Alcohol	PS C	Glaxosmithkline	ORAL		

Date:08/26/03ISR Number: 4178818-2Report Type:Expedited (15-DaCompany Report #A0422244A
Age: Gender:Unknown I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged Other	Aggression Agitation Confusional State Convulsion

		Gastroenteritis Medication Error Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pharmaceutical Product Complaint Prescribed Overdose Vomiting	Literature Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS		ORAL
ORAL							
				Bupropion Hydrochloride (Formulation Unknown) (Generic) (Bupropion	SS		
				Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS		

Date:08/27/03ISR Number: 4174059-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0307572A
Age:70 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Dysarthria		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day	3 WK						
		Dysgraphia Speech Disorder		Chondrosulf	C		

Date:08/28/03ISR Number: 4176001-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0304144A
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Urinary Retention		Zyban	PS	Glaxosmithkline	
150MG Twice							
per day							
				Tamsulosin	C		

Date:08/28/03ISR Number: 4176005-5Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0038838A
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Disability	Aggression
Other	Anxiety
	Bipolar Disorder
	Crying
	Depression
	Diarrhoea
	Disinhibition
	Disturbance In Attention
	Emotional Disorder
	Fatigue
	Gastroenteritis
	Gastrointestinal Disorder
	Gastrooesophageal Reflux
	Disease
	Hyperhidrosis
	Hypomania
	Illusion
	Irritable Bowel Syndrome
	Migraine
	Nausea
	Nervousness

	Pain In Extremity						
	Palpitations						
	Panic Attack	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
	Retching		Zyban	PS	Glaxosmithkline	ORAL	
150MG Per day	6 WK						
	Sleep Disorder		Seroxat	SS	Glaxosmithkline		
UNKNOWN	92 DAY						
	Suicidal Ideation		Sortis	C		ORAL	
	Tachycardia		Diclo	C	Glaxosmithkline		
INTRAMUSCULAR							
	Tongue Disorder		Dexa-Phlogont	C			
INTRAMUSCULAR							
	Vertigo		Perenterol	C		ORAL	
	Weight Decreased		Mutaflor	C		ORAL	

Date:08/29/03ISR Number: 4175894-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0419536A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Alanine Aminotransferase		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day	2 WK					
	Increased					
	Aspartate					
	Aminotransferase					
	Increased					
	Chromaturia					
	Fatigue					
	Myalgia					
	Nausea					
	Viral Infection					

Date:08/29/03ISR Number: 4175896-1Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0420867A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Liver Function Test		Wellbutrin	PS	Glaxosmithkline	ORAL
250MG Per day	1 YR					
	Abnormal		Zocor	C		
			Altace	C		
			Pantaloc	C		

Date:08/29/03ISR Number: 4175900-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0423838A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Phosphokinase Increased						per day	
	Drug Interaction		Cozar	SS			UNKNOWN	
	Rhabdomyolysis							

Date:08/29/03ISR Number: 4176661-1Report Type:Direct Company Report #CTU 200951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Burning Sensation		Wellbutrin 150 Mg					
Intervention to	Difficulty In Walking		Glaxosmithkline	PS	Glaxosmithkline	ORAL	SEE IMAGE	
Prevent Permanent	Pain							
Impairment/Damage	Pruritus							
	Pyrexia							
	Swelling Face							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/02/03ISR Number: 4177018-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0298243A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agoraphobia		Zyban	PS	Glaxosmithkline	ORAL		
	Anorexia							
	Anxiety							
	Claustrophobia							
	Convulsion							
	Depression							
	Headache							
	Insomnia							
	Joint Swelling							
	Lethargy							
	Loss Of Libido							
	Mental Disorder							
	Oedema Peripheral							
	Pain In Extremity							
	Thinking Abnormal							
	Tremor							

Date:09/02/03ISR Number: 4177033-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0307344A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphemia		Zyban	PS	Glaxosmithkline	ORAL		
	Suicidal Ideation		Alcohol	C				

Date:09/02/03ISR Number: 4177034-8Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0307360A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Stem Infarction		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Wallenberg Syndrome							

Date:09/02/03ISR Number: 4177038-5Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0041169A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	21 DAY
Initial or Prolonged	Diabetes Mellitus		Diclofenac	C			UNKNOWN	75MG Twice
	Fatigue						per day	1 WK
	Hepatic Cirrhosis							
	Hepatic Neoplasm							
	Hepatitis B							
	Jaundice							
	Ocular Icterus							

Date:09/03/03ISR Number: 4178076-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0307425A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Zyban	PS	Glaxosmithkline		150MG Twice	
Hospitalization -	Headache						per day	
Initial or Prolonged	Musculoskeletal Stiffness		Valsartan	C				
	Somnolence							
	Subarachnoid Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/04/03ISR Number: 4179006-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0110609A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Application Site		Wellbutrin	PS	Glaxosmithkline			
	Dermatitis		Nicoderm	SS	Glaxosmithkline			
	Body Temperature Increased							
	Erythema Multiforme							
	Hyperlipidaemia							
	Hypersensitivity							
	Leukocytosis							
	Pain							
	Prostatic Specific Antigen Increased							
	Pruritus							
	Purpura							
	Sinusitis							
	Urticaria							

Date:09/04/03ISR Number: 4179007-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0299049A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Application Site		Nicoderm Cq 21mg	PS	Glaxosmithkline	TRANSDERMAL	21MG Per day	7 DAY
	Dermatitis		Wellbutrin	SS	Glaxosmithkline			
	Body Temperature Increased							
	Erythema Multiforme							
	Hyperlipidaemia							
	Hypersensitivity							
	Leukocytosis							
	Pain							
	Prostatic Specific Antigen Increased							
	Pruritus							
	Purpura							
	Sinusitis							
	Urticaria							

Date:09/04/03ISR Number: 4179008-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0423710A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:09/04/03ISR Number: 4179862-1Report Type:Direct Company Report #CTU 201300
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration		Atomoxetine	PS		ORAL	PO	2 WK
	Vomiting		Bupropion	SS				
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/08/03ISR Number: 4180886-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0301940A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brief Psychotic Disorder With Marked Stressors		Zyban Medrol	PS C	Glaxosmithkline	ORAL ORAL	150MG Per day 16MG Twice per day	4 DAY
			Temazepam	C		ORAL	1UNIT Per day	
			Dialgirex	C		ORAL	6UNIT per day	

Date:09/08/03ISR Number: 4180911-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0308339A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatine		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	53 DAY
	Phosphokinase Increased		Co-Amoxiclav	C	Glaxosmithkline	ORAL	738 DAY	
	Muscle Rigidity		Niquitin	C	Glaxosmithkline		21MG per day	
	Myalgia							

Date:09/09/03ISR Number: 4181221-2Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12335733
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Haemorrhage Fall		Taxol	PS	Bristol-Myers Squibb Company	INTRAVENOUS		
Other	Jugular Vein Thrombosis Laceration		Carboplatin	SS	Bristol-Myers Squibb Company	INTRAVENOUS	AUC=6	
	Syncope		Coumadin	SS	Bristol-Myers Squibb Company		1 MON	

			Wellbutrin	SS		
1 MON						
			Lipitor	C		
			Atrovent	C		

Date:09/09/03ISR Number: 4181279-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425104A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Congenital Pulmonary		Bupropion	PS	Glaxosmithkline		100MG Per day	
	Valve Disorder							
	Drug Exposure During Pregnancy							
	Pulmonary Valve Incompetence							

Date:09/09/03ISR Number: 4188408-3Report Type:Expedited (15-DaCompany Report #S03-NOR-03725-01
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign	Cipramil (Citalopram Hydrobromide)	PS		ORAL	40 MG QD PO	
	Drug Interaction	Other						
	Loss Of Consciousness		Zyban (Bupropion Hydrochloride)	SS		ORAL	150 MG BID PO	
	Tongue Biting							
			Zyban (Bupropion Hydrochloride)	SS		ORAL	150 MG QD PO	
			Zopiklon (Zopiclone)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/10/03ISR Number: 4183039-3Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0422610A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	30TAB Per day	
Initial or Prolonged	Self Mutilation		Venlafaxine	SS		ORAL	10TAB Per day	
	Suicide Attempt		Estazolam	SS		ORAL	10TAB Per day	

Date:09/10/03ISR Number: 4183043-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0424726A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:09/10/03ISR Number: 4183045-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0424898A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:09/10/03ISR Number: 4183047-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425148A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:09/10/03ISR Number: 4185410-2Report Type:Periodic Company Report #SOS-2003-039
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health	Vivactil Tablets,					

	Grand Mal Convulsion	Professional	5mg	PS		ORAL
5MG BID; ORAL						
		Company	Luvox Tablets, 50mg	SS		ORAL
50MG QD; ORAL						
		Representative	Wellbutrin Tablets, 100mg	SS		ORAL
100 MG TID;						
ORAL						

Date:09/11/03ISR Number: 4183389-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425336A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
Other	Suicide Attempt							

Date:09/11/03ISR Number: 4187003-XReport Type:Direct Company Report #CTU 201618
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity		Wellbutrin 200 Mg					
	Oedema Peripheral		Qd	PS		ORAL		
200 MG PO QD								
	Serum Sickness							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/12/03ISR Number: 4184643-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0425393A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
Hospitalization - Initial or Prolonged	Pharmaceutical Product Complaint		Paxil	C	Glaxosmithkline	UNKNOWN	per day	
Other			Insulin	C		INTRAVENOUS		

Date:09/12/03ISR Number: 4184651-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0308326A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Zyban	PS	Glaxosmithkline		150MG per day	1 DAY

Date:09/16/03ISR Number: 4186902-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425504A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:09/16/03ISR Number: 4186911-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425700A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:09/16/03ISR Number: 4186913-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425713A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:09/16/03ISR Number: 4190329-7Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20030902464
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Toxicity	Health Professional	Risperdal (Risperidone)	PS		ORAL	2 MG, 2 IN 1	DAY, ORAL
			Wellbutrin Sr (Bupropion Hydrochloride)	SS		ORAL	100 MG, 1 IN	1 DAY, ORAL

Date:09/17/03ISR Number: 4188732-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0309048A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice	
Other	Convulsion						per day	31 DAY
	Migraine		Unspecified Inhaler	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/17/03ISR Number: 4188740-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425927A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Celexa	C				

Date:09/17/03ISR Number: 4188741-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426117A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:09/17/03ISR Number: 4188742-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426129A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	

Date:09/17/03ISR Number: 4188743-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426142A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:09/19/03ISR Number: 4189275-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0309060A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	17 DAY	

	Feeling Drunk		No Concurrent			
	Psoriasis		Medications	C		
	Somnolence					

Date:09/22/03ISR Number: 4190395-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426581A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Paxil	PS	Glaxosmithkline	ORAL	0	DAY
	Mania		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	2 YR
	Suicidal Ideation		Zyrtec	C	Glaxosmithkline			
			Risperdal	C				
			Trazodone	C				
			Lamictal	C	Glaxosmithkline	ORAL		

Date:09/24/03ISR Number: 4192999-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425709A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Exposure During		Wellbutrin	PS	Glaxosmithkline	ORAL	4	YR
Initial or Prolonged	Pregnancy		Zyprexa	C				
	Eclampsia		Lithium	C	Glaxosmithkline			
	Pregnancy		Depakote	C				
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/03ISR Number: 4193001-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426614A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:09/24/03ISR Number: 4193014-0Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0309003A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aptyalism		Zyban	PS	Glaxosmithkline	ORAL		
	Electrocardiogram Qt Prolonged		Synfase	C		ORAL		
	Intentional Misuse							
	Poisoning							
	Somnolence							
	Speech Disorder							
	Tachycardia							
	Tremor							

Date:09/24/03ISR Number: 4193019-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0309572A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	28 DAY
	Gingival Pain		Kliofem	C		ORAL	1TAB Per day	
	Gingival Swelling		Propanolol	C		ORAL	10MG Per day	
	Insomnia							
	Oedema Mouth							
	Oral Pain							

Date:09/24/03ISR Number: 4198239-6Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20030904723
Age:43 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multiple Drug Overdose	Literature	Risperdal					
		Health	(Risperidone)					
		Professional	Unspecified	PS		ORAL		
ORAL								
		Distributor	Paroxetine					
			(Paroxetine)	SS				
			Bupropion					
			(Bupropion)	SS				

Date:09/24/03ISR Number: 4199156-8Report Type:Expedited (15-DaCompany Report #USA-2003-0009569
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly	Health	Oxycontin Cr	PS				
MG								
	Haemorrhage	Professional	Bupropion					
	Pneumonia	Other	(Amfebutamone)	SS				
MG								
	Toxicologic Test Abnormal		Olanzapine					
			(Olanzapine)	SS				
MG								
			Venlafaxine					
			(Venlafaxine)	SS				
MG								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/25/03ISR Number: 4194031-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426180A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Hospitalization -	Clonus							
per day							15	DAY
Initial or Prolonged	Dizziness							
Disability	Drug Hypersensitivity							
Other	Encephalopathy							
	Hyperhidrosis							
	Muscle Spasms							
	Opisthotonus							
	Rash							

Date:09/25/03ISR Number: 4194032-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426921A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:09/25/03ISR Number: 4194035-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427051A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product Complaint							

Date:09/25/03ISR Number: 4194047-0Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0309137A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG See	

Initial or Prolonged Feeling Cold
dosage text 20 DAY
General Physical Health
Deterioration
Myalgia
Pyrexia
Rash Pruritic

Date:09/25/03ISR Number: 4196195-8Report Type:Direct Company Report #CTU 202578
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Circulatory Collapse		Welbutrin 150 Mg					
Initial or Prolonged	Convulsion		Glaxosmithkline	PS	Glaxosmithklin			

150 MG TWICE

A DAY

Date:09/25/03ISR Number: 4196619-6Report Type:Direct Company Report #CTU 202567
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema		Bupropion	PS		ORAL		

BUPROPION

Initial or Prolonged	Urticaria							

ORAL

Vasculitis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/26/03ISR Number: 4195320-2Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0425393A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
Hospitalization -	Dizziness	Professional						per day
Initial or Prolonged	Pharmaceutical Product		Paxil	C	Glaxosmithkline	ORAL	20MG Per day	
Other	Complaint		Insulin	C			INTRAVENOUS	
			Lorazepam	C				
			Micardis	C	Glaxosmithkline			
			Cephalexin	C	Glaxosmithkline			

Date:09/26/03ISR Number: 4195323-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427337A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three	
								times per day

Date:09/26/03ISR Number: 4195326-3Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0299573A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypokalaemia		Zyban	PS	Glaxosmithkline		UNKNOWN	
Initial or Prolonged	Muscular Weakness		Aprovel	C			300MG per day	
	Tremor							

Date:09/26/03ISR Number: 4195334-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0309807A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchopneumonia		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	
	Death							

Date:09/26/03ISR Number: 4199884-4Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20030904632
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis	Literature	Tylox (Oxycodone/Acetaminophen/Dextromethorphan/Pseudoephedrine) Capsules	PS		ORAL	ORAL	
	Base Excess	Health Professional Distributor						
	Blood Bicarbonate Decreased							
	Completed Suicide							
	Drug Level Increased		Acetaminophen/Codeine (Acetaminophen/Codeine) Tablets	SS				
	Drug Screen Positive							
	Hypotension							
	Overdose							
	Po2 Increased		Acetaminophen/Aspirin/Caffeine (All Other Therapeutic Products)	SS				
	Ventricular Tachycardia							
			Buproprion (Bupropion)	SS				
			Aspirin (Acetylsalicylic Acid)	SS				
			Metformin (Metformin)	SS				

			Citalopram (Citalopram)	SS		
			Diethylpropion (Amfepramone Hydrochloride)	SS		
			Oil Base Paint	SS		
			Oil Base Paint (All Other Non-Therapeutic Products)	SS		

Date:09/29/03ISR Number: 4196777-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426919A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
	Myocardial Infarction							
			Xanax	C				
			Alcohol	C				

Date:09/29/03ISR Number: 4196782-7Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0427237A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Zyban	PS	Glaxosmithkline	ORAL		
	Convulsion							
	Hypertension							

Date:09/29/03ISR Number: 4196784-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427367A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:09/29/03ISR Number: 4196786-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427510A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:09/29/03ISR Number: 4196789-XReport Type:Expedited (15-DaCompany Report #IE-GLAXOSMITHKLINE-B0293852A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Zyban	PS	Glaxosmithkline	ORAL	150MG	
	Agitation							
	Confusional State		Alcohol	SS			UNKNOWN	2UNIT
	Drug Interaction							
	Memory Impairment							
	Paranoia							
	Verbal Abuse							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/03ISR Number: 4197754-9Report Type:Direct Company Report #CTU 202773
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Bupropion Hydrochloride	PS	Geneva Pharmceutical	ORAL	75 MG TID	
ORAL			Bupropion Hydrochloride	SS	Geneva Pharmceutical			

Date:09/29/03ISR Number: 4202063-5Report Type:Expedited (15-DaCompany Report #200304730
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Unspecified					
	Drowning	Other	Acetaminophen Product	PS			75 G	
	Drug Level Above Therapeutic		Bupropion	SS				
	Intentional Misuse		Alprazolam	SS				

Date:09/30/03ISR Number: 4197998-6Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0427236A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electrocardiogram Qt Prolonged		Bupropion	PS	Glaxosmithkline		UNKNOWN	150MG Unknown
			Celexa	SS		ORAL	300MG	Unknown
	Grand Mal Convulsion		Methotrimeprazine	SS			UNKNOWN	
	Intentional Misuse							

Date:09/30/03ISR Number: 4197999-8Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0427238A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electrocardiogram Qt		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Prolonged		Celexa	SS		ORAL	300MG	Unknown
	Grand Mal Convulsion		Methotrimeprazine	SS			UNKNOWN	

Date:09/30/03ISR Number: 4198012-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0307622A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL		
	Rash		Flucloxacillin	C	Glaxosmithkline			
	Rash Erythematous							

Date:09/30/03ISR Number: 4200612-4Report Type:Direct Company Report #CTU 202818
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Sr 200mg	PS		ORAL	200 MG PO BID	
			Ortho Evra	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/30/03ISR Number: 4200613-6Report Type:Direct Company Report #CTU 202879
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea		Paxil 20 Mg One Daily	PS			20 GM ONE	DAILY
	Dizziness							
	Pharmaceutical Product Complaint		Wellbutrin 100 Mgs Daily 1/2 Then Bid	SS			100 MG ONE	DAILY AND THEN BID
	Tinnitus							

Date:09/30/03ISR Number: 4202892-8Report Type:Expedited (15-DaCompany Report #SUS1-2003-00289
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Idiopathic Thrombocytopenic Purpura	Health Professional Other	Adderall Xr(Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine	PS			60 MG,	1X/DAY:QD
			Effexor-Xr(Venlafaxine Hydrochloride)	SS			150,	1X/DAY:QD
			Wellbutrin - Slow Release(Bupropion Hydrochloride)	SS			150MG 2X/DAY	

Date:09/30/03ISR Number: 4202923-5Report Type:Expedited (15-DaCompany Report #200304863
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis	Literature	Unspecified					
Hospitalization - Initial or Prolonged	Completed Suicide	Other	Apap/Dm/Pse Product					
	Hypotension		Unknown	PS		ORAL	PO	
Required Intervention to Prevent Permanent Impairment/Damage	Multiple Drug Overdose		Acetaminophen/Aspirin/Caffeine	SS		ORAL	PO	
	Ventricular Tachycardia		Bupropion (Long-Acting)	SS		ORAL	PO	
			Metformin	SS				
			Citalopram	SS		ORAL	PO	
			Acetaminophen/Oxycodone	SS		ORAL	PO	
			Acetaminophen/Codeine	SS		ORAL	PO	
			Diethylpropion	SS		ORAL	PO	
			Oil-Based Paint	SS				
			Aspirin	SS		ORAL	PO	

Date:09/30/03ISR Number: 4203077-1Report Type:Expedited (15-DaCompany Report #NSADSS2003011298
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Anger
	Chronic Obstructive Pulmonary Disease
	Coma

		Confusional State Depression Disturbance In Attention Drug Ineffective Female Orgasmic Disorder Ganglion Hallucination, Auditory Headache Insomnia Mania Memory Impairment Pneumonia Pulmonary Hypertension Renal Failure Restlessness Sleep Apnoea Syndrome Suicidal Ideation Tachycardia Thinking Abnormal Tumour Excision Weight Decreased Weight Increased	Report Source Health Professional	Product Risperdal (Risperidone) Tablets Effexor (Venlafaxine Hydrochloride) Wellbutrin (Bupropion Hydrochloride) Paxil (Paroxetine Hydrochloride) Remeron (Mirtazapine) Zoloft (Sertraline Hydrochloride) Xanax (Alprazolam) Klonopin (Clonazepam) Lithium (Lithium) Lasix (Furosemide) Ambien (Zolpidem Tartrate) Zyprexa (Olanzapine) Neurontin (Gabapentin) Synthroid (Levothyroxine Sodium) Valium (Diazepam) Geodon (Ziprasidone Hydrochloride) Provigil (Modafinil) Medicine For Htn (Antihypertensives) Medicinese For Diabetes (Drug Used In Diabetes) Zenical (Orlistat)	Role PS SS SS SS SS C C C C C C C C C C C C	Manufacturer	Route ORAL	Dose SEE IMAGE	Duration

Date:10/01/03ISR Number: 4199131-3Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0427097A
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tic		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tourette'S Disorder		Risperdal	C			.25MG At night	

Date:10/02/03ISR Number: 4199974-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426614A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/03ISR Number: 4199976-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427051A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Wellbutrin	PS	Glaxosmithkline			

Date:10/02/03ISR Number: 4200864-0Report Type:Direct Company Report #CTU 203000
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Rash Urticaria		Wellbutrin Sr 100 Mg Tablet Hydrochlorothiazide 25mg Tab Bupropion (Wellbutrin Sr) Hydrochlorothiazide Simvastatin	PS SS C C C				

Date:10/03/03ISR Number: 4200860-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427852A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Wellbutrin	PS	Glaxosmithkline			

Date:10/03/03ISR Number: 4200861-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427881A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Wellbutrin	PS	Glaxosmithkline			

Date:10/03/03ISR Number: 4200862-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427883A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Wellbutrin	PS	Glaxosmithkline			

Date:10/03/03ISR Number: 4201737-XReport Type:Direct Company Report #CTU 203103
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Wellbutrin Sr 150 Mg Glaxo Smith Kline	PS	Glaxo Smith Kline	ORAL	150 MG ONCE	DAILY ORAL
			Wellbutrin Xl 150 Mg	SS		ORAL	150 MG ONCE	DAILY ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/03ISR Number: 4206023-XReport Type:Expedited (15-DaCompany Report #2003039894
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Doxepin (Caps)					
Other	Completed Suicide	Health	(Doxepin)	PS		ORAL		
ORAL								
		Professional	Bupropion					
			(Bupropion)	SS		ORAL		
ORAL								
			Clorazepate Dipotassium (Clorazepate					
			Dipotassium)	SS		ORAL		
ORAL								
			All Other					
			Therapeutic Products	SS		ORAL		
ORAL								

Date:10/06/03ISR Number: 4201882-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427597A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal		Bupropion	PS	Glaxosmithkline		100MG Twice	
	Exposure To Therapeutic						per day	
	Drugs							
	Intentional Misuse							
	Stillbirth							

Date:10/06/03ISR Number: 4201883-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427597B
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Exposure During		Bupropion	PS	Glaxosmithkline		100MG Twice	
Congenital Anomaly	Pregnancy						per day	
	Fat Atrophy							

	Flushing					
	Head Deformity					
	Muscle Atrophy					
	Skin Maceration					
	Umbilical Cord Abnormality					

Date:10/06/03ISR Number: 4201885-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427884A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product Complaint		Wellbutrin	SS	Glaxosmithkline			

Date:10/06/03ISR Number: 4201887-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428071A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Pharmaceutical Product Complaint		Wellbutrin	SS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/03ISR Number: 4201888-XReport Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0428095A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	68	DAY
	Insomnia		Effexor Xr	C		ORAL	225MG per day	
	Mania							

Date:10/06/03ISR Number: 4201890-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428121A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice	
							per day	

Date:10/06/03ISR Number: 4201892-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428137A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abasia		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Rash							
	Stevens-Johnson Syndrome							

Date:10/06/03ISR Number: 4205663-1Report Type:Expedited (15-DaCompany Report #2003039883
Age:17 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Literature	Sertraline					
Other	Completed Suicide	Health	(Sertraline)	PS		ORAL	ORAL	
	Drug Level Increased	Professional	Risperidone					

	Respiratory Arrest		(Risperidone)	SS		ORAL
ORAL						
			Bupropion (Bupropion)	SS		ORAL
ORAL						

Date:10/06/03ISR Number: 4205741-7Report Type:Expedited (15-DaCompany Report #2003039667
Age:76 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Amlodipine			
		Health	(Amlodipine)	PS		ORAL
ORAL						
		Professional	Atenolol (Atenolol)	SS		ORAL
ORAL						
			Bupropion (Bupropion)	SS		ORAL
ORAL						

Date:10/07/03ISR Number: 4202507-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428237A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day						
			Wellbutrin	SS	Glaxosmithkline	
150MG Per day 5 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/03ISR Number: 4202508-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428238A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Wellbutrin	PS	Glaxosmithkline			

Date:10/07/03ISR Number: 4202509-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428252A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Hip Fracture Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	10 YR
			Effexor	C				
			Unknown Supplement	C				
			Guaifenesin	C				
			Oral Contraceptives	C				
			Allegra	C				
			Corticosteroids (Unspecified)	C				
			Zyrtec	C	Glaxosmithkline			

Date:10/07/03ISR Number: 4202512-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428688A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:10/07/03ISR Number: 4202513-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428692A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:10/07/03ISR Number: 4202515-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428716A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:10/07/03ISR Number: 4206707-3Report Type:Expedited (15-DaCompany Report #2003178859US
Age:28 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Calan (Verapamil)					
	Intentional Misuse	Health Professional	Tablet	PS				
			Venlafaxine (Venlafaxine)	SS				
			Bupropion (Amfebutamone)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/03ISR Number: 4206710-3Report Type:Expedited (15-DaCompany Report #2003178477US
Age:47 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Xanax (Alprazolam)					
	Completed Suicide	Health	Tablet	PS		ORAL		
ORAL								
	Intentional Misuse	Professional	Metadon Pharmacia (Methadone Hydrochloride) Tablet	SS				
			Bupropion (Amfebutamone)	SS				

Date:10/08/03ISR Number: 4206888-1Report Type:Direct Company Report #USP 080184
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	B-W			
TABLET								
			Wellbutrin	SS	B-W			

Date:10/08/03ISR Number: 4207435-0Report Type:Expedited (15-DaCompany Report #2003034365
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Caesarean Section	Consumer	Neurontin					
	Complications Of Maternal	Health	(Gabapentin)	PS		ORAL		
600 MG (300,								
	Exposure To Therapeutic	Professional						
BID), ORAL								
	Drugs		Bupropion					
	Maternal Drugs Affecting		Hydrochloride					
	Foetus		(Bupropion					
	Pregnancy Test Positive		Hydrochloride)	SS		ORAL		
300 MG (150,								
BID), ORAL								
			Rizatriptan Benzoate (Rizatriptan					

			Benzoate)	SS			

Date:10/09/03ISR Number: 4205033-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428689A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Generalised		Wellbutrin	PS	Glaxosmithkline		200MG per day	
	Systemic Lupus Erythematosus		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Single dose	
	Urticaria		Paxil Cr	C	Glaxosmithkline			
			Valium	C				

Date:10/09/03ISR Number: 4209192-0Report Type:Expedited (15-DaCompany Report #KII-2003-0002499
Age:43 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acidosis
Other	Alanine Aminotransferase
	Aspartate Aminotransferase
	Blood Alkaline Phosphatase
	Blood Potassium
	Blood Pressure Systolic

		Increased Depressed Level Of Consciousness Epistaxis Haematocrit Haemoglobin Heart Rate Increased Intentional Misuse Multiple Drug Overdose Pharyngeal Haemorrhage Prothrombin Time Respiratory Rate Decreased Suicide Attempt White Blood Cell Count	Report Source Health Professional	Product Oxycodone Hydrochloride (Similar To Nda 20-553) (Oxycodone Hydrochloride) Coumadin(Warfarin Sodium) Wellbutrin(Amfebutamone Hydrochloride) Seroquel(Quetiapine) Acetaminophen(Paracetamol)	Role PS SS SS SS SS	Manufacturer	Route ORAL ORAL ORAL ORAL ORAL

Date:10/10/03ISR Number: 4205867-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0422842A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
			Dexedrine	C	Glaxosmithkline			

Date:10/10/03ISR Number: 4205870-8Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0429044A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neutropenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
			Adriamycin	SS			UNKNOWN	
			Taxol	SS			UNKNOWN	

Date:10/10/03ISR Number: 4205874-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429227A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psychotic Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON
	Suicide Attempt		Alcohol	SS				
			Celexa	C				

Date:10/10/03ISR Number: 4205878-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0307425A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache		Zyban	PS	Glaxosmithkline		150MG Twice	
Hospitalization -	Musculoskeletal Stiffness						per day	
Initial or Prolonged	Somnolence		Valsartan	C				
	Subarachnoid Haemorrhage							

Date:10/10/03ISR Number: 4205897-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0311254A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Road Traffic Accident		Zyban	PS	Glaxosmithkline	ORAL		
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/03ISR Number: 4209002-1Report Type:Direct Company Report #CTU 203607
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Bupropion 100 Mg					
	Depression		Mylan	PS	Mylan	ORAL	100MG	4.5
	Loss Of Employment						ORAL	
	Pharmaceutical Product Complaint		Bupropion 100 Mg Tevau	SS	Tevau	ORAL	100MG	4.5
	Sleep Disorder						ORAL	
	Somnolence							

Date:10/13/03ISR Number: 4207221-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0412091A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Exposure During Pregnancy		Prenatal Vitamins	C			per day	10 MON
	Fatigue							
	Pregnancy							
	Premature Baby							
	Stillbirth							

Date:10/13/03ISR Number: 4207222-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0412091B
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Wall Anomaly		Wellbutrin	PS	Glaxosmithkline		150MG Twice	
Congenital Anomaly	Abdominal Wall Disorder						per day	
	Atrial Septal Defect							
	Chorioamnionitis							

Cleft Palate
Congenital Anomaly
Congenital Lymphoedema
Dizziness
Drug Exposure During
Pregnancy
Fatigue
Funnel Chest Acquired
Kyphosis
Lung Disorder
Lymphadenopathy
Placental Necrosis
Pregnancy
Premature Baby
Stillbirth

Date:10/13/03ISR Number: 4207224-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427597A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs Intentional Misuse Maternal Drugs Affecting Foetus Stillbirth		Bupropion	PS	Glaxosmithkline		100MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/03ISR Number: 4207225-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0427597B
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Complications Of Maternal		Bupropion	PS	Glaxosmithkline		100MG Twice	
Congenital Anomaly	Exposure To Therapeutic						per day	
	Drugs							
	Drug Exposure During							
	Pregnancy							
	Flushing							
	Muscle Atrophy							
	Overdose							
	Skin Maceration							
	Stillbirth							
	Umbilical Cord							
	Abnormality							

Date:10/13/03ISR Number: 4207229-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429063A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		150MG Per day	
	Drug Exposure During							
	Pregnancy							
	Maternal Drugs Affecting							
	Foetus							
	Pregnancy							

Date:10/13/03ISR Number: 4207247-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0310773A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
Initial or Prolonged	Congestive Cardiomyopathy							
	Dyspnoea							

Date:10/13/03ISR Number: 4207449-0Report Type:Expedited (15-DaCompany Report #PHEH2003US07744
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Overdose		Zelnorm	PS	Novartis Sector: Pharma		6 mg, BID	
			Wellbutrin	SS				

Date:10/14/03ISR Number: 4207748-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0371291A
Age:36 YR Gender:Female I/FU:F

Outcome	PT
Other	Confusional State
	Convulsion
	Crying
	Dysgeusia
	Emotional Disorder
	Gastric Disorder
	Grand Mal Convulsion
	Head Injury
	Insomnia
	Nausea

		Prescribed Overdose Psoriasis Rash	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Road Traffic Accident		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Twice		Thinking Abnormal					
per day	2 YR						
		Vaginal Infection		Lamictal	SS	Glaxosmithkline	ORAL
		Vaginal Mycosis		Wellbutrin	SS	Glaxosmithkline	ORAL
		Vomiting		Pain Medication	C		ORAL
		Weight Decreased		Klonopin	C		ORAL
				Lorazepam	C		
				Ortho Tri-Cyclen	C		ORAL
				Nicotine Patch	C	Glaxosmithkline	
TRANSDERMAL							
				Nicotine Gum	C	Glaxosmithkline	ORAL

Date:10/14/03ISR Number: 4207780-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426614A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Medication Error		Wellbutrin	PS	Glaxosmithkline	

Date:10/14/03ISR Number: 4209852-1Report Type:Expedited (15-DaCompany Report #2003AP03513
Age:76 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Completed Suicide	Literature	Atenolol	PS		
	Multiple Drug Overdose	Health	Bupropion	SS		
		Professional	Amlodipine	SS		

Date:10/15/03ISR Number: 4208697-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429976A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Medication Error		Wellbutrin	PS	Glaxosmithkline	

Date:10/15/03ISR Number: 4208698-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429978A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY
	Insomnia		Alprazolam	C				
	Medication Error							
	Pollakiuria							

Date:10/15/03ISR Number: 4208699-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429983A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/03ISR Number: 4208703-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0430268A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:10/15/03ISR Number: 4208723-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0311479A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Microgynon	SS			UNKNOWN	1TAB Per day
	Unintended Pregnancy		No Concurrent Medication	C				

Date:10/15/03ISR Number: 4211352-XReport Type:Expedited (15-DaCompany Report #200318842BWH
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Enterocolitis	Health	Cipro					
Hospitalization -	Haemorrhagic	Professional	(Ciprofloxacin)	PS		ORAL	100 MG, TOTAL	
Initial or Prolonged	Giardiasis	Other					DAILY, ORAL	5 DAY
Disability	Rash		Wellbutrin Sr (Bupropion Hydrochloride)	SS				
			Metronidazole	SS			3	DAY

Date:10/16/03ISR Number: 4209763-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0125519A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		

Disability	Bronchial Oedema		Acular	C		
INTRAOCULAR						
	Cardiac Failure		Vancenase Aq	C	Glaxosmithkline	NASAL
	Congestive		Diet Pep	C		
	Coagulopathy		Ginko Biloba	C		
	Coronary Artery					
	Atherosclerosis					
	Gait Disturbance					
	Hepatic Steatosis					
	Malaise					
	Myocardial Ischaemia					
	Nephrosclerosis					
	Polytraumatism					
	Pulmonary Congestion					
	Thrombotic					
	Thrombocytopenic Purpura					

Date:10/16/03ISR Number: 4209769-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0423710A
Age:52 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL
	Depression		Luvox	C		
	Drug Toxicity		Klonopin	C		
1MG As						
	Overdose					
directed						
	Restlessness					
	Status Epilepticus					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/03ISR Number: 4209770-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425135A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:10/16/03ISR Number: 4209777-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0303990A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Haemorrhage		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	1 MON
	Muscle Rupture							
	Phlebitis							

Date:10/16/03ISR Number: 4210542-XReport Type:Direct Company Report #CTU 203927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin 150 Mg					
Required Intervention to Prevent Permanent Impairment/Damage	Nausea		Glaxo	PS	Glaxo	ORAL	150MG 2X DAILY ORAL	
	Pharmaceutical Product							
	Complaint							

Date:10/17/03ISR Number: 4210624-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429382A
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline			
Hospitalization - Initial or Prolonged	Headache		Wellbutrin	SS	Glaxosmithkline	ORAL		
Other	Loss Of Consciousness							

Date:10/17/03ISR Number: 4210625-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429515A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:10/17/03ISR Number: 4210626-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429678A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:10/17/03ISR Number: 4210627-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429687A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/17/03ISR Number: 4214646-7Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20030904723
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bradycardia	Literature	Risperdal					
	Cardiac Arrest	Health	(Risperidone)					
	Decerebration	Professional	Unspecified	PS		ORAL	ORAL	
	Eye Movement Disorder	Distributor	Paroxetine					
	Hyperpyrexia		(Paroxetine)	SS				
	Mental Status Changes		Bupropion					
	Multiple Drug Overdose		(Bupropion)	SS				
	Muscle Rigidity		Clonazepam					
	Pyrexia		(Clonazepam)	SS				

Date:10/20/03ISR Number: 4211989-8Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0398320A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electrocardiogram Qt		Bupropion	PS	Glaxosmithkline			
	Prolonged		Citalopram	SS				
	Grand Mal Convulsion		Methotrimeprazine	SS				
	Intentional Misuse							

Date:10/20/03ISR Number: 4211993-XReport Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0427236A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electrocardiogram Qt		Bupropion	PS	Glaxosmithkline			
UNKNOWN							150MG	Unknown
	Prolonged		Celexa	SS		ORAL	300MG	Unknown
	Grand Mal Convulsion		Methotrimeprazine	SS			UNKNOWN	
	Intentional Misuse							

Date:10/20/03ISR Number: 4211994-1Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0427238A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electrocardiogram Qt		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Prolonged		Celexa	SS		ORAL	300MG	Unknown
	Grand Mal Convulsion		Methotrimeprazine	SS			UNKNOWN	

Date:10/20/03ISR Number: 4212009-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0308919A
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Ageusia
Hospitalization - Initial or Prolonged	Amnesia
Other	Chest Discomfort
	Diarrhoea
	Dizziness
	Dyspnoea
	Feeling Abnormal
	Feeling Hot And Cold
	Hallucination
	Headache
	Immobile
	Lethargy
	Muscle Spasms
	Nausea

	Paraesthesia						
	Respiratory Failure						
	Thirst	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
			Zyban	PS	Glaxosmithkline	ORAL	
8	DAY						
			Norvasc	C		ORAL	
10MG per day	YR						

Date:10/20/03ISR Number: 4212015-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0311639A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Back Pain		Zyban	PS	Glaxosmithkline	ORAL
150MG Unknown	3 DAY					
	Cardio-Respiratory Arrest					
	Myocardial Infarction					
	Nausea					

Date:10/20/03ISR Number: 4212018-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0311648A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Arrest		Zyban	PS	Glaxosmithkline	ORAL
150MG Unknown	WK					
	Pulmonary Oedema		Daonil	C		
			Glucophage	C		
			Kardegic	C		
			Mediator	C		ORAL
			Tenormine	C		
			Coversyl	C		
			Vastarel	C		

Date:10/20/03ISR Number: 4212026-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429530A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization -	Drug Exposure During		Wellbutrin	PS	Glaxosmithkline	
200MG Per day						
Initial or Prolonged	Pregnancy					
	Tremor Neonatal					

Date:10/20/03ISR Number: 4212027-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0429574A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline	
150MG Twice						
	Drug Exposure During					
per day						
	Pregnancy					

Date:10/20/03ISR Number: 4212028-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0306220A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Inflammation		Zyban	PS	Glaxosmithkline	ORAL
150MG Unknown 2 MON						
Other	Joint Swelling					
	Musculoskeletal Pain					
	Streptococcal Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/03ISR Number: 4212029-7Report Type:Expedited (15-DaCompany Report #DK-GLAXOSMITHKLINE-B0309119A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyskinesia		Zyban	PS	Glaxosmithkline	ORAL		
	Dysstasia							
	Hypokinesia							
	Musculoskeletal Discomfort							

Date:10/21/03ISR Number: 4215154-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0311425A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression		Zyban	PS	Glaxosmithkline	ORAL	2 WK	
	Personality Change		Hrt	C				

Date:10/22/03ISR Number: 4213784-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0412091A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	10 MON
			Prenatal Vitamins	C				
	Dizziness							
	Drug Exposure During Pregnancy							
	Fatigue							
	Intra-Uterine Death							

Date:10/22/03ISR Number: 4213785-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0412091B
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Abdominal Wall Anomaly		Wellbutrin	PS	Glaxosmithkline	
150MG Twice						
Congenital Anomaly	Arteriopathic Disease					
per day						
	Atrial Septal Defect					
	Chorioamnionitis					
	Cleft Palate					
	Drug Exposure During					
	Pregnancy					
	Foetal Disorder					
	Intra-Uterine Death					
	Jaw Fracture					
	Kyphosis					
	Lymphangiectasia					
	Macrognathia					
	Pectus Excavatum					
	Traumatic Delivery					

Date:10/22/03ISR Number: 4213789-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428071A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day	5 DAY					
	Pharmaceutical Product Complaint		Wellbutrin	SS	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/03ISR Number: 4213790-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0430630A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:10/22/03ISR Number: 4213826-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0312169A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced		Zyban	PS	Glaxosmithkline	ORAL		

Date:10/24/03ISR Number: 4217108-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0430978A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:10/24/03ISR Number: 4217109-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0430981A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:10/24/03ISR Number: 4217113-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0431158A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
Initial or Prolonged	Convulsion		None	C				
	Joint Dislocation							
	Tongue Biting							

Date:10/24/03ISR Number: 4217115-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0431173A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Road Traffic Accident		Wellbutrin Prozac	PS C	Glaxosmithkline			1 WK

Date:10/24/03ISR Number: 4217127-XReport Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0312102A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Body Temperature Increased Eyelid Oedema Face Oedema Myalgia Oedema Peripheral Urticaria		Zyban	PS	Glaxosmithkline	ORAL		22 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/24/03ISR Number: 4219794-3Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20031003781
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Sleep Walking	Consumer	Concerta (Methylphenidate Hydrochloride) Sustained Release Tablets	PS		ORAL	54 MG, 1 IN 1	DAY, ORAL
			Wellbutrin (Bupropion Hydrochloride)	SS			150 MG	

Date:10/24/03ISR Number: 4219800-6Report Type:Expedited (15-DaCompany Report #HQWYE065613AUG03
Age:1 DY Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Apgar Score Low Caesarean Section Feeding Problem In Newborn Maternal Drugs Affecting Foetus Neonatal Apnoeic Attack Premature Baby	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	75 MG 3X PER 1 DAY,	ORAL
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride)	SS		TRANSPLACENTAL	150 MG 2X PER 1 DAY,	TRANSPLACENTAL

Date:10/24/03ISR Number: 4219806-7Report Type:Expedited (15-DaCompany Report #HQ2220008MAY2002
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Caesarean Section Complications Of Maternal Exposure To Therapeutic Drugs Drug Ineffective Pre-Eclampsia Pregnancy Premature Baby	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	75 MG 3X PER 1 DAY,	ORAL
			Wellbutrin- Slow Release (Amfebutamone	SS		ORAL	150 MG 2X PER 1 DAY,	ORAL

Date:10/24/03ISR Number: 4220011-9Report Type:Expedited (15-DaCompany Report #2003165781US
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Condition Aggravated Enterocolitis Haemorrhagic Rash	Health Professional	Flagyl (Metronidazole) Tablet	PS				
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride)	SS		ORAL	100 MG, QD, ORAL	

			Ciprofloxacin Hydrochloride (Ciprofloxacin Hydrochloride)	SS		
FOR 5 DAYS						

Date:10/27/03ISR Number: 4218507-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0430634A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product Complaint							

Date:10/27/03ISR Number: 4218509-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0431387A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:10/27/03ISR Number: 4218511-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0431427A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Paxil	PS	Glaxosmithkline	ORAL	80MG Per day	8 YR
	Drug Ineffective		Wellbutrin	SS	Glaxosmithkline	ORAL	75MG Per day	
	Drug Withdrawal Syndrome		Paxil Cr	SS	Glaxosmithkline	ORAL		
	Headache		Ortho Novum 1/35	C				
	Nausea		Advair	C	Glaxosmithkline			
	Panic Attack		Prednisone	C				
	Suicidal Ideation		Zyrtec	C	Glaxosmithkline			
	Thinking Abnormal		Flonase	C	Glaxosmithkline			
	Weight Increased		Albuterol	C	Glaxosmithkline			
			Ritalin	C				
			Multivitamin	C				

Date:10/27/03ISR Number: 4220887-5Report Type:Expedited (15-DaCompany Report #HQWYE337420OCT03
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective Drug Interaction Unintended Pregnancy	Health Professional Other	Microgynon (Levonorgestrel/Ethinyl Estradiol, Tablet)	PS		ORAL	1 TABLET	DAILY
			Zyban (Amfebutamone Hydrochloride,)	SS		ORAL	150MG	TABLETS;

Date:10/28/03ISR Number: 4219549-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0423710A
Age:52 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	2 DAY
	Intentional Misuse		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Restlessness		Luvox	C				
	Status Epilepticus		Klonopin	C			1MG As	

directed							
			Gabatril	C			
4MG Twice per							
day							
			Seroquel	C			
200MG At							
night							

Date:10/28/03ISR Number: 4222755-1Report Type:Expedited (15-DaCompany Report #2003112988
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Consumer	Lipitor					
	Balance Disorder		(Atorvastatin)	PS		ORAL	20 MG	
	Flatulence						(DAILY), ORAL	
	Gastrointestinal Motility Disorder		Amoxicillin (Amoxicillin)	SS				
	Gastrooesophageal Reflux Disease		Bupropion Hydrochloride (Bupropion Hydrochloride)	SS				
	Haematemesis		Levothyroxine Sodium (Levothyroxine Sodium)	C				
	Impaired Healing		Insulin (Insulin)	C				
	Liver Function Test Abnormal		Dexamfetamine (Dexamfetamine)	C				
	Memory Impairment							
	Muscular Weakness							
	Myalgia							
	Pain							
	Periodontal Disease							

Date:10/28/03ISR Number: 4222758-7Report Type:Expedited (15-DaCompany Report #USA-2003-0006512
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Consumer	Oxycontin					
	Coma	Health	Tablets(Oxycodone Hydrochloride) Cr					
	Drug Toxicity	Professional						

	Hepatomegaly	Other	Tablet	PS			ORAL
40 MG, BID,							
	Myalgia						
ORAL							
	Portal Triaditis		Celexa(Citalopram				
	Post Procedural Pain		Hydrobromide)	SS			
4 DAY							
	Postoperative Infection		Carisoprodol(Carisop				
	Pulmonary Congestion		rodol)	SS			
4 DAY							
	Pulmonary Oedema		Meprobamate(Meprobam				
			ate)	SS			
4 DAY							
			Bupropion(Amfebutamo				
			ne)	SS			
4 DAY							
			Biaxin				
			(Clarithromycin)	C			

Date:10/29/03ISR Number: 4220678-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0430634A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Medication Error		Wellbutrin	PS	Glaxosmithkline	
	Pharmaceutical Product					
	Complaint					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/03ISR Number: 4220685-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0307425A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Zyban	PS	Glaxosmithkline		150MG Twice	
Hospitalization -	Blood Pressure Increased							per day
Initial or Prolonged	Bradycardia		Valsartan	C				
	Headache							
	Musculoskeletal Stiffness							
	Somnolence							
	Subarachnoid Haemorrhage							

Date:10/29/03ISR Number: 4223117-3Report Type:Expedited (15-DaCompany Report #USA-2003-0007154
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health	Oxycodone					
	Alcohol Use	Professional	Hydrochloride					
	Atherosclerosis	Other	(Similar To Nda					
	Brain Herniation		20-553) (Oxycodone					
	Brain Oedema		Hydrochloride)	PS				
	Cardiomegaly		Bupropion					
	Congestive Cardiomyopathy		(Amfebutamone)	SS				
	Drug Abuser		Ethanol (Ethanol)	SS				
	Drug Screen Positive							
	Drug Toxicity							
	Ecchymosis							
	Scab							

Date:10/29/03ISR Number: 4223361-5Report Type:Expedited (15-DaCompany Report #USA-2003-0007532
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly	Health	Oxycodone					
	Completed Suicide	Professional	Hydrochloride	PS				
	Intentional Misuse	Other	Hydrocodone					
	Multiple Drug Overdose		Bitartrate (Similar					
	Pulmonary Congestion		To Ind					

Pulmonary Oedema	59,175)(Naltrexone,	
	Paracetamol,	SS
	Acetaminophen(Paracetamol)	SS
	Mirtazapine(Mirtazapine)	SS
	Alprazolam(Alprazolam)	SS
	Olanzapine(Olanzapine)	SS
	Sertraline(Sertraline)	SS
	Trazodone(Trazodone)	SS
	Bupropion(Amfebutamone)	SS

Date:10/30/03ISR Number: 4222178-5Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0398320A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Aspiration		Wellbutrin	PS	Glaxosmithkline			
	Depressed Level Of Consciousness		Citalopram	SS				
			Methotrimeprazine	SS				
	Dystonia							
	Electrocardiogram Qt Prolonged							
	Fall							
	Grand Mal Convulsion							
	Intentional Misuse							

Date:10/30/03ISR Number: 4222187-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0432011A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	1	DAY
	Lethargy							
	Medication Error							

Date:10/30/03ISR Number: 4222193-1Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0312414A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Zyban	PS	Glaxosmithkline	ORAL		
	Cardiac Enzymes Increased		Ascorbic Acid	C	Glaxosmithkline			
	Epilepsy		Aspirin Junior	C	Glaxosmithkline			
	Malaise		Multivitamin With Zinc	C				
	Syncope		Selenium	C				
	Ventricular Fibrillation		Glucosamine Sulphate	C				
	White Blood Cell Count Increased							

Date:10/30/03ISR Number: 4223978-8Report Type:Expedited (15-DaCompany Report #S03-USA-04440-01
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State Convulsion	Health Professional	Lexapro (Escitalopram)	PS		ORAL	10 MG QD PO	
	Gastrooesophageal Reflux Disease Staring		Wellbutrin (Bupropion Hydrochloride)	SS			200 MG BID	
	Throat Irritation		Wellbutrin (Bupropion Hydrochloride)	SS			100 MG BID	
			Wellbutrin (Bupropion Hydrochloride)	SS			100 MG QD	
			Neurontin (Gabapentin)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/03ISR Number: 4223303-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0357840A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort		Paxil	PS	Glaxosmithkline			5 MON
Hospitalization - Initial or Prolonged	Abortion Spontaneous		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
Other	Aggression		Effexor	C				
	Agitation		Ativan	C			.5MG As required	
	Agoraphobia							
	Alcoholism		Atenolol	C			25MG Per day	
	Anger		Alcohol	C				
	Anxiety		Valium	C		ORAL		
	Blood Creatinine Decreased							
	Blood Sodium Decreased							
	Chest Discomfort							
	Confusional State							
	Convulsion							
	Dependence							
	Dizziness							
	Drug Abuser							
	Drug Dependence							
	Drug Ineffective							
	Drug Withdrawal Syndrome							
	Dyspepsia							
	Dyspnoea							
	Feeling Hot							
	Flat Affect							
	Hypoaesthesia							
	Influenza							
	Insomnia							
	Intentional Self-Injury							
	Ketoacidosis							
	Loss Of Consciousness							
	Mental Disorder							
	Nausea							
	Nightmare							
	Panic Disorder							
	Paraesthesia							
	Pco2 Decreased							
	Platelet Count Increased							
	Pyrexia							

Suicidal Ideation
Suicide Attempt
Tremor
Urine Analysis Abnormal

Date:10/31/03ISR Number: 4223315-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0424693A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 DAY
	Second Degree							
	Bradycardia							
	Fatigue							
	Syncope Vasovagal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/03ISR Number: 4223317-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0426335A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	16	WK
	Drug Ineffective		Zyprexa	C			10MG Per day	
	Grand Mal Convulsion		Trileptal	C			600MG Twice per day	
	Tongue Biting							

Date:10/31/03ISR Number: 4223318-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0428237A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Wellbutrin	SS	Glaxosmithkline		150MG Per day	5 DAY

Date:10/31/03ISR Number: 4223319-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0431158A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Convulsion		None	C				
	Joint Dislocation							
	Tongue Biting							

Date:10/31/03ISR Number: 4223326-3Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0307425A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Aneurysm	Zyban	PS	Glaxosmithkline
150MG Twice				
Hospitalization -	Bradycardia			
per day				
Initial or Prolonged	Headache	Valsartan	C	
	Musculoskeletal Stiffness			
	Somnolence			
	Subarachnoid Haemorrhage			

Date:10/31/03ISR Number: 4224878-XReport Type:Expedited (15-DaCompany Report #KII-2003-0004112
Age:43 YR Gender:Male I/FU:I

Outcome	PT
Death	Acid Base Balance
Life-Threatening	Abnormal
Hospitalization -	Blood Glucose Abnormal
Initial or Prolonged	Blood Lactic Acid
Other	Increased
	Blood Pressure Decreased
	Blood Pressure Increased
	Body Temperature
	Increased
	Bradycardia
	Cardiac Arrest
	Coma
	Depression
	Electrocardiogram Qt
	Corrected Interval
	Prolonged
	Electroencephalogram
	Abnormal

	Heart Rate Increased Miosis Multiple Drug Overdose	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Muscle Twitching Mydriasis Posturing Pupil Fixed Respiratory Rate Decreased	Health Professional Other	Oxycontin Cr Methadone (Methadone) Trazodone(Trazodone) Gabapentin(Gabapentin)	PS SS SS SS			400 MG
	Respiratory Rate Increased		Quetiapine(Quetiapine)	SS			200 MG
			Citalopram(Citalopram)	SS			20 MG
			Clonazepam (Clonazepam)	SS			1 MG
			Zanaflex(Tizanidine Hydrochloride)	SS		ORAL	4 MG, ORAL
			Bupropion(Amfebutamone)	SS			150 MG
			Cyclobenazprine(Cyclobenzaprine)	SS			10 MG
			Amitriptyline(Amitriptyline)	SS			50 MG
			Estalopram()	SS			

Date:10/31/03ISR Number: 4225127-9Report Type:Direct Company Report #USP 56117
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Medication Error		Wellbutrin Sr	PS	Glaxo Smithkline		TABLET,EXTEND ED RELEASE
			Wellbutrin Xl	SS	Glaxosmithkline		TABLET,

EXTENDED

RELEASE

Date:11/03/03ISR Number: 4224539-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0431972A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Arthritis						per day	5 YR
	Psoriasis		Synthroid	C	Glaxosmithkline			
			Atenolol	C				
			Cozar	C				
			Thiazide	C				
			Fosamax	C				

Date:11/03/03ISR Number: 4224540-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0432114A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Clumsiness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dysgraphia						per day	
	Muscle Rigidity		Risperdal	C				
	Neuroleptic Malignant Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/03ISR Number: 4224542-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0432276A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:11/03/03ISR Number: 4224546-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0309306A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Discomfort		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Respiratory Distress		Duphaston	C		ORAL	1UNIT See dosage text	
	Urticaria Generalised							

Date:11/03/03ISR Number: 4224548-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0309578A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Apathy		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 DAY
	Asthenia							
	Tongue Disorder		Alcohol	C				
	Tremor		Tobacco	C				
	Vertigo							

Date:11/03/03ISR Number: 4224556-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0312731A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	7 DAY
			Bendrofluazide	C	Glaxosmithkline	ORAL	2.5MG per day	

Date:11/03/03ISR Number: 4225263-7Report Type:Direct Company Report #CTU 205089
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Urticaria		Wellbutrin Xl	PS			1 PER DAY	
Intervention to Prevent Permanent Impairment/Damage								

Date:11/03/03ISR Number: 4226117-2Report Type:Expedited (15-DaCompany Report #2003-DE-05117GD
Age:20 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Theophylline	PS				
	Multiple Drug Overdose		Bupropion (Amfebutamone)	SS				
			Heroin (Diamorphine0	SS				

Date:11/03/03ISR Number: 4226470-XReport Type:Expedited (15-DaCompany Report #K200301715
Age:20 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Quibron-T/Sr					
	Intentional Misuse	Health Professional	(Theophylline) Tablet, 300mg	PS		ORAL	ORAL	

			Bupropion (Amfebutamone)	SS		
ORAL						
			Heroin (Diamorphine)	SS		
INHALATION						

Date:11/03/03ISR Number: 4226849-6Report Type:Expedited (15-DaCompany Report #2003-DE-05279GD
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest	Literature	Methadone			
	Intentional Misuse		(Methadone)	PS		ORAL
PO						
			Diazepam Intensol (Diazepam)	SS		
			Bupropion (Amfebutamone)	SS		

Date:11/03/03ISR Number: 4226988-XReport Type:Expedited (15-DaCompany Report #2003-DE-05212GD
Age:47 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest	Literature	Alprazolam	PS		
	Completed Suicide		Methadone			
	Multiple Drug Overdose		(Methadone)	SS		
			Bupropion (Amfebutamone)	SS		

Date:11/03/03ISR Number: 4227089-7Report Type:Expedited (15-DaCompany Report #2003-DE-05417GD
Age:38 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest	Literature	Alprazolam	PS		ORAL
PO						
	Completed Suicide		Paracetamol			
	Respiratory Arrest		(Paracetamol)	SS		ORAL
PO						
			Bupropion			

			(Amfebutamone)	SS		ORAL

PO

Date:11/04/03ISR Number: 4225469-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0303990A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Haemorrhage Muscle Rupture		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	1 MON

Date:11/04/03ISR Number: 4225471-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0312384A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hepatic Trauma Pelvic Fracture Suicide Attempt		Zyban	PS	Glaxosmithkline	ORAL	5	WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/03ISR Number: 4225476-4Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0313032A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL	1TAB See	
	Oropharyngeal Swelling						dosage text	15 DAY

Date:11/04/03ISR Number: 4227174-XReport Type:Expedited (15-DaCompany Report #031023-PM0146-00
Age:45 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Tranxene					
	Completed Suicide	Health Professional	(Clorazepate Dipotassium)	PS		ORAL	PO	
			Doxepin	SS		ORAL	PO	
			Bupropion (Long-Acting)	SS		ORAL	PO	

Date:11/05/03ISR Number: 4226759-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0432609A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:11/05/03ISR Number: 4226760-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0432618A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lymphadenopathy		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice	
	Pitting Oedema						per day	3 WK

Date:11/05/03ISR Number: 4226772-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0312762A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Agitation		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
Hospitalization -	Anxiety							
dosage text							3	WK
Initial or Prolonged	Insomnia							
	Overdose							
	Suicidal Ideation							
	Suicide Attempt							

Date:11/05/03ISR Number: 4226779-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0313313A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	11 DAY
	Dizziness							
	Dyspnoea							
	Feeling Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/03ISR Number: 4227868-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0354550A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	
Initial or Prolonged	Aggression		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice	
Other	Agitation						per day	
	Anger		Ritalin	C				
	Anorexia		Amoxicillin	C	Glaxosmithkline			
	Anxiety							
	Asthenia							
	Confusional State							
	Coordination Abnormal							
	Depression							
	Disturbance In Attention							
	Dizziness							
	Drug Ineffective							
	Drug Withdrawal Syndrome							
	Dystonia							
	Fatigue							
	Gait Disturbance							
	Homicidal Ideation							
	Influenza							
	Intentional Self-Injury							
	Irritability							
	Lethargy							
	Malaise							
	Memory Impairment							
	Myalgia							
	Nausea							
	Nightmare							
	Obsessive Thoughts							
	Obsessive-Compulsive Disorder							
	Paraesthesia							
	Paranoia							
	Pyrexia							
	Suicidal Ideation							
	Suicide Attempt							
	Tremor							
	Vertigo							

Date:11/06/03ISR Number: 4227894-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0371291A
Age:36 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cataract
Other	Confusional State
	Crying
	Dissociation
	Drooling
	Drug Ineffective
	Dysgeusia
	Dyskinesia
	Emotional Disorder
	Excoriation
	Feeling Jittery
	Gastric Disorder
	Grand Mal Convulsion
	Head Injury
	Insomnia

	Mania						
	Musculoskeletal Stiffness						
	Nail Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice
	Pain						per day 2 YR
	Prescribed Overdose		Lamictal	SS	Glaxosmithkline	ORAL	
	Psoriasis		Wellbutrin	SS	Glaxosmithkline	ORAL	
	Road Traffic Accident		Pain Medication	SS		ORAL	
	Scratch		Wellbutrin	SS	Glaxosmithkline	ORAL	600MG per day
	Thinking Abnormal		Ultracet	SS			
	Tooth Loss		Seroquel	SS		ORAL	
	Vaginal Infection		Nicotine Gum	SS	Glaxosmithkline	ORAL	
	Vaginal Mycosis		Zyprexa	SS		ORAL	
	Vomiting		Klonopin	C		ORAL	
	Weight Decreased		Lorazepam	C			
	Weight Increased		Ortho Tri-Cyclen	C		ORAL	
			Nicotine Patch	C	Glaxosmithkline		TRANSDERMAL
			Effexor	C			
			Lescol	C			

Date:11/06/03ISR Number: 4227922-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0313314A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	6 DAY
Initial or Prolonged	Facial Palsy		Thyroxine	C	Glaxosmithkline		UNKNOWN
Disability	Monoplegia						

Date:11/06/03ISR Number: 4227923-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0313315A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice

		Eye Swelling					
per day	18 DAY						
		Rash Pruritic		Viagra	C		
UNKNOWN							
		Swelling Face					

Date:11/06/03ISR Number: 4227925-4Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0313519A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose		Zyban	PS	Glaxosmithkline		150MG Twice per day	

Date:11/07/03ISR Number: 4228850-5Report Type:Expedited (15-DaCompany Report #PHEH2003US07744
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zelnorm	PS	Novartis Sector: Pharma		6 mg, BID	
	Drug Screen Positive							
	Overdose		Wellbutrin	SS			150 mg, BID	87840MIN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229253-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0095466A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Heart Rate Increased		Singulair	SS			UNKNOWN	

Date:11/07/03ISR Number: 4229254-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0124877A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Atrophy		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG per day	7 MON
	Rhabdomyolysis Weight Decreased							

Date:11/07/03ISR Number: 4229255-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0145456A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	250MG per day	
			Prozac	C			20MG Per day	
			Oxycontin	C			80MG Twice per day	
			Antibiotic	C				

Date:11/07/03ISR Number: 4229256-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0150345A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Cheilitis		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Dizziness					
per day 5 DAY						
	Drug Ineffective		Synthroid	C	Glaxosmithkline	
	Herpes Simplex		Estrogen	C		
	Influenza Like Illness		Benzalin	C		
	Lip Pain		Estratest	C		
	Nausea					
	Somnolence					

Date:11/07/03ISR Number: 4229261-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0154448A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL
200MG Twice						
	Depression					
per day						
	Drug Ineffective		Lithium	C	Glaxosmithkline	ORAL
300MG Twice						
	Pharmaceutical Product					
per day						
	Complaint		Klonopin	C		ORAL

Date:11/07/03ISR Number: 4229267-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0156099A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 1 WK						
	Fatigue		Synthroid	C	Glaxosmithkline	
	Hypoaesthesia					
	Myalgia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229268-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0157048A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Rash							
per day								13 DAY
	Tinnitus							

Date:11/07/03ISR Number: 4229269-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0360415A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Multiforme		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Stevens-Johnson Syndrome							
per day								13 DAY

Date:11/07/03ISR Number: 4229270-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0369580A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Headache							
per day								1 DAY
	Nausea		Wellbutrin	C	Glaxosmithkline	ORAL	100MG Twice	
	Pain In Jaw							
per day								3 DAY
	Paraesthesia							
	Paranoia							
	Pharyngolaryngeal Pain							

Date:11/07/03ISR Number: 4229271-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0371577A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG See	
	Anxiety						dosage text	10 YR
	Dizziness		Premarin	C				
	Drug Ineffective		Lopressor	C				
	Euphoric Mood		Trileptal	C				
	Rash		Buspar	C				
	Rosacea		Neurontin	C				
	Stress							
	Vision Blurred							

Date:11/07/03ISR Number: 4229272-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0372805A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Oedema Peripheral	Professional					per day	3 WK
	Pruritus							
	Rash Generalised							
	Swelling Face							

Date:11/07/03ISR Number: 4229279-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0374355A
Age:56 YR Gender:Female I/FU:F

Outcome	PT
	Abdominal Discomfort
	Abdominal Pain Upper

Eructation						
Feeling Hot						
Food Intolerance	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hepatocellular Damage		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice
Weight Decreased						per day 143 DAY
		Glucophage	C			
		Amaryl	C			
		Avandia	C	Glaxosmithkline		
		Calcium	C			
		Vitamin	C			
		Prinivil	C			
		Levoxyl	C	Glaxosmithkline		
		Unknown Medication	C			

Date:11/07/03ISR Number: 4229280-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0375304A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Per day YR
	Hyperhidrosis		Atacand	C			
	Rash		Orth Novum 777	C			
			Amitriptyline	C			

Date:11/07/03ISR Number: 4229281-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0375429A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown
	Pharmaceutical Product Complaint						

Date:11/07/03ISR Number: 4229282-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0376012A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	13 DAY
	Chest Pain		Imipramine	C		ORAL	25MG Unknown	
	Dyspnoea Swelling Face Urticaria		Lipitor	C				

Date:11/07/03ISR Number: 4229284-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0377324A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	6 MON
			Xanax	C		ORAL	.25MG As required	
			Oral Contraceptive	C				
			Zyrtec	C	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229285-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0379148A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice	
	Amnesia						per day	6 MON
	Tremor							

Date:11/07/03ISR Number: 4229286-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0379578A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Stool Analysis Abnormal						per day	
			Multivitamin	C				
			Calcium	C				
			Fosamax	C			70MG Weekly	
			Effexor	C		ORAL	75MG Twice	
							per day	
			Activelle	C		ORAL	1MG Per day	

Date:11/07/03ISR Number: 4229287-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0379734A
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ejaculation Delayed		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	2 MON
	Irritability							
	Tremor							

Date:11/07/03ISR Number: 4229288-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0380279A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion	PS	Glaxosmithkline	ORAL		
			Depakote	SS		ORAL		

Date:11/07/03ISR Number: 4229289-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0380405A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	21	DAY
Other								

Date:11/07/03ISR Number: 4229290-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0380854A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Gastrointestinal Pain						per day	
	Pharmaceutical Product Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229291-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0381642A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Alkaline		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	50MG Per day	
	Phosphatase Increased		Zoloft	SS		ORAL	200MG Per day	
	Fatigue							
	Hepatitis							
	Lethargy							
	Liver Function Test Abnormal							
	Weight Decreased							

Date:11/07/03ISR Number: 4229292-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382141A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	2 WK
			Entex Pse	C				
			Humibid La	C				
			Acyclovir	C	Glaxosmithkline			
			Ibuprofen	C	Glaxosmithkline			
			Trazodone	C				
			Claritin	C				

Date:11/07/03ISR Number: 4229293-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382142A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypothyroidism		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229294-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382155A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomatitis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON

Date:11/07/03ISR Number: 4229295-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382156A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY

Date:11/07/03ISR Number: 4229296-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382157A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
			Vioxx	C				
UNKNOWN							25MG Unknown	
			Synthroid	C	Glaxosmithkline			
			Multivitamin	C				
			Claritin D	C				
			Calcium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229297-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382159A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229298-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382162A
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline		250MG Per day	1 YR
			Diflucan	SS		ORAL		

Date:11/07/03ISR Number: 4229299-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382178A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR

Date:11/07/03ISR Number: 4229300-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382181A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	4 MON
	Hypoaesthesia		Estrogen	C				
	Nausea							
	Paraesthesia							
	Paranoia							
	Tinnitus							

Date:11/07/03ISR Number: 4229301-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382233A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 DAY
	Complaint							
	Somnolence							
	Urticaria							

Date:11/07/03ISR Number: 4229302-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382262A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229303-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382282A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 MON
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229304-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382336A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Unknown
	Nervousness							

Date:11/07/03ISR Number: 4229305-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382337A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Contractions		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 WK
	Involuntary		Synthroid	C	Glaxosmithkline			
			Allegra	C				

Date:11/07/03ISR Number: 4229306-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382399A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Complaint		Unknown Medication	C				
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4229307-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382431A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Complaint						per day	5 MON
	Stool Analysis Abnormal		Imitrex	C	Glaxosmithkline			
			Ambien	C				

Date:11/07/03ISR Number: 4229309-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382447A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229310-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382455A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Paraesthesia						per day	17 DAY
			Menest	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229311-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382461A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	2 WK
	Complaint		Lipitor	C				
	Stool Analysis Abnormal		Ziac	C				
			Paxil	C	Glaxosmithkline			
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229312-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382463A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229313-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382467A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Middle Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	WK
			Estrogen	C				

Date:11/07/03ISR Number: 4229314-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382468A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK
			Klonopin	C				

Date:11/07/03ISR Number: 4229315-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382496A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Abuser Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229316-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382605A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Complaint							
per day								2 YR
	Stool Analysis Abnormal		Glucophage	C				
	Vomiting		Neurontin	C				
			Betapace	C	Glaxosmithkline			
			Lanoxin	C	Glaxosmithkline			
			Buspar	C				

Date:11/07/03ISR Number: 4229318-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382608A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia							
per day								3 MON
	Tremor							

Date:11/07/03ISR Number: 4229319-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382653A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229320-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382681A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Paraesthesia						per day	3 MON
	Pruritus		Mobic	C				

Date:11/07/03ISR Number: 4229321-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382684A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	6 WK

Date:11/07/03ISR Number: 4229322-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382694A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR
			Paxil	C	Glaxosmithkline			
			Ambien	C				
			Hrt	C				

Date:11/07/03ISR Number: 4229323-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382778A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Hormone Replacement	C				

Date:11/07/03ISR Number: 4229324-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382789A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229325-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382801A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
			Adderall	C			10MG Per day	
			Trazodone	C			50MG At night	
			Adderall Xr	C			10MG Twice per day	

Date:11/07/03ISR Number: 4229326-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382804A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Irritability		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229327-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382811A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Urticaria						per day	16 DAY
			Tylenol	SS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229328-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382835A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
Initial or Prolonged	Intentional Misuse	Professional	Celexa	SS				
Other			Alcohol	SS				

Date:11/07/03ISR Number: 4229329-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382843A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
							per day	

Date:11/07/03ISR Number: 4229330-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382844A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229331-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382846A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Fall							
	Salivary Hypersecretion							

Date:11/07/03ISR Number: 4229332-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382852A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 YR
	Fatigue		Zoloft	C				
	Headache		Klonopin	C				
	Somnolence							

Date:11/07/03ISR Number: 4229333-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382858A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
			Effexor	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229334-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382860A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	

Date:11/07/03ISR Number: 4229335-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382896A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 WK

Date:11/07/03ISR Number: 4229336-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382900A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229337-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382930A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	5 DAY

Date:11/07/03ISR Number: 4229338-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382969A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Vitamins	C				

Date:11/07/03ISR Number: 4229339-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383080A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Strabismus							

Date:11/07/03ISR Number: 4229340-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383081A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Urticaria							

Date:11/07/03ISR Number: 4229341-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383086A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229342-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383169A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
			Lexapro	C			5MG Per day	
			Vitamins	C				
			Lorazepam	C				

Date:11/07/03ISR Number: 4229343-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383255A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Female Sexual Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON
	Urticaria		Celexa	SS			UNKNOWN	

Date:11/07/03ISR Number: 4229344-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383267A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Diltiazem	C	Glaxosmithkline			
			Toprol Xl	C				
			Prevacid	C				
			Lipitor	C				
			Plavix	C				
			Cyclobenzaprine	C				
			Darvocet N	C				

Date:11/07/03ISR Number: 4229345-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383269A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229346-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383403A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Body Dysmorphic Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Disturbance In Attention							

Date:11/07/03ISR Number: 4229347-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383404A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG per day	4 YR
	Depression		Xanax	C		ORAL	.25MG	
	Diarrhoea						Variable dose	
	Medication Residue							
	Pharmaceutical Product							
	Complaint							
	Stool Analysis Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229349-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383427A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Irritability						per day	5 YR

Date:11/07/03ISR Number: 4229350-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383431A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229351-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383441A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229352-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383449A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Paxil	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229353-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383566A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Libido		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	

Sexual Dysfunction

per day 1 YR

Clonazepam C

UNKNOWN 2MG Twice per

day

Date:11/07/03ISR Number: 4229354-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383567A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bipolar Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dyspnoea						per day	
	Urticaria							

Date:11/07/03ISR Number: 4229355-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383598A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Carpal Tunnel Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Plantar Fasciitis						per day	
			Valtrex	C	Glaxosmithkline			
			Buspar	C				
			Ritalin	C				
			Trazodone	C				
			Lamictal	C	Glaxosmithkline			
			Vivactil	C				
			Hctz	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229356-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383603A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	7 DAY
			Remeron	C				
			Paxil Cr	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229357-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383634A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Hypertension		Zocor	C				
			Prevacid	C				

Date:11/07/03ISR Number: 4229358-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383637A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	DAY
	Pharmaceutical Product		Lithium	C	Glaxosmithkline			
	Complaint		Risperdal	C				
	Stool Analysis Abnormal		Effexor Xr	C				
			Ativan	C				
			Buspar	C				
			Geodon	C				

Date:11/07/03ISR Number: 4229359-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383659A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Eye Movement Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 3 DAY						
	Hypoaesthesia					
	Rash Vesicular					

Date:11/07/03ISR Number: 4229360-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383667A
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 2 WK						
	Fatigue		Nitro Patch	C	Glaxosmithkline	
	Feeling Abnormal		Nitrostat	C	Glaxosmithkline	
	Headache		Atenolol	C		
	Laziness		Multi-Vitamins	C		
			Ranitidine	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4229361-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383709A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Memory Impairment					
per day DAY						
	Nausea					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229362-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383720A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	2 MON
	Chest Discomfort		Klonopin	C				
	Dysphagia		Buspirone	C				
	Eructation							
	Musculoskeletal Stiffness							

Date:11/07/03ISR Number: 4229367-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383738A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	
	Restlessness		Paxil	SS	Glaxosmithkline	ORAL		
	Tremor							

Date:11/07/03ISR Number: 4229368-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383766A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	250MG per day	6 YR
	Drug Ineffective							
	Dysphagia							
	Dyspnoea							
	Feeling Abnormal							
	Insomnia							
	Respiratory Failure							
	Speech Disorder							

Date:11/07/03ISR Number: 4229369-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383767A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON

Date:11/07/03ISR Number: 4229370-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383774A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229371-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383800A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Swelling							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229376-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383802A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG per day	3 DAY
	Nightmare		Moduretic	C		ORAL	1TAB Per day	
	Tinnitus		Zocor	C			40MG Per day	
			Vitamin	C				

Date:11/07/03ISR Number: 4229378-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383808A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coordination Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Paxil	SS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229379-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383809A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness						per day	5 MON
	Hypoaesthesia		Zithromax	C			5 DAY	
	Nausea							
	Pollakiuria							
	Weight Decreased							

Date:11/07/03ISR Number: 4229386-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383849A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL
	Feeling Jittery					
	Headache					

Date:11/07/03ISR Number: 4229390-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383881A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Complaint						per day	
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4229391-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383886A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Concerta	C			36MG Per day	
			Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229392-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383930A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion	PS	Glaxosmithkline	ORAL	1	YR
	Drug Interaction		Paxil	SS	Glaxosmithkline	ORAL	1	YR
	Road Traffic Accident							

Date:11/07/03ISR Number: 4229394-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383950A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229395-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383963A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 WK
	Positive							

Date:11/07/03ISR Number: 4229396-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383966A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Balance Disorder							
per day	6 MON							
	Dizziness		Morphine	C				
	Feeling Abnormal		Robaxin	C			500MG Twice	
	Feeling Drunk							
per day								

	Flat Affect		Gabapentin	C			
	Sedation		Tegretol	C			
	Transient Ischaemic		Hydroxyzine	C			
50MG At night							
	Attack		Amitriptyline	C			
50MG At night							

Date:11/07/03ISR Number: 4229397-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383969A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG per day	6 WK

Date:11/07/03ISR Number: 4229398-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0383981A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cheilitis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	WK

Date:11/07/03ISR Number: 4229399-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384016A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG In the morning	6 WK
	Insomnia							
	Mood Swings		Prenatal Vitamins	C				
			Progestin	C				

Protonix	C		
Amoxicillin	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4229400-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384025A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	

Date:11/07/03ISR Number: 4229401-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384026A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON
	Complaint							
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4229402-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384031A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229403-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384034A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Food Poisoning							

	Vomiting		Paxil	C	Glaxosmithkline	ORAL

30MG Per day

Date:11/07/03ISR Number: 4229404-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384061A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229405-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384067A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229406-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384072A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	6	WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229407-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384115A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Topamax	SS			UNKNOWN	

Date:11/07/03ISR Number: 4229408-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384116A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgraphia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Heart Rate Increased		Prozac	C				
	Illiteracy		Trazodone	C				
	Performance Status Decreased							
	Vision Blurred							

Date:11/07/03ISR Number: 4229409-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384117A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Tamoxifen	C				

Date:11/07/03ISR Number: 4229410-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384130A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 YR
	Dry Skin		Estrace	C			UNKNOWN	1MG Unknown
	Skin Exfoliation							

Date:11/07/03ISR Number: 4229411-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384213A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229412-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384590A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Grand Mal Convulsion		Ortho Cyclen	C				
	Irritability							

Date:11/07/03ISR Number: 4229413-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384599A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mood Swings		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229414-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384600A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Urinary Tract Infection							

Date:11/07/03ISR Number: 4229415-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384603A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Pharmaceutical Product Complaint							

Date:11/07/03ISR Number: 4229416-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384607A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three	
	Headache						times per day	7 WK
	Hordeolum		Aspirin	C	Glaxosmithkline		81MG per day	
			Vitamin E	C				
			Calcium	C				
			Vitamin C	C	Glaxosmithkline			
			Centrum	C				

Date:11/07/03ISR Number: 4229417-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384909A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Migraine		Xanax	C				

Date:11/07/03ISR Number: 4229418-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384935A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dry Mouth						per day	3 WK
	Headache							
	Hypersensitivity							
	Weight Decreased							

Date:11/07/03ISR Number: 4229419-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384936A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	

Date:11/07/03ISR Number: 4229420-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384940A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Local Swelling		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	5 DAY
	Rash		Avapro	C				

				Mobic	C		

Date:11/07/03ISR Number: 4229421-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0384995A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice	
	Asthenia						per day	
	Confusional State							
	Dizziness							
	Fatigue							

Date:11/07/03ISR Number: 4229422-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385077A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Tremor						per day	5 DAY
			Prozac	C				

Date:11/07/03ISR Number: 4229423-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385078A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Hyperhidrosis						per day	1 MON
			Paxil	C	Glaxosmithkline	ORAL	20MG Per day	MON

Date:11/07/03ISR Number: 4229424-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385146A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Pruritus						per day	15 DAY
	Urticaria							

Date:11/07/03ISR Number: 4229425-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385149A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Headache						per day	
	Tinnitus							

Date:11/07/03ISR Number: 4229426-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385151A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	1 YR
	Insomnia							
	Lethargy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229428-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385155A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Dizziness						per day	5 DAY
	Tic							
	Tinnitus							

Date:11/07/03ISR Number: 4229429-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385157A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229430-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385158A
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	2 DAY
	Vomiting							

Date:11/07/03ISR Number: 4229431-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385252A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229432-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385255A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hordeolum		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK

Date:11/07/03ISR Number: 4229433-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385261A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 DAY
	Depression							
	Dizziness		Hormone Replacement Therapy	C				
	Hyperhidrosis							
	Insomnia							

Date:11/07/03ISR Number: 4229434-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385277A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229435-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385283A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Benadryl	C	Glaxosmithkline			
			Asthma Medication	C				

Date:11/07/03ISR Number: 4229436-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385292A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229437-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385408A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Vomiting							
			Lithium	C	Glaxosmithkline			
			Methadone	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229445-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385419A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229446-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385464A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON

Date:11/07/03ISR Number: 4229447-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385525A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON
	Dysgeusia							
	Parosmia		Prozac	C			UNKNOWN	40MG Per day
			Roxicodone	C			5MG Twice per day	
			Oxycontin	C			20MG Twice per day	
			Flexeril	C			UNKNOWN	10MG Twice per day

Date:11/07/03ISR Number: 4229448-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385532A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229449-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385537A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Depakote	SS		ORAL		

Date:11/07/03ISR Number: 4229450-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385539A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
	Positive		Aspirin	C	Glaxosmithkline		UNKNOWN	

Date:11/07/03ISR Number: 4229451-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385542A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Constipation						per day	13 DAY
	Hangover		Coumadin	C	Glaxosmithkline	ORAL		
	Sebaceous Glands		Zocor	C		ORAL	40MG Per day	
	Overactivity							
	Suicidal Ideation							
	Throat Tightness							

Date:11/07/03ISR Number: 4229453-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385554A
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG At	

	Dry Mouth						
night DAY							
	Fatigue			Celexa	C		
				Altace	C		
				Amaryl	C		
				Aciphex	C		
				Lipitor	C		
				Lopressor	C		

Date:11/07/03ISR Number: 4229455-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385582A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL
	Urinary Incontinence		Flomax	SS		
UNKNOWN						

Date:11/07/03ISR Number: 4229456-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385587A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL
	Aura		Ativan	C		ORAL
1MG Per day						
	Convulsion					
	Grand Mal Convulsion					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229457-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385704A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/07/03ISR Number: 4229458-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385738A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
	Complaint							
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4229459-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385746A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retinal Vascular Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR

Date:11/07/03ISR Number: 4229460-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385762A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Throat Tightness							

Date:11/07/03ISR Number: 4229461-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385787A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG In the morning	
			Prozac	C			20MG Per day	
			Remeron	C			15MG At night	
			Asa	C	Glaxosmithkline			
			Mvi	C				
			Vioxx	C				

Date:11/07/03ISR Number: 4229462-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385819A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	6 DAY
			Diclofenac	C				

Date:11/07/03ISR Number: 4229463-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385825A
Age:10 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
	Eye Swelling							
	Fatigue		Amoxicillin	C	Glaxosmithkline			
	Oedema Peripheral		Trimex	C	Glaxosmithkline			
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229473-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385893A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown YR
	Complaint		Fluoxetine	C				
	Somnolence							

Date:11/07/03ISR Number: 4229474-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385895A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Electrocardiogram		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Abnormal							

Date:11/07/03ISR Number: 4229475-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385896A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:11/07/03ISR Number: 4229476-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385899A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea							
per day	2 WK							
	Palpitations							
	Throat Tightness							
	Tremor							

Date:11/07/03ISR Number: 4229477-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385950A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/07/03ISR Number: 4229478-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385977A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229479-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385984A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229480-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385987A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON

Date:11/07/03ISR Number: 4229481-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386031A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Consciousness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
	Road Traffic Accident							
			Elavil	C	Glaxosmithkline			
			Norvasc	C				
			Blood Pressure Medication	C				

Date:11/07/03ISR Number: 4229482-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386069A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hot Flush							

Date:11/07/03ISR Number: 4229483-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386071A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229484-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386081A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Complaint							
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4229485-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386100A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
			Zoloft	C				
			Depakote	C				
			Valium	C				

Date:11/07/03ISR Number: 4229486-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386162A
Age:38 YR Gender:Female I/FU:F

Outcome	PT
	Contusion
	Formication
	Joint Swelling
	Muscle Tightness

	Pruritus						
	Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day 18 DAY

Date:11/07/03ISR Number: 4229491-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386170A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day
	Hypokalaemia						

Date:11/07/03ISR Number: 4229492-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386175A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day

Date:11/07/03ISR Number: 4229493-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386188A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day
Other			Ritalin	C			
			Unknown Medication	C			

Date:11/07/03ISR Number: 4229494-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386189A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Weight Increased						per day	3 MON

Date:11/07/03ISR Number: 4229495-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386191A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Chest Pain		Levothroid	C	Glaxosmithkline			
	Dizziness		Alcohol	C				
	Headache							
	Panic Attack							

Date:11/07/03ISR Number: 4229501-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386193A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229502-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386230A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 DAY
			Xanax	C				

Date:11/07/03ISR Number: 4229503-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386256A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229504-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386296A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	WK
	Flushing							
	Headache							
	Hypertension							
	Insomnia							

Date:11/07/03ISR Number: 4229505-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386326A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
	Swelling							

	Vasodilatation		Prozac	C		
			Avalide	C		

Date:11/07/03ISR Number: 4229506-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386338A
Age:10 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL		21 DAY
Initial or Prolonged	Arthralgia		Penicillin	SS	Glaxosmithkline			
Other	Eye Swelling		Benadryl	C	Glaxosmithkline			
	Lethargy		Zyrtec	C	Glaxosmithkline			
	Oedema Peripheral		Zithromax	C				
	Serum Sickness		Cleocin	C				
	Urticaria							

Date:11/07/03ISR Number: 4229512-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386396A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Complaint							
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229513-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386425A
Age:44 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Levbid	C			UNKNOWN	
			Allergy Shots	C			UNKNOWN	
			Levsin Sl	C			UNKNOWN	.125MG Per day

Date:11/07/03ISR Number: 4229514-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386462A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradyphrenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Memory Impairment							
			Prozac	C			10MG Per day	

Date:11/07/03ISR Number: 4229515-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386520A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Rash Generalised							
	Serum Sickness							
	Urticaria							

Date:11/07/03ISR Number: 4229526-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386521A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Depression						per day	2 WK
	Insomnia							
	Pruritus							
	Rash							
	Rash Erythematous							

Date:11/07/03ISR Number: 4229527-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386522A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	25MG Per day	6 WK
	Insomnia							

Date:11/07/03ISR Number: 4229528-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386524A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 MON
			Pravachol	C				
			Blood Pressure Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229529-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386525A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphemia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG In the morning	
			Paxil	C	Glaxosmithkline	ORAL	2	YR
			Unknown Medication	C				

Date:11/07/03ISR Number: 4229530-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386526A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/07/03ISR Number: 4229531-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386533A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229532-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386558A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotension		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229533-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386560A
Age: Gender: I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration

Rash Wellbutrin PS Glaxosmithkline ORAL

Date:11/07/03ISR Number: 4229534-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393385A
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration

Irritability Wellbutrin PS Glaxosmithkline ORAL 300MG Per day

Nervousness

Date:11/07/03ISR Number: 4229535-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393392A
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration

Other Pruritus Wellbutrin PS Glaxosmithkline ORAL 150MG Twice

Rash

per day 16 DAY

Date:11/07/03ISR Number: 4229536-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393397A
Age:74 YR Gender:Female I/FU:F

Outcome PT Report Source Product Role Manufacturer Route Dose Duration

Other Convulsion Wellbutrin PS Glaxosmithkline ORAL 150MG Twice

Tremor

per day MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229537-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393403A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness		Wellbutrin	PS	Glaxosmithkline	ORAL		YR
			Celexa	C				YR

Date:11/07/03ISR Number: 4229538-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393409A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229539-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393511A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229541-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393546A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229542-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393552A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotrichosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	

Sleep Disorder
per day 4 MON
Weight Decreased Adderall Xr C
Orthotricyclen C

Date:11/07/03ISR Number: 4229543-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393777A
Age:12 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Swelling Face						per day	451 DAY
	Weight Increased		Risperdal	C			UNKNOWN	1MG Per day 663 DAY
			Lithium	C	Glaxosmithkline		UNKNOWN	150MG Twice per day 532 DAY
			Zoloft	C			UNKNOWN	150MG Per day 991 DAY
			Clozapine	C			UNKNOWN	.5MG Per day 3 YR

Date:11/07/03ISR Number: 4229544-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393797A
Age:9 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	85 DAY	
Hospitalization - Initial or Prolonged	Cyanosis							
	Musculoskeletal Stiffness							
Other	Opisthotonus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229545-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393805A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229546-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393817A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Chest Wall Pain		Birth Control Pills	C				
			Chondroitin	C				

Date:11/07/03ISR Number: 4229547-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393842A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

Date:11/07/03ISR Number: 4229548-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393847A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	DAY
	Bladder Pain		Celexa	C				
	Disturbance In Attention		Remeron	C				
	Feeling Abnormal		Vitamins	C				
	Insomnia		Ultram	C				
	Nightmare		Nexium	C				

Date:11/07/03ISR Number: 4229553-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393859A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotrichosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229554-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393861A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK

Date:11/07/03ISR Number: 4229558-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393863A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Priapism		Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229559-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393886A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON

Date:11/07/03ISR Number: 4229560-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393971A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Metformin	C				

Date:11/07/03ISR Number: 4229561-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393983A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR
	Drug Ineffective							
	Nervousness							
	Toothache							

Date:11/07/03ISR Number: 4229562-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393989A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	33 DAY

Date:11/07/03ISR Number: 4229563-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394031A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	225MG per day	6 WK
	Decreased Appetite		Klonopin	C			.25MG Twice per day	
	Dry Mouth							
	Headache		Tylenol	C	Glaxosmithkline			
	Nausea							
	Nervousness							
	Palpitations							
	Sleep Disorder							

Date:11/07/03ISR Number: 4229564-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394056A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR
			Clinoril	C				
			Atacand	C				
			Plaquenil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229565-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394063A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Rash						per day	4 MON
	Urticaria							

Date:11/07/03ISR Number: 4229566-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394067A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229567-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394204A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bronchospasm		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Depression						per day	
	Hypersensitivity							

Date:11/07/03ISR Number: 4229568-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394264A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash						per day	2 WK

Date:11/07/03ISR Number: 4229569-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394270A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Headache						per day	2 MON
			Advair	C	Glaxosmithkline	RESPIRATORY		
						(INHALATION)		
			Vicodin	C				
			Nebulizer	C				
			Nicotine Patch	C	Glaxosmithkline	INTRADERMAL		

Date:11/07/03ISR Number: 4229570-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394274A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Therapeutic Response						per day	
	Unexpected		Paxil	C	Glaxosmithkline			
			Lipitor	C				
			Vioxx	C				
			Hrt	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229571-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394314A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	6 MON
	Vomiting		Celebrex	C				
			Prilosec	C				

Date:11/07/03ISR Number: 4229572-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394327A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 WK

Date:11/07/03ISR Number: 4229573-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394329A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Potassium Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Serzone	C				
			Thyroid Medication	C				

Date:11/07/03ISR Number: 4229574-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394436A
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash Generalised						per day	2 WK

Date:11/07/03ISR Number: 4229575-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394439A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hyperhidrosis							
	Premature Menopause							

Date:11/07/03ISR Number: 4229576-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394531A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229577-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394639A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	
			Celexa	C			40MG In the	
							morning	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229578-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394644A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Diarrhoea						per day	9 MON
	Flushing							
	Night Sweats							

Date:11/07/03ISR Number: 4229579-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394708A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three	
	Hypersomnia						times per day	
	Sexual Dysfunction							

Date:11/07/03ISR Number: 4229580-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394730A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/07/03ISR Number: 4229581-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394818A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Prempro	C				
			Synthroid	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229582-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394819A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	4 MON

Date:11/07/03ISR Number: 4229583-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394821A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Consciousness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Syncope		Valproic Acid	C				
	Tachycardia		Alka Seltzer	C				

Date:11/07/03ISR Number: 4229584-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394830A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Insomnia		Aciphex	C				
	Pharyngolaryngeal Pain		Flexeril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229585-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394866A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	46 DAY
	Convulsion							
	Grand Mal Convulsion							
	Tonic Clonic Movements							

Date:11/07/03ISR Number: 4229586-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394872A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Gastric Disorder							
per day	1 WK							
	Palpitations							

Date:11/07/03ISR Number: 4229587-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394992A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Fall							
per day	12 MON							
	Feeling Abnormal		Zoloft	C				
	Loss Of Consciousness							
	Road Traffic Accident							
	Skin Laceration							

Date:11/07/03ISR Number: 4229588-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395022A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	
UNKNOWN						

Date:11/07/03ISR Number: 4229589-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395040A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hair Metal Test							
	Parosmia							
	Skin Odour Abnormal							

Date:11/07/03ISR Number: 4229590-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395159A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Myalgia							
per day							2	WK

Date:11/07/03ISR Number: 4229591-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395171A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Migraine		Imitrex	SS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229592-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395176A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delusion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Paranoia						per day	

Date:11/07/03ISR Number: 4229593-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395177A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Prozac	C				

Date:11/07/03ISR Number: 4229594-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395213A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	1	DAY

Date:11/07/03ISR Number: 4229595-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395271A
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Anger						per day	1 MON
	Headache							

Date:11/07/03ISR Number: 4229596-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395380A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Obsessive-Compulsive							
per day								1 MON
	Disorder		Prozac	C				
			Zyprexa	C				

Date:11/07/03ISR Number: 4229597-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395382A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Confusional State							
per day								21 DAY
	Impatience		Atenolol	C				
	Irritability		Aleve	C				
	Memory Impairment							
	Personality Change							
	Stress							

Date:11/07/03ISR Number: 4229610-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395387A
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
per day								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229611-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395411A
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Insomnia							
	Nausea							

Date:11/07/03ISR Number: 4229612-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395419A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229613-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395421A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	DAY
			Elavil	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229614-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395423A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Drug Ineffective						per day	2 YR
	Insomnia		Glucophage	C				
	Irritability							

Date:11/07/03ISR Number: 4229615-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395437A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Clumsiness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Disturbance In Attention						per day	6 DAY
	Feeling Abnormal							

Date:11/07/03ISR Number: 4229616-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395466A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Vision Blurred						per day	2 MON

Date:11/07/03ISR Number: 4229617-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395482A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229618-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395487A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Serum Sickness							

Date:11/07/03ISR Number: 4229619-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395503A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229620-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395510A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
	Feeling Abnormal		Comtrex (Daytime)	SS				
	Sexual Dysfunction							

Date:11/07/03ISR Number: 4229626-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395658A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Urticaria		Premarin	C				
			Acyclovir	C	Glaxosmithkline			
			Celebrex	C				

Date:11/07/03ISR Number: 4229627-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395664A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
			Remeron	C				

Date:11/07/03ISR Number: 4229628-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395682A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Zyprexa	C				
			Unknown Medication	C				

Date:11/07/03ISR Number: 4229629-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395690A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229630-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395728A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229631-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395729A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice	
	Pruritus							
per day	Rash						2	MON

Date:11/07/03ISR Number: 4229632-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395831A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Heart Rate Increased		Zebeta	C				

Date:11/07/03ISR Number: 4229633-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395835A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG per day	3 MON
	Hypotrichosis		Oxycontin	C				
			Nortriptyline	C				

Date:11/07/03ISR Number: 4229634-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395875A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229635-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395878A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Prozac	C				

Date:11/07/03ISR Number: 4229636-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395880A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229637-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395884A
Age:21 YR Gender:Female I/FU:I

Outcome	PT
Other	Eczema
	Erythema
	Pallor

Stevens-Johnson Syndrome

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	34 DAY

Date:11/07/03ISR Number: 4229647-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395888A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Energy Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	5 MON
	Hyperhidrosis		Zoloft	SS		ORAL	100U Per day	1 YR
	Weight Increased		Trileptal	C		ORAL	600U Twice per day	YR
			Lopressor	C		ORAL	5MG Per day	YR
			Furosemide	C	Glaxosmithkline	ORAL	20U Per day	YR

Date:11/07/03ISR Number: 4229648-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395891A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229649-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396026A
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	

	Nausea		Concurrent			
	Tremor		Medications	C		
	Vision Blurred					

Date:11/07/03ISR Number: 4229650-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396027A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Insomnia							
	Irritability							

Date:11/07/03ISR Number: 4229651-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396034A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depersonalisation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dissociation						per day	
	Feeling Abnormal							
	Feeling Cold							
	Flight Of Ideas							
	Headache							
	Insomnia							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229652-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396039A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY

Date:11/07/03ISR Number: 4229653-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396040A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Rash							

Date:11/07/03ISR Number: 4229655-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396044A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dyspnoea						per day	
	Nasal Congestion		Bextra	C				
	Nasal Dryness		Norco	C				
			Trazodone	C				
			Singulair	C				
			Zyrtec	C	Glaxosmithkline			
			Prevacid	C				

Date:11/07/03ISR Number: 4229656-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396169A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Interaction						per day	

	Tinnitus		Avandamet	SS	Glaxosmithkline	
UNKNOWN						
			Insulin	SS		
UNKNOWN						

Date:11/07/03ISR Number: 4229657-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396265A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Depression					
per day 1 YR						
	Drug Ineffective		Prozac	C		
20MG Unknown						

Date:11/07/03ISR Number: 4229658-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396267A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Dizziness					
per day 11 DAY						
	Insomnia					
	Nausea					
	Tinnitus					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229665-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396268A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bleeding Time Prolonged		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Menopausal Symptoms						per day	5 MON
	Menorrhagia		Klonopin	C				

Date:11/07/03ISR Number: 4229666-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396289A
Age:77 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Ambien	C				
			Clonopin	C				

Date:11/07/03ISR Number: 4229667-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396290A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	14 DAY
	Choking		Nicotine	C	Glaxosmithkline	NASAL	21MG Unknown	
	Cough							
	Drug Ineffective							
	Energy Increased							
	Headache							
	Libido Increased							
	Malaise							
	Mental Impairment							
	Therapeutic Response							
	Unexpected							
	Weight Increased							

Date:11/07/03ISR Number: 4229668-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396319A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Blindness Transient		Zoloft	C		ORAL	100MG Per day	MON
	Muscle Contractions Involuntary							
	Muscle Twitching							
	Vision Blurred							
	Vomiting							

Date:11/07/03ISR Number: 4229669-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396322A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
			Prozac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229670-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396463A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Irritability							

Date:11/07/03ISR Number: 4229671-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396473A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse		Wellbutrin	PS	Glaxosmithkline	ORAL		
Other	Psychotic Disorder							
	Suicide Attempt							

Date:11/07/03ISR Number: 4229672-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396618A
Age:49 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229673-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396652A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Emotional Distress							
	Nausea		Thyroid Medication	C			per day	8 DAY
			Birth Control	C				

Date:11/07/03ISR Number: 4229674-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396653A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Electroencephalogram Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229675-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396655A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Apnoea Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG In the morning	

Date:11/07/03ISR Number: 4229676-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396659A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Extrasystoles		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Musculoskeletal Stiffness							
			Lithium	C	Glaxosmithkline			
			Nitroglycerin	C	Glaxosmithkline			
			Plavix	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229678-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396718A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229679-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396731A
Age:12 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complex Partial Seizures		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	
	Convulsion							
	Tongue Paralysis		Risperidal	C		ORAL		

Date:11/07/03ISR Number: 4229680-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396739A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	MON
			Lexapro	C				

Date:11/07/03ISR Number: 4229681-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396760A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product Complaint	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	2 MON
	Retching		Prozac	C		ORAL	40MG Per day	

			Ambien	C		ORAL
10MG At night						
			Provigil	C		ORAL
			Gabatril	C		ORAL

Date:11/07/03ISR Number: 4229682-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396771A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Trigeminal Neuralgia		Wellbutrin	PS	Glaxosmithkline	ORAL
			Medroxyprogesterone	C		

Date:11/07/03ISR Number: 4229683-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396784A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Per day 1 DAY						
	Swelling Face		Vitamins	C		
			Ambien	C		

Date:11/07/03ISR Number: 4229684-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397023A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229685-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397029A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229686-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397033A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
Other	Hypertension							

Date:11/07/03ISR Number: 4229687-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397040A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR
	Feeling Abnormal		Remeron	C			UNKNOWN	45MG Per day
	Insomnia							
	Palpitations							
	Restlessness							
	Tinnitus							

Date:11/07/03ISR Number: 4229688-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397041A
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG In the	

Drug Ineffective
morning 2 YR
Pharmaceutical Product Lorazepam C
Complaint Calcium C
Vitamin C C Glaxosmithkline
500MG Unknown
Norvasc C

Date:11/07/03ISR Number: 4229690-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397116A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229691-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397132A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Snoring		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Nicoderm	C	Glaxosmithkline	INTRADERMAL		

Date:11/07/03ISR Number: 4229692-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397133A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229693-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397143A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Tinnitus							

Date:11/07/03ISR Number: 4229694-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397148A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK

Date:11/07/03ISR Number: 4229695-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397150A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229696-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397152A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Disturbance In Attention		Prozac	C				
	Dysphasia		Xanax	C				
	Feeling Abnormal							
	Heart Rate Increased							
	Incoherent							
	Panic Reaction							

Date:11/07/03ISR Number: 4229697-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397154A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229698-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397161A
Age:34 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Joint Swelling							
per day	Rash						18	DAY

Date:11/07/03ISR Number: 4229699-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397163A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL		
400MG Per day	Muscle Tightness		Perphenazine	C	Glaxosmithkline		3	MON
			Unknown Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229700-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397168A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Flushing						per day	7 WK
	Heart Rate Increased		Oral Contraceptive	C				
	Increased Appetite							
	Insomnia							
	Nausea							

Date:11/07/03ISR Number: 4229701-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397176A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
	Somnolence		Remeron	C			30MG At night	
			Effexor	C			75MG Per day	

Date:11/07/03ISR Number: 4229702-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397200A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Urticaria		Effexor Xr	C			UNKNOWN	225MG Unknown
			Unithroid	C	Glaxosmithkline		UNKNOWN	175MG Unknown

Date:11/07/03ISR Number: 4229710-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397211A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	28 DAY
	Dry Mouth		Nexium	C				
	Rash Erythematous		Actigall	C				
	Sinus Congestion		Sam E	C				
	Urine Output Decreased		Tylenol Pm	C				
			Trazodone	C			UNKNOWN	
			Librium	C			UNKNOWN	

Date:11/07/03ISR Number: 4229711-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397347A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY
	Dyspnoea		Baby Aspirin	C	Glaxosmithkline			
	Heart Rate Increased		Cataflam	C			50MG Twice per day	

Date:11/07/03ISR Number: 4229712-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397352A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Yawning		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG In the morning	
			Zoloft	SS			UNKNOWN	50MG Per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229713-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397375A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229714-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397382A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	100VA Twice per day	36 DAY
	Paraesthesia							
			Lipitor	C		ORAL		

Date:11/07/03ISR Number: 4229715-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397383A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229716-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397515A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	1 YR

Date:11/07/03ISR Number: 4229718-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397522A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	8 DAY

Date:11/07/03ISR Number: 4229719-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397547A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229720-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397552A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	350MG per day	6 YR
Other	Grand Mal Convulsion		Nortriptyline	C		ORAL	50MG Per day	
			Aricept	C		ORAL	10MG Per day	
			Buspar	C		ORAL	30MG Unknown	

Date:11/07/03ISR Number: 4229721-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397568A
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229722-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397572A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	15 DAY
			Ultram	C				
			Albuterol	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229723-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397573A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 DAY
	Insomnia							
			Ambien	C				
			Unknown Medication	C				

Date:11/07/03ISR Number: 4229724-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397578A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Fall		Birth Control Pills	C				
			Vicodin	C				
			Valium	C				

Date:11/07/03ISR Number: 4229725-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397628A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL		

Homicidal Ideation

Date:11/07/03ISR Number: 4229726-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397633A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK
			Vitamins	C				
			Lipitor	C				
			Prevacid	C				

Date:11/07/03ISR Number: 4229727-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397634A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dreamy State		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	10 DAY
	Impaired Driving Ability		Paxil	SS	Glaxosmithkline		25MG At night	
	Somnolence							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229728-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397638A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Sr	PS	Glaxosmithkline	UNKNOWN	150MG Per day	MON

Date:11/07/03ISR Number: 4229729-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397799A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229730-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397817A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 DAY
	Abnormal Dreams							
	Anxiety		Vitamins	C				
	Hypoaesthesia		Flax Seed Oil	C				
	Neck Pain							
	Nervousness							
	Palpitations							

Date:11/07/03ISR Number: 4229731-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397826A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	

Date:11/07/03ISR Number: 4229732-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397837A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Dry Mouth		Astelin	C		NASAL		
	Feeling Jittery		Vitamins	C				
	Heart Rate Increased							
	Hyperhidrosis							
	Menstrual Disorder							

Date:11/07/03ISR Number: 4229733-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397984A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eczema Weeping		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Pruritus							
per day	2	WK						

Date:11/07/03ISR Number: 4229735-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397992A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
Initial or Prolonged								
per day	16	DAY						
			Oscal	C	Glaxosmithkline			

			Allegra D	C		

Date:11/07/03ISR Number: 4229736-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398041A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intentional Misuse		Wellbutrin	PS	Glaxosmithkline	NASAL		

Date:11/07/03ISR Number: 4229737-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398042A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	18 MON
	Night Sweats		Prevacid	C				
	Weight Decreased		Lodine	C			400MG Per day	
			Zanaflex	C				

Date:11/07/03ISR Number: 4229738-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398172A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three times per day	25 DAY
	Dry Mouth							
	Grand Mal Convulsion							
	Head Injury							
	Incontinence							

Date:11/07/03ISR Number: 4229739-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398183A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	
300MG Per day						
			Lexapro	C		

Date:11/07/03ISR Number: 4229740-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398211A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Unknown						

Date:11/07/03ISR Number: 4229741-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398316A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Unknown	3 WK					
	Dry Mouth					
	Headache					
	Insomnia					
	Stress					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229742-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398332A
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	3	MON
			Oxazepam	C				

Date:11/07/03ISR Number: 4229743-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398333A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Strattera	SS			UNKNOWN	

Date:11/07/03ISR Number: 4229744-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398363A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Syncope		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Effexor	C			UNKNOWN	

Date:11/07/03ISR Number: 4229745-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398364A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Halo Vision		Lamictal	C	Glaxosmithkline			
	Insomnia		Prozac	C				

Date:11/07/03ISR Number: 4229746-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398385A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bezoar		Wellbutrin	PS	Glaxosmithkline	ORAL	22.5G	Single
	Overdose						dose	

Date:11/07/03ISR Number: 4229747-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398387A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229748-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398454A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Pain		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tooth Disorder		Crystal Meth	C				

Date:11/07/03ISR Number: 4229749-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398459A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Unknown 1 WK
			Wellbutrin	SS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229750-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398479A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Syncope		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Effexor	C				
UNKNOWN								

Date:11/07/03ISR Number: 4229751-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398538A
Age:2 MON Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia Neonatal		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Exposure Via Breast Milk							

Date:11/07/03ISR Number: 4229752-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398541A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229753-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398542A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tachycardia							

Date:11/07/03ISR Number: 4229754-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398614A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Liver Function Test	Health	Wellbutrin	PS	Glaxosmithkline	ORAL 150MG Twice
	Abnormal	Professional				per day MON
			Alcohol	SS		ORAL
			Tarka	C		ORAL 2 WK
			Pepcid	C		
			Zantac	C	Glaxosmithkline	
			Tylenol	C	Glaxosmithkline	
			Clonidine	C		ORAL .2U At night
			Norvasc	C		ORAL

Date:11/07/03ISR Number: 4229756-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398664A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:11/07/03ISR Number: 4229757-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398856A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Depression Suicidal		Wellbutrin	PS	Glaxosmithkline	ORAL
	Incoherent		Ambien	C		
			Prinzide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229758-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398858A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Interaction	Professional					per day	3 WK
			Sudafed	SS	Glaxosmithkline		UNKNOWN	

Date:11/07/03ISR Number: 4229759-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398873A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Unknown Medication	C				

Date:11/07/03ISR Number: 4229760-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398928A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Testosterone		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Decreased						per day	1 YR
			Prozac	C				

Date:11/07/03ISR Number: 4229761-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398949A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	3 WK
			Adderall	C				
			Zoloft	C				

Date:11/07/03ISR Number: 4229762-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399030A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Migraine						per day	6 MON
			Topamax	C				
			Klonopin	C				

Date:11/07/03ISR Number: 4229763-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399031A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Unknown	
	Complaint							
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4229764-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399033A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tic		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Ssri	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229766-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399077A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	4 MON
	Tremor		Tiazac	C	Glaxosmithkline			
			Activella	C				
			Colace	C				

Date:11/07/03ISR Number: 4229767-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399079A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoacusis		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG See	
	Tinnitus						dosage text	4 MON
			Prozac	C				
			Klonopin	C				
			Atarax	C				
			Zanaflex	C				

Date:11/07/03ISR Number: 4229768-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399080A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Ranitidine	C	Glaxosmithkline			
			Lipitor	C				
			Prinivil	C				
			Atenolol	C				
			Plavix	C				
			Celexa	C				

Date:11/07/03ISR Number: 4229769-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399095A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Nausea						per day	2 YR
	Vomiting		Creon	C				
			Duragesic	C				
			Klonopin	C				

Date:11/07/03ISR Number: 4229770-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399271A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dizziness		Sam E	C				
			Valerian Root	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229771-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399279A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	NASAL		
	Autonomic Nervous System Imbalance							
	Drug Abuser							
	Heart Rate Increased							
	Intentional Misuse							

Date:11/07/03ISR Number: 4229772-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399299A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 DAY

Date:11/07/03ISR Number: 4229773-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399462A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229774-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399594A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	2 MON
	Insomnia							
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4229775-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399605A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229776-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399640A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anxiety						per day	7 DAY
	Dry Mouth		Combivent	C			RESPIRATORY	
	Insomnia						(INHALATION)	
	Tremor							

Date:11/07/03ISR Number: 4229777-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399647A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	DAY
	Dizziness		Zocor	C				
	Nervousness		Temazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229778-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399824A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	350MG per day	5 MON
	Chills		Allegra	C			UNKNOWN	
	Dizziness		Benadryl	C	Glaxosmithkline		25MG Unknown	
	Nausea							
	Sinusitis							
	Tremor							
	Vomiting							

Date:11/07/03ISR Number: 4229779-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399827A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Semen Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	2 YR
			Adderall	C				

Date:11/07/03ISR Number: 4229780-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399828A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Cytomel	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229781-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399835A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	MON
	Headache		Zoloft	C			100MG Per day	

Date:11/07/03ISR Number: 4229782-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399872A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Paraesthesia						per day	11 DAY
	Peripheral Coldness							

Date:11/07/03ISR Number: 4229783-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399947A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229784-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399967A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Pruritus Generalised							
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229785-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399969A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG	Unknown

Date:11/07/03ISR Number: 4229786-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399971A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229787-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399972A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
	Rash		Zoloft	C				
	Urticaria							

Date:11/07/03ISR Number: 4229790-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0056952A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY
	Bruxism		Elavil	C	Glaxosmithkline			
	Feeling Jittery		Zoloft	C				
	Nervousness		Paxil	C	Glaxosmithkline			
			Pepcid	C				
			Antacids	C				
			Tylenol	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229802-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0365399A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Feeling Hot							

Date:11/07/03ISR Number: 4229803-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0371708A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
			Celexa	C				

Date:11/07/03ISR Number: 4229804-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0381524A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
			Oral Contraceptive	C		ORAL		
			Asthma Medication	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229806-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386565A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229807-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386583A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	per day

Date:11/07/03ISR Number: 4229808-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386605A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	per day

Date:11/07/03ISR Number: 4229809-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386640A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	2	YR
	Dizziness		Neurontin	C				
			Dilantin	C				
			Phenobarb	C				
			Triamterene	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229810-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386654A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	6 YR

Date:11/07/03ISR Number: 4229811-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386664A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	WK
	Anxiety							
	Drug Ineffective		Depakote	C				
	Hyperhidrosis							

Date:11/07/03ISR Number: 4229812-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386699A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Estrogenic Effect		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229813-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386719A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dysgeusia						per day	6 WK
			Desogen	C				
			Mvi	C				
INTRAVENOUS								

Date:11/07/03ISR Number: 4229814-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386720A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Aphthous Stomatitis						per day	2 WK
	Dry Mouth		Androgel	C				
	Erythema							
	Pruritus							
	Rash							
	Swelling Face							
	Tongue Exfoliation							
	Weight Decreased							

Date:11/07/03ISR Number: 4229815-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386757A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Eskalith	C	Glaxosmithkline		450MG Twice per day	

			Inderal	C		ORAL
10MG Twice per day						
			Geodon	C		ORAL
20MG Per day						

Date:11/07/03ISR Number: 4229816-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386761A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229817-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386765A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229818-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386766A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Drug Withdrawal Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229819-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386768A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	4500MG Single dose	
	Convulsion							
	Hypertension							
	Intentional Misuse							
	Overdose							
	Rhabdomyolysis							
	Tachycardia							

Date:11/07/03ISR Number: 4229820-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386770A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG per day	
	Cognitive Disorder							

Date:11/07/03ISR Number: 4229821-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386903A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Anger							
	Convulsion							
	Dry Mouth							
	Feeling Jittery							
	Nausea							
	Overdose							
	Vomiting							

Date:11/07/03ISR Number: 4229822-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386939A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lipitor	C				

Date:11/07/03ISR Number: 4229823-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0386947A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK

Date:11/07/03ISR Number: 4229824-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387013A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Food Craving						per day	
	Headache							
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229826-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387107A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON

Date:11/07/03ISR Number: 4229827-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387119A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Drug Ineffective		Vioxx	C				
			Anaplex	C				

Date:11/07/03ISR Number: 4229828-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387122A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	YR

Date:11/07/03ISR Number: 4229829-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387123A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	YR
	Pharmaceutical Product		Unspecified					
	Complaint		Medication	C			TOPICAL	

Date:11/07/03ISR Number: 4229830-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387212A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Nausea						per day	2 DAY
			Lexapro	C				

Date:11/07/03ISR Number: 4229831-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387241A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	600MG Unknown	1 MON
	Aggression	Professional	Alcohol	SS		ORAL		
	Alcohol Use		Prozac	C				
	Convulsion		Ambien	C				
	Medication Error							
	Postictal State							

Date:11/07/03ISR Number: 4229832-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387252A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	8 MON
			Synthroid	C	Glaxosmithkline		1MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229833-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387309A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	MON
			Ativan	C				

Date:11/07/03ISR Number: 4229834-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387322A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
	Tinnitus							
	Urticaria		Altace	C				

Date:11/07/03ISR Number: 4229835-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387340A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229836-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387373A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Complaint							
	Therapeutic Response Decreased		Protonix	C				
			Reglan	C	Glaxosmithkline			
			Pravachol	C				

			Toprol Xl	C		

Date:11/07/03ISR Number: 4229837-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387376A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229838-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387389A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Increased Appetite							
	Lethargy							

Date:11/07/03ISR Number: 4229839-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387425A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chromaturia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Faeces Discoloured		Nicotine Polacrilex	SS	Glaxosmithkline	ORAL	4	DAY
			Aspirin	C	Glaxosmithkline			
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229840-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387468A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective						per day	
	Insomnia		Ambien	C				
	Weight Decreased							

Date:11/07/03ISR Number: 4229841-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387492A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Obsessive-Compulsive Disorder							
	Sleep Disorder							

Date:11/07/03ISR Number: 4229842-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387563A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See	
	Flushing						dosage text	3 WK

Date:11/07/03ISR Number: 4229843-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387585A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tongue Blistering						per day	3 WK

			Androgel	C		
			Baby Aspirin	C	Glaxosmithkline	
			Unknown Medication	C		

Date:11/07/03ISR Number: 4229844-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387622A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotrichosis		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Avonex	C				

Date:11/07/03ISR Number: 4229845-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387645A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Emotional Disorder		Pravachol	C				
			Prempro	C				

Date:11/07/03ISR Number: 4229846-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387646A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON

				Vitamin	C		
				Sonata	C		

Date:11/07/03ISR Number: 4229847-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387651A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229848-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387673A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
	Crying							
	Depression							
	Difficulty In Walking							
	Dry Mouth							
	Impatience							
	Insomnia							
	Irritability							
	Muscle Fatigue							
	Muscle Tightness							
	Nervousness							
	Somnolence							
	Tinnitus							
	Tremor							

Date:11/07/03ISR Number: 4229849-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387678A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Grand Mal Convulsion							
per day							18	MON
	Memory Impairment							

Date:11/07/03ISR Number: 4229850-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387683A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	
	Headache						Alternate	
	Psychomotor Hyperactivity						days	YR
	Tension							

Date:11/07/03ISR Number: 4229858-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387695A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Odour Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229859-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387702A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Altered Visual Depth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Perception						per day	4 WK

Date:11/07/03ISR Number: 4229860-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387730A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Bupropion	PS	Glaxosmithkline	ORAL		
	Agitation		Depakote	C			UNKNOWN	
	Anxiety		Geodon	C			UNKNOWN	
	Confusional State		Prevacid	C			UNKNOWN	
	Delusion		Lexapro	C			UNKNOWN	
	Disturbance In Attention		Fluoxetine	C			UNKNOWN	
	Dizziness		Nexium	C			UNKNOWN	
	Hallucination							
	Hypertension							
	Nausea							
	Paranoia							
	Psychotic Disorder							
	Tremor							

Date:11/07/03ISR Number: 4229861-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387754A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Pruritus							

Date:11/07/03ISR Number: 4229862-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387797A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Unknown	C				

Date:11/07/03ISR Number: 4229863-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387807A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Nausea							
							per day	3 WK

Date:11/07/03ISR Number: 4229864-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387813A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
Hospitalization -	Eye Rolling						per day	
Initial or Prolonged	Tonic Clonic Movements							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229865-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387821A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY

Date:11/07/03ISR Number: 4229866-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387954A
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	DAY
	Tinnitus		Vioxx	C				
			Atacand	C				
			Motrin	C	Glaxosmithkline			
			Synthroid	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229867-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387972A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	2 WK
Other	Incoherent		Celexa	C		ORAL		

Date:11/07/03ISR Number: 4229868-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387973A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Contractions		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	8 MON
	Involuntary Mydriasis							

Date:11/07/03ISR Number: 4229869-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387975A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	1 YR
			Paxil	SS	Glaxosmithkline	ORAL	20MG Per day	1 YR

Date:11/07/03ISR Number: 4229870-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0387993A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 MON

Date:11/07/03ISR Number: 4229871-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388006A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229872-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388019A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin	PS	Glaxosmithkline	ORAL	50MG Per day	4 MON
			No Concurrent Medication	C				

Date:11/07/03ISR Number: 4229873-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388022A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229874-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388025A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 MON
	Nausea							

Date:11/07/03ISR Number: 4229875-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388127A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229876-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388177A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Serotonin Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229877-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388515A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	29 DAY
			Armour	C			UNKNOWN	30MG Three times per day
			Glucophage Xr	C		ORAL	500MG Twice per day	
			Allegra	C		ORAL		
			Vicodin	C		ORAL		

Date:11/07/03ISR Number: 4229878-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388516A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	16 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229880-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388523A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Diastolic Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
	Blood Pressure Systolic Increased		Serzone	C		ORAL	150MG Twice per day	
	Flushing		Avonex	C			UNKNOWN	
			Ibuprofen	C	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229881-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388561A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
Hospitalization - Initial or Prolonged	Hypertension	Professional	Adderall	SS			UNKNOWN	20MG Unknown WK
Other								

Date:11/07/03ISR Number: 4229882-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388589A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	
			Buspar	C				
			Propecia	C				
			Doxycycline	C			100MG Twice	

per day

			Advair	C	Glaxosmithkline
			Nasonex	C	

Date:11/07/03ISR Number: 4229883-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388592A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY

Date:11/07/03ISR Number: 4229884-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388597A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hypertrophy Breast							

Date:11/07/03ISR Number: 4229885-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388600A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tongue Blistering						per day	MON
			Elavil	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229886-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388604A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective						per day	
	Throat Tightness		Depakote	C				
	Tremor		Diazepam	C				
			Trazodone	C				
			Respiradol	C				
			Neurotin	C				

Date:11/07/03ISR Number: 4229887-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388605A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Muscle Tightness							

Date:11/07/03ISR Number: 4229888-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388606A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Effexor	C				
			Valium	C				

Date:11/07/03ISR Number: 4229889-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388607A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL 150MG Twice per day
			Effexor	C		300MG per day
			Klonopin	C		

Date:11/07/03ISR Number: 4229890-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388647A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG per day	4 WK
	Drug Ineffective							
	Tremor							

Date:11/07/03ISR Number: 4229891-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388878A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	2	YR
	Hyperventilation		Allegra	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229892-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388970A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	7	DAY
	Urinary Hesitation		Xanax	C				
			Blood Pressure Medication	C				

Date:11/07/03ISR Number: 4229893-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388971A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swollen Tongue		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	2 WK
	Vomiting		Ritalin	C				
			Effexor Xr	C				

Date:11/07/03ISR Number: 4229894-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388974A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229895-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388980A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229896-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388984A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Synthroid	C	Glaxosmithkline			
			Lantus	C				

Date:11/07/03ISR Number: 4229897-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389047A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	1 MON
			Diazepam	C				
			Provigil	C				
			Fluoxetine	C				

Date:11/07/03ISR Number: 4229898-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389054A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Zyprexa	C				
UNKNOWN	10MG Per day							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229899-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389090A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Flat Affect							
	Tinnitus							

Date:11/07/03ISR Number: 4229900-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389186A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229902-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389197A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Per day	7 YR
	Drug Interaction		Tegretol	SS			UNKNOWN	
			Risperdal	SS			UNKNOWN	
			Klonopin	C			UNKNOWN	

Date:11/07/03ISR Number: 4229904-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389225A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON

	Sinus Headache		Lupron	C		
INTRAVENOUS						

Date:11/07/03ISR Number: 4229906-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389226A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antisocial Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown 6 MON
			Lithium	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229907-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389461A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Flushing							
per day								5 DAY
	Nausea		Pamelor	C				
	Road Traffic Accident		Daypro	C				
			Premarin	C				

Date:11/07/03ISR Number: 4229908-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389471A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229909-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389508A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling Face		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229910-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389515A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline			
RESPIRATORY	Drug Abuser							
(INHALATION)							36	HR
	Intentional Misuse		Beer	C				
	Medication Error							

Date:11/07/03ISR Number: 4229911-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389524A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Abuser		Wellbutrin	PS	Glaxosmithkline			
RESPIRATORY	Intentional Misuse							
(INHALATION)							4	MON
	Medication Error		No Concurrent Medications	C				

Date:11/07/03ISR Number: 4229912-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389628A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL		
100MG Twice	Anger							
per day								YR
	Chest Pain		Effexor Xr	SS				

	Flushing					
	Insomnia					
	Nausea					
	Retching					
	Stress					

Date:11/07/03ISR Number: 4229920-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389668A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Single	
	Vomiting						dose	
			Singulair	C				
			Aerobid	C				
			Maxair	C				
			Oxygen	C				
			Valium	C				
			Flexeril	C				
			Vitamin	C				
			Aspirin	C	Glaxosmithkline			
			Vioxx	C				
			Nebulizer	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229921-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389672A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	121 DAY

Date:11/07/03ISR Number: 4229922-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389676A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Enuresis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229923-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389687A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	7 MON
	Weight Increased							

Date:11/07/03ISR Number: 4229924-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389688A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 DAY
			Zomig	C				

Date:11/07/03ISR Number: 4229925-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389735A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Medication Error						per day	1 YR

Date:11/07/03ISR Number: 4229926-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389736A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
	Psychomotor Hyperactivity		Prozac	C				

Date:11/07/03ISR Number: 4229927-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389809A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Unknown Medication	C				

Date:11/07/03ISR Number: 4229928-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389810A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229929-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389828A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 WK
			Toprol Xl	C				

Date:11/07/03ISR Number: 4229930-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389836A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
			Spironolactone	SS			UNKNOWN	

Date:11/07/03ISR Number: 4229932-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389957A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
	Complaint							
	Stool Analysis Abnormal		Trazodone	C				
			Alprazolam	C				

Date:11/07/03ISR Number: 4229933-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389961A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day						

Date:11/07/03ISR Number: 4229934-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389965A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice per day 3 MON	Feeling Abnormal					
	Pharmaceutical Product Complaint					

Date:11/07/03ISR Number: 4229935-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389967A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:11/07/03ISR Number: 4229936-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389995A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
400MG Per day						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229937-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390032A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
			Albuterol	C	Glaxosmithkline			
			Advair	C	Glaxosmithkline			
			Zocor	C			20MG Per day	
			Aciphex	C			20MG Twice per day	
			Ecotrin	C	Glaxosmithkline			
			Bc	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229938-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390037A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dissociation		Marijuana	SS			UNKNOWN	
	Flat Affect							
	Panic Attack							
	Paranoia							

Date:11/07/03ISR Number: 4229939-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390152A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	4 MON
			Lipitor	C				

Date:11/07/03ISR Number: 4229940-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390175A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Parosmia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 MON
	Pharmaceutical Product							
	Complaint							
	Urine Odour Abnormal							

Date:11/07/03ISR Number: 4229941-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390180A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	3 WK
	Hypersensitivity							
	Rash							
	Therapeutic Response							
	Unexpected							
	Throat Tightness							
	Urticaria							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229942-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390231A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:11/07/03ISR Number: 4229943-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390234A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eructation		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Flatulence						per day	2 YR
			Seroquel	C				
			Celexa	C				

Date:11/07/03ISR Number: 4229944-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390247A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Illusion							
	Keratoconjunctivitis							
	Sicca							
	Muscle Twitching							

Date:11/07/03ISR Number: 4229946-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390250A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Tension							

Date:11/07/03ISR Number: 4229947-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390254A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229948-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390339A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	14 DAY
	Tinnitus							

Date:11/07/03ISR Number: 4229949-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390353A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Lethargy							
	Obsessive-Compulsive		Zoloft	C			50MG Per day	
	Personality Disorder							
	Somnolence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229950-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390357A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Evista	C				
			Levoxyl	C	Glaxosmithkline			
			Glyburide	C				

Date:11/07/03ISR Number: 4229951-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390370A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
			Serzone	C			150MG Three times per day	
			Ritalin	C			150MG Per day	7 YR

Date:11/07/03ISR Number: 4229952-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390380A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4229953-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390388A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Smoker		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
			Klonopin	C				
			Buspar	C				
			Librium	C				

Date:11/07/03ISR Number: 4229954-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390431A
Age:9 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Personality Change							

Date:11/07/03ISR Number: 4229955-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390910A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	46	DAY
	Contusion		Remeron	C		ORAL		
	Glossoptosis		Keppra	C		ORAL	750MG Twice per day	
	Grand Mal Convulsion							
	Tongue Biting		Oxycontin	C		ORAL	80MG Three times per day	
			Olanzapine	C		ORAL	5MG Twice per day	
			Hydroxyzine Pamoate	C		ORAL	50MG Three times per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229956-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390914A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dry Mouth							
	Nervousness							

Date:11/07/03ISR Number: 4229958-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390940A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
	Pruritus							

Date:11/07/03ISR Number: 4229959-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390952A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229960-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390954A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensitivity Of Teeth		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 MON
			Claritin	C				
			Vitamin	C				

Date:11/07/03ISR Number: 4229961-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390959A
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG In the morning	2 MON
			Risperidal	SS			UNKNOWN	3MG per day

Date:11/07/03ISR Number: 4229962-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390970A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Contractions		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	54 DAY
	Involuntary							
			Prevacid	C		ORAL		
			Ambien	C		ORAL		

Date:11/07/03ISR Number: 4229963-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391191A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	9 MON
	Feeling Abnormal		Multivitamins	C				
	Feeling Hot		Zoloft	C		ORAL	50MG Three times per day	
	Therapeutic Response							
	Unexpected							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229964-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391199A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	1 WK
			Propranolol	C				
			Triamterene	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229965-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391209A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			
			Topamax	C				
			Depakote	C				

Date:11/07/03ISR Number: 4229966-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391264A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Nausea							

Date:11/07/03ISR Number: 4229967-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391298A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229968-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391301A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash						per day	2 MON
	Urticaria							

Date:11/07/03ISR Number: 4229969-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391456A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229970-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391461A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affective Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Depression							
	Drug Ineffective							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229971-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391466A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	WK
			Klonopin	C				
			Prilosec	C				
			Lipitor	C				
			Esculine	C				
UNKNOWN								
			Soma	C				
UNKNOWN								
			Ultracet	C				
UNKNOWN								
			Vicodin	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Estrace	C				

Date:11/07/03ISR Number: 4229972-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391480A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR

Date:11/07/03ISR Number: 4229973-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391484A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229974-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391488A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	250MG Per day	

Date:11/07/03ISR Number: 4229975-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391518A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Hypotension						per day	
			Percocet	C				
			Flexeril	C				
			Depo Provera	C				

Date:11/07/03ISR Number: 4229976-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391652A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229977-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391653A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flat Affect		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	7 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229978-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391654A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 MON
			Imitrex	C	Glaxosmithkline	UNKNOWN		

Date:11/07/03ISR Number: 4229979-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391667A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Contractions		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	15 DAY
	Involuntary							
			Prozac	C		UNKNOWN	20MG Per day	8 YR

Date:11/07/03ISR Number: 4229980-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391730A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	17 DAY
	Rash							
	Urticaria		Lexapro	C				

Date:11/07/03ISR Number: 4229981-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391742A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL
6 MON						
	Dyspepsia		Buspar	C		
	Male Sexual Dysfunction		Prozac	C		

Date:11/07/03ISR Number: 4229982-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391747A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cogwheel Rigidity		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Per day	

Date:11/07/03ISR Number: 4229983-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391748A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Insomnia							

Date:11/07/03ISR Number: 4229984-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391749A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229985-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391781A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229986-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391850A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	4 DAY
	Diarrhoea		Atacand	C				

Date:11/07/03ISR Number: 4229987-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391859A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	WK
			Lipitor	C				
			Altace	C				
			Toprol	C				
			Coenzyme Q10	C				
			Baby Aspirin	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229988-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391861A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			Concerta	C				

Buspar	C		
Synthroid	C	Glaxosmithkline	
Baby Aspirin	C	Glaxosmithkline	
Coenzyme Q10	C		

Date:11/07/03ISR Number: 4229989-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391867A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR

Date:11/07/03ISR Number: 4229990-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391886A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Insomnia		Buspar	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229992-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392081A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Psychomotor Hyperactivity		Milk Thistle	C				
			Daily Vitamin	C				
			Vitamin C	C	Glaxosmithkline			
			Calcium Citrate	C				
			Folic Acid	C				
			Birth Control Pill	C				

Date:11/07/03ISR Number: 4229993-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392085A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			Advair	C	Glaxosmithkline	RESPIRATORY (INHALATION)		
			Singulair	C				
			Zithromax	C				
			Medrol Dose Pak	C				
			Prednisone	C				
UNKNOWN							40MG Per day	

Date:11/07/03ISR Number: 4229994-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392100A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
	Stomach Discomfort							
			Valtrex	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229995-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392105A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	DAY
			Albuterol	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4229996-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392158A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4229997-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392192A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	4 WK
			Neurontin	C				
			Lamictal	C	Glaxosmithkline			
			Clonazepam	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4229998-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392194A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
			Celexa	C				

Date:11/07/03ISR Number: 4229999-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392195A
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 MON
			Avapro	C				

Date:11/07/03ISR Number: 4230000-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392365A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON

Date:11/07/03ISR Number: 4230001-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392411A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY

Date:11/07/03ISR Number: 4230002-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392420A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	MON	
			Zoloft	C				
			Surmontil	C				

Date:11/07/03ISR Number: 4230003-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392428A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	
			Lithium	C	Glaxosmithkline		UNKNOWN	

Date:11/07/03ISR Number: 4230005-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392510A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230006-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392580A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hyperhidrosis		Zoloft	C				
			Effexor	C				

Date:11/07/03ISR Number: 4230007-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392597A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG per day	8 YR
	Proteinuria		Luvox	C				
			Lipitor	C				
			Aleve	C				

3 YR

Date:11/07/03ISR Number: 4230008-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392748A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	

per day 1 MON

Date:11/07/03ISR Number: 4230009-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392757A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230010-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392808A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230011-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392915A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash Generalised						per day	10 MON
			Eskalith	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4230012-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392916A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Confusional State						per day	
	Dizziness		Imitrex	C	Glaxosmithkline		UNKNOWN	
	Myalgia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230014-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392934A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crohn'S Disease		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK

Date:11/07/03ISR Number: 4230015-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392935A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL		YR
	Liver Function Test		Ritalin	SS				YR
	Abnormal							
	Road Traffic Accident							

Date:11/07/03ISR Number: 4230016-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392938A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:11/07/03ISR Number: 4230017-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392955A
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Metoprolol	C			25MG Per day	
			Antacid	C				

Date:11/07/03ISR Number: 4230018-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392960A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness Neurosensory		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Per day	5 MON
Other			Prozac	C			80MG Per day	

Date:11/07/03ISR Number: 4230019-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392964A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	7	WK
			Zocor	C				
			Enalapril Maleate	C				

Date:11/07/03ISR Number: 4230020-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392969A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three	
	Insomnia						times per day	10 DAY
	Nervousness		Amitriptyline	SS			UNKNOWN	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230021-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392994A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	7 MON
	Hypervigilance		Celexa	C			UNKNOWN	60MG Unknown
	Indifference		Buspar	C			UNKNOWN	15MG Unknown
	Insomnia		Hydroxyzine	C				
	Nervousness							
	Panic Reaction							

Date:11/07/03ISR Number: 4230022-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393111A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nonspecific Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
	Rash							

Date:11/07/03ISR Number: 4230023-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393124A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Symptom		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Diarrhoea						per day	3 MON
	Haemorrhage							
	Intestinal Spasm							
	Mucous Membrane Disorder							
	Muscle Spasms							

Date:11/07/03ISR Number: 4230024-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393192A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Zoloft	C				

Date:11/07/03ISR Number: 4230025-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393193A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	250MG Per day	1 MON
	Drug Ineffective							
	Pharmaceutical Product Complaint							
	Somnolence							

Date:11/07/03ISR Number: 4230026-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393197A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230027-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393201A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	3 WK
			Flomax	C				
			Zoloft	C				

Date:11/07/03ISR Number: 4230028-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393205A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Alternate days	1 YR

Date:11/07/03ISR Number: 4230029-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393208A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
	Complaint		Paroxetine	C	Glaxosmithkline			
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4230030-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393210A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230032-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407166A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	350MG per day	6 MON
			Seroquel	C				
			Adderall	C				

Date:11/07/03ISR Number: 4230033-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407314A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	1 WK
	Erythema							
	Limb Discomfort		Metoprolol	C				
	Lip Blister		Flexeril	C				
	Oral Mucosal Blistering		Oxycodone	C				
	Oral Pain		Naproxen	C				
	Rash							
	Swollen Tongue							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230042-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407315A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Positive						per day	
			Synthroid	C	Glaxosmithkline			
			Motrin	C	Glaxosmithkline			
			Aspirin	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4230043-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407349A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Odour Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Effexor	C			UNKNOWN	150MG Per day

Date:11/07/03ISR Number: 4230044-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407350A
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG In the	
							morning	
			Trileptal	C				

Date:11/07/03ISR Number: 4230045-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407384A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombocytopenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	
Hospitalization -								

Initial or Prolonged
Other

Date:11/07/03ISR Number: 4230046-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407397A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230047-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407502A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

Date:11/07/03ISR Number: 4230048-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407503A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	MON
	Complaint		Trazodone	C				
	Reading Disorder							
	Speech Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230049-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407542A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Joint Swelling						per day	2 WK
			Tamoxifen	C				
			Nicoderm	C	Glaxosmithkline			
			Vitamin E	C				
			Calcium	C				

Date:11/07/03ISR Number: 4230050-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407546A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	31 DAY
	Urticaria		Protein Drink	C				

Date:11/07/03ISR Number: 4230051-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407550A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 YR

Date:11/07/03ISR Number: 4230052-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407554A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230053-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407639A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230054-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407640A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphasia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230055-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407650A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Verapamil	C				
			Furosemide	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230056-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407653A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	MON
	Chills							
	Connective Tissue Disorder							
	Myalgia							
	Pain							
	Tinnitus							

Date:11/07/03ISR Number: 4230057-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407654A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230058-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407704A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Headache							
	Nausea		Protonix	C			per day	2 MON

Date:11/07/03ISR Number: 4230059-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407726A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Burning Sensation		Diovan Hct	C				
	Dry Mouth		Synthroid	C	Glaxosmithkline			

Tremor

Date:11/07/03ISR Number: 4230060-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407730A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Celexa	C				

Date:11/07/03ISR Number: 4230061-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407802A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230062-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407803A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	2 YR
			Ambien	C				

				Trazodone	C		
				Bextra	C		
				Hypoglycemic	C		

Date:11/07/03ISR Number: 4230063-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407808A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Swollen Tongue						per day	12 DAY
			Depakote	C				

Date:11/07/03ISR Number: 4230064-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407840A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 MON
			Prozac	C				

Date:11/07/03ISR Number: 4230065-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407849A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 WK

Date:11/07/03ISR Number: 4230066-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407877A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
per day								

Date:11/07/03ISR Number: 4230067-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407946A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three	
	Positive							
times per day								
			Celexa	C				
			Motrin	C	Glaxosmithkline			
			Allegra	C				

Date:11/07/03ISR Number: 4230068-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407953A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Depressed Mood							
per day							3	WK
	Eye Irritation		Restoril	C				
	Yawning							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230069-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408231A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
			Clarinex	C				
			Propecia	C				

Date:11/07/03ISR Number: 4230070-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408232A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dyspnoea						per day	16 DAY

Date:11/07/03ISR Number: 4230071-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408249A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	1 YR

Date:11/07/03ISR Number: 4230072-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408262A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cyanosis		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	YR
	Heart Rate Increased		Allegra	C				
	Hyperventilation		Synthroid	C	Glaxosmithkline			
	Palpitations		Coffee	C				
	Panic Reaction							

Stress

Date:11/07/03ISR Number: 4230074-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408351A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230075-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408352A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230076-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408405A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome		Bupropion	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230078-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408554A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Grand Mal Convulsion						per day	28 DAY
	Loss Of Consciousness		Alcohol	C		ORAL		
	Postictal State		Ativan	C		ORAL	3MG Per day	
	Urinary Incontinence		Norco	C		ORAL		
			Effexor	C				

Date:11/07/03ISR Number: 4230083-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408564A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nail Bed Tenderness						per day	
			Antibiotic	C				

Date:11/07/03ISR Number: 4230084-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408565A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230085-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408622A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Stool Analysis Abnormal		Fiber Laxative	C				

Date:11/07/03ISR Number: 4230086-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408624A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	DAY
			Contraceptive	C		ORAL		

Date:11/07/03ISR Number: 4230087-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408625A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	MON	

Date:11/07/03ISR Number: 4230088-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408644A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nocturia		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230089-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408647A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK
			Atenolol	C				
			Progestin	C				
			Estrogen	C				
			Imitrex	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4230090-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408665A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Bupropion	PS	Glaxosmithkline	ORAL	250MG per day	
		Professional	Alcohol	SS				

Date:11/07/03ISR Number: 4230091-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408671A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Bupropion	PS	Glaxosmithkline	ORAL	300MG per day	
		Professional	Benzodiazepine	SS				
			Effexor	C				

Date:11/07/03ISR Number: 4230092-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408683A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230093-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408696A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/07/03ISR Number: 4230094-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408698A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	6	WK

Date:11/07/03ISR Number: 4230095-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408814A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230096-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408815A
Age:48 YR Gender:Female I/FU:F

Outcome	PT
	Dry Mouth
	Dysuria

Urinary Retention

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
			Nexium	C		ORAL	40MG In the morning	1 YR
			Lipitor	C		ORAL	10MG At night	MON
			Arimidex	C		ORAL	1MG In the morning	MON
			Neurontin	C		ORAL	600MG Three times per day	1 YR
			Klonopin	C		ORAL	.5MG Four times per day	MON

Date:11/07/03ISR Number: 4230097-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408816A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Detrol La	SS		ORAL		

Date:11/07/03ISR Number: 4230098-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408916A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:11/07/03ISR Number: 4230099-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408921A
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK

Date:11/07/03ISR Number: 4230100-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408925A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	119 DAY
	Anxiety							
	Demented Relative		Klonopin	C				

Date:11/07/03ISR Number: 4230101-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409018A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Keppra	C				
			Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230102-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409040A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice	
	Medication Error						per day	

Date:11/07/03ISR Number: 4230103-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409058A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Bupropion	PS	Glaxosmithkline	ORAL	150MG Three	
	Loss Of Consciousness						times per day	270 DAY
	Postictal State							
	Simple Partial Seizures							

Date:11/07/03ISR Number: 4230104-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409190A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
							per day	2 MON
			Lexapro	C				

Date:11/07/03ISR Number: 4230105-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409191A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	2 WK

	Vertigo		Zoloft	C		
14 MON						

Date:11/07/03ISR Number: 4230106-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409192A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective						per day	3 YR
			Prevacid	C				
			Lodine	C				

Date:11/07/03ISR Number: 4230107-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409193A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	3 MON
			Synthroid	C	Glaxosmithkline			
			Phentermine	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4230108-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409305A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Unknown	3 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230109-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409466A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 MON

Date:11/07/03ISR Number: 4230110-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409468A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Consciousness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK

Date:11/07/03ISR Number: 4230111-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409469A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Insomnia							

Date:11/07/03ISR Number: 4230112-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409470A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	1 YR
			Paxil	C	Glaxosmithkline		UNKNOWN	10MG Unknown

Date:11/07/03ISR Number: 4230113-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409471A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Allergic		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Unknown 2 YR
			Topamax	C				
			Lexapro	C				
			Provigil	C				

Date:11/07/03ISR Number: 4230114-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409487A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG per day	5 YR
	Insomnia							
	Pollakiuria							
	Tinnitus							

Date:11/07/03ISR Number: 4230116-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409517A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230117-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409562A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion	PS	Glaxosmithkline	ORAL	200MG Twice per day	75 DAY

Date:11/07/03ISR Number: 4230118-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409568A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Electroencephalogram		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230119-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409636A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230127-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409638A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230128-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409640A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

	Depression	Professional	Zoloft	SS		ORAL
5 YR						
	Drug Ineffective		Ansaid	C		
100MG Twice						
	Fatigue					
per day						
	Fibromyalgia					
	Hyperhidrosis					
	Insomnia					
	Muscle Spasms					
	Myalgia					
	Sedation					
	Yawning					

Date:11/07/03ISR Number: 4230129-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409943A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amnesia	Health	Bupropion	PS	Glaxosmithkline	ORAL
2 YR						
Initial or Prolonged	Convulsion	Professional	Alcohol	SS		ORAL
Other	Tongue Biting		Xanax	C		
UNKNOWN .5MG As						
required						
			Ambien	C		
UNKNOWN 10MG Unknown						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230130-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409944A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Motrin	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4230131-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410041A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230132-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410042A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Discolouration		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK

Date:11/07/03ISR Number: 4230133-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410087A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Head Injury Stress	Health Professional	Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR

Date:11/07/03ISR Number: 4230134-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410159A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice	
Other	Hypertension						per day	8 DAY
			Diuretic	C				
			Actonel	C				

Date:11/07/03ISR Number: 4230135-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410172A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230136-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410290A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Priapism		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	40 DAY
	Spontaneous Penile Erection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230141-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410291A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Thinking Abnormal							

Date:11/07/03ISR Number: 4230142-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410304A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	2 WK
	Rash		Birth Control	C				
	Urticaria							

Date:11/07/03ISR Number: 4230143-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410323A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4230144-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410333A
Age:11 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	6 MON
	Insomnia							

Date:11/07/03ISR Number: 4230145-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410335A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4230146-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410339A
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 WK
	Disorientation							
	Fatigue		Zocor	C			.5MG At night	
			Lexapro	C				
			Xalatan	C				
			Lorazepam	C				
			Folic Acid	C				
			Vitamin E	C				
			Imodium	C				
			Aspirin	C	Glaxosmithkline			
			Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230147-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410381A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Keratoconjunctivitis							
	Sicca							
	Nasal Dryness							

Date:11/07/03ISR Number: 4230148-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410500A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Unknown

Date:11/07/03ISR Number: 4230149-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410501A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	See dosage text
	Chest Pain							
	Dyspepsia		Gaviscon	C	Glaxosmithkline			
	Gastric Disorder		Black Cohosh	C	Glaxosmithkline			
	Gastrooesophageal Reflux Disease		Echinacea	C				
			Aloe Vera	C				
			Tylenol Arthritis	C	Glaxosmithkline			
			Calcium	C				
			Aspirin	C	Glaxosmithkline			
			Amitriptyline	C				
			Ginger Root	C				
			Acidophilus	C				
			Hawthorn Berry	C				
			Kava-Kava	C				

Date:11/07/03ISR Number: 4230154-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410502A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY

Date:11/07/03ISR Number: 4230155-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410590A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Urticaria						per day	19 DAY

Date:11/07/03ISR Number: 4230156-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410618A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230157-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410623A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230158-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410743A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Haemorrhage		Lithium	C	Glaxosmithkline			
			Risperdal	C				

Date:11/07/03ISR Number: 4230159-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410781A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tremor						per day	1 YR
			Prilosec	C			UNKNOWN	
			Estrogen Replacement	C			UNKNOWN	

Date:11/07/03ISR Number: 4230160-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410838A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	13 DAY
	Flatulence		Aspirin	C	Glaxosmithkline		UNKNOWN	

			Vitamins	C		
UNKNOWN						
			Folic Acid	C		
UNKNOWN						

Date:11/07/03ISR Number: 4230161-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410842A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Thermal Burn							

Date:11/07/03ISR Number: 4230162-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410843A
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	1200MG Single	
Hospitalization -	Overdose						dose	1 DAY
Initial or Prolonged			Celexa	SS		ORAL	12TAB Single	
Other							dose	1 DAY

Date:11/07/03ISR Number: 4230163-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411022A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Single	
Initial or Prolonged							dose	1 DAY
			No Concurrent Medications	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230164-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411050A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230165-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411187A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dyspepsia		Paxil	SS	Glaxosmithkline	ORAL		
	Headache		Sarafem	SS			UNKNOWN	
	Pruritus							
	Urticaria							

Date:11/07/03ISR Number: 4230166-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411257A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Dry Mouth							
per day	1	MON						
	Tremor		Lexapro	C			UNKNOWN	
			Diovan	C			UNKNOWN	
			Triavil	C			UNKNOWN	

Date:11/07/03ISR Number: 4230167-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411262A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230168-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411264A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230169-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411266A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230170-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411371A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Premature Ejaculation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230171-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411372A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness						per day	1 MON
	Tremor		Tussin With Codeine	C				
	Urine Flow Decreased		Oxygen Therapy	C				

Date:11/07/03ISR Number: 4230172-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411373A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Unknown	YR
	Gastroenteritis Bacterial		Singulair	C			2	YR
	Palpitations		Paxil	C	Glaxosmithkline		UNKNOWN	
	Tremor							
	Weight Decreased							

Date:11/07/03ISR Number: 4230173-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411374A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Pharyngolaryngeal Pain						per day	2 WK

Date:11/07/03ISR Number: 4230179-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411375A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice						
per day 1 MON						

Date:11/07/03ISR Number: 4230180-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411376A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Pharyngolaryngeal Pain					
per day						
	Pruritus					
	Urticaria					

Date:11/07/03ISR Number: 4230182-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411377A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL
200MG Per day						
			Lamictal	C	Glaxosmithkline	ORAL
2 YR						

Date:11/07/03ISR Number: 4230184-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411401A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230185-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411404A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230186-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411407A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230187-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411408A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG per day	20 DAY
			Marijuana	C				

Date:11/07/03ISR Number: 4230188-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411552A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness							
per day	14 DAY							
	Nausea							

Date:11/07/03ISR Number: 4230189-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411553A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anorgasmia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 10 DAY						
	Libido Decreased		Klonopin	C		

Date:11/07/03ISR Number: 4230190-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411555A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Elevated Mood		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Euphoric Mood					
per day 26 DAY						
	Feeling Drunk		Maxzide	C	Glaxosmithkline	
UNKNOWN 37.5MG						
	Somnolence					
Unknown						
			Atenolol	C		
			Synthroid	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4230191-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411556A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL
400MG Per day						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230192-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411557A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	WK
			Premarin	C				
			Vitamins	C				
			Ditropan	C				

Date:11/07/03ISR Number: 4230193-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411558A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Amphetamine Positive		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230194-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411635A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230195-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411780A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:11/07/03ISR Number: 4230196-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411933A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL

150MG Twice

per day 1 WK

Date:11/07/03ISR Number: 4230197-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412081A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Csf Pressure Increased		Bupropion	PS	Glaxosmithkline	ORAL

Dose Duration

Date:11/07/03ISR Number: 4230198-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412085A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dyspepsia		Bupropion	PS	Glaxosmithkline	ORAL

Dose Duration

100MG Three

times per day 3 YR

		Seroquel	C

Date:11/07/03ISR Number: 4230199-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412092A
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Other	Cold Sweat
	Delusion

	Dizziness Dysgeusia Syncope	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day	8 YR					
			Vitamins	C		
UNKNOWN						
			Acidophilis	C		
UNKNOWN						
			Ranitidine	C	Glaxosmithkline	
UNKNOWN						

Date:11/07/03ISR Number: 4230200-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412105A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL
1	YR					
	Depressed Mood					

Date:11/07/03ISR Number: 4230201-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412107A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day						
			Celexa	C		
			Prilosec	C		

Date:11/07/03ISR Number: 4230202-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412214A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Back Pain		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice						

	Dry Mouth					
per day 2 WK						
	Local Swelling		Prevacid	C		
	Micturition Disorder		Saw Palmetto	C		
	Rash		Flonase	C	Glaxosmithkline	NASAL
			Glutamine	C		
			Mega Vitamins	C		
			Melatonin	C		
			5-Htp	C		
			Vitamin B	C		
			Gingko	C		
			Ativan	C		
			Kelp	C		

Date:11/07/03ISR Number: 4230203-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412246A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Energy Increased	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Insomnia					
per day 5 DAY						
	Therapeutic Response		Periostat	C	Glaxosmithkline	
	Unexpected		Norvasc	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230204-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412257A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4230205-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412277A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230206-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412281A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	2 MON
	Dysgeusia							
			Birth Control Pills	C				
			Lomotil	C				

Date:11/07/03ISR Number: 4230207-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412410A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	6 WK
	Complaint							
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4230208-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412411A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	9 YR
			Clarinex	C				
			Valium	C				
RESPIRATORY			Albuterol	C	Glaxosmithkline			
(INHALATION)								

Date:11/07/03ISR Number: 4230209-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412412A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dyspnoea							
per day	2 WK							
	Hyperhidrosis		Synthroid	C	Glaxosmithkline			
	Nausea		Norvasc	C				
			Atacand	C				

Date:11/07/03ISR Number: 4230210-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412413A
Age:45 YR Gender:Male I/FU:I

Outcome	PT
	Abdominal Discomfort
	Fatigue

	Insomnia Weight Increased						
		Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three
times per day	1 YR						
			Buspar	C			
			Prilosec	C			
			Seroquel	C			
			Didanosine	C			

Date:11/07/03ISR Number: 4230211-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412414A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice
	Chest Pain						
per day 1 MON							
	Hunger		Acid Reflux Med.	C			
UNKNOWN							
			Calcium	C			

Date:11/07/03ISR Number: 4230212-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412416A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown

Date:11/07/03ISR Number: 4230213-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412487A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	

Date:11/07/03ISR Number: 4230214-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412617A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	2 MON
	Tremor							
			Effexor	SS			UNKNOWN	

Date:11/07/03ISR Number: 4230215-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412618A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:11/07/03ISR Number: 4230216-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412619A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Syncope		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
Other			Lithium	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230217-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412628A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Weight Decreased							

Date:11/07/03ISR Number: 4230218-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412678A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Obsessive-Compulsive		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Disorder						per day	7 MON
			Zoloft	C		ORAL	200MG Unknown	

Date:11/07/03ISR Number: 4230219-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412812A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	

Date:11/07/03ISR Number: 4230220-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412813A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	18 DAY
	Difficulty In Walking							
	Joint Swelling							
	Urticaria							

Date:11/07/03ISR Number: 4230221-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412814A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG See	
							dosage text	
			Lamictal	C	Glaxosmithkline			
			Ambien	C				

Date:11/07/03ISR Number: 4230222-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413098A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	

Date:11/07/03ISR Number: 4230223-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413139A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	MON	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230224-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413266A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Tooth Abscess							
	Tooth Disorder		Antibiotic	C				

Date:11/07/03ISR Number: 4230225-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413269A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Synthroid	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4230226-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413270A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratoconjunctivitis		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG per day	2 YR
	Sicca		Clonopin	C				

Date:11/07/03ISR Number: 4230227-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413276A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY
	Rash		No Concurrent Medication	C				

Date:11/07/03ISR Number: 4230228-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413292A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown 3 DAY
			Quinine	C		ORAL	250MG	Per day
			Xanax	C				
			Vitamins	C				

Date:11/07/03ISR Number: 4230229-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413368A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Per day 1 DAY
	Vomiting							

Date:11/07/03ISR Number: 4230230-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413382A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Twice per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230232-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413540A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Mood Swings						per day	10 DAY

Date:11/07/03ISR Number: 4230233-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413754A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Memory Impairment		Coreg	C	Glaxosmithkline			
	Vision Blurred		Acyclovir	C	Glaxosmithkline			
			Vitamin C	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4230234-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413755A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230235-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413756A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
Initial or Prolonged	Anorexia						per day	1 DAY
Other	Liver Function Test Abnormal							
	Nausea							
	Vomiting							

Date:11/07/03ISR Number: 4230236-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413757A
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphemia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Minocycline	C				

Date:11/07/03ISR Number: 4230237-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413758A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Vomiting						per day	2 WK
			Zoloft	C				
			Lisinopril	C				
			Omeprazole	C				
			Lescol Xl	C				
			Toprol Xl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230238-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413768A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Unspecified Medications	C			UNKNOWN	

Date:11/07/03ISR Number: 4230239-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413792A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding		Wellbutrin	PS	Glaxosmithkline	ORAL	350MG Per day	8 MON
	Insomnia		Restoril	C				

Date:11/07/03ISR Number: 4230240-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413803A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 YR
	Depressed Level Of Consciousness		Prilosec	C				
	Feeling Abnormal							
	Gait Disturbance							
	Memory Impairment							
	Somnolence							

Date:11/07/03ISR Number: 4230241-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413935A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	

	Agitation					
per day						
	Hepatitis C		Peg-Intron	SS		
UNKNOWN						
	Impulsive Behaviour		Rebetol	SS		
UNKNOWN						
			Neurontin	C		
600MG Per day						
			Amitriptyline	C		

Date:11/07/03ISR Number: 4230242-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413937A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL
200MG Twice						
	Feeling Abnormal					
per day	1 YR					
	Irritability		Lexapro	SS		
UNKNOWN	10MG Per day					
			Ambien	C		
UNKNOWN	10MG At night					

Date:11/07/03ISR Number: 4230243-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413938A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Photosensitivity Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL
225MG Per day	2 WK					
			Sunscreen	C		
TOPICAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230244-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413982A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
			Premarin	C				

Date:11/07/03ISR Number: 4230245-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413999A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230246-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414010A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON
	Pharmaceutical Product							
	Complaint		Synthroid	C	Glaxosmithkline	UNKNOWN		
	Retching							

Date:11/07/03ISR Number: 4230250-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414034A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON

Date:11/07/03ISR Number: 4230251-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414186A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three	
	Phosphokinase Increased						times per day	1 YR
	Myoglobin Blood Increased							

Date:11/07/03ISR Number: 4230252-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414187A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	WK

Date:11/07/03ISR Number: 4230253-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414332A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Daydreaming		Wellbutrin	PS	Glaxosmithkline	ORAL	37.5MG Twice	
	Insomnia						per day	10 DAY
	Somnolence		Potaba	C				
	Yawning		Prevacid	C				
			Oxycodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230254-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414333A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	600MG per day	
	Overdose							

Date:11/07/03ISR Number: 4230255-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414353A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	1 YR
	Fatigue							
	Nausea							
	Pharmaceutical Product Complaint							

Date:11/07/03ISR Number: 4230256-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414402A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	7 WK

Date:11/07/03ISR Number: 4230258-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414409A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON

Date:11/07/03ISR Number: 4230259-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414532A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR

Date:11/07/03ISR Number: 4230260-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414540A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sunburn		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR

Date:11/07/03ISR Number: 4230261-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414553A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	3 DAY
			Fiorinal	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230262-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414554A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dysgeusia						per day	2 WK
	Gingival Infection							
	Oral Candidiasis							
	Oral Fungal Infection							
	Tongue Discolouration							

Date:11/07/03ISR Number: 4230263-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414569A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	

Date:11/07/03ISR Number: 4230264-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414592A
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	3 MON
	Dyskinesia		Zyrtec	C	Glaxosmithkline	UNKNOWN		
	Dystonia							
	Eye Movement Disorder							
	Muscle Spasms							

Date:11/07/03ISR Number: 4230265-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414617A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG per day	9 MON
	Dysgeusia Reaction To Azo-Dyes		Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230266-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414623A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
			Sinus Medication	C				
			Arthritis Medication	C				

Date:11/07/03ISR Number: 4230268-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414627A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230269-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414628A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Fibromyalgia						per day	1 YR
			Armour	C			15MG Three	
							times per day	
			Klonopin	C			.05MG Three	
							times per day	
			Seroquel	C			200MG Per day	
			Trazodone	C			300MG Per day	
			Lamictal	C	Glaxosmithkline		200MG Twice	
							per day	
			Claritin D	C				
			Nasonex	C				
			Allergy Shots	C				
			Dhea	C			25MG Per day	
			Multivitamin	C				
			Selenium	C				
			Magnesium	C				
			Folic Acid	C				
			Calcium	C				
			Miralax	C				
			Tylenol	C	Glaxosmithkline			
			Biotin	C				
			Primrose Oil	C				
			Flax Seed Oil	C				

Date:11/07/03ISR Number: 4230270-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414923A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Weight Increased						per day	1 MON
			Contraceptive	C				

Date:11/07/03ISR Number: 4230271-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415187A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Viagra	C				
			Lipitor	C				
			Nexium	C				
			Methocarbamol	C				
			Vitamins	C				
			Rabeprazole	C				

Date:11/07/03ISR Number: 4230272-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415214A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	8 DAY
	Paranoia		Mvi	C				
	Vision Blurred		Lipitor	C				
			Aspirin	C	Glaxosmithkline			

Nexium	C
Altace	C
Nadolol	C
Folic Acid	C
Ditropan Xl	C
Plavix	C
Flexeril	C

Date:11/07/03ISR Number: 4230273-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415223A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Medication Residue						per day	1 WK
	Stool Analysis Abnormal							
	Urticaria							

Date:11/07/03ISR Number: 4230274-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415232A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230275-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399975A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	YR
			Elavil	C	Glaxosmithkline			
			Effexor	C				

Date:11/07/03ISR Number: 4230276-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399976A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
per day								3 WK
			Birth Control	C				

Date:11/07/03ISR Number: 4230277-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399981A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Nausea		Zestril	C				
			Glucophage	C				

Date:11/07/03ISR Number: 4230283-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399988A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
per day								1 MON
			Klonopin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230284-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399991A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mydriasis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown 8 DAY
	Nervousness							

Date:11/07/03ISR Number: 4230285-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399999A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
	Fatigue							

Date:11/07/03ISR Number: 4230286-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400003A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aptyalism		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dental Caries							
	Depression							
	Dry Mouth							
	Pain							
	Suicidal Ideation							
	Tooth Loss							

Date:11/07/03ISR Number: 4230287-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400008A
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 MON
	Convulsion							

Other			Paxil	C	Glaxosmithkline	ORAL
10MG Per day						

Date:11/07/03ISR Number: 4230288-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400012A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Serotonin Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL
			Prozac	C		
UNKNOWN 40MG Unknown						

Date:11/07/03ISR Number: 4230289-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400014A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
			Prozac	C		

Date:11/07/03ISR Number: 4230290-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400019A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL
150VA See						
	Arthralgia					
dosage text 6 MON						
	Insomnia		Avandia	SS	Glaxosmithkline	ORAL
	Tinnitus		Multivitamin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230291-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400030A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4230292-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400046A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Unknown 1 WK

Date:11/07/03ISR Number: 4230293-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400048A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
			Vioxx	C				

Date:11/07/03ISR Number: 4230294-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400157A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Syncope							

Date:11/07/03ISR Number: 4230295-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400164A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Use For Unknown		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Indication					
per day 31 DAY						
	Rash		Nasonex	C		
			Calcium	C		

Date:11/07/03ISR Number: 4231709-0Report Type:Direct Company Report #CTU 205561
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Headache		Bupropion Sr 150 Mg	PS		
150 MG QD						

Date:11/07/03ISR Number: 4231714-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415242A
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Extrasystoles		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice						
	Hyperacusis					
per day 6 WK						

Date:11/07/03ISR Number: 4231715-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415787A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day						

				Coumadin	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4231716-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415799A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Urticaria							
	Weight Decreased							

Date:11/07/03ISR Number: 4231721-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415801A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Quinine	C				
			Alprazolam	C				

Date:11/07/03ISR Number: 4231722-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415802A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
			Clonopin	C				

Date:11/07/03ISR Number: 4231723-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415803A
Age:26 YR Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration

Disturbance In Attention Wellbutrin PS Glaxosmithkline ORAL 200MG Twice

Drug Ineffective per day 1 MON

Date:11/07/03ISR Number: 4231724-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415805A
Age: Gender: I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration

Insomnia Wellbutrin PS Glaxosmithkline ORAL 150MG Unknown

Nightmare

Date:11/07/03ISR Number: 4231725-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415806A
Age:11 YR Gender: I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration

Tic Wellbutrin PS Glaxosmithkline ORAL

Date:11/07/03ISR Number: 4231726-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415807A
Age: Gender: I/FU:I

Outcome PT Report Source Product Role Manufacturer Route Dose Duration

Agitation Wellbutrin PS Glaxosmithkline ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231727-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415808A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231728-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415809A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	4 YR
	Drug Ineffective		Diovan Hct	C				
			Lipitor	C				

Date:11/07/03ISR Number: 4231729-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415810A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	8 WK
	Photosensitivity Reaction		Celebrex	C				
	Weight Increased		Zoloft	C				

Date:11/07/03ISR Number: 4231730-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415811A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	6 WK
	Fibromyalgia		Lexapro	C				
UNKNOWN	20MG Per day							
	Headache		Synthroid	C	Glaxosmithkline			
	Tremor		Estratest	C				
			Lamisil	C	Glaxosmithkline			
			Bextra	C				
			Vicodin	C				

Date:11/07/03ISR Number: 4231731-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415812A
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dry Mouth						per day	140 DAY
			Klonopin	C			UNKNOWN	.5MG Twice
							per day	69 DAY
			Risperdal	C			UNKNOWN	.5MG At night
			Ambien	C			UNKNOWN	10MG Three
							times per day	

Date:11/07/03ISR Number: 4231732-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415813A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231733-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415815A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Irritability						per day	
	Libido Decreased		Mircette	C				
	Weight Increased							

Date:11/07/03ISR Number: 4231734-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416549A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Odour Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 YR

Date:11/07/03ISR Number: 4231735-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416591A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4231736-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416592A
Age:55 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hunger		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	5 YR
	Weight Increased							

Date:11/07/03ISR Number: 4231737-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416593A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Elevated Mood		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Therapeutic Response						per day	3 WK
	Decreased							

Date:11/07/03ISR Number: 4231738-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416654A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
Initial or Prolonged	Grand Mal Convulsion		Prozac	C				
Other	Incontinence		Elavil	C	Glaxosmithkline		UNKNOWN	
	Tongue Biting							

Date:11/07/03ISR Number: 4231739-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416671A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	30 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231740-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416679A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Pruritus Generalised						per day	7 WK
			Prozac	C				

Date:11/07/03ISR Number: 4231741-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416860A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Panic Reaction							

Date:11/07/03ISR Number: 4231742-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416864A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Gait Disturbance						per day	10 DAY
	Pain In Extremity		Blood Pressure Medication	C				
			Xanax	C				

Date:11/07/03ISR Number: 4231743-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416865A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	3 MON

			Singulair	C		
4 YR						
			Theodur	C		
4 YR						
			Q-Bid La	C		
4 YR						
			Ativan	C		
4 YR						

Date:11/07/03ISR Number: 4231744-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416870A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Bupropion	PS	Glaxosmithkline	ORAL	200MG Twice per day	1 YR
			Nefazodone	C				
			Gabapentin	C				
			Diltiazem	C	Glaxosmithkline			
			Albuterol Inhaler	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231745-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417152A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	8 MON
			Loestrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231746-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417153A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chapped Lips		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	2 WK
	Cheilitis		Buspirone	C			UNKNOWN	15MG Three times per day
	Dry Mouth							
	Oral Pain		Lipitor	C			UNKNOWN	
	Stomatitis		Toprol Xl	C			UNKNOWN	
	Swollen Tongue		Hctz	C			UNKNOWN	
	Tongue Ulceration		Amitriptyline	C			UNKNOWN	

Date:11/07/03ISR Number: 4231747-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417154A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK
	Tinnitus							
	Tremor		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	
			Quinine	C				
			Alprazolam	C				

Date:11/07/03ISR Number: 4231749-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417156A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenopia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	

		Feeling Abnormal					
per day	1 MON						
		Nausea		Birth Control	C		ORAL
		Photophobia					
		Vomiting					

Date:11/07/03ISR Number: 4231750-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417157A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231751-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417158A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Confusional State							
	Disturbance In Attention							
	Feeling Abnormal							
	Memory Impairment							
	Speech Disorder							
	Developmental							
	Thinking Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231752-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417159A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Urticaria							

Date:11/07/03ISR Number: 4231753-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417248A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia		Bupropion	PS	Glaxosmithkline	ORAL	150MG	Twice
	Joint Swelling						per day	
	Musculoskeletal Stiffness							
	Pain							
	Stevens-Johnson Syndrome							
	Urticaria							

Date:11/07/03ISR Number: 4231757-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417461A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG	Per day
	Urticaria							

Date:11/07/03ISR Number: 4231758-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417479A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Twice
	Urticaria						per day	3 WK

Date:11/07/03ISR Number: 4231759-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417626A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	7 MON
	Rash							

Date:11/07/03ISR Number: 4231760-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417628A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG per day	
	Therapeutic Response Decreased		Prilosec	C				
			Blood Pressure Medication	C				

Date:11/07/03ISR Number: 4231761-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417649A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231762-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417824A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lymphadenopathy		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231763-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417843A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Eye Movement Disorder						per day	DAY
	Nausea							

Date:11/07/03ISR Number: 4231765-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417845A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:11/07/03ISR Number: 4231766-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417846A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Disease						per day	
			Klonopin	C				
			Trazodone	C				
			Prilosec	C				

Date:11/07/03ISR Number: 4231767-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417847A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Prozac	C				

Date:11/07/03ISR Number: 4231768-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417848A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Concerta	C				

Date:11/07/03ISR Number: 4231769-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417849A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Disorientation						per day	3 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231770-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417850A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Chest Pain						per day	1 WK
	Dizziness							
	Flatulence							
	Gastrooesophageal Reflux Disease							

Date:11/07/03ISR Number: 4231771-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417864A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	WK
	Vertigo		Neurontin	SS			UNKNOWN	
			Tagamet	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231772-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418008A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Alcohol Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Prozac	SS			UNKNOWN	
			Wine	SS		ORAL	7	HR

Date:11/07/03ISR Number: 4231773-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418010A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dysgeusia						per day	WK
	Energy Increased		Hctz	C				
			Accupril	C				
			Prevacid	C				
			Aspirin	C	Glaxosmithkline			
			Multivitamins	C				
			Activella	C				

Date:11/07/03ISR Number: 4231774-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418050A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 MON
			No Concurrent Medication	C				

Date:11/07/03ISR Number: 4231775-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418051A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Zantac	C	Glaxosmithkline			
			Levothyroxine	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231776-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418069A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Somnolence						per day	11 MON
			Albuterol	C	Glaxosmithkline			
RESPIRATORY								
(INHALATION)								

Date:11/07/03ISR Number: 4231777-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418071A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG In the	
	Disturbance In Attention						morning	
	Dizziness		Prevacid	C				
	Fatigue		Caffeine	C				
	Feeling Abnormal							
	Paraesthesia							
	Temperature Intolerance							
	Tinnitus							
	Tremor							

Date:11/07/03ISR Number: 4231778-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418188A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Personality Change						per day	

Date:11/07/03ISR Number: 4231779-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418232A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
	Heart Rate Irregular							
	Influenza Like Illness							
	Tinnitus							

Date:11/07/03ISR Number: 4231780-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418253A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	4	WK
			Trileptal	C				
			Neurontin	C				
			Cozar	C				
			Toprol	C				
			Zyprexa	C				
			Aricept	C				

Date:11/07/03ISR Number: 4231781-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418420A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Oral		Wellbutrin	PS	Glaxosmithkline	ORAL	5	WK
			No Concurrent					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Medication C

Date:11/07/03ISR Number: 4231784-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418470A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dry Mouth						per day	2 WK
	Insomnia		Vitamins	C				
	Somnolence							
	Weight Decreased							

Date:11/07/03ISR Number: 4231785-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418601A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231786-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418602A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Rash		Testosterone	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231787-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418603A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transferrin Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231788-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418787A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON

Date:11/07/03ISR Number: 4231789-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418788A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Tenderness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231790-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418790A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oligomenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
			Effexor	C				
			Ritalin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231791-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418791A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Hyperhidrosis						per day	4 DAY
	International Normalised		Avandia	C	Glaxosmithkline			
	Ratio Increased		Coumadin	C	Glaxosmithkline			
	Muscle Spasms		Digoxin	C	Glaxosmithkline			
			Pravachol	C				
			Niaspan	C				
			Metformin	C				
			Zetia	C				
			Avapro	C				
			Amaryl	C				
			Prevacid	C				
			Coreg	C	Glaxosmithkline			
			Lantus	C				
			Endocet	C				

Date:11/07/03ISR Number: 4231792-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418799A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Migraine							
	Therapeutic Response							
	Unexpected							

Date:11/07/03ISR Number: 4231793-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418801A
Age:18 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	YR

Date:11/07/03ISR Number: 4231794-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418826A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Flexeril	C				

Date:11/07/03ISR Number: 4231795-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418956A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG In the morning	14 DAY
			Methotrexate	C				
			Vioxx	C				
			Folic Acid	C				
			Imitrex	C	Glaxosmithkline			
			Prevacid	C				
			Prozac	C				
			Estrogen	C				
			Testosterone	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231797-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418957A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231798-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418958A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Single	
	Dysgeusia						dose	
	Gingival Pain		Hydrocodone	C				
	Headache		Klonopin	C				
	Tooth Injury		Zantac	C	Glaxosmithkline			
	Toothache		Zocor	C				
			Baby Aspirin	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231799-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419152A
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	5	DAY
			Neurontin	C				
			Remeron	C				
			Celexa	C				

Date:11/07/03ISR Number: 4231800-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419168A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	

per day 3 MON

Adderall	C
Zelnorm	C
Nexium	C
Lexapro	C

Date:11/07/03ISR Number: 4231801-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419169A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown 2 WK

Date:11/07/03ISR Number: 4231802-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419170A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK

Date:11/07/03ISR Number: 4231803-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419172A
Age: Gender: I/FU:F

Outcome	PT
	Crying
	Lip Ulceration

	Swelling Face						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	

Date:11/07/03ISR Number: 4231804-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419173A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Unknown 7 MON
			Nexium	SS			UNKNOWN 16 MON

Date:11/07/03ISR Number: 4231805-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419174A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Back Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice
	Erythema						per day 16 DAY
	Eyelid Oedema						
	Inflammation						
	Ocular Hyperaemia						
	Swelling Face						
	Urticaria						

Date:11/07/03ISR Number: 4231806-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419175A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day WK
	Increased Appetite		Lotrel	C			
	Weight Increased						

Date:11/07/03ISR Number: 4231807-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419176A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Dizziness							
	Dry Mouth							
	Headache							
	Insomnia							
	Nausea							

Date:11/07/03ISR Number: 4231808-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419177A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	10 DAY
	Dyspnoea							
	Paraesthesia		Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231809-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419181A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	30 DAY
			Metabolife	C				

Date:11/07/03ISR Number: 4231810-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419182A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG In the morning	
			Celexa	C				
UNKNOWN							40MG In the morning	

Date:11/07/03ISR Number: 4231811-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419231A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG per day	

Date:11/07/03ISR Number: 4231814-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419317A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginismus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231815-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419708A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK

Date:11/07/03ISR Number: 4231816-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419709A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	2 WK

Date:11/07/03ISR Number: 4231817-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419710A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	YR	

Date:11/07/03ISR Number: 4231818-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419711A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231819-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419712A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Inderal	C				
			Tenormin	C				
			Contraceptive	C		ORAL		

Date:11/07/03ISR Number: 4231820-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419761A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG In the	
	Mouth Injury						morning	2 WK

Date:11/07/03ISR Number: 4231821-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419917A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice	
							per day	7 DAY
			Loestrin	C				
			Zantac	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231822-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419933A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231823-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419949A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4231824-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419977A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK

Date:11/07/03ISR Number: 4231826-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420005A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 MON
	Postictal State							
			Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231827-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420007A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratoconjunctivitis Sicca		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231828-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420195A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Arthritis						per day	19 MON
	Confusional State		Zoloft	SS			25MG Per day	4 DAY
	Dyskinesia							
	Mental Status Changes							
	Musculoskeletal Stiffness							
	Nervousness							
	Tension							
	Vision Blurred							

Date:11/07/03ISR Number: 4231829-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420307A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231830-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420314A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Pain							

Pharyngolaryngeal Pain
Rhinorrhoea
Sneezing

Date:11/07/03ISR Number: 4231831-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420315A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	1 YR
			Geodon	C				

Date:11/07/03ISR Number: 4231832-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420527A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Joint Swelling		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	2 WK
	Pyrexia							
	Serum Sickness							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231833-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420602A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Amphetamine		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Positive						per day	
			Pseudoephedrine Hcl	SS	Glaxosmithkline			

Date:11/07/03ISR Number: 4231834-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420610A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	
	Constipation						Variable dose	6 WK
	Feeling Abnormal		Advair	C	Glaxosmithkline			
	Suicidal Ideation							

Date:11/07/03ISR Number: 4231835-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420629A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotrichosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Klonopin	C				

Date:11/07/03ISR Number: 4231836-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420632A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
							per day	3 MON

				Geodon	C		
80MG Twice							
per day							
				Ativan	C		
1MG As							
required							
				Trileptal	C		
150MG Twice							
per day							

Date:11/07/03ISR Number: 4231837-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420633A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Paraesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice						
per day						
			Birth Control	C		
			Amoxicillin	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4231838-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420638A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231839-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420646A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	1200MG per day	3 WK
	Hyperhidrosis							
	Overdose							
	Palpitations							

Date:11/07/03ISR Number: 4231840-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420648A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	10 YR
	Malaise							
	Nausea		Lipitor	C				
	Pharmaceutical Product Complaint							

Date:11/07/03ISR Number: 4231841-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420760A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Unknown	3 MON

Date:11/07/03ISR Number: 4231842-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420761A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Single	

	Pallor					
dose						
	Palpitations					

Date:11/07/03ISR Number: 4231843-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420762A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Premarin	SS			UNKNOWN	
			Provera	SS			UNKNOWN	
			Zoloft	C			UNKNOWN	200MG Unknown
			Buspar	C			UNKNOWN	20MG Unknown

Date:11/07/03ISR Number: 4231844-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420763A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
	Foreign Body Trauma		Unspecified					
	Insomnia		Medication	C				
	Pharmaceutical Product Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231845-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420765A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	6	YR

Date:11/07/03ISR Number: 4231846-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420809A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 DAY
			Morphine Sulphate	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231847-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420810A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 YR
	Myalgia							

Date:11/07/03ISR Number: 4231848-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420821A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Monopril	C				
			Hydrochlorothiazide	C				

Date:11/07/03ISR Number: 4231849-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420827A
Age:6 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retching		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	4 MON
			Ritalin	C				

Date:11/07/03ISR Number: 4231850-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420847A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY

Date:11/07/03ISR Number: 4231851-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420850A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	

Date:11/07/03ISR Number: 4231852-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420888A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231853-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420920A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	YR
	Pain In Jaw		Wellbutrin	SS	Glaxosmithkline	ORAL	50MG Per day	YR
	Weight Increased		Xanax	C				

Date:11/07/03ISR Number: 4231854-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420960A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chapped Lips		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Cheilitis		Seroquel	SS				
	Erythema		Celexa	SS				
	Lip Dry		Zoloft	SS				
	Overdose							

Date:11/07/03ISR Number: 4231855-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420963A
Age:6 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retching		Wellbutrin	PS	Glaxosmithkline	ORAL	50MG Per day	4 MON
	Vomiting		Ritalin	C				

Date:11/07/03ISR Number: 4231856-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420975A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
	Vision Blurred							
			Estrogen Patch	C				

			Testosterone Cream	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4231857-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0421226A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231858-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0421244A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Attack						per day	
			Nortriptyline	C				
			Ibuprofen	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231859-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0421256A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231860-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0421259A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Elevated Mood		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Feeling Abnormal							
	Feeling Jittery							

Date:11/07/03ISR Number: 4231861-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0421260A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tremor							

Date:11/07/03ISR Number: 4231862-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422161A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231863-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422164A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dry Mouth							
	Tremor		Ritalin	C			per day	YR

Date:11/07/03ISR Number: 4231864-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422178A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	
	Dyspnoea		Allegra	C				
			Prometrium	C				

Date:11/07/03ISR Number: 4231865-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422180A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swollen Tongue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK

Date:11/07/03ISR Number: 4231866-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422182A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
			Xanax	C				
			Thyroid	C				
			Aciphex	C				
			Estrogen Cream	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231867-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422190A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin	PS	Glaxosmithkline	ORAL	3	YR
			Oral Contraceptives	C				

Date:11/07/03ISR Number: 4231868-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422210A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK

Date:11/07/03ISR Number: 4231869-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422221A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	2 WK
	Chest Discomfort							
	Pruritus		Zoloft	C				
	Rash		Depakote	C				
	Restlessness							

Date:11/07/03ISR Number: 4231870-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422300A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Insomnia		Klonopin	C				

Date:11/07/03ISR Number: 4231871-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422309A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Increased Appetite						per day	3 MON
	Libido Decreased							

Date:11/07/03ISR Number: 4231872-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422318A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	7 MON
			Cardura	C				
			Lisinopril	C				

Date:11/07/03ISR Number: 4231873-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422352A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231874-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422483A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	

Date:11/07/03ISR Number: 4231875-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422484A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphemia		Wellbutrin	PS	Glaxosmithkline	ORAL	3	MON

Date:11/07/03ISR Number: 4231876-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422617A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
	Pharmaceutical Product							
	Complaint							

Date:11/07/03ISR Number: 4231877-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422634A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	4	DAY

Date:11/07/03ISR Number: 4231878-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422655A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
			Zyprexa	C				

Date:11/07/03ISR Number: 4231879-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422656A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
	Hypervigilance		Protonix	C				
	Insomnia		Guiafenesin-Dm	C				
	Onychorrhexis							

Date:11/07/03ISR Number: 4231880-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422682A
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Impatience		Synthroid	C	Glaxosmithkline			
	Tremor		Reglan	C	Glaxosmithkline			
			Ambien	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231881-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422687A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice per day	
	Decreased							

Date:11/07/03ISR Number: 4231882-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422718A
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	10 MON	

Date:11/07/03ISR Number: 4231883-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422723A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Unknown	3 WK

Date:11/07/03ISR Number: 4231884-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422724A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
			Claritin	C				
			Albuterol	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231885-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422730A
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Depression						per day	6 DAY
	Dyspnoea		Advair	C	Glaxosmithkline			
	Irritability		Combivent	C				
	Tremor							

Date:11/07/03ISR Number: 4231886-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422745A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 MON

Date:11/07/03ISR Number: 4231887-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422746A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pupils Unequal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
							per day	5 DAY
			Celexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231888-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422843A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
	Anxiety							
	Asthenia							
	Gastrointestinal Disorder							
	Headache							
	Nausea							
	Weight Decreased							

Date:11/07/03ISR Number: 4231889-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422845A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Belligerence		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231890-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422910A
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	
	Dizziness						Variable dose	

Date:11/07/03ISR Number: 4231891-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422927A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Allergic		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Urticaria						per day	2 WK

Date:11/07/03ISR Number: 4231896-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422929A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Heart Rate Irregular							
	Insomnia							

Date:11/07/03ISR Number: 4231897-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423092A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 WK
	Weight Increased		Flexeril	C		ORAL	10MG At night	3 YR
			Celebrex	C		ORAL	200MG Per day	1 YR

Date:11/07/03ISR Number: 4231898-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423154A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
Disability							per day	12 DAY
Other			Aspirin	C	Glaxosmithkline			
			Tums	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231899-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423369A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective						per day	5 DAY
	Headache		Paxil	C	Glaxosmithkline	ORAL	3	YR

Date:11/07/03ISR Number: 4231900-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423412A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Rash Papular		Flax Seed Oil	C				
			Birth Control Pills	C				

Date:11/07/03ISR Number: 4231901-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423418A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Positive		None	C				

Date:11/07/03ISR Number: 4231902-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423421A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Effexor Xr	C				

			Xanax	C		
			Lamictal	C	Glaxosmithkline	
			Synthroid	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4231903-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423601A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR

Date:11/07/03ISR Number: 4231904-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423620A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	
	Feeling Abnormal							
			Effexor	C				
			Neurontin	C				
			Lamictal	C	Glaxosmithkline			
			Synthroid	C	Glaxosmithkline			
			Xanax Sr	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231905-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423629A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Dry Mouth							
	Dysgeusia		Effexor	C				
	Hyperhidrosis		Triphasil	C				
	Tremor							

Date:11/07/03ISR Number: 4231906-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423633A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 YR
	Hypersensitivity		Buspar	C				
	Rash		Sonata	C				
	Rash Pruritic		Ambien	C			UNKNOWN	
			Ativan	C			UNKNOWN	
			Klonopin	C			UNKNOWN	
			Glucophage	C			UNKNOWN	1G Twice per day
			Actos	C			UNKNOWN	30MG Per day
			Tricor	C			UNKNOWN	160MG Per day
			Lipitor	C			UNKNOWN	10MG Per day
			Levaquin	C		OTHER		
			Flagyl	C	Glaxosmithkline	OTHER		

Date:11/07/03ISR Number: 4231907-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423635A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Gastrooesophageal Reflux						per day	6 MON
	Disease		Risperdal	C				
	Muscle Twitching		Ativan	C				
			Eskalith	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231915-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423698A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231916-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423709A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Benign Soft Tissue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Neoplasm						per day	
	Dizziness		Effexor Xr	C		ORAL	150MG Per day	1 YR
	Painful Response To Normal Stimuli							
	Skin Nodule							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231917-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423713A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	3 YR
			Clonazepam	C				
			Primatene Mist	C				

Date:11/07/03ISR Number: 4231918-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423717A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Activities Of Daily Living Impaired		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Drug Ineffective		Neurontin	C				
	Emotional Distress							

Date:11/07/03ISR Number: 4231922-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423720A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	3 YR
			Lexapro	C				
			Toprol	C				

Date:11/07/03ISR Number: 4231923-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423740A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline			
	Nausea							

Date:11/07/03ISR Number: 4231924-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423839A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231925-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423840A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231926-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423982A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	9 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231927-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423999A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Flushing						per day	4 DAY
	Headache		Amitriptyline	C				

Date:11/07/03ISR Number: 4231928-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424013A
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Testomax	SS				

Date:11/07/03ISR Number: 4231929-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424031A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Yawning							

Date:11/07/03ISR Number: 4231930-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424098A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	8 DAY
			Birth Control Pills	C				

Date:11/07/03ISR Number: 4231931-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424099A
Age:76 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Lipitor	C				
			Zoloft	C				
			Vitamins	C				

Date:11/07/03ISR Number: 4231932-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424100A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Synthroid	C	Glaxosmithkline			
			Toprol	C				
			Lotrel	C				

Date:11/07/03ISR Number: 4231933-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424112A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Social Avoidant Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	21 MON
			Amitriptyline	C				
			Seroquel	C				

			Fioricet	C		

Date:11/07/03ISR Number: 4231934-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424118A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Platelet Count Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
	Platelet Function Test Abnormal		Ambien	C				

Date:11/07/03ISR Number: 4231935-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424127A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Drug Ineffective							
	Stress							

Date:11/07/03ISR Number: 4231936-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424141A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4231937-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424301A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Unknown 1 YR
	Diarrhoea						
	Nausea						

Date:11/07/03ISR Number: 4231938-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424305A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoaesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice
	Lip Dry						per day 1 YR
			Zestril	C			

Date:11/07/03ISR Number: 4231941-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424336A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice
							per day 26 WK
			Weight Loss				
			Medication	C			
			Multi Vitamin + Minerals	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231942-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424377A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Distractibility		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Euphoric Mood							
	Headache							
	Urticaria							

Date:11/07/03ISR Number: 4231943-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424519A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Abnormal		Adderall	C				
			Ortho Tri Cyclen	C				

Date:11/07/03ISR Number: 4231944-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424523A
Age: YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231945-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424688A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Tremor							

Date:11/07/03ISR Number: 4231946-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424698A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 WK
	Apathy		Paxil Cr	C	Glaxosmithkline			
	Asthenia		Naproxen	C				

Date:11/07/03ISR Number: 4231947-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424721A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Insomnia							
	Psychomotor Hyperactivity							

Date:11/07/03ISR Number: 4231948-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424739A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	
	Liver Function Test						Variable dose	
	Abnormal		Avandamet	SS	Glaxosmithkline	ORAL	4MG Per day	
	Memory Impairment		Aspirin	C	Glaxosmithkline			
	Therapeutic Response		Prozac	C				
	Unexpected		Lipitor	C				

			Ativan	C		
			Tetracycline	C		

Date:11/07/03ISR Number: 4231949-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424742A
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tinnitus						per day	2 YR

Date:11/07/03ISR Number: 4231950-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424789A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Elavil	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4231951-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424875A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Muscle Twitching		Wellbutrin	SS	Glaxosmithkline	ORAL	100MG Per day	

Date:11/07/03ISR Number: 4231952-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424876A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

	Muscle Twitching		Wellbutrin	SS	Glaxosmithkline	ORAL
100MG Per day						

Date:11/07/03ISR Number: 4231953-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424950A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Weight Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Twice per day 5 YR						

Date:11/07/03ISR Number: 4231954-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425034A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 3 WK						

Date:11/07/03ISR Number: 4231955-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425050A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hangover		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 2 WK						
			Adipex	C	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231956-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425067A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline		150MG Per day	7 DAY
	Dry Mouth							
	Feeling Jittery							

Date:11/07/03ISR Number: 4231957-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425082A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Dapson	C				

Date:11/07/03ISR Number: 4231958-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425087A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL	300 per day	3 WK
	Headache		Xanax	SS				
	Somnolence		Alcohol	SS		ORAL		
	Weight Increased							

Date:11/07/03ISR Number: 4231959-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425133A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Headache		Synthroid	C	Glaxosmithkline			
	Paraesthesia							

Date:11/07/03ISR Number: 4231960-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425163A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Fatigue						per day	4 MON
	Insomnia		Synthroid	C	Glaxosmithkline			
	Neuropathy		Reglan	C	Glaxosmithkline			
	Sinusitis		Celebrex	C				
	Weight Decreased		Zyprexa	C				
			Prevacid	C				
			Allegra	C				

Date:11/07/03ISR Number: 4231961-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425362A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Energy Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Fatigue						per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231962-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425516A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Headache							

Date:11/07/03ISR Number: 4231963-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425583A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Bupropion	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231964-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425675A
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	24 DAY
	Drug Ineffective		Plendil	C			UNKNOWN	
	Tremor		Atenolol	C				
			Zestril	C				

Date:11/07/03ISR Number: 4231965-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425683A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Unknown	1 DAY
			Dilantin	C				

Date:11/07/03ISR Number: 4231967-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425696A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:11/07/03ISR Number: 4231968-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425710A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Myalgia						per day	
	Pain		Synthroid	C	Glaxosmithkline			
	Pain In Extremity		Atacand	C				
			Atenolol	C				
			Lipitor	C				
			Singulair	C				

Date:11/07/03ISR Number: 4231969-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425926A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombocytopenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
Hospitalization -							per day	60 WK
Initial or Prolonged			Effexor Xr	C				
			Adderall Xr	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231970-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425944A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
			Duragesic	C				
			Neurontin	C				
			Xanax	C				
			Tylenol #3	C				

Date:11/07/03ISR Number: 4231971-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425949A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231972-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425972A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			Ultram	C				
			Vicodin	C				

Date:11/07/03ISR Number: 4231973-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425973A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment		Wellbutrin	PS	Glaxosmithkline	ORAL	1 per day	1 WK

Sluggishness	Serzone	C	
Stress	Haldol	C	
	Depakote	C	
	Lipitor	C	
	Glucotrol	C	

Date:11/07/03ISR Number: 4231974-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425979A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		WK

Date:11/07/03ISR Number: 4231975-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425980A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231976-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426108A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 MON
			Proscar	C				
			Fosamax	C				
			Prinivil	C				

Date:11/07/03ISR Number: 4231977-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426123A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia		Wellbutrin	PS	Glaxosmithkline		2	YR

Date:11/07/03ISR Number: 4231978-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426136A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			Vit. B	C				
			Vit C	C	Glaxosmithkline			
			Vit E	C				
			Flax Seed Oil	C				

Date:11/07/03ISR Number: 4231979-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426138A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Asthenia					
per day						
	Cognitive Disorder		Protonix	C		
	Dissociation		Zyban	C	Glaxosmithkline	ORAL
	Drug Ineffective					
	Dyspepsia					
	Early Morning Awakening					
	Fatigue					
	Muscle Twitching					
	Nausea					
	Reading Disorder					
	Sleep Disorder					

Date:11/07/03ISR Number: 4231987-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426186A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Liver Function Test		Wellbutrin	PS	Glaxosmithkline	ORAL
	Abnormal		Strattera	SS		
UNKNOWN						

Date:11/07/03ISR Number: 4231988-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426452A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231989-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426572A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4231990-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426577A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vulvovaginal Dryness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231991-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426578A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vulvovaginal Dryness		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Depakote	C				

Date:11/07/03ISR Number: 4231992-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426587A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR

Date:11/07/03ISR Number: 4231993-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426594A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice						
per day 2 MON						
			Celexa	C		
			Calcium	C		

Date:11/07/03ISR Number: 4231994-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426599A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice						
per day 1 MON						
			Eye Drop	C		
			Topical Cream	C		

Date:11/07/03ISR Number: 4231995-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426619A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 3 WK						
	Tension					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4231996-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426882A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/07/03ISR Number: 4231997-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426885A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	3 DAY
			Lexapro	C				
			Geodon	C				

Date:11/07/03ISR Number: 4231998-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426893A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4231999-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426902A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR

Date:11/07/03ISR Number: 4232000-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426924A
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
			Effexor	C				

Date:11/07/03ISR Number: 4232001-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426925A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR
			Celexa	C				
			Synthroid	C	Glaxosmithkline			
			Oral Contraceptives	C				
			Eye Drops	C				

Date:11/07/03ISR Number: 4232002-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426935A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 YR
	Palpitations							
			Zoloft	C				
			Doxepin	C				
			Chlorazepate Dipotassium	C				
			Geodon	C				

		Premarin	C	
		Vit E	C	
		Vit C	C	Glaxosmithkline
		Calcium	C	
		Vit D	C	
		Multivitamin	C	
		Evening Primrose Oil	C	

Date:11/07/03ISR Number: 4232003-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426938A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Anxiety						per day	
	Disturbance In Attention		Lithium	C	Glaxosmithkline			
	Insomnia		6mp	C	Glaxosmithkline			
			Blood Pressure Medication	C				
			Unspecified Medication	C				
			Paxil	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4232004-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427014A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Generalised		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232005-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427015A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232006-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427016A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
	Flushing		Paxil	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4232007-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427019A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Feeling Jittery						per day	4 WK
	Nausea							

Date:11/07/03ISR Number: 4232008-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427032A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tinnitus						per day	1 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4232009-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427035A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Male Sexual Dysfunction		Wellbutrin	PS	Glaxosmithkline			

Date:11/07/03ISR Number: 4232010-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427054A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	5	WK
	Road Traffic Accident		Methadone	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4232011-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427055A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	7 MON
			Zoloft	C				

Date:11/07/03ISR Number: 4232012-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427058A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea							
per day	4 MON							

Date:11/07/03ISR Number: 4232013-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427084A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	19 DAY

Date:11/07/03ISR Number: 4232014-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427216A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4232015-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427336A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Zyprexa	C				

Date:11/07/03ISR Number: 4232016-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427349A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice per day	3 MON
			Lamictal	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4232017-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427350A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
	Crying							
	Irritability							
	Nicotine Dependence							

Date:11/07/03ISR Number: 4232018-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427359A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dysgeusia							
per day							13	WK

Date:11/07/03ISR Number: 4232019-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427369A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness							
per day							2	MON
	Palpitations							

Date:11/07/03ISR Number: 4232020-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427391A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	4	YR

Date:11/07/03ISR Number: 4232021-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427403A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232022-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427512A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Acuity Reduced		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 MON
			Estratest	C				
			Prilosec	C				
			Soma	C				
			Vicodin	C				
			Ibuprofen	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4232024-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427514A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
	Pain		None	C				
	Pain In Extremity							
	Pruritus							
	Tongue Blistering							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4232025-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427553A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232026-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427679A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Swelling Face		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	10 DAY
Other			Nicotrol Inhaler	SS	Glaxosmithkline		.25MG Weekly	
			Monopril	C				
			Allopurinol	C	Glaxosmithkline			
			Norvasc	C				
			Prevacid	C				
			Lipitor	C				
			Xanax	C				
			Advair	C	Glaxosmithkline		2PUFF Four times per day	
			Combivent	C				
			Ecotrin	C	Glaxosmithkline		325MG Per day	

Date:11/07/03ISR Number: 4232027-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427694A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
			Aciphex	C				
			Vioxx	C				
			Flexeril	C				
			Hydrochlorothiazide	C				

			Paxil	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4232028-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427703A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232029-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427726A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232030-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427844A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Weight Decreased						per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4232031-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427869A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY

Date:11/07/03ISR Number: 4232032-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427878A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Muscle Tightness						per day	4 DAY

Date:11/07/03ISR Number: 4232033-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427898A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Drunk		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY

Date:11/07/03ISR Number: 4232034-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427902A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232035-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428051A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice
	Irritability						
per day 3 MON							

Date:11/07/03ISR Number: 4232036-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428052A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day
9 DAY							
	Mood Swings		Vitamins	C			
	Weight Decreased						

Date:11/07/03ISR Number: 4232037-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428057A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice
	Feeling Abnormal						
per day 2 WK							
	Insomnia						
	Joint Stiffness						
	Muscle Tightness						
	Tremor						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4232038-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428093A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232039-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428109A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232040-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428115A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4232047-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0432608A
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Nightmare		Bupropion	SS	Glaxosmithkline		1	MON
	Urinary Retention		Heart Medication	C				
			Antihypertensives	C				
			Lopressor	C				

Date:11/07/03ISR Number: 4232048-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0432624A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Medication Error		Wellbutrin	PS	Glaxosmithkline	

Date:11/07/03ISR Number: 4232054-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0296280A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 3 WK
Initial or Prolonged	Phosphokinase Increased		Soprol	C		ORAL	.5TAB	Per day
Other	Dermatomyositis		Microval	C		ORAL		
	Erythema							
	Myalgia							
	Skin Ulcer							

Date:11/07/03ISR Number: 4232057-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0309991A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Injury		Zyban	PS	Glaxosmithkline	ORAL	1TAB	Per day 13 DAY
Other	Facial Bones Fracture		Atorvastatin	C		ORAL	10MG	Per day
	Grand Mal Convulsion		Ketotifen	C		ORAL	2MG	Per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4232060-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0311375A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia		Zyban	PS	Glaxosmithkline	ORAL	3	MON
	Feeling Abnormal							
	Insomnia							
	Palpitations							
	Tremor							
	Weight Decreased							

Date:11/07/03ISR Number: 4232061-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0311639A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 3 DAY
	Cardio-Respiratory Arrest							
	Myocardial Infarction							
	Nausea							
	Sudden Death							

Date:11/07/03ISR Number: 4232062-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0311918A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxosmithkline	ORAL	29	DAY
	Chest X-Ray Abnormal							
	Constipation							
	Hepatic Enzyme Increased							
	Hepatic Neoplasm							
	Hepatic Pain							
	Macrocytosis							
	Nausea							
	Vomiting							
	Weight Decreased							

Date:11/07/03ISR Number: 4232068-XReport Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0313503A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Bupropion	PS	Glaxosmithkline		UNKNOWN	
	Sleep Walking							

Date:11/07/03ISR Number: 4233287-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400173A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Lethargy						per day	18 MON
			Premarin	C				
			Synthroid	C	Glaxosmithkline			
			Cholesterol Reducing Agent Name Not Known	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233288-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400181A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossitis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Mouth Ulceration						per day	WK
	Stomatitis		Wellbutrin	SS	Glaxosmithkline	ORAL	75MG Twice	
							per day	WK

Date:11/07/03ISR Number: 4233289-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400193A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion	PS	Glaxosmithkline	ORAL		
			Prozac	C				

Date:11/07/03ISR Number: 4233290-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400207A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three	
							times per day	5 YR
			Multivitamin	C				
			Zocor	C				
			Atenolol	C				

Date:11/07/03ISR Number: 4233291-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400247A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day						
			Cenestin	C		
			Albuterol	C	Glaxosmithkline	
			Norvasc	C		
			Celebrex	C		
			Singulair	C		
			Maxzide	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4233292-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400248A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
			Caffeine	C		ORAL	6PACK Per day	

Date:11/07/03ISR Number: 4233293-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400275A
Age:12 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233294-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400277A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	6	WK
	Palpitations							
	Pollakiuria							
	Tachycardia							

Date:11/07/03ISR Number: 4233295-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400400A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Abnormal		Depakote	C				
			Zyprexa	C				
			Remeron	C				

Date:11/07/03ISR Number: 4233296-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400438A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
	Drug Interaction							
			Delsym	SS	Glaxosmithkline		UNKNOWN	
			No Concurrent Medication	C				

Date:11/07/03ISR Number: 4233297-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400576A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Food Craving		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day MON						
	Increased Appetite		Celexa	C		
	Weight Increased		Thyrolar	C		

Date:11/07/03ISR Number: 4233298-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400581A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Dizziness					
per day 45 DAY						
	Dyspnoea					
	Insomnia					

Date:11/07/03ISR Number: 4233299-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400603A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 6 MON						
	Muscle Twitching		Flonase	C	Glaxosmithkline	NASAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233300-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400622A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	5	DAY
	Anxiety							
	Irritability							
	Paranoia							

Date:11/07/03ISR Number: 4233301-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400668A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	4 MON
			Zoloft	C				
			Lithobid	C	Glaxosmithkline			
			Enema	C				

Date:11/07/03ISR Number: 4233302-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400669A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:11/07/03ISR Number: 4233303-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400717A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Sensation In Eye		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	1 MON
	Corneal Reflex Decreased							

	Dehydration		Insulin	C		
	Increased Insulin		Ambien	C		
	Requirement		Valium	C		
	Insomnia		Xanax	C		
			Alcohol	C		ORAL

Date:11/07/03ISR Number: 4233304-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400721A
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Decreased Appetite					
per day 536 DAY						
	Nausea		Concerta	C		
			Verapamil	C		
			Zyrtec-D	C		
			Nasonex	C		
			Advair	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4233305-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400727A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 5 YR						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233306-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400776A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Vomiting		Premarin	C				

Date:11/07/03ISR Number: 4233307-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400780A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG per day	3 WK
	Headache		Paxil Cr	C	Glaxosmithkline			
	Social Avoidant Behaviour		Xanax	C				

Date:11/07/03ISR Number: 4233308-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400781A
Age:2 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Exposure		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Single dose	1 DAY
	Tachycardia		Diet Medication	SS		ORAL	1	DAY

Date:11/07/03ISR Number: 4233309-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400966A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Anger							

	Dry Mouth		Fat Burner	SS		ORAL
3CAP Twice						
	Dyspnoea					
per day 1 DAY						
	Energy Increased		Stamina Rx	SS		ORAL
	Irritability					
	Nervousness					
	Palpitations					
	Tachycardia					
	Tremor					

Date:11/07/03ISR Number: 4233310-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401020A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:11/07/03ISR Number: 4233311-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401029A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Therapeutic Response		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice						
	Decreased					
per day 2 YR						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233312-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401038A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Contractions		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Involuntary						per day	3 MON
	Muscle Twitching		Vitamins	C				

Date:11/07/03ISR Number: 4233313-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401141A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	

Date:11/07/03ISR Number: 4233314-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401279A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Hallucination						per day	5 WK
	Headache		Reglan	C	Glaxosmithkline			
	Vision Blurred							

Date:11/07/03ISR Number: 4233315-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401281A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	

per day

Date:11/07/03ISR Number: 4233316-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401286A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown 11 DAY
	Fatigue							
	Nausea							

Date:11/07/03ISR Number: 4233317-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401328A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233318-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401506A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Unknown 19 DAY
	Urticaria		Prednisone	C				
			Fiorinal	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233319-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401524A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	4	MON
	Hunger		Klonopin	C				
	Increased Appetite							
	Nightmare							
	Parosmia							
	Polydipsia							
	Restless Legs Syndrome							
	Smoker							

Date:11/07/03ISR Number: 4233320-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401539A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233321-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401549A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Macular		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY

Date:11/07/03ISR Number: 4233322-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401805A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transmission Of Drug Via		Wellbutrin	PS	Glaxosmithkline	OTHER		
	Semen		Birth Control	C				
	Vaginal Infection							

Date:11/07/03ISR Number: 4233323-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401814A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	15	DAY
			Birth Control Pills	C				

Date:11/07/03ISR Number: 4233324-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401821A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	4 MON
			Prozac	C			80MG per day	
			Zyprexa	C			5MG per day	

Date:11/07/03ISR Number: 4233325-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401827A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Allergic		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233326-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401831A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Feeling Jittery						per day	2 MON
			Strattera	SS				

Date:11/07/03ISR Number: 4233327-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402003A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Neurontin	C				
			Lexapro	C				

Date:11/07/03ISR Number: 4233328-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402006A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/07/03ISR Number: 4233329-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402007A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Tramadol	C				
			Lotensin	C	Glaxosmithkline			
			Vicodin	C				
			Synthroid	C	Glaxosmithkline			
			Toprol	C				

Date:11/07/03ISR Number: 4233330-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402008A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY
	Swollen Tongue		Prometrium	C				
			Clonazepam	C				

Date:11/07/03ISR Number: 4233331-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402013A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	per day

Date:11/07/03ISR Number: 4233332-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402026A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	per day
			Alprazolam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233333-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402041A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Facial Pain		Prozac	SS				
UNKNOWN								
	Nervousness							

Date:11/07/03ISR Number: 4233334-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402168A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
	Weight Decreased		Celexa	C				
UNKNOWN							10MG Per day	

Date:11/07/03ISR Number: 4233335-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402173A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Hypoaesthesia							
per day								4 MON
	Keratoconjunctivitis		Atenolol	C				
	Sicca		Ambien	C				
	Vision Blurred		Ketoprofen	C				
UNKNOWN								
			Methocarbamol	C				
UNKNOWN								
			Imitrex	C	Glaxosmithkline			
UNKNOWN								
			Meclizine	C				
UNKNOWN								

Date:11/07/03ISR Number: 4233336-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402176A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	23 DAY
			Risperidal	C				
			Ativan	C				
			Neurontin	C				

Date:11/07/03ISR Number: 4233337-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402207A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 MON
	Muscle Tightness							
	Nervousness		Anfebutamona	SS	Glaxosmithkline			

Date:11/07/03ISR Number: 4233338-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402279A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment		Wellbutrin	PS	Glaxosmithkline	ORAL	375MG per day	2 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233339-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402291A
Age:2 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Exposure		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233340-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402305A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Odour Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Weight Decreased						per day	1 YR
			Advil	C	Glaxosmithkline			
			Midol	C				

Date:11/07/03ISR Number: 4233341-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402362A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Ssri	C				

Date:11/07/03ISR Number: 4233342-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402414A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG In the	
	Vomiting						morning	11 YR
			Trazodone	C				
			Relafen	C	Glaxosmithkline			
			Birth Control	C				
			Prilosec	C				
			Vitamins	C				

Date:11/07/03ISR Number: 4233343-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402431A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Prozac	C				
			Topamax	C				

Date:11/07/03ISR Number: 4233344-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402541A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
	Dizziness							
	Insomnia							

Date:11/07/03ISR Number: 4233345-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402543A
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Essential Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	12 YR

			Hctz	C		ORAL	
			Hytrin	C		ORAL	5MG Twice per day
			Toprol	C		ORAL	
			Cozaar	C		ORAL	50MG Twice per day
			Norvasc	C		ORAL	
			Wine	C			

Date:11/07/03ISR Number: 4233346-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402567A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4233347-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402569A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		91 DAY
			Risperdal	C				

Date:11/07/03ISR Number: 4233348-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402571A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	18 DAY
	Diarrhoea		Methadone	C	Glaxosmithkline			
	Headache		Hydrocodone	C				

	Nausea		Excedrin	C		

Date:11/07/03ISR Number: 4233349-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402589A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY

Date:11/07/03ISR Number: 4233350-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402591A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Medication Error						per day	

Date:11/07/03ISR Number: 4233351-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402593A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Oral Contraceptive Pills	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233352-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402600A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Yawning							
per day								20 DAY
			Blood Pressure Medication	C				

Date:11/07/03ISR Number: 4233353-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402660A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233354-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402666A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Intentional Misuse							
			Strattera	SS				

Date:11/07/03ISR Number: 4233355-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402672A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Unknown	
	Complaint							
	Stool Analysis Abnormal							

Date:11/07/03ISR Number: 4233356-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402677A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Rash						per day	
	Urticaria							

Date:11/07/03ISR Number: 4233357-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402894A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Per day	3 MON
	Crying		Estrogen	C			INTRADERMAL	
	Depressed Mood		Klonopin	C				
	Irritability		Zyrtec	C	Glaxosmithkline			
	Palpitations							

Date:11/07/03ISR Number: 4233358-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402896A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dermatitis Exfoliative		Prevacid	C				
	Rash		Levaquin	C				

Advair	C	Glaxosmithkline	
Solumedrol	C		
Atrovent	C		
Imdur	C		
Klonopin	C		
Prednisone	C		
Baby Aspirin	C	Glaxosmithkline	
Albuterol	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4233359-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402904A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Fall						per day	3 MON
	Peroneal Nerve Palsy		Prozac	SS		ORAL	60MG Per day	973 DAY

Date:11/07/03ISR Number: 4233360-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403048A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Positive						per day	1 YR
			Paxil	C	Glaxosmithkline			
			Depakote	C				
			Seroquel	C				

Date:11/07/03ISR Number: 4233361-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403091A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	DAY

		Diarrhoea		Prozac	C		
UNKNOWN	20MG Unknown	Feeling Abnormal					
		Headache					
		Insomnia					
		Nausea					

Date:11/07/03ISR Number: 4233362-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403098A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Ineffective							

Date:11/07/03ISR Number: 4233363-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403105A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Advair	C	Glaxosmithkline			
			Albuterol	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233364-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403109A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polymyalgia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	3 WK
			Valproic Acid	C				

Date:11/07/03ISR Number: 4233365-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403118A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
	Cheilitis							
	Dysgeusia							
	Flushing							
	Gingival Pain							
	Hypersensitivity							
	Nervousness							
	Pruritus							
	Stomatitis							

Date:11/07/03ISR Number: 4233366-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403313A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Three times per day	2 WK
	Keratoconjunctivitis							
	Sicca							
	Photophobia							

Date:11/07/03ISR Number: 4233367-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403314A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233368-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403425A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233369-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403441A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	3 MON
	Headache							

Date:11/07/03ISR Number: 4233370-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403495A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 DAY
	Rash		Wellbutrin	SS	Glaxosmithkline	ORAL	5	DAY

Remeron	C
Prozac	C
Xanax	C
Seroquel	C

Date:11/07/03ISR Number: 4233371-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403566A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness						per day	3 DAY
	Dry Mouth							
	Tinnitus							

Date:11/07/03ISR Number: 4233372-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403680A
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	42 DAY
			Insulin	C				

Date:11/07/03ISR Number: 4233373-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403687A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Convulsion		Concerta	C				

Date:11/07/03ISR Number: 4233374-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403734A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233375-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403736A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Positive		Paxil	SS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233376-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403749A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	

Date:11/07/03ISR Number: 4233377-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403781A
Age:42 YR Gender:Female I/FU:I

Outcome	PT
	Drug Ineffective
	Energy Increased

	Feeling Jittery Insomnia Nervousness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Therapeutic Response Unexpected		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day 6 MON

Date:11/07/03ISR Number: 4233378-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403786A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	350MG Unknown
	Weight Increased		Concurrent Medications	C			

Date:11/07/03ISR Number: 4233379-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404002A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day DAY
	Dizziness Dry Mouth Food Craving Insomnia Judgement Impaired Somnolence						

Date:11/07/03ISR Number: 4233380-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404042A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	2 YR
	Drug Ineffective		Hormone	C			

	Fatigue					
	Laziness					

Date:11/07/03ISR Number: 4233381-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404142A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Pruritus						per day	
	Rash							
	Urticaria							

Date:11/07/03ISR Number: 4233382-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404166A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oligomenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG per day	2 MON
			Estrogen Patch	C				
			Klonopin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233383-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404200A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/07/03ISR Number: 4233384-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404220A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Speech Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233385-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404222A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233386-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404311A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	WK
			Effexor	C				

Date:11/07/03ISR Number: 4233387-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404337A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Thyroxine Increased		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice per day 2 WK						
			Motrin	C	Glaxosmithkline	
			Levothyroxine	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4233388-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404375A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL
	Rash					

Date:11/07/03ISR Number: 4233389-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404379A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL
450MG Per day 3 YR						
			Imitrex	C	Glaxosmithkline	
			Flonase	C	Glaxosmithkline	NASAL
			Celexa	C		
			Allegra	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233390-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404387A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Allodynia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233391-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404406A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	3 WK
	Musculoskeletal Stiffness							
	Neck Pain							
	Nightmare							

Date:11/07/03ISR Number: 4233392-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404407A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Impaired Work Ability		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG At night	DAY
	Tremor							
			Plavix	C		ORAL	75MG Per day	
			Potassium	C		ORAL	10MG Per day	
			Prednisone	C		ORAL	10MG Unknown	
			Synthroid	C	Glaxosmithkline	ORAL	.75U Per day	
			Toprol	C		ORAL	100MG Twice per day	
			Advair	C	Glaxosmithkline		RESPIRATORY (INHALATION)	1PUFF Twice

per day

Date:11/07/03ISR Number: 4233393-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404408A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
			Zoloft	C				

Date:11/07/03ISR Number: 4233394-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404439A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	6	MON
			Prevacid	C				
			Prempro	C				
			Serzone	C				

Date:11/07/03ISR Number: 4233395-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404622A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Personality Change		Wellbutrin	PS	Glaxosmithkline	ORAL	10	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233396-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404626A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK

Date:11/07/03ISR Number: 4233397-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404680A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Klonopin	C		ORAL		5 YR
			Marijuana	C				

Date:11/07/03ISR Number: 4233398-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404801A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Depakote	C				
			Zyprexa	C				

Date:11/07/03ISR Number: 4233399-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404802A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	

Date:11/07/03ISR Number: 4233400-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404813A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233401-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404858A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	3 MON

Date:11/07/03ISR Number: 4233402-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404871A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	

Date:11/07/03ISR Number: 4233403-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404872A
Age:23 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233404-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405013A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	17 DAY
	Urticaria							

Date:11/07/03ISR Number: 4233405-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405032A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	
							Variable dose	WK
			Prevacid	C				
			Topomax	C				
			Clonazepam	C				

Date:11/07/03ISR Number: 4233406-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405044A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Zoloft	C				
			Trileptal	C				

Date:11/07/03ISR Number: 4233407-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405144A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Odour Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three	
							times per day	WK

Date:11/07/03ISR Number: 4233408-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405146A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233409-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405153A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	40 DAY
	Back Pain		Zyprexa	C				

Date:11/07/03ISR Number: 4233410-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405155A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Otc Products	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233411-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405156A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG At	
	Dyspnoea						night	MON
			Synthroid	C	Glaxosmithkline			
			Lipitor	C				

Date:11/07/03ISR Number: 4233412-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405176A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Feeling Abnormal						per day	WK

Date:11/07/03ISR Number: 4233416-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405300A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	WK
	Heart Rate Increased		Allegra D	C				
	Hyperhidrosis		Contraceptives	C		ORAL		
	Nausea							
	Sleep Disorder							
	Tremor							

Date:11/07/03ISR Number: 4233417-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405302A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotension		Wellbutrin	PS	Glaxosmithkline	ORAL		

			Amitriptyline	SS		
UNKNOWN	100MG Unknown					

Date:11/07/03ISR Number: 4233418-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405326A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Obsessive-Compulsive		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Disorder						per day	3 YR
	Paraphilia		Lithium	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4233419-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405331A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	DAY
	Heart Rate Increased		Trazodone	C				
	Middle Insomnia							
	Migraine							
	Paraesthesia							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233420-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405366A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myoclonus		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Concurrent Medications	C				

Date:11/07/03ISR Number: 4233421-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405392A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233422-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405431A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	10	DAY
	Irritability							
	Logorrhoea							
	Pharyngolaryngeal Pain							

Date:11/07/03ISR Number: 4233423-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405447A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 DAY
	Limb Injury							
	Sleep Walking		Levoxyl	C	Glaxosmithkline			
			Rhinocort	C				
			Lipitor	C				
			Diovan	C				

			Advair	C	Glaxosmithkline	

Date:11/07/03ISR Number: 4233424-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405461A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Minocycline	C				

Date:11/07/03ISR Number: 4233425-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405489A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233426-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405735A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Bupropion	PS	Glaxosmithkline	ORAL		
			Diflucan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233427-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405757A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	
	Tinnitus		Ativan	C				
			Zantac	C	Glaxosmithkline			
			Prozac	C				
			Menest	C	Glaxosmithkline			
			Azmacort	C				
			Intal	C				
			Flonase	C	Glaxosmithkline			
			Medroxyprogesterone	C				

Date:11/07/03ISR Number: 4233428-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405786A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Feeling Abnormal		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Feeling Jittery		Lorazepam	C				
	Headache							
	Impaired Driving Ability							
	Loss Of Consciousness							

Date:11/07/03ISR Number: 4233429-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405800A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:11/07/03ISR Number: 4233430-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405813A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Nausea		Ambien	C				

Date:11/07/03ISR Number: 4233435-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405933A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	5	WK
	Muscle Tightness							
	Nausea							
	Weight Increased							

Date:11/07/03ISR Number: 4233436-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405964A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233437-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406022A
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR
			Lithium	C	Glaxosmithkline			
			Unspecified Medication	C				

Date:11/07/03ISR Number: 4233438-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406045A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Insomnia							
	Nausea							
	Tinnitus							

Date:11/07/03ISR Number: 4233439-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406059A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Drug Ineffective							

Date:11/07/03ISR Number: 4233440-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406070A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Growth Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	

per day 2 YR

Date:11/07/03ISR Number: 4233441-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406073A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233442-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406086A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Diarrhoea						per day	
	Muscle Spasms		No Concurrent					
	Pharmaceutical Product Complaint		Medications	C				

Date:11/07/03ISR Number: 4233443-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406262A
Age:75 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	per day
			Seroquel	C				

Date:11/07/03ISR Number: 4233444-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406286A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233445-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406293A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tic		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	per day

Date:11/07/03ISR Number: 4233446-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406304A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression Anger		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233447-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406363A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
							per day	1 MON
			Prometrium	C				
			Clomiphene	C				
			Metformin	C				

Date:11/07/03ISR Number: 4233448-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406401A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anxiety							
							per day	4 DAY
	Dissociation		Paxil	C	Glaxosmithkline			
	Nausea							

Date:11/07/03ISR Number: 4233449-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406406A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Dizziness							
							per day	3 WK
			Aspirin	C	Glaxosmithkline			
			Lupron	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233450-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406437A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:11/07/03ISR Number: 4233451-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406454A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anger							
per day							3	WK
	Depression		Birth Control	C				

Date:11/07/03ISR Number: 4233452-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406571A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Distress		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Tinnitus							
per day							66	DAY
			Ambien	C				

Date:11/07/03ISR Number: 4233453-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406688A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Myoclonus							

Date:11/07/03ISR Number: 4233454-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406714A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Cardizem	SS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233455-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406770A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	8 DAY
			Glyburide	C				
			Metformin	C				

Date:11/07/03ISR Number: 4233456-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406852A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Head Injury		Zoloft	C				
	Loss Of Consciousness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233457-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406863A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	9 MON
	Irritability		Glucosamine/Chondroitin	SS			10 DAY	

Date:11/07/03ISR Number: 4233460-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406875A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Odour Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	YR
			Synthroid	C	Glaxosmithkline			
			Lotrel	C				
			Estratest	C				
			Prozac	C				
			Skelaxin	C				
			Relafen	C	Glaxosmithkline			

Date:11/07/03ISR Number: 4233461-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406886A
Age:13 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR
			Strattera	C		ORAL	36MG Unknown	
			Concerta	C		ORAL	SUBCUTANEOUS	
			Gonadotropin	C				

Date:11/07/03ISR Number: 4233462-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406898A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Trazodone	C				

Date:11/07/03ISR Number: 4233463-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406904A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Weight Increased							

Date:11/07/03ISR Number: 4233464-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406907A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Unknown	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233465-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406918A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Somnolence						per day	
			Synthroid	C	Glaxosmithkline			
			Vioxx	C				

Date:11/07/03ISR Number: 4233466-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406920A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	5 DAY
	Belligerence		Thyroid Medication	C				
	Dissociation							

Date:11/07/03ISR Number: 4233467-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406927A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233468-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406929A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233469-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406987A
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Convulsion Bupropion PS Glaxosmithkline ORAL

Date:11/07/03ISR Number: 4233470-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407007A
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Rash Wellbutrin PS Glaxosmithkline ORAL

Date:11/07/03ISR Number: 4233471-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407022A
Age: Gender: I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Drug Ineffective Wellbutrin PS Glaxosmithkline ORAL
400MG per day

Date:11/07/03ISR Number: 4233472-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407068A
Age: Gender: I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Alopecia Wellbutrin PS Glaxosmithkline ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4233473-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407069A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG per day	1 YR
	Chest Pain		Effexor	C				
			Vitamins	C				

Date:11/07/03ISR Number: 4233474-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407074A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electroencephalogram Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233475-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407080A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	

Date:11/07/03ISR Number: 4233476-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407089A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucinations, Mixed		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Urine Amphetamine Positive		Provigil	SS				
			Albuterol	C	Glaxosmithkline			
			Viagra	C				

Date:11/07/03ISR Number: 4233477-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407104A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nonspecific Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/07/03ISR Number: 4233478-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407127A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG per day	1 YR
			Effexor	C			225MG per day	1 YR

Date:11/07/03ISR Number: 4233479-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407131A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/03ISR Number: 4231010-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0433145A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anorexia						per day	22 WK
	Dysgeusia		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	
	Fatigue		Oxycontin	SS				
	Irregular Sleep Phase		Remeron	SS				
	Middle Insomnia							
	Sleep Disorder							

Date:11/10/03ISR Number: 4231012-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0433261A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Depression							
	Fatigue							
	Loss Of Consciousness							
	Myalgia							
	Vomiting							

Date:11/10/03ISR Number: 4231013-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0433263A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Medication Error		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Xanax	C				

Date:11/12/03ISR Number: 4234125-0Report Type:Direct Company Report #CTU 205814
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Wellbutrin Sr 100 Mg					
Required	Agitation		Glaxo	PS	Glaxo	ORAL	1 1 PER DAY	
Intervention to	Anxiety							
ORAL								
Prevent Permanent	Completed Suicide							
Impairment/Damage	Depression							
	Diarrhoea							
	Flatulence							
	Headache							
	Insomnia							
	Nausea							
	Paranoia							
	Psychotic Disorder							
	Pyrexia							
	Toothache							
	Tremor							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/03ISR Number: 4243148-7Report Type:Direct Company Report #USP 56117
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr	PS	Glaxosmithkline			
							TABLET, EXTENDED RELEASE, 150 MG	
			Wellbutrin Xl	SS	Glaxosmithkline			
							150 MG TABLET, EXTENDED RELEASE	

Date:11/13/03ISR Number: 4234347-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0433006A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/13/03ISR Number: 4234348-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0438844A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Spasm		Wellbutrin	PS	Glaxosmithkline			

Date:11/13/03ISR Number: 4234376-5Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0314554A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oropharyngeal Swelling		Zyban	PS	Glaxosmithkline	ORAL	1TAB	See dosage text

Date:11/14/03ISR Number: 4235305-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0354550A
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Other	Aggression
	Agitation
	Anger
	Anorexia
	Anxiety
	Asthenia
	Confusional State
	Coordination Abnormal
	Depression
	Disturbance In Attention
	Dizziness
	Drug Ineffective
	Drug Withdrawal Syndrome
	Fatigue
	Gait Disturbance
	Homicidal Ideation
	Influenza
	Intentional Self-Injury
	Irritability

	Lethargy						
	Malaise						
	Memory Impairment	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myalgia		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day
	Nausea		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice
	Nightmare						per day
	Obsessive Thoughts		Ritalin	C			
	Obsessive-Compulsive		Amoxicillin	C	Glaxosmithkline		
	Disorder						
	Paraesthesia						
	Paranoia						
	Pyrexia						
	Suicidal Ideation						
	Suicide Attempt						
	Tremor						
	Vertigo						

Date:11/14/03ISR Number: 4235313-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0438799A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	3 WK
	Fall						
	Skin Laceration						

Date:11/14/03ISR Number: 4235314-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0438824A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline		

Date:11/14/03ISR Number: 4235330-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0313823A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Arthralgia C-Reactive Protein Increased Erythema Feeling Hot Neutrophil Count Increased Oedema Peripheral Petechiae Pyrexia		Zyban	PS	Glaxosmithkline	ORAL		

Date:11/14/03ISR Number: 4235332-3Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0314310A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Zyban	PS	Glaxosmithkline			14 DAY
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/03ISR Number: 4236118-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0433179A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Drug Exposure During Pregnancy Ventricular Septal Defect		Wellbutrin	PS	Glaxosmithkline			

Date:11/17/03ISR Number: 4236119-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0438833A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:11/17/03ISR Number: 4236120-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439228A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Wellbutrin	PS	Glaxosmithkline			

Date:11/17/03ISR Number: 4236121-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439423A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/17/03ISR Number: 4236122-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439429A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline			
	Insomnia		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Medication Error		Lorazepam	C				

Date:11/17/03ISR Number: 4236123-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439431A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:11/17/03ISR Number: 4236124-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439627A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product		Wellbutrin	SS	Glaxosmithkline	ORAL	450MG Per day	5 WK
	Complaint		Thyroid	C				
			Provigil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/03ISR Number: 4236135-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0313883A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Crying						dosage text	14 DAY
	Insomnia							
	Petit Mal Epilepsy							
	Visual Disturbance							

Date:11/17/03ISR Number: 4236136-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0314049A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
							dosage text	34 DAY

Date:11/17/03ISR Number: 4236140-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0314404A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eczema		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
							dosage text	13 DAY
			Aspirin	C	Glaxosmithkline		UNKNOWN	75MG per day
			Pravastatin	C			UNKNOWN	40MG per day
			Co-Amoxiclav	C	Glaxosmithkline		UNKNOWN	625MG per day 7 DAY
			Nitrofurantoin	C	Glaxosmithkline		UNKNOWN	50MG per day 7 DAY
			Cefadroxil	C			UNKNOWN	500MG per day 7 DAY

			Perindopril	C		
UNKNOWN	4MG per day					

Date:11/17/03ISR Number: 4236141-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0314463A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Circulatory Collapse		Zyban	PS	Glaxosmithkline	ORAL	2TAB Twice	
Initial or Prolonged	Rash Erythematous							
per day							13	DAY

Date:11/17/03ISR Number: 4236250-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439877A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accident		Zyban	PS	Glaxosmithkline	ORAL		
	Convulsion							
	Loss Of Consciousness							

Date:11/17/03ISR Number: 4236559-7Report Type:Direct Company Report #CTU 206230
Age:40 YR Gender:Female I/FU:I

Outcome	PT
Disability	Abnormal Behaviour
Other	Attention
	Deficit/Hyperactivity
	Disorder
	Bulimia Nervosa
	Condition Aggravated
	Crying
	Depression

Diabetes Mellitus Insulin-Dependent Drug Withdrawal Syndrome Morbid Thoughts Post-Traumatic Stress Disorder Relationship Breakdown	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Prozac 20 Mg Eli Lilley	PS	Eli Lilley	ORAL	40 MG PER DAY
		Wellbutrin 150 Mg	SS		ORAL	150 MG PER DAY

Date:11/17/03ISR Number: 4236592-5Report Type:Direct Company Report #CTU 206217
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Intervention to Prevent Permanent Impairment/Damage	Hepatitis Acute		Wellbutrin Xl 300 Mg	PS		ORAL	300 MG QD	Required
			Mircette Ocp	C		ORAL		
			Ecchinacea	C				

Date:11/17/03ISR Number: 4237080-2Report Type:Expedited (15-DaCompany Report #200301196
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Anxiety	Consumer Health	Extra Strength Tylenol Product	PS		ORAL	500 MG BID PO	
	Blood Creatinine Abnormal	Professional	Wellbutrin	SS		ORAL	100 MG TID PO	
	Blood Urea Abnormal Dysphagia Hypokalaemia Renal Disorder	Other	Tylenol Arthritis Pain Er Caplet 650mg/Caplet	SS		ORAL	1300 MG BID PO	

			Atenolol	C		
			Hydrochlorothiazide	C		

Date:11/17/03ISR Number: 4237081-4Report Type:Expedited (15-DaCompany Report #200301196
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Extra Strength					
	Anxiety	Health	Tylenol Product	PS		ORAL	500 MG BID PO	
	Blood Creatinine Abnormal	Professional	Wellbutrin	SS		ORAL	100 MG TID PO	
	Blood Urea Abnormal	Other	Tylenol Arthritis					
	Dysphagia		Pain Er Caplet					
	Hyperkalaemia		650mg/Caplet	SS		ORAL	1300 MG BID	
	Renal Disorder						PO	
			Atenolol	C				
			Hydrochlorothiazide	C				

Date:11/18/03ISR Number: 4236726-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439007A
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice per day	1 MON
	Condition Aggravated							
	Tremor		Flomax	C				
			Cozaar	C				
			Indapamide	C				
			Duragesic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/03ISR Number: 4236727-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439046A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 DAY
			Norvasc	C				
			Xanax	C				
			Zocor	C				

Date:11/18/03ISR Number: 4236728-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439062A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Medication Error		Doxipan	C	Glaxosmithkline			
			Sonata	C				

Date:11/18/03ISR Number: 4236759-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439007A
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice per day	1 MON
	Condition Aggravated							
	Depression		Flomax	C				
	Tremor		Cozaar	C				
			Indapamide	C				
			Duragesic	C				

Date:11/18/03ISR Number: 4236760-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439046A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Blindness	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 2 DAY						
		Professional	Norvasc	C		
			Xanax	C		
			Zocor	C		

Date:11/18/03ISR Number: 4236761-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439062A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day						
	Medication Error	Professional	Doxipan	C	Glaxosmithkline	
			Sonata	C		

Date:11/18/03ISR Number: 4236780-8Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0312102A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthralgia	Health	Zyban	PS	Glaxosmithkline	ORAL
22 DAY						
Initial or Prolonged	Body Temperature	Professional	Methylprednisolone	C		
1TAB Single						
	Increased					
dose						
	Eyelid Oedema					
	Face Oedema					
	Myalgia					
	Oedema Peripheral					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/03ISR Number: 4236781-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0312169A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vision Blurred	Health	Zyban	PS	Glaxosmithkline	ORAL		
	Visual Acuity Reduced	Professional						

Date:11/18/03ISR Number: 4236783-3Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0041959A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	1 DAY
Initial or Prolonged	Cardiovascular Disorder							

Date:11/19/03ISR Number: 4237439-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379981A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Ethanol Increased	Consumer	Bupropion	PS	Glaxosmithkline	ORAL		
	Cardiomegaly		Carbamazepine	SS				
UNKNOWN								
	Coma		Olanzapine	SS				
UNKNOWN								
	Completed Suicide		Clonazepam	SS				
	Convulsion		Ethanol	SS				
	Depressed Level Of Consciousness		Aspirin	SS	Glaxosmithkline			
	Ecchymosis							
	Hepatic Steatosis							
	Intentional Misuse							
	Mydriasis							
	Ovarian Cyst							
	Pulmonary Congestion							
	Pulmonary Oedema							
	Pupil Fixed							

Date:11/19/03ISR Number: 4237440-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379982A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Areflexia		Bupropion	PS	Glaxosmithkline	ORAL		
Hospitalization -	Brain Death		Clonazepam	SS				
UNKNOWN								
Initial or Prolonged	Cardio-Respiratory Arrest		Trazodone	SS				
UNKNOWN								
	Completed Suicide		Gabapentin	SS				
	Depressed Level Of Consciousness							
	Hyporeflexia							
	Intentional Misuse							
	Pupillary Reflex Impaired							
	Subarachnoid Haemorrhage							
	Tachycardia							

Date:11/19/03ISR Number: 4237441-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379983A
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Death	Cardio-Respiratory Arrest
	Completed Suicide
	Coronary Artery Atherosclerosis

		Hypertension					
		Intentional Misuse					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Bupropion	PS	Glaxosmithkline	ORAL
				Ethanol	SS		ORAL

Date:11/19/03ISR Number: 4237446-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439829A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Medication Error		Wellbutrin	PS	Glaxosmithkline	

Date:11/19/03ISR Number: 4237447-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439996A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL
1 MON						
	Insomnia					
	Muscle Tightness					

Date:11/19/03ISR Number: 4237449-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0440188A
Age: YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Back Disorder		Wellbutrin	PS	Glaxosmithkline	
	Convulsion					
	Depression					
	Joint Dislocation					
	Renal Impairment					

Date:11/19/03ISR Number: 4237463-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379984A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Consumer	Bupropion	PS	Glaxosmithkline	ORAL		
	Completed Suicide		Ethylene Glycol	SS		ORAL		
	Convulsion		Hypericum Perforatum	SS		ORAL		
	Drug Toxicity		Nefazodone	SS				
	Fall		St. Johns Wort	C				
	Haemorrhage Intracranial		Lorazepam	C				
	Intentional Misuse							
	Mydriasis							
	Pupil Fixed							
	Ventricular Fibrillation							
	Ventricular Tachycardia							

Date:11/19/03ISR Number: 4237464-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379985A
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Death	Aspiration
	Cardio-Respiratory Arrest
	Cerebellar Haemorrhage
	Cerebral Haemorrhage
	Coma
	Depressed Level Of

	Consciousness						
	Drug Screen Positive						
	Hypotension						
	Mydriasis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Posturing	Consumer	Bupropion	PS	Glaxosmithkline	ORAL	
	Pupil Fixed		Naproxen	SS		ORAL	
	Respiratory Depression		Cocaine	SS			UNKNOWN
	Tachycardia						

Date:11/19/03ISR Number: 4237465-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379987A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Acidosis	Consumer	Bupropion	PS	Glaxosmithkline	ORAL	
Hospitalization -	Cardiovascular Disorder		Venlafaxine	SS			UNKNOWN
Initial or Prolonged	Completed Suicide		Methylphenidate	SS			UNKNOWN
	Convulsion		Quetiapine	SS			
	Depressed Level Of		Clonazepam	SS			
	Consciousness		Trazodone	SS			
	Hypotension		Gabapentin	SS			
	Hypothermia		Lansoprazole	SS			
	Intentional Misuse						
	Respiratory Depression						

Date:11/19/03ISR Number: 4237605-7Report Type:Direct Company Report #CTU 206421
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angioneurotic Oedema		Wellbutrin	PS			100 MG BID
Hospitalization -	Rash Erythematous		Prednisone	C			
Initial or Prolonged	Rash Papular		Lexapro	C			
			Nexium	C			
			Nadolol	C			

Date:11/19/03ISR Number: 4238278-XReport Type:Direct Company Report #CTU 206492
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Stevens-Johnson Syndrome		Wellbutrin 100 Mg Tablet	PS		ORAL	PO BID	

Date:11/19/03ISR Number: 4238962-8Report Type:Expedited (15-DaCompany Report #S03-USA-04440-01
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrooesophageal Reflux Disease	Health Professional	Lexapro (Escitalopram)	PS		ORAL	10 MG QD PO	
	Grand Mal Convulsion		Wellbutrin (Bupropion Hydrochloride)	SS			200 MG BID	
	Throat Irritation		Wellbutrin (Bupropion Hydrochloride)	SS			100 MG BID	
			Wellbutrin (Bupropion Hydrochloride)	SS			100 MG QD	

				Neurontin (Gabapentin)	C		

Date:11/19/03ISR Number: 4239070-2Report Type:Expedited (15-DaCompany Report #2003-03773
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death	Literature Health Professional	Lorazepam (Watson Laboratories) (Lorazepam) Tablet	PS		
			Diphenhydramine (Watson Laboratories) (Diphenhydramine Hydrochloride)	SS		
			Bupropion (Bupropion)	SS		

Date:11/20/03ISR Number: 4238031-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379986A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arrhythmia		Bupropion	PS	Glaxosmithkline	ORAL
	Cardiac Arrest		Olanzapine	SS		
UNKNOWN						
	Completed Suicide		Clonazepam	SS		
UNKNOWN						
	Convulsion		Aspirin	SS	Glaxosmithkline	
	Gastrointestinal Motility		Acetaminophen	SS	Glaxosmithkline	
	Disorder		Sertraline	SS		
	Hypokinesia		Trazodone	SS		
	Hypotension		Ibuprofen	SS	Glaxosmithkline	
	Intentional Misuse					
	Mental Status Changes					
	Overdose					
	Pupillary Reflex Impaired					
	Ventricular Fibrillation					

Date:11/20/03ISR Number: 4238032-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379988A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis		Bupropion	PS	Glaxosmithkline	ORAL		
	Blood Creatine Phosphokinase Increased		Fluoxetine	SS			UNKNOWN	
	Cardiac Arrest		Acetaminophen + Hydrocodone	SS			UNKNOWN	
	Cardio-Respiratory Arrest							
	Dialysis							
	Hypotension							

Date:11/20/03ISR Number: 4238033-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379989A
Age:16 YR Gender: I/FU:F

Outcome	PT
Death	Acidosis
	Cardio-Respiratory Arrest
	Coma
	Completed Suicide
	Convulsion

	Depressed Level Of Consciousness						
	Hypotension	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
	Intentional Misuse		Bupropion	PS	Glaxosmithkline	ORAL	
	Multiple Drug Overdose		Quetiapine	SS			
UNKNOWN							
	Mydriasis		Valproic Acid	SS			
UNKNOWN							
	Pupil Fixed						

Date:11/20/03ISR Number: 4238034-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0379990A
Age:46 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Blood Pressure Decreased		Bupropion	PS	Glaxosmithkline	ORAL
	Cardio-Respiratory Arrest		Alprazolam	SS		
UNKNOWN						
	Coma		Olanzapine	SS		
UNKNOWN						
	Completed Suicide		Gabapentin	SS		
	Cyanosis		Cyanide	SS		
	Depressed Level Of Consciousness					
	Heart Rate Increased					
	Intentional Misuse					
	Miosis					
	Oxygen Saturation Decreased					
	Respiratory Rate Increased					

Date:11/20/03ISR Number: 4238037-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0380101A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Blood Ph Decreased		Bupropion	PS	Glaxosmithkline	ORAL
	Completed Suicide		Amitriptyline	SS		
UNKNOWN						
	Disorientation		Clonidine	SS		
UNKNOWN						

	Hypotension		Buspirone	SS		
	Intentional Misuse		Clonazepam	SS		
	Loss Of Consciousness					
	Vascular Resistance					
	Systemic					

Date:11/20/03ISR Number: 4238038-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0380102A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis		Bupropion	PS	Glaxosmithkline	ORAL		
	Cardio-Respiratory Arrest		Carbamazepine	SS				UNKNOWN
	Completed Suicide		Ethanol	SS				UNKNOWN
	Convulsion		Benzodiazepine	C				
	Drug Ineffective							
	Intentional Misuse							
	Loss Of Consciousness							
	Mydriasis							
	Pupil Fixed							
	Pyrexia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238039-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383127A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL		
	Completed Suicide		Fluvoxamine	SS			UNKNOWN	
	Intentional Misuse							
	Self-Medication							

Date:11/20/03ISR Number: 4238040-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383129A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL		
	Coagulopathy		Isotretinoin	SS			UNKNOWN	
	Completed Suicide		Diphenhydramine	SS			UNKNOWN	
	Intentional Misuse							
	Multi-Organ Failure							

Date:11/20/03ISR Number: 4238041-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383135A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration		Bupropion	PS	Glaxosmithkline	ORAL	150MG Single	
	Cardio-Respiratory Arrest						dose	
	Completed Suicide		Citalopram	SS			UNKNOWN	30MG Single
	Convulsion						dose	
	Intentional Misuse		Dextroamphetamine	SS	Glaxosmithkline		UNKNOWN	30MG Single
	Somnolence						dose	
			Lisinopril	SS				
			Trazodone	SS				

Date:11/20/03ISR Number: 4238042-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383137A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Apnoea		Bupropion	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Trazodone	SS				
	Cardio-Respiratory Arrest		Venlafaxine	SS				
	Coma							
	Completed Suicide							
	Depressed Level Of Consciousness							
	Electroencephalogram Abnormal							
	Intentional Misuse							
	Pupil Fixed							

Date:11/20/03ISR Number: 4238043-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383140A
Age:30 YR Gender:Male I/FU:F

Outcome	PT
Death	Completed Suicide
Hospitalization - Initial or Prolonged	Convulsion
	Disseminated Intravascular Coagulation
	Electroencephalogram Abnormal

		Hepatic Failure Intentional Misuse Mydriasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nystagmus		Bupropion	PS	Glaxosmithkline	ORAL
		Posturing		Relafen	SS	Glaxosmithkline	ORAL
		Pyrexia		Acetaminophen +			
		Renal Failure		Diphenhydramine	SS		
UNKNOWN							
		Rhabdomyolysis		Venlafaxine	SS		
UNKNOWN							
		Tachycardia		Tylenol	SS	Glaxosmithkline	
UNKNOWN							
				Librium	SS		
UNKNOWN							
				Ambien	SS		
UNKNOWN							
				Skelaxin	SS		
UNKNOWN							
				Midol	SS		
UNKNOWN							
				Pyridium	SS		
UNKNOWN							
				Aleve	SS		
UNKNOWN							

Date:11/20/03ISR Number: 4238044-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383143A
Age:19 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL
				Tramadol	SS		
UNKNOWN							
				Metoclopramide	SS	Glaxosmithkline	
UNKNOWN							

Date:11/20/03ISR Number: 4238045-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383146A
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL

	Completed Suicide		Olanzapine	SS		
UNKNOWN						
	Intentional Misuse					
	Loss Of Consciousness					

Date:11/20/03ISR Number: 4238046-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383147A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Agitation		Bupropion	PS	Glaxosmithkline	ORAL
	Cardio-Respiratory Arrest		Quetiapine	SS		
UNKNOWN						
	Completed Suicide		Levofloxacin	SS		
	Intentional Misuse					

Date:11/20/03ISR Number: 4238047-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383148A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL
	Completed Suicide		Quetiapine	SS		
UNKNOWN						
	Intentional Misuse					

Date:11/20/03ISR Number: 4238048-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383151A
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Death	Cardiac Arrest
	Completed Suicide

Intentional Misuse

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Bupropion	PS	Glaxosmithkline	ORAL
				Carvedilol	SS	Glaxosmithkline	
UNKNOWN							
				Amlodipine + Benazepril	SS		
UNKNOWN							
				Oxycodone	SS		
				Celecoxib	SS		

Date:11/20/03ISR Number: 4238051-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0421236A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day	3 DAY					
	Breast Pain		Paxil	SS	Glaxosmithkline	ORAL
25MG Per day	2 MON					
	Depression		Wellbutrin	SS	Glaxosmithkline	ORAL
150MG Twice						
	Derealisation					
per day						
	Disturbance In Attention		Xanax	C		
	Dysgeusia		Bc Powder	C	Glaxosmithkline	
	Dyspepsia		Estradiol	C		
UNKNOWN						
	Eye Pain		Levoxyl	C	Glaxosmithkline	
UNKNOWN	.1MG Unknown					
	Eye Swelling		Medroxyprogesterone	C		
UNKNOWN						
	Fatigue		Calcium	C		
UNKNOWN	500MG Unknown					
	Gastric Disorder		Thera M	C		
UNKNOWN						
	Headache		Flovent	C	Glaxosmithkline	
RESPIRATORY						
	Hunger					
(INHALATION)						
	Hyperventilation		Albuterol	C	Glaxosmithkline	
	Insomnia		Citracal	C		
	Libido Increased		Multivitamins	C		

	Nausea					
	Negative Thoughts					
	Paraesthesia					
	Paraesthesia Oral					
	Respiratory Sighs					
	Restlessness					
	Suicidal Ideation					
	Tension					

Date:11/20/03ISR Number: 4238107-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426613A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
	Paraesthesia		Accuretic	C				
			Celexa	C				
			Advair	C	Glaxosmithkline			

Date:11/20/03ISR Number: 4238108-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426882A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238109-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427548A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hallucination, Auditory		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
Other	Psychotic Disorder		Ambien	C			10MG At night	
			Synthroid	C	Glaxosmithkline		.05MG Per day	
			Tegretol	C			600MG Per day	

Date:11/20/03ISR Number: 4238110-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427869A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY

Date:11/20/03ISR Number: 4238111-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427916A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238112-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428108A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Wellbutrin	C	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238113-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428114A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238114-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428266A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238115-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428703A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
			Vioxx	C				
			Lortab	C				
			Nexium	C				
			Synthroid	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238116-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428730A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			Celexa	SS				

Date:11/20/03ISR Number: 4238117-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428860A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Weight Decreased							

Date:11/20/03ISR Number: 4238118-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428958A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline			
	Pyrexia		Sonata	SS				
	Urticaria		Unknown Medication	C				
	Vomiting							

Date:11/20/03ISR Number: 4238119-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428977A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	2 WK	

Date:11/20/03ISR Number: 4238120-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429120A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238121-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429224A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Rash		Zoloft	C				

Date:11/20/03ISR Number: 4238122-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429225A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Rash							
	Rash Macular							
	Rash Papular							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238123-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429662A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tension Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 DAY

Date:11/20/03ISR Number: 4238124-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429668A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Dry Mouth							
	Myalgia							

Date:11/20/03ISR Number: 4238125-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429689A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY

Date:11/20/03ISR Number: 4238126-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429690A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Date:11/20/03ISR Number: 4238127-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429717A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL
	Feeling Jittery					
	Heart Rate Increased					

Date:11/20/03ISR Number: 4238128-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429813A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/20/03ISR Number: 4238129-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429818A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Mucosal Blistering		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238130-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430013A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Headache		Nexium	C				
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238131-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430054A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	7 DAY
	Pharmaceutical Product		Verapamil	C				
	Complaint		Doxazosin	C				
	Stool Analysis Abnormal							

Date:11/20/03ISR Number: 4238132-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430105A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Alcohol	SS		ORAL		

Date:11/20/03ISR Number: 4238133-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430282A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Toprol	C				

Date:11/20/03ISR Number: 4238134-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430486A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hunger		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238135-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430602A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Headache		Effexor	C				

Date:11/20/03ISR Number: 4238136-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430642A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Sprain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Sleep Walking		Concerta	SS		ORAL	54MG Per day	

Date:11/20/03ISR Number: 4238137-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430643A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Blister		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
	Swelling Face		Hydroquinone	C				
			Ogen	C				
			Prometrium	C				
			Actonel	C				
			Buspar	C				
			Topomax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238138-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430651A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Central Nervous System Stimulation Sleep Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238139-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430973A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Zyprexa	C				
			Nembutal	C				

Date:11/20/03ISR Number: 4238140-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430982A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Lotrel	C				

Date:11/20/03ISR Number: 4238141-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431126A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness		Wellbutrin	PS	Glaxosmithkline	ORAL	2 WK	
	Myalgia							

Date:11/20/03ISR Number: 4238142-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431204A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/20/03ISR Number: 4238143-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431216A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Wellbutrin	C	Glaxosmithkline	ORAL	1	YR

Date:11/20/03ISR Number: 4238144-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431217A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	4	DAY
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238145-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431224A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin	PS	Glaxosmithkline	ORAL	30	DAY
	Therapeutic Response							
	Unexpected							

Date:11/20/03ISR Number: 4238146-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431244A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Paralysis		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lexapro	C				

Date:11/20/03ISR Number: 4238147-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431249A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Paxil	C	Glaxosmithkline			

Date:11/20/03ISR Number: 4238148-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431256A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238149-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431391A
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day 3 DAY
	Depression	Multivitamin	C			
	Drug Withdrawal Syndrome	Vitamin E	C			
	Headache	Niacin	C			
	Muscle Tightness	Zocor	C			
		Flomax	C			
		Verapamil	C			
		Allopurinol	C	Glaxosmithkline		
		Altace	C			
		Avandamet	C	Glaxosmithkline		
		Celebrex	C			
		Xanax	C			

Date:11/20/03ISR Number: 4238150-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431396A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Flushing							
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238151-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431413A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/20/03ISR Number: 4238152-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431421A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Insomnia		Vivelle-Dot	C				

Date:11/20/03ISR Number: 4238153-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431428A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Thyroxine	C	Glaxosmithkline		100MG Per day	8 MON

Date:11/20/03ISR Number: 4238154-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431587A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
			Wellbutrin	C	Glaxosmithkline	ORAL	300MG Per day	

Date:11/20/03ISR Number: 4238155-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431610A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/20/03ISR Number: 4238156-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431613A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238157-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431615A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238158-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431623A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Unknown	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238159-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431624A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	DAY

Date:11/20/03ISR Number: 4238160-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431625A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Risperdal	SS			UNKNOWN	

Date:11/20/03ISR Number: 4238161-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431798A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Heart Rate Increased		Wellbutrin	SS	Glaxosmithkline	ORAL	1	MON

Date:11/20/03ISR Number: 4238162-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431810A
Age:12 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Chills							
	Palpitations							

Date:11/20/03ISR Number: 4238163-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431830A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238164-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431833A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238165-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431834A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238166-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432099A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Depakote	C				
			Abilify	C				
			Klonopin	C				
			Glucovance	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238167-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432100A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Flow Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/20/03ISR Number: 4238168-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432137A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON
	Insomnia		Effexor	SS			225MG Per day	2 MON
	Libido Decreased							
	Tremor							

Date:11/20/03ISR Number: 4238169-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432144A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
			Tylenol	C	Glaxosmithkline			

Date:11/20/03ISR Number: 4238170-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432147A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Enuresis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238171-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432149A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	4 DAY

Date:11/20/03ISR Number: 4238172-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432151A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Energy Increased		Ventolin Mdi	C	Glaxosmithkline			
	Heart Rate Increased		Synthroid	C	Glaxosmithkline			
			Trazodone	C				
			Depakote	C				

Date:11/20/03ISR Number: 4238173-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432152A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Rash Erythematous		Flexeril	C				
			Multivitamin	C				
			Darvocet	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238174-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432153A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY
	Nervousness							
	Somnolence							

Date:11/20/03ISR Number: 4238175-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432263A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Discharge		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	9 DAY
	Galactorrhoea							
	Paraesthesia							

Date:11/20/03ISR Number: 4238176-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432266A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK

Date:11/20/03ISR Number: 4238177-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432296A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Toprol Xl	C				
			Ambien	C				

Date:11/20/03ISR Number: 4238178-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432305A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Premature Ejaculation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238179-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432306A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG In the morning	
			Wellbutrin	C	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/20/03ISR Number: 4238180-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432348A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238181-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432393A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY

Date:11/20/03ISR Number: 4238182-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432409A
Age:29 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238183-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432431A
Age: YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline			

Date:11/20/03ISR Number: 4238184-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432438A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

Date:11/20/03ISR Number: 4238185-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432445A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/20/03ISR Number: 4238186-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433118A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline			

Date:11/21/03ISR Number: 4238845-3Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0440268A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Drug Exposure During Pregnancy		Bupropion	PS	Glaxosmithkline			

Date:11/21/03ISR Number: 4238847-7Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0292359A
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Other	Blood Immunoglobulin E Increased Chest Pain Lymphopenia

	Monocyte Count Increased Neutrophil Count Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Photosensitivity Reaction		Zyntabac	PS	Glaxosmithkline	UNKNOWN	150MG As directed 9 DAY
	Pruritus Generalised						
	White Blood Cell Count		Aluminum Hydroxide	C		UNKNOWN	
	Increased		Almagate	C		UNKNOWN	

Date:11/21/03ISR Number: 4238849-0Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0311911A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Acne Convulsion Fall Respiratory Arrest Tooth Injury		Zyban No Concurrent Medication	PS C	Glaxosmithkline	ORAL	150MG Twice per day

Date:11/21/03ISR Number: 4238853-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0312384A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Drug Withdrawal Syndrome Hepatic Trauma Pelvic Fracture Suicide Attempt		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text 6 WK

Date:11/21/03ISR Number: 4238856-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0313519A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Zyban	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness							
Disability	Overdose							

Date:11/21/03ISR Number: 4238857-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0314631A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Localised Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	11 DAY
	Throat Irritation							
	Urticaria Generalised		Tetrazepam	C		ORAL		

Date:11/21/03ISR Number: 4238866-0Report Type:Expedited (15-DaCompany Report #SK-GLAXOSMITHKLINE-B0315050A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Single dose	1 DAY
	Chest Pain							
	Hypertension		Augmentin	C	Glaxosmithkline	ORAL	625MG Twice per day	6 DAY
	Tension Headache							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/03ISR Number: 4238877-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0315237A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Supraventricular		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	22 DAY
Other	Tachycardia		Salbutamol	C	Glaxosmithkline			3 YR
			Beclomethasone Dipropionate	C	Glaxosmithkline			
UNKNOWN		4 YR						
			Salmeterol	C	Glaxosmithkline			2 YR
			Combivent	C				5 MON
			Quinine Sulphate	C	Glaxosmithkline			
UNKNOWN		5 MON	Montelukast	C			1TAB Per day	
UNKNOWN		4 MON	Co-Codamol	C			1TAB Per day	
UNKNOWN		1 MON	Barrier Cream	C				
								873 DAY

Date:11/21/03ISR Number: 4238879-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0315354A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	6 WK
Initial or Prolonged	Paranoia		Corticoid Ointment	C			TRANSDERMAL	
	Persecutory Delusion							

Date:11/24/03ISR Number: 4239987-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0440346A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline		150MG Per day	

Date:11/24/03ISR Number: 4239988-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0440373A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product Complaint							

Date:11/25/03ISR Number: 4240735-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383113A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Digoxin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Completed Suicide		Bupropion	SS	Glaxosmithkline	ORAL		
	Intentional Misuse		Doxazosin	SS				UNKNOWN
	Multiple Drug Overdose		Lisinopril	SS				
	Nodal Arrhythmia		Warfarin	SS	Glaxosmithkline			
	Urine Output Decreased							

Date:11/25/03ISR Number: 4240736-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383128A
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Death	Aggression
Hospitalization - Initial or Prolonged	Completed Suicide
	Convulsion
	Drug Ineffective
	Intentional Misuse

	Respiratory Arrest Respiratory Rate Decreased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Bupropion	PS	Glaxosmithkline	ORAL	
			Fluvoxamine	SS			UNKNOWN
			Ethanol	SS			UNKNOWN

Date:11/25/03ISR Number: 4240737-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383130A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coma		Bupropion	PS	Glaxosmithkline	ORAL	
	Convulsion		Methylphenidate	SS			UNKNOWN
	Depressed Level Of Consciousness Drug Ineffective Intentional Misuse		Librax Montelukast Synthroid	C C C	Glaxosmithkline		

Date:11/25/03ISR Number: 4240738-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383132A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Blood Creatinine Increased		Bupropion	PS	Glaxosmithkline	ORAL	
			Sertraline	SS			UNKNOWN
	Blood Glucose Increased Cardio-Respiratory Arrest Coma Completed Suicide Depressed Level Of Consciousness Dyskinesia General Physical Health Deterioration Intentional Misuse Lethargy Muscle Rigidity						

Pulmonary Congestion
Tonic Clonic Movements

Date:11/25/03ISR Number: 4240739-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383133A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory		Bupropion	PS	Glaxosmithkline	ORAL	900MG	Single
Hospitalization - Initial or Prolonged	Aspiration		Topiramate	SS			UNKNOWN	60TAB Single
	Coma						dose	
	Completed Suicide		Paracetamol + Propoxyphene	SS			UNKNOWN	60TAB Single
	Convulsion						dose	
	Depressed Level Of Consciousness							
	Hypotension							
	Intentional Misuse							
	Multiple Drug Overdose							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/25/03ISR Number: 4240741-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383134A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Areflexia		Bupropion	PS	Glaxosmithkline	ORAL		
	Cardio-Respiratory Arrest		Valproic Acid	SS				
UNKNOWN								
	Coma		Olanzapine	SS				
UNKNOWN								
	Completed Suicide							
	Convulsion							
	Depressed Level Of Consciousness							
	Electroencephalogram Abnormal							
	Heart Rate Increased							
	Intentional Misuse							
	Pyrexia							

Date:11/25/03ISR Number: 4240742-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383136A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Bupropion	PS	Glaxosmithkline	ORAL		
	Cardio-Respiratory Arrest		Doxepin	SS				
UNKNOWN								
	Completed Suicide							
	Convulsion							
	Intentional Misuse							
	Respiratory Arrest							

Date:11/25/03ISR Number: 4240743-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383142A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL	30TAB	Single
	Coma							
dose								

	Completed Suicide		Aspirin	SS	Glaxosmithkline	
UNKNOWN						
	Confusional State		Olanzapine	SS		
UNKNOWN	40TAB Single					
	Intentional Misuse					
dose						
	Multiple Drug Overdose					
	Postictal State					
	Pyrexia					
	Tachycardia					

Date:11/25/03ISR Number: 4240744-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383144A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Arrhythmia		Bupropion	PS	Glaxosmithkline	ORAL
	Supraventricular		Warfarin	SS	Glaxosmithkline	
UNKNOWN						
	Completed Suicide		Carbamazepine	SS		
UNKNOWN						
	Depressed Level Of		Risperidone	SS		
	Consciousness		Sertraline	SS		
	Intentional Misuse		Marijuana	C		
	International Normalised		Cocaine	C		
	Ratio Increased					
	Multiple Drug Overdose					
	Tachycardia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/25/03ISR Number: 4240745-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383149A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose		Bupropion	PS	Glaxosmithkline	ORAL		
	Blood Sodium Increased		Risperidone	SS				
UNKNOWN								
	Cardiac Arrest		Diphenhydramine	SS				
UNKNOWN								
	Disseminated							
	Intravascular Coagulation							
	Feeling Abnormal							
	Haematocrit Decreased							
	Medication Error							
	Mental Status Changes							
	Pyrexia							
	Staring							
	Tremor							

Date:11/25/03ISR Number: 4240747-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439228A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product							
	Complaint							

Date:11/25/03ISR Number: 4240750-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0440827A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product							
	Complaint							

Date:11/25/03ISR Number: 4240751-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0440829A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Claustrophobia		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Confusional State		Xanax	C				
	Convulsion		Vitamins	C				
	Disorientation							
	Disturbance In Attention							
	Dizziness							
	Feeling Abnormal							
	Flashback							
	Loss Of Consciousness							
	Palpitations							
	Therapeutic Response							
	Unexpected							
	Weight Decreased							

Date:11/25/03ISR Number: 4240752-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0440836A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
			Wellbutrin	SS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/25/03ISR Number: 4240765-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0311195A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Disorientation							
per day	34 DAY							
	Dizziness		Oestradiol Valerate	C		ORAL	1MG Per day	
	Loss Of Consciousness		Lisinopril	C		ORAL	10MG Per day	
	Visual Disturbance		Salbutamol	C	Glaxosmithkline		RESPIRATORY	
	Vomiting						(INHALATION)	

Date:11/25/03ISR Number: 4240768-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0314049A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
per day	22 DAY							

Date:11/25/03ISR Number: 4240771-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0314643A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Increased		Zyban	PS	Glaxosmithkline	ORAL		
	Epilepsy		Librax	C		ORAL		
	Sudden Death		Levothyrox	C	Glaxosmithkline	ORAL		
			Catapressan	C				
			Agreal	C		ORAL		

Date:11/25/03ISR Number: 4240773-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0314874A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Tendon Rupture		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	38 DAY
			Avandia	C	Glaxosmithkline	ORAL		
			Metformine	C		ORAL		

Date:11/25/03ISR Number: 4240777-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0315370A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Bullous Rash Morbilliform Rash Vesicular Scar Skin Exfoliation		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	17 DAY

Date:11/25/03ISR Number: 4241927-3Report Type:Direct Company Report #CTU 206878
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Erythema Multiforme Rash Erythematous Stevens-Johnson Syndrome		Wellbutrin 100 Mg Tablets	PS		ORAL	PO BID	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/25/03ISR Number: 4242123-6Report Type:Direct Company Report #CTU 206884
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Bupropion Sr	PS			100 MG Q DAY	
Required Intervention to Prevent Permanent Impairment/Damage	Urinary Retention		Trazodone	C				

Date:11/25/03ISR Number: 4242177-7Report Type:Expedited (15-DaCompany Report #2003-03934
Age:28 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Literature	Verapamil (Verapamil Hydrochloride)					
		Health Professional	Unknown	PS	Watson Laboratories			
			Venlafaxine (Venlafaxine)	SS				
			Bupropion (Bupropion)	SS				

Date:11/25/03ISR Number: 4242309-0Report Type:Expedited (15-DaCompany Report #2003-04021
Age:47 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Alprazolam (Watson Laboratories)					
		Health Professional	(Alprazolam) Tablet	PS			UNKNOWN	UNK, UNK, UNK
			Methadone (Methadone)	SS			UNKNOWN	UNK, UNK, UNK
			Bupropion (Bupropion)	SS			UNKNOWN	UNK, UNK, UNK

Date:11/25/03ISR Number: 4242348-XReport Type:Expedited (15-DaCompany Report #KII-2003-0006031
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Acidosis Depressed Level Of Consciousness Hypotension Multiple Drug Overdose	Study Health Professional Other	Oxycodone Hydrochloride (Similar To Nda 20-553) (Oxycodone Hydrochloride)	PS				
			Hydrocodone W/Acetaminophen (Paracetamol, Hydrocodone Bitartrate)	SS				
			Benzodiazepine Derivates	SS				
			Cox-2 Inhibitor	SS				
			Gastrointestinal Prep	SS				
			Laxatives	SS				
			Anticonvulsant	SS				
			Muscle Relaxants	SS				
			Bupropion(Amfebutamone)	SS				
			Cyproheptadine(Cypro					

			heptadine)	SS		
			Antipsychotics	SS		
			Proton Pump Inhibitor	SS		
			Ssri	SS		
			Trazodone(Trazodone)	SS		

Date:11/25/03ISR Number: 4242470-8Report Type:Expedited (15-DaCompany Report #03P-163-0241040-00
Age:28 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature Health Professional	Verapamil (Isoptin) (Verapamil) (Verapamil)	PS				
			Venlafaxine	SS				
			Bupropion	SS				

Date:11/25/03ISR Number: 4242499-XReport Type:Expedited (15-DaCompany Report #B0313503A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Increased Appetite Sleep Walking	Foreign Literature Health Professional	Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG / SEE DOSAGE TEXT	

Date:11/25/03ISR Number: 4242501-5Report Type:Expedited (15-DaCompany Report #B0314910A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angioneurotic Oedema Arthralgia C-Reactive Protein Increased Chest Pain Dizziness Electrocardiogram T Wave	Foreign Literature Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS				

	Inversion
	Liver Function Test
	Abnormal
	Myalgia
	Neutrophilia
	Oedema Peripheral
	Palpitations
	Pyrexia
	Serum Sickness
	Sinus Tachycardia
	Skin Discolouration
	Urticaria

Date:11/26/03ISR Number: 4243980-XReport Type:Expedited (15-DaCompany Report #2003-06064
Age:26 YR Gender:Male I/FU:I

Outcome	PT
Other	Blood Phosphorus Decreased
	Cholelithiasis
	Dyspepsia

	Hepatitis Nausea Pancreatitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vomiting	Health	Viread	PS		ORAL	300 MG QD PO
		Professional	Combivir	SS		ORAL	450 MG BID PO
			Wellbutrin	SS			
			Ambien	C			
			Effexor	C			
			Asacol	C			
			Clindagel	C			
			Elidel	C			
			Clotrim/Beta	C			
			Protopic	C			
			Flonase	C			

Date:11/26/03ISR Number: 4244193-8Report Type:Expedited (15-DaCompany Report #2003039894
Age:45 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardio-Respiratory Arrest	Literature	Doxepin (Caps)				
Other	Completed Suicide	Health	(Doxepin)	PS		ORAL	ORAL
	Multiple Drug Overdose	Professional	Bupropion (Bupropion)	SS		ORAL	ORAL
			Clorazepate Dipotassium (Clorazepate Dipotassium)	SS		ORAL	ORAL

Date:11/28/03ISR Number: 4244975-2Report Type:Expedited (15-DaCompany Report #2003-04125
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardio-Respiratory Arrest	Literature Health Professional	Clorazepate(Watson Laboratories)(Clorazepate Dipotassium)				

			Tablet, 3.75mg Doxepin(Watson Laboratories)(Doxepin Hydrochloride)	PS			
			Capsule Bupropion(Long Acting)	SS	Watson Laboratories		

Date:11/28/03ISR Number: 4245222-8Report Type:Expedited (15-DaCompany Report #2003-04088
Age:38 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature Health Professional	Alprazolam (Watson Laboratories)(Alprazolam)Tablet	PS	Watson Laboratories			
			Bupropion(Bupropion)	SS				
			Acetaminophen(Paracetamol)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/03ISR Number: 4245390-8Report Type:Expedited (15-DaCompany Report #USA-2003-0006512
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Consumer	Oxycontin Tablets					
	Hepatomegaly	Health	(Oxycodone					
	Portal Triaditis	Professional	Hydrochloride) Cr					
	Postoperative Infection	Other	Tablet	PS		ORAL	40 MG, BID,	
	Pulmonary Congestion						ORAL; 20 MG	
	Pulmonary Oedema		Celexa (Citalopram Hydrobromide)	SS				
			Carisoprodol (Carisoprodol)	SS				
			Meprobamate (Meprobamate)	SS				
			Bupropion (Amfebutamone)	SS				
			Biaxin (Clarithromycin) Tablet	C				

Date:12/01/03ISR Number: 4243427-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0289128A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased		Zyban	PS	Glaxosmithkline	ORAL	40TABS Single	dose 1 DAY
	Dizziness		Zopiclone	SS		ORAL	1PACK Single	dose 1 DAY
	Dysarthria							
	Intentional Misuse		Valium	SS		ORAL	1PACK Single	dose 1 DAY
	Multiple Drug Overdose							
	Oxygen Saturation Decreased							
	Sinus Tachycardia							
	Somnolence							

	Vomiting					

Date:12/01/03ISR Number: 4243430-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0300655A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Zyban	PS	Glaxosmithkline	ORAL	3.7G per day	1 DAY
Initial or Prolonged	Coordination Abnormal		Xanax	C		ORAL	6.25MG per	
	Dysarthria						day	1 DAY
	Hallucinations, Mixed							
	Intentional Misuse							
	Suicide Attempt							
	Tremor							

Date:12/01/03ISR Number: 4243432-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0308326A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxosmithkline		150MG per day	1 DAY
			Tobacco	C			1UNIT See	
							dosage text	
			Isosorbide	C		ORAL	20MG Twice	
							per day	
			Aspirin	C	Glaxosmithkline	ORAL	150MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/03ISR Number: 4243455-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0316048A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Clumsiness		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
	Escherichia Infection		Urbanyl	SS		ORAL	5MG Three	
	Pyelonephritis						times per day	6 DAY
	Sensation Of Heaviness							

Date:12/02/03ISR Number: 4243884-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0315354A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
Initial or Prolonged	Delirium		Corticoid Ointment	SS			TRANSDERMAL	
	Hallucination							
	Paranoia							
	Persecutory Delusion							
	Psychotic Disorder							

Date:12/02/03ISR Number: 4243908-2Report Type:Expedited (15-DaCompany Report #DK-GLAXOSMITHKLINE-B0316211A
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	51 DAY

Date:12/02/03ISR Number: 4244818-7Report Type:Direct Company Report #CTU 207180
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Amantadine 100mg					
	Dry Mouth		Apothecon	PS	Apothecon	ORAL	200 MG QD	
Required	Heart Rate Increased							
ORAL								
Intervention to	Orthostatic Hypotension		Bupropion Sr 100mg					
Prevent Permanent	Thinking Abnormal		Glaxowellcome	SS	Glaxowellcome	ORAL	100MG HS ORAL	
Impairment/Damage	Tremor		..	C				
			..	C				
			Lorazepam	C				
			Paroxetine	C				
			Ranitidine	C				
			Quetiapine	C				
			Vit E	C				
			Vit C	C				
			Ecasa	C				
			Ibuprofen	C				
			Loratadine	C				
			Meclizine Hcl	C				

Date:12/02/03ISR Number: 4246222-4Report Type:Expedited (15-DaCompany Report #USA-2003-0010936
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Death	Accidental Overdose
	Coronary Artery Atherosclerosis
	Drowning
	Drug Toxicity

		Glomerulosclerosis Hepatomegaly Pyelonephritis Chronic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional Other	Oxycodone Hydrochloride	PS		
				Hydrocodone Bitartrate (Similar To Ind 59,175) (Hydrocodone Bitartrate)	SS		
				Chlorpheniramine (Chlorpheniramine)	SS		
				Citalopram (Citalopram)	SS		
				Diazepam (Diazepam)	SS		
				Lorazepam (Lorazepam)	SS		
				Mirtazapine (Mirtazapine)	SS		
				Bupropion (Amfebutamone)	SS		
				Oxazepam (Oxazepam)	SS		
				Temazepam (Temazepam)	SS		
				Verapamil (Verapamil)	SS		
				Triazolam (Triazolam)	SS		

Date:12/03/03ISR Number: 4244527-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0383141A
Age:42 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Pulmonary Oedema		Bupropion	PS	Glaxosmithkline	ORAL
		Cardio-Respiratory Arrest		Acetaminophen + Hydrocodone	SS		
UNKNOWN		Completed Suicide					
		Intentional Misuse		Propoxyphene	SS		
UNKNOWN		Pulmonary Congestion					
				Doxepin	SS		
				Fluoxetine	SS		
				Zolpidem	SS		
				Ammonia	SS		

			Bleach	SS		
			Nicotine	C	Glaxosmithkline	

Date:12/03/03ISR Number: 4244532-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441016A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anal Fissure		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See dosage text	6 WK
	Constipation							
	Proctalgia		Vitamins	C				
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/03ISR Number: 4244544-4Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0315394A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Asthma							

Date:12/03/03ISR Number: 4244545-6Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0315395A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Joint Swelling		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	3 WK
	Odynophagia							
	Pruritus							
	Pyrexia							
	Rash							
	Serum Sickness							

Date:12/03/03ISR Number: 4244547-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0315632A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Zyban	PS	Glaxosmithkline			
	Hyperhidrosis							
	Insomnia							
	Loss Of Consciousness							

Date:12/03/03ISR Number: 4244548-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0315793A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Chest Pain							
	Dysaesthesia							

Headache
Hypoaesthesia
Speech Disorder
Vertigo

Date:12/03/03ISR Number: 4246221-2Report Type:Direct Company Report #CTU 207438
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin 200 Mg Per Patient	PS		ORAL	200 MG BID	
	Blood Pressure Increased							
	Heart Rate Increased							
	Nervousness		Cipro 500 Mg Per Patient	SS		ORAL	500 MG ONC	

ORAL

Date:12/03/03ISR Number: 4246369-2Report Type:Direct Company Report #CTU 207418
Age: Gender:Female I/FU:I

Outcome
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister		Bupropion	PS		ORAL	75 MG PO QD;	
	Candidiasis						75 MG PO BID	
	Rash		Luvox	C				
	Rash Papular		Fosamax	C				
			Lasix	C				
			Lipitor	C				
			Asa	C				

Date:12/03/03ISR Number: 4246919-6Report Type:Expedited (15-DaCompany Report #DEWYE424826NOV03
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Study	Trevilor (Venlafaxine Hydrochloride, Tablet, 0)	PS		ORAL	SEE IMAGE	46 DAY
	Tremor		Zyban (Amfebutamone Hydrochloride, , 0)	SS		ORAL	SEE IMAGE	11 DAY
			Zopiclone (Zopiclone)	C				

Date:12/03/03ISR Number: 4247125-1Report Type:Direct Company Report #CTU 207333
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour		Wellbutrin	PS				
	Aggression							
	Alcoholism							
	Cardiac Arrest							
	Coma							
	Convulsion							
	Delusion							
	Depressed Level Of							

Consciousness
Disorientation
Drug Abuser
Eye Rolling
Fall
Feeling Hot
Grunting
Incoherent
Mydriasis
Respiration Abnormal

Date:12/03/03ISR Number: 4247187-1Report Type:Direct Company Report #CTU 207343
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anxiety Blood Pressure Increased Nightmare		Wellbutrin Sr Then Xl 150 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	150 MG DAY	
Other			Wellbutrin Xl 300 Mg Glaxosmithkline	SS	Glaxosmithkline	ORAL	300 MG DAY	

ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/03ISR Number: 4247502-9Report Type:Expedited (15-DaCompany Report #DEWYE424826NOV03
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Tremor	Study	Trevilor (Venlafaxine Hydrochloride, Tablet, 0)	PS		ORAL	75 MG 1X PER 1 DAY	ORAL;
SEE IMAGE			Zyban (Amfebutamone Hydrochloride, , 0)	SS		ORAL	150 MG 1X PER 1 DAY	ORAL;
SEE IMAGE			Zopiclone (Zopiclone)	C				

Date:12/04/03ISR Number: 4245720-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441481A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intentional Misuse Suicide Attempt		Wellbutrin	PS	Glaxosmithkline	UNKNOWN	9000MG Single dose	
			Amphetamines	SS				

Date:12/04/03ISR Number: 4245723-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441720A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Cleft Lip		Wellbutrin	PS	Glaxosmithkline			
	Drug Exposure During		Neurontin	SS		UNKNOWN		

	Pregnancy					

Date:12/04/03ISR Number: 4245724-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441723A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Drug Exposure During Pregnancy							

Date:12/04/03ISR Number: 4245726-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0298802A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Insomnia		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Malaise		Dafalgan	SS	Glaxosmithkline	ORAL	500MG Three times per day	
	Painful Respiration							
	Serotonin Syndrome		Granudoxy	SS	Glaxosmithkline	ORAL	100MG Per day	
			Seropram	SS		ORAL	20MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/03ISR Number: 4245728-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0312169A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Zyban	PS	Glaxosmithkline	ORAL		

Date:12/04/03ISR Number: 4245732-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0316104A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression		Zyban	PS	Glaxosmithkline	ORAL	1	WK
	Agitation							
	Bipolar I Disorder							
	Depression							
	Hallucination							
	Mania							
	Mood Swings							
	Suicide Attempt							

Date:12/04/03ISR Number: 4245733-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0316198A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY
	Irritability		Nicopatch	C	Glaxosmithkline	TRANSDERMAL	21MG Twice per day	
	Suicide Attempt							

Date:12/04/03ISR Number: 4245734-7Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0042190A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice	

Confusional State
per day 17 DAY
Depression
Dizziness
Dry Mouth
Dysphonia
Fatigue
Hyperhidrosis
Muscle Spasms
Nervousness
Rash
Stomatitis

Date:12/05/03ISR Number: 4245940-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441718A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR
	Drug Exposure During Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/05/03ISR Number: 4245943-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0313519A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depressed Level Of		Zyban	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Consciousness							
	Grand Mal Convulsion							
Disability	Incontinence							
	Overdose							
	Tongue Biting							

Date:12/05/03ISR Number: 4245956-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0316469A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:12/08/03ISR Number: 4246798-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0312762A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Agitation		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
Hospitalization -	Anxiety							
dosage text							3	WK
Initial or Prolonged	Insomnia							
	Intentional Misuse							
	Suicidal Ideation							
	Suicide Attempt							

Date:12/08/03ISR Number: 4248380-4Report Type:Direct Company Report #CTU 207655
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Wellbutrin Sr 150 Mg					
	Rash		Dsm Pharm/Glaxo					

			Smithkline	PS	Dsm Pharm/Glaxo Smithkline	ORAL
150 MG 2 TIMES ORAL						
			Wellbutrin Xl 300 Mg Dsm Pharm/Glaxo Smithkline	SS	Dsm Pharm/Glaxo Smithkline	ORAL
300 MG 1 PER DAY ORAL						

Date:12/09/03ISR Number: 4247950-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400608A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister		Flonase	PS	Glaxosmithkline	NASAL	DAY	
	Burning Sensation		Wellbutrin	SS	Glaxosmithkline	ORAL	8	MON
	Erythema							
	Hypersensitivity							
	Local Swelling							
	Pyrexia							
	Swelling Face							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/03ISR Number: 4249855-4Report Type:Expedited (15-DaCompany Report #HQWYE843007NOV03
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Drug Withdrawal Syndrome Intentional Misuse Loss Of Consciousness Suicide Attempt	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule Extended Release)	PS		ORAL	OVERDOSE	AMOUNT, UNKNOWN; ORAL
			Atenolol (Atenolol,)	SS			OVERDOSE	AMOUNT UNKNOWN
			Bactrim (Sulfamethoxazole/Trimethoprim)	SS			OVERDOSE	AMOUNT UNKNOWN
			Benzonatate (Benzontate)	SS			OVERDOSE	AMOUNT UNKNOWN
			Flavoxate (Flavoxate)	SS			OVERDOSE	AMOUNT UNKNOWN
			Indocin (Indometacin)	SS			OVERDOSE	

AMOUNT

UNKNOWN

	Lexapro (Escitalopram)	SS

OVERDOSE

AMOUNT

UNKNOWN

	Minocycline (Minocycline, Unspec)	SS

OVERDOSE

AMOUNT

UNKNOWN

	Naprosyn (Naproxen)	SS

OVERDOSE

AMOUNT

UNKNOWN

	Willbutrin (Amfebutamone Hydrochloride)	SS

OVERDOSE

AMOUNT

UNKNOWN

Date:12/11/03ISR Number: 4249634-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0354550A
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Other	Aggression
	Agitation
	Anger
	Anhedonia
	Anorexia
	Anxiety

		Asthenia					
		Confusional State					
		Coordination Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Delusion	Other	Paxil	PS	Glaxosmithkline	ORAL
20MG In the							
		Depressed Mood					
morning							
		Depression		Wellbutrin	SS	Glaxosmithkline	ORAL
150MG Twice							
		Diarrhoea					
per day							
		Disturbance In Attention		Ritalin	C		
		Dizziness		Amoxicillin	C	Glaxosmithkline	
		Drug Ineffective					
		Drug Withdrawal Syndrome					
		Fatigue					
		Gait Disturbance					
		Gingival Infection					
		Hallucinations, Mixed					
		Homicidal Ideation					
		Influenza					
		Insomnia					
		Intentional Self-Injury					
		Irritability					
		Lethargy					
		Malaise					
		Memory Impairment					
		Myalgia					
		Nausea					
		Nightmare					
		Obsessive Thoughts					
		Obsessive-Compulsive					
		Disorder					
		Overdose					
		Paraesthesia					
		Paranoia					
		Psychotic Disorder					
		Pyrexia					
		Sleep Disorder					
		Suicidal Ideation					
		Suicide Attempt					
		Tremor					
		Vertigo					
		Vomiting					

Date:12/11/03ISR Number: 4249643-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0425949A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	1200MG Per day	
	Constipation		Lithobid	SS	Glaxosmithkline		30MG Per day	
	Depressed Mood		Lexapro	C			150MG At night	
	Fall		Nortriptyline	C				
	Fatigue							
	Grand Mal Convulsion							
	Loss Of Consciousness							
	Medication Error							
	Tremor							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/03ISR Number: 4249662-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0316325A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort		Amoxil	PS	Glaxosmithkline			
UNKNOWN							250MG Per day	1 DAY
Initial or Prolonged	Dyspnoea		Zyban	SS	Glaxosmithkline	ORAL		
1 WK								
	Erythema							
	Swelling Face							

Date:12/11/03ISR Number: 4249666-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0316749A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression		Zyban	PS	Glaxosmithkline	ORAL		
150MG Per day	1 DAY							
	Amnesia							
	Confusional State							
	Disinhibition							

Date:12/11/03ISR Number: 4249673-7Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0317068A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Affect Lability		Zyban	PS	Glaxosmithkline			
	Belligerence		Clonazepam	C				
2MG Three								
	Homicidal Ideation							
times per day								
	Intentional Self-Injury							

Date:12/11/03ISR Number: 4251379-5Report Type:Expedited (15-DaCompany Report #S03-FRA-05070-01
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Foreign	Seropram(Citalopram					

Initial or Prolonged	Flushing	Health	Hydrobromide)	PS		ORAL
20 MG QD PO						
	Insomnia	Professional	Dafalgan			
	Malaise	Other	(Paracetamol)	SS		ORAL
500 MG TID PO						
	Respiratory Disorder		Zyban (Bupropion			
	Vomiting		Hydrochloride)	SS		ORAL
1 QD PO						
			Granudoxy			
			(Doxycycline			
			Hyclate)	SS		ORAL
100 MG QD PO						

Date:12/12/03ISR Number: 4250924-3Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0316714A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthralgia		Bupropion			
	Fatigue		Hydrochloride	PS	Glaxosmithkline	ORAL
77 DAY						
	Headache		Unspecified			
	Pyrexia		Medication	C		
	Skin Disorder					

Date:12/12/03ISR Number: 4251791-4Report Type:Expedited (15-DaCompany Report #S03-USA-05003-01
Age:42 YR Gender:Female I/FU:I

Outcome	PT
Other	Contusion
	Convulsion

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation Gait Disturbance Hallucination, Auditory Hallucination, Olfactory Hypoaesthesia	Report Source Consumer	Product Celexa(Citalopram Hydrobromide)	Role PS	Manufacturer	Route ORAL	Dose 20 MG QD PO	Duration
	Injury Tooth Injury Weight Increased		Wellbutrin (Bupropion Hydrochloride)	SS			150 MG QD	

Date:12/12/03ISR Number: 4252301-8Report Type:Expedited (15-DaCompany Report #USA-2003-0006512
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose Coma Drug Toxicity Hepatomegaly	Consumer Health Professional Other	Oxycontin Tablets (Oxycodone Hydrochloride) Cr Tablets	PS		ORAL	SEE IMAGE	
	Pain Portal Triaditis		Celexa (Citalopram Hydrobromide)	SS			MG	30 DAY
	Pulmonary Congestion		Carisoprodol	SS			30 DAY	
	Pulmonary Oedema		Bupropion(Amfebutamone) Meprobamate	SS SS			30 DAY	
			Biaxin (Clarithromycin)	C				

Date:12/15/03ISR Number: 4251471-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442630A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Medication Error		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice	

		Pharmaceutical Product					
per day	1 WK	Complaint					

Date:12/15/03ISR Number: 4251472-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442750A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		300MG per day	
	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus							

Date:12/15/03ISR Number: 4251473-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442800A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/03ISR Number: 4252023-3Report Type:Direct Company Report #CTU 208108
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Zyban 150 Mg Bid	PS			150 MG BID	
	Condition Aggravated							

Date:12/15/03ISR Number: 4252085-3Report Type:Direct Company Report #CTU 208011
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Wellbutrin Xl 150 Mg					
	Inflammation		Glaxxo	PS	Glaxxo	ORAL	TWO TABLET	
	Pharmaceutical Product						ONCE DAILY	
	Complaint						ORAL	
	Tracheal Disorder							
	Tracheal Oedema							

Date:12/15/03ISR Number: 4252135-4Report Type:Direct Company Report #CTU 208031
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Zyban 150 Mg					
	Rash		Glaxosmithkline	PS	Glaxosmithkline	ORAL	150 MG BID	
	Urticaria						ORAL	

Date:12/16/03ISR Number: 4252212-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443093A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Paxil	PS	Glaxosmithkline	ORAL		

	Bipolar I Disorder		Wellbutrin	SS	Glaxosmithkline	ORAL
	Drug Ineffective		Lithium	SS	Glaxosmithkline	
UNKNOWN						
	Paranoia		Prozac	SS		
UNKNOWN	2 YR					
	Suicidal Ideation					

Date:12/16/03ISR Number: 4252218-9Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0314554A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypersensitivity		Zyban	PS	Glaxosmithkline	ORAL
	Medication Error		Doxycycline	SS		ORAL
	Oropharyngeal Swelling					

Date:12/16/03ISR Number: 4252223-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0316104A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Aggression	Health	Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
Hospitalization -	Agitation	Professional				
per day 19 DAY						
Initial or Prolonged	Depression		Qvar	C	Glaxosmithkline	
RESPIRATORY						
	Mood Swings					
(INHALATION)						
	Suicide Attempt		Ventolin	C	Glaxosmithkline	
RESPIRATORY						
(INHALATION)						
			Alcohol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/03ISR Number: 4252305-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442614A
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Fall		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day
Initial or Prolonged							

Date:12/16/03ISR Number: 4252307-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0443220A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Eyelid Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice
Initial or Prolonged	Hyperglycaemia						per day
Other	Hypokalaemia						
	Oedema Peripheral						
	Urticaria Generalised						

Date:12/16/03ISR Number: 4253033-2Report Type:Expedited (15-DaCompany Report #B0316265A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide	Literature	Wellbutrin				
	Overdose	Health	(Bupropion				
		Professional	Hydrochloride)	PS		ORAL	ORAL
			Benzodiazepines	C			
			Alprazolam	C			
			Maprotiline	C			

Date:12/17/03ISR Number: 4252725-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0429044A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Neutropenia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice per day MON						
			Adriamycin	SS		
UNKNOWN						
			Taxol	SS		
UNKNOWN						

Date:12/17/03ISR Number: 4252745-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0316627A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Convulsion		Zyban	PS	Glaxosmithkline	ORAL
30TAB Unknown						
Initial or Prolonged	Intentional Misuse					
	Intentional Self-Injury					
	Loss Of Consciousness					
	Somnolence					
	Suicide Attempt					

Date:12/17/03ISR Number: 4252752-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0317217A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Malaise		Zyban	PS	Glaxosmithkline	ORAL
150MG Unknown 41 DAY						
	Myocardial Infarction		Esperal	C		ORAL
	Sudden Death		Tranxene	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/03ISR Number: 4253781-4Report Type:Direct Company Report #CTU 208333
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Overdose		Bupropion	PS		ORAL	150 MG PO QD	
	Confusional State		Citalopram	SS		ORAL	60 MG PO Q AM	
	Dysarthria		Diazepam 5mg Po Qid Prn Anxiety	SS		ORAL		
	Gait Disturbance							
	Mental Status Changes							

Date:12/17/03ISR Number: 4253869-8Report Type:Direct Company Report #CTU 208279
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Wellbutrin 150 Mg	PS		ORAL	150 MG PO QD	
	Suicide Attempt							

Date:12/17/03ISR Number: 4253882-0Report Type:Direct Company Report #CTU 208277
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Overdose		Wellbutrin Sr 150 Mg	PS		ORAL	150 MG BID PO	
	Suicide Attempt		Prevacid	C				
			Beano	C				

Date:12/17/03ISR Number: 4254661-0Report Type:Expedited (15-DaCompany Report #B0316252A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Poisoning	Literature	Unspecified Tablet					
	Coma	Health	(Bupropion					

	Completed Suicide	Professional	Hydrochloride)	PS		ORAL
ORAL						
	Pulmonary Congestion		Ethanol (Formulation			
	Pulmonary Oedema		Unknown) (Alcohol)	SS		
			Fluoxetine	C		
			Flurazepam	C		
			Lorazepam	C		
			Ibuprofen	C		
			Salbutamol Sulphate	C		

Date:12/17/03ISR Number: 4271077-1Report Type:Periodic Company Report #KII-2003-0004053
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness	Health Professional	Oxycontin Tablets (Oxycodone			
Other	Multiple Drug Overdose		Hydrochloride)	PS		ORAL
SEE TEXT,						
	Nodal Rhythm					
ORAL						
	Somnolence		Wellbutrin (Amfebutamone			
			Hydrochloride)	SS		ORAL
SEE TEXT,						
ORAL						
			Verapamil (Verapamil)	SS		ORAL
SEE TEXT,						
ORAL						
			Hydrochlorothiazide (Hydrochlorothiazide			

			)	SS		ORAL
SEE TEXT,						
ORAL						
			Zoloft (Sertraline Hydrochloride)	SS		ORAL
SEE TEXT,						
ORAL						
			Neuroton (Citicoline Sodium)	SS		ORAL
SEE TEXT,						
ORAL						
			Tricyclic Antidepressants	SS		ORAL
ORAL						
			Cannabis (Cannabis)	SS		

Date:12/17/03ISR Number: 4272416-8Report Type:Periodic Company Report #USA-2003-0008572
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Accidental Overdose	Health	Oxycodone Hydrochloride	PS		
	Multiple Drug Overdose	Professional	Methadone (Methadone)	SS		
		Other	Bupropion (Amfebutamone)	SS		
			Caffeine (Caffeine)	SS		
			Diazepam (Diazepam0	SS		
			Nicotine (Nicotine)	SS		
			Oxymorphone (Oxymorphone)	SS		

Date:12/18/03ISR Number: 4253919-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0084018A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 22 DAY						
	Eating Disorder					

	Oral Discomfort
	Weight Decreased

Date:12/18/03ISR Number: 4253921-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441720A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Cleft Lip		Wellbutrin	PS	Glaxosmithkline			
	Drug Exposure During		Neurontin	SS				UNKNOWN
	Pregnancy		Multivitamins	C				
			Alcohol	C				
			Allegra	C				

Date:12/18/03ISR Number: 4253922-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442426A
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abnormal Behaviour
Hospitalization - Initial or Prolonged	Anxiety
	Chest Pain
	Circulatory Collapse
	Disorientation
	Heart Rate Increased
	Myocardial Infarction

	Panic Disorder Stress Ventricular Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL	51 DAY
			Glucosamine	C		ORAL	
			Nexium	C		ORAL	

Date:12/18/03ISR Number: 4273966-0Report Type:Periodic Company Report #HQWYE078213AUG03
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Mania	Consumer	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release	PS		ORAL/SEE IMAGE	
			Wellbutrin (Amfebutamone Hydrochloride,Extended Release	SS			
			Lithobid (Lithium Carbonate)	C			

Date:12/19/03ISR Number: 4255081-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443009A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline		
	Medication Error		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day

Date:12/19/03ISR Number: 4255096-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0317420A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Disinhibition							
	Suicidal Ideation							

Date:12/22/03ISR Number: 4255852-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0313883A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Crying							
	Insomnia						dosage text	21 DAY
	Malaise							
	Petit Mal Epilepsy							
	Visual Disturbance							

Date:12/22/03ISR Number: 4255857-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0317324A
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Other	Grand Mal Convulsion
	Loss Of Consciousness

		Tongue Biting Urinary Incontinence					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Zyban	PS	Glaxosmithkline	
10	DAY						
				No Concurrent Medication	C		

Date:12/22/03ISR Number: 4257821-8Report Type:Expedited (15-DaCompany Report #B0316387A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Dizziness Grand Mal Convulsion Hallucination, Visual	Foreign Literature Health	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL
150 MG / UNK						
	Intentional Misuse	Professional				
/ ORAL						
	Nausea Sinus Tachycardia Vomiting					

Date:12/23/03ISR Number: 4257090-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0443220A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Eyelid Oedema	Health	Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
Hospitalization -	Hyperglycaemia	Professional				
per day						
Initial or Prolonged	Hypokalaemia					
Other	Loss Of Control Of Legs Oedema Peripheral Urticaria Generalised					

Date:12/23/03ISR Number: 4257114-9Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0317731A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Bupropion Hydrochloride	PS	Glaxosmithkline		150MG per day	3 DAY
			Metoprolol	C			100MG per day	
			Carbasalate Calcium	C			100MG per day	
			Furosemide	C	Glaxosmithkline		40MG per day	

Date:12/23/03ISR Number: 4257148-4Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0084018A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Burning Sensation	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	22 DAY
	Dysgeusia	Professional						
	Eating Disorder							
	Weight Decreased							

Date:12/23/03ISR Number: 4257162-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443236A
Age:28 YR Gender:Female I/FU:I

Outcome	PT
Other	Abortion Spontaneous
	Complications Of Maternal
	Exposure To Therapeutic

	Drugs Maternal Drugs Affecting Foetus						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Bupropion	PS	Glaxosmithkline		300MG per day
			Lexapro	C			

Date:12/23/03ISR Number: 4257163-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443376A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation		Wellbutrin	PS	Glaxosmithkline		300MG per day
	Confusional State		Lexapro	SS			
	Headache						
	Myalgia						
	Serotonin Syndrome						

Date:12/23/03ISR Number: 4257164-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443378A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Agitation		Wellbutrin	PS	Glaxosmithkline		300MG per day
	Confusional State		Lexapro	SS			
	Headache						
	Myalgia						
	Serotonin Syndrome						

Date:12/23/03ISR Number: 4257166-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443651A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice
	Muscle Twitching						per day YR

	Pharmaceutical Product		Vitamins	C	
	Complaint		Calcium	C	
			Advil	C	Glaxosmithkline

Date:12/23/03ISR Number: 4257174-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443925A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:12/23/03ISR Number: 4257189-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0315793A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	39 DAY
Initial or Prolonged	Asthenia	Professional						
	Chest Pain							
	Dysaesthesia							
	Headache							
	Hypoaesthesia							
	Malaise							
	Speech Disorder							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/03ISR Number: 4257196-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0317735A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Zyban	PS	Glaxosmithkline			
UNKNOWN								10 DAY
	Dizziness							
	Feeling Abnormal							
	Hyperventilation							
	Loss Of Consciousness							
	Nausea							
	Pallor							
	Salivary Hypersecretion							

Date:12/23/03ISR Number: 4257212-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0318341A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Respiratory Arrest							
per day								67 DAY
	Sudden Death							

Date:12/23/03ISR Number: 4257213-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0318367A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Loss Of Consciousness		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
Disability	Myocardial Infarction							

Date:12/23/03ISR Number: 4258205-9Report Type:Direct Company Report #USP 56170
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Medication Error		Wellbutrin Sr	PS	Glaxo Smithkline	

TABLET-SUSTAI

NED RELEASE

Date:12/23/03ISR Number: 4258442-3Report Type:Expedited (15-DaCompany Report #2003124656
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Health	Lipitor					
	Myalgia	Professional	(Atorvastatin)	PS		ORAL		
ORAL								
	Sexual Dysfunction		Paroxetine Hydrochloride (Paroxetine Hydrochloride)	SS		ORAL		
20 MG DAILY,								
ORAL								
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS		ORAL		
300 MG (BID),								
ORAL								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/03ISR Number: 4257597-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0444101A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Wellbutrin	PS	Glaxosmithkline			

Date:12/24/03ISR Number: 4257602-5Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0444142A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Tubular Necrosis		Wellbutrin	PS	Glaxosmithkline			

Date:12/24/03ISR Number: 4257616-5Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0317878A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Hypoglycaemia Limb Injury		Zyban Dothiepin Hydrochloride	PS C	Glaxosmithkline		75MG per day	

Date:12/24/03ISR Number: 4257623-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0317972A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Glucose Decreased		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
Hospitalization - Initial or Prolonged	Circulatory Collapse Feeling Abnormal		Becotide	C	Glaxosmithkline		100MG Twice per day	
			Combivent Salbutamol Antiemetic	C C C	Glaxosmithkline			

Date:12/24/03ISR Number: 4257639-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0318401A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	
	Feeling Jittery							
	Sleep Apnoea Syndrome							

Date:12/29/03ISR Number: 4261311-6Report Type:Direct Company Report #CTU 208864
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Simple Partial Seizures		Wellbutrin	PS				

Date:12/30/03ISR Number: 4267021-3Report Type:Periodic Company Report #HQWYE078213AUG03
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Consumer	Effexor Xr (Venlafaxine Hydochloride, Capsule, Extended Release)	PS		ORAL	ORAL; 75 MG	
	Mania							

1X PER 1 DAY,

ORAL; 150 MG

1X PER 1 DAY,

ORAL; 75 MG

			Wellbutrin (Amfebutamone Hydrochloride,)	SS		
			Lithobid (Lithium Carbonate)	C		
			Oral Contraceptive Nos (Oral Contraceptive Nos)	C		

Date:12/31/03ISR Number: 4262581-0Report Type:Expedited (15-DaCompany Report #2003125837
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Consumer	Neurontin					
	Feeling Abnormal		(Gabapentin)	PS		ORAL	100 MG, ORAL	
	Myalgia		Geodon (Ziprasidone)	SS		ORAL	ORAL	
	Nausea		Zoloft (Sertraline)	SS		ORAL	50 MG	
	Pain						(DAILY), ORAL	
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS		ORAL	ORAL	

Date:01/02/04ISR Number: 4262055-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0490866A
Age:2 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accidental Exposure		Wellbutrin	PS	Glaxosmithkline	ORAL	0	DAY

Initial or Prolonged Accidental Overdose

Date:01/02/04ISR Number: 4264230-4Report Type:Expedited (15-DaCompany Report #B0317415A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
	Drug Toxicity	Health						
	Mood Swings	Professional						
	Treatment Noncompliance							
			Alprazolam (Formulation Unknown) (Alprazolam)	SS				
			Temazepam (Formulation Unknown) (Temazepam)	SS				

Date:01/04/04ISR Number: 4263229-1Report Type:Direct Company Report #CTU 209267
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Clavicle Fracture		Bupropion 100mg Tab	PS			100 MG BID	1 DAY
	Convulsion							
	Fall							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/04ISR Number: 4263257-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0490813A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aorta Hypoplasia Atrial Septal Defect Drug Exposure During Pregnancy		Bupropion	PS	Glaxosmithkline			

Date:01/05/04ISR Number: 4263259-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0490904A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Hangover		Avandia	PS	Glaxosmithkline	ORAL	4MG Twice per day	
			Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	
			Starlix Plavix Synthroid Aciphex	C C C C	Glaxosmithkline			

Date:01/05/04ISR Number: 4263812-3Report Type:Direct Company Report #CTU 209312
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation Anger Drug Withdrawal Syndrome Emotional Distress Fear		Paxil - Gsk 60 Mg	PS	Gsk	ORAL	60 MG ORAL @ NIGHT; A TOTAL OF 15 YRS ON SSRI	
			Wellbutrin	SS			300 MG, SSRI	

	Feeling Abnormal					
	Malaise					

Date:01/05/04ISR Number: 4263832-9Report Type:Direct Company Report #CTU 209308
Age:25 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Concussion Fall Grand Mal Convulsion Skull Fracture		Wellbutrin Xr 150mg Began On 12/05/03, Increased To 300mg On 12/11	PS		
150 MG BEGAN 12/5/03 INCREASED TO 300 MG 12/11						
			Clomipramine	C		

Date:01/06/04ISR Number: 4264427-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0309783A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Diabetes Mellitus		Zyban	PS	Glaxosmithkline	ORAL
150MG Unknown 3 WK						
	Headache					
	Thirst					
	Visual Acuity Reduced					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/04ISR Number: 4264430-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0316252A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Poisoning	Consumer	Bupropion	PS	Glaxosmithkline	ORAL		
	Coma		Ethanol	SS				
UNKNOWN								
	Completed Suicide		Fluoxetine	C				
UNKNOWN								
	Pulmonary Congestion		Flurazepam	C				
UNKNOWN								
	Pulmonary Oedema		Lorazepam	C				
UNKNOWN								
			Ibuprofen	C	Glaxosmithkline			
UNKNOWN								
			Albuterol	C	Glaxosmithkline			
RESPIRATORY								
(INHALATION)								

Date:01/06/04ISR Number: 4264431-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0316261A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Intentional Misuse		Carbamazepine	C				
			Thioridazine	C				

Date:01/06/04ISR Number: 4264432-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0316263A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Intentional Misuse		Diphenhydramine	SS				
UNKNOWN								

Date:01/06/04ISR Number: 4264433-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0316265A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL
	Intentional Misuse		Benzodiazepines	C		
UNKNOWN						
			Alprazolam	C		
UNKNOWN						
			Maprotiline	C		
UNKNOWN						

Date:01/06/04ISR Number: 4264435-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0317415A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline	ORAL
	Drug Toxicity		Alprazolam	SS		
UNKNOWN						
	Feeling Abnormal		Temazepam	SS		
UNKNOWN						
	Intentional Misuse					
	Mood Swings					
	Treatment Noncompliance					

Date:01/06/04ISR Number: 4264444-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0318606A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Eczema		Zyban	PS	Glaxosmithkline	ORAL
1 MON						
			Salbutamol	C	Glaxosmithkline	
UNKNOWN						
			Fluticasone	C	Glaxosmithkline	
UNKNOWN						
			Betamethasone	C	Glaxosmithkline	
UNKNOWN						
			Oxytetracycline	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/04ISR Number: 4264449-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0318887A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diplopia Headache Iiird Nerve Paralysis Strabismus		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY

Date:01/06/04ISR Number: 4264450-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0318901A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Congenital Anomaly	Congenital Anomaly Drug Exposure During Pregnancy Talipes		Zyban	PS	Glaxosmithkline		1	WK

Date:01/06/04ISR Number: 4264486-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0491332A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Bipolar Disorder							
	Convulsion		Valium	C				
			Antidepressant (Unspecified)	C				
			Narcotics (Unspecified)	C				

Date:01/06/04ISR Number: 4265056-8Report Type:Direct Company Report #CTU 209440
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hallucination		Wellbutrin Sr 150 Mg					
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Road Traffic Accident		Tab. Sa Glx	PS			1 TABLET TWICE A DAY (A WEEK OR TWO BEFORE PERIOD)	

Date:01/07/04ISR Number: 4265664-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0490959A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	30 DAY
	Condition Aggravated							
Other	Convulsion		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG See dosage text	7 WK
	Medication Error							
			Lipitor	C				
			Synthroid	C	Glaxosmithkline			
			Unknown Medication	C				
			Vitamins	C				
			Aricept	C				

3 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/04ISR Number: 4265673-5Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0314545A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia		Zyban	PS	Glaxosmithkline			15 DAY
	Anxiety		Oxycodone	C			180MG per day	
	Disturbance In Attention							
	Dry Mouth							
	Dyskinesia							
	Dysstasia							
	Hyperhidrosis							
	Lack Of Spontaneous Speech							
	Muscle Twitching							
	Nausea							
	Pallor							
	Tremor							

Date:01/09/04ISR Number: 4267508-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414556A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Birth Control	C		ORAL		

Date:01/09/04ISR Number: 4267509-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415800A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Captopril	C	Glaxosmithkline			

Date:01/09/04ISR Number: 4267510-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415804A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Abnormal	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three	
	Blood Urea						times per day	1 YR
	Hypokalaemia		Extra Strength					
	Renal Injury		Tylenol	SS	Glaxosmithkline	ORAL	500MG Twice	
							per day	YR
			Arthritis/Tylenol	SS	Glaxosmithkline	ORAL	650MG Twice	
							per day	YR

Date:01/09/04ISR Number: 4267511-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416376A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	6	YR

Date:01/09/04ISR Number: 4267512-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417155A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267513-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0417661A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Headache		Zestril	C				
	Memory Impairment		Elavil	C	Glaxosmithkline			
	Somnolence							

Date:01/09/04ISR Number: 4267514-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418009A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Demerol	SS			UNKNOWN	
			Versed	SS			UNKNOWN	

Date:01/09/04ISR Number: 4267515-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418060A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Bupropion	PS	Glaxosmithkline	ORAL	100MG Three	
							times per day	
			Mirapex	C				
			Evista	C				

Date:01/09/04ISR Number: 4267516-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418077A
Age:10 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267517-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418604A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	1	DAY

Date:01/09/04ISR Number: 4267518-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418606A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Stress							
	Swelling Face							
	Tension							
	Weight Increased							

Date:01/09/04ISR Number: 4267519-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418608A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Smoker		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267520-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418955A
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice	
	Tinnitus						per day	
			Tamoxifen	C				
			Fosamax	C				
			Lasix	C	Glaxosmithkline			
			Potassium	C				
			Zocor	C				
			Aricept	C				
			Klonopin	C				

Date:01/09/04ISR Number: 4267521-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419167A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	YR
	Sleep Disorder							

Date:01/09/04ISR Number: 4267522-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419171A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267523-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419180A
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	

	Dizziness		Wellbutrin	SS	Glaxosmithkline	ORAL
2 WK						
	Nausea		Atenolol	C		
	Vision Blurred		Xanax	C		

Date:01/09/04ISR Number: 4267524-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420194A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL
150TAB Four times per day 2 WK						

Date:01/09/04ISR Number: 4267525-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420538A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL
75MG per day 10 DAY						
	Developmental		Zyprexa	C		
	Coordination Disorder		Diazide	C		
			Vasotec	C		
			Insulin	C		
			Digitek	C	Glaxosmithkline	
			Aggrenox	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267526-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420574A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Vertigo							

Date:01/09/04ISR Number: 4267527-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420764A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Bupropion	PS	Glaxosmithkline	ORAL	100MG Twice per day	3 MON
			Aspirin	C	Glaxosmithkline		UNKNOWN	81MG Per day
			Concurrent Medications	C				

Date:01/09/04ISR Number: 4267528-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420766A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267529-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420767A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Nausea							

Date:01/09/04ISR Number: 4267530-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420811A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Coma Confusional State Convulsion Dyspnoea Somnolence		Wellbutrin Synthroid Detrol Methylprednisolone	PS C C C	Glaxosmithkline Glaxosmithkline	ORAL	75MG Per day	2 WK

Date:01/09/04ISR Number: 4267532-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0421215A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus Weight Decreased		Wellbutrin Birth Control Pills Zoloft Centrum Calcium	PS C C C C	Glaxosmithkline	ORAL	150MG Twice per day	8 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267533-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0421266A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:01/09/04ISR Number: 4267534-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422162A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nephrolithiasis		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lexapro	SS		ORAL	10MG Unknown	MON
			Buspar	C				

Date:01/09/04ISR Number: 4267535-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422163A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Drug Screen False							
	Positive		Concerta	SS		ORAL	54MG Per day	

Date:01/09/04ISR Number: 4267536-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422192A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	14 MON

				Norvasc	C	
				Hydrochlorothiazide	C	
				Multi-Vitamin	C	
				Tylenol	C	Glaxosmithkline

Date:01/09/04ISR Number: 4267537-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422194A
Age:46 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100TAB Per	
	Headache						day	27 DAY
	Thinking Abnormal		Zoloft	C				
			Risperdal	C				

Date:01/09/04ISR Number: 4267538-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422214A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Withdrawal Syndrome						per day	2 MON
	Insomnia		Estradiol	C				
			Claritin D	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267539-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422295A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Aspirin	C	Glaxosmithkline			
			Coumadin	C	Glaxosmithkline			
			Proscar	C			5MG Per day	
			Metoprolol Tartrate	C			50MG Twice per day	
			Terazosin	C			5MG Per day	
			Zocor	C			40MG Per day	
			Xanax	C				

Date:01/09/04ISR Number: 4267540-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422316A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 MON
	Herpes Zoster							
			Prozac	C				

Date:01/09/04ISR Number: 4267541-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422329A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Attack		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Xanax	C				

Date:01/09/04ISR Number: 4267542-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422614A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	7 DAY

Date:01/09/04ISR Number: 4267543-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422645A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sluggishness		Wellbutrin	PS	Glaxosmithkline	ORAL	50MG As required	
	Somnolence							

Date:01/09/04ISR Number: 4267544-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422734A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	

Date:01/09/04ISR Number: 4267545-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422844A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	

Lexapro SS
UNKNOWN 20MG Per day

Date:01/09/04ISR Number: 4267546-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422922A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Vomiting							

Date:01/09/04ISR Number: 4267547-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423052A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Chest Pain							

Date:01/09/04ISR Number: 4267548-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423388A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Alopecia						per day	1 MON

Date:01/09/04ISR Number: 4267549-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423434A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267550-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423606A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	
			B12	C	Glaxosmithkline			
			Ferrous Sulfate	C	Glaxosmithkline			
			Cipro	C	Glaxosmithkline			

Date:01/09/04ISR Number: 4267551-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423700A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267552-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423852A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Unknown	
	Complaint							
	Retching							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267570-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424133A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267571-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424151A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267572-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424329A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Discolouration		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	200MG Twice per day	8 WK
			Seroquel	C				

Date:01/09/04ISR Number: 4267573-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424379A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Insomnia							
	Nightmare							

Date:01/09/04ISR Number: 4267574-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424554A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267575-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424689A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267576-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424713A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingivitis		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	18 MON
	Nausea		Lamictal	SS	Glaxosmithkline	ORAL	25MG Per day	
			Effexor	C				
			Elavil	C	Glaxosmithkline			
			Thyroid	C				
			Vivactil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267578-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425090A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	6	WK

Date:01/09/04ISR Number: 4267579-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425179A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	4	WK
			Paxil Cr	C	Glaxosmithkline			

Date:01/09/04ISR Number: 4267580-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425335A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Dizziness						per day	8 WK
	Drug Ineffective		Zyrtec	C	Glaxosmithkline			
	Dry Mouth		Prevacid	C				
	Stool Analysis Abnormal		Advair	C	Glaxosmithkline			
			Singulair	C				
			Albuterol	C	Glaxosmithkline			
			Flonase	C	Glaxosmithkline			
			Flexeril	C				

Date:01/09/04ISR Number: 4267581-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425416A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcohol Intolerance		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY

	Hyperhidrosis		Prozac	C		
			Accupril	C		

Date:01/09/04ISR Number: 4267582-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425719A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	NASAL		

Date:01/09/04ISR Number: 4267583-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425735A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR
	Weight Decreased							

Date:01/09/04ISR Number: 4267584-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425969A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	1 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267585-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426358A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Phenobarbital	C				
			Propoxyphene	C				
			Vicodin	C				
			Potassium Bromide	C				
			Celexa	C				

Date:01/09/04ISR Number: 4267586-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426582A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder		Bupropion	PS	Glaxosmithkline	ORAL	75MG Per day	2 WK
	Visual Acuity Reduced		Lexapro	C				
			Maxzide	C	Glaxosmithkline			
			Prevacid	C				

Date:01/09/04ISR Number: 4267587-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426898A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline			
			Topamax	C				

Date:01/09/04ISR Number: 4267588-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426931A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Headache							
per day	8 DAY							
	Insomnia							

Nausea

Date:01/09/04ISR Number: 4267589-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426932A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline			
			Lexapro	C				

Date:01/09/04ISR Number: 4267590-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426943A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267591-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427072A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267592-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427339A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267593-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427529A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267594-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427667A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Wellbutrin	PS	Glaxosmithkline			
			Alcohol	SS				

Date:01/09/04ISR Number: 4267595-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427689A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267596-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427745A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Stomach Discomfort							

Date:01/09/04ISR Number: 4267597-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427855A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Three times per day	2 MON
			Norvasc	C				

Date:01/09/04ISR Number: 4267598-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427867A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	2 YR

Date:01/09/04ISR Number: 4267599-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428053A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267600-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428128A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	60	DAY
	Neck Mass							
	Pharyngolaryngeal Pain							
	Subcutaneous Nodule							
	Thyroid Neoplasm							

Date:01/09/04ISR Number: 4267601-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428220A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL		
			Paxil	SS	Glaxosmithkline			
			Antidepressants	SS				
UNKNOWN								

Date:01/09/04ISR Number: 4267602-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428690A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Exertional		Wellbutrin	PS	Glaxosmithkline	ORAL	14	DAY
			Lotrel	C			5	DAY

Date:01/09/04ISR Number: 4267603-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428697A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	2	YR
			Insulin	C				

Date:01/09/04ISR Number: 4267604-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428698A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	500MG	Unknown 2 YR
	Hypoglycaemia		Insulin	C				

Date:01/09/04ISR Number: 4267605-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428732A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline		1	DAY

Date:01/09/04ISR Number: 4267606-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429136A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Local Swelling							
	Musculoskeletal Stiffness							
	Rash Pruritic							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267607-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429237A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response		Wellbutrin	PS	Glaxosmithkline			
	Unexpected							

Date:01/09/04ISR Number: 4267608-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429519A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267609-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430010A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267610-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430084A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Prozac	C				
			Zoloft	C				
			Tca	C				

Date:01/09/04ISR Number: 4267611-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430470A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 9 DAY						
	Palpitations		Tranxene	C		
	Somnolence		Glucovance	C		
			Benicar	C		
			Baby Aspirin	C	Glaxosmithkline	

Date:01/09/04ISR Number: 4267612-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430480A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Apathy		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day						

Date:01/09/04ISR Number: 4267613-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430640A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Therapeutic Response		Wellbutrin	PS	Glaxosmithkline	
	Unexpected					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267614-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430648A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Weight Increased						per day	

Date:01/09/04ISR Number: 4267619-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430717A
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Dilantin	C				

Date:01/09/04ISR Number: 4267620-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430719A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash						per day	2 WK
	Urticaria							

Date:01/09/04ISR Number: 4267621-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430757A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	146 DAY

Date:01/09/04ISR Number: 4267622-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430762A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Fluctuation		Wellbutrin	PS	Glaxosmithkline			
UNKNOWN								

Date:01/09/04ISR Number: 4267623-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430933A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	37.5MG Twice	
	Pyrexia						per day	
			Paxil	C	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267624-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430960A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Insulin	C				

Date:01/09/04ISR Number: 4267625-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431193A
Age: Gender:Female I/FU:F

Outcome	PT
	Dizziness
	Drug Ineffective

	Nervousness						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline		
			Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day 2 WK
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day
			Klonopin	C			
			Lipitor	C			
			Insulin	C			

Date:01/09/04ISR Number: 4267626-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431438A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	

Date:01/09/04ISR Number: 4267627-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431608A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoaesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL	
	Muscle Spasms						
	Myalgia						
	Paraesthesia						

Date:01/09/04ISR Number: 4267628-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431807A
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Influenza Like Illness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day 10 YR
	Nervousness		Prevacid	C			
	Pollakiuria		Synthroid	C	Glaxosmithkline		

	Tinnitus		Premarin	C		
	Tremor		Cozar	C		
	Weight Decreased					

Date:01/09/04ISR Number: 4267629-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431815A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267631-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431945A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
			Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267632-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431951A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON

Date:01/09/04ISR Number: 4267633-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431976A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	9 MON
	Loss Of Consciousness							
Other	Nausea		Cold Medicine	SS				

Date:01/09/04ISR Number: 4267634-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431982A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Increased Appetite							
	Nicotine Dependence							

Date:01/09/04ISR Number: 4267635-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432592A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline		1	WK
	Urticaria		Zyban	SS	Glaxosmithkline		1	DAY

Date:01/09/04ISR Number: 4267636-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432897A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	5 YR

Date:01/09/04ISR Number: 4267637-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432981A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Discolouration		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267638-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433001A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown
			Concerta	SS		ORAL	18MG Per day	

Date:01/09/04ISR Number: 4267639-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433328A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267640-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433346A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Medication Error						per day	MON
			Citalopram	C				
			Methylphenidate	C				

Date:01/09/04ISR Number: 4267641-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438902A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Three	
	Lacrimation Increased						times per day	

Date:01/09/04ISR Number: 4267642-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439019A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 YR
			Ambien	C				
			Lexapro	C				

Date:01/09/04ISR Number: 4267643-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439050A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline			
			Prednisone	C				

Date:01/09/04ISR Number: 4267644-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439417A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tinnitus							
	Weight Decreased							

Date:01/09/04ISR Number: 4267645-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439461A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline			
	Feeling Jittery							
	Heart Rate Increased							

Date:01/09/04ISR Number: 4267646-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439498A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retinal Vein Occlusion		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267647-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439637A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test Abnormal		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267649-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439815A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia Hypertrichosis		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267650-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440212A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267651-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440377A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	6	WK

Date:01/09/04ISR Number: 4267652-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440387A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267653-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440585A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/09/04ISR Number: 4267654-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440606A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Menstruation Irregular							

Date:01/09/04ISR Number: 4267655-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440607A
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Tinnitus		Luvox	C				
			Risperdal	C				
			Lithium	C	Glaxosmithkline			
			Zocor	C			40MG Per day	

			Metoprolol	C		
50MG Twice						
per day						
			Prilosec	C		
20MG Per day						

Date:01/09/04ISR Number: 4267656-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440715A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Paxil	SS	Glaxosmithkline	ORAL		
	Fatigue							
	Weight Decreased							

Date:01/09/04ISR Number: 4267657-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440975A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:01/09/04ISR Number: 4267658-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441133A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:01/09/04ISR Number: 4267659-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441521A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL		

			Alcohol	SS		ORAL	2U Monthly

Date:01/09/04ISR Number: 4267660-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441541A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mood Swings		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lamictal	C	Glaxosmithkline	ORAL		

Date:01/09/04ISR Number: 4267814-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0149544A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Amnesia		Nicotrol Inhaler	SS	Glaxosmithkline			
	Brain Damage							
	Concussion							
	Convulsion							
	Difficulty In Walking							
	Fall							
	Head Injury							
	Impaired Work Ability							
	Loss Of Consciousness							
	Lumbar Vertebral Fracture							
	Memory Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267816-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0432608A
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Medication Error	Professional	Bupropion	SS	Glaxosmithkline		1	MON
	Nightmare		Heart Medication	C				
	Palpitations		Antihypertensives	C				
	Treatment Noncompliance		Lopressor	C				
	Urinary Retention							

Date:01/09/04ISR Number: 4267817-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442800A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	No Adverse Effect	Professional					per day	

Date:01/09/04ISR Number: 4267820-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0491694A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product Complaint							

Date:01/12/04ISR Number: 4268588-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0431972A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	

	Arthritis	Professional				
per day 10 YR						
	Psoriasis		Synthroid	C	Glaxosmithkline	
			Thiazide	C		
			Fosamax	C		
			Vasotec	C		

Date:01/12/04ISR Number: 4268590-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0491314A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 2 WK						
	Insomnia		Compazine	C	Glaxosmithkline	
	Medication Error					
	Visual Acuity Reduced					

Date:01/12/04ISR Number: 4268592-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0317735A
Age:27 YR Gender:Male I/FU:F

Outcome	PT
Other	Amnesia
	Dizziness
	Feeling Abnormal
	Hyperventilation
	Loss Of Consciousness
	Nausea
	Pallor

	Salivary Hypersecretion					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Zyban	PS	Glaxosmithkline	
UNKNOWN	10 DAY					

Date:01/12/04ISR Number: 4268599-6Report Type:Expedited (15-DaCompany Report #DK-GLAXOSMITHKLINE-B0318928A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Depression		Zyban	PS	Glaxosmithkline	ORAL
150MG per day						
	Irritability					
	Respiratory Distress					

Date:01/12/04ISR Number: 4268600-XReport Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0319066A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Depression		Zyban	PS	Glaxosmithkline	
9 WK						
	Drug Withdrawal Syndrome		Acetylsalicylic Acid	C	Glaxosmithkline	

Date:01/13/04ISR Number: 4269183-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0491932A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Dizziness					
per day						
	Paraesthesia		Unknown Supplement	SS		
5 DAY						
	Syncope		Estrace	C		
			Calcium	C		
			Progesterone Cream	C		

Date:01/13/04ISR Number: 4269184-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0492275A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:01/13/04ISR Number: 4269192-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0316388A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Zyban	PS	Glaxosmithkline		UNKNOWN	
	Aggression		Sedatives					
	Confusional State		(Unspecified)	C			UNKNOWN	
	Convulsion							
	Fall							
	Hallucination, Visual							
	Intentional Misuse							
	Nervous System Disorder							
	White Blood Cell Count Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/04ISR Number: 4269206-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0318901A
Age:6 MON Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Congenital Anomaly		Zyban	PS	Glaxosmithkline			1 WK
Congenital Anomaly	Drug Exposure During Pregnancy Talipes							

Date:01/13/04ISR Number: 4269217-3Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0319105A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Malaise Pain Pyrexia Skin Injury		Bupropion Hydrochloride	PS	Glaxosmithkline			

Date:01/13/04ISR Number: 4270567-5Report Type:Direct Company Report #CTU 209952
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysgeusia Pharmaceutical Product Complaint		Wellbutrin Sr 200 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	200 MG BID	ORAL

Date:01/13/04ISR Number: 4277275-5Report Type:Expedited (15-DaCompany Report #B0318456A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Choreoathetosis Convulsion	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion					

	Electrocardiogram Qrs		Hydrochloride)	PS		ORAL
ORAL						
	Complex Prolonged Electrocardiogram Qt Corrected Interval Prolonged					
	Overdose					
	Tachycardia					
	Urinary Incontinence					

Date:01/14/04ISR Number: 4270014-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389829A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychotic Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	9	WK

Date:01/14/04ISR Number: 4270015-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0052984A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
	Pharmaceutical Product							
	Complaint		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	
	Therapeutic Response							
	Decreased		Nortriptyline	C			10MG Per day	

				Vasotec	C		
5MG Per day							
				Synthroid	C	Glaxosmithkline	
.1MG Per day							

Date:01/14/04ISR Number: 4270016-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0070258A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Female Orgasmic Disorder		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	7 WK
	Headache		Estrogen	C				
	Libido Decreased							
	Sexual Dysfunction							

Date:01/14/04ISR Number: 4270017-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0379391A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Bupropion	PS	Glaxosmithkline		UNKNOWN	
	Drug Ineffective							
	Lethargy							
	Weight Increased							

Date:01/14/04ISR Number: 4270018-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0385287A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diaphragmalgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dystonia						per day	
	Formication		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice	
	Hypoaesthesia						per day	8 YR

	Muscle Spasms		Zoloft	C		
12.5MG						
	Tension					
Alternate						
	Weight Increased					
days						
			Tenormin	C		
			Naprosyn	C		

Date:01/14/04ISR Number: 4270019-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388023A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laceration		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product Complaint							

Date:01/14/04ISR Number: 4270020-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388176A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270021-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388627A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:01/14/04ISR Number: 4270022-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388679A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Colour Changes		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG See dosage text	5 YR
			Levoxyl	C	Glaxosmithkline			
			Hormones	C				
			Tegretol	C				

Date:01/14/04ISR Number: 4270023-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0388713A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG In the morning	
			Temazepam	C				
			Fosamax	C				
			Estradiol	C				
			Prometrium	C				
			Lamictal	C	Glaxosmithkline			
			Celebrex	C				
			Calcium	C				
			Magnesium Oxide	C				
			Boron	C				
			Biotin	C				
			Vitamin E	C				
			Vitamin C	C	Glaxosmithkline			
			Gingko	C				

Multivitamin	C
Glucosamine	C
Chondroitin	C
Vitamin B50	C
Co Q10	C
L-Glutamine	C

Date:01/14/04ISR Number: 4270024-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389008A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Agitation							
	Amnesia							
	Confusional State							
	Coordination Abnormal							
	Insomnia							
	Nightmare							
	Paranoia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270025-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389097A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Rash						per day	24 DAY

Date:01/14/04ISR Number: 4270026-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389202A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 MON
			Prozac	SS		ORAL		

Date:01/14/04ISR Number: 4270027-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389499A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	2 MON
	Rash							
	Urticaria							

Date:01/14/04ISR Number: 4270028-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389788A
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
							per day	
			Paxil	C	Glaxosmithkline		60MG per day	
			Nexium	C				

				Premarin	C		

YR

Date:01/14/04ISR Number: 4270031-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0389826A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Unknown YR

Date:01/14/04ISR Number: 4270032-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390024A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270033-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390383A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270034-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390887A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Panic Attack							

Date:01/14/04ISR Number: 4270035-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391255A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ocular Hyperaemia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270036-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391316A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Genital Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270037-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391458A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness		Wellbutrin	PS	Glaxosmithkline			
UNKNOWN							2	YR
	Hyperhidrosis							
	Tinnitus							

Date:01/14/04ISR Number: 4270038-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391512A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fibromyalgia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270039-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391522A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			
	Energy Increased							
	Nervous System Disorder							

Date:01/14/04ISR Number: 4270040-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391658A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
	Memory Impairment	Professional	Alcohol	SS		ORAL		
	Personality Change							

Date:01/14/04ISR Number: 4270041-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391719A
Age:45 YR Gender:Female I/FU:F

Outcome	PT
	Disturbance In Attention
	Memory Impairment

Personality Change

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Wellbutrin	PS	Glaxosmithkline	ORAL
			Professional	Alcohol	SS		ORAL

Date:01/14/04ISR Number: 4270042-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0391879A
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Convulsion		Wellbutrin	PS	Glaxosmithkline	
UNKNOWN							

Date:01/14/04ISR Number: 4270043-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392136A
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL
		Nausea					

Date:01/14/04ISR Number: 4270044-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392155A
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rash Generalised		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Unknown	20 DAY						
		Urticaria					

Date:01/14/04ISR Number: 4270045-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392331A
Age:40 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day							

	Headache		Synthroid	C	Glaxosmithkline	ORAL

.05U Per day YR

Date:01/14/04ISR Number: 4270046-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392337A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Convulsion		Bupropion	PS	Glaxosmithkline	

Dose Duration
UNKNOWN

Date:01/14/04ISR Number: 4270047-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392415A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL

Dose Duration
300MG Twice

per day

Date:01/14/04ISR Number: 4270048-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392515A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL

Dose Duration

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270049-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0392602A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Nonspecific Reaction							
	Pharyngolaryngeal Pain							

Date:01/14/04ISR Number: 4270050-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393175A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Anxiety							
	Insomnia							

Date:01/14/04ISR Number: 4270051-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393613A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Choking Sensation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270052-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393998A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Bupropion	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270053-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0393999A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270054-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394011A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	2	DAY
	Formication		Zoloft	C				
	Panic Attack		Xanax	C				
			Nicotine Patch	C	Glaxosmithkline			

Date:01/14/04ISR Number: 4270055-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394058A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
Initial or Prolonged			Topamax	C				
			Depakote	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270056-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394267A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Libido		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	

Date:01/14/04ISR Number: 4270057-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394293A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270058-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394534A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270059-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394742A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270060-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0394873A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:01/14/04ISR Number: 4270061-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395033A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	per day

Date:01/14/04ISR Number: 4270062-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395175A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270063-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395178A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice	per day
			Tylenol #4	C				
			Motrin	C	Glaxosmithkline			
			Viread	C				
			Ziagen	C	Glaxosmithkline			
			Kaletra	C				

	Prevacid	C		
	Valium	C		
	Zoloft	C		
	Atenolol	C		
	Imodium	C		
	Aspirin	C	Glaxosmithkline	

Date:01/14/04ISR Number: 4270064-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395406A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270065-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395449A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Bupropion	PS	Glaxosmithkline	ORAL	100MG In the morning	3 MON
			Luvox	C				

Date:01/14/04ISR Number: 4270074-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395471A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270075-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395672A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270076-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395674A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	5	MON
	Crying		Paxil	SS	Glaxosmithkline	ORAL		
	Headache		Ibuprofen	C	Glaxosmithkline		300MG	Unknown
	Immobile							
	Mood Swings							
	Oedema Peripheral							
	Pain In Extremity							
	Restless Legs Syndrome							

Date:01/14/04ISR Number: 4270077-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395680A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Therapeutic Response							
	Unexpected							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270078-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395719A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Menstrual Disorder							

Date:01/14/04ISR Number: 4270079-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0395864A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL		YR
	Drug Ineffective		Vicodin	C				
			Xanax	C				
			Temazepam	C				

Date:01/14/04ISR Number: 4270080-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396049A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Bupropion	PS	Glaxosmithkline	ORAL	100MG Twice	
	Urticaria						per day	2 WK
			Methocarbamol	C				

Date:01/14/04ISR Number: 4270081-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396277A
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Nausea						per day	DAY
	Somnolence		Tylenol #3 W Codeine	SS		ORAL		
			Glucosamine	C				

Date:01/14/04ISR Number: 4270082-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396295A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	13 DAY
			Gabitril	SS		ORAL	2MG Per day	13 DAY
			Ambien	C				

Date:01/14/04ISR Number: 4270083-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396494A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Drug Interaction							
	Therapeutic Response		Provigil	SS		ORAL	200MG Per day	
	Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270084-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396662A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270085-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0396774A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Level Of Consciousness		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lorazepam	SS		ORAL	1MG Per day	1 DAY
	Drug Ineffective							
	Performance Status Decreased							

Date:01/14/04ISR Number: 4270086-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397207A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270087-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397330A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Depressed Mood							
	Headache							
	Pharmaceutical Product Complaint							
	Somnolence							

Date:01/14/04ISR Number: 4270088-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397336A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270089-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397337A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Anxiety							
	Irritability							

Date:01/14/04ISR Number: 4270090-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0397351A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	10	MON
	Weight Decreased		Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270091-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398324A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270092-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398335A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oligomenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270093-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398841A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270094-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398930A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	10	DAY
	Muscle Spasms		Propecia	C				
			Strattera	C				

Date:01/14/04ISR Number: 4270096-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399076A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Theophylline	C				

Date:01/14/04ISR Number: 4270097-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399087A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion	PS	Glaxosmithkline	ORAL		
			Elavil	C	Glaxosmithkline			

Date:01/14/04ISR Number: 4270099-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399089A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Somnolence							

Date:01/14/04ISR Number: 4270100-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399225A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bilirubin Urine		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Protein Urine Present							
per day							1	MON
			Synthroid	C	Glaxosmithkline			
			Effexor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270101-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399449A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270102-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399583A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotrichosis		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three times per day	10 MON

Date:01/14/04ISR Number: 4270103-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399589A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	WK
			Effexor	C				

Date:01/14/04ISR Number: 4270104-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399601A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	
	Drug Ineffective		Remeron	SS		ORAL	45MG Per day	2 YR
	Drug Withdrawal Syndrome							
	Influenza Like Illness							
	Malaise							
	Nausea							
	Palpitations							

	Restlessness					
	Tremor					

Date:01/14/04ISR Number: 4270105-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399855A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270106-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399856A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Celexa	C				
			Effexor	C				
			Aspirin	C	Glaxosmithkline			
UNKNOWN								
			Toprol Xl	C				
			Hytrin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270107-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0400179A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Emotional Disorder							

Date:01/14/04ISR Number: 4270108-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401146A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False Positive		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270109-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401228A
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Irritability							

Date:01/14/04ISR Number: 4270110-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401256A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Ineffective		Lexapro	C				
	Therapeutic Response Unexpected							

Date:01/14/04ISR Number: 4270111-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0401802A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tremor		Lexapro	SS				
UNKNOWN								

Date:01/14/04ISR Number: 4270112-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402025A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Irritability							
per day								10 DAY
	Oedema Peripheral		Naltrexone	C				
	Pruritus							
	Psychomotor Hyperactivity							
	Vision Blurred							

Date:01/14/04ISR Number: 4270113-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0402323A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270114-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403099A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination, Visual		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	3 YR
			Monopril	C				5 MON

Date:01/14/04ISR Number: 4270115-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403103A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270116-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0403670A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Phosphorus		Zyban	PS	Glaxosmithkline		UNKNOWN	2 MON
	Increased Blood Pressure Increased							

Date:01/14/04ISR Number: 4270117-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404167A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Attack		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270118-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404181A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Goitre		Wellbutrin	PS	Glaxosmithkline	ORAL
8 MON						

Date:01/14/04ISR Number: 4270119-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404218A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Skin Odour Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:01/14/04ISR Number: 4270120-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404318A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL
			Fat Burner	C		

Date:01/14/04ISR Number: 4270121-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404373A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice per day						
			Paxil	C	Glaxosmithkline	
UNKNOWN 300MG Twice per day						
			Klonopin	C		
UNKNOWN 3VA per day						

			Ambien	C		
UNKNOWN	10MG At night					

Date:01/14/04ISR Number: 4270122-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404377A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Premature Ejaculation		Wellbutrin	PS	Glaxosmithkline	ORAL
			Prozac	C		

Date:01/14/04ISR Number: 4270123-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404775A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL
	Depressed Mood					
	Dizziness					
	Malaise					
	Self-Injurious Ideation					

Date:01/14/04ISR Number: 4270124-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404781A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:01/14/04ISR Number: 4270125-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0404991A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL
	Tremor					

Date:01/14/04ISR Number: 4270126-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405330A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270127-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405387A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270128-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405397A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dental Caries		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270129-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405426A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Gastrooesophageal Reflux Disease							

Date:01/14/04ISR Number: 4270130-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405756A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Anger						per day	
	Contusion							

Date:01/14/04ISR Number: 4270136-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405817A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK
	Psychomotor Hyperactivity							
	Restlessness							

Date:01/14/04ISR Number: 4270137-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0405902A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Urticaria						per day	3 WK

Date:01/14/04ISR Number: 4270138-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406446A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			3 YR
			Geodon	C				

Date:01/14/04ISR Number: 4270139-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0406923A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL		4 YR

Date:01/14/04ISR Number: 4270140-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407133A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270141-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407396A
Age:13 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	1 WK
	Hypersensitivity							
	Serum Sickness							
	Urticaria							

Date:01/14/04ISR Number: 4270142-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408075A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Bupropion	PS	Glaxosmithkline	ORAL		
			Alcohol	SS				

Date:01/14/04ISR Number: 4270143-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408212A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Priapism		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270144-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408689A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion	PS	Glaxosmithkline	ORAL	100MG Twice per day	

Date:01/14/04ISR Number: 4270145-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408890A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG At	
	Depression						night	6 WK
	Dizziness							
	Drug Ineffective							
	Fatigue							

Date:01/14/04ISR Number: 4270146-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409525A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270147-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409539A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270148-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409637A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice	
	Disorientation						per day	1 YR
	Dizziness							

Date:01/14/04ISR Number: 4270149-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409942A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Dexedrine	C	Glaxosmithkline			

Date:01/14/04ISR Number: 4270150-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410330A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG per day	
	Irritability		Atarax	C				
	Nervousness							

Date:01/14/04ISR Number: 4270152-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411801A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL	25MG Per day	3 DAY
			Lexapro	C				
UNKNOWN							20MG Per day	10 MON

Date:01/14/04ISR Number: 4270153-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411924A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Bupropion	PS	Glaxosmithkline	ORAL	100MG Twice per day	19 DAY

Date:01/14/04ISR Number: 4270162-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412060A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270163-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412415A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	1 YR
			Prozac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270164-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412977A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	

Date:01/14/04ISR Number: 4270165-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413259A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination, Visual		Wellbutrin	PS	Glaxosmithkline	ORAL	7	DAY

Date:01/14/04ISR Number: 4270166-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413261A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination, Visual		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270167-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413293A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Unknown	WK
			Zocor	C				

Date:01/14/04ISR Number: 4270168-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413314A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270169-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413327A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270170-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413934A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polymenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Rash							
							per day	16 DAY

Date:01/14/04ISR Number: 4270171-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414002A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Bupropion	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270172-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414062A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Effexor	C		ORAL		

Date:01/14/04ISR Number: 4270173-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414188A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/14/04ISR Number: 4270174-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414234A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON
	Muscle Rigidity							
	Muscle Tightness							

Date:01/14/04ISR Number: 4270175-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414335A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
	Rash		Avandia	SS	Glaxosmithkline		UNKNOWN	
	Rash Papular		Lexapro	C				
			Trazodone	C				
			Orthocyclen	C				

Date:01/14/04ISR Number: 4270528-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0317875A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Zyban	PS	Glaxosmithkline	ORAL		
	Nausea							
	Swelling Face							
	Syncope							
	Urticaria							

Date:01/14/04ISR Number: 4270530-4Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0319062A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	8 DAY

Date:01/14/04ISR Number: 4270533-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0319125A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Irritability		Zyban	PS	Glaxosmithkline	ORAL	7	DAY
	Personality Change		Seretide	C	Glaxosmithkline			
			Salbutamol	C	Glaxosmithkline			
			Prednisolone	C	Glaxosmithkline	ORAL	40MG per day	7 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270534-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0319131A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Malaise		Zyban	PS	Glaxosmithkline	ORAL	21	DAY
	Psoriasis							
	Rash Pruritic							
	Skin Exfoliation							

Date:01/14/04ISR Number: 4270535-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0319266A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Abuser		Zyban	PS	Glaxosmithkline			
			Ritalin	SS				

Date:01/15/04ISR Number: 4271781-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0492250A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150TAB Twice per day	5 DAY
	Convulsion							
	Hypoaesthesia Oral		Nicotine Transdermal Patch	C	Glaxosmithkline			
	Salivary Hypersecretion							
	Tongue Biting		Protonix	C				

Date:01/15/04ISR Number: 4271802-XReport Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0319104A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Bupropion Hydrochloride	PS	Glaxosmithkline			
Disability								
UNKNOWN		4 DAY						
			Ethinylestradiol +					

			Levonorgestrel	C		

Date:01/15/04ISR Number: 4271803-1Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0319175A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vaginal Haemorrhage		Bupropion Hydrochloride	PS	Glaxosmithkline			
			No Concurrent Medication	C				

Date:01/16/04ISR Number: 4273114-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0490813A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Induced	Health	Bupropion	PS	Glaxosmithkline		300MG per day	
	Aorta Hypoplasia	Professional						
	Atrial Septal Defect							
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Drug Exposure During Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/04ISR Number: 4273118-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0492588A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Wellbutrin	PS	Glaxosmithkline			

Date:01/16/04ISR Number: 4273119-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0492602A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bite		Wellbutrin	PS	Glaxosmithkline	ORAL	100TAB Twice	
	Confusional State						per day	10 WK
	Cyanosis		Prozac	C			80MG per day	
	Grand Mal Convulsion							
	Respiratory Arrest							

Date:01/16/04ISR Number: 4273120-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0492882A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product Complaint							

Date:01/16/04ISR Number: 4273121-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0492888A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three	
	Medication Error						times per day	2 WK
	Nausea		Glucophage	C				
	Overdose		Spironolactone	C				

			Zelnorm	C		
			Axid	C		
			Alcon	C		

Date:01/16/04ISR Number: 4273122-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0492909A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:01/16/04ISR Number: 4273123-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0493122A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Concussion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown
Initial or Prolonged	Fall		Clomipramine	C			150MG	At
Other	Grand Mal Convulsion						night	
	Medication Error							
	Skull Fracture							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/04ISR Number: 4273134-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0317539A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agraphia		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	5MG Per day	
	Aphagia							
	Aphasia		Warfarin	C	Glaxosmithkline	ORAL	6MG per day	
	Transient Ischaemic		Perindopril Erbumine	C		ORAL	1U per day	
	Attack		Amiloride / Hydrochlorothiazide	C		ORAL	25MG per day	
			Rofecoxib	C		ORAL	.25MG per day	
			Conjugated Oestrogen	C				
			Arthroguard	C				
			Digoxin	C	Glaxosmithkline	ORAL		

Date:01/19/04ISR Number: 4273494-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0314463A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	13	DAY
	Circulatory Collapse		No Concurrent Medications	C				
	Dizziness							
	Pharyngolaryngeal Pain							
	Pruritus							
	Rash Erythematous							
	Rash Generalised							
	Type I Hypersensitivity							

Date:01/20/04ISR Number: 4274086-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0493247A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	30 DAY

	Facial Bones Fracture						

Date:01/20/04ISR Number: 4274095-2Report Type:Expedited (15-DaCompany Report #TR-GLAXOSMITHKLINE-B0314678A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Genital Lesion		Zyban	PS	Glaxosmithkline	ORAL	27	DAY
Initial or Prolonged	Headache							
	Pruritus							

Date:01/20/04ISR Number: 4274102-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0318367A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Stenosis	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
Hospitalization -	Loss Of Consciousness							
Initial or Prolonged	Myocardial Infarction							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/04ISR Number: 4274104-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0319137A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Overdose Suicidal Ideation		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	17 DAY

Date:01/20/04ISR Number: 4274105-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0319365A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angioneurotic Oedema Paraesthesia Oral Pruritus Generalised		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	17 DAY

Date:01/20/04ISR Number: 4274109-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0319493A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia Balance Disorder Depression Lymphadenopathy Weight Decreased		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	8 WK

Date:01/20/04ISR Number: 4274113-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0319635A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG See	

dosage text

Date:01/21/04ISR Number: 4275504-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441481A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Screen Positive	Health	Wellbutrin	PS	Glaxosmithkline	UNKNOWN	9000MG	Single
	Suicide Attempt	Professional						

dose

Date:01/21/04ISR Number: 4275523-9Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0319066A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Zyban	PS	Glaxosmithkline		9	WK
	Drug Withdrawal Syndrome		Acetylsalicylic Acid	C	Glaxosmithkline	ORAL		
	Headache							
	Nausea							

Date:01/21/04ISR Number: 4275680-4Report Type:Direct Company Report #USP 56267
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxo Smith Kline	TABLET		
			Wellbutrin Sr	SS	Glaxo Smith Kline	TABLET		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/04ISR Number: 4276114-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427536A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Valtrex	PS	Glaxosmithkline	ORAL	500MG Per day	4 WK
	Depression		Wellbutrin	SS	Glaxosmithkline		UNKNOWN	
	Drug Ineffective		Serzone	C				
	Obsessive-Compulsive Disorder							

Date:01/21/04ISR Number: 4277332-3Report Type:Direct Company Report #CTU 210552
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chorea		Levaquin 500mg	PS		ORAL	500MG ONCE DAILY	ORAL
	Dyskinesia		Welbutrin Sr 150mg	SS		ORAL	150MG TWICE DAILY	ORAL
			..	C				
			Nyquil	C				
			Diovan Hct	C				

Date:01/21/04ISR Number: 4277616-9Report Type:Expedited (15-DaCompany Report #2004001589
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia	Health	Zoloft (Sertraline)	PS		ORAL	(DAILY), ORAL	
	Blood Potassium Decreased	Professional	Terbinafine Hydrochloride (Terbinafine Hydrochloride)	SS		ORAL	ORAL	
	Convulsion							
	Diarrhoea							
	Drug Hypersensitivity							
	Feeling Abnormal		Bupropion					

	Tremor		Hydrochloride (Bupropion Hydrochloride)	SS		ORAL
ORAL						
			Paroxetine Hydrochloride (Paroxetine Hydrochloride)	SS		ORAL
ORAL						

Date:01/22/04ISR Number: 4277402-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0438799A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
	Fall	Professional	Mircette	C				
	Grand Mal Convulsion							
	Skin Laceration							

Date:01/22/04ISR Number: 4277407-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0493591A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Convulsion		Trazodone	C				
	Paraesthesia		Plavix	C				
	Paralysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/04ISR Number: 4277409-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0493935A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:01/22/04ISR Number: 4277412-2Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0494028A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Vision Blurred						dosage text	
	Visual Acuity Reduced		Birth Control	C		ORAL		
			Herbal Multivitamin	C				

Date:01/22/04ISR Number: 4277418-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0317324A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Zyban	PS	Glaxosmithkline	ORAL	11	DAY
	Grand Mal Convulsion	Professional	No Concurrent					
	Loss Of Consciousness		Medication	C				
	Tongue Biting							
	Urinary Incontinence							

Date:01/22/04ISR Number: 4277420-1Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0319435A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	1 DAY
Initial or Prolonged	Fall							
	Grand Mal Convulsion							
	Musculoskeletal Stiffness							

	Paralysis

Date:01/22/04ISR Number: 4277424-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0320051A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY

Date:01/22/04ISR Number: 4278579-2Report Type:Expedited (15-DaCompany Report #US012622
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Provigil	PS				
			Wellbutrin	SS				

Date:01/22/04ISR Number: 4278906-6Report Type:Direct Company Report #CTU 210620
Age:45 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Anxiety
	Depression
	Pharmaceutical Product Complaint

	Suicidal Ideation						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin-Xl 300 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	ONE QAM ORAL

Date:01/22/04ISR Number: 4278918-2Report Type:Expedited (15-DaCompany Report #B0318456A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Agitation Choreoathetosis Convulsion Electrocardiogram Qrs Complex Prolonged Overdose Tachycardia Urinary Incontinence	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL

Date:01/23/04ISR Number: 4277908-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0494266A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angioneurotic Oedema		Wellbutrin	PS	Glaxosmithkline		3 YR
	Condition Aggravated		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day
	Gastrooesophageal Reflux Disease		Buspar Seizure Medication	C C			
	Retinal Detachment						

Date:01/23/04ISR Number: 4277909-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0494501A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Medication Error		Wellbutrin	PS	Glaxosmithkline	

Date:01/23/04ISR Number: 4277920-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0319950A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Overdose Paralysis	Health Professional	Wellbutrin Ethanol	PS SS	Glaxosmithkline	ORAL	23G	Unknown UNKNOWN

Date:01/23/04ISR Number: 4277922-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320073A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Grand Mal Convulsion Obstructive Airways Disorder Overdose		Zyban	PS	Glaxosmithkline	ORAL	22.5G	per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/04ISR Number: 4279455-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0412091A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chorioamnionitis	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness	Professional					per day	10 MON
	Drug Exposure During		Prenatal Vitamins	C		ORAL		
	Pregnancy		Folic Acid	C		ORAL		
	Fatigue		Alcohol	C				
	Stillbirth		Juice Plus	C				

Date:01/27/04ISR Number: 4279456-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0412091B
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Wall Anomaly	Health	Wellbutrin	PS	Glaxosmithkline		150MG Twice	
Congenital Anomaly	Arteriopathic Disease	Professional					per day	
	Atrial Septal Defect		Alcohol	C				
	Chorioamnionitis		Folic Acid	C				
	Cleft Palate		Juice Plus	C				
	Drug Exposure During		Prenatal Vitamins	C				
	Pregnancy							
	Ear Malformation							
	Intra-Uterine Death							
	Jaw Fracture							
	Kyphosis							
	Liver Disorder							
	Lymphangiectasia							
	Macrognathia							
	Nose Deformity							
	Pectus Excavatum							
	Placental Disorder							
	Spleen Malformation							
	Thyroid Disorder							
	Traumatic Delivery							

Date:01/27/04ISR Number: 4279467-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0494894A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electrocardiogram Qt Prolonged		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/27/04ISR Number: 4279476-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0318901A
Age:6 MON Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Congenital Anomaly	Health	Zyban	PS	Glaxosmithkline		150MG Twice	
Congenital Anomaly	Drug Exposure During Pregnancy	Professional					per day	1 WK
	Talipes							

Date:01/27/04ISR Number: 4279483-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320169A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	27 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/04ISR Number: 4279490-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0320817A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Hypoaesthesia	Professional					dosage text	1 MON
	Muscular Weakness		Corticoid	SS		ORAL	100MG per day	5 DAY
	Paraesthesia							

Date:01/27/04ISR Number: 4280802-5Report Type:Expedited (15-DaCompany Report #163-20785-03120498(1)
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Distension	Consumer	Thalomid					
	Condition Aggravated	Health	(Thalidomide) (100 Milligram, Capsules)	PS		ORAL	400-800 MG, QD, ORAL;	
	Follicular Thyroid Cancer	Professional					500 MG, DAILY, ORAL;	
	Oedema Peripheral						400 MG,	
	Oropharyngeal Swelling							
	Rash Pruritic							
	Thyroglobulin Increased							
	White Blood Cell Count Decreased		Wellbutrin (Bupropion Hydrochloride)	SS				
			Cozaar (Losartan Potassium)	SS				
			Alprazolam (Alprazolam)	C				
			Nifedipine (Nifedipine)	C				
			Synthroid (Levothyroxine Sodium)	C				
			Calcitrol (Calcitrol)	C				
			Pepcid (Famotidine)	C				

Slo-Mag (Magnesium Chloride Anhydrous)	C
K-Dur (Potassium Chloride)	C
Fluvoxamine (Fluvoxamine)	C
Avalide	C

Date:01/28/04ISR Number: 4280190-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0320004A
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety
	Aptyalism
	Asthenia
	Cytolytic Hepatitis
	Dermatitis Exfoliative
	Hypersensitivity
	Hypotension
	Inflammation
	Insomnia
	Leukopenia
	Lymphadenopathy
	Nausea
	Painful Respiration

	Pruritus					
	Purpura					
	Rash Maculo-Papular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Rash Morbilliform		Zyban	PS	Glaxosmithkline	ORAL
150MG	Unknown 22 DAY					
	Rash Scarlatiniform					
	Thrombocytopenia					
	Tremor					

Date:01/28/04ISR Number: 4280202-8Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0320703A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Convulsion	Foreign	Bupropion	PS	Glaxosmithkline	
150MG per day						
Initial or Prolonged	Muscle Twitching		Tramadol	C		
400MG per day						
	Salivary Hypersecretion		Salbutamol / Ipratropium	C		
			Salmeterol Xinafoate + Fluticasone Propionate	C	Glaxosmithkline	
RESPIRATORY						
(INHALATION)						
			Codeine	C		ORAL
30MG per day						
			Morphine Sulphate	C	Glaxosmithkline	ORAL
20MG per day						

Date:01/28/04ISR Number: 4280209-0Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0042891A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Chest Pain		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day	4 DAY					
Other	Circulatory Collapse		Fluoxetin	C		
UNKNOWN	3 MON					
	Dyspnoea					
	Tachycardia					

Date:01/28/04ISR Number: 4281982-8Report Type:Expedited (15-DaCompany Report #SUS1-2003-00554
Age:51 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health Professional	Carbatrol (Carbamazepine)	Capsule Xr	PS			
			Acetaminophen/Propoxyphene()		SS			
			Bupropion (Bupropion)		SS			

Date:01/29/04ISR Number: 4280888-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0431158A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Joint Dislocation Tongue Biting	Professional	None	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/04ISR Number: 4280889-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439046A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Blindness	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day 2 DAY
Other	Optic Ischaemic	Professional	Norvasc	C			
	Neuropathy		Xanax	C			
	Visual Field Defect		Zocor	C			
			Remeron	C			

Date:01/29/04ISR Number: 4280892-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0494241A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day
	Pharmaceutical Product Complaint						

Date:01/29/04ISR Number: 4280914-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0319950A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Alcohol Interaction	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	23G Unknown
	Overdose		Ethanol	SS			UNKNOWN
	Status Epilepticus						

Date:01/30/04ISR Number: 4282065-3Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12130480
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Alopecia		Trazodone Hcl	PS	Apothecon		
			Wellbutrin	SS		ORAL	

Date:01/30/04ISR Number: 4282078-1Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12199782
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Supraventricular Tachycardia		Trazodone Hcl Tabs Wellbutrin Sr	PS SS	Apothecon	ORAL ORAL	DOSE-200-300m g/day	VARIABLE

Date:01/30/04ISR Number: 4282181-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0139855A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Brain Damage Cardiac Arrest Drowning Dysarthria Grand Mal Convulsion Memory Impairment Motor Dysfunction		Wellbutrin Sr Buspar Sedative(Unknown)	PS C C	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/04ISR Number: 4282202-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495331A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Muscle Contractions						per day	
	Involuntary		Paxil	C	Glaxosmithkline			
	Partial Seizures		Ativan	C				
	Tremor		Zyrtec	C	Glaxosmithkline			

Date:01/30/04ISR Number: 4282220-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320766A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	13 DAY	
			Ramipril	C			UNKNOWN	
			Aspirin	C	Glaxosmithkline		UNKNOWN	
			Diltiazem Hydrochloride	C	Glaxosmithkline		UNKNOWN	
			Atorvastatin	C			UNKNOWN	
			Elantan La	C			UNKNOWN	50MG Per day

Date:01/30/04ISR Number: 4282864-8Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12333696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test Abnormal		Serzone Tabs	PS	Bristol-Myers Squibb Company	ORAL	prescribed	
			Effexor	SS				

for "one

week"

			Wellbutrin	SS		

prescribed

for the

"second week"

Date:01/30/04ISR Number: 4283380-XReport Type:Direct Company Report #USP 56276
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	
			Wellbutrin Sr	SS	Glaxosmithkline	
TABLET						

Date:01/30/04ISR Number: 4284481-2Report Type:Direct Company Report #CTU 211209
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Asthenia		Wellbutrin Sr 200 Mg	PS		ORAL
200 MG PO BID						
	Chills		Omeprazole	C		
	Dizziness		Hctz	C		
	Muscle Spasms					
	Tremor					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/04ISR Number: 4283565-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441482A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	5 WK

Date:02/02/04ISR Number: 4283567-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495325A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:02/02/04ISR Number: 4283572-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495942A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/02/04ISR Number: 4283586-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320504A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Zyban	PS	Glaxosmithkline	ORAL	2TABS Per day	7 DAY
	Burning Sensation							
	Eye Swelling							
	Local Swelling							
	Oedema Peripheral							
	Psoriasis							
	Rash							
	Rash Macular							
	Swelling Face							
	Thrombosis							
	Tremor							

Date:02/02/04ISR Number: 4283594-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320609A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Astrocytoma		Zyban	PS	Glaxosmithkline	ORAL	28	DAY
			Fluoxetine Hydrochloride	C			UNKNOWN	

Date:02/02/04ISR Number: 4283595-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320767A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Consumer	Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	18	DAY
	Drug Interaction		Co-Codamol	SS			UNKNOWN	
			Chlorpheniramine Maleate	C	Glaxosmithkline		UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/04ISR Number: 4283596-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320770A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			Dovonex	C			UNKNOWN	
			Bendrofluazide	C	Glaxosmithkline		UNKNOWN	
			Canesten	C	Glaxosmithkline		UNKNOWN	
			Beclomethasone Dipropionate	C	Glaxosmithkline		UNKNOWN	1PUFF Twice per day
			Aqueous Cream Bp	C			UNKNOWN	

Date:02/02/04ISR Number: 4283599-8Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043010A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Use	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Five times per day	
	Suicide Attempt	Professional						
			Alcohol	SS		ORAL		

Date:02/02/04ISR Number: 4285172-4Report Type:Expedited (15-DaCompany Report #2004196093US
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia	Consumer	Nicotrol (Nicotine) Inhaler	PS		BUCCAL	BUCCAL	
	Amnesia							
	Brain Damage		Wellbutrin					

	Concussion		(Amfebutamone			
	Convulsion		Hydrochloride)	SS		ORAL
ORAL						
	Fall					
	Head Injury					
	Loss Of Consciousness					
	Lumbar Vertebral Fracture					

Date:02/03/04ISR Number: 4284134-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495505A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Medication Error		Wellbutrin	PS	Glaxosmithkline	
			Wellbutrin	SS	Glaxosmithkline	

Date:02/03/04ISR Number: 4284135-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495535A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 2 MON						
			Wellbutrin	SS	Glaxosmithkline	

Date:02/03/04ISR Number: 4284157-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320606A
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Sudden Death		Zyban	PS	Glaxosmithkline	ORAL
28 DAY						
Hospitalization -			Aspirin	C	Glaxosmithkline	
UNKNOWN						
Initial or Prolonged			Glyceryl Trinitrate	C	Glaxosmithkline	
UNKNOWN						

			Coracten	C	Glaxosmithkline		
UNKNOWN							
			Co-Tenidone	C			
UNKNOWN							

Date:02/03/04ISR Number: 4284856-1Report Type:Direct Company Report #CTU 211394
Age:12 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Palpitations Sinus Tachycardia		Wellbutrin	PS				

Date:02/03/04ISR Number: 4284891-3Report Type:Direct Company Report #CTU 211442
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS			2	WK

Date:02/03/04ISR Number: 4284896-2Report Type:Direct Company Report #CTU 211457
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dysphemia		Bupropion Sr 150 Glaxo/Smith-Kline	PS	Glaxo/Smith-Kline	ORAL ORAL	150 MG BID	

Date:02/04/04ISR Number: 4285104-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495750A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Renal Failure Acute		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice per day						
			Lexapro	C		
			Avapro	C		
			Coumadin	C	Glaxosmithkline	
			Amiodarone	C		
			Lipitor	C		
			Saw Palmetto	C		
			Multivitamin	C		
			Tricor	C		
			Viagra	C		

Date:02/04/04ISR Number: 4285106-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495985A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
	Drug Exposure During Pregnancy					
	Dyspepsia					
	Headache					
	Loss Of Consciousness					
	Neck Pain					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/04ISR Number: 4285108-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0496012A
Age:1 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Accidental Overdose Agitation Grand Mal Convulsion Metabolic Acidosis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:02/04/04ISR Number: 4285113-XReport Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0319175A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vaginal Haemorrhage	Health Professional	Bupropion Hydrochloride Hormone Replacement Therapy	PS C	Glaxosmithkline			YR

Date:02/04/04ISR Number: 4285127-XReport Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0042959A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper Anaemia Fat Intolerance Gamma-Glutamyltransferase Increased Lipase Increased		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:02/05/04ISR Number: 4285907-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439007A
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Balance Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL
1TAB Twice per day 1 MON	Chills					
Other	Depression		Flomax	C		
	Erectile Dysfunction		Cozaar	C		
	Insomnia		Indapamide	C		
	Myalgia		Duragesic	C		
	Myoclonus					
	Tremor					
	Vestibular Disorder					

Date:02/05/04ISR Number: 4285915-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0307572A
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dysarthria	Health	Zyban	PS	Glaxosmithkline	ORAL
150MG Per day 3 WK						
	Dysgraphia	Professional	Chondrosulf	C		
	Metastases To Central					
	Nervous System					
	Speech Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/04ISR Number: 4285916-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0318010A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice per day	5 DAY
Other	Agitation							
	Blood Pressure Increased							
	Depression							
	Dizziness							
	Feeling Abnormal							
	Headache							

Date:02/05/04ISR Number: 4285926-4Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0321039A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chromatopsia		Zyntabac	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY
	Constipation							
	Dysgeusia							
	Neuralgia							
	Thirst							
	Vertigo							
	Visual Disturbance							

Date:02/05/04ISR Number: 4285930-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0321213A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	2 DAY
	Dry Mouth							
	Headache							
	Intentional Misuse							
	Overdose							
	Palpitations							
	Vertigo							

Date:02/05/04ISR Number: 4286479-7Report Type:Direct Company Report #CTU 211616
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharmaceutical Product		Vicodin 10 Mg	PS				
	Complaint		Wellbutrin	SS				
			Ativan 2mg	SS				

Date:02/06/04ISR Number: 4286730-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495765A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL	5	DAY
			Klonopin	C				
			Unknown Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/06/04ISR Number: 4286731-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495776A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	1	DAY

Date:02/06/04ISR Number: 4286740-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0319984A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Zyban	PS	Glaxosmithkline			
	Anorexia							
	Balance Disorder							
	Constipation							
	Deafness							
	Disturbance In Attention							
	Dysgeusia							
	Ear Discomfort							
	Ear Disorder							
	Feeling Abnormal							
	Nausea							
	Sleep Disorder							
	Tinnitus							

Date:02/06/04ISR Number: 4286745-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0321121A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	1TAB Twice per day	13 DAY
			Ramipril	C			UNKNOWN	
			Aspirin	C	Glaxosmithkline		UNKNOWN	
			Diltiazem					

			Hydrochloride	C	Glaxosmithkline	
UNKNOWN						
			Atorvastatin	C		
UNKNOWN						
			Elantan La	C		
UNKNOWN						

Date:02/06/04ISR Number: 4286746-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0321125A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hallucination, Visual		Zyban	PS	Glaxosmithkline	ORAL
150MG See						
	Muscle Spasms					
dosage text 5 DAY						
			Nicotinell	C	Glaxosmithkline	
TRANSDERMAL						

Date:02/06/04ISR Number: 4286747-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0321126A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Neutropenia		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
per day 69 DAY						
			Co-Proxamol	C		
UNKNOWN						
			Ciprofloxacin	C		
UNKNOWN						
			Amoxycillin	C	Glaxosmithkline	
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/06/04ISR Number: 4286748-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0321129A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Haemorrhage		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Amoxycillin	C	Glaxosmithkline		UNKNOWN	

Date:02/06/04ISR Number: 4290056-1Report Type:Direct Company Report #CTU 211692
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour		Wellbutrin 100 Mg Sr					
	Completed Suicide		Glaxowellcome	PS	Glaxowellcome	ORAL	100 MG SR DAY	
	Confusional State						ORAL	
	Depression		Remeron	C				
	Impaired Driving Ability							
	Irritability							
	Medication Error							
	Social Avoidant Behaviour							

Date:02/06/04ISR Number: 4290313-9Report Type:Direct Company Report #CTU 211702
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity		Wellbutrin Sr 150 Mg	PS		ORAL	ONE DAY ORAL	

Date:02/09/04ISR Number: 4287490-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0416017A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

		Anxiety		Paxil Cr	PS	Glaxosmithkline	
12.5MG Per							
		Tension					
day	6 DAY						
				Wellbutrin Sr	SS	Glaxosmithkline	

Date:02/09/04ISR Number: 4287664-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423063A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness		Paxil Cr	PS	Glaxosmithkline	
	Nausea		Wellbutrin	SS	Glaxosmithkline	
	Sexual Dysfunction					

Date:02/09/04ISR Number: 4287876-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430895A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anorexia		Paxil	PS	Glaxosmithkline	ORAL
12.5MG Per						
	Diarrhoea					
day 6 DAY						
	Dyskinesia		Wellbutrin	SS	Glaxosmithkline	ORAL
150MG Per day 4 WK						
	Euphoric Mood		Ambien	C		
	Libido Decreased					
	Panic Attack					
	Weight Decreased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/04ISR Number: 4287900-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431593A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Paxil	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		
			Paxil	C	Glaxosmithkline	ORAL		

Date:02/09/04ISR Number: 4288013-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439982A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome	Consumer	Paxil	PS	Glaxosmithkline	ORAL	31	WK
	Emotional Disorder		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Mood Swings		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice	
	Weight Increased						per day	100 WK
			Prenatal Vitamins	C				
			Aloe Vera	C				

Date:02/09/04ISR Number: 4288074-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441759A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Paxil	PS	Glaxosmithkline	ORAL	25MG Per day	
			Wellbutrin	SS	Glaxosmithkline			

Date:02/09/04ISR Number: 4288165-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424006A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Disorder		Paxil	PS	Glaxosmithkline	ORAL	6	WK

	Condition Aggravated		Wellbutrin	SS	Glaxosmithkline	ORAL
75MG Per day						
	Dizziness					
	Drug Ineffective					

Date:02/09/04ISR Number: 4288169-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424111A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Libido Decreased		Paxil	PS	Glaxosmithkline	ORAL
20MG Per day 1 YR						
	Urticaria		Wellbutrin	SS	Glaxosmithkline	ORAL

Date:02/09/04ISR Number: 4288209-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424887A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Paxil	PS	Glaxosmithkline	ORAL
40MG Per day 6 YR						
Initial or Prolonged	Crying		Wellbutrin	SS	Glaxosmithkline	ORAL
	Depression		Methadone	C	Glaxosmithkline	ORAL
10MG Three						
	Drug Ineffective					
times per day						
	Drug Withdrawal Syndrome		Vicodin	C		ORAL
	Gastric Disorder		Premarin	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/04ISR Number: 4288424-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428277A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	3 YR
	Anxiety		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Crying							
	Drug Withdrawal Syndrome		Clonazepam	C				
	Libido Decreased							
	Sexual Dysfunction							

Date:02/09/04ISR Number: 4288598-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495970A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Rectal Haemorrhage							

Date:02/09/04ISR Number: 4288600-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0496061A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hallucination							
	Overdose							

Date:02/09/04ISR Number: 4288604-0Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0312102A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health	Zyban	PS	Glaxosmithkline	ORAL	22 DAY	
	Body Temperature	Professional	Methylprednisolone	C			1TAB Single	

		Increased					
dose							
		Drug Hypersensitivity					
		Eyelid Oedema					
		Face Oedema					
		Hypersensitivity					
		Inflammation					
		Myalgia					
		Oedema Peripheral					
		Rash Maculo-Papular					
		Rash Pruritic					
		Urticaria					

Date:02/09/04ISR Number: 4288607-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0317612A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Zyban	PS	Glaxosmithkline		150MG Twice	
	Anaphylactic Reaction						per day	
	Dry Mouth		Cipramil	C				
	Headache		Microgynon	C				
	Night Sweats							
	Restless Legs Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/04ISR Number: 4288610-6Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0319175A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vaginal Haemorrhage	Health Professional	Bupropion Hydrochloride	PS	Glaxosmithkline			
			No Concurrent Medication	C				

Date:02/09/04ISR Number: 4288621-0Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0321501A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Parkinsonism	Health Professional	Zyntabac	PS	Glaxosmithkline			

Date:02/10/04ISR Number: 4289751-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442807A
Age:9 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Level Of		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Consciousness		Metadate Cd	C		ORAL	20MG per day	
	Grand Mal Convulsion							

Date:02/10/04ISR Number: 4289769-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0496663A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Intentional Misuse		Wellbutrin	SS	Glaxosmithkline			

Date:02/10/04ISR Number: 4289778-8Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0319051A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	150MG	
Hospitalization -	Epilepsy							
Variable dose							12	DAY
Initial or Prolonged	Muscle Contractions		Tramadol	C		ORAL	200MG Twice	
	Involuntary						per day	
	Paralysis		Painkiller	C				
	Salivary Hypersecretion							

Date:02/10/04ISR Number: 4294044-0Report Type:Expedited (15-DaCompany Report #2002IC000296
Age:30 YR Gender:Male I/FU:I

Outcome	PT
Death	Body Temperature
Hospitalization -	Increased
Initial or Prolonged	Completed Suicide
	Convulsion
	Disseminated
	Intravascular Coagulation
	Drug Interaction
	Hepatic Failure
	Multiple Drug Overdose
	Nystagmus
	Posturing

	Pupil Fixed Renal Failure Rhabdomyolysis	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Suicide Attempt	Literature	Librium	PS		ORAL ORAL
	Tachycardia	Health Professional	Regular Strength Tylenol	SS		ORAL ORAL
			Extra Strength Tylenol Pm	SS		ORAL ORAL
			Effexor	SS		ORAL ORAL
			Wellbutrin Sr	SS		ORAL ORAL
			Ambien	SS		ORAL ORAL
			Skelaxin	SS		ORAL ORAL
			Midol	SS		ORAL ORAL
			Pyridium	SS		ORAL ORAL
			Aleve	SS		ORAL ORAL
			Relafen	SS		ORAL ORAL

Date:02/11/04ISR Number: 4290995-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431566A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Drug Ineffective		Paxil	PS	Glaxosmithkline	ORAL
	Sexual Dysfunction		Wellbutrin	SS	Glaxosmithkline	ORAL

Date:02/11/04ISR Number: 4291306-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442159A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration

	Headache		Paxil	PS	Glaxosmithkline	ORAL
10MG Per day 1 MON						
	Hyperhidrosis		Wellbutrin	SS	Glaxosmithkline	ORAL
			Narcotic	C		

Date:02/11/04ISR Number: 4291321-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442597A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Personality Change		Paxil	PS	Glaxosmithkline	ORAL
			Wellbutrin	SS	Glaxosmithkline	ORAL
			Nytol	SS	Glaxosmithkline	
UNKNOWN						

Date:02/11/04ISR Number: 4291322-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442624A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Libido Decreased		Paxil	PS	Glaxosmithkline	ORAL
20MG Per day						
	Myalgia		Wellbutrin	SS	Glaxosmithkline	ORAL
150MG Twice						
per day						
			Lipitor	SS		

Date:02/11/04ISR Number: 4292238-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442630A
Age:18 YR Gender:Male I/FU:F

Outcome	PT
	Drug Ineffective
	Medication Error
	Pharmaceutical Product

Complaint

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day	6	DAY					
			Professional	Wellbutrin	SS	Glaxosmithkline	ORAL
150MG Twice							
per day	1	WK					

Date:02/11/04ISR Number: 4292243-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0496778A
Age: YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
	Medication Error		Unspecified Medications	C		

Date:02/11/04ISR Number: 4292256-3Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0321644A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris		Zyban	PS	Glaxosmithkline	
UNKNOWN	16 DAY					
Initial or Prolonged	Breast Disorder					
	Dyspnoea					
	Muscle Spasms					
	Urticaria					

Date:02/11/04ISR Number: 4292540-3Report Type:Direct Company Report #CTU 212065
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Required	Abnormal Behaviour		Wellbutrin	PS		
Intervention to	Aggression					
Prevent Permanent	Anxiety					
Impairment/Damage	Crying					

Fatigue
Fear
Murder
Panic Attack
Paranoia
Psychotic Disorder

Date:02/11/04ISR Number: 4294327-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420816A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis		Lamictal	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL	1TAB Twice per day	
			Lexapro	C				

Date:02/12/04ISR Number: 4293009-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420604A
Age: Gender:Female I/FU:I

Outcome PT
Drug Interaction
Migraine
Nausea

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Paxil	PS	Glaxosmithkline	ORAL	20MG Per day 2 YR
			Wellbutrin	SS	Glaxosmithkline	ORAL	100MG Per day 2 YR

Date:02/12/04ISR Number: 4293153-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412455A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Weight Increased		Paxil	PS	Glaxosmithkline	ORAL	
			Wellbutrin	SS	Glaxosmithkline		
			Lamictal	C	Glaxosmithkline		
			Lexapro	C			

Date:02/12/04ISR Number: 4293717-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0496783A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Depressed Level Of		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day
	Consciousness		Depakote	C			
	Grand Mal Convulsion		Oxycontin	C			
	Incontinence						
	Tongue Biting						

Date:02/12/04ISR Number: 4293724-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0099526A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Astrocytoma		Zyban	PS	Glaxosmithkline	ORAL	29 DAY
Hospitalization - Initial or Prolonged	Body Temperature Increased		Prozac	C			
	Coma						

Dysphagia
Eating Disorder
Incontinence
Infection
Memory Impairment
Sleep Disorder
Vomiting

Date:02/12/04ISR Number: 4293743-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320609A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Astrocytoma	Consumer	Zyban	PS	Glaxosmithkline	ORAL	28	DAY
			Fluoxetine Hydrochloride	C			UNKNOWN	

Date:02/12/04ISR Number: 4293746-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0321954A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine Phosphokinase Increased		Zyban	PS	Glaxosmithkline	ORAL	150MG	
	Muscle Spasms						Variable dose	12 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/12/04ISR Number: 4293747-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0321971A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Alcohol Use						per day	
	Intentional Self-Injury		Ethanol	SS			UNKNOWN	
			Beclomethasone Dipropionate	C	Glaxosmithkline		UNKNOWN	
			Salbutamol	C	Glaxosmithkline		UNKNOWN	
			Erythromycin	C	Glaxosmithkline		UNKNOWN	5ML Four times per day

Date:02/12/04ISR Number: 4293754-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0322806A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	15 DAY

Date:02/12/04ISR Number: 4295020-4Report Type:Direct Company Report #CTU 212221
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction		Zyban 150 Mg	PS		ORAL	PO BID	

Date:02/12/04ISR Number: 4295089-7Report Type:Expedited (15-DaCompany Report #S04-USA-00336-01
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional	Lexapro(Escitalopram)	PS				
			Wellbutrin (Bupropion Hydrochloride)	SS				
			Lipitor (Atorvastatin)	C				
			Avapro (Irbesartan)	C				
			Tricor (Fenofibrate)	C				
			Amiodarone	C				
			Androderm	C				
			Viagra (Sildenafil Citrate)	C				
			Multivitamin	C				
			Saw Pallmetto	C				

Date:02/13/04ISR Number: 4294650-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0431173A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin	PS	Glaxosmithkline			1 WK
	Dizziness		Prozac	C				
	Road Traffic Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/04ISR Number: 4294654-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441481A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Screen Positive	Health	Wellbutrin	PS	Glaxosmithkline	UNKNOWN	9000MG	Single
Hospitalization -	Intentional Misuse	Professional						
dose								
Initial or Prolonged	Suicide Attempt							
Other								

Date:02/13/04ISR Number: 4294666-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0321957A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Panic Attack							
per day	5	DAY						
	Swollen Tongue		Zoladex	C				
UNKNOWN								

Date:02/13/04ISR Number: 4294674-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0322531A
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	14	DAY
	Dry Mouth		Methyldopa	C				
UNKNOWN								
	Insomnia		Gliclazide	C				
UNKNOWN								
	Loss Of Consciousness							

Date:02/13/04ISR Number: 4294675-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0322550A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fall		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 3 DAY
	Loss Of Consciousness							

Date:02/13/04ISR Number: 4297197-3Report Type:Expedited (15-DaCompany Report #2004006886
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Agitation	Health	Geodon (Ziprasidone)	PS		ORAL	ORAL	
Hospitalization - Initial or Prolonged	Aspiration	Professional	Bupropion Hydrochloride					
Other	Cardiac Arrest	Company	(Bupropion Hydrochloride)	SS				
	Cardiac Disorder	Representative	All Other Therapeutic Products	SS				
	Intentional Misuse		Ethanol (Ethanol)	SS				
	Loss Of Consciousness							
	Multiple Drug Overdose							
	Suicide Attempt							
	Tachycardia							

Date:02/13/04ISR Number: 4342622-2Report Type:Periodic Company Report #352771
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Alopecia	Consumer	Pegasys (Peg-Interferon Alfa-2a) 180 Mcg/Ml	PS		OTHER	180 MCG	OTHER
	Anaemia Haemolytic							
	Autoimmune							
			Copegus (Ribavirin) 90 Mg/Ml	SS		ORAL	1000 MG	DAILY
							ORAL	

			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	1 DOSE FORM DAILY ORAL

Date:02/16/04ISR Number: 4294947-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0399865A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Lamictal	PS	Glaxosmithkline	ORAL	37.5MG Per day	55 DAY
			Wellbutrin	SS	Glaxosmithkline	ORAL		
			Allegra	C				

Date:02/16/04ISR Number: 4295075-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441718A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Spontaneous	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
Other	Drug Exposure During Pregnancy	Professional						
	Pregnancy							

Date:02/16/04ISR Number: 4295094-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0316252A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Poisoning	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL		
	Coma		Ethanol	SS		ORAL		
	Completed Suicide		Fluoxetine	C		ORAL		
	Depressed Level Of		Flurazepam	C		ORAL		

	Consciousness		Lorazepam	C	
UNKNOWN					
	Drug Toxicity		Ibuprofen	C	Glaxosmithkline
UNKNOWN					
	Overdose		Albuterol	C	Glaxosmithkline
RESPIRATORY					
	Pulmonary Congestion				
(INHALATION)					
	Pulmonary Oedema				

Date:02/16/04ISR Number: 4295107-6Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043117A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Triglycerides		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Increased Gamma-Glutamyltransferase							
	Increased Hepatic Function Abnormal							

Date:02/16/04ISR Number: 4295340-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413091A
Age:28 YR Gender:Female I/FU:F

Outcome	PT
	Chills
	Deja Vu
	Hallucination
	Hypokinesia
	Pollakiuria

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stereotypy							
			Lamictal	PS	Glaxosmithkline	ORAL	600MG	Unknown 1 YR
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG	Unknown 1 YR
			Prozac	C			UNKNOWN	90MG Weekly
			Inderal La	C			UNKNOWN	60MG Unknown
			Lo/Ovral 28	C				

Date:02/16/04ISR Number: 4295677-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420604A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	2 YR
	Migraine		Wellbutrin	SS	Glaxosmithkline	ORAL	100MG Per day	2 YR
	Nausea							
	Vomiting							

Date:02/16/04ISR Number: 4295697-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0491314A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Disorientation		Wellbutrin	SS	Glaxosmithkline	ORAL	75MG See dosage text	1 MON
	Feeling Abnormal							
	Headache		Paxil	SS	Glaxosmithkline			
	Insomnia		Compazine	C	Glaxosmithkline			
	Libido Decreased		Lorazepam	C				
	Medication Error							
	Mood Altered							
	Muscle Tightness							

	Obsessive-Compulsive Disorder					
	Salivary Hypersecretion					
	Tongue Disorder					
	Visual Acuity Reduced					
	Weight Increased					

Date:02/16/04ISR Number: 4295700-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0497973A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Thorazine	PS	Glaxosmithkline			
	Coma		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:02/16/04ISR Number: 4295913-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442083A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychotic Disorder		Lamictal	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		
			Lithium	SS	Glaxosmithkline		UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/04ISR Number: 4296165-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424884A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Lamictal	PS	Glaxosmithkline	ORAL	500MG Per day	
	Anxiety		Wellbutrin	SS	Glaxosmithkline	ORAL	2	MON
	Delirium		Lamictal	SS	Glaxosmithkline	ORAL	500MG Unknown	
	Depression		Neurontin	C				
	Irritability		Effexor	C				
	Libido Increased		Xanax	C				
	Sensory Disturbance							

Date:02/17/04ISR Number: 4296262-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428105A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oropharyngeal Swelling		Lamictal	PS	Glaxosmithkline	ORAL		
	Throat Tightness		Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:02/17/04ISR Number: 4296284-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429256A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Lamictal	PS	Glaxosmithkline	ORAL	8	MON
	Anxiety		Wellbutrin	SS	Glaxosmithkline	ORAL	5	WK
	Blood Pressure Decreased		Zoloft	C			25MG Per day	
	Bradycardia		Ativan	C			1MG Per day	
	Food Intolerance							
	Hypertension							
	Irritable Bowel Syndrome							
	Labile Blood Pressure							
	Nervousness							
	Rash							

	Vertigo					
	Weight Decreased					

Date:02/17/04ISR Number: 4296311-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430279A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Lamictal	PS	Glaxosmithkline			
			Wellbutrin	SS	Glaxosmithkline			
			Topomax	C				

Date:02/17/04ISR Number: 4296568-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441124A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON

Date:02/17/04ISR Number: 4296584-7Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0319062A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	8 DAY
	Psoriasis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/04ISR Number: 4296586-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320504A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blister Burning Sensation Eye Swelling Local Swelling Oedema Peripheral Psoriasis Rash Rash Macular Swelling Face Thrombosis Toxic Skin Eruption Tremor		Zyban	PS	Glaxosmithkline	ORAL	2TABS Per day	7 DAY

Date:02/17/04ISR Number: 4299207-6Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040201456
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs	Health Professional	Topiramate (Topiramate) Tablets	PS		TRANSPLACENTAL	TRANSPLACENTAL	
	Congenital Anomaly Maternal Drugs Affecting Foetus		Wellbutrin (Bupropion Hydrochloride) S	SS		TRANSPLACENTAL	TRANSLACENTAL	
	Pregnancy Premature Baby Talipes		Prenatal Vitamin (Prenatal Vitamins) Tylenol (Paracetamol)	C C				

Date:02/17/04ISR Number: 4299266-0Report Type:Expedited (15-DaCompany Report #2004006886
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Agitation	Health	Geodon (Ziprasidone)	PS		ORAL
ORAL						
Hospitalization -	Aspiration	Professional	Bupropion			
Initial or Prolonged	Cardiac Arrest	Company	Hydrochiloride			
Other	Cardiac Disorder	Representative	(Bupropion			
	Intentional Misuse		Hydrochloride)	SS		
	Loss Of Consciousness		All Other			
	Suicide Attempt		Therapeutic Products	SS		
	Tachycardia		Ethanol (Ethanol)	SS		

Date:02/18/04ISR Number: 4297488-6Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0321846A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain	Consumer	Zyntabac	PS	Glaxosmithkline	ORAL
Initial or Prolonged	Face Oedema		No Concurrent			
	Muscle Spasms		Medication	C		
	Oedema Peripheral					
	Pruritus Generalised					
	Rash					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/04ISR Number: 4299901-7Report Type:Expedited (15-DaCompany Report #B0307360A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Brain Stem Infarction Eyelid Ptosis Headache Hiccups Hypoaesthesia Photosensitivity Reaction Pupils Unequal Sensory Disturbance Vomiting Wallenberg Syndrome White Blood Cell Count Increased	Foreign Literature Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER DAY/ ORAL	

Date:02/18/04ISR Number: 4300222-4Report Type:Direct Company Report #CTU 212559
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Headache Pruritus		Buproprion	PS		ORAL	150 MG PO BID	

Date:02/18/04ISR Number: 4300397-7Report Type:Direct Company Report #CTU 212512
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Bupropion Hci Er (Generic Wellbutrin Sr) Mfr -Eon Labs	PS	Eon Labs			

Date:02/18/04ISR Number: 4300725-2Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040202419
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction	Consumer	Topamax (Topiramate) Tablets	PS		ORAL	50 MG, 2 IN 1	DAY, ORAL
			Wellbutrin (Bupropion Hydrochloride)	SS				
			Unspecified					
			Flomax (Tamsulosin Hydrochloride)	C				
			Celexa (Citalopram Hydrobromide)	C				
			Amantadine (Amantadine)	C				
			Protonix (Pantoprazole)	C				
			Lipztor (Atorvastatin)	C				
			Atenolol (Atenolol)	C				
			Lisinopril (Lisinopril)	C				
			Imdur (Isosorbide					

			Mononitrate)	C		
			Ultracet (Tramadol/Apap)	C		
			Celebrex (Celecoxib)	C		
			Nitroquik (Glyceryl Trinitrate)	C		

Date:02/19/04ISR Number: 4299463-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439627A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error	Health	Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product	Professional	Wellbutrin	SS	Glaxosmithkline	ORAL	450MG Per day	5 WK
	Complaint		Thyroid	C				
			Provigil	C				

Date:02/19/04ISR Number: 4299469-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0498181A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Spontaneous		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG See dosage text	
	Drug Exposure During Pregnancy		Paxil Cr	SS	Glaxosmithkline	ORAL	37.5MG See dosage text	
	Overdose							
	Suicide Attempt		Geodon	C				
			Neurontin	C				
			Folate	C				

Date:02/19/04ISR Number: 4299477-4Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0321644A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Zyban	PS	Glaxosmithkline	ORAL	15MG Per day	16 DAY

Initial or Prolonged	Breast Disorder	Professional					
	Breast Pain						
	Bronchospasm						
	Burning Sensation						
	Dyspepsia						
	Dyspnoea						
	Mucous Membrane Disorder						
	Muscle Spasms						
	Oral Soft Tissue Disorder						
	Urticaria						

Date:02/19/04ISR Number: 4299481-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0322716A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Anxiety						dosage text	14 DAY
	Depression		Singulair	C		ORAL	10MG per day	
	Panic Attack		Tranexamic Acid	C		ORAL	500MG per day	4 DAY
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/19/04ISR Number: 4299482-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0322717A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Skin Reaction		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	7 DAY
			Miconazole	C		TOPICAL		
			Timodine	C		TOPICAL		

Date:02/19/04ISR Number: 4299490-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0323573A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/19/04ISR Number: 4299491-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0323706A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	9 DAY
	Chest Pain							
	Electrocardiogram St Segment Elevation							
	Lung Infiltration							
	Pericarditis							
	Pharynx Discomfort							

Date:02/19/04ISR Number: 4301504-2Report Type:Expedited (15-DaCompany Report #S03-USA-02425-01
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Coma Grand Mal Convulsion	Health Professional	Lexapro (Escitalopram)	PS	ORAL 10 MG QAM PO
	Libido Decreased Tendon Injury	Company Representative	Wellbutrin - Slow Release (Bupropion Hydrochloride)	SS	150 MG BID
			Wellbutrin (Bupropion Hydrochloride)	SS	100 MG QD
			Dilantin (Phenytoin Sodium)	C	
			Keppra (Levetiracetam)	C	

Date:02/20/04ISR Number: 4300366-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0498768A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	15 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/04ISR Number: 4300368-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0498848A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:02/20/04ISR Number: 4300381-3Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0322567A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Consumer	Zyntabac	PS	Glaxosmithkline	ORAL		
	Alcohol Interaction		Alcohol	SS				
	Disorientation							

Date:02/20/04ISR Number: 4300383-7Report Type:Expedited (15-DaCompany Report #IE-GLAXOSMITHKLINE-B0322640A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Zyban	PS	Glaxosmithkline		300MG per day	2 WK
	Granulocytopenia		No Concurrent					
	Syncope		Medication	C				

Date:02/20/04ISR Number: 4300384-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0322714A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Skin Lesion		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Lansoprazole	C		ORAL	15MG per day	
			Tranexamic Acid	C		ORAL	1.5G Per day	
			Norethisterone	C		ORAL	5MG Per day	

Date:02/23/04ISR Number: 4301837-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443651A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Muscle Twitching						per day	YR
	Pharmaceutical Product		Vitamins	C				
	Complaint		Calcium	C				
			Advil	C	Glaxosmithkline			

Date:02/23/04ISR Number: 4301839-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495505A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
			Wellbutrin	SS	Glaxosmithkline			

Date:02/23/04ISR Number: 4301842-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499051A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Bupropion	PS	Glaxosmithkline		150MG Per day	
	Drug Exposure Via Breast Milk							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/04ISR Number: 4301849-6Report Type:Expedited (15-DaCompany Report #TR-GLAXOSMITHKLINE-B0314678A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Genital Lesion		Zyban	PS	Glaxosmithkline	ORAL	27	DAY
Initial or Prolonged	Headache							
	Pruritus							

Date:02/23/04ISR Number: 4301851-4Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0320703A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Bupropion					
Initial or Prolonged	Convulsion		Hydrochloride	PS	Glaxosmithkline		150MG per day	
	Muscle Twitching		Tramadol	C			400MG per day	
	Salivary Hypersecretion		Salbutamol / Ipratropium	C				
			Salmeterol Xinafoate + Fluticasone Propionate	C	Glaxosmithkline		RESPIRATORY (INHALATION)	
			Codeine	C		ORAL	30MG per day	
			Morphine Sulphate	C	Glaxosmithkline	ORAL	20MG per day	

Date:02/23/04ISR Number: 4301857-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0322707A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	20 DAY
Other	Rash		Serevent	C	Glaxosmithkline		UNKNOWN	

	Toxic Skin Eruption		Salbutamol	C	Glaxosmithkline	
UNKNOWN						
			Becotide	C	Glaxosmithkline	
UNKNOWN						

Date:02/23/04ISR Number: 4301859-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0323130A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abnormal Behaviour		Zyban	PS	Glaxosmithkline	
150MG Twice						
	Aggression					
per day						
	Amnesia		No Concurrent Medication	C		

Date:02/23/04ISR Number: 4301861-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0323980A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Confusional State		Zyban	PS	Glaxosmithkline	ORAL
150MG Unknown						
	Malaise		Neuroleptic	C		
	Sudden Death					
	Tremor					

Date:02/23/04ISR Number: 4303165-5Report Type:Expedited (15-DaCompany Report #USA-2002-0002070
Age:33 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged
Other

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anoxic Encephalopathy	Consumer	Oxycontin Tablets					
	Apallic Syndrome	Health	(Oxycodone					
	Circulatory Collapse	Professional	Hydrochloride) Cr					
	Depression	Other	Tablet	PS			MG	
	Drug Abuser		Trazadone(Trazadone)					
	Drug Dependence		Unknown	SS			MG	
	Loss Of Consciousness		Propoxyphene(Dextrop					
	Medication Error		ropoxyphene)Unknown	SS			MG	
	Multi-Organ Failure		Acetaminophen(Parace					
	Overdose		tamol)Unknown	SS			MG	
	Respiratory Arrest		Bupropion(Amfebutamo					
			ne)Unknown	SS			MG	

Date:02/23/04ISR Number: 4303226-0Report Type:Expedited (15-DaCompany Report #USA-2003-0007481
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis	Health	Oxycodone					
	Coma	Professional	Hydrochloride					
	Drug Toxicity	Other	(Similar To Nda					
	Fatigue		20-553) (Oxycodone					
	Pericardial Effusion		Hydrochloride)	PS				
	Somnolence		Bupropion(Amfebutamo					
	Toxicologic Test Abnormal		ne)	SS				
			Caffeine (Caffeine)	SS				

Date:02/23/04ISR Number: 4304057-8Report Type:Periodic Company Report #PHEH2003US10311
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Affect Lability	Consumer	Zelnorm(Tegaserod)					

	Depression		Tablet	PS		ORAL
6 MG, BID,	Drug Interaction					
ORAL	Gastroenteritis Helicobacter Mood Swings		Wellbutrin (Bupropion Hydrochloride) Klonopin(Clonazepam) Synthroid Prozac (Fluoxetine Hydrochloride) Zinc (Zinc) Trileptal "Novartis"	SS SS C C C C		

Date:02/24/04ISR Number: 4302973-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442630A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Medication Error	Professional	Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK
	Pharmaceutical Product Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/04ISR Number: 4302982-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499451A
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperglycaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Hypertension		Remeron	C				
	Ill-Defined Disorder		Enalapril	C				
	Oral Intake Reduced		Amaryl	C				
	Oral Soft Tissue Disorder		Glucophage	C				
	Speech Disorder							
	Stomach Discomfort							

Date:02/24/04ISR Number: 4302985-0Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0315453A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Febrile		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	MON
	Neutrophilic Dermatosis							
	Dermatitis		No Concurrent Medication	C				
	Hypersensitivity							
	Oral Discomfort							
	Rash Erythematous							
	Rash Papular							

Date:02/24/04ISR Number: 4303010-8Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043010A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Use	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Five times per day	
	Suicide Attempt	Professional						
			Alcohol	SS		ORAL		

Date:02/24/04ISR Number: 4304277-2Report Type:Expedited (15-DaCompany Report #USA-2003-0007716
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Pulmonary Oedema	Health	Oxycodone Hdyrochloride (Similar To Nda 20-553)(Oxycodone Hydrochloride)	PS				
	Adenomyosis	Professional						
	Alcoholism	Other						
	Beta Haemolytic Streptococcal Infection							
	Bulimia Nervosa		Hydrocodone Bitartrate (Similar To Ind 59,175) (Hydrocodone Bitartrate) Unknown	SS				
	Cardio-Respiratory Arrest							
	Coagulopathy							
	Coma							
	Contusion							
	Culture Positive		Phentermine (Phentermine)	SS				
	Fall							
	Gastric Haemorrhage		Bupropion (Amfebutamone)	SS				
	Haematemesis							
	Hand Fracture		Caffeine (Caffeine)	SS				
	Hepatic Steatosis		Citalopram (Citalopram)	C				
	Hepatomegaly							
	Leiomyoma							
	Lung Disorder							
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/04ISR Number: 4305970-8Report Type:Expedited (15-DaCompany Report #HQWYE040517FEB04
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Activities Of Daily Living Impaired Crying Drug Withdrawal Syndrome Suicidal Ideation	Consumer	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	SEE IMAGE	
			Wellbutrin (Amfebutamone Hydrochloride,)	SS		ORAL	ORAL	

Date:02/25/04ISR Number: 4303859-1Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0499286A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Unknown	11 MON
	Blindness Unilateral		Paxil	C	Glaxosmithkline	ORAL	40MG Unknown	

Date:02/25/04ISR Number: 4303860-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499416A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Coumadin	C	Glaxosmithkline			

Date:02/25/04ISR Number: 4303861-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499457A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Self Mutilation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

			Lexapro	C	
			Lithium	C	Glaxosmithkline

Date:02/25/04ISR Number: 4303872-4Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0323086A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	UNKNOWN	150MG Twice per day	
			No Concurrent Medication	C				

Date:02/25/04ISR Number: 4303875-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0323413A
Age:22 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	C-Reactive Protein Increased
	Drug Exposure During Pregnancy
	Face Oedema
	Joint Swelling
	Mobility Decreased
	Neutrophil Percentage

	Increased						
	Odynophagia						
	Oedema						
	Pregnancy	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urticaria		Zyban	PS	Glaxosmithkline	ORAL	150MG See
	White Blood Cell Count						dosage text 10 DAY
	Increased						

Date:02/25/04ISR Number: 4303880-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0324053A
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Accidental Overdose		Zyban	PS	Glaxosmithkline	ORAL	1 DAY
Hospitalization - Initial or Prolonged	Convulsion						
Other	Hallucination						
	Pulmonary Oedema						
	Tachycardia						

Date:02/25/04ISR Number: 4303882-7Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043117A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown 6 DAY
	Dizziness		Beer	C		ORAL	1.5L per day
	Hepatic Enzyme Increased						
	Hepatic Function Abnormal						
	Hyperlipidaemia						

Date:02/26/04ISR Number: 4304613-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425696A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL

76 DAY

Date:02/26/04ISR Number: 4304614-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430054A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	7 DAY
	Pharmaceutical Product		Verapamil	C				
	Complaint		Doxazosin	C				
	Stool Analysis Abnormal							

Date:02/26/04ISR Number: 4304615-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430617A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	15 DAY

Date:02/26/04ISR Number: 4304616-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431217A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	4	DAY
			Zoloft	C				
			Alcohol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304617-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431224A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin	PS	Glaxosmithkline	ORAL	30	DAY
	Therapeutic Response		Lipitor	C			UNKNOWN	20MG Unknown
	Unexpected		Prilosec	C			20MG Unknown	
			Claritin	C			UNKNOWN	
			Ocupress	C				

Date:02/26/04ISR Number: 4304618-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432151A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Energy Increased		Ventolin Mdi	C	Glaxosmithkline			
	Heart Rate Increased		Synthroid	C	Glaxosmithkline			
			Trazodone	C				
			Depakote	C				

Date:02/26/04ISR Number: 4304619-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432580A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Vitamins	C				

Date:02/26/04ISR Number: 4304620-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432616A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						
			Concerta	C		
			Antibiotic (Unspecified)	C		

Date:02/26/04ISR Number: 4304621-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432633A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:02/26/04ISR Number: 4304622-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432859A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL
	Anger		Sam E	C		
	Insomnia		Vitamins	C		

Date:02/26/04ISR Number: 4304623-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432860A
Age:26 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Other	Abdominal Pain Upper

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia							
	Chromaturia							
	Hepatitis Acute		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
	Jaundice		Echinacea	C				
	Nausea		Mircette	C				
	Thrombocytopenia							

Date:02/26/04ISR Number: 4304624-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432864A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline			
	Drug Interaction		Lipitor	SS				
	Heart Rate Increased							
	Hyperventilation							

Date:02/26/04ISR Number: 4304625-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432865A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304626-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432879A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Crying		Robaxin	C				
			Zoloft	C				
			Tagamet	C	Glaxosmithkline			
			Benadryl	C	Glaxosmithkline			
			Singulair	C				
			Humibid	C				
			Dalmane	C				

				Ambien	C		
				Phenergan	C	Glaxosmithkline	
				Zofran	C	Glaxosmithkline	
				Ativan	C		
				Zithromax	C		
				Estrogen Injections	C		

Date:02/26/04ISR Number: 4304627-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432886A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			Trazodone	C				
			Ativan	C				

Date:02/26/04ISR Number: 4304629-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432888A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304630-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432893A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	2	DAY
	Joint Swelling							

Date:02/26/04ISR Number: 4304631-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432982A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown
	Eating Disorder							
	Purging							
	Weight Increased							

Date:02/26/04ISR Number: 4304632-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432999A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Insomnia							
	Nausea							

Date:02/26/04ISR Number: 4304633-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433115A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Per day

Date:02/26/04ISR Number: 4304634-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433117A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	15	DAY
	Restlessness		Trazodone	C			50MG per day	2 DAY

Date:02/26/04ISR Number: 4304635-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433119A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Wellbutrin	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4304636-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433126A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304637-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433138A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	1 MON
			Risperdal	C				

				Trazodone	C		

Date:02/26/04ISR Number: 4304638-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433168A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence		Wellbutrin	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4304639-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433281A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK
	Palpitations		Antihypertensive	C				

Date:02/26/04ISR Number: 4304640-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433289A
Age:13 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Eruption		Wellbutrin	PS	Glaxosmithkline	ORAL	5	DAY
	Urticaria							

Date:02/26/04ISR Number: 4304641-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433299A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Libido Decreased		Paxil Cr	SS	Glaxosmithkline		25MG per day	1 MON
	Urticaria		Toprol Xl	C				
			Micardis	C	Glaxosmithkline			
			Benadryl	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304642-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433300A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG	Per day
			Depakote	C				

Date:02/26/04ISR Number: 4304643-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433338A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304644-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433339A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Three
	Grand Mal Convulsion						times per day	11 DAY
			Sonata	C				
			Ortho Cyclen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304645-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438798A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bedridden		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Dizziness		Zoloft	C				
	Feeling Cold							
	Nausea							
	Vertigo							
	Vomiting							

Date:02/26/04ISR Number: 4304647-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438804A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	7 DAY
	Headache		Xanax	C				

Date:02/26/04ISR Number: 4304648-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438808A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline			

Date:02/26/04ISR Number: 4304649-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438831A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/26/04ISR Number: 4304650-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438873A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Anger							

Date:02/26/04ISR Number: 4304651-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438914A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Apathy		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Depressed Mood							
	Drug Ineffective							
	Lethargy							

Date:02/26/04ISR Number: 4304652-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438925A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304654-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439013A
Age: YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:02/26/04ISR Number: 4304655-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439014A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304656-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439025A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4304657-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439032A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:02/26/04ISR Number: 4304658-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439049A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304659-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439057A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304660-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439109A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304661-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439110A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304662-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439231A
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Other	Hallucination, Visual
	Hypertension

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Exelon	C				
			Beta-Blocker(Unspecified)	C				
			Ace-Inhibitor	C				

Date:02/26/04ISR Number: 4304664-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439342A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:02/26/04ISR Number: 4304665-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439425A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Thyroid Replacement	C				
			Temazepam	C				

Date:02/26/04ISR Number: 4304666-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439432A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304667-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439435A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Oedema Peripheral		Hormone Pill	C				
			Multivitamin	C				
			Calcium	C				
			Vitamin C	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304669-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439440A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Lipitor	C				

Date:02/26/04ISR Number: 4304670-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439478A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304672-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439609A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Prozac	C				

Date:02/26/04ISR Number: 4304673-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439615A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MGM Per day	5 DAY
	Insomnia							
	Myalgia		Zyban	SS	Glaxosmithkline	ORAL	5	WK

Date:02/26/04ISR Number: 4304675-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439616A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Drug Ineffective							

Date:02/26/04ISR Number: 4304676-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439621A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
			Lexapro	C				

Date:02/26/04ISR Number: 4304678-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439624A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Lamictal	C	Glaxosmithkline			
			Risperdal	C				

Date:02/26/04ISR Number: 4304679-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439629A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Visual Disturbance		Depakote	C				
			Altace	C				
			Risperdal	C				

Date:02/26/04ISR Number: 4304680-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439643A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Rash							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304681-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439656A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Nausea		Unknown	C				

Date:02/26/04ISR Number: 4304682-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439663A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	5 DAY
	Dry Mouth							
	Fatigue							
	Feeling Drunk							
	Headache							

Date:02/26/04ISR Number: 4304683-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439679A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304686-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439818A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
			Prozac	C				
			Benadryl	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304687-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439837A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Swelling Face							

Date:02/26/04ISR Number: 4304688-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439849A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Convulsion							

Date:02/26/04ISR Number: 4304689-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439980A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	13 DAY
			Toprol	C				
			Avapro	C				
			Pravachol	C				
			Claritin	C				
			Aspirin	C	Glaxosmithkline			
			Folic Acid	C				

			Multivitamin	C		

Date:02/26/04ISR Number: 4304690-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439984A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	16 DAY
	Muscle Tightness		Zomig	C				

Date:02/26/04ISR Number: 4304691-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440000A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	10 DAY
			Cozaar	C				
			Klonopin	C				

Date:02/26/04ISR Number: 4304692-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440007A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tendonitis							

Date:02/26/04ISR Number: 4304693-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440204A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	7 DAY
	Dry Mouth							

Date:02/26/04ISR Number: 4304694-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440205A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
			Synthroid	C	Glaxosmithkline			
			Lipitor	C				
			Prozac	C				
			Glucotrol	C				
			Zestril	C				
			Provigil	C				
			Dilantin	C				
			Centrum	C				
			Vitamin C	C	Glaxosmithkline		UNKNOWN	
			Tums Ex	C	Glaxosmithkline			
			Prilosec	C				
			Vitamin E	C			UNKNOWN	
			Vitamin B	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304695-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440208A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Per day
			Valtrex	C	Glaxosmithkline			
			Avandia	C	Glaxosmithkline			
			Hyzaar	C				
			Dyazide	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304696-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440210A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown

Date:02/26/04ISR Number: 4304697-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440234A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Attack		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tremor							

Date:02/26/04ISR Number: 4304698-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440251A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304699-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440349A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304700-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440380A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304701-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440389A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
			Ativan	C		ORAL	.5MG Twice per day	
			Ambien	C		ORAL	5MG At night	
			Nortriptyline	C		ORAL	50MG At night	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304702-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440390A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Celebrex	C				

Date:02/26/04ISR Number: 4304703-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440397A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	4 DAY
			Clonazepam	C				
			Paxil	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304704-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440401A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Ear Discomfort		Pepto Bismol	C				
	Nausea							

Date:02/26/04ISR Number: 4304705-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440440A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/26/04ISR Number: 4304706-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440448A
Age:16 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304707-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440449A
Age:17 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304708-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440569A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Joint Swelling		Neurontin	SS				

Date:02/26/04ISR Number: 4304709-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440600A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304710-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440602A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Insomnia							
	Nervousness							

Date:02/26/04ISR Number: 4304711-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440609A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Headache		Lipitor	C				
	Hypoaesthesia							
	Muscular Weakness							
	Nausea							

Date:02/26/04ISR Number: 4304712-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440611A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Xanax	C				
			Pegasys	C				
			Copegus	C				

Date:02/26/04ISR Number: 4304713-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440613A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
			Levoxyl	C	Glaxosmithkline			
			Armour Thyroid	C				

			Nexium	C	
			Bactrim	C	Glaxosmithkline
			Flumadine	C	
			Allegra	C	

Date:02/26/04ISR Number: 4304714-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440697A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery Insomnia Nervousness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304715-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440711A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304716-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440798A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Anxiety							
	Crying							
	Feeling Abnormal							
	Insomnia							

Date:02/26/04ISR Number: 4304718-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440832A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304719-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440848A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY

Date:02/26/04ISR Number: 4304720-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440851A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON
			Lexapro	C				

Date:02/26/04ISR Number: 4304721-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440984A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Anxiety		Lipitor	C				
	Constipation							
	Headache							
	Listless							
	Nausea							

Date:02/26/04ISR Number: 4304724-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440993A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Urticaria		Toprol Xl	C				
			Lipitor	C				
			Aspirin	C	Glaxosmithkline			
			Antivert	C				

Date:02/26/04ISR Number: 4304725-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441012A
Age:50 YR Gender:Female I/FU:F

Outcome	PT
	Anxiety
	Capillary Disorder

Insomnia

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Ativan	C				
			Estrace	C				

Date:02/26/04ISR Number: 4304726-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441018A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	4 WK
			Clonazepam	C				
			Doxepin	C				

Date:02/26/04ISR Number: 4304727-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441021A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

Date:02/26/04ISR Number: 4304728-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441024A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK

Date:02/26/04ISR Number: 4304729-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441029A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	2	DAY
			Seroquel	C				
			Klonopin	C				
			Lexapro	C				

Date:02/26/04ISR Number: 4304730-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441094A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	5	YR
	Blood Triglycerides Increased		Zyprexa	C				

Date:02/26/04ISR Number: 4304731-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441098A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Ortho Tricyclen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304732-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441104A
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	20	DAY
	Grand Mal Convulsion							
	Loss Of Consciousness							

Date:02/26/04ISR Number: 4304733-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441105A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304734-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441106A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304735-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441107A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304736-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441116A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 4 DAY						
	Stool Analysis Abnormal		Thyroid	C		

Date:02/26/04ISR Number: 4304738-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441117A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL
1TAB Per day 5 DAY						
	Blood Pressure Increased		Prevacid	C		
			Zyrtec	C	Glaxosmithkline	
			Vioxx	C		
			Multi-Vitamin	C		

Date:02/26/04ISR Number: 4304739-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441158A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 1 DAY						

Date:02/26/04ISR Number: 4304740-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441164A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304741-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441165A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			St Johns Wort	C				
			Lovastatin	C				
			Atacand	C				
			Glucophage	C				
			Glucotrol	C				
			Actos	C				

Date:02/26/04ISR Number: 4304742-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441186A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304743-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441432A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Fatigue							
	Headache							
	Nervousness							

Date:02/26/04ISR Number: 4304744-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441435A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			None	C				

Date:02/26/04ISR Number: 4304745-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441444A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/26/04ISR Number: 4304746-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441461A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Glipizide	C				

Date:02/26/04ISR Number: 4304747-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441468A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304749-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441483A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nephrolithiasis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Glucosamine	C				

Date:02/26/04ISR Number: 4304750-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441494A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	21 DAY
Hospitalization - Initial or Prolonged			Adderall	C				
Other								

Date:02/26/04ISR Number: 4304751-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441503A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
Hospitalization - Initial or Prolonged	Complete Rash							
Disability	Syncope							
Other								

Date:02/26/04ISR Number: 4304752-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441533A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Toprol Xl	C				
UNKNOWN							100MG Per day	

				Lotrel	C		
				Levoxyl	C	Glaxosmithkline	
UNKNOWN	100MCG Per day						

Date:02/26/04ISR Number: 4304753-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441631A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Date:02/26/04ISR Number: 4304754-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441635A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Angioneurotic Oedema							
	Anxiety							
	Chest Pain							
	Dry Mouth							
	Hypoacusis							
	Nausea							
	Rash Maculo-Papular							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304755-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441638A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304756-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441642A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304757-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441651A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Adderall	C				

Date:02/26/04ISR Number: 4304758-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441658A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 DAY
	Hallucination		Thyroid Medication	C				
	Road Traffic Accident							

Date:02/26/04ISR Number: 4304760-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441743A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Road Traffic Accident		Lexapro	C				

Date:02/26/04ISR Number: 4304761-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441760A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON

Date:02/26/04ISR Number: 4304762-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441769A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	24 DAY
			Pamelor	C				
			Xanax	C				
			Ambien	C				

Date:02/26/04ISR Number: 4304763-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441775A
Age:42 YR Gender:Female I/FU:I

Outcome	PT
Other	Amnesia
	Convulsion

Periorbital Haematoma						
Tooth Fracture						
Tooth Injury	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Toothache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day 2 WK
		Celexa	C			

Date:02/26/04ISR Number: 4304764-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442005A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dysuria		Wellbutrin Xl	PS	Glaxosmithkline		

Date:02/26/04ISR Number: 4304765-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442013A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 2 WK
	Anxiety		Oral Contraceptives	C			
	Diarrhoea						
	Dysmenorrhoea						

Date:02/26/04ISR Number: 4304766-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442024A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day
			Effexor Xr	C		ORAL	300MG Per day

Date:02/26/04ISR Number: 4304767-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442029A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Jaw Disorder		Ritalin	C				

Date:02/26/04ISR Number: 4304768-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442034A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:02/26/04ISR Number: 4304769-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442035A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:02/26/04ISR Number: 4304770-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442045A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304771-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442050A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK

Date:02/26/04ISR Number: 4304772-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442052A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Wellbutrin	SS	Glaxosmithkline			

Date:02/26/04ISR Number: 4304773-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442053A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Weight Loss Poor							

Date:02/26/04ISR Number: 4304774-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442188A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Depression		Lipitor	C				
	Dizziness							
	Nausea							
	Psychomotor Hyperactivity							
	Tremor							

Date:02/26/04ISR Number: 4304775-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442317A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Amnesia		Advair	C	Glaxosmithkline			
	Chest Pain		Singulair	C				
			Allegra	C				
			Unknown Medication	C				

Date:02/26/04ISR Number: 4304776-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442343A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
	Fatigue		Claritin	C				
	Grand Mal Convulsion		Flonase	C	Glaxosmithkline			
	Headache		Oral Contraceptive	C				

Date:02/26/04ISR Number: 4304777-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442355A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304778-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442356A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline		12	DAY
			None	C				

Date:02/26/04ISR Number: 4304779-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442360A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Anxiety		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	
	Drug Ineffective		Hormone Replacement Therapy	C				

Date:02/26/04ISR Number: 4304780-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442436A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304781-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442511A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304782-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442512A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK

Date:02/26/04ISR Number: 4304783-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442521A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
	Parosmia		Chemotherapy	C				

Date:02/26/04ISR Number: 4304784-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442528A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON

Date:02/26/04ISR Number: 4304785-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442549A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304786-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442550A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 YR
			Tylenol Sinus	C				

Date:02/26/04ISR Number: 4304787-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442610A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON

Date:02/26/04ISR Number: 4304788-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442612A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON

Date:02/26/04ISR Number: 4304789-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442652A
Age:54 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Inadequate Lubrication		Wellbutrin	SS	Glaxosmithkline	ORAL	100MG Twice per day	2 YR
	Libido Decreased							
			Combipatch	C				
			Dhea	C				
			Dong Quai Root	C				

			Damiana	C		

Date:02/26/04ISR Number: 4304790-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442653A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	0 DAY
	Insomnia							
	Mouth Ulceration							
	Nervousness							
	Night Sweats							
	Pruritus							

Date:02/26/04ISR Number: 4304791-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442727A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			
			Unspecified Medications	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304792-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442730A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline		450MG Per day	

Date:02/26/04ISR Number: 4304793-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442764A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Effexor	C				

Date:02/26/04ISR Number: 4304794-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442777A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Headache		Zocor	C				
			Zestril	C				

Date:02/26/04ISR Number: 4304795-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442780A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Dry Mouth		Topamax	C				
			Estrogen	C				
			Thyroid	C				

Date:02/26/04ISR Number: 4304796-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442797A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hot Flush							

Date:02/26/04ISR Number: 4304797-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443028A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304798-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443052A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Movement Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tic							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304799-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443101A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/26/04ISR Number: 4304800-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443171A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Restlessness		Tamoxifen	C				
	Tremor		Diovan	C				
			Prednisone	C				
			Neurontin	C				
			Nexium	C				
			Megace	C				

Date:02/26/04ISR Number: 4304801-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443178A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304802-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443207A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK

Date:02/26/04ISR Number: 4304803-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443215A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304804-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443243A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown

Date:02/26/04ISR Number: 4304805-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443357A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG	Per day
	Grand Mal Convulsion		Adderall Xr	C			10MG	Per day
			Focalin	C				
			Ativan	C				
			Ortho Tri-Cyclen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304806-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443471A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
			Hctz	C				

Date:02/26/04ISR Number: 4304807-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443487A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Unknown	C				

Date:02/26/04ISR Number: 4304808-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443493A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Fatigue							
	Headache							
	Insomnia							
	Somnolence							
	Weight Increased							

Date:02/26/04ISR Number: 4304809-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443501A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Unknown	C				

Date:02/26/04ISR Number: 4304831-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443503A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Effexor	C				

Date:02/26/04ISR Number: 4304832-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443506A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304833-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443531A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Disease		Wellbutrin	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304834-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443569A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Dizziness							

Date:02/26/04ISR Number: 4304835-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443571A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the morning	
	Feeling Abnormal							
	Impaired Driving Ability							

Date:02/26/04ISR Number: 4304836-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443654A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Diarrhoea		Wellbutrin	SS	Glaxosmithkline			
	Energy Increased							
	Tearfulness							

Date:02/26/04ISR Number: 4304837-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443656A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304838-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443664A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Irritability		Zoloft	C				
			Insulin	C				

Date:02/26/04ISR Number: 4304839-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443665A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Lithium	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304840-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443670A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 DAY
Hospitalization - Initial or Prolonged	Dyspnoea							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304841-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443679A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304842-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443680A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304843-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443758A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Allegra-D	C				
			Nasonex	C				

Date:02/26/04ISR Number: 4304844-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443797A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	4 WK
	Drug Ineffective		Valium	C				
			Zoloft	C				

Date:02/26/04ISR Number: 4304845-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443902A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 3 DAY						
			Klonopin	C		
			Estrogen	C		
			Cozaar	C		
			Zocor	C		
			Atenolol	C		

Date:02/26/04ISR Number: 4304846-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443905A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 5 DAY						
	Insomnia		Arthritis Medication	C		

Date:02/26/04ISR Number: 4304847-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443926A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
50MG Per day 3 MON						
			Sleeping Medication	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304848-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443944A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			Ddavp	C				
			Cipro	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304850-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443984A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradyphrenia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304851-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444029A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304852-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444056A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304853-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444067A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304854-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444102A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK

Date:02/26/04ISR Number: 4304855-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444160A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Rash							
	Urticaria							

Date:02/26/04ISR Number: 4304856-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444169A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304857-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490776A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 WK

Date:02/26/04ISR Number: 4304858-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490787A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Trileptal	C		ORAL	600MG At night	
			Ambien	C		ORAL	10MG At night	
			Vitamin Complex	C		ORAL		

Date:02/26/04ISR Number: 4304859-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490827A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Uveitis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304860-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490852A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Insomnia		Restoril	C				
	Mouth Ulceration		Ambien	C				
			Blood Pressure Medication	C				

Date:02/26/04ISR Number: 4304861-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490856A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Thyroid Medication	C				

Date:02/26/04ISR Number: 4304862-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490954A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 DAY
			Xanax	C			.25MG As required	

Date:02/26/04ISR Number: 4304863-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490955A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Migraine		Ritalin	C				
			Kdur	C	Glaxosmithkline			
			Metadate	C				
			Allegra D	C				

			Nexium	C		
			Relpax	C		

Date:02/26/04ISR Number: 4304864-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490957A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Pharmaceutical Product Complaint							

Date:02/26/04ISR Number: 4304865-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490960A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Alcohol	C				
			Unspecified Medications	C				

Date:02/26/04ISR Number: 4304866-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490961A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin	PS	Glaxosmithkline			
			Prozac	C			40MG Per day	
			Prevacid	C			20MG Per day	
			Hemocyte Plus	C				
			Zyrtec	C	Glaxosmithkline		10MG Per day	

Date:02/26/04ISR Number: 4304867-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490976A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Paxil Cr	C	Glaxosmithkline	ORAL		
			Neurontin	C				
			Estrogen	C				

Date:02/26/04ISR Number: 4304868-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490979A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Mood Altered							

Date:02/26/04ISR Number: 4304869-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490980A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Pain							
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304870-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490982A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	3TAB	Single dose
	Dyspepsia							
	Lethargy							
	Overdose							

Date:02/26/04ISR Number: 4304871-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491277A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin Xl	PS	Glaxosmithkline		150MG In the morning	
			Norvasc	C			5MG Per day	
			Imitrex	C	Glaxosmithkline		50MG As required	
			Multivitamin	C				
			Aleve	C				
			Dyazide	C	Glaxosmithkline			
			Estratest	C				

Date:02/26/04ISR Number: 4304872-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491312A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Nausea		Buspar	C				
			Ativan	C				

Date:02/26/04ISR Number: 4304873-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491331A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Dysgeusia							
	Insomnia							

Date:02/26/04ISR Number: 4304874-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491334A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	15 DAY

Date:02/26/04ISR Number: 4304875-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491358A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304876-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491361A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY

Date:02/26/04ISR Number: 4304877-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491362A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON

Date:02/26/04ISR Number: 4304878-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491363A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304879-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491569A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304880-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491572A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Premenstrual Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304881-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491689A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See dosage text	3 WK

Date:02/26/04ISR Number: 4304882-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491691A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Feeling Abnormal		Trileptal	C				
	Keratoconjunctivitis							
	Sicca							

Date:02/26/04ISR Number: 4304883-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491704A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline			
	Anorexia							
	Insomnia							
	Panic Attack							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304884-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491706A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response Decreased		Wellbutrin	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4304885-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491719A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON

Date:02/26/04ISR Number: 4304886-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491723A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Constipation		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Dissociative Identity Disorder		Ritalin	SS		ORAL	14	MON
	Gallbladder Operation							

Date:02/26/04ISR Number: 4304887-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491733A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	

Date:02/26/04ISR Number: 4304888-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491745A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Foreign Body Trauma		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Insomnia		Clarinex	C				
			Copaxone	C				

Date:02/26/04ISR Number: 4304889-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491880A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304890-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491884A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neck Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304891-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491886A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Urticaria		None	C				

Date:02/26/04ISR Number: 4304892-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491889A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4304893-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491898A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Agitation							
	Depression							
	Therapeutic Response							
	Unexpected							
	Weight Decreased							

Date:02/26/04ISR Number: 4304894-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491909A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Grand Mal Convulsion							

Date:02/26/04ISR Number: 4304895-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491924A
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Dizziness							
	Nausea							

Date:02/26/04ISR Number: 4304896-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491926A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Rash		Ritalin	C				

Date:02/26/04ISR Number: 4304897-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492006A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Dysuria		Prozac	C				
	Incontinence		Provigil	C				
	Micturition Urgency							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304899-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492008A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:02/26/04ISR Number: 4304900-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492012A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Odour Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304901-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492021A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY

Date:02/26/04ISR Number: 4304902-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492022A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Visual Disturbance		Zoloft	C				

Date:02/26/04ISR Number: 4304903-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492025A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL

300MG Per day 6 MON

Date:02/26/04ISR Number: 4304904-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492208A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Psychomotor Hyperactivity		Wellbutrin	PS	Glaxosmithkline	ORAL
	Tremor					

Dose Duration

Date:02/26/04ISR Number: 4304905-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492258A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Palpitations		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Dose Duration

150MG Per day

Date:02/26/04ISR Number: 4304906-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492269A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
	Panic Reaction		Geodon	C		
	Weight Decreased					

Dose Duration

150MG Per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304907-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492408A
Age:41 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Keratoconjunctivitis							
	Sicca							
	Vision Blurred							

Date:02/26/04ISR Number: 4304908-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492410A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Valium	C		ORAL	2MG Unknown	
			Prozac	C		ORAL	40MG Unknown	
			Seroquel	C				
UNKNOWN							100MG Unknown	

Date:02/26/04ISR Number: 4304909-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492411A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Hyperhidrosis		Amoxicillin	C	Glaxosmithkline			
	Rash		Tylenol 3	C				

Date:02/26/04ISR Number: 4304910-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492435A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304911-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492560A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin Unknown Medication	PS C	Glaxosmithkline	ORAL	150MG Per day	4 WK

Date:02/26/04ISR Number: 4304912-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492578A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4304913-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492592A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	2 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304914-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492696A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304915-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492709A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304916-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492884A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4304917-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492896A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Irritability		Prozac	C				
			Lexapro	C				

Date:02/26/04ISR Number: 4304918-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492897A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY
	Dizziness		Klonopin	C				

	Middle Insomnia					
	Nervousness					
	Panic Attack					
	Tremor					

Date:02/26/04ISR Number: 4304919-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492900A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
			Plavix	C				
			Lopressor	C				
			Pravacol	C				
			Ativan	C				

Date:02/26/04ISR Number: 4304920-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492906A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304921-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492913A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304922-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492916A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinus Tachycardia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Topamax	C				

Date:02/26/04ISR Number: 4304923-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493116A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Energy Increased							
	Feeling Jittery							
	Palpitations							

Date:02/26/04ISR Number: 4304924-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493257A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304925-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493262A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Hyperhidrosis		Zocor	C				
	Insomnia		Vioxx	C				
	Nausea		Atenolol	C				
			Imdur	C				

Date:02/26/04ISR Number: 4304926-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493276A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/26/04ISR Number: 4304927-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493281A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Estroven	C				
			Multivitamins	C				
			Advair	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304928-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493313A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Fatigue		Methadone	SS	Glaxosmithkline		UNKNOWN	

Date:02/26/04ISR Number: 4304929-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493452A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See dosage text	4 MON
			Paxil	C	Glaxosmithkline		80MG Per day	10 YR
			Prozac	C			80MG per day	

Date:02/26/04ISR Number: 4304930-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493464A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 DAY
	Insomnia		Interferon	C				
	Tinnitus		Adalat	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304931-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493492A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

	Euphoric Mood		Zoloft	C		
	Fatigue					

Date:02/26/04ISR Number: 4304932-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493493A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Vision Blurred							

Date:02/26/04ISR Number: 4304933-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493559A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304934-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493562A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304935-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493576A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Urticaria							

Date:02/26/04ISR Number: 4304936-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493580A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304937-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493774A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304938-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493783A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Fatigue							
	Nervousness							

Date:02/26/04ISR Number: 4304939-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493801A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4	MON

Date:02/26/04ISR Number: 4304940-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493938A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300TAB Per day	
			Prozac	C				

Date:02/26/04ISR Number: 4304941-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493941A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Urticaria		Vitamins	C				

Date:02/26/04ISR Number: 4304942-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493950A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304943-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493966A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Tremor		Prilosec	C				
			Lipitor	C				
			Zestril	C				

Date:02/26/04ISR Number: 4304944-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493970A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Arthralgia		Evista	SS			1TAB Per day	3 MON
	Dry Mouth							
	Feeling Hot							
	Visual Disturbance							

Date:02/26/04ISR Number: 4304945-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494032A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hypertension		Unspecified Drug	SS			UNKNOWN	

Date:02/26/04ISR Number: 4304946-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494236A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304947-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494238A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Disturbance In Attention		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Feeling Abnormal		Xanax	C				
	Feeling Drunk		Vioxx	C				
			Ambien	C				
			Vitamin C	C	Glaxosmithkline			
			Vitamine B12	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304948-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494250A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304950-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494268A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Gabitril	C				

			Toprol Xl	C		
			Trazodone	C		
			Fiber	C		
			Oxazepam	C		

Date:02/26/04ISR Number: 4304951-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494273A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Cardura	C				
			Aspirin	C	Glaxosmithkline			
			Multivitamin	C				

Date:02/26/04ISR Number: 4304952-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494277A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304953-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494322A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304954-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494333A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Blister		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
	Rash							

Rash Pruritic

Date:02/26/04ISR Number: 4304956-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494459A
Age: YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304957-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494469A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Zoloft	C				

Date:02/26/04ISR Number: 4304958-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494490A
Age:40 YR Gender:Female I/FU:I

Outcome	PT
	Insomnia
	Menstrual Disorder

Suicidal Ideation						
	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day 20 DAY
		Xanax	C			
		Nexium	C			

Date:02/26/04ISR Number: 4304959-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494492A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day 2 DAY
	Dry Mouth						
	Headache						
	Palpitations						
	Tremor						

Date:02/26/04ISR Number: 4304960-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494519A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	
	Yawning						

Date:02/26/04ISR Number: 4304961-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494534A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day
	Pharmaceutical Product Complaint						

Date:02/26/04ISR Number: 4304962-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494549A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Nipple Pain							
	Nipple Swelling							

Date:02/26/04ISR Number: 4304963-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494682A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Blood Pressure Increased		Actonel	C				
	Drug Ineffective		Calcium	C				
	Increased Appetite		Aspirin	C	Glaxosmithkline			
	Medication Error		Vitamin E	C				
	Sensory Disturbance							
	Stool Analysis Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304965-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494685A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Grand Mal Convulsion							
	Incontinence							
	Tongue Biting							

Date:02/26/04ISR Number: 4304966-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494692A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:02/26/04ISR Number: 4304967-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494697A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Dry Mouth							
	Dyspepsia							
	Flushing							
	Headache							
	Insomnia							

Date:02/26/04ISR Number: 4304968-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494708A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Rash Generalised		Vitamins	C				

Date:02/26/04ISR Number: 4304969-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494718A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
			Synthroid	C	Glaxosmithkline			
			Xanax	C				

Date:02/26/04ISR Number: 4304970-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494721A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	3 MON
	Tinnitus		Synthroid	C	Glaxosmithkline		UNKNOWN	
	Weight Increased		Diovan	C				

Date:02/26/04ISR Number: 4304971-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494725A
Age:33 YR Gender:Female I/FU:I

Outcome	PT
	Anxiety
	Chest Pain
	Confusional State

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Impaired Driving Ability Nervousness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
			Cipro	C	Glaxosmithkline			
			Desogen	C				
			Sudafed	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304972-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494728A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lexapro	SS			20MG Per day	
			Oxycontin	C				
			Benadryl	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304973-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494875A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304974-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494895A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mydriasis		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Effexor	SS				

Date:02/26/04ISR Number: 4304975-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495026A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Neurontin	C				
			Seroquel	C				
			Effexor	C				

Date:02/26/04ISR Number: 4304976-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495029A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vulvovaginal Dryness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304977-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495039A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304978-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495042A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Ranitidine	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304979-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495059A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4304980-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495270A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 DAY
			Nicorette	C	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304981-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495274A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the morning	20 DAY

Date:02/26/04ISR Number: 4304982-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495333A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1560MG Per	
	Fluid Retention						day	6 WK
	Headache		Thyroid	C				
	Insomnia		Estrogen	C				
	Jaw Disorder		Soma	C				
	Nausea		Lasix	C	Glaxosmithkline			
	Pain In Jaw							
	Pharmaceutical Product							
	Complaint							
	Weight Increased							

Date:02/26/04ISR Number: 4304983-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495337A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Effexor Xr	C				

Date:02/26/04ISR Number: 4304984-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495501A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304985-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495504A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4304986-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495507A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline		300MG Per day	3 WK
			Reglan	SS	Glaxosmithkline		10MG Per day	

Date:02/26/04ISR Number: 4304987-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495547A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
			Microzide	C		ORAL		

Date:02/26/04ISR Number: 4304988-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495551A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON

Date:02/26/04ISR Number: 4304989-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495567A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:02/26/04ISR Number: 4304990-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495721A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Vitamin B Complex	C				
			Dostinex	C				

Date:02/26/04ISR Number: 4304992-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495722A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
	Irritability							

Date:02/26/04ISR Number: 4304993-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495724A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Chest Discomfort							
	Heart Rate Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4304994-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495725A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Sinemet	C				
			Comtan	C				
			Mirapex	C				
			Flomax	C				
			Lasix	C	Glaxosmithkline			
			Synthroid	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304995-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495734A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Lithium	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4304996-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495755A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Delirium		Tenormin	C				
	Neuralgia		Valium	C				
	Neuropathy							
	Vertigo							

Date:02/26/04ISR Number: 4304997-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495757A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Lexapro	C	
Ambien	C	
Clonazepam	C	

Date:02/26/04ISR Number: 4304998-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495760A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	DAY

Date:02/26/04ISR Number: 4304999-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495766A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence		Wellbutrin Xl	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4305000-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495773A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Sleep Disorder		Nexium	C				

				Celexa	C		
				Blood Pressure Medication	C		

Date:02/26/04ISR Number: 4305001-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495775A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/26/04ISR Number: 4305002-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495779A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
			Zocor	C				

Date:02/26/04ISR Number: 4305003-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495783A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/26/04ISR Number: 4305004-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495805A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Rash							

Date:02/26/04ISR Number: 4305005-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495931A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	8 WK
	Pruritus							
	Rash							

Date:02/26/04ISR Number: 4305006-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495974A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
			None	C				

Date:02/26/04ISR Number: 4305007-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496028A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4305008-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496270A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
	Decreased Appetite							
	Paranoia							

Date:02/26/04ISR Number: 4305009-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496278A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Depression		Wellbutrin	C	Glaxosmithkline		2	MON
	Drug Ineffective							

Date:02/26/04ISR Number: 4305010-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496282A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Lexapro	SS			1	MON
			Advair	C	Glaxosmithkline		RESPIRATORY (INHALATION)	
			Flonase	C	Glaxosmithkline			

Date:02/26/04ISR Number: 4305011-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496332A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4305012-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496515A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4305013-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496516A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Dizziness							
	Headache							

Date:02/26/04ISR Number: 4305014-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496936A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Respordol	C				
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4305015-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497386A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tremor						per day	

Date:02/26/04ISR Number: 4305016-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497387A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4305019-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497388A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4305073-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499436A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:02/26/04ISR Number: 4305078-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499594A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/26/04ISR Number: 4305798-9Report Type:Direct Company Report #CTU 213269
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Convulsion Influenza Like Illness Loss Of Consciousness Rash		Wellbutrin-Glaxo Xl	PS	Glaxo		500 MG/1 DAY	

Date:02/26/04ISR Number: 4307414-9Report Type:Expedited (15-DaCompany Report #200410862BCC
Age:15 YR Gender: I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Coma Convulsion Electrocardiogram Qt Prolonged Intentional Misuse International Normalised Ratio Decreased Lethargy Suicide Attempt Syncope

		Tachycardia					
Dose	Duration		Report Source	Product	Role	Manufacturer	Route
			Health Professional Other	Aleve Tablet 220mg From Bayer Consumer Care (Naproxen Sodium)	PS		ORAL
2640 MG, ONCE, ORAL							
				Wellbutrin 150 Mg (Bupropion Hydrochloride)	SS		ORAL
3750 MG, ONCE, ORAL							
				Risperdal M-Tab Disintegrating Tablet 0.5 Mg From Janssen Pharmaceutica	SS	Janssen Pharmaceutical	ORAL
12.5 MG, ONCE, ORAL							
				Percocet (5/325) Endo Laboratories	SS	Endo Laboratories	ORAL
ONCE, ORAL							

Date:02/27/04ISR Number: 4306881-4Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0323085A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice per day	19 DAY	Arthralgia				
	C-Reactive Protein Increased		No Concurrent Medication	C		
	Haematoma					
	Headache					
	Joint Swelling					
	Myalgia					

Nausea
Neutrophilia
Pyrexia
Rash Generalised
Stevens-Johnson Syndrome
Urticaria

Date:02/27/04ISR Number: 4306886-3Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0323610A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Zyban	PS	Glaxosmithkline	ORAL	8	DAY

Date:02/27/04ISR Number: 4306888-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0323712A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Zyban	PS	Glaxosmithkline	UNKNOWN	150MG Twice per day	4 DAY
	Dyspnoea							
	Rash		Inhalers	C				
	Status Asthmaticus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/27/04ISR Number: 4306895-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0324788A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Missed		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 22 DAY
	Complications Of Maternal Exposure To Therapeutic Drugs		Oral Contraceptive	C				
	Intra-Uterine Death							
	Pregnancy On Oral Contraceptive							

Date:02/27/04ISR Number: 4307730-0Report Type:Direct Company Report #CTU 213330
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose		Paxil 10 Mg Bid	PS				
			Wellbutrin 30 Mg	SS				

Date:02/27/04ISR Number: 4308727-7Report Type:Expedited (15-DaCompany Report #USA-2003-0011315
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health Professional Other	Morphine Sulfate (Similar To Nda 19-516)(Morphine Sulfate) Unknown	PS				
	Cerebral Haemorrhage		Hydroxyzine (Hydroxyzine)	SS				
	Coma		Carisoprodol (Carisoprodol)	SS				
	Drug Screen Positive		Nicotine (Nicotine)	SS				
	Drug Toxicity		Cannabis (Cannabis)	SS				
	Hypertensive Heart Disease		Temazepam (Temazepam)	SS				
	Somnolence		Bupropion (Amfebutamone)	SS				

Date:03/01/04ISR Number: 4308115-3Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12286316
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Decreased		Glucophage Tabs 850					
	Drug Interaction		Mg	PS	Bristol-Myers Squibb Company	ORAL		
			Neurontin	C				
			Vioxx	C				
			Allegra	C				
			Lisinopril	C				
			Prilosec	C				
			Provigil	I		ORAL	dose increased from 200 to 400 mg 3.5 hours before	
			Wellbutrin	I		ORAL		
			Celexa	I		ORAL		
			Avandia	I				
			Humalog	I			INTRAMUSCULAR	unit QAM/MD

			Humulin Regular	I		
INTRAMUSCULAR	unit QAM/PM					

Date:03/02/04ISR Number: 4309086-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0440829A
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Claustrophobia		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Confusional State		Xanax	C				
	Convulsion		Vitamins	C				
	Disorientation							
	Disturbance In Attention							
	Dizziness							
	Flashback							
	Loss Of Consciousness							
	Palpitations							
	Therapeutic Response							
	Unexpected							
	Weight Decreased							

Date:03/02/04ISR Number: 4309090-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499621A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	

Date:03/02/04ISR Number: 4309322-6Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0321501A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Parkinsonism	Health Professional	Zyntabac	PS	Glaxosmithkline			

Date:03/02/04ISR Number: 4311023-5Report Type:Expedited (15-DaCompany Report #KII-2003-0007440
Age:41 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Arrhythmia
Hospitalization - Initial or Prolonged	Blood Bicarbonate Decreased
Other	Blood Calcium Decreased
	Blood Glucose Increased
	Blood Potassium Decreased
	Body Temperature Increased
	Depressed Level Of Consciousness
	Drug Screen Positive
	Electrocardiogram Qt Corrected Interval Prolonged
	Nausea
	Prothrombin Time Prolonged
	Red Blood Cell Sedimentation Rate

Increased Respiratory Arrest Syncope Torsade De Pointes Ventricular Extrasystoles Ventricular Tachycardia Vomiting White Blood Cell Count	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Increased	Study Health Professional Other	Morphine Sulfate (Similar To Nda 19-516) (Morphine Sulfate)	PS		ORAL	ORAL
		Vistaril(Hydroxyzine Embonate)	SS			
		Benadryl (Diphenhydramine Hydrochloride)	SS			
		Metformin (Metformin)	SS			
		Lipitor (Atorvastatin)	SS			
		Effexor (Venlafaxine Hydrochloride)	SS			
		Lasix (Furosemide)	SS			
		Potassium (Potassium)	SS			
		Reglan (Metoclopramide)	SS			
		Amfetamine (Amfetamine)	SS			
		Ambien (Zolpidem Tartrate)	SS			
		Acebutolol Hydrochloride (Acebutolol Hydrochloride)	SS			
		Baclofen (Baclofen)	SS			
		Nexium (Esomeprazole)	SS			
		Prilosec (Omeprazole)	SS			
		Quinine (Quinine)	SS			
		Promethazine (Promethazine)	SS			
		Klonopin (Clonazepam)	SS			
		Wellbutrin (Amfebutamone Hydrochloride)	SS			
		Celexa (Citalopram				

				Hydrobromide)	C		

Date:03/02/04ISR Number: 4311167-8Report Type:Direct Company Report #CTU 213582
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Prozac 20 Mg	PS		ORAL	20 MG BID	
			Wellbutrin Sr 100 Mg	SS		ORAL	100 MG QD	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/04ISR Number: 4310527-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441482A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
		Professional					per day	5 WK
			Minocycline	C		ORAL	100MG Twice	
							per day	

Date:03/03/04ISR Number: 4310533-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499844A
Age: YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Bupropion	PS	Glaxosmithkline			
	Intentional Misuse							

Date:03/03/04ISR Number: 4310543-7Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0314544A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxosmithkline		22 DAY	
	Anxiety							
	Headache							
	Nightmare							
	Panic Attack							
	Psychotic Disorder							
	Sleep Disorder							
	Syncope							

Date:03/03/04ISR Number: 4310550-4Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0323130A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour	Health	Zyban	PS	Glaxosmithkline		150MG Twice	
	Aggression	Professional					per day	
	Alcohol Poisoning		No Concurrent					
	Amnesia		Medication	C			1	DAY
	Thinking Abnormal							

Date:03/03/04ISR Number: 4310559-0Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0323958A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pericarditis		Zyban	PS	Glaxosmithkline	ORAL	18	DAY
Initial or Prolonged	Sensation Of Pressure							

Date:03/03/04ISR Number: 4311498-1Report Type:Direct Company Report #CTU 213716
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Wellbutrin 150 Mg.	PS		ORAL	150 MG. DAILY	
	Convulsion							
ORAL								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/04ISR Number: 4311592-5Report Type:Direct Company Report #CTU 213690
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Aphasia Vocal Cord Disorder		Wellbutrin Sr 100 Mg Glaxo Lexapro	 PS C	 Glaxo	 ORAL	1 TWICE A DA ORAL	

Date:03/04/04ISR Number: 4311279-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0433343A
Age:2 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Exposure Convulsion	Health Professional	Avandia Wellbutrin Metformin Lipitor	PS SS SS SS	Glaxosmithkline Glaxosmithkline	ORAL ORAL ORAL ORAL		

Date:03/04/04ISR Number: 4311280-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499548A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis Psoriatic Arthropathy Rheumatoid Arthritis		Wellbutrin Nicoderm Cq 21mg	PS SS	Glaxosmithkline Glaxosmithkline	ORAL	 TRANSDERMAL	 6 WK

Date:03/04/04ISR Number: 4311281-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499807A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:03/04/04ISR Number: 4311282-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499947A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Completed Suicide		Wellbutrin	PS	Glaxosmithkline			

Date:03/05/04ISR Number: 4312277-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0357840A
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Discomfort
Hospitalization - Initial or Prolonged	Abortion Spontaneous
Other	Aggression
	Agitation
	Anger
	Anxiety
	Complications Of Maternal Exposure To Therapeutic Drugs
	Confusional State
	Convulsion
	Dependence
	Dizziness
	Drug Dependence

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective							
	Drug Withdrawal Syndrome							
	Influenza		Paxil	PS	Glaxosmithkline		5	MON
	Insomnia		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice	
	Maternal Drugs Affecting Foetus		Effexor	C			per day	
	Motor Dysfunction		Ativan	C			.5MG As	
	Nausea		Atenolol	C			required	
	Nightmare		Alcohol	C			25MG Per day	
	Pregnancy		Valium	C		ORAL		
	Psychotic Disorder							
	Pyrexia							
	Sensory Disturbance							
	Suicidal Ideation							
	Suicide Attempt							
	Tremor							
	Vomiting							

Date:03/05/04ISR Number: 4312298-9Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0319984A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Zyban	PS	Glaxosmithkline			
	Anorexia							
	Balance Disorder							
	Constipation							
	Deafness							
	Disturbance In Attention							
	Dysgeusia							
	Ear Disorder							
	Feeling Abnormal							
	Nausea							
	Sleep Disorder							
	Tinnitus							

Date:03/05/04ISR Number: 4312303-XReport Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0323131A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG Twice per day
	Alcohol Use							
			Alcohol	SS				
			No Concurrent Medication	C				

Date:03/05/04ISR Number: 4312305-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0323706A
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive
	C-Reactive Protein Increased
	Chest Pain
	Electrocardiogram St Segment Elevation
	Leukocytosis
	Lung Infiltration

	Neutrophil Count Increased Pericarditis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pharynx Discomfort		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text 9 DAY
	Viral Pericarditis						

Date:03/05/04ISR Number: 4312309-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0324489A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 2 WK Initial or Prolonged	Anaphylactic Reaction Dysphagia Dyspnoea Local Swelling Pharyngolaryngeal Pain Rash Pruritic		Zyban No Concurrent Medication	PS C	Glaxosmithkline	ORAL	

Date:03/05/04ISR Number: 4312330-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0325566A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 5 DAY

Date:03/08/04ISR Number: 4313521-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0500831A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Abuser Medication Error		Wellbutrin	PS	Glaxosmithkline	NASAL	

Date:03/08/04ISR Number: 4313524-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0501213A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:03/09/04ISR Number: 4314396-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0501024A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Wellbutrin	SS	Glaxosmithkline			

Date:03/09/04ISR Number: 4314412-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0324869A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oropharyngeal Swelling		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	18 DAY
	Swelling Face		Nurofen	C	Glaxosmithkline	ORAL		
	Urticaria Generalised							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/04ISR Number: 4314413-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0324872A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:03/10/04ISR Number: 4314967-3Report Type:Direct Company Report #CTU 214172
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Petit Mal Epilepsy		Remeron 60 Mg (Generic)	PS	Generic		60 MG AT BEDTIME	
			Wellbutrin Xl 300 Mg	SS			ONE TAB Q AM	
			Adderall Xr	C				
			Pamelor	C				
			Zyprexa	C				
			Trazodone	C				
			Ativan	C				

Date:03/10/04ISR Number: 4315134-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0501711A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hemiplegia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Unknown	139 DAY
Hospitalization - Initial or Prolonged	Pain Paraesthesia							
Disability	Simple Partial Seizures Syncope							

Date:03/11/04ISR Number: 4315617-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495750A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
Hospitalization -	Renal Failure Acute	Professional						per day
Initial or Prolonged			Lexapro	C			10MG Per day	
Disability			Avapro	C				
Other			Coumadin	C	Glaxosmithkline			
			Amiodarone	C				
			Lipitor	C				
			Saw Palmetto	C				
			Multivitamin	C				
			Tricor	C				
			Viagra	C				

Date:03/11/04ISR Number: 4315618-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0496778A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
Initial or Prolonged	Electroencephalogram	Professional	Zyprexa	C		ORAL	15MG Per day	
Other	Abnormal		Celexa	C		ORAL	40MG Per day	
	Grand Mal Convulsion							
	Medication Error							
	Postictal State							
	Tongue Biting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/04ISR Number: 4315625-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0502223A
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:03/11/04ISR Number: 4315806-7Report Type:Direct Company Report #USP 56383
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS			150 MG SUSTAINED RELEASE TABLET	

Date:03/11/04ISR Number: 4316643-XReport Type:Expedited (15-DaCompany Report #A0500156A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Depression Dizziness	Consumer	Nicorette Otc Gum 4 Mg (Nicotine Polacrilex)	PS			4 MG/TRANSBUCCAL	
	Drug Dependence Dry Mouth Feeling Abnormal Irritability		Nicoderm Cq Patch 7 Mg (Nicotine)	SS			TRANSDERMAL	7
	Lymphoma Neoplasm Recurrence Pallor Pharyngolaryngeal Pain		Wellbutrin (Formulation				MG/TRANSDERMAL	

			Unknown) (Bupropion Hydrochloride)	SS			
ORAL							
			Atomoxetine Hydrochloride	C			
			Clonazepam	C			

Date:03/12/04ISR Number: 4316190-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441497A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Paxil Cr	PS	Glaxosmithkline	ORAL	50MG Per day	
	Amnesia		Contac	SS	Glaxosmithkline	ORAL		
	Attention		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Deficit/Hyperactivity		Paxil	SS	Glaxosmithkline	ORAL		
	Disorder		Xanax	C				
	Confusional State		Clonopin	C				
	Depression							
	Diarrhoea							
	Disturbance In Attention							
	Drug Interaction							
	Dysphoria							
	Fatigue							
	Initial Insomnia							
	Nausea							
	Obsessive-Compulsive Disorder							
	Psychotic Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/04ISR Number: 4316206-6Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0323086A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	31 DAY
	Complications Of Maternal Exposure To Therapeutic		Bisolvin Linctus	C		ORAL	16 DAY	
	Drugs		Klacid Xl	C		ORAL	6 DAY	
	Maternal Drugs Affecting Foetus Pregnancy							

Date:03/12/04ISR Number: 4316750-1Report Type:Direct Company Report #USP 56332
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline		TABLET	
			Wellbutrin Sr	SS	Glaxosmithkline		TABLET	

Date:03/12/04ISR Number: 4317238-4Report Type:Expedited (15-DaCompany Report #KII-2003-0007821
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Study	Oxycontin Tablets (Oxycodone Hydrochloride) Cr Tablet	PS				
Other	Anion Gap Abnormal	Health Professional Other	Ethanol (Ethanol)	SS				
	Blood Alcohol Increased		Fluoxetine (Fluoxetine)	SS		ORAL	ORAL	
	Confusional State		Bupropion (Amfebutamone)	SS		ORAL	ORAL	
	Convulsion							
	Depressed Level Of Consciousness							
	Dysarthria							
	Hypertension							

	Intention Tremor					
	Multiple Drug Overdose					
	Serotonin Syndrome					
	Tachycardia					
	Tremor					
	Vomiting					

Date:03/15/04ISR Number: 4317635-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0496783A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 21 DAY						
	Depressed Level Of		Depakote	C		
	Consciousness		Ms Contin	C	Glaxosmithkline	
	Dizziness					
	Grand Mal Convulsion					
	Incontinence					
	Myalgia					
	Tongue Biting					
	Visual Disturbance					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/04ISR Number: 4317638-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0502146A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline			
	Medication Error		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Pharmaceutical Product Complaint		Clonazepam	C				

Date:03/15/04ISR Number: 4317640-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0502570A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product		Wellbutrin	SS	Glaxosmithkline	ORAL	200MG Twice per day	2 YR
	Complaint							

Date:03/15/04ISR Number: 4317650-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0325523A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus Generalised		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	21 DAY
	Tongue Ulceration							

Date:03/15/04ISR Number: 4317651-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0325526A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Unintended Pregnancy		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	

			Microval	SS		
UNKNOWN	7 YR					
			Sertraline	C		ORAL
100MG Per day						
			Kapake	C		ORAL
			Ibuprofen	C	Glaxosmithkline	
TOPICAL						

Date:03/15/04ISR Number: 4317653-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0325531A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abnormal Sensation In Eye		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
Initial or Prolonged	Blister					
per day 9 DAY						
	Oral Discomfort		Bendrofluazide	C	Glaxosmithkline	ORAL
2.5MG per day						
	Rash Erythematous		Felodipine	C		
UNKNOWN						
	Stevens-Johnson Syndrome					
	Tongue Discolouration					

Date:03/15/04ISR Number: 4317693-XReport Type:Expedited (15-DaCompany Report #US-ROCHE-360924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Klonopin	PS	Roche	ORAL
	Drug Interaction		Wellbutrin	I		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/04ISR Number: 4318218-5Report Type:Expedited (15-DaCompany Report #GBWYE626508MAR04
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs	Health Professional Other	Microval (Levonorgestrel, Tablet)	PS		ORAL	TAKEN	
	Drug Ineffective						REGULARLY FOR	
	Drug Interaction						SEVEN YEARS	
	Unintended Pregnancy		Zyban (Amfebutamone Hydrochloride, , 0)	SS		ORAL	150 MG	
			Sertraline (Sertraline)	C				
			Kapake (Codeine Phosphate/Paracetamol)	C				
			Ibuprofen (Ibuprofen)	C				

Date:03/15/04ISR Number: 4318671-7Report Type:Expedited (15-DaCompany Report #B0325227A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Crushing	Foreign	Wellbutrin (Formulation Unknown) (Bupropion Hydrochoride)	PS			UNKNOWN	UNK, UNK;
	Convulsion	Literature						
	Spinal Fracture	Health Professional					UNKNOWN	

Date:03/16/04ISR Number: 4317364-XReport Type:Direct Company Report #CTU 214424
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral		Wellbutrin	PS			
150 MG BID							
	Pruritus						

Date:03/16/04ISR Number: 4317366-3Report Type:Direct Company Report #CTU 214426
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS				
150 MG DAILY								
	Pruritus							
	Tremor							

Date:03/16/04ISR Number: 4317826-5Report Type:Expedited (15-DaCompany Report #US-ROCHE-360924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Klonopin	PS	Roche	ORAL		
	Convulsion		Wellbutrin	I		ORAL		
	Drug Interaction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/04ISR Number: 4317932-5Report Type:Expedited (15-DaCompany Report #US-ROCHE-360924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Klonopin	PS	Roche	ORAL		
	Drug Interaction		Wellbutrin	I		ORAL		

Date:03/16/04ISR Number: 4317936-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0493122A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See dosage text	23 DAY
Other	Concussion		Clomipramine	C			150MG At night	
	Fall		Seroquel	C		ORAL	25MG At night	
	Grand Mal Convulsion							
	Medication Error							
	Skull Fracture							

Date:03/16/04ISR Number: 4317960-XReport Type:Expedited (15-DaCompany Report #DK-GLAXOSMITHKLINE-B0325421A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	21 DAY	
	Joint Swelling							
	Lymphadenopathy							
	Urticaria							

Date:03/16/04ISR Number: 4317963-5Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0325690A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Cheilitis		Serevent	C	Glaxosmithkline			
	Eye Disorder		Pulmicort	C				
	Pruritus							
	Swelling Face							
	Urticaria							

Date:03/16/04ISR Number: 4318481-0Report Type:Direct Company Report #USP 214507
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Choking		Wellbutrin Xl 300					
Hospitalization -	Confusional State		Mg, 150mg, Glaxo	PS	Glaxo		300 MG PO Q	
Initial or Prolonged	Convulsion						AM ADDITIONAL	
	Loss Of Consciousness						150 MG QD X 2	
	Skin Discolouration						D, THEN 300	
	Tongue Biting						MG QD X 3D;	
			Lexapro	C				
			Ambien	C				
			Zyprexa	C				
			Protonix	C				
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/04ISR Number: 4319296-XReport Type:Expedited (15-DaCompany Report #GBWYE626508MAR04
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs	Health Professional Other	Microval (Levonorgestrel, Tablet, 0)	PS		ORAL	TAKEN	
	Drug Ineffective						REGULARLY	
	Drug Interaction						OVER SEVEN	
	Pregnancy On Oral Contraceptive						YEARS	
	Unintended Pregnancy		Zyban (Amfebutamone Hydrochloride, , 0)	SS		ORAL	150MG	
			Sertraline (Sertraline)	C				
			Kapake (Codeine Phosphate / Paracetamol)	C				
			Ibuprofen (Ibuprofen)	C				

Date:03/16/04ISR Number: 4320048-5Report Type:Expedited (15-DaCompany Report #USA-2003-0011528
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchitis Chronic Cerebral Infarction Chronic Obstructive Pulmonary Disease Coma Drug Screen Positive Emphysema Pleural Adhesion Pneumonitis Pyelonephritis Chronic Renal Disorder Scar	Health Professional Other	Morphine Sulfate (Morphine Sulfate)	PS				
			Hydrocodone Bitartrate (Hydrocodone Bitartrate)	SS				
			Dihydrocodeine/Caffeine/Acetaminophen (Dihydrocodeine, Caffeine, Paracetamol)	SS				
			Acetaminophen (Paracetamol)	SS				
			Olanzapine					

			(Olanzapine)	SS	
			Amitriptyline (Amitriptyline)	SS	
			Trazodone (Trazodone)	SS	
			Nicotine (Nicotine)	SS	
			Caffeine (Caffeine)	SS	
			Bupropion (Amfebutamone)	SS	

Date:03/17/04ISR Number: 4318139-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0502264A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Drug Exposure During Pregnancy Trisomy 18		Bupropion	PS	Glaxosmithkline		150MG Per day	35 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/04ISR Number: 4318142-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0502603A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myasthenia Gravis	Health Professional	Wellbutrin	PS	Glaxosmithkline			
			Trazodone	SS				

Date:03/18/04ISR Number: 4319549-5Report Type:Direct Company Report #CTU 214745
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated		Wellbutrin 100	PS			100 MG BID	
	Granuloma		Wellbutrin 150	SS			150 MG TID	
	Mental Disorder							
	Nephritis Interstitial							
	Proteinuria							
	Pyuria							
	Renal Failure							

Date:03/19/04ISR Number: 4319737-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441348A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antepartum Haemorrhage		Bupropion	PS	Glaxosmithkline	ORAL	300MG per day	
	Drug Exposure During Pregnancy							

Date:03/19/04ISR Number: 4319746-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0502845A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	

	Pharmaceutical Product		Wellbutrin	SS	Glaxosmithkline	ORAL 150MG Twice
	Complaint					per day

Date:03/19/04ISR Number: 4319747-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0502949A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Corneal Bleb		Zyban	PS	Glaxosmithkline	ORAL 150MG See
	Drug Interaction					dosage text
	Eye Pain		Alcohol	SS		ORAL 8Z See dosage
	Keratoconjunctivitis					text
	Sicca		Antihypertensives	C		

Date:03/19/04ISR Number: 4319749-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0502995A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL 4 WK
	Dyspnoea					
	Loss Of Consciousness					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/04ISR Number: 4319758-5Report Type:Expedited (15-DaCompany Report #PT-GLAXOSMITHKLINE-B0321513A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperaesthesia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash Erythematous							
per day								35 DAY
	Rash Pruritic		Motilium	C		ORAL		
	Urticaria		Sedoxil	C		ORAL		

Date:03/19/04ISR Number: 4319769-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0326019A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	1 MON
	Pruritus							
	Renal Failure							

Date:03/19/04ISR Number: 4319772-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0326277A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	20 DAY
	Face Oedema		Naxy	C		ORAL	500MG Per day	5 DAY
	Laryngeal Oedema							
	Tracheitis							

Date:03/19/04ISR Number: 4319779-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0327034A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	3 WK

	Increased					
	Dermatitis Bullous					
	Porphyria					
	Serum Ferritin Increased					

Date:03/22/04ISR Number: 4321105-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0442426A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		51 DAY
Hospitalization -	Anxiety		Glucosamine	C		ORAL		
Initial or Prolonged	Chest Pain		Nexium	C		ORAL		
	Circulatory Collapse							
	Disorientation							
	Heart Rate Increased							
	Ill-Defined Disorder							
	Stress							
	Supraventricular							
	Tachycardia							

Date:03/22/04ISR Number: 4321116-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0323573A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	MON

			Euphytose	C		ORAL
2UNIT Three times per day						

Date:03/22/04ISR Number: 4321123-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0326155A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Zyban	PS	Glaxosmithkline			

Date:03/22/04ISR Number: 4323073-3Report Type:Expedited (15-DaCompany Report #002#4#2004-00046 (0)
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Reglan-10mg-Tablet					
Required		Professional	(Metoclopramide Hcl)	PS		ORAL	10MG, 1 IN 1	
Intervention to		Other					D, ORAL	
Prevent Permanent			Bupropion	SS		ORAL	ORAL	
Impairment/Damage			Valsartan-Hct	C				
			Amlodipine	C				
			Simvastatin	C				
			Diflunisal	C				
			Doxepin	C				
			Levothyroxine	C				
			Omeprazole	C				
			Venlafaxine	C				
			Fluoxetine	C				
			Hydrochloroquine	C				
			Folic-Acid	C				

Date:03/23/04ISR Number: 4322080-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443907A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Burning Sensation	Consumer	Lamictal	PS	Glaxosmithkline	ORAL 37.5MG Per day 4 WK
	Erythema					
	Hypersensitivity		Wellbutrin Xl	SS	Glaxosmithkline	300MG Per day
	Nerve Injury		Flomax	C		
	Pruritus		Detrol	C		
	Pyrexia		Neurontin	C		
	Stevens-Johnson Syndrome		Propanolol	C		
	Swelling Face					

Date:03/23/04ISR Number: 4322081-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0503391A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL 150MG Per day
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL 150MG Twice per day YR

Date:03/23/04ISR Number: 4322112-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0326881A
Age:32 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Loss Of Consciousness

	Malaise						
	Nightmare						
	Tetany	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
	Tremor		Zyban	PS	Glaxosmithkline	ORAL	
150MG Per day	8 DAY						

Date:03/23/04ISR Number: 4322389-4Report Type:Direct Company Report #CTU 215050
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaphylactic Reaction		Bupropion 300 Mg	PS		ORAL
300 MG DAILY						
Initial or Prolonged	Hypersensitivity					
ORAL						

Date:03/23/04ISR Number: 4322459-0Report Type:Direct Company Report #CTU 215033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Activities Of Daily		Welbutin			
	Living Impaired					
	Anorexia		Glaxo?	PS	Glaxo	
	Anxiety		Zoloft	SS		
	Feeling Of Despair					
	Feelings Of Worthlessness					
	Insomnia					
	Paranoia					
	Suicidal Ideation					

Date:03/23/04ISR Number: 4322462-0Report Type:Direct Company Report #CTU 215036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cerebrovascular Accident		Serzone	PS		ORAL
600 MG DAILY						
Initial or Prolonged	Condition Aggravated					
ORAL						

	Depression		Wellbutrin	SS		ORAL
ORAL						
	Drug Effect Decreased					
	Hypersensitivity					
	Mental Disorder					
	Suicidal Ideation					

Date:03/24/04ISR Number: 4322728-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0498181A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abortion Spontaneous	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	50TAB per day	
Initial or Prolonged	Complications Of Maternal	Professional	Paxil Cr	SS	Glaxosmithkline	ORAL	37.5MG See	
	Exposure To Therapeutic						dosage text	
	Drugs		Geodon	C			80MG Per day	
	Drug Exposure During		Neurontin	C			900MG Per day	
	Pregnancy		Folate	C			1MG Per day	40 DAY
	Overdose		Prenatal Vitamin	C				
	Suicide Attempt							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/04ISR Number: 4322751-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0326452A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Anger							
per day							2	WK
	Headache							

Date:03/24/04ISR Number: 4322757-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0326619A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysgeusia		Zyban	PS	Glaxosmithkline	ORAL	1TAB See	
	Tremor							
dosage text							10	DAY

Date:03/24/04ISR Number: 4322760-0Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0042959A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anaemia	Professional						
per day								
	Fat Intolerance							
	Gamma-Glutamyltransferase Increased							
	Lipase Increased							

Date:03/24/04ISR Number: 4322973-8Report Type:Direct Company Report #CTU 215158
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gun Shot Wound		Paxil	PS				

	Intentional Self-Injury		Welbutrin	SS		

Date:03/24/04ISR Number: 4323228-8Report Type:Direct Company Report #CTU 215194
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Suicide Attempt		Wellbutrin	PS		ORAL	150 MG 1 A	DAY ORAL, 300
							MG 1 A DAY	
							ORAL	

Date:03/24/04ISR Number: 4323238-0Report Type:Direct Company Report #CTU 215201
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fall		Wellbutrin 75 Mg					
Hospitalization -	Head Injury		Glaxo	PS	Glaxo	ORAL	1 DAY MORNIN	
Initial or Prolonged	Intentional Self-Injury						ORAL	
	Nervousness		Paxil	SS		ORAL	1 DAY EVENIN	
	Suicide Attempt						ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/04ISR Number: 4323270-7Report Type:Direct Company Report #CTU 215183
Age:37 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Welbutrin	PS		ORAL	20 MG 1 DAILY	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Suicidal Ideation		Celexa 20 Mg Fore	SS	Fore	ORAL		

Date:03/24/04ISR Number: 4323349-XReport Type:Direct Company Report #CTU 215179
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Wellbutrin Xl 300 Mg	PS		ORAL	1 TABLET PER ORAL	
	Impaired Work Ability							
	Memory Impairment							
	Thinking Abnormal							

Date:03/24/04ISR Number: 4323807-8Report Type:Direct Company Report #CTU 215213
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression		Wellbutrin Sr 150 Mg Bid, Glaxo Smith K	PS	Glaxo Smith K		150 MG BID	
	Alcoholism							
	Impaired Driving Ability							
	Imprisonment							
	Poisoning							
	Suicide Attempt							

Date:03/25/04ISR Number: 4323382-8Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0503364A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Sr	PS	Glaxosmithkline		400MG Per day	
	Drug Interaction		Clozaril	SS		ORAL	575MG Per day	
	Drug Level Decreased		Dilantin	SS				
	Grand Mal Convulsion		Clopixol	C				
	Therapeutic Response Decreased		Cogentin	C				
			Fluoxetine	C				
			Lamictal	C	Glaxosmithkline			
			Lamotrigine	C	Glaxosmithkline			
			Lectopam	C				
			Olanzapine	C				
			Prozac	C				
			Seroquel	C				
			Zyprexa	C				

Date:03/25/04ISR Number: 4323383-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0503515A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/04ISR Number: 4323385-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0503856A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:03/25/04ISR Number: 4323386-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504045A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Problem		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Completed Suicide		Xanax	C				
			Alcohol	C				

Date:03/25/04ISR Number: 4323387-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504061A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See dosage text	
	Joint Dislocation							
	Medication Error		Nicorette Gum	C	Glaxosmithkline			
	Upper Limb Fracture		Diovan	C				
			Stelazine	C	Glaxosmithkline			

Date:03/25/04ISR Number: 4323390-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504190A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Suicide Attempt							

Date:03/25/04ISR Number: 4323403-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0325443A
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Dizziness		Astrix	C	Glaxosmithkline		UNKNOWN	100MG Per day
	Dyspnoea		Caltrate	C	Glaxosmithkline		UNKNOWN	600MG Unknown
	Nausea		Cortisone Acetate	C	Glaxosmithkline		UNKNOWN	25MG Four times per day
	Retching		Eleuphrat	C			UNKNOWN	.5PCT Twice per day
			Fenac	C	Glaxosmithkline		UNKNOWN	50MG Twice per day
			Losec	C			UNKNOWN	20MG Twice per day
			Nitrolingual	C	Glaxosmithkline		UNKNOWN	400MCG As required
			Oroxine	C	Glaxosmithkline		UNKNOWN	.1MG Unknown
			Panadeine Forte	C	Glaxosmithkline		UNKNOWN	
			Panamax	C	Glaxosmithkline		UNKNOWN	500MG Twice per day
			Prednisone	C			UNKNOWN	
			Premarin	C			UNKNOWN	.625MG Per day
			Quinate	C	Glaxosmithkline		UNKNOWN	300MG At night

				Seretide	C	Glaxosmithkline	RESPIRATORY (INHALATION)
				Spiriva	C		
UNKNOWN	18MCG Per day						
				Temaze	C		
UNKNOWN	10MG See dosage text						
				Ventolin	C	Glaxosmithkline	
UNKNOWN							

Date:03/25/04ISR Number: 4324665-8Report Type:Direct Company Report #CTU 215279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal		Paxil 20 Mg	PS		ORAL	ONCE DAILY	
Required Intervention to Prevent Permanent Impairment/Damage	Exposure To Therapeutic Drugs Depression Feeling Of Despair Post-Traumatic Stress Disorder Pregnancy Self-Injurious Ideation		Wellburtin Sr 150 Mg	SS		ORAL	TWICE DAILY	

Date:03/26/04ISR Number: 4324768-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441497A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour	Health	Paxil Cr	PS	Glaxosmithkline	ORAL	50MG Per day	
	Alcohol Poisoning	Professional	Contac	SS	Glaxosmithkline	ORAL		
	Amnesia		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Anxiety		Paxil	SS	Glaxosmithkline	ORAL		

	Attention		Alcohol	SS		ORAL
1 DAY						
	Deficit/Hyperactivity		Xanax	C		
	Disorder		Clonopin	C		
	Confusional State		Seroquel	C		
	Depression		Atenolol	C		
	Diarrhoea					
	Disturbance In Attention					
	Drug Interaction					
	Dysphoria					
	Fatigue					
	Headache					
	Initial Insomnia					
	Laceration					
	Mental Status Changes					
	Mydriasis					
	Nausea					
	Obsessive-Compulsive					
	Disorder					
	Panic Attack					
	Psychotic Disorder					
	Toxicologic Test Abnormal					

Date:03/26/04ISR Number: 4324774-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0498860A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Medication Error							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/04ISR Number: 4324780-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0503547A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Choking		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Convulsion		Seroquel	C				1 YR
	Depressed Level Of Consciousness							
	Disorientation							

Date:03/26/04ISR Number: 4324787-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504270A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Suicidal Ideation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		2 YR
	Suicide Attempt							

Date:03/26/04ISR Number: 4324788-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504316A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		2 YR
	Diabetes Mellitus		Wellbutrin	SS	Glaxosmithkline		150MG Per day	1 MON
	Inadequate Control		Reglan	C	Glaxosmithkline			
	Insomnia		Trental	C				
	Medication Error		Alpha Lipoic Acid	C				
			Chromium Picolinate	C				
			Carbamazepine	C				
			Evening Primrose Oil	C				
			Insulin	C				

Date:03/26/04ISR Number: 4324813-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0327761A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Haematoma							
	Myalgia							
	Oedema Peripheral							
	Serum Sickness							

Date:03/26/04ISR Number: 4325033-5Report Type:Direct Company Report #CTU 215375
Age:29 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Affect Lability
Hospitalization - Initial or Prolonged	Amnesia
Required Intervention to Prevent Permanent Impairment/Damage	Antisocial Behaviour
	Confusional State
	Conversion Disorder
	Hostility
	Migraine
	Myalgia
	Paranoia
	Suicidal Ideation
	Suicide Attempt
	Vertigo

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Prozac	PS		ORAL	1 ORAL	
			Zoloft	SS		ORAL	2-3 ORAL	
			Paxil	SS				
			Wellbutrin	SS				

Date:03/29/04ISR Number: 4325955-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0494894A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electrocardiogram Qt Prolonged	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	6 MON
			Neurontin	C		ORAL	1800MG per day	
			Strattera	C		ORAL	64 DAY	
			Zyprexa	C		ORAL	10MG At night	
			Trazodone	C				

Date:03/29/04ISR Number: 4325956-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495776A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	5	WK
			Trazodone	C			5	WK

Date:03/29/04ISR Number: 4325957-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499051A
Age:6 MON Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure Via Breast	Health	Bupropion	PS	Glaxosmithkline		150MG Per day	
	Milk	Professional						
	Grand Mal Convulsion							

Date:03/29/04ISR Number: 4325960-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0503470A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Pregnancy		Antibiotic	C				
	Fungal Infection							
	Nephrolithiasis							
	Urinary Tract Infection							

Date:03/29/04ISR Number: 4325961-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0503536A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	4 DAY	
	Flight Of Ideas							

Date:03/29/04ISR Number: 4325969-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504565A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	13	MON
	Headache							
	Suicidal Ideation							

Date:03/29/04ISR Number: 4325973-7Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0312414A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG See	
Hospitalization -	Bradycardia	Professional					dosage text	
Initial or Prolonged	Cardiac Enzymes Increased		Ascorbic Acid	C	Glaxosmithkline			
Disability	Epilepsy		Aspirin Junior	C	Glaxosmithkline			
Other	Influenza Like Illness		Multivitamin With					
	Loss Of Consciousness		Zinc	C				
	Malaise		Selenium	C				
	Sudden Death		Glucosamine Sulphate	C				
	Syncope		Ventolin	C	Glaxosmithkline		RESPIRATORY	
	Ventricular Extrasystoles						(INHALATION)	
	Ventricular Fibrillation		Lysomucil	C	Glaxosmithkline	ORAL		
	White Blood Cell Count Increased							

Date:03/29/04ISR Number: 4325987-7Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0327048A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Initial or Prolonged	Eczema						per day	17 DAY
	Oedema Mucosal							

Pruritus
Urticaria
Visual Disturbance

Date:03/29/04ISR Number: 4325993-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0327617A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Suicide Attempt		Zyban	PS	Glaxosmithkline	ORAL	150MG See Hospitalization - dosage text	35 DAY
Initial or Prolonged			Fenofibrate	C			UNKNOWN	
			Maxepa	C	Glaxosmithkline		UNKNOWN	
			Kardegic	C			UNKNOWN	
			Titanoreine	C			UNKNOWN	

Date:03/29/04ISR Number: 4325994-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0327623A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
Initial or Prolonged	Oligomenorrhoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/04ISR Number: 4326341-4Report Type:Direct Company Report #CTU 215449
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bipolar I Disorder		Wellbutrin Glaxo	PS	Glaxo			
Hospitalization - Initial or Prolonged	Suicide Attempt							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:03/29/04ISR Number: 4326342-6Report Type:Direct Company Report #CTU 215451
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS		ORAL	ORAL	

Date:03/29/04ISR Number: 4330951-8Report Type:Expedited (15-DaCompany Report #B0325227A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased	Foreign Literature	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Gliosis	Health Professional						
	Grand Mal Convulsion							
	Hepatic Enzyme Increased							
	Hyperreflexia							
	Inflammation							
	Spinal Compression Fracture							
	Tachycardia							

Date:03/29/04ISR Number: 4332258-1Report Type:Expedited (15-DaCompany Report #S04-USA-01540-01
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Petit Mal Epilepsy Tremor	Consumer	Lexapro (Escitalopram)	PS		ORAL	10 MG QD PO	
			Wellbutrin - Slow Release (Bupropion Hydrochloride)	SS			150 MG QD	
			Prozac (Fluoxetine Hydrochloride)	C				

Date:03/29/04ISR Number: 4332262-3Report Type:Expedited (15-DaCompany Report #S04-USA-01545-01
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Grand Mal Convulsion	Health Professional	Tessalon Perle (Benzonatate)	PS		ORAL	100 MG BID PO	
			Wellbutrin - Slow Release (Bupropion Hydrochloride)	SS			200 MG BID	
			Wellbutrin - Slow Release (Bupropion Hydrochloride)	SS			300 MG QD	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/04ISR Number: 4327145-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0314874A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Tendon Rupture	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	38 DAY
			Avandia	C	Glaxosmithkline	ORAL	850MG Twice per day	
			Metformine	C		ORAL	2UNIT per day	
			Novonorm	C		ORAL		

Date:03/30/04ISR Number: 4327147-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0318887A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diplopia Headache Iiird Nerve Paralysis Strabismus	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY

Date:03/30/04ISR Number: 4327148-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0320004A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Aptyalism Asthenia Cytolytic Hepatitis Cytomegalovirus Antibody Positive Dermatitis Exfoliative Epstein-Barr Virus Antibody Positive	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	22 DAY

	Hypersensitivity
	Hypotension
	Inflammation
	Insomnia
	Leukopenia
	Lymphadenopathy
	Nausea
	Painful Respiration
	Pruritus
	Purpura
	Rash Erythematous
	Rash Maculo-Papular
	Rash Morbilliform
	Rash Scarlatiniform
	Thrombocytopenia
	Tremor

Date:03/30/04ISR Number: 4327155-1Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0326891A
Age:32 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Aggression
	Agitation
	Confusional State
	Headache
	Hypertension

		Hyperventilation Sinus Tachycardia					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Zyban	PS	Glaxosmithkline	ORAL
10	DAY						

Date:03/30/04ISR Number: 4327159-9Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0327209A
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Feeling Abnormal		Zyban	PS	Glaxosmithkline	ORAL
150MG See							
		Hypoaesthesia					
dosage text							
		Insomnia		Formoterol	C		
6MCG Per day							
		Irritability		Budesonide	C		
400MCG Twice							
		Muscular Weakness					
per day							
		Paraesthesia		Ipratropium			
		Peroneal Nerve Palsy		Salbutamol	C		

Date:03/30/04ISR Number: 4327538-XReport Type:Direct Company Report #CTU 215519
Age:53 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Agitation		Lexipro Police			
		Anxiety		Confiscated	PS		ORAL
ONCE A DAY							
		Completed Suicide					
ORAL							
		Intentional Self-Injury		Welbutrin Police			
				Confiscated	SS		ORAL
ONCE A DAY							
ORAL							
				Ambien	C		
				Blood Pressure			
				Medication	C		

			Trazidone	C		
			Maxalt	C		
			Flonase	C		

Date:03/30/04ISR Number: 4332054-5Report Type:Expedited (15-DaCompany Report #B0327440A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Dyspnoea Tachycardia	Foreign Other	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ORAL	1 WK

Date:03/31/04ISR Number: 4327686-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420530A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphoria Tinnitus		Compazine	PS	Glaxosmithkline	ORAL	5MG Four times per day	1 YR
			Wellbutrin	SS	Glaxosmithkline	ORAL		WK
			Vicodin	C		ORAL		
			Lexapro	C				
			Unspecified Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/04ISR Number: 4328185-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504801A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	4 YR
	Blood Pressure Increased		Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
	Insomnia		No Concurrent					
	Irritability		Medication	C				
	Pain							
	Paraesthesia							
	Suicidal Ideation							
	Tinnitus							
	Vision Blurred							
	Weight Increased							

Date:03/31/04ISR Number: 4331004-5Report Type:Expedited (15-DaCompany Report #2004005972
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Zoloft (Sertraline)	PS		ORAL	50 MG	
	Benign Bone Neoplasm	Professional					(DAILY), ORAL	
	Bruxism		Bupropion					
	Drug Withdrawal Syndrome		Hydrochloride					
	Feeling Abnormal		(Bupropion					
	Hot Flush		Hydrochloride)	SS			300 MG (BID)	
	Hyperphagia		Levothyroxine Sodium					
	Paraesthesia		(Levothyroxine					
	Pharmaceutical Product		Sodium)	C				
	Complaint		Clonazepam					
	Sleep Disorder		(Clonazepam)	C				
	Tongue Ulceration		Vitamins	C				
	Weight Increased							

Date:04/01/04ISR Number: 4329728-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0422196A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Back Pain						per day	
	Eye Pain		Clonazepam	C				
	Headache							
	Thinking Abnormal							
	Visual Acuity Reduced							

Date:04/01/04ISR Number: 4329729-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439007A
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice	
Initial or Prolonged	Chills						per day	1 MON
Other	Depression		Flomax	C				
	Erectile Dysfunction		Cozaar	C				
	Insomnia		Indapamide	C				
	Myalgia		Duragesic	C				
	Myoclonus							
	Tremor							
	Vestibular Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/04ISR Number: 4329733-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504292A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Drug Exposure During Pregnancy		Bupropion	PS	Glaxosmithkline		300MG Per day	
			Wellbutrin	SS	Glaxosmithkline			
	Haemangioma							
	Talipes							

Date:04/01/04ISR Number: 4329736-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504889A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glaucoma		Wellbutrin	PS	Glaxosmithkline			

Date:04/01/04ISR Number: 4329737-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505089A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Central Nervous System	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Lymphoma	Professional	Tipranavir + Ritonavir	SS		ORAL		
	Lobar Pneumonia		Bactrim	SS	Glaxosmithkline			
			Zithromax	SS				
			Prevacid	SS				
			T-20	SS				

Date:04/01/04ISR Number: 4329738-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505095A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Antibiotic	C				
			Benadryl	C	Glaxosmithkline			

Date:04/01/04ISR Number: 4329741-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505251A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG per day	

Date:04/01/04ISR Number: 4329744-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505433A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Medication Error		Psychotropic Medications	C				

Date:04/01/04ISR Number: 4330257-7Report Type:Direct Company Report #CTU 215809
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin					
	Impaired Work Ability		(Bupropion)	PS		ORAL	150 MG BID PO	
	Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/04ISR Number: 4330724-6Report Type:Direct Company Report #CTU 215660
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Venofer Iv 100mg	PS		INTRAVENOUS	100MG IV	
Initial or Prolonged	Hypoaesthesia							DAILY
	Mental Impairment		Wellbutrin	SS				
	Speech Disorder							

Date:04/01/04ISR Number: 4331683-2Report Type:Direct Company Report #CTU 215803
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Macular		Wellbutrin Xl 150 Mg	PS		ORAL	ONE DOSE PO	
	Rash Pruritic							QD

Date:04/02/04ISR Number: 4330638-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0443385A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dystonia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	400MG per day	
	Fatigue	Professional						
	Grand Mal Convulsion							
	Hypoaesthesia							
	Impaired Driving Ability							
	Loss Of Consciousness							
	Paraesthesia							
	Tongue Biting							

Date:04/02/04ISR Number: 4330639-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495363A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	4 MON
	Drug Interaction	Professional						
			Prednisolone	SS	Glaxosmithkline			

Date:04/02/04ISR Number: 4330651-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505440A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Klonopin	SS			UNKNOWN	

Date:04/02/04ISR Number: 4330666-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0328013A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dry Mouth		Zyban	PS	Glaxosmithkline	ORAL		
	Hypersensitivity							
	Insomnia							
	Sleep Disorder							
	Suffocation Feeling							
	Throat Tightness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/04ISR Number: 4330669-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0328536A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antinuclear Antibody		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 15 DAY
	Positive		Foncitril 4000	C			UNKNOWN	
	Arthralgia		Orocal	C	Glaxosmithkline		UNKNOWN	
	Drug Toxicity		Sulfarlem	C			UNKNOWN	
	Epidermal Necrosis		Imovane	C			UNKNOWN	
	Inflammation		Aspirin	C	Glaxosmithkline			
	Photosensitivity Reaction							
	Rash Erythematous							
	Systemic Lupus Erythematosus							
	Toxic Skin Eruption							

Date:04/02/04ISR Number: 4330670-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0328580A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Consumer	Zyban	PS	Glaxosmithkline	ORAL	500MG Twice per day	5 DAY
	Confusional State		Ciflox 500	SS		ORAL	500MG Three times per day	
	Delirium Tremens							
	Hyponatraemia		Vitamine B1	C		ORAL		
	Pyelonephritis							
	Renal Failure Acute							

Date:04/02/04ISR Number: 4330675-7Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043506A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Suicide Attempt		Zyban	PS	Glaxosmithkline	ORAL 44TAB Single dose

Date:04/05/04ISR Number: 4332094-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0421244A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL 1TAB Twice per day
	Transient Ischaemic Attack		Nortriptyline	SS		
			Ibuprofen	SS	Glaxosmithkline	

Date:04/06/04ISR Number: 4333832-9Report Type:Direct Company Report #CTU 216002
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Accidental Overdose		Prozac	PS		
Hospitalization - Initial or Prolonged	Anger		Paxil	SS		
	Anorexia		Zoloft	SS		
Disability	Cognitive Disorder		Effexor	SS		
Required Intervention to Prevent Permanent Impairment/Damage	Depression		Wellbutrin	SS		
	Fibromyalgia		Sertraline	SS		
	Suicide Attempt					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/04ISR Number: 4335551-1Report Type:Expedited (15-DaCompany Report #CHPA2004US01801
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger Drug Interaction Personality Change Psychotic Disorder	Consumer	Riteaid Step 1 21mg (Nch)(Nicotine) Trans-Therapeutic-System	PS			TRANSDERMAL	21 MG, QD,
	Social Avoidant Behaviour						TRANSDERMAL	
			Wellbutrin(Bupropion Hydrochloride)	SS			150 MG, QD,	
			Thiothixene (Tiotixene)	C				
			Benztropeine	C				

Date:04/07/04ISR Number: 4334519-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0327924A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose Suicide Attempt		Zyban	PS	Glaxosmithkline	ORAL	1500MG per day	1 DAY
			Aleve	SS		ORAL	1320MG per day	1 DAY

Date:04/07/04ISR Number: 4334524-2Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0328019A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Zyban	PS	Glaxosmithkline		75MG per day	
			Clopidogrel	C				
			Bisoprolol Fumarat	C			2.5MG per day	

			Perindopril Tert-Butylamine	C		
4MG per day						
			Acetylsalicylic Acid	C	Glaxosmithkline	
160MG per day						

Date:04/07/04ISR Number: 4334551-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0328585A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Supraventricular		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Tachycardia							

Date:04/07/04ISR Number: 4334755-1Report Type:Direct Company Report #CTU 216162
Age: Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Anhedonia
	Anxiety
	Cardiac Flutter
	Crying
	Dizziness
	Drug Ineffective
	Electroencephalogram Abnormal
	Fatigue
	Feeling Abnormal
	Feeling Jittery
	Head Injury

		Headache					
		Hypersensitivity					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoaesthesia Oral		Prozac 40 Mg	PS		
		Memory Impairment		Wellbutrin	SS		
		Nausea					
		Paraesthesia					
		Rash					
		Speech Disorder					
		Suicidal Ideation					
		Vision Blurred					
		Visual Disturbance					
		Vomiting					

Date:04/08/04ISR Number: 4335029-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504190A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Suicidal Ideation	Consumer	Wellbutrin Xl	PS	Glaxosmithkline	ORAL
	Suicide Attempt					

Date:04/08/04ISR Number: 4335030-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505092A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Complications Of Maternal		Paxil Cr	PS	Glaxosmithkline	ORAL
62.5MG Per						
	Exposure To Therapeutic					
day	2 YR					
	Drugs		Wellbutrin Xl	SS	Glaxosmithkline	ORAL
150MG Per day	24 HR					
	Drug Exposure During		Buspar	C		
	Pregnancy					
	Pregnancy					
	Suicidal Ideation					

Date:04/08/04ISR Number: 4335034-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505954A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Fall							
	Haemorrhage							
	Head Injury							
	Skull Fracture							

Date:04/08/04ISR Number: 4335035-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505967A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG See dosage text	3 WK
	Medication Error	Professional						

Date:04/08/04ISR Number: 4336941-3Report Type:Expedited (15-DaCompany Report #2004UW06035
Age:46 YR Gender:Male I/FU:I

Outcome
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abasia	Consumer	Seroquel	PS				
	Dysstasia		Wellbutrin	SS				
	Fall		Motrin	C				
	Rhabdomyolysis		Heparin	C				
			Ultram	C				
			Prednisone	C				
			Cellcept	C				
			Sleeping Pill	C				

Date:04/09/04ISR Number: 4335454-2Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12493342
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal		Abilify	PS	Otsuka			
	Exposure To Therapeutic				Pharmaceutical			
	Drugs				Company, Ltd.	ORAL		
	Intra-Uterine Death		Seroquel	SS			12.5 to 25	
	Maternal Drugs Affecting						mg/day as	
	Foetus						needed	
	Pregnancy		Klonopin	SS				
			Lexapro	SS				
			Wellbutrin	SS				

Date:04/09/04ISR Number: 4335677-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505989A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:04/09/04ISR Number: 4335678-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506077A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin Sr	PS	Glaxosmithkline		150MG per day	

Date:04/09/04ISR Number: 4335679-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506101A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	175MG See dosage text	

Date:04/09/04ISR Number: 4335681-4Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0506123A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During		Bupropion	PS	Glaxosmithkline		150MG per day	
	Pregnancy							
	Foetal Heart Rate							
	Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/04ISR Number: 4335700-5Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0326452A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Affective Disorder	Health	Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Aggression	Professional					per day	2 WK
	Anger		Hydroxychloroquine					
	Headache		Sulphate	C		ORAL	200MG Twice	
							per day	

Date:04/09/04ISR Number: 4335701-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0327623A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Abdominal Pain Lower	Professional	Mercilon	C		ORAL		
	Back Pain		Revaxis	C			UNKNOWN	1 DAY
	Oligomenorrhoea							
	Paraesthesia							

Date:04/09/04ISR Number: 4335702-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0328342A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Zyban	PS	Glaxosmithkline	ORAL	150MG Three	
							times per day	

Date:04/09/04ISR Number: 4335707-8Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0328702A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Zyban	PS	Glaxosmithkline		150MG per day	4 WK
	Diplopia		Logimax	C				
	Dysarthria		Thyroxin Sodium	C	Glaxosmithkline			
	Headache		Metformin Hydrochloride	C				
	Hemiparesis		Rosiglitazone Maleate	C	Glaxosmithkline			

Date:04/09/04ISR Number: 4335708-XReport Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0328825A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetic Neuropathy	Health Professional	Zyntabac	PS	Glaxosmithkline	ORAL		
			Unspecified Anti-Diabetic	C				

Date:04/09/04ISR Number: 4342734-3Report Type:Periodic Company Report #03P-163-0213874-00
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Convulsion	Health Professional	Semisodium Valproate (Depakote)					
		Company Representative	(Divalproex Sodium) (Divalproex Sodium)	PS		ORAL	PER ORAL	
		Other	Bupropion Hydrochloride	SS		ORAL	PER ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/04ISR Number: 4336661-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505546A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Drug Exposure During Pregnancy		Ritalin	C				
	Weight Increased							

Date:04/12/04ISR Number: 4336663-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506244A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline			
	Medication Error		Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:04/12/04ISR Number: 4336665-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506288A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Vasculitis							

Date:04/12/04ISR Number: 4336666-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506304A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
Initial or Prolonged	Chest Pain	Professional	Alcohol	SS		ORAL		
	Depressed Level Of Consciousness							
	Suicide Attempt							

Date:04/12/04ISR Number: 4336673-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0328618A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Monoparesis		Zyban	PS	Glaxosmithkline			

Date:04/12/04ISR Number: 4338131-7Report Type:Direct Company Report #CTU 216425
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus Skin Lesion		Wellbutrin	PS		ORAL	150 MG X 2DAILY ORAL	

Date:04/13/04ISR Number: 4337523-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506364A
Age: Gender: I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -
Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Respiratory Failure		Prozac	SS				

Date:04/13/04ISR Number: 4337524-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506389A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:04/13/04ISR Number: 4337526-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506474A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Medication Error							

Date:04/13/04ISR Number: 4337528-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506493A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:04/13/04ISR Number: 4338091-9Report Type:Direct Company Report #CTU 216521
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Buproprion Sr 100 Mg	PS		ORAL	100 MG ONE	
	Aggression						BID PO	

Pharmaceutical Product
Complaint

Date:04/13/04ISR Number: 4338297-9Report Type:Direct Company Report #CTU 216488
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypersensitivity		Wellbutrin Sr 150mr	PS		ORAL	150MG BID	
	Urticaria						ORAL	

Date:04/14/04ISR Number: 4338487-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506365A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
	Dizziness		Calcium + Magnesium					
	Muscle Twitching		Supplement	C				
	Nephrolithiasis		Zoloft	C			100MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/04ISR Number: 4338489-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506833A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	5 DAY
	Medication Error		Toprol	C				
	Nausea							

Date:04/14/04ISR Number: 4338491-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506950A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product		Bupropion					
	Complaint		Hydrochloride	SS	Glaxosmithkline	ORAL	150MG Per day	

Date:04/14/04ISR Number: 4338506-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0329071A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anger		Zyban	PS	Glaxosmithkline	ORAL		
Initial or Prolonged	Psychotic Disorder		Quetiapine	C				
	Suicide Attempt							

Date:04/15/04ISR Number: 4339432-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506081B
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Exposure During		Bupropion	PS	Glaxosmithkline		150MG per day	78 DAY
	Pregnancy							
	Sudden Infant Death							
	Syndrome							

Date:04/15/04ISR Number: 4339439-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0507157A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline		150MG Twice per day	

Date:04/15/04ISR Number: 4339440-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0507194A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Overdose		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:04/16/04ISR Number: 4339924-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0503515A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/04ISR Number: 4339943-6Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0328825A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Atrophy		Zyntabac	PS	Glaxosmithkline	ORAL	58	DAY
	Difficulty In Walking		Avandia	SS	Glaxosmithkline	ORAL	4MG Per day	
	Dizziness		Dianben	SS		ORAL	1700MG per day	
	Polyneuropathy							
	Pyrexia		Adiro	SS	Glaxosmithkline	ORAL		

Date:04/16/04ISR Number: 4339947-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0329259A
Age:36 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Affect Lability		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	2 MON
	Anxiety		Depo-Provera	C		INTRAMUSCULAR	150MG per day	
	Crying							
	Drug Withdrawal Syndrome							
	Psychiatric Symptom							

Date:04/16/04ISR Number: 4339948-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0329261A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cheilitis		Zyban	PS	Glaxosmithkline	ORAL	26	DAY
	Dysphagia		Ranitidine	C	Glaxosmithkline	ORAL	150MG per day	1 MON
	Glossodynia							
	Oral Pain							

Date:04/19/04ISR Number: 4341136-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0439439A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Hyperglycaemia		Wellbutrin Hiv Treatments (Unspecified)	PS C	Glaxosmithkline			

Date:04/19/04ISR Number: 4341151-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0327034A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anti-Thyroid Antibody Positive Arthralgia Blood Cortisol Increased Chromosomal Mutation Cytolytic Hepatitis Dermatitis Bullous Hypothyroidism Porphyria Non-Acute Porphyrinuria Scar Serum Ferritin Increased		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 4 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/04ISR Number: 4341156-9Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0329055A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	15 DAY
	Feeling Abnormal							
	Paraesthesia		Pravachol	C			40MG Per day	
	Speech Disorder							
	Vertigo							
	Visual Acuity Reduced							

Date:04/19/04ISR Number: 4341163-6Report Type:Expedited (15-DaCompany Report #TR-GLAXOSMITHKLINE-B0329470A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	13 DAY	
	Drug Exposure During Pregnancy		No Concurrent Medications	C				
	Pregnancy							

Date:04/19/04ISR Number: 4341545-2Report Type:Direct Company Report #CTU 216878
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder		Bupropion 150 Watson	PS	Watson		1 TABLET DAILY	
	Confusional State							
	Depression							
	Fatigue							
	Feeling Abnormal							
	Hangover							
	Headache							
	Heart Rate Increased							
	Hypersomnia							
	Hypokinesia							

	Lethargy					
	Pharmaceutical Product					
	Complaint					
	Sedation					

Date:04/20/04ISR Number: 4341794-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0495331A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Muscle Contractions	Professional					per day	75 DAY
	Involuntary		Paxil	SS	Glaxosmithkline	ORAL		
	Partial Seizures		Ativan	C		ORAL	.5MG At night	
	Tremor		Zyrtec	C	Glaxosmithkline	ORAL	10MG Per day	

Date:04/20/04ISR Number: 4341796-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0507470A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	15 WK	
	Medication Error		Zantac	C	Glaxosmithkline			
	Nervousness		One A Day Vitamins	C				
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/04ISR Number: 4341808-0Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0329553A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Postmenopausal		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Haemorrhage						per day	
			Symbicort Turbohaler	C				
RESPIRATORY								
(INHALATION)							1U Twice per	
day								

Date:04/21/04ISR Number: 4343107-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506371A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
Initial or Prolonged	Medication Error		Gabitril	C				
Other								

Date:04/21/04ISR Number: 4343111-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506950A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error	Consumer	Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product Complaint		Bupropion Hydrochloride	SS	Glaxosmithkline	ORAL	150MG Per day	

Date:04/21/04ISR Number: 4343122-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0328013A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Dry Mouth	Health	Zyban	PS	Glaxosmithkline	ORAL
1TAB Twice						
Initial or Prolonged	Hypersensitivity	Professional				
per day 8 DAY						
	Oropharyngeal Swelling					
	Pharyngolaryngeal Pain					
	Sleep Disorder					
	Suffocation Feeling					
	Throat Tightness					

Date:04/21/04ISR Number: 4344410-XReport Type:Direct Company Report #CTU 217029
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hospitalisation		Wellbutrin	PS		
1-3X DAILY						
Hospitalization -			Prozac 20 Mg	SS		
1 X DAILY						
Initial or Prolonged			Wellbutrin	C		
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

Date:04/22/04ISR Number: 4344063-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0507922A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
Initial or Prolonged	Medication Error					
per day 6 DAY						
Other			Oral Contraceptives	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/04ISR Number: 4345298-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506106A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Feeling Abnormal		Wellbutrin	SS	Glaxosmithkline		150MG Per day	
	Libido Disorder		Paxil Cr	SS	Glaxosmithkline		12.5MG See dosage text	
	Medication Error							
	Nausea		Xanax	SS				
	Smoker							

Date:04/23/04ISR Number: 4345300-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508064A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See dosage text	
	Pharyngolaryngeal Pain							
	Vertigo							

Date:04/23/04ISR Number: 4345895-5Report Type:Direct Company Report #CTU 217245
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Crying		Wellbutrin Sr 150 Mg					
	Fear		Glaxo Smithkline	PS	Glaxo Smithkline	ORAL	1 DAILY ORAL	
	Suicidal Ideation							

Date:04/23/04ISR Number: 4346282-6Report Type:Direct Company Report #CTU 217296
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Arrhythmia		Wellbutrin	PS		ORAL
150 MG/ PO						
Hospitalization -	Chest Pain					
Initial or Prolonged	Dizziness					
	Dyspnoea					
	Heart Rate Increased					
	Pallor					
	Supraventricular					
	Tachycardia					

Date:04/23/04ISR Number: 4346342-XReport Type:Direct Company Report #CTU 217292
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Nicotine Patch 21mg			
Initial or Prolonged	Dizziness		Tdrm	PS		
TRANSDERMAL 1 PATCH QD						
	Dyspnoea		Bupropion Sr (Zyban)			
	Feeling Abnormal		150 Mg	SS		ORAL
1 TAB PO QD						
	Nausea					
	Palpitations					
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/04ISR Number: 4348558-5Report Type:Expedited (15-DaCompany Report #USA-2004-0014626
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis	Health	Oxycodone					
	Chronic Obstructive Pulmonary Disease	Professional	Hydrochloride					
		Other	(Similar To Nda					
	Coronary Artery Occlusion		20-553)(Oxycodone					
	Drug Screen Positive		Hydrochloride)	PS				
	Granuloma		Hydrocodone					
	Hepatic Cirrhosis		Bitartrate (Similar					
	Hepatitis C		To Ind					
	Pleural Adhesion		59,175)(Hydrocodone					
	Tuberculosis		Bitartrate) Unknown	SS				
			Ethanol (Ethanol)	SS				
			Acetaminophen (Paracetamol)	SS				
			Alprazolam (Alprazolam)	SS				
			Buproprion (Amfebutamone)	SS				
			Doxepin (Doxepin)	SS				
			Salicylic Acid (Salicylic Acid)	SS				
			Citalopram (Citalopram)	SS				
			Dextromethorphan (Dextromethorphan)	SS				
			Lorazepam (Lorazepam)	SS				
			Paroxetine (Paroxetine)	SS				
			Temazepam (Temazepam)	SS				
			Oxazepam (Oxazepam)	SS				

Date:04/26/04ISR Number: 4347073-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0314643A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Zyban	PS	Glaxosmithkline	ORAL		
	Drug Level Increased		Librax	C		ORAL		
	Overdose		Levothyrox	C	Glaxosmithkline	ORAL		

	Sudden Death		Catapressan	C		
			Agreal	C		ORAL

Date:04/26/04ISR Number: 4347323-2Report Type:Direct Company Report #CTU 217372
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Convulsion		Wellbutrin Sr 200 Mg			
Initial or Prolonged	Depression		Generic	PS		ORAL
200 MG TWICE						
	Pharmaceutical Product					
A DA ORAL						
	Complaint					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/04ISR Number: 4347327-XReport Type:Direct Company Report #CTU 217373
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Wellbutrin Sr 100 Mg					
	Pharmaceutical Product		Gsm Non-Generic	PS	Gsm Non-Generic	ORAL	100 MG DAILY	
	Complaint						ORAL	
	Therapeutic Response Decreased							

Date:04/26/04ISR Number: 4347331-1Report Type:Direct Company Report #CTU 217375
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Agitation		Remeron 35 Mg	PS		ORAL	35 MG EVERY NIGH ORAL	
	Anxiety							
	Depression		Wellbutrin	SS		ORAL	300 MG 3X A DAY ORAL	
	General Physical Health Deterioration							
	Hostility							
	Hypomania							
	Impulsive Behaviour							
	Insomnia							
	Irritability							
	Panic Attack							
	Suicide Attempt							

Date:04/26/04ISR Number: 4347463-8Report Type:Direct Company Report #CTU 217352
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Zoloft 100 Mg Tablet					
	Dyskinesia		Roe	PS	Roe		2 A DAY	

			Wellbutrin Sr 150 Mg Tab Sa Gsk	SS	Gsk		
3 ADAY							

Date:04/26/04ISR Number: 4349010-3Report Type:Direct Company Report #CTU 217384
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Wellbutrin Sr					
	Pharmaceutical Product		(Generic)	PS		ORAL	100 MG 2 PO	
	Complaint						BID	
			Trazadone	C				
			Xanax	C				

Date:04/27/04ISR Number: 4348316-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504299A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Laryngeal Oedema		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the	
Other	Rash						morning	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/04ISR Number: 4348321-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508351A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	4500MG Single	
	Overdose						dose	
			No Concurrent Medication	C				

Date:04/27/04ISR Number: 4348326-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508440A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice	
	Headache						per day	
	Medication Error		No Concurrent Medication	C				

Date:04/27/04ISR Number: 4348343-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0329938A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline		150MG See	
	Foetal Growth Retardation						dosage text	1 WK
			Salbutamol	C	Glaxosmithkline			
			Becotide	C	Glaxosmithkline			

Date:04/27/04ISR Number: 4348346-XReport Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0330195A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Myocardial Infarction		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
Other	Overdose					
per day						
			Paroxetine	SS	Glaxosmithkline	ORAL
20TABS per						
day						

Date:04/27/04ISR Number: 4348970-4Report Type:Direct Company Report #CTU 217487
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Feeling Hot		Wellbutrin 150 Mg Xl	PS		ORAL
1/4 TAB PO						
	Renal Pain					

Date:04/27/04ISR Number: 4349130-3Report Type:Direct Company Report #CTU 217441
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Amnesia		Wellbutrin Xl 150			
	Drug Ineffective		Mcg Glaxosmithkline	PS		ORAL
300 MCG DAILY						
	Erythema					
ORAL						
	Pruritus		Levothyroxine	C		
	Self-Medication					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/04ISR Number: 4350573-2Report Type:Expedited (15-DaCompany Report #2004-01566
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Condition Aggravated Myasthenia Gravis	Health Professional Other	Trazodone Hydrochloride (Watson Laboratories) (Trazodone	PS	Watson Laboratories		
			Wellbutrin (Bupropion Hydrochloride)	SS			

Date:04/28/04ISR Number: 4349387-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508423A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability Other	Anaphylactic Reaction Dyspnoea Medication Error Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day 8 DAY

Date:04/28/04ISR Number: 4349390-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508692A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability Other	Affect Lability Crying Depressed Mood		Wellbutrin Xl No Concurrent Medications	PS C	Glaxosmithkline	ORAL	300MG Per day

Date:04/28/04ISR Number: 4349877-9Report Type:Direct Company Report #CTU 217597
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Anxiety		Buproprion Sr 100 Mg	PS		ORAL
TWO Q AM PO +						
	Hyperhidrosis					
ONE Q PM PO						
	Insomnia		Fluoxetine	C		
	Palpitations		Wellbutrin Sr	C		
	Pharmaceutical Product Complaint					
	Trismus					

Date:04/29/04ISR Number: 4350088-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508665A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Carbon Monoxide Poisoning		Wellbutrin	PS	Glaxosmithkline	ORAL
	Completed Suicide		Remeron	C		
	Drug Toxicity		Hydroxyzine	C		
			Ambien	C		

Date:04/29/04ISR Number: 4350090-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313902A
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Death	Cardio-Respiratory Arrest
	Coma

	Completed Suicide Depressed Level Of Consciousness	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Intentional Misuse		Wellbutrin	PS	Glaxosmithkline	ORAL
			Doxepin	SS		ORAL
			Clorazepate	SS		ORAL
			Paxil	SS	Glaxosmithkline	UNKNOWN

Date:04/29/04ISR Number: 4350091-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313906A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Death	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL
Hospitalization -	Cardio-Respiratory Arrest		Insulin	SS		PARENTERAL
Initial or Prolonged	Completed Suicide		Citalopram	SS		UNKNOWN
	Convulsion		Trazodone	SS		UNKNOWN
	Decerebration		Vecuronium Bromide	C		UNKNOWN
	Depressed Level Of Consciousness Hypertension Hyperthermia Tachycardia					

Date:04/29/04ISR Number: 4350092-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313909A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Death	Arrhythmia		Wellbutrin	PS	Glaxosmithkline	UNKNOWN
Hospitalization -	Bundle Branch Block Right		Methadone	SS	Glaxosmithkline	UNKNOWN
Initial or Prolonged	Cardio-Respiratory Arrest		Alprazolam	SS		UNKNOWN
	Completed Suicide		Diphenhydramine	SS		UNKNOWN

	Dyspnoea	Cocaine	SS
UNKNOWN			
	Electrocardiogram Qt Prolonged		
	Hypotension		
	Hypothermia		
	Hypoxia		
	Multi-Organ Failure		
	Respiratory Depression		

Date:04/29/04ISR Number: 4350093-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313947A
Age:20 YR Gender:Female I/FU:F

Outcome	PT
Death	Blood Potassium Decreased
	Brain Death
	Completed Suicide
	Convulsion
	Dialysis
	Disseminated Intravascular Coagulation
	Drug Abuser
	Heart Rate Increased
	Hypotension
	Multi-Organ Failure
	Mydriasis
	Overdose
	Pupillary Reflex Impaired

	Pyrexia						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	100TAB cumulative dose
			Theophylline	SS		ORAL	100TAB cumulative dose
			Heroin	SS		NASAL	

Date:04/29/04ISR Number: 4350094-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313949A
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Arrest		Wellbutrin	PS	Glaxosmithkline	ORAL	
	Completed Suicide		Atenolol	SS			UNKNOWN
	Hypotension		Amlodipine	SS			UNKNOWN
	Lethargy						
	Overdose						

Date:04/29/04ISR Number: 4350097-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0325638A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Alanine Aminotransferase Increased		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice per day 2 WK
	Arthralgia		No Concurrent Medication	C			
	Aspartate Aminotransferase						

Increased
Blood Alkaline
Phosphatase Increased
Gamma-Glutamyltransferase
Increased
Insomnia
Myalgia
Night Sweats
Urticaria
Weight Decreased

Date:04/29/04ISR Number: 4350099-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0328585A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	13 DAY
	Supraventricular Tachycardia							

Date:04/29/04ISR Number: 4350103-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0330307A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/04ISR Number: 4350105-9Report Type:Expedited (15-DaCompany Report #SK-GLAXOSMITHKLINE-B0330434A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abulia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Aphasia						per day	20 DAY
	Cardiopulmonary Failure		Saline Solution	C	Glaxosmithkline			
INTRAVENOUS							2	DAY
	Catatonia		Digoxin	C	Glaxosmithkline	ORAL	.125MCG Twice	
	Cerebral Ataxia						per day	
	Convulsion		Moduretic	C		ORAL		
	Decreased Activity							
	Dehydration							
	Dementia							
	Dizziness							
	Dyspnoea							
	Epistaxis							
	Fatigue							
	Immobile							
	Loss Of Consciousness							
	Urinary Incontinence							

Date:04/29/04ISR Number: 4350108-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0330518A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depressed Level Of		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
Initial or Prolonged	Consciousness						dosage text	14 DAY
	Grand Mal Convulsion		Mepronizine	C			UNKNOWN	
	Malaise		Avlocardyl	C			UNKNOWN	
			Tranxene	C			UNKNOWN	
			Theralene	C			UNKNOWN	

			Loxapac	C		
UNKNOWN						
			Levothyrox	C	Glaxosmithkline	
UNKNOWN						
			Dihydan	C		
UNKNOWN						

Date:04/29/04ISR Number: 4350110-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0330717A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	22 DAY
	Excitability							
	Illusion							
	Irritability							
	Malaise							
	Palpitations							
	Road Traffic Accident							
	Thinking Abnormal							
	Vertigo							

Date:04/29/04ISR Number: 4350111-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0331014A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Diastolic		Zyban	PS	Glaxosmithkline	ORAL	6750MG Single	
	Decreased						dose	
	Grand Mal Convulsion		Polaramine	SS		ORAL	30MG Single	
	Intentional Misuse						dose	
	Suicide Attempt		Aerius	C			UNKNOWN	
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/04ISR Number: 4350127-8Report Type:Expedited (15-DaCompany Report #US-ROCHE-360924
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Klonopin	PS	Roche	ORAL	DOSAGE TAKEN	
Hospitalization - Initial or Prolonged	Drug Interaction						AS REQUIRED (PRN).	
			Wellbutrin	SS		ORAL	DOSAGE REPORTED AS: "AM".	449 DAY

Date:04/30/04ISR Number: 4350917-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313782A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Decreased		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
Other	Completed Suicide Depressed Level Of Consciousness		Acetaminophen + Propoxyphene Napsylate	SS		ORAL		
	Drug Toxicity		Carbamazepine	SS			UNKNOWN	
			Acetaminophen + Aspirin + Caffeine	C			UNKNOWN	

Date:04/30/04ISR Number: 4350918-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313828A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation		Bupropion	PS	Glaxosmithkline	ORAL		
	Completed Suicide Convulsion Haemodynamic Instability		Venlafaxine	SS		ORAL		

	Hostility					
	Mental Impairment					
	Pyrexia					

Date:04/30/04ISR Number: 4350919-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313890A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	60TAB	
	Bundle Branch Block Left							cumulative
	Cardiac Arrest							dose
	Completed Suicide		Lorazepam	SS		ORAL		
	Convulsion		Diphenhydramine	SS		ORAL		
	Hypothermia		Sertraline	C		ORAL	30TAB	
	Hypoxia							cumulative
	Injury							dose
	Loss Of Consciousness							
	Nervous System Disorder							
	Overdose							
	Pupil Fixed							
	Rhabdomyolysis							
	Ventricular Fibrillation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/04ISR Number: 4350920-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313891A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Bupropion	PS	Glaxosmithkline	ORAL	67TAB	
	Completed Suicide							cumulative
	Convulsion							dose
			Methylenedioxymetham phetamine	SS		ORAL		

Date:04/30/04ISR Number: 4350921-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313893A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL		
	Completed Suicide		Risperidone	SS		ORAL		
	Convulsion		Sertraline	SS		ORAL		
	Overdose							

Date:04/30/04ISR Number: 4350922-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313895A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Wellbutrin	PS	Glaxosmithkline	ORAL	7TAB	
	Completed Suicide							cumulative
	Convulsion							dose
	Dysarthria		Sertraline	SS		ORAL	7TAB	
	Hyperhidrosis							cumulative
	Mental Status Changes							dose
	Muscle Rigidity		Caffeine	SS	Glaxosmithkline	ORAL		
	Overdose							

Status Epilepticus

Date:04/30/04ISR Number: 4350923-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313896A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Areflexia		Citalopram	SS		ORAL		
	Aspiration		Zolpidem	SS		ORAL		
	Bradycardia		Diazepam	SS		ORAL		
	Cardio-Respiratory Arrest							
	Coma							
	Completed Suicide							
	Convulsion							
	Depressed Level Of Consciousness							
	Electroencephalogram Abnormal							
	Hyperkalaemia							
	Hypotension							
	Pupil Fixed							
	Pyrexia							
	Rhabdomyolysis							
	Tachycardia							
	Thrombocytopenia							
	Ventricular Fibrillation							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/04ISR Number: 4350924-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313897A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Aspiration		Zolpidem	SS		ORAL		
	Blood Alcohol Increased		Ethanol	SS		ORAL		
	Cardio-Respiratory Arrest		Tetrahydrocannabinol	C				
	Coma		Amphetamines	C				
	Completed Suicide							
	Depressed Level Of Consciousness							
	Foreign Body Aspiration							
	Hypotension							
	Oxygen Saturation Decreased							
	Sedation							
	Toxicologic Test Abnormal							

Date:04/30/04ISR Number: 4350925-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313905A
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine		Bupropion	PS	Glaxosmithkline		UNKNOWN	13TAB per day
Other	Increased		Verapamil	SS		ORAL	30TAB per day	
	Blood Pressure Decreased		Venlafaxine	SS			UNKNOWN	1575MG per day
	Blood Urea Increased							
	Bundle Branch Block		Cocaine	SS			UNKNOWN	
	Cardiac Arrest		Benzodiazepine	C				
	Completed Suicide							
	Convulsion							
	Heart Rate Decreased							
	Respiratory Rate Decreased							

Date:04/30/04ISR Number: 4350926-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313977A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Lamictal	PS	Glaxosmithkline	ORAL	UNKNOWN	
	Completed Suicide		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Convulsion		Citalopram	SS		ORAL		
	Electrocardiogram Qrs		Acetaminophen+Dextro					
	Complex Prolonged		meth.Hbr+Doxyl.Succ+					
	Hypotension		Pseudoephed.Hcl	SS				

Date:04/30/04ISR Number: 4350934-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0327761A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	39 DAY
	Haematoma							
	Myalgia							
	Oedema Peripheral							
	Serum Sickness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/04ISR Number: 4350942-0Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0330365A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	21 DAY

Date:04/30/04ISR Number: 4350947-XReport Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0330593A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coagulopathy		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL		
			Ascal	C				
			Persantin	C				

Date:04/30/04ISR Number: 4350948-1Report Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0330728A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	1 DAY
	Leukoencephalopathy							
	Nervous System Disorder							

Date:04/30/04ISR Number: 4350949-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0330834A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache		Zyban	PS	Glaxosmithkline		150MG See dosage text	2 MON
	Nausea							
	Nystagmus							
	Vertigo							

Date:04/30/04ISR Number: 4350951-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0331251A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Zyban	PS	Glaxosmithkline			
	Aggression							
	Irritability							
	Personality Change							

Date:04/30/04ISR Number: 4351296-6Report Type:Direct Company Report #CTU 217762
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Self Injurious Behaviour		Welbutrin	PS			ONCE DAILY	
	Suicidal Ideation							

Date:04/30/04ISR Number: 4352145-2Report Type:Direct Company Report #CTU 217711
Age:87 YR Gender:Female I/FU:I

Outcome	PT
	Dizziness
	Nausea
	Pharmaceutical Product

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Complaint		Wellbutrin 150 Sr	PS			BID	

Date:05/03/04ISR Number: 4351750-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508981A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON

Date:05/03/04ISR Number: 4351751-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509114A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coma		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
	Convulsion		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	
	Depressed Level Of Consciousness		Ativan Tylenol	C C	Glaxosmithkline			

Date:05/03/04ISR Number: 4351755-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313777A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Completed Suicide		Acetaminophen + Aspirin + Caffeine	SS		ORAL		
	Condition Aggravated		Aspirin	SS	Glaxosmithkline		UNKNOWN	
	Hypotension		Metformin	SS			UNKNOWN	
	Ventricular Tachycardia							

			Citalopram	SS			
UNKNOWN							
			Acetaminophen + Oxycodone	SS			
UNKNOWN							
			Acetaminophen Codeine	SS			
UNKNOWN							
			Diethylpropion	SS			
UNKNOWN							
			Acetaminophen + Dextromethorphan + Pseudoephedrine	SS			
UNKNOWN							
			Unspecified Drugs	SS			
UNKNOWN							

Date:05/03/04ISR Number: 4351756-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313822A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose		Bupropion	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Cardio-Respiratory Arrest		Methadone	SS	Glaxosmithkline	ORAL		
	Death		Diazepam	SS		ORAL		

Date:05/03/04ISR Number: 4351757-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313871A
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Death	Adverse Drug Reaction
Other	Bradycardia
	Cardiac Arrest

	Death Eye Movement Disorder Mental Impairment	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscle Rigidity		Paxil	PS	Glaxosmithkline	ORAL
	Pyrexia		Wellbutrin	SS	Glaxosmithkline	ORAL
			Risperidone	SS		
UNKNOWN						
			Clonazepam	SS		
UNKNOWN						

Date:05/04/04ISR Number: 4352725-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509222A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Fluid Retention		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 5 DAY						
Initial or Prolonged	Joint Stiffness Muscle Disorder					

Date:05/04/04ISR Number: 4352728-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313884A
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest Cardiopulmonary Failure Convulsion Drowning Drug Abuser		Bupropion	PS	Glaxosmithkline	ORAL

Date:05/04/04ISR Number: 4352730-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0313889A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL
	Cardiopulmonary Failure		Acetaminophen	SS	Glaxosmithkline	ORAL
75000MG per						

	Completed Suicide					
day						
	Drowning		Alprazolam	SS		ORAL
	Intentional Misuse		Naproxen	SS		
	Multiple Drug Overdose		Ma Huang	SS		

Date:05/04/04ISR Number: 4352740-0Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043570A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Shock		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
Initial or Prolonged	Cardiovascular Disorder							

Date:05/05/04ISR Number: 4353563-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509115A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Haemorrhage		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Disorientation							
dosage text	Myalgia						3	WK
	Petechiae							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/04ISR Number: 4353573-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0330693A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Bupropion					
	Drug Interaction		Hydrochloride	PS	Glaxosmithkline			
	Hallucination		Cholesterol Reducing					
	Nasopharyngitis		Agent Name Not Known	C				
	Tremor		Cardiac Medication	C				

Date:05/05/04ISR Number: 4353574-3Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0330912A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Bupropion					
	Exanthem		Hydrochloride	PS	Glaxosmithkline	ORAL	150MG per day	18 DAY
	Nasopharyngeal Disorder		Metformine	C		ORAL	500MG per day	
	Pruritus		Diclofenac Sodium	C	Glaxosmithkline	ORAL	150MG per day	
	Urticaria		Pariet	C		ORAL		
			Orgametril	C		ORAL	5MG per day	

Date:05/05/04ISR Number: 4354100-5Report Type:Direct Company Report #CTU 217981
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Menopause		Buproprion 75 Mg Bid	PS		ORAL	PO	
	Pharmaceutical Product Complaint		Fluoxetine	C				

Date:05/06/04ISR Number: 4354221-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509451A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG	Per day
	Medication Error		Unknown Medication	C				

Date:05/06/04ISR Number: 4354223-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509551A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG	Unknown
	Tremor							
	Urinary Incontinence							

Date:05/06/04ISR Number: 4354226-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0319984A
Age: Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain Upper
	Anorexia
	Balance Disorder
	Constipation
	Deafness
	Disturbance In Attention
	Dysgeusia
	Ear Disorder
	Feeling Abnormal

	Nausea						
	Sleep Disorder						
	Tinnitus	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vomiting		Zyban	PS	Glaxosmithkline		
			Valium	C		ORAL	2MG Twice per day

Date:05/06/04ISR Number: 4356319-6Report Type:Expedited (15-DaCompany Report #S03-NOR-03725-01
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign	Cipramil (Citalopram Hydrobromide)	PS		ORAL	40 MG QD PO
	Drug Interaction	Other					
	Loss Of Consciousness		Zyban (Bupropion Hydrochloride)	SS		ORAL	150 MG BID PO
	Tongue Biting						
			Zyban (Bupropion Hydrochloride)	SS		ORAL	150 MG QD PO
			Zopiklon (Zopiclone)	C			

Date:05/07/04ISR Number: 4354833-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506288A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	
	Vasculitis						

Date:05/07/04ISR Number: 4354834-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0507922A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See

Initial or Prolonged Medication Error
dosage text 6 DAY
Other Tongue Biting Oral Contraceptives C
Vomiting

Date:05/07/04ISR Number: 4354836-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509822A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See	
	Medication Error						dosage text	
	Nervousness		Alprazolam	C				

Date:05/07/04ISR Number: 4354842-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0326019A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	150MG	
	Blood Creatine Increased							
Variable dose							1	MON
	Blood Iron Decreased							
	Haemoglobin S Decreased							
	Hypercholesterolaemia							
	Iron Deficiency Anaemia							
	Pruritus Generalised							
	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/04ISR Number: 4355953-7Report Type:Direct Company Report #CTU 218163
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Convulsion		Wellbutrin 75 Mg	PS				

Date:05/10/04ISR Number: 4355578-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509414A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Discomfort		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	300MG Twice per day	125 DAY
Hospitalization - Initial or Prolonged	Abdominal Distension							150 DAY
	Hepatic Failure		Study Drug	C				
	Hepatitis							
	Liver Function Test		Digoxin	C	Glaxosmithkline			5 DAY
	Abnormal		Lasix	C	Glaxosmithkline			151 DAY
	Nausea		Aldactone	C				151 DAY
	Necrosis		Nasonex	C				106 DAY
	Oedema Peripheral		Coumadin	C	Glaxosmithkline			174 DAY
	Vomiting		Valium	C				148 DAY
			Benadryl	C	Glaxosmithkline			87 DAY
			Xylocaine	C				1 DAY
			Kdur	C	Glaxosmithkline			24 DAY

Date:05/10/04ISR Number: 4355579-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0510000A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	9 WK
	Dysarthria		Depakote	C			3000MG per day	
	Judgement Impaired							
	Road Traffic Accident							
	Sluggishness							

Date:05/10/04ISR Number: 4355581-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0315354A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
Initial or Prolonged	Delirium		Corticoid Ointment	C		TRANSDERMAL		
	Depression							
	Hallucination							
	Paranoia							
	Persecutory Delusion							
	Psychotic Disorder							

Date:05/10/04ISR Number: 4355602-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0332102A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Zyban	PS	Glaxosmithkline	ORAL	16 DAY	
	Malaise							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/04ISR Number: 4356307-XReport Type:Direct Company Report #CTU 218278
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Bupropion Sr	PS		ORAL	150 MG PO BID	
	Pharmaceutical Product Complaint							

Date:05/11/04ISR Number: 4356092-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0503424A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Disorientation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Single	
Hospitalization -	Headache						dose	
Initial or Prolonged	White Blood Cell Count		Allegra	C		ORAL	180MG Per day	
Other	Increased		Avalide	C		ORAL	300MG Per day	
			Singulair	C		ORAL	10MG At night	
			Ibuprofen	C	Glaxosmithkline			

Date:05/11/04ISR Number: 4356095-7Report Type:Expedited (15-DaCompany Report #04US01863
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG In the	
Hospitalization -	Drug Interaction						morning	449 DAY
Initial or Prolonged			Klonopin	SS			UNKNOWN	1MG Three times per day

Date:05/11/04ISR Number: 4356097-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509840A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Simple Partial Seizures		Requip	PS	Glaxosmithkline	ORAL		
	Tremor		Wellbutrin	SS	Glaxosmithkline	ORAL	2	YR
			Selective Serotonin Reuptake Inhibitor	C				

Date:05/11/04ISR Number: 4356100-8Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0325638A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice per day	2 WK
	Arthralgia		No Concurrent Medication	C				
	Aspartate Aminotransferase Increased							
	Blood Alkaline Phosphatase Increased							
	Gamma-Glutamyltransferase Increased							
	Insomnia							
	Myalgia							
	Night Sweats							
	Urticaria							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/04ISR Number: 4356105-7Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0329071A
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Hospitalization -	Psychotic Disorder							
per day							18	DAY
Initial or Prolonged	Suicide Attempt		Quetiapine	C		ORAL		
Other			Zoloft	C		ORAL		
			Panadol	C	Glaxosmithkline			
			Endep	C	Glaxosmithkline			
			Vioxx	C				

Date:05/11/04ISR Number: 4356117-3Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0331481A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Injury		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Hypotension							
per day								
	Loss Of Consciousness		Beta Blocker	C				

Date:05/11/04ISR Number: 4356119-7Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0331580A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Bupropion					
	Depersonalisation		Hydrochloride	PS	Glaxosmithkline			
	Food Interaction							
	Hostility							
	Memory Impairment							

Date:05/11/04ISR Number: 4358785-9Report Type:Expedited (15-DaCompany Report #T02-USA-01514-01
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Agitation Blood Glucose Increased Blood Urine Present Coma Dilatation Ventricular Grand Mal Convulsion Heart Rate Increased Incontinence Loss Of Consciousness Oxygen Saturation Decreased	Study Health Professional	Memantine (Open Label, Phase B) (Memantine) Mjenatine (Open Label, Phase B) (Memantine) Memantine (Unblinded, Phase A) (Memantine) Wellbutrin (Bupropion Hydrochloride) Aricept (Donepezil Hydrochloride)	PS SS SS SS C		ORAL ORAL ORAL ORAL	20 MG QD PO 20 MG QD PO 10MG BID PO 150 MG QD PO	

Date:05/12/04ISR Number: 4357036-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508692A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Affect Lability	Health	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
Other	Crying Depressed Mood	Professional	No Concurrent Medications	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/04ISR Number: 4357038-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0510367A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline	ORAL		

Date:05/12/04ISR Number: 4357048-5Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0331679A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Contusion		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	13 DAY
	Loss Of Consciousness							
	Skin Laceration							

Date:05/12/04ISR Number: 4357605-6Report Type:Direct Company Report #CTU 218475
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Wellbutrin	PS		ORAL	300 MG DAILY	
Initial or Prolonged	Convulsion					ORAL		
	Fall		Zoloft	C				
	Road Traffic Accident		Xanax	C				

Date:05/12/04ISR Number: 4357677-9Report Type:Direct Company Report #CTU 218489
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Apathy		Wellbutrin Xl	PS		ORAL	ONE TAB Q DAY	
	Condition Aggravated					ORAL		
	Crying							
	Decreased Interest							
	Depression							

	Drug Effect Decreased					
	Self Esteem Decreased					
	Suicidal Ideation					

Date:05/12/04ISR Number: 4357826-2Report Type:Expedited (15-DaCompany Report #HQWYE676403MAY04
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral	Consumer	Effexor Xr					
	Condition Aggravated		(Venlafaxine					
	Corneal Abrasion		Hydrochloride,					
	Glaucoma		Capsule, Extended					
			Relese)	PS		ORAL	150 MG 1X PER	1 DAY, ORAL
			Wellbutrin					
			(Amfebutanmone					
			Hydrochloride)	SS			HER DOSE "HAD	DOUBLED"
			Xalantan					
			(Latanoprost)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/04ISR Number: 4357708-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0499234A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
	Feeling Abnormal		Yasmin	C				
	Headache							
	Insomnia							
	Medication Error							
	Nausea							
	Vomiting							

Date:05/13/04ISR Number: 4357719-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0331771A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/13/04ISR Number: 4357721-9Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0331807A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Quomem	PS	Glaxosmithkline			

Date:05/14/04ISR Number: 4358507-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0510766A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Wellbutrin	PS	Glaxosmithkline			
			Coumadin	C	Glaxosmithkline			

Date:05/14/04ISR Number: 4358517-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0331984A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Mood		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Self-Injurious Ideation		Logynon	C		ORAL		
	Suicidal Ideation							
	Tearfulness							

Date:05/14/04ISR Number: 4358518-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0331986A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	7 DAY
	Road Traffic Accident		Beclomethasone	C	Glaxosmithkline		200MCG Twice per day	

Date:05/17/04ISR Number: 4359019-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508256A
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion	Health	Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Medication Error	Professional	Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
			Alcohol	SS		ORAL	2U Per day	
Other			Atenolol	C		ORAL	25MG per day	

				Triamterene + Hydrochlorothiazide	C	Glaxosmithkline	ORAL
.5TAB per day							
				Pravacol	C		ORAL
40MG per day	YR						

Date:05/17/04ISR Number: 4359027-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0510886A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		150MG per day	

Date:05/17/04ISR Number: 4359033-6Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0328475A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bite		Zyban	PS	Glaxosmithkline		150MG Twice per day	
	Deafness							
	Dizziness							
	Feeling Abnormal							
	Myoclonus							
	Palpitations							
	Tinnitus							
	Tongue Biting							

Date:05/17/04ISR Number: 4360761-7Report Type:Expedited (15-DaCompany Report #A0509420A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Nicoderm Cq Patch 21 Mg (Nicotine)	PS		TRANSDERMAL	21 MG PER DAY/	
	Cerebrovascular Accident							
	Dizziness							

	Erythema					
TRANSDERMAL						
	Fatigue		Wellbutrin			
	Overdose		(Bupropion			
	Pruritus		Hydrochloride)	SS		ORAL
300 MG PER						
	Rash Papular					
DAY/ ORAL						
	Sensory Disturbance		Tarka	C		
	Speech Disorder		Alprazolam	C		
			Diuretic	C		

Date:05/18/04ISR Number: 4359773-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505954A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						
Initial or Prolonged	Convulsion	Professional	Over Counter			
	Drug Interaction		Medicines	SS		
	Fall					
	Haemorrhage					
	Head Injury					
	Skull Fracture					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/04ISR Number: 4359776-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0510479A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Murder		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Psychotic Disorder							

Date:05/18/04ISR Number: 4359777-6Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0510705A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Visual Disturbance							

Date:05/18/04ISR Number: 4360198-0Report Type:Direct Company Report #CTU 218881
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Intolerance		Wellbutrin Sr 150 Mg	PS		ORAL	150 MG BID	
	Obstructive Airways					ORAL		
	Disorder		Wellbutrin Xr 300 Mg	SS		ORAL	300 MG QD	
	Swollen Tongue					ORAL		

Date:05/19/04ISR Number: 4360531-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511270A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Twice
	Pharmaceutical Product						per day	

Complaint

Date:05/19/04ISR Number: 4360532-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511280A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 WK
	Medication Error		Bupropion	SS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Sluggishness		Protonix	C				

Date:05/19/04ISR Number: 4360533-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511289A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
Life-Threatening	Death							
Other								

Date:05/19/04ISR Number: 4360540-0Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0332296A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 DAY
	Transient Ischaemic Attack							

Date:05/19/04ISR Number: 4360629-6Report Type:Direct Company Report #CTU 218970
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Grand Mal Convulsion Rhabdomyolysis		Tequin 400 Mg Wellbutrin Er Prilosec Motrin	PS SS C C		INTRAVENOUS ORAL	400 MG X 1 INTRAVENOUS 150 MG DAILY ORAL	

Date:05/19/04ISR Number: 4364138-XReport Type:Expedited (15-DaCompany Report #200412076BCC
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Health Professional	Aleve (Naproxen Sodium)	PS		ORAL ORAL		
	Aspartate Aminotransferase Increased	Other	Centrum Vitamins	SS		ORAL ORAL		
	Blood Pressure Diastolic Decreased		Acetaminophen	SS		ORAL ORAL		
	Lethargy		Imodium (Loperamide Hydrochloride)	SS				
	Multiple Drug Overdose		Wellbutrin (Bupropion Hydrochloride)	SS				
	Nausea							
	Prothrombin Time Prolonged							
	Sinus Tachycardia							
	Vomiting							

Date:05/20/04ISR Number: 4361260-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508256A
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion	Health	Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
Hospitalization -		Professional	Alcohol	SS		ORAL	2U Per day	
Initial or Prolonged			Atenolol	C		ORAL	25MG per day	
Other			Triamterene + Hydrochlorothiazide	C	Glaxosmithkline	ORAL	.5TAB per day	
			Pravacol	C		ORAL	40MG per day	YR

Date:05/20/04ISR Number: 4361261-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509115A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Haemorrhage	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Deep Vein Thrombosis	Professional					dosage text	3 WK
	Disorientation		Ortho Tri-Cyclen	C				
	Myalgia							
	Petechiae							

Date:05/20/04ISR Number: 4361269-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511389A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Athetosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
Initial or Prolonged	Cognitive Disorder							
Other	Dyskinesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/04ISR Number: 4361271-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511459A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/20/04ISR Number: 4361272-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511475A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	6G Single dose	1 DAY
	Dizziness							
	Drug Screen Positive		Klonopin	SS			5MG Single dose	
	Muscle Spasms							
	Overdose		Lithium	C	Glaxosmithkline			
	Vomiting							

Date:05/20/04ISR Number: 4361280-4Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0330593A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coagulopathy	Health Professional	Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL		
			Ascal	C				
			Persantin	C				

Date:05/20/04ISR Number: 4361286-5Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0332456A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Exposure		Zyban	PS	Glaxosmithkline			
	Nervous System Disorder							

Date:05/20/04ISR Number: 4363737-9Report Type:Direct Company Report #CTU 219172
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Wellbutrin Sr	PS			150 BID	
	Depression							
	Pharmaceutical Product							
	Complaint							

Date:05/21/04ISR Number: 4361437-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0114838A
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Zyban	PS	Glaxosmithkline	ORAL		
	Nausea							
	Vomiting							

Date:05/21/04ISR Number: 4361438-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0114981A
Age:60 YR Gender:Female I/FU:F

Outcome	PT
	Drug Ineffective
	Dry Mouth

Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Zyban	PS	Glaxosmithkline	ORAL		
	Mvi	C				
	Tamoxifen	C				

Date:05/21/04ISR Number: 4361439-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407078A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urine Present		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY

Date:05/21/04ISR Number: 4361441-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407652A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tremor						per day	6 DAY
			Clarinex	C				
			Spironolactone	C				

Date:05/21/04ISR Number: 4361442-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0407700A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Zyban	PS	Glaxosmithkline	ORAL	18	DAY
			Iron Sulfate	C	Glaxosmithkline			
			Folate	C				
			Celexa	C				

Date:05/21/04ISR Number: 4361443-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408416A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Bupropion	PS	Glaxosmithkline	ORAL	1	WK
	Tinnitus							

Date:05/21/04ISR Number: 4361444-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408563A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Zyban	PS	Glaxosmithkline	ORAL		
	Pharmaceutical Product		Zantac	C	Glaxosmithkline			
	Complaint		Phenergan	C	Glaxosmithkline			
	Vomiting							

Date:05/21/04ISR Number: 4361445-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408817A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tremor						per day	WK
			Ambien	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361446-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0408818A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Smoker		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 4 MON

Date:05/21/04ISR Number: 4361447-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0409189A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG	Twice per day WK

Date:05/21/04ISR Number: 4361448-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410046A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Pruritus							

Date:05/21/04ISR Number: 4361449-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410740A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK

Date:05/21/04ISR Number: 4361450-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410771A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Urticaria							

Date:05/21/04ISR Number: 4361451-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0410772A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Reaction		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Initial or Prolonged	Convulsion							
per day							7	DAY
Other	Drug Ineffective		Antibiotic	C				

Date:05/21/04ISR Number: 4361452-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411252A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Heart Rate Increased							
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361453-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412626A
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash						per day	4 DAY
	Urticaria							

Date:05/21/04ISR Number: 4361454-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0412823A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	6 DAY
			Lisinopril	C				
			Zyrtec	C	Glaxosmithkline			
			Albuterol	C	Glaxosmithkline			
			Combivent	C				
			Flovent	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361455-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413117A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Urticaria						per day	13 DAY

Date:05/21/04ISR Number: 4361456-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413281A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Constipation		Zyban	PS	Glaxosmithkline	ORAL 150MG Twice per day
	Ejaculation Delayed					
	Sexual Dysfunction		Stool Softener	C		
			Titralac	C		
			Nicoderm	C	Glaxosmithkline	TOPICAL

Date:05/21/04ISR Number: 4361457-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413310A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361458-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414038A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	42 DAY
			Neurontin	C			UNKNOWN	
			Zoloft	C		ORAL		
			Zocor	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Triamterene	C	Glaxosmithkline		UNKNOWN	
			Xanax	C		ORAL		
			Soma	C			UNKNOWN	
			Vicoprofen	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361459-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0414538A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice	
	Headache						per day	1 YR
	Myalgia		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Pyrexia		Advil	C	Glaxosmithkline			
	Tinnitus							

Date:05/21/04ISR Number: 4361460-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0415365A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Zyban	PS	Glaxosmithkline	ORAL		
	Tremor							

Date:05/21/04ISR Number: 4361461-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418607A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Zyban	PS	Glaxosmithkline	ORAL	1 DAY	

Date:05/21/04ISR Number: 4361462-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0418793A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dry Mouth						per day	WK

Date:05/21/04ISR Number: 4361463-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419202A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361464-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419716A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hiccups		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Vomiting						per day	2 WK
			Celebrex	C				

Date:05/21/04ISR Number: 4361465-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419717A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Zyban	PS	Glaxosmithkline	ORAL	150MG Single	
	Paraesthesia						dose	1 DAY
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361466-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0419928A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anxiety						per day	
	Disturbance In Attention		Xanax	C				
	Feeling Jittery		Valium	C				
	Insomnia		Ambien	C				
	Mental Impairment		Oral Contraceptive	C				
	Weight Decreased		Dalmane	C				

Date:05/21/04ISR Number: 4361467-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420791A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nonspecific Reaction		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361468-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420806A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	3 WK
			Nicotine	C	Glaxosmithkline			
			Unknown Medication	C				

Date:05/21/04ISR Number: 4361469-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420919A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	

per day 9 DAY

Lipitor C

UNKNOWN

Lopressor C

UNKNOWN

Date:05/21/04ISR Number: 4361471-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420937A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	2	DAY
	Insomnia							
	Nervousness							

Date:05/21/04ISR Number: 4361472-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420938A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Zyban	PS	Glaxosmithkline	ORAL		
	Insomnia							
	Nervousness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361473-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422160A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Zyban	PS	Glaxosmithkline	ORAL	150MG In the	
	Dry Mouth						morning	2 DAY
	Feeling Abnormal		Chewing Tobacco	C		ORAL		
	Hallucination							
	Headache							
	Hyperacusis							
	Keratoconjunctivitis							
	Sicca							
	Nervousness							
	Oily Skin							
	Paraesthesia							

Date:05/21/04ISR Number: 4361474-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422305A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Pruritus						per day	3 WK
	Rash							
	Urticaria							

Date:05/21/04ISR Number: 4361476-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422908A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Zyban	PS	Glaxosmithkline	ORAL	10	DAY

Date:05/21/04ISR Number: 4361477-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422909A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Metrorrhagia		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Ortho Tri-Cyclen	C				
			Xalatan	C				

Date:05/21/04ISR Number: 4361478-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422918A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling		Zyban	PS	Glaxosmithkline	ORAL	1	MON
	Urticaria							

Date:05/21/04ISR Number: 4361479-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423429A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	DAY
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361480-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423602A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Zyban	PS	Glaxosmithkline	ORAL	17	DAY

Date:05/21/04ISR Number: 4361481-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423864A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Bupropion	PS	Glaxosmithkline	ORAL		
	Thinking Abnormal							

Date:05/21/04ISR Number: 4361482-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423979A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anxiety							
per day							8	WK
	Dizziness		Doxycycline	C				
	Drug Ineffective							
	Flight Of Ideas							
	Insomnia							
	Mood Altered							
	Restlessness							

Date:05/21/04ISR Number: 4361483-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424102A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Mood Swings							
per day							6	DAY

	Nausea		Ortho Evra	C		

Date:05/21/04ISR Number: 4361485-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424327A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Local Swelling		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Pruritus						per day	2 WK
			Vitamins	C				

Date:05/21/04ISR Number: 4361486-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424756A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Drug Reaction		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Face Oedema		Vistaril	C				
	Pruritus							
	Rash							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361487-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424885A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dementia		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	3 DAY
	Skin Tightness							

Date:05/21/04ISR Number: 4361488-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425327A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Myalgia						per day	3 WK
	Pruritus		Vitamins	C				
	Swelling Face							
	Urticaria							

Date:05/21/04ISR Number: 4361489-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425340A
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Activities Of Daily		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Living Impaired						per day	8 DAY
	Arthralgia		Synthroid	C	Glaxosmithkline			
	Depression		Amitriptyline	C				
			Ibuprofen	C	Glaxosmithkline			
			Evista	C				
			Prozac	C				
			Indapamide	C				
			Muscle Relaxer	C				
			Catapres-Tts-1	C				

Date:05/21/04ISR Number: 4361490-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425920A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delusion		Zyban	PS	Glaxosmithkline	ORAL	2	WK
	Dry Mouth		None	C				
	Insomnia							
	Nightmare							

Date:05/21/04ISR Number: 4361491-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425936A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Attack		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tremor						per day	6 DAY
			Birth Control	C				

Date:05/21/04ISR Number: 4361492-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427087A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Mood Swings		Celexa	SS			UNKNOWN	
	Personality Change							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361493-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427728A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Zyban	PS	Glaxosmithkline	ORAL		
	Swelling							

Date:05/21/04ISR Number: 4361494-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427879A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tremor						per day	
			Centrum Multivitamin	C				

Date:05/21/04ISR Number: 4361495-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428257A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Zyban	PS	Glaxosmithkline	ORAL	10	DAY
			Chemotherapy	C				

Date:05/21/04ISR Number: 4361496-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428700A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY

Date:05/21/04ISR Number: 4361497-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429240A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361498-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429268A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Zyban	PS	Glaxosmithkline		UNKNOWN	

Date:05/21/04ISR Number: 4361499-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429516A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
	Muscle Rigidity							
	Oedema Peripheral							
	Paraesthesia Oral							

Date:05/21/04ISR Number: 4361500-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429531A
Age:54 YR Gender:Male I/FU:F

Outcome	PT
	Dizziness
	Energy Increased

Insomnia Sinusitis Vertigo	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day 3 MON
		Xanax	C			

Date:05/21/04ISR Number: 4361501-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430039A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urticaria	Consumer	Zyban	PS	Glaxosmithkline	ORAL	2 WK
			Patch (Unspecified)	SS			

Date:05/21/04ISR Number: 4361502-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430440A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Feeling Abnormal		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 1 WK

Date:05/21/04ISR Number: 4361503-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430741A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pyrexia Urticaria		Zyban	PS	Glaxosmithkline	ORAL	

Date:05/21/04ISR Number: 4361504-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431778A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice	per day 2 WK

Date:05/21/04ISR Number: 4361505-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432989A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361506-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439011A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	per day 12 DAY
			Oral Contraception	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361507-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439262A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 DAY
			Prevacid	C				
			Actigall	C				

Date:05/21/04ISR Number: 4361508-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439427A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Zyban	PS	Glaxosmithkline		UNKNOWN	
	Insomnia							

Date:05/21/04ISR Number: 4361509-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440622A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361510-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441190A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Fatigue						per day	11 DAY
	Neck Pain							

Date:05/21/04ISR Number: 4361511-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441528A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown WK
	Pruritus							
	Urticaria							

Date:05/21/04ISR Number: 4361512-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442158A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia		Zyban	PS	Glaxosmithkline	ORAL	2	WK
	Diarrhoea		Synthroid	C	Glaxosmithkline			
	Gastrooesophageal Reflux Disease							
	Nausea							
	Vomiting							

Date:05/21/04ISR Number: 4361513-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442534A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Zyban	PS	Glaxosmithkline	ORAL	2	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361514-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442778A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	2	WK
			Lipitor	C				

Date:05/21/04ISR Number: 4361515-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443560A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dementia		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Homicidal Ideation							

Date:05/21/04ISR Number: 4361516-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490990A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Incoherent							
	Tremor							

Date:05/21/04ISR Number: 4361517-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493285A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
			None	C				

Date:05/21/04ISR Number: 4361518-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493497A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Zyban	PS	Glaxosmithkline	ORAL		
	Fatigue							

Date:05/21/04ISR Number: 4361519-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494821A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Zyban	PS	Glaxosmithkline	ORAL		
	Urticaria		Wellbutrin	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361520-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496019B
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Zyban	PS	Glaxosmithkline			
	Convulsion		Nicoderm Patch	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361521-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496342A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Zyban	PS	Glaxosmithkline	ORAL	2	WK
	Depression							
	Drug Ineffective							

Date:05/21/04ISR Number: 4361522-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497219A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 DAY
			Zetia	C				

Date:05/21/04ISR Number: 4361523-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498011A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361524-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499841A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 DAY

Date:05/21/04ISR Number: 4361525-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500122A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	10 DAY

Date:05/21/04ISR Number: 4361526-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500153A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nicotine Dependence		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON

Date:05/21/04ISR Number: 4361527-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500837A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Zyban	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361528-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500839A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
	Therapeutic Response							
	Unexpected		Imitrex	C	Glaxosmithkline	NASAL		

			Amerge	C	Glaxosmithkline
			Verapamil	C	

Date:05/21/04ISR Number: 4361529-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501341A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	100MG Three	
	Fatigue						times per day	13 DAY
	Myalgia							
	Pyrexia							
	Serum Sickness							
	Urticaria							

Date:05/21/04ISR Number: 4361530-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501412A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Urticaria						per day	4 DAY
			Glucosamine + Chondroitin	SS			1TAB Per day	5 WK
			Multivitamin	C				
			Calcium Supplement	C				
			Vitamin C	C	Glaxosmithkline			
			Benicar	C				
			Magnesium Supplement	C				
			Zinc Supplement	C				

Date:05/21/04ISR Number: 4361531-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503009A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
per day						
			Ortho Tri-Cyclen	C		
			Nicorette	C	Glaxosmithkline	

Date:05/21/04ISR Number: 4361532-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503215A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nausea		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
	Rash					
per day 2 WK						
	Rash Erythematous		Neurontin	C		
	Vomiting		Albuterol	C	Glaxosmithkline	

Date:05/21/04ISR Number: 4361533-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505136A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Convulsion		Zyban	PS	Glaxosmithkline	ORAL
Initial or Prolonged			Hydrocodone	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361534-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505665A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Zyban	PS	Glaxosmithkline	ORAL	3	WK

Date:05/21/04ISR Number: 4361535-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505968A
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Nervousness							
	Tremor		Zocor	C				
			Xalatan	C				
			Aerobid	C				
			Floratil	C				

Date:05/21/04ISR Number: 4361536-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506110A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Insomnia							
			Depo Provera	C				

Date:05/21/04ISR Number: 4361537-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506353A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Zyban	PS	Glaxosmithkline		3	WK
	Drug Withdrawal Syndrome		Wellbutrin Xl	SS	Glaxosmithkline	ORAL		

	Insomnia

Date:05/21/04ISR Number: 4361538-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506388A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Zyban	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361539-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506806A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Zyban	PS	Glaxosmithkline	ORAL		
	Nervousness		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Tinnitus							

Date:05/21/04ISR Number: 4361540-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507937A
Age:65 YR Gender:Male I/FU:F

Outcome	PT
	Dermatitis Exfoliative
	Dry Mouth
	Dry Skin
	Haemorrhage Urinary Tract
	Rash

Rash Papular

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	5 DAY
			Altace	C				
			Atenolol	C				
			Zocor	C				
			Xanax	C				

Date:05/21/04ISR Number: 4361541-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508070A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 WK
			Depo-Provera	C				

Date:05/21/04ISR Number: 4361542-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508438A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
			Hctz	C				
			Accupril	C				
			Zocor	C				

Date:05/21/04ISR Number: 4361543-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508671A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypersensitivity		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day 7 DAY						
	Nausea					
	Urticaria					

Date:05/21/04ISR Number: 4361544-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508929A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia		Zyban	PS	Glaxosmithkline	
24 DAY						
	Urticaria					

Date:05/21/04ISR Number: 4361545-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509163A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash		Zyban	PS	Glaxosmithkline	ORAL
3 WK						

Date:05/21/04ISR Number: 4361547-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505370A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361548-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505372A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
			Amerge	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361549-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505378A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Psychotropic Medications	C				

Date:05/21/04ISR Number: 4361550-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505380A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Headache							
							per day	3 WK
	Insomnia		Celexa	C				
	Pollakiuria		Synthroid	C	Glaxosmithkline			
	Pruritus							

Date:05/21/04ISR Number: 4361551-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505385A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Covera	C				
			Lipitor	C				
			Diovan Hct	C				

				Glucophage	C		
				Vicodin Es	C		
				Mobic	C		

Date:05/21/04ISR Number: 4361552-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505447A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK
	Irritability		Accutane	C				

Date:05/21/04ISR Number: 4361553-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505448A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:05/21/04ISR Number: 4361554-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505458A
Age:37 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain
	Hypertension

Irritability

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL
4	MON					
			Lotrel	C		
			Toprol Xl	C		
			Hctz	C		

Date:05/21/04ISR Number: 4361555-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505463A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG	Unknown 1 MON					

Date:05/21/04ISR Number: 4361556-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505547A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dysphagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG	Per day					

Date:05/21/04ISR Number: 4361557-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505573A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Gynaecomastia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
450MG	Per day 4 YR					
			Wellbutrin Sr	C	Glaxosmithkline	

Date:05/21/04ISR Number: 4361559-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505591A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/21/04ISR Number: 4361560-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505607A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361561-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505672A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			No Concurrent Medication	C				

Date:05/21/04ISR Number: 4361562-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505677A
Age: Gender:Female I/FU:I

Outcome	PT
	Anxiety
	Crying
	Depression

	Hypoventilation					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day	2 WK					
			No Concurrent Medication	C		

Date:05/21/04ISR Number: 4361563-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505682A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Oligomenorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day	3 WK					
			No Concurrent Medication	C		

Date:05/21/04ISR Number: 4361564-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505687A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						
			Prozac	C		

Date:05/21/04ISR Number: 4361565-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505697A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300TAB Per day						

Date:05/21/04ISR Number: 4361566-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505698A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361567-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505700A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
	Swelling Face		Klonopin	C				

Date:05/21/04ISR Number: 4361569-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505932A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Local Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Pruritus		No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361570-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505940A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:05/21/04ISR Number: 4361571-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505961A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Musculoskeletal Stiffness		No Concurrent Medication	C				

Date:05/21/04ISR Number: 4361572-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505981A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Prinivil	C				
			Xanax	C				
			Ativan	C				

Date:05/21/04ISR Number: 4361573-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505985A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON

Date:05/21/04ISR Number: 4361574-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505998A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Effexor	C				
			Diovan	C				

Date:05/21/04ISR Number: 4361575-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505999A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
			Thyroid Medication	C				

Date:05/21/04ISR Number: 4361576-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506016A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	30 MON
	Dyspepsia							
	Hyperhidrosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361577-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506039A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 WK

Date:05/21/04ISR Number: 4361578-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506047A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361579-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506088A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Heart Rate Increased							

Date:05/21/04ISR Number: 4361580-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506090A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK

Date:05/21/04ISR Number: 4361581-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506092A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	MON

Date:05/21/04ISR Number: 4361582-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506093A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Libido Increased		Strattera	C				
			Zoloft	C				

Date:05/21/04ISR Number: 4361583-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506097A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	108 DAY

Date:05/21/04ISR Number: 4361584-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506128A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Depression		Guaifenesin	C				
	Weight Increased		Valium	C		ORAL	5MG As required	
			Kcl	C	Glaxosmithkline	ORAL	20MEQ Unknown	
			Librax	C		ORAL		

			Diovan Hct	C		

Date:05/21/04ISR Number: 4361585-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506129A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Effexor	C				

Date:05/21/04ISR Number: 4361586-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506131A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Feeling Abnormal							
	Memory Impairment							

Date:05/21/04ISR Number: 4361588-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506132A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Prolactin Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361589-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506133A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361590-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506134A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Swelling Face							

Date:05/21/04ISR Number: 4361591-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506240A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	6 MON
	Weight Increased		Bentyl	C				
			Premarin	C				

Date:05/21/04ISR Number: 4361592-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506243A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361593-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506245A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Anxiety		Valtrex	C	Glaxosmithkline			
	Herpes Simplex		Synthroid	C	Glaxosmithkline			
	Mood Altered		Zelnorm	C				

Date:05/21/04ISR Number: 4361595-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506252A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Tremor							

Date:05/21/04ISR Number: 4361596-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506269A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/21/04ISR Number: 4361597-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506289A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361599-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506368A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Nervousness		Zoloft	SS				
	Psychomotor Hyperactivity		Synthroid	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361600-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506390A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Date:05/21/04ISR Number: 4361601-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506402A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
	Tremor							

Date:05/21/04ISR Number: 4361604-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506481A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361605-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506485A
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Balance Disorder		Aricept	C				
	Feeling Abnormal		Coumadin	C	Glaxosmithkline			
			Lopid	C				
			Vitamins	C				
			Actonel	C				
			Calcium	C				

Date:05/21/04ISR Number: 4361606-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506492A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myoclonus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	250MG Per day	
			Celexa	C				

Date:05/21/04ISR Number: 4361607-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506499A
Age:44 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Tremor		Alcohol	C				
	Weight Decreased							

Date:05/21/04ISR Number: 4361608-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506501A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK

Zyprexa	C
Topamax	C
Klonopin	C
Nexium	C
Prozac	C

Date:05/21/04ISR Number: 4361609-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506502A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/21/04ISR Number: 4361610-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506503A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361611-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506516A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Lactic Acid		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Increased		Remeron	C				
			Ovcon	C				
			Vioxx	C				
			Wellbutrin Sr	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361612-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506523A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	MON
			Effexor	C				

Date:05/21/04ISR Number: 4361613-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506577A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	YR
	Pruritus							

Date:05/21/04ISR Number: 4361614-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506578A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK

Date:05/21/04ISR Number: 4361615-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506581A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361616-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506794A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361617-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506825A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Premature Ejaculation		Wellbutrin	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361618-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506832A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361619-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506839A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Mood Altered		Valtrex	C	Glaxosmithkline			
			Synthroid	C	Glaxosmithkline			
			Vitamins	C				
			Tylenol Pm	C				
			Effexor	C				

Date:05/21/04ISR Number: 4361620-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506842A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY
	Weight Decreased		Benicar	C				

Date:05/21/04ISR Number: 4361621-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506843A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Prilosec	SS				
			Centrum	C				

Date:05/21/04ISR Number: 4361622-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506845A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Effexor	SS				

Date:05/21/04ISR Number: 4361623-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506849A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON

Date:05/21/04ISR Number: 4361624-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506915A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Central Nervous System		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Stimulation		Wellbutrin Sr	C	Glaxosmithkline		150MG Twice	
	Crying						per day	5 YR
	Emotional Distress							

Date:05/21/04ISR Number: 4361626-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506916A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
			Diovan	C				
			Synthroid	C	Glaxosmithkline			
			Prevacid	C				

			Zoloft	C		

Date:05/21/04ISR Number: 4361627-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506917A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
			Trazodone	C				

Date:05/21/04ISR Number: 4361628-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506942A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mucous Membrane Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Advair	C	Glaxosmithkline			
			Flovent	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361629-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506945A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Insomnia							
	Somnolence							

Date:05/21/04ISR Number: 4361630-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506956A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361631-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507051A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	16 DAY	
	Delusion		Elavil	C	Glaxosmithkline	ORAL	50MG At night	
	Paranoia							

Date:05/21/04ISR Number: 4361632-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507076A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Hard		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1 MON	
	Haemorrhoids							

Date:05/21/04ISR Number: 4361634-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507160A
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysarthria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Tremor		Synthroid	C	Glaxosmithkline			
			Zestril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361635-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507170A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
			Alcohol	C				

Date:05/21/04ISR Number: 4361636-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507175A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Back Pain		Seroquel	C				
	Nausea		Zoloft	C				
			Zyrtec	C	Glaxosmithkline			
			Xanax	C				
			Mobic	C				
			Protonix	C				
			Albuterol Mdi	C	Glaxosmithkline			
			Neurontin	C				
			Trazodone	C				
			Compazine	C	Glaxosmithkline			
			Prednisone	C				

1 YR

Date:05/21/04ISR Number: 4361637-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507206A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Oxycontin	SS				

Date:05/21/04ISR Number: 4361638-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507207A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Anti-Psychotic Medication	C				

Date:05/21/04ISR Number: 4361639-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507254A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Effexor	C				

Date:05/21/04ISR Number: 4361640-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507267A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361641-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507269A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Overdose		Ambien	C				
			Trazec	C				
			Darvocet	C				

Date:05/21/04ISR Number: 4361642-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507275A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Attack		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
			Birth Control	C				
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361643-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507288A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 YR
	Decreased Interest		Armour Thyroid	C				
			Strattera	C				

40MG Per day

Date:05/21/04ISR Number: 4361644-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507440A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Psychomotor Hyperactivity							

Date:05/21/04ISR Number: 4361645-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507444A
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Trazodone	C				
			Flonase	C	Glaxosmithkline			
			Clarinex	C				

Date:05/21/04ISR Number: 4361646-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507449A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361647-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507452A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361648-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507456A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Xanax	C				

Date:05/21/04ISR Number: 4361649-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507465A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK

Date:05/21/04ISR Number: 4361650-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507469A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Dyspnoea		Hctz	C				
	Fatigue		Lopressor	C				
	Headache		Klonopin	C				
	Nausea							

Date:05/21/04ISR Number: 4361651-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507541A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Unknown	

Date:05/21/04ISR Number: 4361652-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507542A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361653-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507559A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361654-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507566A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Serum Ferritin Increased							

Date:05/21/04ISR Number: 4361655-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507567A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
			Vasotec	C				
			Lasix	C	Glaxosmithkline			

			Birth Control Pills	C		

Date:05/21/04ISR Number: 4361656-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507582A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Pyrexia		None	C				
	Vomiting							

Date:05/21/04ISR Number: 4361657-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507587A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Hiv Treatments (Unspecified)	C				

Date:05/21/04ISR Number: 4361658-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507594A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY
	Nausea		Premarin	C				
			Xanax	C				
			Novastan	C				

Date:05/21/04ISR Number: 4361659-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507624A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Muscle Spasms		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
1 MON						

Date:05/21/04ISR Number: 4361663-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507666A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Headache		Metformin	C				
			Vitamins	C				

Date:05/21/04ISR Number: 4361664-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507679A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Zyprexa	C				
			Zoloft	C				
			Zocor	C				
			Hctz	C				
			Estradiol	C				
			Aspirin	C	Glaxosmithkline			
			Vitamins	C				
			B12 Vitamin	C	Glaxosmithkline			
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361665-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507700A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361666-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507702A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/21/04ISR Number: 4361667-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507843A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Depression							

Date:05/21/04ISR Number: 4361668-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507864A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	16 DAY
	Aura							
	Grand Mal Convulsion							

Date:05/21/04ISR Number: 4361669-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507896A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice per day						
			Accupril	C		

Date:05/21/04ISR Number: 4361670-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507899A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:05/21/04ISR Number: 4361671-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507900A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myoclonus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:05/21/04ISR Number: 4361672-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507921A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Oedema		Lexapro	C				
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361673-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507928A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	6	WK
	Feeling Abnormal							
	Ill-Defined Disorder							
	Suicidal Ideation							

Date:05/21/04ISR Number: 4361674-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507932A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:05/21/04ISR Number: 4361675-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507941A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	30 MON
	Drug Ineffective		Propranolol	C				
	Increased Tendency To Bruise		Atrovent	C				
			Prempro	C				
	Insomnia		Bextra	C				
	Tremor		Calcium	C				
	Weight Decreased		Multivitamin	C				
			Fish Oil	C				
			B12 Vitamin	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361676-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508019A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Memory Impairment		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:05/21/04ISR Number: 4361677-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508054A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Lexapro	C				

Date:05/21/04ISR Number: 4361678-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508055A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
	Anger							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361679-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508061A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
			Celexa	C				

Date:05/21/04ISR Number: 4361680-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508067A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Weight Decreased		Synthroid	C	Glaxosmithkline			
			Lamictal	C	Glaxosmithkline			
			Neurontin	C				
			Klonopin	C				

Date:05/21/04ISR Number: 4361681-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508099A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	10 WK
		Professional	Zoloft	C			200MG per day	

Date:05/21/04ISR Number: 4361682-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508187A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361683-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508332A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361684-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508337A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Cholesterol		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
	Increased		Lexapro	C				
			Zocor	C				

Date:05/21/04ISR Number: 4361685-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508341A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
	Insomnia		Toprol	C				
	Swelling Face		Hctz	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361686-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508355A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361687-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508383A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Energy Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Insomnia							

Date:05/21/04ISR Number: 4361688-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508384A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ill-Defined Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Therapeutic Response Decreased							

Date:05/21/04ISR Number: 4361690-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508402A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Rash Pruritic							
	Swelling							

Date:05/21/04ISR Number: 4361691-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508421A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Anorexia		Vitamin A	C				
	Menorrhagia		Vitamin C	C	Glaxosmithkline			
	Metrorrhagia		Ester C	C				
			Vitamin D	C				
			Vitamin E	C				
			Coenzyme Q10	C				
			Magnesium	C				
			Alpha Lipoic Acid	C				
			Flax Oil	C				
			Fish Oil	C				

Date:05/21/04ISR Number: 4361692-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508429A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	5 MON
	Pruritus		Synthroid	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361693-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508449A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Jaw Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Pain In Jaw		Neurontin	C				

Date:05/21/04ISR Number: 4361694-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508455A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:05/21/04ISR Number: 4361695-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508458A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
	Nausea		Darvon	C				
			Oxycontin	C				

Date:05/21/04ISR Number: 4361696-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508466A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
			No Concurrent Medication	C				

Date:05/21/04ISR Number: 4361697-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508468A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
	Nausea							

Date:05/21/04ISR Number: 4361698-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508638A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Erythema							
per day	3 WK							
	Urticaria		Levothyroxine	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361699-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508653A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	0 DAY
	Dizziness		Hctz	C				
	Tinnitus		Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361700-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508658A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Concerta	C				

Date:05/21/04ISR Number: 4361701-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508662A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361702-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508672A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361703-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508691A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361704-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508732A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Unknown Medication	C				

Date:05/21/04ISR Number: 4361705-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508748A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Muscle Spasms		Zoloft	C				
	Rash Papular		Trazodone	C				

Date:05/21/04ISR Number: 4361706-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508757A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Flatulence		Vioxx	C				
			Reglan	C	Glaxosmithkline			
			Nexium	C				
			Flonase	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361707-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508767A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
			Thyroid Medication	C				

Date:05/21/04ISR Number: 4361708-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508774A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Euphoric Mood		Vitamins	C				
	Headache		Xanax	C				
	Hypoaesthesia Oral							
	Tinnitus							

Date:05/21/04ISR Number: 4361709-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508948A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Adderall	C				
			Lidocaine	C				

Date:05/21/04ISR Number: 4361710-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508950A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome							

Date:05/21/04ISR Number: 4361711-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508953A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361712-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508977A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 WK

Date:05/21/04ISR Number: 4361713-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509122A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Drug Ineffective		Advil	C	Glaxosmithkline			
	Headache							
	Menstrual Discomfort							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361714-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509136A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Nausea							
	Pruritus							

Date:05/21/04ISR Number: 4361715-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509157A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361716-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509158A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	53 DAY
			Ultram	C				
			Celebrex	C				
			Ambien	C				

UNKNOWN

Date:05/21/04ISR Number: 4361718-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509198A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361719-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509206A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			
UNKNOWN								

Date:05/21/04ISR Number: 4361720-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509553A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
300MG Per day								
	Dizziness							
	Hyperhidrosis							
	Nausea							

Date:05/21/04ISR Number: 4361721-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509601A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coordination Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361722-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510023A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Therapeutic Response Decreased		Namenda	SS				

Date:05/21/04ISR Number: 4361724-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500838A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 WK
			Effexor	C				

Date:05/21/04ISR Number: 4361725-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500844A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Headache							
	Nausea							

Date:05/21/04ISR Number: 4361726-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500861A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1TAB Per day	6 WK
	Anxiety		No Concurrent Medication	C				

Date:05/21/04ISR Number: 4361727-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500867A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Dizziness		Provigil	C				
			Valium	C				
			Prevacid	C				
			Tricor	C				
			Zanaflex	C				
			Darvocet	C				
			Climara Patch	C				
			Actonel	C				
			Levoxyl	C	Glaxosmithkline			
			B12 Injections	C	Glaxosmithkline			
			Betaferon	C				
			Niaspan	C				

UNKNOWN

Date:05/21/04ISR Number: 4361728-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500871A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361729-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501034A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Tinnitus							

Date:05/21/04ISR Number: 4361730-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501035A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Drug Ineffective							
	Panic Attack							

Date:05/21/04ISR Number: 4361731-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501037A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	19	DAY
Initial or Prolonged	Convulsion							
	Tongue Biting							
	Tremor							
	Urinary Incontinence							

Date:05/21/04ISR Number: 4361732-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501054A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Dry Mouth		Zoloft	C				

Date:05/21/04ISR Number: 4361733-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501057A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
			Vicodin	C				
			Soma	C				

Date:05/21/04ISR Number: 4361734-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501065A
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON

Date:05/21/04ISR Number: 4361735-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501069A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361736-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501181A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON

Date:05/21/04ISR Number: 4361737-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501186A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361738-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501189A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngolaryngeal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	WK
	Rash							
	Stomach Discomfort							

Date:05/21/04ISR Number: 4361739-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501199A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Pharyngolaryngeal Pain							
	Rash							

Date:05/21/04ISR Number: 4361740-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501204A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	23 DAY
			Allegra D	C				

Date:05/21/04ISR Number: 4361741-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501211A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the morning	
	Pain							
			Lexapro	SS		ORAL	10MG In the morning	

Date:05/21/04ISR Number: 4361742-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501226A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Neck Pain		Neurontin	C				
	Tinnitus		Vicodin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361743-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501229A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Unknown	C				

Date:05/21/04ISR Number: 4361744-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501332A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK

Date:05/21/04ISR Number: 4361745-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501342A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK

Date:05/21/04ISR Number: 4361746-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501346A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Headache							

Date:05/21/04ISR Number: 4361747-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501413A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 2 DAY						

Date:05/21/04ISR Number: 4361749-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501420A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Palpitations		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						

Date:05/21/04ISR Number: 4361750-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501456A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 2 MON						
	Palpitations					
	Weight Decreased					

Date:05/21/04ISR Number: 4361751-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501599A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Depression	Consumer	Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 3 MON						
			Beer	SS		ORAL
10CANS Per						
day						
			Lexapro	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361752-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501605A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Black Hairy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	7	DAY

Date:05/21/04ISR Number: 4361753-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501609A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
			Zyrtec-D	C				
			Armour Thyroid	C				

Date:05/21/04ISR Number: 4361754-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501613A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK

Date:05/21/04ISR Number: 4361755-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501615A
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Medication Error		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Diovan Hct	C				
			Allegra	C				
			Nasonex	C				
			Vioxx	C				
			Vitamins	C				

Date:05/21/04ISR Number: 4361756-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501631A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Urgency		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
	Pollakiuria		Effexor	C				
	Urinary Incontinence							

Date:05/21/04ISR Number: 4361757-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501933A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY

Date:05/21/04ISR Number: 4361758-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501940A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Dyspnoea		Lexapro	C				
	Paraesthesia							
	Rash							
	Sleep Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361759-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501941A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Weight Decreased		Oral Contraceptives	C				

Date:05/21/04ISR Number: 4361760-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501943A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphemia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
			Seroquel	C				
			Klonopin	C				

Date:05/21/04ISR Number: 4361761-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501954A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Muscle Spasms		Norvasc	C				
	Pain In Extremity		Digitek	C	Glaxosmithkline			
	Weight Decreased		Accupril	C				
			Aspirin	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361762-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501957A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:05/21/04ISR Number: 4361763-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501971A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Ambien	C				

Date:05/21/04ISR Number: 4361764-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501973A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Paraesthesia		Synthroid	C	Glaxosmithkline			
	Paraesthesia Oral		Oral Contraceptives	C				

Date:05/21/04ISR Number: 4361765-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501978A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 WK
	Weight Increased		Levoxyl	C	Glaxosmithkline			
			Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361766-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502006A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361767-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502026A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	9	DAY
	Hypersensitivity							
	Oedema Peripheral							
	Rash Pruritic							
	Swelling Face							
	Urticaria							

Date:05/21/04ISR Number: 4361770-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502030A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361771-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502139A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			Concerta	C				

Date:05/21/04ISR Number: 4361772-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502169A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	26 DAY
	Nausea		K-Dur	C	Glaxosmithkline			
			Hctz	C				
			Endocet	C				
			Zocor	C				
			Xanax	C				
			Elavil	C	Glaxosmithkline			
			Flexeril	C				
			Valium	C				
			Albenza	C	Glaxosmithkline			
			Ultram	C				
			Tagamet	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361773-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502176A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Irritability		Paxil	C	Glaxosmithkline	ORAL	20MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361774-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502356A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Depression		Lexapro	SS		ORAL	20MG Per day	5 YR
	Hangover							
	Nausea							
	Vertigo							

Date:05/21/04ISR Number: 4361775-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502359A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361776-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502370A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	17 WK
	Nervousness		Imipramine	C				
	Swelling		Klonopin	C				
			Hormone Replacement	C				
			Indocin	C				
			Neurontin	C				
			Prilosec	C				

Date:05/21/04ISR Number: 4361777-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502371A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 DAY

			Toprol Xl	C		

Date:05/21/04ISR Number: 4361778-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502419A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK

Date:05/21/04ISR Number: 4361779-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502422A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Confusional State		Trileptal	C		ORAL	300MG At night	
Other	Grand Mal Convulsion							
			Risperidal	C		ORAL	1MG At night	
			Paxil Cr	C	Glaxosmithkline	ORAL	25MG In the morning	
			Synthroid	C	Glaxosmithkline	ORAL	.1MG In the morning	
			Estrace	C		ORAL	2MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361780-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502423A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	MON

Date:05/21/04ISR Number: 4361781-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502468A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361782-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502469A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361783-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502562A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
	Anxiety							
	Tension							

Date:05/21/04ISR Number: 4361784-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502565A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	19 DAY

	Fatigue		Atenolol	C		
	Somnolence		Nexium	C		

Date:05/21/04ISR Number: 4361785-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502573A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON

Date:05/21/04ISR Number: 4361786-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502577A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	4 WK
	Dysphagia		Benadryl	SS	Glaxosmithkline		UNKNOWN	
	Insomnia		Lipitor	C				
			Antihypertensive	C				
			Arthritis Medication	C		ORAL		
			Flonase	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361787-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502587A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline			
			Concurrent Medications	C				

Date:05/21/04ISR Number: 4361788-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502631A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	MON

Date:05/21/04ISR Number: 4361789-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502635A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the morning	4 DAY

Date:05/21/04ISR Number: 4361790-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502838A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361791-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502847A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 8 WK						
	Mouth Ulceration		Valtrex	C	Glaxosmithkline	
	Swollen Tongue		Oral Contraceptives	C		
	Therapeutic Response					
	Unexpected					

Date:05/21/04ISR Number: 4361792-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502852A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Increased Appetite		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 4 WK						
	Weight Increased		Prozac	C		
			Topamax	C		
			Motrin	C	Glaxosmithkline	

Date:05/21/04ISR Number: 4361793-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502854A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 4 DAY						
			Guaifenesin	C		
			Albuterol	C	Glaxosmithkline	
			Advil	C	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361795-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502870A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361796-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502881A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK

Date:05/21/04ISR Number: 4361797-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502894A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361798-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502904A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
	Paraesthesia							

Date:05/21/04ISR Number: 4361800-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502923A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
1 WK						
	Libido Disorder		Paxil	SS	Glaxosmithkline	ORAL
	Nervousness					

Date:05/21/04ISR Number: 4361801-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502929A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL

Date:05/21/04ISR Number: 4361802-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502960A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 9 WK						
			Vitamins	C		
			Aspirin	C	Glaxosmithkline	

Date:05/21/04ISR Number: 4361803-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502969A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 3 WK						
			Paxil	C	Glaxosmithkline	

			Trileptal	C		
			Lorazepam	C		

Date:05/21/04ISR Number: 4361804-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502983A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Prozac	C				
			Neurontin	C				
			Ativan	C				
			Ambien	C				

Date:05/21/04ISR Number: 4361805-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502989A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Feeling Jittery							

Date:05/21/04ISR Number: 4361806-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502993A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	23 DAY
	Dizziness		Tylenol Sinus	C				
	Fatigue							
	Irritability							
	Nausea							
	Vertigo							

Date:05/21/04ISR Number: 4361807-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503004A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Vesicular		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361808-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503011A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY

Date:05/21/04ISR Number: 4361809-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503014A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Joint Stiffness		None	C				
	Myalgia							
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361813-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503115A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Discolouration		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361814-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503116A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361815-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503160A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361816-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503199A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	7 WK

Date:05/21/04ISR Number: 4361817-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503214A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL		4 DAY
Initial or Prolonged	Convulsion Hypertension							

Date:05/21/04ISR Number: 4361818-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503225A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361819-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503228A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Dizziness							
	Irritability							

Date:05/21/04ISR Number: 4361820-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503230A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361821-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503346A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1TAB Twice per day	MON

Date:05/21/04ISR Number: 4361822-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503440A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	30 DAY

Date:05/21/04ISR Number: 4361823-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503453A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361824-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503464A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 MON
	Libido Decreased							
	Paranoia							

Date:05/21/04ISR Number: 4361825-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503465A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Birth Control	C				

Date:05/21/04ISR Number: 4361826-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503493A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	6	DAY

Date:05/21/04ISR Number: 4361827-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503530A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361828-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503540A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Wellbutrin Ultram	SS C	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361829-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503546A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	200MG Twice per day	2 MON

Date:05/21/04ISR Number: 4361830-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503818A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY

Date:05/21/04ISR Number: 4361831-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503840A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Anxiety		Paxil Cr	SS	Glaxosmithkline	ORAL	25MG Per day	3 WK
	Erectile Dysfunction		Hydroxyzine Pamoate	C				
			Trazodone	C				
			Vistaril	C				
			Percocet	C				
			Oxycontin	C				

Date:05/21/04ISR Number: 4361832-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503853A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
	Hyperhidrosis		Ativan	C				

Thermal Burn		Diovan	C		
Tremor		Synthroid	C	Glaxosmithkline	
		Amitriptyline	C		

Date:05/21/04ISR Number: 4361833-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503859A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	16 DAY
	Diarrhoea		Asthma Medication	C				
	Influenza Like Illness							
	Oral Mucosal Blistering							
	Pain							
	Pyrexia							
	Rash							
	Swelling Face							
	Tongue Disorder							

Date:05/21/04ISR Number: 4361834-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503862A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Fluctuation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361835-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503875A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	DAY
	Dizziness							
	Dry Mouth							
	Weight Increased							

Date:05/21/04ISR Number: 4361836-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503999A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/21/04ISR Number: 4361837-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504049A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361838-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504051A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361839-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504072A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pollakiuria		Wellbutrin	PS	Glaxosmithkline	ORAL

300MG Per day 15 DAY

Date:05/21/04ISR Number: 4361840-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504082A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Migraine		Wellbutrin	PS	Glaxosmithkline	

Dose Duration

Date:05/21/04ISR Number: 4361841-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504084A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL

Dose Duration

300MG Per day
Initial or Prolonged

Date:05/21/04ISR Number: 4361842-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504091A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Insomnia		Wellbutrin	PS	Glaxosmithkline	

Dose Duration

300MG Per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361843-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504099A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	2 WK
			Synthroid	C	Glaxosmithkline			
			Oxycontin	C				
			Amitriptyline	C				
			Xanax	C				
			Soma	C				

Date:05/21/04ISR Number: 4361844-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504206A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK

Date:05/21/04ISR Number: 4361845-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504207A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361846-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504216A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	6	MON
	Skin Exfoliation							

Date:05/21/04ISR Number: 4361847-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504288A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	MON
	Anger							

Date:05/21/04ISR Number: 4361848-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504293A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lexapro	C				
			Topamax	C				

Date:05/21/04ISR Number: 4361849-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504297A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Oral Contraceptives	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361850-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504303A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Hyperhidrosis		Colace	C				
	Nausea		Serzone	C				
	Tremor							

Date:05/21/04ISR Number: 4361851-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504309A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
	Rash							

Date:05/21/04ISR Number: 4361852-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504317A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Nervousness		Vitamins	C				

Date:05/21/04ISR Number: 4361853-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504320A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysmenorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	45 DAY
	Mood Altered		Celexa	C				
			Zyrtec	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361854-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504324A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Hot Flush							

Date:05/21/04ISR Number: 4361855-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504330A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	4 MON
			Provigil	C				
			Topamax	C				
			Hytrin	C				
			Levoxyl	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361856-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504334A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361857-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504455A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361858-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504561A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
	Drug Ineffective		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice per day	
	Feeling Of Despair							
			Birth Control Pill	C				

Date:05/21/04ISR Number: 4361859-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504563A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Texture Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

Date:05/21/04ISR Number: 4361860-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504572A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	12 DAY
	Insomnia		Xanax	C				
	Nausea							

Date:05/21/04ISR Number: 4361861-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504577A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	0 DAY
	Dyspnoea		Hytrin	C				
	Nervousness		Triavil	C				
			Mevacor	C				
			Valium	C				
			Cipro	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361865-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504586A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Urticaria							

Date:05/21/04ISR Number: 4361866-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504597A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Somnolence		Maxalt	C				
			Flonase	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361867-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504677A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown

Date:05/21/04ISR Number: 4361868-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504704A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361869-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504705A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

Date:05/21/04ISR Number: 4361870-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504781A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 DAY
			Restoril	C				
			Hctz	C				
			Lipitor	C				
			Captopril	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361871-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504791A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Urticaria		Oral Contraceptive	C				
			Hydroxyzine	C				
			Prednisone	C				

Date:05/21/04ISR Number: 4361872-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504793A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:05/21/04ISR Number: 4361873-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504799A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasopharyngitis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Pharyngolaryngeal Pain		Levoxyl	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361874-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504807A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neck Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361875-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504824A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361876-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504871A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON

Date:05/21/04ISR Number: 4361877-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504874A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	DAY
	Hallucination		Antibiotic	C				
	Hypertension							
	Insomnia							
	Night Sweats							
	Paranoia							
	Thinking Abnormal							
	Tremor							

Date:05/21/04ISR Number: 4361878-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504876A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	17 DAY
	Headache		Nexium	C				
	Lethargy		Ibuprofen	C	Glaxosmithkline			
	Mood Altered		Tylenol	C	Glaxosmithkline			
	Nausea		Pseudoephedrine	C				
	Palpitations		Tums	C	Glaxosmithkline			
	Tremor							

Date:05/21/04ISR Number: 4361879-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504881A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361880-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504891A
Age:48 YR Gender:Female I/FU:I

Outcome	PT
	Drug Ineffective
	Dry Mouth

Hepatic Enzyme Increased						
Insomnia						
Memory Impairment	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Pharmaceutical Product		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day
Complaint		Wellbutrin Sr	SS	Glaxosmithkline		
		Klonopin	C			
		Soy Supplement	C			
		Vitamins	C			

Date:05/21/04ISR Number: 4361881-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504895A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 2 WK
	Insomnia						

Date:05/21/04ISR Number: 4361882-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504896A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day
	Dizziness		Coumadin	C	Glaxosmithkline		
	Drug Ineffective		Amoxicillin	C	Glaxosmithkline		
	Dyspnoea						
	Pharyngitis Streptococcal						

Date:05/21/04ISR Number: 4361883-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504915A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 2 WK
	Anorexia		Darvocet	C			
			Plaquenil	C			

			Ambien	C			

Date:05/21/04ISR Number: 4361884-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504919A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	1 MON
			Adderall	C				
			Xanax	C				
			Seroquel	C				

Date:05/21/04ISR Number: 4361885-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505025A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Macular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	7 DAY
	Rash Vesicular		Ritalin	C		ORAL	10MG Three	
	Skin Exfoliation						times per day	
	Stevens-Johnson Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361886-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505093A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/21/04ISR Number: 4361887-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505107A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Nausea		Augmentin	C	Glaxosmithkline			
	Tinnitus		Zyrtec	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361888-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505141A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Throat Tightness		Vitamins	C				
			Wellbutrin Sr	C	Glaxosmithkline		150MG Per day	1 YR

Date:05/21/04ISR Number: 4361889-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505227A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/21/04ISR Number: 4361890-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505228A
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lexapro	C				
			Atenolol	C				

Date:05/21/04ISR Number: 4361891-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505229A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	14 DAY
Initial or Prolonged	Convulsion		Allegra	C				
	Disorientation							
	Tremor							

Date:05/21/04ISR Number: 4361892-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505238A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361893-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505258A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	8	WK

Date:05/21/04ISR Number: 4361894-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505259A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Hytrin	C				
			Proscar	C				

Date:05/21/04ISR Number: 4361896-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505260A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361898-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505261A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Unknown	4 DAY
	Drug Ineffective							
	Irritability							
	Paraesthesia							

Date:05/21/04ISR Number: 4361909-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441775A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Convulsion	Professional	Celexa	C				
	Epistaxis							
	Fall							
	Periorbital Haematoma							
	Tooth Fracture							
	Tooth Injury							
	Toothache							

Date:05/21/04ISR Number: 4361910-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490957A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Pharmaceutical Product Complaint	Professional						

Date:05/21/04ISR Number: 4361911-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491689A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See dosage text	3 WK
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361912-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491733A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Paraesthesia	Professional						
	Rash							
	Stomach Discomfort							

Date:05/21/04ISR Number: 4361913-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492592A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	2 MON
	Grand Mal Convulsion	Professional	Ritalin Sr	C				
	Tongue Biting							

Date:05/21/04ISR Number: 4361914-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493257A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	112 DAY
Initial or Prolonged		Professional	Lexapro	C		ORAL	20MG Per day	
			Norvir	C		ORAL		
			Invirase	C				

Date:05/21/04ISR Number: 4361915-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494685A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
	Grand Mal Convulsion	Professional						
	Incontinence							

	Tongue Biting					

Date:05/21/04ISR Number: 4361916-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495501A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Disorientation	Health	Wellbutrin	PS	Glaxosmithkline			22 DAY
Initial or Prolonged	Fatigue	Professional	Advair	C	Glaxosmithkline			
	Grand Mal Convulsion		Singulair	C				
			Alesse	C				
			Zyrtec	C	Glaxosmithkline			
			Pulmicort	C				
			Proventil	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361917-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495775A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361918-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496051A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Incontinence		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Pollakiuria							

Date:05/21/04ISR Number: 4361919-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496060A
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
			Toprol Xl	C				
			Norvasc	C				
			Accupril	C				
			Metformin	C				
			Lipitor	C				
			Amaryl	C				
			Xalatan	C				

Date:05/21/04ISR Number: 4361920-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496065A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Dry Mouth		Zithromax	C				
	Headache							
	Nausea							

Date:05/21/04ISR Number: 4361921-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496300A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

	Fatigue					
	Tremor					

Date:05/21/04ISR Number: 4361922-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496303A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Proton Pump Inhibitor	SS				
UNKNOWN								

Date:05/21/04ISR Number: 4361923-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496304A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	0 DAY
			Celexa	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361924-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496309A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Constipation		Lasix	C	Glaxosmithkline			
	Sexual Dysfunction		Buspar	C				

Date:05/21/04ISR Number: 4361925-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496315A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Peripheral Coldness							

Date:05/21/04ISR Number: 4361929-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496324A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	MON

Date:05/21/04ISR Number: 4361930-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496336A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
	Obsessive-Compulsive		Lexapro	C				
	Disorder		Trazodone	C				
			Birth Control Pill	C				

Date:05/21/04ISR Number: 4361931-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496665A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	26 DAY
	Bursitis		Prevacid	C				
	Joint Swelling							
	Oedema Peripheral							

Date:05/21/04ISR Number: 4361932-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496670A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK

Date:05/21/04ISR Number: 4361933-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496672A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
Hospitalization - Initial or Prolonged	Pharmaceutical Product Complaint							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361935-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496886A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown 1 MON

Date:05/21/04ISR Number: 4361936-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496899A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day

Date:05/21/04ISR Number: 4361937-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496901A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day

Date:05/21/04ISR Number: 4361938-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496903A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Apathy		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
	Sexual Dysfunction							

Date:05/21/04ISR Number: 4361939-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496912A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361940-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496933A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Weight Decreased							

Date:05/21/04ISR Number: 4361941-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496953A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Suppressed Lactation		Wellbutrin	PS	Glaxosmithkline	ORAL	5	MON

Date:05/21/04ISR Number: 4361942-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496956A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Rash Pruritic							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361943-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496958A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361944-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496959A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361945-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496961A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Amphetamine Positive		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Tylenol	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361946-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496988A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Adderall	C				

Date:05/21/04ISR Number: 4361947-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497062A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Effexor	C				

Date:05/21/04ISR Number: 4361948-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497070A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Glipizide	C				

Date:05/21/04ISR Number: 4361949-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497071A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
	Nausea							

Date:05/21/04ISR Number: 4361951-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497075A
Age:34 YR Gender:Female I/FU:I

Outcome	PT
	Anorexia
	Chest Discomfort
	Feeling Jittery
	Heart Rate Increased

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea							
	Palpitations							
	Retching		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Somnolence		Effexor	SS			37.5MG Per day	3 WK
	Tinnitus		Valium	C				
	Tremor							

Date:05/21/04ISR Number: 4361952-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497099A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 MON
	Tremor							

Date:05/21/04ISR Number: 4361953-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497101A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 MON
	Insomnia		Vicodin	C				
	Libido Increased		Nasonex	C				
	Smoker		Allegra	C				
	Weight Loss Poor							

Date:05/21/04ISR Number: 4361954-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497105A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 DAY
	Dizziness		Aciphex	C				

	Dry Mouth		Yasmin	C	
	Dyspnoea		Nasacort Aq	C	
	Headache		Amoxicillin	C	Glaxosmithkline
	Neck Pain				
	Pain In Jaw				

Date:05/21/04ISR Number: 4361955-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497173A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Eczema		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:05/21/04ISR Number: 4361956-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497175A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash Papular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:05/21/04ISR Number: 4361957-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497193A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Flushing		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day						
	Urticaria		Combivent	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361958-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497198A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Urticaria		Benadryl	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4361959-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497215A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/21/04ISR Number: 4361960-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497346A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Strattera	SS		ORAL		

Date:05/21/04ISR Number: 4361961-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497367A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tic		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	C	Glaxosmithkline	ORAL	150MG Twice per day	

Date:05/21/04ISR Number: 4361962-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497369A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361963-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497376A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK

Date:05/21/04ISR Number: 4361964-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497538A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	2	DAY
	Initial Insomnia							

Date:05/21/04ISR Number: 4361965-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497561A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361966-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497582A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
	Suicidal Ideation							

Date:05/21/04ISR Number: 4361967-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497585A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Muscle Twitching							

Date:05/21/04ISR Number: 4361968-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497588A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Flushing		Wellbutrin Sr	C	Glaxosmithkline	ORAL	150MG Twice per day	3 MON
	Formication							

Date:05/21/04ISR Number: 4361969-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497602A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG per day	7 DAY
	Drug Ineffective		Paxil Cr	C	Glaxosmithkline	ORAL		
	Feeling Jittery							
	Suicidal Ideation							

Date:05/21/04ISR Number: 4361970-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497607A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
	Decreased Appetite		Xanax	C				
	Dry Mouth		Ambien	C				
	Nausea		Duragesic	C				
	Tachycardia		Oxycodone	C				

Date:05/21/04ISR Number: 4361971-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497719A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Foreign Body Trauma		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361973-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497721A
Age:12 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361974-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497726A
Age:8 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Ineffective		Strattera	C			25MG Per day	
	Grand Mal Convulsion							
	Tongue Biting							

Date:05/21/04ISR Number: 4361975-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497728A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
			Xanax	C				

Date:05/21/04ISR Number: 4361976-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497732A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Lexapro	C				
			Topamax	C				

Date:05/21/04ISR Number: 4361977-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497734A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Palpitations		Remeron	C				
	Paranoia		Buspar	C				

Date:05/21/04ISR Number: 4361978-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497736A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Ultram	C				

Date:05/21/04ISR Number: 4361979-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497742A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Muscle Twitching							
	Tremor							

Date:05/21/04ISR Number: 4361980-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497749A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Hypertension		None	C				
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361981-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497759A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
			Librax	C				
			Microzide	C				

Date:05/21/04ISR Number: 4361982-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497764A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	1 WK
	Nausea		Neurontin	C				
			Celexa	C				
			Pravachol	C				
			Celebrex	C				

Date:05/21/04ISR Number: 4361983-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497791A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4361984-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497799A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline			
	Insomnia							

Date:05/21/04ISR Number: 4361985-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497807A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
	Dysgeusia		Buspar	C				
	Stomach Discomfort		Eskalith Cr	C	Glaxosmithkline			
	Tinnitus		Metformin	C				
			Vitamins	C				
			Calcium	C				
			Premarin	C				
			Unspecified Medication	C				
			Prilosec	C				
			Lipitor	C				
			Klonopin	C				

Date:05/21/04ISR Number: 4361986-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497816A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361987-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497849A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Dizziness		Zyban	SS	Glaxosmithkline	ORAL		
	Insomnia							

Date:05/21/04ISR Number: 4361988-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497890A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown DAY
	Pharyngolaryngeal Pain							

Date:05/21/04ISR Number: 4361989-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497971A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Climara	C				

Date:05/21/04ISR Number: 4361990-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498001A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Date:05/21/04ISR Number: 4361991-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498007A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/21/04ISR Number: 4361992-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498010A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline		4	WK
			Ambien	C				
			Celexa	C				
			Zestril	C				
			Diuretic	C				
			Lipitor	C				
			Tylenol With Codeine	C				

Date:05/21/04ISR Number: 4361993-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498016A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361994-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498025A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
	Heart Rate Increased							

Date:05/21/04ISR Number: 4361995-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498026A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4361996-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498027A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Dizziness		Celexa	SS			UNKNOWN	30MG Unknown
	Dry Mouth							
	Fatigue							
	Feeling Abnormal							
	Hyperhidrosis							
	Insomnia							
	Irritability							
	Libido Decreased							
	Migraine							
	Myalgia							
	Nausea							
	Vision Blurred							

Date:05/21/04ISR Number: 4362001-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498029A
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	35	DAY

Date:05/21/04ISR Number: 4362002-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498041A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Hypersensitivity							

Date:05/21/04ISR Number: 4362003-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498153A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Nausea		Lamictal	C	Glaxosmithkline			
			Lorazepam	C				
			Aspirin	C	Glaxosmithkline			
			Excedrin	C				
			Pepto-Bismol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362004-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498156A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	12 DAY
	Alopecia		Relpax	C				
			Dhe	C				
			Depakote	C				

Date:05/21/04ISR Number: 4362005-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498161A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4362006-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498165A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362007-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498201A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the Initial or Prolonged morning	135 DAY
			Xanax	C			.5MG Three times per day	
			Herbal Medicine	C		ORAL		

Date:05/21/04ISR Number: 4362008-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498347A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Date:05/21/04ISR Number: 4362009-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498349A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Orthostatic Hypotension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Lexapro	C				

Date:05/21/04ISR Number: 4362010-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498361A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Chest Discomfort		Effexor	SS			UNKNOWN	
	Dyspnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362011-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498507A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
	Nausea							

Date:05/21/04ISR Number: 4362012-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498508A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 MON
	Pruritus Generalised		Celexa	C				
	Rash							

Date:05/21/04ISR Number: 4362013-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498516A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antisocial Personality		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Disorder		None	C				
	Crying							
	Depressed Mood							
	Dissociation							
	Pallor							

Date:05/21/04ISR Number: 4362014-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498519A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362015-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498524A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Wellbutrin	PS	Glaxosmithkline			2 WK
			Effexor Xr	C				

Date:05/21/04ISR Number: 4362017-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498527A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Aura		Effexor Xr	C			150MG Per day	
	Fatigue		Trazodone	C			25MG As required	
	Grand Mal Convulsion							

Date:05/21/04ISR Number: 4362018-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498540A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362019-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498544A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Joint Stiffness							

Date:05/21/04ISR Number: 4362020-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498545A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling Face		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362021-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498554A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Advair	C	Glaxosmithkline			
			Benadryl	C	Glaxosmithkline			
			Ortho Tri-Cyclen	C				

Date:05/21/04ISR Number: 4362022-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498602A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	6	MON
			Zyprexa	C				

Date:05/21/04ISR Number: 4362023-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498614A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362024-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498737A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150TAB Per	
	Tremor						day	1 DAY
			Prilosec	C				
			Klonopin	C				

Date:05/21/04ISR Number: 4362025-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498767A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Glucophage	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362026-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498777A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Nausea		Lamictal	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4362027-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498781A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362028-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498792A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	MON
	Depression		Neurontin	C				
	Hypotrichosis							

Date:05/21/04ISR Number: 4362029-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498842A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Wellbutrin	PS	Glaxosmithkline	ORAL		
Other	Convulsion							

Date:05/21/04ISR Number: 4362030-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499053A
Age: Gender: I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Lymphadenopathy Wellbutrin PS Glaxosmithkline ORAL

Date:05/21/04ISR Number: 4362031-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499084A
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Alopecia Wellbutrin Xl PS Glaxosmithkline ORAL

Date:05/21/04ISR Number: 4362032-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499202A
Age: YR Gender: I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Drug Ineffective Wellbutrin Xl PS Glaxosmithkline ORAL

Date:05/21/04ISR Number: 4362033-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499205A
Age:60 YR Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Tinnitus Wellbutrin Xl PS Glaxosmithkline ORAL
150MG Per day 3 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362034-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499208A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4362035-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499216A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	600MG Per day	
	Medication Error							
	Speech Disorder							
	Stomach Discomfort							

Date:05/21/04ISR Number: 4362036-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499228A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362037-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499407A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	DAY
	Paraesthesia							

Date:05/21/04ISR Number: 4362038-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499456A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 3 WK						
	Dizziness		Ortho-Novum 777	C		
	Nausea					
	Salivary Hypersecretion					
	Throat Tightness					

Date:05/21/04ISR Number: 4362039-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499593A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 3 WK						
	Pruritus		Evista	C		
	Urticaria		Caltrate	C	Glaxosmithkline	
			Multivitamin	C		

Date:05/21/04ISR Number: 4362040-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499597A
Age:50 YR Gender:Male I/FU:F

Outcome	PT
	Anorexia
	Headache
	Hypersomnia
	Nausea
	Neck Pain

	Pain					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day	36 DAY					
			Lipitor	C		

Date:05/21/04ISR Number: 4362041-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499599A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Orthostatic Hypotension		Wellbutrin Xl	PS	Glaxosmithkline	

Date:05/21/04ISR Number: 4362042-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499610A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day	2 DAY					

Date:05/21/04ISR Number: 4362043-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499624A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:05/21/04ISR Number: 4362044-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499641A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Galactorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
2	WK					

Date:05/21/04ISR Number: 4362045-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499813A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
			Lorazepam	C				

Date:05/21/04ISR Number: 4362046-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499818A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Zoloft	C				

Date:05/21/04ISR Number: 4362047-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499830A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Rash Generalised		Lamictal	SS	Glaxosmithkline	ORAL	3	WK
			Valproic Acid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362048-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499836A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
	Stomach Discomfort							
	Vertigo							

Date:05/21/04ISR Number: 4362049-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499846A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Impatience		Caffeinated Beverage	SS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362050-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499853A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	3 DAY
		Professional	Premarin	C				
			Synthroid	C	Glaxosmithkline			
			Meridia	C				
			Klonopin	C				
			Hyzaar	C				

Date:05/21/04ISR Number: 4362051-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499854A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
	Insomnia		Nexium	C				
	Tremor		Lexapro	C				
			Depakote	C				

Date:05/21/04ISR Number: 4362052-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499868A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Exposure		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Agitation		Nortriptyline	C				
	Palpitations		Concerta	C				
			Depakote	C				
			Ritalin	C				
			Clonidine	C				

Date:05/21/04ISR Number: 4362053-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500113A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	16 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362054-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500115A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	600MG Per day	5 DAY
	Tremor		Paxil	C	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362055-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500125A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Adderall	C				

Date:05/21/04ISR Number: 4362056-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500143A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Palpitations		Effexor	C				

Date:05/21/04ISR Number: 4362057-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500146A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
	Feeling Jittery							
	Mood Swings							

Date:05/21/04ISR Number: 4362058-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500149A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Date:05/21/04ISR Number: 4362060-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500152A
Age:12 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Somnolence		Wellbutrin	SS	Glaxosmithkline	ORAL	100MG Per day	
			Strattera	C				
			Vitamins	C				

Date:05/21/04ISR Number: 4362061-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500181A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362062-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500182A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG In the morning	

Date:05/21/04ISR Number: 4362063-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500360A
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	200MG Per day	
	Blood Pressure Increased		Lexapro	SS		ORAL		
	Decreased Appetite		Aspirin	C	Glaxosmithkline			
	Drug Ineffective		Zocor	C				
	Stress		Prilosec	C				
	Weight Decreased							

Date:05/21/04ISR Number: 4362064-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500361A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Yawning		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	2 MON
			Provigil	C				
			Oral Contraceptive	C				

Date:05/21/04ISR Number: 4362065-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500362A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362066-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500365A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
			Levoxyl	C	Glaxosmithkline			

Date:05/21/04ISR Number: 4362067-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500366A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Asacol	C	Glaxosmithkline			
			Protonix	C				
			Birth Control	C				

Date:05/21/04ISR Number: 4362069-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500367A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall		Wellbutrin	PS	Glaxosmithkline	ORAL	2 WK	
	Grand Mal Convulsion		Glucophage	C			500MG Twice per day	
	Loss Of Consciousness							
	Tongue Biting		Zantac	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362071-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500372A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362072-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500378A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/21/04ISR Number: 4362073-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500387A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362074-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500443A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362075-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500562A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/21/04ISR Number: 4362076-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500607A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Multiple Medications	C				

Date:05/21/04ISR Number: 4362077-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500617A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Crying		Wellbutrin Sr	C	Glaxosmithkline	ORAL	150MG Twice per day	3 YR

Date:05/21/04ISR Number: 4362080-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500637A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Anxiety		Lexapro	C				
	Therapeutic Response		Xanax	C				
	Unexpected		Vaseretic	C				
			Zocor	C				
			Ibuprofen	C	Glaxosmithkline		800MG Unknown	

			Lortab	C		

Date:05/21/04ISR Number: 4362081-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500669A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Crepitations		Synthroid	C	Glaxosmithkline			
	Gait Disturbance		Lasix	C	Glaxosmithkline			
	Tremor		Atenolol	C				
			Imuran	C	Glaxosmithkline			
			Nexium	C				
			Prednisone	C				

Date:05/21/04ISR Number: 4362082-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500671A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Rash		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice per day	MON
	Urticaria							
	Weight Decreased		Vitamins	C				
			Calcium	C				

Date:05/21/04ISR Number: 4362083-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500676A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Tinnitus		Bupropion Sr	SS	Glaxosmithkline	ORAL		
			Paxil	SS	Glaxosmithkline	ORAL		
			Diovan 80	C				
			Vitamins	C				

			Calcium	C		

Date:05/21/04ISR Number: 4362084-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500677A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 DAY

Date:05/21/04ISR Number: 4362085-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500679A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK

Date:05/21/04ISR Number: 4362086-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500694A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362087-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500737A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
			Lexapro	C			UNKNOWN	10MG Unknown

Date:05/21/04ISR Number: 4362444-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511243A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin Sr	PS	Glaxosmithkline			
	Depressed Mood							
	Suicidal Ideation							

Date:05/24/04ISR Number: 4363402-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511608A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/24/04ISR Number: 4363403-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511715A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Cerebrovascular Accident							
	Transient Ischaemic Attack							

Date:05/24/04ISR Number: 4363404-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511742A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse Self-Medication		Wellbutrin	PS	Glaxosmithkline	ORAL	0	DAY

Date:05/24/04ISR Number: 4363406-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511755A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Medication Error		Wellbutrin Lexapro Risperdal	PS C C	Glaxosmithkline	ORAL	150MG Twice per day	4 DAY

Date:05/24/04ISR Number: 4363418-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0323573A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced	Health Professional	Zyban Euphytose	PS C	Glaxosmithkline	ORAL	150MG Twice per day 2UNIT Three times per day	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/04ISR Number: 4363421-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0330307A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myopia	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Visual Acuity Reduced	Professional					dosage text	3 WK

Date:05/24/04ISR Number: 4363427-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0331481A
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Interaction	Professional					per day	30 DAY
	Face Injury		Tenoretic	SS				
	Hypotension							
	Loss Of Consciousness							
	Syncope Vasovagal							
	Transient Ischaemic Attack							

Date:05/24/04ISR Number: 4363440-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0332749A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	7 DAY
	Gingival Pain		Propranolol	C		ORAL	80MG Per day	
	Heart Rate Increased		Zopiclone	C		ORAL	3.75MG As required	
	Insomnia							
	Tinnitus							

Date:05/24/04ISR Number: 4363444-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0333138A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash Vesicular						per day	21 DAY
	Vasculitis		Diclofenac	C		ORAL	50MG Three	
							times per day	5 DAY

Date:05/25/04ISR Number: 4364384-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493781A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Loss Poor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/25/04ISR Number: 4364385-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494320A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/04ISR Number: 4364386-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500121A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Unspecified Drugs	C				

Date:05/25/04ISR Number: 4364435-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508981A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective							
per day	1	MON						
	Medication Error							
	Somnolence							

Date:05/25/04ISR Number: 4364437-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511270A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Pharmaceutical Product							
per day								
	Complaint							

Date:05/25/04ISR Number: 4364438-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511391A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline			

Date:05/25/04ISR Number: 4364444-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511866A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	64 DAY
			Paxil	C	Glaxosmithkline	ORAL	20MG Per day	
			Synthroid	C	Glaxosmithkline		UNKNOWN	
			Zocor	C			UNKNOWN	
			Tricor	C			UNKNOWN	
			Allegra	C			UNKNOWN	

Date:05/25/04ISR Number: 4364448-6Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0321501A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Parkinson'S Disease		Zyntabac	PS	Glaxosmithkline		19	DAY

Date:05/25/04ISR Number: 4364454-1Report Type:Expedited (15-DaCompany Report #HU-GLAXOSMITHKLINE-B0328691A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperaemia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	15	DAY
	Oedema							
	Pruritus							
	Rash Erythematous							
	Rash Maculo-Papular							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/04ISR Number: 4364458-9Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0331807A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Quomem	PS	Glaxosmithkline			
	Conjunctivitis		Zyntabac	C	Glaxosmithkline			

Date:05/25/04ISR Number: 4364465-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0332761A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression		Zyban	PS	Glaxosmithkline	ORAL		
	Amnesia		Alcohol	SS				
	Drug Interaction		Zoloft	C				
	Grand Mal Convulsion							
	Head Injury							
	Loss Of Consciousness							

Date:05/25/04ISR Number: 4364471-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0332974A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL		
	Decreased Appetite							
	Insomnia							
	Mood Altered							
	Obsessive Thoughts							

Date:05/26/04ISR Number: 4364806-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500390A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Lotronex	PS	Glaxosmithkline	ORAL	1MG Per day	1 YR
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
			Nicoderm	SS	Glaxosmithkline		UNKNOWN	

Date:05/26/04ISR Number: 4365515-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506925A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Haemorrhage		Bupropion	PS	Glaxosmithkline	ORAL	75MG See	
	Retinal Haemorrhage						dosage text	
	Vision Blurred							
	Vitreous Floaters							

Date:05/26/04ISR Number: 4365521-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512065A
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
Initial or Prolonged	Insomnia		Lasix	C	Glaxosmithkline			
	Loss Of Consciousness		Procardia Xl	C	Glaxosmithkline			
			Ambien	C				
			Pravacol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/04ISR Number: 4365523-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512078A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	7 MON
	Lymphoplasia		Prozac	SS			40MG per day	
	Memory Impairment							
	Suicidal Ideation							

Date:05/26/04ISR Number: 4365540-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0333110A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Stenosis		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Myocardial Infarction							

Date:05/27/04ISR Number: 4366581-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511889A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR
	Libido Decreased		Paxil Cr	SS	Glaxosmithkline		1	YR
	Medication Error		Birth Control Pill	C				
	Mood Altered							

Date:05/27/04ISR Number: 4366582-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512061A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Exposure During Pregnancy							

Pregnancy

Date:05/27/04ISR Number: 4366585-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0323094A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Allergic		Zyban	PS	Glaxosmithkline	ORAL	10	DAY
	Hallucination		Erymax	C	Glaxosmithkline	ORAL	250MG Twice per day	8 DAY
	Hypersomnia							
	Sleep Disorder		Cocodamol	C		ORAL		
	Stress		Premarin	C		ORAL		

Date:05/27/04ISR Number: 4366587-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0327731A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Drug Reaction		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 DAY
	Skin Lesion							
			Thyroxine	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/04ISR Number: 4366595-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0333228A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	15 DAY
	Necrobiosis							
	Placental Disorder							

Date:05/28/04ISR Number: 4367110-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0505967A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG See	
	Drooling	Professional						
dosage text							3	WK
	Eye Rolling							
	Fall							
	Headache							
	Medication Error							
	Tremor							

Date:05/28/04ISR Number: 4367111-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0507194A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Overdose	Professional	Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Prilosec	C		ORAL	20MG Per day	
			Paxil Cr	C	Glaxosmithkline	ORAL	3.75MG Per	
							day	

			Nasonex	C		
2SPR Per day						

Date:05/28/04ISR Number: 4367112-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508672A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
Other	Rash	Professional	Ambien	C		ORAL	10MG per day	
	Throat Tightness		Xanax	C		ORAL	1MG At night	
	Vomiting							

Date:05/28/04ISR Number: 4367113-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0510000A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	10 WK
	Balance Disorder	Professional	Depakote	C			3000MG per day	
	Coordination Abnormal							
	Dysarthria		Protonix	C				
	Irritability		Pravacol	C				
	Judgement Impaired							
	Road Traffic Accident							
	Sleep Disorder							
	Sluggishness							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/04ISR Number: 4367114-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0510367A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Health Professional	Bupropion	PS	Glaxosmithkline	ORAL		

Date:05/28/04ISR Number: 4367122-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512178A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Multiple Sclerosis		Bupropion	PS	Glaxosmithkline			

Date:05/28/04ISR Number: 4367123-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512399A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:05/28/04ISR Number: 4367128-6Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0327981A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Hepatic Enzyme Increased Pancreatic Abscess		Zyban	PS	Glaxosmithkline	ORAL	150MG Three times per day	

Date:05/28/04ISR Number: 4367145-6Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043570A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock Cardiovascular Disorder Pharmaceutical Product Complaint	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY

Date:05/28/04ISR Number: 4367412-6Report Type:Direct Company Report #CTU 219743
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Conjunctivitis Erythema Multiforme Myalgia Pharyngolaryngeal Pain Pyrexia Rhinorrhoea		Wellbutrin Xl 150 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	150 MG DAILY ORAL	

Date:06/01/04ISR Number: 4367668-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512619A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Interaction		Wellbutrin Sr Decongestant No Concurrent	PS SS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Medication C

Date:06/01/04ISR Number: 4367686-1Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0334085A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	15	DAY
			Nicotine Substitute	C				
			Buventol	C	Glaxosmithkline	RESPIRATORY (INHALATION)		
			Beclomet	C	Glaxosmithkline	RESPIRATORY (INHALATION)		

Date:06/01/04ISR Number: 4367687-3Report Type:Expedited (15-DaCompany Report #2004009670
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Zyban	PS	Glaxosmithkline	ORAL	150MG Single	
	Fatigue						dose	
	Intentional Misuse							
	Suicide Attempt							

Date:06/01/04ISR Number: 4367869-0Report Type:Direct Company Report #CTU 219803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective		Vioxx 25 Mg Merck	PS	Merck	ORAL	1 1 ORAL	
	Fungal Infection		Wellbutrin 300 Mg					
	Stevens-Johnson Syndrome		Glaxo	SS	Glaxo	ORAL	1 1 ORAL	

Date:06/01/04ISR Number: 4369283-0Report Type:Direct Company Report #CTU 219884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Agitation		Paxil	PS				
Hospitalization - Initial or Prolonged	Diarrhoea		Prozac	SS				
	Insomnia		Effexor	SS				
	Intentional Misuse		Celexa	SS				
	Muscle Contractions		Remeron	SS				
	Involuntary		Lexapro	SS				
	Restlessness		Serzone	SS				
	Stress		Wellbutrin	SS				
	Suicidal Ideation		Zoloft	SS				
	Suicide Attempt		Sleep Pills	C				

Date:06/02/04ISR Number: 4368391-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512883A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Hallucination		Toprol Xl	C				
	Insomnia		Plavix	C				
	Sleep Talking		Amiloride	C				
			Norvasc	C				
			Avapro	C				
			Keppra	C				
			Lexapro	C				

			Vicodin	C		
			Ambien	C		

Date:06/02/04ISR Number: 4368392-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512890A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyskinesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Hallucination		Vioxx	C				
	Insomnia		Effexor Xr	C				
	Paraesthesia							
	Tinnitus							

Date:06/02/04ISR Number: 4368393-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512894A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mental Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Depakote	C				

Date:06/02/04ISR Number: 4368394-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512998A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:06/02/04ISR Number: 4371503-3Report Type:Expedited (15-DaCompany Report #TPA2004A00298
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other Required Intervention to	Alanine Aminotransferase Increased Aspartate	Health Professional Company	Actos (Pioglitazone Hydrochloride) (15 Milligram, Tablets)	PS		ORAL	15 MG, 1 IN 1	

Prevent Permanent D, PER ORAL	Aminotransferase	Representative		
Impairment/Damage	Increased Blood Alkaline Phosphatase Increased Liver Function Test Abnormal Medication Error		Wellbutrin Sr (Bupropion Hydrochloride) Cozaar(Losartan Potassium) Niaspan (Nicotinic Acid) Zoloft (Sertraline Hydrochloride) Birth Control Pills (All Other Therapeutic Products)	SS SS SS SS C

Date:06/03/04ISR Number: 4369995-9Report Type:Expedited (15-DaCompany Report #A03200400600
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Suicide Attempt		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
			Ambien	SS		ORAL	5MG See Other dosage text	9 DAY
			Paroxetine					

Hydrochloride C Glaxosmithkline ORAL
4 DAY

Date:06/03/04ISR Number: 4370005-8Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0334041A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	1	DAY
	Delirium Tremens							
	Hallucination							
	Overdose							
	Restlessness							
	Tardive Dyskinesia							

Date:06/03/04ISR Number: 4370006-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0334091A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Zyban	PS	Glaxosmithkline	UNKNOWN		

Date:06/03/04ISR Number: 4371820-7Report Type:Direct Company Report #CTU 220092
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin 33 Mg	PS		ORAL	ONCE DAILY	
	Hostility					ORAL		

Date:06/03/04ISR Number: 4372073-6Report Type:Direct Company Report #CTU 220074
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Wellbutrin 75 Mg					

	Aggression		Burpropion Hcl	PS		ORAL 37.5 MG 2 DAILY ORAL
	Communication Disorder					
	Confusional State		Trazadone	C		
	Crying					
	Mood Swings					
	Screaming					
	Social Avoidant Behaviour					

Date:06/04/04ISR Number: 4371192-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509840A
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Insomnia	Health	Requip	PS	Glaxosmithkline	ORAL 3 DAY
	Myoclonus	Professional	Wellbutrin	SS	Glaxosmithkline	ORAL 2 YR
	Simple Partial Seizures		Celexa	C		ORAL
	Tremor					

Date:06/04/04ISR Number: 4371204-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0334011A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Cerebral Haemorrhage		Zyban	PS	Glaxosmithkline	ORAL 150MG Twice per day 14 DAY
	Coordination Abnormal					
Other	Dizziness					
	Sensory Loss					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/04ISR Number: 4371206-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0334151A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Musculoskeletal Stiffness Neuralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON

Date:06/07/04ISR Number: 4372161-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513282A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Acuity Reduced		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
			Advair	C	Glaxosmithkline			
			Allergy Medication	C				

Date:06/07/04ISR Number: 4372167-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513477A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:06/07/04ISR Number: 4372168-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513555A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue Liver Disorder Pyrexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:06/07/04ISR Number: 4372171-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0327735A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	3 DAY
	Aggression		Inderal	C			UNKNOWN	
	Dehydration							
	Depression							
	Incoherent							
	Insomnia							
	Mood Altered							
	Restlessness							
	Smoker							
	Tearfulness							
	Weight Decreased							

Date:06/08/04ISR Number: 4373241-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513581A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		150MG per day	
	Drug Exposure During Pregnancy							
	Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/04ISR Number: 4373242-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513586A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
			Bupropion	SS	Glaxosmithkline			

Date:06/08/04ISR Number: 4373243-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513587A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
			Bupropion	SS	Glaxosmithkline			

Date:06/08/04ISR Number: 4373244-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513589A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
			Bupropion	SS	Glaxosmithkline			

Date:06/08/04ISR Number: 4373245-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513590A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
			Bupropion	SS	Glaxosmithkline			

Date:06/08/04ISR Number: 4373246-9Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0513592A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	30TAB	Unknown

Hospitalization - Initial or Prolonged | Overdose
Suicide Attempt

Date:06/08/04ISR Number: 4373247-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513593A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
			Bupropion	SS	Glaxosmithkline			

Date:06/08/04ISR Number: 4373248-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513594A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			
			Bupropion	SS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/04ISR Number: 4373251-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513640A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:06/08/04ISR Number: 4373266-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0334223A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abasia		Zyban	PS	Glaxosmithkline			
	Confusional State							
	Convulsion							
	Depression							
	Disability							
	Impaired Driving Ability							

Date:06/08/04ISR Number: 4373279-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0334968A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Induced		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Drug Exposure During						dosage text	
	Pregnancy							
	Pregnancy							
	Trisomy 21							

Date:06/08/04ISR Number: 4373280-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0334968B
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Induced		Zyban	PS	Glaxosmithkline		150MG See	
	Drug Exposure During						dosage text	

Pregnancy
Pregnancy
Trisomy 21

Date:06/08/04ISR Number: 4374157-5Report Type:Direct Company Report #CTU 220286
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bursitis		Bupropion Sr	PS	Watson		150 MG DAILY	
	Urticaria							

Date:06/09/04ISR Number: 4374652-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0334661A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/09/04ISR Number: 4374653-0Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043865A
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Other	Angina Pectoris
	Chest Pain

	Sense Of Oppression					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin	PS	Glaxosmithkline	ORAL
100MG per day	22 DAY					
			Ritalin	C		ORAL

Date:06/10/04ISR Number: 4375645-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0512065A
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Confusional State	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day	3 WK					
Initial or Prolonged	Insomnia		Lasix	C	Glaxosmithkline	
	Loss Of Consciousness		Procardia Xl	C	Glaxosmithkline	
			Ambien	C		
			Pravacol	C		

Date:06/11/04ISR Number: 4376085-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506081B
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Drug Exposure During	Health	Bupropion	PS	Glaxosmithkline	
150MG per day	78 DAY					
	Pregnancy	Professional	Tobacco	SS		
	Sudden Infant Death Syndrome					

Date:06/11/04ISR Number: 4376088-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508423A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaphylactic Reaction	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day	8 DAY					
Hospitalization -	Bronchospasm	Professional	Spectazole Cream	C		
Initial or Prolonged	Dyspnoea					
Disability	Rash					

Other	Urticaria					

Date:06/11/04ISR Number: 4376097-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514128A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
	Flight Of Ideas		No Concurrent					
	Muscle Spasms		Medication	C				
	Suicidal Ideation							

Date:06/11/04ISR Number: 4376106-2Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0334822A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Bupropion					
Initial or Prolonged	Hyperventilation		Hydrochloride	PS	Glaxosmithkline	ORAL	300MG per day	23 DAY
	Pyrexia							
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/14/04ISR Number: 4377013-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514321A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma		Wellbutrin	PS	Glaxosmithkline	ORAL	12.5G Single	
	Overdose							
Disability			Paxil	SS	Glaxosmithkline		120MG Single	
			Ativan	SS			30MG Single	

Date:06/14/04ISR Number: 4377015-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514346A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Clavicle Fracture		Wellbutrin	PS	Glaxosmithkline	ORAL	3	YR
	Grand Mal Convulsion		Accupril	C				
	Laceration		Lipitor	C				

Date:06/14/04ISR Number: 4377016-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0307434A
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Diabetes Mellitus							
	Diabetes Mellitus		Glucophage	C		ORAL	850MG Three	
	Inadequate Control							
			Diamicron	C		ORAL		
			Tahor	C		ORAL		

			Vastarel	C		ORAL 35MG Twice per day
			Aspegic	C		ORAL 250MG Per day
			Mediator	C		ORAL 150MG Three times per day

Date:06/14/04ISR Number: 4377061-1Report Type:Expedited (15-DaCompany Report #US-ROCHE-370114
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Klonopin	PS	Roche		UNKNOWN	
Initial or Prolonged	Dizziness		Wellbutrin Xl	SS		ORAL		
	Drug Screen Positive		Wellbutrin Xl	SS		ORAL		547 DAY
	Muscle Spasms		Lithium Salt	C				
	Overdose							
	Vomiting							

Date:06/14/04ISR Number: 4378327-1Report Type:Direct Company Report #CTU 220700
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lip Pain		Bupropion					
Initial or Prolonged	Pruritus		Hydrochloride	PS				
	Rash							
	Swelling Face							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/04ISR Number: 4377600-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514333A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Wellbutrin Sr	SS	Glaxosmithkline		150MG Per day	

Date:06/16/04ISR Number: 4378533-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514663A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline			

Date:06/16/04ISR Number: 4378534-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514689A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Faecal Incontinence		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Hydrochlorothiazide	C				
			Klonopin	C				
			Seroquel	C				
			Protonix	C				
			Bentyl	C				
			Singulair	C				

Date:06/16/04ISR Number: 4378535-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514694A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Overdose		Zomig	SS				

Date:06/16/04ISR Number: 4378536-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514701A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three	
							times per day	

Date:06/16/04ISR Number: 4378537-3Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0514795A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Suicide Attempt							

Date:06/16/04ISR Number: 4378555-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0335047A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxosmithkline			
	Dermatitis Allergic						UNKNOWN	150MG See dosage text 27 DAY
	Joint Swelling							
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/16/04ISR Number: 4378561-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0335131A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Zyban	PS	Glaxosmithkline	ORAL	6	WK
Initial or Prolonged	Delirium		Atacand	C				
	Headache		Lipex	C				
	Ill-Defined Disorder							

Date:06/16/04ISR Number: 4378562-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0335216A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Zyban	PS	Glaxosmithkline		UNKNOWN	
Initial or Prolonged	Dysstasia							
	Hallucination, Visual							
	Myocardial Infarction							
	Tremor							
	Vomiting							

Date:06/16/04ISR Number: 4378563-4Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0335239A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/16/04ISR Number: 4380351-XReport Type:Direct Company Report #CTU 220794
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion		Wellbutrin Xl 300 Mg	PS		ORAL	PO DAILY	
Hospitalization -	Rash		Seroquel	C				
Initial or Prolonged	Respiratory Arrest							
	Treatment Noncompliance							

Date:06/16/04ISR Number: 4382712-1Report Type:Expedited (15-DaCompany Report #002#4#2004-00046
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health	Reglan-10mg-Tablet					
Required		Professional	(Metoclopramide Hcl)	PS		ORAL	10MG, 1IN 1	
Intervention to		Other						
D, ORAL								
Prevent Permanent			Bupropion	SS		ORAL	300MG, 1 IN 1	
Impairment/Damage								
D, ORAL								
			Valsartan-Hct	C				
			Amlodipine	C				
			Simvastatin	C				
			Diflunisal	C				
			Doxepin	C				
			Levothyroxine	C				
			Omeprazole	C				
			Venlafaxine	C				
			Fluoxetine	C				
			Hydrochloroquine	C				
			Folic-Acid	C				
			Vitamin B-12	C				
			Vitamin B-6	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/04ISR Number: 4381141-4Report Type:Direct Company Report #USP 56576
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline		TABLET, EXTENDED RELEASE	
			Wellbutrin Sr	SS				

Date:06/17/04ISR Number: 4381302-4Report Type:Direct Company Report #CTU 220949
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash Serum Sickness		Bupropion	PS		ORAL	100 MG BID PO	

Date:06/17/04ISR Number: 4381370-XReport Type:Direct Company Report #CTU 220990
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Confusional State Dizziness Headache Nausea Pharmaceutical Product Complaint		Buproprion 150 Mg	PS		ORAL	150 MG TWICE DAIL ORAL	

Date:06/17/04ISR Number: 4381396-6Report Type:Direct Company Report #CTU 220914
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Medication Error		Bupropion Sr 100 Mg Watson	PS	Watson		
			Bupropion Sr 150 Mg Watson	SS	Watson		

Date:06/18/04ISR Number: 4380594-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514646A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline		450MG Per day	
			Bupropion	SS	Glaxosmithkline		450MG Single dose	

Date:06/18/04ISR Number: 4380597-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514884A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Feeling Abnormal		Ultram	C				
	Feeling Jittery							
	Headache							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/04ISR Number: 4380598-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515009A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Anger		Zocor	C				
	Disorientation		Fosamax	C				
	Nervousness		Lotensin	C	Glaxosmithkline			
	Physical Assault		Celebrex	C				
			Nifedipine	C	Glaxosmithkline			
			Flonase	C	Glaxosmithkline			
			Patanol	C				

Date:06/18/04ISR Number: 4380620-3Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0335716A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Zyntabac	PS	Glaxosmithkline	ORAL	300MG Per day	
	Confusional State	Professional	Sertraline	C				
	Disorientation		Antidepressants	C				
	Irritability							

Date:06/18/04ISR Number: 4383496-3Report Type:Expedited (15-DaCompany Report #B0334697A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Foreign	Wellbutrin (Bupropion Hydrochloride)	PS			5	WK
	Anhedonia	Literature						
	Depression	Health						
	Mania	Professional						
	Thought Blocking							

Date:06/18/04ISR Number: 4383691-3Report Type:Expedited (15-DaCompany Report #001738
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia Amnesia Grand Mal Convulsion Incontinence	Health Professional Company Representative Other	Cenestin (Synthetic Conjugated Estrogens,A) Tablet, 1.25mg	PS		ORAL	1.00 TABLET,	QD,ORAL
			Wellbutrin-Slow Release (Bupropion Hydrochloride)	SS		ORAL	300.00 MG,	QD, ORAL
			Singulair (Montelukast Sodium)	C				
			Levothyroxine (Levothyroxine)	C				
			Hydrochlorothiazide	C				

Date:06/21/04ISR Number: 4381499-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514657A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During Pregnancy Vocal Cord Paralysis		Bupropion	PS	Glaxosmithkline		450MG per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/04ISR Number: 4381500-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514662A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During		Bupropion	PS	Glaxosmithkline		150MG per day	
	Pregnancy							
	Metrorrhagia							

Date:06/21/04ISR Number: 4381508-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515139A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Chest Pain							
	Chills		Prednisone	C			per day	4 WK
	Cough		Premarin	C				
	Disorientation		Medroxyprogesterone	C				
	Dizziness		Benadryl	C	Glaxosmithkline			
	Dysphagia		Maxair	C				
	Feeling Abnormal		Serevent	C	Glaxosmithkline			
	Gastric Disorder		Azmacort	C				
	Headache							
	Hyperhidrosis							
	Ill-Defined Disorder							
	Increased Tendency To Bruise							
	Mucous Membrane Disorder							
	Muscle Atrophy							
	Muscle Disorder							
	Muscle Spasms							
	Musculoskeletal Disorder							
	Nausea							
	Nervousness							
	Pain Of Skin							
	Pruritus							
	Pruritus Generalised							
	Pyrexia							
	Skin Disorder							
	Tonsillar Cyst							
	Tremor							

	Urticaria					
	Vasodilatation					
	Wheezing					

Date:06/21/04ISR Number: 4381522-9Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0335216A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Zyban	PS	Glaxosmithkline			
UNKNOWN								
Initial or Prolonged	Dysstasia	Professional						
	Hallucination, Visual							
	Myocardial Infarction							
	Tremor							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/04ISR Number: 4382360-3Report Type:Direct Company Report #CTU 221114
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Bupropion Sr 150 Mg					
Disability	Drug Withdrawal Syndrome		Sr Watson Labs/Penn					
Required	Headache		Labs	PS	Watson Labs/Penn			
Intervention to	Major Depression				Labs	ORAL	150 MG BID	
Prevent Permanent	Panic Attack					ORAL		
Impairment/Damage	Pharmaceutical Product		Bupropion Sr 150 Mg					
	Complaint		Sr Watson Labs/Penn					
	Self-Injurious Ideation		Labs	SS				
	Suicidal Ideation							
	Suicide Attempt							

Date:06/21/04ISR Number: 4382362-7Report Type:Direct Company Report #CTU 221116
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anger		Budeprion Sr 100mg					
Required	Depression		Teva Pharm	PS	Teva Pharm	ORAL	2 TABLET 2X	
Intervention to	Drug Effect Decreased						PER DAY ORAL	
Prevent Permanent	Irritability		Elavil-Amitriptylin-	C				
Impairment/Damage	Pharmaceutical Product							
	Complaint							

Date:06/21/04ISR Number: 4383969-3Report Type:Expedited (15-DaCompany Report #US-2004-026688
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia	Consumer	Betaseron(Interferon					
	Blood Pressure Increased		Beta - 1b)					
	Cardiac Flutter		Injection, 250ug	PS				
SUBCUTANEOUS	8 MIU, EVERY							
	Drug Interaction							
2D,								

	Potentiation					
SUBCUTANEOUS						
	Extrasystoles		Wellbutrin Xr (150			
	Liver Function Test		Mg (Bupropion			
	Abnormal		Hydrochloride)	SS		ORAL
150 MG, 1						
X/DAY, ORAL						
			Provigil (Modafinil)	C		

Date:06/21/04ISR Number: 4393783-0Report Type:Periodic Company Report #KII-2002-0000442
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Accidental Overdose	Health	Oxycontin Tablets			
	Multiple Drug Overdose	Professional	(Oxycodone			
		Company	Hydrochloride)	PS		
80 MG, TID						
		Representative	Amitriptyline			
			(Amitriptyline)	SS		
			Prozac (Fluoxetine			
			Hydrochloride)	SS		
			Ambien (Zolpidem			
			Tartrate)	SS		
			Bupropion			
			(Amfebutamone)	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/04ISR Number: 4396249-7Report Type:Periodic Company Report #USA-2003-0010973
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse Multiple Drug Overdose	Health Professional Other	Oxycontin Hydrochloride (Similar To 20-553) (Oxycodone Hydrochloride)	PS				
			Hydrocodone Bitartrate (Similar To Ind 59,175) (Hydrocodone Bitartrate)	SS				
			Acetaminophen (Acetaminophen)	SS				
			Diphenhydramine (Diphenhydramine)	SS				
			Bupropion (Amfebutamone)	SS				
			Temazepam (Temazepam)	SS				
			Venlafaxine (Venlafaxine)	SS				
			Caffeine (Caffeine)	SS				

Date:06/21/04ISR Number: 4398890-4Report Type:Periodic Company Report #USA-2003-0007098
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multiple Drug Overdose Accidental	Health Professional Other	Oxycodone Hydrochloride (Similar To Nda 20-553) Oxycodone Hydrochloride	PS				
			Hydrocodone Bitartrate (Similar To Ind 59,175) (Hydrocodone Bitartrate)	SS				
			Morphine Sulfate (Similar To Nda 19-516) (Morphine					

Sulfate)	SS
Dihydrocodeine/ Caffeine/ Acetaminophen (Similar To Anda 88-584)	SS
Diazepam (Diazepam)	SS
Temazepam (Temazepam)	SS
Oxazepam (Oxazepam)	SS
Bupropion (Amfebutamone)	SS

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/04ISR Number: 4382632-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514898A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 YR
	Agitation		Unknown Blood Pressure Medication	SS				
	Convulsion							
	Disorientation							
	Headache							
	Hypertension							
	Insomnia							
	Logorrhoea							
	Medication Error							
	Nausea							

Date:06/22/04ISR Number: 4382633-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514998A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Cerebrovascular Accident							
	Confusional State							
	Dysarthria							
	Headache							
	Hypoaesthesia							
	Movement Disorder							
	Speech Disorder							
	Transient Ischaemic Attack							

Date:06/22/04ISR Number: 4382637-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515236A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
	Fatigue		Bupropion	SS	Glaxosmithkline		450MG per day	

	Irritability		Paxil	SS	Glaxosmithkline	ORAL
MON						
	Medication Error		No Concurrent			
	Sexual Dysfunction		Medication	C		

Date:06/22/04ISR Number: 4382654-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0335459A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL
10 DAY						
	Arthralgia					
	Constipation					
	Dizziness					
	Fatigue					
	Hallucination					
	Headache					
	Hypogeusia					
	Insomnia					
	Nausea					
	Nervousness					
	Pruritus					
	Rash					
	Tinnitus					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/04ISR Number: 4383643-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511755A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Medication Error						per day	4 DAY
			Lexapro	C				
			Risperdal	C				

Date:06/23/04ISR Number: 4383658-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0328342A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Zyban	PS	Glaxosmithkline	ORAL	150MG Three	
							times per day	
			No Concurrent Medication	C				

Date:06/23/04ISR Number: 4383671-8Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0335720A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia		Zyban	PS	Glaxosmithkline	ORAL		
	Depression							
	Social Problem							
	Suicidal Ideation							

Date:06/23/04ISR Number: 4383674-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0335860A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Level Of		Zyban	PS	Glaxosmithkline	ORAL	4	WK

	Consciousness		Serepax	C		
	Disturbance In Attention					
	Memory Impairment					
	Sleep Disorder					
	Somnolence					

Date:06/24/04ISR Number: 4384405-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0513060A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Abuser		Wellbutrin	PS	Glaxosmithkline	NASAL	300MG Twice	
	Medication Error		Seroquel	C			per day	
	Psychotic Disorder							
			Trileptal	C			600MG Twice	per day
			Neurontin	C			600MG Twice	per day

Date:06/24/04ISR Number: 4384409-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515707A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		300MG per day	
			Celexa	C				
			Remeron	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/04ISR Number: 4384412-0Report Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0330728A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	18 DAY
Initial or Prolonged	Demyelination	Professional						
Disability	Grand Mal Convulsion							
	Incontinence							
	Leukoencephalomyelitis							
	Leukoencephalopathy							

Date:06/24/04ISR Number: 4384413-2Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0332456A
Age:4 MON Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour	Health	Zyban	PS	Glaxosmithkline	ORAL		
Initial or Prolonged	Accidental Exposure	Professional						
Other	Acidosis							
	Convulsion							
	Crying							
	Cyanosis							
	Drug Toxicity							
	Emotional Distress							
	Extremity Contracture							
	Eye Movement Disorder							
	Haemoglobin Decreased							
	Hypotonia							
	Irritability							
	Nervous System Disorder							
	Pallor							
	Respiratory Acidosis							
	Restlessness							
	Skin Discolouration							
	Treatment Noncompliance							

Date:06/24/04ISR Number: 4384416-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0335535A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Rash		Zyban	PS	Glaxosmithkline	ORAL
1TAB See						
	Skin Exfoliation					
dosage text 20 DAY						
			Nicorette	C	Glaxosmithkline	
UNKNOWN						

Date:06/24/04ISR Number: 4384417-XReport Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0335693A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Convulsion		Zyban	PS	Glaxosmithkline	
150MG Twice						
Initial or Prolonged	Insomnia					
per day						
Other	Starvation					

Date:06/24/04ISR Number: 4388630-7Report Type:Expedited (15-DaCompany Report #B0335075A
Age:15 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Aggression
Initial or Prolonged	Anger
	Attention

		Deficit/Hyperactivity Disorder Condition Aggravated Drug Abuser	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Feeling Abnormal Impulsive Behaviour Irritability Medication Error	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		NASAL
INTRANASAL							
		Restlessness		Salbutamol Sulphate	C		
		Suicidal Ideation		Cannabis	C		
		Theft Treatment Noncompliance					

Date:06/24/04ISR Number: 4388960-9Report Type:Expedited (15-DaCompany Report #2003-06064
Age:26 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cholelithiasis	Study	Viread(Tenofovir Disoproxil Fumarate)	PS		ORAL
300 MG, ONCE							
		Hepatitis	Health				
		Pancreatitis	Professional				
A DAY, ORAL							
				Combivir(Zidovudine W/Lamivudine)	SS		ORAL
450 MG, TWICE							
A DAY, ORAL							
				Wellbutrin(Bupropion Hydrochloride)	SS		
				Ambien (Zolpidem Tartrate)	C		
				Effexor (Venlafaxine Hydrochloride)	C		
				Asacol (Mesalazine)	C		
				Clindagel (Clindamycin)	C		
				Elidel (Pimecrolimus)	C		
				Clotrim/Beta	C		
				Protopic(Tacrolimus)	C		
				Flonase(Fluticasone Propionate)	C		

Date:06/25/04ISR Number: 4385017-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515239A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Thrombosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 DAY
	Road Traffic Accident							
			Tegretol	SS			1	YR
			Librium	SS				
			Nortriptyline	C			1	YR
			Depakote	C			1	YR
			Seroquel	C				
			Trazodone	C			1	YR
			Celexa	C			1	YR

Date:06/25/04ISR Number: 4385020-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515738A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	8TAB per day	
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/04ISR Number: 4385021-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515739A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma Knee Operation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	WK
			Zoloft	C				
			Alcohol	C				

Date:06/25/04ISR Number: 4385043-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0335857A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:06/25/04ISR Number: 4386443-3Report Type:Direct Company Report #CTU 221524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Agitation Anxiety Depression Insomnia Restlessness Suicide Attempt		Prozac 20 Mg Eli-Lilly	PS	Eli-Lilly	ORAL	20 MG 3 X A DAY ORAL	
			Wellbutrin 150 Mg Glaxosmithkline	SS	Glaxosmithkline	ORAL	150 MG 2 X A DAY ORAL	

Date:06/28/04ISR Number: 4386249-5Report Type:Direct Company Report #CTU 221662
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Depression		Wellbutrin	PS			
DAILY 2 WK							
Required Intervention to Prevent Permanent Impairment/Damage	Mental Disorder						

Date:06/28/04ISR Number: 4386252-5Report Type:Direct Company Report #CTU 221667
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations		Wellbutrin Sr	PS		ORAL	150 MG PO	DAILY
			Nicotine Gum	C				

Date:06/28/04ISR Number: 4386898-4Report Type:Direct Company Report #CTU 221717
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Wellbutrin Xl 300 Mg	PS			300 MG 1 PER	
	Pharmaceutical Product							DAY
	Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/04ISR Number: 4389102-6Report Type:Expedited (15-DaCompany Report #2004UW06035
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abasia	Consumer	Seroquel	PS				
Required	Dysstasia		Serzone	SS				
Intervention to	Fall		Wellbutrin	SS				
Prevent Permanent	Medication Error		Motrin	C				
Impairment/Damage	Musculoskeletal Stiffness		Heparin	C				
	Rhabdomyolysis		Ultram	C				
			Prednisone	C				
			Cellcept	C				
			Sleeping Pill	C				

Date:06/29/04ISR Number: 4386599-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515716A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:06/29/04ISR Number: 4386601-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516112A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
Life-Threatening	Gun Shot Wound		Ativan	C				
Other	Murder		Thyroid Medication	C				

Date:06/29/04ISR Number: 4386603-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516246A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematuria		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Pain		Advair	C	Glaxosmithkline			

			Albuterol	C	Glaxosmithkline	
			Singulair	C		

Date:06/29/04ISR Number: 4386624-9Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0336916A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Fibromyalgia		Zyban	PS	Glaxosmithkline	
1TAB See						
	Suicidal Ideation					
dosage text 14 DAY						
	Thinking Abnormal		Morphine	C		

Date:06/30/04ISR Number: 4387784-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516404A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Creatinine		Wellbutrin	PS	Glaxosmithkline	ORAL
	Increased					
	Blood Urea Increased					
	Hepatic Enzyme Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/04ISR Number: 4387785-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516415A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During		Bupropion	PS	Glaxosmithkline		150MG Twice	
	Pregnancy							
per day							15	DAY
	Jaundice							
	Pulmonary Oedema							

Date:06/30/04ISR Number: 4387790-1Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0516554A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vaginal Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	16 DAY
			Sertraline	C				
UNKNOWN							25MG Unknown	
			Clonazepam	C				
UNKNOWN							1MG Unknown	

Date:06/30/04ISR Number: 4387797-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0334223A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Zyban	PS	Glaxosmithkline			
Other	Confusional State							
	Convulsion							
	Depression							
	Disability							
	Epilepsy							
	Impaired Driving Ability							
	Impaired Work Ability							
	Oral Infection							
	Suicidal Ideation							

Date:06/30/04ISR Number: 4390408-5Report Type:Expedited (15-DaCompany Report #2004040614
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Consumer	Tikosyn (Dofetilide)	PS		ORAL	1000 MCG (500	
Initial or Prolonged	Atrial Fibrillation						MCG, 2 IN 1	
Other	Chest Pain						D), ORAL	
	Disease Recurrence		Peginterferon Alfa-2b (Peginterferon Alfa-2b)	SS				
	Dizziness							
	Electrocardiogram Qt Prolonged							
	Gallbladder Disorder		Bupropion Hydrochloride (Bupropion Hydrochloride)	SS				
	Hepatic Enzyme Increased							
	Hyperhidrosis		Valdecoxib (Valdecoxib)	C				
			Metoprolol (Metoprolol)	C				
			Warfarin (Warfarin)	C				
			Potassium (Potassium)	C				
			Nizantidine (Nizantidine	C				
			Antibiotics (Antibiotics)	C				

Date:06/30/04ISR Number: 4390538-8Report Type:Expedited (15-DaCompany Report #2004041004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity Muscle Spasms Nervous System Disorder Pharmaceutical Product Complaint Tremor Weight Increased	Consumer	Neurontin (Tablets) (Gabapentin) Bupropion Hydrochloride (Bupropion Hydrochloride) Venlafaxine Hydrochloride (Venlafaxine Hydrochloride) Levothyroxine Sodium (Levothyroxine Sodium) Baclofen (Baclofen)	PS SS C C C		ORAL	2400 MG (800 MG, 3 IN 1 D), ORAL	

Date:06/30/04ISR Number: 4415545-8Report Type:Periodic Company Report #2003122132
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Asthenia Back Pain Bipolar Ii Disorder Chest Pain Cough Decreased Appetite Disturbance In Attention Dizziness Homicidal Ideation Hyperhidrosis	Consumer Health Professional	Zoloft (Sertraline) Bupropion Hydrochloride (Bupropion Hydrochloride) Paroxetine Hydrochloride	PS SS		ORAL	12.5 MG (DAILY), ORAL 75 MG (DAILY), UNKNOWN	

	Hypersensitivity		(Paroxetine				
	Increased Appetite		Hydrochloride)	C			
	Influenza Like Illness						
	Insomnia						
	Lymphadenopathy						
	Neck Pain						
	Nightmare						
	Pyrexia						
	Rash						
	Renal Pain						
	Suicidal Ideation						
	Swelling Face						
	Vision Blurred						

Date:07/01/04ISR Number: 4388722-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516229A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Pregnancy		Effexor	C				
	Placental Insufficiency							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/04ISR Number: 4388741-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516614A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Akathisia						per day	
	Hallucination		Seroquel	C				
	Tremor		Neurontin	C				
			Topamax	C				

Date:07/01/04ISR Number: 4388757-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0336854A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Generalised Oedema	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Nephrotic Syndrome	Professional	Nexen	SS	Glaxosmithkline	ORAL		
	Renal Failure							
	Weight Increased							

Date:07/01/04ISR Number: 4388763-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0337371A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Betablocker	C		ORAL		
			Zocor	C		ORAL		
			Kardegic	C		ORAL	75MG Per day	
			Stilnox	C		ORAL		

Date:07/01/04ISR Number: 4390067-1Report Type:Direct Company Report #USP 56669
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr	PS	Glaxosmithkline		TABLET 150 MG	
			Wellbutrin Xl	SS	Glaxosmithkline		TABLET 150 MG	

Date:07/01/04ISR Number: 4391700-0Report Type:Expedited (15-DaCompany Report #2003125358
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multiple Drug Overdose	Health Professional	Geodon (Ziprasidone)	PS				
	Accidental	Company Representative	Bupropion Hydrochloride (Bupropion Hydrochloride)	SS				
			Clonazepam (Clonazepam)	SS				

Date:07/01/04ISR Number: 4391982-5Report Type:Expedited (15-DaCompany Report #B0335849A
Age:29 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation
	Bundle Branch Block Left
	Delirium
	Disorientation
	Electrocardiogram Qt

	Corrected Interval Prolonged Electrocardiogram T Wave Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Grand Mal Convulsion Hallucination, Visual Lethargy Multiple Drug Overdose	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL
	Sinus Tachycardia Supraventricular Tachycardia		Ziprasidone Hcl Unspecified Tablet (Ziprasidone Hcl)	SS		ORAL	ORAL
			Semisodium Valproate Tablet (Divalproex Sodium)	SS		ORAL	ORAL
			Fluoxetine Tablet (Fluoxetine)	SS		ORAL	ORAL

Date:07/02/04ISR Number: 4389494-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516613A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Ineffective Psychiatric Symptom		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three times per day 2 MON
			Valium	C			

Date:07/02/04ISR Number: 4389502-4Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0335441A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Depression Dry Mouth Fear Hallucination, Auditory Insomnia	Health Professional	Zyntabac	PS	Glaxosmithkline	ORAL	15 DAY

	Nervousness

Date:07/02/04ISR Number: 4392087-XReport Type:Expedited (15-DaCompany Report #A118566
Age:29 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Atrial Fibrillation Bundle Branch Block Left Delirium Disorientation Electrocardiogram Abnormal Electrocardiogram Qrs Complex Prolonged Electrocardiogram Qt Corrected Interval Prolonged Electrocardiogram St Segment Abnormal Electrocardiogram St Segment Depression Electrocardiogram T Wave Abnormal Grand Mal Convulsion Hallucination, Visual

		Lethargy Multiple Drug Overdose Sinus Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Supraventricular Tachycardia	Literature Health	Ziprasidone (Ziprasidone)	PS		
80 MG							
			Professional Company Representative	Bupropion Hydrochloride (Bupropion Hydrochloride)	SS		
100 MG							
				Fluoxetine Hydrochloride (Fluoxetine Hydrochloride)	SS		
40 MG							
				Valproate Semisodium (Valproate Semisodium)	SS		
250 MG							

Date:07/02/04ISR Number: 4392196-5Report Type:Expedited (15-DaCompany Report #US-2004-026688
Age:36 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anxiety Arrhythmia Blood Pressure Increased	Consumer Health Professional	Betaseron (Interferon Beta-1b) Injection, 250 Ug	PS		
SUBCUTANEOUS	8 MIU, EVERY	Cardiac Flutter					
2D,		Drug Interaction					
SUBCUTANEOUS							
		Liver Function Test Abnormal Palpitations		Wellbutrin Xr 150 Mg (Bupropion Hydrochloride)	SS		ORAL
150 MG,							
1X/DAY, ORAL							
				Provigil (Modafinil)	SS		ORAL
100 MG,							
1X/DAY, ORAL							

			Neurontin (Gabapentin)	C		
			Baclofen	C		

Date:07/06/04ISR Number: 4390151-2Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0516866A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Alcohol Use							
	Insomnia							

Date:07/06/04ISR Number: 4390152-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516903A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
			Zyprexa	C				
			Lito	C	Glaxosmithkline			
			Depakote	C				
			Effexor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/04ISR Number: 4390173-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0335459A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Zyban	PS	Glaxosmithkline	ORAL	15	DAY
	Arthralgia	Professional						
	Constipation							
	Dizziness							
	Fatigue							
	Hallucination							
	Headache							
	Hypogeusia							
	Insomnia							
	Nausea							
	Nervousness							
	Pruritus							
	Rash							
	Tinnitus							

Date:07/06/04ISR Number: 4390206-2Report Type:Expedited (15-DaCompany Report #IL-GLAXOSMITHKLINE-B0337852A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Energy Increased		Zyban	PS	Glaxosmithkline	ORAL		
	Euphoric Mood		No Concurrent					
	Hypomania		Medication	C				
	Insomnia							

Date:07/06/04ISR Number: 4390207-4Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043570A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Shock	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
Initial or Prolonged	Cardiovascular Disorder	Professional						
	Pharmaceutical Product							
	Complaint							

Date:07/06/04ISR Number: 4390780-6Report Type:Direct Company Report #CTU 222148
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Bupropion					
	Pharmaceutical Product		Bupropion100 Mg Teva	PS	Teva	ORAL	100 MG TID	
	Complaint							
ORAL								
			Bupropion					
			Bupropion100 Mg Teva	SS	Teva			

Date:07/06/04ISR Number: 4394305-0Report Type:Expedited (15-DaCompany Report #04P-163-0264468-00
Age:29 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Bundle Branch Block Left
	Disorientation
	Electrocardiogram Qt Corrected Interval Prolonged
	Electrocardiogram T Wave Abnormal

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Grand Mal Convulsion Hallucination, Visual Lethargy Multiple Drug Overdose Sinus Tachycardia Supraventricular Tachycardia	Literature Health Professional	Divalproex Sodium (Depakote) (Divalproex Sodium) (Divalproex Sodium)	PS		ORAL	250 MG, APPROXIMATELY 74 TABLETS, PER ORAL	
			Ziprasidone	SS		ORAL	80 MG, APPROXIMATELY 74 TABLETS, PER ORAL	
			Bupropion	SS		ORAL	100 MG, APPROXIMATELY 157 TABLETS, PER ORAL	
			Fluoxetine	SS		ORAL	40 MG, APPROXIMATELY 180 TABLETS, PER ORAL	

Date:07/07/04ISR Number: 4391419-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517054A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	

Date:07/07/04ISR Number: 4391423-8Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0295775A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aphasia	Consumer	Zyban	PS	Glaxosmithkline	ORAL	43	DAY
Other	Cerebral Arteritis							
	Cerebral Haemorrhage							
	Computerised Tomogram Abnormal							
	Convulsion							
	Electroencephalogram Abnormal							
	Grand Mal Convulsion							
	Headache							
	Nausea							
	Personality Change							
	Vomiting							

Date:07/07/04ISR Number: 4391430-5Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0309137A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	20 DAY
	Feeling Cold							
	General Physical Health Deterioration							
	Myalgia							
	Pyrexia							
	Rash Pruritic							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/04ISR Number: 4391440-8Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0334297A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Hallucination						per day	6 DAY
	Nausea		Spiriva	C		RESPIRATORY		
	Smoker					(INHALATION)		
			Ventolin	C	Glaxosmithkline	RESPIRATORY		
						(INHALATION)		

Date:07/07/04ISR Number: 4391463-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0337415A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diabetes Mellitus		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
	Inadequate Control		Insuline	C				
	Hypoglycaemia							

Date:07/07/04ISR Number: 4391465-2Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0337423A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia		Bupropion					
	Dizziness		Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Hyperhidrosis		Tenormin	SS		ORAL	159	DAY
	Palpitations		Amoxycillin	C	Glaxosmithkline	ORAL	1.5G Per day	9 DAY
	Syncope							
	Tremor							

Date:07/07/04ISR Number: 4391467-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0337502A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Zyban	PS	Glaxosmithkline		6	DAY
	Suicidal Ideation		Risperidal	C				

Date:07/07/04ISR Number: 4391469-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0337576A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Rate Increased		Zyban	PS	Glaxosmithkline		2TAB per day	
	Hot Flush							
	Loss Of Consciousness							

Date:07/07/04ISR Number: 4391471-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0337791A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ageusia		Zyban	PS	Glaxosmithkline	ORAL	12	DAY
	Anosmia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/04ISR Number: 4393442-4Report Type:Direct Company Report #CTU 222340
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Ambien 10 Mg	PS		ORAL	10 MG HS PO	
	Insomnia		Wellbutrin 150 Mg	SS		ORAL	150 MG PO AM AND PM	
	Sedation							
	Somnolence							
	Tremor							

Date:07/07/04ISR Number: 4394274-3Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040201456
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Drug Exposure During Pregnancy	Study Health	Topiramate- Blinded (Topiramate) Tablets	PS		TRANSPLACENTAL	TRANSPLACENTA	
	Talipes	Professional						
			Placebo (Placebo) Tablets	SS		TRANSPLACENTAL	TRANSPLACENTA	
			Wellbutrin (Bupropion Hydrochloride) Unspecified	SS		TRANSPLACENTAL	TRNASPLACENTA	
			Prenatal Vitamin (Prenatal Vitamins) Unspecified	C				
			Tylenol (Paracetamol) Unspecified	C				

Date:07/08/04ISR Number: 4393008-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517052A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG See dosage text	

Date:07/08/04ISR Number: 4393016-5Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0331580A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	15 DAY	
	Anxiety							
	Condition Aggravated							
	Depersonalisation							
	Food Interaction							
	Irritability							
	Memory Impairment							

Date:07/08/04ISR Number: 4393020-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0335692A
Age:25 YR Gender:Female I/FU:F

Outcome	PT
Other	Arthralgia
	Arthritis
	Arthritis Reactive

	Joint Swelling Osteoarthritis Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
			Zyban	PS	Glaxosmithkline	ORAL
150MG Twice per day 89 DAY						
			Norethisterone	C		
200MG per day						
			Vioxx	C		
UNKNOWN						

Date:07/08/04ISR Number: 4396008-5Report Type:Expedited (15-DaCompany Report #2004UW13429
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required Intervention to Prevent Permanent Impairment/Damage	Convulsion Overdose	Health Professional	Zomig Wellbutrin - Slow Release	PS SS		

Date:07/08/04ISR Number: 4397279-1Report Type:Expedited (15-DaCompany Report #2004SE03643
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Bradycardia	Foreign	Tenormin	PS		ORAL
25 MG DAILY						
Intervention to	Dizziness	Health				
PO						
Prevent Permanent	Palpitations	Professional	Tenormin	SS		ORAL
50 MG DAILY						
Impairment/Damage	Syncope	Other				
PO						
	Tremor		Tenormin	SS		ORAL
25 MG DAILY						
PO						
			Zyntabac	SS		ORAL
150 MG DAILY						

PO

			Amoxycillin	C		

Date:07/09/04ISR Number: 4393710-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514346A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Clavicle Fracture		Wellbutrin	PS	Glaxosmithkline	ORAL	3	YR
Other	Face Injury		Accupril	C		ORAL	40MG Per day	
	Fall		Lipitor	C		ORAL	10MG At night	
	Grand Mal Convulsion							
	Laceration							
	Rib Fracture							

Date:07/09/04ISR Number: 4393718-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517370A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Pharmaceutical Product		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
	Complaint							

Date:07/09/04ISR Number: 4396206-0Report Type:Expedited (15-DaCompany Report #04P-163-0265030-00
Age:75 YR Gender:Male I/FU:I

Outcome
Death
Hospitalization -

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Abasia Angle Closure Glaucoma Asthenia Brain Damage Coma Communication Disorder Decreased Appetite Diabetes Mellitus Disturbance In Attention Dysphagia Dyspnoea Feeling Abnormal Infected Cyst Lethargy Medication Error Overdose Parkinson'S Disease Pneumonia Aspiration Sleep Disorder Somnolence	Consumer	Depakote Er 500mg (Depakote Er) (Divalproex Sodium) (Divalproex Sodium) Paroxetine Hydrochloride Bupropion Hydrochloride Sertraline Hydrochloride Mirtazapine Trilazem Panadeine Co Zocor Baby Asa	PS SS SS SS SS C C C		ORAL ORAL ORAL ORAL ORAL	SEE IMAGE 10 MG, 1 IN 1 D, PER ORAL 1 IN 1 D, PER ORAL 1 IN 1 D, PER ORAL SEE IMAGE 1 IN 1 D, PER ORAL	

Date:07/12/04ISR Number: 4394912-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514884A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain Chest Pain	Health Professional	Wellbutrin Ultram	PS SS	Glaxosmithkline	ORAL ORAL	300MG Per day 50MG Twice	14 DAY

	Feeling Abnormal					
per day 20 DAY	Feeling Jittery					
	Grand Mal Convulsion					
	Headache					
	Nausea					

Date:07/12/04ISR Number: 4394916-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517442A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Convulsion						per day	
	Erectile Dysfunction		Ritalin	C				
	Fatigue		Claritin	C				
	Mania		Excedrin	C				
	Mood Altered							
	Tension							

Date:07/12/04ISR Number: 4394946-0Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0337695A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Zyban	PS	Glaxosmithkline	ORAL		
	Exanthem							
	Influenza Like Illness							
	Lupus-Like Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/04ISR Number: 4394947-2Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0337716A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Zyban	PS	Glaxosmithkline	ORAL		

Date:07/12/04ISR Number: 4394948-4Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0337734A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea Haemorrhagic Rash Generalised		Zyban	PS	Glaxosmithkline	ORAL		

Date:07/12/04ISR Number: 4394949-6Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0337740A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Asthenia Dry Mouth Erythema		Zyban	PS	Glaxosmithkline			

Date:07/12/04ISR Number: 4394950-2Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0337744A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying Depressed Mood Excitability Irritability Psychotic Disorder		Zyban	PS	Glaxosmithkline			

Date:07/12/04ISR Number: 4394951-4Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0337779A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Aggression	Consumer	Zyban	PS	Glaxosmithkline	
	Amnesia		Alcohol	SS		
	Loss Of Consciousness					

Date:07/12/04ISR Number: 4394952-6Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0337850A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Erythema Multiforme		Zyban	PS	Glaxosmithkline	ORAL
	Exanthem					
	Periorbital Oedema					
	Rash Vesicular					
	Urticaria Generalised					

Date:07/12/04ISR Number: 4394955-1Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0338473A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Loss Of Consciousness		Zyban	PS	Glaxosmithkline	
			Alcohol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/04ISR Number: 4394957-5Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043173A
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Atrophy		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	17 DAY
	Disturbance In Attention		Allopurinol	C	Glaxosmithkline			
UNKNOWN							300MG Per day	17 DAY
	Dysgraphia		Alpha-Lipon Acid 600	C				
UNKNOWN							600MG Per day	17 DAY
	Encephalopathy		Iscover	C				
UNKNOWN								17 DAY
	Fall		Ace Inhibitor	C				
UNKNOWN								
	Gait Disturbance							
	Pain							
	Parkinson'S Disease							
	Polyneuropathy							
	Vertigo							

Date:07/12/04ISR Number: 4395384-7Report Type:Direct Company Report #CTU 222528
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Budeprion Sr 150 Mg	PS		ORAL	150 MG TWICE	
	Fatigue						DAIL ORAL	
	Headache							
	Nausea							
	Pharmaceutical Product Complaint							
	Somnolence							

Date:07/12/04ISR Number: 4395464-6Report Type:Direct Company Report #CTU 222517
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour		Wellbutrin Sr 200 Mg	PS		ORAL	1 TABLET	

Required	Aggression					
TWICE DAIL						
Intervention to	Apathy					
ORAL						
Prevent Permanent	Bipolar I Disorder		Wellbutrin Xl 300 Mg	SS		ORAL
1 TABLET						
Impairment/Damage	Crying					
DAILY ORAL						
	Depression					
	Disinhibition					
	Emotional Disorder					
	Fear					
	Hallucination					
	Impaired Work Ability					
	Insomnia					
	Libido Increased					
	Mania					
	Suicidal Ideation					
	Thinking Abnormal					

Date:07/13/04ISR Number: 4396284-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0504585A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Alcohol Poisoning	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Contusion	Professional				
per day	5 MON					
	Dizziness		Alcohol	SS		
	Fall		Albuterol	C	Glaxosmithkline	
	Syncope		Advair	C	Glaxosmithkline	
			Elavil	C	Glaxosmithkline	
			Tylenol	C	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/04ISR Number: 4396303-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517688A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL	900MG Per day	
	Medication Error							

Date:07/13/04ISR Number: 4396716-6Report Type:Direct Company Report #CTU 222615
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Bupropion	PS		ORAL	100 MG, Q AM	
							ORAL	

Date:07/13/04ISR Number: 4396825-1Report Type:Direct Company Report #CTU 222710
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal Pharmaceutical Product Complaint		Wellbutrin Sr (Generic) 150 Mg One Bid	PS			ONE BID	
	Somnolence							

Date:07/14/04ISR Number: 4396978-5Report Type:Expedited (15-DaCompany Report #PHEH2004US07298
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Thrombosis Road Traffic Accident		Tegretol	PS	Novartis Sector: Pharma	ORAL	365 DAY	
			Tegretol	SS	Novartis Sector: Pharma	ORAL	dose	

increased

(unspecified)

			Wellbutrin - Slow Release	SS		ORAL
150 mg, BID	7200 MIN					
			Librium "Hoffmann"	SS		
			Nortriptyline	C		
			Valproate Semisodium	C		
			Quetiapine Fumarate	C		
			Trazodone	C		
			Citalopram Hydrobromide	C		

Date:07/14/04ISR Number: 4397309-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511391A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Spontaneous	Health	Wellbutrin	PS	Glaxosmithkline		150MG per day	17 DAY
Other	Drug Exposure During Pregnancy	Professional	Allegra	C			180MG per day	
	Pregnancy		Natalcare Plus	C				
	Vaginal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/04ISR Number: 4397313-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0518091A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Per day
			Wellbutrin Sr	SS	Glaxosmithkline		150MG	per day

Date:07/14/04ISR Number: 4397332-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0337748A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Hot		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Pruritus							
	Urticaria							

Date:07/14/04ISR Number: 4398071-4Report Type:Direct Company Report #CTU 222731
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Buproprion 150 Mg					
	Depression		Teva	PS	Teva	ORAL	1 PER DAY	
	Drug Effect Decreased						ORAL	
	Libido Decreased							
	Pharmaceutical Product Complaint							

Date:07/15/04ISR Number: 4398511-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0518045A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	150MG	Twice

Hallucination
per day 1 WK
Loss Of Consciousness
Road Traffic Accident

Date:07/15/04ISR Number: 4398517-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0518217A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Feeling Abnormal		Oral Contraceptive	C				
	Suicidal Ideation							

Date:07/15/04ISR Number: 4398530-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0337502A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal	Health	Zyban	PS	Glaxosmithkline		6	DAY
	Suicidal Ideation	Professional	Risperidal	C				

Date:07/15/04ISR Number: 4398540-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0337749A
Age:61 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebral Infarction		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dysphagia						per day	23 DAY
	Facial Paresis		Zopiclone	C		ORAL	3.75MG Per	
	Speech Disorder						day	

Date:07/15/04ISR Number: 4398543-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0338492A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Arthralgia						dosage text	
	Asthenia							
	Blood Immunoglobulin E Increased							
	Cough							
	Dysphagia							
	Dyspnoea							
	Joint Swelling							
	Oesophageal Spasm							
	Serum Sickness							
	Urticaria Generalised							

Date:07/15/04ISR Number: 4403016-4Report Type:Expedited (15-DaCompany Report #S04-USA-04018-01
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Consumer	Lexapro					
Required	Arthralgia		(Escitalopram)	PS		ORAL	10 MG QD PO	
Intervention to	Erectile Dysfunction		Lotrel	SS				

Prevent Permanent 0.2 MG BID	Exostosis	Clonidine	SS
Impairment/Damage	Fracture	Amiloride W/Hydrochlorothiazide	SS
	Hypertension	Percocet	SS
	Joint Dislocation	Wellbutrin - Slow Release (Bupropion Hydrochloride) 150 MG	SS
	Limb Injury	Trazodone	C
	Nausea	Nexium (Esomeprazole)	C
	Somnolence	Carisoprodol	C
		Bextra (Valdecoxib)	C

Date:07/16/04ISR Number: 4399514-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0441718A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Spontaneous	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
Other	Drug Exposure During Pregnancy	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/04ISR Number: 4399519-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511866A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	64 DAY
	Palpitations		Paxil	C	Glaxosmithkline	ORAL	20MG Per day	
			Synthroid	C	Glaxosmithkline		UNKNOWN	
			Zocor	C			UNKNOWN	
			Tricor	C			UNKNOWN	
			Allegra	C			UNKNOWN	

Date:07/16/04ISR Number: 4399525-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517685A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amphetamines Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
	Convulsion		No Concurrent Medication	C				

Date:07/16/04ISR Number: 4399536-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0518553A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	6000MG Single	
Hospitalization - Initial or Prolonged Other	Intentional Misuse						dose	
	Suicide Attempt		No Concurrent Medication	C				

Date:07/16/04ISR Number: 4399551-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0338333A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness						per day	10 DAY
	Palpitations		Eltroxin	C	Glaxosmithkline	ORAL	.2MG per day	
			Triphasil	C		ORAL		

Date:07/16/04ISR Number: 4399560-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0338426A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Autoimmune Hepatitis		Zyban	PS	Glaxosmithkline	ORAL		
	Malaise		Zoloft	C				

Date:07/16/04ISR Number: 4399562-2Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0338632A
Age:43 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased
	Discomfort
	Dysphagia
	Exanthem
	Face Oedema
	Hyperhidrosis
	Hypersensitivity
	Oedema Peripheral

	Palpitations						
	Paraesthesia						
	Pruritus	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Vertigo		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice
	White Blood Cell Count						
per day 3 WK	Increased						

Date:07/16/04ISR Number: 4402890-5Report Type:Expedited (15-DaCompany Report #S04-USA-04077-01
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Other	Grand Mal Convulsion	Health Professional	Lexapro (Escitalopram)	PS		ORAL	10 MG QD PO
			Wellbutrin Xl	SS			450 MG QD

Date:07/19/04ISR Number: 4401665-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0148065A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Other	Abasia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice
	Aggression						
per day 9 DAY	Amnesia		Birth Control Pills	C			
	Asthenia						
	Blindness						
	Blood Urine Present						
	Disability						
	Eyelid Function Disorder						
	Grand Mal Convulsion						
	Hypoaesthesia						
	Insomnia						
	Loss Of Consciousness						
	Mouth Haemorrhage						
	Muscle Twitching						
	Renal Impairment						

	Tongue Biting					
	Tremor					
	Vision Blurred					

Date:07/19/04ISR Number: 4401668-6Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0510698A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Initial or Prolonged	Decreased Appetite						per day	
	Depression							
	Disability							
	Impaired Work Ability							

Date:07/19/04ISR Number: 4401671-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0518588A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/04ISR Number: 4402278-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0518769A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Paxil	PS	Glaxosmithkline			
	Injury		Wellbutrin	SS	Glaxosmithkline			
	Injury Asphyxiation							
	Mood Swings							
	Physical Assault							
	Sexual Assault Victim							

Date:07/20/04ISR Number: 4402285-4Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0330195A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Hospitalization -	Overdose	Professional					per day	
Initial or Prolonged	Somnolence		Prozac	SS		ORAL	20TABS per	
Other	Sudden Death						day	

Date:07/20/04ISR Number: 4402297-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0338283A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Throat Tightness							

Date:07/20/04ISR Number: 4402298-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0338286A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Dizziness		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day						
	Headache					
	Nausea					
	Oropharyngeal Swelling					
	Swelling Face					

Date:07/20/04ISR Number: 4402308-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0339189A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Grand Mal Convulsion		Zyban	PS	Glaxosmithkline	ORAL
150MG See						
Initial or Prolonged	Metastases To Central					
dosage text 11 DAY						
	Nervous System		Nicopatch	C	Glaxosmithkline	
TRANSDERMAL 14MG Per day						
			Kardegic	C		ORAL
160MG Per day 1 YR						
			Monotildiem	C	Glaxosmithkline	ORAL
200MG Per day						
			Solupred	C	Glaxosmithkline	
UNKNOWN						
			Valium	C		
UNKNOWN						

Date:07/21/04ISR Number: 4403565-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0518217A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 3 MON						
	Feeling Abnormal		Oral Contraceptive	C		
	Suicidal Ideation					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4403578-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0336338A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Zyban	PS	Glaxosmithkline			1 MON
	Aggression		No Concurrent					
	Anxiety		Medication	C				
	Depression							
	Stress							

Date:07/21/04ISR Number: 4404607-7Report Type:Direct Company Report #CTU 223298
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharmaceutical Product		Generic Paxil 10 Mg					
	Complaint		Po Qam	PS		ORAL	ONE DOSE PO	QAM
			Generic Wellbutrin					
			Sr	SS		ORAL	PO QAM	

Date:07/21/04ISR Number: 4404668-5Report Type:Direct Company Report #CTU 223135
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin 150 Mg 1x					
	Confusional State		Day	PS			150 MG 1X DAY	
	Constipation							
	Dyspnoea							
	Erythema							
	Flatulence							
	Hyperhidrosis							
	Pharmaceutical Product							
	Complaint							

Date:07/22/04ISR Number: 4404716-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515876A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	9 WK
	Depression		Oxycodone	C				
	Drug Ineffective		Xanax	C				
	Feeling Abnormal							
	Nervousness							
	Psychomotor Hyperactivity							
	Suicidal Ideation							

Date:07/22/04ISR Number: 4404726-5Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0519183A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG per day	
	Loss Of Consciousness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/04ISR Number: 4404727-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0519196A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		150MG per day	

Date:07/22/04ISR Number: 4404728-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0519214A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Grand Mal Convulsion		No Concurrent Medication	C				

Date:07/22/04ISR Number: 4405183-5Report Type:Direct Company Report #CTU 223366
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS			150 MG 1X DAY	
	Confusional State							
	Constipation							
	Dyspnoea Exertional							
	Erythema							
	Flatulence							
	Hyperhidrosis							
	Pharmaceutical Product Complaint							

Date:07/22/04ISR Number: 4408411-5Report Type:Expedited (15-DaCompany Report #2004IC000340
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcoholism	Consumer	Librium	PS				
	Convulsion		Bupropion					

		Pulmonary Embolism		Hydrochloride	SS			ORAL
150 MG; TWICE								
		Road Traffic Accident						
A DAY; ORA								
		Somnolence		Carbamazepine	SS			ORAL
ORAL	1 YR							
				Nortriptyline	C			
				Valproate Semisodium	C			
				Quetiapine Fumarate	C			
				Citalopram Hydrobromide	C			

Date:07/23/04ISR Number: 4406045-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504887A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Nausea		Avandia	PS	Glaxosmithkline	ORAL
4MG Per day	5 DAY					
	Vomiting		Paxil	SS	Glaxosmithkline	ORAL
10MG						
Alternate						
days						
			Wellbutrin	SS	Glaxosmithkline	ORAL
300MG Per day	2 WK					
			Glucovance	C		
			Aspirin	C	Glaxosmithkline	
			Nexium	C		
			Vioxx	C		
			Ferrous Sulfate	C	Glaxosmithkline	
			Lamisil	C	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/04ISR Number: 4406262-9Report Type:Periodic Company Report #US010889
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Decreased		Avandia	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	
			Provigil	SS		ORAL		
			Glucophage	SS		ORAL	850MG Three times per day	
			Humalog	SS			INTRAMUSCULAR	156UNIT Per day
			Humulin	SS			INTRAMUSCULAR	50UNIT Twice per day
			Celexa	SS		ORAL	40MG Per day	
			Neurontin	C				
			Vioxx	C				
			Prilosec	C				
			Lisinopril	C				
			Allegra	C				

Date:07/23/04ISR Number: 4406300-3Report Type:Periodic Company Report #12286316
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Avandia	PS	Glaxosmithkline	ORAL		
	Hypoglycaemia		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	
			Provigil	SS		ORAL		
			Celexa	SS		ORAL	40MG Per day	

				Glucophage	SS		ORAL
850MG Three							
times per day							
				Humalog Insulin	SS		
SUBCUTANEOUS							
				Regular Insulin	SS		
SUBCUTANEOUS							
				Neurontin	C		
				Vioxx	C		
				Prilosec	C		
				Allegra	C		
				Lisinopril	C		

Date:07/23/04ISR Number: 4406575-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320766A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angina Pectoris		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL
1TAB Twice						
per day 13 DAY						
			Ramipril	C		
UNKNOWN						
			Aspirin	C	Glaxosmithkline	
UNKNOWN						
			Diltiazem Hydrochloride	C	Glaxosmithkline	
UNKNOWN						
			Atorvastatin	C		
UNKNOWN						
			Elantan La	C		
UNKNOWN 50MG Per day						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/04ISR Number: 4406576-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0321121A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	1TAB Twice per day	13 DAY
			Ramipril	C			UNKNOWN	
			Aspirin	C	Glaxosmithkline		UNKNOWN	
			Diltiazem Hydrochloride	C	Glaxosmithkline		UNKNOWN	
			Atorvastatin	C			UNKNOWN	
			Elantan La	C			UNKNOWN	

Date:07/23/04ISR Number: 4406587-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0337415A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetes Mellitus		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
Other	Inadequate Control Hypoglycaemia		Insulin Humalog Mix50	C			SUBCUTANEOUS	4IU Per day
			Humalog	C			SUBCUTANEOUS	2IU Twice per day
			Lantus	C			SUBCUTANEOUS	6IU At night
			Creon 25000	C		ORAL		
			Inipomp	C		ORAL	1G per day	

Date:07/23/04ISR Number: 4406604-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0339775A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Zyban	PS	Glaxosmithkline	ORAL	1TAB per day	
Initial or Prolonged	Blood Pressure Decreased							
	Cardiac Flutter							
	Chest Pain							
	Feeling Abnormal							
	Headache							
	Hiatus Hernia							
	Insomnia							

Date:07/26/04ISR Number: 4407826-9Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0335716A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Zyntabac	PS	Glaxosmithkline	ORAL	300MG Per day	8 DAY
	Confusional State	Professional	Sertraline	C		ORAL	200MG per day	
	Difficulty In Walking		Tofranil	C				
	Disorientation							
	Drug Interaction							
	Dysphoria							
	Headache							
	Illogical Thinking							
	Irritability							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/04ISR Number: 4407838-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0338941A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicide Attempt		Zyban	PS	Glaxosmithkline	ORAL		

Date:07/26/04ISR Number: 4408230-XReport Type:Direct Company Report #CTU 223526
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Bupropion Hydrochloride	PS	Teva	ORAL	1 PILL	TWICE
	Drug Ineffective						DAIL	ORAL
	Heart Rate Increased							
	Hypoventilation							
	Insomnia							
	Irritability							
	Pharmaceutical Product Complaint							
	Restlessness							

Date:07/26/04ISR Number: 4410635-8Report Type:Expedited (15-DaCompany Report #2004046963
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Doxepin (Caps) (Doxepin)	PS			UNKNOWN	UNKNOWN
	Loss Of Consciousness							
	Nausea		Bupropion Hydrochloride (Bupropion Hydrochloride)	SS			UNKNOWN	UNKNOWN
	Sinus Tachycardia							
	Tremor							
			Venlafaxine Hydrochloride (Venlafaxine Hydrochloride)	C				
			Lorazepam (Lorazepam)	C				

Benazepril Hydrochloride (Benazepril Hydrochloride)	C
Atenolol (Atenolol)	C
Vicodin (Hydrocodone Bitartrate, Paracetamol)	C
Methadone (Methadone)	C

Date:07/27/04ISR Number: 4408850-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0519165A
Age:40 YR Gender:Female I/FU:I

Outcome	PT
Death	Agitation
	Anxiety
	Bedridden
	Completed Suicide
	Diarrhoea
	Dizziness
	Feeling Abnormal
	Headache

	Insomnia Irritability Lethargy	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea Nervousness Pyrexia Social Avoidant Behaviour Toothache Tremor Vomiting		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	

Date:07/27/04ISR Number: 4408856-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0519542A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Nephrolithiasis		Wellbutrin	PS	Glaxosmithkline	ORAL	2 MON

Date:07/27/04ISR Number: 4408875-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0338333A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day 10 DAY
	Dizziness						
	Palpitations		Eltroxin	C	Glaxosmithkline	ORAL	.2MG per day
			Triphasil	C		ORAL	

Date:07/27/04ISR Number: 4411246-0Report Type:Expedited (15-DaCompany Report #B0339624A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to	Alanine Aminotransferase Increased	Foreign Literature	Paxil (Paroxetine Hydrochloride)	PS			PER DAY 4 WK

Prevent Permanent Impairment/Damage	Aspartate Aminotransferase Increased	Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	SS	150 MG / PER DAY 1 WK
	Carotid Artery Occlusion				
	Carotid Artery Thrombosis				
	Cerebral Infarction		Trazodone (Formulation Unknown) (Trazodone)	SS	PER DAY 3 WK
	Epstein-Barr Virus Infection				
	Ischaemic Stroke		Lithium Carbonate	C	
	Lymphocyte Morphology Abnormal		Lorazepam	C	
	Splenomegaly		Cyproheptadine	C	
			Oral Contraceptive	C	

Date:07/27/04ISR Number: 4413039-7Report Type:Expedited (15-DaCompany Report #S04-USA-04077-01
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Electroencephalogram Abnormal	Health Professional	Lexapro (Escitalopram)	PS		ORAL	10 MG QD PO
	Grand Mal Convulsion		Wellbutrin Xl	SS			450 MG QD

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/04ISR Number: 4409939-4Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0043950A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL		
	Hypoaesthesia Oral		Haldol	C			UNKNOWN	
	Muscle Spasms		Atosil	C	Glaxosmithkline		UNKNOWN	

Date:07/29/04ISR Number: 4410975-2Report Type:Expedited (15-DaCompany Report #2004-03238
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Wellbutrin Sr	PS	Glaxosmithkline		150MG Per day	10 YR
	Depressed Level Of Consciousness		Bupropion Hydrochloride	SS	Glaxosmithkline	ORAL	150MG Twice per day	DAY
	Disturbance In Attention							
	Motor Dysfunction		Lithium	C	Glaxosmithkline	ORAL	10 YR	
	Tremor							

Date:07/29/04ISR Number: 4410984-3Report Type:Expedited (15-DaCompany Report #PT-GLAXOSMITHKLINE-B0339717A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vision Blurred	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	300MG per day	

Date:07/29/04ISR Number: 4411973-5Report Type:Direct Company Report #CTU 223864
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Convulsion Intentional Misuse Suicide Attempt		Wellbutrin Sr 100 Mg	PS		ORAL 100 MG PO BID

Date:07/29/04ISR Number: 4411975-9Report Type:Direct Company Report #CTU 223865
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Intentional Misuse Suicide Attempt		Wellbutrin Sr 150 Mg	PS		ORAL 150 MG PO BID 2 YR

Date:07/29/04ISR Number: 4415067-4Report Type:Expedited (15-DaCompany Report #S04-USA-04386-01
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Thrombocytopenia	Health Professional	Lexapro (Escitalopram)	PS		ORAL 20 MG QD PO
			Topamax (Topiramate)	SS		100 MG QAM
			Topamax (Topiramate)	SS		200 MG QHS
			Wellbutrin (Bupropion Hydrochloride)	SS		200 MG BID
			Topamax (Topiramate)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/04ISR Number: 4444293-3Report Type:Periodic Company Report #USA-2003-0011039
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose	Health Professional Other	Morphine Sulfate (Morphine Sulfate)	PS				
			Tylenol With Codeine (Codeine Phosphae, Paracetamol)	SS				
			Bupropion (Amfebutamide)	SS				
			Diphenhydramine (Diphenhydramine)	SS				

Date:07/30/04ISR Number: 4412081-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511243A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin Sr	PS	Glaxosmithkline		150MG See	
	Decreased Appetite						dosage text	
	Depressed Mood							
	Depression							
	Disturbance In Attention							
	Feelings Of Worthlessness							
	Sleep Disorder							
	Social Avoidant Behaviour							
	Suicidal Ideation							
	Tremor							

Date:07/30/04ISR Number: 4412109-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0339907A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Zyban	PS	Glaxosmithkline	ORAL	11	DAY
Initial or Prolonged	Eye Pruritus		Atenolol	C		ORAL	25MG per day	

	Eye Swelling		Ramipril	C		ORAL	10MG per day
	Ocular Hyperaemia		Mixtard	C		SUBCUTANEOUS	
	Oedema Peripheral		Pravastatin	C		ORAL	40MG per day
	Rash Pruritic		Aspirin	C	Glaxosmithkline	ORAL	75MG per day
	Urticaria		Niquitin Cq	C	Glaxosmithkline	INTRADERMAL	21MG per day

Date:07/30/04ISR Number: 4412112-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0339975A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination, Auditory		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Variable dose DAY
	Hallucination, Visual							
	Muscle Spasms		St Johns Wort	C				
	Muscle Twitching							
	Paraesthesia							
	Suicidal Ideation							
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/04ISR Number: 4412119-XReport Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0340435A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Zyban	PS	Glaxosmithkline		150MG Twice	
	Hemiparesis						per day	

Date:07/30/04ISR Number: 4412130-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0341038A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Initial or Prolonged	Bronchospasm						per day	
	Inflammation							
	Lymph Node Pain							
	Lymphadenopathy							
	Oedema							
	Painful Respiration							
	Pyrexia							
	Rash Maculo-Papular							
	Rash Pruritic							

Date:07/30/04ISR Number: 4412822-1Report Type:Direct Company Report #CTU 223929
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Condition Aggravated		Wellbutrin Sr 150 Mg	PS		ORAL	150 MG QAM	
Intervention to	Muscle Spasms						ORAL	
Prevent Permanent	Tremor		Atenolol	C				
Impairment/Damage			Hydroxyzine	C				
			Ranitidine	C				
			Valproic Acid	C				
			Tylenol # 3	C				
			Meperidine	C				

			Fioricet	C			

Date:07/30/04ISR Number: 4413014-2Report Type:Direct Company Report #CTU 223955
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Tolerance Decreased		Wellbutrin Sr	PS		ORAL	150 MG BID PO
	Pharmaceutical Product		Klonopin	SS		ORAL	0.5 MG BID PO
	Complaint Unevaluable Event						

Date:08/02/04ISR Number: 4413068-3Report Type:Direct Company Report #CTU 224046
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion		Bupropion 100 Mg	PS		ORAL	100 MG BID ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/04ISR Number: 4413146-9Report Type:Direct Company Report #CTU 224061
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr Glaxo	PS	Glaxo	ORAL	ORAL	
			Wellbutrin Xl Glaxo	SS	Glaxo	ORAL	ORAL	

Date:08/02/04ISR Number: 4413162-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520283A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hemiparesis		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK
	Palpitations		Unknown Blood Pressure Medication	C				

Date:08/03/04ISR Number: 4414030-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520112A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
Hospitalization - Initial or Prolonged	Joint Dislocation		No Concurrent Medication	C				
Disability								
Other								

Date:08/03/04ISR Number: 4414032-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520465A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Drug Interaction	Professional	Anti-Psychotic					

	Psychotic Disorder		Medication	SS		
UNKNOWN						

Date:08/03/04ISR Number: 4414054-XReport Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0341295A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline			
	Sleep Disorder							

Date:08/04/04ISR Number: 4415228-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520725A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Wellbutrin	PS	Glaxosmithkline	ORAL	60TAB	Unknown
Hospitalization - Initial or Prolonged	Convulsion		Cocaine	C				
	Hepatic Enzyme Increased		Marijuana	C				
Disability	Overdose							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/04ISR Number: 4415238-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0340500A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Psoriaform		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY

Date:08/05/04ISR Number: 4416362-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520475A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		300MG per day	

Date:08/05/04ISR Number: 4416363-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520519A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	1 DAY
	Medication Error							
			Prozac	C				

Date:08/05/04ISR Number: 4416367-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520969A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bladder Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	3 MON
	Micturition Urgency							
	Nocturia		Synthroid	C	Glaxosmithkline			
	Pollakiuria							
	Urinary Incontinence							

Date:08/06/04ISR Number: 4417253-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517688A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	900MG Per day	4 DAY
Initial or Prolonged	Disorientation		Depakote	C		ORAL	1500MG per day	
	Medication Error							

Date:08/06/04ISR Number: 4417255-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520283A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hemiparesis		Unknown Blood Pressure Medication	C				
	Migraine		Diovan	C				
	Muscle Twitching		Aciphex	C				
	Nightmare		Zyrtec	C	Glaxosmithkline			
	Palpitations		Singulair	C				
	Paraesthesia		Vioxx	C				
	Sensation Of Heaviness							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/04ISR Number: 4417319-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517688A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	900MG Per day	4 DAY
	Disorientation	Professional	Depakote	C		ORAL	1500MG per day	
	Medication Error							

Date:08/06/04ISR Number: 4417321-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520283A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hemiparesis	Professional	Unknown Blood Pressure Medication	C				
	Migraine		Diovan	C				
	Muscle Twitching		Aciphex	C				
	Nightmare		Zyrtec	C	Glaxosmithkline			
	Palpitations		Singulair	C				
	Paraesthesia		Vioxx	C				
	Sensation Of Heaviness							
	Tremor							

Date:08/09/04ISR Number: 4418144-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0423404A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Paxil Cr	PS	Glaxosmithkline	ORAL	25MG Per day	2 DAY
	Anxiety		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice per day	3 DAY
	Dizziness							
	Panic Attack		Xanax	C				
	Psychomotor Hyperactivity							

Date:08/09/04ISR Number: 4418199-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490948A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Paxil	PS	Glaxosmithkline	ORAL	6	MON
	Diarrhoea		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK
	Drug Withdrawal Syndrome							
	Influenza Like Illness		Retin-A	C				
	Migraine							
	Nausea							
	Sensory Disturbance							
	Throat Tightness							

Date:08/09/04ISR Number: 4418476-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510014A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Paxil Cr	PS	Glaxosmithkline	ORAL	75MG Per day	
			Wellbutrin	SS	Glaxosmithkline	ORAL	450MG Per day	
			Wellbutrin	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/04ISR Number: 4418488-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510426A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Paxil Cr	PS	Glaxosmithkline	ORAL	12.5MG Per	
	Tremor						day	2 YR
	Weight Increased		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Strattera	C				
			Estratest	C				

Date:08/09/04ISR Number: 4418602-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0413109A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Paxil	PS	Glaxosmithkline	ORAL		
	Alopecia		Neurontin	SS			300MG Four	
	Anger						times per day	YR
	Drug Withdrawal Syndrome		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Per day	5 WK
	Dysphonia		Trazodone	C				
	Hypersensitivity		Klonopin	C				
	Influenza Like Illness							
	Insomnia							
	Nausea							
	Paraesthesia							
	Performance Status Decreased							
	Smoker							
	Somnolence							

Date:08/09/04ISR Number: 4418723-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490907A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective		Paxil	PS	Glaxosmithkline	ORAL
20MG Per day 3 MON						
	Weight Increased		Wellbutrin Sr	SS	Glaxosmithkline	ORAL

Date:08/09/04ISR Number: 4418727-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490970A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash Pruritic		Paxil	PS	Glaxosmithkline	
			Wellbutrin	SS	Glaxosmithkline	ORAL
300MG Per day						

Date:08/09/04ISR Number: 4419115-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493495A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety		Paxil Cr	PS	Glaxosmithkline	ORAL
40MG Per day 4 YR						
	Weight Decreased		Wellbutrin	SS	Glaxosmithkline	ORAL
2 MON						
	Weight Increased		Albuterol	C	Glaxosmithkline	
			Wellbutrin	C	Glaxosmithkline	
			Flovent	C	Glaxosmithkline	
			Alphagan	C		
			Zyprexa	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/04ISR Number: 4419512-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497213A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Paxil	PS	Glaxosmithkline	ORAL	1	YR
	Insomnia		Wellbutrin	SS	Glaxosmithkline	ORAL	1	YR
			Lithium	C	Glaxosmithkline			
			Other Medications	C				

Date:08/09/04ISR Number: 4419629-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500586A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Paxil	PS	Glaxosmithkline		30MG Per day	
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice per day	
			Unspecified Medication	SS				

Date:08/09/04ISR Number: 4419820-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502389A
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Paxil	PS	Glaxosmithkline	ORAL	10MG Per day	
	Anxiety		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Blood Pressure Increased							
	Confusional State		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	2 DAY
	Crying		Levoxyl	C	Glaxosmithkline			
	Decreased Appetite							
	Delusion							
	Depression							

Dizziness
Drug Withdrawal Syndrome
Gastrointestinal Pain
Headache
Hot Flush
Hyperchlorhydria
Insomnia
Nausea
Nervousness
Palpitations
Vomiting
Weight Increased

Date:08/09/04ISR Number: 4420418-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499806A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Energy Increased		Paxil	PS	Glaxosmithkline	ORAL	25MG Per day	
	Insomnia		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	5 DAY
	Loss Of Libido		Xanax	C				
			Herbal Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/04ISR Number: 4420518-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503861A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria		Paxil Cr	PS	Glaxosmithkline	ORAL	12.5MG Per day	7 WK
	Hypertension							
	Pollakiuria		Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:08/09/04ISR Number: 4420543-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504593A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Paxil Cr	PS	Glaxosmithkline	ORAL	50MG Per day	8 YR
	Drug Ineffective		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice per day	
	Paraesthesia							
	Weight Increased							

Date:08/09/04ISR Number: 4420553-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504905A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Paxil Cr	PS	Glaxosmithkline	ORAL	12.5MG Per day	4 DAY
	Weight Decreased							
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	11 DAY
			Oral Contraceptives	C				

Date:08/09/04ISR Number: 4420611-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506505A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Paroxetine	PS	Glaxosmithkline	ORAL	40MG Per day	2 MON
			Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON
			Magnesium	C				
			Calcium	C				
			Albuterol	C	Glaxosmithkline			
			Zinc	C				

Date:08/09/04ISR Number: 4420671-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507901A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	13 YR
	Anger		Paxil Cr	SS	Glaxosmithkline	ORAL	12.5MG Per day	2 WK
	Insomnia							
	Muscle Twitching		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Negative Thoughts							

Date:08/09/04ISR Number: 4420672-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507905A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Paxil	PS	Glaxosmithkline	ORAL	30MG Per day	7 YR
	Confusional State		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	8 MON
	Disturbance In Attention							
	Memory Impairment							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/04ISR Number: 4420755-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511060A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Paxil	PS	Glaxosmithkline			
	Nausea		Wellbutrin	SS	Glaxosmithkline		4	DAY

Date:08/09/04ISR Number: 4420757-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511097A
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation		Paxil	PS	Glaxosmithkline	ORAL		
	Drug Ineffective		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Somnolence							

Date:08/09/04ISR Number: 4420763-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511300A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Paxil	PS	Glaxosmithkline	ORAL		
	Dizziness		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Eructation		Lorazepam	C				
	Flatulence		Lipitor	C				
	Insomnia		Aciphex	C				
	Weight Increased		Ambien	C				

Date:08/09/04ISR Number: 4420799-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513053A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Paxil	PS	Glaxosmithkline	ORAL	10MG Per day	
	Diarrhoea		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	24 DAY
	Drug Ineffective		Lipitor	C				

	Hot Flush		Paxil	C	Glaxosmithkline
	Insomnia		Tenuate	C	
	Nightmare		Xanax	C	
	Tension				

Date:08/09/04ISR Number: 4420993-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514128A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		WK
	Flight Of Ideas	Professional	No Concurrent					
	Suicidal Ideation		Medication	C				

Date:08/09/04ISR Number: 4420994-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516903A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Overdose	Professional					per day	2 WK
			Zyprexa	C				
			Lito	C	Glaxosmithkline			
			Depakote	C				
			Effexor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/04ISR Number: 4421000-1Report Type:Expedited (15-DaCompany Report #2004-03363
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Bupropion	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative Medication Error Respiratory Disorder Skin Reaction							

Date:08/09/04ISR Number: 4421007-4Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0336916A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Zyban	PS	Glaxosmithkline		1TAB See dosage text	15 DAY
	Fibromyalgia							
	Suicidal Ideation		Morphine	C				
	Thinking Abnormal							

Date:08/09/04ISR Number: 4421017-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0340435A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Zyban	PS	Glaxosmithkline		150MG Twice per day	
	Hemiparesis	Professional						

Date:08/09/04ISR Number: 4421751-9Report Type:Direct Company Report #CTU 224598
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Buproprion Sr 150mg Tab	PS			BID	
	Apathy							

	Nausea		Climara Patch	C			
	Pharmaceutical Product Complaint						

Date:08/09/04ISR Number: 4423198-8Report Type:Direct Company Report #CTU 224502
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Budeprion 150 Mg					
	Fluid Retention		Teva	PS	Teva	ORAL	ONE PILL	
	Impatience						TWICE A DA	
	Irritability						ORAL	
	Mood Swings							
	Pharmaceutical Product Complaint							
	Weight Increased							

Date:08/09/04ISR Number: 4425658-2Report Type:Expedited (15-DaCompany Report #S04-USA-04077-01
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Other	Amnesia
	Coma
	Confusional State
	Eye Rolling

	Grand Mal Convulsion Tongue Biting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Lexapro (Escitalopram)	PS		ORAL	10 MG QD PO
			Wellbutrin Xl	SS			450 MG QD

Date:08/10/04ISR Number: 4422310-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520977A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day 3 MON
Initial or Prolonged	Convulsion		Doxepin	C			
	Liver Disorder		Clonazepam	C			
	Migraine		Chloral Hydrate	C			

Date:08/10/04ISR Number: 4422323-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0337087A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion		Zyban	PS	Glaxosmithkline		150MG Twice
	Laceration						per day
	Menarche		Alcohol	C			
	Postictal State						

Date:08/10/04ISR Number: 4422324-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0338405A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Orbital Oedema		Zyban	PS	Glaxosmithkline	ORAL	12 DAY

Initial or Prolonged		Rash Papular		Mixtard	C		
SUBCUTANEOUS	40UNIT Twice						
Other							
per day	14 YR						
				Pravastatin	C		ORAL
				Atenolol	C		ORAL
2 YR							
				Aspirin	C	Glaxosmithkline	ORAL
2 YR							
				Ramipril	C		ORAL
2 YR							

Date:08/10/04ISR Number: 4422325-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0338704A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Enteritis		Zyban	PS	Glaxosmithkline	ORAL
1TAB Per day						
	Feeling Abnormal		Antidepressant	C		
	Nausea		Inhalers	C		
	Nervousness					
	Vomiting					

Date:08/10/04ISR Number: 4422328-1Report Type:Expedited (15-DaCompany Report #238104
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Erythema		Zyban	PS	Glaxosmithkline	
UNKNOWN						
Initial or Prolonged	Eye Swelling		Mixtard	SS		
SUBCUTANEOUS	80IU per day					
	Feeling Hot		Niquitin Cq	C	Glaxosmithkline	
TRANSDERMAL	21MG per day					
	Pruritus		Pravastatin	C		
UNKNOWN						
	Urticaria		Aspirin	C	Glaxosmithkline	
UNKNOWN						

			Atenolol	C		
UNKNOWN						
			Ramipril	C		
UNKNOWN						

Date:08/10/04ISR Number: 4423252-0Report Type:Direct Company Report #CTU 224634
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Libido		Budeprion Teva	PS	Teva	ORAL	150 MG ONCE	
	Nausea						PER D ORAL	
	Pharmaceutical Product Complaint							

Date:08/10/04ISR Number: 4424136-4Report Type:Direct Company Report #CTU 224679
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Bupropion Sr	PS		ORAL	150 MG PO BID	
	Pharmaceutical Product Complaint							

Date:08/10/04ISR Number: 4424170-4Report Type:Direct Company Report #CTU 224669
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Budeprion Sr	PS		ORAL	150 MG PO BID	
	Insomnia							
	Irritability							
	Pharmaceutical Product Complaint							

Date:08/10/04ISR Number: 4424173-XReport Type:Direct Company Report #CTU 224667
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Wellbutrin Sr 150 Mg-Generic	PS		ORAL	150 MG PO BID	
	Pharmaceutical Product							
	Complaint							

Date:08/11/04ISR Number: 4423271-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514128A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	WK	
	Flight Of Ideas	Professional	No Concurrent Medication	C				
	Suicidal Ideation							

Date:08/11/04ISR Number: 4423287-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521121A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Fall							
	Tooth Fracture							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/04ISR Number: 4423295-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521578A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Contusion		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	450MG	Unknown
	Convulsion		Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
	Drug Ineffective		Marijuana	C				
	Grand Mal Convulsion							
	Insomnia							
	Postictal State							

Date:08/11/04ISR Number: 4423299-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521633A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Medication Error							
	Pharmaceutical Product		Bupropion Sr	SS	Glaxosmithkline		per day	1 MON
	Complaint		Zoloft	C			3	WK

Date:08/11/04ISR Number: 4423303-3Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0336371A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Activities Of Daily		Zyban	PS	Glaxosmithkline		150MG See	
	Living Impaired							
	Affect Lability		No Concurrent				dosage text	98 DAY
	Anxiety		Medication	C				
	Crying							
	Depressed Mood							
	Mental Disorder							
	Nicotine Dependence							
	Sleep Disorder							

Date:08/11/04ISR Number: 4423305-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0340435A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Zyban	PS	Glaxosmithkline		150MG Twice	
	Hemiparesis	Professional					per day	

Date:08/11/04ISR Number: 4423307-0Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0341295A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Zyban	PS	Glaxosmithkline	ORAL	5	WK
	Dizziness							
	Fatigue							
	Sleep Disorder							

Date:08/11/04ISR Number: 4423315-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0341680A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline		33	DAY
	Nightmare		Cipramil	C				
	Verbal Abuse							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/04ISR Number: 4423319-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0341933A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	17 DAY
	Anxiety							
	Confusional State							
	Trance							

Date:08/11/04ISR Number: 4425179-7Report Type:Direct Company Report #CTU 224756
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Escitalopram	PS		ORAL	40 MG PO	
	Mental Status Changes						DAILY	
	Tremor		Bupropion	SS		ORAL	150 MG PO Q	
							DAY	
			Benazepril	C				
			Metronidazole	C				
			Benicar	C				
			Advair	C				
			Morphine Ir	C				

Date:08/12/04ISR Number: 4424463-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0509451A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	135 DAY	
	Contusion	Professional	Trileptal	SS		ORAL	32 DAY	
	Convulsion		Lamictal	C	Glaxosmithkline	ORAL	100MG per day	
	Fall		Benadryl	C	Glaxosmithkline		50MG At night	

	Head Injury		Nicorette	C	Glaxosmithkline	ORAL
4TAB Per day						
	Medication Error					
	Sedation					

Date:08/12/04ISR Number: 4424485-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0341269A
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anorexia		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
	Decreased Interest					
per day 5 WK						
	Depression		Rabeprazole	C		ORAL
10MG per day						
	Dizziness					
	Fatigue					
	Tremor					

Date:08/12/04ISR Number: 4425302-4Report Type:Direct Company Report #CTU 224803
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Tinnitus		Wellbutrin Xl	PS		
150 MG DAILY						
X 1 WK 300 MG						
DAILY X 3 WKS						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/04ISR Number: 4426610-3Report Type:Direct Company Report #CTU 224843
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Wellbutrin Sr 150 Glaxosmithkline	PS	Glaxosmithkline			

Date:08/13/04ISR Number: 4425370-XReport Type:Expedited (15-DaCompany Report #2004-03222
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Per day	
	Ill-Defined Disorder							
	Muscular Weakness		Paxil	C	Glaxosmithkline	ORAL	YR	
	Myalgia		Topamax	C			YR	
	Pharmaceutical Product		Altace	C			YR	
	Complaint		Zocor	C			YR	
	Suicidal Ideation							

Date:08/13/04ISR Number: 4425377-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521279A
Age:6 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	37.5MG Per	
	Medication Error							
							day	1 WK
			Strattera	C				
			Clonidine	C				

Date:08/13/04ISR Number: 4425378-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521306A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Four	
Hospitalization -	Death						times per day	
Initial or Prolonged			No Concurrent Medication	C				

Date:08/13/04ISR Number: 4425379-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521407A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Headache		Ativan	C		ORAL		
	Medication Error							

Date:08/13/04ISR Number: 4427245-9Report Type:Direct Company Report #CTU 224931
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS				
	Skin Laceration							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/04ISR Number: 4427264-2Report Type:Direct Company Report #CTU 224940
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Coloboma		Wellbutrin	PS				
	Congenital Eye Disorder		Prozac	SS				
	Cryptophthalmos							
	Drug Exposure During Pregnancy							

Date:08/13/04ISR Number: 4448179-XReport Type:Periodic Company Report #T04-USA-03512-01
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Namenda (Memantine)	PS		ORAL	20 MG BID PO	
	Aphasia	Professional	Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	150 MG BID PO	
	Convulsion		Exelon (Rivastigmine Tartrate)	C				
	Fall		Prempro	C				
			Paxil (Paroxetine Hydrochloride)	C				

Date:08/16/04ISR Number: 4426806-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0521802A
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Rectal Haemorrhage							

Date:08/16/04ISR Number: 4426807-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521812A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Medication Error		Lexapro	SS				
	Somnolence		Clonazepam	SS				

Date:08/16/04ISR Number: 4426816-3Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0334041A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	1	DAY
	Delirium Tremens							
	Hallucination							
	Overdose							
	Restlessness							
	Tardive Dyskinesia							

Date:08/16/04ISR Number: 4426826-6Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0341325A
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain
	Coronary Artery Surgery
	Triple Vessel Bypass

Graft

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Zyban	PS	Glaxosmithkline		150MG Twice per day	
			Atenolol	C		ORAL	50MG per day	
			Trental	C		ORAL	400MG per day	
			Ecotrin	C	Glaxosmithkline	ORAL	81MG per day	
			Coversyl Plus	C		ORAL	4MG per day	

Date:08/16/04ISR Number: 4426838-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0342217A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ankyloglossia Congenital		Zyban	PS	Glaxosmithkline			
	Anorexia							
	Dizziness							
	Flatulence							
	Middle Insomnia							
	Reading Disorder							
	Sleep Disorder							
	Somnolence							
	Thought Blocking							
	Tremor							
	Urticaria							
	Visual Acuity Reduced							
	Visual Disturbance							

Date:08/16/04ISR Number: 4426839-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0342260A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Zyban	PS	Glaxosmithkline		1TAB Variable	

	Mental Disorder					
dose						
	Personality Change					
	Psychotic Disorder					

Date:08/17/04ISR Number: 4427736-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0318010A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression	Health	Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice	
Initial or Prolonged	Agitation	Professional						
per day							5	DAY
Other	Blood Pressure Increased							
	Depression							
	Dizziness							
	Feeling Abnormal							
	Headache							
	Pharmaceutical Product Complaint							

Date:08/17/04ISR Number: 4427747-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0341325A
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Chest Pain
Initial or Prolonged	Coronary Artery Surgery

	Triple Vessel Bypass Graft						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Zyban	PS	Glaxosmithkline		150MG Twice per day
			Atenolol	C		ORAL	50MG per day
			Trental	C		ORAL	400MG per day
			Ecotrin	C	Glaxosmithkline	ORAL	81MG per day
			Coversyl Plus	C		ORAL	4MG per day

Date:08/17/04ISR Number: 4427758-XReport Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0342487A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Zyban	PS	Glaxosmithkline	ORAL	

Date:08/17/04ISR Number: 4429450-4Report Type:Direct Company Report #CTU 225143
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Condition Aggravated		Wellbutron Sr (Generic)	PS		ORAL	120 MG 2 PO BID
	Depression						
	Drug Effect Decreased						
	Pharmaceutical Product Complaint		Trazadone	C			
			Xanax	C			

Date:08/17/04ISR Number: 4430036-6Report Type:Expedited (15-DaCompany Report #S04-USA-04732-01
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour	Consumer	Lexapro (Escitalopram)	PS		ORAL	20 MG QD PO	
	Agitation							
	Belligerence		Lexapro (Escitalopram)	SS		ORAL	10 MG QD PO	
	Confusional State							
	Delusion		Lexapro (Escitalopram)	SS		ORAL	10 MG QD PO	
	Insomnia							
	Mania		Wellbutrin (Bupropion Hydrochloride)	SS			300 MG QD	
	Oral Intake Reduced							
	Paranoia							
	Speech Disorder		Wellbutrin (Bupropion Hydrochloride)	SS			150 MG QD	
			Ambien (Zolpidem Tartrate)	C				
			Trazodone	C				
			Lipitor (Atorvastatin)	C				
			Achiphex (Rabeprazole Sodium)	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/04ISR Number: 4428823-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0339775A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Blood Pressure Decreased Cardiac Flutter Chest Pain Feeling Abnormal Headache Hiatus Hernia Insomnia	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	1TAB per day	

Date:08/18/04ISR Number: 4430053-6Report Type:Direct Company Report #CTU 225159
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression Movement Disorder Muscular Weakness Pharmaceutical Product Complaint Suicidal Ideation		Bupropion Sr 150 Mg Ta Wat	PS	Wat		1 TABLET BY MOUTH TWICE DAILY	

Date:08/18/04ISR Number: 4431278-6Report Type:Expedited (15-DaCompany Report #B0299104A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myoclonic Epilepsy	Foreign Literature Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS				

Date:08/18/04ISR Number: 4431823-0Report Type:Expedited (15-DaCompany Report #HQWYE479016JUN04
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activities Of Daily	Health	Efexor Er					
Disability	Living Impaired	Professional	(Venlafaxine					
	Convulsion		Hydrochloride,					
	Drug Interaction		Capsule, Extended					
	Drug Withdrawal Syndrome		Release)	PS		ORAL	75 MG 1X PER	
	Flight Of Ideas							1 DAY
	Impaired Driving Ability		Zyban (Amfebutamone					
	Irritability		Hydrochloride,)	SS		ORAL	UNKNOWN DOSE	
	Memory Impairment							TWO TIMES PER
	Petit Mal Epilepsy							DAY
	Status Epilepticus							

Date:08/18/04ISR Number: 4432030-8Report Type:Expedited (15-DaCompany Report #2004041004
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety
	Drug Hypersensitivity
	Drug Ineffective
	Muscle Spasms
	Pharmaceutical Product

	Complaint Post Procedural Complication Tremor Weight Decreased Weight Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer Health Professional	Neurontin (Tablets) (Gabapentin)	PS		ORAL	2400 MG (800 MG, 3 IN 1 D), ORAL
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS			
			Venlafaxine Hydrochloride (Venlafaxine Hydrochloride)	C			
			Levothyroxine Sodium (Levothyroxine Sodium)	C			
			Baclofen (Baclofen)	C			

Date:08/19/04ISR Number: 4429532-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514884A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Back Pain Chest Pain Dizziness Feeling Abnormal Feeling Jittery Grand Mal Convulsion Headache Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day 14 DAY
			Ultram	SS		ORAL	50MG Twice per day 20 DAY

Date:08/19/04ISR Number: 4429536-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521578A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Diastolic Increased		Wellbutrin Sr Wellbutrin Xl	PS SS	Glaxosmithkline Glaxosmithkline	ORAL ORAL	450MG Per day	
	Contusion Convulsion Drug Ineffective Grand Mal Convulsion Insomnia Postictal State		Marijuana	C				

Date:08/19/04ISR Number: 4429544-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0522437A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Glossodynia		No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/04ISR Number: 4430640-5Report Type:Direct Company Report #CTU 225302
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Bupropion Hcl 150 Mg	PS			TID	

Date:08/20/04ISR Number: 4430240-7Report Type:Expedited (15-DaCompany Report #2004-03363
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Other	Bupropion	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative							
	Medication Error							
	Polytraumatism							
	Respiratory Disorder							
	Skin Reaction							

Date:08/20/04ISR Number: 4430249-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0338405A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	12 DAY	
	Orbital Oedema		Mixtard	SS			SUBCUTANEOUS	40UNIT Twice
Other	Rash Papular						per day	14 YR
	Skin Degenerative Disorder		Pravastatin	C		ORAL		
			Atenolol	C		ORAL	2 YR	
	Urticaria		Aspirin	C	Glaxosmithkline	ORAL	2 YR	
			Ramipril	C		ORAL	2 YR	
			Niquitin Cq	C	Glaxosmithkline		TRANSDERMAL	21MG per day

Date:08/20/04ISR Number: 4430255-9Report Type:Expedited (15-DaCompany Report #238104
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema	Consumer	Zyban	PS	Glaxosmithkline	UNKNOWN		
	Eye Swelling		Mixtard	SS		SUBCUTANEOUS	80IU per day	
	Feeling Hot		Niquitin Cq	C	Glaxosmithkline	TRANSDERMAL	21MG per day	
	Pruritus		Pravastatin	C		UNKNOWN		
	Urticaria		Aspirin	C	Glaxosmithkline	UNKNOWN		
			Atenolol	C		UNKNOWN		
			Ramipril	C		UNKNOWN		

Date:08/20/04ISR Number: 4430262-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0342245A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	27 DAY

Date:08/20/04ISR Number: 4430265-1Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0342289A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK
	Fall							
	Lower Limb Fracture		Stilnoct	C		UNKNOWN	10MG per day	
	Pelvic Fracture		Cipralex	C		UNKNOWN	30MG per day	

			Imigran	C	Glaxosmithkline
UNKNOWN	100MG per day				
			Atarax	C	
UNKNOWN	25MG per day				
			Stesolid	C	
UNKNOWN	5MG per day				
			Nitrazepam	C	
UNKNOWN	5MG per day				
			Desolett	C	
UNKNOWN					
			Diclofenac	C	
UNKNOWN	50MG per day				
			Propylene Glycol	C	
UNKNOWN					

Date:08/20/04ISR Number: 4432489-6Report Type:Expedited (15-DaCompany Report #A-US2004-07003
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Study	Tracleer (Bosentan)					
	Anorexia	Health	Tablet	PS		ORAL	SEE IMAGE	
Other	Antibody Test Positive	Professional						
	Autoimmune Disorder	Distributor	Lovastatin (Lovastatin)	SS			20 MG, QD	
	Constipation							
	Hepatitis		Wellbutrin (Amfebutamone Hydrochloride)	SS				
	International Normalised Ratio Increased		Coumadin (Warfarin Sodium)	C				
	Nephrolithiasis		Prinivil (Lisinopril)	C				
			Aspirine (Acetylsalicylic Acid)	C				
			Milk Of Magnesia (Magnesium Hydroxide)	C				

Date:08/20/04ISR Number: 4432557-9Report Type:Expedited (15-DaCompany Report #A-US2004-07003
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antibody Test Positive	Study	Tracleer(Bosentan)					
	Hepatitis	Health	Tablet	PS		ORAL	SEE IMAGE	
Other	International Normalised Ratio Increased	Professional Distributor	Lovastatin (Lovastatin)	SS			20 MG, QD	
	Nephrolithiasis		Wellbutrin(Amfebutamone Hydrochloride0	SS				
			Coumadin (Warfarin Sodium)	C				
			Prinivil (Lisinopril)	C				
			Aspirine (Acetylsalicylic Acid0	C				
			Milk Of Magnesia (Magnesium Hydroxide)	C				

Date:08/20/04ISR Number: 4432633-0Report Type:Expedited (15-DaCompany Report #A-US2004-07003
Age:41 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Study	Tracleer (Bosentan)					
	Anorexia	Health	Tablet	PS		ORAL	SEE IMAGE	
	Antibody Test Positive	Professional	Lovastatin					
	Constipation	Distributor	(Lovastatin)	SS			20 MG, QD	
	Hepatitis		Wellbutrin					
	International Normalised		(Amfebutamone					
	Ratio Increased		Hydrochloride)	SS				
	Nephrolithiasis		Coumadin (Warfarin					
			Sodium)	C				
			Prinivil					
			(Lisinopril)	C				
			Aspirine					
			(Acetylsalicylic					
			Acid)	C				
			Milk Of Magnesia					
			(Magnesium					
			Hydroxide)	C				

Date:08/23/04ISR Number: 4430847-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515876A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	9 WK
	Depression	Professional	Oxycodone	C				
	Drug Ineffective		Xanax	C				
	Feeling Abnormal							
	Nervousness							
	Psychomotor Hyperactivity							
	Suicidal Ideation							

Date:08/23/04ISR Number: 4430848-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520969A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Bladder Pain	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice						
	Micturition Urgency	Professional				
per day 3 MON						
	Nocturia		Synthroid	C	Glaxosmithkline	
	Pollakiuria					
	Urinary Incontinence					

Date:08/23/04ISR Number: 4430850-7Report Type:Expedited (15-DaCompany Report #S04--USA-04732-01
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 5 YR						
	Agitation		Lexapro	SS		ORAL
10MG Per day 2 MON						
	Belligerence		Ambien	C		ORAL
	Confusional State		Trazodone	C		
UNKNOWN 25MG Per day						
	Delusion		Lipitor	C		
UNKNOWN						
	Mania		Aciphex	C		
UNKNOWN						
	Paranoia		Aspirin	C	Glaxosmithkline	
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/23/04ISR Number: 4430858-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0522920A
Age:10 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	2550MG Single	
	Grand Mal Convulsion						dose	1 DAY
	Overdose							
	Visual Disturbance							

Date:08/23/04ISR Number: 4430873-8Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0342423A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	1TAB Variable	
	Eczema Vesicular						dose	9 DAY
	Eye Oedema		Seloken Zoc	C		ORAL	47.5MG Per	
	Hypersensitivity						day	5 YR
	Liver Function Test		Linatil	C		ORAL	20MG Per day	10 YR
	Abnormal							
	Pharyngolaryngeal Pain							
	Pyrexia							
	Urticaria							

Date:08/23/04ISR Number: 4447597-3Report Type:Periodic Company Report #PHEH2004US06923
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Zelnorm (Tegaserod)					
	Palpitations		Tablet	PS		ORAL	2 MG, QD,	
	Throat Tightness						ORAL	
			Wellbutrin - Slow					

			Release (Bupropion Hydrochloride)	SS		

200 MG, 6QD

Date:08/24/04ISR Number: 4431406-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514321A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	12.5G Single	
Disability			Paxil	SS	Glaxosmithkline		120MG Single	
Other			Ativan	SS			30MG Single	
			Vitamins	C				
			Minerals	C				

Date:08/24/04ISR Number: 4431421-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0522921A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bulimia Nervosa Oesophageal Varices Haemorrhage		Wellbutrin	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/24/04ISR Number: 4431422-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0522931A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Convulsion						per day	1 WK
	Fall		Ludiomil	C				
	Upper Limb Fracture		Unknown Medication	C				

Date:08/24/04ISR Number: 4431424-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0523061A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	

Date:08/24/04ISR Number: 4431437-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0342585A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY
	Haemorrhage		Marvelon	SS		ORAL		
			Fexofenadine	C		ORAL	180MG Per day	

Date:08/24/04ISR Number: 4433260-1Report Type:Expedited (15-DaCompany Report #A0393333A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Ph Decreased	Literature	Wellbutrin Sr					
	Blood Pressure Systolic Increased	Health Professional	Tablet-Controlled Release (Bupropion					

	Cardio-Respiratory Arrest		Hydrochloride)	PS		
SEE DOSAGE TEXT	Coma					
	Completed Suicide					
	Electrolyte Imbalance					
	Grand Mal Convulsion					
	Heart Rate Increased					
	Hepatic Enzyme Increased					
	Hyperthermia					
	Overdose					
	Renal Failure					

Date:08/24/04ISR Number: 4433764-1Report Type:Direct Company Report #CTU 225531
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin Sr 150mg					
	Feeling Abnormal		Bid	PS		ORAL	150MG 1 BID	
	Nausea						PO	
	Pharmaceutical Product Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/25/04ISR Number: 4432378-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0522795A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Mood		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Ear Pain							
per day							2	YR
	Headache		Bupropion	SS	Glaxosmithkline	ORAL	150MG Twice	
	Neck Pain							
per day							2	MON
	Photophobia		Albuterol	C	Glaxosmithkline			
	Suicidal Ideation		Lexapro	C				
			Synthroid	C	Glaxosmithkline			
			Vioxx	C				
			Protonix	C				

Date:08/25/04ISR Number: 4432397-0Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0341359A
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Delirium		Zyban	PS	Glaxosmithkline		150MG Twice	
	Dizziness							
per day							10	DAY
	Epilepsy		No Concurrent					
	Foaming At Mouth		Medications	C				
	Grand Mal Convulsion							
	Insomnia							

Date:08/25/04ISR Number: 4432411-2Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0342628A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Diplopia		Fludex	C				
	Dizziness		Neurobion	C				

	Gait Disturbance		Norvasc	C		
5MG per day						
	Loss Of Consciousness		Isordil	C		
30MG Three						
	Syncope					
times per day						
			Carbasalate Calcium	C		
100MG per day						
			Dipyridamole	C		
75MG Three						
times per day						
			Lipitor	C		
20MG per day						
			Selokeen	C		
200MG per day						
			Famotidine	C		
40MG Twice						
per day						

Date:08/26/04ISR Number: 4433850-6Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0425393A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
Hospitalization -	Dizziness						per day	
Initial or Prolonged	Pharmaceutical Product		Paxil	C	Glaxosmithkline	ORAL	20MG Per day	
Other	Complaint		Insulin	C			INTRAVENOUS	
			Lorazepam	C				
			Micardis	C	Glaxosmithkline			
			Cephalexin	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/04ISR Number: 4433857-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0523500A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline	ORAL	300MG Per day	
	Drug Exposure During Pregnancy							

Date:08/26/04ISR Number: 4433865-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0320766A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	1TAB Twice per day	13 DAY
			Ramipril	C			UNKNOWN	1UNIT Twice per day
			Aspirin	C	Glaxosmithkline		UNKNOWN	1UNIT Per day
			Diltiazem Hydrochloride	C	Glaxosmithkline		UNKNOWN	1UNIT Per day
			Atorvastatin	C			UNKNOWN	1UNIT At night
			Elantan La	C			UNKNOWN	50MG In the morning

Date:08/26/04ISR Number: 4433875-0Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0342716A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 14 DAY	Cold Sweat		Zyban	PS	Glaxosmithkline	ORAL
Initial or Prolonged	Dizziness					
	Nausea					
	Pruritus					
	Rash					
	Sensation Of Foreign Body					

Date:08/26/04ISR Number: 4433880-4Report Type:Expedited (15-DaCompany Report #IE-GLAXOSMITHKLINE-B0342939A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Alcohol Use		Zyban	PS	Glaxosmithkline	ORAL
	Convulsion		Alcohol	SS		
	Death					

Date:08/27/04ISR Number: 4435225-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0523621A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Intentional Misuse		Wellbutrin	PS	Glaxosmithkline	ORAL
Hospitalization - Initial or Prolonged	Suicide Attempt					
Disability						
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/04ISR Number: 4435253-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0343579A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxosmithkline		150MG Twice	
	Stevens-Johnson Syndrome						per day	

Date:08/27/04ISR Number: 4435258-6Report Type:Expedited (15-DaCompany Report #138579
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Apathy							
	Personality Change							

Date:08/27/04ISR Number: 4435317-8Report Type:Direct Company Report #CTU 225774
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Wellbutrin Sr 100 Mg Tablet	PS				

Date:08/27/04ISR Number: 4443621-2Report Type:Expedited (15-DaCompany Report #B0300505A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression	Literature	Wellbutrin Tablet					
	Cardio-Respiratory Arrest	Health	(Bupropion					
	Completed Suicide	Professional	Hydrochloride)	PS		ORAL	ORAL	
	Convulsion		Imipramine					
	Depressed Level Of Consciousness		(Imipramine)	SS				
	Disorientation		Desipramine (Desipramine)	SS				

	Drug Screen Positive		Clonazepam	C	
	Dysarthria		Thiamine	C	
	Intentional Misuse				
	Lethargy				
	Postictal State				
	Sinus Tachycardia				

Date:08/30/04ISR Number: 4437037-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508671A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Dizziness	Professional					dosage text	7 DAY
	Hot Flush							
	Hyperhidrosis							
	Hypersensitivity							
	Nausea							
	Pain							
	Urticaria							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/30/04ISR Number: 4437040-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511243A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Other	Wellbutrin Sr	PS	Glaxosmithkline		150MG See	
	Decreased Appetite						dosage text	
	Depressed Mood							
	Depression							
	Disturbance In Attention							
	Feelings Of Worthlessness							
	Sleep Disorder							
	Social Avoidant Behaviour							
	Suicidal Ideation							
	Tremor							

Date:08/30/04ISR Number: 4437041-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514321A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL	12.5G Single	
Disability	Overdose		Paxil	SS	Glaxosmithkline		120MG Single	
Other			Ativan	SS			30MG Single	
			Vitamins	C			dose	
			Minerals	C				

Date:08/30/04ISR Number: 4437045-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520976A
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 150MG Per day 1 WK	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL
Initial or Prolonged	Incontinence		Glyburide	C		
Other	Rash		Synthroid	C	Glaxosmithkline	
	Respiratory Distress		Zyloprim	C	Glaxosmithkline	
	Swollen Tongue		Ambien	C		
	Urinary Tract Infection		Vicodin	C		
			Lasix	C	Glaxosmithkline	
			Gabitril	C		

Date:08/30/04ISR Number: 4438714-XReport Type:Direct Company Report #CTU 225881
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abnormal Behaviour		Wellbutrin 150 Mg	PS		
DAILY						
	Aggression		Straterra	C		
	Feelings Of Worthlessness					
	Headache					
	Suicidal Ideation					

Date:08/31/04ISR Number: 4437949-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0523784A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Brain Neoplasm		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 3 WK						
	Grand Mal Convulsion		No Concurrent Medication	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4437951-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0523797A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Suicidal Ideation		Zocor	C				

Date:08/31/04ISR Number: 4437952-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0523830A
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	18	MON
	Drug Ineffective		Clonidine	C				
	Euphoric Mood							
	Insomnia							
	Psychomotor Hyperactivity							

Date:08/31/04ISR Number: 4437960-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0343398A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Multi-Organ Failure							
			Thyroxine	C	Glaxosmithkline			
			Hormone Replacement Therapy	C				
			Amlodipine	C				

Date:08/31/04ISR Number: 4437985-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498029A
Age:8 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	35	DAY

Date:08/31/04ISR Number: 4437986-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503199A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	7 WK

Date:08/31/04ISR Number: 4437987-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504891A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Dry Mouth		Wellbutrin Sr	SS	Glaxosmithkline			
	Hepatic Enzyme Increased		Klonopin	C				
	Insomnia		Soy Supplement	C				
	Memory Impairment		Vitamins	C				
	Pharmaceutical Product Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4437988-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506097A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	108 DAY
	Tongue Biting							

Date:08/31/04ISR Number: 4437989-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506289A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	91	DAY

Date:08/31/04ISR Number: 4437990-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506577A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	YR
	Pruritus		Ativan	C		ORAL	.5MG Four times per day	
			Unknown Medication	C		ORAL	25MG Per day	

Date:08/31/04ISR Number: 4437991-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506578A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Date:08/31/04ISR Number: 4437992-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506849A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	MON
Other	Convulsion		Insulin	C				
			Altace	C			5MG per day	
			Synthroid	C	Glaxosmithkline		150MCG per day	
			Atenolol	C			25MG per day	
			Diltiazem Xr	C	Glaxosmithkline		180MG per day	
			Imdur	C			60MG per day	
			Asa	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4437993-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507267A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	71 DAY	
	Fatigue		Ultram	C		ORAL	50MG As required	
	Grand Mal Convulsion							
	Hypoaesthesia		Fosamax	C				
	Incontinence		Tranxene	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4437994-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508732A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	22	DAY
Other	Hypersensitivity		Unknown Medication	C				
	Throat Tightness							

Date:08/31/04ISR Number: 4437995-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509209A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Disease		Prevacid	C				

Date:08/31/04ISR Number: 4437996-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509214A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 MON
	Dyspepsia		Ticar	C	Glaxosmithkline			
	Paraesthesia							

Date:08/31/04ISR Number: 4437997-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509220A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			Effexor	C				

Date:08/31/04ISR Number: 4437998-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509223A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 WK
			Zocor	C				

Date:08/31/04ISR Number: 4437999-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509237A
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Musculoskeletal Stiffness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
Other								

Date:08/31/04ISR Number: 4438000-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509240A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438001-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509452A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Nasal Oedema Oedema Mouth		Paxil	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438002-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509459A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Facial Bones Fracture Fall		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438003-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509464A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia White Blood Cell Count Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438004-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509465A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Oral Contraceptives	C				

Date:08/31/04ISR Number: 4438005-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509466A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Valium	C		ORAL	10MGM At night	

Date:08/31/04ISR Number: 4438006-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509473A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438007-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509548A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delusion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	7 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438008-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509634A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Nausea							
	Nervousness							

Date:08/31/04ISR Number: 4438009-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509648A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	7 MON
			Celexa	C				
			Lamictal	C	Glaxosmithkline			
			Zyprexa	C				
			Buspar	C				

Date:08/31/04ISR Number: 4438010-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509649A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438011-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509654A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Somnolence							

Date:08/31/04ISR Number: 4438012-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509657A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Triglycerides		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	11 MON
	Increased		Zoloft	C				
			Flintstone Vitamins	C				

Date:08/31/04ISR Number: 4438013-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509812A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
			Flomax	C				

Date:08/31/04ISR Number: 4438014-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509814A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438015-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509818A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Stool Analysis Abnormal		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438016-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509820A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Nodosum		Wellbutrin Xl	PS	Glaxosmithkline			

Date:08/31/04ISR Number: 4438017-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509828A
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Zoloft	C				

Date:08/31/04ISR Number: 4438018-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509850A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438019-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509855A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON
	Anger		Paxil	C	Glaxosmithkline			
	Suicidal Ideation							

Date:08/31/04ISR Number: 4438020-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509918A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Pharmaceutical Product Complaint							

Date:08/31/04ISR Number: 4438021-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509919A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438022-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509925A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438023-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509936A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON
	Anger		Antidepressant					
	Suicidal Ideation		(Unspecified)	C				

Date:08/31/04ISR Number: 4438024-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509991A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Energy Increased		Trazodone	SS				
			Birth Control Pills	C				

Date:08/31/04ISR Number: 4438025-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509992A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438026-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509993A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Reaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK
			Zoloft	C				

Date:08/31/04ISR Number: 4438027-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509996A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Synthroid	C	Glaxosmithkline			
			Effexor	C				

Date:08/31/04ISR Number: 4438028-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510006A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG	Unknown
	Gastrooesophageal Reflux Disease		No Concurrent Medication	C				
	Headache							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438029-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510020A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	55	DAY
			Paxil Cr	SS	Glaxosmithkline	ORAL	75MG	Per day
			Lamictal	C	Glaxosmithkline	ORAL	200MG	per day 76 DAY
			Trileptal	C		ORAL	300MG	Twice per day
			Vistaril	C		ORAL		

Date:08/31/04ISR Number: 4438030-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510021A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Per day 3 WK
	Sensation Of Pressure		Clarinex	C				
	Vision Blurred		Fosamax	C				

Date:08/31/04ISR Number: 4438031-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510024A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Discolouration		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day 3 MON
			Prevacid	C				

Date:08/31/04ISR Number: 4438032-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510032A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dissociation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 1 DAY						
			Tequin	C		

Date:08/31/04ISR Number: 4438033-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510209A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Contusion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 1 MON						
			No Concurrent Medication	C		

Date:08/31/04ISR Number: 4438034-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510212A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 3 MON						
			No Concurrent Medication	C		

Date:08/31/04ISR Number: 4438035-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510214A
Age:83 YR Gender:Male I/FU:I

Outcome	PT
	Balance Disorder
	Constipation
	Dizziness

	Fatigue					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day	2 WK					
			Lexapro	C		

Date:08/31/04ISR Number: 4438036-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510235A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day	3 MON					
	Rash Erythematous		Naproxen	C		
			Allegra	C		

Date:08/31/04ISR Number: 4438037-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510240A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						
	Drug Withdrawal Syndrome		Effexor	SS		
	Headache		Alprazolam	C		
	Mood Altered					

Date:08/31/04ISR Number: 4438038-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510336A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Therapeutic Response		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day	1 YR					
	Decreased					

Date:08/31/04ISR Number: 4438039-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510340A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438040-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510399A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Vomiting		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438041-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510408A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	5 DAY
			Trazodone	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438042-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510413A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Syncope		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438043-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510419A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Lymphadenopathy		Zoloft	C				
	Pyrexia		Ambien	C				
	Swelling Face		Xanax	C				
	Swollen Tongue		Seroquel	C				

Date:08/31/04ISR Number: 4438044-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510424A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 MON
	Dysgeusia		Zyrtec	C	Glaxosmithkline			
	Gastrooesophageal Reflux Disease							

Date:08/31/04ISR Number: 4438045-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510434A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Insomnia		Lipitor	C				

	Nausea		Effexor	C		
225MG Per day						
			Wellbutrin Sr	C	Glaxosmithkline	ORAL
YR						

Date:08/31/04ISR Number: 4438046-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510503A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
	Insomnia					
	Urinary Incontinence					

Date:08/31/04ISR Number: 4438047-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510513A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tendonitis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						

Date:08/31/04ISR Number: 4438048-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510517A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438049-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510523A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
			Plavix	C				
			Lipitor	C				
			Aspirin	C	Glaxosmithkline			
			Platil	C				
			Bextra	C				
			Terazosin	C				
			Aceon	C				
			Indapamide	C				
			Acetaminophen	C	Glaxosmithkline			
			Propoxyphene	C				

Date:08/31/04ISR Number: 4438050-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510527A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438051-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510530A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438052-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510531A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

450MG Per day

Date:08/31/04ISR Number: 4438053-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510534A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 1 WK						
Initial or Prolonged	Localised Oedema		Coumadin	C	Glaxosmithkline	
			Lasix	C	Glaxosmithkline	
			Beta Blocker	C		
			Diovan	C		

Date:08/31/04ISR Number: 4438054-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510537A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438055-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510539A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Heart Rate Increased		Strattera	C				
	Irritability		Trileptal	C				
	Medication Error							
	Stomach Discomfort							

Date:08/31/04ISR Number: 4438056-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510540A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438057-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510686A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			
			Ambien	C				

Date:08/31/04ISR Number: 4438058-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510729A
Age:12 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Subcutaneous		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Advair	C	Glaxosmithkline			
			Flonase	C	Glaxosmithkline			
			Zyrtec	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438059-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510739A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY

Date:08/31/04ISR Number: 4438060-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510746A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Nicotine Patches	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438061-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510752A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
			Ambien	C				
			Synthroid	C	Glaxosmithkline			
			Clonazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438062-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510757A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG	Per day
			Lexapro	C				

Date:08/31/04ISR Number: 4438063-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510758A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG	Per day
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438064-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510761A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG	Per day
			Zoloft	C				

Date:08/31/04ISR Number: 4438065-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510763A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Per day

Date:08/31/04ISR Number: 4438066-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510764A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Grand Mal Convulsion Incontinence		Wellbutrin Cenestin Singulair Levo-Thyroxin Hydrochlorothiazide	PS SS C C C	Glaxosmithkline Glaxosmithkline	ORAL	300MG Per day 2.5MG Per day .025MG Per day 12.5MG Per day	170 DAY

Date:08/31/04ISR Number: 4438068-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510860A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Facial Bones Fracture Fall Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	15 DAY

Date:08/31/04ISR Number: 4438069-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510881A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438070-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510904A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bacterial Infection		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
			Ativan	C				
			Dicyclomine	C				

Date:08/31/04ISR Number: 4438071-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510916A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438072-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510917A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438073-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510929A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438074-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510936A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 1 DAY						
			Celexa	C		

Date:08/31/04ISR Number: 4438075-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510937A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 1 WK						
			No Concurrent Medication	C		

Date:08/31/04ISR Number: 4438076-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510940A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 11 DAY						
	Crying		Zoloft	C		
	Dizziness		Cyclessa	C		
	Dry Mouth		Singulair	C		
	Nausea					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438077-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510947A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Insomnia		Lexapro	C				

Date:08/31/04ISR Number: 4438078-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510948A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Alcohol	SS				
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438079-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511013A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Crying							
	Mood Altered							

Date:08/31/04ISR Number: 4438080-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511025A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	YR

Date:08/31/04ISR Number: 4438081-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511062A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	DAY
	Irritability		Zoloft	C				
	Panic Reaction							

Date:08/31/04ISR Number: 4438082-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511066A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
	Fatigue		Zoloft	C				

Date:08/31/04ISR Number: 4438083-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511086A
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	23 DAY
	Hypertension		Baby Aspirin	C	Glaxosmithkline			
	Insomnia		Ditropan Xl	C				
	Nervousness		Ambien	C				
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438084-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511100A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	14 DAY
	Crying		Xanax	C				
	Dizziness							
	Headache							

Date:08/31/04ISR Number: 4438085-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511106A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Zoloft	C				
			Multiple Medications	C				

Date:08/31/04ISR Number: 4438086-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511113A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinus Congestion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Vision Blurred		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438087-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511120A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Erectile Dysfunction		Trazodone	C				
	Semen Volume Decreased		Viracept	C				
			Combivir	C	Glaxosmithkline			

			Pravachol	C		
			Zetia	C		

Date:08/31/04ISR Number: 4438088-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511233A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK
	Urticaria							

Date:08/31/04ISR Number: 4438089-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511266A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438090-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511303A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	10	DAY
Initial or Prolonged			Cipro	C	Glaxosmithkline			
			Alcohol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438092-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511403A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Emotional Disorder							

Date:08/31/04ISR Number: 4438093-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511410A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438094-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511463A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	29 DAY
			Lorazepam	C				

Date:08/31/04ISR Number: 4438095-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511471A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Nervousness		Norco	C				
			Soma	C				

Date:08/31/04ISR Number: 4438096-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511473A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						

Date:08/31/04ISR Number: 4438097-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511588A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 2 WK						

Date:08/31/04ISR Number: 4438098-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511590A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Withdrawal Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 30 WK						
	Headache		Ambien	C		
	Nausea		Klonopin	C		

Date:08/31/04ISR Number: 4438099-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511598A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 7 DAY						
	Insomnia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438100-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511599A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438101-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511606A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Tremor							

Date:08/31/04ISR Number: 4438102-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511611A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438103-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511617A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Adderall	C				
			Neurontin	C				

Date:08/31/04ISR Number: 4438104-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511620A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Neck Pain Radiotherapy		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438105-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511626A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438106-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511720A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myoclonus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438107-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511741A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438108-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511763A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438109-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511876A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
	Dizziness							
	Hyperhidrosis							
	Nausea							
	Vision Blurred							
	Vomiting							

Date:08/31/04ISR Number: 4438110-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511898A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Prozac	C				
			Lipitor	C				
			Norvasc	C				
			Vitamins	C				
			Water Pill	C				
			Wellbutrin Sr	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438111-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511906A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						
			No Concurrent Medication	C		

Date:08/31/04ISR Number: 4438112-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511907A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Twice						
	Oedema Peripheral					
per day	2 YR					
			Bupropion Hydrochloride	SS	Glaxosmithkline	

Date:08/31/04ISR Number: 4438113-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511912A
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day	2 DAY					
			Amitriptyline	C		
			Perphenazine	C	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438114-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511917A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438115-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512053A
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Capoten	C	Glaxosmithkline			
			Lipitor	C				
			Hctz	C				

Date:08/31/04ISR Number: 4438116-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512054A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Prednisone	C				
			Urso	C				
			Salagen	C				
			Cyclobenzaprine	C				
			Femhrt	C				

Date:08/31/04ISR Number: 4438117-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512060A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	17 DAY
	Drug Ineffective							
	Insomnia							

Date:08/31/04ISR Number: 4438118-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512062A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438119-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512082A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Headache		Lantus	C				
	Nausea		Humalog Insulin	C				
			Lanoxin	C	Glaxosmithkline			
			Potassium	C				
			Lipitor	C				
			Bumex	C				
			Multi-Vitamins	C				
			Aspirin	C	Glaxosmithkline			
			Zaroxolyn	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438120-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512085A
Age:18 MON Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438121-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512087A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Dizziness		No Concurrent					
	Headache		Medication	C				
	Myalgia							
	Neck Pain							
	Tension							

Date:08/31/04ISR Number: 4438122-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512228A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Insomnia		Pain Medication	SS				

Date:08/31/04ISR Number: 4438123-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512234A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	WK
			Lexapro	C				

Date:08/31/04ISR Number: 4438124-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512239A
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438125-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512249A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Insulin	C				
			Blood Pressure Medication	C				
			Thyroid Medication	C				
			Milk Of Magnesium	C	Glaxosmithkline			
			Stool Softener	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438126-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512340A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438127-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512341A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438128-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512343A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oropharyngeal Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438129-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512388A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438130-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512396A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Lexapro	C				

Date:08/31/04ISR Number: 4438131-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512400A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	0	DAY

Date:08/31/04ISR Number: 4438132-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512403A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
			Ativan	C				
			Vivelle	C				
			Singulair	C				
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438133-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512404A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			No Concurrent					

Medication C

Date:08/31/04ISR Number: 4438134-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512414A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Candidiasis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Dry Mouth		No Concurrent					
	Oral Discomfort		Medication	C				

Date:08/31/04ISR Number: 4438135-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512418A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Hypertension		Dhea	C				
	Palpitations		Vitamins	C				
			Antioxidant	C				
			Calcium	C				
			Garlic Capsules	C				
			Ginger Root	C				

Date:08/31/04ISR Number: 4438136-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512451A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438137-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512534A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 14 DAY						
			Depo Medrol	C		
INTRAMUSCULAR						
			Zyrtec	C	Glaxosmithkline	ORAL

Date:08/31/04ISR Number: 4438138-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512603A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Loss Of Consciousness		Wellbutrin	PS	Glaxosmithkline	ORAL
248 DAY						
	Muscle Rigidity		Oral Contraceptives	C		
	Petit Mal Epilepsy					

Date:08/31/04ISR Number: 4438139-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512645A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nightmare		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
	Thinking Abnormal					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438140-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512868A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438141-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512874A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Herpetiformis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Lexapro	C				
			Fosamax	C				
			Nasonex	C				
			Astelin	C				
			Advair	C	Glaxosmithkline			
			Combivent	C				
			Klonopin	C				
			Protonix	C				
			Hydroxyzine	C				
			Dapsone	C				
			Wellbutrin Sr	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438142-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512878A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	
			Zocor	C				
			Aspirin	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438143-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512893A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Feeling Abnormal		Advil	C	Glaxosmithkline			
	Mood Swings		Klonopin	C				
	Negative Thoughts							

Date:08/31/04ISR Number: 4438144-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512960A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Xanax	SS		ORAL		

Date:08/31/04ISR Number: 4438145-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512964A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	14 DAY
			Depo Medrol	C			80MG Per day	
			Zyrtec	C	Glaxosmithkline	ORAL	10MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438146-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513012A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK
	Pain		Diovan	C				
			Procardia	C	Glaxosmithkline			
			Nexium	C				
			Atenolol	C				
			Flonase	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438148-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513023A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Insomnia		Vitamin E	C				
	Nausea		Vitamin B	C				
			Vitamin C	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438149-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513026A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	18 DAY
			Synthroid	C	Glaxosmithkline			
			Birth Control	C				

Date:08/31/04ISR Number: 4438150-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513057A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY

Lopid	C	
Synthroid	C	Glaxosmithkline
Premarin	C	
Zyrtec	C	Glaxosmithkline
Lipitor	C	
Nexium	C	
Accolate	C	

Date:08/31/04ISR Number: 4438151-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513226A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438152-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513267A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False Positive		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438153-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513270A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	14 DAY
	Tremor		Xanax	C				
			Percocet	C				

Date:08/31/04ISR Number: 4438154-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513285A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438155-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513289A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lescol	C				
			Foradil	C				
			Doxazosin	C				
			Albuterol	C	Glaxosmithkline			
			Zantac	C	Glaxosmithkline			
			Ativan	C				
			Aspirin	C	Glaxosmithkline			
			Nasacort	C				

Date:08/31/04ISR Number: 4438156-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513290A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	17 DAY

				Oral Contraceptives	C		

Date:08/31/04ISR Number: 4438157-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513295A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 WK
	Nausea		Sotalol	C				
	Stomach Discomfort							

Date:08/31/04ISR Number: 4438158-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513404A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438159-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513437A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Swollen Tongue		Allegra	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438160-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513438A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Muscle Spasms		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438161-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513443A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 DAY
	Dry Mouth		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438162-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513466A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438163-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513478A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Zoloft	C				

Date:08/31/04ISR Number: 4438164-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513480A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 MON
	Asthenia		No Concurrent					
	Depression		Medication	C				
	Disturbance In Attention							
	Fatigue							

Date:08/31/04ISR Number: 4438165-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513481A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Papaverine	C				

Date:08/31/04ISR Number: 4438166-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513483A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438167-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513486A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Heart Rate Increased		Atenolol	C				
			Xenadrine	C				

Date:08/31/04ISR Number: 4438168-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513490A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Lexapro	C				

Date:08/31/04ISR Number: 4438169-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513618A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervous System Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438170-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513644A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Drug Ineffective		Klonopin	C				
	Headache							
	Nausea							

Date:08/31/04ISR Number: 4438171-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513648A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:08/31/04ISR Number: 4438172-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513653A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctivitis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Constipation Ill-Defined Disorder		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438173-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513656A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438174-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513658A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Weight Increased							

Date:08/31/04ISR Number: 4438175-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513775A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438176-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513779A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
	Myalgia							

Date:08/31/04ISR Number: 4438177-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513783A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Hctz	C			25MG Per day	
			Zocor	C			80MG Per day	

			Vitamins	C		
			Aciphex	C		

20MG Twice

per day

Date:08/31/04ISR Number: 4438178-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513821A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	11 DAY
			Spironolactone	C				
			Estradiol	C				
			Crestor	C				

Date:08/31/04ISR Number: 4438179-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513835A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Tremor		Strattera	C				

Date:08/31/04ISR Number: 4438180-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513957A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438181-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513977A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	YR

Date:08/31/04ISR Number: 4438182-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513978A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Drug Ineffective		No Concurrent					
	Vision Blurred		Medication	C				
			Clonazepam	C			UNKNOWN	
			Zestril	C		ORAL	10MG In the morning	

Date:08/31/04ISR Number: 4438183-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513986A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Psychotropic Drugs	C			UNKNOWN	

Date:08/31/04ISR Number: 4438184-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514094A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:08/31/04ISR Number: 4438185-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514111A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pharmaceutical Product Complaint Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438186-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514140A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Diarrhoea		Lorazepam	C				

Date:08/31/04ISR Number: 4438187-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514149A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438188-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514151A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Effexor	C				
			Prednisone	C				

Date:08/31/04ISR Number: 4438189-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514278A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438190-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514312A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Constipation		Tigan	C	Glaxosmithkline			
	Nausea		Compazine	C	Glaxosmithkline			
	Weight Decreased		Strattera	C				
			Vitamins	C				

Date:08/31/04ISR Number: 4438191-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514322A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			
			Gabitril	C				

Date:08/31/04ISR Number: 4438192-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514323A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438193-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514328A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Musculoskeletal Stiffness							

Date:08/31/04ISR Number: 4438194-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514330A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	14 DAY
	Nausea		Levoxyl	C	Glaxosmithkline			
	Paraesthesia		Tenormin	C				
			Lorazepam	C				
			Amitriptyline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438195-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514345A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Drug Ineffective		Zoloft	C				
	Feeling Abnormal							
	Nausea							

Date:08/31/04ISR Number: 4438196-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514507A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
	Confusional State		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438197-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514510A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Salivary Hypersecretion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438198-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514518A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	7 DAY	
Initial or Prolonged	Drug Ineffective		Restoril	C				
Other	Suicidal Ideation							

Date:08/31/04ISR Number: 4438199-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514615A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	6	MON

Date:08/31/04ISR Number: 4438200-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514626A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Lexapro	C				
			Unspecified Medications	C				

Date:08/31/04ISR Number: 4438201-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514670A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438202-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514674A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retching		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438203-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514679A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Heart Rate Increased							
	Hyperhidrosis							
	Migraine							
	Nausea							

Date:08/31/04ISR Number: 4438204-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514853A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Repetitive Speech		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	30 DAY
			Alcohol	C				

Date:08/31/04ISR Number: 4438205-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514869A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438206-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514870A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 MON
	Hair Texture Abnormal		Multiple Medications	C				

Date:08/31/04ISR Number: 4438207-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514874A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin Xl	PS	Glaxosmithkline			

Date:08/31/04ISR Number: 4438208-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514878A
Age:39 YR Gender:Female I/FU:I

Outcome	PT
	Anxiety
	Blood Pressure Decreased
	Disorientation
	Dizziness
	Heart Rate Increased
	Migraine
	Nausea
	Nervousness

	Tinnitus Tremor						
		Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL	
150MG Per day	2 MON						
			Estrogen	C			
			Aleve Cold + Sinus	C			

Date:08/31/04ISR Number: 4438209-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514885A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day	6 WK					
	Educational Problem		No Concurrent			
	Irritability		Medication	C		

Date:08/31/04ISR Number: 4438210-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514895A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day						
	Headache		Ibuprofen	C	Glaxosmithkline	
			Actos	C		
			Zaroxolyn	C		
			Aldactone	C		
			Butalbital/Apap/Caffeine	C		
			Coumadin	C	Glaxosmithkline	
			Hydrocodone	C		
			Docusate	C		
			Glucophage	C		
			Prevacid	C		
			Diovan	C		
			Lanoxin	C	Glaxosmithkline	
			Betapace	C	Glaxosmithkline	
			Alprazolam	C		
			Albuterol Inhaler	C	Glaxosmithkline	
			Advair	C	Glaxosmithkline	

Phazyme	C	Glaxosmithkline	
Afrin	C	Glaxosmithkline	
Ocean Nasal	C	Glaxosmithkline	
Flonase	C	Glaxosmithkline	
Lasix	C	Glaxosmithkline	
Potassium	C		

Date:08/31/04ISR Number: 4438211-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514908A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Vision Blurred		No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438212-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515014A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Test Negative		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438213-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515025A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438214-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515026A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438215-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515134A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 DAY
	Impatience		Buspar	C				

Date:08/31/04ISR Number: 4438216-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515154A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	6 WK
	Psychomotor Hyperactivity							

	Respiratory Sighs		Nicotine Transdermal Patch	C	Glaxosmithkline	

Date:08/31/04ISR Number: 4438217-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515163A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Amnesia Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	10 MON

Date:08/31/04ISR Number: 4438218-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515225A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopause		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	8 MON
			Prozac	C				
			Oral Contraceptives	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438219-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515309A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438220-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515362A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438221-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515367A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			Diovan	C				
			Metformin	C				
			Blood Pressure Medication	C		ORAL		

Date:08/31/04ISR Number: 4438222-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515383A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Consumer	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150TAB Per day	1 MON
	Dysphagia							
	Nausea		Pravachol	C				
	Vomiting							

Date:08/31/04ISR Number: 4438223-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515385A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Rash Pruritic		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438224-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515395A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	3 MON
	Depressed Level Of Consciousness Eye Rolling Grand Mal Convulsion Postictal State Tongue Biting Tonic Clonic Movements		Lexapro	SS		ORAL	10MG Per day	442 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438225-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515536A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Drug Ineffective							
	Headache							
	Nausea							
	Panic Attack							

Date:08/31/04ISR Number: 4438226-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515573A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON

Date:08/31/04ISR Number: 4438227-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515610A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438228-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515730A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG per day	8 DAY
			Glucophage	C				

Date:08/31/04ISR Number: 4438229-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515731A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 HR
	Nausea		No Concurrent					
	Pain		Medication	C				

Date:08/31/04ISR Number: 4438230-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515753A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	18 DAY
	Menstrual Disorder		Ortho Tricyclen	C			1TAB Per day	5 YR
			Nortriptyline	C			50MG At night	

Date:08/31/04ISR Number: 4438231-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515873A
Age:80 YR Gender:Male I/FU:F

Outcome	PT
	Dermatitis Exfoliative
	Dry Skin
	Erythema
	Oedema
	Pain

	Pruritus Rash					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day	4 DAY					
			Effexor	C		
			Aricept	C		
			Metoprolol	C		
			Neurontin	C		
			Colchicine	C		
			Lipitor	C		
			Terazosin	C		
			Proscar	C		
			Indomethacin	C		

Date:08/31/04ISR Number: 4438232-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515883A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Erythema Multiforme		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day	3 WK					
Initial or Prolonged			Birth Control Pills	C		

Date:08/31/04ISR Number: 4438233-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515897A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
450MG Per day	2 MON					
			Remicade	C		
			Imitrex	C	Glaxosmithkline	
			Effexor	C		

Date:08/31/04ISR Number: 4438234-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515909A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:08/31/04ISR Number: 4438235-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515911A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ocular Hyperaemia		Wellbutrin Xl	PS	Glaxosmithkline		UNKNOWN	

Date:08/31/04ISR Number: 4438236-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515916A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Irritability		No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438237-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516121A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Dry Mouth		Hydrochlorothiazide	C				
	Dyspnoea		Atenolol	C				
	Headache		Albuterol	C	Glaxosmithkline			
	Increased Appetite		Advair	C	Glaxosmithkline			
	Libido Increased							
	Mouth Ulceration							
	Oedema Peripheral							
	Paranoia							

Date:08/31/04ISR Number: 4438238-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516132A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Zocor	C				
			Prevacid	C				
			Plavix	C				
			Klonopin	C				
			Antihypertensive	C				

Date:08/31/04ISR Number: 4438239-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516141A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438240-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516143A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Angioneurotic Oedema Swollen Tongue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:08/31/04ISR Number: 4438241-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516243A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
	Breast Tenderness		Pravachol	C				

Date:08/31/04ISR Number: 4438242-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516248A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438243-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516251A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Cognitive Disorder							
	Dysphasia							
	Tremor							

Date:08/31/04ISR Number: 4438244-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516252A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Depakote Er	C				

Date:08/31/04ISR Number: 4438245-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516258A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG In the	
Initial or Prolonged							morning	
Other			Dilantin	C				

Date:08/31/04ISR Number: 4438246-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516384A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK

Date:08/31/04ISR Number: 4438248-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516423A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438249-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516428A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	DAY
	Confusional State		Synthroid	C	Glaxosmithkline			
			Zyrtec	C	Glaxosmithkline			
			Zestril	C				

Date:08/31/04ISR Number: 4438250-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516436A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK
			Lexapro	C				
			Nexium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438251-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516440A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Agitation						per day	2 MON
	Anxiety		Glucophage	C				
	Energy Increased		Glucovance	C				
			Estrogen Replacement	C				
			Xanax	C				
			Proton Pump Inhibitor	C				

Date:08/31/04ISR Number: 4438252-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516452A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False Positive		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438253-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516460A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	12 MON
			Blood Pressure Medication	C				

Date:08/31/04ISR Number: 4438254-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516549A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438255-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516553A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown 1 YR
	Irritable Bowel Syndrome							

Date:08/31/04ISR Number: 4438256-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516599A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day 3 WK
	Dyspepsia							

Date:08/31/04ISR Number: 4438257-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516601A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438258-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516611A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Mood Swings		Oral Contraceptives	C				

Date:08/31/04ISR Number: 4438259-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516621A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 WK
			Ambien	C				
			Xanax	C				
			Seroquel	C				
			Combivent	C				
			Qvar	C	Glaxosmithkline			
			Xopenex	C				

Date:08/31/04ISR Number: 4438260-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516630A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Eye Pain		Amaryl	C				
	Keratoconjunctivitis		Synthroid	C	Glaxosmithkline			
	Sicca		Avapro	C				
	Vision Blurred							

Date:08/31/04ISR Number: 4438261-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516631A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 3 WK						
			Zoloft	C		

Date:08/31/04ISR Number: 4438262-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516754A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 8 WK						
			Lithium	C	Glaxosmithkline	
			Klonopin	C		

Date:08/31/04ISR Number: 4438263-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516760A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscular Weakness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 8 MON						
	Paraesthesia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438264-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516766A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Depression							
	Nausea							
	Vomiting							

Date:08/31/04ISR Number: 4438265-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516777A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438266-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516778A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	8 WK

Date:08/31/04ISR Number: 4438267-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516911A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Medication Error		Trazodone	C				
			Prozac	C				

Date:08/31/04ISR Number: 4438268-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516990A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coordination Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438269-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517063A
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Twice	
	Sexual Dysfunction						per day	3 YR
	Sleep Disorder		Lamictal	C	Glaxosmithkline			
			Provigil	C				
			Viagra	C				

Date:08/31/04ISR Number: 4438270-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517090A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Vomiting		No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438271-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517091A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Dysphagia		Neurontin	C				
	Migraine		Skelaxin	C				
	Throat Tightness		Elavil	C	Glaxosmithkline			
			Xanax	C				
			Toprol Xl	C				
			Vicodin	C				
			Advil	C	Glaxosmithkline			
			Tylenol Es	C	Glaxosmithkline			
			Ambien	C				
			Maxalt	C				
			Proventil	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438272-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517246A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Drug Ineffective							

Date:08/31/04ISR Number: 4438273-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517248A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
			Effexor	SS				

Date:08/31/04ISR Number: 4438274-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517253A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438275-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517255A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4	MON
			Neurontin	C				

Date:08/31/04ISR Number: 4438276-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517259A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sunburn		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438277-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517263A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Claustrophobia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Insomnia		Zelnorm	C				
	Irritability							
	Mood Altered							

Date:08/31/04ISR Number: 4438278-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517273A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Allegra	C				

Date:08/31/04ISR Number: 4438279-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517389A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	MON

Date:08/31/04ISR Number: 4438280-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517405A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	7 DAY
	Hot Flush							

Date:08/31/04ISR Number: 4438281-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517421A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Tension							

Date:08/31/04ISR Number: 4438282-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517432A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:08/31/04ISR Number: 4438283-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517439A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
	Joint Swelling		Yasmin	C				
	Oedema Peripheral							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438284-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517441A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON

Date:08/31/04ISR Number: 4438285-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517445A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Rash Pustular		Trileptal	C				
			Nexium	C				

Date:08/31/04ISR Number: 4438286-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517667A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline		UNKNOWN	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438287-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517669A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 MON
			Aricept	C				
			Nexium	C				
			Lasix	C	Glaxosmithkline			
			Albuterol	C	Glaxosmithkline			
			Zyprexa	C				

Date:08/31/04ISR Number: 4438288-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517675A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
			Hydrochlorothiazide	C				
			Zyrtec	C	Glaxosmithkline			
			Lipitor	C				
			Plavix	C				
			Nexium	C				

Date:08/31/04ISR Number: 4438289-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517681A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Local Swelling	Consumer	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 WK
			Dhea	SS				
			Fosamax	C				
			Soma	C				
			Ultracet	C				
			Combi-Patch	C				
			Ginseng	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438290-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517683A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	24 DAY
	Faeces Discoloured		Tegretol	C				
	Flatulence							
	Stomach Discomfort							

Date:08/31/04ISR Number: 4438291-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517689A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Synthroid	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438292-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517692A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438293-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517693A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Thinking Abnormal							
	Weight Decreased							

Date:08/31/04ISR Number: 4438294-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517698A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcohol Use		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	90 DAY
	Personality Change		Prozac	C				
			Alcohol	C				

Date:08/31/04ISR Number: 4438295-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517849A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438296-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517857A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukopenia		Wellbutrin	PS	Glaxosmithkline	ORAL	6	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438298-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517878A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438299-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518021A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438300-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518022A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Nightmare							

Date:08/31/04ISR Number: 4438301-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518024A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hiccups		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown

Date:08/31/04ISR Number: 4438302-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518073A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day 3 WK
	Anger		Humalog	C				
	Anorexia		Evista	C				

	Anxiety		Vitamins	C	
	Crying				
	Dizziness				
	Dysgeusia				
	Emotional Disorder				
	Fungal Infection				
	Hyperhidrosis				
	Insomnia				
	Myalgia				
	Nausea				
	Tremor				
	Weight Decreased				

Date:08/31/04ISR Number: 4438303-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518082A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
			No Concurrent Medication	C				

19-Aug-2005 12:44 PM
Page: 2794

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438304-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518095A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438305-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518099A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Insulin	C				

Date:08/31/04ISR Number: 4438306-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518100A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
	Nasal Congestion		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
	Rhinorrhoea		Allergy Shots	C				
	Sneezing		Proventil	C	Glaxosmithkline			
			Singulair	C				

Date:08/31/04ISR Number: 4438307-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518179A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Papular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438308-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518210A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Feeling Abnormal		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
	Nausea		Iron Supplement	C				
	Tinnitus		Calcium Supplement	C				
			Yasmin	C				
			Vitamin D Supplement	C				

Date:08/31/04ISR Number: 4438309-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518227A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline		4	MON
	Fatigue		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438310-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518228A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Hytrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438311-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518231A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Drug Ineffective							
	Heart Rate Increased							
	Insomnia							
	Tremor							

Date:08/31/04ISR Number: 4438312-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518236A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Single dose	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438313-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518246A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON

Date:08/31/04ISR Number: 4438314-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518361A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG See dosage text	
	Weight Increased							

Date:08/31/04ISR Number: 4438315-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518423A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438316-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518518A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
			Luvox	C				
			Anafranil	C				
			Xanax	C				

Date:08/31/04ISR Number: 4438317-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518522A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438318-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518537A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown 1 MON
	Heart Rate Increased Hypervigilance		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438319-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518540A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Metrorrhagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	7 MON
			Provera	C				
			Atenolol	C				

Date:08/31/04ISR Number: 4438320-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518547A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Nervousness		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	200MG per day	

Date:08/31/04ISR Number: 4438321-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518549A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysmenorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438322-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518612A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438323-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518621A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438324-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518630A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Feeling Abnormal		Lexapro	C				
	Headache		Prevacid	C				
	Myalgia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438325-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518642A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
		Professional	No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438326-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518712A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excessive Masturbation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	MON
	Libido Increased							

Date:08/31/04ISR Number: 4438327-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518753A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Dysgeusia							
	Salivary Hypersecretion							

Date:08/31/04ISR Number: 4438328-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518785A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
			Klonopin	C				

Date:08/31/04ISR Number: 4438329-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518791A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Heart Rate Increased		Prozac	C				
	Insomnia							

Date:08/31/04ISR Number: 4438330-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518798A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
			Adderall	C				

Date:08/31/04ISR Number: 4438331-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518819A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Drug Ineffective		Unknown Medication	C				
	Headache		Effexor	C				
	Nausea		Vistaril	C				
	Sensation Of Heaviness		Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438332-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518984A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Zoloft	C				
			Ortho Tricyclen	C				

Date:08/31/04ISR Number: 4438333-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519027A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438334-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519035A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Crying		Estrogen	C				
	Depressive Symptom		Cartia	C	Glaxosmithkline			
	Stool Analysis Abnormal							
	Vision Blurred							

Date:08/31/04ISR Number: 4438335-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519053A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Vitreous Floaters		Zoloft	C				
			Ambien	C				

Date:08/31/04ISR Number: 4438336-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519064A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438337-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519065A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Trazodone	C				
			Levothyroxine	C	Glaxosmithkline			

Date:08/31/04ISR Number: 4438338-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519070A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Palpitations		Wellbutrin	SS	Glaxosmithkline	ORAL	200MG Per day	1 WK
	Throat Tightness		No Concurrent					
	Visual Disturbance		Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438339-6Report Type:Periodic Company Report #S04-USA-04077-01
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	4 MON
		Professional	Lexapro	SS		ORAL	10MG Per day	

Date:08/31/04ISR Number: 4438340-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519210A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Insomnia		Inderal	C				
	Lethargy		Topamax	C				

Date:08/31/04ISR Number: 4438341-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519216A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Methadone	C	Glaxosmithkline			
			Percocet	C				

Date:08/31/04ISR Number: 4438342-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519248A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON
	Tremor		Duragesic	C				
			Xanax	C				
			Prednisone	C				
			Protonix	C				

	Lexapro	C
	Klonopin	C
	Altace	C
	Lipitor	C
	Clindamycin	C
	Levaquin	C
	Neurontin	C
	Percocet	C

Date:08/31/04ISR Number: 4438343-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519390A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	9 MON

Date:08/31/04ISR Number: 4438344-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519391A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438345-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519405A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438346-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519410A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MGML Per day	3 WK
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438347-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519535A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	600MG Per day	
	Insomnia		Wellbutrin	C	Glaxosmithkline	ORAL	75MG Per day	
	Muscle Twitching							
	Overdose							

Date:08/31/04ISR Number: 4438348-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519541A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438349-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519550A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Palpitations							

Date:08/31/04ISR Number: 4438350-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519695A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438351-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519701A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Reaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438352-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519704A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Muscle Spasms		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
	Muscle Twitching		Actonel	C				
	Myalgia		Nexium	C				
			Oral Contraceptives	C				
			Ativan	C				

Date:08/31/04ISR Number: 4438353-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519706A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY
	Insomnia		Lipitor	C				
	Mood Swings		Aspirin	C	Glaxosmithkline			
	Psychomotor Hyperactivity		Vitamins	C				
	Vision Blurred							

Date:08/31/04ISR Number: 4438354-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519707A
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438355-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519723A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 1 MON						
	Heart Rate Increased		Lexapro	C		
	Migraine					
	Nausea					
	Pollakiuria					
	Tremor					

Date:08/31/04ISR Number: 4438356-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519728A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						
			Birth Control	C		ORAL

Date:08/31/04ISR Number: 4438357-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519735A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						
Initial or Prolonged			Seroquel	C		
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438358-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519736A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Thinking Abnormal		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438359-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519855A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Dyspnoea							

Date:08/31/04ISR Number: 4438360-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519869A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Rhinitis							

Date:08/31/04ISR Number: 4438361-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519875A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	19 DAY
	Pruritus		Dhea	C				
	Rash		Herbal Medicine	C				

Date:08/31/04ISR Number: 4438362-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519880A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 3 WK						
	Hypertension		Ambien	C		
	Nausea		Novocaine	C		
	Tremor					

Date:08/31/04ISR Number: 4438363-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519882A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 3 DAY						

Date:08/31/04ISR Number: 4438364-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519896A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 8 DAY						
	Drug Interaction		Ultram	SS		
			Norvasc	C		
			Zyrtec	C	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438365-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519900A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK

Date:08/31/04ISR Number: 4438366-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519908A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4	DAY
	Tinnitus		Ultram	C				

Date:08/31/04ISR Number: 4438367-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519923A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438368-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520077A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Depression		No Concurrent Medication	C				
	Headache							
	Hot Flush							
	Nervousness							
	Vision Blurred							

Date:08/31/04ISR Number: 4438369-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520093A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Aura Grand Mal Convulsion Headache		Wellbutrin Remeron	PS C	Glaxosmithkline	ORAL	150MG Per day	1 DAY

Date:08/31/04ISR Number: 4438370-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520094A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nipple Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438371-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520107A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vaginal Haemorrhage		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	ORAL	450MG Per day	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438372-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520111A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	MON
			Risperdal	C				
			Prozac	C				

Date:08/31/04ISR Number: 4438373-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520281A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Emotional Disorder		Prozac	C				
	Personality Change							

Date:08/31/04ISR Number: 4438374-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520285A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Diastolic		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	105	DAY
	Increased		Hyzaar	C		ORAL		

Date:08/31/04ISR Number: 4438375-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520286A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Ill-Defined Disorder		Toprol	C				

Date:08/31/04ISR Number: 4438376-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520288A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	4	MON
			Toprol	C				

Date:08/31/04ISR Number: 4438377-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520300A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438378-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520310A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	21 WK
	Alopecia Effluvium		No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438379-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520312A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	8 WK

Date:08/31/04ISR Number: 4438380-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520319A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	150MG Unknown 23 DAY
Initial or Prolonged	Overdose		Diphenhydramine	C				
			Benzodiazepine	C				
			Cannabis	C				
			Alcohol	C				
			Sleeping Pill	C				

Date:08/31/04ISR Number: 4438381-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520321A
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438382-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520373A
Age:56 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	600MG Single	
	Tremor						dose	
			Concerta	C				

			Ritalin	C		
			Klonopin	C		

Date:08/31/04ISR Number: 4438383-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520375A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	3 MON
	Stool Analysis Abnormal		Unknown Medication	C				

Date:08/31/04ISR Number: 4438384-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520387A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Walking		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438385-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520485A
Age:46 YR Gender:Female I/FU:F

Outcome	PT
	Fatigue
	Migraine
	Muscle Twitching
	Nightmare

	Palpitations						
	Paraesthesia						
	Sensation Of Heaviness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day 3 WK
			Diovan	C			
			Aciphex	C			
			Zyrtec	C	Glaxosmithkline		
			Singulair	C			
			Zomig	C			
			Vioxx	C			

Date:08/31/04ISR Number: 4438387-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520508A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vomiting		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	

Date:08/31/04ISR Number: 4438388-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520509A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Blood Glucose Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	

Date:08/31/04ISR Number: 4438389-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520521A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day
			Alcohol	C			

Date:08/31/04ISR Number: 4438390-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520523A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:08/31/04ISR Number: 4438391-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520524A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	DAY
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438392-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520541A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438393-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520546A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438394-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521113A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438395-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521115A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438396-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521117A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Furuncle		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Stevens-Johnson Syndrome		No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438397-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521119A
Age:13 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438398-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521834A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Geodon	C				
			Temazepam	C				

Date:08/31/04ISR Number: 4438399-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522803A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438421-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493781A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Loss Poor	Consumer	Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438422-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494320A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional	Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:08/31/04ISR Number: 4438423-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500121A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
		Professional	Unspecified Drugs	C				

Date:08/31/04ISR Number: 4438424-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507659A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	28 DAY	
	Grand Mal Convulsion		Advair	C	Glaxosmithkline			
	Tongue Biting		Beconase	C	Glaxosmithkline			
			Singulair	C				
			Ultram	C				
			Maxalt	C				
			Vioxx	C				
			Allegra D	C				

Date:08/31/04ISR Number: 4438425-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507906A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Osteoporosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	250MG Per day	
			Depakote Er	C		ORAL	1500MG Per day	
			Celexa	C		ORAL	20MG Per day	

Date:08/31/04ISR Number: 4438426-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510522A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:08/31/04ISR Number: 4438427-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513782A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/04ISR Number: 4439062-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524069A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline			
			No Concurrent Medication	C				

Date:09/01/04ISR Number: 4439066-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0335857A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:09/01/04ISR Number: 4439067-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0339775A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	150MG	See dosage text
	Blood Pressure Decreased							
	Cardiac Flutter		Lipitor	C		ORAL	40G	Per day
	Chest Pain		Lopid	C		ORAL	60G	Twice per day
	Feeling Abnormal							
	Headache		Pariet	C		ORAL	20G	Twice per day
	Hiatus Hernia							
	Insomnia		Endep	C	Glaxosmithkline	ORAL	10G	As required
			Premarin	C				

Date:09/01/04ISR Number: 4439078-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0343937A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Hemiplegia		Levothyrox	C	Glaxosmithkline			
			Tenormine	C				
			Mopral	C				

Date:09/01/04ISR Number: 4439721-3Report Type:Direct Company Report #CTU 226057
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin Sr 100 Mg					
	Treatment Noncompliance		Gsk	PS	Gsk		1 TABLET	
							TWICE A DA	

Date:09/01/04ISR Number: 4440010-1Report Type:Expedited (15-DaCompany Report #A-US2004-07003
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Antibody Test Positive
	Constipation
	Hepatitis
	International Normalised Ratio Increased

Nephrolithiasis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Study	Tracleer (Bosentan)					
Health Professional	Tablet	PS		ORAL	125 MG, BID,	
Distributor					ORAL : 62.5 MG, BID, ORAL	
	Lovastatin(Lovastatin)	SS			20 MG, QD	
	Wellbutrin(Amfebutamone Hydrochloride)	SS				
	Coumadin(Warfarin Sodium)	C				
	Prinivil(Lisinopril)	C				
	Aspirine(Acetylsalicylic Acid)	C				
	Milk Of Magnesia (Magnesium Hydroxide)	C				

Date:09/01/04ISR Number: 4440362-2Report Type:Direct Company Report #CTU 226055
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder		Zoloft Down To 50mg					
Other	Drug Ineffective		Unknown	PS			SEE IMAGE PER	
	Muscular Weakness						FDA ONSITE	
	Paraesthesia						REP	
	Vision Blurred		Wellbutrin Xl 150 Mgs Un Known	SS			SEE IMAGE PER	

JW FDA ONSITE

REP

Date:09/02/04ISR Number: 4440061-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0335857A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
		Professional						

Date:09/02/04ISR Number: 4440062-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0337371A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
		Professional	Betablocker	C		ORAL		
			Zocor	C		ORAL		
			Kardegic	C		ORAL	75MG Per day	
			Stilnox	C		ORAL		

Date:09/02/04ISR Number: 4440073-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0344111A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Zyban	PS	Glaxosmithkline		5	DAY
	Sensation Of Pressure							
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/02/04ISR Number: 4444581-0Report Type:Expedited (15-DaCompany Report #2004059295
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Zyrtec-D 12 Hour (Cetirizine, Pseudoephedrine)	PS				
	Chronic Obstructive Pulmonary Disease		Pramipexole (Pramipexole)	SS				
	Dental Operation		Clonazepam (Clonazepam)	SS				
	Hypersensitivity		Mirtazapne (Mirtazapine)	SS				
	Polyneuropathy		Amitriptyline (Amitriptyline)	SS				
	Sinus Disorder		Bupropion Hydrochloride (Bupropion Hydrochloride)	SS				
			Montelukast Sodium (Montelukast Sodium)	C				
			Combivent (Ipratropium Bromide, Salbutamol Sulfate)	C				
			Mirtazapine (Mirtazapine)	C				
			Esomeprazole (Esomeprazole)	C				
			Salbutamol (Salbutamol)	C				

Date:09/02/04ISR Number: 4446647-8Report Type:Expedited (15-DaCompany Report #2004-119599-NL
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Estrogen Progestron	PS		ORAL	DF	
	Haemorrhage		Bupropion Hydrochloride	SS		ORAL	150 MG	13 DAY
	Seasonal Allergy		Fexofenadine	C				

Date:09/03/04ISR Number: 4440813-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520283A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	20 DAY	
	Hemiparesis	Professional	Diovan	C		ORAL		
	Migraine		Aciphex	C		ORAL		
	Muscle Twitching		Zyrtec	C	Glaxosmithkline	ORAL		
	Nightmare		Singulair	C		ORAL		
	Palpitations		Vioxx	C		ORAL		
	Paraesthesia		Lexapro	C		ORAL	.5TAB Per day	
	Sensation Of Heaviness							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/03/04ISR Number: 4440821-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524499A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day 2 WK
	Headache		No Concurrent				
	Psychiatric Symptom		Medication	C			
	Suicidal Ideation						

Date:09/03/04ISR Number: 4440823-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524503A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Homicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day 1 DAY
			Zoloft	C			

Date:09/03/04ISR Number: 4440826-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524516A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Amnesia	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	1 MON
Initial or Prolonged	Convulsion		Alcohol	C			
	Overdose						

Date:09/03/04ISR Number: 4440839-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0342217A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Anorexia	Consumer	Zyban	PS	Glaxosmithkline		
	Dizziness		Fluvax	C	Glaxosmithkline		INTRAMUSCULAR
	Flatulence						
	Middle Insomnia						
	Sleep Disorder						

	Somnolence
	Speech Disorder
	Thought Blocking
	Tremor
	Urticaria
	Visual Acuity Reduced
	Visual Disturbance

Date:09/03/04ISR Number: 4440844-3Report Type:Expedited (15-DaCompany Report #DK-GLAXOSMITHKLINE-B0343749A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL		
	Ill-Defined Disorder		Alcohol	C				
	Laceration							
	Wound							

Date:09/03/04ISR Number: 4440847-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0344156A
Age:56 YR Gender:Male I/FU:I

Outcome	PT
Other	Anxiety
	Drug Dependence
	Euphoric Mood

	Excitability						
	Formication						
	Malaise	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Medication Error		Zyban	PS	Glaxosmithkline	ORAL	150MG See
	Pallor						dosage text
	Transaminases Increased		Lexomil	C			

Date:09/03/04ISR Number: 4440848-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0344204A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event	Health	Zyban	PS	Glaxosmithkline	ORAL	1TAB Unknown
Initial or Prolonged	Aggression	Professional	Valium	SS			
	Amnesia		Warfarin	SS	Glaxosmithkline		
	Mental Disorder		Tritace	SS			
	Overdose		Panadeine Forte	SS	Glaxosmithkline		
	Suicide Attempt						

Date:09/07/04ISR Number: 4441953-5Report Type:Expedited (15-DaCompany Report #2004-03848
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dizziness		Bupropion	PS	Glaxosmithkline	ORAL	150MG Per day 3 DAY
	Loss Of Consciousness		Atenolol	C			25MG Per day
	Syncope						
	Vomiting						

Date:09/07/04ISR Number: 4441955-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524551A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Intentional Misuse		Wellbutrin	PS	Glaxosmithkline	ORAL
1 MON						
	Overdose					
	Suicide Attempt					

Date:09/07/04ISR Number: 4441989-4Report Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0344090A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Confusional State		Zyban	PS	Glaxosmithkline	ORAL
300MG Per day						
	Crying		Coaprovel	SS		ORAL
	Depressed Mood					
	Depression					
	Drug Withdrawal Syndrome					
	Fatigue					
	Feeling Abnormal					

Date:09/07/04ISR Number: 4442955-5Report Type:Direct Company Report #CTU 226470
Age: Gender:Female I/FU:I

Outcome	PT
Other	Contusion
	Dehydration
	Disturbance In Attention
	Dizziness
	Dysgeusia

	Headache						
	Hot Flush						
	Impaired Work Ability	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Influenza Like Illness		Wellbutrin Xl				
	Nausea		Glaxosmithkline	PS	Glaxosmithkline	ORAL	150MG ONCE
	Rash						DAILY ORAL
	Tremor						
	Vomiting						

Date:09/07/04ISR Number: 4443023-9Report Type:Expedited (15-DaCompany Report #A-US2004-07003
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Antibody Test Positive	Study	Tracleer (Bosentan)				
Initial or Prolonged	Hepatitis	Health	Tablet	PS			OROPHARINGEAL SEE IMAGE
Other	International Normalised	Professional	Wellbutrin				
	Ratio Increased	Distributor	(Amfebutamone				
	Nephrolithiasis		Hydrochloride)	SS			
			Coumadin (Warfarin				
			Sodium)	C			
			Prinivil				
			(Lisinopril)	C			
			Aspirine				
			(Acetylsalicylic				
			Acid)	C			
			Milk Of Magnesia				
			(Magnesium				
			Hydroxide)	C			

Date:09/07/04ISR Number: 4444753-5Report Type:Direct Company Report #USP 56827
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Medication Error		Wellbutrin Sr	PS	Glaxosmithkline		TABLET,
							EXTENDED

RELEASE

			Wellbutrin Xl	SS	Glaxosmithkline		

TABLET ,

EXTENDED

RELEASE

Date:09/07/04ISR Number: 4447128-8Report Type:Direct Company Report #USP 56822
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr	PS	Glaxosmithkline			

TABLET ,

EXTENDED

RELEASE

			Wellbutrin Xl	SS	Glaxosmithkline		

TABLET,

EXTENDED

RELEASE

Date:09/07/04ISR Number: 4455142-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524551A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Overdose	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON
	Suicide Attempt	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/08/04ISR Number: 4443650-9Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0524692A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysphonia Tobacco Abuse Tremor		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:09/08/04ISR Number: 4443654-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524757A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation Confusional State Disorientation Fall Heart Rate Increased Hypoaesthesia Palpitations Panic Attack Syncope		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	ORAL	300MG Per day	3 MON

Date:09/08/04ISR Number: 4443655-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524762A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nystagmus		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	4 YR
			Seroquel	C				
			Zinc Sulfate	C	Glaxosmithkline			
			Levothyroxine	C	Glaxosmithkline			
			Ursodiol	C				
			Propanolol	C				
			Ranitidine	C	Glaxosmithkline			

Date:09/08/04ISR Number: 4443659-5Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0336823A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Agitation						per day	61 DAY
	Asthenia		No Concurrent					
	Decreased Interest		Medication	C				
	Depressed Mood							
	Suicidal Ideation							

Date:09/08/04ISR Number: 4443665-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0343830A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	3 DAY
Initial or Prolonged	Hyperhidrosis		Vioxx	C		ORAL	12.5MG Per	
	Nausea						day	
	Pain In Extremity		Co-Codamol	C		ORAL		
			Priadel	C	Glaxosmithkline	ORAL	400MG per day	57 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/08/04ISR Number: 4447167-7Report Type:Direct Company Report #CTU 226644
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Migraine		Bupriopion	PS		ORAL	150 MG SA BID	
	Pharmaceutical Product						PO	
	Complaint							

Date:09/09/04ISR Number: 4444865-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0514663A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error	Health	Wellbutrin	PS	Glaxosmithkline			
	Pharmaceutical Product	Professional						
	Complaint							

Date:09/09/04ISR Number: 4444867-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517054A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	2	YR
	Completed Suicide							
	Dissociation							
	Hostility							
	Weight Increased							

Date:09/09/04ISR Number: 4444900-5Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0344183A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psoriasis		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY

			Thyrax	C	Glaxosmithkline	

.1MG per day

Date:09/09/04ISR Number: 4444902-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0344253A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL
150MG per day 2 MON						
	Blister					
	Oedema Peripheral					
	Rash					

Date:09/09/04ISR Number: 4444904-2Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0344335A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL
300MG Per day 5 WK						
	Chills					
	Oedema Mouth					
	Swollen Tongue					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/09/04ISR Number: 4445382-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02318
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Mevacor	PS	Merck & Co., Inc	ORAL		
Other	Alanine Aminotransferase Increased		Tracleer	SS		ORAL		
	Anorexia		Tracleer	SS		ORAL		
			Wellbutrin	SS		UNKNOWN		
	Aspartate Aminotransferase Increased		Aspirine	C		UNKNOWN		
			Prinivil	C		UNKNOWN		
			Magnesia [Milk Of]	C		UNKNOWN		
	Blood Alkaline Phosphatase Increased		Coumadin	C		UNKNOWN		
	Blood Bilirubin Increased							
	Constipation							
	Hepatitis							
	International Normalised Ratio Increased							

Date:09/10/04ISR Number: 4446022-6Report Type:Expedited (15-DaCompany Report #BPC-SR-04-034
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Remeron	C		ORAL		

Date:09/10/04ISR Number: 4446032-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0340981A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcoholic	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 DAY
	Injury	Professional						

			Alcohol	SS		
1 DAY						
			Depo-Provera	C		
INTRAMUSCULAR						

Date:09/10/04ISR Number: 4446045-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0344251A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Mood		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY
	Feeling Abnormal							
	Insomnia							

Date:09/10/04ISR Number: 4448384-2Report Type:Direct Company Report #CTU 226841
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to	Convulsion		Wellbutrin Sr 150 Mg Bid	PS			ORAL BID	1 YR
Prevent Permanent			Strattera 40 Mg	SS		ORAL	ORAL QD	1 MON
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/04ISR Number: 4449716-1Report Type:Direct Company Report #CTU 226935
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity		Wellbutrin Sr 100 Mg	PS		ORAL	ONE PO BID	
	Drug Tolerance Decreased Gastrointestinal Disorder Pharmaceutical Product Complaint							

Date:09/13/04ISR Number: 4449759-8Report Type:Expedited (15-DaCompany Report #HQWYE752701SEP04
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Drug Level Increased Electrocardiogram Qrs Complex Prolonged Medical Device	Literature	Effexor (Venlafaxine Hydrochloride, Unspec)	PS		SEE IMAGE/OVER		
	Complication		Avelox (Moxifloxacin,)	SS		INTRAVENOUS	400 MG ,	4-5 DAYS
			Bupropion (Amfebutamone,)	SS		INTRAVENOUS		SEE IMAGE/OVER 48 HOURS
			Carvedilol (Carvedilol,)	SS			3.125 MG 2X	PER 1 DAY
			Vancomycin (Vancomycin)	C				
			Aspirin					

(Acetylsalicylic Acid)	C	
Furosemide (Furosemide)	C	
Spironolactone (Spironolactone)	C	
Milrinone (Milrinone)	C	
Clonazepam (Clonazepam)	C	
Calcium (Calcium)	C	
Multivitamins (Ascorbic Acid/Ergocalciferol/ Folic Acid/Nicotinamide/Pa	C	

Date:09/15/04ISR Number: 4449918-4Report Type:Expedited (15-DaCompany Report #BPC-SR-04-034
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Discomfort	Health	Wellbutrin Sr	PS	Glaxosmithkline	ORAL	17	DAY
	Dyspnoea	Professional	Remeron	C		ORAL	30MG	Per day
	Myocardial Infarction							
	Pain In Jaw							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/04ISR Number: 4449925-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0525433A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Suicidal Ideation						per day	5 YR
			Paxil	C	Glaxosmithkline			
			Elavil	C	Glaxosmithkline			
			Klonopin	C				

Date:09/15/04ISR Number: 4449935-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0343937A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	WK
Hospitalization - Initial or Prolonged	Bradyphrenia	Professional	Levothyrox	C	Glaxosmithkline			
Disability	Cerebral Infarction		Tenormine	C		ORAL		
	Cerebrovascular Accident		Mopral	C				
	Coma		Female Hormones	C				
	Confusional State							
	Disturbance In Attention							
	Headache							
	Hemiparesis							
	Hemiplegia							
	Hypertension							
	Hypertensive Crisis							
	Hypertriglyceridaemia							

Date:09/15/04ISR Number: 4449937-8Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0344111A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Hallucination, Auditory	Professional					per day	5 DAY

	Hallucination, Visual		Epilim	C		
500MG Twice						
	Sensation Of Pressure					
per day						

Date:09/15/04ISR Number: 4449938-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0344204A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event	Consumer	Zyban	PS	Glaxosmithkline	ORAL
1TAB Unknown						
Initial or Prolonged	Aggression		Valium	SS		
	Amnesia		Warfarin	SS	Glaxosmithkline	
	Mental Disorder		Tritace	SS		
	Overdose		Panadeine Forte	SS	Glaxosmithkline	
	Suicide Attempt					

Date:09/15/04ISR Number: 4449941-XReport Type:Expedited (15-DaCompany Report #PT-GLAXOSMITHKLINE-B0344722A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL
Initial or Prolonged	Pruritus					
	Pyrexia					
	Rash Generalised					
	Skin Lesion					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/04ISR Number: 4449943-3Report Type:Expedited (15-DaCompany Report #IL-GLAXOSMITHKLINE-B0344959A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Zyban	PS	Glaxosmithkline	UNKNOWN	UNKNOWN	2 WK
	Feeling Abnormal		Aspirin	C	Glaxosmithkline	UNKNOWN		
			Simvastatin	C		UNKNOWN		
			Tritace	C		UNKNOWN		
			Vitamin B12 + B6	C		UNKNOWN		

Date:09/15/04ISR Number: 4451843-XReport Type:Direct Company Report #CTU 227110
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Effexor 75 Mg	PS		ORAL	75 MG DAILY	
	Diarrhoea					ORAL		
	Headache		Wellbutrin 100 Mg	SS		ORAL	200 MG DAILY	
	Nausea					ORAL		
	Night Sweats							
	Pyrexia							
	Vomiting							

Date:09/16/04ISR Number: 4451321-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0525619A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Strattera	C				

Date:09/16/04ISR Number: 4451322-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0525720A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Mouth Injury							
	Muscle Twitching							
	Vomiting							

Date:09/16/04ISR Number: 4451339-5Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0345167A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine		Zyban	PS	Glaxosmithkline	ORAL	50TAB per day	
	Increased							
	Convulsion							
	Gait Disturbance							
	Hallucination							
	Memory Impairment							
	Mydriasis							
	Myoglobin Blood Increased							
	Overdose							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/16/04ISR Number: 4451340-1Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0345169A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Confusional State Convulsion Dysarthria Hallucination Hypertension Overdose Somnolence Tachycardia		Zyban	PS	Glaxosmithkline	ORAL	80TAB per day	

Date:09/16/04ISR Number: 4453046-1Report Type:Direct Company Report #CTU 227348
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Fatigue Heart Rate Increased Hypoventilation Insomnia Pharmaceutical Product Complaint		Bupropion Sr Equiv. Of 150 Mg Wellbutrin Sr - Teva Laboratories	PS	Teva Laboratories	ORAL	150 MG TWICE DAILY ORAL	

Date:09/16/04ISR Number: 4454308-4Report Type:Direct Company Report #CTU 227395
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour Agitation Completed Suicide Hostility Insomnia Irritability		Welbutrin	PS				

Date:09/17/04ISR Number: 4454421-1Report Type:Direct Company Report #CTU 227416
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr 150	PS		ORAL	150 MG TID BY MOUTH	

Date:09/17/04ISR Number: 4454536-8Report Type:Direct Company Report #CTU 227489
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying		Bupropion Hcl Sustained-Release Tablets 100 Mg	PS	Mfd By Watson (Imprint "Wpi, 858")		300 MG DAILY	
	Feeling Abnormal							
	Hallucination, Visual							
	Mood Altered							
	Pharmaceutical Product						AS 1 TID	1 WK
	Complaint		Allegra	C				
	Suicidal Ideation		Albuterol	C				
	Tearfulness		Advair	C				
	Thinking Abnormal		Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/17/04ISR Number: 4458216-4Report Type:Periodic Company Report #US-JNJFOC-20040304012
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombocytopenia	Health Professional	Topamax (Topiramate) Unspecified	PS			300 MG, IN 1	DAY
			Wellbutrin (Bupropion Hydrochloride)	SS			200 MG, 2 IN	1 DAY
			Lexapro (All Other Therapeutics Products)	SS			20 MG, IN 1	DAY

Date:09/20/04ISR Number: 4453953-XReport Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0525756A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	44 DAY
	Drug Ineffective Ill-Defined Disorder		Rivotril (Clonazepam)	C				

Date:09/20/04ISR Number: 4453954-1Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0525758A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Alcoholism		Zyban	PS	Glaxosmithkline	ORAL		

Date:09/20/04ISR Number: 4453971-1Report Type:Expedited (15-DaCompany Report #PT-GLAXOSMITHKLINE-B0344722A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Zyban	PS	Glaxosmithkline	ORAL	15	DAY
Initial or Prolonged	Bronchospasm	Professional						
	Oedema Peripheral							
	Pyrexia							
	Skin Lesion							
	Urticaria							

Date:09/20/04ISR Number: 4453985-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0345610A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradyphrenia		Zyban	PS	Glaxosmithkline		UNKNOWN	2TAB per day
	Dizziness		No Concurrent					
	Syncope		Medication	C				
	Vision Blurred							

Date:09/20/04ISR Number: 4454746-XReport Type:Direct Company Report #CTU 227557
Age:27 YR Gender:Female I/FU:I

Outcome	PT
Other	Condition Aggravated
	Depression

	Drug Effect Decreased Medication Error Pharmaceutical Product	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Complaint Somnolence		Budeprion 150 Mg Teva	PS	Teva	ORAL	150 MG 2 TIMES ORAL

Date:09/20/04ISR Number: 4454769-0Report Type:Expedited (15-DaCompany Report #2004UW19220
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign Health Professional Other	Crestor Wellbutrin	PS SS		ORAL	10 MG DAILY PO

Date:09/21/04ISR Number: 4454868-3Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0526395A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Glaucoma		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day

Date:09/21/04ISR Number: 4457315-0Report Type:Expedited (15-DaCompany Report #B0344156A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Anhedonia Anxiety Asthenia	Foreign Health Professional	Zyban-Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/SEE

	Drug Dependence						
DOSAGE							
	Euphoric Mood						
TEXT/ORAL							
	Excitability			Bromazepam	C		
	Formication						
	Intentional Misuse						
	Malaise						
	Medication Error						
	Morbid Thoughts						
	Pallor						
	Transaminases Increased						

Date:09/21/04ISR Number: 4457395-2Report Type:Expedited (15-DaCompany Report #B0312762A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Agitation	Foreign	Zyban Tablet-Zyban					
Hospitalization -	Anxiety		(Bupropion					
Initial or Prolonged	Insomnia		Hydrochloride)	PS		ORAL	150 MG/	ORAL
	Overdose							
	Suicidal Ideation							
	Suicide Attempt							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/04ISR Number: 4457474-XReport Type:Expedited (15-DaCompany Report #A0525434A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/PER	DAY/ORAL
	Balance Disorder							
	Cerebrovascular Accident							
	Dysphemia							
	Hallucination, Visual							
			Lansoprazole	C				
			Oestradiol	C				
			Thyroxine Sodium	C				
			Hydrochlorothiazide	C				

Date:09/21/04ISR Number: 4457477-5Report Type:Expedited (15-DaCompany Report #A0525250A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Crying	Health Professional	Wellbutrin Xl Tablets-Extended Release (Bupropion Hydrochloride)	PS		ORAL	PER DAY	/ORAL
	Impaired Driving Ability							
	Vision Blurred							
			Aripiprazole	C				
			Oxcarbazepine	C				

Date:09/21/04ISR Number: 4457486-6Report Type:Expedited (15-DaCompany Report #A0519334A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Bupropion Hydrochloride Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER	DAY/ ORAL
	Depression							
	Muscular Weakness							
	Myalgia							
	Pharmaceutical Product							
	Complaint							

Suicidal Ideation	Paroxetine Hydrochloride	C
	Topiramate	C
	Ramipril	C
	Simvastatin	C

Date:09/22/04ISR Number: 4455959-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526418A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Foreign Body Trauma		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:09/22/04ISR Number: 4457195-3Report Type:Expedited (15-DaCompany Report #S04-USA-04018-01
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Other	Alopecia
Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Fluctuation
	Erectile Dysfunction
	Exostosis

		Fracture Hypertension Joint Dislocation	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Nausea Somnolence	Consumer	Lexapro (Escitalopram)	PS		ORAL	10 MG QD PO
				Lotrel	SS			
				Clonidine	SS			0.2 MG BID
				Amiloride W/Hydrochlorothiazide	SS			
				Percocet	SS			
				Percocet	SS			
				Wellbutrin - Slow Release (Bupropion Hydrochloride)	SS			150 MG
				Trazodone	C			
				Nexium (Esomeprazole)	C			
				Bextra (Valdecoxib)	C			
				Carisoprodol	C			

Date:09/23/04ISR Number: 4456996-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526711A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Feeling Abnormal Overdose		Wellbutrin Xanax	PS SS	Glaxosmithkline	ORAL	

Date:09/23/04ISR Number: 4456997-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526785A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion Depressed Level Of Consciousness		Wellbutrin	PS	Glaxosmithkline	ORAL	

Date:09/23/04ISR Number: 4457001-7Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0318010A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression	Health	Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice	
Initial or Prolonged	Agitation	Professional					per day	5 DAY
Other	Blood Pressure Increased							
	Depression							
	Dizziness							
	Feeling Abnormal							
	Headache							
	Pharmaceutical Product Complaint							

Date:09/23/04ISR Number: 4457004-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0333110A
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arteritis
Initial or Prolonged	Blood Pressure Systolic Increased

	Coronary Artery Stenosis Myocardial Infarction Pain In Extremity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 6 DAY

Date:09/23/04ISR Number: 4457025-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0345694A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Asthma		Zyban	PS	Glaxosmithkline	ORAL	150MG per day 3 DAY
	Wheezing		Salbutamol	C	Glaxosmithkline		100MCG per day
			Seretide	C	Glaxosmithkline		250MCG Per day

Date:09/23/04ISR Number: 4457029-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0346004A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Diabetes Mellitus		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 7 DAY
Initial or Prolonged	Inadequate Control		Crestor	C		ORAL	
	Myocardial Infarction		Diamicron	C		ORAL	205MG Three times per day

Date:09/23/04ISR Number: 4457794-9Report Type:Direct Company Report #USP 56844
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Medication Error		Wellbutrin Sr	PS	Glaxosmith Kline		
TABLET, EXTENDED RELEASE							
			Bupropion	SS	Watson		
TABLET, EXTENDED RELEASE							
			Budeprion Sr	SS	Teva		
TABLET, EXTENDED RELEASE							
			Bupropion	SS	Eon Labs		
TABLET, EXTENDED RELEASE							
			Wellbutrin Xl	SS	Glaxosmithkline		
TABLET, EXTENDED RELEASE							

Date:09/23/04ISR Number: 4457797-4Report Type:Direct Company Report #USP 56843
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Bupropion (Generic For Zyban)	PS	Watson/Ndc # 0591-0867-60			
TABLET								
			Bupropion (Generic For Wellbutrin Sr)	SS	Watson / Ndc # 0591-0839-60			
TABLET								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/23/04ISR Number: 4457965-1Report Type:Direct Company Report #USP 56873
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Bupropion Xr	PS				
			Bupropion Sr	SS				

Date:09/23/04ISR Number: 4459838-7Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040903575
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression	Literature	Acetaminophen					
Other	Agitation	Health	(Acetaminophen)					
	Atrioventricular Block	Professional	Unspecified	PS		ORAL	ORAL	
	Blood Creatine Phosphokinase Increased		Bupropion (Long-Actng)					
	Blood Creatine		(Bupropion)	SS		ORAL	ORAL	
	Phosphokinase Mb Increased		Aspirin (Acetylsalicylic					
	Blood Glucose Increased		Acid)	SS		ORAL	ORAL	
	Bradycardia		Caffeine (Caffeine)	SS		ORAL	ORAL	
	Cardiac Arrest		Fluoxetine					
	Convulsion		(Fluoxetine)	SS		ORAL	ORAL	
	Electrocardiogram Qrs Complex Prolonged		Valproic Acid (Valproic Acid)	SS		ORAL	ORAL	
	Incoherent		Sertraline					
	Multiple Drug Overdose		(Sertraline)	SS		ORAL	ORAL	
	Muscle Rigidity							
	Po2 Increased							
	Pyrexia							
	Ventricular Arrhythmia							
	Ventricular Extrasystoles							

Date:09/23/04ISR Number: 4459969-1Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040903508
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Literature	Acetaminophen					
	Coma	Health	(Acetaminophen)					
	Completed Suicide	Professional	Unspecified	PS		ORAL	ORAL	
	Convulsion		Aspirin					
	Haematemesis		(Acetylsalicylic					
	Heart Rate Increased		Acid)	SS		ORAL	ORAL	
	Multiple Drug Overdose		Bupropion					
	Respiratory Rate		(Bupropion)	SS		ORAL	ORAL	
	Increased		Ethanol (Ethanol)	SS		ORAL	ORAL	

Date:09/24/04ISR Number: 4458117-1Report Type:Expedited (15-DaCompany Report #2004-03238
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Wellbutrin Sr	PS	Glaxosmithkline		150MG Per day	10 YR
	Depressed Level Of		Bupropion					
	Consciousness		Hydrochloride	SS	Glaxosmithkline	ORAL	150MG Twice	
	Disturbance In Attention						per day	DAY
	Motor Dysfunction		Lithium	C	Glaxosmithkline	ORAL	10 YR	
	Pharmaceutical Product							
	Complaint							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/04ISR Number: 4458122-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526801A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
	Asthenia							
	Choking							
	Distractibility							
	Early Morning Awakening							
	Insomnia							
	Lethargy							
	Memory Impairment							
	Muscle Tightness							
	Nausea							
	Sleep Disorder							
	Speech Disorder							
	Tinnitus							
	Tongue Paralysis							
	Tremor							
	Vision Blurred							
	Weight Decreased							

Date:09/24/04ISR Number: 4458131-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0338492A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG	See dosage text
	Arthralgia	Professional						
	Asthenia							
	Blood Immunoglobulin E Increased							
	Cough							
	Dysphagia							
	Dyspnoea							
	Insomnia							
	Joint Swelling							
	Oesophageal Spasm							
	Pruritus							
	Serum Sickness							
	Urticaria Generalised							

Date:09/24/04ISR Number: 4458133-XReport Type:Expedited (15-DaCompany Report #IE-GLAXOSMITHKLINE-B0342939A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Consumer	Zyban	PS	Glaxosmithkline	ORAL		
	Death		Alcohol	SS				

Date:09/24/04ISR Number: 4458139-0Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0345594A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Electrocardiogram Qrs	Consumer	Zyntabac	PS	Glaxosmithkline	ORAL	300MG Per day	25 DAY
Initial or Prolonged	Complex Shortened		Vioxx	C			25MG Per day	
Other	Tachycardia		Atrovent	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/04ISR Number: 4461698-5Report Type:Direct Company Report #CTU 227996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin Xl 150 Mg	PS		ORAL	150 MG Q AM	Initial or Prolonged
			Prozac	C				
			Vistaril	C				
			Depakote Er	C				

Date:09/27/04ISR Number: 4459400-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0517054A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	2 YR	
	Anxiety							
	Completed Suicide							
	Condition Aggravated							
	Dissociation							
	Gun Shot Wound							
	Head Injury							
	Hostility							
	Insomnia							
	Irritability							
	Weight Increased							

Date:09/27/04ISR Number: 4459407-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526854A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lung Neoplasm		Wellbutrin	PS	Glaxosmithkline			
	Rash		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	
			Ethambutol	SS	Glaxosmithkline			
			Isoniazid	SS	Glaxosmithkline			
			Pyrazinamide	SS				
			Vitamin B6	C				

Date:09/27/04ISR Number: 4459408-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526859A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Wellbutrin Sr	SS	Glaxosmithkline			

Date:09/27/04ISR Number: 4459409-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526881A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	

Date:09/27/04ISR Number: 4459413-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0527124A
Age: Gender:Male I/FU:I

Outcome	PT
Other	Accident At Work
	Amnesia

	Convulsion Road Traffic Accident						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxosmithkline	ORAL	
			No Concurrent Medication	C			

Date:09/27/04ISR Number: 4459436-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0345641A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dry Mouth Facial Spasm Rash Generalised		Zyban No Concurrent Medication	PS C	Glaxosmithkline	ORAL	1TAB Per day 5 DAY

Date:09/27/04ISR Number: 4462106-0Report Type:Direct Company Report #CTU 228068
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Depression Disease Recurrence Pharmaceutical Product Complaint		Buproprion Sr - Watson	PS	Watson		

Date:09/27/04ISR Number: 4462134-5Report Type:Direct Company Report #CTU 228090
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion		Welbutrin Xl 150mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	450MG QD ORAL

Date:09/28/04ISR Number: 4460476-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524011A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Serevent	PS	Glaxosmithkline			
RESPIRATORY								
	Dyspnoea							
(INHALATION)							1	MON
			Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:09/28/04ISR Number: 4461278-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406391A
Age: Gender:Male I/FU:F

Outcome	PT
Other	Acquired Porphyria
	Aggression
	Agitation
	Akathisia
	Allergy To Chemicals
	Amnesia
	Arthralgia
	Asthenia
	Bipolar Disorder
	Contrast Media Reaction
	Convulsion
	Coordination Abnormal

		Crying						
		Depression						
		Depression Suicidal	Report Source	Product	Role	Manufacturer	Route	Dose
Duration								
		Disability		Wellbutrin	PS	Glaxosmithkline	ORAL	42
DAY								
		Dizziness		Tranquilizer	SS			
		Dysarthria		Depakote	SS			
		Dysphemia		Zyprexa	SS			
		Dyspnoea		Alcohol	C			
		Electric Shock						
		Encephalopathy						
		Facial Palsy						
		Fatigue						
		Feeling Abnormal						
		Head Banging						
		Headache						
		Hyperaesthesia						
		Hypersensitivity						
		Hypoxia						
		Immune System Disorder						
		Injury						
		Insomnia						
		Intentional Self-Injury						
		Mania						
		Mastocytosis						
		Metabolic Encephalopathy						
		Muscle Spasms						
		Myalgia						
		Myoclonus						
		Nervous System Disorder						
		Nightmare						
		Overdose						
		Pain Of Skin						
		Petit Mal Epilepsy						
		Suicidal Ideation						
		Suicide Attempt						
		Temperature Regulation						
		Disorder						
		Throat Tightness						
		Tremor						
		Vestibular Disorder						
		Vomiting						

Date:09/28/04ISR Number: 4461286-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526572A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	3	YR
	Euphoric Mood							
	Formication							
	Imprisonment							
	Loss Of Employment							
	Mania							
	Memory Impairment							
	Muscle Twitching							
	Personality Change							
	Restlessness							
	Suicidal Ideation							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/28/04ISR Number: 4463377-7Report Type:Expedited (15-DaCompany Report #A0525788A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger	Consumer	Wellbutrin Tablet-Zyban (Bupropion Hydrochloride)	PS			1 TABLET/PER	DAY
	Depression							
	Feeling Abnormal							
	Headache							
	Homicidal Ideation							
	Memory Impairment		Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	SS		ORAL	150 MG/PER	DAY/ORAL
	Oral Intake Reduced							

Date:09/28/04ISR Number: 4463388-1Report Type:Expedited (15-DaCompany Report #A0524358A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Consumer	Bupropion Hydrochloride Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ PER	DAY/ ORAL
	Loss Of Consciousness							
	Syncope							
	Vomiting							
			Atenolol	C				

Date:09/28/04ISR Number: 4463391-1Report Type:Expedited (15-DaCompany Report #A0525776A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse	Consumer	Wellbutrin Xl Tablet-Extended Release (Bupropion					
	Suicide Attempt							

			Hydrochloride)	PS		ORAL
300 MG/ ORAL						
			Amitriptyline (Formulation Unknown) (Amitriptyline)	SS		

Date:09/28/04ISR Number: 4463553-3Report Type:Expedited (15-DaCompany Report #B0345474A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angioneurotic Oedema	Foreign	Zyban Tablet-Zyban			
	Skin Reaction	Health Professional	(Bupropion Hydrochloride)	PS		ORAL
ORAL						

Date:09/28/04ISR Number: 4465181-2Report Type:Direct Company Report #CTU 228208
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Affect Lability		Wellbutrin Sr 150 Mg	PS		
THREE TIMES A DAY	Drug Ineffective					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/04ISR Number: 4462243-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0410501A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See	
	Chest Pain						dosage text	
	Dyspepsia		Gaviscon	C	Glaxosmithkline			
	Dysphagia		Black Cohosh	C	Glaxosmithkline			
	Gastric Disorder		Echinacea	C				
	Gastrooesophageal Reflux Disease		Aloe Vera	C				
			Tylenol Arthritis	C	Glaxosmithkline			
	Nasopharyngeal Disorder		Calcium	C				
			Aspirin	C	Glaxosmithkline			
			Amitriptyline	C				
			Ginger Root	C				
			Acidophilus	C				
			Hawthorn Berry	C				
			Kava-Kava	C				

Date:09/29/04ISR Number: 4462252-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0527512A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	MON
	Anger							
	Depression							
	Eating Disorder							
	Feeling Hot							
	Hyperhidrosis							
	Insomnia							
	Nervousness							
	Panic Attack							
	Restlessness							
	Suicidal Ideation							

Date:09/29/04ISR Number: 4462259-4Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0336854A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Generalised Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Initial or Prolonged	Nephrotic Syndrome							
per day							24	DAY
Other	Renal Failure		Nexen	SS	Glaxosmithkline	ORAL	100MG Twice	
	Weight Increased							
per day							14	DAY

Date:09/29/04ISR Number: 4462261-2Report Type:Expedited (15-DaCompany Report #IE-GLAXOSMITHKLINE-B0342939A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Zyban	PS	Glaxosmithkline	ORAL		
			Alcohol	SS				

Date:09/29/04ISR Number: 4464122-1Report Type:Direct Company Report #CTU 228288
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Effect Decreased		Bupropion Xl 150mg					
	Pharmaceutical Product		?	PS		ORAL	1 BID ORAL	
	Complaint		Buproprion Xl	SS		ORAL	3 QAM ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/04ISR Number: 4465736-5Report Type:Direct Company Report #CTU 228328
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Withdrawal Syndrome		Wellbutrin 150 Mg					
	Migraine		-100mg	PS		ORAL		
SEE IMAGE								

Date:09/30/04ISR Number: 4463232-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506106A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Feeling Abnormal		Wellbutrin	SS	Glaxosmithkline			
150MG Per day								
	Libido Disorder		Paxil Cr	SS	Glaxosmithkline			
12.5MG See								
	Medication Error							
dosage text								
	Nausea		Xanax	SS				
	Nightmare		Lexapro	SS				
	Smoker		Seroquel	C				
			Advair	C	Glaxosmithkline			
			Albuterol	C	Glaxosmithkline			

Date:09/30/04ISR Number: 4463234-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524499A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
100MG Per day	2 WK							
	Headache	Professional	No Concurrent					
	Psychiatric Symptom		Medication	C				
	Suicidal Ideation							

Date:09/30/04ISR Number: 4463242-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0338426A
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Agitation
Other	Alanine Aminotransferase Increased
	Anorexia
	Anxiety
	Aspartate Aminotransferase Increased
	Asthenia
	Autoimmune Hepatitis
	Blood Alkaline Phosphatase Increased
	C-Reactive Protein Increased
	Fatigue
	Gamma-Glutamyltransferase Increased
	Liver Function Test Abnormal
	Malaise
	Myalgia
	Nausea
	Red Blood Cell Sedimentation Rate

Increased

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
150MG Twice per day	36 DAY	Health Professional	Zyban	PS	Glaxosmithkline	ORAL
50MG per day			Zoloft	SS		ORAL
300MG Three times per day	4 DAY		Neurontin	C		ORAL
250MG per day	53 DAY		Seroquel	C		ORAL
2U per day			Prednisolone	C	Glaxosmithkline	
40MG per day			Slow Potassium	C		
2U At night			Cipramil	C		
2U At night			Zolpidem	C		
25MG per day			Caltrate	C	Glaxosmithkline	
			Imuran	C	Glaxosmithkline	

Date:10/01/04ISR Number: 4464186-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0525619A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day	2 MON					
			Strattera	C		

Date:10/01/04ISR Number: 4464188-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0525720A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 4 DAY						
	Grip Strength Decreased					
	Mouth Injury					
	Muscle Twitching					
	Tremor					
	Vomiting					

Date:10/01/04ISR Number: 4464189-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0525978A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abortion Spontaneous		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Per day						
	Vaginal Haemorrhage		Glimepiride + Rosiglitazone	SS	Glaxosmithkline	ORAL
176 DAY						
			Effexor Xr	SS		
225MG Per day						
			Vitamin C	C	Glaxosmithkline	

Date:10/01/04ISR Number: 4464194-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0527277A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Zyban	PS	Glaxosmithkline	
UNKNOWN 150MG Twice						
per day						
			No Concurrent Medication	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4464195-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0527304A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Pain In Extremity		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK

Date:10/01/04ISR Number: 4464196-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0527318A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Apathy Drug Ineffective Overdose Pharmaceutical Product Complaint Sleep Disorder Stool Analysis Abnormal Suicide Attempt Thinking Abnormal		Wellbutrin Zoloft Trileptal	PS SS SS	Glaxosmithkline	ORAL	450MG Per day	4 MON

Date:10/01/04ISR Number: 4464217-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0345688A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Eye Rolling Loss Of Consciousness Masked Facies Road Traffic Accident Staring		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 DAY

Date:10/01/04ISR Number: 4464218-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0345690A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Circulatory Collapse							
	Disability							
	Dizziness							
	Vomiting							

Date:10/01/04ISR Number: 4464225-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0346164A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	4 WK
	Depression							
	Disturbance In Attention							
	Hallucination							
	Personality Change							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4464227-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0346382A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Grand Mal Convulsion		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	11 WK

Date:10/01/04ISR Number: 4464231-7Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0346671A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Dehydration Fatigue Feeling Abnormal Syncope		Zyban	PS	Glaxosmithkline			

Date:10/01/04ISR Number: 4464241-XReport Type:Expedited (15-DaCompany Report #US-JNJFOC-20040908652
Age:32 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Topamax	PS		OROPHARINGEAL		
	Completed Suicide		Bupropion	SS		OROPHARINGEAL		
	Overdose		Venlafaxine	SS				

Date:10/01/04ISR Number: 4464243-3Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040908721
Age:20 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Topamax	PS		OROPHARINGEAL		
	Intentional Misuse		Valproic Acid	SS		OROPHARINGEAL		

			Bupropion	SS		

OROPHARINGEAL

Date:10/04/04ISR Number: 4465049-1Report Type:Expedited (15-DaCompany Report #PHBS2004US12809
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Cardiac Failure		Metoprolol	PS	Novartis Sector: Pharma		75 mg, BID	
	Congestive		Bupropion	SS			150 mg, BID	
	Drug Interaction		Diltiazem	C			240 mg, BID	
	Dyspnoea Fatigue Heart Rate Decreased Pitting Oedema Pulmonary Hilum Mass Pulmonary Vascular Disorder Respiratory Rate Increased Sinus Bradycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4465403-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511243A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Other	Wellbutrin Sr	PS	Glaxosmithkline		150MG See	
	Decreased Appetite						dosage text	
	Depressed Mood							
	Disturbance In Attention							
	Feelings Of Worthlessness							
	Gun Shot Wound							
	Major Depression							
	Sleep Disorder							
	Social Avoidant Behaviour							
	Suicidal Ideation							
	Treatment Noncompliance							
	Tremor							

Date:10/04/04ISR Number: 4465417-8Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0528067A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Overdose		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	1800MG Single	
	Paraesthesia						dose	

Date:10/04/04ISR Number: 4465426-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0343398A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Multi-Organ Failure	Professional					per day	
			Thyroxine	C	Glaxosmithkline			
			Hormone Replacement Therapy	C				
			Amlodipine	C				

Date:10/04/04ISR Number: 4465442-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0346880A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Stent Occlusion		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:10/04/04ISR Number: 4467068-8Report Type:Direct Company Report #CTU 228724
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion Medication Error		Wellbutrin Xl 300 Mg Glaxo Smithkline	PS	Glaxo Smithkline	ORAL	300 MG PO	

Date:10/05/04ISR Number: 4466311-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520112A
Age:40 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization - Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	364 DAY	
	Arthralgia	Professional	Prednisone	C		ORAL		
	Arthropathy		Nexium	C		ORAL		
	Aura		Remicade	C		INTRAVENOUS		
	Brachial Plexus Injury		Klonopin	C		ORAL		
	Electroencephalogram Abnormal		Advair	C	Glaxosmithkline	RESPIRATORY (INHALATION)		
	Grand Mal Convulsion		Methotrexate	C		ORAL	15MG Weekly	
	Joint Dislocation		Lovenox	C		SUBCUTANEOUS	80MG Twice per day	28 DAY
	Neck Pain							
	Nuclear Magnetic Resonance Imaging Brain		Multivitamin	C				
			Synvisc	C		INTRAVENOUS		
	Abnormal		Synvisc	C		INTRAVENOUS		
	Ovarian Cyst		Iron	C		INTRAVENOUS		
	Paraesthesia		Flu Vaccine	C	Glaxosmithkline			
	Retinopathy		Lovenox	C				
			Coumadin	C	Glaxosmithkline			
			Fragmin	C			12 DAY	
			Bipap	C				

Date:10/05/04ISR Number: 4466314-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0527585A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Intentional Misuse		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Vomiting		Simvastatin	C				

Date:10/05/04ISR Number: 4466319-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0528132A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	6 MON
Initial or Prolonged	Fall		Ritalin	C				
	Laceration		Lithium	C	Glaxosmithkline			

Date:10/05/04ISR Number: 4466320-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0528136A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Per day	18 MON
Initial or Prolonged	Difficulty In Walking							
	Eating Disorder							
	Headache							
	Speech Disorder							
	Suicidal Ideation							

Date:10/05/04ISR Number: 4466324-7Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0528437A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467295-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0345690A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Circulatory Collapse							
	Disability							
	Dizziness							
	Vomiting							

Date:10/06/04ISR Number: 4467305-XReport Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0346847A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Extrapyramidal Disorder		Zyban	PS	Glaxosmithkline		UNKNOWN	
Initial or Prolonged	Overdose							
	Suicide Attempt							

Date:10/06/04ISR Number: 4467311-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0347143A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Induced		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Drug Exposure During Pregnancy							
	Drug Ineffective							

Date:10/06/04ISR Number: 4467312-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0347143B
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chromosome Abnormality		Zyban	PS	Glaxosmithkline		150MG Per day	1 MON
Congenital Anomaly	Congenital Hand							

	Malformation
	Diaphragmatic Hernia
	Foetal Growth Retardation
	Foetal Malformation
	Gastrointestinal Disorder

Date:10/06/04ISR Number: 4467313-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0347195A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Ischaemia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Completed Suicide						per day	34 DAY
	Injury Asphyxiation		Novonorm	C				
			Actos	C				
			Mediator	C				
			Aspegic	C				

Date:10/06/04ISR Number: 4470677-3Report Type:Direct Company Report #CTU 228999
Age:47 YR Gender:Male I/FU:I

Outcome	PT
Other	Feeling Abnormal
	Headache
	Heart Rate Increased

	Pharmaceutical Product Complaint					
	Sedation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Bupropion Hcl 150sr Watson Pharmaceuticals	PS	Watson Pharmaceuticals	
1	DAILY					

Date:10/06/04ISR Number: 4470826-7Report Type:Direct Company Report #CTU 228983
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Drug Ineffective		Paxil 20 To 40 To 20mg Smj	PS	Smj	
TRANSPLACE						
			Welbutrin 150mg Glw	SS	Glw	

Date:10/07/04ISR Number: 4468365-2Report Type:Expedited (15-DaCompany Report #A03200400600
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Suicide Attempt	Health	Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Per day						
Hospitalization -		Professional	Ambien	SS		ORAL
5MG See Initial or Prolonged dosage text	9 DAY					
Other			Paroxetine Hydrochloride	C	Glaxosmithkline	ORAL
4	DAY					

Date:10/07/04ISR Number: 4468372-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0528477A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Renal Failure		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:10/07/04ISR Number: 4468373-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0528565A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephrolithiasis		Wellbutrin	PS	Glaxosmithkline	ORAL		YR
	Renal Neoplasm							

Date:10/07/04ISR Number: 4468374-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0528776A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	225MG Per day	
	Major Depression							
	Polyuria							

Date:10/07/04ISR Number: 4468376-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0528781A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pelvic Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Urinary Incontinence		Hytrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468392-5Report Type:Expedited (15-DaCompany Report #2004016942
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Skin Discolouration		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG per day
			Lamictal	SS	Glaxosmithkline	ORAL	100MG per day

Date:10/07/04ISR Number: 4473175-6Report Type:Direct Company Report #USP 56898
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Medication Error		Wellbutrin	PS	Eon		TABLET, EXTENDED RELEASE

Date:10/08/04ISR Number: 4469806-7Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0528431A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	55 DAY
	Loss Of Consciousness		Sedative	C		ORAL	

Date:10/08/04ISR Number: 4469811-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0344204A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Adverse Event	Health Professional	Zyban	PS	Glaxosmithkline	ORAL	9 DAY
	Aggression		Valium	SS			
	Agitation		Warfarin	SS	Glaxosmithkline		
	Amnesia		Tritace	SS			

	Hostility		Panadeine Forte	SS	Glaxosmithkline	
	Irritability					
	Mental Disorder					
	Overdose					
	Self-Medication					
	Suicide Attempt					

Date:10/08/04ISR Number: 4469815-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0345688A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Eye Rolling		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Loss Of Consciousness							
per day							9	DAY
	Road Traffic Accident							
	Staring							

Date:10/08/04ISR Number: 4469818-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0346989A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Swelling Face							
dosage text							15	DAY
	Urticaria							
	Wheezing							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4469823-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0347372A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia		Zyban	PS	Glaxosmithkline		150MG	Unknown
	Iiird Nerve Paralysis							
	Nystagmus							

Date:10/08/04ISR Number: 4471120-0Report Type:Expedited (15-DaCompany Report #2004S1002873
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse	Consumer	Wellbutrin Xl Tablet Extended Release 300 Mg	PS	Glaxosmithkline	ORAL	300MG, ORAL	
Other	Suicide Attempt	Other						

Date:10/11/04ISR Number: 4471020-6Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0525978A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous	Health	Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Per day
	Vaginal Haemorrhage	Professional	Glimepiride + Rosiglitazone	SS	Glaxosmithkline	ORAL	177	DAY
			Effexor Xr	SS		ORAL	225MG	Per day
			Vitamin C	C	Glaxosmithkline			

Date:10/11/04ISR Number: 4471022-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0528860A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		200MG	per day

Date:10/11/04ISR Number: 4471046-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0346993A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chromaturia		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 1 MON
	Pruritus							

Date:10/11/04ISR Number: 4471053-XReport Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0347371A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline		UNKNOWN	2 DAY
	Crying							
	Delusion							
	Dry Mouth							

Date:10/12/04ISR Number: 4471574-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0529360A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fracture		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471600-8Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0347567A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Respiratory Disorder Urticaria		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:10/12/04ISR Number: 4472878-7Report Type:Direct Company Report #CTU 229280
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Drug Ineffective Nausea		Prozac Wellbutrin	PS SS				

Date:10/13/04ISR Number: 4472803-9Report Type:Expedited (15-DaCompany Report #200416846US
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased Blood Urea Increased Hallucination, Visual Hyperkinesia Restlessness	Consumer	Ketek Wellbutrin Metoprolol Ssri Baby Aspirin	PS SS C C C	Aventis Pharmaceuticals Inc.	ORAL	dose: NOT PROVIDED dose: NOT PROVIDED dose: NOT PROVIDED dose: NOT PROVIDED	

				Allopurinol	C		
dose: NOT PROVIDED							
				Hydrochlorothiazide	C		
dose: NOT PROVIDED							
				Lasix	C		
dose: NOT PROVIDED							
				Potassium Chloride	C		
dose: NOT PROVIDED							
				Voltaren	C		
dose: NOT PROVIDED							
				Aceon	C		
dose: NOT PROVIDED							
				Hydrocodone	C		
dose: NOT PROVIDED							
				Calcium	C		
dose: NOT PROVIDED							
				Multivitamins, Plain	C		
dose: NOT PROVIDED							
				Coumadine	C		
dose: 6-7							
				Detrol	C		
dose: NOT PROVIDED							

Date:10/13/04ISR Number: 4473037-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521769A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	18 DAY
	Muscle Tightness							

Paraesthesia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4473044-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0529354A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Wellbutrin Sr	PS	Glaxosmithkline		150MG Twice	
	Glaucoma						per day	YR
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	
			Zoloft	C				

Date:10/13/04ISR Number: 4473049-0Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0343107A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Bupropion Hydrochloride	PS	Glaxosmithkline		150MG Unknown	2 DAY
	Arthralgia							
	Erythema Multiforme		Prednisolone	C	Glaxosmithkline		30MG Per day	
	Pain							
	Type Iv Hypersensitivity Reaction							

Date:10/13/04ISR Number: 4476558-3Report Type:Expedited (15-DaCompany Report #A0499051A
Age:6 MON Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure Via Breast Milk	Literature Health	Wellbutrin Sr Tablet-Controlled					
	Febrile Convulsion	Professional	Release (Bupropion					
	Grand Mal Convulsion		Hydrochloride)	PS			TRANSMAMMARY	150 MG/PER
	Postictal State						DAY/	
	Restlessness						TRANSMAMMARY	
	Upper Respiratory Tract Infection							

Date:10/14/04ISR Number: 4474467-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526711A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Feeling Abnormal Intentional Misuse Overdose Refusal Of Treatment By Patient		Wellbutrin Xanax	PS SS	Glaxosmithkline	ORAL		

Date:10/14/04ISR Number: 4474479-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0345610A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradyphrenia Dizziness Hypotension Syncope Vision Blurred	Health Professional	Zyban No Concurrent Medication	PS C	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/04ISR Number: 4475761-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0522931A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	DAY
	Clonic Convulsion	Professional						
	Fall		Ludiomil	C				
	Joint Dislocation		Symbyax	C				
	Loss Of Consciousness							
	Medication Error							
	Upper Limb Fracture							

Date:10/15/04ISR Number: 4475776-8Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0529972A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Hypersensitivity							
	Oropharyngeal Swelling							
	Rash Generalised							
	Swollen Tongue							
	Tremor							

Date:10/15/04ISR Number: 4475789-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0344204A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event	Health	Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice per day	9 DAY
	Aggression	Professional						
	Agitation		Valium	SS				
	Amnesia		Warfarin	SS	Glaxosmithkline			
	Hostility		Tritace	SS				
	Irritability		Panadeine Forte	SS	Glaxosmithkline			
	Mental Disorder		Paracetamol	C	Glaxosmithkline			

	Overdose					
	Suicide Attempt					

Date:10/15/04ISR Number: 4475802-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0347674A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia		Zyban	PS	Glaxosmithkline	ORAL	29	DAY
	Dizziness		Edronax	C				
	Feeling Abnormal		Aropax	C	Glaxosmithkline			
	Mania							
	Nausea							
	Suicidal Ideation							

Date:10/15/04ISR Number: 4479229-2Report Type:Expedited (15-DaCompany Report #2004236066US
Age:50 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Xanax (Alprazolam)					
	Intentional Misuse	Health Professional	Tablet	PS				
			Bupropion (Amfebutamone)	SS				
			Propoxyphene Hcl And Acetaminophen					

				(Dextropropoxyphene Hydrochloride)	SS		

Date:10/15/04ISR Number: 4479315-7Report Type:Expedited (15-DaCompany Report #2004236050US
Age:44 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse	Literature	Solfidin					
		Health	(Clonazepam)Tablet	PS		ORAL	ORAL	
		Professional	Xanax (Alprazolam) Tablet	SS		ORAL	ORAL	
			Bupropion (Amfebutamone)	SS		ORAL	ORAL	

Date:10/15/04ISR Number: 4479343-1Report Type:Expedited (15-DaCompany Report #A0527924A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain Fall Grand Mal Convulsion	Study Health Professional Other	Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	PS		ORAL	SEE DOSAGE TEXT/ORAL	

Date:10/15/04ISR Number: 4507722-2Report Type:Periodic Company Report #2003116563
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Dystonia Eye Disorder Intentional Misuse Medication Error	Health Professional	Neurontin (Tablets) (Gabapentin) Bupropion	PS		ORAL	2400 MG (TID), ORAL	

	Muscle Twitching	Hydrochloride	
	Suicide Attempt	(Bupropion Hydrochloride)	SS
		Baclofen (Baclofen)	C
		Vicodin (Paracetamol, Hydrocodone Bitartrate)	C
		Zolpidem Tartrate (Zolpidem Tartrate)	C
		Clonazepam (Clonazepam)	C
		Fluoxetine Hydrochloride (Fluoxetine Hydrochloride)	C
		Queitapine Fumarate (Quetiapine Fumarate)	C

Date:10/18/04ISR Number: 4477486-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520111A
Age:26 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Arthralgia
	Complex Partial Seizures

	Confusional State					
	Fatigue					
	Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Malaise	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day	MON					
		Professional	Risperdal	C		
			Prozac	C		

Date:10/18/04ISR Number: 4477487-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521279A
Age:6 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Hallucination	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
37.5MG Per						
	Medication Error	Professional				
day	1 WK					
			Strattera	C		
25MG per day						
			Clonidine	C		
.1MG At night						

Date:10/18/04ISR Number: 4477499-8Report Type:Expedited (15-DaCompany Report #200416846US
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cellulitis		Wellbutrin	PS	Glaxosmithkline	ORAL
2 WK						
Initial or Prolonged	Condition Aggravated		Telithromycin	SS		ORAL
800MG Per day	1 WK					
	Dyskinesia		Antibiotic			
	Hallucination, Visual		(Unspecified)	SS		ORAL
	Parasomnia		Metoprolol	C		
	Pneumonia		Lexapro	C		
	Pyrexia		Baby Aspirin	C	Glaxosmithkline	
	Restlessness		Allopurinol	C	Glaxosmithkline	
			Hydrochlorothiazide	C		
			Lasix	C	Glaxosmithkline	
			Potassium Chloride	C	Glaxosmithkline	
			Voltaren	C	Glaxosmithkline	
			Aceon	C		

Hydrocodone	C		
Multivitamin	C		
Coumadin	C	Glaxosmithkline	
Detrol	C		
Uroxatral	C		
Calcium	C		

Date:10/18/04ISR Number: 4477524-4Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0347371A
Age:24 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline		UNKNOWN	2 DAY
	Crying							
	Delusion							
	Dry Mouth							

Date:10/18/04ISR Number: 4477530-XReport Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0044946A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intentional Misuse		Zyban	PS	Glaxosmithkline	ORAL	10TAB	Single
	No Adverse Effect						dose	
	Suicide Attempt							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4478471-4Report Type:Direct Company Report #CTU 229799
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour		Wellbutrin Sr	PS			1X MORNING	
Hospitalization - Initial or Prolonged	Drug Ineffective		Lorazepam	SS			1 X NIGHT	
Required Intervention to Prevent Permanent Impairment/Damage	Intentional Self-Injury Overdose Suicidal Ideation Suicide Attempt							

Date:10/18/04ISR Number: 4478516-1Report Type:Direct Company Report #CTU 229884
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance		Wellbutrin Sr 100 Mg	PS		ORAL	ONE PO BID	
	Gastrointestinal Disorder Hypersensitivity Pharmaceutical Product Complaint							

Date:10/19/04ISR Number: 4478447-7Report Type:Expedited (15-DaCompany Report #PHEH2004US10928
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Apathy		Trileptal	PS	Novartis Sector: Pharma			
	Intentional Misuse							
	Sleep Disorder		Zoloft	SS				
	Stool Analysis Abnormal		Wellbutrin - Slow Release	SS		ORAL	450 mg, QD	
	Suicide Attempt							
	Thinking Abnormal							

Date:10/19/04ISR Number: 4479180-8Report Type:Direct Company Report #CTU 229912
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pharmaceutical Product Complaint Suicidal Ideation		Wellbutrin Sr (Generic)	PS		ORAL	150 MG 2 TWICE BID PO	

Date:10/19/04ISR Number: 4479363-7Report Type:Direct Company Report #CTU 229932
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypomania Insomnia Ovarian Cyst Pelvic Pain		Zyban 150 Mg Cr Tab Accupril (Quinapril) Zoloft (Sertraline Hcl) Flovent (Gluticasone Propionate) Inhal Albuterol Midrin (Apap-Isometheptene-Dichloral) Yasmin (Drospirenone-Ethiny	PS C C C C C			QD X 3 D , THEN BID	

l Estradiol)	C
Atarax (Hydroxyzine Hcl)	C
Allegra (Fexofenadine Hcl)	C
Flonase(Fluticasone Propionate (Nasal))	C
Advair Diskus (Salmeterol-Fluticasone)	C
Lorcet-Hd (Hydrocodone-Acetemi nophen)	C

Date:10/19/04ISR Number: 4480633-7Report Type:Expedited (15-DaCompany Report #2004076041
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Zoloft (Sertraline)	PS		ORAL	50 MG (50 MG,	
	Cystitis	Professional					1 IN 1 D),	
	Feeling Jittery						ORAL	
	Urinary Retention		Bupropion Hydrochloride (Bupropion Hydrochloride)	SS		ORAL	450 MG, ORAL	
			Clonazepam (Clonazepam)	SS				

Date:10/20/04ISR Number: 4479673-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0530207A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			
UNKNOWN							600MG See	
	Overdose						dosage text	

Date:10/20/04ISR Number: 4490081-1Report Type:Expedited (15-DaCompany Report #B0347331A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Drug Interaction Dyspnoea Fatigue Nodal Rhythm Respiratory Rate Increased Sinus Bradycardia Ventricular Hypertrophy	Literature Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride) Metoprolol (Formulation Unknown) (Metoprolol) Diltiazem Hydrochloride	PS SS C		ORAL	150 MG TWICE PER DAY ORAL 75 MG TWICE PER DAY	

Date:10/21/04ISR Number: 4481334-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0530398A
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Decreased Appetite Headache Medication Error

		Tremor Vomiting					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice per day	4 DAY						
				No Concurrent Medication	C		

Date:10/21/04ISR Number: 4483586-0Report Type:Expedited (15-DaCompany Report #2004AL000696
Age:15 YR Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Completed Suicide Intentional Misuse	Literature	Children'S Apap Elixir (Acetaminophen) (Alpharma)	PS	Alpharma	ORAL
PO							
				Infant'S Apap Drops (Acetaminophen) (Alpharma)	SS	Alpharma	ORAL
PO							
				Bupropion	SS		ORAL
PO							
				Aspirin	SS		ORAL
PO							

Date:10/21/04ISR Number: 4483683-XReport Type:Expedited (15-DaCompany Report #2004AL000923
Age:52 YR Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Completed Suicide Overdose	Literature	Children'S Apap Elixir (Acetaminophen) (Alpharma)	PS	Alpharma	ORAL
PO							
				Infants' Apap Drops (Acetaminophen)			

			(Alpharma)	SS	Alpharma	ORAL
PO						
			Aspirin	SS		ORAL
PO						
			Bupropion	SS		ORAL
PO						

Date:10/22/04ISR Number: 4482394-4Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12542486
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Buspar	PS	Bristol-Myers Squibb			
	Swollen Tongue				Company	ORAL		
dose								
increased to								
20mg/day								
,then								
30mg/day, and								
			Keflex	SS		ORAL		
			Wellbutrin	SS		ORAL		
1 DAY								

Date:10/22/04ISR Number: 4482480-9Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0348835A
Age: Gender: I/FU:F

Outcome	PT
Disability	Adverse Event
	Disability
	Feeling Abnormal
	Hypersensitivity

	Impaired Work Ability Malaise						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Zyntabac	PS	Glaxosmithkline		

Date:10/22/04ISR Number: 4483878-5Report Type:Direct Company Report #CTU 230348
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective		Buproprion	PS		ORAL	100MG Q DAY
	Pharmaceutical Product						PO
	Complaint						

Date:10/22/04ISR Number: 4483903-1Report Type:Direct Company Report #CTU 230246
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Intentional Self-Injury Pharmaceutical Product		Wellbutrin Sr (Generic)	PS		ORAL	150 MG 2 BID
	Complaint						PO
	Suicidal Ideation						

Date:10/22/04ISR Number: 4484569-7Report Type:Expedited (15-DaCompany Report #2004AL000695
Age:44 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Multiple Drug Overdose	Literature	Clonazepam	PS	Purepac	ORAL	PO
			Alprazolam	SS	Purepac	ORAL	PO
			Bupropion (Long Acting)	SS		ORAL	PO

Date:10/22/04ISR Number: 4484596-XReport Type:Expedited (15-DaCompany Report #2004AL000698
Age:43 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Multiple Drug Overdose	Literature	Temazepam Capsules, 30 Mg (Purepac)	PS	Purepac	ORAL	PO	
			Bupropion (Long Acting)	SS		ORAL	PO	

Date:10/22/04ISR Number: 4484738-6Report Type:Expedited (15-DaCompany Report #2004AL000680
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Multiple Drug Overdose	Literature	Alprazolam Tablets Usp, 0.25mg,0.5mg,1mg & 2mg (Purepac)	PS		ORAL	PO	
			Propoxyphene Napsylate And Acetaminophen Tablets Usp, 100mg/650 Mg	SS		ORAL	PO	
			Bupropion	SS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4485435-3Report Type:Expedited (15-DaCompany Report #2004AL000694
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Diazepam Tablets					
	Completed Suicide		Usp, 10 Mg (Purepac)	PS	Purepac	ORAL	PO	
	Intentional Misuse		Bupropion	SS		ORAL	PO	
			Quetiapine	SS		ORAL	PO	

Date:10/25/04ISR Number: 4484225-5Report Type:Expedited (15-DaCompany Report #2004-03238
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Wellbutrin Sr	PS	Glaxosmithkline		150MG Per day	10 YR
	Coordination Abnormal		Bupropion					
	Depressed Level Of		Hydrochloride	SS	Glaxosmithkline	ORAL	150MG Twice	
	Consciousness						per day	DAY
	Disturbance In Attention		Lithium	C	Glaxosmithkline	ORAL	10 YR	
	Motor Dysfunction							
	Pharmaceutical Product							
	Complaint							
	Tremor							

Date:10/25/04ISR Number: 4484229-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0530836A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Wellbutrin	PS	Glaxosmithkline		300MG Per day	

Date:10/25/04ISR Number: 4484242-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0347143A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Induced	Consumer	Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Drug Exposure During Pregnancy		Meteospasmyl	C			UNKNOWN	
			Primperan	C	Glaxosmithkline		UNKNOWN	
	Drug Ineffective		Vitamin C	C	Glaxosmithkline		UNKNOWN	
			Ginkor Fort	C			UNKNOWN	
			Stresam	C		ORAL	3UNIT per day	

Date:10/25/04ISR Number: 4484243-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0347143B
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chromosome Abnormality	Consumer	Zyban	PS	Glaxosmithkline		150MG Per day	1 MON
Congenital Anomaly	Congenital Hand Malformation		Meteospasmyl	C				
			Primperan	C	Glaxosmithkline			
	Dextrocardia		Vitamin C	C	Glaxosmithkline			
	Diaphragmatic Hernia		Ginkor Fort	C				
	Drug Exposure During Pregnancy		Stresam	C			3UNIT per day	
	Foetal Growth Retardation							
	Foetal Malformation							
	Gastrointestinal Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484260-7Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0348835A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Zyntabac	PS	Glaxosmithkline			
	Disability							
	Hypersensitivity							
	Malaise							

Date:10/25/04ISR Number: 4487637-9Report Type:Expedited (15-DaCompany Report #US010405
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aura	Health	Gabitril	PS				
Initial or Prolonged	Coma	Professional	Wellbutrin	SS				
	Complex Partial Seizures							
	Grand Mal Convulsion							
	Parosmia							
	Road Traffic Accident							
	Status Epilepticus							
	Treatment Noncompliance							

Date:10/26/04ISR Number: 4485727-8Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0349044A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Insomnia		Zyban	PS	Glaxosmithkline	ORAL		
	Sleep Disorder							

Date:10/26/04ISR Number: 4485728-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0349140A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
Initial or Prolonged	Confusional State							
per day							15	DAY

	Incoherent		Atarax	SS		ORAL
25MG Per day 15 DAY						
	Insomnia		Alprazolam	C		
UNKNOWN						
			Equanil	C		
UNKNOWN						
			Stilnox	C		
UNKNOWN						

Date:10/26/04ISR Number: 4488275-4Report Type:Expedited (15-DaCompany Report #S04-USA-04732-01
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abnormal Behaviour	Health	Lexapro			
	Agitation	Professional	(Escitalopram)	PS		ORAL
10 MG QD PO						
	Belligerence		Lexapro			
	Confusional State		(Escitalopram)	SS		ORAL
20 MG QD PO						
	Delusion		Wellbutrin			
	Diet Refusal		(Bupropion			
	Insomnia		Hydrochloride)	SS		ORAL
300 MG QD						
	Mania		Wellbutrin			
	Paranoia		(Bupropion			
			Hydrochloride)	SS		ORAL
150 MG QD						
			Ambien (Zolpidem			
			Tartrate)	C		
			Trazodone	C		
			Lipitor			

	(Atorvastatin)	C
	Aciphex (Rabeprazole Sodium)	C
	Aspirin	C

Date:10/27/04ISR Number: 4487069-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0530790A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
Other	Death		Abilify	C				

Date:10/27/04ISR Number: 4487070-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0530819A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	1050MG Per day	0 DAY
Hospitalization - Initial or Prolonged	Overdose							
Disability								
Other								

Date:10/27/04ISR Number: 4487076-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531192A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	5	WK
	Convulsion		Trileptal	C				
	Dizziness		Mysoline	C				
	Insomnia		Synthroid	C	Glaxosmithkline			
	Micturition Disorder		Premarin	C				

Date:10/27/04ISR Number: 4487088-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0334395A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Choking		Zyban	PS	Glaxosmithkline	ORAL	UNKNOWN	
	Confusional State		Desloratadine	C				
Disability	Convulsion							
	Headache							
	Therapy Non-Responder							
	Tongue Biting							

Date:10/27/04ISR Number: 4487843-3Report Type:Direct Company Report #CTU 230570
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin 150 Mg (Bupropion Sr)	PS			150 MG BID	

Date:10/28/04ISR Number: 4488047-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0530912A
Age:22 YR Gender:Female I/FU:F

Outcome	PT
Other	Convulsion
	Medication Error

	Overdose						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	2 DAY

Date:10/28/04ISR Number: 4488052-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531408A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4 DAY
	Impaired Driving Ability						

Date:10/28/04ISR Number: 4488072-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0346671A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dehydration	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day 29 DAY
	Fatigue	Professional					
	Feeling Abnormal						
	Syncope						

Date:10/28/04ISR Number: 4488093-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0349464A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Anaphylactic Shock	Health	Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown
	Drug Interaction	Professional	Anesthesia	SS			

Date:10/28/04ISR Number: 4488527-8Report Type:Direct Company Report #CTU 230662
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pharmaceutical Product Complaint		Budeprion Sr 150 Mg Teva-?-	PS	Teva		150 MG TWICE DAILY	ORAL

Date:10/28/04ISR Number: 4490501-2Report Type:Expedited (15-DaCompany Report #2004-BP-09934BP
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Limb Injury Oedema Peripheral Platelet Count Decreased	Consumer	Spiriva Handihaler (Tiotropium Bromide)	PS			RESPIRATORY (INHALATION)	18 MCG (18 MCG), IH
			Bextra (Valdecoxib)	SS		ORAL	PO	
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	PO	
			Foradil (Formoterol Fumarate)	SS			RESPIRATORY (INHALATION)	IH
			Prednisone	C				
			Fosamax (Alendronate Sodium)	C				
			Foltz (Folic Acid)	C				
			Glucosamine	C				

			Duoneb (Combivent)	C		

Date:10/29/04ISR Number: 4490523-1Report Type:Expedited (15-DaCompany Report #2004UW21313
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Convulsion	Foreign	Crestor	PS		ORAL	10 MG QD PO
Intervention to Prevent Permanent Impairment/Damage		Health Professional Other	Wellbutrin - Slow Release	SS			

Date:10/29/04ISR Number: 4491919-4Report Type:Direct Company Report #CTU 230810
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Disorientation		Methylphenidate 20 Mg	PS		ORAL	20 MG 2 TIMES PER DA ORAL
Disability	Lacunar Infarction						
	Speech Disorder						
			Wellbutrin 150 Mg	SS		ORAL	150 MG 2 TIMES PER DA ORAL
			Celexa	C			
			Trazadone	C			
			Luvox	C			

Date:11/01/04ISR Number: 4489942-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531529A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blood Amylase Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day
			No Concurrent				

			Medication	C			

Date:11/01/04ISR Number: 4489968-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0349166A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Head Discomfort						per day	8 DAY
	Swollen Tongue		Nexium	C		ORAL	20MG per day	
			Doxazosin	C		ORAL	4MG per day	
			Amlodipine	C		ORAL	10MG per day	
			Bendroflumethiazide	C	Glaxosmithkline		UNKNOWN	
			Becloforte	C	Glaxosmithkline			
			Ventolin	C	Glaxosmithkline			

Date:11/02/04ISR Number: 4490664-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0521834A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Confusional State		Geodon	C			60MG Twice	
	Grand Mal Convulsion						per day	
	Incontinence		Temazepam	C			30MG At night	2 DAY
	Thinking Abnormal							
	Tongue Biting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/04ISR Number: 4490666-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524516A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON
Initial or Prolonged	Alcohol Intolerance		Alcohol	C				
	Amnesia							
	Convulsion							
	Dissociation							
	Drug Ineffective							
	Overdose							
	Suicidal Ideation							
	Vision Blurred							

Date:11/02/04ISR Number: 4490670-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0528776A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	225MG	Per day
	Benign Prostatic		Zoloft	SS				
	Hyperplasia		Clonazepam	SS				
	Major Depression		Remeron	SS			15MG	Single
	Polyuria						dose	
	Urinary Retention							

Date:11/02/04ISR Number: 4490675-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531761A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	600MG	Unknown
	Overdose							

Date:11/02/04ISR Number: 4490676-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531793A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	15	YR
	Murder		Wellbutrin	SS	Glaxosmithkline		150MG Per day	
	Therapeutic Response		Lopressor	C			UNKNOWN	
	Unexpected		Prilosec	C				
			Premarin	C			UNKNOWN	.3MG Unknown

Date:11/02/04ISR Number: 4490678-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531856A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Abuser		Seizure Medication	C				

Date:11/02/04ISR Number: 4490683-2Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0347567A
Age:18 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
	Dysphagia
	Dyspnoea
	Oedema Peripheral

	Pain Respiratory Disorder Swelling Face	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urticaria		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice
	White Blood Cell Count						per day 18 DAY
	Abnormal		Harmonet	C		ORAL	

Date:11/02/04ISR Number: 4490688-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0349294A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Subarachnoid Haemorrhage		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown
			Venlafaxine	C		ORAL	75MG Twice per day

Date:11/02/04ISR Number: 4493415-7Report Type:Expedited (15-DaCompany Report #A0531315A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Life-Threatening Disability Required Intervention to Prevent Permanent Impairment/Damage	Intentional Misuse	Health Professional	Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	PS		ORAL	300 MG / PER DAY / ORAL
			Ethanol (Alcohol)	SS			
			Citalopram Hydrobromide	C			

Date:11/02/04ISR Number: 4493416-9Report Type:Expedited (15-DaCompany Report #A0531537A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Required Intervention to Prevent Permanent Impairment/Damage	Drug Ineffective	Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS				
			Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	SS		ORAL	ORAL	4 MON
			Celecoxib	C				
			Mirtazapine	C				

Date:11/02/04ISR Number: 4493421-2Report Type:Expedited (15-DaCompany Report #A0531464A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	2 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/04ISR Number: 4493434-0Report Type:Expedited (15-DaCompany Report #A0531546A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS				
	Gastritis							
	Haematemesis							
	Medication Error							
	Migraine							
	Pain							
	Rectal Haemorrhage							
	Vomiting		Wellbutrin Xl Tablet-Extended Release (Bupripion Hydrochloride)	SS		ORAL		
	Weight Decreased		Lorazepam	C				

Date:11/02/04ISR Number: 4494274-9Report Type:Expedited (15-DaCompany Report #B0349472A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aspartate Aminotransferase Increased	Foreign Literature Health	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/ORAL	
	Blood Creatinine Increased	Professional						
	Blood Urea Increased							
	Rhabdomyolysis							

Date:11/03/04ISR Number: 4492143-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524069A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
			No Concurrent Medication	C				

Date:11/03/04ISR Number: 4492157-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531755A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	RESPIRATORY (INHALATION)		
	Drug Abuser							

Date:11/03/04ISR Number: 4492173-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0350226A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Anger		Alcohol	SS		ORAL		
	Disturbance In Attention							
	Impulse-Control Disorder							
	Memory Impairment							
	Road Traffic Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4492428-9Report Type:Direct Company Report #CTU 231193
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Required Intervention to Prevent Permanent Impairment/Damage	Aggression Agitation		Wellbutrin 100 Mg Galxio Smith Kline	PS	Galxio Smith Kline	ORAL	DAILY	ORAL

Date:11/03/04ISR Number: 4494805-9Report Type:Expedited (15-DaCompany Report #2004-BP-10340RO
Age:52 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Completed Suicide Intentional Misuse	Literature	Diazepam Intensol Oral Solution (Concentrate), 5 Mg/Ml (Diazepam) Bupropion (Bupropion) Quetiapine (Quetiapine)	PS SS SS				

Date:11/03/04ISR Number: 4494970-3Report Type:Expedited (15-DaCompany Report #2004-BP-10339RO
Age:44 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multiple Drug Overdose	Literature	Alprazolam Intensol [Oral Solution (Concentrate)] 1 Mg/ Ml (Lorazepam) Bupropion (Bupropion) Clonazepam (Clonazepam)	PS SS SS				

Date:11/03/04ISR Number: 4495701-3Report Type:Expedited (15-DaCompany Report #2004-BP-10338RO
Age:50 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature	Alprazolam Intensol [Oral Solution (Concentrate)] 1 Mg/Ml (Alprazolam	PS				
			Bupropion (Bupropion)	SS				
			Acetaminophen W/Propoxyphene (Doxyphene)	SS				

Date:11/04/04ISR Number: 4493093-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531546A
Age:36 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Convulsion Gastric Disorder Gastritis

		Haematemesis					
		Medication Error					
		Migraine	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rectal Haemorrhage		Wellbutrin	PS	Glaxosmithkline	
		Regurgitation Of Food		Wellbutrin	SS	Glaxosmithkline	ORAL
		Vomiting		Ativan	C		
		Weight Decreased					

Date:11/04/04ISR Number: 4493108-6Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0347425A
Age:56 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Retinopathy Hypertensive		Zyban	PS	Glaxosmithkline	ORAL
150MG Unknown	12 DAY						
		Tinnitus		No Concurrent			
		Visual Acuity Reduced		Medication	C		

Date:11/04/04ISR Number: 4493111-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0349671A
Age:43 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Overdose		Zyban	PS	Glaxosmithkline	ORAL
150MG per day	22 DAY						
Hospitalization -		Personality Change					
Initial or Prolonged		Suicidal Ideation					

Date:11/04/04ISR Number: 4493852-0Report Type:Expedited (15-DaCompany Report #2004UW21313
Age: Gender: I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Required		Convulsion	Foreign	Crestor	PS		ORAL
10 MG QD PO							
Intervention to			Health	Wellbutrin - Slow			
Prevent Permanent			Professional	Release	SS		
Impairment/Damage			Other	Wellbutrin - Slow			
				Release	SS		

Date:11/04/04ISR Number: 4518624-XReport Type:Periodic Company Report #DSA_24601_2004
Age:25 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma		Lorazepam	PS			30 MG ONCE	1 DAY
Initial or Prolonged	Overdose		Lorazepam	SS				
			Wellbutrin	SS		ORAL	12.5 G ONCE	
							PO	1 DAY
			Wellbutrin	SS				
			Paxil	SS			1220 MG ONCE	1 DAY
			Paxil	SS				

Date:11/04/04ISR Number: 4679227-XReport Type:Direct Company Report #CTU 242672
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Therapeutic Response		Bupropione	PS			50 ONE QAM	
	Unexpected With Drug Substitution							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4493795-2Report Type:Expedited (15-DaCompany Report #US-ABBOTT-04P-163-0279296-00
Age:20 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Valproic Acid	PS		ORAL		
			Bupropion	SS		ORAL		
			Topiramate	SS		ORAL		

Date:11/05/04ISR Number: 4494299-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511243A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin Sr	PS	Glaxosmithkline		150MG See dosage text	
	Decreased Appetite							
	Depressed Mood							
	Disease Recurrence							
	Disturbance In Attention							
	Feelings Of Worthlessness							
	Gun Shot Wound							
	Major Depression							
	Sleep Disorder							
	Social Avoidant Behaviour							
	Suicidal Ideation							
	Treatment Noncompliance							
	Tremor							

Date:11/05/04ISR Number: 4494303-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0532210A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Drug Exposure During Pregnancy		Bupropion	PS	Glaxosmithkline			
	Kidney Malformation							
	Pregnancy							
	Renal Disorder							

Date:11/05/04ISR Number: 4494309-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0346394A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Zyban	PS	Glaxosmithkline	ORAL	1TAB	Variable
	Constipation							
dose							20	DAY
	Diarrhoea							
	Dizziness							
	Dysphoria							
	Feeling Abnormal							
	Palpitations							
	Speech Disorder							

Date:11/08/04ISR Number: 4495823-7Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0329055A
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Balance Disorder
	Feeling Abnormal
	Paraesthesia
	Speech Disorder
	Vertigo

Visual Acuity Reduced

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	15 DAY
			Pravachol	C			40MG Per day	

Date:11/08/04ISR Number: 4495850-XReport Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0350696A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline		UNKNOWN	
	Depression							
	Hallucination, Visual							
	Hyperventilation							
	Suicidal Ideation							

Date:11/08/04ISR Number: 4495852-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0350764A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arteriospasm Coronary		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	30 DAY
	Chest Pain		Actiskenan	SS	Glaxosmithkline	ORAL	10MG Per day	1 DAY
			Efferalgan	C	Glaxosmithkline	ORAL	1	DAY

Date:11/08/04ISR Number: 4498732-2Report Type:Expedited (15-DaCompany Report #2004076041
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Condition Aggravated	Health	Zoloft (Sertraline)	PS		ORAL
50 MG (50 MG,						
	Cystitis	Professional				
1 IN 1 D),						
	Drug Effect Decreased					
ORAL						
	Feeling Jittery		Bupropion			
	Pollakiuria		Hydrochloride			
	Urinary Retention		(Bupropion			
			Hydrochloride)	SS		ORAL
450 MG, ORAL						
			Clonazepam			
			(Clonazepam)	SS		
0.5 MG						
			Mirtazapine			
			(Mirtazapine)	SS		
15 MG (15 MG,						
1 IN 1 D)						

Date:11/08/04ISR Number: 4498808-XReport Type:Expedited (15-DaCompany Report #A0530762A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Ineffective	Consumer	Nicoderm Cq Patch			
Initial or Prolonged	Lung Carcinoma Cell Type		(Nicotine)	PS		
TRANSDERMAL VARIABLE						
Required	Unspecified Stage I					
DOSE/TRANSERM						
Intervention to	Medication Error					
AL						
Prevent Permanent	Saliva Altered		Commit Nicotine			
Impairment/Damage	Throat Irritation		Polacrilex Lozenge,			
	Throat Tightness		2mg Lozenge 2 Mg			
			(Nicotine			
			Polacrilex)	SS		
BUCCAL 2 MG/ SINGLE						
DOSE/TRANSBUC						
CAL						

			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	SEE IMAGE
			Atorvastatin Calcium	C			
			Allegra-D	C			

Date:11/09/04ISR Number: 4496422-3Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040908652
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Topamax	PS		OROPHARINGEAL		
	Completed Suicide		Bupropion	SS		OROPHARINGEAL		
	Intentional Misuse		Venlafaxine	SS				
			Olanzapine	SS		OROPHARINGEAL		

Date:11/09/04ISR Number: 4496423-5Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040908721
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis		Topamax	PS		OROPHARINGEAL		
	Blood Pressure Decreased		Valproic Acid	SS		OROPHARINGEAL		
	Brain Oedema		Bupropion	SS		OROPHARINGEAL		
	Coma		Clonidine	SS				
	Completed Suicide							
	Convulsion							
	Hypotension							
	Multiple Drug Overdose							
	Tachycardia							

Date:11/09/04ISR Number: 4496868-3Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0044946A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Alcohol Increased		Zyban	PS	Glaxosmithkline	ORAL	20TAB Single	
	Convulsion						dose	
	Intentional Misuse		Alcohol	C		ORAL	1	DAY
	Somnolence							
	Suicide Attempt							

Date:11/09/04ISR Number: 4498293-8Report Type:Direct Company Report #CTU 231612
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Wellbutrin Sr 150mg Tablet	PS				

Date:11/09/04ISR Number: 4499857-8Report Type:Direct Company Report #CTU 231633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash		Zyban 150 Mg	PS			Q DAY X 3 DAYS THEN BID	1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4499859-1Report Type:Direct Company Report #CTU 231631
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Zyban 150 Mg	PS			Q DAY X 3	DAYS THEN BID 1 WK

Date:11/09/04ISR Number: 4502275-7Report Type:Expedited (15-DaCompany Report #S04-SWE-07224-01
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Foreign	Cipramil (Citalopram					
	Headache	Health	Hydrobromide)	PS		ORAL	20 MG QD PO	
		Professional	Zyban (Bupropion					
		Other	Hydrochloride)	SS		ORAL	150 MG QD PO	

Date:11/09/04ISR Number: 4504356-0Report Type:Direct Company Report #CTU 232348
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharmaceutical Product		Bupropion					
	Complaint		(Wellbutrin Sr)	PS		ORAL	150 MGM PO	
	Vomiting						BID	
			Lithium Carbonate	C				
			Prolixin Decanoate	C				
			Abilify	C				
			Buspirone	C				

Date:11/10/04ISR Number: 4497818-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0393425A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Complex Partial Seizures		Wellbutrin	PS	Glaxosmithkline	ORAL		20 DAY
Initial or Prolonged	Epileptic Aura		Gabitril	SS		ORAL		20 DAY
	Road Traffic Accident							
	Status Epilepticus							
	Tonic Clonic Movements							

Date:11/10/04ISR Number: 4497822-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0519165A
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Death	Agitation
	Anxiety
	Bedridden
	Completed Suicide
	Crying
	Derealisation
	Diarrhoea
	Dizziness
	Feeling Abnormal
	Gun Shot Wound
	Headache
	Insomnia
	Irritability
	Lethargy
	Nausea
	Nervousness

	Pyrexia Social Avoidant Behaviour Toothache	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tremor Vomiting		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	

Date:11/10/04ISR Number: 4497832-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0532724A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Drug Abuser Overdose		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	OTHER	

Date:11/10/04ISR Number: 4497834-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533112A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Psoriasis		Wellbutrin Ssri	PS C	Glaxosmithkline	ORAL	150MG Per day 9 MON

Date:11/10/04ISR Number: 4497835-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533144A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Abuser		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	OTHER	

Date:11/10/04ISR Number: 4497836-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533147A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - Initial or Prolonged	Hot Flush Mood Altered Nonspecific Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:11/10/04ISR Number: 4677951-6Report Type:Direct Company Report #CTU 242643
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anxiety Insomnia Tremor		Bupropion Sr 150 Mg	PS				

Date:11/11/04ISR Number: 4499211-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533252A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amphetamines Positive Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	6	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499213-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533459A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
	Deafness		Levoxine	C	Glaxosmithkline			
	Dermatitis Exfoliative							
	Thirst							

Date:11/12/04ISR Number: 4500096-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533311A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Congestive		No Concurrent Medications	C				

Date:11/12/04ISR Number: 4500118-9Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0351173A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperthyroidism		Bupropion Hydrochloride	PS	Glaxosmithkline		UNKNOWN	14 DAY
	Insomnia							

Date:11/15/04ISR Number: 4500997-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533749A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline			
	Overdose							

Date:11/15/04ISR Number: 4502033-3Report Type:Direct Company Report #CTU 231902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Decreased		Wellbutrin Sr 150 Mg Dsm Pharmaceuticals	PS	Dsm Pharmaceuticals	ORAL	150MG BID	
			Zoloft	C			ORAL	
			Metformin	C				
			Glipizide	C				
			Actos	C				
			Protonix	C				
			Tricor	C				
			Neurontin	C				
			Premarin	C				

Date:11/15/04ISR Number: 4503716-1Report Type:Expedited (15-DaCompany Report #DEWYE183308NOV04
Age:39 YR Gender:Female I/FU:I

Outcome	PT
Other	Antidepressant Drug Level Increased
	Drug Interaction
	Supraventricular Extrasystoles
	Tachycardia

Ventricular Extrasystoles

				Report Source	Product	Role	Manufacturer	Route
Dose	Duration							
				Study	Trevilor (Venlafaxine Hydrochloride, Tablet, 0)	PS		ORAL
SEE IMAGE,								
ORAL	85	DAY						
					Zyban (Amfebutamone Hydrochloride, , 0)	SS		ORAL
SEE IMAGE,								
ORAL	15	DAY						
					Zopiclone (Zopiclone)	C		
					Tibolone (Tibolone)	C		

Date:11/16/04ISR Number: 4502293-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0522931A
Age:35 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Glucose Increased	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice							
		Fall	Professional				
per day	DAY						
		Grand Mal Convulsion		Ludiomil	C		
		Joint Dislocation		Symbyax	C		
		Loss Of Consciousness					
		Medication Error					
		Upper Limb Fracture					

Date:11/16/04ISR Number: 4502295-2Report Type:Expedited (15-DaCompany Report #2004-03848
Age:30 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Dizziness	Consumer	Bupropion	PS	Glaxosmithkline	ORAL
150MG Per day	3 DAY						

	Loss Of Consciousness		Atenolol	C			
25MG Per day							
	Syncope						
	Vomiting						

Date:11/16/04ISR Number: 4502296-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0527318A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Apathy	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	4 MON
Initial or Prolonged	Drug Ineffective		Zoloft	SS				
	Overdose		Trileptal	SS				
	Pharmaceutical Product							
	Complaint							
	Sleep Disorder							
	Stool Analysis Abnormal							
	Suicide Attempt							
	Thinking Abnormal							

Date:11/16/04ISR Number: 4502305-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533775A
Age:25 YR Gender:Female I/FU:I

Outcome	PT
Other	Asthenia
	Convulsion
	Head Discomfort

Loss Of Consciousness

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Wellbutrin Xl	PS	Glaxosmithkline	ORAL
1	MON						

Date:11/16/04ISR Number: 4502327-1Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0356698A
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Convulsion		Zyban	PS	Glaxosmithkline	
UNKNOWN	150MG Twice						
		Grand Mal Convulsion					
per day	2 WK						
		Tongue Biting		Amitriptyline	C		
UNKNOWN							
				Allopurinol	C	Glaxosmithkline	
UNKNOWN							
				Hrt	C		
UNKNOWN							
				Simvastatin	C		
UNKNOWN							
				Enalapril	C		
UNKNOWN							

Date:11/16/04ISR Number: 4502331-3Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0356825A
Age:72 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Interaction	Consumer	Bupropion			
		Hypoglycaemia		Hydrochloride	PS	Glaxosmithkline	
150MG Twice							
per day	14 DAY						
				Insulin Lantus	SS		
				Insulatard Novolet	SS		
				Novorapid	SS		
				Insulin Actrapid	SS		
				Metformin	SS		
500MG Three							

times per day			
600MG Per day	Acetylcysteine	C	Glaxosmithkline
10MG Three	Metoclopramide	C	Glaxosmithkline
times per day			
35MG Weekly	Prednisolon	C	Glaxosmithkline
	Actonel	C	
	Paracetamol + Codeine	C	
10MG As	Temazepam	C	
required			
12MCG Twice	Foradil	C	
per day			
500MCG Twice	Combivent	C	
per day	Pulmicort	C	
20MG Per day	Atrovent	C	
250MG Twice	Pantozol	C	
per day	Theolair Retard	C	
.125MG Per	Lanoxin	C	Glaxosmithkline
day			
40MG Per day	Furosemide	C	Glaxosmithkline
25MG Per day	Spironolactone	C	
2.5MG Per day	Emcor	C	
4MG Per day	Coversyl	C	
20MG Per day	Lipitor	C	
18MCG Per day	Spiriva	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502791-8Report Type:Direct Company Report #CTU 232048
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Maculo-Papular		Wellbutrin 150 Mg Xl	PS		ORAL	PO HS ORAL	
	Rash Pruritic							

Date:11/16/04ISR Number: 4503070-5Report Type:Direct Company Report #CTU 232128
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Welbutrin Xl 150 Mg Glaxosmithklein	PS	Glaxosmithklein	ORAL	150 MG ONCE	
Required Intervention to Prevent Permanent Impairment/Damage			Welbutrin Xl 150 Mg Glaxosmithklein	SS			PER DAY ORAL	
			Multivitamin Supplement	C				
			Glucosamine Chondrointin	C				
			Alpha Lipoic Acid	C				
			Omega 3	C				
			Loratadine	C				

Date:11/16/04ISR Number: 4525687-4Report Type:Periodic Company Report #S04-USA-06882-01
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional	Namenda (Memantine)	PS			150 MG QD	
			Wellbutrin (Bupropion Hydrochloride)	SS				
			Wellbutrin (Bupropion Hydrochloride)	SS			300 MG QD	

			Aricept (Donepezil Hydrochloride)	C		

Date:11/17/04ISR Number: 4503372-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0524503A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Homicidal Ideation	Professional	Zoloft	C		ORAL	150MG Per day	
	Suicidal Ideation							

Date:11/17/04ISR Number: 4503373-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0525740A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
MON								
Initial or Prolonged	Grand Mal Convulsion		Abilify	C			15MG Per day	
	Incontinence							
	Tongue Biting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503408-9Report Type:Expedited (15-DaCompany Report #IT-GLAXOSMITHKLINE-B0357042A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	300MG Per day	9 DAY
	Disturbance In Attention		Nicorette	C	Glaxosmithkline	ORAL		
	Fear							
	Headache							
	Ill-Defined Disorder							
	Psychotic Disorder							

Date:11/17/04ISR Number: 4504393-6Report Type:Direct Company Report #CTU 232292
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hot Flush		Wellbutrin Sr	PS		ORAL	150 MG PO BID	
	Insomnia							
	Pharmaceutical Product Complaint							

Date:11/17/04ISR Number: 4504416-4Report Type:Direct Company Report #CTU 232296
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphthous Stomatitis		Wellbutrin	PS		ORAL	ONE TAB TWICE	
	Oral Intake Reduced						A DAY ORAL	
	Speech Disorder							
	Weight Decreased							

Date:11/17/04ISR Number: 4524586-1Report Type:Periodic Company Report #US-JNJFOC-20040606830
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Anaphylactoid Reaction	Health Professional	Levofloxacin (Levofloxacin)	PS		
			Wellbutrin (Bupropion Hydrochloride) Tablets	SS		ORAL

ORAL

Date:11/18/04ISR Number: 4504405-XReport Type:Expedited (15-DaCompany Report #US-ROCHE-386012
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety		Clonazepam	PS	Roche	
UNKNOWN						
	Benign Prostatic		Wellbutrin	SS		ORAL
	Hyperplasia		Wellbutrin	SS		ORAL
	Polyuria		Wellbutrin	SS		ORAL
	Urinary Retention		Wellbutrin	SS		ORAL
			Zoloft	SS		
UNKNOWN						
			Remeron	SS		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504611-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0351199A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxosmithkline	ORAL	7	WK
	Anxiety							
	Depression							
	Homicidal Ideation							

Date:11/18/04ISR Number: 4507091-8Report Type:Expedited (15-DaCompany Report #B0349825A
Age:52 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	
	Completed Suicide	Health						
	Drug Screen Positive	Professional						
			Quetiapine (Formulation Unknown) (Quetiapine)	SS		ORAL	ORAL	
			Diazepam (Formulation Unknown) (Diazepam)	SS		ORAL	ORAL	

Date:11/18/04ISR Number: 4507097-9Report Type:Expedited (15-DaCompany Report #B0349826A
Age:43 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	
		Health						
		Professional						
			Temazepam (Formulation					

			Unknown) (Temazepam)	SS		ORAL
ORAL						

Date:11/18/04ISR Number: 4507275-9Report Type:Expedited (15-DaCompany Report #B0349822A
Age:15 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature	Wellbutrin Sr			
		Health	Tablet-Controlled			
		Professional	Release (Bupropion			
			Hydrochloride)	PS		ORAL
ORAL						
			Aspirin (Aspirin)	SS		ORAL
ORAL						
			Wellbutrin			
			(Bupropion			
			Hydrochloride)	SS		ORAL
ORAL						
			Topiramate			
			(Topiramate)	SS		ORAL
ORAL						

Date:11/18/04ISR Number: 4507279-6Report Type:Expedited (15-DaCompany Report #B0349816A
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source
Death	Completed Suicide	Literature
		Health

Professional

Dose	Duration	Product	Role	Manufacturer	Route
		Wellbutrin (Bupropion Hydrochloride)	PS		ORAL
ORAL					
		Aspirin (Aspirin)	SS		ORAL
ORAL					
		Paracetamol (Acetaminophen)	SS		ORAL
ORAL					

Date:11/18/04ISR Number: 4507280-2Report Type:Expedited (15-DaCompany Report #B0349817A
Age:32 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardio-Respiratory Arrest	Literature	Wellbutrin			
	Completed Suicide	Health	Unspecified Tablet			
		Professional	(Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Topraimate (Formulation Unknown)			
			(Topiramate)	SS		ORAL
ORAL						

Date:11/18/04ISR Number: 4507304-2Report Type:Expedited (15-DaCompany Report #B0349824A
Age:30 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Completed Suicide	Literature	Wellbutrin Sr			
		Health	Tablet-Controlled			
		Professional	Release (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Citalopram (Citalopram)	SS		ORAL
ORAL						

			Paxil (Paroxetine Hydrochloride)	SS		ORAL
ORAL						

Date:11/18/04ISR Number: 4507305-4Report Type:Expedited (15-DaCompany Report #B0349823A
Age:44 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Intentional Misuse	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Clonazepam (Clonazepam)	SS		ORAL
ORAL						
			Alprazolam (Alprazolam)	SS		ORAL
ORAL						

Date:11/18/04ISR Number: 4510079-4Report Type:Expedited (15-DaCompany Report #B0349818A
Age:20 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
ORAL						

			Valproic Acid (Valproic Acid)	SS		ORAL
ORAL						

Date:11/18/04ISR Number: 4510081-2Report Type:Expedited (15-DaCompany Report #B0349819A
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Alprazolam (Alprazolam)	SS		ORAL
ORAL						

Date:11/18/04ISR Number: 4510083-6Report Type:Expedited (15-DaCompany Report #B0349820A
Age:43 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Alcohol Use Completed Suicide	Literature Health Professional	Wellbutrin (Bupropion Hydrochloride)	PS		ORAL
ORAL						
			Ethanol (Alcohol)	SS		ORAL
ORAL						

Date:11/18/04ISR Number: 4510084-8Report Type:Expedited (15-DaCompany Report #B0349821A
Age:21 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Completed Suicide	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL
ORAL						

Date:11/19/04ISR Number: 4505769-3Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0357250A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Visual		Zyban	PS	Glaxosmithkline			
UNKNOWN								
	Nicotine Dependence		Tetralysal	C				
UNKNOWN								
			Iron	C				
UNKNOWN								
			Vitamin B12	C	Glaxosmithkline			
UNKNOWN								

Date:11/19/04ISR Number: 4505770-XReport Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0357272A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline			
UNKNOWN							150MG	Twice
	Syncope Vasovagal							
per day								

Date:11/19/04ISR Number: 4524232-7Report Type:Periodic Company Report #PHEH2004US09764
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal	Health Professional	Zelnorm (Tegaserod) Tablet	PS		ORAL		
ORAL								
			Wellbutrin- Slow					

			Release (Bupropion Hydrochloride)	SS		ORAL	ORAL

Date:11/22/04ISR Number: 4506797-4Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0528265A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	
	Anger							
	Anxiety							
	Dyspepsia							
	Insomnia							
	Irritability							
	Mood Swings							
	Stomach Discomfort							

Date:11/22/04ISR Number: 4508967-8Report Type:Direct Company Report #CTU 232620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin 200 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	200 MG TWICE DAILY	ORAL

Date:11/22/04ISR Number: 4509041-7Report Type:Direct Company Report #CTU 232548
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State		Wellbutrin Xl 300	PS		ORAL	1TABLET Q AM PO	
Hospitalization - Initial or Prolonged Required	Grand Mal Convulsion							

Intervention to
Prevent Permanent
Impairment/Damage

Date:11/22/04ISR Number: 4510269-0Report Type:Direct Company Report #USP 56965
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Budeprion Sr	PS	Teva	TABLET, EXTENDED RELEASE		
			Wellbutrin Xl	SS	Glaxosmithkline	TABLET, EXTENDED RELEASE		
			Wellbutrin Sr	SS	Glaxosmithkline	TABLET, EXTENDED RELEASE		

Date:11/22/04ISR Number: 4510356-7Report Type:Direct Company Report #USP 56945
Age:55 YR Gender:Male I/FU:I

Outcome	PT
	Dizziness
	Insomnia
	Lethargy

Medication Error

		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin Sr 100 Mg	PS	Glaxo Smith Kline		TABLET
			Wellbutrin Sr 150 Mg	SS	Teva		TABLET

Date:11/22/04ISR Number: 4511217-XReport Type:Direct Company Report #CTU 232739
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Confusional State		Wellbutrin Xl 150mg				
	Fear						
	Feeling Abnormal		Glaxosmithkline	PS	Glaxosmithkline	ORAL	150MG 1 A DAY
	Feeling Hot						
	Memory Impairment		Budeprion Sr 150mg Teva	SS	Teva	ORAL	150MG X2 A DAY
	Mydriasis						
	Paraesthesia						
	Pharmaceutical Product Complaint						
	Thinking Abnormal						

Date:11/22/04ISR Number: 4511254-5Report Type:Direct Company Report #CTU 232725
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Rash		Bupropion 100	PS			1 DAILY
	Urticaria						

Date:11/22/04ISR Number: 4511269-7Report Type:Direct Company Report #CTU 232707
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Buproprion 150 Mg	PS		ORAL	300 MG A DAY	
						ORAL		

Date:11/23/04ISR Number: 4508022-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0164463A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK
			Blood Pressure Medication	C				

Date:11/23/04ISR Number: 4508023-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0360153A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	15 MON
	Depression							
	Drug Withdrawal Syndrome		Paxil	SS	Glaxosmithkline	ORAL	60MG per day	YR
	Gastritis		Valium	C			10MG Twice per day	
	Panic Attack							
			Prevacid	C				
			Nexium	C				
			Percocet	C				

			Donnatal	C		

Date:11/23/04ISR Number: 4508024-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0374355A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Abdominal Pain Upper	Professional					per day	143 DAY
	Eructation		Glucophage	C				
	Food Intolerance		Amaryl	C				
	Hepatocellular Damage		Avandia	C	Glaxosmithkline			
	Impaired Gastric Emptying		Calcium	C				
	Weight Decreased		Vitamin	C				
			Prinivil	C				
			Levoxyl	C	Glaxosmithkline			
			Unknown Medication	C				
			Lantus	C			UNKNOWN	
			Paxil	C	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508025-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0375995A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Anxiety		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	6 MON
			Depakote	C				
			Remeron	C				
			Depakote	C				

Date:11/23/04ISR Number: 4508026-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0382835A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Wellbutrin	PS	Glaxosmithkline	ORAL
Other	Intentional Misuse		Celexa	SS		
			Alcohol	SS		

Date:11/23/04ISR Number: 4508027-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0390353A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Lethargy							
	Muscle Twitching		Zoloft	C			per day	1 YR
	Obsessive-Compulsive						50MG Per day	
	Personality Disorder							
	Somnolence							

Date:11/23/04ISR Number: 4508028-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0420648A
Age:49 YR Gender:Male I/FU:F

Outcome	PT
	Dizziness
	Malaise
	Nausea
	Pharmaceutical Product

	Complaint						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day 10 YR
		Professional					
			Lipitor	C			

Date:11/23/04ISR Number: 4508029-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0422718A
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Amnesia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL	10 MON
Other	Grand Mal Convulsion	Professional					

Date:11/23/04ISR Number: 4508030-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0424115A
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day 0 DAY
	Nausea		Coumadin	C	Glaxosmithkline		
	Somnolence		Norvasc	C			
	Therapeutic Response		Lasix	C	Glaxosmithkline		
	Unexpected		Potassium	C			
			Valium	C			
			Cordarone	C			
			Restoril	C			

Date:11/23/04ISR Number: 4508031-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425710A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Arthralgia					
per day						
	Myalgia		Synthroid	C	Glaxosmithkline	ORAL
	Pain In Extremity		Atacand	C		ORAL
			Atenolol	C		ORAL
			Lipitor	C		ORAL
20MG Unknown						
			Singulair	C		ORAL
10MG At night						
			Hydrocodone	C		

Date:11/23/04ISR Number: 4508033-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0425926A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Thrombocytopenia	Health	Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
Hospitalization -		Professional				
per day 60 WK						
Initial or Prolonged			Effexor Xr	C		ORAL
150MG Per day						
Other			Adderall Xr	C		ORAL

Date:11/23/04ISR Number: 4508034-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0426935A
Age:53 YR Gender:Female I/FU:F

Outcome	PT
	Adverse Event
	Chest Pain

Headache
Palpitations

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 YR
	Zoloft	C				
	Doxepin	C				
	Chlorazepate Dipotassium	C				
	Geodon	C				
	Premarin	C				
	Vit E	C				
	Vit C	C	Glaxosmithkline			
	Calcium	C				
	Vit D	C				
	Multivitamin	C				
	Evening Primrose Oil	C				

Date:11/23/04ISR Number: 4508036-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427054A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	5 WK	
			Heroin	SS				
			Methadone	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508037-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427403A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	17 DAY
			Quinine	C		ORAL	4 DAY	

			Trazodone	C		ORAL
100U Three times per day						
			Topamax	C		ORAL
100U Three times per day						

Date:11/23/04ISR Number: 4508038-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427685A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 MON
	Rash							

Date:11/23/04ISR Number: 4508039-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427726A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lamictal	SS	Glaxosmithkline	ORAL		
			Prevacid	C			UNKNOWN	
			Claritin	C				
			Naprosyn	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508040-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427844A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dysgeusia						per day	
	Increased Appetite		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	
	Weight Decreased		Ortho Novum	C				

Date:11/23/04ISR Number: 4508041-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0427902A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Foaming At Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	513 DAY
	Grand Mal Convulsion		Zoloft	C			50MG Per day	
	Tongue Biting							

Date:11/23/04ISR Number: 4508042-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428249A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Asthenia						per day	4 MON
	Libido Decreased		Wellbutrin	SS	Glaxosmithkline			
	Prostate Infection		Multivitamin With Minerals	C				
			Doxycycline	C				

Date:11/23/04ISR Number: 4508043-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428261A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MCG Twice	
	Nausea						per day	6 WK
			Lexapro	C				

Date:11/23/04ISR Number: 4508044-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428270A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Back Pain						per day	2 YR
	Dry Mouth							

Date:11/23/04ISR Number: 4508045-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428272A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysmenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Vaginal Haemorrhage						per day	4 WK
			Lamisil	C	Glaxosmithkline		250MG Twice	
							per day	6 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508046-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428273A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline			WK
	Hyperhidrosis		Wellbutrin	SS	Glaxosmithkline			WK
	Irritability		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Urticaria		Ultracet	C				

Date:11/23/04ISR Number: 4508048-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428274A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Anger		Keflex	C	Glaxosmithkline			
	Constipation		Advair	C	Glaxosmithkline			
	Dizziness		Detrol	C				
	Dry Mouth		Singulair	C				
	Headache		Prempro	C				
	Heart Rate Increased		Benadryl	C	Glaxosmithkline			
	Hyperhidrosis		Aciphex	C				
	Insomnia		Celebrex	C				
	Irritability		Ambien	C				
	Middle Insomnia		Centrum Multivitamin	C				
	Pruritus		Donnatal	C				
	Somnolence		Lomotil	C				
			Oxygen Therapy	C				
			Antibiotic (Unspecified)	C				

Date:11/23/04ISR Number: 4508049-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428403A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	

per day 2 MON

Neurontin C

Date:11/23/04ISR Number: 4508050-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428415A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508051-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428416A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508052-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428627A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508053-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428685A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ventricular Extrasystoles		Wellbutrin	PS	Glaxosmithkline			
			Vitamin E	C				
			Folate	C				
			Calcium	C				
			Lipitor	C				
			Aspirin	C	Glaxosmithkline			
			Prozac	C				

Date:11/23/04ISR Number: 4508054-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428699A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
	Drug Interaction		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Nervousness		Thyroid Medication	SS				
UNKNOWN								19 DAY
	Tremor							

Date:11/23/04ISR Number: 4508055-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428705A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice	
	No Adverse Effect							
per day								4 YR
	Pharmaceutical Product Complaint							

Date:11/23/04ISR Number: 4508056-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428707A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Diabetes Mellitus						per day	5 YR
			Unknown Medication	C				
			Diltiazem	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508057-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428729A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY
	Fatigue		Unknown-Otc					
	Stomach Discomfort		Medication	C				
	Tunnel Vision							

Date:11/23/04ISR Number: 4508058-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428825A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508059-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428949A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Diarrhoea						per day	18 WK
	Dizziness		Zoloft	C				
	Flatulence		Strattera	C				
	Nausea		Risperdal	C				
	Pharmaceutical Product Complaint		Alprazolam	C				
	Tremor							

Date:11/23/04ISR Number: 4508060-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428950A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	10 DAY

Date:11/23/04ISR Number: 4508061-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428955A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Irritability		Cytomel	C	Glaxosmithkline			
			Levoxyl	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508062-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428964A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL
2 MON						

Date:11/23/04ISR Number: 4508063-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428974A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective							
							per day	6 WK
			Klonopin	C				

Date:11/23/04ISR Number: 4508064-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0428987A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Food Craving		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
							per day	10 YR
			Fluoxetine	C				

Date:11/23/04ISR Number: 4508065-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429003A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Rash		Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508066-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429220A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	100 per day	6 WK
	Insomnia							
	Therapeutic Response							
	Unexpected							

Date:11/23/04ISR Number: 4508067-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429228A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY

Date:11/23/04ISR Number: 4508068-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429233A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Tongue Coated		Lexapro	C				
			Buspar	C				
			Multivitamin	C				

Date:11/23/04ISR Number: 4508069-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429243A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Erythema Multiforme		Wellbutrin	PS	Glaxosmithkline	ORAL	7 DAY	
Initial or Prolonged	Pruritus		Nexium	C				
Other	Urticaria		Lexapro	C				

Date:11/23/04ISR Number: 4508070-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429247A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508071-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429252A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508072-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429265A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508073-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429489A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON
	Insomnia		Sonata	C				

Date:11/23/04ISR Number: 4508074-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429496A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
			Ambien	C				
			Celebrex	C				
			Zyrtec	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508075-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429501A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three times per day	7 YR
	Insomnia							
	Nausea		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Unknown	
	Somnolence		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Unknown	2 DAY

Date:11/23/04ISR Number: 4508076-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429512A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day 1 MON						
			Zoloft	C		
			Fentanyl	C		
			Excedrin	C		
			Diazepam	C		

Date:11/23/04ISR Number: 4508077-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429517A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Syncope					
per day						

Date:11/23/04ISR Number: 4508078-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429523A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:11/23/04ISR Number: 4508079-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429653A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day 3 WK						

Diovan	C	
Diclofenac	C	
Prilosec	C	Glaxosmithkline
Zocor	C	
Plavix	C	
Estradiol	C	
Synthroid	C	Glaxosmithkline
Vitamin D	C	
Calcium	C	

Date:11/23/04ISR Number: 4508080-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429655A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	
			Claritin	C				

Date:11/23/04ISR Number: 4508081-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429663A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	3 MON
			Allegra	C				

Date:11/23/04ISR Number: 4508082-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429666A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Dysuria						per day	14 WK

	Escherichia Infection					
	Pyrexia					

Date:11/23/04ISR Number: 4508083-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429670A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY

Date:11/23/04ISR Number: 4508084-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429714A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Rash Vesicular		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Skin Irritation							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508085-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429794A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Pharmaceutical Product						per day	4 YR
	Complaint							
	Stomach Discomfort							
	Vomiting							

Date:11/23/04ISR Number: 4508086-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429806A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	2 YR
			Oral Contraceptives	C				
			Clarinex	C				

Date:11/23/04ISR Number: 4508087-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429814A
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	YR
	Irritability		Zoloft	SS			UNKNOWN	
	Sexual Dysfunction		Effexor	SS			UNKNOWN	
			Paxil	SS	Glaxosmithkline		UNKNOWN	
			Lexapro	SS			UNKNOWN	
			Lithium	C	Glaxosmithkline		UNKNOWN	

			Thyroid	C		
UNKNOWN						

Date:11/23/04ISR Number: 4508088-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429839A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nonspecific Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:11/23/04ISR Number: 4508089-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429969A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Consciousness		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
			Triphasil	C				

Date:11/23/04ISR Number: 4508090-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430008A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508091-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430036A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Crying		Unspecified					
	Depression		Medication	C				
	Dry Mouth							

Date:11/23/04ISR Number: 4508092-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430077A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Dizziness		Lexapro	C				
	Headache		Provigil	C				
			Toprol Xl	C				
			Xanax	C				
			Protonix	C				

Date:11/23/04ISR Number: 4508093-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430271A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508094-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430277A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
			Dexedrine	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508095-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430281A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
			Ssri	C				

Date:11/23/04ISR Number: 4508096-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430284A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK

Date:11/23/04ISR Number: 4508097-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430445A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Celexa	C				
			Enbrel	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508098-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430468A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Painful Erection		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three times per day	

Date:11/23/04ISR Number: 4508099-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430595A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	3	MON

Date:11/23/04ISR Number: 4508100-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430608A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lithium Carbonate	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508101-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430609A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Lexapro	C				

Date:11/23/04ISR Number: 4508102-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430614A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Enzyme Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	2 MON
			Topomax	C				
			Unknown Medication	C				
			Toprol	C				
			Ibuprofen	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508103-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430624A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Back Pain						per day	7 DAY
	Chest Pain							
	Headache							
	Hot Flush							

Date:11/23/04ISR Number: 4508104-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430628A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508105-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430641A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Viagra	C				
			Aspirin	C	Glaxosmithkline			
			Vitamin	C				

Date:11/23/04ISR Number: 4508106-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430678A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
			Wellbutrin	SS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508107-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430684A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Benadryl	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508108-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430701A
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508109-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430706A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Single	
dose								1 DAY
			Klonopin	C				

Date:11/23/04ISR Number: 4508110-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430709A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
per day								1 YR

Date:11/23/04ISR Number: 4508111-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430722A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Ulceration		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
per day								65 WK
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508112-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430723A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Tightness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Insulin	C				

Date:11/23/04ISR Number: 4508113-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430759A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	31 DAY
			Prednisone	C				
			Plaquenil	C				

Date:11/23/04ISR Number: 4508114-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430853A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Insomnia		Effexor	C				
	Sleep Disorder		Klonopin	C				
	Tremor							

Date:11/23/04ISR Number: 4508115-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430883A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 YR

			Actos	C		
			Glucophage	C		
			Lantus	C		

Date:11/23/04ISR Number: 4508116-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430884A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Abuser		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508117-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430889A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Insomnia						per day	9 MON
			Amitriptyline	C				
			Fish Oil	C				
			Vitamin E	C				
			Topamax	C				
			Kcl	C	Glaxosmithkline			
			Parafon Forte	C				
			Clonazepam	C				
			Hctz	C				
			Doxazosin	C				
			Minipress	C				

			Aceon	C		
			Glucosamine	C		

Date:11/23/04ISR Number: 4508118-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430893A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300 per day	1 MON
			Prozac	C				
			Trazodone	C				

Date:11/23/04ISR Number: 4508119-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430896A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Zyprexa	C				
			Levoxyl	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508120-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430901A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Insomnia		Propecia	C				
	Psychomotor Hyperactivity							

Date:11/23/04ISR Number: 4508121-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430939A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL		

	Flatulence					
	Headache					
	Nausea					

Date:11/23/04ISR Number: 4508122-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430949A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 DAY
			Effexor	SS			75MG Per day	

Date:11/23/04ISR Number: 4508123-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430958A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	14 DAY
	Diarrhoea		Tranxene	C				
	Insomnia		Glucovance	C				
	Nausea		Prilosec	C	Glaxosmithkline			
	Palpitations		Benicar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508124-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430961A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Rash Maculo-Papular		Digoxin	C	Glaxosmithkline			
			Aspirin	C	Glaxosmithkline			
			Flomax	C				

Date:11/23/04ISR Number: 4508125-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430967A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508126-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0430986A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	14 DAY
	Anxiety		Lexapro	C				
	Dizziness		Glucovance	C				
	Nervousness		Benicar	C				

Date:11/23/04ISR Number: 4508127-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431103A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY

Date:11/23/04ISR Number: 4508128-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431164A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	3 WK
			Nyquil	C				

Date:11/23/04ISR Number: 4508129-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431168A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	6 MON
			Topamax	C				
			Levoxyl	C	Glaxosmithkline			
			Zyprexa	C				

Date:11/23/04ISR Number: 4508130-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431175A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	14 YR
			Vivelle	C				
			Celebrex	C		ORAL	200MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508131-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431188A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	4	YR
			Prozac	C				

Date:11/23/04ISR Number: 4508132-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431205A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 DAY
			Atenolol	C				
			Thyroid Medication	C				

Date:11/23/04ISR Number: 4508133-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431220A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urine Present		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
	Muscle Spasms							

Date:11/23/04ISR Number: 4508134-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431409A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Dry Mouth		Valium	C				
			Metabolife	C				
			Ginkoba	C				
			Unknown Medication	C				

			Detrol La	C		

Date:11/23/04ISR Number: 4508135-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431432A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Sensation In Eye		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON

Date:11/23/04ISR Number: 4508136-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431435A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 DAY
			Inderal	C				

Date:11/23/04ISR Number: 4508137-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431436A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 DAY
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508138-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431453A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508139-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431799A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Klonopin	C				
			Methotrexate	C				
			Darvocet	C				
			Prednisolone	C	Glaxosmithkline			
			Flexeril	C				
			Salagen	C				
			Folic Acid	C				
			Phenergan	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508140-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431801A
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Libido		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 MON
			Neurontin	C				
			Norvasc	C				
			Cardura	C				

Date:11/23/04ISR Number: 4508141-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431811A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Per day						
			Tenormin	C		
			Avapro	C		
			Lipitor	C		

Date:11/23/04ISR Number: 4508142-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431817A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Formication					
per day 1 MON						
	Hepatic Enzyme Increased		Topamax	SS		
	Insomnia		Phentermine	SS	Glaxosmithkline	
	Nausea					
	Stress					

Date:11/23/04ISR Number: 4508143-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431821A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 4 MON						
			Lorazepam	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508144-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431826A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Otitis Media		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/23/04ISR Number: 4508145-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431837A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
Other	Hypersensitivity Laryngeal Oedema Urticaria		No Concurrent Medications	C				

Date:11/23/04ISR Number: 4508146-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431971A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 DAY

Date:11/23/04ISR Number: 4508147-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431973A
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG See dosage text	2 MON

Date:11/23/04ISR Number: 4508148-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431975A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508149-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432093A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/23/04ISR Number: 4508150-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432102A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL	150MCG Per day	2 DAY
			Tylenol Cold + Sinus	C				
			Birth Control Pill	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508151-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432105A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508152-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432115A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Memory Impairment		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Musculoskeletal Stiffness							
	Petit Mal Epilepsy							

Date:11/23/04ISR Number: 4508153-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432124A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response		Wellbutrin	PS	Glaxosmithkline			
	Unexpected							

Date:11/23/04ISR Number: 4508154-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432134A
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	8 WK
	Dry Mouth							
	Feeling Abnormal		Paxil	SS	Glaxosmithkline	ORAL	25MG Per day	4 MON
	Hyperhidrosis		Synthroid	C	Glaxosmithkline		.75MG Per day	

	Tremor		Duragesic	C	
TRANSDERMAL					
	Vision Blurred		Bactrim	C	Glaxosmithkline
			Allopurinol	C	Glaxosmithkline
			Colchicine	C	
			Imipramine	C	

Date:11/23/04ISR Number: 4508155-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432135A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Pharmaceutical Product					
per day 1 YR						
	Complaint		Zyrtec	C	Glaxosmithkline	

Date:11/23/04ISR Number: 4508156-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432143A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 3 DAY						
	Chills		Oxycontin	C		
	Dizziness		Oxycodone Immediate			
	Hyperhidrosis		Release	C		
	Insomnia		Cipro	C	Glaxosmithkline	
			Asacol	C	Glaxosmithkline	
			Bentyl	C		
			Valium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508157-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432145A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
			Allopurinol	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508158-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432148A
Age:77 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	3 DAY
	Nausea		Metoprolol	C				

Date:11/23/04ISR Number: 4508159-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432150A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 YR
			Celexa	C				

Date:11/23/04ISR Number: 4508160-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432178A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Zoloft	C				

Date:11/23/04ISR Number: 4508161-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432179A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG In the morning	3 MON
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG In the morning	6 DAY
			Adderall	C				
UNKNOWN							10MG Unknown	
			Lexapro	C		ORAL		
			Adderall Xr	C		ORAL	20MG Per day	

Date:11/23/04ISR Number: 4508162-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432253A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 YR
	Lethargy		Xanax	C				
	Somnolence		Cardura	C				
			Valium	C				
			Clonidine	C				
			Avandia	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508163-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432272A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Fatigue		Zoloft	C				
	Insomnia		Hctz	C				
	Somnolence		Allopurinol	C	Glaxosmithkline			
			Potassium Citrate	C				
			Klor-Con	C	Glaxosmithkline			
			Ibuprofen	C	Glaxosmithkline			
			Chromium	C				

Date:11/23/04ISR Number: 4508164-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432301A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508165-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432325A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508166-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432425A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention		Wellbutrin	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508167-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432430A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline			1 YR

Date:11/23/04ISR Number: 4508168-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432444A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Mental Disorder							

Date:11/23/04ISR Number: 4508169-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432446A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Wellbutrin	C	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508170-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432450A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR

Date:11/23/04ISR Number: 4508171-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432579A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Weight Increased		Narcotics	C				

Date:11/23/04ISR Number: 4508172-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432599A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	152 WK
	Decreased Appetite		Celexa	C				
	Dizziness		Strattera	C				
	Migraine							

Date:11/23/04ISR Number: 4508173-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432605A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	3 YR
			Norvasc	C				
			Aciphex	C				

Date:11/23/04ISR Number: 4508174-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432851A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	
	Vomiting		Zoloft	C			250MG per day	
			Lamictal	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508175-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432884A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 WK

Date:11/23/04ISR Number: 4508176-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433130A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Adderall	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508177-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433132A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Alternate days	3 WK
			Effexor	C				

Date:11/23/04ISR Number: 4508178-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433140A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK

Date:11/23/04ISR Number: 4508179-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433142A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Anaphylactic Reaction Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508180-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433258A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	2 DAY

Date:11/23/04ISR Number: 4508181-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433268A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Phosphokinase Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508182-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433303A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			Lexapro	C			437 DAY	
			Wellbutrin	C	Glaxosmithkline		200MG Twice per day	

Date:11/23/04ISR Number: 4508183-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0433304A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Paraesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508184-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438802A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice	
	Insomnia						per day	2 YR
	Paraesthesia		Geodon	C				
			Atenolol	C				

Date:11/23/04ISR Number: 4508185-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438819A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Eructation						per day	8 MON
	Flatulence		Azulfidine	C				
			Folic Acid	C				
			Lopressor	C				
			Vasotec	C				
			Ultracet	C				
			Zocor	C				
			Protonix	C				
			Flexeril	C				
			Ambien	C				
			Clonazepam	C				
			Aspirin	C	Glaxosmithkline			
			Gas-X	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508186-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438825A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			None	C				

Date:11/23/04ISR Number: 4508187-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0438879A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG In the	
	Restlessness						morning	

Date:11/23/04ISR Number: 4508188-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439005A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 WK

Date:11/23/04ISR Number: 4508189-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439006A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Night Sweats							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508190-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439036A
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
			Lopid	C				
			Aricept	C				
			Foltx	C				
			Vioxx	C				
			Aciphex	C				
			Multivitamin	C				
			Aspirin	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508191-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439038A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK

Date:11/23/04ISR Number: 4508193-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439053A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 MON
			Effexor Xr	C				

Date:11/23/04ISR Number: 4508194-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439245A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

	Weight Decreased		Celexa	C		

Date:11/23/04ISR Number: 4508195-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439248A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Per day
	Paraesthesia							

Date:11/23/04ISR Number: 4508196-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439258A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:11/23/04ISR Number: 4508197-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439264A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Per day
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508198-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439275A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	per day
			Cephalexin	C	Glaxosmithkline			
			Protonix	C				
			Lisinopril	C				
			Furosemide	C	Glaxosmithkline			
			Amiodarone	C				
			Allopurinol	C	Glaxosmithkline			
			Pravachol	C				
			Coreg	C	Glaxosmithkline			
			Digoxin	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508199-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439351A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			
	Drug Exposure Via Breast Milk							

Date:11/23/04ISR Number: 4508200-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439409A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	per day
			Desipramine	C				
			Klonopin	C				
			Tenormin	C				
			Vasotec	C				
			Synthroid	C	Glaxosmithkline			
			Plavix	C				

			Imdur	C	
			Catapres	C	
			Hytrin	C	
			Zantac	C	Glaxosmithkline
			Lansoprazole	C	
			Lipitor	C	

Date:11/23/04ISR Number: 4508201-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439412A
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Blood Thyroid Stimulating						per day	6 WK
	Hormone Abnormal		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Drug Ineffective		Klonopin	SS			UNKNOWN	2 MON
	Dyspepsia		Xanax	SS			UNKNOWN	
	Flatulence		Unithroid	C	Glaxosmithkline			
	Gastrooesophageal Reflux		Ambien	C				
	Disease		Seroquel	C				
	Hepatic Enzyme Increased		Thyroid Supplement	C				
	Weight Decreased		Clonopin	C				
			Remeron	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508203-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439433A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tardive Dyskinesia		Wellbutrin	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508204-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439436A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508205-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439450A
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritable Bowel Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR

Date:11/23/04ISR Number: 4508206-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439628A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	11 MON
			Flexeril	C				
			Z-Pak	C				

Date:11/23/04ISR Number: 4508207-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439638A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gastrointestinal Motility		Wellbutrin	PS	Glaxosmithkline	ORAL
3 YR						
	Disorder		Effexor Xr	C		
			Multivitamin	C		
			Vitamin B	C		
			Vitamin C	C	Glaxosmithkline	
			Vitamin E	C		
			Iron Supplement	C		
			Calcium	C		
			Levoxyl	C	Glaxosmithkline	
			Fosamax	C		

Date:11/23/04ISR Number: 4508208-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439664A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Capillary Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Dizziness					
per day 3 DAY						
	Dry Mouth					
	Dyspnoea					
	Mental Status Changes					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508209-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439677A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508210-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439689A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Auditory		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508211-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439827A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Lisinopril	C				

Date:11/23/04ISR Number: 4508212-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439835A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Diarrhoea							
							per day	4 DAY
	Fatigue							
	Headache							
	Rash Pruritic							

Date:11/23/04ISR Number: 4508213-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439846A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 MON
			Hormone Replacement	C				

Date:11/23/04ISR Number: 4508214-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439969A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
			Celexa	C				
			Proscar	C				
			Flomax	C				

Date:11/23/04ISR Number: 4508215-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0439976A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508216-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440023A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508217-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440184A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	8 YR
			Premarin	C				

Date:11/23/04ISR Number: 4508218-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440364A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Propecia	C				
			Aspirin	C	Glaxosmithkline			
			Aceon	C				
			Arthrotec	C				
			Lipitor	C				

Date:11/23/04ISR Number: 4508219-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440368A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK

Date:11/23/04ISR Number: 4508220-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440385A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 MON

Date:11/23/04ISR Number: 4508221-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440391A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 WK

Date:11/23/04ISR Number: 4508222-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440427A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	3 MON
	Movement Disorder							
			Adderall	C				
			Trazodone	C				
			Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508223-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440559A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Twice per day	1 MON
			Xanax	C				
			Clonazepam	C				
			Topamax	C				
			Claritin	C				

Date:11/23/04ISR Number: 4508224-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440572A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice per day	1 MON
			Anti-Diabetic Medication	C		ORAL		

Date:11/23/04ISR Number: 4508225-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440590A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508226-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440591A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	

per day 2 WK

None C

Date:11/23/04ISR Number: 4508227-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440592A
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 YR
	Decreased		Lipitor	C				
	Blood Urea Decreased		Lotrel	C				
			Hytrin	C				
			Allopurinol	C	Glaxosmithkline			
			Lexapro	C				

Date:11/23/04ISR Number: 4508228-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440603A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Muscle Tightness							
							per day	10 DAY
			Loestrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508229-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440612A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Priapism		Wellbutrin	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508230-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440808A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	4 MON
	Drug Ineffective Pharmaceutical Product Complaint							

Date:11/23/04ISR Number: 4508231-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440815A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 MON

Date:11/23/04ISR Number: 4508232-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440822A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 WK

Date:11/23/04ISR Number: 4508233-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0440825A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Wellbutrin	PS	Glaxosmithkline		150MG Twice	
	Dizziness						per day	7 WK
	Tremor		Wellbutrin	SS	Glaxosmithkline		150MG Per day	
			Lithium	C	Glaxosmithkline	ORAL		
			Abilify	C				
			Trazodone	C				
			Lisinopril	C				

Date:11/23/04ISR Number: 4508235-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441004A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:11/23/04ISR Number: 4508236-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441020A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Headache						per day	2 MON
	Increased Appetite		Birth Control Pill	C				
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508237-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441126A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Paxil	C	Glaxosmithkline			
			Lexapro	C				

Date:11/23/04ISR Number: 4508238-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441156A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Chills							
per day							3	YR
	Dizziness		Prilosec	C	Glaxosmithkline			
	Fatigue		Alprazolam	C				
	Nausea		Darvocet	C				

Date:11/23/04ISR Number: 4508239-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441157A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508240-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441479A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	150MG Twice
								per day
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/23/04ISR Number: 4508241-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441485A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508242-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441527A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
	Burning Sensation		Effexor Xr	C			UNKNOWN	MON
	Dizziness		Kariva	C				
	Emotional Disorder							
	Erythema							
	Feeling Abnormal							
	Flushing							
	Hot Flush							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508243-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441534A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	375 DAY
	Euphoric Mood		Zoloft	SS		ORAL	50MG Unknown	2 YR
	Fatigue		Verapamil	C			240MG Per day	
	Mental Disorder							

Date:11/23/04ISR Number: 4508244-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441633A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	200 per day	2 YR

Date:11/23/04ISR Number: 4508245-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441649A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Complaint							
	Rash		Bextra	C		ORAL	10MG Per day	
			Nexium	C		ORAL	20MG Per day	
			Microgestin Fe	C		ORAL	1TAB Per day	

Date:11/23/04ISR Number: 4508246-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441748A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	1 WK
			Lescol	C				
			Quinine	C				

Date:11/23/04ISR Number: 4508247-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441749A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
	Stool Analysis Abnormal		Zoloft	C				
	Tremor		Klonopin	C				

Date:11/23/04ISR Number: 4508248-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441762A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline			
			Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508249-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441763A
Age: Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain Upper
	Anorexia
	Diarrhoea
	Gastrooesophageal Reflux

		Disease					
		Headache					
		Vomiting					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Wellbutrin	PS	Glaxosmithkline	ORAL
200MG Twice							
per day	6 MON						
				Prevacid	C		
				Seroquel	C		
				Trazodone	C		

Date:11/23/04ISR Number: 4508250-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441772A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day						

Date:11/23/04ISR Number: 4508251-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441784A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Confusional State					
per day	8 YR					
			Prozac 20	C		
			Ambien	C		

Date:11/23/04ISR Number: 4508252-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441791A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Asthma		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day	2 WK					

Effexor Xr	C	
Proventil	C	Glaxosmithkline
Ventolin	C	Glaxosmithkline
Flovent	C	Glaxosmithkline
Allegra	C	
Ibuprofen	C	Glaxosmithkline
Baby Aspirin	C	Glaxosmithkline

Date:11/23/04ISR Number: 4508253-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442007A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
	Drug Ineffective							
	Nausea		Trazodone	C				
	Pharmaceutical Product		Klonopin	C				
	Complaint		Estrogen Patch	C				

Date:11/23/04ISR Number: 4508254-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442040A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
	Pharmaceutical Product							
	Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508255-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442042A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contrast Media Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508256-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442060A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
	Anxiety							
	Feeling Abnormal							

Date:11/23/04ISR Number: 4508257-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442155A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	4 MON
			Depakote	C				
			Neurontin	C				
			Geodon	C				
			Prevacid	C				
			Zocor	C				
			Mobic	C				
			Miralax	C				

Date:11/23/04ISR Number: 4508258-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442156A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Sr	PS	Glaxosmithkline			
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508259-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442162A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Extrasystoles						per day	
			Prozac	C				
			Amitriptyline	C				
			Vioxx	C				
			Methotrexate	C				
			Folic Acid	C				
			Calcium	C				
			Imitrex	C	Glaxosmithkline			
			Fiorinal	C				
			Aspirin	C	Glaxosmithkline			
			Vitamin	C				

Date:11/23/04ISR Number: 4508260-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442170A
Age:56 YR Gender:Female I/FU:I

Outcome	PT
	Dizziness
	Drug Ineffective

	Drug Withdrawal Syndrome Nausea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	
			Paxil	SS	Glaxosmithkline		
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day 2 MON
			Estradiol	C			
			Hyzaar	C			
			Prilosec	C	Glaxosmithkline		
			Meclizine	C			

Date:11/23/04ISR Number: 4508261-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442174A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice
	Dizziness						per day 2 WK
	Dry Mouth		Tenormin	C			
	Insomnia		Zocor	C			
			Aspirin	C	Glaxosmithkline		

Date:11/23/04ISR Number: 4508262-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442176A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day 6 WK

Date:11/23/04ISR Number: 4508263-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442330A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day 5 WK

Date:11/23/04ISR Number: 4508264-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442354A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Tremor							

Date:11/23/04ISR Number: 4508265-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442438A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	2	YR
			Effexor	SS			UNKNOWN	

Date:11/23/04ISR Number: 4508266-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442508A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508267-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442558A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anorexia						per day	2 WK
	Constipation		Altace	C				
	Depression		Niaspan	C				
	Dry Mouth		Actonel	C				
	Insomnia		Calcium	C				
	Weight Decreased		Fish Oil	C				

Date:11/23/04ISR Number: 4508268-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442561A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dry Mouth						per day	2 WK
	Influenza							

Date:11/23/04ISR Number: 4508269-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442562A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Pain Medications	C				

Date:11/23/04ISR Number: 4508270-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442654A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	

		Pharmaceutical Product						
per day	18 MON							
		Complaint			Antibiotics	C		

Date:11/23/04ISR Number: 4508271-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442655A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	8 YR
			Celexa	C				

Date:11/23/04ISR Number: 4508272-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442772A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia							
per day	3 WK							
	Irritability		Valium	C				
			Vicodin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508273-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442779A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 WK
	Flatulence							
	Muscle Spasms							
	Nausea							

Date:11/23/04ISR Number: 4508274-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442810A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective							
	Periorbital Oedema						per day	2 WK
			Patanol Eye Drops	C				
			Flonase	C	Glaxosmithkline			
			Nasalcrom	C				
			Benadryl	C	Glaxosmithkline			
			Allegra	C				
			Docusate	C				
			Zelnorm	C				
			Protonix	C				
			Prednisone	C				
			Creon	C				
			Pentasa	C	Glaxosmithkline			
			Ambien	C				
			Cytotec	C				
			Miacalcin Nasal Spray	C				
			Unspecified Medication	C				

Date:11/23/04ISR Number: 4508275-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442976A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Per day 2 WK						
	Diarrhoea					
	Gastrooesophageal Reflux Disease					

Date:11/23/04ISR Number: 4508276-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442996A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 1 MON						
	Hypoaesthesia		Amitriptyline	C		
	Insomnia		Xanax	C		
	Muscle Tightness					

Date:11/23/04ISR Number: 4508277-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443000A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	White Blood Cell Count		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 2 YR						
	Increased		Unspecified Inhaler	C		
UNKNOWN						
			Promethazine	C		

				Bextra	C		

Date:11/23/04ISR Number: 4508278-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443008A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	7 WK

Date:11/23/04ISR Number: 4508279-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443199A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON
	Influenza Like Illness							
	Insomnia		Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
	Irritability		Atenolol	C				
	Parosmia		Altace	C				
	Tremor		Lamictal	C	Glaxosmithkline			
			Zonegran	C				
			Flexeril	C				
			Omeprazole	C	Glaxosmithkline			
			Mobic	C				
			Tricor	C				

Date:11/23/04ISR Number: 4508280-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443202A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 WK
			Provigil	C				

			Betaseron	C		

Date:11/23/04ISR Number: 4508281-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443208A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Depressed Mood						per day	
	Feeling Abnormal		Zoloft	C				
	Headache		Multivitamin	C				
	Memory Impairment		Flax Seed Oil	C				
	Nasopharyngitis							
	Vision Blurred							

Date:11/23/04ISR Number: 4508282-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443341A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	8	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508283-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443381A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Rash							

Date:11/23/04ISR Number: 4508284-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443389A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Irritability							
per day	1	YR						
	Nervousness		Wellbutrin	SS	Glaxosmithkline	ORAL	2	WK
	Sexual Dysfunction							

Date:11/23/04ISR Number: 4508285-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443390A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	MON	
	Nausea							

Date:11/23/04ISR Number: 4508286-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443476A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
per day	5	WK						
			Ultram	C				
			Sudafed	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508287-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443496A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	142 DAY

Date:11/23/04ISR Number: 4508288-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443511A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
	Sexual Dysfunction							
	Weight Decreased		Synthroid	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508289-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443524A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Systolic Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508290-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443647A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Insomnia						per day	15 DAY

Date:11/23/04ISR Number: 4508291-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443754A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Pharmaceutical Product Complaint							

Date:11/23/04ISR Number: 4508292-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443771A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis		Wellbutrin Sr	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508293-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443782A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Hiv Treatments (Unspecified)	C				
			Lorazepam	C				
			Electroconvulsive Therapy	C				

Date:11/23/04ISR Number: 4508294-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443785A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	3 MON
			Effexor Xr	C				
			Synthroid	C	Glaxosmithkline			
			Neurontin	C				
			Clonazepam	C				

Date:11/23/04ISR Number: 4508295-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443929A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Sr	PS	Glaxosmithkline			
			Adderall	C				

Date:11/23/04ISR Number: 4508296-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443939A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508297-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443943A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	5 YR
			Morphine	C				
			Estrogen	C				
			Synthroid	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508298-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444026A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Delusion		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Flashback							
	Hallucination							
	Medication Error							
	Paranoia							

Date:11/23/04ISR Number: 4508299-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444110A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Three	
	Insomnia							
							times per day	7 YR
	Sleep Disorder		Hormone Replacement Therapy	C				
			Blood Pressure Medication	C				

Date:11/23/04ISR Number: 4508300-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444127A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK
			Paxil	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508301-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444128A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice per day	3 MON
	Insomnia							
	Pollakiuria							

Date:11/23/04ISR Number: 4508302-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444130A
Age:39 YR Gender:Female I/FU:I

Outcome	PT
	Abnormal Dreams
	Anger
	Anxiety
	Depression
	Fatigue

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Irritability		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
			Xanax	C				
			Calcium	C				

Date:11/23/04ISR Number: 4508303-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444161A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	1 MON
	Drug Interaction							
	Insomnia		Kaletra	SS			500MG Per day	
	Irritability		Viread	C			300MG Per day	
	Mania		Combivir	C	Glaxosmithkline		450MG Per day	
			Oxandrin	C			10MG Twice per day	
			Fosinopril	C			10MG Per day	
			Furosemide	C	Glaxosmithkline		25MG Per day	
			Metoprolol	C			100MG Per day	
			Trazodone	C			20MG Per day	
			Zyprexa	C			20MG Per day	
			Paxil	C	Glaxosmithkline		2PUFF Four times per day	
			Combivent	C				

				Flovent	C	Glaxosmithkline	2PUFF Twice per day
				Viagra	C		100MG As required
				Lomotil	C		
				Creon	C		
				Multivitamin	C		
				N-Acetyl-L-Cysteine	C	Glaxosmithkline	600MG Per day
				Alpha Lipoic Acid	C		250MG Per day
				Coenzyme Q10	C		150MG Per day
				Milk Thistle	C		400MG Per day
				Carnitor	C		1G Per day
				Fiber	C		1TAB Per day
				Omega 3	C	Glaxosmithkline	

Date:11/23/04ISR Number: 4508304-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490763A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 MON
	Libido Decreased		Wellbutrin	SS	Glaxosmithkline	ORAL	100MG Twice per day	2 YR
			Lexapro	C				
			Lotensin	C	Glaxosmithkline			
			Vioxx	C				
			Neurontin	C				
			Robaxin	C				
			Oxycontin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508306-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490791A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Scratch						per day	DAY
	Swelling Face		Depo-Provera	C				
	Urticaria		Xanax	C				

Date:11/23/04ISR Number: 4508307-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490843A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Early Morning Awakening		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	2 YR
			Klonopin	C				
			Tegretol	C				
			Abilify	C				
			Elavil	C	Glaxosmithkline			
			Darvocet	C				

Date:11/23/04ISR Number: 4508308-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490845A
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	12 WK
			Synthroid	C	Glaxosmithkline			
			Flonase	C	Glaxosmithkline			
			Prevacid	C				
			Citrucel	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508309-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490969A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Per day	1 MON
	Insomnia							

Date:11/23/04ISR Number: 4508310-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490983A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508311-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490984A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	18 MON

Date:11/23/04ISR Number: 4508312-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491306A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	35 WK
			Lipitor	C				

				Premarin	C		
				Calcium	C		

Date:11/23/04ISR Number: 4508313-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491328A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	4 MON
			Imitrex	C	Glaxosmithkline	ORAL	50MG As required	
			Zomig	C		ORAL	5MG As required	
			Zanaflex	C		ORAL		
			Imitrex	C	Glaxosmithkline	SUBCUTANEOUS	6MG As required	

Date:11/23/04ISR Number: 4508314-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491336A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	
			Provigil	C				
			Hormones	C				
			Vasotec	C				

Date:11/23/04ISR Number: 4508315-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491344A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 YR

Date:11/23/04ISR Number: 4508316-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491345A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
			Protease Inhibitor (Unspecified)	C				
			Interferon	C				

Date:11/23/04ISR Number: 4508317-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491355A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Zoloft	C				

Date:11/23/04ISR Number: 4508318-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491580A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508319-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491697A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:11/23/04ISR Number: 4508320-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491699A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	50MG Per day	3 YR
	Hypoaesthesia Oral							

Date:11/23/04ISR Number: 4508321-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491712A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508322-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491713A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 YR
			Zoloft	C				

Date:11/23/04ISR Number: 4508323-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491743A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	50 DAY
	Loss Of Consciousness							
	Myalgia		Alcohol	SS				
	Paraesthesia							
	Tremor							

Date:11/23/04ISR Number: 4508324-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491772A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Euphoric Mood							

Date:11/23/04ISR Number: 4508325-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491882A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			Advil	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508326-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491892A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ill-Defined Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Oesophageal Pain						per day	6 WK
			Trileptal	C				
			Nexium	C				
			Lamictal	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508327-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491893A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Topamax	C				
			Pravachol	C				
			Aspirin	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508328-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491894A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	

Date:11/23/04ISR Number: 4508329-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491906A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice per day 1 MON						
			Buspar	C		

Date:11/23/04ISR Number: 4508330-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491911A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysuria		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice per day	Prostatic Disorder					
			Saw Palmetto	C		

Date:11/23/04ISR Number: 4508331-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491915A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice per day 5 WK						
			Zoloft	C		
			Seroquel	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508332-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491931A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300 per day	10 YR
	Weight Increased		Zoloft	C				
			Fosamax	C				

Date:11/23/04ISR Number: 4508333-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491994A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bipolar I Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	4	YR
	Confusional State		Levoxyl	C	Glaxosmithkline			
	Disturbance In Attention		Cytomel	C	Glaxosmithkline			
	Headache		Zyrtec	C	Glaxosmithkline			
	Insomnia		Allergy Shots	C				
	Logorrhoea		E-Vista	C				
	Memory Impairment		Ditropan	C				
	Obsessive-Compulsive Disorder		Vioxx	C				
	Pharmaceutical Product Complaint							

Date:11/23/04ISR Number: 4508335-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492013A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Pharmaceutical Product Complaint		Prozac	C				

Date:11/23/04ISR Number: 4508336-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492243A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
			Prinivil	C				
			Premarin	C				
			Estratest	C				

Date:11/23/04ISR Number: 4508337-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492562A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Unknown	1 MON
	Increased Appetite		Doxycyclin	C				
	Irritability							
	Urticaria							

Date:11/23/04ISR Number: 4508338-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492581A
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	250MG Variable dose	7 MON
			Celexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508339-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492598A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice	
	Headache						per day	5 YR
	Nausea							
	Vomiting							

Date:11/23/04ISR Number: 4508340-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492607A
Age:6 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	4 DAY
			Strattera	C				

Date:11/23/04ISR Number: 4508341-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492683A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508342-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492886A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
	Headache		Klonopin	SS			3MG Per day	
	Insomnia							
	Nausea							
	Palpitations							
	Tremor							

Weight Decreased

Date:11/23/04ISR Number: 4508343-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492889A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash							
per day	4	WK						
	Urticaria		Zithromax	C				
			Proscar	C				

Date:11/23/04ISR Number: 4508344-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492890A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
per day	2	WK						
			Methocarbamol	C				
			Guaifenesin	C				
			Unknown Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508345-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492892A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
			Adderall	C				

Date:11/23/04ISR Number: 4508346-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493453A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	8 MON
	Hypertension		Flonase	SS	Glaxosmithkline			
	Palpitations		Hydrochlorothiazide	C				
			Premarin	C				
			Tiazac	C	Glaxosmithkline			
			Altace	C				
			Vioxx	C				
			Maxair	C				
			Advair	C	Glaxosmithkline			
			Nasonex	C				
			Synthroid	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508347-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493454A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	3	WK

Date:11/23/04ISR Number: 4508348-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493472A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Per day	
	Myalgia		Tamoxifen	C				
			Melatonin	C				
			Antihistamine	C				

Date:11/23/04ISR Number: 4508349-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493491A
Age:13 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Medication Error							
	Nausea							
	Yawning							

Date:11/23/04ISR Number: 4508350-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493575A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Enzyme Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 YR
			Buspar	C				
			Glucophage	C				
			Synthroid	C	Glaxosmithkline			

			Vitamins	C		

Date:11/23/04ISR Number: 4508351-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493578A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK
			Lortab	C				
			Soma	C				
			Xanax	C				
			Sleep Aid	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508352-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493579A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Unknown	11 DAY
			Paxil	C	Glaxosmithkline	ORAL	25MG Unknown	
			Toprol Xl	C				
UNKNOWN							100MG Unknown	

Date:11/23/04ISR Number: 4508353-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493584A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508354-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493775A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508356-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493916A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON

Date:11/23/04ISR Number: 4508357-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493931A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	3 WK

Date:11/23/04ISR Number: 4508358-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493942A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 MON
	Insomnia							
	Medication Error							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508359-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493947A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Mental Disorder		Paxil	SS	Glaxosmithkline	ORAL		3 MON
	Sensory Disturbance		Celebrex	C				
			Allegra	C				
			Multivitamin	C				
			Calcium Supplement	C				
			Vitamin E	C				
			Simvastatin	C				
			Prempro	C				
			Sleep Aid	C	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508360-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493948A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
			Antihypertensive	C				

Date:11/23/04ISR Number: 4508361-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493952A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dysgeusia						per day	2 MON
	Hyperhidrosis		Lisinopril	C				
	Skin Odour Abnormal		Diclofenac	C				
			Synthroid	C	Glaxosmithkline			
			Hctz	C				
			Xanax	C				
			Magnesium Oxide	C				
			Dhea	C				

			Vitamins	C		
			Glucosamine	C		

Date:11/23/04ISR Number: 4508362-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493967A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK

Date:11/23/04ISR Number: 4508363-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493971A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	225MG Per day	1 MON
	Fatigue		Wellbutrin	SS	Glaxosmithkline	ORAL	100MG Per day	2 MON
	Palpitations		Lexapro	C				
	Vomiting		Oxizole	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508364-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493973A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	1 MON
			Prempro	C				
			Bextra	C				
			Oxycontin	C				
			Zanaflex	C				

Date:11/23/04ISR Number: 4508365-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493976A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	
	Disturbance In Attention						Variable dose	62 WK
	Dizziness		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	
	Euphoric Mood		Celexa	C				
	Headache		Clarinex	C				
	Insomnia							
	Irritability							
	Mood Swings							
	Screaming							

Date:11/23/04ISR Number: 4508366-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494062A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Feeling Hot		Estrogen	C				
	Rash							
	Rash Papular							

Date:11/23/04ISR Number: 4508369-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494233A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Anorexia		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Crying		Neurontin	C				
	Diarrhoea		Trileptal	C				
	Drug Ineffective		Klonopin	C				
	Hot Flush		Unspecified Inhaler	C				
	Migraine							
	Nervousness							
	Vision Blurred							
	Weight Decreased							

Date:11/23/04ISR Number: 4508371-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494234A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508372-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494247A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Twice	
	Insomnia						per day	2 YR
			Ambien	C				

Date:11/23/04ISR Number: 4508373-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494267A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	4 MON
	Nervousness							
	Social Phobia							

Date:11/23/04ISR Number: 4508374-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494270A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Weight Decreased						per day	11 MON
			Yasmin	C				

Date:11/23/04ISR Number: 4508375-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494280A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vitamin D Deficiency		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150TAB Twice	

per day 1 YR

Vitamin D	C	
Risperdal	C	
Avandia	C	Glaxosmithkline
Axid	C	
Nexium	C	
Baby Aspirin	C	Glaxosmithkline
Calcitrol	C	
Provigil	C	
Effexor	C	

Date:11/23/04ISR Number: 4508376-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494335A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event Tremor		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508377-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494471A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	7	YR
			Famotidine	C				
			Protonix	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508378-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494482A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	1MG Twice per	
	Feeling Jittery						day	1 MON

Date:11/23/04ISR Number: 4508379-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494545A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	MON	
	Stomatitis							
	Urticaria							

Date:11/23/04ISR Number: 4508380-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494680A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 WK
			Celexa	C				

Date:11/23/04ISR Number: 4508381-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494715A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Prolactin Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	3 YR
			Zyprexa	C				

Date:11/23/04ISR Number: 4508382-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494716A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	300 per day	
	Flatulence		Nexium	C				
	Pharmaceutical Product		Amaryl	C				
	Complaint		Plavix	C				
			Unspecified Drug	C				
			Allopurinol	C	Glaxosmithkline			
			Glucophage Xr	C				
			Topral	C				

Date:11/23/04ISR Number: 4508383-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495028A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	
	Pharmaceutical Product		Zoloft	C				
	Complaint		Lorazepam	C				
			Benzaclin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508384-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495037A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complex Partial Seizures		Wellbutrin	PS	Glaxosmithkline	ORAL	2	YR

Date:11/23/04ISR Number: 4508385-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495047A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			Atenolol	C				
			Lovastatin	C				
			Plavix	C				
			Lisinopril	C				
			Famotidine	C				
			Aspirin	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508386-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495335A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three times per day	
	Tremor							

Date:11/23/04ISR Number: 4508387-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495336A
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:11/23/04ISR Number: 4508388-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495351A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON

Date:11/23/04ISR Number: 4508389-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495353A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 WK

Date:11/23/04ISR Number: 4508390-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495356A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	11 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508391-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495528A
Age:13 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	8 MON

Date:11/23/04ISR Number: 4508392-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495529A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Effexor	SS			UNKNOWN	

Date:11/23/04ISR Number: 4508393-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495530A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dysmenorrhoea							
	Menorrhagia							

Date:11/23/04ISR Number: 4508394-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495552A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Pharmaceutical Product Complaint							

Date:11/23/04ISR Number: 4508395-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495574A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508396-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495938A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Three times per day	2 YR

Date:11/23/04ISR Number: 4508397-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495962A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	450MG Per day	7 MON
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508398-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495973A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoacusis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tinnitus						per day	2 YR
			Valtrex	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508399-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496025A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508400-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496033A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngolaryngeal Pain		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Throat Tightness						per day	3 WK
			Prozac	C				
			Estrace	C				
			Ambien	C				
			Tylenol	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508401-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496040A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 YR

Date:11/23/04ISR Number: 4508402-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496044A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Prolactin Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	

Date:11/23/04ISR Number: 4508403-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496057A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Thyroid Medication	C				

Date:11/23/04ISR Number: 4508404-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496078A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508406-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496229A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
							per day	
			Wellbutrin	C	Glaxosmithkline	ORAL	300MG per day	

Date:11/23/04ISR Number: 4508407-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496279A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 MON
			Ambien	C				
			Wellbutrin	C	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508408-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496281A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR

Date:11/23/04ISR Number: 4508409-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496295A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Back Pain						per day	1 YR

	Fall		Effexor Xr	C		ORAL
150MG Per day						
	Grand Mal Convulsion					
	Loss Of Consciousness					
	Neck Pain					

Date:11/23/04ISR Number: 4508410-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496310A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anger		Wellbutrin Sr	PS	Glaxosmithkline	ORAL

Date:11/23/04ISR Number: 4508411-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496344A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tonsillitis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Per day 4 MON						

Date:11/23/04ISR Number: 4508412-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496496A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Claustrophobia		Paxil	PS	Glaxosmithkline	ORAL
	Headache		Wellbutrin Sr	SS	Glaxosmithkline	ORAL
200MG In the						
morning 4 MON						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508413-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496507A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Panic Reaction						per day	
			Albuterol	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508414-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496634A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	1 MON
			Prempro	C				

Date:11/23/04ISR Number: 4508415-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496637A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
							per day	2 YR
			Effexor Xr	C				

Date:11/23/04ISR Number: 4508416-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496655A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Tinnitus		Strattera	C				
			Lorazepam	C				

Date:11/23/04ISR Number: 4508417-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496658A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice	
	Eructation						per day	2 YR
	Nausea		Seroquel	C				
			Trileptal	C				

Date:11/23/04ISR Number: 4508418-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496741A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Unknown	

Date:11/23/04ISR Number: 4508419-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496756A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Mania						per day	3 WK
	Tinnitus		Wellbutrin	SS	Glaxosmithkline		300MG Per day	3 WK
			Klonopin	C				
			Lamictal	C	Glaxosmithkline			
			Lithium	C	Glaxosmithkline			

Ativan	C
Buspar	C
Inderal	C

Date:11/23/04ISR Number: 4508420-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496767A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG See dosage text	10 DAY

Date:11/23/04ISR Number: 4508421-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496784A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Anxiety		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Hypomania		Lamictal	SS	Glaxosmithkline			
	Insomnia							
	Palpitations							
	Tremor							

Date:11/23/04ISR Number: 4508422-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496954A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	

Date:11/23/04ISR Number: 4508423-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496960A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pharyngolaryngeal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 9 MON						
			Protonix	C		
			Imitrex	C	Glaxosmithkline	
			Darvocet	C		

Date:11/23/04ISR Number: 4508424-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497085A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Foreign Body Trauma		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
200MG Twice						
	Pharmaceutical Product					
per day						
	Complaint					

Date:11/23/04ISR Number: 4508425-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497093A
Age:8 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL
1 YR						
			Risperdal	C		ORAL
2MG At night						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508426-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497145A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	2	YR
	Eye Irritation							
	Eyelid Oedema							
	Headache							
	Hypersensitivity							
	Rash Macular							

Date:11/23/04ISR Number: 4508427-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497168A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508428-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497179A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anxiety						per day	
	Confusional State							
	Depression							
	Dizziness							
	Drug Withdrawal Syndrome							
	Insomnia							
	Muscle Tightness							
	Palpitations							
	Panic Attack							

Date:11/23/04ISR Number: 4508430-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497373A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508431-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497603A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Dysgeusia Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508432-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497741A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
			Benicar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508433-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497758A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Euphoric Mood						per day	1 MON
	Hypomania		Depakote	C				
	Insomnia		Lithium	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508434-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497770A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	

Date:11/23/04ISR Number: 4508435-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497773A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Adderall	C				

Date:11/23/04ISR Number: 4508436-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497786A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	3 DAY
	Insomnia		Lipitor	C				

			Lithium	C	Glaxosmithkline	

Date:11/23/04ISR Number: 4508437-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497800A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	2 MON
	Migraine		Nexium	C				

Date:11/23/04ISR Number: 4508438-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497824A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Pravachol	C				

Date:11/23/04ISR Number: 4508439-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497974A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 YR
			Glucovance	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508440-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497994A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactoid Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG per day	
Other	Angioneurotic Oedema		Levaquin	SS			500MG per day	
	Rash							

Date:11/23/04ISR Number: 4508441-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498162A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritable Bowel Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	22 WK
			Fosamax	C				
			Premarin	C				

Date:11/23/04ISR Number: 4508442-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498164A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 MON

Date:11/23/04ISR Number: 4508443-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498178A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	

per day

			Toprol Xl	C	
			Nicotine Patch	C	Glaxosmithkline

Date:11/23/04ISR Number: 4508444-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498179A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MCG Twice	
	Sexual Dysfunction						per day	12 DAY
			Trazodone	C				
			Lipitor	C				

Date:11/23/04ISR Number: 4508445-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498339A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	
	Pharmaceutical Product Complaint		Effexor Xr	C				

Date:11/23/04ISR Number: 4508446-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498343A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Vitamins	C				

Antioxidants C

Date:11/23/04ISR Number: 4508447-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498344A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508448-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498348A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 YR

Date:11/23/04ISR Number: 4508449-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498350A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	15 MON	
	Grand Mal Convulsion		Tessalon Perles	SS				

Date:11/23/04ISR Number: 4508450-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498552A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	

Date:11/23/04ISR Number: 4508451-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498750A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	7	MON
			Chemotherapy	C				

Date:11/23/04ISR Number: 4508452-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498772A
Age:22 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured		Wellbutrin Sr	PS	Glaxosmithkline		100MG Per day	2 MON
	Vomiting		Prevacid	C				
			Levsin	C				

Date:11/23/04ISR Number: 4508453-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498856A
Age: YR Gender:Female I/FU:F

Outcome	PT
Other	Amnesia
	Dry Mouth
	Insomnia
	Panic Attack
	Petit Mal Epilepsy
	Restlessness

	Tremor					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day	14 DAY					
			Thyroid Medication	C		
			Buspar	C		

Date:11/23/04ISR Number: 4508454-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498874A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Twice						
per day	17 WK					
			Spironolactone	SS		ORAL
4 WK						
			Synthroid	C	Glaxosmithkline	
			Vitamins	C		

Date:11/23/04ISR Number: 4508455-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499193A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
200MG Twice						
per day	9 MON					

Date:11/23/04ISR Number: 4508456-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499210A
Age: YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						

Initial or Prolonged
per day 1 WK

Date:11/23/04ISR Number: 4508457-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499226A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
	Headache							
	Insomnia							
	Migraine							

Date:11/23/04ISR Number: 4508458-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499406A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
	Headache		Prozac	C				
	Nausea		Aspirin	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508459-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499448A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Sleep Disorder							
	Weight Decreased		Buspar	C			per day	4 MON

Cardizem Cd C Glaxosmithkline

Date:11/23/04ISR Number: 4508460-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499455A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Swelling Face						per day	3 WK

Date:11/23/04ISR Number: 4508461-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499458A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	1	WK

Date:11/23/04ISR Number: 4508462-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499627A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 YR
			Lipitor	C				

Date:11/23/04ISR Number: 4508463-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499808A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY

Date:11/23/04ISR Number: 4508464-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499809A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	2 YR
			Oral Contraceptives	C				

Date:11/23/04ISR Number: 4508465-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499839A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON
			Ambien	C				

Date:11/23/04ISR Number: 4508466-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499842A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	10 MON
			Lisinopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508467-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499849A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness						per day	
	Weight Gain Poor							

Date:11/23/04ISR Number: 4508468-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499860A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice	
							per day	2 YR

Date:11/23/04ISR Number: 4508469-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499862A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice	
	Depression						per day	
	Sleep Disorder							

Date:11/23/04ISR Number: 4508470-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499865A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective						per day	6 WK

	Nausea		Xanax	C		

Date:11/23/04ISR Number: 4508471-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499870A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice per day	

Date:11/23/04ISR Number: 4508472-9Report Type:Periodic Company Report #04-00071
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
			Nystatin + Triamcinolone Acetonide	SS				
TOPICAL	.1%DS Unknown							

Date:11/23/04ISR Number: 4508473-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500645A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice per day	1 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508475-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500661A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	7 YR
			Diazepam	C				
			Risperdal	C				
			Trazodone	C				

Date:11/23/04ISR Number: 4508476-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500662A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Rash		Wellbutrin	SS	Glaxosmithkline	ORAL	100MG Per day	0 DAY

Date:11/23/04ISR Number: 4508477-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500670A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	3 MON
			Zyprexa	C			20MG Per day	

Date:11/23/04ISR Number: 4508478-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500690A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Disturbance In Attention		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
100MG Twice						
	Drug Ineffective					
per day 6 MON						

Date:11/23/04ISR Number: 4508479-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500695A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
4 WK						

Date:11/23/04ISR Number: 4508480-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500714A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Twice						
	Thinking Abnormal					
per day 8 WK						
			Tamoxifen	C		
			Toprol Xl	C		

Date:11/23/04ISR Number: 4508481-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500715A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Twice						
per day						
			Zoloft	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508482-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500842A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Headache							

Date:11/23/04ISR Number: 4508483-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500849A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508484-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500895A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	
	Convulsion							

Date:11/23/04ISR Number: 4508485-7Report Type:Periodic Company Report #2004-00809
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	100MG Per day	15 DAY
			Topamax	C			UNKNOWN	

Date:11/23/04ISR Number: 4508486-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500935A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508487-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501052A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash Macular						per day	3 WK
			Amoxicillin	C	Glaxosmithkline			
			Guaifen	C				

Date:11/23/04ISR Number: 4508488-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501058A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508489-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501060A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON

Date:11/23/04ISR Number: 4508490-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501062A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	10 DAY
			Glyburide	C				
			Avandia	C	Glaxosmithkline			
			Diovan	C				
			Synthroid	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508491-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501066A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bedridden		Wellbutrin Sr	PS	Glaxosmithkline			
	Drug Interaction		Pain Medication	C			UNKNOWN	

Date:11/23/04ISR Number: 4508492-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501072A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

	Drug Ineffective		Wellbutrin Xl	SS	Glaxosmithkline	ORAL
300MG Per day						
	Nausea		Benicar	C		
	Vomiting		Norvasc	C		
			Fish Oil	C		

Date:11/23/04ISR Number: 4508493-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501103A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
100MG Unknown						

Date:11/23/04ISR Number: 4508494-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501174A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nightmare		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Twice						
	Tremor					
per day 14 DAY						
			Nexium	C		

Date:11/23/04ISR Number: 4508495-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501202A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Deafness		Wellbutrin	PS	Glaxosmithkline	
			Wellbutrin	SS	Glaxosmithkline	ORAL
300MG Per day 2 MON						
			Concerta	C		
3 WK						

			Levoxyl	C	Glaxosmithkline	

Date:11/23/04ISR Number: 4508496-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501228A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG	Unknown
	Hyperhidrosis		Effexor	C				

Date:11/23/04ISR Number: 4508497-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501409A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508498-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501414A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 DAY
			Ritalin	C				
			Concerta	C				

Date:11/23/04ISR Number: 4508499-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501431A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508500-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501443A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice	
	Tremor						per day	
			Zoloft	C				

Date:11/23/04ISR Number: 4508501-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502027A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	3	MON

Date:11/23/04ISR Number: 4508502-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502028A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508503-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502163A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508504-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502177A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	3	YR

Date:11/23/04ISR Number: 4508505-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502179A
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 YR
	Dry Skin							
			Atenolol	SS			UNKNOWN	
			Enalapril	C				
			Synthroid	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508506-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502196A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Single dose	1 DAY

Date:11/23/04ISR Number: 4508507-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502197A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR

Date:11/23/04ISR Number: 4508508-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502365A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508509-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502373A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 WK
	Grand Mal Convulsion							
			Alcohol	SS				
			Zoloft	C			200MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508510-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502563A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	30 DAY

Date:11/23/04ISR Number: 4508511-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502583A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
			Synthroid	C	Glaxosmithkline			
			Xanax	C				
			Allegra D	C				
			Paxil	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508512-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502632A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Zyban	C	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508513-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502657A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
			Lipitor	C				
			Xanax	C				
			Clonidine	C				
			Hctz	C				

Date:11/23/04ISR Number: 4508514-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502715A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG	Unknown
			Effexor	C		ORAL	150MG	Twice
							per day	2 YR
			Protonix	C			UNKNOWN	
			Volmax	C	Glaxosmithkline		UNKNOWN	
			Procrit	C			UNKNOWN	
			Premarin	C			UNKNOWN	

Date:11/23/04ISR Number: 4508515-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502866A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Twice
	Dizziness						per day	1 WK
	Headache		Estrogens	C				
	Myalgia		Synthroid	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508516-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502869A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Depression						per day	5 DAY
	Dizziness		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Dry Mouth		Arimidex	C				
	Gingival Pain		Propranolol	C				
	Glossodynia		Hyzaar	C				
	Headache		Diclofenac	C				
	Mood Altered		Zometa	C				
	Nausea		Aciphex	C				
	Oedema Peripheral		Clonidine	C				
			Synthroid	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508517-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502876A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:11/23/04ISR Number: 4508518-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502878A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dry Mouth						per day	5 DAY
	Headache		Prilosec	C	Glaxosmithkline			
	Nausea							
	Vision Blurred							

Date:11/23/04ISR Number: 4508519-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502889A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508520-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502924A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508521-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502958A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508522-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502963A
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	18 MON

Date:11/23/04ISR Number: 4508523-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502984A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	1 WK

Date:11/23/04ISR Number: 4508524-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503162A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Mycosis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	1	YR

Date:11/23/04ISR Number: 4508525-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503198A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK
Disability	Skin Laceration		Prozac	C				
Other			Ibuprofen	C	Glaxosmithkline			
			Claritin	C				
			Nicotine Patch	C	Glaxosmithkline			
			Axid	C				
			Vicodin	C				
			Vitamin B Complex	C				
			Trazodone	C				
			Klonopin	C				
			Ambien	C				

Date:11/23/04ISR Number: 4508526-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503221A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Rash		Blood Pressure Medication	C				
	Tinnitus		Cholesterol	C				
			Bc	C	Glaxosmithkline	ORAL		
			Sinus Medication	C				

Date:11/23/04ISR Number: 4508527-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503232A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Depression		Biaxin	C				
	Dyspnoea		Albuterol	C	Glaxosmithkline			
	Muscle Spasms		Aciphex	C				
	Swelling Face							
	Swollen Tongue							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508528-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503444A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Of Relaxation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Personality Change							

Date:11/23/04ISR Number: 4508529-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503447A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 YR
			Nexium	C				

Date:11/23/04ISR Number: 4508530-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503449A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Anxiety							
	Depression		Allegra	C				
	Nausea							

Date:11/23/04ISR Number: 4508531-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503450A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/23/04ISR Number: 4508532-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503461A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
per day								2 WK

Date:11/23/04ISR Number: 4508533-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503508A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
per day								10 DAY

Date:11/23/04ISR Number: 4508534-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503510A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Pruritus							
per day								1 WK
			Levaquin	SS				
			Plavix	SS				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508535-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503544A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice	
	Stool Analysis Abnormal						per day	37 MON
			Buspar	C				
			Lisinopril	C				

Date:11/23/04ISR Number: 4508536-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503545A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Disorientation						per day	8 MON
	Mydriasis							

Date:11/23/04ISR Number: 4508537-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503824A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Pollakiuria						per day	1 DAY
			Lamictal	SS	Glaxosmithkline	ORAL	125MG Per day	4 MON

Date:11/23/04ISR Number: 4508538-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503830A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Convulsion Wellbutrin PS Glaxosmithkline ORAL
150MG See

dosage text 8 DAY

Date:11/23/04ISR Number: 4508539-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503831A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Eruption		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 WK
			None	C				

Date:11/23/04ISR Number: 4508540-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503845A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice	
	Dry Mouth							
							per day	2 YR

Date:11/23/04ISR Number: 4508541-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503852A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	3 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508542-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504063A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysarthria		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	per day
			Depakote	C				
			Ambien	C				
			Luvox	C				

Date:11/23/04ISR Number: 4508543-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504069A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	per day 1 DAY

Date:11/23/04ISR Number: 4508544-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504071A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Halitosis							per day 3 YR
	Libido Increased		Ambien	C				

Date:11/23/04ISR Number: 4508545-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504225A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508546-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504301A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ejaculation Failure		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			None	C				

Date:11/23/04ISR Number: 4508547-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504573A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypothermia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	
			Avelox	C				
			Sinus Medication	C				

Date:11/23/04ISR Number: 4508548-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504789A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	2	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508549-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504810A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508550-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504832A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Level Of Consciousness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	8	DAY

Date:11/23/04ISR Number: 4508551-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504888A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice per day	61 WK
	Menstrual Disorder							
	Nausea		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	1	WK
			Levoxyl	C	Glaxosmithkline			
			Atenolol	C				
			Soma	C				
			Imitrex	C	Glaxosmithkline			
			Ibuprofen	C	Glaxosmithkline			
			Tylenol W/ Codeine	C				

Date:11/23/04ISR Number: 4508552-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505099A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL

150MG Twice

per day 4 DAY

Date:11/23/04ISR Number: 4508553-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505139A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Mixed Connective Tissue		Wellbutrin Sr	PS	Glaxosmithkline	ORAL

Dose Duration

150MG Twice

Disease

per day 4 YR

Date:11/23/04ISR Number: 4508554-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505262A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Chest Discomfort		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
	Dyspnoea					
	Eye Pruritus					
	Hypersensitivity					
	Nasal Discomfort					
	Ocular Hyperaemia					
	Pruritus					
	Sneezing					
	Somnolence					
	Throat Irritation					

Dose Duration

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508555-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505382A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Headache						per day	10 DAY
			Klonopin	C				
			Lopid	C				
			Timoptic	C				
			Xalatan	C				

Date:11/23/04ISR Number: 4508556-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505418A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Discharge		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice	
							per day	3 YR

Date:11/23/04ISR Number: 4508557-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505419A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Increased Appetite						per day	1 YR
	Insomnia		Detrol La	C				
	Weight Increased		Yasmin	C				

Date:11/23/04ISR Number: 4508558-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505455A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Crying		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
			Zoloft	C		

12 YR

Date:11/23/04ISR Number: 4508559-0Report Type:Periodic Company Report #2004-01334
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice	
	Flatulence						per day	1 MON
	Frequent Bowel Movements		Zoloft	C			UNKNOWN	
	Headache							
	Nausea							

Date:11/23/04ISR Number: 4508560-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505564A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Cholesterol		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Per day	6 YR
	Increased		Sulfasalazine	C				
	Blood Triglycerides							
	Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508561-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505578A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Xanax	C				
			Coumadin	C	Glaxosmithkline			
			Cosaar	C				

Date:11/23/04ISR Number: 4508562-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505609A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	5 MON
	Myalgia		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	5 MON
			Buspar	C				
			Herbal Supplements	C				
			Fish Oil	C				
			Vitamin Supplements	C				

Date:11/23/04ISR Number: 4508563-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505933A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	9 MON
	Leukopenia							
			Mvi	C				

Date:11/23/04ISR Number: 4508564-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505939A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	50MG Per day	2 WK
			Zantac	C	Glaxosmithkline			
			Prilosec	C	Glaxosmithkline			
			Topamax	C				
			Zoloft	C				
			Allegra	C				

Date:11/23/04ISR Number: 4508565-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505972A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash Pruritic						per day	3 WK

Date:11/23/04ISR Number: 4508566-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505974A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swollen Tongue		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	3 WK
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508567-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505984A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	75MG Per day	6 YR
			Chemotherapy	C				
			Effexor	C				
			Tamoxifen	C				

Date:11/23/04ISR Number: 4508568-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506015A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Sr	PS	Glaxosmithkline			2 WK
	Urticaria							

Date:11/23/04ISR Number: 4508569-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506125A
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bulimia Nervosa		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Per day	
	Therapeutic Response		Paxil Cr	SS	Glaxosmithkline	ORAL	37.5MG Per	
	Decreased						day	

Date:11/23/04ISR Number: 4508570-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506221A
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Unknown	
	Constipation							
	Visual Disturbance							

Date:11/23/04ISR Number: 4508571-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506226A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Twice per day	5 WK
			Zoloft	C				
			Abilify	C				

Date:11/23/04ISR Number: 4508572-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506227A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508573-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506375A
Age:65 YR Gender:Female I/FU:I

Outcome	PT
	Blood Pressure Increased
	Tinnitus

Visual Acuity Reduced

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
			Zoloft	C				2 YR
			Combipatch	C				

Date:11/23/04ISR Number: 4508574-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506376A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Strattera	C				
			Armour Thyroid	C				

Date:11/23/04ISR Number: 4508575-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506484A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotrichosis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	8 YR
			Prevacid	C				
			Estrace	C				
			Ziac	C				
			Bextra	C				
			Guiafenesin-Dm	C				

Date:11/23/04ISR Number: 4508576-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506509A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	
	Insomnia		Effexor Xr	SS		ORAL	150MG Per day	2 YR
			Protonix	C				
			Yasmin	C				

Date:11/23/04ISR Number: 4508577-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506519A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508578-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506520A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	1 WK
	Night Sweats		Zoloft	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508579-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506579A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508580-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506812A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	4 YR
	Drug Withdrawal Syndrome		Synthroid	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508581-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506858A
Age:81 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Norvasc	C				
			Lisinopril	C				
			Atenolol	C				
			Clonidine	C				
			Paroxetine	C	Glaxosmithkline			
			Plavix	C				
			Pepcid	C				
			Nitro Patch	C	Glaxosmithkline			
			Insulin	C				

Date:11/23/04ISR Number: 4508582-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506922A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Restlessness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Twice per day	6 MON					
			Oral Contraceptive	C		

Date:11/23/04ISR Number: 4508583-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506928A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Blood Pressure Increased							
	Heart Rate Increased							

Date:11/23/04ISR Number: 4508584-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506941A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Dyspnoea		Inh	C	Glaxosmithkline			
	Yawning							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508585-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506949A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Rectal Haemorrhage		Zyrtec	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508586-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506958A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	55 DAY
	Stomach Discomfort		No Concurrent					
	Urticaria		Medication	C				

Date:11/23/04ISR Number: 4508587-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506966A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	2 WK
	Nasopharyngitis		Concerta	C				
	Nausea							
	Skin Wrinkling							

Date:11/23/04ISR Number: 4508588-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507162A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	
	Tremor							

Date:11/23/04ISR Number: 4508589-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507169A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
			Celexa	C				
			Lisinopril	C				
			Wellbutrin Xl	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508590-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507189A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hot Flush		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Hyperhidrosis						per day	2 DAY
			Vitamins	C				

Date:11/23/04ISR Number: 4508591-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507196A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychomotor Hyperactivity		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	2 DAY
			Sam-E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508592-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507263A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness						per day	3 WK
	Pruritus							
	Rash							
	Urticaria							

Date:11/23/04ISR Number: 4508593-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507273A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice	
							per day	8 MON
			Seroquel	C				

Date:11/23/04ISR Number: 4508594-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507282A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Per day	30 MON
	Purging							

Date:11/23/04ISR Number: 4508595-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507283A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Sr	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508596-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507454A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Alprazolam	C				

Date:11/23/04ISR Number: 4508597-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507562A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK

Date:11/23/04ISR Number: 4508598-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507695A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Emotional Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508599-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507907A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Suicidal Ideation		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 WK

Date:11/23/04ISR Number: 4508600-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507938A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia Dissociation Dizziness Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508601-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508032A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Plavix	SS		ORAL		
			Xanax	C		ORAL	15 YR	

Date:11/23/04ISR Number: 4508602-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508052A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK

Date:11/23/04ISR Number: 4508603-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508085A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
	Fluid Retention		Synthroid	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508604-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508210A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	8	DAY
	Dry Mouth		Cenestin	C			UNKNOWN	
	Feeling Abnormal							
	Headache							
	Photophobia							
	Therapeutic Response							
	Unexpected							

Date:11/23/04ISR Number: 4508605-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508353A
Age:44 YR Gender:Female I/FU:I

Outcome	PT
	Agitation
	Anger

Insomnia

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Date:11/23/04ISR Number: 4508606-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508428A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cataract		Wellbutrin	PS	Glaxosmithkline	ORAL	20	MON

Date:11/23/04ISR Number: 4508607-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508433A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Twice per day	2 YR
			Prozac	C				

Date:11/23/04ISR Number: 4508608-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508459A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Weight Increased		Paxil	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508609-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508463A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Myalgia		Amitriptyline	C				
	Neck Pain		Perphenazine	C	Glaxosmithkline			
			Lamictal	C	Glaxosmithkline			
			Zoloft	C				
			Amitriptyline	C				

Date:11/23/04ISR Number: 4508610-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508566A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508611-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508745A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective						per day	3 YR
			Bupropion Hydrochloride	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508612-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508768A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Parosmia							

Date:11/23/04ISR Number: 4508613-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508786A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown 2 WK
			Botox Injection	SS				
			Primidone	C				
			Diazepam	C				
			Oxycodone	C				

Date:11/23/04ISR Number: 4508614-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508959A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK

Date:11/23/04ISR Number: 4508615-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508978A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Five times per day	2 YR
	Overdose							
			Cordarone	C				
			Ativan	C				

			Neurontin	C		
			Coumadin	C	Glaxosmithkline	

Date:11/23/04ISR Number: 4508616-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508982A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hunger		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150TAB Per	
	Weight Increased							
day								8 MON
			Prozac	C				
			Vit B12	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508617-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509131A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508618-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509236A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	9 MON
			Estrace	C				

			Provera	C		
			Prenatal Vitamins	C		

Date:11/23/04ISR Number: 4508619-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509246A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Enzyme Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 WK
			Nabumetone	C	Glaxosmithkline			
			Prednisone	C				

Date:11/23/04ISR Number: 4508620-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509446A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
			Asa	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508621-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509454A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508622-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509550A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Headache		Wellbutrin Xl	C	Glaxosmithkline	ORAL		
			Zoloft	C				

Date:11/23/04ISR Number: 4508623-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509566A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Depressed Mood		Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
	Lacrimation Increased		Klonopin	C		ORAL	.5MG Three times per day	
			Effexor	C		ORAL	75MG At night	

Date:11/23/04ISR Number: 4508624-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509624A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Drug Ineffective							
	Fatigue		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Irritability		Yasmin	C				
	Nausea		Metformin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508626-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509653A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 YR
			Bupropion Hydrochloride	SS	Glaxosmithkline			
			Niacin	C				
			Crestor	C				
			Lanoxin	C	Glaxosmithkline			
			Coumadin	C	Glaxosmithkline			
			Atenolol	C				

Date:11/23/04ISR Number: 4508627-3Report Type:Periodic Company Report #2004-01832
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Drug Withdrawal Headache		Bupropion	SS	Glaxosmithkline	ORAL	100MG Per day	
	Headache							
	Pharmaceutical Product Complaint							

Date:11/23/04ISR Number: 4508628-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509781A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Exposure During		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Unknown	YR
	Pregnancy							
	Drug Exposure Via Breast Milk							

Date:11/23/04ISR Number: 4508629-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509817A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Nightmare		Lorazepam	C				
	Thyroid Function Test		Donnatal	C				
	Abnormal		Synthroid	C	Glaxosmithkline			
			Nexium	C				

Date:11/23/04ISR Number: 4508630-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509819A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
	Insomnia							
			Advair	C	Glaxosmithkline			
			Serevent	C	Glaxosmithkline			
			Celebrex	C				
			Allegra	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508631-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509964A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	7	WK

Date:11/23/04ISR Number: 4508632-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510010A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Medication Error		Zyban	SS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Psychomotor Hyperactivity		No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508633-9Report Type:Periodic Company Report #2004-01906
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Bupropion	PS	Glaxosmithkline	ORAL	150MG Per day	
			Multivitamin	C		ORAL		

Date:11/23/04ISR Number: 4508635-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510194A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508636-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0056952A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY
	Bruxism		Elavil	C	Glaxosmithkline			
	Feeling Jittery		Zoloft	C				
	Nervousness		Paxil	C	Glaxosmithkline			
			Pepcid	C				
			Antacids	C				
			Tylenol	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508638-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0365399A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Feeling Hot							

Date:11/23/04ISR Number: 4508639-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0371708A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
			Celexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508640-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0381524A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
			Oral Contraceptive	C		ORAL		
			Asthma Medication	C				
UNKNOWN								

Date:11/23/04ISR Number: 4508641-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0411787A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON

Date:11/23/04ISR Number: 4508642-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441170A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508643-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441171A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508644-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510208A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Disorientation						per day	31 DAY
	Disturbance In Attention		Wellbutrin Xl	SS	Glaxosmithkline			
	Fatigue		Metformin	C				
	Irritability		Oral Contraceptives	C				
	Mood Altered							
	Nausea							

Date:11/23/04ISR Number: 4508645-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510311A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Bupropion	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508646-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510409A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
							per day	
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508647-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510526A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Unknown
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508648-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510536A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Twice
							per day	2 YR
			Ambien	C				

Date:11/23/04ISR Number: 4508649-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510719A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Per day 1 MON
	Nervousness		Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
	Tremor		Zyprexa	C				

Date:11/23/04ISR Number: 4508650-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510730A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG	Twice
	Mood Swings							
							per day	2 YR
	Psychomotor Hyperactivity		Seroquel	C				

			Depakote	C		

Date:11/23/04ISR Number: 4508651-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510738A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Two	
	Decreased						times per	
							week	

Date:11/23/04ISR Number: 4508652-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510751A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	
			Celexa	C				

Date:11/23/04ISR Number: 4508653-4Report Type:Periodic Company Report #2004-02103
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Bupropion					
	Emotional Disorder		Hydrochloride	PS	Glaxosmithkline	ORAL	100MG Per day	
			Wellbutrin Sr	C	Glaxosmithkline	ORAL	100MG Per day	5 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508654-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510907A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
	Sexual Dysfunction							
			Birth Control Pill	C		ORAL		

Date:11/23/04ISR Number: 4508655-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511275A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
			Percocet	C				
			Tylenol Pm	C				

Date:11/23/04ISR Number: 4508656-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511435A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Sr	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508657-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511460A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	

Date:11/23/04ISR Number: 4508658-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511561A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Tendency To		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	6	MON
	Bruise							
	Irritability							

Date:11/23/04ISR Number: 4508659-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511573A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anhedonia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	350MG Per day	
	Anxiety		Benzodiazepam	C				
	Tinnitus		Effexor Xr	C				
			Beconase	C	Glaxosmithkline	NASAL		
			Klonopin	C				

Date:11/23/04ISR Number: 4508660-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511574A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Unknown	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508661-3Report Type:Periodic Company Report #2004-02254
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Bupropion	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Drug Ineffective							
	Meniere'S Disease							
	Nausea							
	Sudden Hearing Loss							
	Tinnitus							
	Vertigo							

Date:11/23/04ISR Number: 4508664-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511751A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
			Topamax	C				

Date:11/23/04ISR Number: 4508665-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511776A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	3 YR
	Muscle Spasms							
	Myalgia							
	Palpitations							

Date:11/23/04ISR Number: 4508666-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511919A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Arthralgia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Twice per day 1 WK	Rash					

Date:11/23/04ISR Number: 4508667-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512032A
Age:11 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG	Unknown

Date:11/23/04ISR Number: 4508668-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512067A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline			
	Therapeutic Response Decreased							

Date:11/23/04ISR Number: 4508669-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512073A
Age:53 YR Gender:Female I/FU:F

Outcome	PT
	Drug Ineffective
	Pharmaceutical Product

Complaint

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	4 YR
			Synthroid	C	Glaxosmithkline			
			Allegra	C				

Date:11/23/04ISR Number: 4508670-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512086A
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON
Other								

Date:11/23/04ISR Number: 4508671-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512231A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	0	DAY
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	6 WK
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508672-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512232A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

			Lexapro	C		

Date:11/23/04ISR Number: 4508673-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512337A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Pharmaceutical Product Complaint		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508674-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512387A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Per day	

Date:11/23/04ISR Number: 4508675-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512395A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	2	WK
			Wellbutrin	SS	Glaxosmithkline	ORAL	2	WK
			Valium	C				
			Remeron	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508676-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512416A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dry Mouth						per day	1 WK
			Fluoxetine	C				
			Lipitor	C				
			Diazepam	C				
			Metoprolol	C				

Date:11/23/04ISR Number: 4508677-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512420A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	

Date:11/23/04ISR Number: 4508678-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512621A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Urticaria		Bupropion	SS	Glaxosmithkline	ORAL		
			Xanax	C				

Date:11/23/04ISR Number: 4508679-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512633A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	

	Rash					
per day						
			Ortho-Evra	C		
TOPICAL						

Date:11/23/04ISR Number: 4508680-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512636A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508681-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512881A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash						per day	
			Allegra	C				

Date:11/23/04ISR Number: 4508682-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512965A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Weight Decreased		Xanax	SS				
			Effexor Xr	C				
6 MON								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508683-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512966A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Tremor							

Date:11/23/04ISR Number: 4508684-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513047A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Unknown	22 WK

Date:11/23/04ISR Number: 4508685-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513051A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Lisinopril	C				
			Rhinocort	C				
			Protonix	C				

Date:11/23/04ISR Number: 4508686-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513268A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Tinnitus							

			Zestril	C		
			Protonix	C		
			Trazodone	C		
			Klonopin	C		
			Zocor	C		

Date:11/23/04ISR Number: 4508687-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513274A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice	
	Erectile Dysfunction						per day	1 YR
			Effexor	C				
			Clonazepam	C				
			Atenolol	C				
			Flomax	C				
			Morphine Sulfate	C	Glaxosmithkline			
			Levoxyl	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508688-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513294A
Age:24 YR Gender:Female I/FU:I

Outcome	PT
Other	Hallucination
	Paranoia
	Therapeutic Response
	Unexpected

Weight Decreased

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508689-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513573A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen False		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	54 MON
	Positive							

Date:11/23/04ISR Number: 4508690-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513616A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Urticaria		No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508693-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513652A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
			Tegretol	C				

Date:11/23/04ISR Number: 4508694-7Report Type:Periodic Company Report #2004-02446
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	100MG	Unknown 31 DAY
	Abdominal Pain		Bentyl	C			UNKNOWN	10MG Twice per day
	Arthralgia		Singular	C			UNKNOWN	
	Diarrhoea		Ortho Novum	C				
	Muscle Spasms		Nexium	C			UNKNOWN	40MG Unknown
	Pharmaceutical Product		Lomotil	C			UNKNOWN	
	Complaint		Topamax	C			UNKNOWN	50MG Per day
	Pyrexia		Chromium	C			400MG	Twice per day
	Vomiting		Phentermine	C	Glaxosmithkline		UNKNOWN	37.5U Unknown

Date:11/23/04ISR Number: 4508698-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513792A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG	Three times per day 1 WK
			Wellbutrin	SS	Glaxosmithkline	ORAL		
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508699-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513804A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508700-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513812A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 DAY
			Allegra	C				

Date:11/23/04ISR Number: 4508701-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513817A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Seroquel	C				

Date:11/23/04ISR Number: 4508702-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513832A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	
	Urticaria		Lexapro	C				

Date:11/23/04ISR Number: 4508703-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513834A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508704-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514148A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK
			Prometrium	C				
			Estradiol	C				

Date:11/23/04ISR Number: 4508705-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514275A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508706-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514339A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY
	Unexpected		Vistaril	C				
			Unknown Medication	C				

Date:11/23/04ISR Number: 4508707-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514467A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Pruritus							

Date:11/23/04ISR Number: 4508708-4Report Type:Periodic Company Report #2004-02596
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Single
	Erythema						dose	
	Feeling Hot		Naproxen	SS		ORAL	500MG	Single
	Pruritus						dose	
	Pruritus Generalised		Mucinex	SS		ORAL	600MG	Single
	Rash Macular						dose	
			Zovirax	C	Glaxosmithkline		UNKNOWN	
			Aspirin	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508713-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514525A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline		150MG Twice	
	Mania						per day	
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			Geodon	C				
			Depakote	C				

Date:11/23/04ISR Number: 4508714-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514656A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Celexa	SS			UNKNOWN	

Date:11/23/04ISR Number: 4508715-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514665A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	5 WK
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508716-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514693A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	2 WK
	Nausea							

Date:11/23/04ISR Number: 4508717-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514845A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Bupropion	PS	Glaxosmithkline	ORAL	150MG Per day	133 DAY

Date:11/23/04ISR Number: 4508718-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514867A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	

Date:11/23/04ISR Number: 4508719-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514883A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	4 DAY
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508720-5Report Type:Periodic Company Report #2004-02598
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Eye Pruritus Parosmia		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508721-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515129A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Libido Increased		Klonopin	C				
			Cholesterol Reducing Agent	C				

Date:11/23/04ISR Number: 4508722-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515142A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508723-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515144A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	200MGK Twice	
	Heart Rate Irregular						per day	
	Hot Flush		Birth Control Pill	C				

Date:11/23/04ISR Number: 4508724-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515162A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Intervertebral Disc		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Twice	
	Protrusion						per day	5 YR
	Lung Infection		Advair	C	Glaxosmithkline			
	Weight Increased		Albuterol	C	Glaxosmithkline			
			Buspar	C				
			Theophylline	C				
			Flexeril	C				
			Klonopin	C				
			Lisinopril	C				
			Trazodone	C				
			Clarinex	C				
			Allegra	C				
			Benadryl	C	Glaxosmithkline			
			Tavist	C				
			Ortho Tri-Cyclen	C				

Date:11/23/04ISR Number: 4508725-4Report Type:Periodic Company Report #2004-02699
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Bupropion					

	Stomach Discomfort		Hydrochloride	PS	Glaxosmithkline	ORAL
150MG Per day						

Date:11/23/04ISR Number: 4508726-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515387A
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 1 YR						
	Therapeutic Response		Hytrin	C		
	Unexpected		Lescol	C		
			Prinivil	C		

Date:11/23/04ISR Number: 4508727-8Report Type:Periodic Company Report #2004-02824
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Bupropion Sr	PS	Glaxosmithkline	ORAL
150MG Twice						
	Therapeutic Response					
per day						
	Decreased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508728-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515598A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508729-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515686A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Yawning							

Date:11/23/04ISR Number: 4508730-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515725A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Unknown	
	Nausea							
	Vomiting							

Date:11/23/04ISR Number: 4508731-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515733A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Gingival Pain						per day	16 DAY
	Lip Blister		Toprol	C				
	Mouth Ulceration		Isordil	C				

	Pain In Extremity		Niaspan	C		
			Zetia	C		

Date:11/23/04ISR Number: 4508732-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515759A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	4 DAY
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508734-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515831A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	1	YR
			Unspecified Medications	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508735-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515849A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice	
	Decreased						per day	
			Wellbutrin	C	Glaxosmithkline	ORAL	150MG Twice	
							per day	YR

Date:11/23/04ISR Number: 4508736-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515905A
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Insomnia						per day	10 WK
			Blood Pressure Medication	C				
			Unknown Medication	C				

Date:11/23/04ISR Number: 4508737-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515908A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr	PS	Glaxosmithkline	NASAL		

Date:11/23/04ISR Number: 4508738-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515910A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY

Coreg	C	Glaxosmithkline
Proscar	C	
Neurontin	C	
Furosemide	C	Glaxosmithkline
Monopril	C	
Potassium	C	
Lanoxin	C	Glaxosmithkline
Nitrodur Patch	C	Glaxosmithkline
Insulin	C	
Hemocyte	C	
Amitriptyline	C	

Date:11/23/04ISR Number: 4508739-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516103A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	1	MON
	Constipation							

Date:11/23/04ISR Number: 4508740-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516133A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	5	MON
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508741-2Report Type:Periodic Company Report #2004-02794
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Bupropion Sr	PS	Glaxosmithkline	ORAL	150MG	
	Constipation						Variable dose	25 DAY
	Feeling Cold		Nicorette	C	Glaxosmithkline	ORAL		
	Heart Rate Increased		Mvi	C				
	Insomnia		Calcium	C				
	Panic Attack		Magnesium	C				
	Pharmaceutical Product Complaint		Aspirin	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508742-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516223A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508743-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516226A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Propecia	C				

Date:11/23/04ISR Number: 4508744-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516253A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	15 MON
	Loss Of Libido		Fosamax	C				
			Effexor	C				

Date:11/23/04ISR Number: 4508745-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516437A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508746-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516626A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice	
	Pharmaceutical Product						per day	4 YR
	Complaint		Xanax	C				
			Synthroid	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508747-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516906A
Age:12 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	32 DAY
			Ritalin	C				

Date:11/23/04ISR Number: 4508748-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517078A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Prednisone	C				

Date:11/23/04ISR Number: 4508749-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517267A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	5 MON
	Dry Mouth		Niacin	C				
			Lipitor	C				

Date:11/23/04ISR Number: 4508750-3Report Type:Periodic Company Report #2004-02794
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Bupropion Hcl	PS	Glaxosmithkline	ORAL	150MG See dosage text	
	Cold Sweat							
	Constipation							
	Dizziness							

Heart Rate Increased
Hyperhidrosis
Insomnia
Micturition Disorder
Panic Attack
Peripheral Coldness
Pharmaceutical Product
Complaint
Sensation Of Heaviness

Date:11/23/04ISR Number: 4508751-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517687A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Weight Decreased						per day	6 MON
			Oral Contraceptives	C				

Date:11/23/04ISR Number: 4508752-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517771A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508753-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517798A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Drug Reaction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
	Sexual Dysfunction							
			Viagra	C				

Date:11/23/04ISR Number: 4508754-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518016A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Three times per day	
	Pain In Extremity							
			Levoxyl	C	Glaxosmithkline	ORAL		
			Metformin	C		ORAL	500MG Twice per day	
			Multivitamin	C				
			Calcium	C				
			Glucophage	C		ORAL	500MG Twice per day	
			Glucosamine + Chondroitin	C		ORAL		

Date:11/23/04ISR Number: 4508755-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518186A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508756-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518230A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 WK
			Celexa	C			20MG per day	

Date:11/23/04ISR Number: 4508757-6Report Type:Periodic Company Report #2004-03080
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Bupropion Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Disturbance In Attention							
	Drug Ineffective		Benadryl	C	Glaxosmithkline		UNKNOWN	
	Dysarthria							
	Euphoric Mood							
	Nervousness							

Date:11/23/04ISR Number: 4508758-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518513A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK
	Nervousness							
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508759-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518545A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
			Fluoxetine	C				

Date:11/23/04ISR Number: 4508760-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518551A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508761-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518555A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR
	Constipation							
			Effexor	C				

Date:11/23/04ISR Number: 4508762-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518616A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	2 YR	
			Lipitor	C				
			Doxepin	C				

Date:11/23/04ISR Number: 4508763-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518793A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	4 WK

Date:11/23/04ISR Number: 4508764-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518820A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	
	Flatulence							
	Pharmaceutical Product		Flexeril	C				
	Complaint		Endocet	C				
	Skin Odour Abnormal		Nasacort Aq Nasal Spray	C		NASAL		
			Protonix	C				
			Allegra	C				
			Zoloft	C				
			Ambien	C				
			Topamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508765-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518822A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection		Wellbutrin Sr	PS	Glaxosmithkline	VAGINAL		
	Vaginal Burning Sensation Vaginal Mycosis		Trazodone	C				

Date:11/23/04ISR Number: 4508766-7Report Type:Periodic Company Report #2004S1001835
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	Unknown
			Lotrel	SS		ORAL	10MG	Per day
			Lexapro	SS		ORAL	10MG	Unknown
			Clonidine Hydrochloride	C		ORAL	.2MG	Twice per day
			Hydrochlorothiazide + Amiloride	C		ORAL	50MG	Per day
			Percocet	C		ORAL	10MG	Unknown
			Trazodone	C				
			Nexium	C				
			Bextra	C				
			Carisoprodol	C				
UNKNOWN							150MG	Unknown
UNKNOWN							40MG	Per day
UNKNOWN							20MG	Unknown
UNKNOWN							350MG	Unknown

Date:11/23/04ISR Number: 4508767-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519050A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR
	Abnormal							
			Accutane	C				

Date:11/23/04ISR Number: 4508768-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519185A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hot Flush		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Bupropion Hydrochloride	SS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508769-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519217A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Wellbutrin	PS	Glaxosmithkline	ORAL	7	DAY
	Arthralgia		No Concurrent Medication	C				
	Paraesthesia							
	Rash							
	Serum Sickness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508770-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519230A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Tremor						per day	3 YR
			Zoloft	C				
			Plavix	C				
			Nitroglycerin	C	Glaxosmithkline			
			Terazosin	C				
			Xalatan	C				

Date:11/23/04ISR Number: 4508771-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519246A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR

Date:11/23/04ISR Number: 4508772-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519332A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508773-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519354A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Metrorrhagia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508774-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519367A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	8	YR
	Drug Ineffective		Zoloft	C				

Date:11/23/04ISR Number: 4508775-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519528A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
	Pruritus		Soy	C		ORAL		

Date:11/23/04ISR Number: 4508776-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519708A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tinnitus						per day	3 YR
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508777-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519716A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	30 WK
	Irritability		No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508778-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519729A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nystagmus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	6 MON

Date:11/23/04ISR Number: 4508779-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519919A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	8 MON
	Rash		Lexapro	C				

Date:11/23/04ISR Number: 4508781-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520512A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Rash							
	Urticaria		Plavix	C				

Date:11/23/04ISR Number: 4508782-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520729A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	450MG Per day	8 YR
			K-Dur	C	Glaxosmithkline			
			Lasix	C	Glaxosmithkline			
			Ambien	C				
			Ativan	C				

Date:11/23/04ISR Number: 4508783-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520768A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	1TAB Twice per day	1 WK

Date:11/23/04ISR Number: 4508784-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520921A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508785-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521295A
Age:60 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	

Date:11/23/04ISR Number: 4508786-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521433A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensory Disturbance		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508787-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521535A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Alcohol	C				

Date:11/23/04ISR Number: 4508788-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521539A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Per day	6 MON
	Stomach Discomfort		No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508789-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521546A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypoaesthesia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
100MG Twice						
	Skin Discolouration					
per day 2 YR						

Date:11/23/04ISR Number: 4508790-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521556A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Twice						
	Headache					
per day 10 MON						
			Ephedra	C		
			Allegra	C		

Date:11/23/04ISR Number: 4508791-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521582A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hallucination		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
	Heart Rate Increased					
	Tremor					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508792-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521634A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	4 YR
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508793-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521637A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK
			Coffee	C				

Date:11/23/04ISR Number: 4508794-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521664A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	8 MON
	Depression		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Dyspepsia		Prempro	C				
			Xanax	C				
			Robaxin	C				

Date:11/23/04ISR Number: 4508795-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521816A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	

Rash
per day 6 DAY

Birth Control Pills C

Date:11/23/04ISR Number: 4508796-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521840A
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Xanax	C				
			Zestril	C				

Date:11/23/04ISR Number: 4508797-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521977A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/23/04ISR Number: 4508798-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521997A
Age:44 YR Gender:Female I/FU:I

Outcome	PT
	Anxiety
	Depression

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Fatigue		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG As required	3 MON
			Klonopin	C				
			Imitrex	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508799-0Report Type:Periodic Company Report #S04-USA-04583-01
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	
			Lexapro	SS		ORAL	10MG Per day	
			Hydrochlorothiazide	C				

Date:11/23/04ISR Number: 4508801-6Report Type:Periodic Company Report #2004-03577
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Constipation		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Per day	39 DAY
	Cough		Mobec	SS			UNKNOWN	99 DAY
	Diarrhoea		Topamax	SS			UNKNOWN	
	Nausea Weight Decreased		Asa	C	Glaxosmithkline			
			Calcium	C				
			Vitamin C	C	Glaxosmithkline			
			Vitamin E	C				
			Centrum Silver	C				
			Osteo Biflex	C				

Date:11/23/04ISR Number: 4508802-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522134A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Sr	PS	Glaxosmithkline			
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508803-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522140A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG	Unknown

Date:11/23/04ISR Number: 4508804-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522257A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eczema		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
			Lipitor	C				
			Lasix	C	Glaxosmithkline			
			Atenolol	C				
			Zestril	C				
			Zoloft	C				

					Hydrochlorothiazide	C		
					Prilosec	C	Glaxosmithkline	
					Loratadine	C		

Date:11/23/04ISR Number: 4508805-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522438A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Twice per day	9 MON

Date:11/23/04ISR Number: 4508806-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522459A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	3 YR
	Insomnia		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	
	Lethargy		Avalide	C				
			Multivitamin	C				

Date:11/23/04ISR Number: 4508807-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522480A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dental Caries		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	18 MON
	Insomnia							
	Salivary Hypersecretion		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	6 MON
			Blood Thinner	C				
			Ultram	C				
			Celebrex	C				

Date:11/23/04ISR Number: 4508808-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522567A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
			Paxil	C	Glaxosmithkline	ORAL		
			Xanax	C				

Date:11/23/04ISR Number: 4508809-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522605A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Eyelid Pain						per day	
	Nausea							

Date:11/23/04ISR Number: 4508810-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522624A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Eye Pain						per day	
	Nausea		No Concurrent					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Medication C

Date:11/23/04ISR Number: 4508811-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522802A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Ineffective						per day	2 MON
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508812-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522820A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Multiforme		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Oedema Peripheral						per day	3 WK
	Urticaria		Toprol Xl	C				
			Levothyroxin	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508813-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522824A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	18	MON
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508814-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523053A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Discomfort		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice
	Anxiety						
per day 2 YR							
	Dry Eye		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day 6 MON
	Headache		Lorazepam	C			
	Tremor						

Date:11/23/04ISR Number: 4508815-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523082A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Granuloma Annulare		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice
per day 2 YR							
			No Concurrent Medication	C			

Date:11/23/04ISR Number: 4508816-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523326A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice
	Toothache						
per day 4 MON							
			Glucophage	C			
			Hctz	C			
			Calcium	C			
			Magnesium	C			

			Zinc	C		
			Unknown Medication	C		

Date:11/23/04ISR Number: 4508817-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523481A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Twice	
	Drug Toxicity						per day	2 WK
	Dysgeusia		Oral Contraceptives	C				
	Ill-Defined Disorder							
	Insomnia							
	Medication Error							
	Rash							

Date:11/23/04ISR Number: 4508818-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523630A
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Amnesia		Vitamins	C				
	Blood Pressure Increased							

Date:11/23/04ISR Number: 4508819-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523641A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Paraesthesia							

Date:11/23/04ISR Number: 4508820-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523767A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508821-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523821A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Pharmaceutical Product						per day	1 YR
	Complaint		Allegra	C				
	Pruritus		Stool Softener	C				
			Aciphex	C				
			Estraderm	C				

Date:11/23/04ISR Number: 4508822-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524243A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	9 WK
			Tylenol #3	C				
			Prevacid	C				

			Hydralazine	C	
			Lotensin	C	Glaxosmithkline
			Neurontin	C	
			Isosorbide	C	

Date:11/23/04ISR Number: 4508823-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524244A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Exposure During		Wellbutrin Sr	PS	Glaxosmithkline		100MG Twice	
	Pregnancy							
	Lethargy						per day	9 MON
			Prenatal	C				
			Anti-Nausea Drugs	C				
			Phenergan	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508824-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524535A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4508825-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524745A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	42 MON
	Lethargy							
			Ambien	C				
			Calcium	C				
			Vitamin E	C				

Date:11/23/04ISR Number: 4508826-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524746A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Genital Pruritus Female		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	MON
	Vaginitis Bacterial		Spironolactone	C				

Date:11/23/04ISR Number: 4508827-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524771A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 MON
			Geodon	C				

Date:11/23/04ISR Number: 4508828-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525238A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice per day	11 DAY
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508829-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525425A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:11/23/04ISR Number: 4508830-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525452A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Smoker		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Stomach Discomfort							1 YR

Date:11/23/04ISR Number: 4508831-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525729A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Papular		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	5 DAY

Date:11/23/04ISR Number: 4508832-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525801A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Tramadol	C				
			Prevacid	C				
			Ziac	C				

Date:11/23/04ISR Number: 4508833-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525825A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Lisinopril	C				
			Aspirin	C	Glaxosmithkline			
			Zocor	C				
			Vitamin	C				
			Insulin	C				

Date:11/23/04ISR Number: 4508834-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525827A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 MON
			Clonidine	SS			UNKNOWN	3 DAY

Date:11/23/04ISR Number: 4508835-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526003A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	900MG Per day	
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508836-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526197A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lipitor	C				

Date:11/23/04ISR Number: 4508837-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526689A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	6 YR
	Somnolence		Celexa	C				

Date:11/23/04ISR Number: 4508838-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526709A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice per day	2 MON
			No Concurrent Medication	C				

Date:11/23/04ISR Number: 4508839-9Report Type:Periodic Company Report #2004/04109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Bupropion Sr	PS	Glaxosmithkline	ORAL	150MG Single dose	
	Dizziness							
	Insomnia		Librium	C			5MG As	

required

			Toprol Xl	C		
50MG Per day						
			Norvasc	C		
5MG Per day						

Date:11/23/04ISR Number: 4508840-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526866A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice	
per day								5 YR
			Depakote	C				

Date:11/23/04ISR Number: 4508841-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526879A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Per day	2 YR
	Increased Blood Alkaline Phosphatase Increased		Klonopin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508842-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527096A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	3 MON
			Cytomel	C	Glaxosmithkline			
			Levoxyl	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508843-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527116A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hot Flush		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Insomnia							
	Menstruation Irregular							

Date:11/23/04ISR Number: 4508847-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527290A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Concerta	C				
			Diet Pill					
			Unspecified	C				

Date:11/23/04ISR Number: 4508848-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527298A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice	

per day 2 MON

No Concurrent Medication C

Date:11/23/04ISR Number: 4508849-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527323A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anxiety						per day	5 MON
	Confusional State		Nicorette	C	Glaxosmithkline			
	Euphoric Mood							
	Irritability							
	Paranoia							

Date:11/23/04ISR Number: 4508852-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527395A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash						per day	17 DAY
	Urticaria		Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508853-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527397A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	56 WK
			Paxil Cr	C	Glaxosmithkline			

Date:11/23/04ISR Number: 4508854-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527407A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	2 DAY
	Fatigue		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Palpitations		Singulair	C				
	Paraesthesia		Zoloft	C				
			Sam-E	C				

Date:11/23/04ISR Number: 4508855-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527423A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Twice per day	6 WK
			Concerta	C				
			Medrol	C				
			Alcohol	C				

Date:11/23/04ISR Number: 4508856-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527583A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	3 YR
	Mania		Lamictal	C	Glaxosmithkline			
			Depakote	C				
			Provigil	C				
			Seroquel	C				

Date:11/23/04ISR Number: 4508858-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527592A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 YR

Date:11/23/04ISR Number: 4508859-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527625A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
	Depression		Synthroid	C	Glaxosmithkline			
	Emotional Disorder		Hormone Patch	C			UNKNOWN	
	Tremor		Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508860-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527709A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508861-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527984A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Bupropion Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	3 YR
	Pain In Extremity							
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
			Adderall	C				
			Estradiol	C				
			Buspar	C				
			Lexapro	C				

Date:11/23/04ISR Number: 4508862-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528268A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL		

Date:11/23/04ISR Number: 4508863-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528543A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice	

	Anxiety						
per day							
			Unknown	C			

Date:11/23/04ISR Number: 4508903-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531408A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bite		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4	DAY
	Convulsion							
	Impaired Driving Ability							
	Medication Error							

Date:11/23/04ISR Number: 4508904-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0532210A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Double Ureter		Bupropion	PS	Glaxosmithkline			
	Drug Exposure During Pregnancy							
	Renal Disorder							
	Vesicoureteric Reflux							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4508914-9Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0534690A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Muscle Spasms Tachycardia Yawning		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	16 DAY

Date:11/23/04ISR Number: 4508918-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0534891A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation Anger Belligerence Delusional Disorder, Persecutory Type Emotional Disorder Psychotic Disorder		Wellbutrin	PS	Glaxosmithkline			

Date:11/23/04ISR Number: 4512050-5Report Type:Expedited (15-DaCompany Report #2004-122401-NL
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anxiety	Health Professional	Remeron	PS			15 MG ONCE	
	Benign Prostatic Hyperplasia		Wellbutrin	SS		ORAL	225 MG DAILY	
	Major Depression		Wellbutrin	SS		ORAL	300 MG DAILY	
	Polyuria					ORAL		
	Urinary Retention		Wellbutrin	SS		ORAL	450 MG DAILY	

ORAL

	Wellbutrin	SS		ORAL

300 MG DAILY

ORAL

	Sertraline Hydrochloride	SS		

50 MG DAILY

	Clonazepam	SS		

Date:11/24/04ISR Number: 4510234-3Report Type:Expedited (15-DaCompany Report #US-ROCHE-379171
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Pegasys	PS	Roche	SUBCUTANEOUS		
	Back Pain		Copegus	SS	Roche	ORAL		
	Blindness		Wellbutrin	SS		ORAL		
FIRST								
	Depression							
THERAPY.								
	Dyspnoea		Wellbutrin	SS		ORAL		
SECOND								
	Headache							
THERAPY.								
	Myalgia		Atenolol	C		ORAL		
	Road Traffic Accident		Bextra	C		ORAL		
	Tinnitus		Zanaflex	C		ORAL		
	Visual Acuity Reduced							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510433-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0534478A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	18	MON
	Bursitis		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Headache		Prozac	C				
	Joint Effusion		Depakote	C				
	Uterine Haemorrhage							

Date:11/24/04ISR Number: 4510462-7Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0351173A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperthyroidism	Health	Bupropion					
	Insomnia	Professional	Hydrochloride	PS	Glaxosmithkline		UNKNOWN	150MG See
	Palpitations							
dosage text	39 DAY							

Date:11/24/04ISR Number: 4513176-2Report Type:Expedited (15-DaCompany Report #USA-2004-0013994
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Atherosclerosis	Consumer	Oxycontin Tablets					
Other	Brain Oedema	Health	(Oxycodone					
	Cardiac Arrest	Professional	Hydrochloride) Cr					
	Coma	Other	Tablet	PS				
	Coronary Artery		Oxyir (Oxycodone					
	Atherosclerosis		Hydfrochloride)	SS			MG	
	Cough		Propoxyphene					
	Drug Dependence		(Dextropropoxyphene)	SS				
	Dyspnoea		Bupropion					
	Emphysema		(Amfebutamone)	SS				
	Feeling Abnormal		Gabapentin					
	Goitre		(Gabapentin)	SS				
	Multiple Drug Overdose		Acetaminophen					

	Accidental	(Paracetamol)	SS
	Pneumonia		
	Pneumonia Aspiration		
	Polysubstance Abuse		
	Pulmonary Congestion		
	Pulmonary Oedema		
	Respiratory Depression		
	Resuscitation		

Date:11/24/04ISR Number: 4513745-XReport Type:Expedited (15-DaCompany Report #HQWYE557919NOV04
Age:62 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation
	Cerebral Atrophy
	Clumsiness
	Confusional State
	Depressed Level Of Consciousness
	Diarrhoea
	Drug Interaction
	Electrocardiogram Qt Prolonged
	Faecal Incontinence

	Gait Disturbance Hallucinations, Mixed Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia Lethargy Myoclonus	Literature	Effexor (Venlfaxine Hydrochloride, Unspec)	PS			75 MG 1X PER
	Serotonin Syndrome						1 DAY
	Transaminases Increased Urinary Incontinence		Bupropion (Amfebutamone,)	SS			300 MG, 1X PER 1 DAY
			Sertraline (Sertraline,)	SS			50 MG 1X PER 1 DAY
			Piracetam (Piracetam)	C			

Date:11/24/04ISR Number: 4514772-9Report Type:Direct Company Report #CTU 233006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Suicide Attempt		Effexor Xr 75 Mg Wyeth	PS	Wyeth	ORAL	75 MG BID ORAL
			Wellbutrin Sr 100 Mg	SS		ORAL	100 MG BID ORAL

Date:11/26/04ISR Number: 4527147-3Report Type:Periodic Company Report #04P-163-0273168-00
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Depression Eye Movement Disorder Fall	Consumer Health Professional	Depakote Er 500mg (Depakote Er) (Divalproex Sodium) (Divalproex Sodium)	PS		ORAL	500 MG, 2 IN 1 D, ORAL	
	Intentional Misuse Weight Increased		Risperidone	SS		ORAL	2 MG, 1 IN 1 D, ORAL	
			Venlafaxine Hydrochloride	SS		ORAL	ORAL	
			Bupropion Hydrochloride	SS		ORAL	ORAL	
			Strattera	C				
			Levothyroxine Sodium	C				
			Quetiapine	C				

Date:11/29/04ISR Number: 4512271-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526859A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Wellbutrin Sr	SS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4512276-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535150A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Anxiety							
	Drug Withdrawal Syndrome							
	Restlessness							
	Sleep Disorder							
	Tremor							

Date:11/29/04ISR Number: 4512287-5Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0347425A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinopathy Hypertensive		Zyban	PS	Glaxosmithkline	ORAL	150MG	
	Tinnitus							
Variable dose	Visual Acuity Reduced		No Concurrent Medication	C			12	DAY

Date:11/29/04ISR Number: 4512303-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0350118A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Vasculitis							
per day							10	DAY
			Cartia	C	Glaxosmithkline	ORAL	1TAB Per day	
			Actonel	C		ORAL		
			Bricanyl	C				
RESPIRATORY								
(INHALATION)								
			Unknown Drug	C				
			Naproxin	C			1G per day	

			Panamax	C	Glaxosmithkline	
			Sinequan	C		
			Spiriva	C		
			Symbicort	C		
			Unknown Drug	C		
			Unknown Drug	C		

Date:11/29/04ISR Number: 4512310-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0356698A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Grand Mal Convulsion						per day	16 DAY
	Tongue Biting		Amitriptyline	C			UNKNOWN	2MG Per day
	Tonic Clonic Movements		Allopurinol	C	Glaxosmithkline		UNKNOWN	100MG Per day
			Hrt	C			UNKNOWN	
			Simvastatin	C			UNKNOWN	10MG Per day
			Enalapril	C			UNKNOWN	10MG Per day

Date:11/29/04ISR Number: 4512314-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0357170A
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Glomerulonephritis		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	9 WK
	Hypertension		Bendrofluazide	C	Glaxosmithkline	ORAL	2.5MG per day	
	Nephrotic Syndrome		Frusemide	C	Glaxosmithkline	ORAL		

			Doxazosin	C		ORAL
			Perindopril	C		ORAL

Date:11/29/04ISR Number: 4512317-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0357185A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	8	DAY
	Chest Discomfort		Ipratropium Bromide	C			40MCG	Three
	Dry Mouth						times per day	
	Feeling Abnormal		Cefaclor	C		ORAL	250MG	Three
	Nausea						times per day	20 DAY
	Tremor		Ventolin	C	Glaxosmithkline		250MCG	As
	Vision Blurred						required	

Date:11/30/04ISR Number: 4513534-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498016A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	36	DAY
	Gastric Perforation		Celexa	C				
	Palpitations		Wellbutrin Sr	C	Glaxosmithkline	ORAL	106	DAY
			Ativan	C				

Date:11/30/04ISR Number: 4513535-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502854A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 4 DAY						
			Guaifenesin	C		
			Albuterol	C	Glaxosmithkline	
			Advil	C	Glaxosmithkline	

Date:11/30/04ISR Number: 4513536-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502870A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 109 DAY						
			Bactrim Ds	C	Glaxosmithkline	ORAL
1U Per day						

Date:11/30/04ISR Number: 4513538-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505370A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	

Date:11/30/04ISR Number: 4513539-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505372A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 1 WK						
			Amerge	C	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513540-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505385A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	52 DAY
			Covera	C				
			Lipitor	C				
			Diovan Hct	C				
			Glucophage	C				
			Vicodin Es	C				
			Mobic	C				

Date:11/30/04ISR Number: 4513541-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505547A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Complaint							

Date:11/30/04ISR Number: 4513542-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507160A
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysarthria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Tremor		Synthroid	C	Glaxosmithkline			
			Zestril	C				

Date:11/30/04ISR Number: 4513543-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508054A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Lexapro	C				

Date:11/30/04ISR Number: 4513544-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508653A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	0 DAY
	Dizziness		Hctz	C				
	Tinnitus		Atenolol	C				

Date:11/30/04ISR Number: 4513545-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515883A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Erythema Multiforme		Wellbutrin	PS	Glaxosmithkline	ORAL	3 WK	
	Rash		Birth Control Pills	C				

Date:11/30/04ISR Number: 4513546-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516258A
Age:45 YR Gender:Male I/FU:F

Outcome
Hospitalization - Initial or Prolonged

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG In the morning	
			Dilantin	C			200MG Three times per day	
			Trazodone	C			200MG At night	
			Zyprexa	C			15MG At night	
			Aspirin	C	Glaxosmithkline		1TAB Per day	
			Plavix	C			75MG Per day	

Date:11/30/04ISR Number: 4513547-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517857A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	6	MON
	Leukopenia							

Date:11/30/04ISR Number: 4513548-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518073A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Anger		Humalog	C				
	Anorexia		Evista	C				
	Anxiety		Vitamins	C				
	Crying							

Dizziness
Dysgeusia
Emotional Disorder
Fungal Infection
Hyperhidrosis
Insomnia
Myalgia
Nausea
Tremor
Weight Decreased

Date:11/30/04ISR Number: 4513549-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518097A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coordination Abnormal		Wellbutrin	PS	Glaxosmithkline			
Other			Cardura	C		ORAL	2MG per day	
			Thalidomide	C				

Date:11/30/04ISR Number: 4513550-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518423A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Oral Contraceptive	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513551-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518798A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
			Adderall	C				

Date:11/30/04ISR Number: 4513552-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518819A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Drug Ineffective		Unknown Medication	C				
	Headache		Effexor	C				
	Nausea		Vistaril	C				
	Sensation Of Heaviness		Vitamins	C				

Date:11/30/04ISR Number: 4513554-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519027A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Tachycardia							

Date:11/30/04ISR Number: 4513555-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519365A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	MON
Disability	Pharmaceutical Product		No Concurrent					
Other	Complaint		Medication	C				
	Suicidal Ideation							

Date:11/30/04ISR Number: 4513556-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520321A
Age:13 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513557-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520375A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	3 MON
	Pharmaceutical Product Complaint Stool Analysis Abnormal		Unknown Medication	C				

Date:11/30/04ISR Number: 4513558-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520513A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Xanax	C				

			Fiorinal 3	C		

Date:11/30/04ISR Number: 4513559-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520520A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoventilation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Insomnia		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513560-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520526A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Depression		Omega 3	C	Glaxosmithkline			
	Insomnia		Selenium	C				
			Niacin	C				
			Vitamin B6	C				
			Vitamin B Complex	C				

Date:11/30/04ISR Number: 4513561-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520527A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 MON
			Buspar	C				
			Zyprexa	C				

Date:11/30/04ISR Number: 4513562-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520537A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
	Urticaria		Claritin	C				

Date:11/30/04ISR Number: 4513563-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520549A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Urticaria		Lexapro	C		ORAL	30MG Per day	
			Xanax	C		ORAL	.15MG Per day	
			Provigil	C		ORAL	100MG In the morning	
			Allegra	C				
			Levoxyl	C	Glaxosmithkline			
			Celebrex	C				
			Cytomel	C	Glaxosmithkline			
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513564-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520552A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513565-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520553A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	13 DAY
	Nausea		Synthroid	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513566-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520558A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Dysphonia		Nexium	C				
	Fatigue		Prednisolone	C	Glaxosmithkline			
	Muscle Tightness							
	Musculoskeletal Stiffness							
	Tremor							

Date:11/30/04ISR Number: 4513567-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520714A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:11/30/04ISR Number: 4513568-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520734A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:11/30/04ISR Number: 4513569-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520744A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline			

Date:11/30/04ISR Number: 4513570-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520747A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 WK
	Visual Disturbance		Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513571-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520758A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Apnoea Syndrome		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
			Ativan	C				
			Flomax	C				
			Advair	C	Glaxosmithkline			
			Claritin	C				
			Flonase	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513572-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520762A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513573-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520774A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	18 MON
	Anxiety		Combivent	C				
	Chest Pain		Norvasc	C				
	Chills		K-Dur	C	Glaxosmithkline			
	Hyperhidrosis		Glucotrol Xl	C				
			Glucophage	C				
			Demadex	C				
			Estratest Hs	C				
			Aygestin	C				
			Methadone	C	Glaxosmithkline			
			Ativan	C				
			Ambien	C				

Date:11/30/04ISR Number: 4513574-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520897A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513575-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520945A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513576-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520949A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Anxiety		Xanax	C				
	Hot Flush							
	Nervousness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513577-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520966A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Xanax	C				
			Zofran	C	Glaxosmithkline			
			Unknown Medication	C				
UNKNOWN								

Date:11/30/04ISR Number: 4513578-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520980A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	17 DAY
	Nervousness		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
			Advil	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513579-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521096A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	11 DAY
			Crestor	C				

Date:11/30/04ISR Number: 4513580-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521105A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513581-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521112A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Genital		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Vulval Oedema		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513582-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521116A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lexapro	C		ORAL	10MG Per day	238 DAY
Other								

Date:11/30/04ISR Number: 4513583-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521222A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Claritin -D	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513584-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521280A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513585-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521284A
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
	Cold Sweat		Prozac	C				
	Nausea		Cardizem	C	Glaxosmithkline			
	Nervousness		Prilosec	C	Glaxosmithkline			
			Bextra	C				
			Tricor	C				
			Premarin	C				
			Zelnorm	C				

Date:11/30/04ISR Number: 4513586-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521298A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Muscle Relaxant	C				

Date:11/30/04ISR Number: 4513587-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521301A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
			Zyprexa	C				

Date:11/30/04ISR Number: 4513588-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521317A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513589-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521408A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown
	Decreased							

Date:11/30/04ISR Number: 4513590-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521430A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Somnolence		Venlafaxine	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513591-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521521A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513592-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521532A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis Interstitial		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Lexapro	C				
			Imitrex	C	Glaxosmithkline			
			Topomax	C				
			Flexeril	C				

Date:11/30/04ISR Number: 4513593-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521562A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 MON
	Throat Tightness		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513594-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521573A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Levoxyl	C	Glaxosmithkline		UNKNOWN	

Date:11/30/04ISR Number: 4513595-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521635A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neck Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513596-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521639A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Blood Pressure Increased		Paxil	C	Glaxosmithkline			
	Dry Mouth		Glucosamine	C				
	Dyspnoea		Tylenol	C	Glaxosmithkline			
	Myalgia		Multivitamin	C				
	Oral Pain		Maalox	C				
	Swollen Tongue		Gaviscon	C	Glaxosmithkline			
	Vision Blurred		Folic Acid	C				
			Visine Tears	C				
			Ranitidine	C	Glaxosmithkline			
			Ditropan	C				
			Lisinopril	C				

			Atenolol	C		

Date:11/30/04ISR Number: 4513597-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521646A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Neurontin	C				

Date:11/30/04ISR Number: 4513598-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521649A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK

Date:11/30/04ISR Number: 4513599-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521655A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Prozac	C				
			Tagamet	C	Glaxosmithkline			
			Multivitamin	C				

Date:11/30/04ISR Number: 4513600-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521657A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Drug Interaction		Robitussin Dm	SS				
			No Concurrent					

			Medication	C		

Date:11/30/04ISR Number: 4513601-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521659A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Amnesia		Triamterene	C	Glaxosmithkline			
	Blood Pressure Increased		Advil Cold + Sinus	C				
	Fatigue							
	Headache							
	Muscular Weakness							

Date:11/30/04ISR Number: 4513602-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521665A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 WK
			Colchicine	C				
			Aspirin	C	Glaxosmithkline			
			Flomax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513603-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521820A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Lymphadenopathy		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513604-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521838A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Headache		No Concurrent Medication	C				
	Nausea							

Date:11/30/04ISR Number: 4513605-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521964A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513606-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521966A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5 WK	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513607-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521967A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Paranoia		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513608-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521969A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Local Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Paraesthesia		Lexapro	C				
	Paraesthesia Oral						UNKNOWN	10MG Unknown

Date:11/30/04ISR Number: 4513609-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521971A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513610-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521975A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
			Flonase	C	Glaxosmithkline			
			Allegra D	C				

Date:11/30/04ISR Number: 4513611-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521978A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	23 WK
	Tremor		Klonopin	C				
			Zoloft	C				
			Verapamil	C				
			Topamax	C				
			Resperidol	C				

Date:11/30/04ISR Number: 4513612-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521983A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Oedema Peripheral							
	Urticaria							

Date:11/30/04ISR Number: 4513613-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522095A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Hyperhidrosis							
	Nausea							

Date:11/30/04ISR Number: 4513614-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522108A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Headache		Hyzaar	C				
			Zoloft	C				
			Yasmin	C				

Date:11/30/04ISR Number: 4513615-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522119A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK
	Insomnia							
	Nausea		Climara	C				
	Vertigo							
	Vestibular Neuronitis							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513616-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522132A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Trazodone	C				

Date:11/30/04ISR Number: 4513617-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522143A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Grand Mal Convulsion		Effexor Xr	C		ORAL	150MG Per day	

Date:11/30/04ISR Number: 4513619-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522220A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Synthroid	C	Glaxosmithkline			
			Vitamins	C				
			Atenolol	C				

Date:11/30/04ISR Number: 4513620-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522221A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513621-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522225A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	WK
	Pancreatitis		Lexapro	C			20MG Per day	
			Unspecified Medications	C				

Date:11/30/04ISR Number: 4513622-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522228A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK

Date:11/30/04ISR Number: 4513623-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522238A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Fatigue		Klor Con	C	Glaxosmithkline			
	Headache		Atenolol	C				
			Hctz	C				
			Estratest Hs	C				
			Effexor Xr	C				

			Provera	C		

Date:11/30/04ISR Number: 4513624-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522240A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Metrorrhagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513625-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522247A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 WK
	Fatigue		No Concurrent					
	Insomnia		Medication	C				

Date:11/30/04ISR Number: 4513626-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522248A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/30/04ISR Number: 4513627-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522254A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Energy Increased		No Concurrent					
	Irritability		Medication	C				

Date:11/30/04ISR Number: 4513628-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522262A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
			Lipitor	C				
			Atenolol	C				
			Zetia	C				
			Plavix	C				

Date:11/30/04ISR Number: 4513629-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522265A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Pruritus		Zoloft	C				
	Rash		Alprazolam	C				
			Bextra	C				
			Albuterol	C	Glaxosmithkline			
			Zyrtec	C	Glaxosmithkline			
			Astelin	C				
			Flonase	C	Glaxosmithkline			
			Temazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513630-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522395A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	57 DAY

Date:11/30/04ISR Number: 4513631-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522439A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Fatigue		No Concurrent					
	Headache		Medication	C				
	Irritability							

Date:11/30/04ISR Number: 4513632-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522445A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	6	MON

Date:11/30/04ISR Number: 4513633-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522448A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
Initial or Prolonged	Urinary Incontinence		Hctz	C				
	Vomiting		Glucophage	C				

Date:11/30/04ISR Number: 4513634-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522460A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513635-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522464A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513636-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522472A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK

Date:11/30/04ISR Number: 4513637-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522478A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Cough							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513638-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522599A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Dry Mouth							
	Insomnia							

Date:11/30/04ISR Number: 4513639-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522629A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Allergic		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day
	Tinnitus		Naprosyn	SS			UNKNOWN	
			Adderall	C				

Date:11/30/04ISR Number: 4513640-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522634A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration	
	Confusional State		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Per day	1 WK
			No Concurrent Medication	C					

Date:11/30/04ISR Number: 4513641-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522635A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration	
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day	3 MON
	Diarrhoea		Unspecified Medication	C			60MG	Per day	35 DAY
	Nausea								

				Lexapro	C		
				Ativan	C		
				Restoril	C		
				Soma	C		
				Codeine	C		
				Premarin	C		
				Fosamax	C		
				Plaquenil	C		
				Prednisone	C		
				Humira	C		
				Norco	C		
				Actonel	C		
				Mvi	C		
				Vitamin D	C		
				Vitamin E	C		

Date:11/30/04ISR Number: 4513643-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522647A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Neurontin	C				
			Synthroid	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513644-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522655A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513645-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522659A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	60MG Per day	MON
Other			Alcohol	SS				
			Adderall	SS				
			Celexa	C				

Date:11/30/04ISR Number: 4513646-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522661A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 DAY
	Feeling Jittery		Klonopin	C				
	Insomnia							

Date:11/30/04ISR Number: 4513647-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522663A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
	Abdominal Pain Upper		Birth Control Pills	C				
	Nausea							

Date:11/30/04ISR Number: 4513648-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522664A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	6	WK
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513649-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522665A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	21 DAY
	Arthralgia		No Concurrent Medication	C				
	Asthenia							
	Dry Mouth							
	Insomnia							
	Pollakiuria							

Date:11/30/04ISR Number: 4513650-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522769A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513651-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522793A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Pharmaceutical Product		Metformin	C				
	Complaint		Actos	C				
	Stool Analysis Abnormal		Zyrtec	C	Glaxosmithkline			
			Lipitor	C				
			L-Thyroxine	C	Glaxosmithkline			
			Estradiol	C				
			Singulair	C				
			Cortisone	C				

Date:11/30/04ISR Number: 4513652-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522794A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
	Irritability							

Date:11/30/04ISR Number: 4513653-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522797A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Increased Appetite							
per day	3 WK							
	Pruritus		Synthroid	C	Glaxosmithkline			
			Maxzide	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513654-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522801A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Movement Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	MON
	Mastication Disorder		Lamictal	C	Glaxosmithkline	ORAL		
	Tardive Dyskinesia		Lexapro	C		ORAL		
			Depakote Er	C		ORAL		
			Geodon	C		ORAL	215 DAY	
			Lorazepam	C		ORAL	.5U As required	

Date:11/30/04ISR Number: 4513655-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522808A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513656-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522809A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513657-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522810A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
	Agitation		Adderall	C		ORAL	10MG Twice	
	Dizziness						per day	
	Nausea							

Date:11/30/04ISR Number: 4513658-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522817A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Tightness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
			Adderall	C				

Date:11/30/04ISR Number: 4513659-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522826A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Memory Impairment							
	Palpitations							
	Panic Reaction							

Date:11/30/04ISR Number: 4513660-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522895A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4 DAY	
	Swelling Face							

	Urticaria					

Date:11/30/04ISR Number: 4513661-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522903A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Sensation Of Blood Flow		Zantac	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513662-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522904A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/30/04ISR Number: 4513663-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522916A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Nausea		Vioxx	C				
			Activella	C				
			Effexor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513664-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522922A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513665-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522929A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513666-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523038A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Eyelid Oedema		Toprol Xl	C				
	Throat Irritation		Levothroid	C	Glaxosmithkline			
	Urticaria		Buspar	C				
			Hyzaar	C				
			Celebrex	C				
			Questran	C				

Date:11/30/04ISR Number: 4513667-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523041A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	26 DAY
			No Concurrent					

			Medication	C		

Date:11/30/04ISR Number: 4513668-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523045A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Subcutaneous		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Gabitril	C				
			Trazodone	C				

Date:11/30/04ISR Number: 4513669-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523047A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Diarrhoea		Oral Contraceptive	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513670-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523057A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	7 WK
	Acne							
	Disturbance In Attention							
	Headache							
	Irritability							
	Sleep Disorder							

Date:11/30/04ISR Number: 4513671-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523065A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513672-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523084A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK

Date:11/30/04ISR Number: 4513673-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523165A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Hypersensitivity							
	Oropharyngeal Swelling							
	Swelling Face							

Date:11/30/04ISR Number: 4513674-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523180A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513675-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523205A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513676-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523320A
Age:58 YR Gender:Female I/FU:I

Outcome	PT
	Anxiety
	Mood Altered
	Nervousness
	Pharmaceutical Product
	Complaint

Tension						
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day	10 MON					
			Premarin	C		
			Trazodone	C		

Date:11/30/04ISR Number: 4513677-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523332A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Arthralgia Joint Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:11/30/04ISR Number: 4513678-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523448A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	

Date:11/30/04ISR Number: 4513679-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523466A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:11/30/04ISR Number: 4513680-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523473A
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day	3 WK					
	Insomnia		Meprobamate	C		

Date:11/30/04ISR Number: 4513681-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523520A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513682-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523523A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:11/30/04ISR Number: 4513683-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523528A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Enzyme Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Unknown	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513684-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523619A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Hyperhidrosis		No Concurrent					
	Tinnitus		Medication	C				

Date:11/30/04ISR Number: 4513685-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523629A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	1MG Per day	
			Hytrin	C				

Date:11/30/04ISR Number: 4513686-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523642A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
			No Concurrent					
			Medication	C				

Date:11/30/04ISR Number: 4513687-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523715A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Nervousness							

Date:11/30/04ISR Number: 4513688-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523718A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Nausea							

Date:11/30/04ISR Number: 4513689-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523721A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513692-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523759A
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	13	WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513693-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523763A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 DAY
	Vision Blurred		Diazepam	C				

Date:11/30/04ISR Number: 4513694-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523779A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	3 MON
			Provigil	C				
			Xanax	C				

Date:11/30/04ISR Number: 4513695-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523785A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 WK
	Anxiety							
	Feeling Hot		Inderal	C				
	Heart Rate Increased		Zomig	C				
	Insomnia		Glucosamine Chondroitin	C				
	Thinking Abnormal							

Date:11/30/04ISR Number: 4513696-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523787A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Insomnia		Depakote	C				

Date:11/30/04ISR Number: 4513697-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523793A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Headache		Nexium	C				
	Insomnia							

Date:11/30/04ISR Number: 4513698-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523799A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	11 MON
	Grand Mal Convulsion		Symbyax	SS				
	Tongue Biting		Fluoxetine	C				

Date:11/30/04ISR Number: 4513700-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523800A
Age:18 YR Gender:Female I/FU:F

Outcome	PT
Other	Dyspnoea
	Hypersensitivity
	Oropharyngeal Swelling

	Urticaria					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day	2 DAY					
			Lipitor	C		
			Ortho Tri Cyclen	C		ORAL
5 YR						
			Zyrtec	C	Glaxosmithkline	ORAL

Date:11/30/04ISR Number: 4513701-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523801A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day	1 MON					
	Nausea		Spiriva	C		
			Niaspan	C		
			Crestor	C		
			Mobic	C		
			Zyloprim	C	Glaxosmithkline	
			Lotensin	C	Glaxosmithkline	
			Trental	C		
			Tricor	C		

Date:11/30/04ISR Number: 4513702-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523806A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day	9 WK					
	Dehydration		Zoloft	SS		
4 WK						
	Diarrhoea		Klonopin	C		
	Drug Ineffective		Fioricet	C		
	Oral Pain					

Date:11/30/04ISR Number: 4513704-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523811A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Per day
	Nausea		Detrol La	C				

Date:11/30/04ISR Number: 4513705-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523815A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:11/30/04ISR Number: 4513706-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523820A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day
	Depression		Paxil Cr	C	Glaxosmithkline			
	Drug Ineffective		Metformin	C				
			Insulin 70/30	C				
			Monopril	C				
			Lopid	C				
			Lipitor	C				

Dyazide	C	Glaxosmithkline	
Singulair	C		
Albuterol	C	Glaxosmithkline	
Aspirin	C	Glaxosmithkline	

Date:11/30/04ISR Number: 4513707-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523831A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	25 DAY
	Constipation		Motrin	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513708-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524051A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Wellbutrin	PS	Glaxosmithkline			
	Convulsion							
	Local Swelling							

Date:11/30/04ISR Number: 4513709-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524076A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychomotor Hyperactivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/30/04ISR Number: 4513710-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524202A
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Ambien	C				

			Vioxx	C		
			Zocor	C		

Date:11/30/04ISR Number: 4513711-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524215A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	DAY
	Rash							

Date:11/30/04ISR Number: 4513712-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524224A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Irritability		Paxil	SS	Glaxosmithkline	ORAL	10MG Per day	
	Nervousness		Klonopin	C				
	Psychomotor Hyperactivity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513713-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524228A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Pruritus		Ranitidine	C	Glaxosmithkline			
	Rash							
	Urticaria							

Date:11/30/04ISR Number: 4513714-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524234A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dystonia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Risperdal	C				

Date:11/30/04ISR Number: 4513715-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524379A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Bupropion	PS	Glaxosmithkline	ORAL		
	Insomnia							

Date:11/30/04ISR Number: 4513716-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524488A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Hormone Replacement	C				

Date:11/30/04ISR Number: 4513717-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524496A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	10 MON
	Hallucination		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513718-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524500A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Irritable Bowel Syndrome		No Concurrent Medication	C				
	Pollakiuria							
	Urinary Tract Infection							

Date:11/30/04ISR Number: 4513719-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524507A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513720-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524509A
Age:35 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
			Lexapro	C				

Date:11/30/04ISR Number: 4513721-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524521A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Initial Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Insomnia		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513722-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524557A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Fatigue							

Date:11/30/04ISR Number: 4513723-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524560A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Twice per day	10 DAY
	Drug Ineffective							
			Depakote	C				

Date:11/30/04ISR Number: 4513724-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524561A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 DAY

Date:11/30/04ISR Number: 4513725-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524563A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:11/30/04ISR Number: 4513726-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524575A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	
			Tenormin	C				
			Calcium	C				
			Magnesium	C				
			Potassium	C				
			Ergocalciferol	C				
			Insulin	C				
			Unknown Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513727-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524584A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513728-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524587A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Insomnia		Lexapro	C				
			Vitamins	C				

Date:11/30/04ISR Number: 4513729-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524663A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Gait Disturbance		Paxil	C	Glaxosmithkline	ORAL		
			Unspecified Medications	C			UNKNOWN	

Date:11/30/04ISR Number: 4513730-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524670A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513731-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524714A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Suicidal Ideation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON

Date:11/30/04ISR Number: 4513732-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524728A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Myalgia		Lithium	C	Glaxosmithkline			
	Panic Attack							
	Pyrexia							

Date:11/30/04ISR Number: 4513733-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524732A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513734-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524734A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513735-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524737A
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Hyperhidrosis		Amoxil	SS	Glaxosmithkline			
			Toprol	C				
			Lipitor	C				
			Nexium	C				
			Plavix	C				

Date:11/30/04ISR Number: 4513736-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524741A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Vomiting		Unspecified Medication	C				

Date:11/30/04ISR Number: 4513737-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524743A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
			Ritalin	C				

Date:11/30/04ISR Number: 4513738-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524763A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Non-Cardiac Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 WK
			Oxycontin	C				
			Percocet	C				
			Valium	C				
			Albuterol Sulfate	C	Glaxosmithkline			
			Albuterol Inhaler	C	Glaxosmithkline			
			Lipitor	C				
			Benadryl	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513739-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524770A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513740-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524874A
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	YR

Date:11/30/04ISR Number: 4513741-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524878A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513763-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511765A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Drug Ineffective		Decongestant	C				
	Irritability		Lexapro	C				
	Nervousness		Armour Thyroid	C				
	Tension							

Date:11/30/04ISR Number: 4513764-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513816A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Depakote	C		ORAL	1250MG per day	
			Klonopin	C		ORAL	.5MG Three	

times per day

Date:11/30/04ISR Number: 4513765-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530786A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	7 MON
	Stool Analysis Abnormal		Lamictal	C	Glaxosmithkline	ORAL	7	MON

Date:11/30/04ISR Number: 4513766-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530805A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline			

Date:11/30/04ISR Number: 4513767-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530831A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flat Affect		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Mood Swings		Zelnorm	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513768-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530882A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline			
			Adderall	C				

Date:11/30/04ISR Number: 4513769-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530888A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Pain In Extremity						per day	4 DAY
			Excedrin Pm	C				

Date:11/30/04ISR Number: 4513770-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530904A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline			

Date:11/30/04ISR Number: 4513771-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530908A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513772-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530922A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Narcotic	PS C	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513773-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530927A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:11/30/04ISR Number: 4513775-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531025A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	11 DAY
	Headache							
	Pain In Jaw							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513776-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531033A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4	YR
	Drug Interaction		Choline	SS				
			Inositol	SS				

Date:11/30/04ISR Number: 4513777-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531178A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intraocular Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513778-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531182A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
	Libido Decreased		Lexapro	C				
	Social Avoidant Behaviour		Ibuprofen	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513779-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531230A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Headache							
	Pharyngolaryngeal Pain							
	Rash							

Date:11/30/04ISR Number: 4513781-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531264A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	7	DAY
			Prozac	C				

Date:11/30/04ISR Number: 4513782-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531285A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 DAY
	Palpitations		Synthroid	C	Glaxosmithkline			
	Swollen Tongue							

Date:11/30/04ISR Number: 4513783-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531287A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Weight Decreased		No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513784-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531288A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Headache		Paxil	C	Glaxosmithkline	ORAL	20MG Unknown	
	Malaise		Aspirin	C	Glaxosmithkline			
	Nausea		Cold Medication	C				

Date:11/30/04ISR Number: 4513785-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531296A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 WK
	Eye Swelling		Synthroid	C	Glaxosmithkline			
	Rash		Allegra D	C				

Date:11/30/04ISR Number: 4513786-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531333A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Therapeutic Response		Abilify	C				
	Unexpected		Univasc	C				
			Maxzide	C	Glaxosmithkline			
			Topamax	C				

Date:11/30/04ISR Number: 4513787-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531413A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON

				Lamictal	C	Glaxosmithkline	ORAL
				Lorazepam	C		
UNKNOWN							
				Keppra	C		
UNKNOWN							
				Unknown Medication	C		

Date:11/30/04ISR Number: 4513788-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531448A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513789-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531450A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513790-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531535A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Headache							
	Hyperhidrosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513791-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531547A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/30/04ISR Number: 4513792-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531548A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513793-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531577A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	18 MON
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice per day	
			Depakote	C				
			Lorazepam	C				
			Remeron	C				
			Prevacid	C				

Date:11/30/04ISR Number: 4513794-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531597A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
	Weight Decreased							

Date:11/30/04ISR Number: 4513795-3Report Type:Periodic Company Report #S04-USA-06882-01
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Drug Interaction		Namenda	SS			UNKNOWN	
			Aricept	C			UNKNOWN	5MG Per day

Date:11/30/04ISR Number: 4513796-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531730A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513797-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531781A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513798-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531819A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Depakote	C				

Date:11/30/04ISR Number: 4513799-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531821A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Xanax	C				

Date:11/30/04ISR Number: 4513800-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531830A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Oestrogen Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Singular	C				
			Ambien	C				
			Viagra	C				
			Prednisone	C				
			Zyrtec	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513801-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531840A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513802-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531851A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	30MG Per day	1 MON
	Asthenia		Prednisone	C				
	Crying		Amitriptyline	C				
	Feeling Jittery		Nexium	C				
	Stress		Singulair	C				
	Tremor		Amoxicillin	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513803-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531853A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Salivary Hypersecretion		Lithium	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513804-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531857A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Oestrogen Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	
							Alternate	
							days	

Date:11/30/04ISR Number: 4513805-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532209A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Migraine		Wellbutrin	SS	Glaxosmithkline		UNKNOWN	1 MON
	Pruritus							

Date:11/30/04ISR Number: 4513806-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532256A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513809-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532257A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Cymbalta	C				

Date:11/30/04ISR Number: 4513810-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524899A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown 1 YR
			Paxil	SS	Glaxosmithkline	ORAL	1TAB	In the morning 1 YR
			Humulin N	C			SUBCUTANEOUS	35UNIT In the morning
			Antihypertensives	C				
			Prednisone	C		ORAL		
			Plaquenil	C		ORAL	200MG	Per day
			Aciphex	C		ORAL	20MG	At night
			Detrol La	C				
			Lasix	C	Glaxosmithkline	ORAL	40MG	Per day

Date:11/30/04ISR Number: 4513811-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524911A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day 4 WK
	Dry Mouth							
	Nausea							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513812-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524917A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lorazepam	C				
			Alcohol	C				

Date:11/30/04ISR Number: 4513813-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524918A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513814-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524919A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hot Flush		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Paraesthesia		Xanax	C			UNKNOWN	

Date:11/30/04ISR Number: 4513815-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525030A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513816-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525034A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Interaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
3 WK						
	Metrorrhagia		Birth Control Pill	C		ORAL

Date:11/30/04ISR Number: 4513817-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525046A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Medication Error							
per day							2	DAY

Date:11/30/04ISR Number: 4513818-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525050A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 MON
	Pharmaceutical Product		Paroxetine	C	Glaxosmithkline			
	Complaint		Synthroid	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513819-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525053A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	7 MON
	Stool Analysis Abnormal		Trileptal	C				
			Zoloft	C				
			Trazodone	C				

Date:11/30/04ISR Number: 4513820-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525056A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/30/04ISR Number: 4513821-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525057A
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY

Date:11/30/04ISR Number: 4513822-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525058A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	9 WK

Date:11/30/04ISR Number: 4513823-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525072A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oropharyngeal Swelling Swelling Face Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513824-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525077A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toothache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Unknown	4 MON
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513825-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525175A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513826-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525182A
Age: Gender:Female I/FU:I

Outcome	PT
	Insomnia Irritability

Nervousness

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL	13	DAY

Date:11/30/04ISR Number: 4513827-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525234A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513828-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525237A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Myalgia		Celexa	C				
			Synthroid	C	Glaxosmithkline			
			Estradiol	C				
			Maxzide	C	Glaxosmithkline			
			Xanax	C				
			Zocor	C				

Date:11/30/04ISR Number: 4513829-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525239A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	18 MON
	Urticaria		Zoloft	C				

Date:11/30/04ISR Number: 4513830-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525242A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inappropriate Affect		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Penicillin	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513831-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525243A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	20 DAY
			Levoxyl	C	Glaxosmithkline			
			Zocor	C				

Date:11/30/04ISR Number: 4513832-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525261A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513833-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525407A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	20 DAY
	Urticaria							

Date:11/30/04ISR Number: 4513836-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525424A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	75MG Single	
	Medication Error						dose	
	Pruritus		No Concurrent					
	Swollen Tongue		Medication	C				

Date:11/30/04ISR Number: 4513837-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525428A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Benign Prostatic Hyperplasia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Dry Mouth							

Date:11/30/04ISR Number: 4513838-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525430A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 MON
	Paraesthesia		Serzone	C				
	Tinnitus		Klonopin	C				
			Lamictal	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513839-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525443A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Mood Swings							

Date:11/30/04ISR Number: 4513840-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525571A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513841-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525572A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513842-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525573A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Palpitations		Ssri	C				

Date:11/30/04ISR Number: 4513843-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525576A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG per day	1 YR
	Stool Analysis Abnormal							

Date:11/30/04ISR Number: 4513844-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525596A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513845-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525608A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513846-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525609A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON

Date:11/30/04ISR Number: 4513847-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525630A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Insomnia		Detrol La	C				
	Mental Impairment							

Date:11/30/04ISR Number: 4513848-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525631A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Papular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	28 DAY
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513849-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525632A
Age:61 YR Gender:Female I/FU:I

Outcome	PT
	Headache
	Hot Flush

Nausea

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 WK

Date:11/30/04ISR Number: 4513850-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525775A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
	Dry Eye		No Concurrent					
	Dry Mouth		Medication	C				
	Pharmaceutical Product							
	Complaint							
	Stool Analysis Abnormal							

Date:11/30/04ISR Number: 4513851-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525798A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Unknown	4 WK
	Rash		Baby Aspirin	C	Glaxosmithkline			
	Swelling Face		Vitamin	C				

Date:11/30/04ISR Number: 4513852-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525800A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513853-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525803A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Drunk		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Accupril	C				
			Norvasc	C				
			Synthroid	C	Glaxosmithkline			
			Lexapro	C				

Date:11/30/04ISR Number: 4513855-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525826A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513856-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525832A
Age: Gender:Female I/FU:I

Outcome	PT
	Dizziness
	Dry Mouth
	Nausea

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria Tinnitus Vertigo		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	24 HR
			Topomax	C				
			Clarinex	C				
			Flonase	C	Glaxosmithkline			
			Astelin	C				
			Birth Control Pills	C				

Date:11/30/04ISR Number: 4513857-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525940A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:11/30/04ISR Number: 4513858-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525953A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Unknown	6 MON

Date:11/30/04ISR Number: 4513859-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525954A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	13 DAY

Date:11/30/04ISR Number: 4513860-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525993A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline			

Date:11/30/04ISR Number: 4513861-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525994A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Vomiting		Zoloft	C				

Date:11/30/04ISR Number: 4513862-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525997A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Muscle Tightness		Nexium	C				

Date:11/30/04ISR Number: 4513863-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526000A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	15 WK
			Insulin	C				

			Synthroid	C	Glaxosmithkline	

Date:11/30/04ISR Number: 4513864-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526001A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ill-Defined Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513865-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526008A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Influenza Like Illness						per day	3 WK
	Nausea		Zoloft	C				
	Palpitations		Singulair	C				
			Prilosec	C	Glaxosmithkline			
			Multivitamin	C				
			Omega 3 Fatty Acids	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513866-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526012A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513867-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526013A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Prozac	C				

Date:11/30/04ISR Number: 4513868-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526030A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513869-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526129A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513870-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526134A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	10	WK

Date:11/30/04ISR Number: 4513871-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526135A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown

Date:11/30/04ISR Number: 4513872-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526138A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown 1 MON
	Photosensitivity Reaction		Levitra	SS	Glaxosmithkline		UNKNOWN	2 DAY

Date:11/30/04ISR Number: 4513873-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526179A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Muscle Spasms		Metoprolol	C				
			Norvasc	C				
			Klonopin	C				
			Semara	C				
			Zoloft	C				

Date:11/30/04ISR Number: 4513874-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526210A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/30/04ISR Number: 4513875-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526213A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	19 DAY
			Pro-Gest	C				

Date:11/30/04ISR Number: 4513876-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526416A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Eye		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
	Irritability		No Concurrent					
	Stool Analysis Abnormal		Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513877-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526437A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Xanax	C				

Date:11/30/04ISR Number: 4513878-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526445A
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513879-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526449A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513880-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526450A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Feeling Hot		Allegra	C				
			Levoxyl	C	Glaxosmithkline			
			Monopril	C				
			Hctz	C				
			Celebrex	C				
			Crestor	C				

Date:11/30/04ISR Number: 4513881-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526636A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Adderall Xr	C		ORAL	15MG	Unknown
			Oral Contraceptive	C		ORAL		

Date:11/30/04ISR Number: 4513882-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526661A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Palpitations		Magnesium Oxide	C				
			Fish Oil	C				

Date:11/30/04ISR Number: 4513883-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526662A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513884-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526674A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombophlebitis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Superficial		Effexor	C				

Date:11/30/04ISR Number: 4513885-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526678A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Weight Decreased							

Date:11/30/04ISR Number: 4513886-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526700A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	400MG Per day	5 WK

Date:11/30/04ISR Number: 4513887-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526704A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	238 DAY	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513888-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526706A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 DAY
	Rash Generalised Urticaria							

Date:11/30/04ISR Number: 4513889-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526798A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Drug Interaction		Zoloft	SS		ORAL	200MG Per day	3 YR
	Vomiting							

Date:11/30/04ISR Number: 4513890-9Report Type:Periodic Company Report #A0526799A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Hallucination							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513891-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526800A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Arthralgia							
	Constipation							
	Dizziness							
	Flatulence							
	Sensation Of Pressure							

Date:11/30/04ISR Number: 4513892-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526834A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 WK
	Toothache							

Date:11/30/04ISR Number: 4513893-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526850A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			Trazodone	C				

Date:11/30/04ISR Number: 4513894-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526862A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Prednisone	C				

Date:11/30/04ISR Number: 4513895-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526868A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513896-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526872A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Flushing		Abilify	C				
	Head Discomfort		Zyprexa	C				
	Mania		Prozac	C				
			Klonopin	C				

Date:11/30/04ISR Number: 4513898-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527093A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Constipation		Trileptal	C				
	Drug Ineffective		Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513899-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527107A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513900-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527121A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Muscle Spasms		No Concurrent Medication	C				
	Tinnitus							

Date:11/30/04ISR Number: 4513901-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527126A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Xanax	C				

Date:11/30/04ISR Number: 4513902-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527286A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
			Vicodin	C				
			Lexapro	C				

Date:11/30/04ISR Number: 4513903-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527295A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Swelling Face		Plaquenil	C				
			Ibuprofen	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513904-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527317A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513905-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527322A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513906-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527332A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	MON

Date:11/30/04ISR Number: 4513907-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527387A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513908-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527389A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 WK
	Anxiety		Estrogen Replacement	C				
	Tremor		Ativan	C				

Date:11/30/04ISR Number: 4513909-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527396A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
			Paxil	SS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513910-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527406A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Headache		Lisinopril	C				
			Hct	C				

Date:11/30/04ISR Number: 4513911-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527408A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	18 MON
			Remeron	C				
			Depakote	C				
			Lorazepam	C				
			Prevacid	C				
			Lisinopril	C				

Date:11/30/04ISR Number: 4513912-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527409A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Feeling Abnormal		Lipitor	C				

			Zetia	C			
			Nexium	C			
			Lexapro	C			

Date:11/30/04ISR Number: 4513913-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527425A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
			Buspar	C				
			Vistaril	C				
			Celebrex	C				

Date:11/30/04ISR Number: 4513914-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527511A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513915-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527513A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Nausea							
	Vomiting							

Date:11/30/04ISR Number: 4513916-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527514A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	5 DAY

Date:11/30/04ISR Number: 4513917-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527538A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	YR
	Hypersomnia							

Date:11/30/04ISR Number: 4513920-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527550A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG At	
	Oedema Peripheral						night	2 DAY
	Palmar Erythema							
	Pruritus							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513922-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527586A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513923-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527590A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Diarrhoea		No Concurrent Medication	C				
	Hallucination							

Date:11/30/04ISR Number: 4513924-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527766A
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	22 DAY
	Urticaria		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513925-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527967A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Nervousness		Ibuprofen	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513926-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527978A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
			Lexapro	C				

Date:11/30/04ISR Number: 4513927-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527981A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	9 DAY
	Pruritus		No Concurrent					
	Throat Tightness		Medication	C				
	Urticaria							

Date:11/30/04ISR Number: 4513928-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528110A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Twice	
	Insomnia						per day	9 MON
			Sinemet	C				
			Clonazepam	C				
			Remeron	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513929-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528118A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Sedation		Valium	C				
			Tenormin	C				
			Nexium	C				
			Fioricet	C				

Date:11/30/04ISR Number: 4513930-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528128A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513931-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528236A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Bruxism		5-Htp	C				
	Dry Mouth							
	Insomnia							

Date:11/30/04ISR Number: 4513932-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528375A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513933-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528385A
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Feeling Abnormal		Sinemet	C				
			Clonazepam	C				
			Remeron	C				

Date:11/30/04ISR Number: 4513936-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528389A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Pain In Extremity		Gabitril	C				
			Prozac	C				
			Evista	C				
			Klonopin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513937-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528421A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK

Date:11/30/04ISR Number: 4513938-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528423A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
	Drug Ineffective		Paxil	SS	Glaxosmithkline	ORAL	25MG Per day	18 MON
	Loss Of Libido		Percocet	C				
			Prilosec	C	Glaxosmithkline			
			Lisinopril	C				
			Lipitor	C				
			Alprazolam	C				
			Ibu	C	Glaxosmithkline			
			Viagra	C				

Date:11/30/04ISR Number: 4513939-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528472A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4	MON

Date:11/30/04ISR Number: 4513940-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528474A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Unknown	1 YR
	Skin Odour Abnormal							

Date:11/30/04ISR Number: 4513941-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528476A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown
	Tachycardia		Adderall Xr	SS			UNKNOWN	10MG Unknown

Date:11/30/04ISR Number: 4513942-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528508A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Twice per day	2 MON

Date:11/30/04ISR Number: 4513943-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528511A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	18 MON
	Headache							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513944-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528522A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
			Atenolol	C				
			Estrace	C				
			Klonopin	C				

Date:11/30/04ISR Number: 4513946-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528533A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513947-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528542A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoglycaemia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513948-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528552A
Age:7 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Feeling Hot		Strattera	C				
			Risperdal	C				
			Hydroxyzine	C				

Date:11/30/04ISR Number: 4513949-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528557A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	6	WK

Date:11/30/04ISR Number: 4513950-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528795A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 DAY
			Lithobid	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513951-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528802A
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Nausea		Coumadin	C	Glaxosmithkline			
			Tambocor	C				
			Imuran	C	Glaxosmithkline			
			Avapro	C				
			Cardura	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513952-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528809A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Synthroid	C	Glaxosmithkline			
			Xanax	C				

Date:11/30/04ISR Number: 4513953-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528985A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Paraesthesia		Flonase	C	Glaxosmithkline			
			Tylenol	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513954-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529007A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Headache							
	Insomnia							
	Nausea							

Date:11/30/04ISR Number: 4513955-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529012A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the morning	5 DAY

Date:11/30/04ISR Number: 4513956-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529024A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Depression		Unknown Medication	C				
			Activella	C				
			Trazodone	C				

Date:11/30/04ISR Number: 4513957-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529089A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
			Ethanol	SS				
			Actos	C				
			Accupril	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513958-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529099A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Pain In Extremity		Blood Pressure Medication	C				
			Vitamins	C				
			Diazepam	C				

Date:11/30/04ISR Number: 4513959-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529331A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	400MG Per day	
	Nausea		Adderall Xr	C				
	Therapeutic Response		Ambien	C				
	Unexpected		Buspirone	C				
	Weight Decreased		Clarinex	C				
			Lithium Carbonate	C	Glaxosmithkline			
			Nexium	C				
			Pravachol	C				
			Tarka	C				
			Diovan	C				

Date:11/30/04ISR Number: 4513960-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529347A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Paxil Cr	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513961-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529352A
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Insomnia		Diabeta	C				
			Avandia	C	Glaxosmithkline			
			Avapro	C				
			Lasix	C	Glaxosmithkline			
			Lipitor	C				

Date:11/30/04ISR Number: 4513962-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529365A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
			Lisinopril	C				
			Levoxyl	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513963-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529457A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513964-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529468A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Headache		Zyban	SS	Glaxosmithkline	ORAL	150MG Twice	
	Nausea						per day	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513965-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529474A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Three	
	Stool Analysis Abnormal						times per day	

Date:11/30/04ISR Number: 4513966-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529478A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Diovan Hct	C				

Date:11/30/04ISR Number: 4513970-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529480A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Increased Appetite		Periactin	SS			UNKNOWN	

Date:11/30/04ISR Number: 4513971-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529492A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
	Pruritus							
	Rash							
	Visual Disturbance							

Date:11/30/04ISR Number: 4513972-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529493A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Erectile Dysfunction							

Date:11/30/04ISR Number: 4513973-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529496A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513974-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529497A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	DAY

Date:11/30/04ISR Number: 4513975-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529499A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	MON
			Zoloft	C				

Date:11/30/04ISR Number: 4513976-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529508A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MCG Per day	10 WK
	Depression							
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513977-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529518A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bipolar Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:11/30/04ISR Number: 4513978-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529520A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513979-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529537A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			Advair	C	Glaxosmithkline			
			Ritalin	C				

Date:11/30/04ISR Number: 4513980-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529672A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myoclonus		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Unknown	
	Tremor		Zoloft	C		ORAL	100MG Unknown	128 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513981-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529676A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Dyspnoea		Xanax	C				
	Headache		Allegra	C				
	Hyperhidrosis		Flonase	C	Glaxosmithkline			
	Nasal Discomfort							
	Pharyngolaryngeal Pain							
	Tachycardia							
	Tremor							

Date:11/30/04ISR Number: 4513982-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529683A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Rash		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513983-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529689A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Convulsion		Astelin	C				
	Grand Mal Convulsion		Nasonex	C				
			Singulair	C				
			Clarinex	C				

Date:11/30/04ISR Number: 4513984-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529693A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	6 WK
	Insomnia		Testosterone Injection	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4513985-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529699A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Feeling Jittery		Synthroid	C	Glaxosmithkline			
	Insomnia							

Date:11/30/04ISR Number: 4513986-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529926A
Age:3 WK Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting Projectile		Wellbutrin Xl	PS	Glaxosmithkline		150MG Per day	1 DAY
			Prenatal Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513987-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529927A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4	WK
	Overdose		No Concurrent					
	Vomiting		Medication	C				

Date:11/30/04ISR Number: 4513989-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529951A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Twice per day	4 MON
	Diarrhoea							
	Flatulence		Glucophage	C				
			Synthroid	C	Glaxosmithkline			
			Multivitamin	C				
			Magnesium	C				
			Potassium	C				
			Zinc	C				

Date:11/30/04ISR Number: 4513990-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529959A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4513991-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529993A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Conjunctivitis Allergic							

	Migraine					
	Pain					

Date:11/30/04ISR Number: 4513992-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529995A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK

Date:11/30/04ISR Number: 4513993-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530002A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown

Date:11/30/04ISR Number: 4513994-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530003A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Postural		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Orthostatic Hypotension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513997-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530013A
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Agitation		Concerta	C				
	Heart Rate Increased							
	Palpitations							

Date:11/30/04ISR Number: 4513998-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530019A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4513999-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530030A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4514000-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530031A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4514001-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530042A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
	Insomnia		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4514002-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530114A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG	Unknown

Date:11/30/04ISR Number: 4514003-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530115A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Buspar	SS			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4514004-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530192A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Heart Rate Increased		Ambien	C				
			Elavil	C	Glaxosmithkline			
			Xanax	C				

Date:11/30/04ISR Number: 4514005-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530197A
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Amnesia							
per day	3 MON							
	Chest Discomfort		Serzone	C				
	Confusional State		Remeron	C				
	Insomnia							

Date:11/30/04ISR Number: 4514006-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530218A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:11/30/04ISR Number: 4514007-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530238A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 DAY
	Insomnia		Klonopin	C				
	Polyuria		Cozaar	C				

	Weight Decreased		Lipitor	C		
			Proscar	C		

Date:11/30/04ISR Number: 4514008-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530246A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	8 WK
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4514009-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530315A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4514010-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530318A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4514011-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530320A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Nausea		Paxil	C	Glaxosmithkline			
			Wellbutrin	C	Glaxosmithkline			

Date:11/30/04ISR Number: 4514012-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530366A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
			Thyroid	C				

Date:11/30/04ISR Number: 4514013-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530367A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Abnormal Dreams		Lisinopril	C				
			Toprol Xl	C				
			Lipitor	C				
			Folic Acid	C				
			Baby Aspirin	C	Glaxosmithkline			
			Multivitamin	C				

Date:11/30/04ISR Number: 4514014-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530385A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 MON
			Effexor	C				

Date:11/30/04ISR Number: 4514015-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530389A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK

Date:11/30/04ISR Number: 4514016-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530485A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:11/30/04ISR Number: 4514017-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530494A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Hangover		Amphetamine	C				
	Somnolence		Dexatrim	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4514019-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530611A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:11/30/04ISR Number: 4514020-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530612A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Weight Decreased		No Concurrent Medication	C				

Date:11/30/04ISR Number: 4514021-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530618A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 DAY

Date:11/30/04ISR Number: 4514022-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530631A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4514023-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530641A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:11/30/04ISR Number: 4514024-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530643A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	25 DAY
			No Concurrent Medication	C				

Date:11/30/04ISR Number: 4514025-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530654A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:11/30/04ISR Number: 4514026-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530672A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Energy Increased		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
	Stool Analysis Abnormal		Trazodone	C		ORAL		

				Zyrtec	C	Glaxosmithkline	ORAL
				Advair	C	Glaxosmithkline	
				Nexium	C		ORAL
				Lexapro	C		ORAL

Date:11/30/04ISR Number: 4514043-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531529A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lipase Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Klonopin	C		ORAL	.5MCG At night	
			B Complex	C				
			Citracal	C				
			Vitamin E	C				

Date:11/30/04ISR Number: 4514047-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535145A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Wellbutrin Xl	PS	Glaxosmithkline		150MG Per day	8 DAY
	Proctalgia		Concerta	C				
	Rectal Haemorrhage							
	Stool Analysis Abnormal							

Date:11/30/04ISR Number: 4514048-XReport Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0535220A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Level Of		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	300MG Per day	1 DAY
	Consciousness		Ritalin	C		ORAL		
	Dizziness							

Date:11/30/04ISR Number: 4514057-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0347143B
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Autosomal Chromosome		Zyban	PS	Glaxosmithkline		150MG Per day	1 MON
Congenital Anomaly	Anomaly		Meteospasmyl	C				
	Chromosome Abnormality		Primperan	C	Glaxosmithkline			
	Congenital Hand		Vitamin C	C	Glaxosmithkline			
	Malformation		Ginkor Fort	C				
	Dextrocardia		Stresam	C			3UNIT per day	
	Diaphragmatic Hernia							
	Drug Exposure During Pregnancy							
	Foetal Growth Retardation							
	Foetal Malformation							
	Gastrointestinal Disorder							
	Trisomy 15							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4514073-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0358400A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accommodation Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Visual Acuity Reduced							

Date:11/30/04ISR Number: 4517586-9Report Type:Expedited (15-DaCompany Report #2004AL001522
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Arteriospasm Coronary Blood Pressure Increased Self-Medication	Foreign Health Professional Other	Kadian (Morphine Sulfate Sustained Release) Capsules, 20 Mg (Alpharma)					
			(Kadian (Morphine	PS		ORAL	10 MG; X1; PO	
			Bupropion Hydrochloride	SS		ORAL	150 MG; PO	
			Efferalgan	C				

Date:12/01/04ISR Number: 4515180-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0534663A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline			
	Headache		Lamictal	SS	Glaxosmithkline	ORAL	4	WK
	Insomnia		Paxil	SS	Glaxosmithkline			
	Pruritus		Progesterone	C				
	Rash							
	Road Traffic Accident							
	Urticaria							

Date:12/01/04ISR Number: 4515190-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535450A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Convulsion							
	Depressed Level Of Consciousness							
	Loss Of Consciousness							

Date:12/01/04ISR Number: 4515191-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535456A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Medication Error							

Date:12/01/04ISR Number: 4515206-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0357320A
Age:36 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Dizziness
	Hyperhidrosis
	Malaise

Medication Error
Paraesthesia
Sense Of Oppression

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	7 DAY

Date:12/01/04ISR Number: 4515218-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0357799A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Stenosis		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	5 WK
Disability			Amoxicillin	C	Glaxosmithkline		UNKNOWN	
			Erythromycin	C	Glaxosmithkline		UNKNOWN	
			Iron Sulphate	C	Glaxosmithkline		UNKNOWN	
			Prednisolone	C	Glaxosmithkline		UNKNOWN	
			Carboplatin	C			INTRAVENOUS	13 WK
			Etoposide	C			INTRAVENOUS	13 WK
			Ibuprofen	C	Glaxosmithkline		UNKNOWN	
			Prochlorpemazine	C	Glaxosmithkline		UNKNOWN	
			Chemotherapy	C				

Date:12/01/04ISR Number: 4515230-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0358672A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG Twice per day
	Loss Of Consciousness							

	Urinary Incontinence					

Date:12/02/04ISR Number: 4516838-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0350118A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Vasculitis						per day	10 DAY
			Cartia	C	Glaxosmithkline	ORAL	1TAB Per day	
			Actonel	C		ORAL		
			Bricanyl	C			RESPIRATORY	
							(INHALATION)	
			Caltrate	C	Glaxosmithkline			
			Naprosyn	C			1G per day	
			Panamax	C	Glaxosmithkline			
			Sinequan	C				
			Spiriva	C				
			Symbicort	C				
			Ostelin (Vitamin D2)	C				
			Vagifem	C				

Date:12/02/04ISR Number: 4516857-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0358654A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder		Zyban	PS	Glaxosmithkline			
	Dizziness		No Concurrent					
	Dizziness Postural		Medication	C				
	Visual Acuity Reduced							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4518063-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535910A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Serotonin Syndrome		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK
			Lexapro	C			8	MON
			Buspar	C			8	MON

Date:12/03/04ISR Number: 4518069-2Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0346147A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tremor		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	
	Vision Blurred		Contraceptive					
	Visual Acuity Reduced		Unspecified	C		ORAL		

Date:12/03/04ISR Number: 4518076-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0358058A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	0 DAY
	Chills		Pravastatin	C		ORAL	40MG per day	
	Circulatory Collapse							
	Dyspnoea							
	Headache							
	Paraesthesia							

Date:12/03/04ISR Number: 4521302-4Report Type:Expedited (15-DaCompany Report #2004-05016
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Drug Interaction Electroencephalogram Abnormal Grand Mal Convulsion	Foreign Literature Health Professional Other	Clomipramine Hydrochloride (Watson Laboratories) (Clomipramine	PS		ORAL

25 MG, DAILY,

ORAL

Bupropion Hydrochloride Sustained Release (Bupropion Hydrochloride)	SS		ORAL
Risperidone (Risperidone)	C		

SEE IMAGE

Date:12/06/04ISR Number: 4519299-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535383A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice per day	4 YR
	Aphasia							
	Bradyphrenia		Vitamin	C				
	Fall		Advil	C	Glaxosmithkline			
	Immobile		Ambien	C				
	Insomnia		Calcium	C				
	Speech Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/04ISR Number: 4519300-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535398A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Medication Error							
per day								3 WK
			Thyroid	C				
			Metoprolol	C				
			Detrol La	C				
			Avapro	C				
			Paxil	C	Glaxosmithkline			
			Premarin	C				

Date:12/06/04ISR Number: 4519317-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0358402A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	15 DAY
	Vitreous Floaters		Nitrazepam	C		ORAL	5MG per day	
			Beclomethasone	C	Glaxosmithkline		100MCG per	
day								
			Salbutamol	C	Glaxosmithkline		100MCG per	
day								

Date:12/06/04ISR Number: 4519334-5Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0358995A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Pain		Zyban	PS	Glaxosmithkline		8 DAY	
	Gaze Palsy							
	Headache							

	Insomnia					
	Nausea					

Date:12/06/04ISR Number: 4520402-2Report Type:Direct Company Report #CTU 233713
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Bupropion Sa 150 Mg	PS		ORAL	150MG	2 X
	Pharmaceutical Product						DAY	ORAL
	Complaint							

Date:12/06/04ISR Number: 4521764-2Report Type:Expedited (15-DaCompany Report #L04-USA-07403-24
Age:30 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Escitalopram	PS				
	Multiple Drug Overdose	Health Professional	Bupropion (Long Acting) (Bupropion)	SS				
			Paroxetine	SS				

Date:12/07/04ISR Number: 4520318-1Report Type:Expedited (15-DaCompany Report #A03200400600
Age:48 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Suicide Attempt		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
			Ambien	SS		ORAL	5MG See dosage text	9 DAY
			Paroxetine Hydrochloride	C	Glaxosmithkline	ORAL	4	DAY

Date:12/07/04ISR Number: 4520327-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535565A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Incontinence		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Lamictal	C	Glaxosmithkline			
			Trazodone	C				

Date:12/07/04ISR Number: 4520350-8Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0359055A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Erythema		Zoloft	C			UNKNOWN	
	Feeling Hot		Lanzo	C			UNKNOWN	
	Paraesthesia							
	Sensation Of Foreign Body							
	Swelling Face							

Date:12/07/04ISR Number: 4523131-4Report Type:Direct Company Report #CTU 233742
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Lipitor 200 Mg					
Required Intervention to Prevent Permanent Impairment/Damage	Cataract Impaired Work Ability		Pfizer Us	PS	Pfizer Us	ORAL	1 TAB DAILY - ORAL	1 YR
			Welbutrin	SS				
			Aspirin Therapy	C				
			Welchol	C				

Date:12/08/04ISR Number: 4521259-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0515139A
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Other	Asthenia
	Chest Pain
	Chills
	Cough
	Disorientation
	Dizziness
	Dysphagia
	Feeling Abnormal
	Headache
	Hyperhidrosis
	Ill-Defined Disorder
	Increased Tendency To Bruise
	Mucous Membrane Disorder

	Muscle Atrophy					
	Muscle Spasms					
	Musculoskeletal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Nausea		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
	Nervousness					
per day	4 WK					
	Pain Of Skin		Prednisone	C		
	Pneumonitis		Premarin	C		
	Pruritus		Medroxyprogesterone	C		
	Pyrexia		Benadryl	C	Glaxosmithkline	
	Tonsillar Cyst		Maxair	C		
	Tremor		Serevent	C	Glaxosmithkline	
	Urticaria		Azmacort	C		
	Vasodilatation					
	Wheezing					

Date:12/08/04ISR Number: 4521263-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533147A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL
Initial or Prolonged	Balance Disorder					
	Diarrhoea					
	Dizziness					
	Hot Flush					
	Mood Altered					
	Oedema Peripheral					
	Pruritus					
	Sleep Disorder					
	Speech Disorder					
	Swelling Face					
	Swollen Tongue					
	Urticaria					

Date:12/08/04ISR Number: 4521273-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0350764A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization -	Cardiospasm		Zyban	PS	Glaxosmithkline	ORAL
150MG Unknown 30 DAY						
Initial or Prolonged	Chest Pain		Actiskenan	SS	Glaxosmithkline	ORAL
10MG Per day 1 DAY						
			Efferalgan	C	Glaxosmithkline	ORAL
1 DAY						

Date:12/08/04ISR Number: 4521705-8Report Type:Direct Company Report #CTU 233876
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Condition Aggravated		Generic Wellbutrin			
	Depression		Sr 150 (Budeprion			
	Pharmaceutical Product		Sr)	PS	Teva	ORAL
1 PO BID						
	Complaint		Glucophage	C		
			Amaryl	C		
			Ativan	C		
			Mobic	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/04ISR Number: 4523033-3Report Type:Expedited (15-DaCompany Report #US-ABBOTT-04P-163-0282509-00
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Depakote	PS				
			Depakote	SS				
			Bupropion Hydrochloride	SS				
			Promethazine Hydrochloride	C				
			Metoclopramide	C				

Date:12/10/04ISR Number: 4523685-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0323413A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	10 DAY
	C-Reactive Protein Increased							
	Drug Exposure During Pregnancy							
	Face Oedema							
	Joint Swelling							
	Neutrophil Percentage Increased							
	Odynophagia							
	Oedema							
	Pregnancy							
	Urticaria							
	White Blood Cell Count Increased							

Date:12/10/04ISR Number: 4523701-3Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0358672A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	

Other	Loss Of Consciousness					
per day						
	Myalgia		Flixonase	C	Glaxosmithkline	
300MCG per						
	Urinary Incontinence					
day						

Date:12/10/04ISR Number: 4523706-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0359029A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Alcohol Interaction		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
Hospitalization -	Depressed Mood					
per day 20 DAY						
Initial or Prolonged	Medication Error		Alcohol	SS		
	Overdose		Famvir	C	Glaxosmithkline	ORAL
750MG per day						
	Suicidal Ideation					

Date:12/10/04ISR Number: 4523707-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0359033A
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Other	Depressive Symptom
	Epistaxis
	Malaise

Tearfulness

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Zyban	PS	Glaxosmithkline	ORAL	17	DAY
			Serevent	C	Glaxosmithkline		50MCG Twice per day	
			Beclomethasone	C	Glaxosmithkline		400MCG Twice per day	
			Salbutamol	C	Glaxosmithkline		200MCG As required	

Date:12/10/04ISR Number: 4528227-9Report Type:Expedited (15-DaCompany Report #B0358110A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autonomic Nervous System Imbalance Cerebral Atrophy Condition Aggravated	Foreign Literature Health Professional	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS			3	WK
	Coordination Abnormal Depressed Level Of Consciousness Diarrhoea		Sertraline (Formulation Unknown) (Sertraline)	SS			3	WK
	Electrocardiogram Qt Prolonged Electrocardiogram Repolarisation Abnormality Faecal Incontinence Fall Hallucination, Auditory Hallucination, Visual Insomnia Mental Status Changes		Piracetam (Formulation Unknown) (Piracetam) Venlafaxine Hydrochloride (Formulation Unknown) (Venlafaxine Fluoxetine	SS SS C				

	Myoclonus					
	Serotonin Syndrome					
	Urinary Incontinence					

Date:12/13/04ISR Number: 4525381-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0536385A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Overdose							

Date:12/13/04ISR Number: 4525389-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0536770A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Paxil	PS	Glaxosmithkline	ORAL		
	Homicidal Ideation		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG	Unknown

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525413-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0359041A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aggression		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 7 DAY
	Emotional Disorder		Sertraline	C		ORAL	50MG per day	204 WK
	Irritability		Omeprazole	C	Glaxosmithkline	ORAL	20MG per day	
	Thinking Abnormal		Amitriptyline	C		ORAL	10MG per day	

Date:12/13/04ISR Number: 4526736-XReport Type:Expedited (15-DaCompany Report #A118566
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Literature	Ziprasidone					
	Bundle Branch Block Left	Health	(Ziprasidone)	PS			(80 MG)	
Required Intervention to Prevent Permanent Impairment/Damage	Delirium	Professional	Bupropion					
	Disorientation	Company	Hydrochloride					
	Electrocardiogram Qrs	Representative	(Bupropion					
	Complex Prolonged		Hydrochloride)	SS			(100 MG)	
	Electrocardiogram Qt		Fluoxetine					
	Corrected Interval		Hydrochloride					
	Prolonged		(Fluoxetine					
	Electrocardiogram Qt		Hydrochloride)	SS			(40 MG)	
	Prolonged		Valproate Semisodium					
	Electrocardiogram St		(Valproate					
	Segment Abnormal		Semisodium)	SS			(250 MG)	
	Electrocardiogram St							
	Segment Depression							
	Electrocardiogram T Wave							
	Abnormal							
	Grand Mal Convulsion							
	Hallucination, Visual							
	Lethargy							
	Multiple Drug Overdose							
	Myocardial Infarction							

	Sinus Tachycardia
	Supraventricular
	Tachycardia

Date:12/13/04ISR Number: 4527063-7Report Type:Expedited (15-DaCompany Report #2004102906
Age:62 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
	Amnesia
	Aspartate Aminotransferase Increased
	Autonomic Nervous System Imbalance
	Balance Disorder
	Cerebral Atrophy
	Condition Aggravated
	Coordination Abnormal
	Depressed Level Of Consciousness
	Depression
	Diarrhoea
	Drug Interaction

	Electrocardiogram Qt Prolonged					
	Faecal Incontinence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Fall	Foreign	Sertraline			
	Hallucinations, Mixed	Literature	(Sertraline)	PS		
50 MG						
	Hyperreflexia	Health	Bupropion			
	Insomnia	Professional	(Bupropion)	SS		
300 MG						
	Myoclonus		Venlafaxine			
	Pyrexia		(Venlafaxine)	SS		
75 MG						
	Serotonin Syndrome		Piracetam			
	Urinary Incontinence		(Piracetam)	C		

Date:12/14/04ISR Number: 4526634-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0522931A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Blood Glucose Increased		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
	Fall					
per day	DAY					
	Grand Mal Convulsion		Ludiomil	SS		
150MG per day	3 MON					
	Joint Dislocation		Symbyax	SS		
2	MON					
	Loss Of Consciousness					
	Medication Error					
	Upper Limb Fracture					

Date:12/14/04ISR Number: 4527312-5Report Type:Direct Company Report #CTU 234263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dizziness		Wellbutrin Xl	PS		ORAL
150 MG PO QD						
	Drug Ineffective					
	Feeling Abnormal					
	Pharmaceutical Product					

Complaint

Date:12/14/04ISR Number: 4527326-5Report Type:Direct Company Report #CTU 234306
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Cerebrovascular Accident		Wellbutrin Xl	150mg	PS			DAILY	

Date:12/14/04ISR Number: 4529932-0Report Type:Expedited (15-DaCompany Report #2004103296
Age:73 YR Gender:Female I/FU:I

Outcome	PT
Other	Anxiety
	Cataract Operation
	Drug Ineffective
	Eye Disorder
	Formication
	Post Procedural

Complication
Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Zoloft (Sertraline)	PS		ORAL	50 MG (50 MG, 1 IN 1 D),	ORAL
	Bupropion Hydrochloride (Bupropion Hydrochloride)	SS				
	Paroxetine Hydrochloride (Paroxetine Hydrochloride0	SS				
	Psycholeptics (Psycholeptics)	SS				
	Provella-14 (Estrogens Conjugated, Medroxyprogesterone Acetate)	C				
	Ciclosporin (Ciclosporin)	C				
	All Otehr Therapeutic Products (All Other Therapeutic Products)	C				

Date:12/14/04ISR Number: 4534504-8Report Type:Periodic Company Report #2004241306US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychomotor Hyperactivity Weight Increased	Consumer	Bextra (Valdecoxib) Tablet	PS		ORAL	10 MG, QD,	ORAL
			Wellbutrin (Amfebutamone					

			Hydrochloride)	SS		
			Lexapro	SS		ORAL
10 MG, QD,						
ORAL						
			Multivitamins (Panthenol, Retinal, Ergocalciferol)	C		
			Vitamin E	C		

Date:12/14/04ISR Number: 4535560-3Report Type:Periodic Company Report #2004236425US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health Professional	Bextra (Valdecoxib) Tablet	PS		
20 MG						
		Company Representative	Wellbutrin (Amfebutamone Hydrochloride)	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4536091-7Report Type:Periodic Company Report #2004237143US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State	Health	Xanax (Alprazolam)					
	Overdose	Professional	Tablet	PS			1 MG, PT TOOK	10 TABLETS
			Wellbutrin(Amfebutamone Hydrochloride)	SS			150 MG, PT	TOOK 6 TABLETS

Date:12/15/04ISR Number: 4527777-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0536768A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Intentional Misuse		Tylenol	SS	Glaxosmithkline			
Other	Suicide Attempt		Zoloft	C				

Date:12/15/04ISR Number: 4527780-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537119A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Abuser		Wellbutrin	PS	Glaxosmithkline	NASAL		
	Medication Error							

Date:12/15/04ISR Number: 4527800-1Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0361120A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Renal Failure Chronic		Zyban	PS	Glaxosmithkline	
UNKNOWN	150MG Twice					
per day						

Date:12/15/04ISR Number: 4529950-2Report Type:Direct Company Report #CTU 234438
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Clonic Convulsion		Wellbutrin 300 Mg Am	PS		
300 MG (2) Q						
Initial or Prolonged						
AM						

Date:12/15/04ISR Number: 4531026-5Report Type:Expedited (15-DaCompany Report #2004AL001522
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arteriospasm Coronary	Foreign	Kadian (Morphin			
Initial or Prolonged	Self-Medication	Health	Sulfate Cr)Sustained			
Required		Professional	Release 20mg	PS	Alpharma	ORAL
10 MG; X1; PO						
Intervention to		Other	Bupropion			
Prevent Permanent			Hydrochloride	SS		ORAL
150 MG; PO						
Impairment/Damage			Efferalgan	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/04ISR Number: 4528799-4Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0140463A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Amnesia		Zyban	PS	Glaxosmithkline	ORAL	10	DAY
	Arrhythmia							
	Cardiac Arrest							
	Confusional State							
	Energy Increased							
	Euphoric Mood							
	Feeling Abnormal							
	Feeling Jittery							
	Heart Rate Increased							
	Hypersensitivity							
	Insomnia							
	Myocardial Infarction							
	Palpitations							
	Psychomotor Hyperactivity							
	Speech Disorder							

Date:12/16/04ISR Number: 4528806-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0530819A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	1050MG Per day	
Hospitalization - Initial or Prolonged	Overdose						0	DAY
Disability								
Other								

Date:12/16/04ISR Number: 4528807-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531192A
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	5	WK
	Convulsion		Trileptal	C				

	Dizziness		Mysoline	C	
	Insomnia		Synthroid	C	Glaxosmithkline
	Micturition Disorder		Premarin	C	

Date:12/16/04ISR Number: 4528818-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537468A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	MON
	Headache							
	Insomnia							
	Loss Of Consciousness							
	Nausea							
	Vomiting							

Date:12/16/04ISR Number: 4528833-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0361828A
Age:38 YR Gender:Female I/FU:I

Outcome	PT
Other	Agitation
	Depression
	Feeling Of Despair

	Restlessness						
	Schizophrenia						
	Tearfulness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxosmithkline		UNKNOWN
			Haldol Decanoate	C			
			Artane	C			
			Tegretol	C			UNKNOWN

Date:12/16/04ISR Number: 4530215-3Report Type:Direct Company Report #CTU 234497
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abnormal Behaviour		Cylert- Pamoline-				
Hospitalization -	Aggression		Prn	PS			PRN
Initial or Prolonged	Alcohol Use		Imipramine	SS			PRN
Disability	Anxiety		Wellbutrin	SS			PRN
Required	Bereavement Reaction						
Intervention to	Disturbance In Social						
Prevent Permanent	Behaviour						
Impairment/Damage	Feeling Of Despair						
	Grandiosity						
	Insomnia						
	Irritability						
	Loss Of Employment						
	Mania						
	Mental Disorder						
	Psychomotor Hyperactivity						
	Relationship Breakdown						
	Stress						
	Suicidal Ideation						

Date:12/16/04ISR Number: 4530278-5Report Type:Direct Company Report #CTU 234493
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Drug Withdrawal Syndrome		Wellbutrin Sr 150 Mg 2x Daily Glaxo Smith Kline	PS	Glaxo Smith Kline	ORAL	150MG	2X DAILY
Other	Drug Interaction International Normalised Ratio Decreased Thrombophlebitis	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	SEE IMAGE	
			Coumadin (Warfarin Sodium,)	SS		ORAL	SEE IMAGE	
			Wellbutrin Xl (Bupropion Hydrochloride,)	SS		ORAL	150 MG 1X PER	1 DAY, ORAL
			Zyprexa (Olanzapine)	C				
			Klonopin (Clonazepam)	C				

Date:12/16/04ISR Number: 4535995-9Report Type:Periodic Company Report #HQWYE206123SEP04
Age:63 YR Gender:Female I/FU:I

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530688-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0536385A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:12/17/04ISR Number: 4530706-5Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0351173A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperthyroidism Insomnia Palpitations		Bupropion Hydrochloride	PS	Glaxosmithkline		UNKNOWN dosage text	150MG See 39 DAY

Date:12/17/04ISR Number: 4530721-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0359865A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Drug Exposure During Pregnancy Ear Disorder		Zyban	PS	Glaxosmithkline			

Date:12/17/04ISR Number: 4530738-7Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0362084A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema Dermatitis Allergic Drug Interaction Paraesthesia Pruritus		Zyban Acenocoumarol	PS C	Glaxosmithkline		UNKNOWN UNKNOWN	150MG per day 1MG Unknown

	Tongue Disorder					

Date:12/20/04ISR Number: 4532018-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537805A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Facial Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	8 DAY
Initial or Prolonged	Facial Palsy		Effexor	C				
Disability	Facial Paresis		Paxil	C	Glaxosmithkline			
Other	Hypertension		Buspar	C				

Date:12/20/04ISR Number: 4532022-4Report Type:Expedited (15-DaCompany Report #2004/02747
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying		Zyban	PS	Glaxosmithkline			
	Depression							
	Insomnia							
	Palpitations							
	Panic Reaction							
	Suicidal Ideation							
	Thinking Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4532029-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0323980A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Contusion		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Confusional State		Fluanxol	SS				
	Epistaxis							
	Facial Bones Fracture							
	Fall							
	Incoherent							
	Malaise							
	Overdose							
	Pulmonary Oedema							
	Sudden Death							
	Tremor							

Date:12/20/04ISR Number: 4532037-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0357358A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxosmithkline			
	Constipation		Lisinopril	C			UNKNOWN	
	Dry Mouth							
	Ventricular Tachycardia							

Date:12/20/04ISR Number: 4532866-9Report Type:Direct Company Report #CTU 234712
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Drug Reaction		Vioxx Unknown					
	Arthralgia		Unknown	PS		ORAL	1 TAB/2 TAB	
Disability	Drug Tolerance Increased						DAY/1WK/2	
	Fibromyalgia						WK	ORAL
	Muscle Spasms		Wellbutrin					

	Myalgia	Unknown	Unknown	SS	ORAL
1 TAB DAY					
	Pruritus				
ORAL					
	Urticaria	Morphine		C	
		Antidepressants		C	

Date:12/20/04ISR Number: 4533070-0Report Type:Direct Company Report #CTU 234699
Age:46 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Agitation
	Anger
Disability	Anorexia
	Anxiety
	Asthenia
	Condition Aggravated
	Confusional State
	Depression
	Dizziness
	Drug Ineffective
	Dysgeusia
	Headache
	Heart Rate Increased
	Hostility
	Hyperhidrosis

	Impulsive Behaviour						
	Insomnia						
	Irritability	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
	Libido Decreased		Wellbutrin 150 Mil.	PS			
	Marital Problem						
	Myalgia						
	Nervousness						
	Panic Attack						
	Restlessness						
	Suicide Attempt						
	Tinnitus						
	Tremor						
	Vision Blurred						
	Vomiting						
	Weight Decreased						

Date:12/21/04ISR Number: 4533689-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537281A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Disability	Arthralgia		Lamictal	PS	Glaxosmithkline	ORAL	
2 YR							
Other	Chest Discomfort		Wellbutrin	SS	Glaxosmithkline	ORAL	
200MG Twice							
	Facial Pain						
per day	2 YR						
	Gait Disturbance						
	Oedema Peripheral						

Date:12/21/04ISR Number: 4533691-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537485A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Induced		Bupropion	PS	Glaxosmithkline	
	Drug Exposure During					
	Pregnancy					

Date:12/21/04ISR Number: 4533694-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537602A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Failure		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Renal Failure							

Date:12/21/04ISR Number: 4533696-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537624A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Somnolence						per day	3 MON
	Stool Analysis Abnormal							

Date:12/21/04ISR Number: 4533697-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537625A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	6 MON	
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/04ISR Number: 4533704-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537916A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin	PS	Glaxosmithkline			
	Medication Error							

Date:12/21/04ISR Number: 4533723-4Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0361120A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypertensive Nephropathy		Zyban	PS	Glaxosmithkline			
UNKNOWN							150MG Twice per day	
	Nephropathy							
	Renal Amyloidosis							
	Renal Failure							

Date:12/21/04ISR Number: 4533946-4Report Type:Expedited (15-DaCompany Report #2004S1003059
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Bupropion					
Required	Arthralgia	Professional	Hydrochloride					
Intervention to	Change Of Bowel Habit		Tablets 75mg Mylan	PS	Mylan	ORAL	75 MG TID,	
Prevent Permanent	Feeling Abnormal							
ORAL								
Impairment/Damage	Gastric Disorder		Antibiotic	C				
	Haematochezia		Indomethacin	C				
	Nervousness							
	Pharmaceutical Product Complaint							
	Restlessness							
	Treatment Noncompliance							

Date:12/21/04ISR Number: 4534057-4Report Type:Direct Company Report #CTU 234759
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Rash		Bupropion	PS		
			Gabapentin	C		
			Prazosin Hcl	C		
			Ketoconazole 2% Shampoo	C		
			Ketoconazole 2% Cream	C		
			Hydrocortisone	C		

Date:12/21/04ISR Number: 4534214-7Report Type:Direct Company Report #CTU 234851
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Nausea		Generic Wellbutrin	PS		
1 QD						
	Pharmaceutical Product Complaint					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/04ISR Number: 4537347-4Report Type:Expedited (15-DaCompany Report #MK200412-0181-1
Age:43 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Restoril Capsules	PS				
	Multiple Drug Overdose	Health Professional	Bupropion	SS				

Date:12/21/04ISR Number: 4537782-4Report Type:Expedited (15-DaCompany Report #MK200411-0327-1
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Propoxyphene					
	Multiple Drug Overdose	Health Professional	Napsylate/Apap	PS				
			Bupropion	SS				
			Alprazolam	SS				

Date:12/22/04ISR Number: 4539754-2Report Type:Expedited (15-DaCompany Report #US-GDB-0411585
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Consumer	Differin (Adapalene) Cream 0.1% (Dpt)	PS		TOPICAL	1 APP	QD TP
	Gastrooesophageal Reflux Disease		Wellbutrin	SS		ORAL	600 MG	QD PO
			Wellbutrin	SS				
			Nuvaring	C				

Date:12/23/04ISR Number: 4536145-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406391A
Age: Gender:Male I/FU:F

Outcome	PT
Other	Acquired Porphyria
	Aggression
	Agitation
	Akathisia
	Amnesia

Arthralgia
Asthenia
Bipolar Disorder
Body Temperature
Fluctuation
Coordination Abnormal
Crying
Depression
Disability
Dizziness
Dysarthria
Dysphemia
Dyspnoea
Electric Shock
Emotional Disorder
Encephalopathy
Facial Palsy
Fatigue
Feeling Abnormal
Headache
Hyperaesthesia
Hypersensitivity
Hypoxia

	Immune System Disorder						
	Injury						
	Insomnia	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
	Intentional Self-Injury		Wellbutrin	PS	Glaxosmithkline	ORAL	
42	DAY						
	Mania		Tranquilizer	SS			
	Mastocytosis		Depakote	SS			
	Metabolic Encephalopathy		Zyprexa	SS			
	Muscle Spasms		Alcohol	C			
	Myalgia						
	Myoclonus						
	Nervous System Disorder						
	Nightmare						
	Overdose						
	Pain Of Skin						
	Petit Mal Epilepsy						
	Suicidal Ideation						
	Suicide Attempt						
	Throat Tightness						
	Tremor						
	Vestibular Disorder						
	Vomiting						

Date:12/23/04ISR Number: 4536189-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0538149A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Drug Exposure During		Bupropion	PS	Glaxosmithkline	
	Pregnancy					
	Premature Rupture Of					
	Membranes					
	Stillbirth					

Date:12/23/04ISR Number: 4536190-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0538149B
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Congenital Anomaly	Chorioamnionitis		Bupropion	PS	Glaxosmithkline	
	Drug Exposure During					
	Pregnancy					

Intra-Uterine Death
Micrognathia
Umbilical Cord
Abnormality

Date:12/23/04ISR Number: 4536210-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0361887A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chorea		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	
	Dystonia		Procyclidine	SS	Glaxosmithkline		UNKNOWN	
	Facial Nerve Disorder		Thyroxine	C	Glaxosmithkline	ORAL	50MCG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/04ISR Number: 4536228-XReport Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0045476A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	
	Delusion							
	Dyspnoea							
	Hyperventilation							
	Panic Attack							
	Suicidal Ideation							

Date:12/23/04ISR Number: 4536846-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0537702A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	
	Crying							
	Depression							
	Homicidal Ideation							
	Insomnia							
	Mood Swings							
	Sleep Disorder							
	Suicidal Ideation							

Date:12/23/04ISR Number: 4536856-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0538325A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	8	MON
	Difficulty In Walking		Unknown Blood Pressure Medication	C				
	Drug Ineffective							
	Visual Disturbance		Diabetes Medication	C				

Date:12/23/04ISR Number: 4536876-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0361906A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Transient		Zyban	PS	Glaxosmithkline	ORAL	1TAB	Variable
Other	Rash						dose	11 DAY
	Swelling		Diclofenac Sodium	C	Glaxosmithkline		UNKNOWN	1UNIT Three times per day
			Metronidazole	C	Glaxosmithkline		UNKNOWN	1UNIT Three times per day
			Co-Codamol	C			UNKNOWN	2UNIT Four times per day
			Co-Careldopa	C			UNKNOWN	.5TAB At night

Date:12/23/04ISR Number: 4536878-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0361910A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 5 DAY
	Vitreous Floaters							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/04ISR Number: 4536907-4Report Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0362601A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	57	DAY
	Excitability							
	Negative Thoughts							
	Suicidal Ideation							

Date:12/23/04ISR Number: 4537073-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0526859A
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Per day
	Depression		Wellbutrin Sr	SS	Glaxosmithkline		150MG	See
	Medication Error						dosage text	

Date:12/23/04ISR Number: 4537074-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0531761A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	600MG	Unknown
	Convulsion							
	Drooling							
	Eye Rolling							
	Overdose							
	Tremor							

Date:12/23/04ISR Number: 4537078-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535456A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
	Medication Error					

Date:12/23/04ISR Number: 4537079-2Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0536818A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Premature Ejaculation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Per day

Date:12/23/04ISR Number: 4537080-9Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0538431A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Visual Acuity Reduced		Zyban	PS	Glaxosmithkline	ORAL	52 DAY
			Nefazodone	C			

Date:12/23/04ISR Number: 4537096-2Report Type:Expedited (15-DaCompany Report #DK-GLAXOSMITHKLINE-B0362606A
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain Upper
	Fatigue
	Feeling Abnormal
	Insomnia

	Mania Tinnitus						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxosmithkline		6 DAY

Date:12/23/04ISR Number: 4537158-XReport Type:Expedited (15-DaCompany Report #GXKR2004US00593
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Metoprolol	PS	Novartis Sector: Pharma		75 mg, BID
	Drug Interaction		Bupropion (Ngx)	SS			150 mg, BID
	Dyspnoea		Diltiazem	C			480 mg/day
	Fatigue Hypotension Metabolic Disorder Oedema Peripheral Pulmonary Hilum Mass Pulmonary Vascular Disorder Rales Sinus Bradycardia						

Date:12/23/04ISR Number: 4539354-4Report Type:Expedited (15-DaCompany Report #B0361967A
Age:12 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Difficulty In Walking Pruritus Serum Sickness Systemic Lupus Erythematosus Rash	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS			100 MG/TWICE PER DAY
			Methylphenidate Hcl	C			

Date:12/27/04ISR Number: 4539589-0Report Type:Direct Company Report #CTU 235183
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Generic Wellbutrin	PS		ORAL	1 PO BID	

Date:12/27/04ISR Number: 4542295-XReport Type:Expedited (15-DaCompany Report #US-GDP-0411585
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Differin (Adapalene) Cream 0.1% (Dpt)	PS			1 APP QD TP	
	Anaphylactic Reaction							
	Blood Oestrogen Decreased		Wellbutrin	SS		ORAL	150 MG QD PO	
	Drug Hypersensitivity		Wellbutrin	SS		ORAL	300 MG QD PO	
	Dysthymic Disorder		Nuvaring	C				
	Emotional Distress							
	Eye Irritation							
	Gastrooesophageal Reflux Disease							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/04ISR Number: 4540558-5Report Type:Direct Company Report #CTU 235221
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Bupropion 10 Mg	PS				3 DAY
	Convulsion							
	Drug Toxicity							

Date:12/28/04ISR Number: 4541299-0Report Type:Expedited (15-DaCompany Report #B0361960A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Literature	Wellbutrin (Formulation Unknown) (Bupropion Hydrochloride)	PS				
	Haemodynamic Instability	Health Professional	Linezolid (Formulation Unknown) (Linezolid)	SS				
	Procedural Complication		Propofol	C				
	Procedural Hypertension		Suxamethonium	C				
			Isoflurane	C				
			Fentanyl	C				
			Antibiotics	C				

Date:12/29/04ISR Number: 4540891-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406391A
Age: Gender:Male I/FU:F

Outcome	PT
Other	Acquired Porphyria
	Aggression
	Agitation
	Akathisia
	Amnesia
	Arthralgia
	Asthenia
	Bipolar Disorder
	Body Temperature Fluctuation
	Coordination Abnormal

Crying
Depression
Disability
Dizziness
Dysarthria
Dysphemia
Dyspnoea
Electric Shock
Emotional Disorder
Encephalopathy
Facial Palsy
Fatigue
Feeling Abnormal
Headache
Hyperaesthesia
Hypersensitivity
Hypoxia
Immune System Disorder
Injury
Insomnia

	Intentional Self-Injury					
	Mania					
	Mastocytosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Metabolic Encephalopathy		Wellbutrin	PS	Glaxosmithkline	ORAL
42	DAY					
	Muscle Spasms		Tranquilizer	SS		
	Myalgia		Depakote	SS		
	Myoclonus		Zyprexa	SS		
	Nervous System Disorder		Alcohol	C		
	Nightmare					
	Overdose					
	Pain Of Skin					
	Petit Mal Epilepsy					
	Schizoaffective Disorder					
	Suicidal Ideation					
	Suicide Attempt					
	Throat Tightness					
	Tremor					
	Vestibular Disorder					
	Vomiting					

Date:12/29/04ISR Number: 4540901-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0538500A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG	Per day					
	Fall		Ditropan	C		
	Loss Of Consciousness		Paroxetine	C	Glaxosmithkline	
	Tinnitus		Lisinopril	C		
	Tremor		Atenolol	C		
			Ranitidine	C	Glaxosmithkline	
			Diuretic	C		
			Folic Acid	C		
			Tylenol Arthritis	C	Glaxosmithkline	

Date:12/29/04ISR Number: 4540902-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0538552A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Deafness	Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice
per day 20 DAY						
		Flovent	C	Glaxosmithkline		
		Serevent	C	Glaxosmithkline		
		Synthroid	C	Glaxosmithkline		

Date:12/29/04ISR Number: 4540933-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0362498A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psychotic Disorder		Zyban	PS	Glaxosmithkline	ORAL	2TAB Twice	
per day	4 WK							

Date:12/29/04ISR Number: 4543654-1Report Type:Direct Company Report #CTU 235322
Age:41 YR Gender:Male I/FU:I

Outcome	PT
	Depressive Symptom
	Drug Ineffective

	Pharmaceutical Product Complaint	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Buproprion	PS		ORAL	100 MG Q DAY	PO

Date:12/30/04ISR Number: 4543388-3Report Type:Direct Company Report #CTU 235434
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Stevens-Johnson Syndrome		Welbutrin	PS				

Date:12/30/04ISR Number: 4544193-4Report Type:Expedited (15-DaCompany Report #GXKR2004US00593
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Literature Health	Metoprolol (Metoprolol Tartrate) Unknown	PS			75 MG, BID	
	Drug Interaction	Professional						
	Hypotension		Bupropion (Ngx) (Bupropion)	SS			150 MG, BID	
	Metabolic Disorder							
	Pulmonary Hilum Mass		Diltiazem (Diltiazem)	C				
	Pulmonary Vascular Disorder							
	Sinus Bradycardia							

Date:12/30/04ISR Number: 4544284-8Report Type:Expedited (15-DaCompany Report #K200401961
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chorea Dystonia	Foreign Health Professional Other	Kemadrin (Procyclidine) Tablet, 5mg	PS				
			Zyban (Bupropion Hydrochloride) Tablet, 1 Tab	SS		ORAL	1 TAB, QD,	ORAL
			Thyroxine Sodium (Levothyroxine Sodium)	C				

Date:01/03/05ISR Number: 4543808-4Report Type:Expedited (15-DaCompany Report #GXKR2004US00593
Age:56 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Drug Interaction Fatigue Hypotension Metabolic Disorder

	Pulmonary Hilum Mass Pulmonary Vascular Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rales Sinus Bradycardia	Literature Health Professional	Metoprolol (Metoprolol Tartrate)	PS			75 MG, BID
			Bupropion (Ngx) Bupropion)	SS			150 MG, BID
			Diltiazem (Diltiazem)	C			
			..	C			

Date:01/04/05ISR Number: 4544140-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533311A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Arrhythmia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	
Life-Threatening	Cardiac Failure		Diovan	C			1 YR
	Congestive		Norvasc	C			1 YR
			Lipitor	C			1 YR
			Aldactone	C			1 YR
			Coreg	C	Glaxosmithkline		1 YR
			Lasix	C	Glaxosmithkline		1 YR
			Potassium	C			1 YR

Date:01/04/05ISR Number: 4544158-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0363099A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown WK

	Drug Interaction		Implanon	SS			
TRANSDERMAL 68MG See							
	Pregnancy						
dosage text							
	Unintended Pregnancy						

Date:01/04/05ISR Number: 4545763-XReport Type:Direct Company Report #USP 57021
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl 150 Mg	PS				
XL TAB								
			Wellbutrin Sr 150 Mg	SS				
SR TAB								

Date:01/05/05ISR Number: 4544989-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0539065A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
300MG Per day							2	MON
	Paranoia							
	Suicide Attempt							

Date:01/05/05ISR Number: 4545007-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0350764A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiospasm		Zyban	PS	Glaxosmithkline	ORAL		
150MG Unknown							31	DAY
Initial or Prolonged	Chest Pain		Actiskenan	SS	Glaxosmithkline	ORAL		
20MG Per day							1	DAY
			Efferalgan	C	Glaxosmithkline	ORAL		
1 DAY								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/05ISR Number: 4545014-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0363078A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Joint Swelling Myalgia Pyrexia Rash Serum Sickness		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	8 DAY

Date:01/05/05ISR Number: 4545017-1Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0363180A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Tetany		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:01/05/05ISR Number: 4545020-1Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0363390A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depressed Mood Dizziness Fall Feeling Abnormal Medication Error Overdose		Zyban	PS	Glaxosmithkline		UNKNOWN	

Date:01/05/05ISR Number: 4548241-7Report Type:Direct Company Report #CTU 235766
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Agitation		Desipramine	PS			
50 MG							
	Anger		Wellbutrin (Samples)	SS			
	Fear		Lamictal	SS			
100 MG							
	Overdose						

Date:01/06/05ISR Number: 4546485-1Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0506123A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		150MG per day	
	Drug Exposure During Pregnancy							
	Foetal Heart Rate Abnormal							
	Ultrasound Antenatal Screen Abnormal							

Date:01/06/05ISR Number: 4546488-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516229B
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Exposure During Pregnancy		Wellbutrin	PS	Glaxosmithkline			
Congenital Anomaly	Pulmonary Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/05ISR Number: 4546489-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0519165A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Anxiety							
	Bedridden							
	Cholelithiasis							
	Completed Suicide							
	Crying							
	Derealisation							
	Diarrhoea							
	Dizziness							
	Feeling Abnormal							
	Gastroenteritis Viral							
	Gun Shot Wound							
	Headache							
	Insomnia							
	Irritability							
	Lethargy							
	Nausea							
	Nervousness							
	Pyrexia							
	Social Avoidant Behaviour							
	Toothache							
	Tremor							
	Vomiting							

Date:01/06/05ISR Number: 4546494-2Report Type:Expedited (15-DaCompany Report #2004-03363
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Bupropion	PS	Glaxosmithkline	ORAL		
Hospitalization -	Dermatitis Exfoliative		Lamisil	C	Glaxosmithkline			
Initial or Prolonged	Discomfort		Allopurinol	C	Glaxosmithkline			
	Ill-Defined Disorder							
	Injury							
	Medication Error							
	Oedema Peripheral							
	Pain							
	Rash Erythematous							
	Rash Pustular							
	Respiratory Disorder							

Skin Exfoliation
Skin Lesion
Skin Reaction
Sleep Disorder
Swollen Tongue

Date:01/06/05ISR Number: 4546495-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533311A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
Life-Threatening	Cardiac Failure		Diovan	C				
							1	YR
	Congestive		Norvasc	C				
							1	YR
			Lipitor	C				
							1	YR
			Aldactone	C				
							1	YR
			Coreg	C	Glaxosmithkline			
							1	YR
			Lasix	C	Glaxosmithkline			
							1	YR

			Potassium	C		
1 YR						

Date:01/06/05ISR Number: 4546506-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0539079A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/06/05ISR Number: 4546513-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0539461A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Fall Overdose Skin Laceration		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	ORAL	300MG Per day	

Date:01/07/05ISR Number: 4547433-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406391A
Age: Gender:Male I/FU:F

Outcome	PT
Other	Acquired Porphyria Aggression Agitation Akathisia Alcohol Use Amnesia Arthralgia Asthenia Bipolar Disorder Body Temperature Fluctuation Convulsion Coordination Abnormal Crying Depression Depression Suicidal

Disability
Dizziness
Dysarthria
Dysphemia
Dyspnoea
Electric Shock
Emotional Disorder
Encephalopathy
Facial Palsy
Fatigue
Feeling Abnormal
Hair Metal Test Abnormal
Headache
Hyperaesthesia
Hypersensitivity
Hypoxia
Immune System Disorder
Injury
Insomnia
Intentional Self-Injury
Mania

		Mastocytosis					
		Metabolic Encephalopathy					
		Multiple Chemical	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL
42	DAY						
		Muscle Spasms		Tranquilizer	SS		
		Myalgia		Depakote	SS		
		Myoclonus		Zyprexa	SS		
		Nervous System Disorder		Alcohol	C		
		Neurotoxicity					
		Nightmare					
		Overdose					
		Pain Of Skin					
		Petit Mal Epilepsy					
		Porphyria					
		Schizoaffective Disorder					
		Suicidal Ideation					
		Suicide Attempt					
		Throat Tightness					
		Tremor					
		Vestibular Disorder					
		Vomiting					

Date:01/07/05ISR Number: 4547434-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516229A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Drug Exposure During		Wellbutrin	PS	Glaxosmithkline	ORAL
	Pregnancy		Effexor	C		
	Placental Insufficiency					
	Pre-Eclampsia					

Date:01/07/05ISR Number: 4547447-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0539707A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cyanosis		Zyban	PS	Glaxosmithkline	ORAL
	Dyspnoea					
	Tremor					

Date:01/07/05ISR Number: 4551887-3Report Type:Expedited (15-DaCompany Report #DEWYE183308NOV04
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antidepressant Drug Level Increased	Foreign Study	Trevilor (Venlafaxine					
	Drug Interaction	Health	Hydrochloride)	PS		ORAL	SEE IMAGE	45 DAY
	Poisoning	Professional	Zyban (Amfebutamone					
	Supraventricular	Other	Hydrochloride)	SS		ORAL	SEE IMAGE	15 DAY
	Extrasystoles		Zopiclone					
	Tachycardia		(Zopiclone)	C				
	Ventricular Extrasystoles		Tibolone (Tibolone)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/05ISR Number: 4548478-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0525434A
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Balance Disorder		Prevacid	C				
	Dizziness		Estradiol	C				
	Dry Mouth		Synthroid	C	Glaxosmithkline			
	Dysphemia		Hctz	C				
	Feeling Abnormal							
	Hallucination							
	Tremor							
	Vision Blurred							

Date:01/10/05ISR Number: 4548479-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0532210A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Double Ureter		Bupropion	PS	Glaxosmithkline			
	Drug Exposure During Pregnancy							
	Renal Disorder							
	Vesicoureteric Reflux							

Date:01/10/05ISR Number: 4548482-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537255A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	WK
	Visual Acuity Reduced		Cozaar	C				

Date:01/10/05ISR Number: 4548492-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0539841A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Blood Urine Present		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 5 DAY						
	Vaginal Haemorrhage		No Concurrent Medication	C		

Date:01/10/05ISR Number: 4548527-6Report Type:Expedited (15-DaCompany Report #2005000353
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypotension		Zyban	PS	Glaxosmithkline	ORAL
4500MG Single						
	Overdose					
dose						
	Suicide Attempt		Ethanol	SS		ORAL

Date:01/10/05ISR Number: 4553828-1Report Type:Direct Company Report #CTU 235994
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pharmaceutical Product		Buproprion	PS		ORAL
150 MGM BID						
	Complaint					
PO						
	Tremor					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/05ISR Number: 4566200-5Report Type:Direct Company Report #CTU 236069
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Zyban (Generic) 150					
	Insomnia		Mg Bid	PS			150 MG BID	
	Tachycardia							
	Tremor							

Date:01/10/05ISR Number: 4567643-6Report Type:Direct Company Report #CTU 236060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Affect Lability		Wellbutrin Sr 150 Mg	PS			THESE TWICE A DAY	
	Drug Ineffective							
	Pharmaceutical Product Complaint							

Date:01/11/05ISR Number: 4549644-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0539903A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Valtrex	PS	Glaxosmithkline	ORAL	500MG Per day	
	Drug Interaction		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Unknown	

Date:01/11/05ISR Number: 4549645-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540033A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	

	Drug Ineffective						
per day 7 MON							
	Irritability		Viagra	C			

Date:01/11/05ISR Number: 4549646-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540040A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Wellbutrin	PS	Glaxosmithkline	ORAL		
Life-Threatening	Convulsion	Professional	Alcohol	SS				
Hospitalization - Initial or Prolonged	Overdose							
Disability								
Other								

Date:01/11/05ISR Number: 4549657-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0363375A
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Periorbital Oedema		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	8 DAY
	Urticaria		Lansoprazole	C		ORAL	30MG per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/05ISR Number: 4550424-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540137A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/12/05ISR Number: 4553858-XReport Type:Direct Company Report #CTU 236375
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS			UNKNOWN DOSE	
	Impulsive Behaviour						ONCE DAILY	
			Sominex	C				

Date:01/12/05ISR Number: 4563722-8Report Type:Direct Company Report #CTU 236486
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paranoia		Bupropion	PS		ORAL	150 MG BID	
	Pharmaceutical Product						ORAL	
	Complaint							
	Thinking Abnormal							

Date:01/13/05ISR Number: 4551752-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0533112A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	9 MON
			Ssri	C				

Date:01/13/05ISR Number: 4551760-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540061A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Damage		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Convulsion							

Date:01/13/05ISR Number: 4551765-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0273496A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	21	DAY
Initial or Prolonged	C-Reactive Protein		Adepal	C			UNKNOWN	
	Increased							
	Coagulation Factor V							
	Level Decreased							
	Coagulation Factor Vii							
	Level Decreased							
	Fibrin D Dimer Increased							
	Leukocytosis							
	Lymphopenia							
	Proteinuria							
	Prothrombin Level							
	Decreased							
	Pyrexia							
	Urticaria Generalised							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/05ISR Number: 4553485-4Report Type:Expedited (15-DaCompany Report #D0039102A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disturbance In Attention Drug Abuser Hallucinations, Mixed Insomnia Psychotic Disorder Schizophreniform Disorder Suicidal Ideation Vision Blurred	Foreign Literature Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	5 DAY

Date:01/13/05ISR Number: 4553883-9Report Type:Direct Company Report #CTU 236672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis		Wellbutrin Xl 150 Mg	PS		ORAL	150 MG P.O.	2 YR

Date:01/13/05ISR Number: 4553884-0Report Type:Direct Company Report #CTU 236669
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphthous Stomatitis		Wellbutrin Sr 150 Mg	PS		ORAL	1 BID P.O.	

Date:01/13/05ISR Number: 4554060-8Report Type:Direct Company Report #CTU 236614
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gun Shot Wound Insomnia Intentional Self-Injury Mania		Wellbutrin Lithium Lamictal Wellbutrin	PS C C C				

Date:01/14/05ISR Number: 4552332-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496788A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Imitrex	PS	Glaxosmithkline	SUBCUTANEOUS	6MG Four	
	Fall						times per day	
			Wellbutrin Sr	SS	Glaxosmithkline			
			Lotronex	SS	Glaxosmithkline			
			Fioricet	SS				
			Prozac	SS				
			Strattera	SS				

Date:01/14/05ISR Number: 4553150-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0320004A
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety
	Aptyalism
	Asthenia
	Cytolytic Hepatitis
	Dermatitis Exfoliative
	Hypersensitivity
	Hypotension

	Inflammation						
	Insomnia						
	Leukopenia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Lymphadenopathy		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 22 DAY
	Nausea		Tiaprofenic Acid	SS		ORAL	3 DAY
	Painful Respiration		Aspegic	SS		ORAL	3 DAY
	Pruritus						
	Purpura						
	Rash Maculo-Papular						
	Rash Morbilliform						
	Rash Scarlatiniform						
	Thrombocytopenia						
	Tremor						

Date:01/14/05ISR Number: 4553159-XReport Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0364019A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Hyperthyroidism		Zyban	PS	Glaxosmithkline		UNKNOWN
	Personality Change						
	Visual Acuity Reduced						
	Visual Field Defect						

Date:01/14/05ISR Number: 4553163-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0364304A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased		Zyban	PS	Glaxosmithkline	ORAL	1TAB See dosage text
	Dizziness						
	Electrocardiogram Abnormal						
	Feeling Abnormal						
	Hypoaesthesia						
	Visual Disturbance						

Date:01/14/05ISR Number: 4553739-1Report Type:Direct Company Report #CTU 236898
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Paxil Cr 50 Mg	PS		ORAL	PAXIL CR	
Hospitalization -	Cholelithiasis						ONCE A DAY	
Initial or Prolonged	Dehydration						ORAL	
Disability	Drug Dependence		Wellbutrin Xl 300					
	Drug Withdrawal Syndrome		Mg	SS		ORAL	ONCE A DAY	
	Feeling Abnormal						ORAL	
	Gallbladder Disorder							
	Influenza							
	Irritability							
	Malaise							
	Muscle Spasms							
	Nervous System Disorder							
	Nervousness							
	Tooth Loss							
	Upper Respiratory Tract Infection							
	White Blood Cell Count Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/05ISR Number: 4567668-0Report Type:Direct Company Report #CTU 236837
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Effect Decreased		Buproprion Er 15 Mg	PS		ORAL	BID PO	
	Pharmaceutical Product Complaint							

Date:01/15/05ISR Number: 4605804-8Report Type:Periodic Company Report #A03200400600
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Chest Pain Confusional State	Consumer	Ambien - Zolpidem Tartrate - Tablet - Other	PS		ORAL	5 MS HS - ORAL	
	Depression Dry Mouth Headache		Ambien - Zolpidem Tartrate - Tablet	SS		ORAL	10 MG HS - ORAL	
	Heart Rate Increased Libido Decreased Mood Swings Suicide Attempt		Wellbutrin - Bupropion Hydrochloride - Tablet - 150 Mg	SS		ORAL	150 MG QD - ORAL	
			Paroxetine Hydrochloride	C				

Date:01/16/05ISR Number: 4606009-7Report Type:Periodic Company Report #HQWYE882211FEB04
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Effexor (Venlafaxine Hydrochloride,					

			Unspec)	PS		ORAL
ORAL						
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride)	SS		ORAL
ORAL						

Date:01/18/05ISR Number: 4554288-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537119A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Abuser		Wellbutrin	PS	Glaxosmithkline	NASAL
	Medication Error					

Date:01/18/05ISR Number: 4554291-7Report Type:Expedited (15-DaCompany Report #2004108860
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dementia		Zyban	PS	Glaxosmithkline	ORAL
	Weight Increased		Nicorette Gum	SS	Glaxosmithkline	
4 DAY						
			Nicorette	SS	Glaxosmithkline	
4 DAY						
			Nicorette Patch	SS	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554736-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0494832A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Paxil	PS	Glaxosmithkline	ORAL		
	Convulsion		Zyban	SS	Glaxosmithkline	ORAL		
	Drug Dependence							
	Drug Withdrawal Syndrome							
	Insomnia							
	Intentional Misuse							
	Laceration							
	Overdose							
	Suicide Attempt							

Date:01/18/05ISR Number: 4554742-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0519822A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Paxil	PS	Glaxosmithkline	ORAL	30MG Per day	
Initial or Prolonged	Dizziness		Wellbutrin	SS	Glaxosmithkline			
	Drug Withdrawal Syndrome		Flexeril	SS				
	Feeling Abnormal		Skelaxin	SS				
	Intentional Misuse		Antiinflammatory	SS				
	Suicidal Ideation		Aspirin	SS	Glaxosmithkline			
	Suicide Attempt		Theophylline	SS				
			Risperdal	SS				
			Cold Medicine	SS				

Date:01/18/05ISR Number: 4554744-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0536055A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the	
Hospitalization -	Skin Exfoliation							
morning							18	DAY
Initial or Prolonged	Stevens-Johnson Syndrome		Seroquel	C				
Disability								
Other								

Date:01/18/05ISR Number: 4554752-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540816A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	
	Anger		Wellbutrin	SS	Glaxosmithkline			
	Crying							
	Drug Withdrawal Syndrome							
	Hyperhidrosis							
	Hyperventilation							
	Hypoaesthesia							
	Irritability							
	Mood Swings							
	Nausea							
	Pain							
	Suicide Attempt							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4555364-5Report Type:Direct Company Report #CTU 237046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Bupropion 75 Mg	PS		ORAL	2 TABS PO BID	
	Pharmaceutical Product Complaint							

Date:01/18/05ISR Number: 4556497-XReport Type:Expedited (15-DaCompany Report #2005-01-0367
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health Professional	Intron A (Interferon Alfa-2b Recombinant) Injectable	PS		INTRAVENOUS	44 MU 5XWK;	
	Confusional State							
	Decreased Appetite							
	Dehydration					INTRAVENOUS		
	Drug Interaction		Wellbutrin (Bupropion)	SS		ORAL	300 MG BID;	
	Eating Disorder							
	Lethargy					ORAL		
			Allopurinol	SS		ORAL	100 MG HS;	
						ORAL		
			Clonazepam	SS		ORAL	0.5 MG QHS;	
						ORAL		
			Trazodone	SS		ORAL	50 MG QHS;	
						ORAL		
			Zocor	SS		ORAL	10 MG QD;	
						ORAL		
			Remeron	SS		ORAL	45 MG HS;	

ORAL						
			Multivitamins	SS		ORAL
PRN; ORAL						
			Glucosamine	SS		ORAL
PRN; ORAL						
			Compazine	SS		ORAL
10 MG PRN;						
ORAL						

Date:01/18/05ISR Number: 4557138-8Report Type:Expedited (15-DaCompany Report #B0273496A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Coagulation Factor V Level Decreased Coagulation Factor Vii Level Decreased Factor Ii Deficiency Inflammation Lymphocyte Count Decreased Neutrophil Count Increased Proteinuria Pyrexia Urticaria Generalised White Blood Cell Count Increased	Foreign Literature Health Professional	Bupropion Hydrochloride Tablet -Zyban (Bupropion Hydrochloride) Adepal	PS C		ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556030-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537277A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	21	DAY
	Loss Of Consciousness							

Date:01/19/05ISR Number: 4556032-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540290A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Unknown
	Medication Error		No Concurrent					
	Panic Attack		Medication	C				

Date:01/19/05ISR Number: 4556044-2Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0346847A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Zyban	PS	Glaxosmithkline	ORAL		
	Alcohol Poisoning							
	Confusional State							
	Dehydration							
	Extrapyramidal Disorder							
	Overdose							
	Suicide Attempt							

Date:01/19/05ISR Number: 4556843-7Report Type:Direct Company Report #CTU 237176
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Wellbutrin Sr 100 Mg Bid	PS			100 MG	BID

Date:01/19/05ISR Number: 4559125-2Report Type:Expedited (15-DaCompany Report #2004AL001522
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Arteriospasm Coronary Self-Medication	Foreign Health Professional Other	Kadian Bupropion Hydrochloride Efferalgan	PS SS C		ORAL ORAL	20 MG; X1; PO PO	

Date:01/20/05ISR Number: 4557056-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406391A
Age: Gender:Male I/FU:F

Outcome	PT
Other	Acquired Porphyria
	Aggression
	Agitation
	Akathisia
	Alcohol Use
	Amnesia
	Arthralgia
	Asthenia

		Bipolar Disorder					
		Body Temperature Fluctuation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
42	DAY						
		Coordination Abnormal		Tranquilizer	SS		
		Crying		Depakote	SS		
		Depression		Zyprexa	SS		
		Depression Suicidal		Alcohol	C		
		Disability					
		Dizziness					
		Dysarthria					
		Dysphemia					
		Dyspnoea					
		Electric Shock					
		Emotional Disorder					
		Encephalopathy					
		Facial Palsy					
		Fatigue					
		Feeling Abnormal					
		Hair Metal Test Abnormal					
		Head Injury					
		Headache					
		Hyperaesthesia					
		Hypersensitivity					
		Hypoxia					
		Immune System Disorder					
		Injury					
		Insomnia					
		Intentional Self-Injury					
		Mania					
		Mastocytosis					
		Medication Error					
		Metabolic Encephalopathy					
		Muscle Spasms					
		Myalgia					
		Myoclonus					
		Nervous System Disorder					
		Nightmare					
		Overdose					
		Pain Of Skin					
		Petit Mal Epilepsy					
		Psychotic Disorder					
		Schizoaffective Disorder					
		Suicidal Ideation					
		Suicide Attempt					

	Throat Tightness					
	Tremor					
	Vestibular Disorder					
	Vomiting					

Date:01/20/05ISR Number: 4557059-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535570A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Excoriation		No Concurrent					
	Grand Mal Convulsion		Medication	C				
	Loss Of Consciousness							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4557060-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0538024A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	30 DAY
	Incontinence		Symbyax	SS				
	Loss Of Consciousness							
	Sexual Dysfunction							

Date:01/20/05ISR Number: 4557064-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540443A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG See dosage text	
	Coma							
	Drug Ineffective		Lexapro	SS				
	Drug Interaction		Atenolol	C				
	Medication Error		Avandia	C	Glaxosmithkline			
			Nexium	C				
			Aspirin	C	Glaxosmithkline			
			Aricept	C				
			Neurontin	C				
			Centrum Silver	C				
			Magnesium	C				
			Potassium	C				
			Duragesic	C				
			B12	C	Glaxosmithkline			
			Hydrocodone	C				
			Zocor	C				
			Diazepam	C				
			Isosorbide	C				

Date:01/20/05ISR Number: 4557065-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540945A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						
Initial or Prolonged	Fall		No Concurrent			
	Joint Injury		Medication	C		

Date:01/20/05ISR Number: 4557066-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540971A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
450MG In the						
	Memory Impairment					
morning						
	Speech Disorder					

Date:01/20/05ISR Number: 4557077-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0364668A
Age: Gender:Male I/FU:I

Outcome	PT
Other	Adverse Event
	Aggression
	Anxiety
	Coordination Abnormal
	Feeling Of Despair
	Irritability

	Panic Attack Sensory Disturbance Suicidal Ideation	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Thinking Abnormal		Zyban	PS	Glaxosmithkline	ORAL	6 WK

Date:01/20/05ISR Number: 4557078-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0364698A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cerebral Artery Embolism Cerebrovascular Accident Coma Convulsion Feeling Abnormal Myocardial Infarction		Zyban	PS	Glaxosmithkline	ORAL	

Date:01/20/05ISR Number: 4557081-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0364815A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Renal Colic		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day
			Celecoxib	C		ORAL	200MG Per day
			Paracetamol	C	Glaxosmithkline		UNKNOWN
			Co-Proxamol	C			UNKNOWN
			Lisinopril	C			UNKNOWN

Date:01/20/05ISR Number: 4557086-3Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0364857A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Valve Disease		Zyntabac	PS	Glaxosmithkline			
	Hemiparesis		Nicotinell	C	Glaxosmithkline			
	Pulmonary Oedema							

Date:01/20/05ISR Number: 4557087-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0364991A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxosmithkline		150MG Twice	
							per day	

Date:01/20/05ISR Number: 4560094-XReport Type:Direct Company Report #CTU 237485
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Sr	PS			150 MG ONE QD	
			Neurontin	C				

Date:01/20/05ISR Number: 4560160-9Report Type:Direct Company Report #CTU 237286
Age:72 YR Gender:Female I/FU:I

Outcome	PT
	Depressive Symptom
	Pharmaceutical Product

		Complaint						
			Report Source	Product	Role	Manufacturer	Route	
Dose	Duration							
				Wellbutrin Sr	PS			

Date:01/20/05ISR Number: 4560207-XReport Type:Direct Company Report #CTU 237476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Depression		Bupropion Ssr 150 Mg	PS		
150 MG						
	Disease Recurrence					
	Drug Ineffective					
	Pharmaceutical Product					
	Complaint					

Date:01/21/05ISR Number: 4558783-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541566A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
Hospitalization - Initial or Prolonged	Overdose					

Date:01/21/05ISR Number: 4558789-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0348497A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Drug Interaction		Zyban	PS	Glaxosmithkline	ORAL
1TAB Twice						
	Weight Increased					
per day	1 MON					
			Reductil	SS		ORAL
15MG per day	2 MON					

Date:01/21/05ISR Number: 4558819-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0364711A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxosmithkline	ORAL		
	Feeling Abnormal							
	Hallucination, Tactile							
	Nervousness							
	Palpitations							

Date:01/24/05ISR Number: 4559526-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0536768A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization -	Grand Mal Convulsion		Tylenol	SS	Glaxosmithkline			
Initial or Prolonged	Intentional Misuse		Zoloft	C				
Other	Refusal Of Treatment By							
	Patient							
	Suicide Attempt							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559531-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540508A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Fatigue		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	MON
	Gait Disturbance		No Concurrent					
	Hallucination		Medication	C				

Date:01/24/05ISR Number: 4559532-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540547A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL	4	WK
	Hypoaesthesia		Synthroid	C	Glaxosmithkline			
	Loss Of Consciousness							

Date:01/24/05ISR Number: 4559555-9Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0045685A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neutropenia		Zyban	PS	Glaxosmithkline	ORAL		

Date:01/24/05ISR Number: 4559761-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02727
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zocor	PS	Merck & Co., Inc	ORAL		
	Confusional State		Intron A	SS			INTRAVENOUS	
	Decreased Appetite					DRIP	37	DAY
	Dehydration		Wellbutrin	SS		ORAL		
	Drug Interaction		Allopurinol	SS		ORAL		

	Lethargy		Clonazepam	SS		ORAL
	Nausea		Trazodone Hydrochloride	SS		ORAL
			Remeron	SS		ORAL
			Vitamins (Unspecified)	SS		ORAL
			Glucosamine	SS		ORAL
			Compazine	SS		ORAL

Date:01/24/05ISR Number: 4560653-4Report Type:Direct Company Report #CTU 237702
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Bupropion 75 Mg Two Tabs Po Bid	PS				
	Pharmaceutical Product							
	Complaint							

Date:01/24/05ISR Number: 4560654-6Report Type:Direct Company Report #CTU 237703
Age:39 YR Gender:Male I/FU:I

Outcome	PT
	Dizziness
	Drug Ineffective
	Nausea
	Pharmaceutical Product

Complaint

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Buproprion Sr 150 Mg	PS		
ONE TAB TWICE						
DAILY						

Date:01/24/05ISR Number: 4560675-3Report Type:Direct Company Report #CTU 237720
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dyspepsia		Bupropion Hydrochloride Extended Release Tabs	PS	Eon Labs	ORAL
TWICE DAILY	1 WK					
			Seroquel	C		
			Adalat Cc	C		
			Aspirin	C		
			Doxazosin	C		
			Hctz	C		
			Zantac	C		

Date:01/24/05ISR Number: 4560775-8Report Type:Direct Company Report #CTU 237723
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dyspepsia		Bupropion Hydrochloride Extended Release Tabs 150 Mg Tab			
			Eon Labs	PS	Eon Labs	ORAL
TWICE DAILY	1 WK					
			Lithium	C		
			Seroquel	C		

Date:01/24/05ISR Number: 4560777-1Report Type:Direct Company Report #CTU 237722
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Bupropion Hydrochloride Extended Release Tabs 150mg Tab					
			Eon Labs	PS	Eon Labs	ORAL	TWICE DAILY	1 WK
			Topiramate	C				

Date:01/24/05ISR Number: 4560778-3Report Type:Direct Company Report #CTU 237721
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Bupropion Hydrochloride Extended Release Tabs 150 Mg Tab					
			Eon Labs	PS	Eon Labs	ORAL	TWICE DAILY	1 WK
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4563691-0Report Type:Expedited (15-DaCompany Report #MK200501-0123-1
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchiolitis	Foreign	Anafranil	PS				
	Drug Interaction	Health Professional	Wellbutrin	SS				
		Other						

Date:01/25/05ISR Number: 4560533-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541125A
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	2 WK
	Medication Error							
	Paranoia		Lithium	C	Glaxosmithkline			
	Pharmaceutical Product Complaint		Ativan	C				

Date:01/25/05ISR Number: 4560534-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541132A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Overdose		Unknown	C				

Date:01/25/05ISR Number: 4560550-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0365184A
Age:37 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	1 DAY
	Migraine		Glucosamine	C				
UNKNOWN								

	Oropharyngeal Swelling		Co Q10 Enzyme	C		ORAL

Date:01/25/05ISR Number: 4560552-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0365187A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Zyban	PS	Glaxosmithkline	ORAL	12 DAY	
	Bronchospasm		Salbutamol	C	Glaxosmithkline	UNKNOWN		

Date:01/26/05ISR Number: 4561595-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0527550A
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG At night	2 DAY
	Oedema Peripheral							
	Palmar Erythema							
	Pruritus							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/05ISR Number: 4561604-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541103A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
	Anger		Synthroid	C	Glaxosmithkline			
	Antisocial Behaviour		Premarin	C				
	Irritability		Klonopin	C				
	Negative Thoughts							

Date:01/26/05ISR Number: 4561605-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541137A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lexapro	C				

Date:01/26/05ISR Number: 4561606-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541138A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Joint Stiffness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Musculoskeletal Stiffness		Lipitor	C				
	Oedema Peripheral		Aspirin	C	Glaxosmithkline			
	Rash							
	Serum Sickness							

Date:01/26/05ISR Number: 4561607-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541141A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Musculoskeletal Stiffness		Micronor	C				
	Oedema Peripheral							

	Orbital Oedema					
	Rash					
	Serum Sickness					
	Urticaria					

Date:01/26/05ISR Number: 4561616-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541965A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Epistaxis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 4 YR
Initial or Prolonged	Erythema		Vitamin B	SS			
	Intentional Misuse		Lamictal	C	Glaxosmithkline		
	Overdose		Seroquel	C			
			Prozac	C			
			Strattera	C			
			Marijuana	C			

Date:01/26/05ISR Number: 4561643-8Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0365434A
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Other	Dysarthria
	Hypoaesthesia Oral

	Paraesthesia Tongue Paralysis						
Dose	Duration	Report Source	Product	Role	Manufacturer	Route	
			Zyban	PS	Glaxosmithkline	ORAL	
150MG Per day	1 DAY						
			Albyl Minor	C	Glaxosmithkline		
			Seloken Zoc	C			
			Nobligan Retard	C			
100MG per day							
			Celebra	C			
100MG per day							

Date:01/26/05ISR Number: 4563027-5Report Type:Expedited (15-DaCompany Report #GXBR2005US00444
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Asthenia	Health	Allopurinol Tablets			
	Confusional State	Professional	Usp (Ngx)			
	Decreased Appetite		(Allopurinol) Tablet	PS		ORAL
100 MG, QHS,						
	Dehydration					
ORAL						
	Drug Interaction		Bupropion Hcl			
	Lethargy		Tablets, (Ngx)			
	Nausea		(Bupropion) Tablet	SS		ORAL
300 MG, BID,						
ORAL						
			Clonazepam (Ngx)			
			(Clonazepam) Tablet	SS		ORAL
0.5 MG, QHS,						
ORAL						
			Mirtazapine Tablets			
			(Ngx) (Mirtazapine)			
			Tablet	SS		ORAL
45 MG, QHS,						
ORAL						
			Prochlorperazine			
			Maleate Tablets Usp			
			(Ngx)			
			(Prochlorperazine)			

Tablets	SS			ORAL
10 MG, PRN, ORAL				
Trazodone Hcl Tablets Usp (Ngx) (Trazodone) Tablet	SS			ORAL
50 MG, QHS, ORAL				
Intron A "Schering-Plough" (Interferon Alfa 2-B) Injection	SS	Schering-Plough		ORAL
44 MIU, QW5, ORAL				
Zocor "Merck" (Simvastatin)	SS	Merck		ORAL
10 MG, QD, ORAL				
Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Panthenol...	SS			ORAL
PRN, ORAL				
Glucosamine (Glucosamine)	SS			ORAL
ORAL				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/05ISR Number: 4566337-0Report Type:Direct Company Report #CTU 238109
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myalgia		Bupropion	PS				

Date:01/26/05ISR Number: 4566367-9Report Type:Direct Company Report #CTU 238104
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Bupropion	PS				
	Irritability		Gabapentin	C				
			Divalproex Ec (Delayed Release)	C				
			Fluoxetine Hcl	C				
			Hydromorphone Hcl	C				
			Morphine	C				
			Ranitidine Hcl	C				
			Bupropion Hcl	C				
			Vitamin B Complex/ Vitamin C Cap	C				
			Prazosin Hcl	C				
			Capsaicin	C				

Date:01/27/05ISR Number: 4570261-7Report Type:Direct Company Report #CTU 238334
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Generalised Oedema		Wellbutrin Sr 150 Mg	PS		ORAL	150 DAILY	
	Hypotension							
	Rash							
	Wheezing							

Date:01/27/05ISR Number: 4576966-6Report Type:Direct Company Report #CTU 238422
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Welbutrin Sr	PS			100 MG 1	
	Cerebrovascular Accident						DAILY	
	Confusional State		Welbutrin Sr	SS			150 MG 1	
	Dysgeusia						DAILY	
	Feeling Abnormal							
	Partial Seizures							
	Sensory Disturbance							
	Visual Disturbance							

Date:01/28/05ISR Number: 4563282-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0042892A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice	
	Drug Ineffective						per day	4 DAY
	Feeling Cold		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	100MG Unknown	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563283-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0126084A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Joint Swelling						per day	2 WK
	Oedema Peripheral		Prozac	C		ORAL		
	Pain In Extremity							
	Rash Pruritic							
	Serum Sickness							
	Urticaria Generalised							

Date:01/28/05ISR Number: 4563286-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0431982A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Increased Appetite							
	Nicotine Dependence							

Date:01/28/05ISR Number: 4563287-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0432445A
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Abuser		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three	
	Hallucination, Visual						times per day	
	Intentional Misuse							

Date:01/28/05ISR Number: 4563288-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441460A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563289-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441484A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563290-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441661A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin	PS	Glaxosmithkline			
	Parosmia							

Date:01/28/05ISR Number: 4563291-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441767A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hepatic Enzyme Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563292-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0441795A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:01/28/05ISR Number: 4563293-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442009A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563294-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442011A
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	2 MON
	Dizziness							
	Feeling Jittery		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	
			Vasotec	C		ORAL	20MG Twice per day	
			Hctz	C		ORAL	25MG Per day	
			Tenormin	C		ORAL	50MG Twice per day	

Date:01/28/05ISR Number: 4563295-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442046A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563296-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442414A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Anger Irritability		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563297-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442538A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:01/28/05ISR Number: 4563298-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442616A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcohol Poisoning		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563299-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0442977A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychotic Disorder		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563300-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443006A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	1	DAY

Date:01/28/05ISR Number: 4563301-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443033A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563302-4Report Type:Periodic Company Report #S03-USA-05003-01
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Contusion		Wellbutrin	PS	Glaxosmithkline		150MG Per day	11 DAY
Initial or Prolonged	Convulsion		Celexa	SS		ORAL	20MG Per day	
Other	Disorientation							
	Fall							
	Parosmia							
	Tooth Fracture							
	Weight Increased							

Date:01/28/05ISR Number: 4563303-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443270A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Seasonal Allergy		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:01/28/05ISR Number: 4563304-8Report Type:Periodic Company Report #S03-USA-04967-01
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Lexapro	SS		ORAL	10MG Per day	

Date:01/28/05ISR Number: 4563305-XReport Type:Periodic Company Report #S03-USA-04869-01
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Effluvium		Wellbutrin	PS	Glaxosmithkline	ORAL	6	MON
			Lexapro	SS		ORAL	10MG Per day	1 YR
			Risperdal	C				
			Klonopin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563306-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443498A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Meniere'S Disease		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563308-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443915A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anhedonia		Wellbutrin	PS	Glaxosmithkline	ORAL	5	WK
	Depression		Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
	Hypersomnia		Lexapro	C				
	Oedema		Hydrochlorothiazide	C				

Date:01/28/05ISR Number: 4563309-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443922A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 MON
	Hallucination							
	Heart Rate Increased		Lexapro	C				
	Tremor							

Date:01/28/05ISR Number: 4563310-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443930A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563311-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443936A
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dystonia		Wellbutrin	PS	Glaxosmithkline	ORAL
	Swollen Tongue		Geodon	C		
			Lexapro	C		

UNKNOWN

Date:01/28/05ISR Number: 4563312-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444037A
Age:13 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Back Pain		Wellbutrin	PS	Glaxosmithkline	ORAL
75MG Per day	6 DAY					
	Diarrhoea		Bupropion	SS	Glaxosmithkline	ORAL
75MG Per day	6 DAY					
	Eye Pain					
	Hypomania					
	Increased Appetite					
	Nightmare					
	Pain In Jaw					
	Pharyngolaryngeal Pain					
	Pyrexia					
	Swelling Face					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563313-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0444111A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Prozac	C				

Date:01/28/05ISR Number: 4563314-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0490789A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Bupropion	PS	Glaxosmithkline	ORAL	3	DAY
	Drug Ineffective		Zyban	SS	Glaxosmithkline	ORAL	150MG Twice per day	5 DAY
			Monopril	C				
			Paxil	C	Glaxosmithkline			

Date:01/28/05ISR Number: 4563315-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491309A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline		1	YR

Date:01/28/05ISR Number: 4563316-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491318A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyponatraemia		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563317-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491566A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563318-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491714A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:01/28/05ISR Number: 4563319-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491779A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Generalised		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	

Date:01/28/05ISR Number: 4563320-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0491973A
Age: Gender:Female I/FU:I

Outcome	PT
	Agitation
	Anorexia
	Asthenia

	Drug Ineffective Insomnia Paranoia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tremor		Bupropion	PS	Glaxosmithkline		4 WK
	Weight Decreased						

Date:01/28/05ISR Number: 4563321-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492259A
Age:6 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Grand Mal Convulsion		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice per day
			Adderall	C			
			Zyprexa	C			

Date:01/28/05ISR Number: 4563322-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0492908A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Renal Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	

Date:01/28/05ISR Number: 4563323-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493260A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline		UNKNOWN

Date:01/28/05ISR Number: 4563324-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493314A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Pain Of Skin							

Date:01/28/05ISR Number: 4563325-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0493962A
Age: YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563326-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494331A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563327-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0494686A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
							per day	3 WK
			Zomig	C				
			Fioricet	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563328-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495030A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin	PS	Glaxosmithkline			
			Oxycontin	C				
			Lexapro	C				

Date:01/28/05ISR Number: 4563329-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495040A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563330-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495043A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563331-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495250A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563332-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495288A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Bupropion	PS	Glaxosmithkline		100MG	Single
	Drug Exposure During							
dose								

	Pregnancy					
	Feeling Abnormal					

Date:01/28/05ISR Number: 4563333-4Report Type:Periodic Company Report #S03-USA-05410-01
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Feeling Abnormal		Lexapro	SS			UNKNOWN	
	Impaired Driving Ability							

Date:01/28/05ISR Number: 4563334-6Report Type:Periodic Company Report #S03-USA-05399-01
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Prolactin Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Celexa	SS			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563335-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495338A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563336-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495339A
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	225MG	Unknown
	Weight Decreased							
			Lorazepam	C				
			Unknown Sleeping Pill	C				

Date:01/28/05ISR Number: 4563337-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495378A
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Per day
			Concerta	C				

Date:01/28/05ISR Number: 4563338-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495948A
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Hydrochlorothiazide	SS				

Date:01/28/05ISR Number: 4563339-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496005A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL
			Celexa	SS		
UNKNOWN						

Date:01/28/05ISR Number: 4563340-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496059A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hyperacusis		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:01/28/05ISR Number: 4563341-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496499A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL
	Suicidal Ideation					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563342-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496666A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563343-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496739A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Celexa	SS			UNKNOWN	

Date:01/28/05ISR Number: 4563344-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496748A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563345-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496772A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563346-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496776A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Luvox	C				

Date:01/28/05ISR Number: 4563347-4Report Type:Periodic Company Report #USA040156776
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563348-6Report Type:Periodic Company Report #03US08760
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563349-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496955A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Premenstrual Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL	10	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563350-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0496957A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Female Orgasmic Disorder		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563351-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497595A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563352-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497762A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Sexual Dysfunction		Ssri	C				
	Weight Increased							

Date:01/28/05ISR Number: 4563353-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497772A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	1 WK
			Zoloft	C				

Date:01/28/05ISR Number: 4563354-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0497820A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:01/28/05ISR Number: 4563355-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498028A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563356-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498337A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563357-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498745A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	75MG Twice per day	18 MON
			Avandia	C	Glaxosmithkline			
			Zocor	C				

			Naproxen	C		
			Prevacid	C		

Date:01/28/05ISR Number: 4563358-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498763A
Age: YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Glaxosmithkline	NASAL		

Date:01/28/05ISR Number: 4563359-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0498774A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Psychomotor Hyperactivity		Ssri	C				

Date:01/28/05ISR Number: 4563360-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499052A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown

Date:01/28/05ISR Number: 4563361-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499219A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:01/28/05ISR Number: 4563362-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499609A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Per day	
			Lithium	C	Glaxosmithkline			

Date:01/28/05ISR Number: 4563363-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0499639A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Parosmia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563364-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500572A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline		300MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563365-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501021A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563366-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501036A
Age: YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563367-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501097A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown
			Seroquel	C				

Date:01/28/05ISR Number: 4563368-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501437A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Discolouration		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lexapro	C				

Date:01/28/05ISR Number: 4563369-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501604A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563370-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0501961A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	12 YR
	Drug Interaction							
	Ear Congestion		Percocet	SS			UNKNOWN	
	Insomnia		Decadron	SS			UNKNOWN	
	Nausea		Kytril	SS	Glaxosmithkline		UNKNOWN	
	Pharyngolaryngeal Pain		Compazine	SS	Glaxosmithkline		UNKNOWN	
	Tinnitus		Ativan	SS				
	Tremor		Benadryl	SS	Glaxosmithkline			
	Vomiting							
	White Blood Cell Count Decreased							

Date:01/28/05ISR Number: 4563371-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502029A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic		Wellbutrin	PS	Glaxosmithkline	ORAL	7 DAY	
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563372-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502147A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:01/28/05ISR Number: 4563373-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502152A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
			Neurontin	C				

Date:01/28/05ISR Number: 4563374-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502178A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombocytopenia		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563375-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502186A
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Bupropion					
	Feeling Abnormal		Hydrochloride	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563376-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502990A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON

	Lethargy					
	Myalgia					
	Nausea					
	Pyrexia					

Date:01/28/05ISR Number: 4563377-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0502991A
Age: YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563378-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503190A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	3	DAY
			Axid	C				
			Lotensin	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563379-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503425A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563380-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503446A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563381-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503459A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three	
	Euphoric Mood							
	Nausea						times per day	6 MON
			Xanax	C				
			Ativan	C				

Date:01/28/05ISR Number: 4563382-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503531A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice	
							per day	8 DAY
			Klonopin	C				
			Prometrium	C				
			Synthroid	C	Glaxosmithkline			
			Voltaren	C	Glaxosmithkline			
			Allegra	C				
			Prevacid	C				

Date:01/28/05ISR Number: 4563383-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0503806A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	100MG	Unknown 2 WK
			Prozac	SS			UNKNOWN	

Date:01/28/05ISR Number: 4563384-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504065A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice per day	3 MON

Date:01/28/05ISR Number: 4563385-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504097A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR
			Diuretic	C				
			Hormone Replacement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563386-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504215A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dermatitis Exfoliative							
	Erythema							

Date:01/28/05ISR Number: 4563387-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504275A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:01/28/05ISR Number: 4563388-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504323A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		2 WK
			Zocor	C				
			Klonopin	C				
			Risperdal	C				
			Ditropan Xl	C				
			Ultram	C				
			Trazodone	C				

Date:01/28/05ISR Number: 4563389-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504329A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563390-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504332A
Age: YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563391-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504592A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Ineffective		Prozac	C				

Date:01/28/05ISR Number: 4563392-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504656A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563393-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504864A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Rash		Adderall	C				

Date:01/28/05ISR Number: 4563394-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504867A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	5	YR
	Hostility		Ambien	C				
	Insomnia		Xanax	C				

Date:01/28/05ISR Number: 4563395-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504868A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Unknown	3 MON
			No Concurrent Medication	C				

Date:01/28/05ISR Number: 4563396-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505132A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three times per day	4 WK

Date:01/28/05ISR Number: 4563397-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505235A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Cough							
	Dysgeusia							
	Dyspepsia							

Date:01/28/05ISR Number: 4563398-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505626A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563399-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505629A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline		9	DAY
	Sleep Disorder							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563400-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505934A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
			Nortriptyline	C				

Date:01/28/05ISR Number: 4563401-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506447A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin	PS	Glaxosmithkline		5	DAY
			Lexapro	C			5	MON

Date:01/28/05ISR Number: 4563402-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506507A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Alcohol	SS				

Date:01/28/05ISR Number: 4563403-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506510A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Enzyme Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tachycardia							

Date:01/28/05ISR Number: 4563404-2Report Type:Periodic Company Report #2004S1000747
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563405-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506580A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Malabsorption		Lamictal	SS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563406-6Report Type:Periodic Company Report #2004S1000814
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dry Mouth							

Date:01/28/05ISR Number: 4563407-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506917A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563408-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506924A
Age:25 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice per day	2 WK
			Alcohol	C				
			Marijuana	C				

Date:01/28/05ISR Number: 4563409-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507091A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:01/28/05ISR Number: 4563410-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507155A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Three times per day	
			Celexa	C				
			Trazodone	C				

Date:01/28/05ISR Number: 4563411-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507281A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	50MG Twice per day	4 MON

Date:01/28/05ISR Number: 4563412-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507422A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris		Wellbutrin	PS	Glaxosmithkline	ORAL	4	DAY

Date:01/28/05ISR Number: 4563413-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507534A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:01/28/05ISR Number: 4563414-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507536A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline		8	MON
	Anxiety							
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563415-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507885A
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Three	
	Medication Error						times per day	11 DAY
	Pharmaceutical Product		Aspirin	C	Glaxosmithkline		UNKNOWN	
	Complaint		Duragesic	C			UNKNOWN	
			Synthroid	C	Glaxosmithkline		UNKNOWN	
			Prozac	C			UNKNOWN	
			Megace	C			UNKNOWN	
			Ativan	C			UNKNOWN	
			Neurotin	C			UNKNOWN	
			Zantac	C	Glaxosmithkline		UNKNOWN	
			Ativan	C			UNKNOWN	

Date:01/28/05ISR Number: 4563416-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0507935A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Restless Legs Syndrome		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563417-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508188A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:01/28/05ISR Number: 4563418-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508356A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	12 MON
			No Concurrent Medication	C				

Date:01/28/05ISR Number: 4563419-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508403A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphemia		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563420-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508420A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness		Wellbutrin	PS	Glaxosmithkline			
Other	Loss Of Consciousness		Unknown Medication	SS				
	Overdose							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563421-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508446A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 MON
			Pepcid	C				

Date:01/28/05ISR Number: 4563422-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508470A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphasia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 YR
	Dysphasia							
			Cellcept	C				
			Plaquenil	C				
			Vioxx	C				

Date:01/28/05ISR Number: 4563423-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508669A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563424-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508737A
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	37.5MG Twice per day	13 DAY
	Disturbance In Attention							
			Risperdal	C				

Date:01/28/05ISR Number: 4563425-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508954A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Weight Increased							

Date:01/28/05ISR Number: 4563426-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509072A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline		1	MON
			Synthroid	C	Glaxosmithkline			
			Lamictal	C	Glaxosmithkline			
			Zyprexa	C				
			Prozac	C				
			Unspecified Inhaler	C				

RESPIRATORY

(INHALATION)

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563427-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509208A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	18 DAY
	Anorexia		Trazodone	C				
	Myalgia							

Date:01/28/05ISR Number: 4563428-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509211A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three times per day	4 WK
			Birth Control Pills	C				

Date:01/28/05ISR Number: 4563429-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509429A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline		2	MON
	Feeling Abnormal							
	Insomnia							

Date:01/28/05ISR Number: 4563430-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509442A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	2	DAY
			Interferon	C				

Date:01/28/05ISR Number: 4563431-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509670A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563432-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509848A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563433-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510193A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Overdose Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563434-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510329A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	3	MON

Date:01/28/05ISR Number: 4563435-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510401A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	17 DAY
	Disorientation							
	Dizziness		Effexor	C				
			Blood Pressure Medication	C				

Date:01/28/05ISR Number: 4563436-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510510A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563437-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510552A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	3	MON
	Tachycardia							
	Ventricular Extrasystoles							

Date:01/28/05ISR Number: 4563438-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510657A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Weight Decreased						per day	1 YR

Date:01/28/05ISR Number: 4563439-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510913A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563440-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510925A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lithium	SS	Glaxosmithkline			
			Bupropion Hydrochloride	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563441-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511232A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Wellbutrin	PS	Glaxosmithkline			
	Drug Interaction		Gabitril	SS		ORAL		
	Euphoric Mood		Estrogen	SS				
			Xanax	SS				
			Thyroid Medication	SS				
			Pain Medication	SS				

Date:01/28/05ISR Number: 4563442-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511445A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	1	YR
			Nicotine Patch	C	Glaxosmithkline			

Date:01/28/05ISR Number: 4563443-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511455A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Insomnia		Neurontin	C				
	Night Sweats		Lamictal	C	Glaxosmithkline			
	Palpitations		Doxepin	C				
			Estrogen	C				
			Xanax	C				

Date:01/28/05ISR Number: 4563444-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511478A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	7	DAY

Date:01/28/05ISR Number: 4563445-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511615A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563446-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511888A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:01/28/05ISR Number: 4563447-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512026A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Twice per day	2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563448-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512089A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563449-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512220A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Three	
	Pharmaceutical Product						times per day	6 YR
	Complaint							

Date:01/28/05ISR Number: 4563450-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512243A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563451-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512245A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Muscle Twitching						per day	2 YR
			Trazodone	C				

Date:01/28/05ISR Number: 4563452-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512335A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline			
	Vomiting						2	WK

Date:01/28/05ISR Number: 4563453-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512390A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline			
			Zyban	SS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563454-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512606A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563455-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513171A
Age:45 YR Gender: I/FU:I

Outcome	PT
	Asthenia
	Blood Pressure Increased
	Disturbance In Attention

	Drug Interaction Heart Rate Increased Vision Blurred	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day
			Provigil	SS		ORAL	100MG Per day

Date:01/28/05ISR Number: 4563456-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513272A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Hepatic Enzyme Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	
			No Concurrent Medication	C			

Date:01/28/05ISR Number: 4563457-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513583A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown
	Parosmia Pharmaceutical Product Complaint						

Date:01/28/05ISR Number: 4563458-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513634A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day 2 WK
	Feeling Jittery		No Concurrent Medication	C			

Date:01/28/05ISR Number: 4563459-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513647A
Age:12 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL	6	WK

Date:01/28/05ISR Number: 4563460-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513649A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	29 DAY
	Weight Increased							
			Zyprexa	C		ORAL		YR
			Neurotin	C		ORAL	400MG Twice per day	YR
			Cogentin	C		ORAL		YR

Date:01/28/05ISR Number: 4563461-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513830A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563462-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513952A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Loss Of Libido							
	Orgasm Abnormal							

Date:01/28/05ISR Number: 4563463-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513992A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingivitis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563464-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514086A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotrichosis		Wellbutrin	PS	Glaxosmithkline		2	MON

Date:01/28/05ISR Number: 4563465-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514280A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Asthenia							
	Depressed Mood							
	Drug Ineffective							
	Emotional Disorder							
	Mood Altered							
	Sleep Disorder							

Date:01/28/05ISR Number: 4563466-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514287A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563467-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514326A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Sodium Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Xanax	C				
			Klonopin	C				

Date:01/28/05ISR Number: 4563468-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514616A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sexual Dysfunction		Wellbutrin	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563469-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514619A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline			
			Pegasys	SS				
			Copegus	SS				

Date:01/28/05ISR Number: 4563470-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514684A
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paranoia		Wellbutrin	PS	Glaxosmithkline	ORAL	37.5MG Twice per day	2 MON
			Risperdal	C				

Date:01/28/05ISR Number: 4563471-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514695A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563472-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514800A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563473-XReport Type:Periodic Company Report #04US03216
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Disturbance In Attention Insomnia Mania		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:01/28/05ISR Number: 4563474-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514902A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563475-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514905A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563476-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515037A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
	Libido Decreased							
	Motion Sickness							
	Vomiting							

Date:01/28/05ISR Number: 4563477-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515131A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oral Mucosal Blistering		Wellbutrin	PS	Glaxosmithkline	ORAL	11	DAY
	Rash Generalised							
	Stevens-Johnson Syndrome							

Date:01/28/05ISR Number: 4563478-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515135A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON
	Antigen Increased							

Date:01/28/05ISR Number: 4563479-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515329A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Mental Disorder							

Date:01/28/05ISR Number: 4563480-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515374A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline			
			Multiple Medications	C				

Date:01/28/05ISR Number: 4563481-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515566A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite		Wellbutrin	PS	Glaxosmithkline	ORAL	18	MON
	Weight Increased							

Date:01/28/05ISR Number: 4563482-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515706A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563483-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515913A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Multiforme		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563484-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516108A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown
			No Concurrent Medication	C				

Date:01/28/05ISR Number: 4563488-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516393A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563489-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516725A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	2	MON

Date:01/28/05ISR Number: 4563490-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516769A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563491-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516775A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563492-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516908A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563493-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517076A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Myalgia		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563494-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517271A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:01/28/05ISR Number: 4563495-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518180A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563496-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518211A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563497-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518339A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin	PS	Glaxosmithkline	ORAL	2	YR
	White Blood Cell Count Decreased							

Date:01/28/05ISR Number: 4563498-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518512A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Bupropion	PS	Glaxosmithkline	ORAL	100MG Per day	3 DAY

	Insomnia		No Concurrent Medication	C		

Date:01/28/05ISR Number: 4563499-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518530A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Zoloft	C				
			Ativan	C				
			Neurontin	C				
			Duragesic	C				
			Lortab	C				
			Restoril	C				
			Naprosyn	C				
			Ambien	C				
			Xanax	C				
			Tylenol Pm	C				

Date:01/28/05ISR Number: 4563500-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518533A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Urticaria		Wellbutrin	SS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563501-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518557A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Urticaria							

Date:01/28/05ISR Number: 4563502-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518986A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Warfarin	C	Glaxosmithkline		8MG Per day	

Date:01/28/05ISR Number: 4563503-5Report Type:Periodic Company Report #20040304012
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Idiopathic		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Thrombocytopenic Purpura						per day	
	Platelet Count Decreased		Topamax	SS			UNKNOWN	300MG per day 317 DAY
			Lexapro	SS			UNKNOWN	20MG Per day

Date:01/28/05ISR Number: 4563504-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519182A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563505-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519370A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease		Wellbutrin	PS	Glaxosmithkline	OTHER		

Date:01/28/05ISR Number: 4563506-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519402A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tachycardia		Effexor	C				
			Strattera	C				

Date:01/28/05ISR Number: 4563507-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519699A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563508-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519712A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	2 MON	
	Depression		Wellbutrin	SS	Glaxosmithkline	ORAL	75MG Per day	22 DAY
	Diarrhoea		Effexor Xr	C		ORAL	112.5MG per day	33 DAY
	Mood Swings							
	Stool Analysis Abnormal		Trazodone	C		ORAL		
			Diazepam	C		ORAL	5MG As required	35 DAY
			Diazepam	C		ORAL	5MG As required	

Date:01/28/05ISR Number: 4563509-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519717A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Effexor	C				

Date:01/28/05ISR Number: 4563510-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519741A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563511-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519842A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	7	YR

Date:01/28/05ISR Number: 4563512-6Report Type:Periodic Company Report #S04-USA-04203-01
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mania		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Weight Increased		Lexapro	SS			UNKNOWN	

Date:01/28/05ISR Number: 4563513-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520110A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Erectile Dysfunction		Unknown Medication	C				
	Libido Decreased							

Date:01/28/05ISR Number: 4563514-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520365A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Unknown	6 MON
	Anxiety		Nexium	C				
			Ambien	C				
			Provigil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563515-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520404A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563516-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520765A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ejaculation Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG	Unknown YR
	Sexual Dysfunction		Celexa	C				
			Unknown Medication	C				

Date:01/28/05ISR Number: 4563517-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521063A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xr	PS	Glaxosmithkline	ORAL	150MG Twice per day	5 MON
	Confusional State							
	Constipation		Effexor Xr	C			75MG Per day	
	Dyspnoea							
	Erythema							
	Flatulence							
	Hyperhidrosis							
	Pharmaceutical Product Complaint							
	Stomach Discomfort							

Date:01/28/05ISR Number: 4563518-7Report Type:Periodic Company Report #DSA_24592_2004
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis Exfoliative		Wellbutrin	PS	Glaxosmithkline	ORAL
	Disease Recurrence		Cardizem	SS	Glaxosmithkline	
UNKNOWN	240MG Per day 21 DAY					
	Hypersensitivity		Advair	C	Glaxosmithkline	
RESPIRATORY						
	Sensory Loss					
(INHALATION)	31 DAY					
	Skin Discolouration		Xopenex	C		
31 DAY						
	Skin Hypertrophy		Unknown Medication	C		
	Weight Decreased		Prednisone	C		
36 DAY						

Date:01/28/05ISR Number: 4563519-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521404A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urticaria		Wellbutrin	PS	Glaxosmithkline	ORAL

Date:01/28/05ISR Number: 4563520-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521423A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						
	Drug Ineffective					
	Drug Tolerance Decreased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563521-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521551A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563522-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521668A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	YR
	Bradyphrenia							
	Mental Impairment							

Date:01/28/05ISR Number: 4563523-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521815A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK

Date:01/28/05ISR Number: 4563524-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521828A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
			Hyzaar	C				
			Zocor	C				
			Norvasc	C				
			Flomax	C				

Date:01/28/05ISR Number: 4563525-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521839A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Abnormal		No Concurrent Medication	C				

Date:01/28/05ISR Number: 4563526-6Report Type:Periodic Company Report #USA040567498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563527-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522170A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
	Drug Ineffective							
	Stool Analysis Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563528-XReport Type:Periodic Company Report #04US05065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563529-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522638A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	6	MON
	Nervousness							

Date:01/28/05ISR Number: 4563530-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522658A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 WK

Date:01/28/05ISR Number: 4563531-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522662A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Burning Sensation							
	Pain In Extremity							

Date:01/28/05ISR Number: 4563532-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523513A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Somnolence							

Date:01/28/05ISR Number: 4563533-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523769A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563534-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523829A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy		Wellbutrin	PS	Glaxosmithkline	ORAL	.5TAB Per day	
	Somnolence		Adderall	C				
	Thinking Abnormal		Valium	C				
	Throat Irritation		Vicodin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563535-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524013A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	1	WK
	Panic Attack							
	Tremor							

Date:01/28/05ISR Number: 4563536-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524060A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG	Unknown
	Head Discomfort		Ativan	C				
			Potassium	C				
			Vitamins	C				

Date:01/28/05ISR Number: 4563537-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524198A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychomotor Hyperactivity		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Tremor		Zantac 75	C	Glaxosmithkline			

Date:01/28/05ISR Number: 4563538-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524532A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Weight Increased							

Date:01/28/05ISR Number: 4563539-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524559A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563540-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524675A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563541-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524682A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
	Compulsions							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563542-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524876A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563543-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525036A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	1 MON

Date:01/28/05ISR Number: 4563545-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525076A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Tendency To		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Bruise		Naprosyn	C				
			Naprosyn	C				
UNKNOWN								

Date:01/28/05ISR Number: 4563546-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525570A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	2	WK
	Skin Disorder							
	Urticaria							

Date:01/28/05ISR Number: 4563547-3Report Type:Periodic Company Report #S2004US11201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Feeling Abnormal Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563548-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525719A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Nicoderm Cq Clear 21mg	SS	Glaxosmithkline	TRANSDERMAL		

Date:01/28/05ISR Number: 4563549-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525815A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Macular		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563550-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525824A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three	
	Pharmaceutical Product						times per day	1 YR
	Complaint		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice	
							per day	2 YR
			Xanax	C				

Date:01/28/05ISR Number: 4563551-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526132A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hormone Level Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563552-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526433A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Paxil	C	Glaxosmithkline			
			Pamelor	C				

Date:01/28/05ISR Number: 4563553-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526660A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563554-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526679A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563555-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526703A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
			Zoloft	SS				5 YR

Date:01/28/05ISR Number: 4563556-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526857A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Discharge		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563557-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527100A
Age:43 YR Gender:Female I/FU:I

Outcome	PT
	Feeling Jittery
	Heart Rate Increased

		Insomnia Sleep Disorder						
			Report Source	Product	Role	Manufacturer		Route
Dose	Duration							
				Wellbutrin	PS	Glaxosmithkline		ORAL
75MG Twice								
per day	2 WK							
				Valtrex	C	Glaxosmithkline		
				Vitamins	C			

Date:01/28/05ISR Number: 4563558-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527280A
Age:43 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer		Route
Dose	Duration							
		Anxiety		Wellbutrin	PS	Glaxosmithkline		ORAL
75MG Twice								
		Nausea						
per day	2 WK							
		Palpitations		Valtrex	C	Glaxosmithkline		

Date:01/28/05ISR Number: 4563559-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527285A
Age:62 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer		Route
Dose	Duration							
		Drug Ineffective		Wellbutrin	PS	Glaxosmithkline		ORAL
3 MON								
				Wellbutrin Sr	SS	Glaxosmithkline		ORAL
150MG Twice								
per day	3 MON							
				Wellbutrin Xl	SS	Glaxosmithkline		ORAL
150MG Twice								
per day	3 MON							
				No Concurrent Medication	C			

Date:01/28/05ISR Number: 4563560-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527363A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polymenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	4	MON
	Weight Decreased							

Date:01/28/05ISR Number: 4563561-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527581A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin	PS	Glaxosmithkline	ORAL	1	MON
	Pyrexia		Trazodone	C				
			Lithium	C	Glaxosmithkline			
			Levoxyl	C	Glaxosmithkline			

Date:01/28/05ISR Number: 4563562-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527622A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test		Wellbutrin	PS	Glaxosmithkline	ORAL	3	YR
	Abnormal		Strattera	C				
			Adderall	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563563-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527971A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin	PS	Glaxosmithkline	ORAL	9	MON
			Toprol	C				
			Celebrex	C				
			Zocor	C				
			Diuretic	C				

Date:01/28/05ISR Number: 4563564-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528261A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563565-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528263A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Bupropion	PS	Glaxosmithkline	ORAL		
	Feeling Abnormal							
	Stomach Discomfort							

Date:01/28/05ISR Number: 4563566-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528271A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Depression							
	Insomnia							

Date:01/28/05ISR Number: 4563567-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528393A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Dilantin	C				

Date:01/28/05ISR Number: 4563568-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528994A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Disturbance In Attention		Sudafed	SS	Glaxosmithkline	ORAL		
	Nervousness							

Date:01/28/05ISR Number: 4563569-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528996A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563570-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529112A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemolytic Anaemia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Neurontin	C				
			Oxycontin	C				

Date:01/28/05ISR Number: 4563571-0Report Type:Periodic Company Report #04US02766 TEAM B
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563572-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529476A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563573-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529502A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563574-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529516A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dissociation		Wellbutrin	PS	Glaxosmithkline			
UNKNOWN								
	Sensory Disturbance		Ethanol	SS				
			No Concurrent					

			Medication	C		

Date:01/28/05ISR Number: 4563575-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530024A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:01/28/05ISR Number: 4563576-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530046A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563577-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530107A
Age:40 YR Gender:Female I/FU:I

Outcome	PT
	Heart Rate Increased
	Insomnia

	Tremor						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS	Glaxosmithkline	ORAL	

Date:01/28/05ISR Number: 4563578-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530112A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Increased Appetite		Wellbutrin	PS	Glaxosmithkline	ORAL	
			Zoloft	C			

Date:01/28/05ISR Number: 4563579-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530113A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Therapeutic Response		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice
	Unexpected						per day 2 MON
			Birth Control Pills	C		ORAL	

Date:01/28/05ISR Number: 4563580-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530116A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day
	Rash Macular						

Date:01/28/05ISR Number: 4563581-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530220A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Pain		Bupropion	PS	Glaxosmithkline	ORAL
0 DAY						
			Luvox	C		

Date:01/28/05ISR Number: 4563582-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530608A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Menstrual Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Twice						
per day 1 WK						
			No Concurrent Medication	C		

Date:01/28/05ISR Number: 4563583-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530651A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice						
per day 5 YR						
			Wellbutrin	SS	Glaxosmithkline	ORAL
300MG Per day 2 MON						
			Wellbutrin	SS	Glaxosmithkline	ORAL
			No Concurrent Medication	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563584-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530828A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice	
							per day	1 MON

Date:01/28/05ISR Number: 4563585-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530903A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563586-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531074A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	2	DAY
	Nausea							

Date:01/28/05ISR Number: 4563587-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531228A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			
			Dilantin	C				

Date:01/28/05ISR Number: 4563588-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531307A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Feeling Jittery		Wellbutrin	PS	Glaxosmithkline	ORAL
1 WK						
			Strattera	SS		
1 WK						

Date:01/28/05ISR Number: 4563589-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531446A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Wellbutrin	PS	Glaxosmithkline	

Date:01/28/05ISR Number: 4563590-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531733A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Unknown						
			Zyprexa	C		

Date:01/28/05ISR Number: 4563591-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531777A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Stool Analysis Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563592-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531959A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563593-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532025A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563594-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532033A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563595-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532361A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563596-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532540A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	3	WK
			Vicodin	C				
			Augmentin	C	Glaxosmithkline			
			Meridia	C				

Date:01/28/05ISR Number: 4563597-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532833A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563598-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532910A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin	PS	Glaxosmithkline			
	Formication							
	Mental Disorder							

Date:01/28/05ISR Number: 4563599-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532916A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline		1	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563600-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533106A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563601-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533249A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown 3 WK
	Fall		Aricept	C				
			Namenda	C				

Date:01/28/05ISR Number: 4563602-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533267A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	600MG	Unknown 4 MON
	Hepatic Enzyme Increased		No Concurrent					
	Jaundice		Medication	C				
	Mental Impairment							
	Panic Attack							
	Restlessness							

Date:01/28/05ISR Number: 4563603-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533280A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4563604-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533445A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Testicular Swelling		Wellbutrin	PS	Glaxosmithkline	ORAL	5	YR
			Citalopram	C				

Date:01/28/05ISR Number: 4563605-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533656A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Interaction						per day	6 MON
	Therapeutic Response		Bupropion	SS	Glaxosmithkline	ORAL	150MG Unknown	8 WK
	Unexpected		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	
			Amoxicillin	SS	Glaxosmithkline		UNKNOWN	875MG Unknown 14 DAY

Date:01/28/05ISR Number: 4563606-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533999A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Agitation Insomnia		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563607-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534128A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Twice per day	7 MON
			No Concurrent Medication	C				

Date:01/28/05ISR Number: 4563608-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534630A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three times per day	
	Hair Plucking							

Date:01/28/05ISR Number: 4563609-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534675A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin	PS	Glaxosmithkline			
			Wellbutrin Xl	C	Glaxosmithkline	ORAL	2	MON

Date:01/28/05ISR Number: 4563610-7Report Type:Periodic Company Report #04US06388
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tinnitus		Wellbutrin	PS	Glaxosmithkline			
	Visual Acuity Reduced							

Date:01/28/05ISR Number: 4563611-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534888A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline		4	DAY
	Fatigue							
	Insomnia							
	Memory Impairment							
	Nervousness							
	Tremor							

Date:01/28/05ISR Number: 4563612-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534895A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline			
	Tinnitus							

Date:01/28/05ISR Number: 4563613-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534903A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mood Swings		Wellbutrin	PS	Glaxosmithkline			
			Lithium	C	Glaxosmithkline			
			Klonopin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4563614-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535046A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563615-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535147A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Wellbutrin	PS	Glaxosmithkline	ORAL	2	YR
			No Concurrent Medication	C				

Date:01/28/05ISR Number: 4563616-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535399A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

Date:01/28/05ISR Number: 4563617-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535403A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Dry Throat Gingival Swelling Swollen Tongue		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563618-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535728A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:01/28/05ISR Number: 4563619-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535729A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Energy Increased		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Psychomotor Hyperactivity							

Date:01/28/05ISR Number: 4563620-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535741A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:01/28/05ISR Number: 4564339-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541320A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
	Photopsia		Effexor	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564340-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541324A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Coprolalia		Testosterone Cream	C	Glaxosmithkline			
	Irritability							
	Judgement Impaired							
	Personality Change							

Date:01/28/05ISR Number: 4564341-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541340A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Crying		Adderall Xr	C				
	Depression							
	Hallucination							
	Pharyngolaryngeal Pain							
	Sleep Disorder							
	Urticaria							

Date:01/28/05ISR Number: 4564343-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541534A
Age:12 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Anger							
per day	18 MON							
	Crying		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Depression							
	Drug Ineffective							
	Tremor							

Date:01/28/05ISR Number: 4564347-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541554A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Feeling Of Despair		Xanax	C				
	Medication Error							
	Panic Attack							
	Suicidal Ideation							

Date:01/28/05ISR Number: 4564350-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541728A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Lamictal	PS	Glaxosmithkline	ORAL	300MG Per day	
	Decreased Appetite		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Dyspepsia		No Concurrent Medication	C				
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4565967-XReport Type:Expedited (15-DaCompany Report #B0133705A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required	Arthralgia Blood Pressure Decreased Chills	Foreign Literature Health	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	SEE DOSAGE	
Intervention to Prevent Permanent Impairment/Damage	Diabetes Mellitus Inadequate Control Inflammation Oedema Peripheral	Professional	Insulin Lispro Injection (Insulin Lispro)	SS		SUBCUTANEOUS SUBCUTANEOUS	TEXT / ORAL	
	Pyrexia Serum Sickness Urticaria Generalised Vomiting							

Date:01/28/05ISR Number: 4575333-9Report Type:Direct Company Report #CTU 238582
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Bupropion Sr 100g	PS			100 MG QAM	
	Disturbance In Attention		Marinol	C				
	Dyskinesia		Bextra	C				
	Eye Disorder		Flovent	C				
	Feeling Abnormal		Zelnorm	C				
	Pharmaceutical Product		Aciphex	C				
	Complaint		Serevent	C				
			Hydrocodone/Apap	C				
			Xanax	C				

Date:01/28/05ISR Number: 4575477-1Report Type:Direct Company Report #CTU 238549
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Bupropion	PS		ORAL	150 MG BID ,	

Hallucination, Auditory
PO

Multiple Sclerosis

Benztropine	C
Fluphenazine	C
Zyprexa	C
Lorazepam	C

Date:01/28/05ISR Number: 4575503-XReport Type:Direct Company Report #CTU 238593
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharmaceutical Product		Bupropion	PS		ORAL	150 MG BID PO	

Complaint
Tremor

Date:01/28/05ISR Number: 4575510-7Report Type:Direct Company Report #CTU 238597
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
Disability	Migraine		Bupropion Sr	150mg	PS		ORAL	150MG QD	
	Pharmaceutical Product								
ORAL									
	Complaint		Neurontin		C				
			Alprazolam		C				
			Trileptal		C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4565496-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541550A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline			
	Death							
	Overdose							

Date:01/31/05ISR Number: 4565502-6Report Type:Expedited (15-DaCompany Report #BPC-ZN-05-048
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol		Zyban	PS	Glaxosmithkline	ORAL		
	Increased							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Epilepsy							
	Hypertension							

Date:01/31/05ISR Number: 4565514-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0363099A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Induced		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Drug Exposure During							
dosage text							42	DAY
	Pregnancy		Implanon	SS				
TRANSDERMAL							68MG See	
	Drug Ineffective							
dosage text								
	Drug Interaction							
	Pregnancy							
	Unintended Pregnancy							

Date:01/31/05ISR Number: 4565515-4Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0364300A
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Zyban	PS	Glaxosmithkline	ORAL	2U per day	17 DAY
	Cholecystitis		Orap	C			UNKNOWN	1MG Unknown
	Hepatic Enzyme Increased		Anafranil	C			UNKNOWN	25MG Unknown
	Insomnia		Glucophage	C			UNKNOWN	600MG Unknown
	Pyrexia		Minidiab	C			UNKNOWN	

Date:01/31/05ISR Number: 4565516-6Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0364369A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG Twice
	Affect Lability						per day	34 DAY
	Delusion							
	Personality Change							
	Psychotic Disorder							

Date:01/31/05ISR Number: 4565521-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0365371A
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Lethargy						per day	

			Propranolol	C		
UNKNOWN	80MG Per day					
			Escitalopram	C		
UNKNOWN	10MG Per day					

Date:01/31/05ISR Number: 4565529-4Report Type:Expedited (15-DaCompany Report #NA-GLAXOSMITHKLINE-B0366028A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Visual Disturbance		Zyban	PS	Glaxosmithkline	
UNKNOWN	8 DAY					
			No Concurrent Medication	C		

Date:01/31/05ISR Number: 4565532-4Report Type:Expedited (15-DaCompany Report #2005000353
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea		Zyban	PS	Glaxosmithkline	ORAL
4500MG Single						
Initial or Prolonged	Hypotension					
dose						
Other	Intentional Misuse		Ethanol	SS		ORAL
	Overdose					
	Suicide Attempt					
	Tachycardia					

Date:01/31/05ISR Number: 4567958-1Report Type:Expedited (15-DaCompany Report #B0365424A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Aggression	Foreign	Wellbutrin Sr Tablet			
Initial or Prolonged	Depression	Literature	- Controlled Release			
	Irritability	Health	(Bupropion			
	Multiple Drug Overdose	Professional	Hydrochloride)	PS		ORAL
SEE DOSAGE						
	Paranoia					
TEXT / ORAL						

	Psychomotor Agitation		Midazolam Tablet			
	Psychotic Disorder		(Midazolam)	SS		ORAL
14 TABLET /						
	Respiratory Rate					
SINGLE DOSE /						
	Increased					
ORAL						
	Somnolence					
	Suicide Attempt					

Date:01/31/05ISR Number: 4569930-4Report Type:Expedited (15-DaCompany Report #2005-124455-NL
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthenia	Health	Remeron /Net/	PS		ORAL
45 MG QD ORAL						
	Confusional State	Professional	Intron A			
	Decreased Appetite		"Schering-Plough"	SS	Schering-Plough	
INTRAVENOUS 44 MIU						
	Dehydration					
INTRAVENOUS						
	Depression					
(NOS)						
	Drug Interaction		Wellbutrin	SS		ORAL
300 MG BID						
	Lethargy					
ORAL						
	Malignant Melanoma Stage		Allopurinol	SS		ORAL
100 MG QD						
	Iii					
ORAL						
	Nausea		Clonazepam	SS		ORAL
0.5 MG QD						
	Oral Intake Reduced					
ORAL						
			Trazodone	SS		ORAL
50 MG QD ORAL						
			Zocor	SS		ORAL
10 MG QD ORAL						
			Glucosamine	SS		
DF PRN ORAL						
			Multivitamins	SS		ORAL
DF PRN ORAL						

			Compazine	SS		ORAL
10 MG PRN						
ORAL						

Date:02/01/05ISR Number: 4566620-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541516A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Application Site Vesicles		Nicoderm Cq Clear 21mg	PS	Glaxosmithkline	TRANSDERMAL
	Chest Pain					
	Electrocardiogram Change		Wellbutrin	SS	Glaxosmithkline	ORAL
150MG per day						
	Heart Rate Decreased		Ativan	C		ORAL
	Nicotine Dependence					
	Ventricular Extrasystoles					

Date:02/01/05ISR Number: 4567164-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0534891A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	
	Anger					
	Belligerence					
	Delusional Disorder, Persecutory Type					
	Emotional Disorder					
	Muscle Spasms					
	Psychotic Disorder					
	Tension					

Date:02/01/05ISR Number: 4567169-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0536385A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Complex Partial Seizures		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
450MG Per day						

Initial or Prolonged	Hemiparesis						
	Ill-Defined Disorder						
	Medication Error						
	Overdose						

Date:02/01/05ISR Number: 4567181-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0542715A
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Fall							
	Hip Fracture							

Date:02/01/05ISR Number: 4567199-8Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0364711A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	1TAB	Variable
	Feeling Abnormal							
							dose	6 DAY
	Formication		Keflex	C	Glaxosmithkline	ORAL	500MG	Four
	Hallucination, Tactile							
							times per day	6 DAY
	Palpitations							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/05ISR Number: 4567213-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0369201A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Inflammation		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
Initial or Prolonged	Myositis						dosage text	9 WK
	Pain In Extremity		Diane 35	C		ORAL		
	Therapeutic Response Decreased							
	Vasculitis							

Date:02/01/05ISR Number: 4578191-1Report Type:Direct Company Report #CTU 238840
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nausea		Wellbutrin Xl 150 Mg	PS		ORAL	1 PO DAILY	
	Vomiting							

Date:02/02/05ISR Number: 4568287-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541948A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Enzyme Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	10 MON	
	Hepatic Neoplasm		Lipitor	C				
	Malignant		Biaxin	C				
	Hepatocellular Damage							
	Lung Neoplasm Malignant							

Date:02/02/05ISR Number: 4568291-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0542699A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/02/05ISR Number: 4568296-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0363857A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Zyban	PS	Glaxosmithkline			
	Asthenia		Sodium Stibogluconate	SS	Glaxosmithkline			
	Back Pain							
	Cerebrovascular Accident							
	Chest Pain		Keflex	C	Glaxosmithkline	ORAL	500MG Three times per day	16 DAY
	Dizziness							
	Fatigue		Fluconazole	C		ORAL	200MG Per day	34 DAY
	Flank Pain		Rifampin	C				
	Headache		Ketoconazole	C				
	Limb Discomfort							
	Muscle Spasms							
	Myalgia							
	Nausea							
	Renal Failure Acute							
	Rhabdomyolysis							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/05ISR Number: 4578096-6Report Type:Direct Company Report #CTU 238908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS		ORAL	150 MG PO 1	PO QD X3D
								THEN 2 / D

Date:02/02/05ISR Number: 4578112-1Report Type:Direct Company Report #CTU 238899
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity Stevens-Johnson Syndrome		Wellbutrin Xl 150 Mg Tab	PS		ORAL	1 TAB PO QD	
	Vomiting							

Date:02/02/05ISR Number: 4578364-8Report Type:Direct Company Report #CTU 238928
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Palpitations		Wellbutrin (Bupropion) Depakote Atenolol Vitamins	PS C C C				

Date:02/03/05ISR Number: 4569330-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540290A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Unknown	
	Medication Error		No Concurrent					

	Panic Attack		Medication	C		

Date:02/03/05ISR Number: 4569331-9Report Type:Expedited (15-DaCompany Report #BPC-ZN-05-048
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Cholesterol Increased Diabetes Mellitus Non-Insulin-Dependent Epilepsy Hypertension		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/03/05ISR Number: 4569332-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0542637A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Suicide Attempt		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
			Amitriptyline	SS			UNKNOWN	
			Fluvoxamine	SS			UNKNOWN	
			Unknown Medication	SS			UNKNOWN	
			Phenazopyridine Pyridium Unknown Medication	SS SS SS				
			Zyprexa	SS			UNKNOWN	

			Alcohol	SS		

Date:02/03/05ISR Number: 4569333-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0542840A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hallucination		Zoloft	C				
	Renal Failure		Neurontin	C				
	Somnolence		Zyrtec	C	Glaxosmithkline			
			Synthroid	C	Glaxosmithkline			

Date:02/03/05ISR Number: 4569344-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0363180A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Tetany		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:02/03/05ISR Number: 4569354-XReport Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0045476A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG	See dosage text
	Cardiac Disorder							
	Delusion							
	Dyspnoea							
	Hyperventilation							
	Panic Attack							
	Suicidal Ideation							

Date:02/03/05ISR Number: 4570536-1Report Type:Direct Company Report #CTU 239213
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Bupropion Hcl 100	PS			3 TABS Q DAY	
	Pharmaceutical Product Complaint							

Date:02/04/05ISR Number: 4570585-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0534857A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	DAY
Initial or Prolonged	Anger		Tagamet	C	Glaxosmithkline			
	Anorexia		Vicodin	C				
	Bipolar Disorder							
	Coordination Abnormal							
	Diarrhoea							
	Disturbance In Attention							
	Fatigue							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/05ISR Number: 4570588-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540443A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG See dosage text	
	Coma							
	Drug Ineffective		Lexapro	SS				
	Drug Interaction		Atenolol	C				
	Medication Error		Avandia	C	Glaxosmithkline			
			Nexium	C				
			Aspirin	C	Glaxosmithkline			
			Aricept	C				
			Neurontin	C				
			Centrum Silver	C				
			Magnesium	C				
			Potassium	C				
			Duragesic	C				
			B12	C	Glaxosmithkline			
			Hydrocodone	C				
			Zocor	C				
			Diazepam	C				
			Isosorbide	C				

Date:02/04/05ISR Number: 4570592-0Report Type:Expedited (15-DaCompany Report #S05-USA-00304-01
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disease Recurrence		Wellbutrin	PS	Glaxosmithkline	ORAL	UNKNOWN	
	Pancreatitis		Lexapro	SS				

Date:02/04/05ISR Number: 4570608-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0365867A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	30 DAY

Initial or Prolonged	Dyspnoea		Vagifem	C		
UNKNOWN						
	Joint Swelling		Combivent	C		
UNKNOWN						
	Tachycardia		Warfarin Sodium	C	Glaxosmithkline	
UNKNOWN						
			Estriol	C		
UNKNOWN						

Date:02/04/05ISR Number: 4570614-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0369124A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	9 DAY
Initial or Prolonged	Creatinine Renal		Vaccine	SS	Glaxosmithkline			
SUBCUTANEOUS	2UNIT Single							
	Clearance Decreased							
dose	1 DAY							
	Cytolytic Hepatitis		Lescol	C		ORAL		
1UNIT per day								
	Dyspnoea Exertional							
	Oedema							
	Oedema Peripheral							

Date:02/04/05ISR Number: 4574444-1Report Type:Expedited (15-DaCompany Report #2004111620
Age:73 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Lower	Health	Celebrex (Celecoxib)	PS		ORAL	200 MG (200	
	Abdominal Tenderness	Professional					MG, 1 AS	
	Asthenia						NECESSARY),	
	Cerebrovascular Accident						ORAL	
	Constipation		Bupropion					
	Diastolic Dysfunction		Hydrochloride					
	Disorientation		(Bupropion					
	Fall		Hydrochloride)	SS			SEE IMAGE	
	Hyperreflexia		Biselect (Bisoprolol					
	Meningioma		Fumarate,					
	Peripheral Coldness		Hydrochlorothiazide)	C				
	Petechiae		Nifedipine					
	Pyuria		(Nifedipine)	C				
	Rash		Diazepam (Diazepam)	C				
	Somnolence		Propacet					
	Treatment Noncompliance		(Dextropropoxyphene					
	Urinary Tract Infection		Napsilate,					
	Vasculitis		Paracetamol)	C				

Date:02/04/05ISR Number: 4578288-6Report Type:Direct Company Report #CTU 239311
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Zyban 150 Mg	PS			Q DAY X 3	
							DAYS THEN BID	
							[~1 WEEK]	1 WK

Date:02/04/05ISR Number: 4578297-7Report Type:Direct Company Report #CTU 239304
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash		Zyban 150 Mg	PS			Q DAY X 3 Initial or Prolonged DAYS THEN BID	
[~1 WEEK]							1	WK

Date:02/07/05ISR Number: 4572411-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0543321A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	
	Abnormal							
	Protein Total Increased		Lamictal	C	Glaxosmithkline		100MG Twice per day	

Date:02/07/05ISR Number: 4572430-9Report Type:Expedited (15-DaCompany Report #DK-GLAXOSMITHKLINE-B0369735A
Age:69 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG Unknown 25 DAY
	Stevens-Johnson Syndrome		Centyl + Kcl	C			UNKNOWN	
			Micardis	C	Glaxosmithkline		UNKNOWN	80MG Unknown
			Selo-Zok	C			UNKNOWN	100MG Unknown

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4575893-8Report Type:Expedited (15-DaCompany Report #004003
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Fluoxetine(Fluoxetin					
	Disorientation	Health	e) Capsule, 20mg	PS		ORAL	20 MG, QD,	
	Drug Interaction	Professional					ORAL	
	Loss Of Consciousness		Wellbutrin - Slow					
	Nausea		Release (Bupropion					
			Hydrochloride) 150					
			Mg	SS		ORAL	150 MG, QD,	
							ORAL	

Date:02/08/05ISR Number: 4572631-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531757A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Paxil Cr	PS	Glaxosmithkline	ORAL	37.5MG Per	
	Abnormal Dreams						day	16 MON
	Diarrhoea		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Disorientation		Clonazepam	C				
	Headache							
	Nausea							
	Paraesthesia							
	Vision Blurred							

Date:02/08/05ISR Number: 4572649-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532717A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Paxil	PS	Glaxosmithkline	ORAL	37.5MG Per	
							day	

				Wellbutrin	SS	Glaxosmithkline	ORAL 300MG Per day
				Geodon	C		

Date:02/08/05ISR Number: 4572657-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533119A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Paxil Cr	PS	Glaxosmithkline	ORAL	37.5MG Per day	8 MON
	Affect Lability							
	Nausea		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	100MG Twice per day	6 WK
	Nightmare							
	Sleep Disorder		No Concurrent Medication	C				
	Vertigo							
	Weight Increased							

Date:02/08/05ISR Number: 4572672-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534324A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Paxil Cr	PS	Glaxosmithkline	ORAL	25MG Per day	
	Hot Flush		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Hyperhidrosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/05ISR Number: 4573207-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0519822A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Paxil	PS	Glaxosmithkline	ORAL	30MG Per day	
Initial or Prolonged	Drug Withdrawal Syndrome		Wellbutrin	SS	Glaxosmithkline			
	Feeling Abnormal		Flexeril	SS				
	Intentional Misuse		Skelaxin	SS				
	Suicidal Ideation		Antiinflammatory	SS				
	Suicide Attempt		Aspirin	SS	Glaxosmithkline			
			Theophylline	SS				
			Risperdal	SS				
			Cold Medicine	SS				

Date:02/08/05ISR Number: 4573474-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523468A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	4 MON
	Food Craving		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	3	DAY
	Somnolence							
	Weight Increased							

Date:02/08/05ISR Number: 4573502-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524232A
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Paxil	PS	Glaxosmithkline	ORAL	50MG Per day	5 YR
	Drug Ineffective		Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
			Zocor	C				

Date:02/08/05ISR Number: 4573505-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524392A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Paxil	PS	Glaxosmithkline	ORAL		
	Drug Exposure During Pregnancy		Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:02/08/05ISR Number: 4573522-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525070A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Paxil	PS	Glaxosmithkline	ORAL		
	Libido Decreased		Wellbutrin	SS	Glaxosmithkline	ORAL	75MG Per day	
	Nervousness							
	Tremor							

Date:02/08/05ISR Number: 4573606-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527300A
Age: Gender:Female I/FU:I

Outcome	PT
	Blood Creatinine Increased
	Drug Ineffective
	Fatigue
	Lethargy

		Malaise Weight Decreased Weight Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Paxil	PS	Glaxosmithkline	ORAL
40MG Per day	10 YR						
				Wellbutrin	SS	Glaxosmithkline	ORAL
300MG Per day	4 MON						
				Benecol	C		
				Aspirin	C	Glaxosmithkline	
				Maxide	C		
				Ranitidine	C	Glaxosmithkline	

Date:02/08/05ISR Number: 4574107-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530234A
Age:72 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Glucose Increased		Paxil	PS	Glaxosmithkline	ORAL
20MG Per day	6 WK						
		Drug Ineffective		Wellbutrin Xl	SS	Glaxosmithkline	ORAL
150MG Per day	1 DAY						
				Insulin Lantus	C		
				Novolog	C		
				Plavix	C		
				Hytrin	C		
				Accupril	C		
				Cordarone	C		
				Lanoxin	C	Glaxosmithkline	
				Coreg	C	Glaxosmithkline	
				Methotrexate	C		
				Crestor	C		
				Triamterene + Hydrochlorothiazide	C	Glaxosmithkline	
				Centrum Silver	C		
				Baby Aspirin	C	Glaxosmithkline	
				Calcium	C		
				Folic Acid	C		

Date:02/08/05ISR Number: 4574113-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530368A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Paxil	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:02/08/05ISR Number: 4574117-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530648A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	
	Depression		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Mental Impairment		Wellbutrin Xl	C	Glaxosmithkline			
	Somnolence		Atrovent	C	Glaxosmithkline			
	Vision Blurred		Advair	C	Glaxosmithkline			
			Hytrin	C				

Date:02/08/05ISR Number: 4574119-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530823A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	18 MON
	Dysgeusia		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	

				No Concurrent Medication	C			

Date:02/08/05ISR Number: 4574149-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531838A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Apathy		Paxil	PS	Glaxosmithkline	ORAL	40MG Per day	2 YR
	Decreased Interest		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	
	Depression							
	Lethargy							
	Sleep Disorder							
	Therapeutic Response							
	Unexpected							

Date:02/08/05ISR Number: 4574173-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533261A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Paroxetine	PS	Glaxosmithkline	ORAL		
	Hyperhidrosis		Paxil	SS	Glaxosmithkline	ORAL	20MG Per day	10 YR
	Insomnia		Paxil	SS	Glaxosmithkline	ORAL	12.5MG Per day	2 MON
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	6 YR
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG In the morning	2 MON
			Trazodone	C				
			Multivitamin	C				
			Fibercon	C				

Date:02/08/05ISR Number: 4574608-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515151A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia		Paxil	PS	Glaxosmithkline	ORAL	3	MON
	Drug Ineffective		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Insomnia		No Concurrent Medication	C				

Date:02/08/05ISR Number: 4574623-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515534A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Paxil	PS	Glaxosmithkline	ORAL	5	YR
	Drug Ineffective		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	
	Libido Decreased							
	Sexual Dysfunction							
	Weight Increased							

Date:02/08/05ISR Number: 4574684-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516755A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Nausea		Paxil	SS	Glaxosmithkline	ORAL		
			Flonase	C	Glaxosmithkline			

				Allegra	C		

Date:02/08/05ISR Number: 4574811-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517089A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Paxil Cr	PS	Glaxosmithkline	ORAL	12.5MG Per	
	Fatigue						day	8 DAY
	Increased Appetite		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice	
							per day	1 MON
			No Concurrent Medication	C				

Date:02/08/05ISR Number: 4575065-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544253A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/08/05ISR Number: 4575078-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0364991A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxosmithkline		150MG Twice	
	Gun Shot Wound						per day	

Date:02/08/05ISR Number: 4575086-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0369079A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Zyban	PS	Glaxosmithkline	ORAL		

Date:02/09/05ISR Number: 4575616-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0349816A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Bupropion	PS	Glaxosmithkline	ORAL		
	Completed Suicide		Aspirin	SS	Glaxosmithkline	ORAL		
	Convulsion		Acetaminophen	SS	Glaxosmithkline	ORAL		
	Haematemesis		Ethanol	SS		ORAL		
	Overdose							

Date:02/09/05ISR Number: 4575617-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0349817A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Bupropion	PS	Glaxosmithkline	ORAL		
	Completed Suicide		Topiramate	SS		ORAL		
	Intentional Misuse		Venlafaxine	SS		ORAL		
	Overdose		Olanzapine	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4575637-XReport Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0370110A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Disability		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	DAY
	Dyspnoea							
	Exercise Tolerance Decreased							
	Heart Rate Increased							
	Malaise							
	Palpitations							
	Panic Attack							
	Visual Disturbance							

Date:02/09/05ISR Number: 4575660-5Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0045685A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neutropenia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Betabion	C		ORAL	100MG Twice per day	
			Diazepam	C			UNKNOWN	
			Vitamin B 12	C	Glaxosmithkline	ORAL	1000UG Per day	

Date:02/09/05ISR Number: 4577254-4Report Type:Expedited (15-DaCompany Report #2004AL000696
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression	Literature	Children'S Apap					
	Agitation	Health	Elixir					

	Anion Gap Abnormal	Professional	(Acetaminophen)			
	Atrioventricular Block		(Alpharma)	PS	Alpharma	ORAL
PO						
	Base Excess Increased		Infants' Apap Drops			
	Bradycardia		(Acetaminophen)			
	Cardiac Arrest		(Alpharma)	SS	Alpharma	ORAL
PO						
	Completed Suicide		Bupropion	SS		ORAL
PO						
	Convulsion		Asa	SS		ORAL
PO						
	Grand Mal Convulsion		Fluoxetine Capsules,			
	Multiple Drug Overdose		20 Mg (Siegfried			
	Ph Body Fluid Decreased		Ltd.)	SS	Siegfried Ltd	ORAL
PO						
	Pyrexia		Fluoxetine Oral			
	Ventricular Extrasystoles		Solution Usp,			
			20mg/5ml (Alpharma)	SS	Alpharma	ORAL
PO						
			Caffeine	SS		ORAL
PO						
			Valproic Acid	SS		ORAL
PO						
			Sertraline	SS		ORAL
PO						
			Aspirin/Acetaminophe			
			n/Caffeine	SS		ORAL
PO						

Date:02/09/05ISR Number: 4578279-5Report Type:Expedited (15-DaCompany Report #BASF-05-001
Age:61 YR Gender:Male I/FU:I

Outcome	PT
Other	Asthenia
	Confusional State
	Decreased Appetite
	Dehydration

	Drug Interaction Lethargy Nausea	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oral Intake Reduced	Health	Intron A	PS		
INTRAVENOUS 44 MU 5X WEEKLY INTRAVENOUS		Professional				
			Wellbutrin	SS		ORAL
300 MG BID ORAL						

Date:02/09/05ISR Number: 4578400-9Report Type:Expedited (15-DaCompany Report #S05-USA-00523-01
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Catheter Related Infection	Consumer	Lexapro (Escitalopram)	PS		ORAL
20 MG QD PO						
	Coma Drug Interaction Hypotension Sepsis		Lexapro (Escitalopram) Wellbutrin (Bupropion Hydrochloride)	SS SS		ORAL
300 MG QD PO						
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
150 MG QD PO						
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
150 MCG BID PO						
			Atenolol	C		
			Isosorbide	C		
			Potassium	C		
			Zocor	C		
			Aspirin	C		
			Avandia			

(Rosiglitazone Maleate)	C
Nexium (Esomeprazole)	C
Aricept (Donepezil Hydrochloride)	C
Neurontin (Gabapentin)	C
Duragesic (Fentanyl)	C
Hydrocodone	C
Centrum Silver	C
Magnesium	C
Vitamin B12	C
Diazepam	C

Date:02/09/05ISR Number: 4579248-1Report Type:Direct Company Report #CTU 239876
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error Pharmaceutical Product Complaint		Bupropion Er 150mg Er Eon Labs	PS	Eon Labs			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/05ISR Number: 4577336-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0543706A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Contusion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day 3 DAY
	Convulsion		Iron	C			
	Impaired Driving Ability						
	Tongue Biting						

Date:02/10/05ISR Number: 4577344-6Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0544312A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abnormal Dreams		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day
	Foaming At Mouth						
	Grand Mal Convulsion		Diane	C			
	Insomnia						
	Urinary Incontinence						

Date:02/10/05ISR Number: 4577345-8Report Type:Expedited (15-DaCompany Report #CHPA2005US00542
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL	

Date:02/10/05ISR Number: 4579610-7Report Type:Expedited (15-DaCompany Report #2004AL000507
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Death	Aggression
	Alanine Aminotransferase Increased
	Aspartate Aminotransferase Increased

Atrioventricular Block
First Degree
Base Excess Negative
Bilirubin Conjugated
Increased
Blood Albumin Decreased
Blood Alkaline
Phosphatase Increased
Blood Bicarbonate
Decreased
Blood Bilirubin Increased
Blood Chloride Increased
Blood Creatine
Phosphokinase Increased
Blood Glucose Increased
Blood Lactate
Dehydrogenase Increased
Blood Ph Decreased
Blood Pressure Decreased
Bundle Branch Block Right
Completed Suicide
Electrocardiogram Pr
Prolongation
Electrocardiogram Qrs

		Complex Prolonged Generalised Oedema Grand Mal Convulsion Hepatic Steatosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Multiple Drug Overdose Oxygen Saturation Decreased Pco2 Decreased Pco2 Increased	Literature Health Professional	Propoxyphene Napsylate And Acetaminophen Tablets Usp, 100 Mg/650 Mg (Purepac)	PS	Purepac	ORAL	PO
		Po2 Decreased Pyrexia		Alprazolam Tablets Usp, 2 Mg (Purepac)	SS	Purepac	ORAL	PO
		Qrs Axis Abnormal		Zolpidem	SS		ORAL	PO
		Splenomegaly		Ethanol	SS		ORAL	PO
		Urine Output Decreased		Bupropion	SS		ORAL	PO
				Quetiapine	SS		ORAL	PO

Date:02/10/05ISR Number: 4579916-1Report Type:Expedited (15-DaCompany Report #2004AL000680
Age:50 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Death		Alanine Aminotransferase Increased	Literature Health	Alprazolam Tablets Usp, 2 Mg (Purepac)	PS	Purepac	ORAL	PO
		Aspartate Aminotransferase Increased Blood Creatine Phosphokinase Increased	Professional	Propoxyphene Napsylate And Acetaminophen Tablets Usp, 100 Mg/650 Mg (Purepac)	SS	Purepac	ORAL	PO
		Blood Urea Increased		Bupropion	SS		ORAL	PO
		Coma		Quetiapine	SS		ORAL	PO
		Completed Suicide Drug Ineffective Electrocardiogram St Segment Elevation Hepatic Steatosis						

	Multiple Drug Overdose					
	Pulmonary Oedema					
	Pupillary Reflex Impaired					
	Splenomegaly					

Date:02/11/05ISR Number: 4578715-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544234A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Lethargy		Seroquel	C				
	Sedation		Asthma Medication	C				

Date:02/11/05ISR Number: 4578717-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544500A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	11 MON
Life-Threatening			Strattera	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4578718-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544527A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Overdose		Adderall	C				

Date:02/11/05ISR Number: 4578726-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0365820A
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia		Zyban	PS	Glaxosmithkline			
UNKNOWN							150MG Twice	
	Anosmia							
per day								
	Dysgeusia		Multivitamin	C				
UNKNOWN							2CAP per day	
	Hypertension							
	Rhinorrhoea							

Date:02/11/05ISR Number: 4578736-1Report Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0370275A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL		
	Drug Exposure During Pregnancy							

Date:02/14/05ISR Number: 4580227-9Report Type:Expedited (15-DaCompany Report #004003
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Sensation In Eye		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
150MG Per day								
	Anxiety		Prozac	SS				
20MG Per day								
	Confusional State							

	Disorientation					
	Hypoaesthesia Oral					
	Loss Of Consciousness					
	Nausea					
	Tremor					

Date:02/14/05ISR Number: 4580235-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544531A
Age:6 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Insomnia		Metadate Cd	C				
	Medication Error		Clonidine	C				
	Pharmaceutical Product							
	Complaint							

Date:02/14/05ISR Number: 4580260-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0370023A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Discomfort						per day	18 DAY
	Hypersensitivity							
	Scar							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4580274-7Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0045476A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	
	Cardiac Disorder							
	Delusion		Saroten	C	Glaxosmithkline	ORAL	25MG Unknown	
	Dysphagia							
	Dyspnoea							
	Hallucination, Visual							
	Hyperventilation							
	Hypoaesthesia							
	Panic Attack							
	Suicidal Ideation							
	Throat Tightness							

Date:02/14/05ISR Number: 4580951-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516772A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Lamictal	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:02/14/05ISR Number: 4580986-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518076A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder		Lamictal	PS	Glaxosmithkline	ORAL	25MG Per day	4 DAY
	Confusional State		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG In the morning	3 YR
	Coordination Abnormal							
	Speech Disorder							

Date:02/14/05ISR Number: 4581081-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520555A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Lamictal	PS	Glaxosmithkline	ORAL	100MG Per day	
			Paxil	SS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		
			Provigil	C				

Date:02/14/05ISR Number: 4581089-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520760A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Lamictal	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/14/05ISR Number: 4581363-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528567A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Lamictal	PS	Glaxosmithkline	ORAL		
			Eskalith	SS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		
			Parnate	SS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4581546-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533960A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Lamictal	PS	Glaxosmithkline	ORAL	25MG Twice	
	Lethargy						per day	21 DAY
	Weight Increased		Wellbutrin	SS	Glaxosmithkline	ORAL		
			Lanoxin	C	Glaxosmithkline			
			Lisinopril	C				
			Claritin	C				

Date:02/14/05ISR Number: 4581856-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504104A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Lamictal	PS	Glaxosmithkline	ORAL	225MG Per day	5 MON
	Dry Eye		Wellbutrin	SS	Glaxosmithkline	ORAL	200MG Per day	
	Influenza		Trazodone	C				
	Muscle Twitching							
	Photosensitivity Reaction							

Date:02/14/05ISR Number: 4581861-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0504308A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness		Lamictal	PS	Glaxosmithkline	ORAL	25MG Four	
	Tremor						times per day	2 MON
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	2 WK
			Klonopin	C				
			Depakote	C				

Date:02/14/05ISR Number: 4581891-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505135A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Lamictal	PS	Glaxosmithkline	ORAL	100MG Per day	6 MON
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	100MG Twice per day	
			Wellbutrin	C	Glaxosmithkline			

Date:02/14/05ISR Number: 4581909-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0505666A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic		Lamictal	PS	Glaxosmithkline	ORAL	50MG Per day	16 DAY
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Lexapro	C				

Date:02/14/05ISR Number: 4581922-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506127A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Lamictal	PS	Glaxosmithkline	ORAL	100MG Three times per day	
Other			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	450MG per day	
			Topamax	C				
			Levothroid	C	Glaxosmithkline			

Reglan	C	Glaxosmithkline		
Singulair	C			
Cytomel	C	Glaxosmithkline		
Insulin	C			
Coreg	C	Glaxosmithkline		
Allegra D	C			
Iron	C			

Date:02/14/05ISR Number: 4581925-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0506219A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Lamictal	PS	Glaxosmithkline	ORAL	50MG Twice per day	3 WK
	Rash Papular							
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		
			Trileptal	C				

Date:02/14/05ISR Number: 4581938-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513406A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Lamictal	PS	Glaxosmithkline	ORAL	2	WK
	Feeling Abnormal		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Headache		Herb Drug	SS				
	Hunger		Ultram	SS				
	Nausea		Fioricet	SS				
			Allegra	C				
			Ambien	C				
			Synthroid	C	Glaxosmithkline			
			Midodrin	C				

Date:02/15/05ISR Number: 4582687-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541516A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Application Site Vesicles Chest Pain		Nicoderm Cq Clear 21mg	PS	Glaxosmithkline	TRANSDERMAL
	Electrocardiogram Change		Wellbutrin	SS	Glaxosmithkline	ORAL 150MG per day
	Heart Rate Decreased Nicotine Dependence Ventricular Extrasystoles		Ativan	C		ORAL

Date:02/15/05ISR Number: 4582769-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544511A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
	Attack		Paxil	SS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/05ISR Number: 4582771-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544769A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Convulsion Medication Error Overdose		Wellbutrin Robitussin	PS C	Glaxosmithkline	NASAL	

Date:02/15/05ISR Number: 4582788-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0369124A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Bradycardia Creatinine Renal Clearance Decreased Cytolytic Hepatitis Dyspnoea Exertional Haemoglobin Decreased Oedema Oedema Peripheral Weight Increased		Zyban Vaccine Lescol	PS SS C	Glaxosmithkline Glaxosmithkline	ORAL SUBCUTANEOUS	300MG per day 9 DAY 2UNIT Single dose 1 DAY 1UNIT per day

Date:02/15/05ISR Number: 4588414-0Report Type:Direct Company Report #CTU 240438
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Abnormal Behaviour Anger Balance Disorder Bipolar Disorder Condition Aggravated Depression Impaired Work Ability Memory Impairment		Wellbutrin Xl 300 Mg Glaxo Smith Kline	PS	Glaxo Smith Kline	ORAL	ONCE A DAY ORAL

Date:02/16/05ISR Number: 4584195-5Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0545331A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Zyban	PS	Glaxosmithkline	ORAL		
	Faeces Hard							
	Rectal Haemorrhage							

Date:02/16/05ISR Number: 4584200-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0364304A
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Increased		Zyban	PS	Glaxosmithkline	ORAL	1TAB See	
Initial or Prolonged	Dizziness						dosage text	
	Dry Mouth		Tritace	C		ORAL	2.5MG Per day	
	Electrocardiogram							
	Abnormal							
	Feeling Abnormal							
	Hypoaesthesia							
	Somnolence							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/05ISR Number: 4588544-3Report Type:Direct Company Report #CTU 240577
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Wellbutrin	PS		ORAL	DAILY	ORAL
	Drug Ineffective		Zoloft	SS		ORAL	DAILY	ORAL
	Emotional Disorder							
	Feeling Abnormal							
	Flat Affect							
	Nervous System Disorder							

Date:02/16/05ISR Number: 4589362-2Report Type:Expedited (15-DaCompany Report #B0349816A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Use	Literature	Wellbutrin					
	Cardiac Arrest	Health	Unspecified Tablet					
	Completed Suicide	Professional	(Bupropion					
	Convulsion		Hydrochloride)	PS		ORAL	ORAL	
	Haematemesis		Aspirin (Aspirin)	SS		ORAL	ORAL	
	Heart Rate Increased		Paracetamol					
	Multiple Drug Overdose		(Paracetamol)	SS		ORAL	ORAL	
	Respiratory Rate		Ethanol (Alcohol)	SS		ORAL	ORAL	
	Increased							

Date:02/16/05ISR Number: 4589363-4Report Type:Expedited (15-DaCompany Report #B0349817A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Literature	Wellbutrin					
	Completed Suicide	Health	Unspecified Tablet					
	Toxicologic Test Abnormal	Professional	(Bupropion					
			Hydrochloride)	PS		ORAL	ORAL	

			Topiramate (Topiramate)	SS		ORAL	ORAL
			Venlafaxine Hydrochloride (Venlafaxine Hydrochloride)	SS		ORAL	ORAL
			Olanzapine (Olanzapine)	SS		ORAL	ORAL

Date:02/16/05ISR Number: 4589364-6Report Type:Expedited (15-DaCompany Report #B0349818A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis	Literature	Wellbutrin					
	Blood Ph Increased	Health	Unspecified Tablet					
	Brain Oedema	Professional	(Bupropion					
	Coma		Hydrochloride)	PS		ORAL	ORAL	
	Completed Suicide		Topiramate					
	Convulsion		(Topiramate)	SS		ORAL	ORAL	
	Heart Rate Decreased		Clonidine					
	Hypotension		(Clonidine)	SS		ORAL	ORAL	
	Multiple Drug Overdose		Valproic Acid					
	Tachycardia		(Valproic Acid)	C		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/05ISR Number: 4589365-8Report Type:Expedited (15-DaCompany Report #B0349825A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest Completed Suicide Drug Toxicity Toxicologic Test Abnormal	Literature Health Professional	Wellbutrin Sr Tablet - Controlled Release (Bipropion Hydrochloride)	PS		ORAL	ORAL	
			Quetiapine (Formulation Unknown) (Quetiapine)	SS		ORAL	ORAL	
			Diazepam (Formulation Unknown) (Diazepam)	SS		ORAL	ORAL	

Date:02/16/05ISR Number: 4590024-6Report Type:Expedited (15-DaCompany Report #B0349819A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatine Phosphokinase Increased Blood Creatinine Increased Blood Urea Increased Coma Completed Suicide Electrocardiogram St Segment Elevation Hepatic Steatosis Multiple Drug Overdose Pulmonary Oedema Splenomegaly	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Alprazolam (Alprazolam)	SS		ORAL	ORAL	
			Paracetamol (Acetaminophen)	SS		ORAL	ORAL	
			Dextropropoxyphene (Dextropropoxyphene)	SS		ORAL	ORAL	
			Quetiapine (Quetiapine)	SS		ORAL	ORAL	

Date:02/16/05ISR Number: 4590025-8Report Type:Expedited (15-DaCompany Report #B0349826A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Distress Syndrome Completed Suicide Grand Mal Convulsion Overdose Paralysis Pneumonia Pneumonia Aspiration Pneumothorax Somnolence	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Temazepam (Temazepam)	SS		ORAL	ORAL	

Date:02/16/05ISR Number: 4590026-XReport Type:Expedited (15-DaCompany Report #B0349823A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxic Encephalopathy Cardiac Arrest Coma Convulsion Pyrexia	Literature Health Professional	Wellbutrin Sr Tablet - Controlled Release (Bupropion Hydrochloride)	PS		ORAL	ORAL	
			Clonazepam (Clonazepam)	SS		ORAL	ORAL	

				Alprazolam (Alprazolam)	SS		ORAL ORAL

Date:02/16/05ISR Number: 4590027-1Report Type:Expedited (15-DaCompany Report #B0349824A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose	Duration
Death	Blood Pressure Decreased Cardiac Arrest Completed Suicide Convulsion	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		ORAL	150 MG/ ORAL
	Ejection Fraction Decreased		Paxil (Paroxetine Hydrochloride)	SS		ORAL	20 MG/ORAL
	Intentional Misuse Mental Impairment		Citalopram (Citalopram)	SS		ORAL	20 MG / ORAL
	Mental Status Changes Nausea		Clonazepam (Clonazepam)	SS		ORAL	.5 MG / ORAL
	Ventricular Dysfunction						

Date:02/16/05ISR Number: 4590028-3Report Type:Expedited (15-DaCompany Report #B0349820A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose	Duration
Death	Blood Ethanol Increased Blood Ph Decreased Blood Pressure Decreased Completed Suicide	Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		ORAL	ORAL
	Convulsion		Ethanol (Alcohol)	SS		ORAL	ORAL
	Drug Level Above Therapeutic		Sertraline (Sertraline)	SS		ORAL	ORAL
	Drug Toxicity Heart Rate Increased Hypoxic Encephalopathy						

	Intentional Self-Injury
	Myoclonus

Date:02/16/05ISR Number: 4590029-5Report Type:Expedited (15-DaCompany Report #B0349821A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Literature	Wellbutrin Sr					
	Completed Suicide	Health	Tablet-Controlled					
	Convulsion	Professional	Release (Bupropion Hydrochloride)	PS		ORAL		ORAL

Date:02/16/05ISR Number: 4590030-1Report Type:Expedited (15-DaCompany Report #B0349822A
Age:15 YR Gender:Male I/FU:F

Outcome	PT
Death	Aggression
	Agitation
	Atrioventricular Block
	Blood Chloride Decreased
	Blood Creatine Phosphokinase Increased
	Blood Creatine Phosphokinase Mb

Increased Blood Glucose Increased Blood Potassium Decreased Body Temperature Increased Bradycardia Cardiac Arrest Completed Suicide	Report Source: Literature, Health Professional	Product: Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	Role: PS	Manufacturer:	Route: ORAL	Dose: Duration:
Convulsion		Aspirin (Aspirin)	SS		ORAL	
Incoherent Muscle Rigidity		Paracetamol (Acetaminophen)	SS		ORAL	
Toxicologic Test Abnormal		Caffeine (Caffeine)	SS		ORAL	
Ventricular Extrasystoles		Fluoxetine (Fluoxetine)	SS		ORAL	
		Valproic Acid (Valproic Acid)	SS		ORAL	
		Sertraline (Sertraline)	SS		ORAL	

Date:02/17/05ISR Number: 4584846-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0443202A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	YR
	Insomnia		Provigil	C				
	Therapeutic Response		Betaseron	C				
	Unexpected							

Date:02/17/05ISR Number: 4584847-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0495725A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Drug Ineffective	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	
300MG Per day 6 MON					
	Sinemet	C			
	Comtan	C			
	Mirapex	C			
	Flomax	C			
	Lasix	C	Glaxosmithkline		
	Synthroid	C	Glaxosmithkline		

Date:02/17/05ISR Number: 4584848-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500360A
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
200MG Per day 2 YR						
	Blood Pressure Increased		Lexapro	SS		ORAL
	Decreased Appetite		Aspirin	C	Glaxosmithkline	
	Drug Ineffective		Zocor	C		
	Energy Increased		Prilosec	C	Glaxosmithkline	
	Stress		Klonopin	C		ORAL
	Weight Decreased					

Date:02/17/05ISR Number: 4584849-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515731A
Age:46 YR Gender:Female I/FU:F

Outcome	PT
	Dizziness
	Drug Ineffective

		Nausea Pain						
			Report Source	Product	Role	Manufacturer	Route	
Dose	Duration							
				Wellbutrin Xl	PS	Glaxosmithkline	ORAL	
150MG Per day	7 MON							
				Synthroid	C	Glaxosmithkline		

Date:02/17/05ISR Number: 4584850-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517689A
Age:39 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration							
		Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	
300MG Per day	2 MON							
				Synthroid	C	Glaxosmithkline		

Date:02/17/05ISR Number: 4584851-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518540A
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration							
		Metrorrhagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	
150MG Twice								
per day	7 MON							
				Provera	C			
				Atenolol	C			
				Hormone	C			

Date:02/17/05ISR Number: 4584852-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528459A
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration							
Other		Agitation Hypertension Hypertensive Crisis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	

Date:02/17/05ISR Number: 4584853-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530922A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	7	DAY

Date:02/17/05ISR Number: 4584854-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531288A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Dizziness		Paxil	C	Glaxosmithkline	ORAL	20MG Unknown	
	Dry Mouth		Aspirin	C	Glaxosmithkline			
	Headache		Cold Medication	C				
	Malaise							
	Nausea							

Date:02/17/05ISR Number: 4584855-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531413A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
			Lamictal	C	Glaxosmithkline	ORAL		

			Lorazepam	C		
UNKNOWN						
			Keppra	C		
UNKNOWN						
			Unknown Medication	C		

Date:02/17/05ISR Number: 4584856-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531548A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	119 DAY	

Date:02/17/05ISR Number: 4584857-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532020A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584858-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532055A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response		Wellbutrin Xl	PS	Glaxosmithkline		UNKNOWN	
	Decreased		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584859-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532064A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL 150MG Per day
	Feeling Hot And Cold		Lexapro	C		
	Rash		Lithium	C	Glaxosmithkline	

Date:02/17/05ISR Number: 4584860-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532065A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL 300MG Per day 12 WK
	Convulsion		Aciphex	C		
	Grand Mal Convulsion		Nasonex	C		
			Hydrocodone	C		
			Ultram	C		
			Zomig	C		

Date:02/17/05ISR Number: 4584861-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532189A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL 1 WK
			Lexapro	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584862-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532195A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	DAY
	Heart Rate Increased							
	Somnolence							

Date:02/17/05ISR Number: 4584863-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532196A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Glipizide	SS				
			Metformin	SS				

Date:02/17/05ISR Number: 4584864-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532197A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Headache		Lexapro	C				
	Hot Flush							
	Nausea							

Date:02/17/05ISR Number: 4584865-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532363A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	YR

Date:02/17/05ISR Number: 4584866-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532508A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584867-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532509A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584868-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532511A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the morning	1 MON
			Celexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584869-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532562A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Zetia	C				
			Allegra	C				

Date:02/17/05ISR Number: 4584870-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532572A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584871-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532573A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	4 MON

Date:02/17/05ISR Number: 4584872-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532681A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	5	DAY
	Nausea		Celexa	C				
	Stomach Discomfort							
	Tinnitus							

Date:02/17/05ISR Number: 4584873-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532702A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Drug Ineffective		Klonopin	C				
			Risperdal	C				
			Metoprolol	C				

Date:02/17/05ISR Number: 4584874-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532712A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584875-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532716A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Prednisone	C				
			Coumadin	C	Glaxosmithkline			
			Codeine	C				
			Methotrexate	C				
			Furosemide	C	Glaxosmithkline			

			Celebrex	C	
			Vitamin Complex	C	
			Folic Acid	C	
			Vit D	C	
			Vit C	C	Glaxosmithkline

Date:02/17/05ISR Number: 4584876-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532720A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Ambien	C				

Date:02/17/05ISR Number: 4584877-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532721A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Prozac	C				

Date:02/17/05ISR Number: 4584878-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532730A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Exposure During		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Pregnancy		Claritin	C				
	Headache		Valium	C				

Date:02/17/05ISR Number: 4584879-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532733A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 12 MON						
	Paraesthesia		Hormone Replacement	C		

Date:02/17/05ISR Number: 4584880-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532830A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:02/17/05ISR Number: 4584881-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532831A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 5 MON						
			Atenolol	C		
			Klonopin	C		
			Xanax	C		
			Luvox	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584882-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532837A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1TAB Per day	3 MON
			Zyprexa	C		ORAL		

Date:02/17/05ISR Number: 4584883-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532840A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:02/17/05ISR Number: 4584884-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532850A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584885-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532851A
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Depakote	C				
			Risperdal	C				
			Ritalin	C				

Date:02/17/05ISR Number: 4584886-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532861A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR

Date:02/17/05ISR Number: 4584887-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532866A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Alkaline		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 MON
	Phosphatase Increased							

Date:02/17/05ISR Number: 4584888-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532868A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:02/17/05ISR Number: 4584889-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532874A
Age:30 YR Gender:Female I/FU:I

Outcome	PT
	Accidental Overdose
	Dizziness

Feeling Abnormal

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4584890-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532918A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sluggishness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
			Paxil	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4584891-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532919A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584892-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533057A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Eructation		Zetia	C				
	Paraesthesia							

Date:02/17/05ISR Number: 4584893-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533066A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584894-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533070A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breath Odour		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	YR
	Libido Decreased							

Date:02/17/05ISR Number: 4584895-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533079A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Twice per day	14 DAY
	Nausea							

Date:02/17/05ISR Number: 4584896-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533091A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Celebrex	C				
			Prednisone	C				
UNKNOWN	10MG Variable							

dose

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584897-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533095A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Effluvium		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 MON

Date:02/17/05ISR Number: 4584898-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533103A
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
	Dry Mouth		Lexapro	C				
	Dyspnoea		Ritalin	C				
	Feeling Abnormal							
	Medication Error							
	Speech Disorder							

Date:02/17/05ISR Number: 4584899-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533116A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584900-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533230A
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrooesophageal Reflux		Wellbutrin	PS	Glaxosmithkline	ORAL	6	WK
	Disease		No Concurrent					
	Insomnia		Medication	C				
	Psychotic Disorder							

Date:02/17/05ISR Number: 4584901-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533248A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Bruxism		Ambien	C				
	Dehydration							
	Depression							
	Heart Rate Increased							
	Hyperhidrosis							
	Insomnia							
	Pollakiuria							

Date:02/17/05ISR Number: 4584902-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533255A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584903-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533286A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	239 DAY

Date:02/17/05ISR Number: 4584904-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533288A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584905-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533407A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Heart Rate Increased							

Date:02/17/05ISR Number: 4584906-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533423A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 DAY
	Anger		Zelnorm	C				
	Tremor							

Date:02/17/05ISR Number: 4584907-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533436A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584908-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533437A
Age:39 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584909-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533444A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
			Effexor	C				
			Restoril	C				
			Ativan	C				
			Ibuprofen	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584910-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533448A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukopenia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Transaminases Increased		Paxil	SS	Glaxosmithkline			
			Plaquenil	C				
			Coumadin	C	Glaxosmithkline			
			Avinza	C	Glaxosmithkline			
			Topamax	C				
			Valium	C				
			Lasix	C	Glaxosmithkline			
			Benadryl	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4584911-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533450A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584912-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533451A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Unknown	

Date:02/17/05ISR Number: 4584913-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533454A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Hot Flush		Meclizine Hcl	C				

	Hyperhidrosis		Diclofenac	C		
	Nausea					

Date:02/17/05ISR Number: 4584914-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533457A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	29 DAY
			Lipitor	C				
			Lorazepam	C				

Date:02/17/05ISR Number: 4584915-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533581A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584916-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533582A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
	Fatigue		Nexium	C				
	Headache		Claritin	C				
	Pruritus							
	Somnolence							

Date:02/17/05ISR Number: 4584917-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533603A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
			Cardizem	C	Glaxosmithkline			
			Dyazide	C	Glaxosmithkline			
			Kdur	C	Glaxosmithkline			
			Glyburide	C				
			Toprol Xl	C				
			Pravachol	C				
			Xanax	C				

Date:02/17/05ISR Number: 4584918-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533620A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Prozac	SS				

Date:02/17/05ISR Number: 4584919-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533745A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspepsia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

150MG Twice

per day 3 MON

			Wellbutrin Sr	SS	Glaxosmithkline	ORAL

150MG Twice

per day

			Synthroid	C	Glaxosmithkline	
			Prevacid	C		

Date:02/17/05ISR Number: 4584920-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533746A
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Balance Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Dose Duration

300MG Per day

	Contusion		Namenda	C		
	Depressive Symptom		Folic Acid	C		
	Drug Ineffective		B1 (Vitamin)	C		
	Dry Mouth		Multivitamin	C		
	Fall		Aricept	C		
			Vytone	C		
			Diovan	C		
			B12	C	Glaxosmithkline	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584921-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533757A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Anorexia		Aspirin	C	Glaxosmithkline			
	Anxiety							
	Heart Rate Increased							
	Hyperhidrosis							
	Nausea							
	Tremor							

Date:02/17/05ISR Number: 4584922-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533763A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	MON
	Visual Disturbance							

Date:02/17/05ISR Number: 4584923-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533821A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK

Date:02/17/05ISR Number: 4584924-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533822A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584925-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533943A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Effexor Xr	C				
			Prevacid	C				
			Verapamil	C				
			Atenolol	C				

Date:02/17/05ISR Number: 4584926-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533946A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
	Chest Pain		Clonazepam	C				
	Dry Eye		Flonase	C	Glaxosmithkline			
	Gastrooesophageal Reflux		Ranitidine	C	Glaxosmithkline			
	Disease		Allegra-D	C				
	Stomatitis		Hydrocone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584927-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533949A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584928-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533951A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensation Of Foreign Body		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Sinusitis		Celexa	C				
			Trazodone	C				

Date:02/17/05ISR Number: 4584929-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533963A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Dizziness		Cymbalta	C				
UNKNOWN	Orthostatic Hypotension						40MG Per day	

Date:02/17/05ISR Number: 4584930-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533965A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Respiration Abnormal		Yasmin	C				
	Tinnitus		Vitamin	C				
			Kondremul	C				

Date:02/17/05ISR Number: 4584931-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533967A
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Depakote	SS		ORAL	500MG Twice per day	
			Phenergan	C	Glaxosmithkline	ORAL		
			Reglan	C	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584932-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534019A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Rash							

Date:02/17/05ISR Number: 4584933-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534117A
Age:37 YR Gender:Female I/FU:I

Outcome	PT
	Dyspnoea
	Hypertension

	Insomnia Tachycardia Tinnitus	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Weight Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day 9 WK
			Allegra	C			
			Nexium	C			

Date:02/17/05ISR Number: 4584934-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534132A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Loss Of Libido		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day 2 WK
			Unspecified Medications	C			

Date:02/17/05ISR Number: 4584935-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534137A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day 5 MON
	Stool Analysis Abnormal		Zoloft	C		ORAL	5MG Four times per day
			Valium	C			.5MG Four times per day
			Trazolan	C			400MG At night
			Aromasin	C			

Date:02/17/05ISR Number: 4584936-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534138A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oesophageal Rupture		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4584937-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534140A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584938-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534143A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Birth Control Pills	C				
			Nasocort	C				
			Astelin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584939-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534145A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

Date:02/17/05ISR Number: 4584940-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534150A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	17 DAY
	Rash		Oral Contraceptives	C				
			Multivitamin	C				

Date:02/17/05ISR Number: 4584941-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534186A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	7	MON

Date:02/17/05ISR Number: 4584942-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534314A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4584943-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534316A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 20 DAY						
Initial or Prolonged	Rash		Effexor Xr	C		ORAL
1 YR						
Other	Urticaria		Vitamin E	C		ORAL
400IU Three						
times per day						
			Inderal	C		ORAL
20MG Three						
times per day 1 YR						
			Geodon	C		ORAL
80MG Twice						
per day 1 YR						
			Artane	C		ORAL
2MG Three						
times per day 1 YR						

Date:02/17/05ISR Number: 4584944-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534321A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Disorientation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						
			Effexor	C		

Date:02/17/05ISR Number: 4584945-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534356A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
2 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584946-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534475A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK

Date:02/17/05ISR Number: 4584947-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534484A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 WK
	Drug Ineffective		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584948-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534494A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584949-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534496A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	5 MON
Initial or Prolonged	Drug Ineffective		Xanax	C				
	Insomnia		Inderal	C				
	Mood Swings		Prilosec	C	Glaxosmithkline			
	Nervousness		Percocet	C				
	Panic Attack							
	Weight Decreased							

Date:02/17/05ISR Number: 4584950-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534502A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Insomnia		Wellbutrin	SS	Glaxosmithkline		100MG Per day	
	Somnolence							

Date:02/17/05ISR Number: 4584951-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534633A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
	Insomnia							
	Nervousness							

Date:02/17/05ISR Number: 4584952-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534649A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Unknown	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584953-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534650A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown 1 YR

Date:02/17/05ISR Number: 4584954-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534656A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day 3 MON
			Hormone Replacement Therapy	C				

Date:02/17/05ISR Number: 4584955-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534658A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Per day
			Viagra	C				

Date:02/17/05ISR Number: 4584956-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534666A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584957-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534668A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY
	Ex-Smoker		Albuterol	C	Glaxosmithkline			
	Tinnitus							

Date:02/17/05ISR Number: 4584959-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534669A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584960-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534674A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584961-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534694A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown 14 DAY

Date:02/17/05ISR Number: 4584962-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534695A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blepharospasm		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584963-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534704A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day
	Pain		Nabumetone	SS	Glaxosmithkline			
			Wellbutrin	SS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	C	Glaxosmithkline	ORAL	150MG	Twice per day
			Vitamin	C				
			Minerals	C				

Date:02/17/05ISR Number: 4584964-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534834A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG	Per day
	Weight Decreased		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584965-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534841A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	37.5MG Per	
	Headache						day	1 WK
	Tremor							

Date:02/17/05ISR Number: 4584966-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534850A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photopsia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584967-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534866A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	20 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584968-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534880A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	8 MON
			Simply Sleep	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4584969-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0534906A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorgasmia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Libido Decreased							

Date:02/17/05ISR Number: 4584970-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535005A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mood Swings		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Suicidal Ideation							

Date:02/17/05ISR Number: 4584971-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535021A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
	Nausea		Paxil Cr	C	Glaxosmithkline			
			Birth Control Pills	C				

Date:02/17/05ISR Number: 4584972-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535028A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Yasmin	C				

Date:02/17/05ISR Number: 4584973-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535047A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	YR

Date:02/17/05ISR Number: 4584974-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535149A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Atrophy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Renal Disorder		Flomax	C				

Date:02/17/05ISR Number: 4584975-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535160A
Age:22 YR Gender:Male I/FU:I

Outcome	PT
	Agitation
	Energy Increased

Thinking Abnormal

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Lithium	C	Glaxosmithkline			
			Seroquel	C				
			Protonix	C				

Date:02/17/05ISR Number: 4584976-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535366A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Dizziness		No Concurrent					
	Pruritus		Medication	C				
	Rash							

Date:02/17/05ISR Number: 4584977-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535385A
Age:42 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eating Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Hyperacusis		Ativan	C				
	Insomnia							

Date:02/17/05ISR Number: 4584978-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535391A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK

Date:02/17/05ISR Number: 4584979-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535395A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Stool Analysis Abnormal		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584980-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535432A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xr	PS	Glaxosmithkline	ORAL	10 DAY	

Date:02/17/05ISR Number: 4584981-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535433A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the morning	17 DAY
			Valium	SS			5MG Four times per day	
			Celexa	C			4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584982-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535560A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584983-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535563A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584984-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535566A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	30 DAY
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584985-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535568A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK

Date:02/17/05ISR Number: 4584986-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535577A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584987-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535587A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Nausea							

Date:02/17/05ISR Number: 4584988-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535589A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	125MG In the morning	1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584989-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535611A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Alcohol	C		ORAL		

Date:02/17/05ISR Number: 4584990-2Report Type:Periodic Company Report #56965
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
			Bupropion	SS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4584991-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535628A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
	Nausea							

Date:02/17/05ISR Number: 4584992-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535715A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Palpitations		Furosemide	C	Glaxosmithkline			
	Paraesthesia		Atenolol	C				

Date:02/17/05ISR Number: 4584993-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535736A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Fatigue		No Concurrent					
	Hunger		Medication	C				
	Loss Of Libido							

Date:02/17/05ISR Number: 4584994-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535740A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Disease		Ritalin	C				

Date:02/17/05ISR Number: 4584995-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535766A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4584996-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535870A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

Date:02/17/05ISR Number: 4584997-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535872A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4584998-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535876A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Adderall Xr	C			60MG Per day	
			Prozac	C			60MG Per day	
			Alprazolam	C			1TAB Twice	per day
			Ambien	C			10MG Per day	

Date:02/17/05ISR Number: 4584999-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535877A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyskinesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						

Date:02/17/05ISR Number: 4585000-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535884A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 2 DAY						
	Urticaria		Effexor Xr	C		
			Prosom	C		
			Lexapro	C		
			Benadryl	C	Glaxosmithkline	

Date:02/17/05ISR Number: 4585001-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535885A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
450MG Per day						
			Benzodiazepine	C		

Date:02/17/05ISR Number: 4585002-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535909A
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fear		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 3 WK						
	Personality Change					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585003-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535923A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585004-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535924A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585005-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535925A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
	Dysphagia							
	Localised Oedema							
	Rash							

Date:02/17/05ISR Number: 4585006-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536016A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatomegaly		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Portal Hypertension		No Concurrent					
	Varices Oesophageal		Medication	C				

Date:02/17/05ISR Number: 4585007-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536022A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
			Klonopin	C		

Date:02/17/05ISR Number: 4585008-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536023A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Headache		Topamax	C				
			Levothyroxine	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585010-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536041A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychomotor Hyperactivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Prozac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585011-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536042A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Atenolol	C				
			Xanax	C				
			Anti Inflammatory	C				

Date:02/17/05ISR Number: 4585012-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536043A
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensory Disturbance		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
			Digoxin	C	Glaxosmithkline			
			Lanoxin	C	Glaxosmithkline			
			Actos	C				
			Glyburide	C				

Date:02/17/05ISR Number: 4585013-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536175A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585014-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536220A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585015-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536240A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG	Unknown
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	300MG	Unknown 3 MON

Date:02/17/05ISR Number: 4585016-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536507A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Energy Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	In the
	Insomnia						morning	3 WK
	Psychomotor Hyperactivity		Temazepam	C				

Date:02/17/05ISR Number: 4585017-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536511A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Twice
							per day	4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585018-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536516A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Effexor	C				
			Glucovance	C				
			Lipitor	C				
			Lisinopril	C				
			Morphine	C				
			Nexium	C				

Date:02/17/05ISR Number: 4585019-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536531A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Hot Flush		Thyroid	C				
	Insomnia							

Date:02/17/05ISR Number: 4585020-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536544A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eructation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Retching							

Date:02/17/05ISR Number: 4585021-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536591A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hiccups		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			No Concurrent					

			Medication	C		

Date:02/17/05ISR Number: 4585022-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536610A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585023-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536623A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Effexor	C				
			Estrogen	C				

Date:02/17/05ISR Number: 4585024-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536624A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1TAB Per day	4 WK
			Protonix	C				
			Melatonin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585025-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536639A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Burning Sensation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585026-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536640A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Unknown Medication	C				
			Effexor	C				

Date:02/17/05ISR Number: 4585027-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536667A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypnagogic Hallucination		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Adderall	SS				
UNKNOWN								

Date:02/17/05ISR Number: 4585028-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536692A
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:02/17/05ISR Number: 4585029-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536771A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	
300MG Per day 2 MON							
	Panic Attack		Synthroid	C	Glaxosmithkline		
	Restlessness		Diazid	C	Glaxosmithkline		

Date:02/17/05ISR Number: 4585030-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536773A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 1 DAY
	Disturbance In Attention		Vitamins	C			
	Dizziness		Synthroid	C	Glaxosmithkline		
	Dry Mouth		Tums	C	Glaxosmithkline		
	Nausea						

Date:02/17/05ISR Number: 4585031-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536777A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dyspepsia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day
	Gastric Ulcer		Lipitor	C			
			Ibuprofen	C	Glaxosmithkline		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585032-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536778A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585033-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536782A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 MON
	Insomnia		Effexor	C				
	Somnolence		Synthroid	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585034-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536786A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
	Hot Flush		Buspar	C				
	Premature Menopause		Glucophage Xr	C				
			Avandia	C	Glaxosmithkline			
			Prevacid	C				

Date:02/17/05ISR Number: 4585035-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536789A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585036-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536793A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypothalamo-Pituitary		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
3 YR	Disorders							

Date:02/17/05ISR Number: 4585037-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536798A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
300MG Per day	Tinnitus		Propecia	C			9	MON
			Valium	C				
			Allegra	C				

Date:02/17/05ISR Number: 4585038-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536842A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Risperdal	C				
			Lithium	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585039-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536937A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psychotic Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585040-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0536959A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Strattera	C				
			Effexor Xr	C				

Date:02/17/05ISR Number: 4585041-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537068A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK

Date:02/17/05ISR Number: 4585042-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537074A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Nausea		Doxycycline	SS				
	Palpitations							
	Vomiting							

Date:02/17/05ISR Number: 4585043-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537106A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Insomnia		Lexapro	C				
	Nausea		Klonopin	C				
	Somnolence							

Date:02/17/05ISR Number: 4585044-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537116A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
	Anxiety		No Concurrent					
	Depression		Medication	C				
	Hypertension							
	Lethargy							
	Oropharyngeal Swelling							
	Pain							
	Pyrexia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585045-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537125A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Xl	PS	Glaxosmithkline			6 MON

Date:02/17/05ISR Number: 4585046-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537229A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	12 DAY	
	Grand Mal Convulsion		Allergy Shots	C				
	Incontinence		Keflex	C	Glaxosmithkline		250MG Four times per day	

Date:02/17/05ISR Number: 4585047-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537234A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4585048-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537242A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585049-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537250A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
			Blood Pressure Medication	C				

Date:02/17/05ISR Number: 4585050-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537269A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Ill-Defined Disorder		Albuterol	C	Glaxosmithkline			
	Migraine		Entex	C				
	Weight Decreased		Serzone	C				
			Hrt	C				
			Flonase	C	Glaxosmithkline			
			Imitrex	C	Glaxosmithkline			
			Vicodin	C				

Date:02/17/05ISR Number: 4585051-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537284A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Prozac	C				
			Antihistamines	C				

			Percocet	C		
			Valium	C		

Date:02/17/05ISR Number: 4585052-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537286A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Effexor	SS		ORAL		

Date:02/17/05ISR Number: 4585053-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537420A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585054-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537422A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
			Benadryl	C	Glaxosmithkline		UNKNOWN	
			Insulin	C				
			Estrogen Patch	C				
			Aspirin	C	Glaxosmithkline			
			Methyltestosterone	C				

Date:02/17/05ISR Number: 4585055-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537432A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Feeling Abnormal		Augmentin	C	Glaxosmithkline			
	Tremor							

Date:02/17/05ISR Number: 4585056-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537444A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Prozac	C				
			Clonopin	C				
			Seroquel	C				

Date:02/17/05ISR Number: 4585057-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537467A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Palpitations		Synthroid	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585058-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537470A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	26 DAY

Date:02/17/05ISR Number: 4585060-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537471A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		WK
	Nausea							

Date:02/17/05ISR Number: 4585061-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537595A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Agitation		Prozac	C				
	Insomnia		Crestor	C				
	Pollakiuria		Diovan	C				
			Nexium	C				
			Zantac	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585062-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537619A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Insomnia		Lipitor	C				
	Weight Decreased		Avandia	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585063-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537644A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585064-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537758A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Lexapro	C				

Date:02/17/05ISR Number: 4585065-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537762A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Constipation		No Concurrent					
	Flatulence		Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585067-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537837A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585068-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537914A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		36 DAY
Initial or Prolonged			Cymbalta	C				1 WK
Disability			Remeron	C				
			Zyprexa	C				

Date:02/17/05ISR Number: 4585069-6Report Type:Periodic Company Report #WLBADROO
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Vomiting							

Date:02/17/05ISR Number: 4585070-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538014A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 DAY
			Paxil	SS	Glaxosmithkline	ORAL		1 DAY
			Zetia	C				
			Ventolin Hfa	C	Glaxosmithkline			
			Prevacid	C				

			Celebrex	C	
			Avandia	C	Glaxosmithkline
			Premarin	C	

Date:02/17/05ISR Number: 4585071-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538025A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Headache		Diamox	C				

Date:02/17/05ISR Number: 4585072-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538033A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Seroquel	C				
			Depakote	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585073-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538043A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Hyperacusis		Klonopin	C				
			Trazodone	C				

Date:02/17/05ISR Number: 4585074-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538056A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585075-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538235A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Casodex	C				
			Amiodarone	C				
			Lasix	C	Glaxosmithkline			
			Carvedilol	C	Glaxosmithkline			
			Lipitor	C				
			Synthroid	C	Glaxosmithkline			
			Magnesium Oxide	C				
			Plavix	C				
			Avapro	C				
			Vitamin B-12	C	Glaxosmithkline			
			Spironolactone	C				
			Zetia	C				
			Prozac	C				
			Glipizide	C				
			Megestrol	C				
			Isosorbide Mononitrate	C				

				Xanax	C		

Date:02/17/05ISR Number: 4585076-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538241A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Depression							
	Dizziness							
	Irritability							

Date:02/17/05ISR Number: 4585077-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538242A
Age:39 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Blood Glucose Decreased
	Chest Pain
	Dry Mouth
	Dyspnoea

Heart Rate Increased						
Muscular Weakness						
Nausea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Nervousness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day 3 DAY
Rash		Nexium	C			
Thinking Abnormal		Estrace	C			
Tinnitus						
Weight Decreased						

Date:02/17/05ISR Number: 4585078-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538301A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day 9 DAY
	Local Swelling		Yasmin	C			

Date:02/17/05ISR Number: 4585079-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538312A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Psychomotor Hyperactivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 1 YR
			Lipitor	C			
			Xanax	C			

Date:02/17/05ISR Number: 4585080-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538324A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day 10 MON
			Synthroid	C	Glaxosmithkline		

Date:02/17/05ISR Number: 4585082-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538498A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Insomnia		Sudafed	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585083-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538509A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Drug Ineffective		Clomid	C				
	Overdose							
	Tremor							

Date:02/17/05ISR Number: 4585084-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538511A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
	Anxiety		Altace	C				
	Tinnitus		Resperidol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585085-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538524A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasopharyngitis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Lisinopril	C				
			Depakote Er	C				
			Trazodone	C				

Date:02/17/05ISR Number: 4585086-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538543A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin	PS	Glaxosmithkline	ORAL	1	DAY

Date:02/17/05ISR Number: 4585087-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538556A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	15 MON
	Muscle Tightness		Effexor	C				
			Xanax	C				
			Atacand	C				

Date:02/17/05ISR Number: 4585088-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538581A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1TAB Per day	11 DAY
	Dizziness							

Date:02/17/05ISR Number: 4585089-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538677A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Electric Shock		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		WK

Date:02/17/05ISR Number: 4585090-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538680A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Odour Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	6	WK

Date:02/17/05ISR Number: 4585091-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538684A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Dry Eye							
	Dry Mouth							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585092-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538685A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin Xr	PS	Glaxosmithkline	ORAL	150MG Twice	
	Nasopharyngeal Disorder						per day	MON
			Nexium	C				
			Magnesium	C				
			Calcium D	C			1200MG Per	
							day	
			Nasal Spray	C		NASAL		

Date:02/17/05ISR Number: 4585093-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538807A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Night Sweats		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585094-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538809A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Stool Analysis Abnormal		Multivitamin	C				
			Wellbutrin Sr	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585095-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538810A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Lipitor	C				
			Accupril	C				
			Hydrochlorothiazide	C				
			Propecia	C				
			Nortriptyline	C				

Date:02/17/05ISR Number: 4585096-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538817A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 DAY
	Headache		Claritin	C				
	Nausea		Premarin	C				

Date:02/17/05ISR Number: 4585097-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538818A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 WK
	Restlessness		Ativan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585098-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538822A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Off Label Use		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1TAB Per day	12 DAY
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585099-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538829A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Dizziness		Methotrexate	C				
	Nausea		Folic Acid	C				
	Paraesthesia		Plaquenil	C				
	Paraesthesia Oral		Naproxen	C				
	Vomiting							

Date:02/17/05ISR Number: 4585100-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538843A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Three times per day	
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585101-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538849A
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pharynx Discomfort	Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 4 DAY
		Glucophage	C			
		Flomax	C			
		Timolol Maleate	C			
		Trusopt	C			
		Coreg	C	Glaxosmithkline		
		Hctz	C			
		Neurontin	C			
		Cozaar	C			
		Zocor	C			
		Lantus	C			
		Novolog	C			
		Plavix	C			
		Robaxin	C			
		Tylenol No. 3	C			
		Lasix	C	Glaxosmithkline		
		Ambien	C			

Date:02/17/05ISR Number: 4585103-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538850A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585104-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538915A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585105-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539064A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 MON
	Drug Ineffective		Glucophage	C				
	Sleep Disorder		Oral Contraceptives	C				

Date:02/17/05ISR Number: 4585106-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539070A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Pharyngolaryngeal Pain		Synthroid	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585107-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539075A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Pharyngolaryngeal Pain		Amiodarone	C				
			Hctz	C				
			Aspirin	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585108-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539076A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK

Date:02/17/05ISR Number: 4585109-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539081A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585110-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539084A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON

Date:02/17/05ISR Number: 4585111-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539097A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
			Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585112-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539112A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 DAY
			Imitrex	C	Glaxosmithkline			
			Synthroid	C	Glaxosmithkline			
			Nexium	C				
			Allegra	C				
			Zocor	C				
			Lexapro	C				
			Senokot	C				
			Multivitamin	C				
			Fibercon	C				
			Glucosamine	C				
			Ibuprofen	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585113-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539113A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Soma	C				
			Motrin	C	Glaxosmithkline			
			Vicodin	C				

Date:02/17/05ISR Number: 4585114-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539269A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	MON	

Date:02/17/05ISR Number: 4585115-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539270A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Mood		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK
	Fatigue							
	Somnolence							

Date:02/17/05ISR Number: 4585117-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539271A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	DAY
	Pruritus Generalised							

Date:02/17/05ISR Number: 4585118-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539278A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Insomnia		Ativan	C				
			Desyrel	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585119-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539283A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	12 DAY
	Crying		Synthroid	C	Glaxosmithkline			
	Panic Attack		Vitamins	C				
	Stomatitis							
	Vision Blurred							

Date:02/17/05ISR Number: 4585120-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539290A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stool Analysis Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	0	DAY
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	2	DAY
			Lexapro	C				

Date:02/17/05ISR Number: 4585121-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539312A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	0 DAY
			Lipitor	C				
			Nexium	C				
			Flonase	C	Glaxosmithkline			
			Allegra	C				

Date:02/17/05ISR Number: 4585122-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539464A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585123-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539465A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 MON
			Prozac	C				

Date:02/17/05ISR Number: 4585124-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539468A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Tic		Imitrex	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585125-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539469A
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	272	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585126-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539471A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585127-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539479A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Dry Mouth		Ambien	C				
	Insomnia		Zelnorm	C				
	Restlessness							
	Weight Decreased							

Date:02/17/05ISR Number: 4585128-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539483A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphemia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4 DAY	
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585129-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539499A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	1 WK
			No Concurrent					

			Medication	C		

Date:02/17/05ISR Number: 4585130-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539520A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Thyroid Medication	C				

Date:02/17/05ISR Number: 4585131-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539669A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Fosamax	C				

Date:02/17/05ISR Number: 4585132-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539672A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Vision Blurred		Centrum	C				
			Vitamin C	C	Glaxosmithkline			
			Tylenol Cold + Flu	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585133-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539678A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	MON
	Rash		Black Cohosh	C	Glaxosmithkline		UNKNOWN	
	Swelling Face							
	Swollen Tongue							
	Urticaria							

Date:02/17/05ISR Number: 4585134-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539684A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
	Hypertension		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
	Insomnia							

Date:02/17/05ISR Number: 4585135-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539828A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Psychomotor Hyperactivity		Cynomel	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585136-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539906A
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	31 DAY

Date:02/17/05ISR Number: 4585137-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539907A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Initial Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Therapeutic Response							
	Unexpected							

Date:02/17/05ISR Number: 4585138-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539913A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
	Headache							

Date:02/17/05ISR Number: 4585139-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540062A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Hyperhidrosis		Effexor	C				
	Nervousness		Wellbutrin Sr	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585140-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540069A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Ritalin	C				
			Lipitor	C				

Date:02/17/05ISR Number: 4585141-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540081A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Pruritus							
	Rash							
	Swelling							

Date:02/17/05ISR Number: 4585142-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540128A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4585143-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540132A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Therapeutic Response							
	Unexpected							

Date:02/17/05ISR Number: 4585144-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540237A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Fatigue		Tylenol	C	Glaxosmithkline			
	Middle Insomnia							

Date:02/17/05ISR Number: 4585145-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540240A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 MON
	Anxiety		Ortho Novum	C				
	Headache		Allegra	C				
	Hot Flush		Prozac	C				
	Insomnia							
	Tinnitus							

Date:02/17/05ISR Number: 4585146-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540249A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			
			No Concurrent					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Medication C

Date:02/17/05ISR Number: 4585147-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540258A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Tenderness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Therapeutic Aspiration		Lexapro	C				

Date:02/17/05ISR Number: 4585148-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540269A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585149-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540280A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4585150-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540324A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disorientation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Memory Impairment							
	Petit Mal Epilepsy							

Date:02/17/05ISR Number: 4585151-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540431A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin	PS	Glaxosmithkline		300MG Per day	5 WK
	Pharyngolaryngeal Pain Sinusitis		Oral Contraceptives	C				

Date:02/17/05ISR Number: 4585152-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540452A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4585153-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540453A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585156-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540461A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585157-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540484A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585158-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540512A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Insomnia		Hytrin	C				
			Maxide	C				
			Procardia	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585159-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540536A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Dry Mouth		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585160-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540538A
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON

Date:02/17/05ISR Number: 4585161-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540539A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			Trazodone	C				
			Lamictal	C	Glaxosmithkline			
			Zoloft	C				

Date:02/17/05ISR Number: 4585162-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540540A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
			Synthroid	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585163-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540544A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	MON
	Tinnitus							

Date:02/17/05ISR Number: 4585164-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540549A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585165-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540550A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Movement Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Muscle Twitching							

Date:02/17/05ISR Number: 4585166-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540551A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585167-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540552A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Zyprexa	C				

Date:02/17/05ISR Number: 4585168-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540556A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Eructation		No Concurrent					
	Tinnitus		Medication	C				

Date:02/17/05ISR Number: 4585169-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540757A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 DAY
Initial or Prolonged			No Concurrent					
Other			Medication	C				

Date:02/17/05ISR Number: 4585170-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540758A
Age: Gender:Female I/FU:I

Outcome	PT
	Agitation
	Dizziness

Feeling Abnormal Pollakiuria Pruritus	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 14 DAY
		Nexium	C			
		Trazodone	C			

Date:02/17/05ISR Number: 4585171-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540765A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hot Flush		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 2 WK
			Xanax	C		ORAL	.25U As required

Date:02/17/05ISR Number: 4585172-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540770A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ear Discomfort Ear Pain Insomnia Tinnitus Vomiting		Wellbutrin Xl Sonata	PS C	Glaxosmithkline	ORAL	

Date:02/17/05ISR Number: 4585173-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540774A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 2 DAY
			Effexor Xr	C			

Date:02/17/05ISR Number: 4585174-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540784A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Dry Mouth		Prozac	C				
	Insomnia		Librium	C				
	Tremor		Ambien	C				
			Lopressor	C				

Date:02/17/05ISR Number: 4585175-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540791A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4585176-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540800A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Stool Analysis Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585177-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540801A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Pharmaceutical Product Complaint		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585178-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540951A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Complaint Stool Analysis Abnormal		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585179-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540954A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
	Heart Rate Increased Memory Impairment		Synthroid	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585180-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541095A
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Nausea		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585181-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541100A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
			Glucophage	C				
			Dynacirc	C	Glaxosmithkline			
			Diovan	C				

Date:02/17/05ISR Number: 4585182-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541106A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	0 DAY

Date:02/17/05ISR Number: 4585183-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541107A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 DAY
	Drug Ineffective							
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585184-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541133A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
	Fatigue		Trazodone	C				

Date:02/17/05ISR Number: 4585185-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541146A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Xanax	C				

Date:02/17/05ISR Number: 4585186-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541147A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585187-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541155A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	239 DAY
Other			Prozac	SS				
UNKNOWN	40MG Per day							

Date:02/17/05ISR Number: 4585188-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541314A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/17/05ISR Number: 4585189-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541316A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Formication		Wellbutrin Xl	PS	Glaxosmithkline			
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585190-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541317A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 DAY
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585191-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541318A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585192-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541374A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4585193-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541382A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Strattera	SS				

Date:02/17/05ISR Number: 4585194-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541395A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/17/05ISR Number: 4585195-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541533A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Panic Attack		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 3 MON						
	Therapeutic Response Decreased					

Date:02/17/05ISR Number: 4585196-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541539A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
1 MON						
			Effexor	C		

Date:02/17/05ISR Number: 4585197-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541541A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 10 DAY						
			No Concurrent Medication	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585198-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541558A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Palpitations		Lexapro	C				
	Panic Reaction		Yasmin	C				

Date:02/17/05ISR Number: 4585199-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541564A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Fatigue		Toprol	SS				
	Irritability		Lexapro	C				
	Somnolence		Nexium	C				
	Tremor		Xanax	C				

Date:02/17/05ISR Number: 4585200-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541570A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	36 MON

Date:02/17/05ISR Number: 4585201-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541571A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	14 WK
	Dizziness							
	Hot Flush							
	Hyperhidrosis							
	Nausea							

Sleep Disorder

Date:02/17/05ISR Number: 4585202-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541603A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585203-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541614A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	15	WK

Date:02/17/05ISR Number: 4585204-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541636A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ill-Defined Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585206-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541713A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Insomnia		Ambien	C				
			Zelnorm	C				
			Lexapro	C				

Date:02/17/05ISR Number: 4585207-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541719A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Stool Analysis Abnormal		Beta-Blocker	C				
			Pravachol	C				
			Folic Acid	C				
			Aspirin	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585208-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541731A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	35 DAY
	Mood Altered							

Date:02/17/05ISR Number: 4585209-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541750A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Dry Mouth		Lithobid	C	Glaxosmithkline			
	Hangover		Topomax	C				

	Hypotension	Seroquel	C
	Nausea	Klonopin	C

Date:02/17/05ISR Number: 4585210-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541751A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585211-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541759A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300U Per day	

Date:02/17/05ISR Number: 4585212-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541764A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585213-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541940A
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK
	Pyrexia		Prozac	C				
	Rash		Propanol	C				

Date:02/17/05ISR Number: 4585214-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541953A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day
			Hormone Replacement	C				

Date:02/17/05ISR Number: 4585215-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541962A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Nodosum		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown 2 MON

Date:02/17/05ISR Number: 4585216-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541963A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585217-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541975A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline	

Date:02/17/05ISR Number: 4585218-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542159A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Insomnia		Blood Pressure Med	C				
	Paranoia		Claritin	C				

Date:02/17/05ISR Number: 4585219-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542160A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Muscle Twitching		No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585220-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542173A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	500MG Per day	1 WK
			Urine Incontinence					

			Medication	SS			
UNKNOWN							
			Effexor	C			

Date:02/17/05ISR Number: 4585221-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542186A
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Parosmia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 YR
			Lexapro	C				

Date:02/17/05ISR Number: 4585222-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542190A
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Metoprolol	C				
			Lisinopril	C				
			Lipitor	C				
			Aspirin	C	Glaxosmithkline			
			Zetia	C				
			Nitroquick	C	Glaxosmithkline			

Date:02/17/05ISR Number: 4585223-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542191A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON

Date:02/17/05ISR Number: 4585224-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542202A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Mood Altered		Wellbutrin Xl	PS	Glaxosmithkline	ORAL

Date:02/17/05ISR Number: 4585225-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542203A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Flutter		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
	Tachycardia							

Date:02/17/05ISR Number: 4585226-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542206A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585227-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542425A
Age:22 YR Gender: I/FU:I

Outcome	PT
	Agitation
	Energy Increased

	Insomnia Somnolence Tinnitus	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 6 WK						
			No Concurrent Medication	C		

Date:02/17/05ISR Number: 4585228-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542430A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						

Date:02/17/05ISR Number: 4585229-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542432A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 2 WK						
			No Concurrent Medication	C		

Date:02/17/05ISR Number: 4585230-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542439A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL
			No Concurrent Medication	C		

Date:02/17/05ISR Number: 4585231-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542440A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585232-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542445A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Anxiety		Unknown Medication	C			UNKNOWN	
	Chest Discomfort							
	Sleep Disorder							
	Tinnitus							

Date:02/17/05ISR Number: 4585233-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542451A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
	Dry Mouth		No Concurrent Medication	C				
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585234-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542456A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585235-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542464A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4585236-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542478A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Auditory		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585237-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542483A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Hypotrichosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585238-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542632A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 3 MON	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
Initial or Prolonged			No Concurrent			
Other			Medication	C		

Date:02/17/05ISR Number: 4585239-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542636A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300G Per day 8 DAY						
			No Concurrent			
			Medication	C		

Date:02/17/05ISR Number: 4585240-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542639A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 7 YR						
	Rash		Metformin	C		
			Diclofenac Sodium	C	Glaxosmithkline	
			Crestor	C		
			Premarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585241-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542643A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585242-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542644A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline			
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585243-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542650A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 DAY
			Birth Control Pills	C				

Date:02/17/05ISR Number: 4585244-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542660A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Pain In Extremity		Wellbutrin Sr	SS	Glaxosmithkline			
			Klonopin	C				

Date:02/17/05ISR Number: 4585245-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542711A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585246-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542828A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585247-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542836A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Stool Analysis Abnormal		Aciphex	C				
			Atenolol	C				
			Dilaudid	C				
			Lasix	C	Glaxosmithkline			
			Ativan	C				
			Paregoric	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585249-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542842A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
	Myalgia		Effexor	C				
	Psychomotor Hyperactivity							

Date:02/17/05ISR Number: 4585250-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542848A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
	Abdominal Pain Upper		Diovan	C				
			Levoxyl	C	Glaxosmithkline			
			Allegra	C				
			Singulair	C				

Date:02/17/05ISR Number: 4585251-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542851A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585252-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542853A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	14 MON
	Pharmaceutical Product Complaint							
	Weight Decreased							

Date:02/17/05ISR Number: 4585253-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542860A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585254-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542862A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585255-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542863A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585256-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543051A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
			No Concurrent Medication	C				

Date:02/17/05ISR Number: 4585257-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543053A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:02/17/05ISR Number: 4585258-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543066A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	81 DAY
			Neurontin	C				

Date:02/17/05ISR Number: 4585259-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543140A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
	Urticaria							

Date:02/17/05ISR Number: 4585260-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543160A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4585261-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543378A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:02/17/05ISR Number: 4585262-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543779A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	15 DAY
			Effexor Xr	C		ORAL	75MG Per day	
			Lasix	C	Glaxosmithkline	ORAL	40MG As required	

Date:02/17/05ISR Number: 4585855-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544770A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585863-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0276896A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
Hospitalization - Initial or Prolonged	Infarction		Cilest	C		ORAL	1TAB Per day	
Other	Cardiac Arrest							
	Cardioversion							
	Chest Pain							
	Coronary Artery Dissection							
	Headache							

Date:02/17/05ISR Number: 4585872-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0365278A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Muscle Spasms		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY

Date:02/17/05ISR Number: 4586824-9Report Type:Direct Company Report #CTU 240701
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban 150 Mg	PS		ORAL	150 MG	4
	Dyskinesia						DAYS ORAL;	
							300 MG	
							DURATION	
							ORAL	
			Triamterene	C				
			Inderol	C				
			Tarka T-240	C				
			Volmax	C				

			Ibuprophoen	C			

Date:02/17/05ISR Number: 4589250-1Report Type:Direct Company Report #CTU 240714
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abasia		Welbutrin Xl 300 Mg	PS	Gsk	ORAL	300 MG /DAILY	
Initial or Prolonged	Confusional State						PO [STARTED	
Required	Dizziness						150 ON 1/29	
Intervention to	Hypertension						INCR 300 MG	
Prevent Permanent	Vision Blurred						ON 2/2/05]	
Impairment/Damage								

Date:02/17/05ISR Number: 4590060-XReport Type:Direct Company Report #CTU 240752
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation		Wellbutrin Xl 300 Mg	PS			1 TAB QD	
	Completed Suicide		Glucovance	C				
	Confusional State		Lotensin	C				
	Gun Shot Wound							
	Hallucination							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4604975-7Report Type:Periodic Company Report #S04-USA-06882-01
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Memantine	PS		ORAL	10 MG QD PO	
		Professional	Memantine	SS		ORAL	5 MG QD PO	
			Memantine	SS		ORAL	10 MG QD PO	
			Memantine	SS		ORAL	15 MG QD PO	
			Wellbutrin (Bupropion Hydrochloride)	SS			150 MG QD	
			Wellbutrin (Bupropion Hydrochloride)	SS			300 MG QD	
			Aricept (Donepezil Hydrochloride)	C				
			Claritin (Loratadine)	C				
			Estradiol	C				
			Tylenol (Paracetamol)	C				
			Aspirin	C				
			Mirapex	C				
			Zinc	C				
			Multivitamin	C				

Date:02/18/05ISR Number: 4587212-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545451A
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Amnesia		Zyprexa	C				
	Anxiety		Depakote Er	C				
	Constipation							
	Headache							
	Irritability							
	Mania							

	Muscle Twitching					
	Nervousness					
	Somnolence					

Date:02/18/05ISR Number: 4587221-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545970A
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Completed Suicide		Adderall	C				

Date:02/18/05ISR Number: 4587247-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0371030A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG	
	Musculoskeletal Stiffness							
							Variable dose	1 MON
			Humalog	C			UNKNOWN	
			Humulin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/21/05ISR Number: 4588192-5Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0370764A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pruritus		Zyban	PS	Glaxosmithkline	UNKNOWN		
	Sleep Disorder							
	Tooth Disorder							
	Toothache							

Date:02/22/05ISR Number: 4588841-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541125A
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice per day	2 WK
	Medication Error							
	Paranoia		Lithium	C	Glaxosmithkline			
	Pharmaceutical Product Complaint		Ativan	C				

Date:02/22/05ISR Number: 4588845-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545918A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	8	DAY
	Dizziness		Delsym	SS	Glaxosmithkline			
	Dysgeusia		Allegra	C				
	Hot Flush		Promethazine Dm	C				
	Loss Of Consciousness		Robitussin Dm	C				
	Muscle Twitching		Levothyroxine	C	Glaxosmithkline			
	Nausea		Z Pack	C				
	Tremor		Biaxin	C				

Date:02/22/05ISR Number: 4588846-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545927A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Drug Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Constipation		Wellbutrin	SS	Glaxosmithkline		150MG Per day	
	Diplopia		Duragesic	C				
	Dry Mouth		Methadone	C	Glaxosmithkline			
	Hallucination, Auditory		Effexor	C				
	Hallucination, Visual		Valium	C				
	Pruritus		Vicodin	C				
	Somnolence		Neurontin	C				
	Vision Blurred		Avandia	C	Glaxosmithkline			

Date:02/22/05ISR Number: 4588847-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545955A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Hallucination		No Concurrent					
	Hypertension		Medication	C				
	Overdose							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/05ISR Number: 4588849-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546103A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline			
	Drug Exposure During Pregnancy							
	Pregnancy							

Date:02/22/05ISR Number: 4588857-5Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0362396A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Overdose		Zyban	PS	Glaxosmithkline			
UNKNOWN	Dizziness						150MG Single dose	
	Hyperventilation							
	Nausea							
	Retching							

Date:02/22/05ISR Number: 4588868-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0371935A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Zyban	PS	Glaxosmithkline			
	Difficulty In Walking		Ventolin	C	Glaxosmithkline			
	Hypertension		Seretide	C	Glaxosmithkline			
	Lung Infection		Atrovent	C	Glaxosmithkline			
	Tremor		Acimax	C	Glaxosmithkline			
			Zanidip	C				
			Losec	C	Glaxosmithkline			

Date:02/22/05ISR Number: 4591875-4Report Type:Expedited (15-DaCompany Report #HQWYE199809FEB05
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion Drug Interaction Photopsia	Health Professional	Effexor (Venlfaxine Hydrochloride,) Wellbutrin Xl (Bupropion Hydrochloride,)	PS SS		ORAL

SEE IMAGE

Date:02/22/05ISR Number: 4592479-XReport Type:Expedited (15-DaCompany Report #2005-01-1690
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemorrhagic Stroke Hypertension	Health Professional Company	Peg-Intron (Peginterferon Alfa-2b) Injectable	PS		
SUBCUTANEOUS 150 MCG QWK						
		Representative				
SUBCUTANEOUS						
			Copegus (Ribavirin) Capsules	SS		ORAL
1200 MG QD						
ORAL						
			Pegasys (Pegylated Interferon Alfa-2a) Injectable	SS		
SUBCUTANEOUS	SUBCUTANEOUS					
			Wellbutrin (Bupropion)	SS		
			Percocet	C		

			Benzodiazepine(Nos)	C		

Date:02/23/05ISR Number: 4589781-4Report Type:Expedited (15-DaCompany Report #BPC-ZN-05-048
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Cholesterol Increased Confusional State Diabetes Mellitus Non-Insulin-Dependent Foaming At Mouth Grand Mal Convulsion Hyperglycaemia Hypertension Impaired Driving Ability Urinary Incontinence		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:02/23/05ISR Number: 4589786-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546075A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Caffeine Increased Convulsion Fatigue Sleep Disorder Weight Decreased		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	ORAL		

Date:02/23/05ISR Number: 4589787-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546080A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL		
Life-Threatening Other	Medication Error		Wellbutrin No Concurrent Medication	SS C	Glaxosmithkline	ORAL		

Date:02/23/05ISR Number: 4589788-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546307A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apnoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Effexor	C				
			Lipitor	C				

Date:02/23/05ISR Number: 4589806-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0371611A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Zyban	PS	Glaxosmithkline		10	DAY
	Night Sweats							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4591382-9Report Type:Direct Company Report #CTU 241243
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Generic Wellbutrin	PS			400 MG A DAY	
	Pharmaceutical Product Complaint Suicidal Ideation Therapy Non-Responder							

Date:02/23/05ISR Number: 4595153-9Report Type:Expedited (15-DaCompany Report #2004103296
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Zoloft (Sertraline)	PS		ORAL	50 MG (50 MG, 1 IN 1 D), ORAL	
	Cataract	Professional						
	Condition Aggravated							
	Depression		Bupropion Hydrochloride (Bupropion Hydrochloride)	SS				
	Drug Ineffective							
	Drug Intolerance							
	Formication							
	Vision Blurred							
			Paroxetine Hydrochloride (Paroxetine Hydrochloride)	SS				
			Psycholeptics (Psycholeptics)	C				
			Provella-14 (Estrogens Conjugated, Medroxyprogesterone Acetate0	C				
			Ciclosporin (Ciclosporin)	C				
			All Other Therapeutic Products (All Other Therapeutic Products)	C				

Date:02/24/05ISR Number: 4590559-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540971A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG In the morning	224 DAY
	Memory Impairment							
	Speech Disorder							
	Tongue Biting							

Date:02/24/05ISR Number: 4590561-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0543779A
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Other	Convulsion
	Eye Injury
	Face Injury
	Fall
	Incontinence
	Limb Injury

Tongue Biting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL	19	DAY
			Effexor Xr	C		ORAL	75MG Per day	
			Lasix	C	Glaxosmithkline	ORAL	40MG As	required

Date:02/24/05ISR Number: 4590567-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546813A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Wellbutrin	PS	Glaxosmithkline	ORAL	75MG Per day	

Date:02/24/05ISR Number: 4590586-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0372275A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Psychiatric Symptom		Zyban	PS	Glaxosmithkline	ORAL		
Disability	Self-Injurious Ideation		Tylex	C		ORAL		
Other								

Date:02/24/05ISR Number: 4590587-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0372277A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Use		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Balance Disorder		Cannabis	C			UNKNOWN	
	Fall		Alcohol	C			UNKNOWN	

	Gait Disturbance						

Date:02/24/05ISR Number: 4591195-8Report Type:Direct Company Report #CTU 241354
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective Pharmaceutical Product Complaint		Bupropion Sr 15	PS		ORAL	150 MG PO BID	

Date:02/25/05ISR Number: 4592042-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0547191A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	WK

Date:02/28/05ISR Number: 4592921-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0547245A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/05ISR Number: 4592948-2Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0372872A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Bupropion					
	Cognitive Disorder		Hydrochloride	PS	Glaxosmithkline		150MG See	
	Hallucination, Visual						dosage text	12 DAY
	Panic Attack		No Concurrent					
	Suicidal Ideation		Medication	C				
	Tremor							

Date:02/28/05ISR Number: 4596202-4Report Type:Direct Company Report #CTU 241505
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Zoloft 50mg 1 Po Qd	PS		ORAL	50MG QDAY	
Initial or Prolonged	Fatigue		Buproprion 150 Mg 1					
	Tremor		Po Qd	SS		ORAL	150 MG QDAILY	

Date:03/01/05ISR Number: 4594134-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0399790A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Intentional Misuse						per day	2 YR

Date:03/01/05ISR Number: 4594139-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546331A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day 16 MON
			No Concurrent Medication	C			

Date:03/01/05ISR Number: 4594168-4Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0357968A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Drug Interaction		Zyban	PS	Glaxosmithkline	ORAL	150MG See
	Emotional Disorder						dosage text 48 DAY
	Haematoma		Alcohol	SS			
	Retrograde Amnesia		No Concurrent Medication	C			

Date:03/01/05ISR Number: 4594169-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0361828A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Agitation		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice
	Depression						per day 10 DAY
	Feeling Of Despair		Haldol Decanoate	C			INTRAMUSCULAR 100MG Every
	Restlessness						two weeks YR
	Tearfulness		Artane	C			5MG Three
							times per day YR
			Tegretol	C			UNKNOWN 400MG Twice
							per day YR
			Lexapro	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4609105-3Report Type:Periodic Company Report #20040200191
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Other	Reglan (Metoclopramide) (Baxter)	PS	Baxter		10 MG DAILY	
			Wellbutrin Xl (Bupropion Hcl) Tablets Glaxo Smith Kline	SS	Glaxo Smith Kline	ORAL	300 MG DAILY	
PO								3 WK

Date:03/02/05ISR Number: 4596699-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544022A
Age:13 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Convulsion							
	Dehydration							
	Electrolyte Imbalance							
	Fall							
	Tremor							

Date:03/02/05ISR Number: 4596701-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545918A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	8	DAY
	Burning Sensation		Delsym	SS	Glaxosmithkline			
	Dizziness		Allegra	C				
	Dysgeusia		Promethazine Dm	C				
	Hot Flush		Robitussin Dm	C				
	Loss Of Consciousness		Levothyroxine	C	Glaxosmithkline			
	Muscle Twitching		Z Pack	C				
	Nausea		Biaxin	C				

	Tremor					

Date:03/02/05ISR Number: 4596703-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546744A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Respiratory Disorder							
			Lotrel	C				

Date:03/02/05ISR Number: 4596704-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0547176A
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Mass		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/05ISR Number: 4598310-0Report Type:Direct Company Report #CTU 241942
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharmaceutical Product		Zyban	PS			/5-6 WEEKS	5 WK
	Complaint							
	Suicidal Ideation							

Date:03/02/05ISR Number: 4598857-7Report Type:Direct Company Report #CTU 241920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation		Bupropion 150	PS		ORAL	150 BID ORAL	
	Rash Macular							

Date:03/02/05ISR Number: 4598955-8Report Type:Expedited (15-DaCompany Report #A0546787A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Creatinine Increased Grand Mal Convulsion Postictal State	Study Health Professional	Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	PS		ORAL	PER DAY / ORAL	
	Refusal Of Treatment By Patient							

Date:03/03/05ISR Number: 4599299-0Report Type:Direct Company Report #CTU 242000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Wellbutrin	PS	Gsk	ORAL	100MG QD	

Required	Duodenal Ulcer					
ORAL						
Intervention to	Haemorrhage		Excedrin	SS		ORAL
TAB Q 4 HRS						
Prevent Permanent	Gastric Ulcer Haemorrhage					
ORAL						
Impairment/Damage	Hypotension					

Date:03/03/05ISR Number: 4599589-1Report Type:Expedited (15-DaCompany Report #SUSI-2005-00116
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest	Other	Adderall Xr			
	Coma		(Dextroamphetamine			
	Fatigue		Sulfate,			
			Dextroamphetamine			
			Saccharate,	PS		
15 MG,						
1X/DAY:QD						
			Wellbutrin-Slow			
			Release (Bupropion			
			Hydrochloride)	SS		
300 MG/DAY;						
SEE IMAGE						
			Strattera			
			(Atomoxetine			
			Hydrochloride)	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4598249-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541138A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Joint Stiffness		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Musculoskeletal Stiffness		Lipitor	C				
	Oedema Peripheral		Aspirin	C	Glaxosmithkline			
	Rash							
	Serum Sickness							

Date:03/04/05ISR Number: 4598250-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541141A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Musculoskeletal Stiffness		Micronor	C				
	Oedema Peripheral							
	Orbital Oedema							
	Rash							
	Serum Sickness							
	Urticaria							

Date:03/04/05ISR Number: 4598251-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544127A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Bupropion	PS	Glaxosmithkline	ORAL		
	Convulsion		Ultram	C			UNKNOWN	
	Road Traffic Accident							

Date:03/04/05ISR Number: 4598252-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546744A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Blood Pressure Increased		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice Initial or Prolonged per day 2 WK	Heart Rate Increased					
	Hypersensitivity		Lotrel	C		
	Rash		Levaquin	C		
	Respiratory Disorder					
	Respiratory Rate Increased					
	Urticaria					

Date:03/04/05ISR Number: 4598732-8Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0357955A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dry Mouth		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	22 DAY
	Ecchymosis							
	Haematoma		Micardis	C	Glaxosmithkline	ORAL		
	Psoriasis		Emconcor	C		ORAL		
			Lipitor	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4598749-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0373608A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Zyban	PS	Glaxosmithkline			
	Respiratory Disorder		Nitrofurantoin	C				
			Sodium Rabeprazole	C				
			Oestradiol	C				
			Doxycycline	C				
			Prednisolone	C	Glaxosmithkline			
			Ipratropium Bromide	C	Glaxosmithkline			
			Salbutamol Sulphate	C	Glaxosmithkline			

Date:03/04/05ISR Number: 4599655-0Report Type:Direct Company Report #CTU 242055
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Wellbutrin Sr 100 Mg	PS		ORAL	DAILY	ORAL
	Medication Error							

Date:03/04/05ISR Number: 4599818-4Report Type:Direct Company Report #CTU 242032
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Bupropion 75 Mg	PS			1 DOSE	ONLY
	Headache		Metoprolol	C				
	Waxy Flexibility		Pantoprazole	C				
			Vitamins	C				

Date:03/04/05ISR Number: 4599974-8Report Type:Direct Company Report #CTU 242104
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin 150 Mg Gsk	PS	Gsk	ORAL	150 MG 2X	DAILY ORAL

Date:03/04/05ISR Number: 4600473-5Report Type:Expedited (15-DaCompany Report #2002133101US
Age:34 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature Health	Diphenhydramine (Diphenhydramine)	PS		ORAL	ORAL	
		Professional	Isotretinoin (Isotretinoin)	SS				
			Bupropion (Bupropion)	SS				

Date:03/04/05ISR Number: 4601322-1Report Type:Expedited (15-DaCompany Report #2002133124US
Age:33 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multiple Drug Overdose	Literature Health	Diphenhydramine (Diphenhydramine)	PS		ORAL	ORAL	
		Professional	Risperidone (Risperidone)	SS		ORAL	UNSPECIFIED	AMT, ORAL

			Bupropion (Bupropion)	SS		ORAL	UNSPECIFIED

AMT, ORAL

Date:03/07/05ISR Number: 4600276-1Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0046030A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
	Supraventricular		Simvastatin	C		ORAL	10MG Per day	
	Tachycardia							

Date:03/08/05ISR Number: 4601602-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0540261A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
	Mania		Lamictal	C	Glaxosmithkline	ORAL	200MG Per day	

Date:03/08/05ISR Number: 4601605-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0543066A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Unknown	81 DAY
	Incontinence		Neurontin	C				
	Postictal State							

Date:03/08/05ISR Number: 4601606-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0543494A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Contusion		Macrobid	C				
	Hypersensitivity		Zyrtec	C	Glaxosmithkline			
	Hypotension							
	Rash Generalised							
	Rash Macular							
	Skin Discolouration							
	Swelling							
	Urinary Tract Infection							
	Urticaria							

Date:03/08/05ISR Number: 4604956-3Report Type:Direct Company Report #CTU 242383
Age:36 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Accidental Overdose
	Anorexia
	Atonic Seizures
	Clonic Convulsion
	Confusional State
	Depression
	Dizziness
	Dysarthria
	Hallucination
	Headache

	Insomnia Tremor Vision Blurred	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Wellbutrin	PS		ORAL	900 MG PO BID 2 WK

Date:03/09/05ISR Number: 4602858-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545928A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Eye Swelling		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice
	Pharyngolaryngeal Pain						per day 1 MON
	Rash		Zocor	C		ORAL	20MG Per day

Date:03/09/05ISR Number: 4602864-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548151A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Asthma		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Unknown
	Dyspnoea		Advair	C	Glaxosmithkline		RESPIRATORY
	Pulmonary Oedema						(INHALATION)

Date:03/09/05ISR Number: 4602879-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0369547A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Medication Error		Zyban	PS	Glaxosmithkline		UNKNOWN 150MG Twice
	Urticaria						per day 2 WK

Date:03/09/05ISR Number: 4602886-4Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0372907A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Zyban	PS	Glaxosmithkline			
	Muscle Spasms							

Date:03/09/05ISR Number: 4602903-1Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0373985A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline		6	WK
	Dyspnoea							
	Hallucination							
	Incoherent							
	Insomnia							
	Pyrexia							
	Sensory Disturbance							
	Tonsillitis							

Date:03/09/05ISR Number: 4604076-8Report Type:Direct Company Report #CTU 242399
Age:32 YR Gender:Female I/FU:I

Outcome	PT
Disability	Depression
Other	Drug Ineffective
	Pharmaceutical Product

	Complaint Sedation						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Bupropion	PS			BID

Date:03/10/05ISR Number: 4603926-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548205A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day
Initial or Prolonged	Medication Error Overdose		Lexapro	C			

Date:03/10/05ISR Number: 4603927-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548219A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL	
	Overdose		No Concurrent				
	Suicide Attempt		Medication	C			

Date:03/10/05ISR Number: 4603929-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548226A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	
	Overdose		No Concurrent				
	Rhabdomyolysis		Medication	C			
	Suicide Attempt						

Date:03/10/05ISR Number: 4603931-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548370A
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
Life-Threatening	Death		No Concurrent					
Hospitalization - Initial or Prolonged	Overdose		Medication	C				
	Respiratory Arrest							
Other	Vomiting							

Date:03/10/05ISR Number: 4603953-1Report Type:Expedited (15-DaCompany Report #FI-GLAXOSMITHKLINE-B0373882A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG See dosage text
	Heart Rate Increased							
	Respiratory Disorder		Unknown Medication	C			UNKNOWN	

Date:03/10/05ISR Number: 4607618-1Report Type:Expedited (15-DaCompany Report #2005038205
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Toxic Epidermal Necrolysis	Foreign Health Professional	Nifedicor Capsule (Nifedipine)	PS				
			Acetylsalicylic Acid					

(Acetylsalicylic Acid)	SS
Furosemid Heumann (Furosemide)	SS
Enalapril Heumann (Enalapril Maleate)	SS
Carvedilol (Carvedilol)	SS
Digoxin (Digoxin)	SS
Canrenoic Acid (Canrenoic Acid)	SS
Allopurinol (Allopurinol)	SS
Bupropion (Bupropion)	SS
Technetium Tc 99m Pentetate (Technetium Tc 99m Pentetate)	SS

Date:03/11/05ISR Number: 4605917-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0516229A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During Pregnancy Placental Insufficiency Pre-Eclampsia Pregnancy		Wellbutrin Effexor	PS C	Glaxosmithkline	ORAL		

Date:03/11/05ISR Number: 4605952-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548178A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion Fall Loss Of Consciousness Tongue Biting Tremor		Wellbutrin Oral Contraceptive	PS C	Glaxosmithkline	ORAL	2	WK

Date:03/11/05ISR Number: 4605953-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548375A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Drug Exposure During Pregnancy							
	Pregnancy							

Date:03/11/05ISR Number: 4605954-6Report Type:Expedited (15-DaCompany Report #US-0501110039
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Wellbutrin	PS	Glaxosmithkline			
	Grand Mal Convulsion		Prozac	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4605956-XReport Type:Expedited (15-DaCompany Report #2005-03-0065
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Collapse Of Lung		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Convulsion		Peg-Intron	SS		SUBCUTANEOUS		
	Pneumonia		Ribavirin	SS		ORAL		
			Paxil Cr	C	Glaxosmithkline	ORAL	25MG Single	dose
			Levoxyl	C	Glaxosmithkline	ORAL	.05MG Unknown	
			Prevacid	C		ORAL	30MG Unknown	

Date:03/11/05ISR Number: 4605957-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548830A
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Medication Error						per day	3 YR
			Zyprexa	C				

Date:03/11/05ISR Number: 4605958-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549055A
Age:2 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged			Unknown Medication	SS				
Disability								

Date:03/11/05ISR Number: 4605959-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549068A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:03/11/05ISR Number: 4605988-1Report Type:Expedited (15-DaCompany Report #139634
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypomania		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Mania		Quilonum Retard	C	Glaxosmithkline	ORAL	42MMOL per day	YR
	Sleep Disorder							
			Remergil	C		ORAL	45MG per day	YR
			Zolpidem	C		ORAL	5MG per day	
			Risperdal	C		ORAL	6MG per day	

Date:03/11/05ISR Number: 4607180-3Report Type:Direct Company Report #CTU 242898
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Grand Mal Convulsion		Tramadol	PS			2 TID	
Intervention to Prevent Permanent Impairment/Damage			Wellbutrin Xr	SS			ONE Q D	
			Methylphenidate	C				
			Relafen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4609084-9Report Type:Expedited (15-DaCompany Report #CEL-2005-00282-ROC
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other Required Intervention to Prevent Permanent Impairment/Damage	Anxiety Blood Pressure Increased Dehydration Dizziness Drug Interaction Dysgeusia Fatigue Feeling Abnormal Feeling Hot Heart Rate Irregular Hyperreflexia Loss Of Consciousness Muscle Twitching Myoclonus Nausea Serotonin Syndrome Tremor	Consumer	Delsym Er Suspension (Dextromethorphan Hydrobromide) Weelbutrin (Bupropion Hydrochloride) Robitussin Promethazine Dm (Promethazine Dm) Allegra (Fexofenadine Hydrochloride) Thyroxine (Levothyroxine Sodium) Azithromycin (Azithromycin) Biaxin (Clarithromycin)	PS SS SS SS C C C C		ORAL ORAL ORAL ORAL	10ML ONCE, ROUTE PER ORAL DEE IMAGE PER ORAL PER ORAL	8	DAY

Date:03/11/05ISR Number: 4609533-6Report Type:Expedited (15-DaCompany Report #GXKR2005US00689
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block Left Cardiovascular Disorder Disorientation Electrocardiogram Qt Corrected Interval	Literature Health Professional	Divalproex (Ngx) (Divalproex) Ziprasidone (Ziprasidone) Bupropion (Ngx)	PS SS		ORAL ORAL	5920 MG, ORAL	

	Prolonged		(Bupropion)	SS		ORAL
15700 MG						
	Grand Mal Convulsion					
(PROBABLY						
	Intentional Misuse					
FEWER), ORAL						
	Lethargy		Fluoxetine (Ngx)			
	Medication Error		(Fluoxetine)	SS		ORAL
72 G, ORAL						
	Supraventricular					
	Tachycardia					

Date:03/14/05ISR Number: 4607745-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537281A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Arthralgia		Lamictal	PS	Glaxosmithkline	ORAL
2 YR						
Other	Chest Discomfort		Wellbutrin	SS	Glaxosmithkline	ORAL
200MG Twice						
	Facial Pain					
per day 2 YR						
	Gait Disturbance					
	Oedema Peripheral					

Date:03/14/05ISR Number: 4607746-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0543520A
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Other	Amnesia
	Grand Mal Convulsion

	Insomnia Tongue Biting					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin	PS	Glaxosmithkline	ORAL
242	DAY					
			Prozac	C		
60MG	Per day					

Date:03/14/05ISR Number: 4607747-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546535A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG	Unknown WK					
Hospitalization -	Grand Mal Convulsion		Trazodone	C		
UNKNOWN	100MG At					
Initial or Prolonged						
night						
Disability			Ultracet	C		
Other						

Date:03/14/05ISR Number: 4607748-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549034A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Rectal Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL
3	MON					
	Stool Analysis Abnormal		Zoloft	C		
			Synthroid	C	Glaxosmithkline	
			Lovastatin	C		
			Accupril	C		
			Estrace	C		
			Multivitamin	C		

Date:03/14/05ISR Number: 4607750-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549064A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Enzyme Increased Hepatic Failure		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Twice Other per day	
			Paxil	C	Glaxosmithkline			
			Coumadin	C	Glaxosmithkline			
			Lipitor	C				
			Toprol	C				
			Klonopin	C				

Date:03/14/05ISR Number: 4607751-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549208A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse Local Swelling		Wellbutrin Xl	PS	Glaxosmithkline	INTRAVENOUS	300MG Unknown Other	

Date:03/14/05ISR Number: 4607753-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549209A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intentional Misuse		Wellbutrin Xl	PS	Glaxosmithkline	INTRAVENOUS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4607754-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549210A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Infection		Wellbutrin Xl	PS	Glaxosmithkline	INTRAVENOUS		
	Intentional Misuse							

Date:03/14/05ISR Number: 4607756-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549256A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Fatigue						per day	3 DAY
	Homicidal Ideation		No Concurrent					
	Irritability		Medication	C				
	Mood Swings							

Date:03/14/05ISR Number: 4607758-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549286A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	300MG per day		

Date:03/14/05ISR Number: 4609724-4Report Type:Direct Company Report #CTU 243085
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Bupropion Hcl	PS				
	Gastrooesophageal Reflux Disease							
	Pharmaceutical Product Complaint							

Date:03/15/05ISR Number: 4608468-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0406391A
Age: Gender:Male I/FU:F

Outcome	PT
Other	Acquired Porphyria
	Aggression
	Agitation
	Akathisia
	Amnesia
	Arthralgia
	Asthenia
	Bipolar Disorder
	Body Temperature
	Fluctuation
	Convulsion
	Coordination Abnormal
	Crying
	Depression
	Disability
	Dizziness
	Dysarthria
	Dysphemia
	Dyspnoea
	Electric Shock
	Emotional Disorder

	Encephalopathy					
	Facial Palsy					
	Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL
42	DAY					
	Hair Metal Test Abnormal		Tranquilizer	SS		
	Head Banging		Depakote	SS		
	Headache		Zyprexa	SS		
	Hyperaesthesia		Alcohol	C		
	Hypersensitivity					
	Hypoxia					
	Immune System Disorder					
	Injury					
	Insomnia					
	Intentional Self-Injury					
	Mania					
	Mastocytosis					
	Metabolic Encephalopathy					
	Multiple Chemical Sensitivity					
	Muscle Spasms					
	Myalgia					
	Myoclonus					
	Nervous System Disorder					
	Nightmare					
	Overdose					
	Pain Of Skin					
	Petit Mal Epilepsy					
	Schizoaffective Disorder					
	Suicidal Ideation					
	Suicide Attempt					
	Throat Tightness					
	Tremor					
	Vestibular Disorder					
	Vomiting					

Date:03/15/05ISR Number: 4608469-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0506955A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Balance Disorder		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
150MG Twice						

Initial or Prolonged		Dizziness					
per day							
		Drug Exposure During	Paxil Cr	SS	Glaxosmithkline	ORAL	
25MG Per day	7 MON						
		Pregnancy	Prenatal Vitamin	C			
		Drug Withdrawal Syndrome					
		Electric Shock					
		Formication					
		Lethargy					
		Nausea					
		Paraesthesia					
		Peripheral Coldness					
		Pregnancy					
		Premature Baby					
		Premature Labour					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4608476-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545918A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	8	DAY
	Burning Sensation		Delsym	SS	Glaxosmithkline			
	Dizziness		Allegra	C				
	Dysgeusia		Promethazine Dm	C				
	Hot Flush		Robitussin Dm	C				
	Hypertension		Levothyroxine	C	Glaxosmithkline			
	Loss Of Consciousness		Z Pack	C				
	Muscle Twitching		Biaxin	C				
	Nausea							
	Skin Burning Sensation							
	Tremor							

Date:03/15/05ISR Number: 4608478-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0547176A
Age:13 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Mass		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Gynaecomastia		No Concurrent Medication	C				

Date:03/15/05ISR Number: 4608485-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549462A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
	Ill-Defined Disorder		Lithium	SS	Glaxosmithkline			
			Cogentin	SS				
			Klonopin	SS				
			Trazodone	SS				
			Prolixin	SS				
			Seroquel	SS				

Date:03/15/05ISR Number: 4608486-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549464A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Cogentin	SS				
			Trazodone	SS				
			Seroquel	SS				
			Klonopin	SS				
			Trilafon	SS	Glaxosmithkline			

Date:03/15/05ISR Number: 4608491-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0374116A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Metrorrhagia		Zyban	PS	Glaxosmithkline	ORAL		
			Loestrin	SS		ORAL	20MCG per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4608492-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0374117A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Field Defect		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	17 DAY
			Fusidic Acid	C			UNKNOWN	

Date:03/15/05ISR Number: 4608493-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0374119A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Constipation		Zyban	PS	Glaxosmithkline	ORAL	300MG Per day	10 DAY
Other	Dizziness		Nicorette Gum	C	Glaxosmithkline	ORAL	2MG per day	11 DAY
	Headache							
	Nausea							
	Speech Disorder							

Date:03/15/05ISR Number: 4608494-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0374120A
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	9 DAY
	Depression							

Date:03/15/05ISR Number: 4608495-5Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0374586A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Bupropion					

Initial or Prolonged	Electrocardiogram		Hydrochloride	PS	Glaxosmithkline	
150MG Twice per day 14 DAY	Abnormal					
			No Concurrent Medication	C		

Date:03/15/05ISR Number: 4608496-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0374613A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day 5 DAY						
Initial or Prolonged	Electrocardiogram St Segment Depression					
	Urticaria Generalised					

Date:03/15/05ISR Number: 4608521-3Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0548662A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Breast Discharge		Zyban	PS	Glaxosmithkline	ORAL
	Fatigue					
	Oligomenorrhoea					
	Vomiting In Pregnancy					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4608824-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544253A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Drug Exposure During Pregnancy							
	Pregnancy							

Date:03/15/05ISR Number: 4608825-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544253B
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Congenital Anomaly		Wellbutrin	PS	Glaxosmithkline			
	Drug Exposure During Pregnancy							

Date:03/15/05ISR Number: 4610483-XReport Type:Expedited (15-DaCompany Report #HQWYE793203MAR05
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Withdrawal Syndrome	Health Professional	Effexor (Venlafaxine Hydrochloride, Unspec)	PS			150 MG - FREQUENCY UNSPECIFIED	
	Hallucination							
	Hyperhidrosis							
			Wellbutrin Xl (Bupropion Hydrochloride,)	SS		ORAL	150 MG 1X PER 1 DAY,	ORAL

Date:03/15/05ISR Number: 4614223-XReport Type:Expedited (15-DaCompany Report #B0372243A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation	Foreign	Zyban Tablet-Zyban					
	Decreased Appetite	Literature	(Bupropion					
	Depersonalisation	Health	Hydrochloride)	PS			SEE DOSAGE TEXT	
	Drug Effect Decreased	Professional						
	Grandiosity							
	Hallucination							
	Ideas Of Reference							
	Illusion							
	Insomnia							
	Irritability							
	Mania							
	Paranoia							
	Psychotic Disorder							
	Suspiciousness							
	Tension							
	Tobacco Abuse							

Date:03/16/05ISR Number: 4609674-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0538024A
Age:23 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Convulsion
	Incontinence

	Loss Of Consciousness Sexual Dysfunction					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day	5 DAY					
			Symbyax	SS		
30 DAY						
			Birth Control Pills	C		

Date:03/16/05ISR Number: 4609675-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0538500A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day						
	Fall		Ditropan	C		
	Loss Of Consciousness		Paroxetine	C	Glaxosmithkline	
	Tinnitus		Lisinopril	C		
	Tremor		Atenolol	C		
			Ranitidine	C	Glaxosmithkline	
			Zaroxolyn	C		
			Folic Acid	C		
			Tylenol Arthritis	C	Glaxosmithkline	

Date:03/16/05ISR Number: 4609681-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549208A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Intentional Misuse		Wellbutrin Xl	PS	Glaxosmithkline	
INTRAVENOUS	300MG Unknown					
Initial or Prolonged	Local Swelling					
Other						

Date:03/16/05ISR Number: 4609682-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549655A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
Other	Convulsion		Trazodone	C		
300MG As required	Dizziness		Neurontin	C		
	Fall					
	Head Injury					
	Loss Of Consciousness					
	Tremor					

Date:03/16/05ISR Number: 4610042-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549640A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dehydration		Wellbutrin	PS	Glaxosmithkline	ORAL
	Grand Mal Convulsion		Klonopin	SS		
UNKNOWN						
	Vomiting					

Date:03/16/05ISR Number: 4618087-XReport Type:Periodic Company Report #S05-USA-00304-01
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Health Professional	Lexapro (Escitalopram)	PS		
			Wellbutrin			

			(Bupropion Hydrochloride)	SS		

Date:03/17/05ISR Number: 4610902-9Report Type:Expedited (15-DaCompany Report #200511975US
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complication Of Delivery		Allegra	PS	Aventis Pharmaceuticals Inc.			
	Drug Exposure During Pregnancy						dose: NOT PROVIDED	
	Haemorrhage		Bupropion	SS				
	Umbilical Cord Abnormality		Celexa	SS			dose: NOT PROVIDED	
			Zantac	SS				

Date:03/17/05ISR Number: 4611423-XReport Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12888830
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Metoprolol Tartrate	PS	Apothecon			1 YR
	Drug Interaction		Diltiazem Hcl	C				1 YR
			Bupropion	I				12 DAY

Date:03/17/05ISR Number: 4611579-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544527A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL		27 DAY

	Dysphemia		Adderall	SS	
	Grand Mal Convulsion		Cold Medication	SS	
	Overdose				
	Postictal State				
	Sleep Disorder				
	Tonic Clonic Movements				

Date:03/17/05ISR Number: 4611580-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546075A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Caffeine Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Drug Level Increased		Concerta	C		ORAL	108MG In the	
	Drug Toxicity							
morning	YR							
	Fatigue		Dextrostat	C	Glaxosmithkline	ORAL	2TAB Per day	YR
	Grand Mal Convulsion							
	Hypertonia							
	Postictal State							
	Sleep Disorder							
	Syncope							
	Weight Decreased							

Date:03/17/05ISR Number: 4611585-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0550044A
Age: Gender:Male I/FU:I

Outcome	PT
Other	Arthralgia
	Fatigue

		Systemic Lupus Erythematosus					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Wellbutrin	PS	Glaxosmithkline	ORAL

Date:03/17/05ISR Number: 4611589-1Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0357968A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Drug Interaction		Zyban	PS	Glaxosmithkline	ORAL
150MG See						
	Ecchymosis					
dosage text	48 DAY					
	Emotional Disorder		Alcohol	SS		
	Retrograde Amnesia		No Concurrent Medication	C		

Date:03/17/05ISR Number: 4611603-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0374756A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Anorexia		Zyban	PS	Glaxosmithkline	ORAL
150MG See						
	Depersonalisation					
dosage text	3 WK					
	Depression					
	Emotional Distress					
	Suicidal Ideation					
	Weight Decreased					

Date:03/17/05ISR Number: 4611606-9Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0374928A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dyspnoea		Zyban	PS	Glaxosmithkline	
UNKNOWN	1TAB Twice					

Eye Rolling
per day
Hallucination No Concurrent
Insomnia Medication C
Nausea
Palpitations

Date:03/17/05ISR Number: 4613437-2Report Type:Direct Company Report #CTU 243509
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Zyban Xl	PS		ORAL	150 G	1 PO
	Insomnia						DAILY	X 3
							DAYS THEN 1	
							PO BID	1 MON

Date:03/17/05ISR Number: 4615820-8Report Type:Expedited (15-DaCompany Report #GXKR2005US00689
Age:29 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Bundle Branch Block Left
	Cardiovascular Disorder
	Disorientation
	Electrocardiogram Qt Corrected Interval Prolonged

	Grand Mal Convulsion Intentional Misuse Lethargy	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Medication Error Overdose	Literature Health	Divalproex (Ngx)(Divalproex)	PS		ORAL ORAL
	Supraventricular Tachycardia	Professional	Ziprasidone (Ngx) (Ziprasidone)	SS		ORAL 5920 MG, ORAL
			Bupropion (Ngx) (Bupropion)	SS		ORAL 15700 MG (PROBABLY FEWER), ORAL
			Fluoxetine (Ngx) (Fluoxetine)	SS		ORAL 72 G, ORAL

Date:03/18/05ISR Number: 4612896-9Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0364857A
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Cardiac Disorder		Zyntabac	PS	Glaxosmithkline	ORAL 150MG Per day 19 DAY
Hospitalization -	Cardiac Valve Disease		Nicotinell	C	Glaxosmithkline	 UNKNOWN
Initial or Prolonged Disability	Hemiparesis Lung Disorder Nervous System Disorder Post Procedural Complication Pulmonary Oedema					

Date:03/18/05ISR Number: 4612906-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0374668A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration

Death	Death		Zyban		PS	Glaxosmithkline	ORAL
50TAB Single							
dose							

Date:03/18/05ISR Number: 4614864-XReport Type:Direct Company Report #CTU 243681
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Bupropion	75mg	PS		ORAL	150MG	BID
Hospitalization - Initial or Prolonged	Injury						ORAL		
Disability	Road Traffic Accident		Formoterol		C				
	Traumatic Brain Injury		Nifedipine		C				
			Isosorbide Mononitrate		C				
			Metoprolol		C				
			Albuterol		C				
			Simvastatin		C				

Date:03/18/05ISR Number: 4616547-9Report Type:Expedited (15-DaCompany Report #L04-USA-07403-24
Age:30 YR Gender:Female I/FU:F

Outcome	PT
Death	Blood Pressure Decreased
Hospitalization - Initial or Prolonged	Cardiac Arrest
	Completed Suicide
	Convulsion
	Ejection Fraction

	Decreased Intentional Misuse Mental Status Changes Nausea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nervous System Disorder Ventricular Dysfunction	Literature Health Professional	Lexapro (Escitalopram)	PS		ORAL	340 MG ONCE PO
			Bupropion (Long-Acting) (Bupropion)	SS		ORAL	2550 MG ONCE PO
			Paroxetine	SS		ORAL	340 MG ONCE PO
			Clonazepam	SS		ORAL	8.5 MG ONCE PO

Date:03/21/05ISR Number: 4613914-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0374737A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Depression		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown 21 DAY
	Dry Mouth		Femoston	C			UNKNOWN
	Insomnia		Co-Codamol	C			UNKNOWN
	Mood Swings		Noctura	C			UNKNOWN 12 WK
	Palpitations						

Date:03/21/05ISR Number: 4613919-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0375117A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour		Zyban	PS	Glaxosmithkline	ORAL	1TABS Per day	3 DAY
Initial or Prolonged	Aggression		Vasten	C			UNKNOWN	40MG Per day
	Insomnia		Sectral	C		ORAL	50MG per day	
	Overdose		Triatec 2.5	C			UNKNOWN	
	Suicidal Ideation		Lexomil	C		ORAL	.25UD See	
	Suicide Attempt						dosage text	
			Kardegic 160	C			UNKNOWN	160MG Per day

Date:03/21/05ISR Number: 4616353-5Report Type:Expedited (15-DaCompany Report #IMP_0840_2005
Age:43 YR Gender:Female I/FU:I

Outcome	PT
Other	Abdominal Pain Upper
	Bone Pain
	Cardiac Disorder
	Chest Pain
	Eating Disorder
	Feeling Abnormal
	Gastrooesophageal Reflux Disease
	Hepatic Steatosis
	Hyperhidrosis
	Hypoaesthesia
	Nausea
	Pain
	Pain In Jaw
	Palpitations
	Pharmaceutical Product Complaint

		Weight Decreased					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Buproprion	PS		ORAL
150 MG QDAY							
PO							
				Atenolol	C		
				Ezetimibe And Simvastatin	C		
				Nexium /Usa/	C		

Date:03/22/05ISR Number: 4615168-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0374668A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death		Zyban	PS	Glaxosmithkline	ORAL
50TAB Single						
	Overdose					
dose						

Date:03/22/05ISR Number: 4617548-7Report Type:Expedited (15-DaCompany Report #HQWYE150815MAR05
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Drug Withdrawal Syndrome	Consumer	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL
	Suicidal Ideation					
	Suicide Attempt					
225 MG 1X PER						
1 DAY, ORAL						
			Ativan (Lorazepam, Unspec)	SS		
			Wellbutrin (Bupropion Hydrochoride,)	SS		

Date:03/22/05ISR Number: 4617549-9Report Type:Expedited (15-DaCompany Report #HQWYE007210MAR05
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying Suicidal Ideation Treatment Noncompliance Vomiting	Consumer	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	SEE IMAGE	
			Ativan (Lorazepam, Unspec)	SS				
			Wellbutrin (Bupropion Hydrochloride)	SS				

Date:03/22/05ISR Number: 4620242-XReport Type:Direct Company Report #CTU 243983
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Erythematous Rash Pruritic		Roxicet 5mg/325mg 5/325 Roxane Lab	PS	Roxane Lab	ORAL	ONE TAB Q8H	
			Bupropion Hcl Extended Rele 150 Mg				ORAL	

			Eon Labs	SS	Eon Labs	ORAL	ONE TAB BID
							ORAL

Date:03/23/05ISR Number: 4617153-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544500A
Age:11 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	11 MON
Life-Threatening			Strattera	SS			40MG per day	

Date:03/23/05ISR Number: 4617166-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0365531A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG Twice per day 8 DAY
	Anxiety							
	Confusional State							
	Coordination Abnormal							
	Disorientation							
	Feeling Abnormal							
	Feeling Of Despair							
	Hallucination							
	Mental Disorder							

Date:03/23/05ISR Number: 4617176-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0374974A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	7 DAY
	Injury		Atorvastatin	C		ORAL	40MG Per day	

			Aspirin	C	Glaxosmithkline	ORAL
300MG Per day						
			Ramipril	C		ORAL
5MG Per day						
			Clopidogrel	C		ORAL
75MG Per day						

Date:03/23/05ISR Number: 4617181-7Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0375449A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Dependence		Zyban	PS	Glaxosmithkline			
UNKNOWN								

Date:03/23/05ISR Number: 4617183-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0375519A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxosmithkline	ORAL		
150MG See								
	Colitis Ischaemic							
dosage text							1	MON
	Insomnia							
	Rectal Haemorrhage							

Date:03/23/05ISR Number: 4618905-5Report Type:Expedited (15-DaCompany Report #S05-USA-00523-01
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Catheter Sepsis
Initial or Prolonged	Coma
	Confusional State

Drug Interaction Hypotension Respiratory Failure		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health Professional	Lexapro (Escitalopram)	PS		
OROPHARINGEAL	20 MG QD PO					
			Lexapro (Escitalopram)	SS		
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
300 MG QD PO						
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
150 MG QD PO						
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
150 MCG BID						
PO						
			Atenolol	C		
			Isosorbide	C		
			Potassium	C		
			Zocor	C		
			Aspirin	C		
			Avandia (Rosiglitazone Maleate)	C		
			Nexium (Esomeprazole)	C		
			Aricept (Donepezil Hydrochloride)	C		
			Neurontin (Gabapentin)	C		
			Duragesic (Fentanyl)	C		
			Hydrocodone	C		
			Centrum Silver	C		
			Magnesium	C		
			Vitamin B12	C		
			Diazepam	C		

Date:03/23/05ISR Number: 4621313-4Report Type:Direct Company Report #CTU 244005
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin Sr	PS		ORAL	150 PO	

Date:03/23/05ISR Number: 4621356-0Report Type:Direct Company Report #CTU 244100
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Bupropion 75mg	PS		ORAL	75MG TABS BID	2
	Fall							
	Gait Disturbance						ORAL	
	Head Injury							
	Subdural Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4617555-4Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20050105542
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Topamax	PS		OROPHARINGEAL		
	Fatigue		Wellbutrin Xl	SS		UNKNOWN		
	Nausea		Lamictal	C				
	Sjogren'S Syndrome							
	Somnolence							
	Tremor							

Date:03/24/05ISR Number: 4617606-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03482
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Cogentin	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Drug Interaction		Wellbutrin Sr	SS				
			Lithium Carbonate	SS		ORAL		
			Klonopin	SS				UNKNOWN
			Trazodone Hydrochloride	SS				UNKNOWN
			Seroquel	SS				UNKNOWN
			Prolixin	SS				UNKNOWN

Date:03/24/05ISR Number: 4617822-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0534857A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	DAY
	Anger		Tagamet	C	Glaxosmithkline			
	Anorexia		Vicodin	C				
	Bipolar Disorder							

	Coordination Abnormal					
	Dementia					
	Diarrhoea					
	Disturbance In Attention					
	Fatigue					
	Nausea					

Date:03/24/05ISR Number: 4617834-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0550280A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Haemorrhage		Lamictal	SS	Glaxosmithkline	ORAL	2	DAY
			Klonopin	C				
			Symbyax	C				

Date:03/24/05ISR Number: 4617837-6Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0550469A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG See	
	Dizziness							
dosage text							7	DAY
	Insomnia							
	Nausea							
	Oedematous Pancreatitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4617841-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0550911A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Hallucination, Auditory							
	Headache							
	Libido Decreased							
	Penis Disorder							
	Testicular Pain							

Date:03/24/05ISR Number: 4617852-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0370073A
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Euphoric Mood		Zyban	PS	Glaxosmithkline	ORAL	10	DAY
	Feeling Abnormal		Lipitor	C				
	Hypomania							
	Paranoia							

Date:03/24/05ISR Number: 4617853-4Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0370764A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pruritus		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG Unknown
	Sleep Disorder							
	Tooth Disorder							
	Toothache							

Date:03/24/05ISR Number: 4617860-1Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0375449A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Dependence		Zyban	PS	Glaxosmithkline		UNKNOWN	

Date:03/24/05ISR Number: 4617862-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0375746A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Allergic		Zyban	PS	Glaxosmithkline			
UNKNOWN								13 DAY
	Erythema		Flunitrazepam	C		ORAL	1MG At night	YR
	Rash							
	Rash Papular							
	Skin Disorder							

Date:03/24/05ISR Number: 4617864-9Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0375754A
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anger
	Crying
	Fall
	Feeling Abnormal
	Intentional Misuse
	Mood Swings
	Multiple Drug Overdose
	Night Sweats

		Suicide Attempt Tearfulness					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Zyban	PS	Glaxosmithkline	
UNKNOWN							
				Contraceptive Pill	C		ORAL
				Valium	C		
				Sleeping Tablets	C		

Date:03/24/05ISR Number: 4619554-5Report Type:Expedited (15-DaCompany Report #2005-00954
Age:56 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Drug Interaction Potentiation Sinus Bradycardia	Literature Health Professional	Metoprolol (Watson Laboratories)(Emtopr olol Tartrate)			
				Tablet	PS	Watson Laboratories	ORAL
75 MG, DAILY,							
ORAL	365 DAY						
				Bupropioin (Bupropion)	SS		ORAL
150 MG, BID,							
ORAL	12 DAY						
				Diltiazem	C		

Date:03/25/05ISR Number: 4619133-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546075A
Age:21 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Caffeine Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
		Drug Toxicity		Concerta	C		ORAL
108MG In the							
		Fatigue					
morning	YR						
		Grand Mal Convulsion		Dextrostat	C	Glaxosmithkline	ORAL
2TAB Per day	YR						
		Hypertonia Loss Of Consciousness					

Postictal State
Sleep Disorder
Stress
Syncope
Weight Decreased

Date:03/25/05ISR Number: 4619138-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549286A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline		300MG per day	
	Drug Exposure During Pregnancy							
	Pregnancy							

Date:03/25/05ISR Number: 4619147-XReport Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0364019A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperthyroidism		Zyban	PS	Glaxosmithkline		UNKNOWN	
	Personality Change		Thyroxine	SS	Glaxosmithkline		UNKNOWN	
	Visual Acuity Reduced							
	Visual Field Defect							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619154-7Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0374919A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxosmithkline			
UNKNOWN								4 DAY
	Feeling Abnormal							
	Hypersensitivity							
	Loss Of Consciousness							

Date:03/25/05ISR Number: 4619162-6Report Type:Expedited (15-DaCompany Report #BE-GLAXOSMITHKLINE-B0375805A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Induced		Zyban	PS	Glaxosmithkline			
Congenital Anomaly	Asphyxiating Thoracic Dystrophy							
	Drug Exposure During Pregnancy							
	Limb Deformity							

Date:03/25/05ISR Number: 4619753-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Unstable
Other	Anxiety
	Arthralgia
	Arthropathy
	Back Pain
	Benign Prostatic Hyperplasia
	Cardiac Failure Congestive
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression

Diabetes Mellitus
Non-Insulin-Dependent
Diabetic Nephropathy
Diabetic Neuropathy
Diabetic Retinopathy
Drug Hypersensitivity
Drug Ineffective
Fall
Hepatitis
Herpes Zoster
Hypercholesterolaemia
Infection
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc
Disorder
Ischaemic Cardiomyopathy
Oedema Peripheral
Pneumonia

		Renal Cyst Sepsis Sexual Dysfunction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
146	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Zyban	SS		
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
146	DAY						
				Zestril	C		
UNKNOWN		2170 DAY					
				Zestril	C		
UNKNOWN		2170 DAY					
				Tenormin	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Micronase	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN		1051 DAY					
				[Therapy Unspecified]	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							

Date:03/25/05ISR Number: 4620882-8Report Type:Expedited (15-DaCompany Report #S05-USA-01449-01
Age:27 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Exposure During Pregnancy Haemorrhage Pregnancy	Health Professional	Celexa (Citalopram Hydrobromide) Wellbutrin (Bupropion	PS		

	Umbilical Cord		Hydrochloride)	SS		ORAL
300 MG QD; PO						
	Abnormality		Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
150 MG QD; PO						
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
300 MG QD; PO						
			Allegra (Fexofenadine Hydrochloride)	SS		
			Zantac (Ranitidine Hydrochloride)	SS		

Date:03/25/05ISR Number: 4622592-XReport Type:Direct Company Report #CTU 244365
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other Required Intervention to Prevent Permanent Impairment/Damage	Pharmaceutical Product Complaint Urticaria		Bupropion Hcl Sr 200mg Watson/ Express Script	PS	Watson/Express Script	ORAL
200MG Q 12 ORAL						

Date:03/28/05ISR Number: 4620510-1Report Type:Expedited (15-DaCompany Report #A03200400600
Age:48 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Impaired Work Ability		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Per day	
	Suicide Attempt		Ambien	SS		ORAL	5MG See dosage text	9 DAY
			Wellbutrin	SS	Glaxosmithkline		150MG Per day	
			Paroxetine Hydrochloride	SS	Glaxosmithkline	ORAL	20MG Per day	3 DAY

Date:03/28/05ISR Number: 4620524-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549256A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	3 DAY
	Fatigue							
	Headache		No Concurrent Medication	C				
	Homicidal Ideation							
	Insomnia							
	Irritability							
	Mood Swings							

Date:03/28/05ISR Number: 4620529-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0550255A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	3 MON	
	Suicide Attempt		Prozac	C				

Date:03/28/05ISR Number: 4620530-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0550455A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
	Agitation		No Concurrent Medication	C				
	Chills							
	Drug Exposure During Pregnancy							
	Insomnia							
	Paraesthesia							

Date:03/28/05ISR Number: 4620531-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0550456A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eczema		Wellbutrin	PS	Glaxosmithkline	ORAL	4	WK
Other	Excoriation		Cardiac Anti-Arrhythmic Medication	C				
	Pruritus		Anti-Hypercholesterolaemic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/05ISR Number: 4620532-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0550641A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Condition Aggravated		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day 11 MON
Initial or Prolonged	Convulsion		Unknown	C			

Date:03/28/05ISR Number: 4622638-9Report Type:Direct Company Report #CTU 244472
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Communication Disorder		Remeron	PS		ORAL	30 MG @ HS PO
	Dizziness		Wellbutrin 150 Daily				
	Feeling Abnormal		X 4 Then	SS			300 MG Q DAY
	Headache						
	Nausea						
	Vision Blurred						

Date:03/29/05ISR Number: 4621894-0Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0550686A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angina Pectoris		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 2 DAY
	Asthenia		Diazepam	C		ORAL	1TAB Weekly
	Diarrhoea						
	Headache						

Date:03/29/05ISR Number: 4621905-2Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0364019A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Hyperthyroidism		Zyban	PS	Glaxosmithkline	
UNKNOWN						
	Personality Change		Thyroxine	SS	Glaxosmithkline	
UNKNOWN						
	Visual Acuity Reduced					
	Visual Field Defect					

Date:03/29/05ISR Number: 4621909-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0375382A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Induced		Zyban	PS	Glaxosmithkline	ORAL
150MG	Unknown					
	Drug Exposure During Pregnancy		Oral Contraception	C		ORAL

Date:03/29/05ISR Number: 4621915-5Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0375976A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Aggression		Zyban	PS	Glaxosmithkline	
UNKNOWN						
	Drug Interaction		Alcohol	SS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4621934-9Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12908679
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Trazodone Hcl	PS	Apothecon			
			Prolixin	I	Apothecon			
			Wellbutrin Sr	I				
			Lithium	I		ORAL		
			Benztropine Mesylate	I				
			Clonazepam	I				
			Quetiapine Fumarate	I				

Date:03/30/05ISR Number: 4622837-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541137A
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcoholic Pancreatitis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
Other	Disease Recurrence		Alcohol	SS				
			Lexapro	C			40MG Per day	

Date:03/30/05ISR Number: 4622838-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541603A
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Alanine Aminotransferase		Percocet	C				
Disability	Increased		Fosamax	C			70MG Weekly	
Other	Anorexia		Allegra	C			180MG Per day	
	Aspartate		Bextra	C			20MG Per day	
	Aminotransferase		Nu-Iron	C			150MG Per day	
	Increased		Magnesium Oxide	C			400MG Three	

	Blood Alkaline						
times per day							
	Phosphatase Increased		Duoneb	C			
	Diarrhoea		Combivent	C			
	Electrolyte Imbalance		Advair	C	Glaxosmithkline		
1PUFF Twice							
	Ileus						
per day							
	Intestinal Perforation		Tiazac	C	Glaxosmithkline		
300MG Per day							
	Liver Function Test		Lotensin	C	Glaxosmithkline		
10MG Per day							
	Abnormal		Bethanecol	C			
50MG Four							
	Nausea						
times per day							
	Peritonitis		Effexor Xr	C			
150MG Per day							
	Volvulus Of Bowel		Sonata	C			
10MG At night							
	Vomiting		Aciphex	C			
20MG Per day							
	Weight Decreased						

Date:03/30/05ISR Number: 4622841-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549064A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Enzyme Increased		Bupropion					
Initial or Prolonged	Hepatic Failure		Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Twice	
Other	Jaundice						per day	
	Prothrombin Time		Paxil	C	Glaxosmithkline			
	Prolonged		Coumadin	C	Glaxosmithkline			
			Lipitor	C				
			Toprol	C				
			Klonopin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/05ISR Number: 4624153-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551834A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline			
	Dizziness							
	Drug Toxicity							
	Feeling Abnormal							
	Headache							
	Loss Of Consciousness							

Date:03/31/05ISR Number: 4624178-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0375831A
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Decreased		Zyban	PS	Glaxosmithkline	ORAL	15MG Twice	
	Circulatory Collapse							
per day								17 DAY
	Hypoglycaemia		Simvastatin	C		ORAL	4MG per day	
	Loss Of Consciousness		Lansoprazole	C		ORAL	15MG per day	
			Enalapril	C		ORAL	20MG per day	
			Mixtard	C			SUBCUTANEOUS	

Date:03/31/05ISR Number: 4627220-5Report Type:Expedited (15-DaCompany Report #2005UW04517
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Health Professional	Seroquel	PS				
			Wellbutrin - Slow Release	SS				
			Lithium	SS				
			Cogentin	SS				
			Klonopin	SS				
			Trazodone	SS				
			Prolixin	SS				

Date:03/31/05ISR Number: 4632038-3Report Type:Periodic Company Report #200411259BCC
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	No Adverse Drug Effect	Health Professional	Aleve Tablets (Naproxen Sodium)	PS		ORAL	1320 MG,	ONCE, ORAL
		Other	Zyban (Bupropion Hydrochloride)	SS		ORAL	1500 MG,	ONCE, ORAL

Date:04/01/05ISR Number: 4625324-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549225A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Aura Grand Mal Convulsion Mania		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/05ISR Number: 4625333-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551303A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	225MG Twice	
	Medication Error						per day	
	Meniere'S Disease		Premarin	C				
	Otosclerosis		Maxalt	C				
			Flexeril	C				
			Temazepam	C				

Date:04/01/05ISR Number: 4625334-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551305A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	10 WK	
	Anger		Clonopin	C				
	Crying		Sudafed	C	Glaxosmithkline			
	Distractibility		Nasonex	C				
	Disturbance In Attention		Antibiotic	C				
	Dizziness							
	Emotional Disorder							
	Memory Impairment							
	Nausea							
	Panic Attack							
	Suicidal Ideation							

Date:04/01/05ISR Number: 4625335-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551463A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Testosterone		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Increased		Testosterone Gel	SS	Glaxosmithkline			
	Gynaecomastia		Ativan	C				
	Haematocrit Increased		Viramune	C				
	Weight Decreased		Videx Ec	C				
			Famvir	C	Glaxosmithkline			

Date:04/01/05ISR Number: 4625336-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551501A
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disturbance In Attention		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Feeling Abnormal							
	Loss Of Consciousness		Percocet	C				
	Vomiting							

Date:04/01/05ISR Number: 4625340-2Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0302490A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache		Zyban	PS	Glaxosmithkline			
	Leukopenia		Bricanyl	C				
	Meningitis		Pulmicort	C				
	Neutropenia							
	Pain							
	Pyrexia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/05ISR Number: 4625364-5Report Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0376363A
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	18 DAY
	Amnesia							
	Blood Prolactin Increased							
	Cerebral Atrophy							
	Clonus							
	Confusional State							
	Convulsion							
	Crying							
	Cyanosis							
	Disorientation							
	Dyskinesia							
	Grand Mal Convulsion							
	Posture Abnormal							
	Respiration Abnormal							

Date:04/01/05ISR Number: 4628372-3Report Type:Expedited (15-DaCompany Report #IMP_0840_2005
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Buproprion	PS		ORAL	150 MG QDAY	
	Alopecia						PO	
	Back Pain		Atenolol	C				
	Chest Pain		Ezetimibe	C				
	Constipation		Nexium	C				
	Decreased Activity							
	Eating Disorder							
	Feeling Abnormal							
	Gastrooesophageal Reflux Disease							
	Hepatic Steatosis							
	Hyperhidrosis							
	Hypoaesthesia							
	Micturition Disorder							
	Nausea							
	Palpitations							
	Pharmaceutical Product							

Complaint
Skin Exfoliation
Weight Decreased

Date:04/04/05ISR Number: 4626324-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549621A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	20 DAY
	Decreased Appetite							
	Decreased Interest							
	Irritability							
	Libido Decreased							
	Mood Swings							
	Sleep Disorder							
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/05ISR Number: 4626335-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551784A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline			

Date:04/04/05ISR Number: 4626340-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551947A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Loss Of Consciousness Myalgia Tremor		Wellbutrin	PS	Glaxosmithkline	ORAL	5	MON

Date:04/05/05ISR Number: 4627135-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0520475A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During Pregnancy Growth Retardation Intra-Uterine Death Pregnancy		Wellbutrin	PS	Glaxosmithkline		300MG per day	

Date:04/05/05ISR Number: 4627136-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548375A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous Drug Exposure During Pregnancy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	12	DAY

Date:04/05/05ISR Number: 4627137-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549655A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG As required	
	Convulsion		Trazodone	C				
	Dizziness		Neurontin	C				
	Fall							
	Head Injury							
	Loss Of Consciousness							
	Tremor							

Date:04/05/05ISR Number: 4627145-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0363857A
Age:29 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Asthenia
	Back Pain
	Cerebrovascular Accident
	Chest Pain
	Dizziness
	Fatigue
	Flank Pain

		PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Headache							
		Limb Discomfort							
		Muscle Spasms		Zyban	PS	Glaxosmithkline	ORAL	8	DAY
		Myalgia							
		Nausea		Sodium Stibogluconate	SS	Glaxosmithkline	INTRAVENOUS	1391MG Per day	15 DAY
		Renal Failure Acute							
		Rhabdomyolysis							
		Vomiting		Keflex	C	Glaxosmithkline	ORAL	500MG Three times per day	16 DAY
				Fluconazole	C		ORAL	200MG Per day	34 DAY
				Rifampin	C				
				Ketoconazole	C				

Date:04/05/05ISR Number: 4627148-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0369079A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Zyban	PS	Glaxosmithkline	ORAL		

Date:04/05/05ISR Number: 4627167-4Report Type:Expedited (15-DaCompany Report #DK-GLAXOSMITHKLINE-B0376672A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Delusion		Zyban	PS	Glaxosmithkline			
	Flushing						UNKNOWN	300MG Per day
	Pruritus							
	Psoriasis							
	Swelling							
	Urticaria							

Date:04/05/05ISR Number: 4629207-5Report Type:Expedited (15-DaCompany Report #DSA_26154_2005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying	Consumer	Ativan	PS				
	Suicidal Ideation		Effexor	SS		ORAL	225 MG Q DAY	
	Treatment Noncompliance						PO	
	Vomiting		Effexor	SS		ORAL	225 MG Q DAY	
							PO	
			Effexor	SS		ORAL	150 MG Q DAY	
							PO	
			Effexor	SS		ORAL	75 MG Q DAY	
							PO	
			Effexor	SS		ORAL	75 MG QOD PO	
			Wellbutrin	SS				

Date:04/05/05ISR Number: 4629326-3Report Type:Expedited (15-DaCompany Report #B0375844A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During Pregnancy Stillbirth	Foreign Study Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/05ISR Number: 4629327-5Report Type:Expedited (15-DaCompany Report #B0375846A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Exposure During Pregnancy Premature Separation Of Placenta	Foreign Study Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		

Date:04/05/05ISR Number: 4629328-7Report Type:Expedited (15-DaCompany Report #B0375846B
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death Neonatal Drug Exposure During Pregnancy	Foreign Study Literature Health Professional	Wellbutrin Unspecified Tablet (Bupropion Hydrochloride)	PS		

TRANSPLACENTA

RY

Date:04/05/05ISR Number: 4629509-2Report Type:Expedited (15-DaCompany Report #HQWYE364525MAR05
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Withdrawal Syndrome Hypotension Therapeutic Response Decreased Tremor	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		
SEE IMAGE						
			Bupropion (Amfebutamone,)	SS		
100 MG 1X PER						
1 DAY						
			Singulair (Montelukast Sodium)	C		
			Advair (Fluticasone			

Propionate/Salmeterol Xinafoate)	C	
Lorazepam (Lorazepam)	C	
Trazodone (Trazodone)	C	

Date:04/06/05ISR Number: 4628098-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549235A
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	367 DAY
Other	Convulsion		Lamictal	C	Glaxosmithkline	ORAL	200MG per day	
	Humerus Fracture		Ambien	C		ORAL	15MG per day	
	Loss Of Consciousness		Xanax	C		ORAL	.5MG per day	
	Tongue Biting		Zyprexa	C		ORAL	5MG per day	
			Paxil	C	Glaxosmithkline	ORAL	60MG per day	
			Strattera	C		ORAL	40MG per day	198 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/05ISR Number: 4628099-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549643A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	WK
	Eye Rolling		Adderall Xr	C			DAY	
	Fall							

Date:04/06/05ISR Number: 4628101-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551938A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blister		Wellbutrin	PS	Glaxosmithkline	ORAL	5	MON
Initial or Prolonged	Dermatitis Exfoliative							
	Skin Reaction							
	Urticaria							

Date:04/06/05ISR Number: 4628103-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551946A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bite		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Mouth Injury		No Concurrent					
	Oral Pain		Medication	C				
	Tourette'S Disorder							

Date:04/06/05ISR Number: 4628104-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551948A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Mood Altered		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	

Initial or Prolonged	Psychotic Disorder				
per day					
	Suicide Attempt		Effexor	SS	ORAL
75MG Per day					
			Remeron	C	
			Effexor	C	
			Metformin	C	
			70/30 Humulin		
			Insulin	C	
			Lescol	C	
			Lisinopril	C	
			Seroquel	C	
			Depakote Er	C	

Date:04/07/05ISR Number: 4629067-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549208A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intentional Misuse		Wellbutrin Xl	PS	Glaxosmithkline			
INTRAVENOUS	300MG	Unknown						
Initial or Prolonged	Local Swelling							
Other	Medication Error							

Date:04/07/05ISR Number: 4629068-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549209A
Age:45 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intentional Misuse		Wellbutrin Xl	PS	Glaxosmithkline	INTRAVENOUS		
	Medication Error							

Date:04/07/05ISR Number: 4629069-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549210A
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	INTRAVENOUS		
Hospitalization - Initial or Prolonged	Intentional Misuse							
Other	Medication Error							

Date:04/07/05ISR Number: 4629083-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0376590A
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY

Date:04/07/05ISR Number: 4631156-3Report Type:Direct Company Report #CTU 245564
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl 300 Mg					
	Feeling Abnormal		Glaxosmithklkline	PS	Glaxosmithkline	ORAL	300 MG ONCE	
	Pain						DAILY ORAL	
	Panic Attack							
	Pharmaceutical Product Complaint							

	Tremor					

Date:04/08/05ISR Number: 4630076-8Report Type:Expedited (15-DaCompany Report #US-ABBOTT-03P-163-0225847-00
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Toxicity		Hydrocodone	PS			Not reported	
			Bupropion	SS			Not reported	
			Venlafaxine	SS			Not reported	

Date:04/08/05ISR Number: 4630527-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545489A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Drug Withdrawal Syndrome		Benzodiazepine	SS				
	Grand Mal Convulsion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/05ISR Number: 4630533-4Report Type:Expedited (15-DaCompany Report #2005/03/0457
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 MON
	Homicidal Ideation		Peg-Intron	SS		INTRAVENOUS		
	Mood Altered		Ribavirin	SS		ORAL		
	Paranoia		Vicodin	C		ORAL		
			Ziac	C		ORAL		

Date:04/08/05ISR Number: 4630534-6Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0552669A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	DAY
	Insomnia							
	Nausea							

Date:04/08/05ISR Number: 4630547-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0376592A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Cardiovascular Disorder		Esomeprazole	C		ORAL	40MG per day	
	Drug Withdrawal Syndrome							
	Headache							

Date:04/08/05ISR Number: 4630548-6Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0376594A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Erythema		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
	Hypersensitivity					
per day 6 DAY						
	Oropharyngeal Swelling					
	Rash Papular					

Date:04/08/05ISR Number: 4630553-XReport Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0376835A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Laryngeal Oedema		Zyntabac	PS	Glaxosmithkline	ORAL
300MG per day 19 DAY						
	Rash					

Date:04/08/05ISR Number: 4630754-0Report Type:Expedited (15-DaCompany Report #US-ROCHE-399988
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthenia		Klonopin	PS	Roche	ORAL
TAKEN EVERY						
	Confusional State					
NIGHT.						
	Decreased Appetite					
STARTED PRIOR						
	Dehydration					
TO 15						
	Drug Interaction					
NOVEMBER						
	Lethargy		Allopurinol	I	Roche	ORAL
TAKEN AT						
	Nausea					
BEDTIME.						
STARTED						
PRIOR TO 15						
NOVEMBER 2004						

			Intron A	I		
INTRAVENOUS	37	DAY				
			Wellbutrin	I		ORAL
			Trazodone	I	Roche	ORAL
TAKEN EVERY NIGHT. STARTED PRIOR TO 15 NOVEMBER						
			Zocor	I		ORAL
STARTED PRIOR TO 15 NOVEMBER 2004 AND REPORTED TO BE 'LONG						
			Remeron	I		ORAL
TAKEN AT NIGHT. STARTED PRIOR TO 15 NOVEMBER 2004						
			Multivitamin Nos	I		ORAL
STARTED PRIOR TO 15 NOVEMBER 2004 AND REPORTED AS 'LONG-TERM						
			Glucosamine	I		ORAL
STARTED PRIOR TO 15						

NOVEMBER 2004

AND REPORTED

AS 'LONG-TERM

			Compazine	I		ORAL

Date:04/08/05ISR Number: 4630755-2Report Type:Expedited (15-DaCompany Report #US-ROCHE-400153
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Klonopin	PS	Roche			UNKNOWN
Initial or Prolonged			Wellbutrin Sr	I		ORAL		
			Lithium Salt	I				UNKNOWN
			Cogentin	I				UNKNOWN
			Trazodone	I	Roche			UNKNOWN
			Prolixin	I				UNKNOWN
			Seroquel	I				UNKNOWN

Date:04/08/05ISR Number: 4630775-8Report Type:Expedited (15-DaCompany Report #US-ROCHE-400318
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Klonopin	PS	Roche			UNKNOWN
Initial or Prolonged			Wellbutrin Sr	I		ORAL		
			Benztropine	I				UNKNOWN
			Trazodone	I	Roche			UNKNOWN
			Seroquel	I				UNKNOWN
			Trilafon	I				UNKNOWN

Date:04/08/05ISR Number: 4632745-2Report Type:Direct Company Report #CTU 245717
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Wellbutrinxl 150mg	PS		ORAL	2 A DAY	

ORAL

Date:04/11/05ISR Number: 4631870-XReport Type:Expedited (15-DaCompany Report #PHEH2005US03916
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Lamisil	PS	Novartis Sector: Pharma			
UNKNOWN								
			Wellbutrin	SS		ORAL		

Date:04/11/05ISR Number: 4633096-2Report Type:Direct Company Report #CTU 245806
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Baclofen	PS		ORAL	20 MG 3 TIMES	
	Pain In Extremity						A DAY ORAL	
			Wellbutrin 300 Mg	SS		ORAL	300 MG 1 TIME	
							A DAY ORAL	
			Vioxx	C				
			Celebrex	C				
			Bextra	C				

Date:04/11/05ISR Number: 4635391-XReport Type:Expedited (15-DaCompany Report #2005051512
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Consumer	Celebrex (Celecoxib)	PS		ORAL	400 MG (200 MG, 2 IN 1 D), ORAL	
Other	Back Pain							
	Depression							
	Nervousness		Bupropion					

	Suicidal Ideation	Hydrochloride (Bupropion Hydrochloride)	SS	ORAL 300 MG (150 MG, 2 IN 1 D),ORAL
		Escitalopram (Escitalopram)	C	
		Trazodone (Trazodone)	C	
		Seretide Mite (Fluticasone Propionate, Salmeterol Xinafoate)	C	
		All Other Therapeutic Products (All Other Therapeutic Products)	C	

Date:04/12/05ISR Number: 4633101-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0537624A
Age: Gender:Female I/FU:F

Outcome	PT
Other	Alopecia
	Colitis Ulcerative
	Lethargy
	Rectal Haemorrhage

	Somnolence						
	Stool Analysis Abnormal						
		Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
			Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice
per day	3 MON						
			Wellbutrin	SS	Glaxosmithkline		
			Interferon	C			

Date:04/12/05ISR Number: 4633102-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0542699A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Other	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	
	Depression						
	Fear						
	Irritability						
	Suicidal Ideation						

Date:04/12/05ISR Number: 4633103-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0543321A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Other	Blood Albumin Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice
	Liver Function Test						per day
	Abnormal		Nsaid	SS			
	Protein Total Increased		Lamictal	C	Glaxosmithkline		100MG Twice
per day							

Date:04/12/05ISR Number: 4633109-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0552814A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Energy Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Loss Of Consciousness						per day	
			Alcohol	C				

Date:04/12/05ISR Number: 4633138-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0376516A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxosmithkline			

Date:04/12/05ISR Number: 4633982-3Report Type:Direct Company Report #CTU 245903
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Welbutrin 300 Mg	PS		ORAL	ONCE DAILY	
Initial or Prolonged	Dizziness						ORAL	
	Feeling Abnormal							
	Insomnia							
	Palpitations							
	Panic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/05ISR Number: 4634800-XReport Type:Direct Company Report #CTU 245977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Paxil Cr/ Paroxetin					
Other	Headache		50mg A Day	PS				
Required	Tinnitus		Wellbrutrin 450mg					
Intervention to Prevent Permanent Impairment/Damage	Treatment Noncompliance		A Day	SS				

Date:04/13/05ISR Number: 4634081-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0544500A
Age:11 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	11 MON
Life-Threatening	Drug Ineffective		Strattera	SS			40MG Per day	
	Fatigue		Amphetamine	SS			UNKNOWN	
	Feeling Drunk		Adderall	C				
	Lethargy							

Date:04/13/05ISR Number: 4634082-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0549256A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Fatigue							
per day	3 DAY							
	Headache		No Concurrent					
	Homicidal Ideation		Medication	C				
	Insomnia							
	Irritability							
	Mood Swings							

Date:04/13/05ISR Number: 4634090-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553014A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypokalaemia		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:04/13/05ISR Number: 4634092-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553163A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Medication Error							

Date:04/13/05ISR Number: 4634093-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553177A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	49	WK
	Medication Error		No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/05ISR Number: 4634094-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553283A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Convulsion		Unspecified					
			Medications	C				
UNKNOWN								

Date:04/13/05ISR Number: 4634730-3Report Type:Direct Company Report #CTU 246047
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin Xl	PS			450 MG 1X	
	Drowning							
DAILY								

Date:04/13/05ISR Number: 4636473-9Report Type:Direct Company Report #CTU 246010
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Buproprion 100 Mg					
	Pharmaceutical Product		Eon	PS	Eon			
	Complaint		Buproprion 150 Mg					
			Eon	SS	Eon			

Date:04/14/05ISR Number: 4635159-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553424A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the	
	Anorexia							
morning							11	MON
	Disturbance In Attention		Protonix	C				
	Drug Withdrawal Syndrome							

Feeling Hot
Insomnia
Nausea

Date:04/14/05ISR Number: 4635163-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0347372A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia		Zyban	PS	Glaxosmithkline		150MG	Unknown 21 DAY
	Diplopia							
	Iiird Nerve Paralysis							
	Nystagmus							
	Vertigo							

Date:04/14/05ISR Number: 4636495-8Report Type:Direct Company Report #CTU 246227
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Bupropion Sr					
	Depression		150mg	PS		ORAL	150MG	DAILY
	Drug Effect Decreased					ORAL		
	Pharmaceutical Product Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4636704-5Report Type:Expedited (15-DaCompany Report #2005052957
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Self-Medication	Health Professional Company Representative	Geodon (Ziprasidone)	PS				
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS				
			Olanzapine/Fluoxetine Hydrochloride (Fluoxetine Hydrochloride, Olanzapine)	SS				
			Mirtazapine (Mirtazepine)	SS				
			Obetrol (Amfetamine Aspartate, Amfetamine Sulfate, Dexamfetamine Saccharate,	SS				

Date:04/14/05ISR Number: 4638581-5Report Type:Direct Company Report #CTU 246206
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Bupropion	PS			ONE	Q AM
	Aggression							
	Crying							
	Headache							
	Mood Swings							
	Pharmaceutical Product Complaint							
	Therapeutic Response							
	Unexpected With Drug Substitution							

Date:04/15/05ISR Number: 4635879-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0552604A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression		Paroxetine	PS	Glaxosmithkline	ORAL	10MG Per day	10 DAY
	Amnesia		Paxil Cr	SS	Glaxosmithkline	ORAL	50MG Per day	
	Confusional State		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Twice per day	
	Drug Ineffective							
	Drug Withdrawal Syndrome		Wellbutrin Sr	C	Glaxosmithkline	ORAL	150MG Twice per day	
	Hypertension							
	Suicidal Ideation		Metoprolol	C				
	Suicide Attempt							
	Tremor							

Date:04/15/05ISR Number: 4635880-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0552663A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
	Mouth Haemorrhage		Lithium	C	Glaxosmithkline			
	Tongue Disorder		Seroquel	C				
			Ambien	C				

			Prevacid	C		

Date:04/15/05ISR Number: 4635881-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0552994A
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day
Initial or Prolonged	Petit Mal Epilepsy Staring		Klonopin	C			

Date:04/15/05ISR Number: 4635883-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553354A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Condition Aggravated		Wellbutrin	PS	Glaxosmithkline	ORAL	4 WK
	Depression		Valium	SS			
	Overdose		No Concurrent				
	Suicide Attempt		Medication	C			

Date:04/15/05ISR Number: 4635884-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553362A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Atrophic Vulvovaginitis		Wellbutrin	PS	Glaxosmithkline	ORAL	

Date:04/15/05ISR Number: 4635885-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553377A
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day
Hospitalization -	Electrocardiogram Qt		Topamax	C			
Initial or Prolonged	Prolonged		Xanax	C			

Disability	Overdose		Clonidine	C		
Other						

Date:04/15/05ISR Number: 4636525-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0552854A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	
	Cystitis		Unspecified				
	Overdose		Medication	C			

Date:04/15/05ISR Number: 4640133-8Report Type:Direct Company Report #CTU 246361
Age:11 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Depression		Bupropion Sr 150 Mg	PS		ORAL	150 MG QAM ORAL
	Drug Effect Decreased						
	Educational Problem						
	Pharmaceutical Product Complaint						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4637628-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0547369A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	225MG In the	morning
	Convulsion		Effexor	SS				
	Muscle Twitching							

Date:04/18/05ISR Number: 4637631-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553387A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	per day
	Feeling Of Despair							
	Hallucination		Aspirin	C	Glaxosmithkline			
	Medication Error							
	Suicidal Ideation							

Date:04/18/05ISR Number: 4638605-5Report Type:Direct Company Report #USP 57143
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin	PS	Mylan		TABLET	
			Serzone	SS	Ivax		TABLET	

Date:04/18/05ISR Number: 4638734-6Report Type:Direct Company Report #CTU 246414
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Erythematous		Roxicet 5/325 Roxane					

	Rash Pruritic		Lab	PS	Roxane Lab	ORAL
ONE TAB Q6H						
ORAL						
			Bupropion Hcl 150 Mg Eon Labs	SS	Eon Labs	ORAL
ONE TAB BID						
ORAL						

Date:04/19/05ISR Number: 4638921-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553367A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiomegaly		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 2 YR						
Initial or Prolonged	Hypertension		Lopressor	C		
			Coumadin	C	Glaxosmithkline	
			Hct	C		
			Lisinopril	C		
			Aspirin	C	Glaxosmithkline	
			Unknown Medication	C		
			Progestin	C		

Date:04/19/05ISR Number: 4638922-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553397A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Parkinson'S Disease		Wellbutrin	PS	Glaxosmithkline	ORAL
400MG Unknown						
			No Concurrent Medication	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4638929-1Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0554063A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Clavulin	PS	Glaxosmithkline	ORAL	250MG Three	
	Fibromyalgia						times per day	11 DAY
	Musculoskeletal Stiffness		Zyban	SS	Glaxosmithkline	ORAL	150MG Twice	
	Myalgia						per day	9 DAY
	Pruritus		Apo-Salvent	C	Glaxosmithkline	RESPIRATORY		
	Wheezing						(INHALATION)	
			Becloforte	C	Glaxosmithkline	RESPIRATORY		
						(INHALATION)		

Date:04/19/05ISR Number: 4638937-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0374613A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus							
	Chest Pain							
	Electrocardiogram St Segment Depression							
	Hiatus Hernia							
	Oesophagitis							
	Urticaria Generalised							

Date:04/19/05ISR Number: 4638948-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0377367A
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Alcohol Interaction		Zyban	PS	Glaxosmithkline	ORAL 150MG Twice
	Hallucination					
per day						
	Injury		Alcohol	SS		
			Omeprazole	C	Glaxosmithkline	ORAL 20MG per day

Date:04/19/05ISR Number: 4638958-8Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0378012A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Convulsion		Zyban	PS	Glaxosmithkline	UNKNOWN
Hospitalization - Initial or Prolonged	Overdose					
	Respiratory Arrest					

Date:04/20/05ISR Number: 4640251-4Report Type:Expedited (15-DaCompany Report #13611
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Deficiency Anaemia		Bupropion	PS	Glaxosmithkline	
	Gastrointestinal		Prenatal Vitamins	C		
	Infection		Calcium	C		
	Polyhydramnios					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640252-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553608A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Wellbutrin	PS	Glaxosmithkline	ORAL	200MG Twice	
	Epistaxis						per day	
	Gastrointestinal		Plavix	SS				
	Haemorrhage		Aspirin	SS	Glaxosmithkline			

Date:04/20/05ISR Number: 4640254-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553794A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 YR
Hospitalization - Initial or Prolonged	Death		Effexor	C				
	Overdose							

Date:04/20/05ISR Number: 4640256-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554033A
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Post Procedural		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Haemorrhage		Klonopin	C				
			Nexium	C				
			Lasix	C	Glaxosmithkline			

Date:04/20/05ISR Number: 4640270-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0377668A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	39 DAY

	Joint Crepitation		Amitriptyline	C		ORAL
10MG per day						
			Ibuprofen	C	Glaxosmithkline	ORAL
200MG per day						

Date:04/20/05ISR Number: 4640273-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0378145A
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL
	Arthralgia					
	Blood Immunoglobulin E Increased					
	Pruritus					

Date:04/20/05ISR Number: 4640316-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530626A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia		Eskalith	PS	Glaxosmithkline	ORAL
6 WK						
	Hypotrichosis		Wellbutrin	SS	Glaxosmithkline	ORAL
300MG Per day 6 WK						
			Wellbutrin	SS	Glaxosmithkline	ORAL
100MG Four						
times per day 5 YR						
			Humibid	C		
			Robaxin	C		
			Ultram	C		
			Neurontin	C		
			Valium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4642083-XReport Type:Expedited (15-DaCompany Report #2005052957
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Self-Medication	Health Professional Company Representative	Geodon (Ziprasidone)	PS				
			Bupropion Hydrochloride (Bupropion Hydrochloride)	SS				
			Olanzapine/Fluoxetine Hydrochloride (Fluoxetine Hydrochloride, Olanzapine)	SS				
			Mirtazapine (Mirtazapine)	SS				
			Obetrol (Amfetamine Aspartate, Amfetamine Sulfate, Dexamethaosne Saccharate,	SS				

Date:04/21/05ISR Number: 4641477-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553582A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder Death Intentional Misuse		Wellbutrin	PS	Glaxosmithkline			

Date:04/21/05ISR Number: 4641498-3Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0370764A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pruritus Sleep Disorder Tooth Disorder Toothache		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG Unknown

Date:04/21/05ISR Number: 4642187-1Report Type:Direct Company Report #CTU 246814
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Wellbutrin Sr	PS				
	Morbid Thoughts							
	Nightmare							
	Pharmaceutical Product Complaint							

Date:04/21/05ISR Number: 4643116-7Report Type:Expedited (15-DaCompany Report #2005057334
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Consumer	Bextra (Valdecoxib)	PS		ORAL	20 MG, ORAL	
	Blood Pressure Increased		Dilantin (Phenytoin Sodium)	SS		ORAL	ORAL	
	Bronchospasm							
	Convulsion		Corticosteroids (Corticosteroids)	SS				
	Weight Increased							

Bupropion Hydrochloride (Bupropion Hydrochloride)	SS
Neurontin (Gabapentin)	SS
Etanercept (Etanercept)	C
Prednisone (Prednisone)	C
Vicodin (Hydrocodone Bitartrate, Paracetamol)	C
Cyclobenzaprine Hydrochloride (Cyclobenzaprine Hydrochloride)	C
Lansoprazole (Lansoprazole)	C

Date:04/22/05ISR Number: 4642369-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0545927A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Drug Reaction		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	
	Constipation		Wellbutrin	SS	Glaxosmithkline		150MG Per day	
	Diplopia		Duragesic	C				
	Dry Mouth		Effexor	C				
	Hallucination, Auditory		Valium	C				
	Hallucination, Visual		Vicodin	C				
	Pruritus		Neurontin	C				
	Somnolence		Avandia	C	Glaxosmithkline			
	Treatment Noncompliance							
	Vision Blurred							

Date:04/22/05ISR Number: 4642376-6Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0302490A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Anaemia	Zyban	PS	Glaxosmithkline
	Dizziness	Bricanyl	C	
	Eye Pain	Pulmicort	C	
	Facial Pain	Zyrlex	C	Glaxosmithkline
UNKNOWN				
	Headache			
	Leukopenia			
	Meningitis			
	Metrorrhagia			
	Nausea			
	Neutropenia			
	Palpitations			
	Paraesthesia			
	Photosensitivity Reaction			
	Pyrexia			
	White Blood Cell Count Decreased			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642380-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0369124A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	9 DAY
Initial or Prolonged	Dyspnoea Exertional		Vaccine	SS	Glaxosmithkline	SUBCUTANEOUS	2UNIT Single dose	1 DAY
	Hepatocellular Damage							
	Pitting Oedema		Lescol	C		ORAL	1UNIT per day	
	Transaminases Increased							
	Weight Increased							

Date:04/22/05ISR Number: 4643809-1Report Type:Direct Company Report #CTU 246932
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Bupropion	PS				
			Isosorbide Dinitrate	C				
			Gemfibrozil	C				
			Metoprolol Tartrate	C				
			Diltiazem (Inwood)	C				
			Irbesartan	C				
			Glyburide	C				
			Sertraline Hcl	C				
			Aspirin	C				
			Calcipotriene	C				
			Alprazolam	C				
			Meloxicam	C				
			Omeprazole	C				
			Salicylic Acid 2/Sulfur 2%	C				
			Atorvastatin Calcium	C				
			Hydrocortisone	C				
			Clobetasol Propionate	C				
			Albuterol	C				
			Coal Tar	C				
			Ipratropium Bromide	C				
			Acetaminophen	C				
			Metformin Hcl	C				

Date:04/22/05ISR Number: 4644497-0Report Type:Direct Company Report #CTU 246867
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Haematemesis		Wellbutrin Sr (Or Placebo)	PS	Glaxosmithkline		150 BID	
	Ulcer Haemorrhage		Bupropion Sr	C				
			Vicodin	C				
			Levothyroxine	C				
			Acetaminophen	C				
			Albuterol Inhaler	C				
			Diphenhydramine Hcl	C				
			Hydrochlorothiazide	C				
			Aspirin	C				
			Lisinopril	C				
			Simvastatin	C				
			Cyclobenzaprine Hcl	C				
			Trazodone	C				
			Felodipine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4644122-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554382A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Lexiva	PS	Glaxosmithkline	ORAL		
	Rash Erythematous		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Rash Generalised		Atazanavir	C				
	Rash Maculo-Papular		Ritonavir	C				
			Epzicom	C	Glaxosmithkline			
			Lipitor	C				
			Neurontin	C				
			Celexa	C				

Date:04/25/05ISR Number: 4644133-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0374776A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	8 WK
	Chest Discomfort							
	Dyspnoea		No Concurrent Medication	C				
	Hyperventilation							
	Paraesthesia							

Date:04/25/05ISR Number: 4644142-4Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0376835A
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Laryngeal Oedema		Zyntabac	PS	Glaxosmithkline	ORAL	300MG per day	19 DAY
	Rash							

Date:04/25/05ISR Number: 4644172-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0378887A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Aggression Anxiety Disturbance In Attention Drug Withdrawal Syndrome Dry Mouth Insomnia		Zyban	PS	Glaxosmithkline	ORAL

Date:04/25/05ISR Number: 4644738-XReport Type:Direct Company Report #CTU 247098
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion Muscle Spasms Paraesthesia		Bupropion	PS		ORAL	200MG QAM ORAL	

Date:04/25/05ISR Number: 4645859-8Report Type:Expedited (15-DaCompany Report #HQWYE023014APR05
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Mood Altered Psychotic Disorder Suicide Attempt	Consumer	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended					

			Release)	PS		ORAL	75 MG 1X PER 1 DAY, ORAL
			Wellbutrin - Slow Release (Amfebutamone Hydrochloride)	SS		ORAL	200 MG 2X PER 1 DAY, ORAL
			Remeron (Mirtazapine)	C			
			Metformin (Metformin)	C			
			Humulin 70/30 (Insulin Human Injection, Isophane/Insulin Human Zinc	C			
			Lescol (Fluvastatin Sodium)	C			
			Lisinopril (Lisinopril)	C			
			Seroquel (Quetiapine)	C			
			Valproate Semisodium (Valproate Semisodium)	C			

Date:04/25/05ISR Number: 4645914-2Report Type:Expedited (15-DaCompany Report #HQWYE017014APR05
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion Overdose	Health Professional Company Representative	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL	ORAL	
			Wellbutrin Xl (Bupropion Hydrochloride,)	SS		ORAL	ORAL	

Date:04/25/05ISR Number: 4646752-7Report Type:Direct Company Report #CTU 247099
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination, Visual Nightmare		Bupropion	150mg	PS		ORAL	150MG BID	

ORAL

Date:04/26/05ISR Number: 4645199-7Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0554466A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Hypospadias		Bupropion	PS	Glaxosmithkline		150MG Per day	
	Microtia		Synthroid	C	Glaxosmithkline		.137MG Per day	
			Domperidone	C			10MG Eight times per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4645200-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554507A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anger		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Three times per day	
	Asthenia							
	Depression							
	Drug Ineffective		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Three times per day	
	Irritability							
	Pathological Gambling							
	Suicidal Ideation							

Date:04/26/05ISR Number: 4645236-XReport Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0379013A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Malignant Respiratory Tract Neoplasm		Zyban	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Metastases To Lymph Nodes							
	Metastases To Skin							

Date:04/27/05ISR Number: 4646701-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553401A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fall		Wellbutrin	PS	Glaxosmithkline	ORAL	11 DAY	
	Grand Mal Convulsion		Effexor Xr	C		ORAL	300MG In the morning	
	Myalgia							
	Periorbital Haematoma		Remeron	C		ORAL	45MG At night	
			Premarin	C			UNKNOWN	.125MG

Unknown

Date:04/27/05ISR Number: 4646703-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554522A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
Initial or Prolonged	Dizziness		Paxil Cr	C	Glaxosmithkline			
	Migraine		Klonopin	C				
			Alcohol	C				

Date:04/27/05ISR Number: 4646704-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554814A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Screen False		Wellbutrin	PS	Glaxosmithkline	ORAL		
Initial or Prolonged	Positive		No Concurrent					
	Overdose		Medication	C				
	Rash							

Date:04/27/05ISR Number: 4646705-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554881A
Age:54 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Adverse Drug Reaction
Initial or Prolonged	Blister
	Malaise

	Musculoskeletal Stiffness Oedema Peripheral Skin Infection	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Toxic Epidermal Necrolysis		Wellbutrin	PS	Glaxosmithkline	ORAL	

Date:04/27/05ISR Number: 4646706-0Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0555062A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	47 DAY
	Deafness Unilateral Tinnitus		Topiramate	C			

Date:04/27/05ISR Number: 4647391-4Report Type:Direct Company Report #CTU 247266
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Other	Aggression Anxiety		Wellbutrin Xl 450 Mg Glaxosmithkline	PS	Glaxosmithkline	ORAL	450 MG DAILY
	Asthenia						ORAL
	Confusional State		Zoloft 75 Mg	SS		ORAL	75 MG DAILY
	Depression						ORAL
	Drug Effect Decreased Dysstasia Hyperhidrosis Tension Tremor						

Date:04/28/05ISR Number: 4647823-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0550641A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		446 DAY
Initial or Prolonged	Aura		Unknown	C				
Other	Grand Mal Convulsion							
	Tic							

Date:04/28/05ISR Number: 4650532-6Report Type:Expedited (15-DaCompany Report #2005UW6257
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Dystonia	Health	Seroquel	PS		ORAL	600 MG PO	
Intervention to		Professional	Seroquel	SS		ORAL	400 MG PO	
Prevent Permanent			Risperdal	SS			6 MG	
Impairment/Damage			Depakote	SS				
			Wellbutrin	SS				
			Strattera	SS				
			Trileptal "Ciba-Geigy"	SS				
			Trileptal "Ciba-Geigy"	SS				

DECREASING

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4650654-XReport Type:Direct Company Report #CTU 247385
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Bupropion Generic	PS			XL 150 MG BID	
	Crying		Lexapro	C				
	Drug Effect Decreased		Zoloft	C				
	Fatigue		Celexa	C				
	Therapeutic Response		Remeron	C				
	Unexpected With Drug Substitution							

Date:04/29/05ISR Number: 4649086-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554844A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchitis		Paxil	PS	Glaxosmithkline	ORAL	15MG Per day	
Initial or Prolonged	Conversion Disorder		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice	
	Multiple Sclerosis						per day	
	Tremor		Avonex	C				
			Ambien	C				
			Xanax	C				
			L-Thyroxine	C	Glaxosmithkline			
			Methadone	C	Glaxosmithkline			
			Baclofen	C				
			Neurotin	C				
			Lisinopril	C				
			Macrodantin	C				
			Gemfibrozil	C				
			Detrol La	C				
			Protonix	C				
			Zetia	C				
			Propoxyphene	C				
			Provigil	C				
			Keppra	C				

Date:04/29/05ISR Number: 4649088-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554853A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Compartment Syndrome		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Swelling		Geodon	C				

Date:04/29/05ISR Number: 4649091-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0555261A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		300MG per day	
			Lamotrigine	SS	Glaxosmithkline			
			Augmentin	C	Glaxosmithkline			
			Excedrin	C				
			Zyrtec	C	Glaxosmithkline			
			Multivitamin	C				
			Fibercon	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4649094-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0555404A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	UNKNOWN		
Life-Threatening	Overdose		Tylenol	SS	Glaxosmithkline	UNKNOWN		
Hospitalization - Initial or Prolonged			Alcohol	SS		UNKNOWN		

Date:04/29/05ISR Number: 4649128-1Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0378887A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL		
	Anxiety							
	Disturbance In Attention							
	Drug Withdrawal Syndrome							
	Dry Mouth							
	Headache							
	Insomnia							
	Tremor							

Date:04/29/05ISR Number: 4649130-XReport Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0378949A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Diplegia							
per day							13	DAY
	Hallucination		Alprazolam	C		UNKNOWN		
	Insomnia							
	Monoplegia							
	Panic Reaction							
	Paranoia							
	Rash							

Date:04/29/05ISR Number: 4650500-4Report Type:Expedited (15-DaCompany Report #2005-DE-01433GD
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Foreign Literature	Mirtazapine (Mirtazapine)	PS				
			Quetiapine (Quetiapine)	SS				
			Bupropion (Bupropion)	SS				
			Amitriptyline (Amitriptyline)	SS				
			Valproate (Valproic Acid)	C				

Date:05/02/05ISR Number: 4649640-5Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20050204345
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Poisoning		Fentanyl	PS				
UNKNOWN								
	Drug Toxicity		Citalopram	SS				
			Clonazepam	SS				
			Bupropion	SS				

				Alcohol	SS		

Date:05/02/05ISR Number: 4651622-4Report Type:Expedited (15-DaCompany Report #S05-USA-02072-01
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional	Lexapro (Escitalopram)	PS		ORAL	10 MG QD PO	
			Lexapro (Escitalopram)	SS		ORAL	5 MG QD PO	
			Wellbutrin Xl (Buproprion)	SS		ORAL	450 MG QD PO	
			Wellbutrin Xl (Buproprion)	SS		ORAL	400 MG QD PO	

Date:05/03/05ISR Number: 4650727-1Report Type:Expedited (15-DaCompany Report #US-2004-BP-09934BP
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral Platelet Count Decreased		Spiriva Handihaler	PS	B.I. Pharmaceuticals,Inc. /Ridgefield		RESPIRATORY (INHALATION)	1 MON
			Bextra	SS		ORAL		
			Wellbutrin	SS		ORAL		
			Foradil	SS			RESPIRATORY (INHALATION)	
			Prednisone	C		ORAL		
			Fosamax	C				
			Foltz (Folic Acid)	C		ORAL		
			Glucosamine	C		ORAL		
			Duoneb	C			RESPIRATORY	

(INHALATION)

Date:05/03/05ISR Number: 4652895-4Report Type:Expedited (15-DaCompany Report #B0378357A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Sinus Tachycardia	Foreign Literature Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	300 MG/ PER DAY / ORAL	
			Budesonide	C				

Date:05/04/05ISR Number: 4651808-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508446A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Convulsion Loss Of Consciousness Night Sweats		Wellbutrin Pepcid Vicodin Flexeril Nasonex Klonopin	PS C C C C C	Glaxosmithkline	ORAL	150MG Twice per day 1MG Twice per day	6 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/05ISR Number: 4651851-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0555664A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Congenital Eye Disorder		Wellbutrin Xl	PS	Glaxosmithkline			
	Drug Exposure During Pregnancy							

Date:05/04/05ISR Number: 4651852-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0555841A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Belligerence		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
	Emotional Disorder		Alcohol	SS				
	Feeling Abnormal		Remeron	C				
	Mental Status Changes		Klonopin	C				
	Screaming							

Date:05/04/05ISR Number: 4651853-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0555847A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephrolithiasis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/04/05ISR Number: 4651881-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0379081A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	3	WK
	Anorexia		No Concurrent					
	Depression		Medication	C				
	Emotional Disorder							
	Hypoaesthesia							
	Insomnia							
	Mania							

	Night Sweats					
	Paraesthesia					

Date:05/04/05ISR Number: 4653998-0Report Type:Expedited (15-DaCompany Report #10953
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Psychosis	Literature	Midazolam	PS			7.5 MG	NOCTE
	Heart Rate Decreased	Health	Bupropion	SS			150 MG	
	Intentional Misuse	Professional						
	Irritability							
	Multiple Drug Overdose							
	Paranoia							
	Persecutory Delusion							
	Psychomotor Agitation							
	Somnolence							
	Suicide Attempt							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/05ISR Number: 4654649-1Report Type:Direct Company Report #CTU 247789
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Erythema Swelling Face Urticaria		Wellbutrin	PS				

Date:05/04/05ISR Number: 4654674-0Report Type:Direct Company Report #CTU 247796
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Increased		Wellbutrin Xl	300	PS		PARENTERAL	300 MG	QAM
	Medication Error						PARENTERAL		
	Multiple Drug Overdose								

Date:05/05/05ISR Number: 4653447-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548370A
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
Life-Threatening	Convulsion		No Concurrent					
Other	Overdose		Medication	C				
	Respiratory Arrest							
	Vomiting							

Date:05/05/05ISR Number: 4653450-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553385A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Unknown	
	Cyanosis		No Concurrent					

	Grand Mal Convulsion		Medication	C		
	Muscle Twitching					

Date:05/05/05ISR Number: 4653451-4Report Type:Expedited (15-DaCompany Report #HQWYE150815MAR05
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Crying		Wellbutrin	PS	Glaxosmithkline	ORAL
	Drug Withdrawal Syndrome		Effexor Xr	SS		ORAL
	Suicidal Ideation		Ativan	SS		
UNKNOWN						
	Suicide Attempt					
	Vomiting					

Date:05/05/05ISR Number: 4653453-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0556329A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pituitary Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL
			Topamax	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4653484-8Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0045843A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coordination Abnormal		Zyban	PS	Glaxosmithkline	ORAL	9	DAY
Initial or Prolonged	Drug Interaction		Saroten Retard	SS	Glaxosmithkline	ORAL	350MG	per day
	Muscle Twitching		Pantozol	C		ORAL	40MG	per day
			Remergil	C		ORAL	45MG	per day
			Seroquel	C		ORAL	300MG	per day
			Paracetamol	C	Glaxosmithkline	ORAL	300MG	per day 2 DAY

Date:05/06/05ISR Number: 4654850-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522799A
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Amoxicillin	PS	Glaxosmithkline	ORAL	1TSP	Three
	Drug Ineffective						times per day	1 DAY
	Nausea		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Paxil	SS	Glaxosmithkline	ORAL		
			Nexium	C				
			Lithium	C	Glaxosmithkline			
			Synthroid	C	Glaxosmithkline			
			Toprol	C				

Date:05/06/05ISR Number: 4655170-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0536358A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Paxil	PS	Glaxosmithkline	ORAL	10MG Per day	

	Chest Pain		Wellbutrin	SS	Glaxosmithkline	ORAL
150MG Per day 19 DAY						
	Depression					
	Drug Withdrawal Syndrome					
	Irritability					
	Pain In Extremity					
	Suicidal Ideation					

Date:05/06/05ISR Number: 4655171-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551303A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Deafness Neurosensory		Wellbutrin Sr	PS	Glaxosmithkline	ORAL
	Drug Administration Error		Premarin	C		
	Meniere'S Disease		Maxalt	C		
	Otosclerosis		Flexeril	C		
	Tinnitus		Temazepam	C		
	Vertigo					

Date:05/06/05ISR Number: 4655188-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557107A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Flight Of Ideas		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 0 DAY						
	Hallucination, Auditory		Zoloft	C		
	Pharmaceutical Product		Prozac	C		
	Complaint					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4655240-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0379751A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Zyban	PS	Glaxosmithkline	UNKNOWN	150MG Twice	
	Dysarthria							
per day	17 DAY							
	Headache		Nicotine	C	Glaxosmithkline	TRANSDERMAL	15MG Per day	
	Somnolence		Zopiclone	C		UNKNOWN		
			Aspirin	C	Glaxosmithkline	UNKNOWN	75MG Per day	
			Atenolol	C		UNKNOWN	25MG Per day	
			Glyceryl Trinitrate	C	Glaxosmithkline			
			Clarithromycin	C		UNKNOWN	500MG Per day	
			Erythromycin	C	Glaxosmithkline	UNKNOWN		

Date:05/06/05ISR Number: 4655834-5Report Type:Direct Company Report #CTU 247969
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache		Zyban 150 Mg	PS		ORAL	1 PO BID	

Date:05/09/05ISR Number: 4657533-2Report Type:Direct Company Report #CTU 248037
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Bupropion Hcl 150 Mg	PS		ORAL	150 MG BID	
	Urticaria							
ORAL								

Date:05/09/05ISR Number: 4658739-9Report Type:Direct Company Report #USP 57126
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dispensing Error		Wellbutrinxl150	PS	Glaxo Smithkline	TABLET		
	Medication Error							

Date:05/09/05ISR Number: 4659042-3Report Type:Expedited (15-DaCompany Report #A0555406A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Study	Lexiva					
	Balance Disorder	Health	(Fosamprenavir)	PS		ORAL	700 MG/TWICE	
	Depressed Mood	Professional					PER DAY/ORAL	
	Dizziness	Other	Epzicom					
	Drug Interaction		(Abacavir So4 +					
	Headache		Lamivudine)	SS		ORAL	1 TABLET/PER	
	Insomnia						DAY/ORAL	
	Irritability		Ritonavir Capsule					
	Photophobia		(Ritonavir)	SS		ORAL	100/TWICE	
	Tremor						PER DAY/ORAL	
			Wellbutrin					
			(Bupropion					
			Hydrochloride)	SS		ORAL	450 MG/PER	
							DAY/ORAL	
			Loperamide					
			Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4657955-XReport Type:Expedited (15-DaCompany Report #2005UW06747
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Seroquel	PS	Zeneca Pharmaceutical	ORAL		
			Wellbutrin Sr Tablet Controlled Release	I				
			Cogentin	I				
			Trazodone	I				
			Klonopin	I				
			Trilafon	I				

Date:05/10/05ISR Number: 4658431-0Report Type:Direct Company Report #CTU 248090
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Therapeutic Response Unexpected With Drug Substitution		Wellbutrin Sr 100 Mg Po Bid (Brand Name Only)	PS		ORAL	100 MG PO BID	

Date:05/10/05ISR Number: 4659314-2Report Type:Expedited (15-DaCompany Report #B0307360A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Stem Infarction	Foreign	Zyban Tablet-Zyban					
	Dysphagia	Literature	(Bupropion					
Other	Eyelid Ptosis	Health	Hydrochloride)	PS		ORAL	150 MG PER DAY ORAL	
	Headache	Professional						
	Hiccups							
	Nausea							
	Neutrophil Count Increased							
	Photosensitivity Reaction							
	Pupils Unequal							
	Vomiting							
	Wallenberg Syndrome							

	White Blood Cell Count Increased					

Date:05/11/05ISR Number: 4658469-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0369124A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	9 DAY
Initial or Prolonged	Dyspnoea Exertional		Vaccine	SS	Glaxosmithkline	SUBCUTANEOUS	2UNIT Single dose	1 DAY
	Hepatocellular Damage							
	Pitting Oedema		Lescol	C		ORAL	1UNIT per day	
	Transaminases Increased		Dhea	C				
	Weight Increased							

Date:05/11/05ISR Number: 4658470-XReport Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0375449A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Dependence		Zyban	PS	Glaxosmithkline	UNKNOWN	150MG Twice per day	
	No Adverse Effect							
			Waran	C	Glaxosmithkline			

			Spiriva	C		
			Simvastatin	C		
			Kalcipos-D	C		
			Zomig	C		
			Oxis	C		
			Pulmicort	C		
			Fosamax	C		

Date:05/11/05ISR Number: 4658479-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0380219A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxosmithkline	ORAL		
	Angina Pectoris							

Date:05/11/05ISR Number: 4658480-2Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0380229A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension		Bupropion Hydrochloride	PS	Glaxosmithkline			
	Micturition Disorder						UNKNOWN	150MG Per day 18 DAY
	Vision Blurred		Insulin Actrapid	C				
			Metoprolol	C				
			Omeprazole	C	Glaxosmithkline		20MG per day	
			Metformin Hydrochloride	C			500MG Twice per day	
			Calcium Carbaspirin	C			100MG per day	
			Oxazepam	C			10MG per day	
			Simvastatin	C				
			Aspirin	C	Glaxosmithkline			

Date:05/11/05ISR Number: 4659009-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0556917A
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	900MG Single dose	2 HR
	Convulsion							
	Fatigue		No Concurrent Medication	C				
	Heart Rate Increased							
	Hypoaesthesia							
	Overdose							
	Posture Abnormal							
	Self-Medication							

Date:05/11/05ISR Number: 4659010-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0556946A
Age:4 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Delirium		Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Hallucination							
	Overdose							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4659013-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557105A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL		
Life-Threatening	Overdose							
Other								

Date:05/11/05ISR Number: 4659027-7Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0379971A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Zyban	PS	Glaxosmithkline			
UNKNOWN	Vision Blurred						150MG Twice	per day
			Insulin	C			UNKNOWN	
			Atorvastatin	C			UNKNOWN	

Date:05/11/05ISR Number: 4659497-4Report Type:Expedited (15-DaCompany Report #2005AP000329
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Foreign	Apo-Citalopram					
	Asthma	Consumer						
	Drug Hypersensitivity	Health	(Citalopram					
	Pyrexia	Professional	Hydrobromide)	PS		ORAL	60 MG; QD; PO	1 YR
		Distributor	Buspar					
		Other	(Buspirone					
			Hydrochloride)	SS		ORAL	10 MG; TID;	
							PO	2 YR
			Wellbutrin					
			(Bupropion					
			Hydrochloride)	SS				
			Avalox					

(Moxifloxacin
Hydrochloride) SS

Date:05/11/05ISR Number: 4660966-1Report Type:Expedited (15-DaCompany Report #KII-2005-0016466
Age:65 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Alanine Aminotransferase
Hospitalization -	Increased
Initial or Prolonged	Aspartate
Other	Aminotransferase
	Increased
	Blood Alkaline
	Phosphatase Increased
	Blood Creatine
	Phosphokinase Increased
	Blood Creatinine
	Increased
	Blood Ph Decreased
	Blood Pressure
	Fluctuation
	Blood Urea Increased
	Bradycardia
	Cardio-Respiratory Arrest
	Confusional State
	Electromechanical

	Dissociation						
	Haemodynamic Instability						
	Hypoxia						
	Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myoclonus	Study	Hydromorphone Hcl	PS		ORAL	ORAL
	Pneumonia	Health	Bupropion				
	Sinus Tachycardia	Professional					
	Vomiting	Other	(Amfebutamone)	SS		ORAL	ORAL
			Citalorpam (Citalorpam)	SS		ORAL	ORAL
			Trazodone (Trazodone)	SS		ORAL	ORAL
			Norvasc (Amlodipine Besilate)	SS		ORAL	ORAL
			Neurontin (Gabapentin)	SS		ORAL	ORAL
			Propranolol	SS		ORAL	ORAL
			Methocarbamol (Methocarbamol)	SS		ORAL	ORAL
			Herbal Preparation	SS		ORAL	ORAL
			Benzodiazepine Derivatives	SS			

Date:05/12/05ISR Number: 4660417-7Report Type:Expedited (15-DaCompany Report #2005/03/0457
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day 3 MON
	Homicidal Ideation		Peg-Intron	SS			INTRAVENOUS
	Mood Altered		Rebetol	SS		ORAL	
	Paranoia		Vicodin	C		ORAL	
			Ziac	C		ORAL	

Date:05/12/05ISR Number: 4660419-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554027A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Aura		Birth Control Pills	C				
	Convulsion							

Date:05/12/05ISR Number: 4660420-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554033A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Post Procedural		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Haemorrhage		Klonopin	C				
			Nexium	C				
			Lasix	C	Glaxosmithkline			

Date:05/12/05ISR Number: 4660428-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557266A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Overdose		Effexor	C				
			Valium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/05ISR Number: 4660429-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557281A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Choking		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 DAY
Hospitalization - Initial or Prolonged	Convulsion		No Concurrent Medication	C				

Date:05/12/05ISR Number: 4660430-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557283A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	16	DAY
	Convulsion		Dilantin	C				
	Head Injury							

Date:05/12/05ISR Number: 4660432-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557413A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ventricular Arrhythmia		Lamictal	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:05/12/05ISR Number: 4661722-0Report Type:Direct Company Report #CTU 248344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Generic Wellbutrin 200 Mg Bid	PS		ORAL	WELLBUTRIN GENERIC	200 MG PO BID
	Condition Aggravated							
	Headache							
	Insomnia							
	Therapeutic Response							

	Decreased					

Date:05/12/05ISR Number: 4661779-7Report Type:Direct Company Report #CTU 248341
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache		Buproprion 150 Mg					
	Migraine		Bid Po	PS		ORAL	150 MG PO BID	
	Pharmaceutical Product							
	Complaint							

Date:05/13/05ISR Number: 4661403-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548217A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	474 DAY	
	Grand Mal Convulsion		Alcohol	C				
	Incontinence							
	Tongue Biting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661408-2Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0554466A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Hypospadias		Wellbutrin	PS	Glaxosmithkline		150MG Per day	
	Microtia		Synthroid	C	Glaxosmithkline		.137MG Per day	
			Domperidone	C			10MG Eight times per day	

Date:05/13/05ISR Number: 4661415-XReport Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0557615A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
	Back Pain							
	Hypoaesthesia							

Date:05/13/05ISR Number: 4661417-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557786A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Convulsion		Alcohol	C				
	Intentional Self-Injury							

Date:05/13/05ISR Number: 4661454-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0379324A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Zyban	PS	Glaxosmithkline	ORAL		

Initial or Prolonged	Mood Altered					
	Rash					

Date:05/13/05ISR Number: 4661457-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0380052A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	27 DAY
	Depressed Mood		Niquitin Cq	C	Glaxosmithkline	TRANSDERMAL		
	Insomnia							
	Suicidal Ideation							

Date:05/13/05ISR Number: 4661458-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0380140A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Zyban	PS	Glaxosmithkline	UNKNOWN		
	Depression							
	Psychiatric Symptom							
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661459-8Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0380489A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cold Sweat		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
	Dizziness		No Concurrent					
	Dry Mouth		Medication	C				
	Gait Disturbance							
	Hallucination, Auditory							
	Hallucination, Visual							
	Insomnia							
	Malaise							
	Tremor							

Date:05/13/05ISR Number: 4662497-1Report Type:Direct Company Report #CTU 248490
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Diabetes Mellitus		Risperdol 2 Mg.	PS		ORAL	2 MG. B.I.D.	ORAL
	Non-Insulin-Dependent							
			Wellbutrin	SS				
			Depakote	C				
			Adderal	C				
			Paxil	C				

Date:05/13/05ISR Number: 4662499-5Report Type:Direct Company Report #CTU 248475
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Buproprion (Budeprion) 150 Mg Sr Unk	PS		ORAL	1 PER DAY	
	Arthralgia							
	Drug Ineffective							
	Fatigue						ORAL	
	Feeling Cold							
	Fluid Retention							

Headache
Pain In Extremity
Speech Disorder
Vision Blurred
Weight Increased

Date:05/13/05ISR Number: 4663159-7Report Type:Expedited (15-DaCompany Report #S05-USA-02393-01
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Discomfort	Health Professional	Lexapro (Escitalopram)	PS		ORAL	20 MG QD PO	
	Fatigue Hypoaesthesia		Lexapro (Escitalopram)	SS		ORAL	10 MG QD PO	
	Joint Contracture Paraesthesia Suicide Attempt Tremor		Wellbutrin (Bupropion Hydrochloride)	SS				
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	900 MG ONCE PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/05ISR Number: 4662672-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508446A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 MON
Other	Convulsion							
	Loss Of Consciousness		Pepcid	C				
	Night Sweats		Vicodin	C				
			Flexeril	C				
			Nasonex	C				
			Klonopin	C			1MG Twice per day	

Date:05/16/05ISR Number: 4662680-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554507A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL	150MG Three times per day	
	Anger							
	Asthenia							
	Depression		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Three times per day	
	Disturbance In Attention							
	Drug Ineffective		Clonazepam	C			UNKNOWN	
	Irritability		Neurontin	C			UNKNOWN	600MG Five times per day
	Mood Swings							
	Pathological Gambling		Atenolol	C			UNKNOWN	
	Sleep Disorder		Trazodone	C			UNKNOWN	50MG At night
	Suicidal Ideation							

Date:05/16/05ISR Number: 4662685-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557263A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colectomy Partial		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three	
Initial or Prolonged	Coronary Artery Surgery						times per day	
	Diarrhoea		Paxil	SS	Glaxosmithkline	ORAL	3	MON
	Diverticulitis		Atenolol	C				
	Drug Ineffective		Prevacid	C				
	Myocardial Infarction		Lotrel	C				
	Pneumonia		Lipitor	C				

Date:05/16/05ISR Number: 4662690-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557567A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Depression		Seroquel	C				
	Drug Ineffective		Paxil Cr	C	Glaxosmithkline			
	Paranoia		Yasmin	C				
	Suicidal Ideation		Multivitamin	C				

Date:05/16/05ISR Number: 4662694-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557761A
Age: Gender:Female I/FU:I

Outcome	PT
Disability	Drug Ineffective
	Pruritus
	Rash

		Tremor					
		Urticaria					
		Urticaria Generalised	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Lamictal	PS	Glaxosmithkline	ORAL
4	YR						
				Wellbutrin	SS	Glaxosmithkline	ORAL
2	WK						
				Lexapro	C		
				Naproxen	C		

Date:05/16/05ISR Number: 4663871-XReport Type:Expedited (15-DaCompany Report #2005069676
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Coma	Health	Geodon (Ziprasidone)	PS		
80 MG (80 MG,						
Initial or Prolonged	Fatigue	Professional				
1 IN 1 D)						
Other	Hemiplegia		Sudafed			
	Loss Of Consciousness		(Pseudoephedrine			
	Metabolic Encephalopathy		Hydrochloride)(Pseud			
	Nasopharyngitis		oephedrine)	SS		
	Pneumonia Aspiration		Metformin			
	Unresponsive To Pain		(Metformin)	SS		
	Stimuli		Bupropion			
	Vomiting		Hydrochloride			
			(Bupropion			
			Hydrochloride)	SS		
			Olanzapine			
			(Olanzapine)	C		
			Morphine (Morphine)	C		

Date:05/16/05ISR Number: 4664358-0Report Type:Direct Company Report #CTU 248728
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Malaise		Buproprion Sr 200 Mg			
	Pharmaceutical Product		Global	PS	Global	
200 MG QD PO						
	Complaint		Humulog U100	C		

	Vomiting Projectile		Cozaar	C			
			Digoxin	C			
			Plavix	C			
			Ms Contin	C			
			Relafen	C			
			Bumex	C			
			Verapamil	C			
			Clonazepam	C			

Date:05/16/05ISR Number: 4664544-XReport Type:Direct Company Report #CTU 248692
Age:12 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Generic Wellbutrin	PS				
	Pharmaceutical Product Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/05ISR Number: 4663498-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0552663A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
	Fatigue		Eskalith	C	Glaxosmithkline		450MG Twice per day	
	Tongue Biting							
			Seroquel	C			25MG At night	
			Ambien	C			10MG At night	
			Prevacid	C			30MG Unknown	
			Allegra	C			180MG Unknown	
			Synthroid	C	Glaxosmithkline		.025MG Unknown	
			Tricor	C			145MG At night	

Date:05/17/05ISR Number: 4663539-XReport Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0380426A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Allergic		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	16 DAY
	Oedema Peripheral							
	Periorbital Oedema							

Date:05/17/05ISR Number: 4666432-1Report Type:Expedited (15-DaCompany Report #S05-USA-00523-01
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Sinusitis

Initial or Prolonged	Anaemia Of Chronic Disease
	Asthenia
	Back Pain
	Bacterial Sepsis
	Blood Glucose Increased
	Catheter Sepsis
	Chest Pain
	Chest Wall Pain
	Clostridium Colitis
	Coma
	Confusional State
	Depression
	Disease Recurrence
	Drug Interaction
	Electrolyte Imbalance
	Fall
	Fluid Overload
	Hypercapnia
	Hyperkalaemia
	Hypotension
	Hypoxia
	Metabolic Acidosis
	Musculoskeletal Discomfort
	Neuropathy
	Pneumonia Bacterial
	Pulmonary Hypertension
	Renal Failure Acute
	Respiratory Failure
	Staphylococcal Infection

		Stenotrophomonas Infection Syncope Tremor Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Lexapro (Escitalopram)	PS		ORAL
20 MG QD PO							
				Lexapro (Escitalopram)	SS		ORAL
30 MG QD PO							
				Lexapro (Escitalopram)	SS		ORAL
10 MG QD PO							
				Lexapro (Escitalopram)	SS		ORAL
20 MG QD PO							
				Lexapro (Escitalopram)	SS		ORAL
30 MG QD PO							
				Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
300 MG QD PO							
				Wellbutrin (Bupropion Hydrochloride)	SS		
150 MG BID							
				Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
300 MG QD PO							
				Wellbutrin (Bupropion Hydrochloride)	SS		ORAL
150 MG QD PO							
				Atenolol	C		
				Potassium	C		
				Zocor	C		
				Enteric Coated Aspirin	C		
				Nexium(Esomeprazole)	C		
				Aricept(Donepezil Hydrochloride)	C		
				Duragesic(Fentanyl)	C		
				Hydrocodone	C		
				Centrum Silver	C		
				Magnesium	C		

Vitamin B12	C
Diazepam	C
Altace(Ramipril)	C
Demadex(Torasemide)	C
Skelaxin(Metaxalone)	C
Isordil(Isosorside Dinitrate)	C
Glucophage (Metformin)	C
Acetazolamide	C
Xalatan (Latanoprost)	C
Oxycontin(Oxycodone Hydrochloride)	C
Miconazole	C
Humulin	C
Astelin(Azelastine Hydrochloride)	C
Meclizine	C
Norvasc(Amlodipine Besilate)	C
Rocephin(Ceftriaxone Sodium)	C
Tobramycin	C

Hydralazine	C
Protonix	C
Valium (Diazepam)	C
Lorcet Plus	C
Diamox (Acetazolamide)	C
Avandia (Rosilglitazone Maleate)	C
Nitrol (Glyceryl Trinitrate)	C

Date:05/18/05ISR Number: 4664550-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548149A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Contusion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Grand Mal Convulsion							
	Laceration							

Date:05/18/05ISR Number: 4664570-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558980A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL	2	DAY
Life-Threatening	Status Epilepticus							
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:05/18/05ISR Number: 4664588-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0380740A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Analgesic Effect		Zyban	PS	Glaxosmithkline	ORAL
300MG per day						
	Drug Abuser		Imiject	SS	Glaxosmithkline	
SUBCUTANEOUS 4INJ per day						
	Therapeutic Response Unexpected					

Date:05/18/05ISR Number: 4664606-7Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0381313A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Coordination Abnormal		Zyban	PS	Glaxosmithkline	ORAL
1TAB Twice						
	Depressed Level Of					
per day 4 DAY						
	Consciousness Impaired Driving Ability		No Concurrent Medication	C		

Date:05/18/05ISR Number: 4664610-9Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0381415A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Overdose		Zyban	PS	Glaxosmithkline	ORAL
	Suicidal Ideation		Mogadon	C		
UNKNOWN						
	Suicide Attempt					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4665271-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01221
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Wellbutrin Sr	SS		ORAL		4 YR
	Hypotension		Wellbutrin Sr	SS		ORAL		
			Norvasc	C				UNKNOWN
			Dyrenium	C				UNKNOWN
			Clonazepam	C				UNKNOWN
			Levoxyl	C				UNKNOWN
			Macrobid	C				UNKNOWN
			Prevacid	C				UNKNOWN

Date:05/18/05ISR Number: 4665403-9Report Type:Direct Company Report #CTU 248958
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Cephalexin 250 Mg					
Other	Diarrhoea		Capsules (Teva)	PS	Teva	ORAL	250 MG Q ID	
	Headache							PO [ONLY 2
	Heart Rate Increased							DOSES]
	Muscle Spasms		Bupropion Sr 150 Mg					
	Oral Intake Reduced		Tablet (Watson)	SS	Watson	ORAL	150 MG DAILY	
	Respiratory Rate							PO
	Increased							[DISCHARGED
	Tremor							ON IT]
	Vision Blurred							

Date:05/18/05ISR Number: 4666447-3Report Type:Expedited (15-DaCompany Report #S05-USA-01759-01
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diplopia Drug Interaction Nausea Vertigo Viith Nerve Paralysis Vomiting	Health Professional Company Representative	Lexapro (Escitalopram) Wellbutrin (Bupropion Hydrochloride)	PS SS		ORAL	40 MG QD PO 150 MG QD	

Date:05/18/05ISR Number: 4668506-8Report Type:Expedited (15-DaCompany Report #B0379971A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Palpitations	Foreign Consumer	Zyban Tablet-Zyban (Bupropion Hydrochloride) Insulin Atorvastatin Calcium	PS C C			150 MG/TWICE PER DAY	

Date:05/18/05ISR Number: 4668645-1Report Type:Expedited (15-DaCompany Report #A0556337A
Age:32 YR Gender:Female I/FU:I

Outcome	PT
Other	Condition Aggravated Dizziness Drug Withdrawal Syndrome

		Heart Rate Increased Hyperhidrosis Night Sweats	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Paraesthesia Psoriasis	Consumer	Paxil Cr Tablet-Controlled Release (Paroxetine Hydrochloride)	PS		ORAL
25 MG/ PER							
ORAL/ ORAL							
				Bupropion Hydrochloride Tablet (Bupropion Hydrochloride)	SS		ORAL
300 MG/ ORAL							

Date:05/18/05ISR Number: 4668665-7Report Type:Expedited (15-DaCompany Report #A0553988A
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Overdose Vomiting	Health Professional	Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	PS		ORAL
Required Intervention to Prevent Permanent Impairment/Damage		Company Representative				
300 MG/ ORAL						

Date:05/18/05ISR Number: 4668666-9Report Type:Expedited (15-DaCompany Report #A0549034A
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Rectal Haemorrhage Rectal Polyp Stool Analysis Abnormal	Health Professional	Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	PS		ORAL
PER DAY/ ORAL						
			Sertraline Hydrochloride	C		
			Thyroxine Sodium	C		

			Lovastatin	C		
			Quinapril Hydrochloride	C		
			Oestradiol	C		
			Multivitamin	C		

Date:05/19/05ISR Number: 4666079-7Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20050307425
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Valtrex	PS	Glaxosmithkline	ORAL		
	Throat Tightness		Wellbutrin	SS	Glaxosmithkline	ORAL		
			Tylenol Cold + Flu	SS		ORAL		

Date:05/19/05ISR Number: 4666103-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0381009A
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anxiety
	Dry Mouth
	Ill-Defined Disorder
	Logorrhoea

		Psychomotor Hyperactivity					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Zyban	PS	Glaxosmithkline	ORAL
150MG Twice							
per day							
				Marvelon	C		
UNKNOWN							
				Salbutamol	C	Glaxosmithkline	
UNKNOWN	200MCG	As					
required							
				Beclometasone	C	Glaxosmithkline	
UNKNOWN	200MCG	Twice					
per day							

Date:05/19/05ISR Number: 4666108-0Report Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0381417A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Erythema		Zyban	PS	Glaxosmithkline	
Other	Systemic Lupus Erythematosus		Spiriva	SS		

Date:05/20/05ISR Number: 4667745-XReport Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0557615A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Angina Pectoris		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day						
	Back Pain					
	Hypoaesthesia					

Date:05/20/05ISR Number: 4667750-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558376A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
	Overdose		Crack Cocaine	C				
	Stress		Valium	C				

Date:05/20/05ISR Number: 4667752-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558525A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
	Feeling Abnormal							
	Suicidal Ideation							

Date:05/20/05ISR Number: 4667753-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558531A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Head Injury		No Concurrent					
	Skull Fracture		Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4667754-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558535A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	30 MON
	Dyspnoea		Trazodone	C				
	Hallucination							
	Nausea							
	Overdose							
	Tremor							
	Vomiting							

Date:05/20/05ISR Number: 4667756-4Report Type:Expedited (15-DaCompany Report #BPC-SR-033
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Drug Exposure During		Bupropion	PS	Glaxosmithkline		150MG Per day	
	Pregnancy							
	Failure To Thrive							
	Laryngomalacia							
	Stridor							

Date:05/20/05ISR Number: 4667757-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558836A
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Overdose		Wellbutrin	PS	Glaxosmithkline	ORAL	1	DAY
Initial or Prolonged	Suicide Attempt		Provigil	SS		ORAL		
	Tachycardia		Ambien	SS		ORAL	60MG Single	
	Vomiting							
dose							1	DAY

Date:05/20/05ISR Number: 4667790-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0381597A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	8	DAY
Initial or Prolonged	Migraine		Inderal	C			UNKNOWN	40MG Per day
	Mydriasis							
	Sensory Loss							

Date:05/23/05ISR Number: 4668948-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0555404A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	150MG Per day
Life-Threatening	Cough		Tylenol	SS	Glaxosmithkline		UNKNOWN	
Hospitalization -	Diarrhoea		Alcohol	SS			UNKNOWN	
Initial or Prolonged	Dyspnoea		Nexium	C				
Disability	Headache		Celebrex	C				
	Hepatic Failure		Lipitor	C				
	Insomnia							
	Metabolic Acidosis							
	Overdose							
	Pneumonia							
	Pneumonia Aspiration							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/05ISR Number: 4670055-8Report Type:Expedited (15-DaCompany Report #IMP_0854_2005
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Literature	Bupropion Sr	PS		ORAL	100 MG DAILY	
	Condition Aggravated	Health					PO	
	Depression	Professional	Bupropion Sr	SS		ORAL	100 MG QAM PO	
	Dizziness		Bupropion Sr	SS		ORAL	200 MG BID PO	
	Inappropriate		Bupropion Sr	SS		ORAL	100 MG QAM PO	
	Antidiuretic Hormone		Divalproex Sodium	SS				
	Secretion		Oxycarbazepine	SS		ORAL	900 MG QDAY	
	Irritable Bowel Syndrome						PO	
	Orthostatic Hypotension							
	Tremor							

Date:05/23/05ISR Number: 4670060-1Report Type:Expedited (15-DaCompany Report #IMP_0847_2005
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Bupropion	PS		ORAL	1 TAB QDAY PO	
	Crying							
	Feeling Abnormal							
	Paranoia							
	Pharmaceutical Product Complaint							
	Suicidal Ideation							

Date:05/23/05ISR Number: 4673228-3Report Type:Direct Company Report #CTU 249268
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Dyspnoea		Wellbutrin	PS		
150 MG ONCE A DAY	Heart Rate Increased					

Date:05/23/05ISR Number: 4673284-2Report Type:Direct Company Report #CTU 249294
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Palpitations		Bupropion Sr	PS		ORAL	150MG PO BID	
			Rocephin	C				
			Prednisone	C				
			Zithromax	C				
			Lovenox	C				
			Nicotine Patch	C				
			Combivent	C				
			Insulin	C				

Date:05/23/05ISR Number: 4673736-5Report Type:Expedited (15-DaCompany Report #S05-USA-01454-01
Age:27 YR Gender:Female I/FU:F

Outcome	PT
Other	Convulsion
	Depressed Level Of Consciousness
	Disorientation
	Fall
	Head Injury
	Hypersomnia

		Tongue Biting Tremor					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Lexapro (Escitalopram)	PS		ORAL
30 MG QD PO							
			Company Representative	Welbutrin (Bupropion Hydrochloride)	SS		
300 MG QAM							
				Lexapro (Escitalopram)	SS		ORAL
20 MG QD PO							

Date:05/24/05ISR Number: 4672555-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0541125A
Age:83 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Dispensing Error		Wellbutrin	PS	Glaxosmithkline	ORAL
100MG Twice		Drug Ineffective					
per day	2 WK						
		Hallucination		Lithium	C	Glaxosmithkline	
		Medication Error		Ativan	C		
		Paranoia					
		Pharmaceutical Product Complaint					

Date:05/24/05ISR Number: 4672564-4Report Type:Expedited (15-DaCompany Report #S05-USA-02393-01
Age:18 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
Initial or Prolonged		Discomfort		Lexapro	SS		ORAL
20MG Per day	15 DAY						
		Fatigue					
		Hypoaesthesia					
		Ill-Defined Disorder					
		Intentional Misuse					
		Muscle Contractions Involuntary					

	Paraesthesia					
	Tremor					

Date:05/24/05ISR Number: 4672566-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558989A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Depression						per day	2 YR
	Dysphagia		Unknown Medication	C				
	Oesophageal Carcinoma		Respiradol	C				

Date:05/24/05ISR Number: 4672568-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559383A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	
	Depression		Eskalith Cr	C	Glaxosmithkline	ORAL	450MG Twice	
	Dyskinesia						per day	
	Feeling Abnormal		Sleeping Pill	C				
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/05ISR Number: 4672575-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559750A
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anger		Eskalith	PS	Glaxosmithkline	ORAL	450MG Twice	
Hospitalization -	Crying							
per day							3	WK
Initial or Prolonged	Depression		Paxil	SS	Glaxosmithkline	ORAL	20MG Per day	9 YR
Disability	Poisoning		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	2 WK
Other	Psychotic Disorder		Seroquel	SS			UNKNOWN	
	Suicide Attempt		Risperdal	C				
			Klonopin	C				

Date:05/24/05ISR Number: 4672599-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0380967A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Disorientation		Zyban	PS	Glaxosmithkline	ORAL		
Initial or Prolonged	Fall							
	Malaise							
	Pneumonia							
	Sleep Disorder							

Date:05/24/05ISR Number: 4672600-5Report Type:Expedited (15-DaCompany Report #CH-GLAXOSMITHKLINE-B0381417A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cutaneous Lupus		Zyban	PS	Glaxosmithkline			
Other	Erythematosus		Spiriva	SS				
	Erythema							

Date:05/24/05ISR Number: 4674327-2Report Type:Expedited (15-DaCompany Report #US-2005-003875
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delusion	Consumer	Betaseron(Interferon Beta - 1b) Injection, 250ug	PS		SUBCUTANEOUS	SUBCUTANEOUS	
			Wellbutrin (Bupropion Hydrochloride)	SS				

Date:05/24/05ISR Number: 4674399-5Report Type:Expedited (15-DaCompany Report #US-2005-003875
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delusion	Consumer	Betaseron (Interferon Beta-1b) Injection, 250 Ug	PS		SUBCUTANEOUS	SUBCUTANEOUS	
			Wellbutrin (Bupropion Hydrochloride)	SS				

Date:05/25/05ISR Number: 4673418-XReport Type:Expedited (15-DaCompany Report #13611
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deficiency Anaemia		Bupropion	PS	Glaxosmithkline			
	Gastrointestinal		Prenatal Vitamins	C				
	Infection		Calcium	C				
	Polyhydramnios							

Date:05/25/05ISR Number: 4673421-XReport Type:Expedited (15-DaCompany Report #MCN # S05-USA-01759-01
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diplopia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
Initial or Prolonged	Drug Interaction		Lexapro	SS		ORAL	40MG Per day	357 DAY
	Facial Palsy							
	Nausea							
	Vertigo							
	Vomiting							

Date:05/25/05ISR Number: 4673423-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558943A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
Initial or Prolonged	Anger							
	Emotional Distress							
	Suicide Attempt							

Date:05/25/05ISR Number: 4673424-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558956A
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Alcohol Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	

	Death		Lexapro	C		
			Lamotrigine	C	Glaxosmithkline	
			Minocycline	C		
			Alcohol	C		

Date:05/25/05ISR Number: 4673425-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559188A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Exposure During		Wellbutrin	PS	Glaxosmithkline	
	Pregnancy		No Concurrent			
	Jaundice Neonatal		Medication	C		

Date:05/25/05ISR Number: 4673459-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0381069A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Depression		Zyban	PS	Glaxosmithkline	ORAL
150MG per day 11 DAY						
	Headache		Microval	C		ORAL
30MCG per day 7 MON						
	Hyperhidrosis		Vitamin C	C	Glaxosmithkline	ORAL
500MG per day						
	Pruritus		Nurofen	C	Glaxosmithkline	ORAL
	Salivary Hypersecretion					
	Skin Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/05ISR Number: 4673466-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0381911A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Convulsive Threshold Lowered Dyskinesia Grand Mal Convulsion Hypertonia Loss Of Consciousness Malaise Postictal State		Zyban	PS	Glaxosmithkline	ORAL	450MG per day	15 DAY

Date:05/25/05ISR Number: 4674012-7Report Type:Expedited (15-DaCompany Report #IMP_0861_2005
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Foreign	Bupropion Sr	PS		ORAL	400 MG ONCE PO	
	Body Temperature Increased	Literature Health	Bupropion Sr	SS		ORAL	150 MG QDAY PO	2 WK
	Depression	Professional						
	Intentional Misuse	Other	Bupropion Sr	SS		ORAL	300 MG QDAY PO	2 DAY
	Irritability							
	Paranoia		Midazolam	SS		ORAL	105 MG ONCE PO	
	Persecutory Delusion							
	Psychomotor Agitation		Midazolam	SS		ORAL	7.5 MG NIGHTLY PO	
	Psychotic Disorder							
	Respiratory Rate Increased							
	Restlessness							
	Somnolence							

	Suicide Attempt					
	Thinking Abnormal					

Date:05/25/05ISR Number: 4674799-3Report Type:Expedited (15-DaCompany Report #231577K05USA
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Depression	Consumer Health	Rebif (Interferon Beta)	PS		SUBCUTANEOUS	44 MCG, 3 IN	1 WEEKS,
	Faecal Incontinence	Professional						
	Psychotic Disorder					SUBCUTANEOUS		
	Self-Injurious Ideation Suicidal Ideation		Wellbutrin (Bupropion Hydrochloride)	SS				
			Effexor (Venlafaxine Hydrochloride)	SS		ORAL	75 MG, 1 IN 1	DAYS, ORAL

Date:05/26/05ISR Number: 4674645-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559557A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypothyroidism		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	8 MON
	Myopathy		Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4674654-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0560003A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline			

Date:05/26/05ISR Number: 4674656-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0560118A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Multiple Sclerosis							

Date:05/26/05ISR Number: 4674672-0Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0381410A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown 8 DAY
	Headache		Nicotine	C	Glaxosmithkline	TRANSDERMAL		30 DAY
	Personality Change		Nicotel	C		ORAL	6MG	Single
	Psychotic Disorder						dose	

Date:05/26/05ISR Number: 4674680-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0382285A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Zyban	PS	Glaxosmithkline	ORAL	9 DAY	
Initial or Prolonged	Dry Mouth		Digoxin	C	Glaxosmithkline	UNKNOWN	250MG	Per day
	Dry Throat		Zestril	C		UNKNOWN	20MG	per day

	Eating Disorder		Lipex	C		
UNKNOWN	20MG per day					
	Headache		Aspirin	C	Glaxosmithkline	
UNKNOWN	300MG See					
	Hyperhidrosis					
dosage text						
	Influenza Like Illness		Diaformin	C		
UNKNOWN	500MG Twice					
	Malaise					
per day						
	Nausea					
	Palpitations					
	Pyrexia					
	Somnolence					
	Vomiting					

Date:05/26/05ISR Number: 4677370-2Report Type:Direct Company Report #CTU 249605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Agoraphobia		Buproprin (Generic)			
	Anxiety		150 Mg One Bid	PS		
	Condition Aggravated					
	Depression					
	Therapeutic Response					
	Unexpected With Drug					
	Substitution					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675920-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548813A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palmar Erythema		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Pruritus		Caltrate	C	Glaxosmithkline			
	Rash Generalised		Asa	C	Glaxosmithkline			
			Vitamin C	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4675921-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548834A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Zoloft	C				

Date:05/27/05ISR Number: 4675922-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548839A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Restlessness		Lexapro	C				
			Vitamin	C				
			Green Tea	C				
			Saw Palmetto	C				
			Vitamin E	C				
			Garlic	C				

Date:05/27/05ISR Number: 4675923-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549008A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Twice	

		Anxiety						
per day	16 MON							
		Circadian Rhythm Sleep			No Concurrent			
		Disorder			Medication	C		
		Delusion						
		Impulsive Behaviour						
		Paranoia						
		Social Phobia						
		Weight Decreased						

Date:05/27/05ISR Number: 4675925-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549009A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Fentanyl	SS				
			Anesthesia	SS				
			Concerta	SS				
			Ortho Cyclen	C				
			Tapazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675927-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549011A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
	Headache		Excedrin	SS				
UNKNOWN	Stomach Discomfort		Celebrex	SS				

Date:05/27/05ISR Number: 4675928-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554240A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 WK
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4675929-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549027A
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4675930-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554249A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	DAY
	Headache		Neurontin	C				

Date:05/27/05ISR Number: 4675931-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549028A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Birth Control	C				

Date:05/27/05ISR Number: 4675932-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554250A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	13 DAY
	Tinnitus		Prevacid	C				

Date:05/27/05ISR Number: 4675933-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549040A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675934-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554283A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
Initial or Prolonged	Convulsion							

Date:05/27/05ISR Number: 4675935-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549108A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Aspartate Aminotransferase Increased		Alcohol	C				
	Hepatic Enzyme Abnormal							

Date:05/27/05ISR Number: 4675936-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554368A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Movement Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON

Date:05/27/05ISR Number: 4675937-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549110A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4675938-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554397A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Rash		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4675939-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549112A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	6 MON	
	Urine Output Decreased							

Date:05/27/05ISR Number: 4675940-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554414A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675941-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549227A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Ortho Evra	C				

Date:05/27/05ISR Number: 4675942-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554455A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4675943-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549265A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Headache		Clonazepam	C				
			Estradiol	C				
			Tylenol	C	Glaxosmithkline			
			Fosamax	C				

Date:05/27/05ISR Number: 4675944-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554474A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/27/05ISR Number: 4675945-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549269A
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	DAY

Date:05/27/05ISR Number: 4675946-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554511A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complex Partial Seizures		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Disorientation		Paxil	C	Glaxosmithkline		4	YR
			Synthroid	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4675947-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549272A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	100MG Per day	1 MON
	Therapeutic Response Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675948-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554561A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Three times per day	

Date:05/27/05ISR Number: 4675949-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549412A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Confusional State		Multivitamins	C				
	Somnolence							
	Thinking Abnormal							

Date:05/27/05ISR Number: 4675950-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554578A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Derealisation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	DAY
	Drug Screen Positive		Trazodone	C			UNKNOWN	
			Citalopram	C			UNKNOWN	

Date:05/27/05ISR Number: 4675951-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549416A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Increased							

	Aspartate Aminotransferase Increased					

Date:05/27/05ISR Number: 4675952-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554599A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4675953-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549419A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4675954-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554813A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675955-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549424A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4	DAY
	Myalgia		No Concurrent					
	Painful Respiration		Medication	C				
	Rash							

Date:05/27/05ISR Number: 4675956-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554816A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vaginal Haemorrhage		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			Effexor	C				
			Lexapro	C				

Date:05/27/05ISR Number: 4675957-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549426A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling Face		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
			Vicodin	C				

Date:05/27/05ISR Number: 4675958-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554835A
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
	Drug Interaction		Lipitor	SS				
			Vitamins	C				

Date:05/27/05ISR Number: 4675959-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549440A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hot Flush		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Hyperhidrosis		Birth Control	C				

Date:05/27/05ISR Number: 4675960-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554839A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON

Date:05/27/05ISR Number: 4675961-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549445A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Heart Rate Increased		Darvon	C				
	Palpitations							
	Panic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675962-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554863A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Burning Sensation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day

Date:05/27/05ISR Number: 4675963-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549460A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:05/27/05ISR Number: 4675964-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554864A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin Xl	PS	Glaxosmithkline	OTHER		

Date:05/27/05ISR Number: 4675965-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549502A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Initial Insomnia							
	Middle Insomnia							

Date:05/27/05ISR Number: 4675966-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554886A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Pharmaceutical Product
Complaint

Date:05/27/05ISR Number: 4675967-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549613A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/27/05ISR Number: 4675968-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555015A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	24 DAY
	Mobility Decreased		Trileptal	C				
	Myalgia		Prevacid	C				
	Swelling							

Date:05/27/05ISR Number: 4675969-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549629A
Age:66 YR Gender:Male I/FU:I

Outcome	PT
	Abnormal Dreams
	Dry Mouth

Thinking Abnormal

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	10 WK
			Naproxen	C				
			Cardura	C				
			Prilosec	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4675970-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555029A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
	Rash		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4675971-9Report Type:Periodic Company Report #CN050048
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
	Pharmaceutical Product Complaint		Concerta	C				

Date:05/27/05ISR Number: 4675972-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555030A
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Tremor		Depakote	C				
			Celexa	C				
			Celebrex	C				
			Plavix	C				

Vitamin E	C		
Vitamin C	C	Glaxosmithkline	
Avandia	C	Glaxosmithkline	
Albuterol	C	Glaxosmithkline	

Date:05/27/05ISR Number: 4675973-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549637A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Vitamins	C				

Date:05/27/05ISR Number: 4675974-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555034A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675975-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549644A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY
	Gingival Pain		Mobic	C				
	Rash		Ultram	C				
	Urticaria							

Date:05/27/05ISR Number: 4675976-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555038A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4675977-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549652A
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	15 DAY
	Dizziness		No Concurrent					
	Insomnia		Medication	C				
	Nausea							

Date:05/27/05ISR Number: 4675978-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555050A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Malaise		Alesse	C				
	Sinus Headache							

Date:05/27/05ISR Number: 4675979-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549654A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Paraesthesia Paraesthesia Oral		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4675980-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555224A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	1 MON
			Zoloft	C				
			Ativan	C				

Date:05/27/05ISR Number: 4675981-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549669A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Insomnia		Bupropion Hydrochloride	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675982-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555229A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lethargy		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 DAY
			Atenolol	C				
			Temaze	C				
			Mevacor	C				

Date:05/27/05ISR Number: 4675983-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549671A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Bupropion					
	Insomnia		Hydrochloride	PS	Glaxosmithkline	ORAL		
	Pruritus							

Date:05/27/05ISR Number: 4675984-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555234A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	8 WK
	Decreased		Lexapro	C				

Date:05/27/05ISR Number: 4675985-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549717A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4675986-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555259A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	MON	

Date:05/27/05ISR Number: 4675987-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549722A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/27/05ISR Number: 4675988-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555370A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin	PS	Glaxosmithkline	ORAL	4	WK
	Pruritus		Cymbalta	C				
	Rash		Allegra D	C				
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675989-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549832A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
			Amaryl	C				
			Prednisone	C				
			Hctz	C				
			Zyrtec	C	Glaxosmithkline			
			Furosemide	C	Glaxosmithkline			
			Ambien	C				
			Spironolactone	C				
			Hydrocodone	C				
			Cortisone	C				

Date:05/27/05ISR Number: 4675990-2Report Type:Periodic Company Report #S05-USA-02072-01
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	3 WK
			Lexapro	SS				

Date:05/27/05ISR Number: 4675991-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549836A
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Hyperhidrosis		Amiodarone	C				
	Insomnia		Aspirin	C	Glaxosmithkline			
	Nervousness		Tenormin	C				
	Restlessness		Lipitor	C				
			Coumadin	C	Glaxosmithkline			
			Norvasc	C				
			Diovan Hct	C				
			Tylenol	C	Glaxosmithkline			
			Citrucel	C	Glaxosmithkline			
			Dulcolax	C				

Date:05/27/05ISR Number: 4675992-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555394A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Heart Rate Increased		Claritin D	C			UNKNOWN	
	Hot Flush							

Date:05/27/05ISR Number: 4675993-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549838A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Insomnia		Lexapro	C				
	Panic Reaction		Trazodone	C				
	Psychomotor Hyperactivity		Alprazolam	C				
	Restlessness		Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4675994-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555398A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Lisinopril	C		ORAL	40MG Per day	
			Atenolol	C		ORAL		
			Lovastatin	C		ORAL		
			Tetracycline	C				

YR

Date:05/27/05ISR Number: 4675995-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549844A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Prozac	C			20MG Per day	

Date:05/27/05ISR Number: 4675996-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555561A
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Eruption		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	0 DAY
Other	Rash Generalised							

Date:05/27/05ISR Number: 4675997-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549850A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK

			Vitamins	C		

Date:05/27/05ISR Number: 4675998-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555565A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day

Date:05/27/05ISR Number: 4675999-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549856A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			Valium	C				

Date:05/27/05ISR Number: 4676000-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555579A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasopharyngitis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676001-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549880A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676002-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555587A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Unilateral		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Effexor	C				
			Ritalin	C				

Date:05/27/05ISR Number: 4676003-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549893A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676004-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555594A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Per day
	Anger		Cymbalta	SS				UNKNOWN
	Confusional State							
	Dizziness							
	Hypersomnia							
	Tremor							

Date:05/27/05ISR Number: 4676005-2Report Type:Periodic Company Report #0011380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676006-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555596A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Ambien	C				
			Depakote	C				

Date:05/27/05ISR Number: 4676007-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549925A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	MON
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676008-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555598A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Effexor	SS				
			Clarinex	C				
			Nasonex	C				
			Zantac	C	Glaxosmithkline			
			Vitamin B	C				
			Vitamin C	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676009-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550036A
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Energy Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	18 MON
	Mouth Ulceration		Darvocet	C				
			Pain Medication	C				
			Blood Pressure Medication	C				

Date:05/27/05ISR Number: 4676010-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555630A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Memory Impairment							

Date:05/27/05ISR Number: 4676011-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550038A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	

			No Concurrent Medication	C		

Date:05/27/05ISR Number: 4676012-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555727A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 DAY

Date:05/27/05ISR Number: 4676013-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550052A
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	27 DAY
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676014-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555834A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	
Variable dose								

Date:05/27/05ISR Number: 4676015-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550069A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676016-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555836A
Age:13 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tic		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Elavil	C	Glaxosmithkline	ORAL	10MG At night	

Date:05/27/05ISR Number: 4676017-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550072A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Pruritus							
	Urticaria							

Date:05/27/05ISR Number: 4676018-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555840A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline		3	YR

Date:05/27/05ISR Number: 4676019-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550073A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Syncope		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Blood Pressure Medication	C				

Date:05/27/05ISR Number: 4676020-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555844A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676021-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550081A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
	Rash		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676022-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555848A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK

Date:05/27/05ISR Number: 4676023-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550088A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Dizziness		Oral Contraceptives	C				
	Nausea							
	Retching							
	Tinnitus							

Date:05/27/05ISR Number: 4676024-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555849A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK

Date:05/27/05ISR Number: 4676025-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550092A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Lethargy		Wellbutrin Sr	C	Glaxosmithkline	ORAL	150MG Twice per day	
			Celexa	C				
			Adderall	C				

Date:05/27/05ISR Number: 4676026-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555864A
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Variable dose	8 MON
			Atenolol	C				
			Levoxyl	C	Glaxosmithkline			
			Maxide	C				
			Arthrotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676027-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550148A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Birth Control	C				YR

Date:05/27/05ISR Number: 4676028-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555897A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676029-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550246A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Nasonex	C				
			Imipramine	C			250MG Per day	10 YR

Date:05/27/05ISR Number: 4676030-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555905A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:05/27/05ISR Number: 4676031-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550253A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Visual Disturbance		Lexapro	SS				

Date:05/27/05ISR Number: 4676032-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556002A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676033-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550256A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 YR
	Pyrexia		Buspar	C				
	Tinnitus		Prozac	C			10	YR
			Klonopin	C				
			Ventolin	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676034-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556011A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 YR
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676035-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550257A
Age:50 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:05/27/05ISR Number: 4676036-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556022A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Dry Mouth		Zoloft	C				
	Hyperhidrosis		Crestor	C				
	Muscle Twitching		Nexium	C				
	Nausea		Actonel	C				
	Pollakiuria							
	Rash							
	Tremor							
	Weight Decreased							

Date:05/27/05ISR Number: 4676037-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550262A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

				Ativan	C		

Date:05/27/05ISR Number: 4676038-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556058A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
	Dry Eye		Depakote	C				
	Somnolence		Premarin	C				
	Tinnitus		Calcium	C				
	Vision Blurred		Multivitamins	C				

Date:05/27/05ISR Number: 4676039-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550277A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Muscle Twitching		Ativan	C				
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676040-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556105A
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Adderall	C				

Date:05/27/05ISR Number: 4676041-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550308A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676042-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556107A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Insomnia							
	Joint Stiffness							

Date:05/27/05ISR Number: 4676043-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550312A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	YR

Date:05/27/05ISR Number: 4676044-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556192A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	9 DAY

			Flonase	C	Glaxosmithkline	
			Flax Seed	C		
			Multivitamin	C		ORAL

Date:05/27/05ISR Number: 4676045-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550433A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Renal Impairment		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 5 YR						
	Tremor		Espazine	C	Glaxosmithkline	
			Mysoline	C		
			Unknown Medication	C		
			Cogentin	C		
			Mevacor	C		
			Glucotrol	C		
			Zithromax	C		

Date:05/27/05ISR Number: 4676046-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556203A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
			Unknown	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676047-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550437A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Attack		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Vision Blurred		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676048-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556210A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 YR
	Rash		Cymbalta	C				
			Cymbalta	C				

Date:05/27/05ISR Number: 4676049-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550443A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
			Prozac	C				
			Lasix	C	Glaxosmithkline			
			Tenormin	C				
			Diovan	C				

Date:05/27/05ISR Number: 4676050-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556213A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Confusional State							
	Crying							

Hypoaesthesia

Date:05/27/05ISR Number: 4676051-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550465A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinus Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Levothyroxine	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676052-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556217A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
			Oral Contraceptive	C				

Date:05/27/05ISR Number: 4676053-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550475A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphemia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676054-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556218A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
			Estrogen	C				
			Diuretics	C				
			Allegra	C				

Date:05/27/05ISR Number: 4676055-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550488A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Hypomania							

Date:05/27/05ISR Number: 4676056-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556310A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Apathy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Crying		Prozac	C				
	Depression		Fioricet	C				
	Drug Ineffective		Klonopin	C				

Date:05/27/05ISR Number: 4676057-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550621A
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:05/27/05ISR Number: 4676058-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556320A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK
			Serzone	C				

Date:05/27/05ISR Number: 4676059-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550627A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676060-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556340A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
			Lamictal	C	Glaxosmithkline			
			Symbyax	C				
			Zyprexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676061-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550634A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Urticaria		Lescol	C				
			Imitrex	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676062-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556342A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Rash Maculo-Papular		Lipitor	C				

Date:05/27/05ISR Number: 4676063-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550674A
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Headache		Zonegran	C				
	Nausea		Lexapro	C				

Date:05/27/05ISR Number: 4676064-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556346A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150G	Unknown
			Effexor	C				

Date:05/27/05ISR Number: 4676065-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550675A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
	Dizziness		No Concurrent					
	Headache		Medication	C				

Date:05/27/05ISR Number: 4676066-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556349A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent					
			Medication	C				

Date:05/27/05ISR Number: 4676067-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550826A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 WK
	Headache		Zoloft	C				
	Nausea							
	Tension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676068-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556441A
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Feeling Jittery							
	Insomnia							
	Palpitations							

Date:05/27/05ISR Number: 4676069-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550855A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Single	
	Irritability							
							dose	1 DAY
			Cozaar	C				
			Hctz	C				
			Theophylline	C				
			Synthroid	C	Glaxosmithkline			
			Corgard	C				
			Combivent	C				
			Lopid	C				
			Flonase	C	Glaxosmithkline			
			Motrin	C	Glaxosmithkline			
			Methotrexate	C				
			Folic Acid	C				
			Glucophage	C				
			Pepcid	C				
			Tums	C	Glaxosmithkline			
			Soy Protein	C				
			Garlic Capsule	C				

Date:05/27/05ISR Number: 4676070-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556673A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Unknown 10 DAY						
	Nausea					

Date:05/27/05ISR Number: 4676071-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550866A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day						
	Overdose		Subutex	C		

Date:05/27/05ISR Number: 4676072-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556674A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Withdrawal Syndrome		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
	Sleep Disorder					
	Stomach Discomfort					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676073-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551011A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
			Ultram	C				

Date:05/27/05ISR Number: 4676074-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0556675A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Fatigue							
	Insomnia							

Date:05/27/05ISR Number: 4676075-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551019A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Xanax	C				
			Ativan	C				

Date:05/27/05ISR Number: 4676076-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0557127A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	6	MON

Date:05/27/05ISR Number: 4676077-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551021A
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Lipitor	C				
			Blood Pressure Med	C				

Date:05/27/05ISR Number: 4676078-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551026A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	13 MON
			Strattera	C				
			Lexapro	C				
			Synthroid	C	Glaxosmithkline			
			Allergy Injections	C				
			Iron Supplement	C				
			Wellbutrin Sr	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676080-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551043A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	300MG Per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676082-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551046A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Beta Blocker	C				

Date:05/27/05ISR Number: 4676084-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551047A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Pruritus		Ortho Tri-Cyclen	C				
	Urticaria		Percocet	C				

Date:05/27/05ISR Number: 4676086-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551072A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Benign Prostatic Hyperplasia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Buspar	SS				

Date:05/27/05ISR Number: 4676088-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551105A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Anxiety		Synthroid	C	Glaxosmithkline			
	Heart Rate Increased		Yasmin	C				
	Insomnia							
	Weight Decreased							

Date:05/27/05ISR Number: 4676090-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551107A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676092-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551116A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
	Diarrhoea		Asacol	C	Glaxosmithkline			
	Dizziness		Lipitor	C				
	Dry Mouth		Toprol Xl	C				
	Fatigue		Valium	C				
	Hyperhidrosis		Codeine	C				
	Nausea		Tylenol	C	Glaxosmithkline			
	Tremor		Dicyclomine Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676093-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551123A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	12	DAY
			Cymbalta	C			MON	

Date:05/27/05ISR Number: 4676094-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551130A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676095-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551258A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling Paraesthesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676096-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551277A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	17 DAY

Date:05/27/05ISR Number: 4676097-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551293A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Mouth Ulceration		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						

Date:05/27/05ISR Number: 4676098-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551301A
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 4 DAY						
	Dizziness		Prenatal Vitamins	C		
	Dry Mouth					
	Myalgia					
	Nausea					
	Somnolence					

Date:05/27/05ISR Number: 4676099-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551324A
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
6 MON						
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676100-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551328A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676101-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551340A
Age:8 MON Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline		150MG Per day	
	Drug Exposure Via Breast Milk		Prenatal Vitamins	C				
	Irritability							
	Somnolence							

Date:05/27/05ISR Number: 4676102-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551347A
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Twitching		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Adderall	C				

Date:05/27/05ISR Number: 4676103-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551453A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	6 MON
			Lipitor	C				
			Zyrtec	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676104-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551720A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Decreased Appetite		No Concurrent					
	Rash		Medication	C				

Date:05/27/05ISR Number: 4676105-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551733A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676106-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551734A
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Headache		Aspirin	C	Glaxosmithkline			
	Heart Rate Increased		Premarin	C				
			Nexium	C				
			Plavix	C				
			Synthroid	C	Glaxosmithkline			
			Avalide	C				

			Doxycycline	C		
			Restoril	C		
			Valium	C		
			Miacalcin	C		
			Vitamin	C		
			Clonidine	C		

Date:05/27/05ISR Number: 4676107-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551735A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Suicidal Ideation		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	34 WK
			Lexapro	C				
			Nexium	C				
			Lipitor	C				
			Lorazepam	C				
			Nasonex	C				
			Unknown Drug	C				

Date:05/27/05ISR Number: 4676108-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551907A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the morning	41 DAY
	Nausea							
			Premarin	C				
			Actonel	C				

Date:05/27/05ISR Number: 4676109-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551935A
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON

Date:05/27/05ISR Number: 4676110-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551952A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676111-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551954A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MGK Three times per day	7 DAY
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676112-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551966A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	5	MON
			Wellbutrin	C	Glaxosmithkline			YR

Date:05/27/05ISR Number: 4676113-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551971A
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	MON

Date:05/27/05ISR Number: 4676114-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551979A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Nausea							

Date:05/27/05ISR Number: 4676115-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551983A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown 3 DAY

Date:05/27/05ISR Number: 4676116-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551985A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Macular		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	DAY
			Wellbutrin Sr	C	Glaxosmithkline	ORAL	12	DAY
			Effexor	C				

Date:05/27/05ISR Number: 4676117-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552009A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the	
	Pruritus						morning	12 DAY
			Bupropion Sr	SS	Glaxosmithkline	ORAL	200MG Twice	
							per day	

Date:05/27/05ISR Number: 4676118-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552119A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676119-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552126A
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
			Lexapro	C				

Date:05/27/05ISR Number: 4676120-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552132A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
			Prozac	C				
			Klonopin	C				

Date:05/27/05ISR Number: 4676121-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552134A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Sodium Decreased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Three	
	Depression						times per day	6 MON
	Gastrointestinal Disorder		Depakote	C				
	Mental Disorder		Remeron	C				
	Thinking Abnormal		Gabitril	C				
			Ranitidine	C	Glaxosmithkline			
			Valtrex	C	Glaxosmithkline			
			Flomax	C				
			Celebrex	C				
			Aricept	C				
			Ditropan Xl	C				
			Propranolol	C				
			Restoril	C				
			Delatestryl	C				
			Prilosec	C	Glaxosmithkline			
			Benicar	C				
			Norvasc	C				

			Toprol Xl	C		

Date:05/27/05ISR Number: 4676122-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552142A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676123-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552159A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
	Tic		Klonopin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676124-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552165A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Skin Lesion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Stevens-Johnson Syndrome							

Date:05/27/05ISR Number: 4676125-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552166A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Movement Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676126-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552168A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Chills		Effexor Xr	C				
	Dyspnoea		Vasotec	C				
	Pyrexia		Hydrochlorothiazide	C				
	Swelling							
	Urticaria							
	White Blood Cell Count Increased							

Date:05/27/05ISR Number: 4676127-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552294A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676128-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552302A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Dizziness		Zoloft	C				
	Somnolence		Lopressor	C				
			Zanaflex	C				

Date:05/27/05ISR Number: 4676129-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552319A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Unknown	C				

Date:05/27/05ISR Number: 4676130-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552323A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676131-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552324A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 DAY
			Allopurinol	C	Glaxosmithkline			
			Cipro	C	Glaxosmithkline			
			Gemfibrozil	C				
			Lisinopril	C				
			Insulin	C				
			Glyburide	C				
			Metoprolol Xl	C				

Date:05/27/05ISR Number: 4676132-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552400A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	DAY

Date:05/27/05ISR Number: 4676133-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552434A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the morning	
			Ambien	C				
			Allegra	C				

Date:05/27/05ISR Number: 4676134-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552576A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 2 YR						

Date:05/27/05ISR Number: 4676135-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552587A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 1 YR						
			Topomax	C		
			Evista	C		
			Lipitor	C		
			Nexium	C		
			Paxil	C	Glaxosmithkline	

Date:05/27/05ISR Number: 4676136-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552589A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cognitive Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day						
	Disturbance In Attention		Xanax	C		
	Tension					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676137-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552616A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	100MG Per day	6 WK
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	100MG Twice per day	1 MON
			Synthroid	C	Glaxosmithkline			
			Prevacid	C				
			Demadex	C				
			Altace	C				
			Claritin	C				
			Glucophage	C				
			Lipitor	C				
			Risperdal	C				
			Singulair	C				
			Baby Aspirin	C	Glaxosmithkline			
			Colace	C				
			Xalatan	C				
			Miralax	C				
			Advair	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676138-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552632A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Suicidal Ideation		Depakote	C				

Date:05/27/05ISR Number: 4676139-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552786A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	20 DAY
			Singulair	C				

			Claritin	C		
			Effexor Xr	C		

Date:05/27/05ISR Number: 4676140-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552807A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Nausea		Oral Contraceptive	C				

Date:05/27/05ISR Number: 4676141-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552815A
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Amoxil	C	Glaxosmithkline	ORAL	500MG Twice per day	4 DAY
			Advil	C	Glaxosmithkline		200MG Twice per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676142-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552818A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON
			Lexapro	C				

Date:05/27/05ISR Number: 4676143-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552819A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	12 DAY
			Claritin	C				

Date:05/27/05ISR Number: 4676144-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552837A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676145-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552858A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	8	DAY
Other	Rash		Adderall Xr	C		ORAL	25MG Per day	
	Swelling							
	Urticaria							

Date:05/27/05ISR Number: 4676146-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552873A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	WK
	Constipation							

Date:05/27/05ISR Number: 4676147-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552875A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676148-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552985A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG	Unknown
			Neurontin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676149-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552993A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676150-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553000A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	MON
	Sluggishness		Prenatal Vitamins	C				
			Potassium Supp	C				
			Nexium	C				
			Bextra	C				
			Nitroglycerin	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676151-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553008A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676152-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553013A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:05/27/05ISR Number: 4676153-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553038A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Alcohol	SS				

Date:05/27/05ISR Number: 4676154-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553053A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the morning	13 DAY
			Lexapro	C			20MG per day	

Date:05/27/05ISR Number: 4676155-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553164A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Discomfort		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Per day	
	Muscle Tightness		No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676156-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553165A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676157-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553167A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676158-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553180A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676159-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553181A
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	61 WK
			Unknown Medication	C				
			Toprol Xl	C				
			Potassium	C				
			B12 Injection	C	Glaxosmithkline			
			Decadurabolin	C				
			Videx	C				
			Viramune	C				
			Paxil	C	Glaxosmithkline			

			Testosterone	C	Glaxosmithkline	

Date:05/27/05ISR Number: 4676160-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553182A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676161-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553183A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:05/27/05ISR Number: 4676162-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553194A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	8 WK
			Percodan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676163-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553197A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Anorexia		Vitamins	C				
	Blepharospasm							
	Dry Skin							
	Dysgeusia							
	Nausea							
	Thinking Abnormal							

Date:05/27/05ISR Number: 4676164-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553198A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the morning	
	Diarrhoea							

Date:05/27/05ISR Number: 4676165-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553223A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensory Disturbance		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Sleep Disorder							

Date:05/27/05ISR Number: 4676166-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553355A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK

Date:05/27/05ISR Number: 4676167-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553357A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	0 DAY

Date:05/27/05ISR Number: 4676168-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553358A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Anxiety		Benadryl	C	Glaxosmithkline			
	Dry Mouth							
	Insomnia							
	Micturition Frequency Decreased							
	Orgasm Abnormal							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676169-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553411A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the	morning
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676170-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553418A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	YR
			Wellbutrin Sr	SS	Glaxosmithkline		UNKNOWN	
			Paxil	SS	Glaxosmithkline		UNKNOWN	

Date:05/27/05ISR Number: 4676171-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553425A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676172-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553565A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the	
	Wheezing						morning	
			Synthroid	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676173-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553570A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
			Synthroid	C	Glaxosmithkline			
			Prilosec	C	Glaxosmithkline			
			Tricor	C				
			Singulair	C				
			Celebrex	C				
			Nalfon	C				
			Glucophage	C				

Date:05/27/05ISR Number: 4676174-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553574A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG In the	
	Nausea						morning	6 WK
	Stomach Discomfort		Valium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676175-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553581A
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
			Geodon	C				

Date:05/27/05ISR Number: 4676176-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553607A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676177-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553615A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Cyst		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
	Fibroadenoma Of Breast		Zoloft	C				

Date:05/27/05ISR Number: 4676178-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553620A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	DAY
	Drug Ineffective		Lexapro	SS				
UNKNOWN		1 YR						
	Drug Interaction							
	Hyperhidrosis							
	Tremor							

Date:05/27/05ISR Number: 4676179-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553621A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676180-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553622A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Auditory		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676181-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553653A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676182-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553777A
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
	Headache		Benicar	C				
	Hyperhidrosis		Skelaxin	C				
	Hypertension		Protonix	C				
	Nausea		Potassium Supplement	C				
	Neuralgia		Celebrex	C				
	Photopsia		Vicodin	C				
	Red Blood Cell Count Decreased		Maxalt	C				
			Prednisolone Acetate	C				
	Vomiting		Betanol 0.3%	C				
	White Blood Cell Count Decreased		Alphagan	C				
			Ditropan	C				
			Benadryl	C	Glaxosmithkline			
			Zyrtec	C	Glaxosmithkline			
			Gerovit (Multivitamin)	C				
			Tylenol	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676183-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553792A
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Vitamins	C				
			Blood Pressure Medication	C				

Date:05/27/05ISR Number: 4676184-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553799A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON

Date:05/27/05ISR Number: 4676185-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553805A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676186-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553812A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676187-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553833A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676188-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553985A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Sleep Disorder		Prozac	C				
			Seroquel	C				
UNKNOWN							25MG Per day	

Date:05/27/05ISR Number: 4676189-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553989A
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	159MG Per day	8 DAY
	Hyperhidrosis		Cipro	C	Glaxosmithkline			
	Nervousness		Xanax	C				
			Vasotec	C				

Date:05/27/05ISR Number: 4676190-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554018A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676191-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554044A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oligomenorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2	MON

Date:05/27/05ISR Number: 4676192-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554057A
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	36	DAY
Initial or Prolonged			Paxil Cr	C	Glaxosmithkline	ORAL	25MG	Per day
Other			Klonopin	C			5MG	Twice per day
			Abilify	C			5MG	At night

Date:05/27/05ISR Number: 4676193-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554081A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	Unknown 1 YR

Date:05/27/05ISR Number: 4676194-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554084A
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676195-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554203A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Parosmia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676196-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554207A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion		Wellbutrin Xl	PS	Glaxosmithkline		UNKNOWN	
			Effexor Xr	C				

Date:05/27/05ISR Number: 4676197-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554210A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Dry Mouth		Homeopathic Medicines	C				
	Hyperhidrosis							
	Lacrimation Increased							
	Nausea							
	Sinus Congestion							
	Throat Irritation							

Date:05/27/05ISR Number: 4676198-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554214A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Rash Generalised		Zoloft	C				

Urticaria

Date:05/27/05ISR Number: 4676199-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554223A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676200-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554224A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coeliac Disease		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Drug Ineffective							

Date:05/27/05ISR Number: 4676201-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554227A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	7 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676202-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554232A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
			Advair	C	Glaxosmithkline			
			Albuterol	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676203-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554238A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676204-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515873A
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Erythema		Effexor	C				
	Oedema		Aricept	C				
	Pain		Metoprolol	C				
	Pruritus		Neurontin	C				
	Rash		Colchicine	C				
	Skin Exfoliation		Lipitor	C				
			Terazosin	C				
			Proscar	C				
			Indomethacin	C				

Date:05/27/05ISR Number: 4676205-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525050A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 MON
	Pharmaceutical Product		Paroxetine	C	Glaxosmithkline			
	Complaint		Synthroid	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676206-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531285A
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 DAY
	Palpitations		Lamictal	SS	Glaxosmithkline	ORAL	300MG Per day	5 MON
	Skin Hyperpigmentation		Synthroid	C	Glaxosmithkline			
	Swollen Tongue		Sunscreen	C			TOPICAL	45Z Unknown
			Levothyroxine	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676207-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532862A
Age:22 YR Gender:Male I/FU:F

Outcome	PT
	Agitation
	Chills
	Diarrhoea
	Dissociation

	Dyskinesia						
	Erectile Dysfunction						
	Fear	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 6 MON
	Insomnia		Paxil Cr	SS	Glaxosmithkline	ORAL	12.5MG Per day 4 DAY
	Muscle Tightness						
	Muscle Twitching		Aciphex	C			
	Nausea		Lopressor	C			
	Sleep Disorder		Antibiotic	C			UNKNOWN
			Nexium	C			UNKNOWN
			Neurontin	C			

Date:05/27/05ISR Number: 4676208-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535736A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Bowel Movement		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day 3 WK
	Irregularity		No Concurrent Medication	C			
	Drug Ineffective						
	Fatigue						
	Hunger						
	Loss Of Libido						
	Weight Increased						

Date:05/27/05ISR Number: 4676209-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538242A
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 3 DAY
	Blood Glucose Decreased		Nexium	C			
	Chest Pain		Estrace	C			
	Dry Mouth						
	Dyspnoea						

Heart Rate Increased
Muscular Weakness
Nausea
Nervousness
Rash
Thinking Abnormal
Tinnitus
Weight Decreased

Date:05/27/05ISR Number: 4676210-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539064A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 MON
	Drug Ineffective		Glucophage	C				
	Sleep Disorder		Oral Contraceptives	C				
			Diflucan	C		ORAL	150MG As required	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676211-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540784A
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 MON
	Anxiety		Prozac	C				
	Dry Mouth		Librium	C				
	Feeling Jittery		Ambien	C				
	Insomnia		Lopressor	C				
	Tremor							

Date:05/27/05ISR Number: 4676212-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541953A
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Hormone Replacement	C				

Date:05/27/05ISR Number: 4676213-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541963A
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	16 DAY
Hospitalization -	Dyspnoea		Depakote	C				
UNKNOWN	500MG Twice							
Initial or Prolonged	Pruritus Generalised							
per day								
Other	Swelling Face		Percocet	C				
UNKNOWN	325MG As							
	Swollen Tongue							
required								
			Lorazepam	C		ORAL		
2MG Four								
times per day								
			Klonopin	C				
UNKNOWN	1MG At night							

				Zoloft	C		ORAL
100MG Twice							
per day							
				Furosemide	C	Glaxosmithkline	
UNKNOWN	40MG Twice						
per day							
				Lotrel	C		
UNKNOWN							
				Klor-Con	C	Glaxosmithkline	
UNKNOWN							
				Oxycontin	C		
UNKNOWN	40MG Three						
times per day							
				Isosorbide	C		
20MG Twice							
per day							

Date:05/27/05ISR Number: 4676214-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542478A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Auditory		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Unknown	20 DAY

Date:05/27/05ISR Number: 4676215-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542853A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	14 MON
	Pharmaceutical Product Complaint							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676216-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542863A
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 YR
	Grand Mal Convulsion		Anti-Viral Medication	C			UNKNOWN	
	Tongue Biting		Toprol	C			UNKNOWN	

Date:05/27/05ISR Number: 4676217-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543284A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676218-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543287A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Insomnia		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676219-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543288A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON

Date:05/27/05ISR Number: 4676220-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543319A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersensitivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
WK								
Initial or Prolonged	Swelling Face							
Other	Urticaria							

Date:05/27/05ISR Number: 4676221-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543322A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Headache							
	Nausea							

Date:05/27/05ISR Number: 4676222-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543326A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Lexapro	C				
			Risperdal	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676223-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543332A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY

Date:05/27/05ISR Number: 4676224-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543333A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Gingival Pruritus		Verapamil	C				
	Local Swelling							
	Mood Altered							
	Mouth Ulceration							
	Sensitivity Of Teeth							

Date:05/27/05ISR Number: 4676225-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543336A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
			Xanax	C				
			Prilosec	C	Glaxosmithkline			
			Cymbalta	C				

Date:05/27/05ISR Number: 4676226-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543338A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Urticaria							

Date:05/27/05ISR Number: 4676227-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543485A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice	
	Memory Impairment						per day	
	Panic Reaction		Synthroid	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676228-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543489A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Agitation		Zoloft	C				
	Depression		Xanax	C				
	Heart Rate Increased		Aciphex	C				
	Irritability							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676229-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543500A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/27/05ISR Number: 4676230-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543502A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Bilateral		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	5 MON
	Tinnitus		Advair	C	Glaxosmithkline			
			Albuterol	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676231-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543506A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			Birth Control Pills	C				

Date:05/27/05ISR Number: 4676232-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543513A
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Insomnia		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
			Ambien	C				
			Naprosyn	C				

Date:05/27/05ISR Number: 4676233-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543516A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngolaryngeal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 YR
	Tongue Discolouration		Actonel	C				
			Prempro	C				
			Calcium	C				
			Vitamin D	C				
			Vitamin C	C	Glaxosmithkline			
			Colestid	C				
			Nexium	C				

Date:05/27/05ISR Number: 4676234-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543528A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
	Throat Tightness		Zyrtec	C	Glaxosmithkline			
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676235-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543699A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Food Allergy		Tylenol	C	Glaxosmithkline			
	Headache		Benadryl	C	Glaxosmithkline			
	Nausea							
	Nicotine Dependence							
	Panic Attack							

Date:05/27/05ISR Number: 4676236-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543701A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysmenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676237-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543716A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Incontinence							
	Weight Decreased							

Date:05/27/05ISR Number: 4676238-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543721A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Anxiety							
	Hypoacusis							
	Tinnitus							

Date:05/27/05ISR Number: 4676239-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543729A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/27/05ISR Number: 4676240-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543730A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Concerta	C				

Date:05/27/05ISR Number: 4676241-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543744A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676242-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543953A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Irritability		Levoxyl	C	Glaxosmithkline			
			Lasix	C	Glaxosmithkline			
			Trazodone	C				
			Morphine	C				
			Klonopin	C				

Date:05/27/05ISR Number: 4676243-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543962A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Ventricular Extrasystoles							

Date:05/27/05ISR Number: 4676244-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543976A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline			

Date:05/27/05ISR Number: 4676245-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543978A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG See	
	Anger							
	Dry Mouth						dosage text	8 WK

Date:05/27/05ISR Number: 4676246-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543986A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK

Date:05/27/05ISR Number: 4676247-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543990A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensation Of Heaviness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Haldol	C				

Date:05/27/05ISR Number: 4676248-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544008A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Unknown	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676249-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544027A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Nightmare		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676250-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544040A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676251-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544221A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Therapeutic Response		Ditropan Xl	C			5MG per day	
	Unexpected		Azathioprine	C	Glaxosmithkline		75MG per day	

Date:05/27/05ISR Number: 4676252-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544247A
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	White Blood Cell Count		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 YR
	Decreased		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676253-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544251A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Feeling Abnormal							
	Tension Headache							
	Therapeutic Response							
	Unexpected							

Date:05/27/05ISR Number: 4676254-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544258A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	24 WK

Date:05/27/05ISR Number: 4676255-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544272A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676256-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544308A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Purpura		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK

Date:05/27/05ISR Number: 4676257-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544498A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	5 MON
	Nausea		Nuvaring	C				

Date:05/27/05ISR Number: 4676258-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544524A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Disturbance In Attention		Prozac	SS				
UNKNOWN	40MG Per day							
	Insomnia							

Date:05/27/05ISR Number: 4676259-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544530A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Eye		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
	Dry Mouth		Namenda	C				

Date:05/27/05ISR Number: 4676260-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544544A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676261-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544661A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
6 WK								
	Crying		Celexa	C				
	Depression							
	Drug Ineffective							

Date:05/27/05ISR Number: 4676262-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544758A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Auditory		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Anti-Psychotic Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676263-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544760A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperchlorhydria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	13	DAY
	Hypersensitivity							
	Oedema Peripheral							
	Pruritus							

Date:05/27/05ISR Number: 4676264-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544783A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			Klonopin	C				
			Neurontin	C				

Date:05/27/05ISR Number: 4676265-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544787A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Twice	
	Tremor							
			Paxil Cr	C	Glaxosmithkline		per day	10 DAY

Date:05/27/05ISR Number: 4676266-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544936A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Diastolic		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Increased		No Concurrent					
	Blood Pressure Systolic		Medication	C				

	Increased					

Date:05/27/05ISR Number: 4676267-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544940A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676268-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544953A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Nausea							
	Palpitations							
	Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676269-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545083A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676270-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545149A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 YR
	Feeling Drunk		Birth Control	C				

Date:05/27/05ISR Number: 4676271-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545167A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Hypertension		Lithium	C	Glaxosmithkline			
	Tinnitus		Levothyroxine	C	Glaxosmithkline			
			Benicar	C				

Date:05/27/05ISR Number: 4676272-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545168A
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Anxiety		Xanax	C		ORAL	.5U Twice per day	
	Burning Sensation							
	Euphoric Mood		Trazodone	C		ORAL	50MG As	

	Feeling Hot					
required						
	Nervousness					
	Therapeutic Response					
	Unexpected					

Date:05/27/05ISR Number: 4676273-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545178A
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Erectile Dysfunction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 5 DAY						
			Aciphex	C		

Date:05/27/05ISR Number: 4676274-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545180A
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Twice						
	Somnolence					
per day 5 WK						
			Xanax	C		
			Sinemet	C		
			Vitamins	C		
			Metoprolol	C		
			Resperidol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676275-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545183A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676276-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545329A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676277-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545448A
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Dyspepsia		Lipram	C				
			Zocor	C				
			Surfak	C				
			Bextra	C				
			Norvasc	C				
			Protonix	C				
			Doxazosin	C				
			Antacid	C				

Date:05/27/05ISR Number: 4676278-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545458A
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 DAY
	Depression		Lipitor	C				

	Insomnia		Norvasc	C	
			Vitamins	C	
			Gabapentin	C	
			Tylenol	C	Glaxosmithkline

Date:05/27/05ISR Number: 4676279-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545478A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Swelling							
	Urticaria							

Date:05/27/05ISR Number: 4676280-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545480A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	5 WK
	Anxiety		Plavix	C				
	Tachycardia		Lipitor	C				
			Diovan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676281-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545487A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG In the	
	Dry Mouth						morning	2 WK
	Insomnia							
	Tremor							
	Weight Decreased							

Date:05/27/05ISR Number: 4676282-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545543A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Auditory		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:05/27/05ISR Number: 4676283-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545678A
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Muscle Rigidity		Toprol Xl	C				
	Suffocation Feeling		Clonazepam	C				
			Ortho Tri Cyclen	C				

Date:05/27/05ISR Number: 4676284-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545686A
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	25 DAY
	Swelling Face		Alprazolam	C				
			Lorazepam	C				

Date:05/27/05ISR Number: 4676285-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545693A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 DAY
	Insomnia		No Concurrent					
	Rash Pruritic		Medication	C				
	Urticaria							

Date:05/27/05ISR Number: 4676286-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545701A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 YR
	Pruritus		Bupropion	SS	Glaxosmithkline	ORAL	75MG Per day	1 WK
	Sleep Disorder		Lexapro	C				
	Vision Blurred		Toprol Xl	C				
			Lipitor	C				
			Allegra	C				
			Atacand	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676287-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545705A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK

Date:05/27/05ISR Number: 4676288-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545711A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676289-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545719A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Jittery		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	2TAB	Three times per day
			Ultram	C		ORAL		9 DAY

Date:05/27/05ISR Number: 4676290-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545736A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline		2	MON
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG	Unknown MON

Date:05/27/05ISR Number: 4676291-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545746A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Diastolic		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Increased							

Date:05/27/05ISR Number: 4676292-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545766A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Agitation							

Date:05/27/05ISR Number: 4676293-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545769A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Unknown	6 WK
	Drug Ineffective							

Date:05/27/05ISR Number: 4676294-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545803A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	16 DAY
	Insomnia		Nicotine Patch	C	Glaxosmithkline		UNKNOWN	
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676295-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545805A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG In the	
	Anxiety						morning	
	Dizziness		Paxil Cr	SS	Glaxosmithkline	ORAL	12.5MG At	
	Nausea						night	
	Tremor		Ativan	SS			UNKNOWN	.5MG At night

Date:05/27/05ISR Number: 4676296-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545917A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Eating Disorder		No Concurrent					
	Tinnitus		Medication	C				

Date:05/27/05ISR Number: 4676297-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545932A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG	
							Alternate	
							days	8 WK
			Synthroid	C	Glaxosmithkline			
			Xanax	C				

Date:05/27/05ISR Number: 4676298-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545935A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676299-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545946A
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 DAY
			Neurontin	C			300MG At night	
			Nortriptyline	C			10MG At night	

Date:05/27/05ISR Number: 4676300-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545954A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Orgasmic Sensation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	8 MON
	Decreased		Birth Control Pills	C				
	Vulvovaginal Dryness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676301-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546033A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline			

Date:05/27/05ISR Number: 4676302-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546035A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hallucination		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	5 DAY
Other	Hyperhidrosis		Effexor Xr	SS				

Date:05/27/05ISR Number: 4676303-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546044A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline		300MG Per day	

Date:05/27/05ISR Number: 4676304-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546046A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	

Date:05/27/05ISR Number: 4676305-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546049A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 MON

	Energy Increased		Xanax	C			
	Insomnia		Ambien	C			
	Thyroid Function Test Abnormal						

Date:05/27/05ISR Number: 4676306-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546050A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	10 MON
			Glucophage	C				
			Atenolol	C				

Date:05/27/05ISR Number: 4676307-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546051A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 DAY
			Adderall	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676308-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546074A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 WK
			Lopressor	C				
			Lipitor	C				
			Xanax	C				

Date:05/27/05ISR Number: 4676309-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546076A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676310-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546081A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	9 DAY
	Headache		Amoxicillin	C	Glaxosmithkline			
	Malaise							

Date:05/27/05ISR Number: 4676311-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546291A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Unknown	

Date:05/27/05ISR Number: 4676312-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546318A
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	8 MON
Initial or Prolonged	Pollakiuria		Ativan	C				
	Weight Decreased		Geodon	C				

Date:05/27/05ISR Number: 4676313-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546323A
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Crying		Levoxyl	C	Glaxosmithkline			
	Irritability		Ambien	C				
			Topamax	C				
			Tricor	C				
			Ibuprofen	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676314-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546325A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Rash		Synthroid	C	Glaxosmithkline			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676315-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546332A
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
			No Concurrent Medication	C				
			Meridia	C				

Date:05/27/05ISR Number: 4676316-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546340A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 YR
	Drug Ineffective		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
	Feeling Jittery							

Date:05/27/05ISR Number: 4676317-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546347A
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	79 DAY
			Effexor	SS		ORAL	75MG Unknown	
			Zonegran	C			UNKNOWN	
			Cozar	C				
			Lipitor	C				
			Glucotrol	C				
			Cialis	C				

Date:05/27/05ISR Number: 4676318-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546505A
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharmaceutical Product		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Complaint		Prozac	C				
	Poor Quality Drug		Lotensin	C	Glaxosmithkline			
	Administered		Seroquel	C				
			Clonazepam	C				
			Celebrex	C				

Date:05/27/05ISR Number: 4676319-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546521A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotrichosis		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/27/05ISR Number: 4676320-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546721A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
	Influenza Like Illness		Synthroid	C	Glaxosmithkline			
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676321-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546722A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Urticaria							

Date:05/27/05ISR Number: 4676322-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546729A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Dizziness		Antibiotic	C				
	Headache							
	Hyperhidrosis							
	Vomiting							

Date:05/27/05ISR Number: 4676323-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546734A
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	10 MON
	Rheumatoid Factor		Neurontin	C				
	Positive		Topamax	C				

Date:05/27/05ISR Number: 4676324-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546761A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK

Date:05/27/05ISR Number: 4676325-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546768A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Feeling Abnormal							
	Feeling Jittery							

Date:05/27/05ISR Number: 4676326-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546812A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	3	WK

Date:05/27/05ISR Number: 4676327-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546926A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	30 MON
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676328-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546931A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Therapeutic Response		No Concurrent					
	Unexpected		Medication	C				

Date:05/27/05ISR Number: 4676329-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546932A
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Paraesthesia		Klonopin	C				
			Glucovance	C				
			Vasotec	C				
			Prometrium	C				

Date:05/27/05ISR Number: 4676331-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546939A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	1 YR
			Omeprazole	SS	Glaxosmithkline	ORAL	20MG Per day	
			Prilosec	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676333-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546942A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - UNKNOWN Initial or Prolonged	Stevens-Johnson Syndrome		Wellbutrin	PS	Glaxosmithkline	

Date:05/27/05ISR Number: 4676334-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540242A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nuclear Magnetic Resonance Imaging Abnormal		Wellbutrin Xl	PS	Glaxosmithkline		UNKNOWN	

Date:05/27/05ISR Number: 4676335-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546943A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Enzyme Increased		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	12 WK
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676336-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541134A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dystonia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the morning	

			Topomax	SS		
			Geodon	C		
			Prozac	C		

Date:05/27/05ISR Number: 4676337-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546944A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Insomnia		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676338-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542666A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline			

Date:05/27/05ISR Number: 4676339-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546948A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:05/27/05ISR Number: 4676340-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543964A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	

Date:05/27/05ISR Number: 4676341-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546964A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Constipation							
	Drug Ineffective							
	Insomnia							
	Paraesthesia							

Date:05/27/05ISR Number: 4676342-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550316A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Pharmaceutical Product Complaint							
	Stool Analysis Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676343-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546968A
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
			Abilify	C				

Date:05/27/05ISR Number: 4676345-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546971A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 DAY
	Stomach Discomfort		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676347-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546999A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	78 DAY
			Ativan	C			.5MG As required	

Date:05/27/05ISR Number: 4676348-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547034A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676349-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547135A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Chest Pain		Xanax	C				
	Tinnitus		Alprazolam	C				

Date:05/27/05ISR Number: 4676350-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547149A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK
			Blood Pressure Medication	C				

Date:05/27/05ISR Number: 4676351-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547157A
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Marijuana	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676352-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547174A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Disorder		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	18	MON
	Tooth Disorder							
	Tooth Infection							

Date:05/27/05ISR Number: 4676353-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547184A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	1 WK
	Anxiety		Voltaren	C	Glaxosmithkline			
	Dry Mouth							
	Dyspnoea							
	Flashback							
	Insomnia							
	Nausea							
	Rash							
	Tremor							

Date:05/27/05ISR Number: 4676354-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547185A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Unknown	WK

Date:05/27/05ISR Number: 4676355-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547186A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Unknown	WK

Date:05/27/05ISR Number: 4676356-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547354A
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		2 WK
Initial or Prolonged	Nausea		Coumadin	C	Glaxosmithkline			
			Ultram	C				

Date:05/27/05ISR Number: 4676357-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547361A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 YR
			Allegra	C				

Date:05/27/05ISR Number: 4676358-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547371A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affect Lability		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 WK
	Drug Ineffective		Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676359-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547372A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
			Clarinex	C				

Date:05/27/05ISR Number: 4676360-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547375A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	21 DAY
	Asthenia		Nexium	C				
	Insomnia							
	Tremor							

Date:05/27/05ISR Number: 4676361-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547376A
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	1 MON

Date:05/27/05ISR Number: 4676362-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547378A
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
			Lexapro	C				

Date:05/27/05ISR Number: 4676363-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547381A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cholecystectomy		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 YR
	Drug Ineffective		Alprazolam	C				
			Quitex	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676364-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547387A
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON

Date:05/27/05ISR Number: 4676365-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547397A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Medication Error		Wellbutrin Sr	SS	Glaxosmithkline	ORAL		
	Pharmaceutical Product		No Concurrent					
	Complaint		Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676366-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547555A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	4 DAY
	Sleep Disorder							

Date:05/27/05ISR Number: 4676367-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547564A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	74 WK
			Multivitamins	C				

Date:05/27/05ISR Number: 4676368-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547566A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Bruxism		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Per day	10 MON
	Feeling Hot		Dexedrine	SS	Glaxosmithkline			
	Insomnia		Paxil	C	Glaxosmithkline			
	Rash		Progesterone Cream	C				
			Tenormin	C				
			Klonopin	C				
			Fioricet	C				
			Vicodin	C				
			Acyclovir	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676369-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547570A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 6 MON						
			Cymbalta	C		
			Protonix	C		

Date:05/27/05ISR Number: 4676370-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547580A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Euphoric Mood		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 7 DAY						
	Sleep Disorder		Nexium	C		
			Tricor	C		

Date:05/27/05ISR Number: 4676371-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547582A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
450MG Per day						
	Drug Ineffective		Nexium	C		
	Irritability		Allegra	C		
	Libido Decreased		Multivitamin	C		
	Pruritus					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676372-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547592A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

Date:05/27/05ISR Number: 4676373-1Report Type:Periodic Company Report #05-01-0123
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
Initial or Prolonged	Grand Mal Convulsion		Clozapine	SS		ORAL	400MG Per day	5 YR

Date:05/27/05ISR Number: 4676374-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547637A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Galactorrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 MON

Date:05/27/05ISR Number: 4676375-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547759A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Wellbutrin	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline		UNKNOWN	

Date:05/27/05ISR Number: 4676376-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547767A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
450MG Per day						
			Prozac	C		
60MG per day						

Date:05/27/05ISR Number: 4676377-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547772A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ejaculation Failure		Wellbutrin	PS	Glaxosmithkline	ORAL
	Libido Increased					

Date:05/27/05ISR Number: 4676378-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547782A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Stool Analysis Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
			Prednisone	C		

Date:05/27/05ISR Number: 4676379-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547790A
Age: Gender:Female I/FU:I

Outcome	PT
	Drug Ineffective
	Dry Mouth
	Palpitations
	Tinnitus

	Vertigo					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day						
			Paxil	SS	Glaxosmithkline	ORAL
			Synthroid	C	Glaxosmithkline	

Date:05/27/05ISR Number: 4676380-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547804A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day						
	Drug Withdrawal Syndrome					
	Hunger					
	Nicotine Dependence					
	Weight Increased					

Date:05/27/05ISR Number: 4676381-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547972A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Muscle Twitching		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
			No Concurrent Medication	C		

Date:05/27/05ISR Number: 4676382-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547979A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						
Initial or Prolonged			Prozac	C		

Date:05/27/05ISR Number: 4676383-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547984A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
	Dizziness		Xanax	C				
	Dyspnoea		Geodon	C				
	Heart Rate Increased							
	Paraesthesia							
	Throat Tightness							
	Urine Abnormality							

Date:05/27/05ISR Number: 4676384-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548002A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676385-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548150A
Age:36 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/27/05ISR Number: 4676386-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548173A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paranoia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	
	Rash Generalised Thinking Abnormal Urticaria		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676387-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548180A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:05/27/05ISR Number: 4676388-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548184A
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	
	Heart Rate Increased		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676389-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548187A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	52 WK
	Flushing		Synthroid	C	Glaxosmithkline			
	Swelling Face							

Date:05/27/05ISR Number: 4676390-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548192A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	10 DAY
	Insomnia		No Concurrent					
	Mouth Ulceration		Medication	C				
	Rash							
	Tinnitus							
	Urticaria							

Date:05/27/05ISR Number: 4676391-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548197A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Unknown	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676392-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548207A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 MON
	Drug Administration Error		Clonidine	C				
			Xanax	C				

Date:05/27/05ISR Number: 4676393-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548230A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Musculoskeletal Chest		Wellbutrin	PS	Glaxosmithkline		150MG Per day	2 DAY
Initial or Prolonged	Pain		Paxil	C	Glaxosmithkline			
			Topomax	C				

Date:05/27/05ISR Number: 4676394-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548231A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Wellbutrin	PS	Glaxosmithkline	ORAL	4	WK
Initial or Prolonged	Tinnitus		Alcohol	C				

Date:05/27/05ISR Number: 4676395-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548259A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	
Other			Ativan	SS		ORAL	1MG Twice per day	

				Remeron	SS		ORAL
7.5MG Per day							
				Zofran	SS	Glaxosmithkline	ORAL
8MG As							
required							
				Seroquel	SS		ORAL
150MG At							
night							
				Prozac	SS		
UNKNOWN	100MG Per day						

Date:05/27/05ISR Number: 4676396-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548361A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
	Lethargy		Valium	C				

Date:05/27/05ISR Number: 4676397-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548374A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day	4 WK
	Flatulence		Paxil	C	Glaxosmithkline			
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676398-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548380A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Unknown	C				

Date:05/27/05ISR Number: 4676399-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548381A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 YR
			Ortho Novum 777	C				

Date:05/27/05ISR Number: 4676400-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548387A
Age:11 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	2 WK
Other			Benadryl	C	Glaxosmithkline			

Date:05/27/05ISR Number: 4676401-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548388A
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Twice per day	8 DAY
	Nausea							
			Minocycline	C				
			Lipitor	C				

Date:05/27/05ISR Number: 4676402-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548407A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Effexor	SS				

Date:05/27/05ISR Number: 4676403-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548443A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritable Bowel Syndrome		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG In the	
	Stool Analysis Abnormal						morning	

Date:05/27/05ISR Number: 4676404-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548598A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676405-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548602A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	6	MON
			Valium	C				

Date:05/27/05ISR Number: 4676406-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548617A
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	3 WK
	Muscle Twitching		No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676407-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548618A
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
			Sinemet	C				
			Comtan	C				
			Mirapex	C				
			Zerit	C				
			Viread	C				
			Sustiva	C				
			Zoloft	C				
			Calcium	C				
			Fosamax	C				
			Valium	C				

Date:05/27/05ISR Number: 4676408-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548648A
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Palpitations		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
150MG Per day 6 MON						
			No Concurrent Medication	C		

Date:05/27/05ISR Number: 4676409-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548651A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Bruxism		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day						
			Buspar	C		

Date:05/27/05ISR Number: 4676410-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548696A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 1 MON						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676411-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548706A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Three	
	Dysphemia						times per day	2 DAY
	Feeling Jittery							
	Influenza Like Illness							
	Medication Error							
	Nausea							
	Pain							
	Restlessness							
	Tremor							
	Vomiting							

Date:05/27/05ISR Number: 4676412-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548812A
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day	7 DAY
			No Concurrent Medication	C				

Date:05/27/05ISR Number: 4676763-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02903
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Cogentin	PS	Merck & Co., Inc	ORAL		
	Drug Interaction		Wellbutrin Sr	SS		ORAL		
			Trazodone Hydrochloride	SS			UNKNOWN	
			Seroquel	SS			UNKNOWN	
			Klonopin	SS			UNKNOWN	

				Trilafon	SS		

UNKNOWN

Date:05/27/05ISR Number: 4677806-7Report Type:Direct Company Report #CTU 249801
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Bupropion Sr 150 Mg	PS			ONE TAB BID	
	Feeling Jittery							

Date:05/31/05ISR Number: 4677473-2Report Type:Expedited (15-DaCompany Report #200511975US
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During Pregnancy		Allegra	PS	Aventis Pharmaceuticals Inc.	ORAL		
	Haemorrhage		Bupropion	SS				
	Umbilical Cord Abnormality		Celexa	SS		ORAL		
			Zantac	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/05ISR Number: 4677864-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0389788A
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Twice	
	Toxic Epidermal						per day	
	Necrolysis		Paxil	C	Glaxosmithkline		60MG per day	
			Nexium	C				
			Premarin	C				

YR

Date:05/31/05ISR Number: 4677867-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553362A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrophic Vulvovaginitis		Wellbutrin	PS	Glaxosmithkline	ORAL		

Date:05/31/05ISR Number: 4677887-0Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0378887A
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Anxiety						per day	6 DAY
	Disturbance In Attention							
	Dizziness							
	Drug Withdrawal Syndrome							
	Dry Mouth							
	Headache							
	Insomnia							
	Irritability							
	Tremor							

Date:05/31/05ISR Number: 4677892-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0380373A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Feeling Abnormal						per day	4 DAY
	Panic Attack		No Concurrent					
	Serotonin Syndrome		Medication	C				

Date:05/31/05ISR Number: 4678432-6Report Type:Direct Company Report #CTU 249981
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Sedation		Bupropion 150mg Bid	PS		ORAL	150MG PO BID	

Date:05/31/05ISR Number: 4678779-3Report Type:Expedited (15-DaCompany Report #S05-USA-01449-01
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bleeding Peripartum	Health	Celexa (Citalopram					
	Drug Exposure During	Professional	Hydrobromide)	PS		ORAL	40 MG QD PO	
	Pregnancy		Wellbutrin					
	Pregnancy		(Bupropion					
	Premature Separation Of		Hydrochloride)	SS		ORAL	300 MG QD PO	
	Placenta		Wellbutrin(Bupropion					
			Hydrochloride)	SS		ORAL	150 MG QD PO	

			Wellbutrin(Bupropion Hydrochloride)	SS		ORAL
300 MG QD PO						
			Allegra(Pexofenadine Hydrochloride)	SS		ORAL
60 MG BID PO						
			Zantac(Ranitidine Hydrochloride)	SS		ORAL
150 MG QD PO						

Date:05/31/05ISR Number: 4678867-1Report Type:Expedited (15-DaCompany Report #2005075887
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abdominal Pain	Health	Zoloft (Sertraline)	PS		ORAL
200 MG (200						
	Autism Spectrum Disorder	Professional				
MG , 1 IN 1						
	Caesarean Section					
D),ORAL						
	Drug Exposure During Pregnancy		Lorazepam (Lorazepam)	SS		ORAL
(0.5 MG AS						
	Neonatal Disorder					
NECESSARY),						
	Pregnancy					
ORAL						
	Small For Dates Baby		Wellbutrin Sr (Bupropion Hydrochloride)	SS		ORAL
(100 MG, AS						
NECESSARY),						
ORAL						
			Ambien (Zolpidem Tartrate)	SS		ORAL
(10 MG, AS						
NECESSARY),						
ORAL						

Date:05/31/05ISR Number: 4678965-2Report Type:Expedited (15-DaCompany Report #A0559763A
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Overdose	Health Professional	Bupropion Hydrochloride Tablet (Generic) (Bupropion Hydrochloride)	PS		ORAL	75 MG/ SEE IMAGE/ORAL	1 DAY
			Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	SS		ORAL	SEE IMAGE/ORAL	
			Olanzapine (Olanzapine)	SS				

Date:05/31/05ISR Number: 4678972-XReport Type:Expedited (15-DaCompany Report #A0559375A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Drug Exposure During Pregnancy	Study	Wellbutrin (Bupropion Hydrochloride)	PS		TRANSPLACENTAL	TRANSPLACENTA RY	
	Dysphagia	Health Professional						
	Neonatal Disorder	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/05ISR Number: 4678973-1Report Type:Expedited (15-DaCompany Report #A0559357A
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Anxiety Psychomotor Hyperactivity	Consumer	Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	PS		ORAL	150 MG / PER DAY/ ORAL	
			Verapamil	C				

Date:05/31/05ISR Number: 4678980-9Report Type:Expedited (15-DaCompany Report #A0560141A
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Accidental Overdose Amnesia Confusional State Disorientation Therapy Non-Responder	Health Professional	Wellbutrin Xl Tablet-Extended Release (Bupropion Hydrochloride)	PS		ORAL	PER DAY/ORAL	
			Ketorolac Trometamol	C				
			Metoprolol Succinate	C				
			Tramadol Hydrochloride	C				
			Lortab	C				

Date:05/31/05ISR Number: 4678982-2Report Type:Expedited (15-DaCompany Report #A0560085A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Road Traffic Accident	Consumer	Wellbutrin Tablet (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ ORAL	

Date:05/31/05ISR Number: 4679615-1Report Type:Expedited (15-DaCompany Report #B0380967A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Disorientation Dizziness Malaise Pneumonia Serotonin Syndrome Sleep Disorder	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride) Amitriptyline Hcl	PS C		ORAL	150 MG/ PER DAY / ORAL	

Date:05/31/05ISR Number: 4679813-7Report Type:Expedited (15-DaCompany Report #B0381635A
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anaphylactic Reaction	Foreign Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	150 MG/TWICE PER DAY/ORAL	

Date:05/31/05ISR Number: 4679816-2Report Type:Expedited (15-DaCompany Report #A0559952A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombophlebitis	Foreign	Wellbutrin Sr					
	Thrombosis	Health	Tablet-Controlled					
		Professional	Release (Bupropion					
		Company	Hydrochloride)	PS		ORAL		
ORAL								
		Representative	Hydromorphone Hcl	C				
			Risperidone	C				
			Amitriptyline	C				

Date:05/31/05ISR Number: 4679954-4Report Type:Expedited (15-DaCompany Report #B0382344A
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Epilepsy	Foreign	Zyban Tablet-Zyban					
Intervention to	Facial Bones Fracture	Consumer	(Bupropion					
Prevent Permanent	Lower Limb Fracture	Other	Hydrochloride)	PS				
150 MG /								
Impairment/Damage								

Date:05/31/05ISR Number: 4679976-3Report Type:Expedited (15-DaCompany Report #B0381636A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Dermatitis Allergic	Foreign	Zyban Tablet-Zyban					
Intervention to	Drug Abuser	Health	(Bupropion					
Prevent Permanent	Drug Administration Error	Professional	Hydrochloride)	PS		ORAL		
150 MG/TWICE								
Impairment/Damage	Joint Swelling							
PER DAY/ ORAL								
			Cannabis	C				

Date:06/02/05ISR Number: 4679353-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559798A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Induced		Bupropion	PS	Glaxosmithkline	ORAL	300MG Per day	

Date:06/02/05ISR Number: 4679354-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559798B
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anencephaly		Bupropion	PS	Glaxosmithkline		300MG Per day	
Congenital Anomaly	Drug Exposure During Pregnancy							

Date:06/02/05ISR Number: 4679379-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0381871A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Distress		Zyban	PS	Glaxosmithkline	ORAL	50 DAY	
Other	Psoriasis		Acitretin	C			UNKNOWN	50MG per day
			Ciclosporin	C			UNKNOWN	400MG per day
			Amlodipine	C			UNKNOWN	10MG per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4679842-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540083A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Augmentin	PS	Glaxosmithkline	ORAL	1000MG Twice per day	3 DAY
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	3 WK
			No Concurrent Medication	C				

Date:06/02/05ISR Number: 4680005-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0560408A
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disturbance In Sexual		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	27 DAY
	Arousal		No Concurrent Medication	C				
	Loss Of Libido							
	Prostate Cancer							

Date:06/02/05ISR Number: 4680033-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0380967A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
	Disorientation		Endep	C	Glaxosmithkline		UNKNOWN	50MG Variable dose
	Dizziness							
	Fall		Androcur	C			UNKNOWN	50MG Per day
	Malaise		Bricanyl Turbohaler	C			RESPIRATORY (INHALATION)	2PUFF Four
	Pneumonia							

		Serotonin Syndrome				
times per day						
		Sleep Disorder	Diamicron	C		
UNKNOWN	80MG Twice					
per day						
			Ditropan	C		
UNKNOWN	5MG Twice per					
day						
			Epilim	C		
UNKNOWN	500MG Three					
times per day						
			Naprosyn Sr	C		
UNKNOWN	1000MG See					
dosage text						
			Panadeine Forte	C	Glaxosmithkline	
UNKNOWN						
			Progynova	C		
UNKNOWN	2MG Twice per					
day						
			Seretide	C	Glaxosmithkline	
RESPIRATORY						
(INHALATION)	1PUFF Twice					
per day						
			Temazepam	C		
UNKNOWN	10MG At night					

Date:06/02/05ISR Number: 4680044-5Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0383114A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Crying		Zyban	PS	Glaxosmithkline	
UNKNOWN						
	Depression		No Concurrent			
	Eating Disorder		Medication	C		
	Insomnia					
	Suicidal Ideation					
	Tremor					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4681499-2Report Type:Expedited (15-DaCompany Report #IMP_0865_2005
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Literature	Bupropion	PS				
	Haemodynamic Instability	Health	Linezolid	SS				
	Hypertension	Professional						
	Hypertensive Crisis							

Date:06/02/05ISR Number: 4681820-5Report Type:Expedited (15-DaCompany Report #IMP_0864_2005
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase	Foreign	Bupropion	PS			300 MG QDAY	3 WK
	Increased	Literature	Sertraline	SS			50 MG QDAY	17 DAY
Required	Aspartate	Health	Piracetam	SS			2400 MG QDAY	17 DAY
Intervention to Prevent Permanent Impairment/Damage	Aminotransferase	Professional	Venlafaxine	SS			75 MG QDAY	17 DAY
	Increased	Other						
	Autonomic Nervous System Imbalance							
	Balance Disorder							
	Blood Pressure Fluctuation							
	Cerebral Atrophy							
	Clumsiness							
	Confusional State							
	Coordination Abnormal							
	Depressed Level Of Consciousness							
	Drug Interaction							
	Inhibition							
	Electrocardiogram Qt Prolonged							
	Electrocardiogram Repolarisation Abnormality							
	Faecal Incontinence							
	Fall							
	Gait Disturbance							

Hallucinations, Mixed
Heart Rate Irregular
Hyperhidrosis
Insomnia
Lethargy
Memory Impairment
Mental Impairment
Myoclonus
Psychomotor Agitation
Pyrexia
Serotonin Syndrome
Tremor
Urinary Incontinence

Date:06/03/05ISR Number: 4681063-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553777A
Age:59 YR Gender:Female I/FU:F

Outcome PT
Other Atrial Flutter
Eye Pain
Headache

	Heart Rate Increased						
	Hyperhidrosis						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	4 MON
	Neuralgia		Benicar	C			
	Photopsia		Skelaxin	C			
	Red Blood Cell Count Decreased		Protonix	C			
			Potassium Supplement	C			
	Vitreous Floaters		Celebrex	C			
	Vomiting		Vicodin	C			
	White Blood Cell Count Decreased		Maxalt	C			
			Prednisolone Acetate	C			
			Betanol 0.3%	C			
			Alphagan	C			
			Ditropan	C			
			Benadryl	C	Glaxosmithkline		
			Zyrtec	C	Glaxosmithkline		
			Gerovit (Multivitamin)	C			
			Tylenol	C	Glaxosmithkline		

Date:06/03/05ISR Number: 4681066-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558861A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Suicidal Ideation		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	450MG Per day
Hospitalization -	Suicide Attempt		Lamictal	C	Glaxosmithkline	ORAL	125MG Per day
Initial or Prolonged			Topamax	C		ORAL	100MG Per day
			Clonazepam	C			.5MG Twice per day

Date:06/03/05ISR Number: 4681069-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0560822A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Diarrhoea Pancreatic Enzymes Increased Weight Decreased		Bupropion	PS	Glaxosmithkline	ORAL		

Date:06/03/05ISR Number: 4681080-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0381635A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction Joint Swelling Oedema Peripheral Orbital Oedema Pruritus Rash Generalised Urticaria		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	15 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4684598-4Report Type:Expedited (15-DaCompany Report #2005017220
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Consumer	Zoloft (Sertraline)	PS			25 MG (25 MG,	
	Alopecia	Health					1 IN 1 D)	
	Body Height Decreased	Professional	Wellbutrin					
	Dry Skin		(Bupropion					
	Eructation		Hydrochloride)	SS		ORAL	ORAL	
	Flatulence		Klonopin					
	Glossodynia		(Clonazepam)	C				
	Movement Disorder							
	Nervous System Disorder							
	Self Mutilation							

Date:06/06/05ISR Number: 4682634-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0560943A
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	General Physical Health		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
	Deterioration		No Concurrent					
			Medication	C				

Date:06/06/05ISR Number: 4682689-5Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0383467A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxosmithkline		UNKNOWN	

Date:06/06/05ISR Number: 4685803-0Report Type:Direct Company Report #CTU 250458
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin Sr 150 Mg (Unk If Generic Dispensed)	PS		ORAL	150 MG QD X 7 THEN BID PO	

Date:06/06/05ISR Number: 4686476-3Report Type:Expedited (15-DaCompany Report #2005079514
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Bextra (Valdecoxib)	PS		ORAL	20 MG(10 MG, 2 IN 1 D), ORAL	
	Cellulitis							
	Erysipelas							
	Eye Allergy		Benadryl Injection (Diphenhydramine)	SS		INTRAVENOUS	INTRAVENOUS	
	Hypersensitivity							
	Pain		Lisinopirl (Lisinopril)	SS		ORAL	20 MG (20 MG, 1 IN 1 D), ORAL	
	Pharyngeal Oedema							
	Pharyngolaryngeal Pain							
	Urticaria							
			Cortisone (Cortisone)	SS		INTRAVENOUS	INTRAVNEOUS	
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	300 MG (150 MG, 2 IN 1 D), ORAL	

			Toprol (Metoprolol)	SS		ORAL
ORAL						

Date:06/06/05ISR Number: 4686519-7Report Type:Expedited (15-DaCompany Report #2005080150
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dizziness	Consumer	Celebrex (Celecoxib)	PS		
	Feeling Abnormal		Paxil (Paroxetine Hydrochloride)	SS		
	Laboratory Test Abnormal		Wellbutrin (Bupropion Hydrochloride)	SS		
	Nasopharyngitis		Aleve (Naproxen Sodium)	SS		
	Pain		Avalide (Hydrochloride, Irbesartan)	C		
	Personality Disorder		Acetylsalicylic Acid (Acetylsalicylic Acid)	C		
	Retching		Multivitamins (Multivitamins)	C		
	Vomiting		Atenolol (Atenolol)	C		

Date:06/07/05ISR Number: 4684149-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0560956A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day 3 YR						
	Head Injury		Alcohol	C		

Date:06/07/05ISR Number: 4684181-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0380880A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Hospitalization -	Anxiety		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day						
Initial or Prolonged	Blood Pressure Increased					
	Chest Pain					
	Palpitations					
	Sense Of Oppression					
	Tachycardia					
	Tension					

Date:06/08/05ISR Number: 4685361-0Report Type:Expedited (15-DaCompany Report #13296
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Apnoea		Wellbutrin	PS	Glaxosmithkline	
300MG Per day						
Hospitalization -	Cyanosis		Tricyclic			
Initial or Prolonged	Drug Exposure During		Antidepressant	C		
Other	Pregnancy		Protonix	C		
	Drug Withdrawal Syndrome		Multivitamins	C		
	Respiratory Distress					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/05ISR Number: 4685392-0Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0378949A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Hallucination						per day	13 DAY
	Insomnia		Alprazolam	C			UNKNOWN	
	Panic Reaction							
	Paranoia							
	Paraplegia							
	Rash							

Date:06/08/05ISR Number: 4685393-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0380967A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
Initial or Prolonged	Disorientation		Endep	C	Glaxosmithkline		UNKNOWN	50MG Variable
	Dizziness						dose	
	Fall		Androcur	C			UNKNOWN	50MG Per day
	Malaise		Bricanyl Turbohaler	C			RESPIRATORY	
	Pneumonia						(INHALATION)	2PUFF Four
	Serotonin Syndrome						times per day	
	Sleep Disorder		Diamicron	C			UNKNOWN	80MG Twice
							per day	
			Ditropan	C			UNKNOWN	5MG Twice per
							day	
			Epilim	C			UNKNOWN	500MG Three

times per day

			Naprosyn Sr	C	
UNKNOWN	1000MG See dosage text				
			Panadeine Forte	C	Glaxosmithkline
UNKNOWN	2MG Twice per day		Progynova	C	
			Seretide	C	Glaxosmithkline
RESPIRATORY (INHALATION)	1PUFF Twice per day				
			Temazepam	C	
UNKNOWN	10MG At night				

Date:06/09/05ISR Number: 4686230-2Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0561473A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Paxil	PS	Glaxosmithkline			
	Drug Withdrawal Syndrome		Wellbutrin Sr	SS	Glaxosmithkline		15	DAY
	Hyperhidrosis							
	Hypoaesthesia							
	Paraesthesia							
	Tremor							

Date:06/09/05ISR Number: 4687440-0Report Type:Direct Company Report #CTU 250815
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fall		Ultram 50 Mg	PS			50 MG 2 TID	
	Grand Mal Convulsion						PRN	
	Loss Of Consciousness		Wellbutrin Sr 150 Mg	SS			150 MG BID	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4687979-8Report Type:Expedited (15-DaCompany Report #PHEH2005US06302
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Trileptal	PS	Novartis Sector: Pharma	ORAL	475 mg, QD	
	Electroencephalogram							
	Abnormal		Wellbutrin (Xl)	SS		ORAL	300 mg, QD	
			Wellbutrin (Xl)	SS		ORAL	150 mg, QD	
			Dexedrine "Smithkline Beecham"	C		ORAL	5 mg, BID	
			Abilify	C			5 mg, UNK	

Date:06/10/05ISR Number: 4688018-5Report Type:Expedited (15-DaCompany Report #2005UW08423
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Seroquel	PS	Zeneca Pharmaceutical	ORAL		
	Crying							
	Depression		Wellbutrin Xl	SS		ORAL		
	Intentional Self-Injury		Risperdal	C				
	Laceration		Klonopin	C				
	Poisoning		Paxil	C		ORAL	9	YR
	Psychotic Disorder							
	Suicide Attempt							

Date:06/10/05ISR Number: 4688211-1Report Type:Expedited (15-DaCompany Report #AU-ABBOTT-05P-008-0302257-00
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Epilim	PS			UNKNOWN	
	Depression		Bupropion Hydrochloride	SS			UNKNOWN	
	Overdose							

	Temazepam	SS
UNKNOWN		
	Diazepam	SS
	Ipratropium Bromide	SS
UNKNOWN		
	Fluticasone Propionate	SS
UNKNOWN		
	Hydrochlorothiazide	SS
UNKNOWN		
	Salbutamol	SS
UNKNOWN		

Date:06/13/05ISR Number: 4688800-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0548205A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	74 DAY
Hospitalization - Initial or Prolonged	Confusional State Grand Mal Convulsion Incorrect Dose Administered Medication Error Overdose Temporal Lobe Epilepsy		Lexapro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4688811-9Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0561484A
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Affect Lability		Paroxetine	PS	Glaxosmithkline	ORAL	20MG Per day	
	Agitation		Bupropion	SS	Glaxosmithkline	ORAL	150MG Per day	1 WK
	Blood Pressure Increased		Trazodone	SS		ORAL	50MG Unknown	
	Carotid Artery Thrombosis		Contraceptive	C				
	Cerebrovascular Accident		Lithium Carbonate	C	Glaxosmithkline			
	Delirium							
	Disorientation							
	Hyperreflexia							
	Muscular Weakness							
	Pyrexia							
	Serotonin Syndrome							
	Tachycardia							

Date:06/13/05ISR Number: 4688817-XReport Type:Expedited (15-DaCompany Report #13148
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tachycardia		Bupropion	PS	Glaxosmithkline		150MG Per day	
			Unspecified Ssri	C				

Date:06/13/05ISR Number: 4688818-1Report Type:Expedited (15-DaCompany Report #13149
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Bupropion	PS	Glaxosmithkline		300MG Per day	
			Unspecified Ssri	C				

Date:06/13/05ISR Number: 4688833-8Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0380012A
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Zyban	PS	Glaxosmithkline	ORAL	10	DAY
	Dry Mouth		Thyroxine	C	Glaxosmithkline			
	Hyperhidrosis		Diphenhydramine					
	Ill-Defined Disorder		Hydrochloride	C	Glaxosmithkline		10MG per day	
	Mouth Ulceration		Prednisolone	C	Glaxosmithkline		5MG per day	
	Oral Pain		Furosemide	C	Glaxosmithkline		20MG per day	
	Swelling Face							
	Tremor							

Date:06/13/05ISR Number: 4688834-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0380740A
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Analgesic Effect		Zyban	PS	Glaxosmithkline	ORAL	300MG per day	
	Drug Abuser		Imiject	SS	Glaxosmithkline			
	Therapeutic Response		No Concurrent				SUBCUTANEOUS	4INJ per day
	Unexpected		Medications	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4688854-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0384025A
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema Cholestasis Cytolytic Hepatitis		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/13/05ISR Number: 4690182-9Report Type:Expedited (15-DaCompany Report #2005-01-1690
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Depression Haemorrhagic Stroke	Health Professional Company Representative	Peg-Intron (Peginterferon Alfa-2b) Redipen	PS		SUBCUTANEOUS	150 MCG QWK	
			Copegus (Ribavirin) Capsules	SS		ORAL	1200 MG QD	
			Pegasys (Pegylated Interferon Alfa-2a) Injectable	SS		SUBCUTANEOUS	180 MCG QWK	
			Wellbutrin (Bupropion)	SS		ORAL	100 MG TID	
			Percocet	C				
			.....	C				
			Protonix (Pantoprazole Sodium)	C				
			Percodan	C				
			Procrit Injectable	C				
			Diazepam	C				
			Lorazepam	C				

			Levoxyl		C		

Date:06/14/05ISR Number: 4690738-3Report Type:Direct Company Report #CTU 251070
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Bupropion	100mg	PS		ORAL	100MG	
Hospitalization -	Life Support							TWICE DAILY	
Initial or Prolonged	Treatment Noncompliance							ORAL	
Required			Cyclobenzaprine Hcl		C				
Intervention to			Diazepam		C				
Prevent Permanent			Fluoxetine Hcl		C				
Impairment/Damage			Gabapentin		C				
			Hydrochlorothiazide		C				
			Irbesartan		C				
			Loratadine		C				
			Omeprazole		C				
			Topiramate		C				
			Verapamil Hcl		C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690270-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0561914A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Spasms		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG	Unknown 1 WK
Other	Muscle Twitching		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG	Unknown

Date:06/15/05ISR Number: 4690305-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0384155A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline		UNKNOWN	7 DAY
	Depression							
	Smoker							
	Suicidal Ideation							

Date:06/15/05ISR Number: 4690626-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0511243A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin Sr	PS	Glaxosmithkline		150MG	See dosage text
	Decreased Appetite							
	Depressed Mood							
	Disturbance In Attention							
	Feelings Of Worthlessness							
	Gun Shot Wound							
	Head Injury							
	Major Depression							
	Sleep Disorder							
	Social Avoidant Behaviour							
	Suicidal Ideation							
	Treatment Noncompliance							
	Tremor							

Date:06/15/05ISR Number: 4690628-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0535145A
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Wellbutrin Xl	PS	Glaxosmithkline		150MG Per day	8 DAY
	Proctalgia		Concerta	C				
	Rectal Haemorrhage							
	Stool Analysis Abnormal							

Date:06/15/05ISR Number: 4690630-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0552342A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Bupropion	PS	Glaxosmithkline	ORAL	150MG Twice per day	21 MON
	Aura							
	Convulsion		Paxil	C	Glaxosmithkline			
			Clonazepam	C			1MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690633-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557288A
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Wellbutrin	PS	Glaxosmithkline	ORAL	306	DAY
	Grand Mal Convulsion		Zyprexa	C		ORAL	10MG	Per day
	Incontinence		Zoloft	C		ORAL	50MG	Per day
	Scratch							
	Somnolence							

Date:06/15/05ISR Number: 4690638-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0562131A
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG	Per day
			Depakote	C				
			Adderall	C				
			Xanax	C				

Date:06/15/05ISR Number: 4690639-0Report Type:Expedited (15-DaCompany Report #CL-GLAXOSMITHKLINE-A0562265A
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Laryngeal Oedema		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG	See
Hospitalization -	Overdose						dosage text	
Initial or Prolonged	Suicide Attempt							
Other								

Date:06/15/05ISR Number: 4691416-7Report Type:Expedited (15-DaCompany Report #2005051512
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Anxiety Back Pain Depression Nervousness Suicidal Ideation	Consumer Health Professional	Celebrex (Celecoxib) Wellbutrin (Bupropion Hydrochloride) Lexapro (Escitalopram) Trazadone (Trazadone) Advair (Fluticasone Propionate, Salmeterol Xinafoate) All Other Therapeutic Products (All Othr Therapeutic Products)	PS SS C C C C		ORAL ORAL	400 MG (200 MG, 2 IN 1 D), ORAL 300 MG (150 MG, 2 IN 1 D), ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4691865-7Report Type:Direct Company Report #CTU 251230
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Buproprion Sr 200 Mg	PS		ORAL	PO BID	
	Condition Aggravated							
	Therapeutic Response		Zanaflex	C				
	Unexpected With Drug		Neurontin	C				
	Substitution		Catapress	C				
			Tetracycline	C				
			Topical Clotrimazole	C				
			Levaquin	C				
			Macrodantin	C				
			Suprofen	C				
			Envlose Fibercon	C				

Date:06/15/05ISR Number: 4693851-XReport Type:Expedited (15-DaCompany Report #S05-USA-02982-01
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Lexapro (Escitalopram)	PS		ORAL	30 MG QD PO	
	Dizziness							
	Dyskinesia		Lexapro (Escitalopram)	SS		ORAL	10 MG QD PO	
	Fall							
	Fatigue		Lexapro (Escitalopram)	SS		ORAL	40 MG QD PO	
	Head Injury							
	Headache		Wellbutrin (Bupropion Hydrochloride)	SS				

Date:06/16/05ISR Number: 4694005-3Report Type:Expedited (15-DaCompany Report #IMP_0847_2005
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Anxiety	Consumer	Bupropion	PS		ORAL
1 TAB QDAY PO						
	Crying		Lexapro	C		
	Depression		Lorazepam	C		
	Paranoia		Calcium Citrate	C		
	Pharmaceutical Product		Glucosamine			
	Complaint		Chondrotin	C		
	Suicidal Ideation		Multivitamin	C		

Date:06/17/05ISR Number: 4692725-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558531A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Alcohol Withdrawal		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 23 DAY						
Hospitalization -	Syndrome		Alcohol	SS		
Initial or Prolonged	Amnesia		Benicar	C		
Other	Extradural Haematoma					
	Fall					
	Grand Mal Convulsion					
	Head Injury					
	Skull Fracture					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693277-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558376A
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eating Disorder		Wellbutrin	PS	Glaxosmithkline	ORAL	450MG Per day	
	Emotional Disorder		Crack Cocaine	SS				
	Flight Of Ideas		Alcohol	SS				
	Grand Mal Convulsion		Valium	C				
	Incontinence		Xanax	C			1MG Twice per day	
	Logorrhoea							
	Overdose							
	Stress							
	Tearfulness							
	Tongue Biting							

Date:06/17/05ISR Number: 4693278-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558504A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Abuser		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	1800MG Per day	1 DAY
	Intentional Misuse							
	Somnolence		Albuterol	C	Glaxosmithkline			
			Advair	C	Glaxosmithkline			
			Singulair	C				

Date:06/17/05ISR Number: 4693279-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558505A
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Abuser		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	900MG Per day	1 DAY
	Intentional Misuse		Albuterol	C	Glaxosmithkline			
	Nausea		Advair	C	Glaxosmithkline			
	Overdose							
	Tremor							

Date:06/17/05ISR Number: 4694916-9Report Type:Expedited (15-DaCompany Report #S05-USA-01449-01
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antepartum Haemorrhage Drug Exposure During Pregnancy Haemorrhage Placental Disorder Pregnancy Umbilical Cord Abnormality	Health Professional	Celexa (Citalopram Hydrobromide)	PS		ORAL	40 MG QD PO	
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	300 MG QD PO	
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	150 MG QD PO	
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	300 MG QD PO	
			Allegra (Fexofenadine Hydrochloride)	SS		ORAL	60 MG BID PO	
			Zantac (Ranitidine Hydrochloride)	SS		ORAL	150 MG QD PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/05ISR Number: 4694661-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0562517A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		
	Injury		Ethanol	C		ORAL		

Date:06/20/05ISR Number: 4694665-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563187A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Eskalith	PS	Glaxosmithkline	ORAL		
	Road Traffic Accident		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	1 MON
			Unknown	C				

Date:06/20/05ISR Number: 4694692-XReport Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0384877A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Zyban	PS	Glaxosmithkline		UNKNOWN	150MG Twice
	Cerebrovascular Accident						per day	6 DAY
	Convulsion							
	Death							

Date:06/21/05ISR Number: 4695995-5Report Type:Expedited (15-DaCompany Report #2005-01-1690
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three	
Hospitalization -								
times per day	413 DAY							
Initial or Prolonged			Pegylated Interferon					

				Alpha 2a	SS		
SUBCUTANEOUS	180MCG Weekly	396	DAY				
				Copegus	SS		ORAL
1200MG Per day		413	DAY				
				Pegylated Interferon Alpha 2b	SS		
SUBCUTANEOUS	150MCG Weekly						
				Percocet	C		
				Benzodiazepine	C		
				Levoxyl	C	Glaxosmithkline	ORAL
.175MG Per day							
				Lorazepam	C		ORAL
1MG Three times per day							
				Protonix	C		ORAL
40MG Per day							
				Percodan	C		ORAL
325MG Twice per day		101	DAY				
				Procrit	C		
SUBCUTANEOUS	40000U Weekly	277	DAY				
				Diazepam	C		ORAL
5MG Twice per day		413	DAY				

Date:06/21/05ISR Number: 4696002-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563000A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dystonia		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 DAY
Other	Feeling Abnormal		No Concurrent Medication	C				
	Speech Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/05ISR Number: 4696030-5Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0384576A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Zyban	PS	Glaxosmithkline			11 DAY
	Heart Rate Increased							
	Hunger							
	Loss Of Consciousness							
	Panic Attack							

Date:06/21/05ISR Number: 4697783-2Report Type:Direct Company Report #CTU 251631
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Bupropion Sa 100 Mg	PS			1 TAB BID	
Initial or Prolonged	Confusional State		Fluoxetine 20 Mg	SS			2 CAPS DAILY	
	Dehydration							
	Serotonin Syndrome							
	Urinary Tract Infection							

Date:06/22/05ISR Number: 4697237-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0385105A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Zyban	PS	Glaxosmithkline		UNKNOWN	5 DAY
Initial or Prolonged	Dizziness		Valerian	C	Glaxosmithkline			
	Heart Alternation							
	Hypertension							
	Palpitations							

Date:06/22/05ISR Number: 4697683-8Report Type:Expedited (15-DaCompany Report #2005080150
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Mood	Consumer	Celebrex (Celecoxib)	PS				
	Dizziness		Paxil (Paroxetine Hydrochloride)	SS				
	Feeling Abnormal		Wellbutrin (Bupropion Hydrochloride)	SS				
	Flat Affect		Aleve (Naproxen Sodium)	SS				
	Multiple Sclerosis		Avalide (Hydrochlorothiazide, Irbesartan)	C				
	Nasopharyngitis		Acetylsalicylic Acid (Acetylsalicylic Acid)	C				
	Pain		Multivitamins (Multivitamins)	C				
	Personality Disorder		Atenolol (Atenolol)	C				
	Retching							
	Vomiting							

Date:06/23/05ISR Number: 4698146-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559188A
Age: Gender:Female I/FU:F

Outcome	PT
Other	Drug Exposure During Pregnancy

	Jaundice Neonatal Premature Baby					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Wellbutrin	PS	Glaxosmithkline	
450MG per day						
			Lexapro	C		
20MG per day						

Date:06/23/05ISR Number: 4698147-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559798A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abortion Induced		Wellbutrin	PS	Glaxosmithkline	ORAL
300MG Per day						
	Stillbirth					

Date:06/23/05ISR Number: 4698148-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559798B
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Abortion Induced		Wellbutrin	PS	Glaxosmithkline	
300MG Per day						
Congenital Anomaly	Anencephaly					
	Drug Exposure During Pregnancy					
	Stillbirth					

Date:06/23/05ISR Number: 4698149-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0562405A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Adverse Event		Wellbutrin	PS	Glaxosmithkline	ORAL
2 YR						
Hospitalization -	Anoxic Encephalopathy		Xanax	SS		
Initial or Prolonged	Cardiac Arrest		Alcohol	SS		
Disability	General Physical Health					
Other	Deterioration					

	Grand Mal Convulsion					
	Hypotension					
	Myocardial Infarction					

Date:06/23/05ISR Number: 4698150-8Report Type:Expedited (15-DaCompany Report #2005-06-0342
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dehydration		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
	Diarrhoea						per day	
	Haematochezia		Ativan	SS			UNKNOWN	
	Hallucination, Visual		Pegylated Interferon					
	Headache		Alpha 2b	SS			SUBCUTANEOUS	
	Neck Pain		Rebetol	SS		ORAL		
	Vomiting							

Date:06/23/05ISR Number: 4698153-3Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0563226A
Age:50 YR Gender:Female I/FU:I

Outcome	PT
Other	Convulsion
	Dizziness
	Drug Withdrawal Syndrome
	Dyskinesia

Fatigue						
Loss Of Control Of Legs						
Malaise	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Nausea		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	150MG Twice
Tremor						per day
		Topamax	C		ORAL	300MG per day
		Clonazepam	C		ORAL	10MG At night 3 YR

Date:06/23/05ISR Number: 4698155-7Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0563485A
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	150MG Single
	Pallor						dose 1 DAY
	Sensory Disturbance		Psorex	C	Glaxosmithkline	ORAL	
			Triptanol	C		ORAL	
			Aspirin	C	Glaxosmithkline	ORAL	
			Buscopan	C			
			Lisador	C			

Date:06/23/05ISR Number: 4698165-XReport Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0383114A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Crying		Zyban	PS	Glaxosmithkline		UNKNOWN
	Depression		No Concurrent				
	Eating Disorder		Medication	C			
	Insomnia						
	Suicidal Ideation						
	Tremor						

Date:06/23/05ISR Number: 4698166-1Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0383245A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying		Zyban	PS	Glaxosmithkline	ORAL		
	Depression		No Concurrent					
	Eating Disorder		Medication	C				
	Insomnia							
	Nausea							
	Suicidal Ideation							
	Tremor							

Date:06/23/05ISR Number: 4698171-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0384598A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Zyban	PS	Glaxosmithkline	ORAL	750MG per day	
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness		Alcohol	C				
	Grand Mal Convulsion							
	Hypothermia							
	Intentional Misuse							
	Status Epilepticus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/05ISR Number: 4699383-7Report Type:Direct Company Report #CTU 251868
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Wellbutrin Sr 150					
	Confusional State		Mgm Q Am, 75 Mgm Q					
	Depressed Level Of		Pm	PS				
	Consciousness		Lexapro 20 Mgm Q Am,					
	Disorientation		10 Mg Mgm Q Pm	SS				
	Road Traffic Accident							
	Status Epilepticus							

Date:06/24/05ISR Number: 4699282-0Report Type:Expedited (15-DaCompany Report #13611
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deficiency Anaemia		Bupropion	PS	Glaxosmithkline			
	Gastrointestinal		Prenatal Vitamins	C			1TAB	Per day
	Infection		Calcium	C			1200MG	Twice
	Polyhydramnios						per day	

Date:06/24/05ISR Number: 4699283-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559914A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	54	DAY
	Fall		Geodon	C				
	Grand Mal Convulsion		Provigil	C		ORAL	200MG	Per day
			Ambien	C		ORAL		

Date:06/24/05ISR Number: 4699288-1Report Type:Expedited (15-DaCompany Report #S05-USA-02982-01
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	30MG Per day	
	Dizziness		Lexapro	SS		ORAL		
	Dyskinesia							
	Epilepsy							
	Fall							
	Fatigue							
	Head Injury							
	Postictal Headache							

Date:06/24/05ISR Number: 4699289-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563222A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Suicidal Ideation							

Date:06/24/05ISR Number: 4699323-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0383467A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Zyban	PS	Glaxosmithkline		UNKNOWN	
	Chest Discomfort		No Concurrent Medication	C				
	Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699329-1Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0384603A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Bullous		Zyban	PS	Glaxosmithkline	ORAL	23	DAY
			Co-Amoxiclav	C	Glaxosmithkline	ORAL	2	DAY
			Omeprazole	C	Glaxosmithkline		UNKNOWN	20MG per day 3 WK
			Diclofenac Sodium	C	Glaxosmithkline	ORAL	50MG Per day	

Date:06/24/05ISR Number: 4699330-8Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0384604A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Orthopnoea		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	1 MON
	Palpitations		Ibuprofen	C	Glaxosmithkline	ORAL	400MG per day	
	Sleep Disorder							

Date:06/24/05ISR Number: 4699334-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0384922A
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coordination Abnormal		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	11 DAY
	Road Traffic Accident							

Date:06/24/05ISR Number: 4700967-8Report Type:Expedited (15-DaCompany Report #B0384487A
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity	Study Literature	Zyban Tablet-Zyban (Bupropion					

		Health	Hydrochloride)	PS		ORAL
150 MG / PER DAY / ORAL WK		Professional				

Date:06/27/05ISR Number: 4700047-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563807A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Congenital Anomaly	Drug Exposure During Pregnancy Nervous System Disorder		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	

Date:06/27/05ISR Number: 4700550-4Report Type:Direct Company Report #CTU 252005
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dysgeusia Feeling Abnormal Nausea Pharmaceutical Product Complaint		Bupropion Sr 150mg Teva Pharma	PS	Teva Pharma	ORAL
150MG BID ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/05ISR Number: 4701458-0Report Type:Expedited (15-DaCompany Report #HQWYE382713JUN05
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Literature	Effexor (Venlafaxine Hydrochloride, Tablet)	PS			OVERDOSE	AMOUNT
	Diarrhoea							
	Drug Interaction							
	Dyspnoea							
	Hepatic Congestion		Manerix (Moclobemide)	SS			OVERDOSE	
	Hepatic Steatosis							
	Hyperhidrosis		Trimipramine (Trimipramine)	SS				
	Multiple Drug Overdose							
	Pulmonary Congestion		Wellbutrin (Bupropion Hydrochloride)	SS				
	Pulmonary Oedema							
	Respiratory Arrest							
	Serotonin Syndrome							

Date:06/27/05ISR Number: 4701808-5Report Type:Expedited (15-DaCompany Report #2005SP001183
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Multiple Drug Overdose	Health Professional	Lunesta (3 Mg)	PS		ORAL	1X; ORAL	
			Trandolapril	SS			IX,	
			Verapamil	SS			IX;	
			Avandia	SS			IX,	
			Metformin	SS			IX;	
			Lasix	SS			IX,	
			Wellbutrin Xl	SS			IX,	
			Alcohol	SS			IX;	

Date:06/28/05ISR Number: 4701131-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563630A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	4 MON
Initial or Prolonged	Blood Creatine Phosphokinase Increased		Methylphenidate	C				
	Dementia							
	Hot Flush							

Date:06/28/05ISR Number: 4701133-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563834A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Feeling Abnormal		Wellbutrin	PS	Glaxosmithkline	ORAL		
Initial or Prolonged			Trazodone	SS				

Date:06/28/05ISR Number: 4701134-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563842A
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Other	Anaemia
	Anorexia
	Asthenia
	Chest Pain
	Colitis
	Eating Disorder
	Gastritis

		Malaise					
		Malnutrition					
		Red Blood Cell	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sedimentation Rate		Wellbutrin	PS	Glaxosmithkline	ORAL
		Increased					
		Weight Decreased					

Date:06/28/05ISR Number: 4701135-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563865A
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anxiety		Wellbutrin	PS	Glaxosmithkline	ORAL
		Faecal Incontinence					
		Psychotic Disorder					

Date:06/28/05ISR Number: 4701145-9Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0381636A
Age:21 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Dermatitis Allergic		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice							
Other		Joint Swelling					
per day	18 DAY						
		Pharmaceutical Product		Marijuana	C		
		Complaint		Cannabis	C		
		Rash					
		Stevens-Johnson Syndrome					
		Urticaria					

Date:06/28/05ISR Number: 4701953-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Angina Unstable
Other	Anxiety
	Arthralgia

Arthropathy
Back Pain
Benign Prostatic
Hyperplasia
Cardiac Failure
Congestive
Chest Pain
Coronary Artery Disease
Coronary Artery
Restenosis
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Diabetic Nephropathy
Diabetic Neuropathy
Diabetic Retinopathy
Drug Hypersensitivity
Drug Ineffective
Fall
Hepatitis
Herpes Zoster
Hypercholesterolaemia

	Infection					
	Injury					
	Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY						
	Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
146 DAY						
	Ischaemic Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL
	Oedema Peripheral		Zyban	SS		
UNKNOWN						
	Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY						
	Renal Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
146 DAY						
	Sepsis		Zestril	C		
UNKNOWN	2170 DAY					
	Sexual Dysfunction		Zestril	C		
UNKNOWN	2170 DAY					
	Weight Increased		Tenormin	C		
UNKNOWN						
			Tenormin	C		
UNKNOWN						
			Glucophage	C		
UNKNOWN						
			Micronase	C		
UNKNOWN						
			Lanoxin	C		
UNKNOWN	1051 DAY					
			[Therapy Unspecified]	C		
UNKNOWN						
			Aciphex	C		
UNKNOWN						

Date:06/28/05ISR Number: 4703071-8Report Type:Direct Company Report #CTU 252109
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Asthenia		Wellbutrin	PS		ORAL
75MG X1 PO	1 DAY					
	Condition Aggravated		Wellbutrin	SS		ORAL
100 MG X1 PO	1 DAY					

	Gout					
	Headache					
	Muscle Spasms					
	Paraesthesia					

Date:06/29/05ISR Number: 4702350-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509984A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain		Ventolin	PS	Glaxosmithkline	RESPIRATORY		
	Muscle Twitching					(INHALATION)		
	Vision Blurred		Wellbutrin	SS	Glaxosmithkline			
			Xenical	C				

Date:06/29/05ISR Number: 4702623-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0102274A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Rash Pruritic						per day	22 DAY

Date:06/29/05ISR Number: 4702624-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0508929A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Zyban	PS	Glaxosmithkline		24	DAY
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702625-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0509455A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:06/29/05ISR Number: 4702626-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510661A
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Insomnia		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702627-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0510662A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702628-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511093A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dizziness		Zyban	PS	Glaxosmithkline	ORAL	150TAB Twice per day	3 DAY
			No Concurrent Medication	C				

Date:06/29/05ISR Number: 4702629-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511110A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Palpitations						per day	11 DAY
	Urticaria		Oral Contraceptives	C				

Date:06/29/05ISR Number: 4702630-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0511623A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Zyban	PS	Glaxosmithkline	ORAL	98	DAY
	Musculoskeletal Stiffness		Birth Control	C				
	Syncope		Pepcid	C				
	Vertigo							

Date:06/29/05ISR Number: 4702631-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0512884A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Zyban	PS	Glaxosmithkline			
	Insomnia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702632-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0513565A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Pharmaceutical Product Complaint							

Date:06/29/05ISR Number: 4702633-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515321A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Stevens-Johnson Syndrome		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702634-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515529A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Zyban	PS	Glaxosmithkline		2	DAY

Date:06/29/05ISR Number: 4702635-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515586A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	1 WK

Date:06/29/05ISR Number: 4702636-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0515900A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Insomnia		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice per day 7 DAY						
			No Concurrent Medication	C		

Date:06/29/05ISR Number: 4702637-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0516245A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day 1 WK						
	Euphoric Mood					

Date:06/29/05ISR Number: 4702638-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0517786A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Adverse Drug Reaction		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice per day						
	Dyspnoea					
	Pharyngolaryngeal Pain					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702639-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0518977A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702640-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520109A
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness						per day	10 DAY
	Heart Rate Increased		Oral Contraceptive	C				
	Panic Attack							
	Paranoia							

Date:06/29/05ISR Number: 4702641-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520184A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Zyban	PS	Glaxosmithkline	ORAL	150MG Unknown	WK
			Hydrochlorothiazide	C				

Date:06/29/05ISR Number: 4702642-2Report Type:Periodic Company Report #2065362
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Zyban	PS	Glaxosmithkline	ORAL		
			Nicoderm Cq	C	Glaxosmithkline	TOPICAL		

Date:06/29/05ISR Number: 4702643-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0520974A
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coordination Abnormal		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Dizziness						per day	10 DAY
	Dysgeusia		Toprol	C				
	Dysphonia		Lanoxin	C	Glaxosmithkline		UNKNOWN	
	Insomnia		Coumadin	C	Glaxosmithkline			

Date:06/29/05ISR Number: 4702644-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0521425A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Generalised		Zyban	PS	Glaxosmithkline	ORAL	1	WK

Date:06/29/05ISR Number: 4702645-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0522144A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus		Zyban	PS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702646-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523210A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702647-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523453A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Zyban	PS	Glaxosmithkline	ORAL	300MG Twice	
	Drug Ineffective						per day	8 DAY
	Feeling Jittery		No Concurrent					
	Myalgia		Medication	C				

Date:06/29/05ISR Number: 4702648-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523538A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Local Swelling		Zyban	PS	Glaxosmithkline	ORAL		
	Obsessive Thoughts		Nicoderm	C	Glaxosmithkline			
	Pruritus							

Date:06/29/05ISR Number: 4702649-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0523656A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bacterial Infection		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Drug Interaction						per day	2 MON
	Flushing		Metronidazole	SS	Glaxosmithkline	ORAL	500MG Unknown	4 DAY
	Tachycardia							

Date:06/29/05ISR Number: 4702650-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524074A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:06/29/05ISR Number: 4702651-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0524373A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702652-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525191A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Zyban	PS	Glaxosmithkline	ORAL	2	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702653-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525192A
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Zyban	PS	Glaxosmithkline	ORAL		
	Gastric Disorder		Unknown Medication	C				
	Heart Rate Increased		Unknown Medication	C				
	Pruritus							
	Rash							
	Urticaria							

Date:06/29/05ISR Number: 4702654-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525197A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Zyban	PS	Glaxosmithkline	ORAL		
	Tremor							

Date:06/29/05ISR Number: 4702655-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0525992A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Zyban	PS	Glaxosmithkline	ORAL	2	WK

Date:06/29/05ISR Number: 4702656-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526192A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood		Zyban	PS	Glaxosmithkline	ORAL	150MCG Per day	1 WK
			No Concurrent Medication	C				

Date:06/29/05ISR Number: 4702657-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0526797A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
			Wellbutrin Sr	C	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702658-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0527947A
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster		Zyban	PS	Glaxosmithkline	ORAL	150MG	Twice
	Rash						per day	4 WK
			Toprol Xl	C				
			Lisinopril	C				

Date:06/29/05ISR Number: 4702659-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0528396A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
	Smoker		Wellbutrin	SS	Glaxosmithkline	ORAL	2	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702660-4Report Type:Periodic Company Report #IMP_0823_2004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Zyban	PS	Glaxosmithkline	ORAL		
			Bupropion Hydrochloride	SS	Glaxosmithkline	ORAL	150MG Per day	

Date:06/29/05ISR Number: 4702661-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0529992A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702662-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530010A
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertrophy Breast		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
	Sexual Dysfunction		Avodart	SS	Glaxosmithkline	ORAL	15	MON
			Atenolol	C				
			Lipitor	C				

Date:06/29/05ISR Number: 4702663-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0530372A
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	4 DAY
	Insomnia		Levoxyl	C	Glaxosmithkline			

Date:06/29/05ISR Number: 4702664-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531196A
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Zyban	PS	Glaxosmithkline	ORAL	300MG Per day	12 DAY
	Oedema Peripheral							
	Urticaria							

Date:06/29/05ISR Number: 4702665-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531250A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypervigilance		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Tremor						per day	
	Vision Blurred							

Date:06/29/05ISR Number: 4702666-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0531550A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Confusional State						per day	1 MON
	Irritability		Ambien	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702668-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532370A
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown

Date:06/29/05ISR Number: 4702669-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0532920A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702670-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533053A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG	Twice
	Constipation						per day	1 MON
	Dizziness							

Date:06/29/05ISR Number: 4702671-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0533264A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Zyban	PS	Glaxosmithkline	ORAL	150MG	Twice
							per day	13 DAY
			Prempro	C				

Date:06/29/05ISR Number: 4702672-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535043A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills		Zyban	PS	Glaxosmithkline	ORAL		
	Insomnia							
	Night Sweats							
	Nightmare							

Date:06/29/05ISR Number: 4702673-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535588A
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Zyban	PS	Glaxosmithkline	ORAL	1	MON

Date:06/29/05ISR Number: 4702674-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535633A
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Zyban	PS	Glaxosmithkline	ORAL	2TAB Twice	
	Pruritus						per day	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702675-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0535782A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder		Zyban	PS	Glaxosmithkline	ORAL		
	Difficulty In Walking							
	Mobility Decreased							

Date:06/29/05ISR Number: 4702676-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538231A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neck Pain		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
			Amoxicillin	C	Glaxosmithkline			

Date:06/29/05ISR Number: 4702677-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0539708A
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	

Date:06/29/05ISR Number: 4702678-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540277A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Zyban	PS	Glaxosmithkline		UNKNOWN	2 WK

Date:06/29/05ISR Number: 4702679-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542846A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
	Oedema						per day	28 DAY
	Rash		Nicorette Gum	C	Glaxosmithkline			
	Rash Maculo-Papular		Oral Contraceptive	C				

Date:06/29/05ISR Number: 4702680-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543061A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	3 WK
			Nicorette Gum	C	Glaxosmithkline			

Date:06/29/05ISR Number: 4702681-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0543948A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Zyban	PS	Glaxosmithkline	ORAL	2	DAY
			No Concurrent Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702682-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544038A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Zyban	PS	Glaxosmithkline	ORAL		
	Drug Interaction		Xenical	SS				

Date:06/29/05ISR Number: 4702683-5Report Type:Periodic Company Report #2005003216
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Zyban	PS	Glaxosmithkline	ORAL		
	Fatigue		Nicoderm	SS	Glaxosmithkline	TOPICAL	21MG Per day	
	Insomnia							
	Psychomotor Hyperactivity							

Date:06/29/05ISR Number: 4702684-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0544543A
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	20 DAY
	Dizziness		Luvox	C				
	Heart Rate Increased							
	Nausea							
	Palpitations							
	Rash							
	Tinnitus							

Date:06/29/05ISR Number: 4702685-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545155A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	

per day 1 WK

Advair	C	Glaxosmithkline
Spiriva	C	
Nicoderm	C	Glaxosmithkline
Reglan	C	Glaxosmithkline
Nexium	C	
Singulair	C	

Date:06/29/05ISR Number: 4702686-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0546355A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Zyban	PS	Glaxosmithkline	ORAL	1	MON

Date:06/29/05ISR Number: 4702687-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0548191A
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 DAY
	Asthenia							
Other	Rash		Prednisone	SS				
	Serum Sickness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702688-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549404A
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Zyban	PS	Glaxosmithkline	ORAL	150MG	Unknown
			Blood Pressure Medication	C				
			Unknown Medication	C				

Date:06/29/05ISR Number: 4702689-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0549904A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702690-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550651A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	6 WK
			No Concurrent Medication	C				

Date:06/29/05ISR Number: 4702691-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551345A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702692-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555386A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	per day

Date:06/29/05ISR Number: 4702693-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555428A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity Therapeutic Response Unexpected		Zyban	PS	Glaxosmithkline	ORAL		

Date:06/29/05ISR Number: 4702694-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555458A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice	per day

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4703108-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0558978A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Asthenia Dysarthria Facial Dysmorphism Memory Impairment		Wellbutrin	PS	Glaxosmithkline	ORAL	40	DAY

Date:06/30/05ISR Number: 4704378-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0556917A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Convulsion Fatigue Heart Rate Increased Hypoaesthesia Overdose Posture Abnormal		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	ORAL	900MG Single dose	2 HR

Date:06/30/05ISR Number: 4704379-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557281A
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration		Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Per day	1 DAY
Hospitalization - Initial or Prolonged Other	Depressed Level Of Consciousness Grand Mal Convulsion Incontinence Pulse Absent Staring Vomiting		Seroquel	C				

Date:06/30/05ISR Number: 4704381-0Report Type:Expedited (15-DaCompany Report #13148
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tachycardia		Wellbutrin	PS	Glaxosmithkline		150MG Per day	
			Unspecified Ssri	C				

Date:06/30/05ISR Number: 4704383-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563942A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline		RESPIRATORY	
Life-Threatening	Drug Abuser						(INHALATION)	
Other	Incorrect Route Of Drug Administration		No Concurrent Medication	C				

Date:06/30/05ISR Number: 4704384-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563979A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Paxil	PS	Glaxosmithkline			
	Pituitary Tumour		Wellbutrin	SS	Glaxosmithkline	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/05ISR Number: 4704386-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0564272A
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 MON
			Synthroid	C	Glaxosmithkline			
			Lithium	C	Glaxosmithkline			

Date:06/30/05ISR Number: 4704387-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0564273A
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	6 WK	
	Hypoaesthesia		Amitriptyline	C				
	Staring		Flexeril	C				
	Unresponsive To Verbal Stimuli		Vasotec	C				
			Carbidopa	C				
			Darvocet	C				
			Enalapril	C				
			Verapamil	C				
			Clavix	C				
			Cyclobenzaprine	C				
			Meclizine	C				

Date:06/30/05ISR Number: 4704390-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0564635A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline			

Date:06/30/05ISR Number: 4704431-1Report Type:Direct Company Report #CTU 252264
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Condition Aggravated		Wellbutrin Sr	PS		ORAL
150 MG PO BID						
	Depression					
	Therapeutic Response					
	Unexpected With Drug					
	Substitution					

Date:07/01/05ISR Number: 4705378-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557786A
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
241 DAY						
	Grand Mal Convulsion		Alcohol	SS		ORAL
	Intentional Self-Injury					
	Memory Impairment					

Date:07/01/05ISR Number: 4705382-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0560141A
Age:42 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	7	DAY
	Amnesia		Toradol	C		ORAL	10MG Four	
	Blood Pressure Increased						times per day	
	Confusional State		Toprol	C				
	Drug Ineffective		Ultram	C				
	Medication Error		Biaxin Xl	C				
			Lortab	C				

Date:07/01/05ISR Number: 4705388-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0564276A
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	4 WK
Initial or Prolonged	Feeling Abnormal		No Concurrent					
	Muscle Tightness		Medication	C				

Date:07/01/05ISR Number: 4705392-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0564494A
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glaucoma		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice	
							per day	
			Sam-E	C				
			Melatonin	C				
			Hctz	C				
			Lovastatin	C				

Date:07/01/05ISR Number: 4705396-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0564755A
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	200MG Twice per day	6 MON
Disability	Dehydration							
	Dementia		Digoxin	C	Glaxosmithkline			
	Hallucination		Norvasc	C				
			Glipizide	C				
			Avandia	C	Glaxosmithkline			
			Prandin	C				
			Toprol Xl	C				
			Lipitor	C				
			Celexa	C				
			Megace	C				
			Reminyl	C				

Date:07/05/05ISR Number: 4706451-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0556337A
Age:32 YR Gender:Female I/FU:F

Outcome	PT
Other	Dizziness
	Heart Rate Increased
	Hyperhidrosis
	Night Sweats

	Paraesthesia						
	Psoriasis						
		Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
			Paxil Cr	PS	Glaxosmithkline	ORAL	
25MG Per day	7 MON						
			Wellbutrin	SS	Glaxosmithkline	ORAL	
10 DAY							
			No Concurrent Medication	C			

Date:07/05/05ISR Number: 4706459-4Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0564879A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Lenticular Opacities		Paxil	PS	Glaxosmithkline	ORAL
	Myopia		Wellbutrin Sr	SS	Glaxosmithkline	ORAL
			Bromazepam	C		
			Losec	C	Glaxosmithkline	
			Starnoc	C		
			Zopiclone	C		

Date:07/05/05ISR Number: 4706474-0Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0381636A
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
Other	Blister					
per day	18 DAY					
	Chest Pain		Marijuana	C		
	Constipation		Cannabis	C		
	Dermatitis Allergic					
	Disorientation					
	Drug Administration Error					
	Eye Swelling					
	Fear					
	Joint Swelling					
	Loss Of Consciousness					
	Mood Altered					
	Oral Pain					

	Palpitations
	Panic Reaction
	Pharmaceutical Product Complaint
	Pharyngitis Streptococcal
	Rash
	Skin Exfoliation
	Stevens-Johnson Syndrome
	Urticaria

Date:07/05/05ISR Number: 4706504-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0386598A
Age: Gender:Female I/FU:F

Outcome	PT
Other	Dizziness
	Eyelid Ptosis
	Hypoaesthesia
	Insomnia
	Malaise
	Nightmare
	Pain In Extremity
	Skin Discolouration

	Thrombosis						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyban	PS	Glaxosmithkline		UNKNOWN

Date:07/05/05ISR Number: 4706505-8Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0386645A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety Bedridden Fatigue Stress Urticaria		Zyban No Concurrent Medication	PS C	Glaxosmithkline		UNKNOWN

Date:07/05/05ISR Number: 4706799-9Report Type:Expedited (15-DaCompany Report #2005-DE-02334GD
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Drug Abuser Drug Toxicity	Literature	Paracetamol (Paracetamol) Oxazepam (Oxazepam) Diazepam (Diazepam) Doxylamine (Doxylamine Succinate) Morphine (Morphine) Oxycodone (Oxycodone) Salicylates (Salicylates) Promethazine (Promethazine) Heroin (Diamorphine) Bupropion (Bupropion) Carbamazepine (Carbamazepine)	PS SS SS SS SS SS SS SS SS SS			

			Metoprolol (Metoprolol)	SS		

Date:07/05/05ISR Number: 4708147-7Report Type:Direct Company Report #USP 57224
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dispensing Error Medication Error		Burpropion Extended Release	PS	Eon Labs		TABLET , EXTENDED RELEASE	
			Wellbutrin Xl	SS	Glaxosmithkline		TABLET, EXTENEDED RELEASE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/05ISR Number: 4709237-5Report Type:Expedited (15-DaCompany Report #2005090868
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Urticaria Generalised	Consumer	Rogaine Fragrance For Women - Spring Bloom (Minoxidil)	PS		
TOPICAL 1 ML, BID,						
TOPICAL			Bupropion Hydrochloride (Bupropoi Hydrochloride)	SS		
150 MG ONCE,						
DAILY						

Date:07/06/05ISR Number: 4707459-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0564736A
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL
300MG Per day 2 WK						
	Medication Error		Marijuana	C		

Date:07/06/05ISR Number: 4708527-XReport Type:Expedited (15-DaCompany Report #S05-USA-03304-01
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dizziness Epilepsy Fall Fatigue Head Injury Memory Impairment Postictal Headache	Consumer	Citalopram Wellbutrin (Bupropion Hydrochloride)	PS SS		

Date:07/07/05ISR Number: 4708512-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546080A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL		
Life-Threatening	Medication Error		Wellbutrin	SS	Glaxosmithkline	ORAL		
Other			Bupropion	SS	Glaxosmithkline			
			No Concurrent Medication	C				

Date:07/07/05ISR Number: 4708543-8Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0386598A
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zyban	PS	Glaxosmithkline	ORAL	8	DAY
	Eyelid Ptosis							
	Hypoaesthesia							
	Insomnia							
	Lip Disorder							
	Malaise							
	Nightmare							
	Pain In Extremity							
	Sensation Of Heaviness							
	Skin Discolouration							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/05ISR Number: 4709065-0Report Type:Expedited (15-DaCompany Report #IMP_0847_2005
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Bupropion	PS		ORAL	1 TAB QDAY PO	
	Condition Aggravated	Professional	Lexapro	C				
	Crying		Lorazepam	C				
	Disease Recurrence		Calcium Citrate	C				
	Feeling Abnormal		Glucosamine					
	Major Depression		Chondrotin	C				
	Mental Disorder		Multivitamin	C				
	Paranoia							
	Pharmaceutical Product Complaint							
	Post-Traumatic Stress Disorder							
	Suicidal Ideation							

Date:07/08/05ISR Number: 4709442-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563942A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	RESPIRATORY		
Life-Threatening	Drug Abuser					(INHALATION)		
Other			No Concurrent Medication	C				

Date:07/08/05ISR Number: 4709443-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0564491A
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
Life-Threatening	Overdose		Cocaine	SS				
Hospitalization - Initial or Prolonged			Advil	SS	Glaxosmithkline			
Other								

Date:07/08/05ISR Number: 4709446-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0565250A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Bupropion	PS	Glaxosmithkline			
	Renal Failure		Lithium	SS	Glaxosmithkline			

Date:07/08/05ISR Number: 4709459-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0386419A
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Zyban	PS	Glaxosmithkline	ORAL	36	DAY
	Bradycardia							
	Chest Pain							
	Chest Wall Pain							
	Cholelithiasis							
	Constipation							
	Hepatic Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/08/05ISR Number: 4711041-9Report Type:Direct Company Report #CTU 252844
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour		Wellbutrin 150 Mg					
Hospitalization - Initial or Prolonged	Mood Swings		Brand	PS				
Other	Suicidal Ideation		Wellbutrin 100 Mg Generic	SS				
			Depakote	C				
			Tenex	C				
			Adderal	C				

Date:07/08/05ISR Number: 4711322-9Report Type:Expedited (15-DaCompany Report #2001058760US
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache	Health Professional	Solu-Medrol (Methylprednisolone Sodium Succinate)	PS			INTRAVENOUS	500 MG (125 MG, 4 IN 1 D), INTRAVENOUS; SEE IMAGE
Other	Pruritus							
	Rash							
	Urticaria							
			Hydroxyzine Hydrochloride (Tablet) (Hydroxyzine Hydrochloride)	SS		ORAL	ORAL	
			Prednisone Tablet (Prednisone)	SS		ORAL	ORAL	
			Wellbutrin (Bupropion Hydrochloride)	SS		ORAL	300 MG (150 MG, 2 IN 1	

D), ORAL

Ortho Tri-Cyclen (Ethinylestradiol, Norgestimate)	C	
Propanolol (Propanolol)	C	
Imitrex (Sumatriptan Succinate)	C	

Date:07/11/05ISR Number: 4710829-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551834A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline			
	Depressed Level Of Consciousness							
	Dizziness							
	Drug Toxicity							
	Fall							
	Headache							
	Loss Of Consciousness							
	Malaise							
	Respiratory Arrest							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/05ISR Number: 4710831-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559557A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypothyroidism		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	8 MON
	Myopathy		Lexapro	C		ORAL	20MG Per day	

Date:07/11/05ISR Number: 4710837-7Report Type:Expedited (15-DaCompany Report #S05-USA-02982-01
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dizziness		Citalopram	SS		ORAL		
	Dyskinesia							
	Epilepsy							
	Fall							
	Fatigue							
	Head Injury							
	Postictal Headache							

Date:07/11/05ISR Number: 4710841-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0565030A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Wellbutrin Xl	PS	Glaxosmithkline	ORAL		MON
	Condition Aggravated							
	Depressed Mood							
	Feeling Abnormal							
	Irritability							
	Psychiatric Symptom							
	Suicidal Ideation							

Date:07/11/05ISR Number: 4710871-7Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0384296A
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation		Zyban	PS	Glaxosmithkline			
UNKNOWN							300MG Per day	13 DAY
	Chills		Celebrex	C				
							200U Per day	
	Difficulty In Walking		Norvasc	C				
	Erythema							
	Feeling Cold							
	Hyperaesthesia							
	Pain							
	Pain In Extremity							
	Psoriasis							
	Rash							
	Rash Generalised							
	Skin Exfoliation							
	Skin Laceration							

Date:07/11/05ISR Number: 4710874-2Report Type:Expedited (15-DaCompany Report #SE-GLAXOSMITHKLINE-B0386513A
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression		Zyban	PS	Glaxosmithkline	ORAL		
1 DAY								
Initial or Prolonged	Anger		Valeriana	C	Glaxosmithkline			
	Anxiety		Antidepressant	C				
	Drug Interaction		Alcohol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/05ISR Number: 4710875-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0386556A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Zyban	PS	Glaxosmithkline	ORAL		
			Atenolol	C				
			Beclomethasone	C	Glaxosmithkline			

Date:07/11/05ISR Number: 4710887-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0387151A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Zyban	PS	Glaxosmithkline	ORAL	10	DAY
	Agitation							
	Anger							
	Crying							
	Dry Mouth							
	Emotional Disorder							
	Insomnia							
	Irritability							
	Stress							

Date:07/11/05ISR Number: 4710888-2Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0046030A
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	
Hospitalization - Initial or Prolonged	Dyspnoea		Simvastatin	C		ORAL	10MG Per day	
	Flank Pain		Metoprolol	C			UNKNOWN	
	Oxygen Saturation		Delix	C			UNKNOWN	
	Decreased		Aldactone	C			UNKNOWN	
	Supraventricular		Sortis	C			UNKNOWN	

	Tachycardia		Torem	C		
UNKNOWN						
			Ass	C	Glaxosmithkline	
UNKNOWN						
			Omeprazol	C	Glaxosmithkline	
UNKNOWN						

Date:07/11/05ISR Number: 4711504-6Report Type:Direct Company Report #CTU 252956
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anger		Paxil 40 Mg.	PS		ORAL	40 MG	QD
	Emotional Disorder						ORAL	
	Hostility		Wellbutrin Xl 450 Mg.	SS		ORAL	450 MG	QD
	Muscle Twitching						ORAL	
	Nervousness							
			Prozac	C				

Date:07/11/05ISR Number: 4712021-XReport Type:Direct Company Report #CTU 252969
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Formication		Bupropion 150 Mg Sr Ta Watson	PS	Watson	ORAL	1 TABLET	
	Therapeutic Response						BID	ORAL
	Unexpected With Drug							
	Substitution							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/05ISR Number: 4712239-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0565550A
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	18	MON
	Overdose							

Date:07/12/05ISR Number: 4712240-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0565551A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Skin Exfoliation		Unknown	C				
	Stevens-Johnson Syndrome							
	White Blood Cell Count Increased							

Date:07/12/05ISR Number: 4712251-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0380373A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice	
	Feeling Abnormal							
per day							4	DAY
	Panic Attack		No Concurrent					
	Serotonin Syndrome		Medication	C				

Date:07/12/05ISR Number: 4712268-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-B0387160A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Zyban	PS	Glaxosmithkline	ORAL		
	Depressed Mood							
	Disability							

	Hostility					
	Overdose					
	Suicidal Ideation					

Date:07/13/05ISR Number: 4713304-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0565250A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During		Lithium	PS	Glaxosmithkline			
	Pregnancy		Bupropion	SS	Glaxosmithkline			
	Hypertension							
	Pregnancy							
	Renal Failure							
	Renal Function Test Abnormal							
	Renal Impairment							

Date:07/13/05ISR Number: 4714340-XReport Type:Direct Company Report #CTU 253163
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Bupropion 150					
	Fatigue		(Generic)	PS			BID	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4714382-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0556917A
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	900MG Single dose	
	Convulsion							
	Discomfort		Lexapro	SS		ORAL	15 DAY	
	Fatigue		No Concurrent Medication	C				
	Heart Rate Increased							
	Hypoaesthesia							
	Intentional Misuse							
	Muscle Contracture							
	Paraesthesia							
	Posture Abnormal							
	Suicide Attempt							
	Tremor							

Date:07/14/05ISR Number: 4714383-6Report Type:Expedited (15-DaCompany Report #S05-USA-02393-01
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	20MG Per day	15 DAY
	Discomfort		Lexapro	SS		ORAL		
	Fatigue							
	Hypoaesthesia							
	Ill-Defined Disorder							
	Intentional Misuse							
	Muscle Contractions Involuntary							
	Paraesthesia							
	Tremor							

Date:07/14/05ISR Number: 4714384-8Report Type:Expedited (15-DaCompany Report #2005-01-1690
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Haemorrhagic Stroke				Wellbutrin	PS	Glaxosmithkline	ORAL	100MG Three
Hospitalization -									
times per day	413	DAY							
Initial or Prolonged					Pegylated Interferon				
					Alpha 2a	SS			
SUBCUTANEOUS	180MCG	Weekly	396	DAY					
					Copegus	SS		ORAL	1200MG Per
day	413	DAY							
					Pegylated Interferon				
					Alpha 2b	SS			
SUBCUTANEOUS	150MCG	Weekly							
					Percocet	C			
					Benzodiazepine	C			
					Levoxyl	C	Glaxosmithkline	ORAL	.175MG Per
day									
					Lorazepam	C		ORAL	1MG Three
times per day									
					Protonix	C		ORAL	40MG Per day
					Percodan	C		ORAL	325MG Twice
per day	101	DAY							
					Procrit	C			
SUBCUTANEOUS	40000U	Weekly	277	DAY					
					Diazepam	C		ORAL	5MG Twice per
day	413	DAY							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4714388-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0566115A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vitreous Detachment		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Twice per day	
			No Concurrent Medication	C				

Date:07/14/05ISR Number: 4714389-7Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0338473A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Zyban	PS	Glaxosmithkline			
			Ethanol	SS				

Date:07/14/05ISR Number: 4714390-3Report Type:Expedited (15-DaCompany Report #NO-GLAXOSMITHKLINE-B0349044A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Insomnia		Zyban	PS	Glaxosmithkline	ORAL		
	Sleep Disorder							
	Visual Disturbance							

Date:07/14/05ISR Number: 4714510-0Report Type:Expedited (15-DaCompany Report #200511975US
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During Pregnancy		Allegra	PS	Aventis Pharmaceuticals Inc.	ORAL		
	Haemorrhage		Bupropion	SS				
	Pregnancy		Celexa	SS		ORAL		
	Umbilical Cord Abnormality		Zantac	SS		ORAL		

Date:07/15/05ISR Number: 4715141-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0566214A
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Wellbutrin Xl	PS	Glaxosmithkline		150MG Per day	3 WK
	Chest Discomfort		Singulair	C				
			Zyrtec	C	Glaxosmithkline			
			Advair	C	Glaxosmithkline			
			Beconase	C	Glaxosmithkline	NASAL		

Date:07/15/05ISR Number: 4715153-5Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0386645A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Zyban	PS	Glaxosmithkline		UNKNOWN	
Initial or Prolonged	Bedridden		No Concurrent					
	Fatigue		Medication	C				
	Stress							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715162-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0387289A
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	3 DAY
			Topalgic (France)	C	Other	ORAL		
			Efferalgan	C	Other	ORAL	4G per day	
			Percutalgine	C	Other		TOPICAL	
			Brexin	C	Other	ORAL	1UNIT per day	

Date:07/15/05ISR Number: 4717312-4Report Type:Expedited (15-DaCompany Report #2005080150
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Consumer	Celebrex (Celecoxib)	PS				
	Feeling Abnormal		Paxil (Paroxetine Hydrochloride)	SS				
	Flat Affect		Wellbutrin (Bupropion Hydrochloride)	SS				
	Multiple Sclerosis		Aleve (Naproxen Sodium)	SS				
	Nasopharyngitis		Avalide (Hydrochlorothiazide, Irbesartan)	C				
	Pain		Acetylsalicylic Acid (Acetylsalicylic Acid)	C				
	Personality Change		Multivitaminis (Multivitaminis)	C				
	Retching		Atenolol (Atenolol)	C				
	Visual Disturbance							
	Vomiting							

Date:07/18/05ISR Number: 4716003-3Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0385105A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Chest Pain Dizziness Heart Alternation Hypertension Palpitations		Zyban Valerian	PS C	Glaxosmithkline Glaxosmithkline	ORAL ORAL

Dose	Duration
1TAB Per day	5 DAY
3U per day	11 DAY

Date:07/18/05ISR Number: 4716019-7Report Type:Expedited (15-DaCompany Report #EE-GLAXOSMITHKLINE-B0387910A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	Grand Mal Convulsion Loss Of Consciousness Screaming		Wellbutrin Seroquel	PS C	Glaxosmithkline	ORAL ORAL

Dose	Duration
150MG Per day	39 DAY
.2G Per day	

Date:07/18/05ISR Number: 4717865-6Report Type:Direct Company Report #CTU 253484
Age:51 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization - Initial or Prolonged
Required

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Intervention to Prevent Permanent Impairment/Damage	Grand Mal Convulsion		Wellbutrin Initial Dosage Glaxosmithkline	PS	Glaxosmithkline	ORAL	ORAL	
			Ms	C				

Date:07/18/05ISR Number: 4718062-0Report Type:Direct Company Report #CTU 253475
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bipolar Disorder		Zoloft	PS		ORAL	20 ML ONCE A	
Hospitalization -	Condition Aggravated						DAY ORAL	
Initial or Prolonged	Depression		Wellbutrin	SS		ORAL	350/400 ML	
Required	Disturbance In Attention						ONCE A DAY	
Intervention to	Headache						ORAL	
Prevent Permanent Impairment/Damage	Intentional Self-Injury		Triliptal	C				
	Suicide Attempt		Lamictal	C				
	Tremor		Topomax	C				
	Vision Blurred		Geoddon	C				
	Weight Decreased		Prozac	C				

Date:07/18/05ISR Number: 4719224-9Report Type:Direct Company Report #CTU 253453
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Bupropion 150mg					
	Pharmaceutical Product Complaint		Watson Pharmaceuticals	PS	Watson Pharmaceuticals	ORAL	150MG BID	
							ORAL	

				Lipitor	C		
				Avandia	C		
				Lisinopril	C		
				Depakote	C		

Date:07/19/05ISR Number: 4717130-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551252A
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vision Blurred		Paxil	PS	Glaxosmithkline			
	Visual Acuity Reduced		Wellbutrin	SS	Glaxosmithkline	ORAL		
			Trazodone	C		ORAL		
							5	YR
			Risperdal	C		ORAL		
							2	YR
			Cogentin	C		ORAL		
							2MG Twice per	
							day	2 YR
			Unknown Medication	C				
			Vitamin B12	C	Glaxosmithkline			
			Multivitamin	C				
			Vitamin C	C	Glaxosmithkline			
			Magnesium	C				
			Iron	C				
			Calcium	C				
			Vitamin E	C				
			Colace	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717132-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0560956A
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 YR
Other	Dehydration		Alcohol	SS				
	Fall		Lexapro	C		ORAL	20MG Per day	
	Grand Mal Convulsion		Yasmin	C		ORAL		
	Head Injury		Multivitamin	C				
	Hypertension							
	Hypoxia							
	Poisoning							
	Pupil Fixed							
	Vomiting							

Date:07/19/05ISR Number: 4717133-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0561914A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Spasms		Wellbutrin Sr	PS	Glaxosmithkline	ORAL	100MG Per day	1 WK
Other	Muscle Twitching		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	24 DAY
			Ambien	C				
			Lexapro	C				

Date:07/19/05ISR Number: 4717138-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0566516A
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Abuser		Wellbutrin	PS	Glaxosmithkline			
			Prozac	SS				
			Alcohol	SS				

Date:07/19/05ISR Number: 4717146-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0386645A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Bedridden Fatigue Stress Urticaria		Zyban No Concurrent Medication	PS C	Glaxosmithkline		UNKNOWN	

Date:07/19/05ISR Number: 4717159-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0387710A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Cholelithiasis		Zyban	PS	Glaxosmithkline	ORAL	1TAB Twice per day	38 DAY
	Constipation		Trimethoprim	C	Glaxosmithkline	ORAL		

Date:07/19/05ISR Number: 4717162-9Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0387737A
Age:23 YR Gender:Female I/FU:F

Outcome	PT
Other	Depression Dry Mouth Emotional Disorder

		Emotional Distress					
		Hallucination, Auditory					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Inappropriate Affect		Zyban	PS	Glaxosmithkline	ORAL
		Insomnia					
		Lethargy					
		Night Sweats					
		Nightmare					

Date:07/19/05ISR Number: 4717165-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0388012A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Asthma		Zyban	PS	Glaxosmithkline	ORAL
Initial or Prolonged	Dyspnoea		Prednisolone	C	Glaxosmithkline	
	Pneumonia					

Date:07/20/05ISR Number: 4718609-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0566773A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death		Wellbutrin	PS	Glaxosmithkline	

Date:07/20/05ISR Number: 4718642-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0388098A
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Feeling Abnormal		Zyban	PS	Glaxosmithkline	
UNKNOWN	3 DAY					
	Hallucination					
	Heart Rate Increased					
	Nightmare					
	Panic Attack					
	Somnolence					

Date:07/20/05ISR Number: 4723534-9Report Type:Direct Company Report #CTU 253756
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Shock		Lexapro	PS				
	Obstructive Airways Disorder		Wellbutrin	SS				
	Swelling							

Date:07/20/05ISR Number: 4723710-5Report Type:Direct Company Report #CTU 253789
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour		Paroxetine	PS		ORAL	30 MG PO BID	
	Aggression		Bupropion	SS			150 MG Q AM	
	Hallucinations, Mixed						2 TSP Q4HR	
	Psychotic Disorder						PRN	
	Serotonin Syndrome		Guaifenesin	SS				
			Dextromethorphan	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4724272-9Report Type:Direct Company Report #CTU 253815
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Wellbutrin Sr	PS		ORAL	150 MG PO BID	
	Depression		Lipitor	C				
	Drug Effect Decreased		Ultram	C				
	Fatigue		Lorazepam	C				
	Social Avoidant Behaviour							
	Therapeutic Response							
	Unexpected With Drug							
	Substitution							

Date:07/21/05ISR Number: 4720718-0Report Type:Expedited (15-DaCompany Report #CA-GLAXOSMITHKLINE-A0566496A
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin Sr	PS	Glaxosmithkline	ORAL		
			Ethanol	C		ORAL		

Date:07/21/05ISR Number: 4720719-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0566707A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
Other	Drug Abuser		Seroquel	C				

Date:07/21/05ISR Number: 4720720-9Report Type:Expedited (15-DaCompany Report #13031
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Wellbutrin	PS	Glaxosmithkline		300MG per day	
			Unspecified Ssri	C				
			Mood Medication	C				
			Tricyclic					

			Antidepressant	C			

Date:07/21/05ISR Number: 4721458-4Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12708301
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction International Normalised Ratio Decreased		Coumadin Tabs	PS	Bristol-Myers Squibb Company	ORAL	Start 5mg qd; present daily dosage was 10mg, 10mg, 5mg,	
			Zyprexa	C				
			Effexor	C				
			Multivitamin	C				
			Plavix	C	Regulatory Health Authority South Africa		Previously on Rx	
			Klonopin	C				
			Wellbutrin	I		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722832-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567026A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Ventricular Tachycardia		Wellbutrin	PS	Glaxosmithkline	ORAL	
			Unknown	C			

Date:07/22/05ISR Number: 4722837-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567064A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Blister		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	150MG Per day 2 DAY
	Haemorrhage		Allergen	SS			
	Local Swelling		No Concurrent Medication	C			

Date:07/22/05ISR Number: 4725665-6Report Type:Direct Company Report #CTU 254066
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Amnesia		Bupropion Hcl Extended Release Tabs Global	PS	Global	ORAL	200 MG TWICE A DAY ORAL
	Therapeutic Response Unexpected With Drug Substitution						
			Wellbutrin	C			

Date:07/25/05ISR Number: 4723460-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0566698A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaemia		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day 5 YR
	Drug Exposure During		Wellbutrin	SS	Glaxosmithkline	ORAL	52 WK

	Pregnancy		Ibuprofen	SS	Glaxosmithkline	ORAL
250MG Single						
	Initial Insomnia					
dose						
	Overdose		Iron	C		
	Somnolence					

Date:07/25/05ISR Number: 4723468-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0382344A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Epilepsy		Zyntabac	PS	Glaxosmithkline	
UNKNOWN 300MG per day						
Initial or Prolonged	Facial Bones Fracture					
Other	Fibula Fracture					
	Ill-Defined Disorder					

Date:07/25/05ISR Number: 4723481-2Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0388188A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Panic Attack		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day 7 DAY						
	Suicidal Ideation		Estraderm	C		
TOPICAL 100MCG per						
day						
			Diclofenac	C		ORAL
50MG Three						
times per day						

Date:07/25/05ISR Number: 4725754-6Report Type:Expedited (15-DaCompany Report #A0499051A
Age:6 MON Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure Via Breast Milk Grand Mal Convulsion Pregnancy Restlessness Staring Upper Respiratory Tract Infection	Literature Health Professional	Wellbutrin Sr Tablet-Controlled Release (Bupropion Hydrochloride)	PS		TRANSMAMMARY	150 MG/ DAY/ TRANSMAMMARY	PER

Date:07/25/05ISR Number: 4726035-7Report Type:Expedited (15-DaCompany Report #D0039102A
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Psychosis Disturbance In Attention Insomnia Schizophreniform Disorder Suicidal Ideation Vision Blurred	Foreign Literature Health Professional	Zyban Tablet-Zyban (Bupropion Hydrochloride)	PS		ORAL	ORAL	5 DAY

Date:07/26/05ISR Number: 4724742-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567176A
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Grand Mal Convulsion Overdose		Wellbutrin Marijuana	PS C	Glaxosmithkline	ORAL		

Date:07/26/05ISR Number: 4724743-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567177A
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine		Wellbutrin	PS	Glaxosmithkline	ORAL		
Hospitalization - Initial or Prolonged	Phosphokinase Increased		Ethylene Glycol	SS				
Other	Convulsion		Marijuana	C				
	Drug Screen Positive							
	Dyskinesia							
	Loss Of Consciousness							
	Metabolic Acidosis							
	Overdose							
	Renal Failure Acute							
	Vomiting							

Date:07/26/05ISR Number: 4724745-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567196A
Age:77 YR Gender:Female I/FU:I

Outcome	PT
Other	Abdominal Pain Upper
	Anger
	Arthralgia
	Chest Pain
	Drug Ineffective
	Ear Haemorrhage
	Insomnia

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability							
	Mouth Ulceration							
	Myalgia							
	Rash Generalised		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	2 WK
	Somnolence		Lipitor	C				
			Aspirin	C	Glaxosmithkline			
			Vitamins	C				
			Glucosamine	C				
			Calcium	C				
			Aleve	C				

Date:07/26/05ISR Number: 4724751-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567576A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills		Paxil	PS	Glaxosmithkline	ORAL	40MG Per day	
	Confusional State		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	
	Coordination Abnormal		Dextromethorphan	C	Glaxosmithkline			
	Diarrhoea							
	Pyrexia							
	Serotonin Syndrome							
	Tremor							

Date:07/26/05ISR Number: 4724779-4Report Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0388621A
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Zyntabac	PS	Glaxosmithkline	ORAL	300MG Twice per day	4 DAY
	Myopia							
	Vision Blurred							

Date:07/26/05ISR Number: 4724783-6Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0388660A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Anger		Zyban	PS	Glaxosmithkline	ORAL		

Date:07/26/05ISR Number: 4725119-7Report Type:Expedited (15-DaCompany Report #GXKR2005US01328
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Confusional State	Literature Health	Bupropion (Ngx)(Bupropion)	PS			150 MG, BID	61 DAY
	Convulsion Depression	Professional	Risperidone (Ngx) (Risperidone)	SS			0.25 MG, BID	213 DAY
	Drug Interaction Dry Mouth		Atomoxetine (Atomoxetine)	SS			INTENTIONAL OVERDOSE OF	
	Electrocardiogram Qt Corrected Interval Prolonged Heart Rate Increased Intentional Misuse Overdose Postictal State Tremor		Alprazolam (Alprazolam)	C			1200 MG	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/05ISR Number: 4726101-6Report Type:Direct Company Report #CTU 254348
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus		Wellbutrin Xr	PS		ORAL	UP TO 225 MG	
							ORAL	
			Numerous Products	C				

Date:07/26/05ISR Number: 4727185-1Report Type:Direct Company Report #CTU 254325
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nausea		Bupropion	PS				
	Vomiting		Docusate Na	C				
			Trazodone Hcl	C				
			Oxycodone Hcl	C				
			Gatifloxacin	C				
			Bupropion Hcl	C				
			Clotrimazole	C				
			Zinc Oxide	C				
			Meloxicam	C				

Date:07/26/05ISR Number: 4727412-0Report Type:Expedited (15-DaCompany Report #2005085576
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine	Health	Zoloft (Sertraline)	PS		ORAL	200 MG (200	
	Phosphokinase Increased	Professional					MG, 1 IN 1	
	Myalgia						D),ORAL	
			Wellbutrin Xl (Bupropion Hydrochloride)	SS				
			Wellbutrin (Bupropion Hydrochloride)	C				

			Ativan (Lorazepam)	C		

Date:07/27/05ISR Number: 4725946-6Report Type:Expedited (15-DaCompany Report #BPC-ZN-05-419
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus Generalised		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	2 WK
	Rash							
	Sensation Of Foreign Body							

Date:07/27/05ISR Number: 4725947-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567258A
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	3 DAY
	Anorexia		Micardis	C	Glaxosmithkline			
	Anxiety		Copaxone	C				
	Homicidal Ideation							
	Insomnia							
	Irritability							
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4725948-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567272A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin	PS	Glaxosmithkline	NASAL		
	Euphoric Mood							
	Incorrect Route Of Drug Administration							

Date:07/27/05ISR Number: 4725949-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567282A
Age:11 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amenorrhoea		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Depression		Trazodone	C				
	Suicide Attempt							

Date:07/27/05ISR Number: 4725953-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567599A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoacusis		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Stress		Tenormin	C				
	Syncope Vasovagal		Topomax	C				
			Klonopin	C				

Date:07/28/05ISR Number: 4727253-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567739A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	
	Iritis							

Date:07/28/05ISR Number: 4727273-XReport Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0388927A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Bupropion Hydrochloride	PS	Glaxosmithkline	UNKNOWN	150MG Per day	5 DAY
	Nausea							
	Pharyngolaryngeal Pain							
	Pyrexia							

Date:07/28/05ISR Number: 4728116-0Report Type:Direct Company Report #CTU 254657
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anger		Wellbutrin Xl 300mg.					
Hospitalization - Initial or Prolonged Disability	Balance Disorder		Glax	PS	Glax	1 A DAY		
	Bipolar Disorder							
	Dysarthria							
	Loss Of Employment							
	Mania							
	Memory Impairment							
	Mental Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/05ISR Number: 4728733-8Report Type:Expedited (15-DaCompany Report #2005-03-0065
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Collapse Of Lung		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG	Unknown
	Convulsion		Peg-Intron	SS		SUBCUTANEOUS		
	Pneumonia		Ribavirin	SS		ORAL		
	Vomiting		Paxil Cr	C	Glaxosmithkline	ORAL	25MG	Single dose
			Levoxyl	C	Glaxosmithkline	ORAL	.05MG	Unknown
			Prevacid	C		ORAL	30MG	Unknown

Date:07/29/05ISR Number: 4728744-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567927A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Wellbutrin	PS	Glaxosmithkline	ORAL	150MG Per day	8 DAY
	Cholelithiasis		Coumadin	C	Glaxosmithkline			
	Constipation		Hydrochlorothiazide	C				
			Metoprolol	C				
			Prevacid	C				

Date:07/29/05ISR Number: 4728745-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567939A
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Grand Mal Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL	1TAB Per day	3 WK
Other	Loss Of Consciousness		Zyrtec	C	Glaxosmithkline			
	Tremor							

Date:07/29/05ISR Number: 4728746-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0567951A
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	3 YR
	Amnesia		Aricept	C				
	Anger							
	Anxiety							
	Back Disorder							
	Back Pain							
	Blood Glucose Increased							
	Confusional State							
	Crying							
	Delirium							
	Hallucination							
	Paranoia							

Date:07/29/05ISR Number: 4728748-XReport Type:Expedited (15-DaCompany Report #ES-GLAXOSMITHKLINE-B0321501A
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Other	Akinesia
	Dyskinesia
	Dysphonia
	Hypokinesia
	Masked Facies
	Monoplegia
	Musculoskeletal Stiffness

Parkinsonism

		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Zyntabac	PS	Glaxosmithkline		300MG Per day 19 DAY

Date:07/29/05ISR Number: 4728756-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0386419A
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Bradycardia Chest Pain Chest Wall Pain Cholelithiasis Constipation Hepatic Pain		Zyban	PS	Glaxosmithkline	ORAL	1TAB See dosage text 36 DAY

Date:07/29/05ISR Number: 4728768-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0388674A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Psoriasis Rash Skin Exfoliation		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day 5 DAY

Date:07/29/05ISR Number: 4728771-5Report Type:Expedited (15-DaCompany Report #NL-GLAXOSMITHKLINE-B0389067A
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Depression Suicidal Ideation		Bupropion Hydrochloride	PS	Glaxosmithkline	UNKNOWN	150MG Per day 4 DAY
			No Concurrent				

			Medication	C		

Date:07/29/05ISR Number: 4734457-3Report Type:Expedited (15-DaCompany Report #S05-USA-03304-01
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Dyskinesia Epilepsy Fall Fatigue Grand Mal Convulsion Headache	Consumer	Citalopram Wellbutrin (Bupropion Hydrochloride)	PS SS				

Date:08/01/05ISR Number: 4730191-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0387737A
Age:23 YR Gender:Female I/FU:F

Outcome	PT
Other	Crying Depression Dry Mouth Emotional Disorder Emotional Distress Hallucination, Auditory

		Headache					
		Inappropriate Affect					
		Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lethargy		Zyban	PS	Glaxosmithkline	ORAL
		Night Sweats					
		Nightmare					

Date:08/01/05ISR Number: 4730196-3Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0388647A
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death		Zyban	PS	Glaxosmithkline	ORAL
	Intentional Misuse		Propanolol	C		
			Benzodiazepine	C		
			Alcohol	C		

Date:08/02/05ISR Number: 4738145-9Report Type:Expedited (15-DaCompany Report #B0321501A
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Parkinsonism	Foreign	Zyban Tablet-Zyban			
		Literature	(Bupropion			
		Health	Hydrochloride)	PS		
300 MG PER						
		Professional				
DAY						

Date:08/03/05ISR Number: 4732508-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0568344A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	

Date:08/03/05ISR Number: 4732533-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0384877A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice per day	6 DAY
	Cerebrovascular Accident							
	Convulsion							
	Subarachnoid Haemorrhage							

Date:08/03/05ISR Number: 4732744-6Report Type:Expedited (15-DaCompany Report #S05-USA-02982-01
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL		
	Dizziness		Citalopram	SS		ORAL		
	Dyskinesia							
	Epilepsy							
	Fall							
	Fatigue							
	Grand Mal Convulsion							
	Head Injury							
	Postictal Headache							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/05ISR Number: 4732748-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0568350A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrioventricular Block		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG See dosage text	
	Cardio-Respiratory Arrest							
	Convulsion							
	Overdose							

Date:08/03/05ISR Number: 4732752-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0568459A
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL	3	YR
Hospitalization - Initial or Prolonged	Ill-Defined Disorder		Ultram	SS				

Date:08/03/05ISR Number: 4732934-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0562033A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Avandamet	PS	Glaxosmithkline	ORAL		
	Muscle Spasms		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	
	Stomach Discomfort		Glucophage	SS		ORAL	3	YR
			No Concurrent Medication	C				

Date:08/04/05ISR Number: 4734761-9Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0387737A
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Crying		Zyban	PS	Glaxosmithkline	ORAL
150MG Twice						
	Depression					
per day 11 DAY						
	Dry Mouth		Levlen Ed	C		ORAL
	Emotional Disorder					
	Emotional Distress					
	Hallucination, Auditory					
	Headache					
	Insomnia					
	Lethargy					
	Night Sweats					
	Nightmare					

Date:08/04/05ISR Number: 4734773-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0389004A
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Depressed Mood		Zyban	PS	Glaxosmithkline	ORAL
150MG Per day 2 DAY						
	Head Discomfort		Ipratropium Bromide	C	Glaxosmithkline	
40MCG Per day						
	Sensory Disturbance		Salmeterol	C	Glaxosmithkline	
			Beclomethasone	C	Glaxosmithkline	
200MCG Per						
day						
			Thyroxine	C	Glaxosmithkline	ORAL
125MCG per						
day						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/05ISR Number: 4734774-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0389007A
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Menorrhagia		Zyban	PS	Glaxosmithkline	ORAL	4	DAY
	Rash		Atorvastatin	C		ORAL	20MG per day	
			Gaviscon	C	Glaxosmithkline	ORAL		

Date:08/04/05ISR Number: 4734778-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0389361A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Zyban	PS	Glaxosmithkline	ORAL		
	Syncope							

Date:08/05/05ISR Number: 4735616-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0563979A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Paxil	PS	Glaxosmithkline			
	Pituitary Tumour		Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:08/05/05ISR Number: 4735620-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0568718A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Macular Degeneration		Wellbutrin	PS	Glaxosmithkline	ORAL	400MG Per day	

Date:08/05/05ISR Number: 4735633-6Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0382344A
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Epilepsy Facial Bones Fracture Fibula Fracture Ill-Defined Disorder		Zyntabac	PS	Glaxosmithkline		UNKNOWN	300MG per day

Date:08/05/05ISR Number: 4735643-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0389012A
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Tremor Visual Disturbance		Zyban	PS	Glaxosmithkline	ORAL	150MG per day	5 DAY

Date:08/05/05ISR Number: 4736567-3Report Type:Direct Company Report #CTU 255513
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Convulsion Headache Vomiting		Wellbutrin 300mg Glascosmithkline	PS	Glascosmithkline		ONCE DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4736856-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0551834A
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Wellbutrin	PS	Glaxosmithkline			
	Depressed Level Of Consciousness							
	Dizziness							
	Drug Toxicity							
	Fall							
	Headache							
	Loss Of Consciousness							
	Malaise							
	Respiratory Arrest							
	Tachycardia							

Date:08/08/05ISR Number: 4736857-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0557105A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL		
Life-Threatening	Overdose							
Other								

Date:08/08/05ISR Number: 4736858-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559798A
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Induced		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day	
Other	Stillbirth							

Date:08/08/05ISR Number: 4736859-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0559798B
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Abortion Induced	Wellbutrin	PS	Glaxosmithkline	
300MG Per day					
Congenital Anomaly	Alpha 1 Foetoprotein				
	Abnormal				
	Anencephaly				
	Drug Exposure During Pregnancy				

Date:08/08/05ISR Number: 4736860-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0565550A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Wellbutrin	PS	Glaxosmithkline	ORAL	18	MON
	Drug Screen Positive							
	Overdose							

Date:08/08/05ISR Number: 4736901-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0389840A
Age: Gender:Male I/FU:F

Outcome	PT
Other	Abdominal Pain
	Blood Glucose Increased

	Blood Pressure Increased Diarrhoea Hallucination	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Headache		Zyban	PS	Glaxosmithkline		UNKNOWN
	Hypertension Impaired Driving Ability Vomiting						

Date:08/09/05ISR Number: 4738368-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0555664A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Congenital Anomaly	Coloboma Drug Exposure During Pregnancy Microphthalmos		Wellbutrin Xl	PS	Glaxosmithkline		

Date:08/09/05ISR Number: 4738372-0Report Type:Expedited (15-DaCompany Report #BPC-ZN-05-419
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pruritus Generalised		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice
	Rash						per day 2 WK
	Sensation Of Foreign Body						

Date:08/09/05ISR Number: 4738378-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0568459A
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death		Wellbutrin	PS	Glaxosmithkline	ORAL	3 YR
Hospitalization - Initial or Prolonged	Drug Interaction Drug Level Increased Fall		Ultram	SS			

Ill-Defined Disorder

Date:08/09/05ISR Number: 4738379-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0569020A
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Murder		Paxil	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline			

Date:08/09/05ISR Number: 4738383-5Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0569132A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Wellbutrin	PS	Glaxosmithkline			
	Adrenal Insufficiency		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Twice	
	Bacterial Infection						per day	2 YR
	Bruxism		Armour Thyroid	C				
	Diarrhoea		Fosamax	C				
	Fatigue		Multivitamins +					
	Flatulence		Supplements	C				
	Headache							
	Medication Error							
	Neck Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738386-0Report Type:Expedited (15-DaCompany Report #BR-GLAXOSMITHKLINE-A0569142A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Attention Deficit/Hyperactivity Disorder		Zyban	PS	Glaxosmithkline	ORAL	150MG Three times per day	21 DAY
Disability	Disorder		Bromazepam	C		ORAL	6MG Per day	51 DAY
	Coordination Abnormal							
	Dizziness							
	Headache							
	Hypoaesthesia							
	Sedation							
	Weight Decreased							

Date:08/09/05ISR Number: 4738387-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0569146A
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Wellbutrin Xl	PS	Glaxosmithkline	ORAL	300MG Per day	6 MON
	Ill-Defined Disorder							

Date:08/09/05ISR Number: 4738407-5Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0389923A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Zyban	PS	Glaxosmithkline		UNKNOWN	

Date:08/09/05ISR Number: 4738408-7Report Type:Expedited (15-DaCompany Report #LU-GLAXOSMITHKLINE-B0389926A
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Convulsion		Zyban	PS	Glaxosmithkline	ORAL
15MG per day 1 DAY						
	Depressed Level Of Consciousness		Alcohol	C		
	Multiple Drug Overdose					
	Suicide Attempt					

Date:08/09/05ISR Number: 4738411-7Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0390060A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Electric Shock		Zyban	PS	Glaxosmithkline	
UNKNOWN						
	Hypervigilance					
	Middle Insomnia					
	Shock					
	Tinnitus					
	Tremor					

Date:08/10/05ISR Number: 4739091-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0554003A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abnormal Dreams		Paxil Cr	PS	Glaxosmithkline	ORAL
25MG Per day 10 MON						
	Insomnia		Wellbutrin Xl	SS	Glaxosmithkline	ORAL
52 DAY						
	Weight Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4739135-2Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0555368A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Distractibility		Paxil Cr	PS	Glaxosmithkline	ORAL	12.5MG Per	
	Disturbance In Attention						day	2 YR
	Irritability		Wellbutrin	SS	Glaxosmithkline		UNKNOWN	0 DAY
	Mood Altered		Lipitor	C				
	Pharmaceutical Product Complaint							
	Therapeutic Response							
	Unexpected							

Date:08/10/05ISR Number: 4739191-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0558860A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Drug Reaction		Paxil Cr	PS	Glaxosmithkline	ORAL	YR	
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL		

Date:08/10/05ISR Number: 4739237-0Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0561374A
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Paxil Cr	PS	Glaxosmithkline	ORAL	12.5MG Per	
	Dizziness						day	2 YR
	Drug Withdrawal Syndrome		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Fatigue		Activella	C				
	Hot Flush		Oxycontin	C				
	Hyperhidrosis		Zyrtec	C	Glaxosmithkline			
	Panic Attack		Ativan	C				
	Tremor							

Date:08/10/05ISR Number: 4739294-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0540282A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Paxil	PS	Glaxosmithkline	ORAL	20MG	Unknown 13 YR
	Chest Pain		Wellbutrin	SS	Glaxosmithkline		UNKNOWN	
	Depression		Ativan	C				
	Drug Withdrawal Syndrome							
	Feeling Jittery							
	Hyperhidrosis							
	Nervousness							
	Palpitations							
	Paraesthesia							
	Social Phobia							

Date:08/10/05ISR Number: 4739323-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0541523A
Age:54 YR Gender:Male I/FU:I

Outcome	PT
	Body Temperature Decreased
	Drug Ineffective
	Skin Odour Abnormal
	Thirst
	Urine Odour Abnormal

Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paxil	PS	Glaxosmithkline	ORAL		
	Wellbutrin	SS	Glaxosmithkline	ORAL	8	WK
	Neurontin	C				
	Wellbutrin	C	Glaxosmithkline			
	Advair	C	Glaxosmithkline			

Date:08/10/05ISR Number: 4739443-5Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0542872A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Paxil	PS	Glaxosmithkline	ORAL		
			Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Klonopin	C				
			Neurontin	C				
			Vitamin E	C				
			Multivitamin	C				
			Vitamin C	C	Glaxosmithkline			

Date:08/10/05ISR Number: 4739470-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551298A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Paroxetine	PS	Glaxosmithkline	ORAL	50MG Per day	
	Drug Ineffective		Paxil	SS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL	300MG Per day	5 YR
			No Concurrent Medication	C				

Date:08/10/05ISR Number: 4739600-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553572A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Paxil	PS	Glaxosmithkline	ORAL	1TAB Per day	
	Irritability		Wellbutrin Sr	SS	Glaxosmithkline	ORAL	150MG Twice	
	Weight Increased						per day	
			Cozaar	C				
			Ultram	C				
			Blood Thinner	C				

Date:08/10/05ISR Number: 4739602-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553586A
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Paxil	PS	Glaxosmithkline	ORAL		
	Drug Ineffective		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	300MG Per day	5 MON
	Panic Reaction		No Concurrent					
	Stress		Medication	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4739749-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0557762A
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	7 YR
	Insomnia		Wellbutrin	SS	Glaxosmithkline	ORAL	300MG At night	2 WK
	Libido Decreased							
	Libido Increased		Crestor	C				
			Aspirin	C	Glaxosmithkline			
			Metoprolol	C				

Date:08/10/05ISR Number: 4739824-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0559025A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness		Paxil	PS	Glaxosmithkline	ORAL	4	YR
	Panic Reaction		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	1	MON
	Tremor							
	Weight Increased							

Date:08/10/05ISR Number: 4739952-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429084A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying		Paxil	PS	Glaxosmithkline	ORAL	20MG Per day	12 MON
	Drug Withdrawal Syndrome		Wellbutrin	SS	Glaxosmithkline	ORAL	4	WK
	Emotional Disorder		Ativan	C				
	Headache							
	Migraine							
	Nausea							
	Paraesthesia							
	Photophobia							

Date:08/10/05ISR Number: 4740183-7Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0545471A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor		Paxil	PS	Glaxosmithkline	ORAL		
			Wellbutrin	SS	Glaxosmithkline	ORAL		

Date:08/10/05ISR Number: 4740219-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0547647A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Paxil	PS	Glaxosmithkline	ORAL	2	YR
	Depression		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	2	WK
	Sexual Dysfunction							

Date:08/10/05ISR Number: 4740280-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550474A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Paxil	PS	Glaxosmithkline	ORAL		
	Female Orgasmic Disorder		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG	Unknown WK
	Irritability							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4740685-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0546519A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams		Lamictal	PS	Glaxosmithkline	ORAL	4	YR
	Adverse Event		Wellbutrin	SS	Glaxosmithkline			
	Hypnagogic Hallucination		Lithium	SS	Glaxosmithkline			
	Nightmare		Zoloft	C				
	Weight Increased							

Date:08/10/05ISR Number: 4740979-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0560142A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Amylase Increased		Paxil	PS	Glaxosmithkline		20MG Per day	1 MON
	Lipase Increased		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	1 MON
			Hyzaar	C				

Date:08/10/05ISR Number: 4740982-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0560255A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Amylase Increased		Paxil	PS	Glaxosmithkline	ORAL	20MG	Unknown
	Lipase Increased		Wellbutrin	SS	Glaxosmithkline	ORAL		
	Pancreatitis							

Date:08/10/05ISR Number: 4741010-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0560966A
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Paxil	PS	Glaxosmithkline	ORAL	40MG Per day	11 YR

	Depression		Wellbutrin	SS	Glaxosmithkline	ORAL
200MG per day 2 WK						
	Drug Ineffective		Protonix	C		
	Headache		Temazepam	C		

Date:08/10/05ISR Number: 4741046-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0561811A
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness		Paxil	PS	Glaxosmithkline	ORAL
	Insomnia		Wellbutrin	SS	Glaxosmithkline	ORAL
150MG Per day 3 DAY						
			Prilosec	C	Glaxosmithkline	
			Valium	C		
			Ativan	C		

Date:08/10/05ISR Number: 4741147-XReport Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0537773A
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia		Paxil	PS	Glaxosmithkline	ORAL
6 YR						
	Drug Ineffective		Wellbutrin	SS	Glaxosmithkline	ORAL
100MG Twice						
	Lethargy					
per day 9 MON						
			No Concurrent Medication	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4741261-9Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538126A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anger		Paxil	PS	Glaxosmithkline	ORAL		
	Anxiety		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG In the morning	
	Depression							
	Dizziness							
	Drug Withdrawal Syndrome							
	Headache							
	Heart Rate Increased							
	Paraesthesia							
	Tearfulness							

Date:08/10/05ISR Number: 4741278-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538318A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Paxil	PS	Glaxosmithkline		UNKNOWN	
			Wellbutrin	SS	Glaxosmithkline	ORAL		
			Geodon	C				

Date:08/10/05ISR Number: 4741286-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0538553A
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams		Paxil	PS	Glaxosmithkline	ORAL	40MG Per day	3 YR
	Drug Ineffective		Wellbutrin	SS	Glaxosmithkline	ORAL	150MG Per day	
	Dry Mouth		Klonopin	C				
			Topamax	C				
			Amitriptyline	C				
			Aspirin	C	Glaxosmithkline			
			Verapamil	C				
			Vitamin B12	C	Glaxosmithkline		TRANSDERMAL	

			Depakote	C		

Date:08/11/05ISR Number: 4742205-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0550467A
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Paxil Cr	PS	Glaxosmithkline	ORAL	12.5MG Per day	13 DAY
	Drug Ineffective							
	Lethargy		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Unknown	
	Mood Altered		Paxil	SS	Glaxosmithkline			
	Sexual Dysfunction							

Date:08/11/05ISR Number: 4742252-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0551724A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Paxil Cr	PS	Glaxosmithkline	ORAL	25MG Per day	1 YR
	Insomnia		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4742274-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0552172A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Paxil Cr	PS	Glaxosmithkline	ORAL	25MG Per day	3 YR
	Depression		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day	9 MON
	Dizziness		Xanax	C				
	Insomnia		Verapamil	C				
			Hct	C				
			Metformin	C				
			Amaryl	C				
			Actos	C				
			Adderall Xr	C				
			Theophylline	C				
			Albuterol	C	Glaxosmithkline			
			Tylenol With Codeine	C				
			Trazodone	C				

Date:08/11/05ISR Number: 4742342-6Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0553408A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Generalised		Paxil Cr	PS	Glaxosmithkline	ORAL	12.5MG Per day	3 YR
			Wellbutrin Sr	SS	Glaxosmithkline	ORAL	200MG Per day	3 YR

Date:08/11/05ISR Number: 4742686-8Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20050801049
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose		Ultram	PS		ORAL		
	Respiratory Distress		Wellbutrin	SS				
			Medication Nos	C				

Date:08/12/05ISR Number: 4743663-3Report Type:Expedited (15-DaCompany Report #US-ABBOTT-05P-163-0307663-00
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Depakote	PS				
	Anxiety		Bupropion Hydrochloride	SS		ORAL		
Other	Depression		Bupropion Hydrochloride	SS				
	Drug Ineffective		Lamotrigine	SS				
	Hepatocellular Damage		Lithium	C				
	Social Phobia		Actos	C				
	Suicidal Ideation		Glipizide	C				
			Levothyroxine Sodium	C				
			Irbesartan	C				
			Clonazepam	C				
			Zolpidem Tartrate	C				
			Amitriptyline Hydrochloride	C				
			Propranolol Hydrochloride	C				
			Fluoxetine Hydrochloride	C				
			Venlafaxine Hydrochloride	C				

Estradiol	C
Cholestyramine	C
Irbesartan	C
Zolpidem Tartrate	C
Amitriptyline Hydrochloride	C
Propranolol Hydrochloride	C
Fluoxetine Hydrochloride	C
Venlafaxine Hydrochloride	C
Oestradiol	C

Date:08/12/05ISR Number: 4743715-8Report Type:Expedited (15-DaCompany Report #13148
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tachycardia		Wellbutrin	PS	Glaxosmithkline		150MG Per day	30 DAY
			Lexapro	SS			10MG per day	134 DAY
			Unspecified Ssri	C				

Date:08/12/05ISR Number: 4743737-7Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0356916A
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abortion Spontaneous		Zyban	PS	Glaxosmithkline	ORAL	150MG See dosage text	50 DAY
			Infertility Therapy Unspecified	C				

Date:08/12/05ISR Number: 4743742-0Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0385105A
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Zyban	PS	Glaxosmithkline	ORAL	1TAB Per day	5 DAY
Initial or Prolonged	Dizziness		Valerian	C	Glaxosmithkline	ORAL	3U per day	11 DAY
	Hypertension							
	Palpitations							
	Supraventricular Extrasystoles							

Date:08/12/05ISR Number: 4743753-5Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0389332A
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Zyban	PS	Glaxosmithkline	ORAL	150MG Per day	3 WK
	Hallucination, Visual		Tramadol	C		ORAL	100MG Four times per day	
			Zopiclone	C		ORAL	7.5MG At night	
			Loratadine	C		ORAL	10MG Per day	
			Cetirizine	C	Glaxosmithkline	ORAL	10MG Per day	
			Co-Codamol	C		ORAL		
			Diclofenac	C		ORAL	50MG Three times per day	
			Propranolol	C		ORAL	80MG Twice	

per day

Beclometasone C Glaxosmithkline

RESPIRATORY

(INHALATION) 400MCG Twice

per day

Formoterol C

RESPIRATORY

(INHALATION) 12MCG

Variable dose

Date:08/12/05ISR Number: 4743760-2Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0390296A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Homicidal Ideation		Zyban	PS	Glaxosmithkline	ORAL		
	Paraesthesia							

Date:08/12/05ISR Number: 4743761-4Report Type:Expedited (15-DaCompany Report #AU-GLAXOSMITHKLINE-B0390305A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Zyban	PS	Glaxosmithkline	ORAL		
	Vision Blurred							

Date:08/15/05ISR Number: 4744822-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553401A
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Excoriation		Wellbutrin	PS	Glaxosmithkline	ORAL	11	DAY
	Fall		Effexor Xr	C		ORAL	300MG	In the morning
	Grand Mal Convulsion							

	Hand Fracture		Remeron	C		ORAL
45MG At night						
	Myalgia		Premarin	C		
UNKNOWN .125MG						
	Pain In Extremity					
Unknown						
	Periorbital Haematoma					

Date:08/15/05ISR Number: 4744826-3Report Type:Expedited (15-DaCompany Report #2005-07-0898
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Depression		Wellbutrin	PS	Glaxosmithkline	ORAL
	Personality Change		Pegylated Interferon			
	Restless Legs Syndrome		Alpha 2b	SS		
UNKNOWN						
	Schizophrenia		Rebetol	SS		ORAL
	Suicidal Ideation					

Date:08/15/05ISR Number: 4744831-7Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0570056A
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Convulsion		Wellbutrin	PS	Glaxosmithkline	ORAL
Hospitalization -	Overdose					
Initial or Prolonged	Suicide Attempt					
Disability						
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/05ISR Number: 4745915-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0565250A
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During		Lithium	PS	Glaxosmithkline			
	Pregnancy		Bupropion	SS	Glaxosmithkline			
	Hypertension		Wellbutrin	SS	Glaxosmithkline		300MG per day	
	Renal Failure		Lexapro	C			30MG per day	
	Renal Function Test		Nortriptyline	C			100MG Per day	
	Abnormal		Topamax	C			150MG per day	
	Renal Impairment							

Date:08/16/05ISR Number: 4745923-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0570086A
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acne		Bupropion	PS	Glaxosmithkline		89	DAY
	Drug Exposure During		Terbutaline	C				
	Pregnancy		Magnesium	C				
	Uterine Contractions							
	During Pregnancy							

Date:08/16/05ISR Number: 4745925-2Report Type:Expedited (15-DaCompany Report #2005-08-0496
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Wellbutrin	PS	Glaxosmithkline		UNKNOWN	
	Condition Aggravated		Peg-Intron	SS			SUBCUTANEOUS	
	Suicidal Ideation		Rebetol	SS		ORAL		

Date:08/17/05ISR Number: 4746709-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0564635A
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression		Wellbutrin	PS	Glaxosmithkline			
	Agitation							
	Anxiety							
	Completed Suicide							
	Crying							
	Emotional Disorder							
	Irritability							
	Social Avoidant Behaviour							
	Tremor							

Date:08/17/05ISR Number: 4746713-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0569266A
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Other	Aggression
	Altered Visual Depth Perception
	Apathy
	Asthenia
	Balance Disorder
	Confusional State
	Coordination Abnormal
	Dizziness
	Drug Ineffective

Drug Interaction Early Morning Awakening Headache	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Insomnia		Lamictal	PS	Glaxosmithkline	ORAL	3 MON
Temperature Intolerance		Wellbutrin Xl	SS	Glaxosmithkline	ORAL	150MG Per day
Visual Acuity Reduced		Clonazepam	SS			

Date:08/17/05ISR Number: 4746717-0Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0570240A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia		Wellbutrin	PS	Glaxosmithkline	ORAL	300MG Per day 5 DAY
Initial or Prolonged	Contusion		Ambien	C			
	Convulsion		Lotrel	C			
	Dysarthria		Depakote	C			
	Fall		Clonazepam	C			
	Feeling Drunk		Vitamins	C			
	Muscular Weakness						

Date:08/17/05ISR Number: 4746719-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0370023A
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Arthralgia		Zyban	PS	Glaxosmithkline	ORAL	150MG Twice
	Discomfort						per day 18 DAY
	Hypersensitivity						
	Scar						

Date:08/17/05ISR Number: 4746733-9Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0390517A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Abdominal Pain Upper		Zyban	PS	Glaxosmithkline	ORAL
150MG Unknown 10 DAY						
	Chest Pain					
	Constipation					
	Diplopia					
	Dry Mouth					
	Headache					
	Hemiparesis					
	Insomnia					
	Palpitations					
	Suicidal Ideation					

Date:08/18/05ISR Number: 4748055-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0570232A
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Gastrooesophageal Reflux		Wellbutrin	PS	Glaxosmithkline	ORAL
150MG Per day 4 MON						
	Disease		Wellbutrin	SS	Glaxosmithkline	ORAL
75MG Per day 4 MON						
	Medication Error		No Concurrent Medication	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748058-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0570423A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Blood Pressure Increased Chest Pain Feeling Jittery Insomnia		Wellbutrin No Concurrent Medication	PS C	Glaxosmithkline	ORAL	150MG Per day	4 MON

Date:08/18/05ISR Number: 4748059-6Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0570427A
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bipolar Disorder Muscle Twitching		Wellbutrin Prozac	PS C	Glaxosmithkline	ORAL	450MG Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Summary report for FOI selections:

Selection by inexact search of active ingredient: BUPROPION%

Selection by inexact search of Tradename/Verbatim: WELLBUTRIN%

Total number of reports: 18,667

From: 01-NOV-1997 To: Present